PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Huang, F; Wachi, S; Thai, P; Loukoianov, A; Tan, KH; Forteza, RM; Wu, R				Huang, Fei; Wachi, Shinichiro; Thai, Philip; Loukoianov, Artem; Tan, Kin Hup; Forteza, Rosanna Malbran; Wu, Reen			Potentiation of IL-19 expression in airway epithelia by IL-17A and IL-4/IL-13: Important implications in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-19; IL-17A; T(H)2 cytokine; IL-4; IL-13; airway epithelium; nuclear factor kappa B; signal transducer and activator of transcription 6; asthma	PLAQUE-TYPE PSORIASIS; GENE-EXPRESSION; TH2 CYTOKINES; ALLERGIC-ASTHMA; MESSENGER-RNA; TNF-ALPHA; INTERLEUKIN-19; CELLS; SUBFAMILY; INFLAMMATION	Background: IL-17A and IL-19 are highly expressed in chronic inflammatory diseases, such as psoriasis and asthma. IL-19 plays a significant role in the enhancement of T(H)2 cytokine secretion in allergic diseases, but its cellular source in asthmatic patients remains unknown. Objective: Our aims were to determine whether the epithelium is a major source of airway mucosal IL-19 and to elucidate the mechanism of gene expression regulation. Methods: Immunofluorescent staining was used to determine IL-19 protein expression in tracheal tissue sections of various airway diseases. Well-differentiated primary human bronchial epithelial cultures and a corresponding cell line were used as in vitro models to study gene regulation. Results: We found significantly higher IL-19 expression in airway epithelia of asthmatic patients than in epithelia of patients with other diseases. Using a cytokine panel, we demonstrated the upregulation of IL-19 expression in cultures by two TH2 cytokines, IL-4 and IL-13, in addition to the previously found T(H)17 cytokine IL-17A. Moreover, cotreatment of IL-17A and IL-4/11L-13 synergistically upregulated IL-19 expression. Using siRNA and chemical inhibitor approaches, we demonstrated a transcriptional regulation of IL-19 by nuclear factor kappa B and signal transducer and activator of transcription (STAT) 6. The addition of IL-13 to IL-17A stimulation triggers a shift from nuclear factor kappa B-dependent transcriptional regulation to one that is STAT6 based. Using chromatin immunoprecipitation assays, we demonstrated the presence of STAT6-binding elements in the IL-19 promoter region. Conclusion: We propose that an IL-17A- and IL-13-induced synergism in IL-19 stimulation in airway epithelia occurs through a STAT6-dependent pathway.	[Huang, Fei; Wachi, Shinichiro; Thai, Philip; Loukoianov, Artem; Tan, Kin Hup; Wu, Reen] Univ Calif Davis, Ctr Comparat Resp Biol, Div Pulm & Crit Care Med, Davis, CA 95616 USA; [Forteza, Rosanna Malbran] Leonard M Miller Sch Med, Div Pulm & Crit Care Med, Miami, FL USA	University of California System; University of California Davis	Huang, F (corresponding author), Univ Calif Davis, Ctr Comparat Resp Biol, Div Pulm & Crit Care Med, Suite 6413,451 Hlth Sci Dr, Davis, CA 95616 USA.	feihuang@ucdavis.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL077315, R01HL077902] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL077902, HL077902, T32 HL07103, R01 HL077315, HL077315] Funding Source: Medline; NIEHS NIH HHS [ES00628, P01 ES000628] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Andoh A, 2005, GASTROENTEROLOGY, V129, P969, DOI 10.1053/j.gastro.2005.06.071; Barczyk A, 2003, RESP MED, V97, P726, DOI 10.1053/rmed.2003.1507; Boniface K, 2005, EUR CYTOKINE NETW, V16, P309; Boniface K, 2005, J IMMUNOL, V174, P3695, DOI 10.4049/jimmunol.174.6.3695; Bullens DMA, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-135; Cai LP, 2002, J RHEUMATOL, V29, P1725; Chakir J, 2003, J ALLERGY CLIN IMMUN, V111, P1293, DOI 10.1067/mai.2003.1557; Chang CS, 2003, J BIOL CHEM, V278, P3308, DOI 10.1074/jbc.M208602200; Chen Y, 2003, J BIOL CHEM, V278, P17036, DOI 10.1074/jbc.M210429200; Conti P, 2003, IMMUNOL LETT, V88, P171, DOI 10.1016/S0165-2478(03)00087-7; Doucet C, 1998, J CLIN INVEST, V101, P2129, DOI 10.1172/JCI741; Gallagher G, 2004, INT IMMUNOPHARMACOL, V4, P615, DOI 10.1016/j.intimp.2004.01.005; Gallagher G, 2000, GENES IMMUN, V1, P442, DOI 10.1038/sj.gene.6363714; Hellings PW, 2003, AM J RESP CELL MOL, V28, P42, DOI 10.1165/rcmb.4832; Hsing CH, 2007, NEPHROL DIAL TRANSPL, V22, P2230, DOI 10.1093/ndt/gfm179; Huang F, 2007, J IMMUNOL, V179, P6504, DOI 10.4049/jimmunol.179.10.6504; HUANG SK, 1995, J IMMUNOL, V155, P2688; Humbert M, 1997, J ALLERGY CLIN IMMUN, V99, P657, DOI 10.1016/S0091-6749(97)70028-9; Kao CY, 2005, J IMMUNOL, V175, P6676, DOI 10.4049/jimmunol.175.10.6676; Kao CY, 2004, J IMMUNOL, V173, P3482, DOI 10.4049/jimmunol.173.5.3482; Koks S, 2005, GENES IMMUN, V6, P407, DOI 10.1038/sj.gene.6364216; Koks S, 2004, GENES IMMUN, V5, P662, DOI 10.1038/sj.gene.6364141; Li HH, 2005, BRIT J DERMATOL, V153, P591, DOI 10.1111/j.1365-2133.2005.06665.x; Li L, 1999, J IMMUNOL, V162, P2477; Liao SC, 2004, J IMMUNOL, V173, P6712, DOI 10.4049/jimmunol.173.11.6712; Liao YC, 2002, J IMMUNOL, V169, P4288, DOI 10.4049/jimmunol.169.8.4288; Linden A, 2001, INT ARCH ALLERGY IMM, V126, P179, DOI 10.1159/000049511; Linden A, 2000, EUR RESPIR J, V15, P973, DOI 10.1034/j.1399-3003.2000.15e28.x; McAllister F, 2005, J IMMUNOL, V175, P404, DOI 10.4049/jimmunol.175.1.404; Molet S, 2001, J ALLERGY CLIN IMMUN, V108, P430, DOI 10.1067/mai.2001.117929; Otkjaer K, 2005, BRIT J DERMATOL, V153, P911, DOI 10.1111/j.1365-2133.2005.06800.x; Park H, 2005, NAT IMMUNOL, V6, P1133, DOI 10.1038/ni1261; Prause O, 2003, EUR J PHARMACOL, V462, P193, DOI 10.1016/S0014-2999(03)01341-4; Romer J, 2003, J INVEST DERMATOL, V121, P1306, DOI 10.1111/j.1523-1747.2003.12626.x; Sa SM, 2007, J IMMUNOL, V178, P2229, DOI 10.4049/jimmunol.178.4.2229; Takeda K, 1996, J IMMUNOL, V157, P3220; Wachi S, 2005, BIOINFORMATICS, V21, P4205, DOI 10.1093/bioinformatics/bti688; Wong CK, 2001, CLIN EXP IMMUNOL, V125, P177, DOI 10.1046/j.1365-2249.2001.01602.x; WU R, 1985, AM REV RESPIR DIS, V132, P311; WU R, 1990, AM J RESP CELL MOL, V3, P467, DOI 10.1165/ajrcmb/3.5.467; Zhong HY, 2006, AM J RESP CELL MOL, V35, P587, DOI 10.1165/rcmb.2005-0476OC; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909	42	82	89	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2008	121	6					1415	1421		10.1016/j.jaci.2008.04.016	http://dx.doi.org/10.1016/j.jaci.2008.04.016			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	313WW	18539194	Bronze, Green Accepted			2022-12-18	WOS:000256771700017
J	Puxeddu, I; Pang, YY; Harvey, A; Haitchi, HM; Nicholas, B; Yoshisue, H; Ribatti, D; Clough, G; Powell, RM; Murphy, G; Hanley, NA; Wilson, DI; Howarth, PH; Holgate, ST; Davies, DE				Puxeddu, Ilaria; Pang, Yun Yun; Harvey, Anna; Haitchi, Hans Michael; Nicholas, Ben; Yoshisue, Hajime; Ribatti, Domenico; Clough, Geraldine; Powell, Rob M.; Murphy, Gillian; Hanley, Neil A.; Wilson, David I.; Howarth, Peter H.; Holgate, Stephen T.; Davies, Donna E.			The soluble form of a disintegrin and metalloprotease 33 promotes angiogenesis: Implications for airway remodeling in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ADAM33; asthma; angiogenesis; airway remodeling	LUNG-FUNCTION DECLINE; HUMAN ADAM33; POLYMORPHISMS; GENE; VASCULARITY; DOMAIN; RECOGNITION; POPULATION; EXPRESSION; PROTEINS	Background: A disintegrin and metalloprotease (ADAM)-33 is a susceptibility gene for asthma and chronic obstructive pulmonary disease whose function remains unknown. Objective: Because asthmatic bronchoalveolar lavage fluid contains high levels of soluble ADAM33 (sADAM33), which includes the catalytic domain, we postulated that its release from cell membranes might play functional roles in airway remodeling by promoting angiogenesis. Methods: The proangiogenic activity of the highly purified catalytic domain of ADAM33 or a catalytically inactive mutant was studied in vitro (Matrigel assay), ex vivo (human embryonic/fetal lung explants) and in vivo (chorioallantoic membrane assay). The regulation of sADAM33 release from cells overexpressing full-length ADAM33 and its biological activity were characterized. Results: We show that the purified catalytic domain of ADAM33, but not its inactive mutant, causes rapid induction of endothelial cell differentiation in vitro, and neovascularization ex vivo and in vivo. We also show that TGF-beta(2) enhances sADAM33 release from cells overexpressing full-length ADAM33 and that this truncated form is biologically active. Conclusion: The discovery that sADAM33 promotes angiogenesis defines it as a tissue remodeling gene with potential to affect airflow obstruction and lung function independently of inflammation. As TGF-beta(2) enhances sADAM33 release, environmental factors that cause epithelial damage may synergize with ADAM33 in asthma pathogenesis, resulting in a disease-related gain of function. This highlights the potential for interplay between genetic and environmental factors in this complex disease.	[Puxeddu, Ilaria; Pang, Yun Yun; Harvey, Anna; Haitchi, Hans Michael; Nicholas, Ben; Yoshisue, Hajime; Clough, Geraldine; Powell, Rob M.; Howarth, Peter H.; Holgate, Stephen T.; Davies, Donna E.] Univ Southampton, Southampton Gen Hosp, Sch Med, Div Infect Inflammat & Repair, Southampton SO16 6YD, Hants, England; [Hanley, Neil A.; Wilson, David I.] Univ Southampton, Southampton Gen Hosp, Sch Med, Div Human Genet, Southampton SO16 6YD, Hants, England; [Ribatti, Domenico] Univ Bari, Fac Med, Dept Anat, Bari, Italy; [Murphy, Gillian] Univ Cambridge, Dept Oncol, Cambridge, England	University of Southampton; University of Southampton; Universita degli Studi di Bari Aldo Moro; University of Cambridge	Davies, DE (corresponding author), Univ Southampton, Southampton Gen Hosp, Sch Med, Div Infect Inflammat & Repair, Mailpoint 810, Southampton SO16 6YD, Hants, England.	donnad@soton.ac.uk	Davies, Donna E/H-2993-2012; Puxeddu, Ilaria/AAB-3263-2019; Wilson, David/A-6264-2010	Wilson, David/0000-0001-8779-2060; Haitchi, Hans Michael/0000-0001-8603-302X; Nicholas, Benjamin/0000-0003-1467-9643; Howarth, Peter/0000-0003-0619-7927; Hanley, Neil/0000-0003-3234-4038; Davies, Donna/0000-0002-5117-2991	MRC [G0400473] Funding Source: UKRI; Medical Research Council [G0400473] Funding Source: Medline; Wellcome Trust Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Blakey J, 2005, THORAX, V60, P274, DOI 10.1136/thx.2004.027227; Blobel CP, 2000, CURR OPIN CELL BIOL, V12, P606, DOI 10.1016/S0955-0674(00)00139-3; Bridges LC, 2005, BIOCHEM J, V387, P101, DOI 10.1042/BJ20041444; Chen C, 2006, MOL CELL BIOL, V26, P6950, DOI 10.1128/MCB.00646-06; Davies DE, 2003, J ALLERGY CLIN IMMUN, V111, P215, DOI 10.1067/mai.2003.128; Del Mastro RG, 2007, BMC MED GENET, V8, DOI 10.1186/1471-2350-8-46; Foley SC, 2007, J ALLERGY CLIN IMMUN, V119, P863, DOI 10.1016/j.jaci.2006.12.665; Gaultier A, 2002, J BIOL CHEM, V277, P23336, DOI 10.1074/jbc.M201792200; Gosman MME, 2007, THORAX, V62, P242, DOI 10.1136/thx.2006.060988; Haitchi HM, 2005, AM J RESP CRIT CARE, V171, P958, DOI 10.1164/rccm.200409-1251OC; Hashimoto M, 2005, CHEST, V127, P965, DOI 10.1378/chest.127.3.965; Jackson JR, 1997, FASEB J, V11, P457, DOI 10.1096/fasebj.11.6.9194526; Janes PW, 2005, CELL, V123, P291, DOI 10.1016/j.cell.2005.08.014; Jongepier H, 2004, CLIN EXP ALLERGY, V34, P757, DOI 10.1111/j.1365-2222.2004.1938.x; Lee JY, 2006, AM J RESP CRIT CARE, V173, P729, DOI 10.1164/rccm.200409-1175OC; Li X, 1997, AM J RESP CRIT CARE, V156, P229, DOI 10.1164/ajrccm.156.1.9607066; Matter H, 1999, J MED CHEM, V42, P4506, DOI 10.1021/jm990250u; Meng JF, 2007, GENES IMMUN, V8, P215, DOI 10.1038/sj.gene.6364376; Orsida BE, 1999, THORAX, V54, P289, DOI 10.1136/thx.54.4.289; Orth P, 2004, J MOL BIOL, V335, P129, DOI 10.1016/j.jmb.2003.10.037; Powell RM, 2004, AM J RESP CELL MOL, V31, P13, DOI 10.1165/rcmb.2003-0330OC; Primakoff P, 2000, TRENDS GENET, V16, P83, DOI 10.1016/S0168-9525(99)01926-5; Puddicombe SM, 2000, FASEB J, V14, P1362, DOI 10.1096/fj.14.10.1362; Ribatti D, 2006, NAT PROTOC, V1, P85, DOI 10.1038/nprot.2006.13; Roy R, 2006, EXP CELL RES, V312, P608, DOI 10.1016/j.yexcr.2005.11.022; Simcock DE, 2007, AM J RESP CRIT CARE, V176, P146, DOI 10.1164/rccm.200701-042OC; Simpson A, 2005, AM J RESP CRIT CARE, V172, P55, DOI 10.1164/rccm.200412-1708OC; van Diemen CC, 2005, AM J RESP CRIT CARE, V172, P329, DOI 10.1164/rccm.200411-1486OC; Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878; Yang YW, 2008, J ALLERGY CLIN IMMUN, V121, P1393, DOI 10.1016/j.jaci.2008.02.031; Zou J, 2005, BIOCHEMISTRY-US, V44, P4247, DOI 10.1021/bi0476230; Zou J, 2004, J BIOL CHEM, V279, P9818, DOI 10.1074/jbc.M309696200	32	82	86	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2008	121	6					1400	1406		10.1016/j.jaci.2008.03.003	http://dx.doi.org/10.1016/j.jaci.2008.03.003			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	313WW	18410963				2022-12-18	WOS:000256771700015
J	Ringvall, M; Roennberg, E; Wernersson, S; Duelli, A; Henningsson, F; Abrink, M; Garcia-Faroldi, G; Fajardo, I; Pejler, G				Ringvall, Maria; Roennberg, Elin; Wernersson, Sara; Duelli, Annette; Henningsson, Frida; Abrink, Magnus; Garcia-Faroldi, Gianni; Fajardo, Ignacio; Pejler, Gunnar			Serotonin and histamine storage in mast cell secretory granules is dependent on serglycin proteoglycan	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						mast cells; proteoglycans; serglycin; histamine; serotonin; histidine decarboxylase; tryptophan hydroxylase	TRYPTOPHAN-HYDROXYLASE; RELEASE; HEPARIN; PROTEASES; EXPRESSION; MATURATION; DEFICIENT; BINDING; MODEL; TPH1	Background: Serotonin and histamine are components of human and rodent mast cell secretory granules. Objective: Serotonin and histamine are stored in the same compartment as serglycin proteoglycan. Here we addressed the possibility that serglycin may be involved in their storage and/or release. Methods: The storage and release of histamine and serotonin was studied in bone marrow-derived mast cells (BMMCs) and in peritoneal mast cells from wild-type or serglycin(-/-) mice. Results: Both serotonin and histamine storage in BMMCs was positively correlated with the degree of mast cell differentiation, and the amount of stored amine was reduced in serglycin(-/-) BMMCs compared with wild-type controls. The amounts of histamine/serotonin stored were reflected by the expression levels of histidine decarboxylase and tryptophan hydroxylase 1, respectively. Calcium ionophore activation resulted in serotonin/histamine release both from wild-type and serglycin(-/-) BMMCs. Interestingly, serotonin release was induced in cells lacking intracellular stores of serotonin, suggesting de novo synthesis. The knockout of serglycin affected the levels of stored and released mast cell serotonin and histamine to an even larger extent in in vivo-derived mast cells than in BMMCs. Conclusion: These results establish a previously assumed, but not proven, role of serglycin in storage of histamine and, further, establish for the first time that serotonin storage in mast cells is dependent on serglycin proteoglycan.	[Ringvall, Maria; Roennberg, Elin; Wernersson, Sara; Duelli, Annette; Henningsson, Frida; Pejler, Gunnar] Swedish Univ Agr Sci, Dept Anat Physiol & Biochem, BMC, S-75123 Uppsala, Sweden; [Abrink, Magnus] Uppsala Univ, Dept Med Biochem & Microbiol, Uppsala, Sweden; [Garcia-Faroldi, Gianni; Fajardo, Ignacio] Univ Malaga, Dept Mol Biol & Biochem, E-29071 Malaga, Spain	Swedish University of Agricultural Sciences; Uppsala University; Universidad de Malaga	Pejler, G (corresponding author), Swedish Univ Agr Sci, Dept Anat Physiol & Biochem, BMC, Box 575, S-75123 Uppsala, Sweden.	Gunnar.Pejler@bmc.uu.se	Wernersson, Sara/D-4580-2011; Fajardo, Ignacio/L-2943-2014; Åbrink, Magnus/AAK-8346-2020; Wernersson, Sara/N-8830-2019	Wernersson, Sara/0000-0003-3067-7875; Fajardo, Ignacio/0000-0001-6676-7579; Wernersson, Sara/0000-0003-3067-7875; Abrink, Magnus/0000-0002-1335-3927				Abrink M, 2004, J BIOL CHEM, V279, P40897, DOI 10.1074/jbc.M405856200; Boyce JA, 2003, PROSTAG LEUKOTR ESS, V69, P195, DOI 10.1016/S0952-3278(03)00081-4; Braga T, 2007, BIOCHEM J, V403, P49, DOI 10.1042/BJ20061257; BUCKLEY MG, 1992, BIOCHEM PHARMACOL, V44, P659, DOI 10.1016/0006-2952(92)90400-D; Chen RY, 2001, J CLIN INVEST, V108, P1151, DOI 10.1172/jci11494; Chuang WL, 2000, BIOCHEMISTRY-US, V39, P3542, DOI 10.1021/bi9926025; Cote F, 2003, P NATL ACAD SCI USA, V100, P13525, DOI 10.1073/pnas.2233056100; Coussens LM, 1999, GENE DEV, V13, P1382, DOI 10.1101/gad.13.11.1382; Csaba G, 2007, INFLAMM RES, V56, P89, DOI 10.1007/s00011-006-6102-2; Fajardo I, 2001, EUR J BIOCHEM, V268, P768, DOI 10.1046/j.1432-1327.2001.01930.x; Forsberg E, 1999, NATURE, V400, P773, DOI 10.1038/23488; Galli SJ, 2005, ANNU REV IMMUNOL, V23, P749, DOI 10.1146/annurev.immunol.21.120601.141025; Grujic M, 2005, J BIOL CHEM, V280, P33411, DOI 10.1074/jbc.M501708200; GURISH MF, 1992, J EXP MED, V175, P1003, DOI 10.1084/jem.175.4.1003; Henningsson F, 2006, FEBS J, V273, P4901, DOI 10.1111/j.1742-4658.2006.05489.x; Humphries DE, 1999, NATURE, V400, P769, DOI 10.1038/23481; Kolset SO, 2004, BIOCHEM J, V379, P217, DOI 10.1042/BJ20031230; Kushnir-Sukhov NM, 2007, J ALLERGY CLIN IMMUN, V119, P498, DOI 10.1016/j.jaci.2006.09.003; Lee DM, 2002, SCIENCE, V297, P1689, DOI 10.1126/science.1073176; LEVISCHAFFER F, 1987, J IMMUNOL, V139, P3431; LOVENBERG W, 1965, BIOCHEM PHARMACOL, V14, P887, DOI 10.1016/0006-2952(65)90109-7; MATHIAU P, 1994, NEUROSCI LETT, V182, P133, DOI 10.1016/0304-3940(94)90781-1; Mossner R, 1998, BRAIN BEHAV IMMUN, V12, P249, DOI 10.1006/brbi.1998.0532; Niemann CU, 2007, BLOOD, V109, P4478, DOI 10.1182/blood-2006-02-001719; Patel PD, 2004, BIOL PSYCHIAT, V55, P428, DOI 10.1016/j.biopsych.2003.09.002; Pejler G, 2007, ADV IMMUNOL, V95, P167, DOI 10.1016/S0065-2776(07)95006-3; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Rabenstein DL, 1998, BIOCHEMISTRY-US, V37, P14121, DOI 10.1021/bi980625y; Secor VH, 2000, J EXP MED, V191, P813, DOI 10.1084/jem.191.5.813; STEVENS RL, 1989, IMMUNOL TODAY, V10, P381, DOI 10.1016/0167-5699(89)90272-7; Sun JS, 2007, NAT MED, V13, P719, DOI 10.1038/nm1601; THEOHARIDES TC, 1985, BIOCHEM PHARMACOL, V34, P1389, DOI 10.1016/0006-2952(85)90675-6; Walther DJ, 2003, SCIENCE, V299, P76, DOI 10.1126/science.1078197; YURT RW, 1977, J IMMUNOL, V118, P1201	34	82	84	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2008	121	4					1020	1026		10.1016/j.jaci.2007.11.031	http://dx.doi.org/10.1016/j.jaci.2007.11.031			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	286YY	18234316				2022-12-18	WOS:000254884000031
J	Szefler, SJ; Baker, JW; Uryniak, T; Goldman, M; Silkoff, PE				Szefler, Stanley J.; Baker, James W.; Uryniak, Tom; Goldman, Mitchell; Silkoff, Philip E.			Comparative study of budesonide inhalation suspension and montelukast in young children with mild persistent asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						budesonide inhalation suspension; montelukast; asthma; pediatric; efficacy; safety	FLUTICASONE PROPIONATE; DOUBLE-BLIND; EFFICACY; INFANTS; SAFETY	Background: Budesonide inhalation suspension and the leukotriene receptor antagonist montelukast have demonstrated efficacy in children with mild persistent asthma, but comparative long-term studies in young children are needed. Objective: To compare the long-term efficacy and safety of budesonide inhalation suspension and montelukast. Methods: After a run-in period, children 2 to 8 years old with mild asthma or recurrent wheezing were randomized to once-daily budesonide inhalation suspension 0.5 mg or once-daily oral montelukast 4 or 5 mg for 52 weeks. Subjects were stepped up to twice-daily budesonide inhalation suspension or oral corticosteroids for mild or severe asthma worsening, respectively. The primary outcome was time to first additional medication for asthma worsening at 52 weeks. Secondary variables included times to the first additional asthma medication measured at 12 and 26 weeks; times to the first asthma exacerbation (mild and severe) measured at 12, 26, and 52 weeks; exacerbation rates (mild and severe) over a period of 52 weeks; diary variables (eg, peak expiratory flow [PEF]); patient-reported outcomes; and Global Physician and Caregiver Assessments. Results: No significant between-group differences were observed for time to first additional asthma medication at 52 weeks; however, time to first additional asthma medication was longer (unadjusted P =.050) at 12 weeks and exacerbation rates were lower over a period of 52 weeks (unadjusted P =.034) for budesonide versus montelukast. Time to first severe exacerbation (requiring oral corticosteroids) was similar in both groups, but the percentage of subjects requiring oral corticosteroids over a period of 52 weeks was lower with budesonide (25.5% vs 32.0%). Peak flow and Caregiver and Physician Global Assessments favored budesonide. Conclusion: Both treatments provided acceptable asthma control; however, overall measures favored budesonide inhalation suspension over montelukast. Clinical implications: These findings are consistent with studies in older children demonstrating better outcomes with inhaled corticosteroids versus montelukast.	Natl Jewish Med & Res Ctr, Div Pediat Clin Pharmacol & Allergy Immunol, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Pediat, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA; Allergy Associates PC, Portland, OR USA; AstraZeneca LP, Wilmington, DE USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; AstraZeneca	Szefler, SJ (corresponding author), Natl Jewish Med & Res Ctr, Div Pediat Clin Pharmacol & Allergy Immunol, 1400 Jackson St, Denver, CO 80206 USA.	szeflers@njc.org	silkoff, philip/S-9037-2016	silkoff, philip/0000-0001-6018-5199				Asmussen L, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.6.e71; Baker JW, 1999, PEDIATRICS, V103, P414, DOI 10.1542/peds.103.2.414; Busse WW, 2002, J ALLERGY CLIN IMMUN, V110, P703, DOI 10.1067/mai.2002.129368; Dolovich MB, 2005, CHEST, V127, P335, DOI 10.1378/chest.127.1.335; *FDA, 2007, GUID IND OR INH INTR; Garcia MLG, 2005, PEDIATRICS, V116, P360, DOI 10.1542/peds.2004-1172; Guilbert TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMoa051378; Juniper EF, 1996, QUAL LIFE RES, V5, P35, DOI 10.1007/BF00435967; Kemp JP, 1999, ANN ALLERG ASTHMA IM, V83, P231, DOI 10.1016/S1081-1206(10)62646-4; Knorr B, 1998, JAMA-J AM MED ASSOC, V279, P1181, DOI 10.1001/jama.279.15.1181; Knorr B, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.3.e48; LANDGRAFF JM, 1996, CHILD MANUAL QUESTIO; Murray CS, 2006, LANCET, V368, P754, DOI 10.1016/S0140-6736(06)69285-4; Ostrom NK, 2005, J PEDIATR-US, V147, P213, DOI 10.1016/j.jpeds.2005.03.052; Peroni D, 2005, ALLERGY, V60, P206, DOI 10.1111/j.1398-9995.2005.00670.x; Shapiro G, 1998, J ALLERGY CLIN IMMUN, V102, P789, DOI 10.1016/S0091-6749(98)70019-3; Sorkness CA, 2007, J ALLERGY CLIN IMMUN, V119, P64, DOI 10.1016/j.jaci.2006.09.042; Szefler SJ, 2005, J ALLERGY CLIN IMMUN, V115, P233, DOI 10.1016/j.jaci.2004.11.014; Vidal C, 2001, ANN ALLERG ASTHMA IM, V86, P655, DOI 10.1016/S1081-1206(10)62294-6; ZIEGLER RS, 2006, J ALLERGY CLIN IMMUN, V117, P45; 2005, PULMICORT RESPULES B	21	82	90	2	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2007	120	5					1043	1050		10.1016/j.jaci.2007.08.063	http://dx.doi.org/10.1016/j.jaci.2007.08.063			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	231TZ	17983871	Bronze			2022-12-18	WOS:000250973400010
J	Nakae, S; Lunderius, C; Ho, LH; Schafer, B; Tsai, M; Galli, SJ				Nakae, Susumu; Lunderius, Carolina; Ho, Lien H.; Schafer, Beatrix; Tsai, Mindy; Galli, Stephen J.			TNF can contribute to multiple features of ovalbumin-induced allergic inflammation of the airways in mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						airway hyperreactivity; asthma; cytokines; mast cells; neutrophils	TUMOR-NECROSIS-FACTOR; DELTA T-CELLS; HUMAN MAST-CELL; FACTOR-ALPHA; REFRACTORY ASTHMA; IMMUNE-RESPONSES; DEFICIENT MICE; HYPERRESPONSIVENESS; MOUSE; GAMMA	Background: TNF is thought to contribute to airway hyperreactivity (AHR) and airway inflammation in asthma. However, studies with TNF-deficient or TNF receptor-deficient mice have not produced a clear picture of the role of TNF in the AHR associated with allergic inflammation in the mouse. Objective: We used a genetic approach to investigate the contributions of TNF to antigen-induced AHR and airway inflammation in mice on the C57BL/6 background. Methods: We analyzed features of airway allergic inflammation, including antigen-induced AHR, in C57BL/6 wild-type and TNF-/- mice, using 2 different methods for sensitizing the mice to ovalbumin (OVA). Results: In mice sensitized to OVA administered with the adjuvant aluminum hydroxide (alum), which develop IgE-independent and mast cell-independent allergic inflammation and AHR, we found no significant differences in OVA-induced AHR in C57BL/6-TNF-/- versus wild-type mice. By contrast, in mice sensitized to OVA without alum, which develop allergic inflammation that is significantly mast cell-dependent, C57BL/6-TNF-/- mice exhibited significant reductions versus wildtype mice in OVA-induced AHR to methacholine; numbers of lymphocytes, neutrophils, and eosinophils in bronchoalveolar lavage fluid; levels of myeloperoxidase, eosinophil peroxidase, and the cytokines IL-4, IL-5, and IL-17 in lung tissue; and histologic evidence of pulmonary inflammation. Conclusion: In pulmonary allergic inflammation induced in mice immunized with OVA without alum, TNF significantly contributes to several features of the response, including antigen-induced inflammation and AHR. Clinical implications: Our findings in mice support the hypothesis that TNF can promote the allergic inflammation and AHR associated with asthma.	Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA; Karolinska Inst, S-10401 Stockholm, Sweden	Stanford University; Karolinska Institutet	Galli, SJ (corresponding author), Stanford Univ, Sch Med, Dept Pathol, L-235,300 Pasteur Dr, Stanford, CA 94305 USA.	sgalli@stanford.edu		Tsai, Mindy/0000-0002-8421-4721	NATIONAL CANCER INSTITUTE [R01CA072074] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL067674, P01HL067674] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023990, R37AI023990] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA072074, CA-72074] Funding Source: Medline; NHLBI NIH HHS [HL-67674, P50 HL067674] Funding Source: Medline; NIAID NIH HHS [R01 AI023990, R01 AI070813, AI-070813, AI-23990] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Babu KS, 2004, IMMUNOL ALLERGY CLIN, V24, P583, DOI 10.1016/j.iac.2004.06.010; Berry MA, 2006, NEW ENGL J MED, V354, P697, DOI 10.1056/NEJMoa050580; Boyce JA, 2005, J EXP MED, V201, P1869, DOI 10.1084/jem.20050584; BRADDING P, 1994, AM J RESP CELL MOL, V10, P471, DOI 10.1165/ajrcmb.10.5.8179909; Brewer JM, 1999, J IMMUNOL, V163, P6448; Broide DH, 2001, AM J RESP CELL MOL, V24, P304, DOI 10.1165/ajrcmb.24.3.4071; Choi IW, 2005, J ALLERGY CLIN IMMUN, V116, P537, DOI 10.1016/j.jaci.2005.05.034; Crosby JR, 2002, J IMMUNOL, V168, P4050, DOI 10.4049/jimmunol.168.8.4050; Erzurum SC, 2006, NEW ENGL J MED, V354, P754, DOI 10.1056/NEJMe058266; Galli SJ, 2005, ANNU REV IMMUNOL, V23, P749, DOI 10.1146/annurev.immunol.21.120601.141025; Galli SJ, 2005, NAT IMMUNOL, V6, P135, DOI 10.1038/ni1158; GORDON JR, 1991, J EXP MED, V174, P103, DOI 10.1084/jem.174.1.103; GORDON JR, 1990, NATURE, V346, P274, DOI 10.1038/346274a0; GURISH MF, 2001, J EXP MED, V194, P1; Halasz A, 2002, RESP MED, V96, P262, DOI 10.1053/rmed.2001.1256; Hessel EM, 1997, AM J RESP CELL MOL, V16, P325, DOI 10.1165/ajrcmb.16.3.9070618; Holgate ST, 2005, CLIN EXP ALLERGY, V35, P408, DOI 10.1111/j.1365-2222.2005.02191.x; Howarth PH, 2005, THORAX, V60, P1012, DOI 10.1136/thx.2005.045260; Kanehiro A, 2001, AM J RESP CRIT CARE, V164, P2229, DOI 10.1164/ajrccm.164.12.2012059; Kanehiro A, 2002, J IMMUNOL, V169, P4190, DOI 10.4049/jimmunol.169.8.4190; KIPS JC, 1993, CLIN EXP ALLERGY, V23, P247, DOI 10.1111/j.1365-2222.1993.tb00317.x; Kips JC, 2003, EUR RESPIR J, V22, P374, DOI 10.1183/09031936.03.00026403; KIPS JC, 1992, AM REV RESPIR DIS, V145, P332, DOI 10.1164/ajrccm/145.2_Pt_1.332; Korner H, 1997, EUR J IMMUNOL, V27, P2600, DOI 10.1002/eji.1830271020; Korsgren M, 1997, J EXP MED, V185, P885, DOI 10.1084/jem.185.5.885; Korsgren M, 1999, J EXP MED, V189, P553, DOI 10.1084/jem.189.3.553; Lahn M, 1999, NAT MED, V5, P1150, DOI 10.1038/13476; Lloyd CM, 2001, ADV IMMUNOL, V77, P263, DOI 10.1016/S0065-2776(01)77019-8; MARTIN TR, 1993, J CLIN INVEST, V91, P1176, DOI 10.1172/JCI116277; Mayr SI, 2002, J IMMUNOL, V169, P2061, DOI 10.4049/jimmunol.169.4.2061; Metcalfe DD, 1997, PHYSIOL REV, V77, P1033, DOI 10.1152/physrev.1997.77.4.1033; Nakae S, 2003, INT IMMUNOL, V15, P483, DOI 10.1093/intimm/dxg054; Robinson DS, 2004, J ALLERGY CLIN IMMUN, V114, P58, DOI 10.1016/j.jaci.2004.03.034; Rouhani FN, 2005, RESP MED, V99, P1175, DOI 10.1016/j.rmed.2005.02.031; Rudmann DG, 2000, AM J PHYSIOL-LUNG C, V279, pL1047, DOI 10.1152/ajplung.2000.279.6.L1047; Russo M, 2001, AM J RESP CELL MOL, V24, P518, DOI 10.1165/ajrcmb.24.5.4320; Ruuls SR, 2001, IMMUNITY, V15, P533, DOI 10.1016/S1074-7613(01)00215-1; Schmitz N, 2003, EUR J IMMUNOL, V33, P991, DOI 10.1002/eji.200323801; Schramm CM, 2000, AM J RESP CELL MOL, V22, P218, DOI 10.1165/ajrcmb.22.2.3620; Shakoory B, 2004, J INTERF CYTOK RES, V24, P271, DOI 10.1089/107999004323065057; Sulakvelidze I, 1998, EUR RESPIR J, V11, P821, DOI 10.1183/09031936.98.11040821; Suto H, 2006, J IMMUNOL, V176, P4102, DOI 10.4049/jimmunol.176.7.4102; Takeda K, 1997, J EXP MED, V186, P449, DOI 10.1084/jem.186.3.449; THOMAS PS, 1995, AM J RESP CRIT CARE, V152, P76, DOI 10.1164/ajrccm.152.1.7599866; Williams CMM, 2000, J EXP MED, V192, P455, DOI 10.1084/jem.192.3.455; Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255; Zuany-Amorim C, 1998, SCIENCE, V280, P1265, DOI 10.1126/science.280.5367.1265	47	82	92	2	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2007	119	3					680	686		10.1016/j.jaci.2006.11.701	http://dx.doi.org/10.1016/j.jaci.2006.11.701			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	146HL	17336618	Bronze			2022-12-18	WOS:000244925000022
J	Nouri-Aria, KT; Pilette, C; Jacobson, MR; Watanabe, H; Durham, SR				Nouri-Aria, KT; Pilette, C; Jacobson, MR; Watanabe, H; Durham, SR			IL-9 and c-Kit(+) mast cells in allergic rhinitis during seasonal allergen exposure: Effect of immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; IL-9; mast cells; eosinophils; cytokine	GRASS-POLLEN IMMUNOTHERAPY; MESSENGER-RNA EXPRESSION; NASAL-MUCOSA; METACHROMATIC CELLS; AIRWAY INFLAMMATION; INTERLEUKIN-9; EOSINOPHILS; BASOPHILS; ASTHMA; ACCUMULATION	Background: IL-9 is an important stimulus for tissue infiltration by mast cells, a feature requiring concomitant activation of c-Kit. Objectives: We assessed IL-9 expression and c-Kit(+) mast cells in the nasal mucosa of patients with allergic rhinitis during seasonal pollen exposure and observed the effects of allergen immunotherapy. Methods: We studied 44 patients with seasonal rhinitis and asthma before and 2 years after a double-blind trial of grass pollen immunotherapy. Nasal mucosal IL-9(+) cells and c-Kit+ mast cells were assessed by means of immunochemistry. Cell types expressing IL-9 protein were determined by means of dual immunofluorescence. IL-9 mRNA-positive cells were assessed by means of in situ hybridization, and their phenotype was determined by using sequential immunohistocbemistry and in situ hybridization. Results: Nasal mucosal c-Kit+ mast cells were increased during the pollen season (P = .0001). IL-9 mRNA-positive cells also tended to increase (P =. 1) and correlated with nasal EG2(+) eosinophils (r = 0.47, P = .05) and IL-5 mRNA-positive cells (r = 0.54, P = .02). The cell sources of IL-9 included T cells, eosinophils, neutrophils, and mast cells. When compared with placebo, successful pollen immunotherapy markedly inhibited seasonal increases in nasal mucosal c-Kit+ mast cells (P = .001) and the seasonal expression of IL-9 mRNA-positive cells (P = .06). Immunotherapy also inhibited IL-9 protein expression from nonendothelial cell sources (P = .0007). Conclusion: IL-9 is upregulated in the nasal mucosa during the pollen season and correlates with tissue infiltration by eosinophils. Successful pollen immunotherapy is associated with inhibition of seasonal increases in both nasal c-Kit(+) mast cells and eosinophils. This effect might be explained, at least in part, by the reduced local expression of IL-9.	Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London SW3 6LY, England	Imperial College London	Nouri-Aria, KT (corresponding author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dovehouse St, London SW3 6LY, England.	s.durham@imperial.ac.uk		Jacobson, Mikila/0000-0002-2921-6169				Bochner BS, 2001, IMMUNOL REV, V179, P5, DOI 10.1034/j.1600-065X.2001.790101.x; BORRES MP, 1990, ALLERGY, V45, P98, DOI 10.1111/j.1398-9995.1990.tb00465.x; Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; Boyce JA, 2003, J ALLERGY CLIN IMMUN, V111, P24, DOI 10.1067/mai.2003.60; Cheng G, 2002, AM J RESP CRIT CARE, V166, P409, DOI 10.1164/rccm.2105079; DRUEZ C, 1990, J IMMUNOL, V145, P2494; DUGAS B, 1993, EUR J IMMUNOL, V23, P1687, DOI 10.1002/eji.1830230743; DURHAM SR, 1992, J IMMUNOL, V148, P2390; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Dus D, 2003, IMMUNOL LETT, V86, P163, DOI 10.1016/S0165-2478(03)00018-X; Erpenbeck VJ, 2003, J ALLERGY CLIN IMMUN, V111, P1319, DOI 10.1067/mai.2003.1485; Gauvreau GM, 2000, AM J RESP CRIT CARE, V161, P1473, DOI 10.1164/ajrccm.161.5.9908090; Godfraind C, 1998, J IMMUNOL, V160, P3989; Hauber HP, 2004, INT ARCH ALLERGY IMM, V134, P79, DOI 10.1159/000078384; HULTNER L, 1990, EUR J IMMUNOL, V20, P1413, DOI 10.1002/eji.1830200632; Ikeda RK, 2003, J IMMUNOL, V171, P4860, DOI 10.4049/jimmunol.171.9.4860; KleinJan A, 2000, J ALLERGY CLIN IMMUN, V106, P677, DOI 10.1067/mai.2000.109621; Levitt RC, 1999, J ALLERGY CLIN IMMUN, V103, pS485, DOI 10.1016/S0091-6749(99)70165-X; Louahed J, 2000, AM J RESP CELL MOL, V22, P649, DOI 10.1165/ajrcmb.22.6.3927; Louahed J, 2001, BLOOD, V97, P1035, DOI 10.1182/blood.V97.4.1035; Macfarlane AJ, 2000, J ALLERGY CLIN IMMUN, V105, P99, DOI 10.1016/S0091-6749(00)90184-2; Matsuzawa S, 2003, J IMMUNOL, V170, P3461, DOI 10.4049/jimmunol.170.7.3461; McLane MP, 1998, AM J RESP CELL MOL, V19, P713, DOI 10.1165/ajrcmb.19.5.3457; McMillan S, 2002, J EXP MED, V195, P51, DOI 10.1084/jem.20011732; Nicolaides NC, 1997, P NATL ACAD SCI USA, V94, P13175, DOI 10.1073/pnas.94.24.13175; Nilsen EM, 1998, GUT, V42, P635, DOI 10.1136/gut.42.5.635; OTSUKA H, 1991, CLIN EXP ALLERGY, V21, P115, DOI 10.1111/j.1365-2222.1991.tb00812.x; RENAULD JC, 1995, J LEUKOCYTE BIOL, V57, P353, DOI 10.1002/jlb.57.3.353; Shimbara A, 2000, J ALLERGY CLIN IMMUN, V105, P108, DOI 10.1016/S0091-6749(00)90185-4; Soussi-Gounni A, 2001, J ALLERGY CLIN IMMUN, V107, P575, DOI 10.1067/mai.2001.114238; Stassen M, 2001, J IMMUNOL, V166, P4391, DOI 10.4049/jimmunol.166.7.4391; Temann UA, 2002, J CLIN INVEST, V109, P29, DOI 10.1172/JCI13696; VIEGAS M, 1987, INT ARCH ALLER A IMM, V82, P275, DOI 10.1159/000234205; Walker SM, 2001, J ALLERGY CLIN IMMUN, V107, P87, DOI 10.1067/mai.2001.112027; Wilson DR, 2001, CLIN EXP ALLERGY, V31, P1705, DOI 10.1046/j.1365-2222.2001.01231.x; Wilson DR, 2001, J ALLERGY CLIN IMMUN, V107, P971, DOI 10.1067/mai.2001.115483; Ying S, 2002, CLIN EXP ALLERGY, V32, P866, DOI 10.1046/j.1365-2222.2002.01376.x	37	82	89	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2005	116	1					73	79		10.1016/j.jaci.2005.03.011	http://dx.doi.org/10.1016/j.jaci.2005.03.011			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IC	15990777				2022-12-18	WOS:000235686300012
J	Aukema, AAC; Mulder, PGH; Fokkens, WJ				Aukema, AAC; Mulder, PGH; Fokkens, WJ			Treatment of nasal polyposis and chronic rhinosinusitis with fluticasone propionate nasal drops reduces need for sinus surgery	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						nasal polyps; rhinosinusitis; fluticasone propionate; nasules; steroid; local; treatment; adult; sinus surgery; computed tomography	SPRAY	Background: Steroid treatment is the mainstay of therapy for nasal polyps and rhinosinusitis. Oral steroids have considerable systemic side effects, and nasal sprays do not sufficiently reach the middle meatus, where polyps originate. Nasal drops might be a more useful formula to deliver steroids into the middle meatus. Objective: We sought to investigate whether treatment with fluticasone propionate nasal drops (FPNDs) can reduce the need for surgery, as measured by signs and symptoms of nasal polyposis and chronic rhinosinusitis, in patients who are on the waiting list for functional endoscopic sinus surgery (FESS). Methods: Fifty-four patients (28 male) with severe nasal polyposis, chronic rhinosinusitis, or both indicated for FESS were included in a 12-week, double-blind, placebo-controlled study. Use of intranasal steroid spray was stopped at least 4 weeks before randomization. Signs and symptoms were recorded before, during, and at the end of the study period. At the end of the study, a computed tomographic scan was performed, and the need for operation was reassessed by using a standardized scoring method. Results: FESS was no longer required in 13 of 27 patients treated with FPNDs versus 6 of 27 in the placebo group (P < .05). Six patients from the placebo group dropped out versus 1 from the FPND group. Symptoms of nasal obstruction, rhinorrhea, postnasal drip, and loss of smell were reduced in the FPND group (P < .05). Peak nasal inspiratory flow scores increased significantly (P < .01). Polyp volume decreased in the FPND group (P < .05), and computed tomographic scores improved in both groups (P < .05). Conclusion: Treatment with FPNDs in patients indicated for FESS can reduce the need for surgery.	Erasmus MC, Dept Otolaryngol, NL-3015 GD Rotterdam, Netherlands; Erasmus MC, Dept Epidemiol & Biostat, NL-3015 GD Rotterdam, Netherlands; Acad Med Ctr, Dept Otorhinolaryngol, Amsterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; University of Amsterdam; Academic Medical Center Amsterdam	Aukema, AAC (corresponding author), Erasmus MC, Dept Otolaryngol, Dr Molewaterpl 40, NL-3015 GD Rotterdam, Netherlands.	aaukema@hotmail.com	Fokkens, Wytske WJ/ABF-2185-2020					Bhattacharyya T, 1997, ARCH OTOLARYNGOL, V123, P1189; Daley-Yates PT, 2001, BRIT J CLIN PHARMACO, V51, P103, DOI 10.1046/j.1365-2125.2001.01325.x; Gazis AG, 1999, CLIN OTOLARYNGOL, V24, P495, DOI 10.1046/j.1365-2273.1999.00299.x; HARDY JG, 1985, J PHARM PHARMACOL, V37, P294, DOI 10.1111/j.2042-7158.1985.tb05069.x; Holmstrom M, 1999, ALLERGY, V54, P21, DOI 10.1111/j.1398-9995.1999.tb05034.x; Johansson L, 2000, ACTA OTO-LARYNGOL, V120, P72; Kenny TJ, 2001, OTOLARYNG HEAD NECK, V125, P40, DOI 10.1067/mhn.2001.116779; LLOYD GAS, 1991, J LARYNGOL OTOL, V105, P181, DOI 10.1017/S0022215100115300; Lund Valerie J., 1993, Rhinology (Utrecht), V31, P183; LUND VJ, 1995, BRIT MED J, V311, P1411, DOI 10.1136/bmj.311.7017.1411; Lund VJ, 1998, ARCH OTOLARYNGOL, V124, P513, DOI 10.1001/archotol.124.5.513; MELEN I, 1994, ACTA OTO-LARYNGOL, P45; Penttila M, 2000, CLIN EXP ALLERGY, V30, P94; Stierna PLE, 1996, ALLERGY ASTHMA PROC, V17, P251, DOI 10.2500/108854196778662282; Van Camp C., 1994, Rhinology (Utrecht), V32, P5	15	82	91	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2005	115	5					1017	1023		10.1016/j.jaci.2004.12.1144	http://dx.doi.org/10.1016/j.jaci.2004.12.1144			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	925LR	15867860				2022-12-18	WOS:000229055100018
J	Bublin, M; Mari, A; Ebner, C; Knulst, A; Scheiner, O; Hoffmann-Sommergruber, K; Breiteneder, H; Radauer, C				Bublin, M; Mari, A; Ebner, C; Knulst, A; Scheiner, O; Hoffmann-Sommergruber, K; Breiteneder, H; Radauer, C			IgE sensitization profiles toward green and gold kiwifruits differ among patients allergic to kiwifruit from 3 European countries	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food allergy; kiwifruit; actinidin; thaumatin; cystatin; immunoglobulin E	FICUS-BENJAMINA LATEX; KIWI FRUIT ALLERGY; CROSS-REACTIVITY; BIRCH-POLLEN; MAJOR ALLERGEN; FIG FRUIT; ACTINIDIN; HYPERSENSITIVITY; IDENTIFICATION; PURIFICATION	Background: Kiwifruits have become a major elicitor of plant food allergy. Until recently, the only species of kiwifruit grown commercially was the common green-fleshed Actinidia deliciosa cv Hayward. In 1999, the yellow-fleshed cultivar Actinidia chinensis cv Hort16A was introduced into the international market. Objective: We compared the allergen compositions of green and gold kiwifruits and assessed the sensitization patterns of patients with kiwifruit allergy toward both varieties. Methods: Sera from 90 patients with kiwifruit allergy from Austria, central Italy, and the Netherlands were tested for IgE binding to green and gold kiwifruit protein extracts and to purified actinidin, the major kiwifruit allergen, by ELISA. In addition, ELISA inhibitions and immunoblots were performed with selected sera. Relevant allergens were identified by N-terminal sequencing and immunoblotting with allergen-specific antibodies. Results: IgE immunoblotting showed marked differences in the allergen compositions of green and gold kiwifruit extracts. Phytocystatin, a novel plant food allergen, and a thaumatin-like protein were identified as allergens common for both cultivars. Two allergens with homologies to chitinases were found in gold kiwifruits, whereas actinidin was detected exclusively in green kiwifruits. Patients from Central Europe and central Italy showed distinct sensitization profiles toward green and gold kiwifruit extracts as well as actinidin. Whereas sera from Austrian and Dutch patients mainly recognized green kiwifruit extract and actinidin, almost all Italian sera showed IgE binding to both kiwifruit species, but only half of them contained actinidin-specific IgE. Green and gold kiwifruit extracts were shown to be highly cross-reactive as determined by IgE ELISA inhibition. Conclusion: The presence of common allergens and the IgE cross-reactivity to green kiwifruit qualifies gold kiwifruit as a potential new allergen source for patients allergic to green kiwifruits.	Med Univ Vienna, Dept Pathophysiol, A-1090 Vienna, Austria; Natl Hlth Serv, Allergy Unit, Rome, Italy; Allergieambulatorium, Vienna, Austria; Univ Utrecht, Ctr Med, Dept Dermatol Allergol, Utrecht, Netherlands	Medical University of Vienna; Utrecht University	Radauer, C (corresponding author), Med Univ Vienna, Dept Pathophysiol, EBO 3Q,Waehringer Guertel 18-20, A-1090 Vienna, Austria.	Christian.Radauer@meduniwien.ac.at	Radauer, Christian/AAN-6260-2021; Ferreira, Fatima/AAB-4321-2019; Ferreira, Fatima/E-4889-2011	Radauer, Christian/0000-0001-9920-4449; Ferreira, Fatima/0000-0003-0989-2335; Ferreira, Fatima/0000-0003-0989-2335; Bublin, Merima/0000-0002-7191-9431; Hoffmann-Sommergruber, Karin/0000-0002-8830-058X				Aleman A, 2004, J ALLERGY CLIN IMMUN, V113, P543, DOI 10.1016/j.jaci.2003.11.043; Arai S, 2002, J AGR FOOD CHEM, V50, P6612, DOI 10.1021/jf0201935; Breiteneder H, 2004, ALLERGY, V59, P479, DOI 10.1046/j.1398-9995.2003.00421.x; BROCKLEHURST K, 1981, BIOCHEM J, V197, P739, DOI 10.1042/bj1970739; Brown WM, 1997, PROTEIN SCI, V6, P5; Bublin M, 2003, FASEB J, V17, P1697, DOI 10.1096/fj.02-0872fje; Butler John E, 2004, Methods Mol Med, V94, P333; Crespo JF, 2002, ALLERGY, V57, P946, DOI 10.1034/j.1398-9995.2002.23626.x; Diaz-Perales A, 1999, J ALLERGY CLIN IMMUN, V104, P681, DOI 10.1016/S0091-6749(99)70342-8; Diez-Gomez ML, 1998, ANN ALLERG ASTHMA IM, V80, P24, DOI 10.1016/S1081-1206(10)62934-1; Elfman L, 1997, INT ARCH ALLERGY IMM, V113, P249, DOI 10.1159/000237561; ERIKSSON NE, 2003, ALLERGOL INT, V52, P199; Ferguson A. R., 1999, PERSPECTIVES NEW CRO, P342; FINE AJ, 1981, J ALLERGY CLIN IMMUN, V68, P235, DOI 10.1016/0091-6749(81)90189-5; Focke M, 2003, CLIN EXP ALLERGY, V33, P971, DOI 10.1046/j.1365-2222.2003.01704.x; GALL H, 1994, J ALLERGY CLIN IMMUN, V94, P70, DOI 10.1016/0091-6749(94)90073-6; GARCIA BE, 1989, ALLERGOL IMMUNOPATH, V17, P217; Gavrovic-Jankulovic M, 2002, J INVEST ALLERG CLIN, V12, P279; Gavrovic-Jankulovic M, 2002, J ALLERGY CLIN IMMUN, V110, P805, DOI 10.1067/mai.2002.128947; Ichikawa K, 2001, CLIN EXP ALLERGY, V31, P1279, DOI 10.1046/j.1365-2222.2001.01169.x; Lavaud F, 1997, CLIN REV ALLERG IMMU, V15, P429, DOI 10.1007/BF02737738; LEWIS SA, 2003, ALLERGY S74, V58, P194; LIANG CF, 1986, NEW ZEAL J BOT, V24, P183; Lucas JSA, 2003, PEDIAT ALLERG IMM-UK, V14, P420, DOI 10.1046/j.0905-6157.2003.00095.x; LUCAS JSA, 2003, ALLERGY, V58, P208; Mattila L, 2003, CLIN EXP ALLERGY, V33, P600, DOI 10.1046/j.1365-2222.2003.01661.x; Moller M, 1997, Z LEBENSM UNTERS F A, V205, P364, DOI 10.1007/s002170050182; Nishiyama I, 2002, J JPN SOC FOOD SCI, V49, P401, DOI 10.3136/nskkk.49.401; Nolle C, 2000, ALLERGOLOGIE, V23, P235; Pastorello EA, 1996, J ALLERGY CLIN IMMUN, V98, P601, DOI 10.1016/S0091-6749(96)70094-5; Pastorello EA, 1998, J ALLERGY CLIN IMMUN, V101, P531, DOI 10.1016/S0091-6749(98)70360-4; Patterson K, 2003, ACTA HORTIC, P267, DOI 10.17660/ActaHortic.2003.610.35; Rassam M, 2004, PHYTOCHEMISTRY, V65, P19, DOI 10.1016/j.phytochem.2003.09.019; SANCHEZMONGE R, 2004, PLANT FOOD ALLERGENS, P87; Steurich F, 1996, ALLERGOLOGIE, V19, P367; van Ree R, 2002, INT ARCH ALLERGY IMM, V129, P189, DOI 10.1159/000066770; Vieths S, 2002, ANN NY ACAD SCI, V964, P47; Voitenko V, 1997, ALLERGY, V52, P136, DOI 10.1111/j.1398-9995.1997.tb00967.x; Wurms KV, 1997, NEW ZEAL J CROP HORT, V25, P213, DOI 10.1080/01140671.1997.9514010	39	82	92	1	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2004	114	5					1169	1175		10.1016/j.jaci.2004.07.016	http://dx.doi.org/10.1016/j.jaci.2004.07.016			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	870HI	15536427				2022-12-18	WOS:000225047800027
J	Orange, JS; Levy, O; Brodeur, SR; Krzewski, K; Roy, RM; Niemela, JE; Fleisher, TA; Bonilla, FA; Geha, RS				Orange, JS; Levy, O; Brodeur, SR; Krzewski, K; Roy, RM; Niemela, JE; Fleisher, TA; Bonilla, FA; Geha, RS			Human nuclear factor kappa B essential modulator mutation can result in immunodeficiency without ectodermal dysplasia	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						NF-kappa B; I kappa B kinase; immunologic deficiency syndromes; X-chromosome-linked genetic diseases; innate immunity	HYPER-IGM SYNDROME; INCONTINENTIA PIGMENTI; IMMUNE-DEFICIENCY; NEMO; ACTIVATION; PATHWAY; INTERLEUKIN-1	Background: Many receptors rely on the appropriate activation of nuclear factor (NF)kappaB to induce cellular function. This process depends critically on the phosphorylation of the inhibitor of NF-kappaB (IkappaB) by the IkappaB kinase. This targets IkappaB for ubiquitination and degradation, allowing NF-kappaB to translocate to the nucleus, where it can direct transcription. Hypomorphic human mutations affecting one IkappaB kinase component, the NF-kappaB essential modulator (NEMO), result in impaired signaling from receptors required for ectodermal development and immune function. Male subjects with these mutant NEMO molecules have an X-linked syndrome known as ectodermal dysplasia with immunodeficiency, which is characterized by severe infections, with herpesviruses, bacteria, and mycobacterial susceptibility. Objective: We sought to genetically and biochemically characterize a patient with a mutant NEMO molecule without ectodermal abnormalities. Methods: We evaluated NEMO in a patient who had immunodeficiency and atypical mycobacterial infection but normal ectoderm. Results: We identified a novel NEMO mutant causing immunodeficiency without ectodermal dysplasia. The mutation, which altered the exon 9 splice site, was present in cells of ectodermal and hematopoetic origin and resulted in a heterogeneous mixture of mutant and wild-type cDNA species. Immunologic function was variably impaired, with reduced CD40-induced B-cell proliferation, partially reduced NF-kappaB p65 nuclear translocation, and variable Toll-like receptor-induced TNF production. This variability might be explained by an inconsistent ratio of mutant to wild-type NEMO. The lack of any ectodermal phenotype, however, suggested a separation in the hematopoetic and ectodermal function of NEMO that leads to NF-kappaB activation. Conclusion: Mutation of the gene encoding NEMO can result in immunodeficiency without ectodermal dysplasia.	Childrens Hosp, Div Immunol, Boston, MA 02115 USA; Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA USA; Childrens Hosp, Div Infect Dis, Boston, MA USA; Childrens Hosp, Div Immunol, Boston, MA USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02138 USA; Harvard Univ, Dept Mol & Cell Biol, Cambridge, MA USA; Warren G Magnuson Clin Ctr, Dept Lab Med, NIH, Bethesda, MD USA	Harvard University; Boston Children's Hospital; University of Pennsylvania; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; National Institutes of Health (NIH) - USA	Geha, RS (corresponding author), Childrens Hosp, Div Immunol, New Res Bldg,1 Blackfan Circle, Boston, MA 02115 USA.	raif.geha@childrens.harvard.edu	Orange, Jordan S/D-5239-2009	Levy, Ofer/0000-0002-5859-1945; orange, jordan/0000-0001-7117-7725; Roy, Rene/0000-0002-4868-9658; Niemela, Julie/0000-0003-4197-3792	NCRR NIH HHS [M01-RR02172] Funding Source: Medline; NIAID NIH HHS [AI-31451, AI-50583, AI-31136, AI-55602] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR002172] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI050583, K08AI055602, R01AI031451, R01AI031136] Funding Source: NIH RePORTER; CLINICAL CENTER [Z01CL010304, ZIACL010304] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); CLINICAL CENTER		Agou F, 2004, J BIOL CHEM, V279, P27861, DOI 10.1074/jbc.M314278200; Aradhya S, 2001, AM J HUM GENET, V68, P765, DOI 10.1086/318806; Bardaro T, 2003, HUM MUTAT, V21, P8, DOI 10.1002/humu.10150; Beutler B, 2003, J LEUKOCYTE BIOL, V74, P479, DOI 10.1189/jlb.0203082; Carrol ED, 2003, ARCH DIS CHILD, V88, P340, DOI 10.1136/adc.88.4.340; Doffinger R, 2001, NAT GENET, V27, P277, DOI 10.1038/85837; Dupuis-Girod S, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.6.e97; Feigelson HS, 2001, CANCER EPIDEM BIOMAR, V10, P1005; Hoffmann A, 2003, EMBO J, V22, P5530, DOI 10.1093/emboj/cdg534; Jain A, 2001, NAT IMMUNOL, V2, P223, DOI 10.1038/85277; Jiang ZF, 2003, J BIOL CHEM, V278, P16713, DOI 10.1074/jbc.M300562200; Kenwrick S, 2001, AM J HUM GENET, V69, P1210; KRAWCZAK M, 1992, HUM GENET, V90, P41; Levy O, 2003, INFECT IMMUN, V71, P6344, DOI 10.1128/IAI.71.11.6344-6353.2003; Medvedev AE, 2003, J EXP MED, V198, P521, DOI 10.1084/jem.20030701; Orange JS, 2004, J ALLERGY CLIN IMMUN, V113, P725, DOI 10.1016/j.jaci.2004.01.762; Orange JS, 2002, J CLIN INVEST, V109, P1501, DOI 10.1172/JCI200214858; Picard C, 2003, SCIENCE, V299, P2076, DOI 10.1126/science.1081902; Seyama K, 1999, J BIOL CHEM, V274, P11310, DOI 10.1074/jbc.274.16.11310; Smahi A, 2002, HUM MOL GENET, V11, P2371, DOI 10.1093/hmg/11.20.2371; Smahi A, 2000, NATURE, V405, P466; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; Yamamoto Y, 2004, TRENDS BIOCHEM SCI, V29, P72, DOI 10.1016/j.tibs.2003.12.003; Zhou HL, 2004, NATURE, V427, P167, DOI 10.1038/nature02273; Zonana J, 2000, AM J HUM GENET, V67, P1555, DOI 10.1086/316914	25	82	85	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2004	114	3					650	656		10.1016/j.jaci.2004.06.052	http://dx.doi.org/10.1016/j.jaci.2004.06.052			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	853AX	15356572				2022-12-18	WOS:000223799600028
J	Pastorello, EA; Pompei, C; Pravettoni, V; Farioli, L; Calamari, AM; Scibilia, J; Robino, AM; Conti, A; Iametti, S; Fortunato, D; Bonomi, S; Ortolani, C				Pastorello, EA; Pompei, C; Pravettoni, V; Farioli, L; Calamari, AM; Scibilia, J; Robino, AM; Conti, A; Iametti, S; Fortunato, D; Bonomi, S; Ortolani, C			Lipid-transfer protein is the major maize allergen maintaining IgE-binding activity after cooking at 100 degrees C, as demonstrated in anaphylactic patients and patients with positive double-blind, placebo-controlled food challenge results	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food anaphylaxis; maize allergy; lipid-transfer protein; thermal treatment; double-blind; placebo-controlled food challenge	IDENTIFICATION; FRAGMENTS; BARLEY; PEACH	Background: In a previous study a 9-kd lipid-transfer protein (LTP) was identified as the major allergen of raw maize in a population of 22 anaphylactic patients. However, the stability of this protein in cooked maize is unknown. Objective: We investigated the allergenicity of 5 maize hybrids and its modification after different thermal treatments by using sera from anaphylactic patients and patients with positive double-blind, placebo-controlled food challenges. Methods: Five maize hybrids were extracted by using different methods, obtaining the water-soluble, zein, total zein, glutelin, and total protein fractions. The IgE-binding capacity of the different extracts, both raw and after thermal treatment, was investigated by means of SDS-PAGE immunoblotting. A 9-kd heat-stable allergen was purified by means of HPLC and sequenced. Changes in its secondary structure during and after heating from 25degreesC to 100degreesC were monitored by means of circular dichroism. Results: All raw maize hybrids showed similar protein and IgE-binding profiles. The SDS-PAGE of all the heat-treated hybrids demonstrated a decreased number of stained bands in respect to the raw samples. The IgE immunoblotting demonstrated that the major allergen of the water-soluble, total zein, total protein, and glutelin fractions was a 9-kd protein identified by means of amino acid sequence as an LTP and a subtilisin-chymotrypsin inhibitor (in total zein fraction). The IgE-binding capacity of this 9-kd protein remained unchanged after thermal treatments, even though circular dichroism demonstrated an altered secondary structure. Conclusions: Maize UP maintains its IgE-binding capacity after heat treatment, thus being the most eligible candidate for a causative role in severe anaphylactic reactions to both raw and cooked maize.	Univ Milan, Osped Maggiore, IRCCS, Div Gen Med 1,Allergy Ctr,Dept Internal Med, Milan, Italy; Univ Milan, Dept Food Sci & Microbiol, Milan, Italy; ICP, CEMOC, UOOML, Milan, Italy; Osped Niguarda Ca Granda, Bizzozzero Div, Milan, Italy; ISPA, Natl Res Council, Turin, Italy; Univ Milan, Dept Agrifood Mol Sci, Milan, Italy	IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; University of Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico; Ospedale Niguarda Ca' Granda; Consiglio Nazionale delle Ricerche (CNR); Istituto Scienze delle Produzioni Alimentari (ISPA-CNR); University of Milan	Pastorello, EA (corresponding author), Osped Maggiore, IRCCS, Dept Internal Med Padiglione Granelli 1, Via F Sforza 35, I-20122 Milan, Italy.		SCIBILIA, GIUSEPPE/AAC-9673-2022; Iametti, Stefania/AGY-9694-2022; PASTORELLO, ELIDE ANNA/E-3897-2017	SCIBILIA, GIUSEPPE/0000-0002-5452-4024; PASTORELLO, ELIDE ANNA/0000-0002-3753-1783; Iametti, Stefania/0000-0002-4159-3768				BERNHARD WR, 1989, ARCH BIOCHEM BIOPHYS, V269, P695, DOI 10.1016/0003-9861(89)90154-9; Brenna O, 2000, J AGR FOOD CHEM, V48, P493, DOI 10.1021/jf9906681; Cavaletto M, 2002, PROTEOMICS, V2, P850, DOI 10.1002/1615-9861(200207)2:7<850::AID-PROT850>3.0.CO;2-C; Fountoulakis M, 2001, ELECTROPHORESIS, V22, P1747, DOI 10.1002/1522-2683(200105)22:9<1747::AID-ELPS1747>3.0.CO;2-H; Garcia-Casado G, 2001, J ALLERGY CLIN IMMUN, V108, P647, DOI 10.1067/mai.2001.118793; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; HENZEL WJ, 1993, P NATL ACAD SCI USA, V90, P5011, DOI 10.1073/pnas.90.11.5011; Lopez A, 1981, COMPLETE COURSE CANN, V1; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maleki SJ, 2000, J ALLERGY CLIN IMMUN, V106, P763, DOI 10.1067/mai.2000.109620; Pasini G, 2002, ALLERGY, V57, P98, DOI 10.1034/j.1398-9995.2002.1o3413.x; PASTORELLO EA, 1994, J ALLERGY CLIN IMMUN, V94, P699, DOI 10.1016/0091-6749(94)90177-5; Pastorello EA, 2002, J ALLERGY CLIN IMMUN, V109, P563, DOI 10.1067/mai.2002.121946; Pastorello EA, 2003, J ALLERGY CLIN IMMUN, V111, P350, DOI 10.1067/mai.2003.35; Pastorello EA, 2000, J ALLERGY CLIN IMMUN, V106, P744, DOI 10.1067/mai.2000.108712; Sanchez-Monge R, 2000, J ALLERGY CLIN IMMUN, V106, P190, DOI 10.1067/mai.2000.107599; Shewry PR, 2002, J EXP BOT, V53, P947, DOI 10.1093/jexbot/53.370.947; SHIN DH, 1995, STRUCTURE, V3, P189, DOI 10.1016/S0969-2126(01)00149-6; WEISS W, 1993, ELECTROPHORESIS, V14, P805, DOI 10.1002/elps.11501401126	19	82	84	1	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2003	112	4					775	783		10.1016/S0091-6749(03)01942-0	http://dx.doi.org/10.1016/S0091-6749(03)01942-0			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	730LA	14564361				2022-12-18	WOS:000185831200019
J	Hauber, HP; Gotfried, M; Newman, K; Danda, R; Servi, RJ; Christodoulopoulos, P; Hamid, Q				Hauber, HP; Gotfried, M; Newman, K; Danda, R; Servi, RJ; Christodoulopoulos, P; Hamid, Q			Effect of HFA-flunisolide on peripheral lung inflammation in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; eosinophil; flunisolide; hydrofluoroalkane; inflammation; peripheral airways	INHALED FLUTICASONE PROPIONATE; MESSENGER-RNA EXPRESSION; AIRWAY INFLAMMATION; EPITHELIAL-CELLS; ALVEOLAR TISSUE; INTERLEUKIN-5; IMMUNOPATHOLOGY; LYMPHOCYTES; INHIBITION; MODULATION	Background: New hydrofluoroalkane (HFA) formulations of glucocorticoids have been shown to effectively control asthma. HFA glucocorticoids are deposited across all sizes of airways, including the small ones. However, it is not clear whether they can suppress peripheral airway inflammation. Objective: We sought to determine whether HFA-flunisolide could suppress peripheral inflammation in asthma. Methods: Twelve patients with mild to moderate asthma received HFA-flunisolide for 6 weeks. Transbronchial and endobronchial biopsy specimens were obtained before and after treatment, and spirometry was performed. Changes in inflammatory cells (eosinophils, neutrophils, lymphocytes, macrophages, basophils) and IL-5 and eotaxin were measured by using immunocytochemistry and in situ hybridization. Results: Lung function significantly improved after treatment (P < .05). HFA-flunisolide significantly reduced eosinophils, IL-5, and eotaxin in both peripheral and central airways (P < .01). Neutrophils significantly increased after treatment in peripheral and central airways (P < .05). The numbers of lymphocytes remained unchanged. Conclusions: These results show that HFA-flunisolide effectively suppressed eosinophilic inflammation in peripheral and central airways. These changes were accompanied by improvement in lung function.	McGill Univ, Meakins Christie Labs, Montreal, PQ H2X 2P2, Canada; Pulm Associates, Phoenix, AZ USA; Forest Labs Inc, New York, NY USA	McGill University	Hamid, Q (corresponding author), McGill Univ, Meakins Christie Labs, 3626 St Urbain St, Montreal, PQ H2X 2P2, Canada.							BOOTH H, 1995, AM J RESP CRIT CARE, V152, P45, DOI 10.1164/ajrccm.152.1.7599861; Boulet LP, 2000, AM J RESP CRIT CARE, V162, P1308, DOI 10.1164/ajrccm.162.4.9910051; BURKE C, 1992, EUR RESPIR J, V5, P73; Busse WW, 1999, J ALLERGY CLIN IMMUN, V104, P1215, DOI 10.1016/S0091-6749(99)70016-3; Carroll N, 1996, EUR RESPIR J, V9, P709, DOI 10.1183/09031936.96.09040709; Carroll N, 1997, EUR RESPIR J, V10, P292, DOI 10.1183/09031936.97.10020292; CHANEZ P, 1996, AM J RESP CRIT CARE, V153, P212; Christodoulopoulos P, 2000, J ALLERGY CLIN IMMUN, V106, P479; Corren J, 2001, ANN ALLERG ASTHMA IM, V87, P405, DOI 10.1016/S1081-1206(10)62922-5; COX G, 1995, J IMMUNOL, V154, P4719; COX G, 1991, AM J RESP CELL MOL, V4, P525, DOI 10.1165/ajrcmb/4.6.525; Davies DE, 2003, J ALLERGY CLIN IMMUN, V111, P215, DOI 10.1067/mai.2003.128; DJUKANOVIC R, 1992, AM REV RESPIR DIS, V145, P669, DOI 10.1164/ajrccm/145.3.669; Esmailpour N, 1997, EUR RESPIR J, V10, P1496, DOI 10.1183/09031936.97.10071496; Faul JL, 1997, EUR RESPIR J, V10, P301, DOI 10.1183/09031936.97.10020301; Fukakusa M, 2002, J ALLERGY CLIN IMMUN, V109, pS274, DOI 10.1016/S0091-6749(02)81971-6; Haley KJ, 1998, AM J RESP CRIT CARE, V158, P565, DOI 10.1164/ajrccm.158.2.9705036; HAMID Q, 1993, LANCET, V342, P1510, DOI 10.1016/S0140-6736(05)80083-2; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; Hamid Q, 1997, J ALLERGY CLIN IMMUN, V100, P44, DOI 10.1016/S0091-6749(97)70193-3; Holm AF, 1999, CLIN EXP ALLERGY, V29, P1356; JEFFERY PK, 1992, AM REV RESPIR DIS, V145, P890, DOI 10.1164/ajrccm/145.4_Pt_1.890; Kraft M, 1999, AM J RESP CRIT CARE, V159, P228, DOI 10.1164/ajrccm.159.1.9804033; Kraft M, 1996, AM J RESP CRIT CARE, V154, P1505, DOI 10.1164/ajrccm.154.5.8912772; Larche M, 2003, J ALLERGY CLIN IMMUN, V111, P450, DOI 10.1067/mai.2003.169; Leach CL, 1998, EUR RESPIR J, V12, P1346, DOI 10.1183/09031936.98.12061346; Leung DYM, 2003, J ALLERGY CLIN IMMUN, V111, P3, DOI 10.1067/mai.2003.97; Lilly CM, 1997, J CLIN INVEST, V99, P1767, DOI 10.1172/JCI119341; MARTIN RJ, 1991, AM REV RESPIR DIS, V143, P351, DOI 10.1164/ajrccm/143.2.351; Martin RJ, 2002, J ALLERGY CLIN IMMUN, V109, pS447, DOI 10.1067/mai.2002.121409; Minshall EM, 1998, J ALLERGY CLIN IMMUN, V101, P386, DOI 10.1016/S0091-6749(98)70252-0; Richards J, 2001, J AEROSOL MED, V14, P197, DOI 10.1089/08942680152484126; ROBINSON D, 1993, AM REV RESPIR DIS, V148, P401, DOI 10.1164/ajrccm/148.2.401; ROLFE FG, 1992, IMMUNOLOGY, V77, P494; Synek M, 1996, EUR RESPIR J, V9, P54, DOI 10.1183/09031936.96.09010054; Taha RA, 1999, J ALLERGY CLIN IMMUN, V103, P476, DOI 10.1016/S0091-6749(99)70474-4; TANIZAKI Y, 1993, J ASTHMA, V30, P309, DOI 10.3109/02770909309054531; Wenzel SE, 1997, AM J RESP CRIT CARE, V156, P737, DOI 10.1164/ajrccm.156.3.9610046; Yoshimura C, 2001, J ALLERGY CLIN IMMUN, V108, P215, DOI 10.1067/mai.2001.116575	39	82	86	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2003	112	1					58	63		10.1067/mai.2003.1612	http://dx.doi.org/10.1067/mai.2003.1612			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	698QQ	12847480				2022-12-18	WOS:000184010600010
J	Rasmussen, F; Taylor, DR; Flanneryb, EM; Cowan, JO; Greene, JM; Herbison, GP; Sears, MR				Rasmussen, F; Taylor, DR; Flanneryb, EM; Cowan, JO; Greene, JM; Herbison, GP; Sears, MR			Risk factors for hospital admission for asthma from childhood to young adulthood: A longitudinal population study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; hospital admission; risk factors; allergy; longitudinal population study; epidemiology	HOUSE-DUST MITE; BRONCHIAL HYPERRESPONSIVENESS; EMERGENCY-DEPARTMENT; INDOOR ALLERGENS; ECONOMIC BURDEN; SCHOOL ABSENCE; CHILDREN; SENSITIZATION; PREVALENCE; EXPOSURE	Background: Predictors of hospital admissions for asthma in children and young adults in a general population are not well defined, because most studies have used selected subpopulations. Objective: The purpose of this investigation was to determine risk factors for single and multiple hospital admissions for asthma. Methods: The members of a population-based, unselected birth cohort of 1037 New Zealanders answered questionnaires and underwent lung function, airway responsiveness, and allergy testing on 7 occasions to the age of 26 years. Results: Among the 766 study members (74% of the cohort) who reported wheezing symptoms ever by the age of 26 years, 136 hospitalizations were reported by 62 individuals (8.3% of those at risk, 6.2% of the total cohort). Only 55 of these 136 admissions involved children less than 9 years of age; admissions continued to occur between the ages of 9 and 18 years (40 admissions) and at >18 years (41 admissions). Those admitted were predominantly male, had earlier ages of onset of symptoms, were more atopic, and had more airway hyperresponsiveness to methacholine than those not admitted. Frequent symptoms and low lung function were evident among the 45 study members with single admissions and even more evident among the 17 study members with multiple (2-10) admissions. Conclusions: A surprisingly large fraction of this unselected population experienced hospitalization for asthma during the 26-year follow-up, many being admitted in later childhood, adolescence, and early adulthood. Clinical characteristics and markers of severity, including frequent respiratory symptoms, airway hyperresponsiveness, atopy, and low lung function, identify those at high risk for hospitalization for asthma, particularly with respect to multiple admissions.	St Josephs Healthcare, Firestone Inst Respiratory Hlth, Hamilton, ON L8N 4A6, Canada; Univ Otago, Dunedin Sch Med, Dept Prevent & Social Med, Dunedin, New Zealand; Univ Otago, Dunedin Sch Med, Dept Med, Dunedin, New Zealand; McMaster Univ, Hamilton, ON, Canada	University of Otago; University of Otago; McMaster University	Sears, MR (corresponding author), St Josephs Healthcare, Firestone Inst Respiratory Hlth, 50 Charlton Ave E, Hamilton, ON L8N 4A6, Canada.			Herbison, Graham Peter/0000-0002-5684-024X				ANDERSON HR, 1989, THORAX, V44, P614, DOI 10.1136/thx.44.8.614; ANDERSON HR, 1983, ARCH DIS CHILD, V58, P777, DOI 10.1136/adc.58.10.777; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Blais L, 1998, THORAX, V53, P1025, DOI 10.1136/thx.53.12.1025; CAMPBELL DA, 1995, THORAX, V50, P254, DOI 10.1136/thx.50.3.254; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; Clough JB, 1998, CLIN EXP ALLERGY, V28, P22; DALES RE, 1995, THORAX, V50, P520, DOI 10.1136/thx.50.5.520; Eisner MD, 2001, RESP RES, V2, P53, DOI 10.1186/rr37; ELLEY WB, 1976, NEW ZEAL J EDUC STUD, V11, P25; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573, DOI 10.1164/ajrccm/147.3.573; Gergen PJ, 2001, J ALLERGY CLIN IMMUN, V107, pS445, DOI 10.1067/mai.2001.114992; JENKINS MA, 1994, BRIT MED J, V309, P90, DOI 10.1136/bmj.309.6947.90; LI D, 1995, AM J RESP CRIT CARE, V151, P647; Lozano P, 1999, J ALLERGY CLIN IMMUN, V104, P957, DOI 10.1016/S0091-6749(99)70075-8; MILES J, 1995, CLIN EXP ALLERGY, V25, P1074; Newacheck PW, 2000, ARCH PEDIAT ADOL MED, V154, P287, DOI 10.1001/archpedi.154.3.287; OSWALD H, 1994, BRIT MED J, V309, P95, DOI 10.1136/bmj.309.6947.95; PATTEMORE PK, 1990, AM REV RESPIR DIS, V142, P549, DOI 10.1164/ajrccm/142.3.549; POLLART SM, 1989, J ALLERGY CLIN IMMUN, V83, P875, DOI 10.1016/0091-6749(89)90100-0; Rabbat A, 1996, INTENS CARE MED, V22, P530; Ray NF, 1998, CHEST, V113, P1277, DOI 10.1378/chest.113.5.1277; Sarpong SB, 1997, ANN ALLERG ASTHMA IM, V79, P455, DOI 10.1016/S1081-1206(10)63043-8; Schaubel D, 1996, J ASTHMA, V33, P97, DOI 10.3109/02770909609054537; SEARS MR, 1993, CLIN EXP ALLERGY, V23, P941, DOI 10.1111/j.1365-2222.1993.tb00279.x; SEARS MR, 1986, THORAX, V41, P283, DOI 10.1136/thx.41.4.283; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; Singh AK, 1999, ARCH INTERN MED, V159, P1237, DOI 10.1001/archinte.159.11.1237; SKOBELOFF EM, 1992, JAMA-J AM MED ASSOC, V268, P3437, DOI 10.1001/jama.268.24.3437; Smith DH, 1997, AM J RESP CRIT CARE, V156, P787, DOI 10.1164/ajrccm.156.3.9611072; Spee-van der Wekke J, 1998, J EPIDEMIOL COMMUN H, V52, P359, DOI 10.1136/jech.52.6.359; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; SPORIK R, 1993, CLIN EXP ALLERGY, V23, P740, DOI 10.1111/j.1365-2222.1993.tb00361.x; SPRINGETT VH, 1969, BMJ-BRIT MED J, V1, P402, DOI 10.1136/bmj.1.5641.402; *STAT CAN CAN I HL, 82570XIE STAT CAN CA; *US DEP HHS, 1991, 9150212 PHS US DEP H; WEISS KB, 1992, NEW ENGL J MED, V326, P862, DOI 10.1056/NEJM199203263261304	37	82	86	1	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2002	110	2					220	227	UNSP 1/81/125295	10.1067/mai.2002.125295	http://dx.doi.org/10.1067/mai.2002.125295			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	585DY	12170261				2022-12-18	WOS:000177509800005
J	Stevenson, LA; Gergen, PJ; Hoover, DR; Rosenstreich, D; Mannino, DM; Matte, TD				Stevenson, LA; Gergen, PJ; Hoover, DR; Rosenstreich, D; Mannino, DM; Matte, TD			Sociodemographic correlates of indoor allergen sensitivity among United States children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						race; indoor allergens; sensitivity; children; prevalence; NHANES	SKIN-TEST REACTIVITY; HOUSE-DUST MITE; DIESEL EXHAUST PARTICLES; ASTHMA HOSPITALIZATION; MEXICAN-AMERICAN; RISK-FACTORS; COCKROACH ALLERGEN; CAT ALLERGENS; PUERTO-RICAN; EXPOSURE	Background: Exposure to indoor allergens is associated with asthma morbidity. Nationally, asthma morbidity disproportionately affects socially disadvantaged populations, but it is unclear whether exposure to indoor allergens follows a similar pattern. Objective: We sought to examine the national prevalences and demographic correlates of sensitivity to indoor allergens related to asthma. Methods: Analysis of a cross-sectional survey of a representative sample of 4164 United States children aged 6 to 16 years who participated in allergen testing in the Third National Health and Nutrition Examination Survey from 1988 to 1994 was performed. The main outcome measures were sensitivity reactions to cockroach, dust mite, cat, and Alternaria alternata, as measured via skin prick testing. Results: Multivariate models, including sex, age, race-ethnicity, education, poverty, family history, region of country, housing age, crowding, and urban residence, revealed significant racial-ethnic disparities in sensitivity. Compared with white children, African American children had higher odds ratios (ORs) of cockroach or dust mite sensitivity (cockroach,. [95% Cl, 1.9-3.2]; dust mite OR, 1.3 [95% CI, 1.0-1.7]), as did Mexican American children (cockroach OR, 1.9 [95% CI, 1.3-2.8]; dust mite OR, 1.6 [95% C1, 1.2-2.2]). African American children also had significantly higher odds of sensitivity to A alternata (OR, 2.1 [95% CI, 1.5-2.8]). Conclusions: African American and Mexican American children are substantially more likely than white children to be sensitized to allergens important in asthma. Differences in indoor allergen sensitivity are consistent with racial differences in asthma morbidity. Along with other data, these findings suggest that racial disparities in housing, community, or both environmental factors play a role in determining national patterns of asthma morbidity.	New York Acad Med, Ctr Urban Epidemiol Studies, New York, NY 10029 USA; New York City Hlth & Hosp Corp, New York, NY USA; Agcy Healthcare Res & Qual, Ctr Primary Care & Res, Rockville, MD USA; Rutgers State Univ, Dept Stat, Piscataway, NJ USA; Rutgers State Univ, Ctr Hlth Hlth Care Policy & Aging Res, Piscataway, NJ USA; Montefiore Med Ctr, Albert Einstein Coll Med, Div Allergy & Immunol, Bronx, NY 10467 USA; Ctr Dis Control & Prevent, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, Atlanta, GA USA	New York Academy of Medicine; Agency for Healthcare Research & Quality; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Centers for Disease Control & Prevention - USA	Stevenson, LA (corresponding author), New York Acad Med, Ctr Urban Epidemiol Studies, 1216 5th Ave, New York, NY 10029 USA.			Mannino, David/0000-0003-3646-7828				[Anonymous], 1994, VITAL HLTH STAT, V32, P1, DOI DOI 10.1136/BMJ.L42; ARLIAN LG, 1992, J ALLERGY CLIN IMMUN, V90, P292, DOI 10.1016/S0091-6749(05)80006-5; BARBEE RA, 1976, ANN INTERN MED, V84, P129, DOI 10.7326/0003-4819-84-2-129; CALL RS, 1992, J PEDIATR-US, V121, P862, DOI 10.1016/S0022-3476(05)80329-4; CARTERPOKRAS OD, 1993, AM J PUBLIC HEALTH, V83, P580, DOI 10.2105/AJPH.83.4.580; CHANYEUNG M, 1995, CLIN EXP ALLERGY, V25, P240, DOI 10.1111/j.1365-2222.1995.tb01035.x; Chew GL, 1999, ALLERGY, V54, P1058, DOI 10.1034/j.1398-9995.1999.00003.x; Christiansen SC, 1996, J ALLERGY CLIN IMMUN, V98, P288, DOI 10.1016/S0091-6749(96)70152-5; Diaz-Sanchez D, 1999, J ALLERGY CLIN IMMUN, V104, P1183, DOI 10.1016/S0091-6749(99)70011-4; DODGE R, 1983, CHEST, V84, P587, DOI 10.1378/chest.84.5.587; Douwes J, 1999, J ALLERGY CLIN IMMUN, V103, P494, DOI 10.1016/S0091-6749(99)70476-8; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573, DOI 10.1164/ajrccm/147.3.573; GERGEN PJ, 1987, J ALLERGY CLIN IMMUN, V80, P669, DOI 10.1016/0091-6749(87)90286-7; GERGEN PJ, 1990, JAMA-J AM MED ASSOC, V264, P1688, DOI 10.1001/jama.264.13.1688; Goodman DC, 1998, PEDIATRICS, V101, P208, DOI 10.1542/peds.101.2.208; Grant EN, 2000, AM J PUBLIC HEALTH, V90, P1923, DOI 10.2105/AJPH.90.12.1923; Halonen M, 1997, AM J RESP CRIT CARE, V155, P1356, DOI 10.1164/ajrccm.155.4.9105079; Homa DM, 2000, AM J RESP CRIT CARE, V161, P504, DOI 10.1164/ajrccm.161.2.9906025; HSU KHK, 1979, J PEDIATR-US, V95, P14, DOI 10.1016/S0022-3476(79)80075-X; Jarvis D, 1997, CLIN EXP ALLERGY, V27, P240; Kitch BT, 2000, ENVIRON HEALTH PERSP, V108, P301, DOI 10.2307/3454347; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; Mannino D M, 1998, MMWR CDC Surveill Summ, V47, P1; MASSICOT JG, 1986, J ALLERGY CLIN IMMUN, V78, P954, DOI 10.1016/0091-6749(86)90284-8; Nel AE, 1998, J ALLERGY CLIN IMMUN, V102, P539, DOI 10.1016/S0091-6749(98)70269-6; Nelson RP, 1996, J ALLERGY CLIN IMMUN, V98, P258, DOI 10.1016/S0091-6749(96)70148-3; Norback D, 1999, INT J TUBERC LUNG D, V3, P368; OHOLLAREN MT, 1991, NEW ENGL J MED, V324, P359, DOI 10.1056/NEJM199102073240602; Phipatanakul W, 2000, J ALLERGY CLIN IMMUN, V106, P1070, DOI 10.1067/mai.2000.110796; Platts-Mills TAE, 2000, J ALLERGY CLIN IMMUN, V105, pS503, DOI 10.1016/S0091-6749(00)90051-4; Platts-Mills TAE, 1998, J ALLERGY CLIN IMMUN, V101, pS364, DOI 10.1016/S0091-6749(98)70221-0; PLATTSMILLS TAE, 1995, INT ARCH ALLERGY IMM, V107, P301, DOI 10.1159/000237008; Ray NF, 1998, CHEST, V113, P1277, DOI 10.1378/chest.113.5.1277; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Ross MA, 2000, ALLERGY, V55, P705, DOI 10.1034/j.1398-9995.2000.00551.x; Sarpong SB, 1998, ANN ALLERG ASTHMA IM, V80, P303, DOI 10.1016/S1081-1206(10)62973-0; Sarpong SB, 1996, J ALLERGY CLIN IMMUN, V97, P1393, DOI 10.1016/S0091-6749(96)70209-9; SEXTON K, 1993, TOXICOL IND HEALTH, V9, P843, DOI 10.1177/074823379300900509; Shah BV, 1997, SUDAAN USERS MANUAL; Stevenson L, 2000, J URBAN HEALTH, V77, P137, DOI 10.1007/BF02350969; TARGONSKI PV, 1994, AM J PUBLIC HEALTH, V84, P1830, DOI 10.2105/AJPH.84.11.1830; *US CENS BUR, 1999, POV US 1998; *US CENS BUR, 1990, CENS HYOUS GEN HOUS, pB8; *US CENS BUR, 1997, AM HOUS SURV 1997 NA; *USDA, 1987, ANN HIST REV FNS PRO; VERHOEFF AP, 1995, AM J EPIDEMIOL, V141, P103, DOI 10.1093/oxfordjournals.aje.a117398; Weiss KB, 2001, J ALLERGY CLIN IMMUN, V107, P3, DOI 10.1067/mai.2001.112262; WICKMAN M, 1991, J ALLERGY CLIN IMMUN, V88, P89, DOI 10.1016/0091-6749(91)90305-8	48	82	82	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2001	108	5					747	752		10.1067/mai.2001.119410	http://dx.doi.org/10.1067/mai.2001.119410			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	498RG	11692099				2022-12-18	WOS:000172523800014
J	Garcia-Casado, G; Crespo, JF; Rodriguez, J; Salcedo, G				Garcia-Casado, G; Crespo, JF; Rodriguez, J; Salcedo, G			Isolation and characterization of barley lipid transfer protein and protein Z as beer allergens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						beer; barley; anaphylaxis; lipid transfer protein; protein Z(4); allergen; double-blinded; placebo-controlled food challenge	ANAPHYLAXIS; URTICARIA	Beer has recently been implicated as the causative agent of contact urticaria and severe IgE-mediated anaphylaxis. However, no allergen from beer has as yet been isolated and characterized. Two major components of 45 kd and 9 kd were detected in crude protein preparations from beer. Both components were purified; they were identified as barley protein Z(4) (45 kd) and lipid transfer protein 1 (LTP1; 9 kd). Protein Z(4) was recognized by the 4 individual sera tested but provoked weak positive responses to skin testing in 2 of 4 beer-allergic patients. Purified LTP1 showed reactivity with 3 of 4 individual sera and induced strong positive skin prick responses in all 4 patients tested. Barley LTP1 and protein Z(4) have been identified as the main beer allergens.	ETS Ingn Agron, Dept Biotechnol, Unidad Bioquim, Madrid 28040, Spain; Hosp Univ Doce Octubre, Serv Alergia, Madrid 28040, Spain	Hospital Universitario 12 de Octubre	Salcedo, G (corresponding author), ETS Ingn Agron, Dept Biotechnol, Unidad Bioquim, Ciudad Univ, Madrid 28040, Spain.							Curioni A, 1999, CLIN EXP ALLERGY, V29, P407, DOI 10.1046/j.1365-2222.1999.00491.x; CURIONI A, 1995, J AGR FOOD CHEM, V43, P2620, DOI 10.1021/jf00058a013; Douliez JP, 2000, J CEREAL SCI, V32, P1, DOI 10.1006/jcrs.2000.0315; Fernandez-Anaya S, 1999, J ALLERGY CLIN IMMUN, V103, P959, DOI 10.1016/S0091-6749(99)70449-5; Figueredo E, 1999, ALLERGY, V54, P630, DOI 10.1034/j.1398-9995.1999.00827.x; HEJGAARD J, 1985, FEBS LETT, V180, P89, DOI 10.1016/0014-5793(85)80238-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Pastorello EA, 2000, J ALLERGY CLIN IMMUN, V106, P744, DOI 10.1067/mai.2000.108712; Sanchez-Monge R, 1999, J ALLERGY CLIN IMMUN, V103, P514, DOI 10.1016/S0091-6749(99)70479-3; Santucci B, 1996, CONTACT DERMATITIS, V34, P368, DOI 10.1111/j.1600-0536.1996.tb02229.x; VANKETEL WG, 1980, CONTACT DERMATITIS, V6, P290	11	82	87	0	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2001	108	4					647	649		10.1067/mai.2001.118793	http://dx.doi.org/10.1067/mai.2001.118793			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	485NK	11590395				2022-12-18	WOS:000171760300028
J	Schmid-Ott, G; Jaeger, B; Adamek, C; Koch, H; Lamprecht, F; Kapp, A; Werfel, T				Schmid-Ott, G; Jaeger, B; Adamek, C; Koch, H; Lamprecht, F; Kapp, A; Werfel, T			Levels of circulating CD8(+) T lymphocytes, natural killer cells, and eosinophils increase upon acute psychosocial stress in patients with atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; psoriasis; T lymphocytes; eosinophils; noradrenaline; stress; coping	ACUTE PSYCHOLOGICAL STRESS; IMMUNOLOGICAL RESPONSE; PSORIASIS PATIENTS; INTERFERON-GAMMA; HEALTHY CONTROLS; SKIN; EXPRESSION; MODULATION; LESIONS; SUBSETS	Background: Different exogenous and endogenous provocation factors such as mental stress are hypothesized as being relevant in the pathophysiology of atopic dermatitis (AD). Objective: The purpose of this study was to examine the effects of acute psychological stress on illness-specific immunologic parameters in AD. Patients with psoriasis and healthy volunteers were investigated in parallel. Methods: Patients with AD (n = 15), patients with psoriasis (n = 15), and control subjects (n = 15) were exposed to mental stress lasting 10 minutes (public speaking, mental arithmetic). In vitro analyses were done 1 hour before, immediately after, and 1 hour after stress exposure. Vital parameters (blood pressure, heart rate) and plasma noradrenaline concentrations were determined to prove the effects of mental stress on the individuals. Lymphocytes were phenotypically analyzed by flow cytometry. Results: The results indicate a higher ability of CD8(+) T lymphocytes to react to stress, including the subpopulations of CD8(+)/CD11b(+) T lymphocytes and eosinophils in patients with AD compared with healthy volunteers. The increases in the subpopulation of CD8(+)/CD11b(+) T lymphocytes on psychological stress were higher in the patients with AD and psoriasis than In healthy control subjects. Significant stress-induced changes of natural killer cells were revealed for all 3 groups. Conclusion: The results suggest that psychological stress has different immunologic effects in patients with AD than in patients with psoriasis and healthy men.	Hannover Med Sch, Dept Psychosomat Med, D-30625 Hannover, Germany; Hannover Med Sch, Dept Dermatol, D-30625 Hannover, Germany	Hannover Medical School; Hannover Medical School	Schmid-Ott, G (corresponding author), Hannover Med Sch, Dept Psychosomat Med, Carl Neuberg Str 1, D-30625 Hannover, Germany.		Werfel, Thomas/B-6921-2012	Kapp, Alexander/0000-0002-1748-6276				ALISON J, 2000, J ALLERGY CLIN IMMUN, V105, P99; Ametz BB, 1985, PSYCHOSOM MED, V47, P528; ARNETZ BB, 1991, ACTA DERM-VENEREOL, P9; BAUME DM, 1990, CELL IMMUNOL, V131, P352, DOI 10.1016/0008-8749(90)90260-X; BENSCHOP RJ, 1994, BRIT J PHARMACOL, V113, P1311, DOI 10.1111/j.1476-5381.1994.tb17141.x; Benschop RJ, 1996, FASEB J, V10, P517, DOI 10.1096/fasebj.10.4.8647351; BuskeKirschbaum A, 1997, PSYCHOSOM MED, V59, P419, DOI 10.1097/00006842-199707000-00012; CHANG JCC, 1994, P NATL ACAD SCI USA, V91, P9282, DOI 10.1073/pnas.91.20.9282; Clausing P, 1996, INT J DEV NEUROSCI, V14, P461; De Panfilis G, 1998, EXP DERMATOL, V7, P121; EHLERS A, 1995, J CONSULT CLIN PSYCH, V63, P624, DOI 10.1037/0022-006X.63.4.624; Elsner J, 1999, ALLERGY, V54, P15, DOI 10.1111/all.1999.54.1.15; Gerritsen W, 1996, PSYCHOSOM MED, V58, P273, DOI 10.1097/00006842-199605000-00011; GINSBURG IH, 1993, INT J DERMATOL, V32, P656, DOI 10.1111/j.1365-4362.1993.tb04021.x; GREWE M, 1994, LANCET, V343, P25, DOI 10.1016/S0140-6736(94)90879-6; Grewe M, 1998, IMMUNOL TODAY, V19, P359, DOI 10.1016/S0167-5699(98)01285-7; Gudmundsdottir AS, 1999, CLIN EXP IMMUNOL, V117, P580; GUPTA MA, 1989, GEN HOSP PSYCHIAT, V11, P166, DOI 10.1016/0163-8343(89)90036-4; JENSEN JR, 1985, ACTA DERM-VENEREOL, P105; JENSEN JR, 1984, J INVEST DERMATOL, V82, P30, DOI 10.1111/1523-1747.ep12259055; Koblenzer CS, 1999, J ALLERGY CLIN IMMUN, V104, pS109, DOI 10.1016/S0091-6749(99)70052-7; Kodama A, 1999, J ALLERGY CLIN IMMUN, V104, P173, DOI 10.1016/S0091-6749(99)70130-2; Kramer U, 1998, BRIT J DERMATOL, V139, P1040; Kronfol Z, 1997, PSYCHOSOM MED, V59, P42, DOI 10.1097/00006842-199701000-00006; LEBWOHL M, 1988, LANCET, V350, P82; Leung DYM, 2000, J ALLERGY CLIN IMMUN, V105, P860, DOI 10.1067/mai.2000.106484; LEUNG DYM, 1995, J EXP MED, V181, P747, DOI 10.1084/jem.181.2.747; LEVER RS, 1984, CLIN ALLERGY, V14, P483, DOI 10.1111/j.1365-2222.1984.tb02232.x; Lonati A, 1999, CLIN EXP IMMUNOL, V115, P1; Mishoe SC, 1998, J ASTHMA, V35, P553, DOI 10.3109/02770909809048958; NALIBOFF BD, 1995, BRAIN BEHAV IMMUN, V9, P207, DOI 10.1006/brbi.1995.1020; Norris DA, 1997, J INVEST DERMATOL, V109, P1, DOI 10.1111/1523-1747.ep12276285; OHMEN JD, 1995, J IMMUNOL, V154, P1956; Orange JS, 1996, J IMMUNOL, V156, P1138; Pawlak CR, 1999, BRAIN BEHAV IMMUN, V13, P287, DOI 10.1006/brbi.1999.0553; Reekers R, 1999, J ALLERGY CLIN IMMUN, V104, P466, DOI 10.1016/S0091-6749(99)70395-7; Ringsberg KC, 1999, J ALLERGY CLIN IMMUN, V103, P601, DOI 10.1016/S0091-6749(99)70231-9; SCHEDLOWSKI M, 1993, J CLIN IMMUNOL, V13, P119, DOI 10.1007/BF00919268; Schmid-Ott G, 1998, PSYCHOTHER PSYCHOSOM, V67, P37, DOI 10.1159/000012257; Schmid-Ott G, 1999, ACTA DERM-VENEREOL, V79, P443; SchmidOtt G, 1996, DERMATOLOGY, V193, P304, DOI 10.1159/000246275; Strickland I, 1999, J INVEST DERMATOL, V112, P249, DOI 10.1046/j.1523-1747.1999.00502.x; Szabo SK, 1998, J INVEST DERMATOL, V111, P1072, DOI 10.1046/j.1523-1747.1998.00419.x; Werfel T, 1998, ALLERGY, V53, P731; Werfel T, 1996, J INVEST DERMATOL, V107, P871, DOI 10.1111/1523-1747.ep12331164; ZACHARY CB, 1983, BRIT J DERMATOL, V108, P411, DOI 10.1111/j.1365-2133.1983.tb04593.x	46	82	83	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2001	107	1					171	177		10.1067/mai.2001.111850	http://dx.doi.org/10.1067/mai.2001.111850			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	394PW	11150008				2022-12-18	WOS:000166533300028
J	Coreno, A; Skowronski, M; Kotaru, C; McFadden, ER				Coreno, A; Skowronski, M; Kotaru, C; McFadden, ER			Comparative effects of long-acting beta(2)-agonists, leukotriene receptor antagonists, and a 5-lipoxygenase inhibitor on exercise-induced asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						exercise-induced asthma; beta(2)-agonist; leukotriene receptor antagonist; 5-lipoxygenase inhibitor	INDUCED BRONCHOCONSTRICTION; INDUCED BRONCHOSPASM; REFRACTORY PERIOD; MONTELUKAST; SALMETEROL; CHILDREN; ZAFIRLUKAST; PROTECTION; DURATION	Background: Exercise-induced asthma (EIA) is a common problem that can be controlled with long-acting beta-agonists and leukotriene-modifying compounds. There is, however, limited information on the comparative effectiveness of the two classes of drugs, as well as the relative potencies of the antileukotriene agents. Objective: The purpose of the present study was to provide data on the above issues. Methods: We performed a random-order, blinded, double-dummy, placebo-controlled trial in 10 patients with EIA. Each subject received standard single doses of salmeterol, montelukast, zafirlukast, zileuton, and placebo on separate days. The participants performed 4 minutes of cycle ergometry while breathing frigid air 1, 4, 8, and 12 hours after administration of the test agents. The primary endpoint was the extent of the decrement in the FEV1 10 minutes after exertion. Results: With placebo, symptomatic airway narrowing developed at all times (mean +/- SE decrease in FEV1 ranged between 21% +/- 5% and 26% +/- 5%). Salmeterol acted quickly and significantly blunted the obstructive response for 12 hours (Delta FEV1 first hour: 8% +/- 3%; Delta FEV1 twelfth hour: 8% +/- 3%; P < .0001 vs placebo and P = .72 vs time). The leukotriene-modifying agents produced effects within 1 hour of ingestion. Like salmeterol, montelukast and zafirlukast also offered long-lasting protection, and there were no significant differences between them (montelukast Delta FEV1 twelfth hour: 9% +/- 4%; zafirlukast Delta FEV1 twelfth hour: 11% +/- 2%; P = .75) or the beta(2)-agonist (montelukast vs salmeterol: P = .72; zafirlukast vs salmeterol: P = .48). Zileuton provided equivalent prophylaxis for the first 4 hours (Delta FEV1 fourth hour: 11% +/- 2%); however, by 8 hours, it was less efficacious than all of the other active compounds, and by 12 hours it did not differ from placebo (Delta FEV1 twelfth hour: 19% +/- 4%; P = .33). Conclusions: Single doses of the currently available leukotriene receptor antagonists provide prompt effective and persistent defense against EIA that equals that seen with a long-acting beta(2)-agonist. The synthesis inhibitor zileuton affords a comparable magnitude of prophylaxis but has a considerably shorter duration of action.	Univ Hosp Cleveland, Div Pulm & Crit Care Med, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Airway Dis Ctr, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Med, Cleveland, OH 44106 USA	University Hospitals of Cleveland; University Hospitals of Cleveland; Case Western Reserve University	McFadden, ER (corresponding author), Univ Hosp Cleveland, Div Pulm & Crit Care Med, 11100 Euclid Ave, Cleveland, OH 44106 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000080] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033791] Funding Source: NIH RePORTER; NCRR NIH HHS [MO 1 RR 00080] Funding Source: Medline; NHLBI NIH HHS [HL-07288, HL-33791] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adelroth E, 1997, J ALLERGY CLIN IMMUN, V99, P210, DOI 10.1016/S0091-6749(97)70098-8; Bronsky EA, 1997, CLIN PHARMACOL THER, V62, P556, DOI 10.1016/S0009-9236(97)90051-5; Calhoun WJ, 1998, AM J RESP CRIT CARE, V157, pS238, DOI 10.1164/ajrccm.157.6.mar6; DEAL EC, 1979, J APPL PHYSIOL, V46, P467, DOI 10.1152/jappl.1979.46.3.467; Edelman JM, 2000, ANN INTERN MED, V132, P97, DOI 10.7326/0003-4819-132-2-200001180-00002; EDMUNDS AT, 1978, AM REV RESPIR DIS, V117, P247; FINNERTY JP, 1992, AM REV RESPIR DIS, V145, P746, DOI 10.1164/ajrccm/145.4_Pt_1.746; GILBERT IA, 1988, J APPL PHYSIOL, V64, P2167, DOI 10.1152/jappl.1988.64.5.2167; KEMP JP, 1994, AM J RESP CRIT CARE, V150, P1612, DOI 10.1164/ajrccm.150.6.7952623; Kemp JP, 1998, J PEDIATR-US, V133, P424, DOI 10.1016/S0022-3476(98)70281-1; Leff JA, 1998, NEW ENGL J MED, V339, P147, DOI 10.1056/NEJM199807163390302; MCFADDEN ER, 1986, J CLIN INVEST, V78, P18, DOI 10.1172/JCI112549; MCFADDEN ER, 1994, NEW ENGL J MED, V330, P1362, DOI 10.1056/NEJM199405123301907; Meltzer SS, 1996, AM J RESP CRIT CARE, V153, P931, DOI 10.1164/ajrccm.153.3.8630575; Nelson JA, 1998, NEW ENGL J MED, V339, P141, DOI 10.1056/NEJM199807163390301; PATESSIO A, 1991, EUR RESPIR J, V4, P296; Pearlman DS, 1999, J PEDIATR-US, V134, P273, DOI 10.1016/S0022-3476(99)70449-X; Reiss TF, 1997, THORAX, V52, P1030, DOI 10.1136/thx.52.12.1030; ROSSING TH, 1982, J APPL PHYSIOL, V52, P1119, DOI 10.1152/jappl.1982.52.5.1119; SILVERMAN M, 1972, ARCH DIS CHILD, V47, P882, DOI 10.1136/adc.47.256.882; STEARNS DR, 1981, J APPL PHYSIOL, V50, P503, DOI 10.1152/jappl.1981.50.3.503; Villaran C, 1999, J ALLERGY CLIN IMMUN, V104, P547, DOI 10.1016/S0091-6749(99)70322-2; Zar J.H, 1999, BIOSTAT ANAL, V4th	23	82	82	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2000	106	3					500	506						7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	356YN	10984370				2022-12-18	WOS:000089471900013
J	Lilly, CM; Woodruff, PG; Camargo, CA; Nakamura, H; Drazen, JM; Nadel, ES; Hanrahan, JP				Lilly, CM; Woodruff, PG; Camargo, CA; Nakamura, H; Drazen, JM; Nadel, ES; Hanrahan, JP			Elevated plasma eotaxin levels in patients with acute asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						chemokines; emergency medicine; lung; pulmonary diseases	BRONCHOALVEOLAR LAVAGE; ATOPIC ASTHMA; RECEPTOR CCR3; EXPRESSION; INFLAMMATION; CELLS; EOSINOPHILS; ACTIVATION; CHEMOKINES; POPULATION	Background: The eosinophil chemotactic and activating effects of eotaxin and the known association of eosinophils with asthma suggest that eotaxin expression is increased during asthma exacerbations. Objective: We sought to determine whether plasma eotaxin levels are elevated in patients presenting for emergency treatment of acute asthma and to correlate eotaxin levels with disease activity and responses to treatment. Methods: A case-control study of plasma eotaxin levels was performed in the 36 patients who presented for emergency asthma treatment and 133 age-, sex-, and ethnicity-matched subjects with stable asthma, Results: Plasma eotaxin levels were significantly higher in 36 patients with acute asthma symptoms and airflow obstruction (520 pg/mL [250, 1100 pg/mL]; geometric mean [-1 SD, +1 SD]) than in 133 subjects with stable asthma (350 pg/mL [190, 620 pg/ml]; P = .0008), Among the patients with emergency asthma flares, those who responded to asthma treatment with an increase in peak expiratory flow rate by an amount equal to at least 20% of their predicted normal value had lower eotaxin levels than those who did not (410 pg/mL [210, 800 pg/mL] and 660 pg/mL [300, 1480 pg/mL], respectively; P = .01). Conclusion: These findings imply that eotaxin either is mechanistically involved in acute asthma or series as a biomarker for activity of the CCR3 receptor ligand system, which is functionally linked to asthma.	Brigham & Womens Hosp, Div Resp, Combined Program Pulm & Crit Care Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Channing Lab, Dept Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Emergency Med, Boston, MA 02115 USA; Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA; Beth Israel Deaconess Med Ctr, Dept Emergency Med, Boston, MA USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Lilly, CM (corresponding author), Brigham & Womens Hosp, Div Resp, Combined Program Pulm & Crit Care Med, 75 Francis St, Boston, MA 02115 USA.		Camargo, Carlos A./C-2145-2008	Camargo, Carlos A./0000-0002-5071-7654	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007427, K08HL003283] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-07427, HL-03533, HL-03283] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; Brown JR, 1998, CLIN EXP IMMUNOL, V114, P137; CAMARGO CA, 1998, AM J RESP CRIT CARE, V157, pA623; CUZICK J, 1985, STAT MED, V4, P87, DOI 10.1002/sim.4780040112; Daugherty BL, 1996, J EXP MED, V183, P2349, DOI 10.1084/jem.183.5.2349; DUNNILL MS, 1960, J CLIN PATHOL, V13, P27, DOI 10.1136/jcp.13.1.27; Elsner J, 1996, EUR J IMMUNOL, V26, P1919, DOI 10.1002/eji.1830260837; LAITINEN A, 1991, AM REV RESPIR DIS, V143, P1159, DOI 10.1164/ajrccm/143.5_Pt_1.1159; Lamkhioued B, 1997, J IMMUNOL, V159, P4593; Lilly CM, 1997, J CLIN INVEST, V99, P1767, DOI 10.1172/JCI119341; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; NAKAMURA H, 1999, IN PRESS AM J RESP C; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROCA J, 1986, B EUR PHYSIOPATH RES, V22, P217; Sallusto F, 1997, SCIENCE, V277, P2005, DOI 10.1126/science.277.5334.2005; Uguccioni M, 1997, J CLIN INVEST, V100, P1137, DOI 10.1172/JCI119624; Vignola AM, 1998, AM J RESP CRIT CARE, V157, P403, DOI 10.1164/ajrccm.157.2.96-08040; WARDLAW AJ, 1988, AM REV RESPIR DIS, V137, P62, DOI 10.1164/ajrccm/137.1.62; Ying S, 1997, EUR J IMMUNOL, V27, P3507, DOI 10.1002/eji.1830271252	19	82	90	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1999	104	4	1				786	790		10.1016/S0091-6749(99)70288-5	http://dx.doi.org/10.1016/S0091-6749(99)70288-5			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	248NG	10518822				2022-12-18	WOS:000083281200009
J	Gershman, NH; Liu, H; Wong, HH; Liu, JT; Fahy, JV				Gershman, NH; Liu, H; Wong, HH; Liu, JT; Fahy, JV			Fractional analysis of sequential induced sputum samples during sputum induction: Evidence that different lung compartments are sampled at different time points	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; sputum induction; induced sputum; hypertonic saline; eosinophil; eosinophil cationic protein; neutrophil; mucin; surfactant protein A; fibrinogen	HEALTHY-SUBJECTS; ASTHMATIC SUBJECTS; DISEASE	Background: The effect of the duration of sputum induction on markers of inflammation in induced sputum is unknown, and the optimal duration of sputum induction for research purposes in airway disease is uncertain. Objective: We sought to determine whether the duration of sputum induction influences the cellular or biochemical characteristics of induced sputum. Methods: Induced sputum was collected sequentially at 4-minute intervals during a 20-minute sputum induction in 12 subjects with mild and moderate asthma. Each 1-minute sample was collected and analyzed separately for total and differential cell counts and for levels of eosinophil cationic protein, fibrinogen, mucin-like glycoprotein, and surfactant protein SP-A. Results: The percentages of eosinophils and neutrophils were significantly higher at the beginning of the 20-minute sputum induction than at the end, whereas the percentage of macrophages was significantly lower at the beginning than at the end. In addition, the levels of eosinophil cationic protein and mucin-like glycoprotein were significantly higher at the beginning of the 20-minute induction than at the end, whereas the level of surfactant protein SP-A was significantly lower. Conclusions: The duration of sputum induction significantly affects the cellular and biochemical composition of induced sputum in a manner suggesting that large airways are sampled at the beginning of sputum induction, whereas peripheral airways and alveoli are sampled at later time periods. Our data demonstrate the importance of standardizing the duration of sputum induction in clinical research studies, and on the basis of these data, we have chosen 12 minutes as the optimal duration for sputum induction in asthmatic subjects.	Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Fahy, JV (corresponding author), Univ Calif San Francisco, Dept Med, Box 0111,505 Parnassus Ave, San Francisco, CA 94143 USA.							Diamant Z, 1997, AM J RESP CRIT CARE, V155, P1247, DOI 10.1164/ajrccm.155.4.9105062; FAHY JV, 1995, AM J RESP CRIT CARE, V152, P53, DOI 10.1164/ajrccm.152.1.7599862; FAHY JV, 1993, AM REV RESPIR DIS, V147, P1132, DOI 10.1164/ajrccm/147.5.1132; FAHY JV, 1993, AM REV RESPIR DIS, V147, P1126, DOI 10.1164/ajrccm/147.5.1126; Gershman NH, 1996, EUR RESPIR J, V9, P2448, DOI 10.1183/09031936.96.09122448; HAAGSMAN HP, 1989, AM J PHYSIOL, V257, pL421, DOI 10.1152/ajplung.1989.257.6.L421; Holz O, 1998, CLIN EXP ALLERGY, V28, P284; IREDALE MJ, 1994, CLIN EXP ALLERGY, V24, P940, DOI 10.1111/j.1365-2222.1994.tb02725.x; Keatings VM, 1996, AM J RESP CRIT CARE, V153, P530, DOI 10.1164/ajrccm.153.2.8564092; Mason RJ, 1998, AM J PHYSIOL-LUNG C, V275, pL1, DOI 10.1152/ajplung.1998.275.1.L1; PIN I, 1992, AM REV RESPIR DIS, V145, P1265, DOI 10.1164/ajrccm/145.6.1265; SPANAVELLO A, 1997, AM J RESP CRIT CARE, V157, P665	12	82	89	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1999	104	2	1				322	328		10.1016/S0091-6749(99)70374-X	http://dx.doi.org/10.1016/S0091-6749(99)70374-X			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	232HH	10452752	Bronze			2022-12-18	WOS:000082364800023
J	Simons, FER				Simons, FER		ETAC Study Grp	Prospective, long-term safety evaluation of the H-1-receptor antagonist cetirizine in very young children with atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; allergy; infant; child; H-1-receptor antagonist; antihistamine; long-term safety; somnolence; QTc interval; randomized trial	SEASONAL ALLERGIC RHINITIS; DOUBLE-BLIND; ASTEMIZOLE OVERDOSE; PHARMACOKINETICS; PROMETHAZINE; KETOTIFEN; PLACEBO	Background: In very young children, Hi-receptor antagonists have not been adequately studied, although they are widely used and assumed to be safe. Objective: Our objective was to test the hypothesis that cetirizine would be as safe as placebo for long-term use in this population. Methods: In the prospective, double-blind, parallel-group, 18-month-long Early Treatment of the Atopic Child (ETAC) study, 817 children with atopic dermatitis who were 12 to 24 months old at study entry were randomized to receive either cetirizine 0.25 mg/kg or placebo twice daily. Safety was assessed by using the reports of all adverse events, diary cards, physical examinations, developmental assessments, electrocardiograms, blood hematology and chemistry tests, and urinalyses, Results: The population evaluated for safety consisted of 399 children receiving cetirizine and 396 children receiving placebo. Drop-outs and serious events, including hospitalizations, occurred infrequently and were less common in the children receiving cetirizine than in those children receiving placebo, although the differences were not statistically significant, Most reported symptoms and events were mild and were attributed to intercurrent respiratory or gastrointestinal infections, exacerbations of allergic disorders, or age-related concerns father than to medication-related adverse effects, There were no clinically relevant differences between the groups for neurologic or cardiovascular symptoms or events, growth, behavioral or developmental assessments, laboratory test results, or electrocardiograms, and no child receiving cetirizine therapy had prolongation of the QTc interval, Conclusions: The safety of cetirizine has been confirmed in this prospective study, the largest and longest randomized, double-blind, placebo-controlled safety investigation of any H-1-antagonist ever conducted in children and the longest prospective safety study of any H-1-antagonist ever conducted in any age group.	Univ Manitoba, Dept Pediat & Child Hlth, Allergy & Clin Immunol Sect, Winnipeg, MB R3T 2N2, Canada	University of Manitoba	Simons, FER (corresponding author), Childrens Hosp Winnipeg, 820 Sherbrook St, Winnipeg, MB R3A 1R9, Canada.							Allegra L, 1993, Pediatr Allergy Immunol, V4, P157, DOI 10.1111/j.1399-3038.1993.tb00085.x; BAELDE Y, 1992, DRUG INVEST, V4, P466, DOI 10.1007/BF03259210; DAHL RE, 1995, ARCH PEDIAT ADOL MED, V149, P856, DOI 10.1001/archpedi.1995.02170210030005; de Longueville M, 1997, PEDIATR ALLERGY IMMU, V8, P177; de Longueville M, 1998, J ALLERGY CLIN IMMUN, V101, pS198; DESAGER JP, 1993, CLIN PHARMACOL THER, V53, P431, DOI 10.1038/clpt.1993.47; DOLLBERG S, 1989, ACTA PAEDIATR SCAND, V78, P131, DOI 10.1111/j.1651-2227.1989.tb10902.x; GOETZ CM, 1990, AM J EMERG MED, V8, P321, DOI 10.1016/0735-6757(90)90085-E; GROSWASSER J, 1995, PEDIAT ALLERGY IMM S, V6, P96; HICKSON GB, 1990, PEDIATRICS, V86, P221; HOPPU K, 1991, LANCET, V338, P538, DOI 10.1016/0140-6736(91)91101-Y; JOBST S, 1994, ALLERGY, V49, P598, DOI 10.1111/j.1398-9995.1994.tb00125.x; KOGAN MD, 1994, JAMA-J AM MED ASSOC, V272, P1025, DOI 10.1001/jama.272.13.1025; LAROSA M, 1994, ANN ALLERGY, V73, P117; LEBLAYE I, 1992, DRUG SAFETY, V7, P387, DOI 10.2165/00002018-199207050-00007; MAGERA BE, 1981, PEDIATRICS, V67, P280; Masi M, 1993, Pediatr Allergy Immunol, V4, P47; McCarthy D, 1972, MANUAL MCCARTHY SCAL; Orange AP, 1997, PEDIAT ALLERG IMM-UK, V8, P28, DOI 10.1111/j.1399-3038.1997.tb00139.x; PARIENTEKHAYAT A, 1995, INT J CLIN PHARM TH, V33, P340; Pearlman DS, 1997, CLIN PEDIATR, V36, P209, DOI 10.1177/000992289703600405; REILLY J F JR, 1990, Journal of Emergency Medicine, V8, P59, DOI 10.1016/0736-4679(90)90389-D; RICHMAN N, 1971, J CHILD PSYCHOL PSYC, V12, P5, DOI 10.1111/j.1469-7610.1971.tb01047.x; Ridout SM, 1997, J ALLERGY CLIN IMMUN, V99, P860, DOI 10.1016/S0091-6749(97)80028-0; SIMONS FER, 1995, J ALLERGY CLIN IMMUN, V95, P759, DOI 10.1016/S0091-6749(95)70183-4; SIMONS FER, 1994, NEW ENGL J MED, V330, P1663; SIMONS FER, 1996, HISTAMINE H1 RECEPTO, P329; SMITH MBH, 1993, JAMA-J AM MED ASSOC, V269, P2258, DOI 10.1001/jama.269.17.2258; Spicak V, 1997, CLIN PHARMACOL THER, V61, P325; TOBIN JR, 1991, JAMA-J AM MED ASSOC, V266, P2737, DOI 10.1001/jama.266.19.2737; WAHN U, 1998, PEDIATR ALLERGY IMMU, V9, P116; Watemberg NM, 1999, PEDIATRICS, V103, P158, DOI 10.1542/peds.103.1.158; WATSON WTA, 1989, J ALLERGY CLIN IMMUN, V84, P457, DOI 10.1016/0091-6749(89)90358-8; WILEY JF, 1992, J PEDIATR-US, V120, P799, DOI 10.1016/S0022-3476(05)80252-5; Winder J., 1996, Journal of Allergy and Clinical Immunology, V97, P342, DOI 10.1016/S0091-6749(96)80858-X; WYNGAARDEN JB, 1951, JAMA-J AM MED ASSOC, V145, P277, DOI 10.1001/jama.1951.02920230001001; YOKOYAMA H, 1993, METHOD FIND EXP CLIN, V15, P183	37	82	91	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1999	104	2	1				433	440		10.1016/S0091-6749(99)70389-1	http://dx.doi.org/10.1016/S0091-6749(99)70389-1			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	232HH	10452767				2022-12-18	WOS:000082364800038
J	Bayram, H; Devalia, JL; Khair, OA; Abdelaziz, MM; Sapsford, RJ; Sagai, M; Davies, RJ				Bayram, H; Devalia, JL; Khair, OA; Abdelaziz, MM; Sapsford, RJ; Sagai, M; Davies, RJ			Comparison of ciliary activity and inflammatory mediator release from bronchial epithelial cells of nonatopic nonasthmatic subjects and atopic asthmatic patients and the effect of diesel exhaust particles in vitro	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic asthma; diesel exhaust particles; bronchial epithelial cells; ciliary beat frequency; cytokines; sICAM-1	PARTICULATE AIR-POLLUTION; COLONY-STIMULATING FACTOR; ACTIVITY IN-VITRO; GM-CSF; EXPRESSION; EOSINOPHILS; RANTES; INTERLEUKIN-8; INFILTRATION; LYMPHOCYTES	Background: Recent studies have suggested that asthmatic patients may be more susceptible to the adverse effects of air pollutants, including diesel exhaust particles (DEP), The underlying mechanisms, however, are not clear. Methods: We cultured bronchial epithelial cells from bronchial biopsy specimens of well-characterized groups of nonatopic, nonasthmatic individuals and atopic patients with mild asthma and compared the ciliary beat frequency (CBF) and release of IL-8, GM-CSF, regulated on activation, normal T-cell expressed and secreted (RANTES), and soluble intercellular adhesion molecule-1 (sICAM-1) from these cells both before and after exposure for 24 hours to 10 to 100 mu g/mL DEP in vitro. Results: The baseline CBF was not found to be significantly different in the bronchial epithelial cell cultures of nonasthmatic and asthmatic individuals. Incubation with DEP significantly attenuated the CBF of both the nonasthmatic and asthmatic bronchial epithelial cell cultures at all concentrations of DEP investigated and were maximal (55.5% and 45.2%, respectively) after incubation with 100 mu g/mL DEP. The bronchial epithelial cell cultures of asthmatic patients constitutively released significantly greater amounts of IL-8, GM-CSF, and sICAM-1 than bronchial epithelial cell cultures of nonasthmatic subjects. The cultures of only asthmatic patients additionally released RANTES. incubation of the asthmatic cultures with 10 mu g/mL DEP significantly increased the release of IL-8 (from 102.0 to 167.8 pg/mu g cellular protein: P < .01), GM-CSF (from 0.43 to 1.87 pd/mu g cellular protein; P < .01), and sICAM-1 (from 14.7 to 38.1 pg/mu g cellular protein; P < .02) after 24 hours. Incubation with 50 to 100 mu g/mL DEP, however, significantly decreased the release of IL-8 and RANTES from these cultures. In contrast, only the higher concentrations of 50 to 100 mu g/mL DEP significantly increased release of IL-8 (from 37.9 to 71.5 pg/mu g cellular protein; P < .05) and GM-CSF (from 0.06 to 0.31 pg/mu g cellular protein: P < .05) from the bronchial epithelial cells of nonasthmatic individuals. Conclusions: These results suggest that bronchial epithelial cells of asthmatic subjects are different from bronchial epithelial cells of nonasthmatic subjects with regard to the amounts and types of proinflammatory mediators they can release and that the increased sensitivity of bronchial epithelial cells of asthmatic subjects to DEP may possibly result in exacerbation of their disease symptoms.	London Chest Hosp, St Bartholomews & Royal London Sch Med & Dent, Acad Dept Resp Med, London E2 9JX, England; Natl Inst Environm Studies, Res Team Hlth Effects Air Pollutants, Tsukuba, Ibaraki, Japan	University of London; Queen Mary University London; National Institute for Environmental Studies - Japan	Devalia, JL (corresponding author), London Chest Hosp, St Bartholomews & Royal London Sch Med & Dent, Acad Dept Resp Med, Bonner Rd, London E2 9JX, England.		Bayram, Hasan/ABE-5094-2021	Bayram, Hasan/0000-0002-5236-766X				ALAM R, 1993, J IMMUNOL, V150, P3442; AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; Bayram H, 1998, AM J RESP CELL MOL, V18, P441, DOI 10.1165/ajrcmb.18.3.2882; Bayram H., 1997, European Respiratory Journal Supplement, V10, p457S; Berkman N, 1996, AM J RESP CRIT CARE, V154, P1804, DOI 10.1164/ajrccm.154.6.8970374; Bloemen PGM, 1997, CLIN EXP ALLERGY, V27, P128; Borish L, 1996, J ALLERGY CLIN IMMUN, V97, P719, DOI 10.1016/S0091-6749(96)80146-1; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; Calderon MA, 1997, J ALLERGY CLIN IMMUN, V99, P65, DOI 10.1016/S0091-6749(97)70302-6; CALDERON MA, 1994, CLIN EXP ALLERGY, V24, P166; DEVALIA JL, 1993, AM J RESP CELL MOL, V9, P271, DOI 10.1165/ajrcmb/9.3.271; DEVALIA JL, 1990, RESP MED, V84, P303, DOI 10.1016/S0954-6111(08)80058-3; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; Freshney R. I., 1987, CULTURE ANIMAL CELLS, P107; GLEICH GJ, 1990, J ALLERGY CLIN IMMUN, V85, P422, DOI 10.1016/0091-6749(90)90151-S; Gormand F, 1995, PULM PHARMACOL, V8, P107, DOI 10.1006/pulp.1995.1013; ICHINOSE T, 1995, TOXICOLOGY, V99, P153, DOI 10.1016/0300-483X(94)03013-R; ISHIZAKI T, 1987, ANN ALLERGY, V58, P265; KUMAGAI Y, 1995, FREE RADICAL BIO MED, V18, P365, DOI 10.1016/0891-5849(94)00125-4; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARINI M, 1992, J ALLERGY CLIN IMMUN, V89, P1001, DOI 10.1016/0091-6749(92)90223-O; Mori Y, 1996, J TOXICOL ENV HEALTH, V47, P125, DOI 10.1080/009841096161834; OHASHI Y, 1992, AM REV RESPIR DIS, V145, P1469, DOI 10.1164/ajrccm/145.6.1469; Peroni DG, 1996, EUR RESPIR J, V9, P2236, DOI 10.1183/09031936.96.09112236; Peters A, 1997, AM J RESP CRIT CARE, V155, P1376, DOI 10.1164/ajrccm.155.4.9105082; POPE CA, 1991, AM REV RESPIR DIS, V144, P668, DOI 10.1164/ajrccm/144.3_Pt_1.668; POPE CA, 1995, AM J RESP CRIT CARE, V151, P669, DOI 10.1164/ajrccm/151.3_Pt_1.669; POSTON RN, 1992, AM REV RESPIR DIS, V145, P918, DOI 10.1164/ajrccm/145.4_Pt_1.918; Rudell B., 1996, European Respiratory Journal Supplement, V9, p439S; RUDELL B, 1990, J AEROSOL SCI, V21, P5411; SAGAI M, 1993, FREE RADICAL BIO MED, V14, P37, DOI 10.1016/0891-5849(93)90507-Q; Sagai M, 1996, FREE RADICAL BIO MED, V21, P199, DOI 10.1016/0891-5849(96)00032-9; Salvi S. S., 1996, European Respiratory Journal Supplement, V9, p415S; SCHWARTZ J, 1993, AM REV RESPIR DIS, V147, P826, DOI 10.1164/ajrccm/147.4.826; SOUSA AR, 1994, AM J RESP CELL MOL, V10, P142, DOI 10.1165/ajrcmb.10.2.8110469; ULFVARSON U, 1995, AM J IND MED, V27, P91, DOI 10.1002/ajim.4700270109; VIGNOLA AM, 1993, AM REV RESPIR DIS, V148, P689, DOI 10.1164/ajrccm/148.3.689; VONMUTIUS E, 1992, BMJ-BRIT MED J, V305, P1395, DOI 10.1136/bmj.305.6866.1395; Wang JH, 1997, EUR RESPIR J, V10, P834; 1991, J ALLERGY CLIN IMMUN, V88, P808	41	82	84	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1998	102	5					771	782		10.1016/S0091-6749(98)70017-X	http://dx.doi.org/10.1016/S0091-6749(98)70017-X			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	139MR	9819294	Bronze			2022-12-18	WOS:000077033400011
J	Chen, ZP; Posch, A; Cremer, R; Raulf-Heimsoth, M; Baur, X				Chen, ZP; Posch, A; Cremer, R; Raulf-Heimsoth, M; Baur, X			Identification of hevein (Hev b 6.02) in Hevea latex as a major cross-reacting allergen with avocado fruit in patients with latex allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						latex allergy; avocado allergy; hevein; cross-reactivity; IgE; immunoblotting	NATURAL-RUBBER LATEX; IGE-BINDING POLYPEPTIDE; BRASILIENSIS; ANTIBODIES; PREVALENCE; PROHEVEIN; EPITOPE; HEV-B-1; PAPAIN; NURSES	Background: Recent studies demonstrated that allergy to natural rubber latex is frequently associated with hypersensitivity to avocado fruit. The responsible cross-sensitizing allergen has not been identified. Objective: The purpose of this study was to investigate the cross-reactivity of a latex major allergen, hevein, with avocado proteins. Methods: Serum samples from 118 health care workers (HCWs) allergic to latex (HCW group) and 78 patients with spina bifida (SB) allergic to latex (SB group) were included in this study Anti-hevein and anti-avocado IgE antibodies were measured by enzyme-linked allergosorbent assay, Cross-reactivity of hevein to avocado proteins was assessed by inhibition of the IgE binding in individual patients' sera containing IgE antibodies to both hevein and avocado. Results: The prevalence of seropositive IgE antibodies to avocado was found to be strongly associated with the presence of hevein-specific IgE antibodies in subjects of both groups (P <.001). Sixty-seven of 91 (73%) subjects from the HCW group and all 19 subjects in the SE group with positive IgE antibodies to hevein also had elevated IgE values to avocado. Competitive RAST inhibition with 42 sera showed that IgE binding to avocado could be completely inhibited in 27 (64%) sera by preincubation with hevein. By contrast, the degrees of inhibition of IgE to hevein by avocado extract ranged from 0% to 36% (n = 16), These results indicate that sensitization to avocado in most patients allergic to latex is caused exclusively by IgE-binding epitopes present in hevein. Results of immunoblots and immunoblot inhibition with 11 serum samples confirmed that a 30-kd protein in avocado was the major IgE-binding component; the IgE-binding reactivity to this protein could be inhibited by hevein in all sera tested. Conclusion: Hevein is the major cross-reacting allergen with avocado in subjects with latex allergy.	Ruhr Univ Bochum, Res Inst Occupat Med, D-44789 Bochum, Germany; Childrens Hosp, Cologne, Germany	Ruhr University Bochum	Chen, ZP (corresponding author), Ruhr Univ Bochum, Res Inst Occupat Med, Buerkle Camp Pl 1, D-44789 Bochum, Germany.							AHLROTH M, 1995, J ALLERGY CLIN IMMUN, V96, P167, DOI 10.1016/S0091-6749(95)70004-8; ALENIUS H, 1995, CLIN EXP ALLERGY, V25, P659, DOI 10.1111/j.1365-2222.1995.tb01114.x; Alenius H, 1996, J IMMUNOL, V156, P1618; BAUR X, 1995, ALLERGY, V50, P604, DOI 10.1111/j.1398-9995.1995.tb01208.x; BEEZHOLD DH, 1994, CLIN EXP IMMUNOL, V98, P408; Beezhold DH, 1996, CLIN EXP ALLERGY, V26, P416, DOI 10.1046/j.1365-2222.1996.d01-334.x; Beezhold DH, 1997, CLIN EXP IMMUNOL, V108, P114, DOI 10.1046/j.1365-2249.1997.d01-983.x; BEINTEMA JJ, 1992, FEBS LETT, V299, P211; BLANCO C, 1994, ANN ALLERGY, V73, P309; BLANCO C, 1994, ALLERGY, V49, P454, DOI 10.1111/j.1398-9995.1994.tb00839.x; Brehler R, 1997, ALLERGY, V52, P404, DOI 10.1111/j.1398-9995.1997.tb01019.x; CEUPPENS JL, 1992, LANCET, V339, P493, DOI 10.1016/0140-6736(92)91101-D; Chen Z, 1996, CLIN EXP ALLERGY, V26, P406, DOI 10.1046/j.1365-2222.1996.d01-327.x; Chen Z, 1996, J ALLERGY CLIN IMMUN, V97, P982; Chen ZP, 1997, J ALLERGY CLIN IMMUN, V99, P402, DOI 10.1016/S0091-6749(97)70059-9; Grzybowski M, 1996, J ALLERGY CLIN IMMUN, V98, P535, DOI 10.1016/S0091-6749(96)70087-8; LAGIER F, 1992, J ALLERGY CLIN IMMUN, V90, P319, DOI 10.1016/S0091-6749(05)80009-0; LAVAUD F, 1992, LANCET, V339, P492, DOI 10.1016/0140-6736(92)91100-M; LAVAUD F, 1995, J ALLERGY CLIN IMMUN, V95, P557, DOI 10.1016/S0091-6749(95)70318-7; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Posch A, 1997, J ALLERGY CLIN IMMUN, V99, P385, DOI 10.1016/S0091-6749(97)70057-5; ROSS BD, 1992, J ALLERGY CLIN IMMUN, V90, P409, DOI 10.1016/S0091-6749(05)80023-5; SOEDJANAATMADJA UMS, 1995, FEBS LETT, V363, P211, DOI 10.1016/0014-5793(95)00309-W; Turjanmaa K, 1996, ALLERGY, V51, P593, DOI 10.1111/j.1398-9995.1996.tb04678.x; TURJANMAA K, 1987, CONTACT DERMATITIS, V17, P270, DOI 10.1111/j.1600-0536.1987.tb01476.x; Vandenplas O, 1996, J ALLERGY CLIN IMMUN, V97, P1421, DOI 10.1016/S0091-6749(96)70216-6; YASSIN MS, 1994, ANN ALLERGY, V72, P245	27	82	82	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1998	102	3					476	481		10.1016/S0091-6749(98)70138-1	http://dx.doi.org/10.1016/S0091-6749(98)70138-1			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	124ZN	9768591	Bronze			2022-12-18	WOS:000076212800024
J	Sander, I; Raulf-Heimsoth, M; Siethoff, C; Lohaus, C; Meyer, HE; Baur, X				Sander, I; Raulf-Heimsoth, M; Siethoff, C; Lohaus, C; Meyer, HE; Baur, X			Allergy to Aspergillus-derived enzymes in the baking industry: Identification of beta-xylosidase from Aspergillus niger as a new allergen (Asp n 14)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Baker's asthma; endoxylanase; beta-xylosidase; cellulase; glucoamylase; alpha-amylase; Aspergillus; enzyme	ALPHA-AMYLASE; BAKERS ASTHMA; PROTEINS; FUMIGATUS; EXPOSURE; SENSITIZATION; ADDITIVES; IGE	Background: Aspergillus-derived enzymes are used in dough improvers in bakeries. Some of these enzymes are identified as causing IgE-mediated sensitization in up to 25% of bakers with workplace-related symptoms. Objective: The aim of this study was to compare the frequency of sensitization to Aspergillus xylanase, cellulase, and glucoamylase with the sensitization to a-amylase (Asp o 2) and to identify IgE-reactive proteins in enzyme preparations. Methods: Sensitization to Aspergillus-derived enzymes and cross-reactivity were retrospectively studied by enzyme allergosorbent test (EAST) and EAST-inhibition experiments. IgE-reactive proteins were detected by electrophoretic separation and immunoblotting. Liquid chromatography with electrospray ionization mass spectrometry and Edman degradation of tryptic protein fragments were used for the biochemical identification of an unknown IgE-binding protein. Results: Twenty-three percent of 171 tested bakers had specific IgE to alpha-amylase, 8% reacted to glucoamylase, 13% reacted to cellulase, and 11% reacted to xylanase, Xylanase and cellulase preparations, each containing at least 6 different proteins, showed cross-reactivity in the range of 80%. The main IgE-binding protein in the xylanase preparation recognized in 7 of 8 xylanase-positive subjects was a protein of about 105 kd. This protein was identified as beta-xylosidase by peptide mass spectrometric fingerprinting. The identification was confirmed by matching 12 peptide sequences obtained by N-terminal and mass spectrometric sequencing to this protein. Conclusions: beta-Xylosidase from Aspergillus niger is an occupational allergen present in currently used baking additives, which causes sensitization in at least 4% of symptomatic bakers. According to the International Union of Immunological Societies nomenclature, we suggest the term Asp n 14 for this allergen.	Res Inst Occupat Med, Bochum, Germany; Ruhr Univ Bochum, Inst Physiol Chem, D-4630 Bochum, Germany	Ruhr University Bochum; Ruhr University Bochum	Sander, I (corresponding author), Burkle de la Camp Pl 1, D-44789 Bochum, Germany.		Sander, Ingrid/R-8940-2017	Sander, Ingrid/0000-0002-5014-4112				ARRUDA LK, 1992, J IMMUNOL, V149, P3354; BAUR X, 1988, RESPIRATION, V54, P70, DOI 10.1159/000195503; BAUR X, 1994, CLIN EXP ALLERGY, V24, P465, DOI 10.1111/j.1365-2222.1994.tb00935.x; BAUR X, 1986, LANCET, V1, P43; BAUR X, 1997, ALLERGY CLIN IMMUN S, V4, P169; Baur X, 1989, IMMUNOL ALLERGY PRAC, V11, P13; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRISMAN J, 1991, BRIT J IND MED, V48, P604; CESKA M, 1972, IMMUNOCHEMISTRY, V9, P1021, DOI 10.1016/0019-2791(72)90112-7; Crameri R, 1996, INT ARCH ALLERGY IMM, V110, P41, DOI 10.1159/000237308; DEZOTTI R, 1994, OCCUP ENVIRON MED, V51, P548, DOI 10.1136/oem.51.8.548; FLINDT MLH, 1979, LANCET, V1, P1407; Gevaert K, 1996, ELECTROPHORESIS, V17, P918, DOI 10.1002/elps.1150170513; Houba R, 1996, AM J RESP CRIT CARE, V154, P130, DOI 10.1164/ajrccm.154.1.8680668; KING TP, 1994, INT ARCH ALLERGY IMM, V105, P224, DOI 10.1159/000236761; KORMELINK FJM, 1993, J BIOTECHNOL, V27, P249, DOI 10.1016/0168-1656(93)90089-6; KUMAR A, 1993, J ALLERGY CLIN IMMUN, V91, P1024, DOI 10.1016/0091-6749(93)90215-2; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAAT J, 1992, PROGR BIOTECHNOL, V7, P349; MANN M, 1993, BIOL MASS SPECTROM, V22, P338, DOI 10.1002/bms.1200220605; MANN M, 1994, MICROCHARACTERIZATIO, P223; MEREDITH S, 1993, J EPIDEMIOL COMMUN H, V47, P459, DOI 10.1136/jech.47.6.459; MUSTERS W, 1995, BIOL UNSERER Z, V25, P239; Posch A, 1997, J ALLERGY CLIN IMMUN, V99, P385, DOI 10.1016/S0091-6749(97)70057-5; QUIRCE S, 1992, J ALLERGY CLIN IMMUN, V90, P970, DOI 10.1016/0091-6749(92)90470-M; Sander I, 1997, INT ARCH ALLERGY IMM, V112, P378, DOI 10.1159/000237483; Sunna A, 1997, CRIT REV BIOTECHNOL, V17, P39, DOI 10.3109/07388559709146606; TARVAINEN K, 1991, CLIN EXP ALLERGY, V21, P609, DOI 10.1111/j.1365-2222.1991.tb00854.x; TESHIMA R, 1993, J ALLERGY CLIN IMMUN, V92, P698, DOI 10.1016/0091-6749(93)90013-6; Vanhanen M, 1996, OCCUP ENVIRON MED, V53, P670, DOI 10.1136/oem.53.10.670; vanPeij NNME, 1997, EUR J BIOCHEM, V245, P164	32	82	84	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1998	102	2					256	264		10.1016/S0091-6749(98)70109-5	http://dx.doi.org/10.1016/S0091-6749(98)70109-5			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	113EH	9723670				2022-12-18	WOS:000075537100018
J	Perzanowski, MS; Sporik, R; Squillace, SP; Gelber, LE; Call, R; Carter, M; Platts-Mills, TAE				Perzanowski, MS; Sporik, R; Squillace, SP; Gelber, LE; Call, R; Carter, M; Platts-Mills, TAE			Association of sensitization to Alternaria allergens with asthma among school-age children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Alternaria; asthma; indoor allergens; Cladosporium; outdoor allergens; children; fungal allergens; atopic dermatitis; serum IgE assays	HOUSE-DUST MITE; CHILDHOOD ASTHMA; RISK-FACTORS; EXPOSURE; SYMPTOMS; SENSITIVITY; AUSTRALIA; IGE	Background: Molds in the Alternaria genus, normally found on outdoor vegetation, produce some of the most common fungal allergens to elicit a skin test response. Objectives: The objectives of this study were to evaluate a serum assay for IgE antibodies to Alternaria allergens and to establish the prevalence of sensitization to Alternaria allergens among children and adults enrolled in epidemiologic studies of asthma. In addition, the significance of sensitization to Alternaria allergens as a risk factor for asthma was compared with that of sensitization to indoor allergens or pollens. Methods: Using the Pharmacia Capsulated Hydrophobic Carrier Polymer (CAP) system, we have evaluated the significance of Alternaria allergens by using sera from several epidemiologic studies of asthma, Results: Comparisons between serum assays and skin test results suggest that this in vitro assay yields results similar to those for traditional RASTs and is as sensitive as skin prick testing. In each of the groups studied, sensitization to Alternaria allergens was more common among asthmatic than control subjects, and in two studies the relationship was highly significant. Alternaria allergens were significantly associated with asthma in middle schools in Charlottesville, Virginia and Los Alamos, New Mexico hut not in Albemarle County, Virginia. Logistic regression analysis of the results for the three schools identified an association between sensitization to Alternaria allergens and asthma independent of, but not as strong as, that found between sensitization to indoor allergens and asthma (p < 0.001). Conclusions: The Pharmacia CAP system is a useful tool for measuring specific IgE to Alternaria allergens. Although not as important as sensitization to dominant local indoor allergens, sensitization to Alternaria allergens appears to be a significant independent risk factor for asthma in children in some locations of the United States.	Univ Virginia, Hlth Sci Ctr, Asthma & Allerg Dis Ctr, Charlottesville, VA 22908 USA; Emory Univ, Atlanta, GA 30322 USA; Inst Resp Med, Campertown, Australia	University of Virginia; Emory University	Platts-Mills, TAE (corresponding author), Univ Virginia, Hlth Sci Ctr, Asthma & Allerg Dis Ctr, Box 225, Charlottesville, VA 22908 USA.			Platts-Mills, Thomas/0000-0002-1263-329X	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000847] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020565, R01AI020565, R01AI030840] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00847] Funding Source: Medline; NIAID NIH HHS [AI-30840, AI-20565] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALDOORY Y, 1984, MOULD ALLERGY, P244; Bush RK, 1997, ANN ALLERG ASTHMA IM, V78, P287, DOI 10.1016/S1081-1206(10)63183-3; CALL RS, 1992, J PEDIATR-US, V121, P862, DOI 10.1016/S0022-3476(05)80329-4; Carter M., 1997, Journal of Allergy and Clinical Immunology, V99, pS86; DALES RE, 1991, AM J EPIDEMIOL, V134, P196, DOI 10.1093/oxfordjournals.aje.a116072; DeVouge MW, 1996, INT ARCH ALLERGY IMM, V111, P385, DOI 10.1159/000237397; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573, DOI 10.1164/ajrccm/147.3.573; GLEICH GJ, 1974, J ALLERGY CLIN IMMUN, V53, P158, DOI 10.1016/0091-6749(74)90004-9; Halonen M, 1997, AM J RESP CRIT CARE, V155, P1356, DOI 10.1164/ajrccm.155.4.9105079; HENDERSON FW, 1995, AM J RESP CRIT CARE, V151, P1786, DOI 10.1164/ajrccm.151.6.7767521; INGRAM JM, 1995, J ALLERGY CLIN IMMUN, V96, P449, DOI 10.1016/S0091-6749(95)70286-5; IVERSEN M, 1995, J INVEST ALLERG CLIN, V5, P205; MELDRUM JR, 1993, P INDOOR AIR, V4, P189; OHOLLAREN MT, 1991, NEW ENGL J MED, V324, P359, DOI 10.1056/NEJM199102073240602; PEAT JK, 1991, CLIN EXP ALLERGY, V21, P573, DOI 10.1111/j.1365-2222.1991.tb00849.x; Peat JK, 1996, AM J RESP CRIT CARE, V153, P141, DOI 10.1164/ajrccm.153.1.8542107; PLATTSMILLS TAE, 1993, AEROBIOLOGY INHALANT, P498; PORTNOY J, 1993, ANN ALLERGY, V71, P401; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; SOLOMON WR, 1975, J ALLERGY CLIN IMMUN, V56, P235, DOI 10.1016/0091-6749(75)90095-0; SPORIK R, 1995, AM J RESP CRIT CARE, V151, P1388, DOI 10.1164/ajrccm.151.5.7735590; SPORIK RB, 1993, CLIN EXP ALLERGY, V23, P326, DOI 10.1111/j.1365-2222.1993.tb00330.x; Squillace SP, 1997, AM J RESP CRIT CARE, V156, P1760, DOI 10.1164/ajrccm.156.6.9704026; STRACHAN DP, 1988, BMJ-BRIT MED J, V297, P1223, DOI 10.1136/bmj.297.6658.1223; Verhoeff AP, 1997, ANN ALLERG ASTHMA IM, V78, P544, DOI 10.1016/S1081-1206(10)63214-0; WICKMAN M, 1992, J ALLERGY CLIN IMMUN, V89, P752, DOI 10.1016/0091-6749(92)90384-E; WILLIAMS PB, 1992, ANN ALLERGY, V68, P35	27	82	84	1	7	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1998	101	5					626	632		10.1016/S0091-6749(98)70170-8	http://dx.doi.org/10.1016/S0091-6749(98)70170-8			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZN926	9600499				2022-12-18	WOS:000073697400010
J	Lung, CC; Chan, EKL; Zuraw, BL				Lung, CC; Chan, EKL; Zuraw, BL			Analysis of an exon 1 polymorphism of the B2 bradykinin receptor gene and its transcript in normal subjects and patients with C1 inhibitor deficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						B2 bradykinin receptor; polymorphism; mRNA; C1 inhibitor deficiency; hereditary angioedema; genomic PCR; 5' RACE; bradykinin	PHARMACOLOGICAL CHARACTERIZATION; KININ FORMATION; B-2 RECEPTOR; EXPRESSION; ANGIOEDEMA; CLONING; PLASMA; ANTAGONISTS; MECHANISMS; KALLIKREIN	The B2 bradykinin receptor (B2BKR) mediates most of the inflammatory actions of bradykinin. To evaluate its potential role in allergic diseases, we assessed the structure of the human B2BKR gene. Screening a human placenta genomic DNA library identified only clones containing exons 2 and 3. Human placenta and colon tissues were used for 5' rapid amplification of complementary DNA ends to identify nine exon 1 clones, each containing one 9 bp and two 1 bp deletions compared with published sequences. Exon 1 genomic polymerase chain reaction of human leukocyte DNA revealed two distinct products, which were shown to differ by the presence of absence of the 9 bp deletion. Alleles with the 9 bp deletion were designated as (-)(21-29), whereas alleles without the deletion were designated as (+)(21-29). Genomic polymerase chain reaction in 39 Caucasian, 31 African-American, and 32 Asian normal subjects revealed a highly significant difference in the allelic frequency of the two genotypes, primarily because of an absence of the (+)(21-29) allele in Asian subjects. Analysis of steady-state B2BKR messenger RNA levels by reverse-transcription polymerase chain reaction in heterozygous normal subjects revealed consistently higher expression of (-)(21-29) transcripts. To investigate the potential clinical significance of the exon 1 polymorphism, 21 patients with angioedema and C1 inhibitor deficiency were genotyped. None were homozygous for the (+)(21-29) allele (p = 0.0088 compared with normal subjects). In contrast, two patients with immunochemical evidence of hereditary angioedema without history of clinical angioedema were (+)(21-29) homozygous. These results suggests that the B2BKR genotype may influence clinical status in diseases characterized by involvement of bradykinin.	Scripps Res Inst, DEPT MOL & EXPT MED, AUTOIMMUNE DIS CTR, LA JOLLA, CA 92037 USA	Scripps Research Institute			Chan, Edward K. L./B-5671-2009	Chan, Edward K. L./0000-0003-3938-9503; Zuraw, Bruce/0000-0003-0640-6768	NCRR NIH HHS [RR00833] Funding Source: Medline; NIAID NIH HHS [AI32834] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI032834] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BACCAGLINI PI, 1983, P NATL ACAD SCI-BIOL, V80, P594, DOI 10.1073/pnas.80.2.594; BATHON JM, 1991, ANNU REV PHARMACOL, V31, P129; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; BRAUN A, 1995, BIOCHEM BIOPH RES CO, V211, P234, DOI 10.1006/bbrc.1995.1801; Braun A, 1996, IMMUNOPHARMACOLOGY, V33, P32, DOI 10.1016/0162-3109(96)00079-3; BYTH BC, 1994, AM J HUM GENET, V55, P126; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CHOU Q, 1992, NUCLEIC ACIDS RES, V20, P1717, DOI 10.1093/nar/20.7.1717; CHRISTIANSEN SC, 1992, AM REV RESPIR DIS, V145, P900, DOI 10.1164/ajrccm/145.4_Pt_1.900; CURD JG, 1982, MOL IMMUNOL, V19, P1365, DOI 10.1016/0161-5890(82)90035-9; CURD JG, 1980, J EXP MED, V152, P742, DOI 10.1084/jem.152.3.742; EGGERICKX D, 1992, BIOCHEM BIOPH RES CO, V187, P1306, DOI 10.1016/0006-291X(92)90445-Q; FARMER SG, 1991, AM J RESP CELL MOL, V4, P273, DOI 10.1165/ajrcmb/4.3.273; FIELDS T, 1983, J ALLERGY CLIN IMMUN, V72, P54, DOI 10.1016/0091-6749(83)90052-0; GRITZMACHER CA, 1989, CRIT REV IMMUNOL, V9, P173; HALL JM, 1992, PHARMACOL THERAPEUT, V56, P131, DOI 10.1016/0163-7258(92)90016-S; HESS JF, 1992, BIOCHEM BIOPH RES CO, V184, P260, DOI 10.1016/0006-291X(92)91187-U; KRAWCZAK M, 1991, HUM GENET, V86, P425; LAMMLE B, 1988, THROMB HAEMOSTASIS, V59, P151; MA JX, 1994, GENOMICS, V23, P362, DOI 10.1006/geno.1994.1512; MARCEAU F, 1983, GEN PHARMACOL, V14, P209, DOI 10.1016/0306-3623(83)90001-0; MCEACHERN AE, 1991, P NATL ACAD SCI USA, V88, P7724, DOI 10.1073/pnas.88.17.7724; MCINTYRE P, 1993, MOL PHARMACOL, V44, P346; NAGAMINE CM, 1989, SCIENCE, V243, P80, DOI 10.1126/science.2563174; POWELL SJ, 1993, GENOMICS, V15, P435, DOI 10.1006/geno.1993.1084; PROUD D, 1988, ANNU REV IMMUNOL, V6, P49, DOI 10.1146/annurev.iy.06.040188.000405; REGOLI D, 1988, METHOD ENZYMOL, V163, P210; Regoli D, 1992, Agents Actions Suppl, V38 ( Pt 1), P475; REGOLI D, 1980, PHARMACOL REV, V32, P1; Sambrook J, 1989, MOL CLONING LAB MANU, V2; SHARMA JN, 1993, GEN PHARMACOL, V24, P267, DOI 10.1016/0306-3623(93)90302-E; SHOEMAKER LR, 1994, CLIN EXP IMMUNOL, V95, P22; SPITZER RE, 1980, INT ARCH ALLER A IMM, V61, P286, DOI 10.1159/000232447; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; ZURAW BL, 1986, J ALLERGY CLIN IMMUN, V78, P1115, DOI 10.1016/0091-6749(86)90259-9; ZURAW BL, 1986, J CLIN INVEST, V78, P567, DOI 10.1172/JCI112610	36	82	85	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1997	99	1	1				134	146		10.1016/S0091-6749(97)81054-8	http://dx.doi.org/10.1016/S0091-6749(97)81054-8			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WD061	9003221				2022-12-18	WOS:A1997WD06100018
J	Nieto, A; Estornell, F; Mazon, A; Reig, C; Nieto, A; GarciaIbarra, F				Nieto, A; Estornell, F; Mazon, A; Reig, C; Nieto, A; GarciaIbarra, F			Allergy to latex in spina bifida: A multivariate study of associated factors in 100 consecutive patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						latex allergy; spina bifida; risk factors; atopy; exposure; multivariate analysis; logistic regression	CONTACT URTICARIA; RISK-FACTORS; OCCUPATIONAL ASTHMA; MANUFACTURING PLANT; RUBBER; HYPERSENSITIVITY; ANAPHYLAXIS; CHILDREN; MYELODYSPLASIA; ANTIGENS	Background: Latex allergy is quite frequent in patients who have undergone multiple operations, such as children with spina bifida. Objective: This investigation was carried to study the prevalence and risk factors associated with latex allergy in patients with spina bifida. Methods: We studied 100 consecutive patients by skin prick tests and quantified specific IgE to latex with commercial antigens. Results: Twenty-nine patients were sensitized to latex, although 14 (49%) did not report symptoms. There was a statistical association (p < 0.05) between sensitization and age, number of operations, number of cystourethrograms, antecedents of intermittent bladder catheterization, personal antecedents of atopy, the presence of a ventricular-peritoneal shunt and levels of serum total IgE, the fatter both in absolute units per milliliter and relative z-units. Through a forward stepwise multiple logistic regression analysis, the number of operations, serum total IgE in z-units, the presence of a ventricular-peritoneal shunt, and personal antecedents of atopy were selected as the synergistic variables that most contributed to identification of sensitized patients. The mathematical model so developed had an area under the receiver operating characteristic curve of 0.95. Alternative models always retained two variables, the number of operations and levels of IgE. Conclusion: Allergy to latex is mainly related to the number of operations and to the atopic diathesis of patients.	CHILDRENS HOSP LA FE,PEDIAT UROL SECT,VALENCIA 46009,SPAIN		Nieto, A (corresponding author), CHILDRENS HOSP LA FE,PEDIAT IMMUNOALLERGY SECT,AV CAMPANAR 21,VALENCIA 46009,SPAIN.		Mazon, Angel/ABG-8016-2020	Mazon, Angel/0000-0001-5639-1037				ALENIUS H, 1994, J ALLERGY CLIN IMMUN, V93, P859, DOI 10.1016/0091-6749(94)90378-6; BANTA JV, 1993, DEV MED CHILD NEUROL, V35, P543; BUBAK ME, 1992, MAYO CLIN PROC, V67, P1075, DOI 10.1016/S0025-6196(12)61122-7; Centers for Disease Control (CDC), 1991, MMWR Morb Mortal Wkly Rep, V40, P443; DILLARD SF, 1992, INT LAT C SENS LAT M; ELLSWORTH PI, 1993, J UROLOGY, V150, P691, DOI 10.1016/S0022-5347(17)35587-8; FORSTROM L, 1980, CONTACT DERMATITIS, V6, P33, DOI 10.1111/j.1600-0536.1980.tb03887.x; KELLY KJ, 1995, IMMUNOL ALLERGY CLIN, V15, P139; KELLY KJ, 1994, J ALLERGY CLIN IMMUN, V94, P53, DOI 10.1016/0091-6749(94)90071-X; KJELLMAN NIM, 1976, CLIN ALLERGY, V6, P51, DOI 10.1111/j.1365-2222.1976.tb01411.x; KONZ KR, 1995, J ALLERGY CLIN IMMUN, V95, P950, DOI 10.1016/S0091-6749(95)70094-3; LAGIER F, 1992, J ALLERGY CLIN IMMUN, V90, P319, DOI 10.1016/S0091-6749(05)80009-0; LEYNADIER F, 1991, CLIN REV ALLERG, V9, P371; MEEROPOL E, 1990, NEW ENGL J MED, V323, P1072; MEYER HE, 1993, J ALLERGY CLIN IMMUN, V92, P690; MONERETVAUTRIN DA, 1993, J ALLERGY CLIN IMMUN, V92, P668, DOI 10.1016/0091-6749(93)90009-5; MORALES C, 1989, CLIN EXP ALLERGY, V19, P425, DOI 10.1111/j.1365-2222.1989.tb02409.x; NUTTER AF, 1979, BRIT J DERMATOL, V101, P597, DOI 10.1111/j.1365-2133.1979.tb15107.x; ORFAN NA, 1994, J ALLERGY CLIN IMMUN, V94, P826, DOI 10.1016/0091-6749(94)90149-X; PEARSON ML, 1994, DEV MED CHILD NEUROL, V36, P64, DOI 10.1111/j.1469-8749.1994.tb11767.x; PECQUET C, 1993, CLIN REV ALLERG, V11, P31; SLATER JE, 1992, J ALLERGY CLIN IMMUN, V89, P673, DOI 10.1016/0091-6749(92)90373-A; SLATER JE, 1989, NEW ENGL J MED, V320, P1126, DOI 10.1056/NEJM198904273201707; SPANER D, 1989, J ALLERGY CLIN IMMUN, V83, P1135, DOI 10.1016/0091-6749(89)90457-0; Stern G, 1927, KLIN WOCHENSCHR, V6, P1096; TARLO SM, 1990, J ALLERGY CLIN IMMUN, V85, P626, DOI 10.1016/0091-6749(90)90103-B; TAYLOR JS, 1989, J AM ACAD DERMATOL, V21, P874, DOI 10.1016/S0190-9622(89)70271-1; TOSSI LL, 1993, J PEDIATR ORTHOPED, V13, P709; TURJANMAA K, 1987, CONTACT DERMATITIS, V17, P270, DOI 10.1111/j.1600-0536.1987.tb01476.x; 1993, J ALLERGY CLIN IMMUN, V92, P16	30	82	83	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1996	98	3					501	507		10.1016/S0091-6749(96)70082-9	http://dx.doi.org/10.1016/S0091-6749(96)70082-9			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VJ428	8828526				2022-12-18	WOS:A1996VJ42800005
J	Oro, AS; Guarino, TJ; Driver, R; Steinman, L; Umetsu, DT				Oro, AS; Guarino, TJ; Driver, R; Steinman, L; Umetsu, DT			Regulation of disease susceptibility: Decreased prevalence of IgE-mediated allergic disease in patients with multiple sclerosis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cytokine regulation; CD4+ T cells; autoimmune disease; Th1; Th2; allergic disease; multiple sclerosis	NUTRITION EXAMINATION SURVEY; UNITED-STATES POPULATION; SKIN-TEST REACTIVITY; 2ND NATIONAL-HEALTH; CD4+ T-CELLS; ATOPIC ALLERGY; INTERLEUKIN-4; SERUM; AUTOIMMUNITY; RESPONSES	The development of restricted cytokine profiles by subsets of CD4(+) T cells is a pivotal point in the regulation of immune responses. T cells producing Th1 cytokines (IL-2 and interferon-gamma) induce cell-mediated immunity, whereas T cells producing Th2 cytokines (IL-4, IL-5, and IL-10) play a prominent role in the induction of humoral immunity. We examined a group of patients with multiple sclerosis, a disease caused by excess production of Th1 cytokines in myelin-reactive T cells, and control patients with noninflammatory neuroconvulsive disorders, for the presence of allergic disease, which is caused by excess production of Th2 cytokines in allergen-specific T cells. The patients with multiple sclerosis had significantly fewer allergic symptoms, a lower number of positive allergen-specific IgE test results, and lower composite allergy indexes than control subjects. These results demonstrate that the prevalence of IgE-mediated allergic disease is decreased in a group of patients with multiple sclerosis and support the hypothesis that genetic factors that promote susceptibility to Th1-medicated inflammatory disease in human beings protect against the development of Th2-medicated disease.	STANFORD UNIV,DEPT PEDIAT,STANFORD,CA 94305; STANFORD UNIV,DEPT NEUROL,STANFORD,CA 94305; MAST IMMUNOSYST,MT VIEW,CA	Stanford University; Stanford University				Steinman, Lawrence/0000-0002-2437-2250	NIAID NIH HHS [R01AI24571, KO7AI01026, R01AI26322] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024571, R01AI026322, K07AI001026] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERG T, 1971, INT ARCH ALLER A IMM, V40, P770, DOI 10.1159/000230461; BROWN CR, 1985, CLIN CHEM, V31, P1500; CLINE MG, 1989, THORAX, V44, P425, DOI 10.1136/thx.44.5.425; COOKSON WOCM, 1992, LANCET, V340, P381, DOI 10.1016/0140-6736(92)91468-N; DECARLI M, 1993, J CLIN ENDOCR METAB, V77, P1120, DOI 10.1210/jc.77.5.1120; DEKRUYFF RH, 1989, J EXP MED, V170, P1477, DOI 10.1084/jem.170.5.1477; GALLO P, 1989, J NEUROL SCI, V92, P9, DOI 10.1016/0022-510X(89)90171-8; GARCHON HJ, 1991, NATURE, V353, P260, DOI 10.1038/353260a0; GERGEN PJ, 1991, ARCH INTERN MED, V151, P487, DOI 10.1001/archinte.151.3.487; GERGEN PJ, 1987, J ALLERGY CLIN IMMUN, V80, P669, DOI 10.1016/0091-6749(87)90286-7; HAHN HJ, 1987, EUR J IMMUNOL, V18, P2037; HELANDER E, 1958, ACTA MED SCAND, V165, P165; HERMANSSON B, 1971, HUM HERED, V21, P504, DOI 10.1159/000152443; HOLGATE ST, 1993, ALLERGY, pCH11; KARIN N, 1994, J EXP MED, V180, P2227, DOI 10.1084/jem.180.6.2227; KASPENBERG ML, 1991, IMMUNOL TODAY, V12, P392; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; MARSHALL JD, 1993, CELL IMMUNOL, V152, P18, DOI 10.1006/cimm.1993.1264; MOORE KW, 1993, ANNU REV IMMUNOL, V11, P165, DOI 10.1146/annurev.immunol.11.1.165; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; NORMAN PS, 1973, J ALLERGY CLIN IMMUN, V52, P210, DOI 10.1016/0091-6749(73)90059-6; OLSSON T, 1990, J CLIN INVEST, V86, P981, DOI 10.1172/JCI114800; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROMAGNANI S, 1994, ANNU REV IMMUNOL, V12, P227, DOI 10.1146/annurev.iy.12.040194.001303; ROMAGNANI S, 1991, IMMUNOL TODAY, V12, P256, DOI 10.1016/0167-5699(91)90120-I; SCOTT B, 1994, IMMUNITY, V1, P73, DOI 10.1016/1074-7613(94)90011-6; SECRIST H, 1993, J EXP MED, V178, P2123, DOI 10.1084/jem.178.6.2123; SHER A, 1992, IMMUNOL REV, V127, P183, DOI 10.1111/j.1600-065X.1992.tb01414.x; SIEBURTH D, 1992, GENOMICS, V14, P59, DOI 10.1016/S0888-7543(05)80283-6; SIEGAL S, 1954, J ALLERGY, V25, P25, DOI 10.1016/0021-8707(54)90044-1; SMITH JM, 1965, AM REV RESPIR DIS, V92, P16; STROMBERG LGE, 1995, J ALLERGY CLIN IMMUN, V96, P188, DOI 10.1016/S0091-6749(95)70007-2; SWERN N, 1932, J ALLERGY, V2, P875; THEOFILOPOULOS AN, 1995, IMMUNOL TODAY, V16, P150, DOI 10.1016/0167-5699(95)80133-2; TRINCHIERI G, 1994, BLOOD, V84, P4008, DOI 10.1182/blood.V84.12.4008.bloodjournal84124008; TURKELTAUB PC, 1991, ANN ALLERGY, V67, P147; VERCELLI D, 1989, J EXP MED, V169, P1295, DOI 10.1084/jem.169.4.1295	39	82	85	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1996	97	6					1402	1408		10.1016/S0091-6749(96)70210-5	http://dx.doi.org/10.1016/S0091-6749(96)70210-5			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VD607	8648038				2022-12-18	WOS:A1996VD60700030
J	SOTHERN, RB; ROITMANJOHNSON, B; KANABROCKI, EL; YAGER, JG; ROODELL, MM; WEATHERBEE, JA; YOUNG, MRI; NEMCHAUSKY, BM; SCHEVING, LE				SOTHERN, RB; ROITMANJOHNSON, B; KANABROCKI, EL; YAGER, JG; ROODELL, MM; WEATHERBEE, JA; YOUNG, MRI; NEMCHAUSKY, BM; SCHEVING, LE			CIRCADIAN CHARACTERISTICS OF CIRCULATING INTERLEUKIN-6 IN MEN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						BLOOD CIRCADIAN; CYTOKINE; INTERLEUKIN-6; RHYTHM	HEALTHY-MEN; HUMAN CANCER; DISEASE; CYTOKINES; CORTISOL; RHYTHMS; SLEEP; ERYTHROPOIETIN	Background: The cytokine interleukin-6 (IL-6) is a multifunctional small-peptide molecule that is produced by various types of lymphoid and nonlymphoid cells. It plays a central role in hematopoiesis, host defense mechanisms, and acute-phase reactions, including regulation of inflammatory and immune responses. Methods: Because a circadian time structure has been shown to characterize nearly every biologic function tested in human beings, including some cytokines, we sought-to investigate the 24-hour pattern of circulating IL-6 in a group of II clinically symptom-free men (median age, 50 years; range, 46 to 72 years). Blood samples were obtained every 3 hours for 24 hours (eight samples per subject), and serum was frozen until analysis for IL-6 with a solid-phase ELISA. Results: Average IL-6 values ranged from 1.66 to 5.38 pg/ml, with lowest to highest values within 24 hours ranging from 1.20 to 7.58 pg/ml (120% to 531%) between subjects. On average, values were greater than the mean throughout the night, with a peak at 01:00 hours and less than the mean throughout the day, with a nadir at 10:00 hours. A significant time effect was found by analysis of variance; and a high-amplitude circadian rhythm was described by the least-squares fit of a 24-hour cosine (p < 0.001; amplitude, 41% +/- 5%; acrophase, 02:16 +/- 00:28 hours). In addition, a positive correlation between mean IL-6 levels and age was found (r = 0.63, p = 0.037). Conclusions: Because monitoring of endogenous cytokine levels is suggested for assessing immune function and pathologic condition, clinical decisions and immunotherapies may be significantly influenced by the large and predictable day-night variations in endogenous cytokine production and bioactivity.	R&D SYST INC,MINNEAPOLIS,MN; VET AFFAIRS EDWARD HINES JR HOSP,RES SERV,HINES,IL; UNIV ARKANSAS,DEPT ANAT,LITTLE ROCK,AR 72204; JOHN L MCCLELLAN MEM VET ADM MED CTR,LITTLE ROCK,AR; ST PAUL RAMSEY MED CTR,RHYTHOMETRY LAB,MINNEAPOLIS,MN	US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital; University of Arkansas System; University of Arkansas Fayetteville; University of Arkansas Little Rock; Saint Paul Ramsey Medical Center	SOTHERN, RB (corresponding author), UNIV MINNESOTA,CHRONOBIOL LABS,RHYTHMOMETRY LAB,BOX 609 UMHC,MINNEAPOLIS,MN 55455, USA.							ANGELI A, 1992, CHRONOBIOLOGIA, V19, P93; BJARNASON GA, 1994, CIRCADIAN CANC THERA, P241; BJARNASON GA, 1994, CIRCADIAN CANC THERA, P211; BRENNAN FM, 1992, CURR OPIN IMMUNOL, V4, P754, DOI 10.1016/0952-7915(92)90057-L; CAHAN C, 1992, J APPL PHYSIOL, V72, P2112, DOI 10.1152/jappl.1992.72.6.2112; COVELLI V, 1992, INT J NEUROSCI, V63, P299, DOI 10.3109/00207459208987204; DEPRESBRUMMER P, 1991, J IMMUNOTHER, V10, P440, DOI 10.1097/00002371-199112000-00008; GUDEWILL S, 1992, EUR ARCH PSY CLIN N, V242, P53, DOI 10.1007/BF02190343; GUTTERMAN JU, 1992, CANCER, V70, P906; HEINRICH PC, 1990, BIOCHEM J, V265, P621, DOI 10.1042/bj2650621; HEROLD M, 1993, J INTERDISC CYCLE RE, V23, P233; HEROLD M, 1992, J INTERDISC CYCLE RE, V22, P129; HIRANO T, 1992, CLIN IMMUNOL IMMUNOP, V62, pS60, DOI 10.1016/0090-1229(92)90042-M; HOHAGEN F, 1993, NEUROPSYCHOBIOLOGY, V28, P9, DOI 10.1159/000118993; KANABROCKI EL, 1990, CHRONOBIOL INT, V7, P445, DOI 10.3109/07420529009059156; KISHIMOTO T, 1992, INT ARCH ALLERGY IMM, V99, P172, DOI 10.1159/000236243; KURZROCK R, 1993, CANCER RES, V53, P2118; Lemmer B, 1992, Eur Cytokine Netw, V3, P335; LEVI FA, 1988, CLIN EXP IMMUNOL, V71, P329; LISSONI P, 1990, ANTICANCER RES, V10, P1759; LOWRY RP, 1993, TRANSPLANTATION SCI, V3, P104; MADHOK R, 1993, ANN RHEUM DIS, V52, P232, DOI 10.1136/ard.52.3.232; MILLER ME, 1981, BRIT J HAEMATOL, V49, P189, DOI 10.1111/j.1365-2141.1981.tb07215.x; MOJON A, 1992, CHRONOBIOL INT, V9, P403, DOI 10.3109/07420529209064552; NEGRIER S, 1992, BRIT J CANCER, V65, P723, DOI 10.1038/bjc.1992.152; NELSON W, 1983, CHRONOBIOLOGIA, V10, P179; OKA Y, 1992, CYTOKINE, V4, P298, DOI 10.1016/1043-4666(92)90070-8; PACIOTTI GF, 1992, PROG NEUROENDOCRINIM, V5, P21; PAUL LC, 1993, TRANSPLANT SCI, V3, P113; Roberts A. B., 1990, PEPTIDE GROWTH FACTO, P633; Sanchez De La Pena Salvador, 1993, Chronobiologia, V20, P1; SMAALAND R, 1994, CIRCADIAN CANCER THE, P119; Sothern R., 1972, PHYSIOL TEACH, V1, P1; TOUITOU Y, 1992, BIOL RHYTHMS CLIN LA; WATSON JM, 1993, GYNECOL ONCOL, V49, P8, DOI 10.1006/gyno.1993.1077; WHICHER JT, 1990, CLIN CHEM, V36, P1269; WOOD PA, 1994, CIRCADIAN CANC THERA, P185; YOUNG MRI, 1995, IN PRESS CHRONOBIOL	38	82	85	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1995	95	5	1				1029	1035		10.1016/S0091-6749(95)70104-4	http://dx.doi.org/10.1016/S0091-6749(95)70104-4			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QY917	7751499				2022-12-18	WOS:A1995QY91700015
J	ROSEN, JP; SELCOW, JE; MENDELSON, LM; GRODOFSKY, MP; FACTOR, JM; SAMPSON, HA				ROSEN, JP; SELCOW, JE; MENDELSON, LM; GRODOFSKY, MP; FACTOR, JM; SAMPSON, HA			SKIN TESTING WITH NATURAL FOODS IN PATIENTS SUSPECTED OF HAVING FOOD ALLERGIES - IS IT A NECESSITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note							CHILDREN; RAST		JOHNS HOPKINS UNIV,DEPT PEDIAT,DIV ALLERGY,BALTIMORE,MD 21218	Johns Hopkins University	ROSEN, JP (corresponding author), HARTFORD HOSP,DEPT PEDIAT,HARTFORD,CT 06115, USA.							ORTOLANI C, 1989, J ALLERGY CLIN IMMUN, V83, P683, DOI 10.1016/0091-6749(89)90083-3; SAMPSON HA, 1984, J ALLERGY CLIN IMMUN, V74, P26, DOI 10.1016/0091-6749(84)90083-6; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603	3	82	83	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1994	93	6					1068	1070		10.1016/S0091-6749(94)70056-7	http://dx.doi.org/10.1016/S0091-6749(94)70056-7			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NT172	8006311				2022-12-18	WOS:A1994NT17200016
J	HOFFMAN, DR				HOFFMAN, DR			ALLERGENS IN HYMENOPTERA VENOM .24. THE AMINO-ACID-SEQUENCES OF IMPORTED FIRE ANT VENOM ALLERGENS SOL-I-II, SOL-I-III, AND SOL-I-IV	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						FIRE ANT; SOLENOPSIS INVICTA; AMINO ACID SEQUENCE; PROTEIN SEQUENCE; ALLERGEN; SOL-I-II; SOL-I-III; SOL-I-IV; VENOM; ANTIGEN-5	SOLENOPSIS-INVICTA; PROTEIN	The most common cause of insect venom allergy in the Southeastern United States is the imported fire ant. The allergens are among the most potent known, with nanogram doses causing sensitization and provoking anaphylaxis. The complete amino acid sequences of imported fire ant venom allergens, Sol i II, III, and IV, were determined by solid-phase protein sequencing of overlapping peptide fragments. Sol i II has a single sequence of 119 amino acids and a molecular weight of 13217. It has seven cysteine residues, and in its native form is a disulfide-linked dimer. The highly purified molecule does not have phospholipase activity and is not structurally related to phospholipases or other known proteins. Sol i IV has 117 amino acids, for a molecular weight of 13340. It has six cysteines and is a monomer. Its sequence is 35% identical to Sol i II, but it is not significantly related to other proteins. The Sol i IV sequence showed two amino acid variations. Sol i III was found to consist of 212 amino acids of molecular weight 24040 in good agreement with 26000 by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The sequence contained eight cysteine residues and was found to be 44% to 50% identical to five vespid venom antigen 5 molecules. IgE antibodies against Sol i III do not exhibit strong cross-reactivity with vespid antigen 5s. The sequence similarity is consistent with other data, suggesting that ants are related to wasps of the superfamily Vespoidea.This sequence data allows future studies to elucidate B- and T-cell determinants and may help to understand the extreme allergenic potency of these proteins.			HOFFMAN, DR (corresponding author), E CAROLINA UNIV, SCH MED, DEPT PATHOL & LAB MED, GREENVILLE, NC 27858 USA.							ANDREWS DW, 1990, CHEM SEQUENCING COVA; BALDO BA, 1991, CURR OPIN IMMUNOL, V3, P841, DOI 10.1016/S0952-7915(05)80002-0; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; CHARBONNEAU H, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P15; DESHAZO RD, 1990, NEW ENGL J MED, V323, P462, DOI 10.1056/NEJM199008163230707; FANG KSY, 1988, P NATL ACAD SCI USA, V85, P895, DOI 10.1073/pnas.85.3.895; HABERMANN E, 1972, ANAL BIOCHEM, V50, P163, DOI 10.1016/0003-2697(72)90495-2; HOFFMAN DR, 1988, J ALLERGY CLIN IMMUN, V82, P828, DOI 10.1016/0091-6749(88)90085-1; HOFFMAN DR, 1984, ANN ALLERGY, V52, P276; HOFFMAN DR, 1988, J ALLERGY CLIN IMMUN, V82, P818, DOI 10.1016/0091-6749(88)90084-X; HOFFMAN DR, 1990, J ALLERGY CLIN IMMUN, V85, P988, DOI 10.1016/0091-6749(90)90042-3; HOFFMAN DR, 1985, J ALLERGY CLIN IMMUN, V75, P599, DOI 10.1016/0091-6749(85)90036-3; Holldobler B., 1990, pi; KING T P, 1990, Protein Sequences and Data Analysis, V3, P263; STAFFORD CT, 1989, SOUTHERN MED J, V82, P1520, DOI 10.1097/00007611-198912000-00015; STAFFORD CT, 1989, SOUTHERN MED J, V82, P1515, DOI 10.1097/00007611-198912000-00014; STAFFORD CT, 1992, J ALLERGY CLIN IMMUN, V90, P653, DOI 10.1016/0091-6749(92)90139-S; STAFFORD CT, 1990, ANN ALLERGY, V64, P368; STONE KL, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P31	19	82	94	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1993	91	1	1				71	78		10.1016/0091-6749(93)90298-T	http://dx.doi.org/10.1016/0091-6749(93)90298-T			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KK044	8423273				2022-12-18	WOS:A1993KK04400005
J	JULIUSSON, S; PIPKORN, U; KARLSSON, G; ENERBACK, L				JULIUSSON, S; PIPKORN, U; KARLSSON, G; ENERBACK, L			MAST-CELLS AND EOSINOPHILS IN THE ALLERGIC MUCOSAL RESPONSE TO ALLERGEN CHALLENGE - CHANGES IN DISTRIBUTION AND SIGNS OF ACTIVATION IN RELATION TO SYMPTOMS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ALLERGIC RHINITIS; ALLERGEN CHALLENGE; MAST CELLS; EOSINOPHILS; HISTAMINE; SYMPTOMS; NASAL MUCOSAL CELLS; NASAL LAVAGE; BRUSH SAMPLES	MAJOR BASIC-PROTEIN; HAY-FEVER; ANTIGEN CHALLENGE; INTRAEPITHELIAL MIGRATION; NASAL-MUCOSA; INFLUX; GRANULOCYTES; PRETREATMENT; HISTAMINE; RELEASE	An allergen challenge was performed in 10 asymptomatic patients with strictly seasonal allergic rhinitis. For comparison; seven nonallergic subjects were challenged with allergen, and seven allergic patients were challenged with diluent. Cell samples, obtained with use of a brush technique to recover cells from within the epithelium and nasal lavage to collect cells from the epithelial surface, and symptom scores were taken before challenge and at 2-hour intervals during 12 hours. The cell suspensions were cytocentrifuged onto object slides for light microscopy. Histamine was determined in the cell pellets. In brush samples from the allergic patients challenged with allergen, eosinophils, expressed as a percentage of the total granulocytes, increased from 4.3% +/- 2.7% (mean +/- SEM) to 10.3% +/- 3.8% (p < 0.05) 4 hours after challenge. This level was maintained for up to 12 hours. A similar increase was noted in the lavage specimens 2, 6, and 8 hours after the challenge. In the brush samples proportion of eosinophils containing two or more cytoplasmic vacuoles, taken as a sign of activation, increased from 20% to 72% (p < 0.05) 8 hours after provocation. In brush samples from the allergic patients challenged with allergen, the numbers of metachromatic cells increased to a maximum of eightfold at 10 hours. In the lavage specimens, no metachromatic cells were observed before provocation, but they progressively increased in number 2 to 12 hours after provocation. Cell pellet histamine content decreased temporarily 2 to 4 hours after challenge (p < 0.05) in brush samples from allergen-challenged allergic patients. The local. metachromatic cell density before challenge, as reflected in the brush specimens, correlated with nasal congestion, sneezing, and the degree of eosinophilia.	GOTHENBURG UNIV, SAHLGRENS HOSP, DEPT PATHOL, S-41345 GOTHENBURG, SWEDEN; UNIV LUND HOSP, DEPT OTORHINOLARYNGOL, S-22185 LUND, SWEDEN; MOLNDAL CTY HOSP, DEPT OTORHINOLARYNGOL, MOLNDAL, SWEDEN	Sahlgrenska University Hospital; University of Gothenburg; Lund University; Skane University Hospital	JULIUSSON, S (corresponding author), GOTHENBURG UNIV, SAHLGRENS HOSP, DEPT OTORHINOLARYNGOL, S-41345 GOTHENBURG, SWEDEN.							ALLENMARK S, 1985, ANAL BIOCHEM, V144, P98, DOI 10.1016/0003-2697(85)90089-2; ANDERSSON M, 1989, ALLERGY, V44, P342, DOI 10.1111/j.1398-9995.1989.tb00456.x; BACHERT C, 1990, Rhinology (Utrecht), V28, P149; BASCOM R, 1989, J ALLERGY CLIN IMMUN, V84, P338, DOI 10.1016/0091-6749(89)90418-1; BASCOM R, 1988, AM REV RESPIR DIS, V138, P406, DOI 10.1164/ajrccm/138.2.406; BASCOM R, 1988, J ALLERGY CLIN IMMUN, V81, P570, DOI 10.1016/0091-6749(88)90198-4; BORRES MP, 1990, ALLERGY, V45, P98, DOI 10.1111/j.1398-9995.1990.tb00465.x; ENERBACK L, 1986, INT ARCH ALLER A IMM, V80, P44, DOI 10.1159/000234024; ENERBACK L, 1986, INT ARCH ALLER A IMM, V81, P289, DOI 10.1159/000234152; Enerback L, 1989, Curr Top Pathol, V79, P169; ENERBACK L, 1966, ACTA PATHOL MIC SC, V66, P289, DOI 10.1111/apm.1966.66.3.289; GREIFF L, 1990, CLIN EXP ALLERGY, V20, P253, DOI 10.1111/j.1365-2222.1990.tb02680.x; HENDERSON WR, 1985, J CELL SCI, V73, P33; JEAN R, 1988, DIAGN CYTOPATHOL, V4, P23, DOI 10.1002/dc.2840040107; KLEMENTSSON H, 1991, ACTA OTO-LARYNGOL, V111, P776, DOI 10.3109/00016489109138412; LOZEWICZ S, 1988, THORAX, V43, pP810; NUTMAN TB, 1988, ALLERGY PROC, V9, P641, DOI 10.2500/108854188778965456; OKUDA M, 1981, J SUBMICR CYTOL PATH, V13, P465; OKUDA M, 1983, EUR J RESPIR DIS, V64, P7; PIPKORN U, 1989, AM REV RESPIR DIS, V140, P729, DOI 10.1164/ajrccm/140.3.729; PIPKORN U, 1988, J IMMUNOL METHODS, V112, P37, DOI 10.1016/0022-1759(88)90030-0; PIPKORN U, 1988, INT ARCH ALLER A IMM, V87, P349, DOI 10.1159/000234700; PIPKORN U, 1987, INT ARCH ALLER A IMM, V84, P123, DOI 10.1159/000234410; PIPKORN U, 1988, J ALLERGY CLIN IMMUN, V82, P1046, DOI 10.1016/0091-6749(88)90143-1; POPPER H, 1989, INFLAMMATION, V13, P147, DOI 10.1007/BF00924786; TAI PC, 1981, BRIT J HAEMATOL, V49, P219, DOI 10.1111/j.1365-2141.1981.tb07218.x; WINTHER B, 1984, ACTA OTO-LARYNGOL, P19	27	82	84	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1992	90	6	1				898	909		10.1016/0091-6749(92)90462-B	http://dx.doi.org/10.1016/0091-6749(92)90462-B			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KD190	1281177	Bronze			2022-12-18	WOS:A1992KD19000006
J	KNANI, J; CAMPBELL, A; ENANDER, I; PETERSON, CGB; MICHEL, FB; BOUSQUET, J				KNANI, J; CAMPBELL, A; ENANDER, I; PETERSON, CGB; MICHEL, FB; BOUSQUET, J			INDIRECT EVIDENCE OF NASAL INFLAMMATION ASSESSED BY TITRATION OF INFLAMMATORY MEDIATORS AND ENUMERATION OF CELLS IN NASAL SECRETIONS OF PATIENTS WITH CHRONIC RHINITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						RHINITIS; INFLAMMATION; ALLERGY; EOSINOPHILS; NEUTROPHILS; HISTAMINE; TRYPTASE; PGD2; LTC4	EOSINOPHIL CATIONIC PROTEIN; NATURAL ALLERGEN EXPOSURE; PLACEBO-CONTROLLED IMMUNOTHERAPY; GRASS-POLLEN ALLERGOIDS; PULMONARY MAST-CELLS; LAVAGE FLUID; ANTIGEN CHALLENGE; HAY-FEVER; MONOCLONAL-ANTIBODIES; BIOCHEMICAL-ANALYSIS	Pathophysiologic mechanisms of perennial rhinitis are poorly understood. The characterization of inflammation was studied in nasal lavage of patients with perennial rhinitis by the enumeration of cells involved in the allergic inflammation and the measurement of six mediators released in nasal secretions to determine whether some mediators were relevant for the etiologic diagnosis and the occurrence of symptoms. Ten healthy subjects and 57 patients with perennial rhinitis were placed into four groups according to the symptoms they presented at the time of the study and the origin of the allergy. Allergy was characterized by the history, skin prick tests to standardized allergens, and RAST. Eosinophil protein X (EPX), tryptase, histamine, myeloperoxidase, prostaglandin D2, and leukotriene C4/D4 (LTC4/D4) were measured in nasal lavage by enzyme assay or radioimmunoassay. Eosinophils and neutrophils were enumerated after cytocentrifugation of the lavage fluid and May Grunwald Giemsa staining. Tryptase, myeloperoxidase and EPX but not histamine levels were increased in all four patient groups. Eosinophils, LTC4/D4, and prostaglandin D2 were significantly (p < 0.001, p < 0.03, and p < 0.01) increased in allergic and symptomatic patients. EPX was significantly increased in symptomatic allergic and nonallergic patients. This study suggests the involvement of mast cells, neutrophils, and eosinophils, but the latter cells appear to have a more prominent role. The importance of EPX and LTC4/D4 in the characterization of chronic symptomatic rhinitis was also observed.	CHU MONTPELLIER, HOP LAIGUELONGUE, MALAD RESP CLIN, F-34059 MONTPELLIER, FRANCE; PHARMACIA DIAGNOST AB, UPPSALA, SWEDEN	Universite de Montpellier; CHU de Montpellier; Pfizer; Pharmacia Corporation			Bousquet, Jean/O-4221-2019					ANDERSSON M, 1989, ALLERGY, V44, P342, DOI 10.1111/j.1398-9995.1989.tb00456.x; ANDERSSON M, 1990, J ALLERGY CLIN IMMUN, V86, P815, DOI 10.1016/S0091-6749(05)80188-5; ANDERSSON M, 1989, AM REV RESPIR DIS, V139, P911, DOI 10.1164/ajrccm/139.4.911; ANGGARD A, 1979, Rhinology (Utrecht), V17, P31; BASCOM R, 1989, J ALLERGY CLIN IMMUN, V84, P338, DOI 10.1016/0091-6749(89)90418-1; BASCOM R, 1988, AM REV RESPIR DIS, V138, P406, DOI 10.1164/ajrccm/138.2.406; BASCOM R, 1988, J ALLERGY CLIN IMMUN, V81, P570, DOI 10.1016/0091-6749(88)90198-4; BAUMGARTEN CR, 1986, J IMMUNOL, V137, P1323; BINDER E, 1984, Rhinology (Utrecht), V22, P255; BISGAARD H, 1990, J ALLERGY CLIN IMMUN, V85, P891, DOI 10.1016/0091-6749(90)90074-E; BISGAARD H, 1988, ALLERGY, V43, P219; BOUSQUET J, 1988, J ALLERGY CLIN IMMUN, V82, P439, DOI 10.1016/0091-6749(88)90017-6; BOUSQUET J, 1985, J ALLERGY CLIN IMMUN, V76, P734, DOI 10.1016/0091-6749(85)90680-3; BRUYNZEEL PLB, 1985, FEBS LETT, V189, P350, DOI 10.1016/0014-5793(85)81054-1; CARLSON M, 1991, J ALLERGY CLIN IMMUN, V87, P27, DOI 10.1016/0091-6749(91)90209-7; CASTELLS M, 1988, J ALLERGY CLIN IMMUN, V82, P348, DOI 10.1016/0091-6749(88)90005-X; CRAIG SS, 1989, IMMUNOL RES, V8, P130, DOI 10.1007/BF02919075; CRETICOS PS, 1984, NEW ENGL J MED, V310, P1626, DOI 10.1056/NEJM198406213102502; ENANDER I, 1991, J IMMUNOL METHODS, V138, P39, DOI 10.1016/0022-1759(91)90062-K; ENERBACK L, 1986, INT ARCH ALLER A IMM, V80, P44, DOI 10.1159/000234024; FOKKENS WJ, 1990, INT ARCH ALLER A IMM, V93, P66, DOI 10.1159/000235281; FRIEDMAN MM, 1985, J ALLERGY CLIN IMMUN, V76, P70, DOI 10.1016/0091-6749(85)90807-3; GLEICH GJ, 1984, ANNU REV IMMUNOL, V2, P429, DOI 10.1146/annurev.immunol.2.1.429; GOMEZ E, 1986, J ALLERGY CLIN IMMUN, V78, P637, DOI 10.1016/0091-6749(86)90082-5; HOLGATE ST, 1984, J IMMUNOL, V133, P2138; ILIOPOULOS O, 1991, J ALLERGY CLIN IMMUN, V87, P855, DOI 10.1016/0091-6749(91)90134-A; IRANI AA, 1988, P NATL ACAD SCI USA, V140, P3936; JACOBS RL, 1981, J ALLERGY CLIN IMMUN, V67, P253, DOI 10.1016/0091-6749(81)90019-1; JULIUSSON S, 1991, ALLERGY, V46, P459; Klebanoff SJ., 1988, INFLAMMATION BASIC P, P391; LEBEL B, 1988, J ALLERGY CLIN IMMUN, V82, P869, DOI 10.1016/0091-6749(88)90092-9; LINDER A, 1987, ALLERGY, V42, P583, DOI 10.1111/j.1398-9995.1987.tb00388.x; LINDER A, 1987, ALLERGY, V42, P126, DOI 10.1111/j.1398-9995.1987.tb02370.x; MACLOUF J, 1986, PROSTAGLANDINS, V31, P123, DOI 10.1016/0090-6980(86)90230-3; MALMBERG H, 1986, ALLERGIC VASOMOTOR R, P91; MCBRIDE PT, 1989, ACI NEWS, V2, P50; MESLIER N, 1988, AM REV RESPIR DIS, V137, P617, DOI 10.1164/ajrccm/137.3.617; MIADONNA A, 1987, AM REV RESPIR DIS, V136, P357, DOI 10.1164/ajrccm/136.2.357; MIKAELIAN A J, 1989, Ear Nose and Throat Journal, V68, P207; MOREL AM, 1988, J ALLERGY CLIN IMMUN, V82, P646, DOI 10.1016/0091-6749(88)90978-5; MULLARKEY MF, 1980, J ALLERGY CLIN IMMUN, V65, P122, DOI 10.1016/0091-6749(80)90196-7; Mygind N, 1978, NASAL ALLERGY; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; NACLERIO RM, 1991, AM REV RESPIR DIS, V143, pS91, DOI 10.1164/ajrccm/143.5_Pt_2.S91; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; OLSSON I, 1977, LAB INVEST, V36, P493; ONORATO J, 1986, J ALLERGY CLIN IMMUN, V78, P1139, DOI 10.1016/0091-6749(86)90263-0; OWEN WF, 1987, J IMMUNOL, V138, P532; PATERSON NAM, 1976, J IMMUNOL, V117, P1356; PELIKAN Z, 1989, J ALLERGY CLIN IMMUN, V83, P1068, DOI 10.1016/0091-6749(89)90448-X; PETERSON CGB, 1983, IMMUNOLOGY, V50, P19; PIPKORN U, 1989, PROGRESS IN ALLERGY AND CLINICAL IMMUNOLOGY, P237; PIPKORN U, 1989, AM REV RESPIR DIS, V140, P729, DOI 10.1164/ajrccm/140.3.729; PIPKORN U, 1989, CLIN EXP ALLERGY, V19, P585, DOI 10.1111/j.1365-2222.1989.tb02750.x; PIPKORN U, 1988, J IMMUNOL METHODS, V112, P37, DOI 10.1016/0022-1759(88)90030-0; PIPKORN U, 1988, EUR RESPIR J, V1, P856; PIPKORN U, 1988, J ALLERGY CLIN IMMUN, V82, P1046, DOI 10.1016/0091-6749(88)90143-1; PRADELLES P, 1985, ANAL CHEM, V57, P1170, DOI 10.1021/ac00284a003; SCHWARTZ LB, 1981, J BIOL CHEM, V256, P1939; SCHWARTZ LB, 1990, J IMMUNOL, V144, P2304; SHAW RJ, 1985, ALLERGY, V40, P1, DOI 10.1111/j.1398-9995.1985.tb04147.x; SKONER DP, 1990, ANN ALLERGY, V65, P206; SMITH TF, 1982, INT ARCH ALLER A IMM, V67, P380, DOI 10.1159/000233051; SPECTOR SL, 1980, J ALLERGY CLIN IMMUN, V66, P129, DOI 10.1016/0091-6749(80)90060-3; SVENSSON C, 1990, J ALLERGY CLIN IMMUN, V85, P828, DOI 10.1016/0091-6749(90)90064-B; UVNAS B, 1970, ACTA PHYSIOL SCAND, V78, P1; VENGE P, 1987, INT ARCH ALLER A IMM, V82, P333, DOI 10.1159/000234219; VIEGAS M, 1987, BRIT MED J, V294, P414, DOI 10.1136/bmj.294.6569.414; VOLOVITZ B, 1988, J ALLERGY CLIN IMMUN, V82, P414, DOI 10.1016/0091-6749(88)90000-0; WALDEN SM, 1988, J ALLERGY CLIN IMMUN, V81, P940, DOI 10.1016/0091-6749(88)90157-1; WENZEL S, 1986, J IMMUNOL METHODS, V86, P139, DOI 10.1016/0022-1759(86)90277-2; WILSON J, 1988, ANN OTO RHINOL LARYN, V97, P389, DOI 10.1177/000348948809700411	72	82	86	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1992	90	6	1				880	889		10.1016/0091-6749(92)90460-J	http://dx.doi.org/10.1016/0091-6749(92)90460-J			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KD190	1334102				2022-12-18	WOS:A1992KD19000004
J	CALDERON, E; LOCKEY, RF				CALDERON, E; LOCKEY, RF			A POSSIBLE ROLE FOR ADHESION MOLECULES IN ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							VASCULAR ENDOTHELIAL-CELLS; BRONCHIAL EPITHELIAL-CELLS; PLATELET-ACTIVATING FACTOR; COLONY-STIMULATING FACTOR; TUMOR-NECROSIS-FACTOR; PRODUCE CHEMOTACTIC ACTIVITY; GRANULE MEMBRANE-PROTEIN; LEUKOCYTE ADHESION; INTERCELLULAR-ADHESION; HUMAN EOSINOPHILS	Recently interest has increased tremendously in the possible roles of adhesion molecules on inflammatory cells, vascular endothelium, and matrix proteins in the allergic inflammatory response. The authors have reviewed some of the recent findings and speculated about their implications, with the understanding that some of the conclusions will require confirmation by in vivo studies of allergic reactions.	UNIV S FLORIDA, DIV ALLERGY & IMMUNOL, TAMPA, FL 33620 USA	State University System of Florida; University of South Florida	CALDERON, E (corresponding author), JAMES A HALEY VET AFFAIRS HOSP, DIV ALLERGY & IMMUNOL, VAR 111 D, 13000 BRUCE B DOWNS BLVD, TAMPA, FL 33612 USA.							ALBELDA SM, 1991, AM J RESP CELL MOL, V4, P195, DOI 10.1165/ajrcmb/4.3.195; ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; ARMITAGE RJ, 1990, J IMMUNOL, V144, P938; BARTH C, 1991, TRANSPLANT P, V23, P824; BEVILACQUA M, 1991, CELL, V67, P233, DOI 10.1016/0092-8674(91)90174-W; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BOCHNER BS, 1990, J IMMUNOL, V145, P1832; BOCHNER BS, 1991, J EXP MED, V173, P1553, DOI 10.1084/jem.173.6.1553; BORISH L, 1991, J IMMUNOL, V146, P63; BUCKLE AM, 1990, EUR J IMMUNOL, V20, P337, DOI 10.1002/eji.1830200216; BURN P, 1988, P NATL ACAD SCI USA, V85, P497, DOI 10.1073/pnas.85.2.497; CORKILL MM, 1991, J RHEUMATOL, V18, P1453; CORRIGAN CJ, 1990, AM REV RESPIR DIS, V141, P970, DOI 10.1164/ajrccm/141.4_Pt_1.; CRONSTEIN BN, 1991, FASEB J, V5, pA510; DEFOUGEROLLES AR, 1992, J EXP MED, V175, P185, DOI 10.1084/jem.175.1.185; DETMERS PA, 1990, J EXP MED, V171, P1155, DOI 10.1084/jem.171.4.1155; DOERSCHUK CM, 1990, J IMMUNOL, V144, P2327; DUITS AJ, 1991, SCAND J IMMUNOL, V33, P151, DOI 10.1111/j.1365-3083.1991.tb03745.x; DUSTIN ML, 1986, J IMMUNOL, V137, P245; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; ELLIOTT MJ, 1990, J IMMUNOL, V145, P167; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; GIMBRONE MA, 1989, SCIENCE, V246, P1601, DOI 10.1126/science.2688092; GORDON J, 1992, CLIN EXP ALLERGY, V22, P199, DOI 10.1111/j.1365-2222.1992.tb03073.x; GRANGETTE C, 1989, J IMMUNOL, V143, P3580; GRIFFIN JD, 1990, J IMMUNOL, V145, P576; GUNDEL RH, 1991, J CLIN INVEST, V88, P1407, DOI 10.1172/JCI115447; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; HANCOCK WW, 1987, J IMMUNOL, V138, P185; HANSEL TT, 1991, CLIN EXP IMMUNOL, V86, P271; HARTNELL A, 1990, IMMUNOLOGY, V69, P264; HATTORI R, 1989, J BIOL CHEM, V264, P7768; HIBBS ML, 1991, SCIENCE, V251, P1611, DOI 10.1126/science.1672776; HOGG N, 1992, IMMUNOL TODAY, V13, P113, DOI 10.1016/0167-5699(92)90103-E; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; ISSEKUTZ TB, 1990, J IMMUNOL, V144, P2140; KIMANI G, 1988, J IMMUNOL, V140, P3161; KLEIN LM, 1989, P NATL ACAD SCI USA, V86, P8972, DOI 10.1073/pnas.86.22.8972; KOMORIYA A, 1991, J BIOL CHEM, V266, P15075; KYANAUNG U, 1991, J IMMUNOL, V146, P521; LAMAS AM, 1988, J IMMUNOL, V140, P1500; LEEUWENBERG JFM, 1990, J IMMUNOL, V145, P2110; LEUNG DYM, 1991, J CLIN INVEST, V87, P1805, DOI 10.1172/JCI115201; LONDEI M, 1990, EUR J IMMUNOL, V20, P425, DOI 10.1002/eji.1830200228; LU L, 1990, EXP HEMATOL, V18, P1180; LUSCINSKAS FW, 1991, J IMMUNOL, V146, P1617; MAGGI E, 1989, IMMUNOLOGY, V68, P300; MASINOVSKY B, 1990, J IMMUNOL, V145, P2886; MATIS WL, 1990, J INVEST DERMATOL, V94, P492, DOI 10.1111/1523-1747.ep12874665; Matsushima K, 1989, Cytokine, V1, P2, DOI 10.1016/1043-4666(89)91043-0; MCEVER RP, 1989, J CLIN INVEST, V84, P92, DOI 10.1172/JCI114175; MCINTYRE TM, 1986, P NATL ACAD SCI USA, V83, P2204, DOI 10.1073/pnas.83.7.2204; MILLER LJ, 1987, J CLIN INVEST, V80, P535, DOI 10.1172/JCI113102; MUDDE GC, 1992, IMMUNOL TODAY, V13, P80; NORTAMO P, 1991, EUR J IMMUNOL, V21, P2629, DOI 10.1002/eji.1830211049; OHNO I, 1990, AM J RESP CELL MOL, V3, P285, DOI 10.1165/ajrcmb/3.4.285; OSBORN L, 1990, CELL, V62, P3, DOI 10.1016/0092-8674(90)90230-C; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; PATARROYO M, 1989, LANCET, V2, P1139; PATEL KD, 1991, J CELL BIOL, V112, P749, DOI 10.1083/jcb.112.4.749; PETZELBAUER P, 1991, J INVEST DERMATOL, V96, P362, DOI 10.1111/1523-1747.ep12465404; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; ROCHE WR, 1989, LANCET, V1, P520; ROTHLEIN R, 1988, J IMMUNOL, V141, P1665; RUOSLAHTI E, 1986, CELL, V44, P517, DOI 10.1016/0092-8674(86)90259-X; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SALONEN RO, 1988, BRIT J PHARMACOL, V95, P1262, DOI 10.1111/j.1476-5381.1988.tb11763.x; SCHLEIMER RP, 1992, J IMMUNOL, V148, P1086; SCHRODER JM, 1989, J EXP MED, V170, P847, DOI 10.1084/jem.170.3.847; SEDGWICK JB, 1990, J ALLERGY CLIN IMMUN, V85, P557, DOI 10.1016/0091-6749(90)90093-J; SHAPPELL SB, 1990, J IMMUNOL, V144, P2702; SHOJI S, 1990, AM REV RESPIR DIS, V141, P218, DOI 10.1164/ajrccm/141.1.218; SHOJI S, 1989, AM J RESP CELL MOL, V1, P13, DOI 10.1165/ajrcmb/1.1.13; SIBILLE Y, 1990, AM REV RESPIR DIS, V141, P471, DOI 10.1164/ajrccm/141.2.471; SMITH CW, 1991, J CLIN INVEST, V87, P609, DOI 10.1172/JCI115037; SOCINSKI MA, 1988, BLOOD, V72, P691; SPERTINI O, 1991, NATURE, V349, P691, DOI 10.1038/349691a0; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SPRINGER TA, 1986, J IMMUNOL, V136, P240; STANDIFORD TJ, 1990, J CLIN INVEST, V86, P1945, DOI 10.1172/JCI114928; STOTTER H, 1991, J IMMUNOL, V146, P150; STRETTON CD, 1988, BRIT J PHARMACOL, V93, P672, DOI 10.1111/j.1476-5381.1988.tb10325.x; SUNG CP, 1991, CIRC RES, V68, P314, DOI 10.1161/01.RES.68.1.314; THOMPSON HL, 1989, J IMMUNOL, V143, P2323; THORNHILL MH, 1990, J IMMUNOL, V144, P3060; THORNHILL MH, 1990, J IMMUNOL, V145, P865; VALENT P, 1990, INT ARCH ALLER A IMM, V91, P198, DOI 10.1159/000235115; VALENT P, 1991, P NATL ACAD SCI USA, V88, P3339, DOI 10.1073/pnas.88.8.3339; WALSH GM, 1990, BLOOD, V76, P105; WALSH GM, 1991, J IMMUNOL, V146, P3419; WALSH GM, 1990, IMMUNOLOGY, V71, P258; WALSH LJ, 1991, P NATL ACAD SCI USA, V88, P4220, DOI 10.1073/pnas.88.10.4220; WEGNER CD, 1990, SCIENCE, V247, P456, DOI 10.1126/science.1967851; WODNARFILIPOWICZ A, 1989, NATURE, V339, P150, DOI 10.1038/339150a0; YAMAUCHI K, 1991, AM REV RESPIR DIS, V43, pA39; ZIMMERMAN GA, 1990, J CELL BIOL, V110, P529, DOI 10.1083/jcb.110.2.529; 1990, LANCET, V336, P1351	98	82	87	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1992	90	5					852	865		10.1016/0091-6749(92)90112-F	http://dx.doi.org/10.1016/0091-6749(92)90112-F			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JZ319	1430710	Bronze			2022-12-18	WOS:A1992JZ31900018
J	SIMONS, FER				SIMONS, FER			THE ANTIALLERGIC EFFECTS OF ANTIHISTAMINES (H1-RECEPTOR ANTAGONISTS)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ALLERGIC RHINITIS; ANTIHISTAMINES; BASOPHILS; BRONCHOCONSTRICTION; MAST CELLS; MEDIATOR RELEASE	CONJUNCTIVAL PROVOCATION TEST; HISTAMINE-RELEASE INVIVO; HUMAN-LUNG INVITRO; MEDIATOR RELEASE; MAST-CELLS; INHALED ALLERGEN; NASAL CHALLENGE; ATOPIC ASTHMA; INHIBITION; AZELASTINE	Most first-generation and second-generation H-1-receptor antagonists have readily demonstrable antiallergic effects in vitro, although high concentrations of some of the medications are required to inhibit mediator secretion from mast cells or basophils. These antiallergic effects can also be seen in vivo in skin, nasal, lung, and ocular challenge studies. Some H-1-receptor antagonists appear to have an antiallergic effect in one organ but not in another. In many in vivo studies, doses of H-1-receptor antagonists three or more times higher than those required for H-1 blockade must be given to achieve the antiallergic effect. It would be premature to attempt to reclassify the H-1 antagonists according to their antiallergic properties because these properties have not been investigated fully and their relative contribution to the overall therapeutic effectiveness of each H-1 receptor antagonist is unknown.	UNIV MANITOBA,DEPT PEDIAT & CHILD HLTH,WINNIPEG R3T 2N2,MANITOBA,CANADA; UNIV MANITOBA,ALLERGY & CLIN IMMUNOL SECT,WINNIPEG R3T 2N2,MANITOBA,CANADA	University of Manitoba; University of Manitoba								ARUNLAKSHANA O, 1953, J PHYSIOL-LONDON, V119, pP47; AWOUTERS FHL, 1983, ARZNEIMITTEL-FORSCH, V33-1, P381; BOUSQUET J, 1988, J ALLERGY CLIN IMMUN, V82, P881, DOI 10.1016/0091-6749(88)90094-2; BRUNET C, 1990, J ALLERGY CLIN IMMUN, V86, P787, DOI 10.1016/S0091-6749(05)80184-8; CHAND N, 1983, EUR J PHARMACOL, V96, P227, DOI 10.1016/0014-2999(83)90311-4; CHARLESWORTH EN, 1989, J ALLERGY CLIN IMMUN, V83, P905, DOI 10.1016/0091-6749(89)90104-8; CHURCH MK, 1980, BRIT J PHARMACOL, V69, P663, DOI 10.1111/j.1476-5381.1980.tb07919.x; DEVOS C, 1989, INT ARCH ALLER A IMM, V88, P212, DOI 10.1159/000234789; GIGL G, 1987, CELL CALCIUM, V8, P327, DOI 10.1016/0143-4160(87)90008-X; HAMID M, 1990, CLIN EXP ALLERGY, V20, P261, DOI 10.1111/j.1365-2222.1990.tb02681.x; HOLGATE ST, 1985, J ALLERGY CLIN IMMUN, V76, P375, DOI 10.1016/0091-6749(85)90657-8; HUSTON DP, 1986, ANN INTERN MED, V104, P507, DOI 10.7326/0003-4819-104-4-507; KATAYAMA S, 1987, INT ARCH ALLER A IMM, V83, P284, DOI 10.1159/000234309; KLEMENTSSON H, 1990, J ALLERGY CLIN IMMUN, V86, P466, DOI 10.1016/S0091-6749(05)80201-5; KREUTNER W, 1987, ALLERGY, V42, P57, DOI 10.1111/j.1398-9995.1987.tb02188.x; LAI CKW, 1989, CLIN EXP ALLERGY, V19, P209, DOI 10.1111/j.1365-2222.1989.tb02366.x; LICHTENSTEIN LM, 1975, J PHARMACOL EXP THER, V192, P441; LITTLE MM, 1989, AGENTS ACTIONS, V28, P16, DOI 10.1007/BF02022975; LITTLE MM, 1989, J ALLERGY CLIN IMMUN, V83, P862, DOI 10.1016/0091-6749(89)90096-1; MAJCHEL AM, 1990, CLIN EXP ALLERGY, V20, P701, DOI 10.1111/j.1365-2222.1990.tb02711.x; MAJCHEL AM, 1991, J ALLERGY CLIN IMMUN, V87, P151; MICHEL L, 1990, ANN ALLERGY, V65, P512; MIDDLETON E, 1989, AGENTS ACTIONS, V28, P9, DOI 10.1007/BF02022974; MORGAN DJR, 1985, CLIN SCI, V69, P63, DOI 10.1042/cs0690063; MOTA I, 1960, BRIT J PHARM CHEMOTH, V15, P396, DOI 10.1111/j.1476-5381.1960.tb01262.x; NABE M, 1989, CLIN EXP ALLERGY, V19, P515, DOI 10.1111/j.1365-2222.1989.tb02426.x; NACLERIO RM, 1990, AM REV RESPIR DIS, V142, P167, DOI 10.1164/ajrccm/142.1.167; NACLERIO RM, 1989, LARYNGOSCOPE, V99, P596; PECOUD A, 1987, INT ARCH ALLER A IMM, V82, P541, DOI 10.1159/000234274; RAFFERTY P, 1989, J ALLERGY CLIN IMMUN, V84, P649, DOI 10.1016/0091-6749(89)90292-3; RIMAS M, 1990, ALLERGY, V45, P18, DOI 10.1111/j.1398-9995.1990.tb01079.x; RIMMER SJ, 1990, CLIN EXP ALLERGY, V20, P3, DOI 10.1111/j.1365-2222.1990.tb02456.x; SCHOENEICH M, 1990, CLIN EXP ALLERGY, V20, P171, DOI 10.1111/j.1365-2222.1990.tb02663.x; SIMONS F E R, 1991, Journal of Allergy and Clinical Immunology, V87, P225, DOI 10.1016/0091-6749(91)91625-4; SIMONS FER, 1989, J ALLERGY CLIN IMMUN, V84, P845, DOI 10.1016/0091-6749(89)90377-1; SIMONS FER, 1991, TXB PHARM, P1104; Staub AM, 1937, CR SOC BIOL, V125, P818; TASAKA K, 1986, ANN ALLERGY, V56, P464; TEMPLE DM, 1988, PROSTAGLANDINS, V35, P549, DOI 10.1016/0090-6980(88)90030-5; TING S, 1985, J ALLERGY CLIN IMMUN, V75, P63, DOI 10.1016/0091-6749(85)90013-2; TOGIAS AG, 1986, JAMA-J AM MED ASSOC, V255, P225, DOI 10.1001/jama.255.2.225; Tomioka H, 1979, Monogr Allergy, V14, P313; TOWN GI, 1990, J ALLERGY CLIN IMMUN, V86, P886, DOI 10.1016/S0091-6749(05)80151-4; TRZECIAKOWSKI JP, 1988, ALLERGY PRINCIPLES P, P715; ZUBER P, 1988, J ALLERGY CLIN IMMUN, V82, P590, DOI 10.1016/0091-6749(88)90969-4	45	82	82	0	7	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1992	90	4	2	S			705	715		10.1016/0091-6749(92)90156-V	http://dx.doi.org/10.1016/0091-6749(92)90156-V			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JV009	1383310				2022-12-18	WOS:A1992JV00900002
J	GUILLOUX, L; RICARDBLUM, S; VILLE, G; MOTIN, J				GUILLOUX, L; RICARDBLUM, S; VILLE, G; MOTIN, J			A NEW RADIOIMMUNOASSAY USING A COMMERCIALLY AVAILABLE SOLID SUPPORT FOR THE DETECTION OF IGE ANTIBODIES AGAINST MUSCLE-RELAXANTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						RADIOIMMUNOASSAY; IGE; MUSCLE RELAXANTS; ALLERGY	SUXAMETHONIUM; ANAPHYLAXIS; DRUGS; DETERMINANTS; ANESTHESIA; ALLERGY	It is well established that muscle-relaxant drugs may be responsible for anaphylactoid reactions during anesthesia. In this study, we developed an in vitro test with a commercially available solid phase for the detection of specific IgE directed to the tertiary or quaternary ammonium groups of neuromuscular-blocking drugs. The solid-phase complex was P-aminophenylphosphoryl-choline (PAPPC) immobilized on agarose, and an RIA was performed with an antihuman IgE labeled with I-125. The results, expressed as the percentage of I-125-labeled anti-IgE linked to the solid phase, were at 0.41 +/- 0.19 for 34 control sera from nonallergic healthy adults, with an upper limit estimated at 1%. The values obtained with the sera of 31 allergic patients ranged from 0.6% to 41% with a sensitivity of 97%. The specificity and the positive predictive value of the PAPPC RIA were 97% and 94%, respectively. These results were compared with results of other RIAs with morphine, trimethylamine, triethylamine immobilized on epoxy-activated Sepharose, and choline hydrochloride immobilized on Sepharose (quaternary ammonium Sepharose RIA) and with Phadebas RAST succinylcholine and Phadebas RAST alcuronium. The PAPPC RIA appears to be the most efficient test to screen sera for the presence of IgE antibodies directed to neuromuscular-blocking drugs. One major advantage is that this solid phase is commercially available and ready to use. This advantage will improve the accuracy in the comparison of the results with results from different laboratories.	HOP EDOUARD HERRIOT,DEPT ANESTHESIE & REANIMAT 4,F-69374 LYON 08,FRANCE	CHU Lyon	GUILLOUX, L (corresponding author), INST PASTEUR LYON,CTR RADIOANAL,13-15 RUE DOMER,F-69366 LYON 07,FRANCE.			RICARD-BLUM, Sylvie/0000-0001-9263-1851				BALDO BA, 1983, MOL IMMUNOL, V20, P1393, DOI 10.1016/0161-5890(83)90171-2; BALDO BA, 1983, NATURE, V306, P262, DOI 10.1038/306262a0; Boileau S, 1985, Ann Fr Anesth Reanim, V4, P195, DOI 10.1016/S0750-7658(85)80200-8; BRAHAMS D, 1989, LANCET, V1, P1400; DIDIER A, 1987, J ALLERGY CLIN IMMUN, V79, P578, DOI 10.1016/S0091-6749(87)80152-5; GUEANT JL, 1991, ALLERGY, V46, P452; HARLE DG, 1990, MOL IMMUNOL, V27, P1039, DOI 10.1016/0161-5890(90)90127-L; HARLE DG, 1984, LANCET, V1, P930; MONERETVAUTRIN DA, 1988, J ALLERGY CLIN IMMUN, V82, P745, DOI 10.1016/0091-6749(88)90074-7; MOSCICKI RA, 1990, J ALLERGY CLIN IMMUN, V86, P325, DOI 10.1016/S0091-6749(05)80095-8; VERVLOET D, 1985, J ALLERGY CLIN IMMUN, V75, P338, DOI 10.1016/0091-6749(85)90069-7	11	82	85	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1992	90	2					153	159		10.1016/0091-6749(92)90066-B	http://dx.doi.org/10.1016/0091-6749(92)90066-B			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JJ423	1500622				2022-12-18	WOS:A1992JJ42300003
J	SANDA, T; YASUE, T; OOHASHI, M; YASUE, A				SANDA, T; YASUE, T; OOHASHI, M; YASUE, A			EFFECTIVENESS OF HOUSE DUST-MITE ALLERGEN AVOIDANCE THROUGH CLEAN ROOM THERAPY IN PATIENTS WITH ATOPIC-DERMATITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ATOPIC DERMATITIS; CLEAN ROOM THERAPY; HEPA FILTER; HOUSE DUST-MITE ALLERGEN; LONG-TERM REMISSION; ALLERGEN-SPECIFIC IGG; DUST PARTICLES		We have investigated the effectiveness of house dust-mite (HDM) allergen avoidance through clean room (CR) therapy in patients with atopic dermatitis (AD) having high HDM-specific IgE RAST levels. All patients (N = 30) demonstrated marked improvement in symptom, a long-term remission (mean, 8.4 months), and significant decreases in eosinophil count (p < 0.01), basophil count (p < 0.05), serum lactate dehydrogenase activity (p < 0.01), and HDM-specific IgG levels (p < 0.05). By contrast, the patients with AD (N = 11), who scored 0 on HDM allergen-specific IgE RAST score underwent "CR" therapy, and the patients with AD (N = 10) having high HDM-specific IgE RAST levels were hospitalized in a common sickroom (nonclean room). All the patients (N = 21) exhibited slight improvement in symptoms and a significant decrease in serum lactate dehydrogenase activity. The period of recurrence after the therapy was brief. The results of measurement of airborne house-dust particles indicated that our "CR" fell within class 10,000. Therefore, it is very likely that the mechanism at work in the CR therapeutic approach is its ability to eliminate fecal pellets of the HDM.	DEPT DERMATOL,NAGOYA,JAPAN; SEIREI HOSP,NAGOYA,JAPAN		SANDA, T (corresponding author), NAGOYA UNIV,SCH MED,DEPT DERMATOL,TSURUMA CHO 65,SHOWA KU,NAGOYA,AICHI 464,JAPAN.							AUGUST PJ, 1984, BRIT J DERMATOL, V110, P10; BLYTHE ME, 1975, BRIT MED J, V11, P62; GONDO A, 1986, BRIT J DERMATOL, V115, P485, DOI 10.1111/j.1365-2133.1986.tb06243.x; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; LANDOW RK, 1984, HDB DERMATOLOGIC TRE, P177; LICHTENSTEIN LM, 1968, J IMMUNOL, V101, P317; MITCHELL EB, 1982, LANCET, V1, P127; Mukai H, 1987, JPN J DERMATOL, V97, P1623; PARISH WE, 1981, BRIT J DERMATOL, V105, P223, DOI 10.1111/j.1365-2133.1981.tb01210.x; PLATTSMILLS TAE, 1983, CLIN EXP DERMATOL, V8, P233, DOI 10.1111/j.1365-2230.1983.tb01776.x; RAJKA G, 1989, ACTA DERM-VENER    S, V144, P13; REITAMO S, 1986, BRIT J DERMATOL, V114, P303, DOI 10.1111/j.1365-2133.1986.tb02821.x; ROBERTS DLL, 1984, BRIT J DERMATOL, V110, P735, DOI 10.1111/j.1365-2133.1984.tb04714.x; SANDA T, 1989, J INVEST DERMATOL, V92, P511; SANDA T, 1989, JPN J DERMATOL, V13, P1373; TANAKA Y, 1988, Hifu, V30, P236; TOVEY ER, 1981, AM REV RESPIR DIS, V124, P630; TOVEY ER, 1981, NATURE, V289, P592, DOI 10.1038/289592a0; YAMAMOTO K, 1989, Hifu, V31, P153	19	82	85	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1992	89	3					653	657		10.1016/0091-6749(92)90370-H	http://dx.doi.org/10.1016/0091-6749(92)90370-H			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HJ340	1545086				2022-12-18	WOS:A1992HJ34000002
J	DEMOLY, P; BOUSQUET, J; MANDERSCHEID, JC; DREBORG, S; DHIVERT, H; MICHEL, FB				DEMOLY, P; BOUSQUET, J; MANDERSCHEID, JC; DREBORG, S; DHIVERT, H; MICHEL, FB			PRECISION OF SKIN PRICK AND PUNCTURE TESTS WITH 9 METHODS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						HISTAMINE; SKIN TEST; PRICK TEST; REPRODUCIBILITY; HUMAN	MORROW-BROWN NEEDLE; INTRADERMAL TEST; REPRODUCIBILITY; HISTAMINE; ALLERGY; HYPERSENSITIVITY; DIAGNOSIS; LANCET; PHAZET; MITE	New devices for puncture tests have been proposed recently, but their precision by comparison to the prick test method is poorly known. Seven puncture tests (Allerprick, Morrow Brown standardized needle, Phazer, Pricker, Stallerpointe, Stallerkit, and Wyeth bifucated needle) were compared with the modified prick test performed with hypodermic or intradermal needles in eight carefully selected normal volunteers. Skin tests with histamine hydrochloride (10 mg/ml) were only performed when there was no factor that might interfere with their interpretation. The site of skin tests on the forearm was demonstrated not to significantly influence the reaction size. The coefficient of variation of the tests ranged from 8.4% to 21.7%. Modified skin prick tests are satisfactory since they are highly reproducible (coefficient of variation: 13.4% and 16.5%) and there is no subject effect. Phazet was found to be more reproducible without subject effect. Pricker is satisfactory since it has no subject effect and a reproducibility similar to that of modified prick tests. Other tests are less reproducible (Stallerkit or Morrow Brown) or vary between subjects (Allerkit, Stallerkit, Stallerpointe, and Wyeth Needle).	HOP AIGUELONGUE, MALAD RESP CLIN, F-34059 MONTPELLIER, FRANCE; LINKOPING UNIV HOSP, DEPT INFORMAT MED, S-58185 LINKOPING, SWEDEN; LINKOPING UNIV HOSP, DEPT PEDIAT, S-58185 LINKOPING, SWEDEN	Linkoping University; Linkoping University			Demoly, Pascal/Y-9938-2019; Bousquet, Jean/O-4221-2019	Demoly, Pascal/0000-0001-7827-7964; 				ADINOFF AD, 1989, J ALLERGY CLIN IMMUN, V84, P168, DOI 10.1016/0091-6749(89)90321-7; [Anonymous], 1989, ALLERGY S10, V10, P1; BASOMBA A, 1985, ALLERGY, V40, P395, DOI 10.1111/j.1398-9995.1985.tb02677.x; BELIN L, 1985, ALLERGY S4, V40, P60; BELIN L, 1986, 4TH P INT P EHRL SEM, P145; BOUSQUET J, 1985, CLIN ALLERGY, V15, P29, DOI 10.1111/j.1365-2222.1985.tb02251.x; BOUSQUET J, 1988, ALLERGY PRINCIPLES P, P414; BROWN HM, 1981, CLIN ALLERGY, V11, P95, DOI 10.1111/j.1365-2222.1981.tb01571.x; CHANAL I, 1988, J ALLERGY CLIN IMMUN, V82, P878, DOI 10.1016/0091-6749(88)90093-0; CLARK EV, 1982, COGNITION, V12, P1, DOI 10.1016/0010-0277(82)90027-0; DIRKSEN A, 1983, ALLERGY, V38, P359, DOI 10.1111/j.1398-9995.1983.tb04131.x; DREBORG S, 1985, ALLERGY, V39, P27; GARIBALDI E, 1990, ANN ALLERGY, V65, P481; HOLGERSSON M, 1985, ALLERGY S4, V40, P64; KNIKER WT, 1979, ANN ALLERGY, V43, P73; LEE RE, 1977, ANN ALLERGY, V38, P231; MALLING HJ, 1985, ALLERGY, V40, P354, DOI 10.1111/j.1398-9995.1985.tb00247.x; MALLING HJ, 1985, ALLERGY, V40, P400, DOI 10.1111/j.1398-9995.1985.tb02678.x; MALLING HJ, 1984, ALLERGY, V39, P596, DOI 10.1111/j.1398-9995.1984.tb01979.x; MENARDO JL, 1982, ANN ALLERGY, V48, P235; NELSON HS, 1983, ANN ALLERGY, V51, P411; NIEROP G, 1981, ANN ALLERGY, V46, P105; OSTERBALLE O, 1979, ALLERGY, V34, P209, DOI 10.1111/j.1398-9995.1979.tb01700.x; OSTERBALLE O, 1989, ALLERGY, V44, P356, DOI 10.1111/j.1398-9995.1989.tb00458.x; PEPYS J, 1973, CLIN ALLERGY, V3, P491, DOI 10.1111/j.1365-2222.1973.tb03057.x; Pepys J., 1975, BR J HOSP MED, V14, P412; PERRIN LF, 1984, CLIN ALLERGY, V14, P581, DOI 10.1111/j.1365-2222.1984.tb02246.x; SANTILLI J, 1980, J ALLERGY CLIN IMMUN, V65, P406, DOI 10.1016/0091-6749(80)90232-8; SWAIN HH, 1952, J ALLERGY, V23, P441, DOI 10.1016/0021-8707(52)90008-7; TAUDORF E, 1985, ALLERGY, V40, P344, DOI 10.1111/j.1398-9995.1985.tb00245.x; TERHO EO, 1989, ALLERGY, V44, P30, DOI 10.1111/j.1398-9995.1989.tb00442.x; VOHLONEN I, 1989, ALLERGY, V44, P525, DOI 10.1111/j.1398-9995.1989.tb04196.x; VOORHORST R, 1973, ANN ALLERGY, V31, P195; Watson H K, 1989, Allergy, V44, P442, DOI 10.1111/j.1398-9995.1989.tb04177.x; 1989, NLN PUBLICATION, V23	35	82	82	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1991	88	5					758	762		10.1016/0091-6749(91)90183-O	http://dx.doi.org/10.1016/0091-6749(91)90183-O			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GQ452	1955634	Bronze			2022-12-18	WOS:A1991GQ45200011
J	JUNIPER, EF; KLINE, PA; HARGREAVE, FE; DOLOVICH, J				JUNIPER, EF; KLINE, PA; HARGREAVE, FE; DOLOVICH, J			COMPARISON OF BECLOMETHASONE DIPROPIONATE AQUEOUS NASAL SPRAY, ASTEMIZOLE, AND THE COMBINATION IN THE PROPHYLACTIC TREATMENT OF RAGWEED POLLEN INDUCED RHINOCONJUNCTIVITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ST JOSEPHS HOSP,DEPT MED,HAMILTON L8N 1Y4,ONTARIO,CANADA; ST JOSEPHS HOSP,DEPT PAEDIAT,HAMILTON L8N 1Y4,ONTARIO,CANADA	McGill University; McMaster University; McGill University; McMaster University	JUNIPER, EF (corresponding author), MCMASTER UNIV,MED CTR,DEPT CLIN EPIDEMIOL & BIOSTAT,1206 MAIN ST W,HAMILTON L8N 325,ONTARIO,CANADA.							BESWICK KBJ, 1985, CURR MED RES OPIN, V9, P560, DOI 10.1185/03007998509109635; BROGDEN RN, 1984, DRUGS, V28, P99, DOI 10.2165/00003495-198428020-00002; DICKSON DJ, 1984, BRIT J CLIN PRACT, V38, P416; DUNN AM, 1984, POSTGRAD MED J, V60, P404, DOI 10.1136/pgmj.60.704.404; HOWARTH PH, 1984, BRIT J CLIN PHARMACO, V18, P1; HOWARTH PH, 1984, THORAX, V39, P668, DOI 10.1136/thx.39.9.668; JUNIPER EF, 1981, CLIN ALLERGY, V11, P61, DOI 10.1111/j.1365-2222.1981.tb01567.x; JUNIPER EF, 1988, J ALLERGY CLIN IMMUN, V82, P670, DOI 10.1016/0091-6749(88)90981-5; KLEINBAUM DG, 1978, APPLIED REGRESSION A, P264; MUNCH EP, 1983, ALLERGY, V38, P517, DOI 10.1111/j.1398-9995.1983.tb02361.x; MYGIND N, 1978, NASAL ALLERGY, P257; SIBBALD B, 1986, CLIN ALLERGY, V16, P203, DOI 10.1111/j.1365-2222.1986.tb00767.x; STRAUS SE, 1988, J ALLERGY CLIN IMMUN, V81, P791, DOI 10.1016/0091-6749(88)90933-5; WIHL JA, 1985, J ALLERGY CLIN IMMUN, V75, P720, DOI 10.1016/0091-6749(85)90100-9; WOOD SF, 1986, CLIN ALLERGY, V16, P195, DOI 10.1111/j.1365-2222.1986.tb00766.x; WOOD SF, 1986, PRACTITIONER, V230, P41	16	82	88	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1989	83	3					627	633		10.1016/0091-6749(89)90075-4	http://dx.doi.org/10.1016/0091-6749(89)90075-4			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	T8596	2494249	Bronze			2022-12-18	WOS:A1989T859600009
J	SLAVIN, RG; BEDROSSIAN, CW; HUTCHESON, PS; PITTMAN, S; SALINASMADRIGAL, L; TSAI, CC; GLEICH, GJ				SLAVIN, RG; BEDROSSIAN, CW; HUTCHESON, PS; PITTMAN, S; SALINASMADRIGAL, L; TSAI, CC; GLEICH, GJ			A PATHOLOGIC-STUDY OF ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ST LOUIS UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63104; ST LOUIS UNIV,SCH MED,DEPT PEDIAT,ST LOUIS,MO 63104; MAYO CLIN & MAYO FDN,DEPT IMMUNOL,ROCHESTER,MN 55905	Saint Louis University; Saint Louis University; Mayo Clinic	SLAVIN, RG (corresponding author), ST LOUIS UNIV,SCH MED,DEPT INTERNAL MED,1402 S GRAND,ST LOUIS,MO 63104, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030652] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI015231, R01AI015231] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 30652] Funding Source: Medline; NIAID NIH HHS [AI-15231] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BEDROSSIAN CWM, 1976, HUM PATHOL, V7, P195, DOI 10.1016/S0046-8177(76)80023-8; CHANYEUN.M, 1971, CHEST, V59, P33, DOI 10.1378/chest.59.1.33; DAVIS WB, 1984, J CLIN INVEST, V74, P269, DOI 10.1172/JCI111411; FRIGAS E, 1981, MAYO CLIN PROC, V56, P345; GOLBERT TM, 1970, ANN INTERN MED, V72, P395, DOI 10.7326/0003-4819-72-3-395; GREENBERGER PA, 1982, J LAB CLIN MED, V99, P288; HINSON KFW, 1952, THORAX, V7, P317, DOI 10.1136/thx.7.4.317; HUNNINGHAKE GW, 1981, NEW ENGL J MED, V305, P429, DOI 10.1056/NEJM198108203050804; HUSU SM, 1984, ADV IMMUNOHISTOCHEMI, P31; IMBEAU SA, 1978, J ALLERGY CLIN IMMUN, V62, P243, DOI 10.1016/0091-6749(78)90214-2; KNUTSEN AL, 1986, PEDIATRICS, V78, P4; KURUP VP, 1983, INFECT IMMUN, V41, P698, DOI 10.1128/IAI.41.2.698-701.1983; LAUFER P, 1984, J ALLERGY CLIN IMMUN, V73, P44, DOI 10.1016/0091-6749(84)90482-2; LEATHERMAN JW, 1984, ANN INTERN MED, V100, P390, DOI 10.7326/0003-4819-100-3-390; MEARNS M, 1965, THORAX, V20, P385, DOI 10.1136/thx.20.5.385; NELSON LA, 1979, AM REV RESPIR DIS, V120, P863; PATTERSON R, 1968, University of Michigan Medical Center Journal, V34, P8; PATTERSON R, 1973, AM J MED, V54, P16, DOI 10.1016/0002-9343(73)90078-8; PETERS MS, 1983, J INVEST DERMATOL, V81, P39, DOI 10.1111/1523-1747.ep12538380; ROSENBERG M, 1977, ANN INTERN MED, V86, P405, DOI 10.7326/0003-4819-86-4-405; SLAVIN R G, 1970, Journal of Pediatrics, V76, P416, DOI 10.1016/S0022-3476(70)80482-6; SLAVIN RG, 1978, INT ARCH ALLER A IMM, V56, P325, DOI 10.1159/000232038; SLAVIN RG, 1987, INT ARCH ALLER A IMM, V83, P337, DOI 10.1159/000234365; SLAVIN RJ, 1968, AM J MED, V47, P306	24	82	87	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1988	81	4					718	725		10.1016/0091-6749(88)91044-5	http://dx.doi.org/10.1016/0091-6749(88)91044-5			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	N0650	3281999				2022-12-18	WOS:A1988N065000013
J	ALLEN, DH; DELOHERY, J; BAKER, G				ALLEN, DH; DELOHERY, J; BAKER, G			MONOSODIUM L-GLUTAMATE INDUCED ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ROYAL N SHORE HOSP,DEPT THORAC MED,SYDNEY,AUSTRALIA	Royal North Shore Hospital; University of Sydney								Allen DH, 1981, NEW ENGL J MED, V278, P796; KENNEY RA, 1972, AM J CLIN NUTR, V25, P140; KWOK RHM, 1968, NEW ENGL J MED, V278, P796; MARSHALL AE, 1948, MONOSODIUM GLUTAMATE, P4; OLNEY JW, 1970, NATURE, V227, P609, DOI 10.1038/227609b0; OLNEY JW, 1980, NEUROTOXICOLOGY, V2, P163; REIFLEHRER L, 1976, PEDIATRICS, V58, P771; REIFLEHRER L, 1977, FED PROC, V36, P1617; REIS DJ, 1981, J AUTONOM NERV SYST, V3, P321, DOI 10.1016/0165-1838(81)90073-4; SCHAUMBURG HH, 1969, SCIENCE, V163, P826, DOI 10.1126/science.163.3869.826	10	82	83	0	7	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1987	80	4					530	537		10.1016/0091-6749(87)90003-0	http://dx.doi.org/10.1016/0091-6749(87)90003-0			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K5224	3312372	Bronze			2022-12-18	WOS:A1987K522400003
J	GOLDSOBEL, AB; ROHR, AS; SIEGEL, SC; SPECTOR, SL; KATZ, RM; RACHELEFSKY, GS; DRAYTON, G; INDIANER, L; PETER, JB; BARR, RJ; GRACEY, VL				GOLDSOBEL, AB; ROHR, AS; SIEGEL, SC; SPECTOR, SL; KATZ, RM; RACHELEFSKY, GS; DRAYTON, G; INDIANER, L; PETER, JB; BARR, RJ; GRACEY, VL			EFFICACY OF DOXEPIN IN THE TREATMENT OF CHRONIC IDIOPATHIC URTICARIA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CALIF LOS ANGELES,DEPT PEDIAT,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT MED,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT DERMATOL,LOS ANGELES,CA 90024; SPECIALTY LABS INC,LOS ANGELES,CA; UNIV CALIF IRVINE,DEPT DERMATOL,IRVINE,CA 92717; UNIV CALIF IRVINE,DEPT PATHOL,IRVINE,CA 92717	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Irvine; University of California System; University of California Irvine								ARONOFF GM, 1982, J CLIN PSYCHIAT, V43, P42; BERNSTEIN JE, 1981, J AM ACAD DERMATOL, V5, P582, DOI 10.1016/S0190-9622(81)70120-8; BERNSTEIN JE, 1982, J INVEST DERMATOL, V78, P353; CHAMPION RH, 1969, BRIT J DERMATOL, V81, P588, DOI 10.1111/j.1365-2133.1969.tb16041.x; COMMENS CA, 1978, BRIT J DERMATOL, V99, P675, DOI 10.1111/j.1365-2133.1978.tb07062.x; COOK J, 1979, BRIT J DERMATOL, V101, P21; GREEN JP, 1977, NATURE, V269, P163, DOI 10.1038/269163a0; HARVEY RP, 1980, J ALLERGY CLIN IMMUN, V65, P136, DOI 10.1016/0091-6749(80)90198-0; HARVEY RP, 1981, J ALLERGY CLIN IMMUN, V68, P262, DOI 10.1016/0091-6749(81)90149-4; HOFF GS, 1981, SCAND J GASTROENTERO, V16, P1041, DOI 10.3109/00365528109181025; KAISER HB, 1980, LANCET, V2, P206; KAPLAN AP, 1983, ALLERGY PRINCIPLES P, P1341; KENNES B, 1977, CLIN ALLERGY, V7, P35, DOI 10.1111/j.1365-2222.1977.tb01422.x; MANGLA JC, 1982, ARCH INTERN MED, V142, P273, DOI 10.1001/archinte.142.2.273; MATHEWS KP, 1980, J ALLERGY CLIN IMMUN, V66, P347, DOI 10.1016/0091-6749(80)90113-X; MONROE EW, 1981, ARCH DERMATOL, V117, P404, DOI 10.1001/archderm.117.7.404; MORLAND TJ, 1979, HEADACHE, V19, P382, DOI 10.1111/j.1526-4610.1979.hed1907382.x; NATBONY SF, 1983, J ALLERGY CLIN IMMUN, V71, P177, DOI 10.1016/0091-6749(83)90096-9; NEITTAANMAKI H, 1984, J AM ACAD DERMATOL, V11, P483, DOI 10.1016/S0190-9622(84)70196-4; PHANUPHAK P, 1980, J ALLERGY CLIN IMMUN, V65, P371, DOI 10.1016/0091-6749(80)90215-8; RICHARDSON JW, 1984, MAYO CLIN PROC, V59, P330, DOI 10.1016/S0025-6196(12)61429-3; RICHELSON E, 1983, MAYO CLIN PROC, V58, P40; RICHELSON E, 1979, MAYO CLIN PROC, V54, P669; RICHELSON E, 1978, NATURE, V274, P176, DOI 10.1038/274176a0; ROBERTSON I, 1978, BRIT J CLIN PHARMACO, V5, P319, DOI 10.1111/j.1365-2125.1978.tb01714.x; ROSENBAUM AH, 1979, MAYO CLIN PROC, V54, P335; SMITH JA, 1980, J ALLERGY CLIN IMMUN, V65, P118, DOI 10.1016/0091-6749(80)90195-5; SPANGLER DL, 1980, ANN ALLERGY, V45, P246; SULLIVAN TJ, 1982, J ALLERGY CLIN IMMUN, V69, P260, DOI 10.1016/S0091-6749(82)80002-X; TANG SW, 1980, N-S ARCH PHARMACOL, V311, P255, DOI 10.1007/BF00569405	30	82	83	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1986	78	5	1				867	873		10.1016/0091-6749(86)90232-0	http://dx.doi.org/10.1016/0091-6749(86)90232-0			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	E9713	3782654				2022-12-18	WOS:A1986E971300007
J	SULLIVAN, TJ				SULLIVAN, TJ			ANTIGEN-SPECIFIC DESENSITIZATION OF PATIENTS ALLERGIC TO PENICILLIN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV TEXAS,HLTH SCI CTR,DEPT MICROBIOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas	SULLIVAN, TJ (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT INTERNAL MED,ALLERGY & CLIN IMMUNOL SECT,DALLAS,TX 75235, USA.							BROWN LA, 1982, J ALLERGY CLIN IMMUN, V69, P51, DOI 10.1016/0091-6749(82)90087-2; de Weck A L, 1972, Int Arch Allergy Appl Immunol, V42, P782; de Weck A L, 1972, Int Arch Allergy Appl Immunol, V42, P798; DEMBO M, 1979, J IMMUNOL, V123, P1864; FELLNER MJ, 1970, J ALLERGY, V45, P55, DOI 10.1016/0021-8707(70)90017-1; FINDLAY SR, 1980, AM REV RESPIR DIS, V122, P53; GARRATTY G, 1975, AM J MED, V58, P398, DOI 10.1016/0002-9343(75)90606-3; GILLMAN S A, 1972, Clinical Allergy, V2, P63, DOI 10.1111/j.1365-2222.1972.tb01268.x; GRAYBILL JR, 1974, SOUTH MED J, V67, P62, DOI 10.1097/00007611-197401000-00017; JOHANSSON SGO, 1978, ALLERGY PRINCIPLES P, P551; LEVINE BB, 1967, ANN NY ACAD SCI, V145, P298, DOI 10.1111/j.1749-6632.1967.tb50227.x; LEVINE BB, 1969, INT ARCH ALLER A IMM, V35, P445, DOI 10.1159/000230197; LEVINE BB, 1962, J MED PHARMACEUT CH, V5, P1025, DOI 10.1021/jm01240a016; LEVINE BB, 1973, J INFECT DIS, V128, P364; LICHTENSTEIN LM, 1979, J ALLERGY CLIN IMMUN, V64, P5, DOI 10.1016/0091-6749(79)90075-7; NORMAN PS, 1976, MANUAL CLIN IMMUNOLO, P585; NORMAN PS, 1978, IMMUNOLOGICAL DISEAS, P832; ODONNOVAN WJ, 1946, LANCET, V2, P444; PARKER CW, 1962, J EXP MED, V115, P821, DOI 10.1084/jem.115.4.821; PARKER CW, 1980, CLIN IMMUNOLOGY, P1372; PARKER CW, 1972, HYPERSENSITIVITY DRU, P367; PARKER CW, 1972, CRC CRIT R TOXICOL, V1, P161; PARKER CW, 1979, NIH79387 PUBL, P508; PATTERSON R, 1973, Journal of Immunology, V110, P1135; PEDERSEN.J, 1969, ACTA ALLERGOL, V24, P333, DOI 10.1111/j.1398-9995.1969.tb03748.x; REISMAN RE, 1962, J ALLERGY, V33, P178, DOI 10.1016/0021-8707(62)90007-2; ROBERTS AE, 1953, AMA ARCH IND HYG OCC, V8, P340; SULLIVAN TJ, 1981, J ALLERGY CLIN IMMUN, V68, P171, DOI 10.1016/0091-6749(81)90180-9; SULLIVAN TJ, 1982, J ALLERGY CLIN IMMUN, V69, P275, DOI 10.1016/S0091-6749(82)80004-3; SULLIVAN TJ, 1982, J ALLERGY CLIN IMMUN, V69, P260, DOI 10.1016/S0091-6749(82)80002-X; VANARSDEL P, 1961, J ALLERGY, V32, P348, DOI 10.1016/0021-8707(61)90103-4; VANDELLEN RG, 1971, J ALLERGY, V47, P230, DOI 10.1016/S0091-6749(71)80468-2; VOSS HE, 1966, J AMER MED ASSOC, V196, P679, DOI 10.1001/jama.1966.03100210049014	33	82	85	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	69	6					500	508		10.1016/0091-6749(82)90174-9	http://dx.doi.org/10.1016/0091-6749(82)90174-9			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NT025	6176609	Bronze			2022-12-18	WOS:A1982NT02500005
J	PRINCE, RA; WING, DS; WEINBERGER, MM; HENDELES, LS; RIEGELMAN, S				PRINCE, RA; WING, DS; WEINBERGER, MM; HENDELES, LS; RIEGELMAN, S			EFFECT OF ERYTHROMYCIN ON THEOPHYLLINE KINETICS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CALIF SAN FRANCISCO,SCH PHARM,SAN FRANCISCO,CA 94143; UNIV IOWA,COLL MED,IOWA CITY,IA 52242	University of California System; University of California San Francisco; University of Iowa	PRINCE, RA (corresponding author), UNIV IOWA,COLL PHARM,IOWA CITY,IA 52242, USA.				NCRR NIH HHS [RR59] Funding Source: Medline; NIAID NIH HHS [AI 16151-01] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BELL SC, 1969, APPL MICROBIOL, V17, P88, DOI 10.1128/AEM.17.1.88-92.1969; CUMMINS LH, 1977, PEDIATRICS, V59, P144; EKWO E, 1978, J ALLERGY CLIN IMMUN, V61, P240, DOI 10.1016/0091-6749(78)90198-7; GIBALDI M, 1975, PHARMACOKINETICS, P69; HENDELES L, 1977, DRUG INTEL CLIN PHAR, V11, P12, DOI 10.1177/106002807701100101; KOZAK PP, 1977, J ALLERGY CLIN IMMUN, V60, P149, DOI 10.1016/0091-6749(77)90042-2; LAFORCE CF, 1981, J PEDIATR-US, V99, P153, DOI 10.1016/S0022-3476(81)80983-3; MITENKO PA, 1973, NEW ENGL J MED, V289, P600, DOI 10.1056/NEJM197309202891202; MUIR KT, 1980, J CHROMATOGR, V221, P85, DOI 10.1016/S0378-4347(00)81010-5; ORCUTT JJ, 1977, CLIN CHEM, V23, P599; PFEIFER HJ, 1979, CLIN PHARMACOL THER, V26, P36; RALSTON M, 1979, BIOMEDICAL COMPUTE P, P484; Snedecor G W, 1967, STATISTICAL METHODS, P172; Snedecor G. W., 1967, STATISTICAL METHODS, P91; WEINBERG.MM, 1974, J PEDIATR-US, V84, P421; WEINBERGER M, 1975, CLIN PHARMACOL THER, V17, P585; WEINBERGER M, 1977, J ALLERGY CLIN IMMUN, V59, P228, DOI 10.1016/0091-6749(77)90154-3; ZAROWITZ BJM, 1981, CLIN PHARMACOL THER, V29, P601, DOI 10.1038/clpt.1981.84; ZWILLICH CW, 1975, ANN INTERN MED, V82, P784, DOI 10.7326/0003-4819-82-6-784	19	82	83	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	68	6					427	431		10.1016/0091-6749(81)90196-2	http://dx.doi.org/10.1016/0091-6749(81)90196-2			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MU790	7031111				2022-12-18	WOS:A1981MU79000004
J	STEEL, L; PLATSHON, L; KALINER, M				STEEL, L; PLATSHON, L; KALINER, M			PROSTAGLANDIN GENERATION BY HUMAN AND GUINEA-PIG LUNG-TISSUE - COMPARISON OF PARENCHYMAL AND AIRWAY RESPONSES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NIAID,CLIN INVEST LAB,BETHESDA,MD 20014	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)									0	82	83	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	64	4					287	293		10.1016/0091-6749(79)90146-5	http://dx.doi.org/10.1016/0091-6749(79)90146-5			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HQ469	479481				2022-12-18	WOS:A1979HQ46900010
J	UMEMOTO, L; POOTHULLIL, J; DOLOVICH, J; HARGREAVE, FE				UMEMOTO, L; POOTHULLIL, J; DOLOVICH, J; HARGREAVE, FE			FACTORS WHICH INFLUENCE LATE CUTANEOUS ALLERGIC RESPONSES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MCMASTER UNIV,HAMILTON L8S 4J9,ONTARIO,CANADA; MCMASTER UNIV,DEPT PEDIAT,HAMILTON L8S 4J9,ONTARIO,CANADA; MCMASTER UNIV,DEPT MED,HAMILTON L8S 4J9,ONTARIO,CANADA	McMaster University; McMaster University; McMaster University								ARBESMAN C E, 1974, Clinical Allergy, V4, P349, DOI 10.1111/j.1365-2222.1974.tb01396.x; Blackley CH., 1873, EXPT RESEARCHES CAUS; BOOIJNOORD H, 1971, J ALLERGY CLIN IMMUN, V48, P344, DOI 10.1016/0091-6749(71)90080-7; CITRON K M, 1958, Thorax, V13, P229, DOI 10.1136/thx.13.3.229; Cooke RA, 1922, J IMMUNOL, V7, P219; DAY RP, 1975, J ALLERGY CLIN IMMUN, V55, P87; DOLOVICH J, 1972, J ALLERGY CLIN IMMUN, V49, P43, DOI 10.1016/0091-6749(72)90122-4; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; GALANT SP, 1973, J ALLERGY CLIN IMMUN, V51, P11, DOI 10.1016/0091-6749(73)90003-1; HERXHEIMER H, 1952, INT ARCH ALLER A IMM, V3, P323, DOI 10.1159/000227979; Lewis T, 1924, HEART-J STUD CIRC, V11, P209; LIHSU SY, 1974, J ALLERGY CLIN IMMUN, V54, P339; LOOKERENCOMPAGN.JG, 1969, SCAND J RESP DIS, V50, P76; McALLEN MONICA K., 1961, THORAX, V16, P30, DOI 10.1136/thx.16.1.30; McCarthy D S, 1971, Clin Allergy, V1, P415, DOI 10.1111/j.1365-2222.1971.tb00793.x; Pepys J, 1973, Clin Allergy, V3, P1, DOI 10.1111/j.1365-2222.1973.tb01304.x; PEPYS J, 1969, LANCET, V1, P1181; POOTHULLIL J, 1976, J ALLERGY CLIN IMMUN, V57, P164, DOI 10.1016/0091-6749(76)90035-X; ROBERTSON DG, 1974, J ALLERGY CLIN IMMUN, V54, P244, DOI 10.1016/0091-6749(74)90067-0; SOLLEY GO, 1975, J ALLERGY CLIN IMMUN, V55, P112; STEVENS FRANKLIN A., 1934, JOUR ALLERGY, V5, P285, DOI 10.1016/S0021-8707(34)90226-4; TOWNLEY RG, 1965, J ALLERGY, V36, P121, DOI 10.1016/0021-8707(65)90161-9	22	82	82	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	58	1					60	68		10.1016/0091-6749(76)90107-X	http://dx.doi.org/10.1016/0091-6749(76)90107-X			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	BX742	947978				2022-12-18	WOS:A1976BX74200007
J	Keet, CA; Matsui, EC; McCormack, MC; Peng, RD				Keet, Corinne A.; Matsui, Elizabeth C.; McCormack, Meredith C.; Peng, Roger D.			Urban residence, neighborhood poverty, race/ethnicity, and asthma morbidity among children on Medicaid	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; inner city; poverty; urbanization	INNER-CITY ASTHMA; INFECTIOUS-DISEASES; LUNG-FUNCTION; EXPOSURE; ALLERGEN; SUSCEPTIBILITY; INEQUALITY; ANCESTRY; HEALTH; RISK	Background: Although poor-urban (inner-city) areas are thought to have high asthma prevalence and morbidity, we recently found that inner cities do not have higher prevalent pediatric asthma. Whether asthma morbidity is higher in inner-city areas across the United States is not known. Objective: This study sought to examine relationships between residence in poor and urban areas, race/ethnicity, and asthma morbidity among children with asthma who are enrolled in Medicaid. Methods: Children aged 5 to 19 enrolled in Medicaid in 2009 to 2010 were included. Asthma was defined by at least 1 outpatient or emergency department (ED) visit with a primary diagnosis code of asthma over the 2-year period. Urbanization status was defined at the county level and neighborhood poverty at the zip-code level. Among children with asthma, logistic models were created to examine the effects of urbanization, neighborhood poverty, and race/ethnicity on rates of asthma outpatient visits, ED visits, and hospitalizations. Results: This study included 16,860,716 children (1,534,820 with asthma). Among children enrolled in Medicaid, residence in inner-city areas did not confer increased risk of prevalent asthma in either crude or adjusted analyses, but it was associated with significantly more asthma-related ED visits and hospitalizations among those with asthma in crude analyses (risk ratio, 1.48; 95% CI, 1.24-1.36; and 1.97; 95% CI, 1.50-1.72, respectively) and when adjusted for race/ethnicity, age, and sex (adjusted risk ratio, 1.23; 95% CI, 1.08-1.15; and 1.62; 95% CI, 1.26-1.43). Residence in urban or poor areas and non-Hispanic black race/ethnicity were all independently associated with increased risk of asthma-related ED visits and hospitalizations. Conclusions: Residence in poor and urban areas is an important risk factor for asthma morbidity, but not for prevalence, among low-income US children.	[Keet, Corinne A.; Matsui, Elizabeth C.] Johns Hopkins Univ, Sch Med, Div Pediat Allergy & Immunol, Baltimore, MD USA; [McCormack, Meredith C.] Johns Hopkins Univ, Sch Med, Div Pulm & Crit Care Med, Baltimore, MD USA; [Peng, Roger D.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Biostat, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Keet, CA (corresponding author), Johns Hopkins Univ Hosp, CMSC 1102,600 N Wolfe St, Baltimore, MD 21287 USA.	ckeet1@jhmi.edu		Matsui, Elizabeth/0000-0001-8134-5593; Ayers, Andrew/0000-0001-5305-7156; Koehl, Rachelle/0000-0002-7797-7456; McCormack, Meredith/0000-0003-1702-3201; Pham, Hewlett/0000-0003-0330-6104	National Institute of Environmental Health Sciences [P50ES018176]; Environmental Protection Agency [STAR83563901]; National Institute of Allergy and Infectious Diseases [K23AI103187, U01AI083238, K24AI114769, R01ES023447, R01ES026170, R21AI107085]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K23AI103187, R21AI107085] Funding Source: NIH RePORTER	National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Environmental Protection Agency(United States Environmental Protection Agency); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the National Institute of Environmental Health Sciences (grant P50ES018176), the Environmental Protection Agency (grant STAR83563901), and the National Institute of Allergy and Infectious Diseases (grants K23AI103187, U01AI083238, K24AI114769, R01ES023447, R01ES026170, and R21AI107085). No funder had any role in the design and conduct of the study; collection, management, analysis, and interpretation of data; or preparation, review, or approval of the manuscript.	Ahluwalia SK, 2013, J ALLERGY CLIN IMMUN, V132, P830, DOI 10.1016/j.jaci.2013.05.005; [Anonymous], 2014, ZIP ZCTA MASTER DATA; Ard K, 2015, SOC SCI RES, V53, P375, DOI 10.1016/j.ssresearch.2015.06.019; Been JV, 2015, EUR J PAEDIATR DENT, V16, P210; Brandt EB, 2015, J ALLERGY CLIN IMMUN, V136, P295, DOI 10.1016/j.jaci.2014.11.043; Busse WW, 2010, J ALLERGY CLIN IMMUN, V125, P529, DOI 10.1016/j.jaci.2010.01.036; Everson PJ, 2000, J ROY STAT SOC B, V62, P399, DOI 10.1111/1467-9868.00239; Gergen PJ, 2016, J ALLER CL IMM-PRACT, V4, P22, DOI 10.1016/j.jaip.2015.07.024; Gergen PJ, 2015, IMMUNOL ALLERGY CLIN, V35, P101, DOI 10.1016/j.iac.2014.09.006; Gruchalla RS, 2005, J ALLERGY CLIN IMMUN, V115, P478, DOI 10.1016/j.jaci.2004.12.006; He H, 2015, AM J RESP CRIT CARE, V192, P520, DOI 10.1164/rccm.201503-0522LE; Ierodiakonou D, 2016, J ALLERGY CLIN IMMUN, V137, P390, DOI 10.1016/j.jaci.2015.05.028; Ingram Deborah D, 2014, Vital Health Stat 2, P1; Kanchongkittiphon W, 2015, ENVIRON HEALTH PERSP, V123, P6, DOI [10.1289/ehp.1307922, 10.1289/ehp.123-A6]; Keet CA, 2015, J ALLERGY CLIN IMMUN, V135, P655, DOI 10.1016/j.jaci.2014.11.022; Krivo LJ, 2004, DEMOGRAPHY, V41, P585, DOI 10.1353/dem.2004.0023; Lynch SV, 2014, J ALLERGY CLIN IMMUN, V134, P593, DOI 10.1016/j.jaci.2014.04.018; Neophytou AM, 2016, AM J RESP CRIT CARE, V193, P1271, DOI 10.1164/rccm.201508-1706OC; Pino-Yanes M, 2015, J ALLERGY CLIN IMMUN, V135, P228, DOI 10.1016/j.jaci.2014.07.053; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Sampson RJ, 2008, P NATL ACAD SCI USA, V105, P845, DOI 10.1073/pnas.0710189104; Togias A, 2010, J ALLERGY CLIN IMMUN, V125, P540, DOI 10.1016/j.jaci.2010.01.040; Vergara C, 2013, GENET EPIDEMIOL, V37, P393, DOI 10.1002/gepi.21702; WEISS KB, 1992, CHEST, V101, pS362, DOI 10.1378/chest.101.6_Supplement.362S; Wright RJ, 2011, AM J RESP CRIT CARE, V184, P752, DOI 10.1164/rccm.201106-1139ED	25	81	81	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2017	140	3					822	827		10.1016/j.jaci.2017.01.036	http://dx.doi.org/10.1016/j.jaci.2017.01.036			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FF8CA	28283418	Green Accepted, Bronze			2022-12-18	WOS:000409241500020
J	Srivastava, A; Nikamo, P; Lohcharoenkal, W; Li, DQ; Meisgen, F; Landen, NX; Stahle, M; Pivarcsi, A; Sonkoly, E				Srivastava, Ankit; Nikamo, Pernilla; Lohcharoenkal, Warangkana; Li, Dongqing; Meisgen, Florian; Landen, Ning Xu; Stahle, Mona; Pivarcsi, Andor; Sonkoly, Eniko			MicroRNA-146a suppresses IL-17-mediated skin inflammation and is genetically associated with psoriasis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Psoriasis; microRNA; miR-146a; single nucleotide polymorphisms; skin inflammation; IL-17; keratinocyte; mouse model	INNATE IMMUNE-RESPONSES; KERATINOCYTES; MIR-146A; POPULATION; REGULATORS; DISEASES; TARGET; CANCER; MICE; SNP	Background: Psoriasis is an immune-mediated inflammatory skin disease with a strong genetic background in which activation of IL-17 signaling is central in the pathogenesis. Little has been known about the role of noncoding RNAs, including microRNAs (miRNAs), in predisposition to the disease. Objective: We sought to investigate the genetic association of single nucleotide polymorphisms in microRNA-146a (miR-146a) to psoriasis and to explore its function in the initiation and resolution of the disease. Methods: Analysis of the genetic association of miR-146a rs2910164 and psoriasis was carried out on 1546 patients with psoriasis and 1526 control subjects. The role of miR-146a in patients with psoriasis was assessed by using miR-146a(-/-) mice in conjunction with the imiquimod-inducedmousemodel of psoriasis. The severity of psoriasis-like skin inflammation was evaluated at morphologic, histologic, and molecular levels. miR-146a was ectopically overexpressed and inhibited in keratinocytes treated with IL-17. Synthetic miR-146a was injected intradermally into mice. Results: Here we report protective association of a functional polymorphism in the miR-146a precursor (rs2910164). Genetic deficiency in miR-146a leads to earlier onset and exacerbated pathology of skin inflammation, with increased expression of IL-17-induced keratinocyte-derived inflammatory mediators, epidermal hyperproliferation, and increased neutrophil infiltration. Moreover, miR-146a-deficient mice do not resolve inflammation after discontinuation of imiquimod challenge. The overexpression of miR-146a suppressed, whereas its inhibition enhanced, IL-17-driven inflammation in keratinocytes. Functionally, miR-146a impairs the neutrophil chemoattractant capacity of keratinocytes. Finally, delivery of miR-146a mimics into the skin leads to amelioration of psoriasiform skin inflammation, decreased epidermal proliferation, and neutrophil infiltration. Conclusions: Our results define a crucial role for miR-146a in modulating IL-17-driven inflammation in the skin.	[Srivastava, Ankit; Nikamo, Pernilla; Lohcharoenkal, Warangkana; Li, Dongqing; Meisgen, Florian; Landen, Ning Xu; Stahle, Mona; Pivarcsi, Andor; Sonkoly, Eniko] Karolinska Inst, Dept Med, Unit Dermatol & Venerol, CMM L8-02, S-17176 Stockholm, Sweden; [Stahle, Mona; Sonkoly, Eniko] Karolinska Univ Hosp, Unit Dermatol, Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital	Sonkoly, E (corresponding author), Karolinska Inst, Dept Med, Unit Dermatol & Venerol, CMM L8-02, S-17176 Stockholm, Sweden.	eniko.sonkoly@ki.se	Landén, Ning Xu/AFL-2883-2022; Li, Dongqing/AAJ-2650-2020; Srivastava, Ankit/ABF-8212-2020; Pivarcsi, Andor/J-5801-2017	Landén, Ning Xu/0000-0003-4868-3798; Li, Dongqing/0000-0003-0588-9390; Srivastava, Ankit/0000-0001-5328-7509; Pivarcsi, Andor/0000-0003-2196-1102	Swedish Medical Research Council (Vetenskapsradet) [2012-1591, 2013-03085, 2015-02218, 2015-02554, 2015-02844]; Swedish Psoriasis Association (Psoriasisforbundet); Welander and Finsen Foundations (Hudfonden) [2207, 2228, 2408]; Swedish Cancer Foundation [CAN 2015/694]; Ake Wibergs Foundation; Karolinska Institutet; Magnus Bergwall Foundation [2014-00083]; Ragnar Soderbergs Foundation [M31/15]; KI/Stockholm County Council; Royal Physiographic Society in Lund [34578]; Stockholm County Council	Swedish Medical Research Council (Vetenskapsradet)(Swedish Medical Research Council (SMRC)Swedish Research Council); Swedish Psoriasis Association (Psoriasisforbundet); Welander and Finsen Foundations (Hudfonden); Swedish Cancer Foundation; Ake Wibergs Foundation; Karolinska Institutet(Karolinska Institutet); Magnus Bergwall Foundation; Ragnar Soderbergs Foundation; KI/Stockholm County Council; Royal Physiographic Society in Lund; Stockholm County Council(Stockholm County Council)	Supported by the Swedish Medical Research Council (Vetenskapsradet, Dnr. 2012-1591, 2013-03085, 2015-02218, 2015-02554, and 2015-02844), Swedish Psoriasis Association (Psoriasisforbundet), Welander and Finsen Foundations (Hudfonden, Dnr. 2207, 2228 and 2408), Karolinska Institutet, Swedish Cancer Foundation (CAN 2015/694), Ake Wibergs Foundation, Magnus Bergwall Foundation (2014-00083), Ragnar Soderbergs Foundation (M31/15), KI/Stockholm County Council supported program on inflammatory diseases, and Royal Physiographic Society in Lund (34578). E.S. was supported by the Stockholm County Council.	Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Boldin MP, 2011, J EXP MED, V208, P1189, DOI 10.1084/jem.20101823; Chiricozzi A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090284; Chiricozzi A, 2011, J INVEST DERMATOL, V131, P677, DOI 10.1038/jid.2010.340; Deng X, 2015, SCAND J IMMUNOL, V81, P153, DOI 10.1111/sji.12261; Giardina E, 2008, CURR GENOMICS, V9, P110, DOI 10.2174/138920208784139528; Harden JL, 2015, J AUTOIMMUN, V64, P66, DOI 10.1016/j.jaut.2015.07.008; Jazdzewski K, 2008, P NATL ACAD SCI USA, V105, P7269, DOI 10.1073/pnas.0802682105; Jazdzewski K, 2009, P NATL ACAD SCI USA, V106, P1502, DOI 10.1073/pnas.0812591106; Li CZ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121918; Lovendorf MB, 2015, EXPERT REV CLIN IMMU, V11, P467, DOI 10.1586/1744666X.2015.1020301; Lowes MA, 2014, ANNU REV IMMUNOL, V32, P227, DOI 10.1146/annurev-immunol-032713-120225; Martin DA, 2013, J INVEST DERMATOL, V133, P17, DOI 10.1038/jid.2012.194; Meisgen F, 2014, J INVEST DERMATOL, V134, P1931, DOI 10.1038/jid.2014.89; Meisgen F, 2012, EXP DERMATOL, V21, P312, DOI 10.1111/j.1600-0625.2012.01462.x; Mitsui H, 2012, J INVEST DERMATOL, V132, P1615, DOI 10.1038/jid.2012.33; Naldi Luigi, 2004, Current Drug Targets - Inflammation and Allergy, V3, P121, DOI 10.2174/1568010043343958; Nestle FO, 2009, NAT REV IMMUNOL, V9, P679, DOI 10.1038/nri2622; Nikamo P, 2012, EXP DERMATOL, V21, P221, DOI 10.1111/j.1600-0625.2011.01423.x; Pivarcsi A, 2014, EXP DERMATOL, V23, P620, DOI 10.1111/exd.12469; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Ramirez-Carrozzi V, 2011, NAT IMMUNOL, V12, P1159, DOI 10.1038/ni.2156; Ray-Jones H, 2016, J INVEST DERMATOL, V136, P567, DOI 10.1016/j.jid.2015.11.025; Rebane A, 2014, J ALLERGY CLIN IMMUN, V134, P836, DOI 10.1016/j.jaci.2014.05.022; Reich K, 2015, EXP DERMATOL, V24, P529, DOI 10.1111/exd.12710; Rennekampff HO, 2000, J SURG RES, V93, P41, DOI 10.1006/jsre.2000.5892; Sonkoly E, 2008, CLIN EXP DERMATOL, V33, P312, DOI 10.1111/j.1365-2230.2008.02804.x; Sonkoly E, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000610; Sonkoly E, 2009, INT REV IMMUNOL, V28, P535, DOI 10.3109/08830180903208303; Suarez-Farinas M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010247; Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103; van der Fits L, 2009, J IMMUNOL, V182, P5836, DOI 10.4049/jimmunol.0802999; Xu N, 2013, J IMMUNOL, V190, P678, DOI 10.4049/jimmunol.1202695; Xu N, 2011, J INVEST DERMATOL, V131, P1521, DOI 10.1038/jid.2011.55; Zhang WG, 2014, J CELL MOL MED, V18, P2225, DOI 10.1111/jcmm.12359	35	81	90	3	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2017	139	2					550	561		10.1016/j.jaci.2016.07.025	http://dx.doi.org/10.1016/j.jaci.2016.07.025			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EO9IM	27568078	Bronze			2022-12-18	WOS:000397002400021
J	Stentzel, S; Teufelberger, A; Nordengrun, M; Kolata, J; Schmidt, F; van Crombruggen, K; Michalik, S; Kumpfmuller, J; Tischer, S; Schweder, T; Hecker, M; Engelmann, S; Volker, U; Krysko, O; Bachert, C; Broker, BM				Stentzel, Sebastian; Teufelberger, Andrea; Nordengruen, Maria; Kolata, Julia; Schmidt, Frank; van Crombruggen, Koen; Michalik, Stephan; Kumpfmueller, Jana; Tischer, Sebastian; Schweder, Thomas; Hecker, Michael; Engelmann, Susanne; Voelker, Uwe; Krysko, Olga; Bachert, Claus; Broeker, Barbara M.			Staphylococcal serine protease-like proteins are pacemakers of allergic airway reactions to Staphylococcus aureus	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; IgE; Staphylococcus aureus; serine proteaselike proteins; type 2 inflammation	CHRONIC RHINOSINUSITIS; CELL-DIFFERENTIATION; BACILLUS-SUBTILIS; ENTEROTOXIN-B; IGE; ASTHMA; SUPERANTIGENS; HOST; COLONIZATION; INFECTION	Background: A substantial subgroup of asthmatic patients have "nonallergic'' or idiopathic asthma, which often takes a severe course and is difficult to treat. The cause might be allergic reactions to the gram-positive pathogen Staphylococcus aureus, a frequent colonizer of the upper airways. However, the driving allergens of S aureus have remained elusive. Objective: We sought to search for potentially allergenic S aureus proteins and characterize the immune response directed against them. Methods: S aureus extracellular proteins targeted by human serum IgG4 were identified by means of immunoblotting to screen for potential bacterial allergens. Candidate antigens were expressed as recombinant proteins and used to analyze the established cellular and humoral immune responses in healthy adults and asthmatic patients. The ability to induce a type 2 immune response in vivo was tested in a mouse asthma model. Results: We identified staphylococcal serine protease-like proteins (Spls) as dominant IgG4-binding S aureus proteins. SplA through SplF are extracellular proteases of unknown function expressed by S aureus in vivo. Spls elicited IgE antibody responses in most asthmatic patients. In healthy S aureus carriers and noncarriers, peripheral blood T cells elaborated TH2 cytokines after stimulation with Spls, as is typical for allergens. In contrast, TH1/TH17 cytokines, which dominated the response to S aureusahemolysin, were of low concentration or absent. In mice inhalation of SplD without adjuvant induced lung inflammation characterized by TH2 cytokines and eosinophil infiltration. Conclusion: We identify Spls as triggering allergens released by S aureus, opening prospects for diagnosis and causal therapy of asthma.	[Stentzel, Sebastian; Nordengruen, Maria; Kolata, Julia; Tischer, Sebastian; Broeker, Barbara M.] Univ Med Greifswald, Dept Immunol, Greifswald, Germany; [Schmidt, Frank; Michalik, Stephan; Voelker, Uwe] Univ Med Greifswald, Interfac Inst Genet & Funt Genom, Dept Funct Genom, Greifswald, Germany; [Schmidt, Frank; Michalik, Stephan] Univ Med Greifswald, Jr Grp Appl Prote, ZIK FunGene, Greifswald, Germany; [Teufelberger, Andrea; Krysko, Olga; Bachert, Claus] Univ Ghent, Upper Airways Res Lab, B-9000 Ghent, Belgium; [Kolata, Julia] Univ Med Ctr Utrecht, Med Microbiol, Utrecht, Netherlands; [Kumpfmueller, Jana; Schweder, Thomas] Ernst Moritz Arndt Univ Greifswald, Inst Pharm, Dept Pharmaceut Biotechnol, Greifswald, Germany; [Hecker, Michael; Engelmann, Susanne] Ernst Moritz Arndt Univ Greifswald, Inst Microbiol, Greifswald, Germany; [Engelmann, Susanne] Tech Univ Carolo Wilhelmina Braunschweig, Inst Microbiol, Braunschweig, Germany; [Engelmann, Susanne] Helmholtz Ctr Infect Res, Microbial Prote, Braunschweig, Germany; [Bachert, Claus] Karolinska Inst, Div Ear Nose & Throat Dis, Clintec, Stockholm, Sweden; [Kumpfmueller, Jana] Leibniz Inst Nat Prod Res & Infect Biol, Dept Biomol Chem, Jena, Germany	Greifswald Medical School; Greifswald Medical School; Greifswald Medical School; Ghent University; Utrecht University; Utrecht University Medical Center; Ernst Moritz Arndt Universitat Greifswald; Ernst Moritz Arndt Universitat Greifswald; Braunschweig University of Technology; Helmholtz Association; Helmholtz-Center for Infection Research; Karolinska Institutet; Hans Knoll Institute (HKI)	Broker, BM (corresponding author), Univ Med Greifswald, Inst Immunol & Transfus Med, Ferdinand Sauerbruch Str,DZ7, D-17475 Greifswald, Germany.	broeker@uni-greifswald.de	Krysko, Olga/C-2481-2009; Bachert, Claus/J-8825-2012; Bröker, Barbara M/O-4850-2015	Krysko, Olga/0000-0001-5019-0752; Bröker, Barbara M/0000-0002-5020-8542; Schweder, Thomas/0000-0002-7213-3596; Teufelberger, Andrea/0000-0002-1142-949X; Nordengrun, Maria/0000-0002-5749-8861; Schmidt, Frank/0000-0001-5406-3988; Krabbe, Jana/0000-0003-3510-8276; Volker, Uwe/0000-0002-5689-3448; Michalik, Stephan/0000-0002-6550-0132	Deutsche Forschungsgemeinschaft [CRC-TRR34, GRK 1870]; German Ministry of Education and Research (Program Infection Genomics) [0315829, 03Z1CN22]; Interuniversity Attraction Poles Program Belgian Science Policy [IAP P7/30]; Research Foundation Flanders (FWO)	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); German Ministry of Education and Research (Program Infection Genomics); Interuniversity Attraction Poles Program Belgian Science Policy(Belgian Federal Science Policy Office); Research Foundation Flanders (FWO)(FWO)	Supported by the Deutsche Forschungsgemeinschaft (CRC-TRR34, GRK 1870), the German Ministry of Education and Research (Program Infection Genomics, 0315829, 03Z1CN22), the Interuniversity Attraction Poles Program Belgian Science Policy (no. IAP P7/30 to C.B.) and by the Research Foundation Flanders (FWO to A.T.).	Aalberse RC, 2009, CLIN EXP ALLERGY, V39, P469, DOI 10.1111/j.1365-2222.2009.03207.x; Bachert C, 2002, ALLERGY, V57, P480, DOI 10.1034/j.1398-9995.2002.02156.x; Bachert C, 2012, J INTERN MED, V272, P133, DOI 10.1111/j.1365-2796.2012.02559.x; Bachert C, 2010, J ALLERGY CLIN IMMUN, V126, pe1, DOI DOI 10.1016/J.JACI.2010.07.007; Bachert C, 2012, J ALLERGY CLIN IMMUN, V130, P376, DOI 10.1016/j.jaci.2012.05.012; Bachert C, 2010, J ALLERGY CLIN IMMUN, V126, P962, DOI 10.1016/j.jaci.2010.07.007; Balenga NA, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7763; Barnes PJ, 2009, CLIN EXP ALLERGY, V39, P1145, DOI 10.1111/j.1365-2222.2009.03298.x; Barnes PJ, 2012, J ALLERGY CLIN IMMUN, V129, P48, DOI 10.1016/j.jaci.2011.11.006; Berube BJ, 2013, TOXINS, V5, P1140, DOI 10.3390/toxins5061140; Brauweiler AM, 2013, J ALLERGY CLIN IMMUN, V131, P421, DOI 10.1016/j.jaci.2012.10.030; Broker BM, 2014, INT J MED MICROBIOL, V304, P204, DOI 10.1016/j.ijmm.2013.11.008; Chandesris MO, 2012, MEDICINE, V91, pE1, DOI 10.1097/MD.0b013e31825f95b9; Cho JS, 2010, J CLIN INVEST, V120, P1762, DOI 10.1172/JCI40891; Cook MC, 2009, INT IMMUNOL, V21, P1003, DOI 10.1093/intimm/dxp076; Davies JM, 2013, J ALLERGY CLIN IMMUN, V131, P972, DOI 10.1016/j.jaci.2012.12.1569; Davis MF, 2015, J ALLERGY CLIN IMMUN, V135, P811, DOI 10.1016/j.jaci.2014.10.052; de Souza GA, 2010, BIOINFORMATICS, V26, P698, DOI 10.1093/bioinformatics/btq004; Dubin G, 2008, J MOL BIOL, V379, P343, DOI 10.1016/j.jmb.2008.03.059; Eichstaedt S, 2009, CELL CALCIUM, V45, P165, DOI 10.1016/j.ceca.2008.09.001; Frank KM, 2012, INFECT IMMUN, V80, P3161, DOI 10.1128/IAI.00191-12; Fraser J, 2000, MOL MED TODAY, V6, P125, DOI 10.1016/S1357-4310(99)01657-3; Galli SJ, 2012, NAT MED, V18, P693, DOI 10.1038/nm.2755; Grumann D, 2008, J IMMUNOL, V181, P5054, DOI 10.4049/jimmunol.181.7.5054; Holgate ST, 2012, NAT MED, V18, P673, DOI 10.1038/nm.2731; Holtfreter S, 2007, J CLIN MICROBIOL, V45, P2669, DOI 10.1128/JCM.00204-07; Holtfreter S, 2009, CLIN VACCINE IMMUNOL, V16, P1607, DOI 10.1128/CVI.00263-09; Hudson Z, 2009, PHYS THER SPORT, V10, P43, DOI 10.1016/j.ptsp.2009.03.002; Huvenne W, 2010, ALLERGY, V65, P1013, DOI 10.1111/j.1398-9995.2009.02313.x; Huvenne W, 2013, INT ARCH ALLERGY IMM, V161, P304, DOI 10.1159/000350329; Inoshima I, 2011, NAT MED, V17, P1310, DOI 10.1038/nm.2451; Ishigame H, 2009, IMMUNITY, V30, P108, DOI 10.1016/j.immuni.2008.11.009; Jarvis D, 2012, ALLERGY, V67, P91, DOI 10.1111/j.1398-9995.2011.02709.x; Jehmlich N, 2013, J PERIODONTAL RES, V48, P392, DOI 10.1111/jre.12025; Kabisch J, 2013, J BIOTECHNOL, V163, P97, DOI 10.1016/j.jbiotec.2012.06.034; Kolata J, 2011, PROTEOMICS, V11, P3914, DOI 10.1002/pmic.201000760; Kolata JB, 2015, J INFECT DIS, V212, P830, DOI 10.1093/infdis/jiv128; Kool M, 2008, J EXP MED, V205, P869, DOI 10.1084/jem.20071087; Krysko O, 2013, ALLERGY, V68, P446, DOI 10.1111/all.12102; Li MZ, 2007, NAT METHODS, V4, P251, DOI 10.1038/NMETH1010; Lin L, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000703; Lowy FD, 1998, NEW ENGL J MED, V339, P520, DOI 10.1056/NEJM199808203390806; Masoli M, 2004, ALLERGY, V59, P469, DOI 10.1111/j.1398-9995.2004.00526.x; McHeyzer-Williams M, 2012, NAT REV IMMUNOL, V12, P24, DOI 10.1038/nri3128; Milner JD, 2008, NATURE, V452, P773, DOI 10.1038/nature06764; Nakamura Y, 2013, NATURE, V503, P397, DOI 10.1038/nature12655; Niebuhr M, 2011, INFECT IMMUN, V79, P1615, DOI 10.1128/IAI.00958-10; Nirula A, 2011, CURR OPIN RHEUMATOL, V23, P119, DOI 10.1097/BOR.0b013e3283412fd4; Oettgen HC, 2000, CURR OPIN IMMUNOL, V12, P618, DOI 10.1016/S0952-7915(00)00153-9; Popowicz GM, 2006, J MOL BIOL, V358, P270, DOI 10.1016/j.jmb.2006.01.098; Prescott SL, 2013, J ALLERGY CLIN IMMUN, V131, P23, DOI 10.1016/j.jaci.2012.11.019; Proft T, 1998, J EXP MED, V187, P819, DOI 10.1084/jem.187.6.819; Pustelny K, 2014, ACTA BIOCHIM POL, V61, P149; R Development Core Team, 2018, R LANG ENV STAT COMP; Reed SB, 2001, INFECT IMMUN, V69, P1521, DOI 10.1128/IAI.69.3.1521-1527.2001; Renner ED, 2008, J ALLERGY CLIN IMMUN, V122, P181, DOI 10.1016/j.jaci.2008.04.037; SCHLIEVERT PM, 2007, SUP MOL BAS THEIR, P21; Silbersack J, 2006, APPL MICROBIOL BIOT, V73, P895, DOI 10.1007/s00253-006-0549-5; Stec-Niemczyk J, 2009, BIOCHEM J, V419, P555, DOI 10.1042/BJ20081351; Stentzel S, 2015, J PROTEOMICS, V128, P1, DOI 10.1016/j.jprot.2015.06.018; Stentzel S, 2014, PROTEOMICS, V14, P1857, DOI 10.1002/pmic.201300512; Van Zele T, 2004, J ALLERGY CLIN IMMUN, V114, P981, DOI 10.1016/j.jaci.2004.07.013; Vidarsson G, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00520; Wertheim HFL, 2005, LANCET INFECT DIS, V5, P751, DOI 10.1016/S1473-3099(05)70295-4; Yamane H, 2012, NAT IMMUNOL, V13, P1037, DOI 10.1038/ni.2431; Zdzalik M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076812; Zdzalik M, 2012, FEMS IMMUNOL MED MIC, V66, P220, DOI 10.1111/j.1574-695X.2012.01005.x; Zielinski CE, 2012, NATURE, V484, P514, DOI 10.1038/nature10957; Zobel S, 2015, APPL MICROBIOL BIOT, V99, P681, DOI 10.1007/s00253-014-6199-0	69	81	83	1	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2017	139	2					492	+		10.1016/j.jaci.2016.03.045	http://dx.doi.org/10.1016/j.jaci.2016.03.045			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EO9IM	27315768	Green Published, hybrid			2022-12-18	WOS:000397002400015
J	Kim, JH; Jeun, EJ; Hong, CP; Kim, SH; Jang, MS; Lee, EJ; Moon, SJ; Yun, CH; Im, SH; Jeong, SG; Park, BY; Kim, KT; Seoh, JY; Kim, YK; Oh, SJ; Ham, JS; Yang, BG; Jang, MH				Kim, Jung-Hwan; Jeun, Eun-Ji; Hong, Chun-Pyo; Kim, Seong-Hoon; Jang, Min Seong; Lee, Eun-Jung; Moon, Sook Jin; Yun, Chang Ho; Im, Sin-Hyeog; Jeong, Seok-Geun; Park, Beom-Young; Kim, Kyong-Tai; Seoh, Ju-Young; Kim, Yoon-Keun; Oh, Sung-Jong; Ham, Jun-Sang; Yang, Bo-Gie; Jang, Myoung Ho			Extracellular vesicle-derived protein from Bifidobacterium longum alleviates food allergy through mast cell suppression	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; Bifidobacterium longum; probiotics; extracellular vesicle; mast cells; family 5 extracellular solute-binding protein; ovalbumin	OUTER-MEMBRANE VESICLES; DENDRITIC CELL; MURINE MODEL; T-CELLS; BACTERIA; ANAPHYLAXIS; PROBIOTICS; EXOSOMES; INFANTS; COMMENSAL	Background: The incidence of food allergies has increased dramatically during the last decade. Recently, probiotics have been studied for the prevention and treatment of allergic disease. Objective: We examined whether Bifidobacterium longum KACC 91563 and Enterococcus faecalis KACC 91532 have the capacity to suppress food allergies. Methods: B longum KACC 91563 and E faecalis KACC 91532 were administered to BALB/c wild-type mice, in which food allergy was induced by using ovalbumin and alum. Food allergy symptoms and various immune responses were assessed. Results: B longum KACC 91563, but not E faecalis KACC 91532, alleviated food allergy symptoms. Extracellular vesicles of B longum KACC 91563 bound specifically tomast cells and induced apoptosis without affecting T-cell immune responses. Furthermore, injection of family 5 extracellular solute-binding protein, a main component of extracellular vesicles, into micemarkedly reduced the occurrence of diarrhea in a mouse food allergy model. Conclusion: B longum KACC 91563 induces apoptosis of mast cells specifically and alleviates food allergy symptoms. Accordingly, B longum KACC 91563 and family 5 extracellular solute-binding protein exhibit potential as therapeutic approaches for food allergies.	[Kim, Jung-Hwan; Jeun, Eun-Ji; Hong, Chun-Pyo; Jang, Min Seong; Lee, Eun-Jung; Moon, Sook Jin; Yun, Chang Ho; Im, Sin-Hyeog; Yang, Bo-Gie; Jang, Myoung Ho] Acad Immunol & Microbiol, Inst Basic Sci, 77 Cheogam Ro, Pohang 790784, Gyeongbuk, South Korea; [Kim, Jung-Hwan; Jeun, Eun-Ji; Hong, Chun-Pyo; Jang, Min Seong; Lee, Eun-Jung; Moon, Sook Jin; Im, Sin-Hyeog; Kim, Kyong-Tai] Pohang Univ Sci & Technol, Div Integrat Biosci & Biotechnol, Pohang, South Korea; [Kim, Seong-Hoon; Kim, Kyong-Tai] Pohang Univ Sci & Technol, Dept Life Sci, Div Mol & Life Sci, Pohang, South Korea; [Jeong, Seok-Geun; Park, Beom-Young; Ham, Jun-Sang] Rural Dev Adm, Natl Inst Anim Sci, Jeonju, South Korea; [Seoh, Ju-Young] Ewha Womans Univ, Grad Sch Med, Dept Microbiol, Seoul, South Korea; [Kim, Yoon-Keun] Ewha Womans Univ, Grad Sch Med, Dept Med, Seoul, South Korea; [Oh, Sung-Jong] Jeju Natl Univ, Coll Appl Life Sci, Fac Biotechnol, Jeju, South Korea	Institute for Basic Science - Korea (IBS); Pohang University of Science & Technology (POSTECH); Pohang University of Science & Technology (POSTECH); National Institute of Animal Science, Republic of Korea; Rural Development Administration (RDA), Republic of Korea; Ewha Womans University; Ewha Womans University; Jeju National University	Yang, BG; Jang, MH (corresponding author), Acad Immunol & Microbiol, Inst Basic Sci, 77 Cheogam Ro, Pohang 790784, Gyeongbuk, South Korea.; Ham, JS (corresponding author), RDA, Natl Inst Anim Sci, 1500 Kongjwipatjwi Ro, Iseo Myeon, Jeollabuk Do, South Korea.	hamjs@korea.kr; yangbg@ibs.re.kr; jangmh@ibs.re.kr	Jang, Myoung Ho/D-1714-2009; Im, Sin-Hyeog/E-6811-2013; Im, Sin-Hyeog/AAM-9586-2021	Jang, Myoung Ho/0000-0001-8909-4725; Im, Sin-Hyeog/0000-0002-3173-1856; Im, Sin-Hyeog/0000-0002-3173-1856; Moon, Sookjin/0000-0003-0645-8875; KIM, KYONG-TAI/0000-0001-7292-2627; Yang, Bo-Gie/0000-0002-1538-8488	Institute for Basic Science (IBS) [IBS-R005-S1-2015-a00, IBS-R005-D1-2015-a00]; National Institute of Animal Science research project of Rural Development Administration of Korea [PJ00932901]; National Research Foundation of Korea (NRF) [2013-056085]	Institute for Basic Science (IBS); National Institute of Animal Science research project of Rural Development Administration of Korea(National Institute of Animal Science, Republic of Korea); National Research Foundation of Korea (NRF)(National Research Foundation of Korea)	Supported by the Institute for Basic Science (IBS; IBS-R005-S1-2015-a00 and IBS-R005-D1-2015-a00), the National Institute of Animal Science research project of Rural Development Administration of Korea (PJ00932901), and the National Research Foundation of Korea (NRF; 2013-056085).	Ahrens R, 2012, AM J PATHOL, V180, P1535, DOI 10.1016/j.ajpath.2011.12.036; Atarashi K, 2013, NATURE, V500, P232, DOI 10.1038/nature12331; Berin MC, 2009, MUCOSAL IMMUNOL, V2, P24, DOI 10.1038/mi.2008.72; Brandt EB, 2003, J CLIN INVEST, V112, P1666, DOI 10.1172/JCI19785; Brandt EB, 2009, J ALLERGY CLIN IMMUN, V123, P53, DOI 10.1016/j.jaci.2008.10.001; Branum AM, 2009, PEDIATRICS, V124, P1549, DOI 10.1542/peds.2009-1210; Bron PA, 2012, NAT REV MICROBIOL, V10, P66, DOI 10.1038/nrmicro2690; Burton OT, 2013, MUCOSAL IMMUNOL, V6, P740, DOI 10.1038/mi.2012.112; Canani RB, 2012, J ALLERGY CLIN IMMUN, V129, P580, DOI 10.1016/j.jaci.2011.10.004; Corr SC, 2007, P NATL ACAD SCI USA, V104, P7617, DOI 10.1073/pnas.0700440104; Dunkin D, 2011, J ALLERGY CLIN IMMUN, V128, P1251, DOI 10.1016/j.jaci.2011.06.007; Ellis TN, 2010, MICROBIOL MOL BIOL R, V74, P81, DOI 10.1128/MMBR.00031-09; Fukuda S, 2011, NATURE, V469, P543, DOI 10.1038/nature09646; Ganeshan K, 2009, J ALLERGY CLIN IMMUN, V123, P231, DOI 10.1016/j.jaci.2008.10.011; Hadis U, 2011, IMMUNITY, V34, P237, DOI 10.1016/j.immuni.2011.01.016; Ham JS, 2013, J MICROBIOL BIOTECHN, V23, P966, DOI 10.4014/jmb.1303.03045; Ham JS, 2011, J BACTERIOL, V193, P5044, DOI 10.1128/JB.05620-11; Jeon Seong Gyu, 2012, PLoS Pathog, V8, pe1002714, DOI 10.1371/journal.ppat.1002714; Kalliomaki M, 2001, J ALLERGY CLIN IMMUN, V107, P129, DOI 10.1067/mai.2001.111237; Kawashima T, 2013, IMMUNITY, V38, P1187, DOI 10.1016/j.immuni.2013.02.024; Kim MR, 2012, ALLERGY, V67, P1271, DOI 10.1111/all.12001; Kim MK, 2011, KOREAN J FOOD SCI AN, V31, P290, DOI 10.5851/kosfa.2011.31.2.290; Konstantinov SR, 2008, P NATL ACAD SCI USA, V105, P19474, DOI 10.1073/pnas.0810305105; Kulp A, 2010, ANNU REV MICROBIOL, V64, P163, DOI 10.1146/annurev.micro.091208.073413; Kwon HK, 2010, P NATL ACAD SCI USA, V107, P2159, DOI 10.1073/pnas.0904055107; Lee EY, 2009, PROTEOMICS, V9, P5425, DOI 10.1002/pmic.200900338; Lopez P, 2012, VACCINE, V30, P825, DOI 10.1016/j.vaccine.2011.11.115; Mashburn-Warren LM, 2006, MOL MICROBIOL, V61, P839, DOI 10.1111/j.1365-2958.2006.05272.x; Mathias CB, 2011, J ALLERGY CLIN IMMUN, V127, P795, DOI 10.1016/j.jaci.2010.11.009; McBroom AJ, 2007, MOL MICROBIOL, V63, P545, DOI 10.1111/j.1365-2958.2006.05522.x; Morelli AE, 2004, BLOOD, V104, P3257, DOI 10.1182/blood-2004-03-0824; Prescott SL, 2007, J ALLERGY CLIN IMMUN, V120, P255, DOI 10.1016/j.jaci.2007.04.027; Rieu S, 2000, EUR J BIOCHEM, V267, P583, DOI 10.1046/j.1432-1327.2000.01036.x; Rivera J, 2010, P NATL ACAD SCI USA, V107, P19002, DOI 10.1073/pnas.1008843107; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P981, DOI 10.1016/S0091-6749(99)70167-3; Schiavi E, 2011, ALLERGY, V66, P499, DOI 10.1111/j.1398-9995.2010.02501.x; Shanahan F, 2010, GASTROENTEROLOGY, V139, P1808, DOI 10.1053/j.gastro.2010.10.025; Shen Y, 2012, CELL HOST MICROBE, V12, P509, DOI 10.1016/j.chom.2012.08.004; Shin TS, 2010, ALLERGY, V65, P1256, DOI 10.1111/j.1398-9995.2010.02359.x; Sicherer SH, 2009, ANNU REV MED, V60, P261, DOI 10.1146/annurev.med.60.042407.205711; Simpson RJ, 2008, PROTEOMICS, V8, P4083, DOI 10.1002/pmic.200800109; Skolnick HS, 2001, J ALLERGY CLIN IMMUN, V107, P367, DOI 10.1067/mai.2001.112129; Smits HH, 2005, J ALLERGY CLIN IMMUN, V115, P1260, DOI 10.1016/j.jaci.2005.03.036; Takayama N, 2007, CLIN IMMUNOL, V123, P199, DOI 10.1016/j.clim.2007.01.007; TAM R, 1993, MICROBIOL REV, V57, P320, DOI 10.1128/MMBR.57.2.320-346.1993; Thery C, 2009, NAT REV IMMUNOL, V9, P581, DOI 10.1038/nri2567; Uematsu S, 2006, NAT IMMUNOL, V7, P868, DOI 10.1038/ni1362; Wang M, 2008, J ALLERGY CLIN IMMUN, V121, P129, DOI 10.1016/j.jaci.2007.09.011; Winkler C, 2007, ELECTROPHORESIS, V28, P2095, DOI 10.1002/elps.200600670	49	81	86	20	96	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2016	137	2					507	+		10.1016/j.jaci.2015.08.016	http://dx.doi.org/10.1016/j.jaci.2015.08.016			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DC5BN	26433560	Bronze			2022-12-18	WOS:000369235500020
J	Shamji, MH; Layhadi, JA; Scadding, GW; Cheung, DKM; Calderon, MA; Turka, LA; Phippard, D; Durham, SR				Shamji, Mohamed H.; Layhadi, Janice A.; Scadding, Guy W.; Cheung, Delica K. M.; Calderon, Moises A.; Turka, Laurence A.; Phippard, Deborah; Durham, Stephen R.			Basophil expression of diamine oxidase: A novel biomarker of allergen immunotherapy response	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Diamine oxidase; basophils; allergen immunotherapy; sublingual immunotherapy; subcutaneous immunotherapy; histamine; basophil activation assay	GRASS-POLLEN IMMUNOTHERAPY; T-CELLS; BLOCKING ANTIBODIES; HISTAMINE-RELEASE; FLOW-CYTOMETRY; IGE; DEGRANULATION; INFLAMMATION; INDUCTION; TOLERANCE	Background: Immunotherapy inhibits basophil histamine release, but the assay is cumbersome, and no one has studied the effects of immunotherapy withdrawal. Objective: Intracellular fluorochrome-labeled diamine oxidase (DAO) was used as a novel functional readout of basophil histamine release after immunotherapy. Results were compared with conventional basophil surface expression of activation markers. Methods: Subcutaneous immunotherapy (SCIT)-treated patients (n = 14), sublingual immunotherapy (SLIT)-treated patients (n = 12), participants who completed 3 years of treatment with grass pollen sublingual immunotherapy (the SLIT-TOL group; n = 6), patients with untreated seasonal allergic rhinitis (SAR; n = 24), and nonatopic control subjects (n = 12) were studied. Intracellularly labeled DAO(+) and surface expression of CD203c(bright), CD63(+), and CD107a(+) on chemoattractant receptor-homologous molecule expressed on T(H)2 lymphocytes (CRTh2)-positive basophils were measured by means of flow cytometry. Serum IgG(4) levels and serum inhibitory activity for IgE-allergen complex binding to B cells (IgE-FAB) and basophil histamine release were also determined. Results: Proportions of allergen-stimulated DAO(+)CRTh2(+) basophils were higher in participants in the SCIT, SLIT, and SLIT-TOL groups (all P < .0001) compared with those in patients in the SAR group. Similarly, there were lower proportions of CRTh2(+) basophils expressing surface CD203c (bright) (all P < .001), CD63 (all P < .001), and CD107a (all P < .01). Rhinitis symptoms were lower in the SCIT, SLIT, and SLIT-TOL groups (P < .001) compared with those in the SAR group. Serum inhibitory activity for IgE-FAB and basophil histamine release were also significantly greater in all immunotherapy groups (P <. 05) compared with the SAR group. Conclusion: These results support long-term clinical and immunologic tolerance during and after grass pollen immunotherapy. Intracellularly labeled DAO expression by basophils merits further investigation as a surrogate biomarker for monitoring efficacy and tolerance after immunotherapy.	[Shamji, Mohamed H.; Layhadi, Janice A.; Scadding, Guy W.; Cheung, Delica K. M.; Calderon, Moises A.; Durham, Stephen R.] Univ London Imperial Coll Sci Technol & Med, Allergy & Clin Immunol Sect, Dept Leukocyte Biol, Div Natl Heart & Lung Inst, London SW7 2AZ, England; [Shamji, Mohamed H.; Layhadi, Janice A.; Scadding, Guy W.; Cheung, Delica K. M.; Calderon, Moises A.; Durham, Stephen R.] MRC, London, England; [Shamji, Mohamed H.; Layhadi, Janice A.; Scadding, Guy W.; Cheung, Delica K. M.; Calderon, Moises A.; Durham, Stephen R.] Asthma UK Ctr Allerg Mech Asthma, London, England; [Shamji, Mohamed H.; Layhadi, Janice A.; Cheung, Delica K. M.] Univ London Imperial Coll Sci Technol & Med, Immunomodulat & Tolerance Grp, Allergy & Clin Immunol Sect, Dept Leukocyte Biol, London SW7 2AZ, England; [Phippard, Deborah] Immune Tolerance Network, Bethesda, MD USA; [Turka, Laurence A.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA	Imperial College London; University of London; King's College London; Imperial College London; Immune Tolerance Network; Harvard University; Beth Israel Deaconess Medical Center	Durham, SR (corresponding author), Univ London Imperial Coll Sci Technol & Med, Allergy & Clin Immunol, Natl Heart & Lung Inst, Sir Alexander Fleming Bldg, London SW7 2AZ, England.	s.durham@imperial.ac.uk	Layhadi, Janice/AAU-8807-2020; Shamji, Mohamed/AAD-1788-2019; Shamji, Mohamed/AAU-8811-2020	Shamji, Mohamed/0000-0003-3425-3463; Layhadi, Janice/0000-0002-5242-1806	Immune Tolerance Network (National Institutes of Health) [N01 AI15416]; National Institute of Allergy and Infectious Diseases; Juvenile Diabetes Research Foundation; Pfizer; Merck; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI015416, R21AI115416] Funding Source: NIH RePORTER	Immune Tolerance Network (National Institutes of Health); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Juvenile Diabetes Research Foundation(Juvenile Diabetes Research Foundation); Pfizer(Pfizer); Merck(Merck & Company); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported in part by the Immune Tolerance Network (National Institutes of Health contract no. N01 AI15416), an international clinical research consortium headquartered at the University of California San Francisco and supported by the National Institute of Allergy and Infectious Diseases and the Juvenile Diabetes Research Foundation.; Disclosure of potential conflict of interest: M. H. Shamji, M. A. Calderon, and S. R. Durham have received research support from the Immune Tolerance Network (National Institutes of Health [NIH] contract no. N01 AI15416). L. A. Turka has received research support from the NIH and Pfizer, has received consultancy fees from Merck, is employed by Novartis, has received royalties from Myriad Genetics, and has stock/stock options in Novartis. The rest of the authors declare that they have no relevant conflicts of interest.	Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Bohle B, 2007, J ALLERGY CLIN IMMUN, V120, P707, DOI 10.1016/j.jaci.2007.06.013; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Durham SR, 2012, J ALLERGY CLIN IMMUN, V129, P717, DOI 10.1016/j.jaci.2011.12.973; DVORAK AM, 1993, J HISTOCHEM CYTOCHEM, V41, P787, DOI 10.1177/41.6.8315271; Ebo DG, 2006, ALLERGY, V61, P1028, DOI 10.1111/j.1398-9995.2006.01039.x; Ebo DG, 2012, J IMMUNOL METHODS, V375, P30, DOI 10.1016/j.jim.2011.09.003; EHRLICH P, 1878, THESIS LEIPZIG U LEI; Francis JN, 2008, J ALLERGY CLIN IMMUN, V121, P1120, DOI 10.1016/j.jaci.2008.01.072; Francis JN, 2003, J ALLERGY CLIN IMMUN, V111, P1255, DOI 10.1067/mai.2003.1570; Gri G, 2008, IMMUNITY, V29, P771, DOI 10.1016/j.immuni.2008.08.018; Hausmann OV, 2011, ALLERGY, V66, P85, DOI 10.1111/j.1398-9995.2010.02431.x; IZHIZAKA T, 1972, J IMMUNOL, V108, P1000; James LK, 2011, J ALLERGY CLIN IMMUN, V127, P509, DOI 10.1016/j.jaci.2010.12.1080; Kepley CL, 2000, J ALLERGY CLIN IMMUN, V106, P337, DOI 10.1067/mai.2000.107931; Lalek N, 2010, CLIN EXP ALLERGY, V40, P1186, DOI 10.1111/j.1365-2222.2010.03524.x; MacGlashan D, 2001, J LEUKOCYTE BIOL, V70, P207; MacGlashan D, 2000, J LEUKOCYTE BIOL, V68, P479; MacGlashan D, 2010, CLIN EXP ALLERGY, V40, P1365, DOI 10.1111/j.1365-2222.2010.03572.x; Nouri-Aria KT, 2004, J IMMUNOL, V172, P3252, DOI 10.4049/jimmunol.172.5.3252; O'Hehir RE, 2009, AM J RESP CRIT CARE, V180, P936, DOI 10.1164/rccm.200905-0686OC; Schroeder JT, 2009, ADV IMMUNOL, V101, P123, DOI 10.1016/S0065-2776(08)01004-3; Shamji MH, 2012, ALLERGY, V67, P217, DOI 10.1111/j.1398-9995.2011.02745.x; Shamji MH, 2006, J IMMUNOL METHODS, V317, P71, DOI 10.1016/j.jim.2006.09.004; Siracusa MC, 2011, NATURE, V477, P229, DOI 10.1038/nature10329; van Neerven RJJ, 1999, J IMMUNOL, V163, P2944; Wachholz PA, 2003, J ALLERGY CLIN IMMUN, V112, P915, DOI 10.1016/S0091-6749(03)02022-0; Wambre E, 2012, J ALLERGY CLIN IMMUN, V129, pe1; Wambre E, 2012, J ALLERGY CLIN IMMUN, V129, P544, DOI 10.1016/j.jaci.2011.08.034; Yoshimoto Tomohiro, 2011, Arerugi, V60, P16	30	81	85	0	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2015	135	4					913	+		10.1016/j.jaci.2014.09.049	http://dx.doi.org/10.1016/j.jaci.2014.09.049			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CF0MQ	25457150	Bronze			2022-12-18	WOS:000352238600012
J	Blumchen, K; Beder, A; Beschorner, J; Ahrens, F; Gruebl, A; Hamelmann, E; Hansen, G; Heinzmann, A; Nemat, K; Niggemann, B; Wahn, U; Beyer, K				Blumchen, Katharina; Beder, Alena; Beschorner, John; Ahrens, Frank; Gruebl, Armin; Hamelmann, Eckard; Hansen, Gesine; Heinzmann, Andrea; Nemat, Katja; Niggemann, Bodo; Wahn, Ulrich; Beyer, Kirsten			Modified oral food challenge used with sensitization biomarkers provides more real-life clinical thresholds for peanut allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Basophil activation; Ara h 2; children; cytokines; peanut allergy; food challenge	DOUBLE-BLIND; HUMAN BASOPHILS; CHILDREN; TESTS; IGE; ANAPHYLAXIS; DIAGNOSIS; SEVERITY; EGG; PREVALENCE	Background: Threshold levels for peanut allergy determined by using oral challenges are important for the food industry with regard to allergen labeling. Moreover, the utility of biological markers in predicting threshold levels is uncertain. Objective: We sought to use a modified oral food challenge regimen that might determine threshold levels for peanut allergy mimicking a more real-life exposure and to correlate the eliciting dose (ED) and severity of clinical reaction in children with peanut allergy with B-cell, T-cell, and effector cell markers. Methods: A modified food challenge procedure with doses scheduled 2 hours apart was used in 63 children with peanut allergy. All children received a maximum of 8 semi-log increasing titration steps of roasted peanuts ranging from 3 to 4500 mg of peanut protein until objective allergic reactions occurred. Severity of symptoms was graded from I to V. Biological markers were measured before challenge. Results: Forty-five of 63 patients showed objective symptoms after greater than 30 minutes, with a median latency of clinical reaction of 55 minutes. By using a log-normal dose-distribution model, the ED5 was calculated to be 1.95 mg of peanut protein. The ED was significantly and inversely correlated with peanut and Ara h 2-specific IgE levels, skin prick test responses, basophil activation, and T(H)2 cytokine production by PBMCs. Symptom severity did not correlate with any of the markers or the ED. Conclusion: This modified food challenge procedure might better reflect threshold levels for peanut allergy than the standard procedure because most of the patients reacted at a time interval of greater than 30 minutes. By using this model, threshold levels, but not severity, could be correlated with biological markers.	[Blumchen, Katharina; Beder, Alena; Beschorner, John; Niggemann, Bodo; Wahn, Ulrich; Beyer, Kirsten] Charite, Dept Pediat Pneumol & Immunol, D-13353 Berlin, Germany; [Ahrens, Frank] Childrens Hosp Altona, Hamburg, Germany; [Gruebl, Armin] Tech Univ Munich, Dept Pediat, D-80290 Munich, Germany; [Hamelmann, Eckard] Ruhr Univ Bochum, Dept Pediat, Bochum, Germany; [Hansen, Gesine] Hannover Med Sch, Dept Pediat Pneumol Allergol & Neonatol, Hannover, Germany; [Heinzmann, Andrea] Univ Freiburg, Ctr Pediat & Adolescent Med, Freiburg, Germany; [Nemat, Katja] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dept Pediat, Dresden, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Hamburg; University Medical Center Hamburg-Eppendorf; Technical University of Munich; Ruhr University Bochum; Hannover Medical School; University of Freiburg; Technische Universitat Dresden; Carl Gustav Carus University Hospital	Blumchen, K (corresponding author), Charite, Dept Pediat Pneumol & Immunol, Augustenburger Pl 1, D-13353 Berlin, Germany.	nina.bluemchen@charite.de	Hamelmann, Eckard/AAJ-9124-2021		Charite (Rahel Hirsch grant); Berlin Sparkassen Foundation for Medicine; Foundation for the Treatment of Peanut Allergic Patients (bea Stiftung)	Charite (Rahel Hirsch grant); Berlin Sparkassen Foundation for Medicine; Foundation for the Treatment of Peanut Allergic Patients (bea Stiftung)	Supported in part by a grant from Charite (Rahel Hirsch grant), the Foundation for the Treatment of Peanut Allergic Patients (bea Stiftung), and the Berlin Sparkassen Foundation for Medicine.	Ahrens B, 2012, J ALLERGY CLIN IMMUN, V130, P549, DOI 10.1016/j.jaci.2012.05.045; Astier C, 2006, J ALLERGY CLIN IMMUN, V118, P250, DOI 10.1016/j.jaci.2006.04.053; Ben-Shoshan M, 2009, J ALLERGY CLIN IMMUN, V123, P783, DOI 10.1016/j.jaci.2009.02.004; Benhamou AH, 2008, PEDIATR ALLERGY IMMU, V19, P173, DOI 10.1111/j.1399-3038.2007.00602.x; Blom WM, 2013, J ALLERGY CLIN IMMUN, V131, P172, DOI 10.1016/j.jaci.2012.10.034; Blumchen K, 2010, J ALLERGY CLIN IMMUN, V126, P83, DOI 10.1016/j.jaci.2010.04.030; BURKS AW, 1992, J ALLERGY CLIN IMMUN, V90, P962, DOI 10.1016/0091-6749(92)90469-I; Crevel RWR, 2007, FOOD CHEM TOXICOL, V45, P691, DOI 10.1016/j.fct.2006.09.005; Dang TD, 2012, J ALLERGY CLIN IMMUN, V129, P1056, DOI 10.1016/j.jaci.2012.01.056; de Weck AL, 2008, INT ARCH ALLERGY IMM, V146, P177, DOI 10.1159/000115885; Eller E, 2013, ALLERGY, V68, P190, DOI 10.1111/all.12075; Eller E, 2012, ANN ALLERG ASTHMA IM, V108, P332, DOI 10.1016/j.anai.2012.03.010; Flinterman AE, 2007, CLIN EXP ALLERGY, V37, P1221, DOI 10.1111/j.1365-2222.2007.02764.x; Hefle SL, 2007, J ALLERGY CLIN IMMUN, V120, P171, DOI 10.1016/j.jaci.2007.04.013; Hourihane JO, 2005, CLIN EXP ALLERGY, V35, P1227, DOI 10.1111/j.1365-2222.2005.02312.x; Jones SM, 2009, J ALLERGY CLIN IMMUN, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Jones Stacie M, 2009, J Allergy Clin Immunol, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Kleine-Tebbe J, 2006, INT ARCH ALLERGY IMM, V141, P79, DOI 10.1159/000094495; Kraut Souci F., 2008, FOOD COMPOSITION NUT; Nopp A, 2006, ALLERGY, V61, P298, DOI 10.1111/j.1398-9995.2006.00987.x; Ocmant A, 2009, CLIN EXP ALLERGY, V39, P1234, DOI 10.1111/j.1365-2222.2009.03292.x; Osterballe M, 2003, J ALLERGY CLIN IMMUN, V112, P196, DOI 10.1067/mai.2003.1603; Peeters KABM, 2007, CLIN EXP ALLERGY, V37, P108, DOI 10.1111/j.1365-2222.2006.02628.x; Pumphrey RSH, 2000, CLIN EXP ALLERGY, V30, P1144, DOI 10.1046/j.1365-2222.2000.00864.x; Rolinck-Werninghaus C, 2012, ALLERGY, V67, P951, DOI 10.1111/j.1398-9995.2012.02838.x; Rubio A, 2011, ALLERGY, V66, P92, DOI 10.1111/j.1398-9995.2010.02432.x; Sampson HA, 2003, PEDIATRICS, V111, P1601; Sampson HA, 2012, J ALLERGY CLIN IMMUN, V130, P1260, DOI 10.1016/j.jaci.2012.10.017; Shreffler WG, 2009, J ALLERGY CLIN IMMUN, V123, P43, DOI [10.1016/j.jaci.2008.12.1128, 10.1016/j.jaci.2008.09.051]; Sicherer SH, 2000, J ALLERGY CLIN IMMUN, V105, P582, DOI 10.1067/mai.2000.104941; Sicherer SH, 2003, J ALLERGY CLIN IMMUN, V112, P1203, DOI 10.1016/S0091-6749(03)02026-8; Taylor SL, 2010, FOOD CHEM TOXICOL, V48, P814, DOI 10.1016/j.fct.2009.12.013; Taylor SL, 2009, FOOD CHEM TOXICOL, V47, P1198, DOI 10.1016/j.fct.2009.02.011; Thyagarajan A, 2012, CLIN EXP ALLERGY, V42, P1197, DOI 10.1111/j.1365-2222.2012.04028.x; van der Zee T, 2011, J ALLERGY CLIN IMMUN, V128, P1031, DOI 10.1016/j.jaci.2011.07.050; Wainstein BK, 2010, PEDIAT ALLERG IMM-UK, V21, P603, DOI 10.1111/j.1399-3038.2010.01063.x; Wensing M, 2002, J ALLERGY CLIN IMMUN, V110, P915, DOI 10.1067/mai.2002.129235; Wood RA, 2003, PEDIATRICS, V111, P1631; Yu JW, 2006, J ALLERGY CLIN IMMUN, V118, P466, DOI 10.1016/j.jaci.2006.04.024	39	81	82	0	20	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2014	134	2					390	+		10.1016/j.jaci.2014.03.035	http://dx.doi.org/10.1016/j.jaci.2014.03.035			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AO5GB	24831438	Bronze			2022-12-18	WOS:000341370800019
J	Van Gerven, L; Alpizar, YA; Wouters, MM; Hox, V; Hauben, E; Jorissen, M; Boeckxstaens, G; Talavera, K; Hellings, PW				Van Gerven, Laura; Alpizar, Yeranddy A.; Wouters, Mira M.; Hox, Valerie; Hauben, Esther; Jorissen, Mark; Boeckxstaens, Guy; Talavera, Karel; Hellings, Peter W.			Capsaicin treatment reduces nasal hyperreactivity and transient receptor potential cation channel subfamily V, receptor 1 (TRPV1) overexpression in patients with idiopathic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Capsaicin treatment; idiopathic rhinitis; nasal hyperreactivity; TRPV1; afferent nerves; TRPV1-SP signaling pathway	COLD DRY AIR; NONALLERGIC RHINITIS; INTRANASAL CAPSAICIN; EPITHELIAL-CELLS; AQUEOUS SPRAY; DOUBLE-BLIND; MAST-CELLS; IN-VITRO; MECHANISMS; EXPRESSION	Background: Idiopathic rhinitis (IR) is a prevalent condition for which capsaicin nasal spray is the most effective treatment. However, the mechanisms underlying IR and the therapeutic action of capsaicin remain unknown. Objective: We sought to investigate the molecular and cellular bases of IR and the therapeutic action of capsaicin. Methods: Fourteen patients with IR and 12 healthy control subjects (HCs) were treated with intranasal capsaicin. The therapeutic effect was assessed in patients with IR by using visual analog scale and therapeutic response evaluation scores, and nasal hyperreactivity was evaluated by means of cold dry air provocation. Nasal samples served to measure the levels of neuromediators and expression of chemosensory cation channels, protein gene product 9.5 (PGP 9.5), and the mast cell marker c-kit. The effects of capsaicin were also tested in vitro on human nasal epithelial cells and mast cells. Results: Patients with IR had higher baseline transient receptor potential cation channel subfamily V, receptor 1 (TRPV1) expression in the nasal mucosa and higher concentrations of substance P (SP) in nasal secretions than HCs. Symptomatic relief was observed in 11 of 14 patients with IR after capsaicin treatment. Expression of TRPV1; transient receptor potential cation channel subfamily M, receptor 8 (TRPM8); and PGP 9.5 was only reduced in patients with IR after capsaicin treatment. Capsaicin did not alter c-KIT expression or nasal epithelial morphology in patients with IR and HCs nor did it induce apoptosis or necrosis in cultured human nasal epithelial cells and mast cells. Conclusion: IR features an overexpression of TRPV1 in the nasal mucosa and increased SP levels in nasal secretions. Capsaicin exerts its therapeutic action by ablating the TRPV1-SP nociceptive signaling pathway in the nasal mucosa.	[Van Gerven, Laura; Hox, Valerie; Jorissen, Mark; Hellings, Peter W.] Univ Hosp Leuven, Clin Div Otorhinolaryngol Head & Neck Surg, B-3000 Louvain, Belgium; [Hauben, Esther] Univ Hosp Leuven, Clin Div Pathol, B-3000 Louvain, Belgium; [Van Gerven, Laura; Hox, Valerie; Hellings, Peter W.] Katholieke Univ Leuven, Clin Immunol Lab, Dept Microbiol & Immunol, Louvain, Belgium; [Alpizar, Yeranddy A.; Talavera, Karel] Katholieke Univ Leuven, Lab Ion Channel Res, Dept Mol & Cell Biol, Louvain, Belgium; [Wouters, Mira M.; Boeckxstaens, Guy] Katholieke Univ Leuven, Translat Res Ctr Gastrointestinal Disorders TARGI, Louvain, Belgium; [Hauben, Esther] Katholieke Univ Leuven, Lab Translat Cell & Tissue Res, Dept Imaging & Pathol, Louvain, Belgium	KU Leuven; University Hospital Leuven; KU Leuven; University Hospital Leuven; KU Leuven; KU Leuven; KU Leuven; KU Leuven	Hellings, PW (corresponding author), Univ Hosp Leuven, Clin Div Otorhinolaryngol Head & Neck Surg, Kapucijnenvoer 33, B-3000 Louvain, Belgium.	peter.hellings@uzleuven.be	Hox, Valérie/AAA-5660-2020; Van Gerven, Laura/ABG-5800-2021; Hellings, Peter W/I-4068-2018; Boeckxstaens, Guy/AAP-2502-2020; Wouters, Mira/K-1371-2013; Hox, Valerie/AAS-6504-2020; Talavera, Karel/K-7990-2014	Hox, Valérie/0000-0003-2390-294X; Van Gerven, Laura/0000-0002-5325-7956; Hellings, Peter W/0000-0001-6898-688X; Wouters, Mira/0000-0002-3438-1919; Talavera, Karel/0000-0002-3124-138X; Alpizar, Yeranddy A/0000-0003-1959-5393	Science and Technology in Flanders, Belgium (IWT); fellowship from the Fund for Scientific Research Flanders, Belgium (FWO); postdoctoral researcher of the Fund for Scientific Research (FWO); governmental grant (Odysseus program) [G. 0905.07]; Belgian Federal Government [IUAP P6/28, G. 0565.07, G. 0686.09]; IWT (TBM project) [130260]; Research Council of the KU Leuven (GOA) [14/011, EF/95/010, PFV/10/006]	Science and Technology in Flanders, Belgium (IWT)(Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT)); fellowship from the Fund for Scientific Research Flanders, Belgium (FWO); postdoctoral researcher of the Fund for Scientific Research (FWO); governmental grant (Odysseus program); Belgian Federal Government; IWT (TBM project); Research Council of the KU Leuven (GOA)(KU Leuven)	L.V.G. is supported by a grant of the Agency for Innovation by Science and Technology in Flanders, Belgium (IWT). P.W.H. is a recipient of a senior researcher fellowship from the Fund for Scientific Research Flanders, Belgium (FWO). M. M. W. is a postdoctoral researcher of the Fund for Scientific Research (FWO), Flanders, Belgium. G. B. is supported by a governmental grant (Odysseus program, G. 0905.07, FWO). This work was also supported by grants from the Belgian Federal Government (IUAP P6/28), the FWO (G. 0565.07 and G. 0686.09), IWT (TBM project 130260), and the Research Council of the KU Leuven (GOA 2009/07 and 14/011, EF/95/010 and PFV/10/006).	Akbar A, 2008, GUT, V57, P923, DOI 10.1136/gut.2007.138982; Alpizar YA, 2013, PFLUG ARCH EUR J PHY, V465, P853, DOI 10.1007/s00424-012-1204-x; Anand P, 2011, BRIT J ANAESTH, V107, P490, DOI 10.1093/bja/aer260; Bautista DM, 2007, NATURE, V448, P204, DOI 10.1038/nature05910; Bernstein JA, 2011, ANN ALLERG ASTHMA IM, V107, P171, DOI 10.1016/j.anai.2011.05.016; BEVAN S, 1990, TRENDS PHARMACOL SCI, V11, P330; Blom HM, 1997, J ALLERGY CLIN IMMUN, V100, P739, DOI 10.1016/S0091-6749(97)70267-7; Blom HM, 1997, CLIN EXP ALLERGY, V27, P796, DOI 10.1046/j.1365-2222.1997.670842.x; Blom HM, 1998, CLIN EXP ALLERGY, V28, P1351; Bobic S, 2010, RHINOLOGY, V48, P401, DOI 10.4193/Rhino10.033; Bousquet J, 2008, ALLERGY, V63, P842, DOI 10.1111/j.1398-9995.2008.01715.x; Braat JPM, 1998, AM J RESP CRIT CARE, V157, P1748, DOI 10.1164/ajrccm.157.6.9701016; Callebaut I, 2010, ALLERGY, V65, P1173, DOI 10.1111/j.1398-9995.2010.02360.x; Ciabatti PG, 2009, ACTA OTO-LARYNGOL, V129, P367, DOI 10.1080/00016480802510186; Decraene A, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-177; Dhaka A, 2007, NEURON, V54, P371, DOI 10.1016/j.neuron.2007.02.024; Enoksson M, 2011, J IMMUNOL, V186, P2523, DOI 10.4049/jimmunol.1003383; Fernandes ES, 2012, BRIT J PHARMACOL, V166, P510, DOI 10.1111/j.1476-5381.2012.01851.x; Hens G, 2011, AM J RESP CELL MOL, V44, P517, DOI 10.1165/rcmb.2009-0425OC; Hox V, 2013, AM J RESP CRIT CARE, V187, P486, DOI 10.1164/rccm.201208-1358OC; Karashima Y, 2009, P NATL ACAD SCI USA, V106, P1273, DOI 10.1073/pnas.0808487106; Keh SM, 2011, RHINOLOGY, V49, P453, DOI 10.4193/Rhino11.089; Kirshenbaum AS, 2003, LEUKEMIA RES, V27, P677, DOI 10.1016/S0145-2126(02)00343-0; Kulka M, 2008, IMMUNOLOGY, V123, P398, DOI 10.1111/j.1365-2567.2007.02705.x; LACROIX JS, 1991, CLIN EXP ALLERGY, V21, P595, DOI 10.1111/j.1365-2222.1991.tb00852.x; Reilly CA, 2003, TOXICOL SCI, V73, P170, DOI 10.1093/toxsci/kfg044; RIECHELMANN H, 1993, HNO, V41, P475; Rondon C, 2007, J ALLERGY CLIN IMMUN, V119, P899, DOI 10.1016/j.jaci.2007.01.006; Salib RJ, 2008, CLIN EXP ALLERGY, V38, P393, DOI 10.1111/j.1365-2222.2007.02926.x; Salib RJ, 2005, CLIN EXP ALLERGY, V35, P811, DOI 10.1111/j.1365-2222.2005.02258.x; Sarin S, 2006, J ALLERGY CLIN IMMUN, V118, P999, DOI 10.1016/j.jaci.2006.09.013; Scadding Glenis, 2011, Clin Transl Allergy, V1, P2, DOI 10.1186/2045-7022-1-2; Silver WL, 2006, CHEM SENSES, V31, P807, DOI 10.1093/chemse/bjl022; Stander S, 2004, EXP DERMATOL, V13, P129, DOI 10.1111/j.0906-6705.2004.0178.x; Story GM, 2003, CELL, V112, P819, DOI 10.1016/S0092-8674(03)00158-2; Van Gerven L, 2012, RHINOLOGY, V50, P227, DOI [10.4193/Rhino11.152, 10.4193/Rhino.11.152]; Van Gerven L, 2012, LARYNGOSCOPE, V122, P2615, DOI 10.1002/lary.23495; Van Rijswijk JB, 2003, ALLERGY, V58, P754, DOI 10.1034/j.1398-9995.2003.00203.x; van Rijswijk JB, 2003, RHINOLOGY, V41, P25	39	81	82	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2014	133	5					1332	U544		10.1016/j.jaci.2013.08.026	http://dx.doi.org/10.1016/j.jaci.2013.08.026			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AG5HS	24139494				2022-12-18	WOS:000335450700014
J	Diamant, Z; Gauvreau, GM; Cockcroft, DW; Boulet, LP; Sterk, PJ; de Jongh, FHC; Dahlen, B; O'Byrne, PM				Diamant, Zuzana; Gauvreau, Gail M.; Cockcroft, Don W.; Boulet, Louis-Philippe; Sterk, Peter J.; de Jongh, Frans H. C.; Dahlen, Barbro; O'Byrne, Paul M.			Inhaled allergen bronchoprovocation tests	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergen challenge; methodology; asthma; drug development	INDUCED AIRWAY RESPONSES; LATE ASTHMATIC RESPONSES; HOUSE-DUST MITE; BRONCHIAL RESPONSIVENESS; RECEPTOR ANTAGONIST; BECLOMETHASONE DIPROPIONATE; DISODIUM-CROMOGLYCATE; CLINICAL DEVELOPMENT; SODIUM CROMOGLYCATE; REPEATED INHALATION	The allergen bronchoprovocation test is a long-standing exacerbation model of allergic asthma that can induce several clinical and pathophysiologic features of asthma in sensitized subjects. Standardized allergen challenge is primarily a research tool, and when properly conducted by qualified and experienced investigators, it is safe and highly reproducible. In combination with validated airway sampling and sensitive detection techniques, allergen challenge allows the study of several features of the physiology of mainly T(H)2 cell-driven asthma in relation to the kinetics of the underlying airway pathology occurring during the allergen-induced late response. Furthermore, given the small within-subject variability in allergen-induced airway responses, allergen challenge offers an adequate disease model for the evaluation of new (targeted) controller therapies for asthma in a limited number of subjects. In proof-of-efficacy studies thus far, allergen challenge showed a fair positive predicted value and an excellent negative predictive value for the actual clinical efficacy of new antiasthma therapies, underscoring its important role in early drug development. In this review we provide recommendations on challenge methods, response measurements, sample size, safety, and harmonization for future applications.	[Diamant, Zuzana] Skane Univ, Dept Resp Med & Allergol, Lund, Sweden; [Diamant, Zuzana] Univ Groningen, Univ Med Ctr Groningen, Dept Gen Practice, Groningen, Netherlands; [Gauvreau, Gail M.; O'Byrne, Paul M.] McMaster Univ, Dept Med, Hamilton, ON L8S 4K1, Canada; [Cockcroft, Don W.] Univ Saskatchewan, Dept Med, Saskatoon, SK S7N 0W0, Canada; [Boulet, Louis-Philippe] Inst Univ Cardiol & Pneumol Quebec, Quebec City, PQ, Canada; [Sterk, Peter J.; de Jongh, Frans H. C.] Univ Amsterdam, Acad Med Ctr, NL-1012 WX Amsterdam, Netherlands; [Dahlen, Barbro] Karolinska Inst, Karolinska Univ Hosp, Ctr Allergy Res, Dept Resp Med & Allergy, Stockholm, Sweden	University of Groningen; McMaster University; University of Saskatchewan; University of Amsterdam; Academic Medical Center Amsterdam; Karolinska Institutet; Karolinska University Hospital	O'Byrne, PM (corresponding author), McMaster Univ, HSC 3W10,1280 Main St West, Hamilton, ON L8S 4K1, Canada.	obyrne@mcmaster.ca	Sterk, P.J./AAK-8175-2020; de Jongh, Frans/N-7739-2013	O'Byrne, Paul/0000-0003-0979-281X	MSD; Biomedical Systems; Benecke BV; Genentech; CSL; ONO; AIM Therapeutics; Novartis; Amgen; Meda; AstraZeneca; GlaxoSmithKline; Merck; Joint Oversight Board for LABA safety study	MSD; Biomedical Systems; Benecke BV; Genentech(Roche HoldingGenentech); CSL; ONO; AIM Therapeutics; Novartis(Novartis); Amgen(Amgen); Meda; AstraZeneca(AstraZeneca); GlaxoSmithKline(GlaxoSmithKline); Merck(Merck & Company); Joint Oversight Board for LABA safety study	Z. Diamant works part time at a CRO (QPS Netherlands, Groningen, NL) and has received one or more grants from or has one or more grants pending with MSD, Biomedical Systems, and Benecke BV. G. M. Gauvreau has been supported by one or more grants from Genentech and CSL and has received one or more consulting fees or honoraria from ONO and AIM Therapeutics. D. W. Cockcroft has received one or more grants from or has one or more grants pending with ONO, Novartis, Amgen, and Genentech and has received royalties for allergen and methacholine challenge standard operating procedures. B. Dahlen has consultancy arrangements with Actelion, has received one or more payments for lecturing from or is on the speakers' bureau for Meda and Novartis, and has received royalties from Studentlitteratur. P. M. O'Byrne has been supported by one or more grants from AIM, AstraZeneca, Amgen, GlaxoSmithKline, ONO, Genentech, and Novartis; has received one or more consulting fees or honoraria from AstraZeneca, GlaxoSmithKline, Merck, and Novartis; and has received one or more fees for participation from the Joint Oversight Board for LABA safety study. The rest of the authors declare that they have no relevant conflicts of interest.	Ali FR, 2004, AM J RESP CRIT CARE, V169, P20, DOI 10.1164/rccm.200305-690OC; ALTOUNYAN R. E. C., 1964, THORAX, V19, P406, DOI 10.1136/thx.19.5.406; Blackley CH., 1873, EXPT RES CAUSES NATU; BOOIJ-NOORD H, 1972, Clinical Allergy, V2, P43, DOI 10.1111/j.1365-2222.1972.tb01267.x; BOOIJNOORD H, 1971, J ALLERGY CLIN IMMUN, V48, P344, DOI 10.1016/0091-6749(71)90080-7; Boot JD, 2007, AM J RESP CRIT CARE, V175, P450, DOI 10.1164/rccm.200608-1186OC; Boulay ME, 2002, CLIN EXP ALLERGY, V32, P1441, DOI 10.1046/j.1365-2745.2002.01508.x; Boulet LP, 2007, ALLERGY, V62, P1101, DOI 10.1111/j.1398-9995.2007.01499.x; BOULET LP, 1983, J ALLERGY CLIN IMMUN, V71, P399, DOI 10.1016/0091-6749(83)90069-6; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; BRYANT D H, 1975, Clinical Allergy, V5, P145, DOI 10.1111/j.1365-2222.1975.tb01847.x; BURTIN P, 1962, INT ARCH ALLER A IMM, V21, P8, DOI 10.1159/000229311; CAMPAGNE JG, 1969, SCAND J RESPIR DIS, V50, P76; Canning BJ, 2001, RESP PHYSIOL, V125, P113, DOI 10.1016/S0034-5687(00)00208-5; Cho HJ, 2010, J CELL BIOCHEM, V109, P1254, DOI 10.1002/jcb.22511; Choi IS, 2005, J ASTHMA, V42, P197, DOI 10.1081/JAS-200054619; Cockcroft DW, 2007, CAN RESPIR J, V14, P414, DOI 10.1155/2007/753450; Cockcroft DW, 2005, ALLERGY, V60, P56, DOI 10.1111/j.1398-9995.2004.00612.x; COCKCROFT DW, 1987, THORAX, V42, P302, DOI 10.1136/thx.42.4.302; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; COCKCROFT DW, 1979, AM REV RESPIR DIS, V120, P1053; COCKCROFT DW, 1987, AM REV RESPIR DIS, V135, P264; COCKCROFT DW, 1983, LANCET, V2, P253; COCKCROFT DW, 1987, J ALLERGY CLIN IMMUN, V79, P734, DOI 10.1016/0091-6749(87)90204-1; COLLDAHL HELGE, 1952, ACTA ALLERGOL, V5, P143, DOI 10.1111/j.1398-9995.1952.tb03445.x; Crimi E, 1999, CLIN EXP ALLERGY, V29, P1663, DOI 10.1046/j.1365-2222.1999.00681.x; Cullinan P, 2001, ANN OCCUP HYG, V45, P97, DOI 10.1093/annhyg/45.2.97; Dahlen B, 2011, CLIN EXP ALLERGY, V41, P1091, DOI 10.1111/j.1365-2222.2011.03763.x; Dahlen B, 2009, EUR RESPIR J, V33, P1; de Blay F, 1999, INT ARCH ALLERGY IMM, V120, P158, DOI 10.1159/000024234; de Kluijver J, 2002, AM J RESP CRIT CARE, V166, P294, DOI 10.1164/rccm.2112097; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; Dente FL, 2000, RESP MED, V94, P441, DOI 10.1053/rmed.1999.0760; Devillier P, 2011, ALLERGY, V66, P163, DOI 10.1111/j.1398-9995.2010.02473.x; Diamant Z, 2005, CLIN EXP ALLERGY, V35, P1080, DOI 10.1111/j.1365-2222.2005.02296.x; DIAMANT Z, 1995, J ALLERGY CLIN IMMUN, V95, P42, DOI 10.1016/S0091-6749(95)70151-6; Diamant Z, 1996, AM J RESP CRIT CARE, V153, P1790, DOI 10.1164/ajrccm.153.6.8665036; Diamant Z, 1996, CLIN EXP ALLERGY, V26, P525; Diamant Z, 1999, CLIN EXP ALLERGY, V29, P42; Diamant Z, 2008, RESP MED, V102, P332, DOI 10.1016/j.rmed.2007.10.018; Duong M, 2008, ALLERGY, V63, P1195, DOI 10.1111/j.1398-9995.2008.01707.x; DURHAM SR, 1988, J ALLERGY CLIN IMMUN, V82, P764, DOI 10.1016/0091-6749(88)90077-2; Fahy JV, 1999, AM J RESP CRIT CARE, V160, P1023, DOI 10.1164/ajrccm.160.3.9810012; Fernandez C, 2007, CLIN EXP ALLERGY, V37, P391, DOI 10.1111/j.1365-2222.2007.02659.x; FROLUND L, 1987, CLIN ALLERGY, V17, P439, DOI 10.1111/j.1365-2222.1987.tb02038.x; GANDEVIA B., 1957, THORAX, V12, P290, DOI 10.1136/thx.12.4.290; Gauvreau G, 2012, AM J RESP CRIT CARE, V185, pA6793; Gauvreau GM, 2008, AM J RESP CRIT CARE, V177, P952, DOI 10.1164/rccm.200708-1251OC; Gauvreau GM, 2006, AM J RESP CRIT CARE, V174, P15, DOI 10.1164/rccm.200601-057OC; Gauvreau GM, 2011, AM J RESP CRIT CARE, V183, P1007, DOI 10.1164/rccm.201008-1210OC; Gauvreau GM, 2000, CLIN EXP ALLERGY, V30, P1235; Gauvreau GM, 1999, AM J RESP CRIT CARE, V159, P31, DOI 10.1164/ajrccm.159.1.9804030; Gauvreau GM, 2005, J ALLERGY CLIN IMMUN, V116, P285, DOI 10.1016/j.jaci.2005.05.021; Gauvreau GM, 1997, AM J RESP CRIT CARE, V156, P1738, DOI 10.1164/ajrccm.156.6.96-08042; Gauvreau GM, 1999, AM J RESP CRIT CARE, V160, P640, DOI 10.1164/ajrccm.160.2.9809130; Gauvreau GM, 1999, J ALLERGY CLIN IMMUN, V104, P66, DOI 10.1016/S0091-6749(99)70115-6; Gauvreau GM, 1996, AM J RESP CRIT CARE, V154, P1267, DOI 10.1164/ajrccm.154.5.8912734; Global Initiative for Asthma (GINA), 2012, GLOB STRAT ASTHM MAN; Grunberg K, 1997, CLIN EXP ALLERGY, V27, P36, DOI 10.1111/j.1365-2222.1997.tb00670.x; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; HARGREAVE FE, 1981, J ALLERGY CLIN IMMUN, V68, P347, DOI 10.1016/0091-6749(81)90132-9; Hatzivlassiou M, 2010, ALLERGY, V65, P355, DOI 10.1111/j.1398-9995.2009.02184.x; HERXHEIMER H, 1951, INT ARCH ALLER A IMM, V2, P27, DOI 10.1159/000227898; HERXHEIMER H, 1952, INT ARCH ALLER A IMM, V3, P323, DOI 10.1159/000227979; HERXHEIMER H, 1951, LANCET, V260, P1337; Hesslinger C, 2009, BIOCHEM SOC T, V37, P886, DOI 10.1042/BST0370886; HILL DJ, 1982, CLIN ALLERGY, V12, P295, DOI 10.1111/j.1365-2222.1982.tb02531.x; HUNT LW, 1994, AM J RESP CRIT CARE, V149, P1471, DOI 10.1164/ajrccm.149.6.8004300; Ihre E, 2006, EUR RESPIR J, V27, P1152, DOI 10.1183/09031936.06.00142905; IHRE E, 1993, CLIN EXP ALLERGY, V23, P298, DOI 10.1111/j.1365-2222.1993.tb00326.x; INMAN MD, 1995, J ALLERGY CLIN IMMUN, V95, P1191, DOI 10.1016/S0091-6749(95)70075-7; Inman MD, 2001, AM J RESP CRIT CARE, V164, P569, DOI 10.1164/ajrccm.164.4.2007063; Inman MD, 1998, J ALLERGY CLIN IMMUN, V101, P342, DOI 10.1016/S0091-6749(98)70246-5; Jaeschke R, 2008, AM J RESP CRIT CARE, V178, P1009, DOI 10.1164/rccm.200804-494OC; Joos GF, 2003, EUR RESPIR J, V21, P1050, DOI 10.1183/09031936.03.00008403; Kauffman Henk F, 2006, Clin Mol Allergy, V4, P5, DOI 10.1186/1476-7961-4-5; Kelly MM, 2010, J ALLERGY CLIN IMMUN, V125, P349, DOI 10.1016/j.jaci.2009.09.011; Kent SE, 2013, CLIN EXP ALLERGY, V43, P177, DOI 10.1111/cea.12002; KHARITONOV SA, 1995, AM J RESP CRIT CARE, V151, P1894, DOI 10.1164/ajrccm.151.6.7767537; Kidney JC, 1997, J ALLERGY CLIN IMMUN, V100, P65, DOI 10.1016/S0091-6749(97)70196-9; KILLIAN D, 1976, CLIN ALLERGY, V6, P219, DOI 10.1111/j.1365-2222.1976.tb01900.x; Kluijver JC, 2003, AM J RESP CRIT CARE, V168, P1174, DOI 10.1164/rccm/200212-1520OC; Kukreja N, 2008, CLIN EXP IMMUNOL, V154, P162, DOI 10.1111/j.1365-2249.2008.03762.x; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Leckie MJ, 2000, CLIN EXP ALLERGY, V30, P1191; Lindstrom I, 2013, OCCUP MED-OXFORD, V63, P294, DOI 10.1093/occmed/kqt020; Lommatzsch M, 2006, J ALLERGY CLIN IMMUN, V118, P91, DOI 10.1016/j.jaci.2006.02.034; LOWELL FC, 1948, J ALLERGY, V19, P100, DOI 10.1016/0021-8707(48)90096-3; Luger EO, 2009, J ALLERGY CLIN IMMUN, V124, P819, DOI 10.1016/j.jaci.2009.06.047; Merget R, 1997, J ALLERGY CLIN IMMUN, V100, P199, DOI 10.1016/S0091-6749(97)70225-2; Merget R, 2010, AM J IND MED, V53, P42, DOI 10.1002/ajim.20786; Merget R, 2009, RESP MED, V103, P607, DOI 10.1016/j.rmed.2008.10.010; Nair P, 2009, NEW ENGL J MED, V360, P985, DOI 10.1056/NEJMoa0805435; Niemeijer NR, 1996, ANN ALLERG ASTHMA IM, V76, P535, DOI 10.1016/S1081-1206(10)63274-7; O'Byrne PM, 2009, CLIN EXP ALLERGY, V39, P181, DOI 10.1111/j.1365-2222.2008.03172.x; O'Byrne PM, 2009, ALLERGY ASTHMA IMMUN, V1, P3, DOI 10.4168/aair.2009.1.1.3; OBYRNE PM, 1987, AM REV RESPIR DIS, V136, P740, DOI 10.1164/ajrccm/136.3.740; Page K, 2003, J ALLERGY CLIN IMMUN, V112, P1112, DOI 10.1016/j.jaci.2003.08.050; Palmqvist M, 1998, RESP MED, V92, P1223, DOI 10.1016/S0954-6111(98)90425-5; Parameswaran K, 2000, Can Respir J, V7, P313; PEPYS J, 1968, LANCET, V2, P134; PEPYS J, 1974, CLIN ALLERGY, V4, P13, DOI 10.1111/j.1365-2222.1974.tb01358.x; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; PIN I, 1992, AM REV RESPIR DIS, V145, P1265, DOI 10.1164/ajrccm/145.6.1265; Raemdonck K, 2012, THORAX, V67, P19, DOI 10.1136/thoraxjnl-2011-200365; Ravensberg AJ, 2007, CLIN EXP ALLERGY, V37, P100, DOI 10.1111/j.1365-2222.2006.02617.x; ROBERTSON DG, 1974, J ALLERGY CLIN IMMUN, V54, P244, DOI 10.1016/0091-6749(74)90067-0; Robinson DS, 2011, CLIN EXP ALLERGY, V41, P606, DOI 10.1111/j.1365-2222.2011.03736.x; Roquet A, 1997, AM J RESP CRIT CARE, V155, P1856, DOI 10.1164/ajrccm.155.6.9196086; Roquet A, 1998, APMIS, V106, P293, DOI 10.1111/j.1699-0463.1998.tb01349.x; Ruddy M., 2010, AM J RESP CRIT CARE, pA4043; Schiller I. W., 1947, ANN ALLERGY, V5, P564; Schulze J, 2013, PEDIAT ALLERG IMM-UK, V24, P19, DOI 10.1111/pai.12031; Seed MJ, 2008, CURR OPIN ALLERGY CL, V8, P103, DOI 10.1097/ACI.0b013e3282f4cadd; STERK PJ, 1993, EUR RESPIR J, V6, P53, DOI 10.1183/09041950.053s1693; STEVENS FRANKLIN A., 1934, JOUR ALLERGY, V5, P285, DOI 10.1016/S0021-8707(34)90226-4; Sulakvelidze I, 1998, EUR RESPIR J, V11, P821, DOI 10.1183/09031936.98.11040821; Swystun VA, 1998, J ALLERGY CLIN IMMUN, V102, P363, DOI 10.1016/S0091-6749(98)70121-6; Taylor DA, 1998, AM J RESP CRIT CARE, V158, P99, DOI 10.1164/ajrccm.158.1.9709091; Taylor DA, 2000, CLIN EXP ALLERGY, V30, P56; TIFFENEAU R, 1959, Pathol Biol, V7, P2293; van de Pol MA, 2012, ALLERGY, V67, P67, DOI 10.1111/j.1398-9995.2011.02722.x; Van Der Veen MJ, 2001, CLIN EXP ALLERGY, V31, P705, DOI 10.1046/j.1365-2222.2001.01120.x; VANHOEYVELD EM, 1985, J ALLERGY CLIN IMMUN, V76, P543, DOI 10.1016/0091-6749(85)90773-0; Wenzel S, 2006, AM J RESP CRIT CARE, V174, P1173, DOI 10.1164/rccm.2609002; WONG BJ, 1992, AM REV RESPIR DIS, V146, P1156, DOI 10.1164/ajrccm/146.5_Pt_1.1156	126	81	85	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2013	132	5					1045	+		10.1016/j.jaci.2013.08.023	http://dx.doi.org/10.1016/j.jaci.2013.08.023			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	242JH	24119772				2022-12-18	WOS:000326235600003
J	Nagarkar, DR; Poposki, JA; Comeau, MR; Biyasheva, A; Avila, PC; Schleimer, RP; Kato, A				Nagarkar, Deepti R.; Poposki, Julie A.; Comeau, Michael R.; Biyasheva, Assel; Avila, Pedro C.; Schleimer, Robert P.; Kato, Atsushi			Airway epithelial cells activate T(H)2 cytokine production in mast cells through IL-1 and thymic stromal lymphopoietin	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Epithelial cells; mast cells; virus; asthma; T(H)2 cytokine; IL-1; thymic stromal lymphopoietin	DOUBLE-STRANDED-RNA; RHINOVIRUS INFECTION; BRONCHOALVEOLAR LAVAGE; ASTHMA; EXPRESSION; INFLAMMATION; TSLP; INTERLEUKIN-1; PHENOTYPE; RECEPTOR	Background: Airway epithelial cells are important regulators of innate and adaptive immunity. Although mast cells are known to play a central role in manifestations of allergic inflammation and are found in the epithelium in patients with T(H)2-related diseases, their role is incompletely understood. Objectives: The objective of this study was to investigate the role of airway epithelial cells in the production of T(H)2 cytokines in mast cells. Methods: Normal human bronchial epithelial (NHBE) cells were stimulated with TNF, IL-4, IFN-gamma, IL-17A, and double-stranded RNA (dsRNA) alone or in combination. Human mast cells were stimulated with epithelial cell-derived supernatants or cocultured with NHBE cells. T(H)2 cytokine responses were blocked with neutralizing antibodies. Results: Supernatants from IL-4- and dsRNA-stimulated NHBE cells significantly enhanced T(H)2 cytokine production from mast cells. The combination of IL-4 and dsRNA itself or supernatants from NHBE cells stimulated with other cytokines did not activate mast cells, suggesting that mast cell responses were induced by epithelial cell factors that were only induced by IL-4 and dsRNA. Epithelial supernatant-dependent T(H)2 cytokine production in mast cells was suppressed by anti-IL-1 and anti- thymic stromal lymphopoietin (TSLP) and was enhanced by anti-IL-1 receptor antagonist. Similar results were observed in coculture experiments. Finally, we found dsRNA-dependent production of IL-1, TSLP, and IL-1 receptor antagonist in NHBE cells was regulated by T-H cytokines, and their ratio in NHBE cells correlated with T(H)2 cytokine production in mast cells. Conclusions: Pathogens producing dsRNA, such as respiratory viral infections, might amplify local T(H)2 inflammation in asthmatic patients through the production of TSLP and IL-1 by epithelial cells and subsequent activation of T(H)2 cytokine production by mast cells in the airways. (J Allergy Clin Immunol 2012; 130: 225-32.)	[Nagarkar, Deepti R.; Poposki, Julie A.; Biyasheva, Assel; Avila, Pedro C.; Schleimer, Robert P.; Kato, Atsushi] Northwestern Univ, Feinberg Sch Med, Div Allergy Immunol, Dept Med, Chicago, IL 60611 USA; [Comeau, Michael R.] Amgen Inc, Dept Inflammat Res, Seattle, WA USA	Northwestern University; Feinberg School of Medicine; Amgen	Kato, A (corresponding author), Northwestern Univ, Feinberg Sch Med, Div Allergy Immunol, Dept Med, 240 E Huron, Chicago, IL 60611 USA.	a-kato@northwestern.edu		Kato, Atsushi/0000-0001-9144-3138	National Institutes of Health [R01 HL078860, R01 AI072570, R37 HL068546, U01AI082984]; Ernest S. Bazley Trust; National Institutes of Health; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL068546, R01HL078860] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI072570, U01AI082984] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ernest S. Bazley Trust; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported in part by National Institutes of Health grants R01 HL078860, R01 AI072570, R37 HL068546, and U01AI082984 and the Ernest S. Bazley Trust.; Disclosure of potential conflict of interest: M. R. Comeau is employed by Amgen Inc. P. C. Avila has received research support from the National Institutes of Health and is on the Data and Safety Monitoring Board for Astellas and Biota. R. P. Schleimer has consulting arrangements with Intersect ENT and GlaxoSmithKline. The rest of the authors declare that they have no relevant conflicts of interest.	Allakhverdi Z, 2007, J EXP MED, V204, P253, DOI 10.1084/jem.20062211; Balzar S, 2011, AM J RESP CRIT CARE, V183, P299, DOI 10.1164/rccm.201002-0295OC; Bischoff SC, 1999, P NATL ACAD SCI USA, V96, P8080, DOI 10.1073/pnas.96.14.8080; Brightling CE, 2002, J ALLERGY CLIN IMMUN, V110, P899, DOI 10.1067/mai.2002.129698; BROIDE DH, 1992, J ALLERGY CLIN IMMUN, V89, P958, DOI 10.1016/0091-6749(92)90218-Q; Carroll NG, 2002, EUR RESPIR J, V19, P879, DOI 10.1183/09031936.02.00275802; de Kluijver J, 2003, CLIN EXP ALLERGY, V33, P1415, DOI 10.1046/j.1365-2222.2003.01770.x; Dinarello CA, 2011, BLOOD, V117, P3720, DOI 10.1182/blood-2010-07-273417; Dinarello CA, 2009, ANNU REV IMMUNOL, V27, P519, DOI 10.1146/annurev.immunol.021908.132612; Dougherty RH, 2010, J ALLERGY CLIN IMMUN, V125, P1046, DOI 10.1016/j.jaci.2010.03.003; Galli SJ, 2005, ANNU REV IMMUNOL, V23, P749, DOI 10.1146/annurev.immunol.21.120601.141025; Hall DJ, 2001, BLOOD, V98, P2014, DOI 10.1182/blood.V98.7.2014; Hershenson MB, 2006, AM J RESP CRIT CARE, V174, P1284, DOI 10.1164/rccm.200609-1387ED; Ito T, 2005, J EXP MED, V202, P1213, DOI 10.1084/jem.20051135; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Kato A, 2007, CURR OPIN IMMUNOL, V19, P711, DOI 10.1016/j.coi.2007.08.004; Kato A, 2007, J IMMUNOL, V179, P1080, DOI 10.4049/jimmunol.179.2.1080; Kato A, 2009, J IMMUNOL, V182, P7233, DOI 10.4049/jimmunol.0801375; Kinoshita H, 2009, J ALLERGY CLIN IMMUN, V123, P179, DOI 10.1016/j.jaci.2008.10.008; Kulka M, 2004, J ALLERGY CLIN IMMUN, V114, P174, DOI 10.1016/j.jaci.2004.03.049; Kulka M, 2008, IMMUNOLOGY, V123, P398, DOI 10.1111/j.1365-2567.2007.02705.x; Lemanske RF, 2010, J ALLERGY CLIN IMMUN, V125, pS95, DOI 10.1016/j.jaci.2009.10.047; Liu YJ, 2007, ANNU REV IMMUNOL, V25, P193, DOI 10.1146/annurev.immunol.25.022106.141718; Lloyd CM, 2010, NAT REV IMMUNOL, V10, P838, DOI 10.1038/nri2870; Lopez-Souza N, 2009, J ALLERGY CLIN IMMUN, V123, P1384, DOI 10.1016/j.jaci.2009.03.010; Metz M, 2007, TRENDS IMMUNOL, V28, P234, DOI 10.1016/j.it.2007.03.003; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; Oshansky CM, 2010, J INFECT DIS, V201, P1201, DOI 10.1086/651431; Papadopoulos NG, 2001, CLIN EXP ALLERGY, V31, P1060, DOI 10.1046/j.1365-2222.2001.01112.x; Pope SM, 2005, J BIOL CHEM, V280, P13952, DOI 10.1074/jbc.M406037200; PROUD D, 1994, J INFECT DIS, V169, P1007, DOI 10.1093/infdis/169.5.1007; Proud D, 2011, IMMUNOL REV, V242, P186, DOI 10.1111/j.1600-065X.2011.01033.x; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Rothenberg ME, 2006, ANNU REV IMMUNOL, V24, P147, DOI 10.1146/annurev.immunol.24.021605.090720; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Sousa AR, 1996, AM J RESP CRIT CARE, V154, P1061, DOI 10.1164/ajrccm.154.4.8887608; Tsuji K, 2005, EUR RESPIR J, V26, P795, DOI 10.1183/09031936.05.00010805; Uller L, 2010, THORAX, V65, P626, DOI 10.1136/thx.2009.125930; Xu G, 2010, ALLERGY, V65, P581, DOI 10.1111/j.1398-9995.2009.02252.x; Ying S, 2005, J IMMUNOL, V174, P8183, DOI 10.4049/jimmunol.174.12.8183; YING S, 1995, AM J RESP CELL MOL, V12, P477, DOI 10.1165/ajrcmb.12.5.7742012; Zahran Hatice S., 2011, Morbidity and Mortality Weekly Report, V60, P547; Zhen GH, 2007, AM J RESP CELL MOL, V36, P244, DOI 10.1165/rcmb.2006-0180OC; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909	44	81	83	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2012	130	1					225	+		10.1016/j.jaci.2012.04.019	http://dx.doi.org/10.1016/j.jaci.2012.04.019			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	977GN	22633328	Green Accepted			2022-12-18	WOS:000306644800031
J	Poon, AH; Chouiali, F; Tse, SM; Litonjua, AA; Hussain, SNA; Baglole, CJ; Eidelman, DH; Olivenstein, R; Martin, JG; Weiss, ST; Hamid, Q; Laprise, C				Poon, Audrey H.; Chouiali, Fazila; Tse, Sze Man; Litonjua, Augusto A.; Hussain, Sabah N. A.; Baglole, Carolyn J.; Eidelman, David H.; Olivenstein, Ronald; Martin, James G.; Weiss, Scott T.; Hamid, Qutayba; Laprise, Catherine			Genetic and histologic evidence for autophagy in asthma pathogenesis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ASSOCIATION		[Poon, Audrey H.; Chouiali, Fazila; Hussain, Sabah N. A.; Baglole, Carolyn J.; Eidelman, David H.; Martin, James G.; Hamid, Qutayba; Laprise, Catherine] McGill Univ, Meakins Christie Labs, Ctr Hlth, Montreal, PQ, Canada; [Olivenstein, Ronald] McGill Univ, Montreal Chest Inst, Ctr Hlth, Montreal, PQ, Canada; [Poon, Audrey H.; Laprise, Catherine] Univ Quebec, Dept Sci Fondamentales, Chicoutimi, PQ, Canada; [Tse, Sze Man; Litonjua, Augusto A.; Weiss, Scott T.] Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA; [Litonjua, Augusto A.] Brigham & Womens Hosp, Div Pulm & Crit Care Med, Boston, MA 02115 USA; [Weiss, Scott T.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA; [Hussain, Sabah N. A.] Royal Victoria Hosp, Crit Care Div, Montreal, PQ H3A 1A1, Canada; [Hussain, Sabah N. A.] Royal Victoria Hosp, Div Resp, Montreal, PQ H3A 1A1, Canada; [Weiss, Scott T.] Partners Hlth Care, Partners Ctr Personalized Genet Med, Boston, MA USA	McGill University; McGill University; University of Quebec; University of Quebec Chicoutimi; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital; Partners Healthcare System	Poon, AH (corresponding author), McGill Univ, Meakins Christie Labs, Ctr Hlth, Montreal, PQ, Canada.	qutayba.hamid@mcgill.ca	Hussain, Sabah/ABC-5315-2021	Laprise, Catherine/0000-0001-5526-9945; Litonjua, Augusto/0000-0003-0422-5875; Martin, James/0000-0001-7574-5363	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL083069, T32HL007427, U01HL075419, U01HL065899, R01HL086601] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL083069, U01 HL65899, R01 HL086601-01, U01 HL075419, T32 HL007427-19, P01 HL083069-01A1, U01 HL075419-01, T32 HL07427, T32 HL007427, R01 HL086601, U01 HL065899-01, U01 HL065899] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Chen ZH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003316; Dudbridge F, 2008, HUM HERED, V66, P87, DOI 10.1159/000119108; Horvath I, 1998, AM J RESP CRIT CARE, V158, P1042, DOI 10.1164/ajrccm.158.4.9710091; Lake SL, 2000, AM J HUM GENET, V67, P1515, DOI 10.1086/316895; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Shannon J, 2008, CHEST, V133, P420, DOI 10.1378/chest.07-1881; Szumiel I, 2011, FREE RADICAL RES, V45, P253, DOI 10.3109/10715762.2010.525233; 1999, CONTROL CLIN TRIALS, V20, P91	9	81	91	1	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2012	129	2					569	571		10.1016/j.jaci.2011.09.035	http://dx.doi.org/10.1016/j.jaci.2011.09.035			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	887TC	22040902	Green Accepted, Green Published			2022-12-18	WOS:000299951700044
J	Keles, S; Karakoc-Aydiner, E; Ozen, A; Izgi, AG; Tevetoglu, A; Akkoc, T; Bahceciler, NN; Barlan, I				Keles, Sevgi; Karakoc-Aydiner, Elif; Ozen, Ahmet; Izgi, Ayse Gul; Tevetoglu, Ayzer; Akkoc, Tunc; Bahceciler, Nerin N.; Barlan, Isil			A novel approach in allergen-specific immunotherapy: Combination of sublingual and subcutaneous routes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Children; cytokine; Der p 1; subcutaneous immunotherapy; sublingual immunotherapy	GRASS-POLLEN IMMUNOTHERAPY; DOUBLE-DUMMY; DOUBLE-BLIND; BEE VENOM; ASTHMA; RESPONSES; EFFICACY; RHINITIS; IGG; MECHANISMS	Background: Subcutaneous allergen-specific immunotherapy (SIT) has an early onset of action, whereas repeated injections and safety concerns have limited its use in the pediatric age group. Meanwhile, the improved safety profile of the sublingual route has been accepted as an alternative despite its relatively late onset of action. Objective: We sought to improve the efficacy and safety of SIT with a combination of the subcutaneous route in the build-up phase and sublingual maintenance in comparison with the sublingual or subcutaneous routes alone. Methods: Fifty-one house dust mite-sensitized children with mild-to-moderate asthma were randomized into one of 4 groups to receive either (1) subcutaneous immunotherapy (SCIT), (2) sublingual immunotherapy (SLIT), (3) SCIT plus SLIT, or (4) pharmacotherapy. Clinical parameters were evaluated at baseline and months 1, 4, 12, and 18. Allergen-specific immunoglobulin levels and allergen-induced IL-5, IL-10, IL-13, IL-17, TGF-beta, and IFN-gamma levels were evaluated as well. Results: In the SCIT and SCIT plus SLIT groups, the number of asthma attacks and inhaled corticosteroid dosage decreased compared with baseline values at the months 4, 12, and 18 but only at month 12 in the SLIT group. The improvement in visual analog scores for rhinitis was significant only in the SCIT plus SLIT group. Increases in the levels of regulatory and T(H)1 cytokines were observed both in the SCIT and SLIT groups, with some differences in dynamics. Antigen-specific IgG(4) levels increased in the SCIT and SCIT plus SLIT groups but not in the SLIT group. Clinical symptom scores were correlated positively with IL-5 levels and negatively with antigen-specific IgG(4), IFN-gamma, and TGF-beta levels. Conclusion: Our novel regimen of immunotherapy, SCIT plus SLIT, appeared promising in that it successfully combined the advantages of the 2 alternatives: rapid onset and potency in SCIT and safety and avoidance of injections in SLIT. (J Allergy Clin Immunol 2011;128:808-15.)	[Keles, Sevgi; Karakoc-Aydiner, Elif; Izgi, Ayse Gul; Tevetoglu, Ayzer; Akkoc, Tunc; Bahceciler, Nerin N.; Barlan, Isil] Marmara Univ, Div Pediat Allergy & Immunol, Istanbul, Turkey; [Ozen, Ahmet] Yeditepe Univ, Div Pediat Allergy & Immunol, Istanbul, Turkey	Marmara University; Yeditepe University	Keles, S (corresponding author), Marmara Univ, Div Pediat Allergy & Immunol, Tophanelioglu Cad 13-15,Altunizade 34660, Istanbul, Turkey.	sevgi_keles@yahoo.com	Ozen, Ahmet/R-6749-2017	Ozen, Ahmet/0000-0002-9065-1901	Marmara University Scientific Research Committee [SAG-C-TUP-030408-0072]	Marmara University Scientific Research Committee(Marmara University)	Supported by the Marmara University Scientific Research Committee (SAG-C-TUP-030408-0072).	Akdis CA, 2006, ALLERGY, V61, P11, DOI 10.1111/j.1398-9995.2006.01159.x; Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Akdis M, 2009, NAT REV DRUG DISCOV, V8, P645, DOI 10.1038/nrd2653; Allam JP, 2006, ALLERGY, V61, P166, DOI 10.1111/j.1398-9995.2005.00965.x; Amin HS, 2006, J ALLERGY CLIN IMMUN, V117, P169, DOI 10.1016/j.jaci.2005.10.010; [Anonymous], GUIDELINE ASTHMA; Bousquet J., 1998, Allergy (Copenhagen), V53, P1; Canonica GW, 2009, ALLERGY, V64, P1, DOI 10.1111/j.1398-9995.2009.02309.x; Francis JN, 2003, J ALLERGY CLIN IMMUN, V111, P1255, DOI 10.1067/mai.2003.1570; Halken S, 2008, PEDIAT ALLERG IMM-UK, V19, P60, DOI 10.1111/j.1399-3038.2008.00768.x; JUTEL M, 1995, J IMMUNOL, V154, P4187; Jutel M, 2005, J ALLERGY CLIN IMMUN, V116, P608, DOI 10.1016/j.jaci.2005.06.004; Khinchi MS, 2004, ALLERGY, V59, P45, DOI 10.1046/j.1398-9995.2003.00387.x; Majori M, 2000, CLIN EXP ALLERGY, V30, P341, DOI 10.1046/j.1365-2222.2000.00701.x; Moingeon P, 2006, ALLERGY, V61, P151, DOI 10.1111/j.1398-9995.2006.01002.x; MULLER U, 1989, ALLERGY, V44, P412, DOI 10.1111/j.1398-9995.1989.tb04172.x; Mungan D, 1999, ANN ALLERG ASTHMA IM, V82, P485, DOI 10.1016/S1081-1206(10)62726-3; Nouri-Aria KT, 2004, J IMMUNOL, V172, P3252, DOI 10.4049/jimmunol.172.5.3252; O'Hehir RE, 2009, AM J RESP CRIT CARE, V180, P936, DOI 10.1164/rccm.200905-0686OC; Ohashi Y, 1996, SCAND J IMMUNOL, V43, P680, DOI 10.1046/j.1365-3083.1996.d01-269.x; Passalacqua G, 2007, J ALLERGY CLIN IMMUN, V119, P881, DOI 10.1016/j.jaci.2007.01.045; Penagos M, 2008, CHEST, V133, P599, DOI 10.1378/chest.06-1425; Pilette C, 2007, J IMMUNOL, V178, P4658, DOI 10.4049/jimmunol.178.7.4658; Quirino T, 1996, CLIN EXP ALLERGY, V26, P1253, DOI 10.1046/j.1365-2222.1996.d01-280.x; Ragusa V Franco, 2004, Eur Ann Allergy Clin Immunol, V36, P52; Rolinck-Werninghaus C, 2005, INT ARCH ALLERGY IMM, V136, P134, DOI 10.1159/000083320; VANDERGIESSEN M, 1976, INT ARCH ALLER A IMM, V50, P625, DOI 10.1159/000231566; VARNEY VA, 1993, J CLIN INVEST, V92, P644, DOI 10.1172/JCI116633	28	81	85	0	30	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2011	128	4					808	U505		10.1016/j.jaci.2011.04.033	http://dx.doi.org/10.1016/j.jaci.2011.04.033			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	841UA	21641635	Bronze			2022-12-18	WOS:000296538100017
J	Guilbert, TW; Singh, AM; Danov, Z; Evans, MD; Jackson, DJ; Burton, R; Roberg, KA; Anderson, EL; Pappas, TE; Gangnon, R; Gern, JE; Lemanske, RF				Guilbert, Theresa W.; Singh, Anne Marie; Danov, Zoran; Evans, Michael D.; Jackson, Daniel J.; Burton, Ryan; Roberg, Kathy A.; Anderson, Elizabeth L.; Pappas, Tressa E.; Gangnon, Ronald; Gern, James E.; Lemanske, Robert F.			Decreased lung function after preschool wheezing rhinovirus illnesses in children at risk to develop asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Rhinovirus; respiratory syncytial virus; wheezing; asthma; spirometry; impulse oscillometry	RESPIRATORY-SYNCYTIAL-VIRUS; 1ST 6 YEARS; IMPULSE OSCILLOMETRY; PULMONARY-FUNCTION; YOUNG-CHILDREN; EARLY-LIFE; BRONCHIOLITIS; INFECTION; IMPEDANCE; INFANCY	Background: Preschool rhinovirus (RV) wheezing illnesses predict an increased risk of childhood asthma; however, it is not clear how specific viral illnesses in early life relate to lung function later on in childhood. Objective: To determine the relationship of virus-specific wheezing illnesses and lung function in a longitudinal cohort of children at risk for asthma. Methods: Two hundred thirty-eight children were followed prospectively from birth to 8 years of age. Early life viral wheezing respiratory illnesses were assessed by using standard techniques, and lung function was assessed annually by using spirometry and impulse oscillometry. The relationships of these virus-specific wheezing illnesses and lung function were assessed by using mixed-effect linear regression. Results: Children with RV wheezing illness demonstrated significantly decreased spirometry values, FEV1 (P = .001), FEV0.5 (P < .001), FEF25-75 (P < .001), and also had abnormal impulse oscillometry measures-more negative reactance at 5 Hz (P < .001)-compared with those who did not wheeze with RV. Children who wheezed with respiratory syncytial virus or other viral illnesses did not have any significant differences in spirometric or impulse oscillometry indices when compared with children who did not. Children diagnosed with asthma at ages 6 or 8 years had significantly decreased FEF25-75 (P = .05) compared with children without asthma. Conclusion: Among outpatient viral wheezing illnesses in early childhood, those caused by RV infections are the most significant predictors of decreased lung function up to age 8 years in a high-risk birth cohort. Whether low lung function is a cause and/or effect of RV wheezing illnesses is yet to be determined. (J Allergy Clin Immunol 2011;128:532-8.)	[Guilbert, Theresa W.; Singh, Anne Marie; Jackson, Daniel J.; Burton, Ryan; Roberg, Kathy A.; Anderson, Elizabeth L.; Pappas, Tressa E.; Gern, James E.; Lemanske, Robert F.] Univ Wisconsin, Dept Pediat, Madison, WI 53716 USA; [Singh, Anne Marie; Jackson, Daniel J.; Burton, Ryan; Lemanske, Robert F.] Univ Wisconsin, Dept Med, Madison, WI 53716 USA; [Evans, Michael D.; Gangnon, Ronald] Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI 53716 USA; [Gangnon, Ronald] Univ Wisconsin, Dept Populat Hlth Sci, Madison, WI 53716 USA; [Danov, Zoran] Univ Kentucky, Dept Pediat, Lexington, KY 40506 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Kentucky	Guilbert, TW (corresponding author), Univ Wisconsin, Dept Pediat, 600 Highland Ave,K4-944,CSC 4108, Madison, WI 53716 USA.	tguilbert@wisc.edu		Evans, Michael/0000-0001-7449-3993; Gangnon, Ronald/0000-0003-2587-6714; Guilbert, Theresa/0000-0002-6932-712X	National Institutes of Health (NIH) [R01 HL61879, P01 HL70831, M01 RR03186]; Altus Pharmaceuticals; Inspire Pharmaceuticals; NHLBI; AAAAI/GlaxoSmithKline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD061879] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025011, M01RR003186] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL070831, R01HL061879] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH061879] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Altus Pharmaceuticals; Inspire Pharmaceuticals; NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); AAAAI/GlaxoSmithKline(GlaxoSmithKline); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	This study was supported by National Institutes of Health (NIH) grants R01 HL61879, P01 HL70831, and M01 RR03186.; Disclosure of potential conflict of interest: T. W. Guilbert has consultant arrangements with GlaxoSmithKline, AstraZeneca, MAP Pharmaceutical, Merck/Schering-Plough, and Genentech/Novartis; has received honororia from Peerpoint Medical Education Institute; has received research support from Altus Pharmaceuticals, Inspire Pharmaceuticals, the NHLBI, and the NIH; and is a member of the American Lung Association, the American Thoracic Society, and the American Academy of Pediatrics. D. J. Jackson has received research support from the AAAAI/GlaxoSmithKline. J. E. Gern has stock options in EraGen Biosciences. R. F. Lemanske, Jr has consultant arrangements with Merck & Co, Inc, AstraZeneca, and GlaxoSmithKline; is an author for Up to Date; and is on the speakers' bureau for the Michigan Public Health Institute. R. Burton has consultant arrangements with Carefusion (ERT). The rest of the authors have declared that they have no conflict of interest.	Akinbami Lara, 2006, Adv Data, P1; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; Bacharier LB, 2004, AM J RESP CRIT CARE, V170, P426, DOI 10.1164/rccm.200308-1178OC; Beydon N, 2007, AM J RESP CRIT CARE, V175, P1304, DOI 10.1164/rccm.200605-642ST; Bochkov YA, 2010, MUCOSAL IMMUNOL, V3, P69, DOI 10.1038/mi.2009.109; Contoli M, 2006, NAT MED, V12, P1023, DOI 10.1038/nm1462; Dencker M, 2006, CLIN PHYSIOL FUNCT I, V26, P247, DOI 10.1111/j.1475-097X.2006.00682.x; Eigen H, 2001, AM J RESP CRIT CARE, V163, P619, DOI 10.1164/ajrccm.163.3.2002054; Evans TM, 2006, J ASTHMA, V43, P49, DOI 10.1080/02770900500448555; Gern JE, 2002, PEDIAT ALLERG IMM-UK, V13, P386, DOI 10.1034/j.1399-3038.2002.01093.x; Goldman MD, 2002, PEDIATR PULM, V34, P312, DOI 10.1002/ppul.10168; Guilbert TW, 2004, CONTROL CLIN TRIALS, V25, P286, DOI 10.1016/j.cct.2004.03.002; Haland G, 2006, NEW ENGL J MED, V355, P1682, DOI 10.1056/NEJMoa052885; Haland G, 2009, PEDIAT ALLERG IMM-UK, V20, P254, DOI 10.1111/j.1399-3038.2008.00781.x; Illi S, 2006, LANCET, V368, P763, DOI 10.1016/S0140-6736(06)69286-6; IRELAND DC, 1993, J MED VIROL, V40, P96, DOI 10.1002/jmv.1890400204; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Jartti T, 2009, EUR RESPIR J, V33, P706, DOI 10.1183/09031936.00155808; Klug B, 1996, PEDIATR PULM, V21, P290; Kneyber M, 2000, ACTA PAEDIATR, V89, P654, DOI 10.1080/080352500750043945; Korppi M, 2004, PEDIATR INFECT DIS J, V23, P995, DOI 10.1097/01.inf.0000143642.72480.53; Larsen GL, 2005, J ALLERGY CLIN IMMUN, V115, P657, DOI 10.1016/j.jaci.2004.12.1112; Lee WM, 2007, J CLIN MICROBIOL, V45, P2626, DOI 10.1128/JCM.02501-06; Leigh R, 2008, J ALLERGY CLIN IMMUN, V121, P1238, DOI 10.1016/j.jaci.2008.01.067; Lemanske RF, 2002, PEDIAT ALLERG IMM-UK, V13, P38, DOI 10.1034/j.1399-3038.13.s.15.8.x; Lemanske RF, 2005, J ALLERGY CLIN IMMUN, V116, P571, DOI 10.1016/j.jaci.2005.06.024; Malmberg LP, 2008, PEDIATR PULM, V43, P538, DOI 10.1002/ppul.20805; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Morgan WJ, 2005, AM J RESP CRIT CARE, V172, P1253, DOI 10.1164/rccm.200504-525OC; National Asthma Education and Prevention Program, 2007, 3 NAT ASTHM ED PREV, P4051; Neaville WA, 2003, J ALLERGY CLIN IMMUN, V112, P740, DOI 10.1016/S0091-6749(03)01868-2; Oppenheimer BW, 2007, CHEST, V132, P1275, DOI 10.1378/chest.07-0913; Phelan PD, 2002, J ALLERGY CLIN IMMUN, V109, P189, DOI 10.1067/mai.2002.120951; PULLAN CR, 1982, BRIT MED J, V284, P1665, DOI 10.1136/bmj.284.6330.1665; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Sigurs N, 2005, AM J RESP CRIT CARE, V171, P137, DOI 10.1164/rccm.200406-730OC; Simon MR, 2010, J ALLERGY CLIN IMMUN, V126, p[527, e1]; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; Strunk RC, 2003, J ALLERGY CLIN IMMUN, V112, P883, DOI 10.1016/j.jaci.2003.08.014; Tomalak W, 2006, PEDIATR PULM, V41, P50, DOI 10.1002/ppul.20310; van der Zalm MM, 2011, AM J RESP CRIT CARE, V183, P262, DOI 10.1164/rccm.200905-0716OC; Vink GR, 2003, PEDIATR PULM, V35, P214, DOI 10.1002/ppul.10235; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Wennergren G, 2001, EUR RESPIR J, V18, P1044, DOI 10.1183/09031936.01.00254101	44	81	83	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2011	128	3					532	U147		10.1016/j.jaci.2011.06.037	http://dx.doi.org/10.1016/j.jaci.2011.06.037			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	812HS	21878241	Green Accepted, Bronze, Green Published			2022-12-18	WOS:000294283400011
J	Joseph, CLM; Ownby, DR; Havstad, SL; Woodcroft, KJ; Wegienka, G; MacKechnie, H; Zoratti, E; Peterson, EL; Johnson, CC				Joseph, Christine L. M.; Ownby, Dennis R.; Havstad, Suzanne L.; Woodcroft, Kimberly J.; Wegienka, Ganesa; MacKechnie, Hugh; Zoratti, Edward; Peterson, Edward L.; Johnson, Christine C.			Early complementary feeding and risk of food sensitization in a birth cohort	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; food sensitization; infant feeding; birth cohort	DIETARY PREVENTION; ALLERGIC DISEASES; SMALL CHILDREN; IGE CONCENTRATIONS; NATIONAL-HEALTH; ORAL TOLERANCE; PEANUT ALLERGY; INFANTS; PREVALENCE; ASTHMA	Background: Exposure to solid food or cow's milk (complementary food) before age 4 months may confer immune protection (tolerance) or detriment (allergy). Objective: We explored the relationship between introduction of complementary food <4 months and IgE to egg, milk, and peanut allergen at 2 years in the Wayne County Health, Environment, Allergy and Asthma Longitudinal Study birth cohort of Detroit, Mich. Methods: At infant ages 1, 6, and 12 months, mothers were interviewed about feeding practices. Blood samples were collected at age 2 to 3 years to assess sensitization (IgE >= 0.35 IU/mL) to egg, milk, or peanut. Results: For the 594 maternal-infant pairs analyzed, maternal mean age was 29.7 years, and 60.6% self-reported as African American or black. Infant exposure to complementary food <4 months was reported by 39.7% of mothers. IgE >= 0.35 IU/mL for egg, milk, or peanut allergen at age 2 years was observed in 23.9% (95% CI, 20.5% to 27.6%), 30.6% (26.9% to 34.5%), and 11.4% (8.9% to 14.3%) of children, respectively. The association between early feeding and sensitization was modified by parental history of asthma or allergy. In multivariable analysis, early feeding reduced the risk of peanut sensitization among children with a parental history (adjusted odds ratio, 0.2 [95% CI, 0.1-0.7]; P = .007). The relationship also became significant for egg when a cutoff for IgE of >= 0.70 IU/mL was used (adjusted odds ratio, 0.5 [95% CI, 0.3-0.9]; P = .022). Conclusion: In this cohort, complementary food introduced <4 months was associated with a reduced risk of peanut (and perhaps egg) sensitization by age 2 to 3 years, but only for children with a parental history of asthma or allergy. (J Allergy Clin Immunol 2011;127:1203-10.)	[Joseph, Christine L. M.; Havstad, Suzanne L.; Wegienka, Ganesa; Peterson, Edward L.; Johnson, Christine C.] Henry Ford Hosp, Dept Publ Hlth Sci, Detroit, MI 48202 USA; [Woodcroft, Kimberly J.] Henry Ford Hosp, Mol Epidemiol Res Lab, Detroit, MI 48202 USA; [MacKechnie, Hugh; Zoratti, Edward] Henry Ford Hosp, Div Allergy & Clin Immunol, Dept Internal Med, Detroit, MI 48202 USA; [Ownby, Dennis R.] Med Coll Georgia, Augusta, GA 30912 USA	Henry Ford Health System; Henry Ford Hospital; Henry Ford Health System; Henry Ford Hospital; Henry Ford Health System; Henry Ford Hospital; University System of Georgia; Augusta University	Joseph, CLM (corresponding author), Henry Ford Hosp, Dept Publ Hlth Sci, 1 Ford Pl,3E, Detroit, MI 48202 USA.	cjoseph1@hfhs.org		Johnson, Christine Cole/0000-0002-6864-6604	NIAID [HL068971, AI050681-06A2, AI050681-06A2S1]; NIH; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068971] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI080066, R01AI050681, R56AI050681] Funding Source: NIH RePORTER	NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by NIAID grant nos. HL068971, AI050681-06A2, and AI050681-06A2S1.; Disclosure of potential conflict of interest: C. L. M. Joseph receives research support from the NIH. D. R. Ownby is on the advisory board for the Merck Childhood Asthma Network. K. J. Woodcroft receives research support from the NIH. G. Wegienka receives research support from the NIH. E. Zoratti receives research support from the NIH. C. C. Johnson receives research support from the NIH. The rest of the authors have declared that they have no conflict of interest.	Al-Muhsen S, 2003, CAN MED ASSOC J, V168, P1279; Anderson JA, 2007, ALLERGIC DIS DIAGNOS, P255; Arbes SJ, 2005, J ALLERGY CLIN IMMUN, V116, P377, DOI 10.1016/j.jaci.2005.05.017; Baker SS, 2000, PEDIATRICS, V106, P346; Bock SA, 2003, PEDIATRICS, V111, P1638; Branum AM, 2009, PEDIATRICS, V124, P1549, DOI 10.1542/peds.2009-1210; Department of Nutrition for Health and Development WHO, 2001, WHONHD01092002 DEP N; Greer FR, 2008, PEDIATRICS, V121, P183, DOI 10.1542/peds.2007-3022; Grundy J, 2002, J ALLERGY CLIN IMMUN, V110, P784, DOI 10.1067/mai.2002.128802; Hockings RR, 2003, METHODS APPL LINEAR, P343; Host A, 2008, PEDIAT ALLERG IMM-UK, V19, P1, DOI 10.1111/j.1399-3038.2007.00680.x; Joseph CLM, 2000, CHEST, V117, P1336, DOI 10.1378/chest.117.5.1336; Kagan RS, 2003, J ALLERGY CLIN IMMUN, V112, P1223, DOI 10.1016/j.jaci.2003.09.026; Kramer MS, 2001, WHONHD0108WHOFCHCAH0; Kwinta P, 2009, PEDIAT ALLERG IMM-UK, V20, P458, DOI 10.1111/j.1399-3038.2008.00814.x; Litonjua AA, 2005, J ALLERGY CLIN IMMUN, V115, P751, DOI 10.1016/j.jaci.2004.12.1138; Liu AH, 2009, J ALLERGY CLIN IMMUN, V123, pS267, DOI 10.1016/j.jaci.2008.12.1036; Liu AH, 2010, J ALLERGY CLIN IMMUN, V126, P798, DOI 10.1016/j.jaci.2010.07.026; Muraro A, 2004, PEDIAT ALLERG IMM-UK, V15, P103, DOI 10.1046/j.1399-3038.2003.00129.x; Muraro A, 2004, PEDIAT ALLERG IMM-UK, V15, P291, DOI 10.1111/j.1399-3038.2004.00127.x; Muraro A, 2004, PEDIAT ALLERG IMM-UK, V15, P196, DOI 10.1111/j.1399-3038.2004.00128.x; Poole JA, 2006, J ALLERGY CLIN IMMUN, V117, pS42, DOI 10.1016/j.jaci.2005.12.174; Poulsen LK, 2005, ALLERGY, V60, P549, DOI 10.1111/j.1398-9995.2005.00821.x; Prescott SL, 2008, PEDIAT ALLERG IMM-UK, V19, P375, DOI 10.1111/j.1399-3038.2008.00718.x; Rona RJ, 2007, J ALLERGY CLIN IMMUN, V120, P638, DOI 10.1016/j.jaci.2007.05.026; Rothman K., 1998, MODERN EPIDEMIOLOGY; Sampson HA, 1996, PEDIAT ALLERG IMM-UK, V7, P42, DOI 10.1111/j.1399-3038.1996.tb00394.x; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444, DOI 10.1016/S0091-6749(97)70133-7; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; Sampson HA, 2007, MIDDLETONS ALLERGY P, P1619; Selvin S, 1996, ANAL CONTINGENCY TAB, P197; Sudo N, 1997, J IMMUNOL, V159, P1739; von Berg A, 2010, CLIN EXP ALLERGY, V40, P627, DOI 10.1111/j.1365-2222.2009.03444.x; Wang JL, 2005, J ALLERGY CLIN IMMUN, V115, P1076, DOI 10.1016/j.jaci.2005.02.014; Wegienka G, 2006, ANN ALLERG ASTHMA IM, V97, P78, DOI 10.1016/S1081-1206(10)61374-9; Zutavern A, 2008, PEDIATRICS, V121, pE44, DOI 10.1542/peds.2006-3553	36	81	81	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2011	127	5					1203	U492		10.1016/j.jaci.2011.02.018	http://dx.doi.org/10.1016/j.jaci.2011.02.018			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	756NG	21458850	Green Accepted			2022-12-18	WOS:000290018600015
J	Bousquet, PJ; Bachert, C; Canonica, GW; Casale, TB; Mullol, J; Klossek, JM; Zuberbier, T; Bousquet, J				Bousquet, Philippe J.; Bachert, Claus; Canonica, Giorgo W.; Casale, Thomas B.; Mullol, Joaquim; Klossek, Jean Michel; Zuberbier, Torsten; Bousquet, Jean			Uncontrolled allergic rhinitis during treatment and its impact on quality of life: A cluster randomized trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Bousquet, Philippe J.] Univ Caremeau, Grp Hosp, Dept Biostat Epidemiol Clin Sante Publ & Informat, Nimes, France; [Bachert, Claus] Ghent Univ Hosp, Dept Otorhinolaryngol, Ghent, Belgium; [Canonica, Giorgo W.] Univ Genoa, DIMI, Allergy & Resp Dis Clin, I-16126 Genoa, Italy; [Casale, Thomas B.] Creighton Univ, Med Ctr, Div Allergy Asthma & Immunol, Omaha, NE USA; [Mullol, Joaquim] Hosp Clin IDIBAPS, Rhinol Unit, Barcelona, Spain; [Mullol, Joaquim] Hosp Clin IDIBAPS, Smell Clin, Dept Ear Nose & Throat, Barcelona, Spain; [Klossek, Jean Michel] Dept Ear Nose & Throat, Poitiers, France; [Zuberbier, Torsten] Charite, Dept Dermatol & Allergy, Berlin, Germany; [Bousquet, Jean] Hop Arnaud Villeneuve, Serv Malad Resp, Montpellier, France; [Bousquet, Jean] Ctr Res Epidemiol & Populat Hlth, INSERM CESP, Villejuif, France	Universite de Montpellier; CHU de Nimes; Ghent University; Ghent University Hospital; University of Genoa; Creighton University; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Universite de Montpellier; CHU de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Bousquet, PJ (corresponding author), Univ Caremeau, Grp Hosp, Dept Biostat Epidemiol Clin Sante Publ & Informat, Nimes, France.	jean.bousquet@inserm.fr	Bachert, Claus/J-8825-2012; Casale, Thomas B/K-4334-2013; Bousquet, Jean/O-4221-2019; Bousquet, Philippe Jean/AAW-8608-2021; canonica, giorgio walter/ABF-2037-2020	Casale, Thomas B/0000-0002-3149-7377; Bousquet, Philippe Jean/0000-0002-0217-5483; canonica, giorgio walter/0000-0001-8467-2557				Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Bousquet J, 2009, J ALLERGY CLIN IMMUN, V124, P428, DOI 10.1016/j.jaci.2009.06.027; Bousquet J, 2009, INT ARCH ALLERGY IMM, V150, P75, DOI 10.1159/000210383; Bousquet PJ, 2007, ALLERGY, V62, P367, DOI 10.1111/j.1398-9995.2006.01276.x; Juniper EF, 1999, J ALLERGY CLIN IMMUN, V104, P364, DOI 10.1016/S0091-6749(99)70380-5; REILLY MC, 1993, PHARMACOECONOMICS, V4, P353, DOI 10.2165/00019053-199304050-00006	7	81	89	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2010	126	3					666	668		10.1016/j.jaci.2010.06.034	http://dx.doi.org/10.1016/j.jaci.2010.06.034			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	646CF	20816198				2022-12-18	WOS:000281512500040
J	Mabalirajan, U; Ahmad, T; Leishangthem, GD; Joseph, DA; Dinda, AK; Agrawal, A; Ghosh, B				Mabalirajan, Ulaganathan; Ahmad, Tanveer; Leishangthem, Geeta Devi; Joseph, Duraisamy Arul; Dinda, Amit Kumar; Agrawal, Anurag; Ghosh, Balaram			Beneficial effects of high dose of L-arginine on airway hyperresponsiveness and airway inflammation in a murine model of asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic airway inflammation; arginase; L-arginine; endothelial nitric oxide synthase; exhaled nitric oxide	EXPERIMENTAL ALLERGIC-ASTHMA; NITRIC-OXIDE SYNTHASE; ORAL L-ARGININE; MOUSE MODEL; MICE; DYSFUNCTION; ARGINASE; OBSTRUCTION; INHIBITION; EXPRESSION	Background: Disturbance in the delicate balance between L-arginine metabolizing enzymes such as nitric oxide synthase (NOS) and arginase may lead to decreased L-arginine availability to constitutive forms of NOS (endothelial NOS), thereby increasing the nitro-oxidative stress and airway hyperresponsiveness (AHR). Objective: In this study, we investigated the effects of high doses of L-arginine on L-arginine metabolizing enzymes and subsequent biological effects such as cyclic guanosine monophosphate production, lipid peroxidation, peroxynitrite, AHR, and airway inflammation in a murine model of asthma. Methods: Different doses of L-arginine were administered to ovalbumin sensitized and challenged mice. Exhaled nitric oxide, AHR, airway inflammation, T(H)2 cytokines, goblet cell metaplasia, nitro-oxidative stress, and expressions of arginase 1, endothelial NOS, and inducible NOS in lung were determined. Results: L-arginine significantly reduced AHR and airway inflammation including bronchoalveolar lavage fluid eosinophilia, TH2 cytokines, TGF-beta(1), goblet cell metaplasia, and subepithelial fibrosis. Further, L-arginine increased ENO levels and cyclic guanosine monophosphate in lung and reduced the markers of nitro-oxidative stress such as nitrotyrosine, 8-isoprostane, and 8-hydroxy-2'-deoxyguanosine. This was associated with reduced activity and expression of arginase 1, increased expression of endothelial NOS, and reduction of inducible NOS in bronchial epithelia. Conclusion: We conclude that L-arginine administration may improve disordered nitric oxide metabolism associated with allergic airway inflammation, and alleviates some features of asthma. (J Allergy Clin Immunol 2010;125:626-35.)	[Mabalirajan, Ulaganathan; Ahmad, Tanveer; Joseph, Duraisamy Arul; Agrawal, Anurag; Ghosh, Balaram] Inst Genom & Integrat Biol, Immunogenet Mol Lab, Delhi 110007, India; [Mabalirajan, Ulaganathan; Ahmad, Tanveer; Joseph, Duraisamy Arul; Agrawal, Anurag; Ghosh, Balaram] Inst Genom & Integrat Biol, Ctr Excellence Translat Res Asthma & Lung Dis, Delhi 110007, India; [Leishangthem, Geeta Devi; Dinda, Amit Kumar] All India Inst Med Sci, Dept Pathol, Div Renal Pathol, New Delhi 110029, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Institute of Genomics & Integrative Biology (IGIB); Council of Scientific & Industrial Research (CSIR) - India; CSIR - Institute of Genomics & Integrative Biology (IGIB); All India Institute of Medical Sciences (AIIMS) New Delhi	Ghosh, B (corresponding author), Inst Genom & Integrat Biol, Immunogenet Mol Lab, Mall Rd, Delhi 110007, India.	bghosh@igib.res.in	Leishangthem, Geeta Devi/AAE-6153-2022; Ghosh, Balaram/G-1248-2010; Agrawal, Anurag/GZL-5821-2022; Agrawal, Anurag/A-7312-2009	Agrawal, Anurag/0000-0002-0340-5252; Ahmad, Tanveer/0000-0002-8384-5273	Institute of Genomics and Integrative Biology, Council of Scientific and Industrial Research, Government of India [NWP0033, MLP 5501]; Indian Council of Medical Research	Institute of Genomics and Integrative Biology, Council of Scientific and Industrial Research, Government of India(Council of Scientific & Industrial Research (CSIR) - India); Indian Council of Medical Research(Indian Council of Medical Research (ICMR))	Supported by projects NWP0033 and MLP 5501 at the Institute of Genomics and Integrative Biology, Council of Scientific and Industrial Research, Government of India. U.M. and G.D.L. are the recipients of fellowships from the Indian Council of Medical Research.	Agrawal A, 2007, J APPL PHYSIOL, V102, P399, DOI 10.1152/japplphysiol.00630.2006; Ahmad T, 2010, AM J RESP CELL MOL, V42, P3, DOI 10.1165/rcmb.2009-0137RC; Ahmad T, 2009, J APPL PHYSIOL, V107, P295, DOI 10.1152/japplphysiol.00235.2009; Appleton Jeremy, 2002, Altern Med Rev, V7, P512; Bode-Boger SM, 2007, PHARMACOL THERAPEUT, V114, P295, DOI 10.1016/j.pharmthera.2007.03.002; Campbell BI, 2004, J INT SOC SPORT NUTR, V1; de Boer J, 1999, BRIT J PHARMACOL, V128, P1114, DOI 10.1038/sj.bjp.0702882; de Gouw HWFM, 1999, THORAX, V54, P1033, DOI 10.1136/thx.54.11.1033; Holgate ST, 2003, EUR RESPIR J, V22, p24S, DOI 10.1183/09031936.03.00000803; Holgate ST, 2007, J ALLERGY CLIN IMMUN, V120, P1233, DOI 10.1016/j.jaci.2007.10.025; Kaczmarek E, 2004, Rocz Akad Med Bialymst, V49 Suppl 1, P155; Keller AC, 2005, MEM I OSWALDO CRUZ, V100, P19, DOI 10.1590/S0074-02762005000900005; Lara A, 2008, AM J RESP CRIT CARE, V178, P673, DOI 10.1164/rccm.200710-1542OC; Lee KS, 2006, MOL PHARMACOL, V70, P1184, DOI 10.1124/mol.106.024737; Lukacs NW, 1996, J LEUKOCYTE BIOL, V59, P13, DOI 10.1002/jlb.59.1.13; Maarsingh H, 2008, AM J RESP CRIT CARE, V178, P565, DOI 10.1164/rccm.200710-1588OC; Maarsingh H, 2008, EUR J PHARMACOL, V585, P375, DOI 10.1016/j.ejphar.2008.02.096; Mabalirajan U, 2008, J IMMUNOL, V181, P3540, DOI 10.4049/jimmunol.181.5.3540; Mabalirajan U, 2009, J IMMUNOL, V183, P2059, DOI 10.4049/jimmunol.0900342; Napoli C, 2003, P NATL ACAD SCI USA, V100, P2112, DOI 10.1073/pnas.0336359100; Ram A, 2008, INT IMMUNOPHARMACOL, V8, P893, DOI 10.1016/j.intimp.2008.02.005; Ram A, 2006, INT IMMUNOPHARMACOL, V6, P1468, DOI 10.1016/j.intimp.2006.04.020; Ricciardolo FLM, 2003, TRENDS PHARMACOL SCI, V24, P560, DOI 10.1016/j.tips.2003.09.007; Ricciardolo FLM, 2004, PHYSIOL REV, V84, P731, DOI 10.1152/physrev.00034.2003; SadeghiHashjin G, 1996, AM J RESP CRIT CARE, V153, P1697, DOI 10.1164/ajrccm.153.5.8630623; Takano H, 1998, J PHARMACOL EXP THER, V286, P767; Ten Broeke R, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-58; Wells SM, 2007, AM J RESP CELL MOL, V36, P520, DOI 10.1165/rcmb.2006-0302SM; Wells SM, 2009, AM J RESP CELL MOL, V40, P179, DOI 10.1165/rcmb.2008-0148OC; West SG, 2005, J NUTR, V135, P212, DOI 10.1093/jn/135.2.212; Wu GY, 1998, BIOCHEM J, V336, P1, DOI 10.1042/bj3360001; Xia Y, 1997, P NATL ACAD SCI USA, V94, P6954, DOI 10.1073/pnas.94.13.6954; Zimmermann N, 2003, J CLIN INVEST, V111, P1863, DOI 10.1172/JCI200317912	33	81	84	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2010	125	3					626	635		10.1016/j.jaci.2009.10.065	http://dx.doi.org/10.1016/j.jaci.2009.10.065			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	573BK	20153031	Bronze			2022-12-18	WOS:000275883200018
J	Elliott, L; Henderson, J; Northstone, K; Chiu, GY; Dunson, D; London, SJ				Elliott, Leslie; Henderson, John; Northstone, Kate; Chiu, Grace Y.; Dunson, David; London, Stephanie J.			Prospective study of breast-feeding in relation to wheeze, atopy, and bronchial hyperresponsiveness in the Avon Longitudinal Study of Parents and Children (ALSPAC)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; atopy; breast-feeding; bronchial hyperresponsiveness; allergy	RISK-FACTORS; EARLY-CHILDHOOD; ASTHMA; DERMATITIS; DISEASE; PROTECT; ALLERGY; HISTORY; LIFE	Background: Breast-feeding clearly protects against early wheezing, but recent data suggest that it might increase later risk of atopic disease and asthma. Objective: We sought to examine the relationship between breast-feeding and later asthma and allergy outcomes by using data from the Avon Longitudinal Study of Parents and Children, a large birth cohort in the United Kingdom. Methods: We used adjusted logistic regression models to evaluate the association between breast-feeding and atopy at age 7 years, bronchial responsiveness to methacholine at age 8 years, and wheeze at ages 3 and 7 1/2 years. Bayesian methods were used to assess the possibility of bias caused by an influence of early wheezing: on the duration of breast-feeding, as well as selection bias. Results: Breast-feeding was protective for wheeze in the first 3 years of life (odds ratio [OR] of 0.80 [95% CI, 0.70-0.90] for >= 6 months relative to never) but not wheeze (OR, 0.98; 95% CI, 0.79-1.22), atopy (OR, 1.12; 95% Cl, 0.92-1.35), or bronchial hyperresponsiveness (OR, 1.07; 95% CI, 0.82-1.40) at ages 7 to 8 years. Bayesian models adjusting for the longer duration of breast-feeding among children with wheezing in early infancy produced virtually identical results. Conclusions: We did not find consistent evidence for either a deleterious effect or a protective effect of breast-feeding on later risk of allergic disease in a large prospective birth cohort of children with objective outcome measures and extensive data on potential confounders and effect modifiers. Neither reverse causation nor loss to follow-up appears to have materially biased our results.	[Elliott, Leslie; London, Stephanie J.] NIEHS, Epidemiol Branch, Div Intramural Res, NIH,Dept Hlth & Human Serv, Res Triangle Pk, NC 27709 USA; [Dunson, David] NIEHS, Biostat Branch, Div Intramural Res, NIH,Dept Hlth & Human Serv, Res Triangle Pk, NC 27709 USA; [Henderson, John; Northstone, Kate] Univ Bristol, Dept Social Med, Bristol BS8 1TH, Avon, England; [Henderson, John] Bristol Royal Hosp Children, Dept Resp Med, Bristol, Avon, England; [Chiu, Grace Y.] Westat Corp, Res Triangle Pk, NC USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Bristol; Bristol Royal Hospital For Children; Westat	London, SJ (corresponding author), NIEHS, Epidemiol Branch, Div Intramural Res, NIH,Dept Hlth & Human Serv, POB 12233,MD A3-05, Res Triangle Pk, NC 27709 USA.	london2@niehs.nih.gov	Northstone, Kate/A-8165-2011; London, Stephanie/C-3734-2019	Northstone, Kate/0000-0002-0602-1983; London, Stephanie/0000-0003-4911-5290	Intramural NIH HHS [Z99 ES999999, Z01 ES049019-12] Funding Source: Medline; Medical Research Council [G0401540, G9815508] Funding Source: Medline; Wellcome Trust Funding Source: Medline; MRC [G0401540] Funding Source: UKRI; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES049019] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Allison P. D., 2010, SURVIVAL ANAL USING, V2nd; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; Becquet R, 2003, LANCET, V361, P174, DOI 10.1016/S0140-6736(03)12203-9; De Stavola BL, 2006, AM J EPIDEMIOL, V163, P84, DOI 10.1093/aje/kwj003; Friedman NJ, 2005, J ALLERGY CLIN IMMUN, V115, P1238, DOI 10.1016/j.jaci.2005.01.069; Gdalevich M, 2001, J PEDIATR-US, V139, P261, DOI 10.1067/mpd.2001.117006; Golding J, 2001, PAEDIATR PERINAT EP, V15, P74; HENNEKENS CH, 1987, EPIDEMIOLOGY MED, P170; Kramer M. S., 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003517; Kramer MS, 2007, BMJ-BRIT MED J, V335, P815, DOI 10.1136/bmj.39304.464016.AE; KRAMER MS, 1988, J PEDIATR-US, V112, P181, DOI 10.1016/S0022-3476(88)80054-4; Kull I, 2004, J ALLERGY CLIN IMMUN, V114, P755, DOI 10.1016/j.jaci.2004.07.036; Laubereau B, 2004, J PEDIATR-US, V144, P602, DOI 10.1016/j.jpeds.2003.12.029; Lima RD, 2003, AM J PUBLIC HEALTH, V93, P1858, DOI 10.2105/AJPH.93.11.1858; Linneberg A, 2006, J ALLERGY CLIN IMMUN, V117, P184, DOI 10.1016/j.jaci.2005.09.042; Lowe AJ, 2006, J ALLERGY CLIN IMMUN, V117, P682, DOI 10.1016/j.jaci.2005.10.027; Mandhane PJ, 2007, J ALLERGY CLIN IMMUN, V119, P1359, DOI 10.1016/j.jaci.2007.01.043; Mihrshahi S, 2007, CLIN EXP ALLERGY, V37, P671, DOI 10.1111/j.1365-2222.2007.02696.x; Muraro A, 2004, PEDIAT ALLERG IMM-UK, V15, P291, DOI 10.1111/j.1399-3038.2004.00127.x; Oddy W H, 2001, Breastfeed Rev, V9, P11; Roberts G, 2005, CLIN EXP ALLERGY, V35, P933, DOI 10.1111/j.1365-2222.2005.02280.x; Rothenbacher D, 2005, CLIN EXP ALLERGY, V35, P1014, DOI 10.1111/j.1365-2222.2005.02298.x; Sears MR, 2002, LANCET, V360, P901, DOI 10.1016/S0140-6736(02)11025-7; Section on Breastfeeding, 2012, Pediatrics, V129, pe827, DOI 10.1542/peds.2011-3552; SMITH PG, 1984, INT J EPIDEMIOL, V13, P356, DOI 10.1093/ije/13.3.356; Tariq SM, 1998, J ALLERGY CLIN IMMUN, V101, P587, DOI 10.1016/S0091-6749(98)70164-2; van Odijk J, 2003, ALLERGY, V58, P833, DOI 10.1034/j.1398-9995.2003.00264.x; von Mutius E, 2004, J ALLERGY CLIN IMMUN, V113, P373, DOI 10.1016/j.jaci.2003.12.040; Wegienka G, 2006, ANN ALLERG ASTHMA IM, V97, P78, DOI 10.1016/S1081-1206(10)61374-9; Wickman M, 2003, ALLERGY, V58, P742, DOI 10.1034/j.1398-9995.2003.00078.x; Wright AL, 2001, THORAX, V56, P192, DOI 10.1136/thorax.56.3.192; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760	33	81	89	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2008	122	1					49	54		10.1016/j.jaci.2008.04.001	http://dx.doi.org/10.1016/j.jaci.2008.04.001			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	325RD	18468669	Green Accepted			2022-12-18	WOS:000257605100008
J	Drouet, C; Desormeaux, A; Robillard, J; Ponard, D; Bouillet, L; Martin, L; Kanny, G; Moneret-Vautrin, DA; Bosson, JL; Quesada, JL; Lopez-Trascasa, M; Adam, A				Drouet, Christian; Desormeaux, Anik; Robillard, Josee; Ponard, Denise; Bouillet, Laurence; Martin, Ludovic; Kanny, Gisele; Moneret-Vautrin, Denise-Anne; Bosson, Jean-Luc; Quesada, Jean-Louis; Lopez-Trascasa, Margarita; Adam, Albert			Metallopeptidase activities in hereditary angioedema: Effect of androgen prophylaxis on plasma aminopeptidase P	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						hereditary angioedema; aminopeptidase P; C1 inhibitor; androgen; danazol; stanozolol; bradykinin; des-Arg(9)-bradykinin	METABOLIC PATHWAYS; KININ SYSTEM; BRADYKININ; PATHOPHYSIOLOGY; ACE	Background: Aminopeptidase P (APP) plays an important role in the catabolism of kinins in human plasma, mostly for des-Arg(9)-bradykinin. Impaired degradation of this active bradykinin metabolite was found to be associated with a decreased APP activity in hypertensive patients who experienced angioedema while being treated with angiotensin I-converting enzyme inhibitors. The pathophysiology of hereditary angioedema is presently attributed only to a quantitative/qualitative C1 inhibitor (CI-INH) defect with increased bradykinin release. Objectives: In the context of androgen prophylaxis, increased CI-INH function cannot fully explain protection from angioedema attacks alone because of the limited reversion of the CI-INH defects. Therefore we hypothesized that androgen prophylaxis could enhance plasma APP activity. Methods: Patients with hereditary angioedema were investigated for plasma metallopeptidase activities responsible for kinin catabolism (APP, angiotensin I-converting enzyme, and carboxypeptidase N) and for CI-INH function in treated and untreated patients. Results: APP activity was asymmetrically distributed in untreated patients (n = 147): the mean value was significantly lower than the value in a reference healthy and unmedicated population (n = 116; P <= .001). Prophylaxis with androgen induced a significant increase in APP activity (P <= .001), whereas it did not affect the other metallopeptidase activities. In both patient groups, APP activity showed a significant inverse relationship to disease severity (P <= .001). Conclusion: In addition to the effect on circulating CI-INH levels, the increase in APP levels brought on by androgens could contribute to a more effective control of the kinin accumulation considered to be responsible for the symptoms of angioedema.	[Drouet, Christian] GREPI, CNRS, UMR 5525, F-38043 Grenoble, France; [Drouet, Christian] Univ Grenoble 1, F-38043 Grenoble, France; [Drouet, Christian; Ponard, Denise; Bouillet, Laurence; Bosson, Jean-Luc] Natl Reference Ctr Angiodema, F-38043 Grenoble, France; [Desormeaux, Anik; Robillard, Josee; Adam, Albert] Univ Montreal, Fac Pharm, Montreal, PQ H3C 3J7, Canada; [Martin, Ludovic] CHU Angers, Serv Dermatol, Angers, France; [Kanny, Gisele; Moneret-Vautrin, Denise-Anne] CHU Nancy, EA Maladies Allergiques Diagnost & Therapeut Med, Nancy, France; [Quesada, Jean-Louis] CHU Grenoble, INSERM, CIC, Grenoble, France; [Lopez-Trascasa, Margarita] Hosp Univ La Paz, Unidad Immunol, Madrid, Spain	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute for Engineering & Systems Sciences (INSIS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Institut National Polytechnique de Grenoble; Universite Grenoble Alpes (UGA); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Universite de Montreal; Universite d'Angers; Centre Hospitalier Universitaire d'Angers; CHU de Nancy; CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Institut National de la Sante et de la Recherche Medicale (Inserm); Hospital Universitario La Paz	Drouet, C (corresponding author), GREPI, CNRS, UMR 5525, BP 217, F-38043 Grenoble, France.	CDrouet@chu-grenoble.fr	Kanny, Gisèle/AHA-8910-2022; DROUET, Christian/AAE-5682-2020; DROUET, Christian/J-8775-2019; bosson, jean-luc/AAP-5163-2020; López-Trascasa, Margarita/L-2699-2014	DROUET, Christian/0000-0003-1318-4278; DROUET, Christian/0000-0003-1318-4278; bosson, jean-luc/0000-0003-0967-6026; López-Trascasa, Margarita/0000-0001-8594-282X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL079184] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL079184-04, R01 HL079184, 1-R01-HL079184] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adam A, 2002, LANCET, V359, P2088, DOI 10.1016/S0140-6736(02)08914-6; Blais C, 2000, PEPTIDES, V21, P1903, DOI 10.1016/S0196-9781(00)00348-X; Blais C, 1997, ARTHRITIS RHEUM, V40, P1327, DOI 10.1002/1529-0131(199707)40:7<1327::AID-ART18>3.0.CO;2-B; Blais C, 1999, PEPTIDES, V20, P421, DOI 10.1016/S0196-9781(99)00020-0; CICARDI M, 2004, J ALLERGY CLIN IMMUN, V114, pS55; Cugno M, 2003, INT IMMUNOPHARMACOL, V3, P311, DOI 10.1016/S1567-5769(02)00162-5; Cyr M, 2001, AM J PHYSIOL-HEART C, V281, pH275, DOI 10.1152/ajpheart.2001.281.1.H275; Davis AE, 2005, CLIN IMMUNOL, V114, P3, DOI 10.1016/j.clim.2004.05.007; Decarie A, 1996, AM J PHYSIOL-HEART C, V271, pH1340, DOI 10.1152/ajpheart.1996.271.4.H1340; Decarie A, 1996, PEPTIDES, V17, P1009; DROUET C, 1988, CLIN CHIM ACTA, V174, P121, DOI 10.1016/0009-8981(88)90379-8; DROUET C, 2004, J ALLERGY CLIN IMMUN, V114, pS66; Duan QL, 2005, AM J HUM GENET, V77, P617, DOI 10.1086/496899; GELFAND JA, 1976, NEW ENGL J MED, V295, P1444, DOI 10.1056/NEJM197612232952602; Han ED, 2002, J CLIN INVEST, V109, P1057, DOI 10.1172/JCI200214211; Kim KS, 2000, J PHARMACOL EXP THER, V292, P295; Leeb-Lundberg LMF, 2005, PHARMACOL REV, V57, P27, DOI 10.1124/pr.57.1.2; Matthews KW, 2004, MOL IMMUNOL, V40, P785, DOI 10.1016/j.molimm.2003.10.002; Molinaro G, 2002, J PHARMACOL EXP THER, V303, P232, DOI 10.1124/jpet.102.038067; MOLINARO G, 1995, BIOCHEM J, V385, P389; Moreau ME, 2005, J PHARMACOL SCI, V99, P6, DOI 10.1254/jphs.SRJ05001X; Nussberger J, 1998, LANCET, V351, P1693, DOI 10.1016/S0140-6736(97)09137-X; Pappalardo E, 2003, IMMUNOL LETT, V86, P271, DOI 10.1016/S0165-2478(03)00029-4; Parkin ET, 2004, J BIOL CHEM, V279, P11170, DOI 10.1074/jbc.M312105200; Raymond P, 1996, PEPTIDES, V17, P1163, DOI 10.1016/S0196-9781(96)00174-X; Ryan JW, 1996, IMMUNOPHARMACOLOGY, V32, P149, DOI 10.1016/0162-3109(95)00078-X; ZILLIACUS J, 1995, MOL ENDOCRINOL, V9, P389, DOI 10.1210/me.9.4.389	27	81	81	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2008	121	2					429	433		10.1016/j.jaci.2007.10.048	http://dx.doi.org/10.1016/j.jaci.2007.10.048			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	265CX	18158172	Green Accepted			2022-12-18	WOS:000253337800023
J	Flohr, C; Weiland, SK; Weinmayr, G; Bjoerksten, B; Braback, L; Brunekreef, B; Buchele, G; Clausen, M; Cookson, WOC; von Mutius, E; Strachan, DP; Williams, HC				Flohr, Carsten; Weiland, Stephan K.; Weinmayr, Gudrun; Bjoerksten, Bengt; Braback, Lennart; Brunekreef, Bert; Buchele, Gisela; Clausen, Michael; Cookson, William O. C.; von Mutius, Erika; Strachan, David P.; Williams, Hywel C.		ISAAC Phase 2 Stdy Grp	The role of atopic sensitization in flexural eczema: Findings from the International Study of Asthma and Allergies in Childhood Phase Two	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eczema; atopic dermatitis; atopy; epidemiology	INTESTINAL MICROFLORA; HELMINTH INFECTION; RURAL ETHIOPIA; DERMATITIS; CHILDREN; PREVALENCE; SYMPTOMS; MUTATIONS; RISK; ASSOCIATION	Background: The association between allergic sensitization and eczema has been debated for years. Objective: We sought to determine and compare the strength of the association between allergen skin sensitization and eczema in both developing and industrialized countries. Methods: Twenty-eight thousand five hundred ninety-one randomly selected 8- to 12-year-old schoolchildren in 20 countries were physically examined for flexural eczema and received skin prick testing to Dermatophagoides pteronyssinus, Dermatophagoides farinae, cat hair, Alternaria tenuis, mixed tree and grass pollen, and allergens of local relevance. Results: The age- and sex-adjusted odds ratios (ORs) for a positive association between flexural eczema and atopy ranged between 0.74 (95 % CI, 0.31-1.81) and 4.53 (95 % CI, 1.72-11.93), with a significantly stronger association in affluent compared with nonaffluent countries (combined age- and sex-adjusted ORaffluent = 2.69 [95% CI, 2.31-3.13] and ORaffluent = 1.17 [95% CI, 0.81-1.70]). The combined population attributable fraction for atopy in flexural eczema was 27.9% for affluent and 1.2% for nonaffluent-country centers. Correlating gross national per-capita income with either ORs or population attributable fractions for atopy in flexural eczema confirmed a highly significant positive association (P =.006 and P <.001, respectively). Conclusions: The association between atopy and flexural eczema is weak and more variable than previously suggested, and the strength of this association is positively linked to gross national income.	[Flohr, Carsten; Brunekreef, Bert; Williams, Hywel C.] Univ Nottingham, Ctr Evidence Dermatol, Nottingham NG7 2RD, England; [Weiland, Stephan K.; Weinmayr, Gudrun; Buchele, Gisela; von Mutius, Erika] Univ Ulm, Inst Epidemiol, D-89069 Ulm, Germany; [Bjoerksten, Bengt] Karolinska Inst, Ctr Allergy Res, Inst Environm Med, Stockholm, Sweden; Univ Utrecht, Inst Risk Assessment Sci, Utrecht, Netherlands; [Brunekreef, Bert] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary, Utrecht, Netherlands; [Clausen, Michael] Landspitalinn Hakskolasjukrahus, Dept Pediat, Reykjavik, Iceland; [von Mutius, Erika] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England; [Strachan, David P.] Univ Munich, Dr Von Haunerschen Kinderspital, D-80337 Munich, Germany; [Strachan, David P.] Univ London St Georges Hosp, London, England	University of Nottingham; Ulm University; Karolinska Institutet; Utrecht University; Utrecht University; Utrecht University Medical Center; University of Oxford; Wellcome Centre for Human Genetics; University of Munich; St Georges University London	Flohr, C (corresponding author), Univ Nottingham, Ctr Evidence Dermatol, Nottingham NG7 2RD, England.	carsten.flohr@nottingham.ac.uk	Cookson, William/HHC-1790-2022; De sario, Manuela/K-1932-2016; KHUBCHANDANI, RAJU/AAI-9871-2020; Martínez-Gimeno, Antonio/A-9416-2010; Di Domenicantonio, Riccardo/H-7867-2018; Ellwood, Philippa/G-7555-2015; Forastiere, Francesco/J-9067-2016; Papadopoulou, Athina/AAR-6407-2020; Braback, Lennart/A-3793-2015	De sario, Manuela/0000-0002-1117-2735; KHUBCHANDANI, RAJU/0000-0003-0294-119X; Martínez-Gimeno, Antonio/0000-0003-4051-1860; Di Domenicantonio, Riccardo/0000-0002-9726-0786; Ellwood, Philippa/0000-0002-1994-4023; Forastiere, Francesco/0000-0002-9162-5684; williams, hywel/0000-0002-5646-3093; von Mutius, Erika/0000-0002-8893-4515; Pearce, Neil/0000-0002-9938-7852; Braback, Lennart/0000-0001-9930-7755; brunekreef, bert/0000-0001-9908-0060; STEIN, RENATO/0000-0003-0269-0757; Nilsson, Lennart/0000-0002-5680-6367				Bergmann RL, 1997, CLIN EXP ALLERGY, V27, P752, DOI 10.1046/j.1365-2222.1997.310899.x; Bjorksten B, 2001, J ALLERGY CLIN IMMUN, V108, P516, DOI 10.1067/mai.2001.118130; Bjorksten B, 1999, CLIN EXP ALLERGY, V29, P342, DOI 10.1046/j.1365-2222.1999.00560.x; CHAMBLESS LE, 1985, COMMUN STAT-THEOR M, V14, P1377, DOI 10.1080/03610928508828982; Cork MJ, 2006, J ALLERGY CLIN IMMUN, V118, P3, DOI 10.1016/j.jaci.2006.04.042; Dagoye D, 2003, AM J RESP CRIT CARE, V167, P1369, DOI 10.1164/rccm.200210-1204OC; Elliott AM, 2005, JAMA-J AM MED ASSOC, V294, P2032, DOI 10.1001/jama.294.16.2032-c; Emerson RM, 1998, BRIT J DERMATOL, V139, P73; Faniran AO, 1999, THORAX, V54, P606, DOI 10.1136/thx.54.7.606; Flohr C, 2003, BRIT J DERMATOL, V148, P871, DOI 10.1046/j.1365-2133.2003.05403.x; Flohr C, 2004, J ALLERGY CLIN IMMUN, V114, P150, DOI 10.1016/j.jaci.2004.04.027; Flohr C, 2006, J ALLERGY CLIN IMMUN, V118, P1305, DOI 10.1016/j.jaci.2006.08.035; Fohr C, 2005, BRIT J DERMATOL, V152, P202, DOI [10.1111/J.1365-2133.2005.06436.X, 10.1111/j.1365-2133.2004.06436.x]; Haileamlak A, 2005, J ALLERGY CLIN IMMUN, V115, P370, DOI 10.1016/j.jaci.2004.10.024; Irvine AD, 2007, J INVEST DERMATOL, V127, P504, DOI 10.1038/sj.jid.5700695; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; Morar N, 2006, J ALLERGY CLIN IMMUN, V118, P24, DOI 10.1016/j.jaci.2006.03.037; Morar N, 2007, J INVEST DERMATOL, V127, P1667, DOI 10.1038/sj.jid.5700739; Normand SLT, 1999, STAT MED, V18, P321, DOI 10.1002/(SICI)1097-0258(19990215)18:3<321::AID-SIM28>3.0.CO;2-P; Palmer CNA, 2007, J ALLERGY CLIN IMMUN, V120, P64, DOI 10.1016/j.jaci.2007.04.001; Pearce N, 1999, THORAX, V54, P268, DOI 10.1136/thx.54.3.268; Richardson DB, 2007, EPIDEMIOLOGY, V18, P441, DOI 10.1097/EDE.0b013e318060d25c; Sandilands A, 2007, NAT GENET, V39, P650, DOI 10.1038/ng2020; Schafer T, 2005, ALLERGY, V60, P1014, DOI 10.1111/j.1398-9995.2005.00801.x; Schafer T, 2000, BRIT J DERMATOL, V143, P992, DOI 10.1046/j.1365-2133.2000.03832.x; Schmid P, 2001, ALLERGY, V56, P841, DOI 10.1034/j.1398-9995.2001.00144.x; Scrivener S, 2001, LANCET, V358, P1493, DOI 10.1016/S0140-6736(01)06579-5; Sunyer J, 2000, ALLERGY, V55, P762, DOI 10.1034/j.1398-9995.2000.00657.x; Watanabe S, 2003, J ALLERGY CLIN IMMUN, V111, P587, DOI 10.1067/mai.2003.105; Weiland SK, 2004, EUR RESPIR J, V24, P406, DOI 10.1183/09031936.04.00090303; Weiland SK, 2004, OCCUP ENVIRON MED, V61, P609, DOI 10.1136/oem.2002.006809; Williams H, 1999, J ALLERGY CLIN IMMUN, V103, P125, DOI 10.1016/S0091-6749(99)70536-1; Williams HC, 1995, BRIT J DERMATOL, V133, P941, DOI 10.1111/j.1365-2133.1995.tb06930.x; Williams H, 2006, J ALLERGY CLIN IMMUN, V118, P209, DOI 10.1016/j.jaci.2006.04.043; Yemaneberhan H, 1997, LANCET, V350, P85, DOI 10.1016/S0140-6736(97)01151-3; Zacharasiewicz A, 2003, J CLIN EPIDEMIOL, V56, P385, DOI 10.1016/S0895-4356(03)00043-X; ZEIGER RS, 1995, J ALLERGY CLIN IMMUN, V95, P1179, DOI 10.1016/S0091-6749(95)70074-9	37	81	82	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2008	121	1					141	147		10.1016/j.jaci.2007.08.066	http://dx.doi.org/10.1016/j.jaci.2007.08.066			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	251KM	17980410				2022-12-18	WOS:000252372000021
J	Jin, C; Hantusch, B; Hemmer, W; Stadimann, J; Altmann, F				Jin, Chunsheng; Hantusch, Brigitte; Hemmer, Wolfgang; Stadimann, Johannes; Altmann, Friedrich			Affinity of IgE and IgG against cross-reactive carbohydrate determinants on plant and insect glycoproteins	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CCDs; carbohydrate determinant; binding affinity; glycoprotein	ALLERGEN-SPECIFIC IMMUNOTHERAPY; GRASS-POLLEN IMMUNOTHERAPY; NATURAL-RUBBER LATEX; YELLOW JACKET VENOM; FC-GAMMA-RIIB; IMMUNOGLOBULIN-E; N-GLYCANS; BLOCKING ANTIBODIES; HYMENOPTERA VENOMS; CLINICAL-RELEVANCE	Background: Cross-reactive carbohydrate determinants (CCDs) are probably the most widely occurring IgE epitopes. Approximately one fifth of patients with allergy develop IgE antibodies against such glycans. However, they appear to be of low clinical significance. Objective: We wanted to elucidate the reasons for this lack of clinical symptoms on contact with CCD allergens by determination of the binding affinities of patients' IgE and IgG antibodies. Methods: IgE and IgG against CCDs were affinity-purified from sera of selected patients. The binding affinity to defined glyco-epitopes was measured by surface plasmon resonance. Results: From a pool of CCD-positive sera, we isolated 0.1 and 25 mu g CCD-specific IgE and IgG, respectively. The binding affinity of purified IgE antibodies to core alpha 1,3-fucosylated glycans was in the 10(-10) mol/L range. The affinity was highest when both fucose and xylose were present, whereas xylosylation alone did not cause IgE binding. CCD-specific IgG exhibited a dissociation constant of approximately 10(-8) mol/L. IgG(4) amounted to only 20% of the CCD-specific IgG (as well as total IgG). Conclusion: Low binding affinity of anti-CCD IgE cannot be the reason for the observed clinical insignificance of IgE against plant/insect glycan epitopes. Notably, the affinity of IgG to CCDs is higher than that to protein allergens, and it may therefore function as blocking antibody.	[Jin, Chunsheng; Stadimann, Johannes; Altmann, Friedrich] Univ Natl Resources & Applied Life Sci, Dept Chem, Vienna, Austria; [Hantusch, Brigitte] Med Univ Vienna, Inst Pathophysiol, Vienna, Austria	Medical University of Vienna	Altmann, F (corresponding author), BOKU Wien, Dept Chem, Muthgasse 18, A-1190 Vienna, Austria.	friedrich.altmann@boku.ac.at	Stadlmann, Johannes/AAC-3157-2021; Hantusch, Brigitte/AAM-9822-2021	Stadlmann, Johannes/0000-0001-5693-6690; Hantusch, Brigitte/0000-0002-9126-003X; Altmann, Friedrich/0000-0002-0112-7877				Aalberse RC, 1997, CLIN REV ALLERG IMMU, V15, P375, DOI 10.1007/BF02737733; Akdis CA, 2006, CHEM IMMUNOL ALLERGY, V91, P195; Altmann F, 2007, INT ARCH ALLERGY IMM, V142, P99, DOI 10.1159/000096114; Bardor M, 2003, GLYCOBIOLOGY, V13, P427, DOI 10.1093/glycob/cwg024; Batanero E, 1999, J ALLERGY CLIN IMMUN, V103, P147, DOI 10.1016/S0091-6749(99)70538-5; Bencurova M, 2004, GLYCOBIOLOGY, V14, P457, DOI 10.1093/glycob/cwh058; Bousquet J, 2006, ALLERGY, V61, P671, DOI 10.1111/j.1398-9995.2006.01048.x; Ebo DG, 2004, CLIN EXP ALLERGY, V34, P137, DOI 10.1111/j.1365-2222.2004.01837.x; Ejrnaes AM, 2004, MOL IMMUNOL, V41, P471, DOI 10.1016/j.molimm.2004.04.018; Foetisch K, 2003, J ALLERGY CLIN IMMUN, V111, P889, DOI 10.1067/mai.2003.173; Fotisch K, 1999, INT ARCH ALLERGY IMM, V120, P30, DOI 10.1159/000024217; Fotisch K, 2001, GLYCOCONJUGATE J, V18, P373, DOI 10.1023/A:1014860030380; GARCIA BE, 1993, J INVEST ALLERG CLIN, V3, P26; Hantusch B, 2005, IMMUNOL LETT, V97, P81, DOI 10.1016/j.imlet.2004.10.002; Hemmer W, 2001, J ALLERGY CLIN IMMUN, V108, P1045, DOI 10.1067/mai.2001.120013; Jakobsen CG, 2005, CLIN EXP ALLERGY, V35, P193, DOI 10.1111/j.1365-2222.2005.02160.x; Jappe U, 2006, ALLERGY, V61, P1220, DOI 10.1111/j.1398-9995.2006.01232.x; Jin CS, 2006, GLYCOBIOLOGY, V16, P349, DOI 10.1093/glycob/cwj071; Kim KE, 1996, MOL IMMUNOL, V33, P873, DOI 10.1016/0161-5890(96)84613-X; Kochuyt AM, 2005, CLIN EXP ALLERGY, V35, P441, DOI 10.1111/j.1365-2222.2005.02217.x; Kolarich D, 2005, FEBS J, V272, P5182, DOI 10.1111/j.1742-4658.2005.04841.x; Kolarich D, 2006, BBA-GEN SUBJECTS, V1760, P715, DOI 10.1016/j.bbagen.2005.11.012; LACOVACCI P, 2002, CLIN EXP ALLERGY, V32, P1620; Lambrigts D, 1998, TRANSPLANTATION, V66, P547, DOI 10.1097/00007890-199809150-00001; Lommerse JPM, 1997, EUR J BIOCHEM, V249, P195, DOI 10.1111/j.1432-1033.1997.00195.x; Mahler V, 2006, CLIN EXP ALLERGY, V36, P1446, DOI 10.1111/j.1365-2222.2006.02587.x; MALANDAIN H, 2005, ALLERG IMMUNOL PARIS, V37, P122; Malbec O, 2002, MOL IMMUNOL, V38, P1295, DOI 10.1016/S0161-5890(02)00078-0; Mari A, 1999, J ALLERGY CLIN IMMUN, V103, P1005, DOI 10.1016/S0091-6749(99)70171-5; Mari A, 2002, INT ARCH ALLERGY IMM, V129, P286, DOI 10.1159/000067591; Mita H, 2000, CLIN EXP ALLERGY, V30, P1582, DOI 10.1046/j.1365-2222.2000.00921.x; Moingeon P, 2006, ALLERGY, V61, P151, DOI 10.1111/j.1398-9995.2006.01002.x; Mothes N, 2003, CLIN EXP ALLERGY, V33, P1198, DOI 10.1046/j.1365-2222.2003.01699.x; Muller-Loennies S, 2000, GLYCOBIOLOGY, V10, P121, DOI 10.1093/glycob/10.2.121; Niederberger V, 2004, P NATL ACAD SCI USA, V101, P14677, DOI 10.1073/pnas.0404735101; Nouri-Aria KT, 2004, J IMMUNOL, V172, P3252, DOI 10.4049/jimmunol.172.5.3252; Paulson JC, 2006, NAT CHEM BIOL, V2, P238, DOI 10.1038/nchembio785; Pierson-Mullany LK, 2002, CLIN EXP ALLERGY, V32, P107, DOI 10.1046/j.0022-0477.2001.01244.x; Smorodin EP, 2005, J IMMUNOASS IMMUNOCH, V26, P145, DOI 10.1081/IAS-200051999; Strait RT, 2006, J CLIN INVEST, V116, P833, DOI 10.1172/JCI25575; TRETTER V, 1993, INT ARCH ALLERGY IMM, V102, P259, DOI 10.1159/000236534; van Ree R, 2002, INT ARCH ALLERGY IMM, V129, P189, DOI 10.1159/000066770; van Ree R, 1999, J ALLERGY CLIN IMMUN, V103, P1000, DOI 10.1016/S0091-6749(99)70169-7; van Ree R, 2004, CURR OPIN ALLERGY CL, V4, P235, DOI [10.1097/00130832-200406000-00017, 10.1097/01.all.0000129457.27092.8f]; vanderVeen MJ, 1997, J ALLERGY CLIN IMMUN, V100, P327, DOI 10.1016/S0091-6749(97)70245-8; VANREE R, 1993, J CLIN IMMUNOASSAY, V16, P124; Wachholz PA, 2003, J ALLERGY CLIN IMMUN, V112, P915, DOI 10.1016/S0091-6749(03)02022-0; Westphal S, 2003, EUR J BIOCHEM, V270, P1327, DOI 10.1046/j.1432-1033.2003.03503.x; Wuhrer M, 2005, BBA-GEN SUBJECTS, V1723, P229, DOI 10.1016/j.bbagen.2005.02.013	49	81	81	1	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2008	121	1					185	190		10.1016/j.jaci.2007.07.047	http://dx.doi.org/10.1016/j.jaci.2007.07.047			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	251KM	17881041				2022-12-18	WOS:000252372000028
J	Letuve, S; Lajoie-Kadoch, S; Audusseau, S; Rothenberg, ME; Fiset, PO; Ludwig, MS; Hamid, Q				Letuve, S; Lajoie-Kadoch, S; Audusseau, S; Rothenberg, ME; Fiset, PO; Ludwig, MS; Hamid, Q			IL-17E upregulates the expression of proinflammatory cytokines in lung fibroblasts	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic inflammation; asthma; chemokines; cytokines; cytokine receptors; IL-17E; lung fibroblasts; TGF-beta(1); TNF-alpha	COLONY-STIMULATING FACTOR; IN-VIVO; AIRWAYS INFLAMMATION; EOSINOPHILS; ASTHMA; CELLS; EOTAXIN; CHEMOATTRACTANT; INTERLEUKIN-8; CHEMOKINES	Background: IL-17E is a new T(H)2 cytokine that promotes airway eosinophilia in mice. IL-17E proinflammatory activity has been proposed to involve induction of cytokine and chemokine production. Recruitment of inflammatory cells may be mediated by tissue-resident cells. Objective: This study aimed to evaluate whether fibroblasts represent a target of IL-17E for the production of eosinophil active mediators in the lung. Methods: Expression of IL-17B receptor (IL-17BR), a receptor for IL-17E, was evaluated by immunofluorescent staining, Western blot, and real-time PCR in human primary lung fibroblasts. Mediator production was analyzed by using real-time PCR and ELISA after stimulation of fibroblasts with II.-17E alone or in combination with TNF-alpha and TGF-beta(1). Expression of IL-17E and of eosinophil major basic protein was evaluated by immunohistochemistry in bronchial biopsies from subjects with asthma. Results: Human primary lung fibroblasts constitutively expressed IL-17BR. IL-17BR mRNA levels were increased in cells stimulated with TNF-alpha and decreased with TGF-beta(1). IL-17E slightly upregulated CC chemokine ligand (CCL)-5, CCL-11, GM-CSF, and CXC chemokine ligand (CXCL)-8 mRNA in fibroblasts. Moreover, IL-17E and TNF-alpha synergistically induced GM-CSF and CXCL-8 mRNA. IL-17E also potentiated the upregulation of CXCL-8 transcripts observed with TGF-beta(1). In contrast, TGF-beta(1) decreased IL-17E-induced CCL-11 mRNA. The capacity of IL-17E to enhance GM-CSF and CXCL-8 responses to TNF-alpha was accompanied by production and secretion of both proteins by lung fibroblasts. Finally, IL-17E was detected in asthma in eosinophil-infiltrated bronchial submucosa. Conclusion: IL-17E may contribute to the induction and maintenance of eosinophilic inflammation in the airways by acting on lung fibroblasts. This study supports a role for IL-17E in asthma pathophysiology.	McGill Univ, Meakins Christie Labs, Dept Pathol & Med, Montreal, PQ H2X 2P2, Canada; Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, Dept Pediat,Div Allergy & Immunol, Cincinnati, OH 45221 USA	McGill University; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Hamid, Q (corresponding author), McGill Univ, Meakins Christie Labs, Dept Pathol & Med, 3626 St Urbain St, Montreal, PQ H2X 2P2, Canada.	qutayba.hamid@mcgill.ca	Letuve, Severine/AAF-3339-2021; Letuve, Severine/J-5506-2017	Letuve, Severine/0000-0002-1954-3633; 				Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Belperio JA, 2000, J LEUKOCYTE BIOL, V68, P1; Bochner BS, 2005, J ALLERGY CLIN IMMUN, V115, P953, DOI 10.1016/j.jaci.2005.02.032; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720, DOI 10.1164/ajrccm.161.5.9903102; Cai LP, 2001, CYTOKINE, V16, P10, DOI 10.1006/cyto.2001.0939; Casado B, 2004, ELECTROPHORESIS, V25, P1386, DOI 10.1002/elps.200305862; Cohn L, 2004, ANNU REV IMMUNOL, V22, P789, DOI 10.1146/annurev.immunol.22.012703.104716; Fort MM, 2001, IMMUNITY, V15, P985, DOI 10.1016/S1074-7613(01)00243-6; GIAID A, 1993, LANCET, V341, P1550; Gratchev A, 2004, SCAND J IMMUNOL, V60, P233, DOI 10.1111/j.0300-9475.2004.01443.x; Humbles AA, 2004, SCIENCE, V305, P1776, DOI 10.1126/science.1100283; Hurst SD, 2002, J IMMUNOL, V169, P443, DOI 10.4049/jimmunol.169.1.443; Hwang SY, 2005, MOL CELLS, V19, P180; Ikeda K, 2003, BLOOD, V101, P3594, DOI 10.1182/blood-2002-09-2817; JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881; KAMEYOSHI Y, 1992, J EXP MED, V176, P587, DOI 10.1084/jem.176.2.587; Kang CM, 2005, AM J RESP CELL MOL, V33, P290, DOI 10.1165/rcmb.2005-0003OC; Kim MR, 2002, BLOOD, V100, P2330, DOI 10.1182/blood-2002-01-0012; Lampinen M, 2004, ALLERGY, V59, P793, DOI 10.1111/j.1398-9995.2004.00469.x; Lee J, 2001, J BIOL CHEM, V276, P1660, DOI 10.1074/jbc.M008289200; MARINI M, 1992, J ALLERGY CLIN IMMUN, V89, P1001, DOI 10.1016/0091-6749(92)90223-O; Minshall EM, 1997, AM J RESP CELL MOL, V17, P326, DOI 10.1165/ajrcmb.17.3.2733; Nocker RET, 1996, INT ARCH ALLERGY IMM, V109, P183, DOI 10.1159/000237218; Ohno I, 1996, AM J RESP CELL MOL, V15, P404, DOI 10.1165/ajrcmb.15.3.8810646; Pan GH, 2001, J IMMUNOL, V167, P6559, DOI 10.4049/jimmunol.167.11.6559; SEHMI R, 1993, CLIN EXP ALLERGY, V23, P1027, DOI 10.1111/j.1365-2222.1993.tb00295.x; Shi YG, 2000, J BIOL CHEM, V275, P19167, DOI 10.1074/jbc.M910228199; Terada N, 2000, CLIN EXP ALLERGY, V30, P348; Teran LM, 1999, AM J RESP CELL MOL, V20, P777, DOI 10.1165/ajrcmb.20.4.3508; Ulfman LH, 2001, J IMMUNOL, V166, P588, DOI 10.4049/jimmunol.166.1.588; WARRINGA RAJ, 1991, BLOOD, V77, P2694; Wenzel SE, 1997, AM J RESP CRIT CARE, V156, P737, DOI 10.1164/ajrccm.156.3.9610046; Wenzel SE, 2002, J IMMUNOL, V169, P4613, DOI 10.4049/jimmunol.169.8.4613; Wong CK, 2005, AM J RESP CELL MOL, V33, P186, DOI 10.1165/rcmb.2005-0034OC; Ying S, 1999, J IMMUNOL, V163, P6321; YING S, 1991, Clinical and Experimental Allergy, V21, P745, DOI 10.1111/j.1365-2222.1991.tb03205.x; YOUSEFI S, 1995, J IMMUNOL, V154, P5481	37	81	92	1	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2006	117	3					590	596		10.1016/j.jaci.2005.10.025	http://dx.doi.org/10.1016/j.jaci.2005.10.025			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	025JY	16522458				2022-12-18	WOS:000236263100014
J	Ober, C				Ober, C			Perspectives on the past decade of asthma genetics	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; allergy; genetics; gene-by-environment interactions	POSITIONAL CLONING; ASSOCIATION; POLYMORPHISM; RESPONSES; TRAITS; LOCUS; ATOPY	Although genetic linkage and association studies have identified more than 25 asthma or allergy susceptibility loci, replication of significant results remains a problem. Moreover, these approaches typically ignore the true complexity of these diseases, such as the role of gene-by-environment and gene-by-gene interactions. As a result, many important associations might have been missed. Recent studies demonstrate not only that such interactions exist but also that the relationship between genotype and phenotype is more complex than previously thought.	Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA	University of Chicago	Ober, C (corresponding author), Univ Chicago, Dept Human Genet, 920 E 58th St,CLSC 507C, Chicago, IL 60637 USA.	c-ober@genetics.uchicago.edu		Ober, Carole/0000-0003-4626-9809	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072414, R01HL066533, P50HL056399, P01HL070831] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56399, HL72414, HL70831, R01 HL072414, P50 HL056399, R01 HL066533, HL66533] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Allen M, 2003, NAT GENET, V35, P258, DOI 10.1038/ng1256; Barr RG, 2001, CHEST, V120, P1474, DOI 10.1378/chest.120.5.1474; Collins FS, 2004, NATURE, V431, P931, DOI 10.1038/nature03001; Gern JE, 2004, J ALLERGY CLIN IMMUN, V113, P307, DOI 10.1016/j.jaci.2003.11.017; Gilliland FD, 2004, LANCET, V363, P119, DOI 10.1016/S0140-6736(03)15262-2; Glazier AM, 2002, SCIENCE, V298, P2345, DOI 10.1126/science.1076641; Hoffjan S, 2005, AM J HUM GENET, V76, P696, DOI 10.1086/429418; Hoffjan S, 2003, RESP RES, V4, DOI 10.1186/1465-9921-4-14; Laitinen T, 2004, SCIENCE, V304, P300, DOI 10.1126/science.1090010; LEMANSKE RF, 2002, PEDIAT ALLERGY IMMUN, V15, P1; McIntire JJ, 2003, NATURE, V425, P576, DOI 10.1038/425576a; Nicolae D, 2005, AM J HUM GENET, V76, P349, DOI 10.1086/427763; Sanak M, 2000, AM J RESP CELL MOL, V23, P290, DOI 10.1165/ajrcmb.23.3.4051; Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878; Vercelli D, 2003, CLIN EXP ALLERGY, V33, P153, DOI 10.1046/j.1365-2222.2003.01606.x; Wang ZX, 2001, AM J RESP CRIT CARE, V163, P1404, DOI 10.1164/ajrccm.163.6.2001101; Werner M, 2003, J ALLERGY CLIN IMMUN, V112, P323, DOI 10.1067/mai.2003.1648; Zhang YM, 2003, NAT GENET, V34, P181, DOI 10.1038/ng1166	18	81	84	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2005	116	2					274	278		10.1016/j.jaci.2005.04.039	http://dx.doi.org/10.1016/j.jaci.2005.04.039			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017ID	16083779				2022-12-18	WOS:000235686400005
J	Untersmayr, E; Poulsen, LK; Platzer, MH; Pedersen, MH; Boltz-Nitulescu, G; Skov, PS; Jensen-Jarolim, E				Untersmayr, E; Poulsen, LK; Platzer, MH; Pedersen, MH; Boltz-Nitulescu, G; Skov, PS; Jensen-Jarolim, E			The effects of gastric digestion on codfish allergenicity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food allergy; digestion; codfish; threshold; histamine release assay; RAST inhibition	SENSITIVE METHOD; FOOD ALLERGY; HUMAN IGE; FISH; PROTEINS; COD; HYPERSENSITIVITY; QUANTITATION; OMEPRAZOLE; ADULTS	Background: In a recent murine study, we showed that impaired gastric digestion supports the induction of fish allergy by protecting the digestion-sensitive major allergen parvalbumin and thus enhancing its sensitizing properties. Objective: The aim of the present study was to investigate whether impairment of peptic degradation might also play a role in the effector phase of codfish allergy. Methods: The resistance of cod proteins to digestion by simulated gastric fluid was assessed in vitro. Gastric solutions with pH values ranging from 1.25 to 5.0 were prepared, and the influence of the pH on protein degradation was evaluated by means of SDS-PAGE and IgE immunoblotting. The allergenic potency of digested and undigested cod extract was further characterized in RAST inhibition and basophil histamine release experiments. Results: The digestion experiments revealed that codfish proteins were degraded within 1 minute under physiologic gastric conditions. An only marginal pH shift from 2.5 to 2.75 abrogated completely the digestion of cod allergens. In RAST inhibition experiments digested cod extracts showed a reduced IgE-binding capability that was dependent on the digestion time. Moreover, peptic fragments expressed a 10,000 times reduced allergenic potency, as evaluated on the basis of histamine release from human basophils. Conclusion: Codfish allergens have a grossly reduced ability to trigger an intestinal allergic reaction when they are physiologically degraded. Impairment or the physiologic digestion might thus lower the threshold levels of a rood allergen in sensitized patients.	Med Univ Vienna, Ctr Physiol & Pathophysiol, A-1090 Vienna, Austria; Natl Univ Hosp Copenhagen, Lab Med Allergol, Copenhagen, Denmark; Reference Lab, Copenhagen, Denmark	Medical University of Vienna; Rigshospitalet; University of Copenhagen	Jensen-Jarolim, E (corresponding author), Med Univ Vienna, Ctr Physiol & Pathophysiol, AKH-3Q,Waehringer Guertel 18-20, A-1090 Vienna, Austria.	erika.jensen-jarolim@meduniwien.ac.at	Poulsen, Lars K/J-3065-2019; Untersmayr, Eva/GRY-4470-2022; Jensen-Jarolim, Erika/C-5120-2018	Poulsen, Lars K/0000-0002-1730-847X; Jensen-Jarolim, Erika/0000-0003-4019-5765; Untersmayr, Eva/0000-0002-1963-499X				AAS K, 1969, J ALLERGY, V44, P333, DOI 10.1016/0021-8707(69)90025-2; BERNHISELBROADBENT J, 1992, J ALLERGY CLIN IMMUN, V89, P730, DOI 10.1016/0091-6749(92)90381-B; Besler M, 2001, J CHROMATOGR B, V756, P207, DOI 10.1016/S0378-4347(01)00110-4; Bindslev-Jensen C, 2002, ALLERGY, V57, P741, DOI 10.1034/j.1398-9995.2002.23797.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bugajska-Schretter A, 1998, J ALLERGY CLIN IMMUN, V101, P67, DOI 10.1016/S0091-6749(98)70195-2; BURR ML, 1989, LANCET, V2, P757; CHIVERTON SG, 1989, GUT, V30, P594, DOI 10.1136/gut.30.5.594; Clark S, 2004, J ALLERGY CLIN IMMUN, V113, P347, DOI 10.1016/j.jaci.2003.10.053; DOUGLAS JDM, 1995, LANCET, V346, P737, DOI 10.1016/S0140-6736(95)91505-2; ELSAYED S, 1971, J ALLERGY, V47, P283, DOI 10.1016/S0091-6749(71)80006-4; Fruton JS, 2002, Q REV BIOL, V77, P127, DOI 10.1086/340729; Galland AV, 1998, J CHROMATOGR B, V706, P63, DOI 10.1016/S0378-4347(97)00457-X; HANSEN TK, 1992, ALLERGY, V47, P610, DOI 10.1111/j.1398-9995.1992.tb02383.x; Hansen TK, 1996, CLIN EXP ALLERGY, V26, P1276, DOI 10.1111/j.1365-2222.1996.tb00525.x; Hefle SL, 1996, FOOD TECHNOL-CHICAGO, V50, P86; HEMMENS VJ, 1989, MOL IMMUNOL, V26, P477, DOI 10.1016/0161-5890(89)90107-7; Jensen-Jarolim E, 1999, FASEB J, V13, P1586, DOI 10.1096/fasebj.13.12.1586; Kelso JM, 2000, CLIN EXP ALLERGY, V30, P905, DOI 10.1046/j.1365-2222.2000.00872.x; Kimura T, 2002, BIOL PHARM BULL, V25, P149, DOI 10.1248/bpb.25.149; KROMHOUT D, 1985, NEW ENGL J MED, V312, P1205, DOI 10.1056/NEJM198505093121901; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; ORTOLANI C, 1988, ANN ALLERGY, V61, P47; Pohle T, 2003, BRIT J CLIN PHARMACO, V56, P156, DOI 10.1046/j.1365-2125.2003.01935.x; POULSEN LK, 1989, ALLERGY, V44, P173, DOI 10.1111/j.1398-9995.1989.tb02258.x; PRICHARD PJ, 1985, GASTROENTEROLOGY, V88, P64, DOI 10.1016/S0016-5085(85)80133-5; Sampson HA, 2003, PEDIATRICS, V111, P1601; Sampson HA, 2004, J ALLERGY CLIN IMMUN, V113, P805, DOI 10.1016/j.jaci.2004.03.014; SCHOLL I, 2005, IN PRESS AM J CLIN N; SHARMA BK, 1984, GUT, V25, P957, DOI 10.1136/gut.25.9.957; Skov PS, 1997, PEDIAT ALLERG IMM-UK, V8, P156, DOI 10.1111/j.1399-3038.1997.tb00171.x; Taylor AV, 2000, J ALLERGY CLIN IMMUN, V105, P166, DOI 10.1016/S0091-6749(00)90192-1; Taylor SL, 2004, CLIN EXP ALLERGY, V34, P689, DOI 10.1111/j.1365-2222.2004.1886.x; Taylor SL, 1996, CRIT REV FOOD SCI, V36, pS91, DOI 10.1080/10408399609527761; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Untersmayr E, 2003, J ALLERGY CLIN IMMUN, V112, P616, DOI [10.1016/S0091-6749(03)01719-6, 10.1016/mai.2003.1681]; UNTERSMAYR E, 2004, IN PRESS FASEB J; Walter F, 2004, BIOCHEM BIOPH RES CO, V315, P281, DOI 10.1016/j.bbrc.2004.01.057; Yagami T, 2000, J ALLERGY CLIN IMMUN, V106, P752, DOI 10.1067/mai.2000.109171	39	81	85	2	23	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2005	115	2					377	382		10.1016/j.jaci.2004.10.029	http://dx.doi.org/10.1016/j.jaci.2004.10.029			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	897YU	15696099				2022-12-18	WOS:000227043600027
J	Lee, KS; Kim, SR; Park, HS; Jin, GY; Lee, YC				Lee, KS; Kim, SR; Park, HS; Jin, GY; Lee, YC			Cysteinyl leukotriene receptor antagonist regulates vascular permeability by reducing vascular endothelial growth factor expression	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cysteinyl leukotrienes; vascular endothelial growth factor; asthma; vascular permeability	NF-KAPPA-B; BRONCHIAL-ASTHMA; AIRWAY HYPERRESPONSIVENESS; INFLAMMATORY MEDIATORS; TRANSCRIPTION FACTOR; GUINEA-PIG; HUMAN-SKIN; ANGIOGENESIS; CELLS; RESPONSIVENESS	Background: Inflammation of the asthmatic airway is usually accompanied by increased vascular permeability and plasma exudation. Cysteinyl leukotrienes (cysLTs) potently elicit increased vascular permeability in airways, leading to airway edema. Vascular endothelial growth factor (VEGF) is 1 of the most potent proangiogenic cytokines and also increases vascular permeability so that plasma proteins can leak into the extravascular space. However, the mechanisms by which cysLTs induce increased vascular permeability are not clearly understood. Objective: An aim of the current study was to determine the role of the cysLTs, more specifically in the increase of vascular permeability. Methods: We used a BALB/c mouse model of allergic asthma to examine effects of cysLT receptor antagonists on bronchial inflammation and airway hyperresponsiveness, more specifically on the increase of vascular permeability. Results: These mice develop the following typical pathophysiological features of asthma in the lungs: increased numbers of inflammatory cells of the airways, airway hyperresponsiveness, increased vascular permeability, and increased levels of VEGF. Administration of cysLT receptor antagonists markedly reduced plasma extravasation and VEGF levels in allergen-induced asthmatic lungs. Conclusion: These results indicate that cysLT receptor antagonists modulate vascular permeability by reducing VEGF expression and suggest that cysLT receptor may regulate the VEGF expression.	Chonbuk Natl Univ, Sch Med, Dept Internal Med, Res Ctr Allerg Immune Dis, Jeonju 561712, South Korea; Chonbuk Natl Univ, Sch Med, Dept Radiol, Res Ctr Allerg Immune Dis, Jeonju 561712, South Korea	Jeonbuk National University; Jeonbuk National University	Lee, YC (corresponding author), Chonbuk Natl Univ, Sch Med, Dept Internal Med, Res Ctr Allerg Immune Dis, 634-18 Keumamdong, Jeonju 561712, South Korea.	leeyc@chonbuk.ac.kr						Alves AC, 1996, EUR J PHARMACOL, V312, P89, DOI 10.1016/0014-2999(96)00357-3; ARAKAWA H, 1993, BRIT J PHARMACOL, V110, P127, DOI 10.1111/j.1476-5381.1993.tb13781.x; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barnes PJ, 1998, PHARMACOL REV, V50, P515; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Barnes PJ, 1997, TRENDS PHARMACOL SCI, V18, P46, DOI 10.1016/S0165-6147(97)89796-9; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; Busse WW, 1998, AM J RESP CRIT CARE, V157, pS210, DOI 10.1164/ajrccm.157.6.mar-1; CAMP RDR, 1983, BRIT J PHARMACOL, V80, P497, DOI 10.1111/j.1476-5381.1983.tb10721.x; Distler JHW, 2004, MOL PHARMACOL, V65, P389, DOI 10.1124/mol.65.2.389; DRAZEN JM, 1980, P NATL ACAD SCI-BIOL, V77, P4354, DOI 10.1073/pnas.77.7.4354; DVORAK AM, 1994, BLOOD, V83, P3600; DVORAK HF, 1995, AM J PATHOL, V146, P1029; EVANS TW, 1989, CLIN SCI, V76, P479, DOI 10.1042/cs0760479; FOSTER WM, 1982, ANN OCCUP HYG, V26, P227, DOI 10.1093/annhyg/26.2.227; Gilmore TD, 1999, ONCOGENE, V18, P6842, DOI 10.1038/sj.onc.1203237; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766, DOI 10.1164/ajrccm.156.3.9606031; Hart LA, 1998, AM J RESP CRIT CARE, V158, P1585, DOI 10.1164/ajrccm.158.5.9706116; HEDQVIST P, 1980, ACTA PHYSIOL SCAND, V110, P331, DOI 10.1111/j.1748-1716.1980.tb06676.x; HENDERSON WR, 1994, ANN ALLERGY, V72, P272; Hoshino M, 2001, J ALLERGY CLIN IMMUN, V107, P1034, DOI 10.1067/mai.2001.115626; Huang SY, 2001, ONCOGENE, V20, P4188, DOI 10.1038/sj.onc.1204535; *I LAB AN RES COMM, 1996, GUID CAR US LAB AN; Kwak YG, 2003, J CLIN INVEST, V111, P1083, DOI 10.1172/JCI200316440; Lee YC, 2002, J IMMUNOL, V168, P3595, DOI 10.4049/jimmunol.168.7.3595; Lee YC, 2001, J ALLERGY CLIN IMMUN, V107, P1106, DOI 10.1067/mai.2001.115628; Persson CGA, 1996, AM J RESP CRIT CARE, V153, pS9, DOI 10.1164/ajrccm/153.6_Pt_2.S9; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SOTER NA, 1983, J INVEST DERMATOL, V80, P115, DOI 10.1111/1523-1747.ep12531738; VANDEGRAAF EA, 1991, AM REV RESPIR DIS, V143, P362, DOI 10.1164/ajrccm/143.2.362; Yang LY, 1998, J EXP MED, V188, P1739, DOI 10.1084/jem.188.9.1739	32	81	87	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2004	114	5					1093	1099		10.1016/j.jaci.2004.07.039	http://dx.doi.org/10.1016/j.jaci.2004.07.039			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	870HI	15536415	Bronze			2022-12-18	WOS:000225047800015
J	Hoffjan, S; Ostrovnaja, I; Nicolae, D; Newman, DL; Nicolae, R; Gangnon, R; Steiner, L; Walker, K; Reynolds, R; Greene, D; Mirel, D; Gern, JE; Lemanske, RF; Ober, C				Hoffjan, S; Ostrovnaja, I; Nicolae, D; Newman, DL; Nicolae, R; Gangnon, R; Steiner, L; Walker, K; Reynolds, R; Greene, D; Mirel, D; Gern, JE; Lemanske, RF; Ober, C			Genetic variation in immunoregulatory pathways and atopic phenotypes in infancy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; immune response; T(H)2 cytokines; Childhood Origins of Asthma Study	FC-EPSILON-RI; HIGH-AFFINITY RECEPTOR; INTERLEUKIN-13 GENE; IMMUNOGLOBULIN-E; GM-CSF; AIRWAY HYPERRESPONSIVENESS; PROMOTER POLYMORPHISMS; CODING VARIANT; BETA-SUBUNIT; ASTHMA	Background: Asthma is a chronic respiratory disease that often originates in early childhood. Although candidate gene studies have identified many potential asthma susceptibility genes in adult populations, few have studied associations with immune phenotypes in the first year that might be early clinical markers of asthma. Objective: The aim of this study was to assess the contribution of genetic variation to cytokine response profiles and atopic phenotypes in the first year of life in the Childhood Origin of Asthma cohort. Methods: Two hundred seven European American children participating in the Childhood Origin of Asthma study were genotyped for 61 single nucleotide polymorphisms in 35 genes involved in immune regulation. We examined the relationship between these single nucleotide polymorphisms and PHA-induced cytokine (IL-5, IL-10, IL-13, and IFN-gamma) response profiles at birth and at year 1, respiratory syncytial virus-induced wheezing and atopic dermatitis in the first year of life, and total IgE levels, peripheral blood eosinophil counts, and allergic sensitization at age 1 year. The data were analyzed by using censored regression for quantitative measurements and logistic regression for qualitative phenotypes. Results: The 237Gly allele of the high-affinity IgE receptor beta chain (FCER1B) and a silent substitution in the nitric oxide synthase (NOS)2A gene were associated with reduced IL-13 responses in cord blood (P=.0025 and P = .0062, respectively). A significant gene-gene interaction between FCER1B 237Gly and NOS2A D346D was detected, with individuals carrying the minor allele for both polymorphisms having the lowest cord blood IL-13 levels. Furthermore, the IL13 110Gln allele showed an association with increased IgE levels at year I (P=.0026), and the colony-stimulating factor 2 (CSF2) 117Thr allele showed an association with a greater increase in IL-5 responses during the first year (P=.0092). The TGF-beta1 (TGFBI)-509T allele was associated with respiratory syncytial virus-related wheezing in the first year (P=.0005). None of the polymorphisms included in this study were associated with atopic dermatitis during the first year or a positive RAST result at I year of age. Conclusion: These data suggest that variations in genes involved in immune regulation are associated with biologic and clinical phenotypes in the first year of life that might increase the risk for the subsequent development of childhood asthma.	Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA; Univ Chicago, Dept Stat, Chicago, IL 60637 USA; Roche Mol Syst, Alameda, CA USA; Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI USA; Univ Wisconsin, Dept Pediat & Med, Madison, WI USA	University of Chicago; University of Chicago; Roche Holding; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Ober, C (corresponding author), Univ Chicago, Dept Human Genet, 920 E 58th St,CLSC 507C, Chicago, IL 60637 USA.			Nicolae, Dan/0000-0002-0918-4630				Arima K, 2002, J ALLERGY CLIN IMMUN, V109, P980, DOI 10.1067/mai.2002.124656; Awad MR, 1998, TRANSPLANTATION, V66, P1014, DOI 10.1097/00007890-199810270-00009; Bidri M, 1997, EUR J IMMUNOL, V27, P2907, DOI 10.1002/eji.1830271124; Bourgain C, 2003, AM J HUM GENET, V73, P612, DOI 10.1086/378208; Colavita AM, 2000, CLIN CHEST MED, V21, P263, DOI 10.1016/S0272-5231(05)70265-3; Cole DN, 2000, US FOR SERV RMRS-P, V1, P1; COOKSON WOCM, 1989, LANCET, V1, P1292; De Sanctis GT, 1999, AM J PHYSIOL-LUNG C, V277, pL1118, DOI 10.1152/ajplung.1999.277.6.L1118; DeMeo DL, 2002, GENET EPIDEMIOL, V23, P335, DOI 10.1002/gepi.10182; Ewart SL, 2000, AM J RESP CELL MOL, V23, P537, DOI 10.1165/ajrcmb.23.4.4199; Gern JE, 2002, PEDIAT ALLERG IMM-UK, V13, P386, DOI 10.1034/j.1399-3038.2002.01093.x; Gerritsen Jorrit, 2002, Paediatr Respir Rev, V3, P184, DOI 10.1016/S1526-0542(02)00193-8; Grainger DJ, 1999, HUM MOL GENET, V8, P93, DOI 10.1093/hmg/8.1.93; Graves PE, 2000, J ALLERGY CLIN IMMUN, V105, P506, DOI 10.1067/mai.2000.104940; Hakonarson H, 2001, AM J RESP CRIT CARE, V164, P2036, DOI 10.1164/ajrccm.164.11.2101086; He JQ, 2003, CHEST, V123, p438S, DOI 10.1378/chest.123.3_suppl.438S; Heinzmann A, 2000, HUM MOL GENET, V9, P549, DOI 10.1093/hmg/9.4.549; Hill MR, 1996, HUM MOL GENET, V5, P959, DOI 10.1093/hmg/5.7.959; Hobbs K, 1998, AM J RESP CRIT CARE, V158, P1958, DOI 10.1164/ajrccm.158.6.9804011; HOFFJAN S, 2003, IN PRESS RESP RES; Howard TD, 2001, AM J RESP CELL MOL, V25, P377, DOI 10.1165/ajrcmb.25.3.4483; Konno S, 2001, J ALLERGY CLIN IMMUN, V108, P810, DOI 10.1067/mai.2001.119030; Kraan TCTMV, 1999, GENES IMMUN, V1, P61, DOI 10.1038/sj.gene.6363630; Laprise C, 2000, IMMUNOGENETICS, V51, P695, DOI 10.1007/s002510000185; Lemanske RF, 2002, J ALLERGY CLIN IMMUN, V109, pS521, DOI 10.1067/mai.2002.124564; LEMANSKE RF, 2002, PEDIAT ALLERGY IMMUN, V15, P1; Letterio JJ, 1998, ANNU REV IMMUNOL, V16, P137, DOI 10.1146/annurev.immunol.16.1.137; Leung TF, 2001, CLIN EXP ALLERGY, V31, P1515, DOI 10.1046/j.1365-2222.2001.01212.x; Liu X, 2000, J ALLERGY CLIN IMMUN, V106, P167, DOI 10.1067/mai.2000.107935; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Meyer KC, 2001, AM J RESP CRIT CARE, V164, P97, DOI 10.1164/ajrccm.164.1.2006096; Mirel DB, 2002, DIABETES, V51, P3336, DOI 10.2337/diabetes.51.11.3336; Nagata H, 2001, HUM GENET, V109, P262, DOI 10.1007/s004390100561; Ober C, 2000, AM J HUM GENET, V67, P1154, DOI 10.1016/S0002-9297(07)62946-2; Pulleyn LJ, 2001, HUM GENET, V109, P623, DOI 10.1007/s00439-001-0617-y; Ritz SA, 2002, TRENDS IMMUNOL, V23, P396, DOI 10.1016/S1471-4906(02)02278-0; Rohrbach M, 1999, J ALLERGY CLIN IMMUN, V104, P247, DOI 10.1016/S0091-6749(99)70147-8; ROSENWASSER LJ, 1995, CLIN EXP ALLERGY, V25, P74, DOI 10.1111/j.1365-2222.1995.tb00428.x; Sagara H, 2002, J ALLERGY CLIN IMMUN, V110, P249, DOI 10.1067/mai.2002.126078; Sandford AJ, 2000, J ALLERGY CLIN IMMUN, V106, P135, DOI 10.1067/mai.2000.107926; Shirakawa T, 1996, HUM MOL GENET, V5, P1129, DOI 10.1093/hmg/5.8.1129; Takabayashi A, 2000, EXP CLIN IMMUNOGENET, V17, P63, DOI 10.1159/000019125; Tsunemi Y, 2002, J DERMATOL SCI, V30, P100, DOI 10.1016/S0923-1811(02)00065-8; Xiong YL, 1999, J IMMUNOL, V162, P445; Xu X, 2001, AM J HUM GENET, V69, P1271, DOI 10.1086/324650; Zhu SK, 2000, AM J RESP CRIT CARE, V161, P1655, DOI 10.1164/ajrccm.161.5.9906086	46	81	84	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2004	113	3					511	518		10.1016/j.jaci.2003.10.044	http://dx.doi.org/10.1016/j.jaci.2003.10.044			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	802DM	15007355				2022-12-18	WOS:000220144200025
J	Ewbank, PA; Murray, J; Sanders, K; Curran-Everett, D; Dreskin, S; Nelson, HS				Ewbank, PA; Murray, J; Sanders, K; Curran-Everett, D; Dreskin, S; Nelson, HS			A double-blind, placebo-controlled immunotherapy dose-response study with standardized cat extract	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						immunotherapy; cluster; dose-response; cat extract; immunologic response	POLLEN-ALLERGIC PATIENTS; HOUSE DUST MITE; CLINICAL EFFICACY; NASAL CHALLENGE; CYTOKINES; ANTIGEN; INHIBITION; DANDER; ASTHMA; CELLS	Background: Allergen immunotherapy with doses of cat extract containing approximately 15 mug of the major allergen, Fel d 1, have been proved clinically effective in several double-blind, placebo-controlled studies. However, the maintenance doses used in allergy practice in the United States are often considerably less than this proven dose. Objective: The purpose of this investigation was to determine whether maintenance immunotherapy with cat dander extract containing 0.6 mug or 3.0 mug of Fel d 1 was more effective than placebo and similar in efficacy to treatment with extracts containing 15.0 mug Fel d 1, immunologic parameters being used as the outcome. Methods: Twenty-eight cat-allergic patients were randomly entered, 7 in each group, into a double-blind, placebo-controlled comparison of the immunologic response to treatment with placebo or cat dander extract containing 0.6 mug, 3.0 mug, or 15.0 mug of Fel d 1. Maintenance doses were achieved in 8 visits over a period of 4 weeks through use of a cluster regimen; each subject then received 1 weekly maintenance injection before posttreatment measurements were made. The response to immunotherapy was assessed before immunotherapy and after the first weekly maintenance injection. Studies included responses to titrated skin prick tests to cat extract and an unrelated allergen and serum allergen-specific IgE and IgG(4). Titrated nasal challenges were performed with cat extract; measurement of mRNA and secreted cytokines (IL-4, IL-5, and IFN-gamma ) was done at 6 hours. Serum cytokines (IL-4, IL-5, IFN-gamma)were measured, and flow cytometric analysis of intracellular cytokines (IL-4, IL-5, IFN-gamma) was performed. Cat allergen-stimulated lymphocyte proliferation was performed with measurement of cytokines in the supernatant (IL-4, IL-5, IFN-gamma). Results: All 28 subjects completed the study. Significant and dose-dependent differences were encountered in the titrated skin prick tests (P =.008), the cat-specific IgG(4) (P =.01), and the reduction in CD4(+)/IL-4(+) PBMCs on flow cytometry (P =.03). There were no significant differences between placebo and cat dander extract containing Fel d 10.6 mug. Both extracts containing 3.0 mug and 15.0 mug produced significant decreases in skin prick test sensitivity (P =.02 and P =.002, respectively). The extracts containing 3.0 mug and 15.0 mug produced significant increases in cat-specific IgG4 (P =.01 and P =.006, respectively). Only the 15.0-mug-per-dose extract produced a significant reduction in the percent of CD4(+)/IL-4(+) PBMCs (P =.003). Conclusion: In this double-blind, placebo-controlled study, a maintenance dose of cat dander extract containing 15.0 mug Fel d 1 produced the most consistent immunologic response. A dose of 3.0 p reduced skin prick test sensitivity and increased cat-specific IgG(4) but did not reduce the circulating CD4(+)/IL-4(+) PBMCs, a change that is likely related to the clinically significant response to allergen immunotherapy. These findings suggest that a maintenance dose of 15.0 mug of Fel d 1 is most apt to be clinically effective for allergen immunotherapy.	Natl Jewish Med & Res Ctr, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Denver, CO USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Nelson, HS (corresponding author), Natl Jewish Med & Res Ctr, 1400 Jackson St, Denver, CO 80206 USA.			Curran-Everett, Douglas/0000-0001-5992-4839				ALAM R, 1992, J IMMUNOL METHODS, V155, P25, DOI 10.1016/0022-1759(92)90267-W; ALVAREZCUESTA E, 1994, J ALLERGY CLIN IMMUN, V93, P556, DOI 10.1016/S0091-6749(94)70067-2; BOUSQUET J, 1988, J ALLERGY CLIN IMMUN, V82, P439, DOI 10.1016/0091-6749(88)90017-6; BOUSQUET J, 1987, CLIN ALLERGY, V17, P529, DOI 10.1111/j.1365-2222.1987.tb02049.x; Chanez P, 1996, ALLERGY, V51, P850; Conover William Jay, 1998, PRACTICAL NONPARAMET, V350; CRETICOS PS, 1989, J ALLERGY CLIN IMMUN, V84, P197, DOI 10.1016/0091-6749(89)90325-4; Curran-Everett D, 2000, AM J PHYSIOL-REG I, V279, pR1, DOI 10.1152/ajpregu.2000.279.1.R1; DJURUP R, 1984, ALLERGY, V39, P433, DOI 10.1111/j.1398-9995.1984.tb01965.x; DRESKIN S, 2002, IN PRESS J IMMUNOL M; FRANKLIN W, 1967, J AMER MED ASSOC, V201, P915, DOI 10.1001/jama.201.12.915; FURIN MJ, 1991, J ALLERGY CLIN IMMUN, V88, P27, DOI 10.1016/0091-6749(91)90297-2; Gehlhar K, 1999, CLIN EXP ALLERGY, V29, P497; Hamid QA, 1997, J ALLERGY CLIN IMMUN, V99, P254, DOI 10.1016/S0091-6749(97)70106-4; HAUGAARD L, 1993, J ALLERGY CLIN IMMUN, V91, P709, DOI 10.1016/0091-6749(93)90190-Q; HEDLIN G, 1991, J ALLERGY CLIN IMMUN, V87, P955, DOI 10.1016/0091-6749(91)90417-M; Lack G, 1997, J ALLERGY CLIN IMMUN, V99, P530, DOI 10.1016/S0091-6749(97)70081-2; MAJCHEL AM, 1992, J ALLERGY CLIN IMMUN, V90, P85, DOI 10.1016/S0091-6749(06)80014-X; Majori M, 2000, CLIN EXP ALLERGY, V30, P341, DOI 10.1046/j.1365-2222.2000.00701.x; NAKAGAWA T, 1987, INT ARCH ALLER A IMM, V82, P95, DOI 10.1159/000234297; Nelson HS, 2000, J ALLERGY CLIN IMMUN, V106, P41, DOI 10.1067/mai.2000.107197; Nielsen L, 1996, J ALLERGY CLIN IMMUN, V97, P1207, DOI 10.1016/S0091-6749(96)70186-0; NISH WA, 1994, J ALLERGY CLIN IMMUN, V93, P484, DOI 10.1016/0091-6749(94)90358-1; SIM TC, 1995, AM J RESP CRIT CARE, V152, P927, DOI 10.1164/ajrccm.152.3.7545059; SIM TC, 1994, AM J RESP CRIT CARE, V149, P339, DOI 10.1164/ajrccm.149.2.8306027; Snedecor GW, 1980, STAT METHODS, V7th; Spahn JD, 2001, ANN ALLERG ASTHMA IM, V87, P501, DOI 10.1016/S1081-1206(10)62264-8; VANMETRE TE, 1988, J ALLERGY CLIN IMMUN, V82, P1055, DOI 10.1016/0091-6749(88)90144-3; Varney VA, 1997, CLIN EXP ALLERGY, V27, P860, DOI 10.1111/j.1365-2222.1997.tb01225.x; Wang T, 1999, ANAL BIOCHEM, V269, P198, DOI 10.1006/abio.1999.4022	30	81	83	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2003	111	1					155	161		10.1067/mai.2003.41	http://dx.doi.org/10.1067/mai.2003.41			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	636PR	12532112				2022-12-18	WOS:000180465500024
J	Sieben, S; Kawakubo, Y; Al Masaoudi, T; Merk, HF; Blomeke, B				Sieben, S; Kawakubo, Y; Al Masaoudi, T; Merk, HF; Blomeke, B			Delayed-type hypersensitivity reaction to paraphenylenediamine is mediated by 2 different pathways of antigen recognition by specific alpha beta(+) human T-cell clones	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						paraphenylenediamine; Bandrowski's base; delayed-type hypersensitivity; antigen processing; T lymphocytes; T-cell clone; PBMC; cytokine; T-cell receptor	DRUG-SPECIFIC CD4(+); CONTACT SENSITIVITY; BENZENE-DERIVATIVES; PROHAPTEN CONCEPT; RESPONSES; SULFAMETHOXAZOLE; REPERTOIRE; METABOLISM; LIDOCAINE; ALLERGEN	Background: Allergic contact dermatitis to paraphenylenediamine (PPD) is a frequent cause of morbidity and occupational disability. Objective: The aim of the study was to characterize T-cell responses to PPD and Bandrow,ski's base (BB), an autoxidation product of PPD, by using polyclonal and monoclonal T-lymphocyte cultures. Methods; PPD- and BB-driven proliferation of PBMCs and T-cell clones (TCCs) was assessed by means of tritiated thymidine incorporation. Surface markers were studied by means of flow cytometry, and cytokine generation was assessed with an ELISA. Results: TCCs, with one exception, were CD4(+)/CD45RO(+) and T-cell receptors were alphabeta(+). Three of 6 TCCs expressed Vbeta 16. TCC stimulation was HLA-DP restricted, and TCCs secreted IL-4, IL-5, and marginal levels of IFN-gamma. TCCs reacted to both PPD and BB. Presentation of BB to TCCs was dependent on viable antigen-presenting cells (APCs) pulsed for 4 hours, and fixed APCs failed to stimulate TCCs. Moreover, polyclonal responses to BB were enhanced by metabolically active enzymes, such as cytochrome P450 enzymes. BB has to be metabolized and processed. In contrast, fixation of APCs did not impair their ability to present PPD to TCC, whereas pulsing of APCs with PPD failed to stimulate TCCs. Thus PPD had to be present during the process, and polyclonal stimulation was not enhanced by cytochromes. Conclusion: These results suggest that PPD itself can be recognized by T cells through a processing-independent pathway, whereas its autoxidation product, BB, required processing and possibly metabolism to stimulate the same TCC. Our data demonstrate that 2 distinct pathways of antigen presentation to activate specific TCCs are involved in the immune response to PPD.	Univ Hosp Aachen, Rhein Westfal TH Aachen, Dept Dermatol, D-52074 Aachen, Germany; Tokai Univ, Sch Med, Isehara, Kanagawa 25911, Japan	RWTH Aachen University; RWTH Aachen University Hospital; Tokai University	Blomeke, B (corresponding author), Univ Hosp Aachen, Rhein Westfal TH Aachen, Dept Dermatol, Pauwelsstr 30, D-52074 Aachen, Germany.							BASKETTER DA, 1992, CONTACT DERMATITIS, V27, P90, DOI 10.1111/j.1600-0536.1992.tb05216.x; BASKETTER DA, 1988, CONTACT DERMATITIS, V19, P248, DOI 10.1111/j.1600-0536.1988.tb02921.x; Belsito DV, 2000, J ALLERGY CLIN IMMUN, V105, P409, DOI 10.1067/mai.2000.104937; Budinger L, 1998, J CLIN INVEST, V102, P2082, DOI 10.1172/JCI3335; Budinger L, 2001, J IMMUNOL, V167, P6038, DOI 10.4049/jimmunol.167.10.6038; EMESTAN L, 1988, ACTA DERM-VENEREOL, V68, P395; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; GOCINSKI BL, 1990, J IMMUNOL, V144, P4121; Gruchalla RS, 2001, J ALLERGY CLIN IMMUN, V108, P475, DOI 10.1067/mai.2001.118509; HANKE JH, 1985, HUM IMMUNOL, V14, P59, DOI 10.1016/0198-8859(85)90065-5; KALISH RS, 1994, J CLIN INVEST, V93, P2039, DOI 10.1172/JCI117198; KAPSENBERG ML, 1992, J INVEST DERMATOL, V98, P59, DOI 10.1111/1523-1747.ep12494841; KAPSENBERG ML, 1992, SPRINGER SEMIN IMMUN, V13, P303; Kawakubo Y, 2000, J PHARMACOL EXP THER, V292, P150; KITAGAKI H, 1995, J INVEST DERMATOL, V105, P749, DOI 10.1111/1523-1747.ep12325538; Kitagaki H, 1997, J IMMUNOL, V159, P2484; KOPONEN M, 1986, J ALLERGY CLIN IMMUN, V78, P645, DOI 10.1016/0091-6749(86)90083-7; KRASTEVA M, 1993, INT ARCH ALLERGY IMM, V102, P200, DOI 10.1159/000236573; Little MC, 1998, BRIT J DERMATOL, V138, P45; MARTIN S, 1994, INT ARCH ALLERGY IMM, V104, P10, DOI 10.1159/000236703; MAURIHELLWEG D, 1995, J IMMUNOL, V155, P462; Merk HF, 1996, SEMIN CUTAN MED SURG, V15, P228, DOI 10.1016/S1085-5629(96)80035-6; MOLLGAARD B, 1990, Contact Dermatitis, V23, P274, DOI 10.1111/j.1600-0536.1990.tb05098.x; Moss P, 1997, J INVEST DERMATOL, V109, P14, DOI 10.1111/1523-1747.ep12276338; Padovan E, 1999, J IMMUNOL, V162, P1171; Park BK, 1995, PHARMACOL THERAPEUT, V68, P385, DOI 10.1016/0163-7258(95)02013-6; PARK BK, 1987, BIOCHEM PHARMACOL, V36, P581; PICARDO M, 1992, BRIT J DERMATOL, V126, P450, DOI 10.1111/j.1365-2133.1992.tb15115.x; PROBST P, 1995, CELL IMMUNOL, V165, P134, DOI 10.1006/cimm.1995.1196; Schnyder B, 1997, J CLIN INVEST, V100, P136, DOI 10.1172/JCI119505; Schnyder B, 2000, J IMMUNOL, V164, P6647, DOI 10.4049/jimmunol.164.12.6647; Sieben S, 2001, TOXICOL APPL PHARM, V172, P172, DOI 10.1006/taap.2001.9125; Sieben S, 1999, INT ARCH ALLERGY IMM, V118, P358, DOI 10.1159/000024135; SINIGAGLIA F, 1985, J IMMUNOL, V135, P3929; Vollmer J, 1997, EUR J IMMUNOL, V27, P1865, DOI 10.1002/eji.1830270808; Weltzien HU, 1996, TOXICOLOGY, V107, P141, DOI 10.1016/0300-483X(95)03253-C; Werfel T, 1997, J IMMUNOL, V158, P2500; Zanni MP, 1998, J CLIN INVEST, V102, P1591, DOI 10.1172/JCI3544; Zanni MP, 1997, J IMMUNOL, V158, P1139; Zanni MP, 1998, INT IMMUNOL, V10, P507, DOI 10.1093/intimm/10.4.507	40	81	86	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2002	109	6					1005	1011		10.1067/mai.2002.123872	http://dx.doi.org/10.1067/mai.2002.123872			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	566RU	12063532				2022-12-18	WOS:000176442700018
J	Robotham, JM; Teuber, SS; Sathe, SK; Roux, KH				Robotham, JM; Teuber, SS; Sathe, SK; Roux, KH			Linear IgE epitope mapping of the English walnut (Juglans regia) major food allergen, Jug r 1	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						epitope mapping; 2S albumin; walnut; nut allergy; Jug r 1; food allergy	OVERLAPPING SYNTHETIC PEPTIDES; TREE NUT ALLERGY; MUTATIONAL ANALYSIS; BINDING EPITOPES; MOLECULAR CHARACTERIZATION; RECOMBINANT ALLERGENS; P-II; PROTEIN; PEANUT; CLONING	Background: Peanut and tree nut allergies can be life-threatening, and they appear to be growing in prevalence. Jug r 1, a 2S albumin seed storage protein, was previously characterized as a major English walnut food allergen. Objective: We sought to identify the linear IgE-binding epitopes of Jug r 1 and to determine which, if any, amino acids are necessary for this binding to occur. Methods: Pools of sera from walnut-allergic patients and overlapping peptides synthesized on an activated cellulose membrane were used to screen for IgE-binding epitopes. Mutational analysis of the immunodominant epitope was carried out through single and multisite amino acid substitutions. Inhibition assays were performed through use of affinity-purified IgE, soluble forms of the epitope peptide, and the recombinant 2S albumin, rJug r 1. Results: One immunodominant linear epitope was identified. Amino acid mutations to the epitope demonstrated that the residues RGEE, at positions 36 through 39, were minimally required for IgE binding. Probing of this epitope with sera from each of 20 patients revealed 15 of the sera to be positive. Binding of patients' IgE to the epitope was inhibited with a soluble form of the peptide; however, soluble peptide did not completely inhibit the binding of IgE to the intact rJug r 1. Conclusion: One major linear IgE-reactive epitope and its critical core amino acid residues have been identified. Mutation of any of these core amino acids resulted in loss of IgE binding to the epitope, and this points toward the feasibility of reducing allergenicity in genetically modified walnuts. However, strong evidence for the existence of conformational epitopes was also obtained.	Florida State Univ, Dept Biol Sci, Biol Unit 1, Tallahassee, FL 32306 USA; Florida State Univ, Struct Biol Program, Tallahassee, FL 32306 USA; Univ Calif Davis, Sch Med, Dept Internal Med, Div Rheumatol Allergy & Clin Immunol, Davis, CA 95616 USA; Florida State Univ, Dept Nutr Food & Exericise Sci, Tallahassee, FL 32306 USA	State University System of Florida; Florida State University; State University System of Florida; Florida State University; University of California System; University of California Davis; State University System of Florida; Florida State University	Roux, KH (corresponding author), Florida State Univ, Dept Biol Sci, Biol Unit 1, Tallahassee, FL 32306 USA.							ATASSI H, 1986, EUR J IMMUNOL, V16, P229, DOI 10.1002/eji.1830160304; Banerjee B, 1999, INFECT IMMUN, V67, P2284, DOI 10.1128/IAI.67.5.2284-2291.1999; BERZOFSKY JA, 1985, SCIENCE, V229, P932, DOI 10.1126/science.2410982; BINDSLEVJENSEN C, 1997, FOOD ALLERGY ADVERSE, P137; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; BOCK SA, 1989, J ALLERGY CLIN IMMUN, V83, P900, DOI 10.1016/0091-6749(89)90103-6; Bredehorst R, 2001, J CHROMATOGR B, V756, P33, DOI 10.1016/S0378-4347(01)00069-X; Breiteneder H, 2000, J ALLERGY CLIN IMMUN, V106, P27, DOI 10.1067/mai.2000.106929; Burks AW, 1997, EUR J BIOCHEM, V245, P334, DOI 10.1111/j.1432-1033.1997.t01-1-00334.x; DOLECEK C, 1993, FEBS LETT, V335, P299, DOI 10.1016/0014-5793(93)80406-K; ELSAYED S, 1989, INT ARCH ALLER A IMM, V89, P410, DOI 10.1159/000234984; ELSAYED S, 1980, SCAND J IMMUNOL, V12, P171, DOI 10.1111/j.1365-3083.1980.tb00055.x; Foucard T, 1999, ALLERGY, V54, P261, DOI 10.1034/j.1398-9995.1999.00924.x; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GHOSH B, 1991, GENE, V101, P231, DOI 10.1016/0378-1119(91)90416-9; Helm RM, 1998, INT ARCH ALLERGY IMM, V117, P29, DOI 10.1159/000023987; Helm RM, 2000, J ALLERGY CLIN IMMUN, V105, P378, DOI 10.1016/S0091-6749(00)90091-5; MAZUR G, 1988, MOL IMMUNOL, V25, P1005, DOI 10.1016/0161-5890(88)90007-7; Pastorello EA, 1998, J ALLERGY CLIN IMMUN, V102, P1021, DOI 10.1016/S0091-6749(98)70341-0; Rabjohn P, 1999, J CLIN INVEST, V103, P535, DOI 10.1172/JCI5349; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P717, DOI 10.1016/S0091-6749(99)70411-2; SCHEINER O, 1995, ALLERGY, V50, P384, DOI 10.1111/j.1398-9995.1995.tb01167.x; Sicherer SH, 2000, CURR OPIN PEDIATR, V12, P567, DOI 10.1097/00008480-200012000-00010; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V103, P559, DOI 10.1016/S0091-6749(99)70224-1; SMITH LJ, 1997, FOOD ALLERGY ADVERSE, P431; Stanley JS, 1997, ARCH BIOCHEM BIOPHYS, V342, P244, DOI 10.1006/abbi.1997.9998; Sze-Tao KWC, 2000, J SCI FOOD AGR, V80, P1393, DOI 10.1002/1097-0010(200007)80:9&lt;1393::AID-JSFA653&gt;3.0.CO;2-F; Teuber SS, 1998, J ALLERGY CLIN IMMUN, V101, P807, DOI 10.1016/S0091-6749(98)70308-2; Valenta R, 1999, BIOL CHEM, V380, P815, DOI 10.1515/BC.1999.101; van Neerven RJJ, 1999, ALLERGY, V54, P552, DOI 10.1034/j.1398-9995.1999.t01-1-00092.x; VANTHOF W, 1993, ALLERGY, V48, P255; VANTHOF W, 1991, MOL IMMUNOL, V28, P1225, DOI 10.1016/0161-5890(91)90009-9; Vrtala S, 1998, J IMMUNOL, V160, P6137; WALSH BJ, 1989, J IMMUNOL METHODS, V121, P275, DOI 10.1016/0022-1759(89)90171-3; YOCUM MW, 1994, MAYO CLIN PROC, V69, P16, DOI 10.1016/S0025-6196(12)61606-1; YUNGINGER JW, 1988, JAMA-J AM MED ASSOC, V260, P1450, DOI 10.1001/jama.260.10.1450; ZHAO YM, 1994, ANAL CHEM, V66, P3723, DOI 10.1021/ac00093a029	38	81	93	3	14	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2002	109	1					143	149		10.1067/mai.2002.120558	http://dx.doi.org/10.1067/mai.2002.120558			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	519RM	11799381	Bronze			2022-12-18	WOS:000173739300024
J	Milgrom, H; Skoner, DR; Bensch, G; Kim, KT; Claus, R; Baumgartner, RA				Milgrom, H; Skoner, DR; Bensch, G; Kim, KT; Claus, R; Baumgartner, RA		Levalbuterol Pediat Study Grp	Low-dose levalbuterol in children with asthma: Safety and efficacy in comparison with placebo and racemic albuterol	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						levalbuterol; racemic albuterol; (R)-albuterol; (S)albuterol; asthma; pediatric; bronchodilator; FEV1; beta-agonist	AIRWAY HYPERREACTIVITY; SALBUTAMOL; ENANTIOMERS; (S)-ALBUTEROL; EXACERBATION	Background: Racemic albuterol (RAC) is an equal mixture of (R)-albuterol and (S)-albuterol. Only the (R)-isomer, levalbuterol (LEV), is therapeutically active. Lower doses of LEV, devoid of (S)-albuterol, have demonstrated efficacy comparable to that of higher doses of the (R)-isomer administered as a component of RAC. Objective: The purpose of this study was to determine whether LEV results in improved safety and efficacy in children. Methods: Asthmatic children aged 4 to 11 years (n = 338; FEV1, 40% to 85% of predicted) participated in this multicenter, randomized, double-blinded study and received 21 days of 3-times-a-day treatment with nebulized LEV (0.31 or 0.63 mg), RAC (1.25 or 2.5 mg), or placebo. The primary endpoint was FEV1 (peak percent change). Adverse events, clinical laboratory test results, vital signs, and electrocardiograms were evaluated for safety. Results: All active treatments significantly improved the primary endpoint in comparison with placebo (P < .001). Significant differences in FEV1 were noted immediately after nebulization (median change, 2.0%, 19.0%, 18.1%, 12.4%, and 15.6% for placebo, LEV 0.31 and 0.63, RAC 1.25 and 2.5 mg, respectively; P < .05 vs placebo; P < .05 for LEV 0.31 and 0.63 vs RAC 1.25 mg). LEV 0.31 mg was the only treatment not different from placebo for changes in ventricular heart rate, QT(c) interval, and glucose (P > .05). All active treatments decreased serum potassium (range, -0.3 to -0.6; P < .002 vs placebo), and RAC 2.5 mg caused the greatest change (P < .005 vs other actives). In a patient subset with severe asthma, a dose-response relationship was observed for levalbuterol, indicating that higher doses were more effective. Conclusion: LEV was clinically comparable to 4- to 8-fold higher doses of RAC, and it demonstrated a more favorable safety profile. LEV 0.31 mg should be used as the starting dose in 4-11 year old children with mild to moderate persistent asthma. Patients with severe disease might benefit from higher doses.	Sepracor Inc, Marlborough, MA 01752 USA; Natl Jewish Med & Res Ctr, Denver, CO USA; Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA; Bensch Res Associates, Stockton, CA USA; Allergy Asthma & Resp Care Ctr, Long Beach, CA USA	Dainippon Sumitomo Pharmaceutical Company; Sunovion Pharmaceuticals Inc.; National Jewish Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Baumgartner, RA (corresponding author), Sepracor Inc, 111 Locke Dr, Marlborough, MA 01752 USA.							*AM AC ASTHM ALL I, 1999, GUID MAN ASTHM CHILD; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; [Anonymous], PUBL NIH; BLAKE KV, 1992, CHEST, V101, P309, DOI 10.1378/chest.101.2.309; Dhand R, 1999, AM J RESP CRIT CARE, V160, P1136, DOI 10.1164/ajrccm.160.4.9812074; Gawchik SM, 1999, J ALLERGY CLIN IMMUN, V103, P615, DOI 10.1016/S0091-6749(99)70233-2; Gumbhir-Shah K, 1998, J CLIN PHARMACOL, V38, P1096; Gumbhir-Shah K, 1999, PULM PHARMACOL THER, V12, P353, DOI 10.1006/pupt.1999.0217; HARTLEY D, 1971, J MED CHEM, V14, P895, DOI 10.1021/jm00291a036; HOSHIKO K, 1993, J ALLERGY CLIN IMMUN, V91, P909, DOI 10.1016/0091-6749(93)90349-K; HOSHIKO K, 1993, JPN J PHARMACOL, V63, P159, DOI 10.1254/jjp.63.159; Mitra S, 1998, MOL PHARMACOL, V53, P347, DOI 10.1124/mol.53.3.347; Morley J, 1996, CLIN REV ALLERG IMMU, V14, P65, DOI 10.1007/BF02772204; Nelson HS, 1998, J ALLERGY CLIN IMMUN, V102, P943, DOI 10.1016/S0091-6749(98)70332-X; Penn RB, 1996, CLIN REV ALLERG IMMU, V14, P37, DOI 10.1007/BF02772201; PERRINFAYOLLE M, 1995, LANCET, V346, P1101, DOI 10.1016/S0140-6736(95)91775-6; SCHULMAN, 1998, ASTHMA AM; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; SIFTON D, 2001, PHYSICIANS DESK REFE, P1480; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; Templeton AGB, 1998, PULM PHARMACOL THER, V11, P1, DOI 10.1006/pupt.1998.0110; *US DEP HHS, 1992, CHIRALITY, V4, P338; White MV, 1999, J ALLERGY CLIN IMMUN, V104, pS47, DOI 10.1016/S0091-6749(99)70273-3; Zhang XY, 1998, AM J PHYSIOL-LUNG C, V274, pL32, DOI 10.1152/ajplung.1998.274.1.L32; 2000, SCOTTLEVINS PHYSICIA	25	81	82	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2001	108	6					938	945		10.1067/mai.2001.120134	http://dx.doi.org/10.1067/mai.2001.120134			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	505WK	11742271				2022-12-18	WOS:000172938400009
J	Nakatani, T; Kaburagi, Y; Shimada, Y; Inaoki, M; Takehara, K; Mukaida, N; Sato, S				Nakatani, T; Kaburagi, Y; Shimada, Y; Inaoki, M; Takehara, K; Mukaida, N; Sato, S			CCR4(+) memory CD4(+) T lymphocytes are increased in peripheral blood and lesional skin from patients with atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; chemokine receptors; CCR4; CXCR3; T(H)2 cells; skin; inflammation	CHEMOKINE RECEPTORS; IN-SITU; INTERFERON-GAMMA; CELLS; EXPRESSION; TH1; PATHOGENESIS; CYTOKINES; MICE; IGE	Background: Recent studies have reported that T(H)1 and T(H)2 cells express CXCR3 and CCR4, respectively. Objective: Our goal was to assess the association of CCR4 and CXCR3 expression with T(H)2 and T(H)1 cells and association of CCR4 and CXCR3 expression with inflammation in patients with atopic dermatitis (AD). Methods: Intracellular cytokine production and chemokine receptor expression in blood T cells were examined by flow cytometry. Immunohistochemical expression of chemokine receptors was also investigated in chronically lesional skin. Results: CCR4(+) and CXCR3(+) CD4(+) T cells predominantly produced IL-4 and IFN-gamma, respectively. Although the frequency of CXCR3(+) cells among CD4(+) CD45RO(+) T cells was similar for patients with AD (n = 29) and healthy control subjects (n = 19), patients with severe AD (n = 14) had a reduced frequency of CXCR3(+) cells. In contrast, the frequency of CCR4(+) cells and the CCR4/CXCR3 ratio were higher in patients with AD (n = 22) than healthy control subjects (n = 16) and correlated with disease severity of AD. The frequency of CCR4(+) cells correlated positively with eosinophil numbers and serum IgE levels, whereas the frequency of CXCR3(+) cells correlated inversely with eosinophil numbers. The frequency of CCR4(+) or CXCR3(+) cells was similar in patients with psoriasis (n = 6) and healthy control subjects. Immunohistochemical analysis showed that the frequency of CCR4(+) cells among CD4(+) T cells in chronically lesional skin of patients with AD (n = 9) was higher than that of patients with psoriasis (n = 4). Conclusion: Our data suggest the association of CCR4 expression with T(H)2 cells, the predominance of CCR4(+) cells in blood from patients with AD, and an important role of CCR4 in the migration of T(H)2 cells from blood into AD lesional skin.	Kanazawa Univ, Sch Med, Dept Dermatol, Kanazawa, Ishikawa 9208641, Japan; Kanazawa Univ, Sch Med, Canc Res Inst, Dept Mol Oncol, Kanazawa, Ishikawa 9208641, Japan	Kanazawa University; Kanazawa University	Sato, S (corresponding author), Kanazawa Univ, Sch Med, Dept Dermatol, 13-1 Takaramachi, Kanazawa, Ishikawa 9208641, Japan.		Mukaida, Naofumi/D-7623-2011	Mukaida, Naofumi/0000-0002-4193-1851				Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Austin LM, 1999, J INVEST DERMATOL, V113, P752, DOI 10.1046/j.1523-1747.1999.00749.x; Bonecchi R, 1998, J EXP MED, V187, P129, DOI 10.1084/jem.187.1.129; Campbell JJ, 1998, SCIENCE, V279, P381, DOI 10.1126/science.279.5349.381; GREWE M, 1995, J INVEST DERMATOL, V105, P407, DOI 10.1111/1523-1747.ep12321078; Grewe M, 1998, IMMUNOL TODAY, V19, P359, DOI 10.1016/S0167-5699(98)01285-7; Hamid Q, 1996, J ALLERGY CLIN IMMUN, V98, P225, DOI 10.1016/S0091-6749(96)70246-4; HAMID Q, 1994, J CLIN INVEST, V94, P870, DOI 10.1172/JCI117408; Hanifin JM, 1999, J AM ACAD DERMATOL, V41, P72, DOI 10.1016/S0190-9622(99)70410-X; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; Imai T, 1999, INT IMMUNOL, V11, P81, DOI 10.1093/intimm/11.1.81; JUJO K, 1992, J ALLERGY CLIN IMMUN, V90, P323, DOI 10.1016/S0091-6749(05)80010-7; JUNG T, 1993, J IMMUNOL METHODS, V159, P197, DOI 10.1016/0022-1759(93)90158-4; Leung DYM, 2000, J ALLERGY CLIN IMMUN, V105, P860, DOI 10.1067/mai.2000.106484; Leung DYM, 1999, J ALLERGY CLIN IMMUN, V104, pS99, DOI 10.1016/S0091-6749(99)70051-5; Loetscher P, 1998, NATURE, V391, P344, DOI 10.1038/34814; Murai M, 1999, J CLIN INVEST, V104, P49, DOI 10.1172/JCI6642; Murphy PM, 2000, PHARMACOL REV, V52, P145; Nakazawa M, 1997, J ALLERGY CLIN IMMUN, V99, P673, DOI 10.1016/S0091-6749(97)70030-7; RAJKA G, 1989, ACTA DERM-VENEREOL, P13; Sallusto F, 1998, J EXP MED, V187, P875, DOI 10.1084/jem.187.6.875; Sallusto F, 1998, IMMUNOL TODAY, V19, P568, DOI 10.1016/S0167-5699(98)01346-2; Sallusto F, 1997, SCIENCE, V277, P2005, DOI 10.1126/science.277.5334.2005; Sato A, 1998, J INVEST DERMATOL, V111, P1079, DOI 10.1046/j.1523-1747.1998.00454.x; Sato S, 1996, IMMUNITY, V5, P551, DOI 10.1016/S1074-7613(00)80270-8; Thepen T, 1996, J ALLERGY CLIN IMMUN, V97, P828, DOI 10.1016/S0091-6749(96)80161-8; UYEMURA K, 1993, J INVEST DERMATOL, V101, P701, DOI 10.1111/1523-1747.ep12371679; Vestergaard C, 1999, J CLIN INVEST, V104, P1097, DOI 10.1172/JCI7613; WAKITA H, 1994, J CUTAN PATHOL, V21, P33, DOI 10.1111/j.1600-0560.1994.tb00688.x; Ward SG, 1998, IMMUNITY, V9, P1, DOI 10.1016/S1074-7613(00)80583-X; Zingoni A, 1998, J IMMUNOL, V161, P547; Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X	32	81	88	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2001	107	2					353	358		10.1067/mai.2001.112601	http://dx.doi.org/10.1067/mai.2001.112601			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	403YV	11174204	Green Submitted			2022-12-18	WOS:000167071400024
J	Schade, RP; Van Ieperen-Van Dijk, AG; Van Reijsen, FC; Versluis, C; Kimpen, JLL; Knol, EF; Bruijnzeel-Koomen, CAFM; Van Hoffen, E				Schade, RP; Van Ieperen-Van Dijk, AG; Van Reijsen, FC; Versluis, C; Kimpen, JLL; Knol, EF; Bruijnzeel-Koomen, CAFM; Van Hoffen, E			Differences in antigen-specific T-cell responses between infants with atopic dermatitis with and without cow's milk allergy: Relevance of T(H)2 cytokines	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; T-cell clone; cow's milk; casein; cytokine; food allergy; IL-4; infants; human; T(H)1/T(H)2 cells	INTERFERON-GAMMA PRODUCTION; LYMPHOCYTE-RESPONSES; PERIPHERAL-BLOOD; CD4(+) CELLS; CHILDREN; EXPRESSION; CLONES; PATTERNS; SUBSETS; IL-4	Background: Cow's milk is the most important food antigen in infancy and may lead to acute cutaneous symptoms and atopic dermatitis (AD). The role of circulating allergen-specific T cells in the pathogenesis of food-allergic skin symptoms is still under investigation. Objective: This study was designed to analyze the cow's milk protein (CMP)-specific T-cell response at the clonal level in infants with AD and cow's milk allergy (CMA) in comparison with infants with AD without CMA. Methods: We used an antigen-specific culturing system with autologous B cells as antigen-presenting cells to establish CMP-specific T-cell clones derived from PBMCs in infants with AD. T-cell reactivity, measured by using a lymphocyte stimulation test, and cytokine production, measured by using ELISA, was compared between infants with AD with and without CMA. Results: Both infants with and without allergy to cow's milk had a CMP-specific T helper cell response directed against the major proteins in milk. Analysis of antigen-specific cytokine production showed that this response was T(H)2 skewed in infants with CMA, with production of high levels of IL-4, IL-5, and IL-13. In contrast, infants without CMA had a T(H)1-skewed response, with high levels of IFN-gamma and low levels of IL-4, IL-5, and IL-13. Conclusion: These data confirm for the first time at the clonal level that food allergy in infants with AD is associated with production of T(H)2 cytokines by circulating antigen-specific CD4(+) T cells, whereas tolerance to food antigens is associated with low levels of these cytokines. This suggests a key role for the T helper cell-derived T(H)2 cytokines in food allergy-related skin symptoms.	Univ Utrecht, Med Ctr, Dept Dermatol Allergol, NL-3508 GA Utrecht, Netherlands; Univ Utrecht, Med Ctr, Dept Gen Pediat & Infect Dis, NL-3508 GA Utrecht, Netherlands	Utrecht University; Utrecht University	Van Hoffen, E (corresponding author), Univ Utrecht, Med Ctr, Dept Dermatol Allergol, G02-124,POB 85-500, NL-3508 GA Utrecht, Netherlands.			Knol, Edward/0000-0001-7368-9820				Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; ABERNATHYCARVER KJ, 1995, J CLIN INVEST, V95, P913, DOI 10.1172/JCI117743; Andre F, 1996, ALLERGY, V51, P350; Bohle B, 1998, J IMMUNOL, V160, P2022; Borish L, 1997, J ALLERGY CLIN IMMUN, V99, P161, DOI 10.1016/S0091-6749(97)70090-3; BOS JD, 1992, ARCH DERMATOL, V128, P1509, DOI 10.1001/archderm.128.11.1509; Burks AW, 1998, J PEDIATR-US, V132, P132, DOI 10.1016/S0022-3476(98)70498-6; Campbell DE, 1998, PEDIAT ALLERG IMM-UK, V9, P68, DOI 10.1111/j.1399-3038.1998.tb00306.x; deJong EC, 1996, J ALLERGY CLIN IMMUN, V98, P73, DOI 10.1016/S0091-6749(96)70228-2; Eigenmann PA, 1996, PEDIATR ALLERGY IMMU, V7, P12, DOI 10.1111/j.1399-3038.1996.tb00100.x; Eigenmann PA, 1998, PEDIATRICS, V101, DOI 10.1542/peds.101.3.e8; Grewe M, 1998, IMMUNOL TODAY, V19, P359, DOI 10.1016/S0167-5699(98)01285-7; GUILLET G, 1992, ARCH DERMATOL, V128, P187, DOI 10.1001/archderm.128.2.187; Hamid Q, 1996, J ALLERGY CLIN IMMUN, V98, P225, DOI 10.1016/S0091-6749(96)70246-4; HAMID Q, 1994, J CLIN INVEST, V94, P870, DOI 10.1172/JCI117408; HANIFIN JM, 1984, J ALLERGY CLIN IMMUN, V73, P211, DOI 10.1016/S0091-6749(84)80008-1; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44; HIGGINS JA, 1995, IMMUNOLOGY, V84, P91; HILL DJ, 1986, J PEDIATR-US, V109, P270, DOI 10.1016/S0022-3476(86)80384-5; Hoffman KM, 1997, J ALLERGY CLIN IMMUN, V99, P360, DOI 10.1016/S0091-6749(97)70054-X; Host A, 1994, Pediatr Allergy Immunol, V5, P1; Kalinski P, 1999, IMMUNOL TODAY, V20, P561, DOI 10.1016/S0167-5699(99)01547-9; KAPSENBERG ML, 1991, IMMUNOL TODAY, V12, P392, DOI 10.1016/0167-5699(91)90137-I; KAY AB, 1991, J EXP MED, V173, P775, DOI 10.1084/jem.173.3.775; KELSO A, 1995, IMMUNOL TODAY, V16, P374, DOI 10.1016/0167-5699(95)80004-2; KONDO N, 1990, J ALLERGY CLIN IMMUN, V86, P253, DOI 10.1016/S0091-6749(05)80073-9; Laan MP, 1998, CLIN EXP ALLERGY, V28, P35, DOI 10.1046/j.1365-2222.1998.00168.x; LOPEZ AF, 1988, J EXP MED, V167, P219, DOI 10.1084/jem.167.1.219; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Noma T, 1996, CLIN EXP ALLERGY, V26, P1298, DOI 10.1111/j.1365-2222.1996.tb00527.x; PLAUT M, 1990, J IMMUNOL, V144, P4497; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; Reekers R, 1996, BRIT J DERMATOL, V135, P935, DOI 10.1046/j.1365-2133.1996.d01-1098.x; Sampson HA, 1997, JAMA-J AM MED ASSOC, V278, P1888, DOI 10.1001/jama.278.22.1888; Suomalainen H, 1993, Pediatr Allergy Immunol, V4, P203, DOI 10.1111/j.1399-3038.1993.tb00092.x; Umetsu DT, 1997, J ALLERGY CLIN IMMUN, V100, P1, DOI 10.1016/S0091-6749(97)70186-6; VANREIJSEN FC, 1992, J ALLERGY CLIN IMMUN, V90, P184, DOI 10.1016/0091-6749(92)90070-I; Werfel T, 1997, J ALLERGY CLIN IMMUN, V99, P124, DOI 10.1016/S0091-6749(97)81053-6; YSSEL H, 1984, J IMMUNOL METHODS, V72, P219, DOI 10.1016/0022-1759(84)90450-2	39	81	84	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2000	106	6					1155	1162		10.1067/mai.2000.110802	http://dx.doi.org/10.1067/mai.2000.110802			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	384ER	11112900	Bronze			2022-12-18	WOS:000165930300019
J	De Lucca, SD; O'Meara, TJ; Tovey, ER				De Lucca, SD; O'Meara, TJ; Tovey, ER			Exposure to mite and cat allergens on a range of clothing items at home and the transfer of cat allergen in the workplace	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						clothing; aeroallergens; Der p 1; Fel d 1; immunostaining	FEL-D-I; HOUSE-DUST MITE; INDOOR ALLERGENS; P-I; F-I; SENSITIZATION; CHILDREN; SYMPTOMS; ANTIGEN; ELISA	Background: Clothing has been proposed as an additional source of exposure to mite and cat allergens. Dispersal of allergen into public places has also been attributed to clothing. Objectives: We sought to study the contribution of various types of clothing on mite and cat exposure in a domestic environment. Also, we studied the ability of clothing to transfer allergen in a workplace. Methods: Personal exposure to mite and cat allergen from a range of clothing was measured by using intranasal air samplers in 11 homes. Five categories of clothing were tested. Wearing no upper clothing was the sixth category tested to distinguish the contribution of clothing over ambient background exposure. An adhesive tape was used to sample allergen from the surface of clothing, and reservoir dust samples mere also collected. The above techniques were also used in the work-place to examine the amount of cat allergen transferred from cat owners to non-cat owners. Results: The amount of mite and cat allergen inhaled differed among the clothing types worn and whether they had been washed recently Wearing a woolen sweater increased personal allergen exposure to cat and mite allergen by a mean of 11 and 10 times, respectively. Clothing items that mere less frequently washed carried more allergen whether assessed by vacuuming or sampled with adhesive tape. This corresponded to the amount of allergen inhaled. We also found that cat levels on non-cat owners' clothing increased significantly at the end of a working day, which lead to the increase in their personal allergen exposure to cat. Conclusions: These studies strongly support the emerging model that personal clothing is an important source of both mite and cat allergen exposure. This article also demonstrates the importance of clothing as a means of distributing cat allergen into cat-free environments.	Univ Sydney, Inst Resp Med, Sydney, NSW 2006, Australia	University of Sydney	De Lucca, SD (corresponding author), Univ Sydney, Inst Resp Med, Room 461,Blackburn Bldg D06, Sydney, NSW 2006, Australia.		Tovey, Euan R/G-8604-2017	Tovey, Euan R/0000-0002-1802-7266				Almqvist C, 1999, J ALLERGY CLIN IMMUN, V103, P1012, DOI 10.1016/S0091-6749(99)70172-7; Bollinger ME, 1998, J ALLERGY CLIN IMMUN, V101, P124, DOI 10.1016/S0091-6749(98)70203-9; Bollinger ME, 1996, J ALLERGY CLIN IMMUN, V97, P907, DOI 10.1016/S0091-6749(96)80064-9; CHAPMAN MD, 1988, J IMMUNOL, V140, P812; Custovic A, 1998, ALLERGY, V53, P115, DOI 10.1111/j.1398-9995.1998.tb05011.x; Custovic A, 1998, THORAX, V53, P33, DOI 10.1136/thx.53.1.33; CUSTOVIC A, 1994, CLIN EXP ALLERGY, V24, P1164, DOI 10.1111/j.1365-2222.1994.tb03323.x; DAmato G, 1997, J ALLERGY CLIN IMMUN, V99, P577, DOI 10.1016/S0091-6749(97)70088-5; De Lucca S, 1999, J ALLERGY CLIN IMMUN, V103, P174, DOI 10.1016/S0091-6749(99)70543-9; De Lucca SD, 1999, J ALLERGY CLIN IMMUN, V104, P672, DOI 10.1016/S0091-6749(99)70341-6; Droste JHJ, 1996, J ALLERGY CLIN IMMUN, V97, P922, DOI 10.1016/S0091-6749(96)80066-2; ENBERG RN, 1993, ANN ALLERGY, V70, P471; Lewis RD, 1998, AM IND HYG ASSOC J, V59, P606, DOI 10.1080/15428119891010776; LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; MUNIR AKM, 1995, CLIN EXP ALLERGY, V25, P119, DOI 10.1111/j.1365-2222.1995.tb01016.x; Munir AKM, 1997, J ALLERGY CLIN IMMUN, V100, P177, DOI 10.1016/S0091-6749(97)70221-5; O'Meara TJ, 1998, LANCET, V351, P1488, DOI 10.1016/S0140-6736(05)78870-X; Peat JK, 1996, AM J RESP CRIT CARE, V153, P141, DOI 10.1164/ajrccm.153.1.8542107; Platts-Mills Thomas A. E., 1997, Journal of Allergy and Clinical Immunology, V100, pS1; PRICE JA, 1990, LANCET, V336, P895, DOI 10.1016/0140-6736(90)92268-M; QUIRCE S, 1995, ANN ALLERG ASTHMA IM, V75, P325; Sakaguchi M, 1996, J ALLERGY CLIN IMMUN, V97, P1040, DOI 10.1016/S0091-6749(96)70255-5; Sercombe JK, 1998, J ALLERGY CLIN IMMUN, V101, pS80; Sporik R, 1998, J ALLERGY CLIN IMMUN, V101, P451, DOI 10.1016/S0091-6749(98)70352-5; Tovey ER, 1995, J ALLERGY CLIN IMMUN, V96, P999, DOI 10.1016/S0091-6749(95)70239-3; YEUNG MC, 1999, CLIN EXP ALLERGY, V29, P762	26	81	81	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2000	106	5					874	879		10.1067/mai.2000.110804	http://dx.doi.org/10.1067/mai.2000.110804			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	417ZK	11080709				2022-12-18	WOS:000167865200011
J	Paris-Kohler, A; Demoly, P; Persi, L; Lebel, B; Bousquet, J; Arnoux, B				Paris-Kohler, A; Demoly, P; Persi, L; Lebel, B; Bousquet, J; Arnoux, B			In vitro diagnosis of cypress pollen allergy by using cytofluorimetric analysis of basophils (Basotest)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						basophil; IgE; Basotest; cypress pollen; allergy	PHARMACIA CAP SYSTEM; IGE ANTIBODIES; IMMUNOLOGICAL CHARACTERISTICS; PERFORMANCE-CHARACTERISTICS; CUPRESSUS-ARIZONICA; CROSS-REACTIVITY; CEDAR POLLINOSIS; IDENTIFICATION; SENSITIVITY; ACTIVATION	Background: Cupressaceae pollen allergy is a worldwide pollinosis, but its in vitro diagnosis is notoriously difficult, The Basotest is a newly available in vitro test for the detection of allergen-specific IgE based on the level of cellular activation of basophils by using flow cytometry, Objectives: The Basotest was compared with the measurement of cypress pollen-specific IgE in highly selected patients. Methods: We analyzed 34 patients allergic to cypress pollen selected on the basis of a suggestive clinical history and positive skin test and nasal challenge responses to cypress pollen extract. We also analyzed 8 patients with positive skin test responses to cypress pollen extract who did not present symptoms during the pollen season (intermediate group) and 33 control subjects. Sensitivity, specificity, and efficiency of the Basotest and serum specific IgE levels measured by using the CAP System were determined in patients allergic to cypress pollen. Histamine release was studied in a selected group of patients. Results: The Basotest was more sensitive (91.2%) than the CAP System (76%) for the in vitro diagnosis of cypress pollen allergy. A dose-response curve was observed in basophils obtained from patients allergic to cypress pollen. There were no false-positive results with either test (specificity 100%). The results of the Basotest or those of the CAP System did not correlate with the patients' in vivo threshold sensitivity assessed by skin tests and nasal challenge. Conclusions: The Basotest was found to be an effective diagnostic test in patients allergic to cypress pollen.	Hop Arnaud de Villeneuve, INSERM, U454, IFR3, F-34295 Montpellier 5, France; CHU Montpellier, Clin Malad Resp, Montpellier, France; Montpellier Asthme, Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier; Universite de Montpellier; CHU de Montpellier	Arnoux, B (corresponding author), Hop Arnaud de Villeneuve, INSERM, U454, IFR3, F-34295 Montpellier 5, France.		Demoly, Pascal/Y-9938-2019; Bousquet, Jean/O-4221-2019	Demoly, Pascal/0000-0001-7827-7964; 				*AM AC ALL IMM, 1992, J ALLERGY CLIN IMMUN, V90, P263; AZORSA DO, 1995, LEUCOCYTE TYPING, V2, P1352; Barletta B, 1996, J ALLERGY CLIN IMMUN, V98, P797, DOI 10.1016/S0091-6749(96)70129-X; BOUSQUET J, 1985, CLIN ALLERGY, V15, P29, DOI 10.1111/j.1365-2222.1985.tb02251.x; BOUSQUET J, 1984, CLIN ALLERGY, V14, P249, DOI 10.1111/j.1365-2222.1984.tb02204.x; BOUSQUET J, 1993, ALLERGY, V48, P183, DOI 10.1111/j.1398-9995.1993.tb00711.x; BOUSQUET J, 1990, J ALLERGY CLIN IMMUN, V85, P1039, DOI 10.1016/0091-6749(90)90048-9; BOUSQUET J, 1991, J ALLERGY CLIN IMMUN, V87, P737, DOI 10.1016/0091-6749(91)90397-7; COREY JP, 1995, OTOLARYNG HEAD NECK, V112, P665, DOI 10.1016/S0194-5998(95)70173-7; DIFELICE G, 1994, J ALLERGY CLIN IMMUN, V94, P547, DOI 10.1016/0091-6749(94)90212-7; EWAN PW, 1990, ALLERGY, V45, P22, DOI 10.1111/j.1398-9995.1990.tb01080.x; FORD SA, 1991, INT ARCH ALLER A IMM, V95, P178, DOI 10.1159/000235426; Galen RS, 1975, PREDICT VALUE EFFIC; Ganbo Tetsuya, 1995, Auris Nasus Larynx, V22, P158; GANE P, 1993, CYTOMETRY, V14, P344, DOI 10.1002/cyto.990140316; HASHIMOTO M, 1995, CLIN EXP ALLERGY, V25, P848, DOI 10.1111/j.1365-2222.1995.tb00027.x; Iacovacci P, 1998, J ALLERGY CLIN IMMUN, V101, P755, DOI 10.1016/S0091-6749(98)70304-5; ISHIZAKI T, 1987, ANN ALLERGY, V58, P265; ITO H, 1995, ANN ALLERG ASTHMA IM, V74, P299; ITO Y, 1986, INT ARCH ALLER A IMM, V81, P174, DOI 10.1159/000234128; KELSO JM, 1991, ANN ALLERGY, V67, P511; KNOL EF, 1991, EUR J IMMUNOL, V21, P881, DOI 10.1002/eji.1830210404; KNOL EF, 1991, J ALLERGY CLIN IMMUN, V88, P328, DOI 10.1016/0091-6749(91)90094-5; LEBEL B, 1988, J ALLERGY CLIN IMMUN, V82, P869, DOI 10.1016/0091-6749(88)90092-9; Lebel B, 1996, ALLERGY, V51, P394, DOI 10.1111/j.1398-9995.1996.tb04636.x; LEIMGRUBER A, 1991, CLIN EXP ALLERGY, V21, P127, DOI 10.1111/j.1365-2222.1991.tb00814.x; Mari A, 1996, J ALLERGY CLIN IMMUN, V98, P21, DOI 10.1016/S0091-6749(96)70222-1; Mari A, 1997, ALLERGY, V52, P355, DOI 10.1111/j.1398-9995.1997.tb01008.x; METZELAAR MJ, 1992, THROMB HAEMOSTASIS, V68, P378; MOREL AM, 1988, J ALLERGY CLIN IMMUN, V82, P646, DOI 10.1016/0091-6749(88)90978-5; Nolte H, 1997, ANN ALLERG ASTHMA IM, V79, P27, DOI 10.1016/S1081-1206(10)63080-3; ONORATO J, 1986, J ALLERGY CLIN IMMUN, V78, P1139, DOI 10.1016/0091-6749(86)90263-0; PANZANI R, 1986, ANN ALLERGY, V56, P460; PASTORELLO EA, 1995, J ALLERGY CLIN IMMUN, V96, P580, DOI 10.1016/S0091-6749(95)70255-5; PASTORELLO EA, 1991, ANN ALLERGY, V67, P365; PHAM NH, 1994, CLIN EXP ALLERGY, V24, P558, DOI 10.1111/j.1365-2222.1994.tb00953.x; PHAM NH, 1995, CLIN EXP ALLERGY, V25, P599, DOI 10.1111/j.1365-2222.1995.tb01107.x; RAMIREZ DA, 1984, J ALLERGY CLIN IMMUN, V73, P88, DOI 10.1016/0091-6749(84)90489-5; REID MJ, 1988, NEW ENGL REG ALLERGY, V9, P225; Sainte-Laudy J, 1998, Allerg Immunol (Paris), V30, P41	40	81	86	1	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2000	105	2	1				339	+		10.1016/S0091-6749(00)90085-X	http://dx.doi.org/10.1016/S0091-6749(00)90085-X			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	285RQ	10669856				2022-12-18	WOS:000085402200020
J	Warner, JA; Frederick, JM; Bryant, TN; Weich, C; Raw, GJ; Hunter, C; Stephen, FR; McIntyre, DA; Warner, JO				Warner, JA; Frederick, JM; Bryant, TN; Weich, C; Raw, GJ; Hunter, C; Stephen, FR; McIntyre, DA; Warner, JO			Mechanical ventilation and high-efficiency vacuum cleaning: A combined strategy of mite and mite allergen reduction in the control of mite-sensitive asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						humidity; mechanical ventilation; asthma; allergy; house dust mites; Der p 1	CHILDHOOD ASTHMA; HIGH-ALTITUDE; EOSINOPHIL; AVOIDANCE; DWELLINGS; MARKERS	Background: The relationship between exposure to house dust mite (HDM) allergens and prevalence of sensitization to these allergens in patients with asthma has been confirmed in many studies. Mite population growth is regulated by humidity. Reducing humidity and removing allergen by efficient vacuuming should control mite allergen and reduce symptoms. Objective: We sought to investigate the effect of mechanical ventilation and high-efficiency vacuuming on HDM numbers and Der p 1 concentrations in the homes of mite-sensitive asthmatic subjects and to evaluate the effect of any reductions on symptoms. Methods: The homes of 40 HDM-sensitive asthmatic subjects were randomized to receive (1) mechanical ventilation and a high-efficiency vacuum cleaner (HEVC); (2) mechanical ventilation alone; (3) an HEVC alone; and (4) no intervention. Homes and patients were monitored for 12 months. Change in absolute humidity, mite numbers, Der p 1 concentrations, lung function, bronchial hyperresponsiveness, and symptom scores were analyzed. Results: Homes with mechanical ventilation achieved significantly Lower humidity levels than those without (P < .001), with an associated reduction of mite numbers (P < .05) and Her p 1 concentrations (P < .001 [in nanograms per gram], P = .006 [in milligrams per square meter]) in bedroom carpets and some other mite sources in the ventilated areas of the homes. The addition of a vacuum cleaner enhanced this effect. There was a trend for an improvement in histamine PC20 (P =.085) in the patients whose homes were ventilated. Conclusion: The use of a mechanical ventilation system in suitable homes resulted in some reduction in numbers of HDM and Der p 1 concentrations. The addition of an HEVC slightly enhanced the effect but not sufficiently to see an improvement in symptoms.	Univ Southampton, Sch Med, Allergy & Inflammat Sci Div Child Hlth, Southampton, Hants, England; Bldg Res Estab, Watford WD2 7JR, England; EA Technol, Capenhurst, England	University of Southampton	Warner, JO (corresponding author), Southampton Gen Hosp, Allergy & Inflammat Sci Div, Level G,Ctr Block,Tremona Rd, Southampton SO16 6YD, Hants, England.		Warner, John/AAF-9587-2020					ARLIAN LG, 1989, IMMUNOL ALLERGY CLIN, V9, P339; BERRY RW, 1996, 1996 BRE; BONER AL, 1993, CLIN EXP ALLERGY, V23, P1021, DOI 10.1111/j.1365-2222.1993.tb00294.x; Cox D.R, 1992, PLANNING EXPT; Fletcher AM, 1996, CLIN EXP ALLERGY, V26, P1051, DOI 10.1111/j.1365-2222.1996.tb00643.x; HENDRICK DJ, 1975, THORAX, V30, P2, DOI 10.1136/thx.30.1.2; KORSGAARD J, 1991, ALLERGY, V46, P14, DOI 10.1111/j.1398-9995.1991.tb00643.x; KORSGAARD J, 1983, ALLERGY, V38, P93, DOI 10.1111/j.1398-9995.1983.tb01592.x; KORSGAARD J, 1991, DUST MITE ALLERGENS, P87; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; MERRETT TG, 1980, ALLERGY, V35, P491, DOI 10.1111/j.1398-9995.1980.tb01796.x; Peat JK, 1996, AM J RESP CRIT CARE, V153, P141, DOI 10.1164/ajrccm.153.1.8542107; PERONI DG, 1994, AM J RESP CRIT CARE, V149, P1442, DOI 10.1164/ajrccm.149.6.8004296; POLAR G, 1971, PULMONARY FUNCTION T; QUANJER PH, 1989, EUR RESPIR J S, V4, P1845; Rao R, 1996, CLIN EXP ALLERGY, V26, P789; STEPHEN FR, 1997, BUILDING SERV ENG RE, V18, P141; TOVEY E, 1993, P C POW MUS 1993 15, P3; Warner JA, 1991, PEDIATR ALLERGY IMMU, V1, P79; WICKMAN M, 1994, CLIN EXP ALLERGY, V24, P109, DOI 10.1111/j.1365-2222.1994.tb00205.x	20	81	82	0	15	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2000	105	1	1				75	82		10.1016/S0091-6749(00)90181-7	http://dx.doi.org/10.1016/S0091-6749(00)90181-7			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	278LW	10629456				2022-12-18	WOS:000084992100011
J	Kaminsky, DA; Mitchell, J; Carroll, N; James, A; Soultanakis, R; Janssen, Y				Kaminsky, DA; Mitchell, J; Carroll, N; James, A; Soultanakis, R; Janssen, Y			Nitrotyrosine formation in the airways and lung parenchyma of patients with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; nitric oxide; nitrotyrosine; peroxynitrite	EXHALED NITRIC-OXIDE; IN-VIVO; PEROXYNITRITE; INFLAMMATION; INJURY; CHALLENGE; CELLS; AIR	Background: Recent evidence has shown that nitric oxide (NO) levels are increased in asthmatic airways. Although the role of NO in asthma is unknown, reactive metabolites of NO may lead to nitrotyrosine formation and promote airway dysfunction. Objective: The aim of this study was to determine whether nitrotyrosine, as a marker of nitrating species, could be found in the airways and lung parenchyma of subjects with asthma who died of status asthmaticus or other nonrespiratory causes. Methods: Lung tissue specimens were obtained from 5 patients who died of status asthmaticus, 2 asthmatic patients who died of nonrespiratory causes, and 6 nonasthmatic control subjects who died of nonrespiratory causes. Lung sections were stained for immunofluorescence with use of an antinitrotyrosine antibody, followed by a indiocarbocyanine (Cy5, Jackson Immunochemicals, Westgrove, Pa)-conjugated secondary antibody. Results: Nonasthmatic lungs showed little or no nitrotyrosine staining, whereas asthmatic lungs demonstrated significantly more staining of nitrotyrosine residues distributed in both the airways and lung parenchyma. Conclusion: This study demonstrates the presence of nitrotyrosine, and hence evidence of formation of nitrating species, in the airways and lung parenchyma of patients with asthma who died of status asthmaticus or other nonrespiratory causes, This finding supports the concept that widespread airway and parenchymal inflammation occurs in asthma, and, more specifically, that NO and its reactive metabolites may play a pathophysiologic role in asthma.	Univ Vermont, Coll Med, Div Pulm Dis & Crit Care Med, Dept Mol Physiol, Burlington, VT 05405 USA; Univ Vermont, Coll Med, Div Pulm Dis & Crit Care Med, Dept Biophys, Burlington, VT 05405 USA; Univ Vermont, Coll Med, Div Pulm Dis & Crit Care Med, Dept Pathol, Burlington, VT 05405 USA; Sir Charles Gairdiner Hosp, Dept Pulm Physiol, Nedlands, WA, Australia	University of Vermont; University of Vermont; University of Vermont	Kaminsky, DA (corresponding author), Univ Vermont, Coll Med, Div Pulm Dis & Crit Care Med, Dept Mol Physiol, Given C-317, Burlington, VT 05405 USA.				NHLBI NIH HHS [K08 HL03517] Funding Source: Medline; NIOSH CDC HHS [R03 OH03457] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003517] Funding Source: NIH RePORTER; NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH [R01OH003457] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIOSH CDC HHS; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USANational Institute for Occupational Safety & Health (NIOSH))		ALVING K, 1993, EUR RESPIR J, V6, P1368; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; CALHOUN WJ, 1990, J ALLERGY CLIN IMMUN, V86, P306, DOI 10.1016/S0091-6749(05)80092-2; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; Flak TA, 1996, AM J RESP CRIT CARE, V154, pS202, DOI 10.1164/ajrccm/154.4_Pt_2.S202; HADDAD IY, 1993, AM J PHYSIOL, V265, pL555, DOI 10.1152/ajplung.1993.265.6.L555; HADDAD IY, 1994, J CLIN INVEST, V94, P2407, DOI 10.1172/JCI117607; HOGMAN M, 1993, AM REV RESPIR DIS, V148, P1474; Jatakanon A, 1998, THORAX, V53, P91, DOI 10.1136/thx.53.2.91; Kageyama N, 1997, EUR RESPIR J, V10, P13, DOI 10.1183/09031936.97.10010013; Kaminsky DA, 1997, AM J RESP CRIT CARE, V155, P1260, DOI 10.1164/ajrccm.155.4.9105064; KHARITONOV SA, 1994, LANCET, V343, P133, DOI 10.1016/S0140-6736(94)90931-8; KHARITONOV SA, 1995, AM J RESP CRIT CARE, V152, P609, DOI 10.1164/ajrccm.152.2.7543345; KHARITONOV SA, 1995, AM J RESP CRIT CARE, V151, P1894, DOI 10.1164/ajrccm.151.6.7767537; KOOY NW, 1995, AM J RESP CRIT CARE, V151, P1250; Kraft M, 1996, AM J RESP CRIT CARE, V154, P1505, DOI 10.1164/ajrccm.154.5.8912772; LAITINEN LA, 1993, AM REV RESPIR DIS, V147, P697, DOI 10.1164/ajrccm/147.3.697; MACKLEM PT, 1989, EUR RESPIR J S2, V2, P516; Muller T, 1997, CARCINOGENESIS, V18, P295, DOI 10.1093/carcin/18.2.295; SadeghiHashjin G, 1996, AM J RESP CRIT CARE, V153, P1697, DOI 10.1164/ajrccm.153.5.8630623; Saleh D, 1998, FASEB J, V12, P929, DOI 10.1096/fasebj.12.11.929; Saleh D, 1997, AM J RESP CRIT CARE, V155, P1763, DOI 10.1164/ajrccm.155.5.9154889; WENZEL SE, 1988, AM REV RESPIR DIS, V137, P1002, DOI 10.1164/ajrccm/137.5.1002	24	81	82	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1999	104	4	1				747	754		10.1016/S0091-6749(99)70283-6	http://dx.doi.org/10.1016/S0091-6749(99)70283-6			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	248NG	10518817	Bronze			2022-12-18	WOS:000083281200004
J	Fukagawa, K; Nakajima, T; Tsubota, K; Shimmura, S; Saito, H; Hirai, K				Fukagawa, K; Nakajima, T; Tsubota, K; Shimmura, S; Saito, H; Hirai, K			Presence of eotaxin in tears of patients with atopic keratoconjunctivitis with severe corneal damage	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							CHEMOATTRACTANT; CELLS		Natl Childrens Med Res Ctr, Dept Allergy & Immunol, Setagaya Ku, Tokyo 1548509, Japan; Tokyo Dent Coll, Dept Ophthalmol, Chiba, Japan; Univ Tokyo, Grad Sch Med, Dept Bioregulatory Funct, Tokyo, Japan	National Center for Child Health & Development - Japan; Tokyo Dental College; University of Tokyo	Saito, H (corresponding author), Natl Childrens Med Res Ctr, Dept Allergy & Immunol, Setagaya Ku, 3-35-31 Taishido, Tokyo 1548509, Japan.		Shimmura, Shigeto/J-4678-2013	Saito, Hirohisa/0000-0002-6630-8337				GarciaZepeda EA, 1996, NAT MED, V2, P449, DOI 10.1038/nm0496-449; JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881; Nakajima T, 1998, FEBS LETT, V434, P226, DOI 10.1016/S0014-5793(98)00863-1; Sakata M, 1997, CURR EYE RES, V16, P810, DOI 10.1076/ceyr.16.8.810.8992; Trocme SD, 1997, INVEST OPHTH VIS SCI, V38, P593	5	81	87	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1999	103	6					1220	1221		10.1016/S0091-6749(99)70206-X	http://dx.doi.org/10.1016/S0091-6749(99)70206-X			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	207GT	10359913				2022-12-18	WOS:000080929500040
J	Cohen, JJ				Cohen, JJ			Apoptosis: Mechanisms of life and death in the immune system	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						apoptosis; autoimmune lymphoproliferative syndrome; Bcl-2; calpain; caspase; glucocorticoids; necrosis; phosphatidylserine	PROGRAMMED CELL-DEATH; AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME; T-CELLS; THYMOCYTE APOPTOSIS; LYMPHOCYTES; RECOGNITION; ELEGANS; BCL-2; PHOSPHATIDYLSERINE; ENDONUCLEASE	When normal cells die, it is almost always by the process of apoptosis, which is a morphologic description. Some cells die readily and are rapidly replaced; others live as long as we do. Because apoptotic morphology is similar from cell to cell, researchers have embarked on an intense search for a common underlying biochemical process. There is an apoptotic mechanism or cell death program, which is expressed in embryos and throughout life. Most tissues, and especially the skin, gut, and immune system, depend on well-ordered apoptosis and cell replacement. Apoptosis can fail to occur, as in the newly described autoimmune lymphoproliferative syndrome, or be turned on pathologically, as in degenerative diseases, We would like to induce apoptosis in dangerous cells or block it to preserve valuable cells. We need to know more about how apoptosis is regulated and what we can do to influence the process.	Univ Colorado, Sch Med, Dept Immunol, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Cohen, JJ (corresponding author), Univ Colorado, Sch Med, Dept Immunol, B-184, Denver, CO 80262 USA.			Cohen, J. John/0000-0003-1772-8236				Ameisen J C, 1995, Curr Top Microbiol Immunol, V200, P195; Anderson R E, 1976, Adv Immunol, V24, P215, DOI 10.1016/S0065-2776(08)60331-4; Bartus RT, 1998, BRAIN RES, V790, P1, DOI 10.1016/S0006-8993(97)01414-5; Bortner CD, 1996, AM J PHYSIOL-CELL PH, V271, pC950, DOI 10.1152/ajpcell.1996.271.3.C950; Burek MJ, 1996, BRAIN PATHOL, V6, P427, DOI 10.1111/j.1750-3639.1996.tb00874.x; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; COHEN JJ, 1984, J IMMUNOL, V132, P38; CONNOR J, 1991, BIOCHIM BIOPHYS ACTA, V1066, P37, DOI 10.1016/0005-2736(91)90247-6; COSTERO I, 1951, AM J ANAT, V89, P405, DOI 10.1002/aja.1000890304; DUKE RC, 1986, LYMPHOKINE RES, V5, P289; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; FADOK VA, 1992, J IMMUNOL, V148, P2207; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; FINKEL TH, 1994, CURR OPIN IMMUNOL, V6, P605, DOI 10.1016/0952-7915(94)90149-X; GODMAN GC, 1975, J CELL BIOL, V64, P644, DOI 10.1083/jcb.64.3.644; HALL SE, 1994, J IMMUNOL, V153, P3218; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Hurle JM, 1996, MICROSC RES TECHNIQ, V34, P236; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Lim MS, 1998, AM J PATHOL, V153, P1541, DOI 10.1016/S0002-9440(10)65742-2; MATSUYAMA M, 1966, J EXP MED, V123, P559, DOI 10.1084/jem.123.3.559; MEAGHER LC, 1992, J LEUKOCYTE BIOL, V52, P269, DOI 10.1002/jlb.52.3.269; MERRITT AJ, 1995, J CELL SCI, V108, P2261; Metzstein MM, 1998, TRENDS GENET, V14, P410, DOI 10.1016/S0168-9525(98)01573-X; Minn AJ, 1998, ADV IMMUNOL, V70, P245, DOI 10.1016/S0065-2776(08)60388-0; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; NEWELL MK, 1990, NATURE, V347, P286, DOI 10.1038/347286a0; Potten CS, 1996, BRIT J CANCER, V74, P1743, DOI 10.1038/bjc.1996.624; Pradhan D, 1997, MOL BIOL CELL, V8, P767, DOI 10.1091/mbc.8.5.767; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Reed John C., 1995, Current Opinion in Oncology, V7, P541, DOI 10.1097/00001622-199511000-00012; SAVILL J, 1993, IMMUNOL TODAY, V14, P131, DOI 10.1016/0167-5699(93)90215-7; SELLINS KS, 1987, J IMMUNOL, V139, P3199; SHORTMAN K, 1974, CELL IMMUNOL, V12, P230, DOI 10.1016/0008-8749(74)90075-6; Sneller MC, 1997, BLOOD, V89, P1341, DOI 10.1182/blood.V89.4.1341; SQUIER MKT, 1994, J CELL PHYSIOL, V159, P229, DOI 10.1002/jcp.1041590206; Squier MKT, 1997, J IMMUNOL, V158, P3690; Stern M, 1996, AM J PATHOL, V149, P911; STRATLING WH, 1981, BIOCHEMISTRY-US, V20, P1386, DOI 10.1021/bi00508a054; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Tolosa E, 1998, IMMUNITY, V8, P67, DOI 10.1016/S1074-7613(00)80459-8; Vacchio MS, 1998, ANN NY ACAD SCI, V840, P317, DOI 10.1111/j.1749-6632.1998.tb09571.x; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Xue D, 1996, GENE DEV, V10, P1073, DOI 10.1101/gad.10.9.1073; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H	47	81	83	0	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1999	103	4					548	554		10.1016/S0091-6749(99)70222-8	http://dx.doi.org/10.1016/S0091-6749(99)70222-8			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	186HY	10199999				2022-12-18	WOS:000079723900002
J	van Ree, R; van Leeuwen, A; Aalberse, RC				van Ree, R; van Leeuwen, A; Aalberse, RC			How far can we simplify in vitro diagnostics for grass pollen allergy?: A study with 17 whole pollen extracts and purified natural and recombinant major allergens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						grass pollen allergy; diagnostics; purified allergens; recombinant allergens; group 1 allergen; group 5 allergen	PHLEUM-PRATENSE POLLEN; GROUP-I ALLERGENS; GROUP-V ALLERGENS; CROSS-REACTIVITY; P-I; PRACTICAL ASPECTS; IGE ANTIBODIES; BIRCH POLLEN; SKIN-TEST; CLONING	Background: Current diagnostics for grass pollen allergy are composed of mixtures of pollen of different grass species. Their complex composition hampers accurate standardization. Objective: The aim of the study was to investigate whether mixtures of grass pollen extracts can be replaced by a single pollen species and whether a single pollen species can be replaced by a limited number of purified natural or recombinant major allergens, Methods: Sera (n = 800) were selected on the basis of a general suspicion for inhalant allergy and tested in a RAST for IgE reactivity with pollen from 17 different grass species. Cross-reactivity of IgE responses was studied by means of RAST inhibition. Sera with positive test results for grass pollen were tested in a RAST for natural Lol p 1 and Lol p 5 and recombinant Phl p 1 and Phl p 5. Results: Specific IgE antibodies against one or more of the 17 pollen species were detected in 209 of 800 sera (26.1%). The highest responses were observed against Poa pratensis followed by Festuca rubra, Phleum pratense, and Dactylis glomerata, IgE responses were clearly lower (approximately by a factor of 5) against only three species (Phragmites communis, Cynodon dactylon, and Zea mays). With the exception of a few low-responder sera, no sera were found to have negative test results to the high responder species and positive results to any of the other species. Sera with positive test results for grass pollen (n = 154) were tested with purified Lol p 1 and Lol p 5, IgE anti-Lol p 1 and Lol p 5 accounted for an average of 81% +/- 7% of total anti-grass pollen IgE, For 14 sera (all with low anti-grass pollen IgE titers), a RAST with purified allergens resulted in a false-negative diagnosis for grass pollen allergy. With recombinant Phl p 1 and Phl p 5, the mean IgE reactivity was 57% +/- 6% of the anti-grass pollen IgE response (n = 141), with 13 false-negative results. Conclusion: One grass species is sufficient for in vitro diagnosis of grass pollen allergy, With purified natural Lol p 1 and Lol p 5, greater than 90% of grass-positive sera is detected. Around 80% of the IgE response to grass pollen is directed to these major allergens. Recombinant allergens, produced in Escherichia coli, did not equal the IgE-binding capacity of their natural counterparts.	CLB, Sanquin Blood Supply Fdn, Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Expt & Clin Immunol Lab, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam	van Ree, R (corresponding author), CLB, Dept Allergy, Plesmanlaan 125, NL-1066 CX Amsterdam, Netherlands.							AALBERSE RC, 1981, J ALLERGY CLIN IMMUN, V68, P356, DOI 10.1016/0091-6749(81)90133-0; [Anonymous], 1997, J ALLERGY CLIN IMMUN, V99, P583; Cosgrove DJ, 1997, P NATL ACAD SCI USA, V94, P6559, DOI 10.1073/pnas.94.12.6559; DRIESSEN MNB, 1988, POLLENATLAS NEDERLAN; ESCH RE, 1987, J ALLERGY CLIN IMMUN, V79, P489, DOI 10.1016/0091-6749(87)90367-8; FREIDHOFF LR, 1986, J ALLERGY CLIN IMMUN, V78, P1190, DOI 10.1016/0091-6749(86)90271-X; GONZALEZ RM, 1987, ANN ALLERGY, V59, P149; LAFFER S, 1994, J ALLERGY CLIN IMMUN, V94, P689, DOI 10.1016/0091-6749(94)90176-7; Laffer S, 1996, MOL IMMUNOL, V33, P417, DOI 10.1016/0161-5890(95)00152-2; LEIFERMAN KM, 1976, J ALLERGY CLIN IMMUN, V58, P129, DOI 10.1016/0091-6749(76)90148-2; MARTIN BG, 1985, ANN ALLERGY, V54, P99; MATTHIESEN F, 1991, CLIN EXP ALLERGY, V21, P309, DOI 10.1111/j.1365-2222.1991.tb01662.x; Menz G, 1996, CLIN EXP ALLERGY, V26, P50, DOI 10.1111/j.1365-2222.1996.tb00056.x; MOHAPATRA SS, 1992, INT ARCH ALLERGY IMM, V99, P265, DOI 10.1159/000236262; OLSEN E, 1994, ANN ALLERGY, V72, P499; Pauli G, 1996, J ALLERGY CLIN IMMUN, V97, P1100, DOI 10.1016/S0091-6749(96)70264-6; PEREZ M, 1990, J BIOL CHEM, V265, P16210; PHAM NH, 1995, CLIN EXP ALLERGY, V25, P599, DOI 10.1111/j.1365-2222.1995.tb01107.x; SCHEINER O, 1995, ALLERGY, V50, P384, DOI 10.1111/j.1398-9995.1995.tb01167.x; SCHEINER O, 1992, INT ARCH ALLERGY IMM, V98, P93, DOI 10.1159/000236170; SMITH PM, 1994, MOL IMMUNOL, V31, P491, DOI 10.1016/0161-5890(94)90068-X; SRIDHARA S, 1995, ANN ALLERG ASTHMA IM, V75, P73; Stewart GA, 1996, CLIN EXP ALLERGY, V26, P1020, DOI 10.1111/j.1365-2222.1996.tb00641.x; VALENTA R, 1992, INT ARCH ALLERGY IMM, V97, P287, DOI 10.1159/000236135; VALENTI JAM, 1995, ENCYC ENVIR, V7, P1; VANREE R, 1992, CLIN EXP ALLERGY, V22, P611; vanRee R, 1997, ALLERGY, V52, P795; VANREE R, 1989, J ALLERGY CLIN IMMUN, V83, P144, DOI 10.1016/0091-6749(89)90489-2; VRTALA S, 1993, J IMMUNOL, V151, P4773; WEBER RW, 1985, CLIN REV ALLERG, V3, P291, DOI 10.1007/BF02992997	30	81	86	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1998	102	2					184	190		10.1016/S0091-6749(98)70084-3	http://dx.doi.org/10.1016/S0091-6749(98)70084-3			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	113EH	9723659				2022-12-18	WOS:000075537100006
J	Matsumoto, K; Hashimoto, S; Gon, Y; Nakayama, T; Horie, T				Matsumoto, K; Hashimoto, S; Gon, Y; Nakayama, T; Horie, T			Proinflammatory cytokine-induced and chemical mediator-induced IL-8 expression in human bronchial epithelial cells through p38 mitogen-activated protein kinase-dependent pathway	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						tumor necrosis factor-alpha; IL-1 alpha; platelet-activating factor; p38 mitogen-activated protein kinase; bronchial epithelial cells	TUMOR-NECROSIS-FACTOR; EOSINOPHIL ACCUMULATION; INFLAMMATORY CYTOKINES; ASTHMA; INTERLEUKIN-1; PHOSPHORYLATION; RELEASE; CASCADE; STRESS; ALPHA	The p38 mitogen-activated protein (MAP) kinase is activated in various cells by proinflammatory cytokines and environmental stresses. However, little is known about the role of p38 MAP kinase in proinflammatory cytokine- and chemical mediator-induced cytokine expression in human bronchial epithelial cells (BECs), In this study we examined the role of p38 MAP kinase in IL-8 expression in BECs to clarify the signal transduction pathway regulating IL-8 expression in BECs stimulated with tumor necrosis factor-alpha (TNF-alpha), IL-1 alpha, and platelet-activating factor (PAF). We used TNF-a, IL-la, and PAF as inducers for the analysis of the signal transduction pathway and determined IL-8 expression in BECs because TNF-alpha, IL-1 alpha, and PAF are known to induce cytokine expression in BECs, and these proinflammatory cytokines and PAF are described to have a role in the production of allergic inflammation. The results showed that TNF-alpha, IL-1 alpha, and PAF induced tyrosine phosphorylation of p38 MAP kinase in a dose- and time-dependent manner. The specific p38 MAP kinase inhibitor, SB 203580, completely inhibited TNF-alpha-, IL-1 alpha-, or PAF-induced IL-8 protein and mRNA expression in BECs, These results indicated that p38 MAP kinase plays an important role in TNF-alpha- IL-1 alpha-, or PAF-activated signaling pathway, which regulates IL-8 expression in BECs, In addition, these results provide new evidence on a strategy for treatment of airway inflammation with the specific p38 MAP kinase inhibitor.	Nihon Univ, Sch Med, Dept Internal Med 1, Itabashi Ku, Tokyo 173, Japan	Nihon University	Hashimoto, S (corresponding author), Nihon Univ, Sch Med, Dept Internal Med 1, Itabashi Ku, 30-1 Oyaguchikamimachi, Tokyo 173, Japan.							[Anonymous], 1987, AM REV RESPIR DIS, V136, P225; ARM JP, 1992, ADV IMMUNOL, V51, P323, DOI 10.1016/S0065-2776(08)60491-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BELLINI A, 1993, J ALLERGY CLIN IMMUN, V92, P412, DOI 10.1016/0091-6749(93)90120-5; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; BORISH L, 1992, MED CLIN N AM, V76, P765, DOI 10.1016/S0025-7125(16)30325-X; COLLINS PD, 1993, IMMUNOLOGY, V79, P312; CORRIGAN CJ, 1992, IMMUNOL TODAY, V13, P501, DOI 10.1016/0167-5699(92)90026-4; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; Foltz IN, 1997, J BIOL CHEM, V272, P3296, DOI 10.1074/jbc.272.6.3296; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; HALLSWORTH MP, 1994, EUR RESPIR J, V7, P1096; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HERNANDEZ A, 1991, PHARMACOL RES, V24, P385, DOI 10.1016/1043-6618(91)90043-W; Hobbie S, 1997, J IMMUNOL, V159, P5550; KAY AB, 1991, J ALLERGY CLIN IMMUN, V87, P893, DOI 10.1016/0091-6749(91)90408-G; KIPS JC, 1992, AM REV RESPIR DIS, V145, P332, DOI 10.1164/ajrccm/145.2_Pt_1.332; KWON OJ, 1994, IMMUNOLOGY, V81, P389; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEVINE SJ, 1995, J INVEST MED, V43, P241; MARINI M, 1991, AM J RESP CELL MOL, V4, P519, DOI 10.1165/ajrcmb/4.6.519; MARINI M, 1992, J ALLERGY CLIN IMMUN, V89, P1257; Moriguchi T, 1996, J BIOL CHEM, V271, P26981, DOI 10.1074/jbc.271.43.26981; MUKAIDA N, 1989, J IMMUNOL, V143, P1366; Nick JA, 1996, J IMMUNOL, V156, P4867; Pandey P, 1996, J BIOL CHEM, V271, P23775, DOI 10.1074/jbc.271.39.23775; Pietersma A, 1997, BIOCHEM BIOPH RES CO, V230, P44, DOI 10.1006/bbrc.1996.5886; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SHAH A, 1995, CLIN EXP ALLERGY, V25, P1038; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; TAKIZAWA H, 1992, BIOCHEM BIOPH RES CO, V187, P596, DOI 10.1016/0006-291X(92)91236-J; TAKIZAWA H, 1995, INT ARCH ALLERGY IMM, V108, P260, DOI 10.1159/000237162; THOMAS PS, 1983, METHOD ENZYMOL, V100, P255; Walters E H, 1996, Respirology, V1, P233, DOI 10.1111/j.1440-1843.1996.tb00039.x; WANE XZ, 1996, SCIENCE, V272, P1347; WATSON ML, 1993, AM J RESP CELL MOL, V8, P365, DOI 10.1165/ajrcmb/8.4.365; Wesselborg S, 1997, J BIOL CHEM, V272, P12422, DOI 10.1074/jbc.272.19.12422	41	81	87	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1998	101	6	1				825	831		10.1016/S0091-6749(98)70311-2	http://dx.doi.org/10.1016/S0091-6749(98)70311-2			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZW470	9648711				2022-12-18	WOS:000074414200018
J	Schuurman, J; Perdok, GJ; Lourens, TE; Parren, PWHI; Chapman, MD; Aalberse, RC				Schuurman, J; Perdok, GJ; Lourens, TE; Parren, PWHI; Chapman, MD; Aalberse, RC			Production of a mouse/human chimeric IgE monoclonal antibody to the house dust mite allergen Der p 2 and its use for the absolute quantification of allergen-specific IgE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IgE; chimeric antibody; Der p 2; RAST; house dust mite; allergen-specific IgE	DERMATOPHAGOIDES; EXPRESSION; CLONING; GENES	A chimeric human IgE monoclonal antibody was developed against the house dust mite allergen Der p 2. This chimeric antibody (hIgE-Dp2A) was composed of the heavy-chain variable domains and light chains of the original murine monoclonal antibody retaining its binding characteristics, whereas the heavy-chain constant domains were exchanged with the human IgE heavy chain. The chimeric IgE expression level was IgE 600 IU/ml (1 IU = 2.4 ng/ml). The binding of the chimeric hIgE-Dp2A to mite extract was indistinguishable from that of the original mouse monoclonal antibody, Parallel dose-response curves were found when the binding of hIgE-Dp2A to mite extract and anti-IgE coupled to sepharose were compared. Binding levels were not identical; however, hIgE-Dp2A bound significantly better to the mite-extract sepharose. This result indicates that the commonly used anti-IgE on solid phase calibration systems may lead to an overestimation of the amount of allergen-specific IgE present in the serum sample. The less efficient binding of the detector anti-IgE in case of the anti-IgE sepharose is likely to be because of the occupation of epitopes of the IgE by the sepharose-bound anti-IgE. Dose-response curves of serial dilutions of patient samples were parallel with the hIgE-Dp2A dose-response curve, which indicates that hIgE-Dp2A behaves like natural IgE antibodies in binding to allergen coupled to solid phase. This antibody is well suited for use as a reference reagent in the RAST and enables the expression of the amount of allergen-specific IgE present in a patient sample in absolute amounts.	NETHERLANDS RED CROSS, BLOOD TRANSFUS SERV, CENT LAB, DEPT ALLERGY, NL-1066 CX AMSTERDAM, NETHERLANDS; UNIV AMSTERDAM, EXPT & CLIN IMMUNOL LAB, AMSTERDAM, NETHERLANDS; Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; UNIV VIRGINIA, ASTHMA & ALLERG DIS CTR, CHARLOTTESVILLE, VA USA	University of Amsterdam; Scripps Research Institute; University of Virginia				Chapman, Martin/0000-0002-0845-3632; Parren, Paul/0000-0002-4365-3859	NIAID NIH HHS [AI 34607] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI034607, U19AI034607] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AALBERSE RC, 1981, J ALLERGY CLIN IMMUN, V68, P356, DOI 10.1016/0091-6749(81)90133-0; BAZARAL M, 1972, J ALLERGY CLIN IMMUN, V49, P189, DOI 10.1016/0091-6749(72)90113-3; BOOT JHA, 1989, THESIS U AMSTERDAM A, P47; BOOT JHA, 1988, J IMMUNOL METHODS, V106, P95; BRAKENHOFF JPJ, 1987, J IMMUNOL, V139, P4116; BRUGGEMANN M, 1987, J EXP MED, V166, P1351, DOI 10.1084/jem.166.5.1351; FLANAGAN JG, 1982, NATURE, V300, P709, DOI 10.1038/300709a0; FLANAGAN JG, 1982, EMBO J, V1, P655, DOI 10.1002/j.1460-2075.1982.tb01223.x; LIND P, 1985, J ALLERGY CLIN IMMUN, V76, P753, DOI 10.1016/0091-6749(85)90682-7; NEUBERGER MS, 1985, NATURE, V314, P268, DOI 10.1038/314268a0; ORLANDI R, 1989, P NATL ACAD SCI USA, V86, P3833, DOI 10.1073/pnas.86.10.3833; OVSYANNIKOVA IG, 1994, J ALLERGY CLIN IMMUN, V94, P537, DOI 10.1016/0091-6749(94)90211-9; PARREN PWHI, 1991, RES IMMUNOL, V142, P749, DOI 10.1016/0923-2494(91)90121-X; Sambrook J, 1989, MOL CLONING LAB MANU; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; WIDE L, 1967, LANCET, V2, P1105	16	81	84	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1997	99	4					545	550		10.1016/S0091-6749(97)70083-6	http://dx.doi.org/10.1016/S0091-6749(97)70083-6			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WU274	9111501				2022-12-18	WOS:A1997WU27400019
J	vanderVeen, MJ; Mulder, M; Witteman, AM; vanRee, R; Aalberse, RC; Jansen, HM; vanderZee, JS				vanderVeen, MJ; Mulder, M; Witteman, AM; vanRee, R; Aalberse, RC; Jansen, HM; vanderZee, JS			False-positive skin prick test responses to commercially available dog dander extracts caused by contamination with house dust mite (Dermatophagoides pteronyssinus) allergens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						skin prick test; dog dander; Dermatophagoides pteronyssinus; RAST	DER-II; INTERNATIONAL STANDARD	Background: In an outpatient population, a high frequency of positive skin prick test responses to dog dander was found in the absence of detectable IgE to dog dander in the RAST The majority of these patients were sensitized to house dust mites (Dermatophagoides pteronyssinus) and had no obvious dog-related allergic symptoms. These findings prompted us to investigate whether dog dander skin test preparations are contaminated with house dust mite allergens in amounts sufficient to cause false-positive skin prick test responses in patients sensitized to house dust mites. Methods: Antigen detection assays with monoclonal and polyclonal antibodies were rued to determine concentrations of the major allergen Can f 1 from dog dander and the major allergens Der p 1 and Der p 2 from house dust mites in five commercially available dog dander skin prick test preparations (A to E). Results: Can f 1 concentrations varied for the different extracts (A: 170 mu g/ml B: 11.1 mu g/ml, C: 13.3 mu g/ml, D: 3.8 mu g/ml, and E: 59.4 mu g/ml). Der p 1 was detectable in all extracts (A: 33.4 ng/ml, B: 5.1 ng/ml, C: 29.6 ng/ml, D: 0.4 ng/ml, and E: 1.9 ng/ml), and Der p 2 was detectable in some of the commercially available dog dander skin prick test preparations rested (A. 31.3 ng/ml, B: 3.0 ng/ml, and C: 7.5 ng/ml). The median house dust mite threshold in the skin prick test was found to be 5.8 ng/ml of Der p 1 (range, 3.5 to 20.8 ng/ml) in nine patients rested. Conclusion: Contamination of commercially available dog dander skin pride test preparations with the major allergens (Der p 1 and Der p 2) of the house dust mite (D. pteronyssinus) was demonstrated. These contaminations cause false-positive responses to skin prick tests with dog dander in patients sensitized to house dust mite.	UNIV AMSTERDAM,ACAD MED CTR,DEPT PULMONOL,NL-1105 AZ AMSTERDAM,NETHERLANDS; NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,DEPT ALLERGY,AMSTERDAM,NETHERLANDS	University of Amsterdam; Academic Medical Center Amsterdam			van der Zee, Jaring/AAQ-6669-2021; van der Zee, Jaring S/M-8462-2013; van der Zee, Jaring/HGU-9235-2022	van der Zee, Jaring S/0000-0002-8698-6039; 				AALBERSE RC, 1981, J ALLERGY CLIN IMMUN, V68, P356, DOI 10.1016/0091-6749(81)90133-0; AALBERSE RC, 1986, J IMMUNOL METHODS, V87, P51, DOI 10.1016/0022-1759(86)90343-1; CHAPMAN MD, 1980, J IMMUNOL, V125, P587; DREBORG S, 1993, ALLERGY, V48, P49, DOI 10.1111/j.1398-9995.1993.tb04756.x; FORD A, 1985, J ALLERGY CLIN IMMUN, V75, P676, DOI 10.1016/0091-6749(85)90093-4; LARSEN JN, 1988, J ALLERGY CLIN IMMUN, V82, P318, DOI 10.1016/0091-6749(88)90002-4; LINNA O, 1994, ALLERGY, V49, P795, DOI 10.1111/j.1398-9995.1994.tb02107.x; MEYER CH, 1994, CLIN EXP ALLERGY, V24, P1041, DOI 10.1111/j.1365-2222.1994.tb02741.x; PLATTSMILLS TAE, 1991, DUST MITE ALLERGENS, P12; SAKAGUCHI M, 1993, J ALLERGY CLIN IMMUN, V92, P797, DOI 10.1016/0091-6749(93)90056-L; SAKAGUCHI M, 1989, INT ARCH ALLER A IMM, V90, P190, DOI 10.1159/000235022; VANDERZEE JS, 1988, J ALLERGY CLIN IMMUN, V81, P884, DOI 10.1016/0091-6749(88)90946-3; VANREE R, 1994, ARB PEI GSH, V87, P127; Witteman AM, 1996, J ALLERGY CLIN IMMUN, V97, P16, DOI 10.1016/S0091-6749(96)70278-6; YASUEDA H, 1989, INT ARCH ALLER A IMM, V90, P182, DOI 10.1159/000235021	15	81	81	1	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1996	98	6	1				1028	1034		10.1016/S0091-6749(96)80187-4	http://dx.doi.org/10.1016/S0091-6749(96)80187-4			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WB378	8977501				2022-12-18	WOS:A1996WB37800005
J	Witteman, AM; Stapel, SO; Perdok, GJ; Sjamsoedin, DHS; Jansen, HM; Aalberse, RC; vanderZee, JS				Witteman, AM; Stapel, SO; Perdok, GJ; Sjamsoedin, DHS; Jansen, HM; Aalberse, RC; vanderZee, JS			The relationship between RAST and skin test results in patients with asthma or rhinitis: A quantitative study with purified major allergens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						RAST; skin test; Der p 1; Der 2 Fel d 1; Lol p 1,; Lol p 5; potency	FEL-D-I; HISTAMINE-RELEASE; MITE ALLERGEN; IGE; ANTIBODIES; PURIFICATION; BASOPHILS; EXTRACT; POLLEN	Background: Study of the relationship between skin test results and IgE antibody levels is seriously hampered by the use of conventional allergen extracts because the precise amount of relevant allergen for each patient is unknown. Objective: This study was designed to investigate skin reactivity with purified major allergens and to assess the relation with serum levels of IgE antibodies and to determine which additional factors contribute to the skirt test result. Methods: We used five purified major allergens (Der p 1, Der p 2, Fel d 1, Lol p 1, and Lol p 5) in skin tests, RASTs, and histamine release tests in 43 multisensitized patients with asthma or rhinitis. Results: The differences in biologic activity of the five major allergens at a given level of specific IgE art within one order of magnitude. A significant residual variation remains in the correlation between skin test the results and levels of IgE antibodies, which cannot be explained by imprecision of both tests (Pearson log skirt test vs log specific IgE: r = -0.46-0.92). With similar levels of specific IgE, the amount of allergen that is required for a positive skin test result may differ by as which as a factor of 100 between patients. The amount of total IgE in serum contributes significantly to the skirl test result. High values of total IgE are accompanied by a lower skin reactivity for allergen. Within individuals, allergens that cause skin test results that deviate from the prediction based on IgE antibody level often show a similar deviation in the histamine release test. This indicates that die type of lgE response (i.e., affinity or epitope recognition pattern) contributes significantly to the skin test result. Skin reactivity for histamine does nor significantly influence the skin reactions expressed as allergen threshold However; increased skin reactions with higher allergen dosages depend on histamine reactivity. Conclusion: The major allergens tested show similar biologic activities. In addition to IgE antibody level, total serum IgE and type of IgE antibody response contribute significantly to rite skirt test threshold for allergens. Even in a system with purified allergens, IgE antibody levels and skin test results are not interchangeable as an indicator of the degree of allergic sensitization.	UNIV AMSTERDAM,ACAD MED CTR,DEPT PULMONOL,1100 DE AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,DEPT OTORHINOLARYNGOL,1100 DE AMSTERDAM,NETHERLANDS; NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,CENT LAB,EXPTL & CLIN IMMUNOL LAB,AMSTERDAM,NETHERLANDS	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam			van der Zee, Jaring/AAQ-6669-2021; van der Zee, Jaring S/M-8462-2013; van der Zee, Jaring/HGU-9235-2022	van der Zee, Jaring S/0000-0002-8698-6039; 				AALBERSE RC, 1981, J ALLERGY CLIN IMMUN, V68, P356, DOI 10.1016/0091-6749(81)90133-0; AALBERSE RC, 1976, PROTIDES BIOL FLUIDS, P725; BAZARAL M, 1973, CLIN EXP IMMUNOL, V14, P117; BENYON RC, 1987, J IMMUNOL, V138, P861; BERTHER T, 1980, SCHWEIZ MED WSCHR, V110, P758; BRYANT D H, 1975, Clinical Allergy, V5, P145, DOI 10.1111/j.1365-2222.1975.tb01847.x; CASOLARO V, 1990, AM REV RESPIR DIS, V142, P1106; CHAPMAN MD, 1980, J IMMUNOL, V125, P587; CHUA KY, 1990, INT ARCH ALLER A IMM, V91, P118, DOI 10.1159/000235101; COCKCROFT DW, 1987, AM REV RESPIR DIS, V135, P264; DEBLAY F, 1991, J ALLERGY CLIN IMMUN, V88, P919, DOI 10.1016/0091-6749(91)90249-N; DEGROOT H, 1988, J ALLERGY CLIN IMMUN, V82, P778, DOI 10.1016/0091-6749(88)90079-6; DEMBO M, 1978, J IMMUNOL, V121, P345; DREBORG S, 1992, ALLERGY, V14, P49; ERIKSSON NE, 1989, ANN ALLERGY, V63, P65; FINDLEY SR, 1993, AM REV RESPIR DIS, V122, P53; FORD A, 1985, J ALLERGY CLIN IMMUN, V75, P676, DOI 10.1016/0091-6749(85)90093-4; GODFREY R C, 1975, Clinical Allergy, V5, P201, DOI 10.1111/j.1365-2222.1975.tb01853.x; GODFREY RC, 1976, NATURE, V259, P484, DOI 10.1038/259484a0; JENNRICH RI, 1986, BIOMETRICS, V42, P805, DOI 10.2307/2530695; KOENDERMAN L, 1989, J IMMUNOL, V142, P623; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; LYNCH NR, 1993, J ALLERGY CLIN IMMUN, V92, P404, DOI 10.1016/0091-6749(93)90119-Z; MARONE G, 1981, INT ARCH ALLER A IMM, V65, P339, DOI 10.1159/000232773; MCGLASHAN D, 1983, J IMMUNOL, V130, P2330; MERRETT TG, 1976, CLIN ALLERGY, V6, P131, DOI 10.1111/j.1365-2222.1976.tb01890.x; MIYAMOTO T, 1974, J ALLERGY CLIN IMMUN, V53, P9, DOI 10.1016/0091-6749(74)90094-3; NORMAN PS, 1973, J ALLERGY CLIN IMMUN, V52, P210, DOI 10.1016/0091-6749(73)90059-6; NORMAN PS, 1973, J ALLERGY CLIN IMMUN, V52, P94, DOI 10.1016/0091-6749(73)90081-X; PLATTSMILLS TAE, 1991, DUST MITE ALLERGENS, P1; SIRAGANIAN RP, 1975, J IMMUNOL METHODS, V7, P283, DOI 10.1016/0022-1759(75)90025-3; SMITH TF, 1992, ANN ALLERGY, V68, P293; STENIUS B, 1971, Clinical Allergy, V1, P37, DOI 10.1111/j.1365-2222.1971.tb02446.x; STUBER D, 1990, IMMUNOLOGICAL METHOD, V4, P121; TURKELTAUB PC, 1982, J ALLERGY CLIN IMMUN, V70, P343, DOI 10.1016/0091-6749(82)90023-9; VANDERZEE JS, 1988, J ALLERGY CLIN IMMUN, V81, P884, DOI 10.1016/0091-6749(88)90946-3; VANREE R, 1989, J ALLERGY CLIN IMMUN, V83, P144, DOI 10.1016/0091-6749(89)90489-2; VOORHORST R, 1980, ALLERGY, V35, P247, DOI 10.1111/j.1398-9995.1980.tb01762.x; WEISS ME, 1989, J ALLERGY CLIN IMMUN, V83, P1040, DOI 10.1016/0091-6749(89)90445-4; WRIGHT SP, 1992, BIOMETRICS, V48, P1005, DOI 10.2307/2532694; 1987, AM REV RESPIR DIS, V137, P225	41	81	82	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1996	97	1	1				16	25		10.1016/S0091-6749(96)70278-6	http://dx.doi.org/10.1016/S0091-6749(96)70278-6			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TR947	8568133				2022-12-18	WOS:A1996TR94700003
J	TINKELMAN, DG; COLE, WQ; TUNNO, J				TINKELMAN, DG; COLE, WQ; TUNNO, J			IMMUNOTHERAPY - A ONE-YEAR PROSPECTIVE-STUDY TO EVALUATE RISK-FACTORS OF SYSTEMIC REACTIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IMMUNOTHERAPY; SYSTEMIC REACTION; HYPOTENSION; MOLD COUNTS; BUILDUP	POLLEN EXTRACTS	Background: We did a prospective study in Atlanta, Georgia, during 1991 on the rate of systemic reactions caused by immunotherapy in a clinic that uses aqueous allergen extracts, Methods: Immunotherapy reactions were monitored. Symptoms were recorded with respect to time of onset, involvement of respiratory tract or skin, and presence of hypotension. Results: There were 98 systemic reactions in 96 patients (1 per 1600 visits or 1 per 47 patients). There was no direct relationship to seasonal pollen counts. There was, however; a correlation with the August to October increase in mold counts. There was no correlation between reactions and the age of the patient or the age of the extract patients were more likely to experience a reaction during the buildup phase than during maintenance therapy. The time of onset and the severity of the reaction were in agreement with previous reports. Severe reactions that included hypotension all occurred less than 30 minutes after the injection. In contrast to previous reports, patients with asthma were not at higher risk for a systemic reaction. Conclusion: Immunotherapy has a significant but low rate of systemic reaction. Potentially serious reactions may be mitigated by taking extra precautions during the earlier phases of an immunotherapy program and during seasons when mold counts are high.			TINKELMAN, DG (corresponding author), ATLANTA ALLERGY CLIN,6667 VERNON WOODS DR,SUITE A-30,ATLANTA,GA 30328, USA.							[Anonymous], 1986, BMJ-BRIT MED J, V293, P948; FRANKLIN W, 1967, J AMER MED ASSOC, V201, P915, DOI 10.1001/jama.201.12.915; Freeman J, 1911, LANCET, V2, P814; GREENBERG MA, 1988, J ALLERGY CLIN IMMUN, V82, P287, DOI 10.1016/0091-6749(88)91013-5; HEJJAOUI A, 1992, J ALLERGY CLIN IMMUN, V89, P925, DOI 10.1016/0091-6749(92)90214-M; LEVINE MI, 1979, J ALLERGY CLIN IMMUN, V63, P209; LOCKEY RF, 1987, J ALLERGY CLIN IMMUN, V79, P660, DOI 10.1016/S0091-6749(87)80164-1; MALLING HJ, 1986, ALLERGY, V41, P505; NELSON BL, 1986, ANN ALLERGY, V56, P331; NOON L, 1911, LANCET, V1, P1952; NORMAN PS, 1969, J ALLERGY, V44, P129, DOI 10.1016/0021-8707(69)90137-3; PENCE HL, 1976, J ALLERGY CLIN IMMUN, V58, P39, DOI 10.1016/0091-6749(76)90105-6; SALVAGGIO J, 1971, J ALLERGY CLIN IMMUN, V48, P96, DOI 10.1016/0091-6749(71)90091-1; VANMETRE TE, 1982, J ALLERGY CLIN IMMUN, V69, P181, DOI 10.1016/0091-6749(82)90098-7; VERVLOET D, 1980, CLIN ALLERGY, V10, P59, DOI 10.1111/j.1365-2222.1980.tb02080.x; 1989, LANCET, V1, P259	16	81	82	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1995	95	1	1				8	14		10.1016/S0091-6749(95)70146-X	http://dx.doi.org/10.1016/S0091-6749(95)70146-X			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QC312	7822668				2022-12-18	WOS:A1995QC31200002
J	OVSYANNIKOVA, IG; VAILES, LD; LI, Y; HEYMANN, PW; CHAPMAN, MD				OVSYANNIKOVA, IG; VAILES, LD; LI, Y; HEYMANN, PW; CHAPMAN, MD			MONOCLONAL-ANTIBODIES TO GROUP-II DERMATOPHAGOIDES SPP ALLERGENS - MURINE IMMUNE-RESPONSE, EPITOPE ANALYSIS, AND DEVELOPMENT OF A 2-SITE ELISA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						MONOCLONAL ANTIBODY; MITE ALLERGENS; ELISA; DERMATOPHAGOIDES; ASTHMA	HOUSE-DUST MITE; DER-P-I; HUMAN IGE ANTIBODIES; F-I; ASTHMATIC-CHILDREN; PTERONYSSINUS; EXPOSURE; ANTIGEN; SENSITIZATION; FARINAE	Background: Group II allergens are a major cause of sensitization in patients allergic to mites. To facilitate the antigenic analysis of group II allergens and to develop improved methods of allergen detection we compared IgG anti-group II antibody responses in inbred mouse strains and raised a panel of monoclonal antibodies (mAbs). Methods: IgE antibody responses were compared by antigen-binding radioimmunoassay. Epitope specificity of the mAbs was analyzed by two-site binding assays and by cross-inhibition radioimmunoassays. Results: Comparison of polyclonal IgG antibody responses in five BALB congenic strains showed that H-2(d) mice had poor responses, whereas H-2(b) and H-2(k) mice had strong, cross-reactive, IgG anti-group II responses. The specificities of nine anti-Der p II IgE mAbs raised in A/J mice were compared with specificities of seven mAbs produced previously. Most mAbs (11 of 16) recognized common epitopes on Der p II and Der f II: three were specific to Der p II, and two showed high binding to Der f II. Epitope analysis showed that the mAbs defined four cross-reactive, nonoverlapping sites on the group II allergens. Binding of several combinations of mAbs was compared, and a two-site ELISA for group II antigens was developed. Linear regression analysis showed an excellent correlation between results of this assay and group II radioimmunoassay of house dust samples (n = 40, r = 0.85, p < 0.001). Conclusions: There are multiple cross-reactive B-cell epitopes on group II allergens. The group II ELISA has several important applications including assessment of environmental allergen exposure, monitoring of the efficacy of avoidance procedures, and standardization of commercial mite allergen extracts.	UNIV VIRGINIA, CTR UVA ASTHMA & ALLERG DIS, DEPT MED, DIV ALLERGY & CLIN IMMUNOL, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, DEPT PEDIAT, CHARLOTTESVILLE, VA USA	University of Virginia; University of Virginia				Chapman, Martin/0000-0002-0845-3632	NIAID NIH HHS [AI 34607, AI-24261, AI-24687] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI034607, R29AI024261, R29AI024687, U19AI034607] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKAGAWA M, 1991, Japanese Journal of Allergology, V40, P1239; ARRUDA LK, 1991, CLIN EXP ALLERGY, V21, P433, DOI 10.1111/j.1365-2222.1991.tb01683.x; ARSHAD SH, 1992, LANCET, V339, P1493, DOI 10.1016/0140-6736(92)91260-F; CHAPMAN MD, 1987, J IMMUNOL, V139, P1479; CHAPMAN MD, 1984, J IMMUNOL, V133, P2488; CHARPIN D, 1991, AM REV RESPIR DIS, V143, P983, DOI 10.1164/ajrccm/143.5_Pt_1.983; DEBLAY F, 1991, J ALLERGY CLIN IMMUN, V88, P919, DOI 10.1016/0091-6749(91)90249-N; DIETEMANN A, 1993, J ALLERGY CLIN IMMUN, V91, P738, DOI 10.1016/0091-6749(93)90193-J; EHNERT B, 1992, J ALLERGY CLIN IMMUN, V90, P135, DOI 10.1016/S0091-6749(06)80024-2; HAYDEN ML, 1992, J ALLERGY CLIN IMMUN, V89, P536, DOI 10.1016/0091-6749(92)90320-2; HEYMANN PW, 1986, J IMMUNOL, V137, P2841; HEYMANN PW, 1989, J ALLERGY CLIN IMMUN, V83, P1055, DOI 10.1016/0091-6749(89)90447-8; HOYNE GF, 1993, IMMUNOLOGY, V78, P65; KLINMAN NR, 1969, CLIN EXP IMMUNOL, V4, P473; LAU S, 1989, J ALLERGY CLIN IMMUN, V84, P718, DOI 10.1016/0091-6749(89)90300-X; LEMAO J, 1992, MOL IMMUNOL, V29, P205, DOI 10.1016/0161-5890(92)90101-3; LIND P, 1988, J IMMUNOL, V140, P4256; LIND P, 1986, ALLERGY, V41, P442, DOI 10.1111/j.1398-9995.1986.tb00325.x; LOMBARDERO M, 1990, J IMMUNOL, V144, P1353; LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; MCDONALD LG, 1992, J ALLERGY CLIN IMMUN, V90, P599, DOI 10.1016/0091-6749(92)90132-L; OWEN S, 1990, LANCET, V335, P396, DOI 10.1016/0140-6736(90)90219-U; PLATTSMILLS TAE, 1992, J ALLERGY CLIN IMMUN, V89, P1046, DOI 10.1016/0091-6749(92)90228-T; PLATTSMILLS TAE, 1991, J ALLERGY CLIN IMMUN, V87, P621, DOI 10.1016/0091-6749(91)90379-3; PRICE JA, 1990, LANCET, V336, P895, DOI 10.1016/0140-6736(90)92268-M; SAKAGUCHI M, 1989, INT ARCH ALLER A IMM, V90, P190, DOI 10.1159/000235022; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; SPORIK R, 1992, CLIN EXP ALLERGY, V22, P897, DOI 10.1111/j.1365-2222.1992.tb02062.x; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; STEWART GA, 1987, INT ARCH ALLER A IMM, V83, P44, DOI 10.1159/000234329; TRUDINGER M, 1991, CLIN EXP ALLERGY, V21, P33, DOI 10.1111/j.1365-2222.1991.tb00801.x; VAILES LD, 1994, J ALLERGY CLIN IMMUN, V93, P22, DOI 10.1016/0091-6749(94)90229-1; VAILES LD, 1994, J ALLERGY CLIN IMMUN, V93, P208; VANDERZEE JS, 1988, J ALLERGY CLIN IMMUN, V81, P884, DOI 10.1016/0091-6749(88)90946-3; VANLEEUWEN J, 1991, 2ND INT WORKSH BRUSS, P70; WOODFOLK JA, 1994, IN PRESS J ALLERGY C; YASUEDA H, 1989, INT ARCH ALLER A IMM, V90, P182, DOI 10.1159/000235021	37	81	83	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1994	94	3	1				537	546		10.1016/0091-6749(94)90211-9	http://dx.doi.org/10.1016/0091-6749(94)90211-9			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PG907	7521892				2022-12-18	WOS:A1994PG90700014
J	CUGNO, M; CICARDI, M; AGOSTONI, A				CUGNO, M; CICARDI, M; AGOSTONI, A			ACTIVATION OF THE CONTACT SYSTEM AND FIBRINOLYSIS IN AUTOIMMUNE ACQUIRED ANGIOEDEMA - A RATIONALE FOR PROPHYLACTIC USE OF TRANEXAMIC ACID	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ACQUIRED ANGIOEDEMA; AUTOIMMUNITY; C1-INHIBITOR; HIGH MOLECULAR WEIGHT KININOGEN; PLASMIN; TRANEXAMIC ACID	HEREDITARY ANGIONEUROTIC-EDEMA; MOLECULAR-WEIGHT KININOGEN; EPSILON-AMINOCAPROIC ACID; C1 INHIBITOR DEFICIENCY; C1-INHIBITOR DEFICIENCY; HUMAN-PLASMA; PLASMIN-ALPHA-2-ANTIPLASMIN COMPLEX; IMMUNOSORBENT-ASSAY; ANTIBODY; INVIVO	C1-inhibitor deficiency results in bouts of mucocutaneous edema and may be inherited (hereditary angioedema) or acquired (acquired angioedema [AAE]). The two forms have the same clinical picture but differ in the response to treatment. Prophylaxis with antifibrinolytic agents produces better results in the acquired form than in the inherited form, in which androgen derivatives are more effective. It is hypothesized that activation of the contact and fibrinolytic systems is involved in the pathogenesis of attacks. We evaluated these two systems in plasma from eight patients with AAE and anti-C1-inhibitor autoantibodies (autoimmune AAE) by measuring the cleavage of high molecular weight kininogen and the completes formed by plasmin and its inhibitor alpha(2)-antiplasmin. We also measured complement parameters, autoantibody titer, and cleaved C1-inhibitor (relative molecular mass = 96,000), because autoantibodies to C1-inhibitor are known to facilitate its cleavage by proteases. Plasma was obtained from patients in remission, during prophylactic treatment with the antifibrinolytic agent tranexamic acid (2 to 4.5 gm/day) and also from two patients during acute attacks of edema. Levels of cleaved high molecular weight kininogen and antiplasmin-plasmin complexes in patients with AAE were both higher in basal conditions, during treatment, and during acute attacks than those in normal subjects (p < 0.001). The cleaved inactive form of C1-inhibitor was also present in all patients in all three conditions. Therapy with antifibrinolytic agents reduced the frequency and intensity of symptoms without significantly changing any of the biochemical parameters. Our data demonstrate that in patients with autoimmune AAE there is continuous activation of contact and fibrinolytic systems, which might be counteracted by antifibrinolytic agents, as indicated by the favorable effects of prophylactic treatment with tranexamic acid.	UNIV MILAN,IST MED INTERNA,MED CLIN,I-20122 MILAN,ITALY	University of Milan			cicardi, marco/K-9219-2016; Cugno, Massimo/K-8106-2016	cicardi, marco/0000-0003-1251-225X; Cugno, Massimo/0000-0002-9918-0763				AGOSTONI A, 1992, MEDICINE, V71, P206, DOI 10.1097/00005792-199207000-00003; AGOSTONI A, 1978, ALLERGY, V33, P211; ALSENZ J, 1989, J CLIN INVEST, V83, P1794, DOI 10.1172/JCI114084; ALSENZ J, 1987, NEW ENGL J MED, V316, P1360, DOI 10.1056/NEJM198705283162202; ANONICK PK, 1992, ARTERIOSCLER THROMB, V12, P708, DOI 10.1161/01.ATV.12.6.708; ASTEDT B, 1987, SCAND J GASTROENTERO, V22, P22, DOI 10.3109/00365528709089756; BERRETTINI M, 1986, BLOOD, V68, P455; Caldwell JR, 1972, CLIN IMMUNOL IMMUNOP, V1, P39; CHHIBBER G, 1990, J LAB CLIN MED, V115, P112; CICARDI M, 1993, AM J MED, V95, P169, DOI 10.1016/0002-9343(93)90257-P; COCHRANE CG, 1972, J CLIN INVEST, V51, P2736, DOI 10.1172/JCI107093; CUGNO M, 1993, J LAB CLIN MED, V121, P38; CUGNO M, 1988, J CLIN CHEM CLIN BIO, V6, P423; CURD JG, 1980, J EXP MED, V152, P742, DOI 10.1084/jem.152.3.742; DAVIS AE, 1988, ANNU REV IMMUNOL, V6, P595, DOI 10.1146/annurev.iy.06.040188.003115; DONALDSON VH, 1964, J CLIN INVEST, V43, P2204, DOI 10.1172/JCI105094; DONALDSON VH, 1969, J CLIN INVEST, V48, P642, DOI 10.1172/JCI106022; DONALDSON VH, 1963, AM J MED, V31, P36; DONALDSON VH, 1977, T ASSOC AM PHYSICIAN, V40, P174; FALUS A, 1990, MOL IMMUNOL, V27, P191, DOI 10.1016/0161-5890(90)90114-F; FIELDS T, 1983, J ALLERGY CLIN IMMUN, V72, P54, DOI 10.1016/0091-6749(83)90052-0; FRANK MM, 1987, CLIN RES, V35, pA641; GEHA RS, 1985, NEW ENGL J MED, V312, P534, DOI 10.1056/NEJM198502283120902; GELFAND JA, 1976, NEW ENGL J MED, V295, P1444, DOI 10.1056/NEJM197612232952602; GELFAND JA, 1979, MEDICINE, V58, P311; HARPEL PC, 1981, J CLIN INVEST, V68, P46, DOI 10.1172/JCI110253; HOLVOET P, 1986, THROMB HAEMOSTASIS, V56, P124; JACKSON J, 1989, J CLIN INVEST, V83, P698, DOI 10.1172/JCI113934; JACKSON J, 1986, NATURE, V313, P722; KAPLAN AP, 1987, BLOOD, V70, P1; KAUFMAN N, 1991, BLOOD, V79, P1053; KLUFT C, 1987, SEMIN THROMB HEMOST, V13, P50, DOI 10.1055/s-2007-1003475; LAMMLE B, 1988, THROMB HAEMOSTASIS, V59, P151; LEVI M, 1992, THROMB HAEMOSTASIS, V67, P111; MELAMED J, 1986, J ALLERGY CLIN IMMUN, V77, P322; OLTVAI ZN, 1991, LAB INVEST, V65, P381; SHAPIRA M, 1983, NEW ENGL J MED, V308, P1050; SHEFFER AL, 1972, NEW ENGL J MED, V287, P452, DOI 10.1056/NEJM197208312870907; SOTER NA, 1975, J IMMUNOL, V114, P928; VERSTRAETE M, 1985, DRUGS, V29, P236, DOI 10.2165/00003495-198529030-00003; ZURAW BL, 1986, J CLIN INVEST, V78, P567, DOI 10.1172/JCI112610	41	81	86	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1994	93	5					870	876		10.1016/0091-6749(94)90380-8	http://dx.doi.org/10.1016/0091-6749(94)90380-8			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NL919	8182230	Bronze			2022-12-18	WOS:A1994NL91900011
J	REISMAN, RE				REISMAN, RE			DURATION OF VENOM IMMUNOTHERAPY - RELATIONSHIP TO THE SEVERITY OF SYMPTOMS OF INITIAL INSECT STING ANAPHYLAXIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						DURATION OF VENOM IMMUNOTHERAPY; SEVERITY OF STING ANAPHYLAXIS	ALLERGIC PATIENTS; CHALLENGE	Background: This study assessed the postulate that the adequate duration of venom immunotherapy (VIT) is related to the seventy of the initial sting anaphylactic symptoms. Methods: Data were collected from patients with venom allergy who had sting anaphylaxis and subsequent positive venom skin test results, received maintenance VIT, and had field re-stings after cessation of VIT. There were 217 re-stings in 113 patients with 15 systemic reactions in 10 patients (a re-sting reaction rate of 9% per sting and 7% per patient). Results: Re-sting reactions occurred in 1 of 25 patients with initial mild anaphylaxis (4%), 2 of 41 patients with moderate reactions (5%), and 7 of 47 patients with initial severe symptoms (15%). The results were not influenced by the duration of VIT or the interval between cessation of VIT and the re-sting. Eighteen patients who converted to negative skin test reactions had no reactions when re-stung Conclusions: These results suggest a relationship between the severity of anaphylaxis and subsequent duration of VIT Two to three years is sufficient for patients who had mild to moderate anaphylaxis. Longer duration of therapy is advisable for patients who had severe symptoms and continue to have positive venom skin test results.	SUNY BUFFALO,SCH MED,BUFFALO,NY 14214	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo								BOUSQUET J, 1989, J ALLERGY CLIN IMMUN, V84, P944, DOI 10.1016/0091-6749(89)90393-X; GEORGITIS JW, 1985, J ALLERGY CLIN IMMUN, V76, P803, DOI 10.1016/0091-6749(85)90752-3; GOLDBERG A, 1988, ANN ALLERGY, V61, P177; GOLDEN D B K, 1991, Journal of Allergy and Clinical Immunology, V87, P237, DOI 10.1016/0091-6749(91)91675-J; GOLDEN DBK, 1989, J ALLERGY CLIN IMMUN, V83, P273; GOLDEN DBK, 1986, J ALLERGY CLIN IMMUN, V77, P435, DOI 10.1016/0091-6749(86)90177-6; GOLDEN DBK, 1989, J ALLERGY CLIN IMMUN, V84, P162, DOI 10.1016/0091-6749(89)90320-5; HAUGAARD L, 1991, J ALLERGY CLIN IMMUN, V87, P699, DOI 10.1016/0091-6749(91)90391-Z; KEATING MU, 1991, J ALLERGY CLIN IMMUN, V88, P339, DOI 10.1016/0091-6749(91)90095-6; MULLER U, 1991, J ALLERGY CLIN IMMUN, V87, P702, DOI 10.1016/0091-6749(91)90392-2; REISMAN RE, 1992, J ALLERGY CLIN IMMUN, V90, P335, DOI 10.1016/S0091-6749(05)80012-0; REISMAN RE, 1992, J ALLERGY CLIN IMMUN, V89, P1189, DOI 10.1016/0091-6749(92)90304-K; REISMAN RE, 1989, J ALLERGY CLIN IMMUN, V83, P1049, DOI 10.1016/0091-6749(89)90446-6; VALENTINE MD, 1991, NEW ENGL J MED, V23, P1601	14	81	81	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1993	92	6					831	836		10.1016/0091-6749(93)90060-S	http://dx.doi.org/10.1016/0091-6749(93)90060-S			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ML893	8258617				2022-12-18	WOS:A1993ML89300008
J	WHITE, MV; KALINER, MA				WHITE, MV; KALINER, MA			MEDIATORS OF ALLERGIC RHINITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ALLERGIC RHINITIS; MAST CELLS; MEDIATOR RELEASE; NASAL MUCOSA; NEUROPEPTIDES	HUMAN NASAL-MUCOSA; MAST-CELLS; SECRETIONS; PROTEIN; PEPTIDE; IGE	Although histamine is the principal mediator of the immediate allergic reaction, other inflammatory mediators as well as neuropeptides also contribute to rhinorrhea and nasal congestion. Within minutes of exposure to allergen, mast cells produce histamine, leukotriene C4, and prostaglandin D2. A concomitant increase occurs in neuropeptides and bradykinin. In vitro mast cell activation also leads to the release of tumor necrosis factor-alpha, several interleukins, and granulocyte-macrophage colony-stimulating factor. Because all these various mediators and neuropeptides may play a role in producing rhinorrhea and congestion, antihistamines alone cannot control all of the symptoms of allergic rhinitis. However, the combination of antihistamines with topical corticosteroids can inhibit the generation, release, and activity of most if not all of the mediators potentially involved in the allergic response.	NIAID,CLIN INVEST LAB,ALLERG DIS SECT,BLDG 10,11C205,9000 ROCKVILLE PIKE,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)								ATKINSON TP, IN PRESS ASTHMA RHIN; BARANIUK JN, 1990, AM J RESP CELL MOL, V3, P165, DOI 10.1165/ajrcmb/3.2.165; BARANIUK JN, 1990, J CLIN INVEST, V85, P998, DOI 10.1172/JCI114577; BARANIUK JN, 1991, AM J RESP CELL MOL, V4, P228, DOI 10.1165/ajrcmb/4.3.228; BARANIUK JN, 1990, J CLIN INVEST, V86, P825, DOI 10.1172/JCI114780; BARANIUK JN, IN PRESS ASTHMA RHIN; BARANIUK JN, IN PRESS AM J RHINOL; BARANIUK JN, 1990, J APPL PHYSIOL, V258, P81; BENTLEY AM, 1992, J ALLERGY CLIN IMMUN, V89, P877, DOI 10.1016/0091-6749(92)90444-7; BOCHNER BS, 1990, J ALLERGY CLIN IMMUN, V86, P830, DOI 10.1016/S0091-6749(05)80143-5; BURD PR, 1989, J EXP MED, V170, P245, DOI 10.1084/jem.170.1.245; DRETTNER B, 1974, ACTA OTOLARYNGOL, V74, P259; DRUCE HM, 1984, J APPL PHYSIOL, V57, P1276, DOI 10.1152/jappl.1984.57.4.1276; DURHAM SR, 1992, J IMMUNOL, V148, P2390; FRIEDMAN MM, 1985, J ALLERGY CLIN IMMUN, V76, P70, DOI 10.1016/0091-6749(85)90807-3; GORDON JR, 1990, NATURE, V346, P274, DOI 10.1038/346274a0; GUNDEL RH, 1991, J CLIN INVEST, V88, P1407, DOI 10.1172/JCI115447; GURISH MF, 1991, J IMMUNOL, V146, P1527; IGARASHI Y, 1992, FASEB J, V6, pA2005; IGARASHI Y, 1992, J ALLERGY CLIN IMMUN, V89, P204; KALINER MA, 1991, AM REV RESPIR DIS, V144, pS52, DOI 10.1164/ajrccm/144.3_pt_2.S52; KALINER MA, IN PRESS JAMA; LOZEWICZ S, 1990, J ALLERGY CLIN IMMUN, V85, P125, DOI 10.1016/0091-6749(90)90233-T; MOSIMANN B, 1992, J ALLERGY CLIN IMMUN, V89, P210; MOSS R B, 1992, Journal of Allergy and Clinical Immunology, V89, P179; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; OKAYAMA M, IN PRESS J ALLERGY C; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; PROUD D, 1987, J IMMUNOL, V138, P428; RAPHAEL GD, 1991, J ALLERGY CLIN IMMUN, V88, P33, DOI 10.1016/0091-6749(91)90298-3; RAPHAEL GD, 1991, J ALLERGY CLIN IMMUN, V87, P457, DOI 10.1016/0091-6749(91)90001-5; RAPHAEL GD, 1989, AM REV RESPIR DIS, V139, P791, DOI 10.1164/ajrccm/139.3.791; Raphael GD, 1988, AM J RHINOL, V2, P109; SIM TC, 1992, J ALLERGY CLIN IMMUN, V89, P216; SIMONS FER, 1989, J ALLERGY CLIN IMMUN, V84, P845, DOI 10.1016/0091-6749(89)90377-1; STEINBERG DG, 1992, J ALLERGY CLIN IMMUN, V89, P217; SUR S, 1988, AM J RHINOL, V2, P109; WHITE M, 1992, J ALLERGY CLIN IMMUN, V89, P206	39	81	83	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1992	90	4	2	S			699	704		10.1016/0091-6749(92)90155-U	http://dx.doi.org/10.1016/0091-6749(92)90155-U			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JV009	1401652				2022-12-18	WOS:A1992JV00900001
J	HISAMATSU, K; GANBO, T; NAKAZAWA, T; MURAKAMI, Y; GLEICH, GJ; MAKIYAMA, K; KOYAMA, H				HISAMATSU, K; GANBO, T; NAKAZAWA, T; MURAKAMI, Y; GLEICH, GJ; MAKIYAMA, K; KOYAMA, H			CYTOTOXICITY OF HUMAN EOSINOPHIL GRANULE MAJOR BASIC-PROTEIN TO HUMAN NASAL SINUS MUCOSA INVITRO	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MAYO CLIN & MAYO FDN, DEPT IMMUNOL, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, DEPT INTERNAL MED, ROCHESTER, MN 55905 USA; NIHON UNIV, SCH MED, DEPT OTORHINOLARYNGOL, TOKYO 101, JAPAN	Mayo Clinic; Mayo Clinic; Nihon University	HISAMATSU, K (corresponding author), YAMANASHI COLL MED, DEPT OTORHINOLARYNGOL, 1110 SHIMOGATO, TAMAHO, YAMANASHI 40938, JAPAN.				NIAID NIH HHS [AI 09728, AI 15231] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI009728, R37AI009728, R01AI015231, R37AI015231] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACKERMAN SJ, 1983, J IMMUNOL, V131, P2977; AYARS GH, 1989, AM REV RESPIR DIS, V140, P125; BARNES PJ, 1985, BRIT J PHARMACOL, V86, P685, DOI 10.1111/j.1476-5381.1985.tb08946.x; BARNES PJ, 1986, LANCET, V1, P242; BROFMAN JD, 1989, J APPL PHYSIOL, V66, P1867, DOI 10.1152/jappl.1989.66.4.1867; BUTTERWORTH AE, 1979, J IMMUNOL, V122, P221; DOR PJ, 1984, AM REV RESPIR DIS, V130, P1072; FILLEY WV, 1982, LANCET, V2, P11; FLAVAHAN NA, 1985, J APPL PHYSIOL, V58, P834, DOI 10.1152/jappl.1985.58.3.834; FRIGAS E, 1980, LAB INVEST, V42, P35; FRIGAS E, 1986, J ALLERGY CLIN IMMUN, V77, P527, DOI 10.1016/0091-6749(86)90341-6; FRIGAS E, 1981, MAYO CLIN PROC, V56, P345; GLEICH GJ, 1986, ADV IMMUNOL, V39, P177; GLEICH GJ, 1988, J ALLERGY CLIN IMMUN, V81, P776, DOI 10.1016/0091-6749(88)90931-1; GLEICH GJ, 1986, P NATL ACAD SCI USA, V83, P3146, DOI 10.1073/pnas.83.10.3146; GLEICH GJ, 1990, J ALLERGY CLIN IMMUN, V85, P422, DOI 10.1016/0091-6749(90)90151-S; GLEICH GJ, 1979, J IMMUNOL, V123, P2925; GLEICH GJ, 1976, J CLIN INVEST, V57, P633, DOI 10.1172/JCI108319; HAMANN KJ, 1987, FASEB J, V46, P615; HARLIN SL, 1988, J ALLERGY CLIN IMMUN, V81, P867, DOI 10.1016/0091-6749(88)90944-X; HASTIE AT, 1987, AM REV RESPIR DIS, V135, P848, DOI 10.1164/arrd.1987.135.4.848; JONG EC, 1981, J IMMUNOL, V126, P468; LEE TC, 1984, J BIOL CHEM, V259, P5526; MCLAREN DJ, 1981, PARASITE IMMUNOL, V3, P359, DOI 10.1111/j.1365-3024.1981.tb00414.x; MOTOJIMA S, 1989, AM REV RESPIR DIS, V139, P801, DOI 10.1164/ajrccm/139.3.801; NAKAJIMA H, 1988, FASEB J, V2, pA811; SASAKI T, 1986, AM REV RESPIR DIS, V133, pA295; WARDLAW AJ, 1988, AM REV RESPIR DIS, V137, P62, DOI 10.1164/ajrccm/137.1.62; WELLER PF, 1983, P NATL ACAD SCI-BIOL, V80, P7626, DOI 10.1073/pnas.80.24.7626; WHITE S R, 1989, American Review of Respiratory Disease, V139, pA84	30	81	84	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1990	86	1					52	63		10.1016/S0091-6749(05)80123-X	http://dx.doi.org/10.1016/S0091-6749(05)80123-X			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DQ688	2370389	Bronze			2022-12-18	WOS:A1990DQ68800009
J	BISGAARD, H; GRONBORG, H; MYGIND, N; DAHL, R; LINDQVIST, N; VENGE, P				BISGAARD, H; GRONBORG, H; MYGIND, N; DAHL, R; LINDQVIST, N; VENGE, P			ALLERGEN-INDUCED INCREASE OF EOSINOPHIL CATIONIC PROTEIN IN NASAL LAVAGE FLUID - EFFECT OF THE GLUCOCORTICOID BUDESONIDE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									RIGSHOSP,DEPT OTORHINOLARYNGOL,OTOPATHOL LAB,DK-2100 COPENHAGEN,DENMARK; AARHUS UNIV HOSP,DEPT LUNG MED & ALLERGY,DK-8000 AARHUS,DENMARK; AB DRACO,S-22101 LUND,SWEDEN; UNIV HOSP UPPSALA,DEPT CLIN CHEM,UPPSALA,SWEDEN	Rigshospitalet; University of Copenhagen; Aarhus University; Uppsala University; Uppsala University Hospital			Dahl, Ronahl/F-8170-2013; Bisgaard, Hans/N-4761-2016; Kronow, Joern/B-1054-2011	Bisgaard, Hans/0000-0003-4131-7592; 				ANDERSSON M, 1989, ALLERGY, V44, P342, DOI 10.1111/j.1398-9995.1989.tb00456.x; BASCOM R, 1988, AM REV RESPIR DIS, V138, P406, DOI 10.1164/ajrccm/138.2.406; BASCOM R, 1986, J ALLERGY CLIN IMMUN, V77, P246; BISGAARD H, 1987, CLIN SCI, V73, P217, DOI 10.1042/cs0730217; BISGAARD H, 1988, ALLERGY, V43, P219; BISGAARD H, 1986, CLIN ALLERGY, V16, P289, DOI 10.1111/j.1365-2222.1986.tb01960.x; DAHL R, 1978, ALLERGY, V33, P211, DOI 10.1111/j.1398-9995.1978.tb01536.x; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; FILLEY WV, 1982, LANCET, V2, P11; FREDENS K, UNPUB TISSUE DAMAGIN; FRIGAS E, 1980, LAB INVEST, V42, P35; FRIGAS E, 1986, J ALLERGY CLIN IMMUN, V77, P527, DOI 10.1016/0091-6749(86)90341-6; GLEICH GJ, 1988, J ALLERGY CLIN IMMUN, V81, P776, DOI 10.1016/0091-6749(88)90931-1; GLEICH GJ, 1979, J IMMUNOL, V123, P2925; GRONBORG H, UNPUB ALLERGY; HARLIN SL, 1987, J ALLERGY CLIN IMMUN, V79, P128; KAY AB, 1986, J ALLERGY CLIN IMMUN, V77, P236; LINDER A, 1987, ALLERGY, V42, P583, DOI 10.1111/j.1398-9995.1987.tb00388.x; MUNCH EP, 1982, EUR J RESPIR DIS, V63, P176; MYGIND N, 1974, ACTA OTO-LARYNGOL, V78, P436, DOI 10.3109/00016487409126377; MYGIND N, 1973, ACTA ALLERGOL, V28, P9, DOI 10.1111/j.1398-9995.1973.tb02562.x; MYGIND N, 1974, Rhinology (Utrecht), V12, P131; MYGIND N, 1978, ACTA OTO-LARYNGOL, V85, P437; MYGIND N, 1979, NASAL ALLERGY, P177; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; VENGE P, 1977, BRIT J HAEMATOL, V37, P331, DOI 10.1111/j.1365-2141.1977.tb01003.x; VENGE P, IN PRESS INT ARCH AL; VENGE P, 1988, AM REV RESPIR DIS, V138, P54; WLADISLAVOSKYWASERMAN P, 1984, CLIN ALLERGY, V14, P241, DOI 10.1111/j.1365-2222.1984.tb02203.x	30	81	83	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1990	85	5					891	895		10.1016/0091-6749(90)90074-E	http://dx.doi.org/10.1016/0091-6749(90)90074-E			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DD959	2185293	Bronze			2022-12-18	WOS:A1990DD95900012
J	BOEY, H; ROSENBAUM, R; CASTRACANE, J; BORISH, L				BOEY, H; ROSENBAUM, R; CASTRACANE, J; BORISH, L			INTERLEUKIN-4 IS A NEUTROPHIL ACTIVATOR	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									TUFTS UNIV,NEW ENGLAND MED CTR,DIV ALLERGY,BOX 90,750 WASHINGTON ST,BOSTON,MA 02111; TUFTS UNIV,SCH MED,DEPT MED,BOSTON,MA 02111	Tufts Medical Center; Tufts University; Tufts University								BERGER M, 1984, J CLIN INVEST, V74, P1566, DOI 10.1172/JCI111572; Bergmeyer H.U., 1963, METHOD ENZYMAT AN, P736; BORISH L, 1987, J IMMUNOL, V138, P1475; BUSSE WW, 1977, J CLIN INVEST, V59, P1080, DOI 10.1172/JCI108731; COFFMAN RL, 1986, J IMMUNOL, V136, P4538; CRAWFORD RM, 1987, J IMMUNOL, V139, P135; DAHER KA, 1986, J VIROL, V60, P1068, DOI 10.1128/JVI.60.3.1068-1074.1986; DEFRANCE T, 1987, J EXP MED, V165, P1459, DOI 10.1084/jem.165.6.1459; ELSBACH P, 1985, IMMUNOL LETT, V11, P159, DOI 10.1016/0165-2478(85)90163-4; FEARON DT, 1983, J IMMUNOL, V130, P370; FLETCHER MP, 1982, J IMMUNOL, V128, P941; FLETCHER MP, 1983, BLOOD, V62, P792; GIN W, 1985, J ALLERGY CLIN IMMUN, V76, P675, DOI 10.1016/0091-6749(85)90670-0; GIN W, 1985, AM REV RESPIR DIS, V132, P1199; GUTHRIE LA, 1984, J EXP MED, V160, P1656, DOI 10.1084/jem.160.6.1656; HOWARD M, 1982, J EXP MED, V155, P914, DOI 10.1084/jem.155.3.914; KLEMPNER MS, 1979, J CLIN INVEST, V64, P996, DOI 10.1172/JCI109566; LEE F, 1986, P NATL ACAD SCI USA, V83, P2061, DOI 10.1073/pnas.83.7.2061; LITWACK G, 1955, P SOC EXP BIOL MED, V89, P401; MITA H, 1985, LIFE SCI, V37, P907, DOI 10.1016/0024-3205(85)90526-0; MOSMANN TR, 1986, P NATL ACAD SCI USA, V83, P5654, DOI 10.1073/pnas.83.15.5654; NOELLE R, 1984, P NATL ACAD SCI-BIOL, V81, P6149, DOI 10.1073/pnas.81.19.6149; NOMA Y, 1986, NATURE, V319, P640, DOI 10.1038/319640a0; ODEBERGT H, 1975, INFECT IMMUN, V56, P1834; OHARA J, 1987, NATURE, V325, P537, DOI 10.1038/325537a0; ROOT RK, 1972, J CLIN INVEST, V51, P649, DOI 10.1172/JCI106854; STYRT B, 1988, J ALLERGY CLIN IMMUN, V81, P20, DOI 10.1016/0091-6749(88)90215-1; TALALAY P, 1946, J BIOL CHEM, V166, P756; VITETTA ES, 1985, J EXP MED, V162, P1726, DOI 10.1084/jem.162.5.1726; WANG SR, 1986, J ALLERGY CLIN IMMUN, V77, P465, DOI 10.1016/0091-6749(86)90181-8; YAKOTA T, 1986, P NATL ACAD SCI USA, V83, P5894; ZIMMERLI W, 1986, J CLIN INVEST, V77, P925, DOI 10.1172/JCI112391	32	81	81	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1989	83	5					978	984		10.1016/0091-6749(89)90115-2	http://dx.doi.org/10.1016/0091-6749(89)90115-2			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	U7161	2541192				2022-12-18	WOS:A1989U716100021
J	TOGIAS, A; NACLERIO, RM; PROUD, D; PIPKORN, U; BASCOM, R; ILIOPOULOS, O; KAGEYSOBOTKA, A; NORMAN, PS; LICHTENSTEIN, LM				TOGIAS, A; NACLERIO, RM; PROUD, D; PIPKORN, U; BASCOM, R; ILIOPOULOS, O; KAGEYSOBOTKA, A; NORMAN, PS; LICHTENSTEIN, LM			STUDIES ON THE ALLERGIC AND NONALLERGIC NASAL INFLAMMATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHNS HOPKINS UNIV, SCH MED, DEPT MED, DIV CLIN IMMUNOL, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT OTOLARYNGOL HEAD & NECK SURG, BALTIMORE, MD 21205 USA; JOHNS HOPKINS MED INST, CTR OCCUPAT & ENVIRONM HLTH, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine					NHLBI NIH HHS [HL 32272] Funding Source: Medline; NIAID NIH HHS [AI 07290, AI 08270] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032272] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI008270, R37AI008270] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BASCOM R, 1988, J ALLERGY CLIN IMMUN, V81, P570, DOI 10.1016/0091-6749(88)90198-4; BASCOM R, 1986, J ALLERGY CLIN IMMUN, V77, P246; BAUMGARTEN CR, 1986, J IMMUNOL, V137, P977; BAUMGARTEN CR, 1985, J CLIN INVEST, V76, P191, DOI 10.1172/JCI111945; BICKMORE JT, 1981, LARYNGOSCOPE, V91, P1600; BLACKLEY CH, 1873, EXPT RES CAUSE NATUR; BOIJNOORD K, 1972, CLIN ALLERGY, V2, P43; BROWN MS, 1987, ARCH OTOLARYNGOL, V113, P179; CONNELL JT, 1968, J ALLERGY, V41, P101; CONNELL JT, 1968, J ALLERGY, V41, P123, DOI 10.1016/0021-8707(68)90053-1; CONROY MC, 1976, J IMMUNOL, V116, P1677; CRETICOS PS, 1984, NEW ENGL J MED, V310, P1626, DOI 10.1056/NEJM198406213102502; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; EGGLESTON PA, 1984, AM REV RESPIR DIS, V130, P86; FOX CC, 1985, J IMMUNOL, V135, P483; FREELAND HS, 1987, J ALLERGY CLIN IMMUN, V79, P157; FREELAND HS, 1986, J ALLERGY CLIN IMMUN, V77, P244; GALLI SJ, 1984, PROG ALLERGY, V34, P1; GARCIALEME J, 1978, HDB EXPT PHARM, V50, P464; GLEICH GJ, 1979, J IMMUNOL, V123, P2925; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P160, DOI 10.1016/0091-6749(82)90037-9; HAYES EC, 1983, J IMMUNOL, V131, P429; ILIOPOULOS O, 1987, J ALLERGY CLIN IMMUN, V79, P253; IMANARI T, 1976, DHEW NIH76791 PUBL, P205; JACOBS RL, 1981, J ALLERGY CLIN IMMUN, V67, P253, DOI 10.1016/0091-6749(81)90019-1; KEELE CA, 1969, PROC R SOC SER B-BIO, V173, P361, DOI 10.1098/rspb.1969.0062; LAWRENCE ID, 1987, J IMMUNOL, V139, P3062; LICHTENSTEIN LM, 1983, 11 P INT C ALL CLIN, P11; MACGLASHAN D, 1983, 12 P C EUR AC ALL CL, P267; MCLEAN JA, 1976, J ALLERGY CLIN IMMUN, V57, P153, DOI 10.1016/0091-6749(76)90034-8; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; ODONNELL MC, 1983, J EXP MED, V157, P1981, DOI 10.1084/jem.157.6.1981; PELIKAN Z, 1978, ANN ALLERGY, V41, P37; PIPKORN U, 1987, J CLIN INVEST, V80, P957, DOI 10.1172/JCI113188; PIPKORN U, 1987, NEW ENGL J MED, V316, P1506, DOI 10.1056/NEJM198706113162403; PLAUT M, 1983, ALLERGY PRINCIPLES P, V1, P119; PROUD D, 1987, J ALLERGY CLIN IMMUN, V79, P254; PROUD D, 1983, J CLIN INVEST, V72, P1678, DOI 10.1172/JCI111127; RANKIN JA, 1982, NATURE, V297, P329, DOI 10.1038/297329a0; ROBERTSON DG, 1974, J ALLERGY CLIN IMMUN, V54, P244, DOI 10.1016/0091-6749(74)90067-0; SCHLEIMER RP, 1981, NATURE, V292, P454, DOI 10.1038/292454a0; SCHLEIMER RP, 1983, J CLIN INVEST, V71, P1830, DOI 10.1172/JCI110938; SCHULMAN ES, 1981, AM REV RESPIR DIS, V124, P402; SCHWARTZ LB, 1987, NEW ENGL J MED, V316, P1622, DOI 10.1056/NEJM198706253162603; SEEBOLM PM, 1978, ALLERGY PRINCIPLES P, V2, P868; SILBER G, 1985, J ALLERGY CLIN IMMUN, V75, P176, DOI 10.1016/0091-6749(85)90420-8; SIRAGANIAN R, 1974, ANAL BIOCHEM, V57, P283; TAYLOR G, 1971, Clinical Allergy, V1, P63, DOI 10.1111/j.1365-2222.1971.tb02448.x; TOGIAS A, 1987, J ALLERGY CLIN IMMUN, V79, P599, DOI 10.1016/S0091-6749(87)80155-0; TOGIAS AG, 1985, J CLIN INVEST, V76, P1375, DOI 10.1172/JCI112113; TOGIAS AG, 1986, AM REV RESPIR DIS, V133, P1133; TOGIAS AG, 1988, AM REV RESPIR DIS, V137, P625, DOI 10.1164/ajrccm/137.3.625; TOGIAS AG, 1986, JAMA-J AM MED ASSOC, V255, P225, DOI 10.1001/jama.255.2.225; WACHS M, 1987, J ALLERGY CLIN IMMUN, V79, P253; WASSERMAN SI, 1979, MAST CELL ITS ROLE H, P9; WASSOM DL, 1981, J CLIN INVEST, V67, P651, DOI 10.1172/JCI110080; WELLER PF, 1983, P NATL ACAD SCI-BIOL, V80, P7626, DOI 10.1073/pnas.80.24.7626; 1975, NATIONAL HLTH SURVEY, V10	59	81	83	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1988	81	5	1				782	790		10.1016/0091-6749(88)90932-3	http://dx.doi.org/10.1016/0091-6749(88)90932-3			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	N7036	3286718				2022-12-18	WOS:A1988N703600004
J	WELLER, PF				WELLER, PF			EOSINOPHILIA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									BETH ISRAEL HOSP, CHARLES A DANA RES INST, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	WELLER, PF (corresponding author), BETH ISRAEL HOSP, DEPT MED, HARVARD THORNDIKE LAB, BOSTON, MA 02215 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020241, R37AI020241] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-20241] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACKERMAN SJ, 1982, J EXP MED, V155, P1597, DOI 10.1084/jem.155.6.1597; ACKERMAN SJ, 1983, J EXP MED, V158, P946, DOI 10.1084/jem.158.3.946; ACKERMAN SJ, 1981, J IMMUNOL, V127, P1093; ACKERMAN SJ, 1983, IMMUNOBIOLOGY EOSINO, P181; ATKINS P, 1973, J ALLERGY CLIN IMMUN, V51, P263, DOI 10.1016/0091-6749(73)90128-0; BARTELMEZ SH, 1980, BLOOD, V56, P706; BASS DA, 1980, J CLIN INVEST, V66, P1265, DOI 10.1172/JCI109978; BASS DA, 1977, INFECT IMMUN, V15, P410, DOI 10.1128/IAI.15.2.410-416.1977; BASTEN A, 1970, J EXP MED, V131, P1288, DOI 10.1084/jem.131.6.1288; Beeson PB, 1977, EOSINOPHIL; BURGESS AW, 1980, BIOCHEM J, V185, P301, DOI 10.1042/bj1850301; BUTTERWORTH AE, 1982, IMMUNOL REV, V61, P5, DOI 10.1111/j.1600-065X.1982.tb00372.x; CAPRON M, 1981, J IMMUNOL, V126, P2087; CARRINGT.CB, 1969, NEW ENGL J MED, V280, P787, DOI 10.1056/NEJM196904102801501; CHUSID MJ, 1975, MEDICINE, V54, P1, DOI 10.1097/00005792-197501000-00001; CLARK RAF, 1975, J EXP MED, V142, P1462, DOI 10.1084/jem.142.6.1462; COHEN S, 1971, J EXP MED, V133, P133, DOI 10.1084/jem.133.1.133; COHEN SC, 1983, ALLERGY PRINCIPLES P; COLLEY DG, 1973, J IMMUNOL, V110, P1419; CONNELL JT, 1968, J ALLERGY, V41, P1, DOI 10.1016/0021-8707(68)90002-6; CONRAD ME, 1971, SEMIN HEMATOL, V8, P267; DAVID JR, 1980, NEW ENGL J MED, V303, P1147, DOI 10.1056/NEJM198011133032004; FAUCI AS, 1983, J ALLERGY CLIN IMMUN, V72, P211, DOI 10.1016/0091-6749(83)90021-0; FAUCI AS, 1982, ANN INTERN MED, V97, P78, DOI 10.7326/0003-4819-97-1-78; FILLEY WV, 1982, LANCET, V2, P11; FRIGAS E, 1980, LAB INVEST, V42, P35; FRIGAS E, 1981, MAYO CLIN PROC, V56, P345; GLEICH GJ, 1979, IMMUNOLOGY, V38, P343; GLEICH GJ, 1979, J IMMUNOL, V123, P2925; GLEICH GJ, 1976, J CLIN INVEST, V57, P633, DOI 10.1172/JCI108319; GOETZL EJ, 1975, P NATL ACAD SCI USA, V72, P4123, DOI 10.1073/pnas.72.10.4123; GOTTDIENER JS, 1983, CIRCULATION, V67, P572, DOI 10.1161/01.CIR.67.3.572; HENDERSON WR, 1982, J IMMUNOL, V128, P2609; HENDERSON WR, 1980, J EXP MED, V152, P265, DOI 10.1084/jem.152.2.265; HIRASHIMA M, 1976, IMMUNOLOGY, V30, P203; HSU CK, 1976, NATURE, V262, P397, DOI 10.1038/262397a0; HUBSCHER T, 1975, J IMMUNOL, V114, P1389; JONG EC, 1981, J IMMUNOL, V126, P468; KAZURA JW, 1980, J IMMUNOL, V124, P355; KAZURA JW, 1981, J CLIN INVEST, V67, P93, DOI 10.1172/JCI110037; KLEBANOFF SJ, 1980, EOSINOPHIL HLTH DISE, P99; LOFFLER W, 1956, INT ARCH ALLER A IMM, V8, P54, DOI 10.1159/000228268; LOWELL F C, 1967, Journal of the American Medical Association, V202, P109; MAHMOUD AAF, 1982, J INFECT DIS, V145, P613, DOI 10.1093/infdis/145.2.613; MCLAREN DJ, 1982, SEMIN HEMATOL, V19, P100; MCLAREN DJ, 1981, PARASITE IMMUNOL, V3, P359, DOI 10.1111/j.1365-3024.1981.tb00414.x; MULLARKEY MF, 1980, J ALLERGY CLIN IMMUN, V65, P122, DOI 10.1016/0091-6749(80)90196-7; NAGY L, 1982, CLIN EXP IMMUNOL, V47, P541; NEVA FA, 1978, NEW ENGL J MED, V298, P1129, DOI 10.1056/NEJM197805182982006; ODONNELL MC, 1983, J EXP MED, V157, P1981, DOI 10.1084/jem.157.6.1981; PARMLEY RT, 1974, LAB INVEST, V30, P557; PARRILLO JE, 1979, AM J MED, V67, P572, DOI 10.1016/0002-9343(79)90227-4; PARRILLO JE, 1978, ANN INTERN MED, V89, P167, DOI 10.7326/0003-4819-89-2-167; PETERS MS, 1983, J INVEST DERMATOL, V81, P39, DOI 10.1111/1523-1747.ep12538380; PINCUS SH, 1983, UPDATE DERMATOLOGY G, P13; RUITENBERG EJ, 1977, IMMUNOLOGY, V33, P581; RUSCETTI FW, 1976, BLOOD, V47, P757; SAMTER M, 1957, ANN INTERN MED, V68, P339; SCHATZ M, 1981, MED CLIN N AM, V65, P1055, DOI 10.1016/S0025-7125(16)31489-4; SLUNGAARD A, 1983, NEW ENGL J MED, V309, P778, DOI 10.1056/NEJM198309293091307; SOTER NA, 1983, J INVEST DERMATOL, V80, P115, DOI 10.1111/1523-1747.ep12531738; SPRY CJF, 1976, CLIN EXP IMMUNOL, V24, P423; TAI PC, 1981, BRIT J HAEMATOL, V49, P219, DOI 10.1111/j.1365-2141.1981.tb07218.x; TING S, 1981, J IMMUNOL, V127, P557; TURK J, 1982, J BIOL CHEM, V257, P7068; TURNBULL LW, 1976, IMMUNOLOGY, V31, P797; VENGE P, 1983, IMMUNOBIOLOGY EOSINO, P163; WALDMANN TA, 1967, NEW ENGL J MED, V276, P761, DOI 10.1056/NEJM196704062761401; WALLS RS, 1971, BRIT MED J, V3, P157, DOI 10.1136/bmj.3.5767.157; WASSERMAN SI, 1975, J IMMUNOL, V114, P645; WASSOM DL, 1981, J CLIN INVEST, V67, P651, DOI 10.1172/JCI110080; WEISS JW, 1982, SCIENCE, V216, P196, DOI 10.1126/science.7063880; Weller P F, 1979, Adv Immunol, V27, P339, DOI 10.1016/S0065-2776(08)60264-3; WELLER PF, 1982, J IMMUNOL, V128, P1346; WELLER PF, 1978, CELL IMMUNOL, V40, P91, DOI 10.1016/0008-8749(78)90318-0; WELLER PF, 1981, FED PROC, V40, P1023; WELLER PF, 1981, P NATL ACAD SCI USA, V77, P7740; WELLER PF, P NATL ACAD SCI US; WELLER PF, 1983, SEMINARS INFECTIOUS, V5, P229; WINTROUB BU, 1981, CLIN RES, V29, pA618	80	81	84	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	1					1	10		10.1016/0091-6749(84)90474-3	http://dx.doi.org/10.1016/0091-6749(84)90474-3			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SB990	6693661				2022-12-18	WOS:A1984SB99000001
J	SCHUMACHER, MJ; TAIT, BD; HOLMES, MC				SCHUMACHER, MJ; TAIT, BD; HOLMES, MC			ALLERGY TO MURINE ANTIGENS IN A BIOLOGICAL-RESEARCH INSTITUTE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ROYAL MELBOURNE HOSP,TISSUE TYPING LAB,MELBOURNE,VIC 3050,AUSTRALIA; ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,MELBOURNE,VIC 3050,AUSTRALIA	Royal Melbourne Hospital; Royal Melbourne Hospital; Walter & Eliza Hall Institute	SCHUMACHER, MJ (corresponding author), UNIV ARIZONA,ARIZONA HLTH SCI CTR,DEPT PEDIAT,TUCSON,AZ 85724, USA.							ADA GL, 1964, AUST J EXP BIOL MED, V42, P295, DOI 10.1038/icb.1964.31; BENACERRAF B, 1978, IMMUNOL REV, V38, P70, DOI 10.1111/j.1600-065X.1978.tb00385.x; BODMER JG, 1978, HISTOCOMPATIBILITY T, P35; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P31; BURGE PS, 1980, CLIN ALLERGY, V10, P355, DOI 10.1111/j.1365-2222.1980.tb02119.x; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; COCHRAN WG, 1954, BIOMETRICS, V10, P417, DOI 10.2307/3001616; de Weck A L, 1977, Monogr Allergy, V11, P3; GRIER JO, 1977, TISSUE ANTIGENS, V10, P236; GROSS NJ, 1980, J ALLERGY CLIN IMMUN, V66, P158, DOI 10.1016/0091-6749(80)90064-0; KARR RM, 1978, J ALLERGY CLIN IMMUN, V62, P143, DOI 10.1016/0091-6749(78)90098-2; LINCOLN TA, 1974, J OCCUP ENVIRON MED, V16, P465; LUTSKY II, 1975, ANN ALLERGY, V35, P201; MACKAY IR, 1978, GENETIC CONTROL AUTO, P27; MARSH DG, 1980, J ALLERGY CLIN IMMUN, V65, P322, DOI 10.1016/0091-6749(80)90208-0; MARSH DG, 1976, NOBEL S, V33, P23; MINDEN P, 1969, J EXP MED, V130, P931, DOI 10.1084/jem.130.5.931; MITTAL KK, 1968, TRANSPLANTATION, V6, P913, DOI 10.1097/00007890-196811000-00006; MORRIS MJ, 1980, CLIN ALLERGY, V10, P173, DOI 10.1111/j.1365-2222.1980.tb02094.x; NELSON DL, 1977, J IMMUNOL, V118, P943; NEWHOUSE ML, 1970, LANCET, V1, P689; NEWMANTAYLOR A, 1977, LANCET, V2, P847; RAJKA G, 1961, ACTA ALLERGOL, V16, P168, DOI 10.1111/j.1398-9995.1961.tb02891.x; SCHUMACHER MJ, 1980, MOL IMMUNOL, V17, P1087, DOI 10.1016/0161-5890(80)90105-4; SCHUMACHER MJ, 1975, J ALLERGY CLIN IMMUN, V56, P54, DOI 10.1016/0091-6749(75)90034-2; SCHUMACHER MJ, 1979, INT ARCH ALLER A IMM, V58, P38, DOI 10.1159/000232171; SIRAGANIAN RP, 1979, J ALLERGY CLIN IMMUN, V63, P435, DOI 10.1016/0091-6749(79)90219-7; SLAVIN RG, 1971, J ALLERGY CLIN IMMUN, V48, P262, DOI 10.1016/0091-6749(71)90026-1; SLOVAK AJM, 1981, BRIT J IND MED, V38, P38; Terasaki PI, 1967, TRANSPLANTATION, V5, P1057; THORSBY E, 1971, TRANSPLANT P, V3, P1305; Turner M W, 1977, Monogr Allergy, V11, P19; WEILL H, 1971, J AMER MED ASSOC, V217, P425, DOI 10.1001/jama.217.4.425	33	81	81	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	68	4					310	318		10.1016/0091-6749(81)90157-3	http://dx.doi.org/10.1016/0091-6749(81)90157-3			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ML525	7288048	Bronze			2022-12-18	WOS:A1981ML52500011
J	KEPRON, W; JAMES, JM; KIRK, B; SEHON, AH; TSE, KS				KEPRON, W; JAMES, JM; KIRK, B; SEHON, AH; TSE, KS			CANINE MODEL FOR REAGINIC HYPERSENSITIVITY AND ALLERGIC BRONCHOCONSTRICTION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV MANITOBA,FAC MED,DEPT IMMUNOL,MRC,ALLERGY RES GRP,WINNIPEG R3E OW3,MANITOBA,CANADA; UNIV MANITOBA,FAC MED,DEPT MED,MRC,ALLERGY RES GRP,WINNIPEG R3E OW3,MANITOBA,CANADA; HLTH SCI CTR,CLIN INVEST UNIT,WINNIPEG R3E OW1,MANITOBA,CANADA	University of Manitoba; University of Manitoba; University of Manitoba; Children's Hospital Research Institute of Manitoba								BINAGHI RA, 1966, INT ARCH ALLER A IMM, V29, P105, DOI 10.1159/000229692; GOLD WM, 1972, J APPL PHYSIOL, V33, P496, DOI 10.1152/jappl.1972.33.4.496; GOLDMAN M, 1970, J APPL PHYSIOL, V28, P113, DOI 10.1152/jappl.1970.28.1.113; HALLIWELL REW, 1975, TRANSPLANT P, V7, P537; HARGIS BJ, 1970, J IMMUNOL, V104, P942; KEPRON W, 1976, J ALLERGY CLIN IMMUN, V57, P201; KESSLER GF, 1974, INT ARCH ALLER A IMM, V47, P313, DOI 10.1159/000231225; KISIL F T, 1971, Clinical Allergy, V1, P387, DOI 10.1111/j.1365-2222.1971.tb00790.x; LEE WY, 1975, J IMMUNOL, V114, P829; LEVINE BB, 1971, J IMMUNOL, V106, P29; LEVINE BB, 1970, INT ARCH ALLER A IMM, V39, P156, DOI 10.1159/000230343; MATSUMOTO M, 1973, INT ARCH ALLER A IMM, V44, P171, DOI 10.1159/000230926; MCCONNEL.LH, 1973, J ALLERGY CLIN IMMUN, V52, P47, DOI 10.1016/0091-6749(73)90120-6; PATTERSON R, 1972, J ALLERGY CLIN IMMUN, V49, P292, DOI 10.1016/0091-6749(72)90097-8; PATTERSON R, 1970, AM REV RESPIR DIS, V102, P412; PATTERSON R, 1969, PROG ALLERGY, V13, P322; PINCKARD RN, 1972, J ALLERGY CLIN IMMUN, V49, P301; PROUVOSTDANON A, 1970, INT ARCH ALLER A IMM, V38, P648, DOI 10.1159/000230320; SCHWARTZMAN RM, 1971, CLIN EXP IMMUNOL, V9, P549; SUNTHONP.P, 1971, CLIN EXP IMMUNOL, V8, P825	20	81	81	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	59	1					64	69		10.1016/0091-6749(77)90178-6	http://dx.doi.org/10.1016/0091-6749(77)90178-6			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CS828	833375				2022-12-18	WOS:A1977CS82800010
J	Sozener, ZC; Cevhertas, L; Nadeau, K; Akdis, M; Akdis, CA				Soezener, Zeynep Celebi; Cevhertas, Lacin; Nadeau, Kari; Akdis, Muebeccel; Akdis, Cezmi A.			Environmental factors in epithelial barrier dysfunction	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Epithelial barrier; detergents; particulate matter; ozone; nanoparticles; microplastics; protease allergens	PARTICULATE MATTER; INTESTINAL BARRIER; CLEANING PRODUCTS; AIRWAY EPITHELIUM; ATOPIC-DERMATITIS; OXIDATIVE STRESS; TIGHT; ASTHMA; SKIN; EXPOSURE	The main interfaces controlling and attempting to homeostatically balance communications between the host and the environment are the epithelial barriers of the skin, gastrointestinal system, and airways. The epithelial barrier constitutes the first line of physical, chemical, and immunologic defenses and provides a protective wall against environmental factors. Following the industrial revolution in the 19th century, urbanization and socioeconomic development have led to an increase in energy consumption, and waste discharge, leading to increased exposure to air pollution and chemical hazards. Particularly after the 1960s, biological and chemical insults from the surrounding environment-the exposome have been disrupting the physical integrity of the barrier by degrading the intercellular barrier proteins at tight and adherens junctions, triggering epithelial alarmin cytokine responses such as IL-25, IL-33, and thymic stromal lymphopoietin, and increasing the epithelial barrier permeability. A typical type 2 immune response develops in affected organs in asthma, rhinitis, chronic rhinosinusitis, eosinophilic esophagitis, food allergy, and atopic dermatitis. The aim of this article was to discuss the effects of environmental factors such as protease enzymes of allergens, detergents, tobacco, ozone, particulate matter, diesel exhaust, nanoparticles, and microplastic on the integrity of the epithelial barriers in the context of epithelial barrier hypothesis.	[Soezener, Zeynep Celebi; Cevhertas, Lacin; Akdis, Muebeccel; Akdis, Cezmi A.] Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Herman Burchard Str 9, Davos, Switzerland; [Soezener, Zeynep Celebi] Ankara Univ, Dept Chest Dis, Div Allergy & Immunol, Sch Med, Ankara, Turkey; [Cevhertas, Lacin] Bursa Uludag Univ, Inst Hlth Sci, Dept Med Immunol, Bursa, Turkey; [Cevhertas, Lacin; Akdis, Cezmi A.] Christine Kuhne Ctr Allergy Res & Educ CK CARE, Davos, Switzerland; [Nadeau, Kari] Stanford Univ, Naddisy Fdn, Sean Parker Asthma & Allergy Ctr, Stanford, CA 94305 USA	Swiss Institute of Allergy & Asthma Research; University of Zurich; Ankara University; Uludag University; Stanford University	Akdis, CA (corresponding author), Swiss Inst Allergy & Asthma Res, Herman Burchard Str 9, CH-7265 Davos, Wolfgang, Switzerland.	akdisac@siaf.uzh.ch	Akdis, Cezmi/AAV-4844-2020; Sözener, zeynep çelebi/X-3688-2019	Akdis, Cezmi/0000-0001-8020-019X; 				Abdallah F, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/5095293; Aerts O, 2017, EUR J DERMATOL, V27, P115, DOI 10.1684/ejd.2016.2951; Agache I, 2019, ALLERGY, V74, P449, DOI 10.1111/all.13690; Aghapour M, 2018, AM J RESP CELL MOL, V58, P157, DOI 10.1165/rcmb.2017-0200TR; Allen S, 2019, NAT GEOSCI, V12, P339, DOI 10.1038/s41561-019-0335-5; American Lung Association, 2019, WHATS CIG; Angelova-Fischer I, 2016, ACTA DERM-VENEREOL, V96, P880, DOI 10.2340/00015555-2363; Becker S, 2003, J TOXICOL ENV HEAL A, V66, P847, DOI 10.1080/15287390306381; Blume C, 2013, EUR RESPIR J, V42, P87, DOI 10.1183/09031936.00075612; BURNS AR, 1989, J APPL PHYSIOL, V66, P2109, DOI 10.1152/jappl.1989.66.5.2109; Cani PD, 2015, TRENDS ENDOCRIN MET, V26, P273, DOI 10.1016/j.tem.2015.03.009; Caraballo JC, 2011, RESPIROLOGY, V16, P340, DOI 10.1111/j.1440-1843.2010.01910.x; Carder M, 2019, OCCUP ENVIRON MED, V76, P530, DOI 10.1136/oemed-2018-105646; Cecchi L, 2018, J ALLERGY CLIN IMMUN, V141, P846, DOI 10.1016/j.jaci.2018.01.016; Centers for Disease Control and Prevention, 2020, EL CIG; Chakraborty S, 2017, J TOXICOL ENV HEAL A, V80, P53, DOI 10.1080/15287394.2016.1238329; Chassaing B, 2015, NATURE, V519, P92, DOI 10.1038/nature14232; Chaudhary Neelkamal, 2011, Clin Transl Allergy, V1, P4, DOI 10.1186/2045-7022-1-4; Cho CC, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15071380; Chuang HC, 2015, TOXICOL LETT, V237, P174, DOI 10.1016/j.toxlet.2015.06.013; Cooper DM, 2019, EUR RESPIR REV, V28, DOI 10.1183/16000617.0066-2019; Cordier M, 2019, SCI TOTAL ENVIRON, V670, P789, DOI 10.1016/j.scitotenv.2019.03.258; De Benedetto A, 2011, J ALLERGY CLIN IMMUN, V127, P773; De Santis S, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00612; Doherty TA, 2019, ALLERGOL INT, V68, P9, DOI 10.1016/j.alit.2018.11.001; Douwes J, 2017, INT J OCCUP ENV HEAL, V23, P110, DOI 10.1080/10773525.2018.1427307; Egawa G, 2018, ALLERGOL INT, V67, P3, DOI 10.1016/j.alit.2017.10.002; Eguiluz-Gracia I, 2020, ALLERGY, V75, P2170, DOI 10.1111/all.14177; Fahy JV, 2010, NEW ENGL J MED, V363, P2233, DOI 10.1056/NEJMra0910061; Fasano A, 2012, CLIN REV ALLERG IMMU, V42, P71, DOI 10.1007/s12016-011-8291-x; Fetterman JL, 2018, ARTERIOSCL THROM VAS, V38, P1607, DOI 10.1161/ATVBAHA.118.311156; Flohr C, 2014, J INVEST DERMATOL, V134, P345, DOI 10.1038/jid.2013.298; Folletti I, 2017, CURR OPIN ALLERGY CL, V17, P90, DOI 10.1097/ACI.0000000000000349; Galloway TS, 2015, MARINE ANTHROPOGENIC LITTER, P343, DOI 10.1007/978-3-319-16510-3_13; Gavrovic-Jankulovic M., 2015, DRUG DISCOV TODAY DI, V17-18, P29, DOI [10.1016/j.ddmod.2016.09.002, DOI 10.1016/J.DDMOD.2016.09.002, DOI 10.1016/j.ddmod.2016.09.002]; Georas SN, 2014, J ALLERGY CLIN IMMUN, V134, P509, DOI 10.1016/j.jaci.2014.05.049; Glennie E.B., 2002, PHOSPHATES ALTERNATI; Godsel LM, 2004, HANDB EXP PHARM, V165, P137, DOI 10.1007/978-3-540-68170-0_6; Gopalakrishnan S, 2009, INT J PHARMACEUT, V365, P121, DOI 10.1016/j.ijpharm.2008.08.047; Groschwitz KR, 2009, J ALLERGY CLIN IMMUN, V124, P3, DOI 10.1016/j.jaci.2009.05.038; Grozdanovic MM, 2016, BBA-GEN SUBJECTS, V1860, P516, DOI 10.1016/j.bbagen.2015.12.005; Haahtela T, 2019, ALLERGY, V74, P1445, DOI 10.1111/all.13763; Hammad H, 2015, IMMUNITY, V43, P29, DOI 10.1016/j.immuni.2015.07.007; Harmon AC, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205412; Hew M, 2019, ALLERGY, V74, P122, DOI 10.1111/all.13609; Hiroike M, 2013, J DERMATOL, V40, P357, DOI 10.1111/1346-8138.12132; Holloczki O, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-52495-w; Hosoki K, 2015, CURR OPIN ALLERGY CL, V15, P79, DOI 10.1097/ACI.0000000000000136; Huff RD, 2019, J ALLERGY CLIN IMMUN, V143, P1989, DOI 10.1016/j.jaci.2019.04.012; Irvine AD, 2011, NEW ENGL J MED, V365, P1315, DOI 10.1056/NEJMra1011040; Itazawa T, 2019, IMPACT EXPOSURE DESE, DOI [10.1111/all.14166, DOI 10.1111/ALL.14166]; Jahnel J, 2013, J PHYS CONF SER, V429, DOI 10.1088/1742-6596/429/1/012063; Jin YX, 2019, SCI TOTAL ENVIRON, V649, P308, DOI 10.1016/j.scitotenv.2018.08.353; JONES JG, 1980, LANCET, V1, P66; Kechagia JZ, 2019, NAT REV MOL CELL BIO, V20, P457, DOI 10.1038/s41580-019-0134-2; Kehoe T., 1992, ENVIRON, V16, P21, DOI [10.2307/3984751, DOI 10.2307/3984751]; Khanna P, 2015, NANOMATERIALS-BASEL, V5, P1163, DOI 10.3390/nano5031163; Kim BG, 2018, ENVIRON TOXICOL, V33, P798, DOI 10.1002/tox.22566; KOMANO H, 1995, P NATL ACAD SCI USA, V92, P6147, DOI 10.1073/pnas.92.13.6147; Krohn IK, 2020, ALLERGY, V75, P1155, DOI 10.1111/all.14132; Krutmann J, 2014, J DERMATOL SCI, V76, P163, DOI 10.1016/j.jdermsci.2014.08.008; Kubo T, 2015, J ALLERGY CLIN IMMUN, V136, P1413, DOI 10.1016/j.jaci.2015.05.006; Kuo IH, 2013, J ALLERGY CLIN IMMUN, V131, P266, DOI 10.1016/j.jaci.2012.12.1563; Lambrecht BN, 2014, J ALLERGY CLIN IMMUN, V134, P499, DOI 10.1016/j.jaci.2014.06.036; Leisola M., 2001, IND USE ENZYMES; Lichtenstein D, 2017, EUR J PHARM BIOPHARM, V118, P21, DOI 10.1016/j.ejpb.2016.12.004; Lim SL, 2019, NANOTOXICOLOGY, V13, P1117, DOI 10.1080/17435390.2019.1640913; Liu JG, 2019, J THORAC DIS, V11, P2617, DOI 10.21037/jtd.2019.05.77; Lloyd CM, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aat1604; Loxham M, 2017, J ALLERGY CLIN IMMUN, V139, P1736, DOI 10.1016/j.jaci.2017.04.005; Maeda K, 2019, ALLERGY, V74, P1660, DOI 10.1111/all.13788; Marchiando AM, 2010, ANNU REV PATHOL-MECH, V5, P119, DOI 10.1146/annurev.pathol.4.110807.092135; Matejuk A, 2018, ARCH IMMUNOL THER EX, V66, P45, DOI 10.1007/s00005-017-0477-3; Matsumura Yasuhiro, 2012, J Allergy (Cairo), V2012, P903659, DOI 10.1155/2012/903659; Medina-Ramon M, 2005, OCCUP ENVIRON MED, V62, P598, DOI 10.1136/oem.2004.017640; Meisser SS, 2020, J ALLERGY CLIN IMMUN, V145, P619, DOI 10.1016/j.jaci.2019.11.023; Menon GK, 2018, J DERMATOL SCI, V92, P10, DOI 10.1016/j.jdermsci.2018.03.005; Michaudel C, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28261-9; Michaudel C, 2018, J ALLERGY CLIN IMMUN, V142, P942, DOI 10.1016/j.jaci.2017.11.044; Moens E, 2012, IMMUNOLOGY, V135, P1, DOI 10.1111/j.1365-2567.2011.03506.x; Nishida K, 2017, AM J PHYSIOL-LUNG C, V313, pL581, DOI 10.1152/ajplung.00074.2017; OISHI H, 1976, CHEM PHARM BULL, V24, P1765; Pan TL, 2015, J DERMATOL SCI, V78, P51, DOI 10.1016/j.jdermsci.2015.01.011; Peake S, 2012, ENERGY SYSTEMS SUSTA, P505; Peterson LW, 2014, NAT REV IMMUNOL, V14, P141, DOI 10.1038/nri3608; Piao MJ, 2018, ARCH TOXICOL, V92, P2077, DOI 10.1007/s00204-018-2197-9; Pothoven KL, 2017, TISSUE BARRIERS, V5, DOI 10.1080/21688370.2017.1341367; Prunicki M, 2019, J ALLERGY CLIN IMMUN, V143, pAB81; Recke A, 2015, CONTACT DERMATITIS, V72, P339, DOI 10.1111/cod.12351; Rinaldi AO, 2019, ALLERGY, V74, P1934, DOI 10.1111/all.13824; Roberts CL, 2010, GUT, V59, P1331, DOI 10.1136/gut.2009.195370; Roscioli E, 2018, RESP RES, V19, DOI 10.1186/s12931-018-0945-2; Ruiz-Hornillos J, 2020, ALLERGY, V75, P853, DOI 10.1111/all.14140; Sandvik A, 2019, CONTACT DERMATITIS, V80, P243, DOI 10.1111/cod.13182; Sasseville Denis, 2008, Allergy Asthma Clin Immunol, V4, P59, DOI 10.1186/1710-1492-4-2-59; Sbihi H, 2019, ALLERGY, V74, P2103, DOI 10.1111/all.13812; Schmitz H, 1999, GASTROENTEROLOGY, V116, P301, DOI 10.1016/S0016-5085(99)70126-5; Schultz MG, 2017, ELEMENTA-SCI ANTHROP, V5, DOI 10.1525/elementa.244; SCHULZKE JD, 1990, RES EXP MED, V190, P59, DOI 10.1007/PL00020007; SCHULZKE JD, 1989, Z GASTROENTEROL, V27, P693; Shigetomi K, 2018, J BIOCHEM, V163, P265, DOI 10.1093/jb/mvx077; Quaresma JAS, 2019, CLIN MICROBIOL REV, V32, DOI 10.1128/CMR.00034-18; Siracusa A, 2013, ALLERGY, V68, P1532, DOI 10.1111/all.12279; Sjo A, 2010, J MEMBRANE BIOL, V236, P181, DOI 10.1007/s00232-010-9289-7; Sokolowska M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02169; Soyka MB, 2012, J ALLERGY CLIN IMMUN, V130, P1087, DOI 10.1016/j.jaci.2012.05.052; Steelant B, 2016, J ALLERGY CLIN IMMUN, V137, P1043, DOI 10.1016/j.jaci.2015.10.050; Stock V, 2019, ARCH TOXICOL, V93, P1817, DOI 10.1007/s00204-019-02478-7; Sugita K, 2018, J ALLERGY CLIN IMMUN, V141, P300, DOI 10.1016/j.jaci.2017.02.038; Swindle EJ, 2009, J ALLERGY CLIN IMMUN, V124, P23, DOI 10.1016/j.jaci.2009.05.037; Takai Toshiro, 2011, Allergology International, V60, P25, DOI 10.2332/allergolint.10-RAI-0273; Tang KT, 2017, ANN ALLERG ASTHMA IM, V118, P351, DOI 10.1016/j.anai.2016.12.005; Tatsuta M, 2019, RESP RES, V20, DOI 10.1186/s12931-019-1226-4; Thevenot PT, 2013, AM J RESP CELL MOL, V48, P188, DOI 10.1165/rcmb.2012-0052OC; Tian XR, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/567305; Toedter G, 2012, INFLAMM BOWEL DIS, V18, P1399, DOI 10.1002/ibd.22853; Urbancic I, 2018, NANO LETT, V18, P5294, DOI 10.1021/acs.nanolett.8b02291; Van Steenkiste E, 2015, CONTACT DERMATITIS, V72, P237, DOI 10.1111/cod.12359; Vasileva E, 2018, TISSUE BARRIERS, V6, DOI 10.1080/21688370.2018.1539596; Vinhas R, 2011, ALLERGY, V66, P1088, DOI 10.1111/j.1398-9995.2011.02598.x; Vita AA, 2019, J LEUKOCYTE BIOL, V106, P95, DOI 10.1002/JLB.3MIR1118-414RR; Vizcaya D, 2015, OCCUP ENVIRON MED, V72, P757, DOI 10.1136/oemed-2013-102046; Wan H, 2001, CLIN EXP ALLERGY, V31, P279, DOI 10.1046/j.1365-2222.2001.00970.x; Wang M, 2019, J ALLERGY CLIN IMMUN, V143, P1892, DOI 10.1016/j.jaci.2018.11.016; Wang TY, 2017, ACS CHEM BIOL, V12, P1170, DOI 10.1021/acschembio.7b00237; Ware LB, 2014, AM J TRANSPLANT, V14, P2295, DOI 10.1111/ajt.12853; Wawrzyniak P, 2017, J ALLERGY CLIN IMMUN, V139, P93, DOI 10.1016/j.jaci.2016.03.050; West HC, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01941; World Health Organization, TOB; Wright SL, 2017, ENVIRON SCI TECHNOL, V51, P6634, DOI 10.1021/acs.est.7b00423; Xian M, 2020, ALLERGY ASTHMA IMMUN, V12, P56, DOI 10.4168/aair.2020.12.1.56; Xian M, 2016, J ALLERGY CLIN IMMUN, V138, P890, DOI 10.1016/j.jaci.2016.07.003; Xiao C, 2011, J ALLERGY CLIN IMMUN, V128, P549, DOI 10.1016/j.jaci.2011.05.038; Xu M, 2019, SCI TOTAL ENVIRON; Zhao RW, 2018, J APPL TOXICOL, V38, P678, DOI 10.1002/jat.3573; Zock JP, 2007, AM J RESP CRIT CARE, V176, P735, DOI 10.1164/rccm.200612-1793OC	136	80	82	10	40	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2020	145	6					1517	1528		10.1016/j.jaci.2020.04.024	http://dx.doi.org/10.1016/j.jaci.2020.04.024			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LW4ZZ	32507229	Bronze			2022-12-18	WOS:000539157800004
J	Thio, CLP; Chi, PY; Lai, ACY; Chang, YJ				Thio, Christina Li-Ping; Chi, Po-Yu; Lai, Alan Chuan-Ying; Chang, Ya-Jen			Regulation of type 2 innate lymphoid cell-dependent airway hyperreactivity by butyrate	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Short-chain fatty acids; butyrate; type 2 innate lymphoid cells; allergic asthma; eosinophilic airway inflammation	CHAIN FATTY-ACIDS; HISTONE DEACETYLASE INHIBITOR; SEVERE ASTHMA; ALLERGIC INFLAMMATION; LUNG INFLAMMATION; SODIUM-BUTYRATE; GUT MICROBIOTA; PROLIFERATION; ACETYLATION; METABOLITE	Background: Allergic asthma is characterized by airway hyperreactivity (AHR) and inflammation driven by aberrant T(H)2 responses. Type 2 innate lymphoid cells (ILC2s) are a critical source of the T(H)2 cytokines IL-5 and IL-13, which promote acute asthma exacerbation. Short-chain fatty acids (SCFAs) have been shown to attenuate T cell-mediated allergic airway inflammation. However, their role in regulation of ILC2-driven AHR and lung inflammation remains unknown. Objective: We investigated the immunomodulatory role of SCFAs in regulation of ILC2-induced AHR and airway inflammation and delineated the mechanism involved. Methods: We assessed the role of SCFAs in regulating survival, proliferation, and cytokine production in lung sorted ILC2s. The SCFA butyrate was administered through drinking water or intranasally in BALB/c mice to evaluate its role in the ILC2-driven inflammatory response in IL-33 and Alternaria alternata models of allergic inflammation. We further confirmed our findings in human ILC2s. Results: We show that butyrate, but not acetate or propionate, inhibited IL-13 and IL-5 production by murine ILC2s. Systemic and local administration of butyrate significantly ameliorated ILC2-driven AHR and airway inflammation. We further demonstrate that butyrate inhibited ILC2 proliferation and GATA3 expression but did not induce cell apoptosis, likely through histone deacetylase (HDAC) inhibition, because trichostatin A, a pan-HDAC inhibitor, exerted similar effects on ILC2s. Importantly, cotreatment with trichostatin A and butyrate did not result in an additive effect. Finally, we show that butyrate reduces cytokine production in human ILC2s. Conclusion: Our findings identify butyrate as a critical regulator of ILC2 proliferation and function through its HDAC inhibitory activity and can serve as a potential therapeutic target for asthma.	[Thio, Christina Li-Ping; Chang, Ya-Jen] Natl Yang Ming Univ, TIGP Mol Med, Taipei, Taiwan; [Thio, Christina Li-Ping; Chang, Ya-Jen] Acad Sinica, Taipei, Taiwan; [Thio, Christina Li-Ping; Chi, Po-Yu; Lai, Alan Chuan-Ying; Chang, Ya-Jen] Acad Sinica, Inst Biomed Sci, 128 Acad Rd,Sect 2, Taipei 11529, Taiwan	National Yang Ming Chiao Tung University; Academia Sinica - Taiwan; Academia Sinica - Taiwan	Chang, YJ (corresponding author), Acad Sinica, Inst Biomed Sci, 128 Acad Rd,Sect 2, Taipei 11529, Taiwan.	yajchang@ibms.sinica.edu.tw	Chang, Ya-Jen/O-1584-2018	Chang, Ya-Jen/0000-0003-1377-6142	Ministry of Science and Technology [105-2628-B-001-009-MY3, 105-2320-B-001-001]; Academia Sinica Career Development Award [104-CDA-L05]	Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea); Academia Sinica Career Development Award	Supported in part by the Ministry of Science and Technology (105-2628-B-001-009-MY3 and 105-2320-B-001-001 to Y.-J.C.) and by the Academia Sinica Career Development Award (104-CDA-L05 to Y.-J.C.) in Taiwan.	[Anonymous], 2011, APPL PHARM; Arpaia N, 2013, NATURE, V504, P451, DOI 10.1038/nature12726; Bailon E, 2010, IMMUNOBIOLOGY, V215, P863, DOI 10.1016/j.imbio.2010.01.001; Barlow JL, 2012, J ALLERGY CLIN IMMUN, V129, P191, DOI 10.1016/j.jaci.2011.09.041; Bartemes KR, 2012, J IMMUNOL, V188, P1503, DOI 10.4049/jimmunol.1102832; Brestoff JR, 2015, NATURE, V519, P242, DOI 10.1038/nature14115; Canani RB, 2011, WORLD J GASTROENTERO, V17, P1519, DOI [10.3748/wjg.v17.i12.1519, 10.3748/wjg.v17.i12. 1519]; Castanhinha S, 2015, J ALLERGY CLIN IMMUN, V136, P312, DOI 10.1016/j.jaci.2015.01.016; Chang PV, 2014, P NATL ACAD SCI USA, V111, P2247, DOI 10.1073/pnas.1322269111; Chang YJ, 2011, NAT IMMUNOL, V12, P631, DOI 10.1038/ni.2045; CUMMINGS JH, 1987, GUT, V28, P1221, DOI 10.1136/gut.28.10.1221; Davie JR, 2003, J NUTR, V133, p2485S, DOI 10.1093/jn/133.7.2485S; den Besten G, 2013, J LIPID RES, V54, P2325, DOI 10.1194/jlr.R036012; Derrick SC, 2014, CLIN VACCINE IMMUNOL, V21, P1443, DOI 10.1128/CVI.00394-14; Doherty TA, 2012, AM J PHYSIOL-LUNG C, V303, pL577, DOI 10.1152/ajplung.00174.2012; Drake LY, 2014, ADV IMMUNOL, V124, P1, DOI 10.1016/B978-0-12-800147-9.00001-7; Furusawa J, 2013, J IMMUNOL, V191, P1818, DOI 10.4049/jimmunol.1300379; Furusawa Y, 2013, NATURE, V504, P446, DOI 10.1038/nature12721; Gao X, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11960; Ghorbani P, 2015, EUR RESPIR J, V46, P1033, DOI 10.1183/09031936.00143614; Hadjiagapiou C, 2000, AM J PHYSIOL-GASTR L, V279, pG775, DOI 10.1152/ajpgi.2000.279.4.G775; Halim TYF, 2016, NAT IMMUNOL, V17, P57, DOI 10.1038/ni.3294; Halim TYF, 2014, IMMUNITY, V40, P425, DOI 10.1016/j.immuni.2014.01.011; Halnes I, 2017, NUTRIENTS, V9, DOI 10.3390/nu9010057; Huang YJ, 2015, J ALLERGY CLIN IMMUN, V136, P874, DOI 10.1016/j.jaci.2015.05.044; Ito K, 2002, MOL BIOTECHNOL, V20, P99, DOI 10.1385/MB:20:1:099; Ito T, 2015, IMMUN INFLAMM DIS, V3, P196, DOI 10.1002/iid3.59; Ji J, 2016, SCI REP-UK, V6, DOI 10.1038/srep24838; Kabata H, 2015, ALLERGOL INT, V64, P227, DOI 10.1016/j.alit.2015.03.004; Kabata H, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3675; Kamp F, 2006, PROSTAG LEUKOTR ESS, V75, P149, DOI 10.1016/j.plefa.2006.05.003; Kiefer J, 2006, BRIT J NUTR, V96, P803, DOI 10.1017/BJN20061948; Kim BS, 2017, CELL REP, V21, P195, DOI 10.1016/j.celrep.2017.09.021; Kim HY, 2012, J ALLERGY CLIN IMMUN, V129, P216, DOI 10.1016/j.jaci.2011.10.036; Kim MH, 2013, GASTROENTEROLOGY, V145, P396, DOI 10.1053/j.gastro.2013.04.056; Lambrecht BN, 2015, NAT IMMUNOL, V16, P45, DOI 10.1038/ni.3049; Liu SC, 2018, J ALLERGY CLIN IMMUN, V141, P257, DOI 10.1016/j.jaci.2017.03.032; Lu YC, 2016, SCI REP-UK, V6, DOI 10.1038/srep18985; Luhrs H, 2002, SCAND J GASTROENTERO, V37, P458, DOI 10.1080/003655202317316105; Lund Sean, 2013, Current Immunology Reviews, V9, P214; Mackenzie KJ, 2014, P NATL ACAD SCI USA, V111, pE784, DOI 10.1073/pnas.1316178111; Mackie RI, 1997, GASTROINTESTINAL MIC; Martinez-Gonzalez I, 2016, IMMUNITY, V45, P198, DOI 10.1016/j.immuni.2016.06.017; Mirkovic B, 2015, AM J RESP CRIT CARE, V192, P1314, DOI 10.1164/rccm.201505-0943OC; Nguyen NHT, 2007, J NEUROCHEM, V101, P806, DOI 10.1111/j.1471-4159.2006.04397.x; Park J, 2015, MUCOSAL IMMUNOL, V8, P80, DOI 10.1038/mi.2014.44; Possa SS, 2013, FRONT PHARMACOL, V4, DOI 10.3389/fphar.2013.00046; Ramos MG, 2002, BRAZ J MED BIOL RES, V35, P161, DOI 10.1590/S0100-879X2002000200004; Remot A, 2017, ISME J, V11, P1061, DOI 10.1038/ismej.2016.181; Rigas D, 2017, J ALLERGY CLIN IMMUN, V139, P1468, DOI 10.1016/j.jaci.2016.08.034; Roger T, 2011, BLOOD, V117, P1205, DOI 10.1182/blood-2010-05-284711; Rumberger JM, 2014, PEERJ, V2, DOI 10.7717/peerj.611; Sanchez HN, 2016, IMMUNOLOGY, V196, p[127, 6]; Smith PM, 2013, SCIENCE, V341, P569, DOI 10.1126/science.1241165; Suzuki J, 2013, SCIENCE, V341, P403, DOI 10.1126/science.1236758; Tamm M, 2012, RESP MED, V106, pS9, DOI 10.1016/S0954-6111(12)70005-7; Taylor S, 2017, J EXP MED, V214, P1663, DOI 10.1084/jem.20161653; Tazoe H, 2008, J PHYSIOL PHARMACOL, V59, P251; Thorburn AN, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8320; Toki S, 2016, THORAX, V71, P633, DOI 10.1136/thoraxjnl-2015-207728; Topping DL, 2001, PHYSIOL REV, V81, P1031, DOI 10.1152/physrev.2001.81.3.1031; Trompette A, 2014, NAT MED, V20, P159, DOI 10.1038/nm.3444; Vinolo MAR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021205; Walsh ER, 2010, DISCOV MED, V9, P357; Wang J, 2016, DNA CELL BIOL, V35, P203, DOI 10.1089/dna.2015.3037; Xie CH, 2016, ONCOTARGETS THER, V9, P4005, DOI 10.2147/OTT.S105418; Yagi RJ, 2014, IMMUNITY, V40, P378, DOI 10.1016/j.immuni.2014.01.012; Yu X, 2014, MUCOSAL IMMUNOL, V7, P730, DOI 10.1038/mi.2013.92; Zaiss MM, 2015, IMMUNITY, V43, P998, DOI 10.1016/j.immuni.2015.09.012; Zhang JT, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147218; Zhang QL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152724; Zimmerman MA, 2012, AM J PHYSIOL-GASTR L, V302, pG1405, DOI 10.1152/ajpgi.00543.2011	72	80	82	4	27	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2018	142	6					1867	+		10.1016/j.jaci.2018.02.032	http://dx.doi.org/10.1016/j.jaci.2018.02.032			29	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HD2BJ	29522844	Bronze			2022-12-18	WOS:000452315800021
J	van Hage, M; Hamsten, C; Valenta, R				van Hage, Marianne; Hamsten, Carl; Valenta, Rudolf			ImmunoCAP assays: Pros and cons in allergology	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Allergy; IgE; ImmunoCAP; ISAC; allergen extract; allergen molecule; diagnosis	ALLERGEN MOLECULES; DIAGNOSIS; MICROARRAY	Allergen-specific IgE measurements and the clinical history are the cornerstones of allergy diagnosis. During the past decades, both characterization and standardization of allergen extracts and assay technology have improved. Here we discuss the uses, advantages, misinterpretations, and limitations of ImmunoCAP IgE assays (Thermo Fisher Scientific/Phadia, Uppsala, Sweden) in the field of allergology. They can be performed as singleplex (ImmunoCAP) and, for the last decade, as multiplex (Immuno Solid-phase Allergen Chip [ISAC]). The major benefit of ImmunoCAP is the obtained quantified allergen-specific IgE antibody level and the lack of interference from allergen-specific IgG antibodies. However, ImmunoCAP allergen extracts are limited to the composition of the extract. The introduction of allergen molecules has had a major effect on analytic specificity and allergy diagnosis. They are used in both singleplex ImmunoCAP and multiplex ImmunoCAP ISAC assays. The major advantage of ISAC is the comprehensive IgE pattern obtained with a minute amount of serum. The shortcomings are its semiquantitative measurements, lower linear range, and cost per assay. With respect to assay performance, ImmunoCAP allergen extracts are good screening tools, but allergen molecules dissect the IgE response on a molecular level and put allergy research on the map of precision medicine.	[van Hage, Marianne; Hamsten, Carl] Karolinska Inst, Dept Med Solna, Immunol & Allergy Unit, Stockholm, Sweden; [van Hage, Marianne; Hamsten, Carl] Karolinska Univ Hosp, Stockholm, Sweden; [Valenta, Rudolf] Med Univ Vienna, Ctr Pathophysiol Infectiol & Immunol, Dept Pathophysiol & Allergy Res, Vienna, Austria	Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Medical University of Vienna	van Hage, M (corresponding author), Karolinska Univ Hosp, Karolinska Inst, Dept Med Solna, Immunol & Allergy Unit, Solna L2 04, S-17176 Stockholm, Sweden.	marianne.van.hage@ki.se	van Hage, Marianne/A-9678-2017	van Hage, Marianne/0000-0003-3091-1596; Valenta, Rudolf/0000-0001-5944-3365; Hamsten, Carl/0000-0002-1830-9431	Stockholm County Council (ALF project); Swedish Research Council; Swedish Heart-Lung Foundation; Swedish Cancer and Allergy Foundation; Swedish Asthma and Allergy Research Foundation; Konsul Th C Berg's Foundation; Magnus Bergvall Foundation; Hesselman Foundation; Swedish Association for Allergology; SFB program of the Austrian Science Fund (FWF) [F4605, F46]	Stockholm County Council (ALF project)(Stockholm County Council); Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Heart-Lung Foundation(Swedish Heart-Lung Foundation); Swedish Cancer and Allergy Foundation; Swedish Asthma and Allergy Research Foundation; Konsul Th C Berg's Foundation; Magnus Bergvall Foundation; Hesselman Foundation; Swedish Association for Allergology; SFB program of the Austrian Science Fund (FWF)(Austrian Science Fund (FWF))	Supported by the Stockholm County Council (ALF project), the Swedish Research Council, the Swedish Heart-Lung Foundation, the Swedish Cancer and Allergy Foundation, the Swedish Asthma and Allergy Research Foundation, the Konsul Th C Berg's Foundation, the Magnus Bergvall Foundation, the Hesselman Foundation, the Swedish Association for Allergology, and SFB program F46 of the Austrian Science Fund (FWF) project F4605.	Asarnoj A., 2017, J ALLERGY CLIN IMMUN; Asarnoj A, 2016, J ALLERGY CLIN IMMUN, V137, P813, DOI 10.1016/j.jaci.2015.09.052; Hiller R, 2002, FASEB J, V16, P414, DOI 10.1096/fj.01-0711fje; Klimek L, 2015, ALLERGY, V70, P1329, DOI 10.1111/all.12676; Lupinek C, 2014, METHODS, V66, P106, DOI 10.1016/j.ymeth.2013.10.008; Matricardi PM, 2016, PEDIAT ALLERG IMM-UK, V27, P1, DOI 10.1111/pai.12563; Stringari G, 2014, J ALLERGY CLIN IMMUN, V134, P75, DOI 10.1016/j.jaci.2014.01.042; VALENTA R, 1991, J ALLERGY CLIN IMMUN, V88, P889, DOI 10.1016/0091-6749(91)90245-J; van Hage M, 2017, CLIN CHEM LAB MED, V55, P571, DOI 10.1515/cclm-2016-0586; Westman M, 2015, J ALLERGY CLIN IMMUN, V135, P1199, DOI 10.1016/j.jaci.2014.10.042; WIDE L, 1967, LANCET, V2, P1105; Wollmann E, 2015, ALLERGY, V70, P638, DOI 10.1111/all.12592; Wollmann E, 2015, J ALLERGY CLIN IMMUN, V136, P806, DOI 10.1016/j.jaci.2015.02.034	13	80	84	1	19	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2017	140	4					974	977		10.1016/j.jaci.2017.05.008	http://dx.doi.org/10.1016/j.jaci.2017.05.008			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FI7JL	28552762	Bronze			2022-12-18	WOS:000412172900007
J	Druey, KM; Parikh, SM				Druey, Kirk M.; Parikh, Samir M.			Idiopathic systemic capillary leak syndrome (Clarkson disease)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Vascular leak; anaphylaxis; angioedema; intravenous immunoglobulin	INTRAVENOUS IMMUNOGLOBULIN; COMPARTMENT SYNDROME; CASE SERIES; SHOCK; INVOLVEMENT; EDEMA; HYPOTENSION; INFARCTION; THERAPY; PATIENT	In 1960, Dr Bayard Clarkson described a woman experiencing sporadic recurrent episodes of shock and anasarca. Plasma from an acute attack induced a shock-like syndrome when injected into rats. The enigmatic systemic capillary leak syndrome (SCLS) named for Dr Clarkson is characterized by transient and severe but reversible hemoconcentration and hypoalbuminemia caused by leakage of fluids and macromolecules into tissues. Although less than 500 cases of SCLS have been reported in the literature since 1960, the condition is probably underdiagnosed because of a lack of awareness and a high mortality without treatment. Allergists should be vigilant of this diagnosis because its presentation can resemble more common plasma leakage syndromes, including angioedema or systemic anaphylaxis. Although the precise molecular cause of SCLS remains unknown, substantial advances over the last 5 years have increased our understanding of SCLS pathogenesis.	[Druey, Kirk M.] NIAID, Lab Allerg Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Parikh, Samir M.] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA USA; [Parikh, Samir M.] Harvard Med Sch, Ctr Vasc Biol Res, Boston, MA USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard Medical School	Druey, KM (corresponding author), NIH, 10 Ctr Dr,Rm 11N242, Bethesda, MD 20952 USA.	kdruey@niaid.nih.gov			Intramural Research Program of the National Institutes of Allergy and Infectious Diseases/National Institutes of Health; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL125275, R01HL093234] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001083] Funding Source: NIH RePORTER	Intramural Research Program of the National Institutes of Allergy and Infectious Diseases/National Institutes of Health; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported in part by the Intramural Research Program of the National Institutes of Allergy and Infectious Diseases/National Institutes of Health.	Ahn J, 2012, AM SURGEON, V78, pE443; Aldemir-Kocabas B, 2013, TURKISH J PEDIATR, V55, P90; Almagro P, 2012, REV CLIN ESP, V212, P218, DOI 10.1016/j.rce.2011.08.004; Amoura Z, 1997, AM J MED, V103, P514, DOI 10.1016/S0002-9343(97)00272-6; Ansari A, 2011, BMJ CASE REP; Arato E, 2009, CLIN HEMORHEOL MICRO, V41, P1, DOI 10.3233/CH-2009-1145; Arheden H, 1999, RADIOLOGY, V211, P698, DOI 10.1148/radiology.211.3.r99jn41698; Aroney N, 2015, CLIN CASE REP, V3, P527, DOI 10.1002/ccr3.280; ATKINSON JP, 1977, MEDICINE, V56, P225, DOI 10.1097/00005792-197705000-00004; Bencsath KP, 2011, MAYO CLIN PROC, V86, P260, DOI 10.4065/mcp.2010.0819; Bouchet JL, 2014, REV NEUROL-FRANCE, V170, P713, DOI 10.1016/j.neurol.2014.05.010; Brown Rodger H, 2011, Hand (N Y), V6, P110, DOI 10.1007/s11552-010-9305-5; Chlus N, 2016, CUREUS, V8, DOI 10.7759/cureus.649; Choi Kun Moo, 2014, Korean J Hepatobiliary Pancreat Surg, V18, P38, DOI 10.14701/kjhbps.2014.18.1.38; CLARKSON B, 1960, AM J MED, V29, P193, DOI 10.1016/0002-9343(60)90018-8; Corada M, 1999, P NATL ACAD SCI USA, V96, P9815, DOI 10.1073/pnas.96.17.9815; David S, 2011, ARTERIOSCL THROM VAS, V31, P2643, DOI 10.1161/ATVBAHA.111.233189; de Marinis GB, 2012, INTERN EMERG MED, V7, P453, DOI 10.1007/s11739-011-0692-6; Dezsi L, 2016, EXPERT OPIN DRUG MET, P1; Dowden AM, 2009, J ALLERGY CLIN IMMUN, V124, P1111, DOI 10.1016/j.jaci.2009.06.043; Druey KM, 2010, ANN INTERN MED, V153, P90, DOI 10.7326/0003-4819-153-2-201007200-00005; Dudek AZ, 2007, BRIT J CANCER, V97, P513, DOI 10.1038/sj.bjc.6603883; Durand Bechu M, 2016, CASE REP EMERG MED, V2016; Ertel A, 2015, J CARDIOVASC MAGN R, V17, DOI 10.1186/s12968-015-0181-6; Flett AS, 2010, CIRCULATION, V122, P138, DOI 10.1161/CIRCULATIONAHA.109.930636; Garnes M, 2015, TIDSSKR NORSKE LAEGE, V135, P2073, DOI 10.4045/tidsskr.13.1692; Ghosh CC, 2016, P NATL ACAD SCI USA, V113, P2472, DOI 10.1073/pnas.1519467113; Ghosh CC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119577; Martinez MLG, 2012, REV ESP ANEST REANIM, V59, P107, DOI 10.1016/j.redar.2012.02.022; Gousseff M, 2011, ANN INTERN MED, V154, DOI 10.7326/0003-4819-154-7-201104050-00004; Gunes AR, 2016, CLIN CASE REP, V4, P429, DOI 10.1002/ccr3.525; Guillaume M, 2011, Rev Med Interne, V32, pe69, DOI 10.1016/j.revmed.2010.06.002; Hayama M, 2014, BMJ CASE REP, V2014, DOI [10.1136/bcr-2014-203764, DOI 10.1136/BCR-2014-203764]; Hirosaki Yuri, 2015, J Med Case Rep, V9, P90, DOI 10.1186/s13256-015-0544-5; Hsu P, 2015, PEDIATRICS, V135, pE730, DOI 10.1542/peds.2014-2268; Iwasa T, 2014, BMC PEDIATR, V14, DOI 10.1186/1471-2431-14-137; Juthier F, 2012, EUR HEART J-ACUTE CA, V1, P248, DOI 10.1177/2048872612455142; Kapoor P, 2010, MAYO CLIN PROC, V85, P905, DOI 10.4065/mcp.2010.0159; Kellman P, 2012, J CARDIOVASC MAGN R, V14, DOI 10.1186/1532-429X-14-64; Kerketta J, 2015, PAEDIATR INT CHILD H, V35, P160, DOI 10.1179/2046905514Y.0000000161; Kulihova K, 2016, INDIAN J PEDIATR, V83, P1197, DOI 10.1007/s12098-016-2134-y; Lambert M, 2008, CRIT CARE MED, V36, P2184, DOI 10.1097/CCM.0b013e31817d7c71; Lamou Hayat, 2014, J Med Case Rep, V8, P196, DOI 10.1186/1752-1947-8-196; Ledochowski S, 2015, ANAESTH CRIT CARE PA, V34, P251, DOI 10.1016/j.accpm.2015.05.003; Lesterhuis WJ, 2009, AM J MED, V122, pE5, DOI 10.1016/j.amjmed.2009.01.020; Liu H, 2015, INT IMMUNOPHARMACOL, V29, P937, DOI 10.1016/j.intimp.2015.10.010; Mammoto T, 2007, J BIOL CHEM, V282, P23910, DOI 10.1074/jbc.M702169200; Manning TE, 2015, NEW ZEAL MED J, V128, P51; Marra AM, 2014, EXPERT REV CLIN IMMU, V10, P349, DOI 10.1586/1744666X.2014.882771; Merceron S, 2011, MED MALADIES INFECT, V41, P336, DOI 10.1016/j.medmal.2011.02.006; Milam KE, 2015, TISSUE BARRIERS, V3, DOI DOI 10.4161/21688362.2014.957508; Milani GP, 2013, PEDIATR INT, V55, pE81, DOI 10.1111/ped.12068; Miyata K, 2013, CASE REP NEUROL, V5, P175, DOI 10.1159/000355637; Munoz-Guillen N M, 2014, Semergen, V40, pe33, DOI 10.1016/j.semerg.2013.01.003; Nagao Y, 2011, AM J MED, V124, pE7, DOI 10.1016/j.amjmed.2010.04.024; Nakagawa N, 2011, INTERNAL MED, V50, P597, DOI 10.2169/internalmedicine.50.4857; Ng SB, 2010, NAT GENET, V42, P30, DOI 10.1038/ng.499; Ozawa T, 2015, INT SURG, V100, P58, DOI 10.9738/INTSURG-D-13-00206.1; Perme T, 2014, PEDIATR INFECT DIS J, V33, P222, DOI 10.1097/INF.0000000000000029; Piastra M, 2012, LANCET, V379, P976, DOI 10.1016/S0140-6736(11)61819-9; Pratesi A, 2016, INTERN EMERG MED, V11, P719, DOI 10.1007/s11739-016-1449-z; Rahn T, 2012, INTERNIST, V53, P341, DOI 10.1007/s00108-011-2961-x; Roberts OL, 2014, BIOCHEM SOC T, V42, P89, DOI 10.1042/BST20130253; Saugel B, 2010, SCAND J TRAUMA RESUS, V18, DOI 10.1186/1757-7241-18-38; Scanvion Q, 2016, AM J MED, V129, pE77, DOI 10.1016/j.amjmed.2016.02.046; Sek AC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133266; Sheehan JR, 2013, BMJ CASE REP; Simon DA, 2010, J BONE JOINT SURG BR, V92B, P1700, DOI 10.1302/0301-620X.92B12.25225; Sion-Sarid R, 2010, PEDIATRICS, V125, pE687, DOI 10.1542/peds.2009-1691; Tahirkheli NK, 1999, ANN INTERN MED, V130, P905, DOI 10.7326/0003-4819-130-11-199906010-00015; Teutonico A, 2012, J NEPHROL, V25, P262, DOI 10.5301/jn.5000065; Theaudin M, 2011, REV NEUROL-FRANCE, V167, P897, DOI 10.1016/j.neurol.2011.04.005; Then C, 2015, CASE REP MED, V2015, DOI 10.1155/2015/958283; Umbrello M., 2014, CASE REP CRIT CARE, V2014; Val-Flores Luis Silva, 2014, Rev. bras. ter. intensiva, V26, P416, DOI 10.5935/0103-507X.20140064; Xie Z, 2014, J CLIN CELL IMMUNOL, V5, DOI [10.4172/2155-9899.1000213, DOI 10.4172/2155-9899.1000213]; Xie ZH, 2013, RARE DIS, V1, DOI 10.4161/rdis.27445; Xie ZH, 2015, AM J MED, V128, P91, DOI 10.1016/j.amjmed.2014.08.015; Xie ZH, 2014, AM J RESP CRIT CARE, V189, P1145, DOI 10.1164/rccm.201310-1746LE; Xie ZH, 2012, BLOOD, V119, P4321, DOI 10.1182/blood-2011-08-375816; Yardimci B, 2016, IRAN RED CRESCENT ME, V18, DOI 10.5812/ircmj.29249; Zancanaro A, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000591; ZHANG W, 1993, CLIN EXP IMMUNOL, V93, P424, DOI 10.1111/j.1365-2249.1993.tb08195.x; Zipponi M, 2011, BMJ CASE REP	84	80	85	2	21	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2017	140	3					663	670		10.1016/j.jaci.2016.10.042	http://dx.doi.org/10.1016/j.jaci.2016.10.042			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FF8CA	28012935	Bronze, Green Accepted			2022-12-18	WOS:000409241500004
J	McAleer, MA; Pohler, E; Smith, FJD; Wilson, NJ; Cole, C; MacGowan, S; Koetsier, JL; Godsel, LM; Harmon, RM; Gruber, R; Crumrine, D; Elias, PM; McDermott, M; Butler, K; Broderick, A; Sarig, O; Sprecher, E; Green, KJ; McLean, WHI; Irvine, AD				McAleer, Maeve A.; Pohler, Elizabeth; Smith, Frances J. D.; Wilson, Neil J.; Cole, Christian; MacGowan, Stuart; Koetsier, Jennifer L.; Godsel, Lisa M.; Harmon, Robert M.; Gruber, Robert; Crumrine, Debra; Elias, Peter M.; McDermott, Michael; Butler, Karina; Broderick, Annemarie; Sarig, Ofer; Sprecher, Eli; Green, Kathleen J.; McLean, W. H. Irwin; Irvine, Alan D.			Severe dermatitis, multiple allergies, and metabolic wasting syndrome caused by a novel mutation in the N-terminal plakin domain of desmoplakin	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopy; skin barrier; atopic dermatitis; desmosome; desmoplakin; atopic sensitization; eosinophilic esophagitis	SERINE-PROTEASE INHIBITOR; PALMOPLANTAR KERATODERMA; SKIN; DESMOSOMES; FILAGGRIN; DIFFERENTIATION; BARRIER; HAIR; SUBSTITUTION; VARIANTS	Background: Severe dermatitis, multiple allergies, and metabolic wasting (SAM) syndrome is a recently recognized syndrome caused by mutations in the desmoglein 1 gene (DSG1). To date, only 3 families have been reported. Objective: We studied a new case of SAM syndrome known to have no mutations in DSG1 to detail the clinical, histopathologic, immunofluorescent, and ultrastructural phenotype and to identify the underlying molecular mechanisms in this rare genodermatosis. Methods: Histopathologic, electron microscopy, and immunofluorescent studies were performed. Whole-exome sequencing data were interrogated for mutations in desmosomal and other skin structural genes, followed by Sanger sequencing of candidate genes in the patient and his parents. Results: No mutations were identified in DSG1; however, a novel de novo heterozygous missense c.1757A>C mutation in the desmoplakin gene (DSP) was identified in the patient, predicting the amino acid substitution p.His586Pro in the desmoplakin polypeptide. Conclusions: SAM syndrome can be caused by mutations in both DSG1 and DSP. Knowledge of this genetic heterogeneity is important for both analysis of patients and genetic counseling of families. This condition and these observations reinforce the importance of heritable skin barrier defects, in this case desmosomal proteins, in the pathogenesis of atopic disease.	[McAleer, Maeve A.; Irvine, Alan D.] Univ Dublin Trinity Coll, Clin Med, Dublin 2, Ireland; [McAleer, Maeve A.; Irvine, Alan D.] Our Ladys Childrens Hosp Crumlin, Pediat Dermatol, Dublin 12, Ireland; [McAleer, Maeve A.; McDermott, Michael; Irvine, Alan D.] Our Ladys Childrens Hosp Crumlin, Natl Childrens Res Ctr, Dublin 12, Ireland; [Butler, Karina] Our Ladys Childrens Hosp Crumlin, Dept Infect Dis, Dublin 12, Ireland; [Pohler, Elizabeth; Smith, Frances J. D.; Wilson, Neil J.; McLean, W. H. Irwin] Univ Dundee, Dermatol & Genet Med, Dundee DD1 4HN, Scotland; [Cole, Christian; MacGowan, Stuart] Univ Dundee, Coll Life Sci, Div Computat Biol, Dundee DD1 4HN, Scotland; [Koetsier, Jennifer L.; Godsel, Lisa M.; Harmon, Robert M.; Green, Kathleen J.] Northwestern Univ, Dept Pathol, Feinberg Sch Med, Chicago, IL 60611 USA; [Godsel, Lisa M.; Green, Kathleen J.] Northwestern Univ, Dept Dermatol, Feinberg Sch Med, Chicago, IL 60611 USA; [Gruber, Robert] Med Univ Innsbruck, Dept Dermatol & Venereol, A-6020 Innsbruck, Austria; [Crumrine, Debra; Elias, Peter M.] Vet Affairs Med Ctr, Dermatol Serv, San Francisco, CA 94121 USA; [Crumrine, Debra; Elias, Peter M.] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA; [Broderick, Annemarie; Sprecher, Eli] Our Ladys Childrens Hosp Crumlin, Dept Gastroenterol, Dublin 12, Ireland; [Broderick, Annemarie; Sprecher, Eli] Univ Coll Dublin, Sch Med & Med Sci, Dublin, Ireland; [Sarig, Ofer; Sprecher, Eli] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Dept Dermatol, IL-69978 Tel Aviv, Israel; [Sarig, Ofer; Sprecher, Eli] Tel Aviv Univ, Sackler Fac Med, Dept Human Mol Genet & Biochem, IL-69978 Tel Aviv, Israel	Trinity College Dublin; National Children's Research Centre (NCRC); National Children's Research Centre (NCRC); National Children's Research Centre (NCRC); University of Dundee; University of Dundee; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Medical University of Innsbruck; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; National Children's Research Centre (NCRC); University College Dublin; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty of Medicine	Irvine, AD (corresponding author), Our Ladys Childrens Hosp Crumlin, Natl Childrens Res Ctr, Dublin 12, Ireland.	irvinea@tcd.ie	Irvine, Alan D/A-3982-2008; McDermott, Michael Francis/GZM-5330-2022; MacGowan, Stuart/AAY-7296-2021	Irvine, Alan D/0000-0002-9048-2044; MacGowan, Stuart/0000-0003-4233-5071; Harmon, Robert/0000-0003-4843-0168; Cole, Christian/0000-0002-2560-2484	National Children's Research Centre, Dublin, Ireland; Wellcome Trust [090066/B/09/Z, 092530/Z/10/Z, 098439/Z/12/Z]; Pachyonychia Congenita Project; National Institutes of Health [R37 AR043380, R01 AR041836, R01AR061106]; J.L. Mayberry Endowment; Wellcome Trust (WT strategic awards) [WT097945, WT092340, WT083481]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041836, R01AR061106, R37AR043380] Funding Source: NIH RePORTER; Medical Research Council [G0700314, G0900740, MR/K001744/1, G0802780] Funding Source: researchfish; Natural Environment Research Council [NBAF010003] Funding Source: researchfish; BBSRC [BBS/E/D/20310000] Funding Source: UKRI; MRC [MR/K001744/1, G0802780, G0700314, G0900740] Funding Source: UKRI; NERC [NBAF010003] Funding Source: UKRI	National Children's Research Centre, Dublin, Ireland; Wellcome Trust(Wellcome TrustEuropean Commission); Pachyonychia Congenita Project; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); J.L. Mayberry Endowment; Wellcome Trust (WT strategic awards)(Wellcome Trust); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NERC(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))	The Irvine group is funded by the National Children's Research Centre, Dublin, Ireland. M.A.M. is supported by the National Children's Research Centre, Dublin, Ireland. A.D.I. and W.H.I.M. are supported by the Wellcome Trust (090066/B/09/Z and 092530/Z/10/Z). The Centre for Dermatology and Genetic Medicine, University of Dundee, is supported a Wellcome Trust Strategic Award (098439/Z/12/Z to W.H.I.M.). F.J.D.S. and N.J.W. are supported by grants from the Pachyonychia Congenita Project. Work in K.J.G.'s laboratory is supported by the National Institutes of Health (R37 AR043380 and R01 AR041836) and in part by the J.L. Mayberry Endowment. P.M.E. is supported by National Institutes of Health grant R01AR061106. C. Cole is supported by the Wellcome Trust (WT strategic awards WT097945, WT092340, and WT083481).	Brooke MA, 2012, J PATHOL, V226, P158, DOI 10.1002/path.3027; Chavanas S, 2000, NAT GENET, V25, P141, DOI 10.1038/75977; Choi HJ, 2011, J MOL BIOL, V409, P800, DOI 10.1016/j.jmb.2011.04.046; Cork MJ, 2009, J INVEST DERMATOL, V129, P1892, DOI 10.1038/jid.2009.133; Dusek RL, 2006, J BIOL CHEM, V281, P3614, DOI 10.1074/jbc.M508258200; Getsios S, 2009, J CELL BIOL, V185, P1243, DOI 10.1083/jcb.200809044; Harmon RM, 2013, J CLIN INVEST, V123, P1556, DOI 10.1172/JCI65220; Has C, 2015, BRIT J DERMATOL, V172, P257, DOI 10.1111/bjd.13247; Ishida-Yamamoto A, 2014, J DERMATOL SCI, V74, P99, DOI 10.1016/j.jdermsci.2014.02.005; Israeli S, 2011, J INVEST DERMATOL, V131, P779, DOI 10.1038/jid.2010.363; Jonkman MF, 2005, AM J HUM GENET, V77, P653, DOI 10.1086/496901; Kabesch M, 2004, CLIN EXP ALLERGY, V34, P340, DOI 10.1111/j.1365-2222.2004.01860.x; Kowalczyk AP, 1999, J BIOL CHEM, V274, P18145, DOI 10.1074/jbc.274.26.18145; Kowalczyk AP, 1997, J CELL BIOL, V139, P773, DOI 10.1083/jcb.139.3.773; Kurzen H, 1998, DIFFERENTIATION, V63, P295, DOI 10.1007/s002580050254; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/nmeth.1923, 10.1038/NMETH.1923]; Leung DYM, 2013, ALLERGOL INT, V62, P151, DOI 10.2332/allergolint.13-RAI-0564; McAleer MA, 2013, J ALLERGY CLIN IMMUN, V131, P280, DOI 10.1016/j.jaci.2012.12.668; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; McLaren W, 2010, BIOINFORMATICS, V26, P2069, DOI 10.1093/bioinformatics/btq330; Norgett EE, 2000, HUM MOL GENET, V9, P2761, DOI 10.1093/hmg/9.18.2761; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Patel DM, 2014, J CELL BIOL, V206, P779, DOI 10.1083/jcb.201312110; Pellerin L, 2013, J ALLERGY CLIN IMMUN, V131, P1094, DOI 10.1016/j.jaci.2012.12.1566; Petrof G, 2012, BRIT J DERMATOL, V166, P36, DOI 10.1111/j.1365-2133.2011.10640.x; Samuelov L, 2013, NAT GENET, V45, P1244, DOI 10.1038/ng.2739; Sandilands A, 2007, J INVEST DERMATOL, V127, P1282, DOI 10.1038/sj.jid.5700876; SERRANO L, 1992, J MOL BIOL, V227, P544, DOI 10.1016/0022-2836(92)90906-Z; Sherrill JD, 2014, MUCOSAL IMMUNOL, V7, P718, DOI 10.1038/mi.2013.90; Smith FJD, 2006, NAT GENET, V38, P337, DOI 10.1038/ng1743; Smith FJD, 1999, BRIT J DERMATOL, V141, P1010, DOI 10.1046/j.1365-2133.1999.03198.x; Suarez-Farinas M, 2011, J ALLERGY CLIN IMMUN, V127, P954, DOI 10.1016/j.jaci.2010.12.1124; Whittock NV, 1999, J INVEST DERMATOL, V113, P940, DOI 10.1046/j.1523-1747.1999.00783.x; Whittock NV, 2002, J INVEST DERMATOL, V118, P232, DOI 10.1046/j.0022-202x.2001.01664.x	34	80	83	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2015	136	5					1268	1276		10.1016/j.jaci.2015.05.002	http://dx.doi.org/10.1016/j.jaci.2015.05.002			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CW1YE	26073755	Green Published, hybrid			2022-12-18	WOS:000364787200016
J	Beigelman, A; Isaacson-Schmid, M; Sajol, G; Baty, J; Rodriguez, OM; Leege, E; Lyons, K; Schweiger, TL; Zheng, J; Schechtman, KB; Castro, M; Bacharier, LB				Beigelman, Avraham; Isaacson-Schmid, Megan; Sajol, Geneline; Baty, Jack; Rodriguez, Oscar M.; Leege, Erin; Lyons, Kevin; Schweiger, Toni L.; Zheng, Jie; Schechtman, Kenneth B.; Castro, Mario; Bacharier, Leonard B.			Randomized trial to evaluate azithromycin's effects on serum and upper airway IL-8 levels and recurrent wheezing in infants with respiratory syncytial virus bronchiolitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Azithromycin; IL-8; respiratory syncytial virus; wheezing	PLACEBO-CONTROLLED-TRIAL; CHILDHOOD ASTHMA; EPITHELIAL-CELLS; CYSTIC-FIBROSIS; PRETERM INFANTS; DOUBLE-BLIND; INFECTION; DISEASE; PHARMACOKINETICS; INFLAMMATION	Background: Respiratory syncytial virus (RSV) bronchiolitis in infancy is a major risk factor for recurrent wheezing and asthma. Because azithromycin attenuated neutrophilic airway inflammation in a murine viral bronchiolitis model, demonstration of similar effects in human subjects might provide a strategy for the prevention of postbronchiolitis recurrent wheezing. Objectives: We sought to investigate whether azithromycin treatment during RSV bronchiolitis reduces serum and nasal lavage IL-8 levels and the occurrence of postbronchiolitis recurrent wheezing. Method: We performed a randomized, double-masked, placebo-controlled proof-of-concept trial in 40 otherwise healthy infants hospitalized with RSV bronchiolitis who were treated with azithromycin or placebo for 14 days. IL-8 levels were measured in nasal lavage fluid and serum on randomization, day 8, and day 15 (nasal lavage only). The occurrence of wheezing episodes was assessed monthly over the ensuing 50 weeks. Results: Compared with placebo, azithromycin treatment did not reduce serum IL-8 levels at day 8 (P = .6) but resulted in a greater decrease in nasal lavage fluid IL-8 levels by day 15 (P = .03). Twenty-two percent of azithromycin-treated participants experienced at least 3 wheezing episodes compared with 50% of participants in the placebo group (P = .07). Azithromycin treatment resulted in prolonged time to the third wheezing episode (P = .048) and in fewer days with respiratory symptoms over the subsequent year in comparison with placebo (36.7 vs 70.1 days, P = .01). Conclusion: In this proof-of-concept study azithromycin treatment during RSV bronchiolitis reduced upper airway IL-8 levels, prolonged the time to the third wheezing episode, and reduced overall respiratory morbidity over the subsequent year.	[Beigelman, Avraham; Isaacson-Schmid, Megan; Rodriguez, Oscar M.; Leege, Erin; Lyons, Kevin; Bacharier, Leonard B.] Washington Univ, Sch Med, Dept Pediat, Div Allergy Immunol & Pulm Med, St Louis, MO 63110 USA; [Sajol, Geneline; Schweiger, Toni L.; Castro, Mario] Washington Univ, Sch Med, Dept Internal Med, Div Pulm & Crit Care Med, St Louis, MO 63110 USA; [Baty, Jack; Zheng, Jie; Schechtman, Kenneth B.] Washington Univ, Sch Med, Div Biostat, St Louis, MO 63110 USA; [Baty, Jack; Zheng, Jie; Schechtman, Kenneth B.] St Louis Childrens Hosp, St Louis, MO USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL)	Beigelman, A (corresponding author), Washington Univ, Sch Med, Dept Pediat, Div Allergy Immunol & Pulm Med, 660 S Euclid Ave,Campus Box 8116, St Louis, MO 63110 USA.	beigelman_a@kids.wustl.edu		Bacharier, Leonard/0000-0003-0432-2704; ZHENG, JIE/0000-0003-4958-2091	Washington University Institute of Clinical and Translational Sciences from the National Center for Advancing Translational Sciences [UL1 TR000448, KL2 TR000450]; Children's Discovery Institute of Washington University; St Louis Children's Hospital; CTSA [UL1 TR000448]; NCI Cancer Center [P30 CA091842]; Siteman Comprehensive Cancer Center; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000448, KL2TR000450] Funding Source: NIH RePORTER	Washington University Institute of Clinical and Translational Sciences from the National Center for Advancing Translational Sciences; Children's Discovery Institute of Washington University; St Louis Children's Hospital; CTSA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NCI Cancer Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Siteman Comprehensive Cancer Center; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	Supported by Washington University Institute of Clinical and Translational Sciences grant UL1 TR000448 from the National Center for Advancing Translational Sciences (subaward KL2 TR000450) and the Children's Discovery Institute of Washington University and St Louis Children's Hospital. Supported in part (REDCap database) by CTSA grant UL1 TR000448 and Siteman Comprehensive Cancer Center and NCI Cancer Center support grant P30 CA091842.	Asada M, 2009, ANTIVIR RES, V83, P191, DOI 10.1016/j.antiviral.2009.05.003; Bacharier LB, 2012, J ALLERGY CLIN IMMUN, V130, P91, DOI 10.1016/j.jaci.2012.02.010; Ballard HO, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-41; Beigelman A, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-90; Beringer P, 2005, ANTIMICROB AGENTS CH, V49, P5013, DOI 10.1128/AAC.49.12.5013-5017.2005; Berry M, 2007, THORAX, V62, P1043, DOI 10.1136/thx.2006.073429; Bisgaard H, 2008, AM J RESP CRIT CARE, V178, P854, DOI 10.1164/rccm.200706-910OC; Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; Blanken MO, 2013, NEW ENGL J MED, V368, P1791, DOI 10.1056/NEJMoa1211917; Blom D, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004881.pub2; Bulow SM, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.6.e77; Cameron EJ, 2012, CLIN EXP ALLERGY, V42, P1302, DOI 10.1111/j.1365-2222.2012.03979.x; Carroll KN, 2009, J ALLERGY CLIN IMMUN, V123, P964, DOI 10.1016/j.jaci.2008.12.011; Carroll KN, 2009, J ALLERGY CLIN IMMUN, V123, P1055, DOI 10.1016/j.jaci.2009.02.021; Danesi R, 2003, J ANTIMICROB CHEMOTH, V51, P939, DOI 10.1093/jac/dkg138; Diaz PV, 2013, REV MED CHILE, V141, P574, DOI 10.4067/S0034-98872013000500004; Ermers MJJ, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b897; Escobar GJ, 2013, BMC PEDIATR, V13, DOI 10.1186/1471-2431-13-97; Escobar GJ, 2010, ARCH PEDIAT ADOL MED, V164, P915, DOI 10.1001/archpediatrics.2010.177; EVERARD ML, 1994, ARCH DIS CHILD, V71, P428, DOI 10.1136/adc.71.5.428; Friedlander AL, 2010, CHEST, V138, P1202, DOI 10.1378/chest.10-0196; Gielen V, 2010, EUR RESPIR J, V36, P646, DOI 10.1183/09031936.00095809; GLEZEN WP, 1986, AM J DIS CHILD, V140, P543, DOI 10.1001/archpedi.1986.02140200053026; Grayson MH, 2007, J EXP MED, V204, P2759, DOI 10.1084/jem.20070360; James KM, 2013, J ALLERGY CLIN IMMUN, V132, P227, DOI 10.1016/j.jaci.2013.01.009; Jartti T, 2006, PEDIATR INFECT DIS J, V25, P482, DOI 10.1097/01.inf.0000215226.69696.0c; Kloepfer KM, 2014, J ALLERGY CLIN IMMUN, V133, P1301, DOI 10.1016/j.jaci.2014.02.030; Korppi M, 2007, EUR RESPIR J, V29, P1283, DOI 10.1183/09031936.00001907; Leader S, 2003, J PEDIATR-US, V143, pS127, DOI 10.1067/S0022-3476(03)00510-9; Leader S, 2002, PEDIATR INFECT DIS J, V21, P629, DOI 10.1097/00006454-200207000-00005; Lieberthal AS, 2006, PEDIATRICS, V118, P1774, DOI 10.1542/peds.2006-2223; Littel-van den Hurk SV, 2012, CURR OPIN VIROL, V2, P300, DOI 10.1016/j.coviro.2012.01.008; Lotz MT, 2012, CURR ALLERGY ASTHM R, V12, P380, DOI 10.1007/s11882-012-0278-z; Marguet C, 2008, PEDIAT ALLERG IMM-UK, V19, P157, DOI 10.1111/j.1399-3038.2007.00600.x; McNamara PS, 2002, BRIT MED BULL, V61, P13, DOI 10.1093/bmb/61.1.13; Olsen KM, 1996, ANTIMICROB AGENTS CH, V40, P2582, DOI 10.1128/AAC.40.11.2582; Peng WS, 2014, PEDIAT ALLERG IMM-UK, V25, P143, DOI 10.1111/pai.12124; Reis EAG, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002457; Sigurs N, 2005, AM J RESP CRIT CARE, V171, P137, DOI 10.1164/rccm.200406-730OC; SIGURS N, 1995, PEDIATRICS, V95, P500; Sigurs N, 2001, AM J RESP CRIT CARE, V163, pS2, DOI 10.1164/ajrccm.163.supplement_1.2011109; Sigurs N, 2000, AM J RESP CRIT CARE, V161, P1501, DOI 10.1164/ajrccm.161.5.9906076; Simoes EAF, 1999, LANCET, V354, P847, DOI 10.1016/S0140-6736(99)80040-3; Simoes EAF, 2001, AM J RESP CRIT CARE, V163, pS14, DOI 10.1164/ajrccm.163.supplement_1.2011112; Simpson JL, 2008, AM J RESP CRIT CARE, V177, P148, DOI 10.1164/rccm.200707-1134OC; Smyth RL, 2002, PEDIATR PULM, V33, P339, DOI 10.1002/ppul.10080; Tahan F, 2007, EUR RESPIR J, V29, P1284, DOI 10.1183/09031936.00013107; Tahan F, 2007, EUR RESPIR J, V29, P91, DOI 10.1183/09031936.00029206; Wilms EB, 2006, THER DRUG MONIT, V28, P219, DOI 10.1097/01.ftd.0000195617.69721.a5; Wright AKA, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003274; Yamaya M, 2010, J PHARMACOL EXP THER, V333, P81, DOI 10.1124/jpet.109.162149; Yoshihara S, 2013, PEDIATRICS, V132, P811, DOI 10.1542/peds.2013-0982; Zomer-Kooijker K, 2014, PEDIATR INFECT DIS J, V33, P19, DOI 10.1097/01.inf.0000437807.83845.d6	53	80	84	1	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2015	135	5					1171	U543		10.1016/j.jaci.2014.10.001	http://dx.doi.org/10.1016/j.jaci.2014.10.001			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CH4DA	25458910	Green Accepted			2022-12-18	WOS:000353980700009
J	Nassiri, M; Babina, M; Dolle, S; Edenharter, G; Rueff, F; Worm, M				Nassiri, Maria; Babina, Magda; Doelle, Sabine; Edenharter, Guenter; Rueff, Franziska; Worm, Margitta			Ramipril and metoprolol intake aggravate human and murine anaphylaxis: Evidence for direct mast cell priming	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Anaphylaxis; beta-blocker; angiotensin-converting enzyme inhibitor; cofactor; mast cells; cardiovascular medication	HISTAMINE-RELEASE; MEDIATOR RELEASE; RISK-FACTORS; CARDIOVASCULAR-DISEASE; TASK-FORCE; BASE-LINE; ALLERGY; MOUSE; LEUKOTRIENES; MECHANISMS	Background: Cofactors contribute to the elicitation of anaphylaxis. beta-Blockers and angiotensin-converting enzyme (ACE) inhibitors are widely used cardiovascular drugs. We specially designed a mouse model to further analyze the cofactor potential of these drugs. Objective: We sought to test the hypothesis that beta-Blockers and ACE inhibitors alter the risk for severe anaphylaxis and to pinpoint the associated mechanism. Methods: The risk factor potency of cardiovascular drugs on the severity of anaphylaxis in patients from German-speaking countries was analyzed. In vivo interaction of the cardiovascular drugs metoprolol (beta-blocker) and ramipril (ACE inhibitor) with the anaphylactic response was determined. Mast cell (MC) mediators (histamine, serotonin, leukotriene C-4, prostaglandin D-2, and mouse mast cell protease 1) were quantified in serum. Bone marrow-derived cultured MCs served to identify whether the therapeutics targeted MCs directly. Results: Our anaphylaxis database indicated a higher risk of severe anaphylaxis after monotherapy with beta-Blockers or ACE inhibitors, which was more pronounced when both drugs were combined. This was confirmed in our mouse model. While single therapeutics had either no significant (ramipril) or a modestly aggravating (metoprolol) effect, their combined administration exacerbated anaphylactic symptoms potently and simultaneously enhanced MC mediators, hinting at MCs as direct targets. In fact, Fc epsilon RI-mediated MC histamine release was synergistically increased by metoprolol/ramipril or metoprolol/ bradykinin (the latter increased after ACE inhibitor intake), whereas the substances had no significant effect on their own. MC priming was particularly pronounced when Fc epsilon RI aggregation was in the suboptimal range, reflecting common clinical settings. Conclusion: beta-Blockers and ACE inhibitors synergistically aggravate anaphylaxis at least partly by decreasing the threshold of MC activation.	[Nassiri, Maria; Babina, Magda; Doelle, Sabine; Worm, Margitta] Charite, Allergy Ctr Charite, CCM, Dept Dermatol & Allergol, D-10117 Berlin, Germany; [Edenharter, Guenter] Edenharter Res, Berlin, Germany; [Rueff, Franziska] Univ Munich, Dept Dermatol & Allergol, Munich, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Munich	Nassiri, M (corresponding author), Charite, Allergy Ctr Charite, CCM, Dept Dermatol & Allergol, Charitepl 1, D-10117 Berlin, Germany.	Margitta.worm@charite.de		Worm, Margitta/0000-0002-3449-1245; Dolle-Bierke, Sabine/0000-0002-3339-0709; Babina, Magda/0000-0002-4500-7615				Ahimastos AA, 2005, HYPERTENSION, V45, P1194, DOI 10.1161/01.HYP.0000168945.44069.aa; Ben-Shoshan M, 2011, ALLERGY, V66, P1, DOI 10.1111/j.1398-9995.2010.02422.x; Beyer K, 2012, ALLERGY, V67, P1451, DOI 10.1111/all.12012; Bristow MR, 2000, CIRCULATION, V101, P558, DOI 10.1161/01.CIR.101.5.558; Brockow K, 2008, ALLERGY, V63, P226, DOI 10.1111/j.1398-9995.2007.01569.x; Brown SGA, 2013, J ALLERGY CLIN IMMUN, V132, P1141, DOI 10.1016/j.jaci.2013.06.015; CHAKRAVARTY N, 1984, AGENTS ACTIONS, V14, P386, DOI 10.1007/BF01973834; DAYER P, 1985, EUR J CLIN PHARMACOL, V28, P149, DOI 10.1007/BF00609683; GRAFE M, 1993, AM J PHYSIOL, V264, pH1493, DOI 10.1152/ajpheart.1993.264.5.H1493; GROSMAN N, 1981, AGENTS ACTIONS, V11, P196, DOI 10.1007/BF01967614; Guhl S, 2005, J INVEST DERMATOL, V124, P453, DOI 10.1111/j.0022-202X.2004.23523.x; Helbling A, 2004, CLIN EXP ALLERGY, V34, P285, DOI 10.1111/j.1365-2222.2004.01882.x; Hompes S, 2011, PEDIAT ALLERG IMM-UK, V22, P568, DOI 10.1111/j.1399-3038.2011.01154.x; Kato T, 2002, ALLERGOL INT, V53, P197; Kemp SF, 2002, J ALLERGY CLIN IMMUN, V110, P341, DOI 10.1067/mai.2002.126811; Kimata M, 1999, BIOCHEM BIOPH RES CO, V257, P895, DOI 10.1006/bbrc.1999.0557; Knight PA, 2000, J EXP MED, V192, P1849, DOI 10.1084/jem.192.12.1849; Liu HY, 2013, MED HYPOTHESES, V81, P71, DOI 10.1016/j.mehy.2013.02.014; Lopez-Sendon J, 2004, EUR HEART J, V25, P1454, DOI 10.1016/j.ehj.2004.06.003; MACGLASHAN DW, 1982, J CLIN INVEST, V70, P747, DOI 10.1172/JCI110670; Metcalfe DD, 2009, J ALLERGY CLIN IMMUN, V124, P639, DOI 10.1016/j.jaci.2009.08.035; Miyajima I, 1997, J CLIN INVEST, V99, P901, DOI 10.1172/JCI119255; Mueller UR, 2007, CURR OPIN ALLERGY CL, V7, P337, DOI 10.1097/ACI.0b013e328259c328; Ono E, 2009, CLIN EXP ALLERGY, V39, P72, DOI 10.1111/j.1365-2222.2008.03104.x; Peachell P, 2006, CLIN REV ALLERG IMMU, V31, P131, DOI 10.1385/CRIAI:31:2:131; PEARCE FL, 1981, AGENTS ACTIONS, V11, P51, DOI 10.1007/BF01991455; Poulos LM, 2007, J ALLERGY CLIN IMMUN, V120, P878, DOI 10.1016/j.jaci.2007.07.040; Razin E, 1999, SIGNAL TRANSDUCTION; Renaudin JM, 2013, ALLERGY, V68, P929, DOI 10.1111/all.12168; RING J, 1977, LANCET, V1, P466; Rueff F, 2009, J ALLERGY CLIN IMMUN, V124, P1047, DOI 10.1016/j.jaci.2009.08.027; Ryan TJ, 1996, CIRCULATION, V94, P2341, DOI 10.1161/01.CIR.94.9.2341; SCHLEIMER RP, 1983, J CLIN INVEST, V71, P1830, DOI 10.1172/JCI110938; SCHLEIMER RP, 1986, AM REV RESPIR DIS, V133, P614; Sheen CH, 2007, ALLERGY, V62, P532, DOI 10.1111/j.1398-9995.2007.01345.x; Siegel D, 1997, JAMA-J AM MED ASSOC, V278, P1745, DOI 10.1001/jama.278.21.1745; SIRAGANIAN RP, 1975, INT ARCH ALLER A IMM, V49, P108, DOI 10.1159/000231384; STEVENS RL, 1994, P NATL ACAD SCI USA, V91, P128, DOI 10.1073/pnas.91.1.128; Stoevesandt J, 2012, J ALLERGY CLIN IMMUN, V130, P698, DOI 10.1016/j.jaci.2012.03.024; Thong BYH, 2004, ANN ALLERG ASTHMA IM, V92, P619, DOI 10.1016/S1081-1206(10)61427-5; Trcka J, 2008, AM J ROENTGENOL, V190, P666, DOI 10.2214/AJR.07.2872; Triggiani M, 2008, CLIN EXP IMMUNOL, V153, P7, DOI 10.1111/j.1365-2249.2008.03714.x; Webb LM, 2006, ANN ALLERG ASTHMA IM, V97, P39, DOI 10.1016/S1081-1206(10)61367-1; Weston MC, 1998, GEN PHARMACOL-VASC S, V31, P715, DOI 10.1016/S0306-3623(98)00080-9; WHITE JR, 1985, P NATL ACAD SCI USA, V82, P8193, DOI 10.1073/pnas.82.23.8193; Wolbing F, 2013, ALLERGY, V68, P1085, DOI 10.1111/all.12193; Worm M, 2012, ALLERGY, V67, P691, DOI 10.1111/j.1398-9995.2012.02795.x; Worm M, 2013, J DTSCH DERMATOL GES, V11, P44, DOI 10.1111/j.1610-0387.2012.08045.x; Xiao R P, 2001, Sci STKE, V2001, pre15, DOI 10.1126/stke.2001.104.re15	49	80	81	1	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2015	135	2					491	499		10.1016/j.jaci.2014.09.004	http://dx.doi.org/10.1016/j.jaci.2014.09.004			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CB1FL	25441633				2022-12-18	WOS:000349372300023
J	Galanter, JM; Gignoux, CR; Torgerson, DG; Roth, LA; Eng, C; Oh, SS; Nguyen, EA; Drake, KA; Huntsman, S; Hu, DL; Sen, S; Davis, A; Farber, HJ; Avila, PC; Brigino-Buenaventura, E; LeNoir, MA; Meade, K; Serebrisky, D; Borrell, LN; Rodriguez-Cintron, W; Estrada, AM; Mendoza, KS; Winkler, CA; Klitz, W; Romieu, I; London, SJ; Gilliland, F; Martinez, F; Bustamante, C; Williams, LK; Kumar, R; Rodriguez-Santana, JR; Burchard, EG				Galanter, Joshua M.; Gignoux, Christopher R.; Torgerson, Dara G.; Roth, Lindsey A.; Eng, Celeste; Oh, Sam S.; Nguyen, Elizabeth A.; Drake, Katherine A.; Huntsman, Scott; Hu, Donglei; Sen, Saunak; Davis, Adam; Farber, Harold J.; Avila, Pedro C.; Brigino-Buenaventura, Emerita; LeNoir, Michael A.; Meade, Kelley; Serebrisky, Denise; Borrell, Luisa N.; Rodriguez-Cintron, William; Estrada, Andres Moreno; Mendoza, Karla Sandoval; Winkler, Cheryl A.; Klitz, William; Romieu, Isabelle; London, Stephanie J.; Gilliland, Frank; Martinez, Fernando; Bustamante, Carlos; Williams, L. Keoki; Kumar, Rajesh; Rodriguez-Santana, Jose R.; Burchard, Esteban G.			Genome-wide association study and admixture mapping identify different asthma-associated loci in Latinos: The Genes-environments & Admixture in Latino Americans study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; Latinos; admixture mapping; genome-wide association study; local ancestry; 17q21; 6p21	AFRICAN-AMERICAN; UNITED-STATES; CANCER RISK; ANCESTRY; IDENTIFICATION; HERITABILITY; INDIVIDUALS; POPULATIONS; IMPUTATION; INFERENCE	Background: Asthma is a complex disease with both genetic and environmental causes. Genome-wide association studies of asthma have mostly involved European populations, and replication of positive associations has been inconsistent. Objective: We sought to identify asthma-associated genes in a large Latino population with genome-wide association analysis and admixture mapping. Methods: Latino children with asthma (n = 1893) and healthy control subjects (n = 1881) were recruited from 5 sites in the United States: Puerto Rico, New York, Chicago, Houston, and the San Francisco Bay Area. Subjects were genotyped on an Affymetrix World Array IV chip. We performed genome-wide association and admixture mapping to identify asthma-associated loci. Results: We identified a significant association between ancestry and asthma at 6p21 (lowest P value: rs2523924, P < 5 x 10(-6)). This association replicates in a meta-analysis of the EVE Asthma Consortium (P = .01). Fine mapping of the region in this study and the EVE Asthma Consortium suggests an association between PSORS1C1 and asthma. We confirmed the strong allelic association between SNPs in the 17q21 region and asthma in Latinos (IKZF3, lowest P value: rs90792, odds ratio, 0.67; 95% CI, 0.61-0.75; P = 6 x 10(-13)) and replicated associations in several genes that had previously been associated with asthma in genome-wide association studies. Conclusions: Admixture mapping and genome-wide association are complementary techniques that provide evidence for multiple asthma-associated loci in Latinos. Admixture mapping identifies a novel locus on 6p21 that replicates in a meta-analysis of several Latino populations, whereas genome-wide association confirms the previously identified locus on 17q21.	[Galanter, Joshua M.; Torgerson, Dara G.; Roth, Lindsey A.; Eng, Celeste; Oh, Sam S.; Huntsman, Scott; Hu, Donglei; Burchard, Esteban G.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [Galanter, Joshua M.; Gignoux, Christopher R.; Drake, Katherine A.; Burchard, Esteban G.] Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA; [Nguyen, Elizabeth A.] St Louis Univ, Sch Med, St Louis, MO 63103 USA; [Sen, Saunak] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; [Davis, Adam; Meade, Kelley] Childrens Hosp & Res Ctr Oakland, Oakland, CA USA; [Farber, Harold J.] Baylor Coll Med, Dept Pediat, Sect Pulmonol, Houston, TX 77030 USA; [Farber, Harold J.] Texas Childrens Hosp, Houston, TX 77030 USA; [Avila, Pedro C.] Northwestern Univ, Div Allergy Immunol, Feinberg Sch Med, Chicago, IL 60611 USA; [Brigino-Buenaventura, Emerita] Kaiser Permanente Vallejo Med Ctr, Dept Allergy & Immunol, Vallejo, CA USA; [LeNoir, Michael A.] Bay Area Pediat, Oakland, CA USA; [Serebrisky, Denise] Jacobi Med Ctr, Pediat Pulm Div, Bronx, NY USA; [Borrell, Luisa N.] CUNY Herbert H Lehman Coll, Dept Hlth Sci, Grad Program Publ Hlth, Bronx, NY 10468 USA; [Rodriguez-Cintron, William] Vet Caribbean Hlth Care Syst, San Juan, PR USA; [Estrada, Andres Moreno; Mendoza, Karla Sandoval; Bustamante, Carlos] Stanford Univ, Dept Genet, Stanford, CA 94305 USA; [Winkler, Cheryl A.] NIH, Frederick Natl Lab Canc Res, Frederick, MD USA; [Klitz, William] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA; [Romieu, Isabelle] Int Agcy Res Canc, F-69372 Lyon, France; [London, Stephanie J.] NIEHS, NIH, Dept Hlth & Human Serv, Res Triangle Pk, NC 27709 USA; [Gilliland, Frank] Univ So Calif, Dept Prevent Med, Los Angeles, CA 90089 USA; [Martinez, Fernando] Univ Arizona, Dept Pediat, Tucson, AZ 85721 USA; [Williams, L. Keoki] Henry Ford Hlth Syst, Dept Internal Med, Detroit, MI USA; [Kumar, Rajesh] Ann & Robert H Lurie Childrens Hosp Chicago, Chicago, IL USA; [Rodriguez-Santana, Jose R.] Ctr Neumol Pediat, San Juan, PR USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Saint Louis University; University of California System; University of California San Francisco; Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland; Baylor College of Medicine; Baylor College of Medicine; Northwestern University; Feinberg School of Medicine; Kaiser Permanente; Jacobi Medical Center; City University of New York (CUNY) System; Lehman College (CUNY); Stanford University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of California System; University of California Berkeley; World Health Organization; International Agency for Research on Cancer (IARC); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Southern California; University of Arizona; Henry Ford Health System; Henry Ford Hospital; Ann & Robert H. Lurie Children's Hospital of Chicago	Galanter, JM (corresponding author), Univ Calif San Francisco, Dept Bioengn & Therapeut Sci & Med, UCSF Box 2911, San Francisco, CA 94143 USA.	joshua.galanter@ucsf.edu	London, Stephanie/C-3734-2019; Moreno-Estrada, Andres/R-3950-2017; Borrell, Luisa N./G-8753-2018; Moreno-Estrada, Andres/AAP-4657-2021	London, Stephanie/0000-0003-4911-5290; Moreno-Estrada, Andres/0000-0001-8329-8292; Borrell, Luisa N./0000-0002-0560-4853; Moreno-Estrada, Andres/0000-0001-8329-8292; Bustamante, Carlos D./0000-0002-4187-7920; Nguyen, Elizabeth/0000-0002-8070-6382; Galanter, Joshua/0000-0002-2561-6384; Kumar, Rajesh/0000-0002-1962-7108	National Institutes of Health (NIH) [R01 ES015794, R01 HL088133, M01 RR000083, R01 HL078885, R01 HL104608, P60 MD006902, U19 AI077439, M01 RR00188]; ARRA grant [RC2 HL101651]; Flight Attendant Medical Research Institute (FAMRI); Sandler Foundation; American Asthma Foundation; NIH [K23HL004464]; NIH Training Grant [T32, GM007546, GM007175]; NHLBI [K23HL111636, K23HL093023]; NCATS KL2 [KL2TR000143]; Hewett Fellowship; UCSF Chancellor's Research Fellowship; Dissertation Year Fellowship; GCRC [RR00188]; Division of Intramural Research, National Institute of Environmental Health Sciences [ZIA ES49019]; NIH; NATIONAL CANCER INSTITUTE [ZIABC010022] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [KL2TR000143] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000188, M01RR000083] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL088133, K23HL093023, T32HL007185, K23HL111636] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES043012, ZIAES049019, R01ES015794] Funding Source: NIH RePORTER; National Institute on Minority Health and Health Disparities [P60MD006902] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ARRA grant; Flight Attendant Medical Research Institute (FAMRI); Sandler Foundation; American Asthma Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH Training Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCATS KL2; Hewett Fellowship; UCSF Chancellor's Research Fellowship; Dissertation Year Fellowship; GCRC(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Division of Intramural Research, National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); National Institute on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD))	Supported in part by the National Institutes of Health (NIH; R01 ES015794, R01 HL088133, M01 RR000083, R01 HL078885, R01 HL104608, P60 MD006902, U19 AI077439, and M01 RR00188) and ARRA grant RC2 HL101651. E.G.B. was supported in part through grants from the Flight Attendant Medical Research Institute (FAMRI), the Sandler Foundation, the American Asthma Foundation and NIH (K23 HL004464). J.M.G. was supported in part by NIH Training Grant T32 (GM007546) and career development awards from the NHLBI K23 (K23HL111636) and NCATS KL2 (KL2TR000143), as well as the Hewett Fellowship. C.R.G. was supported in part by NIH Training Grant T32 (GM007175) and the UCSF Chancellor's Research Fellowship and Dissertation Year Fellowship. R. K. was supported with a career development award from the NHLBI (K23HL093023). H.J.F. was supported in part by the GCRC (RR00188). P.C.A. was supported in part by the Ernest S. Bazley Grant. S.J.L. was supported in part by the Division of Intramural Research, National Institute of Environmental Health Sciences (ZIA ES49019). This publication was supported by various institutes within the NIH. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH.	Alexander DH, 2009, GENOME RES, V19, P1655, DOI 10.1101/gr.094052.109; Allanore Y, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002091; Altshuler D, 2010, NATURE, V467, P1061, DOI 10.1038/nature09534; Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632; Apostolakis J, 1996, RESP MED, V90, P201, DOI 10.1016/S0954-6111(96)90287-5; Baran Y, 2012, BIOINFORMATICS, V28, P1359, DOI 10.1093/bioinformatics/bts144; Brisbin A, 2012, HUM BIOL, V84, P343, DOI 10.3378/027.084.0401; Bustamante CD, 2011, NATURE, V475, P163, DOI 10.1038/475163a; Dickson SP, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000294; Fagnani C, 2008, TWIN RES HUM GENET, V11, P121, DOI 10.1375/twin.11.2.121; Fejerman L, 2012, HUM MOL GENET, V21, P1907, DOI 10.1093/hmg/ddr617; Ferreira MAR, 2011, EUR J HUM GENET, V19, P458, DOI 10.1038/ejhg.2010.191; Flores G, 2002, JAMA-J AM MED ASSOC, V288, P82, DOI 10.1001/jama.288.1.82; Freedman ML, 2006, P NATL ACAD SCI USA, V103, P14068, DOI 10.1073/pnas.0605832103; Galanter JM, 2011, J ALLERGY CLIN IMMUN, V128, P37, DOI 10.1016/j.jaci.2011.03.050; Genin E, 2011, ORPHANET J RARE DIS, V6, DOI 10.1186/1750-1172-6-52; Gilliland FD, 2002, AM J RESP CRIT CARE, V166, P457, DOI 10.1164/rccm.2112064; Guilbert TW, 2004, CONTROL CLIN TRIALS, V25, P286, DOI 10.1016/j.cct.2004.03.002; Hancock DB, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000623; Hijikata M, 2011, HUM GENET, V129, P117, DOI 10.1007/s00439-010-0906-4; Hindorff LA, 2009, P NATL ACAD SCI USA, V106, P9362, DOI 10.1073/pnas.0903103106; Hirota T, 2011, NAT GENET, V43, P893, DOI 10.1038/ng.887; Hoffmann TJ, 2011, GENOMICS, V98, P422, DOI 10.1016/j.ygeno.2011.08.007; Hou SP, 2012, ARTHRITIS RHEUM-US, V64, P4104, DOI 10.1002/art.37708; Howie B, 2011, G3-GENES GENOM GENET, V1, P457, DOI 10.1534/g3.111.001198; Howie BN, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000529; Ivkovic-Jurekovic I, 2011, COLLEGIUM ANTROPOL, V35, P1243; Jostins L, 2012, NATURE, V491, P119, DOI 10.1038/nature11582; Kao WHL, 2008, NAT GENET, V40, P1185, DOI 10.1038/ng.232; Kim DK, 2012, AM J RESP CRIT CARE, V186, P1238, DOI 10.1164/rccm.201206-1013OC; Kopp JB, 2008, NAT GENET, V40, P1175, DOI 10.1038/ng.226; Li J, 2005, HEREDITY, V95, P221, DOI 10.1038/sj.hdy.6800717; Li XN, 2012, J ALLERGY CLIN IMMUN, V130, P861, DOI 10.1016/j.jaci.2012.04.041; Lin PI, 2007, AM J HUM GENET, V80, P531, DOI 10.1086/512133; Mathieu A, 2007, REUMATISMO, V59, P25, DOI 10.4081/reumatismo.2007.1s.25; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; Moorman Jeanne E., 2007, Morbidity and Mortality Weekly Report, V56, P1; Moorman Jeanne E., 2011, Morbidity and Mortality Weekly Report, V60, P84; National Asthma Education and Prevention Program (National Heart Lung and Blood Institute), 2010, GUID DIAGN MAN ASTHM, p[xxii, 326]; Nyholt DR, 2004, AM J HUM GENET, V74, P765, DOI 10.1086/383251; Oh SS, 2012, J ALLERGY CLIN IMMUN, V129, P1478, DOI 10.1016/j.jaci.2012.03.017; Pasaniuc B, 2009, BIOINFORMATICS, V25, pI213, DOI 10.1093/bioinformatics/btp197; Paz Z, 2011, ISR MED ASSOC J, V13, P625; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Ramasamy A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044008; Reich D, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000360; Rogers AJ, 2009, AM J RESP CRIT CARE, V179, P1084, DOI 10.1164/rccm.200812-1860OC; Rose MC, 2006, PHYSIOL REV, V86, P245, DOI 10.1152/physrev.00010.2005; Rosenberg NA, 2010, NAT REV GENET, V11, P356, DOI 10.1038/nrg2760; Salari K, 2007, PAEDIATR PERINAT EP, V21, P15, DOI 10.1111/j.1365-3016.2007.00880.x; Seibold MA, 2011, NEW ENGL J MED, V364, P1503, DOI 10.1056/NEJMoa1013660; Shriner D, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002325; Sleiman PMA, 2010, NEW ENGL J MED, V362, P36, DOI 10.1056/NEJMoa0901867; Team RC, 2012, R LANG ENV STAT COMP; Tohkin M, 2011, PHARMACOGENOMICS J, V13, P60; Torgerson DG, 2012, J ALLERGY CLIN IMMUN, V130, P622, DOI 10.1016/j.jaci.2012.03.045; Torgerson DG, 2012, J ALLERGY CLIN IMMUN, V130, P76, DOI 10.1016/j.jaci.2012.02.040; Torgerson DG, 2011, NAT GENET, V43, P887, DOI 10.1038/ng.888; Verlaan DJ, 2009, AM J HUM GENET, V85, P377, DOI 10.1016/j.ajhg.2009.08.007; Wan YI, 2012, THORAX, V67, P762, DOI 10.1136/thoraxjnl-2011-201262; Willemsen G, 2008, TWIN RES HUM GENET, V11, P132, DOI 10.1375/twin.11.2.132; Winkler CA, 2010, ANNU REV GENOM HUM G, V11, P65, DOI 10.1146/annurev-genom-082509-141523; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC; Wu H, 2010, J ALLERGY CLIN IMMUN, V125, P321, DOI 10.1016/j.jaci.2009.09.007	66	80	80	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2014	134	2					295	305		10.1016/j.jaci.2013.08.055	http://dx.doi.org/10.1016/j.jaci.2013.08.055			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AO5GB	24406073	Green Accepted			2022-12-18	WOS:000341370800007
J	Kaesler, S; Volz, T; Skabytska, Y; Koberle, M; Hein, U; Chen, KM; Guenova, E; Wolbing, F; Rocken, M; Biedermann, T				Kaesler, Susanne; Volz, Thomas; Skabytska, Yuliya; Koeberle, Martin; Hein, Ulrike; Chen, Ko-Ming; Guenova, Emmanuella; Woelbing, Florian; Roecken, Martin; Biedermann, Tilo			Toll-like receptor 2 ligands promote chronic atopic dermatitis through IL-4-mediated suppression of IL-10	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Staphylococcus aureus; Toll-like receptor 2; innate immunity; IL-4; T(H)2; atopic dermatitis; IL-10	IL-4R-ALPHA MAB REGN668/SAR231893; STAPHYLOCOCCUS-AUREUS; EPIDERMAL BARRIER; LIPOTEICHOIC ACID; IN-SITU; CYTOKINE; TLR2; INTERLEUKIN-10; ECZEMA; CELLS	Background: Atopic dermatitis (AD) is a T cell-mediated inflammatory skin disease, with T(H)2 cells initiating acute flares. This inflamed skin is immediately colonized with Staphylococcus aureus, which provides potent Toll-like receptor (TLR) 2 ligands. However, the effect of TLR2 ligands on the development of T(H)2-mediated AD inflammation remains unclear. Objective: We investigated the progression of T(H)2 cell-mediated dermatitis after TLR2 activation. Methods: Using models for acute AD with T(H)2 cells initiating cutaneous inflammation, we investigated the consequences of TLR2 activation. Dermatitis, as assessed by changes in ear skin thickness and histology, was analyzed in different BALB/c and C57BL/6 wild-type and knockout mouse strains, and immune profiling was carried out by using in vitro and ex vivo cytokine analyses. Results: We show that T(H)2 cell-mediated dermatitis is self-limiting and depends on IL-4. Activation of TLR2 converted the limited T(H)2 dermatitis to chronic cutaneous inflammation. We demonstrate that the concerted activation of TLR2 and IL-4 receptor on dendritic cells is sufficient for this conversion. As an underlying mechanism, we found that the combinatorial sensing of the innate TLR2 ligands and the adaptive T(H)2 cytokine IL-4 suppressed anti-inflammatory IL-10 and consequently led to the exacerbation and persistence of dermatitis. Conclusion: Our data demonstrate that innate TLR2 signals convert transient T(H)2 cell-mediated dermatitis into persistent inflammation, as seen in chronic human AD, through IL-4-mediated suppression of IL-10. For the first time, these data show how initial AD lesions convert to chronic inflammation and provide another rationale for targeting IL-4 in patients with AD, a therapeutic approach that is currently under development.	[Kaesler, Susanne; Volz, Thomas; Skabytska, Yuliya; Koeberle, Martin; Hein, Ulrike; Chen, Ko-Ming; Guenova, Emmanuella; Woelbing, Florian; Roecken, Martin; Biedermann, Tilo] Univ Tubingen, Dept Dermatol, D-72076 Tubingen, Germany; [Guenova, Emmanuella] Univ Zurich Hosp, Dept Dermatol, CH-8091 Zurich, Switzerland; [Biedermann, Tilo] Tech Univ Munich, Dept Dermatol & Allergy Biederstein, D-80290 Munich, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; University of Zurich; University Zurich Hospital; Technical University of Munich	Biedermann, T (corresponding author), Univ Tubingen, Dept Dermatol, Liebermeisterstr 25, D-72076 Tubingen, Germany.	tilo.biedermann@med.uni-tuebingen.de	Köberle, Martin/HCI-8264-2022; Guenova, Emmanuella/G-7441-2017	Köberle, Martin/0000-0001-6825-2667; Guenova, Emmanuella/0000-0001-5478-8735; Biedermann, Tilo/0000-0002-5352-5105; Rocken, Martin/0000-0003-3795-7001	Baden-Wurttemberg Stiftung [P-LS-AL2/4]; Deutsche Forschungsgemeinschaft (DFG) [BI696/10-1, B1696/5-1, BI696/5-2, SFB 685 A06, C01]; Wilhelm Sander-Stiftung [2012.056.1]	Baden-Wurttemberg Stiftung; Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Wilhelm Sander-Stiftung	Supported by contract research "Allergologie 2'' of the Baden-Wurttemberg Stiftung (P-LS-AL2/4) and by grants of the Deutsche Forschungsgemeinschaft (DFG; BI696/10-1, B1696/5-1, BI696/5-2, SFB 685 A06, C01) and the Wilhelm Sander-Stiftung (2012.056.1).	Asadullah K, 1998, J CLIN INVEST, V101, P783, DOI 10.1172/JCI1476; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; Baroni A, 2006, ARCH DERMATOL RES, V297, P280, DOI 10.1007/s00403-005-0594-4; Beck LA, 2013, J INVEST DERMATOL, V133, pS178; Beck LA, 2009, J ALLERGY CLIN IMMUN, V124, P260, DOI 10.1016/j.jaci.2009.05.020; Biedermann T, 2006, ACTA DERM-VENEREOL, V86, P99, DOI 10.2340/00015555-047; Biedermann T, 2002, EUR J IMMUNOL, V32, P3171, DOI 10.1002/1521-4141(200211)32:11<3171::AID-IMMU3171>3.0.CO;2-4; Biedermann T, 2001, NAT IMMUNOL, V2, P1054, DOI 10.1038/ni725; Biedermann T, 2006, J IMMUNOL, V177, P3763, DOI 10.4049/jimmunol.177.6.3763; Boguniewicz M, 2011, IMMUNOL REV, V242, P233, DOI 10.1111/j.1600-065X.2011.01027.x; Commins S, 2008, J ALLERGY CLIN IMMUN, V121, P1108, DOI 10.1016/j.jaci.2008.02.026; De Benedetto A, 2011, J ALLERGY CLIN IMMUN, V128, P242, DOI 10.1016/j.jaci.2011.02.014; Fallon PG, 2009, NAT GENET, V41, P602, DOI 10.1038/ng.358; Fournier B, 2013, FRONT CELL INFECT MI, V3, DOI 10.3389/fcimb.2012.00167; Gong JQ, 2006, BRIT J DERMATOL, V155, P680, DOI 10.1111/j.1365-2133.2006.07410.x; GREWE M, 1995, J INVEST DERMATOL, V105, P407, DOI 10.1111/1523-1747.ep12321078; Guenova E, 2008, EUR J IMMUNOL, V38, P3138, DOI 10.1002/eji.200838463; Gunther C, 2005, J IMMUNOL, V174, P1723, DOI 10.4049/jimmunol.174.3.1723; HAMID Q, 1994, J CLIN INVEST, V94, P870, DOI 10.1172/JCI117408; Hamilton JD, 2013, J INVEST DERMATOL, V133, pS178; Hamilton JD, 2013, J INVEST DERMATOL, V133, pS177; Hashimoto M, 2006, J IMMUNOL, V177, P3162, DOI 10.4049/jimmunol.177.5.3162; Howell MD, 2009, J ALLERGY CLIN IMMUN, V124, pR7, DOI 10.1016/j.jaci.2009.07.012; Iwasaki A, 2010, SCIENCE, V327, P291, DOI 10.1126/science.1183021; Jee MK, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.4; Jin HL, 2009, J ALLERGY CLIN IMMUN, V123, P875, DOI 10.1016/j.jaci.2009.02.007; Jung BG, 2010, J VET SCI, V11, P213, DOI 10.4142/jvs.2010.11.3.213; Jung T, 2008, J ALLERGY CLIN IMMUN, V122, P1074, DOI 10.1016/j.jaci.2008.09.042; Kaesler S, 2012, EUR J IMMUNOL, V42, P831, DOI 10.1002/eji.201141690; Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863; Kim BE, 2012, ALLERGY ASTHMA IMMUN, V4, P12, DOI 10.4168/aair.2012.4.1.12; Komai-Koma M, 2004, P NATL ACAD SCI USA, V101, P3029, DOI 10.1073/pnas.0400171101; Kubo A, 2012, J CLIN INVEST, V122, P440, DOI 10.1172/JCI57416; Kuo IH, 2013, J INVEST DERMATOL, V133, P988, DOI 10.1038/jid.2012.437; Laouini D, 2005, J ALLERGY CLIN IMMUN, V116, P390, DOI 10.1016/j.jaci.2005.03.042; Leung DYM, 2011, J ALLERGY CLIN IMMUN, V127, P965, DOI 10.1016/j.jaci.2011.02.010; Michaud F, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013742; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Nieuwenhuizen N, 2007, J IMMUNOL, V179, P2758, DOI 10.4049/jimmunol.179.5.2758; Novak N, 2012, J ALLERGY CLIN IMMUN, V129, P879, DOI 10.1016/j.jaci.2012.01.062; Oh CK, 2010, EUR RESPIR REV, V19, P46, DOI 10.1183/09059180.00007609; Saraiva M, 2010, NAT REV IMMUNOL, V10, P170, DOI 10.1038/nri2711; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; Shaw TE, 2011, J INVEST DERMATOL, V131, P67, DOI 10.1038/jid.2010.251; Spergel JM, 1999, J CLIN INVEST, V103, P1103, DOI 10.1172/JCI5669; Takeda K, 2002, J ENDOTOXIN RES, V8, P459, DOI 10.1179/096805102125001073; Travers JB, 2010, J ALLERGY CLIN IMMUN, V125, P146, DOI 10.1016/j.jaci.2009.09.052; vanDeventer SJH, 1997, GASTROENTEROLOGY, V113, P383, DOI 10.1053/gast.1997.v113.pm9247454; Volz T, 2012, EXP DERMATOL, V21, P61, DOI 10.1111/j.1600-0625.2011.01393.x; Volz T, 2010, FASEB J, V24, P4089, DOI 10.1096/fj.09-151001; Yosipovitch G, 2013, J INVEST DERMATOL, V133, pS178; Zahringer U, 2008, IMMUNOBIOLOGY, V213, P205, DOI 10.1016/j.imbio.2008.02.005; Ziegler SF, 2010, NAT IMMUNOL, V11, P289, DOI 10.1038/ni.1852	53	80	84	0	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2014	134	1					92	+		10.1016/j.jaci.2014.02.017	http://dx.doi.org/10.1016/j.jaci.2014.02.017			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AL2BH	24698321	Bronze			2022-12-18	WOS:000338930300013
J	Hardyman, MA; Wilkinson, E; Martin, E; Jayasekera, NP; Blume, C; Swindle, EJ; Gozzard, N; Holgate, ST; Howarth, PH; Davies, DE; Collins, JE				Hardyman, Michelle A.; Wilkinson, Emily; Martin, Emma; Jayasekera, Nivenka P.; Blume, Cornelia; Swindle, Emily J.; Gozzard, Neil; Holgate, Stephen T.; Howarth, Peter H.; Davies, Donna E.; Collins, Jane E.			TNF-alpha-mediated bronchial barrier disruption and regulation by src-family kinase activation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Airway; bronchial; barrier; epithelial; TNF-alpha; cytokines; proMMP-9; src kinase; SU6656	NECROSIS-FACTOR-ALPHA; E-CADHERIN; EPITHELIAL-CELLS; P120 CATENIN; ADHERENS JUNCTIONS; TIGHT JUNCTIONS; EXPRESSION; PHOSPHORYLATION; IDENTIFICATION; INTERLEUKIN-6	Background: Because TNF-alpha is increased in severe asthma, we hypothesized that TNF-alpha contributes to barrier dysfunction and cell activation in bronchial epithelial cells. We further hypothesized that src-family kinase inhibition would improve barrier function in healthy cells in the presence of TNF-alpha and directly in cultures of severe asthmatic cells where the barrier is disrupted. Objectives: We assessed the effect of TNF-alpha, with or without src-family kinase inhibitor SU6656, on barrier properties and cytokine release in differentiated human bronchial epithelial cultures. Further, we tested the effect of SU6656 on differentiated primary cultures from severe asthma. Methods: Barrier properties of differentiated human bronchial epithelial air-liquid interface cultures from healthy subjects and subjects with severe asthma were assessed with transepithelial electrical resistance and fluorescent dextran passage. Proteins were detected by immunostaining or Western blot analysis and cytokines by immunoassay. Mechanisms were investigated with src kinase and other inhibitors. Results: TNF-alpha lowered transepithelial electrical resistance and increased fluorescent dextran permeability, caused loss of occludin and claudins from tight junctions with redistribution of p120 catenin and E-cadherin from adherens junctions, and also increased endogenous TNF-alpha, IL-6, IL-1 beta, IL-8, thymic stromal lymphoprotein, and pro-matrix metalloprotease 9 release. SU6656 reduced TNF-alpha-mediated paracellular permeability changes, restored occludin, p120, and E-cadherin and lowered autocrine TNF-alpha release. Importantly, SU6656 improved the barrier properties of severe asthmatic air-liquid interface cultures. Redistribution of E-cadherin and p120 was observed in bronchial biopsies from severe asthmatic airways. Conclusions: Inhibiting TNF-alpha or src kinases may be a therapeutic option to normalize barrier integrity and cytokine release in airway diseases associated with barrier dysfunction.	[Hardyman, Michelle A.; Wilkinson, Emily; Martin, Emma; Jayasekera, Nivenka P.; Blume, Cornelia; Swindle, Emily J.; Holgate, Stephen T.; Howarth, Peter H.; Davies, Donna E.; Collins, Jane E.] Univ Southampton, Acad Unit Clin & Expt Sci, Southampton Univ Hosp, Fac Med, Southampton SO9 5NH, Hants, England; [Jayasekera, Nivenka P.; Holgate, Stephen T.; Howarth, Peter H.; Davies, Donna E.; Collins, Jane E.] Univ Southampton, Sir Henry Wellcome Labs, Southampton Univ Hosp, Southampton NIHR Resp Biomed Res Unit,Fac Med, Southampton SO9 5NH, Hants, England; [Gozzard, Neil] UCB Celltech, Slough, Berks, England	University of Southampton; University of Southampton; Celltech Group Ltd	Collins, JE (corresponding author), Southampton Univ Hosp, Sir Henry Wellcome Labs, Clin & Expt Sci Unit, Level E,South Block,Mailpoint 813, Southampton SO16 6YD, Hants, England.	J.E.Collins@soton.ac.uk	Davies, Donna E/H-2993-2012	Swindle, Emily/0000-0003-3644-7747; Blume, Cornelia/0000-0001-6133-7318; Collins, Jane/0000-0002-9914-3890; Davies, Donna/0000-0002-5117-2991; Howarth, Peter/0000-0003-0619-7927	Biotechnology and Biological Sciences Research Council; Medical Research Council; UCB Celltech; Medical Research Council UK; Synairgen; Janssen RD; MRC [G0800649, G0900453] Funding Source: UKRI; Medical Research Council [G0900453, G0800649] Funding Source: researchfish; National Institute for Health Research [NF-SI-0510-10021] Funding Source: researchfish	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); UCB Celltech(UCB Pharma SA); Medical Research Council UK(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Synairgen; Janssen RD; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR))	Supported by Biotechnology and Biological Sciences Research Council, Medical Research Council, UCB Celltech, and the Medical Research Council-funded Wessex severe asthma cohort. S.T.H. is a Medical Research Council-funded professor.; N. Gozzard is employed by and has stock in UCB Pharma. P. H. Howarth has received research support from the Medical Research Council UK. D. E. Davies has received consultancy fees from Synairgen and Janssen R&D and is a founder and shareholder in Synairgen. The rest of the authors declare they have no relevant conflicts.	Alema S, 2007, BBA-MOL CELL RES, V1773, P47, DOI 10.1016/j.bbamcr.2006.06.001; Anastasiadis PZ, 2000, J CELL SCI, V113, P1319; Angelini DJ, 2006, AM J PHYSIOL-LUNG C, V291, pL1232, DOI 10.1152/ajplung.00109.2006; Babu SK, 2011, CLIN IMMUNOL, V140, P18, DOI 10.1016/j.clim.2011.03.005; Balda MS, 2000, J CELL BIOCHEM, V78, P85, DOI 10.1002/(SICI)1097-4644(20000701)78:1<85::AID-JCB8>3.3.CO;2-6; Baum B, 2011, J CELL BIOL, V192, P907, DOI 10.1083/jcb.201009141; Bazzoni G, 2011, ANTIOXID REDOX SIGN, V15, P1221, DOI 10.1089/ars.2010.3867; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; Brightling C, 2008, J ALLERGY CLIN IMMUN, V121, P5, DOI 10.1016/j.jaci.2007.10.028; BRITTEN KM, 1993, BIOTECH HISTOCHEM, V68, P271, DOI 10.3109/10520299309105629; BROIDE DH, 1992, J ALLERGY CLIN IMMUN, V89, P958, DOI 10.1016/0091-6749(92)90218-Q; Brooke MA, 2012, J PATHOL, V226, P158, DOI 10.1002/path.3027; Bucchieri F, 2002, AM J RESP CELL MOL, V27, P179, DOI 10.1165/ajrcmb.27.2.4699; Carayol N, 2002, AM J RESP CELL MOL, V26, P341, DOI 10.1165/ajrcmb.26.3.4684; Citi S, 2011, MOL MEMBR BIOL, V28, P427, DOI 10.3109/09687688.2011.603101; Coyne CB, 2002, MOL BIOL CELL, V13, P3218, DOI 10.1091/mbc.E02-03-0134; de Boer WI, 2008, CAN J PHYSIOL PHARM, V86, P105, DOI [10.1139/Y08-004, 10.1139/y08-004]; DJUKANOVIC R, 1991, AM REV RESPIR DIS, V143, P772, DOI 10.1164/ajrccm/143.4_Pt_1.772; Dorfel MJ, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/807356; GALARDY RE, 1994, ANN NY ACAD SCI, V732, P315, DOI 10.1111/j.1749-6632.1994.tb24746.x; Gallelli L, 2010, INT J IMMUNOPATH PH, V23, P471, DOI 10.1177/039463201002300209; Gray TE, 1996, AM J RESP CELL MOL, V14, P104, DOI 10.1165/ajrcmb.14.1.8534481; GUMBINER B, 1986, J CELL BIOL, V102, P457, DOI 10.1083/jcb.102.2.457; Hackett TL, 2008, RESP RES, V9, DOI 10.1186/1465-9921-9-47; Hardyman MA, 2011, AM J RESP CRIT CARE, V183; Hartsock A, 2008, BBA-BIOMEMBRANES, V1778, P660, DOI 10.1016/j.bbamem.2007.07.012; Heijink IH, 2007, J IMMUNOL, V178, P7678, DOI 10.4049/jimmunol.178.12.7678; Howarth PH, 2005, THORAX, V60, P1012, DOI 10.1136/thx.2005.045260; Hozumi A, 2001, AM J PHYSIOL-LUNG C, V281, pL1444, DOI 10.1152/ajplung.2001.281.6.L1444; Huang S, 2003, J BIOL CHEM, V278, P8326, DOI 10.1074/jbc.M208264200; Ikari A, 2011, LIFE SCI, V88, P628, DOI 10.1016/j.lfs.2011.02.002; Kamekura R, 2009, CELL TISSUE RES, V338, P283, DOI 10.1007/s00441-009-0855-1; Kato A, 2007, J IMMUNOL, V179, P1080, DOI 10.4049/jimmunol.179.2.1080; Kirk A, 2010, NEPHROL DIAL TRANSPL, V25, P2107, DOI 10.1093/ndt/gfq006; Knight D, 2011, PULM PHARMACOL THER, V24, P193, DOI 10.1016/j.pupt.2010.10.005; Lambrecht BN, 2012, NAT MED, V18, P684, DOI 10.1038/nm.2737; Mariano C, 2011, EUR J CELL BIOL, V90, P787, DOI 10.1016/j.ejcb.2011.06.005; Mariner DJ, 2001, J BIOL CHEM, V276, P28006, DOI 10.1074/jbc.M102443200; MARINI M, 1992, J ALLERGY CLIN IMMUN, V89, P1001, DOI 10.1016/0091-6749(92)90223-O; Miyamori H, 2001, J BIOL CHEM, V276, P28204, DOI 10.1074/jbc.M103083200; Nawijn MC, 2011, TRENDS IMMUNOL, V32, P248, DOI 10.1016/j.it.2011.03.004; O'Donnell RA, 2004, THORAX, V59, P1032, DOI 10.1136/thx.2004.028043; Park HI, 2003, J BIOL CHEM, V278, P51646, DOI 10.1074/jbc.M310109200; Peifer M, 2003, J CELL BIOL, V163, P437, DOI 10.1083/jcb.200310090; Piedra J, 2003, MOL CELL BIOL, V23, P2287, DOI 10.1128/MCB.23.7.2287-2297.2003; Pohl C, 2009, EUR J PHARM BIOPHARM, V72, P339, DOI 10.1016/j.ejpb.2008.07.012; Rajasekaran AK, 1996, J CELL BIOL, V132, P451, DOI 10.1083/jcb.132.3.451; REYNOLDS AB, 1994, MOL CELL BIOL, V14, P8333, DOI 10.1128/MCB.14.12.8333; Reynolds AB, 2010, CELL, V141, P20, DOI 10.1016/j.cell.2010.03.022; Shen L, 2011, ANNU REV PHYSIOL, V73, P283, DOI 10.1146/annurev-physiol-012110-142150; Smith AL, 2012, MOL BIOL CELL, V23, P99, DOI 10.1091/mbc.E11-06-0497; Steed E, 2010, TRENDS CELL BIOL, V20, P142, DOI 10.1016/j.tcb.2009.12.002; Sullivan NJ, 2009, ONCOGENE, V28, P2940, DOI 10.1038/onc.2009.180; Suzuki T, 2011, J BIOL CHEM, V286, P31263, DOI 10.1074/jbc.M111.238147; Swindle EJ, 2009, J ALLERGY CLIN IMMUN, V124, P23, DOI 10.1016/j.jaci.2009.05.037; THOMAS PS, 1995, AM J RESP CRIT CARE, V152, P76, DOI 10.1164/ajrccm.152.1.7599866; Turksen K, 2011, BBA-REV CANCER, V1816, P73, DOI 10.1016/j.bbcan.2011.04.001; Van Itallie C, 2001, J CLIN INVEST, V107, P1319, DOI 10.1172/JCI12464; Van Itallie CM, 2008, J CELL SCI, V121, P298, DOI 10.1242/jcs.021485; Vermeer PD, 2009, AM J PHYSIOL-LUNG C, V296, pL751, DOI 10.1152/ajplung.90578.2008; West MR, 2002, CELL COMMUN ADHES, V9, P29, DOI 10.1080/15419060212185; Woodcock SA, 2009, MOL CELL, V33, P639, DOI 10.1016/j.molcel.2009.02.012; Xiao C, 2011, J ALLERGY CLIN IMMUN, V128, P549, DOI 10.1016/j.jaci.2011.05.038; Yamamoto M, 1998, J MED CHEM, V41, P1209, DOI 10.1021/jm970404a; Yao PM, 1997, AM J PHYSIOL-LUNG C, V273, pL866, DOI 10.1152/ajplung.1997.273.4.L866; Zabner J, 2003, J APPL PHYSIOL, V95, P394, DOI 10.1152/japplphysiol.01134.2002	66	80	82	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2013	132	3					665	+		10.1016/j.jaci.2013.03.005	http://dx.doi.org/10.1016/j.jaci.2013.03.005			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	207OS	23632299	hybrid			2022-12-18	WOS:000323612000019
J	Linder, JE; Kraft, DC; Mohamed, Y; Lu, ZQ; Heil, L; Tollefson, S; Saville, BR; Wright, PF; Williams, JV; Miller, EK				Linder, Jodell E.; Kraft, David C.; Mohamed, Yassir; Lu, Zengqi; Heil, Luke; Tollefson, Sharon; Saville, Benjamin R.; Wright, Peter F.; Williams, John V.; Miller, E. Kathryn			Human rhinovirus C: Age, season, and lower respiratory illness over the past 3 decades	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Rhinovirus; HRV-C; children; season; lower respiratory illness	OTHERWISE HEALTHY INFANTS; TRACT INFECTIONS; YOUNG-CHILDREN; HUMAN METAPNEUMOVIRUS; CLINICAL-FEATURES; VIRUS-INFECTIONS; SYNCYTIAL VIRUS; SPECIES C; HRV-C; INFLUENZA	Background: Human rhinoviruses (HRVs) cause common colds, and the recently discovered HRV-C is increasingly associated with lower respiratory illness among populations such as children and asthmatic patients. Objective: To determine how HRV-C is associated with respiratory illness and to evaluate changes in prevalence and species over 2 decades. Methods: A prospective study of children younger than 5 years was performed at the Vanderbilt Vaccine Clinic over a 21-year period. Nasal-wash specimens from children presenting with upper or lower respiratory illness at acute care visits were tested for HRV and HRV-positives genotyped. Demographic and clinical features were compared between children with or without HRV, and with different HRV species. Results: HRV was detected in 190 of 527 (36%) specimens from a population of 2009 children from 1982 through 2003. Of these, 36% were HRV-C. Age (P = .039) and month of illness (P < .001) were associated with HRV infection and HRV species. HRV-C was significantly associated with lower respiratory illness, compared with HRV-A (P = .014). HRV-A and HRV-C prevalence fluctuated throughout the 21-year period; HRV-C was more prevalent during winter (P = .058). Conclusions: HRV-C is not a new virus but has been significantly associated with childhood lower respiratory illness in this population for several decades. Temporal changes in virus prevalence occur, and season may predict virus species. Our findings have implications for diagnostic, preventive, and treatment strategies due to the variation in disease season and severity based on species of HRV infection. (J Allergy Clin Immunol 2013;131:69-77.)	[Linder, Jodell E.; Kraft, David C.; Mohamed, Yassir; Heil, Luke; Tollefson, Sharon; Williams, John V.; Miller, E. Kathryn] Vanderbilt Univ, Dept Pediat, Sch Med, Nashville, TN 37232 USA; [Lu, Zengqi; Saville, Benjamin R.] Vanderbilt Univ, Dept Biostat, Sch Med, Nashville, TN 37232 USA; [Williams, John V.] Vanderbilt Univ, Dept Pathol Microbiol & Immunol, Sch Med, Nashville, TN 37232 USA; [Wright, Peter F.] Geisel Sch Med Dartmouth, Div Infect Dis & Int Hlth, Hanover, NH USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Dartmouth College	Miller, EK (corresponding author), Vanderbilt Univ, Dept Pediat, Sch Med, 1161 21st Ave S,D7201 Med Ctr N, Nashville, TN 37232 USA.	eva.k.miller@vanderbilt.edu	Williams, John/ABE-3227-2020	Williams, John/0000-0001-8377-5175	National Institutes of Health [RR-24977-03, AI-091691-02, AI-085062]; Vanderbilt Institutional Clinical and Translational Research [UL1 RR024975-01, UL1 TR000445-06]; National Institute of Allergy and Infectious Diseases/Vaccine and Treatment Evaluation Units; Gates Foundation; National Institutes of Health (NIH); NIH; March of Dimes; Thrasher; MedImmune; Vanderbilt Institutional Clinical and Translational Research; FOOCUS Asthma Group; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000445] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024975, KL2RR024977] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K23AI091691, R01AI085062] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Vanderbilt Institutional Clinical and Translational Research; National Institute of Allergy and Infectious Diseases/Vaccine and Treatment Evaluation Units; Gates Foundation(Bill & Melinda Gates Foundation); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); March of Dimes(March of Dimes); Thrasher; MedImmune(AstraZenecaMedimmune); Vanderbilt Institutional Clinical and Translational Research; FOOCUS Asthma Group; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This study was supported by the National Institutes of Health (grant nos. RR-24977-03 and AI-091691-02 to E.K.M. and grant no. AI-085062 to J.V.W.) and Vanderbilt Institutional Clinical and Translational Research (grant nos. UL1 RR024975-01 and UL1 TR000445-06 to E.K.M.).; P. F. Wright has received grants from the National Institute of Allergy and Infectious Diseases/Vaccine and Treatment Evaluation Units, the Gates Foundation, and the National Institutes of Health (NIH) and is employed by Dartmouth College and Vanderbilt University. J. V. Williams has received grants from the NIH and is on the scientific advisory board for Quidel. E. K. Miller has received grants from the NIH, the March of Dimes, Thrasher, MedImmune, and Vanderbilt Institutional Clinical and Translational Research; has consultant arrangements with the American Association for the Advancement of Science; and has received payment for lectures from the FOOCUS Asthma Group. The rest of the authors declare that they have no relevant conflicts of interest.	Bezerra PGM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018928; Bizzintino J, 2011, EUR RESPIR J, V37, P1037, DOI 10.1183/09031936.00092410; Brittain-Long R, 2012, SCAND J INFECT DIS, V44, P9, DOI 10.3109/00365548.2011.598876; Denlinger LC, 2011, AM J RESP CRIT CARE, V184, P1007, DOI 10.1164/rccm.201103-0585OC; EDWARDS KM, 1985, PEDIATRICS, V76, P420; Fry AM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017780; Gern JE, 2002, AM J MED, V112, p19S; Greer RM, 2009, J CLIN VIROL, V45, P10, DOI 10.1016/j.jcv.2009.03.008; HAMPARIAN VV, 1987, VIROLOGY, V159, P191; Hardin J. W., 2013, GEN ESTIMATING EQUAT; Jackson DJ, 2010, IMMUNOL ALLERGY CLIN, V30, P513, DOI 10.1016/j.iac.2010.08.004; JAMJOOM GA, 1993, J TROP PEDIATRICS, V39, P346, DOI 10.1093/tropej/39.6.346; Jartti T, 2004, EMERG INFECT DIS, V10, P1095, DOI 10.3201/eid1006.030629; Kaida A, 2011, JPN J INFECT DIS, V64, P488; Klein MI, 2008, PEDIATRICS, V121, pE1510, DOI 10.1542/peds.2007-1757; Lamson D, 2006, J INFECT DIS, V194, P1398, DOI 10.1086/508551; Lau SKP, 2007, J CLIN MICROBIOL, V45, P3655, DOI 10.1128/JCM.01254-07; Ledford RM, 2004, J VIROL, V78, P3663, DOI 10.1128/JVI.78.7.3663-3674.2004; Lee WM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000966; Lemanske RF, 2005, J ALLERGY CLIN IMMUN, V116, P571, DOI 10.1016/j.jaci.2005.06.024; Louie JK, 2009, PEDIATR INFECT DIS J, V28, P337, DOI 10.1097/INF.0b013e31818ffc1b; Lu XY, 2008, J CLIN MICROBIOL, V46, P533, DOI 10.1128/JCM.01739-07; McErlean P, 2007, J CLIN VIROL, V39, P67, DOI 10.1016/j.jcv.2007.03.012; Miller EK, 2007, J INFECT DIS, V195, P773, DOI 10.1086/511821; Miller EK, 2012, PEDIATRICS, V129, pE60, DOI 10.1542/peds.2011-0583; Miller EK, 2011, J ALLERGY CLIN IMMUN, V127, P883, DOI 10.1016/j.jaci.2010.11.041; Miller EK, 2009, J CLIN VIROL, V46, P85, DOI 10.1016/j.jcv.2009.06.007; Miller EK, 2009, J ALLERGY CLIN IMMUN, V123, P98, DOI 10.1016/j.jaci.2008.10.007; Neuzil KM, 2002, J INFECT DIS, V185, P147, DOI 10.1086/338363; Olenec JP, 2010, J ALLERGY CLIN IMMUN, V125, P1001, DOI 10.1016/j.jaci.2010.01.059; PELON W, 1957, P SOC EXP BIOL MED, V94, P262; Peltola V, 2008, J CLIN VIROL, V43, P411, DOI 10.1016/j.jcv.2008.08.014; Pica N, 2012, J VIROL, V86, P4279, DOI 10.1128/JVI.06645-11; Reed G, 1997, J INFECT DIS, V175, P807, DOI 10.1086/513975; Sato M, 2009, J CLIN MICROBIOL, V47, P771, DOI 10.1128/JCM.02331-08; Savolainen C, 2002, VIRUS RES, V85, P41, DOI 10.1016/S0168-1702(02)00016-3; Savolainen-Kopra C, 2009, VIRUSES-BASEL, V1, P1178, DOI 10.3390/v1031178; Simmonds P, 2010, J GEN VIROL, V91, P2409, DOI 10.1099/vir.0.023994-0; Talbot HK, 2009, PEDIATR INFECT DIS J, V28, P682, DOI 10.1097/INF.0b013e31819d0d27; Tamura K, 2011, MOL BIOL EVOL, V28, P2731, DOI 10.1093/molbev/msr121; Turner RB, 2007, J INFECT DIS, V195, P765, DOI 10.1086/511829; United States Census Bureau, 2010, SUMM FIL 1; van Piggelen RO, 2010, PEDIATR INFECT DIS J, V29, P364, DOI 10.1097/INF.0b013e3181c6e60f; Williams JV, 2006, J INFECT DIS, V193, P387, DOI 10.1086/499274; Williams JV, 2004, NEW ENGL J MED, V350, P443, DOI 10.1056/NEJMoa025472; Wisdom A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008518; Wright PF, 2007, J CLIN MICROBIOL, V45, P2126, DOI 10.1128/JCM.02553-06; WRIGHT PF, 1977, NEW ENGL J MED, V296, P829, DOI 10.1056/NEJM197704142961501	48	80	87	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2013	131	1					69	U114		10.1016/j.jaci.2012.09.033	http://dx.doi.org/10.1016/j.jaci.2012.09.033			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	062YR	23146382	Green Published, Bronze, Green Accepted			2022-12-18	WOS:000312961200008
J	Molina-Infante, J; Martin-Noguerol, E; Alvarado-Arenas, M; Porcel-Carreno, SL; Jimenez-Timon, S; Hernandez-Arbeiza, FJ				Molina-Infante, Javier; Martin-Noguerol, Elisa; Alvarado-Arenas, Manuela; Porcel-Carreno, Sergio L.; Jimenez-Timon, Soledad; Javier Hernandez-Arbeiza, Francisco			Selective elimination diet based on skin testing has suboptimal efficacy for adult eosinophilic esophagitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CHILDREN; PRICK		[Molina-Infante, Javier; Martin-Noguerol, Elisa] Hosp San Pedro de Alcantara, Dept Gastroenterol, Caceres, Spain; [Alvarado-Arenas, Manuela; Porcel-Carreno, Sergio L.; Jimenez-Timon, Soledad; Javier Hernandez-Arbeiza, Francisco] Hosp San Pedro de Alcantara, Dept Allergy, Caceres, Spain		Molina-Infante, J (corresponding author), Hosp San Pedro de Alcantara, Dept Gastroenterol, Caceres, Spain.	xavi_molina@hotmail.com						Fogg MI, 2003, J ALLERGY CLIN IMMUN, V112, P796, DOI 10.1016/S0091-6749(03)01715-9; Gonsalves N, 2012, GASTROENTEROLOGY, V142, P1451, DOI 10.1053/j.gastro.2012.03.001; Gonzalez-Cervera J, 2012, J CLIN GASTROENTEROL; Henderson CJ, 2012, J ALLERGY CLIN IMMUN, V129, P1570, DOI 10.1016/j.jaci.2012.03.023; Kagalwalla AF, 2011, J PEDIATR GASTR NUTR, V53, P145, DOI 10.1097/MPG.0b013e31821cf503; Liacouras C, 2011, J ALLERGY CLIN IMMUN, V128, P3, DOI 10.1016/j.jaci.2011.02.040; Simon D, 2006, ALLERGY, V61, P1480, DOI 10.1111/j.1398-9995.2006.01224.x; Spergel JM, 2005, ANN ALLERG ASTHMA IM, V95, P336, DOI 10.1016/S1081-1206(10)61151-9; Spergel JM, 2007, J ALLERGY CLIN IMMUN, V119, P509, DOI 10.1016/j.jaci.2006.11.016	9	80	86	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2012	130	5					1200	1202		10.1016/j.jaci.2012.06.027	http://dx.doi.org/10.1016/j.jaci.2012.06.027			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	030LE	22867695				2022-12-18	WOS:000310571400024
J	Buckley, RH				Buckley, Rebecca H.			The long quest for neonatal screening for severe combined immunodeficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						T-cell receptor recombination excision circles; dried bloodspots; severe combined immunodeficiency; T-cell lymphopenia; T-cell function studies; early treatment; molecular testing	STEM-CELL TRANSPLANTATION; GENE-THERAPY; MUTATIONS; DEFICIENCY; ROTAVIRUS; ARTEMIS; IL7R; JAK3; CD45	Early recognition of severe combined immunodeficiency (SCID) is a pediatric emergency because a diagnosis before live vaccines or nonirradiated blood products are given and before development of infections permits lifesaving unfractionated HLA-identical or T cell-depleted haploidentical hematopoietic stem cell transplantation, enzyme replacement therapy, or gene therapy. The need for newborn screening for this condition has been recognized for the past 15 years. However, implementation of screening required development of an assay for T-cell lymphopenia that could be performed on dried bloodspots routinely collected from newborn infants for the past 48 years. This was accomplished 6 years ago, and there have already been 7 successful pilot studies. A recommendation to add SCID to the routine newborn-screening panel was approved by the Secretary's Advisory Committee on Heritable Disorders of Newborns and Children in 2010 and was soon after approved by the Secretary of Health and Human Services. It is important for allergists, immunologists, and other health care providers to take an active role in promoting newborn screening for SCID and other T-lymphocyte abnormalities in their states. Even more important will be their roles in establishing accurate diagnoses for infants with positive screen results and in ensuring that they are given the best possible treatment. (J Allergy Clin Immunol 2012; 129: 597-604.)	[Buckley, Rebecca H.] Duke Univ, Med Ctr, Dept Pediat, Durham, NC 27710 USA; [Buckley, Rebecca H.] Duke Univ, Med Ctr, Dept Immunol, Durham, NC 27710 USA	Duke University; Duke University	Buckley, RH (corresponding author), Duke Univ, Med Ctr, Dept Pediat, Box 2898, Durham, NC 27710 USA.	buckL003@mc.duke.edu	Buckley, Rebecca/AAB-1578-2019		National Institute of Allergy and Infectious Diseases; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047605, R01AI042951] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	R. H. Buckley has received research support from the National Institute of Allergy and Infectious Diseases and is Chair of the Immune Deficiency Foundation Medical Advisory Committee.	Aiuti A, 2009, NEW ENGL J MED, V360, P447, DOI 10.1056/NEJMoa0805817; Altman PL, 1961, BLOOD OTHER BODY FLU, P125; Azzari C, 2011, J ALLERGY CLIN IMMUN, V127, P1394, DOI 10.1016/j.jaci.2011.03.040; Baker MW, 2009, J ALLERGY CLIN IMMUN, V124, P522, DOI 10.1016/j.jaci.2009.04.007; Brown L, 2011, BLOOD, V117, P3243, DOI 10.1182/blood-2010-08-300384; Buck D, 2006, EUR J IMMUNOL, V36, P224, DOI 10.1002/eji.200535401; Buckley RH, 2011, IMMUNOL RES, V49, P25, DOI 10.1007/s12026-010-8191-9; Buckley RH, 2010, J ALLERGY CLIN IMMUN, V125, P790, DOI 10.1016/j.jaci.2010.02.012; Buckley RH, 1999, NEW ENGL J MED, V340, P508, DOI 10.1056/NEJM199902183400703; Buckley RH, 1997, J PEDIATR-US, V130, P378, DOI 10.1016/S0022-3476(97)70199-9; Chan K, 2005, J ALLERGY CLIN IMMUN, V115, P391, DOI 10.1016/j.jaci.2004.10.012; Chan K, 2011, MOL GENET METAB, V104, P383, DOI 10.1016/j.ymgme.2011.07.007; Comeau AM, 2010, J INHERIT METAB DIS, V33, pS273, DOI 10.1007/s10545-010-9103-9; Dadi HK, 2003, NEW ENGL J MED, V349, P1821, DOI 10.1056/NEJMoa031178; de Saint Basile G, 2004, J CLIN INVEST, V114, P1512, DOI 10.1172/JCI200422588; Gaspar HB, 2011, SCI TRANSL MED, V3, DOI [10.1126/scitranslmed.3002716, 10.1126/scitranslmed.3002715]; Gerstel-Thompson JL, 2010, CLIN CHEM, V56, P1466, DOI 10.1373/clinchem.2010.144915; GUTHRIE R, 1963, PEDIATRICS, V32, P338; Hacein-Bey-Abina S, 2008, J CLIN INVEST, V118, P3132, DOI 10.1172/JCI35700; Hacein-Bey-Abina S, 2010, NEW ENGL J MED, V363, P355, DOI 10.1056/NEJMoa1000164; Hale JE, 2010, J ALLERGY CLIN IMMUN, V126, P1073, DOI 10.1016/j.jaci.2010.08.043; HERSHFIELD MS, 1987, NEW ENGL J MED, V316, P589, DOI 10.1056/NEJM198703053161005; Howe SJ, 2008, J CLIN INVEST, V118, P3143, DOI 10.1172/JCI35798; Kalman L, 2004, GENET MED, V6, P16, DOI 10.1097/01.GIM.0000105752.80592.A3; Kane L, 2001, ARCH DIS CHILD-FETAL, V85, pF110, DOI 10.1136/fn.85.2.F110; Kung C, 2000, NAT MED, V6, P343; Lindegren Mary Lou, 2004, Morbidity and Mortality Weekly Report, V53, P1; Lipstein EA, 2010, PEDIATRICS, V125, pE1226, DOI 10.1542/peds.2009-1567; Markert ML, 2010, CLIN IMMUNOL, V135, P236, DOI 10.1016/j.clim.2010.02.007; McGhee SA, 2005, J PEDIATR-US, V147, P603, DOI 10.1016/j.jpeds.2005.06.001; McGhee SA, 2005, MOL GENET METAB, V86, P427, DOI 10.1016/j.ymgme.2005.09.005; Moshous D, 2001, CELL, V105, P177, DOI 10.1016/S0092-8674(01)00309-9; Myers LA, 2002, BLOOD, V99, P872, DOI 10.1182/blood.V99.3.872; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; Patel DD, 2000, NEW ENGL J MED, V342, P1325, DOI 10.1056/NEJM200005043421804; Patel NC, 2010, NEW ENGL J MED, V362, P314, DOI 10.1056/NEJMoa0904485; Puck JM, 2007, J ALLERGY CLIN IMMUN, V120, P760, DOI 10.1016/j.jaci.2007.08.043; Puel A, 1998, NAT GENET, V20, P394, DOI 10.1038/3877; Roberts JL, 2007, BLOOD, V109, P3198, DOI 10.1182/blood-2006-08-043166; Routes JM, 2009, JAMA-J AM MED ASSOC, V302, P2465, DOI 10.1001/jama.2009.1806; RUSSELL SM, 1995, SCIENCE, V270, P797, DOI 10.1126/science.270.5237.797; Schwarz K, 1996, SCIENCE, V274, P97, DOI 10.1126/science.274.5284.97; Shearer WT, 2003, J ALLERGY CLIN IMMUN, V112, P973, DOI 10.1016/j.jaci.2003.07.003; Uygungil B, 2010, J ALLERGY CLIN IMMUN, V125, P270, DOI 10.1016/j.jaci.2009.10.029; van der Burg M, 2009, J CLIN INVEST, V119, P91, DOI 10.1172/JCI37141; Werther RL, 2009, J ALLERGY CLIN IMMUN, V124, P600, DOI 10.1016/j.jaci.2009.07.005	46	80	82	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2012	129	3					597	606		10.1016/j.jaci.2011.12.964	http://dx.doi.org/10.1016/j.jaci.2011.12.964			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	904IW	22277203	Green Accepted			2022-12-18	WOS:000301189300001
J	Martos, G; Lopez-Exposito, I; Bencharitiwong, R; Berin, MC; Nowak-Wegrzyn, A				Martos, Gustavo; Lopez-Exposito, Ivan; Bencharitiwong, Ramon; Berin, M. Cecilia; Nowak-Wegrzyn, Anna			Mechanisms underlying differential food allergy response to heated egg	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Egg allergy; ovalbumin; ovomucoid; heat treatment; heating; gastrointestinal digestion; antigen absorption; mice oral sensitization; anaphylaxis; basophil activation; passive sensitization	IN-VITRO DIGESTIBILITY; MOLTEN GLOBULE STATE; ARA H 1; ALLERGENICITY; DIGESTION; PROTEINS; IGE; STABILITY; PASTEURIZATION; SENSITIZATION	Background: Egg white proteins are usually subjected to heating, making them edible for the majority of children with egg allergy. Objective: We sought to investigate the underlying mechanisms responsible for the reduced allergenicity displayed by heat-treated egg white allergens. Methods: C3H/HeJ mice were orally sensitized with ovalbumin (OVA) or ovomucoid and challenged with native or heated proteins to evaluate their allergenicity. Immunoreactivity was assessed by immunoblotting using sera from children with egg allergy. In vitro gastrointestinal digestion of native and heated OVA and ovomucoid was studied by SDS-PAGE and liquid chromatography. Intestinal uptake of intact native and heated OVA and ovomucoid by human intestinal epithelial (Caco-2) cells was investigated. Rat basophil leukemia cells passively sensitized with mouse serum and human basophils passively sensitized with serum from children with egg allergy were used to assess the effector cell activation by heated, digested, and transported OVA and ovomucoid. Results: Heated OVA and ovomucoid did not induce symptoms of anaphylaxis in sensitized mice when administered orally. Heating did not completely destroy IgE-binding capacity of OVA or ovomucoid but enhanced in vitro digestibility of OVA. Digestion of both OVA and ovomucoid diminished mediator release in rat basophil leukemia assay and basophil activation. Heating of allergens prevented transport across human intestinal epithelial cells in a form capable of triggering basophil activation or T-cell activation. Conclusion: Heat treatment reduces allergenicity of OVA and ovomucoid. This is partially a result of the enhanced gastrointestinal digestibility of heated OVA and the inability of heated OVA or ovomucoid to be absorbed in a form capable of triggering basophils. (J Allergy Clin Immunol 2011;127:990-7.)	[Martos, Gustavo; Lopez-Exposito, Ivan; Bencharitiwong, Ramon; Berin, M. Cecilia; Nowak-Wegrzyn, Anna] Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA; [Martos, Gustavo; Lopez-Exposito, Ivan; Bencharitiwong, Ramon; Berin, M. Cecilia; Nowak-Wegrzyn, Anna] Mt Sinai Sch Med, Jaffe Food Allergy Inst, New York, NY 10029 USA; [Martos, Gustavo; Lopez-Exposito, Ivan] UAM, CSIC, CIAL, Food Sci Res Inst, Madrid, Spain	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-UAM - Instituto de Investigacion en Ciencias de la Alimentacion (CIAL)	Nowak-Wegrzyn, A (corresponding author), Mt Sinai Sch Med, Dept Pediat, Box 1198,1 Gustave L Levy Pl, New York, NY 10029 USA.	anna.nowak-wegrzyn@mssm.edu	Martos, Gustavo/K-3457-2019; López-Expósito, Iván/M-1150-2014	Martos, Gustavo/0000-0001-6434-1769; López-Expósito, Iván/0000-0003-3011-3527	Spanish Research Council; Ministry of Science and Innovation [AGL2008-01740]; Nutricia Foundation; National Institutes of Health (NIH)-NIAID [AI044236, AI059318]; National Center for Research Resources [CTSA ULI RR 029887]; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR029887] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K23AI059318] Funding Source: NIH RePORTER	Spanish Research Council; Ministry of Science and Innovation(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Nutricia Foundation(Danone Nutricia); National Institutes of Health (NIH)-NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	G.M. was supported by the Spanish Research Council through the JAE program and by the Ministry of Science and Innovation through project AGL2008-01740. R. B. was supported in part by the Nutricia Foundation. C. B. was supported by National Institutes of Health (NIH)-NIAID AI044236. A.N.-W. was supported in part by NIH-NIAID AI059318. The project was supported in part by grant no. CTSA ULI RR 029887 from the National Center for Research Resources, a component of the NIH. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of National Center for Research Resources or the NIH.; Disclosure of potential conflict of interest: G. Martos receives research support from the Spanish Research Council. A. Nowak-Wegrzyn receives research support from the National Institutes of Health-NIAID. The rest of the authors have declared that they have no conflict of interest.	Ando H, 2008, J ALLERGY CLIN IMMUN, V122, P583, DOI 10.1016/j.jaci.2008.06.016; Astwood JD, 1996, NAT BIOTECHNOL, V14, P1269, DOI 10.1038/nbt1096-1269; BERNHISELBROADBENT J, 1992, J ALLERGY CLIN IMMUN, V90, P622, DOI 10.1016/0091-6749(92)90135-O; Breiteneder H, 2005, J ALLERGY CLIN IMMUN, V115, P14, DOI 10.1016/j.jaci.2004.10.022; Cooke SK, 1997, J IMMUNOL, V159, P2026; Des Roches A, 2006, ALLERGY, V61, P1487, DOI 10.1111/j.1398-9995.2006.01200.x; DJURTOFT R, 1991, ADV EXP MED BIOL, V289, P281; Eiwegger T, 2006, CLIN EXP ALLERGY, V36, P1281, DOI 10.1111/j.1365-2222.2006.02565.x; FIOCCHI A, 1995, J AM COLL NUTR, V14, P245; HEYMAN M, 1982, AM J PHYSIOL, V242, pG558, DOI 10.1152/ajpgi.1982.242.6.G558; HEYMAN M, 1996, ANTIGEN PRESENTATION, P1; Hirose J, 2004, BIOSCI BIOTECH BIOCH, V68, P2490, DOI 10.1271/bbb.68.2490; HIROSE M, 1993, TRENDS FOOD SCI TECH, V4, P48, DOI 10.1016/0924-2244(93)90059-J; HOFFMANN A, 2003, ARB P EHRLICH I, V94, P76; HOFFMANN A, 2003, ARB P EHRLICH I BUES, V94, P85; Ilchmann A, 2010, J ALLERGY CLIN IMMUN, V125, P175, DOI 10.1016/j.jaci.2009.08.013; Kato Y, 2000, BIOSCI BIOTECH BIOCH, V64, P198, DOI 10.1271/bbb.64.198; Konstantinou GN, 2008, J ALLERGY CLIN IMMUN, V122, P414, DOI 10.1016/j.jaci.2008.05.032; Koppelman SJ, 2010, MOL NUTR FOOD RES, V54, P1711, DOI 10.1002/mnfr.201000011; KOSEKI T, 1988, J BIOCHEM-TOKYO, V103, P425, DOI 10.1093/oxfordjournals.jbchem.a122286; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; Lemon-Mule H, 2008, J ALLERGY CLIN IMMUN, V122, P977, DOI 10.1016/j.jaci.2008.09.007; Lucas JSA, 2008, PEDIAT ALLERG IMM-UK, V19, P392, DOI 10.1111/j.1399-3038.2007.00678.x; Maleki SJ, 2000, J IMMUNOL, V164, P5844, DOI 10.4049/jimmunol.164.11.5844; Martos G, 2010, J AGR FOOD CHEM, V58, P5640, DOI 10.1021/jf904538w; Metcalfe DD, 1996, CRIT REV FOOD SCI, V36, pS165, DOI 10.1080/10408399609527763; Moreno FJ, 2005, BBA-PROTEINS PROTEOM, V1752, P142, DOI 10.1016/j.bbapap.2005.07.022; Moreno FJ, 2005, FEBS J, V272, P341, DOI 10.1111/j.1742-4658.2004.04472.x; Nowak-Wegrzyn AH, 2009, J ALLERGY CLIN IMMUN, V123, P949, DOI 10.1016/j.jaci.2009.01.070; Peng HJ, 1998, SCAND J IMMUNOL, V48, P491; Peyron S, 2006, J AGR FOOD CHEM, V54, P5643, DOI 10.1021/jf053178j; POULSEN OM, 1987, CLIN ALLERGY, V17, P449, DOI 10.1111/j.1365-2222.1987.tb02039.x; PRUZANSKY JJ, 1983, J IMMUNOL, V131, P1949; Restani P, 1997, J AM COLL NUTR, V16, P376, DOI 10.1080/07315724.1997.10718700; Roth-Walter F, 2008, ALLERGY, V63, P882, DOI 10.1111/j.1398-9995.2008.01673.x; Scheurer S, 2004, J ALLERGY CLIN IMMUN, V114, P900, DOI 10.1016/j.jaci.2004.06.017; Takagi K, 2003, BIOL PHARM BULL, V26, P969, DOI 10.1248/bpb.26.969; Taylor SL, 2002, ANNU REV PHARMACOL, V42, P99, DOI 10.1146/annurev.pharmtox.42.082401.130208; Taylor SL, 2001, J ALLERGY CLIN IMMUN, V107, P765, DOI 10.1067/mai.2001.114241; Teuber SS, 2002, ANN NY ACAD SCI, V964, P111; Thomas K, 2007, FOOD CHEM TOXICOL, V45, P1116, DOI 10.1016/j.fct.2006.12.016; Untersmayr E, 2003, J ALLERGY CLIN IMMUN, V112, P616, DOI [10.1016/S0091-6749(03)01719-6, 10.1016/mai.2003.1681]; Untersmayr E, 2007, J ALLERGY CLIN IMMUN, V119, P711, DOI 10.1016/j.jaci.2006.10.039; Urisu A, 1997, J ALLERGY CLIN IMMUN, V100, P171, DOI 10.1016/S0091-6749(97)70220-3; van Boxtel EL, 2008, J AGR FOOD CHEM, V56, P2223, DOI 10.1021/jf072907n; Vassilopoulou E, 2006, J ALLERGY CLIN IMMUN, V118, P473, DOI 10.1016/j.jaci.2006.04.057; VIETHS S, 1997, ARBEITEN P EHRLICH I, V91, P250	47	80	85	2	39	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2011	127	4					990	U244		10.1016/j.jaci.2011.01.057	http://dx.doi.org/10.1016/j.jaci.2011.01.057			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	743YL		Green Accepted, Green Submitted			2022-12-18	WOS:000289055800021
J	Bochner, BS; Gleich, GJ				Bochner, Bruce S.; Gleich, Gerald J.			What targeting eosinophils has taught us about their role in diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Eosinophil; granules; asthma; hypereosinophilic syndrome; IL-5; chemokines; airways hyperreactivity; Churg-Strauss syndrome	MAJOR BASIC-PROTEIN; ANTI-IL-5 MEPOLIZUMAB THERAPY; ALLERGIC AIRWAY INFLAMMATION; ANTIGEN-PRESENTING CELLS; HYPEREOSINOPHILIC SYNDROME; BONE-MARROW; DIFFERENTIATION FACTOR; MURINE MODEL; SIGLEC-F; IN-VIVO	Eosinophil-associated disease is a term used to encompass a range of disorders from hypereosinophilic syndrome to asthma. Despite the longstanding belief that eosinophils can be primary contributors to disease pathophysiology, it is only in recent years that direct and selective reduction or elimination of eosinophils can be achieved in animals or human subjects. These developments have been made possible in mice through clever targeting of eosinophil production. Antibodies and other agents that target soluble eosinophil-related molecules, such as IL-5, or cell-surface structures, such as CCR3, have also proved useful in reducing blood and tissue eosinophil counts. In human subjects the only eosinophil-selective agents tested in clinical trials thus far are neutralizing antibodies to IL-5, with promising but mixed results. At the very least, such forms of pharmacologic hypothesis testing of the role of eosinophils in certain airway, gastrointestinal, and hematologic diseases has finally provided us with new insights into disease pathogenesis. At its optimistic best, these and other targeted agents might someday become available for those afflicted with eosinophil-associated disorders. This review summarizes what has been learned in vivo in both preclinical and clinical studies of eosinophil-directed therapies, with an emphasis on recent advances. (J Allergy Clin Immunol 2010;126:16-25.)	[Bochner, Bruce S.] Johns Hopkins Univ, Sch Med, Johns Hopkins Asthma & Allergy Ctr, Div Allergy & Clin Immunol,Dept Med, Baltimore, MD 21224 USA; [Gleich, Gerald J.] Univ Utah, Sch Med, Hlth Sci Ctr, Dept Dermatol, Salt Lake City, UT USA; [Gleich, Gerald J.] Univ Utah, Sch Med, Hlth Sci Ctr, Dept Med, Salt Lake City, UT USA; [Gleich, Gerald J.] Univ Utah, Sch Med, Hlth Sci Ctr, Dept Pediat, Salt Lake City, UT USA	Johns Hopkins University; Johns Hopkins Medicine; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Bochner, BS (corresponding author), Johns Hopkins Univ, Sch Med, Johns Hopkins Asthma & Allergy Ctr, Div Allergy & Clin Immunol,Dept Med, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.	bbochner@jhmi.edu			National Institutes of Health [AI072265]; Dana Foundation; Johns Hopkins University; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI072265, R01AI072265] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Dana Foundation; Johns Hopkins University(Johns Hopkins University); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported in part by grant AI072265 from the National Institutes of Health. Dr Bochner also received support for human immunology research from the Dana Foundation and as a Cosner Scholar in Translational Research from the Johns Hopkins University.	Aceves SS, 2008, CURR MOL MED, V8, P350, DOI 10.2174/156652408785161023; Ackerman SJ, 2007, IMMUNOL ALLERGY CLIN, V27, P357, DOI 10.1016/j.iac.2007.07.004; Akuthota P, 2008, CLIN EXP ALLERGY, V38, P1254, DOI 10.1111/j.1365-2222.2008.03037.x; Asquith KL, 2008, J IMMUNOL, V180, P1199, DOI 10.4049/jimmunol.180.2.1199; AYARS GH, 1985, J ALLERGY CLIN IMMUN, V76, P595, DOI 10.1016/0091-6749(85)90781-X; Bedi R, 2009, BLOOD, V113, P317, DOI 10.1182/blood-2008-02-139741; Bochner BS, 2004, J ALLERGY CLIN IMMUN, V113, P3, DOI 10.1016/j.jaci.2003.09.046; Bochner BS, 2000, J ALLERGY CLIN IMMUN, V106, P817, DOI 10.1067/mai.2000.110813; Boehme SA, 2009, INT IMMUNOL, V21, P81, DOI 10.1093/intimm/dxn127; Boucher RM, 2008, NEW ENGL J MED, V358, P2838, DOI 10.1056/NEJMc080856; Brandt EB, 2006, CLIN EXP ALLERGY, V36, P543, DOI 10.1111/j.1365-2222.2006.02456.x; Broide DH, 2008, J ALLERGY CLIN IMMUN, V121, P560, DOI 10.1016/j.jaci.2008.01.031; CAMPBELL HD, 1987, P NATL ACAD SCI USA, V84, P6629, DOI 10.1073/pnas.84.19.6629; Carlens J, 2009, J IMMUNOL, V183, P5600, DOI 10.4049/jimmunol.0801581; Cho JY, 2004, J CLIN INVEST, V113, P551, DOI 10.1172/JCI200419133; Cho KJ, 2010, AM J RESP CELL MOL, V42, P294, DOI 10.1165/rcmb.2008-0445OC; CLUTTERBUCK E, 1987, EUR J IMMUNOL, V17, P1743, DOI 10.1002/eji.1830171210; COWDEN JM, 2009, J INVEST DERMATOL; DENT LA, 1990, J EXP MED, V172, P1425, DOI 10.1084/jem.172.5.1425; DOR PJ, 1984, AM REV RESPIR DIS, V130, P1072; Du J, 2002, J BIOL CHEM, V277, P43481, DOI 10.1074/jbc.M204777200; Dyer KD, 2008, J IMMUNOL, V181, P4004, DOI 10.4049/jimmunol.181.6.4004; Ehrlich P., 1879, ARCH ANAT PHYSL, V3, P166; FILLEY WV, 1982, LANCET, V2, P11; FLAVAHAN NA, 1988, AM REV RESPIR DIS, V138, P685, DOI 10.1164/ajrccm/138.3.685; Flood-Page P, 2003, J CLIN INVEST, V112, P1029, DOI 10.1172/JCI200317974; Flood-Page P, 2007, AM J RESP CRIT CARE, V176, P1062, DOI 10.1164/rccm.200701-085OC; Flood-Page PT, 2003, AM J RESP CRIT CARE, V167, P199, DOI 10.1164/rccm.200208-789OC; Forbes E, 2004, J IMMUNOL, V172, P5664, DOI 10.4049/jimmunol.172.9.5664; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; FRIGAS E, 1981, MAYO CLIN PROC, V56, P345; Fulkerson PC, 2006, P NATL ACAD SCI USA, V103, P16418, DOI 10.1073/pnas.0607863103; Fulkerson PC, 2006, AM J PATHOL, V169, P2117, DOI 10.2353/ajpath.2006.060617; Garrett JK, 2004, J ALLERGY CLIN IMMUN, V113, P115, DOI 10.1016/j.jaci.2003.10.049; Gevaert P, 2006, J ALLERGY CLIN IMMUN, V118, P1133, DOI 10.1016/j.jaci.2006.05.031; Gleich GJ, 2009, NEW ENGL J MED, V360, P2577; GLEICH GJ, 1979, IMMUNOLOGY, V38, P343; GLEICH GJ, 1996, INHALED GLUCOCORTICO, P279; GOETZL EJ, 1975, ARCH PATHOL, V99, P1; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Gurish MF, 2002, J IMMUNOL, V168, P5730, DOI 10.4049/jimmunol.168.11.5730; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Hamelmann E, 1999, AM J RESP CRIT CARE, V160, P934, DOI 10.1164/ajrccm.160.3.9806029; Hirasawa R, 2002, J EXP MED, V195, P1379, DOI 10.1084/jem.20020170; Hogan SP, 2008, CLIN EXP ALLERGY, V38, P709, DOI 10.1111/j.1365-2222.2008.02958.x; Hogan SP, 2000, P NATL ACAD SCI USA, V97, P6681, DOI 10.1073/pnas.97.12.6681; Humbles AA, 2002, P NATL ACAD SCI USA, V99, P1479, DOI 10.1073/pnas.261462598; Humbles AA, 2004, SCIENCE, V305, P1776, DOI 10.1126/science.1100283; Jacobsen EA, 2008, J EXP MED, V205, P699, DOI 10.1084/jem.20071840; JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881; Kahn JE, 2010, J ALLERGY CLIN IMMUN, V125, P267, DOI 10.1016/j.jaci.2009.10.014; Kay AB, 2004, IMMUNOL ALLERGY CLIN, V24, P645, DOI 10.1016/j.iac.2004.06.007; Kim YJ, 2004, J ALLERGY CLIN IMMUN, V114, P1449, DOI 10.1016/j.jaci.2004.08.027; Kips JC, 2003, AM J RESP CRIT CARE, V167, P1655, DOI 10.1164/rccm.200206-525OC; Knott ML, 2009, MOL IMMUNOL, V46, P2714, DOI 10.1016/j.molimm.2009.05.016; Kopf M, 1996, IMMUNITY, V4, P15, DOI 10.1016/S1074-7613(00)80294-0; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Lee JJ, 1997, J EXP MED, V185, P2143, DOI 10.1084/jem.185.12.2143; Lee JJ, 2004, SCIENCE, V305, P1773, DOI 10.1126/science.1099472; Lee WY, 2009, AM J RESP CRIT CARE, V179; Lefort J, 1996, J CLIN INVEST, V97, P1117, DOI 10.1172/JCI118505; Linch SN, 2009, INFECT IMMUN, V77, P4976, DOI 10.1128/IAI.00306-09; Ma W, 2002, J CLIN INVEST, V109, P621, DOI 10.1172/JCI200214097; Matsuoka T, 2000, SCIENCE, V287, P2013, DOI 10.1126/science.287.5460.2013; Medoff BD, 2009, J IMMUNOL, V182, P623, DOI 10.4049/jimmunol.182.1.623; Menzies-Gow A, 2003, J ALLERGY CLIN IMMUN, V111, P714, DOI 10.1067/mai.2003.1382; Miller M, 2001, J IMMUNOL, V167, P2292, DOI 10.4049/jimmunol.167.4.2292; Mishra A, 2002, J BIOL CHEM, V277, P4406, DOI 10.1074/jbc.M110424200; Mishra A, 1999, J CLIN INVEST, V103, P1719, DOI 10.1172/JCI6560; Mishra A, 2008, GASTROENTEROLOGY, V134, P204, DOI 10.1053/j.gastro.2007.10.002; Miyahara N, 2009, AM J RESP CELL MOL, V40, P672, DOI 10.1165/rcmb.2008-0095OC; Myou S, 2001, NAT IMMUNOL, V2, P145, DOI 10.1038/84244; Nair P, 2009, NEW ENGL J MED, V360, P985, DOI 10.1056/NEJMoa0805435; Ochkur SI, 2007, J IMMUNOL, V178, P7879, DOI 10.4049/jimmunol.178.12.7879; Ogbogu PU, 2009, J ALLERGY CLIN IMMUN, V124, P1319, DOI 10.1016/j.jaci.2009.09.022; Padigel UM, 2007, J INFECT DIS, V196, P1844, DOI 10.1086/522968; Palframan RT, 1998, J EXP MED, V188, P1621, DOI 10.1084/jem.188.9.1621; Palframan RT, 1998, BLOOD, V91, P2240, DOI 10.1182/blood.V91.7.2240.2240_2240_2248; Pease JE, 2006, J ALLERGY CLIN IMMUN, V118, P305, DOI 10.1016/j.jaci.2006.06.010; Phipps S, 2004, J INVEST DERMATOL, V122, P1406, DOI 10.1111/j.0022-202X.2004.22619.x; Plotz S, 2003, NEW ENGL J MED, V349, P2334, DOI 10.1056/NEJMoa031261; Reed JL, 2008, J ALLERGY CLIN IMMUN, V121, pS47, DOI 10.1016/j.jaci.2007.12.191; Reese TA, 2007, NATURE, V447, P92, DOI 10.1038/nature05746; Rosenberg HF, 2007, J ALLERGY CLIN IMMUN, V119, P1303, DOI 10.1016/j.jaci.2007.03.048; Rosenberg HF, 2001, J LEUKOCYTE BIOL, V70, P691; Rothenberg ME, 2008, NEW ENGL J MED, V358, P1215, DOI 10.1056/NEJMoa070812; Rothenberg ME, 2006, ANNU REV IMMUNOL, V24, P147, DOI 10.1146/annurev.immunol.24.021605.090720; SAMTER M, 1953, J HEMATOL, V8, P1078; SCHLECHT H, 1912, DTSCH ARCH KLIN MED, V108, P405; Schratl P, 2007, J IMMUNOL, V179, P4792, DOI 10.4049/jimmunol.179.7.4792; Shen HHH, 2003, J IMMUNOL, V170, P3296, DOI 10.4049/jimmunol.170.6.3296; Shi HZ, 2000, J CLIN INVEST, V105, P945, DOI 10.1172/JCI8945; SIMON D, 2010, J ALLERGY C IN PRESS; Song DJ, 2009, J IMMUNOL, V183, P5333, DOI 10.4049/jimmunol.0801421; Song DJ, 2009, CLIN IMMUNOL, V131, P157, DOI 10.1016/j.clim.2008.11.009; Specht S, 2006, INFECT IMMUN, V74, P5236, DOI 10.1128/IAI.00329-06; Stein ML, 2006, J ALLERGY CLIN IMMUN, V118, P1312, DOI 10.1016/j.jaci.2006.09.007; Stein ML, 2008, J ALLERGY CLIN IMMUN, V121, P1473, DOI 10.1016/j.jaci.2008.02.033; Straumann A, 2010, GUT, V59, P21, DOI 10.1136/gut.2009.178558; Tager AM, 2000, J EXP MED, V192, P439, DOI 10.1084/jem.192.3.439; Takatsu K, 2008, CURR OPIN IMMUNOL, V20, P288, DOI 10.1016/j.coi.2008.04.001; Thurmond RL, 2008, NAT REV DRUG DISCOV, V7, P41, DOI 10.1038/nrd2465; TOMINAGA A, 1991, J EXP MED, V173, P429, DOI 10.1084/jem.173.2.429; Trifilieff A, 2001, CLIN EXP ALLERGY, V31, P934, DOI 10.1046/j.1365-2222.2001.01084.x; Voehringer D, 2007, J LEUKOCYTE BIOL, V81, P1434, DOI 10.1189/jlb.1106686; Walsh ER, 2010, TRENDS IMMUNOL, V31, P39, DOI 10.1016/j.it.2009.10.001; Walsh GM, 2009, CURR OPIN MOL THER, V11, P329; Wang HB, 2007, J IMMUNOL, V179, P7585, DOI 10.4049/jimmunol.179.11.7585; Wenzel SE, 2009, NEW ENGL J MED, V360, P1026, DOI 10.1056/NEJMe0900334; Wise EL, 2007, J BIOL CHEM, V282, P27935, DOI 10.1074/jbc.M703255200; WONG CK, 2009, AM J RESP CELL MOL B; Yamada T, 1998, J ALLERGY CLIN IMMUN, V101, P677, DOI 10.1016/S0091-6749(98)70177-0; Yamada Y, 2006, BLOOD, V107, P4071, DOI 10.1182/blood-2005-08-3153; Yamaguchi Y, 1999, BLOOD, V94, P1429, DOI 10.1182/blood.V94.4.1429.416k13_1429_1439; Yamanaka R, 1997, P NATL ACAD SCI USA, V94, P13187, DOI 10.1073/pnas.94.24.13187; Yousefi S, 2008, NAT MED, V14, P949, DOI 10.1038/nm.1855; Yu CN, 2002, J EXP MED, V195, P1387, DOI 10.1084/jem.20020656; Zhang M, 2007, BLOOD, V109, P4280, DOI 10.1182/blood-2006-08-039255; Zheng T, 2009, J INVEST DERMATOL, V129, P742, DOI 10.1038/jid.2008.295; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909; Zimmermann N, 2008, ALLERGY, V63, P1156, DOI 10.1111/j.1398-9995.2008.01709.x	121	80	83	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2010	126	1					16	25		10.1016/j.jaci.2010.02.026	http://dx.doi.org/10.1016/j.jaci.2010.02.026			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	627SE	20434203	Green Accepted			2022-12-18	WOS:000280061800003
J	Palmenberg, AC; Rathe, JA; Liggett, SB				Palmenberg, Ann C.; Rathe, Jennifer A.; Liggett, Stephen B.			Analysis of the complete genome sequences of human rhinovirus	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; chronic obstructive pulmonary disease; inflammation; virus	RECEPTOR-BINDING; HRV-C; INFECTIONS; DIVERSITY; CHILDREN; FEATURES; ASTHMA; EVOLUTIONARY; POPULATION; PLECONARIL	Human rhinovirus (HRV) infection is the cause of about one half of asthma and chronic obstructive pulmonary disease exacerbations. With more than 100 serotypes in the HRV reference set, an effort was undertaken to sequence their complete genomes so as to understand the diversity, structural variation, and evolution of the virus. Analysis revealed conserved motifs, hypervariable regions, a potential fourth HRV species, within-serotype variation in field isolates, a nonscanning internal ribosome entry site, and evidence for HRV recombination. Techniques have now been developed using next-generation sequencing to generate complete genomes from patient isolates with high throughput, deep coverage, and low costs. Thus relationships can now be sought between obstructive lung phenotypes and variation in HRV genomes in infected patients and potential novel therapeutic strategies developed based on HRV sequence. (J Allergy Clin Immunol 2010;125:1190-9.)	[Liggett, Stephen B.] Univ Maryland, Sch Med, Dept Med, Cardiopulm Genom Program, Baltimore, MD 21201 USA; [Palmenberg, Ann C.] Univ Wisconsin, Inst Mol Virol, Madison, WI 53706 USA	University System of Maryland; University of Maryland Baltimore; University of Wisconsin System; University of Wisconsin Madison	Liggett, SB (corresponding author), Univ Maryland, Sch Med, Dept Med, Cardiopulm Genom Program, 20 Penn St,HSF 2,Room S-114, Baltimore, MD 21201 USA.	sligg001@umaryland.edu	liggett, stephen b/E-7453-2012	Liggett, Stephen B./0000-0002-0128-3669	National Institutes of Health [HL091490, AI070503]; National Institute of Allergy and Infectious Diseases [HHSN272200900009C]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL091490] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI070503] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grants HL091490 and AI070503 and National Institute of Allergy and Infectious Diseases contract HHSN272200900009C.	[Anonymous], 1967, NATURE, V213, P761; COLONNO RJ, 1988, P NATL ACAD SCI USA, V85, P5449, DOI 10.1073/pnas.85.15.5449; CONANT RM, 1968, J IMMUNOL, V100, P114; COUCH RB, 2001, FIELDS VIROLOGY, P777; Djikeng A, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-5; Dominguez SR, 2008, J CLIN VIROL, V43, P219, DOI 10.1016/j.jcv.2008.06.007; GWALTNEY JM, 1966, NEW ENGL J MED, V275, P1261, DOI 10.1056/NEJM196612082752301; Hayden FG, 2003, CLIN INFECT DIS, V36, P1523, DOI 10.1086/375069; Herold J, 2001, MOL CELL, V7, P581, DOI 10.1016/S1097-2765(01)00205-2; Huang T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006355; Huson DH, 2006, MOL BIOL EVOL, V23, P254, DOI 10.1093/molbev/msj030; Huson DH, 1998, BIOINFORMATICS, V14, P68, DOI 10.1093/bioinformatics/14.1.68; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; JACKSON RJ, 1996, TRANSLATIONAL CONTRO, P71; Johnston SL, 1996, AM J RESP CRIT CARE, V154, P654, DOI 10.1164/ajrccm.154.3.8810601; Kistler AL, 2007, VIROL J, V4, DOI 10.1186/1743-422X-4-40; Lau SKP, 2007, J CLIN MICROBIOL, V45, P3655, DOI 10.1128/JCM.01254-07; LIN Y, 2009, J CLIN MICROBIOL, V47, P2895; McErlean P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001847; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; OLSON NH, 1993, P NATL ACAD SCI USA, V90, P507, DOI 10.1073/pnas.90.2.507; Palmenberg AC, 1997, SEMIN VIROL, V8, P231, DOI 10.1006/smvy.1997.0126; PALMENBERG AC, 2001, MOL BIOL PICORNAVIRU, P149; Palmenberg AC, 2009, SCIENCE, V324, P55, DOI 10.1126/science.1165557; Paul AV, 1998, NATURE, V393, P280, DOI 10.1038/30529; Pevear DC, 2005, ANTIMICROB AGENTS CH, V49, P4492, DOI 10.1128/AAC.49.11.4492-4499.2005; Piralla A, 2009, J CLIN VIROL, V45, P311, DOI 10.1016/j.jcv.2009.04.016; Rathe JA, 2010, ARCH VIROL, V155, P83, DOI 10.1007/s00705-009-0549-8; Savolainen C, 2002, VIRUS RES, V85, P41, DOI 10.1016/S0168-1702(02)00016-3; Tapparel C, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-224; Turner R. B., 2009, Clinical virology, P1063; Varkey JB, 2008, CURR OPIN PULM MED, V14, P89, DOI 10.1097/MCP.0b013e3282f4a99f; Vignuzzi M, 2006, NATURE, V439, P344, DOI 10.1038/nature04388; Vlasak M, 2005, J VIROL, V79, P7389, DOI 10.1128/JVI.79.12.7389-7395.2005	34	80	88	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2010	125	6					1190	1199		10.1016/j.jaci.2010.04.010	http://dx.doi.org/10.1016/j.jaci.2010.04.010			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	611PH	20471068	Green Accepted, Bronze			2022-12-18	WOS:000278831000002
J	Brignier, AC; Gewirtz, AM				Brignier, Anne C.; Gewirtz, Alan M.			Embryonic and adult stem cell therapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Stem cells; human embryonic stem cells; induced pluripotent stem cells; regenerative medicine; gene therapy; cell therapy	CORD BLOOD TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; VERSUS-HOST-DISEASE; BONE-MARROW; GENE-THERAPY; PERIPHERAL-BLOOD; HUMAN FIBROBLASTS; DOPAMINE NEURONS; UMBILICAL-CORD; HIGH-RISK	There are many types of stem cells. All share the characteristics of being able to self-renew and to give rise to differentiated progeny. Over the last decades, great excitement has been generated by the prospect of being able to exploit these properties for the repair, improvement, and/or replacement of damaged organs. However, many hurdles, both scientific and ethical, remain in the path of using human embryonic stem cells for tissue-engineering purposes. In this report we review current strategies for isolating, enriching, and, most recently, inducing the development of human pluripotent stem cells. In so doing, we discuss the scientific and ethical issues associated with this endeavor. Finally, progress in the use of stem cells as therapies for type 1 diabetes mellitus, congestive heart failure, and various neurologic and immunohematologic disorders, and as vehicles for the delivery of gene therapy, is briefly discussed. (J Allergy Clin Immunol 2010;125:S336-44.)	[Brignier, Anne C.] Univ Penn, Sch Med, Dept Med, Div Hematol Oncol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine	Brignier, AC (corresponding author), Univ Penn, Sch Med, Dept Med, Div Hematol Oncol, Rm 727,BRB 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.	brignier@free.fr			Fondation pour la Recherche Medicale (FRM)	Fondation pour la Recherche Medicale (FRM)(Fondation pour la Recherche Medicale)	A.C.B. is supported by a Fondation pour la Recherche Medicale (FRM) fellowship.	Abdel-Latif A, 2007, ARCH INTERN MED, V167, P989, DOI 10.1001/archinte.167.10.989; Aiuti A, 2009, NEW ENGL J MED, V360, P447, DOI 10.1056/NEJMoa0805817; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Aversa F, 2005, J CLIN ONCOL, V23, P3447, DOI 10.1200/JCO.2005.09.117; Ball LM, 2007, BLOOD, V110, P2764, DOI 10.1182/blood-2007-04-087056; BATTEY JF, 2006, REGENERATIVE MED; Bayer AL, 2009, BLOOD, V113, P733, DOI 10.1182/blood-2008-08-173179; Braak H, 2008, NAT MED, V14, P483, DOI 10.1038/nm0508-483; Burt RK, 2008, JAMA-J AM MED ASSOC, V299, P925, DOI 10.1001/jama.299.8.925; Chen SL, 2004, AM J CARDIOL, V94, P92, DOI 10.1016/j.amjcard.2004.03.034; Chin MH, 2009, CELL STEM CELL, V5, P111, DOI 10.1016/j.stem.2009.06.008; Cho MS, 2008, P NATL ACAD SCI USA, V105, P3392, DOI 10.1073/pnas.0712359105; Conrad S, 2008, NATURE, V456, P344, DOI 10.1038/nature07404; Couri CEB, 2009, JAMA-J AM MED ASSOC, V301, P1573, DOI 10.1001/jama.2009.470; Cowan CA, 2005, SCIENCE, V309, P1369, DOI 10.1126/science.1116447; Cutler C, 2001, J CLIN ONCOL, V19, P3685, DOI 10.1200/JCO.2001.19.16.3685; Huangfu DW, 2008, NAT BIOTECHNOL, V26, P1269, DOI 10.1038/nbt.1502; Demirer T, 2008, NAT CLIN PRACT ONCOL, V5, P256, DOI 10.1038/ncponc1104; Dill T, 2009, AM HEART J, V157, P541, DOI 10.1016/j.ahj.2008.11.011; Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905; Eminli S, 2009, NAT GENET, V41, P968, DOI 10.1038/ng.428; Flomenberg N, 2005, BLOOD, V106, P1867, DOI 10.1182/blood-2005-02-0468; Freed CR, 2001, NEW ENGL J MED, V344, P710, DOI 10.1056/NEJM200103083441002; French AJ, 2008, STEM CELLS, V26, P485, DOI 10.1634/stemcells.2007-0252; Gurdon JB, 2008, SCIENCE, V322, P1811, DOI 10.1126/science.1160810; Hacein-Bey-Abina S, 2008, J CLIN INVEST, V118, P3132, DOI 10.1172/JCI35700; Hamamoto H, 2009, ANN THORAC SURG, V87, P794, DOI 10.1016/j.athoracsur.2008.11.057; Howe SJ, 2008, J CLIN INVEST, V118, P3143, DOI 10.1172/JCI35798; Keene CD, 2009, ACTA NEUROPATHOL, V117, P329, DOI 10.1007/s00401-008-0465-0; Kim SM, 2008, CANCER RES, V68, P9614, DOI 10.1158/0008-5472.CAN-08-0451; Klimanskaya I, 2006, NATURE, V444, P481, DOI 10.1038/nature05142; Komanduri KV, 2007, BLOOD, V110, P4543, DOI 10.1182/blood-2007-05-092130; Kondziolka D, 2005, J NEUROSURG, V103, P38, DOI 10.3171/jns.2005.103.1.0038; Kroon E, 2008, NAT BIOTECHNOL, V26, P443, DOI 10.1038/nbt1393; LeBlanc K, 2008, LANCET, V371, P1579, DOI 10.1016/S0140-6736(08)60690-X; Lee RH, 2006, P NATL ACAD SCI USA, V103, P17438, DOI 10.1073/pnas.0608249103; Leist M, 2008, ALTEX-ALTERN TIEREXP, V25, P163; Levy YS, 2008, CYTOTHERAPY, V10, P340, DOI 10.1080/14653240802021330; Lu XZ, 2008, EUR J HAEMATOL, V81, P18, DOI 10.1111/j.1600-0609.2008.01073.x; Mackay-Sim A, 2008, BRAIN, V131, P2376, DOI 10.1093/brain/awn173; Martin-Rendon E, 2008, VOX SANG, V95, P137, DOI 10.1111/j.1423-0410.2008.01076.x; Mavilio F, 2006, NAT MED, V12, P1397, DOI 10.1038/nm1504; Mitalipova MM, 2005, NAT BIOTECHNOL, V23, P19, DOI 10.1038/nbt0105-19; Montini E, 2006, NAT BIOTECHNOL, V24, P687, DOI 10.1038/nbt1216; Muraro PA, 2005, J EXP MED, V201, P805, DOI 10.1084/jem.20041679; Murrell W, 2008, STEM CELLS, V26, P2183, DOI 10.1634/stemcells.2008-0074; Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0; Neuman T., 2009, OPEN STEM CELL J, V1, P20, DOI DOI 10.2174/1876893800901010020; Okita K, 2008, SCIENCE, V322, P949, DOI 10.1126/science.1164270; Olanow CW, 2003, ANN NEUROL, V54, P403, DOI 10.1002/ana.10720; Ott MG, 2006, NAT MED, V12, P401, DOI 10.1038/nm1393; Puymirat E, 2009, MOL THER, V17, P176, DOI 10.1038/mt.2008.208; Raya A, 2009, NATURE, V460, P53, DOI 10.1038/nature08129; Revazova ES, 2007, CLONING STEM CELLS, V9, P432, DOI 10.1089/clo.2007.0033; Robinson SN, 2006, BONE MARROW TRANSPL, V37, P359, DOI 10.1038/sj.bmt.1705258; Ruggeri A, 2008, BRIT J HAEMATOL, V143, P404, DOI 10.1111/j.1365-2141.2008.07364.x; Ruggeri L, 2002, SCIENCE, V295, P2097, DOI 10.1126/science.1068440; Savitz SI, 2005, CEREBROVASC DIS, V20, P101, DOI 10.1159/000086518; Selmani Z, 2008, STEM CELLS, V26, P212, DOI 10.1634/stemcells.2007-0554; Shapiro AMJ, 2006, NEW ENGL J MED, V355, P1318, DOI 10.1056/NEJMoa061267; Smith RR, 2007, CIRCULATION, V115, P896, DOI 10.1161/CIRCULATIONAHA.106.655209; Stadtfeld M, 2008, SCIENCE, V322, P945, DOI 10.1126/science.1162494; Storb R, 2007, BEST PRACT RES CL HA, V20, P85, DOI 10.1016/j.beha.2006.10.008; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Takahashi S, 2007, BLOOD, V109, P1322, DOI 10.1182/blood-2006-04-020172; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; TILL JE, 1961, RADIAT RES, V14, P213, DOI 10.2307/3570892; Turnpenny L, 2003, STEM CELLS, V21, P598, DOI 10.1634/stemcells.21-5-598; van der Bogt KEA, 2008, CIRCULATION, V118, pS121, DOI 10.1161/CIRCULATIONAHA.107.759480; van Laake LW, 2007, STEM CELL RES, V1, P9, DOI 10.1016/j.scr.2007.06.001; Wan CD, 2008, HEPATOB PANCREAT DIS, V7, P29; Wernig M, 2008, P NATL ACAD SCI USA, V105, P5856, DOI 10.1073/pnas.0801677105; Wu LC, 2006, BLOOD, V108, P1183, DOI 10.1182/blood-2006-02-004812; Wu XL, 2003, SCIENCE, V300, P1749, DOI 10.1126/science.1083413; Xu XB, 2008, CELL, V132, P197, DOI 10.1016/j.cell.2007.12.015; Yoon SH, 2007, STEM CELLS, V25, P2066, DOI 10.1634/stemcells.2006-0807; Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526; Zhou HY, 2009, CELL STEM CELL, V4, P381, DOI 10.1016/j.stem.2009.04.005; Zhou Q, 2008, NATURE, V455, P627, DOI 10.1038/nature07314	80	80	84	0	44	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2010	125	2		2			S336	S344		10.1016/j.jaci.2009.09.032	http://dx.doi.org/10.1016/j.jaci.2009.09.032			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	629CC	20061008	Bronze			2022-12-18	WOS:000280170600031
J	Osterfeld, H; Ahrens, R; Strait, R; Finkelman, FD; Renauld, JC; Hogan, SP				Osterfeld, Heather; Ahrens, Richard; Strait, Richard; Finkelman, Fred D.; Renauld, Jean-Christophe; Hogan, Simon P.			Differential roles for the IL-9/IL-9 receptor alpha-chain pathway in systemic and oral antigen-induced anaphylaxis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Cytokine; anaphylaxis; mast cells; IgE	MAST-CELLS; IN-VIVO; IL-9; ANTIBODIES; INFLAMMATION; EXPRESSION; BASOPHILS; RESPONSES; PROMOTES; IGG	Background: The cytokine IL-9 has been implicated in allergic reactions, including food allergy, but its contribution to parenteral versus oral antigen-induced anaphylaxis remains unclear. Objectives: We sought to delineate the contribution of the IL-9/IL-9 receptor alpha-chain (IL-9R) pathway to parenteral and oral antigen-induced anaphylaxis. Methods: Wild-type, IL-9-deficient (Il9(-/-)), and IL-9R-deficient (Il9R(-/-)) mice were subjected to passive and active parenteral and oral antigen (ovalbumin [OVA])-induced anaphylaxis. Severity of systemic anaphylaxis was ganged by decreased body temperature; intestinal anaphylaxis was assessed based on secretory diarrhea, intestinal mastocytosis, and serum murine mast cell protease I level. Specific immunoglobulin isotypes or immunoglobulin receptor-blocking antibodies were administered before challenge to define the role of the IgE and IgG pathways. Results: Repeated oral antigen challenge of OVA-sensitized wild-type mice induced anaphylaxis with both systemic and intestinal involvement; both were IgE dependent and attenuated in Il9(-/-) and Il9R(-/-) mice. In contrast, parenteral OVA challenge of OVA-sensitized wild-type mice induced systemic anaphylaxis, which was independent of the IL-9/IL-9R pathway. Strikingly, the IL-9/IL-9R pathway had no role in either the IgG or IgE component of parenteral antigen-induced or anti-IgE and anti-Fc gamma RII/III mAb-induced systemic anaphylaxis. Conclusions: Parenteral antigen-induced murine systemic anaphylaxis is mediated by both IgG- and IgE-dependent pathways, and both can occur independently of IL-9/IL-9R signaling. In contrast, oral antigen-induced intestinal and systemic anaphylaxis is strictly IgE mediated and requires IL-9/IL-9R signaling. These studies indicate differential involvement of the IL-9/IL-9R pathway in systemic and oral antigen-induced anaphylaxis. (J Allergy Clin Immunol 2010;125:469-76.)	[Osterfeld, Heather; Ahrens, Richard; Hogan, Simon P.] Univ Cincinnati, Cincinnati Childrens Hosp, Coll Med, Med Ctr,Dept Pediat,Div Allergy & Immunol, Cincinnati, OH 45229 USA; [Strait, Richard; Finkelman, Fred D.] Univ Cincinnati, Cincinnati Childrens Hosp, Coll Med, Med Ctr,Dept Pediat,Div Immunobiol, Cincinnati, OH 45229 USA; [Strait, Richard] Univ Cincinnati, Cincinnati Childrens Hosp, Coll Med, Med Ctr,Dept Pediat,Div Emergency Med, Cincinnati, OH 45229 USA; [Renauld, Jean-Christophe] Univ Louvain, Ludwig Inst Canc Res, Brussels Branch, Brussels, Belgium; [Renauld, Jean-Christophe] Univ Louvain, Expt Med Unit, Brussels, Belgium	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Ludwig Institute for Cancer Research; Universite Catholique Louvain; Universite Catholique Louvain	Hogan, SP (corresponding author), Univ Cincinnati, Cincinnati Childrens Hosp, Coll Med, Med Ctr,Dept Pediat,Div Allergy & Immunol, 3333 Burnet Ave,ML7028, Cincinnati, OH 45229 USA.	simon.hogan@cchmc.org	Renauld, Jean-Christophe/B-7268-2012	Renauld, Jean-Christophe/0000-0003-1736-2131	American Heart Association Midwest Affiliate; American Academy of Allergy, Asthma and Immunology; Food Allergy and Anaphylaxis Network and National Institutes of Health [R01AI073553-01]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI073553] Funding Source: NIH RePORTER	American Heart Association Midwest Affiliate(American Heart Association); American Academy of Allergy, Asthma and Immunology; Food Allergy and Anaphylaxis Network and National Institutes of Health; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported in part by the American Heart Association Midwest Affiliate (S.P.H), the American Academy of Allergy, Asthma and Immunology Interest section Award 2007 (S.P.H.), Food Allergy and Anaphylaxis Network and National Institutes of Health grant R01AI073553-01 (S.P.H).	BANIYASH M, 1984, EUR J IMMUNOL, V14, P799, DOI 10.1002/eji.1830140907; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; Brandt EB, 2003, J CLIN INVEST, V112, P1666, DOI 10.1172/JCI19785; Dardalhon V, 2008, NAT IMMUNOL, V9, P1347, DOI 10.1038/ni.1677; DUGAS B, 1993, EUR J IMMUNOL, V23, P1687, DOI 10.1002/eji.1830230743; Eigenmann PA, 2002, PEDIAT ALLERG IMM-UK, V13, P162, DOI 10.1034/j.1399-3038.2002.01015.x; Eigenmann PA, 1996, ADV EXP MED BIOL, V409, P217; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; FINKELMAN FD, 1981, J IMMUNOL, V126, P680; Finkelman FD, 2007, J ALLERGY CLIN IMMUN, V120, P506, DOI 10.1016/j.jaci.2007.07.033; Forbes EE, 2008, J EXP MED, V205, P897, DOI 10.1084/jem.20071046; Godfraind C, 1998, J IMMUNOL, V160, P3989; Greenberger PA, 2006, J ALLERGY CLIN IMMUN, V117, pS464, DOI 10.1016/j.jaci.2005.11.002; Hauber HP, 2004, INT ARCH ALLERGY IMM, V134, P79, DOI 10.1159/000078384; Knoops L, 2005, J IMMUNOL, V175, P335, DOI 10.4049/jimmunol.175.1.335; MADDEN KB, 1991, J IMMUNOL, V147, P1387; Matsuzawa S, 2003, J IMMUNOL, V170, P3461, DOI 10.4049/jimmunol.170.7.3461; McLane MP, 1998, AM J RESP CELL MOL, V19, P713, DOI 10.1165/ajrcmb.19.5.3457; Sicherer SH, 2005, J ALLERGY CLIN IMMUN, V116, P153, DOI 10.1016/j.jaci.2005.03.017; Simons FER, 2007, J ALLERGY CLIN IMMUN, V120, pS2, DOI [10.1016/j.jaci.2007.05.001, 10.1016/j.jaci.2007.05.016]; Strait RT, 2006, J CLIN INVEST, V116, P833, DOI 10.1172/JCI25575; Strait RT, 2003, J IMMUNOL, V170, P3835, DOI 10.4049/jimmunol.170.7.3835; Strait RT, 2002, J ALLERGY CLIN IMMUN, V109, P658, DOI 10.1067/mai.2002.123302; Temann UA, 2002, J CLIN INVEST, V109, P29, DOI 10.1172/JCI13696; Temann UA, 1998, J EXP MED, V188, P1307, DOI 10.1084/jem.188.7.1307; Townsend MJ, 2000, IMMUNITY, V13, P573, DOI 10.1016/S1074-7613(00)00056-X; Tsujimura Y, 2008, IMMUNITY, V28, P581, DOI 10.1016/j.immuni.2008.02.008; Turcanu V, 2003, J CLIN INVEST, V111, P1065, DOI 10.1172/JCI200316142; Ujike A, 1999, J EXP MED, V189, P1573, DOI 10.1084/jem.189.10.1573; Vink A, 1999, J EXP MED, V189, P1413, DOI 10.1084/jem.189.9.1413; Wang JL, 2007, CLIN EXP ALLERGY, V37, P651, DOI 10.1111/j.1365-2222.2007.02682.x	31	80	85	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2010	125	2					469	476		10.1016/j.jaci.2009.09.054	http://dx.doi.org/10.1016/j.jaci.2009.09.054			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	558RU	20159257	Green Accepted			2022-12-18	WOS:000274764000027
J	Griffith, LM; Cowan, MJ; Notarangelo, LD; Puck, JM; Buckley, RH; Candotti, F; Conley, ME; Fleisher, TA; Gaspar, HB; Kohn, DB; Ochs, HD; O'Reilly, RJ; Rizzo, JD; Roifman, CM; Small, TN; Shearer, WT				Griffith, Linda M.; Cowan, Morton J.; Notarangelo, Luigi D.; Puck, Jennifer M.; Buckley, Rebecca H.; Candotti, Fabio; Conley, Mary Ellen; Fleisher, Thomas A.; Gaspar, H. Bobby; Kohn, Donald B.; Ochs, Hans D.; O'Reilly, Richard J.; Rizzo, J. Douglas; Roifman, Chaim M.; Small, Trudy N.; Shearer, William T.		Workshop	Improving cellular therapy for primary immune deficiency diseases: Recognition, diagnosis, and management	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allogeneic hematopoietic stem cell transplantation; gene therapy; primary immunodeficiency; clinical trial	SEVERE COMBINED IMMUNODEFICIENCY; VERSUS-HOST-DISEASE; AUTOIMMUNE HEMOLYTIC-ANEMIA; GENE-THERAPY; MARROW-TRANSPLANTATION; MOLECULAR DEFECTS; EUROPEAN-SOCIETY; THYMIC OUTPUT; BLOOD; CELLS	More than 20 North American academic centers account for the majority of hematopoietic stem cell transplantation (HCT) procedures for primary immunodeficiency diseases (PIDs), with smaller numbers performed at additional sites. Given the importance of a timely diagnosis of these rare diseases and the diversity of practice sites, there is a need for guidance as to best practices in management of patients with PIDs before, during, and in follow-up for definitive treatment. In this conference report of immune deficiency experts and HCT physicians who care for patients with PIDs, we present expert guidance for (1) PID diagnoses that are indications for HCT, including severe combined immunodeficiency disease (SCID), combined immunodeficiency disease, and other non-SCID diseases; (2) the critical importance of a high degree of suspicion of the primary care physician and timeliness of diagnosis for PIDs; (3) the need for rapid referral to an immune deficiency expert, center with experience in HCT, or both for patients with PIDs; (4) medical management of a child with suspicion of SCID/combined immunodeficiency disease while confirming the diagnosis, including infectious disease management and workup; (5) the posttransplantation follow-up visit schedule; (6) antimicrobial prophylaxis after transplantation, including gamma globulin administration; and (7) important indications for return to the transplantation center after discharge. Finally, we discuss the role of high-quality databases in treatment of PIDs and HCT as an element of the infrastructure that will be needed for productive multicenter clinical trials in these rare diseases. (J Allergy Clin Immunol 2009;124:1152-60.)	[Shearer, William T.] Texas Childrens Hosp, Baylor Coll Med, Dept Allergy & Immunol, Houston, TX 77030 USA; [Griffith, Linda M.] NIAID, Div Allergy Immunol & Transplantat, Bethesda, MD 20892 USA; [Cowan, Morton J.] UCSF Childrens Hosp, Pediat Blood & Marrow Transplant Div, San Francisco, CA USA; [Notarangelo, Luigi D.] Harvard Univ, Childrens Hosp, Sch Med, Div Immunol, Boston, MA 02115 USA; [Notarangelo, Luigi D.] Harvard Univ, Childrens Hosp, Sch Med, Manton Ctr Orphan Dis Res, Boston, MA 02115 USA; [Puck, Jennifer M.] Univ Calif San Francisco, Dept Pediat, Inst Human Genet, San Francisco, CA 94143 USA; [Buckley, Rebecca H.] Duke Univ, Sch Med, Durham, NC 27706 USA; [Candotti, Fabio] NHGRI, Genet & Mol Biol Branch, NIH, Bethesda, MD 20892 USA; [Conley, Mary Ellen] Univ Tennessee, Coll Med, Dept Pediat, Memphis, TN USA; [Conley, Mary Ellen] St Jude Childrens Hosp, Dept Immunol, Memphis, TN 38105 USA; [Fleisher, Thomas A.] NIH, Dept Lab Med, Ctr Clin, Bethesda, MD 20892 USA; [Gaspar, H. Bobby] UCL, Great Ormond St Hosp, Inst Child Hlth, London WC1E 6BT, England; [Kohn, Donald B.] Univ Calif Los Angeles, Dept Microbiol, Los Angeles, CA 90024 USA; [Kohn, Donald B.] Univ Calif Los Angeles, Dept Immunol, Los Angeles, CA USA; [Kohn, Donald B.] Univ Calif Los Angeles, Dept Mol Genet, Los Angeles, CA USA; [Ochs, Hans D.] Seattle Childrens Hosp, Res Inst, Ctr Immunol & Immunotherapy, Seattle, WA USA; [O'Reilly, Richard J.; Small, Trudy N.] Mem Sloan Kettering Canc Ctr, Dept Pediat, New York, NY 10021 USA; [O'Reilly, Richard J.; Small, Trudy N.] Mem Sloan Kettering Canc Ctr, Dept Immunol, New York, NY 10021 USA; [Rizzo, J. Douglas] Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA; [Roifman, Chaim M.] Univ Toronto, Hosp Sick Children, Div Immunol & Allergy, Toronto, ON M5G 1X8, Canada	Baylor College of Medicine; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of California System; University of California San Francisco; UCSF Medical Center; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; University of California System; University of California San Francisco; Duke University; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of Tennessee System; University of Tennessee Health Science Center; St Jude Children's Research Hospital; National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Seattle Children's Hospital; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Center for International Blood & Marrow Transplant Research; Medical College of Wisconsin; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Shearer, WT (corresponding author), Texas Childrens Hosp, Baylor Coll Med, Dept Allergy & Immunol, MC FC330-01,6621 Fannin St,Ste A-380, Houston, TX 77030 USA.	wshearer@bcm.edu	Kohn, Donald/N-5085-2016; Buckley, Rebecca/AAB-1578-2019; Notarangelo, Luigi D/F-9718-2016	Kohn, Donald/0000-0003-1840-6087; Notarangelo, Luigi D/0000-0002-8335-0262; Shearer, William/0000-0002-2483-2130; Malech, Harry/0000-0001-5874-5775; Candotti, Fabio/0000-0001-6399-6042; De Ravin, Suk See/0000-0002-9800-774X; Schultz, Kirk/0000-0002-0001-6438	Division of Allergy, Immunology and Transplantation; National Institute of Allergy and Infectious Diseases; Office of Rare Diseases Research, National Institutes of Health, Bethesda, Md; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [ZIAHG000122] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI071163, U54AI082973] Funding Source: NIH RePORTER	Division of Allergy, Immunology and Transplantation; National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Office of Rare Diseases Research, National Institutes of Health, Bethesda, Md(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This workshop was supported by the Division of Allergy, Immunology and Transplantation, National Institute of Allergy and Infectious Diseases. and the Office of Rare Diseases Research. National Institutes of Health, Bethesda, Md.; Disclosure of potential conflict of interest: M. J. Cowan has received research support from the National Institutes of Health; has provided expert witness testimony on the topic of transplant-related mortality and is Chair of PSIG at the American Society for Blood and Marrow Transplantation. L. D. Notarangelo has received research support from the Manton Foundation, and is on the Steering Committee for the United States Immunodeficiency Network. J. Puck has received research support from the National Institutes of Health, Jeffrey Modell Foundation, United States Immunodeficiency Network. and Baxter. Inc. R. H. Buckley has received research support from the National Institutes of Health, and is Chair of the Medical Advisory Committee for the Immune Deficiency Foundation. M. E. Conley is a consultant for Pharmacyclics; has received royalties from Santa Cruz Biotechnology: and has received research support from the National Institutes of Health. H. R. Gaspar has received research support from the Medical Research Council (UK) and the European Union. H.D. Ochs is on advisory boards for Baxter and CSL Behring, and has received research support from the Jeffrey Modell Foundation, Genetic Defects of Immunity (NIH/NIAID), and Flebogamma 5%. T.N. Small is speaker for Pfizer; is on an advisory board for Wyeth: is on the Data and Safety Monitoring Committee for the American Medical Directors Association: and is married to an employee of Pfizer. The other authors declare that they have no relevant conflicts of interest to disclose.	Aiuti A, 2009, NEW ENGL J MED, V360, P447, DOI 10.1056/NEJMoa0805817; Alter HJ, 2008, BLOOD, V112, P2617, DOI 10.1182/blood-2008-07-077370; Antoine C, 2003, LANCET, V361, P553, DOI 10.1016/S0140-6736(03)12513-5; Baker MW, 2009, J ALLERGY CLIN IMMUN, V124, P522, DOI 10.1016/j.jaci.2009.04.007; Bertrand Y, 1999, J PEDIATR-US, V134, P740, DOI 10.1016/S0022-3476(99)70291-X; Buckley RH, 2004, ANNU REV IMMUNOL, V22, P625, DOI 10.1146/annurev.immunol.22.012703.104614; Chan K, 2005, J ALLERGY CLIN IMMUN, V115, P391, DOI 10.1016/j.jaci.2004.10.012; Chao NJ, 2006, SEMIN HEMATOL, V43, P32, DOI 10.1053/j.seminhematol.2005.09.007; Dvorak CC, 2008, BIOL BLOOD MARROW TR, V14, P1125, DOI 10.1016/j.bbmt.2008.07.008; Fleisher TA, 2004, J ALLERGY CLIN IMMUN, V114, P227, DOI 10.1016/j.jaci.2004.06.001; Garcia-Vidal C, 2008, CLIN INFECT DIS, V47, P1041, DOI 10.1086/591969; Gaspar HB, 2006, MOL THER, V14, P505, DOI 10.1016/j.ymthe.2006.06.007; Gaspar HB, 2009, BLOOD, V114, P3524, DOI 10.1182/blood-2009-06-189209; Griffith LM, 2008, J ALLERGY CLIN IMMUN, V122, P1087, DOI 10.1016/j.jaci.2008.09.045; Hacein-Bey-Abina S, 2003, SCIENCE, V302, P415, DOI 10.1126/science.1088547; Handgretinger R, 2001, BONE MARROW TRANSPL, V27, P777, DOI 10.1038/sj.bmt.1702996; Horn B, 1999, BONE MARROW TRANSPL, V24, P1009, DOI 10.1038/sj.bmt.1702011; Hymes SR, 2006, BIOL BLOOD MARROW TR, V12, P1101, DOI 10.1016/j.bbmt.2006.08.043; Mazzolari E, 2007, J ALLERGY CLIN IMMUN, V120, P892, DOI 10.1016/j.jaci.2007.08.007; Muller SM, 2001, BLOOD, V98, P1847, DOI 10.1182/blood.V98.6.1847; Myers LA, 2002, BLOOD, V99, P872, DOI 10.1182/blood.V99.3.872; Neven B, 2009, BLOOD, V113, P4114, DOI 10.1182/blood-2008-09-177923; Notarangelo LD, 2008, J ALLERGY CLIN IMMUN, V122, P1069, DOI 10.1016/j.jaci.2008.08.038; Ozsahin H, 2008, BLOOD, V111, P439, DOI 10.1182/blood-2007-03-076679; Patel NC, 2009, J ALLERGY CLIN IMMUN, V124, P1062, DOI 10.1016/j.jaci.2009.08.041; Patel NC, 2008, J ALLERGY CLIN IMMUN, V122, P1185, DOI 10.1016/j.jaci.2008.10.030; PAUL M, 2008, CLIN IMMUNOLOGY PRIN, P463; Puck JM, 2007, J ALLERGY CLIN IMMUN, V120, P760, DOI 10.1016/j.jaci.2007.08.043; Railey MD, 2009, J PEDIATR-US, V155, P834, DOI 10.1016/j.jpeds.2009.07.049; READ EJ, 2002, CELLULAR THERAPY NEW, P29; REISNER Y, 1983, BLOOD, V61, P341; Roifman CM, 2008, BONE MARROW TRANSPL, V41, P947, DOI 10.1038/bmt.2008.11; Ruhl H, 2009, TRANSFUS MED REV, V23, P62, DOI 10.1016/j.tmrv.2008.09.006; Sarzotti-Kelsoe M, 2009, BLOOD, V114, P1445, DOI 10.1182/blood-2009-01-199323; Sevilla J, 2001, BONE MARROW TRANSPL, V28, P89, DOI 10.1038/sj.bmt.1703087; Shearer WT, 2003, J ALLERGY CLIN IMMUN, V112, P973, DOI 10.1016/j.jaci.2003.07.003; Small TN, 2009, THOMAS HEMATOPOIETIC, V75, P1105; Titman P, 2008, BLOOD, V112, P3907, DOI 10.1182/blood-2008-04-151332; Tomblyn M, 2009, BIOL BLOOD MARROW TR, V15, P1143, DOI 10.1016/j.bbmt.2009.06.019; Werther RL, 2009, J ALLERGY CLIN IMMUN, V124, P600, DOI 10.1016/j.jaci.2009.07.005	40	80	85	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2009	124	6					1152	1160		10.1016/j.jaci.2009.10.022	http://dx.doi.org/10.1016/j.jaci.2009.10.022			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	536VH	20004776	Bronze, Green Accepted			2022-12-18	WOS:000273071500003
J	He, JQ; Hallstrand, TS; Knight, D; Chan-Yeung, M; Sandford, A; Tripp, B; Zamar, D; Bosse, Y; Kozyrskyj, AL; James, A; Laprise, C; Daley, D				He, Jian-Qing; Hallstrand, Teal S.; Knight, Darryl; Chan-Yeung, Moira; Sandford, Andrew; Tripp, Ben; Zamar, David; Bosse, Yohan; Kozyrskyj, Anita L.; James, Alan; Laprise, Catherine; Daley, Denise			A thymic stromal lymphopoietin gene variant is associated with asthma and airway hyperresponsiveness	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Airway hyperresponsiveness; association study; asthma genetics; atopy; polymorphisms; thymic stromal lymphopoietin	SINGLE-NUCLEOTIDE POLYMORPHISMS; PRIMARY PREVENTION; LUNG-FUNCTION; CHILDHOOD; RECEPTOR; TSLP; DISEQUILIBRIUM; DISEASE; RISK; INFLAMMATION	Background: The epithelial cell-derived protein thymic stromal lymphopoietin stimulates dendritic and mast cells to promote proallergic T(H)2 responses. Studies of transgenic expression of thymic stromal lymphopoietin and its receptor knockout mice have emphasized its critical role in the development of allergic inflammation. Association of genetic variation in thymic stromal lymphopoietin with IgE levels has been reported for human subjects. Objective: The aim of this study was to evaluate the relationship between variants of thymic stromal lymphopoietin and asthma and related phenotypes. Methods: We selected 6 single nucleotide polymorphisms in thymic stromal lymphopoietin and genotyped 5565 individuals from 4 independent asthma studies and tested for association with asthma, atopy, atopic asthma, and airway hyperresponsiveness by using a general allelic likelihood ratio test. P values. were corrected for the effective number of independent single nucleotide polymorphisms and phenotypes. Results: The A allele of rs1837253, which is 5.7 kb upstream of the transcription start site of the gene, was associated with protection from asthma, atopic asthma, and airway hyperresponsiveness, with the odds ratios and corrected P values for each being 0.79 and 0.0058; 0.75 and 0.0074; and 0.76 and 0.0094, respectively. Associations between thymic stromal lymphopoietin and asthma-related phenotypes were the most statistically significant observations in our study, which has to date examined 98 candidate genes. Full results are available online at http://genapha.icapture.ubc.ca/. Conclusions: A genetic variant in the region of the thymic stromal lymphopoietin gene is associated with the phenotypes of asthma and airway hyperresponsiveness. (J Allergy Clin Immunol 2009;124:222-9.)	[He, Jian-Qing; Knight, Darryl; Sandford, Andrew; Tripp, Ben; Zamar, David; Daley, Denise] Univ British Columbia, UBC James Hogg iCAPTURE Ctr, Vancouver, BC V6Z 1Y6, Canada; [Knight, Darryl] Univ British Columbia, Dept Anesthesiol Pharmacol & Therapeut, Vancouver, BC V5Z 1M9, Canada; [Chan-Yeung, Moira] Univ British Columbia, Occupat & Environm Lung Dis Unit, Vancouver, BC V5Z 1M9, Canada; [Sandford, Andrew; Daley, Denise] Univ British Columbia, Div Resp Med, Dept Med, Vancouver, BC V5Z 1M9, Canada; [Hallstrand, Teal S.] Univ British Columbia, Div Pulm & Crit Care, Dept Med, Vancouver, BC V5Z 1M9, Canada; [Bosse, Yohan] Inst Univ Cardiol & Pneumol Quebec, Quebec City, PQ, Canada; [Bosse, Yohan] Laval Univ Hosp Res Ctr, Laval, PQ, Canada; [Kozyrskyj, Anita L.] Univ Alberta, Fac Med & Dent, Dept Pediat, Edmonton, AB, Canada; [Kozyrskyj, Anita L.; James, Alan] Univ Manitoba, Fac Med, Dept Pediat & Child Hlth, Winnipeg, MB, Canada; [James, Alan] Sir Charles Gairdner Hosp, W Australian Sleep Disorders Res Inst, Perth, WA, Australia; [Laprise, Catherine] Univ Quebec Chicoutimi, Dept Sci Fondamentales, Chicoutimi, PQ, Canada; [Laprise, Catherine] Univ Montreal, Chicoutimi Hosp, Community Genom Med Ctr, Montreal, PQ H3C 3J7, Canada	University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia; Laval University; University of Alberta; University of Manitoba; University of Western Australia; University of Quebec; University of Quebec Chicoutimi; Universite de Montreal	Daley, D (corresponding author), Univ British Columbia, UBC James Hogg iCAPTURE Ctr, 1081 Burrard Street, Vancouver, BC V6Z 1Y6, Canada.	ddaley@mrl.ubc.ca	He, Jian-Qing/AAA-6269-2021; Bosse, Yohan/C-7617-2012	Laprise, Catherine/0000-0001-5526-9945; He, Jian-Qing/0000-0002-0966-1302; Hallstrand, Teal/0000-0002-5059-6872	AllerGen, a National Centre of Excellence Network (Canada); Canadian Institutes of Health Research; Institutes of Gender and Health; British Columbia Lung Association; Genome Quebec; Fonds de la Recherche en Sante du Quebec; Healthway, Australia; Michael Smith Foundation for Health Research Doctoral Award; Izaak Walton Killam Memorial Scholarship Award; William Thurlbeck Distinguished Research Award; National Health and Medical Research Council of Australia [303145, 458513]; Child Health Research Foundation of Western Australia; Asthma Foundation of Western Australia	AllerGen, a National Centre of Excellence Network (Canada); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Institutes of Gender and Health; British Columbia Lung Association; Genome Quebec; Fonds de la Recherche en Sante du Quebec(Fonds de la Recherche en Sante du Quebec); Healthway, Australia; Michael Smith Foundation for Health Research Doctoral Award(Michael Smith Foundation for Health Research); Izaak Walton Killam Memorial Scholarship Award; William Thurlbeck Distinguished Research Award; National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Child Health Research Foundation of Western Australia; Asthma Foundation of Western Australia	Supported by AllerGen, a National Centre of Excellence Network (Canada); the Canadian Institutes of Health Research; the Institutes of Gender and Health; British Columbia Lung Association; Genome Quebec; and the Respiratory Health Network of the Fonds de la Recherche en Sante du Quebec. The 1994 Busselton follow-up study was funded by Healthway, Australia. J.-Q.H. is the recipient of a Michael Smith Foundation for Health Research Doctoral Award and an Izaak Walton Killam Memorial Scholarship Award. D.K. is a Canada Research Chair, a recipient of a Michael Smith Foundation Scholarship and the William Thurlbeck Distinguished Research Award. A.J. is a recipient of a National Health and Medical Research Council of Australia Practitioner Fellowship. Y.B. and D.D. were recipients of fellowship awards (Canadian Institutes of Health Research), and A.L.K. is a recipient of a New Investigator Award (Canadian Institutes of Health Research). D.D. is the recipient of a Michael Smith Foundation Career Scholar Award. D.D., C.L., and A.S. hold Canadian Research Chair appointments. This work was also supported by the National Health and Medical Research Council of Australia (303145, 458513), the Child Health Research Foundation of Western Australia, and the Asthma Foundation of Western Australia.	Allakhverdi Z, 2007, J EXP MED, V204, P253, DOI 10.1084/jem.20062211; Begin P, 2007, AM J RESP CRIT CARE, V175, P1109, DOI 10.1164/rccm.200607-1012OC; Bremner PR, 1998, AM J RESP CRIT CARE, V158, P1724, DOI 10.1164/ajrccm.158.6.9702068; Carlson CS, 2004, AM J HUM GENET, V74, P106, DOI 10.1086/381000; Chan-Yeung M, 2005, J ALLERGY CLIN IMMUN, V116, P49, DOI 10.1016/j.jaci.2005.03.029; Chan-Yeung M, 2000, ARCH PEDIAT ADOL MED, V154, P657, DOI 10.1001/archpedi.154.7.657; Conde L, 2006, NUCLEIC ACIDS RES, V34, pW621, DOI 10.1093/nar/gkl071; CURTIS D, 1995, AM J HUM GENET, V56, P811; Daley D, 2009, HUM GENET, V125, P445, DOI 10.1007/s00439-009-0643-8; Dudbridge F, 2003, GENET EPIDEMIOL, V25, P115, DOI 10.1002/gepi.10252; Dudbridge F, 2008, HUM HERED, V66, P87, DOI 10.1159/000119108; Godfrey S, 2000, Paediatr Respir Rev, V1, P148, DOI 10.1053/prrv.2000.0042; Godfrey S, 1999, EUR RESPIR J, V14, P659, DOI 10.1034/j.1399-3003.1999.14c28.x; Harada M, 2009, AM J RESP CELL MOL, V40, P368, DOI 10.1165/rcmb.2008-0041OC; Headley MB, 2009, J IMMUNOL, V182, P1641, DOI 10.4049/jimmunol.182.3.1641; Hunninghake GM, 2008, AM J RESP CRIT CARE, V177, P830, DOI 10.1164/rccm.200711-1697OC; Ito T, 2005, J EXP MED, V202, P1213, DOI 10.1084/jem.20051135; James AL, 2005, AM J RESP CRIT CARE, V171, P109, DOI 10.1164/rccm.200402-230OC; James Alan L, 2005, Med J Aust, V183, pS17; Kato A, 2007, J IMMUNOL, V179, P1080, DOI 10.4049/jimmunol.179.2.1080; Kowalewska J, 2007, AM J PATHOL, V170, P981, DOI 10.2353/ajpath.2007.060474; Kozyrskyj AL, 2008, AM J RESP CRIT CARE, V177, P142, DOI 10.1164/rccm.200703-381OC; Laprise C, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-21; Lemanske RF, 2006, J ALLERGY CLIN IMMUN, V117, pS456, DOI 10.1016/j.jaci.2005.07.006; Li J, 2005, HEREDITY, V95, P221, DOI 10.1038/sj.hdy.6800717; Li M, 2006, P NATL ACAD SCI USA, V103, P11736, DOI 10.1073/pnas.0604575103; Lincoln MR, 2005, NAT GENET, V37, P1108, DOI 10.1038/ng1647; Liu YJ, 2006, J EXP MED, V203, P269, DOI 10.1084/jem.20051745; Liu YJ, 2007, J ALLERGY CLIN IMMUN, V120, P238, DOI 10.1016/j.jaci.2007.06.004; Liu YJ, 2007, ANNU REV IMMUNOL, V25, P193, DOI 10.1146/annurev.immunol.25.022106.141718; Mai XM, 2007, J ALLERGY CLIN IMMUN, V120, P551, DOI 10.1016/j.jaci.2007.05.004; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Neale BM, 2004, AM J HUM GENET, V75, P353, DOI 10.1086/423901; Nyholt DR, 2004, AM J HUM GENET, V74, P765, DOI 10.1086/383251; Ober C, 2006, GENES IMMUN, V7, P95, DOI 10.1038/sj.gene.6364284; Park LS, 2000, J EXP MED, V192, P659, DOI 10.1084/jem.192.5.659; Pearce N, 2007, THORAX, V62, P758, DOI 10.1136/thx.2006.070169; Poon AH, 2005, GENES IMMUN, V6, P519, DOI 10.1038/sj.gene.6364238; Poon AH, 2004, AM J RESP CRIT CARE, V170, P967, DOI 10.1164/rccm.200403-412oc; Raby BA, 2004, AM J RESP CRIT CARE, V170, P1057, DOI 10.1164/rccm.200404-447OC; Seshasayee D, 2007, J CLIN INVEST, V117, P3868, DOI 10.1172/JCI33559; Shamim Z, 2007, INT J IMMUNOGENET, V34, P149, DOI 10.1111/j.1744-313X.2007.00657.x; Shen R, 2005, MUTAT RES-FUND MOL M, V573, P70, DOI 10.1016/j.mrfmmm.2004.07.022; SPIELMAN RS, 1993, AM J HUM GENET, V52, P506; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Taneda S, 2001, AM J PATHOL, V159, P2355, DOI 10.1016/S0002-9440(10)63085-4; Tonozuka Y, 2001, CYTOGENET CELL GENET, V93, P23, DOI 10.1159/000056941; Tremblay K, 2006, GENES IMMUN, V7, P632, DOI 10.1038/sj.gene.6364340; TREMBLAY K, 2005, P AM THORAC SOC, V2, pA30; Vonk JM, 2006, CURR OPIN PULM MED, V12, P42, DOI 10.1097/01.mcp.0000188371.30508.54; Wang YH, 2007, J CLIN INVEST, V117, P3655, DOI 10.1172/JCI34182; Wills-Karp M, 2001, NAT REV IMMUNOL, V1, P69, DOI 10.1038/35095579; Ying S, 2005, J IMMUNOL, V174, P8183, DOI 10.4049/jimmunol.174.12.8183; Yoo J, 2005, J EXP MED, V202, P541, DOI 10.1084/jem.20041503; Zhou BH, 2005, NAT IMMUNOL, V6, P1047, DOI 10.1038/ni1247; Ziegler SF, 2006, NAT IMMUNOL, V7, P709, DOI 10.1038/ni1360	56	80	89	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2009	124	2					222	229		10.1016/j.jaci.2009.04.018	http://dx.doi.org/10.1016/j.jaci.2009.04.018			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	482CD	19539984				2022-12-18	WOS:000268860400007
J	Ring, S; Oliver, SJ; Cronstein, BN; Enk, AH; Mahnke, K				Ring, Sabine; Oliver, Stephen J.; Cronstein, Bruce N.; Enk, Alexander H.; Mahnke, Karsten			CD4(+)CD25(+) regulatory T cells suppress contact hypersensitivity reactions through a CD39, adenosine-dependent mechanism	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Contact hypersensitivity; regulatory T cells; adenosine; endothelial cells; skinfold chamber	INTESTINAL INFLAMMATION; TARGETED DISRUPTION; RECEPTOR ACTIVATION; IMMUNE SUPPRESSION; ENDOTHELIAL-CELLS; EXTRACELLULAR ATP; DENDRITIC CELLS; CUTTING EDGE; EXPRESSION; INTERLEUKIN-10	Background: Injection of regulatory T (Treg) cells into sensitized mice abrogates the elicitation phase of contact hypersensitivity (CHS) reactions by blocking the adherence of leukocytes to vascular endothelium. Objective: We set out to analyze whether adenosine, a suppressive factor recently described as produced by Treg cells, can account for the suppression of the effector T-cell-endothelial cell (EC) interaction. Methods: T cells and ECs were cultured in the presence of adenosine, and expression of adhesion molecules and adhesion of T cells to ECs under shear stress were assessed. Furthermore, we injected Treg cells derived from ectonucleotidase-deficient (CD39(-/-)) mice into sensitized mice and analyzed the sticking and rolling of leukocytes during a CHS response using intravital microscopy. Results: Adenosine or Treg cells, respectively, abrogated the adherence of effector T cells to ECs in vitro. Likewise, injection of adenosine and Treg cells abrogated the ear-swelling reaction, indicating a role of adenosine during Treg cell-induced suppression of CHS responses. As a source for Treg cell-derived adenosine, we identified the ectonucleotidase CD39 because CD39-deficient Treg cells did not prevent adhesion of leukocytes to the endothelium. Furthermore, we show that the impaired adhesion of effector T cells to inflamed endothelium was induced by adenosine-mediated downregulation of expression of E- and P-selectin on the vascular endothelium. Conclusion: Adenosine release by Treg cells is essential to block leukocyte adhesion to endothelium, providing a novel mechanism by which Treg cells mediate immune suppression in vivo. (J Allergy Clin Immunol 2009;123:1287-96.)	[Ring, Sabine; Enk, Alexander H.; Mahnke, Karsten] Univ Heidelberg Hosp, Dept Dermatol, Heidelberg, Germany; [Oliver, Stephen J.; Cronstein, Bruce N.] NYU, Sch Med, Dept Med, New York, NY 10003 USA	Ruprecht Karls University Heidelberg; New York University	Mahnke, K (corresponding author), Univ Heidelberg, Dept Dermatol, Vossstr 11, D-69115 Heidelberg, Germany.	Karsten.Mahnke@med.uni-heidelberg.de	Cronstein, Bruce N/D-4678-2011	Cronstein, Bruce N/0000-0002-4295-7383	DFG [SFB 405 B 15, SFB 405 B 16, 1924/2-2]; Wilhelm Sander Foundation; European Union [LSHC-CT-2005-518178]; Helmholtz Association; National Institutes of Health [GM56268, AR41911, AA 13336, 5K23AR2187, 1R21 HL077461, 5R21 NS048594]; King Pharmaceuticals; General Clinical Research Center [M01RR00096]; Kaplan Cancer Center; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000096] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R21HL077461] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K23AR002187, R01AR041911] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056268] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS048594] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA013336] Funding Source: NIH RePORTER	DFG(German Research Foundation (DFG)); Wilhelm Sander Foundation; European Union(European Commission); Helmholtz Association(Helmholtz Association); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); King Pharmaceuticals; General Clinical Research Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Kaplan Cancer Center; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))	Supported by grants to K. Malinke and A. H. Enk (SFB 405 B 15, B 16 DFG KM 1924/2-2; the Wilhelm Sander Foundation; European Union grant LSHC-CT-2005-518178 and the Helmholtz Association: Alliance on Immunotherapy of Cancer). S. J. Oliver and B. N. Cronstein were supported by grants from the National Institutes of Health (GM56268, AR41911, AA 13336,5K23AR2187, 1R21 HL077461, and 5R21 NS048594), King Pharmaceuticals, the General Clinical Research Center (M01RR00096), and the Kaplan Cancer Center.	Anderson CF, 2007, J EXP MED, V204, P285, DOI 10.1084/jem.20061886; Asseman C, 1999, J EXP MED, V190, P995, DOI 10.1084/jem.190.7.995; Borsellino G, 2007, BLOOD, V110, P1225, DOI 10.1182/blood-2006-12-064527; Bouma MG, 1996, AM J PHYSIOL-CELL PH, V270, pC522, DOI 10.1152/ajpcell.1996.270.2.C522; Bours MJL, 2006, PHARMACOL THERAPEUT, V112, P358, DOI 10.1016/j.pharmthera.2005.04.013; Collison LW, 2007, NATURE, V450, P566, DOI 10.1038/nature06306; Cronstein BN, 2005, PHARMACOL REV, V57, P163, DOI 10.1124/pr.57.2.3; CRONSTEIN BN, 1992, J IMMUNOL, V148, P2201; Deaglio S, 2007, J EXP MED, V204, P1257, DOI 10.1084/jem.20062512; Denning TL, 2005, J IMMUNOL, V174, P7487, DOI 10.4049/jimmunol.174.12.7487; Dudda JC, 2008, J EXP MED, V205, P1559, DOI 10.1084/jem.20072594; Eltzschig HK, 2006, BLOOD, V108, P1602, DOI 10.1182/blood-2006-02-001016; Enjyoji K, 1999, NAT MED, V5, P1010, DOI 10.1038/12447; Idzko M, 2007, NAT MED, V13, P913, DOI 10.1038/nm1617; Imai M, 2000, BIOCHEM BIOPH RES CO, V270, P272, DOI 10.1006/bbrc.2000.2410; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Jankovic D, 2007, J EXP MED, V204, P273, DOI 10.1084/jem.20062175; Koszalka P, 2004, CIRC RES, V95, P814, DOI 10.1161/01.RES.0000144796.82787.6f; Lappas CM, 2005, J IMMUNOL, V174, P1073, DOI 10.4049/jimmunol.174.2.1073; Lennon PF, 1998, J EXP MED, V188, P1433, DOI 10.1084/jem.188.8.1433; Lisinski TJ, 2002, J LEUKOCYTE BIOL, V72, P503; Mizumoto N, 2003, J INVEST DERMATOL, V121, P1066, DOI 10.1046/j.1523-1747.2003.12558.x; Mizumoto N, 2002, NAT MED, V8, P358, DOI 10.1038/nm0402-358; Montesinos MC, 2007, ARTHRITIS RHEUM-US, V56, P1440, DOI 10.1002/art.22643; MOSTAFA ME, 2001, CARDIOVASC RES, V49, P882; Naganuma M, 2006, J IMMUNOL, V177, P2765, DOI 10.4049/jimmunol.177.5.2765; Nakamura K, 2004, J IMMUNOL, V172, P834, DOI 10.4049/jimmunol.172.2.834; Nemeth ZH, 2005, J IMMUNOL, V175, P8260, DOI 10.4049/jimmunol.175.12.8260; Nemeth ZH, 2007, FASEB J, V21, P2379, DOI 10.1096/fj.07-8213com; NEWBY AC, 1984, TRENDS BIOCHEM SCI, V9, P42, DOI 10.1016/0968-0004(84)90176-2; Ochando JC, 2005, J IMMUNOL, V174, P6993, DOI 10.4049/jimmunol.174.11.6993; Odashima M, 2005, GASTROENTEROLOGY, V129, P26, DOI 10.1053/j.gastro.2005.05.032; Ohta A, 2006, P NATL ACAD SCI USA, V103, P13132, DOI 10.1073/pnas.0605251103; Pastor-Anglada M, 2001, MOL MEMBR BIOL, V18, P81, DOI 10.1080/096876800110033783; Powrie F, 1996, J EXP MED, V183, P2669, DOI 10.1084/jem.183.6.2669; Read S, 2000, J EXP MED, V192, P295, DOI 10.1084/jem.192.2.295; Ring S, 2007, J IMMUNOL METHODS, V326, P10, DOI 10.1016/j.jim.2007.06.007; Ring S, 2006, EUR J IMMUNOL, V36, P2981, DOI 10.1002/eji.200636207; Rubtsov YP, 2008, IMMUNITY, V28, P546, DOI 10.1016/j.immuni.2008.02.017; Siewert C, 2007, EUR J IMMUNOL, V37, P978, DOI 10.1002/eji.200636575; Sullivan GW, 2004, J LEUKOCYTE BIOL, V75, P127, DOI 10.1189/jlb.0603300; Thornton AM, 2000, J IMMUNOL, V164, P183, DOI 10.4049/jimmunol.164.1.183; Tietz W, 1998, J IMMUNOL, V161, P963; Vignali DAA, 2008, NAT REV IMMUNOL, V8, P523, DOI 10.1038/nri2343	44	80	82	1	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2009	123	6					1287	1296		10.1016/j.jaci.2009.03.022	http://dx.doi.org/10.1016/j.jaci.2009.03.022			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	455WO	19427686				2022-12-18	WOS:000266799100019
J	Miyara, M; Wing, K; Sakaguchi, S				Miyara, Makoto; Wing, Kajsa; Sakaguchi, Shimon			Therapeutic approaches to allergy and autoimmunity based on FoxP3(+) regulatory T-cell activation and expansion	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						FoxP3; regulatory T cell; activation	ANTI-CD3 MONOCLONAL-ANTIBODY; TGF-BETA; IN-VITRO; NAIVE; EXPRESSION; INDUCTION; ONSET; DIFFERENTIATION; MECHANISMS; TOLERANCE	Forkhead box protein 3-positive regulatory T (Treg) cells are indispensable for the maintenance of self-tolerance and immune homeostasis. They can also be exploited for the treatment of immunologic diseases, including autoimmune diseases and allergy, by way of activating and expanding antigen-specific Treg cells in vivo. Cell therapy with in vitro activated and expanded Treg cells can be another therapeutic modality. The feasibility of such Treg cell-based therapeutic strategies is discussed based on recent advances in our understanding of the molecular and cellular basis of Treg cell development and function. (J Allergy Clin Immunol 2009;123:749-55.)	[Miyara, Makoto; Wing, Kajsa; Sakaguchi, Shimon] Kyoto Univ, Dept Expt Pathol, Inst Frontier Med Sci, Kyoto 6068507, Japan; [Sakaguchi, Shimon] Japan Sci & Technol Agcy, CREST, Kawaguchi, Saitama, Japan; [Sakaguchi, Shimon] Osaka Univ, WPI Immunol Frontier Res Ctr, Suita, Osaka, Japan	Kyoto University; Japan Science & Technology Agency (JST); Osaka University	Sakaguchi, S (corresponding author), Kyoto Univ, Dept Expt Pathol, Inst Frontier Med Sci, Kyoto 6068507, Japan.	shimon@frontier.kyoto-u.ac.jp	Miyara, Makoto/P-4491-2017; Sakaguchi, Shimon/C-9535-2009	Miyara, Makoto/0000-0001-8743-8846; Wing, Kajsa/0000-0001-7744-4847	Ministry of Education, Sports, and Culture of Japan; Japan Science and Technology Agency	Ministry of Education, Sports, and Culture of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japan Science and Technology Agency(Japan Science & Technology Agency (JST))	Supported by a grant-in-aid from the Ministry of Education, Sports, and Culture of Japan, Japan Science and Technology Agency. M. Miyara was a Japan Society for the Promotion of Science Fellow.	Allan SE, 2007, INT IMMUNOL, V19, P345, DOI 10.1093/intimm/dxm014; Allan SE, 2008, EUR J IMMUNOL, V38, P3282, DOI 10.1002/eji.200838373; Apostolou I, 2004, J EXP MED, V199, P1401, DOI 10.1084/jem.20040249; Baecher-Allan C, 2001, J IMMUNOL, V167, P1245, DOI 10.4049/jimmunol.167.3.1245; Basu S, 2008, J IMMUNOL, V180, P5794, DOI 10.4049/jimmunol.180.9.5794; Battaglia M, 2005, BLOOD, V105, P4743, DOI 10.1182/blood-2004-10-3932; Battaglia M, 2006, J IMMUNOL, V177, P8338, DOI 10.4049/jimmunol.177.12.8338; Bennett CL, 2001, NAT GENET, V27, P20, DOI 10.1038/83713; Benson MJ, 2007, J EXP MED, V204, P1765, DOI 10.1084/jem.20070719; Bisikirska B, 2005, J CLIN INVEST, V115, P2904, DOI 10.1172/JCI23961; Bohle B, 2007, J ALLERGY CLIN IMMUN, V120, P707, DOI 10.1016/j.jaci.2007.06.013; Bresson D, 2006, J CLIN INVEST, V116, P1371, DOI 10.1172/JCI27191; Brunkow ME, 2001, NAT GENET, V27, P68, DOI 10.1038/83784; CHATENOUD L, 1994, P NATL ACAD SCI USA, V91, P123, DOI 10.1073/pnas.91.1.123; Chen GJ, 2008, J LEUKOCYTE BIOL, V83, P280, DOI 10.1189/jlb.0707498; Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; Clarke SL, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000129; Dieckmann D, 2001, J EXP MED, V193, P1303, DOI 10.1084/jem.193.11.1303; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Fisson S, 2003, J EXP MED, V198, P737, DOI 10.1084/jem.20030686; Fontenot JD, 2017, J IMMUNOL, V198, P986, DOI 10.1038/ni904; Fritzsching B, 2006, BLOOD, V108, P3371, DOI 10.1182/blood-2006-02-005660; Haxhinasto S, 2008, J EXP MED, V205, P565, DOI 10.1084/jem.20071477; Herold KC, 2002, NEW ENGL J MED, V346, P1692, DOI 10.1056/NEJMoa012864; Hoffmann P, 2006, BLOOD, V108, P4260, DOI 10.1182/blood-2006-06-027409; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Hsieh CS, 2006, NAT IMMUNOL, V7, P401, DOI 10.1038/ni1318; Itoh M, 1999, J IMMUNOL, V162, P5317; Jonuleit H, 2001, J EXP MED, V193, P1285, DOI 10.1084/jem.193.11.1285; Jordan MS, 2001, NAT IMMUNOL, V2, P301, DOI 10.1038/86302; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; Kahan BD, 2001, TRANSPLANTATION, V72, P1181, DOI 10.1097/00007890-200110150-00001; Keymeulen B, 2005, NEW ENGL J MED, V352, P2598, DOI 10.1056/NEJMoa043980; Khattri R, 2003, NAT IMMUNOL, V4, P337, DOI 10.1038/ni909; Kleinewietfeld M, 2009, BLOOD, V113, P827, DOI 10.1182/blood-2008-04-150524; Koenen HJPM, 2008, BLOOD, V112, P2340, DOI 10.1182/blood-2008-01-133967; Kohm AP, 2005, J IMMUNOL, V174, P4525, DOI 10.4049/jimmunol.174.8.4525; Larche M, 2006, NAT REV IMMUNOL, V6, P761, DOI 10.1038/nri1934; Levings MK, 2001, J EXP MED, V193, P1295, DOI 10.1084/jem.193.11.1295; Lin W, 2005, J ALLERGY CLIN IMMUN, V116, P1106, DOI 10.1016/j.jaci.2005.08.046; Liu WH, 2006, J EXP MED, V203, P1701, DOI 10.1084/jem.20060772; Masteller EL, 2005, J IMMUNOL, V175, P3053, DOI 10.4049/jimmunol.175.5.3053; Meiler F, 2008, J EXP MED, V205, P2887, DOI 10.1084/jem.20080193; Miyara M, 2007, TRENDS MOL MED, V13, P108, DOI 10.1016/j.molmed.2007.01.003; Mucida D, 2007, SCIENCE, V317, P256, DOI 10.1126/science.1145697; NAGAHAMA K, 2009, INT IMMUNOL; Nagato T, 2007, J IMMUNOL, V178, P1189, DOI 10.4049/jimmunol.178.2.1189; Ng WF, 2001, BLOOD, V98, P2736, DOI 10.1182/blood.V98.9.2736; Onishi Y, 2008, P NATL ACAD SCI USA, V105, P10113, DOI 10.1073/pnas.0711106105; Pandiyan P, 2007, NAT IMMUNOL, V8, P1353, DOI 10.1038/ni1536; Radhakrishnan S, 2008, J IMMUNOL, V181, P3137, DOI 10.4049/jimmunol.181.5.3137; Roncarolo MG, 2006, IMMUNOL REV, V212, P28; Sakaguchi S, 2008, CELL, V133, P775, DOI 10.1016/j.cell.2008.05.009; Sakaguchi Shimon, 2003, Novartis Found Symp, V252, P6; Sauer S, 2008, P NATL ACAD SCI USA, V105, P7797, DOI 10.1073/pnas.0800928105; Seddiki N, 2006, J EXP MED, V203, P1693, DOI 10.1084/jem.20060468; Seddon B, 2000, IMMUNOL TODAY, V21, P95, DOI 10.1016/S0167-5699(99)01559-5; Shreffler WG, 2009, J ALLERGY CLIN IMMUN, V123, P43, DOI [10.1016/j.jaci.2008.12.1128, 10.1016/j.jaci.2008.09.051]; Smith JA, 1997, J EXP MED, V185, P1413, DOI 10.1084/jem.185.8.1413; Strauss L, 2007, J IMMUNOL, V178, P320, DOI 10.4049/jimmunol.178.1.320; Sun CM, 2007, J EXP MED, V204, P1775, DOI 10.1084/jem.20070602; Taams LS, 2001, EUR J IMMUNOL, V31, P1122, DOI 10.1002/1521-4141(200104)31:4<1122::AID-IMMU1122>3.0.CO;2-P; Takahashi T, 1998, INT IMMUNOL, V10, P1969, DOI 10.1093/intimm/10.12.1969; Tang QZ, 2004, J EXP MED, V199, P1455, DOI 10.1084/jem.20040139; Thornton AM, 1998, J EXP MED, V188, P287, DOI 10.1084/jem.188.2.287; Tran DQ, 2007, BLOOD, V110, P2983, DOI 10.1182/blood-2007-06-094656; Valmori D, 2005, J CLIN INVEST, V115, P1953, DOI 10.1172/JCI23963; van de Kerkhof PCM, 2006, DERMATOL THER, V19, P252, DOI 10.1111/j.1529-8019.2006.00082.x; Vignali DAAA, 2008, EUR J IMMUNOL, V38, P908, DOI 10.1002/eji.200738114; Wahl SM, 2006, IMMUNOL REV, V213, P213, DOI 10.1111/j.1600-065X.2006.00437.x; Wang J, 2007, EUR J IMMUNOL, V37, P129, DOI 10.1002/eji.200636435; Weiner HL, 2001, IMMUNOL REV, V182, P207, DOI 10.1034/j.1600-065X.2001.1820117.x; Wildin RS, 2001, NAT GENET, V27, P18, DOI 10.1038/83707; Wing K, 2008, SCIENCE, V322, P271, DOI 10.1126/science.1160062; Yagi H, 2004, INT IMMUNOL, V16, P1643, DOI 10.1093/intimm/dxh165; Yamaguchi T, 2006, SEMIN CANCER BIOL, V16, P115, DOI 10.1016/j.semcancer.2005.11.005; You S, 2007, P NATL ACAD SCI USA, V104, P6335, DOI 10.1073/pnas.0701171104	77	80	97	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2009	123	4					749	755		10.1016/j.jaci.2009.03.001	http://dx.doi.org/10.1016/j.jaci.2009.03.001			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	431JW	19348913	Bronze			2022-12-18	WOS:000265058600002
J	Blais, L; Forget, A				Blais, Lucie; Forget, Amelie			Asthma exacerbations during the first trimester of pregnancy and the risk of congenital malformations among asthmatic women	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; pregnancy; exacerbation; congenital malformations; cohort study; administrative health databases	INHALED CORTICOSTEROIDS; INDUCED HYPERTENSION; COMBINATION THERAPY; MEDICATION USE; SEVERITY; MANAGEMENT; MORBIDITY; DATABASE; OUTCOMES; HYPOXIA	Background: Uncontrolled maternal asthma during pregnancy has been hypothesized as a cause of congenital malformation, but literature is scare on this topic. Objective: The aim of this study was to investigate whether asthmatic women who had an exacerbation during the first trimester of pregnancy were more at risk of having a baby with a congenital malformation. Methods: From the linkage of 3 Canadian administrative databases, we reconstructed a cohort of 4344 pregnancies of asthmatic women. Asthma exacerbations were assessed during the first trimester of pregnancy and were defined as a filled prescription for oral corticosteroids, an emergency department visit, or a hospitalization for asthma. Congenital malformations were assessed at birth and during the first year of life of the newborn by using diagnoses recorded in the databases. Generalized estimating equation models were used to estimate adjusted odds ratios of congenital malformations in association with asthma exacerbations. Results: In the cohort we identified 398 (9.2%) babies with at least 1 malformation and 261 (6.0%) with a major malformation. The crude prevalences of malformations were 12.8% and 8.9%, respectively, for women who had and those who did not have an exacerbation. The adjusted odds ratio for all malformations was 1.48 (95% CI, 1.04-2.09) when comparing women who had and those who did not have an exacerbation. The corresponding figures were 1.32 (95% CI, 0.86-2.04) for major malformations. Conclusion: Asthma exacerbations during the first trimester of pregnancy were found to significantly increase the risk of a congenital malformation.	[Blais, Lucie; Forget, Amelie] Univ Montreal, Fac Pharm, Montreal, PQ H3C 3J7, Canada	Universite de Montreal	Blais, L (corresponding author), Univ Montreal, Fac Pharm, CP 6128,Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada.	lucie.blais@umontreal.ca						[Anonymous], 2005, J ALLERGY CLIN IMMUN, V115, P34, DOI 10.1016/j.jaci.2004.10.023; Bakhireva LN, 2005, J ALLERGY CLIN IMMUN, V116, P503, DOI 10.1016/j.jaci.2005.05.027; Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC; Battino D, 2007, DRUGS, V67, P2727, DOI 10.2165/00003495-200767180-00007; Blais L, 2004, THORAX, V59, P943, DOI 10.1136/thx.2004.022475; BLAIS L, 2004, PHARMACOEPIDEM DR S, V13, pS32; Blais L, 2007, THORAX, V62, P320, DOI 10.1136/thx.2006.062950; Boulet LP, 1999, CAN MED ASSOC J, V161, pS1; Braems G, 2003, EUR J OBSTET GYN R B, V110, pS63, DOI 10.1016/S0301-2115(03)00174-X; Carmichael SL, 1999, AM J MED GENET, V86, P242, DOI 10.1002/(SICI)1096-8628(19990917)86:3<242::AID-AJMG9>3.0.CO;2-U; Carroll KN, 2005, OBSTET GYNECOL, V106, P66, DOI 10.1097/01.AOG.0000164471.87157.4c; Cousins L, 1999, J ALLERGY CLIN IMMUN, V103, pS343, DOI 10.1016/S0091-6749(99)70260-5; Dombrowski MP, 2004, OBSTET GYNECOL, V103, P5, DOI 10.1097/01.AOG.0000103994.75162.16; Dombrowski MP, 2004, AM J OBSTET GYNECOL, V190, P737, DOI 10.1016/j.ajog.2003.09.071; Firoozi F, 2007, THORAX, V62, P581, DOI 10.1136/thx.2006.061572; FITZSIMONS R, 1986, J ALLERGY CLIN IMMUN, V78, P349, DOI 10.1016/S0091-6749(86)80088-4; GREENBERGER PA, 1988, NEW ENGL REG ALLERGY, V9, P539, DOI 10.2500/108854188778965555; Guy ES, 2004, CRIT CARE CLIN, V20, P731, DOI 10.1016/j.ccc.2004.05.013; Heinonen OP, 1977, BIRTH DEFECTS DRUGS; Jana N, 1995, J Obstet Gynaecol (Tokyo 1995), V21, P227; Kallen B, 2000, EUR J EPIDEMIOL, V16, P167, DOI 10.1023/A:1007678404911; Koren G, 1998, NEW ENGL J MED, V338, P1128, DOI 10.1056/NEJM199804163381607; Kurinczuk JJ, 1999, WOMEN HEALTH, V29, P31, DOI 10.1300/J013v29n03_03; LEVY AR, 1995, AM J EPIDEMIOL, V142, P428, DOI 10.1093/oxfordjournals.aje.a117651; Marceau C, 2006, J ALLERGY CLIN IMMUN, V118, P574, DOI 10.1016/j.jaci.2006.06.034; Martel MJ, 2007, J ALLERGY CLIN IMMUN, V119, P576, DOI 10.1016/j.jaci.2006.10.034; Martel MJ, 2005, BMJ-BRIT MED J, V330, P230, DOI 10.1136/bmj.38313.624352.8F; MILLICOVSKY G, 1981, P NATL ACAD SCI-BIOL, V78, P5722, DOI 10.1073/pnas.78.9.5722; Murphy VE, 2006, THORAX, V61, P169, DOI 10.1136/thx.2005.049718; Murphy VE, 2005, OBSTET GYNECOL, V106, P1046, DOI 10.1097/01.AOG.0000185281.21716.02; O'Byrne PM, 2005, AM J RESP CRIT CARE, V171, P129, DOI 10.1164/rccm.200407-884OC; Olesen C, 1999, EUR J CLIN PHARMACOL, V55, P139, DOI 10.1007/s002280050608; Park-Wyllie L, 2000, TERATOLOGY, V62, P385, DOI 10.1002/1096-9926(200012)62:6<385::AID-TERA5>3.0.CO;2-Z; PERLOW JH, 1992, AM J OBSTET GYNECOL, V167, P963, DOI 10.1016/S0002-9378(12)80020-2; Rabe KF, 2006, LANCET, V368, P744, DOI 10.1016/S0140-6736(06)69284-2; *REG ASS MAL QUEB, 1997, STAT ANN; Rodriguez-Pinilla E, 1998, TERATOLOGY, V58, P2, DOI 10.1002/(SICI)1096-9926(199807)58:1<2::AID-TERA2>3.0.CO;2-4; Schatz M, 2004, J ALLERGY CLIN IMMUN, V113, P1040, DOI 10.1016/j.jaci.2004.03.017; Schatz M, 2003, J ALLERGY CLIN IMMUN, V112, P283, DOI 10.1067/mai.2003.1516; Schatz M, 1997, J ALLERGY CLIN IMMUN, V100, P301, DOI 10.1016/S0091-6749(97)70241-0; SteniusAarniala BSM, 1996, THORAX, V51, P411, DOI 10.1136/thx.51.4.411; TAMBLYN R, 1995, J CLIN EPIDEMIOL, V48, P999, DOI 10.1016/0895-4356(94)00234-H; Webster William S., 2007, Birth Defects Research, V81, P215, DOI 10.1002/bdrc.20102; ZEGER SL, 1988, BIOMETRICS, V44, P1049, DOI 10.2307/2531734	45	80	82	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2008	121	6					1379	1384		10.1016/j.jaci.2008.02.038	http://dx.doi.org/10.1016/j.jaci.2008.02.038			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	313WW	18410961				2022-12-18	WOS:000256771700012
J	Matheson, MC; Erbas, B; Balasuriya, A; Jenkins, MA; Wharton, CL; Tang, MLK; Abramson, MJ; Walters, EH; Hopper, JL; Dharmage, SC				Matheson, Melanie Claire; Erbas, Bircan; Balasuriya, Aindralal; Jenkins, Mark Andrew; Wharton, Cathryn Leisa; Tang, Mimi Lai-Kuan; Abramson, Michael John; Walters, Eugene Haydn; Hopper, John Llewelyn; Dharmage, Shyamali Chandrika			Breast-feeding and atopic disease: A cohort study from childhood to middle age	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						breast-feeding; asthnia; allergic rhinitis; food allergy; maternal atopy	FOLLOW-UP; ALLERGIC DISEASE; HAY-FEVER; ASTHMA; CHILDREN; INFANTS; RISK; METAANALYSIS; PREVENTION; STATEMENT	Background: The literature regarding the association between breast-feeding and atopic diseases has been contradictory. Objective: We have assessed the relationship between breast-feeding and atopic disorders in a cohort followed into middle age. Methods: The Tasmanian Asthma Study is a population-based prospective cohort study that has followed participants from the age of 7 to 44 years. Exclusive breast-feeding in the first 3 months of life was examined as a risk factor for atopic diseases by using multiple logistic regression and generalized estimating equation analyses. Results: At age 7 years, exclusively breast-fed children with a maternal history of atopy had a marginally lesser risk of current asthma than those not exclusively breast-fed (odds ratio [OR], 0.8; 95% CI, 0.6-1.0). However, after age 7 years, the risk reversed, and exclusively breast-fed children had an increased risk of current asthma at 14 (OR, 1.46; 95% CI, 1.02-2.07), 32 (OR, 1.84; 95% CI, 1.06-3.3), and 44 (OR, 1.57; 95% CI, 1.15-2.14) years. Exclusively breast-fed children also had a reduced risk of food allergy at age 7 years but an increased risk of foodallergy (OR, 1.26; 95% CI, 1.1-1.5) and allergic rhinitis (OR, 1.2; 95% CI, 1.0-1.3) at 44 years. Conclusion: Exclusively breast-fed babies with a maternal history of atopy were less likely to develop asthma before the age of 7 years, but more likely to develop asthma after the age of 7 years. Clinical implications: The current recommendation to breast-feed high-risk infants for protection against early wheezing illness can be confirmed. However, the recommendation should be reconsidered for protection against allergic asthma and atopy in the longer term.	Univ Melbourne, Sch Populat Hlth, Dept Publ Hlth, Ctr Mol Environm Genet & Analyt Epidemiol, Carlton, Vic 3053, Australia; Royal Childrens Hosp, Dept Allergy & Immunol, Melbourne, Vic, Australia; Monash Univ, Dept Epidemiol & Prevent Med, Monash, Australia; Univ Tasmania, Menzies Res Inst, Hobart, Tas, Australia	University of Melbourne; Royal Children's Hospital Melbourne; Monash University; University of Tasmania; Menzies Institute for Medical Research	Matheson, MC (corresponding author), Univ Melbourne, Sch Populat Hlth, Dept Publ Hlth, Ctr Mol Environm Genet & Analyt Epidemiol, Level 2-723,Swanston St, Carlton, Vic 3053, Australia.	mcmat@unimelb.edu.au	Jenkins, Mark/P-7803-2015; Abramson, Michael/AAQ-2671-2020; Tang, Mimi/ABD-8350-2020; WALTERS, Eugene/AAL-2264-2021; Matheson, Melanie C/O-4721-2015	Jenkins, Mark/0000-0002-8964-6160; Abramson, Michael/0000-0002-9954-0538; Tang, Mimi/0000-0002-3839-5293; Matheson, Melanie C/0000-0002-5822-3499; Walters, Eugene/0000-0002-0993-4374				ABERG N, 1989, ACTA PAEDIATR SCAND, V78, P246, DOI 10.1111/j.1651-2227.1989.tb11064.x; Bloch AM, 2002, ACTA PAEDIATR, V91, P275, DOI 10.1080/08035250252833914; BOTTACHER MF, 2006, PEDIATR RES, V176, P762; Chandra RK, 1997, J PEDIATR GASTR NUTR, V24, P380, DOI 10.1097/00005176-199704000-00005; DOUGLASS JA, 1986, MED J AUSTRALIA, V185, P228; Dupont WD, 2002, STAT MODELLING BIOME; Gdalevich M, 2001, J PEDIATR-US, V139, P261, DOI 10.1067/mpd.2001.117006; GIBSON T, 1969, J BIOMECH, V2, P201, DOI 10.1016/0021-9290(69)90032-3; GILES GG, 1984, AUST NZ J MED, V14, P631, DOI 10.1111/j.1445-5994.1984.tb05015.x; Hahn EL, 2005, IMMUNOL ALLERGY CLIN, V25, P231, DOI 10.1016/j.iac.2005.02.004; HOPPER JL, 1995, AUST J PUBLIC HEALTH, V19, P120; Host A, 1999, ARCH DIS CHILD, V81, P80, DOI 10.1136/adc.81.1.80; Jenkins M A, 1993, Paediatr Perinat Epidemiol, V7, P67, DOI 10.1111/j.1365-3016.1993.tb00602.x; JENKINS MA, 1994, BRIT MED J, V309, P90, DOI 10.1136/bmj.309.6947.90; Jenkins MA, 1996, INT J EPIDEMIOL, V25, P609, DOI 10.1093/ije/25.3.609; KAPLAN BA, 1985, J EPIDEMIOL COMMUN H, V39, P152, DOI 10.1136/jech.39.2.152; KAUFMAN HS, 1976, ANN ALLERGY, V37, P410; Leme AS, 2006, J IMMUNOL, V176, P762, DOI 10.4049/jimmunol.176.2.762; Lowe AJ, 2006, J ALLERGY CLIN IMMUN, V117, P682, DOI 10.1016/j.jaci.2005.10.027; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Oddy WH, 1999, BMJ-BRIT MED J, V319, P815, DOI 10.1136/bmj.319.7213.815; Prescott SL, 2005, MED J AUSTRALIA, V182, P464, DOI 10.5694/j.1326-5377.2005.tb06787.x; Romieu I, 2000, J ASTHMA, V37, P575, DOI 10.3109/02770900009090812; Rusconi F, 1999, AM J RESP CRIT CARE, V160, P1617, DOI 10.1164/ajrccm.160.5.9811002; SAARINEN UM, 1995, LANCET, V346, P1065, DOI 10.1016/S0140-6736(95)91742-X; Sears MR, 2002, LANCET, V360, P901, DOI 10.1016/S0140-6736(02)11025-7; Section on Breastfeeding, 2012, Pediatrics, V129, pe827, DOI 10.1542/peds.2011-3552; Strachan David P., 2000, Thorax, V55, pS2, DOI 10.1136/thorax.55.suppl_1.S2; Strachan DP, 1996, ARCH DIS CHILD, V74, P422, DOI 10.1136/adc.74.5.422; TAYLOR B, 1983, J EPIDEMIOL COMMUN H, V37, P95, DOI 10.1136/jech.37.2.95; van Odijk J, 2003, ALLERGY, V58, P833, DOI 10.1034/j.1398-9995.2003.00264.x; Wafula EM, 1999, E AFR MED J, V76, P606; Wharton C, 2006, AUST NZ J PUBL HEAL, V30, P105, DOI 10.1111/j.1467-842X.2006.tb00100.x; Wilson AC, 1998, BMJ-BRIT MED J, V316, P21, DOI 10.1136/bmj.316.7124.21; Wright AL, 1999, J ALLERGY CLIN IMMUN, V104, P589, DOI 10.1016/S0091-6749(99)70328-3; WRIGHT AL, 1989, BRIT MED J, V299, P946, DOI 10.1136/bmj.299.6705.946; Wright AL, 2001, THORAX, V56, P192, DOI 10.1136/thorax.56.3.192	37	80	84	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2007	120	5					1051	1057		10.1016/j.jaci.2007.06.030	http://dx.doi.org/10.1016/j.jaci.2007.06.030			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	231TZ	17764732	Green Published			2022-12-18	WOS:000250973400011
J	Ando, T; Hatsushika, K; Wako, M; Ohba, T; Koyama, K; Ohnuma, Y; Katoh, R; Ogawa, H; Okumura, K; Luo, J; Wyss-Coray, T; Nakao, A				Ando, Takashi; Hatsushika, Kyosuke; Wako, Masanori; Ohba, Tetsuro; Koyama, Kensuke; Ohnuma, Yuko; Katoh, Ryohei; Ogawa, Hideoki; Okumura, Ko; Luo, Jian; Wyss-Coray, Tony; Nakao, Atsuhito			Orally administered TGF-beta is biologically active in the intestinal mucosa and enhances oral tolerance	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						TGF-beta; intestinal mucosa; Smad; oral tolerance; food allergy	GROWTH-FACTOR-BETA; HUMAN-MILK; ALLERGY MODEL; FOOD ALLERGY; BREAST-MILK; RESPONSES; PROTEINS; MICE; SUPPRESSION; DISEASE	Background: Epidemiologic studies suggest that TGF-beta in breast milk provides protection against allergic disease during infancy. However, it is unclear whether orally administered TGF-beta, such as TGF-beta in human milk, retains and exerts its activity in the intestinal mucosa and can affect immune response (tolerance) to dietary antigens. Objective: We sought to determine whether orally administered TGF-beta is biologically active in intestinal mucosa and affects oral tolerance. Methods: Activity of orally administered TGF-beta in the intestinal mucosa was evaluated by means of in vivo imaging with transgenic mice expressing a Smad-responsive reporter construct (SBE-luc mice), by means of immunohistochemical staining with anti-phosphorylated Smad2 antibody, and by means of real-time RT-PCR analysis of TGF-beta and Smad7 mRNA expression. The effects of orally administered TGF-beta on oral tolerance induction were assessed in mice tolerized by means of high-dose ovalbumin (OVA) feeding. Results: The oral administration of TGF-beta increased Smad-responsive reporter activity in the intestines of SBE-luc mice and induced Smad2 phosphorylation and TGF-beta and Smad7 mRNA expression in the intestines of BALB/c mice. Serum TGF-beta levels were also increased after oral administration of TGF-beta. BALB/c mice treated orally with OVA and TGF-beta showed augmented reduction of OVA-specific IgE and IgG1 antibodies, T-cell reactivity, and immediate-type skin reactions when compared with the mice treated orally with OVA alone. Conclusions: Orally administered TGF-beta retains sufficient biologic activity in intestinal mucosa and enhances oral tolerance. Clinical implications: Oral administration of TGF-beta might become a potential strategy to prevent allergic diseases, such as food allergy.	Univ Yamanashi, Fac Med, Dept Immunol, Chuo Ku, Yamanashi 4093898, Japan; Univ Yamanashi, Fac Med, Dept Human Pathol, Chuo Ku, Yamanashi 4093898, Japan; Juntendo Univ, Sch Med, Atopy Res Ctr, Tokyo 113, Japan; Stanford Univ, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA	University of Yamanashi; University of Yamanashi; Juntendo University; Stanford University	Nakao, A (corresponding author), Univ Yamanashi, Fac Med, Dept Immunol, Chuo Ku, 1110 Shimokato, Yamanashi 4093898, Japan.	anakao@yamanashi.ac.jp	Wyss-Coray, Tony/AAF-3380-2019; Luo, Jian/B-8449-2014	Wyss-Coray, Tony/0000-0001-5893-0831; Luo, Jian/0000-0002-2064-8467				Annes JP, 2003, J CELL SCI, V116, P217, DOI 10.1242/jcs.00229; Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Donnet-Hughes A, 2000, IMMUNOL CELL BIOL, V78, P74, DOI 10.1046/j.1440-1711.2000.00882.x; Faria AMC, 2005, IMMUNOL REV, V206, P232, DOI 10.1111/j.0105-2896.2005.00280.x; Hawkes JS, 2002, CYTOKINE, V17, P182, DOI 10.1006/cyto.2002.0987; Hawkes JS, 1999, PEDIATR RES, V46, P194, DOI 10.1203/00006450-199908000-00012; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Kalliomaki M, 1999, J ALLERGY CLIN IMMUN, V104, P1251, DOI 10.1016/S0091-6749(99)70021-7; Kikuchi Y, 2006, J IMMUNOL, V177, P1609, DOI 10.4049/jimmunol.177.3.1609; KIM SJ, 1989, J BIOL CHEM, V264, P7041; Letterio JJ, 1998, ANNU REV IMMUNOL, V16, P137, DOI 10.1146/annurev.immunol.16.1.137; Lin AH, 2005, J IMMUNOL, V175, P547, DOI 10.4049/jimmunol.175.1.547; Luo J, 2006, P NATL ACAD SCI USA, V103, P18326, DOI 10.1073/pnas.0605077103; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakao A, 1998, INT IMMUNOL, V10, P387, DOI 10.1093/intimm/10.4.387; Oddy WH, 2003, J ALLERGY CLIN IMMUN, V112, P723, DOI 10.1016/S0091-6749(03)01941-9; Okamoto A, 2005, INT IMMUNOL, V17, P705, DOI 10.1093/intimm/dxh250; Rigotti E, 2006, CLIN EXP ALLERGY, V36, P614, DOI 10.1111/j.1365-2222.2006.02483.x; SAITO S, 1993, CLIN EXP IMMUNOL, V94, P220, DOI 10.1111/j.1365-2249.1993.tb06004.x; Strobel S, 2006, CURR OPIN ALLERGY CL, V6, P207, DOI 10.1097/01.all.0000225162.98391.81; SWARBRICK ET, 1979, GUT, V20, P121, DOI 10.1136/gut.20.2.121; Untersmayr E, 2003, J ALLERGY CLIN IMMUN, V112, P616, DOI [10.1016/S0091-6749(03)01719-6, 10.1016/mai.2003.1681]	24	80	85	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2007	120	4					916	923		10.1016/j.jaci.2007.05.023	http://dx.doi.org/10.1016/j.jaci.2007.05.023			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	220LH	17606291				2022-12-18	WOS:000250157700028
J	Nelson, HS				Nelson, Harold S.			Allergen immunotherapy: Where is it now?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						immunotherapy; SCIT; SLIT; sublingual; subcutaneous; asthma; rhinitis	HOUSE-DUST-MITE; RANDOMIZED CONTROLLED-TRIAL; PARTIALLY PURIFIED EXTRACT; STANDARDIZED CAT EXTRACT; PLACEBO-CONTROLLED TRIAL; LONG-TERM PREVENTION; DOUBLE-BLIND PLACEBO; SUBLINGUAL IMMUNOTHERAPY; CLINICAL-EFFICACY; DERMATOPHAGOIDES-PTERONYSSINUS	The scientific basis and the proof of clinical effectiveness of allergen immunotherapy administered by subcutaneous injection (SCIT) are well established. It is effective treatment for sensitivity to Hymenoptera venom and for allergic rhinitis and allergic asthma. SCIT administered in the proper setting reduces the development of new sensitivities and progression from rhinitis to asthma. Further, the beneficial effects persist long after completion of a course of treatment. Although many people enjoy the benefits of SCIT, extension of its use to the many others who might be candidates for this treatment is limited by its drawbacks of safety concerns and the inconvenience of repeated clinic visits over several years to receive the injections. There are many attempts underway to improve on the safety and convenience while still retaining the benefits of SCIT. These include approaches using current allergen extracts, especially by administering them sublingually. Alternatively, through recombinant technology, extracts are being modified to reduce their allergenicity without reducing their immunogenicity. They are being linked to immunostimulatory DNA sequences that will modify their in vivo processing resulting in an enhanced nonallergic response or they are being incorporated into fusion proteins with inhibitory properties for mast cells and basophils.	Natl Jewish Med & Res Ctr, Denver, CO 80206 USA	National Jewish Health	Nelson, HS (corresponding author), Natl Jewish Med & Res Ctr, 1400 Jackson St, Denver, CO 80206 USA.	nelsonh@njc.org						Abramson MJ, 2003, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD001186; Alexander C, 2005, ALLERGY, V60, P1269, DOI 10.1111/j.1398-9995.2005.00885.x; ALVAREZCUESTA E, 1994, J ALLERGY CLIN IMMUN, V93, P556, DOI 10.1016/S0091-6749(94)70067-2; Asero R, 2003, ALLERGY, V58, P435, DOI 10.1034/j.1398-9995.2003.00139.x; Basomba A, 2002, J ALLERGY CLIN IMMUN, V109, P943, DOI 10.1067/mai.2002.124465; Bernstein DI, 2004, J ALLERGY CLIN IMMUN, V113, P1129, DOI 10.1016/j.jaci.2004.02.006; Bolhaar STHP, 2004, CLIN EXP ALLERGY, V34, P761, DOI 10.1111/j.1365-2222.2004.1939.x; Bordignon V, 2006, ANN ALLERG ASTHMA IM, V97, P158, DOI 10.1016/S1081-1206(10)60006-3; Bucher X, 2004, ALLERGY, V59, P1272, DOI 10.1111/j.1398-9995.2004.00626.x; Busse W, 2006, J ALLERGY CLIN IMMUN, V117, pS88, DOI 10.1016/j.jaci.2005.12.354; Calamita Z, 2006, ALLERGY, V61, P1162, DOI 10.1111/j.1398-9995.2006.01205.x; Canonica GW, 2003, J ALLERGY CLIN IMMUN, V111, P437, DOI 10.1067/mai.2003.129; Casale TB, 2006, J ALLERGY CLIN IMMUN, V117, P134, DOI 10.1016/j.jaci.2005.09.036; Chanez P, 1996, ALLERGY, V51, P850; Corrigan CJ, 2005, ALLERGY, V60, P801, DOI 10.1111/j.1398-9995.2005.00790.x; Cox LS, 2006, J ALLERGY CLIN IMMUN, V117, P1021, DOI 10.1016/j.jaci.2006.02.040; Creticos PS, 2006, NEW ENGL J MED, V355, P1445, DOI 10.1056/NEJMoa052916; CRETICOS PS, 1985, J CLIN INVEST, V76, P2247, DOI 10.1172/JCI112233; CRETICOS PS, 1989, J ALLERGY CLIN IMMUN, V84, P197, DOI 10.1016/0091-6749(89)90325-4; Dahl R, 2006, J ALLERGY CLIN IMMUN, V118, P434, DOI 10.1016/j.jaci.2006.05.003; DesRoches A, 1997, J ALLERGY CLIN IMMUN, V99, P450, DOI 10.1016/S0091-6749(97)70069-1; Di Rienzo V, 2003, CLIN EXP ALLERGY, V33, P206, DOI 10.1046/j.1365-2222.2003.01587.x; Drachenberg KJ, 2001, ALLERGY, V56, P498, DOI 10.1034/j.1398-9995.2001.056006498.x; DREBORG S, 1986, ALLERGY, V41, P131, DOI 10.1111/j.1398-9995.1986.tb00289.x; Dunsky EH, 2006, ALLERGY, V61, P1235, DOI 10.1111/j.1398-9995.2006.01137.x; Durham SR, 2006, J ALLERGY CLIN IMMUN, V117, P802, DOI 10.1016/j.jaci.2005.12.1358; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; EBNER C, 1994, ALLERGY, V49, P38, DOI 10.1111/j.1398-9995.1994.tb00771.x; Enrique E, 2005, J ALLERGY CLIN IMMUN, V116, P1073, DOI 10.1016/j.jaci.2005.08.027; ESCH RE, 1992, ARB PEI GSH, V85, P171; EWAN PW, 1988, CLIN ALLERGY, V18, P501, DOI 10.1111/j.1365-2222.1988.tb02900.x; Ewbank PA, 2003, J ALLERGY CLIN IMMUN, V111, P155, DOI 10.1067/mai.2003.41; FRANKLIN W, 1967, J AMER MED ASSOC, V201, P915, DOI 10.1001/jama.201.12.915; Frew AJ, 2006, J ALLERGY CLIN IMMUN, V117, P319, DOI 10.1016/j.jaci.2005.11.014; FURIN MJ, 1991, J ALLERGY CLIN IMMUN, V88, P27, DOI 10.1016/0091-6749(91)90297-2; Gidaro GB, 2005, CLIN EXP ALLERGY, V35, P565, DOI 10.1111/j.1365-2222.2005.02240.x; Grier TJ, 2002, ALLERGY ASTHMA PROC, V23, P125; HAUGAARD L, 1993, J ALLERGY CLIN IMMUN, V91, P709, DOI 10.1016/0091-6749(93)90190-Q; HEDLIN G, 1991, J ALLERGY CLIN IMMUN, V87, P955, DOI 10.1016/0091-6749(91)90417-M; HORST M, 1990, J ALLERGY CLIN IMMUN, V85, P460, DOI 10.1016/0091-6749(90)90156-X; Ippoliti F, 2003, PEDIATR ALLERGY IMMU, V14, P216, DOI 10.1034/j.1399-3038.2003.00025.x; JOHNSTONE D, 1961, PEDIATRICS, V27, P39; Jutel M, 2005, J ALLERGY CLIN IMMUN, V116, P608, DOI 10.1016/j.jaci.2005.06.004; Khinchi MS, 2004, ALLERGY, V59, P45, DOI 10.1046/j.1398-9995.2003.00387.x; LAVINS BJ, 1992, J ALLERGY CLIN IMMUN, V89, P658, DOI 10.1016/0091-6749(92)90371-8; Lent AM, 2006, J ALLERGY CLIN IMMUN, V118, P1249, DOI 10.1016/j.jaci.2006.07.055; Lima MT, 2002, CLIN EXP ALLERGY, V32, P507, DOI 10.1046/j.0954-7894.2002.01327.x; LIN MS, 1993, ANN ALLERGY, V71, P557; LOWELL FC, 1965, NEW ENGL J MED, V273, P675, DOI 10.1056/NEJM196509232731302; MALLING HJ, 1986, ALLERGY, V41, P507, DOI 10.1111/j.1398-9995.1986.tb00336.x; Marcucci F, 2005, ALLERGY, V60, P952, DOI 10.1111/j.1398-9995.2005.00786.x; Marogna M, 2005, J ALLERGY CLIN IMMUN, V115, P1184, DOI 10.1016/j.jaci.2005.02.031; Mempel M, 2003, J ALLERGY CLIN IMMUN, V111, P1406, DOI 10.1067/mai.2003.1497; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; Nanda A, 2004, J ALLERGY CLIN IMMUN, V114, P1339, DOI 10.1016/j.jaci.2004.08.049; Nelson HS, 1996, J ALLERGY CLIN IMMUN, V98, P382, DOI 10.1016/S0091-6749(96)70162-8; Nelson HS, 1997, J ALLERGY CLIN IMMUN, V99, P744, DOI 10.1016/S0091-6749(97)80006-1; Nelson HS, 2000, J ALLERGY CLIN IMMUN, V106, P41, DOI 10.1067/mai.2000.107197; Niederberger V, 2004, P NATL ACAD SCI USA, V101, P14677, DOI 10.1073/pnas.0404735101; Niggemann B, 2006, ALLERGY, V61, P855, DOI 10.1111/j.1398-9995.2006.01068.x; NORMAN PS, 1978, J ALLERGY CLIN IMMUN, V61, P370, DOI 10.1016/0091-6749(78)90116-1; Novembre E, 2004, J ALLERGY CLIN IMMUN, V114, P851, DOI 10.1016/j.jaci.2004.07.012; OHOLLAREN M, 1991, NEW ENGL J MED, V324, P759; Olaguibel JM, 1999, J INVEST ALLERG CLIN, V9, P110; Olsen OT, 1997, ALLERGY, V52, P853, DOI 10.1111/j.1398-9995.1997.tb02157.x; Pajno GB, 2006, J ALLERGY CLIN IMMUN, V117, pS233, DOI 10.1016/j.jaci.2005.12.921; Pajno GB, 2005, J ALLERGY CLIN IMMUN, V116, P1380, DOI 10.1016/j.jaci.2005.07.034; Pajno GB, 2001, CLIN EXP ALLERGY, V31, P1392, DOI 10.1046/j.1365-2222.2001.01161.x; Passlacqua G, 2006, J ALLERGY CLIN IMMUN, V117, P946, DOI 10.1016/j.jaci.2005.12.1312; Patterson ML, 2002, CLIN EXP ALLERGY, V32, P721, DOI 10.1046/j.1365-2222.2002.01397.x; Penagos M, 2006, ANN ALLERG ASTHMA IM, V97, P141, DOI 10.1016/S1081-1206(10)60004-X; Purello-D'Ambrosio F, 2001, CLIN EXP ALLERGY, V31, P1295, DOI 10.1046/j.1365-2222.2001.01027.x; Rak S, 2005, ALLERGY, V60, P643, DOI 10.1111/j.1398-9995.2005.00763.x; REID MJ, 1993, J ALLERGY CLIN IMMUN, V92, P6, DOI 10.1016/0091-6749(93)90030-J; Ross RN, 2000, CLIN THER, V22, P342, DOI 10.1016/S0149-2918(00)80038-7; Ross RN, 2000, CLIN THER, V22, P351, DOI 10.1016/S0149-2918(00)80039-9; SALVAGGIO J, 1981, J ALLERGY CLIN IMMUN, V68, P327, DOI 10.1016/0091-6749(81)90131-7; SALVAGGIO JE, 1993, J ALLERGY CLIN IMMUN, V92, P217, DOI 10.1016/0091-6749(93)90164-B; Sharkey P, 1996, ANN ALLERG ASTHMA IM, V76, P175, DOI 10.1016/S1081-1206(10)63419-9; Tabar AI, 2005, J ALLERGY CLIN IMMUN, V116, P109, DOI 10.1016/j.jaci.2005.05.005; Tankersley MS, 2000, J ALLERGY CLIN IMMUN, V106, P840, DOI 10.1067/mai.2000.110468; TARGONSKI PV, 1995, J ALLERGY CLIN IMMUN, V95, P955, DOI 10.1016/S0091-6749(95)70095-1; Terada T, 2006, CLIN IMMUNOL, V120, P45, DOI 10.1016/j.clim.2005.12.010; TINKELMAN DG, 1995, J ALLERGY CLIN IMMUN, V95, P8, DOI 10.1016/S0091-6749(95)70146-X; Vailes L, 2001, J ALLERGY CLIN IMMUN, V107, P641, DOI 10.1067/mai.2001.114118; Valovirta E, 2006, J ALLERGY CLIN IMMUN, V117, P721, DOI 10.1016/j.jaci.2006.01.023; VANMETRE TE, 1982, J ALLERGY CLIN IMMUN, V69, P181, DOI 10.1016/0091-6749(82)90098-7; Varney VA, 1997, CLIN EXP ALLERGY, V27, P860, DOI 10.1111/j.1365-2222.1997.tb01225.x; Werfel T, 2006, ALLERGY, V61, P202, DOI 10.1111/j.1398-9995.2006.00974.x; Wilson DR, 2005, ALLERGY, V60, P4, DOI 10.1111/j.1398-9995.2005.00699.x; Zhu DC, 2005, NAT MED, V11, P446, DOI 10.1038/nm1219	91	80	90	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2007	119	4					769	777		10.1016/j.jaci.2007.01.036	http://dx.doi.org/10.1016/j.jaci.2007.01.036			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	157OK	17337297				2022-12-18	WOS:000245729500001
J	Parrino, J; Graham, BS				Parrino, Janie; Graham, Barney S.			Smallpox vaccines: Past, present, and future	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						poxvirus; vaccination; immunization; variola; monkeypox	RANDOMIZED CONTROLLED-TRIAL; VIRUS ANKARA; CLINICAL-RESPONSES; LETHAL MONKEYPOX; CELL-CULTURE; VACCINATION; IMMUNOGENICITY; CHALLENGE; PROTECTS; STRAIN	The global eradication of smallpox was a tremendous achievement made possible by the development of an effective vaccine. Routine vaccination of the general population is no longer recommended. However, stocks of variola virus, the causative agent of smallpox, still exist in 2 secure laboratories, and permanent disposal has been controversial. In addition, there is speculation that variola virus may exist outside of these 2 facilities, and there is a concern that the threat of smallpox will be used as a bioterrorist weapon. In 2002, this concern led to a vaccination campaign in US military and civilian healthcare workers and first responders. Although the historical live virus vaccine has proven efficacy, it also is associated with serious adverse events and rare fatal reactions, particularly in the setting of immunodeficiency and atopic eczema. In addition, this vaccine was historically produced using animal intermediaries in a process that was prone to contamination and not acceptable for current manufacturing standards. Development of alternative poxvirus vaccines is focused on replication-defective viruses, gene-based vectors, and subunit approaches to improve safety and immunogenicity. The conundrum is that in the absence of an intentional release of variola, efficacy evaluation of new candidate vaccines will be limited to animal model testing, which creates new challenges for the vaccine licensure process. Although motivated by the threat of bioterrorism, the hope is for new poxvirus vaccines to have their greatest utility against other pathogenic orthopoxviruses such as monkeypox and for the development of recombinant poxvirus-based vectors to treat and prevent other diseases.	NIAID, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Graham, BS (corresponding author), NIAID, Vaccine Res Ctr, NIH, 40 Convent Dr,MSC-3017,Bldg 40,Room 2502, Bethesda, MD 20892 USA.	bgraham@nih.gov	Graham, Barney S./AAC-5898-2019	Graham, Barney S./0000-0001-8112-0853	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI005036] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Bartlett J, 2003, CLIN INFECT DIS, V36, P883, DOI 10.1086/374792; Belshe RB, 2004, J INFECT DIS, V189, P493, DOI 10.1086/380906; Casey CG, 2005, JAMA-J AM MED ASSOC, V294, P2734, DOI 10.1001/jama.294.21.2734; Cassimatis DC, 2004, J AM COLL CARDIOL, V43, P1503, DOI 10.1016/j.jacc.2003.11.053; Chen NH, 2005, VIROLOGY, V340, P46, DOI 10.1016/j.virol.2005.05.030; Crotty S, 2003, J IMMUNOL, V171, P4969, DOI 10.4049/jimmunol.171.10.4969; Di Giulio DB, 2004, LANCET INFECT DIS, V4, P15, DOI 10.1016/S1473-3099(03)00856-9; Earl PL, 2004, NATURE, V428, P182, DOI 10.1038/nature02331; Edghill-Smith Y, 2005, J INFECT DIS, V191, P372, DOI 10.1086/427265; Empig C, 2006, VACCINE, V24, P3686, DOI 10.1016/j.vaccine.2005.03.029; Fenner F, 1988, SMALLPOX ITS ERADICA; Fogg C, 2004, J VIROL, V78, P10230, DOI 10.1128/JVI.78.19.10230-10237.2004; Frey SE, 2002, NEW ENGL J MED, V346, P1265, DOI 10.1056/NEJMoa020534; Frey SE, 2002, NEW ENGL J MED, V346, P1275, DOI 10.1056/NEJMoa013431; Grabenstein JD, 2003, JAMA-J AM MED ASSOC, V289, P3278, DOI 10.1001/jama.289.24.3278; Greenberg RN, 2005, LANCET, V365, P398, DOI 10.1016/S0140-6736(05)70234-8; Henderson DA, 1999, JAMA-J AM MED ASSOC, V281, P2127, DOI 10.1001/jama.281.22.2127; Hooper JW, 2004, J VIROL, V78, P4433, DOI 10.1128/JVI.78.9.4433-4443.2004; Kidokoro M, 2005, P NATL ACAD SCI USA, V102, P4152, DOI 10.1073/pnas.0406671102; Kim SH, 2005, J INFECT DIS, V192, P1066, DOI 10.1086/432765; Likos AM, 2005, J GEN VIROL, V86, P2661, DOI 10.1099/vir.0.81215-0; McCurdy LH, 2004, J VIROL, V78, P12471, DOI 10.1128/JVI.78.22.12471-12479.2004; McCurdy LH, 2004, CLIN INFECT DIS, V38, P1749, DOI 10.1086/421266; Meseda CA, 2005, VIROLOGY, V339, P164, DOI 10.1016/j.virol.2005.06.002; Monath TP, 2004, INT J INFECT DIS, V8, pS31, DOI 10.1016/j.ijid.2004.09.002; Murphy FA, 2005, EMERG INFECT DIS, V11, P1086; Ober BT, 2002, J VIROL, V76, P7713, DOI 10.1128/JVI.76.15.7713-7723.2002; Otero M, 2006, VACCINE, V24, P4461, DOI 10.1016/j.vaccine.2005.08.010; PARRINO J, 2006, IN PRESS VACCINE; Rosenthal SR, 2001, EMERG INFECT DIS, V7, P920, DOI 10.3201/eid0706.010602; STICKL H, 1974, DEUT MED WOCHENSCHR, V99, P2386, DOI 10.1055/s-0028-1108143; Talbot TR, 2004, JAMA-J AM MED ASSOC, V292, P1205, DOI 10.1001/jama.292.10.1205; Vollmar J, 2006, VACCINE, V24, P2065, DOI 10.1016/j.vaccine.2005.11.022; Weltzin R, 2003, NAT MED, V9, P1125, DOI 10.1038/nm916; WHO, 1980, GLOB ER SMALLP FIN R; WINKENWERDER W, 2006, SMALLPOX VACCINATION; Wyatt LS, 2004, P NATL ACAD SCI USA, V101, P4590, DOI 10.1073/pnas.0401165101; 2006, SMALLPOX VACCINE DRI; 2006, 8 REPORTS INT COMMIT; 2002, FED REG         0531, V67, P37988	40	80	84	1	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2006	118	6					1320	1326		10.1016/j.jaci.2006.09.037	http://dx.doi.org/10.1016/j.jaci.2006.09.037			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	117NP	17157663	Green Published			2022-12-18	WOS:000242880300018
J	Bateman, ED; Jacques, L; Goldfrad, C; Atienza, T; Mihaescu, T; Duggan, M				Bateman, ED; Jacques, L; Goldfrad, C; Atienza, T; Mihaescu, T; Duggan, M			Asthma control can be maintained when fluticasone propionate/salmeterol in a single inhaler is stepped down	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; fluticasone propionate; fluticasone propionate/salmeterol; maintenance; control; step-down	METERED-DOSE INHALER; CLINICAL EQUIVALENCE; HYPERRESPONSIVENESS; CORTICOSTEROIDS; PROPIONATE; MANAGEMENT; INSIGHTS; MODERATE; REALITY	Background: Asthma control is the goal of treatment, but little data exist to support treatment strategies for stepping down treatment once control has been achieved. Objective: We assessed whether either the long-acting beta(2)-agonist or corticosteroid could be reduced without loss of asthma control once control had been attained with fluticasone propionate/salmeterol (FSC). Methods: After 12 weeks of open-label treatment with FSC 250/ 50 mu g twice daily, patients whose asthma was well controlled were randomized to FSC 100/50 mu g twice daily or fluticasone propionate (FP) 250 mu g twice daily. for 12 weeks. The primary endpoint was mean morning peak expiratory flow over the randomized study period. Secondary endpoints included symptom scores, rescue albuterol use, and asthma control. Results: During open-label treatment., improvements from baseline were seen, and 435 of 641 patients (68%) achieved well controlled status during each of the last 4 weeks of this period. A total of 246 patients received FSC 100/50 mu g twice daily and 238 FP 250 mu g twice daily. The adjusted mean change in morning peak expiratory flow from the end of open-label treatment was -0.3 L/min for FSC and -13.2 L/min for FP (treatment difference, 12.9 L/min; 95% Cl, 8.1-17.6. P <.001). Secondary efficacy endpoints also showed FSC 100/50 mu g twice daily to be more effective than FP 250 mu g twice daily alone. The majority of patients remained well controlled, but the proportion was higher with FSC. Conclusion: In patients achieving asthma control with FSC 250/50 mu g twice daily, stepping treatment down to a lower dose of FSC 100/50 mu g twice daily is more effective than switching to an inhaled corticosteroid alone.	GlaxoSmithKline Inc, Greenford, Middx, England; Univ Cape Town, ZA-7700 Rondebosch, South Africa; Vet Mem Med Ctr, Quezon City, Philippines; Univ Med & Pharm, Iasi, Romania	GlaxoSmithKline; University of Cape Town; Grigore T Popa University of Medicine & Pharmacy	Jacques, L (corresponding author), GlaxoSmithKline Res & Dev Ltd, Greenford Rd, Greenford UB6 0HE, Middx, England.	loretta.a.jacques@gsk.com						Bateman ED, 2002, EUR RESPIR J, V20, P588, DOI 10.1183/09031936.02.00294702; Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC; Bateman ED, 2001, RESP MED, V95, P136, DOI 10.1053/rmed.2000.1008; Bateman ED, 2001, EUR RESPIR J, V17, P589, DOI 10.1183/09031936.01.17405890; *EUR AG EV MED PRO, 1999, CPMPEWP48299 EUR AG; *GINA, 2002, NIH PUBL; Hawkins G, 2003, BMJ-BRIT MED J, V326, P1115, DOI 10.1136/bmj.326.7399.1115; Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008; Rabe KF, 2004, J ALLERGY CLIN IMMUN, V114, P40, DOI 10.1016/j.jaci.2004.04.042; Rabe KF, 2000, EUR RESPIR J, V16, P802, DOI 10.1183/09031936.00.16580200; Reddel HK, 2000, EUR RESPIR J, V16, P226, DOI 10.1034/j.1399-3003.2000.16b08.x; Reddel HK, 2004, EUR RESPIR J, V24, P715, DOI 10.1183/09031936.04.10104904; Sont JK, 1999, AM J RESP CRIT CARE, V159, P1043, DOI 10.1164/ajrccm.159.4.9806052; Stoloff S, 2002, PHARMACOTHERAPY, V22, P212, DOI 10.1592/phco.22.3.212.33550; van Noord JA, 2001, CLIN DRUG INVEST, V21, P243, DOI 10.2165/00044011-200121040-00002; Ward C, 2002, THORAX, V57, P309, DOI 10.1136/thorax.57.4.309	16	80	82	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2006	117	3					563	570		10.1016/j.jaci.2005.11.036	http://dx.doi.org/10.1016/j.jaci.2005.11.036			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	025JY	16522454				2022-12-18	WOS:000236263100010
J	Miller, MK; Johnson, C; Miller, DP; Deniz, Y; Bleecker, ER; Wenzel, SE				Miller, MK; Johnson, C; Miller, DP; Deniz, Y; Bleecker, ER; Wenzel, SE		TENOR Study Grp	Severity assessment in asthma: An evolving concept	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						epidemiology; practice guidelines; questionnaires; respiratory function tests; health care	HEALTH-CARE UTILIZATION; QUALITY-OF-LIFE; PHYSICIAN ESTIMATE; BASE	Background: Guidelines for the clinical management of asthma base specific treatment recommendations on the assessment of disease severity. Thus, the accuracy of such assessments is essential for proper clinical management. The consistency of asthma severity assessment in patients with difficult-to-treat disease is unknown. Objective: The objectives of this analysis were to compare the asthma severity assessment according to 3 methodologies in patients from The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens study. Methods: Asthma severity on the basis of the National Asthma Education and Prevention Program and the Global Initiative for Asthma guidelines was compared with physician assessment and benchmarked against asthma-related health care use. Guideline-based asthma severity symptom components were derived from patient-reported questionnaires. Lung function levels were determined by prebronchodilator FEV1 measurements; asthma-related medication and recent health care use were reported by patients. Results: There was a clear lack of agreement among the asthma severity assessment modalities. Asthma severity was associated with asthma-related health care use, and patients considered to have severe asthma according to both sets of guidelines and physicians' assessment had the highest health care and medication use. Conclusion: Classification of asthma severity on the basis of current asthma symptoms and lung function may be useful but not completely reflective of a patient's true asthma condition. Clinical assessment of asthma severity should consider a patient's medication use and consumption of health care resources for asthma exacerbations. Additional studies that apply criteria for asthma severity longitudinally are needed to support recommendations for optimal assessment of asthma severity.	Genentech Inc, San Francisco, CA 94080 USA; Ovat Res Grp, San Francisco, CA USA; Wake Forest Univ, Winston Salem, NC 27109 USA; Natl Jewish Med & Res Ctr, Denver, CO USA	Roche Holding; Genentech; Wake Forest University; National Jewish Health	Miller, MK (corresponding author), Genentech Inc, 1 DNA Way,Mail Stop 84, San Francisco, CA 94080 USA.	mkmiller@gene.com		Miller, Dave/0000-0003-2947-152X				[Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; Antonicelli L, 2004, EUR RESPIR J, V23, P723, DOI 10.1183/09031936.04.00004904; Baker KM, 2003, CHEST, V124, P2156, DOI 10.1378/chest.124.6.2156; Braganza S, 2003, J ASTHMA, V40, P661, DOI 10.1081/JAS-120019037; Busse WW, 2002, J ALLERGY CLIN IMMUN, V110, P703, DOI 10.1067/mai.2002.129368; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; Colice GL, 1999, AM J RESP CRIT CARE, V160, P1962, DOI 10.1164/ajrccm.160.6.9902112; Colice GL, 2002, CURR OPIN PULM MED, V8, P4, DOI 10.1097/00063198-200201000-00002; Diette GB, 2004, ANN ALLERG ASTHMA IM, V93, P546, DOI 10.1016/S1081-1206(10)61261-6; Doerschug KC, 1999, AM J RESP CRIT CARE, V159, P1735, DOI 10.1164/ajrccm.159.6.9809051; Dolan CM, 2004, ANN ALLERG ASTHMA IM, V92, P32, DOI 10.1016/S1081-1206(10)61707-3; *GINA, 2003, GLOB STRAT ASTHM MAN; Juniper EF, 1999, EUR RESPIR J, V14, P32, DOI 10.1034/j.1399-3003.1999.14a08.x; Juniper EF, 1996, QUAL LIFE RES, V5, P35, DOI 10.1007/BF00435967; Li JTC, 1996, ANN ALLERG ASTHMA IM, V76, P1, DOI 10.1016/S1081-1206(10)63400-X; MCDERMOTT M, 1999, CHEST, V116, pS145; *NAT ASTHM ED PREV, 1997, 2 US DEP HHS; Osborne ML, 1999, CHEST, V115, P85, DOI 10.1378/chest.115.1.85; Petrou S, 2002, INT J TECHNOL ASSESS, V18, P705, DOI 10.1017/S026646230200051X; Proceedings of the ATS workshop on refractory asthma, 2000, AM J RESP CRIT CARE, V162, P2341, DOI DOI 10.1164/AJRCCM.162.6.ATS9-00; Schatz M, 2005, J ALLERGY CLIN IMMUN, V115, P564, DOI 10.1016/j.jaci.2004.12.005; Shegog R, 2004, J ASTHMA, V41, P385, DOI 10.1081/JAS-120026098; Sullivan SD, 2001, J ALLERGY CLIN IMMUN, V107, P203, DOI 10.1067/mai.2001.112851; Vollmer WM, 2002, AM J RESP CRIT CARE, V165, P195, DOI 10.1164/ajrccm.165.2.2102127; Weissman JS, 1996, AIDS, V10, P775, DOI 10.1097/00002030-199606001-00013; Wolfenden LL, 2003, ARCH INTERN MED, V163, P231, DOI 10.1001/archinte.163.2.231	26	80	83	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2005	116	5					990	995		10.1016/j.jaci.2005.08.018	http://dx.doi.org/10.1016/j.jaci.2005.08.018			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IG	16275365				2022-12-18	WOS:000235686700006
J	Bieneman, AP; Chichester, KL; Chen, YH; Schroeder, JT				Bieneman, AP; Chichester, KL; Chen, YH; Schroeder, JT			Toll-like receptor 2 ligands activate human basophils for both IgE-dependent and IgE-independent secretion	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						innate immunity; basophil; IgE; cytokines; Toll-like receptors; allergy; human	TOLL-LIKE RECEPTOR-2; MIXED LEUKOCYTE-CULTURES; HUMAN MAST-CELLS; HISTAMINE-RELEASE; CUTTING EDGE; CYTOKINE GENERATION; IMMUNE-RESPONSE; IL-4 SECRETION; LEUKOTRIENE C4; BLOOD	Background: Toll-like receptor (TLR) molecules play a critical role in directing the course of acquired immunity, including that associated with allergic disease, by recognizing specific microbial products that activate immune cells for effector functions. Objective: We investigated whether human basophils express 2 such molecules (TLR2 and TLR4), and assessed whether putative ligands for these receptors activate nuclear factor kappaB (NFkappaB) and modulate mediator release and cytokine secretion either alone or in response to stimulation. Methods: Toll-like receptor expression was assessed by using RT-PCR and flow cytometry. Immunoblotting detected nuclear NFkappaB. Automated fluorometry, RIA, and ELISA detected concurrent changes in histamine, leukotriene C-4, and cytokine, respectively, after culture with specific ligands. Results: mRNA and protein for TLR2 and TLR4 were detected in basophils. However, in assessing nuclear localization of NFkappaB as a measure of functional receptor responses, basophils selectively reacted only to peptidoglyean, a TLR2 ligand, and not to LPS, a TLR4 ligand. Likewise, basophils secreted both IL-4 and IL-13 in direct response to peptidoglycan but not to LPS. Although neither ligand induced histamine or leukotriene C-4 release, several TLR2-specific ligands augmented the secretion of these mediators (and cytokine) in response to IgE-dependent activation and of IL-13 in response to IgE-independent stimulation. Finally, a selective inhibitor of NFkappaB did not prevent these enhancing effects mediated by TLR2 ligands. Conclusion: These data suggest that innate immune responses mediated through TLR2 play a role in augmenting;allergic reactions, in part by modulating basophil cytokine secretion and mediator release independently of NFkappaB activation.	Johns Hopkins Univ, Johns Hopkins Asthma & Allergy Ctr, Dept Med, Div Clin Immunol,Unit Off 2, Baltimore, MD 21224 USA	Johns Hopkins University; Johns Hopkins Medicine	Schroeder, JT (corresponding author), Johns Hopkins Univ, Johns Hopkins Asthma & Allergy Ctr, Dept Med, Div Clin Immunol,Unit Off 2, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.	schray@jhmi.edu			NIAID NIH HHS [AI22241] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adkinson NF, 1980, MEASUREMENT TOTAL SE; Beutler B, 2004, NATURE, V430, P257, DOI 10.1038/nature02761; Chen YH, 2003, J ALLERGY CLIN IMMUN, V112, P944, DOI 10.1016/j.jaci.2003.08.027; Chisholm D, 2004, J ALLERGY CLIN IMMUN, V113, P448, DOI 10.1016/j.jaci.2003.12.011; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; GILBERT HS, 1975, BLOOD, V46, P279; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Kadowaki N, 2001, J EXP MED, V194, P863, DOI 10.1084/jem.194.6.863; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Liu AH, 2002, J ALLERGY CLIN IMMUN, V109, P379, DOI 10.1067/mai.2002.122157; McCurdy JD, 2003, J IMMUNOL, V170, P1625, DOI 10.4049/jimmunol.170.4.1625; OCHENSBERGER B, 1995, BLOOD, V86, P4039, DOI 10.1182/blood.V86.11.4039.bloodjournal86114039; Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497; Redecke V, 2004, J IMMUNOL, V172, P2739, DOI 10.4049/jimmunol.172.5.2739; Redrup AC, 1998, J IMMUNOL, V160, P1957; Sabroe I, 2002, J IMMUNOL, V168, P4701, DOI 10.4049/jimmunol.168.9.4701; SCHROEDER JT, 1994, J ALLERGY CLIN IMMUN, V94, P1189, DOI 10.1016/0091-6749(94)90331-X; SCHROEDER JT, 1994, J IMMUNOL, V153, P1808; Schroeder JT, 2002, J ALLERGY CLIN IMMUN, V109, P507, DOI 10.1067/mai.2002.122460; Schroeder JT, 2001, CLIN EXP ALLERGY, V31, P1369, DOI 10.1046/j.1365-2222.2001.01130.x; Schroeder JT, 1998, J LEUKOCYTE BIOL, V63, P692, DOI 10.1002/jlb.63.6.692; Sin AZ, 2001, J ALLERGY CLIN IMMUN, V108, P387; Supajatura V, 2002, J CLIN INVEST, V109, P1351, DOI 10.1172/JCI200214704; Takeuchi O, 2002, J IMMUNOL, V169, P10, DOI 10.4049/jimmunol.169.1.10; Toba K, 1999, CYTOMETRY, V35, P249, DOI 10.1002/(SICI)1097-0320(19990301)35:3<249::AID-CYTO8>3.0.CO;2-O; Varadaradjalou S, 2003, EUR J IMMUNOL, V33, P899, DOI 10.1002/eji.200323830; Wagner H, 2001, IMMUNITY, V14, P499, DOI 10.1016/S1074-7613(01)00144-3; Wang PY, 1999, J BIOL CHEM, V274, P23235, DOI 10.1074/jbc.274.33.23235; Zhang DK, 2004, SCIENCE, V303, P1522, DOI 10.1126/science.1094351	29	80	88	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2005	115	2					295	301		10.1016/j.jaci.2004.10.018	http://dx.doi.org/10.1016/j.jaci.2004.10.018			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	897YU	15696084				2022-12-18	WOS:000227043600013
J	Norman, PS				Norman, PS			Current reviews of allergy and clinical immunology	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						immunotherapy; allergen; T cells; cytokines; mast cell; basophil; CpG motif; peptide; anti-IgE	GRASS-POLLEN IMMUNOTHERAPY; STANDARDIZED LATEX EXTRACT; MESSENGER-RNA EXPRESSION; IN-VITRO; CYTOKINE PRODUCTION; ASTHMATIC-PATIENTS; SENSITIVE PATIENTS; DOUBLE-BLIND; NASAL; EFFICACY	Allergen immunotherapy continues to be used worldwide in the management of allergic rhinitis and asthma. We continue to refine our knowledge of the indications for immunotherapy, the allergens that can be used successfully, and the requirements for dosage and route of administration. Several additional allergens have been shown to be effective in controlled studies. The sublingual route of administration is safe and can be effective if the dose is large enough. Since reviews in 1998, further studies of immunologic changes after immunotherapy have confirmed that T(II)2 lymphocyte-mediated responses are suppressed, and T(H)1 responses are stimulated. Eosinophil and basophil inflammatory responses to allergen exposure are downregulated through one or both of these mechanisms. Research continues to seek improvements through allergen vaccine modifications suggested by recent immunologic discoveries. None of these is available in practice.	Johns Hopkins Univ, Sch Med, Johns Hopkins Asthma & Allergy Ctr, Baltimore, MD 21224 USA	Johns Hopkins University; Johns Hopkins Medicine	Norman, PS (corresponding author), Johns Hopkins Univ, Sch Med, Johns Hopkins Asthma & Allergy Ctr, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.	pnorman@jhmi.edu						Abramson MJ, 2003, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD001186; Adkinson NF, 2001, AM J RESP CRIT CARE, V164, P2140; Akdis CA, 2001, MICROBES INFECT, V3, P891, DOI 10.1016/S1286-4579(01)01449-6; Bagnasco M, 1997, J ALLERGY CLIN IMMUN, V100, P122, DOI 10.1016/S0091-6749(97)70203-3; Bagnasco M, 2001, CLIN EXP ALLERGY, V31, P54, DOI 10.1046/j.1365-2222.2001.00999.x; Bannon GA, 2001, INT ARCH ALLERGY IMM, V124, P70, DOI 10.1159/000053672; Bousquet J, 2004, ALLERGY, V59, P1, DOI 10.1111/j.1398-9995.2004.00425.x; Bousquet J, 2001, AM J RESP CRIT CARE, V164, P2139, DOI 10.1164/ajrccm.164.12.2110107a; Canonica GW, 2003, J ALLERGY CLIN IMMUN, V111, P437, DOI 10.1067/mai.2003.129; Chapman MD, 2000, J ALLERGY CLIN IMMUN, V106, P409, DOI 10.1067/mai.2000.109832; Cools M, 2000, ALLERGY, V55, P69, DOI 10.1034/j.1398-9995.2000.00191.x; Creticos PS, 2000, J ALLERGY CLIN IMMUN, V105, pS70, DOI 10.1016/S0091-6749(00)90645-6; Creticos PS, 2002, J ALLERGY CLIN IMMUN, V109, P743; Creticos PS, 2001, J ALLERGY CLIN IMMUN, V107, pS216; Creticos PS, 1997, J ALLERGY CLIN IMMUN, V99, P1631; De Amici M, 2001, ANN ALLERG ASTHMA IM, V86, P311, DOI 10.1016/S1081-1206(10)63304-2; Durham SR, 1999, CLIN EXP ALLERGY, V29, P1490; Durham SR, 1998, J ALLERGY CLIN IMMUN, V102, P157, DOI 10.1016/S0091-6749(98)70079-X; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Fanta C, 1999, INT ARCH ALLERGY IMM, V120, P218, DOI 10.1159/000024270; Francis JN, 2003, J ALLERGY CLIN IMMUN, V111, P1255, DOI 10.1067/mai.2003.1570; Guerra F, 2001, J ALLERGY CLIN IMMUN, V107, P647, DOI 10.1067/mai.2001.112263; Hakansson L, 1998, CLIN EXP ALLERGY, V28, P791; Haselden BM, 1999, J EXP MED, V189, P1885, DOI 10.1084/jem.189.12.1885; Haselden BM, 2000, INT ARCH ALLERGY IMM, V122, P229, DOI 10.1159/000024403; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; Khinchi MS, 2004, ALLERGY, V59, P45, DOI 10.1046/j.1398-9995.2003.00387.x; Klimek L, 1999, CLIN EXP ALLERGY, V29, P1326; Krieg AM, 2000, IMMUNOL TODAY, V21, P521, DOI 10.1016/S0167-5699(00)01719-9; Kuehr J, 2002, J ALLERGY CLIN IMMUN, V109, P274, DOI 10.1067/mai.2002.121949; Laaksonen K, 2003, J ALLERGY CLIN IMMUN, V112, P1171, DOI 10.1016/j.jaci.2003.08.043; Leynadier F, 2000, J ALLERGY CLIN IMMUN, V106, P585, DOI 10.1067/mai.2000.109173; Majori M, 2000, CLIN EXP ALLERGY, V30, P341, DOI 10.1046/j.1365-2222.2000.00701.x; Meissner N, 1999, CLIN EXP ALLERGY, V29, P618; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; Monteseirin J, 2001, J ALLERGY CLIN IMMUN, V107, P623, DOI 10.1067/mai.2001.113566; Moverare R, 2000, SCAND J IMMUNOL, V52, P200; Mungan D, 1999, ANN ALLERG ASTHMA IM, V82, P485, DOI 10.1016/S1081-1206(10)62726-3; Nelson HS, 1997, J ALLERGY CLIN IMMUN, V99, P744, DOI 10.1016/S0091-6749(97)80006-1; Norman PS, 1998, J ALLERGY CLIN IMMUN, V102, P1, DOI 10.1016/S0091-6749(98)70046-6; Norman PS, 1996, AM J RESP CRIT CARE, V154, P1623, DOI 10.1164/ajrccm.154.6.8970345; Nouri-Aria KT, 2004, J IMMUNOL, V172, P3252, DOI 10.4049/jimmunol.172.5.3252; Oda N, 1998, CELL IMMUNOL, V190, P43, DOI 10.1006/cimm.1998.1391; Oldfield WLG, 2002, LANCET, V360, P47, DOI 10.1016/S0140-6736(02)09332-7; Oldfield WLG, 2001, J IMMUNOL, V167, P1734, DOI 10.4049/jimmunol.167.3.1734; OPPENHEIMER JJ, 1992, J ALLERGY CLIN IMMUN, V90, P256, DOI 10.1016/0091-6749(92)90080-L; Park HS, 2001, ANN ALLERG ASTHMA IM, V86, P444, DOI 10.1016/S1081-1206(10)62493-3; Pereira C, 1999, ALLERGY, V54, P291, DOI 10.1034/j.1398-9995.1999.00954.x; PEREIRA C, 2003, ALLERG IMMUNOL PARIS, V35, P217; Pierson-Mullany LK, 2000, ANN ALLERG ASTHMA IM, V84, P241, DOI 10.1016/S1081-1206(10)62761-5; Sade K, 2003, ALLERGY, V58, P430, DOI 10.1034/j.1398-9995.2003.00055.x; Sastre J, 2003, J ALLERGY CLIN IMMUN, V111, P985, DOI 10.1067/mai.2003.1390; Soderlund A, 1997, IMMUNOL LETT, V57, P177, DOI 10.1016/S0165-2478(97)00051-5; Tighe H, 2000, J ALLERGY CLIN IMMUN, V106, P124, DOI 10.1067/mai.2000.107927; Tulic MK, 2004, J ALLERGY CLIN IMMUN, V113, P235, DOI 10.1016/j.jaci.2003.11.001; Valenta R, 2002, CURR OPIN IMMUNOL, V14, P718, DOI 10.1016/S0952-7915(02)00402-8; Van Bever HP, 1998, CLIN EXP ALLERGY, V28, P943; Wachholz PA, 2002, IMMUNOLOGY, V105, P56, DOI 10.1046/j.1365-2567.2002.01338.x; Wachholz PA, 2003, J ALLERGY CLIN IMMUN, V112, P915, DOI 10.1016/S0091-6749(03)02022-0; Wilson DR, 2001, CLIN EXP ALLERGY, V31, P1705, DOI 10.1046/j.1365-2222.2001.01231.x; Wilson DR, 2001, J ALLERGY CLIN IMMUN, V107, P971, DOI 10.1067/mai.2001.115483; Zuany-Amorim C, 2002, NAT REV DRUG DISCOV, V1, P797, DOI 10.1038/nrd914	62	80	92	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2004	113	6					1013	1023		10.1016/j.jaci.2004.03.020	http://dx.doi.org/10.1016/j.jaci.2004.03.020			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	829ZI	15208577				2022-12-18	WOS:000222091000001
J	Kim, CK; Kim, SW; Park, CS; Kim, BI; Kang, H; Koh, YY				Kim, CK; Kim, SW; Park, CS; Kim, BI; Kang, H; Koh, YY			Bronchoalveolar lavage cytokine profiles in acute asthma and acute bronchiolitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						bronchiolitis; asthma; bronchoalveolar lavage; IFN-gamma; IL-4; IL-5	RESPIRATORY SYNCYTIAL VIRUS; INTERFERON-GAMMA PRODUCTION; T-CELL-ACTIVATION; PERIPHERAL-BLOOD; IFN-GAMMA; INFANTS; INTERLEUKIN-4; EOSINOPHILIA; INFECTIONS; EXPRESSION	Background: The pathogenetic basis for the relationship between acute bronchiolitis and asthma has not yet been completely elucidated. Objective: The aim of this study was to compare these 2 diseases in terms of their patterns of airway cytokine response (T(H)1 or T(H)2). Methods: By using a bronchoalveolar lavage (BAL) technique, this study investigated the cytokine levels of BAL fluid in children with acute asthma who had no identifiable respiratory syncytial virus (RSV) infection (n = 18) and in infants with acute bronchiolitis caused by RSV (n = 22). Comparisons were made with normal control subjects (n = 14). IFN-gamma (T(H)1) and IL-4 and IL-5 (T(H)2) levels were measured in concentrated BAL fluids by means of ELISA. Results: The IL-5 level (P < .001) and IL-5/IFN-gamma ratio (P < .001) were significantly increased in the asthmatic group with no identifiable RSV infection and in the RSV-induced bronchiolitis group compared with values in the control group. When infants in the bronchiolitis group were divided into eosinophil-positive and eosinophil-negative subgroups, the eosinophil-positive subgroup had significantly increased IL-5 levels (P < .001) and IL-5/IFN-gamma ratios (P < .01) compared with those in the control group, but similar cytokine responses were not induced in the eosinophil-negative subgroup. The percentage of BAL eosinophils correlated significantly with levels of BAL IL-5 in both the asthma group (r = 0.80, P = .000) and the bronchiolitis group (r = 0.82, P = .000). Conclusions: These findings suggest that a subgroup of the RSV-induced bronchiolitis group results in a T(H)2-type response, and this could provide a valuable framework to explain the link between RSV-induced bronchiolitis and asthma.	Seoul Natl Univ Hosp, Dept Pediat, Seoul 110744, South Korea; Inje Univ Sanggye Paik Hosp, Dept Pediat, Seoul, South Korea; Soonchunhyang Univ Hosp, Dept Internal Med, Seoul, South Korea; Seoul Natl Univ Hosp, Clin Res Inst, Seoul 110744, South Korea	Seoul National University (SNU); Seoul National University Hospital; Inje University; Soonchunhyang University; Soonchunhyang University Hospital; Seoul National University (SNU); Seoul National University Hospital	Koh, YY (corresponding author), Seoul Natl Univ Hosp, Dept Pediat, 28 Yongon Dong, Seoul 110744, South Korea.		Kim, Beyong Il/J-5396-2012; Koh, Young Yull/D-6059-2012; Koh, Young Yull/J-5368-2012					Aberle JH, 1999, AM J RESP CRIT CARE, V160, P1263, DOI 10.1164/ajrccm.160.4.9812025; ALWAN WH, 1992, CLIN EXP IMMUNOL, V88, P527; Bont L, 2000, AM J RESP CRIT CARE, V161, P1518, DOI 10.1164/ajrccm.161.5.9904078; BROIDE DH, 1992, J ALLERGY CLIN IMMUN, V89, P958, DOI 10.1016/0091-6749(92)90218-Q; DERISH MT, 1991, J PEDIATR-US, V119, P761, DOI 10.1016/S0022-3476(05)80295-1; Djukanovic R, 1998, EUR RESPIR J, V11, p39S; Ehlenfield DR, 2000, PEDIATRICS, V105, P79, DOI 10.1542/peds.105.1.79; Everard ML, 1996, LANCET, V348, P279, DOI 10.1016/S0140-6736(05)64467-4; GAROFALO R, 1992, J PEDIATR-US, V120, P28, DOI 10.1016/S0022-3476(05)80592-X; GemouEngesaeth V, 1997, PEDIATRICS, V99, P695, DOI 10.1542/peds.99.5.695; Gern JE, 2000, J ALLERGY CLIN IMMUN, V106, P201, DOI 10.1067/mai.2000.108604; GLEZEN WP, 1973, NEW ENGL J MED, V288, P498, DOI 10.1056/NEJM197303082881005; Harrison AM, 1999, AM J RESP CRIT CARE, V159, P1918, DOI 10.1164/ajrccm.159.6.9805083; Haslam PL, 1999, EUR RESPIR J, V14, P245, DOI 10.1034/j.1399-3003.1999.14b01.x; KAUL A, 1978, AM J DIS CHILD, V132, P1088, DOI 10.1001/archpedi.1978.02120360044006; Kelly EAB, 1997, AM J RESP CRIT CARE, V156, P1421, DOI 10.1164/ajrccm.156.5.9703054; Kim CK, 2000, J PEDIATR-US, V137, P517, DOI 10.1067/mpd.2000.108392; Krawiec ME, 2001, AM J RESP CRIT CARE, V163, P1338, DOI 10.1164/ajrccm.163.6.2005116; Martinez FD, 1998, J ALLERGY CLIN IMMUN, V102, P915, DOI 10.1016/S0091-6749(98)70328-8; Pizzichini E, 1998, EUR RESPIR J, V11, P828, DOI 10.1183/09031936.98.11040828; RATJEN F, 1994, EUR RESPIR J, V7, P1865, DOI 10.1183/09031936.94.07101865; Renzi PM, 1999, AM J RESP CRIT CARE, V159, P1417, DOI 10.1164/ajrccm.159.5.9805080; RIEDLER J, 1995, AM J RESP CRIT CARE, V152, P163, DOI 10.1164/ajrccm.152.1.7599817; ROBINSON D, 1993, AM REV RESPIR DIS, V148, P401, DOI 10.1164/ajrccm/148.2.401; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROBINSON DS, 1993, THORAX, V48, P845, DOI 10.1136/thx.48.8.845; Roman M, 1997, AM J RESP CRIT CARE, V156, P190, DOI 10.1164/ajrccm.156.1.9611050; Schwarze J, 1999, J IMMUNOL, V162, P4207; Schwarze J, 1999, J IMMUNOL, V162, P2997; Smart JM, 2001, PEDIATR ALLERGY IMMU, V12, P181, DOI 10.1034/j.1399-3038.2001.012004181.x; Thurau AM, 1998, CLIN EXP IMMUNOL, V113, P450; van Schaik SM, 1999, J ALLERGY CLIN IMMUN, V103, P630, DOI 10.1016/S0091-6749(99)70235-6; VERCELLI D, 1990, J IMMUNOL, V144, P570; WALKER C, 1992, AM REV RESPIR DIS, V146, P109, DOI 10.1164/ajrccm/146.1.109; WALTERS EH, 1991, THORAX, V46, P613, DOI 10.1136/thx.46.9.613; Wang SZ, 1998, AM J PHYSIOL-LUNG C, V275, pL983, DOI 10.1152/ajplung.1998.275.5.L983; WARNER JO, 1992, ARCH DIS CHILD, V67, P240; WELLIVER RC, 1981, NEW ENGL J MED, V305, P841, DOI 10.1056/NEJM198110083051501; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001, DOI 10.1164/ajrccm.160.3.9812110	40	80	82	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2003	112	1					64	71		10.1067/mai.2003.1618	http://dx.doi.org/10.1067/mai.2003.1618			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	698QQ	12847481				2022-12-18	WOS:000184010600011
J	Leung, TF; Wong, CK; Chan, IHS; Ip, WK; Lam, CWK; Wong, GWK				Leung, TF; Wong, CK; Chan, IHS; Ip, WK; Lam, CWK; Wong, GWK			Plasma concentration of thymus and activation-regulated chemokine is elevated in childhood asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; atop immunoglobulin E; spirometry thymus and activation-regulated chemokine	EXHALED NITRIC-OXIDE; ATOPIC-DERMATITIS; TARC; CELLS; HYPERRESPONSIVENESS; RESPONSIVENESS; INFLAMMATION; LYMPHOCYTES; RECRUITMENT; EXPRESSION	Background: Thymus and activation-regulated chemokine (TARC) is responsible for the trafficking of T(H)2 lymphocytes into sites of allergic inflammation. Serum TARC levels correlate with the severity of atopic dermatitis. The relationship between this marker and the occurrence and severity of asthma has not been evaluated. Objective: We tested whether plasma TARC level is a useful marker for asthma and atopy in children. Methods: Plasma total IgE levels were measured by means of microparticle immunoassay, and specific IgE levels to common aeroallergens were measured by, using a fluorescent enzyme immunoassay. We used a sandwich enzyme immunoassay to measure plasma TARC concentrations. Results: Sixty asthmatic children and 28 age- and sex-matched control subjects were recruited, with mean logarithmic plasma total IgE levels of 2.66 +/- 0.60 kIU/L and 1.74 +/- 0.58 kIU/L, respectively (P<.0001). The median plasma TARC concentration was higher in asthmatic patients without inhaled corticosteroid treatment (131.0 pg/mL) compared with those seen in steroid-treated patients (97.5 pg/ml.) and control subjects (76.0 pg/ml,; P=.01 and P<.0001, respectively,). Plasma TARC concentration was found to correlate with total IgE level in plasma (r=0.219, P=.04). This marker was also increased in subjects who were sensitized to cat allergen (P=.001) but not in subjects sensitized to other aeroallergens. Disease severity, score, FEV1 value, and atopy were not associated with increased plasma TARC levels. Conclusion: Our results suggest that plasma TARC concentrations are elevated in childhood asthma. This marker is also linked to plasma total IgE levels and cat allergen sensitization.	Chinese Univ Hong Kong, Prince Wales Hosp, Dept Pediat, Shatin, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Prince Wales Hosp, Dept Chem Pathol, Shatin, Hong Kong, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital	Leung, TF (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Pediat, 6-F,Clin Sci Bldg, Shatin, Hong Kong, Peoples R China.		LEUNG, Ting Fan/E-7728-2013; Wong, Gary WK/AAY-9207-2020; Wong, CK/H-3256-2016	LEUNG, Ting Fan/0000-0002-6469-1926; Wong, Gary WK/0000-0001-5939-812X; Wong, CK/0000-0002-5637-8331				[Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; [Anonymous], 1987, AM REV RESPIR DIS, V136, P225; Beasley R, 2000, J ALLERGY CLIN IMMUN, V105, pS466, DOI 10.1016/S0091-6749(00)90044-7; Berin MC, 2001, AM J RESP CELL MOL, V24, P382, DOI 10.1165/ajrcmb.24.4.4360; Bonecchi R, 1998, J EXP MED, V187, P129, DOI 10.1084/jem.187.1.129; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BROOKS SM, 1990, J ALLERGY CLIN IMMUN, V85, P17, DOI 10.1016/0091-6749(90)90216-Q; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; de Lavareille A, 2001, EUR J IMMUNOL, V31, P1037, DOI 10.1002/1521-4141(200104)31:4<1037::AID-IMMU1037>3.0.CO;2-#; Imai T, 1997, J BIOL CHEM, V272, P15036, DOI 10.1074/jbc.272.23.15036; Imai T, 1996, J BIOL CHEM, V271, P21514, DOI 10.1074/jbc.271.35.21514; Imai T, 1999, INT IMMUNOL, V11, P81, DOI 10.1093/intimm/11.1.81; Kakinuma T, 2001, J ALLERGY CLIN IMMUN, V107, P535, DOI 10.1067/mai.2001.113237; Kawasaki S, 2001, J IMMUNOL, V166, P2055, DOI 10.4049/jimmunol.166.3.2055; Lai CKW, 1996, CLIN EXP ALLERGY, V26, P5, DOI 10.1111/j.1365-2222.1996.tb00050.x; LAM KK, 1983, BRIT J DIS CHEST, V77, P390, DOI 10.1016/S0007-0971(83)80076-X; Lloyd CM, 2000, J EXP MED, V191, P265, DOI 10.1084/jem.191.2.265; *NIH NAT HEART LUN, 1998, PUBL NIH NAT HEART L; Nomiyama H, 1997, GENOMICS, V40, P211, DOI 10.1006/geno.1996.4552; Panina-Bordignon P, 2001, J CLIN INVEST, V107, P1357, DOI 10.1172/JCI12655; Piacentini GL, 2000, EUR RESPIR J, V15, P839, DOI 10.1034/j.1399-3003.2000.15e05.x; Romagnani S, 2000, J ALLERGY CLIN IMMUN, V105, P399, DOI 10.1067/mai.2000.104575; Rosa-Rosa L, 1999, J ALLERGY CLIN IMMUN, V104, P1008, DOI 10.1016/S0091-6749(99)70082-5; Silvestri M, 2001, THORAX, V56, P857, DOI 10.1136/thorax.56.11.857; Terada N, 2001, CLIN EXP ALLERGY, V31, P1923, DOI 10.1046/j.1365-2222.2001.01152.x; Vestergaard C, 2000, J INVEST DERMATOL, V115, P640, DOI 10.1046/j.1523-1747.2000.00115.x; Vestergaard C, 1999, J CLIN INVEST, V104, P1097, DOI 10.1172/JCI7613; Wong GWK, 2001, CLIN EXP ALLERGY, V31, P1225, DOI 10.1046/j.1365-2222.2001.01140.x; Zimmerman B, 2000, J ALLERGY CLIN IMMUN, V105, P495, DOI 10.1067/mai.2000.104933	29	80	84	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2002	110	3					404	409		10.1067/mai.2002.126378	http://dx.doi.org/10.1067/mai.2002.126378			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	592KM	12209086	Bronze			2022-12-18	WOS:000177936900009
J	Buckley, RH				Buckley, RH			Primary cellular immunodeficiencies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						severe combined immunodeficiency; T-cell activation defects; combined immunodeficiency; bone marrow transplantation; gene therapy	WISKOTT-ALDRICH-SYNDROME; BONE-MARROW TRANSPLANTATION; RECEPTOR-GAMMA-CHAIN; CLASS-II DEFICIENCY; ADENOSINE-DEAMINASE DEFICIENCY; COMBINED IMMUNE-DEFICIENCY; BARE LYMPHOCYTE SYNDROME; DIGEORGE-SYNDROME; ATAXIA-TELANGIECTASIA; GENE-THERAPY	Genetic defects in T-cell function lead to susceptibility to infections or to other clinical problems that are more grave than those seen in disorders resulting in antibody deficiency alone. Those affected usually present during infancy with either common or opportunistic infections and rarely survive beyond infancy or childhood. The spectrum of T-cell defects ranges from the syndrome of severe combined immunodeficiency, in which T-cell function is absent, to combined immunodeficiency disorders in which there is some, but not adequate, T-cell function for a normal life span. Recent discoveries of the molecular causes of many of these defects have led to a new understanding of the flawed biology underlying the ever-growing number of defects. Most of these conditions could be diagnosed by means of screening for lymphopenia or for T-cell deficiency in cord blood at birth. Early recognition of those so afflicted is essential to the application of the most appropriate treatments for these conditions at a very early age. The latter treatments include both transplantation and gene therapy in addition to immunoglobulin replacement. Fully defining the molecular defects of such patients is also essential for genetic counseling of family members and prenatal diagnosis.	Duke Univ, Med Ctr, Dept Pediat, Div Allergy & Immunol, Durham, NC 27710 USA	Duke University	Buckley, RH (corresponding author), Duke Univ, Med Ctr, Dept Pediat, Div Allergy & Immunol, Box 2898, Durham, NC 27710 USA.		Buckley, Rebecca/AAB-1578-2019					Altman PL, 1961, BLOOD OTHER BODY FLU, P125; [Anonymous], 1999, PRIMARY IMMUNODEFICI; Ariga T, 1997, PEDIATR RES, V41, P535, DOI 10.1203/00006450-199704000-00013; ARNAIZVILLENA A, 1992, NEW ENGL J MED, V327, P529, DOI 10.1056/NEJM199208203270805; ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; Aspenstrom P, 1996, CURR BIOL, V6, P70, DOI 10.1016/S0960-9822(02)00423-2; BASILE GD, 1989, LANCET, V2, P1319; Basile GD, 1996, J PEDIATR-US, V129, P56, DOI 10.1016/S0022-3476(96)70190-7; Beamish H, 1996, J BIOL CHEM, V271, P20486, DOI 10.1074/jbc.271.34.20486; Brooks EG, 1999, BLOOD, V93, P242, DOI 10.1182/blood.V93.1.242.401k27_242_250; Broome CB, 1996, J PEDIATR-US, V128, P373, DOI 10.1016/S0022-3476(96)70285-8; BRUTON OC, 1952, PEDIATRICS, V9, P722; Buckley RH, 1999, PRIMARY IMMUNODEFICIENCY DISEASES, P459; Buckley RH, 2000, NEW ENGL J MED, V343, P1313, DOI 10.1056/NEJM200011023431806; Buckley RH, 1999, NEW ENGL J MED, V340, P508, DOI 10.1056/NEJM199902183400703; Buckley RH, 1997, J PEDIATR-US, V130, P378, DOI 10.1016/S0022-3476(97)70199-9; BUCKLEY RH, 1991, NEW ENGL J MED, V325, P110, DOI 10.1056/NEJM199107113250207; Buckley RH, 2000, IMMUNOL RES, V22, P237, DOI 10.1385/IR:22:2-3:237; BUDARF ML, 1995, NAT GENET, V10, P269, DOI 10.1038/ng0795-269; Candotti F, 2000, PEDIATR CLIN N AM, V47, P1389, DOI 10.1016/S0031-3955(05)70277-7; Candotti F, 1999, PRIMARY IMMUNODEFICIENCY DISEASES, P111; Cavazzana-Calvo M, 2000, SCIENCE, V288, P669, DOI 10.1126/science.288.5466.669; Conley ME, 1999, CLIN IMMUNOL, V93, P190, DOI 10.1006/clim.1999.4799; CONLEY ME, 1990, J CLIN INVEST, V85, P1548, DOI 10.1172/JCI114603; CORMIERDAIRE V, 1995, AM J MED GENET, V56, P39, DOI 10.1002/ajmg.1320560111; Corneo B, 2001, BLOOD, V97, P2772, DOI 10.1182/blood.V97.9.2772; Daw SCM, 1996, NAT GENET, V13, P458, DOI 10.1038/ng0896-458; de la Salle H, 1999, J CLIN INVEST, V103, pR9, DOI 10.1172/JCI5687; DELASALLE H, 1994, SCIENCE, V265, P237, DOI 10.1126/science.7517574; DEMCZUK S, 1995, HUM GENET, V96, P9, DOI 10.1007/BF00214179; DEMCZUK S, 1995, ANN GENET-PARIS, V38, P59; DERRY JM, 1994, CELL, V79, pA922; DERRY JMJ, 1994, CELL, V78, P635, DOI 10.1016/0092-8674(94)90528-2; DONATO L, 1995, J PEDIATR-US, V127, P895, DOI 10.1016/S0022-3476(95)70024-2; Driscoll DA, 1999, PRIMARY IMMUNODEFICIENCY DISEASES, P198; Durand B, 1997, EMBO J, V16, P1045, DOI 10.1093/emboj/16.5.1045; Elder ME, 1996, PEDIATR RES, V39, P743, DOI 10.1203/00006450-199605000-00001; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; Filipovich AH, 2001, BLOOD, V97, P1598, DOI 10.1182/blood.V97.6.1598; Filipovich AH, 1997, J ALLERGY CLIN IMMUN, V99, P415; Finan PM, 1996, J BIOL CHEM, V271, P26291, DOI 10.1074/jbc.271.42.26291; Fischer A, 2000, CLIN EXP IMMUNOL, V122, P143, DOI 10.1046/j.1365-2249.2000.01359.x; Fischer A, 2000, IMMUNOL REV, V178, P13, DOI 10.1034/j.1600-065X.2000.17806.x; Furukawa H, 1999, J CLIN INVEST, V103, P755, DOI 10.1172/JCI5335; GATTI RA, 1991, MEDICINE, V70, P99, DOI 10.1097/00005792-199103000-00003; Gilad S, 1998, AM J HUM GENET, V62, P551, DOI 10.1086/301755; GLANZMANN E, 1950, ANN PAEDIAT, V174, P1; GOLDSOBEL AB, 1987, J PEDIATR-US, V111, P40, DOI 10.1016/S0022-3476(87)80339-6; Gong WK, 1996, HUM MOL GENET, V5, P789, DOI 10.1093/hmg/5.6.789; GRANDEA AG, 1995, SCIENCE, V270, P105, DOI 10.1126/science.270.5233.105; Greer WL, 1996, HUM GENET, V98, P685, DOI 10.1007/s004390050285; Haddad E, 2001, BLOOD, V97, P33, DOI 10.1182/blood.V97.1.33; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; Heintz N, 1996, CURR OPIN NEUROL, V9, P137, DOI 10.1097/00019052-199604000-00014; Henwood J, 1996, J IMMUNOL, V156, P895; HERSHFIELD MS, 1995, CLIN IMMUNOL IMMUNOP, V76, pS228, DOI 10.1016/S0090-1229(95)90306-2; HERSHFIELD MS, 1995, HUM MUTAT, V5, P107, DOI 10.1002/humu.1380050202; HERSHFIELD MS, 1987, NEW ENGL J MED, V316, P589, DOI 10.1056/NEJM198703053161005; Hirschhorn R, 1999, PRIMARY IMMUNODEFICIENCY DISEASES, P121; HONG R, 1991, Immunodeficiency Reviews, V3, P1; INOUE R, 1995, SCAND J IMMUNOL, V41, P188, DOI 10.1111/j.1365-3083.1995.tb03552.x; Jawad AF, 2001, J PEDIATR-US, V139, P715, DOI 10.1067/mpd.2001.118534; Jirapongsananuruk O, 1999, CLIN EXP IMMUNOL, V118, P1; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; JUNKER AK, 1995, J PEDIATR-US, V127, P231, DOI 10.1016/S0022-3476(95)70300-4; KAWAMURA M, 1994, P NATL ACAD SCI USA, V91, P6374, DOI 10.1073/pnas.91.14.6374; KLEIN C, 1993, J PEDIATR-US, V123, P921, DOI 10.1016/S0022-3476(05)80388-9; Kohn DB, 1998, NAT MED, V4, P775, DOI 10.1038/nm0798-775; Kokron CM, 1997, J CLIN IMMUNOL, V17, P109, DOI 10.1023/A:1027322314256; KONDOH T, 1995, AM J MED GENET, V60, P364, DOI 10.1002/ajmg.1320600504; Kung C, 2000, NAT MED, V6, P343; KURAHASHI H, 1995, HUM MOL GENET, V4, P541, DOI 10.1093/hmg/4.4.541; KWAN SP, 1995, P NATL ACAD SCI USA, V92, P4706, DOI 10.1073/pnas.92.10.4706; Lavin MF, 1999, PRIMARY IMMUNODEFICIENCY DISEASES, P306; Lipson A, 1996, AM J MED GENET, V65, P304, DOI 10.1002/(SICI)1096-8628(19961111)65:4<304::AID-AJMG11>3.0.CO;2-Y; Litzman J, 1996, ARCH DIS CHILD, V75, P436, DOI 10.1136/adc.75.5.436; Llevadot R, 1996, MAMM GENOME, V7, P911, DOI 10.1007/s003359900268; MACCHI P, 1995, NATURE, V377, P65, DOI 10.1038/377065a0; MARKERT M L, 1991, Immunodeficiency Reviews, V3, P45; Markert ML, 1999, NEW ENGL J MED, V341, P1180, DOI 10.1056/NEJM199910143411603; MARTIN JV, 1995, AM J SURG PATHOL, V19, P1082, DOI 10.1097/00000478-199509000-00013; Masternak K, 1998, NAT GENET, V20, P273, DOI 10.1038/3081; MULLEN CA, 1993, BLOOD, V82, P2961; Myers LA, 2002, BLOOD, V99, P872, DOI 10.1182/blood.V99.3.872; NEGISHI I, 1995, NATURE, V376, P435, DOI 10.1038/376435a0; Nicolas N, 1998, J EXP MED, V188, P627, DOI 10.1084/jem.188.4.627; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; Ochs HD, 1999, PRIMARY IMMUNODEFICIENCY DISEASES, P292; Pannicke U, 1996, HUM GENET, V98, P706, DOI 10.1007/s004390050290; Parolini O, 1998, NEW ENGL J MED, V338, P291, DOI 10.1056/NEJM199801293380504; Patel DD, 2000, NEW ENGL J MED, V342, P1325, DOI 10.1056/NEJM200005043421804; PUCK JM, 1993, HUM MOL GENET, V2, P1099, DOI 10.1093/hmg/2.8.1099; PUCK JM, 1993, AM J HUM GENET, V53, P176; Puck JM, 1996, IMMUNOL TODAY, V17, P507, DOI 10.1016/0167-5699(96)30062-5; PUCL A, 1998, NAT GENET, V20, P394; Rieux-Laucat F, 1998, J CLIN INVEST, V102, P312, DOI 10.1172/JCI332; Rocca B, 1996, BLOOD, V87, P4538, DOI 10.1182/blood.V87.11.4538.bloodjournal87114538; Rong SB, 2000, J MOL MED, V78, P530, DOI 10.1007/s001090000136; RUSSELL SM, 1995, SCIENCE, V270, P797, DOI 10.1126/science.270.5237.797; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; Saito S, 1996, BLOOD, V87, P3344, DOI 10.1182/blood.V87.8.3344.bloodjournal8783344; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Schindelhauer D, 1996, HUM GENET, V98, P68, DOI 10.1007/s004390050162; SCHUFFENHAUER S, 1995, ANN GENET-PARIS, V38, P162; Schwartz M, 1996, THROMB HAEMOSTASIS, V75, P546; Schwarz K, 1996, SCIENCE, V274, P97, DOI 10.1126/science.274.5284.97; Schwarz K, 1996, IMMUNOL TODAY, V17, P496, DOI 10.1016/0167-5699(96)30061-3; Schwarz K, 1999, PRIMARY IMMUNODEFICIENCY DISEASES, P155; SOUDAIS C, 1993, NAT GENET, V3, P77, DOI 10.1038/ng0193-77; STEIMLE V, 1995, GENE DEV, V9, P1021, DOI 10.1101/gad.9.9.1021; STEPHAN JL, 1993, J PEDIATR-US, V123, P564, DOI 10.1016/S0022-3476(05)80951-5; SULLIVAN KE, 1994, J PEDIATR-US, V125, P876, DOI 10.1016/S0022-3476(05)82002-5; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; TACCIOLI GE, 1995, CURR OPIN IMMUNOL, V7, P436, DOI 10.1016/0952-7915(95)80085-9; Taylor AMR, 1996, BLOOD, V87, P423, DOI 10.1182/blood.V87.2.423.bloodjournal872423; Tchilian EZ, 2001, J IMMUNOL, V166, P1308, DOI 10.4049/jimmunol.166.2.1308; Teisserenc H, 1997, IMMUNOL LETT, V57, P183, DOI 10.1016/S0165-2478(97)00072-2; THOENES G, 1992, J BIOL CHEM, V267, P487; Villa A, 1998, CELL, V93, P885, DOI 10.1016/S0092-8674(00)81448-8; Vosshenrich CAJ, 2001, CURR BIOL, V11, pR175, DOI 10.1016/S0960-9822(01)00087-2; Watson HG, 1997, LANCET, V349, P179, DOI 10.1016/S0140-6736(05)60980-4; Webber SA, 1996, J PEDIATR-US, V129, P26, DOI 10.1016/S0022-3476(96)70186-5; WENGLER G, 1995, BLOOD, V85, P2471, DOI 10.1182/blood.V85.9.2471.bloodjournal8592471; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; Yin EZ, 2001, AM J ROENTGENOL, V176, P1541; ZHOU H, 1995, IMMUNITY, V2, P545, DOI 10.1016/1074-7613(95)90034-9	128	80	89	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2002	109	5					747	757		10.1067/mai.2002.123617	http://dx.doi.org/10.1067/mai.2002.123617			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	553QW	11994695				2022-12-18	WOS:000175687800001
J	Tankersley, MS; Walker, RL; Butler, WK; Hagan, LL; Napoli, DC; Freeman, TM				Tankersley, MS; Walker, RL; Butler, WK; Hagan, LL; Napoli, DC; Freeman, TM			Safety and efficacy of an imported fire ant rush immunotherapy protocol with and without prophylactic treatment	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						imported fire ant; whole body extract; Hymenoptera; immunotherapy	RAPID VENOM IMMUNOTHERAPY; PLACEBO-CONTROLLED TRIAL; HYMENOPTERA VENOM; SOLENOPSIS-INVICTA; STING ALLERGY; PRETREATMENT; HYPERSENSITIVITY; SENSITIVITY; REDUCTION; HISTORY	Background: Hypersensitivity to the sting of the imported fire ant (IFA) is a growing and significant cause of morbidity and mortality in the United States. Conventional immunotherapy with IFA whole body extract (WBE) has been shown to be effective; however, rush immunotherapy (RIT) with IFA WBE has not been studied. Objective: In this study, we evaluated the safety and efficacy of RIT with IFA WBE and sought to determine whether prophylactic pretreatment with antihistamines and steroids reduces the systemic reaction rate associated with RIT. Methods: Patients with IFA hypersensitivity were randomized to placebo or twice-daily terfenadine 60 mg, ranitidine 150 mg, and prednisone 30 mg initiated 2 days before RIT in a double-blinded study. The 2-day RIT protocol consisted of hourly injections to achieve a final dose of 0.3 mL 1:100 wt/vol. Patients returned on day 8 to receive 2 hourly injections of 0.25 mL 1: 100 wt/vol (total, 0.5 mL) and again on day 15 for a single injection of 0.5 mL 1:100 wt/vol. Efficacy of the protocol was determined on day 22, a pair of IFA sting challenges being performed 2 hours apart. Results: Fifty-nine patients were enrolled into the study; a total of 58 patients (age range, 18 to 49 years) initiated the 2-day RIT. Only 3 patients (5.2%) experienced a mild systemic reaction during the protocol. Among those experiencing a systemic reaction with RIT, there was no statistical difference between the 2 premedication groups (3.6% active and 6.7% placebo, P = .87). Sting challenges were performed on 56 patients for a total of 112+ stings; only 1 mild systemic reaction occurred (efficacy, 98.2%). Conclusion: RIT with IFA WBE for IFA hypersensitivity is both safe and efficacious; the rate of mild systemic reactions is low. Premedication is not necessary, inasmuch as prophylactic pretreatment with antihistamines and steroids did not reduce the systemic reaction rate associated with RIT.	Wilford Hall USAF Med Ctr, Allergy & Immunol Dept, Lackland AFB, TX 78236 USA	United States Department of Defense; United States Air Force	Freeman, TM (corresponding author), 59th Med Wing,MMIA,2200 Bergquist Dr,Suite 1, Lackland AFB, TX 78236 USA.							BERCHTOLD E, 1992, CLIN EXP ALLERGY, V22, P59, DOI 10.1111/j.1365-2222.1992.tb00115.x; BERNSTEIN DI, 1989, J ALLERGY CLIN IMMUN, V84, P951, DOI 10.1016/0091-6749(89)90394-1; BERNSTEIN JA, 1994, ANN ALLERGY, V73, P423; BOUSQUET J, 1987, ALLERGY, V42, P401, DOI 10.1111/j.1398-9995.1987.tb00355.x; Brockow K, 1997, J ALLERGY CLIN IMMUN, V100, P458, DOI 10.1016/S0091-6749(97)70135-0; DESHAZO RD, 1994, J ALLERGY CLIN IMMUN, V93, P847, DOI 10.1016/0091-6749(94)90376-X; deShazo RD, 1999, ANN INTERN MED, V131, P424, DOI 10.7326/0003-4819-131-6-199909210-00005; FREEMAN TM, 1992, J ALLERGY CLIN IMMUN, V90, P210, DOI 10.1016/0091-6749(92)90073-B; Freeman TM, 1997, ANN ALLERG ASTHMA IM, V78, P369, DOI 10.1016/S1081-1206(10)63198-5; Graft DF, 1998, J ALLERGY CLIN IMMUN, V101, P573, DOI 10.1016/S0091-6749(98)70161-7; GRAFT DF, 1994, ANN ALLERGY, V73, P481; HARDWICK WE, 1992, PEDIATRICS, V90, P622; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; Insect Allergy Committee of the American Academy of Allergy, 1965, JAMA-J AM MED ASSOC, V193, P109; Kemp SF, 2000, J ALLERGY CLIN IMMUN, V105, P683, DOI 10.1067/mai.2000.105707; LOCKERY RF, 1995, MONOGRAPH INSECT ALL, P81; LOCKEY RF, 1988, J ALLERGY CLIN IMMUN, V82, P370, DOI 10.1016/0091-6749(88)90008-5; LOCKEY RF, 1990, J ALLERGY CLIN IMMUN, V86, P775, DOI 10.1016/S0091-6749(05)80182-4; NATAF P, 1984, CLIN ALLERGY, V14, P269, DOI 10.1111/j.1365-2222.1984.tb02206.x; PRINCE HOMER E., 1939, JOUR ALLERGY, V10, P379, DOI 10.1016/S0021-8707(39)90153-X; Reimers A, 2000, ALLERGY, V55, P484, DOI 10.1034/j.1398-9995.2000.00520.x; RHOADES RB, 1989, J ALLERGY CLIN IMMUN, V84, P159, DOI 10.1016/0091-6749(89)90319-9; RHOADES RB, 1977, J FLA MED ASSOC, V64, P247; Schmidt M, 1996, J ALLERGY CLIN IMMUN, V98, P82, DOI 10.1016/S0091-6749(96)70229-4; STAFFORD CT, 1992, J ALLERGY CLIN IMMUN, V90, P653, DOI 10.1016/0091-6749(92)90139-S; TARHINI H, 1992, J ALLERGY CLIN IMMUN, V89, P1198, DOI 10.1016/0091-6749(92)90306-M; TRACY JM, 1995, J ALLERGY CLIN IMMUN, V95, P824, DOI 10.1016/S0091-6749(95)70125-7; TRIPLETT RF, 1973, SOUTHERN MED J, V66, P477, DOI 10.1097/00007611-197304000-00019; YUNGINGER JW, 1979, J ALLERGY CLIN IMMUN, V63, P340, DOI 10.1016/0091-6749(79)90129-5	29	80	83	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2002	109	3					556	562		10.1067/mai.2002.121956	http://dx.doi.org/10.1067/mai.2002.121956			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	534KW	11898006	Green Submitted			2022-12-18	WOS:000174586400026
J	Nouri-Aria, KT; Irani, AMA; Jacobson, MR; O'Brien, F; Varga, EM; Till, SJ; Durham, SR; Schwartz, LB				Nouri-Aria, KT; Irani, AMA; Jacobson, MR; O'Brien, F; Varga, EM; Till, SJ; Durham, SR; Schwartz, LB			Basophil recruitment and IL-4 production during human allergen-induced late asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; late asthmatic responses; basophils; IL-4	COLONY-STIMULATING FACTOR; PHASE CUTANEOUS REACTIONS; MESSENGER-RNA; MAST-CELLS; BLOOD BASOPHILS; ATOPIC SUBJECTS; T-CELLS; INTERLEUKIN-3 IL-3; BRONCHIAL BIOPSIES; NONATOPIC ASTHMA	Background: Basophils represent an important source of inflammatory mediators and cytokines after IgE-dependent activation in human beings. Objective: To assess the role of basophils in allergic asthma, we measured the number of basophils in the bronchial mucosa and their capacity to express IL-4 mRNA and protein during allergen-induced late asthmatic responses. Methods: Fiberoptic bronchoscopic bronchial biopsies were obtained at 24 hours from sites of segmental bronchial allergen challenge and control sites in 19 patients with atopic asthma and 6 nonatopic healthy volunteers. Basophil numbers were assessed by immunohistochemistry through use of mAb 2D7. IL-4 mRNA-positive cells were detected through use of in situ hybridization and colocalized to basophils through use of sequential immunohistochemistry/in situ hybridization. IL-4 protein was detected and colocalized to basophils through use of dual immunohistochemistry. Results: After allergen challenge, there was an increase in the median number of 2D7-positive basophils per square millimeter in the bronchial mucosa in patients with asthma (0.9 cells/mm(2) at baseline to 8.8 cells/mm(2) after challenge; P=.002), which also was significantly higher than what was seen in nonasthmatic controls (P=.01). Similarly, IL-4 mRNA-positive cells were increased at 24 hours in patients with asthma (1.4 to 14) in comparison with controls (0 to 0; P=.02). Colocalization studies revealed that 15% and 41% of the basophil population in patients with asthma after allergen-challenge expressed, respectively, IL-4 mRNA and protein. Conversely, 19% of IL-4 mRNA-positive cells and 72% of IL-4 protein-positive cells were accounted for by basophils. Conclusion: After allergen provocation in sensitive patients with atopic asthma, basophils are recruited to the bronchial mucosa and express IL-4 mRNA and protein, which might contribute to local IgE synthesis and/or tissue eosinophilia or other aspects of allergic inflammation during late responses and ongoing asthma.	Natl Heart & Lung Inst, Imperial Coll Sch Med, Dept Upper Resp Med, London SW3 6LY, England; Royal Brompton Hosp, London SW3 6LY, England; Virginia Commonwealth Univ, Dept Pediat, Richmond, VA USA; Virginia Commonwealth Univ, Dept Internal Med, Div Rheumatol, Richmond, VA USA; Virginia Commonwealth Univ, Dept Internal Med, Div Allergy, Richmond, VA USA; Virginia Commonwealth Univ, Dept Internal Med, Div Immunol, Richmond, VA USA	Imperial College London; Royal Brompton Hospital; Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University	Durham, SR (corresponding author), Natl Heart & Lung Inst, Imperial Coll Sch Med, Dept Upper Resp Med, Dovehouse St, London SW3 6LY, England.			Jacobson, Mikila/0000-0002-2921-6169; Till, Stephen/0000-0003-4518-3093	NIAMS NIH HHS [AR45441] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045441] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Black KM, 1996, INT ARCH ALLERGY IMM, V111, P142, DOI 10.1159/000237359; Borish LC, 1999, AM J RESP CRIT CARE, V160, P1816, DOI 10.1164/ajrccm.160.6.9808146; BRUNNER T, 1991, J IMMUNOL, V147, P237; BRUNNER T, 1993, J EXP MED, V177, P605, DOI 10.1084/jem.177.3.605; Dahinden CA, 1997, INT ARCH ALLERGY IMM, V113, P134, DOI 10.1159/000237527; GAUCHAT JF, 1993, NATURE, V365, P340, DOI 10.1038/365340a0; Gauvreau GM, 2000, AM J RESP CRIT CARE, V161, P1473, DOI 10.1164/ajrccm.161.5.9908090; Gibbs BF, 1996, EUR J IMMUNOL, V26, P2493, DOI 10.1002/eji.1830261033; GIBSON PG, 1992, CLIN EXP ALLERGY, V22, P525, DOI 10.1111/j.1365-2222.1992.tb00161.x; GUO CB, 1994, AM J RESP CELL MOL, V10, P384, DOI 10.1165/ajrcmb.10.4.7510984; Humbert M, 1996, AM J RESP CRIT CARE, V154, P1497, DOI 10.1164/ajrccm.154.5.8912771; ILIOPOULOS O, 1992, J IMMUNOL, V148, P2223; Irani AMA, 1998, J ALLERGY CLIN IMMUN, V101, P354, DOI 10.1016/S0091-6749(98)70248-9; KAY AB, 1991, J EXP MED, V173, P775, DOI 10.1084/jem.173.3.775; KEPLEY CL, 1995, J IMMUNOL, V154, P6548; Kon OM, 1998, ALLERGY, V53, P891, DOI 10.1111/j.1398-9995.1998.tb03997.x; Laberge S, 2000, J ALLERGY CLIN IMMUN, V106, P293; Li HM, 1996, J IMMUNOL, V157, P1207; Li HM, 1996, J IMMUNOL, V156, P4833; MacDonald KPA, 1997, J CLIN INVEST, V100, P2404, DOI 10.1172/JCI119781; Macfarlane AJ, 2000, J ALLERGY CLIN IMMUN, V105, P99, DOI 10.1016/S0091-6749(00)90184-2; MACGLASHAN D, 1994, J IMMUNOL, V152, P3006; Marone G, 1997, INT ARCH ALLERGY IMM, V114, P207, DOI 10.1159/000237670; MARUYAMA N, 1994, AM J RESP CRIT CARE, V150, P1086, DOI 10.1164/ajrccm.150.4.7921441; McEuen AR, 1999, LAB INVEST, V79, P27; Nouri-Aria KT, 2000, CLIN EXP ALLERGY, V30, P1709, DOI 10.1046/j.1365-2222.2000.00998.x; PRAT J, 1993, ALLERGY, V48, P587, DOI 10.1111/j.1398-9995.1993.tb00753.x; Schroeder JT, 1997, J ALLERGY CLIN IMMUN, V99, P429, DOI 10.1016/S0091-6749(97)70065-4; SCHROEDER JT, 1994, J ALLERGY CLIN IMMUN, V94, P1189, DOI 10.1016/0091-6749(94)90331-X; Varga EM, 2000, J IMMUNOL, V165, P2877, DOI 10.4049/jimmunol.165.5.2877; VARNEY VA, 1992, AM REV RESPIR DIS, V146, P170, DOI 10.1164/ajrccm/146.1.170; VERCELLI D, 1991, J ALLERGY CLIN IMMUN, V88, P285, DOI 10.1016/0091-6749(91)90087-5; VERCELLI D, 1992, CURR OPIN IMMUNOL, V4, P794, DOI 10.1016/0952-7915(92)90064-L; Ying S, 1997, J IMMUNOL, V158, P5050; Ying S, 1999, J IMMUNOL, V163, P3976; Ying S, 1997, J IMMUNOL, V158, P3539	36	80	85	0	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2001	108	2					205	211		10.1067/mai.2001.117175	http://dx.doi.org/10.1067/mai.2001.117175			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	465HY	11496235				2022-12-18	WOS:000170584600007
J	Zuberbier, T; Chong, SU; Grunow, K; Guhl, S; Welker, P; Grassberger, M; Henz, BM				Zuberbier, T; Chong, SU; Grunow, K; Guhl, S; Welker, P; Grassberger, M; Henz, BM			The ascomycin macrolactam pimecrolimus (Elidel, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophils	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						mast cell; allergy histamine; SDZ ASM 981; pimecrolimus; macrophilin; ascomycin	SKIN DISEASES; TNF-ALPHA; ANTIINFLAMMATORY DRUG; CYCLOSPORINE-A; IN-VITRO; TRYPTASE; SDZ-ASM-981; EXPRESSION; HISTAMINE; HETEROGENEITY	Background: The ascomycin macrolactam pimecrolimus (Elidel, SDZ ASM 981) has recently been developed as a novel and cell-selective inhibitor of inflammatory cytokine secretion; it has fewer adverse effects than currently available drugs. Objective: In this study, we investigated the capacity of pimecrolimus to directly inhibit in vitro mediator release from human skin mast cells and basophils. Methods: Purified cutaneous mast cells or basophil-containing peripheral blood leukocytes were obtained from healthy human donors and preincubated with pimecrolimus (0.1 nmol/L to 1 mu mol/L) in the absence or presence of its specific antagonist (rapamycin), cyclosporin A (100 nmol/L to 1 mu mol/L), or dexamethasone (1 mu mol/L) and then stimulated with anti-IgE or with calcium ionophore A23187 plus phorbol myristate acetate. Cell supernatants were kept for analysis of histamine, tryptase, LTC4, and TNF-alpha. Results: Pimecrolimus caused a strong and dose-dependent inhibition of anti-IgE-induced release of histamine from mast cells and basophils (maximally 73% and 82%, respectively, at 500 nmol/L pimecrolimus) and of mast cell tryptase (maximally 75%) and a less pronounced inhibition of LTC4 (maximally 32%) and of calcium ionophore plus phorbol myristate acetate-induced mast cell TNF-alpha release (90% maximum at 100 nmol/L pimecrolimus). In contrast, inhibition achieved during mast cell histamine release was maximally 60% with cyclosporin A and only 28% with dexamethasone. Conclusion: These data demonstrate a marked inhibitory capacity of pimecrolimus on mediator release from human mast cells and basophils with a potency exceeding that of cyclosporin A and dexamethasone. Pimecrolimus might thus be expected to be effective in the treatment of mast cell- and basophil-dependent diseases.	Humboldt Univ, Charite, Dept Dermatol & Allergy, D-10117 Berlin, Germany; Novartis Forsch Inst, Vienna, Austria	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Novartis	Zuberbier, T (corresponding author), Humboldt Univ, Charite, Dept Dermatol & Allergy, Schumannstr 20-21, D-10117 Berlin, Germany.							Ackermann L, 1998, ARCH DERMATOL RES, V290, P353, DOI 10.1007/s004030050317; Berger P, 1999, CLIN EXP ALLERGY, V29, P804; BIERER BE, 1990, SCIENCE, V250, P556, DOI 10.1126/science.1700475; Compton SJ, 1998, J IMMUNOL, V161, P1939; DEPAULIS A, 1992, J INVEST DERMATOL, V99, P723, DOI 10.1111/1523-1747.ep12614216; dePaulis A, 1997, ARTHRITIS RHEUM-US, V40, P469, DOI 10.1002/art.1780400313; Elbe-Burger A, 2000, J INVEST DERMATOL, V114, P219; Grassberger M, 1999, BRIT J DERMATOL, V141, P264; HARVIMA IT, 1988, BIOCHIM BIOPHYS ACTA, V957, P71, DOI 10.1016/0167-4838(88)90158-6; He SH, 1997, J IMMUNOL, V159, P6216; Hermes B, 1999, J ALLERGY CLIN IMMUN, V103, P307, DOI 10.1016/S0091-6749(99)70506-3; Hultsch T, 1998, ARCH DERMATOL RES, V290, P501, DOI 10.1007/s004030050343; HULTSCH T, 1991, P NATL ACAD SCI USA, V88, P6229, DOI 10.1073/pnas.88.14.6229; Kato M, 1999, ALLERGY, V54, P278, DOI 10.1034/j.1398-9995.1999.00942.x; Laan MP, 1998, ALLERGY, V53, P51, DOI 10.1111/j.1398-9995.1998.tb03773.x; LERNER NB, 1991, BLOOD, V77, P1876; Levi-Schaffer F, 1998, J IMMUNOL, V160, P5554; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LOWMAN MA, 1988, J ALLERGY CLIN IMMUN, V81, P574, DOI 10.1016/0091-6749(88)90199-6; Meingassner J., 2000, Journal of Investigative Dermatology, V114, P832; Meingassner JG, 1997, BRIT J DERMATOL, V137, P568, DOI 10.1111/j.1365-2133.1997.tb03788.x; Metcalfe DD, 1997, PHYSIOL REV, V77, P1033, DOI 10.1152/physrev.1997.77.4.1033; Neckermann G, 2000, BRIT J DERMATOL, V142, P669, DOI 10.1046/j.1365-2133.2000.03411.x; Noether G.E., 1991, INTRO STAT NONPARAME; Paul C, 2000, EXPERT OPIN INV DRUG, V9, P69, DOI 10.1517/13543784.9.1.69; Paul C, 1998, SEMIN CUTAN MED SURG, V17, P256, DOI 10.1016/S1085-5629(98)80021-7; Pearlman DS, 1999, J ALLERGY CLIN IMMUN, V104, pS132, DOI 10.1016/S0091-6749(99)70308-8; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SCHWARTZ LB, 1983, J IMMUNOL, V130, P1891; SIRAGANIAN RP, 1975, J IMMUNOL METHODS, V7, P283, DOI 10.1016/0022-1759(75)90025-3; STELLATO C, 1992, J INVEST DERMATOL, V98, P800, DOI 10.1111/1523-1747.ep12499960; STUETZ A, IN PRESS J EUR ACAD	32	80	85	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2001	108	2					275	280		10.1067/mai.2001.116865	http://dx.doi.org/10.1067/mai.2001.116865			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	465HY	11496246	Bronze			2022-12-18	WOS:000170584600018
J	Mygind, N; Nielsen, LP; Hoffmann, HJ; Shukla, A; Blumberga, G; Dahl, R; Jacobi, H				Mygind, N; Nielsen, LP; Hoffmann, HJ; Shukla, A; Blumberga, G; Dahl, R; Jacobi, H			Mode of action of intranasal corticosteroids	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						airway inflammation; allergic rhinitis; anti-inflammation effects; corticosteroids; eosinophils; Langerhans cells; lymphocytes; mast cells	SEASONAL ALLERGIC RHINITIS; MUCOSAL MAST-CELLS; HISTAMINE-RELEASING FACTORS; AQUEOUS NASAL SPRAY; BECLOMETHASONE DIPROPIONATE AEROSOL; BRONCHIAL EPITHELIAL-CELLS; MESSENGER-RNA EXPRESSION; NECROSIS-FACTOR-ALPHA; KAPPA-B ACTIVITY; FLUTICASONE PROPIONATE	The mode of action of intranasal corticosteroids (INCS) is complex. It is not known whether INCS penetrate the nasal mucosa or act on target cells; however, their low systemic activity supports the concept of local action on nasal mucosa. This local effect can nonetheless influence a variety of inflammatory cells and their mediators such as epithelial cells, lymphocytes, basophils, mast cells, and Langerhans cells. Corticosteroid-induced inhibition of immunoglobulin E-dependent release of histamine is a possible but unproven mode of action. Epithelial cells are an important target for corticosteroids, and INCS concentration is high at the epithelial surface. INCS may combine with the corticosteroid receptors in epithelial cells, which are then expelled into the airway lumen together with the dead epithelial cells or migrating inflammatory cells. A reduced influx of mediator cells may explain some of the effects of INCS on rhinitis symptoms, but it cannot explain all of the effects because INCS also reduce the early-phase sneezing and rhinorrhea after an allergen challenge outside the pollen season. In this situation, the number of surface mast cells/basophils is very I low, as it is in the absence of allergic rhinitis. The mechanism by which INCS treatment of allergic rhinitis reduces itching, sneezing, and rhinorrhea, the characteristic symptoms of an early-phase response involving mast cell release of histamine, remains to be determined. Studies should be conducted to characterize the broad range of mechanisms by which INCS produce their therapeutic effects in allergic rhinitis.	Aarhus Univ Hosp, Dept Resp Dis, DK-8000 Aarhus, Denmark; Natl Univ Hosp, Allergy Clin 7511, Copenhagen, Denmark	Aarhus University	Mygind, N (corresponding author), Aarhus Univ Hosp, Dept Resp Dis, DK-8000 Aarhus, Denmark.		Hoffman, Hans Jurgen/I-6969-2018; Dahl, Ronahl/F-8170-2013	Hoffman, Hans Jurgen/0000-0002-6743-7931; Nielsen, Lars Peter/0000-0001-7083-5781				ALAM R, 1994, J IMMUNOL, V153, P3155; ANDERSSON M, 1988, J ALLERGY CLIN IMMUN, V82, P1019, DOI 10.1016/0091-6749(88)90139-X; ANDERSSON M, 1989, ACTA OTO-LARYNGOL, V107, P270, DOI 10.3109/00016488909127508; Atsuta J, 1999, AM J RESP CELL MOL, V20, P643, DOI 10.1165/ajrcmb.20.4.3265; Baraniuk JN, 1997, J ALLERGY CLIN IMMUN, V99, pS763, DOI 10.1016/S0091-6749(97)70125-8; BAROODY F, 1989, J ALLERGY CLIN IMMUN, V82, P163; Baroody FM, 1998, AM J RESP CRIT CARE, V157, P899, DOI 10.1164/ajrccm.157.3.97-07060; BASCOM R, 1988, J ALLERGY CLIN IMMUN, V81, P570, DOI 10.1016/0091-6749(88)90198-4; BAUMGARTEN CR, 1985, J CLIN INVEST, V76, P191, DOI 10.1172/JCI111945; BENDE M, 1983, ALLERGY, V38, P461, DOI 10.1111/j.1398-9995.1983.tb02354.x; BENTLEY AM, 1992, J ALLERGY CLIN IMMUN, V89, P877, DOI 10.1016/0091-6749(92)90444-7; BIRCHALL MA, 1995, CLIN OTOLARYNGOL, V20, P204, DOI 10.1111/j.1365-2273.1995.tb01848.x; BISCHOFF SC, 1993, EUR J IMMUNOL, V23, P761, DOI 10.1002/eji.1830230329; Blom HM, 1997, J ALLERGY CLIN IMMUN, V100, P739, DOI 10.1016/S0091-6749(97)70267-7; Bochner BS, 1996, J IMMUNOL, V157, P844; BOCHNER BS, 1994, J ALLERGY CLIN IMMUN, V94, P427, DOI 10.1016/0091-6749(94)90195-3; BOCHNER BS, 1994, J ALLERGY CLIN IMMUN, V94, P1157, DOI 10.1016/0091-6749(94)90326-3; BORUM P, 1987, ALLERGY, V42, P26, DOI 10.1111/j.1398-9995.1987.tb02183.x; BRADDING P, 1995, AM J RESP CRIT CARE, V151, P1900, DOI 10.1164/ajrccm.151.6.7767538; BRADDING P, 1995, CLIN EXP ALLERGY, V25, P406, DOI 10.1111/j.1365-2222.1995.tb01071.x; BRADDING P, 1995, J IMMUNOL, V155, P297; BRADLEY R, 1993, WIDE ANGLE, V15, P1; Brostjan C, 1996, J BIOL CHEM, V271, P19612, DOI 10.1074/jbc.271.32.19612; BRUNNER T, 1993, J EXP MED, V177, P605, DOI 10.1084/jem.177.3.605; BUTTERFIELD JH, 1986, J ALLERGY CLIN IMMUN, V78, P450, DOI 10.1016/0091-6749(86)90032-1; Cameron LA, 1998, J ALLERGY CLIN IMMUN, V101, P330, DOI 10.1016/S0091-6749(98)70244-1; COHAN VL, 1989, AM REV RESPIR DIS, V140, P951, DOI 10.1164/ajrccm/140.4.951; COX G, 1991, AM J RESP CELL MOL, V4, P525, DOI 10.1165/ajrcmb/4.6.525; Day JH, 1996, J ALLERGY CLIN IMMUN, V97, P1050, DOI 10.1016/S0091-6749(96)70257-9; De Graaf-In't Veld C., 1995, Clinical and Experimental Allergy, V25, P966, DOI 10.1111/j.1365-2222.1995.tb00399.x; ENERBACK L, 1986, INT ARCH ALLER A IMM, V80, P44, DOI 10.1159/000234024; ENERBACK L, 1986, INT ARCH ALLER A IMM, V81, P289, DOI 10.1159/000234152; FOKKENS WJ, 1992, CLIN EXP ALLERGY, V22, P701, DOI 10.1111/j.1365-2222.1992.tb00194.x; Frieri M, 1998, ANN ALLERG ASTHMA IM, V81, P431, DOI 10.1016/S1081-1206(10)63141-9; Ghaffar O, 1997, AM J RESP CELL MOL, V17, P17, DOI 10.1165/ajrcmb.17.1.2696; GODDING V, 1995, AM J RESP CELL MOL, V13, P555, DOI 10.1165/ajrcmb.13.5.7576691; GODFREY MP, 1957, LANCET, V1, P767; GODTHELP T, 1995, ALLERGY, V50, P21, DOI 10.1111/j.1398-9995.1995.tb02737.x; GOMEZ E, 1988, BRIT MED J, V296, P1572, DOI 10.1136/bmj.296.6636.1572-a; GRONBORG H, 1993, ALLERGY, V48, P87, DOI 10.1111/j.1398-9995.1993.tb00691.x; Hasegawa T, 1997, AM J RESP CELL MOL, V16, P683, DOI 10.1165/ajrcmb.16.6.9191470; HOLM AF, 1995, ALLERGY, V50, P204, DOI 10.1111/j.1398-9995.1995.tb01134.x; HOLT PG, 1995, ALLERGY, V50, P34, DOI 10.1111/j.1398-9995.1995.tb04274.x; HORAK F, 1982, ANN ALLERGY, V48, P305; HOWARTH P, 1997, TREATMENT ALLERGIC R, P521; HOWARTH PH, 1999, RHINITIS MECH MANAGE, P109; HUTCHISON KA, 1993, ANN NY ACAD SCI, V684, P35, DOI 10.1111/j.1749-6632.1993.tb32269.x; IGARASHI Y, 1995, J ALLERGY CLIN IMMUN, V95, P716, DOI 10.1016/S0091-6749(95)70177-X; IGARASHI Y, 1993, J ALLERGY CLIN IMMUN, V91, P1082, DOI 10.1016/0091-6749(93)90223-3; ILIOPOULOS O, 1992, J IMMUNOL, V148, P2223; JULIUSSON S, 1995, ALLERGY, V50, P15, DOI 10.1111/j.1398-9995.1995.tb02478.x; JULIUSSON S, 1993, CLIN EXP ALLERGY, V23, P591, DOI 10.1111/j.1365-2222.1993.tb00899.x; KARLSSON MG, 1995, DIAGN MOL PATHOL, V4, P85, DOI 10.1097/00019606-199506000-00003; KIRKEGAARD J, 1983, BRIT J DIS CHEST, V77, P113, DOI 10.1016/0007-0971(83)90017-7; Kleinert H, 1996, MOL PHARMACOL, V49, P15; KLEMENTSSON H, 1991, CLIN EXP ALLERGY, V21, P705, DOI 10.1111/j.1365-2222.1991.tb03199.x; KNUTSSON U, 1995, J ENDOCRINOL, V144, P301, DOI 10.1677/joe.0.1440301; KONNO A, 1994, INT ARCH ALLERGY IMM, V103, P79, DOI 10.1159/000236609; Kuna P, 1996, J ALLERGY CLIN IMMUN, V97, P104, DOI 10.1016/S0091-6749(96)70288-9; KUNA P, 1993, J IMMUNOL, V150, P1932; LeVan TD, 1997, AM J PHYSIOL-LUNG C, V272, pL838, DOI 10.1152/ajplung.1997.272.5.L838; Li HM, 1996, J IMMUNOL, V157, P1207; Li HM, 1996, J IMMUNOL, V156, P4833; Liden J, 1997, J BIOL CHEM, V272, P21467, DOI 10.1074/jbc.272.34.21467; Lilly CM, 1997, J CLIN INVEST, V99, P1767, DOI 10.1172/JCI119341; LINDQVIST N, 1989, CLIN OTOLARYNGOL, V14, P519, DOI 10.1111/j.1365-2273.1989.tb00416.x; LUNDGREN JD, 1990, J ALLERGY CLIN IMMUN, V85, P399, DOI 10.1016/0091-6749(90)90147-V; MACDONALD SM, 1987, J IMMUNOL, V139, P506; MALM L, 1981, ALLERGY, V36, P209, DOI 10.1111/j.1398-9995.1981.tb01836.x; Masuyama K, 1998, J ALLERGY CLIN IMMUN, V102, P610, DOI 10.1016/S0091-6749(98)70277-5; MASUYAMA K, 1994, IMMUNOLOGY, V82, P192; MASUYAMA K, 1994, EUR RESPIR REV, V4, P252; MATTOLI S, 1992, J ALLERGY CLIN IMMUN, V89, P164; McDowall JE, 1997, CLIN DRUG INVEST, V14, P44, DOI 10.2165/00044011-199714010-00006; McKay LI, 1998, MOL ENDOCRINOL, V12, P45, DOI 10.1210/mend.12.1.0044; Meagher LC, 1996, J IMMUNOL, V156, P4422; MELTZER EO, 1994, J ALLERGY CLIN IMMUN, V94, P708, DOI 10.1016/0091-6749(94)90178-3; MELTZER EO, 1990, J ALLERGY CLIN IMMUN, V86, P221, DOI 10.1016/S0091-6749(05)80069-7; MULLOL J, 1995, CLIN EXP ALLERGY, V25, P607, DOI 10.1111/j.1365-2222.1995.tb01108.x; Mygind N, 1996, CLIN IMMUNOTHER, V5, P122, DOI 10.1007/BF03259319; MYGIND N, 1973, BRIT MED J, V4, P464, DOI 10.1136/bmj.4.5890.464; Naclerio RM, 1996, J ALLERGY CLIN IMMUN, V98, P721, DOI 10.1016/S0091-6749(96)70118-5; NACLERIO RM, 1993, J ALLERGY CLIN IMMUN, V92, P717, DOI 10.1016/0091-6749(93)90015-8; Nagata M, 1998, AM J RESP CELL MOL, V19, P158, DOI 10.1165/ajrcmb.19.1.3001; Nielsen LP, 1998, ALLERGY, V53, P778; NORMAN PS, 1967, J ALLERGY, V40, P57, DOI 10.1016/0021-8707(67)90060-3; OKUDA M, 1983, ANN ALLERGY, V50, P116; OKUDA M, 1980, CLIN OTOLARYNGOL, V5, P315, DOI 10.1111/j.1365-2273.1980.tb00897.x; OKUDA M, 1978, ARCH OHREN NASEN KEH, V221, P215, DOI 10.1007/BF01886298; OKUDA M, 1985, ANN ALLERGY, V54, P152; OTSUKA H, 1985, J ALLERGY CLIN IMMUN, V76, P695, DOI 10.1016/0091-6749(85)90673-6; OTSUKA H, 1986, CLIN ALLERGY, V16, P589, DOI 10.1111/j.1365-2222.1986.tb01998.x; OTSUKA H, 1995, J ALLERGY CLIN IMMUN, V96, P528, DOI 10.1016/S0091-6749(95)70297-0; PAWANKAR RU, 1995, AM J RESP CRIT CARE, V152, P2059, DOI 10.1164/ajrccm.152.6.8520776; PEPPEL K, 1991, J EXP MED, V173, P349, DOI 10.1084/jem.173.2.349; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; PERONI D, 1993, J ALLERGY CLIN IMMUN, V91, P260; PICHLER WJ, 1988, ALLERGY, V43, P87, DOI 10.1111/j.1398-9995.1988.tb00399.x; PIPKORN U, 1987, NEW ENGL J MED, V316, P1506, DOI 10.1056/NEJM198706113162403; PIPKORN U, 1982, ALLERGY, V37, P359, DOI 10.1111/j.1398-9995.1982.tb01922.x; PIPKORN U, 1982, ALLERGY, V37, P591, DOI 10.1111/j.1398-9995.1982.tb02345.x; PIPKORN U, 1983, ALLERGY, V38, P125, DOI 10.1111/j.1398-9995.1983.tb01596.x; PIPKORN U, 1988, J ALLERGY CLIN IMMUN, V82, P1046, DOI 10.1016/0091-6749(88)90143-1; Ponath PD, 1996, J CLIN INVEST, V97, P604, DOI 10.1172/JCI118456; PROUD D, 1983, J CLIN INVEST, V72, P1678, DOI 10.1172/JCI111127; Pullerits T, 1997, J ALLERGY CLIN IMMUN, V100, P601, DOI 10.1016/S0091-6749(97)70162-3; RAK S, 1994, CLIN EXP ALLERGY, V24, P930, DOI 10.1111/j.1365-2222.1994.tb02724.x; Ray KP, 1997, BIOCHEM J, V328, P707; ROBINSON D, 1993, AM REV RESPIR DIS, V148, P401, DOI 10.1164/ajrccm/148.2.401; RYAN G, 1985, J ALLERGY CLIN IMMUN, V75, P25, DOI 10.1016/0091-6749(85)90007-7; SCADDING GK, 1994, BRIT J CLIN PHARMACO, V38, P447, DOI 10.1111/j.1365-2125.1994.tb04381.x; SCHLEIMER RP, 1981, NATURE, V292, P454, DOI 10.1038/292454a0; SCHLEIMER RP, 1994, J ALLERGY CLIN IMMUN, V94, P1202, DOI 10.1016/0091-6749(94)90333-6; SCHLEIMER RP, 1982, J IMMUNOL, V129, P1632; SCHLEIMER RP, 1989, J IMMUNOL, V143, P1310; Schroeder JT, 1997, J IMMUNOL, V158, P5448; SCHROEDER JT, 1995, ALLERGY, V50, P463, DOI 10.1111/j.1398-9995.1995.tb01180.x; Schwiebert LM, 1996, AM J RESP CRIT CARE, V154, pS16, DOI 10.1164/ajrccm/154.2_Pt_2.S16; SCOTT P, 1993, SCIENCE, V260, P496, DOI 10.1126/science.8097337; SEIBERLINK M, 1996, J ALLERGY CLIN IMMUN, V97, P198; SHALIT M, 1995, CELL IMMUNOL, V160, P50, DOI 10.1016/0008-8749(95)80008-7; SIM TC, 1995, AM J RESP CRIT CARE, V152, P927, DOI 10.1164/ajrccm.152.3.7545059; SIM TC, 1992, AM REV RESPIR DIS, V145, P1316, DOI 10.1164/ajrccm/145.6.1316; SORENSEN H, 1976, ACTA OTO-LARYNGOL, V82, P260, DOI 10.3109/00016487609120899; STELLATO C, 1995, J IMMUNOL, V155, P410; Stellato C, 1997, J CLIN INVEST, V99, P926, DOI 10.1172/JCI119257; SVENSSON C, 1994, ALLERGY, V49, P177, DOI 10.1111/j.1398-9995.1994.tb00822.x; TOFT A, 1982, CLIN ALLERGY, V12, P391, DOI 10.1111/j.1365-2222.1982.tb02544.x; Umland SP, 1997, J ALLERGY CLIN IMMUN, V100, P511, DOI 10.1016/S0091-6749(97)70144-1; VANWIJK RG, 1987, CLIN ALLERGY, V17, P563; VENGE P, 1994, ALLERGY, V49, P1, DOI 10.1111/j.1398-9995.1994.tb00765.x; VIEGAS M, 1987, INT ARCH ALLER A IMM, V82, P275, DOI 10.1159/000234205; VILSVIK J S, 1975, Clinical Allergy, V5, P291, DOI 10.1111/j.1365-2222.1975.tb01865.x; WALLEN N, 1991, J IMMUNOL, V147, P3490; WANG DY, 1995, INT ARCH ALLERGY IMM, V106, P278, DOI 10.1159/000236855; WARDLAW AJ, 1994, ALLERGY, V49, P797, DOI 10.1111/j.1398-9995.1994.tb00778.x; Weido AJ, 1996, ANN ALLERG ASTHMA IM, V77, P407, DOI 10.1016/S1081-1206(10)63340-6; Wihl JA, 1997, ALLERGY, V52, P620, DOI 10.1111/j.1398-9995.1997.tb01040.x; Wilson AM, 1998, J ALLERGY CLIN IMMUN, V101, P470, DOI 10.1016/S0091-6749(98)70354-9; Wissink S, 1997, IMMUNOBIOLOGY, V198, P50, DOI 10.1016/S0171-2985(97)80026-5; Wissink S, 1998, MOL ENDOCRINOL, V12, P355, DOI 10.1210/me.12.3.355	141	80	86	1	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2001	108	1		S			S16	S25		10.1067/mai.2001.115561	http://dx.doi.org/10.1067/mai.2001.115561			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	459BU	11449202				2022-12-18	WOS:000170230600004
J	Li, XM; Kleiner, G; Huang, CK; Lee, SY; Schofield, B; Soter, NA; Sampson, HA				Li, XM; Kleiner, G; Huang, CK; Lee, SY; Schofield, B; Soter, NA; Sampson, HA			Murine model of atopic dermatitis associated with food hypersensitivity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; eczema; food hypersensitivity; murine model; T(H)2-like cytokines; IgE-mediated hypersensitivity	POLYMERASE CHAIN-REACTION; ALOPECIA-AREATA; T-CELLS; INTESTINAL PERMEABILITY; ALLERGIC DERMATITIS; IGE HYPERPRODUCTION; AEROSOLIZED ANTIGEN; MESSENGER-RNA; C3H/HEJ MICE; NC/NGA MICE	Background: Atopic dermatitis (AD) is an eczematous skin eruption that generally begins in early infancy and affects up to 126 of the population. The cause of this disorder is not fully understood, although it is frequently the first sign of atopic disease and is characterized by an elevated serum IgE level, eosinophilia, and histologic tissue changes characterized early by spongiosis and a CD4(+) T(H)2 cellular infiltrate. Hypersensitivity to foods has been implicated as one causative factor in up to 40% of children with moderate-to-severe AD. Objective: The purpose of this study was to establish a murine model of food-induced AD. Methods: Female C3H/HeJ mice were sensitized orally to cow's milk or peanut with a cholera toxin adjuvant and then subjected to low-grade allergen exposure. Histologic examination of skin lesions, allergen-specific serum Ig levels, and allergen-induced T-cell proliferation and cytokine production were examined. Results: An eczematous eruption developed in approximately one third of mice after low-grade exposure to milk or peanut proteins. Peripheral blood eosinophilia and elevated serum IgE levels were noted. Histologic examination of the Lesional skin revealed spongiosis and a cellular infiltrate consisting of CD4(+) lymphocytes, eosinophils, and mast cells, IL-5 and IL-13 mRNA expression was elevated only in the skin of mice with the eczematous eruption. Treatment of the eruption with topical corticosteroids led to decreased pruritus and resolution of the cutaneous eruption. Conclusion: This eczematous eruption resembles AD in human subjects and should provide a useful model for studying immunopathogenic mechanisms of food hypersensitivity in AD.	CUNY Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA; NYU, Sch Med, Ronald O Perelman Dept Dermatol, New York, NY USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; New York University; Johns Hopkins University	Sampson, HA (corresponding author), CUNY Mt Sinai Sch Med, Dept Pediat, Box 1198,1 Gustave L Levy Pl, New York, NY 10029 USA.				NIAID NIH HHS [AI24439, AI43668, AI44236] Funding Source: Medline; NIEHS NIH HHS [ES 03819] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043668, R01AI024439] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES003819] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABERNATHYCARVER KJ, 1995, J CLIN INVEST, V95, P913, DOI 10.1172/JCI117743; ALBANI S, 1989, ANN ALLERGY, V63, P489; BILLINGHAM RE, 1953, NATURE, V172, P603, DOI 10.1038/172603a0; Bunikowski R, 1999, J ALLERGY CLIN IMMUN, V103, P119, DOI 10.1016/S0091-6749(99)70535-X; BUTLER JM, 1983, J AM ACAD DERMATOL, V8, P33, DOI 10.1016/S0190-9622(83)70004-6; Eigenmann PA, 1998, PEDIATRICS, V101, DOI 10.1542/peds.101.3.e8; ELIAS J, 1986, J ALLERGY CLIN IMMUN, V78, P914, DOI 10.1016/0091-6749(86)90240-X; FLICK J A, 1988, Pediatric Research, V23, p303A; GAVETT SH, 1995, J EXP MED, V182, P1527, DOI 10.1084/jem.182.5.1527; GEAVES MW, 2000, J ALLERGY CLIN IMMUN, V105, P664; GEBA GP, 1997, ALLERGY ALLERGIC DIS, P1056; GUNDEL RH, 1997, ALLERGY ALLERGIC DIS, P1037; Hamid Q, 1996, J ALLERGY CLIN IMMUN, V98, P225, DOI 10.1016/S0091-6749(96)70246-4; HAMID Q, 1994, J CLIN INVEST, V94, P870, DOI 10.1172/JCI117408; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; HANIFIN JM, 1993, ALLERGY PRINCIPLES P, P1581; HILL DJ, 1989, J PEDIATR-US, V114, P761, DOI 10.1016/S0022-3476(89)80133-7; HOFFMANN R, 1994, J INVEST DERMATOL, V103, P530, DOI 10.1111/1523-1747.ep12395722; Hsu CH, 1996, CLIN EXP ALLERGY, V26, P1329, DOI 10.1111/j.1365-2222.1996.tb00530.x; JACKSON PG, 1981, LANCET, V1, P1285; JONES SM, 1996, ATOPIC DERMATITIS PA, P41; Krzesicki RF, 1997, AM J RESP CELL MOL, V16, P693, DOI 10.1165/ajrcmb.16.6.9191471; LEIFERMAN KM, 1985, NEW ENGL J MED, V313, P282, DOI 10.1056/NEJM198508013130502; Leung DYM, 2000, J ALLERGY CLIN IMMUN, V105, P860, DOI 10.1067/mai.2000.106484; Li XM, 1999, J ALLERGY CLIN IMMUN, V103, P206, DOI 10.1016/S0091-6749(99)70492-6; Li XM, 1999, J IMMUNOL, V162, P3045; Madani S, 2000, J AM ACAD DERMATOL, V42, P549, DOI 10.1016/S0190-9622(00)90164-6; Matsuda H, 1997, INT IMMUNOL, V9, P461, DOI 10.1093/intimm/9.3.461; MIHM MC, 1976, J INVEST DERMATOL, V67, P305, DOI 10.1111/1523-1747.ep12514346; Morita E, 1999, J DERMATOL SCI, V19, P37, DOI 10.1016/S0923-1811(98)00047-4; MUDDE GC, 1995, IMMUNOL TODAY, V16, P380, DOI 10.1016/0167-5699(95)80005-0; Noh GW, 1998, ALLERGY, V53, P1202, DOI 10.1111/j.1398-9995.1998.tb03842.x; Nomura I, 1999, J ALLERGY CLIN IMMUN, V104, P441, DOI 10.1016/S0091-6749(99)70390-8; PIKE MG, 1986, J INVEST DERMATOL, V86, P101, DOI 10.1111/1523-1747.ep12284035; Roosje PJ, 1998, VET PATHOL, V35, P268, DOI 10.1177/030098589803500405; SAGER N, 1992, J ALLERGY CLIN IMMUN, V89, P801, DOI 10.1016/0091-6749(92)90434-4; SALOGA J, 1993, J CLIN INVEST, V91, P133, DOI 10.1172/JCI116162; SAMPSON HA, 1984, NEW ENGL J MED, V311, P372, DOI 10.1056/NEJM198408093110605; Sampson HA, 1999, IMMUNOL ALLERGY CLIN, V19, P495, DOI 10.1016/S0889-8561(05)70104-1; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P717, DOI 10.1016/S0091-6749(99)70411-2; SICHERER SH, 1999, J ALLERGY CLIN IMM S, V104, P717; Simpson AECM, 1997, INFLAMM RES, V46, P65, DOI 10.1007/s000110050078; SOTER NA, 1989, ALLERGY, V44, P16, DOI 10.1111/j.1398-9995.1989.tb02449.x; Spergel JM, 1998, J CLIN INVEST, V101, P1614, DOI 10.1172/JCI1647; Spergel JM, 1999, J CLIN INVEST, V103, P1103, DOI 10.1172/JCI5669; SUNDBERG JP, 1994, J INVEST DERMATOL, V102, P847, DOI 10.1111/1523-1747.ep12382416; Suto H, 1999, INT ARCH ALLERGY IMM, V120, P70, DOI 10.1159/000053599; Tobin DJ, 1997, J INVEST DERMATOL, V109, P329, DOI 10.1111/1523-1747.ep12335848; UDALL JN, 1981, PEDIATR RES, V15, P241, DOI 10.1203/00006450-198103000-00008; UNO H, 1980, J INVEST DERMATOL, V75, P52, DOI 10.1111/1523-1747.ep12521130; WALKER C, 1993, CLIN EXP ALLERGY, V23, P145, DOI 10.1111/j.1365-2222.1993.tb00310.x; Wang LF, 1996, J IMMUNOL, V156, P4079; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258	53	80	82	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2001	107	4					693	702		10.1067/mai.2001.114110	http://dx.doi.org/10.1067/mai.2001.114110			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	423RG	11295660	Green Published			2022-12-18	WOS:000168190100023
J	Szepfalusi, Z; Pichler, J; Elsasser, S; van Duren, K; Ebner, C; Bernaschek, G; Urbanek, R				Szepfalusi, Z; Pichler, J; Elsasser, S; van Duren, K; Ebner, C; Bernaschek, G; Urbanek, R			Transplacental priming of the human immune system with environmental allergens can occur early in gestation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cord blood cells; allergen; T-cell proliferation; diaplacentral transfer; sensitization	CELL PROLIFERATIVE RESPONSES; BLOOD MONONUCLEAR-CELLS; RESPIRATORY-TRACT; DENDRITIC CELLS; BIRCH-POLLEN; T-CELLS; ANTIGENS; MEMORY; IMMUNIZATION; TOLERANCE	Background: Allergen-specific T cells play an important role in the allergic immune response to various environmental allergens. In vitro studies have shown that T-cell responses to these allergens do occur prenatally. Some allergens (milk proteins) appear to lead more often to fetal T-cell priming than others (house dust mite allergen, ovalbumin, and birch and grass pollen allergens). Objective: We sought to determine the window of opportunity for prenatal T-cell priming with inhalant and nutritive allergens. Methods: The T-cell reactivity of cord blood cells derived through cordocentesis from unborn (n = 62) and term babies (n = 114) in response to inhalant allergens (birch pollen major allergen, recombinant Bet v 1, and timothy grass major allergen, recombinant Phl p 1) was investigated. Results: The results demonstrate that allergen-specific T-cell reactivity is as common in preterm as in term infants (Bet v 1, 8% and 5%, respectively; Phl p 1, 20% and 25%, respectively). Conclusions: Our data support the hypothesis that differential handling of the allergenic proteins by the feto-placental barrier and possibly by antigen-presenting cells may directly modulate the ensuing T-cell immune response.	Univ Vienna, AKH, Dept Pediat, A-1090 Vienna, Austria; Univ Vienna, Inst Gen & Expt Pathol, A-1090 Vienna, Austria; Univ Vienna, Dept Gynecol & Obstet, A-1090 Vienna, Austria	University of Vienna; University of Vienna; University of Vienna	Szepfalusi, Z (corresponding author), Univ Vienna, AKH, Dept Pediat, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.			Szepfalusi, Zsolt/0000-0003-4852-3102				AASE JM, 1972, NEW ENGL J MED, V286, P1379, DOI 10.1056/NEJM197206292862603; BACH JF, 1978, DEFINITION IMMUNOLOG; BAKER CJ, 1988, NEW ENGL J MED, V319, P1180, DOI 10.1056/NEJM198811033191802; BJORKSTEN F, 1980, CLIN ALLERGY, V10, P585, DOI 10.1111/j.1365-2222.1980.tb02140.x; FERREIRA FD, 1993, J BIOL CHEM, V268, P19574; HAHNZORIC M, 1992, PEDIATR RES, V32, P150, DOI 10.1203/00006450-199208000-00005; Hara T, 1996, P NATL ACAD SCI USA, V93, P5136, DOI 10.1073/pnas.93.10.5136; HOLT PG, 1990, PEDIATR ALLERGY IMMU, V1, P3; Jones AC, 1996, PEDIATR ALLERGY IMMU, V7, P109, DOI 10.1111/j.1399-3038.1996.tb00117.x; Kondo N, 1998, CLIN EXP ALLERGY, V28, P1340; KONDO N, 1992, ARCH DIS CHILD, V67, P1003, DOI 10.1136/adc.67.8.1003; Kopp MV, 2000, PEDIATR ALLERGY IMMU, V11, P4, DOI 10.1034/j.1399-3038.2000.00053.x; Malhotra I, 1997, J CLIN INVEST, V99, P1759, DOI 10.1172/JCI119340; Miles EA, 1996, CLIN EXP ALLERGY, V26, P780, DOI 10.1111/j.1365-2222.1996.tb00608.x; NELSON DJ, 1995, J IMMUNOL, V155, P3517; NELSON DJ, 1994, J EXP MED, V179, P203, DOI 10.1084/jem.179.1.203; PIASTRA M, 1994, INT ARCH ALLERGY IMM, V104, P358, DOI 10.1159/000236692; PICINNI MP, 1993, INT ARCH ALLERGY IMM, V102, P301; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; Prescott SL, 1997, INT ARCH ALLERGY IMM, V113, P75, DOI 10.1159/000237512; Prescott SL, 1998, J IMMUNOL, V160, P4730; RAWLE FC, 1984, J IMMUNOL, V133, P195; Ridge JP, 1996, SCIENCE, V271, P1723, DOI 10.1126/science.271.5256.1723; Singh RR, 1996, J EXP MED, V183, P1613, DOI 10.1084/jem.183.4.1613; Szepfalusi Z, 1997, CLIN EXP ALLERGY, V27, P28, DOI 10.1046/j.1365-2222.1997.d01-417.x; Szepfalusi Z, 1998, J ALLERGY CLIN IMMUN, V101, P514, DOI 10.1016/S0091-6749(98)70359-8; TANG MLK, 1994, LANCET, V344, P983, DOI 10.1016/S0140-6736(94)91641-1; VANDURENSCHMIDT K, 1997, PEDIATR RES, V41, P1; WIERENGA EA, 1990, J IMMUNOL, V144, P4651; Yabuhara A, 1997, CLIN EXP ALLERGY, V27, P1261, DOI 10.1111/j.1365-2222.1997.tb01170.x	30	80	83	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2000	106	3					530	536						7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	356YN	10984374				2022-12-18	WOS:000089471900017
J	Brehler, R; Wolf, H; Kutting, B; Schnitker, J; Luger, T				Brehler, R; Wolf, H; Kutting, B; Schnitker, J; Luger, T			Safety of a two-day ultrarush insect venom immunotherapy protocol in comparison with protocols of longer duration and involving a larger number of injections	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						venom immunotherapy; insect; honeybee venom; yellow jacket venom; safety; 2-day ultrarush protocol	HYMENOPTERA STING ALLERGY; ADVERSE REACTIONS; RUSH-IMMUNOTHERAPY; WASP VENOM; HYPOSENSITIZATION; EFFICACY; PRETREATMENT; EPIDEMIOLOGY; SENSITIVITY; PROGRAM	Background: Insect venom inmunotherapy (VIT) is initiated by a dose increase protocol administered usually over 7 to 9 days. Shorter protocols have the advantage of reducing the patient's stay in the hospital. Very few data are currently available on the safety of shorter VIT dose increase protocols. Objective: The aim of this study was to investigate whether a reduction in the duration of the VIT dose increase protocol from 7 to 9 days to 2 days causes an increase in the incidence and severity of adverse reactions. Methods: Between 1992 and 1997 we administered VIT to 1055 patients allergic to bee or wasp venom. We shortened the 7- to 9-day rush protocol stepwise to 2 days by reducing the number of injections and increasing the initial dose and compared the incidence and severity of adverse reactions. The patients were retrospectively divided into 3 cohorts: 20 injections over 7 to 9 days (cohort 1, 317 patients), 10 to 14 injections over 3 to 6 days (cohort 2, 335 patients), and 9 injections over 2 days (cohort 3, 403 patients). Results: We observed no severe adverse reactions in any of the cohorts during VIT. Adverse reactions were treated in 7.1% of the patients by oral and in 2.9% by intravenous antihistamines and in 0.8% by systemic corticosteroids. The incidence of adverse reactions declined significantly from 22.4% in cohort 1 to 13.7% in cohort 2 and 10.7% in cohort 3 with reduced number of injections (P < .001). Conclusion: The incidence and severity of adverse reactions decline if the VIT dose increase protocol is shortened to 2 days.	Univ Munster, Dept Dermatol, D-48149 Munster, Germany; ALK SCHERAX Arzneimittel, Klin Forsch, Hamburg, Germany; Inst Angew Stat, Bielefeld, Germany	University of Munster	Brehler, R (corresponding author), Univ Munster, Dept Dermatol, Von Esmarch Str 56, D-48149 Munster, Germany.							BERCHTOLD E, 1992, CLIN EXP ALLERGY, V22, P59, DOI 10.1111/j.1365-2222.1992.tb00115.x; BERNSTEIN DI, 1989, J ALLERGY CLIN IMMUN, V84, P951, DOI 10.1016/0091-6749(89)90394-1; BERNSTEIN JA, 1994, ANN ALLERGY, V73, P423; BIRNBAUM J, 1993, CLIN EXP ALLERGY, V23, P226, DOI 10.1111/j.1365-2222.1993.tb00886.x; BIRNBAUM J, 1988, MED HYG, V46, P2405; Brockow K, 1997, J ALLERGY CLIN IMMUN, V100, P458, DOI 10.1016/S0091-6749(97)70135-0; CHARPIN D, 1994, CLIN EXP ALLERGY, V24, P1010, DOI 10.1111/j.1365-2222.1994.tb02736.x; GOLDEN DBK, 1980, ANN INTERN MED, V92, P620, DOI 10.7326/0003-4819-92-5-620; GOLDEN DBK, 1989, ALLERGY PROC, V10, P103, DOI 10.2500/108854189778960964; Laurent J, 1997, ALLERGY, V52, P94, DOI 10.1111/j.1398-9995.1997.tb02551.x; LICHTENSTEIN LM, 1974, NEW ENGL J MED, V290, P1223, DOI 10.1056/NEJM197405302902204; MULLER U, 1979, ALLERGY, V34, P369, DOI 10.1111/j.1398-9995.1979.tb02006.x; MULLER U, 1992, J ALLERGY CLIN IMMUN, V89, P529, DOI 10.1016/0091-6749(92)90319-W; MULLER U, 1993, ALLERGY          S14, V48, P36; NATAF P, 1984, CLIN ALLERGY, V14, P269, DOI 10.1111/j.1365-2222.1984.tb02206.x; PRZYBILLA B, 1987, DEUT MED WOCHENSCHR, V112, P416, DOI 10.1055/s-2008-1068068; RAMIREZ DA, 1981, ANN ALLERGY, V47, P435; ROCKLIN R E, 1982, Journal of Allergy and Clinical Immunology, V69, P125; Skrbic D, 1996, ALLERGOLOGIE, V19, P123; TAMIR R, 1992, ALLERGY, V47, P260, DOI 10.1111/j.1398-9995.1992.tb00660.x; THURNHEER U, 1983, ALLERGY, V38, P465, DOI 10.1111/j.1398-9995.1983.tb02355.x; Treudler R, 1997, HAUTARZT, V48, P734, DOI 10.1007/s001050050652; VANDERZWAN JC, 1983, BRIT MED J, V287, P1329, DOI 10.1136/bmj.287.6402.1329; YOULTEN LJF, 1995, CLIN EXP ALLERGY, V25, P159, DOI 10.1111/j.1365-2222.1995.tb01021.x; YUNGINGER JW, 1979, J ALLERGY CLIN IMMUN, V63, P340, DOI 10.1016/0091-6749(79)90129-5	25	80	83	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2000	105	6	1				1231	1235		10.1067/mai.2000.105708	http://dx.doi.org/10.1067/mai.2000.105708			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	327EX	10856159				2022-12-18	WOS:000087781800026
J	Gerli, R; Paganelli, R; Cossarizza, A; Muscat, C; Piccolo, G; Barbieri, D; Mariotti, S; Monti, D; Bistoni, O; Raiola, E; Venanzi, FM; Bertotto, A; Franceschi, C				Gerli, R; Paganelli, R; Cossarizza, A; Muscat, C; Piccolo, G; Barbieri, D; Mariotti, S; Monti, D; Bistoni, O; Raiola, E; Venanzi, FM; Bertotto, A; Franceschi, C			Long-term immunologic effects of thymectomy in patients with myasthenia gravis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						myasthenia gravis; thymectomy T cell; B cell; anti-DNA; anticardiolipin; systemic lupus erythematosus	SYSTEMIC LUPUS-ERYTHEMATOSUS; AUTOIMMUNE-DISEASE; POST-THYMECTOMY; T-CELLS; ANTICARDIOLIPIN ANTIBODIES; TRANSVERSE MYELITIS; DOWNS-SYNDROME; SPECIFICITY; CENTENARIANS; AUTOANTIBODY	Background: Thymectomy (Tx) is a common therapeutic option to treat myasthenia gravis (MG), but its effects on the immune system are still obscure in humans. Objective: We sought to evaluate long-term immunologic effects of therapeutic Tx in patients with MG. Methods: T- and B-cell subsets and T-cell repertoire were analyzed in 35 patients with MG, 16 with previous Tx (at least 8 years before), 6 with recent (<1 year) Tx, and 13 without Tx, as well as in 32 healthy subjects used as normal control subjects. Serum immunoglobulins and a variety of autoantibodies were also measured. A subsequent 3-gear clinical follow-up was performed to verify the possible appearance of systemic autoimmune diseases. Results: The long-term thymectomized (Txd) patients had mild T-cell lymphopenia and an expansion of some V beta families among circulating CD4+ and CD8+ T cells. They displayed a normal number of total B and CD5+ B-circulating lymphocytes, but they also displayed a polyclonal increase in serum IgM and IgG associated with the presence of high levels of a variety of organ- and nonorgan-specific autoantibodies, including anti-dsDNA and anticardiolipin, without clinical evidence of autoimmune disease. These serologic abnormalities mere not detectable in both non-Txd and recently Txd patients. After 3 years, 2 long-term Txd patients had systemic lupus erythematosus and an undifferentiated connective tissue disease. Conclusions: The association between MG and laboratory findings of systemic autoimmune disease may be in part related to Tx rather than to MG. Tx may represent a risk for the development of systemic autoimmune disorders over years in patients with MG.	Univ Perugia, Dipartimento Med Clin & Sperimentale, Sez Med Interna & Sci Oncol, Ctr Studio Malattie Reumat,Policlin Monteluce, I-06122 Perugia, Italy; Univ Rome, Inst Allergol & Clin Immunol, Rome, Italy; Univ Modena, Inst Gen Pathol, I-41100 Modena, Italy; Univ Pavia, Inst Neurol 4, I-27100 Pavia, Italy; Univ Cagliari, Inst Internal Med, Cagliari, Italy; Univ Camerino, Dept Biol, MCA, I-62032 Camerino, Italy; Univ Perugia, Inst Pediat, I-06100 Perugia, Italy; Univ Bologna, Dept Expt Pathol, Ancona, Italy; Italian Natl Res Ctr Ageing, Ancona, Italy	University of Perugia; Sapienza University Rome; Universita di Modena e Reggio Emilia; University of Pavia; University of Cagliari; University of Camerino; University of Perugia; University of Bologna; IRCCS INRCA	Gerli, R (corresponding author), Univ Perugia, Dipartimento Med Clin & Sperimentale, Sez Med Interna & Sci Oncol, Ctr Studio Malattie Reumat,Policlin Monteluce, I-06122 Perugia, Italy.		Franceschi, Claudio/L-4484-2017; Paganelli, Roberto/AAF-5712-2020; Mariotti, Stefano/AAN-1948-2020; Monti, Daniela/G-9556-2012; bistoni, onelia/G-8234-2011	Franceschi, Claudio/0000-0001-9841-6386; Monti, Daniela/0000-0001-8651-8123; Cossarizza, Andrea/0000-0002-5381-1558				ABBRUZZESE G, 1979, NEUROLOGY, V29, P1436, DOI 10.1212/WNL.29.10.1436; ALARCONSEGOVIA D, 1963, LANCET, V2, P662; BONOMO A, 1995, IMMUNOL TODAY, V16, P61, DOI 10.1016/0167-5699(95)80089-1; BONOMO A, 1995, J IMMUNOL, V154, P6602; CALABRESE LH, 1981, ARCH INTERN MED, V141, P253, DOI 10.1001/archinte.141.2.253; CHAN MKL, 1980, J RHEUMATOL, V7, P838; Cossarizza A, 1995, Int Rev Immunol, V12, P41, DOI 10.3109/08830189509056701; Cossarizza A, 1996, MECH AGEING DEV, V86, P173, DOI 10.1016/0047-6374(95)01691-0; COSSARIZZA A, 1995, AIDS, V9, P547, DOI 10.1097/00002030-199506000-00003; COSSARIZZA A, 1991, BLOOD, V77, P1263; De Carvalho MF, 1998, ARQ NEURO-PSIQUIAT, V56, P137, DOI 10.1590/S0004-282X1998000100025; DRACHMAN DB, 1994, NEW ENGL J MED, V330, P1797, DOI 10.1056/NEJM199406233302507; FABRIS N, 1984, LANCET, V1, P983; FISCHBACH M, 1981, CLIN EXP IMMUNOL, V43, P73; FRANCESCHI C, 1995, IMMUNOL TODAY, V16, P12, DOI 10.1016/0167-5699(95)80064-6; GALBRAITH RF, 1964, NEW ENGL J MED, V270, P229, DOI 10.1056/NEJM196401302700504; GERSHWIN ME, 1976, INT ARCH ALLER A IMM, V51, P245; GHARAVI AE, 1987, ANN RHEUM DIS, V46, P1, DOI 10.1136/ard.46.1.1; GOLDMAN M, 1984, ARTHRITIS RHEUM, V27, P701, DOI 10.1002/art.1780270616; GRINLINTON FM, 1991, ARTHRITIS RHEUM, V34, P916, DOI 10.1002/art.1780340719; HABERHAUER G, 1993, CLIN EXP RHEUMATOL, V11, P459; HARATI Y, 1984, LANCET, V1, P792; HASSEL B, 1992, ACTA NEUROL SCAND, V85, P63; JEFFERIS R, 1985, IMMUNOL LETT, V10, P223, DOI 10.1016/0165-2478(85)90082-3; KENNES B, 1978, ACTA CLIN BELG, V33, P110; KOBASHI H, 1994, HEPATOLOGY, V19, P1424, DOI 10.1002/hep.1840190617; LEWIS RA, 1995, ANN NEUROL, V37, P51; LIGTHART GJ, 1990, MECH AGEING DEV, V55, P89, DOI 10.1016/0047-6374(90)90108-R; Machens A, 1998, J NEUROIMMUNOL, V88, P177, DOI 10.1016/S0165-5728(98)00120-9; MANCINI G, 1965, IMMUNOCHEMISTRY, V2, P185; MARIOTTI S, 1992, LANCET, V339, P1506, DOI 10.1016/0140-6736(92)91265-A; MARTINO G, 1994, ACTA NEUROL SCAND, V89, P18; MEVORACH D, 1995, LUPUS, V4, P33, DOI 10.1177/096120339500400108; MILLER JFA, 1967, PHYSIOL REV, V47, P437, DOI 10.1152/physrev.1967.47.3.437; MIZON JP, 1979, ANN MED INTERNE, V130, P489; MOLDEN DP, 1984, AM J CLIN PATHOL, V82, P57, DOI 10.1093/ajcp/82.1.57; OLANOW CW, 1987, ANN NY ACAD SCI, V505, P595, DOI 10.1111/j.1749-6632.1987.tb51328.x; OOSTERHUIS HJ, 1981, ANN NY ACAD SCI, V377, P678, DOI 10.1111/j.1749-6632.1981.tb33766.x; Osserman K, 1958, MYASTHENIA GRAVIS; PENHALE WJ, 1990, AUTOIMMUNITY, V7, P169, DOI 10.3109/08916939008993389; PERLO VP, 1975, NEUROLOGY, V25, P294, DOI 10.1212/WNL.25.3.294; PETERSEN P, 1969, DAN MED BULL, V16, P179; POSNETT DN, 1994, J EXP MED, V179, P609, DOI 10.1084/jem.179.2.609; ROWLAND LP, 1987, ANN NY ACAD SCI, V505, P607, DOI 10.1111/j.1749-6632.1987.tb51329.x; SANMARCO M, 1994, AUTOIMMUNITY, V18, P57, DOI 10.3109/08916939409014680; SANSONI P, 1993, BLOOD, V82, P2767; Sant SM, 1997, IRISH MED J, V90, P116; SHERER Y, 1997, SEMIN CLIN IMMUNOL, V1, P5; Shoenfeld Y, 1997, LUPUS, V6, P474, DOI 10.1177/096120339700600511; SIMPSON JA, 1964, J NEUROL NEUROSUR PS, V27, P485, DOI 10.1136/jnnp.27.6.485; SMEENK R, 1982, ARTHRITIS RHEUM-US, V25, P631, DOI 10.1002/art.1780250605; SMITH HR, 1983, CLIN EXP IMMUNOL, V51, P579; STEINBERG AD, 1970, ARTHRITIS RHEUM-US, V13, P369, DOI 10.1002/art.1780130402; SZOBOR A, 1984, LANCET, V1, P277; TOH BH, 1992, AUTOIMMUNITY, V13, P165, DOI 10.3109/08916939209001918; TOLA MR, 1994, ACTA NEUROL SCAND, V90, P318; Tola MR, 1996, EUR NEUROL, V36, P327; Tomer Y, 1988, Autoimmunity, V1, P141, DOI 10.3109/08916938809001927; TSUCHIYA M, 1989, Keio Journal of Medicine, V38, P383; TUNG KSK, 1994, CLIN IMMUNOL IMMUNOP, V73, P275, DOI 10.1006/clin.1994.1199; Tung KSK, 1995, HORM METAB RES, V27, P539, DOI 10.1055/s-2007-980021; VALESINI G, 1983, LANCET, V1, P831	62	80	83	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1999	103	5	1				865	872		10.1016/S0091-6749(99)70431-8	http://dx.doi.org/10.1016/S0091-6749(99)70431-8			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	199FP	10329821	Bronze			2022-12-18	WOS:000080470200022
J	Hamilton, RG; Biagini, RE; Krieg, EF				Hamilton, RG; Biagini, RE; Krieg, EF		Multictr Latex Skin Testing Study Task Force	Diagnostic performance of Food and Drug Administration - cleared serologic assays for natural rubber latex-specific IgE antibody	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						natural rubber latex; IgE anti-latex; diagnosis; serologic testing; human	HISTAMINE-RELEASE; AMMONIATED LATEX; ALLERGY; PREVALENCE; EXTRACTS; PROTEINS	Background: In the absence of Food and Drug Administration-approved natural rubber latex skin testing reagents, latex-specific IgE antibody immunoassays are used in the diagnosis of latex allergy. Comparative diagnostic performance of these tests has not been definitively determined. Objective: We sought to study the predictive value of available Food and Drug Administration (510K)-cleared latex-specific IgE antibody immunoassays in the diagnosis of latex allergy. Methods: Subjects (n = 312) were classified as having a positive (n = 117) or a negative (n = 195) latex allergy history (Hx) or having a positive (n = 131) or a negative (n = 181) puncture skin test (PST) response (Greer reagent). The 14 subjects with a negative Hx and a positive PST response had negative responses to glove provocation testing and thus were considered sensitized but asymptomatic. Sera from 22 subjects were split to evaluate intra-assay variation. All 334 coded sera were analyzed for latex-specific IgE antibodies in the Diagnostic Products Corporation microplate AlaSTAT, Hycor HY-TEC EIA System, and Pharmacia-UpJohn CAP System. Variance and diagnostic performance parameters of each test were computed with 95% confidence intervals in relation to the subjects' Hx and PST status. Results: Intra-assay concordance of split sera results was 96.0% for all 3 assays, with coefficients of variation of less than 25% and between-assay coefficients of variation of less than 21%. The diagnostic performance of the CAP and AlaSTAT assays were equivalent in comparison with PST results: sensitivity, CAP 76.3% and ALASTAT 73.3% and specificity, CAP 96.7% and AlaSTAT 97.2% (P = NS). The HY-TEC assay was more sensitive (91.6%) and less specific (73.3%) than the CAP and AlaSTAT assays (P < .001). From 9% to 25% of the sera were discordant, being positive in at least 1, but not all 3, assays. Conclusion: The CAP and AlaSTAT assays produce 24% and 27% of false-negative results, respectively, whereas the HY-TEC produces 27% of false-positive results when compared with the PST.	Johns Hopkins Univ, Sch Med, Johns Hopkins Asthma & Allergy Ctr, Div Clin Immunol & Allergy, Baltimore, MD 21224 USA; NIOSH, Div Biomed & Behav Sci, Dept Hlth & Human Serv, Publ Hlth Serv,Ctr Dis Control & Prevent, Cincinnati, OH USA	Johns Hopkins University; Johns Hopkins Medicine; Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH); United States Public Health Service	Hamilton, RG (corresponding author), Johns Hopkins Univ, Sch Med, Johns Hopkins Asthma & Allergy Ctr, Div Clin Immunol & Allergy, Room 1A20,5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.							ALEMOHAMMAD MM, 1995, CONTACT DERMATITIS, V32, P298, DOI 10.1111/j.1600-0536.1995.tb00785.x; Beezhold DH, 1997, CLIN EXP IMMUNOL, V108, P114, DOI 10.1046/j.1365-2249.1997.d01-983.x; Brown RH, 1998, ANESTHESIOLOGY, V89, P292, DOI 10.1097/00000542-199808000-00004; GALEN RS, 1986, TXB CLIN CHEM, P394; HAMILTON RG, 1994, J LAB CLIN MED, V123, P594; Hamilton RG, 1998, J ALLERGY CLIN IMMUN, V102, P482, DOI 10.1016/S0091-6749(98)70139-3; Hamilton RG, 1996, J ALLERGY CLIN IMMUN, V98, P872, DOI 10.1016/S0091-6749(96)80003-0; Hamilton RG, 1997, ANN ALLERG ASTHMA IM, V79, P266, DOI 10.1016/S1081-1206(10)63013-X; Hornung RW, 1990, APPL OCCUP ENV HYG, V5, P46, DOI DOI 10.1080/1047322X.1990.10389587; Hunt LW, 1996, J OCCUP ENVIRON MED, V38, P765, DOI 10.1097/00043764-199608000-00011; JAEGER D, 1992, J ALLERGY CLIN IMMUN, V89, P759, DOI 10.1016/0091-6749(92)90385-F; KELLY KJ, 1994, J ALLERGY CLIN IMMUN, V93, P813, DOI 10.1016/0091-6749(94)90370-0; Kibby T, 1997, ANN ALLERG ASTHMA IM, V78, P41, DOI 10.1016/S1081-1206(10)63370-4; Kim KT, 1998, ANN ALLERG ASTHMA IM, V80, P66, DOI 10.1016/S1081-1206(10)62942-0; Kobrynski L, 1996, CLIN DIAGN LAB IMMUN, V3, P42, DOI 10.1128/CDLI.3.1.42-46.1996; KURUP VP, 1992, ALLERGY PROC, V13, P329, DOI 10.2500/108854192778816915; MATSSON P, 1998, EVALUATION METHODS A, V16, P19; MURALI PS, 1994, J LAB CLIN MED, V124, P638; Posch A, 1997, Pneumologie, V51, P1058; Posch A, 1997, ELECTROPHORESIS, V18, P2803, DOI 10.1002/elps.1150181515; SainteLaudy J, 1996, INFLAMM RES, V45, pS35, DOI 10.1007/BF03354077; TURJANMAA K, 1989, ALLERGY, V44, P181, DOI 10.1111/j.1398-9995.1989.tb02259.x; TURJANMAA K, 1988, CONTACT DERMATITIS, V19, P241, DOI 10.1111/j.1600-0536.1988.tb02920.x; Turjanmaa K, 1997, ALLERGY, V52, P41, DOI 10.1111/j.1398-9995.1997.tb02544.x; WILLIAMS PB, 1992, ANN ALLERGY, V69, P48; Yeang HY, 1998, J ALLERGY CLIN IMMUN, V101, P145; Yeang HY, 1996, J ALLERGY CLIN IMMUN, V98, P628, DOI 10.1016/S0091-6749(96)70097-0	27	80	83	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1999	103	5	1				925	930		10.1016/S0091-6749(99)70440-9	http://dx.doi.org/10.1016/S0091-6749(99)70440-9			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	199FP	10329830				2022-12-18	WOS:000080470200031
J	Ellis, MH				Ellis, MH			Successful treatment of chronic urticaria with leukotriene antagonists	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									Childrens Hosp Orange Cty, Div Allergy & Immunol, Orange, CA 92868 USA	Childrens Hospital of Orange County	Ellis, MH (corresponding author), Childrens Hosp Orange Cty, Pediat Subspecialty Fac, Div Allergy Asthma & Immunol, 725 W La Verta,Suite 100, Orange, CA 92868 USA.							Chu TJ, 1998, J ALLERGY CLIN IMMUN, V101, pS155; deAlmeida MAM, 1997, ALLERGY ASTHMA PROC, V18, P313; HENDERSON WR, 1994, ANN INTERN MED, V121, P684, DOI 10.7326/0003-4819-121-9-199411010-00010; Norris JG, 1998, J ALLERGY CLIN IMMUN, V101, pS128; Spector S, 1998, J ALLERGY CLIN IMMUN, V101, P572	5	80	80	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1998	102	5					876	877		10.1016/S0091-6749(98)70032-6	http://dx.doi.org/10.1016/S0091-6749(98)70032-6			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	139MR	9819309				2022-12-18	WOS:000077033400026
J	Miyabara, Y; Ichinose, T; Takano, H; Lim, HB; Sagai, M				Miyabara, Y; Ichinose, T; Takano, H; Lim, HB; Sagai, M			Effects of diesel exhaust on allergic airway inflammation in mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						diesel exhaust; eosinophil; goblet cell; airway hyperresponsiveness; IL-5	MAST-CELL DEGRANULATION; FC-GAMMA-RIII; IGE PRODUCTION; EOSINOPHILIC INFLAMMATION; ADJUVANT ACTIVITY; DEFICIENT MICE; IN-VIVO; PARTICLES; ASTHMA; MOUSE	Background: Eosinophilic infiltration and goblet cell hyperplasia were induced by the intratracheal instillation of diesel exhaust particles and ovalbumin in mice. However, it is unknown whether its results differ from the effects of the inhalation of diesel exhaust and allergen. Objectives: The purpose of this study was to compare the effects of diesel exhaust inhalation and intratracheal instillation of diesel exhaust particles in a murine asthma model. Methods: ICR mice were exposed to 3 mg soot per cubic meter of diesel exhaust for 6 weeks. After the first week, animals were sensitized by intraperitoneal injection of ovalbumin and aluminum hydroxide gel, After 5 weeks of diesel exhaust exposure the mice were challenged with ovalbumin, The animals were killed 1, 2, 3, and 7 days after the challenge and investigated for airway inflammation, hyperplasia of goblet cells, airway hyperresponsiveness, local cytokine expression, and antigen-specific IgE and IgG1 production. Results: Exposure to diesel exhaust enhanced infiltration of eosinophils and neutrophils in murine airways even 1 day after the challenge, An increment of goblet cells under the bronchial epithelium was followed by the recruitment of inflammatory cells. Furthermore, exposure to diesel exhaust combined with ovalbumin sensitization enhanced respiratory resistance and expression of IL-5 in lung tissue and IgG1 production but not IgE, However, diesel exhaust alone did not induce pathologic changes in mice, Conclusions: Diesel exhaust enhanced allergic airway inflammation, hyperplasia of goblet cells, and airway hyperresponsiveness caused bg ovalbumin sensitization.	Natl Inst Environm Studies, Res Team Hlth Effects Air Pollutants, Ibaraki 3050053, Japan	National Institute for Environmental Studies - Japan	Miyabara, Y (corresponding author), Natl Inst Environm Studies, Res Team Hlth Effects Air Pollutants, 16-2 Onogawa, Ibaraki 3050053, Japan.							Ando M, 1996, ATMOS ENVIRON, V30, P695, DOI 10.1016/1352-2310(94)00216-9; BARNES PJ, 1994, POSTGRAD MED J, V70, P319, DOI 10.1136/pgmj.70.823.319; Bascom R, 1996, AM J RESP CRIT CARE, V153, P477, DOI 10.1164/ajrccm.153.2.8564086; Bayram H, 1998, AM J RESP CELL MOL, V18, P441, DOI 10.1165/ajrcmb.18.3.2882; BRUSSELLE GG, 1994, CLIN EXP ALLERGY, V24, P73, DOI 10.1111/j.1365-2222.1994.tb00920.x; BURNEY PGJ, 1990, BRIT MED J, V300, P1306, DOI 10.1136/bmj.300.6735.1306; Custovic A, 1996, CLIN EXP ALLERGY, V26, P1246, DOI 10.1111/j.1365-2222.1996.tb00521.x; DiazSanchez D, 1996, J ALLERGY CLIN IMMUN, V98, P114, DOI 10.1016/S0091-6749(96)70233-6; DIAZSANCHEZ D, 1994, J CLIN INVEST, V94, P1417, DOI 10.1172/JCI117478; Dombrowicz D, 1997, J CLIN INVEST, V99, P915, DOI 10.1172/JCI119256; GOUNNI AS, 1994, NATURE, V367, P183, DOI 10.1038/367183a0; Hirata A, 1996, CLIN EXP ALLERGY, V26, P848, DOI 10.1046/j.1365-2222.1996.d01-377.x; Hogan SP, 1997, J CLIN INVEST, V99, P1329, DOI 10.1172/JCI119292; Ichinose T, 1997, TOXICOLOGY, V122, P183, DOI 10.1016/S0300-483X(97)00096-6; KANEKO M, 1995, J CLIN INVEST, V95, P2813, DOI 10.1172/JCI117986; KITA H, 1994, J ALLERGY CLIN IMMUN, V94, P1272, DOI 10.1016/0091-6749(94)90342-5; Lovik M, 1997, TOXICOLOGY, V121, P165, DOI 10.1016/S0300-483X(97)00075-9; Mehlhop PD, 1997, P NATL ACAD SCI USA, V94, P1344, DOI 10.1073/pnas.94.4.1344; Miyajima I, 1997, J CLIN INVEST, V99, P901, DOI 10.1172/JCI119255; OETTGEN HC, 1994, NATURE, V370, P367, DOI 10.1038/370367a0; Oshiba A, 1996, J CLIN INVEST, V97, P1398, DOI 10.1172/JCI118560; SAGAI M, 1993, FREE RADICAL BIO MED, V14, P37, DOI 10.1016/0891-5849(93)90507-Q; Sagai M, 1996, FREE RADICAL BIO MED, V21, P199, DOI 10.1016/0891-5849(96)00032-9; SAKAGUCHI M, 1989, J IMMUNOL METHODS, V116, P181, DOI 10.1016/0022-1759(89)90202-0; Sewell WA, 1996, IMMUNOL CELL BIOL, V74, P274, DOI 10.1038/icb.1996.48; SORKNESS R, 1994, AM J RESP CRIT CARE, V150, P28, DOI 10.1164/ajrccm.150.1.8025764; TAKAFUJI S, 1987, J ALLERGY CLIN IMMUN, V79, P639, DOI 10.1016/S0091-6749(87)80161-6; Takano H, 1997, AM J RESP CRIT CARE, V156, P36, DOI 10.1164/ajrccm.156.1.9610054; TAKENAKA H, 1995, J ALLERGY CLIN IMMUN, V95, P103, DOI 10.1016/S0091-6749(95)70158-3; TAMURA K, 1996, ENV SCI TOKYO, V4, P37; Tokuyama Y, 1996, CELL IMMUNOL, V170, P230, DOI 10.1006/cimm.1996.0156; Tsien A, 1997, TOXICOL APPL PHARM, V142, P256, DOI 10.1006/taap.1996.8063; WARDLAW AJ, 1993, CLIN EXP ALLERGY, V23, P81, DOI 10.1111/j.1365-2222.1993.tb00303.x	33	80	81	1	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1998	102	5					805	812		10.1016/S0091-6749(98)70021-1	http://dx.doi.org/10.1016/S0091-6749(98)70021-1			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	139MR	9819298				2022-12-18	WOS:000077033400015
J	[Anonymous]				[Anonymous]			The use of standardized allergen extracts	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material																		ALVAREZCUESTA E, 1994, J ALLERGY CLIN IMMUN, V93, P556, DOI 10.1016/S0091-6749(94)70067-2; Board of Directors of the American Academy of Allergy, 1993, J ALLERGY CLIN IMMUN, V92, P636; CARREIRA J, 1994, ARB PEI GSH, V87, P155; *CBER, 1993, 94N0012 CBER FDA; CHAPMAN M, 1994, ARB PEI GSH, V87, P119; DREBORG S, 1992, ALLERGY, V47, P418, DOI 10.1111/j.1398-9995.1992.tb02082.x; *EX COMM AM AC ALL, 1992, J ALLERGY CLIN IMMUN, V90, P263; KRAFT D, 1992, MOL BIOL IMMUNOLOGY; LIU DT, 1994, ARB PEI GSH, V87, P7; MOHAPATRA SS, 1992, J ALLERGY CLIN IMMUN, V89, P921, DOI 10.1016/0091-6749(92)90451-7; NORMAN PS, 1986, J ALLERGY CLIN IMMUN, V77, P405, DOI 10.1016/0091-6749(86)90173-9; NORMAN PS, 1994, ARB PEI GSH, V87, P59; PLATTSMILLS TAE, 1991, J ALLERGY CLIN IMMUN, V87, P621, DOI 10.1016/0091-6749(91)90379-3; REED CE, 1989, J ALLERGY CLIN IMMUN, V84, P4, DOI 10.1016/0091-6749(89)90171-1; Turkeltaub PC, 1988, ALLERGY PRINCIPLES P, V3rd, P388; WAHN U, 1988, J ALLERGY CLIN IMMUN, V82, P360, DOI 10.1016/0091-6749(88)90007-3	16	80	82	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1997	99	5					583	586						4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WY600	9155821				2022-12-18	WOS:A1997WY60000002
J	Hoffman, KM; Ho, DG; Sampson, HA				Hoffman, KM; Ho, DG; Sampson, HA			Evaluation of the usefulness of lymphocyte proliferation assays in the diagnosis of allergy to cow's milk	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food allergy; lymphocyte proliferation; milk-induced enterocolitis	1ST 3 YEARS; ATOPIC-DERMATITIS; HYPERSENSITIVITY REACTIONS; INDUCED ENTEROCOLITIS; PROTEIN INTOLERANCE; FOOD ANTIGENS; DOUBLE-BLIND; CHILDREN; INFANTS; RESPONSES	Background: The significance of cell-mediated mechanisms in IgE-mediated milk allergy (IgE-MA) and in milk-induced enterocolitis syndrome (ME) is controversial, Some investigators have claimed that lymphocyte proliferation assays are useful in the diagnosis of food hypersensitivity, despite the great variability in study designs and results reported, This study was undertaken to address many of these variables slid to determine whether lymphocyte proliferation assays correlate with clinical diagnoses. Methods: Lymphocyte proliferative responses to milk antigen were evaluated in two groups of children, 27 with IgE-MA, and nine with ME and in 21 pediatric control subjects. IgE-mediated food allergy was documented by positive double-blind, placebo-controlled food challenges and positive skin prick test results, ME was diagnosed by oral challenge or by a history of repeated episodes of delayed vomiting (> 2 hours) after ingestion of milk and by negative skin prick test responses. Peripheral blood mononuclear cells were isolated and cultured, Cultures stimulated with milk (the food antigen of interest), soy antigen (a nonrelevant food antigen), or tetanus antigen (a positive control antigen) and unstimulated controls were performed in quadruplicate, On days 5, 7, and 9, cells were pulsed with tritium-labeled thymidine and incubated for 4 hours, Results were compared as counts per minute (cpm) and as stimulation indices (SIs). Results: Maximal proliferation was generally seen on day 7, The median cpm (20,941) and the median SI (19.2) in response to milk antigen in the 27 children with IgE-MA were significantly greater than those in the control patients (6969 cpm; SI = 14.2; p = 0.001 and p < 0.05, respectively), However, the ranges mere large and overlapped extensively (IgE-MA, 5616 to 52,053 cpm; controls, 469 to 39,260 cpm), The non-soy-allergic patients with IgE-MA also had a significantly greater response to soy antigen than did the control subjects when cpm were compared (0.01 < p < 0.05). There were no differences in background or in response to tetanus antigen, The median response to milk in the patients with ME (11,975 cpm) was significantly greater than that in control subjects (6969 cpm; 0.01 < p < 0.05), when cpm were compared but not when SIs mere compared, There were no significant differences between the patients with IgE-MA and those with ME. Conclusion: Overall, these results indicate that lymphocyte proliferation assays are neither diagnostic nor predictive of clinical reactivity in individual patients with milk allergy, Lymphocytes of many control patients are highly responsive to milk antigens, and lymphocytes of many patients with milk allergy are not, Statistically significant differences are only evident when the patients are compared as groups.	JOHNS HOPKINS UNIV HOSP, BALTIMORE, MD 21287 USA; JOHNS HOPKINS UNIV, SCH MED, DIV PEDIAT ALLERGY & IMMUNOL, BALTIMORE, MD 21287 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University					NCRR NIH HHS [RR00052] Funding Source: Medline; PHS HHS [R01 A124439] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALBANI S, 1989, ANN ALLERGY, V63, P489; BOCK SA, 1987, PEDIATRICS, V79, P683; BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; Burks A W, 1994, Pediatr Allergy Immunol, V5, P40; BURKS AW, 1988, J PEDIATR-US, V113, P447, DOI 10.1016/S0022-3476(88)80626-7; EIGENMANN PA, 1995, J ALLERGY CLIN IMMUN, V96, P549, DOI 10.1016/S0091-6749(95)70300-4; ENDRE L, 1975, ACTA ALLERGOL, V30, P34; HIDE DW, 1983, BRIT J CLIN PRACT, V37, P285; HOST A, 1990, ALLERGY, V45, P587, DOI 10.1111/j.1398-9995.1990.tb00944.x; KONDO N, 1990, J ALLERGY CLIN IMMUN, V86, P253, DOI 10.1016/S0091-6749(05)80073-9; KONDO N, 1992, ARCH DIS CHILD, V67, P1003, DOI 10.1136/adc.67.8.1003; May C D, 1972, Clin Allergy, V2, P335, DOI 10.1111/j.1365-2222.1972.tb01298.x; MAY CD, 1976, J ALLERGY CLIN IMMUN, V58, P500, DOI 10.1016/0091-6749(76)90194-9; POWELL GK, 1978, J PEDIATR-US, V93, P553, DOI 10.1016/S0022-3476(78)80887-7; SAMPSON HA, 1984, J ALLERGY CLIN IMMUN, V74, P26, DOI 10.1016/0091-6749(84)90083-6; SCHEINMANN P, 1976, CLIN ALLERGY, V6, P515, DOI 10.1111/j.1365-2222.1976.tb01936.x; SCHRANDER JJP, 1993, EUR J PEDIATR, V152, P640, DOI 10.1007/BF01955238; Suomalainen H, 1994, Pediatr Allergy Immunol, V5, P20, DOI 10.1111/j.1399-3038.1994.tb00214.x; TAINIO VM, 1990, ALLERGY, V45, P189, DOI 10.1111/j.1398-9995.1990.tb00482.x; VANSICKLE GJ, 1985, GASTROENTEROLOGY, V88, P1915, DOI 10.1016/0016-5085(85)90019-8; WARNER JA, 1994, CLIN EXP ALLERGY, V24, P423, DOI 10.1111/j.1365-2222.1994.tb00930.x	21	80	80	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1997	99	3					360	366		10.1016/S0091-6749(97)70054-X	http://dx.doi.org/10.1016/S0091-6749(97)70054-X			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WM422	9058692				2022-12-18	WOS:A1997WM42200013
J	Hill, DJ; Hudson, IL; Sheffield, LJ; Shelton, MJ; Menahem, S; Hosking, CS				Hill, DJ; Hudson, IL; Sheffield, LJ; Shelton, MJ; Menahem, S; Hosking, CS			A low allergen diet is a significant intervention in infantile colic: Results of a community-based study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						infantile colic; food protein intolerance; dietary change	RANDOMIZED CONTROLLED TRIAL; DOUBLE-BLIND CROSSOVER; COW MILK ALLERGY; EARLY-CHILDHOOD; PROTEIN; MANIFESTATIONS; FORMULA	Background: The effect of diet change in 38 bottle-fed and 77 breast-fed ''colicky'' infants, referred from community-based pediatric facilities was studied over a 1-week period in a double-blind (within each feeding mode), randomized, placebo-controlled trial. Methods: Bottle-fed infants were assigned to either casein hydrolysate or cow's milk formula. All mothers of breast-fed infants were started on all artificial color-free, preservative-free, additive-free diet and also randomized to an active low allergen diet (milk-, egg-, wheat-, nut-free) or a control diet. Results: The response to diet was assessed on day I and day 8 with the use of a previously validated infant distress chart on which parents recorded distress levels. IS successful outcome was defined as a reduction in distress of 25% or more, after adjusting for age and feeding mode, infants on active diet had a significantly higher rate of improvement than those on the control diet (odds ratio, 2.32; 95% confidence interval, 1.07-5.0; p = 0.03). Analysis of the day 8 to day I distress ratio, again adjusted for age and feeding mode, showed that infants on the active diet had distress reduced by 39% (95% confidence interval, 26-50) compared with 16% (95% confidence interval, 0-30) for those on the control diet (p = 0.012). Conclusion: The results suggest a period of dietary modification with a low allergen diet and appropriate nutritional support should be considered in healthy infants with colic.	ROYAL CHILDRENS HOSP, MELBOURNE, VIC, AUSTRALIA; UNIV MELBOURNE, DEPT STAT, MELBOURNE, VIC, AUSTRALIA; MURDOCH INST RES BIRTH DEFECTS, MELBOURNE, VIC, AUSTRALIA	Royal Children's Hospital Melbourne; University of Melbourne; Murdoch Children's Research Institute				Hudson, Irene/0000-0002-9000-9556				ANDERSON S, 1980, STATISTICAL METHODS; BARR RG, 1991, PEDIATRICS, V87, P623; BARR RG, 1988, ARCH DIS CHILD, V63, P380, DOI 10.1136/adc.63.4.380; BISHOP JM, 1990, J PEDIATR-US, V116, P862, DOI 10.1016/S0022-3476(05)80641-9; BOULTON TJC, 1979, AUST PAEDIATR J, V15, P87; BRAZELTON TB, 1962, PEDIATRICS, V29, P579; CAREY WB, 1984, PEDIATRICS, V84, P1124; DONNER A, 1984, STAT MED, V3, P199, DOI 10.1002/sim.4780030302; EVANS RW, 1981, LANCET, V1, P1340; FORD RPK, 1986, AUST PAEDIATR J, V22, P37; FORSYTH BWC, 1989, J PEDIATR-US, V115, P521, DOI 10.1016/S0022-3476(89)80274-4; HIDE DW, 1982, ARCH DIS CHILD, V57, P559, DOI 10.1136/adc.57.7.559; HILL DJ, 1993, ALLERGY, V48, P75, DOI 10.1111/j.1398-9995.1993.tb00689.x; HILL DJ, 1992, J PEDIATR-US, V121, P755, DOI 10.1016/S0022-3476(05)81911-0; HILL DJ, 1986, J PEDIATR-US, V109, P270, DOI 10.1016/S0022-3476(86)80384-5; HILL DJ, 1989, J PEDIATR-US, V114, P761, DOI 10.1016/S0022-3476(89)80133-7; HILL DJ, 1988, CLIN ALLERGY, V18, P469, DOI 10.1111/j.1365-2222.1988.tb02897.x; HILL DJ, 1988, CLIN ALLERGY, V18, P481, DOI 10.1111/j.1365-2222.1988.tb02898.x; HUNZIKER UA, 1986, PEDIATRICS, V77, P641; Inc S. P. S. S., 1988, SPSS X USERS GUIDE; JACOBSSON I, 1983, PEDIATRICS, V71, P268; KAHN A, 1989, PEDIATRICS, V84, P595; LACHENBRUCH PA, 1988, STAT MED, V7, P467, DOI 10.1002/sim.4780070403; LOTHE L, 1982, PEDIATRICS, V70, P7; LOTHE L, 1989, PEDIATRICS, V83, P262; PARADISE JL, 1966, J AMER MED ASSOC, V197, P191, DOI 10.1001/jama.1966.03110030085031; Pocock S. J., 1983, CLIN TRIALS PRACTICA; RAUTAVA P, 1993, BRIT MED J, V307, P600, DOI 10.1136/bmj.307.6904.600; SAMPSON HA, 1989, J PEDIATR-US, V115, P583, DOI 10.1016/S0022-3476(89)80285-9; TAUBMAN B, 1988, PEDIATRICS, V81, P756; TAUBMAN B, 1984, PEDIATRICS, V74, P998; WESSEL MA, 1954, PEDIATRICS, V14, P421; WOLKE D, 1994, PEDIATRICS, V94, P322; 1991, EPI INFO VERSION 5; 1992, GLIM SYSTEM RELEASE	35	80	85	0	7	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1995	96	6	1				886	892		10.1016/S0091-6749(95)70224-5	http://dx.doi.org/10.1016/S0091-6749(95)70224-5			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TN124	8543745	Bronze			2022-12-18	WOS:A1995TN12400004
J	TOOGOOD, JH; MARKOV, AE; BASKERVILLE, J; DYSON, C				TOOGOOD, JH; MARKOV, AE; BASKERVILLE, J; DYSON, C			ASSOCIATION OF OCULAR CATARACTS WITH INHALED AND ORAL STEROID-THERAPY DURING LONG-TERM TREATMENT OF ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CATARACTS; STEROID COMPLICATIONS; GLUCOCORTICOIDS; INHALED STEROIDS; BUDESONIDE; BECLOMETHASONE; DEXAMETHASONE	POSTERIOR SUBCAPSULAR CATARACTS; CORTICOSTEROID TREATMENT; BONE TURNOVER; BECLOMETHASONE DIPROPIONATE; SERUM OSTEOCALCIN; PREDNISOLONE; BUDESONIDE; CHILDREN; AEROSOL	Background: Posterior subcapsular cataracts (PSCs) have been reported to occur in some asthmatic patients treated with inhaled steroids. Methods: We studied the associations between the occurrence of PSCs and inhaled and oral steroid therapy in 48 adults in a cross-sectional survey by slit lamp. Accurate records of the patients' long-term usage of these drugs were available: 9.2 +/- 5.2 years for inhaled steroid and 9.1 +/- 9.3 years for prednisone (mean +/- SD). Their current inhaled steroid dosage averaged 1.46 +/- 0.85 mg/day (range, 0 to 3.2 mg/day). Results: Twenty-seven percent of the group had PSCs. The occurrence of PSCs correlated with the current daily dose and duration of prednisone use (p = 0.002 and p = 0.01, respectively), but not with the dose or duration of inhaled steroid treatment. As judged by multiple logistic regression analysis, neither the particular inhaled steroid drug used, nor its daily dose or cumulative dose, nor the additional nonsteroidal risk factors for PSCs also present in some of these patients contributed significantly to their risk of developing PSCs. Conclusions: The findings do not exclude the possibility that inhaled steroid therapy might lead to PSCs if a person has an exceptionally high inherent susceptibility. However, in the asthmatic population at large, the risk appears negligible, even if high doses of inhaled steroid are administered.	UNIV WESTERN ONTARIO,DEPT MED,LONDON N6A 3K7,ONTARIO,CANADA; KIEV INST PHTHISIATRY & PULM,DEPT ALLERGOL,KIEV,UKRAINE; UNIV WESTERN ONTARIO,DEPT STAT & ACTUARIAL SCI STATLAB,LONDON N6A 3K7,ONTARIO,CANADA; UNIV WESTERN ONTARIO,DEPT OPHTHALMOL,LONDON N6A 3K7,ONTARIO,CANADA; VICTORIA HOSP,IVEY INST OPHTHALMOL,LONDON N6A 4G5,ONTARIO,CANADA	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); University of Victoria; Western University (University of Western Ontario)	TOOGOOD, JH (corresponding author), VICTORIA HOSP,DEPT MED,375 SOUTH ST,LONDON N6A 4G5,ONTARIO,CANADA.							ALI NJ, 1991, THORAX, V46, P160, DOI 10.1136/thx.46.3.160; ALLEN MB, 1989, BRIT MED J, V299, P432, DOI 10.1136/bmj.299.6696.432; AMEMIYA T, 1980, OPHTHALMOLOGICA, V180, P129, DOI 10.1159/000308965; BACHMANN HJ, 1977, EUR J PEDIATR, V124, P277, DOI 10.1007/BF00441935; BARNES PJ, 1989, NEW ENGL J MED, V321, P1517; BLACK RL, 1960, JAMA-J AM MED ASSOC, V174, P150; BOCHOW TW, 1989, ARCH OPHTHALMOL-CHIC, V107, P369, DOI 10.1001/archopht.1989.01070010379027; BROWN HM, 1972, BRIT MED J, V1, P585, DOI 10.1136/bmj.1.5800.585; CAMERON SJ, 1973, BRIT MED J, V4, P205, DOI 10.1136/bmj.4.5886.205; CASTROW FF, 1981, J AM ACAD DERMATOL, V5, P64, DOI 10.1016/S0190-9622(81)70079-3; CHYLACK LT, 1989, ARCH OPHTHALMOL-CHIC, V107, P991, DOI 10.1001/archopht.1989.01070020053028; CREWS S. J., 1963, BRIT MED JOUR, V5346, P1644; DAVIES G, 1977, ANN INTERN MED, V86, P549, DOI 10.7326/0003-4819-86-5-549; DUGMORE WN, 1980, BRIT J OPHTHALMOL, V64, P689, DOI 10.1136/bjo.64.9.689; FANCOURT G J, 1988, European Respiratory Journal, V1, p196S; FINE RN, 1975, ANN SURG, V182, P585, DOI 10.1097/00000658-197511000-00009; FORMAN AR, 1977, AM J OPHTHALMOL, V84, P75, DOI 10.1016/0002-9394(77)90328-2; FRAUNFELDER FT, 1990, AM J OPHTHALMOL, V109, P489, DOI 10.1016/S0002-9394(14)74627-6; GAMBERTOGLIO JG, 1980, J CLIN ENDOCR METAB, V51, P561, DOI 10.1210/jcem-51-3-561; GILES CL, 1962, JAMA-J AM MED ASSOC, V182, P719, DOI 10.1001/jama.1962.03050460011003; HARDING JH, 1991, COMPUTER SIMULATION, P159; HARGREAVE FE, 1990, J ALLERGY CLIN IMMUN, V85, P1098, DOI 10.1016/0091-6749(90)90056-A; HODSMAN AB, 1991, J CLIN ENDOCR METAB, V72, P530, DOI 10.1210/jcem-72-3-530; JENNINGS BH, 1991, EUR J CLIN PHARMACOL, V40, P77, DOI 10.1007/BF00315143; JENNINGS BH, 1990, ASSESSMENT SYSTEMIC, V7, P1; KARIM AKA, 1989, BRIT MED J, V299, P918, DOI 10.1136/bmj.299.6704.918; KERREBIJN KF, 1990, AM REV RESPIR DIS, V141, pS77; KEWLEY GD, 1980, AUST PAEDIATR J, V16, P117; KOZOWER M, 1974, J CLIN ENDOCR METAB, V38, P407, DOI 10.1210/jcem-38-3-407; LIMAYE SR, 1988, ANN OPHTHALMOL, V20, P225; LOREDO A, 1972, NEW ENGL J MED, V286, P160; NASSIF E, 1987, J ALLERGY CLIN IMMUN, V80, P518, DOI 10.1016/0091-6749(87)90002-9; NISHIGORI H, 1987, INVEST OPHTH VIS SCI, V28, P168; OGLESBY RB, 1961, ARCH OPHTHALMOL-CHIC, V66, P97; OGLESBY RB, 1961, ARCH OPHTHALMOL-CHIC, V66, P41; POUW EM, 1991, BRIT MED J, V302, P627, DOI 10.1136/bmj.302.6777.627; ROOKLIN AR, 1979, J ALLERGY CLIN IMMUN, V63, P383, DOI 10.1016/0091-6749(79)90210-0; SEVEL D, 1977, J ALLERGY CLIN IMMUN, V60, P215, DOI 10.1016/0091-6749(77)90132-4; SHUNSHIN GA, 1989, BRIT J OPHTHALMOL, V73, P522, DOI 10.1136/bjo.73.7.522; SKALKA HW, 1980, ARCH OPHTHALMOL-CHIC, V98, P1773; Spaeth G L, 1966, Int Ophthalmol Clin, V6, P915, DOI 10.1097/00004397-196606040-00009; TEELUCKSINGH S, 1991, LANCET, V338, P60, DOI 10.1016/0140-6736(91)90058-W; TOOGOOD JH, 1989, J ALLERGY CLIN IMMUN, V84, P688, DOI 10.1016/0091-6749(89)90297-2; TOOGOOD JH, 1990, AM REV RESPIR DIS, V141, pS89; TOOGOOD JH, 1984, AM REV RESPIR DIS, V129, P723, DOI 10.1164/arrd.1984.129.5.723; TOOGOOD JH, 1991, J ALLERGY CLIN IMMUN, V88, P572, DOI 10.1016/0091-6749(91)90150-M; TOOGOOD JH, 1991, ANN ALLERGY, V67, P87; TOOGOOD JH, 1992, J ALLERGY CLIN IMMUN, V89, P186; TOOGOOD JH, 1978, J ALLERGY CLIN IMMUN, V61, P355, DOI 10.1016/0091-6749(78)90114-8; TOOGOOD JH, 1991, TODAYS THERAPEUTIC T, V9, P9; TURPEINEN M, 1991, J ALLERGY CLIN IMMUN, V88, P384, DOI 10.1016/0091-6749(91)90101-S; URBAN RC, 1986, SURV OPHTHALMOL, V31, P102, DOI 10.1016/0039-6257(86)90077-9; WALES JKH, 1991, LANCET, V338, P1535, DOI 10.1016/0140-6736(91)92362-6; WALMAN GB, 1972, CAN MED ASSOC J, V117, P1257; WILLIAMSON J, 1969, BRIT J OPHTHALMOL, V53, P361, DOI 10.1136/bjo.53.6.361; WOLTHERS OD, 1991, BMJ-BRIT MED J, V303, P163, DOI 10.1136/bmj.303.6795.163; YOUNG RW, 1991, AGE RELATED CATARACT, P95; 1991, CAN MED ASSOC J, V145, P637; 1976, BR J DIS CHEST, V70, P95; 1989, SAS STATE USERS GUID, V2; 1989, SAS STATE USERS GUID, V1	61	80	80	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1993	91	2					571	579		10.1016/0091-6749(93)90263-F	http://dx.doi.org/10.1016/0091-6749(93)90263-F			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KN548	8436773	Bronze			2022-12-18	WOS:A1993KN54800005
J	HAYDEN, ML; ROSE, G; DIDUCH, KB; DOMSON, P; CHAPMAN, MD; HEYMANN, PW; PLATTSMILLS, TAE				HAYDEN, ML; ROSE, G; DIDUCH, KB; DOMSON, P; CHAPMAN, MD; HEYMANN, PW; PLATTSMILLS, TAE			BENZYL BENZOATE MOIST POWDER - INVESTIGATION OF ACARICAL ACTIVITY IN CULTURES AND REDUCTION OF DUST MITE ALLERGENS IN CARPETS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						DUST MITES; CARPETS; ACARICIDES; BENZYL BENZOATE; ALLERGEN AVOIDANCE	HOUSE-DUST; DERMATOPHAGOIDES-PTERONYSSINUS; CHILDHOOD ASTHMA; CONTROLLED TRIAL; GRASS-POLLEN; P-I; F-I; QUANTIFICATION; AVOIDANCE; CHILDREN	Despite advances in the understanding of dust mites, it remains difficult to control exposure to mite allergens, and it is particularly difficult to reduce mites in fitted carpets or sofas. Several chemicals have been demonstrated to kill mites or denature mite allergens, and some of these chemicals have been investigated in carpets. Benzyl benzoate (BB), which has been widely used to kill scabies mites and is known to kill mites of the genus Dermatophagoides, has been used as a method of treating carpets. The present article describes experiments in the laboratory and in houses in testing two preparations of BB, a moist powder and a foam. The moist powder is composed of two ingredients, a wetted "inert" cellulose, which is designed to act as a cleaning agent, and the active BB adsorbed onto silicates. The active powder kills 90% of mites in culture within 12 hours and 100% in 24 hours, whereas the cellulose is not acaricidal. The moist-powder preparation was highly effective at killing D. farinae and D. pteronyssinus mites in the laboratory. In carpets the moist powder, applied for 12 hours with repeated brushing, was demonstrated to reduce the concentrations of group I and group II dust mite allergens in dust recovered at 1 month. This decrease in concentration could, in part, be explained by a persistent increased recovery of dust caused by residual white powder. However, when the recovery of group II allergens was calculated as the total allergen recovered, the decrease was highly significant at 2 weeks and 4 weeks after treatment (p < 0.001). Application of the powder to carpets for 4 hours or of the foam to sofas was less effective. After 2 months the effect on mite antigen in carpets was still present, but some increase was apparent, suggesting that repeat application after 2 or 3 months would be necessary to control mite-allergen levels.	UNIV VIRGINIA, DEPT MED, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, DEPT PEDIAT, CHARLOTTESVILLE, VA 22908 USA	University of Virginia; University of Virginia				Chapman, Martin/0000-0002-0845-3632	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020565, R37AI020565] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-20565] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARLIAN LG, 1981, PHYSIOL ZOOL, V54, P393, DOI 10.1086/physzool.54.4.30155831; BISCHOFF E, 1987, ALLERGOLOGIE, V10, P473; BURR ML, 1980, THORAX, V35, P506, DOI 10.1136/thx.35.7.506; CHAPMAN MD, 1987, J ALLERGY CLIN IMMUN, V80, P184, DOI 10.1016/0091-6749(87)90128-X; COLLOFF MJ, 1986, CLIN ALLERGY, V16, P41, DOI 10.1111/j.1365-2222.1986.tb01952.x; DESAINTGEORGESG.D, 1988, REV FR ALLERGOL, V28, P121; DOWSE GK, 1985, J ALLERGY CLIN IMMUN, V75, P75, DOI 10.1016/0091-6749(85)90016-8; FORD AW, 1985, INT ARCH ALLER A IMM, V76, P58, DOI 10.1159/000233662; GREEN WF, 1986, AUST NZ J MED, V16, P639, DOI 10.1111/j.1445-5994.1986.tb00002.x; GREEN WF, 1989, CLIN EXP ALLERGY, V19, P203, DOI 10.1111/j.1365-2222.1989.tb02365.x; HELLERHAUPT A, 1974, J MED ENTOMOL, V11, P551; HEYMANN PW, 1989, J ALLERGY CLIN IMMUN, V83, P1055, DOI 10.1016/0091-6749(89)90447-8; HOLCK A, 1986, ALLERGY, V41, P408, DOI 10.1111/j.1398-9995.1986.tb00320.x; KERREBIJN KF, 1970, BRONCHITIS, V3, P38; KNIEST FM, 1991, CLIN EXP ALLERGY, V21, P39, DOI 10.1111/j.1365-2222.1991.tb00802.x; KORSGAARD J, 1983, AM REV RESPIR DIS, V128, P231; KORSGAARD J, 1982, AM REV RESPIR DIS, V125, P80; LAUSCHADENDORF S, 1991, J ALLERGY CLIN IMMUN, V87, P41, DOI 10.1016/0091-6749(91)90211-6; LIND P, 1985, J ALLERGY CLIN IMMUN, V76, P753, DOI 10.1016/0091-6749(85)90682-7; LOMBARDERO M, 1990, J IMMUNOL, V144, P1353; LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; MITCHELL EB, 1985, CLIN ALLERGY, V15, P235, DOI 10.1111/j.1365-2222.1985.tb02280.x; MURRAY AB, 1983, PEDIATRICS, V71, P418; PAULI G, 1986, REV FR ALLERGOL, V26, P163, DOI 10.1016/S0335-7457(86)80027-2; PENAUD A, 1975, Clinical Allergy, V5, P109, DOI 10.1111/j.1365-2222.1975.tb01842.x; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V80, P755, DOI 10.1016/S0091-6749(87)80261-0; PLATTSMILLS TAE, 1982, LANCET, V2, P675; PLATTSMILLS TAE, 1989, J ALLERGY CLIN IMMUN, V83, P416, DOI 10.1016/0091-6749(89)90128-0; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V79, P781, DOI 10.1016/0091-6749(87)90211-9; SARSFIELD JK, 1974, ARCH DIS CHILD, V49, P711, DOI 10.1136/adc.49.9.711; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; SMITH JM, 1969, BRIT MED J, V2, P723, DOI 10.1136/bmj.2.5659.723; TOVEY ER, 1981, AM REV RESPIR DIS, V124, P630; VERVLOET D, 1982, J ALLERGY CLIN IMMUN, V69, P290, DOI 10.1016/S0091-6749(82)80006-7; VOORHORS.R, 1967, J ALLERGY, V39, P325, DOI 10.1016/0021-8707(67)90045-7; Voorhorst R., 1969, HOUSE DUST ATOPY HOU; WALSHAW MJ, 1986, Q J MED, V58, P199; WHARTON GW, 1976, J MED ENTOMOL, V12, P577, DOI 10.1093/jmedent/12.6.577	38	80	85	1	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1992	89	2					536	545		10.1016/0091-6749(92)90320-2	http://dx.doi.org/10.1016/0091-6749(92)90320-2			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HD753	1740584				2022-12-18	WOS:A1992HD75300005
J	JENSENJAROLIM, E; POULSEN, LK; WITH, H; KIEFFER, M; OTTEVANGER, V; SKOV, PS				JENSENJAROLIM, E; POULSEN, LK; WITH, H; KIEFFER, M; OTTEVANGER, V; SKOV, PS			ATOPIC-DERMATITIS OF THE FACE, SCALP, AND NECK - TYPE-I REACTION TO THE YEAST PITYROSPORUM-OVALE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ATOPIC DERMATITIS; PITYROSPORUM OVALE; YEAST; IGE; IMMUNOBLOTTING; HISTAMINE-RELEASE TEST; RAST	HISTAMINE-RELEASE; CANDIDA-ALBICANS; PROTEINS; DISEASE	We have previously reported that a lipophilic yeast, Pityrosporum ovale (P. ovale) produced a high frequency of positive skin prick tests and in vitro histamine-release (HR) tests in patients suffering from atopic dermatitis (AD) of the face, scalp, and neck. In the present study, our aim was to confirm the involvement of P. ovale-specific IgE and to produce a standardized extract for diagnostic tests; 7/20 sera from patients with a positive HR test were positive in RAST. Several IgE-binding proteins could be detected with sodium dodecyl sulfate-polyacrylamide gel electrophoresis, followed by immunoblotting. Comparison of different extraction methods demonstrated that allergens were not released from P. ovale until after mechanical destruction of the yeast cells. Extraction of cultured P. ovale, obtained from the skin of various individuals suffering from AD of the face, scalp, and neck, resulted in very heterogenous patterns of constituents in sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunoblotting analysis. Nevertheless, all extracts were recognized by patients' IgE. P. ovale may express varying protein patterns, depending on either source or stage of differentiation. Thus, at present, skin and HR tests may be superior to other available assays for diagnosing type I reactions to P. ovale in AD of the face, neck, and scalp.	NATL UNIV HOSP, MED DEPT TTA 7542, MED ALLERGOL LAB, TAGENSVEJ 20, DK-2200 COPENHAGEN N, DENMARK; NATL UNIV HOSP, DEPT DERMATOL & VENEREAL DIS, COPENHAGEN, DENMARK; UNIV COPENHAGEN, GENTOFTE HOSP, DEPT DERMATOL, DK-2900 HELLERUP, DENMARK; TECH UNIV DENMARK, DEPT BIOCHEM & NUTR, DK-2800 LYNGBY, DENMARK	University of Copenhagen; Herlev & Gentofte Hospital; Technical University of Denmark			Poulsen, Lars K/J-3065-2019; Jensen-Jarolim, Erika/C-5120-2018	Poulsen, Lars K/0000-0002-1730-847X; Jensen-Jarolim, Erika/0000-0003-4019-5765				ARCHER CB, 1988, BR J DERMATOL S33, V19, P32; AXELSEN NH, 1973, INFECT IMMUN, V7, P949, DOI 10.1128/IAI.7.6.949-960.1973; BLAYLOCK WK, 1976, J ALLERGY CLIN IMMUN, V57, P62, DOI 10.1016/0091-6749(76)90080-4; CLEMMENSEN OJ, 1983, SEMIN DERMATOL, V2, P26; COCA AF, 1922, J INFECT DIS, V30, P95; DAMERT GJ, 1980, INT ARCH ALLER A IMM, V63, P97, DOI 10.1159/000232614; DREBORG S, 1989, ALLERGY S10, V44; FAERGEMANN J, 1985, SEMIN DERMATOL, V4, P173; GORDON MA, 1951, MYCOLOGIA, V43, P524, DOI 10.2307/3755426; GORDON MA, 1951, J INVEST DERMATOL, V17, P267, DOI 10.1038/jid.1951.93; GREWE SR, 1982, J ALLERGY CLIN IMMUN, V70, P452, DOI 10.1016/0091-6749(82)90008-2; HANCOCK K, 1983, ANAL BIOCHEM, V133, P157, DOI 10.1016/0003-2697(83)90237-3; HANIFIN JM, 1982, J AM ACAD DERMATOL, V6, P1, DOI 10.1016/S0190-9622(82)70001-5; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; HASENCLEVER HF, 1964, J IMMUNOL, V93, P763; JOHANSSON S, IN PRESS ACTA DERM V; JUHLIN L, 1969, ARCH DERMATOL, V100, P12, DOI 10.1001/archderm.100.1.12; KIEFFER M, 1990, J AM ACAD DERMATOL, V22, P739, DOI 10.1016/0190-9622(90)70100-V; KOIVIKKO A, 1988, ALLERGY, V43, P192; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; PHAFF HJ, 1963, ANNU REV MICROBIOL, V17, P15, DOI 10.1146/annurev.mi.17.100163.000311; POULSEN LK, 1988, INT ARCH ALLER A IMM, V86, P383, DOI 10.1159/000234623; RACHELEFSKY GS, 1976, J ALLERGY CLIN IMMUN, V57, P569, DOI 10.1016/0091-6749(76)90008-7; RANDJANDICHE M, 1976, Bulletin de la Societe Francaise de Mycologie Medicale, V5, P79; RING J, 1981, INT ARCH ALLER A IMM, V65, P1, DOI 10.1159/000232730; ROBERTS SOB, 1969, BRIT J DERMATOL, V81, P264, DOI 10.1111/j.1365-2133.1969.tb13978.x; SALKIN I F, 1977, Canadian Journal of Microbiology, V23, P471, DOI 10.1139/m77-069; SAVOLAINEN J, 1990, ALLERGY, V45, P54, DOI 10.1111/j.1398-9995.1990.tb01084.x; SKOV PS, 1984, AGENTS ACTIONS, V14, P414, DOI 10.1007/BF01973840; WAERSTED A, 1985, ACTA DERM-VENEREOL, P146	30	80	85	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1992	89	1	1				44	51		10.1016/S0091-6749(05)80039-9	http://dx.doi.org/10.1016/S0091-6749(05)80039-9			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GZ908	1730839	Bronze			2022-12-18	WOS:A1992GZ90800005
J	KONDO, N; AGATA, H; FUKUTOMI, O; MOTOYOSHI, F; ORII, T				KONDO, N; AGATA, H; FUKUTOMI, O; MOTOYOSHI, F; ORII, T			LYMPHOCYTE-RESPONSES TO FOOD ANTIGENS IN PATIENTS WITH ATOPIC-DERMATITIS WHO ARE SENSITIVE TO FOODS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											KONDO, N (corresponding author), GIFU UNIV,SCH MED,DEPT PEDIAT,TSUKASA CHO 40,GIFU 500,JAPAN.							BLACK PL, 1980, J ALLERGY CLIN IMMUN, V66, P394, DOI 10.1016/0091-6749(80)90119-0; BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; CHUA YY, 1976, J ALLERGY CLIN IMMUN, V58, P477, DOI 10.1016/0091-6749(76)90191-3; HANIFIN JM, 1984, J ALLERGY CLIN IMMUN, V73, P211, DOI 10.1016/S0091-6749(84)80008-1; HOFFMAN DR, 1975, J ALLERGY CLIN IMMUN, V55, P256, DOI 10.1016/0091-6749(75)90145-1; HSIEH KH, 1984, J ALLERGY CLIN IMMUN, V74, P34, DOI 10.1016/0091-6749(84)90084-8; KONDO N, 1989, J RHEUMATOL, V16, P936; LEUNG DYM, 1983, J ALLERGY CLIN IMMUN, V71, P47, DOI 10.1016/0091-6749(83)90546-8; MIHM MC, 1976, J INVEST DERMATOL, V67, P305, DOI 10.1111/1523-1747.ep12514346; RAWLE FC, 1984, J IMMUNOL, V133, P195; SAMPSON HA, 1988, J ALLERGY CLIN IMMUN, V81, P635, DOI 10.1016/0091-6749(88)91033-0; SAMPSON HA, 1984, J ALLERGY CLIN IMMUN, V74, P26, DOI 10.1016/0091-6749(84)90083-6; SAMPSON HA, 1983, J ALLERGY CLIN IMMUN, V71, P473, DOI 10.1016/0091-6749(83)90464-5; SCHEINMANN P, 1976, CLIN ALLERGY, V6, P515, DOI 10.1111/j.1365-2222.1976.tb01936.x; SCHUR S, 1974, J ALLERGY CLIN IMMUN, V54, P174, DOI 10.1016/0091-6749(74)90054-2; VANSICKLE GJ, 1985, GASTROENTEROLOGY, V88, P1915, DOI 10.1016/0016-5085(85)90019-8; WRAITH DG, 1979, CLIN ALLERGY, V9, P25, DOI 10.1111/j.1365-2222.1979.tb01519.x	17	80	80	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1990	86	2					253	260		10.1016/S0091-6749(05)80073-9	http://dx.doi.org/10.1016/S0091-6749(05)80073-9			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DV316	2384653	Bronze			2022-12-18	WOS:A1990DV31600017
J	NAGPAL, S; RAJAPPA, L; METCALFE, DD; RAO, PVS				NAGPAL, S; RAJAPPA, L; METCALFE, DD; RAO, PVS			ISOLATION AND CHARACTERIZATION OF HEAT-STABLE ALLERGENS FROM SHRIMP (PENAEUS-INDICUS)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NIAID,MAST CELL PHYSIOL SECT,CLIN INVEST LAB,BLDG 10,RM 11C210,BETHESDA,MD 20892; INDIAN INST SCI,DEPT BIOCHEM,ALLERGY & APPL IMMUNOL LAB,BANGALORE 560012,KARNATAKA,INDIA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Indian Institute of Science (IISC) - Bangalore			Nagpal, Sunil/A-8007-2009; Srinivasa Rao, Prof. P/ABG-1688-2021	Srinivasa Rao, Prof. P/0000-0003-1379-4906				AAS K, 1973, Clinical Allergy, V3, P255, DOI 10.1111/j.1365-2222.1973.tb01331.x; ATKINS FM, 1985, J ALLERGY CLIN IMMUN, V75, P356, DOI 10.1016/0091-6749(85)90072-7; BERNSTEIN M, 1982, J ALLERGY CLIN IMMUN, V70, P205, DOI 10.1016/0091-6749(82)90043-4; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; HOFFMAN DR, 1981, ANN ALLERGY, V47, P17; HUSSAIN R, 1985, J IMMUNOL, V135, P1415; JOHNSON P, 1965, EUR POLYM J, V1, P63; KING TP, 1964, BIOCHEMISTRY-US, V3, P458, DOI 10.1021/bi00891a026; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHRER SB, 1986, ANN ALLERGY, V57, P267; Lowenstein H, 1978, Prog Allergy, V25, P1, DOI 10.1159/000314432; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NAGPAL S, 1987, J IMMUNOL, V138, P4169; RAO PVVS, 1985, J IMMUNOL METHODS, V57, P71; SACHS MI, 1981, J ALLERGY CLIN IMMUN, V67, P27, DOI 10.1016/0091-6749(81)90041-5; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WARING NP, 1985, J ALLERGY CLIN IMMUN, V76, P440, DOI 10.1016/0091-6749(85)90724-9	19	80	90	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1989	83	1					26	36		10.1016/0091-6749(89)90474-0	http://dx.doi.org/10.1016/0091-6749(89)90474-0			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	T0419	2913137				2022-12-18	WOS:A1989T041900005
J	HOFFMAN, DR; DOVE, DE; MOFFITT, JE; STAFFORD, CT				HOFFMAN, DR; DOVE, DE; MOFFITT, JE; STAFFORD, CT			ALLERGENS IN HYMENOPTERA VENOM .21. CROSS-REACTIVITY AND MULTIPLE REACTIVITY BETWEEN FIRE ANT VENOM AND BEE AND WASP VENOMS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV MISSISSIPPI,MED CTR,DEPT PEDIAT,JACKSON,MS 39216; MED COLL GEORGIA,ALLERGY IMMUNOL SECT,AUGUSTA,GA 30912	University of Mississippi; University of Mississippi Medical Center; University System of Georgia; Augusta University	HOFFMAN, DR (corresponding author), E CAROLINA UNIV,SCH MED,DEPT PATHOL,GREENVILLE,NC 27858, USA.							GOLDEN D B K, 1982, Journal of Allergy and Clinical Immunology, V69, P124; GOLDEN DBK, 1987, CLIN REV ALLERG, V5, P119; HOFFMAN DR, 1981, ANN ALLERGY, V46, P304; HOFFMAN DR, 1986, J ALLERGY CLIN IMMUN, V78, P337, DOI 10.1016/S0091-6749(86)80086-0; HOFFMAN DR, 1984, J ALLERGY CLIN IMMUN, V74, P93, DOI 10.1016/0091-6749(84)90094-0; HOFFMAN DR, 1977, J ALLERGY CLIN IMMUN, V59, P364, DOI 10.1016/0091-6749(77)90019-7; HOFFMAN DR, 1988, J ALLERGY CLIN IMMUN, V82, P818, DOI 10.1016/0091-6749(88)90084-X; HOFFMAN DR, 1985, J ALLERGY CLIN IMMUN, V75, P611, DOI 10.1016/0091-6749(85)90038-7; HOFFMAN DR, 1987, J ALLERGY CLIN IMMUN, V80, P300, DOI 10.1016/0091-6749(87)90035-2; HOFFMAN DR, 1985, J ALLERGY CLIN IMMUN, V75, P599, DOI 10.1016/0091-6749(85)90036-3; HOFFMAN DR, 1979, ANN ALLERGY, V42, P224; MOFFITT JE, 1986, J ALLERGY CLIN IMMUN, V77, P141; NORDVALL SL, 1985, J ALLERGY CLIN IMMUN, V75, P122, DOI 10.1016/0091-6749(85)90207-6; Rhoades R.B., 1977, MED ASPECTS IMPORTED; STAFFORD CT, 1987, J ALLERGY CLIN IMMUN, V79, P233	15	80	85	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1988	82	5	1				828	834		10.1016/0091-6749(88)90085-1	http://dx.doi.org/10.1016/0091-6749(88)90085-1			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	R1708	3192866				2022-12-18	WOS:A1988R170800017
J	REISMAN, J; GALDESSEBALT, M; KAZIM, F; CANNY, G; LEVISON, H				REISMAN, J; GALDESSEBALT, M; KAZIM, F; CANNY, G; LEVISON, H			FREQUENT ADMINISTRATION BY INHALATION OF SALBUTAMOL AND IPRATROPIUM BROMIDE IN THE INITIAL MANAGEMENT OF SEVERE ACUTE ASTHMA IN CHILDREN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HOSP SICK CHILDREN,DEPT PEDIAT,DIV CHEST DIS,555 UNIV AVE,TORONTO M5G 1X8,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)								BECK R, 1985, J PEDIATR-US, V107, P605, DOI 10.1016/S0022-3476(85)80033-0; BECKER AB, 1983, J PEDIATR-US, V102, P465, DOI 10.1016/S0022-3476(83)80679-9; BENZVI Z, 1982, PEDIATRICS, V70, P348; CANNY GJ, 1986, CHEST, V90, P46; CHOWIENCZYK PJ, 1982, BRIT MED J, V285, P15, DOI 10.1136/bmj.285.6334.15; DAVIS A, 1984, J PEDIATR-US, V105, P1002, DOI 10.1016/S0022-3476(84)80099-2; GROSS NJ, 1984, AM REV RESPIR DIS, V129, P856, DOI 10.1164/arrd.1984.129.5.856; REBUCK AS, 1987, AM J MED, V82, P59, DOI 10.1016/0002-9343(87)90378-0; REBUCK AS, 1982, CHEST S, V82, P55; ROBERTSON CF, 1985, J PEDIATR-US, V106, P672, DOI 10.1016/S0022-3476(85)80101-3; WENG TR, 1969, AM REV RESPIR DIS, V99, P879; 1983, ANTICHOLINERGIC THER	12	80	80	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1988	81	1					16	20		10.1016/0091-6749(88)90214-X	http://dx.doi.org/10.1016/0091-6749(88)90214-X			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	M0274	2963059				2022-12-18	WOS:A1988M027400003
J	PLATTSMILLS, TAE; HEYMANN, PW; CHAPMAN, MD; HAYDEN, ML; WILKINS, SR				PLATTSMILLS, TAE; HEYMANN, PW; CHAPMAN, MD; HAYDEN, ML; WILKINS, SR			CROSS-REACTING AND SPECIES-SPECIFIC DETERMINANTS ON A MAJOR ALLERGEN FROM DERMATOPHAGOIDES-PTERONYSSINUS AND D FARINAE - DEVELOPMENT OF A RADIOIMMUNOASSAY FOR ANTIGEN P-1 EQUIVALENT IN HOUSE DUST AND DUST MITE EXTRACTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											PLATTSMILLS, TAE (corresponding author), UNIV VIRGINIA,DEPT MED,DIV ALLERGY & CLIN IMMUNOL,BOX 225,CHARLOTTESVILLE,VA 22908, USA.			Chapman, Martin/0000-0002-0845-3632	NIAID NIH HHS [AI 20565] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020565, R37AI020565] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARLIAN LG, 1982, J ALLERGY CLIN IMMUN, V69, P527, DOI 10.1016/0091-6749(82)90178-6; BRONSWIJK JE, 1971, J ALLERGY, V47, P31; BURR ML, 1980, THORAX, V35, P506, DOI 10.1136/thx.35.7.506; CHAPMAN MD, 1980, J IMMUNOL, V125, P587; CHAPMAN MD, 1980, INT ARCH ALLER A IMM, V61, P431, DOI 10.1159/000232471; CHAPMAN MD, 1981, THESIS U LONDON; CLARKE CW, 1979, CLIN ALLERGY, V9, P147, DOI 10.1111/j.1365-2222.1979.tb01535.x; FORD A, 1985, J ALLERGY CLIN IMMUN, V75, P676, DOI 10.1016/0091-6749(85)90093-4; FORD AW, 1985, INT ARCH ALLER A IMM, V76, P58, DOI 10.1159/000233662; GARVEY JS, 1977, METHOD IMMUNOL, P280; GREEN W, 1982, PAPUA NEW GUINEA MED, V25, P219; HENDRICK DJ, 1975, THORAX, V30, P2, DOI 10.1136/thx.30.1.2; HOLCK AL, 1982, 11 P INT C ALL CLIN, P474; Hughes, 1976, MITES STORED FOOD HO; KAHN CR, 1983, J ALLERGY CLIN IMMUN, V71, P95, DOI 10.1016/0091-6749(83)90149-5; KAWAI T, 1972, J ALLERGY CLIN IMMUN, V50, P117, DOI 10.1016/0091-6749(72)90007-3; KERN A, 1921, MED CLIN N AM, V5, P751; KERREBIJN KF, 1970, BRONCHITIS, V3, P38; KORSGAARD J, 1983, AM REV RESPIR DIS, V128, P231; KORSGAARD J, 1982, AM REV RESPIR DIS, V125, P80; LANG JD, 1978, ENVIRON ENTOMOL, V7, P281, DOI 10.1093/ee/7.2.281; LEMAO J, 1983, J ALLERGY CLIN IMMUN, V71, P588, DOI 10.1016/0091-6749(83)90441-4; LIND P, 1979, ALLERGY, V34, P319; LIND P, 1982, Journal of Allergy and Clinical Immunology, V69, P127; MARSH DG, 1975, ANTIGENS, V3, P271; MAUNSELL K, 1968, LANCET, V1, P1267; MIYAMOTO T, 1974, J ALLERGY CLIN IMMUN, V53, P9, DOI 10.1016/0091-6749(74)90094-3; MIYAMOTO T, 1970, ANN ALLERGY, V28, P405; MURRAY AB, 1983, PEDIATRICS, V71, P418; MURRAY AB, 1979, J ALLERGY CLIN IMMUN, V64, P266, DOI 10.1016/0091-6749(79)90142-8; PLATTSMILLS TAE, 1982, LANCET, V2, P675; Romagnani S, 1972, Clin Allergy, V2, P115, DOI 10.1111/j.1365-2222.1972.tb01276.x; SARSFIELD JK, 1974, ARCH DIS CHILD, V49, P716, DOI 10.1136/adc.49.9.716; SHAMIYEH NB, 1973, J ECON ENTOMOL, V66, P998, DOI 10.1093/jee/66.4.998; SHARP JL, 1970, P HAWAII ENTOMOL SOC, V20, P583; SMITH JM, 1969, BRIT MED J, V2, P723, DOI 10.1136/bmj.2.5659.723; SMITH TF, 1985, J ALLERGY CLIN IMMUN, V76, P782, DOI 10.1016/0091-6749(85)90748-1; Spivacke CA, 1925, J IMMUNOL, V10, P465; TOVEY E, 1979, CLIN ALLERGY, V9, P253, DOI 10.1111/j.1365-2222.1979.tb01551.x; TOVEY ER, 1981, AM REV RESPIR DIS, V124, P630; TOVEY ER, 1981, NATURE, V289, P592, DOI 10.1038/289592a0; Van Leeuwen WS, 1927, LANCET, V1, P1287; VANNIER WE, 1961, J ALLERGY, V32, P36, DOI 10.1016/0021-8707(61)90037-5; VOORHORS.R, 1967, J ALLERGY, V39, P325, DOI 10.1016/0021-8707(67)90045-7; VOORHORST R, 1969, ACTA ALLERGOL, V24, P124; WHARTON GW, 1976, J MED ENTOMOL, V12, P577, DOI 10.1093/jmedent/12.6.577	46	80	80	3	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1986	78	3	1				398	407		10.1016/0091-6749(86)90024-2	http://dx.doi.org/10.1016/0091-6749(86)90024-2			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	E1148	2428855				2022-12-18	WOS:A1986E114800005
J	STRICKER, WE; ANORVELOPEZ, E; REED, CE				STRICKER, WE; ANORVELOPEZ, E; REED, CE			FOOD SKIN TESTING IN PATIENTS WITH IDIOPATHIC ANAPHYLAXIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MAYO CLIN & MAYO FDN,ALLERG DIS & INTERNAL MED,ROCHESTER,MN 55905	Mayo Clinic								AAS K, 1978, CLIN ALLERGY, V8, P39, DOI 10.1111/j.1365-2222.1978.tb00446.x; BACAL E, 1978, CLIN ALLERGY, V8, P295, DOI 10.1111/j.1365-2222.1978.tb03227.x; BENNER MH, 1973, J ALLERGY CLIN IMMUN, V52, P307, DOI 10.1016/0091-6749(73)90050-X; BOOTH BH, 1972, ALLERGIC DIS DIAGNOS, P74; BROOM BC, 1983, CLIN ALLERGY, V13, P169, DOI 10.1111/j.1365-2222.1983.tb02585.x; GILLESPIE DN, 1976, J ALLERGY CLIN IMMUN, V57, P302, DOI 10.1016/0091-6749(76)90086-5; LIEBERMAN P, 1979, ARCH INTERN MED, V139, P1032, DOI 10.1001/archinte.139.9.1032; MAULITZ RM, 1979, J ALLERGY CLIN IMMUN, V63, P433, DOI 10.1016/0091-6749(79)90218-5; PARKER JL, 1981, J ALLERGY CLIN IMMUN, V67, P78, DOI 10.1016/0091-6749(81)90050-6; SALBERG DJ, 1980, ARCH INTERN MED, V140, P864, DOI 10.1001/archinte.1980.00330180138047; SALE SR, 1981, JAMA-J AM MED ASSOC, V246, P2336, DOI 10.1001/jama.246.20.2336; SAMPSON HA, 1984, J ALLERGY CLIN IMMUN, V74, P26, DOI 10.1016/0091-6749(84)90083-6; SONIN L, 1983, ANN INTERN MED, V99, P634, DOI 10.7326/0003-4819-99-5-634	13	80	81	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1986	77	3					516	519		10.1016/0091-6749(86)90188-0	http://dx.doi.org/10.1016/0091-6749(86)90188-0			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	A5367	3950255				2022-12-18	WOS:A1986A536700017
J	ANDERSON, SD				ANDERSON, SD			ISSUES IN EXERCISE-INDUCED ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											ANDERSON, SD (corresponding author), ROYAL PRINCE ALFRED HOSP,DEPT THORAC MED,CAMPERDOWN,NSW 2050,AUSTRALIA.			Anderson, Sandra/0000-0002-6308-8770				AITKEN ML, 1985, AM REV RESPIR DIS, V131, P357; ANDERSON S, 1979, J ALLERGY CLIN IMMUN, V64, P612, DOI 10.1016/0091-6749(79)90024-1; ANDERSON SD, 1981, THORAX, V36, P259, DOI 10.1136/thx.36.4.259; ANDERSON SD, 1979, LANCET, V2, P629; ANDERSON SD, 1985, EUR J RESPIR DIS, V67, P20; ANDERSON SD, 1983, THORAX, V38, P284, DOI 10.1136/thx.38.4.284; ANDERSON SD, 1975, BRIT J DIS CHEST, V69, P1; ANDERSON SD, 1982, EUR J RESPIR DIS, V63, P459; ANDERSON SD, 1983, ALLERGY, V38, P289, DOI 10.1111/j.1398-9995.1983.tb04122.x; ANDERSON SD, 1976, AM REV RESPIR DIS, V114, P493; ANDERSON SD, 1976, SCAND J RESPIR DIS, V57, P41; ANDERSON SD, 1985, CLIN REV ALLERGY; ANDERSON SD, 1983, ASTHMATIC CHILD PLAY, P21; ANDERSON SD, 1985, CHEST, V87, P191; ANDERSON SD, 1984, J ALLERGY CLIN IMMUN, V73, P661; BARNES PJ, 1981, THORAX, V36, P435, DOI 10.1136/thx.36.6.435; BARNES PJ, 1981, THORAX, V36, P726, DOI 10.1136/thx.36.10.726; BARNES PJ, 1981, CLIN SCI, V61, P159, DOI 10.1042/cs0610159; BARNES PJ, 1981, J ALLERGY CLIN IMMUN, V68, P411, DOI 10.1016/0091-6749(81)90193-7; BARNES PJ, 1983, EUR J RESPIR DIS, V64, P559; BARYISHAY E, 1984, LUNG, V162, P195, DOI 10.1007/BF02715648; BEIL M, 1977, KLIN WOCHENSCHR, V55, P577, DOI 10.1007/BF01490511; BIANCO S, 1974, BMJ-BRIT MED J, V4, P18, DOI 10.1136/bmj.4.5935.18; BIERMAN WC, 1984, J ALLERGY CLIN IMMUN, V73, P654; BLACK J, 1981, EUR J PHARMACOL, V72, P83, DOI 10.1016/0014-2999(81)90300-9; BLACK J, 1985, BRIT J CLIN PHARMACO, V20, P41, DOI 10.1111/j.1365-2125.1985.tb02796.x; BLACK JL, 1984, BRIT J CLIN PHARMACO, V18, P349, DOI 10.1111/j.1365-2125.1984.tb02475.x; BLACK JL, 1982, BRIT J CLIN PHARMACO, V14, P464, DOI 10.1111/j.1365-2125.1982.tb02012.x; BLACK JL, 1985, B EUR PHYSIOPATHOL R; BRESLIN FJ, 1980, AM REV RESPIR DIS, V122, P11; BYE PTP, 1980, EUR J RESPIR DIS, V61, P287; CHANYEUNG MM, 1971, AM REV RESPIR DIS, V104, P915; CHEN WY, 1977, RESPIRATION, V34, P305, DOI 10.1159/000193842; CHRYSSANTHOPOULOS C, 1978, J ALLERGY CLIN IMMUN, V61, P17, DOI 10.1016/0091-6749(78)90468-2; CHUNG JTN, 1979, BMJ-BRIT MED J, V2, P1033, DOI 10.1136/bmj.2.6197.1033; DEAL EC, 1979, J APPL PHYSIOL, V46, P484, DOI 10.1152/jappl.1979.46.3.484; DEAL EC, 1979, J APPL PHYSIOL, V46, P467, DOI 10.1152/jappl.1979.46.3.467; DEAL EC, 1979, J APPL PHYSIOL, V46, P476, DOI 10.1152/jappl.1979.46.3.476; DEAL EC, 1980, J CLIN INVEST, V65, P659, DOI 10.1172/JCI109711; EGGLESTON PA, 1984, AM REV RESPIR DIS, V130, P86; ELWOOD RK, 1982, AM REV RESPIR DIS, V125, P61; ESCHENBACHER WL, 1985, AM REV RESPIR DIS, V131, P894; FANTA CH, 1981, AM REV RESPIR DIS, V123, P161; FANTA CH, 1980, AM REV RESPIR DIS, V122, P381; HAHN A, 1984, AM REV RESPIR DIS, V130, P575; HAHN AG, 1984, THORAX, V39, P919, DOI 10.1136/thx.39.12.919; HARRIES MG, 1981, LANCET, V1, P5; HARTLEY JPR, 1980, THORAX, V35, P675, DOI 10.1136/thx.35.9.675; HARTLEY JPR, 1980, THORAX, V35, P680, DOI 10.1136/thx.35.9.680; HENDERSON AF, 1983, THORAX, V38, P512, DOI 10.1136/thx.38.7.512; HOGG JC, 1984, AM REV RESPIR DIS, V129, P207; INGELSTEDT S, 1956, Acta Otolaryngol Suppl, V131, P1; INGRAM RH, 1983, EUR J RESPIR DIS, V64, P242; JACKSON DM, 1977, BRIT J PHARMACOL, V61, P257, DOI 10.1111/j.1476-5381.1977.tb08413.x; KILBURN KH, 1968, AM REV RESPIR DIS, V98, P449; KILHAM H, 1979, THORAX, V34, P582, DOI 10.1136/thx.34.5.582; KIVILOOG J, 1973, SCAND J RESPIR DIS, V54, P359; KIVITY S, 1980, RESPIRATION, V40, P169, DOI 10.1159/000194275; KNEUSSL MP, 1978, J APPL PHYSIOL, V45, P307, DOI 10.1152/jappl.1978.45.2.307; LARSSON K, 1982, CHEST, V82, P560, DOI 10.1378/chest.82.5.560; LATIMER KM, 1983, AM REV RESPIR DIS, V128, P440, DOI 10.1164/arrd.1983.128.3.440; LEE TH, 1984, J ALLERGY CLIN IMMUN, V73, P634, DOI 10.1016/0091-6749(84)90296-3; LEE TH, 1982, J ALLERGY CLIN IMMUN, V70, P73, DOI 10.1016/0091-6749(82)90232-9; LEE TH, 1983, LANCET, V2, P164; LEE TH, 1983, NEW ENGL J MED, V308, P1502, DOI 10.1056/NEJM198306233082504; LEE TH, 1982, J CLIN INVEST, V69, P889, DOI 10.1172/JCI110528; MCFADDEN ER, 1982, J CLIN INVEST, V69, P700, DOI 10.1172/JCI110498; MCFADDEN ER, 1979, NEW ENGL J MED, V301, P763; MITCHELL JW, 1972, J APPL PHYSIOL, V32, P474, DOI 10.1152/jappl.1972.32.4.474; NADEL JA, 1975, POSTGRAD MED J, V51, P86; NADEL JA, 1984, J ALLERGY CLIN IMMUN, V73, P651, DOI 10.1016/0091-6749(84)90299-9; NADEL JA, 1985, ASTHMA, V3, P129; NAGAKURA T, 1983, AM REV RESPIR DIS, V128, P294; NIINIMAA V, 1980, RESP PHYSIOL, V42, P61, DOI 10.1016/0034-5687(80)90104-8; OBRYNE PM, 1982, AM REV RESPIR DIS, V125, P281; OBYRNE PM, 1983, AM REV RESPIR DIS, V128, P611; PAKES GE, 1980, DRUGS, V20, P237, DOI 10.2165/00003495-198020040-00001; PATEL KR, 1976, J ALLERGY CLIN IMMUN, V57, P285, DOI 10.1016/0091-6749(76)90084-1; PHILLIPS YY, 1985, AM REV RESPIR DIS, V131, P31; POTTER JL, 1967, AM REV RESPIR DIS, V96, P83; RICHARDSON J, 1976, J APPL PHYSIOL, V41, P764, DOI 10.1152/jappl.1976.41.5.764; ROSENTHAL R R, 1984, Journal of Allergy and Clinical Immunology, V73, P179; ROSENTHAL RR, 1985, J ALLERGY CLIN IMMUN, V75, P194, DOI 10.1016/0091-6749(85)90493-2; SCHOEFFEL RE, 1981, BRIT MED J, V283, P1285, DOI 10.1136/bmj.283.6302.1285; SCHOEFFEL RE, 1980, THORAX, V35, P164, DOI 10.1136/thx.35.3.164; SCHOEFFEL RE, 1983, AUST NZ J MED, V13, P157, DOI 10.1111/j.1445-5994.1983.tb02672.x; SHEPPARD D, 1982, J APPL PHYSIOL, V53, P169, DOI 10.1152/jappl.1982.53.1.169; SILVERMAN M, 1972, Clinical Allergy, V2, P137, DOI 10.1111/j.1365-2222.1972.tb01278.x; SIMONSSON SG, 1972, SCAND J RESPIR DIS, V53, P227; SMITH CM, 1985, J ALLERGY CLIN IMMUN, V75, P143, DOI 10.1016/0091-6749(85)90288-X; STEARNS DR, 1981, J APPL PHYSIOL, V50, P503, DOI 10.1152/jappl.1981.50.3.503; STRAUSS RH, 1978, J CLIN INVEST, V61, P433, DOI 10.1172/JCI108954; STRAUSS RH, 1977, NEW ENGL J MED, V297, P743, DOI 10.1056/NEJM197710062971402; TENNEY SM, 1956, AM J PHYSIOL, V187, P341, DOI 10.1152/ajplegacy.1956.187.2.341; THOMSON NC, 1978, THORAX, V33, P694, DOI 10.1136/thx.33.6.694; TULLETT WM, 1982, THORAX, V37, P737, DOI 10.1136/thx.37.10.737; WALDEN SM, 1984, AM REV RESPIR DIS, V130, P357; Weibel ER, 1964, HDB PHYSIOLOGY RES 3, V1, P285; WEILERRAVELL D, 1981, J ALLERGY CLIN IMMUN, V67, P391, DOI 10.1016/0091-6749(81)90085-3; WEISS JW, 1983, J ALLERGY CLIN IMMUN, V72, P140, DOI 10.1016/0091-6749(83)90521-3; WIDDICOMBE JG, 1977, ASTHMA PHYSL IMMUNOP, V2, P225; WILSON N, 1984, THORAX, V39, P588, DOI 10.1136/thx.39.8.588; WILSON NM, 1982, THORAX, V37, P657, DOI 10.1136/thx.37.9.657; WOENNE R, 1979, AM REV RESPIR DIS, V119, P927; ZIELINSKI J, 1980, THORAX, V35, P823, DOI 10.1136/thx.35.11.823	105	80	80	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1985	76	6					763	772		10.1016/0091-6749(85)90745-6	http://dx.doi.org/10.1016/0091-6749(85)90745-6			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AWX93	2999208				2022-12-18	WOS:A1985AWX9300001
J	BASICH, JE; GRAVES, TS; BAZ, MN; SCANLON, G; HOFFMANN, RG; PATTERSON, R; FINK, JN				BASICH, JE; GRAVES, TS; BAZ, MN; SCANLON, G; HOFFMANN, RG; PATTERSON, R; FINK, JN			ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS IN CORTICOSTEROID-DEPENDENT ASTHMATICS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MED COLL WISCONSIN, DEPT LOW TEMP ENGN PHYS, ALLERGY SECT, MILWAUKEE, WI 53226 USA; MED COLL WISCONSIN, DEPT PREVENT MED, MILWAUKEE, WI 53226 USA; MED COLL WISCONSIN, DEPT RADIOL, MILWAUKEE, WI 53226 USA; VET ADM CTR, WOOD, WI 53193 USA; NORTHWESTERN UNIV, SCH MED, DEPT MED, ALLERGY SECT, CHICAGO, IL 60611 USA	Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin; Northwestern University					NHLBI NIH HHS [HL-15389] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		GREENBERGER PA, 1980, J ALLERGY CLIN IMMUN, V66, P327, DOI 10.1016/0091-6749(80)90029-9; HENDERSON AH, 1968, THORAX, V23, P513, DOI 10.1136/thx.23.5.513; HINSON KFW, 1952, THORAX, V7, P317, DOI 10.1136/thx.7.4.317; HOEHNE JH, 1973, CHEST, V63, P177, DOI 10.1378/chest.63.2.177; HORN BR, 1975, NEW ENGL J MED, V292, P1152, DOI 10.1056/NEJM197505292922204; IMBEAU SA, 1978, J ALLERGY CLIN IMMUN, V62, P91, DOI 10.1016/0091-6749(78)90084-2; IMBEAU SA, 1978, J ALLERGY CLIN IMMUN, V62, P243, DOI 10.1016/0091-6749(78)90214-2; KURUP VP, 1977, MICROBIOS, V19, P191; KURUP VP, 1978, AM J CLIN PATHOL, V69, P414; MALO JL, 1977, THORAX, V32, P254, DOI 10.1136/thx.32.3.254; PATTERSON R, 1974, INT ARCH ALLER A IMM, V46, P150, DOI 10.1159/000231119; PEPYS J, 1959, AM REV RESPIR DIS, V80, P167; ROSENBERG M, 1977, ANN INTERN MED, V86, P405, DOI 10.7326/0003-4819-86-4-405; ROSENBERG M, 1978, AM J MED, V64, P599, DOI 10.1016/0002-9343(78)90579-X; ROSENBERG M, 1979, J CHRON DIS, V30, P193; SAFIRSTEIN BH, 1973, AM REV RESPIR DIS, V108, P450; SLAVIN RG, 1969, AM J MED, V47, P306, DOI 10.1016/0002-9343(69)90156-9; VANSELOW NA, 1967, MANUAL CLIN ALLERGY, P55; WANG JLF, 1978, AM REV RESPIR DIS, V117, P917; WANG JLF, 1979, AM REV RESPIR DIS, V120, P87	20	80	81	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	68	2					98	102		10.1016/0091-6749(81)90165-2	http://dx.doi.org/10.1016/0091-6749(81)90165-2			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MD162	7252001				2022-12-18	WOS:A1981MD16200003
J	GEHA, RS; RAPPAPORT, JM; TWAROG, FJ; PARKMAN, R; ROSEN, FS				GEHA, RS; RAPPAPORT, JM; TWAROG, FJ; PARKMAN, R; ROSEN, FS			INCREASED SERUM IMMUNOGLOBULIN-E LEVELS FOLLOWING ALLOGENEIC BONE-MARROW TRANSPLANTATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CHILDRENS HOSP MED CTR, DIV HEMATOL ONCOL, BOSTON, MA 02115 USA; SIDNEY FARBER CANC INST, BOSTON, MA 02115 USA; PETER BENT BRIGHAM HOSP, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PEDIAT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	GEHA, RS (corresponding author), CHILDRENS HOSP MED CTR, DIV ALLERGY & IMMUNOL, BOSTON, MA 02115 USA.							ARBESMAN CE, 1975, BIOL ROLE IMMUNOGLOB, P269; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; CHIORAZZI N, 1977, J EXP MED, V146, P302, DOI 10.1084/jem.146.1.302; CHIORAZZI N, 1977, J IMMUNOL, V118, P48; FASS L, 1973, TRANSPLANTATION, V16, P630, DOI 10.1097/00007890-197312000-00015; GEHA RS, 1975, J CLIN INVEST, V56, P386, DOI 10.1172/JCI108103; ISHIZAKA K, 1976, J IMMUNOL, V117, P40; KATZ DH, 1974, J IMMUNOL, V113, P974; KIKKAWA Y, 1973, PEDIATRICS, V51, P690; REINHERZ EL, 1979, NEW ENGL J MED, V300, P1061, DOI 10.1056/NEJM197905103001901; RINGDEN O, 1979, J IMMUNOL, V123, P2729; TADA T, 1975, PROG ALLERGY, V19, P122, DOI 10.1159/000313387; TAKATSU K, 1976, J IMMUNOL, V116, P1257; THOMAS ED, 1975, NEW ENGL J MED, V292, P832, DOI 10.1056/NEJM197504172921605; WALDMANN TA, 1972, J IMMUNOL, V109, P304; WITHERSPOON RP, 1978, TRANSPLANTATION, V26, P407, DOI 10.1097/00007890-197812000-00008	16	80	80	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	66	1					78	81		10.1016/0091-6749(80)90142-6	http://dx.doi.org/10.1016/0091-6749(80)90142-6			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JZ541	6991585	Bronze			2022-12-18	WOS:A1980JZ54100012
J	YUNGINGER, JW; PAULL, BR; JONES, RT; SANTRACH, PJ				YUNGINGER, JW; PAULL, BR; JONES, RT; SANTRACH, PJ			RUSH VENOM IMMUNOTHERAPY PROGRAM FOR HONEYBEE STING SENSITIVITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MAYO CLIN & MAYO FDN,DEPT PEDIAT,ROCHESTER,MN 55901; MAYO CLIN & MAYO FDN,DEPT INTERNAL MED,ROCHESTER,MN 55901	Mayo Clinic; Mayo Clinic	YUNGINGER, JW (corresponding author), MAYO CLIN & MAYO FDN,ALLERG DIS RES LAB,ROCHESTER,MN 55901, USA.							BENTON AW, 1963, SCIENCE, V142, P228, DOI 10.1126/science.142.3589.228; BUSSE WW, 1975, JAMA-J AM MED ASSOC, V231, P1154, DOI 10.1001/jama.231.11.1154; FRANKLIN R, 1975, J ALLERGY CLIN IMMUN, V55, P285, DOI 10.1016/0091-6749(75)90001-9; GLEICH GJ, 1976, MANUAL CLIN IMMUNOLO, P575; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; HABERMANN E, 1972, ANAL BIOCHEM, V50, P163, DOI 10.1016/0003-2697(72)90495-2; HOFFMAN DR, 1976, J ALLERGY CLIN IMMUN, V58, P551, DOI 10.1016/0091-6749(76)90201-3; HOFFMAN DR, 1977, J ALLERGY CLIN IMMUN, V59, P147, DOI 10.1016/0091-6749(77)90217-2; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; KABAT EA, 1967, EXPT IMMUNOCHEMISTRY, P559; KARPAS AB, 1977, J ALLERGY CLIN IMMUN, V60, P155, DOI 10.1016/0091-6749(77)90118-X; KING TP, 1976, ARCH BIOCHEM BIOPHYS, V172, P661, DOI 10.1016/0003-9861(76)90121-1; LICHTENSTEIN LM, 1974, NEW ENGL J MED, V290, P1223, DOI 10.1056/NEJM197405302902204; LIGHT WC, 1976, J ALLERGY CLIN IMMUN, V58, P322, DOI 10.1016/0091-6749(76)90138-X; LOVELESS MARY HEWITT, 1956, ANN ALLERGY, V14, P347; LOVELESS MH, 1977, ANN ALLERGY, V38, P299; PAULL BR, 1977, J ALLERGY CLIN IMMUN, V59, P334, DOI 10.1016/0091-6749(77)90056-2; SOBOTKA AK, 1976, J ALLERGY CLIN IMMUN, V57, P29, DOI 10.1016/0091-6749(76)90076-2; SOBOTKA AK, 1974, J ALLERGY CLIN IMMUN, V53, P170, DOI 10.1016/0091-6749(74)90005-0; YUNGINGER JW, 1978, J ALLERGY CLIN IMMUN, V61, P93, DOI 10.1016/0091-6749(78)90231-2	20	80	82	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	63	5					340	347		10.1016/0091-6749(79)90129-5	http://dx.doi.org/10.1016/0091-6749(79)90129-5			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GU943	429714				2022-12-18	WOS:A1979GU94300008
J	ISHIZAKA, T; ISHIZAKA, K; CONRAD, DH; FROESE, A				ISHIZAKA, T; ISHIZAKA, K; CONRAD, DH; FROESE, A			NEW CONCEPT OF TRIGGERING MECHANISMS OF IGE-MEDIATED HISTAMINE-RELEASE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV MANITOBA, FAC MED, DEPT IMMUNOL, MRC, ALLERGY RES GRP, WINNIPEG R3T 2N2, MANITOBA, CANADA; JOHNS HOPKINS UNIV, GOOD SAMARITAN HOSP, SCH MED, DEPT MED & MICROBIOL, BALTIMORE, MD 21239 USA	University of Manitoba; Johns Hopkins University	ISHIZAKA, T (corresponding author), GOOD SAMARITAN HOSP, BALTIMORE, MD 21239 USA.							AUSTEN KF, 1976, MOL BIOL ASPECTS ACU, P293; BECKER KE, 1973, J EXP MED, V138, P394, DOI 10.1084/jem.138.2.394; CONRAD DH, 1976, J IMMUNOL, V116, P319; CONRAD DH, 1977, J IMMUNOL, V120, P507; CONRAD DH, 1977, J IMMUNOL, V120, P429; CONRAD DH, 1975, J IMMUNOL, V114, P1688; DAERON M, 1975, CELL IMMUNOL, V20, P133, DOI 10.1016/0008-8749(75)90092-1; de Weck A L, 1972, Int Arch Allergy Appl Immunol, V42, P782; FOREMAN JC, 1973, NATURE, V245, P249, DOI 10.1038/245249a0; GOLDSCHNEIDER I, 1973, J EXP MED, V138, P1443, DOI 10.1084/jem.138.6.1443; ISERSKY C, 1977, J IMMUNOL, V119, P123; ISHIZAKA K, 1969, J IMMUNOL, V103, P588; ISHIZAKA K, 1968, J IMMUNOL, V101, P68; ISHIZAKA K, 1970, IMMUNOCHEMISTRY, V7, P687, DOI 10.1016/0019-2791(70)90175-8; ISHIZAKA T, 1975, PROG ALLERGY, V19, P60, DOI 10.1159/000313384; ISHIZAKA T, 1973, J IMMUNOL, V111, P500; ISHIZAKA T, 1978, J IMMUNOL, V120, P800; ISHIZAKA T, 1974, J IMMUNOL, V112, P1078; ISHIZAKA T, 1977, J IMMUNOL, V119, P1589; ISHIZAKA T, 1975, J IMMUNOL, V115, P1078; KULCZYCK.A, 1974, J EXP MED, V140, P1676, DOI 10.1084/jem.140.6.1676; KULCZYCKI A, 1976, J IMMUNOL, V117, P661; KULCZYCKI A, 1974, J EXP MED, V139, P600, DOI 10.1084/jem.139.3.600; LEVINE BB, 1968, J CLIN INVEST, V47, P556, DOI 10.1172/JCI105752; Metzger H, 1974, Adv Immunol, V18, P169, DOI 10.1016/S0065-2776(08)60310-7; MOSSMANN H, 1976, EUR J IMMUNOL, V6, P591, DOI 10.1002/eji.1830060813; NEWMAN SA, 1977, P NATL ACAD SCI USA, V74, P869, DOI 10.1073/pnas.74.3.869; OVARY Z, 1965, J IMMUNOL, V94, P410; ROSSI G, 1977, J BIOL CHEM, V252, P704; SEGAL DM, 1977, P NATL ACAD SCI USA, V74, P2993, DOI 10.1073/pnas.74.7.2993; SIRAGANIAN RP, 1975, IMMUNOCHEMISTRY, V12, P149, DOI 10.1016/0019-2791(75)90111-1; VALENTINE MD, 1967, J IMMUNOL, V99, P98; YIU SH, 1976, J IMMUNOL, V117, P269	33	80	80	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	61	5					320	330		10.1016/0091-6749(78)90054-4	http://dx.doi.org/10.1016/0091-6749(78)90054-4			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EY714	76642				2022-12-18	WOS:A1978EY71400008
J	LAVIN, N; RACHELEFSKY, GS; KAPLAN, SA				LAVIN, N; RACHELEFSKY, GS; KAPLAN, SA			ACTION OF DISODIUM-CROMOGLYCATE - INHIBITION OF CYCLIC 3',5'-AMP PHOSPHODIESTERASE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CALIF,SCH MED,DEPT PEDIAT,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles								ASHIM CR, 1974, BIOCH PARMACOL, V23, P917; ASSEM ESK, 1971, INT ARCH ALLER A IMM, V40, P576, DOI 10.1159/000230439; ASSEM ESK, 1971, IMMUNOLOGY, V21, P729; ASSEM ESK, 1970, INT ARCH ALLER A IMM, V38, P68, DOI 10.1159/000230260; BERNSTEIN IL, 1972, J ALLERGY CLIN IMMUN, V50, P235, DOI 10.1016/0091-6749(72)90017-6; BOYUM A, 1968, SCAND J CLIN LAB INV, V21, P97; CHEN JL, 1969, J ALLERGY, V43, P89, DOI 10.1016/0021-8707(69)90129-4; COOKSON DU, 1963, AM REV RESPIR DIS, V88, P636; COX JSG, 1967, NATURE, V216, P1328, DOI 10.1038/2161328a0; DAVIES SE, 1968, BRIT MED J, V3, P593, DOI 10.1136/bmj.3.5618.593; GILLESPIE E, 1974, J ALLERGY CLIN IMMUN, V53, P27, DOI 10.1016/0091-6749(74)90096-7; GILMAN AG, 1970, P NATL ACAD SCI USA, V67, P305, DOI 10.1073/pnas.67.1.305; HOWELL JBL, 1967, LANCET, V2, P539; INOUE S, 1967, J ALLERGY, V40, P337, DOI 10.1016/0021-8707(67)90023-8; KUSNER EJ, 1973, J PHARMACOL EXP THER, V184, P41; LICHTENS.LM, 1968, SCIENCE, V161, P902, DOI 10.1126/science.161.3844.902; LOCKEY SD, 1967, J ALLERGY, V40, P349, DOI 10.1016/0021-8707(67)90024-X; MIDDLETON E, 1968, J ALLERGY, V42, P288, DOI 10.1016/0021-8707(68)90022-1; MORAN F, 1968, LANCET, V2, P137; MORRISONSMITH J, 1968, BRIT MED J, V2, P340; MORSE HC, 1969, J IMMUNOL, V102, P327; ORR T S C, 1970, Clinical and Experimental Immunology, V7, P745; ORR TSC, 1971, LIFE SCI, V10, P805, DOI 10.1016/0024-3205(71)90035-X; ORR TSG, 1973, BRIT J DIS CHEST, V77, P87; PARKER CW, 1973, J CLIN INVEST, V52, P48, DOI 10.1172/JCI107173; PARKER CW, 1973, J CLIN INVEST, V52, P1342, DOI 10.1172/JCI107306; READ J, 1969, MED J AUSTRALIA, V1, P566, DOI 10.5694/j.1326-5377.1969.tb92293.x; Robison G.A., 1971, CYCLIC AMP, DOI [10.1146/annurev.bi.37.070168.001053, DOI 10.1146/ANNUREV.BI.37.070168.001053]; RUSSELL TR, 1973, J BIOL CHEM, V248, P1334; SMITH JM, 1968, BRIT MED J, V2, P340, DOI 10.1136/bmj.2.5601.340; SZENTIVANYI A, 1968, J ALLERGY, V42, P203, DOI 10.1016/S0021-8707(68)90117-2; TSANG CPW, 1972, J CLIN ENDOCR METAB, V35, P809, DOI 10.1210/jcem-35-6-809; 1973, INTAL CROMOLYN SODIU, P37	33	80	80	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	57	1					80	88		10.1016/0091-6749(76)90081-6	http://dx.doi.org/10.1016/0091-6749(76)90081-6			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	BC141	173750				2022-12-18	WOS:A1976BC14100009
J	GROSSMAN, J; BAUM, J; GLUCKMAN, J; FUSNER, J; CONDEMI, JJ				GROSSMAN, J; BAUM, J; GLUCKMAN, J; FUSNER, J; CONDEMI, JJ			EFFECT OF AGING AND ACUTE ILLNESS ON DELAYED-HYPERSENSITIVITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									USA,WILLIAM BEAUMONT MED CTR,DEPT MED,ALLERGY IMMUNOL SECT,EL PASO,TX; UNIV ROCHESTER,MED CTR,DEPT MED,ALLERGY IMMUNOL SECT,ROCHESTER,NY	William Beaumont Army Medical Center; University of Rochester								AISENBERG AC, 1962, J CLIN INVEST, V41, P1964, DOI 10.1172/JCI104654; ALSARRAF M, 1970, CANCER-AM CANCER SOC, V26, P262, DOI 10.1002/1097-0142(197008)26:2<262::AID-CNCR2820260204>3.0.CO;2-K; GIANNINI D, 1957, LANCET, V1, P525; GROSS L, 1965, CANCER, V18, P201, DOI 10.1002/1097-0142(196502)18:2<201::AID-CNCR2820180211>3.0.CO;2-V; HORWITZ DA, 1972, ARTHRITIS RHEUM-US, V15, P353, DOI 10.1002/art.1780150406; HOWARD WL, 1970, CHEST, V57, P530, DOI 10.1378/chest.57.6.530; LAW DK, 1973, ANN INTERN MED, V79, P545, DOI 10.7326/0003-4819-79-4-545; LICHTMAN MA, 1967, ARTHRITIS RHEUM, V10, P204, DOI 10.1002/art.1780100306; LISCHNER HW, 1972, J PEDIATR-US, V80, P174, DOI 10.1016/S0022-3476(72)80489-X; MERRILL JP, 1968, CANCER RES, V28, P1449; NILLSSON BS, 1971, SCAND J RESPIR DIS, V52, P39; NOVICK A, 1972, J AM GERIATR SOC, V20, P455, DOI 10.1111/j.1532-5415.1972.tb00836.x; PARK SK, 1971, LANCET, V1, P53; RAJKA G, 1969, ACTA DERM-VENEREOL, V49, P503; SILTZBACH LE, 1971, IMMUNOLOGICAL DISEAS, P582; STRAUS B, 1971, AM J DIG DIS, V16, P509, DOI 10.1007/BF02235541; WALDORF DS, 1968, J AMER MED ASSOC, V203, P831, DOI 10.1001/jama.203.10.831	17	80	80	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1975	55	4					268	275		10.1016/0091-6749(75)90146-3	http://dx.doi.org/10.1016/0091-6749(75)90146-3			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	W1385	235584				2022-12-18	WOS:A1975W138500008
J	HOFFMAN, DR				HOFFMAN, DR			ESTIMATION OF SERUM IGE BY AN ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV SO CALIF,MED CTR,DIV PEDIAT ALLERGY,LOS ANGELES,CA 90033; UNIV SO CALIF,MED CTR,DEPT PEDIAT,LOS ANGELES,CA 90033	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of Southern California; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of Southern California								ARBESMAN CE, 1972, J ALLERGY CLIN IMMUN, V49, P72, DOI 10.1016/0091-6749(72)90058-9; AXEN R, 1967, NATURE, V214, P1302, DOI 10.1038/2141302a0; BAZARAL M, 1971, J IMMUNOL, V107, P794; BAZARAL M, 1972, J ALLERGY CLIN IMMUN, V49, P189, DOI 10.1016/0091-6749(72)90113-3; CAMPBELL DH, 1970, METHODS IMMUNOLOGY; CARREL S, 1971, BIOCHEM J, V122, P405, DOI 10.1042/bj1220405; CATT K, 1967, SCIENCE, V158, P1570, DOI 10.1126/science.158.3808.1570; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; CUATRECASAS P, 1970, J BIOL CHEM, V245, P3059; ENGVALL E, 1971, IMMUNOCHEMISTRY, V8, P871, DOI 10.1016/0019-2791(71)90454-X; ENGVALL E, 1972, J IMMUNOL, V109, P129; GLEICH GJ, 1971, J LAB CLIN MED, V77, P690; JOHANSSON SG, 1968, IMMUNOLOGY, V14, P265; MANCINI G, 1965, IMMUNOCHEMISTRY, V2, P255; ROWE DS, 1969, B WORLD HEALTH ORGAN, V40, P613; SALMON SE, 1970, CLIN RES, V18, P432	16	80	80	0	11	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1973	51	5					303	307		10.1016/0091-6749(73)90132-2	http://dx.doi.org/10.1016/0091-6749(73)90132-2			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	P5931	4633250				2022-12-18	WOS:A1973P593100006
J	PINCKARD, RN; HALONEN, M; MENG, AL				PINCKARD, RN; HALONEN, M; MENG, AL			PREFERENTIAL EXPRESSION OF ANTIBOVINE SERUM-ALBUMIN IGE HOMOCYTOTROPIC ANTIBODY-SYNTHESIS AND ANAPHYLACTIC SENSITIVITY IN NEONATAL RABBIT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		AMOS HE, 1971, POSTGRAD MED J, V47, P166, DOI 10.1136/pgmj.47.545.166; BINAGHI RA, 1966, INT ARCH ALLER A IMM, V29, P105, DOI 10.1159/000229692; BLOCH KJ, 1967, PROG ALLERGY, V10, P84; Dresser D W, 1968, Adv Immunol, V8, P129, DOI 10.1016/S0065-2776(08)60466-6; FARR RS, 1958, J INFECT DIS, V103, P239, DOI 10.1093/infdis/103.3.239; HARGIS BJ, 1970, J IMMUNOL, V104, P942; HENSON PM, 1969, J EXP MED, V129, P153, DOI 10.1084/jem.129.1.153; ISHIZAKA K, 1970, IMMUNOCHEMISTRY, V7, P515, DOI 10.1016/0019-2791(70)90273-9; JOHNSTONE DE, 1966, NEW ENGL J MED, V274, P715, DOI 10.1056/NEJM196603312741305; LEVIN S, 1970, ISRAEL J MED SCI, V6, P742; LINDQVIST KJ, 1968, IMMUNOCHEMISTRY, V5, P525, DOI 10.1016/0019-2791(68)90089-X; NEWCOMB RW, 1969, J ALLERGY, V43, P292, DOI 10.1016/0021-8707(69)90150-6; PINCKARD R. N., 1968, CLIN EXP IMMUNOL, V3, P413; PINCKARD RN, 1971, J IMMUNOL, V106, P1602; PINCKARD RN, 1967, NATURE, V215, P1084, DOI 10.1038/2151084a0; PINCKARD RN, UNPUBLISHED OBSERVAT; PROUVOSTDANON A, 1970, INT ARCH ALLER A IMM, V38, P148; REVOLTELLA R, 1969, INT ARCH ALLER A IMM, V36, P282, DOI 10.1159/000230749; STEVENSON DD, 1971, J ALLERGY CLIN IMMUN, V48, P61, DOI 10.1016/0091-6749(71)90088-1; ZVAIFLER NJ, 1969, J EXP MED, V130, P907, DOI 10.1084/jem.130.4.907	20	80	80	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1972	49	5					301	&						0	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	M4215					2022-12-18	WOS:A1972M421500006
J	GRIECO, MH; PIERSON, RN				GRIECO, MH; PIERSON, RN			MECHANISM OF BRONCHOCONSTRICTION DUE TO BETA ADRENERGIC BLOCKADE - STUDIES WITH PRACTOLOL, PROPRANOLOL, AND ATROPINE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		AHLQUIST RP, 1948, AM J PHYSIOL, V153, P586, DOI 10.1152/ajplegacy.1948.153.3.586; ASTIN TW, 1967, AM REV RESPIR DIS, V95, P567; CROMPTON GK, 1968, THORAX, V23, P165, DOI 10.1136/thx.23.2.165; DAUTREBANDE L, 1962, ARCH INT PHARMACOD T, V139, P198; DUNLOP D, 1968, BRIT J PHARMACOL, V32, P201, DOI 10.1111/j.1476-5381.1968.tb00444.x; EPPINGER H, 1917, VAGOTONIA CLINICAL S; FISCHEL CW, 1962, J IMMUN, V89, P8; FITZ GERALD JD, 1969, CLIN PHARMACOL THER, V10, P292; GOODMAN LS, 1965, PHARMACOL BASIS, P526; GORTEN RJ, 1959, AM J MED SCI, V238, P274, DOI 10.1097/00000441-195909000-00002; GRIECO MH, 1970, J ALLERGY, V45, P195, DOI 10.1016/0021-8707(70)90131-0; GUIRGIS HM, 1969, THORAX, V24, P613, DOI 10.1136/thx.24.5.613; HARTLEY D, 1968, NATURE, V219, P861, DOI 10.1038/219861a0; HERXHEIMER H, 1967, J PHYSIOL-LONDON, V190, P41; KAUFMAN J, 1969, AM REV RESPIR DIS, V100, P626; LANDS AM, 1967, NATURE, V214, P597, DOI 10.1038/214597a0; LANGER I, 1967, J PHYSL, V190, P41; MACDONALD AG, 1968, BRIT J ANAESTH, V40, P508, DOI 10.1093/bja/40.7.508; MACDONALD AG, 1967, BRIT J ANAESTH, V39, P919, DOI 10.1093/bja/39.12.919; MCNEILL RS, 1966, AM J CARDIOL, V18, P473, DOI 10.1016/0002-9149(66)90072-5; MCNEILL RS, 1964, LANCET, V2, P1101; MEIER J, 1966, DEUT MED WOCHENSCHR, V91, P145, DOI 10.1055/s-0028-1110536; OUELLETTE JJ, 1967, J ALLERGY, V39, P234, DOI 10.1016/0021-8707(67)90016-0; OUELLETTE JJ, 1965, J ALLERGY, V36, P558, DOI 10.1016/0021-8707(65)90193-0; PALMER KNV, 1969, LANCET, V2, P1092; PIERSON RN, 1969, AM REV RESPIR DIS, V100, P533; POWLES R, 1969, THORAX, V24, P616, DOI 10.1136/thx.24.5.616; REED CE, 1968, J ALLERGY, V42, P238, DOI 10.1016/S0021-8707(68)90119-6; SIMONSSON BG, 1967, J CLIN INVEST, V46, P1812, DOI 10.1172/JCI105671; SZENTIVANYI A, 1963, J INFECT DIS, V113, P86, DOI 10.1093/infdis/113.2.86; SZENTIVANYI A, 1968, J ALLERGY, V42, P203, DOI 10.1016/S0021-8707(68)90117-2; TATTERSFIELD AE, 1969, NEW ENGL J MED, V281, P1323, DOI 10.1056/NEJM196912112812402; WARRELL DA, 1970, BMJ-BRIT MED J, V1, P65, DOI 10.1136/bmj.1.5688.65; WIDDICOMBE JG, 1962, J APPL PHYSIOL, V17, P613, DOI 10.1152/jappl.1962.17.4.613; ZAID G, 1966, NEW ENGL J MED, V275, P580, DOI 10.1056/NEJM196609152751103	35	80	80	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1971	48	3					143	&		10.1016/0091-6749(71)90009-1	http://dx.doi.org/10.1016/0091-6749(71)90009-1			0	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K3234	4398175				2022-12-18	WOS:A1971K323400003
J	Wang, HH; Md, YCL; Huang, YC				Wang, Hsiao-Han; Md, Yu-Chuan Li; Huang, Yu-Chen			Efficacy of omalizumab in patients with atopic dermatitis: A systematic review andmeta-analysis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ANTI-IGE THERAPY; ECZEMA		[Wang, Hsiao-Han; Md, Yu-Chuan Li; Huang, Yu-Chen] Taipei Med Univ, Wan Fang Hosp, Dept Dermatol, Taipei, Taiwan; [Wang, Hsiao-Han; Huang, Yu-Chen] Taipei Med Univ, Coll Med, Sch Med, Dept Dermatol, Taipei, Taiwan	Taipei Medical University; Taipei Municipal WanFang Hospital; Taipei Medical University	Wang, HH (corresponding author), Taipei Med Univ, Wan Fang Hosp, Dept Dermatol, Taipei, Taiwan.; Wang, HH (corresponding author), Taipei Med Univ, Coll Med, Sch Med, Dept Dermatol, Taipei, Taiwan.	dhist2002@yahoo.com.tw		Li, Yu-Chuan (Jack)/0000-0001-6497-4232				Amrol D, 2010, SOUTH MED J, V103, P554, DOI 10.1097/SMJ.0b013e3181de0cf6; Barrios JL, 2013, J AM ACAD DERMATOL, V69, P832, DOI 10.1016/j.jaad.2013.05.035; Belloni B, 2007, J ALLERGY CLIN IMMUN, V120, P1223, DOI 10.1016/j.jaci.2007.08.060; Martinez MCFA, 2012, ACTAS DERMO-SIFILOGR, V103, P624, DOI 10.1016/j.ad.2011.07.013; Heil PM, 2010, J DTSCH DERMATOL GES, V8, P990, DOI 10.1111/j.1610-0387.2010.07497.x; Hotze M, 2014, ALLERGY, V69, P132, DOI 10.1111/all.12234; Iyengar SR, 2013, INT ARCH ALLERGY IMM, V162, P89, DOI 10.1159/000350486; Kim DH, 2013, CLIN EXP DERMATOL, V38, P496, DOI 10.1111/j.1365-2230.2012.04438.x; Kornmann O, 2014, PULM PHARMACOL THER, V28, P149, DOI 10.1016/j.pupt.2014.03.003; Krathen RA, 2005, J AM ACAD DERMATOL, V53, P338, DOI 10.1016/j.jaad.2005.02.014; Lane JE, 2006, J AM ACAD DERMATOL, V54, P68, DOI 10.1016/j.jaad.2005.09.030; Makris MP, 2014, CURR OPIN ALLERGY CL, V14, P409, DOI 10.1097/ACI.0000000000000096; Del Pozo MER, 2011, J INVEST ALLERG CLIN, V21, P416; Romano C, 2015, CLIN DRUG INVEST, V35, P159, DOI 10.1007/s40261-015-0267-9; Sheinkopf LE, 2008, ALLERGY ASTHMA PROC, V29, P530, DOI 10.2500/aap.2008.29.3160; Thaiwat S, 2011, ASIAN PAC J ALLERGY, V29, P357; Vigo PG, 2006, J AM ACAD DERMATOL, V55, P168, DOI 10.1016/j.jaad.2005.12.045	17	79	82	1	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2016	138	6					1719	+		10.1016/j.jaci.2016.05.038	http://dx.doi.org/10.1016/j.jaci.2016.05.038			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EF0MK	27543070	Bronze			2022-12-18	WOS:000390019300032
J	Looney, TJ; Lee, JY; Roskin, KM; Hoh, RA; King, J; Glanville, J; Liu, Y; Pham, TD; Dekker, CL; Davis, MM; Boyd, SD				Looney, Timothy J.; Lee, Ji-Yeun; Roskin, Krishna M.; Hoh, Ramona A.; King, Jasmine; Glanville, Jacob; Liu, Yi; Pham, Tho D.; Dekker, Cornelia L.; Davis, Mark M.; Boyd, Scott D.			Human B-cell isotype switching origins of IgE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IgE; isotype switching; direct; indirect; antibody; B cell; repertoire; high-throughput DNA sequencing	IN-VIVO; EPSILON; MU; MEMORY; RECOMBINATION; LYMPHOCYTES; INFECTION; PROGRAM; UNIQUE; DOCK8	Background: B cells expressing IgE contribute to immunity against parasites and venoms and are the source of antigen specificity in allergic patients, yet the developmental pathways producing these B cells in human subjects remain a subject of debate. Much of our knowledge of IgE lineage development derives from model studies in mice rather than from human subjects. Objective: We evaluate models for isotype switching to IgE in human subjects using immunoglobulin heavy chain (IGH) mutational lineage data. Methods: We analyzed IGH repertoires in 9 allergic and 24 healthy adults using high-throughput DNA sequencing of 15,843,270 IGH rearrangements to identify clonal lineages of B cells containing members expressing IgE. Somatic mutations in IGH inherited from common ancestors within the clonal lineage are used to infer the relationships between B cells. Results: Data from 613,641 multi-isotype B-cell clonal lineages, of which 592 include an IgE member, are consistent with indirect switching to IgE from IgG-or IgA-expressing lineage members in human subjects. We also find that these inferred isotype switching frequencies are similar in healthy and allergic subjects. Conclusions: We found evidence that secondary isotype switching of mutated IgG1-expressing B cells is the primary source of IgE in human subjects, with lesser contributions from precursors expressing other switched isotypes and rarely IgM or IgD, suggesting that IgE is derived from previously antigen-experienced B cells rather than naive B cells that typically express low-affinity unmutated antibodies. These data provide a basis from which to evaluate allergen-specific human antibody repertoires in healthy and diseased subjects.	[Looney, Timothy J.; Lee, Ji-Yeun; Roskin, Krishna M.; Hoh, Ramona A.; King, Jasmine; Glanville, Jacob; Liu, Yi; Pham, Tho D.; Boyd, Scott D.] Stanford Univ, Dept Pathol, Stanford, CA 94305 USA; [Glanville, Jacob] Stanford Univ, Program Immunol, Stanford, CA 94305 USA; [Liu, Yi] Stanford Univ, Biomed Informat Training Program, Stanford, CA 94305 USA; [Dekker, Cornelia L.] Stanford Univ, Dept Pediat, Stanford, CA 94305 USA; [Davis, Mark M.] Stanford Univ, Dept Microbiol & Immunol, Stanford, CA 94305 USA; [King, Jasmine] Stanford Univ, Dept Biol, Stanford, CA 94305 USA; [Davis, Mark M.] Stanford Univ, Howard Hughes Med Inst, Stanford, CA 94305 USA; [Davis, Mark M.] Stanford Univ, Inst Immun Transplantat & Infect, Stanford, CA 94305 USA	Stanford University; Stanford University; Stanford University; Stanford University; Stanford University; Stanford University; Howard Hughes Medical Institute; Stanford University; Stanford University	Boyd, SD (corresponding author), Stanford Univ, Dept Pathol, Stanford, CA 94305 USA.	sboyd1@stanford.edu		Davis, Mark/0000-0001-6868-657X	National Institutes of Health/National Institute of Allergy and Infectious Diseases (NIAID) [1U19AI0420901, U19AI090019]; NIH/National Center for Research Resources CTSA award [UL1 RR025744]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001085] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025744] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI090019, U19AI104209, U19AI057229, T32AI007290] Funding Source: NIH RePORTER	National Institutes of Health/National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH/National Center for Research Resources CTSA award; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health/National Institute of Allergy and Infectious Diseases (NIAID) grants 1U19AI0420901 (S.D.B., PD) and U19AI090019 (M.M.D., PI; S.D.B., PD) and NIH/National Center for Research Resources CTSA award UL1 RR025744.	Aalberse RC, 2009, CLIN EXP ALLERGY, V39, P469, DOI 10.1111/j.1365-2222.2009.03207.x; Aalberse RC, 2004, J ALLERGY CLIN IMMUN, V113, P983, DOI 10.1016/j.jaci.2004.02.046; BARBEE RA, 1981, J ALLERGY CLIN IMMUN, V68, P106, DOI 10.1016/0091-6749(81)90167-6; Baskin B, 1997, EUR J IMMUNOL, V27, P130, DOI 10.1002/eji.1830270120; Boyd SD, 2009, SCI TRANSL MED, V1, DOI 10.1126/scitranslmed.3000540; Cameron L, 2003, J IMMUNOL, V171, P3816, DOI 10.4049/jimmunol.171.7.3816; Davies JM, 2013, J ALLERGY CLIN IMMUN, V131, P972, DOI 10.1016/j.jaci.2012.12.1569; Engelhardt KR, 2009, J ALLERGY CLIN IMMUN, V124, P1289, DOI 10.1016/j.jaci.2009.10.038; Erazo A, 2007, IMMUNITY, V26, P191, DOI 10.1016/j.immuni.2006.12.006; Gergen PJ, 2009, J ALLERGY CLIN IMMUN, V124, P447, DOI 10.1016/j.jaci.2009.06.011; Gould HJ, 2003, ANNU REV IMMUNOL, V21, P579, DOI 10.1146/annurev.immunol.21.120601.141103; Hamilton Robert G., 2003, Journal of Allergy and Clinical Immunology, V111, pS687; Hamilton RG, 2010, ARCH PATHOL LAB MED, V134, P975, DOI 10.1043/2009-0518-OA.1; He JS, 2015, CURR TOP MICROBIOL, V388, P1, DOI 10.1007/978-3-319-13725-4_1; He JS, 2013, J EXP MED, V210, P2755, DOI 10.1084/jem.20131539; JABARA HH, 1993, J IMMUNOL, V151, P4528; Janeway CA, 2001, IMMUNOBIOLOGY; Kunkel EJ, 2003, NAT REV IMMUNOL, V3, P822, DOI 10.1038/nri1203; Li WZ, 2006, BIOINFORMATICS, V22, P1658, DOI 10.1093/bioinformatics/btl158; Lin M, 2014, MUCOSAL IMMUNOL, V7, P511, DOI 10.1038/mi.2013.68; Magoc T, 2011, BIOINFORMATICS, V27, P2957, DOI 10.1093/bioinformatics/btr507; MILLS FC, 1995, J IMMUNOL, V155, P3021; MILLS FC, 1992, J IMMUNOL, V149, P1075; Sunyer J, 1999, INT J EPIDEMIOL, V28, P728; Talay O, 2013, NAT IMMUNOL, V14, P1302, DOI 10.1038/ni.2770; Talay O, 2012, NAT IMMUNOL, V13, P396, DOI 10.1038/ni.2256; VANDERSTOEP N, 1994, EUR J IMMUNOL, V24, P1307, DOI 10.1002/eji.1830240610; Wang C, 2014, J IMMUNOL, V192, P603, DOI 10.4049/jimmunol.1301384; WITTIG HJ, 1980, J ALLERGY CLIN IMMUN, V66, P305, DOI 10.1016/0091-6749(80)90026-3; Wuerffe R, 2007, IMMUNITY, V27, P711, DOI 10.1016/j.immuni.2007.09.007; Xiong HZ, 2012, ADV IMMUNOL, V116, P113, DOI 10.1016/B978-0-12-394300-2.00004-1; Xiong HZ, 2012, J EXP MED, V209, P353, DOI 10.1084/jem.20111941; Yang ZY, 2012, IMMUNITY, V36, P857, DOI 10.1016/j.immuni.2012.02.009; Ye J, 2013, NUCLEIC ACIDS RES, V41, pW34, DOI 10.1093/nar/gkt382; YOSHIDA K, 1990, P NATL ACAD SCI USA, V87, P7829, DOI 10.1073/pnas.87.20.7829; Zhang Q, 2009, NEW ENGL J MED, V361, P2046, DOI 10.1056/NEJMoa0905506	36	79	79	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2016	137	2					579	+		10.1016/j.jaci.2015.07.014	http://dx.doi.org/10.1016/j.jaci.2015.07.014			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DC5BN	26309181	Green Accepted, Bronze			2022-12-18	WOS:000369235500028
J	Pothoven, KL; Norton, JE; Hulse, KE; Suh, LA; Carter, RG; Rocci, E; Harris, KE; Shintani-Smith, S; Conley, DB; Chandra, RK; Liu, MC; Kato, A; Gonsalves, N; Grammer, LC; Peters, AT; Kern, RC; Bryce, PJ; Tan, BK; Schleimer, RP				Pothoven, Kathryn L.; Norton, James E.; Hulse, Kathryn E.; Suh, Lydia A.; Carter, Roderick G.; Rocci, Erin; Harris, Kathleen E.; Shintani-Smith, Stephanie; Conley, David B.; Chandra, Rakesh K.; Liu, Mark C.; Kato, Atsushi; Gonsalves, Nirmala; Grammer, Leslie C., III; Peters, Anju T.; Kern, Robert C.; Bryce, Paul J.; Tan, Bruce K.; Schleimer, Robert P.			Oncostatin M promotes mucosal epithelial barrier dysfunction, and its expression is increased in patients with eosinophilic mucosal disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Oncostatin M; epithelial barrier; chronic rhinosinusitis; eosinophilic esophagitis; atopic asthma; transepithelial electrical resistance; tight junctions	LEUKEMIA-INHIBITORY FACTOR; CHRONIC RHINOSINUSITIS; AIRWAY HYPERRESPONSIVENESS; MONOCLONAL-ANTIBODY; INTERFERON-GAMMA; ION-TRANSPORT; NASAL POLYPS; M OSM; PROTEIN; CELLS	Background: Epithelial barrier dysfunction is thought to play a role in many mucosal diseases, including asthma, chronic rhinosinusitis (CRS), and eosinophilic esophagitis. Objective: The objective of this study was to investigate the role of oncostatin M (OSM) in epithelial barrier dysfunction in human mucosal disease. Methods: OSM expression was measured in tissue extracts, nasal secretions, and bronchoalveolar lavage fluid. The effects of OSM stimulation on barrier function of normal human bronchial epithelial cells and nasal epithelial cells cultured at the air-liquid interface were assessed by using transepithelial electrical resistance and fluorescein isothiocyanate-dextran flux. Dual-color immunofluorescence was used to evaluate the integrity of tight junction structures in cultured epithelial cells. Results: Analysis of samples from patients with CRS showed that OSM mRNA and protein levels were highly increased in nasal polyps compared with those seen in control uncinate tissue (P < .05). OSM levels were also increased in bronchoalveolar lavage fluid of allergic asthmatic patients after segmental allergen challenge and in esophageal biopsy specimens from patients with eosinophilic esophagitis. OSM stimulation of air-liquid interface cultures resulted in reduced barrier function, as measured by decreased transepithelial electrical resistance and increased fluorescein isothiocyanate-dextran flux (P < .05). Alterations in barrier function by OSM were reversible, and the viability of epithelial cells was unaffected. OSM levels in lysates of nasal polyps and uncinate tissue positively correlated with levels of alpha(2)-macroglobulin, a marker of epithelial leak, in localized nasal secretions (r = 0.4855, P < .05). Conclusions: These results suggest that OSM might play a role in epithelial barrier dysfunction in patients with CRS and other mucosal diseases.	[Pothoven, Kathryn L.; Norton, James E.; Hulse, Kathryn E.; Suh, Lydia A.; Carter, Roderick G.; Harris, Kathleen E.; Kato, Atsushi; Grammer, Leslie C., III; Peters, Anju T.; Bryce, Paul J.; Schleimer, Robert P.] Northwestern Univ, Feinberg Sch Med, Div Allergy Immunol, Chicago, IL 60611 USA; [Gonsalves, Nirmala] Northwestern Univ, Feinberg Sch Med, Div Gastroenterol & Hepatol, Dept Med, Chicago, IL 60611 USA; [Shintani-Smith, Stephanie; Conley, David B.; Chandra, Rakesh K.; Kern, Robert C.; Tan, Bruce K.; Schleimer, Robert P.] Northwestern Univ, Feinberg Sch Med, Dept Otolaryngol, Chicago, IL 60611 USA; [Rocci, Erin] Loyola Univ Chicago, Stritch Sch Med, Chicago, IL USA; [Liu, Mark C.] Johns Hopkins Asthma & Allergy Ctr, Div Allergy & Clin Immunol, Baltimore, MD USA; [Liu, Mark C.] Johns Hopkins Asthma & Allergy Ctr, Div Pulm & Crit Care Med, Baltimore, MD USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Loyola University Chicago; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Schleimer, RP (corresponding author), Northwestern Univ, Feinberg Sch Med, McGaw Pavil Suite M318,240 E Huron, Chicago, IL 60611 USA.	rpschleimer@northwestern.edu	Smith, Stephanie Shintani/AAY-4854-2020	Smith, Stephanie Shintani/0000-0002-0605-3993; Gonsalves, Nirmala/0000-0003-0722-6099; Hulse, Kathryn/0000-0003-0969-999X; Kato, Atsushi/0000-0001-9144-3138; Grammer, Leslie/0000-0001-6860-2014; Chandra, Rakesh/0000-0002-3612-0026	National Institutes of Health [R37HL068546, R01HL078860, U19AI106683, T32AI007476-16]; Ernest S. Bazley Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD055884] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL068546, R01HL078860] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI106683, T32AI007476] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [K23DC012067] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ernest S. Bazley Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	Supported in part by grants R37HL068546, R01HL078860, U19AI106683, and T32AI007476-16 from the National Institutes of Health and by the Ernest S. Bazley Foundation.	BERNSTEIN JM, 1994, ARCH OTOLARYNGOL, V120, P993; Bernstein JM, 1997, J ALLERGY CLIN IMMUN, V99, P165, DOI 10.1016/S0091-6749(97)70091-5; Boniface K, 2007, J IMMUNOL, V178, P4615, DOI 10.4049/jimmunol.178.7.4615; Botelho FM, 2013, J IMMUNOL, V191, P1453, DOI 10.4049/jimmunol.1203318; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; Brolund L, 2011, BMC BIOTECHNOL, V11, DOI 10.1186/1472-6750-11-3; BROWN TJ, 1987, J IMMUNOL, V139, P2977; Choy EH, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4312; Dejima K, 2006, ARCH OTOLARYNGOL, V132, P1352, DOI 10.1001/archotol.132.12.1352; Ernst M, 1996, J BIOL CHEM, V271, P30136, DOI 10.1074/jbc.271.47.30136; Fanning AS, 1998, J BIOL CHEM, V273, P29745, DOI 10.1074/jbc.273.45.29745; Fritz DK, 2011, J IMMUNOL, V186, P1107, DOI 10.4049/jimmunol.0903476; Gazel A, 2006, J INVEST DERMATOL, V126, P2647, DOI 10.1038/sj.jid.5700461; Hackett TL, 2013, AM J RESP CELL MOL, V49, P662, DOI 10.1165/rcmb.2013-0124OC; Hackett TL, 2011, AM J RESP CELL MOL, V45, P1090, DOI 10.1165/rcmb.2011-0031OC; Holgate ST, 2000, AM J RESP CRIT CARE, V162, pS113, DOI 10.1164/ajrccm.162.supplement_2.ras-12; HOLTER JF, 1986, J CLIN INVEST, V78, P1513, DOI 10.1172/JCI112743; Hulse KE, 2014, J ALLERGY CLIN IMMUN, V133, P275, DOI 10.1016/j.jaci.2013.08.015; Hulse KE, 2013, J ALLERGY CLIN IMMUN, V131, P1075, DOI 10.1016/j.jaci.2013.01.043; Hulse KE, 2013, J ALLERGY CLIN IMMUN, V131, pe1; Jostock T, 2001, EUR J BIOCHEM, V268, P160, DOI 10.1046/j.1432-1327.2001.01867.x; Kang HJ, 2005, LARYNGOSCOPE, V115, P2213, DOI 10.1097/01.mlg.0000187819.89889.4a; Kato A, 2008, J ALLERGY CLIN IMMUN, V121, P1385, DOI 10.1016/j.jaci.2008.03.002; Kato A, 2009, J ALLERGY CLIN IMMUN, V123, P369, DOI 10.1016/j.jaci.2008.11.022; Kern RC, 2008, AM J RHINOL, V22, P549, DOI 10.2500/ajr.2008.22.3228; Krysko O, 2011, ALLERGY, V66, P396, DOI 10.1111/j.1398-9995.2010.02498.x; Kuropatwinski KK, 1997, J BIOL CHEM, V272, P15135, DOI 10.1074/jbc.272.24.15135; LAMB P, 1995, NUCLEIC ACIDS RES, V23, P3283, DOI 10.1093/nar/23.16.3283; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; LIU MC, 1990, AM REV RESPIR DIS, V142, P126, DOI 10.1164/ajrccm/142.1.126; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; Meltzer Eli O, 2004, J Allergy Clin Immunol, V114, P155, DOI 10.1016/j.jaci.2004.09.029; Meyer P, 1999, EUR RESPIR J, V13, P633, DOI 10.1183/09031936.99.13363399; Migita K, 2013, CLIN EXP IMMUNOL, V174, P356, DOI 10.1111/cei.12190; Nicodeme F, 2013, CLIN GASTROENTEROL H, V11, P1101, DOI 10.1016/j.cgh.2013.03.020; Oppenheim JJ, 2007, ADV EXP MED BIOL, V601, P185; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Peters AT, 2010, J ALLERGY CLIN IMMUN, V125, P397, DOI 10.1016/j.jaci.2009.10.072; Peterson S, 2012, J ALLERGY CLIN IMMUN, V129, P119, DOI 10.1016/j.jaci.2011.08.021; Podolsky DK, 1999, AM J PHYSIOL-GASTR L, V277, pG495, DOI 10.1152/ajpgi.1999.277.3.G495; ROSE TM, 1991, P NATL ACAD SCI USA, V88, P8641, DOI 10.1073/pnas.88.19.8641; Roth HM, 2012, PULM PHARMACOL THER, V25, P420, DOI 10.1016/j.pupt.2012.09.004; Saitoh T, 2009, RHINOLOGY, V47, P273, DOI [10.4193/Rhin.08.109, 10.4193/Rhin08.109]; Salamon P, 2008, J ALLERGY CLIN IMMUN, V121, P448, DOI 10.1016/j.jaci.2007.08.054; Scaffidi AK, 2002, BRIT J PHARMACOL, V136, P793, DOI 10.1038/sj.bjp.0704769; Seshadri S, 2012, ALLERGY, V67, P920, DOI 10.1111/j.1398-9995.2012.02848.x; Simpson JL, 2009, EXP LUNG RES, V35, P781, DOI 10.3109/01902140902906412; Soyka MB, 2012, J ALLERGY CLIN IMMUN, V130, P1087, DOI 10.1016/j.jaci.2012.05.052; Suda T, 2002, CYTOKINE, V17, P335, DOI 10.1006/cyto.2002.1023; Takabayashi T, 2013, J ALLERGY CLIN IMMUN, V132, P584, DOI 10.1016/j.jaci.2013.02.003; Takabayashi T, 2013, AM J RESP CRIT CARE, V187, P49, DOI 10.1164/rccm.201207-1292OC; Takata F, 2008, NEUROSCI LETT, V441, P163, DOI 10.1016/j.neulet.2008.06.030; Tamura S, 2002, DEV DYNAM, V225, P327, DOI 10.1002/dvdy.10156; Tieu DD, 2010, J ALLERGY CLIN IMMUN, V125, P667, DOI 10.1016/j.jaci.2009.11.045; Trautmann A, 2005, INT ARCH ALLERGY IMM, V138, P142, DOI 10.1159/000088436; Vasse M, 1996, HAEMOSTASIS, V26, P331; Vignola AM, 2001, J ALLERGY CLIN IMMUN, V108, P738, DOI 10.1067/mai.2001.119160; Wardlaw AJ, 2002, CLIN SCI, V103, P201; Wenzel S, 2007, LANCET, V370, P1422, DOI 10.1016/S0140-6736(07)61600-6; Wenzel SE, 2012, NAT MED, V18, P716, DOI 10.1038/nm.2678; Wise SK, 2014, INT FORUM ALLERGY RH, V4, P361, DOI 10.1002/alr.21298; Xiao C, 2011, J ALLERGY CLIN IMMUN, V128, P549, DOI 10.1016/j.jaci.2011.05.038; Yamaguchi Y, 2001, J DERMATOL, V28, P521, DOI 10.1111/j.1346-8138.2001.tb00025.x	63	79	83	1	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2015	136	3					737	+		10.1016/j.jaci.2015.01.043	http://dx.doi.org/10.1016/j.jaci.2015.01.043			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CQ9EA	25840724	Green Accepted			2022-12-18	WOS:000360913300026
J	Mazzeo, C; Canas, JA; Zafra, MP; Marco, AR; Fernandez-Nieto, M; Sanz, V; Mittelbrunn, M; Izquierdo, M; Baixaulli, F; Sastre, J; del Pozo, V				Mazzeo, Carla; Antonio Canas, Jose; Paz Zafra, Maria; Rojas Marco, Ainara; Fernandez-Nieto, Mar; Sanz, Veronica; Mittelbrunn, Maria; Izquierdo, Manuel; Baixaulli, Francesc; Sastre, Joaquin; del Pozo, Victoria			Exosome secretion by eosinophils: A possible role in asthma pathogenesis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; eosinophils; exosomes; multivesicular bodies; biomarker; IFN-gamma; endosomes; lysobisphosphatidic acid; CD63; secretion	RECOMBINANT HUMAN INTERLEUKIN-5; MONONUCLEAR CELL-CULTURES; LAVAGE FLUID EXOSOMES; IN-VITRO; IMMUNE-RESPONSES; ALLERGIC-ASTHMA; MAST-CELLS; CLASS-II; VESICLES; RECEPTOR	Background: Eosinophils secrete several granules that are involved in the propagation of inflammatory responses in patients with pathologies such as asthma. Objective: We hypothesized that some of these granules are exosomes, which, when transferred to the recipient cells, could modulate asthma progression. Methods: Eosinophils were purified from peripheral blood and cultured with or without IFN-gamma or eotaxin. Multivesicular bodies (MVBs) in eosinophils were studied by using fluorescence microscopy, transmission electron microscopy (TEM), and flow cytometry. Exosome secretion was measured and exosome characterization was performed with TEM, Western blotting, and NanoSight analysis. Results: Generation of MVBs in eosinophils was confirmed by using fluorescence microscopy and flow cytometry and corroborated by means of TEM. Having established that eosinophils contain MVBs, our aim was to demonstrate that eosinophils secrete exosomes. To do this, we purified exosomes from culture medium of eosinophils and characterized them. Using Western blot analysis, we demonstrated that eosinophils secreted exosomes and that the discharge of exosomes to extracellular media increases after IFN-gamma stimulation. We measured exosome size and quantified exosome production from healthy and asthmatic subjects using nanotracking analysis. We found that exosome production was augmented in asthmatic patients. Conclusion: Our findings are the first to demonstrate that eosinophils contain functional MVBs and secrete exosomes and that their secretion is increased in asthmatic patients. Thus exosomes might play an important role in the progression of asthma and eventually be considered a biomarker.	[Mazzeo, Carla; Antonio Canas, Jose; Paz Zafra, Maria; Rojas Marco, Ainara; Sanz, Veronica; del Pozo, Victoria] IIS Fdn Jimenez Diaz, Dept Immunol, Madrid, Spain; [Mazzeo, Carla; Antonio Canas, Jose; Paz Zafra, Maria; Fernandez-Nieto, Mar; Sanz, Veronica; Sastre, Joaquin; del Pozo, Victoria] CIBER Enfermedades Resp CIBERES, Madrid, Spain; [Fernandez-Nieto, Mar; Sastre, Joaquin] IIS Fdn Jimenez Diaz, Dept Allergy, Madrid, Spain; [Mittelbrunn, Maria; Baixaulli, Francesc] Ctr Nacl Invest Cardiovasc, Madrid, Spain; [Izquierdo, Manuel] Univ Autonoma Madrid, Fac Med, CSIC, Dept Biochem,Inst Invest Biomed Alberto Sols, E-28029 Madrid, Spain	Fundacion Jimenez Diaz; CIBER - Centro de Investigacion Biomedica en Red; CIBERES; Fundacion Jimenez Diaz; Centro Nacional de Investigaciones Cardiovasculares (CNIC); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	del Pozo, V (corresponding author), Fdn Jimenez Diaz, Dept Immunol, Ave Reye Catolicos 2, Madrid 28040, Spain.	vpozo@fjd.es	Izquierdo, Manuel/I-4812-2013; Mittelbrunn, Maria/J-9146-2019; Izquierdo, Manuel/D-2971-2017; Cañas, José Antonio/AAA-6693-2020; Mittelbrunn, Maria/I-5882-2015; Mazzeo, Carla/M-1976-2014; Zafra, Maria Paz/ABH-4756-2020; Baixauli, Francesc/L-4957-2016; Izquierdo, Manuel/I-4812-2013	Izquierdo, Manuel/0000-0002-7701-1002; Mittelbrunn, Maria/0000-0003-3487-8762; Izquierdo, Manuel/0000-0002-7701-1002; Cañas, José Antonio/0000-0002-0460-2813; Mittelbrunn, Maria/0000-0003-3487-8762; Mazzeo, Carla/0000-0001-7916-8209; Zafra, Maria Paz/0000-0001-9303-0097; Baixauli, Francesc/0000-0002-9676-2901; Izquierdo, Manuel/0000-0002-7261-404X	Fondo de Investigacion Sanitaria-FIS [PS09/00153, PI12/00691]; CIBER de Enfermedades Respiratorias (CIBERES); Conchita Rabago Foundation; Carlos III Institute of Health initiative	Fondo de Investigacion Sanitaria-FIS(Instituto de Salud Carlos III); CIBER de Enfermedades Respiratorias (CIBERES); Conchita Rabago Foundation; Carlos III Institute of Health initiative	Supported by Fondo de Investigacion Sanitaria-FIS (PS09/00153 and PI12/00691); CIBER de Enfermedades Respiratorias (CIBERES), a Carlos III Institute of Health initiative; and the Conchita Rabago Foundation (MPZ).	Admyre C, 2008, ALLERGY, V63, P404, DOI 10.1111/j.1398-9995.2007.01600.x; Admyre C, 2003, EUR RESPIR J, V22, P578, DOI 10.1183/09031936.03.00041703; Admyre C, 2007, J IMMUNOL, V179, P1969, DOI 10.4049/jimmunol.179.3.1969; Akuthota P, 2012, AM J RESP CELL MOL, V46, P188, DOI 10.1165/rcmb.2010-0335OC; Almqvist N, 2008, IMMUNOLOGY, V125, P21, DOI 10.1111/j.1365-2567.2008.02812.x; Alonso R, 2011, CELL DEATH DIFFER, V18, P1161, DOI 10.1038/cdd.2010.184; Andreola G, 2002, J EXP MED, V195, P1303, DOI 10.1084/jem.20011624; Bateman ED, 2008, EUR RESPIR J, V31, P143, DOI 10.1183/09031936.00138707; Bolte S, 2006, J MICROSC-OXFORD, V224, P213, DOI 10.1111/j.1365-2818.2006.01706.x; Burgoyne RD, 2003, PHYSIOL REV, V83, P581, DOI 10.1152/physrev.00031.2002; Caby MP, 2005, INT IMMUNOL, V17, P879, DOI 10.1093/intimm/dxh267; Dragovic RA, 2011, NANOMED-NANOTECHNOL, V7, P780, DOI 10.1016/j.nano.2011.04.003; DVORAK AM, 1991, AM J PATHOL, V138, P69; DVORAK AM, 1989, LAB INVEST, V61, P116; Egesten A, 2001, CLIN EXP ALLERGY, V31, P1173, DOI 10.1046/j.1365-2222.2001.01138.x; Eissa NT, 2013, J ALLERGY CLIN IMMUN, V131, P904, DOI 10.1016/j.jaci.2013.01.021; Elishmereni M, 2013, ALLERGY, V68, P171, DOI 10.1111/all.12059; Esser J, 2010, J ALLERGY CLIN IMMUN, V126, P1032, DOI 10.1016/j.jaci.2010.06.039; Fernvik E, 1995, APMIS, V103, P699, DOI 10.1111/j.1699-0463.1995.tb01426.x; Fernvik E, 1999, INFLAMM RES, V48, P28, DOI 10.1007/s000110050383; FUKUDA M, 1991, J BIOL CHEM, V266, P21327; Gercel-Taylor C, 2012, ANAL BIOCHEM, V428, P44, DOI 10.1016/j.ab.2012.06.004; HARDING C, 1983, J CELL BIOL, V97, P329, DOI 10.1083/jcb.97.2.329; Holgate ST, 2012, NAT MED, V18, P673, DOI 10.1038/nm.2731; Jambrina E, 2003, J BIOL CHEM, V278, P14134, DOI 10.1074/jbc.M211388200; Kesimer M, 2009, FASEB J, V23, P1858, DOI 10.1096/fj.08-119131; Kim JT, 1997, J IMMUNOL, V159, P926; Klion AD, 2004, J ALLERGY CLIN IMMUN, V113, P30, DOI 10.1016/j.jaci.2003.10.050; Kobayashi T, 2000, MOL BIOL CELL, V11, P1829, DOI 10.1091/mbc.11.5.1829; Lee JJ, 2005, CLIN EXP ALLERGY, V35, P986, DOI 10.1111/j.1365-2222.2005.02302.x; Levanen B, 2013, J ALLERGY CLIN IMMUN, V131, P894, DOI 10.1016/j.jaci.2012.11.039; Logan MR, 2003, J ALLERGY CLIN IMMUN, V111, P923, DOI 10.1067/mai.2003.1573; Lopez E, 2011, CLIN DEV IMMUNOL, DOI 10.1155/2011/917015; Ludwig AK, 2012, INT J BIOCHEM CELL B, V44, P11, DOI 10.1016/j.biocel.2011.10.005; Mahmudi-Azer S, 2002, BLOOD, V99, P4039, DOI 10.1182/blood.V99.11.4039; Matsuo H, 2004, SCIENCE, V303, P531, DOI 10.1126/science.1092425; Melo RCN, 2013, ALLERGY, V68, P274, DOI 10.1111/all.12103; Michael A, 2010, ORAL DIS, V16, P34, DOI 10.1111/j.1601-0825.2009.01604.x; Moqbel R, 1999, CLIN EXP ALLERGY, V29, P1017; Muller G., 2012, J BIOANAL BIOMED, V4, P46, DOI [10.4172/1948-593X.1000063, DOI 10.4172/1948-593X.1000063]; Neves JS, 2009, CURR OPIN IMMUNOL, V21, P694, DOI 10.1016/j.coi.2009.07.011; Neves JS, 2008, P NATL ACAD SCI USA, V105, P18478, DOI 10.1073/pnas.0804547105; Ogawa Y, 2011, BIOL PHARM BULL, V34, P13, DOI 10.1248/bpb.34.13; Paredes PT, 2012, ALLERGY, V67, P911, DOI 10.1111/j.1398-9995.2012.02835.x; Park JA, 2012, J ALLERGY CLIN IMMUN, V130, P1375, DOI 10.1016/j.jaci.2012.05.031; Zafra MP, 2013, J GASTROENTEROL, V48, P910, DOI 10.1007/s00535-012-0723-8; Pisitkun T, 2004, P NATL ACAD SCI USA, V101, P13368, DOI 10.1073/pnas.0403453101; Raiborg C, 2003, CURR OPIN CELL BIOL, V15, P446, DOI 10.1016/S0955-0674(03)00080-2; Rothenberg ME, 1998, NEW ENGL J MED, V338, P1592, DOI 10.1056/NEJM199805283382206; Sanderson MP, 2008, J CELL BIOCHEM, V103, P1783, DOI 10.1002/jcb.21569; Sheldon H, 2010, BLOOD, V116, P2385, DOI 10.1182/blood-2009-08-239228; Simons M, 2009, CURR OPIN CELL BIOL, V21, P575, DOI 10.1016/j.ceb.2009.03.007; Spencer LA, 2009, J LEUKOCYTE BIOL, V85, P117, DOI 10.1189/jlb.0108058; Subra C, 2010, J LIPID RES, V51, P2105, DOI 10.1194/jlr.M003657; Thery C, 2009, NAT REV IMMUNOL, V9, P581, DOI 10.1038/nri2567; Vallhov H, 2011, J IMMUNOL, V186, P73, DOI 10.4049/jimmunol.1001145; Vlassov AV, 2012, BBA-GEN SUBJECTS, V1820, P940, DOI 10.1016/j.bbagen.2012.03.017; Wang R, 2001, J IMMUNOL METHODS, V249, P167, DOI 10.1016/S0022-1759(00)00357-4; 1987, AM REV RESP DIS, V136, P225	59	79	87	3	43	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2015	135	6					1603	1613		10.1016/j.jaci.2014.11.026	http://dx.doi.org/10.1016/j.jaci.2014.11.026			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CK0ZC	25617225				2022-12-18	WOS:000355933400024
J	Bunyavanich, S; Schadt, EE				Bunyavanich, Supinda; Schadt, Eric E.			Systems biology of asthma and allergic diseases: A multiscale approach	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Systems biology; network; asthma; allergy; atopic; genome; transcriptome; epigenome; microbiome; metabolome; individual health profile; big data	GENOME-WIDE ASSOCIATION; MAGNETIC-RESONANCE-SPECTROSCOPY; IMPLICATES RARE VARIANTS; AIRWAY SMOOTH-MUSCLE; ATOPIC-DERMATITIS; DNA METHYLATION; SUSCEPTIBILITY LOCI; CHILDHOOD ASTHMA; GENE-EXPRESSION; EOSINOPHILIC ESOPHAGITIS	Systems biology is an approach to understanding living systems that focuses on modeling diverse types of high-dimensional interactions to develop a more comprehensive understanding of complex phenotypes manifested by the system. High-throughput molecular, cellular, and physiologic profiling of populations is coupled with bioinformatic and computational techniques to identify new functional roles for genes, regulatory elements, and metabolites in the context of the molecular networks that define biological processes associated with system physiology. Given the complexity and heterogeneity of asthma and allergic diseases, a systems biology approach is attractive, as it has the potential to model the myriad connections and interdependencies between genetic predisposition, environmental perturbations, regulatory intermediaries, and molecular sequelae that ultimately lead to diverse disease phenotypes and treatment responses across individuals. The increasing availability of high-throughput technologies has enabled system-wide profiling of the genome, transcriptome, epigenome, microbiome, and metabolome, providing fodder for systems biology approaches to examine asthma and allergy at a more holistic level. In this article we review the technologies and approaches for system-wide profiling, as well as their more recent applications to asthma and allergy. We discuss approaches for integrating multiscale data through network analyses and provide perspective on how individually captured health profiles will contribute to more accurate systems biology views of asthma and allergy.	[Bunyavanich, Supinda; Schadt, Eric E.] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA; [Bunyavanich, Supinda; Schadt, Eric E.] Icahn Sch Med Mt Sinai, Icahn Inst Genom & Multiscale Biol, New York, NY 10029 USA; [Bunyavanich, Supinda] Icahn Sch Med Mt Sinai, Dept Pediat, Div Pediat Allergy & Immunol, New York, NY 10029 USA; [Bunyavanich, Supinda] Icahn Sch Med Mt Sinai, Mindich Child Hlth & Dev Inst, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Bunyavanich, S (corresponding author), Icahn Sch Med Mt Sinai, One Gustave L Levy Pl 1198, New York, NY 10029 USA.	supinda@post.harvard.edu			National Institutes of Health/National Institute of Allergy and Infectious Disease [NIH K08AI093538]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI093538] Funding Source: NIH RePORTER	National Institutes of Health/National Institute of Allergy and Infectious Disease(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	S. Bunyavanich has received research support from the National Institutes of Health/National Institute of Allergy and Infectious Disease (NIH K08AI093538). E. E. Schadt declares that he has no relevant conflicts of interest.	Abrahamsson TR, 2014, CLIN EXP ALLERGY, V44, P842, DOI 10.1111/cea.12253; Abrahamsson TR, 2012, J ALLERGY CLIN IMMUN, V129, P434, DOI 10.1016/j.jaci.2011.10.025; Amaral AFS, 2014, J ALLERGY CLIN IMMUN, V133, P1497, DOI 10.1016/j.jaci.2014.02.010; Assfalg M, 2012, BRIT J DERMATOL, V166, P1123, DOI 10.1111/j.1365-2133.2011.10711.x; Bisgaard H, 2011, J ALLERGY CLIN IMMUN, V128, P646, DOI 10.1016/j.jaci.2011.04.060; Bonnelykke K, 2014, NAT GENET, V46, P51, DOI 10.1038/ng.2830; Bonnelykke K, 2013, NAT GENET, V45, P902, DOI 10.1038/ng.2694; Breton CV, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099716; Bunyavanich S, 2014, BMC MED GENOMICS, V7, DOI 10.1186/1755-8794-7-48; Caldeira M, 2012, J CHROMATOGR A, V1254, P87, DOI 10.1016/j.chroma.2012.07.023; Campbell CD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104396; Cantero-Recasens G, 2010, HUM MOL GENET, V19, P111, DOI 10.1093/hmg/ddp471; Carraro S, 2013, ALLERGY, V68, P110, DOI 10.1111/all.12063; Charlson ES, 2011, AM J RESP CRIT CARE, V184, P957, DOI 10.1164/rccm.201104-0655OC; Chen YQ, 2008, NATURE, V452, P429, DOI 10.1038/nature06757; Clifford RL, 2012, J IMMUNOL, V189, P819, DOI 10.4049/jimmunol.1103641; Cole C, 2014, J ALLERGY CLIN IMMUN, V134, P82, DOI 10.1016/j.jaci.2014.04.021; Dahlin A, 2012, PHARMACOGENOMICS, V13, P1387, DOI [10.2217/pgs.12.126, 10.2217/PGS.12.126]; Dobrin R, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-5-r55; Drake KA, 2014, J ALLERGY CLIN IMMUN, V133, P370, DOI 10.1016/j.jaci.2013.06.043; Enomoto T, 2014, ALLERGOL INT; Eriksson N, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000993; Esparza-Gordillo J, 2009, NAT GENET, V41, P596, DOI 10.1038/ng.347; Fang G, 2012, NAT BIOTECHNOL, V30, P1232, DOI 10.1038/nbt.2432; Ferreira MAR, 2011, LANCET, V378, P1006, DOI 10.1016/S0140-6736(11)60874-X; Fitzpatrick AM, 2014, J ALLERGY CLIN IMMUN, V133, P258, DOI 10.1016/j.jaci.2013.10.012; Forno Erick, 2008, Clin Mol Allergy, V6, P11, DOI 10.1186/1476-7961-6-11; Gahleitner F, 2013, BIOANALYSIS, V5, P2239, DOI 10.4155/bio.13.184; Gilstrap DL, 2013, J ALLERGY CLIN IMMUN, V131, P1449, DOI 10.1016/j.jaci.2013.03.004; Goleva E, 2013, AM J RESP CRIT CARE, V188, P1193, DOI 10.1164/rccm.201304-0775OC; Gudbjartsson DF, 2009, NAT GENET, V41, P342, DOI 10.1038/ng.323; Gunawardhana LP, 2014, PEDIATR PULM, V49, P852, DOI 10.1002/ppul.22930; Han J, 2012, BIOCHEM BIOPH RES CO, V422, P157, DOI 10.1016/j.bbrc.2012.04.128; Hilty M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008578; Himes BE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099625; Himes BE, 2009, AM J HUM GENET, V84, P581, DOI 10.1016/j.ajhg.2009.04.006; Hindorff LA, CATALOG PUBLISHED GE; Hinds DA, 2013, NAT GENET, V45, P907, DOI 10.1038/ng.2686; Hirota T, 2012, NAT GENET, V44, P1222, DOI 10.1038/ng.2438; Hirota T, 2011, NAT GENET, V43, P893, DOI 10.1038/ng.887; Hormannsperger G, 2012, J ALLERGY CLIN IMMUN, V129, P1452, DOI 10.1016/j.jaci.2011.12.993; Huang YJ, 2011, J ALLERGY CLIN IMMUN, V127, P372, DOI 10.1016/j.jaci.2010.10.048; Ibrahim B, 2013, ALLERGY, V68, P1050, DOI 10.1111/all.12211; Jostins L, 2012, NATURE, V491, P119, DOI 10.1038/nature11582; Jung J, 2013, CLIN EXP ALLERGY, V43, P425, DOI 10.1111/cea.12089; Kidd BA, 2014, NAT IMMUNOL, V15, P118, DOI 10.1038/ni.2787; Kim JH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071958; Kim YJ, 2013, BMC MED GENET, V14, DOI 10.1186/1471-2350-14-39; Kong HDH, 2012, GENOME RES, V22, P850, DOI 10.1101/gr.131029.111; Kottyan LC, 2014, NAT GENET, V46, P895, DOI 10.1038/ng.3033; Ku CS, 2011, J MED GENET, V48, P721, DOI 10.1136/jmedgenet-2011-100242; Ley RE, 2006, CELL, V124, P837, DOI 10.1016/j.cell.2006.02.017; Liang Y, 2012, ALLERGY, V67, P424, DOI 10.1111/j.1398-9995.2011.02760.x; Liu YJ, 2006, J EXP MED, V203, P269, DOI 10.1084/jem.20051745; Loureiro CC, 2014, J ALLERGY CLIN IMMUN, V133, P261, DOI 10.1016/j.jaci.2013.11.004; Lu SL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040676; Lu TX, 2012, J ALLERGY CLIN IMMUN, V129, P1064, DOI 10.1016/j.jaci.2012.01.060; Luo Y, 2014, CLIN EXP DERMATOL, V39, P48, DOI 10.1111/ced.12206; Margolis DJ, 2014, J INVEST DERMATOL, V134, P2272, DOI 10.1038/jid.2014.126; Marioni JC, 2008, GENOME RES, V18, P1509, DOI 10.1101/gr.079558.108; Marri PR, 2013, J ALLERGY CLIN IMMUN, V131, P346, DOI 10.1016/j.jaci.2012.11.013; Martino D, 2014, EPIGENETICS-US, V9, P998, DOI 10.4161/epi.28945; Mathias RA, 2014, ADV EXP MED BIOL, V795, P125, DOI 10.1007/978-1-4614-8603-9_9; Mattarucchi E, 2012, BIOMED CHROMATOGR, V26, P89, DOI 10.1002/bmc.1631; McErlean P, 2014, BMC MED GENOMICS, V7, DOI 10.1186/1755-8794-7-37; McLoughlin RM, 2011, J ALLERGY CLIN IMMUN, V127, P1097, DOI 10.1016/j.jaci.2011.02.012; Meyer KC, 2012, DIFFUSE LUNG DISEASE: A PRACTICAL APPROACH, SECOND EDITION, P3, DOI 10.1007/978-1-4419-9771-5_1; Mikhaylova L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070387; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Nestor CE, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004059; Pascual M, 2014, J ALLERGY CLIN IMMUN, V134, P972, DOI 10.1016/j.jaci.2014.05.015; Paternoster L, 2012, NAT GENET, V44, P187, DOI 10.1038/ng.1017; Platt C, 2014, J ALLERGY CLIN IMMUN, V134, P262, DOI 10.1016/j.jaci.2013.08.021; Poole A, 2014, J ALLERGY CLIN IMMUN, V133, P670, DOI 10.1016/j.jaci.2013.11.025; Ramasamy A, 2011, J ALLERGY CLIN IMMUN, V128, P996, DOI 10.1016/j.jaci.2011.08.030; Rebane A, 2014, J ALLERGY CLIN IMMUN, V134, P836, DOI 10.1016/j.jaci.2014.05.022; Reisdorph N, 2013, ALLERGY, V68, P959, DOI 10.1111/all.12238; Ried JS, 2013, ALLERGY, V68, P629, DOI 10.1111/all.12110; Rivas MN, 2013, J ALLERGY CLIN IMMUN, V131, P201, DOI 10.1016/j.jaci.2012.10.026; Rodriguez E, 2014, J INVEST DERMATOL, V134, P1873, DOI 10.1038/jid.2014.87; Rothenberg ME, 2010, NAT GENET, V42, P289, DOI 10.1038/ng.547; Salam MT, 2014, ADV EXP MED BIOL, V795, P183, DOI 10.1007/978-1-4614-8603-9_11; Saude EJ, 2011, J ALLERGY CLIN IMMUN, V127, P757, DOI 10.1016/j.jaci.2010.12.1077; Schadt EE, 2005, NAT GENET, V37, P710, DOI 10.1038/ng1589; Schadt EE, 2013, GENOME RES, V23, P129, DOI 10.1101/gr.136739.111; Schadt EE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3002132; Schadt EE, 2010, NAT REV GENET, V11, P647, DOI 10.1038/nrg2857; Scrivo R, 2014, CURR ALLERGY ASTHM R, V14, DOI 10.1007/s11882-014-0445-5; Seumois G, 2014, NAT IMMUNOL, V15, P777, DOI 10.1038/ni.2937; Sharma S, 2014, J ALLERGY CLIN IMMUN; Sherrill JD, 2014, GENES IMMUN, V15, P361, DOI 10.1038/gene.2014.27; Sinha A, 2012, EUR RESPIR J, V39, P500, DOI 10.1183/09031936.00047711; Sleiman PMA, 2010, NEW ENGL J MED, V362, P36, DOI 10.1056/NEJMoa0901867; Sordillo J, 2014, ADV EXP MED BIOL, V795, P157, DOI 10.1007/978-1-4614-8603-9_10; Stefanowicz D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044213; Sun LD, 2011, NAT GENET, V43, P690, DOI 10.1038/ng.851; Topol Eric, 2014, Health Data Manag, V22, P48; Torgerson DG, 2012, AM J HUM GENET, V90, P273, DOI 10.1016/j.ajhg.2012.01.008; Torgerson DG, 2011, NAT GENET, V43, P887, DOI 10.1038/ng.888; Ursell LK, 2012, J ALLERGY CLIN IMMUN, V129, P1204, DOI 10.1016/j.jaci.2012.03.010; Virgin HW, 2011, CELL, V147, P44, DOI 10.1016/j.cell.2011.09.009; Wan YI, 2012, THORAX, V67, P762, DOI 10.1136/thoraxjnl-2011-201262; Wang IJ, 2013, CLIN EXP ALLERGY, V43, P535, DOI 10.1111/cea.12108; Wang M, 2008, J ALLERGY CLIN IMMUN, V121, P129, DOI 10.1016/j.jaci.2007.09.011; Wang Z, 2009, NAT REV GENET, V10, P57, DOI 10.1038/nrg2484; Weidinger S, 2013, HUM MOL GENET, V22, P4841, DOI 10.1093/hmg/ddt317; Weisse K, 2013, ALLERGY, V68, P220, DOI 10.1111/all.12081; Yang IV, 2012, J ALLERGY CLIN IMMUN, V130, P1243, DOI 10.1016/j.jaci.2012.07.052; Yick CY, 2013, EUR RESPIR J, V42, P662, DOI 10.1183/09031936.00115412; Yick CY, 2013, AM J RESP CRIT CARE, V187, P1076, DOI 10.1164/rccm.201210-1886OC; Zhang B, 2013, CELL, V153, P707, DOI 10.1016/j.cell.2013.03.030; Ziyab AH, 2013, J EUR ACAD DERMATOL, V27, pe420, DOI 10.1111/jdv.12000	113	79	81	0	45	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2015	135	1					31	42		10.1016/j.jaci.2014.10.015	http://dx.doi.org/10.1016/j.jaci.2014.10.015			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AY0PG	25468194	Green Accepted			2022-12-18	WOS:000347298200004
J	Aguilar, C; Lenoir, C; Lambert, N; Begue, B; Brousse, N; Canioni, D; Berrebi, D; Roy, M; Gerart, S; Chapel, H; Schwerd, T; Siproudhis, L; Schappi, M; Al-Ahmari, A; Mori, M; Yamaide, A; Galicier, L; Neven, B; Routes, J; Uhlig, HH; Koletzko, S; Patel, S; Kanegane, H; Picard, C; Fischer, A; Bensussan, NC; Ruemmele, F; Hugot, JP; Latour, S				Aguilar, Claire; Lenoir, Christelle; Lambert, Nathalie; Begue, Bernadette; Brousse, Nicole; Canioni, Danielle; Berrebi, Dominique; Roy, Maryline; Gerart, Stephane; Chapel, Helen; Schwerd, Tobias; Siproudhis, Laurent; Schaeppi, Michela; Al-Ahmari, Ali; Mori, Masaaki; Yamaide, Akiko; Galicier, Lionel; Neven, Benedicte; Routes, John; Uhlig, Holm H.; Koletzko, Sibylle; Patel, Smita; Kanegane, Hirokazu; Picard, Capucine; Fischer, Alain; Bensussan, Nadine Cerf; Ruemmele, Frank; Hugot, Jean-Pierre; Latour, Sylvain			Characterization of Crohn disease in X-linked inhibitor of apoptosis-deficient male patients and female symptomatic carriers	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Inflammatory bowel disease; Crohn disease; X-linked inhibitor of apoptosis immunodeficiency; NOD receptors; monocytes	INFLAMMATORY-BOWEL-DISEASE; XIAP DEFICIENCY; NOD2; MUTATION; IMMUNODEFICIENCY; SUSCEPTIBILITY; ASSOCIATION; AUTOPHAGY; VARIANTS; PATHWAYS	Background: Crohn disease is an inflammatory bowel disease (IBD) with a complex mode of inheritance. Although nucleotide binding and oligomerization domain containing 2 (NOD2) is the strongest risk factor, the cause of Crohn disease remains unknown in the majority of the cases. X-linked inhibitor of apoptosis (XIAP) deficiency causes X-linked lymphoproliferative syndrome type 2. IBD has been reported in some XIAP-deficient patients. Objective: We characterize the IBD affecting a large cohort of patients with mutations in XIAP and examine the possible pathophysiologic mechanisms. Methods: We performed a phenotypical and histologic analysis of the IBD affecting 17 patients with hemizygous mutations in XIAP, including 3 patients identified by screening 83 patients with pediatric-onset IBD. The X chromosome inactivation was analyzed in female carriers of heterozygous XIAP mutations, including 2 adults with IBD. The functional consequences of XIAP deficiency were analyzed. Results: Clinical presentation and histology of IBD in patients with XIAP deficiency overlapped with those of patients with Crohn disease. The age at onset was variable (from 3 months to 41 years), and IBD was severe and difficult to treat. In 2 patients hematopoietic stem cell transplantation fully restored intestinal homeostasis. Monocytes of patients had impaired NOD2-mediated IL-8 and monocyte chemoattractant protein 1 (MCP-1) production, as well as IL-10, in response to NOD2 and Toll-like receptor 2/4 costimulation. Nucleotide binding and oligomerization domain containing 1 (NOD1)-mediated IL-6 and IL-8 production was defective in fibroblasts from XIAP-deficient patients. The 2 heterozygous female carriers of XIAP mutations with IBD displayed abnormal expression of the XIAP mutated allele, resulting in impaired activation of the NOD2 pathway. Conclusion: IBD in patients with XIAP deficiency is similar to Crohn disease and is associated with defective NOD2 function in monocytes. Importantly, we report that it is not restricted to male patients because we identified 2 symptomatic female heterozygous carriers of XIAP mutations.	[Aguilar, Claire; Lenoir, Christelle; Gerart, Stephane; Picard, Capucine; Fischer, Alain; Latour, Sylvain] Hop Necker Enfants Malad, Lab Lymphocyte Activat & EBV Susceptibil, F-75015 Paris, France; [Begue, Bernadette; Bensussan, Nadine Cerf; Ruemmele, Frank] Hop Necker Enfants Malad, Lab Interact Intestinal Epithelium & Immune Syst, F-75015 Paris, France; [Picard, Capucine] Hop Necker Enfants Malad, Lab Human Genet Infect Dis, INSERM, UMR 1163, F-75015 Paris, France; [Aguilar, Claire; Lenoir, Christelle; Begue, Bernadette; Gerart, Stephane; Picard, Capucine; Fischer, Alain; Bensussan, Nadine Cerf; Ruemmele, Frank; Latour, Sylvain] Univ Paris 05, Sorbonne Paris Cite, Inst Imagine, Paris, France; [Lambert, Nathalie; Picard, Capucine] Hosp Necker Enfants Malad, AP HP, Study Ctr Primary Immunodeficiencies CEDI, Paris, France; [Brousse, Nicole; Canioni, Danielle] Hosp Necker Enfants Malades, AP HP, Dept Pathol, Paris, France; [Neven, Benedicte; Fischer, Alain] Hosp Necker Enfants Malades, AP HP, Dept Immunol & Haematol, Paris, France; [Ruemmele, Frank] Hosp Necker Enfants Malades, AP HP, Pediat Gastroenterol Unit, Paris, France; [Berrebi, Dominique] Hosp Robert Debre, Dept Pathol, Paris, France; [Berrebi, Dominique; Roy, Maryline; Hugot, Jean-Pierre] Hosp Bichat, INSERM, UMR 843, Paris, France; [Berrebi, Dominique; Roy, Maryline; Hugot, Jean-Pierre] Univ Paris Diderot, Sorbonne Paris Cite, Paris, France; [Chapel, Helen; Patel, Smita] Univ Oxford, Oxford NIHR Biomed Res Ctr, Primary Immunodeficiency Unit, Oxford OX1 2JD, England; [Schwerd, Tobias; Koletzko, Sibylle] Univ Munich, Med Ctr, Dr von Hauner Childrens Hosp, Munich, Germany; [Siproudhis, Laurent] Univ Hosp Rennes, Dept Hepatogastroenterol, Rennes, France; [Schaeppi, Michela] Clin Grangettes, Pediat Ctr, Geneva, Switzerland; [Schaeppi, Michela] Ctr Med Univ Geneva, Geneva, Switzerland; [Al-Ahmari, Ali] Alfaisal Univ, King Faisal Specialist Hosp, Dept Pediat Hematol Oncol, Riyadh, Saudi Arabia; [Al-Ahmari, Ali] Alfaisal Univ, Res Ctr, Riyadh, Saudi Arabia; [Mori, Masaaki] Yokohama City Univ, Ctr Med, Dept Pediat, Yokohama, Kanagawa 232, Japan; [Yamaide, Akiko] Chiba Childrens Hosp, Div Allergy & Rheumatol, Chiba, Japan; [Galicier, Lionel] Hosp St Louis, AP HP, Dept Clin Immunol, Paris, France; [Routes, John] Med Coll Wisconsin, Childrens Canc Inst, Div Allergy & Clin Immunol, Milwaukee, WI 53226 USA; [Uhlig, Holm H.] Univ Oxford, Translat Gastroenterol Unit, Oxford OX1 2JD, England; [Uhlig, Holm H.] Univ Oxford, Childrens Hosp, Oxford OX1 2JD, England; [Kanegane, Hirokazu] Toyama Univ, Grad Sch Med & Pharmaceut Sci, Dept Pediat, Toyama, Japan; [Hugot, Jean-Pierre] Hosp Robert Debre, AP HP, Pediat Gastroenterol Unit, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Oxford; University of Munich; CHU Rennes; Universite de Rennes; University of Geneva; Alfaisal University; King Faisal Specialist Hospital & Research Center; Alfaisal University; Yokohama City University; Chiba Children's Hospital; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Medical College of Wisconsin; University of Oxford; University of Oxford; University of Toyama; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP	Latour, S (corresponding author), Hop Necker Enfants Malad, Lab Lymphocyte Activat & EBV Susceptibil, Imagine Inst Malad Genet, INSERM UMR 1163, 24 Blvd Montparnasse, F-75015 Paris, France.	sylvain.latour@inserm.fr	Aguilar, Claire/L-4459-2017; Begue, Bernadette/I-2744-2017; Routes, john/AAA-4833-2021; Picard, Capucine/H-3914-2017; Latour, Sylvain/H-3652-2017; Cerf-Bensussan, nadine/H-9505-2017	Aguilar, Claire/0000-0001-9181-2239; Begue, Bernadette/0000-0002-1228-9978; Routes, john/0000-0001-8378-3773; Picard, Capucine/0000-0001-8788-5056; Latour, Sylvain/0000-0001-8238-4391; Siproudhis, laurent/0000-0002-2575-6790; Hugot, Jean-Pierre/0000-0002-8446-6056; Uhlig, Holm/0000-0002-6111-7355; Cerf-Bensussan, nadine/0000-0003-0665-1245	INSERM; Agence Nationale de la Recherche (ANR) [ANR08 MIEN-012-01, ANR-2010-MIDI-005-02, ANR-10-IAHU-01]; Fondation ARC pour la Recherche sur le Cancer (France); European Research Council [ERC-2009-AdG_20090506]; Rare Diseases Fondation (France); Deutsche Forschungsgemeinschaft [SCHW1730/1-1]; Fondation ARC pour la Recherche sur le Cancer; Ministere de la Recherche et de l'Ecole Polytechnique (France); Fondation ARC	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Agence Nationale de la Recherche (ANR)(French National Research Agency (ANR)); Fondation ARC pour la Recherche sur le Cancer (France)(Fondation ARC pour la Recherche sur le Cancer); European Research Council(European Research Council (ERC)European Commission); Rare Diseases Fondation (France); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Fondation ARC pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le Cancer); Ministere de la Recherche et de l'Ecole Polytechnique (France); Fondation ARC	Supported by grants from INSERM, the Agence Nationale de la Recherche (ANR; ANR08 MIEN-012-01, ANR-2010-MIDI-005-02, and ANR-10-IAHU-01), the Fondation ARC pour la Recherche sur le Cancer (France), the European Research Council (ERC-2009-AdG_20090506 no. FP7-249816), and the Rare Diseases Fondation (France). This work was also supported by a grant from the Deutsche Forschungsgemeinschaft (SCHW1730/1-1; to T. S). S. L. is a senior scientist at the Centre National de la Recherche Scientifique-CNRS (France). C. A. is supported by the Fondation ARC pour la Recherche sur le Cancer. S. G. was a fellowship recipient of the Ministere de la Recherche et de l'Ecole Polytechnique (France) and the Fondation ARC.	Ammann S, 2014, CLIN EXP IMMUNOL, V176, P394, DOI 10.1111/cei.12306; Casanova JL, 2009, J EXP MED, V206, P1839, DOI 10.1084/jem.20091683; Cooney R, 2010, NAT MED, V16, P90, DOI 10.1038/nm.2069; Damgaard RB, 2013, EMBO MOL MED, V5, P1278, DOI 10.1002/emmm.201303090; Damgaard RB, 2012, MOL CELL, V46, P746, DOI 10.1016/j.molcel.2012.04.014; Eckelman BP, 2006, EMBO REP, V7, P988, DOI 10.1038/sj.embor.7400795; Galban S, 2010, CELL DEATH DIFFER, V17, P54, DOI 10.1038/cdd.2009.81; Gerart S, 2013, BLOOD, V121, P614, DOI 10.1182/blood-2012-09-456095; Glocker EO, 2011, ANN NY ACAD SCI, V1246, P102, DOI 10.1111/j.1749-6632.2011.06339.x; Glocker EO, 2009, NEW ENGL J MED, V361, P2033, DOI 10.1056/NEJMoa0907206; Gold MC, 2013, NAT REV MICROBIOL, V11, P14, DOI 10.1038/nrmicro2918; Huang X, 2013, EMBO J, V32, P2204, DOI 10.1038/emboj.2013.133; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560; Jostins L, 2012, NATURE, V491, P119, DOI 10.1038/nature11582; Khor B, 2011, NATURE, V474, P307, DOI 10.1038/nature10209; Krieg A, 2009, P NATL ACAD SCI USA, V106, P14524, DOI 10.1073/pnas.0907131106; Li J, 2004, HUM MOL GENET, V13, P1715, DOI 10.1093/hmg/ddh182; Liu Z, 2006, ONCOGENE, V25, P7680, DOI 10.1038/sj.onc.1209753; Marks DJB, 2009, AM J GASTROENTEROL, V104, P117, DOI 10.1038/ajg.2008.72; Marsh RA, 2010, J IMMUNOL METHODS, V362, P1, DOI 10.1016/j.jim.2010.08.010; Muise AM, 2012, GUT, V61, P1028, DOI 10.1136/gutjnl-2011-300078; Netea MG, 2005, J IMMUNOL, V174, P6518, DOI 10.4049/jimmunol.174.10.6518; Noguchi E, 2009, NAT IMMUNOL, V10, P471, DOI 10.1038/ni.1722; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Rigaud S, 2006, NATURE, V444, P110, DOI 10.1038/nature05257; Rigaud S, 2011, BLOOD, V118, P252, DOI 10.1182/blood-2011-01-328849; Rivas MA, 2011, NAT GENET, V43, P1066, DOI 10.1038/ng.952; Schmid JP, 2011, BLOOD, V117, P1522, DOI 10.1182/blood-2010-07-298372; Smith AM, 2009, J EXP MED, V206, P1883, DOI 10.1084/jem.20091233; Speckmann C, 2013, CLIN IMMUNOL, V149, P133, DOI 10.1016/j.clim.2013.07.004; Speckmann C, 2013, GUT; Strober W, 2006, NAT REV IMMUNOL, V6, P9, DOI 10.1038/nri1747; Strober W, 2011, MUCOSAL IMMUNOL, V4, P484, DOI 10.1038/mi.2011.29; Travassos LH, 2010, NAT IMMUNOL, V11, P55, DOI 10.1038/ni.1823; van Heel DA, 2005, LANCET, V365, P1794, DOI 10.1016/S0140-6736(05)66582-8; Worthey EA, 2011, GENET MED, V13, P255, DOI 10.1097/GIM.0b013e3182088158; Yang X, 2012, J CLIN IMMUNOL, V32, P411, DOI 10.1007/s10875-011-9638-z; Zeissig Y, 2014, GUT	39	79	82	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2014	134	5					1131	+		10.1016/j.jaci.2014.04.031	http://dx.doi.org/10.1016/j.jaci.2014.04.031			20	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AT4UN	24942515				2022-12-18	WOS:000344938900019
J	Rudders, SA; Arias, SA; Camargo, CA				Rudders, Susan A.; Arias, Sarah A.; Camargo, Carlos A., Jr.			Trends in hospitalizations for food-induced anaphylaxis in US children, 2000-2009	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							EMERGENCY-DEPARTMENT VISITS; UNITED-STATES; ALLERGY		[Rudders, Susan A.] Brown Univ, Rhode Isl Hosp, Alpert Sch Med, Dept Pediat,Div Asthma & Allergy, Providence, RI 02912 USA; [Arias, Sarah A.; Camargo, Carlos A., Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Emergency Med, Boston, MA USA; [Camargo, Carlos A., Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Rheumatol Allergy & Immunol, Boston, MA USA	Brown University; Lifespan Health Rhode Island; Rhode Island Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital	Rudders, SA (corresponding author), Brown Univ, Rhode Isl Hosp, Alpert Sch Med, Dept Pediat,Div Asthma & Allergy, Providence, RI 02912 USA.	srudders@lifespan.org	Camargo, Carlos A./C-2145-2008	Camargo, Carlos A./0000-0002-5071-7654; Arias, Sarah/0000-0003-1832-8824				Agency for Healthcare Research and Quality, 2011, INTR HCUP KIDS INP D; Branum AM, 2009, PEDIATRICS, V124, P1549, DOI 10.1542/peds.2009-1210; Brosch M, 2009, J PROTEOME RES, V8, P3176, DOI 10.1021/pr800982s; Camargo CA, 2007, J ALLERGY CLIN IMMUN, V120, P131, DOI 10.1016/j.jaci.2007.03.049; Clark S, 2006, ANN EPIDEMIOL, V16, P696, DOI 10.1016/j.annepidem.2005.12.003; Clark S, 2013, ALLERGY ASTHMA PROC, V34, P439, DOI 10.2500/aap.2013.34.3679; Gupta R, 2013, JAMA PEDIATR, V167, P1026, DOI 10.1001/jamapediatrics.2013.2376; Lin RY, 2008, ANN ALLERG ASTHMA IM, V101, P387, DOI 10.1016/S1081-1206(10)60315-8; Rudders SA, 2010, J ALLERGY CLIN IMMUN, V126, P385, DOI 10.1016/j.jaci.2010.05.018; Sheehan WJ, 2009, J ALLERGY CLIN IMMUN, V124, P850, DOI 10.1016/j.jaci.2009.06.044	10	79	79	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2014	134	4					960	962		10.1016/j.jaci.2014.06.018	http://dx.doi.org/10.1016/j.jaci.2014.06.018			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AQ9GC	25109801				2022-12-18	WOS:000343155700027
J	Slejko, JF; Ghushchyan, VH; Sucher, B; Globe, DR; Lin, SL; Globe, G; Sullivan, PW				Slejko, Julia F.; Ghushchyan, Vahram H.; Sucher, Brandon; Globe, Denise R.; Lin, Shao-Lee; Globe, Gary; Sullivan, Patrick W.			Asthma control in the United States, 2008-2010: Indicators of poor asthma control	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; Medical Expenditure Panel Survey; control; survey; United States; treatment; exacerbation; peak flow	BETA-AGONISTS; BURDEN; HEALTH; ASSOCIATION; MANAGEMENT; PATTERNS; INSIGHT; LEVEL; RISK	Background: An estimated 23 million Americans have asthma, of whom at least 12 million experience an asthma exacerbation every year. Clinical practice guidelines focus on asthma control, with an emphasis on reducing both impairment and risk. Objective: We sought to explore broad patterns of asthma prevalence, self-reported medication use, and indicators of control in a nationally representative sample. Methods: The 2008, 2009, and 2010 Medical Expenditure Panel Surveys were used to examine the national prevalence of self-reported asthma, trends in medication use, and demographic characteristics of asthmatic patients. History of lifetime asthma and current diagnosis were ascertained based on self-report. Asthma management and control were examined by using patient-reported medication use. Results: Of the 102,544 subjects asked about an asthma diagnosis, 9,782 reported lifetime asthma, and 8,837 reported current asthma. Five thousand five subjects (4.8% of the population) reported experiencing an asthma exacerbation in the previous year. Four thousand five hundred twenty-one subjects used a quick-relief inhaler for asthma symptoms, and 14.6% used more than 3 canisters of this type of medication in the past 3 months. Of this group, 60% were using daily long-term control medication but still required significant use of quick-relief inhalers, whereas 28% had never used long-term control medication. Of those who had a recent exacerbation, 29% were using daily preventive medication, whereas 54% had never used long-term control medication. Conclusions: Improvement of asthma control continues to be a US public health concern. Results suggest suboptimal asthma control with underuse of long-term control medications, overuse of quick-relief inhalers, and a significant number of self-reported asthma exacerbations.	[Slejko, Julia F.] Univ Washington, Dept Pharm, Pharmaceut Outcomes Res & Policy Program, Seattle, WA 98195 USA; [Ghushchyan, Vahram H.] Amer Univ Armenia, Coll Business & Econ, Yerevan, Armenia; [Sucher, Brandon; Sullivan, Patrick W.] Regis Univ, Sch Pharm, Denver, CO 80221 USA; [Globe, Denise R.; Lin, Shao-Lee; Globe, Gary] Amgen Inc, Global Hlth Econ, Thousand Oaks, CA USA	University of Washington; University of Washington Seattle; American University of Armenia; Regis University; Amgen	Sullivan, PW (corresponding author), Regis Univ, Sch Pharm, 3333 Regis Blvd,H-28, Denver, CO 80221 USA.	psulliva@regis.edu	Slejko, Julia/M-9335-2019		Amgen	Amgen(Amgen)	Supported by a research grant from Amgen.	Adams RJ, 2002, J ALLERGY CLIN IMMUN, V110, P58, DOI 10.1067/mai.2002.125489; AHRQ, MED EXP PAN SURV MEP; Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC; Benner JS, 2005, AM J HEALTH-SYST PH, V62, P1468, DOI 10.2146/ajhp040419; Carlton BG, 2005, J ASTHMA, V42, P529, DOI 10.1081/JAS-200067000; Centers for Disease Control and Prevention, 2013, ASTHM IMP NAT; Clark NM, 2010, J ASTHMA, V47, P150, DOI 10.3109/02770900903483824; Diette GB, 1999, ARCH INTERN MED, V159, P2697, DOI 10.1001/archinte.159.22.2697; Fuhlbrigge AL, 2002, AM J RESP CRIT CARE, V166, P1044, DOI 10.1164/rccm.2107057; Fuhlbrigge A, 2009, ALLERGY ASTHMA PROC, V30, P529, DOI 10.2500/aap.2009.30.3276; Gold LS, 2012, ANN ALLERG ASTHMA IM, V109, P260, DOI 10.1016/j.anai.2012.07.024; Harver A, 2009, J ASTHMA, V46, P940, DOI 10.3109/02770900903274475; McHugh MK, 2009, J ASTHMA, V46, P759, DOI 10.3109/02770900903067895; Meltzer EO, 2012, ALLERGY ASTHMA PROC, V33, P36, DOI 10.2500/aap.2011.32.3519; Murphy KR, 2012, ALLERGY ASTHMA PROC, V33, P54, DOI 10.2500/aap.2011.32.3518; National Center for Health Statistics- Leisure Time Physical Activity, 2013, EARL REL SEL EST BAS; National Heart Lung and Blood Institute. National Asthma Education and Prevention Program, 2007, 3 NAT HEART LUNG BLO; National Heart Lung Blood Institute, 1997, 2 NAT HEART LUNG BLO; National Institutes of Health; National Heart Lung and Blood Institute (NHLBI), 2012, MORB MORT 2012 CHART; Nichols B, 2009, J ASTHMA, V46, P498, DOI 10.1080/02770900902866776; Schatz M, 2005, CHEST, V128, P1968, DOI 10.1378/chest.128.4.1968; Schatz M, 2006, J ALLERGY CLIN IMMUN, V118, P1048, DOI 10.1016/j.jaci.2006.07.057; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; Stafford RS, 2003, J ALLERGY CLIN IMMUN, V111, P729, DOI 10.1067/mai.2003.177; Sullivan PW, 2011, J ALLERGY CLIN IMMUN, V127, P363, DOI 10.1016/j.jaci.2010.10.042; Sullivan SD, 2007, ALLERGY, V62, P126, DOI 10.1111/j.1398-9995.2006.01254.x; Vollmer WM, 1999, AM J RESP CRIT CARE, V160, P1647, DOI 10.1164/ajrccm.160.5.9902098	27	79	80	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2014	133	6					1579	1587		10.1016/j.jaci.2013.10.028	http://dx.doi.org/10.1016/j.jaci.2013.10.028			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AI2FI	24331376				2022-12-18	WOS:000336672500009
J	Takabayashi, T; Kato, A; Peters, AT; Hulse, KE; Suh, LA; Carter, R; Norton, J; Grammer, LC; Tan, BK; Chandra, RK; Conley, DB; Kern, RC; Fujieda, S; Schleimer, RP				Takabayashi, Tetsuji; Kato, Atsushi; Peters, Anju T.; Hulse, Kathryn E.; Suh, Lydia A.; Carter, Roderick; Norton, James; Grammer, Leslie C.; Tan, Bruce K.; Chandra, Rakesh K.; Conley, David B.; Kern, Robert C.; Fujieda, Shigeharu; Schleimer, Robert P.			Increased expression of factor XIII-A in patients with chronic rhinosinusitis with nasal polyps	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chronic rhinosinusitis; nasal polyps; factor XIII-A (FXIII-A); M2 macrophages; fibrin; coagulation cascade	CELL-ACTIVATING FACTOR; COAGULATION-FACTOR; TNF FAMILY; SUBUNIT-A; MACROPHAGES; MONOCYTE; PLASMA; INFLAMMATION; IMMUNITY; PATHOGENESIS	Background: Profound edema or formation of a pseudocyst containing plasma proteins is a prominent characteristic of nasal polyps (NP). However, the mechanisms underlying NP retention of plasma proteins in the submucosa remain unclear. Recently, we reported that impairment of fibrinolysis causes excessive fibrin deposition in NP and this might be involved in the retention of plasma proteins. Although the coagulation cascade plays a critical role in fibrin clot formation at extravascular sites, the expression and role of coagulation factors in NP remain unclear. Objective: The objective of this study was to investigate the expression of coagulation factors in patients with chronic rhinosinusitis (CRS). Methods: Sinonasal tissues were collected from patients with CRS and control subjects. We assayed mRNA for factor XIII-A (FXIII-A) by using real-time PCR and measured FXIII-A protein by means of ELISA, immunohistochemistry, and immunofluorescence. Results: FXIII-A mRNA levels were significantly increased in NP tissue from patients with CRS with NP (P < .001) compared with uncinate tissue from patients with CRS or control subjects. Similarly, FXIII-A protein levels were increased in NP. Immunofluorescence analysis revealed that FXIII-A expression in inflammatory cells and FXIII-A(+) cell numbers were significantly increased in NP. Most FXIII-A staining was observed within CD68(+)/CD163(+) M2 macrophages in NP. Levels of FXIII-A correlated with markers of M2 macrophages, suggesting that M2 macrophages are major FXIIIA-producing cells in NP. Conclusion: Overproduction of FXIII-A by M2 macrophages might contribute to the excessive fibrin deposition in the submucosa of NP, which might contribute to the tissue remodeling and pathogenesis of CRS with NP.	[Takabayashi, Tetsuji; Kato, Atsushi; Peters, Anju T.; Hulse, Kathryn E.; Suh, Lydia A.; Carter, Roderick; Norton, James; Grammer, Leslie C.; Schleimer, Robert P.] Northwestern Univ, Feinberg Sch Med, Dept Med, Div Allergy & Immunol, 240 E Huron, Chicago, IL 60611 USA; [Tan, Bruce K.; Chandra, Rakesh K.; Conley, David B.; Kern, Robert C.; Schleimer, Robert P.] Northwestern Univ, Feinberg Sch Med, Dept Otolaryngol, Chicago, IL 60611 USA; [Takabayashi, Tetsuji; Fujieda, Shigeharu] Univ Fukui, Dept Sensory & Locomotor Med, Div Otolaryngol Head & Neck Surg, Fukui 910, Japan	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; University of Fukui	Schleimer, RP (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Med, Div Allergy & Immunol, 240 E Huron, Chicago, IL 60611 USA.	rpschleimer@northwestern.edu		Grammer, Leslie/0000-0001-6860-2014; Kato, Atsushi/0000-0001-9144-3138; Chandra, Rakesh/0000-0002-3612-0026; Hulse, Kathryn/0000-0003-0969-999X	National Institutes of Health [R37HL068546-27, R01HL078860, RO1AI072570]; Ernest S. Bazley Trust; National Institutes of Health (NIH); Baxter; NIH; Bazley Foundation grant; Food Allergy Network; SC Electric; American Academy of Allergy, Asthma Immunology; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL078860, R37HL068546] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI072570, P01AI106683, T32AI083216] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ernest S. Bazley Trust; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Baxter; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Bazley Foundation grant; Food Allergy Network; SC Electric; American Academy of Allergy, Asthma Immunology; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grants R37HL068546-27, R01HL078860, and RO1AI072570 and the Ernest S. Bazley Trust.r A. Kato and B.K. Tan have received grants from the National Institutes of Health (NIH). A. T. Peters has received payments for lectures from Baxter. L. C. Grammer has received a grant and travel support from the NIH; has received a Bazley Foundation grant; has consultant arrangements with Astellas Pharmaceuticals; is employed by Northwestern University and Northwestern Medical Faculty Foundation; has received grants from the NIH, the Food Allergy Network, and S&C Electric; has received payment for lectures from the American Academy of Allergy, Asthma & Immunology; and has received royalties from Lippincott, UpToDate, BMJ, and Elsevier. R. P. Schleimer has received grants from the NIH and has consultant arrangements with Intersect ENT, GlaxoSmithKline, Allakos, and Aurasense. The rest of the authors declare that they have no relevant conflicts of interest.	Abraham SN, 2010, NAT REV IMMUNOL, V10, P440, DOI 10.1038/nri2782; Adany R, 2003, CELL MOL LIFE SCI, V60, P1049, DOI 10.1007/s00018-003-2178-9; Akassoglou K, 2004, P NATL ACAD SCI USA, V101, P6698, DOI 10.1073/pnas.0303859101; Bachert C, 2000, AM J RHINOL, V14, P279, DOI 10.2500/105065800781329573; Bachert Claus, 2002, Curr Allergy Asthma Rep, V2, P252, DOI 10.1007/s11882-002-0027-9; Bagoly Z, 2012, THROMB RES, V129, pS77, DOI 10.1016/j.thromres.2012.02.040; Cordell PA, 2010, BLOOD, V115, P2674, DOI 10.1182/blood-2009-08-231316; Dardik R, 2005, ARTERIOSCL THROM VAS, V25, P526, DOI 10.1161/01.ATV.0000154137.21230.80; Dardik R, 2003, ARTERIOSCL THROM VAS, V23, P1472, DOI 10.1161/01.ATV.0000081636.25235.C6; Dardik R, 2007, CELL PHYSIOL BIOCHEM, V19, P113, DOI 10.1159/000099199; de Boer JD, 2012, BLOOD, V119, P3236, DOI 10.1182/blood-2011-11-391532; Del Rosso M, 2008, FRONT BIOSCI-LANDMRK, V13, P4667, DOI 10.2741/3032; DERRICK EK, 1993, HISTOPATHOLOGY, V22, P157, DOI 10.1111/j.1365-2559.1993.tb00095.x; Fairweather D, 2009, J AUTOIMMUN, V33, P222, DOI 10.1016/j.jaut.2009.09.012; GABAZZA EC, 1994, THROMB HAEMOSTASIS, V71, P199; Gordon S, 2010, IMMUNITY, V32, P593, DOI 10.1016/j.immuni.2010.05.007; Hanf G, 2004, EUR RESPIR J, V23, P414, DOI 10.1183/09031936.04.00024504; Hao NB, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/948098; Hirshoren N, 2011, INFLAMM RES, V60, P321, DOI 10.1007/s00011-010-0271-8; HUDSON M, 1992, BLOOD COAGUL FIBRIN, V3, P773, DOI 10.1097/00001721-199212000-00011; Ichinose A, 2012, INT J HEMATOL, V95, P362, DOI 10.1007/s12185-012-1064-3; Jennewein C, 2011, MOL MED, V17, P568, DOI 10.2119/molmed.2010.00146; Kato A, 2008, J ALLERGY CLIN IMMUN, V121, P1385, DOI 10.1016/j.jaci.2008.03.002; Kato A, 2006, J IMMUNOL, V177, P7164, DOI 10.4049/jimmunol.177.10.7164; Kato A, 2009, J IMMUNOL, V182, P7233, DOI 10.4049/jimmunol.0801375; Katona E, 2001, J IMMUNOL METHODS, V258, P127, DOI 10.1016/S0022-1759(01)00479-3; Katona L, 2005, J THROMB HAEMOST, V3, P1407, DOI 10.1111/j.1538-7836.2005.01353.x; Kern RC, 2008, AM J RHINOL, V22, P549, DOI 10.2500/ajr.2008.22.3228; Kiefer R, 2001, PROG NEUROBIOL, V64, P109, DOI 10.1016/S0301-0082(00)00060-5; Kondo T, 2010, FORENSIC SCI INT, V203, P93, DOI 10.1016/j.forsciint.2010.07.004; Krysko O, 2011, ALLERGY, V66, P396, DOI 10.1111/j.1398-9995.2010.02498.x; Lauer P, 2002, THROMB HAEMOSTASIS, V88, P967, DOI 10.1055/s-0037-1613342; Lee HS, 2009, AM J RESP CRIT CARE, V180, P1056, DOI 10.1164/rccm.200905-0740OC; Malara A, 2011, BLOOD, V117, P2476, DOI 10.1182/blood-2010-06-288795; Martinez FO, 2008, FRONT BIOSCI-LANDMRK, V13, P453, DOI 10.2741/2692; Meltzer EO, 2004, OTOLARYNG HEAD NECK, V131, pS1, DOI 10.1016/j.otohns.2004.09.067; Mjosberg J, 2012, IMMUNITY, V37, P649, DOI 10.1016/j.immuni.2012.08.015; Mjosberg JM, 2011, NAT IMMUNOL, V12, P1055, DOI 10.1038/ni.2104; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Murray PJ, 2011, NAT REV IMMUNOL, V11, P723, DOI 10.1038/nri3073; Muszbek L, 2011, PHYSIOL REV, V91, P931, DOI 10.1152/physrev.00016.2010; NEALE TJ, 1988, LANCET, V2, P421; OKAMOTO M, 1992, BIOCHIM BIOPHYS ACTA, V1138, P53, DOI 10.1016/0925-4439(92)90151-C; Pawliczak R, 2005, CURR ALLERGY ASTHM R, V5, P463, DOI 10.1007/s11882-005-0027-7; Pearlman AN, 2008, CURR OPIN OTOLARYNGO, V16, P226, DOI 10.1097/MOO.0b013e3282fdcc9a; PERSSON CGA, 1991, EUR RESPIR J, V4, P1268; Peterson S, 2012, J ALLERGY CLIN IMMUN, V129, P119, DOI 10.1016/j.jaci.2011.08.021; Poposki JA, 2011, J ALLERGY CLIN IMMUN, V128, P73, DOI 10.1016/j.jaci.2011.03.017; Quatresooz P, 2008, INT J MOL MED, V22, P403, DOI 10.3892/ijmm_00000036; Sarvary A, 2004, CELL IMMUNOL, V228, P81, DOI 10.1016/j.cellimm.2004.04.007; Schleimer Robert P, 2009, Proc Am Thorac Soc, V6, P288, DOI 10.1513/pats.200808-088RM; Semba U, 2010, AM J PATHOL, V176, P1542, DOI 10.2353/ajpath.2010.090720; Seshadri S, 2012, ALLERGY, V67, P920, DOI 10.1111/j.1398-9995.2012.02848.x; Szaba FM, 2002, BLOOD, V99, P1053, DOI 10.1182/blood.V99.3.1053; Takabayashi T, 2013, AM J RESP CRIT CARE, V187, P49, DOI 10.1164/rccm.201207-1292OC; Takabayashi T, 2012, J ALLERGY CLIN IMMUN, V130, P410, DOI 10.1016/j.jaci.2012.02.046; Taylor MD, 2012, TRENDS IMMUNOL, V33, P181, DOI 10.1016/j.it.2012.01.001; Torocsik D, 2010, THROMB HAEMOSTASIS, V104, P709, DOI 10.1160/TH09-11-0805; Torocsik D, 2005, CELL MOL LIFE SCI, V62, P2132, DOI 10.1007/s00018-005-5242-9; Van Bruaene N, 2009, J ALLERGY CLIN IMMUN, V124, P253, DOI 10.1016/j.jaci.2009.04.013; Van Zele T, 2006, ALLERGY, V61, P1280, DOI 10.1111/j.1398-9995.2006.01225.x	61	79	82	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2013	132	3					584	+		10.1016/j.jaci.2013.02.003	http://dx.doi.org/10.1016/j.jaci.2013.02.003			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	207OS	23541322	Green Accepted			2022-12-18	WOS:000323612000009
J	Park, JA; Sharif, AS; Tschumperlin, DJ; Lau, L; Limbrey, R; Howarth, P; Drazen, JM				Park, Jin-Ah; Sharif, Asma S.; Tschumperlin, Daniel J.; Lau, Laurie; Limbrey, Rachel; Howarth, Peter; Drazen, Jeffrey M.			Tissue factor-bearing exosome secretion from human mechanically stimulated bronchial epithelial cells in vitro and in vivo	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; tissue factor; exosomes; bronchoconstriction; mechanotransduction; bronchial epithelium	EXPRESSION; MICROPARTICLES; MICROVESICLES; STRESS; VASCULARITY; MEDIATORS; AIRWAYS; FIBRIN; LUNGS; LINE	Background: Tissue factor (TF), a primary initiator of blood coagulation, also plays a pivotal role in angiogenesis. TF expression in the airways is associated with asthma, a disease characterized in part by subepithelial angiogenesis. Objectives: To determine potential sources of TF and the mechanisms of its availability in the lung microenvironment. Methods: Normal human bronchial epithelial cells grown in air-liquid interface culture were subjected to a compressive stress of 30 cm H2O; this is comparable to that generated in the airway epithelium during bronchoconstriction in asthma. Conditioned media and cells were harvested to measure TF mRNA and TF protein. We also tested bronchoalveolar lavage fluid and airway biopsies from asthmatic patients and healthy controls for TF. Results: TF mRNA was upregulated 2.2-fold after 3 hours of stress compared with unstressed cells. Intracellular and secreted TF proteins were enhanced 1.6-fold and more than 50-fold, respectively, compared with those of control cells after the onset of compression. The amount of TF in the bronchoalveolar lavage fluid from patients with asthma was found at mean concentrations that were 5 times greater than those of healthy controls. Immunohistochemical staining of endobronchial biopsies identified epithelial localization of TF with increased expression in asthma. Exosomes isolated from the conditioned media of normal human bronchial epithelial cells and the bronchoalveolar lavage fluid of asthmatic subjects by ultracentrifugation contained TF. Conclusions: Our in vitro and in vivo studies show that mechanically stressed bronchial epithelial cells are a source of secreted TF and that exosomes are potentially a key carrier of the TF signal. (J Allergy Clin Immunol 2012;130:1375-83.)	[Park, Jin-Ah; Sharif, Asma S.; Tschumperlin, Daniel J.; Drazen, Jeffrey M.] Harvard Univ, Sch Publ Hlth, Mol & Integrat Physiol Sci Program, Dept Environm Hlth, Boston, MA 02115 USA; [Lau, Laurie; Limbrey, Rachel; Howarth, Peter] Univ Southampton, Fac Med, Clin & Expt Sci Acad Unit, Southampton SO9 5NH, Hants, England; [Lau, Laurie; Limbrey, Rachel; Howarth, Peter] Southampton Gen Hosp, Natl Inst Hlth Resp Biosci Res Unit, Southampton SO9 4XY, Hants, England	Harvard University; Harvard T.H. Chan School of Public Health; University of Southampton; University of Southampton	Drazen, JM (corresponding author), Harvard Univ, Sch Publ Hlth, Mol & Integrat Physiol Sci Program, Dept Environm Hlth, 665 Huntington Ave,SPH1-309, Boston, MA 02115 USA.	jdrazen@nejm.org		Park, Jin-Ah/0000-0002-8930-9287; Howarth, Peter/0000-0003-0619-7927	National Institutes of Health [HL88028, T32-HL007118]; Medical Research Council [G0900453]; Medical Research Council [G0400473, G19/34] Funding Source: researchfish; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007118, R01HL088028] Funding Source: NIH RePORTER; MRC [G0400473, G0900453, G19/34] Funding Source: UKRI	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This study was supported by National Institutes of Health grants HL88028 (to J.M.D.) and T32-HL007118 (to J.-A.P.) and Medical Research Council grant G0900453 (to P.H.).	Aharon A, 2009, BEST PRACT RES CL HA, V22, P61, DOI 10.1016/j.beha.2008.11.002; Al-Nedawi K, 2009, P NATL ACAD SCI USA, V106, P3794, DOI 10.1073/pnas.0804543106; Bastarache JA, 2009, AM J PHYSIOL-LUNG C, V297, pL1035, DOI 10.1152/ajplung.00214.2009; Belting M, 2004, NAT MED, V10, P502, DOI 10.1038/nm1037; Bogdanov VY, 2003, NAT MED, V9, P458, DOI 10.1038/nm841; Brims FJH, 2009, THORAX, V64, P1037, DOI 10.1136/thx.2009.114439; BRITTEN KM, 1993, BIOTECH HISTOCHEM, V68, P271, DOI 10.3109/10520299309105629; Button B, 2008, RESP PHYSIOL NEUROBI, V163, P189, DOI 10.1016/j.resp.2008.04.020; Carmeliet P, 1996, NATURE, V383, P73, DOI 10.1038/383073a0; Chen J, 2001, THROMB HAEMOSTASIS, V86, P334; Cheruvanky A, 2007, AM J PHYSIOL-RENAL, V292, pF1657, DOI 10.1152/ajprenal.00434.2006; Cocucci E, 2009, TRENDS CELL BIOL, V19, P43, DOI 10.1016/j.tcb.2008.11.003; del Conde I, 2005, BLOOD, V106, P1604, DOI 10.1182/blood-2004-03-1095; DRAKE TA, 1989, AM J PATHOL, V134, P1087; ExoCarta, EX MARK; Gabazza EC, 1999, LUNG, V177, P253, DOI 10.1007/PL00007645; Grainge CL, 2011, NEW ENGL J MED, V364, P2006, DOI 10.1056/NEJMoa1014350; Gyorgy B, 2011, CELL MOL LIFE SCI, V68, P2667, DOI 10.1007/s00018-011-0689-3; Holgate ST, 2007, J ALLERGY CLIN IMMUN, V120, P1233, DOI 10.1016/j.jaci.2007.10.025; Hugel B, 2005, PHYSIOLOGY, V20, P22, DOI 10.1152/physiol.00029.2004; Imokawa S, 1997, AM J RESP CRIT CARE, V156, P631, DOI 10.1164/ajrccm.156.2.9608094; Lee TH, 2011, SEMIN IMMUNOPATHOL, V33, P455, DOI 10.1007/s00281-011-0250-3; Li X, 1997, AM J RESP CRIT CARE, V156, P229, DOI 10.1164/ajrccm.156.1.9607066; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mathivanan S, 2010, MOL CELL PROTEOMICS, V9, P197, DOI 10.1074/mcp.M900152-MCP200; Mineo M, 2012, ANGIOGENESIS, V15, P33, DOI 10.1007/s10456-011-9241-1; Orsida BE, 1999, THORAX, V54, P289, DOI 10.1136/thx.54.4.289; Paredi P, 2009, THORAX, V64, P444, DOI 10.1136/thx.2008.100032; Park JA, 2010, J BIOL CHEM, V285, P29817, DOI 10.1074/jbc.M110.103416; Park JA, 2009, AM J RESP CELL MOL, V41, P459, DOI 10.1165/rcmb.2008-0195OC; Pisitkun T, 2004, P NATL ACAD SCI USA, V101, P13368, DOI 10.1073/pnas.0403453101; Record M, 2011, BIOCHEM PHARMACOL, V81, P1171, DOI 10.1016/j.bcp.2011.02.011; Ressler B, 2000, AM J PHYSIOL-LUNG C, V278, pL1264, DOI 10.1152/ajplung.2000.278.6.L1264; Sanderson MP, 2008, J CELL BIOCHEM, V103, P1783, DOI 10.1002/jcb.21569; Shetty S, 2010, AM J RESP CRIT CARE, V181, P1355, DOI 10.1164/rccm.200901-0015OC; Swartz MA, 2001, P NATL ACAD SCI USA, V98, P6180, DOI 10.1073/pnas.111133298; Thery Clotilde, 2006, Curr Protoc Cell Biol, VChapter 3, DOI 10.1002/0471143030.cb0322s30; Tschumperlin DJ, 2004, NATURE, V429, P83, DOI 10.1038/nature02543; Tschumperlin DJ, 2003, AM J RESP CELL MOL, V28, P142, DOI 10.1165/rcmb.2002-0121OC; van den Berg YW, 2012, BLOOD, V119, P924, DOI 10.1182/blood-2011-06-317685; Wagers SS, 2004, J CLIN INVEST, V114, P104, DOI 10.1172/JCI200419569; Wiggs BR, 1997, J APPL PHYSIOL, V83, P1814, DOI 10.1152/jappl.1997.83.6.1814; Yu J, 2008, ARTERIOSCL THROM VAS, V28, P1975, DOI 10.1161/ATVBAHA.108.175083; Yu X, 2006, CANCER RES, V66, P4795, DOI 10.1158/0008-5472.CAN-05-4579; ZHANG YM, 1994, J CLIN INVEST, V94, P1320, DOI 10.1172/JCI117451	45	79	85	0	27	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2012	130	6					1375	1383		10.1016/j.jaci.2012.05.031	http://dx.doi.org/10.1016/j.jaci.2012.05.031			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	044RP	22828416	Green Accepted			2022-12-18	WOS:000311641100019
J	Fernandes, BN; Boyle, RJ; Gore, C; Simpson, A; Custovic, A				Fernandes, Bryan N.; Boyle, Robert J.; Gore, Claudia; Simpson, Angela; Custovic, Adnan			Food protein-induced enterocolitis syndrome can occur in adults	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							MANAGEMENT		[Fernandes, Bryan N.; Simpson, Angela; Custovic, Adnan] NHS Fdn Trust, Univ S Manchester Hosp, Allergy Ctr, Manchester, Lancs, England; [Fernandes, Bryan N.; Simpson, Angela; Custovic, Adnan] Univ Manchester, Manchester, Lancs, England; [Boyle, Robert J.] Univ London Imperial Coll Sci Technol & Med, Dept Paediat, London, England; [Gore, Claudia] St Marys Hosp, Dept Paediat Allergy, London, England	Oxford University Hospitals NHS Foundation Trust; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; University of Manchester; Imperial College London; Imperial College London	Fernandes, BN (corresponding author), NHS Fdn Trust, Univ S Manchester Hosp, Allergy Ctr, Manchester, Lancs, England.	bryan.fernandes@manchester.ac.uk	Custovic, Adnan/A-2435-2012	Custovic, Adnan/0000-0001-5218-7071; Boyle, Robert/0000-0002-4913-7580; Simpson, Angela/0000-0003-2733-6666				Busse PJ, 2000, J ALLERGY CLIN IMMUN, V105, pS129, DOI 10.1016/S0091-6749(00)90815-7; Hayashi Daisuke, 2010, Arerugi, V59, P1628; Jones KDJ, 2010, ALLERGY, V65, P1061, DOI 10.1111/j.1398-9995.2009.02276.x; Leonard SA, 2011, ANN ALLERG ASTHMA IM, V107, P95, DOI 10.1016/j.anai.2011.06.004; Mehr S, 2009, PEDIATRICS, V123, pe459, DOI 10.1542/peds.2008-2029; Sampson HA, 2000, J PEDIATR GASTR NUTR, V30, pS87, DOI 10.1097/00005176-200001001-00013; Sicherer SH, 2005, J ALLERGY CLIN IMMUN, V115, P149, DOI 10.1016/j.jaci.2004.09.033; Woo Chee K, 2011, Clin Transl Allergy, V1, P3, DOI 10.1186/2045-7022-1-3; Zapatero Remon L, 2005, Allergol Immunopathol (Madr), V33, P312	9	79	83	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2012	130	5					1199	1200		10.1016/j.jaci.2012.06.017	http://dx.doi.org/10.1016/j.jaci.2012.06.017			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	030LE	22835404	Bronze			2022-12-18	WOS:000310571400023
J	Brehm, JM; Acosta-Perez, E; Klei, L; Roeder, K; Barmada, MM; Boutaoui, N; Forno, E; Cloutier, MM; Datta, S; Kelly, R; Paul, K; Sylvia, J; Calvert, D; Thornton-Thompson, S; Wakefield, D; Litonjua, AA; Alvarez, M; Colon-Semidey, A; Canino, G; Celedon, JC				Brehm, John M.; Acosta-Perez, Edna; Klei, Lambertus; Roeder, Kathryn; Barmada, Michael M.; Boutaoui, Nadia; Forno, Erick; Cloutier, Michelle M.; Datta, Soma; Kelly, Roxanne; Paul, Kathryn; Sylvia, Jody; Calvert, Deanna; Thornton-Thompson, Sherell; Wakefield, Dorothy; Litonjua, Augusto A.; Alvarez, Maria; Colon-Semidey, Angel; Canino, Glorisa; Celedon, Juan C.			African ancestry and lung function in Puerto Rican children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Ancestry; FEV1; forced vital capacity; Puerto Ricans; childhood	CHILDHOOD ASTHMA; COSTA-RICA; POPULATION; SEVERITY; EXPOSURE; ASSOCIATION; INFERENCE; ADMIXTURE; ALLERGEN; PRETERM	Background: Puerto Rican and African American subjects share a significant proportion of African ancestry. Recent findings suggest that African ancestry influences lung function in African American adults. Objective: We sought to examine whether a greater proportion of African ancestry is associated with lower FEV1 and forced vital capacity (FVC) in Puerto Rican children independently of socioeconomic status, health care access, or key environmental/lifestyle factors. Methods: We performed a cross-sectional case-control study of 943 Puerto Rican children aged 6 to 14 years with (n = 520) and without (n = 423) asthma (defined as physician-diagnosed asthma and wheeze in the prior year) living in Hartford, Connecticut (n = 383), and San Juan, Puerto Rico (n = 560). We estimated the percentage of African racial ancestry in study participants using genome-wide genotypic data. We tested whether African ancestry is associated with FEV1 and FVC using linear regression. Multivariate models were adjusted for indicators of socioeconomic status and health care and selected environmental/lifestyle exposures. Results: After adjustment for household income and other covariates, each 20% increment in African ancestry was significantly associated with lower prebronchodilator FEV1 (-105 mL; 95% CI, -159 to -51 mL; P < .001) and FVC (-133 mL; 95% CI, -197 to -69 mL; P < .001) and postbronchodilator FEV1 (-152 mL; 95% CI, -210 to -94 mL; P < .001) and FVC (-145 mL; 95% CI, -211 to -79 mL; P < .001) in children with asthma. Similar but weaker associations were found for prebronchodilator and postbronchodilator FEV1 (change for each 20% increment in African ancestry, -78 mL; 95% CI, -131 to -25 mL; P = .004) and for postbronchodilator FVC among children without asthma. Conclusions: Genetic factors, environmental/lifestyle factors, or both correlated with African ancestry might influence childhood lung function in Puerto Rican subjects. (J Allergy Clin Immunol 2012;129:1484-90.)	[Brehm, John M.; Boutaoui, Nadia; Celedon, Juan C.] Univ Pittsburgh, Childrens Hosp Pittsburgh, Dept Pediat, Div Pediat Pulm Med Allergy & Immunol,Sch Med,UPM, Pittsburgh, PA 15224 USA; [Acosta-Perez, Edna; Alvarez, Maria; Colon-Semidey, Angel; Canino, Glorisa] Univ Puerto Rico, Behav Sci Res Inst, San Juan, PR 00936 USA; [Klei, Lambertus] Univ Pittsburgh, Dept Psychiat, Sch Med, Pittsburgh, PA 15224 USA; [Roeder, Kathryn] Carnegie Mellon Univ, Dept Stat, Pittsburgh, PA 15213 USA; [Barmada, Michael M.] Univ Pittsburgh, Dept Human Genet, Grad Sch Publ Hlth, Pittsburgh, PA 15224 USA; [Forno, Erick] Univ Miami, Dept Pediat, Div Pediat Pulmonol, Coral Gables, FL 33124 USA; [Cloutier, Michelle M.; Wakefield, Dorothy] Univ Connecticut, Ctr Hlth, Dept Pediat, Farmington, CT USA; [Datta, Soma; Kelly, Roxanne; Paul, Kathryn; Sylvia, Jody; Litonjua, Augusto A.] Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA USA; [Calvert, Deanna; Thornton-Thompson, Sherell] Connecticut Childrens Med Ctr, Hartford, CT USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Puerto Rico; University of Puerto Rico Medical Sciences Campus; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Carnegie Mellon University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Miami; University of Connecticut; Harvard University; Brigham & Women's Hospital; Connecticut Children's Medical Center	Celedon, JC (corresponding author), Univ Pittsburgh, Childrens Hosp Pittsburgh, Dept Pediat, Div Pediat Pulm Med Allergy & Immunol,Sch Med,UPM, 4401 Penn Ave, Pittsburgh, PA 15224 USA.	juan.celedon@chp.edu	Forno, Erick/I-1476-2019; Alvarez, Maria/GZH-1345-2022; Pérez, Edna Acosta/AAW-6672-2021	Forno, Erick/0000-0001-6497-9885; acosta, edna/0000-0001-7101-3157; Barmada, M Michael/0000-0002-3604-6460; Roeder, Kathryn/0000-0002-8869-6254; Litonjua, Augusto/0000-0003-0422-5875	National Institutes of Health (NIH) [R01HL079966, K12HD052892]; Children's Hospital of Pittsburgh of the UPMC Health System; UpToDate, Inc.; UpToDate; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD052892] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000005] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024153] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL079966] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Children's Hospital of Pittsburgh of the UPMC Health System; UpToDate, Inc.; UpToDate; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by National Institutes of Health (NIH) grant R01HL079966. J.M.B. receives support from NIH grant K12HD052892. Supported in part by Children's Hospital of Pittsburgh of the UPMC Health System.; A. A. Litonjua has received research support from the National Institutes of Health and has received author royalties from UpToDate, Inc. J. C. Celedon is on the advisory board for Genentech, has received research support from the National Institutes of Health, and has received author royalties from UpToDate. The rest of the authors declare that they have no relevant conflicts of interest.	[Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; [Anonymous], HOUSEHOLD INCOME STA; Bird HR, 2006, J AM ACAD CHILD PSY, V45, P1032, DOI 10.1097/01.chi.0000227879.65651.cf; Brehm JM, 2009, AM J RESP CRIT CARE, V179, P765, DOI 10.1164/rccm.200808-1361OC; Choudhry S, 2006, AM J RESP CRIT CARE, V174, P1086, DOI [10.1164/RCCM.200605-596OC, 10.1164/rccm.200605-596OC]; Cohen RT, 2007, CHEST, V131, P1331, DOI 10.1378/chest.06-1917; Crump C, 2011, PEDIATRICS, V127, pE913, DOI 10.1542/peds.2010-2603; Earle CD, 2007, J ALLERGY CLIN IMMUN, V119, P428, DOI 10.1016/j.jaci.2006.11.004; Freeman NCG, 2003, J EXPO ANAL ENV EPID, V13, P169, DOI 10.1038/sj.jea.7500266; Gent JF, 2009, ENVIRON RES, V109, P768, DOI 10.1016/j.envres.2009.04.010; Hunninghake GM, 2007, J ALLERGY CLIN IMMUN, V119, P654, DOI 10.1016/j.jaci.2006.12.609; Kuczmarski R J, 2000, Adv Data, P1; Kumar R, 2010, NEW ENGL J MED, V363, P321, DOI 10.1056/NEJMoa0907897; Li JZ, 2008, SCIENCE, V319, P1100, DOI 10.1126/science.1153717; Martin Joyce A., 2011, Morbidity and Mortality Weekly Report, V60, P78; Pasaniuc B, 2009, BIOINFORMATICS, V25, pI213, DOI 10.1093/bioinformatics/btp197; Perez-Perdomo R, 2003, J ASTHMA, V40, P465, DOI 10.1081/JAS-120018713; Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847; Pritchard JK, 2000, GENETICS, V155, P945; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Ramsey CD, 2005, PEDIATR PULM, V39, P268, DOI 10.1002/ppul.20177; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Salari K, 2005, GENET EPIDEMIOL, V29, P76, DOI 10.1002/gepi.20079; Sankararaman S, 2008, AM J HUM GENET, V82, P290, DOI 10.1016/j.ajhg.2007.09.022; Tang H, 2007, AM J HUM GENET, V81, P626, DOI 10.1086/520769; Thorisson GA, 2005, GENOME RES, V15, P1592, DOI 10.1101/gr.4413105; Vergara C, 2009, HUM GENET, V125, P565, DOI 10.1007/s00439-009-0649-2	27	79	80	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2012	129	6					1484	+		10.1016/j.jaci.2012.03.035	http://dx.doi.org/10.1016/j.jaci.2012.03.035			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	952BL	22560959	Green Accepted			2022-12-18	WOS:000304764600007
J	Imboden, M; Bouzigon, E; Curjuric, I; Ramasamy, A; Kumar, A; Hancock, DB; Wilk, JB; Vonk, JM; Thun, GA; Siroux, V; Nadif, R; Monier, F; Gonzalez, JR; Wjst, M; Heinrich, J; Loehr, LR; Franceschini, N; North, KE; Altmuller, J; Koppelman, GH; Guerra, S; Kronenberg, F; Lathrop, M; Moffatt, MF; O'Connor, GT; Strachan, DP; Postma, DS; London, SJ; Schindler, C; Kogevinas, M; Kauffmann, F; Jarvis, DL; Demenais, F; Probst-Hensch, NM				Imboden, Medea; Bouzigon, Emmanuelle; Curjuric, Ivan; Ramasamy, Adaikalavan; Kumar, Ashish; Hancock, Dana B.; Wilk, Jemma B.; Vonk, Judith M.; Thun, Gian A.; Siroux, Valerie; Nadif, Rachel; Monier, Florent; Gonzalez, Juan R.; Wjst, Matthias; Heinrich, Joachim; Loehr, Laura R.; Franceschini, Nora; North, Kari E.; Altmueller, Janine; Koppelman, Gerard H.; Guerra, Stefano; Kronenberg, Florian; Lathrop, Mark; Moffatt, Miriam F.; O'Connor, George T.; Strachan, David P.; Postma, Dirkje S.; London, Stephanie J.; Schindler, Christian; Kogevinas, Manolis; Kauffmann, Francine; Jarvis, Debbie L.; Demenais, Florence; Probst-Hensch, Nicole M.			Genome-wide association study of lung function decline in adults with and without asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; cohort studies; genome-wide association; lung function decline; heterogeneity	S-TRANSFERASE M1; PULMONARY-FUNCTION; LARGE-SCALE; CANDIDATE GENE; POLYMORPHISMS; LOCI; PHENOTYPES; VARIANTS; HYPERRESPONSIVENESS; ENVIRONMENT	Background: Genome-wide association studies have identified determinants of chronic obstructive pulmonary disease, asthma, and lung function level; however, none have addressed decline in lung function. Objective: We conducted the first genome-wide association study on the age-related decrease in FEV1 and its ratio to forced vital capacity (FVC) stratified a priori by asthma status. Methods: Discovery cohorts included adults of European ancestry (1,441 asthmatic and 2,677 nonasthmatic participants: the Epidemiological Study on the Genetics and Environment of Asthma, the Swiss Cohort Study on Air Pollution and Lung and Heart Disease in Adults, and the European Community Respiratory Health Survey). The associations of FEV1 and FEV1/FVC ratio decrease with 2.5 million single nucleotide polymorphisms (SNPs) were estimated. Thirty loci were followed up by in silico replication (1,160 asthmatic and 10,858 nonasthmatic participants: Atherosclerosis Risk in Communities, the Framingham Heart Study, the British 1958 Birth Cohort, and the Dutch Asthma Study). Results: Main signals identified differed between asthmatic and nonasthmatic participants. None of the SNPs reached genome-wide significance. The association between the height-related gene DLEU7 and FEV1 decrease suggested for nonasthmatic participants in the discovery phase was replicated (discovery, P = 4.8 x 10(-6); replication, P = .03), and additional sensitivity analyses point to a relation to growth. The top ranking signal, TUSC3, which is associated with FEV1/FVC ratio decrease in asthmatic participants (P = 5.3 x 10(-8)), did not replicate. SNPs previously associated with cross-sectional lung function were not prominently associated with decline. Conclusions: Genetic heterogeneity of lung function might be extensive. Our results suggest that genetic determinants of longitudinal and cross-sectional lung function differ and vary by asthma status. (J Allergy Clin Immunol 2012;129:1218-28.)	[Imboden, Medea; Curjuric, Ivan; Kumar, Ashish; Thun, Gian A.; Schindler, Christian; Probst-Hensch, Nicole M.] Swiss Trop & Publ Hlth Inst, Basel, Switzerland; [Imboden, Medea; Curjuric, Ivan; Kumar, Ashish; Thun, Gian A.; Schindler, Christian; Probst-Hensch, Nicole M.] Univ Basel, CH-4003 Basel, Switzerland; [Bouzigon, Emmanuelle; Monier, Florent; Demenais, Florence] INSERM, UMRS 946, Paris, France; [Bouzigon, Emmanuelle; Monier, Florent; Lathrop, Mark; Demenais, Florence] Fdn Jean Dausset, CEPH, Paris, France; [Bouzigon, Emmanuelle; Monier, Florent; Demenais, Florence] Univ Paris 07, Inst Univ Hematol, Paris, France; [Moffatt, Miriam F.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London SW7 2AZ, England; [Ramasamy, Adaikalavan; Jarvis, Debbie L.] MRC HPA Ctr Environm & Hlth, London, England; [Kumar, Ashish] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX1 2JD, England; [Hancock, Dana B.; London, Stephanie J.] NIEHS, Epidemiol Branch, Div Intramural Res, NIH,Dept Hlth & Human Serv, Res Triangle Pk, NC 27709 USA; [Hancock, Dana B.] Res Triangle Inst Int, Behav Hlth Epidemiol Program, Res Triangle Pk, NC USA; [Wilk, Jemma B.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [O'Connor, George T.] Boston Univ, Sch Med, Dept Med, Ctr Pulm, Boston, MA 02118 USA; [Vonk, Judith M.; Koppelman, Gerard H.; Postma, Dirkje S.] Univ Groningen, Univ Med Ctr Groningen, Dept Pulmonol Pediat Pulmonol & Pediat Allergol, Beatrix Childrens Hosp,Groningen Res Inst Asthma, NL-9700 AB Groningen, Netherlands; [Siroux, Valerie] INSERM, U823, Team Environm Epidemiol Appl Reprod & Resp Hlth, Grenoble, France; [Siroux, Valerie] Univ Grenoble 1, Grenoble, France; [Nadif, Rachel; Kauffmann, Francine] CESP Ctr Res Epidemiol & Populat Hlth, INSERM, U1018, Resp & Environm Epidemiol Team, Villejuif, France; [Nadif, Rachel; Kauffmann, Francine] Univ Paris 11, UMRS 1018, Villejuif, France; [Gonzalez, Juan R.; Guerra, Stefano; Kogevinas, Manolis] Ctr Res Environm Epidemiol, Barcelona, Spain; [Gonzalez, Juan R.; Guerra, Stefano; Kogevinas, Manolis] CIBER Epidemiol & Salud Publ, Barcelona, Spain; [Wjst, Matthias; Heinrich, Joachim] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Inst Epidemiol, Neuherberg, Germany; [Loehr, Laura R.; Franceschini, Nora] Univ N Carolina Chapel Hill, UNC Gillings Sch Global Publ Hlth, Dept Epidemiol, Chapel Hill, NC USA; [North, Kari E.] Univ N Carolina Chapel Hill, Carolina Ctr Genome Sci, Chapel Hill, NC USA; [Altmueller, Janine] Univ Cologne, CCG, Cologne, Germany; [Guerra, Stefano] Univ Arizona, Arizona Resp Ctr, Tucson, AZ USA; [Kronenberg, Florian] Innsbruck Med Univ, Div Genet Epidemiol, Dept Med Genet Mol & Clin Pharmacol, Innsbruck, Austria; [Lathrop, Mark] Commissariat Energie Atom, Inst Genom, Ctr Natl Genotypage, Evry, France; [O'Connor, George T.] NHLBI, Framingham Heart Study, Framingham, MA USA; [Strachan, David P.] Univ London, Div Populat Hlth Sci & Educ, London WC1E 7HU, England; [Guerra, Stefano; Kogevinas, Manolis] IMIM Municipal Inst Med Res, Barcelona, Spain; [Kogevinas, Manolis] Natl Sch Publ Hlth, Athens, Greece	University of Basel; Swiss Tropical & Public Health Institute; University of Basel; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Foundation Jean Dausset-CEPH; UDICE-French Research Universities; Universite Paris Cite; Imperial College London; Imperial College London; University of Oxford; Wellcome Centre for Human Genetics; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Research Triangle Institute; Boston University; Boston University; University of Groningen; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay; CIBER - Centro de Investigacion Biomedica en Red; CIBERESP; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of Cologne; University of Arizona; Medical University of Innsbruck; CEA; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Universite Paris Saclay; Framingham Heart Study; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of London; Institut Hospital del Mar d'Investigacions Mediques (IMIM); National & Kapodistrian University of Athens	Probst-Hensch, NM (corresponding author), SwissTPH, Socinstr 57, CH-4002 Basel, Switzerland.	Nicole.Probst@unibas.ch	Vonk, Judith M/ABA-3009-2020; Bouzigon, Emmanuelle/L-2766-2017; Jarvis, Deborah/E-6494-2011; Schindler, Christian/D-3472-2015; Nadif, Rachel/R-2876-2016; siroux, valerie/N-1865-2013; Kronenberg, Florian/B-1736-2008; Koppelman, Gerard/AAG-9187-2020; Ramasamy, Adaikalavan/G-2632-2010; Kogevinas, Manolis/C-3918-2017; Vonk, Judith/K-8477-2019; Heinrich, Joachim/N-1720-2013; Demenais, Florence/G-3298-2013; Gonzalez, Juan R/B-7860-2018; London, Stephanie/C-3734-2019	Vonk, Judith M/0000-0001-7531-4547; Bouzigon, Emmanuelle/0000-0001-5756-4286; Nadif, Rachel/0000-0003-4938-9339; siroux, valerie/0000-0001-7329-7237; Kronenberg, Florian/0000-0003-2229-1120; Ramasamy, Adaikalavan/0000-0002-7598-2892; Kogevinas, Manolis/0000-0002-9605-0461; Vonk, Judith/0000-0001-7531-4547; Heinrich, Joachim/0000-0002-9620-1629; Demenais, Florence/0000-0001-8361-0936; Gonzalez, Juan R/0000-0003-3267-2146; Jarvis, Deborah/0000-0002-1753-3896; London, Stephanie/0000-0003-4911-5290; Hancock, Dana/0000-0003-2240-3604; Altmuller, Janine/0000-0003-4372-1521; Thun, Gian Andri/0000-0003-4436-3455; O'Connor, George/0000-0002-6476-3926; Koppelman, Gerard/0000-0001-8567-3252; Loehr, Laura/0000-0002-9054-1825; Kumar, Ashish/0000-0002-7075-5930	National Institutes of Health/National Heart, Lung, and Blood Institute; Flight Attendant Medical Research Institute; Netherlands Asthma Foundation; Top Institute Pharma; AstraZeneca; French Agency of Research; French Agency for Environmental and Occupational Health and Safety; INSERM-Ministry of Research "Cohortes et Collections"; Medical Research Council [G1000758, G0000934, G0801056B, G0901214, G1000758B, G1001799] Funding Source: researchfish; MRC [G0901214, G0000934, G1001799] Funding Source: UKRI; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025005] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL086694, R01HL087641, R01HL059367, R01HL062633] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [U01HG004402] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U01DK062418] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES043012, ZIAES043012, P30ES007048] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH062633] Funding Source: NIH RePORTER	National Institutes of Health/National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Flight Attendant Medical Research Institute; Netherlands Asthma Foundation; Top Institute Pharma; AstraZeneca(AstraZeneca); French Agency of Research(French National Research Agency (ANR)); French Agency for Environmental and Occupational Health and Safety; INSERM-Ministry of Research "Cohortes et Collections"; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	Disclosure of potential conflict of interest: J. B. Wilk has received research support from the National Institutes of Health/National Heart, Lung, and Blood Institute and the Flight Attendant Medical Research Institute. G. H. Koppelman has received research support from the Netherlands Asthma Foundation. D. S. Postma is a consultant for Nycomed and has received research support from the Top Institute Pharma and AstraZeneca. F. Kauffmann has received research support from the French Agency of Research, French Agency for Environmental and Occupational Health and Safety, and INSERM-Ministry of Research "Cohortes et Collections." The rest of the authors declare that they have no relevant conflicts of interest.	[Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; Barton SJ, 2009, J ALLERGY CLIN IMMUN, V123, P1391, DOI 10.1016/j.jaci.2009.03.014; Bouzigon E, 2004, HUM MOL GENET, V13, P3103, DOI 10.1093/hmg/ddh340; Caporaso N, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004653; Cho MH, 2010, NAT GENET, V42, P200, DOI 10.1038/ng.535; Cooke SL, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-288; Cornelis MC, 2010, GENET EPIDEMIOL, V34, P364, DOI 10.1002/gepi.20492; DeWan AT, 2010, J ALLERGY CLIN IMMUN, V126, P871, DOI 10.1016/j.jaci.2010.06.051; Dijkstra A, 2006, J ALLERGY CLIN IMMUN, V117, P604, DOI 10.1016/j.jaci.2005.11.023; Dijkstra A, 2006, THORAX, V61, P105, DOI 10.1136/thx.2004.039271; Downs SH, 2007, NEW ENGL J MED, V357, P2338, DOI 10.1056/NEJMoa073625; Flamant C, 2004, PHARMACOGENETICS, V14, P295, DOI 10.1097/00008571-200405000-00004; Gilliland FD, 2002, AM J RESP CRIT CARE, V166, P710, DOI 10.1164/rccm.2112065; Guerra S, 2009, CURR OPIN ALLERGY CL, V9, P409, DOI 10.1097/ACI.0b013e3283300baf; Hammarsund M, 2004, FEBS LETT, V556, P75, DOI 10.1016/S0014-5793(03)01371-1; Hancock DB, 2010, NAT GENET, V42, P45, DOI 10.1038/ng.500; Hancock DB, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000623; HANKINS D, 1982, AM REV RESPIR DIS, V125, P119; Himes BE, 2009, AM J HUM GENET, V84, P581, DOI 10.1016/j.ajhg.2009.04.006; Holberg CJ, 1998, AM J RESP CRIT CARE, V158, P162, DOI 10.1164/ajrccm.158.1.9706117; Imboden M, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-2; Jarvis D, 2002, EUR RESPIR J, V20, P1071, DOI 10.1183/09031936.02.00046802; Jongepier H, 2004, CLIN EXP ALLERGY, V34, P757, DOI 10.1111/j.1365-2222.2004.1938.x; Kang SJ, 2010, HUM MOL GENET, V19, P2725, DOI 10.1093/hmg/ddq154; Kauffmann F, 1997, AM J RESP CRIT CARE, V156, pS123, DOI 10.1164/ajrccm.156.4.12tac9; Kong XY, 2011, AM J RESP CRIT CARE, V183, P43, DOI 10.1164/rccm.201004-0541OC; KUNZLI N, 1995, EUR RESPIR J, V8, P371, DOI 10.1183/09031936.95.08030371; Li XN, 2011, J ALLERGY CLIN IMMUN, V127, P1457, DOI 10.1016/j.jaci.2011.01.056; Malhotra A, 2003, AM J RESP CRIT CARE, V168, P556, DOI 10.1164/rccm.200303-410OC; Marossy AE, 2007, AM J RESP CRIT CARE, V175, P355, DOI 10.1164/rccm.200607-1023OC; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Ober C, 2001, AM J HUM GENET, V69, P1068, DOI 10.1086/324025; Palamarchuk A, 2010, BLOOD, V115, P3916, DOI 10.1182/blood-2009-10-249367; Palmer LJ, 2001, EUR RESPIR J, V17, P696, DOI 10.1183/09031936.01.17406960; Pekarsky Y, 2010, SEMIN CANC BIOL; Pillai SG, 2010, AM J RESP CRIT CARE, V182, P1498, DOI 10.1164/rccm.201002-0151OC; Pillai SG, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000421; Postma Dirkje S, 2004, Chest, V126, p96S, DOI 10.1378/chest.126.2_suppl_1.96S; Postma DS, 2005, AM J RESP CRIT CARE, V172, P446, DOI 10.1164/rccm.200407-864OC; POSTMA DS, 2004, CHEST S, V126, pS59; QUANJER PH, 1993, EUR RESPIR J, V6, P5, DOI 10.1183/09041950.005s1693; Rahmatpanah FB, 2009, EPIGENOMICS-UK, V1, P39, DOI [10.2217/epi.09.10, 10.2217/EPI.09.10]; REDLINE S, 1989, AM J EPIDEMIOL, V129, P827, DOI 10.1093/oxfordjournals.aje.a115197; Repapi E, 2010, NAT GENET, V42, P36, DOI 10.1038/ng.501; Romieu I, 2004, THORAX, V59, P8; Sadeghnejad A, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-21; Silverman EK, 2002, AM J HUM GENET, V70, P1229, DOI 10.1086/340316; Simpson A, 2005, AM J RESP CRIT CARE, V172, P55, DOI 10.1164/rccm.200412-1708OC; Sleiman PMA, 2010, NEW ENGL J MED, V362, P36, DOI 10.1056/NEJMoa0901867; Soler Artigas M, 2011, NAT GENET, V43, P1082, DOI 10.1038/ng.941; Sovio U, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000409; van Diemen CC, 2005, AM J RESP CRIT CARE, V172, P329, DOI 10.1164/rccm.200411-1486OC; Vercelli D, 2006, J ALLERGY CLIN IMMUN, V117, P1303, DOI 10.1016/j.jaci.2006.03.030; WANG XB, 1993, PEDIATR PULM, V15, P75, DOI 10.1002/ppul.1950150204; Weedon MN, 2008, NAT GENET, V40, P575, DOI 10.1038/ng.121; Weiss ST, 2010, AM J RESP CRIT CARE, V181, P1170, DOI 10.1164/rccm.201001-0069PP; Weiss ST, 2010, NAT GENET, V42, P14, DOI 10.1038/ng0110-14; Wilk JB, 2003, AM J RESP CRIT CARE, V167, P1528, DOI 10.1164/rccm.200207-755OC; Wilk JB, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000429; WILLIAMS OD, 1989, AM J EPIDEMIOL, V129, P687, DOI 10.1093/oxfordjournals.aje.a115184; Xu X, 2001, AM J HUM GENET, V69, P1271, DOI 10.1086/324650	62	79	79	0	21	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2012	129	5					1218	1228		10.1016/j.jaci.2012.01.074	http://dx.doi.org/10.1016/j.jaci.2012.01.074			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	934CG	22424883	Green Submitted, Green Accepted			2022-12-18	WOS:000303418000007
J	Li, MC; Li, Q; Yang, G; Kolosov, VP; Perelman, JM; Zhou, XD				Li, MinChao; Li, Qi; Yang, Gang; Kolosov, Victor P.; Perelman, Juliy M.; Zhou, Xiang Dong			Cold temperature induces mucin hypersecretion from normal human bronchial epithelial cells in vitro through a transient receptor potential melastatin 8 (TRPM8)-mediated mechanism	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Transient receptor potential melastatin 8; mucus hypersecretion; MUC5AC; cold air; myristoylated alanine-rich C kinase substrate; Ca(2+); phosphatidylinositol 4,5-bisphosphate	OBSTRUCTIVE PULMONARY-DISEASE; PHOSPHOLIPASE-C; MARCKS PROTEIN; TRPM8 CHANNEL; MENTHOL; AIRWAY; ACTIVATION; DESENSITIZATION; EXPRESSION; SECRETION	Background: Cold air stimulus is a major environmental factor that exacerbates chronic inflammatory airway diseases, such as chronic obstructive pulmonary disease (COPD) and asthma. At the molecular level, cold is detected by transient receptor potential melastatin 8 (TRPM8). To date, TRPM8 expression has not been characterized in the airway epithelium of patients with COPD. The role of TRPM8 channels in a series of airway responses induced by cold stimuli and the molecular and biochemical pathways of TRPM8 in regulating cold-induced responses are largely unknown. Objective: We sought to explore the role of TRPM8 in cold air-provoked mucus hypersecretion and the potential signaling pathway involved in this process. Methods: The expression of TRPM8 in the bronchial epithelium was examined by means of immunohistochemistry, RT-PCR, and Western blotting. TRPM8 receptor function and hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) were characterized by means of Ca(2+) imaging and spatiotemporal dynamics of phospholipase C (PLC) delta 1-pleckstrin homology-green fluorescent protein, respectively. The expression of MUC5AC mRNA and MUC5AC mucin protein was measured by using real-time PCR and ELISA, respectively. Four serine residues in the myristoylated alanine-rich C kinase substrate (MARCKS)-phosphorylation site domain were mutated to identify the function of MARCKS in TRPM8-mediated airway mucus hypersecretion. Results: TRPM8 protein and mRNA expression were significantly increased in patients with COPD compared with expression seen in healthy subjects. Cold produced robust increases in intracellular Ca(2+) levels and promoted translocation of PLC delta 1-pleckstrin homology-green fluorescent protein. Cold increased expression of MUC5AC mRNA and intracellular and secreted MUC5AC protein in a nonsustained way. Phosphorylation site domain-mutant MARCKS cDNA hindered MUC5AC secretion induced by cold. Conclusions: These results indicate that the TRPM8 receptor is involved in cold-induced mucus hypersecretion through the Ca(2+)-PLC-PIP2-MARCKS signaling pathway. (J Allergy Clin Immunol 2011;128:626-34.)	[Li, MinChao; Li, Qi; Zhou, Xiang Dong] Chongqing Med Univ, Affiliated Hosp 2, Dept Resp Med, Chongqing 400010, Peoples R China; [Yang, Gang] Chongqing Med Univ, Affiliated Hosp 1, Dept Neurosurg, Chongqing, Peoples R China; [Kolosov, Victor P.; Perelman, Juliy M.] Russian Acad Med Sci, Far Eastern Sci Ctr Physiol & Pathol Resp, Blagoveshchensk, Russia; [Kolosov, Victor P.; Perelman, Juliy M.] Russian Acad Med Sci, Siberian Branch, Blagoveshchensk, Russia	Chongqing Medical University; Chongqing Medical University; Russian Academy of Medical Sciences; Far Eastern Scientific Centre of Physiology and Pathology of Respiration, RAMS; Russian Academy of Medical Sciences	Zhou, XD (corresponding author), Chongqing Med Univ, Affiliated Hosp 2, Dept Resp Med, 74 Linjiang Rd, Chongqing 400010, Peoples R China.	longman185@163.com	Kolosov, Victor P./AAO-4504-2020; Perelman, Juliy M./F-9517-2014	Perelman, Juliy M./0000-0002-9411-7474; Kolosov, Victor P./0000-0002-8854-4752	National Nature Science Foundation of China [NSF81070031]; China-Russia Cooperation Research Foundation [NSF81011120108, RFBR10-04-91160]	National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); China-Russia Cooperation Research Foundation	Supported by the National Nature Science Foundation of China (no. NSF81070031) and the China-Russia Cooperation Research Foundation (no. NSF81011120108; RFBR10-04-91160).	Abe J, 2006, NEUROSCI LETT, V397, P140, DOI 10.1016/j.neulet.2005.12.005; Arbuzova A, 2002, BIOCHEM J, V362, P1, DOI 10.1042/0264-6021:3620001; Bandell M, 2006, NAT NEUROSCI, V9, P493, DOI 10.1038/nn1665; BARANIUK JN, 1992, NEUROPEPTIDES, V21, P81, DOI 10.1016/0143-4179(92)90518-2; Bautista DM, 2007, NATURE, V448, P204, DOI 10.1038/nature05910; Bautista MV, 2009, J IMMUNOL, V183, P2159, DOI 10.4049/jimmunol.0803022; Colburn RW, 2007, NEURON, V54, P379, DOI 10.1016/j.neuron.2007.04.017; Daniels RL, 2009, J BIOL CHEM, V284, P1570, DOI 10.1074/jbc.M807270200; Donaldson GC, 1999, EUR RESPIR J, V13, P844, DOI 10.1034/j.1399-3003.1999.13d25.x; ELLIS EF, 1983, J ALLERGY CLIN IMMUN, V72, P526, DOI 10.1016/0091-6749(83)90479-7; Kim CH, 2009, J CELL BIOCHEM, V108, P974, DOI 10.1002/jcb.22330; Larsson K, 1998, EUR RESPIR J, V12, P825, DOI 10.1183/09031936.98.12040825; Li Q, 2009, ONCOLOGY-BASEL, V77, P335, DOI 10.1159/000264627; Li YH, 2001, J BIOL CHEM, V276, P40982, DOI 10.1074/jbc.M105614200; Liu BY, 2005, J NEUROSCI, V25, P1674, DOI 10.1523/JNEUROSCI.3632-04.2005; Liu D, 2003, P NATL ACAD SCI USA, V100, P15160, DOI 10.1073/pnas.2334159100; Mahieu F, 2007, J BIOL CHEM, V282, P3325, DOI 10.1074/jbc.M605213200; Malkia A, 2007, J PHYSIOL-LONDON, V581, P155, DOI 10.1113/jphysiol.2006.123059; Mata M, 2005, THORAX, V60, P144, DOI 10.1136/thx.2004.025692; McKemy DD, 2002, NATURE, V416, P52, DOI 10.1038/nature719; Naruse Hideo, 2005, Anatomical Science International, V80, P97, DOI 10.1111/j.1447-073x.2005.00103.x; Nealen ML, 2003, J NEUROPHYSIOL, V90, P515, DOI 10.1152/jn.00843.2002; Park JA, 2007, AM J PATHOL, V171, P1822, DOI 10.2353/ajpath.2007.070318; Peier AM, 2002, CELL, V108, P705, DOI 10.1016/S0092-8674(02)00652-9; Puzianowska-Kuznicka M, 2009, AGEING RES REV, V8, P160, DOI 10.1016/j.arr.2009.05.002; Rabe KF, 2007, AM J RESP CRIT CARE, V176, P532, DOI 10.1164/rccm.200703-456SO; Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291; Rogers DF, 2007, RESP CARE, V52, P1134; Rohacs T, 2005, NAT NEUROSCI, V8, P626, DOI 10.1038/nn1451; Runnels LW, 2002, NAT CELL BIOL, V4, P329, DOI 10.1038/ncb781; Sabnis AS, 2008, AM J RESP CELL MOL, V39, P466, DOI 10.1165/rcmb.2007-0440OC; Sabnis AS, 2008, AM J PHYSIOL-LUNG C, V295, pL194, DOI 10.1152/ajplung.00072.2008; Swierczynski SL, 1996, J BIOL CHEM, V271, P23424, DOI 10.1074/jbc.271.38.23424; Tsavaler L, 2001, CANCER RES, V61, P3760; Van Haute C, 2010, THESCIENTIFICWORLDJO, V10, P1597, DOI 10.1100/tsw.2010.149; Voets T., 2007, V179, P329; Voets T, 2007, NAT CHEM BIOL, V3, P174, DOI 10.1038/nchembio862; Voynow JA, 2006, AM J RESP CELL MOL, V34, P661, DOI 10.1165/rcmb.2006-0035SF; Wang IJ, 2007, CLIN OPHTHALMOL, V1, P71; WANG YY, 1993, ANAT REC, V236, P198, DOI 10.1002/ar.1092360124; Xing H, 2008, MOL PAIN, V4, DOI 10.1186/1744-8069-4-22; Yang XR, 2006, AM J PHYSIOL-LUNG C, V290, pL1267, DOI 10.1152/ajplung.00515.2005; Zhang Z, 2005, J BIOL CHEM, V280, P39185, DOI 10.1074/jbc.M506965200; Zhao JM, 2009, AM J RESP CRIT CARE, V179, P782, DOI 10.1164/rccm.200811-1744OC	44	79	93	0	22	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2011	128	3					626	U293		10.1016/j.jaci.2011.04.032	http://dx.doi.org/10.1016/j.jaci.2011.04.032			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	812HS	21762971				2022-12-18	WOS:000294283400023
J	Andersson, CK; Bergqvist, A; Mori, M; Mauad, T; Bjermer, L; Erjefalt, JS				Andersson, Cecilia K.; Bergqvist, Anders; Mori, Michiko; Mauad, Thais; Bjermer, Leif; Erjefalt, Jonas S.			Mast cell-associated alveolar inflammation in patients with atopic uncontrolled asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Mast cells; asthma; Fc epsilon RI; IgE; allergy; peripheral inflammation; alveolar parenchyma	AIRWAY SMOOTH-MUSCLE; ALLERGIC RHINITIS; PERIPHERAL AIRWAYS; CYSTIC-FIBROSIS; DISTAL AIRWAYS; NASAL-MUCOSA; HAY-FEVER; LUNG; IGE; OMALIZUMAB	Background: A significant proportion of patients with asthma have persistent symptoms despite treatment with inhaled glucocorticosteroids. Objective: We hypothesized that in these patients, the alveolar parenchyma is subjected to mast cell-associated alterations. Methods: Bronchial and transbronchial biopsies from healthy controls (n = 8), patients with allergic rhinitis (n = 8), and patients with atopic uncontrolled asthma (symptoms despite treatment with inhaled glucocorticosteroids; mean dose, 743 mu g/d; n = 14) were processed for immunohistochemical identification of mast cell subtypes and mast cell expression of Fc epsilon RI and surface-bound IgE. Results: Whereas no difference in density of total bronchial mast cells was observed between patients with asthma and healthy controls, the total alveolar mast cell density was increased in the patients with asthma (P < .01). Division into mast cell subtypes revealed that in bronchi of patients with asthma, tryptase positive mast cells (MCT) numbers decreased compared with controls (P <= .05), whereas tryptase and chymase positive mast cells (MCTC) increased (P <= .05). In the alveolar parenchyma from patients with asthma, an increased density was found for both MCT (P <= .05) and MCTC (P <= .05). The increased alveolar mast cell densities were paralleled by an increased mast cell expression of FceRI (P < .001) compared with the controls. The patients with asthma also had increased numbers (P < .001) and proportions (P < .001) of alveolar mast cells with surface-bound IgE. Similar increases in densities, FceRI expression, and surface-bound IgE were not seen in separate explorations of alveolar mast cells in patients with allergic rhinitis. Conclusion: Our data suggest that patients with atopic uncontrolled asthma have an increased parenchymal infiltration of MCT and MCTC populations with increased expression of FceRI and surface-bound IgE compared with atopic and nonatopic controls. (J Allergy Clin Immunol 2011;127:905-12.)	[Erjefalt, Jonas S.] Lund Univ, Dept Expt Med Sci, Airway Inflammat Unit, SE-22184 Lund, Sweden; [Andersson, Cecilia K.; Bergqvist, Anders; Bjermer, Leif; Erjefalt, Jonas S.] Lund Univ, Dept Resp Med, SE-22184 Lund, Sweden; [Mauad, Thais] Univ Sao Paulo, Dept Pathol, Sao Paulo, Brazil	Lund University; Lund University; Universidade de Sao Paulo	Erjefalt, JS (corresponding author), Lund Univ, Dept Expt Med Sci, Airway Inflammat Unit, BMC D12, SE-22184 Lund, Sweden.	jonas.erjefalt@med.lu.se	Andersson, Cecilia/ABC-1950-2021; Bjermer, Leif H/I-4899-2014; Mauad, Thais/G-1254-2012	Bjermer, Leif H/0000-0002-3441-8099; Mauad, Thais/0000-0002-3354-1466; Erjefalt, Jonas/0000-0002-6716-3010	Heart and Lung Foundation, Sweden; Swedish Medical Research Council; Swedish Asthma and Allergy Associations Research Foundation; Crafoord Foundation	Heart and Lung Foundation, Sweden(Swedish Heart-Lung Foundation); Swedish Medical Research Council(Swedish Medical Research Council (SMRC)); Swedish Asthma and Allergy Associations Research Foundation; Crafoord Foundation	Supported by the Heart and Lung Foundation, Sweden; the Swedish Medical Research Council; the Swedish Asthma and Allergy Associations Research Foundation; and the Crafoord Foundation.	Andersson CK, 2009, THORAX, V64, P297, DOI 10.1136/thx.2008.101683; Andersson CK, 2010, AM J RESP CRIT CARE, V181, P206, DOI 10.1164/rccm.200906-0932OC; Balzar S, 2005, AM J RESP CRIT CARE, V171, P431, DOI 10.1164/rccm.200407-949OC; Balzar S, 2002, EUR RESPIR J, V20, P254, DOI 10.1183/09031936.02.00261102; Balzar S, 2007, J ALLERGY CLIN IMMUN, V119, P855, DOI 10.1016/j.jaci.2006.12.642; Baraldo S, 2004, THORAX, V59, P308, DOI 10.1136/thx.2003.012146; Barnes PJ, 2008, NAT REV IMMUNOL, V8, P183, DOI 10.1038/nri2254; Barnes PJ, 2009, LANCET, V373, P1905, DOI 10.1016/S0140-6736(09)60326-3; BARNES PJ, 1995, NEW ENGL J MED, V332, P868, DOI 10.1056/NEJM199503303321307; Bentley AM, 1996, AM J RESP CRIT CARE, V153, P551, DOI 10.1164/ajrccm.153.2.8564096; Berger P, 2003, FASEB J, V17, P2139, DOI 10.1096/fj.03-0041fje; Berger P, 2003, RADIOLOGY, V228, P85, DOI 10.1148/radiol.2281020187; Bergeron C, 2005, J ALLERGY CLIN IMMUN, V116, P983, DOI 10.1016/j.jaci.2005.07.029; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Bousquet J, 2005, ALLERGY, V60, P302, DOI 10.1111/j.1398-9995.2004.00770.x; Bradding P, 2006, J ALLERGY CLIN IMMUN, V117, P1277, DOI 10.1016/j.jaci.2006.02.039; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; Brown JL, 2007, CLIN EXP ALLERGY, V37, P688, DOI 10.1111/j.1365-2222.2007.02695.x; Brown JK, 2004, J HISTOCHEM CYTOCHEM, V52, P1219, DOI 10.1369/jhc.3A6200.2004; Busse WW, 2001, NEW ENGL J MED, V344, P350, DOI 10.1056/NEJM200102013440507; Busse WW, 2001, AM J RESP CRIT CARE, V164, pS12, DOI 10.1164/ajrccm.164.supplement_1.2103026; Cazzoletti L, 2007, J ALLERGY CLIN IMMUN, V120, P1360, DOI 10.1016/j.jaci.2007.09.019; CRAIG SS, 1986, AM J PATHOL, V124, P427; CRAPO RO, 1981, AM REV RESPIR DIS, V123, P659; Custovic A, 1999, PEDIATR ALLERGY IMMU, V10, P258, DOI 10.1034/j.1399-3038.1999.00050.x; De Boeck K, 2006, THORAX, V61, P627, DOI 10.1136/thx.2005.043539; den Otter I, 2010, CLIN EXP ALLERGY, V40, P1473, DOI 10.1111/j.1365-2222.2010.03576.x; Elliot JG, 2009, RESPIROLOGY, V14, P808, DOI 10.1111/j.1440-1843.2009.01551.x; Farrell PM, 2008, J PEDIATR-US, V153, pS4, DOI 10.1016/j.jpeds.2008.05.005; FINKELSTEIN R, 1995, AM J RESP CRIT CARE, V152, P1666, DOI 10.1164/ajrccm.152.5.7582312; FitzGerald JM, 2010, J ALLERGY CLIN IMMUN, V125, P307, DOI 10.1016/j.jaci.2009.12.978; Gelfand EW, 2009, J ALLERGY CLIN IMMUN, V124, pS84, DOI 10.1016/j.jaci.2009.07.062; *GLOB IN ASTHM, 2006, GINA REP GLOB STRAT; Gonzalez-Perez A, 2010, J ALLERGY CLIN IMMUN, V125, P1098, DOI 10.1016/j.jaci.2010.02.009; Gould HJ, 2008, NAT REV IMMUNOL, V8, P205, DOI 10.1038/nri2273; Grashoff WFH, 1997, AM J PATHOL, V151, P1785; Greisner WA, 1998, ALLERGY ASTHMA PROC, V19, P185, DOI 10.2500/108854198778557836; Guerra S, 2002, J ALLERGY CLIN IMMUN, V109, P419, DOI 10.1067/mai.2002.121701; Hamid Qutayba, 2007, Ann Thorac Med, V2, P28, DOI 10.4103/1817-1737.30361; Holgate S, 2005, J ALLERGY CLIN IMMUN, V115, P459, DOI 10.1016/j.jaci.2004.11.053; Holgate S, 2009, ALLERGY, V64, P1728, DOI 10.1111/j.1398-9995.2009.02201.x; Holgate ST, 2009, CURR OPIN PULM MED, V15, P63, DOI 10.1097/MCP.0b013e32831da867; Holt PG, 1999, NATURE, V402, pB12; Humbert M, 1996, AM J RESP CRIT CARE, V153, P1931, DOI 10.1164/ajrccm.153.6.8665058; IRANI AA, 1986, P NATL ACAD SCI USA, V83, P4464, DOI 10.1073/pnas.83.12.4464; IRANI AMA, 1992, BLOOD, V80, P3009; KleinJan A, 2000, J ALLERGY CLIN IMMUN, V106, P677, DOI 10.1067/mai.2000.109621; Kraft M, 1996, AM J RESP CRIT CARE, V154, P1505, DOI 10.1164/ajrccm.154.5.8912772; Linneberg A, 2002, ALLERGY, V57, P1048, DOI 10.1034/j.1398-9995.2002.23664.x; Martin RJ, 2002, J ALLERGY CLIN IMMUN, V109, pS447, DOI 10.1067/mai.2002.121409; Mori A, 1997, HUM REPROD, V12, P368, DOI 10.1093/humrep/12.2.368; Nihlberg K, 2010, THORAX, V65, P670, DOI 10.1136/thx.2009.129320; Pauwels Romain A., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1256; Saetta M, 2002, AM J RESP CRIT CARE, V165, P1404, DOI 10.1164/rccm.2107139; Schatz M, 2006, J ALLERGY CLIN IMMUN, V117, P549, DOI 10.1016/j.jaci.2006.01.011; SETTIPANE RJ, 1994, ALLERGY PROC, V15, P21, DOI 10.2500/108854194778816634; Simoes SD, 2005, CLIN EXP ALLERGY, V35, P602, DOI 10.1111/j.1365-2222.2005.02235.x; Smurthwaite L, 2001, EUR J IMMUNOL, V31, P3422, DOI 10.1002/1521-4141(200112)31:12<3422::AID-IMMU3422>3.0.CO;2-T; Strunk RC, 2006, NEW ENGL J MED, V354, P2689, DOI 10.1056/NEJMct055184; Sutherland ER, 2004, J ALLERGY CLIN IMMUN, V113, P1046, DOI 10.1016/j.jaci.2004.03.016; Taylor PE, 2004, CLIN EXP ALLERGY, V34, P1591, DOI 10.1111/j.1365-2222.2004.02078.x; Taylor PE, 2002, J ALLERGY CLIN IMMUN, V109, P51, DOI 10.1067/mai.2002.120759; Toivonen R, 2010, HISTOCHEM CELL BIOL, V133, P349, DOI 10.1007/s00418-009-0666-1; WAGNER EM, 1990, AM REV RESPIR DIS, V141, P584, DOI 10.1164/ajrccm/141.3.584; WEIDNER N, 1991, J INVEST DERMATOL, V96, pS26, DOI 10.1111/1523-1747.ep12468966; WEIDNER N, 1993, PATHOL RES PRACT, V189, P156, DOI 10.1016/S0344-0338(11)80086-5	66	79	79	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2011	127	4					905	U123		10.1016/j.jaci.2011.01.022	http://dx.doi.org/10.1016/j.jaci.2011.01.022			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	743YL	21388666	Green Submitted			2022-12-18	WOS:000289055800011
J	Meltzer, EO; Busse, WW; Wenzel, SE; Belozeroff, V; Weng, HLH; Feng, JY; Chon, Y; Chiou, CF; Globe, D; Lin, SL				Meltzer, Eli O.; Busse, William W.; Wenzel, Sally E.; Belozeroff, Vasily; Weng, Haoling H.; Feng, JingYuan; Chon, Yun; Chiou, Chiun-Fang; Globe, Denise; Lin, Shao-Lee			Use of the Asthma Control Questionnaire to predict future risk of asthma exacerbation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma exacerbation; ACQ score; asthma control; prediction; IL-4 receptor alpha; antagonist	UNITED-STATES; INSIGHTS; REALITY; ATTACKS; BURDEN; FEV1	Background: Direct correlation of assessments of a validated composite measure such as the Asthma Control Questionnaire (ACQ) and risk of exacerbation has not been previously demonstrated in a randomized controlled trial. Objective: To evaluate the ability of the ACQ score over time to predict risk of a future asthma exacerbation. Methods: This analysis included data from a 12-week placebo-controlled trial (N = 292) of AMG 317, an IL-4 receptor alpha antagonist, in patients with moderate to severe atopic asthma. At baseline, patients had an ACQ score >= 1.5. Exacerbations were defined as requirement for systemic corticosteroids. A Cox proportional hazards model was used, with ACQ score as the time-dependent covariate. The analysis was repeated for individual components of the ACQ. Results: Each 1-point increase in ACQ was associated with a 50% increased risk of exacerbation (hazard ratio, 1.50; 95% CI, 1.03-2.20) for the following 2-week period. Evaluation of individual ACQ components also demonstrated a similar trend, though each to a lesser degree than the full composite ACQ. Conclusion: Although based on a retrospective analysis, with small number of exacerbations, these findings support the utility of the composite ACQ score measurement to predict risk of future exacerbation in clinical trials and clinical practice. The composite ACQ score measurement was found to be a better predictor of future risk than individual ACQ components. (J Allergy Clin Immunol 2011;127:167-72.)	[Meltzer, Eli O.] Allergy & Asthma Med Grp, San Diego, CA 92123 USA; [Meltzer, Eli O.] Res Ctr, San Diego, CA 92123 USA; [Busse, William W.] Univ Wisconsin, Madison, WI 53706 USA; [Wenzel, Sally E.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15260 USA; [Belozeroff, Vasily; Weng, Haoling H.; Feng, JingYuan; Chon, Yun; Chiou, Chiun-Fang; Globe, Denise; Lin, Shao-Lee] Amgen Inc, Thousand Oaks, CA 91320 USA	University of Wisconsin System; University of Wisconsin Madison; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Amgen	Meltzer, EO (corresponding author), Allergy & Asthma Med Grp, 9610 Granite Ridge Dr,Suite B, San Diego, CA 92123 USA.	eomeltzer@aol.com			Amgen Inc.; UCB; Alcon; Alexza; Amgen; Antigen Labs; Apotex; Astellas; AstraZeneca; Boehringer Ingelheim; Capnia; Critical Therapeutics; GlaxoSmithKline; MAP; MEDA; Merck; Novartis; Proctor Gamble; Schering-Plough; NIH-NIAID; NIH-NHLBI; GlazoSmithKline; MedImmune; Ception	Amgen Inc.(Amgen); UCB(UCB Pharma SA); Alcon(Novartis); Alexza; Amgen(Amgen); Antigen Labs; Apotex; Astellas(Astellas Pharmaceuticals); AstraZeneca(AstraZeneca); Boehringer Ingelheim(Boehringer Ingelheim); Capnia; Critical Therapeutics; GlaxoSmithKline(GlaxoSmithKline); MAP; MEDA; Merck(Merck & Company); Novartis(Novartis); Proctor Gamble(Procter & Gamble); Schering-Plough(Merck & CompanySchering Plough Corporation); NIH-NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH-NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); GlazoSmithKline; MedImmune(AstraZenecaMedimmune); Ception	Supported by Amgen Inc.; E. O. Meltzer has received research support from UCB, Alcon, Alexza, Amgen, Antigen Labs, Apotex, Astellas, AstraZeneca, Boehringer Ingelheim, Capnia, Critical Therapeutics, GlaxoSmithKline, MAP, MEDA, Merck, Novartis, Proctor & Gamble, Schering-Plough, and Teva; has served as a consultant or on an advisory board for Schering Plough, Alcon, Alexza Pharmaceuticals, Amgen, AstraZeneca, Boehringer Ingelheim, Capnia, Dainippon Sumitomo Pharma, Dey, ISTA, Johnson & Johnson, Kalypsys, MAP, Meda, Merck, National Jewish Health, Rady Children's Hospital San Diego, Sandoz, Sepracor, SRxA, Teva, VentiRx, Wockhardt, and Wyeth; is a speaker for GlaxoSmithKline, MEDA, Merck, Sanofi-Aventis, Schering-Plough, Sepracor, and SRxA; has served as an expert in legal matters on the topics of desloratadine, fexofenadine, montelukast, and levocetirizine; and is a fellow for the AAAAI and the American College of Allergy, Asthma and Immunology. W. W. Busse is on the advisory board for Altair, GlaxoSmithKline, Merck, Wyeth, Pfizer Centocor, Amgen, and Johnson & Johnson; is a speaker for Merck; is a consultant for Novartis, Astra Zeneca, TEVA, Boehringer Ingelhim, and GlaxoSmithKline; and has received research support from NIH-NIAID, NIH-NHLBI, Novartis, AstraZeneca, GlazoSmithKline, MedImmune, and Ception. S. E. Wenzel is a consultant for GlaxoSmithKline, Merck, Amgen, and Pearl Therapeutics; is on the advisory board for Amira, Altair, and Epigenesis; and has received research support from GlaxoSmithKline, Amgen, and MedImmune. V. Belozeroff, H. H. Weng, D. Globe, and S.-L. Lin are employed by Amgen. Y. Chon holds stock in Amgen. The rest of the authors have declared that they have no conflict of interest.	ALLISON PD, 1995, SURVIVAL ANAL USING, P138; Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC; Bateman ED, 2010, J ALLERGY CLIN IMMUN, V125, P600, DOI 10.1016/j.jaci.2009.11.033; Chapman KR, 2008, EUR RESPIR J, V31, P320, DOI 10.1183/09031936.00039707; Corren J, 2010, AM J RESP CRIT CARE, V181, P788, DOI 10.1164/rccm.200909-1448OC; Fuhlbrigge AL, 2002, AM J RESP CRIT CARE, V166, P1044, DOI 10.1164/rccm.2107057; Fuhlbrigge AL, 2001, J ALLERGY CLIN IMMUN, V107, P61, DOI 10.1067/mai.2001.111590; Fuhlbrigge AL, 2006, PEDIATRICS, V118, pE347, DOI 10.1542/peds.2005-2962; GINA, 2017, REP GLOB STRAT ASTHM; Haselkorn T, 2009, J ALLERGY CLIN IMMUN, V124, pe1, DOI DOI 10.1016/J.JACI.2009.07.035.PUBMED; Haselkorn T, 2009, J ALLERGY CLIN IMMUN, V124, P895, DOI 10.1016/j.jaci.2009.07.035; Humbert M, 2005, ALLERGY, V60, P309, DOI 10.1111/j.1398-9995.2004.00772.x; Juniper EF, 2006, RESP MED, V100, P616, DOI 10.1016/j.rmed.2005.08.012; Juniper EF, 2005, RESP MED, V99, P553, DOI 10.1016/j.rmed.2004.10.008; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; Kitch BT, 2004, CHEST, V126, P1875, DOI 10.1378/chest.126.6.1875; Lai CKW, 2003, J ALLERGY CLIN IMMUN, V111, P263, DOI 10.1067/mai.2003.30; Masoli M, 2004, ALLERGY, V59, P469, DOI 10.1111/j.1398-9995.2004.00526.x; National Heart Lung and Blood Institute. National Asthma Education and Prevention Program, 2007, 3 NAT HEART LUNG BLO; Osborne ML, 2007, CHEST, V132, P1151, DOI 10.1378/chest.05-3084; Partridge Martyn R, 2006, BMC Pulm Med, V6, P13, DOI 10.1186/1471-2466-6-13; Peters SP, 2007, J ALLERGY CLIN IMMUN, V119, P1454, DOI 10.1016/j.jaci.2007.03.022; Rabe KF, 2000, EUR RESPIR J, V16, P802, DOI 10.1183/09031936.00.16580200; Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST; Sato R, 2009, J ASTHMA, V46, P677, DOI 10.1080/02770900902972160; SVENSSON K, 2003, QUAL LIFE RES, V12, P771; Weiss KB, 2000, J ALLERGY CLIN IMMUN, V106, P493, DOI 10.1067/mai.2000.109426; 2009, ASTHMA INSIGHT MANAG	28	79	82	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2011	127	1					167	172		10.1016/j.jaci.2010.08.042	http://dx.doi.org/10.1016/j.jaci.2010.08.042			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	702SY	21093024				2022-12-18	WOS:000285917300024
J	Niebuhr, M; Scharonow, H; Gathmann, M; Mamerow, D; Werfel, T				Niebuhr, Margarete; Scharonow, Helena; Gathmann, Merle; Mamerow, Diana; Werfel, Thomas			Staphylococcal exotoxins are strong inducers of IL-22: A potential role in atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						SEB; alpha-toxin; IL-22; T(H)22; human; atopic dermatitis; psoriasis	ALPHA-TOXIN; T-CELL; INTERLEUKIN 22; ENTEROTOXIN-B; SKIN; AUREUS; TH17; KERATINOCYTES; EXPRESSION; CYTOKINES	Background: Patients with atopic dermatitis (AD) and psoriasis are frequently colonized with Staphylococcus aureus that produces staphylococcal enterotoxin B (SEB) and alpha-toxin. In patients with AD, S aureus colonization is positively correlated with the severity of their eczema. Moreover, IL-22-producing cells have been shown to accumulate in AD skin and to correlate with disease severity. Objective: To assess IL-22 production in response to SEB and sublytic alpha-toxin stimulation in patients with AD and psoriasis compared with healthy controls. Methods: IL-22 induction was investigated in PBMCs, T cells, and autologous cocultures of keratinocytes and T cells on SEB and alpha-toxin stimulation in a time-dependent and dose-dependent manner at the mRNA and protein (ELISA and flow cytometry) level. Anti-IL-1 receptor or anti-IL-6 antibodies were used in blocking experiments. Results: Staphylococcal enterotoxin B and sublytic alpha-toxin concentrations induced IL-22 production in PBMCs and isolated CD4(+) T cells. IL-22 secretion was enhanced by alpha-toxin stimulation in autologous cocultures of keratinocytes and T cells. In T cells and PBMCs from patients with AD, IL-22 secretion was significantly enhanced on alpha-toxin stimulation compared with patients with psoriasis and healthy controls. Conclusion: Increased IL-22 secretion induced by staphylococcal exotoxins in the skin partially explains how skin colonization and infection with S aureus can contribute to chronic skin inflammation in AD. (J Allergy Clin Immunol 2010;126:1176-83.)	[Niebuhr, Margarete; Scharonow, Helena; Gathmann, Merle; Mamerow, Diana; Werfel, Thomas] Hannover Med Sch, Div Immunodermatol & Allergy Res, Dept Dermatol & Allergy, D-30449 Hannover, Germany	Hannover Medical School	Niebuhr, M (corresponding author), Hannover Med Sch, Div Immunodermatol & Allergy Res, Dept Dermatol & Allergy, Ricklinger Str 5, D-30449 Hannover, Germany.	niebuhr.margarete@mh-hannover.de	Werfel, Thomas/B-6921-2012		 [SFB 566];  [GRK 1441]	; 	Supported by SFB 566 and GRK 1441.	BHAKDI S, 1989, INFECT IMMUN, V57, P3512, DOI 10.1128/IAI.57.11.3512-3519.1989; Boniface K, 2007, CLIN EXP IMMUNOL, V150, P407, DOI 10.1111/j.1365-2249.2007.03511.x; Breuer K, 2005, CLIN EXP ALLERGY, V35, P1088, DOI 10.1111/j.1365-2222.2005.02295.x; Breuer K, 2002, BRIT J DERMATOL, V147, P55, DOI 10.1046/j.1365-2133.2002.04872.x; Breuer K, 2001, ALLERGY, V56, P1034, DOI 10.1034/j.1398-9995.2001.00146.x; Breuer K, 2000, ALLERGY, V55, P551, DOI 10.1034/j.1398-9995.2000.00432.x; Dinges MM, 2000, CLIN MICROBIOL REV, V13, P16, DOI 10.1128/CMR.13.1.16-34.2000; Duhen T, 2009, NAT IMMUNOL, V10, P857, DOI 10.1038/ni.1767; Eyerich S, 2009, J CLIN INVEST, V119, P3573, DOI 10.1172/JCI40202; Gurcel L, 2006, CELL, V126, P1135, DOI 10.1016/j.cell.2006.07.033; Guttman-Yassky E, 2008, J IMMUNOL, V181, P7420, DOI 10.4049/jimmunol.181.10.7420; Gutzmer R, 2009, J ALLERGY CLIN IMMUN, V123, P619, DOI 10.1016/j.jaci.2008.12.1110; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44; Harper EG, 2009, J INVEST DERMATOL, V129, P2175, DOI 10.1038/jid.2009.65; Kagami S, 2010, J INVEST DERMATOL, V130, P1373, DOI 10.1038/jid.2009.399; LEUNG DYM, 1993, J CLIN INVEST, V92, P1374, DOI 10.1172/JCI116711; MARPLES RR, 1973, ARCH DERMATOL, V107, P568, DOI 10.1001/archderm.107.4.568; Matsui K, 2000, MICROBIOL IMMUNOL, V44, P945, DOI 10.1111/j.1348-0421.2000.tb02587.x; MCFADDEN JP, 1993, BRIT J DERMATOL, V128, P631, DOI 10.1111/j.1365-2133.1993.tb00257.x; McKenzie BS, 2006, TRENDS IMMUNOL, V27, P17, DOI 10.1016/j.it.2005.10.003; Munoz-Planillo R, 2009, J IMMUNOL, V183, P3942, DOI 10.4049/jimmunol.0900729; Niebuhr M, 2008, ALLERGY, V63, P728, DOI 10.1111/j.1398-9995.2008.01721.x; Nograles KE, 2008, BRIT J DERMATOL, V159, P1092, DOI 10.1111/j.1365-2133.2008.08769.x; Nograles KE, 2009, J ALLERGY CLIN IMMUN, V123, P1244, DOI 10.1016/j.jaci.2009.03.041; Ouyang WJ, 2008, IMMUNITY, V28, P454, DOI 10.1016/j.immuni.2008.03.004; Rao DA, 2007, J IMMUNOL, V179, P6536, DOI 10.4049/jimmunol.179.10.6536; Skov L, 2000, J ALLERGY CLIN IMMUN, V105, P820, DOI 10.1067/mai.2000.105524; Spolski R, 2009, EUR J IMMUNOL, V39, P658, DOI 10.1002/eji.200839066; Tomi NS, 2005, J AM ACAD DERMATOL, V53, P67, DOI 10.1016/j.jaad.2005.02.034; Trifari S, 2009, NAT IMMUNOL, V10, P864, DOI 10.1038/ni.1770; van Beelen AJ, 2007, CURR OPIN ALLERGY CL, V7, P374, DOI 10.1097/ACI.0b013e3282ef869e; Wang D, 2008, ARTHRITIS RHEUM, V58, P3205, DOI 10.1002/art.23868; Werfel T, 2009, J INVEST DERMATOL, V129, P1878, DOI 10.1038/jid.2009.71; Wichmann K, 2009, BRIT J DERMATOL, V161, P300, DOI 10.1111/j.1365-2133.2009.09229.x; Wolk K, 2004, IMMUNITY, V21, P241, DOI 10.1016/j.immuni.2004.07.007; Wolk K, 2006, CYTOKINE GROWTH F R, V17, P367, DOI 10.1016/j.cytogfr.2006.09.001; Wolk K, 2006, EUR J IMMUNOL, V36, P1309, DOI 10.1002/eji.200535503; Zheng Y, 2007, NATURE, V445, P648, DOI 10.1038/nature05505	38	79	83	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2010	126	6					1176	U172		10.1016/j.jaci.2010.07.041	http://dx.doi.org/10.1016/j.jaci.2010.07.041			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	689RZ	20864149	Bronze			2022-12-18	WOS:000284947800015
J	Uermosi, C; Beerli, RR; Bauer, M; Manolova, V; Dietmeier, K; Buser, RB; Kundig, TM; Saudan, P; Bachmann, MF				Uermoesi, Christina; Beerli, Roger R.; Bauer, Monika; Manolova, Vania; Dietmeier, Klaus; Buser, Regula B.; Kuendig, Thomas M.; Saudan, Philippe; Bachmann, Martin F.			Mechanisms of allergen-specific desensitization	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; vaccination; Fc gamma RIIB-mediated inhibition; mast cell activation requirements; Fel d 1; mAbs	FC-GAMMA-RII; VIRUS-LIKE PARTICLES; DOG-DANDER EXTRACTS; IMMUNOGLOBULIN-G; MAST-CELLS; IN-VITRO; CAT-DANDER; EPSILON-RI; IMMUNOTHERAPY; IGG	Background: Allergen-specific desensitization (SIT) is the most effective therapy for allergies. Although allergen-specific antibodies have an important role in the process, mechanisms of IgG-mediated inhibition of allergic reactions are not well defined. Objective: We investigated mechanisms by which SIT-induced allergen-specific IgGs inhibit allergic reactions. Methods: We generated mAbs that recognize 3 nonoverlapping epitopes of the major cat allergen Fel d 1. Each of the mAbs was produced as an IgE and different IgG isotype. Results: IgEs against 2 nonoverlapping epitopes on Fel d 1 are necessary and sufficient to sensitize mast cells for maximal Fc epsilon RI signaling and degranulation on exposure to monomeric Fel d 1. IgE antibodies of a third specificity did not further increase mast cell degranulation, indicating that formation of large Fc epsilon RI clusters are not required to induce maximal activation of mast cells. A single IgG that was specific for an epitope different from those recognized by the IgEs was a potent inhibitor of Fel d 1-mediated mast cell activation in vitro and in vivo. This inhibition required Fc gamma receptor-IIB. In human beings, IgGs of a single specificity were able to block degranulation of basophils from individuals with cat allergy. The inhibitory potential of these antibodies increased when larger allergen-IgG complexes were formed. Conclusions: These data reconcile conflicting theories in the literature and might explain the reason IgE levels do not necessarily decrease during therapy, despite clinical efficacy. These findings have important implications for vaccine design. (J Allergy Clin Immunol 2010;126:375-83.)	[Uermoesi, Christina; Beerli, Roger R.; Bauer, Monika; Manolova, Vania; Dietmeier, Klaus; Buser, Regula B.; Saudan, Philippe; Bachmann, Martin F.] Cytos Biotechnol AG, CH-8952 Zurich, Switzerland; [Kuendig, Thomas M.] Univ Zurich Hosp, Dept Dermatol, Unit Expt Immunotherapy, CH-8091 Zurich, Switzerland	University of Zurich; University Zurich Hospital	Bachmann, MF (corresponding author), Cytos Biotechnol AG, Wagistr 25, CH-8952 Zurich, Switzerland.	Martin.bachmann@cytos.com		Manolova, Vania/0000-0002-2072-8942				Akdis CA, 1996, J CLIN INVEST, V98, P1676, DOI 10.1172/JCI118963; Akdis M, 2007, J ALLERGY CLIN IMMUN, V119, P780, DOI 10.1016/j.jaci.2007.01.022; Beerli RR, 2008, P NATL ACAD SCI USA, V105, P14336, DOI 10.1073/pnas.0805942105; Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; Cielens I, 2000, FEBS LETT, V482, P261, DOI 10.1016/S0014-5793(00)02061-5; DAERON M, 1995, J CLIN INVEST, V95, P577, DOI 10.1172/JCI117701; Ebner C, 1997, CLIN EXP ALLERGY, V27, P1007, DOI 10.1111/j.1365-2222.1997.tb01252.x; Ejrnaes AM, 2006, CLIN EXP ALLERGY, V36, P273, DOI 10.1111/j.1365-2222.2006.02442.x; Ejrnaes AM, 2004, MOL IMMUNOL, V41, P471, DOI 10.1016/j.molimm.2004.04.018; FRIGUET B, 1985, J IMMUNOL METHODS, V77, P305, DOI 10.1016/0022-1759(85)90044-4; Galli SJ, 2005, ANNU REV IMMUNOL, V23, P749, DOI 10.1146/annurev.immunol.21.120601.141025; GALLI SJ, 1991, CURR OPIN IMMUNOL, V3, P865, DOI 10.1016/S0952-7915(05)80005-6; GOLDEN DBK, 1982, J ALLERGY CLIN IMMUN, V69, P489, DOI 10.1016/0091-6749(82)90172-5; Gronlund H, 2003, J BIOL CHEM, V278, P40144, DOI 10.1074/jbc.M301416200; HEDLIN G, 1991, J ALLERGY CLIN IMMUN, V87, P955, DOI 10.1016/0091-6749(91)90417-M; HEDLIN G, 1986, J ALLERGY CLIN IMMUN, V77, P488, DOI 10.1016/0091-6749(86)90184-3; Holgate ST, 1999, NATURE, V402, pB2, DOI 10.1038/35037000; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; Jutel M, 2005, J ALLERGY CLIN IMMUN, V116, P608, DOI 10.1016/j.jaci.2005.06.004; Kepley CL, 2000, J ALLERGY CLIN IMMUN, V106, P337, DOI 10.1067/mai.2000.107931; Kepley CL, 2004, J BIOL CHEM, V279, P35139, DOI 10.1074/jbc.M404318200; King C, 1996, J ALLERGY CLIN IMMUN, V98, P739, DOI 10.1016/S0091-6749(96)70121-5; Larche M, 2006, NAT REV IMMUNOL, V6, P761, DOI 10.1038/nri1934; LICHTENSTEIN LM, 1968, J IMMUNOL, V101, P317; MULLER U, 1989, ALLERGY, V44, P412, DOI 10.1111/j.1398-9995.1989.tb04172.x; Niederberger V, 2004, P NATL ACAD SCI USA, V101, P14677, DOI 10.1073/pnas.0404735101; Sanz M.L., 2003, Anales Sis San Navarra, V26, P39, DOI 10.4321/s1137-66272003000400006; Schmitz N, 2009, J EXP MED, V206, P1941, DOI 10.1084/jem.20090199; Sellge G, 2005, CLIN EXP ALLERGY, V35, P774, DOI 10.1111/j.1365-2222.2005.02248.x; Takai T, 1996, NATURE, V379, P346, DOI 10.1038/379346a0; TRIGGIANI M, 1995, CHEM IMMUNOL, V61, P135; Upton MN, 2000, BMJ-BRIT MED J, V321, P88, DOI 10.1136/bmj.321.7253.88; van Ree R, 1999, J ALLERGY CLIN IMMUN, V104, P1223, DOI 10.1016/S0091-6749(99)70017-5; Verhoef A, 2005, PLOS MED, V2, P253, DOI 10.1371/journal.pmed.0020078; Wachholz PA, 2004, CURR OPIN ALLERGY CL, V4, P313, DOI 10.1097/01.all.0000136753.35948.c0; Walker SM, 2001, J ALLERGY CLIN IMMUN, V107, P87, DOI 10.1067/mai.2001.112027; Watanabe T, 2004, AM J RESP CRIT CARE, V169, P105, DOI 10.1164/rccm.200302-239OC; Zhu DC, 2005, NAT MED, V11, P446, DOI 10.1038/nm1219	38	79	84	0	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2010	126	2					375	383		10.1016/j.jaci.2010.05.040	http://dx.doi.org/10.1016/j.jaci.2010.05.040			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	642IL	20624641	Green Submitted			2022-12-18	WOS:000281203800024
J	Kainulainen, L; Vuorinen, T; Rantakokko-Jalava, K; Osterback, R; Ruuskanen, O				Kainulainen, Leena; Vuorinen, Tytti; Rantakokko-Jalava, Kaisu; Osterback, Riikka; Ruuskanen, Olli			Recurrent and persistent respiratory tract viral infections in patients with primary hypogammaglobulinemia	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Primary immunodeficiency; hypogammaglobulinemia; X-linked agammaglobulinemia; common variable immunodeficiency; rhinovirus; respiratory virus; respiratory tract infection; immunoglobulin replacement therapy	COMMUNITY-ACQUIRED PNEUMONIA; X-LINKED AGAMMAGLOBULINEMIA; PARALYTIC POLIOMYELITIS; RHINOVIRUS; CHILDREN; IMMUNODEFICIENCY; ASSOCIATION; BACTERIA; VIRUSES; AIRWAYS	Background: The occurrence of respiratory tract viral infections in patients with primary hypogammaglobulinemia has not been studied. Objective: We conducted a prospective 12-month follow-up study of respiratory tract infections in 12 adult patients with primary hypogammaglobulinemia. Methods: Nasal swab samples and induced sputum samples were taken at the onset of acute respiratory tract infection and every 3 months thereafter. Samples were tested for bacteria and viruses. PCR tests were performed for 15 respiratory tract viruses. In case the results for rhinovirus were positive, follow-up nasal swab samples were taken every 2 weeks until rhinoviral PCR results became negative. Patients completed symptom diaries, which were collected every month. The spouses of the patients served as healthy control subjects. Results: During the 12-month period, the 12 patients had 65 episodes of acute respiratory tract infections, and the 11 spouses had 12 acute episodes (P<.001). Respiratory tract viruses were found in sputum in 54% of the infections. Rhinovirus was the most common virus. In more than half of our patients, rhinoviral PCR results stayed positive for more than 2 months. The most long-acting persistence with the same rhinovirus was 4 months. Conclusions: Despite adequate immunoglobulin replacement therapy, patients with primary hypogammaglobulinemia have increased susceptibility to respiratory tract viral infections. Rhinoviral infections are frequent and prolonged. (J Allergy Clin Immunol 2010;126:120-6.)	[Kainulainen, Leena; Ruuskanen, Olli] Turku Univ Hosp, Dept Pediat, Turku 20521, Finland; [Kainulainen, Leena] Turku Univ Hosp, Dept Internal Med, Turku 20521, Finland; [Rantakokko-Jalava, Kaisu] Turku Univ Hosp, Dept Med Microbiol, Turku 20521, Finland; [Vuorinen, Tytti; Osterback, Riikka] Turku Univ, Dept Virol, Turku, Finland	University of Turku; University of Turku; University of Turku; University of Turku	Kainulainen, L (corresponding author), Turku Univ Hosp, Dept Pediat, PB 52, Turku 20521, Finland.	leena.kainulainen@tyks.fi		Kainulainen, Leena/0000-0002-7776-3626	Turku University Hospital; Research Foundation of Orion Corporation	Turku University Hospital; Research Foundation of Orion Corporation	Supported by grants from the government to Turku University Hospital and the Research Foundation of Orion Corporation.	ABO W, 1979, EUR J PEDIATR, V132, P11, DOI 10.1007/BF00443199; [Anonymous], 1999, CLIN EXP IMMUNOL, V118, P1; Bjoro K, 1999, QJM-INT J MED, V92, P433, DOI 10.1093/qjmed/92.8.433; Cunningham-Rundles C, 1999, CLIN IMMUNOL, V92, P34, DOI 10.1006/clim.1999.4725; Cunningham-Rundles C, 2006, J IMMUNOL, V176, P1978, DOI 10.4049/jimmunol.176.3.1978; Doyle SL, 2007, J BIOL CHEM, V282, P36953, DOI 10.1074/jbc.M707682200; Gern JE, 2000, AM J RESP CRIT CARE, V162, P2226, DOI 10.1164/ajrccm.162.6.2003019; Halliday E, 2003, J INFECTION, V46, P1, DOI 10.1053/jinf.2002.1066; HARA M, 1981, MICROBIOL IMMUNOL, V25, P905, DOI 10.1111/j.1348-0421.1981.tb00095.x; Jennings LC, 2008, THORAX, V63, P42, DOI 10.1136/thx.2006.075077; Kainulainen L, 1999, J ALLERGY CLIN IMMUN, V104, P1031, DOI 10.1016/S0091-6749(99)70085-0; Kainulainen L, 1999, AM J RESP CRIT CARE, V159, P1199, DOI 10.1164/ajrccm.159.4.9807067; Kainulainen L, 2007, ARCH OTOLARYNGOL, V133, P597, DOI 10.1001/archotol.133.6.597; Kaiser L, 2006, AM J RESP CRIT CARE, V174, P1392, DOI 10.1164/rccm.200604-489OC; LEDERMAN HM, 1985, MEDICINE, V64, P145, DOI 10.1097/00005792-198505000-00001; MacLennan C, 2004, LANCET, V363, P1509, DOI 10.1016/S0140-6736(04)16150-3; MATSUSE T, 1992, AM REV RESPIR DIS, V146, P177, DOI 10.1164/ajrccm/146.1.177; MCKINNEY RE, 1987, REV INFECT DIS, V9, P334; Monto AS, 2002, AM J MED, V112, p4S; Oksenhendler E, 2008, CLIN INFECT DIS, V46, P1547, DOI 10.1086/587669; Oliver BGG, 2008, THORAX, V63, P519, DOI 10.1136/thx.2007.081752; Papadopoulos NG, 2000, J INFECT DIS, V181, P1875, DOI 10.1086/315513; Peltola V, 2008, J INFECT DIS, V197, P382, DOI 10.1086/525542; Quinti I, 2007, J CLIN IMMUNOL, V27, P308, DOI 10.1007/s10875-007-9075-1; Retamales I, 2001, AM J RESP CRIT CARE, V164, P469, DOI 10.1164/ajrccm.164.3.2007149; Rudge P, 1996, BRAIN, V119, P1, DOI 10.1093/brain/119.1.1; van Elden LJR, 2008, J CLIN VIROL, V41, P116, DOI 10.1016/j.jcv.2007.10.028; Wheat WH, 2005, J EXP MED, V202, P479, DOI 10.1084/jem.20050381; WILFERT CM, 1977, NEW ENGL J MED, V296, P1485, DOI 10.1056/NEJM197706302962601; Winkelstein JA, 2006, MEDICINE, V85, P193, DOI 10.1097/01.md.0000229482.27398.ad; Winther B, 2006, J MED VIROL, V78, P644, DOI 10.1002/jmv.20588; Wos M, 2008, AM J RESP CRIT CARE, V177, P1082, DOI 10.1164/rccm.200607-973OC; Zar HJ, 2003, PEDIATR PULM, V36, P58, DOI 10.1002/ppul.10302	33	79	79	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2010	126	1					120	126		10.1016/j.jaci.2010.04.016	http://dx.doi.org/10.1016/j.jaci.2010.04.016			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	627SE	20541246	Bronze, Green Published			2022-12-18	WOS:000280061800021
J	Seibold, MA; Donnelly, S; Solon, M; Innes, A; Woodruff, PG; Boot, RG; Burchard, EG; Fahy, JV				Seibold, Max A.; Donnelly, Samantha; Solon, Margaret; Innes, Anh; Woodruff, Prescott G.; Boot, Rolf G.; Burchard, Esteban Gonzalez; Fahy, John V.			Chitotriosidase is the primary active chitinase in the human lung and is modulated by genotype and smoking habit	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						AMCase; CHITI; chitinase; asthma; smokers; bronchoalveolar lavage	ACIDIC MAMMALIAN CHITINASE; SMOOTH-MUSCLE; ASTHMA; PROTEIN; GENE; FUNGAL; CELLS; ACTIVATION; EXPRESSION; PLASMA	Background: Chitinolytic enzymes play important roles in the pathophysiology of allergic airway responses in mouse models of asthma. Acidic mammalian chitinase (AMCase) and chitotriosidase (CHIT1) have chitinolytic activity, but relatively little is known about their expression in human asthma. Objective: We sought to determine the expression and activity of AMCase and CHIT1 in healthy subjects, subjects with asthma, and habitual smokers, taking account of the null 24-bp duplication in the CHIT1 gene. Methods: We measured chitinase activity in bronchoalveolar lavage (BAL) fluid at multiple pHs by using a synthetic chitin substrate. We also determined AMCase and CHIT1 gene expression in epithelial brushings and BAL fluid macrophages by means of real time RT-PCR. Paired DNA samples were genotyped for the CHIT1 duplication. Results: In all subgroups the pH profile of chitinase activity in BAL fluid matched that of CHIT1, but not AMCase, and chitinase activity was absent in subjects genetically deficient in active CHIT1. Although AMCase protein was detectable in lavage fluid, AMCase transcripts in macrophages were consistent with an isoform lacking enzymatic activity. Median chitinase activity in BAL fluid tended to be lower than normal in asthmatic subjects but was increased 7-fold in habitual smokers, where CHIT1 gene expression in macrophages was increased. Conclusions: Chitinase activity in the lung is the result of CHIT1 activity. Although AMCase protein is detectable in the lung, our data indicate that it is inactive. Chitinase activity is not increased in subjects with asthma and in fact tends to be decreased. The high levels of chitinase activity in habitual smokers result from upregulation of CHIT1 gene expression, especially in macrophages. Q Allergy Clin Immunol 2008;122:944-50.)	[Seibold, Max A.; Innes, Anh; Woodruff, Prescott G.; Burchard, Esteban Gonzalez; Fahy, John V.] Univ Calif San Francisco, Dept Med, Div Pulm & Crit Care Med, San Francisco, CA 94143 USA; [Donnelly, Samantha; Solon, Margaret; Innes, Anh; Woodruff, Prescott G.; Fahy, John V.] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; [Burchard, Esteban Gonzalez] Univ Calif San Francisco, Lung Biol Ctr, San Francisco, CA 94143 USA; [Burchard, Esteban Gonzalez] Univ Calif San Francisco, Inst Human Genet, San Francisco, CA 94143 USA; [Boot, Rolf G.] Univ Amsterdam, Acad Med Ctr, Dept Med Biochem, NL-1105 AZ Amsterdam, Netherlands	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Amsterdam; Academic Medical Center Amsterdam	Fahy, JV (corresponding author), Univ Calif San Francisco, Dept Med, Div Pulm & Crit Care Med, Box 0111,505 Parnassus Ave, San Francisco, CA 94143 USA.	john.fahy@ucsf.edu		Boot, Rolf/0000-0002-7031-3390	National Institutes of Health [AI077439, HL080414, HL078885, RR17002]; Sandler Asthma Basic Research Center; Sandler program for Asthma Research; Genentech; Boehringer Ingelheim; Roche; Bochringer Ingelheim; NATIONAL CENTER FOR RESEARCH RESOURCES [K23RR017002] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL078885, R01HL080414] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI077439] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Sandler Asthma Basic Research Center; Sandler program for Asthma Research; Genentech(Roche HoldingGenentech); Boehringer Ingelheim(Boehringer Ingelheim); Roche(Roche Holding); Bochringer Ingelheim; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grains AI077439 (J.V.F. and E.G.B.). HL080414 (J.V.F.), HL078885 (E.G.B.), and RR17002 (P.G.W.): the Sandler Asthma Basic Research Center (J.V.F. and E.G.B.): and the Sandler program for Asthma Research (E.G.B.).; Disclosure of potential conflict of interest: A. Innes has received research support form Genentech. P.G. Woodruff has received research support from Boehringer Ingelheim and Genentech. J. V. Fahy has received research support from Genentech, Roche, and Bochringer Ingelheim. The rest of the authors have declared that they have no conflict of interest.	Aerts JMFG, 1997, BAILLIERE CLIN HAEM, V10, P691, DOI 10.1016/S0950-3536(97)80034-0; Aguilera B, 2003, J BIOL CHEM, V278, P40911, DOI 10.1074/jbc.M301804200; ARAUJO ACG, 1993, J HISTOCHEM CYTOCHEM, V41, P571, DOI 10.1177/41.4.8450196; Barone R, 2003, AM J HEMATOL, V72, P285, DOI 10.1002/ajh.10294; BOGDEN JD, 1981, J NATL CANCER I, V66, P27; Boot RG, 2005, J IMMUNOL, V175, P2041, DOI 10.4049/jimmunol.175.4.2041-a; Boot RG, 2001, J BIOL CHEM, V276, P6770, DOI 10.1074/jbc.M009886200; Boot RG, 1998, J BIOL CHEM, V273, P25680, DOI 10.1074/jbc.273.40.25680; Bussink AP, 2007, GENETICS, V177, P959, DOI 10.1534/genetics.107.075846; Chen XN, 1999, GENOME RES, V9, P492; Chou YT, 2006, BIOCHEMISTRY-US, V45, P4444, DOI 10.1021/bi0525977; Chupp GL, 2007, NEW ENGL J MED, V357, P2016, DOI 10.1056/NEJMoa073600; *COMM GE, 2007, GOLD EX SUMM UPD 200; De Ceuninck F, 2001, BIOCHEM BIOPH RES CO, V285, P926, DOI 10.1006/bbrc.2001.5253; DEBONO M, 1994, ANNU REV MICROBIOL, V48, P471, DOI 10.1146/annurev.mi.48.100194.002351; Dolganov GM, 2001, GENOME RES, V11, P1473, DOI 10.1101/gr.191301; Innes AL, 2006, CHEST, V130, P1102, DOI 10.1378/chest.130.4.1102; Jamois F, 2005, GLYCOBIOLOGY, V15, P393, DOI 10.1093/glycob/cwi020; Kasprzewska A, 2003, CELL MOL BIOL LETT, V8, P809; Kuperman DA, 2005, J ALLERGY CLIN IMMUN, V116, P305, DOI 10.1016/j.jaci.2005.03.024; Labadaridis I, 2005, ARCH DIS CHILD-FETAL, V90, pF531, DOI 10.1136/adc.2004.051284; Ling H, 2004, BIOCHEM J, V380, P651, DOI 10.1042/BJ20040099; Malinda KM, 1999, EXP CELL RES, V250, P168, DOI 10.1006/excr.1999.4511; NACLERIO RM, 1999, RHINITIS MECH MANAGE; NEVILLE AC, 1976, J CELL SCI, V21, P73; Ober C, 2008, NEW ENGL J MED, V358, P1682, DOI 10.1056/NEJMoa0708801; Recklies AD, 2002, BIOCHEM J, V365, P119, DOI 10.1042/BJ20020075; Reese TA, 2007, NATURE, V447, P92, DOI 10.1038/nature05746; Saito A, 1999, GENE, V239, P325, DOI 10.1016/S0378-1119(99)00394-7; SALO PM, 2004, AM J RESP CARE ME S7, V169, pA368; van Eijk M, 2005, INT IMMUNOL, V17, P1505, DOI 10.1093/intimm/dxh328; Verweij PE, 2000, JAMA-J AM MED ASSOC, V284, P2875, DOI 10.1001/jama.284.22.2875; Woodruff PG, 2005, AM J RESP CRIT CARE, V172, P1383, DOI 10.1164/rccm.200505-686OC; Woodruff PG, 2004, AM J RESP CRIT CARE, V169, P1001, DOI 10.1164/rccm.200311-1529OC; Woodruff PG, 2007, P NATL ACAD SCI USA, V104, P15858, DOI 10.1073/pnas.0707413104; Zhu Z, 2004, SCIENCE, V304, P1678, DOI 10.1126/science.1095336	36	79	84	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2008	122	5					944	950		10.1016/j.jaci.2008.08.023	http://dx.doi.org/10.1016/j.jaci.2008.08.023			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	372ZF	18845328	Green Accepted			2022-12-18	WOS:000260940100013
J	Ginde, AA; Espinola, JA; Camargo, CA				Ginde, Adit A.; Espinola, Janice A.; Camargo, Carlos A., Jr.			Improved overall trends but persistent racial disparities in emergency department visits for acute asthma, 1993-2005	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; disparities; emergency department; epidemiology; public health	UNITED-STATES; AFRICAN-AMERICAN; SEX-DIFFERENCES; CARE; HOSPITALIZATIONS; GUIDELINES; MEDICATIONS; MANAGEMENT; DECREASES; MORTALITY	Background: Emergency department (ED) visits for acute asthma provide an important marker of morbidity. Objective: To describe the epidemiology of ED visits for acute asthma. Methods: We obtained data from the National Hospital Ambulatory Medical Care Survey, 1993 to 2005, and used the primary diagnosis code for asthma (493) to identify cases. We calculated national estimates by using assigned patient visit weights and national rates per 1000 US population with demographic-specific population data from the US Census Bureau. Results: From 1993 to 2005, there were approximately 23,800,000 asthma visits, representing 1.8% of all ED visits, or an overall rate of 6.7 visits per 1000 US population. The national visit rate rose between 1993 and 1998 (P-trend =.05), but was stable (or possibly decreasing) from 1998 to 2005 (P-trend =.07). Although rates for white subjects decreased by 25% from 1998 to 2005 (P-trend =.02), the rates for black subjects remained constant (P-trend =.80). The overall asthma-related ED visit rate was highest among the following groups: age <10 years (13), women (7.2), black subjects (19), Hispanic subjects (7.1), and subjects in the Northeast (9.2). ED administration of inhaled anticholinergic agents increased 20-fold and systemic corticosteroids increased 2-fold from 1993 to 2005 (P-trend =.02 and .03, respectively), whereas inhaled beta-agonist and inhaled corticosteroid administration was stable (P-trend = .09 and .34, respectively). Conclusion: Although asthma-related ED visit rates showed a significant upward trend from 1993 to 1998, our results support the emerging view that the asthma epidemic may have reached a plateau. Nevertheless, the higher visit rates observed among specific demographic groups and widening disparities, particularly among black subjects, remain problematic and warrant further investigation.	[Camargo, Carlos A., Jr.] Harvard Univ, Emergency Med Network, Massachusetts Gen Hosp, Sch Med,Dept Emergency Med, Boston, MA 02114 USA; [Ginde, Adit A.] Univ Colorado, Denver Sch Med, Dept Emergency Med, Aurora, CO USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; University of Colorado System; University of Colorado Anschutz Medical Campus	Camargo, CA (corresponding author), Harvard Univ, Emergency Med Network, Massachusetts Gen Hosp, Sch Med,Dept Emergency Med, 326 Cambridge St,Suite 410, Boston, MA 02114 USA.	ccamargo@partners.org	Camargo, Carlos A./C-2145-2008	Camargo, Carlos A./0000-0002-5071-7654	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL084401] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-84401, R01 HL084401] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKINBANI L, 2003, ASTHMA PREVALENCE HL; Baibergenova A, 2006, ANN ALLERG ASTHMA IM, V96, P666, DOI 10.1016/S1081-1206(10)61063-0; Burt C W, 2001, Vital Health Stat 13, P1; CARR W, 1989, SOC SCI MED, V29, P705, DOI 10.1016/0277-9536(89)90149-4; Cloutier MM, 2005, J PEDIATR-US, V146, P591, DOI 10.1016/j.jpeds.2004.12.017; Coventry J A, 1996, J Ambul Care Manage, V19, P9; CUZICK J, 1985, STAT MED, V4, P87, DOI 10.1002/sim.4780040112; Cydulka RK, 2005, ANN EMERG MED, V46, P316, DOI 10.1016/j.annemergmed.2004.12.024; Doerschug KC, 1999, AM J RESP CRIT CARE, V159, P1735, DOI 10.1164/ajrccm.159.6.9809051; Fuhlbrigge A, 2004, MED CARE, V42, P465, DOI 10.1097/01.mlr.0000124249.84045.d7; Gibson PG, 2004, THORAX, V59, P94, DOI 10.1136/thorax.2003.011858; Grant EN, 1999, J ALLERGY CLIN IMMUN, V104, pS1, DOI 10.1016/S0091-6749(99)70268-X; HAIREJOSHU D, 1993, J ASTHMA, V30, P359, DOI 10.3109/02770909309056740; KEMP JP, 1993, ARCH INTERN MED, V153, P805, DOI 10.1001/archinte.153.7.805; Krishnan JA, 2001, ARCH INTERN MED, V161, P1660, DOI 10.1001/archinte.161.13.1660; Ma J, 2005, ARCH INTERN MED, V165, P1354, DOI 10.1001/archinte.165.12.1354; McCaig L F, 1994, Vital Health Stat 1, P1; Moorman Jeanne E., 2007, Morbidity and Mortality Weekly Report, V56, P1; Murray MD, 1997, J CLIN EPIDEMIOL, V50, P167, DOI 10.1016/S0895-4356(96)00333-2; *NAT CTR HLTH STAT, 2007, AMB CAR DRUG DAT SYS; National Heart Lung and Blood Institute. National Asthma Education and Prevention Program, 2007, 3 NAT HEART LUNG BLO; NAWAR EW, 2005, ADV DATA, V386, P1; Rand CS, 2000, J ALLERGY CLIN IMMUN, V105, P83, DOI 10.1016/S0091-6749(00)90182-9; Rodrigo GJ, 2005, THORAX, V60, P740, DOI 10.1136/thx.2005.040444; Rowe BH, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000195.pub2; Rowe BH, 1999, JAMA-J AM MED ASSOC, V281, P2119, DOI 10.1001/jama.281.22.2119; Schatz M, 2003, ANN ALLERG ASTHMA IM, V91, P553, DOI 10.1016/S1081-1206(10)61533-5; Self TH, 2005, J ASTHMA, V42, P807, DOI 10.1080/02770900500369835; Sin DD, 2002, ARCH INTERN MED, V162, P1591, DOI 10.1001/archinte.162.14.1591; Sly RM, 2004, ANN ALLERG ASTHMA IM, V92, P313, DOI 10.1016/S1081-1206(10)61568-2; Sly RM, 2000, ANN ALLERG ASTHMA IM, V85, P121, DOI 10.1016/S1081-1206(10)62451-9; *US DEP HHS, 2000, HLTH PEOPL 2010, P3; WEISS KB, 1990, JAMA-J AM MED ASSOC, V263, P2323; Weiss KB, 2000, J ALLERGY CLIN IMMUN, V106, P493, DOI 10.1067/mai.2000.109426; Zanolin ME, 2004, ALLERGY, V59, P306, DOI 10.1046/j.1398-9995.2003.00391.x; Zoratti EM, 1998, AM J RESP CRIT CARE, V158, P371, DOI 10.1164/ajrccm.158.2.9608039; 1997, INT CLASSIFICATION	37	79	80	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2008	122	2					313	318		10.1016/j.jaci.2008.04.024	http://dx.doi.org/10.1016/j.jaci.2008.04.024			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	337HO	18538382	Green Accepted			2022-12-18	WOS:000258426300016
J	Bakhireva, LN; Jones, KL; Schatz, M; Klonoff-Cohen, HS; Johnson, D; Slymen, DJ; Chambers, CD				Bakhireva, Ludmila N.; Jones, Kenneth Lyons; Schatz, Michael; Klonoff-Cohen, Hillary S.; Johnson, Diania; Slymen, Donald J.; Chambers, Christina D.		Org Teratology Information	Safety of leukotriene receptor antagonists in pregnancy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; asthma medications; leukotriene receptor antagonists; montelukast; zafirlukast; pregnancy; major structural anomalies	ASTHMATIC-PATIENTS; OUTCOMES; ASSOCIATION; WOMEN; PREVALENCE; MEDICATION; DIAGNOSIS; SEVERITY; EXPOSURE; GROWTH	Background: Asthma is a chronic disorder that affects about 8% of pregnant women and may complicate pregnancy. Adequate asthma therapy in pregnancy is crucial but challenging because of safety concerns for the fetus. Objective: To evaluate the safety of gestational asthma therapy with leukotriene receptor antagonists (LTRAs) for the mother and fetus/newborn. Methods: Subjects were participants of the Organization of Teratology Information Specialists Asthma Medications in Pregnancy Study. Perinatal outcomes among 96 women who took LTRAs (montelukast or zafirlukast) were compared with women who exclusively took short-acting beta(2)-agonists (n = 122) and women without asthma (n = 346). Results: Use of LTRAs was not associated with an increased risk of pregnancy loss, gestational diabetes, preeclampsia, low maternal weight gain, preterm delivery, low Apgar scores, or reduced measures of birth length and head circumference in infants (P > .05). Slightly decreased birth weight in infants born to LTRA users could be attributed to maternal asthma severity/control. The birth prevalence of major structural defects in the LTRA group (5.95%) was significantly higher compared with controls without asthma (P = .007), but not different from the comparison group with asthma (P = .524). Furthermore, the defects observed in the LTRA group did not represent a consistent pattern. Conclusions: Use of LTRAs in pregnancy was not associated with a specific pattern of major structural anomalies in offspring or a large risk of other adverse perinatal outcomes. Clinical implications: This study suggests that LTRAs do not appear to be a major human teratogen; however, results should be interpreted with caution because of limited sample size.	Univ Calif San Diego, Dept Pediat, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Family & Prevent Med, La Jolla, CA 92093 USA; Kaiser Permanente, Med Ctr, Dept Allergy Immunol, San Diego, CA USA; San Diego State Univ, Grad Sch Publ Hlth, San Diego, CA 92182 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Kaiser Permanente; California State University System; San Diego State University	Bakhireva, LN (corresponding author), Univ Calif San Diego, Dept Pediat, 9500 Gilman Dr,MC 8446, La Jolla, CA 92093 USA.	lbakhireva@ucsd.edu	Jones, Kenneth/GXF-4945-2022	Chambers, Christina D/0000-0003-4675-7722				Acs N, 2005, J MATERN-FETAL NEO M, V18, P107, DOI 10.1080/14767050500198337; [Anonymous], 2005, J ALLERGY CLIN IMMUN, V115, P34, DOI 10.1016/j.jaci.2004.10.023; BAKHIREVA L, 2007, IN PRESS J ASTHMA; Bakhireva LN, 2005, J ALLERGY CLIN IMMUN, V116, P503, DOI 10.1016/j.jaci.2005.05.027; Bracken MB, 2003, OBSTET GYNECOL, V102, P739, DOI 10.1016/S0029-7844(03)00621-5; Chambers C, 2006, IMMUNOL ALLERGY CLIN, V26, P13, DOI 10.1016/j.iac.2005.10.001; Demissie K, 1998, AM J RESP CRIT CARE, V158, P1091, DOI 10.1164/ajrccm.158.4.9802053; Enriquez R, 2006, AM J OBSTET GYNECOL, V195, P149, DOI 10.1016/j.ajog.2006.01.065; *EUROCAT WORK GROU, 2003, WHO COLL CTR EP SURV; FITZSIMONS R, 1986, J ALLERGY CLIN IMMUN, V78, P349, DOI 10.1016/S0091-6749(86)80088-4; Garcia-Marcos L, 2003, DRUG SAFETY, V26, P483, DOI 10.2165/00002018-200326070-00004; Hollingshead A., 2011, 4 FACTOR INDEX SOCIA, V8; Jana N, 1995, J Obstet Gynaecol (Tokyo 1995), V21, P227; Johnson KA, 2001, TERATOLOGY, V64, P79, DOI 10.1002/tera.1048; Jones KL., 2006, SMITHS RECOGNIZABLE, V6th ed., P268; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; Kallen B, 2000, EUR J EPIDEMIOL, V16, P167, DOI 10.1023/A:1007678404911; Kuczmarski RJ, 2000, ADV DATA, P1; Kwon HL, 2006, IMMUNOL ALLERGY CLIN, V26, P29, DOI 10.1016/j.iac.2005.11.002; LECK I, 1995, J EPIDEMIOL COMMUN H, V49, P171, DOI 10.1136/jech.49.2.171; Liu SL, 2001, AM J OBSTET GYNECOL, V184, P90, DOI 10.1067/mob.2001.108073; LUBCHENCO LO, 1966, PEDIATRICS, V37, P403; *MERCK PROG REG PR, 8 ANN REP EXP PREGN; *METR ATL DEF PROG, MACDP REP; MILLER HC, 1971, PEDIATRICS, V48, P511; Murphy VE, 2006, THORAX, V61, P169, DOI 10.1136/thx.2005.049718; Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008; Olesen C, 2001, EPIDEMIOLOGY, V12, P497, DOI 10.1097/00001648-200109000-00006; PERLOW JH, 1992, AM J OBSTET GYNECOL, V167, P963, DOI 10.1016/S0002-9378(12)80020-2; Sarkar M, 2005, CLIN PHARMACOL THER, V77, pP30, DOI 10.1016/j.clpt.2004.12.005; Schatz M, 2006, AM J OBSTET GYNECOL, V194, P120, DOI 10.1016/j.ajog.2005.06.028; Schatz M, 2005, ANN ALLERG ASTHMA IM, V95, P234, DOI 10.1016/S1081-1206(10)61219-7; Scialli AR, 1999, J ALLERGY CLIN IMMUN, V103, pS373, DOI 10.1016/S0091-6749(99)70267-8; Sheiner E, 2005, J MATERN-FETAL NEO M, V18, P237, DOI 10.1080/14767050500260616; Sobande AA, 2002, INT J GYNECOL OBSTET, V77, P117, DOI 10.1016/S0020-7292(02)00017-6; Spector SL, 2001, ANN ALLERG ASTHMA IM, V86, P18, DOI 10.1016/S1081-1206(10)62307-1; Van den Berg LTWDJ, 1999, TERATOLOGY, V60, P33; Vollmer WM, 1999, AM J RESP CRIT CARE, V160, P1647, DOI 10.1164/ajrccm.160.5.9902098; *WOLT KLUW HLTH IN, 2004, DRUG FACTS COMP	39	79	80	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2007	119	3					618	625		10.1016/j.jaci.2006.12.618	http://dx.doi.org/10.1016/j.jaci.2006.12.618			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	146HL	17336611				2022-12-18	WOS:000244925000014
J	Munitz, A; Bachelet, I; Letri-Schaffer, F				Munitz, Ariel; Bachelet, Ido; Letri-Schaffer, Francesca			Reversal of airway inflammation and remodeling in asthma by a bispecific antibody fragment linking CCR3 to CD300a	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; airway remodeling; eosinophils; CD300a; bispecific antibody	RECEPTOR IRP60 CD300A; T-CELLS; MAST-CELLS; EOSINOPHILS; BETA; ALLERGEN; ACTIVATION; EXPRESSION; KINASES; EOTAXIN	Background: Mast cells (MCs) and eosinophils are critically involved in asthma-associated airway damage and remodeling. However, molecular pathways that inhibit their functions in this process have been scarcely characterized. Recently we established that cross-linking of CD300a inhibits MC and eosinophil activation. Objective: To inhibit effector cell functions in a chronic model of experimental asthma by coaggregation of CD300a with CC chemokine receptor 3 (CCR3) using a bispecific antibody fragment (LC1). Methods: Mast cells and eosinophils were treated with LC1 before their activation. Mediator release, survival, and intracellular signaling were assessed. Furthermore, chronic experimental asthma was induced, and starting on day 30, the mice were challenged (3 challenges/wk) for an additional 38 days. With each challenge, the mice received LC1 intranasally. Results: LC1 inhibited MCs and eosinophil activation in vitro and in vivo. Mice that displayed airway inflammation on day 28 and were treated with LC1 completely recovered from the disease process. In the bronchoalveolar lavage fluid of these mice, cellular inflammation cytokine expression was comparable to that of saline-treated mice. Bronchoalveolar lavage fluid levels of TGF-beta 1 correlated significantly with reduced eosinophilia. Histologic analysis revealed significant reduction in lung inflammation, mucus production, collagen deposition, and peribronchial smooth-muscle thickening. Conclusion: CD300a is a critical modulator of MCs and eosinophil functions in allergic settings. Clinical implications: Specific targeting of CD300a in CCR3(+) cells may be a potent tool for treating airway inflammation and tissue remodeling in asthma.	Hebrew Univ Jerusalem, Fac Med, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Letri-Schaffer, F (corresponding author), Hebrew Univ Jerusalem, Fac Med, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel.	fls@cc.huji.ac.il		Levi-Schaffer, Francesca/0000-0003-0620-2810				Adachi T, 1998, AM J PHYSIOL-CELL PH, V275, pC623, DOI 10.1152/ajpcell.1998.275.3.C623; Bachelet I, 2005, J IMMUNOL, V175, P7989, DOI 10.4049/jimmunol.175.12.7989; Beaulieu S, 2002, J IMMUNOL, V169, P2925, DOI 10.4049/jimmunol.169.6.2925; Blyth DI, 2000, AM J RESP CELL MOL, V23, P241, DOI 10.1165/ajrcmb.23.2.3999; BRENNAN M, 1985, SCIENCE, V229, P81, DOI 10.1126/science.3925553; Busse WW, 2001, NEW ENGL J MED, V344, P350, DOI 10.1056/NEJM200102013440507; Ghiringhelli F, 2005, J EXP MED, V202, P1075, DOI 10.1084/jem.20051511; Gray JD, 1998, J IMMUNOL, V160, P2248; Humbles AA, 2002, P NATL ACAD SCI USA, V99, P1479, DOI 10.1073/pnas.261462598; Humbles AA, 2004, SCIENCE, V305, P1776, DOI 10.1126/science.1100283; Jarjour NN, 2002, MED CLIN N AM, V86, P925, DOI 10.1016/S0025-7125(02)00087-1; Justice JP, 2003, AM J PHYSIOL-LUNG C, V284, pL169, DOI 10.1152/ajplung.00260.2002; Khodoun MV, 2004, J EXP MED, V200, P857, DOI 10.1084/jem.20040598; Kumagai H, 2003, BIOCHEM BIOPH RES CO, V307, P719, DOI 10.1016/S0006-291X(03)01245-2; Kumar RK, 2004, CLIN EXP ALLERGY, V34, P567, DOI 10.1111/j.1365-2222.2004.1917.x; Lee JJ, 2004, SCIENCE, V305, P1773, DOI 10.1126/science.1099472; Lee NA, 2001, J ALLERGY CLIN IMMUN, V107, P945, DOI 10.1067/mai.2001.116002; Levi-Schaffer F, 1999, P NATL ACAD SCI USA, V96, P9660, DOI 10.1073/pnas.96.17.9660; Levi-Schaffer F, 2003, TRENDS IMMUNOL, V24, P158, DOI 10.1016/S1471-4906(03)00058-9; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Mekori YA, 1999, J ALLERGY CLIN IMMUN, V104, P517, DOI 10.1016/S0091-6749(99)70316-7; Moretta A, 2001, ANNU REV IMMUNOL, V19, P197, DOI 10.1146/annurev.immunol.19.1.197; Munitz A, 2006, BLOOD, V107, P1996, DOI 10.1182/blood-2005-07-2926; Munitz A, 2004, ALLERGY, V59, P268, DOI 10.1111/j.1398-9995.2003.00442.x; Munitz A, 2006, J IMMUNOL, V177, P77, DOI 10.4049/jimmunol.177.1.77; Puxeddu I, 2006, J ALLERGY CLIN IMMUN, V117, P103, DOI 10.1016/j.jaci.2005.08.057; Puxeddu I, 2003, INT J BIOCHEM CELL B, V35, P1601, DOI 10.1016/S1357-2725(03)00208-5; ROTHENBERG ME, 2003, ANNU REV IMMUNOL, V24, P147; Sano A, 2001, AM J PHYSIOL-LUNG C, V281, pL844, DOI 10.1152/ajplung.2001.281.4.L844; van Rijt LS, 2004, J IMMUNOL METHODS, V288, P111, DOI 10.1016/j.jim.2004.03.004; WALKER C, 1991, J ALLERGY CLIN IMMUN, V88, P935, DOI 10.1016/0091-6749(91)90251-I; Wong CK, 2002, IMMUNOPHARM IMMUNOT, V24, P165, DOI 10.1081/IPH-120003748; Youn CJ, 2004, J IMMUNOL, V173, P7556, DOI 10.4049/jimmunol.173.12.7556; Yousefi S, 1996, J EXP MED, V183, P1407, DOI 10.1084/jem.183.4.1407; Yu M, 2006, J CLIN INVEST, V116, P1633, DOI 10.1172/JCI25702	35	79	84	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2006	118	5					1082	1089		10.1016/j.jaci.2006.07.041	http://dx.doi.org/10.1016/j.jaci.2006.07.041			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	137GY	17088133				2022-12-18	WOS:000244282300013
J	Barczyk, A; Pierzchala, W; Kon, OM; Cosio, B; Adcock, IM; Barnes, PJ				Barczyk, Adam; Pierzchala, Wladyslaw; Kon, Onn M.; Cosio, Borja; Adcock, Ian M.; Barnes, Peter J.			Cytokine production by bronchoalveolar lavage T lymphocytes in chronic obstructive pulmonary disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cytokines; chronic obstructive pulmonary disease; T cells; bronchoalveolar lavage	CHRONIC-BRONCHITIS; AIRWAY EOSINOPHILIA; PERIPHERAL-BLOOD; CELL SUBSETS; INHIBIT IGE; IN-VITRO; CD8(+); INFLAMMATION; EXPRESSION; ASTHMA	Background: T lymphocytes (predominantly CD8(+) cells) have previously been implicated in the pathogenesis of chronic obstructive pulmonary disease (COPD). Objective: We sought to describe the profile of cytokine production by CD8(+) and CD4(+) cells isolated from bronchoalveolar lavage fluid. Methods: Bronchoalveolar lavage was performed in 11 patients with COPD (median FEV1, 63.3% of predicted value) and 9 healthy control subjects. CD8(+) and CD4+ T cells were isolated by means of positive selection after macrophage depletion. CD8(+) and CD4(+) cells were activated with anti-CD3/CD28 antibodies for 60 hours before restimulation with phorbol 12-myristate 13-acetate-ionomycin and brefeldin. Three-color How cytometry was used to simultaneously measure levels of intracellular cytokines. Results: IL-4 was expressed by a higher percentage of stimulated CD8(+) T cells (T(C)2) compared with CD4(+) T cells (T(H)2) in patients with COPD (P = .01). In contrast, IFN-gamma was expressed in a significantly higher percentage of stimulated CD4(+) T cells (T(H)1) than CD8(+) T cells (T(C)1) in the COPD group (P = .04). TNF-alpha was expressed by almost all T(C)1 and T(H)1 cells, with virtually no expression by T(C)2 and TH2 cells. In addition, a small number of T cells expressing TNF-alpha: alone without concomitant IFN-gamma or IL-4 expression were seen in the majority of subjects. There was a higher percentage of T(C)2 cells in subjects with COPD compared with that seen in the control group (P = .03). Stimulation with anti-CD3/CD28 antibodies increased the percentage of T(C)2 cells and decreased the percentage of T(H)2 cells. Conclusion: Our results suggest that there are increased numbers of T(C)2-like cytokine-expressing cells in the lungs of patients with COPD. Clinical implications: These cells might be a source of T(H)2 cytokines, which might, at least in part, explain the lung eosinophilia associated with COPD exacerbations.	Imperial Coll London, Natl Heart & Lung Inst, Airways Dis Sect, London SW3 6LY, England; Med Univ Silesia, Dept Pneumol, Katowice, Poland	Imperial College London; Medical University Silesia	Barnes, PJ (corresponding author), Imperial Coll London, Natl Heart & Lung Inst, Airways Dis Sect, Dovehouse St, London SW3 6LY, England.	p.j.barnes@imperial.ac.uk	G.Cosio, Borja/P-4963-2017; Barczyk, Adam/GYV-4487-2022; Adcock, Ian/L-3217-2019	G.Cosio, Borja/0000-0002-6388-8209; Barczyk, Adam/0000-0002-6567-9208; Barnes, Peter/0000-0002-5122-4018; Kon, Onn Min/0000-0003-2647-4688; Adcock, Ian/0000-0003-2101-8843				ALAM R, 2003, J ALLERGY CLIN IMM S, V11, pS476; Bocek P, 2004, J EXP MED, V199, P1619, DOI 10.1084/jem.20032014; Borish Larry C., 2003, Journal of Allergy and Clinical Immunology, V111, pS460; Brightling CE, 2002, J ALLERGY CLIN IMMUN, V110, P899, DOI 10.1067/mai.2002.129698; Cerwenka A, 1998, J IMMUNOL, V161, P97; CONSTABEL U, 1992, RESPIRATION, V59, P17; COYLE AJ, 1995, J EXP MED, V181, P1229, DOI 10.1084/jem.181.3.1229; DeJong JW, 1997, RESP MED, V91, P67, DOI 10.1016/S0954-6111(97)90070-6; Grumelli S, 2004, PLOS MED, V1, P75, DOI 10.1371/journal.pmed.0010008; Heaton T, 2005, LANCET, V365, P142, DOI 10.1016/S0140-6736(05)17704-6; Hodge SJ, 2003, AM J PHYSIOL-LUNG C, V285, pL492, DOI 10.1152/ajplung.00428.2002; Hogg JC, 2004, NEW ENGL J MED, V350, P2645, DOI 10.1056/NEJMoa032158; Holmes BJ, 1997, EUR J IMMUNOL, V27, P2657, DOI 10.1002/eji.1830271027; Isogai S, 2004, J ALLERGY CLIN IMMUN, V114, P1345, DOI 10.1016/j.jaci.2004.09.021; Kemeny DM, 1999, AM J RESP CRIT CARE, V160, pS33, DOI 10.1164/ajrccm.160.supplement_1.10; Krug N, 2001, AM J RESP CELL MOL, V25, P125, DOI 10.1165/ajrcmb.25.1.4194; LACOSTE JY, 1993, J ALLERGY CLIN IMMUN, V92, P537, DOI 10.1016/0091-6749(93)90078-T; Lim S, 2000, AM J RESP CRIT CARE, V162, P1912, DOI 10.1164/ajrccm.162.5.9909081; Lofdahl JM, 2005, EUR RESPIR J, V25, P275, DOI 10.1183/09031936.05.00033504; MAESTRELLI P, 1995, AM J RESP CRIT CARE, V152, P1926, DOI 10.1164/ajrccm.152.6.8520757; Majori M, 1999, J ALLERGY CLIN IMMUN, V103, P458, DOI 10.1016/S0091-6749(99)70471-9; Miotto D, 2003, EUR RESPIR J, V22, P602, DOI 10.1183/09031936.03.00046402; Miyahara N, 2004, J IMMUNOL, V172, P2549, DOI 10.4049/jimmunol.172.4.2549; Mueller R, 1996, RESP MED, V90, P79, DOI 10.1016/S0954-6111(96)90202-4; Nel AE, 2002, J ALLERGY CLIN IMMUN, V109, P901, DOI 10.1067/mai.2002.124965; OShaughnessy TC, 1997, AM J RESP CRIT CARE, V155, P852, DOI 10.1164/ajrccm.155.3.9117016; Panzner P, 2003, CHEST, V124, P1909, DOI 10.1378/chest.124.5.1909; Pauwels Romain A., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1256; RIISE GC, 1995, THORAX, V50, P360, DOI 10.1136/thx.50.4.360; Saetta M, 1996, CLIN EXP ALLERGY, V26, P766, DOI 10.1111/j.1365-2222.1996.tb00606.x; Saetta M, 1998, AM J RESP CRIT CARE, V157, P822, DOI 10.1164/ajrccm.157.3.9709027; SAETTA M, 1994, AM J RESP CRIT CARE, V150, P1646, DOI 10.1164/ajrccm.150.6.7952628; Saetta M, 2001, AM J RESP CRIT CARE, V163, P1304, DOI 10.1164/ajrccm.163.6.2009116; Schuler T, 2001, J EXP MED, V194, P1767, DOI 10.1084/jem.194.12.1767; Schwarze J, 1999, J IMMUNOL, V162, P4207; Sun G, 1998, EUR J CLIN INVEST, V28, P364; Thomas MJ, 2002, J IMMUNOL, V168, P216, DOI 10.4049/jimmunol.168.1.216; Vukmanovic-Stejic M, 2000, BLOOD, V95, P231; Zhu J, 2001, AM J RESP CRIT CARE, V164, P2220, DOI 10.1164/ajrccm.164.12.2009060	39	79	89	2	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2006	117	6					1484	1492		10.1016/j.jaci.2006.02.013	http://dx.doi.org/10.1016/j.jaci.2006.02.013			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	053UX	16751017				2022-12-18	WOS:000238332300044
J	Boswell-Smith, V; Cazzola, M; Page, CP				Boswell-Smith, Victoria; Cazzola, Mario; Page, Clive P.			Are phosphodiesterase 4 inhibitors just more theophylline?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						theophylline; phosphodiesterase 4 inhibitors; chronic obstructive pulmonary disease; asthma	OBSTRUCTIVE PULMONARY-DISEASE; AIRWAY EPITHELIAL-CELLS; IN-VITRO; DIFFERENTIAL REGULATION; ORAL THEOPHYLLINE; ASTHMA; ISOENZYMES; EXPRESSION; ROFLUMILAST; TARGETS	Theophylline has been relegated to a second- or even third-line therapy in the treatment of asthma and chronic obstructive pulmonary disease (COPD), behind glucocorticosteroids and beta(2)-agonists, although recent findings have suggested that theophylline possesses anti-inflammatory and immunomodulatory effects in addition to its well-recognized effects as a bronchodilator. In part, theophylline has fallen out of favor because of its adverse side-effect profile, and this has led to the search for more effective and safer drugs based on the knowledge that theophylline is orally active and that it is a nonselective phosphodiesterase (PDE) inhibitor. This has led to the development of selective PDE4 inhibitors, originally designed for depression, for the treatment of both COPD and asthma. Such drugs have shown clinical efficacy in the treatment of respiratory disease while having a considerably safer side-effect profile in comparison with theophylline, particularly because there are no reported drug interactions with PDE4 inhibitors, a feature that complicates the use of theophylline. In addition, it is also becoming increasingly apparent that theophylline is not working solely through PDE inhibition, as formerly assumed, and that this drug has other relevant pharmacologic activities that are likely to contribute to its efficacy, such as adenosine receptor antagonism and induction of histone deacetylase. Thus, the introduction of PDE4 inhibitors represents an entirely new class of drugs for the treatment of respiratory disease.	Kings Coll London, Sch Biomed Hlth & Life Sci, Sackler Inst Pulm Pharmacol, London SE1 1UL, England; Osperdale A Cardarelli, Div Pneumol & Allergol, Naples, Italy	University of London; King's College London; Antonio Cardarelli Hospital	Page, CP (corresponding author), Kings Coll London, Sch Biomed Hlth & Life Sci, Sackler Inst Pulm Pharmacol, 5th Floor,Hodgkin Bldg,Guys Campus, London SE1 1UL, England.	clive.page@kcl.ac.uk	Cazzola, Mario/G-9397-2012	Page, Clive Peter/0000-0002-9358-3799				Ariga M, 2004, J IMMUNOL, V173, P7531, DOI 10.4049/jimmunol.173.12.7531; Au BT, 1998, BRIT J PHARMACOL, V123, P1260, DOI 10.1038/sj.bjp.0701723; AUBIER M, 2003, EUR RESPIR J, V22, pA1392; Barber R, 2004, AM J PHYSIOL-LUNG C, V287, pL332, DOI 10.1152/ajplung.00384.2003; Barnes PJ, 2003, AM J RESP CRIT CARE, V167, P813, DOI 10.1164/rccm.200210-1142PP; Barnette MS, 1998, J PHARMACOL EXP THER, V284, P420; BATEMAN ED, 2003, EUR RESPIR J, V22, pA1393; BATEMAN ED, 2004, AM J RESP CRIT CARE, V169, pA596; Bennett JA, 1998, BRIT J CLIN PHARMACO, V45, P402, DOI 10.1046/j.1365-2125.1998.t01-1-00691.x; Blease K, 1998, BRIT J PHARMACOL, V124, P229, DOI 10.1038/sj.bjp.0701833; BOSZORMENYINAGY G, 2005, P AM THORAC SOC, V2, pA544; Bousquet J, 2006, ALLERGY, V61, P72, DOI 10.1111/j.1398-9995.2005.00931.x; Cortijo J, 1996, BRIT J PHARMACOL, V119, P99, DOI 10.1111/j.1476-5381.1996.tb15682.x; Draheim R, 2004, J PHARMACOL EXP THER, V308, P555, DOI 10.1124/jpet.103.059097; Engelstaetter R., 2005, ANN ALLERG ASTHMA IM, V94, P169; Essayan DM, 1997, J PHARMACOL EXP THER, V282, P505; Fuhrmann M, 1999, AM J RESP CELL MOL, V20, P292, DOI 10.1165/ajrcmb.20.2.3140; Gale DD, 2002, BRIT J CLIN PHARMACO, V54, P478, DOI 10.1046/j.1365-2125.2002.01682.x; Giembycz MA, 1996, BRIT J PHARMACOL, V118, P1945, DOI 10.1111/j.1476-5381.1996.tb15629.x; Giembycz MA, 2001, EXPERT OPIN INV DRUG, V10, P1361, DOI 10.1517/13543784.10.7.1361; Global Initiative for Asthma, 2002, NIH PUBL; *GOLD GLOB IN CHRO, 2006, NHLBI WHO WORKSH; Grootendorst DC, 2003, PULM PHARMACOL THER, V16, P115, DOI 10.1016/S1094-5539(02)00172-4; GROOTENDORST DC, 2005, P AM THORAC SOC, V2, pA543; Haddad JJ, 2002, J PHARMACOL EXP THER, V300, P559, DOI 10.1124/jpet.300.2.559; HATZELMANN A, 1995, BRIT J PHARMACOL, V114, P821, DOI 10.1111/j.1476-5381.1995.tb13278.x; Houslay MD, 2001, PROG NUCLEIC ACID RE, V69, P249, DOI 10.1016/S0079-6603(01)69049-4; *INFL PHARM, 2005, HT0712 SEL PDE4 INH; Ito K, 2002, P NATL ACAD SCI USA, V99, P8921, DOI 10.1073/pnas.132556899; Jin SLC, 2002, P NATL ACAD SCI USA, V99, P7628, DOI 10.1073/pnas.122041599; Jones NA, 2005, PULM PHARMACOL THER, V18, P93, DOI 10.1016/j.pupt.2004.10.001; JONES NA, 2006, IN PRESS PULM PHARM, DOI DOI 10.1016/4.PUPT.2005.11.010; KELLOWAY JS, 1994, ARCH INTERN MED, V154, P1349, DOI 10.1001/archinte.154.12.1349; KWAK HJ, 2005, J PHARMACOL EXP THER, V30, P98; Lamontagne S, 2001, BRAIN RES, V920, P84, DOI 10.1016/S0006-8993(01)03023-2; Lee AJ, 2005, ANN PHARMACOTHER, V39, P869, DOI 10.1345/aph.1E426; Leichtl S, 2002, AM J RESP CRIT CARE, V165, pA229; Lim S, 2000, THORAX, V55, P837, DOI 10.1136/thorax.55.10.837; Losco PE, 2004, TOXICOL PATHOL, V32, P295, DOI 10.1080/01926230490431493; Martorana PA, 2005, AM J RESP CRIT CARE, V172, P848, DOI 10.1164/rccm.200411-1549OC; Mata M, 2005, THORAX, V60, P144, DOI 10.1136/thx.2004.025692; Mecklenburg L, 2006, TOXICOL LETT, V163, P54, DOI 10.1016/j.toxlet.2005.09.037; Muller T, 1996, TRENDS PHARMACOL SCI, V17, P294, DOI 10.1016/0165-6147(96)10035-3; NICHOLSON CD, 1994, PULM PHARMACOL THER, V7, P1; Rabe KF, 2005, LANCET, V366, P563, DOI 10.1016/S0140-6736(05)67100-0; Rennard SI, 2006, CHEST, V129, P56, DOI 10.1378/chest.129.1.56; Robichaud A, 2002, J CLIN INVEST, V110, P1045, DOI 10.1172/JCI200215506; SCHUDT C, 1995, EUR RESPIR J, V8, P1179, DOI 10.1183/09031936.95.08071179; SELDON PM, 1995, MOL PHARMACOL, V48, P747; Shapiro SD, 2002, BIOCHEM SOC T, V30, P98, DOI 10.1042/BST0300098; Siegmund B, 1997, EUR J PHARMACOL, V321, P231, DOI 10.1016/S0014-2999(96)00947-8; Souness JE, 1997, CELL SIGNAL, V9, P227, DOI 10.1016/S0898-6568(96)00173-8; SPINA D, 1995, BRIT J PHARMACOL, V116, P2334, DOI 10.1111/j.1476-5381.1995.tb15074.x; Spoelstra FM, 1998, EUR RESPIR J, V12, P585, DOI 10.1183/09031936.98.12030585; SULLIVAN P, 1994, LANCET, V343, P1006, DOI 10.1016/S0140-6736(94)90127-9; TANG HF, 2006, BIOCHIM BIOPHYS ACTA, DOI DOI 10.1016/4.BBAD2S.2005.12.009; Tenor H, 1996, BRIT J PHARMACOL, V118, P1727, DOI 10.1111/j.1476-5381.1996.tb15598.x; Torphy TJ, 1998, AM J RESP CRIT CARE, V157, P351, DOI 10.1164/ajrccm.157.2.9708012; Trifilieff A, 2002, J PHARMACOL EXP THER, V301, P241, DOI 10.1124/jpet.301.1.241; Uckert S, 2001, WORLD J UROL, V19, P14, DOI 10.1007/PL00007090; Ukena D, 1997, EUR RESPIR J, V10, P2754, DOI 10.1183/09031936.97.10122754; VAKKALANKA SKV, 2004, EUR RESPIR J, V24, P1391; van Schalkwyk E, 2005, J ALLERGY CLIN IMMUN, V116, P292, DOI 10.1016/j.jaci.2005.04.023; Yasui K, 2000, J LEUKOCYTE BIOL, V67, P529, DOI 10.1002/jlb.67.4.529; Yoshimura T, 1998, GEN PHARMACOL-VASC S, V30, P175, DOI 10.1016/S0306-3623(97)00103-1	65	79	90	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2006	117	6					1237	1243		10.1016/j.jaci.2006.02.045	http://dx.doi.org/10.1016/j.jaci.2006.02.045			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	053UX	16750981				2022-12-18	WOS:000238332300006
J	Ong, YE; Menzies-Gow, A; Barkans, J; Benyahia, F; Ou, TT; Ying, S; Kay, AB				Ong, YE; Menzies-Gow, A; Barkans, J; Benyahia, F; Ou, TT; Ying, S; Kay, AB			Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Fc epsilon RI; eosinophils; allergy; must cells; T cells; omalizumab	FC-EPSILON-RI; HUMANIZED MONOCLONAL-ANTIBODY; CUTANEOUS RESPONSES; TISSUE EOSINOPHILIA; CYTOKINE PRODUCTION; LYMPHOCYTES-T; EXPRESSION; EOTAXIN; BASOPHILS; ASTHMA	Background: Anti-IgE (omalizumab) inhibited early and late asthmatic reactions and infiltration of inflammatory cells in asthmatic bronchial biopsies at baseline. The effect of chronic allergen exposure on these outcomes is unknown. Repeat allergen challenge in human skin represents a suitable model to address this question. Objective: To study the effect of anti-IgE (omalizumab) on early-phase (EPR) and late-phase (LPR) skin reactions and cellular infiltration by using a repeat skin allergen challenge designed to imitate chronic allergen exposure. Methods: Twenty-four atopic allergic volunteers received omalizumab or placebo for 12 weeks. Paired intradermal challenges of allergen (30 biological units) and diluent control were administered on 9 occasions at 2-week intervals. Early-phase and late-phase skin reactions and cellular infiltration in skin biopsies (using immunohistochemistry and in situ hybridization) were measured at intervals. Results: Compared with placebo, omalizumab-treated patients had a progressive reduction in the LPR that was significantly greater than its effect on the EPR (median, -63% vs -24% respectively; P = .009). In addition, significant reduction of the LPR was reached within 2 weeks of commencing treatment, compared with 8 weeks for the EPR. There was a priming effect of repeated allergen challenge on infiltration of eosinophil, neutrophil, T(H)2 (CD3(+)/IL-4(+)), and total Fc epsilon RI+ cells in patients on placebo that was abrogated in those receiving omalizumab. Conclusion: The more marked effect of omalizumab on the LPR and prevention of the repeat-dose priming effect on several inflammatory cell types support a role for anti-IgE treatment in conditions associated with chronic allergic inflammation.	Univ London Imperial Coll Sci Technol & Med, Dept Allergy & Clin Immunol, Leukocyte Biol Sect, Natl Heart & Lung Inst, London SW7 2AZ, England; Guys Hosp, Guys Kings & St Thomas Sch Med, Dept Asthma Allergy & Resp Sci, London, England	Imperial College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Kay, AB (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Allergy & Clin Immunol, Leukocyte Biol Sect, Natl Heart & Lung Inst, Room 374,Sir Alexander Fleming Bldg,S Kensington, London SW7 2AZ, England.	a.b.kay@imperial.ac.uk						AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; Beck LA, 2004, J ALLERGY CLIN IMMUN, V114, P527, DOI 10.1016/j.jaci.2004.06.032; BRUINWELLER MS, 1999, CLIN EXP ALLERGY, V29, P159; Busse W, 2001, J ALLERGY CLIN IMMUN, V108, P184, DOI 10.1067/mai.2001.117880; Casale TB, 1997, J ALLERGY CLIN IMMUN, V100, P110, DOI 10.1016/S0091-6749(97)70202-1; Coyle AJ, 1996, J EXP MED, V183, P1303, DOI 10.1084/jem.183.4.1303; Djukanovic R, 2004, AM J RESP CRIT CARE, V170, P583, DOI 10.1164/rccm.200312-1651OC; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; Fahy JV, 1997, AM J RESP CRIT CARE, V155, P1828, DOI 10.1164/ajrccm.155.6.9196082; Flood-Page P, 2003, J CLIN INVEST, V112, P1029, DOI 10.1172/JCI200317974; FREW AJ, 1990, J ALLERGY CLIN IMMUN, V85, P533, DOI 10.1016/0091-6749(90)90090-Q; Haselden BM, 1999, J EXP MED, V189, P1885, DOI 10.1084/jem.189.12.1885; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; MacGlashan DW, 1997, J IMMUNOL, V158, P1438; Menzies-Gow A, 2002, J IMMUNOL, V169, P2712, DOI 10.4049/jimmunol.169.5.2712; Menzies-Gow A, 2004, CLIN EXP ALLERGY, V34, P1276, DOI 10.1111/j.1365-2222.2004.02014.x; Milgrom H, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.2.e36; Oldfield WLG, 2002, LANCET, V360, P47, DOI 10.1016/S0140-6736(02)09332-7; Palframan RT, 1998, BLOOD, V91, P2240, DOI 10.1182/blood.V91.7.2240.2240_2240_2248; Phipps S, 2002, J IMMUNOL, V169, P4604, DOI 10.4049/jimmunol.169.8.4604; PICKER LJ, 1993, J IMMUNOL, V150, P1122; Prussin C, 2003, J ALLERGY CLIN IMMUN, V112, P1147, DOI 10.1016/j.jaci.2003.10.003; RISKE F, 1991, J BIOL CHEM, V266, P11245; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; Stingl G, 1997, INT ARCH ALLERGY IMM, V113, P24, DOI 10.1159/000237499; VARNEY VA, 1993, J CLIN INVEST, V92, P644, DOI 10.1172/JCI116633; Ying S, 1999, J IMMUNOL, V163, P3976; YING S, 2002, ACI INT, V14, P64	28	79	84	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2005	116	3					558	564		10.1016/j.jaci.2005.05.035	http://dx.doi.org/10.1016/j.jaci.2005.05.035			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IE	16159624				2022-12-18	WOS:000235686500014
J	Corrigan, C; Mallett, K; Ying, S; Roberts, D; Parikh, A; Scadding, G; Lee, T				Corrigan, C; Mallett, K; Ying, S; Roberts, D; Parikh, A; Scadding, G; Lee, T			Expression of the cysteinyl leukotriene receptors cysLT(1) and cysLT(2) in aspirin-sensitive and aspirin-tolerant chronic rhinosinusitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						rhinosinusitis; aspirin; cysteinyl leukotriene; cysLT reccptor	INFLAMMATORY CELL-POPULATIONS; ASTHMATIC SUBJECTS; BRONCHIAL BIOPSIES; NASAL PROVOCATION; ALLERGIC RHINITIS; LYSINE-ASPIRIN; C-4 SYNTHASE; CHALLENGE; THERAPY; MONTELUKAST	Background: Cysteinyl leukotrienes play a disease-regulating role in rhinosinusitis and asthma, particularly aspirin-sensitive disease. They act through 2 G-protein coupled receptors termed cysteinyl leukotriene type 1 receptor (cysLT(1)) and cysteinyl leukotriene type 2 receptor (cysLT(2)). We previously compared expression of cysLT(1) on mucosal leukocytes in patients with aspirin-sensitive and aspirin-tolerant rhinosinusitis. Objective: To compare expression of cysLT(1) and cysLT(2) on leukocytes, mucus glands, and epithelium in 32 patients with chronic polypoid rhinosinusitis (21 aspirin-sensitive, 11 aspirin-tolerant) and 9 normal controls. Methods: Total numbers of CD45(+) leukocytes, percentages of these cells expressing cysLT(1) or cysLT(2), and percentages of the total epithelial and glandular areas expressing cysLT(1) or cysLT(2) were measured in sections of nasal biopsies by using immunohistochemistry and image analysis. Results: The percentages of mucosal CD45(+) leukocytes expressing cysLT(1) were significantly (P < .0001) elevated in the aspirin-sensitive but not the aspirin-tolerant patients compared with the controls. In contrast, the percentages of leukocytes expressing cysLT(2) did not differ significantly in the 3 groups. On epithelial and glandular cells, expression of cysLT(2) significantly exceeded that of cysLT(1) in both the patients With rhinosinusitis and the controls (P less than or equal to .004), although there was no significant difference in the expression of either receptor in the patients with rhinosinusitis (aspirin-sensitive or aspirin-tolerant) and the controls. Conclusion: Although cysLT(1) expression predominates on inflammatory leukocytes in patients with aspirin-sensitive rhinosinusitis, the effects of cysteinyl leukotrienes on glands and epithelium may be mediated predominantly through cysLT(2). This has potentially important therapeutic implications.	Univ London Kings Coll, Guys & St Thomas Hosp, Sch Med, Dept Asthma Allergy & Resp Sci, London SE1 9RT, England; Univ London Kings Coll, Guys & St Thomas Hosp, Sch Med, Dept Otorhinolaryngol, London SE1 9RT, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Corrigan, C (corresponding author), Univ London Kings Coll, Guys & St Thomas Hosp, Sch Med, Dept Asthma Allergy & Resp Sci, 5th Floor,Thomas Guy House, London SE1 9RT, England.	chris.corrigan@kcl.ac.uk	Lee, Tak/AAA-9526-2020	Lee, Tak/0000-0002-7554-4059; Corrigan, Chris/0000-0002-0706-6534				Arango P, 2002, OTOLARYNG HEAD NECK, V127, P512, DOI 10.1067/mhn.2002.129858; ARM JP, 1989, AM REV RESPIR DIS, V140, P148, DOI 10.1164/ajrccm/140.1.148; Beller TC, 2004, P NATL ACAD SCI USA, V101, P3047, DOI 10.1073/pnas.0400235101; Borish L, 2002, ANN ALLERG ASTHMA IM, V88, P16, DOI 10.1016/S1081-1206(10)62024-8; Calhoun William J., 2001, Current Opinion in Pharmacology, V1, P230, DOI 10.1016/S1471-4892(01)00041-8; CHRISTIE PE, 1992, AM REV RESPIR DIS, V146, P1531, DOI 10.1164/ajrccm/146.6.1531; Cowburn AS, 1998, J CLIN INVEST, V101, P834, DOI 10.1172/JCI620; Dahlen B, 1998, AM J RESP CRIT CARE, V157, P1187, DOI 10.1164/ajrccm.157.4.9707089; Figueroa DJ, 2003, CLIN EXP ALLERGY, V33, P1380, DOI 10.1046/j.1365-2222.2003.01786.x; Fregonese L, 2002, CLIN EXP ALLERGY, V32, P745, DOI 10.1046/j.1365-2222.2002.01384.x; Gauvreau GM, 2001, AM J RESP CRIT CARE, V164, P1495, DOI 10.1164/ajrccm.164.8.2102033; Greenberger PA, 2003, ALLERGY ASTHMA PROC, V24, P403; Heise CE, 2000, J BIOL CHEM, V275, P30531, DOI 10.1074/jbc.M003490200; Lynch KR, 1999, NATURE, V399, P789; Mellor EA, 2003, P NATL ACAD SCI USA, V100, P11589, DOI 10.1073/pnas.2034927100; Milewski M, 1998, J ALLERGY CLIN IMMUN, V101, P581, DOI 10.1016/S0091-6749(98)70163-0; Nagata M, 2002, J ALLERGY CLIN IMMUN, V109, P676, DOI 10.1067/mai.2002.122841; Nasser S, 1996, THORAX, V51, P64, DOI 10.1136/thx.51.1.64; Nasser SMS, 1996, AM J RESP CRIT CARE, V153, P90, DOI 10.1164/ajrccm.153.1.8542168; ORTOLANI C, 1987, ANN ALLERGY, V59, P106; Pizzichini E, 1999, EUR RESPIR J, V14, P12, DOI 10.1034/j.1399-3003.1999.14a04.x; Sanak M, 1997, LANCET, V350, P1599, DOI 10.1016/S0140-6736(05)64015-9; SLADEK K, 1994, AM J RESP CRIT CARE, V149, P940, DOI 10.1164/ajrccm.149.4.8143059; Sont JK, 2003, AM J RESP CRIT CARE, V167, P1496, DOI 10.1164/rccm.2205003; Sousa AR, 1997, AM J RESP CRIT CARE, V156, P1384, DOI 10.1164/ajrccm.156.5.9702072; Sousa AR, 2002, NEW ENGL J MED, V347, P1493, DOI 10.1056/NEJMoa013508; Stevenson DD, 2000, ANN ALLERG ASTHMA IM, V85, P477, DOI 10.1016/S1081-1206(10)62575-6; Swierczynska M, 2003, J ALLERGY CLIN IMMUN, V112, P995, DOI 10.1016/S0091-6749(03)02015-3; Thivierge M, 2000, J IMMUNOL, V165, P5221, DOI 10.4049/jimmunol.165.9.5221; Thivierge M, 2001, J IMMUNOL, V167, P2855, DOI 10.4049/jimmunol.167.5.2855; Ueda T, 2003, ANN OTO RHINOL LARYN, V112, P955, DOI 10.1177/000348940311201107; Varga EM, 1999, EUR RESPIR J, V14, P610, DOI 10.1034/j.1399-3003.1999.14c21.x; Wilson AM, 2001, RHINOLOGY, V39, P142	33	79	82	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2005	115	2					316	322		10.1016/j.jaci.2004.10.051	http://dx.doi.org/10.1016/j.jaci.2004.10.051			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	897YU	15696087				2022-12-18	WOS:000227043600016
J	Kim, YJ; Prussin, C; Martin, B; Law, MA; Haverty, TP; Nutman, TB; Klion, AD				Kim, YJ; Prussin, C; Martin, B; Law, MA; Haverty, TP; Nutman, TB; Klion, AD			Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti-IL-5 antibody SCH55700	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						anti-IL-5; hypereosinophilic syndrome; eosinophilic gastroenteritis; monoclonal antibody; eosinophil	ANTI-INTERLEUKIN-5 ANTIBODY; HUMAN INTERLEUKIN-5; BLOOD EOSINOPHILS; IMATINIB MESYLATE; RECEPTOR-ALPHA; IL-5; EFFICACY; THERAPY; MUCOSA; ASTHMA	Background: Hypereosinophilic syndrome and eosinophilic gastroenteritis with peripheral eosinophilia are characterized by sustained eosinophilia and eosinophil-mediated tissue damage. Although treatment with the humanized monoclonal anti-IL-5 antibody SCH55700 resulted in improvement of eosinophilia and clinical symptoms in 6 of 8 of patients with hypereosinophilic syndrome or eosinophilic gastroenteritis with peripheral eosinophilia for as long as 12 weeks, eosinophil counts subsequently rose above baseline levels, accompanied by an exacerbation of symptoms. Objective: To identify the mechanism underlying this rebound eosinophilia. Methods: Purified eosinophils from patients or normal donors were cultured with IL-5, patient serum, and/or anticytokine antibodies, and eosinophil survival was assessed by flow cytometry. Serum and intracellular cytokine levels were measured by multiplex sandwich ELISA and flow cytometry, respectively. Results: Before treatment with SCH55700, in vitro eosinophil survival in media and in response to recombinant IL-5 was similar in patients and normal donors. At 1 month posttreatment, the eosinophil survival curves were unchanged in 4 of 5 patients in media and in all 5 patients in response to recombinant IL-5. Normal eosinophil survival was prolonged in cultures containing posttreatment but not pretreatment sera (pretreatment vs posttreatment, 10.74% vs 73.02% live cells; P = .01). This posttreatment serum effect on eosinophil survival was reversed by the addition of the monoclonal anti-IL-5 antibody TRFK5. Although increased levels of serum IL-5 were observed at 1 month compared with 2 to 3 days posttreatment in 5 of 6 patients (P =.04), intracellular cytokine analysis did not reveal increased production of IL-5 by peripheral blood mononuclear cells. Conclusions: The rebound eosinophilia after SCH55700 treatment is a result of a serum factor that enhances eosinophil survival. Reversal of this effect by the addition of antibody to IL-5 suggests that this factor may be IL-5 itself.	NIAID, Parasit Dis Lab, NIH, Bethesda, MD 20892 USA; NIAID, Lab Allerg Dis, NIH, Bethesda, MD 20892 USA; Schering Plough Corp, Inst Res, Kenilworth, NJ 07033 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Merck & Company; Schering Plough Corporation	Klion, AD (corresponding author), NIAID, Parasit Dis Lab, NIH, Bldg 4,Room B1-05,9000 Rockville Pike, Bethesda, MD 20892 USA.	aklion@niaid.nih.gov		Klion, Amy/0000-0002-4986-5326; Prussin, Calman/0000-0002-3917-3326	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000439, Z01AI000805, ZIAAI000761, ZIAAI000805, ZIAAI000439, Z01AI000761] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ault P, 2002, LEUKEMIA RES, V26, P881, DOI 10.1016/S0145-2126(02)00046-2; BRADDING P, 1993, J IMMUNOL, V151, P3853; BUTTERFIELD JH, 1994, J ALLERGY CLIN IMMUN, V94, P1318, DOI 10.1016/0091-6749(94)90348-4; CHUSID MJ, 1975, MEDICINE, V54, P1, DOI 10.1097/00005792-197501000-00001; Cools J, 2003, NEW ENGL J MED, V348, P1201, DOI 10.1056/NEJMoa025217; Cortes J, 2003, BLOOD, V101, P4714, DOI 10.1182/blood-2003-01-0081; Egan RW, 1999, ARZNEIMITTEL-FORSCH, V49, P779; ENOKIHARA H, 1989, BLOOD, V73, P1809; Finkelman FD, 1999, INT IMMUNOL, V11, P1811, DOI 10.1093/intimm/11.11.1811; HANSEL TT, 1991, J IMMUNOL METHODS, V145, P105, DOI 10.1016/0022-1759(91)90315-7; Hellman C, 2003, CLIN EXP IMMUNOL, V131, P75, DOI 10.1046/j.1365-2249.2003.02051.x; Kelly KJ, 2000, J PEDIATR GASTR NUTR, V30, pS28, DOI 10.1097/00005176-200001001-00005; Kips JC, 2003, AM J RESP CRIT CARE, V167, P1655, DOI 10.1164/rccm.200206-525OC; Klion AD, 2004, BLOOD, V103, P2939, DOI 10.1182/blood-2003-10-3620; Klion AD, 2003, BLOOD, V101, P4660, DOI 10.1182/blood-2003-01-0006; Lee M, 1996, SOUTHERN MED J, V89, P189, DOI 10.1097/00007611-199602000-00006; Liu LY, 2002, J IMMUNOL, V169, P6459, DOI 10.4049/jimmunol.169.11.6459; Menzies-Gow A, 2003, J ALLERGY CLIN IMMUN, V111, P714, DOI 10.1067/mai.2003.1382; Pardanani A, 2003, BLOOD, V101, P3391, DOI 10.1182/blood-2002-10-3103; Parrillo J E, 1977, Trans Assoc Am Physicians, V90, P135; Plotz S, 2003, NEW ENGL J MED, V349, P2334, DOI 10.1056/NEJMoa031261; Prussin C., 2003, Journal of Allergy and Clinical Immunology, V111, pS275, DOI 10.1016/S0091-6749(03)80986-7; WALKER C, 1991, J IMMUNOL, V146, P1829; Zabeau L, 2001, EUR J IMMUNOL, V31, P1087, DOI 10.1002/1521-4141(200104)31:4<1087::AID-IMMU1087>3.0.CO;2-Q	24	79	93	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2004	114	6					1449	1455		10.1016/j.jaci.2004.08.027	http://dx.doi.org/10.1016/j.jaci.2004.08.027			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	877NN	15577851				2022-12-18	WOS:000225577400030
J	Sanders, SP; Proud, D; Permutt, S; Siekierski, ES; Yachechko, R; Liu, MC				Sanders, SP; Proud, D; Permutt, S; Siekierski, ES; Yachechko, R; Liu, MC			Role of nasal nitric oxide in the resolution of experimental rhinovirus infection	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						rhinovirus; common cold; asthma; epithelial cells; inducible nitric oxide synthase; nitric oxide; host defense	ASTHMATIC SUBJECTS; LOWER AIRWAYS; PARANASAL SINUSES; EPITHELIAL-CELLS; IN-VIVO; COLDS; REPLICATION; HYPERRESPONSIVENESS; INTERLEUKIN-8; VOLUNTEERS	Background: Human rhinovirus (HRV) infections are associated with exacerbations of asthma, chronic obstructive pulmonary disease, and sinusitis. Nitric oxide (NO) might play an important role in host defense through its potent antiviral properties. Previous studies have shown that HRV infection in human subjects increased nasal epithelial expression of type 2 nitric oxide synthase (NOS2), an isoform of the enzyme that produces NO. Objective: We sought to investigate whether increases in exhaled NO (eNO) would accompany the increased NOS2 expression and would be associated with clearance of the virus. Methods: Six human subjects were infected with HRV-16 intranasally. eNO from nasal and lower airways was measured by means of direct measurement at multiple controlled How rates. eNO was monitored at baseline (day 1) and on days 2 to 5, 8, 14, and 42 after infection. Nasal lavages were performed on days 1 to 5 and 8, and nasal scrapings were performed on days 1 to 4. NOS2 mRNA expression in nasal cells was measured by using quantitative real-time RT-PCR. Viral shedding in nasal la age fluid was monitored by using real-time RT-PCR and bioassay. Results: Peak HRV titers and symptom scores were correlated on day 3, and HRV persisted until day 5 (n = 4) or day 8 (n = 2). Infection was associated with transient but significant increases in lymphocytes and monocytes in nasal lavage fluid. Significant increases in both nasal and lower airway eNO concentrations accompanied HRV infection and were positively correlated. Increased nasal eNO concentrations on day 3 were associated with increased expression of NOS2 mRNA in nasal scrapings. Symptom scores on day 4 were inversely correlated with the increases in nasal eNO concentration. Conclusions: We conclude that increased production of NO occurs as part of the host response to HRV infection and speculate that NO plays a beneficial role in viral clearance.	Johns Hopkins Univ, Sch Med, Dept Med, Div Pulm, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Med, Div Crit Care Med, Baltimore, MD 21205 USA; Univ Calgary, Resp Res Grp, Calgary, AB, Canada	Johns Hopkins University; Johns Hopkins University; University of Calgary	Sanders, SP (corresponding author), Johns Hopkins Asthma & Allergy Ctr, Div Clin Immunol, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.				NHLBI NIH HHS [HL 61011] Funding Source: Medline; NIAID NIH HHS [AI 37163] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061011] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI037163] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; ALVING K, 1993, EUR RESPIR J, V6, P1368; de Gouw HWFM, 1998, EUR RESPIR J, V11, P126, DOI 10.1183/09031936.98.11010126; Fleming HE, 1999, AM J RESP CRIT CARE, V160, P100, DOI 10.1164/ajrccm.160.1.9808074; FRAENKEL DJ, 1995, AM J RESP CRIT CARE, V151, P879; Gentile DA, 2002, ACTA OTO-LARYNGOL, V122, P61, DOI 10.1080/00016480252775751; Gern JE, 1997, AM J RESP CRIT CARE, V155, P1159, DOI 10.1164/ajrccm.155.3.9117003; Grunberg K, 1997, CLIN EXP ALLERGY, V27, P36, DOI 10.1111/j.1365-2222.1997.tb00670.x; GWALTNEY JM, 1992, PROG MED VIROL, V39, P256; GWALTNEY JM, 1967, J AMER MED ASSOC, V202, P494, DOI 10.1001/jama.202.6.494; Kaul P, 1999, AM J RESP CRIT CARE, V159, P1193, DOI 10.1164/ajrccm.159.4.9808043; KHARITONOV SA, 1995, EUR RESPIR J, V8, P295, DOI 10.1183/09031936.95.08020295; KNIGHT V, 1964, PROG MED VIROL, V6, P1; LUNDBERG JON, 1995, NAT MED, V1, P370, DOI 10.1038/nm0495-370; LUNDBERG JON, 1994, ACTA PHYSIOL SCAND, V152, P431, DOI 10.1111/j.1748-1716.1994.tb09826.x; Mannick JB, 1999, J ACQ IMMUN DEF SYND, V22, P1, DOI 10.1097/00042560-199909010-00001; Matthews DA, 1999, P NATL ACAD SCI USA, V96, P11000, DOI 10.1073/pnas.96.20.11000; Murphy AW, 1998, CHEST, V114, P452, DOI 10.1378/chest.114.2.452; Papadopoulos NG, 1999, J MED VIROL, V58, P100, DOI 10.1002/(SICI)1096-9071(199905)58:1&lt;100::AID-JMV16&gt;3.0.CO;2-D; Papadopoulos NG, 2000, J INFECT DIS, V181, P1875, DOI 10.1086/315513; PROUD D, 1994, J INFECT DIS, V169, P1007, DOI 10.1093/infdis/169.5.1007; Sanders SP, 1998, J VIROL, V72, P934, DOI 10.1128/JVI.72.2.934-942.1998; Sanders SP, 2001, J ALLERGY CLIN IMMUN, V107, P235, DOI 10.1067/mai.2001.112028; Sanders SP, 2001, AM J RESP CELL MOL, V24, P317, DOI 10.1165/ajrcmb.24.3.4131; Saura M, 1999, IMMUNITY, V10, P21, DOI 10.1016/S1074-7613(00)80003-5; Silkoff PE, 2000, AM J RESP CRIT CARE, V161, P1218, DOI 10.1164/ajrccm.161.4.9903111; Skoner DP, 1996, EUR RESPIR J, V9, P1402, DOI 10.1183/09031936.96.09071402; Slutsky AS, 1999, AM J RESP CRIT CARE, V160, P2104; Togias A, 2003, J ALLERGY CLIN IMMUN, V111, P1171, DOI 10.1067/mai.2003.1592; Turner RB, 2001, ANTIVIR RES, V49, P1, DOI 10.1016/S0166-3542(00)00135-2; TYRRELL DAJ, 1993, EPIDEMIOL INFECT, V111, P143, DOI 10.1017/S0950268800056764; Wu GY, 2002, ANNU REV NUTR, V22, P61, DOI 10.1146/annurev.nutr.22.110901.145329	32	79	87	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2004	113	4					697	702		10.1016/j.jaci.2004.01.755	http://dx.doi.org/10.1016/j.jaci.2004.01.755			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	814DY	15100676	Bronze			2022-12-18	WOS:000220956600018
J	von Mutius, E				von Mutius, E			Influences in allergy: Epidemiology and the environment	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						epidemiology; asthma; allergic diseases	DAY-CARE ATTENDANCE; HAY-FEVER; LUNG-FUNCTION; CHILDHOOD ASTHMA; ATOPIC ECZEMA; RISK-FACTORS; BIRTH-ORDER; SCHOOL-AGE; EARLY-LIFE; CHILDREN	Many decades after the first descriptions of hay fever in the 19th century, we still struggle with the formation of a cogent conception embracing all the many fragments of insight into the various aspects of allergic and asthmatic diseases. Although in daily practice we can grasp and allocate most of the clinical manifestations, in research the fundamental structures are only in part recognized. We therefore presume that the underlying mechanisms are complex and multifaceted. We have explored in countless directions while branching into ever more detailed analyses of phenomena, all of which are associated with the conditions of interest. But how can we rearrange these pieces to advance toward a broader understanding of asthma and allergies? Epidemiology as a scientific tool to study the occurrence, the natural course, and the determinants of a condition in various sociocultural environments might contribute to the edifice of such a scaffold. This review does not intend to present a comprehensive digest of the relevant literature: the reader can refer to other "state of the art" reviews. The intention is to discuss some conceptual cornerstones and to illustrate them with a few examples.	Univ Munich, Childrens Hosp, D-80337 Munich, Germany	University of Munich	von Mutius, E (corresponding author), Univ Munich, Childrens Hosp, Lindwurmstr 4, D-80337 Munich, Germany.			von Mutius, Erika/0000-0002-8893-4515				Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; Beasley R, 2000, J ALLERGY CLIN IMMUN, V105, pS466, DOI 10.1016/S0091-6749(00)90044-7; BRANTLY M, 1988, AM J MED, V84, P13; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28, DOI 10.1046/j.1365-2222.1999.00479.x; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; BRAUNFAHRLANDER C, 2004, IN PRESS EUR RESP J; BRUCE RM, 1984, AM REV RESPIR DIS, V130, P386; Celedon JC, 2003, AM J RESP CRIT CARE, V167, P1239, DOI 10.1164/rccm.200209-1063OC; Chinn S, 2001, THORAX, V56, P845, DOI 10.1136/thorax.56.11.845; Corbo GM, 2003, THORAX, V58, P237, DOI 10.1136/thorax.58.3.237; DUFF AL, 1993, PEDIATRICS, V92, P535; DUFFY DL, 1990, AM REV RESPIR DIS, V142, P1351, DOI 10.1164/ajrccm/142.6_Pt_1.1351; EDER W, UNPUB J ALLERGY CLIN; EDFORSLUBS ML, 1971, ACTA ALLERGOL, V26, P249, DOI 10.1111/j.1398-9995.1971.tb01300.x; FRISCHER T, 1993, EUR J PEDIATR, V152, P771, DOI 10.1007/BF01954000; Gadek J., 1982, METABOLIC BASIS INHE, P1450; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; HOPP RJ, 1984, J ALLERGY CLIN IMMUN, V73, P265, DOI 10.1016/S0091-6749(84)80018-4; Howard TD, 2002, AM J HUM GENET, V70, P230, DOI 10.1086/338242; Illi S, 2001, BMJ-BRIT MED J, V322, P390, DOI 10.1136/bmj.322.7283.390; Jones CA, 2002, PEDIAT ALLERG IMM-UK, V13, P19, DOI 10.1034/j.1399-3038.13.s.15.6.x; Kabesch M, 2004, CLIN EXP ALLERGY, V34, P340, DOI 10.1111/j.1365-2222.2004.01860.x; KABESCH M, 2000, SERIES LUNG BIOL HLT, P63; Kramer U, 1999, LANCET, V353, P450, DOI 10.1016/S0140-6736(98)06329-6; Kulig M, 2000, J ALLERGY CLIN IMMUN, V106, P832, DOI 10.1067/mai.2000.110098; Marbury MC, 1997, AM J RESP CRIT CARE, V155, P156, DOI 10.1164/ajrccm.155.1.9001305; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MARTINEZ FD, 2002, CHILDHOOD ASTHMA OTH, P29; Matricardi PM, 2000, BMJ-BRIT MED J, V320, P412, DOI 10.1136/bmj.320.7232.412; Matricardi PM, 1998, J ALLERGY CLIN IMMUN, V101, P439, DOI 10.1016/S0091-6749(98)70350-1; Matricardi PM, 2002, J ALLERGY CLIN IMMUN, V110, P381, DOI 10.1067/mai.2002.126658; McKeever TM, 2001, THORAX, V56, P758, DOI 10.1136/thorax.56.10.758; Morgan K, 1997, INT J BIOCHEM CELL B, V29, P1501, DOI 10.1016/S1357-2725(97)00118-0; Nafstad P, 1999, PEDIATRICS, V103, P753, DOI 10.1542/peds.103.4.753; OWNBY DR, 1990, J ALLERGY CLIN IMMUN, V86, P279, DOI 10.1016/S0091-6749(05)80088-0; Pearce N, 1999, THORAX, V54, P268, DOI 10.1136/thx.54.3.268; Rakes CP, 1999, AM J RESP CRIT CARE, V159, P785, DOI 10.1164/ajrccm.159.3.9801052; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194, DOI 10.1046/j.1365-2222.2000.00799.x; Ronchetti R, 2001, EUR RESPIR J, V17, P881, DOI 10.1183/09031936.01.17508810; ROTHMAN KJ, 1998, MODERN EPIDEMIOLOGY, P524; Rullo VEV, 2002, J ALLERGY CLIN IMMUN, V110, P582, DOI 10.1067/mai.2002.127511; Schafer T, 2000, BRIT J DERMATOL, V143, P992, DOI 10.1046/j.1365-2133.2000.03832.x; SHERMAN CB, 1990, AM J EPIDEMIOL, V132, P83, DOI 10.1093/oxfordjournals.aje.a115646; SIBBALD B, 1980, ARCH DIS CHILD, V55, P354, DOI 10.1136/adc.55.5.354; Song BJ, 2003, CURR OPIN ALLERGY CL, V3, P331, DOI 10.1097/01.all.0000092601.76804.76; *STAT BUND DEUTSCH, 2003, STAT INF; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Sunyer J, 1999, EUR RESPIR J, V14, P885, DOI 10.1034/j.1399-3003.1999.14d26.x; TARJAN E, 1994, EUR RESPIR J, V7, P2199, DOI 10.1183/09031936.94.07122199; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187, DOI 10.1046/j.1365-2222.2000.00801.x; von Ehrenstein OS, 2002, EUR RESPIR J, V19, P1099, DOI 10.1183/09031936.02.00104302; von Mutius E, 2002, ATOPIC DERMATITIS, P111; von Mutius E, 1998, CLIN EXP ALLERGY, V28, P1454; Weiland SK, 1999, EUR RESPIR J, V14, P862, DOI 10.1034/j.1399-3003.1999.14d23.x; Williams H, 1999, J ALLERGY CLIN IMMUN, V103, P125, DOI 10.1016/S0091-6749(99)70536-1; WRIGHT AL, 1989, BRIT MED J, V299, P946, DOI 10.1136/bmj.299.6705.946; YUNGINGER JW, 1992, AM REV RESPIR DIS, V146, P888, DOI 10.1164/ajrccm/146.4.888	58	79	83	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2004	113	3					373	379		10.1016/j.jaci.2003.12.040	http://dx.doi.org/10.1016/j.jaci.2003.12.040			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	802DM	15007331	Bronze			2022-12-18	WOS:000220144200001
J	Rosenwasser, LJ; Busse, WW; Lizambri, RG; Olejnik, TA; Totoritis, MC				Rosenwasser, LJ; Busse, WW; Lizambri, RG; Olejnik, TA; Totoritis, MC			Allergic asthma and an anti-CD23 mAb (IDEC-152): Results of a phase I, singledose, dose-escalating clinical trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; asthma; B cells; CD23; IDEC-152; IgE; monoclonal antibody	AFFINITY IGE RECEPTOR; HUMAN-LYMPHOCYTE RECEPTOR; CYTOKINE PRODUCTION; B-CELLS; CD23; EXPRESSION; INHIBITION; INDUCTION; ANTIGEN	Background: CD23, a cell-surface molecule, is involved in a variety of pathways likely to influence IgE production and inflammation in allergic disorders, such as allergic rhinitis and allergic asthma. Objective: This study investigated the safety, clinical activity, and pharmacokinetic profile of IDEC-152, an IgG1 anti-CD23 antibody, in patients with mild-to-moderate persistent allergic asthma. Methods: This single-dose, dose-escalating, placebo-controlled study involved 30 patients. Cohorts of 3 to 6 patients received single intravenous infusions of either placebo or IDEC-152 (0.05, 0.25, 1.0, 4.0, 10.0, or 15.0 mg/kg) on study day 1. Safety, clinical activity, and pharmacokinetics were assessed for 12 weeks after treatment. Results: IDEC-152 was well tolerated. Adverse events (AEs) were mild, no grade 4 or serious AEs were reported, and no relationships were apparent between the dose of IDEC-152 and the frequency, severity, or type of event. The most common AEs in the IDEC-152 group included ecchymosis at the injection site, sinusitis, headache, arthralgia, cold syndrome, infection, throat irritation, and dysmenorrhea. Commonly reported AEs in the placebo group included headache, abdominal pain, and infection. Sustained and dose-dependent decreases in mean IgE concentrations were noted. The mean maximum concentration and area under the curve of IDEC-152 were proportional to the dose administered for the dose range 4.0 to 15.0 mg/kg. The serum half-life of the IDEC-152 antibody increased from 2 to 10 days with increasing doses. After single-dose administration of IDEC-152, no dose-dependent change in FEV1 was observed, and most changes in peak expiratory flow rate were within 10% of baseline values. Conclusion: These data suggest that IDEC-152 is safe and has the potential for clinical activity in allergic asthma.	Natl Jewish Med & Res Ctr, Div Clin Immunol & Allergy, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Boulder, CO 80309 USA; Univ Wisconsin, Sch Med, Madison, WI USA; Idec Pharmaceut Corp, San Diego, CA USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Boulder; University of Wisconsin System; University of Wisconsin Madison; Biogen	Rosenwasser, LJ (corresponding author), Natl Jewish Med & Res Ctr, Div Clin Immunol & Allergy, 1400 Jackson St, Denver, CO 80206 USA.							Becherel PA, 1997, J IMMUNOL, V159, P5761; BORISH L, 1991, J IMMUNOL, V146, P63; BORISH L, 1992, CLIN EXP ALLERGY, V22, P984, DOI 10.1111/j.1365-2222.1992.tb03025.x; CAMPBELL KA, 1992, EUR J IMMUNOL, V22, P2107, DOI 10.1002/eji.1830220822; CEMADAS M, 1999, AM J RESP CELL MOL B, V20, P1; Coyle AJ, 1996, J EXP MED, V183, P1303, DOI 10.1084/jem.183.4.1303; Dasic G, 1999, EUR J IMMUNOL, V29, P2957, DOI 10.1002/(SICI)1521-4141(199909)29:09<2957::AID-IMMU2957>3.0.CO;2-4; DELESPESSE G, 1991, ADV IMMUNOL, V49, P149; DELESPESSE G, 1986, EUR J IMMUNOL, V16, P1043, DOI 10.1002/eji.1830160903; GOULD HJ, 1997, IGE REGULATION MOL M, P37; Gounni AS, 2001, FASEB J, V15, P940, DOI 10.1096/fj.00-0378com; GROSJEAN I, 1994, EUR J IMMUNOL, V24, P2982, DOI 10.1002/eji.1830241209; Haczku A, 2000, AM J RESP CRIT CARE, V161, P952, DOI 10.1164/ajrccm.161.3.9905046; Hakonarson H, 1999, J ALLERGY CLIN IMMUN, V104, P575, DOI 10.1016/S0091-6749(99)70326-X; Joseph M, 1997, EUR J IMMUNOL, V27, P2212, DOI 10.1002/eji.1830270914; KEHRY MR, 1989, P NATL ACAD SCI USA, V86, P7556, DOI 10.1073/pnas.86.19.7556; KIKUTANI H, 1986, CELL, V47, P657, DOI 10.1016/0092-8674(86)90508-8; LAWRENCE DA, 1975, J CLIN INVEST, V55, P368, DOI 10.1172/JCI107940; MATZ J, 1994, J ALLERGY CLIN IMMUN, V93, P650, DOI 10.1016/S0091-6749(94)70077-X; Milgrom H, 1999, NEW ENGL J MED, V341, P1966, DOI 10.1056/NEJM199912233412603; Nakamura T, 2000, INT J IMMUNOPHARMACO, V22, P131, DOI 10.1016/S0192-0561(99)00068-5; PIRRON U, 1990, EUR J IMMUNOL, V20, P1547, DOI 10.1002/eji.1830200721; Riffo-Vasquez Y, 2000, CLIN EXP ALLERGY, V30, P728; SARFATI M, 1988, J IMMUNOL, V141, P2195; SHERR E, 1989, J IMMUNOL, V142, P481; Tsicopoulos A, 2000, CLIN EXP ALLERGY, V30, P602; WILLIAMS J, 1992, J IMMUNOL, V149, P2823; Yabuuchi S, 2002, INT IMMUNOPHARMACOL, V2, P453, DOI 10.1016/S1567-5769(01)00187-4	28	79	85	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2003	112	3					563	570		10.1067/mai.2003.1709	http://dx.doi.org/10.1067/mai.2003.1709			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	719XW	13679816				2022-12-18	WOS:000185231200016
J	Asero, R				Asero, R			Intolerance to nonsteroidal anti-inflammatory drugs might precede by years the onset of chronic urticaria	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						drug allergy; nonsteroidal anti-inflammatory drug intolerance; chronic urticaria	PARACETAMOL ACETAMINOPHEN HYPERSENSITIVITY; CHRONIC IDIOPATHIC URTICARIA; INDUCED SKIN DISORDERS; ANTIINFLAMMATORY DRUGS; ASPIRIN INTOLERANCE; ADVERSE REACTIONS; TOLERABILITY; NIMESULIDE; AUTOANTIBODIES; SENSITIVITY	Background: Recent studies have found that most otherwise normal subjects with a history of acute urticaria induced by several nonsteroidal anti-inflammatory drugs (NSAIDs) show a wheal-and-flare reaction on intradermal injection of autologous serum. This phenomenon has been previously observed in patients with chronic urticaria (CU) and suggests a possible common background in CU and NSAID-induced urticaria. A relationship between these 2 conditions is further suggested by the fact that up to 30% of patients with CU have a worsening of their skin disorders after the ingestion of chemically unrelated NSAIDs. Objective: I sought to assess whether otherwise normal subjects with multiple or single NSAID intolerance show a propensity to have CU. Methods: Two hundred eighty otherwise normal patients with an unequivocal history of acute urticaria induced by NSAIDs seen during the last 10 years were studied. On the basis of both clinical history and oral challenge tests with at least 2 alternative NSAIDs, the patients were classified as having single or multiple NSAID intolerance. All the patients were reevaluated within the end of 2002, 1 to 10 years after the first visit, to assess the onset of CU. One hundred allergic adults without a history of CU and of drug allergy followed up for I to 10 years were used as control subjects. Results: One hundred fifty-nine and 121 patients were finally considered as having single or multiple NSAID intolerance, respectively. At the follow-up visit, 93 (33%) of 280 patients had CU. The prevalence of CU was very similar in subjects with single or multiple NSAID intolerance (48/159 [30%] vs 45/121 [37%], respectively; P = not significant). Only 1 (1%) of 100 atopic control subjects had CU during the follow-up period (P < .001). Among single NSAID reactors, patients who had CU had a significantly higher prevalence of intolerance to aspirin than those who did not have CU (36/48 [75%] vs 41/111 [37%], P < .001), whereas the latter had a markedly higher prevalence of intolerance to pyrazolone drugs (52/111 [47%] vs 10/48 [21%], P < .01). Altogether, only 12 (15%) of 82 patients intolerant to drugs other than aspirin versus 36 (47%) of 77 aspirin reactors had CU (P < .001). Conclusion: NSAID intolerance might precede the onset of CU by years. Both multiple and single NSAID reactors with a history of aspirin-induced:urticaria seem at higher risk for CU than patients with a history of single intolerance to NSAIDs other than aspirin.	Clin San Carlo, I-20037 Paderno Dugnano, MI, Italy		Asero, R (corresponding author), Clin San Carlo, Via Osped 21, I-20037 Paderno Dugnano, MI, Italy.							ANDRI L, 1994, ANN ALLERGY, V72, P29; Asero R, 2002, ANN ALLERG ASTHMA IM, V88, P468, DOI 10.1016/S1081-1206(10)62384-8; Asero R, 2001, ALLERGY, V56, P916, DOI 10.1034/j.1398-9995.2001.00300.x; Asero R, 1999, ANN ALLERG ASTHMA IM, V82, P554, DOI 10.1016/S1081-1206(10)63166-3; Asero R, 1998, ALLERGY, V53, P214, DOI 10.1111/j.1398-9995.1998.tb03875.x; Asero R, 1998, ANN ALLERG ASTHMA IM, V81, P237, DOI 10.1016/S1081-1206(10)62818-9; Asero R, 2000, ALLERGY, V55, P893, DOI 10.1034/j.1398-9995.2000.00698.x; BLANCA M, 1989, ANN ALLERGY, V62, P295; CZERNIAWSKAMYSIK G, 1981, ALLERGY, V36, P381, DOI 10.1111/j.1398-9995.1981.tb01842.x; de Paramo BJ, 2000, ANN ALLERG ASTHMA IM, V85, P508; Fiebiger E, 1995, J CLIN INVEST, V96, P2606, DOI 10.1172/JCI118325; Grant JA, 2001, ANN ALLERG ASTHMA IM, V87, P227, DOI 10.1016/S1081-1206(10)62231-4; GREAVES MW, 1995, NEW ENGL J MED, V332, P1767, DOI 10.1056/NEJM199506293322608; Grob M, 2002, ALLERGY, V57, P264, DOI 10.1034/j.1398-9995.2002.1n3581.x; HIDE M, 1993, NEW ENGL J MED, V328, P1599, DOI 10.1056/NEJM199306033282204; Kaplan AP, 2002, NEW ENGL J MED, V346, P175, DOI 10.1056/NEJMcp011186; Mendizabal SL, 1998, ALLERGY, V53, P457, DOI 10.1111/j.1398-9995.1998.tb03927.x; Nettis E, 2002, ANN ALLERG ASTHMA IM, V88, P331, DOI 10.1016/S1081-1206(10)62017-0; Papa G, 1997, ANN ALLERG ASTHMA IM, V78, P74, DOI 10.1016/S1081-1206(10)63376-5; Pastorello EA, 1998, ALLERGY, V53, P880, DOI 10.1111/j.1398-9995.1998.tb03995.x; PLESKOW WW, 1982, J ALLERGY CLIN IMMUN, V69, P11, DOI 10.1016/0091-6749(82)90081-1; Quaratino D, 1997, ANN ALLERG ASTHMA IM, V79, P47, DOI 10.1016/S1081-1206(10)63083-9; Quiralte J, 1996, J ALLERGY CLIN IMMUN, V98, P678, DOI 10.1016/S0091-6749(96)70102-1; Quiralte J, 1997, ANN ALLERG ASTHMA IM, V78, P293, DOI 10.1016/S1081-1206(10)63184-5; Sabroe RA, 1999, BRIT J DERMATOL, V140, P446; Sanchez-Borges N, 2000, ANN ALLERG ASTHMA IM, V84, P101, DOI 10.1016/S1081-1206(10)62748-2; Scala E, 2001, J ALLERGY CLIN IMMUN, V107, P557, DOI 10.1067/mai.2001.113241; SETTIPANE RA, 1980, ALLERGY, V35, P149, DOI 10.1111/j.1398-9995.1980.tb01730.x; Stevenson DD, 2001, ANN ALLERG ASTHMA IM, V87, P177, DOI 10.1016/S1081-1206(10)62221-1; Stevenson DD, 1993, ALLERGY PRINCIPLES P, V4th, P1747; STEVENSON DD, 1998, ALLERGY PRINCIPLES P, P1225; SZCZEKLIK A, 1987, ANN ALLERGY, V59, P113; Tong LJ, 1997, J ALLERGY CLIN IMMUN, V99, P461, DOI 10.1016/S0091-6749(97)70071-X; Vidal C, 1997, ANN ALLERG ASTHMA IM, V79, P320, DOI 10.1016/S1081-1206(10)63021-9; Zweiman B, 1996, J ALLERGY CLIN IMMUN, V98, P89, DOI 10.1016/S0091-6749(96)70230-0	35	79	80	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2003	111	5					1095	1098		10.1067/mai.2003.1444	http://dx.doi.org/10.1067/mai.2003.1444			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	679DA	12743575				2022-12-18	WOS:000182904500025
J	Pomes, A; Helm, RM; Bannon, GA; Burks, AW; Tsay, A; Chapman, MD				Pomes, A; Helm, RM; Bannon, GA; Burks, AW; Tsay, A; Chapman, MD			Monitoring peanut allergen in food products by measuring Ara h 1	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						peanut allergen; food allergy; immunoassay; environmental test	LINKED-IMMUNOSORBENT-ASSAY; LEGUME BOTANICAL FAMILY; MONOCLONAL-ANTIBODIES; IGE-BINDING; CROSS-ALLERGENICITY; ATOPIC-DERMATITIS; SOYBEAN PRODUCTS; SANDWICH ELISA; QUANTIFICATION; PROTEIN	Background: Peanut allergy is an important health problem in the United States, affecting approximately 0.6% of children. Inadvertent exposure to peanut is a risk factor for life-threatening food-induced anaphylaxis. Objective: The purpose of this investigation was to develop an immunoassay for a major peanut allergen, Ara h 1, to detect peanut allergen in foods so that the risk of inadvertent exposure can be reduced. Methods: A specific 2-site monoclonal antibody-based ELISA was developed to measure Ara h 1 in foods. The sensitivity of the assay was 30 ng/mL. Ara h I was measured in foods (n 83) with or without peanut and in experiments to optimize allergen yield and to determine peanut contamination in spiked foods. Results: Ara h I levels in food products ranged from less than 0.1 mug/g to 500 mug/g. Ara h 1 measured in ng/mL was transformed to mug/g for food products. Peanut butter contained the highest amounts of Ara h 1. Peanut extracts contained from 0.5 to 15 mg Ara h 1/g of peanut depending on the extraction conditions. Optimal extraction of Ara h 1 was obtained by using phosphate buffer with 1 mol/L NaCl and Tween at 60degreesC. Ara h 1 was not always detected in presence of chocolate under the extraction conditions tested. Spiking experiments showed that the assay could detect similar to0.1% Ara h I contamination of food with ground peanut. There was an excellent correlation between Ara h 1 levels and peanut content measured by using a commercial polyclonal antibody-based ELISA (r = 93, n = 31, P <.001). Conclusion: A new sensitive and specific monoclonal antibody-based ELISA was used to monitor Ara h 1 content in food products. This assay should be useful for monitoring peanut contamination in the food manufacturing and processing industry and in developing thresholds for sensitization or allergic reaction in persons with peanut allergy.	INDOOR Biotechnol Inc, Charlottesville, VA 22903 USA; Arkansas Childrens Hosp, Res Inst, Dept Pediat, Little Rock, AR 72202 USA	INDOOR Biotechnologies; Arkansas Children's Hospital	Pomes, A (corresponding author), INDOOR Biotechnol Inc, 1216 Harris St, Charlottesville, VA 22903 USA.		Pomés, Anna/H-7010-2019	Pomés, Anna/0000-0002-8729-1829; Chapman, Martin/0000-0002-0845-3632	NIAID NIH HHS [AI01666-04] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K24AI001666] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bando N, 1998, J NUTR SCI VITAMINOL, V44, P655, DOI 10.3177/jnsv.44.655; Beardslee TA, 2000, INT ARCH ALLERGY IMM, V123, P299, DOI 10.1159/000053642; BERNHISELBROADBENT J, 1989, J ALLERGY CLIN IMMUN, V83, P435, DOI 10.1016/0091-6749(89)90130-9; BERNHISELBROADBENT J, 1989, J ALLERGY CLIN IMMUN, V84, P701, DOI 10.1016/0091-6749(89)90298-4; Beyer KB, 2001, J ALLERGY CLIN IMMUN, V107, P1077, DOI 10.1067/mai.2001.115480; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; BURKS AW, 1991, J ALLERGY CLIN IMMUN, V88, P172, DOI 10.1016/0091-6749(91)90325-I; BURKS AW, 1995, J CLIN INVEST, V96, P1715, DOI 10.1172/JCI118216; BURKS AW, 1992, J ALLERGY CLIN IMMUN, V90, P889, DOI 10.1016/0091-6749(92)90461-A; CHANG JH, 1995, METHOD ENZYMOL, V254, P430; CHAPMAN MD, 1984, J IMMUNOL, V133, P2488; Clarke MCA, 1998, CLIN EXP ALLERGY, V28, P1251, DOI 10.1046/j.1365-2222.1998.00386.x; De Jong EC, 1998, CLIN EXP ALLERGY, V28, P743, DOI 10.1046/j.1365-2222.1998.00301.x; Eigenmann PA, 1998, PEDIATRICS, V101, DOI 10.1542/peds.101.3.e8; Emmett SE, 1999, ALLERGY, V54, P380, DOI 10.1034/j.1398-9995.1999.00768.x; Hefle SL, 2001, J FOOD PROTECT, V64, P1812, DOI 10.4315/0362-028X-64.11.1812; Hlywka JJ, 2000, J FOOD PROTECT, V63, P252, DOI 10.4315/0362-028X-63.2.252; Holzhauser T, 1999, J AGR FOOD CHEM, V47, P603, DOI 10.1021/jf980775f; Holzhauser T, 1999, J AGR FOOD CHEM, V47, P4209, DOI 10.1021/jf990478q; Hourihane JO, 1997, J ALLERGY CLIN IMMUN, V100, P596, DOI 10.1016/S0091-6749(97)70161-1; Jeoung BJ, 1997, J ALLERGY CLIN IMMUN, V100, P229, DOI 10.1016/S0091-6749(97)70229-X; KEATING MU, 1990, J ALLERGY CLIN IMMUN, V86, P41, DOI 10.1016/S0091-6749(05)80121-6; KHOLIEF TS, 1987, Z ERNAHRUNGSWISS, V26, P56, DOI 10.1007/BF02023820; Kleber-Janke T, 1999, INT ARCH ALLERGY IMM, V119, P265, DOI 10.1159/000024203; Koppelman SJ, 1999, J IMMUNOL METHODS, V229, P107, DOI 10.1016/S0022-1759(99)00119-2; Koppelman SJ, 1999, J BIOL CHEM, V274, P4770, DOI 10.1074/jbc.274.8.4770; Koppelman SJ, 2002, J AGR FOOD CHEM, V50, P1562, DOI 10.1021/jf0106998; Koppelman SJ, 2001, ALLERGY, V56, P132, DOI 10.1034/j.1398-9995.2001.056002132.x; LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; Maleki SJ, 2000, J IMMUNOL, V164, P5844, DOI 10.4049/jimmunol.164.11.5844; Newsome WH, 1999, J AOAC INT, V82, P666; Sicherer SH, 2000, ALLERGY, V55, P515, DOI 10.1034/j.1398-9995.2000.00119.x; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V103, P559, DOI 10.1016/S0091-6749(99)70224-1; Skolnick HS, 2001, J ALLERGY CLIN IMMUN, V107, P367, DOI 10.1067/mai.2001.112129; Taylor SL, 2002, J ALLERGY CLIN IMMUN, V109, P24, DOI 10.1067/mai.2002.120564; TSUJI H, 1995, BIOSCI BIOTECH BIOCH, V59, P150, DOI 10.1271/bbb.59.150; Vieths S, 1998, ALLERGY, V53, P65, DOI 10.1111/j.1398-9995.1998.tb04965.x; Wood RA, 2002, J ALLERGY CLIN IMMUN, V109, P920, DOI 10.1067/mai.2002.124889; YLONEN J, 1994, ALLERGY, V49, P707, DOI 10.1111/j.1398-9995.1994.tb02091.x; YUNGINGER JW, 1988, JAMA-J AM MED ASSOC, V260, P1450, DOI 10.1001/jama.260.10.1450	40	79	83	0	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2003	111	3					640	645		10.1067/mai.2003.118	http://dx.doi.org/10.1067/mai.2003.118			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	656YW	12642850				2022-12-18	WOS:000181639500031
J	Law, AW; Reed, SD; Sundy, JS; Schulman, KA				Law, AW; Reed, SD; Sundy, JS; Schulman, KA			Direct costs of allergic rhinitis in the United States: estimates from the 1996 Medical Expenditure Panel Survey	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	6th Annual International Meeting of the International-Society-for-Pharmacoeconomics-and-Outcomes-Research	MAY 20-23, 2001	ARLINGTON, VA	Int Soc Pharmacoecon Outcomes Res		allergic rhinitis; costs and cost analysis; health insurance	ECONOMICS	Background: Previous estimates of the cost of allergic rhinitis predate the substantial increase in the use of second-generation antihistamines and intranasal corticosteroids. Objective: We sought to update estimates of the direct costs of allergic rhinitis in the United States and to estimate prescription medication expenditures by type of insurance coverage. Methods: Data from the 1996 Medical Expenditure Panel Survey were used in a cross-sectional analysis of resource use and costs. Results: Approximately 7.7% of the population are estimated to have had allergic rhinitis in 1996. The total direct medical cost of allergic rhinitis was estimated at $3.4 billion, with the majority attributable to prescription medications (46.6%) and outpatient visits (51.9%). Fifty-one percent of the prescription medication expenditures were for second-generation antihistamines, 25% for intranasal corticosteroids, and 5% for first-generation antihistamines. Fifty-eight percent of patients with allergic rhinitis received 1 or more prescription drugs for its treatment during the study year. Among these patients, mean prescription expenditures were $131 (95% CI, $119-$143), of which $50 (95% CI, $43-$56) were paid out of pocket. The mean prescription medication expenditure was $103 (95% Cl, $70-$136) for persons with Medicaid, $155 (95% CI, $140-$169) for private insurance, $213 (95% CI, $0-$521) for other insurance, and $69 (95% Cl, $57-$80) for no prescription drug insurance. Conclusion: The direct costs of allergic rhinitis have increased substantially since the introduction of second-generation antihistamines and intranasal corticosteroids, especially costs attributable to prescription medications. Individuals with no insurance coverage have higher total out-of-pocket prescription expenditures than those with coverage. (J Allergy Clin Immunol 2003;111:296-300.)	Duke Univ, Clin Res Inst, Ctr Clin & Genet Econ, Durham, NC 27715 USA; Duke Univ, Med Ctr, Dept Med, Div Rheumatol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Div Allergy, Durham, NC 27710 USA	Duke University; Duke University; Duke University	Schulman, KA (corresponding author), Duke Univ, Clin Res Inst, Ctr Clin & Genet Econ, POB 17969, Durham, NC 27715 USA.				AHRQ HHS [U18 HS 10385] Funding Source: Medline; NIEHS NIH HHS [1K23 ES 011185-01] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [U18HS010385] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [K23ES011185] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adams P F, 1999, Vital Health Stat 10, P1; ARROW KJ, 1963, AM ECON REV, V53, P941; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; CARDINALE V, 1996, DRUG TOPICS; Cherry DK, 2001, ADV DATA VITAL HLTH, V322, P1; COHEN SB, 1997, 2 MEPS AG HEALTHC RE; Crystal-Peters J, 2000, AM J MANAG CARE, V6, P373; Dykewicz MS, 1998, ANN ALLERG ASTHMA IM, V81, P478, DOI 10.1016/S1081-1206(10)63155-9; Federman AD, 2001, JAMA-J AM MED ASSOC, V286, P1732, DOI 10.1001/jama.286.14.1732; HARRIS G, 2002, WALL ST J       0606, pA1; Lee J, 2001, AM J MANAG CARE, V7, pS103; Malone DC, 1997, J ALLERGY CLIN IMMUN, V99, P22, DOI 10.1016/S0091-6749(97)81040-8; MCMENAMIN P, 1994, ANN ALLERGY, V73, P35; Nathan RA, 1997, J ALLERGY CLIN IMMUN, V99, pS808, DOI 10.1016/S0091-6749(97)80040-1; PAULY MV, 1968, AM ECON REV, V58, P531; *PFIZ INC, 2002, 2001 ANN REP; *SCHER PLOUGH CORP, 2002, 2001 ANN REP; Stempel DA, 1997, AM J MANAG CARE, V3, pS8; Storms W, 1997, J ALLERGY CLIN IMMUN, V99, pS820, DOI 10.1016/S0091-6749(97)80042-5; 2002, AVENTIS REPORTS FULL	20	79	81	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2003	111	2					296	300		10.1067/mai.2003.68	http://dx.doi.org/10.1067/mai.2003.68			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	644WF	12589348				2022-12-18	WOS:000180942700012
J	Plewako, H; Arvidsson, M; Petruson, K; Oancea, I; Holmberg, K; Adelroth, E; Gustafsson, H; Sandstrom, T; Rak, S				Plewako, H; Arvidsson, M; Petruson, K; Oancea, I; Holmberg, K; Adelroth, E; Gustafsson, H; Sandstrom, T; Rak, S			The effect of omalizumab on nasal allergic inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic rhinitis; nasal biopsy; IgE; anti-IgE eosinophils; omalizumab	ANTI-IGE ANTIBODY; BRONCHIAL HYPERRESPONSIVENESS; ACTIVATED EOSINOPHILS; RHINITIS; EXPRESSION; INCREASES; CELLS; PHASE	Background: In sensitized patients, coupling between IgE and FcepsilonRI receptors on mast cells leads to release of proinflammatory mediators and a subsequent influx of inflammatory cells to the affected organ. Omalizumab (Xolair; formerly rhuMAb-E25) binds to circulating IgE, thus preventing induction of the allergic process. Objective: We investigated the effect of treatment with omalizumab on seasonal allergic rhinitis and related changes in inflammatory cell numbers in nasal biopsy specimens. Methods: Patients were randomized to treatment with omalizumab or placebo before the pollen season; the treatment was started and continued during season. Symptoms and use of medication were recorded, and blood samples and nasal biopsy specimens were obtained before and during season. Immunocytochemistry was performed on biopsy sections through use of the following antibodies: anti-CD4, CD8 (T lymphocytes), EG2, and anti-eosinophil peroxidase (eosinophils), antitryptase (mast cells), human neutrophil lipocalin (neutrophils), and antibodies against IgE and FcepsilonRI. Results: During the season, blood eosinophils increased in placebo-treated patients but not in omalizumab-treated patients (P =.01); the difference between the treatment groups was significant (P =.04). Free IgE in serum decreased significantly (P =.0002) in omalizumab-treated patients but not in placebo-treated patients; the difference between the groups was significant (P =.0001). In nasal biopsy specimens, the number of eosinophil peroxidase-positive staining cells increased in the placebo-treated patients (P =.003) but not in the actively treated patients during the season; the difference between the groups was significant (P =.0001). The number of IgE(+) staining cells decreased significantly in the omalizumab group during the season in comparison with the placebo group (P =.04). Conclusion: The clinical benefit of treatment with omalizumab is associated with an anti-inflammatory effect on cellular markers in blood and nasal tissue.	Sahlgrens Univ Hosp, Dept Resp Med & Allergol, Asthma & Allergy Res Grp, S-41345 Gothenburg, Sweden; Orebro Univ Hosp, Dept Otorhinolaryngol Head & Neck Surg, Orebro, Sweden; Univ Umea Hosp, Dept Resp Med & Allergy, S-90185 Umea, Sweden	Sahlgrenska University Hospital; Orebro University; Umea University	Rak, S (corresponding author), Sahlgrens Univ Hosp, Dept Resp Med & Allergol, Asthma & Allergy Res Grp, S-41345 Gothenburg, Sweden.							Adelroth E, 2000, J ALLERGY CLIN IMMUN, V106, P253, DOI 10.1067/mai.2000.108310; BENTLEY AM, 1992, J ALLERGY CLIN IMMUN, V89, P877, DOI 10.1016/0091-6749(92)90444-7; Bjornsson E, 1996, RESP MED, V90, P39, DOI 10.1016/S0954-6111(96)90243-7; Durham SR, 1997, EUR J IMMUNOL, V27, P2899, DOI 10.1002/eji.1830271123; Fahy JV, 1997, AM J RESP CRIT CARE, V155, P1828, DOI 10.1164/ajrccm.155.6.9196082; FREW AJ, 1988, J IMMUNOL, V141, P4158; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; MacGlashan DW, 1997, J IMMUNOL, V158, P1438; Nielsen LP, 1998, ALLERGY, V53, P778; RAK S, 1988, J ALLERGY CLIN IMMUN, V82, P470, DOI 10.1016/0091-6749(88)90021-8; SHIELDS RL, 1995, INT ARCH ALLERGY IMM, V107, P308, DOI 10.1159/000237010; Soler M, 2001, EUR RESPIR J, V18, P254, DOI 10.1183/09031936.01.00092101; TOMASSINI M, 1991, J ALLERGY CLIN IMMUN, V88, P365, DOI 10.1016/0091-6749(91)90099-A	13	79	84	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2002	110	1					68	71		10.1067/mai.2002.125488	http://dx.doi.org/10.1067/mai.2002.125488			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	574CF	12110823				2022-12-18	WOS:000176870300015
J	Herrick, CA; Xu, L; Wisnewski, AV; Das, J; Redlich, CA; Bottomly, K				Herrick, CA; Xu, L; Wisnewski, AV; Das, J; Redlich, CA; Bottomly, K			A novel mouse model of diisocyanate-induced asthma showing allergic-type inflammation in the lung after inhaled antigen challenge	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; diisocyanate; skin; airway; lung; eosinophils; T(H)2; IL-4; IL-13; IFN-gamma	HUMAN SERUM-ALBUMIN; TOLUENE DIISOCYANATE; OCCUPATIONAL ASTHMA; NONATOPIC ASTHMA; BRONCHIAL-MUCOSA; INTERFERON-GAMMA; EXPOSURE; WORKERS; IL-4; ISOCYANATES	Background: Exposure to diisocyanates, a group of highly reactive, low-molecular-weight compounds, is a major cause of occupational asthma. In contrast to mouse models of atopic asthma, previous mouse models of diisocyanate-induced asthma have failed to show lung inflammation with characteristics of human disease. Objective: Our goal was to establish a novel mouse model of diisocyanate-induced asthma in which lung inflammation reminiscent of that seen in human asthma is generated after inhaled antigen challenge. Methods: BALB/c mice were epicutaneously sensitized to hexamethylene diisocyanate (HDI) and then challenged with an HDI-protein conjugate administered by means of an intranasal droplet. Results: HDI sensitization resulted in development of contact hypersensitivity and HDI-specific antibody production. Most importantly, however, vigorous inflammatory responses with characteristics of human asthma were generated in the lung after inhaled HDI challenge. Challenge of sensitized, but not unsensitized, mice resulted in airway eosinophilia, mucus hypersecretion, and production of T(H)1-type (IFN-gamma) and T(H)2 type (IL-4, IL-5, and IL-13) cytokines by lung inflammatory cells. Despite the mixed T(H)1/T(H)2 response induced by HDI sensitization, use of cytokine-dericient mice revealed that airway eosinophilia was mediated by T(H)2 cytokines and not by IFN-gamma. Conclusion: We report a novel mouse model of diisocyanate-induced asthma that, in contrast to previous models, demonstrates antigen-induced lung inflammation with characteristics of human disease. This model will allow investigation of the immunopathogenesis of diisocyanate-induced asthma and should provide insight into this common form of occupational disease.	Yale Univ, Sch Med, Dept Dermatol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA	Yale University; Yale University; Yale University	Herrick, CA (corresponding author), Yale Univ, Sch Med, Dept Dermatol, 333 Cedar St,POB 208059, New Haven, CT 06520 USA.				NHLBI NIH HHS [R01-HL65209, R01 HL062622-01, R01 HL062622-02, R01-HL62622, P50-HL56389, R01 HL062622] Funding Source: Medline; NIEHS NIH HHS [K24-ES00355] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056389, R01HL062622, R01HL065209] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [K24ES000355] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Amin K, 2000, AM J RESP CRIT CARE, V162, P2295, DOI 10.1164/ajrccm.162.6.9912001; BAUR X, 1984, J ALLERGY CLIN IMMUN, V73, P610, DOI 10.1016/0091-6749(84)90520-7; BENTLEY AM, 1992, J ALLERGY CLIN IMMUN, V89, P821, DOI 10.1016/0091-6749(92)90437-7; BENTLEY AM, 1994, J INVEST ALLERG CLIN, V4, P222; Bernstein JA, 1996, TOXICOLOGY, V111, P181, DOI 10.1016/0300-483X(96)03375-6; Busse WW, 2001, NEW ENGL J MED, V344, P350, DOI 10.1056/NEJM200102013440507; CARTIER A, 1989, J ALLERGY CLIN IMMUN, V84, P507, DOI 10.1016/0091-6749(89)90364-3; CHANYEUNG M, 1995, NEW ENGL J MED, V333, P107, DOI 10.1056/NEJM199507133330207; Cohn L, 2001, J IMMUNOL, V166, P2760, DOI 10.4049/jimmunol.166.4.2760; Ebino K, 1999, INHAL TOXICOL, V11, P171, DOI 10.1080/089583799197131; FABBRI LM, 1987, AM REV RESPIR DIS, V136, P36, DOI 10.1164/ajrccm/136.1.36; Herrick CA, 2000, J CLIN INVEST, V105, P765, DOI 10.1172/JCI8624; Hnizdo E, 2001, CLIN EXP ALLERGY, V31, P32, DOI 10.1046/j.1365-2222.2001.00981.x; Humbert M, 1996, AM J RESP CRIT CARE, V154, P1497, DOI 10.1164/ajrccm.154.5.8912771; Lee Millina, 1998, Journal of Korean Medical Science, V13, P459; Lilly CM, 2001, AM J RESP CRIT CARE, V163, P1669, DOI 10.1164/ajrccm.163.7.9812044; Lushniak BD, 1998, AM J IND MED, V33, P471, DOI 10.1002/(SICI)1097-0274(199805)33:5<471::AID-AJIM6>3.0.CO;2-V; Maestrelli P, 1997, CLIN EXP ALLERGY, V27, P1292; MAESTRELLI P, 1994, SCAND J WORK ENV HEA, V20, P376, DOI 10.5271/sjweh.1383; Maestrelli P, 1997, CLIN EXP ALLERGY, V27, P47, DOI 10.1111/j.1365-2222.1997.tb01826.x; Matheson JM, 2001, CLIN EXP ALLERGY, V31, P1067, DOI 10.1046/j.1365-2222.2001.01125.x; PAGGIARO PL, 1994, EUR RESPIR J, V7, P761, DOI 10.1183/09031936.94.07040761; Park HS, 1999, J ALLERGY CLIN IMMUN, V104, P847, DOI 10.1016/S0091-6749(99)70297-6; Petsonk EL, 2000, CHEST, V118, P1183, DOI 10.1378/chest.118.4.1183; RATTRAY NJ, 1994, TOXICOLOGY, V88, P15, DOI 10.1016/0300-483X(94)90108-2; Scheerens H, 1999, AM J RESP CRIT CARE, V159, P1074, DOI 10.1164/ajrccm.159.4.9701012; Scheerens H, 1996, AM J RESP CRIT CARE, V154, P858, DOI 10.1164/ajrccm.154.4.8887575; TSE KS, 1985, ALLERGY, V40, P314, DOI 10.1111/j.1398-9995.1985.tb00242.x; Vandebriel RJ, 2000, TOXICOL APPL PHARM, V162, P77, DOI 10.1006/taap.1999.8841; VANDENPLAS O, 1993, BRIT J IND MED, V50, P213; Wisnewski AV, 1999, AM J RESP CRIT CARE, V159, pA234	31	79	79	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2002	109	5					873	878		10.1067/mai.2002.123533	http://dx.doi.org/10.1067/mai.2002.123533			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	553QW	11994714				2022-12-18	WOS:000175687800020
J	Redington, AE; Roche, WR; Madden, J; Frew, AJ; Djukanovic, R; Holgate, ST; Howarth, PH				Redington, AE; Roche, WR; Madden, J; Frew, AJ; Djukanovic, R; Holgate, ST; Howarth, PH			Basic fibroblast growth factor in asthma: Measurement in bronchoalveolar lavage fluid basally and following allergen challenge	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						airway remodeling; basic fibroblast growth factor; bronchoalveolar lavage; bronchoscopy; fibrosis	SAFETY ASPECTS; CELLS	Airway remodeling in asthma refers to a collection of chronic structural changes including subepithelial fibrosis, airway smooth muscle hypertrophy/hyperplasia, and possibly angiogenesis. The mechanisms leading to remodeling are not well defined. One molecule of possible relevance is basic fibroblast growth factor (bFGF), which is a potent mitogen for fibroblasts, airway smooth muscle cells, and endothelial cells. To test the hypothesis that bFGF expression is increased in asthma, we measured levels of the growth factor in bronchoalveolar lavage (BAL) fluid. Basally, BAL fluid bFGF concentrations were significantly higher in subjects with atopic asthma than in control subjects without asthma (median 0.22 vs 0.06 pg/mL, P = .003). The effect of acute allergen exposure was examined with a segmental bronchoprovocation model in a separate group of subjects with atopic asthma. Ten minutes after segmental bronchoprovocation there was a 5-fold increase in bFGF levels in BAL fluid recovered from allergen-challenged sites compared with control saline-challenged sites (1.52 vs 0.30 pg/mL, P < .002). We conclude that basal levels of BAL fluid bFGF are increased in atopic asthma and that a further increase occurs in response to acute allergen exposure. These findings lend support to the hypothesis that bFGF is implicated in airway remodeling in asthma.	Southampton Gen Hosp, Univ Med, Southampton SO9 4XY, Hants, England; Southampton Gen Hosp, Univ Pathol, Southampton SO9 4XY, Hants, England	University of Southampton; University of Southampton	Redington, AE (corresponding author), Guys Hosp, Dept Resp Med, 2nd Floor,thomas Guy House, London SE1 9RT, England.		Kelly, Frank J/C-6125-2009	Kelly, Frank J/0000-0003-2558-8392; Howarth, Peter/0000-0003-0619-7927; Djukanovic, Ratko/0000-0001-6039-5612				BASHKIN P, 1989, BIOCHEMISTRY-US, V28, P1737, DOI 10.1021/bi00430a047; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CAMPBELL AM, 1994, IMMUNOLOGY, V82, P506; DJUKANOVIC R, 1991, AM REV RESPIR DIS, V143, P772, DOI 10.1164/ajrccm/143.4_Pt_1.772; GONZALEZ AM, 1990, J CELL BIOL, V110, P753, DOI 10.1083/jcb.110.3.753; Krug N, 1996, AM J RESP CRIT CARE, V153, P1391, DOI 10.1164/ajrccm.153.4.8616571; Li X, 1997, AM J RESP CRIT CARE, V156, P229, DOI 10.1164/ajrccm.156.1.9607066; Qu ZH, 1998, J HISTOCHEM CYTOCHEM, V46, P1119, DOI 10.1177/002215549804601004; REDINGTON AE, 1995, CHEM IMMUNOL, V62, P22; Redington AE, 1997, THORAX, V52, P310, DOI 10.1136/thx.52.4.310	10	79	85	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2001	107	2					384	387		10.1067/mai.2001.112268	http://dx.doi.org/10.1067/mai.2001.112268			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	403YV	11174209	Green Accepted			2022-12-18	WOS:000167071400029
J	Chu, HW; Trudeau, JB; Balzar, S; Wenzel, SE				Chu, HW; Trudeau, JB; Balzar, S; Wenzel, SE			Peripheral blood and airway tissue expression of transforming growth factor beta by neutrophils in asthmatic subjects and normal control subjects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; airway remodeling; transforming growth factor beta; neutrophils	MESSENGER-RNA EXPRESSION; LAVAGE; GLUCOCORTICOIDS; FACTOR-BETA-1; INFLAMMATION; TGF-BETA-1; CYTOKINES; DISEASE	Background: Airway remodeling may play an important role in asthma pathophysiology, Transforming growth factor beta (TGF-beta) has a critical role in the remodeling process, Although cellular sources for TGF-beta have been previously investigated in asthma airways, the expression, release, or both of TGF-beta from asthmatic airways and blood neutrophils has not been reported. Objective: The current study evaluated the TGF-beta protein and messenger (m)RNA expression by airway and peripheral blood neutrophils in asthmatic and normal subjects. Methods: TGF-beta protein expression by airway and peripheral blood neutrophils was detected by using immunocytochemistry: TGF-beta protein levels in blood neutrophil supernatant were measured by using an enzyme immunoassay, TGF-beta mRNA expression was evaluated by using reverse transcription-PCR. Results: Higher numbers of TGF-beta (+) cells and neutrophils were found in airway tissue of asthmatic (n = 15) compared with normal subjects (n = 10), Although neutrophils in both asthmatic and normal airway tissue expressed TGP-beta protein and the percentage of neutrophils expressing TGF-beta was similar between the two groups, the total number of TGF-beta (+) neutrophils was higher in the asthmatic subjects (P = .01). Peripheral blood neutrophils from asthmatic (n = 5) and normal subjects: (n = 7) also expressed TGF-beta protein and mRNA, Blood neutrophils from asthmatic subjects spontaneously released significantly higher levels of TGF-beta than those from normal subjects (P = .007). Conclusion: These data suggest that airway and blood neutrophils from both asthmatic and normal subjects can express and release TGF-beta. Higher levels of TGF-beta expression-release from asthmatic neutrophils indicate that neutrophils may be involved in the airway remodeling process of asthmatic subjects.	Natl Jewish Med & Res Ctr, Dept Med, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Denver, CO 80202 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Chu, HW (corresponding author), Natl Jewish Med & Res Ctr, Dept Med, D104,1400 Jackson St, Denver, CO 80206 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000051] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036577] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040600] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1RR00051] Funding Source: Medline; NHLBI NIH HHS [HL 36577] Funding Source: Medline; NIAID NIH HHS [AI 40600] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bosse M, 1996, IMMUNOLOGY, V87, P149; Busse W, 1999, AM J RESP CRIT CARE, V160, P1035, DOI 10.1164/ajrccm.160.3.9902064; CASSATELLA MA, 1995, IMMUNOL TODAY, V16, P21, DOI 10.1016/0167-5699(95)80066-2; Chu HW, 1998, AM J RESP CRIT CARE, V158, P1936, DOI 10.1164/ajrccm.158.6.9712073; Cox G, 1998, Can Respir J, V5 Suppl A, p37A; FAVA RA, 1991, J EXP MED, V173, P1121, DOI 10.1084/jem.173.5.1121; FAVA RA, 1990, BLOOD, V76, P1946; GROTENDORST GR, 1989, J CELL PHYSIOL, V140, P396, DOI 10.1002/jcp.1041400226; Humbert M, 1997, AM J RESP CRIT CARE, V156, P704, DOI 10.1164/ajrccm.156.3.9610033; Lagraoui M, 1997, CELL MOL BIOL, V43, P313; Miadonna A, 1997, LUNG, V175, P195, DOI 10.1007/PL00007567; Minshall EM, 1997, AM J RESP CELL MOL, V17, P326, DOI 10.1165/ajrcmb.17.3.2733; Ohno K, 1996, DNA CELL BIOL, V15, P401, DOI 10.1089/dna.1996.15.401; PATEL VG, 1994, AM J PATHOL, V144, P7; Pellegrino M, 1996, Minerva Pediatr, V48, P309; Redington AE, 1997, AM J RESP CRIT CARE, V156, P642, DOI 10.1164/ajrccm.156.2.9605065; REIBMAN J, 1991, P NATL ACAD SCI USA, V88, P6805, DOI 10.1073/pnas.88.15.6805; Shukla A, 1999, WOUND REPAIR REGEN, V7, P133, DOI 10.1046/j.1524-475X.1999.00133.x; Sousa AR, 1997, THORAX, V52, P407, DOI 10.1136/thx.52.5.407; STAVNEZER J, 1996, CYTOKINE REGULATION, P292; SZEFLER SJ, 1987, BIOCHEM PHARMACOL, V36, P1589, DOI 10.1016/0006-2952(87)90041-4; Tillie-Leblond I, 1999, AM J RESP CRIT CARE, V159, P487, DOI 10.1164/ajrccm.159.2.9805115; Vignola AM, 1997, AM J RESP CRIT CARE, V156, P591, DOI 10.1164/ajrccm.156.2.9609066; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001, DOI 10.1164/ajrccm.160.3.9812110; Wenzel SE, 1997, AM J RESP CRIT CARE, V156, P737, DOI 10.1164/ajrccm.156.3.9610046	25	79	86	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2000	106	6					1115	1123						9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	384ER	11112895				2022-12-18	WOS:000165930300014
J	Li, XM; Huang, CK; Zhang, TF; Teper, AA; Srivastava, K; Schofield, BH; Sampson, HA				Li, XM; Huang, CK; Zhang, TF; Teper, AA; Srivastava, K; Schofield, BH; Sampson, HA			The Chinese herbal medicine formula MSSM-002 suppresses allergic airway hyperreactivity and modulates T(H)1/T(H)2 responses in a murine model of allergic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						traditional Chinese medicine; murine model of allergic asthma; TH1/TH2	SAIBOKU-TO TJ-96; HYPERRESPONSIVENESS; MICE; INDUCTION; CELLS; IGE; INFLAMMATION; EOSINOPHILIA; EXPRESSION; ANTIBODY	Background: Asthma is a major public health problem worldwide, and the morbidity and mortality of asthma have increased in the past two decades. The reputed efficacy, low cost, and relative absence of side effects of traditional Chinese medicines (TCMs) have led to increasing interest in the use of TCMs for the treatment of asthma in Western countries. However, there are few well-controlled scientific studies on the efficacy, safety, and mechanisms of action of TCMs used to treat asthma. Objective: The goal of this study was to investigate the effects of the Chinese herbal medicine formula MSSM-002, derived from TCMs used to treat allergic asthma, on a well-characterized mouse model of allergic asthma, Methods: Mice sensitized intraperitoneally and challenged intratracheally with conalbumin were treated with MSSM-002 24 hours after the first intratracheal challenge. Dexamethasone-treated, saline solution sham-treated, and naive mice served as controls. The effects of MSSM-002 on allergic airway hyperreactivity, inflammation, antigen-specific antibody production, lung histologic features, and cytokine profiles were evaluated. Results: MSSM-002 treatment virtually eliminated airway hyperreactivity and markedly reduced the total number of cells and the percent eosinophils in bronchoalveolar lavage fluids compared with the sham-treated group. Lung histologic features showed that MSSM-002 reduced inflammation and mucus production. These effects were equivalent to the effects of dexamethasone. but in contrast to the overall immunosuppressive effects of dexamethasone MSSM-002 treatment decreased antigen-specific IgE, IL-4, IL-5, and IL-13 levels without suppressing IgG2a and IFN-gamma synthesis. Conclusion: MSSM-002 exhibits anti-airway hyperresponsiveness, anti-airway inflammation, and immunoregulatory effects on T(H)1/T(H)2 responses, which may be useful fur treatment of allergic asthma.	CUNY Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Johns Hopkins University	Li, XM (corresponding author), CUNY Mt Sinai Sch Med, Dept Pediat, 1 Gustave L Levy Pl, New York, NY 10029 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043668, R01AI024439] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES003819] Funding Source: NIH RePORTER; NIAID NIH HHS [AI43668, AI24439] Funding Source: Medline; NIEHS NIH HHS [ES03819] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Barnes PJ, 1998, J ALLERGY CLIN IMMUN, V102, P531, DOI 10.1016/S0091-6749(98)70268-4; Beasley R, 2000, J ALLERGY CLIN IMMUN, V105, pS466, DOI 10.1016/S0091-6749(00)90044-7; Bensky D, 1990, CHINESE HERBAL MED F; Bielory L, 1999, J ASTHMA, V36, P1, DOI 10.3109/02770909909065150; Bleecker E, 1998, J ALLERGY CLIN IMMUN, V101, pS400, DOI 10.1016/S0091-6749(98)70230-1; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720, DOI 10.1164/ajrccm.161.5.9903102; But P, 1996, CLIN REV ALLERG IMMU, V14, P253; Canete JD, 2000, ANN RHEUM DIS, V59, P263, DOI 10.1136/ard.59.4.263; DE BJ, 1996, BRIT J PHARMACOL, V119, P1484; Gavett SH, 1997, AM J PHYSIOL-LUNG C, V272, pL253, DOI 10.1152/ajplung.1997.272.2.L253; Gleich GJ, 2000, J ALLERGY CLIN IMMUN, V105, P651, DOI 10.1067/mai.2000.105712; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Hamelmann E, 1999, ALLERGY, V54, P297, DOI 10.1034/j.1398-9995.1999.00085.x; HELSM PJ, 2000, DRUGS S, V59, P15; HUANG KC, PHARM CHINESE HERBS; *I LAB AN RES COMM, 1996, GUID CARE US LAB AN; ISHIZAKA T, 1971, J IMMUNOL, V106, P705; Kato Y, 1999, J IMMUNOL, V162, P7470; Keane-Myers AM, 1998, J IMMUNOL, V160, P1036; LEVITT RC, 1988, FASEB J, V2, P2605, DOI 10.1096/fasebj.2.10.3384240; Li XM, 1998, J IMMUNOL, V160, P1378; Li XM, 1996, J IMMUNOL, V157, P3216; MARQUARDT DL, 1983, ALLERGY PRINCIPLES P, P1525; MARTIN TR, 1989, J CLIN INVEST, V83, P1375, DOI 10.1172/JCI114025; Mathur M, 1999, AM J RESP CRIT CARE, V159, P580, DOI 10.1164/ajrccm.159.2.9712018; NAKAJIMA S, 1993, ANN NY ACAD SCI, V685, P549, DOI 10.1111/j.1749-6632.1993.tb35918.x; Oldendick R, 2000, SOUTH MED J, V93, P375; PAUWELS R, 1989, CLIN EXP ALLERGY, V19, P395, DOI 10.1111/j.1365-2222.1989.tb02404.x; Raz E, 1996, P NATL ACAD SCI USA, V93, P5141, DOI 10.1073/pnas.93.10.5141; RENZ H, 1993, J EXP MED, V177, P1175, DOI 10.1084/jem.177.4.1175; Romagnani S, 2000, J ALLERGY CLIN IMMUN, V105, P399, DOI 10.1067/mai.2000.104575; Shim JJ, 2000, J ALLERGY CLIN IMMUN, V105, P739, DOI 10.1067/mai.2000.105221; TODA M, 1993, ANN NY ACAD SCI, V685, P561, DOI 10.1111/j.1749-6632.1993.tb35919.x; Tournoy KG, 2000, CLIN EXP ALLERGY, V30, P79; TREMBLEAU S, 1995, IMMUNOL TODAY, V16, P383, DOI 10.1016/0167-5699(95)80006-9; TREMBLEAU S, 1995, J EXP MED, V181, P817, DOI 10.1084/jem.181.2.817; *US CDCP, 1998, MMWR MORBID MORTAL W, P1022; von Mutius E, 2000, J ALLERGY CLIN IMMUN, V105, P9, DOI 10.1016/S0091-6749(00)90171-4; Webb DC, 2000, J IMMUNOL, V165, P108, DOI 10.4049/jimmunol.165.1.108; Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Xiu S., 1986, EXPT METHOD PHARM; Zhao GD, 2000, INT ARCH ALLERGY IMM, V121, P116, DOI 10.1159/000024306; 1998, RECENT ADV PHARM KAM	44	79	90	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2000	106	4					660	668		10.1067/mai.2000.110102	http://dx.doi.org/10.1067/mai.2000.110102			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	365ZP	11031336				2022-12-18	WOS:000089980600009
J	Benson, M; Strannegard, IL; Strannegard, O; Wennergren, G				Benson, M; Strannegard, IL; Strannegard, O; Wennergren, G			Topical steroid treatment of allergic rhinitis decreases nasal fluid T(H)2 cytokines, eosinophils, eosinophil cationic protein, and IgE but has no significant effect on IFN-gamma, IL-1 beta,TNF-alpha, or neutrophils	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cytokines; IgE; eosinophil cationic protein; nasal fluids; glucocorticoids; allergic rhinitis	FLUTICASONE PROPIONATE; INTRANASAL FLUTICASONE; CELLULAR INFILTRATION; SCHOOL-CHILDREN; MESSENGER-RNA; EXPRESSION; MUCOSA; ASTHMA; INTERLEUKIN-5; INFLAMMATION	Background: Topical treatment with glucocorticoids (GCs) is known to decrease eosinophils but not neutrophils in patients with allergic rhinitis. Objective: We sought to examine whether the differential effects of CC treatment on eosinophils and neutrophils are mirrored by differential effects on T(H)1/T(H)2 cytokines and the neutrophil-associated cytokines IL-1 beta and TNF-alpha. Methods: Differential counts of eosinophils and neutrophils in nasal fluids from 60 children with seasonal allergic rhinitis treated with a topical GC were examined after staining with May-Grunwald-Giemsa stain. Nasal fluid levels of IFN-gamma, IL-4, IL-6, IL-10, IL-1 beta, and TNF-alpha were examined with ELISA, and IgE and eosinophil cationic protein (ECP) levels were examined with RIA, Results: After GC treatment, there was a statistically significant decrease of the T(H)2 cytokines IL-4, IL-6, and IL-10, as well as ECP and IgE. By contrast, there were no significant changes of the levels of IFN-gamma, IL-1 beta, TNP-alpha, or neutrophils. In the CC-treated patients IL-1 beta and TNF-alpha levels correlated with neutrophils and ECP, and IL-IP correlated with eosinophils. Furthermore, ECP correlated with both eosinophils and neutrophils. Neither IL-IP nor TNF-alpha correlated with IgE. Patients with high neutrophil counts after GC treatment were found to have significantly higher eosinophil counts and ECP than patients with low counts. Conclusions: The beneficial effects of topical treatment with GC in patients with allergic rhinitis could be attributed to downregulation of T(H)2 cytokines, with an ensuing decrease of eosinophils, ECP, and IgE. It is possible that neutrophils could counteract the beneficial effects of GCs by releasing the proinflammatory cytokines IL-1 beta and TNF-alpha.	Sahlgrenska Univ Hosp, Dept Pediat, Gothenburg, Sweden; Sahlgrenska Univ Hosp, Dept Clin Virol, Gothenburg, Sweden	Sahlgrenska University Hospital; Sahlgrenska University Hospital	Benson, M (corresponding author), Gothenburg Univ, Queen Silvia Childrens Hosp, Dept Pediat, SE-41685 Gothenburg, Sweden.							ALTMAN DG, 1995, PRACTICAL STAT MED R, P199; Benson M, 1997, PEDIATR ALLERGY IMMU, V8, P143, DOI 10.1111/j.1399-3038.1997.tb00168.x; Benson M, 1999, PEDIATR ALLERGY IMMU, V10, P178; Benson M, 2000, PEDIAT ALLERG IMM-UK, V11, P20, DOI 10.1034/j.1399-3038.2000.00051.x; BISGAARD H, 1990, J ALLERGY CLIN IMMUN, V85, P891, DOI 10.1016/0091-6749(90)90074-E; BRADDING P, 1995, AM J RESP CRIT CARE, V151, P19006; Cameron LA, 1998, J ALLERGY CLIN IMMUN, V101, P330, DOI 10.1016/S0091-6749(98)70244-1; CASSATELLA MA, 1995, IMMUNOL TODAY, V16, P21, DOI 10.1016/0167-5699(95)80066-2; FAHY JV, 1995, J ALLERGY CLIN IMMUN, V95, P843, DOI 10.1016/S0091-6749(95)70128-1; GUNDEL RH, 1991, J CLIN INVEST, V88, P1407, DOI 10.1172/JCI115447; Hamilos DL, 1999, J ALLERGY CLIN IMMUN, V103, P79, DOI 10.1016/S0091-6749(99)70529-4; Hamilos DL, 1996, AM J RESP CELL MOL, V15, P443, DOI 10.1165/ajrcmb.15.4.8879177; Horie S, 1996, J ALLERGY CLIN IMMUN, V98, P371, DOI 10.1016/S0091-6749(96)70161-6; Lamblin C, 1998, AM J RESP CRIT CARE, V157, P394, DOI 10.1164/ajrccm.157.2.97-02099; Leung DYM, 1997, PEDIATR RES, V42, P559, DOI 10.1203/00006450-199711000-00001; MASUYAMA K, 1994, IMMUNOLOGY, V82, P192; Meagher LC, 1996, J IMMUNOL, V156, P4422; MELTZER EO, 1994, J ALLERGY CLIN IMMUN, V94, P708, DOI 10.1016/0091-6749(94)90178-3; NACLERIO RM, 1993, J ALLERGY CLIN IMMUN, V92, P717, DOI 10.1016/0091-6749(93)90015-8; Nelson HS, 1999, J ALLERGY CLIN IMMUN, V104, pS138, DOI 10.1016/S0091-6749(99)70309-X; OKADA S, 1995, J ALLERGY CLIN IMMUN, V95, P1236, DOI 10.1016/S0091-6749(95)70081-1; Pullerits T, 1997, J ALLERGY CLIN IMMUN, V100, P601, DOI 10.1016/S0091-6749(97)70162-3; RAK S, 1994, CLIN EXP ALLERGY, V24, P930, DOI 10.1111/j.1365-2222.1994.tb02724.x; ROBINSON D, 1993, AM REV RESPIR DIS, V148, P401, DOI 10.1164/ajrccm/148.2.401; Romagnani S, 1997, INT ARCH ALLERGY IMM, V113, P153, DOI 10.1159/000237532; SANZ MJ, 1995, J IMMUNOL, V154, P1364; Schwiebert LA, 1996, J ALLERGY CLIN IMMUN, V97, P143, DOI 10.1016/S0091-6749(96)80214-4; Shimizu Y, 1998, CLIN EXP ALLERGY, V28, P497, DOI 10.1046/j.1365-2222.1998.00267.x; SHUTE J, 1994, CLIN EXP ALLERGY, V24, P203, DOI 10.1111/j.1365-2222.1994.tb00220.x; Sur S, 1998, J LEUKOCYTE BIOL, V63, P715, DOI 10.1002/jlb.63.6.715; VENGE P, 1988, AM REV RESPIR DIS, V138, P54	31	79	85	2	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2000	106	2					307	312		10.1067/mai.2000.108111	http://dx.doi.org/10.1067/mai.2000.108111			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	343NH	10932075				2022-12-18	WOS:000088708100014
J	Taha, RA; Minshall, EM; Leung, DYM; Boguniewicz, M; Luster, A; Muro, S; Toda, M; Hamid, QA				Taha, RA; Minshall, EM; Leung, DYM; Boguniewicz, M; Luster, A; Muro, S; Toda, M; Hamid, QA			Evidence for increased expression of eotaxin and monocyte chemotactic protein-4 in atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; eotaxin; monocyte chemotactic protein-4; eosinophils; lymphocytes; chemokines	C-C CHEMOKINES; HUMAN EOSINOPHILS; ENDOTHELIAL-CELLS; MESSENGER-RNA; NASAL-MUCOSA; BONE-MARROW; INFLAMMATION; LYMPHOCYTES; CCR3; BASOPHILS	Background: Atopic dermatitis (AD) is a chronic inflammatory skin disease associated with tissue eosinophilia and the activation of T lymphocytes. The novel eosinophil chemoattractants, eotaxin and monocyte chemotactic protein (MCP)-4, are up-regulated at sites of allergic inflammation, Set their contribution to the pathophysiologic mechanisms of AD remains to be determined. Objective: We sought to investigate the expression of eotaxin and MCP-4 in acute and chronic lesions from patients with AD and to determine their relationship to the numbers of resident inflammatory cells. Methods: With use of in situ hybridization, the expression of eotaxin and MCP-4 messenger RNA (mRNA) in skin biopsy specimens from patients with acute and chronic AD skin Lesions was compared with that of uninvolved skin from these patients and skin from healthy volunteers. Results: There was a constitutive expression of eotaxin and MCP-4 mRNA in skin biopsy specimens from healthy subjects. Positive signal for chemokine mRNA was observed both within the epidermis and inflammatory cells macrophages, eosinophils. and T cells of the subepidermis in AD skin lesions. Within the subepithelium acute and chronic skin lesions exhibited a significant increase in the numbers of eotaxin and MCP-4 mRNA-positive cells compared with uninvolved skin (P < .01), whereas the numbers of eotaxin and MCP-4 mRNA-positive cells were significantly higher in chronic AD compared with acute AD skin lesions (P < .005. P < .001, respectively). Correlations were observed between the expression of eotaxin and MCP-4 mRNA and the presence of eosinophils and macrophages, respectively, in AD lesions (r(2) = 0.84, r(2) = 0.94). Conclusion: There is an increased expression of eotaxin and MCP-4 in acute and chronic lesions, suggesting that these chemotactic factors play a major role in the pathophysiologic mechanisms of AD.	McGill Univ, Meakins Christie Labs, Montreal, PQ H2X 2P2, Canada; Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO USA; Harvard Univ, Sch Med, Boston, MA USA	McGill University; National Jewish Health; Harvard University; Harvard Medical School	Hamid, QA (corresponding author), McGill Univ, Meakins Christie Labs, 3626 St Urbain St, Montreal, PQ H2X 2P2, Canada.		Luster, Andrew/ABE-6504-2020	Luster, Andrew/0000-0001-9679-7912	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL037260, R01HL037260] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041256] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00051] Funding Source: Medline; NHLBI NIH HHS [HL37260] Funding Source: Medline; NIAMS NIH HHS [AR41256] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Christodoulopoulos P, 1999, J ALLERGY CLIN IMMUN, V103, P1036, DOI 10.1016/S0091-6749(99)70176-4; FREW AJ, 1988, J IMMUNOL, V141, P4158; GarciaZepeda EA, 1996, J IMMUNOL, V157, P5613; HAMID Q, 1994, J CLIN INVEST, V94, P870, DOI 10.1172/JCI117408; HANIFIN JM, 1984, J ALLERGY CLIN IMMUN, V73, P211, DOI 10.1016/S0091-6749(84)80008-1; Heath H, 1997, J CLIN INVEST, V99, P178, DOI 10.1172/JCI119145; Hohki G, 1997, BIOCHEM BIOPH RES CO, V241, P136, DOI 10.1006/bbrc.1997.7785; Jia GQ, 1999, INT IMMUNOL, V11, P1, DOI 10.1093/intimm/11.1.1; Kitayama J, 1997, J IMMUNOL, V159, P3929; Lacy P, 1997, MEM I OSWALDO CRUZ, V92, P125, DOI 10.1590/S0074-02761997000800017; Lamkhioued B, 1997, J IMMUNOL, V159, P4593; LEUNG DYM, 1983, J ALLERGY CLIN IMMUN, V71, P47, DOI 10.1016/0091-6749(83)90546-8; Minshall EM, 1997, AM J RESP CELL MOL, V17, P683, DOI 10.1165/ajrcmb.17.6.2865; Palframan RT, 1998, BLOOD, V91, P2240, DOI 10.1182/blood.V91.7.2240.2240_2240_2248; Robinson DS, 1999, INT ARCH ALLERGY IMM, V118, P98, DOI 10.1159/000024039; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Rothenberg ME, 1999, AM J RESP CELL MOL, V21, P291, DOI 10.1165/ajrcmb.21.3.f160; Sallusto F, 1998, J EXP MED, V187, P875, DOI 10.1084/jem.187.6.875; Sallusto F, 1997, SCIENCE, V277, P2005, DOI 10.1126/science.277.5334.2005; Sanz MJ, 1998, J IMMUNOL, V160, P3569; Stellato C, 1997, J CLIN INVEST, V99, P926, DOI 10.1172/JCI119257; Taha RA, 1999, J ALLERGY CLIN IMMUN, V103, P476, DOI 10.1016/S0091-6749(99)70474-4; Tenscher K, 1997, BIOCHEM BIOPH RES CO, V240, P32, DOI 10.1006/bbrc.1997.7601; UEHARA M, 1990, CLIN EXP DERMATOL, V15, P264, DOI 10.1111/j.1365-2230.1990.tb02086.x; Wright ED, 1998, J OTOLARYNGOL, V27, P281; Yawalkar N, 1999, J INVEST DERMATOL, V113, P43, DOI 10.1046/j.1523-1747.1999.00619.x; YING S, 1994, IMMUNOLOGY, V82, P200; Ying S, 1999, J IMMUNOL, V163, P3976	28	79	85	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2000	105	5					1002	1007		10.1067/mai.2000.106483	http://dx.doi.org/10.1067/mai.2000.106483			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	316TW	10808183				2022-12-18	WOS:000087185000021
J	van Hage-Hamsten, M; Kronqvist, M; Zetterstrom, O; Johansson, E; Niederberger, V; Vrtala, S; Gronlund, H; Gronneberg, R; Valenta, R				van Hage-Hamsten, M; Kronqvist, M; Zetterstrom, O; Johansson, E; Niederberger, V; Vrtala, S; Gronlund, H; Gronneberg, R; Valenta, R			Skin test evaluation of genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1: Results obtained with a mix of two recombinant Bet v 1 fragments and recombinant Bet v 1 trimer in a Swedish population before the birch pollen season	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						recombinant birch pollen allergens; Bet v 1; hypoallergenic Bet v 1 derivatives; intradermal testing; skin prick testing	IGE; IMMUNOTHERAPY; EXPRESSION; BET-V-1; PROFILIN; PROTEINS; BINDING; IDENTIFICATION; PURIFICATION; INDIVIDUALS	Background: More than 95% of birch pollen-allergic subjects react with the major birch pollen allergen, Bet v 1, and almost 60% of them are sensitized exclusively to this allergen. Objective: The aim of this study was to compare the in vivo biologic activity of genetically engineered hypoallergenic derivatives of Bet v 1 (an equimolar mixture of 2 recombinant [r] Bet v 1 fragments and of rBet v I trimer) with that of rBet v 1 wild-type by skin prick and intradermal testing. Methods: Birch pollen-allergic patients who had not received immunotherapy (n = 23), a group of allergic patients without birch pollen allergy (n = 12), and nonatopic persons (n = 8) from northern Europe (Sweden) underwent skin prick and intradermal testing with different concentrations of the recombinant allergens and commercial birch pollen extract before the birch pollen season. Immediate and late-phase reactions were recorded and allergen-specific IgE and IgG subclass responses were determined by CAP radioallergosorbent test and ELISA, respectively. Results: Atopic persons without birch pollen allergy and nonatopic individuals did not have skin reactions to rBet v 1 wild-type and genetically engineered hypoallergenic derivatives, By intradermal testing, 8 of 23 and 13 of 23 birch pollen-allergic patients did not react with the highest concentration (1 mu g/mL) of the rBet v 1 fragment mix and rBet v 1 trimer, respectively, compared with 1 with rBet v 1 wild type. Likewise, the highest concentration (100 mu g/mL) of fragment mix or trimer failed to elicit a positive skin prick test in 18 of 23 and 15 of 23 patients in comparison with 0/23 with the monomer. No late reactions were observed. Conclusion: The recombinant hypoallergenic birch pollen allergens can probably be used for patient-tailored immunotherapy with a reduced risk to induce anaphylactic reactions.	Karolinska Hosp, Dept Clin Immunol, S-17176 Stockholm, Sweden; Karolinska Hosp, Dept Resp Med, S-17176 Stockholm, Sweden; Danderyd Hosp, Dept Med, Stockholm, Sweden; Karolinska Inst, Huddinge Hosp, Dept Resp Med, S-10401 Stockholm, Sweden; Pharmacia & Upjohn Diagnost, Uppsala, Sweden; Univ Vienna, Vienna Gen Hosp, Dept Otorhinolaryngol, Vienna, Austria; Univ Vienna, Vienna Gen Hosp, Dept Gen & Expt Pathol, Mol Immunopathol Grp, Vienna, Austria	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Danderyds Hospital; Karolinska Institutet; Pfizer; Pharmacia Corporation; University of Vienna; University of Vienna	van Hage-Hamsten, M (corresponding author), Karolinska Hosp, Dept Clin Immunol, S-17176 Stockholm, Sweden.		van Hage, Marianne/A-9678-2017	van Hage, Marianne/0000-0003-3091-1596; Valenta, Rudolf/0000-0001-5944-3365; Gronlund, Hans/0000-0003-4882-7624; Vrtala, Susanne/0000-0003-4250-8243				Akdis CA, 1998, EUR J IMMUNOL, V28, P914, DOI 10.1002/(SICI)1521-4141(199803)28:03<914::AID-IMMU914>3.0.CO;2-C; Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; EBNER C, 1993, J IMMUNOL, V150, P1047; EBNER C, 1995, J ALLERGY CLIN IMMUN, V95, P962, DOI 10.1016/S0091-6749(95)70096-X; Elfman L, 1997, INT ARCH ALLERGY IMM, V113, P249, DOI 10.1159/000237561; Engel E, 1997, J BIOL CHEM, V272, P28630, DOI 10.1074/jbc.272.45.28630; ERIKSSON NE, 1978, ALLERGY, V33, P299, DOI 10.1111/j.1398-9995.1978.tb01555.x; FERREIRA FD, 1993, J BIOL CHEM, V268, P19574; Fritsche R, 1997, J ALLERGY CLIN IMMUN, V100, P266, DOI 10.1016/S0091-6749(97)70235-5; Gajhede M, 1996, NAT STRUCT BIOL, V3, P1040, DOI 10.1038/nsb1296-1040; HoffmannSommergruber K, 1997, PROTEIN EXPRES PURIF, V9, P33, DOI 10.1006/prep.1996.0671; JAROLIM E, 1989, ALLERGY, V44, P385, DOI 10.1111/j.1398-9995.1989.tb04169.x; KING TP, 1995, J ALLERGY CLIN IMMUN, V96, P5, DOI 10.1016/S0091-6749(95)70027-7; KOLBE L, 1991, INT ARCH ALLER A IMM, V95, P202, DOI 10.1159/000235430; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Menz G, 1996, CLIN EXP ALLERGY, V26, P50, DOI 10.1111/j.1365-2222.1996.tb00056.x; Muller U, 1998, J ALLERGY CLIN IMMUN, V101, P747, DOI 10.1016/S0091-6749(98)70402-6; Niederberger V, 1998, J ALLERGY CLIN IMMUN, V102, P579, DOI 10.1016/S0091-6749(98)70273-8; NORMAN PS, 1982, J ALLERGY CLIN IMMUN, V70, P248, DOI 10.1016/0091-6749(82)90061-6; Pauli G, 1996, J ALLERGY CLIN IMMUN, V97, P1100, DOI 10.1016/S0091-6749(96)70264-6; SECRIST H, 1995, J EXP MED, V181, P1081, DOI 10.1084/jem.181.3.1081; SEIBERLER S, 1994, EMBO J, V13, P3481, DOI 10.1002/j.1460-2075.1994.tb06654.x; Simons FER, 1996, INT IMMUNOL, V8, P1937, DOI 10.1093/intimm/8.12.1937; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Twardosz A, 1997, BIOCHEM BIOPH RES CO, V239, P197, DOI 10.1006/bbrc.1997.6860; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; VALENTA R, 1991, J ALLERGY CLIN IMMUN, V88, P889, DOI 10.1016/0091-6749(91)90245-J; VALENTA R, 1993, J ALLERGY CLIN IMMUN, V91, P88, DOI 10.1016/0091-6749(93)90300-5; Valenta R, 1998, ALLERGY, V53, P552, DOI 10.1111/j.1398-9995.1998.tb03930.x; Valenta R, 1996, J ALLERGY CLIN IMMUN, V97, P893, DOI 10.1016/S0091-6749(96)80062-5; VALENTA R, 1998, ALLERGEN IMMUNOTHERA, P85; Vrtala S, 1999, INT ARCH ALLERGY IMM, V118, P218, DOI 10.1159/000024075; Vrtala S, 1998, J IMMUNOL, V160, P6137; Vrtala S, 1997, J CLIN INVEST, V99, P1673, DOI 10.1172/JCI119330; VRTALA S, 1993, INT ARCH ALLERGY IMM, V102, P160, DOI 10.1159/000236567	36	79	90	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1999	104	5					969	977		10.1016/S0091-6749(99)70077-1	http://dx.doi.org/10.1016/S0091-6749(99)70077-1			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	257JH	10550741				2022-12-18	WOS:000083778400019
J	Eggleston, PA; Wood, RA; Rand, C; Nixon, J; Chen, PH; Lukk, P				Eggleston, PA; Wood, RA; Rand, C; Nixon, J; Chen, PH; Lukk, P			Removal of cockroach allergen from inner-city homes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cockroach allergen; inner city; homes; insecticides	ASTHMA; DUST; EXPOSURE; CHILDREN	Background: Allergen avoidance has been shown to improve the morbidity and physiology of asthma, Although cockroach allergen has been implicated in chronic asthma, little work has been reported on the feasibility of allergen removal from infested homes. Objective: The objective of this study was to examine the effect of professional pest control and home cleaning on cockroach infestation and allergen concentrations in settled dust samples from the kitchens, bedrooms, and television-living rooms of inner-city homes. Methods: Thirteen homes in inner-city Baltimore, Maryland, received a professional cleaning, with vacuuming and a thorough cleaning in the kitchen. Pest control technicians applied abamectin 0.05% gel to the kitchen and, to a limited extent, to the rest of the home and the cleaning was repeated, Technicians visited monthly from month 2 to month 8 to inspect, collect dust samples, and place passive cockroach traps, Bla g 1 concentrations in dust extract were measured by means of ELISA. Results: The number of cockroaches captured in passive traps decreased rapidly in 11 homes, but complete extermination was achieved in only 7 homes. Bla g 1 concentrations were reduced by 93% in kitchens, 77% in television-living rooms, and 74% in bedrooms. The relative reduction in cockroach allergen was not related to successful extermination or to signs of poor housecleaning. Conclusion: We concluded that cockroach extermination is feasible in inner-city homes but that standard housecleaning procedures are only partially effective in removing residual allergen over 8 months.	Amer Pest Management Inc, Tacoma Pk, MD USA; Johns Hopkins Univ, Dept Pediat, Baltimore, MD 21218 USA; Johns Hopkins Univ, Dept Med, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins University	Eggleston, PA (corresponding author), Johns Hopkins Hosp, Dept Pediat, CMSC 1102,600 N Wolfe St, Baltimore, MD 21287 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES009606, R01ES007527] Funding Source: NIH RePORTER; NIEHS NIH HHS [P01 ES09606, R01 ES07527] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BENNETT GW, 1988, TRUMANS SCI GUIDE PE; CHAPMAN MD, 1993, INSIGHTS ALLERGY, V8, P1; DEBLAY F, J ALLERGY CLIN IMMUN, V7, P99; DEBLAY F, J ALLERGY CLIN IMMUN, V7, P107; EHNERT B, 1992, J ALLERGY CLIN IMMUN, V90, P135, DOI 10.1016/S0091-6749(06)80024-2; Gergen PJ, 1999, J ALLERGY CLIN IMMUN, V103, P501, DOI 10.1016/S0091-6749(99)70477-X; KANG B, 1976, J ALLERGY CLIN IMMUN, V58, P357, DOI 10.1016/0091-6749(76)90115-9; POLLART S, 1995, J ALLERGY CLIN IMMUN, V87, P505; REID BL, 1989, INSECTICIDE ACARACID, V17, P4; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Sarpong SB, 1996, ANN ALLERG ASTHMA IM, V76, P257, DOI 10.1016/S1081-1206(10)63437-0; WALSHAW MJ, 1986, Q J MED, V58, P199; WILLIAMS LW, 1998, ERADICATION COCKROAC, V101, pS156; WOOD RA, 1989, J ALLERGY CLIN IMMUN, V83, P70; WRIGHT CG, 1988, INSECTICIDE ACARACID, V15, P355	15	79	82	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1999	104	4	1				842	846		10.1016/S0091-6749(99)70296-4	http://dx.doi.org/10.1016/S0091-6749(99)70296-4			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	248NG	10518830	Bronze			2022-12-18	WOS:000083281200017
J	Wright, AL; Sherrill, D; Holberg, CJ; Halonen, M; Martinez, FD				Wright, AL; Sherrill, D; Holberg, CJ; Halonen, M; Martinez, FD			Breast-feeding, maternal IgE, and total serum IgE in childhood	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IgE; breast-feeding; childhood; allergy; infant feeding; longitudinal studies; asthma	SKIN-TEST REACTIVITY; FOLLOW-UP; 1ST YEAR; NEONATAL-PERIOD; ATOPIC DISEASE; FED INFANTS; HUMAN-MILK; ASTHMA; CHILDREN; RISK	Background: There is controversy regarding the relationship of the effect of breast-feeding on markers of allergy such as total serum IgE in childhood. Objective: This study, using longitudinal data, tested the hypothesis that the relation of breast-feeding to IgE in childhood differs depending on maternal total IgE level, Methods: Total serum IgE was assessed with the paper radioimmunosorbent test at 4 ages in nonselected children enrolled at birth into the prospective Tucson Children's Respiratory Study. Children were classified as never breast-fed, breast-fed less than 4 months, or breast-fed 4 months or longer, on the basis of physician report or questionnaires completed by parents by the time the child was 18 months old. A longitudinal random effects model was used to test for group differences and temporal trends in IgE for children classified,vith reference to maternal IgE (high tertile vs all others) and breast-feeding history, A total of 664 children with 1457 observations were included. Results: Among children whose mothers were in the 2 lower tertiles of IgE, breast-feeding was associated with lower total serum IgE at age 6 years (24.2 vs 44.3 IU/mL for never breastfed children; P < .02); similar trends existed at age 11 years. In contrast, for children whose mothers were in the highest tertile of IgE, breast feeding of 4 months or longer was associated with higher IgE levels in the child compared with those never breast-fed or breast-fed less than 4 months (97.0 vs 38.9 IU/mL; P < .005). These cross-sectional analyses were confirmed with the longitudinal random effects model, which also showed no effect of confounders. Paternal IgE showed no similar relation with child IgE. Conclusion: Breast feeding appears to have paradoxic relations with IgE in childhood, depending on maternal IgE level. These findings may help explain the contradictory results found in other investigations of the relation of breast-feeding to allergic symptoms and markers.	Univ Arizona, Arizona Hlth Sci Ctr, Resp Sci Ctr, Tucson, AZ 85724 USA; Univ Arizona, Dept Pediat, Tucson, AZ 85724 USA; Univ Arizona, Steele Mem Childrens Res Ctr, Tucson, AZ 85724 USA; Univ Arizona, Arizona Prevent Ctr, Tucson, AZ 85724 USA; Univ Arizona, Dept Pharmacol, Tucson, AZ 85724 USA	University of Arizona; University of Arizona Health Sciences; University of Arizona; University of Arizona; University of Arizona; University of Arizona	Wright, AL (corresponding author), Univ Arizona, Arizona Hlth Sci Ctr, Resp Sci Ctr, 1501 N Campbell Ave, Tucson, AZ 85724 USA.			Halonen, Marilyn/0000-0001-9606-935X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014136, R01HL056177] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL R01 56177, HL 14136] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLARDYCE RA, 1984, CLIN ALLERGY, V14, P259, DOI 10.1111/j.1365-2222.1984.tb02205.x; BARBEE RA, 1981, J ALLERGY CLIN IMMUN, V68, P106, DOI 10.1016/0091-6749(81)90167-6; BRUNO G, 1993, ALLERGY PROC, V14, P181, DOI 10.2500/108854193778878682; BUONOCORE G, 1992, BIOL NEONATE, V62, P10; BURROWS B, 1992, J ALLERGY CLIN IMMUN, V90, P376, DOI 10.1016/S0091-6749(05)80018-1; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; CUNNINGHAM AS, 1991, J PEDIATR-US, V118, P659, DOI 10.1016/S0022-3476(05)80023-X; DOWNHAM MAPS, 1976, BRIT MED J, V2, P274, DOI 10.1136/bmj.2.6030.274; Duchen K, 1996, PEDIATR ALLERGY IMMU, V7, P44, DOI 10.1111/j.1399-3038.1996.tb00104.x; Duchen K, 1998, PEDIATR RES, V44, P478, DOI 10.1203/00006450-199810000-00003; DUFFY LC, 1986, AM J PUBLIC HEALTH, V76, P259, DOI 10.2105/AJPH.76.3.259; DUNCAN B, 1993, PEDIATRICS, V91, P867; EGLINTON BA, 1994, IMMUNOL CELL BIOL, V72, P306, DOI 10.1038/icb.1994.46; GAROFALO R, 1995, PEDIATR RES, V37, P444, DOI 10.1203/00006450-199504000-00010; Goldman AS, 1996, J MAMMARY GLAND BIOL, V1, P251, DOI 10.1007/BF02018078; HALONEN M, 1991, CLIN EXP ALLERGY, V21, P235, DOI 10.1111/j.1365-2222.1991.tb00836.x; HALONEN M, 1982, J ALLERGY CLIN IMMUN, V69, P221, DOI 10.1016/0091-6749(82)90103-8; Hattevig G, 1993, Pediatr Allergy Immunol, V4, P182, DOI 10.1111/j.1399-3038.1993.tb00089.x; HOLBERG CJ, 1991, AM J EPIDEMIOL, V133, P1135, DOI 10.1093/oxfordjournals.aje.a115826; Holt PG, 1997, PEDIATR ALLERGY IMMU, V8, P53, DOI 10.1111/j.1399-3038.1997.tb00145.x; Jones RH, 1993, LONGITUDINAL DATA SE; JUTO P, 1980, CLIN ALLERGY, V10, P593, DOI 10.1111/j.1365-2222.1980.tb02141.x; KELLY YJ, 1995, THORAX, V50, P525, DOI 10.1136/thx.50.5.525; KERSTJENS HAM, 1995, AM J RESP CRIT CARE, V151, P360, DOI 10.1164/ajrccm.151.2.7842192; Koning H, 1996, PEDIATR RES, V40, P363, DOI 10.1203/00006450-199609000-00001; KRAMER MS, 1988, J PEDIATR-US, V112, P181, DOI 10.1016/S0022-3476(88)80054-4; LAIRD NM, 1982, BIOMETRICS, V38, P963, DOI 10.2307/2529876; Litonjua AA, 1998, AM J RESP CRIT CARE, V158, P176, DOI 10.1164/ajrccm.158.1.9710014; MAGNUSSON CGM, 1985, INT ARCH ALLER A IMM, V77, P292, DOI 10.1159/000233834; MARTINEZ FD, 1994, AM J HUM GENET, V55, P555; MARTINEZ FD, 1994, THORAX, V49, P1189, DOI 10.1136/thx.49.12.1189; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; ORYSZCZYN MP, 1995, AM J RESP CRIT CARE, V151, P663; Peat JK, 1996, ALLERGY, V51, P804, DOI 10.1111/j.1398-9995.1996.tb00026.x; POYSA L, 1991, ALLERGY PROC, V12, P107, DOI 10.2500/108854191779011800; SAARINEN UM, 1995, LANCET, V346, P1065, DOI 10.1016/S0140-6736(95)91742-X; SAARINEN UM, 1979, CLIN ALLERGY, V9, P339, DOI 10.1111/j.1365-2222.1979.tb02492.x; SAVILAHTI E, 1987, ARCH DIS CHILD, V62, P269, DOI 10.1136/adc.62.3.269; SEARS MR, 1991, NEW ENGL J MED, V325, P1067, DOI 10.1056/NEJM199110103251504; SHERRILL DL, IN PRESS J ALLERGY C; STARK PL, 1982, J MED MICROBIOL, V15, P189, DOI 10.1099/00222615-15-2-189; TAUSSIG LM, 1989, AM J EPIDEMIOL, V129, P1219, DOI 10.1093/oxfordjournals.aje.a115242; TOLLERUD DJ, 1991, AM REV RESPIR DIS, V144, P776, DOI 10.1164/ajrccm/144.4.776; UNDERDOWN BJ, 1976, J IMMUNOL, V116, P1435; WRIGHT AL, 1989, BRIT MED J, V299, P946, DOI 10.1136/bmj.299.6705.946; Wright AL, 1998, PEDIATRICS, V101, P837, DOI 10.1542/peds.101.5.837; WRIGHT AL, 1989, AM J EPIDEMIOL, V129, P1232, DOI 10.1093/oxfordjournals.aje.a115243; YOSHIOKA H, 1983, PEDIATRICS, V72, P317	48	79	80	0	6	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1999	104	3	1				589	594		10.1016/S0091-6749(99)70328-3	http://dx.doi.org/10.1016/S0091-6749(99)70328-3			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	241EP	10482832				2022-12-18	WOS:000082870000020
J	Ohta, K; Yamashita, N				Ohta, K; Yamashita, N			Apoptosis of eosinophils and lymphocytes in allergic inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						apoptosis; eosinophils; lymphocytes; asthma; allergic inflammation; corticosteroids; theophylline; phosphodiesterase inhibitors; IL-5; GM-CSF	COLONY-STIMULATING FACTOR; PROGRAMMED CELL-DEATH; LEUKEMIA CELLS; ASTHMA; THEOPHYLLINE; RECEPTOR; SURVIVAL; INTERLEUKIN-5; INHIBITION; PHOSPHODIESTERASE	A characteristic feature of apoptosis is that the cellular contents that are biologically active are always surrounded by the cell membrane throughout the entire process. Thus the apoptotic cells are eliminated calmly and quickly without evoking inflammation. In allergic inflammation activated eosinophils and lymphocytes have been known to accumulate at the site of inflammation at least in part because of their prolonged survival, Corticosteroids are the most potent anti-inflammatory agent used for treating asthma. They inhibit the prolonged survival of eosinophils and lymphocytes directly by inducing apoptosis and indirectly by suppressing the release of cytokines supporting their survival. Theophylline, a classical bronchodilator, has been reported to hare anti-inflammatory effects. Surprisingly, theophylline inhibited the prolonged survival of eosinophils in the presence of IL-5 in vitro by means of induction of apoptosis, Lymphocytes also undergo apoptosis in the presence of theophylline. One of the mechanisms for theophylline to induce apoptosis in eosinophils and lymphocytes is to elevate intracellular cyclic adenosine monophosphate because phosphodiesterase inhibitors and adenylate cyclase activators, which increase intracellular cyclic adenosine monophosphate, can cause apoptosis in those cells. Induction of apoptosis is beneficial in allergic inflammation, and the use of corticosteroids and theophylline in combination may be appropriate to induce apoptosis in eosinophils and lymphocytes.	Teikyo Univ, Sch Med, Dept Med, Itabashi Ku, Tokyo 1738605, Japan	Teikyo University	Ohta, K (corresponding author), Teikyo Univ, Sch Med, Dept Med, Itabashi Ku, 2-11-1 Kaga, Tokyo 1738605, Japan.		Yamashita, Naomi/F-5045-2011					Adachi T, 1996, J ALLERGY CLIN IMMUN, V98, pS207, DOI 10.1016/S0091-6749(96)70068-4; ALMAWI WY, 1991, J IMMUNOL, V146, P3523; BERGSTRAND H, 1980, EUR J RESPIR DIS, V61, P37; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; DENT LA, 1990, J EXP MED, V172, P1425, DOI 10.1084/jem.172.5.1425; DJUKANOVIC R, 1992, AM REV RESPIR DIS, V145, P669, DOI 10.1164/ajrccm/145.3.669; Evans DJ, 1997, NEW ENGL J MED, V337, P1412, DOI 10.1056/NEJM199711133372002; FRIED J, 1978, J HISTOCHEM CYTOCHEM, V26, P921, DOI 10.1177/26.11.82573; GLEICH GJ, 1990, J ALLERGY CLIN IMMUN, V85, P422, DOI 10.1016/0091-6749(90)90151-S; HALLSWORTH MP, 1992, IMMUNOLOGY, V75, P382; Hallsworth MP, 1996, BRIT J PHARMACOL, V117, P79, DOI 10.1111/j.1476-5381.1996.tb15157.x; HER E, 1991, J CLIN INVEST, V88, P1982, DOI 10.1172/JCI115524; HUANG RW, 1993, INT J HEMATOL, V58, P83; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745, DOI 10.1164/ajrccm/140.6.1745; Jiang X, 1996, P NATL ACAD SCI USA, V93, P11236, DOI 10.1073/pnas.93.20.11236; KAWABORI S, 1991, LAB INVEST, V64, P224; KAY AB, 1991, J ALLERGY CLIN IMMUN, V87, P893, DOI 10.1016/0091-6749(91)90408-G; KAY AB, 1991, J EXP MED, V173, P775, DOI 10.1084/jem.173.3.775; Kay AB, 1997, INT ARCH ALLERGY IMM, V113, P196, DOI 10.1159/000237545; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KIDNEY J, 1995, AM J RESP CRIT CARE, V151, P1907, DOI 10.1164/ajrccm.151.6.7767539; Kim DH, 1998, BLOOD, V92, P2484, DOI 10.1182/blood.V92.7.2484.2484_2484_2494; KITAMURA T, 1992, BLOOD, V80, P84; KIZAKI H, 1990, J BIOL CHEM, V265, P5280; LAITINEN LA, 1993, AM REV RESPIR DIS, V147, P697, DOI 10.1164/ajrccm/147.3.697; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599, DOI 10.1164/arrd.1985.131.4.599; Leung DYM, 1998, ANN NY ACAD SCI, V840, P735, DOI 10.1111/j.1749-6632.1998.tb09612.x; LOMO J, 1995, J IMMUNOL, V154, P1634; Meagher LC, 1996, J IMMUNOL, V156, P4422; Mentz F, 1998, CYTOMETRY, V32, P95; Mentz F, 1996, BLOOD, V88, P2172, DOI 10.1182/blood.V88.6.2172.bloodjournal8862172; MENTZ F, 1995, BRIT J HAEMATOL, V90, P957, DOI 10.1111/j.1365-2141.1995.tb05225.x; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NASSIF EG, 1981, NEW ENGL J MED, V304, P71, DOI 10.1056/NEJM198101083040202; NIETO MA, 1992, ANN NY ACAD SCI, V650, P115; NIETO MA, 1989, J IMMUNOL, V143, P4166; NORTHROP JP, 1992, J EXP MED, V175, P1235, DOI 10.1084/jem.175.5.1235; Ohta K, 1996, CLIN EXP ALLERGY, V26, P10, DOI 10.1111/j.1365-2222.1996.tb01137.x; Ohta K, 1997, J ALLERGY CLIN IMMUN, V99, P1451; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Rabe KF, 1998, CLIN EXP ALLERGY, V28, P35; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; RYAN JJ, 1994, P NATL ACAD SCI USA, V91, P5878, DOI 10.1073/pnas.91.13.5878; SCHULZEOSTHOFF K, 1994, EMBO J, V13, P4587, DOI 10.1002/j.1460-2075.1994.tb06780.x; Shute JK, 1998, CLIN EXP ALLERGY, V28, P47; SULLIVAN P, 1994, LANCET, V343, P1006, DOI 10.1016/S0140-6736(94)90127-9; TAI PC, 1991, CLIN EXP IMMUNOL, V85, P312; Tsuyuki S, 1995, J CLIN INVEST, V96, P2924, DOI 10.1172/JCI118364; Varfolomeev EE, 1996, J EXP MED, V183, P1271, DOI 10.1084/jem.183.3.1271; Woolley KL, 1996, AM J RESP CRIT CARE, V154, P237, DOI 10.1164/ajrccm.154.1.8680686; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YAMAGUCHI Y, 1991, BLOOD, V78, P2542; Yasui K, 1997, J CLIN INVEST, V100, P1677, DOI 10.1172/JCI119692	55	79	86	1	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1999	104	1					14	21		10.1016/S0091-6749(99)70107-7	http://dx.doi.org/10.1016/S0091-6749(99)70107-7			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	221QZ	10400833				2022-12-18	WOS:000081738900002
J	Puhakka, T; Makela, MJ; Alanen, A; Kallio, T; Korsoff, L; Arstila, P; Leinonen, M; Pulkkinen, M; Suonpaa, J; Mertsola, J; Ruuskanen, O				Puhakka, T; Makela, MJ; Alanen, A; Kallio, T; Korsoff, L; Arstila, P; Leinonen, M; Pulkkinen, M; Suonpaa, J; Mertsola, J; Ruuskanen, O			Sinusitis in the common cold	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						sinusitis; paranasal sinusitis; viral sinusitis; common cold; rhinovirus; viral respiratory infection; fluticasone propionate	ACUTE MAXILLARY SINUSITIS; ORAL ANTIBIOTIC-THERAPY; GENERAL-PRACTICE; RHINOVIRUS; IRRIGATION; DIAGNOSIS; CHILDREN; EFFICACY; ADJUNCT; ADULTS	Background: Acute community-acquired sinusitis is considered a bacterial complication of the common cold. Radiologic abnormalities in sinuses occur, however, in most patients with upper respiratory virus infections. Objective: Assessment of the occurrence, clinical profile, laboratory findings, and outcome of radiologically confirmed sinusitis was carried out as part of a common cold study in young adults. Methods: Clinical examinations and radiography of the paranasal sinuses were carried out on days 1, 7, and 21 in 197 patients with the common cold. The symptoms were recorded on diary cards on days 1 to 20, Ten viruses and 5 bacteria were studied as etiologic agents of common cold as reported earlier. Serum C reactive protein concentrations, erythrocyte sedimentation rates, and total white blood cell counts with differentials were determined in 40 randomized subjects on day 7, The effect of 6 days of intranasal fluticasone propionate treatment of the common cold in the prevention of sinusitis was analyzed. Results: On day 7, 39% of patients with the common cold in the placebo group (n = 98) had sinusitis, which we would prefer to call viral sinusitis. The symptoms of patients with sinusitis and those without it were not clinically distinguishable. Viral infection was detected in 81.6% of patients with sinusitis. No significantly increased levels of antibodies to bacteria were detected. Serum C reactive protein concentrations, erythrocyte sedimentation rates, and white blood cell counts were low in patients with sinusitis. All patients made a clinical recovery within 21 days without antibiotic treatment. Fluticasone propionate treatment tended to prevent paranasal sinusitis, especially in rhinovirus-positive subjects. Conclusion: Viral sinusitis frequently occurs in the early days of the common cold, but it is a self-limited illness. The sinuses should not be imaged in patients with the common cold if the signs and symptoms of illness gradually become less severe and no specific signs suggestive of bacterial sinusitis occur.	Turku Univ Hosp, Dept Pediat, FIN-20520 Turku, Finland; Turku Univ Hosp, Dept Pulm Dis & Clin Allergol, FIN-20520 Turku, Finland; Turku Univ Hosp, Dept Diagnost Radiol, FIN-20520 Turku, Finland; Turku Univ Hosp, Dept Otorhinolaryngol, FIN-20520 Turku, Finland; Turku Univ, Dept Virol, Turku, Finland; Natl Publ Hlth Inst, Oulu, Finland; Glaxo Wellcome Ltd, Espoo, Finland	University of Turku; University of Turku; University of Turku; University of Turku; University of Turku; Finland National Institute for Health & Welfare; GlaxoSmithKline	Puhakka, T (corresponding author), Univ Turku, Dept Pediat, Res Unit, Vaha Hameenkatu 1A3, SF-20500 Turku, Finland.		Mertsola, Jussi/AAE-3460-2021					Arruda E, 1997, J CLIN MICROBIOL, V35, P2864, DOI 10.1128/JCM.35.11.2864-2868.1997; AXELSSON A, 1970, ACTA OTO-LARYNGOL, V69, P302, DOI 10.3109/00016487009123368; Barlan IB, 1997, ANN ALLERG ASTHMA IM, V78, P598, DOI 10.1016/S1081-1206(10)63223-1; CUENANT G, 1986, ORL J OTO-RHINO-LARY, V48, P226, DOI 10.1159/000275873; GWALTNEY JM, 1994, NEW ENGL J MED, V330, P25, DOI 10.1056/NEJM199401063300105; GWALTNEY JM, 1995, PRINCIPLES PRACTICE, P585; HANSEN JG, 1995, BRIT MED J, V311, P233, DOI 10.1136/bmj.311.6999.233; Kaiser L, 1996, LANCET, V347, P1507, DOI 10.1016/S0140-6736(96)90670-4; Kaliner MA, 1997, J ALLERGY CLIN IMMUN, V99, pS829, DOI 10.1016/S0091-6749(97)70041-1; Makela MJ, 1998, J CLIN MICROBIOL, V36, P539; MELTZER EO, 1993, J ALLERGY CLIN IMMUN, V92, P812, DOI 10.1016/0091-6749(93)90058-N; Pitkaranta A, 1997, J CLIN MICROBIOL, V35, P1791; PUHAKKA T, IN RPESS J ALLERGY C; Qvarnberg Yrjo, 1992, Rhinology (Utrecht), V30, P103; SAVOLAINEN S, 1997, ACTA OTOLARYNGOL S5, V29, P144; SHAPIRO GG, 1992, J ALLERGY CLIN IMMUN, V90, P417, DOI 10.1016/0091-6749(92)90160-4; SYKES DA, 1986, LANCET, V2, P359; vanBuchem FL, 1997, LANCET, V349, P683, DOI 10.1016/S0140-6736(96)07585-X; VANDUIJN NP, 1992, BRIT MED J, V305, P684, DOI 10.1136/bmj.305.6855.684; WILLETT LR, 1994, J GEN INTERN MED, V9, P38, DOI 10.1007/BF02599141; Wiseman LR, 1997, DRUGS, V53, P885, DOI 10.2165/00003495-199753050-00014	21	79	87	0	6	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1998	102	3					403	408		10.1016/S0091-6749(98)70127-7	http://dx.doi.org/10.1016/S0091-6749(98)70127-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	124ZN	9768580	Bronze, Green Published			2022-12-18	WOS:000076212800011
J	Sussman, GL; Liss, GM; Deal, K; Brown, S; Cividino, M; Siu, S; Beezhold, DH; Smith, G; Swanson, MC; Yunginger, J; Douglas, A; Holness, DL; Lebert, P; Keith, P; Waserman, S; Turjanmaa, K				Sussman, GL; Liss, GM; Deal, K; Brown, S; Cividino, M; Siu, S; Beezhold, DH; Smith, G; Swanson, MC; Yunginger, J; Douglas, A; Holness, DL; Lebert, P; Keith, P; Waserman, S; Turjanmaa, K			Incidence of latex sensitization among latex glove users	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						latex gloves; sensitization; powdered gloves; powder-free gloves; latex protein concentrations; prospective study; skin testing; airborne exposure	HEALTH-CARE WORKERS; OCCUPATIONAL ASTHMA; HOSPITAL PERSONNEL; ALLERGY; PREVALENCE; PROTEIN	Background: Although there are several reports of the prevalence of latex sensitization among health care workers, the incidence of sensitization is unknown. Objective: The objective of this study was to estimate the incidence of sensitization among latex glove users at a hospital in Hamilton, Ontario, Canada. Methods: Workers with negative results to the skin test at baseline were followed prospectively over 1 year, some wearing powdered gloves and others using powder-free gloves. They were reevaluated in 1995 with a questionnaire and skin prick test (SPT) sensitivity to Latex reagents, three common inhalants, and six foods. A conversion was defined as a (new) latex SPT with wheal diameter at least 4 mm greater than saline control. Clove extracts were assayed for antigenic protein, and air samples were obtained to estimate exposure to airborne latex protein. Results: During powdered glove use, personal exposures ranged from 5 to 616 ng/m(3), whereas during powder-free glove use, all but two results for air samples were below the limit of detection (about 0.1 ng/m(3)). During the study period, the protein concentration in the powdered gloves, initially mean 557 mu g/gm of sample, declined at a rate of 295 mu g/gm per year (p < 0.0001). Of the 1075 SPT-negative participants at baseline, 479 were working in eligible wards, and of these, 435 (91%) participated in follow-up, 227 using powder-free gloves and 208 using powdered gloves. We identified four conversions, two (1.0%) in the powdered glove group and two (0.9%) in the powder-free group. The two participants using powdered gloves were the only converters who were symptomatic. The significance of skin test conversions identified in the powder-free group, both asymptomatic patients, is unclear. The limitations of the study are discussed, including the limited power, the declines in latex protein concentrations, and the possibility of information (observer) bias. Conclusion: To our knowledge, this represents the first reported estimate (about 1%) of incidence of sensitization in hospital personnel using latex gloves.	Univ Toronto, Wellesley Hosp, Sect Allergy, Toronto, ON M4Y 1J3, Canada; Ontario Minist Labour, Toronto, ON, Canada; Univ Toronto, Dept Prevent Med & Biostat, Toronto, ON, Canada; McMaster Univ, Michael G DeGroot Sch Business, Hamilton, ON, Canada; Hamilton Hlth Sci Corp, Employee Hlth Serv, Hamilton, ON, Canada; Guthrie Res Inst, Sayre, PA USA; Mayo Clin, Allerg Dis Res Lab, Rochester, MN USA; Hlth Canada, Med Devices Bur, Ottawa, ON K1A 0L2, Canada; Univ Toronto, St Michaels Hosp, Dept Occupat & Environm Hlth, Toronto, ON M5B 1W8, Canada; McMaster Univ, Dept Med, Hamilton, ON, Canada; Tampere Univ Hosp, Dept Dermatol, Tampere, Finland	University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; McMaster University; McMaster University; Mayo Clinic; Health Canada; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; McMaster University; Tampere University; Tampere University Hospital	Sussman, GL (corresponding author), 202 St Clair Ave W, Toronto, ON M4V 1R2, Canada.			Beezhold, Donald/0000-0001-5543-5747				ARELLANO R, 1992, ANESTHESIOLOGY, V77, P905, DOI 10.1097/00000542-199211000-00011; Beezhold D, 1996, J ALLERGY CLIN IMMUN, V98, P1097, DOI 10.1016/S0091-6749(96)80197-7; BEEZHOLD D, 1992, GUTHRIE J, V61, P77; BEEZHOLD DH, 1994, CLIN EXP IMMUNOL, V98, P408; Beezhold DH, 1996, CLIN EXP ALLERGY, V26, P416, DOI 10.1046/j.1365-2222.1996.d01-334.x; BLANCO C, 1994, ANN ALLERGY, V73, P309; CHAROUS BL, 1994, ANN ALLERGY, V73, P277; Grzybowski M, 1996, J ALLERGY CLIN IMMUN, V98, P535, DOI 10.1016/S0091-6749(96)70087-8; Hamann CP, 1993, AM J CONTACT DERMATI, V4, P4, DOI DOI 10.1097/01634989-199303000-00003; HUNT LW, 1995, J OCCUP ENVIRON MED, V37, P1204, DOI 10.1097/00043764-199510000-00011; LAGIER F, 1992, J ALLERGY CLIN IMMUN, V90, P319, DOI 10.1016/S0091-6749(05)80009-0; LAHTI A, 1992, CONTACT DERMATITIS, V26, P259, DOI 10.1111/j.1600-0536.1992.tb00239.x; LISS GM, 1993, J ALLERGY CLIN IMMUN, V92, P237, DOI 10.1016/0091-6749(93)90167-E; Liss GM, 1997, OCCUP ENVIRON MED, V54, P335, DOI 10.1136/oem.54.5.335; SLATER JE, 1994, J ALLERGY CLIN IMMUN, V94, P139, DOI 10.1016/0091-6749(94)90031-0; SMITH AB, 1987, AM J IND MED, V12, P205, DOI 10.1002/ajim.4700120209; SUSSMAN GL, 1995, ANN INTERN MED, V122, P43, DOI 10.7326/0003-4819-122-1-199501010-00007; SUSSMAN GL, 1991, JAMA-J AM MED ASSOC, V265, P2844, DOI 10.1001/jama.265.21.2844; SWANSON MC, 1994, J ALLERGY CLIN IMMUN, V94, P445, DOI 10.1016/0091-6749(94)90199-6; TARLO SM, 1994, J ALLERGY CLIN IMMUN, V93, P985, DOI 10.1016/S0091-6749(94)70045-1; TARLO SM, 1990, J ALLERGY CLIN IMMUN, V85, P626, DOI 10.1016/0091-6749(90)90103-B; TAYLOR AN, 1995, EPIDEMIOLOGY WORK RE, P117; TURJANMAA K, 1987, CONTACT DERMATITIS, V17, P270, DOI 10.1111/j.1600-0536.1987.tb01476.x; TURJANMAA K, 1994, PROTECTIVE GLOVES OC, P41; VANDENPLAS O, 1995, AM J RESP CRIT CARE, V151, P54, DOI 10.1164/ajrccm.151.1.7812572; Vandenplas O, 1996, THORAX, V51, P452, DOI 10.1136/thx.51.4.452; VANDENPLAS O, 1995, AM J RESP CRIT CARE, V151, P8857; Zehr Bradley D., 1995, Biomedical Instrumentation and Technology, V29, P434	28	79	83	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1998	101	2	1				171	178		10.1016/S0091-6749(98)70381-1	http://dx.doi.org/10.1016/S0091-6749(98)70381-1			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YZ342	9500749				2022-12-18	WOS:000072244800005
J	Avner, DB; Perzanowski, MS; PlattsMills, TAE; Woodfolk, JA				Avner, DB; Perzanowski, MS; PlattsMills, TAE; Woodfolk, JA			Evaluation of different techniques for washing cats: Quantitation of allergen removed from the cat and the effect on airborne Fel d 1	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Fel d 1; cat washing; airborne allergen; allergen avoidance	PARTICLE-SIZE DISTRIBUTION; D-I PRODUCTION; SEQUENCE-ANALYSIS; SEBACEOUS GLANDS; TESTOSTERONE; POPULATION; DOMESTICUS; CASTRATION; EXPOSURE; ANTIBODY	Background and Objective: The purpose of this study was to examine the quantity and distribution of the major cat allergen, Fel d 1, on cats and to evaluate the efficacy of washing, both in removing allergen from the cat and reducing airborne allergen levels. Methods: Airborne samples were collected on four glass fiber filters in a 30 m(3) room, before and 3 hours after serial washing of eight cats (45-minute sampling at 18 L/min for each filter). Aliquots of hair and bath water were also collected and assayed for Eel d 1 content. Results: Extracting cat hair with tap water or pet shampoo for 3 minutes removed mean levels of 191 and 245 mu g of Fel d 1 per gram of hair, respectively; the quantity of allergen on samples of cat hair ranged from 1 mu g/gm to more than 1770 mu g/gm. The highest concentration of allergen was found on hair from the neck Estimates of the total Eel d I on the cat, based on shaving the whole cat, ranged from 3 to 142 mg (mean = 67 mg). Washing cats reduced airborne allergen 3 hours later. Washing three cats at weekly intervals for 5 weeks in a veterinarian's office produced a mean decrease of 44% in airborne Eel d 1 (n = 15, p < 0.02). Washing three cats by immersion for 3 minutes at weekly intervals for a 1-month period produced a mean decrease in airborne allergen of 79% (n = 12, p < 0.001). However, after repeated washing, the airborne levels before the next wash were not consistently decreased. The quantity of Fel d 1 removed by immersion varied from 1 to 35 mg. Conclusion: Cats carry large quantities of Fel d 1, only a small proportion of which (similar to 0.002%/hr) becomes airborne. Washing cats by immersion will remove significant allergen from the cat and can reduce the quantity of Eel d 1 becoming airborne, However, the decrease is not maintained at 1 week.	UNIV VIRGINIA,HLTH SCI CTR,ASTHMA & ALLERG DIS CTR,CHARLOTTESVILLE,VA 22908	University of Virginia				Platts-Mills, Thomas/0000-0002-1263-329X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI034607, R01AI020565, R37AI020565] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-20565, 1U01-AI-34607] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON MC, 1985, J ALLERGY CLIN IMMUN, V76, P563, DOI 10.1016/0091-6749(85)90776-6; BARTHOLOME K, 1985, J ALLERGY CLIN IMMUN, V76, P503, DOI 10.1016/0091-6749(85)90734-1; Bollinger ME, 1996, J ALLERGY CLIN IMMUN, V97, P907, DOI 10.1016/S0091-6749(96)80064-9; CHAPMAN MD, 1988, J IMMUNOL, V140, P812; CHARPIN C, 1994, CLIN EXP ALLERGY, V24, P1174, DOI 10.1111/j.1365-2222.1994.tb03325.x; DEBLAY F, 1991, AM REV RESPIR DIS, V143, P1334, DOI 10.1164/ajrccm/143.6.1334; DEBLAY F, 1991, J ALLERGY CLIN IMMUN, V88, P77; GERGEN PJ, 1987, J ALLERGY CLIN IMMUN, V80, P669, DOI 10.1016/0091-6749(87)90286-7; GLINERT R, 1990, J ALLERGY CLIN IMMUN, V85, P327; Juliusson S., 1997, Journal of Allergy and Clinical Immunology, V99, pS388; KLUCKA CV, 1995, J ALLERGY CLIN IMMUN, V95, P1164, DOI 10.1016/S0091-6749(95)70072-2; LEITERMANN K, 1984, J ALLERGY CLIN IMMUN, V74, P147, DOI 10.1016/0091-6749(84)90278-1; LOWENSTEIN H, 1985, ALLERGY, V40, P430, DOI 10.1111/j.1398-9995.1985.tb02682.x; LUCZYNSKA CM, 1990, AM REV RESPIR DIS, V141, P361, DOI 10.1164/ajrccm/141.2.361; MORGENSTERN JP, 1991, P NATL ACAD SCI USA, V88, P9690, DOI 10.1073/pnas.88.21.9690; OHMAN JL, 1984, J ALLERGY CLIN IMMUN, V74, P230, DOI 10.1016/0091-6749(84)90251-3; OHMAN JL, 1978, J AM VET MED ASSOC, V172, P1403; OHMAN JL, 1983, J ALLERGY CLIN IMMUN, V72, P288, DOI 10.1016/0091-6749(83)90033-7; OHMAN JL, 1977, J ALLERGY CLIN IMMUN, V60, P317, DOI 10.1016/0091-6749(77)90112-9; OHMAN JL, 1982, J ALLERGY CLIN IMMUN, V69, P319; SOLDATOV D, 1995, J ALLERGY CLIN IMMUN, V95, P263; SWANSON MC, 1989, J ALLERGY CLIN IMMUN, V83, P776, DOI 10.1016/0091-6749(89)90014-6; SWANSON MC, 1985, J ALLERGY CLIN IMMUN, V76, P724, DOI 10.1016/0091-6749(85)90678-5; VANMETRE TE, 1986, J ALLERGY CLIN IMMUN, V78, P62, DOI 10.1016/0091-6749(86)90116-8; WENTZ PE, 1990, J ALLERGY CLIN IMMUN, V85, P94, DOI 10.1016/0091-6749(90)90228-V; Wood Robert A., 1997, Journal of Allergy and Clinical Immunology, V99, pS388; WOODFOLK JA, 1992, ANN ALLERGY, V69, P273; WOODFOLK JA, 1993, J ALLERGY CLIN IMMUN, V91, P829, DOI 10.1016/0091-6749(93)90339-H; ZIELONKA TM, 1994, CLIN EXP ALLERGY, V24, P1169, DOI 10.1111/j.1365-2222.1994.tb03324.x; 1983, J AM VET MED ASSOC, V183, P841	30	79	83	1	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1997	100	3					307	312		10.1016/S0091-6749(97)70242-2	http://dx.doi.org/10.1016/S0091-6749(97)70242-2			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XX479	9314341	Bronze			2022-12-18	WOS:A1997XX47900006
J	Agertoft, L; Pedersen, S				Agertoft, L; Pedersen, S			A randomized, double-blind dose reduction study to compare the minimal effective dose of budesonide Turbuhaler and fluticasone propionate Diskhaler	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						children; asthma; inhaled steroids; efficacy; safety	SEVERE ASTHMA; MODERATE; CHILDREN; INHALATION; EFFICACY	Background: New inhaled glucocorticosteroids and inhalers are being developed. Their clinical equipotency is difficult to assess and is often discussed. Objective: This study was carried out to compare the effect of budesonide Turbuhaler and fluticasone propionate (FP) Diskhaler in a dose reduction study in children (ages 5 to 16 years) with asthma. Methods: Children treated with budesonide administered through a pressurized metered-dose inhaler with a large volume spacer had their budesonide dose gradually reduced to define the minimal effective dose with this delivery system. After this period, 217 children were randomly allocated to treatment with half the dose of either budesonide Turbuhaler or FP Diskhaler for 5 weeks in a double-blind trial. If no deterioration in asthma control was seen, the dose was further reduced by 50% at 5-week intervals until deterioration in asthma control was seen. Throughout the study, morning and evening peak expiratory how, symptoms, and use of rescue beta(2)-agonist were recorded in diaries. Lung function tests and a standardized exercise test were performed at the clinic at the end of each treatment period. Urine cortisol excretion (24 hours) was measured before and after the first 5-week treatment period. Standardized criteria for deterioration in asthma control, based on diary card variables and exercise testing, were used to determine the minimal effective dose for each patient; and from this, the number of dose reduction steps was calculated. Results: No statistically significant difference was seen in number of dose reduction steps from baseline or in minimal effective dose between the two treatments; mean reduction was 1.59 dose steps for budesonide Turbuhaler and 1.65 dose steps for FP Diskhaler (p = 0.52), and minimal effective dose was 188 mu g for budesonide Turbuhaler and 180 mu g for FP Diskhaler. After these dose reductions, the same level of asthma control was observed in the budesonide Turbuhaler and FP Diskhaler groups. Furthermore, no statistically significant differences between the two inhaler-drug combinations were seen in daytime or nighttime symptoms, morning and evening peak expiratory flow, Use of rescue beta(2)-agonist, lung functions at the clinic, exercise-induced fall in lung function, or 24-hour urinary cortisol excretion during the first 5-week period. Conclusion: Microgram for microgram, budesonide Turbuhaler and FP Diskhaler are equally effective in treatment of children with moderate asthma.			Agertoft, L (corresponding author), KOLDING CTY HOSP,DEPT PEDIAT,DK-6000 KOLDING,DENMARK.			Agertoft, Lone/0000-0001-6840-7921				AGERTOFT L, 1993, ARCH DIS CHILD, V69, P130, DOI 10.1136/adc.69.1.130; AGERTOFT L, 1994, RESP MED, V88, P373, DOI 10.1016/0954-6111(94)90044-2; AGERTOFT L, 1997, IN PRESS EUR RESP J; ANDERSSON N, 1994, AM J RESP CRIT CARE, V149, pA467; AYRES JG, 1995, EUR RESPIR J, V8, P579; BARNES PJ, 1993, AM REV RESPIR DIS, V148, P1; BASRAN G, 1995, THORAX, V50, pP469; BOE J, 1994, EUR RESPIR J, V7, P2179, DOI 10.1183/09031936.94.07122179; Boorsma M, 1996, EUR RESPIR J, V9, P1427, DOI 10.1183/09031936.96.09071427; Brattsand R., 1992, NEW DRUGS ASTHMA, V2, P193; BUSSE W, 1994, J ALLERGY CLIN IMMUN, V93, P186; CHERVINSKY P, 1994, J ALLERGY CLIN IMMUN, V94, P676, DOI 10.1016/0091-6749(94)90174-0; Clark DJ, 1996, THORAX, V51, P262, DOI 10.1136/thx.51.3.262; Clark DJ, 1996, THORAX, V51, P941, DOI 10.1136/thx.51.9.941; CONNOLLY A, 1995, EUR J CLIN RES, V7, P15; DAHL R, 1993, CHEST, V104, P1352, DOI 10.1378/chest.104.5.1352; ENGLISH AF, 1994, AM J RESP CRIT CAR S, V149, pA212; FABBRI L, 1993, THORAX, V48, P817, DOI 10.1136/thx.48.8.817; GIBSON PG, 1992, CLIN EXP ALLERGY, V22, P525, DOI 10.1111/j.1365-2222.1992.tb00161.x; GRAHNEN A, 1994, BRIT J CLIN PHARMACO, V38, P521, DOI 10.1111/j.1365-2125.1994.tb04393.x; GROVE A, 1994, BRIT J CLIN PHARMACO, V38, P527, DOI 10.1111/j.1365-2125.1994.tb04394.x; Hoekx JCM, 1996, EUR RESPIR J, V9, P2263, DOI 10.1183/09031936.96.09112263; HOFFMANNSTREB A, 1993, MONATSSCHR KINDERH, V141, P508; LANGDON CG, 1994, BR J CLIN RES, V5, P73; LANGDON CG, 1994, BR J CLIN RES, V5, P85; Lonnebo A, 1996, EUR J CLIN PHARMACOL, V49, P459; PEDERSEN S, 1993, BRIT J CLIN PHARMACO, V36, P211, DOI 10.1111/j.1365-2125.1993.tb04219.x; PEDERSEN S, 1995, J ALLERGY CLIN IMMUN, V95, P29, DOI 10.1016/S0091-6749(95)70149-4; Pedersen S, 1996, RESP MED, V90, P69, DOI 10.1016/S0954-6111(96)90201-2; Randwall G., 1994, European Respiratory Journal, V7, p381S; VIKREJORGENSEN J, 1997, IN PRESS PEDIAT PULM	31	79	81	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1997	99	6	1				773	780		10.1016/S0091-6749(97)80011-5	http://dx.doi.org/10.1016/S0091-6749(97)80011-5			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XH193	9215245				2022-12-18	WOS:A1997XH19300010
J	Werfel, T; Ahlers, G; Schmidt, P; Boeker, M; Kapp, A; Neumann, C				Werfel, T; Ahlers, G; Schmidt, P; Boeker, M; Kapp, A; Neumann, C			Milk-responsive atopic dermatitis is associated with a casein-specific lymphocyte response in adolescent and adult patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; eczema; skin; T cells; casein; milk; cytokines; IL-4; interferon-gamma	ALLERGEN PATCH TEST; COWS MILK; DIAGNOSTIC-VALUE; DOUBLE-BLIND; SKIN-TESTS; T-CELLS; IN-SITU; ECZEMA; INTOLERANCE; EXPRESSION	Background: Specific T-cell responses to food antigens have been described in children with atopic dermatitis (AD). However, a subgroup of adolescent and adult patients still experiences food-responsive AD. Objective: This study was designed to evaluate lymphocyte responses to bovine casein in adult patients with AD. Methods: The stimulatory capacity of lipopolysaccharide-depleted bovine casein was tested in proliferation assays and in limiting dilution assays. Casein-specific T-cell clones (TCCs) were generated and characterized. Results: Higher proliferative responses to casein and modulation of cytokine receptors were observed in patients with milk-responsive AD compared with individuals without clinical reactions on milk ingestion. The results did nor correlate with the amount of casein-specific IgE in the serum. The frequencies of T cells that grew in the presence of casein or. house dust mire antigens were similar. Only 27% of CD4(+) casein-specific TCCs from these patients, but the majority of house dust mite-specific TCCs, produced IL-4 on mitogen stimulation Interferon-gamma, on the other hand, was produced by the majority of TCCs with both specificities. Conclusion: A specific T-cell-mediated immune response to casein can be found in the blood of adolescent and adult patients with milk-related exacerbation of AD. In contrast to house dust mite-specific T cells, casein-specific T cells of adult patients who respond to cow's milk with worsening of AD produce little or. no IL-4.	UNIV GOTTINGEN, DEPT DERMATOL, D-3400 GOTTINGEN, GERMANY	University of Gottingen	Werfel, T (corresponding author), HANNOVER MED SCH, DEPT DERMATOL, RICKLINGER STR 5, D-3000 HANNOVER, GERMANY.		Werfel, Thomas/B-6921-2012; Boeker, Martin/N-3854-2016	Boeker, Martin/0000-0003-2972-2042; Kapp, Alexander/0000-0002-1748-6276				ABERNATHYCARVER KJ, 1995, J CLIN INVEST, V95, P913, DOI 10.1172/JCI117743; ALBANI S, 1989, ANN ALLERGY, V63, P489; ATHERTON DJ, 1978, LANCET, V1, P401; BOEKER M, 1995, LEUCOCYTE TYPING, V5, P1960; FLIEGERT F, 1993, ARCH DERMATOL RES, V285, P99; GREWE M, 1994, LANCET, V343, P25, DOI 10.1016/S0140-6736(94)90879-6; GREWE M, 1995, J INVEST DERMATOL, V105, P407, DOI 10.1111/1523-1747.ep12321078; Gutgesell C, 1994, Exp Dermatol, V3, P304, DOI 10.1111/j.1600-0625.1994.tb00293.x; HAMID Q, 1994, J CLIN INVEST, V94, P870, DOI 10.1172/JCI117408; HAMMAR H, 1977, ACTA DERM-VENEREOL, V57, P159; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; HILL DJ, 1988, CLIN ALLERGY, V18, P481, DOI 10.1111/j.1365-2222.1988.tb02898.x; KAPP A, 1995, CLIN EXP ALLERGY, V25, P210, DOI 10.1111/j.1365-2222.1995.tb01031.x; KARPLUS TE, 1987, J IMMUNOL METHODS, V105, P211, DOI 10.1016/0022-1759(87)90268-7; KONDO N, 1990, J ALLERGY CLIN IMMUN, V86, P253, DOI 10.1016/S0091-6749(05)80073-9; KONDO N, 1993, J ALLERGY CLIN IMMUN, V91, P658, DOI 10.1016/0091-6749(93)90272-H; May C D, 1972, Clin Allergy, V2, P335, DOI 10.1111/j.1365-2222.1972.tb01298.x; MINOR JD, 1980, J ALLERGY CLIN IMMUN, V66, P314, DOI 10.1016/0091-6749(80)90027-5; Niggemann B, 1994, Pediatr Allergy Immunol, V5, P11, DOI 10.1111/j.1399-3038.1994.tb00212.x; PRAUSNITZ C, 1921, ZBL BAKT           1, V86, P160; RAMBLINDHAUER C, 1991, ARCH DERMATOL RES, V283, P71, DOI 10.1007/BF00371611; RASANEN L, 1992, CLIN EXP ALLERGY, V22, P385, DOI 10.1111/j.1365-2222.1992.tb03100.x; SAGER N, 1992, J ALLERGY CLIN IMMUN, V89, P801, DOI 10.1016/0091-6749(92)90434-4; SAMPSON HA, 1992, ACTA DERM-VENEREOL, P34; SAMPSON HA, 1984, J ALLERGY CLIN IMMUN, V74, P26, DOI 10.1016/0091-6749(84)90083-6; SAMPSON HA, 1985, J PEDIATR-US, V107, P669, DOI 10.1016/S0022-3476(85)80390-5; SCHEINMANN P, 1976, CLIN ALLERGY, V6, P515, DOI 10.1111/j.1365-2222.1976.tb01936.x; SHINODA S, 1992, ACTA PAEDIATR, V81, P896, DOI 10.1111/j.1651-2227.1992.tb12131.x; SILLEVISSMITT JH, 1985, BRIT J DERMATOL, V112, P149; SLOPER KS, 1991, Q J MED, V80, P677; STALDER JF, 1993, DERMATOLOGY, V186, P23, DOI 10.1159/000247298; STRIJBOSCH LWG, 1988, INT J BIOMED COMPUT, V23, P279, DOI 10.1016/0020-7101(88)90020-7; TASWELL C, 1981, J IMMUNOL, V126, P1614; Walzer M, 1927, J IMMUNOL, V14, P143; WERFEL T, IN PRESS J INVEST DE; ZACHARY CB, 1985, BRIT J DERMATOL, V112, P149, DOI 10.1111/j.1365-2133.1985.tb00078.x	36	79	80	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1997	99	1	1				124	133		10.1016/S0091-6749(97)81053-6	http://dx.doi.org/10.1016/S0091-6749(97)81053-6			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WD061	9003220				2022-12-18	WOS:A1997WD06100017
J	deGraafintVeld, T; Koenders, S; Garrelds, IM; vanWijk, RG				deGraafintVeld, T; Koenders, S; Garrelds, IM; vanWijk, RG			The relationships between nasal hyperreactivity, quality of life, and nasal symptoms in patients with perennial allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						perennial allergic rhinitis; daily symptoms; quality of life; nasal hyperreactivity; histamine challenge	OF-LIFE; HEALTH-STATUS; QUESTIONNAIRE; METHACHOLINE; HISTAMINE; REACTIVITY; CHALLENGE; TRIALS; ASTHMA	Background: A clinical test that could inform the clinician about the severity of a patient's nasal symptoms and health-related quality of life (QOL) would be very useful. Objective: We attempted to determine whether, in patients with perennial allergic rhinitis, nasal challenge with histamine could be used to estimate daily symptoms and QOL. Methods: Forty-eight patients with perennial allergic rhinitis were challenged with histamine to determine nasal hyperreactivity. Nasal response was monitored by the number of sneezes, the amount of secretion, and a symptom score. Daily nasal symptoms were recorded during the 2 preceding weeks. Patients also completed a rhinitis QOL questionnaire. Results: Responsiveness to histamine and total daily nasal symptoms were moderately correlated (r = 0.51, p = 0.001). Comparison of total daily nasal symptoms with the overall QOL score showed a moderate correlation (r = 0.59, p < 0.001). Nasal response to histamine and overall QOL score were also correlated (r = 0.43, p = 0.002). However, overall QOL and daily nasal symptoms could be predicted by wide 95% confidence intervals only for each decade of nasal responsiveness to histamine (expressed as a composite symptom score). Conclusion: In patients with perennial allergic rhinitis nasal hyperreactivity as determined by histamine challenge, QOL, and daily nasal symptoms are moderately correlated. Therefore nasal histamine challenge can be used as a tool for estimating the severity of daily nasal symptoms and QOL, although it cannot predict nasal symptoms and QOL very accurately.	ERASMUS UNIV ROTTERDAM,DEPT PHARMACOL,NL-3000 DR ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam	deGraafintVeld, T (corresponding author), UNIV HOSP DIJKZIGT,DEPT ALLERGOL,DR MOLEWATERPLEIN 40,NL-3015 GD ROTTERDAM,NETHERLANDS.							ANDERSSON M, 1989, ACTA OTO-LARYNGOL, V107, P270, DOI 10.3109/00016488909127508; BACON JR, 1981, J ALLERGY CLIN IMMUN, V67, P111, DOI 10.1016/0091-6749(81)90005-1; BORUM P, 1979, J ALLERGY CLIN IMMUN, V63, P253, DOI 10.1016/0091-6749(79)90109-X; BOUSQUET J, 1994, J ALLERGY CLIN IMMUN, V94, P182, DOI 10.1016/0091-6749(94)90038-8; CONNELL JT, 1968, J ALLERGY, V41, P123, DOI 10.1016/0021-8707(68)90053-1; DEGRAAFINTVELD C, IN PRESS CLIN EXP AL; GRONBORG H, 1986, CLIN ALLERGY, V16, P597, DOI 10.1111/j.1365-2222.1986.tb01999.x; HALLEN H, 1994, ORL J OTO-RHINO-LARY, V56, P51, DOI 10.1159/000276608; JUNIPER EF, 1993, ANN ALLERGY, V70, P225; JUNIPER EF, 1991, CLIN EXP ALLERGY, V21, P77, DOI 10.1111/j.1365-2222.1991.tb00807.x; LEBEL B, 1988, J ALLERGY CLIN IMMUN, V82, P869, DOI 10.1016/0091-6749(88)90092-9; MALO JL, 1993, J ALLERGY CLIN IMMUN, V91, P1121, DOI 10.1016/0091-6749(93)90313-5; MARKS GB, 1993, J CLIN EPIDEMIOL, V46, P1103, DOI 10.1016/0895-4356(93)90109-E; NORMAN PS, 1972, J ALLERGY CLIN IMMUN, V50, P31, DOI 10.1016/0091-6749(72)90077-2; TVELD CD, 1995, CLIN EXP ALLERGY, V25, P966; VANWIJK RG, 1987, CLIN ALLERGY, V17, P563; VANWIJK RG, 1989, CLIN EXP ALLERGY, V19, P293; VANWIJK RG, 1994, J ALLERGY CLIN IMMUN, V93, P273	18	79	83	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1996	98	3					508	513		10.1016/S0091-6749(96)70083-0	http://dx.doi.org/10.1016/S0091-6749(96)70083-0			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VJ428	8828527	Green Published			2022-12-18	WOS:A1996VJ42800006
J	Hollander, A; Doekes, G; Heederik, D				Hollander, A; Doekes, G; Heederik, D			Cat and dog allergy and total IgE as risk factors of laboratory animal allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						laboratory animal allergy; cross-sectional; atopy; gender; smoking	OCCUPATIONAL ALLERGY; ATOPY; SENSITIZATION; PREVALENCE; WORKERS; SMOKING; TECHNICIANS; REACTIVITY; SYMPTOMS; EXPOSURE	Background: Laboratory animal workers are at high risk of developing occupational allergy. In many cases the severity of allergy symptoms makes further work with laboratory animals impossible. Objective: This study was designed to estimate prevalence rates of sensitization and symptoms of allergy in a population of laboratory animal workers and to determine the association between various host factors and these prevalence rates. Methods: A cross-sectional survey was undertaken in 540 workers at eight facilities in the Netherlands. All participants completed a questionnaire and underwent skin prick testing with common and occupational allergens. In addition total and specific IgE measurements were obtained. Results: Prevalence rates of allergy symptoms caused by working with vats and mice were 19% and 10%, respectively. Symptoms, especially chest tightness, were strongly related to sensitization. Rat and mouse allergy, defined as symptoms of allergy accompanied by specific atopic sensitization were highly associated with elevated total IgE, reported adverse reactions, and positive skin prick test responses to common allergens. This relationship could be explained by a response to cat or dog allergens. Conclusions: Allergy to cats or dogs seemed to be an important risk factor for laboratory animal allergy, whereas allergy to pollen or house dust mite, in the absence of cat and dog allergy, appeared to be insignificant. More conclusive evidence about cat and dog allergy preceding laboratory animal allergy can only be provided after analysis of follow-up data.	AGR UNIV WAGENINGEN, DEPT EPIDEMIOL & PUBL HLTH, NL-6700 AE WAGENINGEN, NETHERLANDS	Wageningen University & Research				Heederik, Dick/0000-0002-4550-1437				AGRUP G, 1986, BRIT J IND MED, V43, P192; [Anonymous], 1989, ALLERGY S10, V10, P1; AOYAMA K, 1992, BRIT J IND MED, V49, P41; AXELSON O, 1994, OCCUP ENVIRON MED, V51, P574, DOI 10.1136/oem.51.8.574; BEESON MF, 1983, CLIN ALLERGY, V13, P433, DOI 10.1111/j.1365-2222.1983.tb02619.x; BLAND SM, 1986, J OCCUP ENVIRON MED, V28, P1151; BOTHAM PA, 1987, BRIT J IND MED, V44, P627; BOTHAM PA, 1995, OCCUP ENVIRON MED, V52, P129, DOI 10.1136/oem.52.2.129; CHANYEUNG M, 1985, ARCH ENVIRON HEALTH, V40, P53, DOI 10.1080/00039896.1985.10545889; COCKCROFT A, 1981, LANCET, V1, P827; CULLINAN P, 1994, OCCUP ENVIRON MED, V51, P589, DOI 10.1136/oem.51.9.589; DAS R, 1992, J OCCUP ENVIRON MED, V34, P53; DAVIES GE, 1981, INT ARCH ALLER A IMM, V64, P302, DOI 10.1159/000232707; Doekes G, 1996, OCCUP ENVIRON MED, V53, P63, DOI 10.1136/oem.53.1.63; EGGLESTON PA, 1990, J ALLERGY CLIN IMMUN, V86, P63, DOI 10.1016/S0091-6749(05)80124-1; ELSHAMI AS, 1989, ADV BIOSCI, V74, P191; GERRARD JW, 1980, ANN ALLERGY, V44, P261; GORDON S, 1993, J ALLERGY CLIN IMMUN, V92, P298, DOI 10.1016/0091-6749(93)90173-D; GROSS NJ, 1980, J ALLERGY CLIN IMMUN, V66, P158, DOI 10.1016/0091-6749(80)90064-0; HEEDERIK D, 1991, INT ARCH OCC ENV HEA, V62, P595, DOI 10.1007/BF00381114; HOOLBOOM H, 1985, ALLERGIE DOOR OMGAAN; HOUBA R, 1996, IN PRESS AM J CRIT C; KIBBY T, 1989, J OCCUP ENVIRON MED, V31, P842, DOI 10.1097/00043764-198910000-00010; LEE J, 1993, BRIT J IND MED, V50, P861; *MRC COMM AET CHRO, 1966, INSTR US QUEST RESP; RENSTROM A, 1994, ALLERGY, V49, P548, DOI 10.1111/j.1398-9995.1994.tb01127.x; SCHUMACHER MJ, 1981, J ALLERGY CLIN IMMUN, V68, P310, DOI 10.1016/0091-6749(81)90157-3; SJOSTEDT L, 1989, AM J IND MED, V16, P199, DOI 10.1002/ajim.4700160211; SJOSTEDT L, 1993, AM J IND MED, V24, P459, DOI 10.1002/ajim.4700240410; SLOVAK AJM, 1981, BRIT J IND MED, V38, P38; SLOVAK AJM, 1987, BRIT J IND MED, V44, P129; VENABLES KM, 1988, BRIT J IND MED, V45, P660; VENABLES KM, 1985, BRIT MED J, V290, P201, DOI 10.1136/bmj.290.6463.201; VENABLES KM, 1988, BRIT J IND MED, V45, P667; WILLERS S, 1992, INDOOR ENVIRON, V1, P82; ZETTERSTROM O, 1981, BRIT MED J, V283, P1215, DOI 10.1136/bmj.283.6301.1215	36	79	79	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1996	98	3					545	554		10.1016/S0091-6749(96)70088-X	http://dx.doi.org/10.1016/S0091-6749(96)70088-X			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VJ428	8828532				2022-12-18	WOS:A1996VJ42800011
J	Zweiman, B; Valenzano, M; Atkins, PC; Tanus, T; Getsy, JA				Zweiman, B; Valenzano, M; Atkins, PC; Tanus, T; Getsy, JA			Characteristics of histamine-releasing activity in the sera of patients with chronic idiopathic urticaria	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						urticaria; histamine release; IgE; IgE; receptors; basophils	AUTOANTIBODIES; BASOPHILS	Background: The serum histamine-releasing activity (HRA) found in a sizable percentage of patients with chronic idiopathic urticaria (CIU) has been partially characterized. However, the variable effect of individual HRA(+) sera in basophils of different donors and the relationship of HRA to the clinical course require further investigation. Objective: The study was performed to characterize the HRA found in sera of some members of a sizable group of carefully evaluated patients with CIU. Methods: Sera of 70 patients with CIU, evaluated with a standard protocol, were screened for increased HRA. HRA(+) sera were fractionated, heated, and tested on unaltered and altered basophils obtained from a panel of normal donors. HRA levels were compared with concomitant clinical manifestations. Results: HRA(+) sera were found in 30% of our patients with CIU. HRA was predominantly in the IgG fraction, sensitive to 56 degrees heating for 4 hours, and generally reacted more with IgE-stripped basophils. Considerable variation in the degree of response to HRA(+) sera in the basophils of different normal subjects did not correlate with the degree of response of these cells to heterologous anti-IgE antiserum. Serum HRA levels were generally much lower when symptoms decreased in these patients with CIU. Conclusion: Serum HRA from patients with CIU appears to bind most commonly to the IgE receptor and may be a marker of clinical disease activity. HRA appears in an IgG-containing fraction of the serum and may contain IgE in some cases.			Zweiman, B (corresponding author), UNIV PENN,SCH MED,DEPT MED,DIV ALLERGY & IMMUNOL,512 JOHNSON PAVIL,PHILADELPHIA,PA 19104, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI014332] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI 14332] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ATKINS PC, 1990, J ALLERGY CLIN IMMUN, V86, P371, DOI 10.1016/S0091-6749(05)80100-9; CHAMPION RH, 1969, BRIT J DERMATOL, V81, P588, DOI 10.1111/j.1365-2133.1969.tb16041.x; DORRINGTON KJ, 1978, IMMUNOL REV, V41, P3, DOI 10.1111/j.1600-065X.1978.tb01458.x; DUNSKY EH, 1979, J ALLERGY CLIN IMMUN, V63, P426, DOI 10.1016/0091-6749(79)90217-3; GRATTAN CEH, 1986, BRIT J DERMATOL, V114, P583, DOI 10.1111/j.1365-2133.1986.tb04065.x; GRATTAN CEH, 1990, INT ARCH ALLER A IMM, V93, P198, DOI 10.1159/000235301; GRATTAN CEH, 1991, CLIN EXP ALLERGY, V21, P695, DOI 10.1111/j.1365-2222.1991.tb03198.x; GRATTAN CEH, 1992, LANCET, V339, P1078, DOI 10.1016/0140-6736(92)90666-Q; GREAVES MW, 1995, NEW ENGL J MED, V332, P1767, DOI 10.1056/NEJM199506293322608; GRUBER BL, 1989, J INVEST DERMATOL, V93, P246; HIDE M, 1994, CLIN EXP ALLERGY, V24, P624, DOI 10.1111/j.1365-2222.1994.tb00965.x; HIDE M, 1993, NEW ENGL J MED, V328, P1599, DOI 10.1056/NEJM199306033282204; KERN F, 1976, J CLIN INVEST, V57, P1369, DOI 10.1172/JCI108405; MACDONALD SM, 1990, CLIN EXP ALLERGY, V21, P133; MACGLASHAN D, 1994, J ALLERGY CLIN IMMUN, V94, P1146, DOI 10.1016/0091-6749(94)90324-7; MARONE G, 1989, J INVEST DERMATOL, V93, P246, DOI 10.1111/1523-1747.ep12277582; RORSMAN H, 1962, ACTA ALLERGOL, V17, P168, DOI 10.1111/j.1398-9995.1962.tb02937.x; TANUS T, 1994, J ALLERGY CLIN IMMUN, V93, P277; THUESON DO, 1979, J IMMUNOL, V123, P626; TWENA DM, 1989, CLIN IMMUNOL IMMUNOP, V53, P40, DOI 10.1016/0090-1229(89)90099-8	20	79	80	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1996	98	1					89	98		10.1016/S0091-6749(96)70230-0	http://dx.doi.org/10.1016/S0091-6749(96)70230-0			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VA692	8765822	hybrid			2022-12-18	WOS:A1996VA69200011
J	SANDERS, LAM; RIJKERS, GT; KUIS, W; TENBERGENMEEKES, AJ; DEGRAEFFMEEDER, BR; HIEMSTRA, I; ZEGERS, BJM				SANDERS, LAM; RIJKERS, GT; KUIS, W; TENBERGENMEEKES, AJ; DEGRAEFFMEEDER, BR; HIEMSTRA, I; ZEGERS, BJM			DEFECTIVE ANTIPNEUMOCOCCAL POLYSACCHARIDE ANTIBODY-RESPONSE IN CHILDREN WITH RECURRENT RESPIRATORY-TRACT INFECTIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						PNEUMOCOCCI; ANTEPOLYSACCHARIDE ANTIBODIES; RESPIRATORY TRACT; FALLOT; IMMUNODEFICIENCY; CELL WALL POLYSACCHARIDE; OTITIS	INFLUENZAE TYPE-B; COMMON VARIABLE IMMUNODEFICIENCY; PROTEIN CONJUGATE VACCINE; HUMAN LYMPHOCYTES-B; CAPSULAR POLYSACCHARIDE; PNEUMOCOCCAL POLYSACCHARIDE; STREPTOCOCCUS-PNEUMONIAE; IGA DEFICIENCY; SERUM ANTIBODIES; IMMUNE-RESPONSE	Background: Recurrent pyogenic infections are known to occur in patients with an impaired resPonse to PolYsaccharide antigens. We investigated the occurrence of deficient responses to pneumococcal capsular polysaccharides in patients with recurrent respiratory tract and recurrent systemic infections. Methods: Forty-five patients, 1.7 to 17.1 years of age, were immunized with 23-valent pneumococcal polysaccharide vaccine. Antibody levels to seven pneumococcal serotypes (3, 4, 6A, 9N, 14, 19F, 23F) were determined by ELISA before and after immunization. In addition, patients received a booster immunization with diphtheria toxoid, tetanus toxoid, and poliomyelitis virus vaccine. Results: Thirty-five patients had normal serum immunoglobulin levels. Five of these patients (14%) had low antipneumococcal preimmunization antibody levels and failed to respond to pneumococcal vaccination, whereas the response to booster immunization with protein antigens was appropriate. Three patients were younger than 3 years old, and one had a family history of IgG2 deficiency. Low IgG developed in a fifth patient during follow-up. Ten patients had a humoral immunodeficiency. Seven of these patients failed to respond to pneumococcal vaccination. Conclusions: We conclude that a defective immune response to polysaccharide antigens in patients requires long-term follow-up to distinguish transient maturational delay from a persistent selective impaired response to polysaccharide antigens, which on occasion may precede the development of humoral immunodeficiency disease.			SANDERS, LAM (corresponding author), UNIV UTRECHT,HOSP CHILDREN & YOUTH HET WILHELMINA KINDERZIEKENHUIS,DEPT IMMUNOL,POB 18009,3501 CA UTRECHT,NETHERLANDS.		Rijkers, Ger/AAW-6143-2020; Rijkers, Ger/R-7236-2019	Rijkers, Ger/0000-0001-6948-6123				AMBROSINO DM, 1987, NEW ENGL J MED, V316, P790, DOI 10.1056/NEJM198703263161306; AMBROSINO DM, 1988, J ALLERGY CLIN IMMUN, V81, P1175, DOI 10.1016/0091-6749(88)90887-1; AUSTRIAN R, 1989, PEDIATR INFECT DIS J, V8, pS21; BAKER PJ, 1981, REV INFECT DIS, V3, P332; Barrett D J, 1985, Adv Pediatr, V32, P139; BARRETT DJ, 1984, PEDIATR RES, V18, P1067, DOI 10.1203/00006450-198411000-00001; BORGONO JM, 1978, P SOC EXP BIOL MED, V157, P148, DOI 10.3181/00379727-157-40010; BRALEYMU.H, 1974, J IMMUNOL, V113, P1909; CUNNINGHAMRUNDLES C, 1989, J CLIN IMMUNOL, V9, P22, DOI 10.1007/BF00917124; DOUGLAS RM, 1983, J INFECT DIS, V148, P131, DOI 10.1093/infdis/148.1.131; FRENCH MAH, 1990, IMMUNOL TODAY, V11, P271, DOI 10.1016/0167-5699(90)90110-U; GIGLIOTTI F, 1988, PEDIATR INFECT DIS J, V7, P417, DOI 10.1097/00006454-198806000-00010; GRANOFF DM, 1989, J PEDIATR-US, V114, P925, DOI 10.1016/S0022-3476(89)80432-9; GRAY BM, 1986, PEDIATR INFECT DIS J, V5, P201, DOI 10.1097/00006454-198603000-00009; GRIFFIOEN AW, 1991, INFECT IMMUN, V59, P1839, DOI 10.1128/IAI.59.5.1839-1845.1991; GRIFFIOEN AW, 1992, CELL IMMUNOL, V143, P11, DOI 10.1016/0008-8749(92)90002-7; HAMMARSTROM L, 1985, IMMUNOLOGY, V54, P821; HAMMERSTROM L, 1991, TISSUE ANTIGENS, V21, P75; HENDRIKSEN CFM, 1989, J BIOL STAND, V17, P191, DOI 10.1016/0092-1157(89)90009-7; HERROD HG, 1989, J CLIN IMMUNOL, V9, P429, DOI 10.1007/BF00917109; INSEL RA, 1986, NEW ENGL J MED, V315, P499, DOI 10.1056/NEJM198608213150807; JETTE LP, 1989, J CLIN MICROBIOL, V27, P1; KAYHTY H, 1984, PEDIATRICS, V74, P857; KEHRL JH, 1983, J CLIN INVEST, V71, P1032, DOI 10.1172/JCI110830; KLEIN JO, 1981, REV INFECT DIS, V3, P246; KNUTSEN AP, 1989, J ALLERGY CLIN IMMUN, V84, P640, DOI 10.1016/0091-6749(89)90203-0; KOSKELA M, 1981, J CLIN PATHOL, V34, P93, DOI 10.1136/jcp.34.1.93; KOSKELA M, 1987, PEDIATR INFECT DIS J, V6, P519, DOI 10.1097/00006454-198706000-00006; KOSKELA M, 1986, PEDIATR INFECT DIS J, V5, P45, DOI 10.1097/00006454-198601000-00009; LANE PJL, 1986, CLIN EXP IMMUNOL, V65, P427; LEINONEN M, 1986, PEDIATR INFECT DIS J, V5, P39, DOI 10.1097/00006454-198601000-00008; MOSIER DE, 1982, IMMUNOL TODAY, V3, P217, DOI 10.1016/0167-5699(82)90095-0; MUSHER DM, 1990, J INFECT DIS, V161, P728, DOI 10.1093/infdis/161.4.728; OXELIUS VA, 1981, NEW ENGL J MED, V304, P1476, DOI 10.1056/NEJM198106113042408; PABST HF, 1980, J PEDIATR-US, V97, P519, DOI 10.1016/S0022-3476(80)80003-5; PEETERS CCA, 1982, MED MICROBIOL IMMUN, V181, P35; PELTOLA H, 1977, PEDIATRICS, V60, P730; Preud'homme J L, 1990, Immunodefic Rev, V2, P129; QUINTI I, 1990, J CLIN IMMUNOL, V10, P160, DOI 10.1007/BF00917916; RADFORD DJ, 1989, INT J CARDIOL, V22, P229, DOI 10.1016/0167-5273(89)90072-7; RIJKERS GT, 1987, SCAND J IMMUNOL, V25, P447; RIJKERS GT, 1987, NEW ENGL J MED, P317; RIJKERS GT, 1985, J IMMUNOL, P135; SANDERS EAM, 1991, EUR J IMMUNOL, V21, P2293, DOI 10.1002/eji.1830210946; SANDERS EAM, 1991, PROG IMMUNE DEFICIEN, V3, P115; SCHAFFER FM, 1989, P NATL ACAD SCI USA, V86, P8015, DOI 10.1073/pnas.86.20.8015; SCHIFFMAN G, 1983, P SOC EXP BIOL MED, V174, P309; SCHNEIDER LC, 1990, J ALLERGY CLIN IMMUN, V85, P948, DOI 10.1016/0091-6749(90)90082-F; SHACKELFORD PG, 1990, J PEDIATR-US, V116, P529, DOI 10.1016/S0022-3476(05)81598-7; SIBER GR, 1978, NEW ENGL J MED, V299, P442, DOI 10.1056/NEJM197808312990903; SIBER GR, 1984, INFECT IMMUN, V45, P248, DOI 10.1128/IAI.45.1.248-254.1984; SIBER GR, 1989, PEDIATR INFECT DIS J, V8, pS84; SORENSEN UBS, 1990, MICROB PATHOGENESIS, V8, P325, DOI 10.1016/0882-4010(90)90091-4; TIMENS W, 1989, J IMMUNOL, V143, P3200; UMETSU DT, 1985, NEW ENGL J MED, V313, P1247, DOI 10.1056/NEJM198511143132002; ZEEGERS BJM, 1980, CLIN CHIM ACTA, V101, P255; ZEGERS BJM, 1975, CLIN CHIM ACTA, V65, P319, DOI 10.1016/0009-8981(75)90257-0	58	79	80	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1993	91	1	1				110	119		10.1016/0091-6749(93)90303-W	http://dx.doi.org/10.1016/0091-6749(93)90303-W			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KK044	8423268				2022-12-18	WOS:A1993KK04400010
J	SLAVIN, RG				SLAVIN, RG			ASTHMA AND SINUSITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						UPPER AND LOW AIRWAY; SINUSITIS; ASTHMA	BRONCHIAL-ASTHMA; CHILDREN; DISEASE; AIRWAY	Important relationships exist between the upper and lower airways. It is well known that sinusitis and asthma coexist in many patients, and evidence is accumulating that there may be a cause-and-effect relationship, that is, that sinusitis is an important trigger for asthma. Studies in children and adults indicate that appropriate medical and/or surgical therapy of sinusitis frequently leads to improvement in the asthmatic state. Possible mechanisms for this relationship include the eosinophil acting as an effector cell, inflammatory mediators, and a vagal reflex. Further investigations need to examine both prospective studies of the effect of medical therapy for sinusitis on asthma and basic mechanisms relating the upper and lower airways.			SLAVIN, RG (corresponding author), ST LOUIS UNIV, SCH MED, DEPT INTERNAL MED & MICROBIOL, DIV ALLERGY & IMMUNOL, ST LOUIS, MO 63110 USA.							BARDIN PG, 1990, J ALLERGY CLIN IMMUN, V86, P82, DOI 10.1016/S0091-6749(05)80126-5; BERMAN SZ, 1974, J ALLERGY CLIN IMMUN, V53, P311, DOI 10.1016/0091-6749(74)90111-0; BULLEN SS, 1932, J ALLERGY, V4, P402; Dixon WE, 1903, J PHYSIOL-LONDON, V29, P97; FRIEDMAN R, 1984, J ALLERGY CLIN IMMUN, V74, P185, DOI 10.1016/0091-6749(84)90284-7; FULLER C, 1990, Journal of Allergy and Clinical Immunology, V85, P222; Gottlieb MJ, 1925, J AMER MED ASSOC, V85, P105, DOI 10.1001/jama.1925.02670020025013; HARLIN SL, 1988, J ALLERGY CLIN IMMUN, V81, P867, DOI 10.1016/0091-6749(88)90944-X; HOEHNE JH, 1971, J ALLERGY CLIN IMMUN, V48, P36, DOI 10.1016/0091-6749(71)90053-4; KATZ R, 1978, J ALLERGY CLIN IMMUN, V61, P190, DOI 10.1016/0091-6749(78)90446-3; KAUFMAN J, 1969, AM REV RESPIR DIS, V100, P626; KIYOSHI A, 1966, LARYNGOSCOPE, V76, P30; KRATCHMER I, CITED INDIRECTLY; MINGS R, 1988, AM J RHINOL, V71, P123; OGURA JH, 1971, ACTA OTO-LARYNGOL, V71, P123, DOI 10.3109/00016487109125340; RACHELEFSKY GS, 1984, PEDIATRICS, V73, P526; SCHUMACHER MJ, 1986, J ALLERGY CLIN IMMUN, V78, P30, DOI 10.1016/0091-6749(86)90111-9; SLAVIN RG, 1982, ANN ALLERGY, V49, P76; SLAVIN RG, 1980, J ALLERGY CLIN IMMUN, V66, P250, DOI 10.1016/0091-6749(80)90048-2; SPEIZER FE, 1966, BRIT J IND MED, V23, P75; STONE B D, 1990, Journal of Allergy and Clinical Immunology, V85, P222; Weille FL, 1936, NEW ENGL J MED, V215, P235, DOI 10.1056/NEJM193608062150602; YAN K, 1983, EUR J RESPIR DIS, V64, P105	23	79	80	1	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1992	90	3	2	S			534	537		10.1016/0091-6749(92)90180-A	http://dx.doi.org/10.1016/0091-6749(92)90180-A			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JP521	1527345				2022-12-18	WOS:A1992JP52100021
J	FREEMAN, TM; HYLANDER, R; ORTIZ, A; MARTIN, ME				FREEMAN, TM; HYLANDER, R; ORTIZ, A; MARTIN, ME			IMPORTED FIRE ANT IMMUNOTHERAPY - EFFECTIVENESS OF WHOLE-BODY EXTRACTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IMMUNOTHERAPY; IMPORTED FIRE ANT; HYMENOPTERA; WHOLE BODY EXTRACT	VENOM IMMUNOTHERAPY; HYPERSENSITIVITY; ALLERGY; SENSITIVITY	The purpose of this study was to determine if whole body extract (WBE) immunotherapy for imported fire ant (IFA) hypersensitivity is effective. This evaluation was carried out by retrospectively interviewing 76 patients with a history of generalized allergic reactions to IFA stings and positive skin tests to IFA-WBE. The study groups consisted of 65 patients on immunotherapy and 11 similar patients who were not treated for various reasons. In addition, an IFA sting challenge was performed in 30 volunteers of the 65 patients on immunotherapy. The retrospective review showed that of the 65 patients on immunotherapy there had been 112 subsequent field re-sting episodes in 47 patients. Only one sting episode in this group (2.1%) produced an anaphylactic reaction. Six of the 11 patients not on immunotherapy have had subsequent field resting episodes, and each has had a systemic reaction. Repeat skin testing on 31 of the 65 patients in the immunotherapy group showed persistent positive responses in five (16%), but each was at a lower dilution than initially. Responses of the other 26 of the 31 patients who had skin testing had become negative. The four untreated patients who were available for skin testing continued to have positive responses at comparable dilutions on skin testing. Sting challenges carried out on 30 volunteers from the 65 patients (all from the 31 who had repeat skin tests) on immunotherapy resulted in only local reactions. Therefore it appears IFA-WBE is effective in decreasing the incidence of anaphylaxis during subsequent field stings; reducing specific immunoglobulin E as demonstrated by skin testing; and protecting against systemic reactions provoked by a sting challenge with a single IFA.			FREEMAN, TM (corresponding author), WILFORD HALL USAF MED CTR,DEPT ALLERGY IMMUNOL,LACKLAND AFB,TX 78236, USA.							BAHNA SL, 1988, J ALLERGY CLIN IMMUN, V82, P419, DOI 10.1016/0091-6749(88)90014-0; BOUSQUET J, 1989, J ALLERGY CLIN IMMUN, V84, P944, DOI 10.1016/0091-6749(89)90393-X; GOLDEN DBK, 1989, J ALLERGY CLIN IMMUN, V84, P162, DOI 10.1016/0091-6749(89)90320-5; HOFFMAN DR, 1991, ANN ALLERGY, V66, P29; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; JAMES FK, 1976, J ALLERGY CLIN IMMUN, V58, P110, DOI 10.1016/0091-6749(76)90112-3; NORDVALL SL, 1988, J ALLERGY CLIN IMMUN, V82, P567, DOI 10.1016/0091-6749(88)90966-9; PAULL BR, 1986, J ALLERGY CLIN IMMUN, V77, P141; PAULL BR, 1983, J ALLERGY CLIN IMMUN, V71, P448, DOI 10.1016/0091-6749(83)90460-8; REISMAN RE, 1989, J ALLERGY CLIN IMMUN, V83, P1049, DOI 10.1016/0091-6749(89)90446-6; RHOADES RB, 1989, J ALLERGY CLIN IMMUN, V84, P159, DOI 10.1016/0091-6749(89)90319-9; RHOADES RB, 1977, J FLA MED ASSOC, V64, P247; STAFFORD CT, 1989, SOUTHERN MED J, V82, P1520, DOI 10.1097/00007611-198912000-00015; STROM GB, 1983, J ALLERGY CLIN IMMUN, V72, P46, DOI 10.1016/0091-6749(83)90051-9; TRIPLETT RF, 1973, SOUTHERN MED J, V66, P477, DOI 10.1097/00007611-197304000-00019	15	79	81	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1992	90	2					210	215		10.1016/0091-6749(92)90073-B	http://dx.doi.org/10.1016/0091-6749(92)90073-B			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JJ423	1500625	Green Submitted			2022-12-18	WOS:A1992JJ42300010
J	PASTORELLO, EA; STOCCHI, L; PRAVETTONI, V; BIGI, A; SCHILKE, ML; INCORVAIA, C; ZANUSSI, C				PASTORELLO, EA; STOCCHI, L; PRAVETTONI, V; BIGI, A; SCHILKE, ML; INCORVAIA, C; ZANUSSI, C			ROLE OF THE ELIMINATION DIET IN ADULTS WITH FOOD ALLERGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV MILAN,SCH MED,INST INTERNAL MED INFECT DIS & IMMUNOPATHOL,DEPT INTERNAL MED 1,I-20122 MILAN,ITALY	University of Milan			PASTORELLO, ELIDE ANNA/E-3897-2017	PASTORELLO, ELIDE ANNA/0000-0002-3753-1783				ATKINS FM, 1986, J ALLERGY CLIN IMMUN, V78, P174, DOI 10.1016/0091-6749(86)90010-2; ATKINS FM, 1985, J ALLERGY CLIN IMMUN, V75, P348, DOI 10.1016/0091-6749(85)90071-5; ATKINS FM, 1985, J ALLERGY CLIN IMMUN, V75, P356, DOI 10.1016/0091-6749(85)90072-7; BAHNA SL, 1984, ANN ALLERGY, V53, P678; BAHNA SL, 1983, ANN ALLERGY, V51, P574; BERNSTEIN M, 1982, J ALLERGY CLIN IMMUN, V70, P205, DOI 10.1016/0091-6749(82)90043-4; BOCK SA, 1978, J ALLERGY CLIN IMMUN, V62, P327, DOI 10.1016/0091-6749(78)90132-X; BOCK SA, 1985, J ALLERGY CLIN IMMUN, V75, P178, DOI 10.1016/0091-6749(85)90429-4; BOCK SA, 1986, J ALLERGY CLIN IMMUN, V78, P165, DOI 10.1016/0091-6749(86)90009-6; BOCK SA, 1983, ALLERGY PRINCIPLES P, V2, P1415; BOCK SA, 1982, J ALLERGY CLIN IMMUN, V69, P171; DREBORG S, 1983, ALLERGY, V38, P167, DOI 10.1111/j.1398-9995.1983.tb01602.x; MAY CD, 1982, J ALLERGY CLIN IMMUN, V69, P255, DOI 10.1016/S0091-6749(82)80001-8; MAY CD, 1976, J ALLERGY CLIN IMMUN, V58, P500, DOI 10.1016/0091-6749(76)90194-9; MAY CD, 1985, J ALLERGY CLIN IMMUN, V75, P329, DOI 10.1016/0091-6749(85)90067-3; METCALFE DD, 1984, J ALLERGY CLIN IMMUN, V73, P749, DOI 10.1016/0091-6749(84)90442-1; ONORATO J, 1986, J ALLERGY CLIN IMMUN, V78, P1139, DOI 10.1016/0091-6749(86)90263-0; PEARSON DJ, 1983, LANCET, V1, P1259; SAMPSON HA, 1986, ANN ALLERGY, V57, P209; SAMPSON HA, 1988, J ALLERGY CLIN IMMUN, V81, P635, DOI 10.1016/0091-6749(88)91033-0; SAMPSON HA, 1984, J ALLERGY CLIN IMMUN, V74, P26, DOI 10.1016/0091-6749(84)90083-6; SAMPSON HA, 1987, ANN ALLERGY, V59, P71; SAMPSON HA, 1983, J ALLERGY CLIN IMMUN, V71, P473, DOI 10.1016/0091-6749(83)90464-5; ZANUSSI C, 1987, FOOD ALLERGY INTOLER, P971; ZEIGER RS, 1986, J ALLERGY CLIN IMMUN, V78, P224, DOI 10.1016/0091-6749(86)90016-3	25	79	80	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1989	84	4	1				475	483		10.1016/0091-6749(89)90360-6	http://dx.doi.org/10.1016/0091-6749(89)90360-6			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AW760	2794292	Bronze			2022-12-18	WOS:A1989AW76000008
J	WATSON, WTA; SIMONS, KJ; CHEN, XY; SIMONS, FER				WATSON, WTA; SIMONS, KJ; CHEN, XY; SIMONS, FER			CETIRIZINE - A PHARMACOKINETIC AND PHARMACODYNAMIC EVALUATION IN CHILDREN WITH SEASONAL ALLERGIC RHINITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV MANITOBA,FAC MED,HLTH SCI CLIN RES CTR,WINNIPEG R3T 2N2,MANITOBA,CANADA; UNIV MANITOBA,FAC PHARM,WINNIPEG R3T 2N2,MANITOBA,CANADA; UNIV MANITOBA,FAC SCI,WINNIPEG R3T 2N2,MANITOBA,CANADA	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Manitoba; University of Manitoba								[Anonymous], 1980, PRINCIPLES PROCEDURE; BERMAN B, 1988, J ALLERGY CLIN IMMUN, V81, P177, DOI 10.1016/0091-6749(88)90273-4; BROIDE DH, 1988, J ALLERGY CLIN IMMUN, V81, P176, DOI 10.1016/0091-6749(88)90268-0; GENDREAUREID L, 1986, J ALLERGY CLIN IMMUN, V77, P335, DOI 10.1016/S0091-6749(86)80114-2; GENGO FM, 1987, CLIN PHARMACOL THER, V42, P265, DOI 10.1038/clpt.1987.145; Gibaldi M, 1982, PHARMACOKINETICS; JUHLIN L, 1987, J ALLERGY CLIN IMMUN, V80, P599, DOI 10.1016/0091-6749(87)90014-5; LEPREVOST C, 1988, INT ARCH ALLER A IMM, V87, P9, DOI 10.1159/000234641; MATZKE GR, 1987, ANN ALLERGY, V59, P25; MICHEL L, 1988, J ALLERGY CLIN IMMUN, V82, P101, DOI 10.1016/0091-6749(88)90058-9; MULLER FO, 1988, EUR J CLIN PHARMACOL, V35, P319, DOI 10.1007/BF00558272; PECHADRE JC, 1988, EUR J CLIN PHARMACOL, V35, P255, DOI 10.1007/BF00558262; ROMAN IJ, 1986, ANN ALLERGY, V57, P253; SEIDEL WF, 1987, ANN ALLERGY, V59, P58; SHUMAKER RC, 1986, DRUG METAB REV, V17, P331, DOI 10.3109/03602538608998295; SIMONS FE, 1987, ANN ALLERGY, V59, P20; SIMONS FER, 1987, J ALLERGY CLIN IMMUN, V80, P884; SIMONS FER, 1982, J ALLERGY CLIN IMMUN, V69, P376, DOI 10.1016/0091-6749(82)90149-X; SIMONS FER, 1988, J ALLERGY CLIN IMMUN, V82, P1068; SIMONS FER, 1984, J PEDIATR-US, V104, P123; SIMONS KJ, 1984, J PHARM SCI, V73, P595, DOI 10.1002/jps.2600730505; SIMONS KJ, 1987, J ALLERGY CLIN IMMUN, V79, P928, DOI 10.1016/0091-6749(87)90242-9; SIMONS KJ, 1989, CLIN PHARMACOL THER, V45, P9, DOI 10.1038/clpt.1989.2; TAYLOR RJ, 1985, J ALLERGY CLIN IMMUN, V76, P103, DOI 10.1016/0091-6749(85)90811-5; WOOD SG, 1987, ANN ALLERGY, V59, P31	25	79	83	0	7	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1989	84	4	1				457	464		10.1016/0091-6749(89)90358-8	http://dx.doi.org/10.1016/0091-6749(89)90358-8			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AW760	2571627				2022-12-18	WOS:A1989AW76000006
J	METZGER, WJ; RICHERSON, HB; WASSERMAN, SI				METZGER, WJ; RICHERSON, HB; WASSERMAN, SI			GENERATION AND PARTIAL CHARACTERIZATION OF EOSINOPHIL CHEMOTACTIC ACTIVITY AND NEUTROPHIL CHEMOTACTIC ACTIVITY DURING EARLY AND LATE-PHASE ASTHMATIC RESPONSE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV IOWA, DEPT MED, DIV ALLERGY IMMUNOL, IOWA CITY, IA USA; UNIV CALIF SAN DIEGO, DEPT MED, DIV ALLERGY, SAN DIEGO, CA 92103 USA	University of Iowa; University of California System; University of California San Diego	METZGER, WJ (corresponding author), E CAROLINA UNIV, SCH MED, DEPT INTERNAL MED, ALLERGY CLIN IMMUNOL SECT, GREENVILLE, NC 27834 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI019093, R01AI017268] Funding Source: NIH RePORTER; NCRR NIH HHS [RR59] Funding Source: Medline; NIAID NIH HHS [AI 17268, AI 19093] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ATKINS PC, 1982, J ALLERGY CLIN IMMUN, V69, P39, DOI 10.1016/0091-6749(82)90085-9; BECKER EL, 1979, AM J PATHOL, V95, P81; BOYDEN S, 1962, J EXP MED, V115, P453, DOI 10.1084/jem.115.3.453; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P31; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; COCKCROFT DW, 1983, LANCET, V2, P253; DOLOVICH J, 1981, THORAX, V36, P641, DOI 10.1136/thx.36.9.614; DURACK DT, 1981, P NATL ACAD SCI-BIOL, V78, P5165, DOI 10.1073/pnas.78.8.5165; DURHAM SR, 1984, NEW ENGL J MED, V311, P1398, DOI 10.1056/NEJM198411293112202; FRIGAS E, 1980, LAB INVEST, V42, P35; GODARD P, 1982, BRONCHES ASTHMATIQUE, P49; JUBIZ W, 1982, J BIOL CHEM, V257, P6106; KAY AB, 1971, J EXP MED, V133, P602, DOI 10.1084/jem.133.3.602; LEE TC, 1984, J BIOL CHEM, V259, P5526; LEMANSKE R, 1982, CRC CRIT REV IMMUNOL, V1, P547; LUDWIG JC, 1985, ARCH BIOCHEM BIOPHYS, V241, P337, DOI 10.1016/0003-9861(85)90555-7; METZER WJ, 1985, CHEST, V88, P369, DOI 10.1378/chest.88.3.369; METZGER WJ, 1985, CHEST, V87, pS16, DOI 10.1378/chest.87.1_Supplement.16S; METZGER WJ, 1985, CLIN REV ALLERG, V3, P145, DOI 10.1007/BF02992980; NAGY L, 1981, EUR J RESPIR DIS, V62, P198; NAGY L, 1982, NEW ENGL J MED, V306, P497, DOI 10.1056/NEJM198203043060901; OERTEL HL, 1981, J IMMUNOL, V127, P1398; OFLAHERTY JT, 1981, AM J PATHOL, V105, P264; RICHERSON HB, 1979, J ALLERGY CLIN IMMUN, V64, P67, DOI 10.1016/0091-6749(79)90085-X; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; TING S, 1981, J IMMUNOL, V127, P557; VENGE P, 1980, EOSINOPHIL HLTH DISE, P131; WASSERMAN SI, 1974, J IMMUNOL, V112, P351; WASSERMAN SI, 1982, CLIN EXP IMMUNOL, V47, P570	30	79	79	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1986	78	2					282	290						9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	D7261	3734281				2022-12-18	WOS:A1986D726100007
J	ZEIGER, RS; HELLER, S; MELLON, M; OCONNOR, R; HAMBURGER, RN				ZEIGER, RS; HELLER, S; MELLON, M; OCONNOR, R; HAMBURGER, RN			EFFECTIVENESS OF DIETARY MANIPULATION IN THE PREVENTION OF FOOD ALLERGY IN INFANTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CALIF SAN DIEGO,DIV PEDIAT IMMUNOL & ALLERGY,LA JOLLA,CA 92093	University of California System; University of California San Diego	ZEIGER, RS (corresponding author), KAISER PERMANENTE MED CTR,DEPT ALLERGY,7060 CLAIREMONT MESA BLVD,SAN DIEGO,CA 92111, USA.			Zeiger, Robert/0000-0001-5788-5063	NICHD NIH HHS [1-HD-9-2832] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALLANSMITH M, 1964, J ALLERGY, V35, P339, DOI 10.1016/0021-8707(64)90097-8; BAZARAL M, 1974, J ALLERGY CLIN IMMUN, V54, P288, DOI 10.1016/0091-6749(74)90015-3; BERGER M, 1980, J IMMUNOL, V125, P2437; BJORKSTEN F, 1980, CLIN ALLERGY, V10, P585, DOI 10.1111/j.1365-2222.1980.tb02140.x; BJORKSTEN F, 1981, ACTA MED SCAND, V209, P299; BJORKSTEN F, 1976, CLIN ALLERGY, V6, P165, DOI 10.1111/j.1365-2222.1976.tb01894.x; BROWN EB, 1969, AM J DIS CHILD, V117, P693, DOI 10.1001/archpedi.1969.02100030695013; BUSH RK, 1977, CLIN ALLERGY, V7, P369, DOI 10.1111/j.1365-2222.1977.tb01465.x; BUSINCO L, 1983, CLIN ALLERGY, V13, P503, DOI 10.1111/j.1365-2222.1983.tb02631.x; CHANDRA RK, 1979, ACTA PAEDIATR SCAND, V68, P691, DOI 10.1111/j.1651-2227.1979.tb18439.x; CHANDRA RK, 1985, CLIN ALLERGY, V15, P517, DOI 10.1111/j.1365-2222.1985.tb02304.x; COLTEN HR, 1975, NEW ENGL J MED, V292, P1050, DOI 10.1056/NEJM197505152922003; CRONER S, 1982, ARCH DIS CHILD, V57, P364, DOI 10.1136/adc.57.5.364; CUNNINGHAMRUNDLES C, 1978, P NATL ACAD SCI USA, V75, P3387, DOI 10.1073/pnas.75.7.3387; DANNAEUS A, 1977, ACTA PAEDIATR SCAND, V66, P31, DOI 10.1111/j.1651-2227.1977.tb07803.x; DELESPESSE G, 1983, MONOGR ALLERGY, V18, P83; Donnally HH, 1930, J IMMUNOL, V19, P15; DUCHATEAU J, 1983, LANCET, V1, P413; DUMONT GCL, 1984, CLIN ALLERGY, V14, P55; EASTHAM EJ, 1978, J PEDIATR-US, V93, P561, DOI 10.1016/S0022-3476(78)80888-9; FERGUSSON DM, 1983, ARCH DIS CHILD, V58, P48, DOI 10.1136/adc.58.1.48; FERGUSSON DM, 1981, CLIN ALLERGY, V11, P325; FRICK OL, 1979, J ALLERGY CLIN IMMUN, V63, P228, DOI 10.1016/0091-6749(79)90106-4; Gamo I, 1966, Acta Paediatr Jpn, V8, P1; GERRARD JW, 1974, J PEDIATR-US, V85, P660, DOI 10.1016/S0022-3476(74)80510-X; GERRARD JW, 1979, ANN ALLERGY, V42, P69; GORDON RR, 1982, LANCET, V1, P72; Grulee CG, 1936, J PEDIATR-US, V9, P223, DOI 10.1016/S0022-3476(36)80058-4; GRUSKAY FL, 1982, CLIN PEDIATR, V21, P486, DOI 10.1177/000992288202100807; HALPERN SR, 1973, J ALLERGY CLIN IMMUN, V51, P139, DOI 10.1016/0091-6749(73)90019-5; HAMBURGER RN, 1983, ANN ALLERGY, V51, P281; HEMMINGS C, 1977, P R SOC LOND, V198, P39; HEMMINGS WA, 1978, LANCET, V2, P575; HIDE DW, 1981, ARCH DIS CHILD, V56, P172, DOI 10.1136/adc.56.3.172; JARRETT E, 1979, NATURE, V280, P145, DOI 10.1038/280145a0; JOHNSTONE DE, 1966, NEW ENGL J MED, V274, P715, DOI 10.1056/NEJM196603312741305; JUTO P, 1982, CLIN ALLERGY, V12, P409, DOI 10.1111/j.1365-2222.1982.tb02546.x; JUTO P, 1980, CLIN ALLERGY, V10, P593, DOI 10.1111/j.1365-2222.1980.tb02141.x; KAJOSAARI M, 1983, ACTA PAEDIATR SCAND, V72, P411, DOI 10.1111/j.1651-2227.1983.tb09738.x; KAPLAN MS, 1979, J ALLERGY CLIN IMMUN, V64, P122, DOI 10.1016/0091-6749(79)90045-9; KAUFMAN H S, 1971, Clinical Allergy, V1, P363, DOI 10.1111/j.1365-2222.1971.tb00787.x; KAUFMAN HS, 1972, ARCH DERMATOL, V105, P400, DOI 10.1001/archderm.105.3.400; KAUFMAN HS, 1976, ANN ALLERGY, V37, P410; KJELLMAN NIM, 1981, LANCET, V1, P993; KJELLMAN NIM, 1984, ANN ALLERGY, V53, P167; KJELLMAN NIM, 1976, ACTA PAEDIATR SCAND, V65, P465, DOI 10.1111/j.1651-2227.1976.tb04915.x; KJELLMAN NIM, 1979, CLIN ALLERGY, V9, P347, DOI 10.1111/j.1365-2222.1979.tb02493.x; KJELLMAN NIM, 1976, ACTA PAEDIATR SCAND, V65, P495; KORGSGAARD J, 1982, AM REV RESPIR DIS, V125, P80; LEVIN S, 1971, PEDIATR RES, V5, P87, DOI 10.1203/00006450-197102000-00028; Lyon GT, 1928, AM J DIS CHILD, V36, P1012, DOI 10.1001/archpedi.1928.01920290140009; MACRIS NT, 1958, AM J OBSTET GYNECOL, V76, P1214; MARSH DG, 1974, P NATL ACAD SCI USA, V71, P3588, DOI 10.1073/pnas.71.9.3588; MATTHEW DJ, 1977, LANCET, V1, P321; MELLON M, 1983, J ALLERGY CLIN IMMUN, V71, P40; MICHEL FB, 1980, J ALLERGY CLIN IMMUN, V65, P422, DOI 10.1016/0091-6749(80)90234-1; MILLER DL, 1973, J ALLERGY CLIN IMMUN, V52, P182, DOI 10.1016/0091-6749(73)90035-3; MORTIMER EZ, 1961, J PEDIATR-US, V58, P90, DOI 10.1016/S0022-3476(61)80065-6; NAESLUND J, 1951, ACTA OBSTET GYN SCAN, V30, P231; NAESLUND J, 1946, ACTA MED SCAND, V170, P390; OCONNOR RD, 1984, NEW ENGL REGIONAL AL, V5, P149; OKEEFE ES, 1920, BOSTON MED SURG J, V183, P569; ORGEL HA, 1975, J ALLERGY CLIN IMMUN, V56, P296, DOI 10.1016/0091-6749(75)90104-9; PATTERSON R, 1973, AM J MED, V54, P16, DOI 10.1016/0002-9343(73)90078-8; PETERS GA, 1965, ANN ALLERGY, V23, P1970; RADERMECKER M, 1974, INT ARCH ALLER A IMM, V47, P285, DOI 10.1159/000231221; RAO DC, 1980, AM J HUM GENET, V32, P620; RATNER B, 1922, MED CLIN N AM, V6, P815; ROBERTON DM, 1982, ARCH DIS CHILD, V57, P369, DOI 10.1136/adc.57.5.369; SAARINEN UM, 1979, LANCET, V2, P163; Schatz M, 1983, ALLERGY PRINCIPLES P, P935; SEBAN A, 1977, AM J CLIN NUTR, V30, P840, DOI 10.1093/ajcn/30.6.840; SELNER JC, 1968, J PEDIATR-US, V72, P685, DOI 10.1016/S0022-3476(68)80014-9; SETTIPANE RJ, 1979, R I MED J, V62, P477; Shannon WR, 1921, AM J DIS CHILD, V22, P223; Sherman WB, 1940, J EXP MED, V72, P611, DOI 10.1084/jem.72.5.611; SINGER AD, 1974, J ALLERGY CLIN IMMUN, V53, P94; SMITH K, 1961, OBSTET GYNECOL, V18, P673; STUART CA, 1984, CLIN ALLERGY, V14, P533, DOI 10.1111/j.1365-2222.1984.tb02240.x; TALBOT FB, 1918, MED CLIN N AM, V1, P985; UDALL JN, 1981, PEDIATR RES, V15, P245, DOI 10.1203/00006450-198103000-00009; VANASPEREN PP, 1984, CLIN ALLERGY, V14, P525; VANASPEREN PP, 1983, ARCH DIS CHILD, V58, P253, DOI 10.1136/adc.58.4.253; WALKER WA, 1977, MEAD JOHNSON S PERIN, V11, P49; WARNER JO, 1980, CLIN ALLERGY, V10, P133, DOI 10.1111/j.1365-2222.1980.tb02090.x; WEIL GJ, 1983, J CLIN INVEST, V71, P1124, DOI 10.1172/JCI110862; WELLIVER RC, 1980, NEW ENGL J MED, V303, P1198, DOI 10.1056/NEJM198011203032103; WHITINGTON PF, 1977, PEDIATRICS, V59, P730; ZAROU DM, 1964, AM J OBSTET GYNECOL, V88, P565, DOI 10.1016/0002-9378(64)90881-6; ZIERING RW, 1979, J ALLERGY CLIN IMMUN, V63, P199	90	79	79	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1986	78	1	2	S			224	238		10.1016/0091-6749(86)90016-3	http://dx.doi.org/10.1016/0091-6749(86)90016-3			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	D2997	3722649				2022-12-18	WOS:A1986D299700016
J	GREENBERG, MA; KAUFMAN, CR; GONZALEZ, GE; ROSENBLATT, CD; SMITH, LJ; SUMMERS, RJ				GREENBERG, MA; KAUFMAN, CR; GONZALEZ, GE; ROSENBLATT, CD; SMITH, LJ; SUMMERS, RJ			LATE AND IMMEDIATE SYSTEMIC-ALLERGIC REACTIONS TO INHALANT ALLERGEN IMMUNOTHERAPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MARTIN ARMY HOSP,ALLERGY & IMMUNIZAT CLIN,FT BENNING,GA; WALTER REED ARMY INST RES,ALLERGY IMMUNOL SERV,WASHINGTON,DC 20307	United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR)	GREENBERG, MA (corresponding author), WOMACK ARMY HOSP,ALLERGY & IMMUNIZAT CLIN,FT BRAGG,NC 28307, USA.							BAER H, 1983, ALLERGY PRINCIPLES P, P258; Cooke RA, 1922, J IMMUNOL, V7, P119; FIGLEY KD, 1931, J ALLERGY, V2, P39; Freeman J, 1911, LANCET, V2, P814; Furstenberg FF, 1937, B JOHNS HOPKINS HOSP, V60, P412; GLEICH GJ, 1976, J ALLERGY CLIN IMMUN, V58, P31, DOI 10.1016/0091-6749(76)90104-4; GLEICH GJ, 1974, J ALLERGY CLIN IMMUN, V53, P158, DOI 10.1016/0091-6749(74)90004-9; KAUFMAN CR, 1984, ANN ALLERGY, V52, P220; LEVINE MI, 1979, J ALLERGY CLIN IMMUN, V63, P209; LOCKEY R, 1985, J ALLERGY CLIN IMMUN, V75, P166, DOI 10.1016/0091-6749(85)90381-1; Noon L, 1911, LANCET, V1, P1572; PATTERSON R, 1983, ALLERGY PRINCIPLES P, P1137; RANSOM JH, 1971, ANN ALLERGY, V29, P635; ROCKLIN RE, 1983, J ALLERGY CLIN IMMUN, V72, P323, DOI 10.1016/0091-6749(83)90492-X; SOLOMON WR, 1983, ALLERGY PRINCIPLES P, V2, P1169; VANARSDEL PP, 1957, J ALLERGY, V28, P251, DOI 10.1016/0021-8707(57)90130-2; VERVLOET D, 1980, CLIN ALLERGY, V10, P59, DOI 10.1111/j.1365-2222.1980.tb02080.x; YUNGINGER JW, 1976, J ALLERGY CLIN IMMUN, V58, P405, DOI 10.1016/0091-6749(76)90121-4	18	79	82	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1986	77	6					865	870		10.1016/0091-6749(86)90385-4	http://dx.doi.org/10.1016/0091-6749(86)90385-4			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	C8694	3711554				2022-12-18	WOS:A1986C869400012
J	SMITH, TF; KELLY, LB; HEYMANN, PW; WILKINS, SR; PLATTSMILLS, TAE				SMITH, TF; KELLY, LB; HEYMANN, PW; WILKINS, SR; PLATTSMILLS, TAE			NATURAL EXPOSURE AND SERUM ANTIBODIES TO HOUSE DUST MITE OF MITE-ALLERGIC CHILDREN WITH ASTHMA IN ATLANTA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV VIRGINIA,MED CTR,SCH MED,DEPT MED,DIV ALLERGY,CHARLOTTESVILLE,VA 22901	University of Virginia	SMITH, TF (corresponding author), EMORY UNIV,SCH MED,DEPT PEDIAT,DIV ALLERGY IMMUNOL,69 BUTLER ST SE,ATLANTA,GA 30303, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020565, R01AI020565] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-20565] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARLIAN LG, 1976, J ASTHMA RES, V13, P165, DOI 10.3109/02770907609104172; ARLIAN LG, 1982, J ALLERGY CLIN IMMUN, V69, P527, DOI 10.1016/0091-6749(82)90178-6; BURR ML, 1980, THORAX, V35, P506, DOI 10.1136/thx.35.7.506; CHAPMAN MD, 1983, J ALLERGY CLIN IMMUN, V72, P27, DOI 10.1016/0091-6749(83)90048-9; CHAPMAN MD, 1980, J IMMUNOL, V125, P587; CHAPMAN MD, 1980, INT ARCH ALLER A IMM, V61, P431, DOI 10.1159/000232471; CHAPMAN MD, 1984, J IMMUNOL, V133, P2488; CLARKE CW, 1979, CLIN ALLERGY, V9, P147, DOI 10.1111/j.1365-2222.1979.tb01535.x; FORD AW, 1985, INT ARCH ALLER A IMM, V76, P58, DOI 10.1159/000233662; HENDRICK DJ, 1975, THORAX, V30, P2, DOI 10.1136/thx.30.1.2; HUGHES A M, 1973, Clinical Allergy, V3, P127, DOI 10.1111/j.1365-2222.1973.tb01316.x; JOHNSON L E, 1984, Journal of Allergy and Clinical Immunology, V73, P119; KERREBIJN KF, 1970, BRONCHITIS, V3, P38; KORSGAARD J, 1983, AM REV RESPIR DIS, V128, P231; KORSGAARD J, 1983, ALLERGY, V38, P93, DOI 10.1111/j.1398-9995.1983.tb01592.x; LANG JD, 1978, ENVIRON ENTOMOL, V7, P281, DOI 10.1093/ee/7.2.281; LEMAO J, 1983, J ALLERGY CLIN IMMUN, V71, P588, DOI 10.1016/0091-6749(83)90441-4; LIND P, 1984, ALLERGY, V39, P259, DOI 10.1111/j.1398-9995.1984.tb00863.x; MAUNSELL K, 1968, LANCET, V1, P1267; MIYAMOTO T, 1970, ANN ALLERGY, V28, P405; MURRAY AB, 1983, PEDIATRICS, V71, P418; MURRAY AB, 1979, J ALLERGY CLIN IMMUN, V64, P266, DOI 10.1016/0091-6749(79)90142-8; PLATTSMILLS T, UNPUB CROSS REACTING; PLATTSMILLS TAE, 1982, LANCET, V2, P675; PLATTSMILLS TAE, 1983, CLIN EXP DERMATOL, V8, P233, DOI 10.1111/j.1365-2230.1983.tb01776.x; PLATTSMILLS TAE, 1982, LANCET, V2, P1334; Romagnani S, 1972, Clin Allergy, V2, P115, DOI 10.1111/j.1365-2222.1972.tb01276.x; SARSFIELD JK, 1974, ARCH DIS CHILD, V49, P716, DOI 10.1136/adc.49.9.716; SHAMIYEH NB, 1970, J EC ENTOMOL, V66, P998; SHARP JL, 1970, P HAWAII ENTOMOL SOC, V20, P583; SMITH MJ, 1969, BR MED J, V2, P723; Spieksma F. Th. M., 1967, Acarologia, V9, P226; STEWART GA, 1982, INT ARCH ALLER A IMM, V69, P224, DOI 10.1159/000233175; TOVEY ER, 1981, AM REV RESPIR DIS, V124, P630; TURNER MW, 1984, CLIN ALLERGY, V14, P221, DOI 10.1111/j.1365-2222.1984.tb02201.x; VANBRONSWIJK J, 1981, 5TH C BIOM AM MET SO; VOORHORS.R, 1967, J ALLERGY, V39, P325, DOI 10.1016/0021-8707(67)90045-7; WHARTON GW, 1976, J MED ENTOMOL, V12, P577, DOI 10.1093/jmedent/12.6.577; 1962, AM REV RESPIR DIS, V85, P762	39	79	80	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1985	76	6					782	788		10.1016/0091-6749(85)90748-1	http://dx.doi.org/10.1016/0091-6749(85)90748-1			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AWX93	3877746				2022-12-18	WOS:A1985AWX9300004
J	DVORACEK, JE; YUNGINGER, JW; KERN, EB; HYATT, RE; GLEICH, GJ				DVORACEK, JE; YUNGINGER, JW; KERN, EB; HYATT, RE; GLEICH, GJ			INDUCTION OF NASAL LATE-PHASE REACTIONS BY INSUFFLATION OF RAGWEED-POLLEN EXTRACT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV MINNESOTA,MAYO GRAD SCH MED,DEPT MED,ROCHESTER,MN 55901; UNIV MINNESOTA,MAYO GRAD SCH MED,DEPT IMMUNOL,ROCHESTER,MN 55901; UNIV MINNESOTA,MAYO GRAD SCH MED,DEPT OTORHINOLARYNGOL,ROCHESTER,MN 55901; UNIV MINNESOTA,MAYO GRAD SCH MED,DEPT PEDIAT,ROCHESTER,MN 55901; MAYO CLIN & MAYO FDN,ALLERG DIS RES LAB,ROCHESTER,MN 55901	Mayo Clinic; University of Minnesota System; University of Minnesota Rochester; Mayo Clinic; University of Minnesota System; University of Minnesota Rochester; Mayo Clinic; University of Minnesota System; University of Minnesota Rochester; Mayo Clinic; University of Minnesota System; University of Minnesota Rochester; Mayo Clinic					NIAID NIH HHS [AI-11483] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011483] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Dixon W. J, 1969, INTRO STAT ANAL, P344; DOLOVICH J, 1972, J ALLERGY CLIN IMMUN, V49, P43, DOI 10.1016/0091-6749(72)90122-4; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P160, DOI 10.1016/0091-6749(82)90037-9; MCLEAN JA, 1976, J ALLERGY CLIN IMMUN, V57, P153, DOI 10.1016/0091-6749(76)90034-8; PELIKAN Z, 1978, ANN ALLERGY, V41, P37; Ramirez MA, 1919, J AMER MED ASSOC, V73, P984, DOI 10.1001/jama.1919.02610390036012; RICHERSON HB, 1979, J ALLERGY CLIN IMMUN, V64, P67, DOI 10.1016/0091-6749(79)90085-X; SCHUMACHER MJ, 1979, J ALLERGY CLIN IMMUN, V64, P202, DOI 10.1016/0091-6749(79)90096-4; SHAMPAIN MP, 1982, AM REV RESPIR DIS, V126, P493; SHERMAN H, 1937, J ALLERGY, V9, P1; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; SOLOMON WR, 1965, J ALLERGY, V36, P62, DOI 10.1016/0021-8707(65)90033-X; TAYLOR G, 1971, Clinical Allergy, V1, P407, DOI 10.1111/j.1365-2222.1971.tb00792.x; TAYLOR G, 1973, J ALLERGY CLIN IMMUN, V52, P193, DOI 10.1016/0091-6749(73)90057-2	15	79	80	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	3					363	368		10.1016/0091-6749(84)90409-3	http://dx.doi.org/10.1016/0091-6749(84)90409-3			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SK155	6699316				2022-12-18	WOS:A1984SK15500010
J	VANMETRE, TE; ADKINSON, NF; LICHTENSTEIN, LM; MARDINEY, MR; NORMAN, PS; ROSENBERG, GL; SOBOTKA, AK; VALENTINE, MD				VANMETRE, TE; ADKINSON, NF; LICHTENSTEIN, LM; MARDINEY, MR; NORMAN, PS; ROSENBERG, GL; SOBOTKA, AK; VALENTINE, MD			A CONTROLLED-STUDY OF THE EFFECTIVENESS OF THE RINKEL METHOD OF IMMUNOTHERAPY FOR RAGWEED POLLEN HAY-FEVER	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV CLIN IMMUNOL,BALTIMORE,MD 21218; JOHNS HOPKINS UNIV HOSP,ALLERGY CLIN,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine								ADKINSON NF, 1976, MANUAL CLIN IMMUNOLO; ANDERSON JM, 1932, J ALLERGY, V3, P306; ANDERSON JM, 1935, J ALLERGY, V6, P244; CONNELL JT, 1967, ANN ALLERGY, V25, P239; DUKE WW, 1926, ALLERGY ASTHMA HAY F; FADAL RG, 1975, T AM SOC OPHTHALMOL, V15, P158; FRANKLIN W, 1967, J AMER MED ASSOC, V201, P915, DOI 10.1001/jama.201.12.915; GLEICH GJ, 1977, J ALLERGY CLIN IMMUN, V60, P188, DOI 10.1016/0091-6749(77)90123-3; HAMILTON RG, 1979, J IMMUNOL, V122, P1073; HANSEL FK, 1936, ALLERGY NOSE PARANAS; HANSEL FRENCH K., 1941, JOUR ALLERGY, V12, P457, DOI 10.1016/S0021-8707(41)90222-8; IRONS JS, 1977, J ALLERGY CLIN IMMUN, V59, P190, DOI 10.1016/0091-6749(77)90149-X; JOHNSTONE DE, 1957, AMA J DIS CHILD, V94, P1; LEVY DA, 1967, J IMMUNOL, V99, P1068; LEVY DA, 1971, J CLIN INVEST, V50, P360, DOI 10.1172/JCI106503; LICHTENS.LM, 1968, AM J MED, V44, P514, DOI 10.1016/0002-9343(68)90052-1; LICHTENSTEIN LM, 1971, ANN INTERN MED, V75, P663, DOI 10.7326/0003-4819-75-5-663; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; LICHTENSTEIN LM, 1966, J CLIN INVEST, V45, P1126, DOI 10.1172/JCI105419; Lieberman P, 1974, Adv Intern Med, V19, P391; LOWELL FC, 1963, J ALLERGY, V34, P165, DOI 10.1016/0021-8707(63)90069-8; LOWELL FC, 1965, NEW ENGL J MED, V273, P675, DOI 10.1056/NEJM196509232731302; MELAM H, 1971, J ALLERGY, V47, P262, DOI 10.1016/S0091-6749(71)80004-0; MELAM HL, 1970, J ALLERGY, V46, P292, DOI 10.1016/0021-8707(70)90069-9; Noon L, 1911, LANCET, V1, P1572; NORMAN PS, 1972, J ALLERGY CLIN IMMUN, V50, P31, DOI 10.1016/0091-6749(72)90077-2; NORMAN PS, 1968, J ALLERGY, V42, P93, DOI 10.1016/0021-8707(68)90139-1; NORMAN PS, 1971, J ALLERGY, V47, P273, DOI 10.1016/S0091-6749(71)80005-2; NORMAN PS, 1969, J ALLERGY, V44, P129, DOI 10.1016/0021-8707(69)90137-3; NORMAN PS, 1973, J ALLERGY CLIN IMMUN, V52, P210, DOI 10.1016/0091-6749(73)90059-6; NORMAN PS, 1973, RECENT ADV IMMUNOTHE; OGDEN EC, 1967, J ALLERGY, V40, P1, DOI 10.1016/0021-8707(67)90053-6; Phillips EW, 1926, J AMER MED ASSOC, V86, P182, DOI 10.1001/jama.1926.02670290022008; PLATTSMILLS TAE, 1976, J CLIN INVEST, V57, P1041, DOI 10.1172/JCI108346; PRUZANSKY JJ, 1967, J ALLERGY, V39, P44, DOI 10.1016/0021-8707(67)90126-8; RINKEL HJ, 1963, ARCHIV OTOLARYNGOL, V77, P205; RINKEL HJ, 1963, ARCHIV OTOLARYNGOL, V77, P42; SADAN N, 1969, NEW ENGL J MED, V280, P623, DOI 10.1056/NEJM196903202801201; SHAMBAUGH GE, 1974, OTOLARYNG CLIN N AM, V7, P569; Sherman WB, 1941, J IMMUNOL, V40, P289; Siegel S., 1956, NONPARAMETRIC STAT B; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P383, DOI 10.1016/0003-2697(74)90093-1; VANMETRE TE, 1977, J ALLERGY CLIN IMMUN, V59, P341, DOI 10.1016/0091-6749(77)90058-6; Vaughan WT, 1923, J AMER MED ASSOC, V80, P0245, DOI 10.1001/jama.1923.02640310025009; VAUGHAN WT, 1932, J ALLERGY, V3, P542; WILLOUGHBY JW, 1974, OTOLARYNG CLIN N AM, V7, P579	46	79	80	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	65	4					288	297		10.1016/0091-6749(80)90158-X	http://dx.doi.org/10.1016/0091-6749(80)90158-X			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JN548	6987291				2022-12-18	WOS:A1980JN54800009
J	MARTINEZ, JD; SANTOS, J; STECHSCHULTE, DJ; ABDOU, NI				MARTINEZ, JD; SANTOS, J; STECHSCHULTE, DJ; ABDOU, NI			NONSPECIFIC SUPPRESSOR CELL-FUNCTION IN ATOPIC SUBJECTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV KANSAS,MED CTR,DIV ALLERGY CLIN IMMUNOL & RHEUMATOL,KANSAS CITY,KS 66103	University of Kansas; University of Kansas Medical Center								ABDOU NI, 1971, J IMMUNOL, V107, P1637; ALBERTSON BD, 1977, ENDOCR RES COMMUN, V4, P295, DOI 10.3109/07435807709052949; BALLET JJ, 1976, CELL IMMUNOL, V24, P250, DOI 10.1016/0008-8749(76)90210-0; BEAVEN MA, 1972, CLIN CHIM ACTA, V37, P91, DOI 10.1016/0009-8981(72)90419-6; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BUCKLEY RH, 1978, IMMUNOL REV, V41, P288, DOI 10.1111/j.1600-065X.1978.tb01469.x; DRAZEN JM, 1978, AM REV RESPIR DIS, V117, P479; ISHIZAKA K, 1976, ADV IMMUNOL, V23, P1, DOI 10.1016/S0065-2776(08)60318-1; KAPP JA, 1978, FED PROC, V37, P2361; KATZ DH, 1974, J IMMUNOL, V113, P974; OUSLEY M, 1977, FED PROC, V36, P1241; PLAUT M, 1975, J CLIN INVEST, V55, P856, DOI 10.1172/JCI107997; ROBINSON RA, 1978, BLOOD             S1, V52, P142; ROCKLIN RE, 1977, J IMMUNOL, V118, P1734; SAGAWA A, 1978, J CLIN INVEST, V62, P789, DOI 10.1172/JCI109190; SMITH JW, 1971, J CLIN INVEST, V50, P442, DOI 10.1172/JCI106511; STRANNEGARD IL, 1977, INT ARCH ALLER A IMM, V55, P217, DOI 10.1159/000231930; STRANNEGARD IL, 1977, SCAND J IMMUNOL, V6, P1225; STRANNEGARD O, 1978, IMMUNOL REV, V41, P149, DOI 10.1111/j.1600-065X.1978.tb01463.x; TADA T, 1975, PROG ALLERGY, V19, P122, DOI 10.1159/000313387; UYTDEHAAG F, 1978, NATURE, V271, P556, DOI 10.1038/271556a0; VERHAEGEN H, 1977, J ALLERGY CLIN IMMUN, V59, P266, DOI 10.1016/0091-6749(77)90161-0; WAKSMAN BH, 1977, CELL IMMUNOL, V30, P189, DOI 10.1016/0008-8749(77)90062-4; WANG SR, 1978, CELL IMMUNOL, V36, P28, DOI 10.1016/0008-8749(78)90247-2; WEINSTEIN Y, 1976, IMMUNOL COMMUN, V5, P401, DOI 10.3109/08820137609033857	25	79	79	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	64	6					485	490		10.1016/0091-6749(79)90057-5	http://dx.doi.org/10.1016/0091-6749(79)90057-5			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HX840	159920	Bronze			2022-12-18	WOS:A1979HX84000003
J	CASTERLINE, CL; EVANS, R				CASTERLINE, CL; EVANS, R			FURTHER-STUDIES ON MECHANISM OF HUMAN HISTAMINE-INDUCED ASTHMA - EFFECT OF AN AEROSOLIZED H-1 RECEPTOR ANTAGONIST (DIPHENHYDRAMINE)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									WALTER REED ARMY MED CTR,ALLERGY IMMUNOL SERV,WASHINGTON,DC 20012	United States Department of Defense; United States Army; Walter Reed National Military Medical Center								ARUNLAKSHANA O, 1953, J PHYSL, V119, P47; AUSTEN KF, 1973, REV IMMUNOLOGICAL BI, P109; BHAT KN, 1976, J ALLERGY CLIN IMMUN, V58, P647; CASTERLINE CL, 1976, J ALLERGY CLIN IMMUN, V58, P607, DOI 10.1016/0091-6749(76)90207-4; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; DEKOCK MA, 1966, J APPL PHYSIOL, V21, P185, DOI 10.1152/jappl.1966.21.1.185; EMPEY DW, 1976, AM REV RESPIR DIS, V113, P131; FRIEDMAN L L, 1949, South Med J, V42, P491; GOLD WM, 1972, J APPL PHYSIOL, V33, P719, DOI 10.1152/jappl.1972.33.6.719; GOLDMAN LSL, 1975, PHARMACOLOGIC BASIS, P605; HAWKINS DF, 1955, BRIT J PHARM CHEMOTH, V10, P230, DOI 10.1111/j.1476-5381.1955.tb00088.x; KARLIN JM, 1975, PEDIATR CLIN N AM, V22, P157; PAPA VT, 1976, J ALLERGY CLIN IMMUN, V58, P351; PORTER R, 1971, IDENTIFICATION ASTHM, P136; SELLICK H, 1971, J APPL PHYSIOL, V31, P15, DOI 10.1152/jappl.1971.31.1.15; SIMONSSON BG, 1967, J CLIN INVEST, V46, P1812, DOI 10.1172/JCI105671; SPECTOR S, 1976, AM REV RESPIR DIS, V113, P43; TAPLIN G V, 1948, Ann Allergy, V6, P42; YU DYC, 1972, J APPL PHYSIOL, V32, P823, DOI 10.1152/jappl.1972.32.6.823	19	79	79	0	6	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	59	6					420	424		10.1016/0091-6749(77)90004-5	http://dx.doi.org/10.1016/0091-6749(77)90004-5			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DJ990	16944				2022-12-18	WOS:A1977DJ99000003
J	SCHATZ, M; PATTERSON, R; OROURKE, J; NICKELSEN, J; NORTHUP, C				SCHATZ, M; PATTERSON, R; OROURKE, J; NICKELSEN, J; NORTHUP, C			ADMINISTRATION OF RADIOGRAPHIC CONTRAST-MEDIA TO PATIENTS WITH A HISTORY OF A PREVIOUS REACTION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NORTHWESTERN UNIV,MED SCH,DEPT MED,SECT ALLERGY IMMUNOL,303 E CHICAGO AVE,CHICAGO,IL 60611	Northwestern University								ANSELL G, 1970, INVEST RADIOL, V5, P374, DOI 10.1097/00004424-197011000-00002; BOOTH BH, 1972, ALLERGIC DISEASES DI, P63; BRASCH RC, 1970, INVEST RADIOL, V5, P510, DOI 10.1097/00004424-197011000-00017; COLEMAN WP, 1964, SOUTHERN MED J, V57, P1401, DOI 10.1097/00007611-196412000-00004; DESWARTE RD, 1972, ALLERGIC DISEASES DI, P476; FISCHER HW, 1972, RADIOLOGY, V103, P497, DOI 10.1148/103.3.497; GATES DF, 1972, J UROLOGY, V108, P627, DOI 10.1016/S0022-5347(17)60821-8; LASSER EC, 1971, RADIOLOGY, V100, P683, DOI 10.1148/100.3.683; Mathov E, 1969, Prensa Med Argent, V56, P1459; PENDERGRASS HP, 1958, RADIOLOGY, V71, P1; ROCKOFF SD, 1970, INVEST RADIOL, V5, P503, DOI 10.1097/00004424-197011000-00016; SANGER MAURY D., 1959, ANN ALLERGY, V17, P762; WEISZER I, 1972, ALLERGIC DISEASES DI, P327; WITTEN DM, 1973, AM J ROENTGENOL, V119, P832, DOI 10.2214/ajr.119.4.832; ZWEIMAN B, 1974, J ALLERGY CLIN IMMUN, V53, P97	15	79	79	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1975	55	5					358	366		10.1016/0091-6749(75)90007-X	http://dx.doi.org/10.1016/0091-6749(75)90007-X			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AB754	1120854				2022-12-18	WOS:A1975AB75400007
J	Perugino, CA; AlSalem, SB; Mattoo, H; Della-Torre, E; Mahajan, V; Ganesh, G; Allard-Chamard, H; Wallace, Z; Montesi, SB; Kreuzer, J; Haas, W; Stone, JH; Pillai, S				Perugino, Cory A.; AlSalem, Sultan B.; Mattoo, Hamid; Della-Torre, Emanuel; Mahajan, Vinay; Ganesh, Gayathri; Allard-Chamard, Hugues; Wallace, Zachary; Montesi, Sydney B.; Kreuzer, Johannes; Haas, Wilhelm; Stone, John H.; Pillai, Shiv			Identification of galectin-3 as an autoantigen in patients with IgG(4)-related disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IgG(4)-related disease; plasmablast; autoantigen; galectin-3; autoantibody	IGG4-RELATED DISEASE; AUTOANTIBODIES; PANCREATITIS; ANTIBODIES; ANTIGEN; EXPRESSION; CELLS	Background: The antigenic trigger that drives expansion of circulating plasmablasts and CD4(+) cytotoxic T cells in patients with IgG(4)-related disease (IgG(4)-RD) is presently unknown. Objective: We sought to sequence immunoglobulin genes from single-cell clones of dominantly expanded plasmablasts and generate recombinant human mAbs to identify relevant antigens in patients with IgG(4)-RD by using mass spectrometry. Methods: Paired heavy and light chain cDNAs from dominant plasmablast clones were expressed as mAbs and used to purify antigens by using immunoaffinity chromatography. Affinity-purified antigens were identified by using mass spectrometry and validated by means of ELISA. Plasma levels of the antigen of interest were also determined by using ELISA. Results: mAbs expressed from the 2 dominant plasmablast clones of a patient with multiorgan IgG(4)-RD stained human pancreatic tissue sections. Galectin-3 was identified as the antigen specifically recognized by both mAbs. Anti-galectin-3 autoantibody responses were predominantly of the IgG(4) isotype (28% of the IgG(4)-RD cohort, P = .0001) and IgE isotype (11% of the IgG(4)-RD cohort, P = .009). No significant responses were seen from the IgG(1), IgG(2), or IgG(3) isotypes. IgG(4) anti-galectin-3 autoantibodies correlated with increased plasma galectin-3 levels (P = .001), lymphadenopathy (P = .04), total IgG level increase (P = .05), and IgG(4) level increase (P = .03). Conclusion: Affinity chromatography using patient-derived mAbs identifies relevant autoantigens in patients with IgG(4)-RD. IgG(4) galectin-3 autoantibodies are present in a subset of patients with IgG(4)-RD and correlate with galectin-3 plasma levels. The marked increases in levels of circulating IgG(4) and IgE observed clinically are, at least in part, caused by the development of IgG(4)- and IgE-specific autoantibody responses.	[Perugino, Cory A.; Wallace, Zachary; Stone, John H.; Pillai, Shiv] Harvard Med Sch, Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, Boston, MA USA; [Perugino, Cory A.; AlSalem, Sultan B.; Mattoo, Hamid; Della-Torre, Emanuel; Mahajan, Vinay; Ganesh, Gayathri; Allard-Chamard, Hugues; Pillai, Shiv] MIT & Harvard, Ragon Inst MGH, 400 Technol Sq, Cambridge, MA 02139 USA; [AlSalem, Sultan B.] King Saud Univ, Coll Med, Dept Dermatol, Riyadh, Saudi Arabia; [Della-Torre, Emanuel] IRCCS San Raffaele Sci Inst, Unit Immunol Rheumatol Allergy & Rare Dis UnIRAR, Milan, Italy; [Mahajan, Vinay] Brigham & Womens Hosp, Div Pathol, 75 Francis St, Boston, MA 02115 USA; [Montesi, Sydney B.] Massachusetts Gen Hosp, Div Pulm & Crit Care Med, Boston, MA 02114 USA; [Kreuzer, Johannes; Haas, Wilhelm] Harvard Med Sch, Massachusetts Gen Hosp, Canc Ctr, Charlestown, MA USA; [Kreuzer, Johannes; Haas, Wilhelm] Harvard Med Sch, Dept Med, Charlestown, MA USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Massachusetts Institute of Technology (MIT); Ragon Institute; King Saud University; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Pillai, S (corresponding author), MIT & Harvard, Ragon Inst MGH, 400 Technol Sq, Cambridge, MA 02139 USA.	spillai@mgh.harvard.edu	Della Torre, Emanuel/AAB-5024-2022; Mahajan, Vinay S/AAF-3303-2019	Ganesh, Gayathri/0000-0001-5377-7663; Mahajan, Vinay/0000-0003-0814-2989	National Institutes of Health (NIH) [U19 AI110495]; NIH [T32 AR007258, AI 113163, S10RR023440]; Rheumatology Research Foundation; NIH Loan Repayment Program; FIRA Onlus; Collegio Ghislieri di Pavia (Italy); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI110495, K08AI113163] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007258] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK043351] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Rheumatology Research Foundation; NIH Loan Repayment Program(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); FIRA Onlus; Collegio Ghislieri di Pavia (Italy); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Supported by National Institutes of Health (NIH) grant U19 AI110495 (to S.P.). C.A.P. was supported by NIH grant T32 AR007258, and V.M. was supported by NIH grant AI 113163. Z.W. has received support through a Scientist Development Award from the Rheumatology Research Foundation and the NIH Loan Repayment Program. E.D.-T. was supported by FIRA Onlus and Collegio Ghislieri di Pavia (Italy). The MGH flow core is supported by grant S10RR023440 from the NIH.	Asada M, 2006, PANCREAS, V33, P20, DOI 10.1097/01.mpa.0000226881.48204.fd; Carruthers MN, 2015, ANN RHEUM DIS, V74, P1171, DOI 10.1136/annrheumdis-2014-206605; Carruthers MN, 2012, INT J RHEUMATOL, V2012, DOI 10.1155/2012/259408; CHERAYIL BJ, 1989, J EXP MED, V170, P1959, DOI 10.1084/jem.170.6.1959; Deshpande V, 2012, MODERN PATHOL, V25, P1181, DOI 10.1038/modpathol.2012.72; Du HW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125331; Edwards A, 2016, METHODS MOL BIOL, V1394, P1, DOI 10.1007/978-1-4939-3341-9_1; Endo T, 2009, DIABETES, V58, P732, DOI 10.2337/db08-0493; Faludi R, 2017, INT J CARDIOL, V233, P118, DOI 10.1016/j.ijcard.2016.12.140; Frulloni L, 2009, NEW ENGL J MED, V361, P2135, DOI 10.1056/NEJMoa0903068; Beccaria CG, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04063-5; Henderson NC, 2006, P NATL ACAD SCI USA, V103, P5060, DOI 10.1073/pnas.0511167103; Henderson NC, 2008, AM J PATHOL, V172, P288, DOI 10.2353/ajpath.2008.070726; Hirani N, 2017, AM THOR SOC 2017 INT; Hubers LM, 2018, GUT, V67, P728, DOI 10.1136/gutjnl-2017-314548; Jeannin P, 1998, J IMMUNOL, V160, P3555; Li LC, 2014, J PHARMACOL EXP THER, V351, P336, DOI 10.1124/jpet.114.218370; Lohr JM, 2010, AM J GASTROENTEROL, V105, P2060, DOI 10.1038/ajg.2010.141; MacKinnon AC, 2012, AM J RESP CRIT CARE, V185, P537, DOI 10.1164/rccm.201106-0965OC; Maehara T, 2018, LIFE SCI ALLIANCE, V1, DOI 10.26508/lsa.201800050; Mattoo H, 2014, ALLERGY, V69, P399, DOI 10.1111/all.12342; Mattoo H, 2016, J ALLERGY CLIN IMMUN, V138, P825, DOI 10.1016/j.jaci.2015.12.1330; Mattoo H, 2014, J ALLERGY CLIN IMMUN, V134, P679, DOI 10.1016/j.jaci.2014.03.034; MELERO JA, 1979, VIROLOGY, V93, P466, DOI 10.1016/0042-6822(79)90250-2; NISHIMORI I, 1994, PANCREAS, V9, P374, DOI 10.1097/00006676-199405000-00015; Nisihara R, 2013, J AM GERIATR SOC, V61, P2044, DOI 10.1111/jgs.12533; Okazaki K, 2000, GASTROENTEROLOGY, V118, P573, DOI 10.1016/S0016-5085(00)70264-2; Salah A., 2017, PATHOLOG RES INT, V2017; Shiokawa M, 2016, GUT, V65, P1322, DOI 10.1136/gutjnl-2015-310336; Soussi T, 2000, CANCER RES, V60, P1777; Tiller T, 2008, J IMMUNOL METHODS, V329, P112, DOI 10.1016/j.jim.2007.09.017; Ting L, 2011, NAT METHODS, V8, P937, DOI [10.1038/NMETH.1714, 10.1038/nmeth.1714]; Wallace ZS, 2015, ARTHRITIS RHEUMATOL, V67, P2466, DOI 10.1002/art.39205; Wallace ZS, 2015, ANN RHEUM DIS, V74, P190, DOI 10.1136/annrheumdis-2014-205233; Yu LL, 2013, CIRC-HEART FAIL, V6, P107, DOI 10.1161/CIRCHEARTFAILURE.112.971168	35	78	82	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2019	143	2					736	+		10.1016/j.jaci.2018.05.011	http://dx.doi.org/10.1016/j.jaci.2018.05.011			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HK2DJ	29852256	Bronze, Green Accepted			2022-12-18	WOS:000457718700032
J	Kadowaki, T; Ohnishi, H; Kawamoto, N; Hori, T; Nishimura, K; Kobayashi, C; Shigemura, T; Ogata, S; Inoue, Y; Kawai, T; Hiejima, E; Takagi, M; Imai, K; Nishikomori, R; Ito, S; Heike, T; Ohara, O; Morio, T; Fukao, T; Kanegane, H				Kadowaki, Tomonori; Ohnishi, Hidenori; Kawamoto, Norio; Hori, Tomohiro; Nishimura, Kenichi; Kobayashi, Chie; Shigemura, Tomonari; Ogata, Shohei; Inoue, Yuzaburo; Kawai, Tomoki; Hiejima, Eitaro; Takagi, Masatoshi; Imai, Kohsuke; Nishikomori, Ryuta; Ito, Shuichi; Heike, Toshio; Ohara, Osamu; Morio, Tomohiro; Fukao, Toshiyuki; Kanegane, Hirokazu			Haploinsufficiency of A20 causes autoinflammatory and autoimmune disorders	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									[Kadowaki, Tomonori; Ohnishi, Hidenori; Kawamoto, Norio; Hori, Tomohiro; Fukao, Toshiyuki] Gifu Univ, Grad Sch Med, Dept Pediat, Gifu, Japan; [Nishimura, Kenichi; Ito, Shuichi] Yokohama City Univ, Dept Pediat, Yokohama, Kanagawa, Japan; [Kobayashi, Chie] Univ Tsukuba, Fac Med, Dept Child Hlth, Tsukuba, Ibaraki, Japan; [Shigemura, Tomonari] Shinshu Univ, Sch Med, Dept Pediat, Matsumoto, Nagano, Japan; [Ogata, Shohei] Kitasato Univ Hosp, Dept Pediat, Sagamihara, Kanagawa, Japan; [Inoue, Yuzaburo] Eastern Chiba Med Ctr, Dept Pediat, Chiba, Japan; [Kawai, Tomoki; Hiejima, Eitaro; Nishikomori, Ryuta; Heike, Toshio] Kyoto Univ Hosp, Dept Pediat, Kyoto, Japan; [Imai, Kohsuke] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Community Pediat Perinatal & Maternal Med, Tokyo, Japan; [Ohara, Osamu] Kazusa DNA Res Inst, Dev Technol Dept, Chiba, Japan; [Morio, Tomohiro; Kanegane, Hirokazu] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Pediat & Dev Biol, Tokyo, Japan	Gifu University; Yokohama City University; University of Tsukuba; Shinshu University; Kitasato University; Kyoto University; Tokyo Medical & Dental University (TMDU); Kazusa DNA Research Institute; Tokyo Medical & Dental University (TMDU)	Kadowaki, T (corresponding author), Gifu Univ, Grad Sch Med, Dept Pediat, Gifu, Japan.		Kawamoto, Norio/AAN-5302-2021; Ohara, Osamu/G-5448-2015; Hori, Tomohiro/HHA-3840-2022; Inoue, Yuzaburo/E-3262-2019; Ito, Shuichi/AAD-1962-2022; Nishikomori, Ryuta/AAM-5771-2020; Imai, Kohsuke/Q-2602-2015; Nishikomori, Ryuta/N-4039-2018; Nishimura, Kenichi/AAC-7056-2021	Kawamoto, Norio/0000-0002-3482-7781; Ohara, Osamu/0000-0002-3328-9571; Inoue, Yuzaburo/0000-0001-5904-687X; Nishikomori, Ryuta/0000-0002-9407-6158; Imai, Kohsuke/0000-0003-2132-8403; Nishikomori, Ryuta/0000-0002-9407-6158; Nishimura, Kenichi/0000-0002-9827-3503; Morio, Tomohiro/0000-0002-9259-1025	Health and Labour Sciences Research Grants for Research on Intractable Diseases from the Ministry of Health, Labour and Welfare of Japan [17933688, 17933299]; Grants-in-Aid for Scientific Research [15K09640] Funding Source: KAKEN	Health and Labour Sciences Research Grants for Research on Intractable Diseases from the Ministry of Health, Labour and Welfare of Japan; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by Health and Labour Sciences Research Grants for Research on Intractable Diseases from the Ministry of Health, Labour and Welfare of Japan (grant nos. 17933688 and 17933299).	Aksentijevich I, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00399; Duncan C.J.A., 2017, ANN RHEUM DIS; Gaffen SL, 2014, NAT REV IMMUNOL, V14, P585, DOI 10.1038/nri3707; Ideguchi H, 2011, MEDICINE, V90, P125, DOI 10.1097/MD.0b013e318211bf28; Jing H, 2014, J ALLERGY CLIN IMMUN, V133, P1667, DOI 10.1016/j.jaci.2014.03.025; Livneh A, 1997, ARTHRITIS RHEUM-US, V40, P1879, DOI 10.1002/art.1780401023; Ma A, 2012, NAT REV IMMUNOL, V12, P774, DOI 10.1038/nri3313; Ohnishi H, 2017, ALLERGOL INT, V66, P146, DOI 10.1016/j.alit.2016.06.006; Ritchlin CT, 2017, NEW ENGL J MED, V376, P957, DOI 10.1056/NEJMra1505557; Shigemura T, 2016, RMD OPEN, V2, DOI 10.1136/rmdopen-2015-000223; SILMAN AJ, 1990, LANCET, V335, P1078; Takagi M, 2017, J ALLERGY CLIN IMMUN, V139, P1914, DOI 10.1016/j.jaci.2016.09.038; Tavares RM, 2010, IMMUNITY, V33, P181, DOI 10.1016/j.immuni.2010.07.017; Thomas KT, 1999, J PEDIATR-US, V135, P15, DOI 10.1016/S0022-3476(99)70321-5; Ueda N, 2016, ARTHRITIS RHEUMATOL, V68, P2760, DOI 10.1002/art.39793; Zhou Q, 2016, NAT GENET, V48, P67, DOI 10.1038/ng.3459	16	78	81	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2018	141	4					1485	+		10.1016/j.jaci.2017.10.039	http://dx.doi.org/10.1016/j.jaci.2017.10.039			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GB6QV	29241730	Bronze			2022-12-18	WOS:000429197800036
J	Shah, RM; Elfeky, R; Nademi, Z; Qasim, W; Amrolia, P; Chiesa, R; Rao, K; Lucchini, G; Silva, JMF; Worth, A; Barge, D; Ryan, D; Conn, J; Cant, AJ; Skinner, R; Abd Hamid, IJ; Flood, T; Abinun, M; Hambleton, S; Gennery, AR; Veys, P; Slatter, M				Shah, Ravi M.; Elfeky, Reem; Nademi, Zohreh; Qasim, Waseem; Amrolia, Persis; Chiesa, Robert; Rao, Kanchan; Lucchini, Giovanna; Silva, Juliana M. F.; Worth, Austen; Barge, Dawn; Ryan, David; Conn, Jane; Cant, Andrew J.; Skinner, Roderick; Abd Hamid, Intan Juliana; Flood, Terence; Abinun, Mario; Hambleton, Sophie; Gennery, Andrew R.; Veys, Paul; Slatter, Mary			T-cell receptor alpha beta(+) and CD19(+) cell-depleted haploidentical and mismatched hematopoietic stem cell transplantation in primary immune deficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Primary immunodeficiency; haploidentical; mismatched unrelated; hematopoietic stem cell transplantation; CD3(+) T-cell receptor alpha beta(+) cell depletion	VERSUS-HOST-DISEASE; SEVERE COMBINED IMMUNODEFICIENCY; LARGE-SCALE METHOD; TCR-ALPHA-BETA; CYTOMEGALOVIRUS-INFECTION; PEDIATRIC RECIPIENTS; CONDITIONING REGIMEN; ACUTE GVHD; GRAFT; LYMPHOCYTES	Background: Allogeneic hematopoietic stem cell transplantation (HSCT) is used as a therapeutic approach for primary immunodeficiencies (PIDs). The best outcomes have been achieved with HLA-matched donors, but when a matched donor is not available, a haploidentical or mismatched unrelated donor (mMUD) can be useful. Various strategies are used to mitigate the risk of graft-versus-host disease (GvHD) and rejection associated with such transplants. Objective: We sought to evaluate the outcomes of haploidentical or mMUD HSCT after depleting GvHD-causing T-cell receptor (TCR) alpha beta CD3(+) cells from the graft. Methods: CD3(+)TCR alpha beta(+)/CD19(+) depleted grafts were given in conditioned (except 3) children with PIDs. Treosulfan (busulfan in 1 patient), fludarabine, thiotepa, and anti-thymocyte globulin or alemtuzumab conditioning were used in 77% of cases, and all but 4 received GvHD prophylaxis. Results: Twenty-five patients with 12 types of PIDs received 26 HSCTs. Three underwent transplantation for refractory GvHD that developed after the first cord transplantation. At a median follow-up of 20.8 months (range, 5 month-3.3 years), 21 of 25 patients survived and were cured of underlying immunodeficiency. Overall and event-free survival at 3 years were 83.9% and 80.4%, respectively. Cumulative incidence of grade II to IV acute GvHD was 22% +/- 8.7%. No case of visceral or chronic GvHD was seen. Cumulative incidences of graft failure, cytomegalovirus, and/or adenoviral infections and transplant-related mortality at 1 year were 4.2% +/- 4.1%, 58.8% +/- 9.8%, and 16.1% +/- 7.4%, respectively. Patients undergoing transplantation with systemic viral infections had poor survival in comparison with those with absent or resolved infections (33.3% vs 100%). Conclusion: CD3(+)TCR alpha beta(+) and CD19(+) cell-depleted haploidentical or mMUD HSCT is a practical and viable alternative for children with a range of PIDs.	[Shah, Ravi M.; Nademi, Zohreh; Cant, Andrew J.; Abd Hamid, Intan Juliana; Flood, Terence; Abinun, Mario; Hambleton, Sophie; Gennery, Andrew R.; Slatter, Mary] Great North Childrens Hosp, Royal Victoria Infirm, Dept Immunol & BMT, Newcastle Upon Tyne, Tyne & Wear, England; [Skinner, Roderick] Great North Childrens Hosp, Royal Victoria Infirm, Dept Paediat Oncol & BMT, Newcastle Upon Tyne, Tyne & Wear, England; [Elfeky, Reem; Qasim, Waseem; Amrolia, Persis; Chiesa, Robert; Rao, Kanchan; Lucchini, Giovanna; Silva, Juliana M. F.; Worth, Austen; Veys, Paul] Great Ormond St Hosp Children NHS Fdn Trust, Dept Immunol & BMT, London, England; [Barge, Dawn; Ryan, David] Newcastle Tyne Hosp Natl Hlth Serv Trust, Immunol Lab, Newcastle Upon Tyne, Tyne & Wear, England; [Conn, Jane] Northern Ctr Canc Care, Dept Haematooncol, Newcastle Upon Tyne, Tyne & Wear, England	Newcastle University - UK; Newcastle University - UK; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; Newcastle Upon Tyne Hospitals NHS Foundation Trust	Shah, RM (corresponding author), Royal Victoria Infirm, Paediat Immunol & BMT, Level 4,Block 2,Clin Resource Bldg, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.	rshah_haemonc@yahoo.ca	Shah, Ravi/J-8168-2019; Hamid, Intan Abd/S-5630-2019	Hamid, Intan Abd/0000-0001-6749-1498; QASIM, WASEEM/0000-0001-8353-4494; Hambleton, Sophie/0000-0001-7954-3267	Orchard; Autolus; Bellicum; Miltenyi; Biotest; NIHR grant; Welcome Trust; British Journal of Haematology; Sanofi Pasteur MSD; Biotest Immunology forum; UCB Pharma; Sir Jules Thorn Charitable Trust; Wellcome Trust; Gilead; Chimerix; CIBMT; National Institute for Health Research [RP-2014-05-007] Funding Source: researchfish	Orchard; Autolus; Bellicum; Miltenyi; Biotest; NIHR grant; Welcome Trust(Wellcome Trust); British Journal of Haematology; Sanofi Pasteur MSD; Biotest Immunology forum; UCB Pharma(UCB Pharma SA); Sir Jules Thorn Charitable Trust; Wellcome Trust(Wellcome TrustEuropean Commission); Gilead(Gilead Sciences); Chimerix; CIBMT; National Institute for Health Research(National Institute for Health Research (NIHR))	W. Qasim received consultancy fees from Orchard and Autolus and travel expenses from Miltenyi; his institution received grants from Bellicum and Miltenyi for other works; both the institution and the coauthor submitted a patent for T-cell gene editing; both received royalties from Orchard; and both received stock options from Autolus. A. Worth's institution received consultancy fees from advisory board work for Biotest, assessment of evidence of efficacy for cytomegalovirus specific IG, an NIHR grant for patient benefit and a grant from Welcome Trust Clinical research training Fellowship for other works; he personally received payment for manuscript preparation from the British Journal of Haematology for a commissioned review article. A. J. Cant received consultancy fees from Sanofi Pasteur MSD. S. Hambleton received board membership from MRC Infection and Immunity Board, is employed by Newcastle University, and received payment for lectures from Biotest Immunology forum; her institution received ad hoc consultancy fees from UCB Pharma and grants the from Sir Jules Thorn Charitable Trust and the Wellcome Trust for other works. P. Veys received payment for lectures from Gilead, Chimerix, and CIBMT. The rest of the authors declare that they have no relevant conflicts of interest.	Airoldi I, 2015, BLOOD, V125, P2349, DOI 10.1182/blood-2014-09-599423; Al-Homsi AS, 2015, BIOL BLOOD MARROW TR, V21, P604, DOI 10.1016/j.bbmt.2014.08.014; Balashov D, 2015, BIOL BLOOD MARROW TR, V21, P1955, DOI 10.1016/j.bbmt.2015.07.008; Barfield RC, 2004, CYTOTHERAPY, V6, P1, DOI 10.1080/14653240310004411; Bertaina A, 2014, BLOOD, V124, P822, DOI 10.1182/blood-2014-03-563817; Blazar BR, 1996, BLOOD, V87, P827, DOI 10.1182/blood.V87.2.827.bloodjournal872827; Buckley RH, 2011, IMMUNOL RES, V49, P25, DOI 10.1007/s12026-010-8191-9; Buckley RH, 1999, NEW ENGL J MED, V340, P508, DOI 10.1056/NEJM199902183400703; CARNEY WP, 1983, J IMMUNOL, V130, P390; Chaleff S, 2007, CYTOTHERAPY, V9, P746, DOI 10.1080/14653240701644000; Christopeit M, 2009, BLOOD, V113, P3130, DOI 10.1182/blood-2009-01-200527; Dertschnig S, 2015, BLOOD, V125, P2720, DOI 10.1182/blood-2014-08-597245; Drobyski W R, 1999, Biol Blood Marrow Transplant, V5, P222, DOI 10.1053/bbmt.1999.v5.pm10465102; DROBYSKI WR, 1994, BLOOD, V83, P1980, DOI 10.1182/blood.V83.7.1980.bloodjournal8371980; Dvorak CC, 2008, BIOL BLOOD MARROW TR, V14, P1125, DOI 10.1016/j.bbmt.2008.07.008; Gennery AR, 2010, J ALLERGY CLIN IMMUN, V126, P602, DOI 10.1016/j.jaci.2010.06.015; Ghosh S, 2014, CLIN IMMUNOL, V152, P111, DOI 10.1016/j.clim.2014.03.006; Giebel S, 2005, BONE MARROW TRANSPL, V36, P503, DOI 10.1038/sj.bmt.1705094; Huang YM, 2001, TRANSPLANTATION, V72, P1907, DOI 10.1097/00007890-200112270-00007; Jain NA, 2014, CYTOTHERAPY, V16, P927, DOI 10.1016/j.jcyt.2014.02.010; Jodele S, 2014, BIOL BLOOD MARROW TR, V20, P518, DOI 10.1016/j.bbmt.2013.12.565; Kawanishi Y, 1997, BONE MARROW TRANSPL, V19, P1069, DOI 10.1038/sj.bmt.1700807; Kharya G, 2014, J ALLERGY CLIN IMMUN, V134, P1199, DOI 10.1016/j.jaci.2014.04.041; Knight A, 2010, BLOOD, V116, P2164, DOI 10.1182/blood-2010-01-255166; Krenger W, 2008, SEMIN IMMUNOPATHOL, V30, P439, DOI 10.1007/s00281-008-0131-6; Laberko A, 2017, BIOL BLOOD MARROW TR, V23, P483, DOI 10.1016/j.bbmt.2016.12.635; Lafarge X, 2001, J INFECT DIS, V184, P533, DOI 10.1086/322843; Lang P, 2015, BONE MARROW TRANSPL, V50, pS6, DOI 10.1038/bmt.2015.87; Locatelli F, 2013, IMMUNOL LETT, V155, P21, DOI 10.1016/j.imlet.2013.09.027; Maeda Y, 2005, BLOOD, V106, P749, DOI 10.1182/blood-2004-10-4087; Maschan M, 2016, BONE MARROW TRANSPL, V51, P668, DOI 10.1038/bmt.2015.343; Naik S, 2016, J ALLERGY CLIN IMMUN, V137, P1498, DOI 10.1016/j.jaci.2015.12.1311; Oshrine BR, 2014, PEDIATR BLOOD CANCER, V61, P1852, DOI 10.1002/pbc.25113; Pabst C, 2007, CLIN CANCER RES, V13, P2916, DOI 10.1158/1078-0432.CCR-06-2602; Pai SY, 2014, NEW ENGL J MED, V371, P434, DOI 10.1056/NEJMoa1401177; PRZEPIORKA D, 1995, BONE MARROW TRANSPL, V15, P825; Rachamim N, 1998, TRANSPLANTATION, V65, P1386, DOI 10.1097/00007890-199805270-00017; REISNER Y, 1983, BLOOD, V61, P341; Sairafi D, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/5601204; Scheper W, 2013, LEUKEMIA, V27, P1328, DOI 10.1038/leu.2012.374; Shah RM, 2017, J CLIN IMMUNOL, V37, P419, DOI 10.1007/s10875-017-0402-x; Slatter M, 2016, J ALLERGY CLIN IMMUN, V138, P603, DOI 10.1016/j.jaci.2015.12.1335; Teschner D, 2014, BONE MARROW TRANSPL, V49, P138, DOI 10.1038/bmt.2013.114; Vantourout P, 2013, NAT REV IMMUNOL, V13, P88, DOI 10.1038/nri3384; Wang LR, 2008, BONE MARROW TRANSPL, V42, P673, DOI 10.1038/bmt.2008.238; Watanabe N, 2011, INT J LAB HEMATOL, V33, P378, DOI 10.1111/j.1751-553X.2011.01300.x	46	78	81	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2018	141	4					1417	+		10.1016/j.jaci.2017.07.008	http://dx.doi.org/10.1016/j.jaci.2017.07.008			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GB6QV	28780238	Bronze			2022-12-18	WOS:000429197800027
J	Dowling, DJ; Scott, EA; Scheid, A; Bergelson, I; Joshi, S; Pietrasanta, C; Brightman, S; Sanchez-Schmitz, G; Van Haren, SD; Ninkovic, J; Kats, D; Guiducci, C; de Titta, A; Bonner, DK; Hirosue, S; Swartz, MA; Hubbell, JA; Levy, O				Dowling, David J.; Scott, Evan A.; Scheid, Annette; Bergelson, Ilana; Joshi, Sweta; Pietrasanta, Carlo; Brightman, Spencer; Sanchez-Schmitz, Guzman; Van Haren, Simon D.; Ninkovic, Jana; Kats, Dina; Guiducci, Cristiana; de Titta, Alexandre; Bonner, Daniel K.; Hirosue, Sachiko; Swartz, Melody A.; Hubbell, Jeffrey A.; Levy, Ofer			Toll-like receptor 8 agonist nanoparticles mimic immunomodulating effects of the live BCG vaccine and enhance neonatal innate and adaptive immune responses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Newborn; dendritic cells; Toll-like receptor 8; polymersome; nanoparticle; BCG; vaccine	DENDRITIC CELLS; TLR LIGANDS; ANTIGEN; TUBERCULOSIS; ADJUVANTS; SAFETY; IMMUNIZATION; RECOGNITION; ACTIVATION; EFFICACY	Background: Newborns display distinct immune responses, leaving them vulnerable to infections and impairing immunization. Targeting newborn dendritic cells (DCs), which integrate vaccine signals into adaptive immune responses, might enable development of age-specific vaccine formulations to overcome suboptimal immunization. Objective: Small-molecule imidazoquinoline Toll-like receptor (TLR) 8 agonists robustly activate newborn DCs but can result in reactogenicity when delivered in soluble form. We used rational engineering and age-and species-specific modeling to construct and characterize polymer nanocarriers encapsulating a TLR8 agonist, allowing direct intracellular release after selective uptake by DCs. Methods: Chemically similar but morphologically distinct nanocarriers comprised of amphiphilic block copolymers were engineered for targeted uptake by murine DCs in vivo, and a range of TLR8 agonist-encapsulating polymersome formulations were then synthesized. Novel 96-well in vitro assays using neonatal human monocyte-derived DCs and humanized TLR8 mouse bone marrow-derived DCs enabled benchmarking of the TLR8 agonist-encapsulating polymersome formulations against conventional adjuvants and licensed vaccines, including live attenuated BCG vaccine. Immunogenicity of the TLR8 agonist adjuvanted antigen 85B (Ag85B)/peptide 25-loaded BCG-mimicking nanoparticle formulation was evaluated in vivo by using humanized TLR8 neonatal mice. Results: Although alum-adjuvanted vaccines induced modest costimulatory molecule expression, limited TH-polarizing cytokine production, and significant cell death, BCG induced a robust adult-like maturation profile of neonatal DCs. Remarkably, TLR8 agonist polymersomes induced not only newborn DC maturation profiles similar to those induced by BCG but also stronger IL-12p70 production. On subcutaneous injection to neonatal mice, the TLR8 agonist-adjuvanted Ag85B peptide 25 formulation was comparable with BCG in inducing Ag85B-specific CD4(+) T-cell numbers. Conclusion: TLR8 agonist-encapsulating polymersomes hold substantial potential for early-life immunization against intracellular pathogens. Overall, our study represents a novel approach for rational design of early-life vaccines.	[Dowling, David J.; Scheid, Annette; Bergelson, Ilana; Joshi, Sweta; Pietrasanta, Carlo; Brightman, Spencer; Sanchez-Schmitz, Guzman; Van Haren, Simon D.; Ninkovic, Jana; Levy, Ofer] Boston Childrens Hosp, Div Infect Dis, Dept Med, Boston, MA USA; [Dowling, David J.; Scheid, Annette; Pietrasanta, Carlo; Sanchez-Schmitz, Guzman; Van Haren, Simon D.; Ninkovic, Jana; Levy, Ofer] Harvard Med Sch, Boston, MA USA; [Scott, Evan A.; Kats, Dina] Northwestern Univ, Dept Biomed Engn, Silverman Hall,2170 Campus Dr,Rm 4627, Evanston, IL 60208 USA; [Scheid, Annette] Floating Hosp Children, Tufts Med Ctr, Div Newborn Med, Boston, MA USA; [Pietrasanta, Carlo] Univ Milan, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Dept Clin Sci & Community Hlth, Neonatal Intens Care Unit, Milan, Italy; [Guiducci, Cristiana] Dynavax Technol, Berkeley, CA USA; [de Titta, Alexandre; Bonner, Daniel K.; Hirosue, Sachiko; Swartz, Melody A.; Hubbell, Jeffrey A.] Ecole Polytech Fed Lausanne, Sch Life Sci, Inst Bioengn, Lausanne, Switzerland; [de Titta, Alexandre; Bonner, Daniel K.; Hirosue, Sachiko; Swartz, Melody A.; Hubbell, Jeffrey A.] Ecole Polytech Fed Lausanne, Sch Engn, Lausanne, Switzerland; [Swartz, Melody A.; Hubbell, Jeffrey A.] Univ Chicago, Inst Mol Engn, Chicago, IL 60637 USA; [Scheid, Annette; Joshi, Sweta; Brightman, Spencer; Sanchez-Schmitz, Guzman; Van Haren, Simon D.; Levy, Ofer] Boston Childrens Hosp, Div Infect Dis, Precis Vaccine Program, Boston, MA USA; [Scheid, Annette] Brigham & Womens Hosp, Dept Pediat Newborn Med, 75 Francis St, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Northwestern University; Floating Hospital For Children; Tufts Medical Center; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; University of Chicago; Harvard University; Boston Children's Hospital; Harvard University; Brigham & Women's Hospital	Scott, EA (corresponding author), Northwestern Univ, Dept Biomed Engn, Silverman Hall,2170 Campus Dr,Rm 4627, Evanston, IL 60208 USA.; Dowling, DJ (corresponding author), Boston Childrens Hosp, Div Infect Dis, Enders Res Labs, Room 730,300 Longwood Ave, Boston, MA 02115 USA.; Levy, O (corresponding author), Boston Childrens Hosp, Div Infect Dis, Enders Res Labs, Room 861-1,300 Longwood Ave, Boston, MA 02115 USA.	david.dowling@childrens.harvard.edu; evan.scott@northwestern.edu; ofer.levy@childrens.harvard.edu	pietrasanta, carlo/K-5786-2018; Scott, Evan/K-1963-2014; van Haren, Simon/K-7066-2019; Sanchez-Schmitz, Guzman/T-8497-2017	pietrasanta, carlo/0000-0002-1019-4422; van Haren, Simon/0000-0002-1791-0161; Sanchez-Schmitz, Guzman/0000-0002-3566-7505; /0000-0003-3356-178X; Dowling, David/0000-0003-1095-6156; Levy, Ofer/0000-0002-5859-1945; Swartz, Melody/0000-0001-5484-1903	US National Institutes of Health (NIH)/National Institutes of Allergy and Infectious Diseases (NIAID) [1R01AI100135-01, 3R01AI067353-05S1, U01AI124284-01]; Department of Health and Human Services [HHSN272201400052C]; Global Health award from Bill & Melinda Gates Foundation [OPPGH5284]; Grand Challenges Explorations award from Bill & Melinda Gates Foundation [OPP1035192]; internal Boston Children's Hospital; VentiRx Pharmaceuticals; 3M Drug Delivery Systems; MedImmune; Crucell (Johnson Johnson); Shire; European Research Counsel Advanced Grant NanoImmune; "J. Miglierina'' scholarship, Fondazione Comunitaria del Varesotto, Varese, Italy; Directorate For Engineering [1453576] Funding Source: National Science Foundation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI100135, U01AI124284, R01AI067353] Funding Source: NIH RePORTER	US National Institutes of Health (NIH)/National Institutes of Allergy and Infectious Diseases (NIAID); Department of Health and Human Services; Global Health award from Bill & Melinda Gates Foundation; Grand Challenges Explorations award from Bill & Melinda Gates Foundation; internal Boston Children's Hospital; VentiRx Pharmaceuticals; 3M Drug Delivery Systems(3M); MedImmune(AstraZenecaMedimmune); Crucell (Johnson Johnson); Shire; European Research Counsel Advanced Grant NanoImmune; "J. Miglierina'' scholarship, Fondazione Comunitaria del Varesotto, Varese, Italy; Directorate For Engineering(National Science Foundation (NSF)NSF - Directorate for Engineering (ENG)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	O.L. is supported by US National Institutes of Health (NIH)/National Institutes of Allergy and Infectious Diseases (NIAID) grants 1R01AI100135-01, 3R01AI067353-05S1, and U01AI124284-01; the Department of Health and Human Services, Adjuvant Discovery Program contract no. HHSN272201400052C; Global Health (OPPGH5284) and Grand Challenges Explorations (OPP1035192) awards from the Bill & Melinda Gates Foundation and an internal Boston Children's Hospital grant to the Precision Vaccines Program. The Levy Laboratory has received sponsored research support from VentiRx Pharmaceuticals, 3M Drug Delivery Systems, MedImmune, Crucell (Johnson & Johnson), and Shire. The Hubbell Laboratory was supported by the European Research Counsel Advanced Grant NanoImmune. C.P. was also supported by the "J. Miglierina'' scholarship, Fondazione Comunitaria del Varesotto, Varese, Italy.	Adkins B, 2004, NAT REV IMMUNOL, V4, P553, DOI 10.1038/nri1394; Bachmann MF, 2010, NAT REV IMMUNOL, V10, P787, DOI 10.1038/nri2868; Cerritelli S, 2007, BIOMACROMOLECULES, V8, P1966, DOI 10.1021/bm070085x; Cerritelli S, 2009, LANGMUIR, V25, P11328, DOI 10.1021/la900649m; Coffman RL, 2010, IMMUNITY, V33, P492, DOI 10.1016/j.immuni.2010.10.002; D'Argenio DA, 2010, IMMUNITY, V33, P437, DOI 10.1016/j.immuni.2010.10.011; Demirjian A, 2009, EUR J IMMUNOL, V39, P36, DOI 10.1002/eji.200838620; Dobrovolskaia MA, 2007, NAT NANOTECHNOL, V2, P469, DOI 10.1038/nnano.2007.223; Dowling D, 2008, CYTOKINE, V41, P254, DOI 10.1016/j.cyto.2007.11.020; Dowling DJ, 2015, PEDIATR INFECT DIS J, V34, P1395, DOI 10.1097/INF.0000000000000893; Dowling DJ, 2014, TRENDS IMMUNOL, V35, P299, DOI 10.1016/j.it.2014.04.007; Dowling DJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058164; Ganapathi L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134640; Geng Y, 2007, NAT NANOTECHNOL, V2, P249, DOI 10.1038/nnano.2007.70; Guiducci C, 2013, J EXP MED, V210, P2903, DOI 10.1084/jem.20131044; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Hubbell JA, 2009, NATURE, V462, P449, DOI 10.1038/nature08604; Kollmann TR, 2012, IMMUNITY, V37, P771, DOI 10.1016/j.immuni.2012.10.014; Levitz SM, 2012, CELL, V148, P1284, DOI 10.1016/j.cell.2012.02.012; Levy O, 2007, NAT REV IMMUNOL, V7, P379, DOI 10.1038/nri2075; Levy O, 2006, BLOOD, V108, P1284, DOI 10.1182/blood-2005-12-4821; Levy O, 2013, VACCINE, V31, P2500, DOI 10.1016/j.vaccine.2012.10.016; Marciano BE, 2014, J ALLERGY CLIN IMMUN, V133, P1134, DOI 10.1016/j.jaci.2014.02.028; Mastelic B, 2013, BIOLOGICALS, V41, P458, DOI 10.1016/j.biologicals.2013.08.006; Nabel GJ, 2013, NEW ENGL J MED, V368, P551, DOI 10.1056/NEJMra1204186; O'Garra A, 2009, NAT IMMUNOL, V10, P929, DOI 10.1038/ni0909-929; Oh DY, 2016, MOL CELL PROTEOMICS, V15, P1877, DOI 10.1074/mcp.M115.055541; Palmer CD, 2014, BIOMATERIALS, V35, P8876, DOI 10.1016/j.biomaterials.2014.06.043; Pettengill MA, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00457; Philbin VJ, 2012, J ALLERGY CLIN IMMUN, V130, P195, DOI 10.1016/j.jaci.2012.02.042; PrabhuDas M, 2011, NAT IMMUNOL, V12, P189, DOI 10.1038/ni0311-189; Prota G, 2015, VACCINE, V33, P6823, DOI 10.1016/j.vaccine.2015.09.024; Rappuoli R, 2011, NATURE, V473, P463, DOI 10.1038/nature10124; Reddy ST, 2006, TRENDS IMMUNOL, V27, P573, DOI 10.1016/j.it.2006.10.005; Schreibelt G, 2010, BLOOD, V116, P564, DOI 10.1182/blood-2009-11-251884; Scott EA, 2012, BIOMATERIALS, V33, P6211, DOI 10.1016/j.biomaterials.2012.04.060; Shann F, 2015, CLIN INFECT DIS, V61, P960, DOI 10.1093/cid/civ454; Stano A, 2013, BIOMATERIALS, V34, P4339, DOI 10.1016/j.biomaterials.2013.02.024; Swartz MA, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003763; Tacken PJ, 2011, BLOOD, V118, P6836, DOI 10.1182/blood-2011-07-367615; Tanji H, 2013, SCIENCE, V339, P1426, DOI 10.1126/science.1229159; Trumpfheller C, 2012, J INTERN MED, V271, P183, DOI 10.1111/j.1365-2796.2011.02496.x; van den Biggelaar AHJ, 2013, VACCINE, V31, P2525, DOI 10.1016/j.vaccine.2012.06.019; van Haren SD, 2016, CYTOKINE, V83, P99, DOI 10.1016/j.cyto.2016.04.001; Vekemans J, 2001, EUR J IMMUNOL, V31, P1531, DOI 10.1002/1521-4141(200105)31:5<1531::AID-IMMU1531>3.0.CO;2-1; Walkey CD, 2012, J AM CHEM SOC, V134, P2139, DOI 10.1021/ja2084338; Wu TYH, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009980; Zaitseva M, 2012, VACCINE, V30, P4859, DOI 10.1016/j.vaccine.2012.05.002	49	78	82	3	22	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2017	140	5					1339	1350		10.1016/j.jaci.2016.12.985	http://dx.doi.org/10.1016/j.jaci.2016.12.985			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FL5RV	28343701	Green Published, hybrid			2022-12-18	WOS:000414304300014
J	Al-Mousa, H; Abouelhoda, M; Monies, DM; Al-Tassan, N; Al-Ghonaium, A; Al-Saud, B; Al-Dhekri, H; Arnaout, R; Al-Muhsen, S; Ades, N; Elshorbagi, S; Al Gazlan, S; Sheikh, F; Dasouki, M; El-Baik, L; Elamin, T; Jaber, A; Kheir, O; El-Kalioby, M; Subhani, S; Al Idrissi, E; Al-Zahrani, M; Alhelale, M; Alnader, N; Al-Otaibi, A; Kattan, R; Al Abdelrahman, K; Al Breacan, MM; Bin Humaid, FS; Wakil, SM; Alzayer, F; Al-Dusery, H; Faquih, T; Al-Hissi, S; Meyer, BF; Hawwari, A				Al-Mousa, Hamoud; Abouelhoda, Mohamed; Monies, Dorota M.; Al-Tassan, Nada; Al-Ghonaium, Abdulaziz; Al-Saud, Bandar; Al-Dhekri, Hasan; Arnaout, Rand; Al-Muhsen, Saleh; Ades, Nazema; Elshorbagi, Sahar; Al Gazlan, Sulaiman; Sheikh, Farrukh; Dasouki, Majed; El-Baik, Lina; Elamin, Tanzeil; Jaber, Amal; Kheir, Omnia; El-Kalioby, Mohamed; Subhani, Shazia; Al Idrissi, Eman; Al-Zahrani, Mofareh; Alhelale, Maryam; Alnader, Noukha; Al-Otaibi, Afaf; Kattan, Rana; Al Abdelrahman, Khalid; Al Breacan, Muna M.; Bin Humaid, Faisal S.; Wakil, Salma Majid; Alzayer, Fadi; Al-Dusery, Haya; Faquih, Tariq; Al-Hissi, Safa; Meyer, Brian F.; Hawwari, Abbas			Unbiased targeted next-generation sequencing molecular approach for primary immunodeficiency diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Immunodeficiency; next-generation sequencing; targeted; genetic; primary immunodeficiency; mutation; variants; Saudi; diagnosis	WHOLE-EXOME; IDENTIFICATION; MUTATIONS; DIAGNOSIS; DEFECTS; CAPTURE	Background: Molecular genetics techniques are an essential diagnostic tool for primary immunodeficiency diseases (PIDs). The use of next-generation sequencing (NGS) provides a comprehensive way of concurrently screening a large number of PID genes. However, its validity and cost-effectiveness require verification. Objectives: We sought to identify and overcome complications associated with the use of NGS in a comprehensive gene panel incorporating 162 PID genes. We aimed to ascertain the specificity, sensitivity, and clinical sensitivity of the gene panel and its utility as a diagnostic tool for PIDs. Methods: A total of 162 PID genes were screened in 261 patients by using the Ion Torrent Proton NGS sequencing platform. Of the 261 patients, 122 had at least 1 known causal mutation at the onset of the study and were used to assess the specificity and sensitivity of the assay. The remaining samples were from unsolved cases that were biased toward more phenotypically and genotypically complicated cases. Results: The assay was able to detect the mutation in 117 (96%) of 122 positive control subjects with known causal mutations. For the unsolved cases, our assay resulted in a molecular genetic diagnosis for 35 of 139 patients. Interestingly, most of these cases represented atypical clinical presentations of known PIDs. Conclusions: The targeted NGS PID gene panel is a sensitive and cost-effective diagnostic tool that can be used as a first-line molecular assay in patients with PIDs. The assay is an alternative choice to the complex and costly candidate gene approach, particularly for patients with atypical presentation of known PID genes.	[Al-Mousa, Hamoud; Al-Ghonaium, Abdulaziz; Al-Saud, Bandar; Al-Dhekri, Hasan; Arnaout, Rand; Al-Muhsen, Saleh; Ades, Nazema; Elshorbagi, Sahar] King Faisal Specialist Hosp & Res Ctr, Dept Pediat, POB 3354,MBC 58, Riyadh 11211, Saudi Arabia; [Al-Mousa, Hamoud; Abouelhoda, Mohamed; Monies, Dorota M.; Al-Tassan, Nada; Dasouki, Majed; El-Baik, Lina; Elamin, Tanzeil; Jaber, Amal; Kheir, Omnia; El-Kalioby, Mohamed; Subhani, Shazia; Alnader, Noukha; Al-Otaibi, Afaf; Al Breacan, Muna M.; Bin Humaid, Faisal S.; Wakil, Salma Majid; Al-Dusery, Haya; Faquih, Tariq; Al-Hissi, Safa; Meyer, Brian F.; Hawwari, Abbas] King Faisal Specialist Hosp & Res Ctr, Dept Genet, Res Ctr, Riyadh 11211, Saudi Arabia; [Al Gazlan, Sulaiman; Sheikh, Farrukh] King Faisal Specialist Hosp & Res Ctr, Dept Med, Riyadh 11211, Saudi Arabia; [Alzayer, Fadi] King Faisal Specialist Hosp & Res Ctr, Dept Pathol & Lab Med, Riyadh 11211, Saudi Arabia; [Al-Mousa, Hamoud; Al-Saud, Bandar] Alfaisal Univ, Coll Med, Riyadh, Saudi Arabia; [Abouelhoda, Mohamed; Monies, Dorota M.; Al-Tassan, Nada; Subhani, Shazia; Kattan, Rana; Al Abdelrahman, Khalid; Meyer, Brian F.] King Abdulaziz City Sci & Technol, Saudi Human Genome Project, Riyadh, Saudi Arabia; [Al-Muhsen, Saleh] King Saud Univ, Dept Pediat, Riyadh, Saudi Arabia; [Al Idrissi, Eman; Al-Zahrani, Mofareh] King Fahad Med City, Dept Pediat, Riyadh, Saudi Arabia; [Alhelale, Maryam] Prince Sultan Mil Med City, Dept Pediat, Riyadh, Saudi Arabia	King Faisal Specialist Hospital & Research Center; King Faisal Specialist Hospital & Research Center; King Faisal Specialist Hospital & Research Center; King Faisal Specialist Hospital & Research Center; Alfaisal University; King Abdulaziz City for Science & Technology; King Saud University; King Fahad Medical City; Prince Sultan Military Medical City	Al-Mousa, H (corresponding author), King Faisal Specialist Hosp & Res Ctr, Dept Pediat, POB 3354,MBC 58, Riyadh 11211, Saudi Arabia.	hamoudalmousa@kfshrc.edu.sa; ahawwari@kfshrc.edu.sa	Al-Mousa, Hamoud/AAS-4477-2020; Al-muhsen, saleh/E-9315-2014; Majid, Salma/AAT-6166-2020; Hawwari, Abbas/L-1934-2019; Majid, Salma/AAT-2616-2020; Tassan, Nada Al/K-5605-2019	Al-muhsen, saleh/0000-0003-3698-9968; Majid, Salma/0000-0002-7883-2515; Hawwari, Abbas/0000-0001-9643-6500; Majid, Salma/0000-0002-1724-5405; Tassan, Nada Al/0000-0001-9076-0334	National Science, Technology and Innovation Plan strategic technologies program in Saudi Arabia [KACST: 11-BIO-1441-20]	National Science, Technology and Innovation Plan strategic technologies program in Saudi Arabia	Supported by the National Science, Technology and Innovation Plan strategic technologies program in Saudi Arabia (KACST: 11-BIO-1441-20).	Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248; Al-Herz W, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00162; Alsum Z, 2013, J CLIN IMMUNOL, V33, P55, DOI 10.1007/s10875-012-9769-x; Chou J, 2012, CURR OPIN ALLERGY CL, V12, P623, DOI 10.1097/ACI.0b013e3283588ca6; de Villartay JP, 2005, J CLIN INVEST, V115, P3291, DOI 10.1172/JCI25178; Evans BJ, 2013, GENET MED, V15, P915, DOI 10.1038/gim.2013.135; Fokstuen S, 2014, CLIN GENET, V85, P365, DOI 10.1111/cge.12168; Ghosh S, 2012, SCAND J IMMUNOL, V75, P350, DOI 10.1111/j.1365-3083.2011.02658.x; Guilmatre A, 2013, HUM MUTAT, V34, P1304, DOI 10.1002/humu.22359; Kumar P, 2009, NAT PROTOC, V4, P1073, DOI 10.1038/nprot.2009.86; Moens LN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114901; Navin N, 2011, GENOME MED, V3, DOI 10.1186/gm247; Nijman IJ, 2014, J ALLERGY CLIN IMMUN, V133, P529, DOI 10.1016/j.jaci.2013.08.032; Notarangelo LD, 2008, J ALLERGY CLIN IMMUN, V122, P1069, DOI 10.1016/j.jaci.2008.08.038; Routier FH, 1998, J IMMUNOL METHODS, V213, P113, DOI 10.1016/S0022-1759(98)00032-5; Santagata S, 2000, IMMUNOL REV, V178, P64, DOI 10.1034/j.1600-065X.2000.17818.x; Sobacchi C, 2006, HUM MUTAT, V27, P1174, DOI 10.1002/humu.20408; Stoddard JL, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00531; Villa A, 2001, BLOOD, V97, P81, DOI 10.1182/blood.V97.1.81; Villa A, 2001, CURR OPIN ALLERGY CL, V1, P491, DOI 10.1097/00130832-200112000-00001; Villa A, 2008, J ALLERGY CLIN IMMUN, V122, P1082, DOI 10.1016/j.jaci.2008.09.037; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603; Weiss MM, 2013, HUM MUTAT, V34, P1313, DOI 10.1002/humu.22368; Yang YP, 2013, NEW ENGL J MED, V369, P1502, DOI 10.1056/NEJMoa1306555	24	78	82	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2016	137	6					1780	1787		10.1016/j.jaci.2015.12.1310	http://dx.doi.org/10.1016/j.jaci.2015.12.1310			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DO1GT	26915675	Bronze			2022-12-18	WOS:000377527200019
J	Naik, S; Nicholas, SK; Martinez, CA; Leen, AM; Hanley, PJ; Gottschalk, SM; Rooney, CM; Hanson, IC; Krance, RA; Shpall, EJ; Cruz, CR; Amrolia, P; Lucchini, G; Bunin, N; Heimall, J; Klein, OR; Gennery, AR; Slatter, MA; Vickers, MA; Orange, JS; Heslop, HE; Bollard, CM; Keller, MD				Naik, Swati; Nicholas, Sarah K.; Martinez, Caridad A.; Leen, Ann M.; Hanley, Patrick J.; Gottschalk, Steven M.; Rooney, Cliona M.; Hanson, I. Celine; Krance, Robert A.; Shpall, Elizabeth J.; Cruz, Conrad R.; Amrolia, Persis; Lucchini, Giovanna; Bunin, Nancy; Heimall, Jennifer; Klein, Orly R.; Gennery, Andrew R.; Slatter, Mary A.; Vickers, Mark A.; Orange, Jordan S.; Heslop, Helen E.; Bollard, Catherine M.; Keller, Michael D.			Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Primary immunodeficiency; immunotherapy; cytotoxic T lymphocytes; antiviral therapy	STEM-CELL TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; CORD BLOOD; VIRAL-INFECTIONS; EBV; CMV; MULTICENTER; ADENOVIRUS; THERAPIES; LYMPHOMA	Background: Viral infections are a leading fatal complication for patients with primary immunodeficiencies (PIDs) who require hematopoietic stem cell transplantation (HSCT). Use of virus-specific T lymphocytes (VSTs) has been successful for the treatment and prevention of viral infections after HSCT for malignant and nonmalignant conditions. Here we describe the clinical use of VSTs in patients with PIDs at 4 centers. Objective: We sought to evaluate the safety and efficacy of VSTs for treatment of viral infections in patients with PIDs. Methods: Patients with PIDs who have received VST therapy on previous or current protocols were reviewed in aggregate. Clinical information, including transplantation details, viral infections, and use of antiviral and immunosuppressive pharmacotherapy, were evaluated. Data regarding VST production, infusions, and adverse reactions were compared. Results: Thirty-six patients with 12 classes of PID diagnoses received 37 VST products before or after HSCT. Twenty-six (72%) patients had received a diagnosis of infection with cytomegalovirus, EBV, adenovirus, BK virus, and/or human herpesvirus 6. Two patients were treated before HSCT because of EBV-associated lymphoproliferative disease. Partial or complete responses against targeted viruses occurred in 81% of patients overall. Time to response varied from 2 weeks to 3 months ( median, 28 days). Overall survival at 6 months after therapy was 80%. Four patients had graft-versus-host disease in the 45 days after VST infusion, which in most cases was therapy responsive. Conclusion: VSTs derived from either stem cell donors or third-party donors are likely safe and effective for the treatment of viral infections in patients with PIDs.	[Naik, Swati; Martinez, Caridad A.; Leen, Ann M.; Rooney, Cliona M.; Heslop, Helen E.] Texas Childrens Hosp, Baylor Coll Med, Ctr Cell & Gene Therapy, Houston Methodist Hosp, Houston, TX 77030 USA; [Naik, Swati; Martinez, Caridad A.; Gottschalk, Steven M.; Krance, Robert A.; Heslop, Helen E.] Texas Childrens Hosp, Baylor Coll Med, Texas Childrens Canc Ctr, Houston, TX 77030 USA; [Nicholas, Sarah K.; Hanson, I. Celine; Orange, Jordan S.] Baylor Coll Med, Sect Immunol Allergy & Rheumatol, Dept Pediat, Houston, TX 77030 USA; [Hanley, Patrick J.; Bollard, Catherine M.; Keller, Michael D.] Childrens Natl Med Ctr, Ctr Canc & Immunol Res, Washington, DC 20010 USA; [Hanley, Patrick J.; Bollard, Catherine M.] Childrens Natl Med Ctr, Div Blood & Marrow Transplantat, Washington, DC 20010 USA; [Cruz, Conrad R.] Childrens Natl Med Ctr, Sheikh Zayed Inst, Washington, DC 20010 USA; [Amrolia, Persis; Lucchini, Giovanna] Great Ormond St Hosp Sick Children, Bone Marrow Transplantat Dept, London, England; [Bunin, Nancy] Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA; [Heimall, Jennifer] Childrens Hosp Philadelphia, Div Allergy& Immunol, Philadelphia, PA 19104 USA; [Klein, Orly R.] Johns Hopkins Univ, Sch Med, Dept Oncol, Div Pediat Hematol Oncol, Baltimore, MD 21205 USA; [Gennery, Andrew R.; Slatter, Mary A.] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Vickers, Mark A.] Scottish Natl Blood Transfus Serv, Glasgow, Lanark, Scotland; [Vickers, Mark A.] Univ Aberdeen, Aberdeen AB9 1FX, Scotland; [Orange, Jordan S.] Baylor Coll Med, Ctr Human Immunobiol, Houston, TX 77030 USA; [Orange, Jordan S.] Texas Childrens Hosp, Houston, TX 77030 USA; [Keller, Michael D.] Childrens Natl Med Ctr, Div Allergy & Immunol, Washington, DC 20010 USA; [Shpall, Elizabeth J.] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat, Div Canc Med, Houston, TX 77030 USA	Baylor College of Medicine; The Methodist Hospital System; The Methodist Hospital - Houston; Baylor College of Medicine; Texas Children's Cancer Center; Baylor College of Medicine; Children's National Health System; Children's National Health System; Children's National Health System; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Johns Hopkins University; Newcastle University - UK; University of Aberdeen; Baylor College of Medicine; Baylor College of Medicine; Children's National Health System; University of Texas System; UTMD Anderson Cancer Center	Keller, MD (corresponding author), Childrens Natl Med Ctr, 111 Michigan Ave NW,M7745A, Washington, DC 20010 USA.	mkeller@cnmc.org	Rooney, Cliona/ABD-5475-2021; Heslop, Helen/AAC-9500-2020; Gottschalk, Stephen/M-9343-2018	Gottschalk, Stephen/0000-0003-3991-7468; orange, jordan/0000-0001-7117-7725; Hanley, Patrick/0000-0002-0102-7892; Bollard, Catherine M./0000-0001-5140-9090; Vickers, Mark/0000-0002-3154-1040	National Institutes of Health [RO1CA061384, P50CA126752, U54 HL081007]; National Cancer Institute [PO1 CA148600e02]; SPORE [5P50CA126752]; SCOR from the Leukemia and Lymphoma Society; Production Assistance for Cellular Therapies (PACT) program (NHLBI) [HHSN268201000007C]; Clinical Research Center at Texas Children's Hospital; Dan L. Duncan Institute for Clinical and Translational Research at Baylor College of Medicine; Amy Strelzer Manasevit Scholar Award; Clinical Immunology Society; Jeffrey Modell Diagnostic and Research Center Grant; American Academy of Allergy, Asthma Immunology; American College of Allergy, Asthma Immunology; Clinical and Translational Science Institute at Children's National; Jeffrey Modell Foundation; Medical Research Council [MR/K007491/1] Funding Source: researchfish; MRC [MR/K007491/1] Funding Source: UKRI; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD001399] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P50CA126752, P01CA148600, P01CA094237, R01CA061508] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U54HL081007, T32HL092332] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); SPORE; SCOR from the Leukemia and Lymphoma Society; Production Assistance for Cellular Therapies (PACT) program (NHLBI); Clinical Research Center at Texas Children's Hospital; Dan L. Duncan Institute for Clinical and Translational Research at Baylor College of Medicine; Amy Strelzer Manasevit Scholar Award; Clinical Immunology Society; Jeffrey Modell Diagnostic and Research Center Grant; American Academy of Allergy, Asthma Immunology; American College of Allergy, Asthma Immunology; Clinical and Translational Science Institute at Children's National; Jeffrey Modell Foundation; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This research was funded by grants from the National Institutes of Health (RO1CA061384 to C.M.R., P50CA126752 to H.E.H., and U54 HL081007 to C.M.R. and H.E.H.); the National Cancer Institute (PO1 CA148600e02 to C.M.B. and E.J.S.); a SPORE 5P50CA126752 (to H.E.H.); an SCOR from the Leukemia and Lymphoma Society (to H.E.H.); the Production Assistance for Cellular Therapies (PACT) program (NHLBI contract no. HHSN268201000007C); the Clinical Research Center at Texas Children's Hospital; the Dan L. Duncan Institute for Clinical and Translational Research at Baylor College of Medicine; the Amy Strelzer Manasevit Scholar Award (to C.M.B. and A.M.L.); the Clinical Immunology Society (to S.K.N.); a Jeffrey Modell Diagnostic and Research Center Grant (to J.S.O.), the American Academy of Allergy, Asthma & Immunology (to S.K.N.); American College of Allergy, Asthma & Immunology (to M.D.K.); the Clinical and Translational Science Institute at Children's National (to M.D.K.); and a Translational Research Grant from the Jeffrey Modell Foundation (to M.D.K.).	Barker JN, 2010, BLOOD, V116, P5045, DOI 10.1182/blood-2010-04-281873; Blyth E, 2013, BLOOD, V121, P3745, DOI 10.1182/blood-2012-08-448977; Buckley RH, 2011, IMMUNOL RES, V49, P25, DOI 10.1007/s12026-010-8191-9; Cruz CR, 2010, CYTOTHERAPY, V12, P743, DOI 10.3109/14653241003709686; Doubrovina E, 2012, BLOOD, V119, P2644, DOI 10.1182/blood-2011-08-371971; Feuchtinger T, 2010, BLOOD, V116, P4360, DOI 10.1182/blood-2010-01-262089; Gennery AR, 2010, J ALLERGY CLIN IMMUN, V126, P602, DOI 10.1016/j.jaci.2010.06.015; Gerdemann U, 2013, MOL THER, V21, P2113, DOI 10.1038/mt.2013.151; Gerdemann U, 2012, MOL THER, V20, P1622, DOI 10.1038/mt.2012.130; Ghosh S, 2015, BRIT J HAEMATOL, V171, P155, DOI 10.1111/bjh.13520; Hanley PJ, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa2546; Hanley PJ, 2012, JOVE-J VIS EXP, DOI 10.3791/3627; Hanley PJ, 2009, BLOOD, V114, P1958, DOI 10.1182/blood-2009-03-213256; Haque T, 2001, TRANSPLANTATION, V72, P1399, DOI 10.1097/00007890-200110270-00012; Haque T, 2007, BLOOD, V110, P1123, DOI 10.1182/blood-2006-12-063008; Heslop HE, 2010, BLOOD, V115, P925, DOI 10.1182/blood-2009-08-239186; Kwan A, 2014, JAMA-J AM MED ASSOC, V312, P729, DOI 10.1001/jama.2014.9132; Leen AM, 2006, NAT MED, V12, P1160, DOI 10.1038/nm1475; Leen AM, 2014, IMMUNOL REV, V258, P12, DOI 10.1111/imr.12138; Leen AM, 2013, BLOOD, V121, P5113, DOI 10.1182/blood-2013-02-486324; Leen AM, 2010, EXPERT OPIN BIOL TH, V10, P337, DOI 10.1517/14712590903456003; Leen AM, 2009, BLOOD, V114, P4283, DOI 10.1182/blood-2009-07-232454; Micklethwaite KP, 2010, BLOOD, V115, P2695, DOI 10.1182/blood-2009-09-242263; Neudorfer J, 2007, J IMMUNOL METHODS, V320, P119, DOI 10.1016/j.jim.2007.01.001; Nicholson E, 2015, IMMUNOTHERAPY-UK, V7, P135, DOI 10.2217/imt.14.99; Odek C, 2014, J CLIN IMMUNOL, V34, P309, DOI 10.1007/s10875-014-9994-6; Pai SY, 2014, NEW ENGL J MED, V371, P434, DOI 10.1056/NEJMoa1401177; Papadopoulou A, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008825; Papadopoulou A, 2014, MOL THER, V22, P1134, DOI 10.1038/mt.2014.48; Qasim W, 2011, BRIT J HAEMATOL, V154, P150, DOI 10.1111/j.1365-2141.2011.08579.x; Savoldo B, 2001, TRANSPLANTATION, V72, P1078, DOI 10.1097/00007890-200109270-00017; Sellar RS, 2012, BRIT J HAEMATOL, V156, P559, DOI 10.1111/j.1365-2141.2011.08988.x; Smith C A, 1995, J Hematother, V4, P73, DOI 10.1089/scd.1.1995.4.73; Vera JF, 2010, J IMMUNOTHER, V33, P305, DOI 10.1097/CJI.0b013e3181c0c3cb; Vickers MA, 2014, BRIT J HAEMATOL, V167, P402, DOI 10.1111/bjh.13051; Worth AJJ, 2013, CURR OPIN HEMATOL, V20, P501, DOI 10.1097/MOH.0b013e328365a13b; Wynn RF, 2005, LANCET ONCOL, V6, P344, DOI 10.1016/S1470-2045(05)70171-6	37	78	81	1	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2016	137	5					1498	+		10.1016/j.jaci.2015.12.1311	http://dx.doi.org/10.1016/j.jaci.2015.12.1311			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DM2MF	26920464	Bronze, Green Accepted			2022-12-18	WOS:000376180200026
J	Hoh, RA; Joshi, SA; Liu, Y; Wang, C; Roskin, KM; Lee, JY; Pham, T; Looney, TJ; Jackson, KJL; Dixit, VP; King, J; Lyu, SC; Jenks, J; Hamilton, RG; Nadeau, KC; Boyd, SD				Hoh, Ramona A.; Joshi, Shilpa A.; Liu, Yi; Wang, Chen; Roskin, Krishna M.; Lee, Ji-Yeun; Pham, Tho; Looney, Tim J.; Jackson, Katherine J. L.; Dixit, Vaishali P.; King, Jasmine; Lyu, Shu-Chen; Jenks, Jennifer; Hamilton, Robert G.; Nadeau, Kari C.; Boyd, Scott D.			Single B-cell deconvolution of peanut-specific antibody responses in allergic patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Peanut; allergy; B cell; antibody; IgE; IgG(4); immunotherapy; high-throughput DNA sequencing; antigen specific; allergen specific; repertoire; somatic mutation	ARA H 1; IGE-BINDING EPITOPES; ORAL IMMUNOTHERAPY; ATOPIC-DERMATITIS; POLLEN ALLERGEN; MUTATIONAL ANALYSIS; IDENTIFICATION; EPSILON; MU; CYTOMEGALOVIRUS	Background: The frequencies, cellular phenotypes, epitope specificity, and clonal diversity of allergen-specific B cells in patients with food allergy are not fully understood but are of major pathogenic and therapeutic significance. Objective: We sought to characterize peanut allergen-specific B-cell populations and the sequences and binding activities of their antibodies before and during immunotherapy. Methods: B cells binding fluorescently labeled Ara h 1 or Ara h 2 were phenotyped and isolated by means of flow cytometric sorting from 18 patients at baseline and 13 patients during therapy. Fifty-seven mAbs derived from allergen-binding single B cells were evaluated by using ELISA, Western blotting, and peptide epitope mapping. Deep sequencing of the B-cell repertoires identified additional members of the allergen-specific B-cell clones. Results: Median allergen-binding B-cell frequencies were 0.0097% (Ara h 1) or 0.029% (Ara h 2) of B cells in baseline blood from allergic patients and approximately 3-fold higher during immunotherapy. Five of 57 allergen-specific cells belonged to clones containing IgE-expressing members. Almost all allergen-specific antibodies were mutated, and binding to both conformational and linear allergen epitopes was detected. Increasing somatic mutation of IgG(4) members of a clone was seen in immunotherapy, whereas IgE mutation levels in the clone did not increase. Conclusion: Most peanut allergen-binding B cells isolated by means of antigen-specific flow sorting express mutated and isotype-switched antibodies. Immunotherapy increases their frequency in the blood, and even narrowly defined allergen epitopes are recognized by numerous distinct B-cell clones in a patient. The results also suggest that oral immunotherapy can stimulate somatic mutation of allergen-specific IgG(4).	[Hoh, Ramona A.; Joshi, Shilpa A.; Liu, Yi; Wang, Chen; Roskin, Krishna M.; Lee, Ji-Yeun; Pham, Tho; Looney, Tim J.; Jackson, Katherine J. L.; Dixit, Vaishali P.; King, Jasmine; Boyd, Scott D.] Stanford Univ, Dept Pathol, Stanford, CA 94305 USA; [Liu, Yi] Stanford Univ, Biomed Informat Training Program, Stanford, CA 94305 USA; [Lyu, Shu-Chen; Jenks, Jennifer; Nadeau, Kari C.] Stanford Univ, Biomed Informat Training Program, Stanford, CA 94305 USA; [Hamilton, Robert G.] Johns Hopkins Univ, Sch Med, Div Clin Immunol & Allergy, Baltimore, MD USA	Stanford University; Stanford University; Stanford University; Johns Hopkins University	Boyd, SD (corresponding author), Stanford Univ, Pathol, 300 Pasteur Dr,Lane Bldg L235, Stanford, CA 94305 USA.	sboyd1@stanford.edu	Jackson, Katherine/AAE-4326-2019	Jenks, Jennifer/0000-0002-6865-5615; Jackson, Katherine/0000-0002-9952-7069	National Institutes of Health (NIH)/National Institute of Allergy and Infectious Disease (NIAID) [1U19AI0420901]; Child Health Research Institute at Stanford University [UL1 TR000093]; NIH CTSA award [UL1 RR025744-04, 39719]; NIH award [R21AI09583801]; Stanford Allergy Center Fund; Myra Reinhard Foundation; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000093, UL1TR001085] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025744] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI104209] Funding Source: NIH RePORTER	National Institutes of Health (NIH)/National Institute of Allergy and Infectious Disease (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Child Health Research Institute at Stanford University; NIH CTSA award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Stanford Allergy Center Fund; Myra Reinhard Foundation; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health (NIH)/National Institute of Allergy and Infectious Disease (NIAID) grant 1U19AI0420901 and support from the Child Health Research Institute at Stanford University grant UL1 TR000093, NIH CTSA award UL1 RR025744-04 (Project 39719), NIH award R21AI09583801, the Stanford Allergy Center Fund, and the Myra Reinhard Foundation.	Akdis M, 2014, J ALLERGY CLIN IMMUN, V133, P621, DOI 10.1016/j.jaci.2013.12.1088; Berkowska MA, 2014, J ALLERGY CLIN IMMUN, V134, P688, DOI 10.1016/j.jaci.2014.03.036; Blumchen K, 2010, J ALLERGY CLIN IMMUN, V126, P83, DOI 10.1016/j.jaci.2010.04.030; BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; Bublin M, 2013, J ALLERGY CLIN IMMUN, V132, P118, DOI 10.1016/j.jaci.2013.01.022; Burks AW, 2012, NEW ENGL J MED, V367, P233, DOI 10.1056/NEJMoa1200435; BURKS AW, 1992, J ALLERGY CLIN IMMUN, V90, P962, DOI 10.1016/0091-6749(92)90469-I; BURKS AW, 1991, J ALLERGY CLIN IMMUN, V88, P172, DOI 10.1016/0091-6749(91)90325-I; Burks AW, 1997, EUR J BIOCHEM, V245, P334, DOI 10.1111/j.1432-1033.1997.t01-1-00334.x; Edwards MR, 2002, J IMMUNOL, V168, P6305, DOI 10.4049/jimmunol.168.12.6305; Flicker S, 2002, EUR J IMMUNOL, V32, P2156, DOI 10.1002/1521-4141(200208)32:8<2156::AID-IMMU2156>3.0.CO;2-A; Flinterman AE, 2008, J ALLERGY CLIN IMMUN, V121, P737, DOI 10.1016/j.jaci.2007.11.039; Franz B, 2011, BLOOD, V118, P348, DOI 10.1182/blood-2011-03-341917; Hamilton RG, 2010, J ALLERGY CLIN IMMUN, V126, P33, DOI 10.1016/j.jaci.2010.03.014; JABARA HH, 1993, J IMMUNOL, V151, P4528; Jones SM, 2009, J ALLERGY CLIN IMMUN, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Jones Stacie M, 2009, J Allergy Clin Immunol, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Karnowski A, 2006, EUR J IMMUNOL, V36, P1917, DOI 10.1002/eji.200535495; Kashiwakura JI, 2012, ALLERGY ASTHMA IMMUN, V4, P332, DOI 10.4168/aair.2012.4.6.332; Kodituwakku AP, 2003, IMMUNOL CELL BIOL, V81, P163, DOI 10.1046/j.1440-1711.2003.01152.x; Krause S, 2010, MOL NUTR FOOD RES, V54, P381, DOI 10.1002/mnfr.200900072; Larman HB, 2011, NAT BIOTECHNOL, V29, P535, DOI 10.1038/nbt.1856; Liao HX, 2009, J VIROL METHODS, V158, P171, DOI 10.1016/j.jviromet.2009.02.014; McLean GR, 2005, J IMMUNOL, V174, P4768, DOI 10.4049/jimmunol.174.8.4768; MILLS FC, 1992, J IMMUNOL, V149, P1075; Moody MA, 2008, CYTOM PART A, V73A, P1086, DOI 10.1002/cyto.a.20599; Notkins AL, 2004, TRENDS IMMUNOL, V25, P174, DOI 10.1016/j.it.2004.02.004; Nouri-Aria KT, 2004, J IMMUNOL, V172, P3252, DOI 10.4049/jimmunol.172.5.3252; Persson H, 2008, MOL IMMUNOL, V45, P2715, DOI 10.1016/j.molimm.2008.01.004; Santos AF, 2015, J ALLERGY CLIN IMMUN, V135, P1249, DOI 10.1016/j.jaci.2015.01.012; SASANO M, 1993, J IMMUNOL, V151, P5822; Shreffler WG, 2005, J ALLERGY CLIN IMMUN, V116, P893, DOI 10.1016/j.jaci.2005.06.033; Sicherer SH, 2014, J ALLERGY CLIN IMMUN, V133, P291, DOI 10.1016/j.jaci.2013.11.020; Sicherer SH, 2014, J ALLERGY CLIN IMMUN, V133, P324, DOI 10.1016/j.jaci.2013.11.013; Stanley JS, 1997, ARCH BIOCHEM BIOPHYS, V342, P244, DOI 10.1006/abbi.1997.9998; Syed A, 2014, J ALLERGY CLIN IMMUN, V133, P500, DOI 10.1016/j.jaci.2013.12.1037; Townsend SE, 2001, J IMMUNOL METHODS, V249, P137, DOI 10.1016/S0022-1759(00)00352-5; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; Varshney P, 2011, J ALLERGY CLIN IMMUN, V127, P654, DOI 10.1016/j.jaci.2010.12.1111; Vickery BP, 2013, J ALLERGY CLIN IMMUN, V131, pe1; Vickery BP, 2013, J ALLERGY CLIN IMMUN, V131, P128, DOI 10.1016/j.jaci.2012.10.048; Wang C, 2014, J IMMUNOL, V192, P603, DOI 10.4049/jimmunol.1301384; Wu LC, 2014, NAT REV IMMUNOL, V14, P247, DOI 10.1038/nri3632; Yang ZY, 2012, IMMUNITY, V36, P857, DOI 10.1016/j.immuni.2012.02.009; ZHANG K, 1994, J IMMUNOL, V152, P3427; Zhang MX, 2006, MOL IMMUNOL, V43, P2195, DOI 10.1016/j.molimm.2005.12.015	46	78	82	1	22	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2016	137	1					157	167		10.1016/j.jaci.2015.05.029	http://dx.doi.org/10.1016/j.jaci.2015.05.029			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DA3UK	26152318	Bronze, Green Accepted			2022-12-18	WOS:000367724300006
J	Manners, S; Alam, R; Schwartz, DA; Gorska, MM				Manners, Sarah; Alam, Rafeul; Schwartz, David A.; Gorska, Magdalena M.			A mouse model links asthma susceptibility to prenatal exposure to diesel exhaust	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Prenatal exposure; diesel exhaust particles; asthma; mouse model; natural killer cells; aryl hydrocarbon receptor; IL-5; IL-13; IL-17	ARYL-HYDROCARBON RECEPTOR; NATURAL-KILLER-CELLS; POLYCYCLIC AROMATIC-HYDROCARBONS; ALLERGIC AIRWAY INFLAMMATION; LYMPH-NODE CELLS; NK CELLS; INTRANASAL INSTILLATION; ENVIRONMENTAL-POLLUTANT; TH2 DIFFERENTIATION; CYTOKINE PRODUCTION	Background: Most asthma begins in the first years of life. This early onset cannot be attributed merely to genetic factors because the prevalence of asthma is increasing. Epidemiologic studies have indicated roles for prenatal and early childhood exposures, including exposure to diesel exhaust. However, little is known about the mechanisms. This is largely due to a paucity of animal models. Objective: We aimed to develop a mouse model of asthma susceptibility through prenatal exposure to diesel exhaust. Methods: Pregnant C57BL/6 female mice were given repeated intranasal applications of diesel exhaust particles (DEPs) or PBS. Offspring underwent suboptimal immunization and challenge with ovalbumin (OVA) or received PBS. Pups were examined for features of asthma; lung and liver tissues were analyzed for transcription of DEP-regulated genes. Results: Offspring of mice exposed to DEPs were hypersensitive to OVA, as indicated by airway inflammation and hyperresponsiveness, increased serum OVA-specific IgE levels, and increased pulmonary and systemic T(H)2 and T(H)17 cytokine levels. These cytokines were primarily produced by natural killer (NK) cells. Antibody-mediated depletion of NK cells prevented airway inflammation. Asthma susceptibility was associated with increased transcription of genes known to be specifically regulated by the aryl hydrocarbon receptor and oxidative stress. Features of asthma were either marginal or absent in OVA-treated pups of PBS-exposed mice. Conclusion: We created a mouse model that linked maternal exposure to DEPs with asthma susceptibility in offspring. Development of asthma was dependent on NK cells and associated with increased transcription from aryl hydrocarbon receptor-and oxidative stress-regulated genes.	[Manners, Sarah; Alam, Rafeul; Gorska, Magdalena M.] Natl Jewish Hlth, Dept Med, Div Allergy & Clin Immunol, Denver, CO 80206 USA; [Alam, Rafeul; Gorska, Magdalena M.] Univ Colorado Denver, Div Allergy & Clin Immunol, Dept Med, Aurora, CO USA; [Schwartz, David A.] Univ Colorado Denver, Div Pulm Sci & Crit Care Med, Dept Med, Aurora, CO USA	National Jewish Health; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus	Gorska, MM (corresponding author), Natl Jewish Hlth, Dept Med, Div Allergy & Clin Immunol, 1400 Jackson St, Denver, CO 80206 USA.	gorskam@njhealth.org			Denver Children's Environmental Health Center Faculty Development Investigator Award, a part of NIEHS [PO1 ES-018181/EPA GAD 834515010]; NIH/NCATS Colorado CTSI [KL2 TR000156]; Sheldon C. Siege-Asthma and Allergy Foundation of America Investigator Grant Award; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001082, KL2TR001080, KL2TR000156] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL122995] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI102943, R01AI091614] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES018181] Funding Source: NIH RePORTER	Denver Children's Environmental Health Center Faculty Development Investigator Award, a part of NIEHS; NIH/NCATS Colorado CTSI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); Sheldon C. Siege-Asthma and Allergy Foundation of America Investigator Grant Award; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by the Denver Children's Environmental Health Center Faculty Development Investigator Award, a part of NIEHS PO1 ES-018181/EPA GAD 834515010 (to M. M. G.), the NIH/NCATS Colorado CTSI KL2 TR000156 Award (to M. M. G.), and the Sheldon C. Siege-Asthma and Allergy Foundation of America Investigator Grant Award (to M.M.G.).	Aktas E, 2005, CLIN EXP IMMUNOL, V140, P301, DOI 10.1111/j.1365-2249.2005.02777.x; Arimoto T, 2005, AM J RESP CRIT CARE, V171, P379, DOI 10.1164/rccm.200402-248OC; Auten RL, 2012, AM J RESP CELL MOL, V46, P454, DOI 10.1165/rcmb.2011-0256OC; Babu S, 2007, J IMMUNOL, V179, P2445, DOI 10.4049/jimmunol.179.4.2445; Barnig C, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3004812; Behndig AF, 2006, EUR RESPIR J, V27, P359, DOI 10.1183/09031936.06.00136904; BILLINGHAM RE, 1953, NATURE, V172, P603, DOI 10.1038/172603a0; Bock KW, 2006, BIOCHEM PHARMACOL, V72, P393, DOI 10.1016/j.bcp.2006.01.017; Bommel H, 2000, J ALLERGY CLIN IMMUN, V105, P796, DOI 10.1067/mai.2000.105124; Burke H, 2012, PEDIATRICS, V129, P735, DOI 10.1542/peds.2011-2196; Caraballo JC, 2013, AM J RESP CELL MOL, V48, P306, DOI 10.1165/rcmb.2012-0056OC; Chang Y, 2006, J ALLERGY CLIN IMMUN, V118, P354, DOI 10.1016/j.jaci.2006.04.050; Chen PH, 2012, ONCOGENE, V31, P2555, DOI 10.1038/onc.2011.438; Corson Lin, 2010, Allergy Asthma Clin Immunol, V6, P7, DOI 10.1186/1710-1492-6-7; Diaz-Sanchez D, 2000, CLIN IMMUNOL, V97, P140, DOI 10.1006/clim.2000.4921; DiazSanchez D, 1997, ALLERGY, V52, P52; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; DIXON FJ, 1955, J EXP MED, V101, P245, DOI 10.1084/jem.101.3.245; Douwes J, 2008, EUR RESPIR J, V32, P603, DOI 10.1183/09031936.00033707; Ege MJ, 2006, J ALLERGY CLIN IMMUN, V117, P817, DOI 10.1016/j.jaci.2005.12.1307; Fedulov AV, 2008, AM J RESP CELL MOL, V38, P57, DOI 10.1165/rcmb.2007-0124OC; Feng M, 2012, INT IMMUNOPHARMACOL, V13, P135, DOI 10.1016/j.intimp.2012.03.007; FUJIMAKI H, 1994, TOXICOLOGY, V92, P261, DOI 10.1016/0300-483X(94)90182-1; FUJIMAKI H, 1995, INT ARCH ALLERGY IMM, V108, P268, DOI 10.1159/000237163; Gent JF, 2009, ENVIRON HEALTH PERSP, V117, P1168, DOI 10.1289/ehp.0800335; Geurtsvan Kessel CH, 2009, PLOS ONE, V4, pe7187; Goplen N, 2012, FASEB J, V26, P1934, DOI 10.1096/fj.11-196477; Goplen N, 2009, J ALLERGY CLIN IMMUN, V123, P925, DOI 10.1016/j.jaci.2009.02.009; Gorska MM, 2007, J EXP MED, V204, P1637, DOI 10.1084/jem.20062621; Gorska MM, 2010, J IMMUNOL, V184, P4488, DOI 10.4049/jimmunol.0903115; Hahn ME, 2009, BIOCHEM PHARMACOL, V77, P485, DOI 10.1016/j.bcp.2008.09.016; Haworth O, 2011, J IMMUNOL, V186, P6129, DOI 10.4049/jimmunol.1004007; Horikawa M, 2005, J INVEST DERMATOL, V125, P731, DOI 10.1111/j.0022-202X.2005.23767.x; Suen JL, 2013, ALLERGY, V68, P780, DOI 10.1111/all.12156; Hughes T, 2010, IMMUNITY, V32, P803, DOI 10.1016/j.immuni.2010.06.007; Hwang YJ, 2010, INHAL TOXICOL, V22, P1127, DOI 10.3109/08958378.2010.528805; Jacquemin B, 2009, EUR RESPIR J, V34, P834, DOI 10.1183/09031936.00138208; Jedrychowski WA, 2010, PEDIAT ALLERG IMM-UK, V21, pE723, DOI 10.1111/j.1399-3038.2010.01034.x; Joncker NT, 2010, J EXP MED, V207, P2065, DOI 10.1084/jem.20100570; Kanoh T, 1996, J Clin Lab Immunol, V48, P133; Kepley CL, 2003, CLIN IMMUNOL, V107, P10, DOI 10.1016/S1521-6616(03)00004-4; Kim J, 2011, AM J PATHOL, V179, P2730, DOI 10.1016/j.ajpath.2011.08.008; Kiss EA, 2011, SCIENCE, V334, P1561, DOI 10.1126/science.1214914; Korsgren M, 1999, J EXP MED, V189, P553, DOI 10.1084/jem.189.3.553; Kotsimbos ATC, 1997, J ALLERGY CLIN IMMUN, V99, P666, DOI 10.1016/S0091-6749(97)70029-0; Li N, 2004, J IMMUNOL, V173, P3467, DOI 10.4049/jimmunol.173.5.3467; Li N, 2010, AM J PHYSIOL-LUNG C, V299, pL374, DOI 10.1152/ajplung.00115.2010; Litonjua AA, 1998, AM J RESP CRIT CARE, V158, P176, DOI 10.1164/ajrccm.158.1.9710014; Lommatzsch M, 2012, SEMIN RESP CRIT CARE, V33, P579, DOI 10.1055/s-0032-1325617; Luebke RW, 2001, TOXICOL SCI, V62, P71, DOI 10.1093/toxsci/62.1.71; McConnell R, 2006, ENVIRON HEALTH PERSP, V114, P766, DOI 10.1289/ehp.8594; McConnell R, 2010, ENVIRON HEALTH PERSP, V118, P1021, DOI 10.1289/ehp.0901232; McCreanor J, 2007, NEW ENGL J MED, V357, P2348, DOI 10.1056/NEJMoa071535; Miyabara Y, 1998, AM J RESP CRIT CARE, V157, P1138, DOI 10.1164/ajrccm.157.4.9708066; Mizutani N, 2007, J PHARMACOL SCI, V105, P291, DOI 10.1254/jphs.FP0071067; Moorman JE, NATL SURVEILLANCE AS; Mundandhara SD, 2006, TOXICOL IN VITRO, V20, P614, DOI 10.1016/j.tiv.2005.10.018; MURANAKA M, 1986, J ALLERGY CLIN IMMUN, V77, P616, DOI 10.1016/0091-6749(86)90355-6; Nakamura R, 2012, J IMMUNOTOXICOL, V9, P72, DOI 10.3109/1547691X.2011.629638; Negishi T, 2005, J IMMUNOL, V175, P7348, DOI 10.4049/jimmunol.175.11.7348; Nel AE, 1998, J ALLERGY CLIN IMMUN, V102, P539, DOI 10.1016/S0091-6749(98)70269-6; Nightingale JA, 2000, AM J RESP CRIT CARE, V162, P161, DOI 10.1164/ajrccm.162.1.9908092; Nilsen A, 1997, TOXICOLOGY, V124, P225, DOI 10.1016/S0300-483X(97)00150-9; Nordenhall C, 2001, EUR RESPIR J, V17, P909, DOI 10.1183/09031936.01.17509090; Passos ST, 2010, J IMMUNOL, V184, P1776, DOI 10.4049/jimmunol.0901843; Patel MM, 2011, ENVIRON RES, V111, P1222, DOI 10.1016/j.envres.2011.08.004; Perzanowski MS, 2013, J ALLERGY CLIN IMMUN, V131, P886, DOI 10.1016/j.jaci.2012.12.666; Ple C, 2010, SCAND J IMMUNOL, V72, P118, DOI 10.1111/j.1365-3083.2010.02419.x; Qiu J, 2012, IMMUNITY, V36, P92, DOI 10.1016/j.immuni.2011.11.011; Reiprich M, 2013, ALLERGY, V68, P481, DOI 10.1111/all.12121; Ris C, 2007, INHAL TOXICOL, V19, P229, DOI 10.1080/08958370701497960; Ristovski ZD, 2012, RESPIROLOGY, V17, P201, DOI 10.1111/j.1440-1843.2011.02109.x; Rodriguez-Sosa M, 2005, FEBS LETT, V579, P6403, DOI 10.1016/j.febslet.2005.10.023; Rosa MJ, 2011, RESP MED, V105, P869, DOI 10.1016/j.rmed.2010.11.022; RUIZ RGG, 1992, CLIN EXP ALLERGY, V22, P762, DOI 10.1111/j.1365-2222.1992.tb02816.x; Ryan PH, 2005, J ALLERGY CLIN IMMUN, V116, P279, DOI 10.1016/j.jaci.2005.05.014; Salvi S, 1999, AM J RESP CRIT CARE, V159, P702, DOI 10.1164/ajrccm.159.3.9709083; Schmidt JV, 1996, P NATL ACAD SCI USA, V93, P6731, DOI 10.1073/pnas.93.13.6731; Schulz VJ, 2011, TOXICOL SCI, V123, P491, DOI 10.1093/toxsci/kfr175; Sears MR, 1996, ARCH DIS CHILD, V75, P392, DOI 10.1136/adc.75.5.392; Sharkhuu T, 2010, TOXICOL LETT, V196, P12, DOI 10.1016/j.toxlet.2010.03.017; Sibilano R, 2012, J IMMUNOL, V189, P120, DOI 10.4049/jimmunol.1200009; Spanier AJ, 2012, ENVIRON HEALTH PERSP, V120, P916, DOI 10.1289/ehp.1104175; SRIVASTAVA VK, 1986, J TOXICOL ENV HEALTH, V18, P459, DOI 10.1080/15287398609530885; Stafford S, 1997, J IMMUNOL, V158, P4953; Stevens EA, 2009, IMMUNOLOGY, V127, P299, DOI 10.1111/j.1365-2567.2009.03054.x; Sun JC, 2011, J EXP MED, V208, P357, DOI 10.1084/jem.20100479; Suzuki T, 1993, Arerugi, V42, P963; Tauchi M, 2005, MOL CELL BIOL, V25, P9360, DOI 10.1128/MCB.25.21.9360-9368.2005; Veldhoen M, 2008, NATURE, V453, P106, DOI 10.1038/nature06881; Veldhoen M, 2010, CURR OPIN IMMUNOL, V22, P747, DOI 10.1016/j.coi.2010.09.001; Veldhoen M, 2009, J EXP MED, V206, P43, DOI 10.1084/jem.20081438; Vivier E, 2008, NAT IMMUNOL, V9, P503, DOI 10.1038/ni1582; Walker C, 1998, J IMMUNOL, V161, P1962; Wang W, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017766; Wei HM, 2005, J ALLERGY CLIN IMMUN, V115, P841, DOI 10.1016/j.jaci.2004.11.026; Xue WL, 2005, TOXICOL APPL PHARM, V206, P73, DOI 10.1016/j.taap.2004.11.006; Zhou YF, 2013, BLOOD, V121, P3195, DOI 10.1182/blood-2012-08-453597; Zhu J, 2011, ASIAN PAC J ALLERGY, V29, P266	99	78	82	1	39	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2014	134	1					63	+		10.1016/j.jaci.2013.10.047	http://dx.doi.org/10.1016/j.jaci.2013.10.047			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AL2BH	24365139	Green Accepted			2022-12-18	WOS:000338930300009
J	Yip, KH; Kolesnikoff, N; Yu, CP; Hauschild, N; Taing, H; Biggs, L; Goltzman, D; Gregory, PA; Anderson, PH; Samuel, MS; Galli, SJ; Lopez, AF; Grimbaldeston, MA				Yip, Kwok-Ho; Kolesnikoff, Natasha; Yu, Chunping; Hauschild, Nicholas; Taing, Houng; Biggs, Lisa; Goltzman, David; Gregory, Philip A.; Anderson, Paul H.; Samuel, Michael S.; Galli, Stephen J.; Lopez, Angel F.; Grimbaldeston, Michele A.			Mechanisms of vitamin D-3 metabolite repression of IgE-dependent mast cell activation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Mast cells; anaphylaxis; inflammation; IgE; vitamin D-3; vitamin D receptor; CYP27B1	D-RECEPTOR; CONTACT HYPERSENSITIVITY; SKIN PATHOLOGY; D-3; DERMATITIS; ROLES	Background: Mast cells have gained notoriety based on their detrimental contributions to IgE-mediated allergic disorders. Although mast cells express the vitamin D receptor (VDR), it is not clear to what extent 1 alpha, 25-dihydroxyvitamin D-3 (1 alpha, 25[OH](2)D-3) or its predominant inactive precursor metabolite in the circulation, 25-hydroxyvitamin D-3 (25OHD(3)), can influence IgE-mediated mast cell activation and passive cutaneous anaphylaxis (PCA) in vivo. Objective: We sought to assess whether the vitaminD(3) metabolites 25OHD(3) and 1 alpha, 25(OH)(2)D-3 can repress IgE-dependent mast cell activation through mast cell-25-hydroxyvitamin D-1 alpha-hydroxylase (CYP27B1) and mast cell-VDR activity. Methods: We measured the extent of vitamin D-3 suppression of IgE-mediated mast cell degranulation and mediator production in vitro, as well as the vitamin D-3-induced curtailment of PCA responses in WBB6F(1)-Kit(W/W-v) or C57BL/6J-Kit(W-sh/W-sh) mice engrafted with mast cells that did or did not express VDR or CYP27B1. Results: Here we show that mouse and human mast cells can convert 25OHD(3) to 1 alpha, 25(OH)(2)D-3 through CYP27B1 activity and that both of these vitaminD(3) metabolites suppressed IgE-induced mast cell-derived proinflammatory and vasodilatory mediator production in a VDR-dependent manner in vitro. Furthermore, epicutaneously applied vitamin D-3 metabolites significantly reduced the magnitude of skin swelling associated with IgE-mediated PCA reactions in vivo; a response that required functional mast cell-VDRs and mast cell-CYP27B1. Conclusion: Taken together, our findings provide a mechanistic explanation for the anti-inflammatory effects of vitamin D-3 on mast cell function by demonstrating that mast cells can actively metabolize 25OHD(3) to dampen IgE-mediated mast cell activation in vitro and in vivo.	[Yip, Kwok-Ho; Kolesnikoff, Natasha; Yu, Chunping; Hauschild, Nicholas; Taing, Houng; Biggs, Lisa; Gregory, Philip A.; Samuel, Michael S.; Lopez, Angel F.; Grimbaldeston, Michele A.] SA Pathol, Ctr Canc Biol, Div Human Immunol, Adelaide, SA, Australia; [Yu, Chunping; Taing, Houng; Samuel, Michael S.; Lopez, Angel F.; Grimbaldeston, Michele A.] Univ Adelaide, Adelaide, SA 5005, Australia; [Goltzman, David] McGill Univ, Dept Med, Montreal, PQ, Canada; [Goltzman, David] McGill Univ, Dept Physiol, Montreal, PQ, Canada; [Anderson, Paul H.; Samuel, Michael S.; Lopez, Angel F.; Grimbaldeston, Michele A.] Univ S Australia, Adelaide, SA 5000, Australia; [Galli, Stephen J.] Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA; [Galli, Stephen J.] Stanford Univ, Sch Med, Dept Microbiol, Stanford, CA 94305 USA; [Galli, Stephen J.] Stanford Univ, Sch Med, Dept Immunol, Stanford, CA 94305 USA	Centre for Cancer Biology; SA Pathology; University of Adelaide; McGill University; McGill University; University of South Australia; Stanford University; Stanford University; Stanford University	Grimbaldeston, MA (corresponding author), Univ S Australia, Ctr Canc Biol, Div Human Immunol, Mast Cell Lab, Frome Rd, Adelaide, SA 5000, Australia.	michele.grimbaldeston@health.sa.gov.au	Samuel, Michael/D-2706-2011; Anderson, Paul H/F-4198-2013; Gregory, Philip/F-4089-2013	Samuel, Michael/0000-0001-7880-6379; Anderson, Paul H/0000-0002-8685-3252; Gregory, Philip/0000-0002-0999-0632; Lopez, Angel F/0000-0001-7430-0135; Yip, Kwok Ho/0000-0002-8453-0118; Kolesnikoff Prizzi, Natasha/0000-0003-4314-4779	Australian National Health and Medical Research Council (NHMRC) Career Development Fellowship; NHMRC; Canadian Institutes of Health Research; US National Institutes of Health [AI070813, AI023990, CA072074]; NATIONAL CANCER INSTITUTE [R01CA072074] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI070813, R01AI023990, R37AI023990] Funding Source: NIH RePORTER	Australian National Health and Medical Research Council (NHMRC) Career Development Fellowship(National Health and Medical Research Council (NHMRC) of Australia); NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by an Australian National Health and Medical Research Council (NHMRC) Career Development Fellowship (to M.A.G.) and NHMRC project grants (to M.A.G., P.A.G., M.S.S., and A.F.L.), by a grant from the Canadian Institutes of Health Research (to D.G.), and by grants from US National Institutes of Health grants AI070813, AI023990, and CA072074 to S.J.G.	Adams JS, 2012, ARCH BIOCHEM BIOPHYS, V523, P95, DOI 10.1016/j.abb.2012.02.016; Baroni E, 2007, J LEUKOCYTE BIOL, V81, P250, DOI 10.1189/jlb.0506322; Biggs L, 2010, J EXP MED, V207, P455, DOI 10.1084/jem.20091725; Bikle DD, 2010, TRENDS ENDOCRIN MET, V21, P375, DOI 10.1016/j.tem.2010.01.003; Bouillon R, 2008, ENDOCR REV, V29, P726, DOI 10.1210/er.2008-0004; Burton OT, 2011, IMMUNOL REV, V242, P128, DOI 10.1111/j.1600-065X.2011.01024.x; Galli SJ, 2008, NAT REV IMMUNOL, V8, P478, DOI 10.1038/nri2327; Galli SJ, 2012, NAT MED, V18, P693, DOI 10.1038/nm.2755; Goleva E, 2012, J ALLERGY CLIN IMMUN, V129, P1243, DOI 10.1016/j.jaci.2012.01.044; Gorman S, 2007, J IMMUNOL, V179, P6273, DOI 10.4049/jimmunol.179.9.6273; Grimbaldeston MA, 2005, AM J PATHOL, V167, P835, DOI 10.1016/S0002-9440(10)62055-X; Grimbaldeston MA, 2007, NAT IMMUNOL, V8, P1095, DOI 10.1038/ni1503; GUO Z, 1992, ARCH DERMATOL RES, V284, P368, DOI 10.1007/BF00372042; Hart PH, 2011, NAT REV IMMUNOL, V11, P584, DOI 10.1038/nri3045; Haussler MR, 2011, BEST PRACT RES CL EN, V25, P543, DOI 10.1016/j.beem.2011.05.010; Hershko AY, 2011, IMMUNITY, V35, P562, DOI 10.1016/j.immuni.2011.07.013; Hirota T, 2012, NAT GENET, V44, P1222, DOI 10.1038/ng.2438; Holick MF, 2011, NAT REV ENDOCRINOL, V7, P73, DOI 10.1038/nrendo.2010.234; Jones AP, 2012, PEDIATRICS, V130, pE1128, DOI 10.1542/peds.2012-1172; Katayama I, 1996, INT ARCH ALLERGY IMM, V111, P71, DOI 10.1159/000237348; Li M, 2006, P NATL ACAD SCI USA, V103, P11736, DOI 10.1073/pnas.0604575103; Menegaz D, 2011, MOL ENDOCRINOL, V25, P1289, DOI 10.1210/me.2010-0442; Norman MU, 2008, AM J PATHOL, V172, P1638, DOI 10.2353/ajpath.2008.070559; Olivera A, 2007, IMMUNITY, V26, P287, DOI 10.1016/j.immuni.2007.02.008; Oskeritzian CA, 2010, J EXP MED, V207, P465, DOI 10.1084/jem.20091513; Panda DK, 2001, P NATL ACAD SCI USA, V98, P7498, DOI 10.1073/pnas.131029498; Pike JW, 2011, MOL CELL ENDOCRINOL, V347, P3, DOI 10.1016/j.mce.2011.05.012; Schafer B, 2013, J ALLERGY CLIN IMMUN, V131, P541, DOI 10.1016/j.jaci.2012.05.009; Takeyama K, 2011, BIOSCI BIOTECH BIOCH, V75, P208, DOI 10.1271/bbb.100684; Vercelli D, 2008, NAT REV IMMUNOL, V8, P169, DOI 10.1038/nri2257	30	78	85	1	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2014	133	5					1356	U590		10.1016/j.jaci.2013.11.030	http://dx.doi.org/10.1016/j.jaci.2013.11.030			23	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AG5HS	24461581	Green Accepted			2022-12-18	WOS:000335450700018
J	Doherty, TA; Scott, D; Walford, HH; Khorram, N; Lund, S; Baum, R; Chang, J; Rosenthal, P; Beppu, A; Miller, M; Broide, DH				Doherty, Taylor A.; Scott, David; Walford, Hannah H.; Khorram, Naseem; Lund, Sean; Baum, Rachel; Chang, Jinny; Rosenthal, Peter; Beppu, Andrew; Miller, Marina; Broide, David H.			Allergen challenge in allergic rhinitis rapidly induces increased peripheral blood type 2 innate lymphoid cells that express CD84	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							INFLAMMATION; T(H)2		[Doherty, Taylor A.; Scott, David; Walford, Hannah H.; Khorram, Naseem; Lund, Sean; Baum, Rachel; Chang, Jinny; Rosenthal, Peter; Beppu, Andrew; Miller, Marina; Broide, David H.] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; [Scott, David; Chang, Jinny] Scripps Clin, Div Allergy Asthma & Immunol, La Jolla, CA 92037 USA; [Walford, Hannah H.] Radys Childrens Hosp San Diego, Div Rheumatol Allergy & Immunol, San Diego, CA USA	University of California System; University of California San Diego; Scripps Research Institute	Doherty, TA (corresponding author), Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.	tdoherty@ucsd.edu		Doherty, Taylor/0000-0003-3256-0398; Baum, Rachel/0000-0002-8227-7462; Lund, Sean/0000-0002-9807-6585; Broide, David/0000-0001-8405-9090	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000100] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI080938] Funding Source: NIH RePORTER; NCATS NIH HHS [UL1TR000100] Funding Source: Medline; NIAID NIH HHS [K08 AI080938] Funding Source: Medline; PHS HHS [ULRR031980] Funding Source: Medline	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Bochenek G, 2004, THORAX, V59, P459, DOI 10.1136/thx.2003.013573; Cannons JL, 2010, IMMUNITY, V32, P253, DOI 10.1016/j.immuni.2010.01.010; Chang JE, 2013, J ALLERGY CLIN IMMUN, DOI DOI 10.1016/J.JACI.2013.09.020.[; Doherty TA, 2013, J ALLERGY CLIN IMMUN, V132, P205, DOI 10.1016/j.jaci.2013.03.048; Doherty TA, 2012, AM J PHYSIOL-LUNG C, V303, pL577, DOI 10.1152/ajplung.00174.2012; Kim BS, 2013, CURR OPIN IMMUNOL, V25, P738, DOI 10.1016/j.coi.2013.07.013; Licona-Limon P, 2013, NAT IMMUNOL, V14, P536, DOI 10.1038/ni.2617; Mjosberg J, 2012, IMMUNITY, V37, P649, DOI 10.1016/j.immuni.2012.08.015; Mjosberg JM, 2011, NAT IMMUNOL, V12, P1055, DOI 10.1038/ni.2104	9	78	82	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2014	133	4					1203	1205		10.1016/j.jaci.2013.12.1086	http://dx.doi.org/10.1016/j.jaci.2013.12.1086			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AD8QW	24582313	Green Accepted, Bronze			2022-12-18	WOS:000333531700032
J	Novak, N; Bieber, T; Hoffmann, M; Folster-Holst, R; Homey, B; Werfel, T; Sager, A; Zuberbier, T				Novak, Natalija; Bieber, Thomas; Hoffmann, Matthias; Foelster-Holst, Regina; Homey, Bernhard; Werfel, Thomas; Sager, Angelika; Zuberbier, Torsten			Efficacy and safety of subcutaneous allergen-specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; atopic dermatitis; house dust mites; specific immunotherapy	HOUSE-DUST MITES; THERAPEUTIC OPTION; DISEASE	Background: Exposure to house dust mites (HDMs) aggravates the course of atopic dermatitis (AD) in patients sensitized to HDMs. Objectives: This study investigated the efficacy and safety of subcutaneous allergen-specific immunotherapy with the use of depigmented polymerized mite extract as an add-on therapy to basic (ie, topical and, as necessary, systemic) medication. Methods: Patients (n = 168) were recruited in a randomized, double-blind, placebo-controlled parallel group phase III study conducted in Germany (21 sites), in adult patients with AD aggravated by HDMs. The primary end points of the study were the assessments of the area under the curves of the total Severity Scoring Atopic Dermatitis (SCORAD) score and of the use of basic medication during the 18-month treatment period. Post hoc subgroup analyses were also performed. Results: Overall efficacy analysis of the intention-to-treat and per-protocol study populations showed no statistically significant differences between the active treatment and placebo groups. However, the subgroup of patients with severe AD (SCORAD > 50) showed a statistically significant reduction of the median total SCORAD by 18% (P = .02) compared with placebo. The frequency of adverse reactions was similar in both groups, suggesting the safety of the active treatment. Conclusion: Although subcutaneous allergen-specific immunotherapy showed no statistically significant difference in the overall population of patients with AD, statistically significant reduction of the total SCORAD could be achieved in a subgroup of patients with severe AD. (J Allergy Clin Immunol 2012; 130:925-31.)	[Novak, Natalija; Bieber, Thomas] Univ Bonn, Dept Dermatol & Allergy, D-53105 Bonn, Germany; [Foelster-Holst, Regina] Univ Kiel, Dept Dermatol & Venerol, Univ Hosp Schleswig Holstein, D-24098 Kiel, Germany; [Homey, Bernhard] Univ Hosp Dusseldorf, Dept Dermatol, Dusseldorf, Germany; [Werfel, Thomas] MHH Univ, Dept Dermatol, Hannover, Germany; [Sager, Angelika] LETI Pharma, Witten, Germany; [Zuberbier, Torsten] Univ Med Berlin, Allergy Ctr Charite, Dept Dermatol & Allergy Charite, Berlin, Germany	University of Bonn; University of Kiel; Schleswig Holstein University Hospital; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf Hospital; Hannover Medical School; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Novak, N (corresponding author), Univ Bonn, Dept Dermatol & Allergy, Sigmund Freud Str 25, D-53105 Bonn, Germany.	natalija.novak@ukb.uni-bonn.de	Werfel, Thomas/B-6921-2012		LETI Pharma GmbH, Germany; German Research Council; ALK-Abello; Bencard Allergy Therapeutics; Astellas; LETI Pharma; Medac; MSD; LEO Pharma; Spirig; Allergopharma; Almirall-Hermal; HAL Allergy; MEDA Pharma; Novartis; Pfizer; Schering-Plough; Stallergenes; Pierre Fabre; Regeneron; Roche Posay	LETI Pharma GmbH, Germany; German Research Council(German Research Foundation (DFG)); ALK-Abello; Bencard Allergy Therapeutics; Astellas(Astellas Pharmaceuticals); LETI Pharma; Medac; MSD; LEO Pharma(LEO Pharma); Spirig; Allergopharma; Almirall-Hermal(Almirall); HAL Allergy(HAL Allergy Group); MEDA Pharma; Novartis(Novartis); Pfizer(Pfizer); Schering-Plough(Merck & CompanySchering Plough Corporation); Stallergenes; Pierre Fabre; Regeneron(Regeneron); Roche Posay	Supported by LETI Pharma GmbH, Germany. LETI Pharma GmbH was involved in the design and conduct of the study and provided logistical support during the trial. Employees of the sponsor worked with the investigators to prepare the statistical analysis plan, but the analyses were performed by Pierrel Research Europe.; N. Novak has received research support from the German Research Council and ALK-Abello; has received lecture fees from ALK-Abello, Bencard Allergy Therapeutics, and Astellas; and has received consultancy fees from LETI Pharma. M. Hoffmann is on the advisory board for Janssen; has received consultancy fees from Medac and MSD; has provided expert testimony for Abbott; has received lecture fees from LEO Pharma and Spirig; and has participated in clinical trials sponsored by Allergopharma, ALK-Abello, Almirall-Hermal, HAL Allergy, MEDA Pharma, Novartis, Pfizer, Schering-Plough, and Stallergenes. R. Folster-Holst has received research support from Novartis, Pierre Fabre, Regeneron, LETI Pharma, and ALK-Abello; is on the Johnson & Johnson advisory board; and has received lecture fees from Roche Posay. B. Homey has received consulting fees from ALK-Abello. A. Sager is employed by LETI Pharma. The rest of the authors declare they have no relevant conflicts of interest.	Alvarez-Cuesta E, 2006, ALLERGY, V61, P1, DOI 10.1111/j.1398-9995.2006.01219_1.x; Bieber T, 2008, NEW ENGL J MED, V358, P1483, DOI 10.1056/NEJMra074081; Bussmann C, 2007, CLIN EXP ALLERGY, V37, P1277, DOI 10.1111/j.1365-2222.2007.02783.x; Bussmann C, 2006, J ALLERGY CLIN IMMUN, V118, P1292, DOI 10.1016/j.jaci.2006.07.054; Calderon MA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001936.pub2; Darsow U, 1996, BRIT J DERMATOL, V135, P182, DOI 10.1111/j.1365-2133.1996.tb01144.x; Durham SR, 2011, J ALLERGY CLIN IMMUN, V127, P3, DOI 10.1016/j.jaci.2010.11.032; Gutowska-Owsiak D, 2011, BRIT J DERMATOL, V165, P492, DOI 10.1111/j.1365-2133.2011.10400.x; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44; Henderson J, 2008, J ALLERGY CLIN IMMUN, V121, P872, DOI 10.1016/j.jaci.2008.01.026; Kim ME, 2011, J KOREAN MED SCI, V26, P1159, DOI 10.3346/jkms.2011.26.9.1159; Kosik-Bogacka DI, 2012, ZOONOSES PUBLIC HLTH, V59, P8, DOI 10.1111/j.1863-2378.2011.01409.x; Moniaga CS, 2010, AM J PATHOL, V176, P2385, DOI 10.2353/ajpath.2010.090957; Novak N, 2011, ALLERGY, V66, P830, DOI 10.1111/j.1398-9995.2011.02571.x; Novak N, 2007, CURR OPIN ALLERGY CL, V7, P542, DOI 10.1097/ACI.0b013e3282f1d66c; Novak N, 2011, INT ARCH ALLERGY IMM, V155, P252, DOI 10.1159/000320058; Pajno GB, 2003, PEDIAT ALLERG IMM-UK, V14, P292, DOI 10.1034/j.1399-3038.2003.00060.x; Patrizi A, 2011, J ALLERGY CAIRO, V2011; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V79, P781, DOI 10.1016/0091-6749(87)90211-9; SAGER N, 1992, J ALLERGY CLIN IMMUN, V89, P801, DOI 10.1016/0091-6749(92)90434-4; Schulz KF, 2010, J CLIN EPIDEMIOL, V63, P834, DOI [10.1016/j.jclinepi.2010.02.005, 10.1016/j.ijsu.2011.09.004, 10.1186/1741-7015-8-18, 10.4103/0976-500X.72352]; Sheikh A, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001563.pub2; Svensson A, 2011, CURR MED RES OPIN, V27, P1395, DOI 10.1185/03007995.2011.582483; Tupker RA, 1996, J ALLERGY CLIN IMMUN, V97, P1064, DOI 10.1016/S0091-6749(96)70259-2; Tupker RA, 1998, ALLERGY, V53, P92, DOI 10.1111/j.1398-9995.1998.tb05006.x; Werfel T, 2006, ALLERGY, V61, P202, DOI 10.1111/j.1398-9995.2006.00974.x	26	78	85	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2012	130	4					925	+		10.1016/j.jaci.2012.08.004	http://dx.doi.org/10.1016/j.jaci.2012.08.004			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017MT	22947344	Bronze			2022-12-18	WOS:000309594800014
J	Bacharier, LB; Guilbert, TW				Bacharier, Leonard B.; Guilbert, Theresa W.			Diagnosis and management of early asthma in preschool-aged children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Asthma; wheezing; preschool; inhaled corticosteroids; leukotriene receptor antagonists; intermittent treatment; wheezing phenotypes	BUDESONIDE INHALATION SUSPENSION; INHALED FLUTICASONE PROPIONATE; RANDOMIZED CONTROLLED-TRIAL; LEUKOTRIENE RECEPTOR ANTAGONIST; 1ST 6 YEARS; YOUNG-CHILDREN; PERSISTENT ASTHMA; GASTROESOPHAGEAL-REFLUX; CHILDHOOD ASTHMA; LUNG-FUNCTION	Asthma is a common disease in young children and is associated with significant morbidity and an increasing prevalence over time. Early childhood wheezing and asthma are heterogeneous disorders; thus identifying phenotypes of asthma remains a goal to identify high-risk children who might benefit from specific therapies or secondary prevention interventions. The typical pattern of illness in preschool-aged children consists of short but recurrent exacerbations of cough and wheeze usually triggered by viral respiratory tract infections. Documenting reversible airflow obstruction on lung function, allergen sensitization, increased IgE levels, or blood eosinophilia is helpful in establishing a diagnosis of asthma in preschool-aged children, if present; however, the diagnosis is most often based on symptom patterns, presence of risk factors, and therapeutic responses. The preschool-aged asthmatic population tends to be characterized as exacerbation prone with relatively limited impairment, unlike older children and adolescents who have more impairment-dominant disease. However, management of persistent disease is based largely on expert opinion and extrapolation from studies in older children given the relative lack of data in this age group. Strategies used to manage intermittent disease include daily and intermittent controller therapy. Management strategies for persistent asthma include daily inhaled corticosteroids, daily leukotriene receptor antagonists, and combination therapies. Finally, regular monitoring of symptom control and medication side effects is important along with titrating controllers to the minimally effective dose. (J Allergy Clin Immunol 2012;130:287-96.)	[Bacharier, Leonard B.] Washington Univ, Sch Med, Div Pediat Allergy Immunol & Pulm Med, Dept Pediat, St Louis, MO 63110 USA; [Bacharier, Leonard B.] St Louis Childrens Hosp, St Louis, MO USA; [Guilbert, Theresa W.] Univ Wisconsin Madison, Dept Pediat, Madison, WI USA	Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL); University of Wisconsin System; University of Wisconsin Madison	Bacharier, LB (corresponding author), Washington Univ, Sch Med, Div Pediat Allergy Immunol & Pulm Med, Dept Pediat, Campus Box 8116,660 S Euclid, St Louis, MO 63110 USA.	bacharier_L@kids.wustl.edu		Guilbert, Theresa/0000-0002-6932-712X; Bacharier, Leonard/0000-0003-0432-2704	National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute's AsthmaNet; NIH; Centers for Disease Control; US Department of Health and Human Services; University of Wisconsin Medical and Education Research Committee	National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute's AsthmaNet; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Centers for Disease Control(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); US Department of Health and Human Services; University of Wisconsin Medical and Education Research Committee	L. B. Bacharier has received honoraria from Merck and GlaxoSmithKline and has received research support from the National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute's AsthmaNet. T. W. Guilbert was a research consultant for Teva; was on the GlaxoSmithKline Data and Safety Monitoring Board; has received research support from the NIH, Centers for Disease Control, US Department of Health and Human Services, and University of Wisconsin Medical and Education Research Committee; is a member of the American Thoracic Society and Society for Pediatric Radiology; is a member and on the subboard committee of the American Academy of Pediatrics; has received royalties from UpToDate; has provided lectures for Merck-Schering-Plough; and has developed educational presentations for Teva.	Allen DB, 2005, ENDOCRIN METAB CLIN, V34, P555, DOI 10.1016/j.ecl.2005.04.013; Amirav I, 2010, J ALLERGY CLIN IMMUN, V125, P1206, DOI 10.1016/j.jaci.2010.01.034; [Anonymous], 2011, MMWR MORB MORTAL WKL, V60, P547; Bacharier LB, 2002, J ALLERGY CLIN IMMUN, V109, pS266, DOI 10.1016/S0091-6749(02)81946-7; Bacharier LB, 2007, J ALLERGY CLIN IMMUN, V119, P604, DOI 10.1016/j.jaci.2006.12.607; Bacharier LB, 2011, J ALLERGY CLIN IMMUN, V128, P690, DOI 10.1016/j.jaci.2011.07.034; Bacharier LB, 2009, J ALLERGY CLIN IMMUN, V123, P1077, DOI 10.1016/j.jaci.2008.12.1120; Bacharier LB, 2008, J ALLERGY CLIN IMMUN, V122, P1127, DOI 10.1016/j.jaci.2008.09.029; Baker JW, 1999, PEDIATRICS, V103, P414, DOI 10.1542/peds.103.2.414; Baraldi E, 2009, EARLY HUM DEV, V85, pS1, DOI 10.1016/j.earlhumdev.2009.08.002; Bisgaard H, 1999, AM J RESP CRIT CARE, V160, P126, DOI 10.1164/ajrccm.160.1.9811024; Bisgaard H, 2005, AM J RESP CRIT CARE, V171, P315, DOI 10.1164/rccm.200407-894OC; Bisgaard H, 2004, PEDIATRICS, V113, P87; Bisgaard H, 2006, NEW ENGL J MED, V354, P1998, DOI 10.1056/NEJMoa054692; Bisgaard H, 2009, PEDIATR PULM, V44, P568, DOI 10.1002/ppul.21018; Brand PLP, 2008, EUR RESPIR J, V32, P1096, DOI 10.1183/09031936.00002108; Brand PLP, 2011, RESP MED, V105, P1588, DOI 10.1016/j.rmed.2011.07.017; Castile Robert, 2004, Pediatr Infect Dis J, V23, pS246, DOI 10.1097/01.inf.0000144676.40897.ec; Castro-Rodriguez JA, 2000, AM J RESP CRIT CARE, V162, P1403, DOI 10.1164/ajrccm.162.4.9912111; Castro-Rodriguez JA, 2011, CURR OPIN ALLERGY CL, V11, P157, DOI 10.1097/ACI.0b013e3283464c4a; Castro-Rodriguez JA, 2010, J ALLERGY CLIN IMMUN, V126, P212, DOI 10.1016/j.jaci.2010.06.032; Castro-Rodriguez JA, 2009, PEDIATRICS, V123, pe519, DOI 10.1542/peds.2008-2867; Caudri D, 2009, J ALLERGY CLIN IMMUN, V124, P903, DOI 10.1016/j.jaci.2009.06.045; Chipps BE, 2011, J PEDIATR-US, V158, P878, DOI 10.1016/j.jpeds.2011.01.057; Clough JB, 1999, AM J RESP CRIT CARE, V160, P1473, DOI 10.1164/ajrccm.160.5.9807019; de Blic J, 2007, J ALLERGY CLIN IMMUN, V119, P808, DOI 10.1016/j.jaci.2006.12.657; Devulapalli CS, 2008, THORAX, V63, P8, DOI 10.1136/thx.2006.060616; Ducharme FM, 2009, NEW ENGL J MED, V360, P339, DOI 10.1056/NEJMoa0808907; Galant SP, 2010, CURR OPIN ALLERGY CL, V10, P149, DOI 10.1097/ACI.0b013e328335ce48; Guilbert TW, 2011, J ALLERGY CLIN IMMUN, V128, P956, DOI 10.1016/j.jaci.2011.06.027; Guilbert TW, 2010, J ALLERGY CLIN IMMUN, V126, P417, DOI 10.1016/j.jaci.2010.06.024; Guilbert TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMoa051378; Guilbert TW, 2004, J ALLERGY CLIN IMMUN, V114, P1282, DOI 10.1016/j.jaci.2004.09.020; Guilbert TW, 2011, J ALLERGY CLIN IMMUN, V128, pe1; Hakim F, 2007, CHEST, V131, P180, DOI 10.1378/chest.06-1402; Harding SM, 1999, J ALLERGY CLIN IMMUN, V104, P251, DOI 10.1016/S0091-6749(99)70360-X; Henderson J, 2008, THORAX, V63, P974, DOI 10.1136/thx.2007.093187; Holbrook JT, 2012, JAMA-J AM MED ASSOC, V307, P373, DOI 10.1001/jama.2011.2035; Johnston NW, 2007, PEDIATRICS, V120, pE702, DOI 10.1542/peds.2006-3317; Kaditis AG, 2007, PEDIATR PULM, V42, P407, DOI 10.1002/ppul.20591; Kemp JP, 1999, ANN ALLERG ASTHMA IM, V83, P231, DOI 10.1016/S1081-1206(10)62646-4; Knorr B, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.3.e48; Kooi EMW, 2008, PULM PHARMACOL THER, V21, P798, DOI 10.1016/j.pupt.2008.06.004; Kurukulaaratchy RJ, 2003, CLIN EXP ALLERGY, V33, P573, DOI 10.1046/j.1365-2222.2003.01657.x; Lea E, 2005, J PEDIATR SURG, V40, P1122, DOI 10.1016/j.jpedsurg.2005.03.049; Leonardi NA, 2011, J ALLERGY CLIN IMMUN, V127, P1466, DOI 10.1016/j.jaci.2011.03.001; MARTINEZ F, 2003, WHEEZING DISORDERS P; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Meyer KA, 2003, J ALLERGY CLIN IMMUN, V111, P757, DOI 10.1067/mai.2003.1391; Moeller A, 2008, PEDIATR PULM, V43, P179, DOI 10.1002/ppul.20753; Morgan WJ, 2005, AM J RESP CRIT CARE, V172, P1253, DOI 10.1164/rccm.200504-525OC; MOSS MH, 2003, MIDDLETONS ALLERGY P, P1225; Murray CS, 2006, LANCET, V368, P754, DOI 10.1016/S0140-6736(06)69285-4; National Asthma Education and Prevention Program, 2007, HYPERLIPIDAEMIA; Papi A, 2009, ALLERGY, V64, P1463, DOI 10.1111/j.1398-9995.2009.02134.x; Patra S, 2011, J TROP PEDIATRICS, V57, P99, DOI 10.1093/tropej/fmq056; Pedersen SE, 2011, PEDIATR PULM, V46, P1, DOI 10.1002/ppul.21321; Philip G, 2009, J ALLERGY CLIN IMMUN, V124, P699, DOI 10.1016/j.jaci.2009.08.011; Qaqundah PY, 2006, J PEDIATR-US, V149, P663, DOI 10.1016/j.jpeds.2006.07.045; Robertson CF, 2007, AM J RESP CRIT CARE, V175, P323, DOI 10.1164/rccm.200510-1546OC; Roorda RJ, 2001, J ALLERGY CLIN IMMUN, V108, P540, DOI 10.1067/mai.2001.118789; Rusconi F, 1999, AM J RESP CRIT CARE, V160, P1617, DOI 10.1164/ajrccm.160.5.9811002; Savenije OE, 2011, J ALLERGY CLIN IMMUN, V127, P1505, DOI 10.1016/j.jaci.2011.02.002; Schultz A, 2010, ACTA PAEDIATR, V99, P56, DOI 10.1111/j.1651-2227.2009.01508.x; Sekhsaria S, 2004, J ASTHMA, V41, P575, DOI 10.1081/JAS-120033986; Shapiro G, 1998, J ALLERGY CLIN IMMUN, V102, P789, DOI 10.1016/S0091-6749(98)70019-3; Sheikh S, 1999, PEDIATR PULM, V28, P181, DOI 10.1002/(SICI)1099-0496(199909)28:3<181::AID-PPUL4>3.0.CO;2-S; Skoner DP, 2000, J ALLERGY CLIN IMMUN, V105, P259, DOI 10.1016/S0091-6749(00)90074-5; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; Szefler SJ, 2002, J ALLERGY CLIN IMMUN, V109, P730, DOI 10.1067/mai.2002.122712; Szefler SJ, 2007, J ALLERGY CLIN IMMUN, V120, P1043, DOI 10.1016/j.jaci.2007.08.063; Valovirta E, 2011, ANN ALLERG ASTHMA IM, V106, P518, DOI 10.1016/j.anai.2011.01.017; Wasserman RL, 2006, ANN ALLERG ASTHMA IM, V96, P808, DOI 10.1016/S1081-1206(10)61343-9; Weiss KB, 2010, ANN ALLERG ASTHMA IM, V105, P174, DOI 10.1016/j.anai.2010.04.018; Zeiger RS, 2011, NEW ENGL J MED, V365, P1990, DOI 10.1056/NEJMoa1104647	75	78	83	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2012	130	2					287	296		10.1016/j.jaci.2012.04.025	http://dx.doi.org/10.1016/j.jaci.2012.04.025			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	981WC	22664162				2022-12-18	WOS:000307002200006
J	Roifman, CM; Somech, R; Kavadas, F; Pires, L; Nahum, A; Dalal, I; Grunebaum, E				Roifman, Chaim M.; Somech, Raz; Kavadas, Fotini; Pires, Linda; Nahum, Amit; Dalal, Ilan; Grunebaum, Eyal			Defining combined immunodeficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Combined immunodeficiency; CD3; phytohemagglutinin; T-cell receptor excision circles	COMBINED IMMUNE-DEFICIENCY; OMENN-SYNDROME; ALPHA-CHAIN; HYPER-IGM; MUTATIONS; RECEPTOR; INTERLEUKIN-2-RECEPTOR; MANIFESTATIONS; EXPRESSION; DEFECTS	Background: Although the extreme condition of typical profound T-cell dysfunction (TD), severe combined immunodeficiency (SCID), has been carefully defined, we are currently in the process of better defining less typical T-cell deficiencies, which tend to present with autologous circulating T-cell combined immunodeficiency (CID). Because autologous cells might interfere with the outcome of bone marrow transplantation, protocols usually include conditioning regimens. Therefore it is important to define the numbers of autologous cells usually detected in patients with CID versus those with SCID. Objectives: We sought to determine the number of circulating T cells in patients with SCID as opposed to those with CID, to study their function, and to evaluate their possible detection during newborn screening using T-cell receptor excision circle (TREC) analysis. Methods: Numbers of circulating CD3(+) T cells (as determined by means of flow cytometry), in vitro responses to PHA, and TREC levels, all measured at presentation, were compiled from the research charts of the entire cohort of patients followed prospectively for T-cell immunodeficiency at the Hospital for Sick Children. Clinical data were ascertained retrospectively from the patient's hospital charts. Results: One hundred three patients had CD3(+) determinations, and 80 of them had a genetic diagnosis. All patients considered to have typical SCID had CD3(+) T-cell counts of fewer than 500 cells/mu L. Some variability was observed among different genotypes. In vitro responses to PHA were recorded in 88 patients, of whom 68 had a genetic diagnosis. All patients with low CD3(+) T-cell numbers (< 500 cells/mu L) also had markedly decreased responses to PHA (typical SCIDs). However, responses ranged widely in the groups of patients with TD who had more than 500 CD3(+) autologous circulating T cells per microliter. Although patients with Omenn syndrome and zeta chain-associated protein, 70 kDa (ZAP70), and purine nucleoside phosphorylase (PNP) deficiencies had low responses, patients with the p.R222C mutation in the IL-2 receptor gamma (IL2RG) gene as well as IL-10 receptor and CD40 ligand deficiencies had normal or near-normal mitogen responses. Finally, 51 patients had TREC levels measured. All patients with typical SCID, Omenn syndrome, and ZAP70 deficiency had low TREC levels. In contrast, patients with mutations in forkhead box protein 3 (FOXP3), CD40 ligand (CD40L), and IL-10 receptor alpha (IL10RA), as well as patients with the p.R222C mutation in the IL2RG gene, had normal TREC levels. Conclusion: Patients with typical SCID can be defined as having fewer than 500 circulating CD3(+) T cells. Most patients with autologous T cells still have profound TD, as defined by reduced in vitro function and thymus output. Some patients with conditions including TD have normal TREC levels and will therefore not be detected in a TREC-based newborn screening program. (J Allergy Clin Immunol 2012; 130: 177-83.)	[Roifman, Chaim M.; Pires, Linda; Grunebaum, Eyal] Hosp Sick Children, Canadian Ctr Primary Immunodeficiency, JeffreyModell Res Lab Diag Primary Immunodeficien, Div Immunol & Allergy,Dept Pediat, Toronto, ON M5G 1X8, Canada; [Roifman, Chaim M.; Pires, Linda; Grunebaum, Eyal] Univ Toronto, Toronto, ON, Canada; [Roifman, Chaim M.; Pires, Linda; Nahum, Amit; Dalal, Ilan; Grunebaum, Eyal] Canada Israel Immunodeficiency Res Alliance, Toronto, ON, Canada; [Kavadas, Fotini] Alberta Childrens Prov Gen Hosp, Calgary, AB T2T 5C7, Canada; [Somech, Raz] Tel Aviv Univ, Chaim Sheba Med Ctr, Tel Hashomer, Israel; [Nahum, Amit] Hebrew Univ Jerusalem, Kaplan Med Ctr, Rehovot, Israel; [Dalal, Ilan] Tel Aviv Univ, Edith Wolfson Med Ctr, Holon, Israel	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; Alberta Childrens Hospital; University of Calgary; Chaim Sheba Medical Center; Tel Aviv University; Hebrew University of Jerusalem; Kaplan Medical Center; Tel Aviv University	Roifman, CM (corresponding author), Div Allergy Immunol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	chaim.roifman@sickkids.ca			Canadian Centre for Primary Immunodeficiency; Jeffrey Modell Foundation; Canadian Immunodeficiency Society; Canada-Israel Alliance for Primary Immunodeficiency, a Chaim Roifman Scholar award	Canadian Centre for Primary Immunodeficiency; Jeffrey Modell Foundation; Canadian Immunodeficiency Society; Canada-Israel Alliance for Primary Immunodeficiency, a Chaim Roifman Scholar award	Supported by the Canadian Centre for Primary Immunodeficiency, the Jeffrey Modell Foundation, the Canadian Immunodeficiency Society, and the Canada-Israel Alliance for Primary Immunodeficiency, a Chaim Roifman Scholar award. C.M.R. is the holder of the Donald and Audrey Campbell Chair of Immunology.	ALARCON B, 1988, NEW ENGL J MED, V319, P1203, DOI 10.1056/NEJM198811033191806; ALLEN RC, 1993, SCIENCE, V259, P990, DOI 10.1126/science.7679801; ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; Bennett CL, 2001, NAT GENET, V27, P20, DOI 10.1038/83713; Chatila TA, 2000, J CLIN INVEST, V106, pR75, DOI 10.1172/JCI11679; De Ravin SS, 2010, BLOOD, V116, P1263, DOI 10.1182/blood-2010-02-267583; Ege M, 2005, BLOOD, V105, P4179, DOI 10.1182/blood-2004-12-4861; Felgentreff K, 2011, CLIN IMMUNOL, V141, P73, DOI 10.1016/j.clim.2011.05.007; Giliani S, 2006, J PEDIATR-US, V148, P272, DOI 10.1016/j.jpeds.2005.10.004; Glocker EO, 2009, NEW ENGL J MED, V361, P2033, DOI 10.1056/NEJMoa0907206; Grunebaum E, 2008, J ALLERGY CLIN IMMUN, V122, P1219, DOI 10.1016/j.jaci.2008.08.031; KORTHAUER U, 1993, NATURE, V361, P539, DOI 10.1038/361539a0; Newell A, 2011, J ALLERGY CLIN IMMUN, V127, P517, DOI 10.1016/j.jaci.2010.09.016; Notarangelo LD, 2000, IMMUNOL REV, V178, P39, DOI 10.1034/j.1600-065X.2000.17812.x; Railey MD, 2009, J PEDIAT, V155; Roifman CM, 2008, J ALLERGY CLIN IMMUN, V121, P1056, DOI 10.1016/j.jaci.2007.12.1148; Roifman CM, 2010, J ALLERGY CLIN IMMUN, V126, P1226, DOI 10.1016/j.jaci.2010.07.029; Roifman CM, 2006, J ALLERGY CLIN IMMUN, V117, P897, DOI 10.1016/j.jaci.2006.01.003; Roifman CM, 2000, PEDIATR RES, V48, P6, DOI 10.1203/00006450-200007000-00004; ROIFMAN CM, 1989, J EXP MED, V170, P2177, DOI 10.1084/jem.170.6.2177; Sharfe N, 1997, J CLIN INVEST, V100, P3036, DOI 10.1172/JCI119858; Sharfe N, 1997, P NATL ACAD SCI USA, V94, P3168, DOI 10.1073/pnas.94.7.3168; Shibata F, 2007, EUR J HAEMATOL, V79, P81, DOI 10.1111/j.1600-0609.2007.00874.x; Somech R, 2005, J PEDIATR-US, V147, P555, DOI 10.1016/j.jpeds.2005.05.010; TIMON M, 1993, EUR J IMMUNOL, V23, P1440, DOI 10.1002/eji.1830230706; van der Burg M, 2006, J CLIN INVEST, V116, P137, DOI 10.1172/JCI26121; Villa A, 1998, CELL, V93, P885, DOI 10.1016/S0092-8674(00)81448-8; Zhang JY, 2005, PEDIATRICS, V116, pE445, DOI 10.1542/peds.2005-0369	28	78	83	1	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2012	130	1					177	183		10.1016/j.jaci.2012.04.029	http://dx.doi.org/10.1016/j.jaci.2012.04.029			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	977GN	22664165	Bronze			2022-12-18	WOS:000306644800026
J	Leonard, SA; Martos, G; Wang, W; Nowak-Wegrzyn, A; Berin, MC				Leonard, Stephanie A.; Martos, Gustavo; Wang, Wei; Nowak-Wegrzyn, Anna; Berin, M. Cecilia			Oral immunotherapy induces local protective mechanisms in the gastrointestinal mucosa	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Oral immunotherapy; food allergy; heated egg allergen; epithelium	FOOD ALLERGY; TOLERANCE INDUCTION; MAST-CELLS; T-CELLS; MILK; CHILDREN; DESENSITIZATION; EXPRESSION; EFFICACY; EGG	Background: Oral immunotherapy (OIT) is a promising treatment for food allergy. Studies are needed to elucidate mechanisms of clinical protection and to identify safer and potentially more efficacious methods for desensitizing patients to food allergens. Objective: We established a mouse model of OIT to determine how the dose or form of antigen may affect desensitization and to identify mechanisms of desensitization. Methods: Increasing doses of egg white or ovomucoid as OIT were administered orally to sensitized mice. The impact of OIT on anaphylaxis elicited by oral allergen challenge was determined. Allergen-specific antibody and cytokine responses and mast cell and basophil activation in response to OIT were measured. Gene expression in the small intestine was studied by microarray and real-time PCR. Results: OIT resulted in desensitization but not tolerance of mice to the allergen. OIT did not result in desensitization of systemic effector cells, and protection was localized to the gastrointestinal tract. OIT was associated with significant changes in gene expression in the jejunum, including genes expressed by intestinal epithelial cells. Extensively heated ovomucoid that does not trigger anaphylaxis when given orally to sensitized mice was as efficacious as native ovomucoid in desensitizing mice. Conclusions: OIT results in clinical protection against food-induced anaphylaxis through a novel mechanism that is localized to the intestinal mucosa and is associated with significant changes in small intestinal gene expression. Extensively heating egg allergen decreases allergenicity and increases safety while still retaining the ability to induce effective desensitization. (J Allergy Clin Immunol 2012;129:1579-87.)	[Leonard, Stephanie A.; Martos, Gustavo; Wang, Wei; Nowak-Wegrzyn, Anna; Berin, M. Cecilia] Mt Sinai Sch Med, Div Pediat Allergy & Immunol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Berin, MC (corresponding author), Mt Sinai Sch Med, Div Pediat Allergy & Immunol, Box 1198,1 Gustave L Levy Pl, New York, NY 10029 USA.	cecilia.berin@mssm.edu	Martos, Gustavo/K-3457-2019	Martos, Gustavo/0000-0001-6434-1769; Nowak-Wegrzyn, Anna/0000-0002-0960-9854; berin, cecilia/0000-0002-9051-9249	National Institute of Allergy and Infectious Diseases [U19AI044236]; AAAAI at Mount Sinai School of Medicine; Spanish Research Council; Spanish Ministry of Science and Innovation [AGL2008-01740]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI044236] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); AAAAI at Mount Sinai School of Medicine; Spanish Research Council; Spanish Ministry of Science and Innovation(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institute of Allergy and Infectious Diseases grant U19AI044236 (Project 2, to M. C. B.); 2010 AAAAI/Elliot and Roslyn Jaffe Third-Year Fellowship Food Allergy Research Award at Mount Sinai School of Medicine (to S. A. L.); and the Spanish Research Council through the JAE program and the Spanish Ministry of Science and Innovation through project AGL2008-01740 (to G. M.).	Akdis CA, 2009, J ALLERGY CLIN IMMUN, V123, P735, DOI 10.1016/j.jaci.2009.02.030; Arias K, 2011, J ALLERGY CLIN IMMUN, V127, P1552, DOI 10.1016/j.jaci.2011.03.044; Blazquez AB, 2010, GASTROENTEROLOGY, V139, P1301, DOI 10.1053/j.gastro.2010.06.055; Blumchen K, 2010, J ALLERGY CLIN IMMUN, V126, P83, DOI 10.1016/j.jaci.2010.04.030; Boyce JA, 2011, NUTRITION, V27, P253, DOI 10.1016/j.nut.2010.12.001; Branum Amy M, 2008, NCHS Data Brief, P1; Buchanan AD, 2007, J ALLERGY CLIN IMMUN, V119, P199, DOI 10.1016/j.jaci.2006.09.016; Castells M, 2009, IMMUNOL ALLERGY CLIN, V29, P585, DOI 10.1016/j.iac.2009.04.012; Chen YH, 1996, P NATL ACAD SCI USA, V93, P388, DOI 10.1073/pnas.93.1.388; Ghosh D, 2002, NAT IMMUNOL, V3, P583, DOI 10.1038/ni797; Groschwitz KR, 2009, P NATL ACAD SCI USA, V106, P22381, DOI 10.1073/pnas.0906372106; Grutzkau A, 2004, CYTOM PART A, V61A, P62, DOI 10.1002/cyto.a.20068; Jones SM, 2009, J ALLERGY CLIN IMMUN, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Keet CA, 2012, J ALLERGY CLIN IMMUN, V129, P448, DOI 10.1016/j.jaci.2011.10.023; Kim JS, 2011, J ALLERGY CLIN IMMUN, V128, P125, DOI 10.1016/j.jaci.2011.04.036; Knight AK, 2007, AM J PHYSIOL-GASTR L, V293, pG1234, DOI 10.1152/ajpgi.00323.2007; Kraus TA, 2005, J CLIN INVEST, V115, P2234, DOI 10.1172/JCI19102; Kulis M, 2012, J ALLERGY CLIN IMMUN, V129, P1159, DOI 10.1016/j.jaci.2011.11.045; Lemon-Mule H, 2008, J ALLERGY CLIN IMMUN, V122, P977, DOI 10.1016/j.jaci.2008.09.007; Li XM, 2000, J ALLERGY CLIN IMMUN, V106, P150, DOI 10.1067/mai.2000.107395; Martos G, 2011, J ALLERGY CLIN IMMUN, V127, P990, DOI 10.1016/j.jaci.2011.01.057; Nelson HS, 1997, J ALLERGY CLIN IMMUN, V99, P744, DOI 10.1016/S0091-6749(97)80006-1; Nowak-Wegrzyn A, 2008, J ALLERGY CLIN IMMUN, V122, P342, DOI 10.1016/j.jaci.2008.05.043; Rolinck-Werninghaus C, 2005, ALLERGY, V60, P1320, DOI 10.1111/j.1398-9995.2005.00882.x; Roth-Walter F, 2008, ALLERGY, V63, P882, DOI 10.1111/j.1398-9995.2008.01673.x; Shreffler WG, 2009, J ALLERGY CLIN IMMUN, V123, P43, DOI [10.1016/j.jaci.2008.12.1128, 10.1016/j.jaci.2008.09.051]; Sicherer SH, 2011, J ALLERGY CLIN IMMUN, V127, P594, DOI 10.1016/j.jaci.2010.11.044; Skripak JM, 2008, J ALLERGY CLIN IMMUN, V122, P1154, DOI 10.1016/j.jaci.2008.09.030; Staden U, 2007, ALLERGY, V62, P1261, DOI 10.1111/j.1398-9995.2007.01501.x; Strait RT, 2011, J ALLERGY CLIN IMMUN, V127, P982, DOI 10.1016/j.jaci.2011.01.034; Sun JF, 2007, J IMMUNOL, V179, P6696, DOI 10.4049/jimmunol.179.10.6696; Thyagarajan A, 2010, J ALLERGY CLIN IMMUN, V126, P31, DOI 10.1016/j.jaci.2010.05.012; Torrero MN, 2009, CLIN EXP ALLERGY, V39, P361, DOI 10.1111/j.1365-2222.2008.03154.x; Uermosi C, 2010, J ALLERGY CLIN IMMUN, V126, P375, DOI 10.1016/j.jaci.2010.05.040; Varshney P, 2011, J ALLERGY CLIN IMMUN, V127, P654, DOI 10.1016/j.jaci.2010.12.1111; Vickery BP, 2011, J ALLERGY CLIN IMMUN, V127, pAB26, DOI 10.1016/j.jaci.2010.12.114	36	78	79	3	23	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2012	129	6					1579	+		10.1016/j.jaci.2012.04.009	http://dx.doi.org/10.1016/j.jaci.2012.04.009			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	952BL	22554705	Bronze, Green Accepted, Green Published			2022-12-18	WOS:000304764600019
J	Ingelsson, E; Yin, L; Back, M				Ingelsson, Erik; Yin, Li; Back, Magnus			Nationwide cohort study of the leukotriene receptor antagonist montelukast and incident or recurrent cardiovascular disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atherosclerosis; inflammation; myocardial infarction; pharmacoepidemiology; stroke	ACUTE MYOCARDIAL-INFARCTION; 5-LIPOXYGENASE PATHWAY; PROMOTER GENOTYPE; ATHEROSCLEROSIS; RISK; ASTHMA; ASSOCIATION; PROTEIN; STROKE; ATHEROGENESIS	Background: The leukotriene pathway has been associated with an increased cardiovascular risk. However, the effects of the antileukotriene treatment used in asthmatic patients on cardiovascular outcomes have remained largely unexplored. Objective: We sought to examine a potential protective role of the leukotriene receptor antagonist montelukast on future risk of incident and recurrent myocardial infarction and ischemic stroke. Methods: A nationwide population-based cohort of approximately 7 million persons integrating data from the Prescribed Drug, Patient, Cause of Death, Income, Educational, and Emigration Registers was followed from July 1, 2005, to December 31, 2008. Analyses were performed in the whole population after exclusion of subjects with a prior cardiovascular diagnosis (incident events; sample size, n = 6,910,923 for myocardial infarction and n = 6,932,578 for stroke) and in subjects with a prior diagnosis (recurrent events; n = 153,937 and n = 132,291 for stroke and myocardial infarction, respectively). Results: Cox proportional hazard ratios (HRs) did not reveal an association of montelukast use with incident events. In contrast to these findings, montelukast use was associated with a lower risk for recurrent stroke (HR, 0.62; 95% CI, 0.38-0.99) accounting for age, sex, education level, and yearly income. Adjusting the latter finding also for respiratory and cardiovascular medications and diagnoses revealed similar point estimates (HR, 0.62; 95% CI, 0.39-1.0). Post hoc analyses revealed a significant association of montelukast use with a lower risk for recurrent myocardial infarction in male subjects (HR, 0.65; 95% CI, 0.43-0.99). Conclusion: These data provide a first indication for a potential role of the antiasthma drug montelukast for secondary prevention of cardiovascular disease. (J Allergy Clin Immunol 2012; 129: 702-7.)	[Back, Magnus] Karolinska Univ Hosp, Dept Med, Karolinska Inst, S-17176 Stockholm, Sweden; [Ingelsson, Erik; Yin, Li] Karolinska Univ Hosp, Dept Med Epidemiol & Biostat, Karolinska Inst, S-17176 Stockholm, Sweden; [Back, Magnus] Karolinska Univ Hosp, Dept Cardiol, S-17176 Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital	Back, M (corresponding author), Karolinska Univ Hosp, Dept Med, Karolinska Inst, CMM L8 03, S-17176 Stockholm, Sweden.	Magnus.Back@ki.se	Back, Magnus/E-4879-2011	Back, Magnus/0000-0003-0853-5141	Crafoord Foundation; Swedish Society of Medicine; Swedish Heart and Lung Foundation.; Swedish Research Council; Swedish Foundation for Strategic Research	Crafoord Foundation; Swedish Society of Medicine; Swedish Heart and Lung Foundation.(Swedish Heart-Lung Foundation); Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Foundation for Strategic Research(Swedish Foundation for Strategic Research)	Supported by the Crafoord Foundation and the Swedish Society of Medicine. M. B. was supported by a grant from the Swedish Heart and Lung Foundation. E. I. was supported by grants from the Swedish Research Council and the Swedish Foundation for Strategic Research.	Allayee H, 2007, CHEST, V132, P868, DOI 10.1378/chest.07-0831; Back M, 2007, ATHEROSCLEROSIS, V193, P389, DOI 10.1016/j.atherosclerosis.2006.07.003; Back M, 2009, CURR PHARM DESIGN, V15, P3116, DOI 10.2174/138161209789058020; Back M, 2009, CARDIOVASC DRUG THER, V23, P41, DOI 10.1007/s10557-008-6140-9; Cipollone F, 2005, ARTERIOSCL THROM VAS, V25, P1665, DOI 10.1161/01.ATV.0000172632.96987.2d; Drazen JM, 1999, NAT GENET, V22, P168, DOI 10.1038/9680; Dwyer JH, 2004, NEW ENGL J MED, V350, P29, DOI 10.1056/NEJMoa025079; Furie KL, 2011, STROKE, V42, P227, DOI 10.1161/STR.0b013e3181f7d043; Goldstein LB, 2011, STROKE, V42, P517, DOI 10.1161/STR.0b013e3181fcb238; Goyal A, 2010, CIRCULATION, V122, P1167, DOI 10.1161/CIRCULATIONAHA.109.919274; Hakonarson H, 2005, JAMA-J AM MED ASSOC, V293, P2245, DOI 10.1001/jama.293.18.2245; Hammar N, 2001, INT J EPIDEMIOL, V30, pS30, DOI 10.1093/ije/30.suppl_1.S30; Hardy G, 2001, ARTERIOSCL THROM VAS, V21, P1751, DOI 10.1161/hq1201.098769; Helgadottir A, 2004, NAT GENET, V36, P233, DOI 10.1038/ng1311; Iribarren C, 2004, INT J EPIDEMIOL, V33, P743, DOI 10.1093/ije/dyh081; LINDBLAD U, 1993, SCAND J SOC MED, V21, P3, DOI 10.1177/140349489302100102; Montuschi P, 2010, CLIN EXP ALLERGY, V40, P1732, DOI 10.1111/j.1365-2222.2010.03630.x; Mueller CFH, 2008, CIRCULATION, V117, P2912, DOI 10.1161/CIRCULATIONAHA.107.747667; Peters-Golden M, 2007, NEW ENGL J MED, V357, P1841, DOI 10.1056/NEJMra071371; PIOMELLI D, 1987, J PHARMACOL EXP THER, V241, P763; Ridker PM, 2008, NEW ENGL J MED, V359, P2195, DOI 10.1056/NEJMoa0807646; Schanen JG, 2005, THORAX, V60, P633, DOI 10.1136/thx.2004.026484; Soriano JB, 2005, CHEST, V128, P2099, DOI 10.1378/chest.128.4.2099; Spanbroek R, 2003, P NATL ACAD SCI USA, V100, P1238, DOI 10.1073/pnas.242716099; Tardif JC, 2010, CIRC-CARDIOVASC IMAG, V3, P298, DOI 10.1161/CIRCIMAGING.110.937169	25	78	84	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2012	129	3					702	U153		10.1016/j.jaci.2011.11.052	http://dx.doi.org/10.1016/j.jaci.2011.11.052			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	904IW	22244598	Bronze			2022-12-18	WOS:000301189300014
J	Castro, M; Fain, SB; Hoffman, EA; Gierada, DS; Erzurum, SC; Wenzel, S				Castro, Mario; Fain, Sean B.; Hoffman, Eric A.; Gierada, David S.; Erzurum, Serpil C.; Wenzel, Sally		Natl Heart Lung & Blood Inst Sever	Lung imaging in asthmatic patients: The picture is clearer	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; imaging; chest computed tomography; magnetic resonance imaging	AIRWAY WALL THICKNESS; HYPERPOLARIZED HE-3 MRI; POSITRON-EMISSION-TOMOGRAPHY; DYNAMIC COMPUTED-TOMOGRAPHY; PULMONARY-FUNCTION TESTS; BRAIN TRANSFER CONSTANTS; IN-VIVO ASSESSMENT; MAGNETIC-RESONANCE; MULTIDETECTOR CT; FLOW LIMITATION	Imaging of the lungs in patients with asthma has evolved dramatically over the last decade with sophisticated techniques, such as computed tomography, magnetic resonance imaging, positron emission tomography, and single photon emission computed tomography. New insights into current and future modalities for imaging in asthmatic patients and their application are discussed to potentially shed a clearer picture of the underlying pathophysiology of asthma, especially severe asthma, and the proposed clinical utility of imaging in patients with this common disease. (J Allergy Clin Immunol 2011;128:467-78.)	[Castro, Mario; Gierada, David S.] Washington Univ, Sch Med, Div Pulm & Crit Care Med, St Louis, MO 63110 USA; [Fain, Sean B.] Univ Wisconsin, Dept Med Phys, Madison, WI 53706 USA; [Hoffman, Eric A.] Univ Iowa, Coll Med, Iowa City, IA USA; [Erzurum, Serpil C.] Cleveland Clin Fdn, Cleveland, OH USA; [Wenzel, Sally] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA	Washington University (WUSTL); University of Wisconsin System; University of Wisconsin Madison; University of Iowa; Cleveland Clinic Foundation; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Castro, M (corresponding author), Washington Univ, Sch Med, Div Pulm & Crit Care Med, Campus Box 8052,660 S Euclid, St Louis, MO 63110 USA.	castrom@wustl.edu	Fain, Sean B./K-4260-2016	Fain, Sean B./0000-0001-5461-0646; Hoffman, Eric/0000-0001-8456-9437	National Institutes of Health/National Heart, Lung, and Blood Institute [HL69149, HL64368, HL69349, HL69170, HL-69155, HL69130, HL69167, HL69116, HL69174]; Hartwell Foundation; Asthmatx; Amgen; Ception; Genentech; MedImmune; Merck; Novartis; National Institutes of Health; GlaxoSmithKline; GE Healthcare; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000448] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024992] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL091762, R01HL064368, R01HL069167, R01HL069149, R01HL069155, R01HL069170, R01HL069349, R01HL069116, R01HL069174, R01HL069130] Funding Source: NIH RePORTER	National Institutes of Health/National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Hartwell Foundation; Asthmatx; Amgen(Amgen); Ception; Genentech(Roche HoldingGenentech); MedImmune(AstraZenecaMedimmune); Merck(Merck & Company); Novartis(Novartis); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); GlaxoSmithKline(GlaxoSmithKline); GE Healthcare(General ElectricGE Healthcare); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by National Institutes of Health/National Heart, Lung, and Blood Institute grants HL69149, HL64368, HL69349, HL69170, HL-69155, HL69130, HL69167, HL69116, and HL69174 and the Hartwell Foundation (S. B. F.).; Disclosure of potential conflict of interest: M. Castro is a consultant for Electrocore, NKIT, Schering-Plough, Asthmatx, and Cephalon; is on the advisory board and is a speaker for Genentech; is a speaker for AstraZeneca, Boehringer Ingelheim, Pfizer, Merck, and GlaxoSmithKline; has received royalties from Elsevier; and has received grants from Asthmatx, Amgen, Ception, Genentech, MedImmune, Merck, Novartis, the National Institutes of Health, and GlaxoSmithKline. S. B. Fain is a consultant for and has received research support from GE Healthcare. E. A. Hoffman is a consultant for Roche, Sanofi-Aventis, and Spiration and is a founder and shareholder of VIDA Diagnostics. S. C. Erzurum is owner of Asthmatx. The rest of the authors have declared that they have no conflict of interest.	Abdeen N, 2006, MAGN RESON MED, V56, P255, DOI 10.1002/mrm.20943; Alford SK, 2010, P NATL ACAD SCI USA, V107, P7485, DOI 10.1073/pnas.0913880107; ALJARAD N, 1992, BRIT J IND MED, V49, P73; Altes TA, 2001, J MAGN RESON IMAGING, V13, P378, DOI 10.1002/jmri.1054; Altes TA, 2007, P 15 M INT SOC MAGN, P1305; Altes Talissa A, 2003, Top Magn Reson Imaging, V14, P231, DOI 10.1097/00002142-200306000-00003; AMIRAV I, 1993, J APPL PHYSIOL, V75, P2239, DOI 10.1152/jappl.1993.75.5.2239; Aulak KS, 2001, P NATL ACAD SCI USA, V98, P12056, DOI 10.1073/pnas.221269198; Awadh N, 1998, THORAX, V53, P248, DOI 10.1136/thx.53.4.248; Aysola RS, 2008, CHEST, V134, P1183, DOI 10.1378/chest.07-2779; BALL WC, 1962, J CLIN INVEST, V41, P519, DOI 10.1172/JCI104505; Bartel SET, 2008, J APPL PHYSIOL, V104, P1495, DOI 10.1152/japplphysiol.01005.2007; BAST A, 1991, AM J MED, V91, pS2, DOI 10.1016/0002-9343(91)90278-6; Benayoun L, 2003, AM J RESP CRIT CARE, V167, P1360, DOI 10.1164/rccm.200209-1030OC; BERDINE GG, 1986, J APPL PHYSIOL, V61, P1388, DOI 10.1152/jappl.1986.61.4.1388; Biernacki W, 1997, EUR RESPIR J, V10, P2455, DOI 10.1183/09031936.97.10112455; BIERNACKI W, 1989, AM REV RESPIR DIS, V139, P1509, DOI 10.1164/ajrccm/139.6.1509; Boroto K, 2008, EUR J RADIOL, V68, P375, DOI 10.1016/j.ejrad.2008.08.016; BOUCHIAT MA, 1960, PHYS REV LETT, V5, P373, DOI 10.1103/PhysRevLett.5.373; BOULET LP, 1995, AM J RESP CRIT CARE, V152, P865, DOI 10.1164/ajrccm.152.3.7663797; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720, DOI 10.1164/ajrccm.161.5.9903102; BOYD DP, 1983, P IEEE, V71, P298, DOI 10.1109/PROC.1983.12588; BROWN RH, 1993, J APPL PHYSIOL, V74, P2615, DOI 10.1152/jappl.1993.74.6.2615; BROWN RH, 1991, AM REV RESPIR DIS, V144, P208, DOI 10.1164/ajrccm/144.1.208; Brown RH, 2006, J APPL PHYSIOL, V101, P30, DOI 10.1152/japplphysiol.01190.2005; BRUDIN LH, 1994, EUR J NUCL MED, V21, P297, DOI 10.1007/BF00947964; BUNOW B, 1979, J NUCL MED, V20, P703; Busacker A, 2009, CHEST, V135, P48, DOI 10.1378/chest.08-0049; CALHOUN WJ, 1992, AM REV RESPIR DIS, V145, P317, DOI 10.1164/ajrccm/145.2_Pt_1.317; Chae EJ, 2010, INVEST RADIOL, V45, P354, DOI 10.1097/RLI.0b013e3181dfdae0; Chen DL, 2006, MOL PHARMACEUT, V3, P488, DOI 10.1021/mp060050w; Chen DL, 2006, AM J RESP CRIT CARE, V173, P1363, DOI 10.1164/rccm.200506-934OC; Chen DL, 2004, AM J PHYSIOL-LUNG C, V286, pL834, DOI 10.1152/ajplung.00339.2003; Chon D, 2005, RESP PHYSIOL NEUROBI, V148, P65, DOI 10.1016/j.resp.2005.06.003; Chon D, 2007, J APPL PHYSIOL, V102, P1535, DOI 10.1152/japplphysiol.01235.2005; Chon D, 2006, J APPL PHYSIOL, V101, P1451, DOI 10.1152/japplphysiol.01131.2005; Christensen GE, 2001, INT J RADIAT ONCOL, V51, P227, DOI 10.1016/S0360-3016(01)01667-4; Comhair S, 2005, AM J PATHOL, V166, P664; Comhair SAA, 2000, LANCET, V355, P624, DOI 10.1016/S0140-6736(99)04736-4; Comhair SAA, 2001, FASEB J, V15, P70, DOI 10.1096/fj.00-0085com; Comhair SAA, 2010, ANTIOXID REDOX SIGN, V12, P93, DOI 10.1089/ARS.2008.2425; Cox G, 2009, AM J RESP CRIT CARE, V179; Coxson HO, 2008, AM J RESP CRIT CARE, V177, P1201, DOI 10.1164/rccm.200712-1776OC; Coxson HO, 2009, AM J RESP CRIT CARE, V180, P588, DOI 10.1164/rccm.200901-0159PP; de Gonzalez AB, 2009, ARCH INTERN MED, V169, P2071, DOI 10.1001/archinternmed.2009.440; de Jong PA, 2005, EUR RESPIR J, V26, P140, DOI 10.1183/09031936.05.00007105; de Lange EE, 2007, J ALLERGY CLIN IMMUN, V119, P1072, DOI 10.1016/j.jaci.2006.12.659; de Lange EE, 2006, CHEST, V130, P1055, DOI 10.1378/chest.130.4.1055; de Lange EE, 2009, RADIOLOGY, V250, P567, DOI 10.1148/radiol.2502080188; DeRaeve HR, 1997, AM J PHYSIOL-LUNG C, V272, pL148, DOI 10.1152/ajplung.1997.272.1.L148; Diaz S, 2008, J MAGN RESON IMAGING, V27, P763, DOI 10.1002/jmri.21212; Diaz S, 2009, EUR J RADIOL, V71, P257, DOI 10.1016/j.ejrad.2008.04.013; Diaz S, 2009, ACAD RADIOL, V16, P700, DOI 10.1016/j.acra.2008.12.017; Ding K, 2009, SPIE C LAK BUEN VIST; Ding K, 2008, 1 INT WORKSH PULM IM, P63; Dolovich Myrna B, 2007, Proc Am Thorac Soc, V4, P328, DOI 10.1513/pats.200611-173HT; Dregely I, 2010, AM J RESP CRIT CARE, V181; Dweik RA, 2001, P NATL ACAD SCI USA, V98, P2622, DOI 10.1073/pnas.051629498; Einstein AJ, 2007, JAMA-J AM MED ASSOC, V298, P317, DOI 10.1001/jama.298.3.317; Fain SB, 2005, ACAD RADIOL, V12, P1385, DOI 10.1016/j.acra.2005.08.005; Fain SB, 2008, ACAD RADIOL, V15, P753, DOI 10.1016/j.acra.2007.10.019; Fain SB, 2007, J MAGN RESON IMAGING, V25, P910, DOI 10.1002/jmri.20876; Fain SB, 2006, RADIOLOGY, V239, P875, DOI 10.1148/radiol.2393050111; FREDBERG JJ, 1984, J APPL PHYSIOL, V57, P788, DOI 10.1152/jappl.1984.57.3.788; Fuld M, 2007, AM THOR SOC ANN M SA; Gentile TR, 2000, MAGNET RESON MED, V43, P290, DOI 10.1002/(SICI)1522-2594(200002)43:2<290::AID-MRM17>3.0.CO;2-A; Ghosh S, 2006, J IMMUNOL, V176, P5587, DOI 10.4049/jimmunol.176.9.5587; Goris ML, 2003, CHEST, V123, P1655, DOI 10.1378/chest.123.5.1655; GOULD GA, 1993, EUR RESPIR J, V6, P698; GOULD GA, 1988, AM REV RESPIR DIS, V137, P380, DOI 10.1164/ajrccm/137.2.380; Gould KL, 1991, CORONARY ARTERY STEN; Grenier PA, 2002, EUR RADIOL, V12, P1022, DOI 10.1007/s00330-002-1342-1; GUR D, 1981, J COMPUT ASSIST TOMO, V5, P678, DOI 10.1097/00004728-198110000-00015; GUR D, 1979, J COMPUT ASSIST TOMO, V3, P749; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Harris RS, 2007, J APPL PHYSIOL, V102, P448, DOI 10.1152/japplphysiol.00763.2006; HARTLEY PG, 1994, J APPL PHYSIOL, V76, P271, DOI 10.1152/jappl.1994.76.1.271; Hoffman E, 1983, J APPL PHYSIOL, V59, P481; HOFFMAN EA, 1983, J APPL PHYSIOL, V54, P1414, DOI 10.1152/jappl.1983.54.5.1414; Hoffman Eric A, 2005, Proc Am Thorac Soc, V2, P492, DOI 10.1513/pats.200509-099DS; Holmes JH, 2008, MAGN RESON MED, V59, P1062, DOI 10.1002/mrm.21437; Holmnes JH, 2009, MAGN RESON MED, V62, P1543, DOI 10.1002/mrm.22150; Hoshino M, 2010, RESP MED, V104, P794, DOI 10.1016/j.rmed.2009.12.005; HUBMAYR RD, 1983, J APPL PHYSIOL, V54, P1048, DOI 10.1152/jappl.1983.54.4.1048; Hubmayr RD, 1996, J APPL PHYSIOL, V80, P522, DOI 10.1152/jappl.1996.80.2.522; JacquierSarlin MR, 1996, J NUCL MED, V37, P1413; JARJOUR NN, 1994, J LAB CLIN MED, V123, P131; JARJOUR NN, 1992, AM REV RESPIR DIS, V146, P905, DOI 10.1164/ajrccm/146.4.905; Jolliet Philippe, 2002, Respir Care Clin N Am, V8, P295, DOI 10.1016/S1078-5337(02)00010-2; Jones HA, 1997, EUR RESPIR J, V10, P795; Jones HA, 2003, EUR RESPIR J, V21, P567, DOI 10.1183/09031936.03.00048502; JONES RL, 1977, J APPL PHYSIOL, V42, P548, DOI 10.1152/jappl.1977.42.4.548; KALENDER WA, 1991, J COMPUT ASSIST TOMO, V15, P248, DOI 10.1097/00004728-199103000-00011; Kang MJ, 2010, RADIOGRAPHICS, V30, P685, DOI 10.1148/rg.303095101; Kasahara K, 2002, THORAX, V57, P242, DOI 10.1136/thorax.57.3.242; Kauczor HU, 1998, EUR RADIOL, V8, P820, DOI 10.1007/s003300050479; KINSELLA M, 1990, CHEST, V97, P315, DOI 10.1378/chest.97.2.315; KNUDSON RJ, 1991, CHEST, V99, P1357, DOI 10.1378/chest.99.6.1357; Lee EY, 2009, J THORAC IMAG, V24, P110, DOI 10.1097/RTI.0b013e3181909f4a; Lemanske RF, 2010, J ALLERGY CLIN IMMUN, V125, pS95, DOI 10.1016/j.jaci.2009.10.047; Little SA, 2002, THORAX, V57, P247, DOI 10.1136/thorax.57.3.247; Lodi U, 1997, CHEST, V111, P65, DOI 10.1378/chest.111.1.65; Lutey BA, 2008, RADIOLOGY, V248, P655, DOI 10.1148/radiol.2482071838; MacDonald A, 1978, PHYSL ASPECTS ANESTH; MacNee W, 2001, EUR J PHARMACOL, V429, P195, DOI 10.1016/S0014-2999(01)01320-6; Mansson S, 2003, MAGNET RESON MED, V50, P1170, DOI 10.1002/mrm.10649; Marcucci C, 2001, J APPL PHYSIOL, V90, P421, DOI 10.1152/jappl.2001.90.2.421; Matsumoto H, 2005, THORAX, V60, P277, DOI 10.1136/thx.2004.028936; Mayo John R, 2008, Proc Am Thorac Soc, V5, P934, DOI 10.1513/pats.200808-079QC; MILLAR AB, 1986, THORAX, V41, P932, DOI 10.1136/thx.41.12.932; Mitsunobu F, 2003, EUR RESPIR J, V22, P106, DOI 10.1183/09031936.03.00081702; Montaudon M, 2009, RADIOLOGY, V253, P844, DOI 10.1148/radiol.2533090303; Moore WC, 2007, J ALLERGY CLIN IMMUN, V119, P405, DOI 10.1016/j.jaci.2006.11.639; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; Mugler JP, 2010, P NATL ACAD SCI USA, V107, P21707, DOI 10.1073/pnas.1011912107; MULLER NL, 1988, CHEST, V94, P782, DOI 10.1378/chest.94.4.782; Musch G, 2007, ANESTHESIOLOGY, V106, P723, DOI 10.1097/01.anes.0000264748.86145.ac; Nakano Y, 2005, AM J RESP CRIT CARE, V171, P142, DOI 10.1164/rccm.200407-874OC; NEWMAN KB, 1994, CHEST, V106, P105, DOI 10.1378/chest.106.1.105; Niimi A, 2000, AM J RESP CRIT CARE, V162, P1518, DOI 10.1164/ajrccm.162.4.9909044; Niimi A, 2003, AM J RESP CRIT CARE, V168, P983, DOI 10.1164/rccm.200211-1268OC; Niimi A, 2004, AM J MED, V116, P725, DOI 10.1016/j.amjmed.2003.11.026; Paganin F, 1996, AM J RESP CRIT CARE, V153, P110, DOI 10.1164/ajrccm.153.1.8542102; Park EA, 2010, RADIOLOGY, V256, P985, DOI 10.1148/radiol.10091502; PATLAK CS, 1985, J CEREBR BLOOD F MET, V5, P584, DOI 10.1038/jcbfm.1985.87; PATLAK CS, 1983, J CEREBR BLOOD F MET, V3, P1, DOI 10.1038/jcbfm.1983.1; Peterson ET, 2010, AM J RESP CRIT CARE, V181; Pontana F, 2008, J THORAC IMAG, V25, P100; POSTMA DS, 1988, AM REV RESPIR DIS, V137, P57, DOI 10.1164/ajrccm/137.1.57; Rahman I, 2000, EUR RESPIR J, V16, P534, DOI 10.1034/j.1399-3003.2000.016003534.x; Rennen HJJM, 2001, EUR J NUCL MED, V28, P241, DOI 10.1007/s002590000447; RIENMULLER RK, 1991, J COMPUT ASSIST TOMO, V15, P742, DOI 10.1097/00004728-199109000-00003; Ritman EL, 1985, IMAGING PHYSL FUNCTI; Robertson HT, 1997, J APPL PHYSIOL, V82, P943, DOI 10.1152/jappl.1997.82.3.943; Ruppert K, 2004, MAGNET RESON MED, V51, P676, DOI 10.1002/mrm.10736; Ruset IC, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.053002; Saam BT, 2000, MAGN RESON MED, V44, P174, DOI 10.1002/1522-2594(200008)44:2<174::AID-MRM2>3.0.CO;2-4; SAITO T, 1990, IEEE T BIO-MED ENG, V37, P768, DOI 10.1109/10.102792; Saito Y, 1998, MED REV, V98, P1; Saleh D, 1998, FASEB J, V12, P929, DOI 10.1096/fasebj.12.11.929; Salerno M, 2002, RADIOLOGY, V222, P252, DOI 10.1148/radiol.2221001834; Samee S, 2003, J ALLERGY CLIN IMMUN, V111, P1205, DOI 10.1067/mai.2003.1544; SANDERS C, 1988, INVEST RADIOL, V23, P262, DOI 10.1097/00004424-198804000-00004; Schroeder T, 2008, ACAD RADIOL, V15, P763, DOI 10.1016/j.acra.2007.12.016; Schroeder T, 2007, J NUCL MED, V48, P413; SEDGWICK JB, 1992, J IMMUNOL, V149, P3710; Shaw TJ, 2004, EUR RESPIR J, V23, P813, DOI 10.1183/09031936.04.00119904; SHIH WJ, 1993, CLIN NUCL MED, V18, P227, DOI 10.1097/00003072-199303000-00010; Shimizu K, 2010, RESP MED, V104, P1809, DOI 10.1016/j.rmed.2010.06.013; Simon BA, 1998, J APPL PHYSIOL, V84, P709, DOI 10.1152/jappl.1998.84.2.709; Hoffman Eric A, 2006, Proc Am Thorac Soc, V3, P519, DOI 10.1513/pats.200603-086MS; Smith-Bindman R, 2009, ARCH INTERN MED, V169, P2078, DOI 10.1001/archinternmed.2009.427; Soja J, 2009, CHEST, V136, P797, DOI 10.1378/chest.08-2759; STERN EJ, 1994, AM J ROENTGENOL, V162, P555, DOI 10.2214/ajr.162.3.8109495; Stoel Berend C, 2008, Proc Am Thorac Soc, V5, P919, DOI 10.1513/pats.200804-040QC; Stoel Berend C, 2008, Proc Am Thorac Soc, V5, P929, DOI 10.1513/pats.200804-039QC; SUGA K, 1994, J NUCL MED, V35, P1520; Tajik JK, 2002, ACAD RADIOL, V9, P130, DOI 10.1016/S1076-6332(03)80163-0; Taylor IK, 1996, LANCET, V347, P937, DOI 10.1016/S0140-6736(96)91416-6; Tgavalekos NT, 2007, EUR RESPIR J, V29, P1174, DOI 10.1183/09031936.00113606; Tgavalekos NT, 2005, J APPL PHYSIOL, V99, P2388, DOI 10.1152/japplphysiol.00391.2005; Thakur Mathew, 2006, AJR Am J Roentgenol, V186, P297, DOI 10.2214/AJR.06.5020; Tschirren J, 2005, IEEE T MED IMAGING, V24, P1529, DOI 10.1109/TMI.2005.857654; Tschirren J, 2005, IEEE T MED IMAGING, V24, P1540, DOI 10.1109/TMI.2005.857653; Tschirren J, 2005, P AM THORAC SOC, V2, P503, DOI DOI 10.1513/PATS.200507-078DS; Tschirren Juerg, 2005, Proc Am Thorac Soc, V2, P484, DOI 10.1513/pats.200507-078DS; Tunon-de-Lara JM, 2007, J ALLERGY CLIN IMMUN, V119, P583, DOI 10.1016/j.jaci.2006.11.005; Tzeng YS, 2009, J APPL PHYSIOL, V106, P813, DOI 10.1152/japplphysiol.01133.2007; Ueda T, 2006, J ALLERGY CLIN IMMUN, V118, P1019, DOI 10.1016/j.jaci.2006.07.032; van Beek EJR, 2009, EUR RESPIR J, V34, P1311, DOI 10.1183/09031936.00138508; VANDERMARK TW, 1984, J NUCL MED, V25, P1175; VENEGAS JG, 1988, J APPL PHYSIOL, V64, P2108, DOI 10.1152/jappl.1988.64.5.2108; VOCK P, 1986, CLIN RADIOL, V37, P459, DOI 10.1016/S0009-9260(86)80054-X; Walker TG, 1997, REV MOD PHYS, V69, P629, DOI 10.1103/RevModPhys.69.629; Wang CB, 2008, J MAGN RESON IMAGING, V28, P80, DOI 10.1002/jmri.21408; WANG G, 1993, IEEE T MED IMAGING, V12, P486, DOI 10.1109/42.241876; WATANUKI Y, 1994, CHEST, V106, P806, DOI 10.1378/chest.106.3.806; WOLFKIEL CJ, 1992, INVEST RADIOL, V27, P211, DOI 10.1097/00004424-199203000-00006; WOLLMER P, 1986, CHEST, V90, P387, DOI 10.1378/chest.90.3.387; Won C, 2003, J APPL PHYSIOL, V94, P2483, DOI 10.1152/japplphysiol.00688.2002; WOOD SA, 1993, P SOC PHOTO-OPT INS, V1905, P316, DOI 10.1117/12.148644; WOOD SA, 1995, J APPL PHYSIOL, V79, P1687, DOI 10.1152/jappl.1995.79.5.1687; Woodhouse N, 2005, J MAGN RESON IMAGING, V21, P365, DOI 10.1002/jmri.20290; Xiu Y, 2005, CLIN NUCL MED, V30, P193, DOI 10.1097/00003072-200503000-00013; Yablonskiy DA, 2002, P NATL ACAD SCI USA, V99, P3111, DOI 10.1073/pnas.052594699; Zeidler MR, 2006, J ALLERGY CLIN IMMUN, V118, P1075, DOI 10.1016/j.jaci.2006.06.042; Zeidler MR, 2006, EUR RESPIR J, V27, P307, DOI 10.1183/09031936.06.00005605; Zerhouni E A, 1993, J Thorac Imaging, V8, P265, DOI 10.1097/00005382-199323000-00002; Zheng LM, 2004, J CLIN INVEST, V114, P529, DOI 10.1172/JCI200421109	189	78	78	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2011	128	3					467	478		10.1016/j.jaci.2011.04.051	http://dx.doi.org/10.1016/j.jaci.2011.04.051			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	812HS	21636118	Green Accepted			2022-12-18	WOS:000294283400004
J	Roufosse, F; de Lavareille, A; Schandene, L; Cogan, E; Georgelas, A; Wagner, L; Xi, LQ; Raffeld, M; Goldman, M; Gleich, GJ; Klion, A				Roufosse, Florence; de Lavareille, Aurore; Schandene, Liliane; Cogan, Elie; Georgelas, Ann; Wagner, Lori; Xi, Liqiang; Raffeld, Mark; Goldman, Michel; Gleich, Gerald J.; Klion, Amy			Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CD3(-)CD4(+); lymphocytic variant HES; clonal T-cell; TARC; IL-5; mepolizumab	ACTIVATION-REGULATED CHEMOKINE; T-CELLS; IDIOPATHIC EOSINOPHILIA; DISEASE-ACTIVITY; SERUM THYMUS; INTERLEUKIN-5; TARC/CCL17; EXPRESSION; LEVEL; TARC	Background: Mepolizumab, a monoclonal anti-IL-5 antibody, is an effective corticosteroid-sparing agent for patients with Fip1-like 1/platelet-derived growth factor receptor a fusion (F/P)-negative hypereosinophilic syndrome (HES). Lymphocytic variant hypereosinophilic syndrome (L-HES) is characterized by marked overproduction of IL-5 by dysregulated T cells. Objective: To determine whether patients with L-HES respond to mepolizumab in terms of corticosteroid tapering and eosinophil depletion to the same extent as corticosteroid-responsive F/P-negative patients with HES and a normal T-cell profile. Methods: Patients enrolled in the mepolizumab trial were evaluated for L-HES on the basis of T-cell phenotyping and T-cell receptor gene rearrangement patterns, and their serum thymus-and-activation-regulated chemokine (TARC) levels were measured. Response to treatment was compared in patient subgroups based on results of these analyses. Results: Lymphocytic variant HES was diagnosed in 13 of 63 patients with HES with complete T-cell assessments. The ability to taper corticosteroids on mepolizumab was similar in patients with L-HES and those with a normal T-cell profile, although a lower proportion of patients with L-HES maintained eosinophil levels below 600/mu L. Increased serum TARC levels (> 1000 pg/mL) had no significant impact on the ability to reduce corticosteroid doses, but a lower proportion of patients with elevated TARC achieved eosinophil control on mepolizumab. Conclusion: Mepolizumab is an effective corticosteroid-sparing agent for patients with L-HES. In some cases however, eosinophil levels remain above 600/mL, suggesting incomplete neutralization of overproduced IL-5 or involvement of other eosinophilopoietic factors. (J Allergy Clin Immunol 2010;126:828-35.)	[Roufosse, Florence; Cogan, Elie] Univ Libre Bruxelles, Erasme Hosp, Dept Internal Med, B-1070 Brussels, Belgium; [de Lavareille, Aurore; Schandene, Liliane] Univ Libre Bruxelles, Erasme Hosp, Immunol Lab, B-1070 Brussels, Belgium; [Roufosse, Florence; Goldman, Michel] Univ Libre Bruxelles, Inst Med Immunol, Gosselies, Belgium; [Georgelas, Ann; Wagner, Lori; Gleich, Gerald J.] Univ Utah, Dept Dermatol, Salt Lake City, UT USA; [Gleich, Gerald J.] Univ Utah, Dept Med & Pediat, Salt Lake City, UT USA; [Xi, Liqiang; Raffeld, Mark] NCI, Pathol Lab, Bethesda, MD 20892 USA; [Klion, Amy] NIAID, Parasit Dis Lab, NIH, Bethesda, MD 20892 USA	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Universite Libre de Bruxelles; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Roufosse, F (corresponding author), Univ Libre Bruxelles, Erasme Hosp, Dept Internal Med, 808 Route Lennik, B-1070 Brussels, Belgium.	froufoss@ulb.ac.be		Klion, Amy/0000-0002-4986-5326; Cogan, Elie/0000-0003-2890-766X	Belgian National Fund for Scientific Research (FNRS) [3.4.582.05.4, 7.4.573.08]; David and Alice Van Buuren Foundation (Universite Libre de Bruxelles); National Institutes of Health; National Cancer Institute [AI-061097]; National Institute of Allergy and Infectious Diseases; GlaxoSmithKline; NATIONAL CANCER INSTITUTE [ZICBC011079] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001130, R01AI061097] Funding Source: NIH RePORTER	Belgian National Fund for Scientific Research (FNRS)(Fonds de la Recherche Scientifique - FNRS); David and Alice Van Buuren Foundation (Universite Libre de Bruxelles); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); GlaxoSmithKline(GlaxoSmithKline); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	GlaxoSmithKline purchased the mAbs for flow cytometry and sponsored the MHE100185 clinical trial (Clinicaltrials.gov identifier: NCT00086658) through which patients were recruited for the current study. This study was supported by the Belgian National Fund for Scientific Research (FNRS) through FRSM grant 3.4.582.05.4 and Televie grant 7.4.573.08. F and received funding from the David and Alice Van Buuren Foundation (Universite Libre de Bruxelles). This work was supported, in part, by the Intramural Research Program of the National Institutes of Health, National Institute of Allergy and Infectious Diseases and National Cancer Institute, and work at the University of Utah was supported through National Institutes of Health grant AI-061097.; Disclosure of potential conflict of interest: F. Roufosse, L. Schandene, and A. Georgelas have received research support from GlaxoSmithKline. G. J. Gleich is an equity holder of Ception Therapeutics and has received research support from GlaxoSmithKline. The rest of the authors have declared that they have no conflict of interest.	CHUSID MJ, 1975, MEDICINE, V54, P1, DOI 10.1097/00005792-197501000-00001; COGAN E, 1994, NEW ENGL J MED, V330, P535, DOI 10.1056/NEJM199402243300804; de Lavareille A, 2002, J ALLERGY CLIN IMMUN, V110, P476, DOI 10.1067/mai.2002.127003; FAUCI AS, 1982, ANN INTERN MED, V97, P78, DOI 10.7326/0003-4819-97-1-78; Galimberti S, 2007, CLIN EXP RHEUMATOL, V25, P17; Greiner TC, 2002, J MOL DIAGN, V4, P137, DOI 10.1016/S1525-1578(10)60694-0; Helbig G, 2009, HAEMATOL-HEMATOL J, V94, P1236, DOI 10.3324/haematol.2008.005447; Kakinuma T, 2003, J AM ACAD DERMATOL, V48, P23, DOI 10.1067/mjd.2003.132; Kakinuma T, 2003, BRIT J DERMATOL, V148, P203, DOI 10.1046/j.1365-2133.2003.05066.x; Kakinuma T, 2001, J ALLERGY CLIN IMMUN, V107, P535, DOI 10.1067/mai.2001.113237; Klion A, 2009, ANNU REV MED, V60, P293, DOI 10.1146/annurev.med.60.062107.090340; Ogbogu PU, 2009, J ALLERGY CLIN IMMUN, V124, P1319, DOI 10.1016/j.jaci.2009.09.022; Rothenberg ME, 2008, NEW ENGL J MED, V358, P1215, DOI 10.1056/NEJMoa070812; Roufosse F, 2007, IMMUNOL ALLERGY CLIN, V27, P389, DOI 10.1016/j.iac.2007.07.002; Schandene L, 1996, J CLIN INVEST, V97, P309, DOI 10.1172/JCI118417; Sekiya T, 2002, ALLERGY, V57, P173, DOI 10.1034/j.1398-9995.2002.1s3256.x; Simon HU, 1999, NEW ENGL J MED, V341, P1112, DOI 10.1056/NEJM199910073411503; Simon HU, 1996, J EXP MED, V183, P1071, DOI 10.1084/jem.183.3.1071; Stein ML, 2008, J ALLERGY CLIN IMMUN, V121, P1473, DOI 10.1016/j.jaci.2008.02.033; Vaklavas C, 2007, LEUKEMIA RES, V31, P691, DOI 10.1016/j.leukres.2006.10.005; Wirnsberger G, 2006, EUR J IMMUNOL, V36, P1882, DOI 10.1002/eji.200635972; Yagi H, 1997, BRIT J DERMATOL, V136, P918, DOI 10.1111/j.1365-2133.1997.tb03934.x	22	78	80	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2010	126	4					828	U240		10.1016/j.jaci.2010.06.049	http://dx.doi.org/10.1016/j.jaci.2010.06.049			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	658SP	20810155	Green Accepted			2022-12-18	WOS:000282510000022
J	Vinh, DC; Sugui, JA; Hsu, AP; Freeman, AF; Holland, SM				Vinh, Donald C.; Sugui, Janyce A.; Hsu, Amy P.; Freeman, Alexandra F.; Holland, Steven M.			Invasive fungal disease in autosomal-dominant hyper-IgE syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							INFECTION; STAT3; EPITHELIUM; MUTATIONS		[Vinh, Donald C.; Hsu, Amy P.; Freeman, Alexandra F.; Holland, Steven M.] NIAID, Immunopathogenesis Sect, Lab Clin Infect Dis, NIH, Bethesda, MD 20892 USA; [Sugui, Janyce A.] NIAID, Mol Microbiol Sect, Lab Clin Infect Dis, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Vinh, DC (corresponding author), NIAID, Immunopathogenesis Sect, Lab Clin Infect Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.	vinhd@niaid.nih.gov		VINH, DONALD/0000-0003-1347-7767	CIHR Funding Source: Medline; Intramural NIH HHS [Z99 AI999999] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000646] Funding Source: NIH RePORTER	CIHR(Canadian Institutes of Health Research (CIHR)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		De Pauw B, 2008, CLIN INFECT DIS, V46, P1813, DOI 10.1086/588660; Freeman AF, 2007, J ALLERGY CLIN IMMUN, V119, P1234, DOI 10.1016/j.jaci.2006.12.666; Holland SM, 2007, NEW ENGL J MED, V357, P1608, DOI 10.1056/NEJMoa073687; JACOBS DH, 1984, GASTROENTEROLOGY, V87, P201; Kida H, 2008, AM J PATHOL, V172, P1542, DOI 10.2353/ajpath.2008.071052; Matsuzaki Y, 2006, J IMMUNOL, V177, P527, DOI 10.4049/jimmunol.177.1.527; Minegishi Y, 2007, NATURE, V448, P1058, DOI 10.1038/nature06096; Minegishi Y, 2009, J EXP MED, V206, P1291, DOI 10.1084/jem.20082767; Zarember KA, 2007, J IMMUNOL, V178, P6367, DOI 10.4049/jimmunol.178.10.6367	9	78	81	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2010	125	6					1389	1390		10.1016/j.jaci.2010.01.047	http://dx.doi.org/10.1016/j.jaci.2010.01.047			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	611PH	20392475	Green Accepted			2022-12-18	WOS:000278831000030
J	Basu, K; Palmer, CNA; Tavendale, R; Lipworth, BJ; Mukhopadhyay, S				Basu, Kaninika; Palmer, Colin N. A.; Tavendale, Roger; Lipworth, Brian J.; Mukhopadhyay, Somnath			Adrenergic beta(2)-receptor genotype predisposes to exacerbations in steroid-treated asthmatic patients taking frequent albuterol or salmeterol	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; child; polymorphism; asthma exacerbations; albuterol; salmeterol; beta(2)-adrenoceptor; adrenergic beta(2)-receptor agonist gene	FILAGGRIN NULL MUTATIONS; EARLY-CHILDHOOD; LUNG-FUNCTION; BETA(2)-ADRENERGIC RECEPTOR; BETA(2)-AGONIST THERAPY; CHILDREN; POLYMORPHISMS; BRONCHIOLITIS; EXPRESSION; PREVENTION	Background: On-demand inhaled albuterol is commonly prescribed worldwide. We have shown that the Arg16 allele of the adrenergic beta(2)-receptor agonist gene (ADRB2) predisposes to exacerbations in young asthmatic patients taking regular salmeterol. Objective: We have now extended our previous population by 636 patients and explored the role of the Arg16 allele on asthma exacerbations in the context of the use of on-demand albuterol and regular salmeterol. Methods: Arg/Gly status at position 16 of ADRB2 was assessed in 1182 young asthmatic patients (age, 3-22 years) from Scotland. Asthma exacerbations, use of beta-agonists and other medications over the previous 6 months, and lung function were also studied. Results: An increased risk of exacerbations per copy of he Arg16 allele was observed in asthmatic patients, regardless of treatment regimen (odds ratio [OR], 1.30; 95% CI, 1.09-1.55; P = .003). This appears to be largely due to exposure to beta(2)-agonists because the risk of exacerbations observed in patients with the Arg16 allele was only observed in those receiving daily inhaled long- or short-acting beta(2)-agonist treatment (OR, 1.64; 95% CI, 1.22-2.20; P =.001). In contrast, there was no genotypic risk for exacerbations in patients using inhaled beta(2)-agonists less than once a day (OR, 1.08; 95% CI, 0.85-1.36; P =.525). The Arg16 genotype-associated risk for exacerbations was significantly different in those exposed to beta(2)-agonists daily versus those that were not (test for interaction, P =.022). Conclusion: The Arg16 genotype of ADRB2 is associated with exacerbations in asthmatic children and young adults exposed daily to beta(2)-agonists, regardless of whether the exposure is to albuterol or long-acting agonists, such as salmeterol. (J Allergy Clin Immunol 2009;124:1188-94.)	[Basu, Kaninika; Mukhopadhyay, Somnath] Royal Alexandra Childrens Hosp, Brighton BN2 5BE, E Sussex, England; [Basu, Kaninika; Mukhopadhyay, Somnath] Sussex Med Sch, Brighton, E Sussex, England; [Basu, Kaninika; Mukhopadhyay, Somnath] Univ Dundee, Ninewells Hosp & Med Sch, Tayside Inst Child Hlth, Dundee DD1 9SY, Scotland; [Palmer, Colin N. A.; Tavendale, Roger] Univ Dundee, Ninewells Hosp & Med Sch, Populat Pharmacogenet Grp, Biomed Res Inst, Dundee DD1 9SY, Scotland; [Lipworth, Brian J.] Univ Dundee, Ninewells Hosp & Med Sch, Div Med & Therapeut, Asthma & Allergy Res Grp, Dundee DD1 9SY, Scotland	University of Brighton; University of Brighton; University of Dundee; University of Dundee; University of Dundee	Mukhopadhyay, S (corresponding author), Royal Alexandra Childrens Hosp, Brighton BN2 5BE, E Sussex, England.	s.mukhopadhyay@bsms.ac.uk	Palmer, Colin NA/C-7053-2008	Palmer, Colin NA/0000-0002-6415-6560	Gannochy Trust (Perth, Scotland); Scottish Enterprises Tayside; Perth and Kinross Council; Scottish Executive Genetic Health Initiative Award; Merck Sharpe Dohme; Neolab	Gannochy Trust (Perth, Scotland); Scottish Enterprises Tayside; Perth and Kinross Council; Scottish Executive Genetic Health Initiative Award; Merck Sharpe Dohme(Merck & Company); Neolab	Support for the study, was approved by the Gannochy Trust (Perth, Scotland), Scottish Enterprises Tayside, and the Perth and Kinross Council. C. N. A. P. is supported by the Scottish Executive Genetic Health Initiative Award.; Disclosure of potential conflict of interest: B. J. Lipworth has provided consulting advice regarding the fluticasone/formoterol combination for Mundipharma, provided a speakers' bureau talk on budesomide formoterol for AstraZeneca and a speakers' bureau talk on heterogeneity in asthma and airway remodeling for Merck. has received research support from Merck Sharpe & Dohme and Neolab, and has provided legal consultation on formoterol equivalence for TEVA. S. Mukhopadhyay has served as an expert advisor for and received research support from Merck Sharpe & Dohme. The rest of the authors have declared that they have no conflict of interest.	British Thoracic Society Scottish Intercollegiate Guidelines Network, 2008, Thorax, V63 Suppl 4, piv1, DOI 10.1136/thx.2008.097741; Basu K, 2008, ALLERGY, V63, P1211, DOI 10.1111/j.1398-9995.2008.01660.x; Bateman ED, 2008, EUR RESPIR J, V31, P143, DOI 10.1183/09031936.00138707; Bieche I, 1998, INT J CANCER, V78, P661, DOI 10.1002/(SICI)1097-0215(19981123)78:5<661::AID-IJC22>3.3.CO;2-9; Bleecker ER, 2007, LANCET, V370, P2118, DOI 10.1016/S0140-6736(07)61906-0; Currie GP, 2003, AM J RESP CRIT CARE, V167, P1232, DOI 10.1164/rccm.200209-1116OC; DAWSON KP, 1992, J PAEDIATR CHILD H, V28, P321, DOI 10.1111/j.1440-1754.1992.tb02677.x; Deen JL, 1999, B WORLD HEALTH ORGAN, V77, P518; Drysdale CM, 2000, P NATL ACAD SCI USA, V97, P10483, DOI 10.1073/pnas.97.19.10483; Flores G, 2005, PEDIATRICS, V116, P957, DOI 10.1542/peds.2005-0712; Fuhlbrigge AL, 2002, AM J RESP CRIT CARE, V166, P1044, DOI 10.1164/rccm.2107057; Hall IP, 2006, LANCET, V368, P771, DOI 10.1016/S0140-6736(06)69287-8; Hancox RJ, 1998, EUR RESPIR J, V11, P589; Holgate ST, 2005, AM J RESP CRIT CARE, V172, P941, DOI 10.1164/rccm.2507007; Hyvarinen M, 2005, ACTA PAEDIATR, V94, P1378, DOI 10.1080/08035250510036831; Israel E, 2004, LANCET, V364, P1505, DOI 10.1016/S0140-6736(04)17273-5; Israel E, 2000, AM J RESP CRIT CARE, V162, P75, DOI 10.1164/ajrccm.162.1.9907092; Jindal S K, 2005, Indian J Chest Dis Allied Sci, V47, P309; Korppi M, 1996, ACTA PAEDIATR, V85, P190, DOI 10.1111/j.1651-2227.1996.tb13990.x; KORPPI M, 1994, ARCH PEDIAT ADOL MED, V148, P1079, DOI 10.1001/archpedi.1994.02170100077015; Kotaniemi-Syrjanen A, 2002, PEDIAT ALLERG IMM-UK, V13, P418, DOI 10.1034/j.1399-3038.2002.02091.x; Lee DKC, 2003, BRIT J CLIN PHARMACO, V56, P494, DOI 10.1046/j.1365-2125.2003.01887.x; Martinez FD, 1997, J CLIN INVEST, V100, P3184, DOI 10.1172/JCI119874; Milton B, 2004, CHILD CARE HLTH DEV, V30, P711, DOI 10.1111/j.1365-2214.2004.00486.x; Mitra AD, 2002, ACTA PAEDIATR, V91, P789, DOI 10.1080/08035250213230; National Institutes of Health, 2002, GLOB STRAT ASTHM MAN; OCONNOR BJ, 1992, NEW ENGL J MED, V327, P1204, DOI 10.1056/NEJM199210223271704; Palmer CNA, 2007, CLIN PHARMACOL THER, V81, P713, DOI 10.1038/sj.clpt.6100119; Palmer CNA, 2006, THORAX, V61, P940, DOI 10.1136/thx.2006.059386; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Palmer CNA, 2007, J ALLERGY CLIN IMMUN, V120, P64, DOI 10.1016/j.jaci.2007.04.001; Palmer CNA, 2006, PEDIATRICS, V118, P710, DOI 10.1542/peds.2005-3030; Piippo-Savolainen E, 2008, ACTA PAEDIATR, V97, P5, DOI 10.1111/j.1651-2227.2007.00558.x; Piippo-Savolainen E, 2006, ALLERGY ASTHMA PROC, V27, P341, DOI 10.2500/aap.2006.27.2912; Stein RT, 1999, AM J EPIDEMIOL, V149, P1030; Tavendale R, 2008, J ALLERGY CLIN IMMUN, V121, P860, DOI 10.1016/j.jaci.2008.01.015; Taylor DA, 1997, AM J RESP CRIT CARE, V156, P1731, DOI 10.1164/ajrccm.156.6.9703047; Taylor DR, 2000, THORAX, V55, P762, DOI 10.1136/thorax.55.9.762; Wechsler ME, 2006, AM J RESP CRIT CARE, V173, P519, DOI 10.1164/rccm.200509-1519OC; [No title captured]	40	78	81	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2009	124	6					1188	1194		10.1016/j.jaci.2009.07.043	http://dx.doi.org/10.1016/j.jaci.2009.07.043			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	536VH	19800676				2022-12-18	WOS:000273071500007
J	Bossi, F; Fischetti, F; Regoli, D; Durigutto, P; Frossi, B; Gobeil, F; Ghebrehiwet, B; Peerschke, EI; Cicardi, M; Tedesco, F				Bossi, Fleur; Fischetti, Fabio; Regoli, Domenico; Durigutto, Paolo; Frossi, Barbara; Gobeil, Fernand, Jr.; Ghebrehiwet, Berhane; Peerschke, Ellinor I.; Cicardi, Marco; Tedesco, Francesco			Novel pathogenic mechanism and therapeutic approaches to angioedema associated with C1 inhibitor deficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Angioedema; C1 inhibitor; complement; endothelial cells; vascular leakage; B1R; B2R; gC1QR; bradykinin; leakage assay	TERMINAL COMPLEMENT COMPLEX; MOLECULAR-WEIGHT KININOGEN; HEREDITARY ANGIOEDEMA; ENDOTHELIAL-CELLS; BINDING-PROTEIN; BRADYKININ RECEPTOR; EXPRESSION CLONING; GLOBULAR HEADS; MAST-CELLS; FACTOR-XII	Background: Activation of bradykinin-mediated B2 receptor has been shown to play an important role in the onset of angioedema associated with C1 inhibitor deficiency. This finding has led to the development of novel therapeutic drugs such as the B2 receptor antagonist icatibant. However, it is unclear whether other receptors expressed on endothelial cells contribute to the release of kinins and vascular leakage in these patients. The recognition of their role may have obvious therapeutic implications. Objective: Our aim was to investigate the involvement of B1 and gC1q receptors in in vitro and in vivo models of vascular leakage induced by plasma samples obtained from patients with C1 inhibitor deficiency. Methods: The vascular leakage was evaluated in vitro on endothelial cells by a transwell model system and in vivo on rat mesentery microvessels by intravital microscopy. Results: We observed that the attack phase plasma from C1 inhibitor-deficient patients caused a delayed fluorescein-labeled albumin leakage as opposed to the rapid effect of bradykinin, whereas remission plasma elicited a modest effect compared with control plasma. The plasma permeabilizing effect was prevented by blocking the gC1q receptor-high-molecular-weight kininogen interaction, was partially inhibited by B2 receptor or B1 receptor antagonists, and was totally prevented by the mixture of the 2 antagonists. Involvement of B1 receptor was supported by the finding that albumin leakage caused by attack phase plasma was enhanced by IL-1 beta and was markedly reduced by brefeldin A. Conclusion: Our data suggest that both B1 receptor and gC1q receptor are involved in the vascular leakage induced by hereditary and acquired angioedema plasma. (J Allergy Clin Immunol 2009;124:1303-10.)	[Bossi, Fleur; Durigutto, Paolo; Tedesco, Francesco] Univ Trieste, Dept Life Sci, I-34127 Trieste, Italy; [Fischetti, Fabio] Univ Trieste, Dept Med & Neurosci, I-34127 Trieste, Italy; [Regoli, Domenico] Univ Ferrara, Dept Expt & Clin Med, I-44100 Ferrara, Italy; [Frossi, Barbara] Univ Udine, Dept Biomed Sci & Technol, I-33100 Udine, Italy; [Gobeil, Fernand, Jr.] Univ Sherbrooke, Dept Pharmacol, Sherbrooke, PQ J1K 2R1, Canada; [Ghebrehiwet, Berhane] SUNY Stony Brook, Dept Med, Stony Brook, NY 11794 USA; [Peerschke, Ellinor I.] Mt Sinai Sch Med, Dept Pathol, Ctr Clin Labs, Mt Sinai, NY USA; [Cicardi, Marco] Univ Milan, Dept Internal Med, Milan, Italy	University of Trieste; University of Trieste; University of Ferrara; University of Udine; University of Sherbrooke; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Icahn School of Medicine at Mount Sinai; University of Milan	Tedesco, F (corresponding author), Univ Trieste, Dept Life Sci, Via Valerio 28, I-34127 Trieste, Italy.	tedesco@units.it	Tedesco, Francesco/F-1929-2011; Frossi, Barbara/AFL-0800-2022; cicardi, marco/K-9219-2016	Frossi, Barbara/0000-0001-9855-2396; cicardi, marco/0000-0003-1251-225X; Durigutto, Paolo/0000-0003-3862-4970	Ministero dell'Istruzione, Universita e Ricerca; National Institutes of Health [AI 060866, HL5029101]; Telathon Italy [GGP08223]; Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050291] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI060866] Funding Source: NIH RePORTER	Ministero dell'Istruzione, Universita e Ricerca(Ministry of Education, Universities and Research (MIUR)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Telathon Italy(Fondazione Telethon); Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by grants front Ministero dell'Istruzione, Universita e Ricerca (Programmi di ricerca di Rilevante Interesse Nazionale 2007) and Associazione Italiana Ricerca sul Cancro to F.T., from the National Institutes of Health to B.G. (grant no. AI 060866) and E.I.P. (grant no. HL5029101), and from Telathon Italy (grant no. GGP08223) to M.C.	Agostoni A, 2004, J ALLERGY CLIN IMMUN, V114, pS51, DOI 10.1016/j.jaci.2004.06.047; Bork K, 2007, J ALLERGY CLIN IMMUN, V119, P1497, DOI 10.1016/j.jaci.2007.02.012; Bossi F, 2004, J IMMUNOL, V173, P6921, DOI 10.4049/jimmunol.173.11.6921; Bossi F, 2008, INT IMMUNOPHARMACOL, V8, P143, DOI 10.1016/j.intimp.2007.08.006; Cicardi M, 1996, NEW ENGL J MED, V334, P1666, DOI 10.1056/NEJM199606203342510; Colman RW, 1997, J CLIN INVEST, V100, P1481, DOI 10.1172/JCI119669; Cugno M, 2003, INT IMMUNOPHARMACOL, V3, P311, DOI 10.1016/S1567-5769(02)00162-5; Cyr M, 2001, AM J PHYSIOL-HEART C, V281, pH275, DOI 10.1152/ajpheart.2001.281.1.H275; Davis AE, 2005, CLIN IMMUNOL, V114, P3, DOI 10.1016/j.clim.2004.05.007; Davis Alvin E 3rd, 2008, Clin Mol Allergy, V6, P2, DOI 10.1186/1476-7961-6-2; FIELDS T, 1983, J ALLERGY CLIN IMMUN, V72, P54, DOI 10.1016/0091-6749(83)90052-0; Fisher RA, 1935, DESIGN EXPT; Frank MM, 2006, J ALLERGY CLIN IMMUN, V118, P1327, DOI 10.1016/j.jaci.2006.08.040; Frank MM, 2008, J ALLERGY CLIN IMMUN, V121, pS398, DOI 10.1016/j.jaci.2007.07.057; Frank MM, 2008, J ALLERGY CLIN IMMUN, V121, P272, DOI 10.1016/j.jaci.2007.11.019; Frank MM, 2008, J ALLERGY CLIN IMMUN, V121, pS419; Frossi B, 2003, EUR J IMMUNOL, V33, P2168, DOI 10.1002/eji.200323995; Ghebrehiwet B, 1996, HYBRIDOMA, V15, P333, DOI 10.1089/hyb.1996.15.333; Han ED, 2002, J CLIN INVEST, V109, P1057, DOI 10.1172/JCI200214211; Hasan AAK, 1998, P NATL ACAD SCI USA, V95, P3615, DOI 10.1073/pnas.95.7.3615; Herwald H, 1996, J BIOL CHEM, V271, P13040, DOI 10.1074/jbc.271.22.13040; Joseph K, 1996, P NATL ACAD SCI USA, V93, P8552, DOI 10.1073/pnas.93.16.8552; Joseph K, 2002, P NATL ACAD SCI USA, V99, P896, DOI 10.1073/pnas.022626899; KRALING BM, 1994, LAB INVEST, V71, P745; Marceau F, 1998, CLIN REV ALLERG IMMU, V16, P385, DOI 10.1007/BF02737658; Marceau F, 2004, NAT REV DRUG DISCOV, V3, P845, DOI 10.1038/nrd1522; Marceau F, 2002, INT IMMUNOPHARMACOL, V2, P1729, DOI 10.1016/S1567-5769(02)00189-3; MARCEAU F, 1995, IMMUNOPHARMACOLOGY, V30, P1, DOI 10.1016/0162-3109(95)00011-H; MCEACHERN AE, 1991, P NATL ACAD SCI USA, V88, P7724, DOI 10.1073/pnas.88.17.7724; MENKE JG, 1994, J BIOL CHEM, V269, P21583; Ni AG, 1998, J BIOL CHEM, V273, P2784, DOI 10.1074/jbc.273.5.2784; Nussberger J, 1998, LANCET, V351, P1693, DOI 10.1016/S0140-6736(97)09137-X; Sainz IM, 2007, THROMB HAEMOSTASIS, V98, P77, DOI 10.1160/Th07-04-0250; Sardi SP, 1998, EUR J PHARMACOL, V358, P221, DOI 10.1016/S0014-2999(98)00609-8; Schneider L, 2007, J ALLERGY CLIN IMMUN, V120, P416, DOI 10.1016/j.jaci.2007.04.028; SCHWARTZ LB, 1979, J IMMUNOL, V123, P1445; Shariat-Madar Z, 2002, INT IMMUNOPHARMACOL, V2, P1841, DOI 10.1016/S1567-5769(02)00178-9; Tedesco F, 1997, J EXP MED, V185, P1619, DOI 10.1084/jem.185.9.1619; Zhang XM, 2008, J BIOL CHEM, V283, P7994, DOI 10.1074/jbc.M709837200; Zuraw BL, 2008, EXPERT OPIN INV DRUG, V17, P697, DOI [10.1517/13543784.17.5.697, 10.1517/13543784.17.5.697 ]	40	78	79	2	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2009	124	6					1303	1310		10.1016/j.jaci.2009.08.007	http://dx.doi.org/10.1016/j.jaci.2009.08.007			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	536VH	19796797	Green Accepted			2022-12-18	WOS:000273071500023
J	Nance, CL; Siwak, EB; Shearer, WT				Nance, Christina L.; Siwak, Edward B.; Shearer, William T.			Preclinical development of the green tea catechin, epigallocatechin gallate, as an HIV-1 therapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						EGCG; HIV; p24; subtypes; lymphocytes; alternative therapy; green tea; apoptosis; cytotoxicity; proliferation	POLYPHENON-E; IN-VITRO; (-)-EPIGALLOCATECHIN GALLATE; HEALTHY-INDIVIDUALS; GENETIC DIVERSITY; CELL-RECEPTOR; BLACK TEA; B-CELLS; KAPPA-B; CANCER	Background: Previously, we presented evidence that at physiologic concentrations the green tea catechin, epigallocatechin gallate (EGCG), inhibited attachment of HIV-1 glycoprotein 120 to the CD4 molecule on T cells, but the downstream effects of EGCG on HIV-1 infectivity were not determined. Objective: To evaluate the inhibition of HIV-1 infectivity by EGCG and begin preclinical development of EGCG as a possible therapy. Methods: PBMCs, CD4(+) T cells, and macrophages were isolated from blood of HIV-1-uninfected donors. HIV-1 infectivity was assessed by an HIV-1 p24 ELISA. Cell survival was assessed by cell viability by Trypan blue exclusion assay, cell growth by thymidine incorporation, and apoptosis by flow-cytometric analysis of annexin-V binding. Results: Epigallocatechin gallate inhibited HIV-1 infectivity on human CD4(+) T cells and macrophages in a dose-dependent manner. At a physiologic concentration of 6 mu mol/L, EGCG significantly inhibited HIV-1 p24 antigen production across a broad spectrum of both HIV-1 clinical isolates and laboratory-adapted subtypes (B [P < .001], C, D, and G [P < .01]). The specificity of the EGCG-induced inhibition was substantiated by the failure of EGCG derivatives lacking galloyl and/or pyrogallol side groups to alter HIV-1 p24 levels. EGCG-induced inhibition of HV-1 infectivity was not a result of cytotoxicity, cell growth inhibition, or apoptosis. Conclusion: We conclude that by preventing the attachment of HIV-1-glycoprotein 120 to the CD4 molecule, EGCG inhibits HIV-1 infectivity. Because this inhibition can be achieved at physiologic concentrations, the natural anti-HIV agent EGCG is a candidate as an alternative therapy in HIV-1 therapy. (J Allergy Clin Immunol 2009;123:459-65.)	[Nance, Christina L.] Texas Childrens Hosp, Dept Allergy & Immunol, Houston, TX 77030 USA; [Nance, Christina L.; Shearer, William T.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; [Siwak, Edward B.] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Nance, CL (corresponding author), Texas Childrens Hosp, Dept Allergy & Immunol, 6621 Fannin, Houston, TX 77030 USA.	clnance@texaschildrens.org		Shearer, William/0000-0002-2483-2130	National Institutes of Health [AT003084, AI036211, P30AI036211]; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R21AT003084] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI036211] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grants AT003084, AI036211, and P30AI036211. Disclosure of potential conflict of interest: The authors have declared that they have no conflict of interest.	Ahmad N, 2000, ARCH BIOCHEM BIOPHYS, V376, P338, DOI 10.1006/abbi.2000.1742; Aktas O, 2004, J IMMUNOL, V173, P5794, DOI 10.4049/jimmunol.173.9.5794; Asres K, 2005, PHYTOTHER RES, V19, P557, DOI 10.1002/ptr.1629; Babich H, 2005, TOXICOL IN VITRO, V19, P231, DOI 10.1016/j.tiv.2004.09.001; Baeten JM, 2007, J INFECT DIS, V195, P1177, DOI 10.1086/512682; Bettuzzi S, 2006, CANCER RES, V66, P1234, DOI 10.1158/0008-5472.CAN-05-1145; Butler IF, 2007, CURR HIV RES, V5, P23, DOI 10.2174/157016207779316297; Campbell GR, 2008, J BIOL CHEM, V283, P30745, DOI 10.1074/jbc.M804112200; Chow HHS, 2005, CLIN CANCER RES, V11, P4627, DOI 10.1158/1078-0432.CCR-04-2549; Chow HHS, 2003, CLIN CANCER RES, V9, P3312; Chow HHS, 2001, CANCER EPIDEM BIOMAR, V10, P53; Cohen MS, 2008, J CLIN INVEST, V118, P1244, DOI 10.1172/JCI34706; Cos P, 2004, J NAT PROD, V67, P284, DOI 10.1021/np034016p; De Clercq E, 2000, MED RES REV, V20, P323, DOI 10.1002/1098-1128(200009)20:5<323::AID-MED1>3.0.CO;2-A; Dona M, 2003, J IMMUNOL, V170, P4335, DOI 10.4049/jimmunol.170.8.4335; Donovan JL, 2004, DRUG METAB DISPOS, V32, P906, DOI 10.1124/dmd.104.000083; Fassina G, 2002, AIDS, V16, P939, DOI 10.1097/00002030-200204120-00020; Havsteen BH, 2002, PHARMACOL THERAPEUT, V96, P67, DOI 10.1016/S0163-7258(02)00298-X; Hofbauer R, 1999, WIEN KLIN WOCHENSCHR, V111, P278; HU ZQ, 1992, INT J IMMUNOPHARMACO, V14, P1399; Kanadzu M, 2006, CANCER LETT, V241, P250, DOI 10.1016/j.canlet.2005.10.021; Kawai K, 2003, J ALLERGY CLIN IMMUN, V112, P951, DOI 10.1016/S0091-6749(03)02007-4; Kawai K, 2005, J ALLERGY CLIN IMMUN, V115, P186, DOI 10.1016/j.jaci.2004.10.005; Khan N, 2006, CANCER RES, V66, P2500, DOI 10.1158/0008-5472.CAN-05-3636; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; Lambert JD, 2003, J NUTR, V133, p3262S, DOI 10.1093/jn/133.10.3262S; Lambert JD, 2003, MUTAT RES-FUND MOL M, V523, P201, DOI 10.1016/S0027-5107(02)00336-6; Landis-Piwowar KR, 2005, INT J MOL MED, V15, P735; LEE MJ, 1995, CANCER EPIDEM BIOMAR, V4, P393; Leung LK, 2001, J NUTR, V131, P2248, DOI 10.1093/jn/131.9.2248; Liu SW, 2005, BBA-GEN SUBJECTS, V1723, P270, DOI 10.1016/j.bbagen.2005.02.012; McCutchan FE, 2000, AIDS, V14, pS31; Nair MP, 2002, BIOL RES, V35, P421, DOI 10.4067/S0716-97602002000300016; Noda C, 2007, BIOCHEM BIOPH RES CO, V362, P951, DOI 10.1016/j.bbrc.2007.08.079; Patke CL, 2000, J ALLERGY CLIN IMMUN, V105, P975, DOI 10.1067/mai.2000.105315; Roy AM, 2005, MOL CANCER THER, V4, P81; Shammas MA, 2006, BLOOD, V108, P2804, DOI 10.1182/blood-2006-05-022814; Sleasman John W., 2003, Journal of Allergy and Clinical Immunology, V111, pS582; Song JM, 2005, ANTIVIR RES, V68, P66, DOI 10.1016/j.antiviral.2005.06.010; Suzuki M, 2000, J AGR FOOD CHEM, V48, P5649, DOI 10.1021/jf000313d; Takano K, 2004, J AGR FOOD CHEM, V52, P4571, DOI 10.1021/jf0355194; Ullmann U, 2003, J INT MED RES, V31, P88, DOI 10.1177/147323000303100205; *UNAIDS, 2009, WHO UNAIDS WHO EP FA; Wang RR, 2008, J ETHNOPHARMACOL, V117, P249, DOI 10.1016/j.jep.2008.01.037; Williamson MP, 2006, J ALLERGY CLIN IMMUN, V118, P1369, DOI 10.1016/j.jaci.2006.08.016; Wu JH, 2003, BIOORG MED CHEM LETT, V13, P1813, DOI 10.1016/S0960-894X(03)00197-5; Xu J, 2008, ANTIVIR RES, V78, P242, DOI 10.1016/j.antiviral.2007.11.011; Yamaguchi K, 2002, ANTIVIR RES, V53, P19, DOI 10.1016/S0166-3542(01)00189-9; Yamashita K, 2000, BIOCHEM BIOPH RES CO, V274, P603, DOI 10.1006/bbrc.2000.3200; Zaveri NT, 2001, ORG LETT, V3, P843, DOI 10.1021/ol007000o	50	78	92	0	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2009	123	2					459	465		10.1016/j.jaci.2008.12.024	http://dx.doi.org/10.1016/j.jaci.2008.12.024			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	409GU	19203663	Green Accepted			2022-12-18	WOS:000263495000026
J	Santos, ABR; Rocha, GM; Oliver, C; Ferriani, VPL; Lima, RC; Palma, MS; Sales, VSF; Aalberse, RC; Chapman, MD; Arruda, LK				Santos, Ana Beatriz R.; Rocha, Gutemberg M.; Oliver, Constance; Ferriani, Virginia P. L.; Lima, Rodrigo C.; Palma, Mirio S.; Sales, Valdria S. F.; Aalberse, Rob C.; Chapman, Martin D.; Arruda, L. Karla			Cross-reactive IgE antibody responses to tropomyosins from Ascaris lumbricoides and cockroach	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						tropomyosin; Ascaris lumbricoides; periplaneta americana; IgE cross-reactivity; allergy; parasites; asthma	HOUSE-DUST-MITE; SKIN-TEST REACTIVITY; GEOHELMINTH INFECTIONS; IMMUNOGLOBULIN-E; MAJOR ALLERGEN; RURAL AREA; CHILDREN; ASTHMA; SHRIMP; ATOPY	Background: Evidence indicates that infection with Ascaris lumbricoides may promote development of allergy and asthma. Objective: To study the role of tropomyosin, a pan-allergen in invertebrates, in IgE responses to A lumbricoides. Methods: Recombinant A lumbricoides and Periplaneta americana tropomyosins were expressed in Pichia pastoris. Levels of IgE to tropomyosins from A lumbricoides and P americana were determined by chimeric ELISA in sera from 119 children living in a parasite-endemic area and 112 patients with cockroach allergy from the allergy clinics. Presence of tropomyosin in A lumbricoides larvae at L3 stage was evaluated by immunofluorescence using mAb IA6, directed against mite tropomyosin. Molecular modeling of P americana and A lumbricoides tropomyosins was performed by using the MODELLER program. Results: A lumbricoides tropomyosin showed 69% to 98% sequence identity to tropomyosins from other invertebrates. The predicted structure of A lumbricoides tropomyosin was similar to that of P americana tropomyosin and showed the characteristic coiled-coil structure. Strong correlation was found for IgE antibodies to tropomyosins from A lumbricoides and P americana in sera from children living in a parasite-endemic area and from patients with cockroach allergy. Larvae of A lumbricoides reacted strongly with mAb IA6. Conclusion: Tropomyosin induces IgE responses in A lumbricoides-infected children and in patients allergic to cockroach.	[Santos, Ana Beatriz R.; Lima, Rodrigo C.; Arruda, L. Karla] Univ Sao Paulo, Sch Med Ribeirao Preto, Dept Internal Med, BR-14049900 Ribeirao Preto, SP, Brazil; [Rocha, Gutemberg M.; Oliver, Constance] Univ Sao Paulo, Sch Med Ribeirao Preto, Dept Cell & Mol Biol, BR-14049900 Ribeirao Preto, SP, Brazil; [Rocha, Gutemberg M.; Oliver, Constance] Univ Sao Paulo, Sch Med Ribeirao Preto, Dept Pathogen Bioagents, BR-14049900 Ribeirao Preto, SP, Brazil; [Ferriani, Virginia P. L.] Univ Sao Paulo, Sch Med Ribeirao Preto, Dept Pediat, BR-14049900 Ribeirao Preto, SP, Brazil; [Palma, Mirio S.] State Univ Sao Paulo, Biosci Inst, Rio Claro, Brazil; [Sales, Valdria S. F.] Univ Fed Rio Grande do Norte, BR-59072970 Natal, RN, Brazil; [Aalberse, Rob C.] Netherlands Red Cross, Blood Transfus Serv, Cent Lab, Sanquin Res, Amsterdam, Netherlands; [Chapman, Martin D.] Indoor Biotechnol Inc, Charlottesville, VA USA	Universidade de Sao Paulo; Universidade de Sao Paulo; Universidade de Sao Paulo; Universidade de Sao Paulo; Universidade Federal de Sao Paulo (UNIFESP); Universidade Estadual Paulista; Universidade Federal do Rio Grande do Norte; INDOOR Biotechnologies	Arruda, LK (corresponding author), Univ Sao Paulo, Sch Med Ribeirao Preto, Dept Internal Med, Av Bandeirantes 3900, BR-14049900 Ribeirao Preto, SP, Brazil.	karla@fmrp.usp.br	Palma, Mario/N-3903-2019; Arruda, L. Karla/D-5845-2013; Ferriani, Virginia PL/E-2209-2012; Palma, Mario Sergio/E-7800-2012	Arruda, L. Karla/0000-0002-7505-210X; Palma, Mario Sergio/0000-0002-7363-8211; Chapman, Martin/0000-0002-0845-3632				Araujo MI, 2000, INT ARCH ALLERGY IMM, V123, P145, DOI 10.1159/000024433; Arruda LK, 2001, J ALLERGY CLIN IMMUN, V107, P419, DOI 10.1067/mai.2001.112854; Asturias JA, 2000, MOL BIOCHEM PARASIT, V108, P263, DOI 10.1016/S0166-6851(00)00218-8; Ayuso R, 2002, INT ARCH ALLERGY IMM, V129, P38, DOI 10.1159/000065172; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Camara AA, 2004, J ALLERGY CLIN IMMUN, V113, P551, DOI 10.1016/j.jaci.2003.11.027; Carvalho EM, 2006, PARASITE IMMUNOL, V28, P525, DOI 10.1111/j.1365-3024.2006.00894.x; Cooper PJ, 2006, BRIT MED BULL, V79-80, P203, DOI 10.1093/bmb/ldl015; Cooper PJ, 2006, LANCET, V367, P1598, DOI 10.1016/S0140-6736(06)68697-2; Cooper PJ, 2003, J ALLERGY CLIN IMMUN, V111, P995, DOI 10.1067/mai.2003.1348; Cooper PJ, 2000, J INFECT DIS, V182, P1207, DOI 10.1086/315830; Cooper PJ, 2003, AM J RESP CRIT CARE, V168, P313, DOI 10.1164/rccm.200211-1320OC; Crompton DWT, 2001, ADV PARASIT, V48, P285, DOI 10.1016/S0065-308X(01)48008-0; Culley FJ, 2002, EUR J IMMUNOL, V32, P1376, DOI 10.1002/1521-4141(200205)32:5<1376::AID-IMMU1376>3.0.CO;2-8; Fallon PG, 2007, NAT REV IMMUNOL, V7, P220, DOI 10.1038/nri2039; Fernandes J, 2003, CLIN EXP ALLERGY, V33, P956, DOI 10.1046/j.1365-2222.2003.01722.x; Flohr C, 2006, J ALLERGY CLIN IMMUN, V118, P1305, DOI 10.1016/j.jaci.2006.08.035; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leonardi-Bee J, 2006, AM J RESP CRIT CARE, V174, P514, DOI 10.1164/rccm.200603-331OC; Lynch NR, 1997, AM J RESP CRIT CARE, V156, P50, DOI 10.1164/ajrccm.156.1.9606081; Maizels RM, 2003, NAT REV IMMUNOL, V3, P733, DOI 10.1038/nri1183; Medeiros M, 2003, J ALLERGY CLIN IMMUN, V111, P947, DOI 10.1067/mai.2003.1381; O'Lorcain P, 2000, PARASITOLOGY, V121, pS51, DOI 10.1017/S0031182000006442; Obihara CC, 2006, CLIN EXP ALLERGY, V36, P640, DOI 10.1111/j.1365-2222.2006.02479.x; Pajno GB, 2002, J ALLERGY CLIN IMMUN, V109, P627, DOI 10.1067/mai.2002.122844; Palmer LJ, 2002, AM J RESP CRIT CARE, V165, P1489, DOI 10.1164/rccm.2107020; Ponte EV, 2006, ANN ALLERG ASTHMA IM, V96, P713, DOI 10.1016/S1081-1206(10)61070-8; PUROHIT A, 2007, ALLERG IMMUNOL PARIS, V39, P85; Rakes CP, 1999, AM J RESP CRIT CARE, V159, P785, DOI 10.1164/ajrccm.159.3.9801052; Reese G, 2006, CLIN EXP ALLERGY, V36, P517, DOI 10.1111/j.1365-2222.2006.02454.x; Reese G, 1999, INT ARCH ALLERGY IMM, V119, P247, DOI 10.1159/000024201; Sales VS, 2002, J ALLERGY CLIN IMMUN, V109, pS27, DOI 10.1016/S0091-6749(02)81160-5; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Santos ABR, 1999, J ALLERGY CLIN IMMUN, V104, P329, DOI 10.1016/S0091-6749(99)70375-1; Schuurman J, 1997, J ALLERGY CLIN IMMUN, V99, P545, DOI 10.1016/S0091-6749(97)70083-6; Silva JM, 2005, PEDIAT ALLERG IMM-UK, V16, P393, DOI 10.1111/j.1399-3038.2005.00308.x; Trombone APF, 2002, CLIN EXP ALLERGY, V32, P1323, DOI 10.1046/j.1365-2745.2002.01455.x; van den Biggelaar AHJ, 2004, J INFECT DIS, V189, P892, DOI 10.1086/381767; van der Kleij D, 2002, J BIOL CHEM, V277, P48122, DOI 10.1074/jbc.M206941200; vanRee R, 1996, ALLERGY, V51, P387, DOI 10.1111/j.1398-9995.1996.tb00147.x; vanRee R, 1996, ALLERGY, V51, P108, DOI 10.1111/j.1398-9995.1996.tb00043.x; WITTEMAN AM, 1994, INT ARCH ALLERGY IMM, V105, P56, DOI 10.1159/000236803	42	78	81	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2008	121	4					1040	1046		10.1016/j.jaci.2007.12.1147	http://dx.doi.org/10.1016/j.jaci.2007.12.1147			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	286YY	18275995				2022-12-18	WOS:000254884000034
J	Gupta, RS; Zhang, XY; Sharp, LK; Shannon, JJ; Weiss, KB				Gupta, Ruchi S.; Zhang, Xingyou; Sharp, Lisa K.; Shannon, John J.; Weiss, Kevin B.			Geographic variability in childhood asthma prevalence in Chicago	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; children; disparities; neighborhood variability; asthma prevalence	HOUSE-DUST MITE; SOCIOECONOMIC-STATUS; AIR-POLLUTION; ENVIRONMENTAL EXPOSURE; ALLERGEN EXPOSURE; TOBACCO-SMOKE; HEALTH; MORBIDITY; RISK; POPULATION	Background: Childhood asthma prevalence has been shown to be higher in urban communities overall without an understanding of differences by neighborhood. Objective: To characterize the geographic variability of childhood asthma prevalence among neighborhoods in Chicago. Methods: Asthma screening was conducted among children attending 105 Chicago schools as part of the Chicago Initiative to Raise Asthma Health Equity. Additional child information included age, sex, race/ethnicity, and household members with asthma. Surveys were geocoded and linked with neighborhoods. Neighborhood information on race, education, and income was based on 2000 census data. Bivariate and multilevel analyses were performed. Results: Of the 48,917 surveys, 41,255 (84.3%) were geocoded into 287 neighborhoods. Asthma prevalence among all children was 12.9%. Asthma rates varied among neighborhoods from 0% to 44% (interquartile range, 8% to 24%). Asthma prevalence (mean, SD, range) in predominantly black neighborhoods (19.9, +/- 7, 4% to 44%) was higher than in predominantly white neighborhoods (11.4, +/- 4.7, 2% to 30%) and predominantly Hispanic neighborhoods (12.1, +/- 6.8, 0% to 29%). Although sex, age, household members with asthma, and neighborhood income significantly affected asthma prevalence, they did not explain the differences seen between neighborhoods. Race explained a significant proportion (about 80%) but not all of this variation. Conclusion: Childhood asthma prevalence varies widely by neighborhood within this urban environment. Adjacent areas in Chicago were identified with significantly different asthma prevalence. A better understanding of the effect of neighborhood characteristics may lend insight into potential interventions to reduce childhood asthma.	[Gupta, Ruchi S.] Childrens Mem Hosp, Smith Child Hlth Res Program, Chicago, IL 60614 USA; [Gupta, Ruchi S.; Weiss, Kevin B.] Northwestern Univ, Feinberg Sch Med, Inst Healthcare Studies, Chicago, IL 60611 USA; [Weiss, Kevin B.] Northwestern Univ, Feinberg Sch Med, Div Gen Internal Med, Chicago, IL 60611 USA; [Zhang, Xingyou] Amer Acad Family Phys, Policy Studies Family Med & Primary Care, Robert Graham Ctr, Washington, DC USA; [Sharp, Lisa K.] Univ Illinois, Sect Hlth Promot, Dept Med, Chicago, IL 60680 USA; [Shannon, John J.] Cook Cty Hosp, Dept Med, Div Pulm & Crit Care Med, Chicago, IL 60612 USA; [Weiss, Kevin B.] US Dept Vet Affairs, Midwest Ctr Hlth Serv & Policy Res, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA	Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; John H Stroger Junior Hospital Cook County; US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital	Gupta, RS (corresponding author), Childrens Mem Hosp, Smith Child Hlth Res Program, 2300 Childrens Plaza,Box 157, Chicago, IL 60614 USA.	r-gupta@northwestern.edu		Sharp, Lisa/0000-0002-7809-9042	NHLBI NIH HHS [5U01 HL072478-05] Funding Source: Medline; NICHD NIH HHS [K12 HD052902] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K12HD052902] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL072478] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akinbami, 2006, STATE CHILDHOOD ASTH, V381; Akinbami LJ, 2002, PEDIATRICS, V110, P315, DOI 10.1542/peds.110.2.315; Aligne CA, 2000, AM J RESP CRIT CARE, V162, P873; Almqvist C, 2005, CLIN EXP ALLERGY, V35, P612, DOI 10.1111/j.1365-2222.2005.02243.x; ANSELIN L, 1995, GEOGR ANAL, V27, P93, DOI 10.1111/j.1538-4632.1995.tb00338.x; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; BENER A, 2005, ALLERG IMMUNOL PARIS, V37, P163; Black PN, 1997, EUR RESPIR J, V10, P6, DOI 10.1183/09031936.97.10010006; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Byrd RS, 2006, CURR OPIN PULM MED, V12, P68, DOI 10.1097/01.mcp.0000199001.68908.45; Cesaroni G, 2003, EUR RESPIR J, V22, P619, DOI 10.1183/09031936.03.00091202; Chen E, 2007, AM J RESP CRIT CARE, V176, P644, DOI 10.1164/rccm.200610-1473OC; Chen E, 2007, PEDIATRICS, V120, pE297, DOI 10.1542/peds.2006-3098; Claudio L, 2006, ANN EPIDEMIOL, V16, P332, DOI 10.1016/j.annepidem.2005.06.046; Cook DG, 1997, THORAX, V52, P1081, DOI 10.1136/thx.52.12.1081; Debley JS, 2004, PEDIATR PULM, V38, P443, DOI 10.1002/ppul.20108; Eder W, 2006, NEW ENGL J MED, V355, P2226, DOI 10.1056/NEJMra054308; Fagan JK, 2001, ANN ALLERG ASTHMA IM, V86, P177, DOI 10.1016/S1081-1206(10)62688-9; Gauderman WJ, 2004, NEW ENGL J MED, V351, P1057, DOI 10.1056/NEJMoa040610; Gilmour M, 2006, ENVIRON HEALTH PERSP, V114, P627, DOI 10.1289/ehp.8380; Gold DR, 2005, ANNU REV PUBL HEALTH, V26, P89, DOI 10.1146/annurev.publhealth.26.021304.144528; Grant EN, 2005, ANN ALLERG ASTHMA IM, V95, P19, DOI 10.1016/S1081-1206(10)61183-0; Gruchalla RS, 2005, J ALLERGY CLIN IMMUN, V115, P478, DOI 10.1016/j.jaci.2004.12.006; Gupta RS, 2006, J ALLERGY CLIN IMMUN, V117, P351, DOI 10.1016/j.jaci.2005.11.047; Hirsch T, 1999, EUR RESPIR J, V14, P669, DOI 10.1034/j.1399-3003.1999.14c29.x; *I SOC RES, PROJ HUM DEV CHIC NE; Larsen K, 2000, BIOMETRICS, V56, P909, DOI 10.1111/j.0006-341X.2000.00909.x; Larsen K, 2005, AM J EPIDEMIOL, V161, P81, DOI 10.1093/aje/kwi017; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; Litonjua AA, 2001, J ALLERGY CLIN IMMUN, V107, P41, DOI 10.1067/mai.2001.111143; MARDER D, 1992, CHEST, V101, pS426, DOI 10.1378/chest.101.6.426S; Matsui EC, 2004, J ALLERGY CLIN IMMUN, V113, P910, DOI 10.1016/j.jaci.2004.02.034; Migilaretti G, 2004, PEDIATR PULM, V38, P198, DOI 10.1002/ppul.20057; Mihrshahi S, 2003, J ALLERGY CLIN IMMUN, V111, P162, DOI 10.1067/mai.2003.36; Miller JE, 2000, AM J PUBLIC HEALTH, V90, P428, DOI 10.2105/AJPH.90.3.428; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; Perry T, 2003, J ALLERGY CLIN IMMUN, V112, P346, DOI 10.1067/mai.2003.1640; Persky VW, 1998, ANN ALLERG ASTHMA IM, V81, P266, DOI 10.1016/S1081-1206(10)62824-4; Ryan PH, 2005, J ALLERGY CLIN IMMUN, V116, P279, DOI 10.1016/j.jaci.2005.05.014; Shah AM, 2006, AM J PUBLIC HEALTH, V96, P1485, DOI 10.2105/AJPH.2004.052076; Shalowitz MU, 2007, AMBUL PEDIATR, V7, P271, DOI 10.1016/j.ambp.2007.03.004; Smith LA, 2005, PUBLIC HEALTH REP, V120, P109, DOI 10.1177/003335490512000203; Strachan David P., 2000, Thorax, V55, pS2, DOI 10.1136/thorax.55.suppl_1.S2; TARGONSKI PV, 1994, AM J PUBLIC HEALTH, V84, P1830, DOI 10.2105/AJPH.84.11.1830; Tatum AJ, 2005, IMMUNOL ALLERGY CLIN, V25, P15, DOI 10.1016/j.iac.2004.09.003; Thomas SD, 1999, CHEST, V116, p135S, DOI 10.1378/chest.116.suppl_2.135S; Venn AJ, 2001, AM J RESP CRIT CARE, V164, P2177, DOI 10.1164/ajrccm.164.12.2106126; WEISS KB, 1990, JAMA-J AM MED ASSOC, V264, P1683, DOI 10.1001/jama.264.13.1683; WEISS KB, 1993, ANNU REV PUBL HEALTH, V14, P491, DOI 10.1146/annurev.pu.14.050193.002423; WEISS KB, 1990, CHEST, V98, pS179, DOI 10.1378/chest.98.5.179S; Weiss ST, 2002, NEW ENGL J MED, V347, P930, DOI 10.1056/NEJMe020092; Wright RJ, 1998, THORAX, V53, P1066, DOI 10.1136/thx.53.12.1066; Wright RJ, 2004, AM J PUBLIC HEALTH, V94, P625, DOI 10.2105/AJPH.94.4.625; Wright RJ, 2002, AM J RESP CRIT CARE, V165, P358, DOI 10.1164/ajrccm.165.3.2102016; Wright RJ, 2001, ENVIRON HEALTH PERSP, V109, P1085, DOI 10.2307/3454965	55	78	79	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2008	121	3					639	645		10.1016/j.jaci.2007.11.036	http://dx.doi.org/10.1016/j.jaci.2007.11.036			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	273GR	18243285				2022-12-18	WOS:000253918900015
J	Levesque, MC; Clair, EWS				Levesque, Marc C.; Clair, E. William St.			B cell-directed therapies for autoimmune disease and correlates of disease response and relapse	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						B lymphocyte; antigens; CD20; B-lymphocyte activating factor; rituximab	SYSTEMIC-LUPUS-ERYTHEMATOSUS; ANTI-CD20 MONOCLONAL-ANTIBODY; LYMPHOCYTE DEPLETION THERAPY; RITUXIMAB-TREATED PATIENTS; EARLY RHEUMATOID-ARTHRITIS; PERIPHERAL-BLOOD; T-CELL; WEGENERS-GRANULOMATOSIS; CEREBROSPINAL-FLUID; MYASTHENIA-GRAVIS	Recent advances have led to the development of mAbs that effectively deplete B cells in human beings and target pathways essential for B-cell development. B cell-directed therapies represent promising treatments for autoimmune disorders, although many questions remain about their optimal use in the clinic. Autoantibody depletion correlates with the clinical effectiveness of these drugs in some diseases but not all. This finding implies that self-reactive B cells are playing important pathogenic roles in autoimmune disorders beyond the production of autoantibodies. Clinical studies of B cell-directed therapies are beginning to illuminate the effects of B-cell modulation on immune function using a variety of mechanistic approaches, including delineation of B-cell subsets by How cytometry, measurement of serum autoantibodies and cytokines, and tests of immunocompetence. Recent clinical studies have been performed in patients with rheumatoid arthritis and SLE suggesting the depletion of memory cells accounts at least in part for the clinical efficacy of rituximab therapy, but these findings, although provocative, require further investigation in larger cohorts. Memory B cells are not the only targets of depleting antibodies; therefore, other B-cell populations of therapeutic relevance may be modulated by these interventions. Moreover, pathologic B-cell responses may be favorably influenced by other targeted approaches such as those using anti-B-cell activating factor belonging to the TNF family (BAFF) or anti-CD22 antibodies.	[Levesque, Marc C.] Duke Univ, Med Ctr, Durham, NC 27710 USA; [Levesque, Marc C.; Clair, E. William St.] Duke Univ, Med Ctr, Dept Med, Div Rheumatol & Immunol, Durham, NC 27710 USA	Duke University; Duke University	Levesque, MC (corresponding author), Duke Univ, Med Ctr, Box 3266, Durham, NC 27710 USA.	niaic.levesque@duke.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI015416, U19AI056362] Funding Source: NIH RePORTER; NIAID NIH HHS [7U19AI056362, N01-AI-15416] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agarwal A, 2004, AM J TRANSPLANT, V4, P1357, DOI 10.1111/j.1600-6143.2004.00502.x; Ahmed AR, 2006, NEW ENGL J MED, V355, P1772, DOI 10.1056/NEJMoa062930; AHN ER, 2005, BLOOD, V106, P4006; Andersohn F, 2007, ANN INTERN MED, V146, P657, DOI 10.7326/0003-4819-146-9-200705010-00009; Anolik JH, 2007, ARTHRITIS RHEUM, V56, P3044, DOI 10.1002/art.22810; Anolik JH, 2007, CLIN IMMUNOL, V122, P139, DOI 10.1016/j.clim.2006.08.009; Anolik JH, 2004, ARTHRITIS RHEUM-US, V50, P3580, DOI 10.1002/art.20592; [Anonymous], 2007, FDA Consum, V41, P3; Arnold DM, 2007, ANN INTERN MED, V146, P25, DOI 10.7326/0003-4819-146-1-200701020-00006; Bearden CM, 2005, AM J TRANSPLANT, V5, P50, DOI 10.1111/j.1600-6143.2003.00646.x; Berinstein NL, 1998, ANN ONCOL, V9, P995, DOI 10.1023/A:1008416911099; Bohnhorst JO, 2001, J IMMUNOL, V167, P3610, DOI 10.4049/jimmunol.167.7.3610; Browning JL, 2006, NAT REV DRUG DISCOV, V5, P564, DOI 10.1038/nrd2085; Brulhart L, 2006, ANN RHEUM DIS, V65, P974, DOI 10.1136/ard.2005.045898; Cambridge G, 2003, ARTHRITIS RHEUM-US, V48, P2146, DOI 10.1002/art.11181; Cambridge G, 2006, ARTHRITIS RHEUM-US, V54, P3612, DOI 10.1002/art.22211; Cambridge G, 2006, ARTHRITIS RHEUM-US, V54, P723, DOI 10.1002/art.21650; Carter RH, 2006, MAYO CLIN PROC, V81, P377, DOI 10.4065/81.3.377; Cartron G, 2007, CRIT REV ONCOL HEMAT, V62, P43, DOI 10.1016/j.critrevonc.2006.09.004; Chan OTM, 1999, J EXP MED, V189, P1639, DOI 10.1084/jem.189.10.1639; Chung L, 2007, ARCH DERMATOL, V143, P763, DOI 10.1001/archderm.143.6.763; Cohen SB, 2006, ARTHRITIS RHEUM-US, V54, P2793, DOI 10.1002/art.22025; Coiffier B, 2007, ONCOGENE, V26, P3603, DOI 10.1038/sj.onc.1210376; Cooper N, 2006, BRIT J HAEMATOL, V133, P364, DOI 10.1111/j.1365-2141.2006.06024.x; Cross AH, 2006, J NEUROIMMUNOL, V180, P63, DOI 10.1016/j.jneuroim.2006.06.029; Devauchelle-Pensec V, 2007, ARTHRIT RHEUM-ARTHR, V57, P310, DOI 10.1002/art.22536; Do RKG, 2000, J EXP MED, V192, P953, DOI 10.1084/jem.192.7.953; Dorner T, 2005, J EXP MED, V201, P497, DOI 10.1084/jem.20050218; Edwards JCW, 2006, NAT REV IMMUNOL, V6, P394, DOI 10.1038/nri1838; Edwards JCW, 2004, NEW ENGL J MED, V350, P2572, DOI 10.1056/NEJMoa032534; Eisenberg R, 2005, CLIN IMMUNOL, V117, P207, DOI 10.1016/j.clim.2005.08.006; El Fassi D, 2007, J CLIN ENDOCR METAB, V92, P1769, DOI 10.1210/jc.2006-2388; Emery P, 2006, ARTHRITIS RHEUM, V54, P1390, DOI 10.1002/art.21778; Gajra A, 2004, AM J HEMATOL, V77, P196, DOI 10.1002/ajh.20169; GENOVESE M, 2007, ARTHRITIS RHEUM, V56, pS149; Ghia P, 1998, IMMUNOL TODAY, V19, P480, DOI 10.1016/S0167-5699(98)01330-9; Gillis JZ, 2007, ARTHRIT RHEUM-ARTHR, V57, P538, DOI 10.1002/art.22629; Goldenberg DM, 2006, ARTHRITIS RHEUM-US, V54, P2344, DOI 10.1002/art.21937; Gong Q, 2005, J IMMUNOL, V174, P817, DOI 10.4049/jimmunol.174.2.817; Gonzalez-Stawinski GV, 2001, CLIN IMMUNOL, V98, P175, DOI 10.1006/clim.2000.4980; Gunnarsson I, 2007, ARTHRITIS RHEUM-US, V56, P1263, DOI 10.1002/art.22505; Hain B, 2006, MUSCLE NERVE, V33, P575, DOI 10.1002/mus.20479; Halpern WG, 2006, TOXICOL SCI, V91, P586, DOI 10.1093/toxsci/kfj148; Hamaguchi Y, 2005, J IMMUNOL, V174, P4389, DOI 10.4049/jimmunol.174.7.4389; Harris DP, 2000, NAT IMMUNOL, V1, P475, DOI 10.1038/82717; HAUSER S, 2007, PHASE 2 RANDOMIZED P; HODGKIN PD, 1995, CURR OPIN IMMUNOL, V7, P121, DOI 10.1016/0952-7915(95)80037-9; Hoque SR, 2007, CLIN EXP DERMATOL, V32, P172, DOI 10.1111/j.1365-2230.2006.02331.x; Joly P, 2007, NEW ENGL J MED, V357, P545, DOI 10.1056/NEJMoa067752; Kalled SL, 2005, IMMUNOL REV, V204, P43, DOI 10.1111/j.0105-2896.2005.00219.x; Keogh KA, 2006, AM J RESP CRIT CARE, V173, P180, DOI 10.1164/rccm.200507-1144OC; Keogh KA, 2005, ARTHRITIS RHEUM-US, V52, P262, DOI 10.1002/art.20718; Klein U, 1998, J EXP MED, V188, P1679, DOI 10.1084/jem.188.9.1679; LANZAVECCHIA A, 1990, ANNU REV IMMUNOL, V8, P773, DOI 10.1146/annurev.immunol.8.1.773; Lavie F, 2007, ANN RHEUM DIS, V66, P700, DOI 10.1136/ard.2006.060772; Leandro MJ, 2007, RHEUMATOLOGY, V46, P29, DOI 10.1093/rheumatology/kel148; Leandro MJ, 2005, RHEUMATOLOGY, V44, P1542, DOI 10.1093/rheumatology/kei080; Leandro MJ, 2006, ARTHRITIS RHEUM-US, V54, P613, DOI 10.1002/art.21617; LeBien TW, 2000, BLOOD, V96, P9, DOI 10.1182/blood.V96.1.9; Levine TD, 2005, ARTHRITIS RHEUM, V52, P601, DOI 10.1002/art.20849; Lin TS, 2004, HEMATOL ONCOL CLIN N, V18, P895, DOI 10.1016/j.hoc.2004.04.008; Looney RJ, 2004, ARTHRITIS RHEUM, V50, P2580, DOI 10.1002/art.20430; Lund Frances E., 2005, V8, P25; Mackay F, 2002, NAT REV IMMUNOL, V2, P465, DOI 10.1038/nri844; Marks SD, 2005, ARTHRITIS RHEUM, V52, P3168, DOI 10.1002/art.21351; Martin A, 2002, NATURE, V415, P802, DOI 10.1038/nature714; Martin F, 2006, ANNU REV IMMUNOL, V24, P467, DOI 10.1146/annurev.immunol.24.021605.090517; McKenna RW, 2001, BLOOD, V98, P2498, DOI 10.1182/blood.V98.8.2498; Mebius RE, 1998, J IMMUNOL, V161, P3836; Medina F, 2002, BLOOD, V99, P2154, DOI 10.1182/blood.V99.6.2154; Meyer O, 2003, ANN RHEUM DIS, V62, P120, DOI 10.1136/ard.62.2.120; Mongini PKA, 2005, J IMMUNOL, V175, P6143, DOI 10.4049/jimmunol.175.9.6143; Monson NL, 2005, ARCH NEUROL-CHICAGO, V62, P258, DOI 10.1001/archneur.62.2.258; Muramatsu M, 1999, J BIOL CHEM, V274, P18470, DOI 10.1074/jbc.274.26.18470; Nehring AK, 2007, BRIT J HAEMATOL, V136, P628, DOI 10.1111/j.1365-2141.2006.06482.x; Ng CM, 2005, J CLIN PHARMACOL, V45, P792, DOI 10.1177/0091270005277075; Ng KP, 2007, ANN RHEUM DIS, V66, P1259, DOI 10.1136/ard.2006.067124; Ng LG, 2004, J IMMUNOL, V173, P807, DOI 10.4049/jimmunol.173.2.807; Nishio M, 2007, BRIT J HAEMATOL, V137, P349, DOI 10.1111/j.1365-2141.2007.06584.x; Nitta E, 2007, ANN ONCOL, V18, P364, DOI 10.1093/annonc/mdl393; Noss EH, 2006, J RHEUMATOL, V33, P1021; Omdal R, 2005, SCAND J RHEUMATOL, V34, P229, DOI 10.1080/02813430510015269; PANAYI GS, 2005, RHEUMATOLOGY S2, V44, P3, DOI DOI 10.1093/RHEUMATOLOGY/KEH616; Pers JO, 2007, ARTHRITIS RHEUM, V56, P1464, DOI 10.1002/art.22603; Pijpe J, 2005, ANN RHEUM DIS, V64, P958, DOI 10.1136/ard.2004.030684; Pijpe J, 2005, ARTHRITIS RHEUM-US, V52, P2740, DOI 10.1002/art.21260; Popa C, 2007, RHEUMATOLOGY, V46, P626, DOI 10.1093/rheumatology/kel393; Rantapaa-Dahlqvist S, 2003, ARTHRITIS RHEUM, V48, P2741, DOI 10.1002/art.11223; Roll P, 2006, ARTHRITIS RHEUM-US, V54, P2377, DOI 10.1002/art.22019; Rouziere A, 2005, ARTHRITIS RES THER, V7, pR714, DOI 10.1186/ar1731; Sabahi R, 2006, DRUGS, V66, P1933, DOI 10.2165/00003495-200666150-00004; Salvi M, 2007, EUR J ENDOCRINOL, V156, P33, DOI 10.1530/eje.1.02325; Schellekens GA, 1998, J CLIN INVEST, V101, P273, DOI 10.1172/JCI1316; Scofield RH, 2004, LANCET, V363, P1544, DOI 10.1016/S0140-6736(04)16154-0; Seror R, 2007, ANN RHEUM DIS, V66, P351, DOI 10.1136/ard.2006.057919; Sfikakis PP, 2007, CLIN IMMUNOL, V123, P66, DOI 10.1016/j.clim.2006.12.006; Sfikakis PP, 2005, ARTHRITIS RHEUM-US, V52, P501, DOI 10.1002/art.20858; Silverman GJ, 2003, ARTHRITIS RES THER, V5, pS1, DOI 10.1186/ar1010; Silverman GJ, 2006, ARTHRITIS RHEUM-US, V54, P2356, DOI 10.1002/art.22020; Simon D, 2008, J ALLERGY CLIN IMMUN, V121, P122, DOI 10.1016/j.jaci.2007.11.016; Sims GP, 2005, BLOOD, V105, P4390, DOI 10.1182/blood-2004-11-4284; Smith KGC, 2006, ARTHRITIS RHEUM-US, V54, P2970, DOI 10.1002/art.22046; Specks U, 2001, ARTHRITIS RHEUM, V44, P2836, DOI 10.1002/1529-0131(200112)44:12<2836::AID-ART471>3.0.CO;2-W; St Clair EW, 2006, ARTHRITIS RHEUM-US, V54, P1, DOI 10.1002/art.21525; Stohl W, 2006, ARTHRITIS RHEUM, V54, pS780; Stohl W, 2006, CLIN IMMUNOL, V121, P1, DOI 10.1016/j.clim.2006.03.010; Stuve O, 2005, ARCH NEUROL-CHICAGO, V62, P1620, DOI 10.1001/archneur.62.10.1620; TAN EM, 1994, J EXP MED, V179, P1083, DOI 10.1084/jem.179.4.1083; TEDDER TE, 1994, IMMUNOL TODAY, V15, P450, DOI 10.1016/0167-5699(94)90276-3; tenBoekel E, 1997, IMMUNITY, V7, P357; TERBORG EJ, 1990, ARTHRITIS RHEUM-US, V33, P634, DOI 10.1002/art.1780330505; THURLINGS RM, 2008, IN PRESS ANN RHEUM D; Todd DJ, 2007, J RHEUMATOL, V34, P430; Tokunaga M, 2007, ANN RHEUM DIS, V66, P470, DOI 10.1136/ard.2006.057885; Uchida JJ, 2004, J EXP MED, V199, P1659, DOI 10.1084/jem.20040119; Vallerskog T, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar2076; Vallerskog T, 2007, CLIN IMMUNOL, V122, P62, DOI 10.1016/j.clim.2006.08.016; VANZEBEN D, 1992, ANN RHEUM DIS, V51, P1029, DOI 10.1136/ard.51.9.1029; Visser H, 2002, ARTHRITIS RHEUM, V46, P357, DOI 10.1002/art.10117; Vos K, 2007, ARTHRITIS RHEUM, V56, P772, DOI 10.1002/art.22400; Withers DR, 2007, BLOOD, V109, P4856, DOI 10.1182/blood-2006-08-043414; Wylam ME, 2003, J PEDIATR-US, V143, P674, DOI 10.1067/S0022-3476(03)00300-7; Zhang ZX, 2001, RHEUM DIS CLIN N AM, V27, P335, DOI 10.1016/S0889-857X(05)70205-2	123	78	93	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2008	121	1					13	21		10.1016/j.jaci.2007.11.030	http://dx.doi.org/10.1016/j.jaci.2007.11.030			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	251KM	18206502				2022-12-18	WOS:000252372000002
J	Bieli, C; Eder, W; Frei, R; Braun-Fahrlander, C; Klimecki, W; Waser, M; Riedler, J; von Mutius, E; Scheynius, A; Pershagen, G; Doekes, G; Lauener, R; Martinez, FD				Bieli, Christian; Eder, Waltraud; Frei, Remo; Braun-Fahrlaender, Charlotte; Klimecki, Walt; Waser, Marco; Riedler, Josef; von Mutius, Erika; Scheynius, Annika; Pershagen, Goran; Doekes, Gert; Lauener, Roger; Martinez, Fernando D.		PARSIFAL Study Grp	A polymorphism in CD14 modifies the effect of farm milk consumption on allergic diseases and CD14 gene expression	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; asthma; CD14; gene-environment interaction; gene expression; farming; epidemiology	LIPOPOLYSACCHARIDE-BINDING PROTEIN; SCHOOL-AGE-CHILDREN; SERUM IGE LEVELS; ATOPIC SENSITIZATION; INVERSE ASSOCIATION; LIFE-STYLE; EXPOSURE; RECEPTOR; ASTHMA; OMEGA-3-FATTY-ACIDS	Background: Consumption of farm milk in early life is associated with less asthma and allergies. Objective: We hypothesized that genetic variation in the innate immunity receptor CD14 might modify the association between farm milk consumption and asthma and atopy. Methods: Questionnaire data, serum IgE levels, and genotypes for 4 single nucleotide polymorphisms in CD14 were assessed in farmers' and nonfarmers' children from 2 European populations (Allergy and Endotoxin study, n = 576; Prevention of Allergy Risk factors for Sensitization in children related to Farming and Anthroposophic Lifestyle study, n = 1539). In a subsample (n = 222) CD14 gene expression was measured in peripheral blood leukocytes. The effects of farm milk and CD14 genotypes on asthma, allergies, and CD14 expression and their interactions were investigated. Results: We found a significant interaction between genetic variation in CD14/-1721 and farm milk consumption. Adjusted odds ratios for the association between farm milk and asthma varied between the genotypes: AA, 0.18 (95% CI, 0.07-0.47); AG, 0.47 (95% CI, 0.26-0.86); and GG, 0.98 (95% CI, 0.46-2.08). Similar patterns were observed for symptoms of allergic rhinoconjunctivitis and pollen sensitization. CD14/-1721 also modified the association between farm milk and CD14 gene expression (adjusted geometric means ratios: AA, 1.61 (95% CI, 0.98-2.66); AG, I. 11 (95% CI, 0.71-1.72); and GG, 0.76 (95% CI, 0.39-1.48). Conclusion: The protective effect of farm milk consumption on allergic diseases is stronger in children carrying the A allele in CD14/-1721 than in children homozygous for the G allele. This might be mediated through farm milk-induced upregulated CD14 gene expression. Clinical implications: Our results support the hypothesis that the inverse association between farm milk consumption and allergic diseases is mediated by CD14-activated innate immune mechanisms.	[Bieli, Christian; Braun-Fahrlaender, Charlotte; Waser, Marco] Univ Basel, Inst Social & Prevent Med, CH-4051 Basel, Switzerland; [Eder, Waltraud; Klimecki, Walt; Martinez, Fernando D.] Univ Arizona, Arizona Resp Ctr, Tucson, AZ USA; [Eder, Waltraud; von Mutius, Erika] Univ Childrens Hosp Munich, Munich, Germany; [Frei, Remo; Lauener, Roger] Univ Zurich, Childrens Hosp, CH-8006 Zurich, Switzerland; [Riedler, Josef] Childrens Hosp Schwarzach, Schwarzach, Austria; [Scheynius, Annika] Karolinska Inst, Clin Allergy Res Unit, Dept Med, Stockholm, Sweden; [Scheynius, Annika] St Gorans Univ Hosp, S-11281 Stockholm, Sweden; [Pershagen, Goran] Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden; [Doekes, Gert] Univ Utrecht, Inst Risk Assessment Sci, Utrecht, Netherlands	University of Basel; University of Arizona; University of Munich; University Children's Hospital Zurich; University of Zurich; Karolinska Institutet; Saint Goran's Hospital; Karolinska Institutet; Utrecht University	Bieli, C (corresponding author), Univ Basel, Inst Social & Prevent Med, Steinengraben 49, CH-4051 Basel, Switzerland.	christian.bieli@unibas.ch	riedler, josef/AAQ-4666-2020; van Hage, Marianne/A-9678-2017; Frei, Remo/AAI-9180-2020; Lauener, Roger P/O-8612-2016; Bieli, Christian/F-7209-2014	van Hage, Marianne/0000-0003-3091-1596; Lauener, Roger P/0000-0002-8412-606X; von Mutius, Erika/0000-0002-8893-4515; Bieli, Christian/0000-0002-2128-6082; Pershagen, Goran/0000-0002-9701-1130	NHLBI NIH HHS [HL66800, HL67672, HL66806] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL066806, P50HL067672, P01HL067672, U01HL066800] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alfven T, 2006, ALLERGY, V61, P414, DOI 10.1111/j.1398-9995.2005.00939.x; Blumer N, 2007, J PERINAT MED, V35, pS12, DOI 10.1515/JPM.2007.031; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Braun-Fahrlander C, 2002, ALLERGY, V57, P1094, DOI 10.1034/j.1398-9995.2002.23644.x; Carlson CS, 2004, AM J HUM GENET, V74, P106, DOI 10.1086/381000; Cleveland MG, 1996, INFECT IMMUN, V64, P1906, DOI 10.1128/IAI.64.6.1906-1912.1996; Desmasures N, 1997, J APPL MICROBIOL, V83, P53, DOI 10.1046/j.1365-2672.1997.00166.x; Eder W, 2005, J ALLERGY CLIN IMMUN, V116, P601, DOI 10.1016/j.jaci.2005.05.003; Ege MJ, 2006, J ALLERGY CLIN IMMUN, V117, P817, DOI 10.1016/j.jaci.2005.12.1307; Gern JE, 2004, J ALLERGY CLIN IMMUN, V113, P307, DOI 10.1016/j.jaci.2003.11.017; Gupta D, 1996, J BIOL CHEM, V271, P23310, DOI 10.1074/jbc.271.38.23310; HEBEISEN DF, 1993, INT J VITAM NUTR RES, V63, P229; Hwang I, 2007, LIPIDS, V42, P345, DOI 10.1007/s11745-007-3033-9; Jiang QQ, 2000, J IMMUNOL, V165, P3541, DOI 10.4049/jimmunol.165.7.3541; Kalliomaki M, 2001, J ALLERGY CLIN IMMUN, V107, P129, DOI 10.1067/mai.2001.111237; Landmann R, 2000, MICROBES INFECT, V2, P295, DOI 10.1016/S1286-4579(00)00298-7; Lauener RP, 2002, LANCET, V360, P465, DOI 10.1016/S0140-6736(02)09641-1; LeVan TD, 2001, J IMMUNOL, V167, P5838, DOI 10.4049/jimmunol.167.10.5838; McKeever TM, 2004, AM J RESP CRIT CARE, V170, P725, DOI 10.1164/rccm.200405-611PP; Muta T, 2001, EUR J BIOCHEM, V268, P4580, DOI 10.1046/j.1432-1327.2001.02385.x; Perkin MR, 2006, J ALLERGY CLIN IMMUN, V117, P1374, DOI 10.1016/j.jaci.2006.03.008; Posada D, 2004, SYST BIOL, V53, P793, DOI 10.1080/10635150490522304; Radon K, 2004, CLIN EXP ALLERGY, V34, P1178, DOI 10.1111/j.1365-2222.2004.02005.x; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Schlimme E, 1996, KIELER MILCHW FORSCH, V48, P5; Schmitz G, 2002, CURR OPIN LIPIDOL, V13, P513, DOI 10.1097/00041433-200210000-00007; Stern DA, 2007, J ALLERGY CLIN IMMUN, V119, P351, DOI 10.1016/j.jaci.2006.10.013; Sugiyama T, 2001, J IMMUNOL, V166, P826, DOI 10.4049/jimmunol.166.2.826; Tomita Mikio, 2004, Drug Metab Pharmacokinet, V19, P33, DOI 10.2133/dmpk.19.33; Waser M, 2007, CLIN EXP ALLERGY, V37, P661, DOI 10.1111/j.1365-2222.2006.02640.x; Wickens K, 2002, ALLERGY, V57, P1171, DOI 10.1034/j.1398-9995.2002.t01-1-23644.x; Williams LK, 2006, J ALLERGY CLIN IMMUN, V118, P851, DOI 10.1016/j.jaci.2006.07.007; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Yu B, 1997, J CLIN INVEST, V99, P315, DOI 10.1172/JCI119160; Zambelli-Weiner A, 2005, J ALLERGY CLIN IMMUN, V115, P1203, DOI 10.1016/j.jaci.2005.03.001	35	78	81	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2007	120	6					1308	1315		10.1016/j.jaci.2007.07.034	http://dx.doi.org/10.1016/j.jaci.2007.07.034			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	241JX	17919709				2022-12-18	WOS:000251653800010
J	Mazzolari, E; Forino, C; Guerci, S; Imberti, L; Lanfranchi, A; Porta, F; Notarangelo, LD				Mazzolari, Evelina; Forino, Concetta; Guerci, Sara; Imberti, Luisa; Lanfranchi, Arnalda; Porta, Fulvio; Notarangelo, Luigi D.			Long-term immune reconstitution and clinical outcome after stem cell transplantation for severe T-cell immunodeficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						T-cell immunodeficiency; severe combined immune deficiency; hematopoietic stem cell transplantation; immune reconstitution; quality of life	BONE-MARROW-TRANSPLANTATION; THYMIC OUTPUT; DEFICIENCY; DISEASE; REPERTOIRE; CHIMERISM; SURVIVAL; DEFECTS; THERAPY	Background: Currently, hematopoietic stem cell transplantation allows long-term survival in a high proportion of infants with congenital severe T-cell immunodeficiency. However, relatively little is known of their long-term quality of life. Objective: We sought to assess the long-term immune reconstitution and clinical status in children treated with stem cell transplantation for severe T-cell immunodeficiency. Methods: Immune function and clinical status have been analyzed in a cohort of 40 patients with severe T-cell immunodeficiency who are alive at a follow-up of at least 5 years after transplantation. Results: Most patients have attained normal T- and B-cell function. Weight and height were normal at last follow-up in most patients. Endocrine and severe neurologic abnormalities have been observed in 17.5 % and 10 % of the patients, respectively. Conclusions: These data indicate that with current management strategies, stem cell transplantation can lead to long-term survival and good quality of life in the majority of patients with severe T-cell immunodeficiency. Clinical implications: Prompt recognition of congenital severe T-cell immunodeficiency, followed by stem cell transplantation, allows excellent perspectives of long-term survival and good quality of life for these otherwise fatal disorders.	Harvard Univ, Sch Med, Childrens Hosp, Div Immunol, Boston, MA 02115 USA; Univ Brescia, Dipartimento Maternoinfantile & Tecnol Biomed, I-25121 Brescia, Italy	Harvard University; Boston Children's Hospital; Harvard Medical School; University of Brescia	Notarangelo, LD (corresponding author), Harvard Univ, Sch Med, Childrens Hosp, Div Immunol, Karp Family Bldg,9th Floor,Room 9210,1 Blackfan C, Boston, MA 02115 USA.	luigi.notarangelo@childrens.harvard.edu	Notarangelo, Luigi D/F-9718-2016	Notarangelo, Luigi D/0000-0002-8335-0262; Imberti, Luisa/0000-0002-2075-8391				Antoine C, 2003, LANCET, V361, P553, DOI 10.1016/S0140-6736(03)12513-5; Borghans JA, 2006, BLOOD, V108, P763, DOI 10.1182/blood-2006-01-009241; Buckley RH, 1999, NEW ENGL J MED, V340, P508, DOI 10.1056/NEJM199902183400703; Buckley RH, 2004, ANNU REV IMMUNOL, V22, P625, DOI 10.1146/annurev.immunol.22.012703.104614; Cavazzana-Calvo M, 2007, BLOOD, V109, P4575, DOI 10.1182/blood-2006-07-029090; Chan K, 2005, J ALLERGY CLIN IMMUN, V115, P391, DOI 10.1016/j.jaci.2004.10.012; Fischer A, 2005, IMMUNOL REV, V203, P98, DOI 10.1111/j.0105-2896.2005.00223.x; FISCHER A, 2004, IMMUNOLOGIC DISORDER, P447; Grunebaum E, 2006, JAMA-J AM MED ASSOC, V295, P508, DOI 10.1001/jama.295.5.508; Haddad E, 1999, BLOOD, V94, P2923, DOI 10.1182/blood.V94.8.2923.420k44_2923_2930; Haddad E, 1998, BLOOD, V91, P3646; Honig M, 2007, BLOOD, V109, P3595, DOI 10.1182/blood-2006-07-034678; Laffort C, 2004, LANCET, V363, P2051, DOI 10.1016/S0140-6736(04)16457-X; Lee V, 2006, J PEDIAT HEMATOL ONC, V28, P293, DOI 10.1097/01.mph.0000212907.14642.41; Myers LA, 2002, BLOOD, V99, P872, DOI 10.1182/blood.V99.3.872; Oakes SA, 1996, IMMUNITY, V5, P605, DOI 10.1016/S1074-7613(00)80274-5; Ozaki K, 2002, SCIENCE, V298, P1630, DOI 10.1126/science.1077002; Patel DD, 2000, NEW ENGL J MED, V342, P1325, DOI 10.1056/NEJM200005043421804; Pirovano S, 2004, HAEMATOLOGICA, V89, P450; Puck JM, 2007, J ALLERGY CLIN IMMUN, V120, P760, DOI 10.1016/j.jaci.2007.08.043; Roberts JL, 2004, BLOOD, V103, P2009, DOI 10.1182/blood-2003-06-2104; Rogers MH, 2001, J PEDIATR-US, V139, P44, DOI 10.1067/mpd.2001.115023; Sarzotti M, 2003, J IMMUNOL, V170, P2711, DOI 10.4049/jimmunol.170.5.2711; SKLAR C, 2001, FRONT BIOSCI, V6, pG7; Slatter MA, 2004, BONE MARROW TRANSPL, V33, P949, DOI 10.1038/sj.bmt.1704456; Waruiru C, 2007, PEDIATR INFECT DIS J, V26, P129, DOI 10.1097/01.inf.0000250621.46742.b5; White H, 2000, EUR J IMMUNOL, V30, P732; Zhang LQ, 1999, J EXP MED, V190, P725, DOI 10.1084/jem.190.5.725	28	78	80	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2007	120	4					892	899		10.1016/j.jaci.2007.08.007	http://dx.doi.org/10.1016/j.jaci.2007.08.007			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	220LH	17825895				2022-12-18	WOS:000250157700025
J	Larche, M				Larche, Mark			Update on the current status of peptide immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						epitope; immunologic tolerance; T cell; regulatory T cell; peptide; allergen; immunotherapy; IL-10	LATE ASTHMATIC REACTIONS; CAT-ALLERGIC SUBJECTS; T-CELL PEPTIDES; INDUCTION; THERAPY; TRIAL	The use of synthetic peptide fragments of allergen molecules holds promise for the delivery of effective immunotherapy without IgE-mediated adverse events. Early studies were associated with frequent induction of allergic symptoms after treatment, mostly related to activation of allergen-specific effector T cells with high doses of peptides. More recently, low doses of peptides have been shown to modify clinical and laboratory surrogates without inducing adverse events. Studies are ongoing to define the optimal dose, dose interval, and route of administration. Current results indicate that treatment with peptides modulates the immune response by reducing T(H)2 responses to allergen and increasing IL-10 production and the activity of allergen-specific regulatory T cells. Further studies are required in larger numbers of subjects and with peptides derived from a variety of allergens.	McMaster Univ, Fac Hlth Sci, Dept Med, Div Clin Immunol & Allergy,HSC, Hamilton, ON L8N 3Z5, Canada	McMaster University	Larche, M (corresponding author), McMaster Univ, Fac Hlth Sci, Dept Med, Div Clin Immunol & Allergy,HSC, Room 4H20,1200 Main St W, Hamilton, ON L8N 3Z5, Canada.	larche@mcmaster.ca	Larche, Mark/B-4326-2010	Larche, Mark/0000-0002-1439-7593				Alexander C, 2005, ALLERGY, V60, P1269, DOI 10.1111/j.1398-9995.2005.00885.x; Alexander C, 2005, CLIN EXP ALLERGY, V35, P52, DOI 10.1111/j.1365-2222.2005.02143.x; Fellrath JM, 2003, J ALLERGY CLIN IMMUN, V111, P854, DOI 10.1067/mai.2003.1337; Haselden BM, 1999, J EXP MED, V189, P1885, DOI 10.1084/jem.189.12.1885; Larche M, 2005, PHARMACOL THERAPEUT, V108, P353, DOI 10.1016/j.pharmthera.2005.05.004; Maguire P, 1999, CLIN IMMUNOL, V93, P222, DOI 10.1006/clim.1999.4795; Muller U, 1998, J ALLERGY CLIN IMMUN, V101, P747, DOI 10.1016/S0091-6749(98)70402-6; Norman PS, 1996, AM J RESP CRIT CARE, V154, P1623, DOI 10.1164/ajrccm.154.6.8970345; Oldfield WLG, 2002, LANCET, V360, P47, DOI 10.1016/S0140-6736(02)09332-7; Oldfield WLG, 2001, J IMMUNOL, V167, P1734, DOI 10.4049/jimmunol.167.3.1734; Pene J, 1998, J ALLERGY CLIN IMMUN, V102, P571, DOI 10.1016/S0091-6749(98)70294-5; Simons FER, 1996, INT IMMUNOL, V8, P1937, DOI 10.1093/intimm/8.12.1937; Smith TRF, 2004, ALLERGY, V59, P1097, DOI 10.1111/j.1398-9995.2004.00601.x; Tarzi M, 2006, CLIN EXP ALLERGY, V36, P465, DOI 10.1111/j.1365-2222.2006.02469.x; Verhoef A, 2005, PLOS MED, V2, P253, DOI 10.1371/journal.pmed.0020078	15	78	86	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2007	119	4					906	909		10.1016/j.jaci.2007.02.015	http://dx.doi.org/10.1016/j.jaci.2007.02.015			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	157OK	17418662	Bronze			2022-12-18	WOS:000245729500019
J	MacGlashan, DW				MacGlashan, Donald W., Jr.			Relationship between spleen tyrosine kinase and phosphatidylinositol 5 ' phosphatase expression and secretion from human basophils in the general population	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						human; basophil; allergy; Fc receptors	HISTAMINE-RELEASING FACTOR; IGE-MEDIATED STIMULATION; NONRELEASING HUMAN BASOPHILS; PROTEIN-LEVELS; MESSENGER-RNA; MAST-CELLS; SERUM IGE; ACTIVATION; SHIP; 5'-PHOSPHATASE	Background: Previous studies have suggested that expression levels of spleen tyrosine kinase (syk) or phosphatidylinositol 5' phosphatase (SHIP) may explain certain extreme human basophil phenotypes. Objective: This study is designed to explore whether variability in syk and SHIP expression levels in the general population, alone or in concert, can account for the variability in basophil function. Methods: A survey of maximum responsiveness to IgE-mediated stimulation, sensitivity, and expression levels of 6 early signaling elements was performed on 36 subjects' basophils. Results: Of the 6 signaling elements, only syk and SHIP showed a correlation with maximum histamine release or cellular sensitivity. In a multiple regression, syk and SHIP together could account for 67 % of population variance, although most of the variance was explained by syk expression. The pattern of expression variance syk >> SHIP1 > SHIP2 approximate to lyn approximate to p85 approximate to cbl suggested a process that primarily modulated syk levels. IL-3 is known to modulate syk levels, but we found that a 3-day incubation with IL-3 resulted in increased expression of other signaling elements to a greater degree: cbl > SHIEP1 > SHIP2 approximate to lyn approximate to p85 >= syk, opposite the pattern in the population survey. In contrast, 18-hour stimulation with anti-IgE antibody led to marked downregulation of syk expression, modest downregulation of Fc is an element of RI expression, weak downregulation of lyn expression, and no effect on 23 other signaling elements. Conclusion: Unlike studies in mice, we conclude that expression of syk is a good preconditioning predictor of basophil function in the general population. Clinical implications: The finding that expression of syk levels may strongly influence functional responses of basophils suggests a mechanism underlying the severity of atopic diseases.	Johns Hopkins Asthma & Allergy Ctr, Baltimore, MD 21224 USA	Johns Hopkins University; Johns Hopkins Medicine	MacGlashan, DW (corresponding author), Johns Hopkins Asthma & Allergy Ctr, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.	dmacglas@jhmi.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020253] Funding Source: NIH RePORTER; NIAID NIH HHS [AI20253] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALAM R, 1995, INT ARCH ALLERGY IMM, V107, P226, DOI 10.1159/000236985; Brauweiler AM, 2000, IMMUNOL REV, V176, P69; CONROY MC, 1977, J IMMUNOL, V118, P1317; GILBERT HS, 1975, BLOOD, V46, P279; GOLDSTEIN B, 1979, J IMMUNOL, V123, P1873; Huber M, 1998, P NATL ACAD SCI USA, V95, P11330, DOI 10.1073/pnas.95.19.11330; Kepley CL, 2000, J IMMUNOL, V165, P5913, DOI 10.4049/jimmunol.165.10.5913; Kepley CL, 1999, J ALLERGY CLIN IMMUN, V104, P279, DOI 10.1016/S0091-6749(99)70367-2; Kepley CL, 2005, INT ARCH ALLERGY IMM, V138, P29, DOI 10.1159/000087355; Lavens-Phillips SE, 2000, AM J RESP CELL MOL, V23, P566, DOI 10.1165/ajrcmb.23.4.4123; MacDonald SM, 1996, J INVEST MED, V44, pA222; MACDONALD SM, 1995, SCIENCE, V269, P688, DOI 10.1126/science.7542803; MacGlashan D, 2004, J ALLERGY CLIN IMMUN, V114, P1317, DOI 10.1016/j.jaci.2004.08.037; MACGLASHAN D, 1994, J IMMUNOL, V152, P3006; MacGlashan D, 2001, J LEUKOCYTE BIOL, V69, P224; MacGlashan D, 2000, J LEUKOCYTE BIOL, V68, P479; Macglashan D. W. Jr., 1997, Journal of Allergy and Clinical Immunology, V99, pS103; MACGLASHAN DW, 1986, J IMMUNOL, V136, P2231; MACGLASHAN DW, 1993, J ALLERGY CLIN IMMUN, V91, P605, DOI 10.1016/0091-6749(93)90266-I; MALVEAUX FJ, 1978, J CLIN INVEST, V62, P176, DOI 10.1172/JCI109103; Miura K, 2000, BLOOD, V96, P2199, DOI 10.1182/blood.V96.6.2199.h8002199_2199_2205; NGUYEN KL, 1990, J ALLERGY CLIN IMMUN, V85, P1020, DOI 10.1016/0091-6749(90)90046-7; Rauh MJ, 2003, BIOCHEM SOC T, V31, P286, DOI 10.1042/bst0310286; Sly LM, 2003, EXP HEMATOL, V31, P1170, DOI 10.1016/j.exphem.2003.09.011; Torigoe C, 1997, P NATL ACAD SCI USA, V94, P1372, DOI 10.1073/pnas.94.4.1372; Vilarino N, 2005, J IMMUNOL, V175, P3006, DOI 10.4049/jimmunol.175.5.3006; Vilarino N, 2005, J IMMUNOL METHODS, V296, P11, DOI 10.1016/j.jim.2004.10.009; Vilarino N, 2004, J LEUKOCYTE BIOL, V75, P928, DOI 10.1189/jlb.0903431; Vonakis BM, 2001, J ALLERGY CLIN IMMUN, V108, P822, DOI 10.1067/mai.2001.119159; WARNER JA, 1990, J IMMUNOL, V145, P1897; Yamaguchi M, 1996, J ALLERGY CLIN IMMUN, V97, P1279, DOI 10.1016/S0091-6749(96)70196-3	31	78	80	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2007	119	3					626	633		10.1016/j.jaci.2006.09.040	http://dx.doi.org/10.1016/j.jaci.2006.09.040			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	146HL	17336612				2022-12-18	WOS:000244925000015
J	Kull, I; Bergstrom, A; Melen, E; Lilja, G; van Hage, M; Pershagen, G; Wickman, M				Kull, Inger; Bergstrom, Anna; Melen, Erik; Lilja, Gunnar; van Hage, Marianne; Pershagen, Goran; Wickman, Magnus			Early-life supplementation of vitamins A and D, in water-soluble form or in peanut oil, and allergic diseases during childhood	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic disease; asthma; BAMSE; childhood; fatty acids; prevention; sensitization; vitamin D	BIRTH COHORT; RISK; ASTHMA	Background: Early vitamin supplementation is given routinely to infants in many countries, but it is unclear whether this affects the risk of allergic diseases. Objectives: We sought to study the association between early-life supplementation of vitamins A and D in water-soluble form or in peanut oil and allergic diseases up to 4 years of age. Methods: A prospective birth cohort of 4089 newborn infants was followed for 4 years using parental questionnaires repeatedly to collect information on exposure and health. At 4 years, the response rate was 90%, and allergen-specific IgE levels to food and airborne allergens were measured in 2614 of the participating children. Results: Vitamins A and D were given to 98% of the children in infancy, and vitamins based in peanut oil dominated (90%). Children supplemented with vitamins A and D in water-soluble form during the first year of life had an almost 2-fold increased risk of asthma (adjusted odds ratio [OD], 2.18; 95% CI, 1.45-3.28), food hypersensitivity (adjusted OR, 1.89; 95% CI, 1.33-2.65), and sensitization to common food and airborne allergens (adjusted OR, 1.88; 95% CI, 1.34-2.64) at age 4 years compared with those receiving vitamins in peanut oil. No increased risk of IgE antibodies to peanut was seen in children receiving vitamins in peanut oil. Conclusion: Supplementation of vitamins A and D in water-soluble form seems to increase the risk of allergic disease up to the age of 4 years compared with supplementation with the same vitamins given in peanut oil. Clinical implications: Vitamins A and D in oil does not seem to increase the risk of allergic disease during childhood.	Stockholm Cty Council, Dept Environm & Occupat Hlth, SE-17176 Stockholm, Sweden; Karolinska Inst, Natl Inst Environm Med, S-10401 Stockholm, Sweden; Karolinska Inst, Sachs Childrens Hosp, Inst Sodersjukhuset, S-10401 Stockholm, Sweden; Karolinska Inst, Ctr Allergy Res, S-10401 Stockholm, Sweden; Karolinska Inst, Dept Med, Allergy & Clin Immunol Unit, S-10401 Stockholm, Sweden	Stockholm County Council; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet	Kull, I (corresponding author), Stockholm Cty Council, Dept Environm & Occupat Hlth, SE-17176 Stockholm, Sweden.	inger.kull@sll.se	van Hage, Marianne/A-9678-2017	van Hage, Marianne/0000-0003-3091-1596; Pershagen, Goran/0000-0002-9701-1130; Kull, Inger/0000-0001-6096-3771				APRO W, 2002, NARINGSTABELLERNA NA; Bohme M, 2002, ACTA DERM-VENEREOL, V82, P98, DOI 10.1080/00015550252948112; Calder PC, 2002, EUR J CLIN NUTR, V56, pS14, DOI 10.1038/sj.ejcn.1601478; DEMONTIS G, 1993, LANCET, V341, P1411, DOI 10.1016/0140-6736(93)90976-N; Devereux G, 2005, J ALLERGY CLIN IMMUN, V115, P1109, DOI 10.1016/j.jaci.2004.12.1139; Gartner LM, 2003, PEDIATRICS, V111, P908, DOI 10.1542/peds.111.4.908; Harik-Khan RI, 2004, AM J EPIDEMIOL, V159, P351, DOI 10.1093/aje/kwh053; Hypponen E, 2004, ANN NY ACAD SCI, V1037, P84, DOI 10.1196/annals.1337.013; Hypponen E, 2001, LANCET, V358, P1500, DOI 10.1016/S0140-6736(01)06580-1; JOHNSON EJ, 1992, AM J CLIN NUTR, V55, P857, DOI 10.1093/ajcn/55.4.857; Kull I, 2004, J ALLERGY CLIN IMMUN, V114, P755, DOI 10.1016/j.jaci.2004.07.036; Kull I, 1999, PEDIATR ALLERGY IMMU, V10, P21, DOI 10.1034/j.1398-9995.1999.101019.x; Lack G, 2003, NEW ENGL J MED, V348, P977, DOI 10.1056/NEJMoa013536; Long KZ, 1999, PEDIATR INFECT DIS J, V18, P283, DOI 10.1097/00006454-199903000-00018; Martindale S, 2005, AM J RESP CRIT CARE, V171, P121, DOI 10.1164/rccm.200402-220OC; McKeever TM, 2004, J ALLERGY CLIN IMMUN, V114, P1398, DOI 10.1016/j.jaci.2004.08.006; Milner JD, 2004, PEDIATRICS, V114, P27, DOI 10.1542/peds.114.1.27; Myhre AM, 2003, AM J CLIN NUTR, V78, P1152, DOI 10.1093/ajcn/78.6.1152; Nafstad P, 2003, J ASTHMA, V40, P343, DOI 10.1081/JAS-120018633; *NAT BOARD HLTH WE, 1978, SOC KUNG AD VIT PROF, V25; Oddy WH, 2002, J ALLERGY CLIN IMMUN, V110, P65, DOI 10.1067/mai.2002.125296; RAM FS, 2004, COCHRANE DB SYST REV; Simopoulos AP, 2002, J AM COLL NUTR, V21, P495, DOI 10.1080/07315724.2002.10719248; Wickman M, 2003, ALLERGY, V58, P742, DOI 10.1034/j.1398-9995.2003.00078.x; Wickman M, 2004, ALLERGY, V59, P30, DOI 10.1111/j.1398-9995.2004.00572.x; Wickman M, 2002, PEDIATR ALLERGY IMMU, V13, P11, DOI 10.1034/j.1399-3038.13.s.15.10.x	26	78	79	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2006	118	6					1299	1304		10.1016/j.jaci.2006.08.022	http://dx.doi.org/10.1016/j.jaci.2006.08.022			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	117NP	17157660				2022-12-18	WOS:000242880300014
J	Herszberg, B; Ramos-Barbon, D; Tamaoka, M; Martin, JG; Lavoie, JP				Herszberg, Berenice; Ramos-Barbon, David; Tamaoka, Meiyo; Martin, James G.; Lavoie, Jean-Pierre			Heaves, an asthma-like equine disease, involves airway smooth muscle remodeling	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						airway obstruction; apoptosis; animal disease models; hyperplasia; smooth muscle cells	ANIMAL-MODELS; PULMONARY; HORSES; INFLAMMATION; APOPTOSIS; MOLD; FAS; IGE	Background: Increased airway smooth muscle mass is a prominent feature of asthmatic airway remodeling. Airway smooth muscle hyperplasia occurs in rodent models of experimental asthma, but the relevance of such finding to spontaneously occurring disease in large mammals is unknown. Objective: We examined horses with heaves, a naturally occurring equine asthma related to sensitization and exposure to moldy hay. We hypothesized that airway remodeling occurs in heaves and shares disease mechanisms with asthma. Methods: We quantified the airway smooth muscle mass and the numbers of proliferating and apoptotic airway smooth muscle cells in 5 horses with heaves and 5 control horses using morphometric techniques. Cell proliferation was detected in tissue sections by immunostaining for proliferating cell nuclear antigen, and apoptotic cells were detected by terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling of fragmented DNA. Both signals were colocalized with smooth muscle specific alpha-actin. Results: Horses with heaves had a significant increase in the amount of smooth muscle in the airways (nearly triple that of the controls) associated with increased myocyte proliferation (7-fold proliferating cell nuclear antigen-positive airway myocytes) and apoptosis (6-fold). Conclusion: Heaves involves airway smooth muscle growth associated with myocyte hyperplasia, which may contribute to the growth, and increased myocyte apoptosis that may reflect a compensatory mechanism serving to limit the abnormal smooth muscle growth. Clinical implications: Airway smooth muscle remodeling in heaves may be involved in the mechanism of airway hyperresponsiveness and chronic lung function impairment in a way comparable to human asthma.	McGill Univ, Meakins Christie Labs, Montreal, PQ H2X 2P2, Canada; Univ Montreal, Fac Med Vet, St Hyacinthe, PQ J2S 7C6, Canada	McGill University; Universite de Montreal	Martin, JG (corresponding author), McGill Univ, Meakins Christie Labs, 3626 St Urbain St, Montreal, PQ H2X 2P2, Canada.	james.martin@mcgill.ca	RAMOS-BARBON, DAVID/C-6624-2009	RAMOS-BARBON, DAVID/0000-0002-9615-6557; Martin, James/0000-0001-7574-5363				Benayoun L, 2003, AM J RESP CRIT CARE, V167, P1360, DOI 10.1164/rccm.200209-1030OC; Bice DE, 2000, INHAL TOXICOL, V12, P829; *CAN THOR SOC, 2004, CAN RESP J SA, V11, pA10; CARROLL N, 1993, AM REV RESPIR DIS, V147, P405, DOI 10.1164/ajrccm/147.2.405; Davies DE, 2003, J ALLERGY CLIN IMMUN, V111, P215, DOI 10.1067/mai.2003.128; DUNNILL MS, 1969, THORAX, V24, P176, DOI 10.1136/thx.24.2.176; EBINA M, 1990, AM REV RESPIR DIS, V141, P1327, DOI 10.1164/ajrccm/141.5_Pt_1.1327; Eder C, 2000, VET IMMUNOL IMMUNOP, V73, P241, DOI 10.1016/S0165-2427(00)00154-9; Ellis R, 2003, LAB INVEST, V83, P1285, DOI 10.1097/01.LAB.0000087586.25982.B5; EYRE P, 1972, VET REC, V91, P134, DOI 10.1136/vr.91.6.134; Geng YJ, 1997, ARTERIOSCL THROM VAS, V17, P2200, DOI 10.1161/01.ATV.17.10.2200; HALLIWELL REW, 1993, VET IMMUNOL IMMUNOP, V38, P201, DOI 10.1016/0165-2427(93)90081-E; Hamann KJ, 2000, AM J PHYSIOL-LUNG C, V278, pL618, DOI 10.1152/ajplung.2000.278.3.L618; Hirst Stuart J, 2004, J Allergy Clin Immunol, V114, pS2, DOI 10.1016/j.jaci.2004.04.039; HOSSAIN S, 1973, AM REV RESPIR DIS, V107, P99; Huber HL, 1922, ARCH INTERN MED, V30, P689, DOI 10.1001/archinte.1922.00110120002001; JAMES AL, 1988, AM REV RESPIR DIS, V138, P136, DOI 10.1164/ajrccm/138.1.136; Johnson PRA, 2001, AM J RESP CRIT CARE, V164, P474, DOI 10.1164/ajrccm.164.3.2010109; LAMBERT RK, 1993, J APPL PHYSIOL, V74, P2771, DOI 10.1152/jappl.1993.74.6.2771; Lavoie JP, 2001, AM J RESP CRIT CARE, V164, P1410, DOI 10.1164/ajrccm.164.8.2012091; Leguillette R, 2003, VET CLIN N AM-EQUINE, V19, P63, DOI 10.1016/S0749-0739(02)00067-6; Leigh R, 2002, AM J RESP CELL MOL, V27, P526, DOI 10.1165/rcmb.2002-0048OC; LOWELL FC, 1964, J ALLERGY, V35, P322, DOI 10.1016/0021-8707(64)90095-4; Lugo J, 2002, AM J VET RES, V63, P1232, DOI 10.2460/ajvr.2002.63.1232; *NAT HEART LUNG BL, 2002, 2 NAT HEART LUNG BLO; Panettieri Reynold Jr., 1998, American Journal of Physiology, V274, pL417; Ramos-Barbon D, 2005, J CLIN INVEST, V115, P1580, DOI 10.1172/JCI19711; SAETTA M, 1991, AM REV RESPIR DIS, V143, P138, DOI 10.1164/ajrccm/143.1.138; Salmon M, 1999, BRIT J PHARMACOL, V127, P1151, DOI 10.1038/sj.bjp.0702669; SAPIENZA S, 1991, AM REV RESPIR DIS, V144, P423, DOI 10.1164/ajrccm/144.2.423; Savage CJ, 1998, J VET INTERN MED, V12, P456, DOI 10.1111/j.1939-1676.1998.tb02150.x; Schmallenbach KH, 1998, VET IMMUNOL IMMUNOP, V66, P245, DOI 10.1016/S0165-2427(98)00202-5; Shinagawa K, 2003, AM J RESP CRIT CARE, V168, P959, DOI 10.1164/rccm.200210-1188OC; SNAPPER JR, 1986, AM REV RESPIR DIS, V133, P351; THURLBECK WM, 1964, AM REV RESPIR DIS, V89, P82; WIGGS BR, 1992, AM REV RESPIR DIS, V145, P1251, DOI 10.1164/ajrccm/145.6.1251; WIGGS BR, 1990, J APPL PHYSIOL, V69, P849, DOI 10.1152/jappl.1990.69.3.849; Xu KF, 2002, J APPL PHYSIOL, V93, P1833, DOI 10.1152/japplphysiol.00738.2001; Zacour ME, 2000, AM J PHYSIOL-LUNG C, V278, pL59, DOI 10.1152/ajplung.2000.278.1.L59	39	78	78	3	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2006	118	2					382	388		10.1016/j.jaci.2006.03.044	http://dx.doi.org/10.1016/j.jaci.2006.03.044			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	075IH	16890762				2022-12-18	WOS:000239877700013
J	Flinterman, AE; Pasmans, SG; Hoekstra, MO; Meijer, Y; van Hoffen, E; Knol, EF; Hefle, SL; Bruijnzeel-Koomen, CA; Knulst, AC				Flinterman, AE; Pasmans, SG; Hoekstra, MO; Meijer, Y; van Hoffen, E; Knol, EF; Hefle, SL; Bruijnzeel-Koomen, CA; Knulst, AC			Determination of no-observed-adverse-effect levels and eliciting doses in a representative group of peanut-sensitized children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						peanut allergy; children; double-blind placebo-controlled; challenge; no-observed-adverse-effect level; eliciting dose; dietary management; food labeling	DOUBLE-BLIND; ALLERGY; ANAPHYLAXIS; PREVALENCE; FOODS; MANAGEMENT	Background: Current labeling practices for allergenic foods like peanut can be inadequate. For future regulatory and industry guidelines, information on no-observed-adverse-effect levels (NOAELs) and eliciting doses (EDs) for allergenic foods is necessary. Objective: To determine NOAEL and ED in a representative group of peanut-sensitized children, relate these data to history and sensitization, and evaluate the outcome of dietary management. Methods: From an overall eligible group of 96 peanut-sensitized children, a representative group of 27 was evaluated by questionnaires, skin prick test, determination of specific IgE, and double-blind placebo-controlled food challenge (DBPCFC) with peanut according to the international consensus protocol, with 9 doses ranging from 10 mu g to 3 g peanut flour. Dietary management was evaluated over a 12-month period. Results: Twenty-two children (81%) had a positive DBPCFC. The NOAEL in this group was 1 mg peanut flour, corresponding to 2 mg whole peanut. The ED for subjective symptoms (10 mg to 3 g) was significantly lower than for objective symptoms (100 mg to 3 g; P = .002). Severe reactions occurred only at high doses. EDs were not correlated to previous reactions by history, skin prick test, or specific IgE levels. All patients with a positive DBPCFC were advised to follow a strict diet. During the follow-up period, 10 patients had a less strict diet likely containing traces of peanut. In 3 cases, a mild reaction occurred with food products labeled "may contain peanut." Conclusion: The NOAEL in a representative group of children with peanut allergy was 2 mg. Dietary compliance in half of this group was inadequate.	Univ Utrecht, Med Ctr, Dept Dermatol Allergol, NL-3508 GA Utrecht, Netherlands; Univ Utrecht, Med Ctr, Dept Pediat, NL-3508 GA Utrecht, Netherlands; Univ Nebraska, Food allergy Res & Resource Program, Lincoln, NE USA	Utrecht University; Utrecht University; University of Nebraska System; University of Nebraska Lincoln	Flinterman, AE (corresponding author), Univ Utrecht, Med Ctr, Dept Dermatol Allergol, G02-124,POB 85500, NL-3508 GA Utrecht, Netherlands.	a.e.flinterman@umcutrecht.nl	Pasmans, Suzanne/AAI-6016-2021	Pasmans, Suzanne/0000-0003-1018-4475; Knol, Edward/0000-0001-7368-9820				Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; Briggs D, 2001, ALLERGY, V56, P83, DOI 10.1034/j.1398-9995.2001.00925.x; Colland VT, 2004, PATIENT EDUC COUNS, V55, P416, DOI 10.1016/j.pec.2003.04.010; Eigenmann PA, 2002, ALLERGY, V57, P449, DOI 10.1034/j.1398-9995.2002.13494.x; Grimshaw KEC, 2003, CLIN EXP ALLERGY, V33, P1581, DOI 10.1046/j.1365-2222.2003.01795.x; Grundy J, 2002, J ALLERGY CLIN IMMUN, V110, P784, DOI 10.1067/mai.2002.128802; HATHAWAY MJ, 1983, ARCH DIS CHILD, V58, P463, DOI 10.1136/adc.58.6.463; Hourihane JO, 1997, J ALLERGY CLIN IMMUN, V100, P596, DOI 10.1016/S0091-6749(97)70161-1; Humieres J, 2004, ALLERGY, V59, P1259, DOI 10.1111/j.1398-9995.2004.00618.x; Joshi P, 2002, J ALLERGY CLIN IMMUN, V109, P1019, DOI 10.1067/mai.2002.123305; Kagan RS, 2003, J ALLERGY CLIN IMMUN, V112, P1223, DOI 10.1016/j.jaci.2003.09.026; Kemp SF, 1996, JAMA-J AM MED ASSOC, V275, P1636, DOI 10.1001/jama.275.21.1636; Kiening M, 2005, J AGR FOOD CHEM, V53, P3321, DOI 10.1021/jf048394r; Mills ENC, 2004, ALLERGY, V59, P1262, DOI 10.1111/j.1398-9995.2004.00720.x; Moneret-Vautrin DA, 2001, ALLERGY, V56, P1071, DOI 10.1034/j.1398-9995.2001.00047.x; Morisset M, 2003, CLIN EXP ALLERGY, V33, P1046, DOI 10.1046/j.1365-2222.2003.01734.x; Mueller H L, 1966, J Asthma Res, V3, P331; Osterballe M, 2005, ALLERGY, V60, P218, DOI 10.1111/j.1398-9995.2005.00674.x; POULSEN LK, 1993, CLIN EXP ALLERGY, V23, P61, DOI 10.1111/j.1365-2222.1993.tb02485.x; Rance F, 1999, PEDIATR PULM, P165; Rangaraj S, 2004, PEDIAT ALLERG IMM-UK, V15, P449, DOI 10.1111/j.1399-3038.2004.00174.x; Sampson HA, 2003, PEDIATRICS, V111, P1601; Sicherer SH, 2000, J ALLERGY CLIN IMMUN, V105, P582, DOI 10.1067/mai.2000.104941; Sicherer SH, 2005, J ALLERGY CLIN IMMUN, V116, P153, DOI 10.1016/j.jaci.2005.03.017; Sicherer SH, 2003, J ALLERGY CLIN IMMUN, V112, P1203, DOI 10.1016/S0091-6749(03)02026-8; Skolnick HS, 2001, J ALLERGY CLIN IMMUN, V107, P367, DOI 10.1067/mai.2001.112129; Sloane D, 2001, ALLERGY ASTHMA PROC, V22, P321; Spergel JM, 2000, ANN ALLERG ASTHMA IM, V85, P473, DOI 10.1016/S1081-1206(10)62574-4; STALDER JF, 1993, DERMATOLOGY, V186, P23, DOI 10.1159/000247298; Taylor SL, 2004, CLIN EXP ALLERGY, V34, P689, DOI 10.1111/j.1365-2222.2004.1886.x; Vierk K, 2002, J ALLERGY CLIN IMMUN, V109, P1022, DOI 10.1067/mai.2002.124500; Warner JO, 2005, PEDIATR ALLERGY IMMU, V16, P1, DOI 10.1111/j.1399-3038.2005.00260.x; Wensing M, 2002, J ALLERGY CLIN IMMUN, V110, P915, DOI 10.1067/mai.2002.129235	33	78	82	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2006	117	2					448	454		10.1016/j.jaci.2005.11.035	http://dx.doi.org/10.1016/j.jaci.2005.11.035			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IM	16461147				2022-12-18	WOS:000235687300028
J	Kusel, MMH; Holt, PG; de Klerk, N; Sly, PD				Kusel, MMH; Holt, PG; de Klerk, N; Sly, PD			Support for 2 variants of eczema	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eczema; atopiclextrinsic; nonatopiclintrinsic; risk factors	ATOPIC-DERMATITIS; CLINICAL MANIFESTATIONS; ALLERGIC RHINITIS; CHILDHOOD ECZEMA; FAMILY-HISTORY; NATURAL COURSE; HAY-FEVER; DAY-CARE; PREVALENCE; CHILDREN	Background: Studies investigating the natural history and risk factors for eczema have historically considered eczema as a single entity, without regard for the individual's atopic status. The association between atopy and eczema is complex, and as many as (2)/(3) of patients with eczema are not atopic. Objective: To investigate the risk factors for eczema in relation to the child's atopic status in a cohort of high-risk children. Methods: A prospective birth cohort of 263 children was followed for 5 years and closely examined for eczema. Antenatal and postnatal data on environmental exposures were collected by interview. Skin prick test to define atopic status was performed at 6 months and 2 and 5 years of age. Results: Of the subjects, 66.1% had eczema in the first 5 years, and the majority, (85.5%) reported onset of rash in the first year. A third of those with eczema were not atopic (nonatopic/intrinsic eczema). Children with atopic eczema (extrinsic eczema) were more likely to he male, to have been breast-fed longer, and to have a history of food allergies, allergic rhinitis, and current wheeze. Nonatopic eczema was more common in girls, and an association was found with early daycare attendance. Conclusion: This study supports the presence of 2 variants of eczema: atopic eczema occurring early in childhood and nonatopic eczema with early daycare attendance. It is likely that environmental factors have a different effect on these 2 variants of eczema, and future studies should thus consider eczema as 2 variants in determining the effect of attributable risks.	Univ Western Australia, Telethon Inst Child Hlth Res, Ctr Child Hlth Res, Div Clin Sci, Subiaco, WA, Australia; Univ Western Australia, Telethon Inst Child Hlth Res, Ctr Child Hlth Res, Div Cell Biol, Subiaco, WA, Australia; Univ Western Australia, Telethon Inst Child Hlth Res, Ctr Child Hlth Res, Div Biostat & Genet Epidemiol, Subiaco, WA, Australia	Telethon Kids Institute; University of Western Australia; Telethon Kids Institute; University of Western Australia; Telethon Kids Institute; University of Western Australia	Kusel, MMH (corresponding author), Univ Western Australia, Telethon Inst Child Hlth Res, Ctr Child Hlth Res, Div Clin Sci, 100 Roberts Rd, Subiaco, WA, Australia.	mercik@ichr.uwa.edu.au	Holt, Patrick G/H-1548-2011; Sly, Peter D/F-1486-2010; de Klerk, Nicholas H/D-8388-2016	Holt, Patrick G/0000-0003-1193-0935; Sly, Peter D/0000-0001-6305-2201; de Klerk, Nicholas H/0000-0001-9223-0767				ABERG N, 1995, CLIN EXP ALLERGY, V25, P815, DOI 10.1111/j.1365-2222.1995.tb00023.x; ANDERSON LJ, 1988, PEDIATRICS, V82, P300; BOCK SA, 1978, CLIN ALLERGY, V8, P559, DOI 10.1111/j.1365-2222.1978.tb01509.x; Bohme M, 2003, CLIN EXP ALLERGY, V33, P1226, DOI 10.1046/j.1365-2222.2003.01749.x; Butland BK, 1997, BRIT MED J, V315, P717, DOI 10.1136/bmj.315.7110.717; Cabon N, 1996, CONTACT DERMATITIS, V35, P27, DOI 10.1111/j.1600-0536.1996.tb02262.x; Caffarelli C, 1998, ARCH DIS CHILD, V78, P230, DOI 10.1136/adc.78.3.230; Dhar S, 1998, PEDIATR DERMATOL, V15, P347, DOI 10.1046/j.1525-1470.1998.1998015347.x; Flohr C, 2004, J ALLERGY CLIN IMMUN, V114, P150, DOI 10.1016/j.jaci.2004.04.027; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44; Heinrich J, 1999, ENVIRON HEALTH PERSP, V107, P53, DOI 10.2307/3434289; HIDE DW, 1981, ARCH DIS CHILD, V56, P172, DOI 10.1136/adc.56.3.172; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; KAY J, 1994, J AM ACAD DERMATOL, V30, P35, DOI 10.1016/S0190-9622(94)70004-4; Kerkhof M, 2003, CLIN EXP ALLERGY, V33, P1336, DOI 10.1046/j.1365-2222.2003.01751.x; Kulig M, 1999, J ALLERGY CLIN IMMUN, V103, P1173, DOI 10.1016/S0091-6749(99)70195-8; LEVER R, 1988, BRIT J DERMATOL, V119, P189, DOI 10.1111/j.1365-2133.1988.tb03201.x; Marks R, 1999, BRIT J DERMATOL, V140, P468; Moore MM, 2004, PEDIATRICS, V113, P468, DOI 10.1542/peds.113.3.468; Nystad W, 1998, ALLERGY, V53, P1189, DOI 10.1111/j.1398-9995.1998.tb03840.x; Oddy WH, 1999, BMJ-BRIT MED J, V319, P815, DOI 10.1136/bmj.319.7213.815; Oehling A, 1998, ALLERGY, V53, P139, DOI 10.1111/j.1398-9995.1998.tb04985.x; Olesen AB, 1997, BRIT MED J, V314, P1003, DOI 10.1136/bmj.314.7086.1003; OWNBY DR, 1990, J ALLERGY CLIN IMMUN, V86, P279, DOI 10.1016/S0091-6749(05)80088-0; PLATTSMILLS TAE, 1983, CLIN EXP DERMATOL, V8, P233, DOI 10.1111/j.1365-2230.1983.tb01776.x; Rasanen M, 1998, ALLERGY, V53, P885, DOI 10.1111/j.1398-9995.1998.tb03996.x; Remes ST, 1998, ALLERGY, V53, P682, DOI 10.1111/j.1398-9995.1998.tb03954.x; SAARINEN UM, 1979, LANCET, V2, P163; Schafer T, 1997, ALLERGY, V52, P14, DOI 10.1111/j.1398-9995.1997.tb04864.x; SCHAFER T, 1994, ALLERGY CLIN IMMUN S, V2, P170; Schultz Larsen F., 2000, ATOPIC DERMATITIS EP, P113; Schultz-Larsen F., 1993, EPIDEMIOLOGY CLIN AL, V31, P9; SCHWARTZ J, 1990, AM REV RESPIR DIS, V142, P555, DOI 10.1164/ajrccm/142.3.555; Sugiura H, 1998, ACTA DERM-VENEREOL, V78, P293; Takemura Y, 2001, AM J EPIDEMIOL, V154, P115, DOI 10.1093/aje/154.2.115; Tariq SM, 1998, J ALLERGY CLIN IMMUN, V101, P587, DOI 10.1016/S0091-6749(98)70164-2; TAYLOR B, 1984, LANCET, V2, P1255, DOI 10.1016/S0140-6736(84)92805-8; UEHARA M, 1993, ACTA DERM-VENEREOL, V73, P62; VANASPEREN PP, 1984, ACTA PAEDIATR SCAND, V73, P80; Varela P, 1999, PEDIATR DERMATOL, V16, P1, DOI 10.1046/j.1525-1470.1999.99001.x; WALD ER, 1991, J PEDIATR-US, V118, P509, DOI 10.1016/S0022-3476(05)83370-0; WILLIAMS HC, 1992, CLIN EXP DERMATOL, V17, P385, DOI 10.1111/j.1365-2230.1992.tb00244.x; WILLIAMS HC, 1995, DERMATOL CLIN, V13, P649, DOI 10.1016/S0733-8635(18)30070-6; WILLIAMS HC, 1994, BRIT MED J, V308, P1132, DOI 10.1136/bmj.308.6937.1132; WJST M, 1992, MONATSSCHR KINDERH, V140, P769; Wright AL, 2001, THORAX, V56, P192, DOI 10.1136/thorax.56.3.192; WUTHRICH B, 1989, WIEN MED WOCHENSCHR, V139, P156; Wuthrich B, 2002, ALLERGY, V57, P267, DOI 10.1034/j.1398-9995.2002.1n3572.x	48	78	79	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2005	116	5					1067	1072		10.1016/j.jaci.2005.06.038	http://dx.doi.org/10.1016/j.jaci.2005.06.038			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IG	16275378				2022-12-18	WOS:000235686700019
J	Braunstahl, GJ				Braunstahl, GJ			The unified immune system: Respiratory tract-nasobronchial interaction mechanisms in allergic airway disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic rhinitis; asthma; interaction mechanisms; mucosal inflammation; gastrointestinal tract	INDEPENDENT RISK-FACTOR; BRONCHIAL HYPERRESPONSIVENESS; HAY-FEVER; EOSINOPHIL TRAFFICKING; CHILDHOOD ASTHMA; INDUCED SPUTUM; NASAL-MUCOSA; MAST-CELLS; EARLY-LIFE; T-CELLS	Allergy is a systemic disorder that can affect the nose, lungs, eyes, skin, and gastrointestinal tract, simultaneously or in succession, during the course of a patient's life. The reason for the variety in clinical expression of allergic disease is not known. Genetic predisposition, as well as environmental factors, contribute to the development of the allergic phenotype. Local and systemic inflammatory processes also seem to play a role; however, their exact contribution to the clinical manifestation of airway allergy still remains to be. clarified. Although it is clear that allergen exposure of a sensitized target organ is associated with immunopathologic changes at the level of other target organs, the mechanisms underlying this relationship are far from being resolved. Today, most data suggest a systemic link between mucosal sites, involving the bloodstream, bone marrow, and mucosa-associated lymphoid tissue. This review will focus on the interaction between the nose and lungs in allergic disease and the possible implications for the gastrointestinal mucosa.	Erasmus MC, Dept Pulm Med, NL-3015 GD Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC	Braunstahl, GJ (corresponding author), Erasmus MC, Dept Pulm Med, Dr Molewaterplein 40, NL-3015 GD Rotterdam, Netherlands.	g.braunstahl@erasmusmc.nl	Braunstahl, Gert-Jan/AAA-3047-2020	Braunstahl, Gert-Jan/0000-0001-7671-3742				ABERG N, 1993, CLIN EXP ALLERGY, V23, P829, DOI 10.1111/j.1365-2222.1993.tb00260.x; Alvarez MJ, 2000, ALLERGY, V55, P531, DOI 10.1034/j.1398-9995.2000.00534.x; Alvarez MJ, 2000, ALLERGY, V55, P355, DOI 10.1034/j.1398-9995.2000.00312.x; Assanasen P, 2001, AM J RESP CRIT CARE, V164, P1640, DOI 10.1164/ajrccm.164.9.2103086; Assanasen P, 2000, J ALLERGY CLIN IMMUN, V106, P1045; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; BARDIN PG, 1990, J ALLERGY CLIN IMMUN, V86, P82, DOI 10.1016/S0091-6749(05)80126-5; Barnes Kathleen C., 2000, Journal of Allergy and Clinical Immunology, V106, pS192; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Beeh KM, 2003, CLIN EXP ALLERGY, V33, P475, DOI 10.1046/j.1365-2222.2003.01632.x; Berger P, 1999, CLIN EXP ALLERGY, V29, P804; Bjorksten B, 1999, ALLERGY, V54, P17, DOI 10.1111/j.1398-9995.1999.tb04383.x; BLACKLEY CH, 1988, EXPT RESEARCHES CAUS; BLUMENTHAL MN, 1990, GENETIC ENV FACTORS, P132; Boulet LP, 1997, CLIN EXP ALLERGY, V27, P52, DOI 10.1111/j.1365-2222.1997.tb00672.x; Bousquet J, 2004, CLIN EXP ALLERGY, V34, P897, DOI 10.1111/j.1365-2222.2004.01969.x; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; Braunstahl GJ, 2000, AM J RESP CRIT CARE, V161, P2051, DOI 10.1164/ajrccm.161.6.9906121; Braunstahl GJ, 2003, CLIN EXP ALLERGY, V33, P579, DOI 10.1046/j.1365-2222.2003.01652.x; Braunstahl GJ, 2001, J ALLERGY CLIN IMMUN, V107, P469, DOI 10.1067/mai.2001.113046; BUCCA C, 1995, J ALLERGY CLIN IMMUN, V95, P52, DOI 10.1016/S0091-6749(95)70152-4; BUCCA C, 1995, LANCET, V346, P791, DOI 10.1016/S0140-6736(95)91617-2; Campbell JJ, 2001, J IMMUNOL, V166, P2842, DOI 10.4049/jimmunol.166.4.2842; Ceyhan BB, 2003, RESPIRATION, V70, P60, DOI 10.1159/000068407; CHANYEUNG M, 1995, NEW ENGL J MED, V333, P107, DOI 10.1056/NEJM199507133330207; Corren J, 2004, J ALLERGY CLIN IMMUN, V113, P415, DOI 10.1016/j.jaci.2003.11.034; CORREN J, 1992, J ALLERGY CLIN IMMUN, V89, P611, DOI 10.1016/0091-6749(92)90329-Z; CURSCHMANN H, 1883, DTSCH ARCH KLIN MED, V32, P1; Custovic A, 2001, LANCET, V358, P188, DOI 10.1016/S0140-6736(01)05406-X; Danielsson J, 1997, ALLERGY, V52, P331, DOI 10.1111/j.1398-9995.1997.tb00999.x; DELPRETE GF, 1993, EUR J IMMUNOL, V23, P1445, DOI 10.1002/eji.1830230707; Denburg JA, 1998, INT ARCH ALLERGY IMM, V117, P155, DOI 10.1159/000024004; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; Djukanovic R, 1996, THORAX, V51, P575, DOI 10.1136/thx.51.6.575; Finn PW, 2000, J ALLERGY CLIN IMMUN, V105, P933, DOI 10.1067/mai.2000.106546; FOKKENS WJ, 1992, CLIN EXP ALLERGY, V22, P701, DOI 10.1111/j.1365-2222.1992.tb00194.x; Fontanari P, 1996, J APPL PHYSIOL, V81, P1739, DOI 10.1152/jappl.1996.81.4.1739; Fontanari P, 1997, EUR RESPIR J, V10, P2250, DOI 10.1183/09031936.97.10102250; Foresi A, 1997, J ALLERGY CLIN IMMUN, V100, P58, DOI 10.1016/S0091-6749(97)70195-7; Gaga M, 2000, CLIN EXP ALLERGY, V30, P663; GEM JE, 2000, J ALLERGY CLIN IMMUN, V106, P201; GERGEN PJ, 1992, J ALLERGY CLIN IMMUN, V90, P579, DOI 10.1016/0091-6749(92)90130-T; Greisner WA, 1998, ALLERGY ASTHMA PROC, V19, P185, DOI 10.2500/108854198778557836; Guerra S, 2002, J ALLERGY CLIN IMMUN, V109, P419, DOI 10.1067/mai.2002.121701; Hellgren J, 2002, CLIN EXP ALLERGY, V32, P64, DOI 10.1046/j.0022-0477.2001.01253.x; HUXLEY EJ, 1978, AM J MED, V64, P564, DOI 10.1016/0002-9343(78)90574-0; Inman MD, 1999, AM J RESP CELL MOL, V21, P473, DOI 10.1165/ajrcmb.21.4.3622; ISHIZAKA K, 1966, J IMMUNOL, V97, P840; JOHANSSO.SG, 1967, LANCET, V2, P951; Kelly EAB, 2003, J ALLERGY CLIN IMMUN, V111, P79, DOI 10.1067/mai.2003.28; Kerkhof M, 2000, CLIN EXP ALLERGY, V30, P1387, DOI 10.1046/j.1365-2222.2000.00907.x; Koskela H, 1995, EUR RESPIR J, V8, P2088, DOI 10.1183/09031936.95.08122088; Lanzavecchia A, 1996, CURR OPIN IMMUNOL, V8, P348, DOI 10.1016/S0952-7915(96)80124-5; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Leynaert B, 1999, J ALLERGY CLIN IMMUN, V104, P301, DOI 10.1016/S0091-6749(99)70370-2; Leynaert B, 1997, AM J RESP CRIT CARE, V156, P1413, DOI 10.1164/ajrccm.156.5.9701060; Leynaert B, 2001, AM J RESP CRIT CARE, V164, P1829, DOI 10.1164/ajrccm.164.10.2103137; Leynaert Benedicte, 2000, Journal of Allergy and Clinical Immunology, V106, pS201; Leynaert N, 2004, J ALLERGY CLIN IMMUN, V113, P86, DOI 10.1016/j.jaci.2003.10.010; Linneberg A, 2002, ALLERGY, V57, P1048, DOI 10.1034/j.1398-9995.2002.23664.x; LITTELL NT, 1990, AM REV RESPIR DIS, V141, P580, DOI 10.1164/ajrccm/141.3.580; Marcucci F, 2001, ALLERGY, V56, P231; McLane ML, 2000, J APPL PHYSIOL, V88, P1043, DOI 10.1152/jappl.2000.88.3.1043; Mishra A, 2001, J CLIN INVEST, V107, P83, DOI 10.1172/JCI10224; Mishra A, 2002, J IMMUNOL, V168, P2464, DOI 10.4049/jimmunol.168.5.2464; Nakamura H, 1999, AM J RESP CRIT CARE, V160, P1952, DOI 10.1164/ajrccm.160.6.9811089; Oddy WH, 1999, BMJ-BRIT MED J, V319, P815, DOI 10.1136/bmj.319.7213.815; Palczynski C, 2001, ALLERGY, V56, P1186, DOI 10.1034/j.1398-9995.2001.00236.x; Parameswaran K, 2004, AM J RESP CRIT CARE, V169, P915, DOI 10.1164/rccm.200312-1645OC; Platts-Mills TAE, 2000, J ALLERGY CLIN IMMUN, V105, pS503, DOI 10.1016/S0091-6749(00)90051-4; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; Rasanen M, 1998, ALLERGY, V53, P885, DOI 10.1111/j.1398-9995.1998.tb03996.x; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Saito H, 2001, IMMUNOLOGY, V104, P226, DOI 10.1046/j.1365-2567.2001.01253.x; SCHUMACHER MJ, 1986, J ALLERGY CLIN IMMUN, V78, P30, DOI 10.1016/0091-6749(86)90111-9; SEDGWICK JD, 1985, CELL IMMUNOL, V94, P182, DOI 10.1016/0008-8749(85)90095-4; SETTIPANE RJ, 1994, ALLERGY PROC, V15, P21, DOI 10.2500/108854194778816634; Stirling RG, 2001, AM J RESP CRIT CARE, V164, P1403, DOI 10.1164/ajrccm.164.8.2010002; Strachan DP, 1998, THORAX, V53, P204, DOI 10.1136/thx.53.3.204; STRAUSS RH, 1977, NEW ENGL J MED, V297, P743, DOI 10.1056/NEJM197710062971402; Thaminy A, 2000, EUR RESPIR J, V16, P1091, DOI 10.1034/j.1399-3003.2000.16f12.x; Togias Alkis, 2004, Journal of Allergy and Clinical Immunology, V113, pS8, DOI 10.1016/j.jaci.2003.09.051; Tomaki M, 2000, J IMMUNOL, V165, P4040, DOI 10.4049/jimmunol.165.7.4040; Undem BJ, 1999, ALLERGY, V54, P81, DOI 10.1111/j.1398-9995.1999.tb04409.x; Upton MN, 2000, BMJ-BRIT MED J, V321, P88, DOI 10.1136/bmj.321.7253.88; Van den Toorn LM, 2001, AM J RESP CRIT CARE, V164, P2107, DOI 10.1164/ajrccm.164.11.2006165; von Mutius E, 1998, LANCET, V351, P862, DOI 10.1016/S0140-6736(97)10100-3; von Wattenwyl F, 2001, EUR J GASTROEN HEPAT, V13, P721, DOI 10.1097/00042737-200106000-00018; VONPIRQUET C, 1968, CLIN ASPECTS IMMUNOL, P1295; WALLAERT B, 1995, J EXP MED, V182, P1897, DOI 10.1084/jem.182.6.1897; Wang CH, 1999, J ALLERGY CLIN IMMUN, V104, P803, DOI 10.1016/S0091-6749(99)70291-5; Wang J, 1998, J CLIN INVEST, V102, P1132, DOI 10.1172/JCI2686; Wardlaw AJ, 1999, J ALLERGY CLIN IMMUN, V104, P917, DOI 10.1016/S0091-6749(99)70069-2; Weinberg EG, 2000, J ALLERGY CLIN IMMUN, V105, P224, DOI 10.1016/S0091-6749(00)90069-1; WOOD RA, 1995, AM J RESP CRIT CARE, V151, P315, DOI 10.1164/ajrccm.151.2.7842184	96	78	79	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2005	115	1					142	148		10.1016/j.jaci.2004.10.041	http://dx.doi.org/10.1016/j.jaci.2004.10.041			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	886XS	15637561				2022-12-18	WOS:000226267000021
J	Kawai, K; Tsuno, NH; Kitayama, J; Okaji, Y; Yazawa, K; Asakage, M; Hori, N; Watanabe, T; Takahashi, K; Nagawa, H				Kawai, K; Tsuno, NH; Kitayama, J; Okaji, Y; Yazawa, K; Asakage, M; Hori, N; Watanabe, T; Takahashi, K; Nagawa, H			Epigallocatechin gallate attenuates adhesion and migration of CD8(+) T cells by binding to CD11b	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						catechin; CD11b; anti-inflammation; CD8(+) T cells; adhesion; migration	TEA POLYPHENOL (-)-EPIGALLOCATECHIN-3-GALLATE; HUMAN-NEUTROPHILS; MATRIX PROTEINS; LYMPHOCYTES; EXPRESSION; ADHERENCE; LEUKOCYTES; CATECHINS; RECEPTOR; LFA-1	Background: Although green tea polyphenol catechin has been reported to have antiallergic and anti-inflammatory activities, the precise mechanisms of its effect on the immune system have been poorly investigated. Objective: In this study, we aimed to elucidate the mechanisms of the anti-inflammatory effect of catechin. For this purpose, we studied the effect of 2 kinds of catechin, epigallocatechin gallate (EGCG) and epicatechin gallate, on peripheral blood CD8(+) T cells, which play the key role in immune responses. Methods: Isolated peripheral blood mononuclear cells or CD8(+) T cells were incubated without or with catechin, and the changes in the surface expression of integrin molecules were investigated by flow cytometry and the direct binding of catechin to CD11b molecule by competitive ELISA. Also, the effect of catechin on the ability of CD8(+) T cells to bind intracellular adhesion molecule 1 and to migrate in response to chemokines was evaluated by using the adhesion and migration assays. Results: The 2 catechins directly bound to CD11b expressed on CD8(+) T cells, which caused a consequent decrease of flow-cytometric CD11b expression. The effect was more prominent with EGCG than epicatechin gallate, and the impaired expression of CD11b induced by EGCG resulted in decreased ability of CD8(+) T cells to adhere intercellular adhesion molecule 1, and consequently decreased migration in response to chemokines. Conclusion: We concluded that catechin, especially EGCG, by downregulating CD11b expression on CD8(+) T cells and, in consequence, inhibiting infiltration of these cells into the sites of inflammation, is a promising new potent anti-inflammatory agent.	Univ Tokyo, Fac Med, Dept Transfus Med, Tokyo 113, Japan; Univ Tokyo, Fac Med, Dept Surg Oncol, Tokyo 113, Japan	University of Tokyo; University of Tokyo	Kawai, K (corresponding author), 7-3-1 Hongo,Bunkyo Ku, Tokyo 1130033, Japan.	kz-kawai@mvd.biglobe.ne.jp	Kawai, Kazushige/AAF-4334-2020	Kawai, Kazushige/0000-0002-5881-0036				BOHNSACK JF, 1990, J EXP MED, V171, P1221, DOI 10.1084/jem.171.4.1221; Capodici C, 1998, J IMMUNOL, V160, P1901; Cavers M, 2002, CLIN EXP IMMUNOL, V127, P60, DOI 10.1046/j.1365-2249.2002.01711.x; Christensen JE, 2001, INT IMMUNOL, V13, P593, DOI 10.1093/intimm/13.4.593; Conran N, 2003, BIOCHEM PHARMACOL, V66, P43, DOI 10.1016/S0006-2952(03)00243-0; Ding ZM, 1999, J IMMUNOL, V163, P5029; ENNEN J, 1994, P NATL ACAD SCI USA, V91, P7207, DOI 10.1073/pnas.91.15.7207; Fiorentini S, 2001, J IMMUNOL, V166, P900, DOI 10.4049/jimmunol.166.2.900; Gabor M, 1986, Prog Clin Biol Res, V213, P471; Gerli R, 1998, BLOOD, V92, P2389, DOI 10.1182/blood.V92.7.2389.2389_2389_2398; Hong J, 2002, CANCER RES, V62, P7241; Katiyar SK, 2001, J LEUKOCYTE BIOL, V69, P719; Kawai K, 2003, J ALLERGY CLIN IMMUN, V112, P951, DOI 10.1016/S0091-6749(03)02007-4; Kono K, 1994, Kansenshogaku Zasshi, V68, P1518; Lang S, 2002, FASEB J, V16, P286, DOI 10.1096/fj.02-0417fje; LOU FQ, 1989, CHINESE MED J-PEKING, V102, P579; LUNDGRENAKERLUND E, 1993, SCAND J IMMUNOL, V37, P569, DOI 10.1111/j.1365-3083.1993.tb02573.x; Matsuo N, 1997, ALLERGY, V52, P58, DOI 10.1111/j.1398-9995.1997.tb02546.x; NIELSEN HV, 1994, J IMMUNOL, V153, P2021; SMITH CW, 1989, J CLIN INVEST, V83, P2008, DOI 10.1172/JCI114111; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; Suzuki M, 2000, J AGR FOOD CHEM, V48, P5649, DOI 10.1021/jf000313d; THOMPSON HL, 1992, CLIN EXP IMMUNOL, V90, P280; Valcic S, 1996, ANTI-CANCER DRUG, V7, P461, DOI 10.1097/00001813-199606000-00011; Wagner C, 2001, EUR J IMMUNOL, V31, P1173, DOI 10.1002/1521-4141(200104)31:4<1173::AID-IMMU1173>3.0.CO;2-9; Yamaguchi K, 2002, ANTIVIR RES, V53, P19, DOI 10.1016/S0166-3542(01)00189-9; Yang CS, 1997, NATURE, V389, P134, DOI 10.1038/38154; Zeidler R, 2000, FASEB J, V14, P661, DOI 10.1096/fasebj.14.5.661; ZHAO BL, 1992, ACTA PHARM SINIC, V13, P9	29	78	87	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2004	113	6					1211	1217		10.1016/j.jaci.2004.02.044	http://dx.doi.org/10.1016/j.jaci.2004.02.044			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	829ZI	15208607				2022-12-18	WOS:000222091000031
J	Mahut, B; Delclaux, C; Tillie-Leblond, I; Gosset, P; Delacourt, C; Zerah-Lancner, F; Harf, A; de Blic, J				Mahut, B; Delclaux, C; Tillie-Leblond, I; Gosset, P; Delacourt, C; Zerah-Lancner, F; Harf, A; de Blic, J			Both inflammation and remodeling influence nitric oxide output in children with refractory asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						bronchial biopsy; reticular basement membrane; eosinophil; exhaled nitric oxide	AIRWAY SMOOTH-MUSCLE; DIFFICULT ASTHMA; CELLS	Background: Exhaled nitric oxide can be used to monitor airway inflammation in asthma. We hypothesized that the strong link between nitric oxide and inflammation may obscure a weaker link with airway remodeling. Objective: The aim of this study was to determine whether airway remodeling influenced exhaled nitric oxide in 28 asthmatic children (median age [25th-75th], 11 [10-14] years old) with refractory asthma defined as airflow limitation and/or exacerbations despite high-dose inhaled steroids. Methods: Multiple-flow analysis of exhaled nitric oxide was used to correlate alveolar nitric oxide concentration and maximal conducting airway nitric oxide output to pulmonary function tests, bronchoalveolar lavage, and bronchial biopsy findings. Results: Nitric oxide measurements were related to inflammation and T(H)1/T(H)2 balance, that is, subepithelial eosinophilic infiltration and eosinophilic cationic protein and IFN-gamma/IL-4 ratio in bronchoalveolar lavage fluids. Nitric oxide measurements were also correlated with several parameters of airway remodeling: alveolar nitric oxide concentration with TGF-beta in bronchoalveolar lavage fluid (r = 0.42, P =.03) and maximal conducting airway nitric oxide output with reticular basement membrane thickness (r = 0.61, P =.0007) and tissue inhibitor of matrix metalloproteinases; 1/matrix metalloproteinase 9 ratio in bronchoalveolar lavage fluid (r = 0.43, P =.04). Moreover, alveolar nitric oxide concentration was correlated with MEF25-75 (r = 0.60,P =.02). Conclusions: These findings suggest that both subacute inflammation and remodeling influence nitric oxide output in refractory asthma.	Hop Henri Mondor, Serv Physiol, Explorat Fonct, APHP, F-94010 Creteil, France; INSERM, U416, Inst Pasteur, Lille, France; Ctr Hosp Intercommunal, Serv Pediat, Creteil, France; Hop Necker Enfants Malad, Serv Pneumol allergol Pediat, APHP, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	Delclaux, C (corresponding author), Hop Henri Mondor, Serv Physiol, Explorat Fonct, APHP, 51,Ave Marechal Lattre Tassigny, F-94010 Creteil, France.	christophe.delclaux@creteil.inserm.fr	Delacourt, Christophe/K-6161-2019; Gosset, Philippe/C-6174-2018	Gosset, Philippe/0000-0002-4043-6429				Balfour-Lynn I, 1999, ARCH DIS CHILD, V80, P201, DOI 10.1136/adc.80.2.201; de Blic J, 2002, EUR RESPIR J, V20, P1271, DOI 10.1183/09031936.02.02072001; Delclaux C, 2002, AM J RESP CRIT CARE, V165, P332, DOI 10.1164/ajrccm.165.3.2107017; Guo FH, 1997, J CLIN INVEST, V100, P829, DOI 10.1172/JCI119598; Hamad AM, 1999, AM J PHYSIOL-LUNG C, V277, pL910, DOI 10.1152/ajplung.1999.277.5.L910; Lieberman P, 2001, J INVEST ALLERG CLIN, V11, P220; Nelson BV, 1997, J PEDIATR-US, V130, P423, DOI 10.1016/S0022-3476(97)70204-X; Okamoto T, 2002, AM J RESP CELL MOL, V27, P463, DOI 10.1165/rcmb.2002-0039OC; Patel HJ, 1999, FASEB J, V13, P1810, DOI 10.1096/fasebj.13.13.1810; Payne DNR, 2003, AM J RESP CRIT CARE, V167, P78, DOI 10.1164/rccm.200205-414OC; Payne DNR, 2001, AM J RESP CRIT CARE, V164, P1376, DOI 10.1164/ajrccm.164.8.2101145; Payne DNR, 2001, THORAX, V56, P345, DOI 10.1136/thorax.56.5.345; Proceedings of the ATS workshop on refractory asthma, 2000, AM J RESP CRIT CARE, V162, P2341, DOI DOI 10.1164/AJRCCM.162.6.ATS9-00; Ranganathan SC, 2001, PEDIATR PULM, V31, P114, DOI 10.1002/1099-0496(200102)31:2<114::AID-PPUL1018>3.0.CO;2-O; Silkoff PE, 2000, AM J RESP CRIT CARE, V161, P1218, DOI 10.1164/ajrccm.161.4.9903111; Sippel JM, 2000, J ALLERGY CLIN IMMUN, V106, P645, DOI 10.1067/mai.2000.109618; Slutsky AS, 1999, AM J RESP CRIT CARE, V160, P2104; Tsoukias NM, 1998, J APPL PHYSIOL, V85, P653, DOI 10.1152/jappl.1998.85.2.653; Vignola A M, 1997, Monaldi Arch Chest Dis, V52, P159; Vignola AM, 1998, AM J RESP CRIT CARE, V157, P403, DOI 10.1164/ajrccm.157.2.96-08040	20	78	78	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2004	113	2					252	256		10.1016/j.jaci.2003.10.038	http://dx.doi.org/10.1016/j.jaci.2003.10.038			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	773EX	14767438				2022-12-18	WOS:000188885700011
J	Trivedi, L; Valerio, C; Slater, JE				Trivedi, L; Valerio, C; Slater, JE			Endotoxin content of standardized allergen vaccines	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						endotoxin; lipopolysaccharide; allergen; allergen vaccine; allergen immunotherapy; Limulus amebocyte lysate; endotoxin-neutralizing protein; standardization; protease	LIMULUS AMEBOCYTE LYSATE; SYSTEMIC REACTIONS; ASTHMA; IMMUNOTHERAPY; MITE; EXPOSURE; LAL	Background: Endotoxin is a ubiquitous and potent proinflammatory agent. Previous limited studies suggest that it is present in allergen vaccines and that this could affect the safety and efficacy of allergen immunotherapy. The endotoxin content of standardized allergen vaccines is unknown. Objective: The purpose of this study was to quantify the amount of endotoxin contained in standardized allergen vaccines. Methods: The endotoxin content of 14 allergen vaccines was measured by using the Limulus amebocyte lysate (LAL) gel-clot assay. To account for (1,3)-beta-D-glucan and protease interference, vaccines were selectively depleted of endotoxin and then retested with the gel-clot assay. Proteases were also heat-inactivated in selected vaccines. Fifty-eight lots of vaccines were tested, including at least two manufacturers per vaccine. Results: The endotoxin content of the 58 vaccines ranged from undetectable to 34,000 EU/mL. Cat pelt (12,735 EU/mL; range, 5177 to 33,805) had significantly more endotoxin activity than cat hair (2883 EU/mL; range, 1 to 16,962), and Dermatophagoides farinae extracts (4619 EU/mL; range, 849 to 8485) had more than Dermatophagoides pteronyssinus (11 EU/mL; range, 1 to 34). Grass (160 EU/mL; range, 3 to 1561) and ragweed pollen (341 EU/mL; range, 8 to 1697) vaccines contained less endotoxin. (1,3)-beta-D-glucan interference was significant (>10%) only in three ragweed vaccines and two grass vaccines. Heat inactivation had no effect. There were considerable differences in endotoxin content of the same vaccines made by different manufacturers. Conclusions: The endotoxin content of standardized allergen vaccines is extremely variable. Interference by proteases and (1,3)-beta-D-glucans is minimal. The effects of the high levels of endotoxin in some vaccines on the immunomodulatory changes associated with allergen immunotherapy require further study.	NIAID, NIH, Bethesda, MD 20892 USA; US FDA, Ctr Biol Evaluat & Res, Bethesda, MD USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); US Food & Drug Administration (FDA)	Slater, JE (corresponding author), US FDA, Ctr Drug Evaluat & Res, Lab Immunobiochem HFM422, 1401 Rockville Pike, Rockville, MD 20852 USA.							ADNER N, 1991, J PARENT SCI TECHN, V45, P88; [Anonymous], 1987, GUIDELINE VALIDATION; Bagarozzi DA, 1998, PHYTOCHEMISTRY, V47, P593, DOI 10.1016/S0031-9422(97)00634-1; Cooper JF, 1997, PDA J PHARM SCI TECH, V51, P2; COOPER JF, 1990, CLIN APPL LIMULUS AM, P159; DANNEMAN PJ, 1976, CELL IMMUNOL, V22, P128, DOI 10.1016/0008-8749(76)90014-9; Ebner C, 1999, INT ARCH ALLERGY IMM, V119, P1, DOI 10.1159/000024168; ESCH RE, 1992, ARB PEI GSH, V85, P171; GARCIA C, 1994, CRIT CARE MED, V22, P1211, DOI 10.1097/00003246-199408000-00003; Gehring U, 2001, EUR RESPIR J, V18, P555, DOI 10.1183/09031936.01.00096801; Hewitt CRA, 1998, ALLERGY, V53, P60, DOI 10.1111/j.1398-9995.1998.tb05000.x; Hochstein H. D., 1990, CLIN APPL LIMULUS AM, P37; Iraneta SG, 1999, J INVEST ALLERG CLIN, V9, P235; Liu AH, 2002, J ALLERGY CLIN IMMUN, V109, P379, DOI 10.1067/mai.2002.122157; Lockey RF, 2001, ANN ALLERG ASTHMA IM, V87, P47, DOI 10.1016/S1081-1206(10)62195-3; Michel O, 1996, AM J RESP CRIT CARE, V154, P1641, DOI 10.1164/ajrccm.154.6.8970348; Michel O, 1997, AM J RESP CRIT CARE, V156, P1157, DOI 10.1164/ajrccm.156.4.97-02002; Michel O, 2000, TOXICOLOGY, V152, P25, DOI 10.1016/S0300-483X(00)00288-2; MICHIE HR, 1988, NEW ENGL J MED, V318, P1481, DOI 10.1056/NEJM198806093182301; MILLER MA, 1990, CLIN APPL LIMULUS AM, P1; Park JH, 2001, AM J RESP CRIT CARE, V163, P322, DOI 10.1164/ajrccm.163.2.2002088; PRIOR RB, 1990, CLIN APPLICATIONS LI, P27; Ragusa FV, 1997, J INVEST ALLERG CLIN, V7, P151; Reed CE, 2001, J ALLERGY CLIN IMMUN, V108, P157, DOI 10.1067/mai.2001.116862; ROSLANSKY PF, 1991, J CLIN MICROBIOL, V29, P2477, DOI 10.1128/JCM.29.11.2477-2483.1991; SIRAGANIAN RP, 1979, J ALLERGY CLIN IMMUN, V64, P526, DOI 10.1016/0091-6749(79)90063-0; Slater JE, 1998, J ALLERGY CLIN IMMUN, V102, P977, DOI 10.1016/S0091-6749(98)70336-7; SMITH TF, 1986, ANN ALLERGY, V57, P410; TAI JY, 1977, J BIOL CHEM, V252, P4773; *US PHARM CONV INC, 1994, US PHARM, P1696; WARREN HS, 1992, INFECT IMMUN, V60, P2506, DOI 10.1128/IAI.60.6.2506-2513.1992; WOLFF SM, 1973, J INFECT DIS S, V128, P259; ZHANG GH, 1994, J CLIN MICROBIOL, V32, P1537, DOI 10.1128/JCM.32.6.1537-1541.1994; Zimmer S., 1996, Journal of Burn Care and Rehabilitation, V17, P491, DOI 10.1097/00004630-199611000-00004	34	78	81	1	10	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2003	111	4					777	783		10.1067/mai.2003.1338	http://dx.doi.org/10.1067/mai.2003.1338			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	667WW	12704357				2022-12-18	WOS:000182258500017
J	Novak, N; Kraft, S; Bieber, T				Novak, N; Kraft, S; Bieber, T			Unraveling the mission of Fc epsilon RI on antigen-presenting cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						antigen-presenting cells; dendritic cells; IgE; IgE receptor; allergy; atopic dermatitis	EPIDERMAL LANGERHANS CELLS; ATOPY PATCH TEST; HIGH-AFFINITY RECEPTOR; DENDRITIC CELLS; IMMUNOGLOBULIN-E; IGE RECEPTOR; ENDOPLASMIC-RETICULUM; TACROLIMUS FK506; HUMAN MONOCYTES; MONOMERIC IGE	A decade ago, the discovery of the high-affinity receptor for IgE (FcepsilonRI) on epidermal Langerhans cells documented the end of the dogma that FcepsilonRI is only expressed on effector cells of anaphylaxis. Since then, the functional significance of this receptor on antigen-presenting cells (APCs) has been an area of intense research work. Scientists have focused on a better understanding of the molecular structure, regulation, and role of FcepsilonRI on APCs in the human immune system. Insights into the cellular events linked to the activation of APCs on ligation of FcepsilonRI by IgE and allergens might provide the basis for new aspects in the pathophysiology of allergic diseases and the design of future diagnostic and therapeutic strategies. This review is dedicated to the 10th anniversary of the discovery of FcepsilonRI on APCs and describes the numerous areas of research in this field.	Univ Bonn, Dept Dermatol, D-53105 Bonn, Germany; Beth Israel Deaconess Med Ctr, Dept Pathol, Lab Allergy & Immunol, Boston, MA 02215 USA	University of Bonn; Harvard University; Beth Israel Deaconess Medical Center	Novak, N (corresponding author), Univ Bonn, Dept Dermatol, Sigmund Freud Str 25, D-53105 Bonn, Germany.							Albrecht B, 2000, J IMMUNOL, V165, P5686, DOI 10.4049/jimmunol.165.10.5686; Asai K, 2001, IMMUNITY, V14, P791, DOI 10.1016/S1074-7613(01)00157-1; Babu KS, 2001, ALLERGY, V56, P1121, DOI 10.1034/j.1398-9995.2001.00019.x; BIEBER T, 1992, J EXP MED, V175, P1285, DOI 10.1084/jem.175.5.1285; Borkowski TA, 2001, J IMMUNOL, V167, P1290, DOI 10.4049/jimmunol.167.3.1290; BRUIJNZEEL PLB, 1993, CLIN EXP ALLERGY, V23, P97, DOI 10.1111/j.1365-2222.1993.tb00304.x; Darsow U, 1999, J AM ACAD DERMATOL, V40, P187, DOI 10.1016/S0190-9622(99)70186-6; Dombrowicz D, 2001, J EXP MED, V193, P25, DOI 10.1084/jem.193.1.25; Donnadieu E, 2000, IMMUNITY, V12, P515, DOI 10.1016/S1074-7613(00)80203-4; Frumento G, 2002, J EXP MED, V196, P459, DOI 10.1084/jem.20020121; Hanifin JM, 1999, ARCH DERMATOL, V135, P1551, DOI 10.1001/archderm.135.12.1551; JURGENS M, 1995, J IMMUNOL, V155, P5184; Kalesnikoff J, 2001, IMMUNITY, V14, P801, DOI 10.1016/S1074-7613(01)00159-5; Katoh N, 2000, J CLIN INVEST, V105, P183, DOI 10.1172/JCI6895; Kinet JP, 1999, ANNU REV IMMUNOL, V17, P931, DOI 10.1146/annurev.immunol.17.1.931; Kraft S, 2002, J INVEST DERMATOL, V118, P830, DOI 10.1046/j.1523-1747.2002.01757.x; Kraft S, 1998, J IMMUNOL, V161, P1000; KRAFT S, 2002, IN PRESS J INVEST DE; Langeveld-Wildschut EG, 2000, J ALLERGY CLIN IMMUN, V105, P1008, DOI 10.1067/mai.2000.106544; LETOURNEUR O, 1995, J BIOL CHEM, V270, P8249, DOI 10.1074/jbc.270.14.8249; Lin SQ, 1996, CELL, V85, P985, DOI 10.1016/S0092-8674(00)81300-8; Lin SY, 2001, SCIENCE, V291, P445, DOI 10.1126/science.291.5503.445; Maurer D, 1996, J IMMUNOL, V157, P607; MAURER D, 1994, J EXP MED, V179, P745, DOI 10.1084/jem.179.2.745; Maurer D, 1998, J IMMUNOL, V161, P2731; MILLER L, 1989, SCIENCE, V244, P334, DOI 10.1126/science.2523561; MUDDE GC, 1992, J INVEST DERMATOL, V99, P103; Niggemann B, 2001, PEDIATR ALLERGY IMMU, V12, P37, DOI 10.1034/j.1399-3038.2001.121408.x; Novak N, 2002, NAT IMMUNOL, V3, P607, DOI 10.1038/ni0702-607; Novak N, 2001, J IMMUNOL, V167, P797, DOI 10.4049/jimmunol.167.2.797; NOVAK N, 2002, IN PRESS J INVEST DE; Oldfield WLG, 2001, J IMMUNOL, V167, P1734, DOI 10.4049/jimmunol.167.3.1734; Oliver JM, 2000, IMMUNOPHARMACOLOGY, V48, P269, DOI 10.1016/S0162-3109(00)00224-1; Oppel T, 2000, BRIT J DERMATOL, V143, P1193, DOI 10.1046/j.1365-2133.2000.03887.x; OSTERHOFF B, 1994, J INVEST DERMATOL, V102, P315, DOI 10.1111/1523-1747.ep12371789; Panhans-Gross A, 2001, J ALLERGY CLIN IMMUN, V107, P345, DOI 10.1067/mai.2001.112600; Reich K, 2001, J IMMUNOL, V167, P6321, DOI 10.4049/jimmunol.167.11.6321; RIEGER A, 1992, J INVEST DERMATOL, V99, pS30, DOI 10.1111/1523-1747.ep12668293; Ring J, 2001, J AM ACAD DERMATOL, V45, pS49, DOI 10.1067/mjd.2001.117015.24; TUNER H, 1999, NATURE, V402, pB24; von Bubnoff D, 2002, J IMMUNOL, V169, P1810, DOI 10.4049/jimmunol.169.4.1810; WANG B, 1992, J EXP MED, V175, P1353, DOI 10.1084/jem.175.5.1353; Wistokat-Wulfing A, 1999, CLIN EXP ALLERGY, V29, P513; WOLLENBERG A, 1993, J EXP MED, V178, P777, DOI 10.1084/jem.178.3.777; WOLLENBERG A, 1995, LANCET, V346, P1626, DOI 10.1016/S0140-6736(95)91958-9; Wollenberg A, 2001, J ALLERGY CLIN IMMUN, V107, P519, DOI 10.1067/mai.2001.112942; Wurzburg BA, 2000, IMMUNITY, V13, P375, DOI 10.1016/S1074-7613(00)00037-6	47	78	79	0	7	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2003	111	1					38	44		10.1067/mai.2003.2	http://dx.doi.org/10.1067/mai.2003.2			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	636PR	12532094	Bronze			2022-12-18	WOS:000180465500006
J	Zeiger, RS				Zeiger, RS			Current issues with influenza vaccination in egg allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						influenza vaccination; egg allergy; asthma	FOOD ALLERGY; DOUBLE-BLIND; ASTHMATIC-CHILDREN; IGE CONCENTRATIONS; PULMONARY-FUNCTION; VIRUS; CHALLENGES; VACCINES; EXACERBATIONS; IMMUNIZATION	Influenza infection, with its accompanying morbidity and mortality, represents a major public health concern yearly to the elderly and high-risk groups, including asthmatic patients. Active prevention with vaccination consistently falls short of reaching optimal immunization rates in all risk groups. Asthmatic patients and others with concomitant egg allergy might be denied active immunization because of the risk of inducing adverse reactions with a vaccine derived from egg embryo tissue. Evidence supports the relatively safe administration of influenza vaccine to individuals with egg allergy in whom vaccination is indicated when specific protocols are followed under the supervision of experienced physicians. A practical protocol that includes incremental dosing of influenza vaccine is presented to guide clinicians in influenza vaccination in this high-risk group.	Kaiser Permanente Med Ctr, Dept Allergy, San Diego, CA 92111 USA; Univ Calif San Diego, Dept Pediat, San Diego, CA 92103 USA	Kaiser Permanente; University of California System; University of California San Diego	Zeiger, RS (corresponding author), Kaiser Permanente Med Ctr, Dept Allergy, 7060 Clairemont Mesa Blvd, San Diego, CA 92111 USA.			Zeiger, Robert/0000-0001-5788-5063				ANOLIK R, 1992, ANN ALLERGY, V68, P69; ATKINS FM, 1985, J ALLERGY CLIN IMMUN, V75, P348, DOI 10.1016/0091-6749(85)90071-5; ATMAR RL, 1990, VACCINE, V8, P217, DOI 10.1016/0264-410X(90)90049-R; BELL TD, 1978, CHEST, V73, P140, DOI 10.1378/chest.73.2.140; Belshe RB, 1998, NEW ENGL J MED, V338, P1405, DOI 10.1056/NEJM199805143382002; BIERMAN CW, 1977, J INFECT DIS, V136, pS652, DOI 10.1093/infdis/136.Supplement_3.S652; BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; Burks AW, 1998, J PEDIATR-US, V132, P132, DOI 10.1016/S0022-3476(98)70498-6; Castro M, 2001, NEW ENGL J MED, V345, P1529, DOI 10.1056/NEJMoa011961; CATES C, 1999, INFLUENZA VACCINATIO; Chaloupka I, 1996, EUR J CLIN MICROBIOL, V15, P121, DOI 10.1007/BF01591484; Chung EK, 1998, ANN ALLERG ASTHMA IM, V80, P318, DOI 10.1016/S1081-1206(10)62976-6; Couch RB, 2000, NEW ENGL J MED, V343, P1778, DOI 10.1056/NEJM200012143432407; DANNAEUS A, 1981, CLIN ALLERGY, V11, P533, DOI 10.1111/j.1365-2222.1981.tb02171.x; DAVIES R, 1976, J ALLERGY CLIN IMMUN, V57, P373, DOI 10.1016/0091-6749(76)90095-6; DEMICHELI V, 1999, VACCINES PREVENTING; Eggesbo M, 2001, ALLERGY, V56, P403, DOI 10.1034/j.1398-9995.2001.056005403.x; Fairchok MP, 1998, ARCH PEDIAT ADOL MED, V152, P1191; Glezen WP, 2000, JAMA-J AM MED ASSOC, V283, P499, DOI 10.1001/jama.283.4.499; GLEZEN WP, 1982, EPIDEMIOL REV, V4, P25, DOI 10.1093/oxfordjournals.epirev.a036250; HATTEVIG G, 1987, CLIN ALLERGY, V17, P571, DOI 10.1111/j.1365-2222.1987.tb02053.x; Hill DJ, 2001, CLIN EXP ALLERGY, V31, P1031, DOI 10.1046/j.1365-2222.2001.01113.x; James JM, 1998, J PEDIATR-US, V133, P624, DOI 10.1016/S0022-3476(98)70101-5; JANSEN JJN, 1994, J ALLERGY CLIN IMMUN, V93, P446; KAJOSAARI M, 1982, ACTA PAEDIATR SCAND, V71, P815, DOI 10.1111/j.1651-2227.1982.tb09525.x; Kanny G, 2001, J ALLERGY CLIN IMMUN, V108, P133, DOI 10.1067/mai.2001.116427; KONDO S, 1991, CHEST, V100, P1235, DOI 10.1378/chest.100.5.1235; Kramarz P, 2001, J PEDIATR-US, V138, P306, DOI 10.1067/mpd.2001.112168; LANGELAND T, 1983, CLIN ALLERGY, V13, P371, DOI 10.1111/j.1365-2222.1983.tb02611.x; LANGELAND T, 1985, ACTA DERM-VENEREOL, P109; Luce BR, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.2.e24; Mannino D M, 1998, MMWR CDC Surveill Summ, V47, P1; Martinez TB, 2001, CLIN EXP ALLERGY, V31, P1464; MILLER JR, 1983, J ALLERGY CLIN IMMUN, V71, P568; MURPHY KR, 1985, J PEDIATR-US, V106, P931, DOI 10.1016/S0022-3476(85)80241-9; National institutes of Health National Heart Lung and Blood Institute, 1997, NIH PUBL, V97-4051; Neuzil KM, 2000, J PEDIATR-US, V137, P856, DOI 10.1067/mpd.2000.110445; Neuzil KM, 2001, J PEDIATR-US, V138, P301, DOI 10.1067/mpd.2001.113101; Nicholson KG, 1998, LANCET, V351, P326, DOI 10.1016/S0140-6736(97)07468-0; Niggemann B, 1999, CLIN EXP ALLERGY, V29, P91, DOI 10.1046/j.1365-2222.1999.00454.x; NORGAARD A, 1992, ALLERGY, V47, P503, DOI 10.1111/j.1398-9995.1992.tb00673.x; NOVEMBRE E, 1988, J ALLERGY CLIN IMMUN, V81, P1059, DOI 10.1016/0091-6749(88)90181-9; OBRIEN TC, 1971, APPL MICROBIOL, V21, P780, DOI 10.1128/AEM.21.4.780-782.1971; ONORATO J, 1986, J ALLERGY CLIN IMMUN, V78, P1139, DOI 10.1016/0091-6749(86)90263-0; Park CL, 1996, PEDIATRICS, V98, P196; PICKERING LK, 2000, 2000 RED BOOK REPORT, P36; POOLE PJ, 2002, COCHRANE AIRWAYS GRO; Rani S, 2022, SPAT INF RES, V30, P417, DOI 10.1007/s41324-022-00442-9; RATNER B, 1946, JAMA-J AM MED ASSOC, V132, P899, DOI 10.1001/jama.1946.02870500005002; RATNER B, 1952, AMA AM J DIS CHILD, V83, P309, DOI 10.1001/archpedi.1952.02040070055006; Reichert TA, 2001, NEW ENGL J MED, V344, P889, DOI 10.1056/NEJM200103223441204; Reid DW, 1998, RESP MED, V92, P1010, DOI 10.1016/S0954-6111(98)90346-8; RETAILLIAU HF, 1980, AM J EPIDEMIOL, V111, P270, DOI 10.1093/oxfordjournals.aje.a112896; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P981, DOI 10.1016/S0091-6749(99)70167-3; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444, DOI 10.1016/S0091-6749(97)70133-7; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; Sener M, 1999, J ASTHMA, V36, P165, DOI 10.3109/02770909909056313; Sicherer SH, 2000, J ALLERGY CLIN IMMUN, V105, P582, DOI 10.1067/mai.2000.104941; Smits AJ, 2002, EPIDEMIOL INFECT, V128, P205, DOI 10.1017/S0950268801006574; Stempel DA, 1997, ANN ALLERG ASTHMA IM, V79, P517, DOI 10.1016/S1081-1206(10)63059-1; STENIUSAARNIALA B, 1986, CHEST, V89, P786, DOI 10.1378/chest.89.6.786; Stuart HC, 1926, AM J DIS CHILD, V32, P341; STULL A, 1946, J IMMUNOL, V53, P343; Yazicioglu M, 1999, Allergol Immunopathol (Madr), V27, P287	64	78	87	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2002	110	6					834	840		10.1067/mai.2002.129372	http://dx.doi.org/10.1067/mai.2002.129372			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	624TL	12464947				2022-12-18	WOS:000179777400003
J	Eggleston, PA; Arruda, LK				Eggleston, PA; Arruda, LK			Ecology and elimination of cockroaches and allergens in the home	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cockroach; cockroach allergen; environmental exposure; asthma; intervention; integrated pest management	HIGH-LEVEL EXPRESSION; INNER-CITY CHILDREN; HOUSE-DUST MITE; BLA G 4; RISK-FACTORS; PERIPLANETA-AMERICANA; BLATTELLA-GERMANICA; IMMUNOLOGICAL CHARACTERIZATION; DOMESTIC ALLERGENS; MOLECULAR-CLONING	Cockroach infestations have been indicated as a major contributor to asthma throughout the world. Several studies have shown that large numbers of asthmatic patients are sensitized to cockroach allergens. Eliminating this pest from homes, schools, and public buildings involves a Long-term commitment to a rational extermination process. This article covers the characteristics of the major cockroach species that invade homes, assesses the role of environmental exposure to cockroaches in asthma, and provides an intervention program for their extermination.	Johns Hopkins Univ Hosp, Dept Pediat, Baltimore, MD 21287 USA; Fac Med Ribeirao Preto, Dept Microbiol Immunol & Parasitol, Sao Paulo, Brazil	Johns Hopkins University; Johns Hopkins Medicine	Eggleston, PA (corresponding author), Johns Hopkins Univ Hosp, Dept Pediat, CMSC 1102,600 N Wolfe St, Baltimore, MD 21287 USA.		Arruda, L. Karla/D-5845-2013	Arruda, L. Karla/0000-0002-7505-210X				AKI T, 1995, J ALLERGY CLIN IMMUN, V96, P74, DOI 10.1016/S0091-6749(95)70035-8; Arruda LK, 1997, J BIOL CHEM, V272, P20907, DOI 10.1074/jbc.272.33.20907; Arruda LK, 1995, J BIOL CHEM, V270, P31196, DOI 10.1074/jbc.270.52.31196; ARRUDA LK, 1995, J BIOL CHEM, V270, P19563, DOI 10.1074/jbc.270.33.19563; Asturias JA, 1998, BBA-GENE STRUCT EXPR, V1397, P27, DOI 10.1016/S0167-4781(98)00006-2; Asturias JA, 1999, J IMMUNOL, V162, P4342; BERNTON H S, 1972, British Journal of Diseases of the Chest, V66, P61, DOI 10.1016/S0007-0971(72)80008-1; BERNTON HS, 1964, J ALLERGY, V35, P506, DOI 10.1016/0021-8707(64)90082-6; BIRBAUM J, 1995, J ALLERGY CLIN IMMUN, V96, P561; BOCSKEI Z, 1992, NATURE, V360, P186, DOI 10.1038/360186a0; CALL RS, 1992, J PEDIATR-US, V121, P862, DOI 10.1016/S0022-3476(05)80329-4; Chapman MD, 1996, ALLERGY ALLERGIC DIS, P942; Chew GL, 1998, AM J RESP CRIT CARE, V157, P1536, DOI 10.1164/ajrccm.157.5.9708011; Christiansen SC, 1996, J ALLERGY CLIN IMMUN, V98, P288, DOI 10.1016/S0091-6749(96)70152-5; Custovic A, 1998, CLIN EXP ALLERGY, V28, P53, DOI 10.1046/j.1365-2222.1998.00183.x; Custovic A, 1996, CLIN EXP ALLERGY, V26, P1246, DOI 10.1111/j.1365-2222.1996.tb00521.x; DAUL CB, 1994, INT ARCH ALLERGY IMM, V105, P49, DOI 10.1159/000236802; De Lucca SD, 1999, J ALLERGY CLIN IMMUN, V104, P672, DOI 10.1016/S0091-6749(99)70341-6; DEANDRADE AD, 1995, J ALLERGY CLIN IMMUN, V95, P1158, DOI 10.1016/S0091-6749(95)70071-4; deBlay F, 1997, J ALLERGY CLIN IMMUN, V99, P107, DOI 10.1016/S0091-6749(97)70307-5; DUFF AL, 1993, PEDIATRICS, V92, P535; Eggleston PA, 1999, J ALLERGY CLIN IMMUN, V104, P842, DOI 10.1016/S0091-6749(99)70296-4; Eggleston PA, 1998, J ALLERGY CLIN IMMUN, V102, P563, DOI 10.1016/S0091-6749(98)70272-6; FLOWER DR, 1993, PROTEIN SCI, V2, P753, DOI 10.1002/pro.5560020507; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573, DOI 10.1164/ajrccm/147.3.573; Gergen PJ, 1999, J ALLERGY CLIN IMMUN, V103, P501, DOI 10.1016/S0091-6749(99)70477-X; Gold DR, 1999, AM J RESP CRIT CARE, V160, P227, DOI 10.1164/ajrccm.160.1.9807104; Gregoire C, 1996, J BIOL CHEM, V271, P32951, DOI 10.1074/jbc.271.51.32951; Helm R, 1996, J ALLERGY CLIN IMMUN, V98, P172, DOI 10.1016/S0091-6749(96)70240-3; KANG B, 1979, J ALLERGY CLIN IMMUN, V63, P80, DOI 10.1016/0091-6749(79)90196-9; KANG BC, 1992, ANN ALLERGY, V68, P237; KING TP, 1994, INT ARCH ALLERGY IMM, V105, P224, DOI 10.1159/000236761; KOEHLER PG, 1990, HDB PEST CONTROL BEH, P101; Konieczny A, 1997, IMMUNOLOGY, V92, P577, DOI 10.1046/j.1365-2567.1997.00386.x; LEUNG PSC, 1994, J ALLERGY CLIN IMMUN, V94, P882, DOI 10.1016/0091-6749(94)90156-2; LONGBOTTOM JL, 1980, ADV ALLERGOLOGY APPL, P483; Mantyjarvi R, 1996, J ALLERGY CLIN IMMUN, V97, P1297, DOI 10.1016/S0091-6749(96)70198-7; Melen E, 1999, J ALLERGY CLIN IMMUN, V103, P859, DOI 10.1016/S0091-6749(99)70430-6; MENDOZA J, 1970, ANN ALLERGY, V28, P159; Mollet JA, 1997, J MED ENTOMOL, V34, P307, DOI 10.1093/jmedent/34.3.307; Peruzzi M, 1999, ANN ALLERG ASTHMA IM, V83, P167, DOI 10.1016/S1081-1206(10)62631-2; Platts-Mills TAE, 1997, J ALLERGY CLIN IMMUN, V100, pS2, DOI 10.1016/S0091-6749(97)70292-6; POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P511, DOI 10.1016/0091-6749(91)90010-L; POLLART SM, 1989, J ALLERGY CLIN IMMUN, V83, P875, DOI 10.1016/0091-6749(89)90100-0; Pomes A, 1998, J BIOL CHEM, V273, P30801, DOI 10.1074/jbc.273.46.30801; Reese G, 1999, INT ARCH ALLERGY IMM, V119, P247, DOI 10.1159/000024201; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Santos ABR, 1999, J ALLERGY CLIN IMMUN, V104, P329, DOI 10.1016/S0091-6749(99)70375-1; Sarpong SB, 1998, J ALLERGY CLIN IMMUN, V101, P566, DOI 10.1016/S0091-6749(98)70369-0; Sarpong SB, 1996, ANN ALLERG ASTHMA IM, V76, P257, DOI 10.1016/S1081-1206(10)63437-0; Sarpong SB, 1997, J ALLERGY CLIN IMMUN, V99, P486, DOI 10.1016/S0091-6749(97)70074-5; Sarpong SB, 1996, J ALLERGY CLIN IMMUN, V97, P1393, DOI 10.1016/S0091-6749(96)70209-9; SCHOU C, 1990, J ALLERGY CLIN IMMUN, V86, P935, DOI 10.1016/S0091-6749(05)80157-5; SCHULANER FA, 1970, PEDIATRICS, V45, P465; SHANTI KN, 1993, J IMMUNOL, V151, P5354; Vailes LD, 1998, J ALLERGY CLIN IMMUN, V101, P274, DOI 10.1016/S0091-6749(98)70393-8; Wang NM, 1999, ALLERGY, V54, P119, DOI 10.1034/j.1398-9995.1999.00902.x; Wu CH, 1997, MOL IMMUNOL, V34, P1, DOI 10.1016/S0161-5890(97)00009-6; Wu CH, 1996, J BIOL CHEM, V271, P17937, DOI 10.1074/jbc.271.30.17937; WU CH, 1988, J ALLERGY CLIN IMMUN, V82, P727, DOI 10.1016/0091-6749(88)90071-1; Wu CH, 1998, J ALLERGY CLIN IMMUN, V101, P832, DOI 10.1016/S0091-6749(98)70312-4	61	78	81	1	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2001	107	3		S			S422	S429		10.1067/mai.2001.113671	http://dx.doi.org/10.1067/mai.2001.113671			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	418KR	11242603	Bronze			2022-12-18	WOS:000167891800004
J	Luttkopf, D; Ballmer-Weber, BK; Wuthrich, B; Vieths, S				Luttkopf, D; Ballmer-Weber, BK; Wuthrich, B; Vieths, S			Celery allergens in patients with positive double-blind placebo-controlled food challenge	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						celery allergy; double-blind placebo-controlled food challenge; Api g 1; Api g 4; carbohydrate epitopes; cross-reactive carbohydrate determinants; IgE; enzyme allergosorbent test; immunoblotting	REACTIVE CARBOHYDRATE DETERMINANTS; BIRCH POLLEN ALLERGEN; CROSS-REACTIVITY; MAJOR ALLERGEN; CLINICAL RELEVANCE; VEGETABLE FOODS; TREE POLLEN; N-GLYCANS; IGE; IDENTIFICATION	Background: Recently, for the first time, allergy to celery was confirmed by double-blind placebo-controlled food challenge (DBPCFC), Api g 1, Api g 4, cross-reactive carbohydrate determinants (CCD), and a 60 kDa allergen have been described as celery allergens. Objective: To get insights in IgE responses of patients with a positive DBPCFC to celery tuber (celeriac) compared with patients with a negative challenge test, Methods: Specific IgE to native and heated celery tuber and to recombinant Api g 1, the major celery allergen, were determined by enzyme allergosorbent test and immunoblotting, IgE binding to Api g 1, Api g 4, and CCD was confirmed by inhibition experiments that used recombinant Api g 1, recombinant Api g 4, pure N-glycans, and extracts of celeriac, lychee fruit, and pollens of birch, mugwort, and timothy grass as inhibitors. Results: Immunoblotting with sera from 22 patients with a positive DBPCFC to celeriac confirmed the presence of known allergenic structures: The major allergen Api g 1 (16 kDa) was recognized by IgE from 13 of 22 patients (59%), Another major allergen was CCD, determined by IgE reactivity in 12 of 22 patients (55%), Celery profilin, Api g 4, was recognized by IgE from 5 of 22 patients (23%), Conclusion: Our DBPCFC-positive patients exclusively presented IgE to known celery allergens, although the prevalences were slightly different than were previously reported. No obvious differences were found in patients with positive IgE antibody but negative challenge test, IgE binding to all 3 structures in celeriac extract was inhibited by birch pollen extract, whereas mugwort pollen extract could only inhibit IgE reactivity to Api g 4 and CCD, Inhibition experiments with a purified carbohydrate moiety clearly showed that the IgE epitope mannose-xylose-fucose-glycan (Man alpha 1-6[Xyl beta 1-2]Man beta 1-4GlcNAc beta 1-4[Fuc alpha 1-3]GlcNAc) or a closely related structure is present in celeriac extract and is important in patients with clinical allergy to celery.	Paul Ehrlich Inst, Dept Allergol, D-63225 Langen, Germany; Univ Zurich Hosp, Dept Allergol, Allergy Unit, CH-8091 Zurich, Switzerland	Paul Ehrlich Institute; University of Zurich; University Zurich Hospital	Vieths, S (corresponding author), Paul Ehrlich Inst, Dept Allergol, Paul Ehrlich Str 51, D-63225 Langen, Germany.							AALBERSE RC, 1981, J ALLERGY CLIN IMMUN, V68, P356, DOI 10.1016/0091-6749(81)90133-0; AALBERSE RC, 1992, INT ARCH ALLERGY IMM, V99, P261, DOI 10.1159/000236261; Aalberse RC, 1997, ENVIRON TOXICOL PHAR, V4, P55, DOI 10.1016/S1382-6689(97)10042-4; Aalberse RC, 1996, MONOGR ALLERGY, V32, P78; Aalberse RC, 1998, ALLERGY, V53, P54, DOI 10.1111/j.1398-9995.1998.tb04940.x; Aalberse RC, 1997, CLIN REV ALLERG IMMU, V15, P375, DOI 10.1007/BF02737733; ALTMANN F, 1992, ANAL BIOCHEM, V204, P215, DOI 10.1016/0003-2697(92)90164-3; Ballmer-Weber BK, 2000, J ALLERGY CLIN IMMUN, V106, P373, DOI 10.1067/mai.2000.107196; Batanero E, 1999, J ALLERGY CLIN IMMUN, V103, P147, DOI 10.1016/S0091-6749(99)70538-5; Bauer L, 1996, CLIN EXP ALLERGY, V26, P1161, DOI 10.1111/j.1365-2222.1996.tb00503.x; BREITENEDER H, 1995, EUR J BIOCHEM, V233, P484, DOI 10.1111/j.1432-1033.1995.484_2.x; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; BRUIJNZEELKOOMEN C, 1995, ALLERGY, V50, P623, DOI 10.1111/j.1398-9995.1995.tb02579.x; CESKA M, 1972, IMMUNOCHEMISTRY, V9, P1021, DOI 10.1016/0019-2791(72)90112-7; EBNER C, 1995, J ALLERGY CLIN IMMUN, V95, P962, DOI 10.1016/S0091-6749(95)70096-X; Fotisch K, 1999, INT ARCH ALLERGY IMM, V120, P30, DOI 10.1159/000024217; FU DT, 1995, ANAL BIOCHEM, V227, P377, DOI 10.1006/abio.1995.1294; Ganglberger E, 2000, CLIN EXP ALLERGY, V30, P566, DOI 10.1046/j.1365-2222.2000.00773.x; Heiss S, 1996, J ALLERGY CLIN IMMUN, V98, P938, DOI 10.1016/S0091-6749(96)80010-8; Hoffmann-Sommergruber K, 1999, J ALLERGY CLIN IMMUN, V104, P478, DOI 10.1016/S0091-6749(99)70397-0; Jankiewicz A, 1997, J SCI FOOD AGR, V75, P359, DOI 10.1002/(SICI)1097-0010(199711)75:3&lt;359::AID-JSFA889&gt;3.0.CO;2-Y; JANKIEWICZ A, 1998, ALLERGO J, V7, P87; Karamloo F, 1999, J ALLERGY CLIN IMMUN, V104, P991, DOI 10.1016/S0091-6749(99)70080-1; KHYSEANDERSON J, 1984, J BIOCHEM BIOPH METH, V10, P203; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mari A, 1999, J ALLERGY CLIN IMMUN, V103, P1005, DOI 10.1016/S0091-6749(99)70171-5; PETERSEN A, 1995, J ALLERGY CLIN IMMUN, V95, P987, DOI 10.1016/S0091-6749(95)70099-4; RUDESCHKO O, 1996, ALLERGOLOGIE, V8, P361; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Scheurer S, 2000, CLIN EXP ALLERGY, V30, P962, DOI 10.1046/j.1365-2222.2000.00821.x; SCHONING B, 1995, J SCI FOOD AGR, V67, P431, DOI 10.1002/jsfa.2740670403; TRETTER V, 1993, INT ARCH ALLERGY IMM, V102, P259, DOI 10.1159/000236534; TRETTER V, 1991, EUR J BIOCHEM, V199, P647, DOI 10.1111/j.1432-1033.1991.tb16166.x; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; VALLIER P, 1992, CLIN EXP ALLERGY, V22, P774, DOI 10.1111/j.1365-2222.1992.tb02818.x; vanderVeen MJ, 1997, J ALLERGY CLIN IMMUN, V100, P327, DOI 10.1016/S0091-6749(97)70245-8; VANREE R, 1993, J CLIN IMMUNOASSAY, V16, P124; VANREE R, 1992, INT ARCH ALLERGY IMM, V98, P97, DOI 10.1159/000236171; VIETHS S, 1994, INT ARCH ALLERGY IMM, V104, P399, DOI 10.1159/000236698; Vieths S, 1997, ENVIRON TOXICOL PHAR, V4, P61, DOI 10.1016/S1382-6689(97)10043-6; Vieths S., 1992, Food and Agricultural Immunology, V4, P181, DOI 10.1080/09540109209354767; Vieths S, 1999, EUR FOOD RES TECHNOL, V209, P379, DOI 10.1007/s002170050513; VIETHS S, 1995, ANN ALLERG ASTHMA IM, V74, P48; Wilson IBH, 1998, GLYCOBIOLOGY, V8, P651, DOI 10.1093/glycob/8.7.651; Wilson IBH, 1998, GLYCOCONJUGATE J, V15, P1055, DOI 10.1023/A:1006960401562; WUTHRICH B, 1990, ALLERGY, V45, P566, DOI 10.1111/j.1398-9995.1990.tb00941.x	47	78	79	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2000	106	2					390	399						10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	343NH	10932086				2022-12-18	WOS:000088708100025
J	Simons, FER; Gu, XC; Simons, KJ				Simons, FER; Gu, XC; Simons, KJ			Outdated EpiPen and EpiPen Jr autoinjectors: Past their prime?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						epinephrine; adrenaline; EpiPen; EpiPen Jr; autoinjector; anaphylaxis; allergic reaction; food/venom/latex allergy; adult; child	ANAPHYLAXIS; EPINEPHRINE; CHILDREN; HISTORY; FOOD	Background: EpiPen and EpiPen Jr autoinjectors are often recommended for prehospital treatment of anaphylaxis. When these units become outdated, there may be a delay in replacing them. Objectives: Our purpose was to evaluate unused, outdated EpiPen and EpiPen Jr autoinjectors, obtained from patients at risk for anaphylaxis, for epinephrine bioavailability and epinephrine content. Methods: We conducted a prospective, randomized, cross-over study of epinephrine bioavailability after injection from outdated autoinjectors in rabbits; controls included EpiPen and EpiPen Jr autoinjectors that had not expired ("in-date" autoinjectors) and intramuscular injection of 0.9% saline solution. In addition, the epinephrine content of the outdated EpiPen and EpiPen Jr autoinjectors was measured by a spectrophotometric method and an HPLC-UV method. Results: Twenty-eight EpiPen and 6EpiPen Jr autoinjectors were studied 1 to 90 months after the stated expiration date. Most were not discolored and did not contain precipitates. Epinephrine bioavailability from the outdated EpiPen autoinjectors was significantly reduced (P < .05) compared with epinephrine bioavailability from the in-date autoinjectors. The inverse correlation between the decreased epinephrine content of the outdated autoinjectors, assessed with an HPLC-UV method, and the number of months past the expiration date was 0.63. Conclusions: For prehospital treatment of anaphylaxis, we recommend the use of EpiPen and EpiPen Jr autoinjectors that are not outdated. If, however, the only autoinjector available is an outdated one, it could be used as long as no discoloration or precipitates are apparent because the potential benefit of using it Is greater than the potential risk of a suboptimal epinephrine dose or of no epinephrine treatment at all.	Univ Manitoba, Fac Med, Dept Pediat & Child Hlth, Allergy & Clin Immunol Sect, Winnipeg, MB, Canada; Univ Manitoba, Fac Pharm, Div Pharmaceut Sci, Winnipeg, MB R3T 2N2, Canada	University of Manitoba; University of Manitoba	Simons, KJ (corresponding author), Childrens Hosp Winnipeg, 820 Sherbrook St, Winnipeg, MB R3A 1R9, Canada.							AAAI Board Directors, 1998, J ALLERGY CLIN IMMUN, V102, P173; Chamberlain D, 1999, J ACCID EMERG MED, V16, P243; CHURCH WH, 1994, AM J EMERG MED, V12, P306, DOI 10.1016/0735-6757(94)90145-7; GILLS MC, 1999, COMPENDIUM PHARM SPE; GRANT TA, 1994, AM J EMERG MED, V12, P319, DOI 10.1016/0735-6757(94)90148-1; Hoffmann BB, 1996, GOODMAN GILMANS PHAR, P204; Huang SW, 1998, J ALLERGY CLIN IMMUN, V102, P525, DOI 10.1016/S0091-6749(98)70145-9; Hughes G, 1999, BRIT MED J, V319, P1; LUCIUK GH, 1993, J ALLERGY CLIN IMMUN, V91, P153; *MED EC, 1999, PHYS DESK REF, P916; NETER J, 1993, APPL LINEAR STAT MOD; NEWMAN BR, 1981, ANN ALLERGY, V47, P35; NICKLAS RA, 1998, J ALLERGY CLIN IMMUN, V101, pS465; Noone SA, 1999, J ALLERGY CLIN IMMUN, V103, pS54; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Simons FER, 1998, J ALLERGY CLIN IMMUN, V101, P33, DOI 10.1016/S0091-6749(98)70190-3; SIMONS FER, 2000, IN PRESS PEDIATRICS, P105; *US PHARM CONV, 2000, US PHARM, V24; Wollman H., 1993, PHARMAZIE, V38, P37; YUNGINGER JW, 1988, JAMA-J AM MED ASSOC, V260, P1450, DOI 10.1001/jama.260.10.1450	20	78	85	1	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2000	105	5					1025	1030		10.1067/mai.2000.106042	http://dx.doi.org/10.1067/mai.2000.106042			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	316TW	10808186				2022-12-18	WOS:000087185000024
J	Plaschke, P; Janson, C; Norrman, E; Bjornsson, E; Ellbjar, S; Jarvholm, B				Plaschke, P; Janson, C; Norrman, E; Bjornsson, E; Ellbjar, S; Jarvholm, B			Association between atopic sensitization and asthma and bronchial hyperresponsiveness in Swedish adults: Pets, and not mites, are the most important allergens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopy; cats; dogs; mites; asthma; bronchial hyperresponsiveness; skin test reactivity; specific IgE; total IgE; European Community Respiratory Health Survey	DIFFERENT CLIMATIC AREAS; CROSS-SECTIONAL DATA; HOUSE-DUST MITE; F-I ALLERGENS; FEL-D-I; YOUNG-ADULTS; RESPIRATORY SYMPTOMS; CHILDHOOD ASTHMA; RELATIVE RISKS; CAT FEL-D-1	Background: Atopic sensitization is a well-known risk factor for asthma and bronchial hyperresponsiveness (BHR). Mites have been regarded as the most important allergens, but the prevalence of sensitization to mites Is relatively low in Sweden. Objective: The aim of the study was to investigate possible associations between sensitization to various allergens and asthma and BHR in adults, Methods: A random sample of 1859 subjects, aged 20 to 46 years, was investigated in a cross-sectional study by using a questionnaire, skin prick tests (SPTs), specific and total IgE measurements, and methacholine bronchial challenge tests. Possible associations were analyzed univariately and by using multivariate logistic regression analysis and proportional hazard regression analysis, Results: Positive SPT and specific IgE results were more common in subjects with asthma and BHR than in subjects without these conditions for all allergens, The independent associations between positive SPT responses and asthma and BHR are given as adjusted prevalence ratios (PRRs): pets and asthma, PRR = 3.6; pets and BHR, PRR = 2.0; grass and asthma, PRR = 2.0; grass and BHR, PRR = 1.7; mites and asthma, PRR = 1.4; and mites and BHR, PRR = 1.2. The use of specific IgE measurements instead of SPTs showed essentially similar results. Conclusion: Cats and dogs were the sensitizing allergens most closely associated with asthma and BHR, The relationships with sensitization to grass and mites were less pronounced.	Roskilde Cty Hosp, Dept Med, DK-4000 Roskilde, Denmark; Sahlgrens Univ Hosp, Allergy Res Ctr, Gothenburg, Sweden; Uppsala Univ, Akad Sjukhuset, Asthma Res Ctr, Uppsala, Sweden; Univ Hosp No Sweden, Dept Pulm Med & Allergol, Umea, Sweden; Umea Univ, Dept Occupat & Environm Med, Umea, Sweden; Uppsala Univ, Akad Sjukhuset, Dept Lung Med, Uppsala, Sweden	Sahlgrenska University Hospital; Uppsala University; Uppsala University Hospital; Umea University; Umea University; Uppsala University; Uppsala University Hospital	Plaschke, P (corresponding author), Roskilde Cty Hosp, Dept Med, Kogevej 7-13, DK-4000 Roskilde, Denmark.			Bjornsson, Eythor/0000-0003-1186-8473				ABERG N, 1995, CLIN EXP ALLERGY, V25, P815, DOI 10.1111/j.1365-2222.1995.tb00023.x; ABERG N, 1989, ACTA PAEDIATR SCAND, V78, P246, DOI 10.1111/j.1651-2227.1989.tb11064.x; ABERG N, 1989, CLIN EXP ALLERGY, V19, P59, DOI 10.1111/j.1365-2222.1989.tb02345.x; Altman DG, 1990, PRACTICAL STAT MED R; [Anonymous], 1989, ALLERGY S10, V10, P1; AUGUSTO A, 1997, AM J RESP CRIT CARE, V156, P23; BELIN L, 1985, ALLERGY S4, V40, P60; Berge M, 1998, PEDIATR ALLERGY IMMU, V9, P25, DOI 10.1111/j.1399-3038.1998.tb00296.x; BJORNSSON E, 1994, EUR RESPIR J, V7, P2146, DOI 10.1183/09031936.94.07122146; Boezen HM, 1996, AM J RESP CRIT CARE, V154, P30, DOI 10.1164/ajrccm.154.1.8680695; BOUSQUET J, 1990, J ALLERGY CLIN IMMUN, V85, P1039, DOI 10.1016/0091-6749(90)90048-9; BURNEY P, 1987, CHEST, V91, pS79, DOI 10.1378/chest.91.6.79S; Burney P, 1997, J ALLERGY CLIN IMMUN, V99, P314, DOI 10.1016/S0091-6749(97)70048-4; Burney P, 1997, AM J RESP CRIT CARE, V156, P1773; BURNEY PGJ, 1989, EUR RESPIR J, V2, P940; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; COOKSON WOCM, 1991, CLIN EXP ALLERGY, V21, P473, DOI 10.1111/j.1365-2222.1991.tb01688.x; *DEP ENV HLTH, 1998, ENV HLTH REP 1998; Egmar AC, 1998, PEDIATR ALLERGY IMMU, V9, P31, DOI 10.1111/j.1399-3038.1998.tb00297.x; *EUR COMM RESP HLT, 1993, PUBL 6, V2920; GERGEN PJ, 1992, J ALLERGY CLIN IMMUN, V90, P579, DOI 10.1016/0091-6749(92)90130-T; INGRAM JM, 1995, J ALLERGY CLIN IMMUN, V96, P449, DOI 10.1016/S0091-6749(95)70286-5; Janson C, 1997, EUR RESPIR J, V10, P1795, DOI 10.1183/09031936.97.10081795; KUEHR J, 1995, J ALLERGY CLIN IMMUN, V95, P655, DOI 10.1016/S0091-6749(95)70168-0; LEE J, 1994, INT J EPIDEMIOL, V23, P201, DOI 10.1093/ije/23.1.201; LIN RY, 1993, ANN ALLERGY, V71, P33; LINDFORS A, 1995, ARCH DIS CHILD, V73, P408, DOI 10.1136/adc.73.5.408; MUNIR AKM, 1993, J ALLERGY CLIN IMMUN, V91, P1067, DOI 10.1016/0091-6749(93)90221-Z; MUNIR AKM, 1995, CLIN EXP ALLERGY, V25, P119, DOI 10.1111/j.1365-2222.1995.tb01016.x; MURRAY AB, 1985, J ALLERGY CLIN IMMUN, V76, P108, DOI 10.1016/0091-6749(85)90812-7; Patchett K, 1997, J ALLERGY CLIN IMMUN, V100, P755, DOI 10.1016/S0091-6749(97)70269-0; PEAT JK, 1993, CLIN EXP ALLERGY, V23, P812, DOI 10.1111/j.1365-2222.1993.tb00258.x; PEAT JK, 1990, J ALLERGY CLIN IMMUN, V85, P65, DOI 10.1016/0091-6749(90)90223-Q; PEAT JK, 1991, CLIN EXP ALLERGY, V21, P573, DOI 10.1111/j.1365-2222.1991.tb00849.x; Plaschke P, 1996, ALLERGY, V51, P461, DOI 10.1111/j.1398-9995.1996.tb00163.x; PLATTSMILLS TAE, 1992, AM REV RESPIR DIS, V145, pS44, DOI 10.1164/ajrccm/145.2_Pt_2.S44; PLATTSMILLS TAE, 1995, ALLERGY, V50, P5, DOI 10.1111/j.1398-9995.1995.tb02729.x; SEARS MR, 1993, CLIN EXP ALLERGY, V23, P941, DOI 10.1111/j.1365-2222.1993.tb00279.x; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; SEARS MR, 1993, CLIN EXP ALLERGY, V23, P949, DOI 10.1111/j.1365-2222.1993.tb00280.x; Soriano JB, 1996, AM J RESP CRIT CARE, V154, P1636, DOI 10.1164/ajrccm.154.6.8970347; Spitzauer S, 1997, J ALLERGY CLIN IMMUN, V99, P100, DOI 10.1016/S0091-6749(97)70306-3; Sunyer Y, 1997, EUR RESPIR J, V10, P2490, DOI 10.1183/09031936.97.10112490; SUONIEMI I, 1981, ALLERGY, V36, P263, DOI 10.1111/j.1398-9995.1981.tb01573.x; Thompson ML, 1998, OCCUP ENVIRON MED, V55, P272, DOI 10.1136/oem.55.4.272; TOREN K, 1993, CHEST, V104, P600, DOI 10.1378/chest.104.2.600; Ulrik CS, 1996, J ALLERGY CLIN IMMUN, V97, P761, DOI 10.1016/S0091-6749(96)80153-9; VANTO T, 1983, ACTA PAEDIATR SCAND, V72, P571, DOI 10.1111/j.1651-2227.1983.tb09773.x	48	78	79	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1999	104	1					58	65		10.1016/S0091-6749(99)70114-4	http://dx.doi.org/10.1016/S0091-6749(99)70114-4			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	221QZ	10400840				2022-12-18	WOS:000081738900009
J	Kelso, JM; Mootrey, GT; Tsai, TF				Kelso, JM; Mootrey, GT; Tsai, TF			Anaphylaxis from yellow fever vaccine	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; anaphylaxis; yellow fever vaccine	IMMEDIATE-TYPE REACTIONS; GELATIN; CHILDREN; MEASLES; IGE; ALLERGY	Background: There are very few reports of anaphylactic reactions to yellow fever (YF) vaccine in the literature, and these date from the 1940s, Objective: We sought to estimate the rate of YF vaccine-related anaphylaxis, Methods: All reports of adverse reactions to YF vaccine submitted to the Vaccine Adverse Event Reporting System between 1990 and 1997 were reviewed for those meeting criteria for probable or possible anaphylactic reactions. Results: Of 243 reports submitted, 40 describe probable or possible anaphylactic reactions. In 22 of these 40, YF vaccine was the only vaccine administered. There were 5,236,820 doses of YF vaccine distributed in the United States during this period. By using all 40 Eases, the rate of YF vaccine-related anaphylaxis would be 40 in 5,236,820 or about 1 in 131,000, In 35 of the reports, information was provided on whether previous doses of YF vaccine had been given. In 34 of these 35, the reaction occurred after the first dose of YF vaccine, suggesting that vaccine constituents other than the viral proteins may have been the allergens. The vaccine is grown in chicken embryos and contains gelatin as a stabilizer. Conclusion: YP vaccine can cause anaphylactic reactions. Persons presenting for YF vaccine should be asked if they have had adverse reactions to previous doses of this or other vaccines and if they are allergic to eggs, chicken, or gelatin. Health care workers administering YF vaccine should be prepared to recognize and treat anaphylactic reactions should they occur.	USN, Med Ctr, Dept Internal Med, Div Allergy, San Diego, CA 92134 USA; Ctr Dis Control & Prevent, Natl Immunizat Program, Vaccine Safety & Dev Act, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Div Vector Borne Infect Dis, Ft Collins, CO USA	United States Department of Defense; United States Navy; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Kelso, JM (corresponding author), USN, Med Ctr, Dept Clin Res, San Diego, CA 92134 USA.							*AM COLL PHYS, 1994, GUID AD IMM, P140; CHEN RT, 1994, VACCINE, V12, P542, DOI 10.1016/0264-410X(94)90315-8; *CONN LAB INC, 1986, PACK INS YF VAX YELL; FREESTONE DS, 1977, J BIOL STAND, V5, P181, DOI 10.1016/S0092-1157(77)80003-6; HERMAN JJ, 1983, J PEDIATR-US, V102, P196, DOI 10.1016/S0022-3476(83)80519-8; JAMES JM, 1995, NEW ENGL J MED, V332, P1262, DOI 10.1056/NEJM199505113321904; KELSO JM, 1993, J ALLERGY CLIN IMMUN, V91, P867, DOI 10.1016/0091-6749(93)90344-F; MONATH TP, IN PRESS VACCINES; MOSIMANN B, 1995, J ALLERGY CLIN IMMUN, V95, P1064, DOI 10.1016/S0091-6749(95)70118-4; MOSSBLUNDELL AJ, 1981, J BIOL STAND, V9, P445, DOI 10.1016/S0092-1157(81)80036-4; PETER G, 1997, 1997 RED BOOK REPORT, P32; Rosenthal S, 1995, AM J PUBLIC HEALTH, V85, P1706, DOI 10.2105/AJPH.85.12.1706; RUBIN SS, 1946, J ALLERGY, V17, P21, DOI 10.1016/0021-8707(46)90017-2; Sakaguchi M, 1996, J ALLERGY CLIN IMMUN, V98, P1058, DOI 10.1016/S0091-6749(96)80191-6; Sakaguchi M, 1997, J ALLERGY CLIN IMMUN, V99, P263, DOI 10.1016/S0091-6749(97)70108-8; Sakaguchi M, 1997, J ALLERGY CLIN IMMUN, V99, P720, DOI 10.1016/S0091-6749(97)70038-1; SPRAGUE HB, 1945, US NAV M B, V45, P71; Swartz H, 1943, J LAB CLIN MED, V28, P1663	18	78	82	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1999	103	4					698	701		10.1016/S0091-6749(99)70245-9	http://dx.doi.org/10.1016/S0091-6749(99)70245-9			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	186HY	10200022				2022-12-18	WOS:000079723900026
J	SUNYER, J; ANTO, JM; SABRIA, J; ROCA, J; MORELL, F; RODRIGUEZROISIN, R; RODRIGO, MJ				SUNYER, J; ANTO, JM; SABRIA, J; ROCA, J; MORELL, F; RODRIGUEZROISIN, R; RODRIGO, MJ			RELATIONSHIP BETWEEN SERUM IGE AND AIRWAY RESPONSIVENESS IN ADULTS WITH ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASTHMA; BRONCHIAL RESPONSIVENESS; IGE; METHACHOLINE CHALLENGE TEST; SKIN REACTIVITY	SKIN-TEST REACTIVITY; BRONCHIAL HYPERRESPONSIVENESS; LONGITUDINAL CHANGES; LUNG-DISEASE; ATOPY; POPULATION; PATHOGENESIS; EPIDEMIOLOGY; COMMUNITY; HISTAMINE	Background: General population studies have shown a relationship between total serum IgE levels and airway responsiveness, but this association has not been documented in patients with asthma. Objective: The study assesses the cross-sectional relationship between IgE levels and airway responsiveness in 208 subjects who had had emergency department treatment for asthma at lest 2 years earlier. Methods: All participants completed a standardized respiratory questionnaire and underwent spirometry, allergy skin testing, and a dose-response methacholine challenge test. Results: After adjusting for age and gender, the percentage of patients with asthma and airway responsiveness (provocative concentration causing a 20% fall in forced expiratory volume in 1 second [PC20] less than or equal to 8 mg/ml) increased from 52% in the lower quintile of IgE to 72% in the upper quintile (p < 0.01). After adjusting for age, gender, baseline percent predicted forced expiratory volume in 1 second, and smoking, the association between IgE (both in quintiles and continuous) and PC20 appeared consistent and statistically significant (p < 0.01). This association was stronger in patients who were not given inhaled steroid (odds ratio for twice the concentration of IgE, 1.42; 95% confidence interval, 1.09 and 1.84), than in patients treated with inhaled steroid (odds ratio, 1.10; 95% confidence interval, 0.82 and 1.50). Eosinophilia and skin reactivity were associated with PC20 although to a lesser extent. Conclusion: These findings strengthen the role played by IgE in facilitating the development of bronchial responsiveness in patients with asthma.	HOSP CLIN BARCELONA, SERV PNEUMOL ALLERGIA RESP, BARCELONA, SPAIN; HOSP GEN VALLE HEBRON, SERV PNEUMOL, BARCELONA, SPAIN; HOSP GEN VALLE HEBRON, SERV BIOQUIM, BARCELONA, SPAIN	University of Barcelona; Hospital Clinic de Barcelona; Hospital Universitari Vall d'Hebron; Hospital Universitari Vall d'Hebron	SUNYER, J (corresponding author), UNIV AUTONOMA BARCELONA, INST MUNICIPAL INVEST MED, DEPT EPIDEMIOL SALUT PUBL, E-08003 BARCELONA, SPAIN.		Anto, J M/H-2676-2014; Sunyer, Jordi/G-6909-2014; Roca, Josep/J-2583-2015	Anto, J M/0000-0002-4736-8529; Sunyer, Jordi/0000-0002-2602-4110; Roca, Josep/0000-0003-4768-8722; Morell Brotad, Ferran/0000-0002-7206-4543				ALTOUNYAN REC, 1970, DISODIUM CROMOGLYCAT, P47; [Anonymous], 1987, AM REV RESPIR DIS, V136, P1285; ANTO JM, 1993, NEW ENGL J MED, V329, P1760, DOI 10.1056/NEJM199312093292402; ANTO JM, 1990, CHEST, V98, pS185, DOI 10.1378/chest.98.5_Supplement.185S; BARNES PJ, 1989, J ALLERGY CLIN IMMUN, V83, P1013, DOI 10.1016/0091-6749(89)90441-7; BARNES PJ, 1990, AM REV RESPIR DIS, V141, pS70; BRYANT DH, 1976, CLIN ALLERGY, V6, P373, DOI 10.1111/j.1365-2222.1976.tb01919.x; BURNEY P, 1987, CHEST, V91, pS79, DOI 10.1378/chest.91.6.79S; BURNEY PGJ, 1987, THORAX, V42, P38, DOI 10.1136/thx.42.1.38; BURNEY PGJ, 1989, INT J EPIDEMIOL, V18, P165, DOI 10.1093/ije/18.1.165; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; Cox D.R., 1989, ANAL BINARY DATA; CROCKCROFT DW, 1984, ANN ALLERGY, V53, P26; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; GRAINGER DN, 1990, CLIN EXP ALLERGY, V20, P181, DOI 10.1111/j.1365-2222.1990.tb02665.x; LAM S, 1983, J ALLERGY CLIN IMMUN, V72, P134, DOI 10.1016/0091-6749(83)90520-1; MURANAKA M, 1974, J ALLERGY CLIN IMMUN, V54, P32, DOI 10.1016/S0091-6749(74)80006-0; OCONNOR GT, 1989, AM REV RESPIR DIS, V140, P1520, DOI 10.1164/ajrccm/140.6.1520; OCONNOR GT, 1989, AM REV RESPIR DIS, V140, P225, DOI 10.1164/ajrccm/140.1.225; PEAT JK, 1992, EUR RESPIR J, V5, P921; PEAT JK, 1990, J ALLERGY CLIN IMMUN, V85, P65, DOI 10.1016/0091-6749(90)90223-Q; PLATTSMILLS TAE, 1982, LANCET, V2, P675; RADFORD PJ, 1992, CHEST, V101, P624, DOI 10.1378/chest.101.3.624; RIJCKEN B, 1993, EUR RESPIR J, V6, P617; ROGERS DF, 1993, THORAX, V48, P1095, DOI 10.1136/thx.48.11.1095; SABRIA J, 1992, THESIS U BARCELONA B; SEARS MR, 1991, NEW ENGL J MED, V325, P1067, DOI 10.1056/NEJM199110103251504; SPARROW D, 1988, EPIDEMIOL REV, V10, P29, DOI 10.1093/oxfordjournals.epirev.a036027; SUNYER J, 1992, AM REV RESPIR DIS, V145, P1098, DOI 10.1164/ajrccm/145.5.1098; TOLLERUD DJ, 1991, AM REV RESPIR DIS, V144, P776, DOI 10.1164/ajrccm/144.4.776; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366; WOOLCOCK AJ, 1978, CLIN ALLERGY, V8, P155, DOI 10.1111/j.1365-2222.1978.tb00460.x; WOOLCOCK AJ, 1987, THORAX, V42, P361, DOI 10.1136/thx.42.5.361; 1980, AM THORACIC SOC NEWS, V2, P11	36	78	80	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1995	95	3					699	706		10.1016/S0091-6749(95)70175-3	http://dx.doi.org/10.1016/S0091-6749(95)70175-3			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QM017	7897153				2022-12-18	WOS:A1995QM01700010
J	VIGANO, A; PRINCIPI, N; CRUPI, L; ONORATO, J; VINCENZO, ZG; SALVAGGIO, A				VIGANO, A; PRINCIPI, N; CRUPI, L; ONORATO, J; VINCENZO, ZG; SALVAGGIO, A			ELEVATION OF IGE IN HIV-INFECTED CHILDREN AND ITS CORRELATION WITH THE PROGRESSION OF DISEASE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IGE HYPERPRODUCTION; VERTICAL HIV INFECTION; CHILDREN; MARKERS OF PROGRESSION	IMMUNODEFICIENCY-VIRUS TYPE-1; DYSFUNCTION; PATTERNS	Background: According to recent data, a switch from a T-H1 to a T-H2 pattern of cytokines might be a critical step in the progression of human immunodeficiency virus (HN) infection. Previous studies have demonstrated a disturbance in IgE synthesis in HIV-infected adults. Methods: Fifty-eight children infected vertically with HN and 35 children with seroreversion, aged 4 months to 11 years, were evaluated for IgE serum level, CD4(+) cell count, skin prick test responses to common airborne and food allergens individual and family history of atopy, and presence of opportunistic infections. In thirty of the 58 HIV-infected children serum interleukin-4 and interferon-gamma levels were assessed. Thirty-three of the 58 HIV-infected children had a follow-up of 1 year for IgE levels, CD4(+) cell count, and occurrence of opportunistic infections and recurrent bacterial infections. Results: Both IgE concentration and the percentage of children with IgE elevation were markedly increased (with no correlation to skin prick test responses or opportunistic infections) in the group of 58 HIV-infected children as compared with the 35 children with seroreversion (p < 0.05). The same parameters were higher in children with acquired immunodeficiency syndrome as compared with children with asymptomatic or mildly symptomatic disease (p < 0.05). Serum interleukin-4 and interferon-gamma levels do not account for IgE hyperproduction. There was a significant association between persistent IgE elevation and severe decline (greater than or equal to 30% over 1 year) in CD4(+) counts, as well as increased susceptibility to bacterial infections. Conclusions: Our study demonstrates a spectrum of IgE dysfunction in children, which is similar to that observed in adults. A persistent IgE hyperproduction appears to be associated with a severe decline in CD4(+) cell count, suggesting that this clinical test is a useful marker of disease progression.	UNIV MILAN,DEPT HYG & PREVENT MED,MILAN,ITALY	University of Milan	VIGANO, A (corresponding author), UNIV MILAN,L SACCO HOSP VIALBA,DEPT PAEDIAT 4,PEDIAT CLIN 4,VIA GB GRASSI 74,I-20157 MILAN,ITALY.							AMMANN AJ, 1983, CLIN IMMUNOL IMMUNOP, V27, P315, DOI 10.1016/0090-1229(83)90084-3; CLERICI M, 1989, J CLIN INVEST, V84, P1892, DOI 10.1172/JCI114376; CLERICI M, 1993, IMMUNOL TODAY, V14, P107, DOI 10.1016/0167-5699(93)90208-3; CLERICI M, 1993, J CLIN INVEST, V91, P759, DOI 10.1172/JCI116294; COHEN J, 1993, SCIENCE, V262, P175, DOI 10.1126/science.8211135; Gascan H, 1991, Clin Exp Allergy, V21 Suppl 1, P162, DOI 10.1111/j.1365-2222.1991.tb01721.x; GIORGI JV, 1987, J IMMUNOL, V138, P3725; ISRAELBIET D, 1992, J ALLERGY CLIN IMMUN, V89, P68, DOI 10.1016/S0091-6749(05)80042-9; KANAGAWA O, 1993, SCIENCE, V262, P240, DOI 10.1126/science.8211142; LUCEY DR, 1991, J INFECT DIS, V163, P971, DOI 10.1093/infdis/163.5.971; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; PETERSEN J, 1989, J PEDIATR-US, V115, P944, DOI 10.1016/S0022-3476(89)80747-4; ROILIDES E, 1991, J PEDIATR-US, V118, P724, DOI 10.1016/S0022-3476(05)80033-2; ROMAGNANI S, 1990, IMMUNOL TODAY, V11, P316, DOI 10.1016/S0167-5699(10)80004-0; ROMAGNANI S, 1991, HIGHLIGHTS ALLERGY C, P21; SHORE RE, 1976, AM J EPIDEMIOL, V103, P527, DOI 10.1093/oxfordjournals.aje.a112255; WRIGHT DN, 1990, J ALLERGY CLIN IMMUN, V85, P45; YMAN L, 1985, ALLERGY S, V40, P10; 1987, MMWR-MORBID MORTAL W, V36, pS1	19	78	79	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1995	95	2					627	632		10.1016/S0091-6749(95)70326-8	http://dx.doi.org/10.1016/S0091-6749(95)70326-8			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QH697	7852675				2022-12-18	WOS:A1995QH69700016
J	SHERRILL, DL; HALONEN, M; BURROWS, B				SHERRILL, DL; HALONEN, M; BURROWS, B			RELATIONSHIPS BETWEEN TOTAL SERUM IGE, ATOPY, AND SMOKING - A 20-YEAR FOLLOW-UP ANALYSIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ALLERGY SKIN TEST; ATOPY; IMMUNOGLOBULIN; LONGITUDINAL; TOTAL SERUM IGE	IMMUNOGLOBULIN-E LEVELS; SKIN-TEST REACTIVITY; PULMONARY-FUNCTION; SERIAL-CORRELATION; POPULATION-SAMPLE; AGE; SEX; RESPONSIVENESS; SENSITIVITY; OBSTRUCTION	Background: A number of cross-sectional studies have demonstrated that higher levels of IgE are found in subjects who currently smoke cigarettes and/or who are atopic and that IgE levels decline with age. Objective: This report examines the interactions among atopic status, smoking, and IgE with longitudinal data and methods. Methods: Subjects were participants in the Tucson Epidemiological Study of Airways Obstructive Disease and were 6 years of age and older. Total serum IgE measures and allergen skin test results were obtained during three surveys spanning a period of rep to 20 years. Results: The results showed no significant gender differences between nonatopic nonsmoking subjects, who were considered the reference group. Nonatopic current smokers had IgE levels similar to those of the reference subjects initially, but IgE levels did nor decline with age at the same rate as in the reference subjects, causing significant differences at older ages. There was a significant relationship between number of cigarettes smoked and IgE level. Conclusions: Atopy and smoking are both associated with elevated total serum IgE levels. Although the exact mechanism for elevated IgE levels in smokers is not known, the significant dose relationship is suggestive of a causal association.			SHERRILL, DL (corresponding author), UNIV ARIZONA,COLL MED,CTR SCI RESP,1501 N CAMPBELL AVE,TUCSON,AZ 85724, USA.			Halonen, Marilyn/0000-0001-9606-935X	NHLBI NIH HHS [HL14136] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014136] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAHNA SL, 1983, ALLERGY, V38, P57, DOI 10.1111/j.1398-9995.1983.tb00857.x; BARBEE RA, 1976, ANN INTERN MED, V84, P129, DOI 10.7326/0003-4819-84-2-129; BARBEE RA, 1987, J ALLERGY CLIN IMMUN, V79, P919, DOI 10.1016/0091-6749(87)90241-7; BARBEE RA, 1981, J ALLERGY CLIN IMMUN, V68, P106, DOI 10.1016/0091-6749(81)90167-6; BURROWS B, 1983, CHEST, V84, P657, DOI 10.1378/chest.84.6.657; BURROWS B, 1981, AM REV RESPIR DIS, V124, P523; DOW L, 1992, AM REV RESPIR DIS, V146, P402, DOI 10.1164/ajrccm/146.2.402; ERICSSON CH, 1993, AM REV RESPIR DIS, V147, P296, DOI 10.1164/ajrccm/147.2.296; FREIDHOFF LR, 1984, J ALLERGY CLIN IMMUN, V73, P490, DOI 10.1016/0091-6749(84)90360-9; GERRARD JW, 1980, ANN ALLERGY, V44, P261; GRUNDBACHER FJ, 1985, J ALLERGY CLIN IMMUN, V75, P651, DOI 10.1016/0091-6749(85)90089-2; HALLGREN R, 1982, ACTA MED SCAND, V211, P269; HARVILLE DA, 1977, J AM STAT ASSOC, V72, P320, DOI 10.2307/2286796; HENNEUSE Y, 1978, CLIN ALLERGY, V8, P165; HOLFORDSTREVENS V, 1984, J ALLERGY CLIN IMMUN, V73, P516, DOI 10.1016/0091-6749(84)90363-4; HOURI M, 1972, Clinical Allergy, V2, P285, DOI 10.1111/j.1365-2222.1972.tb01292.x; JOHANSSO.SG, 1967, LANCET, V2, P951; JONES RH, 1990, COMMUN STAT SIMULAT, V19, P1105; JONES RH, 1991, BIOMETRICS, V47, P161, DOI 10.2307/2532504; KRZYZANOWSKI M, 1990, AM J EPIDEMIOL, V131, P412, DOI 10.1093/oxfordjournals.aje.a115516; LEBOWITZ MD, 1975, AM J EPIDEMIOL, V102, P137, DOI 10.1093/oxfordjournals.aje.a112141; LOEFFLER JA, 1973, ANN ALLERGY, V31, P331; OCONNOR GT, 1989, AM REV RESPIR DIS, V140, P1520, DOI 10.1164/ajrccm/140.6.1520; Pepys J, 1975, CLIN ASPECTS IMMUNOL, P55; SHERRILL DL, 1993, EUR RESPIR J, V6, P342; SHERRILL DL, 1992, AM REV RESPIR DIS, V145, P1136, DOI 10.1164/ajrccm/145.5.1136; SHERRILL DL, 1993, AM REV RESPIR DIS, V148, P116, DOI 10.1164/ajrccm/148.1.116; VENABLES KM, 1985, BRIT MED J, V290, P201, DOI 10.1136/bmj.290.6463.201; VOLLMER WM, 1986, CHEST, V90, P416, DOI 10.1378/chest.90.3.416; WARREN CPW, 1982, J ALLERGY CLIN IMMUN, V69, P370, DOI 10.1016/0091-6749(82)90148-8; ZETTERSTROM O, 1981, BRIT MED J, V283, P1215, DOI 10.1136/bmj.283.6301.1215	31	78	79	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1994	94	6	1				954	962		10.1016/0091-6749(94)90113-9	http://dx.doi.org/10.1016/0091-6749(94)90113-9			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PY230	7798543				2022-12-18	WOS:A1994PY23000003
J	KUMAR, A; REDDY, LV; SOCHANIK, A; KURUP, VP				KUMAR, A; REDDY, LV; SOCHANIK, A; KURUP, VP			ALLERGENS, IGE, MEDIATORS, INFLAMMATORY MECHANISMS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						HEAT SHOCK PROTEIN; ASPERGILLUS-FUMIGATUS; MESSENGER RNA; CDNA LIBRARY; IMMUNOSCREENING; RECOMBINANT PROTEIN; NORTHERN ANALYSIS	HEAT-SHOCK PROTEIN; ASPERGILLUS-FUMIGATUS ANTIGENS; STRESS PROTEINS; IMMUNOCHEMICAL CHARACTERIZATION; BRONCHOPULMONARY ASPERGILLOSIS; CANDIDA-ALBICANS; GENE; SEQUENCE; DNA; ELECTROPHORESIS	Background: Aspergillus fumigatus, a common environmental fungus, is responsible for a number of lung disorders, including allergy and infection, in human beings. For immunodiagnosis of these diseases, standardized, pure, and relevant antigens are not currently available. Methods: A complementary DNA library of A. fumigatus was constructed with messenger RNA isolated from 96-hour-old culture of the organism. Fusion proteins expressed with the cDNA were characterized and evaluated. Results: One of the clones, which reacted with both rabbit anti-A. fumigatus serum and a pool of sera from patients with allergic bronchopulmonary aspergillosis, expressed a 65 kd protein of A. fumigatus. The recombinant protein reacted with immunoglobulin E and immunoglobulin G antibodies in the sera from patients with allergic bronchopulmonary aspergillosis. The deduced amino acid sequence of the partially sequenced complementary DNA of the clone is homologous with the hsp 90 family of heat shock proteins in human beings and other organisms. Conclusion: The immunodominant nature and the homology to human heat shock proteins suggest a possible role for this protein in protective immunity and autoimmunity.	VET ADM MED CTR, RES SERV, MILWAUKEE, WI USA; MED COLL WISCONSIN, DEPT MED, MILWAUKEE, WI 53226 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Medical College of Wisconsin				Sochanik, Aleksander/0000-0003-2674-246X				ARRUDA LK, 1990, J EXP MED, V172, P1529, DOI 10.1084/jem.172.5.1529; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BARDANA E, 1980, CRC CRIT REV CLIN LA, V13, P85; BARDANA E. J, 1980, CRC CRIT REV CLIN LA, V13, P21; BARDWELL JCA, 1987, P NATL ACAD SCI USA, V84, P5177, DOI 10.1073/pnas.84.15.5177; BLACKMAN RK, 1986, J MOL BIOL, V188, P499, DOI 10.1016/S0022-2836(86)80001-8; BURNIE JP, 1991, J CLIN MICROBIOL, V29, P2099, DOI 10.1128/JCM.29.10.2099-2106.1991; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DRAGON EA, 1987, MOL CELL BIOL, V7, P1271, DOI 10.1128/MCB.7.3.1271; FARRELLY FW, 1984, J BIOL CHEM, V259, P5745; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HEARN VM, 1990, J GEN MICROBIOL, V136, P1525, DOI 10.1099/00221287-136-8-1525; HEARN VM, 1992, J MED VET MYCOL, V30, P11; HICKEY E, 1989, MOL CELL BIOL, V9, P2615, DOI 10.1128/MCB.9.6.2615; KAUFMANN SHE, 1990, IMMUNOL TODAY, V11, P129, DOI 10.1016/0167-5699(90)90050-J; KIM SJ, 1978, AM REV RESPIR DIS, V118, P553; KURUP VP, 1987, DIAGN CLIN IMMUNOL, V5, P25; KURUP VP, 1977, MICROBIOS, V19, P191; KURUP VP, 1991, CLIN MICROBIOL REV, V4, P439, DOI 10.1128/CMR.4.4.439-456.1991; KURUP VP, 1986, INT ARCH ALLER A IMM, V79, P263, DOI 10.1159/000233984; KURUP VP, 1983, INFECT IMMUN, V41, P698, DOI 10.1128/IAI.41.2.698-701.1983; KURUP VP, 1986, J ALLERGY CLIN IMMUN, V78, P1166, DOI 10.1016/0091-6749(86)90267-8; LEUNG PSC, 1988, INT ARCH ALLER A IMM, V85, P416, DOI 10.1159/000234544; LONGBOTTOM JL, 1983, CLIN EXP IMMUNOL, V53, P354; Maniatis T, 1989, MOL CLONING; MATTHEWS R, 1989, FEMS MICROBIOL LETT, V60, P25, DOI 10.1016/0378-1097(89)90071-2; MATTHEWS RC, 1987, J CLIN MICROBIOL, V25, P230, DOI 10.1128/JCM.25.2.230-237.1987; MOORE SK, 1989, J BIOL CHEM, V264, P5343; MOSER M, 1992, J IMMUNOL, V149, P454; MOTTRAM JC, 1989, MOL BIOCHEM PARASIT, V37, P115, DOI 10.1016/0166-6851(89)90108-4; PIECHURA JE, 1983, IMMUNOLOGY, V49, P657; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; ULLMANN A, 1984, GENE, V29, P27, DOI 10.1016/0378-1119(84)90162-8; WINFIELD JB, 1989, ARTHRITIS RHEUM, V32, P1497, DOI 10.1002/anr.1780321202; YOUNG D, 1988, P NATL ACAD SCI USA, V85, P4267, DOI 10.1073/pnas.85.12.4267; YOUNG RA, 1989, CELL, V59, P5, DOI 10.1016/0092-8674(89)90861-1	37	78	83	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1993	91	5					1024	1030		10.1016/0091-6749(93)90215-2	http://dx.doi.org/10.1016/0091-6749(93)90215-2			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LC978	8491935				2022-12-18	WOS:A1993LC97800009
J	NISHIKAWA, K; MORII, T; AKO, H; HAMADA, K; SAITO, S; NARITA, N				NISHIKAWA, K; MORII, T; AKO, H; HAMADA, K; SAITO, S; NARITA, N			INVIVO EXPRESSION OF CD69 ON LUNG EOSINOPHILS IN EOSINOPHILIC PNEUMONIA - CD69 AS A POSSIBLE ACTIVATION MARKER FOR EOSINOPHILS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CD69; LUNG EOSINOPHILS; EOSINOPHILIC PNEUMONIA; ACTIVATED EOSINOPHILS; PMA; IL-3; IL-5; GM-CSF	T-CELL ACTIVATION; ANTIGEN; RECEPTORS; DENSITY; LEU-23; INDUCTION; ABILITY; RELEASE; IGE	The antigen, CD69, has been demonstrated to be expressed on activated T cells and natural killer cells. There have been no studies concerning the expression of CD69 on eosinophils. In this article, we demonstrate that lung eosinophils obtained from the bronchoalveolar lavage fluid of patients with eosinophilic pneumonia expressed significant levels of CD69, whereas peripheral blood (PB) eosinophils did not express CD69. We also activated PB eosinophils in vitro using phorbol myristate acetate and cytokines to determine whether CD69 was expressed. PB eosinophils expressed CD69 after short-term culture with phorbol myristate acetate and eosinophil hemopoietic cytokines (interleukin-3, granulocyte-macrophage-colony-stimulating factor, and interleukin-5). These findings suggest that CD69 may be a useful marker for activated eosinophils at inflammatory sites.	NARA MED UNIV,DEPT OBSTET & GYNECOL,KASHIHARA,NARA 634,JAPAN	Nara Medical University	NISHIKAWA, K (corresponding author), NARA MED UNIV,DEPT INTERNAL MED 2,840 SHIJO CHO,KASHIHARA,NARA 634,JAPAN.							BASS DA, 1980, J CLIN INVEST, V66, P1265, DOI 10.1172/JCI109978; CAPRON M, 1989, CLIN EXP ALLERGY, V19, P3; CAPRON M, 1981, J IMMUNOL, V126, P2087; CEBRIAN M, 1988, J EXP MED, V168, P1621, DOI 10.1084/jem.168.5.1621; COSULICH ME, 1987, P NATL ACAD SCI USA, V84, P4205, DOI 10.1073/pnas.84.12.4205; DESIMONE C, 1982, CLIN EXP IMMUNOL, V48, P249; FISHER E, 1986, CELL IMMUNOL, V97, P297; HARA T, 1986, J EXP MED, V164, P1988, DOI 10.1084/jem.164.6.1988; KAJITA T, 1985, INT ARCH ALLER A IMM, V78, P406, DOI 10.1159/000233922; KHALIFE J, 1986, J IMMUNOL, V137, P1659; LANIER LL, 1988, J EXP MED, V167, P1572, DOI 10.1084/jem.167.5.1572; LIEBOW AA, 1969, MEDICINE, V48, P251, DOI 10.1097/00005792-196907000-00001; LUCEY DR, 1989, P NATL ACAD SCI USA, V86, P1348, DOI 10.1073/pnas.86.4.1348; NISHIKAWA K, 1990, INT IMMUNOL, V2, P481, DOI 10.1093/intimm/2.6.481; PRIN L, 1983, INT ARCH ALLER A IMM, V72, P336, DOI 10.1159/000234893; REYNOLDS HY, 1987, AM REV RESPIR DIS, V135, P250; SHAW RJ, 1984, CLIN EXP IMMUNOL, V56, P716; TESTI R, 1989, J IMMUNOL, V142, P1854; TESTI R, 1988, J IMMUNOL, V141, P2557; TESTI R, 1990, J EXP MED, V172, P701, DOI 10.1084/jem.172.3.701; VADAS MA, 1979, J IMMUNOL, V122, P1228; WINQVIST I, 1982, IMMUNOLOGY, V47, P531	22	78	78	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1992	90	2					169	174		10.1016/0091-6749(92)90068-D	http://dx.doi.org/10.1016/0091-6749(92)90068-D			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JJ423	1500624	Bronze			2022-12-18	WOS:A1992JJ42300005
J	RAPHAEL, GD; IGARASHI, Y; WHITE, MV; KALINER, MA				RAPHAEL, GD; IGARASHI, Y; WHITE, MV; KALINER, MA			THE PATHOPHYSIOLOGY OF RHINITIS .5. SOURCES OF PROTEIN IN ALLERGEN-INDUCED NASAL SECRETIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ALLERGIC RHINITIS; NASAL CHALLENGE; LAVAGE; PROTEIN; ALBUMIN; LACTOFERRIN; LYSOZYME	MEDIATOR RELEASE; ANTIGEN CHALLENGE; PATHO-PHYSIOLOGY; AIRWAY CHALLENGE; HAY-FEVER; HISTAMINE; RADIOIMMUNOASSAY; METHACHOLINE; INDIVIDUALS; PROVOCATION	Allergic rhinitis is characterized by a profuse rhinorrhea in addition to paroxysms of sneezing, nasal congestion, and pruritus. To define better the sources of nasal secretion produced during rhinitis, nasal allergen challenges were performed on nine atopic subjects with seasonal rhinitis. A single dose of allergen was sprayed into one side of the nose, and nasal lavages were collected bilaterally for 7 hours. Nasal lavages were assayed for protein (total protein, albumin, lactoferrin, and lysozyme) and mediator (histamine and prostaglandin D2) content. Protein concentrations increased and remained elevated above baseline levels in both ipsilateral and contralateral secretions for up to 3 hours after allergen challenge. The proportion of albumin relative to total protein (the albumin percent) increased on the ipsilateral side, whereas the relative proportions of lactoferrin and lysozyme (the lactoferrin percent and lysozyme percent) increased on the contralateral side. Prostaglandin D2, but not histamine, increased selectively on the ipsilateral side. These data suggest that the ipsilateral protein secretory response is due to allergen-induced mast cell mediator release causing increased vascular permeability, whereas the contralateral protein secretory response is primarily a reflex-induced glandular secretion.			RAPHAEL, GD (corresponding author), NIAID, CLIN INVEST LAB,ALLERG DIS SECT, 9000 ROCKVILLE PIKE,BLDG 10, 11C207, BETHESDA, MD 20892 USA.							ANDERSSON M, 1989, AM REV RESPIR DIS, V139, P911, DOI 10.1164/ajrccm/139.4.911; BASCOM R, 1988, AM REV RESPIR DIS, V138, P406, DOI 10.1164/ajrccm/138.2.406; BAUMGARTEN CR, 1985, J CLIN INVEST, V76, P191, DOI 10.1172/JCI111945; BISGAARD H, 1988, ALLERGY, V43, P219; BORUM P, 1983, EUR J RESPIR DIS, V64, P65; BROFELDT S, 1986, AM REV RESPIR DIS, V133, P1138; BROWN MS, 1987, ARCH OTOLARYNGOL, V113, P179; CASTELLS M, 1988, J ALLERGY CLIN IMMUN, V82, P348, DOI 10.1016/0091-6749(88)90005-X; COHEN RA, 1988, CLIN ALLERGY, V18, P435, DOI 10.1111/j.1365-2222.1988.tb02893.x; CRETICOS PS, 1985, J CLIN INVEST, V76, P2247, DOI 10.1172/JCI112233; Eccles R., 1982, NOSE UPPER AIRWAY PH, P191; Granstrom E, 1978, Adv Prostaglandin Thromboxane Res, V5, P119; ILLIOPOULOS O, 1988, AM J RHINOL, V2, P97; KONNO A, 1987, J ALLERGY CLIN IMMUN, V79, P620, DOI 10.1016/S0091-6749(87)80158-6; KONNO A, 1979, ANN OTO RHINOL LARYN, V88, P258, DOI 10.1177/000348947908800219; KRAYENBUHL MC, 1989, ALLERGY, V44, P25, DOI 10.1111/j.1398-9995.1989.tb00441.x; LEBEL B, 1988, J ALLERGY CLIN IMMUN, V82, P869, DOI 10.1016/0091-6749(88)90092-9; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALMBERG H, 1989, ACTA OTO-LARYNGOL, V107, P446, DOI 10.3109/00016488909127538; MCBRIDE P, 1988, J ALLERGY CLIN IMMUN, V82, P638, DOI 10.1016/0091-6749(88)90977-3; METCALF JA, 1986, LABORATORY MANUAL NE, P149; MURRAY JJ, 1986, NEW ENGL J MED, V315, P800, DOI 10.1056/NEJM198609253151304; MYERS G, 1981, J ALLERGY CLIN IMMUN, V67, P305, DOI 10.1016/0091-6749(81)90026-9; NACLERIO RM, 1985, AM J MED, V79, P43, DOI 10.1016/0002-9343(85)90087-7; NACLERIO RM, 1983, EUR J RESPIR DIS, V64, P26; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; NORMAN PS, 1985, INT ARCH ALLER A IMM, V77, P57, DOI 10.1159/000233753; PIPKORN U, 1987, J CLIN INVEST, V80, P957, DOI 10.1172/JCI113188; PROUD D, 1983, J CLIN INVEST, V72, P1678, DOI 10.1172/JCI111127; RAPHAEL GD, 1988, AM REV RESPIR DIS, V138, P413, DOI 10.1164/ajrccm/138.2.413; RAPHAEL GD, 1989, J CLIN INVEST, V84, P1528, DOI 10.1172/JCI114329; RAPHAEL GD, 1989, AM REV RESPIR DIS, V139, P791, DOI 10.1164/ajrccm/139.3.791; SHAPIRO SS, 1965, BIOMETRIKA, V52, P591, DOI 10.1093/biomet/52.3-4.591; SHAW RJ, 1985, ALLERGY, V40, P1, DOI 10.1111/j.1398-9995.1985.tb04147.x; TOGIAS A, 1985, AM J MED, V79, P26, DOI 10.1016/0002-9343(85)90084-1; WHITE MV, 1987, J IMMUNOL, V139, P1624	37	78	83	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1991	88	1					33	42		10.1016/0091-6749(91)90298-3	http://dx.doi.org/10.1016/0091-6749(91)90298-3			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FY204	1712803				2022-12-18	WOS:A1991FY20400004
J	WITKIN, SS; JEREMIAS, J; LEDGER, WJ				WITKIN, SS; JEREMIAS, J; LEDGER, WJ			A LOCALIZED VAGINAL ALLERGIC RESPONSE IN WOMEN WITH RECURRENT VAGINITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											WITKIN, SS (corresponding author), CORNELL UNIV,MED CTR,COLL MED,DEPT OBSTET & GYNECOL,DIV IMMUNOL,515 E 71ST ST,NEW YORK,NY 10021, USA.		Witkin, Steven/AAF-3812-2019; Witkin, Steven/AAW-8602-2021	Witkin, Steven/0000-0002-3502-3929				BEER DJ, 1984, J ALLERGY CLIN IMMUN, V73, P439, DOI 10.1016/0091-6749(84)90353-1; BERMAN BA, 1964, ANN ALLERGY, V22, P594; BONNEY RJ, 1984, J LEUKOCYTE BIOL, V35, P1; CHOUAIB S, 1984, J IMMUNOL, V132, P1851; GORDON EH, 1986, IMMUNOL ALLERGY PRAC, V8, P29; GREEN RL, 1985, JAMA-J AM MED ASSOC, V254, P531, DOI 10.1001/jama.254.4.531; HALPERN BN, 1967, IMMUNOLOGY, V12, P247; HOBBS JR, 1977, P ROY SOC MED, V70, P11, DOI 10.1177/00359157770700S404; KAPLAN AP, 1985, ALLERGY; KUDELKO NM, 1971, ANN ALLERGY, V29, P266; PALACIOS HJ, 1976, ANN ALLERGY, V37, P110; ROGERS TJ, 1980, MICROBIOL REV, V44, P660, DOI 10.1128/MMBR.44.4.660-682.1980; ROSEDALE N, 1979, ANN ALLERGY, V43, P250; SELL MB, 1985, AM J PSYCHIAT, V142, P271; SIMON MR, 1979, CLIN IMMUNOL IMMUNOP, V14, P56, DOI 10.1016/0090-1229(79)90125-9; WITKIN SS, 1983, AM J OBSTET GYNECOL, V147, P809, DOI 10.1016/0002-9378(83)90044-3; WITKIN SS, 1986, AM J OBSTET GYNECOL, V155, P790, DOI 10.1016/S0002-9378(86)80022-9	17	78	82	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1988	81	2					412	416		10.1016/0091-6749(88)90909-8	http://dx.doi.org/10.1016/0091-6749(88)90909-8			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	M0993	3422256	Bronze			2022-12-18	WOS:A1988M099300007
J	HEDLIN, G; GRAFFLONNEVIG, V; HEILBORN, H; LILJA, G; NORRLIND, K; PEGELOW, KO; SUNDIN, B; LOWENSTEIN, H				HEDLIN, G; GRAFFLONNEVIG, V; HEILBORN, H; LILJA, G; NORRLIND, K; PEGELOW, KO; SUNDIN, B; LOWENSTEIN, H			IMMUNOTHERAPY WITH CAT-DANDER AND DOG-DANDER EXTRACTS .2. INVIVO AND INVITRO IMMUNOLOGICAL EFFECTS OBSERVED IN A 1-YEAR DOUBLE-BLIND PLACEBO STUDY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									DANDERYD HOSP,S-18288 DANDERYD,SWEDEN; UNIV COPENHAGEN,PROT LAB,DK-1168 COPENHAGEN K,DENMARK; SACHS UNIV HOSP,STOCKHOLM,SWEDEN	Danderyds Hospital; University of Copenhagen	HEDLIN, G (corresponding author), HUDDINGE UNIV HOSP,DEPT PEDIAT,S-14186 HUDDINGE,SWEDEN.							AAS K, 1978, ALLERGY, V33, P130, DOI 10.1111/j.1398-9995.1978.tb01522.x; BEER DJ, 1984, ADV IMMUNOL, V35, P209, DOI 10.1016/S0065-2776(08)60577-5; BERG T, 1980, INT ARCH ALLER A IMM, V63, P266, DOI 10.1159/000232636; BROWN FR, 1968, ANN ALLERGY, V26, P305; CONNELL JT, 1969, J ALLERGY, V43, P22, DOI 10.1016/0021-8707(69)90017-3; D'SOUZA M F, 1973, Clinical Allergy, V3, P177, DOI 10.1111/j.1365-2222.1973.tb01320.x; DJURUP R, 1984, ALLERGY, V39, P51, DOI 10.1111/j.1398-9995.1984.tb01933.x; FOUCARD T, 1978, CLIN ALLERGY, V8, P249, DOI 10.1111/j.1365-2222.1978.tb03221.x; GLEICH GJ, 1977, J ALLERGY CLIN IMMUN, V60, P188, DOI 10.1016/0091-6749(77)90123-3; GOLDEN DBK, 1982, J ALLERGY CLIN IMMUN, V69, P489, DOI 10.1016/0091-6749(82)90172-5; HAMILTON RG, 1981, J ALLERGY CLIN IMMUN, V67, P14, DOI 10.1016/0091-6749(81)90039-7; HAMILTON RG, 1979, J IMMUNOL, V122, P1073; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; Hunter W.M., 1971, RADIOIMMUNOASSAY MET; IRONS JS, 1979, J ALLERGY CLIN IMMUN, V59, P190; KJELLMAN NIM, 1980, ALLERGY, V35, P323, DOI 10.1111/j.1398-9995.1980.tb01774.x; KJELLMAN NIM, 1976, CLIN ALLERGY, V6, P51, DOI 10.1111/j.1365-2222.1976.tb01411.x; KJELLMAN NIM, 1977, CLIN ALLERGY, V7, P465, DOI 10.1111/j.1365-2222.1977.tb01477.x; LICHTENSTEIN LM, 1971, ANN INTERN MED, V75, P663, DOI 10.7326/0003-4819-75-5-663; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; LICHTENSTEIN LM, 1979, J ALLERGY CLIN IMMUN, V64, P5, DOI 10.1016/0091-6749(79)90075-7; LICHTENSTEIN LM, 1972, CLIN IMMUNOBIOL, P243; LOWENSTEIN H, 1986, J ALLERGY CLIN IMMUN, V77, P497, DOI 10.1016/0091-6749(86)90185-5; LOWENSTEIN H, 1975, SCAND J IMMUNOL S3, V4, P59; NORDVALL SL, 1982, INT ARCH ALLER A IMM, V67, P132, DOI 10.1159/000233003; NORMAN PS, 1978, ALLERGY, V33, P62; NORMAN PS, 1980, J ALLERGY CLIN IMMUN, V65, P87, DOI 10.1016/0091-6749(80)90191-8; OHMAN JL, 1984, J ALLERGY CLIN IMMUN, V74, P230, DOI 10.1016/0091-6749(84)90251-3; OHMAN JL, 1982, J ALLERGY CLIN IMMUN, V69, P320; OSTERBALLE O, 1982, ALLERGY, V37, P379, DOI 10.1111/j.1398-9995.1982.tb02316.x; OSTERBALLE O, 1981, ALLERGY, V36, P183, DOI 10.1111/j.1398-9995.1981.tb01834.x; OSTERBALLE O, 1982, ALLERGY, V37, P169, DOI 10.1111/j.1398-9995.1982.tb01893.x; PEGELOW KO, 1984, ALLERGY, V39, P275, DOI 10.1111/j.1398-9995.1984.tb00864.x; PRICE JF, 1984, CLIN ALLERGY, V14, P209, DOI 10.1111/j.1365-2222.1984.tb02200.x; REISMAN RE, 1979, CLIN ALLERGY, V9, P167, DOI 10.1111/j.1365-2222.1979.tb01538.x; ROCKLIN RE, 1983, J ALLERGY CLIN IMMUN, V72, P323, DOI 10.1016/0091-6749(83)90492-X; SPRECACE GA, 1966, J ALLERGY, V38, P9, DOI 10.1016/0021-8707(66)90068-2; STARR MS, 1970, INT ARCH ALLER A IMM, V38, P514, DOI 10.1159/000230304; TAYLOR WW, 1978, J ALLERGY CLIN IMMUN, V61, P283, DOI 10.1016/0091-6749(78)90048-9; TUFT L, 1967, AM J MED SCI, V253, P19, DOI 10.1097/00000441-196701000-00005; TURNER MW, 1984, CLIN ALLERGY, V14, P221, DOI 10.1111/j.1365-2222.1984.tb02201.x; WEEKE B, 1972, ACTA MED SCAND, V192, P149; WEYER A, 1981, ALLERGY, V36, P319, DOI 10.1111/j.1398-9995.1981.tb01583.x; WIDE L, 1967, LANCET, V2, P1105	44	78	78	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1986	77	3					488	496		10.1016/0091-6749(86)90184-3	http://dx.doi.org/10.1016/0091-6749(86)90184-3			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	A5367	2419383				2022-12-18	WOS:A1986A536700013
J	SHEFFER, AL; AUSTEN, KF; ROSEN, FS; FEARON, DT				SHEFFER, AL; AUSTEN, KF; ROSEN, FS; FEARON, DT			ACQUIRED DEFICIENCY OF THE INHIBITOR OF THE 1ST COMPONENT OF COMPLEMENT - REPORT OF 5 ADDITIONAL CASES WITH COMMENTARY ON THE SYNDROME	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT RHEUMATOL & IMMUNOL,BOSTON,MA 02115; CHILDRENS HOSP MED CTR,DIV IMMUNOL,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Boston Children's Hospital					NIAID NIH HHS [AI-17917, AI-10356, AI-22531] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI022531, R01AI022531] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON KC, 1984, BLOOD, V63, P1424, DOI 10.1182/blood.V63.6.1424.1424; BORSOS T, 1963, J IMMUNOL, V91, P851; Caldwell JR, 1972, CLIN IMMUNOL IMMUNOP, V1, P39; CASALI P, 1978, ACTA HAEMATOL-BASEL, V59, P277, DOI 10.1159/000207773; COHEN SH, 1978, J ALLERGY CLIN IMMUN, V62, P217, DOI 10.1016/0091-6749(78)90210-5; DAY NK, 1976, CLIN EXP IMMUNOL, V26, P189; DONALDSON VH, 1963, AM J MED, V35, P37, DOI 10.1016/0002-9343(63)90162-1; DONALDSON VH, 1964, J CLIN INVEST, V43, P2204, DOI 10.1172/JCI105094; GEHA RS, 1985, NEW ENGL J MED, V312, P534, DOI 10.1056/NEJM198502283120902; GELFAND JA, 1979, MEDICINE, V58, P321, DOI 10.1097/00005792-197907000-00004; GELFAND JA, 1976, NEW ENGL J MED, V295, P1444, DOI 10.1056/NEJM197612232952602; GIGLI I, 1968, J IMMUNOL, V100, P1154; HARRISON RA, 1983, BIOCHEMISTRY-US, V22, P5001, DOI 10.1021/bi00290a019; HAUPTMANN G, 1977, ANN INTERN MED, V87, P577, DOI 10.7326/0003-4819-87-5-577; HAUPTMANN G, 1976, BLUT, V32, P195, DOI 10.1007/BF00995913; JORDON RE, 1974, CLIN EXP IMMUNOL, V18, P407; KENT JF, 1963, AM J TROP MED HYG, V12, P103, DOI 10.4269/ajtmh.1963.12.103; NILSEN A, 1980, ACTA MED SCAND, V207, P123; QUASTEL M, 1983, J CLIN INVEST, V71, P1041, DOI 10.1172/JCI110831; ROSEN FS, 1965, SCIENCE, V148, P957, DOI 10.1126/science.148.3672.957; ROSENFELD SI, 1975, J ALLERGY CLIN IMMUN, V56, P104; RUDDY S, 1967, J IMMUNOL, V99, P1162; RUDDY S, 1972, P INT S BIOL ACTIVIT, P13; SCHREIBER AD, 1976, BLOOD, V48, P567; SHEFFER AL, 1983, J ALLERGY CLIN IMMUN, V71, P107, DOI 10.1016/0091-6749(83)90197-5; SHEFFER AL, 1981, J ALLERGY CLIN IMMUN, V68, P181, DOI 10.1016/0091-6749(81)90181-0; SHEFFER AL, 1977, ANN INTERN MED, V86, P306, DOI 10.7326/0003-4819-86-3-306; SPAULDING WB, 1960, ANN INTERN MED, V53, P739, DOI 10.7326/0003-4819-53-4-739; ZICCARDI RJ, 1983, SPRINGER SEMIN IMMUN, V6, P213	29	78	78	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	75	6					640	646		10.1016/0091-6749(85)90087-9	http://dx.doi.org/10.1016/0091-6749(85)90087-9			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ALA84	4008793				2022-12-18	WOS:A1985ALA8400002
J	FREIDHOFF, LR; MEYERS, DA; MARSH, DG				FREIDHOFF, LR; MEYERS, DA; MARSH, DG			A GENETIC-EPIDEMIOLOGIC STUDY OF HUMAN IMMUNE RESPONSIVENESS TO ALLERGENS IN AN INDUSTRIAL-POPULATION .2. THE ASSOCIATIONS AMONG SKIN SENSITIVITY, TOTAL SERUM IGE, AGE, SEX, AND THE REPORTING OF ALLERGIES IN A STRATIFIED RANDOM SAMPLE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											FREIDHOFF, LR (corresponding author), JOHNS HOPKINS UNIV,GOOD SAMARITAN HOSP,SCH MED,DIV CLIN IMMUNOL,BALTIMORE,MD 21239, USA.				NIAID NIH HHS [AI-20059] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020059] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARBEE RA, 1976, ANN INTERN MED, V84, P129, DOI 10.7326/0003-4819-84-2-129; BARBEE RA, 1981, J ALLERGY CLIN IMMUN, V68, P106, DOI 10.1016/0091-6749(81)90167-6; BARBEE RA, 1981, J ALLERGY CLIN IMMUN, V68, P15, DOI 10.1016/0091-6749(81)90117-2; BURROWS B, 1981, AM REV RESPIR DIS, V124, P523; CURRAN WS, 1961, ANN INTERN MED, V44, P323; DAVIDSON AG, 1947, J ALLERGY, V18, P359, DOI 10.1016/0021-8707(47)90085-3; DAVIS JB, 1976, CLIN ALLERGY, V6, P329, DOI 10.1111/j.1365-2222.1976.tb01913.x; DAWSON B, 1969, LANCET, V1, P827; FREIDHOFF LR, 1983, J ALLERGY CLIN IMMUN, V72, P274, DOI 10.1016/0091-6749(83)90032-5; FREIDHOFF LR, 1981, AM J MED GENET, V9, P323, DOI 10.1002/ajmg.1320090409; GLEICH GJ, 1971, J LAB CLIN MED, V77, P690; GRUNDBACHER FJ, 1975, J ALLERGY CLIN IMMUN, V56, P104, DOI 10.1016/0091-6749(75)90114-1; HAGY GW, 1969, J ALLERGY, V44, P323, DOI 10.1016/0021-8707(69)90024-0; JOHANSSON S, 1972, PROG CLIN IMMUNOL, V1, P100; JOHANSSON SG, 1968, INT ARCH ALLER A IMM, V34, P1; KLEINBAUM DG, 1978, APPLIED REGRESSION A, P315; LAMSON R. W., 1936, Journal of Allergy, V7, P582, DOI 10.1016/S0021-8707(36)90495-1; LINDBLAD JH, 1961, J ALLERGY, V32, P392, DOI 10.1016/0021-8707(61)90016-8; MEYERS DA, 1982, HUM HERED, V32, P15, DOI 10.1159/000153262; NELSON TELL, 1934, JOUR ALLERGY, V5, P124, DOI 10.1016/S0021-8707(34)80004-4; Nye L, 1975, Clin Allergy, V5, P13; ORREN A, 1975, INT ARCH ALLER A IMM, V48, P824, DOI 10.1159/000231370; SANTILLI J, 1980, J ALLERGY CLIN IMMUN, V65, P406, DOI 10.1016/0091-6749(80)90232-8; Siegel S., 1956, NONPARAMETRIC STAT B; Smith J. M., 1978, ALLERGY PRINCIPLES P, P633; WARREN CPW, 1982, J ALLERGY CLIN IMMUN, V69, P370, DOI 10.1016/0091-6749(82)90148-8; WILLIAMS H, 1969, BRIT MED J, V4, P321, DOI 10.1136/bmj.4.5679.321; ZETTERSTROM O, 1981, ALLERGY, V36, P537, DOI 10.1111/j.1398-9995.1981.tb01871.x; ZETTERSTROM O, 1981, BRIT MED J, V283, P1215, DOI 10.1136/bmj.283.6301.1215	29	78	79	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	4					490	499		10.1016/0091-6749(84)90360-9	http://dx.doi.org/10.1016/0091-6749(84)90360-9			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	SM089	6707392				2022-12-18	WOS:A1984SM08900011
J	SCHATZ, M				SCHATZ, M			SKIN TESTING AND INCREMENTAL CHALLENGE IN THE EVALUATION OF ADVERSE REACTIONS TO LOCAL-ANESTHETICS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											SCHATZ, M (corresponding author), KAISER PERMANENTE MED CTR, DEPT ALLERGY IMMUNOL, SAN DIEGO, CA 92111 USA.							ADLER P, 1949, ORAL SURG ORAL MED O, V2, P1029, DOI 10.1016/0030-4220(49)90214-5; ALDRETE JA, 1971, SOUTH MED J, V64, P1118, DOI 10.1097/00007611-197109000-00018; ALDRETE JA, 1969, J AMER MED ASSOC, V207, P356, DOI 10.1001/jama.207.2.356; ALDRETE JA, 1970, ANESTH ANAL CURR RES, V49, P173; ARORA S, 1976, ANESTHESIOLOGY REV, V3, P13; BARER MR, 1982, BRIT MED J, V284, P1229, DOI 10.1136/bmj.284.6324.1229-a; Barnard D P, 1976, J Dent Assoc S Afr, V31, P241; BATEMAN PP, 1974, MED J AUSTRALIA, V2, P449, DOI 10.5694/j.1326-5377.1974.tb70901.x; BROWN DT, 1981, BRIT J ANAESTH, V53, P435, DOI 10.1093/bja/53.4.435; CHERNOW B, 1983, ARCH INTERN MED, V143, P2141, DOI 10.1001/archinte.143.11.2141; DEJONG RH, 1978, JAMA-J AM MED ASSOC, V239, P1166, DOI 10.1001/jama.239.12.1166; DESHAZO RD, 1979, J ALLERGY CLIN IMMUN, V63, P387, DOI 10.1016/0091-6749(79)90211-2; EYRE J, 1971, LANCET, V1, P264; FISHER MM, 1982, BRIT J ANAESTH, V54, P893, DOI 10.1093/bja/54.8.893; GAUL LE, 1955, ANESTHESIOLOGY, V16, P606, DOI 10.1097/00000542-195507000-00016; GELL PGH, 1975, CLIN ASPECTS IMMUNOL; GIOVANNITTI JA, 1979, J AM DENT ASSOC, V98, P701, DOI 10.14219/jada.archive.1979.0148; GOODMAN M. H., 1939, JOUR INVEST DERMAT, V2, P53; HALPERN B, 1967, J ALLERGY, V40, P168, DOI 10.1016/0021-8707(67)90006-8; Harris R, 1972, Aust Dent J, V17, P333; HENRY JC, 1979, ARCH DERMATOL, V115, P1231, DOI 10.1001/archderm.115.10.1231; HOFMANN H, 1975, ARCH DERMATOL, V111, P266, DOI 10.1001/archderm.1975.01630140124022; HOLTI G, 1965, Dent Pract Dent Rec, V15, P294; HORIO T, 1979, ARCH DERMATOL, V115, P986, DOI 10.1001/archderm.115.8.986; INCAUDO G, 1978, J ALLERGY CLIN IMMUN, V61, P339, DOI 10.1016/0091-6749(78)90057-X; LANE CG, 1951, JAMA-J AM MED ASSOC, V146, P717, DOI 10.1001/jama.1951.03670080025007; LATRONICA RJ, 1969, ORAL SURG ORAL MED O, V28, P439, DOI 10.1016/0030-4220(69)90240-0; LEHNER T, 1971, LANCET, V1, P1245; LUEBKE NH, 1978, J AM DENT ASSOC, V97, P656, DOI 10.14219/jada.archive.1978.0344; MITCHELL HS, 1953, J CAN DENT ASSOC, V19, P127; MULVEY PM, 1980, MED J AUSTRALIA, V1, P386, DOI 10.5694/j.1326-5377.1980.tb134940.x; NAGEL JE, 1977, JAMA-J AM MED ASSOC, V237, P1594; NOBLE DS, 1961, LANCET, V2, P1436; RAVINDRANATHAN N, 1975, BRIT DENT J, V138, P101, DOI 10.1038/sj.bdj.4803376; RICKLES NH, 1953, ORAL SURG ORAL MED O, V6, P375, DOI 10.1016/0030-4220(53)90063-2; ROOD JP, 1973, BRIT DENT J, V135, P411, DOI 10.1038/sj.bdj.4803093; ROTHMAN S, 1945, J INVEST DERMATOL, V6, P191, DOI 10.1038/jid.1945.15; SIDON MA, 1971, J AM DENT ASSOC, V82, P366, DOI 10.14219/jada.archive.1971.0040; SIEGAL S, 1958, J ALLERGY, V29, P329, DOI 10.1016/0021-8707(58)90038-8; STEFANINI M, 1978, AM J MED SCI, V275, P365, DOI 10.1097/00000441-197805000-00015; TANNENBAUM H, 1975, J ALLERGY CLIN IMMUN, V56, P226, DOI 10.1016/0091-6749(75)90094-9; TILLMAN HH, 1958, ORAL SURG, V11, P1372; WALDMAN HB, 1967, J AM DENT ASSOC, V74, P747, DOI 10.14219/jada.archive.1967.0111; WALKER RT, 1971, BRIT DENT J, V130, P2; WELLINS SL, 1969, ORAL SURG ORAL MED O, V28, P761, DOI 10.1016/0030-4220(69)90425-3	45	78	79	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	4					606	616		10.1016/0091-6749(84)90114-3	http://dx.doi.org/10.1016/0091-6749(84)90114-3			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TQ163	6491108	Bronze			2022-12-18	WOS:A1984TQ16300011
J	NORMAN, PS; LICHTENSTEIN, LM; KAGEYSOBOTKA, A; MARSH, DG				NORMAN, PS; LICHTENSTEIN, LM; KAGEYSOBOTKA, A; MARSH, DG			CONTROLLED EVALUATION OF ALLERGOID IN THE IMMUNOTHERAPY OF RAGWEED HAY-FEVER	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHNS HOPKINS UNIV,BALTIMORE,MD 21218	Johns Hopkins University	NORMAN, PS (corresponding author), GOOD SAMARITAN HOSP,DEPT MED,DIV CLIN IMMUNOL,BALTIMORE,MD 21239, USA.				NIAID NIH HHS [AI 10403] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADKINSON NF, 1980, MANUAL CLIN IMMUNOLO, P794; GLEICH GJ, 1975, SCIENCE, V190, P1106, DOI 10.1126/science.1188389; GOLDEN DBK, 1980, ANN INTERN MED, V92, P620, DOI 10.7326/0003-4819-92-5-620; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; MARSH DG, 1970, IMMUNOLOGY, V18, P705; MARSH DG, 1981, J ALLERGY CLIN IMMUN, V68, P449, DOI 10.1016/0091-6749(81)90199-8; MARSH DG, UNPUB KINETIC STUDY; MAY CD, 1970, J ALLERGY, V46, P12, DOI 10.1016/0021-8707(70)90056-0; NORMAN PS, 1981, J ALLERGY CLIN IMMUN, V68, P460, DOI 10.1016/0091-6749(81)90200-1; NORMAN PS, 1965, J ALLERGY, V36, P284, DOI 10.1016/0021-8707(65)90087-0; NORMAN PS, 1980, MANUAL CLIN IMMUNOLO, P789; VANMETRE TE, 1982, J ALLERGY CLIN IMMUN, V69, P181, DOI 10.1016/0091-6749(82)90098-7	12	78	82	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	70	4					248	260		10.1016/0091-6749(82)90061-6	http://dx.doi.org/10.1016/0091-6749(82)90061-6			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PL151	6181113	Bronze			2022-12-18	WOS:A1982PL15100005
J	AGARWAL, MK; YUNGINGER, JW; SWANSON, MC; REED, CE				AGARWAL, MK; YUNGINGER, JW; SWANSON, MC; REED, CE			AN IMMUNOCHEMICAL METHOD TO MEASURE ATMOSPHERIC ALLERGENS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MAYO CLIN & FDN,DEPT INTERNAL MED ALLERGY,ALLERG DIS RES LAB,ROCHESTER,MN 55905; MAYO CLIN & FDN,DEPT PEDIAT,ROCHESTER,MN 55905; MAYO CLIN & FDN,MAYO GRAD SCH MED,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic; Mayo Clinic					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI016791] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-16791] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADOLPHSON C, 1978, J ALLERGY CLIN IMMUN, V62, P197, DOI 10.1016/0091-6749(78)90208-7; Bates D V, 1966, Health Phys, V12, P173; BUSSE WW, 1972, J ALLERGY CLIN IMMUN, V50, P289, DOI 10.1016/0091-6749(72)90027-9; DIXON WJ, 1969, INTRO STATISTICAL AN, P222; GLEICH GJ, 1980, J ALLERGY CLIN IMMUN, V65, P20, DOI 10.1016/0091-6749(80)90172-4; KING TP, 1962, BIOCHEMISTRY-US, V1, P709, DOI 10.1021/bi00910a027; LARSON JB, 1975, J ALLERGY CLIN IMMUN, V56, P112, DOI 10.1016/0091-6749(75)90115-3; LEIFERMAN KM, 1976, J ALLERGY CLIN IMMUN, V58, P140, DOI 10.1016/0091-6749(76)90149-4; OGDEN EC, 1967, J ALLERGY, V40, P1, DOI 10.1016/0021-8707(67)90053-6; Prince H. E., 1947, ANN ALLERGY, V5, P434; SHAFIEE A, 1973, J PHARM SCI, V62, P1654, DOI 10.1002/jps.2600621015; SIMMONS EG, 1967, MYCOLOGIA, V59, P67, DOI 10.2307/3756943; SOLOMON WR, 1980, J ALLERGY CLIN IMMUN, V65, P467, DOI 10.1016/0091-6749(80)90241-9; SOLOMON WR, 1978, ALLERGY PRINCIPLES P, P899; WELSH PW, 1979, J ALLERGY CLIN IMMUN, V64, P209, DOI 10.1016/0091-6749(79)90097-6; Yunginger J. W., 1980, MANUAL CLIN IMMUNOLO, P778; YUNGINGER JW, 1980, J ALLERGY CLIN IMMUN, V66, P138, DOI 10.1016/0091-6749(80)90061-5	17	78	80	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	68	3					194	200		10.1016/0091-6749(81)90183-4	http://dx.doi.org/10.1016/0091-6749(81)90183-4			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MG544	7264101				2022-12-18	WOS:A1981MG54400005
J	SAFKO, MJ; CHAN, SC; COOPER, KD; HANIFIN, JM				SAFKO, MJ; CHAN, SC; COOPER, KD; HANIFIN, JM			HETEROLOGOUS DESENSITIZATION OF LEUKOCYTES - A POSSIBLE MECHANISM OF BETA-ADRENERGIC-BLOCKADE IN ATOPIC-DERMATITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV OREGON,HLTH SCI CTR,DEPT DERMATOL,PORTLAND,OR 97201	University of Oregon				Cooper, Kevin/0000-0002-1986-3602	NIADDK NIH HHS [T T32 AM07153-05] Funding Source: Medline; NIAID NIH HHS [5 ROL AI15557-2] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [T32AM007153] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015557] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS GK, 1979, J IMMUNOL, V122, P555; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BUSSE WW, 1976, J ALLERGY CLIN IMMUN, V58, P586, DOI 10.1016/0091-6749(76)90205-0; BUSSE WW, 1979, J INVEST DERMATOL, V73, P184, DOI 10.1111/1523-1747.ep12581674; GALILI U, 1974, J IMMUNOL, V112, P1628; GREENACRE JK, 1978, BRIT J CLIN PHARMACO, V5, P199, DOI 10.1111/j.1365-2125.1978.tb01624.x; HANIFIN JM, 1977, ARCH DERMATOL, V113, P663, DOI 10.1001/archderm.113.5.663; HANIFIN JM, 1977, ANN ALLERGY, V39, P153; HO RJ, 1971, J BIOL CHEM, V246, P6822; JOHNSON GL, 1978, J BIOL CHEM, V253, P1465; JOHNSON HH, 1960, J INVEST DERMATOL, V34, P237, DOI 10.1038/jid.1960.38; KALISKER A, 1977, J ALLERGY CLIN IMMUN, V60, P259, DOI 10.1016/0091-6749(77)90141-5; MORRIS HG, 1980, J ALLERGY CLIN IMMUN, V65, P83, DOI 10.1016/0091-6749(80)90190-6; PARKER CW, 1973, J CLIN INVEST, V52, P48, DOI 10.1172/JCI107173; PARKER CW, 1977, J INVEST DERMATOL, V68, P302, DOI 10.1111/1523-1747.ep12494569; RING J, 1979, BRIT J DERMATOL, V100, P521, DOI 10.1111/j.1365-2133.1979.tb05577.x; SU YF, 1976, J CYCLIC NUCL PROT, V2, P257; SZENTIVANYI A, 1968, J ALLERGY, V42, P203, DOI 10.1016/S0021-8707(68)90117-2; VENTER JC, 1980, SCIENCE, V207, P1361, DOI 10.1126/science.6153472; 1975, CLIN IMMUNOL PATHOL, V3, P584	20	78	79	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	68	3					218	225		10.1016/0091-6749(81)90187-1	http://dx.doi.org/10.1016/0091-6749(81)90187-1			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MG544	6114971				2022-12-18	WOS:A1981MG54400009
J	BALLOW, M; MENDELSON, L				BALLOW, M; MENDELSON, L			SPECIFIC IMMUNOGLOBULIN-E ANTIBODIES IN TEAR SECRETIONS OF PATIENTS WITH VERNAL CONJUNCTIVITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											BALLOW, M (corresponding author), UNIV CONNECTICUT,CTR HLTH,DEPT PEDIAT,FARMINGTON,CT 06032, USA.							ABELSON MB, 1977, AM J OPHTHALMOL, V83, P417, DOI 10.1016/0002-9394(77)90743-7; ALLANSMITH M, 1963, J ALLERGY, V34, P535, DOI 10.1016/0021-8707(63)90095-9; ALLANSMITH MR, 1979, AM J OPHTHALMOL, V87, P544, DOI 10.1016/0002-9394(79)90247-2; ALLANSMITH MR, 1976, AM J OPHTHALMOL, V81, P506, DOI 10.1016/0002-9394(76)90310-X; BLOCHMICHEL E, 1977, ARCH OPHTALMOL-PARIS, V37, P89; BRAUNINGER GE, 1971, AM J OPHTHALMOL, V72, P558, DOI 10.1016/0002-9394(71)90853-1; DEUSCHL H, 1974, CLIN EXP IMMUNOL, V16, P401; DEUSCHL H, 1976, INT ARCH ALLER A IMM, V52, P376, DOI 10.1159/000231704; DEUSCHL H, 1977, CLIN ALLERGY, V7, P195, DOI 10.1111/j.1365-2222.1977.tb01442.x; Frankland A W, 1971, Trans Ophthalmol Soc U K, V91, P479; HUGGINS KG, 1975, LANCET, V2, P148; JOSEPHSON AS, 1968, J IMMUNOL, V100, P1080; LITTLE JM, 1969, AM J OPHTHALMOL, V68, P898, DOI 10.1016/0002-9394(69)94587-5; LOWERY OH, 1951, J BIOL CHEM, V193, P265; LUNDKVIST U, 1975, ADV DIAGNOSIS ALLERG, P85; MERRETT TG, 1976, CLIN ALLERGY, V6, P69, DOI 10.1111/j.1365-2222.1976.tb01413.x; Morgan G, 1971, Trans Ophthalmol Soc U K, V91, P467; PLATTSMILLS TAE, 1979, J IMMUNOL, V122, P2218; RICE NSC, 1973, CLIN IMMUNOL ALLERGY, P139; SETTIPANE GA, 1965, J ALLERGY, V36, P92, DOI 10.1016/0021-8707(65)90036-5; Theodore F.H., 1958, OCULAR ALLERGY	21	78	80	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	66	2					112	118		10.1016/0091-6749(80)90057-3	http://dx.doi.org/10.1016/0091-6749(80)90057-3			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KD119	7400474	Bronze			2022-12-18	WOS:A1980KD11900004
J	SHELHAMER, JH; METCALFE, DD; SMITH, LJ; KALINER, M				SHELHAMER, JH; METCALFE, DD; SMITH, LJ; KALINER, M			ABNORMAL BETA-ADRENERGIC RESPONSIVENESS IN ALLERGIC SUBJECTS - ANALYSIS OF ISOPROTERENOL-INDUCED CARDIOVASCULAR AND PLASMA CYCLIC ADENOSINE-MONOPHOSPHATE RESPONSES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NIAID,CLIN INVEST LAB,ALLERG DIS SECT,BETHESDA,MD 20205	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)								APOLD J, 1977, J ALLERGY CLIN IMMUN, V59, P343, DOI 10.1016/0091-6749(77)90015-X; BALL JH, 1972, J CLIN INVEST, V51, P2124, DOI 10.1172/JCI107019; BARBEE RA, 1976, ANN INTERN MED, V84, P129, DOI 10.7326/0003-4819-84-2-129; CAILLA HL, 1973, ANAL BIOCHEM, V56, P394, DOI 10.1016/0003-2697(73)90205-4; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CONOLLY ME, 1976, J CLIN INVEST, V58, P1307, DOI 10.1172/JCI108586; CONOLLY ME, 1971, BRIT J PHARMACOL, V43, P389; COOKSON DU, 1963, AM REV RESPIR DIS, V88, P636; EPPINGER H, 1917, NERVOUS MENTAL DISEA, P47; FIREMAN P, 1973, INT ARCH ALLER A IMM, V45, P123, DOI 10.1159/000231014; FIREMAN P, 1970, J ALLERGY, V45, P117; GALANT SP, 1978, NEW ENGL J MED, V299, P933, DOI 10.1056/NEJM197810262991707; GEHAN EA, 1965, BIOMETRIKA, V52, P207; GREICO MH, 1968, AM J MED, V44, P863; HAGY GW, 1976, J ALLERGY CLIN IMMUN, V58, P330, DOI 10.1016/0091-6749(76)90139-1; HENDERSON WR, 1979, NEW ENGL J MED, V300, P642, DOI 10.1056/NEJM197903223001203; HERXHEIMER H, 1954, Acta Allergol, V7, P380, DOI 10.1111/j.1398-9995.1954.tb03534.x; INOUE S, 1967, J ALLERGY, V40, P337, DOI 10.1016/0021-8707(67)90023-8; JENNE JW, 1977, J ALLERGY CLIN IMMUN, V60, P346, DOI 10.1016/0091-6749(77)90065-3; KALINER M, 1976, J ALLERGY CLIN IMMUN, V58, P308, DOI 10.1016/0091-6749(76)90136-6; KALINER M, 1977, J ALLERGY CLIN IMMUN, V60, P204, DOI 10.1016/0091-6749(77)90125-7; KRZANOWSKI JJ, 1979, CLIN EXP PHARMACOL P, V6, P111, DOI 10.1111/j.1440-1681.1979.tb00013.x; LANG P, 1978, J ALLERGY CLIN IMMUN, V61, P248, DOI 10.1016/0091-6749(78)90199-9; LOCKEY SD, 1967, J ALLERGY, V40, P349, DOI 10.1016/0021-8707(67)90024-X; LOGSDON PJ, 1972, J ALLERGY CLIN IMMUN, V50, P45, DOI 10.1016/0091-6749(72)90078-4; MAKINO S, 1970, J ALLERGY, V46, P178, DOI 10.1016/0021-8707(70)90096-1; MAKINO S, 1977, J ALLERGY CLIN IMMUN, V59, P348, DOI 10.1016/0091-6749(77)90016-1; MASELLI R, 1970, J ALLERGY, V45, P117; MIDDLETON E, 1968, J ALLERGY, V42, P288, DOI 10.1016/0021-8707(68)90022-1; MORRIS HG, 1978, J ALLERGY CLIN IMMUN, V61, P294, DOI 10.1016/0091-6749(78)90050-7; NELSON HS, 1975, J ALLERGY CLIN IMMUN, V55, P299, DOI 10.1016/0091-6749(75)90002-0; ORANGE RP, 1971, FED PROC, V30, P1725; OUELLETTE J J, 1967, Journal of Allergy, V39, P160, DOI 10.1016/0021-8707(67)90033-0; PARKER CW, 1973, J CLIN INVEST, V52, P48, DOI 10.1172/JCI107173; PARKER CW, 1973, J CLIN INVEST, V52, P1336, DOI 10.1172/JCI107305; RABINOWITZ B, 1973, CLIN CHEM, V19, P312; REED CE, 1967, J ALLERGY, V39, P127; ROSMAN PM, 1976, J CLIN ENDOCR METAB, V42, P531, DOI 10.1210/jcem-42-3-531; SCHWARTZ HJ, 1973, J ALLERGY CLIN IMMUN, V51, P88, DOI 10.1016/S0091-6749(73)80024-7; SIDDLE K, 1976, CLIN SCI MOL MED, V50, P487, DOI 10.1042/cs0500487; SOKOL WN, 1975, J ALLERGY CLIN IMMUN, V55, P310, DOI 10.1016/0091-6749(75)90003-2; STEINER AL, 1972, ADV CYCL NUCL RES<D>, V2, P51; SZENTIVANYI A, 1968, J ALLERGY, V42, P203, DOI 10.1016/S0021-8707(68)90117-2; WEHMANN RE, 1974, J CLIN INVEST, V53, P173, DOI 10.1172/JCI107535; ZAID G, 1966, N ENGL J MED, V275, P578	45	78	78	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	66	1					52	60		10.1016/0091-6749(80)90138-4	http://dx.doi.org/10.1016/0091-6749(80)90138-4			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JZ541	6247380				2022-12-18	WOS:A1980JZ54100008
J	KATZ, DH				KATZ, DH			CONTROL OF IGE ANTIBODY-PRODUCTION BY SUPPRESSOR SUBSTANCES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											KATZ, DH (corresponding author), SCRIPPS CLIN & RES FDN, DEPT CELLULAR & DEV IMMUNOL, LA JOLLA, CA 92037 USA.							BOREL Y, 1971, NATURE-NEW BIOL, V230, P180, DOI 10.1038/newbio230180a0; BOREL Y, 1976, TRANSPLANT REV, V31, P3; BOREL Y, 1976, NATURE, V261, P49, DOI 10.1038/261049a0; BOREL Y, 1975, J EXP MED, V142, P1254, DOI 10.1084/jem.142.5.1254; CHIORAZZI N, 1977, J EXP MED, V146, P302, DOI 10.1084/jem.146.1.302; CHIORAZZI N, 1976, P NATL ACAD SCI USA, V73, P2091, DOI 10.1073/pnas.73.6.2091; CHIORAZZI N, 1977, J IMMUNOL, V119, P685; CHIORAZZI N, 1976, J IMMUNOL, V117, P1629; CHIORAZZI N, 1977, J IMMUNOL, V118, P48; ESHHAR Z, 1975, J IMMUNOL, V114, P872; FOX DA, 1976, J IMMUNOL, V117, P1622; HAMAOKA T, 1974, J IMMUNOL, V113, P958; HAMAOKA T, 1974, J EXP MED, V139, P1446, DOI 10.1084/jem.139.6.1446; HAMAOKA T, 1973, J EXP MED, V138, P538, DOI 10.1084/jem.138.3.538; ISHIZAKA K, 1976, ADV IMMUNOL, V23, P1, DOI 10.1016/S0065-2776(08)60318-1; ISHIZAKA K, 1975, J IMMUNOL, V114, P110; KATZ DH, 1974, J IMMUNOL, V113, P974; KATZ DH, 1972, J EXP MED, V136, P1404, DOI 10.1084/jem.136.6.1404; KATZ DH, 1974, J EXP MED, V139, P1464, DOI 10.1084/jem.139.6.1464; KATZ DH, 1976, COLD SPRING HARB SYM, V41, P611, DOI 10.1101/SQB.1977.041.01.070; KATZ DH, 1971, J EXP MED, V134, P201, DOI 10.1084/jem.134.1.201; KATZ DH, 1974, 1974 P C BROOK LODG, P249; KATZ DH, 1974, 1974 P C BROOK LODG, P189; KATZ DH, J IMMUNOL; KATZ DH, 1977, LYMPHOCYTE DIFFERENT; KISHIMOT.T, 1973, J IMMUNOL, V111, P1; KISHIMOTO T, 1973, J IMMUNOL, V111, P720; LAKIN JD, 1975, ANN INTERN MED, V83, P204, DOI 10.7326/0003-4819-83-2-204; LAKIN JD, 1975, J ALLERGY CLIN IMMUN, V56, P94, DOI 10.1016/0091-6749(75)90113-X; LEE WY, 1977, NATURE, V267, P618, DOI 10.1038/267618a0; LEVINE BB, 1970, INT ARCH ALLER A IMM, V39, P156, DOI 10.1159/000230343; LIU FT, J BIOL CHEM; OKUMURA K, 1971, J IMMUNOL, V107, P1682; SCHREINER GF, 1976, ADV IMMUNOL, V24, P38; STOLLAR BD, 1975, J IMMUNOL, V115, P1095; TADA T, 1975, PROG ALLERGY, V19, P122, DOI 10.1159/000313387; TAKATSU K, 1976, J IMMUNOL, V116, P1257; TAKATSU K, 1976, J IMMUNOL, V117, P1211; TAKATSU K, 1975, J IMMUNOL, V115, P1469; TUNG AS, J IMMUNOL; WATANABE N, 1977, J IMMUNOL, V118, P485; WATANABE N, 1976, J EXP MED, V143, P833, DOI 10.1084/jem.143.4.833	42	78	78	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	62	1					44	55		10.1016/0091-6749(78)90072-6	http://dx.doi.org/10.1016/0091-6749(78)90072-6			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FG870	307012				2022-12-18	WOS:A1978FG87000010
J	LAKIN, JD; BLOCKER, TJ; STRONG, DM; YOCUM, MW				LAKIN, JD; BLOCKER, TJ; STRONG, DM; YOCUM, MW			ANAPHYLAXIS TO PROTAMINE SULFATE MEDIATED BY A COMPLEMENT-DEPENDENT IGG ANTIBODY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									USN,NAVAL MED RES INST,DIV CLIN IMMUNOL,BETHESDA,MD 20034	Naval Medical Research Center (NMRC); United States Department of Defense; United States Navy								BOOTH BH, 1972, ALLERGIC DISEASES DI, P63; BRYANT DH, 1975, J ALLERGY CLIN IMMUN, V56, P417, DOI 10.1016/0091-6749(75)90060-3; BULL BS, 1975, J THORAC CARDIOV SUR, V69, P685; BULL BS, 1975, J THORAC CARDIOV SUR, V69, P674; EGERTON WS, 1961, LANCET, V2, P635; GOURIN A, 1971, J THORAC CARDIOV SUR, V62, P193, DOI 10.1016/S0022-5223(19)42071-0; ISHIZAKA K, 1966, J IMMUNOL, V97, P840; JAQUES LB, 1949, BRIT J PHARM CHEMOTH, V4, P135, DOI 10.1111/j.1476-5381.1949.tb00526.x; JASTRZEBSKI J, 1974, THORAX, V29, P534, DOI 10.1136/thx.29.5.534; Kabat E. A., 1971, EXPT IMMUNOCHEMISTRY; KELLER R, 1968, INT ARCH ALLER A IMM, V34, P139, DOI 10.1159/000230104; Kern RA, 1939, J AMER MED ASSOC, V113, P198, DOI 10.1001/jama.1939.02800280010003; LAKIN JD, 1976, J ALLERGY CLIN IMMUN, V58, P160, DOI 10.1016/0091-6749(76)90151-2; LAKIN JD, 1976, J ALLERGY CLIN IMMUN, V57, P204; LAKIN JD, 1969, J IMMUNOL, V102, P253; LAKIN JD, 1967, J IMMUNOL, V98, P745; LAKIN JD, 1972, ALLERGIC DISEASES DI, P1; MAY JE, 1973, P NATL ACAD SCI USA, V70, P649, DOI 10.1073/pnas.70.3.649; MULLEREB.HJ, 1969, ANNU REV BIOCHEM, V38, P389, DOI 10.1146/annurev.bi.38.070169.002133; OVARY Z, 1958, PROG ALLERGY, V5, P459, DOI 10.1159/000277653; PARISH W E, 1971, Clinical Allergy, V1, P369, DOI 10.1111/j.1365-2222.1971.tb00788.x; PARISH WE, 1970, LANCET, V2, P591; RADEGRAN K, 1972, ACTA ANAESTH SCAND, V16, P76, DOI 10.1111/j.1399-6576.1972.tb00573.x; REID RT, 1970, J IMMUNOL, V104, P935; RENT R, 1975, J IMMUNOL, V114, P120; SIEGEL J, 1974, J EXP MED, V140, P631, DOI 10.1084/jem.140.3.631; Snyder G B, 1966, Surg Forum, V17, P478	27	78	79	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	61	2					102	107		10.1016/0091-6749(78)90232-4	http://dx.doi.org/10.1016/0091-6749(78)90232-4			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EL413	621346				2022-12-18	WOS:A1978EL41300006
J	Yu, JL; Luo, Y; Zhu, ZL; Zhou, YF; Sun, LC; Gao, JX; Sun, JL; Wang, G; Yao, X; Li, W				Yu, Jinlei; Luo, Yang; Zhu, Zhenlai; Zhou, Yufeng; Sun, Licheng; Gao, Jixin; Sun, Jinlv; Wang, Gang; Yao, Xu; Li, Wei			A tryptophan metabolite of the skin microbiota attenuates inflammation in patients with atopic dermatitis through the aryl hydrocarbon receptor	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; skin; microbiota; tryptophan; metabolites; indole-3-aldehyde; aryl hydrocarbon receptor; thymic stromal lymphopoietin	THYMIC STROMAL LYMPHOPOIETIN; GUT MICROBIOTA; KERATINOCYTES; ACTIVATION; VITAMIN-D3; RESPONSES; RISK; AHR	Background: Previous studies have revealed significant alterations in the skin microbiota of patients with atopic dermatitis (AD) not only in diversity and composition but also in function, and the tryptophan (Trp) metabolic pathway is attenuated in the skin microbiota of patients with AD. Objective: We sought to assessTrpmetabolites on the skin surfaces of patients withADand to explore the function of the microbialTrp metabolites in skin inflammation in patients with AD. Methods: A gel-patch method was developed to collect metabolites on the skin surface, which were then assessed by using liquid chromatography-tandem mass spectrometry. A mouse model of calcipotriol (MC903)-induced AD-like dermatitis was used to evaluate the effects of microbial metabolites on AD, and aryl hydrocarbon receptor (AhR)-null mice and keratinocyte cultures were used to investigate the mechanism. Results: Major microbial metabolites of Trp were detected on the skin surfaces of healthy subjects, and the level of indole-3-aldehyde (IAId), an indole derivative of Trp catabolism, was significantly lower in lesional and nonlesional skin of patients with AD than that of healthy subjects. IAId significantly attenuated skin inflammation in mice with MC903-induced AD-like dermatitis, and this effect was blocked by an AhR antagonist and abolished in AhR-null mice. Furthermore, IAId was found to inhibit the MC903-induced expression of thymic stromal lymphopoietin in keratinocytes in vivo and in vitro, which was mediated by binding of AhR to the thymic stromal lymphopoietin promoter. Conclusion: IAId, a skin microbiota-derived Trp metabolite, negatively regulated skin inflammation in patients with AD, revealing that skin microbiota play a significant functional role in the pathogenesis of AD.	[Yu, Jinlei; Zhu, Zhenlai; Gao, Jixin; Wang, Gang; Li, Wei] Fourth Mil Med Univ, Dept Dermatol, Xijing Hosp, Xian 710032, Shaanxi, Peoples R China; [Luo, Yang; Yao, Xu] Chinese Acad Med Sci, Inst Dermatol, 12 Jiangwangmiao St, Nanjing 210042, Jiangsu, Peoples R China; [Luo, Yang; Yao, Xu] Peking Union Med Coll, 12 Jiangwangmiao St, Nanjing 210042, Jiangsu, Peoples R China; [Zhou, Yufeng; Sun, Licheng] Fudan Univ, Huashan Hosp, Childrens Hosp, Shanghai, Peoples R China; [Zhou, Yufeng; Sun, Licheng] Fudan Univ, Huashan Hosp, Inst Biomed Sci, Shanghai, Peoples R China; [Li, Wei] Fudan Univ, Huashan Hosp, Dept Dermatol, Shanghai 200040, Peoples R China; [Sun, Jinlv] Peking Union Hosp, Peking Union Med Coll, Dept Allergy, Beijing, Peoples R China	Air Force Military Medical University; Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Dermatology - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Fudan University; Fudan University; Fudan University; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Peking Union Medical College Hospital	Li, W (corresponding author), Fourth Mil Med Univ, Dept Dermatol, Xijing Hosp, Xian 710032, Shaanxi, Peoples R China.; Yao, X (corresponding author), Chinese Acad Med Sci, Inst Dermatol, 12 Jiangwangmiao St, Nanjing 210042, Jiangsu, Peoples R China.; Yao, X (corresponding author), Peking Union Med Coll, 12 Jiangwangmiao St, Nanjing 210042, Jiangsu, Peoples R China.	dryao_xu@126.com; liweiderma@163.com	Wang, Gang/H-6710-2019	Zhu, Zhenlai/0000-0001-8518-8222; Wang, Gang/0000-0002-5842-8080; zhou, Yufeng/0000-0002-6050-4951	National Natural Science Foundation of China [81573038, 91642116, 81573045, 31400782]; CAMS Innovation Fund for Medical Sciences [2016-I2M-1-005]; Natural Science Foundation of Jiangsu Province [BK20151066, BK20170162]; Milstein Medical Asian American Partnership Foundation; Municipal Human Resources Development Program for Outstanding Leaders in Medical Disciplines in Shanghai [2017BR039]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); CAMS Innovation Fund for Medical Sciences; Natural Science Foundation of Jiangsu Province(Natural Science Foundation of Jiangsu Province); Milstein Medical Asian American Partnership Foundation; Municipal Human Resources Development Program for Outstanding Leaders in Medical Disciplines in Shanghai	Supported by the National Natural Science Foundation of China (81573038, 91642116, 81573045, and 31400782), the CAMS Innovation Fund for Medical Sciences (2016-I2M-1-005), the Natural Science Foundation of Jiangsu Province (BK20151066 and BK20170162), and the Milstein Medical Asian American Partnership Foundation. W.L. was founded by a Municipal Human Resources Development Program for Outstanding Leaders in Medical Disciplines in Shanghai (2017BR039).	Bager P, 2008, CLIN EXP ALLERGY, V38, P634, DOI 10.1111/j.1365-2222.2008.02939.x; Belkaid Y, 2017, IMMUNITY, V46, P562, DOI 10.1016/j.immuni.2017.04.008; Byrd AL, 2018, NAT REV MICROBIOL, V16, P143, DOI 10.1038/nrmicro.2017.157; Chen YE, 2018, NATURE, V553, P427, DOI 10.1038/nature25177; Chng KR, 2016, NAT MICROBIOL, V1, DOI [10.1038/NMICROBIOL.2016.106, 10.1038/nmicrobiol.2016.106]; Colonna M, 2014, IMMUNITY, V40, P863, DOI 10.1016/j.immuni.2014.06.001; Di Meglio P, 2014, IMMUNITY, V40, P989, DOI 10.1016/j.immuni.2014.04.019; Gostner JM, 2016, INT ARCH ALLERGY IMM, V169, P203, DOI 10.1159/000445500; Guo YF, 2016, SCI REP-UK, V6, DOI 10.1038/srep29751; Hammiller BO, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00177; Hidaka T, 2017, NAT IMMUNOL, V18, P64, DOI 10.1038/ni.3614; Huang YJ, 2017, J ALLERGY CLIN IMMUN, V139, P1099, DOI 10.1016/j.jaci.2017.02.007; Kawasaki H, 2014, ALLERGY, V69, P445, DOI 10.1111/all.12346; Kennedy EA, 2017, J ALLERGY CLIN IMMUN, V139, P166, DOI 10.1016/j.jaci.2016.07.029; Kepert I, 2017, J ALLERGY CLIN IMMUN, V139, P1525, DOI 10.1016/j.jaci.2016.09.003; Kong HDH, 2012, GENOME RES, V22, P850, DOI 10.1101/gr.131029.111; Lamas B, 2016, NAT MED, V22, P598, DOI 10.1038/nm.4102; Landheer J, 2015, IMMUN INFLAMM DIS, V3, P32, DOI 10.1002/iid3.48; Lee TY, 2014, J INVEST DERMATOL, V134, P704, DOI 10.1038/jid.2013.389; Levy M, 2017, CURR OPIN MICROBIOL, V35, P8, DOI 10.1016/j.mib.2016.10.003; Li M, 2006, P NATL ACAD SCI USA, V103, P11736, DOI 10.1073/pnas.0604575103; Macia L, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7734; Mathewson ND, 2016, NAT IMMUNOL, V17, P505, DOI 10.1038/ni.3400; Morris G, 2017, MOL NEUROBIOL, V54, P4271, DOI 10.1007/s12035-016-9975-2; Park SL, 2015, J INVEST DERMATOL, V135, P1649, DOI 10.1038/jid.2014.503; Postler TS, 2017, CELL METAB, V26, P110, DOI 10.1016/j.cmet.2017.05.008; Rooks MG, 2016, NAT REV IMMUNOL, V16, P341, DOI 10.1038/nri.2016.42; Rosas-Salazar C, 2018, J ALLERGY CLIN IMMUN, V142, P1447, DOI 10.1016/j.jaci.2017.10.049; Rothhammer V, 2016, NAT MED, V22, P586, DOI 10.1038/nm.4106; Shapiro H, 2014, CURR OPIN IMMUNOL, V30, P54, DOI 10.1016/j.coi.2014.07.003; Shi BC, 2016, J ALLERGY CLIN IMMUN, V138, P1233, DOI 10.1016/j.jaci.2016.04.053; Sridharan GV, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6492; Stockinger B, 2014, ANNU REV IMMUNOL, V32, P403, DOI 10.1146/annurev-immunol-032713-120245; Thavagnanam S, 2008, CLIN EXP ALLERGY, V38, P629, DOI 10.1111/j.1365-2222.2007.02780.x; van den Bogaard EH, 2013, J CLIN INVEST, V123, P917, DOI 10.1172/JCI65642; Venkatesh M, 2014, IMMUNITY, V41, P296, DOI 10.1016/j.immuni.2014.06.014; Zelante T, 2013, IMMUNITY, V39, P372, DOI 10.1016/j.immuni.2013.08.003; Zhao B, 2010, TOXICOL SCI, V117, P393, DOI 10.1093/toxsci/kfq217; Zhu ZL, 2016, MOL IMMUNOL, V78, P98, DOI 10.1016/j.molimm.2016.09.003; Ziegler SF, 2012, J ALLERGY CLIN IMMUN, V130, P845, DOI 10.1016/j.jaci.2012.07.010	40	77	83	4	33	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2019	143	6					2108	+		10.1016/j.jaci.2018.11.036	http://dx.doi.org/10.1016/j.jaci.2018.11.036			24	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IB2QG	30578876	Bronze			2022-12-18	WOS:000470113200016
J	Bousquet, J; Hellings, PW; Agache, I; Amat, F; Annesi-Maesano, I; Ansotegui, IJ; Anto, JM; Bachert, C; Bateman, ED; Bedbrook, A; Bennoor, K; Bewick, M; Bindslev-Jensen, C; Bosnic-Anticevich, S; Bosse, I; Brozek, J; Brussino, L; Canonica, GW; Cardona, V; Casale, T; Sarabia, AMC; Chavannes, NH; Cecchi, L; de Sousa, JC; Costa, E; Cruz, AA; Czarlewski, W; De Carlo, G; De Feo, G; Demoly, P; Devillier, P; Dykewicz, MS; El-Gamal, Y; Eller, EE; Fonseca, JA; Fontaine, JF; Fokkens, WJ; Guzman, MA; Haahtela, T; Illario, M; Ivancevich, JC; Just, J; Kaidashev, I; Khaitov, M; Kalayci, O; Keil, T; Klimek, L; Kowalski, ML; Kuna, P; Kvedariene, V; Larenas-Linnemann, D; Laune, D; Le, LTT; Carlsen, KL; Lourenco, O; Mahboub, B; Mair, A; Menditto, E; Milenkovic, B; Morais-Almeida, M; Mosges, R; Mullol, J; Murray, R; Naclerio, R; Namazova-Baranova, L; Novellino, E; O'Hehir, RE; Ohta, K; Okamoto, Y; Okubo, K; Onorato, GL; Palkonen, S; Panzner, P; Papadopoulos, NG; Park, HS; Paulino, E; Pawankar, R; Pfaar, O; Plavec, D; Popov, TA; Potter, P; Prokopakis, EP; Rottem, M; Ryan, D; Salimaki, J; Samolinski, B; Sanchez-Borges, M; Schunemann, HJ; Sheikh, A; Sisul, JC; Rajabian-Soderlund, R; Sooronbaev, T; Stellato, C; To, T; Todo-Bom, AM; Tomazic, PV; Toppila-Salmi, S; Valero, A; Valiulis, A; Valovirta, E; Ventura, MT; Wagenmann, M; Wang, DY; Wallace, D; Waserman, S; Wickman, M; Yorgancioglu, A; Zhang, L; Zhong, N; Zidarn, M; Zuberbier, T; Bousquet, J; Hellings, PW; Aberer, W; Agache, I; Akdis, CA; Akdis, M; Alberti, MR; Almeida, R; Amat, F; Angles, R; Annesi-Maesano, I; Ansotegui, IJ; Anto, JM; Arnavielle, S; Asayag, E; Asarnoj, A; Arshad, H; Avolio, F; Bacci, E; Bachert, C; Baiardini, I; Barbara, C; Barbagallo, M; Baroni, I; Barreto, BA; Basagana, X; Bateman, ED; Bedolla-Barajas, M; Bedbrook, A; Bewick, M; Beghe, B; Bel, EH; Bergmann, KC; Bennoor, KS; Benson, M; Bertorello, L; Biaoszewski, AZ; Bieber, T; Bialek, S; Bindslev-Jensen, C; Bjermer, L; Blain, H; Blasi, F; Blua, A; Marciniak, MB; Bogus-Buczynska, I; Boner, AL; Bonini, M; Bonini, S; Bosnic-Anticevich, CS; Bosse, I; Bouchard, J; Boulet, LP; Bourret, R; Bousquet, PJ; Braido, F; Briedis, V; Brightling, CE; Brozek, J; Bucca, C; Buhl, R; Buonaiuto, R; Panaitescu, C; Cabanas, MTB; Burte, E; Bush, A; Caballero-Fonseca, F; Caillot, D; Caimmi, D; Calderon, MA; Camargos, PAM; Camuzat, T; Canfora, G; Canonica, GW; Cardona, V; Carlsen, KH; Carreiro-Martins, P; Carriazo, AM; Carr, W; Cartier, C; Casale, T; Castellano, G; Cecchi, L; Sarabia, AMC; Chavannes, NH; Chen, Y; Chiron, R; Chivato, T; Chkhartishvili, E; Chuchalin, AG; Chung, KF; Ciaravolo, MM; Ciceran, A; Cingi, C; Ciprandi, G; Coehlo, ACC; Colas, L; Colgan, E; Coll, J; Conforti, D; de Sousa, JC; Cortes-Grimaldo, RM; Corti, F; Costa, E; Costa-Dominguez, C; Courbis, AL; Cox, L; Crescenzo, M; Cruz, AA; Custovic, A; Czarlewski, W; Dahlen, SE; Dario, C; da Silva, J; Dauvilliers, Y; Darsow, U; De Blay, F; De Carlo, G; Dedeu, T; Emerson, MD; De Feo, G; De Vries, G; De Martino, B; Rubini, NDM; Deleanu, D; Demoly, P; Denburg, JA; Devillier, P; Ercolano, SDC; Di Carluccio, N; Didier, A; Dokic, D; Dominguez-Silva, MG; Douagui, H; Dray, G; Dubakiene, R; Durham, SR; Du Toit, G; Dykewicz, MS; El-Gamal, Y; Eklund, P; Eller, E; Emuzyte, R; Farrell, J; Farsi, A; de Mello, JF; Ferrero, J; Fink-Wagner, A; Fiocchi, A; Fokkens, WJ; Fonseca, JA; Fontaine, JF; Forti, S; Fuentes-Perez, JM; Galvez-Romero, JL; Gamkrelidze, A; Garcia-Aymerich, J; Garcia-Cobas, CY; Garcia-Cruz, MH; Gemicioglu, B; Genova, S; Christoff, G; Gereda, JE; van Wijk, RG; Gomez, RM; Gomez-Vera, J; Diaz, SG; Gotua, M; Grisle, I; Guidacci, M; Guldemond, NA; Gutter, Z; Guzman, MA; Haahtela, T; Hajjam, J; Hernandez, L; Hourihane, JO; Huerta-Villalobos, YR; Humbert, M; Iaccarino, G; Illario, M; Ivancevich, JC; Jares, EJ; Jassem, E; Johnston, SL; Joos, G; Jung, KS; Jutel, M; Kaidashev, I; Kalayci, O; Kalyoncu, AF; Karjalainen, J; Kardas, P; Keil, T; Keith, PK; Khaitov, M; Khaltaev, N; Kleine-Tebbe, J; Klimek, L; Kowalski, ML; Kuitunen, M; Kull, I; Kuna, P; Kupczyk, M; Kvedariene, V; Krzych-Fata, E; Lacwik, P; Larenas-Linnemann, D; Laune, D; Lauri, D; Lavrut, J; Le, LTT; Lessa, M; Levato, G; Li, J; Lieberman, P; Lipiec, A; Lipworth, B; Carlsen, KCL; Louis, R; Lourenco, O; Luna-Pech, JA; Maciej, K; Magnan, A; Mahboub, B; Maier, D; Mair, A; Majer, I; Malva, J; Mandajieva, E; Manning, P; Keenoy, EDM; Marshall, GD; Masjedi, MR; Maspero, JF; Mathieu-Dupas, E; Campos, JJM; Matos, AL; Maurer, M; Mavale-Manuel, S; Mayora, O; Medina-Avalos, MA; Melen, E; Melo-Gomes, E; Meltzer, EO; Menditto, E; Mercier, J; Miculinic, N; Mihaltan, F; Milenkovic, B; Moda, G; Mogica-Martinez, MD; Mohammad, Y; Momas, I; Montefort, S; Monti, R; Bogado, DM; Morais-Almeida, M; Morato-Castro, FF; Mosges, RM; Mota-Pinto, A; Santo, PM; Mullol, J; Munter, L; Muraro, A; Murray, R; Naclerio, R; Nadif, R; Nalin, M; Napoli, L; Namazova-Baranova, L; Neffen, H; Niedeberger, V; Nekam, K; Neou, A; Nieto, A; Nogueira-Silva, L; Nogues, M; Novellino, E; Nyembue, TD; O'Hehir, RE; Odzhakova, C; Ohta, K; Okamoto, Y; Okubo, K; Onorato, GL; Cisneros, MO; Ouedraogo, S; Pali-Scholl, I; Palkonen, S; Panzner, P; Papadopoulos, NG; Park, HS; Papi, A; Passalacqua, G; Paulino, E; Pawankar, R; Pedersen, S; Pepin, JL; Pereira, AM; Persico, M; Pfaar, O; Phillips, J; Picard, R; Pigearias, B; Pin, I; Pitsios, C; Plavec, D; Pohl, W; Popov, TA; Portejoie, F; Potter, P; Pozzi, AC; Price, D; Prokopakis, EP; Puy, R; Pugin, B; Ross, REP; Przemecka, M; Rabe, KF; Raciborski, F; Rajabian-Soderlund, R; Reitsma, S; Ribeirinho, I; Rimmer, J; Rivero-Yeverino, D; Rizzo, JA; Rizzo, MC; Robalo-Cordeiro, C; Rodenas, F; Rodo, X; Gonzalez, MR; Rodriguez-Manas, L; Rolland, C; Valle, SR; Rodriguez, MR; Romano, A; Rodriguez-Zagal, E; Rolla, G; Roller-Wirnsberger, RE; Romano, M; Rosado-Pinto, J; Rosario, N; Rottem, M; Ryan, D; Sagara, H; Salimaki, J; Samolinski, B; Sanchez-Borges, M; Sastre-Dominguez, J; Scadding, GK; Schunemann, HJ; Scichilone, N; Schmid-Grendelmeier, P; Serpa, FS; Shamai, S; Sheikh, A; Sierra, M; Simons, FER; Siroux, V; Sisul, JC; Skrindo, I; Sole, D; Somekh, D; Sondermann, M; Sooronbaev, T; Sova, M; Sorensen, M; Sorlini, M; Spranger, O; Stellato, C; Stelmach, R; Stukas, R; Sunyer, J; Strozek, J; Szylling, A; Tebyrica, JN; Thibaudon, M; To, T; Todo-Bom, A; Tomazic, PV; Toppila-Salmi, S; Trama, U; Triggiani, M; Ulrik, CS; Urrutia-Pereira, M; Valenta, R; Valero, A; Valiulis, A; Valovirta, E; van Eerd, M; van Ganse, E; van Hague, M; Vandenplas, O; Ventura, MT; Vezzani, G; Vasankari, T; Vatrella, A; Verissimo, MT; Viart, F; Viegi, M; Vicheva, D; Vontetsianos, T; Wagenmann, M; Walker, S; Wallace, D; Wang, DY; Waserman, S; Werfel, T; Westman, M; Wickman, M; Williams, DM; Williams, S; Wilson, N; Wright, J; Wroczynski, P; Yakovliev, P; Yawn, BP; Yiallouros, PK; Yorgancioglu, A; Yusuf, OM; Zar, HJ; Zhang, L; Zhong, N; Zernotti, ME; Zidarn, M; Zuberbier, T; Zubrinich, C; Zurkuhlen, A				Bousquet, Jean; Hellings, Peter W.; Agache, Ioana; Amat, Flore; Annesi-Maesano, Isabella; Ansotegui, Ignacio J.; Anto, Josep M.; Bachert, Claus; Bateman, Eric D.; Bedbrook, Anna; Bennoor, Kazi; Bewick, Mickael; Bindslev-Jensen, Carsten; Bosnic-Anticevich, Sinthia; Bosse, Isabelle; Brozek, Jan; Brussino, Luisa; Canonica, Giorgio W.; Cardona, Victoria; Casale, Thomas; Sarabia, Alfonso M. Cepeda; Chavannes, Niels H.; Cecchi, Lorenzo; de Sousa, Jaime Correia; Costa, Elisio; Cruz, Alvaro A.; Czarlewski, Wienczyslawa; De Carlo, Giuseppe; De Feo, Giulia; Demoly, Pascal; Devillier, Philippe; Dykewicz, Mark S.; El-Gamal, Yehia; Eller, Esben E.; Fonseca, Joao A.; Fontaine, Jean-Francois; Fokkens, Wytske J.; Guzman, Maria-Antonieta; Haahtela, Tari; Illario, Maddalena; Ivancevich, Juan-Carlos; Just, Jocelyne; Kaidashev, Igor; Khaitov, Musa; Kalayci, Omer; Keil, Thomas; Klimek, Ludger; Kowalski, Marek L.; Kuna, Piotr; Kvedariene, Violeta; Larenas-Linnemann, Desiree; Laune, Daniel; Le, Lan T. T.; Carlsen, Karin Lodrup; Lourenco, Olga; Mahboub, Bassam; Mair, Alpana; Menditto, Enrica; Milenkovic, Branislava; Morais-Almeida, Mario; Mosges, Ralph; Mullol, Joaquim; Murray, Ruth; Naclerio, Robert; Namazova-Baranova, Leyla; Novellino, Ettore; O'Hehir, Robyn E.; Ohta, Ken; Okamoto, Yoshitaka; Okubo, Kimi; Onorato, Gabrielle L.; Palkonen, Susanna; Panzner, Petr; Papadopoulos, Nikos G.; Park, Hae-Sim; Paulino, Ema; Pawankar, Ruby; Pfaar, Oliver; Plavec, Davor; Popov, Ted A.; Potter, Paul; Prokopakis, Emmanuel P.; Rottem, Menachem; Ryan, Dermot; Salimaki, Johanna; Samolinski, Boleslaw; Sanchez-Borges, Mario; Schunemann, Holger J.; Sheikh, Aziz; Sisul, Juan-Carlos; Rajabian-Soderlund, Rojin; Sooronbaev, Talant; Stellato, Cristiana; To, Teresa; Todo-Bom, Ana-Maria; Tomazic, Peter-Valentin; Toppila-Salmi, Sanna; Valero, Antonio; Valiulis, Arunas; Valovirta, Erkka; Ventura, Maria-Teresa; Wagenmann, Martin; Wang, De Yun; Wallace, Dana; Waserman, Susan; Wickman, Magnus; Yorgancioglu, Arzu; Zhang, Luo; Zhong, Nanshan; Zidarn, Mihaela; Zuberbier, Torsten; Bousquet, J.; Hellings, P. W.; Aberer, W.; Agache, I.; Akdis, C. A.; Akdis, M.; Alberti, M. R.; Almeida, R.; Amat, F.; Angles, R.; Annesi-Maesano, I.; Ansotegui, I. J.; Anto, J. M.; Arnavielle, S.; Asayag, E.; Asarnoj, A.; Arshad, H.; Avolio, F.; Bacci, E.; Bachert, C.; Baiardini, I.; Barbara, C.; Barbagallo, M.; Baroni, I.; Barreto, B. A.; Basagana, X.; Bateman, E. D.; Bedolla-Barajas, M.; Bedbrook, A.; Bewick, M.; Beghe, B.; Bel, E. H.; Bergmann, K. C.; Bennoor, K. S.; Benson, M.; Bertorello, L.; Biaoszewski, A. Z.; Bieber, T.; Bialek, S.; Bindslev-Jensen, C.; Bjermer, L.; Blain, H.; Blasi, F.; Blua, A.; Marciniak, M. Bochenska; Bogus-Buczynska, I.; Boner, A. L.; Bonini, M.; Bonini, S.; Bosnic-Anticevich, C. S.; Bosse, I.; Bouchard, J.; Boulet, L. P.; Bourret, R.; Bousquet, P. J.; Braido, F.; Briedis, V.; Brightling, C. E.; Brozek, J.; Bucca, C.; Buhl, R.; Buonaiuto, R.; Panaitescu, C.; Cabanas, M. T. Burguete; Burte, E.; Bush, A.; Caballero-Fonseca, F.; Caillot, D.; Caimmi, D.; Calderon, M. A.; Camargos, P. A. M.; Camuzat, T.; Canfora, G.; Canonica, G. W.; Cardona, V.; Carlsen, K. H.; Carreiro-Martins, P.; Carriazo, A. M.; Carr, W.; Cartier, C.; Casale, T.; Castellano, G.; Cecchi, L.; Sarabia, A. M. Cepeda; Chavannes, N. H.; Chen, Y.; Chiron, R.; Chivato, T.; Chkhartishvili, E.; Chuchalin, A. G.; Chung, K. F.; Ciaravolo, M. M.; Ciceran, A.; Cingi, C.; Ciprandi, G.; Coehlo, A. C. Carvalho; Colas, L.; Colgan, E.; Coll, J.; Conforti, D.; de Sousa, J. Correia; Cortes-Grimaldo, R. M.; Corti, F.; Costa, E.; Costa-Dominguez, C.; Courbis, A. L.; Cox, L.; Crescenzo, M.; Cruz, A. A.; Custovic, A.; Czarlewski, W.; Dahlen, S. E.; Dario, C.; da Silva, J.; Dauvilliers, Y.; Darsow, U.; De Blay, F.; De Carlo, G.; Dedeu, T.; Emerson, M. de Fatima; De Feo, G.; De Vries, G.; De Martino, B.; Rubini, N. de Paula Motta; Deleanu, D.; Demoly, P.; Denburg, J. A.; Devillier, P.; Ercolano, S. Di Capua; Di Carluccio, N.; Didier, A.; Dokic, D.; Dominguez-Silva, M. G.; Douagui, H.; Dray, G.; Dubakiene, R.; Durham, S. R.; Du Toit, G.; Dykewicz, M. S.; El-Gamal, Y.; Eklund, P.; Eller, E.; Emuzyte, R.; Farrell, J.; Farsi, A.; de Mello, J. Ferreira, Jr.; Ferrero, J.; Fink-Wagner, A.; Fiocchi, A.; Fokkens, W. J.; Fonseca, J. A.; Fontaine, J. F.; Forti, S.; Fuentes-Perez, J. M.; Galvez-Romero, J. L.; Gamkrelidze, A.; Garcia-Aymerich, J.; Garcia-Cobas, C. Y.; Garcia-Cruz, M. H.; Gemicioglu, B.; Genova, S.; Christoff, G.; Gereda, J. E.; van Wijk, R. Gerth; Gomez, R. M.; Gomez-Vera, J.; Diaz, S. Gonzalez; Gotua, M.; Grisle, I.; Guidacci, M.; Guldemond, N. A.; Gutter, Z.; Guzman, M. A.; Haahtela, T.; Hajjam, J.; Hernandez, L.; Hourihane, J. O'B.; Huerta-Villalobos, Y. R.; Humbert, M.; Iaccarino, G.; Illario, M.; Ivancevich, J. C.; Jares, E. J.; Jassem, E.; Johnston, S. L.; Joos, G.; Jung, K. S.; Jutel, M.; Kaidashev, I.; Kalayci, O.; Kalyoncu, A. F.; Karjalainen, J.; Kardas, P.; Keil, T.; Keith, P. K.; Khaitov, M.; Khaltaev, N.; Kleine-Tebbe, J.; Klimek, L.; Kowalski, M. L.; Kuitunen, M.; Kull, I.; Kuna, P.; Kupczyk, M.; Kvedariene, V.; Krzych-Fata, E.; Lacwik, P.; Larenas-Linnemann, D.; Laune, D.; Lauri, D.; Lavrut, J.; Le, L. T. T.; Lessa, M.; Levato, G.; Li, J.; Lieberman, P.; Lipiec, A.; Lipworth, B.; Carlsen, K. C. Lodrup; Louis, R.; Lourenco, O.; Luna-Pech, J. A.; Maciej, K.; Magnan, A.; Mahboub, B.; Maier, D.; Mair, A.; Majer, I.; Malva, J.; Mandajieva, E.; Manning, P.; Keenoy, E. De Manuel; Marshall, G. D.; Masjedi, M. R.; Maspero, J. F.; Mathieu-Dupas, E.; Campos, J. J. Matta; Matos, A. L.; Maurer, M.; Mavale-Manuel, S.; Mayora, O.; Medina-Avalos, M. A.; Melen, E.; Melo-Gomes, E.; Meltzer, E. O.; Menditto, E.; Mercier, J.; Miculinic, N.; Mihaltan, F.; Milenkovic, B.; Moda, G.; Mogica-Martinez, M. D.; Mohammad, Y.; Momas, I.; Montefort, S.; Monti, R.; Bogado, D. Mora; Morais-Almeida, M.; Morato-Castro, F. F.; Mosges, R.; Mota-Pinto, A.; Santo, P. Moura; Mullol, J.; Munter, L.; Muraro, A.; Murray, R.; Naclerio, R.; Nadif, R.; Nalin, M.; Napoli, L.; Namazova-Baranova, L.; Neffen, H.; Niedeberger, V.; Nekam, K.; Neou, A.; Nieto, A.; Nogueira-Silva, L.; Nogues, M.; Novellino, E.; Nyembue, T. D.; O'Hehir, R. E.; Odzhakova, C.; Ohta, K.; Okamoto, Y.; Okubo, K.; Onorato, G. L.; Cisneros, M. Ortega; Ouedraogo, S.; Pali-Scholl, I.; Palkonen, S.; Panzner, P.; Papadopoulos, N. G.; Park, H. S.; Papi, A.; Passalacqua, G.; Paulino, E.; Pawankar, R.; Pedersen, S.; Pepin, J. L.; Pereira, A. M.; Persico, M.; Pfaar, O.; Phillips, J.; Picard, R.; Pigearias, B.; Pin, I.; Pitsios, C.; Plavec, D.; Pohl, W.; Popov, T. A.; Portejoie, F.; Potter, P.; Pozzi, A. C.; Price, D.; Prokopakis, E. P.; Puy, R.; Pugin, B.; Ross, R. E. Pulido; Przemecka, M.; Rabe, K. F.; Raciborski, F.; Rajabian-Soderlund, R.; Reitsma, S.; Ribeirinho, I.; Rimmer, J.; Rivero-Yeverino, D.; Rizzo, J. A.; Rizzo, M. C.; Robalo-Cordeiro, C.; Rodenas, F.; Rodo, X.; Gonzalez, M. Rodriguez; Rodriguez-Manas, L.; Rolland, C.; Valle, S. Rodrigues; Rodriguez, M. Roman; Romano, A.; Rodriguez-Zagal, E.; Rolla, G.; Roller-Wirnsberger, R. E.; Romano, M.; Rosado-Pinto, J.; Rosario, N.; Rottem, M.; Ryan, D.; Sagara, H.; Salimaki, J.; Samolinski, B.; Sanchez-Borges, M.; Sastre-Dominguez, J.; Scadding, G. K.; Schunemann, H. J.; Scichilone, N.; Schmid-Grendelmeier, P.; Serpa, F. S.; Shamai, S.; Sheikh, A.; Sierra, M.; Simons, F. E. R.; Siroux, V.; Sisul, J. C.; Skrindo, I.; Sole, D.; Somekh, D.; Sondermann, M.; Sooronbaev, T.; Sova, M.; Sorensen, M.; Sorlini, M.; Spranger, O.; Stellato, C.; Stelmach, R.; Stukas, R.; Sunyer, J.; Strozek, J.; Szylling, A.; Tebyrica, J. N.; Thibaudon, M.; To, T.; Todo-Bom, A.; Tomazic, P. V.; Toppila-Salmi, S.; Trama, U.; Triggiani, M.; Ulrik, C. Suppli; Urrutia-Pereira, M.; Valenta, R.; Valero, A.; Valiulis, A.; Valovirta, E.; van Eerd, M.; van Ganse, E.; van Hague, M.; Vandenplas, O.; Ventura, M. T.; Vezzani, G.; Vasankari, T.; Vatrella, A.; Verissimo, M. T.; Viart, F.; Viegi, M.; Vicheva, D.; Vontetsianos, T.; Wagenmann, M.; Walker, S.; Wallace, D.; Wang, D. Y.; Waserman, S.; Werfel, T.; Westman, M.; Wickman, M.; Williams, D. M.; Williams, S.; Wilson, N.; Wright, J.; Wroczynski, P.; Yakovliev, P.; Yawn, B. P.; Yiallouros, P. K.; Yorgancioglu, A.; Yusuf, O. M.; Zar, H. J.; Zhang, L.; Zhong, N.; Zernotti, M. E.; Zidarn, M.; Zuberbier, T.; Zubrinich, C.; Zurkuhlen, A.		Mobile Airways Sentinel Network M	Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Change management; rhinitis; asthma; Allergic Rhinitis and Its Impact on Asthma	EUROPEAN INNOVATION PARTNERSHIP; PATIENT PARTICIPATION; WORK PRODUCTIVITY; CHRONIC DISEASES; DECISION-MAKING; GLOBAL STRATEGY; MASK-RHINITIS; MACVIA-ARIA; GUIDELINES; QUALITY	Allergic Rhinitis and its Impact on Asthma (ARIA) has evolved from a guideline by using the best approach to integrated care pathways using mobile technology in patients with allergic rhinitis (AR) and asthma multimorbidity. The proposed next phase of ARIA is change management, with the aim of providing an active and healthy life to patients with rhinitis and to those with asthma multimorbidity across the lifecycle irrespective of their sex or socioeconomic status to reduce health and social inequities incurred by the disease. ARIA has followed the 8-step model of Kotter to assess and implement the effect of rhinitis on asthma multimorbidity and to propose multimorbid guidelines. A second change management strategy is proposed by ARIA Phase 4 to increase self-medication and shared decision making in rhinitis and asthma multimorbidity. An innovation of ARIA has been the development and validation of information technology evidence-based tools (Mobile Airways Sentinel Network [MASK]) that can inform patient decisions on the basis of a self-care plan proposed by the health care professional.	[Bousquet, Jean] Univ Hosp, Montpellier, France; [Bousquet, Jean; Bedbrook, Anna; Onorato, Gabrielle L.] MACVIA France, Fdn Partenariale FMC VIA LR, Montpellier, France; [Bousquet, Jean] Univ Versailles St Quentin en Yvelines, Ageing & Chron Dis Epidemiol & Publ Hlth Approach, UMR S 1168, Montigny Bretonneux & Euforea, Villejuif, France; [Hellings, Peter W.] Katholieke Univ Leuven, Dept Microbiol & Immunol, Clin Immunol Lab, Leuven, Belgium; [Agache, Ioana] Transylvania Univ Brasov, Brasov, Romania; [Annesi-Maesano, Isabella; Demoly, Pascal] INSERM, Inst Pierre Louis Epidemiol & Publ Hlth, Epidemiol Allerg & Resp Dis Dept, Paris, France; [Annesi-Maesano, Isabella; Demoly, Pascal] UPMC Sorbonne Univ, Med Sch St Antoine, Paris, France; [Ansotegui, Ignacio J.] Hosp Quiron Bizkaia, Dept Allergy & Immunol, Erandio, Spain; [Anto, Josep M.] ISGlobal, Ctr Res Environm Epidemiol CREAL, Barcelona, Spain; [Anto, Josep M.] IMIM Hosp Mar Res Inst, Barcelona, Spain; [Anto, Josep M.] CIBER Epidemiol & Salud Publ CIBERESP, Barcelona, Spain; [Anto, Josep M.] Univ Pompeu Fabra UPF, Barcelona, Spain; [Bachert, Claus] Ghent Univ Hosp, ENT Dept, Upper Airways Res Lab, Ghent, Belgium; [Bateman, Eric D.] Univ Cape Town, Dept Med, Rondebosch, South Africa; [Bennoor, Kazi] Natl Inst Dis Chest & Hosp, Dept Resp Med, Dhaka, Bangladesh; [Bewick, Mickael] iQ4U Consultants, London, England; [Bindslev-Jensen, Carsten; Eller, Esben E.] Odense Univ Hosp, Dept Dermatol & Allergy Ctr, Odense Res Ctr Anaphylaxis ORCA, Odense, Denmark; [Bosnic-Anticevich, Sinthia] Univ Sydney, Woolcock Inst Med Res, Glebe, NSW, Australia; [Bosnic-Anticevich, Sinthia] Woolcock Emphysema Ctr, Glebe, NSW, Australia; [Bosnic-Anticevich, Sinthia] Local Hlth Dist, Glebe, NSW, Australia; [Brozek, Jan; Schunemann, Holger J.] McMaster Univ, Div Immunol & Allergy, Dept Hlth Res Methods Evidence & Impact, Dept Med, Hamilton, ON, Canada; [Brussino, Luisa] Univ Torino, Dept Med Sci, Allergy & Clin Immunol Unit, Turin, Italy; [Brussino, Luisa] Mauriziano Hosp, Turin, Italy; [Canonica, Giorgio W.] Humanitas Univ, Humanitas Res Hosp, Personalized Med Clin Asthma & Allergy, Milan, Italy; [Cardona, Victoria] Hosp Valle De Hebron, Allergy Sect, Dept Internal Med, Barcelona, Spain; [Cardona, Victoria] ARADyAL Spanish Res Network, Barcelona, Spain; [Casale, Thomas] Univ S Florida, Div Allergy Immunol, Tampa, FL USA; [Sarabia, Alfonso M. Cepeda] Simon Bolivar Univ, Metropolitan Univ, Allergy & Immunol Lab, Barranquilla, Colombia; [Sarabia, Alfonso M. Cepeda] SLaai, Soc Latinoamer Alergia Asma & Immunol, Barranquilla, Colombia; [Chavannes, Niels H.] Leiden Univ Med Ctr, Dept Publ Hlth & Primary Care, Leiden, Netherlands; [Cecchi, Lorenzo] USL Toscana Ctr, SOS Allergol & Clin Immunol, Prato, Italy; [de Sousa, Jaime Correia] Univ Minho, Life & Hlth Sci Res Inst ICVS, Sch Med, Braga, Portugal; [de Sousa, Jaime Correia] ICVS 3Bs, PT Govt Associate Lab, Braga, Portugal; [Costa, Elisio] Univ Porto Porto4Ageing, UCIBIO, REQUINTE, Fac Pharm, Porto, Portugal; [Costa, Elisio] Univ Porto Porto4Ageing, UCIBIO, REQUINTE, Competence Ctr Act & Healthy Ageing, Porto, Portugal; [Cruz, Alvaro A.] Univ Fed Bahia, ProAR Nucleo Excelencia Asma, Salvador, BA, Brazil; [Cruz, Alvaro A.] WHO GARD Planning Grp, Salvador, BA, Brazil; [Czarlewski, Wienczyslawa] Med Consulting Czarlewski, Levallois Perret, France; [De Carlo, Giuseppe; Palkonen, Susanna] European Federat Allergy & Airways Dis Patients A, Brussels, Belgium; [De Feo, Giulia; Stellato, Cristiana] Univ Salerno, Dept Med, Surg & Dent Scuola Med Salernitana, Salerno, Italy; [Demoly, Pascal] Montpellier Univ Hosp, Dept Resp Dis, Montpellier, France; [Devillier, Philippe] Univ Paris Saclay, Univ Versailles St Quentin, Lab Phamacol Resp UPRES EA220, Hop Foch, Paris, France; [Dykewicz, Mark S.] St Louis Univ, Sect Allergy & Immunol, Sch Med, St Louis, France; [El-Gamal, Yehia] Ain Shams Univ, Childrens Hosp, Pediat Allergy & Immunol Unit, Cairo, Egypt; [Fonseca, Joao A.] Univ Porto, Ctr Res Hlth Technol & Informat Syst, CINTESIS, Fac Med,Lda, Porto, Portugal; [Fokkens, Wytske J.] AMC, Dept Otorhinolaryngol, Amsterdam, Netherlands; [Guzman, Maria-Antonieta] Univ Chile, Immunol & Allergy Div, Clin Hosp, Santiago, Chile; [Haahtela, Tari; Toppila-Salmi, Sanna] Helsinki Univ Hosp, Skin & Allergy Hosp, Helsinki, Finland; [Haahtela, Tari; Toppila-Salmi, Sanna] Univ Helsinki, Helsinki, Finland; [Illario, Maddalena; Novellino, Ettore] Div Hlth Innovat, Naples, Italy; [Illario, Maddalena] Federico II Univ & Hosp Naples, DISMET & RID Unit, Naples, Italy; [Ivancevich, Juan-Carlos] Clin Santa Isabel, Serv Alergia Immunol, Buenos Aires, DF, Argentina; [Amat, Flore; Just, Jocelyne] UPMC Univ Paris 06, Allergol Dept, Ctr Asthme & Allergies, Hop Enfants Armand Trousseau APHP, Paris, France; [Amat, Flore; Just, Jocelyne] UPMC Univ Paris 06, Sorbonne Univ, UMR S 1136, Inst Pierre Louis Epidemiol & Sante Publ Equipe E, Paris, France; [Kaidashev, Igor] Ukrainina Med Stomatol Acad, Poltava, Ukraine; [Khaitov, Musa] Natl Res Ctr, Inst Immunol, Lab Mol Immunol, Fed Medicobiol Agcy, Moscow, Russia; [Kalayci, Omer] Hacettepe Univ, Pediat Allergy & Asthma Unit, Sch Med, Ankara, Turkey; [Keil, Thomas] Charite Univ Med Berlin, Inst Social Med Epidemiol & Hlth Econ, Berlin, Germany; [Keil, Thomas] Univ Wurzburg, Inst Clin Epidemiol & Biometry, Wurzburg, Germany; [Klimek, Ludger] Ctr Rhinol & Allergol, Wiesbaden, Germany; [Kowalski, Marek L.] Med Univ Lodz, Dept Immunol & Allergy, Healthy Ageing Res Ctr, Lodz, Poland; [Kuna, Piotr] Med Univ Lodz, Barlicki Univ Hosp, Div Internal Med Asthma & Allergy, Lodz, Poland; [Kvedariene, Violeta] Vilnius Univ, Fac Med, Vilnius, Lithuania; [Larenas-Linnemann, Desiree] Med Clin Fdn & Hosp, Ctr Excellence Asthma & Allergy, Mexico City, DF, Mexico; [Laune, Daniel] Kyomed, Montpellier, France; [Le, Lan T. T.] Univ Med & Pharm, Hochiminh City, Vietnam; [Carlsen, Karin Lodrup] Oslo Univ Hosp, Dept Paediat, Oslo, Norway; [Carlsen, Karin Lodrup] Univ Oslo, Fac Med, Inst Clin Med, Oslo, Norway; [Lourenco, Olga] Univ Beira Interior, Fac Hlth Sci, Covilha, Portugal; [Lourenco, Olga] Univ Beira Interior, CICS UBI, Hlth Sci Res Ctr, Covilha, Portugal; [Mahboub, Bassam] Rashid Hosp, Dept Pulm Med, Dubai, U Arab Emirates; [Mair, Alpana] Scottish Govt, DG Hlth Social Care, Edinburgh, Midlothian, Scotland; [Menditto, Enrica] Univ Naples Federico II, CIRFF, Naples, Italy; [Milenkovic, Branislava] Univ Belgrade, Clin Pulm Dis, Clin Ctr Serbia, Fac Med,Serbian Assoc Asthma & COPD, Belgrade, Serbia; [Morais-Almeida, Mario] CUF Descobertas Hosp, Allergy Ctr, Lisbon, Portugal; [Mosges, Ralph] Univ Cologne, Inst Med Stat & Computat Biol, Fac Med, Hamburg, Germany; [Mosges, Ralph] CRI Clin Res Int, Hamburg, Germany; [Mullol, Joaquim] Univ Barcelona, Rhinol Unit, Barcelona, Spain; [Mullol, Joaquim] Univ Barcelona, Clin & Expt Resp Immunoallergy, ENT Dept, Smell Clin,Hosp Clin,IDIBAPS,CIBERES, Barcelona, Spain; [Murray, Ruth] Med Script, Dundalk, Ireland; [Naclerio, Robert] Johns Hopkins Sch Med, Baltimore, MD USA; [Namazova-Baranova, Leyla] Sci Ctr Childrens Hlth MoH, Moscow, Russia; [Novellino, Ettore] Univ Naples Federico II, Dept Pharm, Naples, Italy; [O'Hehir, Robyn E.] Monash Univ, Dept Allergy Immunol & Resp Med, Alfred Hosp, OHEHIR, Melbourne, Vic, Australia; [O'Hehir, Robyn E.] Monash Univ, Cent Clin Sch, Melbourne, Vic, Australia; [O'Hehir, Robyn E.] Monash Univ, Dept Immunol, Melbourne, Vic, Australia; [Ohta, Ken] Tokyo Natl Hosp, Natl Hosp Org, Tokyo, Japan; [Okamoto, Yoshitaka] Chiba Univ Hosp, Dept Otorhinolaryngol, Chiba, Japan; [Okubo, Kimi] Nippon Med Sch, Dept Otolaryngol, Tokyo, Japan; [Panzner, Petr] Charles Univ Prague, Fac Med Pilsen, Dept Immunol & Allergol, Prague, Czech Republic; [Papadopoulos, Nikos G.] Univ Manchester, Inst Human Dev, Royal Manchester Childrens Hosp, Ctr Pediat & Child Hlth, Manchester, Lancs, England; [Papadopoulos, Nikos G.] Univ Athens, Dept Allergy, Pediat Clin 2, Athens Gen Childrens Hosp P&A Kyriakou, Athens, Greece; [Park, Hae-Sim] Ajou Univ, Sch Med, Dept Allergy & Clin Immunol, Suwon, South Korea; [Paulino, Ema] Farmacias Holon, Lisbon, Portugal; [Pawankar, Ruby] Nippon Med Sch, Dept Pediat, Tokyo, Japan; [Pfaar, Oliver] Ctr Rhinol & Allergol, Wiesbaden, Germany; [Pfaar, Oliver] Heidelberg Univ, Univ Med Mannheim, Dept Otorhinolaryngol Head & Neck Surg, Med Fac Mannheim, Mannheim, Germany; [Plavec, Davor] Childrens Hosp Srebrnjak, Zagreb, Croatia; [Plavec, Davor] Univ JJ Strossmayer, Sch Med, Osijek, Croatia; [Popov, Ted A.] Univ Hosp Sv Ivan Rilski, Sofia, Bulgaria; [Potter, Paul] Univ Cape Town, Lung Inst, Allergy Diagnost & Clin Res Unit, Cape Town, South Africa; [Prokopakis, Emmanuel P.] Univ Crete, Dept Otorhinolaryngol, Sch Med, Iraklion, Greece; [Rottem, Menachem] Emek Med Ctr, Div Allergy Asthma & Clin Immunol, Afula, Israel; [Ryan, Dermot] Univ Edinburgh, Allergy & Resp Res Grp, Edinburgh, Midlothian, Scotland; [Salimaki, Johanna] Assoc Finnish Pharm, Helsinki, Finland; [Samolinski, Boleslaw] Med Univ Warsaw, Dept Prevent Environm Hazards & Allergol, Warsaw, Poland; [Sanchez-Borges, Mario] Trinidad & Clin El Avila, Allergy & Clin Immunol Dept, Ctr Med Docente La, Caracas, Venezuela; [Sheikh, Aziz] Univ Edinburgh, Usher Inst Populat Hlth Sci & Informat, Edinburgh, Midlothian, Scotland; [Sisul, Juan-Carlos] Sociedad Paraguaya Alergia Asma & Inmunol, Asuncion, Paraguay; [Rajabian-Soderlund, Rojin] Karolinska Univ Hosp, Dept Nephrol & Endocrinol, Stockholm, Sweden; [Sooronbaev, Talant] Euro Asian Resp Soc, Kyrgyzstan Natl Ctr Cardiol & Internal Med, Bishkek, Kyrgyzstan; [To, Teresa] Sidkkids Hosp, Toronto, ON, Canada; [To, Teresa] Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada; [Todo-Bom, Ana-Maria] Univ Coimbra, Ctr Hosp Univ Coimbra, Imunoalergol, Coimbra, Portugal; [Todo-Bom, Ana-Maria] Univ Coimbra, Fac Med, Coimbra, Portugal; [Tomazic, Peter-Valentin] Med Univ Graz, Dept ENT, Graz, Austria; [Valero, Antonio] Univ Barcelona, Pneumol & Allergy Dept, CIBERES, Barcelona, Spain; [Valero, Antonio] Univ Barcelona, Clin & Expt Resp Immunoallergy, IDIBAPS, Barcelona, Spain; [Valiulis, Arunas] Vilnius Univ, Inst Clin Med, Clin Childrens Dis, Vilnius, Lithuania; [Valiulis, Arunas] Vilnius Univ, Inst Hlth Sci, Dept Publ Hlth, Vilnius, Lithuania; [Valiulis, Arunas] European Acad Paediat EAP UEMS SP, Brussels, Belgium; [Valovirta, Erkka] Univ Turku, Dept Lung Dis & Clin Immunol Allergol, Turku, Finland; [Valovirta, Erkka] Terveystalo Allergy Clin, Turku, Finland; [Ventura, Maria-Teresa] Univ Bari, Sch Med, Unit Geriatr Immunoallergol, Bari, Italy; [Wagenmann, Martin] Univ Klinikum Dusseldorf, Dept Otorhinolaryngol, Dusseldorf, Germany; [Wang, De Yun] Natl Univ Singapore, Dept Otolaryngol, Yong Loo Lin Sch Med, Singapore, Singapore; [Wallace, Dana] Nova Southeastern Univ, Ft Lauderdale, FL USA; [Waserman, Susan] McMaster Univ, Dept Med Clin Immunol & Allergy, Hamilton, ON, Canada; [Wickman, Magnus] Uppsala Univ, Ctr Clin Res Sormland, Eskilstuna, Sweden; [Yorgancioglu, Arzu] Celal Bayar Univ, Dept Pulmonol, Manisa, Turkey; [Zhang, Luo] Beijing TongRen Hosp, Dept Otolaryngol Head & Neck Surg, Beijing, Peoples R China; [Zhang, Luo] Beijing Inst Otolaryngol, Beijing, Peoples R China; [Zhong, Nanshan] Guangzhou Med Univ, State Key Lab Resp Dis, Guangzhou Inst Resp Dis, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China; [Zidarn, Mihaela] Univ Clin Resp & Allerg Dis, Golnik, Slovenia; [Zuberbier, Torsten] Charite Univ Med Berlin, Dept Dermatol & Allergy, Comprehens Allergy Ctr Charite, Berlin, Germany; [Zuberbier, Torsten] Global Allergy & Asthma European Network GA2LEN, Berlin, Germany; [Bousquet, J.] Univ Hosp, Montpellier, France; [Bousquet, J.; Bedbrook, A.; Nogues, M.; Onorato, G. L.; Portejoie, F.] MACVIA France, Fdn Partenariale FMC VIA LR, Montpellier, France; [Bousquet, J.; Burte, E.; Nadif, R.] INSERM, VIMA, VIMA Ageing & Chron Dis Epidemiol & Publ Hlth App, U 1168, Villejuif, France; [Bousquet, J.; Burte, E.; Nadif, R.] Univ Versailles St Quentin en Yvelines, UMR S 1168, Montigny Le Bretonneux, France; [Bousquet, J.; Burte, E.; Nadif, R.] Euforea, Brussels, Belgium; [Hellings, P. W.] Katholieke Univ Leuven, Dept Microbiol & Immunol, Clin Immunol Lab, Leuven, Belgium; [Aberer, W.] Med Univ Graz, Dept Dermatol, Graz, Austria; [Agache, I.] Transylvania Univ Brasov, Brasov, Romania; [Akdis, C. A.; Akdis, M.] Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Davos, Switzerland; [Alberti, M. R.] Council Municipal Salerno, Salerno, Italy; [Almeida, R.] Univ Porto, Ctr Hlth Technol & Serv Res CINTESIS, Fac Med, Porto, Portugal; [Almeida, R.] Medida Lda, Porto, Portugal; [Amat, F.] UPMC Univ Paris 06, Ctr Asthme & Allergies, Inst Pierre Louis Epidemiol & Sante Publ, Sorbonne Univ,Hop Enfants Armand Trousse APHP,UMR, Paris, France; [Angles, R.] Salud Sect Sanitario Barbastro, Innovac & Nuevas Tecnol, Barbastro, Spain; [Annesi-Maesano, I.; Bousquet, P. J.; Demoly, P.] INSERM, Epidemiol Allerg & Resp Dis, Dept Inst Pierre Louis Epidemiol & Publ Hlth, Paris, France; [Annesi-Maesano, I.; Bousquet, P. J.; Demoly, P.] UPMC Sorbonne Univ, Med Sch St Antoine, Paris, France; [Ansotegui, I. J.] Hosp Quiron Bizkaia, Dept Allergy & Immunol, Erandio, Spain; [Anto, J. M.; Basagana, X.; Garcia-Aymerich, J.; Rodo, X.; Sunyer, J.] ISGlobAL, Ctr Res Environm Epidemiol CREAL, Barcelona, Spain; [Anto, J. M.; Sunyer, J.] IMIM Hosp Mar, Res Inst, Barcelona, Spain; [Anto, J. M.; Sunyer, J.] CIBER Epidemiol & Salud Publ CIBERESP, Barcelona, Spain; [Anto, J. M.; Sunyer, J.] UPF, Barcelona, Spain; [Arnavielle, S.; Laune, D.; Mathieu-Dupas, E.] Kyomed, Montpellier, France; [Asayag, E.] Argentine Soc Allergy & Immunopathol, Buenos Aires, DF, Argentina; [Asarnoj, A.] Karolinska Inst, Dept Med Solna, Clin Immunol & Allergy Unit, Stockholm, Sweden; [Asarnoj, A.] Karolinska Univ Hosp, Astrid Lindgren Childrens Hosp, Dept Pediat Pulmonol & Allergy, Stockholm, Sweden; [Arshad, H.] David Hide Asthma & Allergy Res Ctr, Isle Of Wight, England; [Avolio, F.] Reg Puglia, Bari, Italy; [Bacci, E.; Bertorello, L.] Reg Liguria, Genoa, Italy; [Bachert, C.] Ghent Univ Hosp, Upper Airways Res Lab, ENT Dept, Ghent, Belgium; [Baiardini, I.; Braido, F.; Canonica, G. W.] Humanitas Univ, Dept Biomed Sci, Milan, Italy; [Barbara, C.; Melo-Gomes, E.] Portuguese Natl Programme Resp Dis, PNDR, Fac Med Lisboa, Lisbon, Portugal; [Barbagallo, M.] Univ Palermo, Dept Internal Med DIBIMIS, Geriatr Unit, Palermo, Italy; [Baroni, I.; Nalin, M.; Romano, M.] Telbios SRL, Milan, Italy; [Barreto, B. A.] Univ Estado Para, Belem, Para, Brazil; [Bateman, E. D.] Univ Cape Town, Dept Med, Cape Town, South Africa; [Bedolla-Barajas, M.] Hosp Civil Guadalajara Dr Juan I Menchaca, Guadalarara, Mexico; [Bewick, M.] iQ4U Consultants, London, England; [Beghe, B.] Univ Modena & Reggio Emilia, Sect Resp Dis, Dept Oncol Haematol & Resp Dis, Modena, Italy; [Bel, E. H.] Univ Amsterdam, Acad Med Ctr AMC, Dept Resp Med, Amsterdam, Netherlands; [Bergmann, K. C.; Zuberbier, T.] Charite Univ Med Berlin, Berlin Inst Hlth, Dept Dermatol & Allergy, Comprehens Allergy Ctr,Global Allergy & Asthma Eu, Berlin, Germany; [Bennoor, K. S.] Natl Inst Dis Chest & Hosp, Dept Resp Med, Dhaka, Bangladesh; [Benson, M.] Ctr Individualized Med, Dept Pediat, Fac Med, Linkoping, Sweden; [Biaoszewski, A. Z.] Med Univ Warsaw, Dept Prevent Environm Hazards & Allergol, Warsaw, Poland; [Bieber, T.] Rhein Friedrich Wilhelms Univ Bonn, Dept Dermatol & Allergy, BIEBER, Bonn, Germany; [Bialek, S.; Todo-Bom, A.; Wroczynski, P.] Warsaw Med Univ, Dept Biochem & Clin Chem, Fac Pharm, Div Lab Med Div, Warsaw, Poland; [Bindslev-Jensen, C.; Eller, E.] Odense Univ Hosp, Dept Dermatol & Allergy Ctr, Odense Res Ctr Anaphylaxis ORCA, Odense, Denmark; [Bjermer, L.] Univ Hosp, Dept Resp Med & Allergol, Lund, Sweden; [Blain, H.] Montpellier Univ Hosp, Dept Geriatr, Montpellier, France; [Blain, H.] Univ Montpellier, EA 2991, Euromov, Montpellier, France; [Blasi, F.] Univ Milan, Dept Pathophysiol & Transplantat, IRCCS Fdn Ca Granda Osped Maggiore Policlin, Milan, Italy; [Blua, A.] Argentine Assoc Resp Med, Buenos Aires, DF, Argentina; [Marciniak, M. Bochenska; Bogus-Buczynska, I.; Kuna, P.; Kupczyk, M.; Lacwik, P.; Maciej, K.; Przemecka, M.] Med Univ Lodz, Barlicki Univ Hosp, Div Internal Med Asthma & Allergy, Lodz, Poland; [Boner, A. L.] Univ Verona Hosp, Dept Pediat, Verona, Italy; [Bonini, M.] Sapienza Univ Rome, Dept Publ Hlth & Infect Dis, Rome, Italy; [Bonini, S.] Univ Naples 2, Naples, Italy; [Bonini, S.] Italian Natl Res Council, Inst Translat Med, Naples, Italy; [Bosnic-Anticevich, C. S.] Univ Sydney, Woolcock Inst Med Res, Glebe, NSW, Australia; [Bosnic-Anticevich, C. S.] Sydney Local Hlth Dist, Glebe, NSW, Australia; [Bouchard, J.] Laval Univ, Med Clin, Hop Malbaie, La Malbaie, PQ, Canada; [Boulet, L. P.] Laval Univ, Quebec Heart & Lung Inst, Quebec City, PQ, Canada; [Bourret, R.] Ctr Hosp Valenciennes, Valenciennes, France; [Briedis, V.; Nogues, M.] Lithuanian Univ Hlth Sci, Dept Clin Pharm, Kaunas, Lithuania; [Brightling, C. E.] Univ Hosp Leicester NHS Trust, Inst Lung Hlth, Resp Biomed Unit, Leicester, Leics, England; [Brightling, C. E.] Univ Leicester, Dept Infect Immun & Inflammat, Leicester, Leics, England; [Brozek, J.; Schunemann, H. J.] McMaster Univ, Div Immunol & Allergy, Dept Hlth Res Methods Evidence & Impact, Dept Med, Hamilton, ON, Canada; [Bucca, C.] Hosp City Hlth & Sci Torino, Pneumol Unit AOU Molinette, Turin, Italy; [Buhl, R.] Johannes Gutenberg Univ Mainz, Univ Med, Mainz, Germany; [Buonaiuto, R.] Municipal Pharm, Sarno, Italy; [Panaitescu, C.] Univ Med & Farm Timisoara, Timisoara, Romania; [Cabanas, M. T. Burguete] Hosp Zambrano Hell Tec Monterrey, Inst Pediat, Monterrey, Mexico; [Bush, A.] Imperial Coll & Royal Brompton Hosp, London, England; [Caballero-Fonseca, F.] Centro Med Docente La Trinidad, Caracas, Venezuela; [Di Carluccio, N.] Assofarm Campania & Cofaser, Salerno, Italy; [Caillot, D.] CHU, Serv Pneumol, Clermont Ferrand, France; [Caillot, D.] Univ Auvergne, Clermont Ferrand, France; [Caimmi, D.; Chiron, R.; Demoly, P.] Montpellier Univ Hosp, Dept Resp Dis, Montpellier, France; [Calderon, M. A.] Imperial Coll London, Natl Heart & Lung Inst, Royal Brompton Hosp NHS, London, England; [Camargos, P. A. M.] Univ Fed Minas Gerais, Sch Med, Dept Pediat, Belo Horizonte, MG, Brazil; [Camuzat, T.] Reg Occitanie, Montpellier, France; [Canfora, G.] Sarno Martiri Villa Malta Hosp, Anesthesiol Serv, Sarno, Italy; [Cardona, V.] Hosp Valle De Hebron, Allergy Sect, Dept Internal Med, Barcelona, Spain; [Cardona, V.] Spanish Res Network, ARADyAL, Barcelona, Spain; [Carlsen, K. H.] Oslo Univ Hosp, Dept Paediat, Oslo, Norway; [Carlsen, K. H.] Oslo Univ Hosp, Univ Oslo, Oslo, Norway; [Carreiro-Martins, P.] CEDOC, Nova Med Sch, Integrated Pathophysiol Mech Res Grp, Campo Martires Patria, Lisbon, Portugal; [Carreiro-Martins, P.] Ctr Hosp Lisboa Cent, Serv Imunoalergol, EPE, Lisbon, Portugal; [Carriazo, A. M.] Reg Minist Hlth Andalusia, Seville, Spain; [Carr, W.] Allergy & Asthma Associates Southern Calif, Mission Viejo, CA USA; [Cartier, C.; Viart, F.] ASA Adv Solut Accelerator, Clapiers, France; [Casale, T.] Univ S Florida, Div Allergy Immunol, Tampa, FL USA; [Castellano, G.] Celentano Pharm, Massa Lubrense, Italy; [Cecchi, L.; Farsi, A.] USL Toscana Ctr, SOS Allergol & Clin Immunol, Prato, Italy; [Sarabia, A. M. Cepeda] Simon Bolivar Univ, Metropolitan Univ, Allergy & Immunol Lab, Barranquilla, Colombia; [Sarabia, A. M. Cepeda] SLaai, Sociedad Latinoamer Allergia Asma & Immunol, Barranquilla, Colombia; [Chavannes, N. H.] Leiden Univ, Dept Publ Hlth & Primary Care, Med Ctr, Leiden, Netherlands; [Chen, Y.] Capital Inst Pediat, Beijing, Peoples R China; [Chivato, T.] Univ CEU San Pablo, Sch Med, Madrid, Spain; [Chkhartishvili, E.] David Tvildiani Med Univ, AIETI Highest Med Sch, David Tatishvili Med Ctr Tbilisi, Tbilisi, Georgia; [Chuchalin, A. G.] FMBA & GARD Execut Comm, Pulm Res Inst, Moscow, Russia; [Chung, K. F.] Imperial Coll, Natl Heart & Lung Inst, London, England; [Ciaravolo, M. M.] Social Worker, Sorrento, Italy; [Ciceran, A.] Argentine Federat Otorhinolaryngol Soc, Buenos Aires, DF, Argentina; [Cingi, C.] Eskisehir Osmangazi Univ, Fac Med, ENT Dept, Eskisehir, Turkey; [Ciprandi, G.] IRCCS Azienda Ospedaliera Univ San Martino, Dept Med, Genoa, Italy; [Coehlo, A. C. Carvalho] Univ Fed Bahia, Escola Enfermagem, Salvador, BA, Brazil; [Colas, L.; Magnan, A.] CHU Nantes, Inst Thorax, Plateforme Transversale Allergol, Nantes, France; [Colgan, E.; Farrell, J.] LANUA Int Healthcare Consultancy, Warrenpoint, North Ireland; [Coll, J.; Sierra, M.] Salud Sect Sanitario Barbastro, Innovac & Nuevas Tecnol, Barbastro, Spain; [Conforti, D.; Forti, S.; Mayora, O.] Autonomous Prov Trento, Dept Hlth & Social Solidar, Innovat & Res Off, Trento, Italy; [de Sousa, J. Correia] Univ Minho, Life & Hlth Sci Res Inst ICVS, Sch Med, Braga, Portugal; [de Sousa, J. Correia] PT Govt Associate Lab, ICVS 3Bs, Braga, Portugal; [Cortes-Grimaldo, R. M.] Hosp Angeles Carmen, Serv Allergol, Guadalarara, Mexico; [Corti, F.] FIMMG Federaz Italiana Med Med Gen, Milan, Italy; [Costa, E.] Univ Porto Porto4Ageing, Fac Pharm, REQUINTE, UCIBIO, Porto, Portugal; [Costa, E.] Univ Porto Porto4Ageing, Competence Ctr Act & Healthy Ageing, Porto, Portugal; [Costa-Dominguez, C.] Allergologo, Mexico City, DF, Mexico; [Courbis, A. L.; Dray, G.] Univ Montpellier, IMT Mines Ales, Ales, France; [Cox, L.] Univ Miami, Dept Med, Nova Southeastern Univ, Davie, Miami, FL USA; [Crescenzo, M.] Assofarm Campania & Cofaser, Salerno, Italy; [Cruz, A. A.] Univ Fed Bahia, ProAR Nucleo Excelencia Asma, Salvador, BA, Brazil; [Cruz, A. A.] WHO GARD Planning Grp, Salvador, BA, Brazil; [Custovic, A.] Univ Manchester, Ctr Resp Med & Allergy, Inst Inflammat & Repair, Manchester, Lancs, England; [Custovic, A.] Univ Hosp South Manchester, Manchester, Lancs, England; [Czarlewski, W.] Med Consulting Czarlewski, Levallois Perret, France; [Dahlen, S. E.] Karolinska Inst, Inst Environm Med, Ctr Allergy Res, Stockholm, Sweden; [Dario, C.] Azienda Prov & Serv Sanit Trento APSS Trento, Trento, Italy; [da Silva, J.] Fed Univ Santa Catarina UFSC, Dept Internal Med & Allergy, Clin Pr Plydoro Ernani, Sao Thiago Univ Hosp, Florianopolis, SC, Brazil; [Dauvilliers, Y.] Hop Gui de Chauliac Montpellier, INSERM U1061, Dept Neurol, Sleep Unit, Montpellier, France; [Darsow, U.] Tech Univ Munich, Dept Dermatol & Allergy, Munich, Germany; [Darsow, U.] Tech Univ Munich, ZAUM Ctr Allergy & Environm, Helmholtz Ctr Munich, Munich, Germany; [De Blay, F.] Univ Hosp Strasbourg, Chest Dis Dept, Allergy Div, Chest Dis Dept, Strasbourg, France; [De Carlo, G.; Palkonen, S.] European Federat Allergy & Airways Dis Patients A, Brussels, Belgium; [Dedeu, T.] AQuAS, Barcelona, Spain; [Dedeu, T.] European Reg & Local Hlth Assoc, EUREGHA, Brussels, Belgium; [Emerson, M. de Fatima] Policlin Geral Rio de Janeiro, Rio De Janeiro, Brazil; [De Feo, G.; Stellato, C.; Triggiani, M.; Vatrella, A.] Univ Salerno, Dept Med Surg & Dent, Scuola Med Salernitana, Salerno, Italy; [De Vries, G.; van Eerd, M.] Peercode BV, Geldermalsen, Netherlands; [Rubini, N. de Paula Motta] Fed Univ State Rio De Janeiro, Sch Med & Surg, Rio De Janeiro, Brazil; [Deleanu, D.] Iuliu Hatieganu Univ Med & Pharm, Allergol & Immunol Discipline, Cluj Napoca, Romania; [Denburg, J. A.] McMaster Univ, Div Clin Immunol & Allergy, Dept Med, Hamilton, ON, Canada; [Devillier, P.] Univ Paris Saclay, Univ Versailles St Quentin, Lab Pharmacol Resp, Hop Foch,UPRES EA220, Paris, France; [Ercolano, S. Di Capua] Farm Golfi Grp, Massa Lubrense, Italy; [Didier, A.] Rangueil Larrey Hosp, Dept Resp Dis, Toulouse, France; [Dokic, D.] Univ Clin Pulmol & Allergy, Med Fac Skopje R Macedonia, Skopje, North Macedonia; [Dominguez-Silva, M. G.] Allergologo, Mexico City, DF, Mexico; [Douagui, H.] Ctr Hosp Univ Beni Messous, Serv Pneumoallergol, Algiers, Algeria; [Dubakiene, R.] Vilnius Univ, Clin Infect Chest Dis Dermatol & Allergol, Vilnius, Lithuania; [Durham, S. R.] Imperial Coll London, Allergy & Clin Immunol Natl Heart & Lung Inst, London, England; [Du Toit, G.] Kings Coll London, Guys & St Thomas NHS Trust, London, England; [Dykewicz, M. S.] St Louis Univ, Sect Allergy & Immunol, Sch Med, St Louis, MO USA; [El-Gamal, Y.] Ain Shams Univ, Childrens Hosp, Pediat Allergy & Immunol Unit, Cairo, Egypt; [Eklund, P.] Umea Univ, Dept Comp Sci, Umea, Sweden; [Eklund, P.] Four Comp Oy, Salo, Finland; [Emuzyte, R.] Vilnius Univ, Clin Childrens Dis, Fac Med, Vilnius, Lithuania; [de Mello, J. Ferreira, Jr.] Univ Sao Paulo, Med Sch, Sao Paulo, Brazil; [Ferrero, J.] Andalusian Agcy Healthcare Qual, Seville, Spain; [Fink-Wagner, A.; Spranger, O.] Global Allergy & Asthma Platform GAAPP, Vienna, Austria; [Fiocchi, A.] Bambino Gesu Childrens Res Hosp Holy See, Div Allergy, Dept Pediat Med, Rome, Italy; [Fokkens, W. J.; Reitsma, S.] Acad Med Ctr, Dept Otorhinolaryngol, Amsterdam, Netherlands; [Fonseca, J. A.] Univ Porto, Ctr Res Hlth Technol & Informat Syst, CINTESIS, Fac Med, Porto, Portugal; [Fonseca, J. A.] MEDIDA, Porto, Portugal; [Fuentes-Perez, J. M.] Hosp Gen Reg 1 Dr Carlos Mc Gregor Sanchez Navarr, Mexico City, DF, Mexico; [Galvez-Romero, J. L.] ISSSTE, Reg Hosp, Puebla, Mexico; [Gamkrelidze, A.] Natl Ctr Dis Control & Publ Hlth Georgia, Tbilisi, Georgia; [Garcia-Cobas, C. Y.] Allergologo, Guadalarara, Mexico; [Garcia-Cruz, M. H.] Natl Inst Resp Dis, Allergy Clin, Mexico City, DF, Mexico; [Gemicioglu, B.] Istanbul Univ, Cerrahpasa Fac Med, Dept Pulm Dis, Istanbul, Turkey; [Genova, S.] UHATEM NIPirogov, Allergol Unit, Sofia, Bulgaria; [Christoff, G.] Med Univ, Fac Publ Hlth, Sofia, Bulgaria; [Gereda, J. E.] Clin Ricardo Palma, Allergy & Immunol Div, Lima, Peru; [van Wijk, R. Gerth] Erasmus MC, Sect Allergol, Dept ment Internal Med, Rotterdam, Netherlands; [Gomez, R. M.] Hosp San Bernardo, Allergy & Asthma Unit, Salta, Argentina; [Gomez-Vera, J.] Hosp Reg ISSSTE Lic Lopez Mateos, Allergy Clin, Mexico City, DF, Mexico; [Diaz, S. Gonzalez] Univ Autonoma Nuevo Leon, Univ Hosp, Ctr Reg Excelencia CONACYT & WAO Alergia Asma & I, Monterrey, Mexico; [Gotua, M.] Georgian Assoc Allergol & Clin Immunol, Ctr Allergy & Immunol, Tbilisi, Georgia; [Grisle, I.] Latvian Assoc Allergists, Ctr TB & Lung Dis, Riga, Latvia; [Guidacci, M.] Fed Dist Base Hosp Inst, Brasilia, DF, Brazil; [Guldemond, N. A.] Erasmus Univ, Inst Hlth Policy & Management iBMG, Rotterdam, Netherlands; [Gutter, Z.] Univ Hosp Olomouc, Natl eHlth Ctr, Olomouc, Czech Republic; [Guzman, M. A.] Univ Chile, Immunol & Allergy Div, Clin Hosp, Santiago, Chile; [Haahtela, T.; Toppila-Salmi, S.] Univ Helsinki, Helsinki Univ Hosp, Skin & Allergy Hosp, Helsinki, Finland; [Hajjam, J.] Centich Ctr Expertise Natl Technol Informat & Com, Conseil Reg Pays Loire, Ctr Expertise Partenariat Europeen Innovat Vieill, Nantes, France; [Hernandez, L.] Univ Autonoma Baja California, Ensenada, Baja California, Mexico; [Hourihane, J. O'B.] Univ Coll Cork, Dept Paediat & Child Hlth, Cork, Ireland; [Huerta-Villalobos, Y. R.] Hosp Gen Reg 1 Dr Carlos MacGregor Sanchez Navarr, Mexico City, DF, Mexico; [Humbert, M.] Univ Paris Sud, Serv Pneumol, Hop Bicetre, Inserm UMR S999, Le Kremlin Bicetre, France; [Iaccarino, G.] Univ Salerno, Dipartimento Med Chirurg & Odontoiatria, Salerno, Italy; [Illario, M.] Federico II Univ Hosp Naples, Div Hlth Innovat, R&D & DISMET, Naples, Italy; [Ivancevich, J. C.] Serv Alergia & Immunol Clin Santa Isabel, Buenos Aires, DF, Argentina; [Jares, E. J.] Libra Fdn, Buenos Aires, DF, Argentina; [Jassem, E.] Med Univ Gdansk, Dept Allergol, Gdansk, Poland; [Johnston, S. L.] Imperial Coll, Natl Heart & Lung Inst, Airway Dis Infect Sect, London, England; [Johnston, S. L.] Imperial Coll, MRC & Asthma UK Ctr Allerg Mech Asthma, London, England; [Joos, G.] Ghent Univ Hosp, Dept Resp Med, Ghent, Belgium; [Jung, K. S.] Hallym Univ, Sacred Heart Hosp, Coll Med, Gyeonggi Do, South Korea; [Jutel, M.] Wroclaw Med Univ, Dept Clin Immunol, Wroclaw, Poland; [Kaidashev, I.] Ukrainina Med Stomatol Acad, Poltava, Ukraine; [Kalayci, O.] Hacettepe Univ, Pediat Allergy & Asthma Unit, Sch Med, Ankara, Turkey; [Kalyoncu, A. F.] Hacettepe Univ, Sch Med, Immunol & Allergy Div, Dept Chest Dis, Ankara, Turkey; [Karjalainen, J.] Tampere Univ Hosp, Allergy Ctr, Tampere, Finland; [Kardas, P.] Med Univ Lodz, Dept Family Med 1, Lodz, Poland; [Keil, T.] Charite Univ Med Berlin, Inst Social Med Epidemiol & Hlth Econ, Berlin, Germany; [Keil, T.] Univ Wurzburg, Inst Clin Epidemiol & Biometry, Wurzburg, Germany; [Keith, P. K.] McMaster Univ, Dept Med, Hlth Sci Ctr, 3V47West, Hamilton, ON, Canada; [Khaitov, M.] Natl Res Ctr, Inst Immunol, Lab Mol Immunol, Fed Medicobiol Agcy, Moscow, Russia; [Khaltaev, N.] GARD, Geneva, Switzerland; [Kleine-Tebbe, J.] Allergy Asthma Ctr Westend, Berlin, Germany; [Klimek, L.] Ctr Rhinol & Allergol, Wiesbaden, Germany; [Kowalski, M. L.] Med Univ Lodz, Dept Immunol Rheumatol & Allergy, Lodz, Poland; [Kowalski, M. L.] HARC, Lodz, Poland; [Kuitunen, M.] Childrens Hosp, Helsinki, Finland; [Kuitunen, M.] Univ Helsinki, Helsinki, Finland; [Kull, I.; Wickman, M.] Karlinska Inst, Dept Clin Sci & Educ, Sodersjukhuset, Stockholm, Sweden; [Kull, I.; Wickman, M.] Sachs Children & Youth Hosp, Sodersjukhuset, Stockholm, Sweden; [Kvedariene, V.] Vilnius Univ, Fac Med, Vilnius, Lithuania; [Krzych-Fata, E.; Lipiec, A.; Raciborski, F.; Samolinski, B.; Strozek, J.; Szylling, A.] Med Univ Warsaw, Dept Prevent Envinronm Hazards & Allergol, Warsaw, Poland; [Larenas-Linnemann, D.] Med Clin Fdn & Hosp, Ctr Excellence Asthma & Allergy, Mexico City, DF, Mexico; [Lauri, D.] CMMC, Milan, Italy; [Lavrut, J.] Elizalde Childrens Hosp, Allergy Dept Pedro, Buenos Aires, DF, Argentina; [Le, L. T. T.] Univ Med & Pharm, Hochiminh City, Vietnam; [Lessa, M.] Univ Fed Bahia, Salvador, Brazil; [Levato, G.] Sifmed, Milan, Italy; [Li, J.; Zhong, N.] Guangzhou Med Univ, Affiliated Hosp 1, State Key Lab Resp Dis, Guangzhou Inst Resp Dis, Guangzhou, Guangdong, Peoples R China; [Lieberman, P.] Univ Tennessee, Dept Internal Med & Pediat, Div Allergy & Immunol, Coll Med, German Town, TN USA; [Lipworth, B.] Univ Dundee, Ninewells Hosp, Med Res Inst, Scottish Ctr Resp Res Cardiovasc & Diabet Med, Dundee, Scotland; [Carlsen, K. C. Lodrup] Oslo Univ Hosp, Dept Paediat, Oslo, Norway; [Carlsen, K. C. Lodrup] Univ Oslo, Fac Med, Inst Clin Med, Oslo, Norway; [Louis, R.] CHU Sart Tilman, Dept Pulm Med, Liege, Belgium; [Louis, R.] GIGA I3 Res Grp, Liege, Belgium; [Lourenco, O.] Univ Beira Interior, Fac Hlth Sci, Covilha, Portugal; [Lourenco, O.] Univ Beira Interior, CICS UBI, Hlth Sci Res Ctr, Covilha, Portugal; [Luna-Pech, J. A.] Univ Guadalajara, Dept Philosoph Methodol & Instrumental Discipline, CUCS, Guadalajara, Jalisco, Mexico; [Mahboub, B.] Rashid Hosp, Dept Pulm Med, Dubai, U Arab Emirates; [Maier, D.] Biomax Informat AG, Munich, Germany; [Mair, A.] Scottish Govt Hlth Dept, Directorate Finance eHlth & Pharmaceut, Edinburgh, Midlothian, Scotland; [Majer, I.] Univ Bratislava, Dept Resp Med, Bratislava, Slovakia; [Malva, J.; Verissimo, M. T.] Univ Coimbra, Coimbra Inst Clin & Biomed Res iCBR, Fac Med, Coimbra, Portugal; [Malva, J.; Verissimo, M. T.] Ageing Coimbra EIP AHA Reference Site, Coimbra, Portugal; [Mandajieva, E.] Iskar, Med Ctr, Sofia, Bulgaria; [Manning, P.] Bon Secours Hosp, Dept Med RCSI, Dublin, Ireland; [Keenoy, E. De Manuel] Kronikgune, Int Ctr Excellence Chron Res Barakaldo, Bizkaia, Spain; [Marshall, G. D.] Univ Mississippi, Div Clin Immunol & Allergy, Lab Behav Immunol Res, Med Ctr, Jackson, MS USA; [Masjedi, M. R.] Iranian Antitobacco Assoc, Tobacco Control Res Ctr, Tehran, Iran; [Maspero, J. F.] Argentine Assoc Allergy & Clin Immunol, Buenos Aires, DF, Argentina; [Campos, J. J. Matta] Hosp Especialidades Ctr Med La Raza, Ctr Med Nacl Siglo XXI, Mexico City, DF, Mexico; [Matos, A. L.] Univ Southeast Bahia, Vitoria Da Conquista, Brazil; [Maurer, M.] Charite Univ Med Berlin, Dept Dermatol & Allergy, Allergie Ctr Charite, Berlin, Germany; [Mavale-Manuel, S.] Maputo Cent Hosp, Dept Paediat, Maputo, Mozambique; [Medina-Avalos, M. A.] Allergologo, Veracruz, Mexico; [Melen, E.] Sachs Children & Youth Hosp, Sodersjukhuset, Stockholm, Sweden; [Melen, E.] Karolinska Inst, Inst Environm Med, Stockholm, Sweden; [Meltzer, E. O.] Allergy & Asthma Med Grp & Res Ctr, San Diego, CA USA; [Menditto, E.] Univ Naples Federico II, CIRFF, Naples, Italy; [Mercier, J.] Univ Montpellier, CHRU, Dept Physiol, PhyMedExp,INSERM U1046, Montpellier, France; [Miculinic, N.] Croatian Pulm Soc, Zagreb, Croatia; [Miculinic, N.] Natl Inst Pneumol M Nasta, Bucharest, Romania; [Mihaltan, F.] Natl Inst Pneumol M Nasta, Bucharest, Romania; [Milenkovic, B.] Univ Belgrade, Serbian Assoc Asthma & COPD, Clin Pulm Dis, Clin Ctr Serbia,Fac Med, Belgrade, Serbia; [Moda, G.] Reg Piemonte, Turin, Italy; [Mogica-Martinez, M. D.] Col Jardines Sta Monica, Tlalnepantla, Mexico; [Mohammad, Y.] Tishreen Univ, Natl Ctr Res Chron Resp Dis, Sch Med, Latakia, Syria; [Momas, I.] Paris Descartes Univ, Dept Publ Hlth & Hlth Prod, Sorbonne Paris Cite, EA 4064, Paris, France; [Momas, I.] Paris Municipal Dept Social Act Childhood & Hlth, Paris, France; [Momas, I.] Paris Municipal Dept Social Act Childhood & Hlth, Paris, France; [Montefort, S.] Univ Malta, Univ Med, Mater Dei Hosp Malta, Fac Med & Surg, La Valette, Malta; [Monti, R.] Univ Torino, Dept Med Sci, Allergy & Clin Immunol Unit, Turin, Italy; [Monti, R.] Mauriziano Hosp, Turin, Italy; [Bogado, D. Mora] Tesorera SLAAI, Inst Previs Social IPS HC, Socia SPAAI, Asuncion, Paraguay; [Morais-Almeida, M.] CUF Descobertas Hosp, Allergy Ctr, Lisbon, Portugal; [Morato-Castro, F. F.] Univ Sao Paulo, Sao Paulo, Brazil; [Mosges, R.; Shamai, S.] Univ Cologne, Inst Med Stat & Computat Biol, Fac Med, Cologne, Germany; [Mosges, R.; Shamai, S.] CRI Clin Res Int, Hamburg, Germany; [Mota-Pinto, A.] Univ Coimbra, Inst Gen Pathol, Fac Med, Coimbra, Portugal; [Mota-Pinto, A.] Ageing Coimbra EIP AHA Reference Site, Coimbra, Portugal; [Santo, P. Moura] Univ Fed Bahia, Salvador, BA, Brazil; [Mullol, J.] Univ Barcelona, Hosp Clin, ENT Dept, Rhinol Unit & Smell Clin, Barcelona, Spain; [Munter, L.] Danish Comm Hlth Educ, Copenhagen, Denmark; [Muraro, A.] Padua Gen Univ Hosp, Dept Women & Child Hlth, Food Allergy Referral Ctr Veneto Reg, Padua, Italy; [Murray, R.] MedScript, Dundalk, Ireland; [Naclerio, R.] Johns Hopkins Sch Med, Baltimore, MD USA; [Napoli, L.] COFASER Pharm Serv Consortium, Salerno, Italy; [Namazova-Baranova, L.] Russian Natl Res Med Univ, Sci Ctr Childrens Hlth MoH, Moscow, Russia; [Neffen, H.] Santa Fe Argentina Ctr Allergy & Immunol, Ctr Allergy Immunol & Resp Dis, Santa Fe, Argentina; [Niedeberger, V.] Med Univ Vienna, Dept Otorhinolaryngol, AKH, Vienna, Austria; [Nekam, K.] Hosp Hospitaller Bros Buda, Budapest, Hungary; [Neou, A.] Die Hautambulanz & Rothhaar Study Ctr, Berlin, Germany; [Nieto, A.] Hosp La Fe, Neumol & Alergol Infantil, Valencia, Spain; [Nogueira-Silva, L.] CINTESIS, Ctr Hlth Technol & Serv Res, Porto, Portugal; [Nogueira-Silva, L.] Ctr Hosp Sao Joao, Dept Internal Med, Porto, Portugal; CARSAT LR, Montpellier, France; [Novellino, E.] Univ Naples Federico II, Dept Pharm, Naples, Italy; [Nyembue, T. D.] Univ Hosp Kinshasa, ENT Dept, Kinshasa, DEM REP CONGO; [O'Hehir, R. E.; Puy, R.; Zubrinich, C.] Monash Univ, Alfred Hosp & Cent Clin Sch, Dept Allergy Immunol & Resp Med, Melbourne, Vic, Australia; [O'Hehir, R. E.; Puy, R.; Zubrinich, C.] Monash Univ, Dept Immunol, Melbourne, Vic, Australia; [Odzhakova, C.] Med Ctr, Varna, Bulgaria; [Ohta, K.] Tokyo Natl Hosp, Natl Hosp Org, Tokyo, Japan; [Okamoto, Y.] Chiba Univ Hosp, Dept Otorhinolaryngol, Chiba, Japan; [Okubo, K.] Nippon Med Sch, Dept Otolaryngol, Tokyo, Japan; [Cisneros, M. Ortega] Allergologo, Jalisco, Guadalarara, Mexico; [Ouedraogo, S.] Ctr Hosp Univ Pediat Charles de Gaulle, Ouagadougou, Burkina Faso; [Pali-Scholl, I.] Univ Vet Med, Dept Comparat Med, Messerli Res Inst, Vienna, Austria; [Pali-Scholl, I.] Med Univ, Vienna, Austria; [Panzner, P.] Charles Univ Prague, Fac Med, Dept Immunol & Allergol, Plzen, Czech Republic; [Panzner, P.] Charles Univ Prague, Fac Hosp Pilsen, Plzen, Czech Republic; [Papadopoulos, N. G.] Univ Manchester, Inst Human Dev, Royal Manchester Childrens Hosp, Ctr Pediat & Child Hlth, Manchester, Lancs, England; [Papadopoulos, N. G.] Univ Athens, Athens Gen Childrens Hosp P&A Kyriakou, Pediat Clin 2, Dept Allergy, Athens, Greece; [Park, H. S.] Ajou Univ, Dept Allergy & Clin Immunol, Sch Med, Suwon, South Korea; [Papi, A.] Univ Ferrara, Dept Med Sci, Resp Med, Ferrara, Italy; [Passalacqua, G.] Univ Genoa, Osped Policlino San Martino, Allergy & Resp Dis, Genoa, Italy; [Paulino, E.] Farm Holon, Lisbon, Portugal; [Pawankar, R.] Nippon Med Sch, Dept Pediat, Tokyo, Japan; [Pedersen, S.] Univ Southern Denmark, Kolding, Denmark; [Pepin, J. L.] Univ Grenoble Alpes, Lab HP2, INSERM U1042, Grenoble, France; [Pepin, J. L.] CHU Grenoble, Grenoble, France; [Pereira, A. M.] Univ Porto, CUF Porto Hosp & Inst, Allergy Unit, Porto, Portugal; [Pereira, A. M.] Univ Porto, Ctr Res Hlth Technol & Informat Syst CINTESIS, Porto, Portugal; [Persico, M.] Municipal Area N33, Sorrento, Italy; [Pfaar, O.] Ctr Rhinol & Allergol, Wiesbaden, Germany; [Pfaar, O.] Heidelberg Univ, Univ Med Mannheim, Med Fac Mannheim, Dept Otorhinolaryngol Head & Neck Surg, Mannheim, Germany; [Phillips, J.] Ctr Empowering People & Commun, Dublin, Ireland; [Picard, R.] Conseil Gen Econ Minist Econ, Ind Numer, Paris, France; [Pigearias, B.] Societe & Pneumol Langue Francaise, Espace Francophone Pneumol, Paris, France; [Pin, I.] CHUde Grenoble, Dept Pediat, Grenoble, France; [Pitsios, C.] Univ Cyprus, Sch Med, Nicosia, Cyprus; [Plavec, D.] Univ JJ Strossmayer, Sch Med, Childrens Hosp Srebrnjak, Osijek, Croatia; [Pohl, W.] Hietzing Hosp, Karl Landsteiner Inst Clin & Expt Pneumol, Vienna, Austria; [Popov, T. A.] Univ Hosp Sv Ivan Rilski, Sofia, Bulgaria; [Potter, P.] Univ Cape Town, Allergy Diagnost & Clin Res Unit, Lung Inst, Cape Town, South Africa; [Pozzi, A. C.] IML, Milan, Italy; [Price, D.] Univ Aberdeen, Div Appl Hlth Sci, Ctr Acad Primary Care, Aberdeen, Scotland; [Price, D.] Observat & Pragmat Res Inst, Singapore, Singapore; [Prokopakis, E. P.] Univ Crete, Dept Otorhinolaryngol, Sch Med, Iraklion, Greece; [Pugin, B.] European Forum Res & Educ Allergy & Airway Dis EU, Brussels, Belgium; [Ross, R. E. Pulido] Allergologo, Quintana Roo, Cancun, Mexico; [Rabe, K. F.] German Ctr Lung Res DZL, Lungen Clin Grosshansdorf, Airway Res Ctr North, Grosshansdorf, Germany; [Rabe, K. F.] Univ Kiel, German Ctr Lung Res DZL, Airway Res Ctr North, Med, Kiel, Germany; [Rajabian-Soderlund, R.] Karolinska Univ Hosp, Dept Nephrol & Endocrinol, Stockholm, Sweden; [Ribeirinho, I.] Farm Sao Paio, Vila Nova Gaia, Porto, Portugal; [Rimmer, J.] St Vincents Hosp, Sydney, NSW, Australia; [Rimmer, J.] Univ Sydney, Sydney, NSW, Australia; [Rivero-Yeverino, D.] Allergologo, Mexico City, DF, Mexico; [Rizzo, J. A.] Hosp Clin UFPE EBSERH, Serv Pneumol, Recife, PE, Brazil; [Rizzo, M. C.] Univ Fed Sao Paulo, Sao Paulo, Brazil; [Robalo-Cordeiro, C.] Coimbra Univ Hosp, Ctr Pneumol, Coimbra, Portugal; [Rodenas, F.] Univ Valencia, Polibienestar Res Inst, Valencia, Spain; [Gonzalez, M. Rodriguez] Hosp Angeles Pedregal, Pediat Allergy & Clin Immunol, Mexico City, DF, Mexico; [Rodriguez-Manas, L.] Getafe Univ Hosp, Dept Geriatr, Madrid, Spain; [Rolland, C.] Assoc Asthme & Allergie, Paris, France; [Valle, S. Rodrigues] Univ Fed Rio de Janeiro, Rio De Janeiro, Brazil; [Rodriguez, M. Roman] Inst Invest Sanitaria Palma IdisPa, Primary Care Resp Res Unit, Palma De Mallorca, Spain; [Romano, A.] Univ Cattolica Sacro Cuore, Allergy Unit, Presidio Columbus, Rome, Italy; [Romano, A.] IRCCS Oasi Maria SS, Troina, Italy; [Rodriguez-Zagal, E.] Hosp Gen, Mexico City, DF, Mexico; [Rolla, G.] Reg Piemonte, Turin, Italy; [Roller-Wirnsberger, R. E.] Med Univ Graz, Dept Internal Med, Graz, Austria; [Rosado-Pinto, J.] Hosp Luz Lisboa Portugal, Serv Imunoalergol, Lisbon, Portugal; [Rosario, N.] Univ Parana, Hosp Clin, Curitiba, Parana, Brazil; [Rottem, M.] Emek Med Ctr, Div Allergy Asthma & Clin Immunol, Afula, Israel; [Ryan, D.] Univ Edinburgh, Allergy & Resp Res Grp, Edinburgh, Midlothian, Scotland; [Sagara, H.] Showa Univ, Sch Med, Tokyo, Japan; [Salimaki, J.] Assoc Finnish Pharm, Helsinki, Finland; [Sanchez-Borges, M.] Ctr Med Docente La, Allergy & Clin Immunol Dept, Trinidad & Clin El Avila, Caracas, Venezuela; [Sastre-Dominguez, J.] Autnonous Univ Madrid, Fac Med, Madrid, Spain; [Scadding, G. K.] UCL, Royal Natl TNE Hosp, London, England; [Scichilone, N.] Univ Palermo, DIBIMIS, Palermo, Italy; [Schmid-Grendelmeier, P.] Univ Hosp Zurich, Dept Dermatol, Allergy Unit, Zurich, Switzerland; [Serpa, F. S.] Asthma Reference Ctr, Escola Super Ciencias Santa Casa Misericordia Vit, Santo, Brazil; [Sheikh, A.] Univ Edinburgh, Allergy & Resp Res Grp, Ctr Populat Hlth Sci, Sch Med, Edinburgh, Midlothian, Scotland; [Simons, F. E. R.] Univ Manitoba, Dept Pediat & Child Hlth, Dept Immunol, Fac Med, Winnipeg, MB, Canada; [Siroux, V.] Univ Grenoble Alpes, Univ Joseph Fourier, Team Environm Epidemiol Appl Reprod & Resp Hlth, INSERM,IAB,U 1209, Grenoble, France; [Sisul, J. C.] Sociedad Paraguaya Alergia Asma & Inmunol, Asuncion, Paraguay; [Sole, D.] Univ Fed Sao Paulo, Div Allergy Clin Immunol & Rheumatol, Dept Pediat, Sao Paulo, Brazil; [Somekh, D.] European Hlth Futures Forum EHFF, Isle Of Wright, England; [Sondermann, M.] ENT, Aachen, Germany; [Sooronbaev, T.] Kyrgyzstan Natl Ctr Cardiol & Internal Med, Euro Asian Resp Soc, Bishkek, Kyrgyzstan; [Sova, M.] Univ Hosp Olomouc, Olomouc, Czech Republic; [Sorensen, M.] Univ Hosp North Norway, Dept Paediat & Adolescent Med, Tromso, Norway; [Sorensen, M.] UiT Arctic Univ Norway, Paediat Res Grp, Dept Clin Med, Fac Hlth Sci, Tromso, Norway; [Sorlini, M.] IML Lombardy Med Initiat, Bergamo, Italy; [Stelmach, R.] Univ Sao Paulo, Heart Inst InCor, Hosp Clin, Div Pulm,Fac Med, Sao Paulo, Brazil; [Stukas, R.] Vilnius Univ, Publ Hlth Inst, Vilnius, Lithuania; [Tebyrica, J. N.] Univ Fed Estado Rio de Janeiro, Rio De Janeiro, Brazil; [Thibaudon, M.] RNSA Reseau Natl Surveillance Aerobiol, Brussieu, France; [To, T.] Univ Toronto, Dalla Lana Sch Publ Hlth, Hosp Sick Children, Toronto, ON, Canada; Univ Coimbra, Ctr Hosp Univ Coimbra, Imunoalergol, Coimbra, Portugal; Univ Coimbra, Fac Med, Coimbra, Portugal; [Tomazic, P. V.] Med Univ Graz, Dept ENT, Graz, Austria; [Trama, U.] Div Pharm & Devices Policy, Naples, Campania Region, Italy; [Ulrik, C. Suppli] Hvidovre Univ Hosp, Dept Resp Med, Copenhagen, Denmark; [Ulrik, C. Suppli] Univ Copenhagen, Copenhagen, Denmark; [Urrutia-Pereira, M.] Univ Fed Pampas, Uruguaiana, Brazil; [Valenta, R.] Med Univ Vienna, Div Immunopathol, Dept Pathophysiol & Allergy Res, Ctr Pathophysiol Infectiol & Immunol, Vienna, Austria; [Valero, A.] Univ Barcelona, Pneumol & Allergy Dept CIBERES & Clin Expt Resp I, IDIBAPS, Barcelona, Spain; [Valiulis, A.] Vilnius Univ, Inst Clin Med, Clin Childrens Dis, Vilnius, Lithuania; [Valiulis, A.] Vilnius Univ, Inst Hlth Sci, Dept Publ Hlth, Vilnius, Lithuania; [Valiulis, A.] European Acad Paediat EAP UEMS SP, Brussels, Belgium; [Valovirta, E.] Univ Turku, Dept Lung Dis & Clin Immunol Allergol, Turku, Finland; [Valovirta, E.] Terveystalo Allergy Clin, Turku, Finland; [van Ganse, E.] Univ Claude Bernard, HESPER 7425, Hlth Serv & Performance Res, PELyon, Lyon, France; [van Hague, M.] Karolinska Inst, Dept Med Solna, Immunol & Allergy Unit, Stockholm, Sweden; [van Hague, M.] Univ Hosp, Stockholm, Sweden; [Vandenplas, O.] Catholic Univ Louvain, Dept Chest Med, Ctr Hosp Univ UCL Namur, Yvoir, Belgium; [Ventura, M. T.] Univ Bari, Unit Geriatr Immunoallergol, Med Sch, Bari, Italy; [Vezzani, G.] Arcispedale SMaria Nuova IRCCS, Dept Med Specialties, Pulm Unit, AUSL Reggio Emilia, Rome, Italy; [Vasankari, T.] finnish Lung Assoc, FILHA, Helsinki, Finland; [Viegi, M.] CNR, Pulm Environm Epidemiol Unit, Inst Clin Physiol, Pisa, Italy; [Viegi, M.] CNR, Inst Biomed & Mol Immunol A Monroy, Palermo, Italy; [Vicheva, D.] Med Univ, Plovdiv, Bulgaria; [Vicheva, D.] Dept Otorhinolaryngol, Plovdiv, Bulgaria; [Vontetsianos, T.] Sotiria Hosp, Athens, Greece; [Wagenmann, M.] Univ Klinikum Dusseldorf, Dept Otorhinolaryngol, Dusseldorf, Germany; [Walker, S.] Asthma UK, Mansell St, London, England; [Wallace, D.] Nova Southeastern Univ, Ft Lauderdale, FL USA; [Wang, D. Y.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Otolaryngol, Singapore, Singapore; [Waserman, S.] McMaster Univ, Dept Med Clin Immunol & Allergy, Hamilton, ON, Canada; [Werfel, T.] Hannover Med Sch, Div Immunodermatol & Allergy Res, Dept Dermatol & Allergy, Hannover, Germany; [Westman, M.] Karolinska Inst, Dept Med Solna, Immunol & Allergy Unit, Stockholm, Sweden; [Westman, M.] Karolinska Univ Hosp, Dept ENT Dis, Stockholm, Sweden; [Williams, D. M.] Univ N Carolina, Eshelman Sch Pharm, Chapel Hill, NC USA; [Williams, S.] Int Primary Care Resp Grp, Aberdeen, Scotland; [Wright, J.] Bradford Inst Hlth Res, Bradford Royal Infirm, Bradford, W Yorkshire, England; [Yakovliev, P.] Thracian Univ, Med Fac, Med Coll, Stara Zagora, Bulgaria; [Yawn, B. P.] Olmsted Med Ctr, Dept Res, Rochester, MN USA; [Yiallouros, P. K.] Cyprus Univ Technol, Harvard Sch Publ Hlth, Cyprus Int Inst Environm Publ Hlth Assoc, Limassol, Cyprus; [Yiallouros, P. K.] Hosp Archbishop Makarios III, Dept Pediat, Nicosia, Cyprus; [Yorgancioglu, A.] Celal Bayar Univ, Dept Pulmonol, Manisa, Turkey; [Yusuf, O. M.] Allergy & Asthma Inst, Islamabad, Pakistan; [Zar, H. J.] Univ Cape Town, Dept Paediat & Child Hlth, Red Cross Childrens Hosp, Cape Town, South Africa; [Zar, H. J.] Univ Cape Town, MRC Unit Child & Adolescent Hlth, Cape Town, South Africa; [Zhang, L.] Beijing TongRen Hosp, Dept Otolaryngol Head & Neck Surg, Beijing, Peoples R China; [Zhang, L.] Beijing Inst Otolaryngol, Beijing, Peoples R China; [Zernotti, M. E.] Univ Catolica Cordoba, Cordoba, Argentina; [Zidarn, M.] Univ Clin Resp & Allerg Dis, Golnik, Slovenia; [Zurkuhlen, A.] Gesundheitsreg KolnBonn HRCB Projekt GmbH, Cologne, Germany; [Skrindo, I.] Akershus Univ Hosp, Dept Otorhinolaryngol, Akershus, Norway; [Wilson, N.] Northern Hlth Sci Alliance, Manchester, Lancs, England; [Wilson, N.] No Hlth Matters Ltd, Manchester, Lancs, England	Universite de Montpellier; CHU de Montpellier; Universite de Montpellier; UDICE-French Research Universities; Universite Paris Saclay; KU Leuven; Transylvania University of Brasov; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; ISGlobal; Pompeu Fabra University; Institut Hospital del Mar d'Investigacions Mediques (IMIM); CIBER - Centro de Investigacion Biomedica en Red; CIBERESP; Pompeu Fabra University; Ghent University; Ghent University Hospital; University of Cape Town; University of Southern Denmark; Odense University Hospital; University of Sydney; Woolcock Institute of Medical Research; University of Sydney; Woolcock Institute of Medical Research; McMaster University; University of Turin; A.O.U. Citta della Salute e della Scienza di Torino; AOU San Giovanni Battista-Molinette; Humanitas University; Hospital Universitari Vall d'Hebron; State University System of Florida; University of South Florida; Leiden University; Leiden University Medical Center (LUMC); Universidade do Minho; Universidade do Porto; Universidade Federal da Bahia; University of Salerno; Universite de Montpellier; CHU de Montpellier; Hospital Foch; UDICE-French Research Universities; Universite Paris Saclay; Universite de Franche-Comte; Egyptian Knowledge Bank (EKB); Ain Shams University; Universidade do Porto; University of Amsterdam; Academic Medical Center Amsterdam; Universidad de Chile; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Armand-Trousseau - APHP; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite; Poltava State Medical University; NRC Institute of Immunology FMBA of Russia; Hacettepe University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Wurzburg; Medical University Lodz; Medical University Lodz; Vilnius University; Hochiminh City University of Medicine & Pharmacy; University of Oslo; University of Oslo; Universidade da Beira Interior; Universidade da Beira Interior; University of Naples Federico II; Clinical Centre of Serbia; University of Belgrade; University of Cologne; University of Barcelona; CIBER - Centro de Investigacion Biomedica en Red; CIBERES; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Johns Hopkins University; Johns Hopkins Medicine; University of Naples Federico II; Florey Institute of Neuroscience & Mental Health; Monash University; Monash University; Monash University; Chiba University; Nippon Medical School; Charles University Prague; Royal Manchester Children's Hospital; University of Manchester; National & Kapodistrian University of Athens; Ajou University; Nippon Medical School; Ruprecht Karls University Heidelberg; University of JJ Strossmayer Osijek; Medical University Sofia; University of Cape Town; University of Crete; Emek Medical Center; University of Edinburgh; Medical University of Warsaw; University of Edinburgh; Karolinska Institutet; Karolinska University Hospital; Universidade de Coimbra; Centro Hospitalar e Universitario de Coimbra (CHUC); Universidade de Coimbra; Medical University of Graz; CIBER - Centro de Investigacion Biomedica en Red; CIBERES; University of Barcelona; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Vilnius University; Vilnius University; University of Turku; Universita degli Studi di Bari Aldo Moro; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf Hospital; National University of Singapore; Nova Southeastern University; McMaster University; Uppsala University; Celal Bayar University; Capital Medical University; Guangzhou Medical University; State Key Laboratory of Respiratory Disease; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Universite de Montpellier; CHU de Montpellier; Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay; KU Leuven; Medical University of Graz; Transylvania University of Brasov; Swiss Institute of Allergy & Asthma Research; University of Zurich; Universidade do Porto; UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; ISGlobal; Pompeu Fabra University; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; CIBER - Centro de Investigacion Biomedica en Red; CIBERESP; Pompeu Fabra University; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Ghent University; Ghent University Hospital; Humanitas University; Universidade de Lisboa; University of Palermo; Universidade do Estado do Para (UEPA); University of Cape Town; Universita di Modena e Reggio Emilia; University of Amsterdam; Academic Medical Center Amsterdam; Berlin Institute of Health; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Medical University of Warsaw; University of Bonn; Medical University of Warsaw; University of Southern Denmark; Odense University Hospital; Lund University; Skane University Hospital; Universite de Montpellier; CHU de Montpellier; Universite de Montpellier; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; Medical University Lodz; University of Verona; Azienda Ospedaliera Universitaria Integrata Verona; Sapienza University Rome; Universita della Campania Vanvitelli; Consiglio Nazionale delle Ricerche (CNR); University of Sydney; Woolcock Institute of Medical Research; Laval University; Laval University; Quebec Heart & Lung Institute; CH de Valenciennes; Lithuanian University of Health Sciences; University Hospitals of Leicester NHS Trust; University of Leicester; University of Leicester; McMaster University; A.O.U. Citta della Salute e della Scienza di Torino; Johannes Gutenberg University of Mainz; Victor Babes University of Medicine & Pharmacy, Timisoara; Tecnologico de Monterrey; Imperial College London; Royal Brompton Hospital; CHU Clermont Ferrand; Universite Clermont Auvergne (UCA); Universite de Montpellier; CHU de Montpellier; Imperial College London; Royal Brompton Hospital; Universidade Federal de Minas Gerais; Hospital Universitari Vall d'Hebron; University of Oslo; University of Oslo; Centro Hospitalar de Lisboa Central, EPE; Universidade de Lisboa; State University System of Florida; University of South Florida; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Capital Institute of Pediatrics (CIP); San Pablo CEU University; Imperial College London; Eskisehir Osmangazi University; University of Genoa; Universidade Federal da Bahia; Nantes Universite; CHU de Nantes; Universidade do Minho; Universidade do Porto; IMT - Institut Mines-Telecom; IMT Mines Ales; Universite de Montpellier; Nova Southeastern University; Universidade Federal da Bahia; University of Manchester; Wythenshawe Hospital NHS Foundation Trust; Karolinska Institutet; Universidade Federal de Santa Catarina (UFSC); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier; Technical University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich; CHU Strasbourg; University of Salerno; Iuliu Hatieganu University of Medicine & Pharmacy; McMaster University; Hospital Foch; UDICE-French Research Universities; Universite Paris Saclay; CHU de Toulouse; Vilnius University; Imperial College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Saint Louis University; Egyptian Knowledge Bank (EKB); Ain Shams University; Umea University; Vilnius University; Universidade de Sao Paulo; University of Amsterdam; Academic Medical Center Amsterdam; Universidade do Porto; National Center for Disease Control & Public Health - Georgia; Istanbul University; Istanbul University - Cerrahpasa; Medical University Sofia; Erasmus University Rotterdam; Erasmus MC; Universidad Autonoma de Nuevo Leon; University Hospital Autonomous University of Nuevo Leon; Erasmus University Rotterdam; University Hospital Olomouc; Universidad de Chile; University of Helsinki; Helsinki University Central Hospital; Universidad Autonoma de Baja California; University College Cork; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; University of Salerno; Fahrenheit Universities; Medical University Gdansk; Imperial College London; Imperial College London; University of London; King's College London; Ghent University; Ghent University Hospital; Hallym University; Wroclaw Medical University; Poltava State Medical University; Hacettepe University; Hacettepe University; Tampere University; Tampere University Hospital; Medical University Lodz; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Wurzburg; McMaster University; University of Manitoba; Children's Hospital Research Institute of Manitoba; NRC Institute of Immunology FMBA of Russia; Medical University Lodz; University of Helsinki; Sodersjukhuset Hospital; Sodersjukhuset Hospital; Vilnius University; Medical University of Warsaw; Hochiminh City University of Medicine & Pharmacy; Universidade Federal da Bahia; Guangzhou Medical University; State Key Laboratory of Respiratory Disease; University of Dundee; University of Oslo; University of Oslo; University of Liege; Universidade da Beira Interior; Universidade da Beira Interior; Universidad de Guadalajara; Biomax Informatics; Comenius University Bratislava; Universidade de Coimbra; Royal College of Surgeons - Ireland; University of Mississippi; University of Mississippi Medical Center; Instituto Mexicano del Seguro Social; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Sodersjukhuset Hospital; Karolinska Institutet; University of Naples Federico II; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier; "Marius Nasta" Pneumophtisiology Institute; "Marius Nasta" Pneumophtisiology Institute; Clinical Centre of Serbia; University of Belgrade; UDICE-French Research Universities; Universite Paris Cite; University of Malta; University of Turin; A.O.U. Citta della Salute e della Scienza di Torino; AOU San Giovanni Battista-Molinette; Universidade de Sao Paulo; University of Cologne; Universidade de Coimbra; Universidade Federal da Bahia; University of Barcelona; Hospital Clinic de Barcelona; University of Padua; Azienda Ospedaliera - Universita di Padova; Johns Hopkins University; Johns Hopkins Medicine; Pirogov Russian National Research Medical University; Medical University of Vienna; Hospital Universitari i Politecnic La Fe; Universidade do Porto; Sao Joao Hospital; University of Naples Federico II; Monash University; Monash University; Chiba University; Nippon Medical School; University of Veterinary Medicine Vienna; Charles University Prague; Charles University Prague; Royal Manchester Children's Hospital; University of Manchester; National & Kapodistrian University of Athens; Ajou University; University of Ferrara; University of Genoa; Nippon Medical School; University of Southern Denmark; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Universidade do Porto; Universidade do Porto; Ruprecht Karls University Heidelberg; University of Cyprus; University of JJ Strossmayer Osijek; Hietzing Hospital; Medical University Sofia; University of Cape Town; University of Aberdeen; University of Crete; Grosshansdorf Hospital; University of Kiel; Karolinska Institutet; Karolinska University Hospital; St Vincents Hospital Sydney; University of Sydney; Universidade Federal de Sao Paulo (UNIFESP); Universidade de Coimbra; Centro Hospitalar e Universitario de Coimbra (CHUC); University of Valencia; Hospital Universitario de Getafe; Universidade Federal do Rio de Janeiro; Atencio Primaria de Mallorca; Institut Investigacio Sanitaria Illes Balears (IdISBa); Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; IRCCS Oasi Maria SS; Medical University of Graz; Emek Medical Center; University of Edinburgh; Showa University; University of London; University College London; University of Palermo; University of Zurich; University Zurich Hospital; Escola Superior de Ciencias da Santa Casa de Misericordia de Vitoria; University of Edinburgh; University of Manitoba; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Universidade Federal de Sao Paulo (UNIFESP); University Hospital Olomouc; UiT The Arctic University of Tromso; University Hospital of North Norway; UiT The Arctic University of Tromso; Universidade de Sao Paulo; Vilnius University; Universidade Federal do Estado do Rio de Janeiro; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Universidade de Coimbra; Centro Hospitalar e Universitario de Coimbra (CHUC); Universidade de Coimbra; Medical University of Graz; University of Copenhagen; University of Copenhagen; Universidade Federal do Pampa; Medical University of Vienna; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Vilnius University; Vilnius University; University of Turku; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Karolinska Institutet; Universite Catholique Louvain; Universita degli Studi di Bari Aldo Moro; IRCCS Arcispedale S. Maria Nuova; Consiglio Nazionale delle Ricerche (CNR); Istituto di Fisiologia Clinica (IFC-CNR); Consiglio Nazionale delle Ricerche (CNR); Istituto di Biomedicina e di Immunologia Molecolare "Alberto Monroy" (IBIM-CNR); Medical University Plovdiv; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf Hospital; Nova Southeastern University; National University of Singapore; McMaster University; Hannover Medical School; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; University of North Carolina; University of North Carolina Chapel Hill; Bradford Royal Infirmary; Trakia University; Olmsted Medical Center; Cyprus International Institute for Environmental & Public Health; Cyprus University of Technology; Celal Bayar University; University of Cape Town; University of Cape Town; Capital Medical University; Catholic University of Cordoba; University of Oslo	Bousquet, J (corresponding author), Univ Hosp, Montpellier, France.		Annesi-Maesano, Isabella/D-9173-2016; Martins, Pedro/A-1433-2011; Namazova-Baranova, Leyla/C-9485-2019; Almeida, Rute/Q-1621-2019; Maurer, Marcus/ABG-2174-2020; Akdis, Cezmi/AAV-4844-2020; Marshall, Gailen D./R-7459-2019; Christoff, George/ABF-9789-2021; stelmach, rafael/AAH-1638-2019; Yorgancioglu, Arzu/AAC-7548-2020; Blain, Hubert/AAZ-8017-2020; Todo Bom, Ana/AHD-3630-2022; Rizzo, Maria/HGD-6576-2022; Park, Hae-Sim/S-7974-2019; Humbert, Marc/ABD-5112-2021; O'Hehir, Robyn E/H-3627-2011; N.G., Papadopoulos/L-8670-2013; Popov, Todor/Q-9928-2016; Papi, alberto/AAC-1888-2019; Solé, Dirceu/D-7789-2013; Amat, Flore/GPF-4655-2022; Cox, Linda/AAP-1697-2021; Gemicioglu, Bilun/AAH-6927-2019; Humbert, Marc/AAC-8459-2019; Rabe, Klaus F./AAW-6296-2021; Werfel, Thomas/B-6921-2012; Mayora Ibarra, Oscar/GRS-2566-2022; Asarnoj, Anna/ABC-4112-2020; PIN, Isabelle/N-3020-2013; Gotua, Maia/ABA-1648-2021; Bousquet, Jean/O-4221-2019; Jung, Ki-Suck/AAN-2473-2021; Chung, Kian Fan/B-1872-2012; Caimmi, Davide/AAA-1277-2019; Bindslev-Jensen, Carsten/H-1877-2011; Kaidashev, Igor/L-2606-2019; Bachert, Claus/J-8825-2012; Ivancevich, Juan Carlos/AAB-4937-2020; Demoly, Pascal/Y-9938-2019; Briedis, Vitalis/AAY-9241-2020; Barbara, C./AAF-3397-2020; Lourenço, Olga/S-6233-2016; Serpa, Faradiba Sarquis/AAC-8477-2021; Johnston, Sebastian Lennox/I-2423-2012; Bergmann, Karl-Christian/AAA-4104-2019; brussino, luisa/J-2486-2012; Emilie, Burte/AAA-5048-2022; Toppila-Salmi, Sanna/ABF-5840-2020; Anto, J M/H-2676-2014; Cingi, Cemal/AAA-1951-2021; Sova, Milan/AAH-3802-2020; Fiocchi, Alessandro/K-9235-2016; BARBAGALLO, MARIO/K-4794-2017; Lipiec, Agnieszka/X-7523-2018; Nadif, Rachel/R-2876-2016; braido, fulvio/C-5320-2012; Kvedarienė, Violeta/GON-7937-2022; Chavannes, Niels/F-1148-2011; Lessa, Marcus Miranda/AAV-8573-2021; Vicheva, Dilyana/AAI-7136-2020; Rizzo, Jose A/M-4322-2014; Bonini, Sergio/T-6594-2019; MAGNAN, ANTOINE/GVT-4308-2022; IACCARINO, Guido/A-7702-2010; Sunyer, Jordi/G-6909-2014; Martins, Pedro/GWC-7702-2022; Fokkens, Wytske WJ/ABF-2185-2020; J, Garcia-Aymerich/G-6867-2014; Pereira, Ana Margarida/K-3343-2014; Namazova-Baranova, Leyla/HDN-1442-2022; Khaitov, Musa/AAC-1516-2021; Agache, Ioana/AAP-7403-2020; Iaccarino, Guido/D-4540-2009; Cardona, Victoria/GRX-4196-2022; Rigla, Francisco Ródenas/L-5293-2014; Wright, John/H-1624-2012; Bonini, Matteo/AAB-1093-2019; Rodó, Xavier/F-7663-2017; Basagaña, Xavier/C-3901-2017; de Sousa, Jaime Correia/H-5607-2015; Ciprandi, Giorgio/G-7462-2012; Fonseca, João A./B-7562-2008; Constantinos, Pitsios/AFQ-0259-2022; Farsi, Alessandro/GPG-0010-2022; Yiallouros, Panayiotis/AAF-6026-2019; Bosnic-Anticevich, Sinthia/AAD-2526-2021; Dray, Gerard/ACO-1836-2022; Zar, Heather/GZL-5350-2022; Triggiani, Massimo/K-8271-2016; Romano, Antonino/D-3102-2017; Yusuf, M Osman/AAI-1142-2020; Barreto, Bruno/T-9252-2019; Mota-Pinto, Anabela/M-1523-2013; Custovic, Adnan/A-2435-2012; Pugin, Benoit/X-2984-2018; Guldemond, Nick/AAS-7755-2020; Khaitov, Musa R/L-3369-2017; Stellato, Cristiana/P-3001-2015; Ryan, Dermot/AAJ-2329-2021; Plavec, Davor/J-1515-2019; canonica, giorgio walter/ABF-2037-2020; Vatrella, Alessandro/K-8001-2016; Luna-Pech, Jorge A./F-8817-2019; Nogueira-Silva, Luis/M-3474-2014; Gonzalez-Diaz, Sandra Nora/H-3271-2018; Costa, Elisio/K-1990-2013; Panzner, Petr/I-7034-2017; Mashiya, Nombeko Monica/AET-3950-2022; Namazova-Baranova, Leyla/C-9485-2019; Blasi, Francesco/O-5885-2017; Malva, Joao/L-3557-2014	Annesi-Maesano, Isabella/0000-0002-6340-9300; Martins, Pedro/0000-0002-4129-133X; Namazova-Baranova, Leyla/0000-0002-2209-7531; Almeida, Rute/0000-0001-7755-5002; Maurer, Marcus/0000-0002-4121-481X; Akdis, Cezmi/0000-0001-8020-019X; stelmach, rafael/0000-0002-5132-1934; O'Hehir, Robyn E/0000-0002-3489-7595; N.G., Papadopoulos/0000-0002-4448-3468; Popov, Todor/0000-0001-5052-5866; Cox, Linda/0000-0002-5258-6870; Gemicioglu, Bilun/0000-0001-5953-4881; Humbert, Marc/0000-0003-0703-2892; Rabe, Klaus F./0000-0002-7020-1401; Chung, Kian Fan/0000-0001-7101-1426; Caimmi, Davide/0000-0003-4481-6194; Bindslev-Jensen, Carsten/0000-0002-8940-038X; Kaidashev, Igor/0000-0002-4708-0859; Demoly, Pascal/0000-0001-7827-7964; Briedis, Vitalis/0000-0002-5106-6638; Barbara, C./0000-0003-0915-4105; Lourenço, Olga/0000-0002-8401-5976; Johnston, Sebastian Lennox/0000-0003-3009-9200; brussino, luisa/0000-0001-7249-7616; Toppila-Salmi, Sanna/0000-0003-0890-6686; Anto, J M/0000-0002-4736-8529; Sova, Milan/0000-0002-8542-7841; Fiocchi, Alessandro/0000-0002-2549-0523; BARBAGALLO, MARIO/0000-0002-1349-6530; Lipiec, Agnieszka/0000-0003-3037-2326; Nadif, Rachel/0000-0003-4938-9339; braido, fulvio/0000-0003-2460-4709; Kvedarienė, Violeta/0000-0002-6119-211X; Chavannes, Niels/0000-0002-8607-9199; Lessa, Marcus Miranda/0000-0002-5003-0828; Vicheva, Dilyana/0000-0002-6805-3825; Rizzo, Jose A/0000-0002-6876-3122; Bonini, Sergio/0000-0003-0079-3031; IACCARINO, Guido/0000-0002-8997-835X; Sunyer, Jordi/0000-0002-2602-4110; J, Garcia-Aymerich/0000-0002-7097-4586; Pereira, Ana Margarida/0000-0002-5468-0932; Khaitov, Musa/0000-0003-4961-9640; Iaccarino, Guido/0000-0002-8997-835X; Rigla, Francisco Ródenas/0000-0003-3264-4735; Wright, John/0000-0001-9572-7293; Rodó, Xavier/0000-0003-4843-6180; Basagaña, Xavier/0000-0002-8457-1489; de Sousa, Jaime Correia/0000-0001-6459-7908; Ciprandi, Giorgio/0000-0001-7016-8421; Fonseca, João A./0000-0002-0887-8796; Bosnic-Anticevich, Sinthia/0000-0001-5077-8329; Zar, Heather/0000-0002-9046-759X; Triggiani, Massimo/0000-0001-7318-2093; Romano, Antonino/0000-0001-9742-9898; Yusuf, M Osman/0000-0002-8067-1204; Mota-Pinto, Anabela/0000-0002-0820-9568; Custovic, Adnan/0000-0001-5218-7071; Pugin, Benoit/0000-0001-7132-9477; Khaitov, Musa R/0000-0003-4961-9640; Stellato, Cristiana/0000-0002-1294-8355; Ryan, Dermot/0000-0002-4115-7376; Plavec, Davor/0000-0003-2020-8119; canonica, giorgio walter/0000-0001-8467-2557; Zhang, Luo/0000-0002-0910-9884; Vatrella, Alessandro/0000-0001-8265-3037; Cecchi, Lorenzo/0000-0002-0658-2449; yorgancioglu, arzu/0000-0002-4032-0944; Bousquet, Jean/0000-0002-4061-4766; VENTURA, Maria Teresa/0000-0002-2637-4583; Luna-Pech, Jorge A./0000-0001-6278-964X; Pepin, Jean Louis/0000-0003-3832-2358; Farsi, Alessandro/0000-0001-6036-9094; GALVEZ ROMERO, JOSE LUIS/0000-0002-6560-3596; Dray, Gerard/0000-0003-1525-5682; Park, Hae-Sim/0000-0003-2614-0303; Verissimo, Manuel/0000-0002-2793-2129; Cardona, Victoria/0000-0003-2197-9767; Monti, Riccardo/0000-0002-1003-3629; Nogueira-Silva, Luis/0000-0002-5519-707X; Valenta, Rudolf/0000-0001-5944-3365; Stukas, Rimantas/0000-0002-4591-5891; Ivancevich, Juan Carlos/0000-0001-8713-6258; Larenas Linnemann, Desiree/0000-0002-5713-5331; Gonzalez-Diaz, Sandra Nora/0000-0002-3612-0042; Schunemann, Holger/0000-0003-3211-8479; Lacwik, Piotr/0000-0001-7020-0719; Bialek, Slawomir/0000-0002-0112-6786; Onorato, Gabrielle Laura/0000-0002-7867-5345; Asarnoj, Anna/0000-0002-0797-2369; Zidarn, Mihaela/0000-0003-0515-5207; Costa, Elisio/0000-0003-1158-1480; Panzner, Petr/0000-0002-1291-450X; momas, isabelle/0000-0003-4344-3787; El-Gamal, Yehia/0000-0002-8177-4520; Mayora Ibarra, Oscar/0000-0002-5773-3876; Reitsma, Sietze/0000-0003-1734-2632; Du Toit, George/0000-0002-0321-2928; Raciborski, Filip/0000-0003-0562-0260; Zuberbier, Torsten/0000-0002-1466-8875; Kuna, Piotr/0000-0003-2401-0070; Sheikh, Aziz/0000-0001-7022-3056; Dauvilliers, yves/0000-0003-0683-6506; Gotua, Maia/0000-0003-2497-4128; menditto, enrica/0000-0001-8633-5650; Mashiya, Nombeko Monica/0000-0003-0124-9118; Namazova-Baranova, Leyla/0000-0002-7902-6427; Blasi, Francesco/0000-0002-2285-9970; Pitsios, Constantinos/0000-0001-8935-278X; Nalin, Marco/0000-0002-9957-3225; Malva, Joao/0000-0002-5438-4447; brightling, chris/0000-0002-9345-4903; orlando, valentina/0000-0002-8209-8878	European Innovation Partnership on Active and Healthy Ageing; POLLAR (EIT Health, European Union)	European Innovation Partnership on Active and Healthy Ageing; POLLAR (EIT Health, European Union)	Supported by the European Innovation Partnership on Active and Healthy Ageing and POLLAR (EIT Health, European Union).	Agency for Healthcare Research and Quality, 2020, CAHPS AMB CAR IMPR G; Aguilar D, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179125; Anto JM, 2017, J ALLERGY CLIN IMMUN, V139, P388, DOI 10.1016/j.jaci.2016.12.940; Antwi M, CHANGE MANAGEMENT HE; Barry MJ, 2012, NEW ENGL J MED, V366, P780, DOI 10.1056/NEJMp1109283; Bateman ED, 2008, EUR RESPIR J, V31, P143, DOI 10.1183/09031936.00138707; Bourret Rodolphe, 2015, World Hosp Health Serv, V51, P36; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Bousquet J, 2007, ALLERGY, V62, P216, DOI 10.1111/j.1398-9995.2007.01307.x; Bousquet J, 2018, ALLERGY, V73, P1622, DOI 10.1111/all.13448; Bousquet J, 2018, ALLERGY, V73, P1763, DOI 10.1111/all.13406; Bousquet J, 2018, J INVEST ALLERG CLIN, V28, P42, DOI 10.18176/jiaci.0197; Bousquet J, 2018, ALLERGY, V73, P505, DOI 10.1111/all.13307; Bousquet J, 2018, ALLERGY, V73, P77, DOI 10.1111/all.13218; Bousquet J, 2017, CLIN TRANSL ALLERGY, V7, DOI 10.1186/s13601-017-0173-8; Bousquet J, 2017, ALLERGY, V72, P1475, DOI 10.1111/all.13177; Bousquet J, 2017, ALLERGY, V72, P857, DOI 10.1111/all.13125; Bousquet J, 2016, CLIN TRANSL ALLERGY, V6, DOI 10.1186/s13601-016-0137-4; Bousquet J, 2017, J NUTR HEALTH AGING, V21, P92, DOI 10.1007/s12603-016-0803-1; Bousquet J, 2016, CLIN TRANSL ALLERGY, V6, DOI 10.1186/s13601-016-0116-9; Bousquet J, 2015, ALLERGY, V70, P1372, DOI 10.1111/all.12686; Bousquet J, 2015, ALLERGY, V70, P1062, DOI 10.1111/all.12637; Bousquet J, 2015, THORAX, V70, P595, DOI 10.1136/thoraxjnl-2014-206304; Bousquet J, 2014, EUR GERIATR MED, V5, P361, DOI 10.1016/j.eurger.2014.09.010; Bousquet J, 2014, EUR RESPIR J, V44, P304, DOI 10.1183/09031936.00014614; Bousquet J, 2012, J ALLERGY CLIN IMMUN, V130, P1049, DOI 10.1016/j.jaci.2012.07.053; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Bousquet J, 2016, J ALLERGY CLIN IMMUN, V138, P367, DOI 10.1016/j.jaci.2016.03.025; Bousquet J, 2016, EUR RESPIR J, V47, P1028, DOI 10.1183/13993003.01856-2015; Brozek JL, 2009, ALLERGY, V64, P669, DOI 10.1111/j.1398-9995.2009.01973.x; Brozek JL, 2017, J ALLERGY CLIN IMMUN, V140, P950, DOI 10.1016/j.jaci.2017.03.050; Brozek JL, 2010, J ALLERGY CLIN IMMUN, V126, P466, DOI 10.1016/j.jaci.2010.06.047; Burden Mel, 2016, Br J Nurs, V25, P949; Burte E, 2017, CLIN EXP ALLERGY, V47, P520, DOI 10.1111/cea.12897; Caimmi D, 2017, CLIN EXP ALLERGY, V47, P1526, DOI 10.1111/cea.13025; Carr WW, 2017, POSTGRAD MED, V129, P572, DOI 10.1080/00325481.2017.1333384; Chanez P, 1999, AM J RESP CRIT CARE, V159, P588, DOI 10.1164/ajrccm.159.2.9801022; Dykewicz MS, 2017, ANN ALLERG ASTHMA IM, V119, P489, DOI 10.1016/j.anai.2017.08.012; Florin J, 2008, J CLIN NURS, V17, P2935, DOI 10.1111/j.1365-2702.2008.02328.x; Fokkens WJ, 2012, RHINOLOGY, V50, P1, DOI 10.4193/Rhin20.600; Fromer LM, 2014, ALLERGY ASTHMA PROC, V35, P307, DOI 10.2500/aap.2014.35.3766; Guadagnoli E, 1998, SOC SCI MED, V47, P329, DOI 10.1016/S0277-9536(98)00059-8; Hellings PW, 2017, RHINOLOGY, V55, P202, DOI [10.4193/Rhino17.028, 10.4193/Rhin17.028]; Henry Laura S, 2017, Nurs Womens Health, V21, P372, DOI 10.1016/j.nwh.2017.07.007; Kew KM, 2017, COCHRANE DB SYST REV, V10, DOI DOI 10.1002/14651858.CD012330.PUB2; Kotter JP, 1996, LEADING CHANGE; Lewin K, 1943, PSYCHOL REV, V50, P292, DOI 10.1037/h0062738; Lewin K., 1943, FIELD THEORY SOCIAL; Leynaert B, 1999, J ALLERGY CLIN IMMUN, V104, P301, DOI 10.1016/S0091-6749(99)70370-2; Lippitt R., 1958, DYNAMICS PLANNED CHA; Lombardi Carlo, 2015, Asthma Res Pract, V1, P4; Mahmud AJ, 2013, BMC MED INFORM DECIS, V13, DOI 10.1186/1472-6947-13-17; Navarro AM, 2017, CLIN TRANSL ALLERGY, V7, DOI 10.1186/s13601-017-0150-2; Okubo K, 2017, ALLERGOL INT, V66, P205, DOI 10.1016/j.alit.2016.11.001; Onder G, 2015, EUR J INTERN MED, V26, P157, DOI 10.1016/j.ejim.2015.02.020; Padjas A, 2014, J ALLERGY CLIN IMMUN, V133, P777, DOI 10.1016/j.jaci.2013.08.029; Reddel HK, 2015, EUR RESPIR J, V46, P622, DOI 10.1183/13993003.00853-2015; Reddeman L, 2016, J ONCOL PRACT, V12, P81, DOI 10.1200/JOP.2015.006882; Rodriguez-Roisin R, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.00671-2017; Shekelle PG, 1999, BRIT MED J, V318, P593, DOI 10.1136/bmj.318.7183.593; Simons FER, 1999, J ALLERGY CLIN IMMUN, V104, P534, DOI 10.1016/S0091-6749(99)70320-9; Stoller JK, 2010, RESP CARE, V55, P749; Teixeira B, 2017, CAN PHARM J, V150, P198, DOI 10.1177/1715163517701470; Togias A, 2003, J ALLERGY CLIN IMMUN, V111, P1171, DOI 10.1067/mai.2003.1592; Toney-Butler, 2017, CHANGE MANAGEMENT; Vogelmeier CF, 2017, EUR RESPIR J, V49, DOI [10.1164/rccm.201701-0218PP, 10.1183/13993003.00214-2017, 10.1111/resp.13012, 10.1016/j.arbres.2017.02.001]; Wallace DV, 2017, CURR OPIN ALLERGY CL, V17, P286, DOI 10.1097/ACI.0000000000000375; Wustenberg E, 2017, ALLERGO J, V26, P14	68	77	84	7	133	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2019	143	3					864	879		10.1016/j.jaci.2018.08.049	http://dx.doi.org/10.1016/j.jaci.2018.08.049			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HN6CQ	30273709	Green Submitted, Green Published, Green Accepted, Bronze			2022-12-18	WOS:000460272900005
J	Hekking, PP; Loza, MJ; Pavlidis, S; de Meulder, B; Lefaudeux, D; Baribaud, F; Auffray, C; Wagener, AH; Brinkman, P; Lutter, R; Bansal, AT; Sousa, AR; Bates, SA; Pandis, Y; Fleming, LJ; Shaw, DE; Fowler, SJ; Guo, Y; Meiser, A; Sun, K; Corfield, J; Howarth, PH; Bel, EH; Adcock, IM; Chung, KF; Djukanovic, R; Sterk, PJ				Hekking, Pieter-Paul; Loza, Matt J.; Pavlidis, Stelios; de Meulder, Bertrand; Lefaudeux, Diane; Baribaud, Fred; Auffray, Charles; Wagener, Ariane H.; Brinkman, Paul; Lutter, Rene; Bansal, Aruna T.; Sousa, Ana R.; Bates, Steve A.; Pandis, Yannis; Fleming, Louise J.; Shaw, Dominique E.; Fowler, Stephen J.; Guo, Y.; Meiser, Andrea; Sun, Kai; Corfield, Julie; Howarth, Peter H.; Bel, Elisabeth H.; Adcock, Ian M.; Chung, Kian Fan; Djukanovic, Ratko; Sterk, Peter J.		U-BIOPRED Study Grp	Pathway discovery using transcriptomic profiles in adult-onset severe asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Adult-onset asthma; severe asthma; gene set variation analysis; phenotyping; transcriptomics; mechanisms; eosinophils; mast cells; ILC3	INNATE LYMPHOID-CELLS; EOSINOPHILIC ASTHMA; CLUSTER-ANALYSIS; GENE-EXPRESSION; PHENOTYPES; INFLAMMATION; QUESTIONNAIRE; DISEASE; MODEL; IL-33	Background: Adult-onset severe asthma is characterized by highly symptomatic disease despite high-intensity asthma treatments. Understanding of the underlying pathways of this heterogeneous disease is needed for the development of targeted treatments. Gene set variation analysis is a statistical technique used to identify gene profiles in heterogeneous samples. Objective: We sought to identify gene profiles associated with adult-onset severe asthma. Methods: This was a cross-sectional, observational study in which adult patients with adult-onset of asthma (defined as starting at age >= 18 years) as compared with childhood-onset severe asthma (<18 years) were selected from the U-BIOPRED cohort. Gene expression was assessed on the total RNA of induced sputum (n = 83), nasal brushings (n = 41), and endobronchial brushings (n = 65) and biopsies (n = 47) (Affymetrix HT HG-U1331+ PM). Gene set variation analysis was used to identify differentially enriched predefined gene signatures of leukocyte lineage, inflammatory and induced lung injury pathways. Results: Significant differentially enriched gene signatures in patients with adult-onset as compared with childhood-onset severe asthma were identified in nasal brushings (5 signatures), sputum (3 signatures), and endobronchial brushings (6 signatures). Signatures associated with eosinophilic airway inflammation, mast cells, and group 3 innate lymphoid cells were more enriched in adult-onset severe asthma, whereas signatures associated with induced lung injury were less enriched in adult-onset severe asthma. Conclusions: Adult-onset severe asthma is characterized by inflammatory pathways involving eosinophils, mast cells, and group 3 innate lymphoid cells. These pathways could represent useful targets for the treatment of adult-onset severe asthma.	[Hekking, Pieter-Paul; Wagener, Ariane H.; Brinkman, Paul; Bel, Elisabeth H.; Sterk, Peter J.] Acad Med Ctr, Resp Med, Amsterdam, Netherlands; [Loza, Matt J.; Baribaud, Fred] Johnson & Johnson, Janssen Res & Dev, Spring House, PA USA; [Pavlidis, Stelios; Pandis, Yannis; Fleming, Louise J.; Guo, Y.; Meiser, Andrea; Sun, Kai] Imperial Coll, Data Sci Inst, London, England; [de Meulder, Bertrand; Lefaudeux, Diane; Auffray, Charles] Univ Lyon, European Inst Syst Biol & Med, Lyon, France; [Bansal, Aruna T.] Acclarogen, Cambridge, England; [Sousa, Ana R.; Bates, Steve A.] GlaxoSmithKline, Discovery Med, Brentford, England; [Shaw, Dominique E.] Univ Nottingham, Resp Res Unit, Nottingham, England; [Fowler, Stephen J.] Univ Manchester, Ctr Resp Med & Allergy, Inst Inflammat & Repair, Manchester, Lancs, England; [Fowler, Stephen J.] Univ Hosp South Manchester, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England; [Corfield, Julie] Areteva, Nottingham, England; [Howarth, Peter H.; Djukanovic, Ratko] Univ Southampton, NIHR Southampton Ctr Biomed Res, Southampton, Hants, England; [Adcock, Ian M.; Chung, Kian Fan] Imperial Coll, Natl Heart & Lung Inst, London, England	University of Amsterdam; Academic Medical Center Amsterdam; Johnson & Johnson; Janssen Pharmaceuticals; Johnson & Johnson USA; Imperial College London; GlaxoSmithKline; University of Nottingham; University of Manchester; University of Manchester; Wythenshawe Hospital NHS Foundation Trust; University of Southampton; Imperial College London	Hekking, PP (corresponding author), Acad Med Ctr, Dept Resp Med, F5-260, NL-1105 AZ Amsterdam, Netherlands.	p.w.hekking@amc.uva.nl	Bisgaard, Hans/N-4761-2016; Sterk, P.J./AAK-8175-2020; Fleming, Louise/ABD-7452-2020; Brinkman, Paul/AAV-5110-2021; Adcock, Ian/L-3217-2019; Chung, Kian Fan/B-1872-2012; Caruso, Massimo/P-4161-2016; Musiał, Jacek/U-5930-2018	Bisgaard, Hans/0000-0003-4131-7592; Chung, Kian Fan/0000-0001-7101-1426; Caruso, Massimo/0000-0002-4412-2080; Musiał, Jacek/0000-0002-8994-0036; Singer, Florian/0000-0003-3471-5664; Brinkman, Paul/0000-0003-4546-8478; Fleming, Louise/0000-0002-7268-7433; Pahus, Laurie/0000-0002-5265-2874; Bonnelykke, Klaus/0000-0003-2003-1018; Hashimoto, Simone/0000-0001-8995-3817; Frey, Urs/0000-0003-3773-2822; Rowe, Anthony/0000-0003-1829-1179; Loza, Matthew/0000-0002-8609-118X; Murray, Clare/0000-0002-8961-8055; Fowler, Stephen/0000-0002-4524-1663; Howarth, Peter/0000-0003-0619-7927; Djukanovic, Ratko/0000-0001-6039-5612; chanez, pascal/0000-0003-4059-0917; Adcock, Ian/0000-0003-2101-8843	Innovative Medicines Initiative; European Federation of Pharmaceutical Industries and Associations; Medical Research Council [G1000758B, G1000758] Funding Source: researchfish; National Institute for Health Research [NF-SI-0514-10085] Funding Source: researchfish; Asthma UK [MRC-AsthmaUKCentre, MRC-Asthma UK Centre] Funding Source: researchfish	Innovative Medicines Initiative; European Federation of Pharmaceutical Industries and Associations; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR)); Asthma UK	U-BIOPRED was funded by a grant from the Innovative Medicines Initiative that was covered by the European Union and the European Federation of Pharmaceutical Industries and Associations.	Abbas AR, 2011, AM J PATHOL, V179, P1667, DOI 10.1016/j.ajpath.2011.06.009; Accordini S, 2013, INT ARCH ALLERGY IMM, V160, P93, DOI 10.1159/000338998; Amelink M, 2013, ALLERGY, V68, P674, DOI 10.1111/all.12136; Amelink M, 2012, CLIN EXP ALLERGY, V42, P769, DOI 10.1111/j.1365-2222.2012.03977.x; Amelink M, 2013, J ALLERGY CLIN IMMUN, V132, P336, DOI 10.1016/j.jaci.2013.04.052; Bel EH, 2014, NEW ENGL J MED, V371, P1189, DOI 10.1056/NEJMoa1403291; Bel EH, 2011, THORAX, V66, P910, DOI 10.1136/thx.2010.153643; Bernink JH, 2015, IMMUNITY, V43, P146, DOI 10.1016/j.immuni.2015.06.019; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; Choy DF, 2011, J IMMUNOL, V186, P1861, DOI 10.4049/jimmunol.1002568; Chung KF, 2016, J INTERN MED, V279, P192, DOI 10.1111/joim.12382; Chung KF, 2015, LANCET, V386, P1086, DOI 10.1016/S0140-6736(15)00157-9; Chung KF, 2014, EUR RESPIR J, V43, P343, DOI 10.1183/09031936.00202013; Dyer KD, 2013, IMMUNOL LETT, V150, P41, DOI 10.1016/j.imlet.2012.12.002; Folliet L, 2015, EUR RESPIR J, V46, DOI 10.1183/13993003.congress-2015.PA5009; Grainge CL, 2013, CHEST, V144, P1906, DOI 10.1378/chest.12-1944; Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7; Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI 10.1164/rccm.200711-1754OC; Harris P, 2013, MUCOSAL IMMUNOL, V6, P474, DOI 10.1038/mi.2012.86; Hekking PPW, 2015, J ALLERGY CLIN IMMUN, V135, P896, DOI 10.1016/j.jaci.2014.08.042; Hinks TSC, 2015, J ALLERGY CLIN IMMUN, V136, P323, DOI 10.1016/j.jaci.2015.01.014; Juniper EF, 2006, RESP MED, V100, P616, DOI 10.1016/j.rmed.2005.08.012; Juniper EF, 1999, CHEST, V115, P1265, DOI 10.1378/chest.115.5.1265; Junttila IS, 2013, J ALLERGY CLIN IMMUN, V132, P704, DOI 10.1016/j.jaci.2013.03.033; Kim SH, 2014, ALLERGY ASTHMA IMMUN, V6, P189, DOI 10.4168/aair.2014.6.3.189; Leaker BR, 2017, MUCOSAL IMMUNOL, V10, P408, DOI 10.1038/mi.2016.74; Lefaudeux D, 2017, J ALLERGY CLIN IMMUN, V139, P1797, DOI 10.1016/j.jaci.2016.08.048; Li R, 2015, INT J CLIN EXP MED, V8, P14935; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Miranda C, 2004, J ALLERGY CLIN IMMUN, V113, P101, DOI 10.1016/j.jaci.2003.10.041; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; Newby C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102987; Paggiaro PL, 2002, EUR RESPIR J, V20, p3S, DOI 10.1183/09031936.02.00000302; Parulekar AD, 2016, CURR OPIN PULM MED, V22, P59, DOI 10.1097/MCP.0000000000000231; Peng RQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059348; Robinette ML, 2015, NAT IMMUNOL, V16, P306, DOI 10.1038/ni.3094; Shaw DE, 2015, EUR RESPIR J, V46, P1308, DOI 10.1183/13993003.00779-2015; Shi LM, 2006, NAT BIOTECHNOL, V24, P1151, DOI 10.1038/nbt1239; Song WJ, 2016, CLIN EXP ALLERGY, V46, P411, DOI 10.1111/cea.12652; Spits H, 2013, NAT REV IMMUNOL, V13, P145, DOI 10.1038/nri3365; Wagener AH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080257; Wang G, 2016, EUR RESPIR J, V47, P1123, DOI 10.1183/13993003.01098-2015; Wenzel SE, 2007, AM J RESP CRIT CARE, V175, P570, DOI 10.1164/rccm.200607-909OC; Wenzel SE, 2006, LANCET, V368, P804, DOI 10.1016/S0140-6736(06)69290-8; Wenzel SE, 2012, NAT MED, V18, P716, DOI 10.1038/nm.2678; Woodruff PG, 2007, P NATL ACAD SCI USA, V104, P15858, DOI 10.1073/pnas.0707413104; Xue J, 2014, IMMUNITY, V40, P274, DOI 10.1016/j.immuni.2014.01.006	47	77	79	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2018	141	4					1280	1290		10.1016/j.jaci.2017.06.037	http://dx.doi.org/10.1016/j.jaci.2017.06.037			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GB6QV	28756296	Green Accepted, Green Submitted, Bronze			2022-12-18	WOS:000429197800014
J	Liu, WM; Liu, SC; Verma, M; Zafar, I; Good, JT; Rollins, D; Groshong, S; Gorska, MM; Martin, RJ; Alam, R				Liu, Weimin; Liu, Sucai; Verma, Mukesh; Zafar, Iram; Good, James T.; Rollins, Donald; Groshong, Stephen; Gorska, Magdalena M.; Martin, Richard J.; Alam, Rafeul			Mechanism of T(H)2/T(H)17-predominant and neutrophilic T(H)2/T(H)17-low subtypes of asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma endotype; T(H)2/T(H)17-predominant asthma; neutrophilic asthma; IL-1; C3a; infection	BRONCHOALVEOLAR LAVAGE FLUID; T-HELPER-CELLS; ALLERGIC-ASTHMA; REFRACTORY ASTHMA; INNATE IMMUNITY; URIC-ACID; INFLAMMATION; MICE; C3A; PHENOTYPES	Background: The mechanism of T(H)2/T(H)17-predominant and T(H)2/T(H)17-low asthma is unknown. Objective: We sought to study the immune mechanism of T(H)2/T(H)17-predominant and T(H)2/T(H)17-low asthma. Methods: In a previously reported cohort of 60 asthmatic patients, 16 patients were immunophenotyped withT(H)2/T(H)17-predominant asthma and 22 patients with T(H)2/T(H)17-low asthma. We examined bronchoalveolar lavage (BAL) fluid leukocytes, cytokines, mediators, and epithelial cell function for these asthma subgroups. Results: Patients with T(H)2/T(H)17-predominant asthma had increased IL-1 beta, IL-6, IL-23, C3a, and serum amyloid A levels in BAL fluid, and these correlated with IL-1 beta and C3a levels. T(H)2/T(H)17 cells expressed higher levels of the IL-1 receptor and phospho-p38 mitogen-activated protein kinase. Anakinra, an IL-1 receptor antagonist protein, inhibited BALT(H)2/T(H)17 cell counts. T(H)2/T(H)17-low asthma had 2 distinct subgroups: neutrophilic asthma (45%) and pauci-inflammatory asthma (55%). This contrasted with patients with T(H)2/T(H)17-predominant and T(H)2-predominant asthma, which included neutrophilic asthma in 6% and 0% of patients, respectively. BAL fluid neutrophils strongly correlated with BAL fluid myeloperoxidase, IL-8, IL-1a, IL-6, granulocyte colony-stimulating factor, and GM-CSF levels. Sixty percent of the patients with neutrophilic asthma had a pathogenic microorganism in BAL culture, which suggested a subclinical infection. Conclusion: We uncovered a critical role for the IL-1 beta pathway in patients with T(H)2/T(H)17-predminant asthma. A subgroup of patients with T(H)2/T(H)17-low asthma had neutrophilic asthma and increased BAL fluid IL-1 alpha, IL-6, IL-8, granulocyte colony-stimulating factor, and GM-CSF levels. IL-1 alpha was directly involved in IL-8 production and likely contributed to neutrophilic asthma. Sixty percent of neutrophilic patients had a subclinical infection.	[Liu, Weimin; Liu, Sucai; Verma, Mukesh; Zafar, Iram; Good, James T.; Rollins, Donald; Groshong, Stephen; Gorska, Magdalena M.; Martin, Richard J.; Alam, Rafeul] Univ Colorado Denver, Dept Med, Div Allergy & Immunol, Natl Jewish Hlth, Denver, CO USA; [Liu, Weimin; Liu, Sucai; Verma, Mukesh; Zafar, Iram; Good, James T.; Rollins, Donald; Groshong, Stephen; Gorska, Magdalena M.; Martin, Richard J.; Alam, Rafeul] Univ Colorado Denver, Div Pulm & Crit Care Med, Natl Jewish Hlth, Denver, CO USA; [Good, James T.; Rollins, Donald; Groshong, Stephen; Gorska, Magdalena M.; Martin, Richard J.; Alam, Rafeul] Univ Colorado Denver, Sch Med, Denver, CO USA	Children's Hospital Colorado; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Children's Hospital Colorado; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Alam, R (corresponding author), Natl Jewish Hlth, Dept Med, 1400 Jackson St, Denver, CO 80206 USA.	alamr@njhealth.org	verma, mukesh/AAB-9330-2020		National Institutes of Health [RO1 AI091614, HL126895, AI102943]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL122995, R01HL126895] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI091614, R01AI102943] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grants RO1 AI091614, HL126895, AI102943, and HL126895.	Acosta-Rodriguez EV, 2007, NAT IMMUNOL, V8, P942, DOI 10.1038/ni1496; AKIRA S, 1992, IMMUNOL REV, V127, P25, DOI 10.1111/j.1600-065X.1992.tb01407.x; Al-Alwan LA, 2012, J ALLERGY CLIN IMMUN, V130, P977, DOI 10.1016/j.jaci.2012.04.042; Ather JL, 2011, J IMMUNOL, V187, P64, DOI 10.4049/jimmunol.1100500; Barnes KC, 2006, GENES IMMUN, V7, P27, DOI 10.1038/sj.gene.6364267; Berry MA, 2006, NEW ENGL J MED, V354, P697, DOI 10.1056/NEJMoa050580; Botelho FM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028457; Cayrol C, 2014, CURR OPIN IMMUNOL, V31, P31, DOI 10.1016/j.coi.2014.09.004; Chang Y, 2012, FASEB J, V26, P5152, DOI 10.1096/fj.12-208033; Choy DF, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab3142; CLUITMANS FHM, 1994, ANN HEMATOL, V68, P293, DOI 10.1007/BF01695035; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; COULPIER M, 1995, CLIN EXP IMMUNOL, V101, P142; DeKruyff RH, 2014, IMMUNOL REV, V260, P235, DOI 10.1111/imr.12187; Desai D, 2013, RESP RES, V14, DOI 10.1186/1465-9921-14-17; Di Paolo NC, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004035; Fregonese L, 2005, J ALLERGY CLIN IMMUN, V115, P1148, DOI 10.1016/j.jaci.2005.01.068; Gelfand EW, 2015, J ALLERGY CLIN IMMUN, V135, P1196, DOI 10.1016/j.jaci.2015.01.032; Gold MJ, 2016, MUCOSAL IMMUNOL, V9, P809, DOI 10.1038/mi.2015.104; Good JT, 2012, CHEST, V141, P599, DOI 10.1378/chest.11-0741; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Hirahara K, 2013, J ALLERGY CLIN IMMUN, V131, P1276, DOI 10.1016/j.jaci.2013.03.015; Humbles AA, 2000, NATURE, V406, P998, DOI 10.1038/35023175; Irvin C, 2014, J ALLERGY CLIN IMMUN, V134, P1175, DOI 10.1016/j.jaci.2014.05.038; Jatakanon A, 1999, AM J RESP CRIT CARE, V160, P1532, DOI 10.1164/ajrccm.160.5.9806170; Johnston RA, 2005, AM J PHYSIOL-LUNG C, V288, pL61, DOI 10.1152/ajplung.00101.2004; Kool M, 2011, IMMUNITY, V34, P527, DOI 10.1016/j.immuni.2011.03.015; Kraft M, 1998, AM J RESP CRIT CARE, V158, P998, DOI 10.1164/ajrccm.158.3.9711092; Krug N, 2001, AM J RESP CRIT CARE, V164, P1841, DOI 10.1164/ajrccm.164.10.2010096; Liu WM, 2010, MOL CELL BIOL, V30, P1783, DOI 10.1128/MCB.01003-09; Lukens JR, 2013, NATURE, V498, P224, DOI 10.1038/nature12174; McKinley L, 2008, J IMMUNOL, V181, P4089, DOI 10.4049/jimmunol.181.6.4089; Nair P, 2012, CLIN EXP ALLERGY, V42, P1097, DOI 10.1111/j.1365-2222.2012.04014.x; Nair P, 2009, NEW ENGL J MED, V360, P985, DOI 10.1056/NEJMoa0805435; ONeill LAJ, 1995, INT J CLIN LAB RES, V25, P169, DOI 10.1007/BF02592694; Raundhal M, 2015, J CLIN INVEST, V125, P3037, DOI 10.1172/JCI80911; Rosin DL, 2011, J AM SOC NEPHROL, V22, P416, DOI 10.1681/ASN.2010040430; Saber AT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069020; Schuh JM, 2002, J IMMUNOL, V168, P1447, DOI 10.4049/jimmunol.168.3.1447; Sheng W, 2014, CELL RES, V24, P1387, DOI 10.1038/cr.2014.154; Sutherland ER, 2010, J ALLERGY CLIN IMMUN, V126, P747, DOI 10.1016/j.jaci.2010.07.024; Takabayashi T, 1996, J IMMUNOL, V156, P3455; Wang YH, 2010, J EXP MED, V207, P2479, DOI 10.1084/jem.20101376; Wenzel SE, 2012, NAT MED, V18, P716, DOI 10.1038/nm.2678; Wilson RH, 2009, AM J RESP CRIT CARE, V180, P720, DOI 10.1164/rccm.200904-0573OC; Wong EHC, 2014, LANCET RESP MED, V2, P657, DOI 10.1016/S2213-2600(14)70107-9; Wood LG, 2012, CHEST, V142, P86, DOI 10.1378/chest.11-1838; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC	48	77	84	2	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2017	139	5					1548	+		10.1016/j.jaci.2016.08.032	http://dx.doi.org/10.1016/j.jaci.2016.08.032			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ET7HI	27702673	Bronze, Green Accepted			2022-12-18	WOS:000400465300015
J	Johansson, K; Malmhall, C; Ramos-Ramirez, P; Radinger, M				Johansson, Kristina; Malmhall, Carina; Ramos-Ramirez, Patricia; Radinger, Madeleine			MicroRNA-155 is a critical regulator of type 2 innate lymphoid cells and IL-33 signaling in experimental models of allergic airway inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						miR-155; ILC2; IL-33; IL-13; allergy; asthma; eosinophils	THYMIC STROMAL LYMPHOPOIETIN; TRANSCRIPTION FACTOR GATA3; T-BET; IL-25; IMMUNITY; ASTHMA; ASSOCIATION; HOMEOSTASIS; EXPRESSION; INDUCTION	Background: Allergic airway inflammation is triggered by allergen exposure through several steps including release of IL-33, which promotes cytokine (IL-5, IL-13) production by type 2 innate lymphoid cells (ILC2s). MicroRNA (miR)-155 has recently been described to regulate adaptive responses in allergic inflammation. However, the role of miR-155 in the regulation of ILC2s remains unexplored. Objective: We sought to elucidate the contribution of miR-155 in ILC2 expansion using experimental murine models of allergic airway inflammation. Methods: To determine the role of miR-155 in the regulation of ILC2s in allergic airway inflammation, miR-155 deficient (miR-155 2/2) and wild-type (WT) mice were subjected to acute or chronic allergen-induced inflammation or treated with recombinant IL-33. Results: miR-155 was 10-fold upregulated in WT-derived ILC2s in response to IL-33. Furthermore, miR-155 2/2 mice demonstrated impaired lung IL-33 levels in response to allergen challenge and the number of ILC2s was significantly reduced in allergen-challenged miR-155 2/2 mice compared with WT mice. Exogenous IL-33 treatment revealed that miR-155 is needed for IL-33-induced ILC2 expansion and eosinophilic airway inflammation. Indeed, ILC2s from IL-33-challenged miR-155 2/2 lungs exhibited impaired proliferation, GATA-3 expression, and IL-13 production as compared with IL-33-challengedWTILC2s. Conclusions: Our findings for the first time demonstrate that ILC2s and IL-33 signaling are regulated by miR-155 in allergic airway inflammation.	[Johansson, Kristina; Malmhall, Carina; Ramos-Ramirez, Patricia; Radinger, Madeleine] Gothenburg Univ, Krefting Res Ctr, Inst Med, Dept Internal Med & Clin Nutr, S-41124 Gothenburg, Sweden	University of Gothenburg	Radinger, M (corresponding author), Univ Gothenburg, Krefting Res Ctr, Box 424, SE-40530 Gothenburg, Sweden.	madeleine.radinger@gu.se		Radinger, Madeleine/0000-0002-0652-7378	VBG Group Herman Krefting Foundation for Asthma and Allergy Research; Vardalstiftelsen; Swedish Heart and Lung Foundation	VBG Group Herman Krefting Foundation for Asthma and Allergy Research; Vardalstiftelsen; Swedish Heart and Lung Foundation(Swedish Heart-Lung Foundation)	This study was funded by the VBG Group Herman Krefting Foundation for Asthma and Allergy Research, Vardalstiftelsen, and the Swedish Heart and Lung Foundation.	Barlow JL, 2013, J ALLERGY CLIN IMMUN, V132, P933, DOI 10.1016/j.jaci.2013.05.012; Bartemes KR, 2012, J IMMUNOL, V188, P1503, DOI 10.4049/jimmunol.1102832; Bonnelykke K, 2014, NAT GENET, V46, P51, DOI 10.1038/ng.2830; Christianson CA, 2015, J ALLERGY CLIN IMMUN, V136, P59, DOI 10.1016/j.jaci.2014.11.037; Chu DK, 2013, J ALLERGY CLIN IMMUN, V131, P187, DOI 10.1016/j.jaci.2012.08.002; Collison A, 2014, AM J RESP CELL MOL, V51, P86, DOI 10.1165/rcmb.2013-0490OC; Divekar R, 2015, CURR OPIN ALLERGY CL, V15, P98, DOI 10.1097/ACI.0000000000000133; Gregory LG, 2013, THORAX, V68, P82, DOI 10.1136/thoraxjnl-2012-202003; Gudbjartsson DF, 2009, NAT GENET, V41, P342, DOI 10.1038/ng.323; Halim Timotheus Y F, 2014, Curr Protoc Immunol, V106, DOI 10.1002/0471142735.im0325s106; Halim TYF, 2014, IMMUNITY, V40, P425, DOI 10.1016/j.immuni.2014.01.011; Hayakawa M, 2005, BBA-GENE STRUCT EXPR, V1728, P53, DOI 10.1016/j.bbaexp.2005.01.012; Hoyler T, 2013, CURR OPIN IMMUNOL, V25, P139, DOI 10.1016/j.coi.2013.02.007; Hoyler T, 2012, IMMUNITY, V37, P634, DOI 10.1016/j.immuni.2012.06.020; Huang YF, 2015, NAT IMMUNOL, V16, P161, DOI 10.1038/ni.3078; Hwang YY, 2013, ADV EXP MED BIOL, V785, P9, DOI 10.1007/978-1-4614-6217-0_2; Kamijo S, 2013, J IMMUNOL, V190, P4489, DOI 10.4049/jimmunol.1201212; Li D, 2014, J ALLERGY CLIN IMMUN, V134, P1422, DOI 10.1016/j.jaci.2014.05.011; Louten J, 2011, INT IMMUNOL, V23, P307, DOI 10.1093/intimm/dxr006; Lu TX, 2013, J ALLERGY CLIN IMMUN, V132, P3, DOI 10.1016/j.jaci.2013.04.039; Lu TX, 2009, J IMMUNOL, V182, P4994, DOI 10.4049/jimmunol.0803560; Maazi H, 2015, IMMUNITY, V42, P538, DOI 10.1016/j.immuni.2015.02.007; Malmhall C, 2014, J ALLERGY CLIN IMMUN, V133, P1429, DOI 10.1016/j.jaci.2013.11.008; Martinez-Gonzalez I, 2015, TRENDS IMMUNOL, V36, P189, DOI 10.1016/j.it.2015.01.005; Mchedlidze T, 2013, IMMUNITY, V39, P357, DOI 10.1016/j.immuni.2013.07.018; Mjosberg J, 2012, IMMUNITY, V37, P649, DOI 10.1016/j.immuni.2012.08.015; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Molofsky AB, 2015, IMMUNITY, V43, P161, DOI 10.1016/j.immuni.2015.05.019; Monticelli LA, 2011, NAT IMMUNOL, V12, P1045, DOI [10.1031/ni.2131, 10.1038/ni.2131]; Oboki K, 2010, P NATL ACAD SCI USA, V107, P18581, DOI 10.1073/pnas.1003059107; Okoye IS, 2014, P NATL ACAD SCI USA, V111, pE3081, DOI 10.1073/pnas.1406322111; Plank MW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144810; Ramasamy A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044008; Rebane A, 2013, J ALLERGY CLIN IMMUN, V132, P15, DOI 10.1016/j.jaci.2013.04.011; Rodriguez A, 2007, SCIENCE, V316, P608, DOI 10.1126/science.1139253; Salimi M, 2013, J EXP MED, V210, P2939, DOI 10.1084/jem.20130351; Savinko T, 2013, J INVEST DERMATOL, V133, P2522, DOI 10.1038/jid.2013.195; Smith SG, 2016, J ALLERGY CLIN IMMUN, V137, P75, DOI 10.1016/j.jaci.2015.05.037; Tan AHM, 2008, J BIOL CHEM, V283, P128, DOI 10.1074/jbc.M707693200; Torgerson DG, 2011, NAT GENET, V43, P887, DOI 10.1038/ng.888; Townsend MJ, 2000, J EXP MED, V191, P1069, DOI 10.1084/jem.191.6.1069; Wilczynska A, 2015, CELL DEATH DIFFER, V22, P22, DOI 10.1038/cdd.2014.112; Wolterink RGJK, 2013, P NATL ACAD SCI USA, V110, P10240, DOI 10.1073/pnas.1217158110; Wolterink RGJK, 2012, EUR J IMMUNOL, V42, P1106, DOI 10.1002/eji.201142018; Zech A, 2015, ALLERGY, V70, P1121, DOI 10.1111/all.12643	45	77	80	0	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2017	139	3					1007	+		10.1016/j.jaci.2016.06.035	http://dx.doi.org/10.1016/j.jaci.2016.06.035			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EP3QC	27492144	Bronze			2022-12-18	WOS:000397295800032
J	Andersen, YMF; Egeberg, A; Gislason, GH; Hansen, PR; Skov, L; Thyssen, JP				Andersen, Yuki M. F.; Egeberg, Alexander; Gislason, Gunnar H.; Hansen, Peter R.; Skov, Lone; Thyssen, Jacob P.			Risk of myocardial infarction, ischemic stroke, and cardiovascular death in patients with atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							DANISH; REGISTER; ASSOCIATION; PSORIASIS; VALIDITY; DISEASE		[Andersen, Yuki M. F.; Egeberg, Alexander; Skov, Lone; Thyssen, Jacob P.] Univ Copenhagen, Herlev & Gentofte Hosp, Dept Dermato Allergol, Hellerup, Denmark; [Andersen, Yuki M. F.; Egeberg, Alexander; Gislason, Gunnar H.; Hansen, Peter R.] Univ Copenhagen, Herlev & Gentofte Hosp, Dept Cardiol, Hellerup, Denmark; [Thyssen, Jacob P.] Univ Copenhagen, Herlev & Gentofte Hosp, Natl Allergy Res Ctr, Hellerup, Denmark; [Gislason, Gunnar H.] Danish Heart Fdn, Copenhagen, Denmark; [Gislason, Gunnar H.] Univ Southern Denmark, Natl Inst Publ Hlth, Copenhagen, Denmark	University of Copenhagen; University of Copenhagen; University of Copenhagen; University of Southern Denmark	Andersen, YMF (corresponding author), Univ Copenhagen, Herlev & Gentofte Hosp, Dept Dermato Allergol, Hellerup, Denmark.; Andersen, YMF (corresponding author), Univ Copenhagen, Herlev & Gentofte Hosp, Dept Cardiol, Hellerup, Denmark.	yuki.maria.fukuda.andersen.01@regionh.dk	Egeberg, Alexander/AFO-3479-2022; Hansen, Peter Riis/AAR-7659-2020; Thyssen, Jacob/ABD-8517-2020; Skov, Lone/W-3575-2018; Gislason, Gunnar/B-7561-2009	Egeberg, Alexander/0000-0001-8257-1816; Gislason, Gunnar/0000-0002-0548-402X; Thyssen, Jacob Pontoppidan/0000-0003-3770-1743; Skov, Lone/0000-0002-4784-9680; Andersen, Yuki/0000-0001-6131-2815; Hansen, Peter Riis/0000-0002-9056-535X	Lundbeck Foundation [R139-2012-12679] Funding Source: researchfish; Novo Nordisk Fonden [NNF12OC1015957] Funding Source: researchfish	Lundbeck Foundation(Lundbeckfonden); Novo Nordisk Fonden(Novo Nordisk Foundation)		Andersen TF, 1999, DAN MED BULL, V46, P263; Baadsgaard M, 2011, SCAND J PUBLIC HEALT, V39, P103, DOI 10.1177/1403494811405098; Cheng CM, 2015, J AFFECT DISORDERS, V178, P60, DOI 10.1016/j.jad.2015.02.025; Egeberg A, 2016, J INVEST DERMATOL, V136, P93, DOI 10.1038/JID.2015.350; Gaist D, 1997, DAN MED BULL, V44, P445; Greenland P, 2015, J ALLERGY CLIN IMMUN, V135, pe6; Helweg-Larsen K, 2011, SCAND J PUBLIC HEALT, V39, P26, DOI 10.1177/1403494811399958; Hjuler KF, 2015, AM J MED, V128, P1325, DOI 10.1016/j.amjmed.2015.05.041; Krarup LH, 2007, NEUROEPIDEMIOLOGY, V28, P150, DOI 10.1159/000102143; Madsen M, 2003, J CLIN EPIDEMIOL, V56, P124, DOI 10.1016/S0895-4356(02)00591-7; Olesen Jonas Bjerring, 2011, BMJ, V342, pd124, DOI 10.1136/bmj.d124; Schmidt M, 2014, EUR J EPIDEMIOL, V29, P541, DOI 10.1007/s10654-014-9930-3; Shlyankevich J, 2014, AM J MED, V127, P1148, DOI 10.1016/j.amjmed.2014.08.008; Silverberg JI, 2015, ALLERGY, V70, P1300, DOI 10.1111/all.12685; Su VYF, 2014, ANN MED, V46, P84, DOI 10.3109/07853890.2013.870018; Uehara M, 2002, BRIT J DERMATOL, V146, P631, DOI 10.1046/j.1365-2133.2002.04717.x; von Elm E, 2014, INT J SURG, V12, P1495, DOI 10.1016/j.ijsu.2014.07.013; Weidinger S, 2015, LANCET, V2015	18	77	77	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2016	138	1					310	+		10.1016/j.jaci.2016.01.015	http://dx.doi.org/10.1016/j.jaci.2016.01.015			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DR1IL	26971689	Bronze			2022-12-18	WOS:000379659100042
J	Dannemiller, KC; Gent, JF; Leaderer, BP; Peccia, J				Dannemiller, Karen C.; Gent, Janneane F.; Leaderer, Brian P.; Peccia, Jordan			Indoor microbial communities: Influence on asthma severity in atopic and nonatopic children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; asthma severity; atopy; bacteria; children; DNA sequencing; fungi; indoor environment; microbial communities; nonallergic asthma	IN-HOUSE DUST; NITROGEN-DIOXIDE; VIRUS-INFECTION; EXPOSURE; DIVERSITY; FUNGAL; ENDOTOXIN; ALLERGENS; EXACERBATIONS; SYMPTOMS	Background: Allergic and nonallergic asthma severity in children can be affected by microbial exposures. Objective: We sought to examine associations between exposures to household microbes and childhood asthma severity stratified by atopic status. Methods: Participants (n = 196) were selected from a cohort of asthmatic children in Connecticut and Massachusetts. Children were grouped according to asthma severity (mild with no or minimal symptoms and medication or moderate to severe persistent) and atopic status (determined by serum IgE levels). Microbial community structure and concentrations in house dust were determined by using next-generation DNA sequencing and quantitative PCR. Logistic regression was used to explore associations between asthma severity and exposure metrics, including richness, taxa identification and quantification, community composition, and concentration of total fungi and bacteria. Results: Among all children, increased asthma severity was significantly associated with an increased concentration of summed allergenic fungal species, high total fungal concentrations, and high bacterial richness by using logistic regression in addition to microbial community composition by using the distance comparison t test. Asthma severity in atopic children was associated with fungal community composition (P = .001). By using logistic regression, asthma severity in nonatopic children was associated with total fungal concentration (odds ratio, 2.40; 95% CI, 1.06-5.44). The fungal genus Volutella was associated with increased asthma severity in atopic children (P = .0001, q = 0.04). The yeast genera Kondoa might be protective; Cryptococcus species might also affect asthma severity. Conclusion: Asthma severity among this cohort of children was associated with microbial exposure, and associations differed based on atopic status.	[Dannemiller, Karen C.; Peccia, Jordan] Yale Univ, Dept Chem & Environm Engn, New Haven, CT 06520 USA; [Gent, Janneane F.; Leaderer, Brian P.] Yale Sch Publ Hlth, Yale Ctr Perinatal Pediat & Environm Epidemiol, New Haven, CT USA	Yale University; Yale University	Peccia, J (corresponding author), Yale Univ, Dept Chem & Environm Engn, Mason Lab, 9 Hillhouse Ave, New Haven, CT 06520 USA.	Jordan.Peccia@Yale.edu		Peccia, Jordan/0000-0002-6482-2084; Dannemiller, Karen/0000-0003-4754-6804	Alfred P. Sloan Foundation (Microbiology of the Build Environment); National Institutes of Health [ES05410]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001863] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005410] Funding Source: NIH RePORTER	Alfred P. Sloan Foundation (Microbiology of the Build Environment); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by the Alfred P. Sloan Foundation (Microbiology of the Build Environment) and a grant from the National Institutes of Health (ES05410).	Adams RI, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128022; Amin K, 2000, AM J RESP CRIT CARE, V162, P2295, DOI 10.1164/ajrccm.162.6.9912001; Belanger K, 2006, AM J RESP CRIT CARE, V173, P297, DOI 10.1164/rccm.200408-1123OC; Belanger K, 2003, AM J EPIDEMIOL, V158, P195, DOI 10.1093/aje/kwg148; Belanger K, 2013, EPIDEMIOLOGY, V24, P320, DOI 10.1097/EDE.0b013e318280e2ac; Blatter Joshua, 2014, Ann Am Thorac Soc, V11, P925, DOI 10.1513/AnnalsATS.201402-077OC; Breitenbach M, 2008, INT ARCH ALLERGY IMM, V145, P58, DOI 10.1159/000107578; Caporaso JG, 2011, P NATL ACAD SCI USA, V108, P4516, DOI 10.1073/pnas.1000080107; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Cui LJ, 2013, GENOME MED, V5, DOI 10.1186/gm467; Dannemiller KC, 2014, INDOOR AIR, V24, P236, DOI 10.1111/ina.12072; Dannemiller K. C., 2015, INDOOR AIR; Dannemiller KC, 2014, J BASIC MICROB, V54, P315, DOI 10.1002/jobm.201200507; Dannemiller KC, 2014, ATMOS ENVIRON, V84, P113, DOI 10.1016/j.atmosenv.2013.11.036; Douwes J, 2000, AM J RESP CRIT CARE, V162, P1348, DOI 10.1164/ajrccm.162.4.9909118; Douwes J, 2002, THORAX, V57, P643, DOI 10.1136/thorax.57.7.643; Findley K, 2013, NATURE, V498, P367, DOI 10.1038/nature12171; Fujimura KE, 2014, P NATL ACAD SCI USA, V111, P805, DOI 10.1073/pnas.1310750111; GAUCH HG, 1977, J ECOL, V65, P157; Gent JF, 2012, ENVIRON RES, V118, P86, DOI 10.1016/j.envres.2012.07.005; Goldman DL, 2012, MBIO, V3, DOI 10.1128/mBio.00056-12; HORN HS, 1966, AM NAT, V100, P419, DOI 10.1086/282436; Kim HY, 2010, NAT IMMUNOL, V11, P577, DOI 10.1038/ni.1892; Kozyrskyj AL, 2001, ARCH PEDIAT ADOL MED, V155, P1219; Larena I, 1999, J BIOTECHNOL, V75, P187, DOI 10.1016/S0168-1656(99)00154-6; Leaderer BP, 2002, ENVIRON HEALTH PERSP, V110, P419, DOI 10.1289/ehp.02110419; Levine SJ, 2010, ANN INTERN MED, V152, P232, DOI 10.7326/0003-4819-152-4-201002160-00008; Liu AH, 2002, J ALLERGY CLIN IMMUN, V109, P379, DOI 10.1067/mai.2002.122157; Lozupone C, 2005, APPL ENVIRON MICROB, V71, P8228, DOI 10.1128/AEM.71.12.8228-8235.2005; Lynch SV, 2014, J ALLERGY CLIN IMMUN, V134, P593, DOI 10.1016/j.jaci.2014.04.018; Manter DK, 2007, J MICROBIOL METH, V71, P7, DOI 10.1016/j.mimet.2007.06.016; Mayo Clinic, 2006, IMM E IGE SER; Mendell MJ, 2011, ENVIRON HEALTH PERSP, V119, P748, DOI 10.1289/ehp.1002410; Michel O, 1996, AM J RESP CRIT CARE, V154, P1641, DOI 10.1164/ajrccm.154.6.8970348; Murray CS, 2006, THORAX, V61, P376, DOI 10.1136/thx.2005.042523; National Oceanic and Atmospheric Administration National Centers for Environmental Information, 1981, HARTF BRADL INT AIRP; Pearce N, 1999, THORAX, V54, P268, DOI 10.1136/thx.54.3.268; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Trent MS, 2006, J ENDOTOXIN RES, V12, P205, DOI 10.1179/096805106X118825; Umetsu DT, 2002, NAT IMMUNOL, V3, P715, DOI 10.1038/ni0802-715; US Department of Health and Human Services, 2002, GLOB IN ASTHM GLOB S; Yamamoto N, 2012, ISME J, V6, P1801, DOI 10.1038/ismej.2012.30; Zambelli-Weiner A., 2004, Journal of Allergy and Clinical Immunology, V113, pS304, DOI 10.1016/j.jaci.2004.01.584	43	77	77	1	38	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2016	138	1					76	+		10.1016/j.jaci.2015.11.027	http://dx.doi.org/10.1016/j.jaci.2015.11.027			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DR1IL	26851966	Bronze, Green Accepted			2022-12-18	WOS:000379659100008
J	Fishbein, AB; Vitaterna, O; Haugh, IM; Bavishi, AA; Zee, PC; Turek, FW; Sheldon, SH; Silverberg, JI; Paller, AS				Fishbein, Anna B.; Vitaterna, Olivia; Haugh, Isabel M.; Bavishi, Aakash A.; Zee, Phyllis C.; Turek, Fred W.; Sheldon, Stephen H.; Silverberg, Jonathan I.; Paller, Amy S.			Nocturnal eczema: Review of sleep and circadian rhythms in children with atopic dermatitis and future research directions	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; eczema; sleep; sleep disturbance; circadian rhythms	PEDIATRIC-PATIENTS; DISEASE SEVERITY; MELATONIN; QUALITY; DISTURBANCE; ADULTS; SKIN; EFFICACY; CLOCK; LIFE	Children with atopic dermatitis (AD) experience significant sleep disruption, and clinically, the disease is noted to worsen in a circadian manner at night. Epidemiologic findings highlight many negative consequences of AD, such as impaired linear growth, which is uniquely related to disturbed sleep. Clinical guidelines currently recommend assessing sleep in patients with AD as a crucial parameter of disease control with appropriate treatment. In this review we describe our current understanding of the roles of sleep cycles and circadian rhythms in the nighttime exacerbation of AD (nocturnal eczema). We present a schematic to explain the mechanism of nocturnal eczema. Treatment options for sleep disturbance and future directions for research are discussed in the context of AD.	[Fishbein, Anna B.; Bavishi, Aakash A.] Northwestern Univ, Ann & Robert H Lurie Childrens Hosp Chicago, Dept Pediat, Div Allergy & Immunol, Chicago, IL 60611 USA; [Vitaterna, Olivia; Turek, Fred W.] Northwestern Univ, Dept Neurobiol, Ctr Sleep & Circadian Biol, Evanston, IL USA; [Haugh, Isabel M.; Silverberg, Jonathan I.; Paller, Amy S.] Northwestern Univ, Dept Dermatol, Chicago, IL 60611 USA; [Haugh, Isabel M.; Silverberg, Jonathan I.; Paller, Amy S.] Northwestern Univ, Dept Pediat, Chicago, IL 60611 USA; [Sheldon, Stephen H.] Northwestern Univ, Dept Pediat, Div Sleep & Pulmonol, Chicago, IL 60611 USA; [Zee, Phyllis C.] Northwestern Univ, Feinberg Sch Med, Dept Neurol, Chicago, IL 60611 USA; [Zee, Phyllis C.] Northwestern Univ, Feinberg Sch Med, Ctr Circadian & Sleep Med, Chicago, IL 60611 USA	Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Northwestern University; Northwestern University; Northwestern University; Northwestern University; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	Fishbein, AB (corresponding author), Northwestern Univ, Ann & Robert H Lurie Childrens Hosp Chicago, Dept Allergy & Immunol, 225 E Chicago Ave 60, Chicago, IL 60611 USA.	afishbein@luriechildrens.org	Zee, Phyllis C/GPF-3704-2022; silverberg, jonathan/ABH-2765-2021; Haugh, Isabel/AAW-9354-2020	silverberg, jonathan/0000-0003-3686-7805; Paller, Amy/0000-0001-6187-6549; Fishbein, Anna/0000-0003-0228-592X	Jazz; Department of Defense; Office of Naval Research; National Institutes of Health; NASA; Merck; Vanda Pharmaceuticals; Cadwell Diagnostics	Jazz(Jazz Pharmaceuticals); Department of Defense(United States Department of Defense); Office of Naval Research(Office of Naval Research); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NASA(National Aeronautics & Space Administration (NASA)); Merck(Merck & Company); Vanda Pharmaceuticals; Cadwell Diagnostics	P. C. Zee owns stock in Teva; has consultant arrangements with Merck, Jazz, Vanda, Philips Respironics, and Pernix; and has received grants from Jazz. F. W. Turek has consultant arrangements with PatientsLikeMe and has received grants from the Department of Defense, the Office of Naval Research, the National Institutes of Health, NASA, Merck, and Vanda Pharmaceuticals. S. H. Sheldon has consultant arrangements with Dymedix and has received payment for lectures from Cadwell Diagnostics. The rest of the authors declare that they have no relevant conflicts of interest.	Becker D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020566; Bender BG, 2003, J ALLERGY CLIN IMMUN, V111, P598, DOI 10.1067/mai.2003.174; Bender BG, 2008, J AM ACAD DERMATOL, V58, P415, DOI 10.1016/j.jaad.2007.10.010; Blume-Peytavi U, 2012, J EUR ACAD DERMATOL, V26, P2, DOI 10.1111/j.1468-3083.2012.04710.x; Boguniewicz M, 2008, SEMIN CUTAN MED SURG, V27, P115, DOI 10.1016/j.sder.2008.05.001; Bollinger T, 2009, CLIN EXP IMMUNOL, V155, P231, DOI 10.1111/j.1365-2249.2008.03822.x; Camfferman D, 2010, SLEEP MED REV, V14, P359, DOI 10.1016/j.smrv.2010.01.004; Carson CG, 2013, DAN MED J, V60; Chamlin SL, 2005, ARCH PEDIAT ADOL MED, V159, P745, DOI 10.1001/archpedi.159.8.745; Chang YS, 2014, PEDIATRICS, V134, pE397, DOI 10.1542/peds.2014-0376; Cicek D, 2012, CLIN EXP DERMATOL, V37, P469, DOI 10.1111/j.1365-2230.2012.04356.x; DAHL RE, 1995, ARCH PEDIAT ADOL MED, V149, P856, DOI 10.1001/archpedi.1995.02170210030005; Darsow U, 2005, J EUR ACAD DERMATOL, V19, P286, DOI 10.1111/j.1468-3083.2005.01249.x; DelRosso L, 2012, J CLIN SLEEP MED, V8, P459, DOI 10.5664/jcsm.2050; Dertlioglu SB, 2013, INT J DERMATOL, V52, P96, DOI 10.1111/j.1365-4632.2012.05616.x; Doss N, 2010, PEDIAT ALLERG IMM-UK, V21, P321, DOI 10.1111/j.1399-3038.2009.00895.x; Durrington HJ, 2014, THORAX, V69, P90, DOI 10.1136/thoraxjnl-2013-203482; Ebata T, 1998, BRIT J DERMATOL, V138, P631; Ebata T, 1999, BRIT J DERMATOL, V141, P82; Ehlayel M S, 2007, Eur Ann Allergy Clin Immunol, V39, P232; Eichenfield LF, 2014, J AM ACAD DERMATOL, V70, P338, DOI 10.1016/j.jaad.2013.10.010; Engel-Yeger B, 2011, J EUR ACAD DERMATOL, V25, P152, DOI 10.1111/j.1468-3083.2010.03729.x; Ersser SJ, 2014, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD004054.PUB3; Foster EL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022029; Fujita H, 2014, EUR J DERMATOL, V24, P120, DOI 10.1684/ejd.2013.2242; Fukuda H, 2013, J DERMATOL, V40, P43, DOI 10.1111/j.1346-8138.2012.01678.x; Garg N, 2015, JAMA DERMATOL, V151, P33, DOI 10.1001/jamadermatol.2014.2098; Genois A, 2014, PEDIATR DERMATOL, V31, P76, DOI 10.1111/j.1525-1470.2012.01756.x; Geyfman M, 2009, J INVEST DERMATOL, V129, P1063, DOI 10.1038/jid.2008.384; Goldbart AD, 2005, AM J RESP CRIT CARE, V172, P364, DOI 10.1164/rccm.200408-1064OC; Goldbart AD, 2006, CHEST, V130, P143, DOI 10.1378/chest.130.1.143; Gupta MA, 2013, CLIN DERMATOL, V31, P118, DOI 10.1016/j.clindermatol.2011.11.016; Hanifin JM, 2004, J AM ACAD DERMATOL, V50, P391, DOI 10.1016/j.jaad.2003.08.003; HANIFIN JM, 1990, J ALLERGY CLIN IMMUN, V86, P666, DOI 10.1016/S0091-6749(05)80237-4; Hara-Chikuma M, 2008, J INVEST DERMATOL, V128, P2145, DOI 10.1038/jid.2008.70; HEUBECK B, 1988, HAUTARZT, V39, P12; Hon KLE, 2008, CLIN EXP DERMATOL, V33, P705, DOI 10.1111/j.1365-2230.2008.02853.x; Hon KL, 2011, PEDIAT ALLERG IMM-UK, V22, P704, DOI 10.1111/j.1399-3038.2011.01174.x; Hon KLE, 2006, BRIT J DERMATOL, V154, P629, DOI 10.1111/j.1365-2133.2006.07213.x; Hon KLE, 2005, J DERMATOL TREAT, V16, P22, DOI 10.1080/09546630410020145; Iber C, 2007, AASM MANUAL SCORING, V1st; Kahn A, 1996, J CLIN NEUROPHYSIOL, V13, P184, DOI 10.1097/00004691-199605000-00002; Kelsay K, 2006, J ALLERGY CLIN IMMUN, V118, P198, DOI 10.1016/j.jaci.2006.04.038; Kim J, 2011, RESP PHYSIOL NEUROBI, V178, P465, DOI 10.1016/j.resp.2011.04.024; Klein PA, 1999, ARCH DERMATOL, V135, P1522, DOI 10.1001/archderm.135.12.1522; Koinis-Mitchell D, 2012, J ALLERGY CLIN IMMUN, V130, P1275, DOI 10.1016/j.jaci.2012.06.026; Korossy S, 1972, Ther Hung, V20, P95; KRAFT M, 1994, AM J RESP CRIT CARE, V149, P947; Kraft M, 1999, CHRONOBIOL INT, V16, P683, DOI 10.3109/07420529908998735; Kumar V, 2013, GENOME BIOL, V14, DOI 10.1186/gb4142; LABRECQUE G, 1995, PHARMACOL THERAPEUT, V68, P129, DOI 10.1016/0163-7258(95)02003-9; Le Fur I, 2001, J INVEST DERMATOL, V117, P718, DOI 10.1046/j.0022-202x.2001.01433.x; LEWISJONES MS, 1995, BRIT J DERMATOL, V132, P942; Lissoni P, 1998, NAT IMMUN, V16, P1, DOI 10.1159/000069464; Lu BS, 2006, CHEST, V130, P1915, DOI 10.1378/chest.130.6.1915; Marseglia L, 2014, INT J MOL SCI, V15, P13482, DOI 10.3390/ijms150813482; Matsunaga N, 2014, J INVEST DERMATOL, V134, P1636, DOI 10.1038/jid.2014.13; Merenstein D, 2006, ARCH PEDIAT ADOL MED, V160, P707, DOI 10.1001/archpedi.160.7.707; Nakamura Y, 2014, J ALLERGY CLIN IMMUN, V133, P568, DOI 10.1016/j.jaci.2013.07.040; Ndiaye MA, 2014, ANTIOXID REDOX SIGN, V20, P2982, DOI 10.1089/ars.2013.5645; Nguyen KD, 2013, SCIENCE, V341, P1483, DOI 10.1126/science.1240636; Novak N, 2011, CURR OPIN IMMUNOL, V23, P778, DOI 10.1016/j.coi.2011.09.007; Oranje AP, 2006, J EUR ACAD DERMATOL, V20, P1277, DOI 10.1111/j.1468-3083.2006.01790.x; Ozturk L, 1999, Sleep Res Online, V2, P107; Paller AS, 2012, SEMIN CUTAN MED SURG, V31, pS10, DOI 10.1016/j.sder.2012.07.004; Paller AS, 2002, CLIN PEDIATR, V41, P323, DOI 10.1177/000992280204100505; Papoiu ADP, 2011, NEUROPEPTIDES, V45, P417, DOI 10.1016/j.npep.2011.07.008; Petrovsky N, 1998, Int Rev Immunol, V16, P635, DOI 10.3109/08830189809043012; Raap U, 2012, PEDIAT ALLERG IMM-UK, V23, P285, DOI 10.1111/j.1399-3038.2011.01241.x; REINBERG A, 1965, J ALLERGY, V36, P273, DOI 10.1016/0021-8707(65)90086-9; Reis ES, 2011, BRAIN BEHAV IMMUN, V25, P1416, DOI 10.1016/j.bbi.2011.04.011; Reuveni H, 1999, ARCH PEDIAT ADOL MED, V153, P249; Rohleder N, 2012, ANN NY ACAD SCI, V1261, P88, DOI 10.1111/j.1749-6632.2012.06634.x; Romanos M, 2010, J EPIDEMIOL COMMUN H, V64, P269, DOI 10.1136/jech.2009.093534; RUPPRECHT M, 1995, PSYCHONEUROENDOCRINO, V20, P543, DOI 10.1016/0306-4530(94)00082-L; RUSSO RM, 1976, J CLIN PHARMACOL, V16, P284, DOI 10.1002/j.1552-4604.1976.tb02406.x; Sack R, 2010, SLEEP MED REV, V14, P349, DOI 10.1016/j.smrv.2010.03.003; Sadeh A, 2009, J SLEEP RES, V18, P60, DOI 10.1111/j.1365-2869.2008.00699.x; Sanchez-Barcelo EJ, 2011, INT J PEDIAT, V2011, DOI 10.1155/2011/892624; Sandoval LF, 2014, J CUTAN MED SURG, V18, P49, DOI 10.2310/7750.2013.13093; SAVIN JA, 1975, BRIT J DERMATOL, V93, P297, DOI 10.1111/j.1365-2133.1975.tb06495.x; SAVIN JA, 1979, ARCH DERMATOL, V115, P313, DOI 10.1001/archderm.115.3.313; SAVIN JA, 1973, LANCET, V2, P296, DOI 10.1016/S0140-6736(73)90797-6; Scheiermann C, 2013, NAT REV IMMUNOL, V13, P190, DOI 10.1038/nri3386; Schleimer Robert P., 2000, Journal of Allergy and Clinical Immunology, V106, pS270; Schneider L, 2013, J ALLERGY CLIN IMMUN, V131, P295, DOI 10.1016/j.jaci.2012.12.672; SCHWARZ W, 1988, ACTA DERM-VENEREOL, V68, P224; SCHWARZ W, 1987, ARCH DERMATOL RES, V279, pS59, DOI 10.1007/BF00585922; Scuri Mario, 2010, Inflammation & Allergy Drug Targets, V9, P173; Shani-Adir A, 2009, PEDIATR DERMATOL, V26, P143, DOI 10.1111/j.1525-1470.2009.00904.x; Shaw TE, 2011, J INVEST DERMATOL, V131, P67, DOI 10.1038/jid.2010.251; Sheldon SH, 2014, PRINCIPLES PRACTICES, VSecond; Silver AC, 2012, IMMUNITY, V36, P251, DOI 10.1016/j.immuni.2011.12.017; Silverberg JI, 2015, JAMA DERMATOL, V151, P401, DOI 10.1001/jamadermatol.2014.3432; Silverberg JI, 2015, JAMA DERMATOL, V151, P144, DOI 10.1001/jamadermatol.2014.3059; Silverberg JI, 2015, J INVEST DERMATOL, V135, P56, DOI 10.1038/jid.2014.325; Sporl F, 2012, P NATL ACAD SCI USA, V109, P10903, DOI 10.1073/pnas.1118641109; Sporl F, 2011, J INVEST DERMATOL, V131, P338, DOI 10.1038/jid.2010.315; Storch KF, 2002, NATURE, V417, P78, DOI 10.1038/nature744; Stores G, 1998, PEDIATR DERMATOL, V15, P264, DOI 10.1046/j.1525-1470.1998.1998015264.x; Sugarman JL, 2009, J DRUGS DERMATOL, V8, P1106; Sutherland ER, 2002, AM J RESP CRIT CARE, V166, P1055, DOI 10.1164/rccm.200204-356OC; TANTAM D, 1982, PSYCHOTHER PSYCHOSOM, V37, P26, DOI 10.1159/000287552; Turek FW, 2008, NATURE, V456, P881, DOI 10.1038/456881a; Weiss SC, 2008, CLIN DERMATOL, V26, P565, DOI 10.1016/j.clindermatol.2008.01.016; Wolter S, 2014, PEDIATR CLIN N AM, V61, P241, DOI 10.1016/j.pcl.2013.11.002; Yosipovitch G, 1998, J INVEST DERMATOL, V110, P20, DOI 10.1046/j.1523-1747.1998.00069.x; Yudina MM, 2011, ACTA DERM-VENEREOL, V91, P656, DOI 10.2340/00015555-1173; Zisapel N, 2012, EXPERT OPIN EMERG DR, V17, P299, DOI 10.1517/14728214.2012.690735	109	77	78	1	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2015	136	5					1170	1177		10.1016/j.jaci.2015.08.028	http://dx.doi.org/10.1016/j.jaci.2015.08.028			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CW1YE	26549635	Bronze			2022-12-18	WOS:000364787200004
J	Newcomb, DC; Cephus, JY; Boswell, MG; Fahrenholz, JM; Langley, EW; Feldman, AS; Zhou, WS; Dulek, DE; Goleniewska, K; Woodward, KB; Sevin, CM; Hamilton, RG; Kolls, JK; Peebles, RS				Newcomb, Dawn C.; Cephus, Jacqueline Yvonne; Boswell, Madison G.; Fahrenholz, John M.; Langley, Emily W.; Feldman, Amy S.; Zhou, Weisong; Dulek, Daniel E.; Goleniewska, Kasia; Woodward, Kimberly B.; Sevin, Carla M.; Hamilton, Robert G.; Kolls, Jay K.; Peebles, R. Stokes, Jr.			Estrogen and progesterone decrease let-7f microRNA expression and increase IL-23/IL-23 receptor signaling and IL-17A production in patients with severe asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Estrogen; IL-17A; IL-23 signaling; Let-7f; progesterone; severe asthma	TH17 CELLS; T-LYMPHOCYTES; T(H)17 CELLS; IFN-GAMMA; TGF-BETA; CYTOKINE; DISEASE; SEX; DIFFERENTIATION; TRANSCRIPTION	Background: Women have an increased prevalence of severe asthma compared with men. IL-17A is associated with severe asthma and requires IL-23 receptor (IL-23R) signaling, which is negatively regulated by let-7f microRNA. Objective: We sought to Determine the mechanism by which 17 beta-estradiol (E2) and progesterone (P4) increase IL-17A production. Methods: IL-17A production was determined by using flow cytometry in T(H)17 cells from women (n = 14) and men (n = 15) with severe asthma. Cytokine levels were measured by using ELISA, and IL-23R and let-7f expression was measured by using quantitative PCR in T(H)17-differentiated cells from healthy women (n = 13) and men (n = 14). In sham-operated or ovariectomized female mice, 17 beta-E2, P4, 17 beta-E21P4, or vehicle pellets were administered for 3 weeks before ex vivo T(H)17 cell differentiation. Airway neutrophil infiltration and CXCL1 (KC) expression were also determined in ovalbumin (OVA)challenged wild-type female recipient mice with an adoptive transfer of OVA-specific T(H)17 cells from female and male mice. Results: In patients with severe asthma and healthy control subjects, IL-17A production was increased in T(H)17 cells from women compared with men. IL-23R expression was increased and let-7f expression was decreased in T(H)17-differentiated cells from women compared with men. In ovariectomized mice IL-17A and IL-23R expression was increased and Let-7f expression was decreased in T(H)17 cells from mice administered 17 beta-E21P4 compared with those administered vehicle. Furthermore, transfer of female OVA-specific T(H)17 cells increased acute neutrophil infiltration in the lungs of OVA-challenged recipient mice compared with transfer of male OVA-specific T(H)17 cells. Conclusions: 17 beta-E21P4 increased IL-17A production from T(H)17 cells, providing a potential mechanism for the increased prevalence of severe asthma in women compared with men.	[Newcomb, Dawn C.; Cephus, Jacqueline Yvonne; Boswell, Madison G.; Fahrenholz, John M.; Langley, Emily W.; Feldman, Amy S.; Zhou, Weisong; Goleniewska, Kasia; Woodward, Kimberly B.; Sevin, Carla M.; Peebles, R. Stokes, Jr.] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN 37232 USA; [Dulek, Daniel E.] Vanderbilt Univ, Med Ctr, Dept Pediat, Nashville, TN 37232 USA; [Hamilton, Robert G.] Johns Hopkins Univ, Sch Med, Dept Pathol & Med, Baltimore, MD USA; [Kolls, Jay K.] Childrens Hosp Pittsburgh, Dept Pediat, Pittsburgh, PA USA	Vanderbilt University; Vanderbilt University; Johns Hopkins University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Newcomb, DC (corresponding author), Vanderbilt Univ, Med Ctr, Med Ctr North T 1221, 1161 21st Ave, Nashville, TN 37232 USA.	newcomb@vanderbilt.edu	Kolls, Jay/AAH-1829-2019	Kolls, Jay/0000-0001-5151-6304	NCATS NIH HHS [KL2 TR000446] Funding Source: Medline; NHLBI NIH HHS [T32 HL094296, R01 HL122554] Funding Source: Medline; NIAID NIH HHS [U19 AI 095227, R01 AI111820, R01 AI 111820, U19 AI095227] Funding Source: Medline; NICHD NIH HHS [K12 HD043483, K12HD043483-08] Funding Source: Medline; BLRD VA [I01 BX000624] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD043483] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [KL2TR000446] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL122554, T32HL094296] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI095227, R01AI111820] Funding Source: NIH RePORTER; Veterans Affairs [I01BX000624] Funding Source: NIH RePORTER	NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); BLRD VA; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Veterans Affairs(US Department of Veterans Affairs)		Acosta-Rodriguez EV, 2007, NAT IMMUNOL, V8, P639, DOI 10.1038/ni1467; Al-Ramli W, 2009, J ALLERGY CLIN IMMUN, V123, P1185, DOI 10.1016/j.jaci.2009.02.024; American Lung Association, 2012, TRENDS ASTHM MORB MO; Bhat-Nakshatri P, 2009, NUCLEIC ACIDS RES, V37, P4850, DOI 10.1093/nar/gkp500; Buonocore S, 2010, NATURE, V464, P1371, DOI 10.1038/nature08949; Busse WW, 2013, AM J RESP CRIT CARE, V188, P1294, DOI 10.1164/rccm.201212-2318OC; Card JW, 2006, J IMMUNOL, V177, P621, DOI 10.4049/jimmunol.177.1.621; Carey MA, 2007, AM J PHYSIOL-LUNG C, V293, pL272, DOI 10.1152/ajplung.00174.2007; Chakir J, 2003, J ALLERGY CLIN IMMUN, V111, P1293, DOI 10.1067/mai.2003.1557; Cohen CJ, 2011, J IMMUNOL, V187, P5615, DOI 10.4049/jimmunol.1101058; Collier SP, 2012, J IMMUNOL, V189, P2084, DOI 10.4049/jimmunol.1200774; Fahy John V, 2009, Proc Am Thorac Soc, V6, P256, DOI 10.1513/pats.200808-087RM; Fairweather D, 2008, AM J PATHOL, V173, P600, DOI 10.2353/ajpath.2008.071008; Fitzpatrick AM, 2011, J ALLERGY CLIN IMMUN, V127, P382, DOI 10.1016/j.jaci.2010.11.015; Gilliver SC, 2010, J STEROID BIOCHEM, V120, P105, DOI 10.1016/j.jsbmb.2009.12.015; Hershey GKK, 2003, J ALLERGY CLIN IMMUN, V111, P677, DOI 10.1067/mai.2003.1333; Hirota K, 2007, J EXP MED, V204, P2803, DOI 10.1084/jem.20071397; Hogan SP, 2008, CLIN EXP ALLERGY, V38, P709, DOI 10.1111/j.1365-2222.2008.02958.x; Irvin C, 2014, J ALLERGY CLIN IMMUN, V134, P1175, DOI 10.1016/j.jaci.2014.05.038; Ishigame H, 2009, IMMUNITY, V30, P108, DOI 10.1016/j.immuni.2008.11.009; Khan D, 2010, EUR J IMMUNOL, V40, P2549, DOI 10.1002/eji.201040303; Lelu K, 2011, J IMMUNOL, V187, P2386, DOI 10.4049/jimmunol.1101578; Li ZX, 2011, J IMMUNOL, V186, P6182, DOI 10.4049/jimmunol.1000917; Liva SM, 2001, J IMMUNOL, V167, P2060, DOI 10.4049/jimmunol.167.4.2060; McGeachy MJ, 2007, NAT IMMUNOL, V8, P1390, DOI 10.1038/ni1539; McGeachy MJ, 2009, NAT IMMUNOL, V10, P314, DOI 10.1038/ni.1698; Mease PJ, 2014, DRUGS, V74, P423, DOI 10.1007/s40265-014-0191-y; Miossec P, 2012, NAT REV DRUG DISCOV, V11, P763, DOI 10.1038/nrd3794; Molet S, 2001, J ALLERGY CLIN IMMUN, V108, P430, DOI 10.1067/mai.2001.117929; Moore WC, 2007, J ALLERGY CLIN IMMUN, V119, P405, DOI 10.1016/j.jaci.2006.11.639; Newcomb DC, 2013, CURR OPIN IMMUNOL, V25, P755, DOI 10.1016/j.coi.2013.08.002; Newcomb DC, 2012, J IMMUNOL, V188, P1027, DOI 10.4049/jimmunol.1102216; Newcomb DC, 2011, J ALLERGY CLIN IMMUN, V127, P1006, DOI 10.1016/j.jaci.2010.11.043; Newcomb DC, 2009, J IMMUNOL, V182, P5317, DOI 10.4049/jimmunol.0803868; Polikepahad S, 2010, J BIOL CHEM, V285, P30139, DOI 10.1074/jbc.M110.145698; Relloso M, 2012, J LEUKOCYTE BIOL, V91, P159, DOI 10.1189/jlb.1110645; Wang XH, 2012, IMMUNITY, V36, P23, DOI 10.1016/j.immuni.2011.10.019; Wang YH, 2010, J EXP MED, V207, P2479, DOI 10.1084/jem.20101376; Wenzel SE, 2006, LANCET, V368, P804, DOI 10.1016/S0140-6736(06)69290-8; Whitacre CC, 1999, SCIENCE, V283, P1277, DOI 10.1126/science.283.5406.1277; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Wu C, 2013, NATURE, V496, P513, DOI 10.1038/nature11984; Xu YD, 2010, RESP RES, V11, DOI [10.1186/1465-9921-11-166, 10.1186/1465-9921-11-107]; Yang XXO, 2008, J EXP MED, V205, P1063, DOI 10.1084/jem.20071978; Zhang MA, 2012, P NATL ACAD SCI USA, V109, P9505, DOI 10.1073/pnas.1118458109	45	77	82	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2015	136	4					1025	+		10.1016/j.jaci.2015.05.046	http://dx.doi.org/10.1016/j.jaci.2015.05.046			21	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CT7EJ	26242299	Bronze, Green Accepted			2022-12-18	WOS:000362976300021
J	Clark, S; Wei, WH; Rudders, SA; Camargo, CA				Clark, Sunday; Wei, Wenhui; Rudders, Susan A.; Camargo, Carlos A., Jr.			Risk factors for severe anaphylaxis in patients receiving anaphylaxis treatment in US emergency departments and hospitals	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Anaphylaxis; severity; emergency department; hospitalization	ALLERGY; MANAGEMENT; HOSPITALIZATIONS; EPIDEMIOLOGY; FATALITIES; COLLEGE; FOOD	Background: Although reported risk factors for severe anaphylaxis include older age, presence of comorbid medical conditions, and concomitant medications, previous studies have used varying definitions for anaphylaxis and heterogeneous methodology. Objective: To describe risk factors for severe anaphylaxis among US patients treated in emergency departments (EDs) or hospitals for anaphylaxis. Methods: Individuals with an ED visit/hospitalization for anaphylaxis were identified from 2 MarketScan Research Databases using an expanded International Classification of Diseases, Ninth Revision, Clinical Modification diagnosis code algorithm. Eligibility for the current study required continuous medical and prescription coverage for at least 1 year before and after the index date. Severe anaphylaxis was defined as a reaction requiring hospital admission. Results: Among 11,972 individuals, 2,622 (22%) had severe anaphylaxis. Unadjusted analysis showed that severe anaphylaxis was associated with older age and higher comorbidity burden. These patients were also less likely to have filled an epinephrine autoinjector (EAI) prescription or visited an allergist/immunologist, but more likely to have had an ED visit/hospitalization (any cause). On multivariable analysis, filling an EAI prescription (odds ratio [OR], 0.64; 95% CI, 0.53-0.78) or visiting an allergist/immunologist (OR, 0.78; 95% CI, 0.63-0.95) before the index event was associated with a lower risk of severe anaphylaxis, while any previous ED visit (OR, 1.18; 95% CI, 1.07-1.30) or hospitalization (OR, 1.55; 95% CI, 1.36-1.75) was associated with a higher risk of severe anaphylaxis. Conclusions: In this large cohort with an ED visit or hospitalization for anaphylaxis, 22% had severe anaphylaxis. Pre-index preventive anaphylaxis care (ie, EAI prescription fill and allergist/immunologist visit) was associated with a significantly lower risk, supporting the benefits of preventive anaphylaxis care in real-world practice.	[Clark, Sunday] Weill Cornell Med Coll, Dept Emergency Med, New York, NY 10065 USA; [Wei, Wenhui] Sanofi US, Bridgewater, MA USA; [Rudders, Susan A.] Brown Univ, Alpert Sch Med, Rhode Isl Hosp, Dept Pediat, Providence, RI 02912 USA; [Camargo, Carlos A., Jr.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Rheumatol Allergy & Immunol,Dept Med, Boston, MA USA; [Camargo, Carlos A., Jr.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Emergency Med, Boston, MA USA	Cornell University; Brown University; Lifespan Health Rhode Island; Rhode Island Hospital; Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary	Clark, S (corresponding author), Weill Cornell Med Coll, Dept Emergency Med, 525 E 68th St,Box 179, New York, NY 10065 USA.	sunday.clark@gmail.com	Clark, Sunday/AAA-5458-2021; Camargo, Carlos A./C-2145-2008	Camargo, Carlos A./0000-0002-5071-7654				Bock SA, 2007, J ALLERGY CLIN IMMUN, V119, P1016, DOI 10.1016/j.jaci.2006.12.622; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; Brown SGA, 2004, J ALLERGY CLIN IMMUN, V114, P371, DOI 10.1016/j.jaci.2004.04.029; Chaudhuri K, 2008, INT J OBSTET ANESTH, V17, P350, DOI 10.1016/j.ijoa.2008.05.002; Estelle F, 2006, J ALLERGY CLIN IMMUN, V117, P367, DOI 10.1016/j.jaci.2005.12.002; Gaeta TJ, 2007, ANN ALLERG ASTHMA IM, V98, P360, DOI 10.1016/S1081-1206(10)60883-6; Greenberger PA, 2007, ANN ALLERG ASTHMA IM, V98, P252, DOI 10.1016/S1081-1206(10)60714-4; Greenhawt MJ, 2009, J ALLERGY CLIN IMMUN, V124, P323, DOI 10.1016/j.jaci.2009.05.028; Gupta R, 2007, THORAX, V62, P91, DOI 10.1136/thx.2004.038844; Gupta R, 2003, BRIT MED J, V327, P1142, DOI 10.1136/bmj.327.7424.1142; Harduar-Morano L, 2010, J ALLERGY CLIN IMMUN, V126, P98, DOI 10.1016/j.jaci.2010.04.017; Kumar Arvind, 2005, Clin Dev Immunol, V12, P281, DOI 10.1080/17402520500376277; Lang DM, 2008, CURR ALLERGY ASTHM R, V8, P37, DOI 10.1007/s11882-008-0008-8; Lieberman P, 2006, ANN ALLERG ASTHMA IM, V97, P596, DOI 10.1016/S1081-1206(10)61086-1; LIEBERMAN PL, 2009, MIDDLETONS ALLERGY P, P1027; Liew WK, 2009, J ALLERGY CLIN IMMUN, V123, P434, DOI 10.1016/j.jaci.2008.10.049; Lin RY, 2008, ANN ALLERG ASTHMA IM, V101, P387, DOI 10.1016/S1081-1206(10)60315-8; Metcalfe DD, 2009, J ALLERGY CLIN IMMUN, V123, P687, DOI 10.1016/j.jaci.2009.02.003; Mueller UR, 2007, CURR OPIN ALLERGY CL, V7, P337, DOI 10.1097/ACI.0b013e328259c328; Nowak R, 2013, J EMERG MED, V45, P299, DOI 10.1016/j.jemermed.2013.01.018; Poulos LM, 2007, J ALLERGY CLIN IMMUN, V120, P878, DOI 10.1016/j.jaci.2007.07.040; Pumphrey R, 2004, CURR OPIN ALLERGY CL, V4, P285, DOI 10.1097/01.all.0000136762.89313.0b; Rueff F, 2009, J ALLERGY CLIN IMMUN, V124, P1047, DOI 10.1016/j.jaci.2009.08.027; Sampson HA, 2005, J ALLERGY CLIN IMMUN, V115, P584, DOI 10.1016/j.jaci.2005.01.009; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Simons FER, 2007, J ALLERGY CLIN IMMUN, V120, pS2, DOI [10.1016/j.jaci.2007.05.001, 10.1016/j.jaci.2007.05.016]; Simons FER, 2007, J ALLERGY CLIN IMMUN, V120, P537, DOI 10.1016/j.jaci.2007.06.025; Simons FER, 2010, J ALLERGY CLIN IMMUN, V125, pS161, DOI 10.1016/j.jaci.2009.12.981; Simons FER, 2009, J ALLERGY CLIN IMMUN, V124, P625, DOI 10.1016/j.jaci.2009.08.025; Tang MLK, 2009, CURR OPIN ALLERGY CL, V9, P351, DOI 10.1097/ACI.0b013e32832db95a; Triggiani M, 2008, CLIN EXP IMMUNOL, V153, P7, DOI 10.1111/j.1365-2249.2008.03714.x	31	77	78	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2014	134	5					1125	1130		10.1016/j.jaci.2014.05.018	http://dx.doi.org/10.1016/j.jaci.2014.05.018			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AT4UN	24985399				2022-12-18	WOS:000344938900018
J	Guxens, M; Sonnenschein-van der Voort, AMM; Tiemeier, H; Hofman, A; Sunyer, J; de Jongste, JC; Jaddoe, VWV; Duijts, L				Guxens, Monica; Sonnenschein-van der Voort, Agnes M. M.; Tiemeier, Henning; Hofman, Albert; Sunyer, Jordi; de Jongste, Johan C.; Jaddoe, Vincent W. V.; Duijts, Liesbeth			Parental psychological distress during pregnancy and wheezing in preschool children: The Generation R Study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Anxiety; asthma; child; preschool; child development; cohort studies; depression; prospective studies; stress; psychological	MATERNAL STRESS; GLUCOCORTICOID-RECEPTOR; EPIGENETIC REGULATION; ASTHMA; CHILDHOOD; SYMPTOMS; ANXIETY; FETAL; EXPRESSION; DEPRESSION	Background: Maternal psychological distress during pregnancy might affect fetal lung development and subsequently predispose children to childhood asthma. Objective: We sought to assess the associations of maternal psychological distress during pregnancy with early childhood wheezing. Methods: We performed a population-based prospective cohort study among 4848 children. We assessed maternal and paternal psychological distress at the second trimester of gestation and 3 years after delivery and maternal psychological distress at 2 and 6 months after delivery by using the Brief Symptom Inventory questionnaire. Wheezing in the children was annually examined by using questionnaires from 1 to 4 years. Physician-diagnosed ever asthma was reported at 6 years. Results: Mothers with psychological distress during pregnancy had increased odds of wheezing in their children from 1 to 4 years of life (overall distress: odds ratio [OR], 1.60 [95% CI, 1.32-1.93]; depression: OR, 1.46 [95% CI, 1.20-1.77]; and anxiety: OR, 1.39 [95% CI, 1.15-1.67]). We observed similar positive associations with the number of wheezing episodes, wheezing patterns, and physician-diagnosed asthma at 6 years. Paternal distress during pregnancy and maternal and paternal distress after delivery did not affect these results and were not associated with childhood wheezing. Conclusion: Maternal psychological distress during pregnancy is associated with increased odds of wheezing in their children during the first 6 years of life independent of paternal psychological distress during pregnancy and maternal and paternal psychological distress after delivery. These results suggest a possible intrauterine programming effect of maternal psychological distress leading to respiratory morbidity.	[Guxens, Monica; Sonnenschein-van der Voort, Agnes M. M.; Jaddoe, Vincent W. V.] Erasmus MC, Generat Study Grp R, Rotterdam, Netherlands; [Guxens, Monica; Sunyer, Jordi] Ctr Res Environm Epidemiol CREAL, Barcelona, Spain; [Guxens, Monica; Sunyer, Jordi] Hosp del Mar Res Inst IMIM, Barcelona, Spain; [Guxens, Monica] CIBER Epidemiol & Salud Publ CIBERESP, Barcelona, Spain; [Sonnenschein-van der Voort, Agnes M. M.; de Jongste, Johan C.; Duijts, Liesbeth] Sophia Childrens Univ Hosp, Erasmus Med Ctr, Dept Pediat, Div Resp Med, NL-3000 CB Rotterdam, Netherlands; [Tiemeier, Henning] Sophia Childrens Univ Hosp, Erasmus Med Ctr, Dept Child & Adolescent Psychiat, NL-3000 CB Rotterdam, Netherlands; [Jaddoe, Vincent W. V.] Sophia Childrens Univ Hosp, Erasmus Med Ctr, Dept Pediat, NL-3000 CB Rotterdam, Netherlands; [Duijts, Liesbeth] Sophia Childrens Univ Hosp, Erasmus Med Ctr, Dept Pediat, Div Neonatol, NL-3000 CB Rotterdam, Netherlands; [Sonnenschein-van der Voort, Agnes M. M.; Tiemeier, Henning; Hofman, Albert; Jaddoe, Vincent W. V.; Duijts, Liesbeth] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands; [Sunyer, Jordi] Pompeu Fabra Univ, Barcelona, Spain	Erasmus University Rotterdam; Erasmus MC; Pompeu Fabra University; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; CIBER - Centro de Investigacion Biomedica en Red; CIBERESP; Erasmus University Rotterdam; Erasmus MC; Erasmus MC - Sophia Children's Hospital; Erasmus University Rotterdam; Erasmus MC; Erasmus MC - Sophia Children's Hospital; Erasmus University Rotterdam; Erasmus MC; Erasmus MC - Sophia Children's Hospital; Erasmus University Rotterdam; Erasmus MC; Erasmus MC - Sophia Children's Hospital; Erasmus University Rotterdam; Erasmus MC; Pompeu Fabra University	Duijts, L (corresponding author), Sophia Childrens Univ Hosp, Erasmus Med Ctr, Sp 3435,POB 2060, NL-3000 CB Rotterdam, Netherlands.	l.duijts@erasmusmc.nl	Guxens, Monica/T-2285-2018; Tiemeier, Henning/H-6534-2019; Sunyer, Jordi/G-6909-2014	Guxens, Monica/0000-0002-8624-0333; Tiemeier, Henning/0000-0002-4395-1397; Sunyer, Jordi/0000-0002-2602-4110	Netherlands Organization for Health Research and Development [ZonMw 90700303, 916.10159]; European Respiratory Society/Marie Curie Joint Research Fellowship [MC 1226-2009]; European Respiratory Society; European Community [RESPIRE, PCOFUND-GA-2008-229571]; seventh framework programme, project CHICOS [HEALTH-F2-2009-241504]; European Science Foundation; Erasmus Medical Center, Rotterdam; Erasmus University, Rotterdam	Netherlands Organization for Health Research and Development(Netherlands Organization for Health Research and Development); European Respiratory Society/Marie Curie Joint Research Fellowship; European Respiratory Society; European Community(European Commission); seventh framework programme, project CHICOS; European Science Foundation(European Science Foundation (ESF)European Commission); Erasmus Medical Center, Rotterdam; Erasmus University, Rotterdam	The Generation R Study is conducted by the Erasmus Medical Center in close collaboration with the School of Law and Faculty of Social Sciences of the Erasmus University Rotterdam, the Municipal Health Service Rotterdam area, the Rotterdam Homecare Foundation, and the Stichting Trombosedienst and Artsenlaboratorium Rijnmond (STAR). The first phase of the Generation R Study is made possible by financial support from the Erasmus Medical Center, Rotterdam; Erasmus University, Rotterdam; and the Netherlands Organization for Health Research and Development. V. W. V. J. received an additional grant from The Netherlands Organization for Health Research and Development (ZonMw 90700303, 916.10159). L. D. is the recipient of a European Respiratory Society/Marie Curie Joint Research Fellowship, no. MC 1226-2009. The research leading to these results has received funding from the European Respiratory Society and the European Community's Seventh Framework Programme FP7/2007-2013-Marie Curie Actions under grant agreement RESPIRE, PCOFUND-GA-2008-229571 and from the seventh framework programme, project CHICOS (HEALTH-F2-2009-241504). This manuscript was written with the support of the European Child Cohort Network EUCCONET, a Research Networking Programme financed by the European Science Foundation.	Alikhani-Koopaei R, 2004, J CLIN INVEST, V114, P1146, DOI 10.1172/JCI200421647; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Beijers R, 2010, PEDIATRICS, V126, pE401, DOI 10.1542/peds.2009-3226; Brion MJ, 2011, PEDIATRICS, V127, pE202, DOI 10.1542/peds.2010-0651; Brussee JE, 2004, AM J RESP CRIT CARE, V169, P209, DOI 10.1164/rccm.200306-800OC; Caudri D, 2007, AM J RESP CRIT CARE, V175, P1078, DOI 10.1164/rccm.200610-1441OC; Chiu YHM, 2012, AM J RESP CRIT CARE, V186, P147, DOI 10.1164/rccm.201201-0162OC; Cookson H, 2009, J ALLERGY CLIN IMMUN, V123, P847, DOI 10.1016/j.jaci.2009.01.042; de Beurs E., 2009, BRIEF SYMPTOM INVENT; De Beurs E, 2004, BRIEF SYMPTOM INVENT; Duijts L, 2012, CHEST, V141, P876, DOI 10.1378/chest.11-0112; Duijts L, 2012, EUR J EPIDEMIOL, V27, P5, DOI 10.1007/s10654-012-9657-y; Edwards CA, 2003, CHEST, V124, P18, DOI 10.1378/chest.124.1.18; Hara MR, 2011, NATURE, V477, P349, DOI 10.1038/nature10368; Henderson AJ, 2012, SEMIN FETAL NEONAT M, V17, P82, DOI 10.1016/j.siny.2012.01.006; Henrichs J, 2010, PSYCHOL MED, V40, P633, DOI 10.1017/S0033291709990894; Jaddoe VWV, 2010, EUR J EPIDEMIOL, V25, P823, DOI 10.1007/s10654-010-9516-7; Jenkins MA, 1996, INT J EPIDEMIOL, V25, P609, DOI 10.1093/ije/25.3.609; Joachim RA, 2008, AM J PATHOL, V173, P1379, DOI 10.2353/ajpath.2008.080105; Lefevre F, 2011, PEDIAT ALLERG IMM-UK, V22, P608, DOI 10.1111/j.1399-3038.2011.01155.x; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Martinez Fernando D, 2002, Paediatr Respir Rev, V3, P193, DOI 10.1016/S1526-0542(02)00188-4; McGowan PO, 2009, NAT NEUROSCI, V12, P342, DOI 10.1038/nn.2270; Munk-Olsen T, 2006, JAMA-J AM MED ASSOC, V296, P2582, DOI 10.1001/jama.296.21.2582; Oberlander TF, 2008, EPIGENETICS-US, V3, P97, DOI 10.4161/epi.3.2.6034; Oostveen E, 2010, EUR RESPIR J, V35, P865, DOI 10.1183/09031936.00023409; Oya H, 2000, CLIN EXP IMMUNOL, V121, P384, DOI 10.1046/j.1365-2249.2000.01310.x; Pan W, 2001, BIOMETRICS, V57, P120, DOI 10.1111/j.0006-341X.2001.00120.x; Pincus-Knackstedt MK, 2006, J IMMUNOL, V177, P8484, DOI 10.4049/jimmunol.177.12.8484; Reyes M, 2011, ANN ALLERG ASTHMA IM, V107, P42, DOI 10.1016/j.anai.2011.03.004; Smith GD, 2008, BASIC CLIN PHARMACOL, V102, P245, DOI 10.1111/j.1742-7843.2007.00191.x; Sonnenschein-van der Voort AMM, 2012, EUR RESPIR J, V39, P81, DOI 10.1183/09031936.00178110; Sonnenschein-van der Voort AMM, 2012, AM J RESP CRIT CARE, V185, P731, DOI 10.1164/rccm.201107-1266OC; Spasojevic N, 2011, ACTA PHYSIOL HUNG, V98, P433, DOI 10.1556/APhysiol.98.2011.4.6; Spratt M, 2010, AM J EPIDEMIOL, V172, P478, DOI 10.1093/aje/kwq137; Sterne Jonathan A C, 2009, BMJ, V338, pb2393, DOI 10.1136/bmj.b2393; Tegethoff M, 2011, ENVIRON HEALTH PERSP, V119, P1647, DOI 10.1289/ehp.1003253; Van Batenburg-Eddes T, 2013, J CHILD PSYCHOL PSYC, V54, P591, DOI 10.1111/jcpp.12023; von Hertzen LC, 2002, J ALLERGY CLIN IMMUN, V109, P923, DOI 10.1067/mai.2002.124776; Weaver ICG, 2004, NAT NEUROSCI, V7, P847, DOI 10.1038/nn1276; Wright RJ, 2011, IMMUNOL ALLERGY CLIN, V31, P19, DOI 10.1016/j.iac.2010.09.011; Wright RJ, 2010, AM J RESP CRIT CARE, V182, P25, DOI 10.1164/rccm.200904-0637OC; Wright RJ, 2010, BIOL PSYCHOL, V84, P46, DOI 10.1016/j.biopsycho.2010.01.007; Xiang LB, 2012, NEUROPSYCHOBIOLOGY, V65, P12, DOI 10.1159/000328160	44	77	77	0	29	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2014	133	1					59	+		10.1016/j.jaci.2013.04.044	http://dx.doi.org/10.1016/j.jaci.2013.04.044			21	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	281MM	23777854				2022-12-18	WOS:000329105700008
J	Cole, T; Pearce, MS; Cant, AJ; Cale, CM; Goldblatt, D; Gennery, AR				Cole, Theresa; Pearce, Mark S.; Cant, Andrew J.; Cale, Catherine M.; Goldblatt, David; Gennery, Andrew R.			Clinical outcome in children with chronic granulomatous disease managed conservatively or with hematopoietic stem cell transplantation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chronic granulomatous disease; hematopoietic stem cell transplant; children	EUROPEAN EXPERIENCE; UNRELATED DONOR; ADHERENCE	Background: Chronic granulomatous disease (CGD) is a primary immunodeficiency characterized by serious infections and inflammation. It can be managed conservatively with prophylactic antimicrobial agents or curatively with hematopoietic stem cell transplantation (HSCT). In the United Kingdom and Ireland there are cohorts of children managed both conservatively and curatively. Objectives: This study aimed to compare clinical outcomes (mortality and morbidity) in children managed conservatively and curatively. Methods: Children were identified from specialist centers and advertising through special interest groups. Clinical data were collected from medical records regarding infections, inflammatory complications and growth, other admissions, and curative treatment. Comparisons were made for patients not undergoing HSCT and patients after HSCT. Results: Seventy-three living children were identified, 59 (80%) of whom were recruited. Five deceased children were also identified. Clinical information was available for 62 children (4 deceased). Thirty (48%) children had undergone HSCT. Children who did not undergo transplantation had 0.71 episodes of infection/admission/surgery per CGD life year (95% CI, 0.69-0.75 events per year). Post-HSCT children had 0.15 episodes of infection/admission/surgery per transplant year (95% CI, 0.09-0.21 events per year). The mean z score for height and body mass index (BMI) for age was significantly better in post-HSCT children. Survival in the non-HSCT group was 90% at age 15 years. Survival in the post-HSCT group was 90%. Conclusions: Children with CGD not undergoing transplantation have more serious infections, episodes of surgery, and admissions compared with post-HSCT children. Children undergoing transplantation have better height for age. Survival is good at the end of the pediatric age range and also after HSCT.	[Cole, Theresa; Cant, Andrew J.; Gennery, Andrew R.] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Pearce, Mark S.] Newcastle Univ, Inst Hlth & Soc, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Cale, Catherine M.] Great Ormond St Hosp Sick Children, Dept Clin Immunol, London, England; [Goldblatt, David] UCL, Inst Child Hlth, London WC1E 6BT, England	Newcastle University - UK; Newcastle University - UK; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London	Cole, T (corresponding author), Royal Victoria Infirm, Dept Paediat Immunol & Infect Dis, Old Childrens Outpatients, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.	theresa.cole@ncl.ac.uk	Cole, Theresa/AAX-7893-2021; Goldblatt, David/C-5972-2008	Cole, Theresa/0000-0002-8272-4074; Goldblatt, David/0000-0002-0769-5242; Pearce, Mark/0000-0002-0583-3779	National Institute for Health Research (NIHR) [PB-PG-0909-19060]; National Institute for Health Research [NF-SI-0611-10066] Funding Source: researchfish; Great Ormond Street Hospital Childrens Charity [V1223, V1259] Funding Source: researchfish	National Institute for Health Research (NIHR)(National Institute for Health Research (NIHR)); National Institute for Health Research(National Institute for Health Research (NIHR)); Great Ormond Street Hospital Childrens Charity	This article presents independent research funded by the National Institute for Health Research (NIHR) under its Research for Patient Benefit (RfPB) Programme (grant reference no. PB-PG-0909-19060). The views expressed are those of the author(s) and not necessarily those of the National Health Service, the NIHR, or the Department of Health.	Adeyemi AO, 2012, CLIN THER, V34, P712, DOI 10.1016/j.clinthera.2012.01.028; Cole T, 2013, J CLIN IMMUNOL, V33, P8, DOI 10.1007/s10875-012-9758-0; Dobbels F, 2005, PEDIATR TRANSPLANT, V9, P381, DOI 10.1111/j.1399-3046.2005.00356.x; Holland SM, 2010, CLIN REV ALLERG IMMU, V38, P3, DOI 10.1007/s12016-009-8136-z; Jones LBKR, 2008, CLIN EXP IMMUNOL, V152, P211, DOI 10.1111/j.1365-2249.2008.03644.x; Mackner LM, 2005, INFLAMM BOWEL DIS, V11, P1006, DOI 10.1097/01.MIB.0000186409.15392.54; Martinez CA, 2012, J ALLERGY CLIN IMMUN, V129, P176, DOI 10.1016/j.jaci.2011.10.005; Martire B, 2008, CLIN IMMUNOL, V126, P155, DOI 10.1016/j.clim.2007.09.008; Seger RA, 2002, BLOOD, V100, P4344, DOI 10.1182/blood-2002-02-0583; Soncini E, 2009, BRIT J HAEMATOL, V145, P73, DOI 10.1111/j.1365-2141.2009.07614.x; van den Berg JM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005234; WHO Anthro for personal computers, 2011, WHO ANTHR PERS COMP; WHO AnthroPlus for personal computers, 2009, WHO ANTHROPLUS PERS	13	77	82	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2013	132	5					1150	1155		10.1016/j.jaci.2013.05.031	http://dx.doi.org/10.1016/j.jaci.2013.05.031			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	242JH	23870668				2022-12-18	WOS:000326235600016
J	Driessen, GJ; IJspeert, H; Weemaes, CMR; Haraldsson, A; Trip, M; Warris, A; van der Flier, M; Wulffraat, N; Verhagen, MMM; Taylor, MA; van Zelm, MC; van Dongen, JJM; van Deuren, M; van der Burg, M				Driessen, Gertjan J.; IJspeert, Hanna; Weemaes, Corry M. R.; Haraldsson, Asgeir; Trip, Margreet; Warris, Adilia; van der Flier, Michiel; Wulffraat, Nico; Verhagen, Mijke M. M.; Taylor, Malcolm A.; van Zelm, Menno C.; van Dongen, Jacques J. M.; van Deuren, Marcel; van der Burg, Mirjam			Antibody deficiency in patients with ataxia telangiectasia is caused by disturbed B- and T-cell homeostasis and reduced immune repertoire diversity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Ataxia telangiectasia; class switch recombination; somatic hypermutation; kappa-deleting recombination excision circle; hypogammaglobulinemia; B-cell subsets; T-cell subsets	SOMATIC HYPERMUTATION; SWITCH RECOMBINATION; REPLICATION HISTORY; DNA-DAMAGE; ATM; IMMUNOGLOBULIN; IMMUNODEFICIENCY; LYMPHOCYTES; STANDARDIZATION; MUTATIONS	Background: Ataxia telangiectasia (AT) is a multisystem DNA-repair disorder caused by mutations in the ataxia telangiectasia mutated (ATM) gene. Patients with AT have reduced B-and T-cell numbers and a highly variable immunodeficiency. ATM is important for V(D)J recombination and immunoglobulin class-switch recombination (CSR); however, little is known about the mechanisms resulting in antibody deficiency severity. Objective: We sought to examine the immunologic mechanisms responsible for antibody deficiency heterogeneity in patients with AT. Methods: In this study we included patients with classical AT plus early-onset hypogammaglobulinemia (n = 3), classical AT (n = 8), and variant AT (late onset, n = 4). We studied peripheral B-and T-cell subsets, B-cell subset replication history, somatic hypermutation frequencies, CSR patterns, B-cell repertoire, and ATM kinase activity. Results: Patients with classical AT lacked ATM kinase activity, whereas patients with variant AT showed residual function. Most patients had disturbed naive B-cell and T-cell homeostasis, as evidenced by low cell numbers, increased proliferation, a large proportion CD21(low) CD38(low) anergic B cells, and decreased antigen receptor repertoire diversity. Impaired formation of T cell-dependent memory B cells was predominantly found in patients with AT plus hypogammaglobulinemia. These patients had extremely low naive CD4(+) T-cell counts, which were more severely reduced compared with those seen in patients with classical AT without hypogammaglobulinemia. Finally, AT deficiency resulted in defective CSR to distal constant regions that might reflect an impaired ability of B cells to undergo multiple germinal center reactions. Conclusion: The severity of the antibody deficiency in patients with AT correlates with disturbances in B-and T-cell homeostasis resulting in reduced immune repertoire diversity, which consequently affects the chance of successful antigen-dependent cognate B-T interaction.	[Driessen, Gertjan J.; IJspeert, Hanna; Trip, Margreet] Univ Med Ctr Rotterdam, Erasmus MC, Dept Pediat Infect Dis & Immunol, Rotterdam, Netherlands; [Driessen, Gertjan J.; IJspeert, Hanna; Trip, Margreet; van Zelm, Menno C.; van Dongen, Jacques J. M.; van der Burg, Mirjam] Univ Med Ctr Rotterdam, Erasmus MC, Dept Immunol, Rotterdam, Netherlands; [Weemaes, Corry M. R.; Warris, Adilia; van der Flier, Michiel; Verhagen, Mijke M. M.] Radboud Univ Nijmegen, Med Ctr, Dept Pediat Infect Dis & Immunol, Nijmegen, Netherlands; [Warris, Adilia; van der Flier, Michiel; van Deuren, Marcel] Radboud Univ Nijmegen, Med Ctr, Nijmegen Inst Infect Immun & Inflammat, Nijmegen, Netherlands; [van Deuren, Marcel] Radboud Univ Nijmegen, Med Ctr, Dept Internal Med, Nijmegen, Netherlands; [Haraldsson, Asgeir] Landspitali Univ Hosp Reykjavik, Childrens Hosp Iceland, Reykjavik, Iceland; [Haraldsson, Asgeir] Univ Iceland, Fac Med, Reykjavik, Iceland; [Wulffraat, Nico] Univ Med Ctr Utrecht, Subunit Pediat Rheumatol, Dept Pediat, Utrecht, Netherlands; [Taylor, Malcolm A.] Univ Birmingham, Inst Canc Studies, Birmingham B15 2TT, W Midlands, England	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen; Landspitali National University Hospital; University of Iceland; Utrecht University; Utrecht University Medical Center; University of Birmingham	van der Burg, M (corresponding author), Erasmus MC, Dept Immunol, Dr Molewaterpl 50, NL-3015 GE Rotterdam, Netherlands.	m.vanderburg@erasmusmc.nl	van Dongen, Jacques J.M./F-8537-2015; Driessen, Gertjan/AAI-9711-2020; Weemaes, C.M.R./L-4747-2015; IJspeert, Hanna/U-9479-2019; Deuren, Marcel/O-1846-2013; van der Flier, M./L-4307-2015; van Zelm, Menno C/O-4404-2015; Warris, A./L-4745-2015; Wulffraat, Nico M/AAE-8929-2020; Aye, Lu/J-8733-2013	van Dongen, Jacques J.M./0000-0001-7686-0021; van der Flier, M./0000-0003-1296-0159; van Zelm, Menno C/0000-0003-4161-1919; Wulffraat, Nico M/0000-0001-9548-5562; Aye, Lu/0000-0002-5495-1683; Warris, Adilia/0000-0001-6586-3358; Haraldsson, Asgeir/0000-0001-5364-7877; van Dongen, Jacques J.M./0000-0002-3650-7087	foundation "Sophia Kinderziekenhuis Fonds'' [589]; ZonMW [91712323]; GlaxoSmithKline; Cancer Research UK [14346] Funding Source: researchfish	foundation "Sophia Kinderziekenhuis Fonds''; ZonMW(Netherlands Organization for Health Research and Development); GlaxoSmithKline(GlaxoSmithKline); Cancer Research UK(Cancer Research UK)	Supported by grants from the foundation "Sophia Kinderziekenhuis Fonds'' (grant 589 H.I.) and ZonMW (Vidi grant 91712323 to M.v.d.B.).; Disclosure of potential conflict of interest: H. IJspeert has been supported by one or more grants from Sophia Kinderziekenhuis Fonds (grant 589). A. Haraldsson has received one or more grants from or has one or more grants pending with GlaxoSmithKline, has received one or more payments for lecturing from or is on the speakers' bureau for GlaxoSmithKline and Pfizer, and has received one or more payments for travel/accommodations/meeting expenses from GlaxoSmithKline, AstraZeneca, and CSL Behring. A. Warris has consultancy arrangements with and has received one or more grants from or has one or more grants pending with Pfizer and Gilead and has received one or more payments for the development of educational presentations for Pfizer. M. A. Taylor has been supported by one or more grants from Cancer Research UK. M. van der Burg has been supported by a VIDI grant of the Dutch Scientific Organization. The rest of the authors declare that they have no relevant conflicts of interest.	Barone G, 2009, HUM MUTAT, V30, P1222, DOI 10.1002/humu.21034; Berkowska MA, 2011, BLOOD, V118, P2150, DOI 10.1182/blood-2011-04-345579; Boyd SD, 2009, SCI TRANSL MED, V1, DOI 10.1126/scitranslmed.3000540; Bredemeyer AL, 2008, J IMMUNOL, V181, P2620, DOI 10.4049/jimmunol.181.4.2620; Bredemeyer AL, 2006, NATURE, V442, P466, DOI 10.1038/nature04866; Carney EF, 2012, J IMMUNOL, V189, P261, DOI 10.4049/jimmunol.1101909; ComansBitter WM, 1997, J PEDIATR-US, V130, P388, DOI 10.1016/S0022-3476(97)70200-2; Driessen GJ, 2011, BLOOD, V118, P6814, DOI 10.1182/blood-2011-06-361881; Exley AR, 2011, CLIN IMMUNOL, V140, P26, DOI 10.1016/j.clim.2011.03.007; Giovannetti A, 2002, BLOOD, V100, P4082, DOI 10.1182/blood-2002-03-0976; Hazenberg MD, 2001, J MOL MED, V79, P631, DOI 10.1007/s001090100271; Isnardi I, 2010, BLOOD, V115, P5026, DOI 10.1182/blood-2009-09-243071; Kracker S, 2011, IMMUNOL LETT, V138, P97, DOI 10.1016/j.imlet.2011.02.004; Lefranc MP, 2003, LEUKEMIA, V17, P260, DOI 10.1038/sj.leu.2402637; Lumsden JM, 2004, J EXP MED, V200, P1111, DOI 10.1084/jem.20041074; Noordzij JG, 2009, ARCH DIS CHILD, V94, P448, DOI 10.1136/adc.2008.149351; Palanichamy A, 2009, J IMMUNOL, V182, P5982, DOI 10.4049/jimmunol.0801859; Pan Q, 2002, EUR J IMMUNOL, V32, P1300, DOI 10.1002/1521-4141(200205)32:5<1300::AID-IMMU1300>3.0.CO;2-L; Pan-Hammarstrom Q, 2003, J IMMUNOL, V170, P3707, DOI 10.4049/jimmunol.170.7.3707; PETERSON RD, 1964, LANCET, V1, P1189; Rakhmanov M, 2009, P NATL ACAD SCI USA, V106, P13451, DOI 10.1073/pnas.0901984106; Reina-San-Martin B, 2004, J EXP MED, V200, P1103, DOI 10.1084/jem.20041162; Rotman G, 1998, HUM MOL GENET, V7, P1555, DOI 10.1093/hmg/7.10.1555; Staples ER, 2008, CLIN EXP IMMUNOL, V153, P214, DOI 10.1111/j.1365-2249.2008.03684.x; Stray-Pedersen A, 2005, CLIN EXP IMMUNOL, V140, P507, DOI 10.1111/j.1365-2249.2005.02791.x; van der Burg M, 2011, LEUKEMIA, V25, P1467, DOI 10.1038/leu.2011.118; van der Burg M, 2010, BLOOD, V115, P4770, DOI 10.1182/blood-2009-10-250514; Van der Burg M, 2007, EUR J IMMUNOL, V37, P3522, DOI 10.1002/eji.200737624; van Dongen JJM, 2003, LEUKEMIA, V17, P2257, DOI 10.1038/sj.leu.2403202; van Zelm MC, 2007, J EXP MED, V204, P645, DOI 10.1084/jem.20060964; Verhagen MMM, 2012, HUM MUTAT, V33, P561, DOI 10.1002/humu.22016; Xu Y, 2006, NAT REV IMMUNOL, V6, P261, DOI 10.1038/nri1804; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	33	77	80	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2013	131	5					1367	U183		10.1016/j.jaci.2013.01.053	http://dx.doi.org/10.1016/j.jaci.2013.01.053			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	144AU	23566627				2022-12-18	WOS:000318912200014
J	Busse, WW; Wenzel, SE; Meltzer, EO; Kerwin, EM; Liu, MC; Zhang, N; Chon, Y; Budelsky, AL; Lin, J; Lin, SL				Busse, William W.; Wenzel, Sally E.; Meltzer, Eli O.; Kerwin, Edward M.; Liu, Mark C.; Zhang, Nan; Chon, Yun; Budelsky, Alison L.; Lin, Joseph; Lin, Shao-Lee			Safety and efficacy of the prostaglandin D-2 receptor antagonist AMG 853 in asthmatic patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; chemoattractant receptor homologous molecule expressed on T(H)2 cells; D-prostanoid; Asthma Control Questionnaire; prostaglandin D-2	HELPER TYPE-2 CELLS; INFLAMMATION; GENERATION; VALIDATION	Background: The D-prostanoid receptor and the chemoattractant receptor homologous molecule expressed on T(H)2 cells (CRTH2) are implicated in asthma pathogenesis. AMG 853 is a potent, selective, orally bioavailable, small-molecule dual antagonist of human D-prostanoid and CRTH2. Objective: We sought to determine the efficacy and safety of AMG 853 compared with placebo in patients with inadequately controlled asthma. Methods: Adults with moderate-to-severe asthma were randomized to placebo; 5, 25, or 100 mg of oral AMG 853 twice daily; or 200 mg of AMG 853 once daily for 12 weeks. All patients continued their inhaled corticosteroids. Long-acting beta-agonists were not allowed during the treatment period. Allowed concomitant medications included short-acting beta-agonists and a systemic corticosteroid burst for asthma exacerbation. The primary end point was change in total Asthma Control Questionnaire score from baseline to week 12. Secondary and exploratory end points included FEV1, symptom scores, rescue short-acting beta-agonist use, and exacerbations. Results: Among treated patients, no effect over placebo (n = 79) was observed in mean changes in Asthma Control Questionnaire scores at 12 weeks (placebo, -0.492; range for AMG 853 groups [n = 317], -0.444 to -0.555). No significant differences between the active and placebo groups were observed for secondary end points. The most commonly reported adverse events were asthma, upper respiratory tract infection, and headache; 9 patients experienced serious adverse events, all of which were deemed unrelated to study treatment by the investigator. Conclusion: AMG 853 as an add-on to inhaled corticosteroid therapy demonstrated no associated risks but was not effective at improving asthma symptoms or lung function in patients with inadequately controlled moderate-to-severe asthma. (J Allergy Clin Immunol 2013;131:339-45.)	[Busse, William W.] Univ Wisconsin, Dept Med, Madison, WI 53792 USA; [Wenzel, Sally E.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15260 USA; [Meltzer, Eli O.] Allergy & Asthma Med Grp & Res Ctr, San Diego, CA USA; [Kerwin, Edward M.] Clin Res Inst So Oregon, Medford, OR USA; [Liu, Mark C.] Johns Hopkins Asthma & Allergy Ctr, Baltimore, MD USA; [Zhang, Nan; Chon, Yun; Budelsky, Alison L.; Lin, Joseph; Lin, Shao-Lee] Amgen Inc, Thousand Oaks, CA USA	University of Wisconsin System; University of Wisconsin Madison; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Johns Hopkins University; Johns Hopkins Medicine; Amgen	Busse, WW (corresponding author), Univ Wisconsin, Sch Med & Publ Hlth, K4-910 CSC,MC 9988,600 Highland Ave, Madison, WI 53792 USA.	Wwb@medicine.wisc.edu		Wenzel, Sally/0000-0002-4242-0164	National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases; NIH/National Heart, Lung, and Blood Institute; Amgen; GlaxoSmithKline; MedImmune; Sanofi Aventis	National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH/National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Amgen(Amgen); GlaxoSmithKline(GlaxoSmithKline); MedImmune(AstraZenecaMedimmune); Sanofi Aventis(Sanofi-Aventis)	W. W. Busse has served on the advisory board for Merck; has consultant arrangements with Amgen, AstraZeneca, Novartis, GlaxoSmithKline, MedImmune, and Genentech; has received research support from the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases and the NIH/National Heart, Lung, and Blood Institute. S. E. Wenzel has received research support from Amgen. E. M. Kerwin has received research support from Amgen; has served on advisory boards or speakers' panels for Astra Zeneca (MAP Pharma), Dey Laboratories, Ironwood Pharmaceuticals, Pfizer, Sanofi Aventis, Sunovion (Sepracor), and Targacept; has received travel reimbursement from Merck (Schering-Plough), Forest Labs, and Novartis; has conducted clinical research trials for Abbott, Actelion, Adams, Alcon, ALK-Abello, Allergy Therapeutics, Almirall, Amgen, Amphastar, Astellas, Astra Zeneca (MAP Pharma), Asubio, Biota, Boehringer Ingelheim, Cephalon (Centocor, Ception), Chiesi, Critical Therapeutics, Daiichi Sankyo, Dey Labs, Elevation Pharma, Elixir, Exelixis, Forest, Genentech, GlaxoSmithKline, Incyte, Inflazyme, Johnson & Johnson, Lilly, Meda, Medicinova, MedImmune, Med Pointe, Merck (Schering-Plough), Mpex, Novartis, Novo Nordisk, Otsuka, Pearl, Pfizer (Wyeth), Phenomix, Replidyne, Roche, Sanofi-Aventis, Skye Pharma, Stallergenes, Sunovion (Altana, Sepracor), TAP, Takeda, Targacept, Teva (Ivax), UCB Pharma, and Wellstat. M. C. Liu has received research support from GlaxoSmithKline, MedImmune, Sanofi Aventis, and Amgen and has served on the Data Safety Monitoring Board for Cephalon. N. Zhang, A. L. Budelsky, J. Lin, and S.-L. Lin are employed by Amgen. Y. Chon is employed by and holds stock in Amgen. The rest of the authors declare that they have no relevant conflicts of interest.	Arimura A, 2001, J PHARMACOL EXP THER, V298, P411; Banfield C, 2010, J ALLERGY CLIN IMMUN, V125, pAB66, DOI 10.1016/j.jaci.2009.12.260; Barnes N, 2012, CLIN EXP ALLERGY, V42, P38, DOI 10.1111/j.1365-2222.2011.03813.x; Chen JJ, 2011, PROGR MED CHEM, V50, P49, DOI 10.1016/B978-0-12-381290-2.00002-1; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; Corren J, 2010, AM J RESP CRIT CARE, V181, P788, DOI 10.1164/rccm.200909-1448OC; FITZPATRICK FA, 1983, J BIOL CHEM, V258, P1713; Gervais FG, 2011, MOL PHARMACOL, V79, P69, DOI 10.1124/mol.110.068585; Hirai H, 2001, J EXP MED, V193, P255, DOI 10.1084/jem.193.2.255; Juniper EF, 2006, RESP MED, V100, P616, DOI 10.1016/j.rmed.2005.08.012; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; Juniper EF, 1999, CHEST, V115, P1265, DOI 10.1378/chest.115.5.1265; Kaiko GE, 2011, CURR OPIN ALLERGY CL, V11, P39, DOI 10.1097/ACI.0b013e328342322f; LEWIS RA, 1982, J IMMUNOL, V129, P1627; Liu JW, 2011, ACS MED CHEM LETT, V2, P326, DOI 10.1021/ml1002234; Lukacs NW, 2008, AM J PHYSIOL-LUNG C, V295, pL767, DOI 10.1152/ajplung.90351.2008; Matsuoka T, 2000, SCIENCE, V287, P2013, DOI 10.1126/science.287.5460.2013; National Asthma Education and Prevention Program Third Expert Panel on the Diagnosis and Management of Asthma, 2007, 3 NAT ASTHM ED PREV; Parnes J, 2010, EUR RESP SOC ANN C S, P1165; Philip G, 2009, J ALLERGY CLIN IMMUN, V124, pe1; Philip G, 2009, J ALLERGY CLIN IMMUN, V124, P942, DOI 10.1016/j.jaci.2009.07.006; Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST; ROBERTS LJ, 1985, PROSTAGLANDINS, V30, P383, DOI 10.1016/0090-6980(85)90114-5; Shichijo M, 2009, CLIN EXP ALLERGY, V39, P1404, DOI 10.1111/j.1365-2222.2009.03275.x; Singh D, 2010, EUR RESP SOC ANN C S	25	77	78	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2013	131	2					339	345		10.1016/j.jaci.2012.10.013	http://dx.doi.org/10.1016/j.jaci.2012.10.013			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	086CT	23174659	Bronze			2022-12-18	WOS:000314661500009
J	Wechsler, ME; Fulkerson, PC; Bochner, BS; Gauvreau, GM; Gleich, GJ; Henkel, T; Kolbeck, R; Mathur, SK; Ortega, H; Patel, J; Prussin, C; Renzi, P; Rothenberg, ME; Roufosse, F; Simon, D; Simon, HU; Wardlaw, A; Weller, PF; Klion, AD				Wechsler, Michael E.; Fulkerson, Patricia C.; Bochner, Bruce S.; Gauvreau, Gail M.; Gleich, Gerald J.; Henkel, Tim; Kolbeck, Roland; Mathur, Sameer K.; Ortega, Hector; Patel, Jatin; Prussin, Calman; Renzi, Paolo; Rothenberg, Marc E.; Roufosse, Florence; Simon, Dagmar; Simon, Hans-Uwe; Wardlaw, Andrew; Weller, Peter F.; Klion, Amy D.			Novel targeted therapies for eosinophilic disorders	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Hypereosinophilic syndromes; eosinophil-associated gastrointestinal disorders; eosinophilic esophagitis; Churg-Strauss syndrome; IL-5; mepolizumab; reslizumab	IDIOPATHIC HYPEREOSINOPHILIC SYNDROME; ANTI-IL-5 MEPOLIZUMAB THERAPY; CHURG-STRAUSS-SYNDROME; T-CELL POPULATION; AIRWAY INFLAMMATION; PERIPHERAL-BLOOD; ANTI-INTERLEUKIN-5 ANTIBODY; INHIBITORY RECEPTORS; ALEMTUZUMAB THERAPY; MONOCLONAL-ANTIBODY	Hypereosinophilic syndromes (HESs) are a diverse group of conditions characterized by clinical manifestations attributable to eosinophilia and eosinophilic infiltration of tissues. HESs are chronic disorders with significant morbidity and mortality. Although the availability of targeted chemotherapeutic agents, including imatinib, has improved quality of life and survival in some patients with HESs, additional agents with increased efficacy and decreased toxicity are sorely needed. The purpose of this review is to provide an overview of eosinophil biology with an emphasis on potential targets of pharmacotherapy and to provide a summary of potential eosinophil-targeting agents, including those in development, in clinical trials, or approved for other disorders. (J Allergy Clin Immunol 2012;130:563-71.)	[Wechsler, Michael E.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA USA; [Fulkerson, Patricia C.; Rothenberg, Marc E.] Cincinnati Childrens Hosp, Med Ctr, Dept Pediat, Div Allergy & Immunol, Baltimore, MD USA; [Bochner, Bruce S.] Johns Hopkins Univ, Sch Med, Dept Med, Div Clin Immunol & Allergy, Baltimore, MD 21205 USA; [Gauvreau, Gail M.] McMaster Univ, Hamilton, ON L8S 4L8, Canada; [Gleich, Gerald J.] Univ Utah, Dept Dermatol & Med, Salt Lake City, UT USA; [Henkel, Tim] Ceptaris Therapeut, Malvern, PA USA; [Kolbeck, Roland] MedImmune Resp Inflammat & Autoimmun, Gaithersburg, MD USA; [Mathur, Sameer K.] Univ Wisconsin, Sch Med, Dept Med, Div Allergy Pulm & Crit Care, Madison, WI 53706 USA; [Ortega, Hector] GlaxoSmithKline Res & Dev Ltd, Res Triangle Pk, NC USA; [Patel, Jatin] GlaxoSmithKline Res & Dev Ltd, Uxbridge, Middx, England; [Prussin, Calman] NIAID, Lab Allerg Dis, Bethesda, MD 20892 USA; [Renzi, Paolo] Univ Montreal, Notre Dame Hosp, Montreal, PQ H3C 3J7, Canada; [Roufosse, Florence] Univ Libre Bruxelles, Erasme Hosp, Dept Internal Med, Brussels, Belgium; [Roufosse, Florence] Univ Libre Bruxelles, Inst Med Immunol, Gosselies, Belgium; [Simon, Dagmar] Univ Hosp Bern, Dept Dermatol, Inselspital, Bern, Switzerland; [Simon, Hans-Uwe] Univ Bern, Inst Pharmacol, CH-3012 Bern, Switzerland; [Wardlaw, Andrew] Univ Leicester, Inst Lung Hlth, Dept Infect Immun & Inflammat, Leicester LE1 7RH, Leics, England; [Weller, Peter F.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA USA; [Klion, Amy D.] NIAID, Parasit Dis Lab, NIH, Bethesda, MD 20892 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Cincinnati Children's Hospital Medical Center; University System of Maryland; University of Maryland Baltimore; Johns Hopkins University; McMaster University; Utah System of Higher Education; University of Utah; Actelion Pharmaceuticals Ltd; AstraZeneca; Medimmune; University of Wisconsin System; University of Wisconsin Madison; GlaxoSmithKline; GlaxoSmithKline; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Universite de Montreal; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; University of Bern; University Hospital of Bern; University of Bern; University of Leicester; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Wechsler, ME (corresponding author), Div Hlth, 1400 Jackson St, Denver, CO 80206 USA.	mikewechsler@gmail.com	Wechsler, Michael/B-3979-2013; Wechsler, Michael/AAC-5506-2019; Simon, Hans-Uwe/AAU-7410-2020	Wechsler, Michael/0000-0003-3505-2946; Simon, Hans-Uwe/0000-0002-9404-7736; Klion, Amy/0000-0002-4986-5326; Prussin, Calman/0000-0002-3917-3326; Wardlaw, Andrew/0000-0001-6583-0791	Division of Intramural Research, National Institute of Allergy and Infectious Diseases/National Institutes of Health (NIH); Office of Rare Diseases/NIH; National Institutes of Health (NIH); GlaxoSmithKline; Cephalon; Novartis; Sepracor/Sunovion; Schering-Plough; NKT Therapeutics; Asthmatx/BSCI; Genzyme; MapPharma; Genentech; Boehringer Ingelheim; National Institute of Allergy and Infectious Diseases; National Heart, Lung, and Blood Institute; UpToDate; Elsevier; Topigen Pharma; TRIA Bioscience Corp; ImmViz; Teva; Teva Pharmaceuticals; NIH; Pharmaxis; Immune Pharmaceuticals; UpToDate Online; OPO Foundation Zurich; Basilea Pharmaceutica; Pfizer; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL107151] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020241, ZIAAI000993, R37AI020241, R01AI051645, R01AI072265, ZIAAI001130] Funding Source: NIH RePORTER	Division of Intramural Research, National Institute of Allergy and Infectious Diseases/National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Office of Rare Diseases/NIH; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); GlaxoSmithKline(GlaxoSmithKline); Cephalon; Novartis(Novartis); Sepracor/Sunovion; Schering-Plough(Merck & CompanySchering Plough Corporation); NKT Therapeutics; Asthmatx/BSCI; Genzyme(Sanofi-AventisGenzyme Corporation); MapPharma; Genentech(Roche HoldingGenentech); Boehringer Ingelheim(Boehringer Ingelheim); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); UpToDate; Elsevier; Topigen Pharma; TRIA Bioscience Corp; ImmViz; Teva(Teva Pharmaceutical Industries); Teva Pharmaceuticals(Teva Pharmaceutical Industries); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Pharmaxis; Immune Pharmaceuticals; UpToDate Online; OPO Foundation Zurich; Basilea Pharmaceutica; Pfizer(Pfizer); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported in part by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases/National Institutes of Health (NIH), and by the Office of Rare Diseases/NIH.; M. E. Wechsler has received research support from the National Institutes of Health (NIH); has received consulting fees from GlaxoSmithKline, Cephalon, Novartis, Sepracor/Sunovion, Schering-Plough, NKT Therapeutics, Asthmatx/BSCI, Genzyme, MapPharma, Genentech, and Boehringer Ingelheim; and has received honoraria from Merck. B. S. Bochner has received grants from the National Institute of Allergy and Infectious Diseases and the National Heart, Lung, and Blood Institute; has consultant arrangements with Sanofi-Aventis, Genentech, Merck, Roche, GlaxoSmithKline, TEVA, GlycoFi, and Medicis; is on a scientific advisory board for Merck; is a coinventor on existing and pending Siglec-8-related patents; might be entitled to a share of royalties received by his university on the potential sales of Siglec-8-related products but thus far has received no such royalties; receives royalties from UpToDate and Elsevier; is a cofounder of and has purchased stock in Allakos; and holds stock options for Glycomimetics. G. M. Gauvreau has received research support from Topigen Pharma. G. J. Gleich is a board member of the American Partnership for Eosinophilic Disorders (APFED) without compensation; has received consultancy fees from GlaxoSmithKline; has received research support from TRIA Bioscience Corp and ImmViz; has a patent with ImmViz; has received royalties from Teva; and has stock/stock options in Immune Design Corp. T. Henkel has received consultancy fees from Cephalon and is employed by and has received stock/stock options in Ception Therapeutics. R. Kolbeck is employed by and owns stock/stock options in MedImmune. S. K. Mathur has received consultancy fees from Teva Pharmaceuticals, is employed by the University of Wisconsin and William S Middleton VA Hospital, and has received research support from the NIH. H. Ortega is employed by and has received stock/stock options in GlaxoSmithKline. P. Renzi has received research support, consulting fees, and fees for participation in review activities from Pharmaxis and has received royalties and owns a patent as the inventor of TPI-ASM8. M. E. Rothenberg is a member of the board for APFED and the International Eosinophil Society, has received consultancy fees from Immune Pharmaceuticals, is the inventor of patents owned by Cincinnati Children's, and has stock/stock options in Immune Pharmaceuticals and Teva. F. Roufosse has received consulting fees and travel support from GlaxoSmithKline and received royalties from UpToDate Online. D. Simon has provided expert testimony for Basilea Pharmaceutica and Astellas Schweiz, has received research support from OPO Foundation Zurich, and has received lecture fees from Basilea Pharmaceutica. H.-U. Simon has received consultancy fees from Pfizer. P. F. Weller has received consultancy fees from GlaxoSmithKline and receives royalties from UpToDate. A. Wardlaw was a member of the Cephalon-Teva data monitoring board; has received research support from Pfizer and GlaxoSmithKline; and has provided legal consultation/expert witness testimony for Bayer. The rest of the authors declare that they have no relevant conflicts of interest.	Ackerman SJ, 2007, IMMUNOL ALLERGY CLIN, V27, P357, DOI 10.1016/j.iac.2007.07.004; Ahrens R, 2008, J IMMUNOL, V181, P7390, DOI 10.4049/jimmunol.181.10.7390; Assa'ad AH, 2011, GASTROENTEROLOGY, V141, P1593, DOI 10.1053/j.gastro.2011.07.044; Bedi R, 2009, BLOOD, V113, P317, DOI 10.1182/blood-2008-02-139741; Blanchard C, 2006, J CLIN INVEST, V116, P536, DOI 10.1172/JCI26679; Bloomgren G, 2012, NEW ENGL J MED, V366, P1870, DOI 10.1056/NEJMoa1107829; Bochner BS, 2009, CLIN EXP ALLERGY, V39, P317, DOI 10.1111/j.1365-2222.2008.03173.x; Bochner BS, 2004, J ALLERGY CLIN IMMUN, V113, P3, DOI 10.1016/j.jaci.2003.09.046; Busse WW, 2010, J ALLERGY CLIN IMMUN, V125, P1237, DOI 10.1016/j.jaci.2010.04.005; Castro M, 2011, AM J RESP CRIT CARE, V184, P1125, DOI 10.1164/rccm.201103-0396OC; Cherry WB, 2008, J ALLERGY CLIN IMMUN, V121, P1484, DOI 10.1016/j.jaci.2008.04.005; Cools J, 2003, NEW ENGL J MED, V348, P1201, DOI 10.1056/NEJMoa025217; da Silva AJ, 2002, J IMMUNOL, V168, P4462, DOI 10.4049/jimmunol.168.9.4462; Djukanovic R, 2004, AM J RESP CRIT CARE, V170, P583, DOI 10.1164/rccm.200312-1651OC; Egan RW, 1999, ARZNEIMITTEL-FORSCH, V49, P779; Feltenmark S, 2008, P NATL ACAD SCI USA, V105, P680, DOI 10.1073/pnas.0710127105; Fulkerson PC, 2006, P NATL ACAD SCI USA, V103, P16418, DOI 10.1073/pnas.0607863103; Garcia NV, 2011, J IMMUNOL, V187, P2268, DOI 10.4049/jimmunol.1101008; Garrett JK, 2004, J ALLERGY CLIN IMMUN, V113, P115, DOI 10.1016/j.jaci.2003.10.049; Gauvreau GM, 2008, AM J RESP CRIT CARE, V177, P952, DOI 10.1164/rccm.200708-1251OC; Gevaert P, 2006, J ALLERGY CLIN IMMUN, V118, P1133, DOI 10.1016/j.jaci.2006.05.031; Gleich GJ, 2000, J ALLERGY CLIN IMMUN, V105, P651, DOI 10.1067/mai.2000.105712; Goedkoop AY, 2004, ARCH DERMATOL RES, V295, P465, DOI 10.1007/s00403-004-0450-y; Heath H, 1997, J CLIN INVEST, V99, P178, DOI 10.1172/JCI119145; Henderson WR, 1997, J CLIN INVEST, V100, P3083, DOI 10.1172/JCI119863; Holgate S, 2005, J ALLERGY CLIN IMMUN, V115, P459, DOI 10.1016/j.jaci.2004.11.053; Iwasaki H, 2005, J EXP MED, V201, P1891, DOI 10.1084/jem.20050548; Kim S, 2010, J ALLERGY CLIN IMMUN, V125, P1336, DOI 10.1016/j.jaci.2010.03.028; Kim YJ, 2004, J ALLERGY CLIN IMMUN, V114, P1449, DOI 10.1016/j.jaci.2004.08.027; Kips JC, 2003, AM J RESP CRIT CARE, V167, P1655, DOI 10.1164/rccm.200206-525OC; Klion AD, 2004, BLOOD, V103, P2939, DOI 10.1182/blood-2003-10-3620; Klion AD, 2006, J ALLERGY CLIN IMMUN, V117, P1292, DOI 10.1016/j.jaci.2006.02.042; Kolbeck R, 2010, J ALLERGY CLIN IMMUN, V125, P1344, DOI 10.1016/j.jaci.2010.04.004; Komai M, 2010, J PHARMACOL SCI, V112, P203, DOI 10.1254/jphs.09277FP; Kraan MC, 2002, ARTHRITIS RHEUM-US, V46, P2776, DOI 10.1002/art.10543; MAJEAU GR, 1994, J IMMUNOL, V152, P2753; Massanari M, 2010, RESP MED, V104, P188, DOI 10.1016/j.rmed.2009.09.011; Milanovic M, 2008, J IMMUNOL, V181, P5045, DOI 10.4049/jimmunol.181.7.5045; MILLER GT, 1993, J EXP MED, V178, P211, DOI 10.1084/jem.178.1.211; Moosig F, 2011, ANN INTERN MED, V155, P341, DOI 10.7326/0003-4819-155-5-201109060-00026; Moqbel Redwan, 2006, Sci STKE, V2006, ppe26, DOI 10.1126/stke.3382006pe26; Mori Y, 2009, J EXP MED, V206, P183, DOI 10.1084/jem.20081756; Moul DK, 2008, J AM ACAD DERMATOL, V58, P984, DOI 10.1016/j.jaad.2008.02.007; Munitz A, 2006, BLOOD, V107, P1996, DOI 10.1182/blood-2005-07-2926; Munitz A, 2008, BLOOD, V111, P5694, DOI 10.1182/blood-2007-12-126748; Munitz A, 2007, J ALLERGY CLIN IMMUN, V119, P1382, DOI 10.1016/j.jaci.2007.01.031; Nair P, 2009, NEW ENGL J MED, V360, P985, DOI 10.1056/NEJMoa0805435; NAKAJIMA H, 1994, J EXP MED, V179, P1145, DOI 10.1084/jem.179.4.1145; Nutku E, 2003, BLOOD, V101, P5014, DOI 10.1182/blood-2002-10-3058; O'Byrne PM, 2006, CHEST, V130, P244, DOI 10.1378/chest.130.1.244; Ogbogu PU, 2009, J ALLERGY CLIN IMMUN, V124, P1319, DOI 10.1016/j.jaci.2009.09.022; Okigami H, 2007, EUR J PHARMACOL, V559, P202, DOI 10.1016/j.ejphar.2006.11.065; Perini Guilherme Fleury, 2009, Br J Haematol, V147, P592, DOI 10.1111/j.1365-2141.2009.07723.x; Pitini Vincenzo, 2004, Br J Haematol, V127, P477, DOI 10.1111/j.1365-2141.2004.05206.x; Plotz S, 2003, NEW ENGL J MED, V349, P2334, DOI 10.1056/NEJMoa031261; Rothenberg ME, 2008, NEW ENGL J MED, V358, P1215, DOI 10.1056/NEJMoa070812; Rothenberg ME, 2006, ANNU REV IMMUNOL, V24, P147, DOI 10.1146/annurev.immunol.24.021605.090720; Roufosse FE, 2012, J ALLERGY C IN PRESS; Roufosse F, 2007, IMMUNOL ALLERGY CLIN, V27, P389, DOI 10.1016/j.iac.2007.07.002; Roufosse F, 2010, J ALLERGY CLIN IMMUN, V126, P828, DOI 10.1016/j.jaci.2010.06.049; Schuligoi R, 2010, PHARMACOLOGY, V85, P372, DOI 10.1159/000313836; Sefcick A, 2004, BRIT J HAEMATOL, V124, P558, DOI 10.1046/j.1365-2141.2003.04801.x; Simon D, 2008, J ALLERGY CLIN IMMUN, V122, P423, DOI 10.1016/j.jaci.2008.06.010; Simon D, 2007, J ALLERGY CLIN IMMUN, V119, P1291, DOI 10.1016/j.jaci.2007.02.010; Simon HU, 2010, J ALLERGY CLIN IMMUN, V126, P45, DOI 10.1016/j.jaci.2010.03.042; Slager RE, 2012, J ALLERGY CLIN IMMUN, V130, P516, DOI 10.1016/j.jaci.2012.03.030; Spencer LA, 2009, J LEUKOCYTE BIOL, V85, P117, DOI 10.1189/jlb.0108058; Stein ML, 2006, J ALLERGY CLIN IMMUN, V118, P1312, DOI 10.1016/j.jaci.2006.09.007; Stein ML, 2008, J ALLERGY CLIN IMMUN, V121, P1473, DOI 10.1016/j.jaci.2008.02.033; Sugimoto H, 2003, J PHARMACOL EXP THER, V305, P347, DOI 10.1124/jpet.102.046748; Syed FF, 2012, J AM COLL CARDIOL, V59, P430, DOI 10.1016/j.jacc.2011.06.078; Rensen ELJ, 2009, ALLERGY, V64, P72, DOI 10.1111/j.1398-9995.2008.01881.x; Verstovsek S, 2009, CLIN CANCER RES, V15, P368, DOI 10.1158/1078-0432.CCR-08-1302; von Gunten S, 2009, MIDDLETONS ALLERGY P, P1711; Waddell A, 2011, J IMMUNOL, V186, P5993, DOI 10.4049/jimmunol.1003844; Wagner LA, 2009, J ALLERGY CLIN IMMUN, V123, P1407, DOI 10.1016/j.jaci.2009.01.069; Wegmann M, 2007, AM J RESP CELL MOL, V36, P61, DOI 10.1165/rcmb.2006-0188OC; WELLER PF, 1993, IMMUNOPHARMACOLOGY E, P25; Wenzel S, 2007, LANCET, V370, P1422, DOI 10.1016/S0140-6736(07)61600-6; Yamane-Ohnuki N, 2004, BIOTECHNOL BIOENG, V87, P614, DOI 10.1002/bit.20151; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569; Zimmermann N, 2008, ALLERGY, V63, P1156, DOI 10.1111/j.1398-9995.2008.01709.x	82	77	107	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2012	130	3					563	571		10.1016/j.jaci.2012.07.027	http://dx.doi.org/10.1016/j.jaci.2012.07.027			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	001LZ	22935585	Green Accepted, Green Submitted			2022-12-18	WOS:000308463500001
J	Rondon, C; Campo, P; Herrera, R; Blanca-Lopez, N; Melendez, L; Canto, G; Torres, MJ; Blanca, M				Rondon, Carmen; Campo, Paloma; Herrera, Rocio; Blanca-Lopez, Natalia; Melendez, Lidia; Canto, Gabriela; Torres, Maria J.; Blanca, Miguel			Nasal allergen provocation test with multiple aeroallergens detects polysensitization in local allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Acoustic rhinometry; local allergic rhinitis; nasal allergen provocation test; visual analog scale	IDIOPATHIC RHINITIS; CHALLENGES; IGE; ABSENCE; ASTHMA; CELL	Background: Patients previously given a diagnosis of nonallergic rhinitis (NAR) might have a new form of local allergic rhinitis (LAR) with local production of specific IgE antibodies and a positive response to a nasal allergen provocation test (NAPT). Objective: We evaluated an NAPT protocol using multiple aeroallergens (NAPT-M) for the detection of polysensitization to several aeroallergens in patients with LAR. Methods: NAPT-Ms with 2 different panels of aeroallergens for patients with perennial and seasonal rhinitis were performed in 25 patients with LAR and 25 patients with NAR whose disease was diagnosed by means of NAPTs 1 year earlier. The response to nasal challenge was evaluated based on subjective (nasal-ocular symptoms) and objective (acoustic rhinometry) parameters. Nasal levels of tryptase and eosinophil cationic protein were determined by means of immunoassay at baseline, 15 minutes, and 1, 2, and 24 hours after challenge. Results: NAPT-Ms showed 100% concordance with the gold standard of NAPTs with a single aeroallergen. No false-positive or false-negative responses were detected. The use of NAPT-Ms achieved 75% reduction in the total number of visits required for final diagnosis in the NAR group (from 168 to 42 visits) and a 55% reduction in the LAR group (from 144 to 65 visits) compared with NAPTs with a single aeroallergen. Conclusions: These results demonstrate that clinically relevant polysensitization to aeroallergens in patients with LAR occurred and that the NAPT-M is a useful, specific, sensitive, reproducible, and less time-consuming in vivo diagnostic test for the screening of patients with LAR. (J Allergy Clin Immunol 2011;128:1192-7.)	[Rondon, Carmen; Campo, Paloma; Torres, Maria J.; Blanca, Miguel] Carlos Haya Hosp, Allergy Serv, Malaga, Spain; [Herrera, Rocio; Melendez, Lidia] Carlos Haya Hosp Fdn IMABIS, Res Lab, Malaga, Spain; [Blanca-Lopez, Natalia; Canto, Gabriela] Infanta Leonor Hosp, Allergy Serv, Madrid, Spain	Hospital Carlos Haya; Hospital Carlos Haya; Hospital Universitario Infanta Leonor	Rondon, C (corresponding author), Hosp Civil, Lab Invest, Pabellon 5,Plaza Hosp Civil, Malaga 29009, Spain.	carmenrs61@gmail.com	Torres, María José/T-3518-2017; Torres, Maria/GVU-3391-2022	Torres, María José/0000-0001-5228-471X; RONDON SEGOVIA, CARMEN/0000-0003-0976-3402	FIS network RIRAAF [RD07/0064]	FIS network RIRAAF	Supported by grants from FIS network RIRAAF (RD07/0064).	Belda J, 2001, CLIN EXP ALLERGY, V31, P1111, DOI 10.1046/j.1365-2222.2001.01133.x; Berger G, 1997, AM J RHINOL, V11, P63, DOI 10.2500/105065897781446775; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Carney AS, 2002, CLIN EXP ALLERGY, V32, P1436, DOI 10.1046/j.1365-2745.2002.01465.x; CONNELL JT, 1969, J ALLERGY, V43, P33, DOI 10.1016/0021-8707(69)90018-5; Demoly P., 2003, MIDDLETONS ALLERGY P, P631; DRUCE HM, 1990, J ALLERGY CLIN IMMUN, V86, P261; Hilberg O, 2000, RHINOLOGY, P3; HUGGINS KG, 1975, LANCET, V2, P148; Lopez S, 2010, CLIN EXP ALLERGY, V40, P1007, DOI 10.1111/j.1365-2222.2010.03492.x; Malm L, 2000, RHINOLOGY, V38, P1; MALM L, 1999, RHINOLOGY, V37, P133; MELILLO G, 1997, ALLERGY S35, V52, P26; Oldenbeuving NB, 2005, ALLERGY, V60, P751, DOI 10.1111/j.1398-9995.2005.00789.x; Powe DG, 2001, CLIN EXP ALLERGY, V31, P864, DOI 10.1046/j.1365-2222.2001.01106.x; Rondon C, 2008, ALLERGY, V63, P1352, DOI 10.1111/j.1398-9995.2008.01695.x; Rondon C, 2007, J ALLERGY CLIN IMMUN, V119, P899, DOI 10.1016/j.jaci.2007.01.006; Rondon C, 2009, J ALLERGY CLIN IMMUN, V124, P1005, DOI 10.1016/j.jaci.2009.07.018; Schumacher MJ, 1992, RHINOLOGY S, V14, P242; Smith HE, 2009, J ALLERGY CLIN IMMUN, V123, P646, DOI 10.1016/j.jaci.2008.11.005; VENGE P, 1994, ALLERGY, V49, P1, DOI 10.1111/j.1398-9995.1994.tb00765.x; Wedback A, 2005, RHINOLOGY, V43, P86; Wierzbicki DA, 2008, ANN ALLERG ASTHMA IM, V100, P533, DOI 10.1016/S1081-1206(10)60051-8	23	77	78	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2011	128	6					1192	1197		10.1016/j.jaci.2011.06.012	http://dx.doi.org/10.1016/j.jaci.2011.06.012			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	865WX	21783237	Bronze			2022-12-18	WOS:000298342700006
J	Schroeder, JT; Bieneman, AP; Chichester, KL; Hamilton, RG; Xiao, HQ; Saini, SS; Liu, MC				Schroeder, John T.; Bieneman, Anja P.; Chichester, Kristin L.; Hamilton, Robert G.; Xiao, HuiQing; Saini, Sarbjit S.; Liu, Mark C.			Decreases in human dendritic cell-dependent T(H)2-like responses after acute in vivo IgE neutralization	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Dendritic cells; IgE; antigen presentation; cytokine; receptor	FC-EPSILON-RI; DOWN-REGULATION; EXPRESSION; RECEPTOR; BASOPHILS; ALPHA	Background: Dendritic cells (DCs) and other professional antigen-presenting cells express a variant of the high-affinity IgE receptor known as alpha gamma(2), which, on the basis of in vitro findings, has long been implicated to function in facilitating allergen uptake and presentation to T-H cells. Objectives: To use omalizumab as an in vivo tool to neutralize IgE binding to circulating dendritic cells and to assess whether this results in altered DC-dependent T-cell responsiveness to allergen ex vivo. Methods: Subjects with cat allergy were enrolled in a 3.5-month, double blind, randomized (3.5:1), placebo-controlled trial of omalizumab using standard dosing for allergic asthma. Blood plasmacytoid and myeloid DCs were assessed at baseline and posttreatment for expression of surface IgE, Fc is an element of RI alpha, and induction of CD4(+)T-cell proliferation and cytokine responses to cat allergen. Results: IgE expression on plasmacytoid and myeloid DCs from omalizumab-treated subjects (n = 12) decreased by >= 95% posttreatment (P=.0005), whereas Fc is an element of RI alpha expression decreased by 66% and 48%, respectively (P=.0005). Cat allergen induced proliferation in DC/T-cell cocultures observed at baseline was suppressed similar to 20% to 40% postomalizumab treatment (P=.001). Multiplexing for cytokines in plasmacytoid DC/T-cell cocultures also showed decreases in IL-5, IL-13, and IL-10 (P<.05), whereas IL-2 and IFN-gamma were unaltered or slightly increased. These changes were not evident in placebo-control subjects (n = 4). Conclusion: IgE likely facilitates allergen presentation by dendritic cells in vivo and is also important in regulating DC-dependent T-cell cytokines during effector phases of allergic disease. (J Allergy Clin Immunol 2010;125:896-901.)	[Schroeder, John T.; Bieneman, Anja P.; Chichester, Kristin L.; Hamilton, Robert G.; Saini, Sarbjit S.; Liu, Mark C.] Johns Hopkins Univ, Dept Med, Johns Hopkins Asthma & Allergy Ctr, Div Allergy & Clin Immunol, Baltimore, MD 21224 USA; [Xiao, HuiQing; Liu, Mark C.] Johns Hopkins Univ, Dept Med, Johns Hopkins Asthma & Allergy Ctr, Div Pulm & Crit Care Med, Baltimore, MD 21224 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Schroeder, JT (corresponding author), Johns Hopkins Univ, Dept Med, Johns Hopkins Asthma & Allergy Ctr, Div Allergy & Clin Immunol, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.	schray@jhmi.edu			National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md [U19AI070345-01]; Sanofi-Aventis; Schering-Plough; Inotek; Genentech/Novartis; GlaxoSmithKline; AstraZeneca; Sepracor; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI070345] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md; Sanofi-Aventis(Sanofi-Aventis); Schering-Plough(Merck & CompanySchering Plough Corporation); Inotek; Genentech/Novartis(Roche HoldingGenentech); GlaxoSmithKline(GlaxoSmithKline); AstraZeneca(AstraZeneca); Sepracor; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the Asthma and Allergic Diseases Cooperative Research Centers grant U19AI070345-01 (project 3; J.T.S.) from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md.; Disclosure of potential conflict of interest: J. T. Schroeder has received research support front Sanofi-Aventis. Schering-Plough, and Inotek. S. S. Saini is a consultant for and has received research support from Genentech/Novartis. M. C. Liu is a speaker for GlaxoSmithKline. AstraZeneca, and Sepracor: is on the Ad Board for Merck, Amgen. and Centocor; is on the Data Safety Monitoring Board for Ception; has received research support front Amgen. Pfizer, and Centocor; and is a Board Member of the American Lung Association of the Atlantic Coast. The rest of the authors have declared that they have no conflict of interest.	Beck LA, 2004, J ALLERGY CLIN IMMUN, V114, P527, DOI 10.1016/j.jaci.2004.06.032; Bieber T, 2007, IMMUNOBIOLOGY, V212, P499, DOI 10.1016/j.imbio.2007.03.001; ECKMAN JA, 2009, J ALLERGY C IN PRESS; Farkas L, 2004, J ALLERGY CLIN IMMUN, V114, P436, DOI 10.1016/j.jaci.2004.04.035; Foster B, 2003, J ALLERGY CLIN IMMUN, V112, P1132, DOI 10.1016/j.jaci.2003.09.011; Kadowaki N, 2009, FRONT BIOSCI-LANDMRK, V14, P808, DOI 10.2741/3279; Le T, 2009, J ALLERGY CLIN IMMUN, V123, P217, DOI 10.1016/j.jaci.2008.09.013; MacGlashan DW, 1997, J IMMUNOL, V158, P1438; MAURER D, 1995, J IMMUNOL, V154, P6285; Novak N, 2004, J ALLERGY CLIN IMMUN, V114, P364, DOI 10.1016/j.jaci.2004.05.038; Prussin C, 2003, J ALLERGY CLIN IMMUN, V112, P1147, DOI 10.1016/j.jaci.2003.10.003; Saini SS, 1999, J IMMUNOL, V162, P5624; Schroeder JT, 2009, ADV IMMUNOL, V101, P123, DOI 10.1016/S0065-2776(08)01004-3; Schroeder JT, 2005, J IMMUNOL, V175, P5724, DOI 10.4049/jimmunol.175.9.5724; Tversky JR, 2008, CLIN EXP ALLERGY, V38, P781, DOI 10.1111/j.1365-2222.2008.02954.x	15	77	78	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2010	125	4					896	901		10.1016/j.jaci.2009.10.021	http://dx.doi.org/10.1016/j.jaci.2009.10.021			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	584XP	20132969				2022-12-18	WOS:000276787900016
J	Covar, RA; Strunk, R; Zeiger, RS; Wilson, LA; Liu, AH; Weiss, S; Tonascia, J; Spahn, JD; Szefler, SJ				Covar, Ronina A.; Strunk, Robert; Zeiger, Robert S.; Wilson, Laura A.; Liu, Andrew H.; Weiss, Scott; Tonascia, James; Spahn, Joseph D.; Szefler, Stanley J.		Childhood Asthma Management Progra	Predictors of remitting, periodic, and persistent childhood asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Remission; natural history; persistent asthma	PULMONARY-FUNCTION; ALLERGEN SENSITIZATION; NATURAL-HISTORY; PROGNOSIS; EXPOSURE; CHILDREN; AGE; RESPONSIVENESS; REMISSION; SYMPTOMS	Background: The course of mild to moderate persistent asthma in children is not clearly established. Objective: To determine the rate and predictors for remitting, periodic, and persistent asthma in adolescence. Methods: The Childhood Asthma Management Program (CAMP) was a 4.3-year randomized, double-masked, multicenter trial in children with mild to moderate persistent asthma that compared continuous therapy with either budesonide or nedocromil, each to placebo, followed by a 4-year observational follow-up period. Asthma activity during the observation period included remitting (no asthma activity in the last year), persistent (asthma activity in every quarter), and periodic asthma (neither remitting nor persistent). Results: Asthma was identified as remitting in 6%, periodic in 39%, and persistent in 55% of the 909 participants, with no effect noted from earlier anti-inflammatory treatment during the CAMP trial. Within all 3 asthma activity categories, improvements in airway hyperresponsiveness, eosinophilia, and asthma morbidity were observed over time. Features at entry into CAMP associated with remitting versus persistent asthma were lack of allergen sensitization and exposure to indoor allergens (odds ratio [OR], 3.23; P < .001), milder asthma (OR, 2.01; P = .03), older age (OR, 1.23; P = .01), less airway hyperresponsiveness (higher log methacholine FEV1 PC20 (OR, 1.39; P = .03), higher prebronchodilator FEV1 percent predicted (OR, 1.05; P = .02), and lower forced vital capacity percent predicted (OR, 0.96; P = .04). Conclusion: Remission of asthma in adolescence is infrequent and not affected by 4 years of anti-inflammatory controller therapy. Factors such as sensitization and exposure, low lung function, and airway greater hyperresponsiveness decrease the likelihood of remitting asthma. (J Allergy Clin Immunol 2010;125:359-66.)	[Covar, Ronina A.; Liu, Andrew H.; Spahn, Joseph D.; Szefler, Stanley J.] Natl Jewish Hlth, Denver, CO 80206 USA; [Strunk, Robert] St Louis Childrens Hosp, St Louis, MO 63178 USA; [Zeiger, Robert S.] Univ Calif San Diego, San Diego, CA 92103 USA; [Zeiger, Robert S.] Kaiser Permanente, Oakland, CA USA; [Wilson, Laura A.; Tonascia, James] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA; [Weiss, Scott] Brigham Women & Childrens Hosp, Boston, MA USA	National Jewish Health; St. Louis Children's Hospital; Washington University (WUSTL); University of California System; University of California San Diego; Kaiser Permanente; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Covar, RA (corresponding author), Natl Jewish Hlth, 1400 Jackson St, Denver, CO 80206 USA.	covarr@njhealth.org		Zeiger, Robert/0000-0001-5788-5063	National Center for Research Resources [NO1-HR-16044, NO1-HR-16045, NO1-HR-16046, NO1-HR-16047, NO1-HR-16048, NO1-HR-16049, NO1-HR-16050, NO1-HR-16051, NO1-HR-16052, M01RR00051, M01RR0099718-24, M01RR02719-14, RR00036]; NHLBL; AstraZeneca; Aerocrine; Genentech; GSK; Merck; Novartis; GlaxoWellcome; Pfizer; NIH/NHLBI; NIH/NIAID; GlaxoSmithKline; DIVISION OF LUNG DISEASES [N01HR016044, N01HR016047, N01HR016046, N01HR016051, N01HR016045, N01HR016048, N01HR016052, N01HR016050, N01HR016049] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000036, M01RR000051, M01RR002719] Funding Source: NIH RePORTER	National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBL; AstraZeneca(AstraZeneca); Aerocrine; Genentech(Roche HoldingGenentech); GSK(GlaxoSmithKline); Merck(Merck & Company); Novartis(Novartis); GlaxoWellcome; Pfizer(Pfizer); NIH/NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIH/NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); GlaxoSmithKline(GlaxoSmithKline); DIVISION OF LUNG DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	The Childhood Asthma Management program is supported by contracts NO1-HR-16044, 16045, 16046, 16047, 16048, 16049, 16050, 16051, and 16052 with the National Heart, Lung, and Blood Institute and General Clinical Research Center grants M01RR00051, M01RR0099718-24, M01RR02719-14. and RR00036 from the National Center for Research Resources.; Disclosure of potential conflict of interest: R. A. Covar receives research support from the NHLBL. R. S. Zeiger is a consultant for AstraZeneca, Aercrine. Genentech, GSK, MedImmune, Merck. and Schering-Plough and receives research support from AstraZeneca, Aerocrine. Genentech, GSK, and Merck. A. H. Liu receives speakers' honoraria from GlaxoSmithKline, Merck, AstraZeneca, Aerocrine, and Phadia: is on the advisory board for GlaxoSmithKline and AstraZeneca; and receives research support front Novartis. S, Weiss is a consultant for Glaxo-Wellcome, Roche Pharmaceuticals, Millenium Pharmaceuticals, Genentech, Schering-Plough, Variagenics, Genome Therapeutics, and Merck Frost and receives research support from GlaxoWellcome, AstraZeneca, and Pfizer. J. D. Spahn is a consultan for GlaxoSmithKline, receives honoraria front GlaxoSmithKline, and receives research Support from Merck. S. J. Szefler is a consultant for GlaxoSmithKline, Genentech, Merck, and Boehringer-Ingelheim and receives research support from the NIH/NHLBI, the NIH/NIAID, and GlaxoSmithKline. The rest of the authors have declared that they have no conflict of interest.	BLAIR H, 1977, ARCH DIS CHILD, V52, P613, DOI 10.1136/adc.52.8.613; BUFFUM WP, 1966, AM J DIS CHILD, V112, P214, DOI 10.1001/archpedi.1966.02090120082007; Cherniack R, 1999, CONTROL CLIN TRIALS, V20, P91; *CHILDH ASTHM MAN, 2000, NEW ENGLAND J MED, V0343; *CHILDH ASTHM MAN, 2009, J PEDIAT, V154, P682; CONOVER WJ, 1981, AM STAT, V35, P124, DOI 10.2307/2683975; Covar RA, 2004, AM J RESP CRIT CARE, V170, P234, DOI 10.1164/rccm.200308-1174OC; de Marco R, 2004, J ALLERGY CLIN IMMUN, V113, P845, DOI 10.1016/j.jaci.2004.01.780; GERRITSEN J, 1989, AM REV RESPIR DIS, V140, P1325, DOI 10.1164/ajrccm/140.5.1325; GODDEN DJ, 1994, AM J RESP CRIT CARE, V149, P106, DOI 10.1164/ajrccm.149.1.8111567; Gruchalla RS, 2005, J ALLERGY CLIN IMMUN, V115, P478, DOI 10.1016/j.jaci.2004.12.006; Guerra S, 2004, AM J RESP CRIT CARE, V170, P78, DOI 10.1164/rccm.200309-1224OC; Guilbert TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMoa051378; Illi S, 2006, LANCET, V368, P763, DOI 10.1016/S0140-6736(06)69286-6; JENKINS MA, 1994, BRIT MED J, V309, P90, DOI 10.1136/bmj.309.6947.90; JOHNSTON.DE, 1968, AM J DIS CHILD, V115, P213, DOI 10.1001/archpedi.1968.02100010215010; KELLY WJW, 1988, AM REV RESPIR DIS, V138, P26, DOI 10.1164/ajrccm/138.1.26; KOKKONEN J, 1993, EUR RESPIR J, V6, P657; Limb SL, 2005, J ALLERGY CLIN IMMUN, V115, P61, DOI 10.1016/j.jaci.2004.09.032; *NAT CTR HLTH STAT, 2000, HLTH E STAYS ASTHM A; Nelson HS, 1999, J ALLERGY CLIN IMMUN, V104, P775, DOI 10.1016/S0091-6749(99)70287-3; Pauwels RA, 2003, LANCET, V361, P1071, DOI 10.1016/S0140-6736(03)12891-7; Phelan PD, 2002, J ALLERGY CLIN IMMUN, V109, P189, DOI 10.1067/mai.2002.120951; RACKEMANN FM, 1952, NEW ENGL J MED, V246, P815, DOI 10.1056/NEJM195205222462104; ROORDA RJ, 1994, J ALLERGY CLIN IMMUN, V93, P575, DOI 10.1016/S0091-6749(94)70069-9; RYSSING E, 1963, ACTA PAEDIATR, V52, P97, DOI 10.1111/j.1651-2227.1963.tb04083.x; SAS, 1999, SAS SOFTW VERS 8 SAS; SEARLE SR, 1980, AM STAT, V34, P216, DOI 10.2307/2684063; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; StataCorp, 2007, STAT STAT SOFTW REL; Strachan DP, 1996, BRIT MED J, V312, P1195; Szefler SJ, 2005, J ALLERGY CLIN IMMUN, V115, P233, DOI 10.1016/j.jaci.2004.11.014; Tantisira KG, 2008, AM J RESP CRIT CARE, V178, P325, DOI 10.1164/rccm.200708-1174OC; ULRIK CS, 1995, RESP MED, V89, P547, DOI 10.1016/0954-6111(95)90156-6; Vonk JM, 2004, THORAX, V59, P925, DOI 10.1136/thx.2003.016246	36	77	79	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2010	125	2					359	366		10.1016/j.jaci.2009.10.037	http://dx.doi.org/10.1016/j.jaci.2009.10.037			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	558RU	20159245	Green Accepted, Bronze			2022-12-18	WOS:000274764000012
J	Sublett, JL; Seltzer, J; Burkhead, R; Williams, PB; Wedner, HJ; Phipatanakul, W				Sublett, James L.; Seltzer, James; Burkhead, Robert; Williams, P. Brock; Wedner, H. James; Phipatanakul, Wanda		Amer Acad Allergy	Air filters and air cleaners: Rostrum by the American Academy of Allergy, Asthma & Immunology Indoor Allergen Committee	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Air conditioning; air ionization; air Pollution; indoor/adverse effects/prevention and control; allergens/adverse effects; asthma/prevention and control; environmental exposure/adverse effects/prevention and control; filtration/methods/standards; inhalation exposure/adverse effects/prevention and control; ozone/adverse effects; particulate matter/adverse effects	HAY-FEVER SYMPTOMS; ENVIRONMENTAL INTERVENTION; FILTRATION SYSTEMS; CONTROLLED TRIAL; CHILDREN; HOMES; RHINITIS; PARTICLES; COVERS; DEVICE	The allergist is generally recognized as possessing the greatest expertise in relating airborne contaminants to respiratory health, both atopic and nonatopic. Consequently, allergists are most often asked for their professional opinions regarding the appropriate use of air-cleaning equipment. This rostrum serves as a resource for the allergist and other health care professionals seeking a better understanding of air filtration. (J Allergy Clin Immunol 2010;125:32-8.)	[Sublett, James L.] Univ Louisville, Sch Med, Dept Pediat, Sect Allergy & Immunol, Louisville, KY 40223 USA; [Sublett, James L.] Family Allergy & Asthma, Louisville, KY USA; [Seltzer, James] Univ Calif Irvine, Sch Med, Pediat Environm Hlth Specialty Unit, Div Occupat & Environm Med, Irvine, CA 92717 USA; [Burkhead, Robert] Blue Heaven Technol, Louisville, KY USA; [Williams, P. Brock] Childrens Mercy Hosp, Kansas City, MO 64108 USA; [Wedner, H. James] Washington Univ, Sch Med, Dept Med, Div Allergy & Immunol, St Louis, MO 63130 USA; [Phipatanakul, Wanda] Childrens Hosp, Dept Med, Div Allergy & Immunol, Boston, MA 02115 USA; [Phipatanakul, Wanda] Harvard Univ, Sch Med, Boston, MA USA	University of Louisville; University of California System; University of California Irvine; Children's Mercy Hospital; Washington University (WUSTL); Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Sublett, JL (corresponding author), Univ Louisville, Sch Med, Dept Pediat, Sect Allergy & Immunol, 9800 Shelbyville Rd, Louisville, KY 40223 USA.	jsublett@familyallergy.com		SUBLETT, JAMES L/0000-0003-4696-4609	Novartis; Merck; GlaxoSmithKline; American Society of Heating, Refrigerating, and Air-conditioning Engineers (ASH-RAE); Genentech; Dyax; National Institutes of Health; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI073964] Funding Source: NIH RePORTER	Novartis(Novartis); Merck(Merck & Company); GlaxoSmithKline(GlaxoSmithKline); American Society of Heating, Refrigerating, and Air-conditioning Engineers (ASH-RAE); Genentech(Roche HoldingGenentech); Dyax; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Disclosure of potential conflict of interest: J. L. Sublett is a shareholder in AllergyZone LLC, a speaker for Merck, and a consultant/speaker for GlaxoSmithKline; he has also received research support from Novartis, Merck, GlaxoSmithKline, Capnia. Greer, and Cobalis. J. Seltzer has provided legal consultation or expert witness testimony on the topics of mold, asbestos. carbon monoxide. and benzene. R. Burkhead is the president of Blue Heavens Technologies LLC and has received research support from the American Society of Heating, Refrigerating, and Air-conditioning Engineers (ASH-RAE). H. J. Wedner has received research support from Genentech and Dyax and has provided legal consultation or expert witness testimony on the topics of mold, formaldehyde. and toxic chemicals. W. Phipatanakul has received research support from the National Institutes of Health. P. B. Williams declares that he has no conflict of interest.	AHAM AASA, 2006, METH MEAS PERF PORT; *AM LUNG ASS, 2008, FURN FILT TIPS YOUR; *AM SOC HEAT REFR, 2008, 5222007 ANSIASHRAE; *AM SOC HEAT REFR, 2007, 6222007 ANSIASHRAE; ANTONICELLI L, 1991, ALLERGY, V46, P594, DOI 10.1111/j.1398-9995.1991.tb00629.x; Araujo R, 2008, AM J INFECT CONTROL, V36, P129, DOI 10.1016/j.ajic.2007.02.001; Barn P, 2008, J EXPO SCI ENV EPID, V18, P503, DOI 10.1038/sj.jes.7500640; Brandt DM, 2008, J ALLERGY CLIN IMMUN, V121, P1053, DOI 10.1016/j.jaci.2007.11.025; Brauner EV, 2008, AM J RESP CRIT CARE, V177, P419, DOI 10.1164/rccm.200704-632OC; Brehler R, 2003, INT ARCH ALLERGY IMM, V130, P60, DOI 10.1159/000068376; Burroughs HEB, 1998, ASHRAE J, V40, P47; Eggleston PA, 2005, ANN ALLERG ASTHMA IM, V95, P518, DOI 10.1016/S1081-1206(10)61012-5; Gent JF, 2003, JAMA-J AM MED ASSOC, V290, P1859, DOI 10.1001/jama.290.14.1859; KOOISTRA JB, 1978, J ALLERGY CLIN IMMUN, V61, P315, DOI 10.1016/0091-6749(78)90053-2; Macintosh DL, 2008, J AIR WASTE MANAGE, V58, P1474, DOI 10.3155/1047-3289.58.11.1474; McDonald E, 2002, CHEST, V122, P1535, DOI 10.1378/chest.122.5.1535; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; Morris RJ, 2006, ALLERGY ASTHMA PROC, V27, P63; Myatt TA, 2008, ENVIRON HEALTH-GLOB, V7, DOI 10.1186/1476-069X-7-43; REISMAN RE, 1990, J ALLERGY CLIN IMMUN, V85, P1050, DOI 10.1016/0091-6749(90)90050-E; Reisman RE, 2001, ANN ALLERG ASTHMA IM, V87, P41, DOI 10.1016/S1081-1206(10)62339-3; Subbarao P, 2005, J ALLERGY CLIN IMMUN, V115, P745, DOI 10.1016/j.jaci.2004.11.023; Sulser C, 2009, INT ARCH ALLERGY IMM, V148, P23, DOI 10.1159/000151502; Terreehorst I, 2003, NEW ENGL J MED, V349, P237, DOI 10.1056/NEJMoa023171; Tovey ER, 2008, CURR ALLERGY ASTHM R, V8, P126, DOI 10.1007/s11882-008-0022-x; U.S. Department of Housing and Urban Development, 2008, AM HOUS SURV US 2007; van der Heide S, 1999, J ALLERGY CLIN IMMUN, V104, P447, DOI 10.1016/S0091-6749(99)70391-X; vanderHeide S, 1997, EUR RESPIR J, V10, P1217, DOI 10.1183/09031936.97.10061217; VERRALL B, 1988, ANN ALLERGY, V61, P117; VILLAVECES JW, 1977, ANN ALLERGY, V38, P400; WARBURTON CJ, 1994, RESP MED, V88, P771, DOI 10.1016/S0954-6111(05)80200-8; Williams P., 1999, ANN ALLERG ASTHMA IM, V82, P115; Wood RA, 1998, AM J RESP CRIT CARE, V158, P115, DOI 10.1164/ajrccm.158.1.9712110; Wood Robert A, 2002, Curr Allergy Asthma Rep, V2, P397, DOI 10.1007/s11882-002-0073-3; Zock JP, 2002, J ALLERGY CLIN IMMUN, V110, P285, DOI 10.1067/mai.2002.126383; ZWEMER RJ, 1973, ANN ALLERGY, V31, P284	36	77	84	3	49	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2010	125	1					32	38		10.1016/j.jaci.2009.08.036	http://dx.doi.org/10.1016/j.jaci.2009.08.036			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	544MG	19910039	Green Accepted			2022-12-18	WOS:000273660500003
J	Siroux, V; Boudier, A; Bousquet, J; Bresson, JL; Cracowski, JL; Ferran, J; Gormand, F; Just, J; Le Moual, N; Morange, S; Nadif, R; Oryszczyn, MP; Pison, C; Scheinmann, P; Varraso, R; Vervloet, D; Pin, I; Kauffmann, F				Siroux, Valerie; Boudier, Anne; Bousquet, Jean; Bresson, Jean-Louis; Cracowski, Jean-Luc; Ferran, Joane; Gormand, Frederic; Just, Jocelyne; Le Moual, Nicole; Morange, Sophie; Nadif, Rachel; Oryszczyn, Marie-Pierre; Pison, Christophe; Scheinmann, Pierre; Varraso, Raphaelle; Vervloet, Daniel; Pin, Isabelle; Kauffmann, Francine		Epidemiological Study Genetics Environm Asthma	Phenotypic determinants of uncontrolled asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma control; risk factor	BODY-MASS INDEX; INDOOR ALLERGEN SENSITIZATION; RESPIRATORY HEALTH SURVEY; REAL-WORLD EVALUATION; PERSISTENT ASTHMA; SEVERITY; ADULTS; MORBIDITY; DISEASE; RISK	Background: Although uncontrolled asthma remains frequent, determinants of asthma control are poorly studied. Objectives: The aim was to estimate the distribution and the phenotypic characteristics of asthma control in 2 groups of subjects defined by the use of inhaled corticosteroids (ICS) in the past 12 months, in the Epidemiological study on the Genetics and Environment of Asthma, bronchial hyperresponsiveness and atopy (EGEA). Methods: Five hundred one adult current patients with asthma who participated in the follow-up of the EGEA study were included. Asthma control was assessed from survey questions reflecting asthma control, as defined in the 2006 Global Initiative for Asthma guidelines. The factors analyzed were age, sex, educational level, body mass index, active and passive smoking, sensitization to aeroallergens, total IgE, rhinitis, chronic cough/phlegm, and age at asthma onset. Analyses were stratified according to ICS use. Results: Uncontrolled asthma was more frequent in ICS users (27.6%, 35.0%, and 37.4% with controlled, partly-controlled, and uncontrolled asthma respectively) compared with non-ICS users (60.0%, 23.9%, and 16.1%, respectively). In ICS users, chronic cough or phlegm and female sex were independently and significantly related to uncontrolled asthma. In non-ICS users, high total IgE and sensitization to molds were associated with uncontrolled asthma. Smoking and rhinitis were not associated with asthma control. Conclusion: Optimal asthma control remained unachieved in the majority of patients with asthma in this study. Factors associated with uncontrolled asthma were different in ICS users (chronic cough/phlegm, female sex) and non-ICS users (high total IgE and sensitization to molds). (J Allergy Clin Immunol 2009;124:681-7.)	[Siroux, Valerie] UJF, INSERM, Ctr Rech, Inst Albert Bonniot,U823, F-38042 Grenoble 9, France; [Bousquet, Jean] CHU Montpellier, Montpellier, France; [Bousquet, Jean; Le Moual, Nicole; Nadif, Rachel; Oryszczyn, Marie-Pierre; Pison, Christophe; Varraso, Raphaelle; Kauffmann, Francine] INSERM, U780, Villejuif, France; [Bresson, Jean-Louis] CIC, Paris, France; [Cracowski, Jean-Luc] INSERM, CIC3, Grenoble, France; [Ferran, Joane; Pison, Christophe] CHU Grenoble, Clin Pneumol, F-38043 Grenoble, France; [Gormand, Frederic] CHU, Lyon, France; [Just, Jocelyne] Hop Trousseau, F-75571 Paris, France; [Le Moual, Nicole; Nadif, Rachel; Oryszczyn, Marie-Pierre; Varraso, Raphaelle; Kauffmann, Francine] Univ Paris Sud, IFR69, Villejuif, France; [Morange, Sophie; Vervloet, Daniel] CIC, Marseille, France; [Pison, Christophe] INSERM, U884, Grenoble, France; [Scheinmann, Pierre] Hop Necker Enfants Malad, Paris, France; [Scheinmann, Pierre] Univ Paris 05, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Universite de Montpellier; CHU de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); CHU Lyon; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Armand-Trousseau - APHP; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Siroux, V (corresponding author), UJF, INSERM, Ctr Rech, Inst Albert Bonniot,U823, BP 170, F-38042 Grenoble 9, France.	valerie.siroux@ujf-grenoble.fr	Boudier, Anne/N-2430-2013; Le Moual, Nicole/R-8976-2016; Varraso, Raphaelle/R-8740-2016; Bousquet, Jean/O-4221-2019; siroux, valerie/N-1865-2013; PIN, Isabelle/N-3020-2013; , CRACOWSKI/M-6946-2014; Nadif, Rachel/R-2876-2016; Le Moual, Nicole/GNP-5114-2022; GORMAND, FREDERIC/I-1414-2017	Le Moual, Nicole/0000-0002-2723-5569; Varraso, Raphaelle/0000-0002-3338-7825; siroux, valerie/0000-0001-7329-7237; , CRACOWSKI/0000-0003-0787-1469; Nadif, Rachel/0000-0003-4938-9339; Le Moual, Nicole/0000-0002-2723-5569; 	Merck Sharp Dohme (MSD); Hospital program of clinical research (PHRC)-Paris; National Research Agency (ANR); French Agency of health safety, environment and work (AFSSET); Isere committee against respiratory diseases (COMARES); AB Science	Merck Sharp Dohme (MSD)(Merck & Company); Hospital program of clinical research (PHRC)-Paris; National Research Agency (ANR)(French National Research Agency (ANR)); French Agency of health safety, environment and work (AFSSET); Isere committee against respiratory diseases (COMARES); AB Science	C. Pison has served as a consultant for GlaxoSmithKline, Bochringer Ingelheim France, AstraZeneca, Nutricia, Numico, and Actellion and has received research support from AB Science. The rest of the authors have declared that they have no conflict of interest.	Abraham B, 2003, EUR RESPIR J, V22, P470, DOI 10.1183/09031936.03.00261903; Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC; Boulet LP, 2007, RESP MED, V101, P2240, DOI 10.1016/j.rmed.2007.06.031; Bousquet J, 2005, CLIN EXP ALLERGY, V35, P723, DOI 10.1111/j.1365-2222.2005.02251.x; Cazzoletti L, 2007, J ALLERGY CLIN IMMUN, V120, P1360, DOI 10.1016/j.jaci.2007.09.019; Cerveri I, 1999, EUR RESPIR J, V14, P288, DOI 10.1034/j.1399-3003.1999.14b09.x; Chaudhuri R, 2008, ALLERGY, V63, P132, DOI 10.1111/j.1398-9995.2007.01538.x; de Marco R, 2003, ALLERGY, V58, P221, DOI 10.1034/j.1398-9995.2003.00059.x; de Marco R, 2006, J ALLERGY CLIN IMMUN, V117, P1249, DOI 10.1016/j.jaci.2006.03.019; Denning DW, 2006, EUR RESPIR J, V27, P615, DOI 10.1183/09031936.06.00074705; Frey U, 2008, LANCET, V372, P1088, DOI 10.1016/S0140-6736(08)61450-6; *GLOB IN ASTHM, 1995, NIH PUBL; Green RM, 2002, BMJ-BRIT MED J, V324, P763, DOI 10.1136/bmj.324.7340.763; Humbert M, 2005, ALLERGY, V60, P309, DOI 10.1111/j.1398-9995.2004.00772.x; Kauffmann F, 1999, CLIN EXP ALLERGY, V29, P17; KAUFFMANN F, 1997, AM J RESP CRIT CARE, V156, P123; Laforest L, 2006, J ALLERGY CLIN IMMUN, V117, P1404, DOI 10.1016/j.jaci.2006.03.007; Lavoie KL, 2006, RESP MED, V100, P648, DOI 10.1016/j.rmed.2005.08.001; Lewis SA, 2002, AM J RESP CRIT CARE, V165, P961, DOI 10.1164/ajrccm.165.7.2103044; Mosen DM, 2008, J ALLERGY CLIN IMMUN, V122, P507, DOI 10.1016/j.jaci.2008.06.024; Nadif R, 2009, THORAX, V64, P374, DOI 10.1136/thx.2008.103069; Naqvi M, 2007, J ALLERGY CLIN IMMUN, V120, P137, DOI 10.1016/j.jaci.2007.02.045; *NAT ASTHM ED PREV, 1997, NIH PUBL; Peters SP, 2007, J ALLERGY CLIN IMMUN, V119, P1454, DOI 10.1016/j.jaci.2007.03.022; Peters-Golden M, 2006, EUR RESPIR J, V27, P495, DOI 10.1183/09031936.06.00077205; Ponte EV, 2008, ALLERGY, V63, P564, DOI 10.1111/j.1398-9995.2007.01624.x; Rabe KF, 2004, J ALLERGY CLIN IMMUN, V114, P40, DOI 10.1016/j.jaci.2004.04.042; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Schatz M, 2007, J ASTHMA, V44, P341, DOI 10.1080/02770900701344421; Siroux V, 2000, EUR RESPIR J, V15, P470, DOI 10.1034/j.1399-3003.2000.15.08.x; Taylor B, 2008, THORAX, V63, P14, DOI 10.1136/thx.2007.082784; Tomlinson JEM, 2005, THORAX, V60, P282, DOI 10.1136/thx.2004.033688; Van Ganse E, 2002, EUR RESPIR J, V20, P260, DOI 10.1183/09031936.02.02542001; Varraso R, 2005, AM J RESP CRIT CARE, V171, P334, DOI 10.1164/rccm.200405-674OC; Vermeire PA, 2002, RESP MED, V96, P142, DOI 10.1053/rmed.2001.1241; Wisnivesky JP, 2007, J ALLERGY CLIN IMMUN, V120, P113, DOI 10.1016/j.jaci.2007.03.044; Zureik M, 2002, BMJ-BRIT MED J, V325, P411, DOI 10.1136/bmj.325.7361.411	37	77	79	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2009	124	4					681	687		10.1016/j.jaci.2009.06.010	http://dx.doi.org/10.1016/j.jaci.2009.06.010			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	506UV	19665764	Bronze			2022-12-18	WOS:000270802800008
J	Austen, KF; Maekawa, A; Kanaoka, Y; Boyce, JA				Austen, K. Frank; Maekawa, Akiko; Kanaoka, Yoshihide; Boyce, Joshua A.			The leukotriene E-4 puzzle: Finding the missing pieces and revealing the pathobiologic implications	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Leukotriene E-4; G protein-coupled receptor; bronchial asthma; inflammation; knockout mouse	SLOW-REACTING SUBSTANCE; HUMAN MAST-CELLS; GENE DISRUPTION REVEALS; C-4 SYNTHASE; GUINEA-PIG; VASCULAR-PERMEABILITY; ASTHMATIC SUBJECTS; MICE LACKING; TIME-COURSE; SRS-A	The intracellular parent of the cysteinyl leukotrienes (cysLTs), leukotriene (LT) C-4, is formed by conjugation of LTA(4) and reduced glutathione by LTC4 synthase in mast cells, eosinophils, basophils, and macrophages. After extracellular export, LTC4 is converted to LTD4 and LTE4 through sequential enzymatic removal of glutamic acid and then glycine. Only LTE4 is sufficiently stable to be prominent in biologic fluids, such as urine or bronchoalveolar lavage fluid, of asthmatic individuals and at sites of inflammation in animal models. LTE4 has received little attention because it binds poorly to the classical type 1 and 2 cysLT receptors and is much less active on normal airways than LTC4 or LTD4. However, early studies indicated that LTE4 caused skin swelling in human subjects as potently as LTC4 and LTD4, that airways of asthmatic subjects particularly those that were aspirin sensitive) were selectively hyperresponsive to LTE4, and that a potential distinct LTE4 receptor was present in guinea pig trachea. Recent studies have begun to uncover receptors selective for LTE4: P2Y(12), an adenosine diphosphate receptor, and CysLT(E)R, which was observed functionally in the skin of mice lacking the type 1 and 2 cysLT receptors. These findings prompt a renewed focus on LTE4 receptors as therapeutic targets that are not currently addressed by available receptor antagonists. (J Allergy Clin Immunol 2009; 124: 406-14.)	[Austen, K. Frank; Maekawa, Akiko; Kanaoka, Yoshihide; Boyce, Joshua A.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy,Dept Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Austen, KF (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy,Dept Med, 1 Jimmy Fund Way, Boston, MA 02115 USA.	fausten@rics.bwh.harvard.edu			Merck Co., Inc; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036110] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052353, R01AI078908, R56AI052353, P01AI031599] Funding Source: NIH RePORTER	Merck Co., Inc(Merck & Company); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This CME activity is supported by an educational grant from Merck & Co., Inc.	Beller TC, 2004, J BIOL CHEM, V279, P46129, DOI 10.1074/jbc.M407057200; BROCKLEHURST WE, 1960, J PHYSIOL-LONDON, V151, P416, DOI 10.1113/jphysiol.1960.sp006449; CHRISTIE PE, 1993, EUR RESPIR J, V6, P1468; DAVIDSON AB, 1987, AM REV RESPIR DIS, V135, P333; DRAZEN JM, 1982, AM REV RESPIR DIS, V125, P290; DRAZEN JM, 1980, P NATL ACAD SCI-BIOL, V77, P4354, DOI 10.1073/pnas.77.7.4354; DRAZEN JM, 1983, LEUKOTRIENES PROSTAC; Feng CL, 2004, J IMMUNOL, V173, P7539, DOI 10.4049/jimmunol.173.12.7539; Gauvreau GM, 2001, AM J RESP CRIT CARE, V164, P1495, DOI 10.1164/ajrccm.164.8.2102033; GRIFFIN M, 1983, NEW ENGL J MED, V308, P436, DOI 10.1056/NEJM198302243080807; Heise CE, 2000, J BIOL CHEM, V275, P30531, DOI 10.1074/jbc.M003490200; JEDLITSCHKY G, 1991, J BIOL CHEM, V266, P24763; Jiang Y, 2007, BLOOD, V110, P3263, DOI 10.1182/blood-2007-07-100453; Jiang YF, 2006, J IMMUNOL, V177, P2755, DOI 10.4049/jimmunol.177.5.2755; Kanaoka Y, 2001, J BIOL CHEM, V276, P22608, DOI 10.1074/jbc.M103562200; KRILIS S, 1983, J CLIN INVEST, V71, P909, DOI 10.1172/JCI110845; LAM BK, 1994, P NATL ACAD SCI USA, V91, P7663, DOI 10.1073/pnas.91.16.7663; Lam BK, 1996, EUR J BIOCHEM, V238, P606, DOI 10.1111/j.1432-1033.1996.0606w.x; LEE CW, 1982, P NATL ACAD SCI-BIOL, V79, P4166, DOI 10.1073/pnas.79.13.4166; LEE CW, 1983, J BIOL CHEM, V258, P5004; LEE TH, 1984, P NATL ACAD SCI-BIOL, V81, P4922, DOI 10.1073/pnas.81.15.4922; LEWIS RA, 1980, BIOCHEM BIOPH RES CO, V96, P271, DOI 10.1016/0006-291X(80)91210-3; Lynch KR, 1999, NATURE, V399, P789; Maekawa A, 2002, J BIOL CHEM, V277, P20820, DOI 10.1074/jbc.M203163200; Maekawa A, 2008, P NATL ACAD SCI USA, V105, P16695, DOI 10.1073/pnas.0808993105; Mamedova L, 2005, BIOCHEM PHARMACOL, V71, P115, DOI 10.1016/j.bcp.2005.10.003; MARFAT A, 1985, ADV PROSTAG THROMB L, V14, P155; Mellor EA, 2003, P NATL ACAD SCI USA, V100, P11589, DOI 10.1073/pnas.2034927100; Mellor EA, 2001, P NATL ACAD SCI USA, V98, P7964, DOI 10.1073/pnas.141221498; Mitra P, 2006, P NATL ACAD SCI USA, V103, P16394, DOI 10.1073/pnas.0603734103; MORRIS HR, 1980, PROSTAG OTH LIPID M, V19, P185, DOI 10.1016/0090-6980(80)90019-2; MURPHY RC, 1979, P NATL ACAD SCI USA, V76, P4275, DOI 10.1073/pnas.76.9.4275; Murphy RC, 2007, BIOCHEM J, V405, P379, DOI 10.1042/BJ20070289; Naik S, 2005, J BIOL CHEM, V280, P8722, DOI 10.1074/jbc.M413014200; Nonaka Y, 2005, BIOCHEM BIOPH RES CO, V337, P281, DOI 10.1016/j.bbrc.2005.09.052; ORANGE RP, 1973, J IMMUNOL, V110, P760; PARKER CW, 1980, PROSTAGLANDINS, V20, P863, DOI 10.1016/0090-6980(80)90139-2; Paruchuri S, 2008, J BIOL CHEM, V283, P16477, DOI 10.1074/jbc.M705822200; SALA A, 1990, J BIOL CHEM, V265, P21771; SOTER NA, 1983, J INVEST DERMATOL, V80, P115, DOI 10.1111/1523-1747.ep12531738; WEISS JW, 1982, SCIENCE, V216, P196, DOI 10.1126/science.7063880; WEISS JW, 1983, JAMA-J AM MED ASSOC, V249, P2814, DOI 10.1001/jama.249.20.2814; YOSHIMOTO T, 1988, J CLIN INVEST, V81, P866, DOI 10.1172/JCI113396	43	77	80	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2009	124	3					406	416		10.1016/j.jaci.2009.05.046	http://dx.doi.org/10.1016/j.jaci.2009.05.046			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	552TG	19647860	Green Accepted			2022-12-18	WOS:000274315900002
J	Arias, K; Baig, M; Bhsc, MC; Chu, D; Walker, T; Goncharova, S; Coyle, A; Vadas, P; Waserman, S; Jordana, M				Arias, Katherine; Baig, Moiz; Bhsc, Marc Colangel; Chu, Derek; Walker, Tina; Goncharova, Susanna; Coyle, Anthony; Vadas, Peter; Waserman, Susan; Jordana, Manel			Concurrent blockade of platelet-activating factor and histamine prevents life-threatening peanut-induced anaphylactic reactions	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Peanut allergy; anaphylaxis; mast cells; histamine; PAF; leukotrienes; mathematical modeling	COLONY-STIMULATING FACTOR; FACTOR RECEPTOR; MAST-CELLS; ALLERGY; PATHOPHYSIOLOGY; PREVALENCE; EXPRESSION; EMERGENCY; ENDOTOXIN; RESPONSES	Background: Food anaphylaxis is an acute and life-threatening systemic allergic reaction. Fatality registries place peanut as the most common culprit of fatal and near-fatal reactions in North America. Because prophylaxis and treatment have advanced little in recent years, it is imperative to evaluate novel therapies. Objective: To investigate the impact of blocking mast cell mediators in a mouse model of peanut-induced anaphylaxis. Methods: Mice were sensitized with peanut protein and cholera toxin via oral gavage weekly for 4 weeks. One week after the last sensitization, separate groups of mice were treated with either a (1) 5-lypoxygenase inhibitor, (2) a platelet-activating factor (PAF) receptor antagonist, (3) histamine receptor antagonists, or (4) a PAF receptor antagonist along with histamine receptor antagonists before peanut challenge. Results: Treatment targeting either leukotrienes or histamine alone had no beneficial effects. In contrast, PAF antagonism significantly attenuated the magnitude and duration of the anaphylactic reactions. Particularly, it prevented severe reactions. Moreover, 83% of PAF-treated versus 43% of untreated mice reached recovery within 120 minutes after peanut challenge. Notably, combined blockade of PAF and histamine had a clearly greater beneficial effect. In fact, all but 1 mouse developed mild, if any, anaphylactic reactions. In addition, combination therapy was associated with a significant decrease in vascular leakage and release of vasoactive mediators after peanut challenge. Conclusion: Combination therapy blocking both PAF and histamine markedly reduces the severity of peanut-induced anaphylaxis, and thus it may be a potential life-saving therapeutic approach in peanut and, likely, other food-induced anaphylaxis. (J Allergy Clin Immunol 2009;124:307-14.)	[Arias, Katherine; Baig, Moiz; Bhsc, Marc Colangel; Chu, Derek; Walker, Tina; Goncharova, Susanna; Jordana, Manel] McMaster Univ, Ctr Gene Therapeut, Dept Pathol & Mol Med, Hamilton, ON L8N 3Z5, Canada; [Waserman, Susan] McMaster Univ, Dept Med, Hamilton, ON L8N 3Z5, Canada; [Coyle, Anthony] MedImmune Inc, Dept Inflammat & Autoimmun, Gaithersburg, MD USA; [Vadas, Peter] St Michaels Hosp, Dept Med, Div Clin Immunol & Allergy, Toronto, ON M5B 1W8, Canada; [Vadas, Peter] St Michaels Hosp, Dept Emergency Med, Toronto, ON M5B 1W8, Canada	McMaster University; McMaster University; AstraZeneca; Medimmune; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto	Jordana, M (corresponding author), McMaster Univ, Ctr Gene Therapeut, Dept Pathol & Mol Med, MDCL Room 4013,1200 Main St W, Hamilton, ON L8N 3Z5, Canada.	jordanam@mcmaster.ca		Chu, Derek/0000-0001-8269-4496	Anaphylaxis Canada; Food Allergy Initiative Organization (New York, NY); AllerGen Network Centre of Excellence (NCE)	Anaphylaxis Canada; Food Allergy Initiative Organization (New York, NY); AllerGen Network Centre of Excellence (NCE)	Supported by Anaphylaxis Canada, the Food Allergy Initiative Organization (New York, NY) and AllerGen Network Centre of Excellence (NCE). M.J. holds a Senior Canada Research Chair on the Immunobiology of Respiratory Diseases and Allergy. K.A. holds an Eva Lillian Cope Research Scholarship.	Bock SA, 2007, J ALLERGY CLIN IMMUN, V119, P1016, DOI 10.1016/j.jaci.2006.12.622; Brandt EB, 2003, J CLIN INVEST, V112, P1666, DOI 10.1172/JCI19785; Brown AFT, 2001, J ALLERGY CLIN IMMUN, V108, P861, DOI 10.1067/mai.2001.119028; BRUNNER T, 1991, J IMMUNOL, V147, P237; COLUMBO M, 1995, J ALLERGY CLIN IMMUN, V95, P565, DOI 10.1016/S0091-6749(95)70319-5; DARIUS H, 1986, SCIENCE, V232, P58, DOI 10.1126/science.3082008; DENZLINGER C, 1995, INT ARCH ALLERGY IMM, V108, P158, DOI 10.1159/000237133; FISHER MM, 1986, ANAESTH INTENS CARE, V14, P17, DOI 10.1177/0310057X8601400105; HANAHAN DJ, 1986, ANNU REV BIOCHEM, V55, P483, DOI 10.1146/annurev.bi.55.070186.002411; Ishii S, 1998, J EXP MED, V187, P1779, DOI 10.1084/jem.187.11.1779; Izumi T, 1995, BBA-LIPID LIPID MET, V1259, P317, DOI 10.1016/0005-2760(95)00171-9; Kagan RS, 2003, J ALLERGY CLIN IMMUN, V112, P1223, DOI 10.1016/j.jaci.2003.09.026; Kemp SF, 2002, J ALLERGY CLIN IMMUN, V110, P341, DOI 10.1067/mai.2002.126811; Khodoun M, 2009, J ALLERGY CLIN IMMUN, V123, P342, DOI 10.1016/j.jaci.2008.11.004; Montrucchio G, 2000, PHYSIOL REV, V80, P1669, DOI 10.1152/physrev.2000.80.4.1669; Sampson HA, 2003, PEDIATRICS, V111, P1601; Sheikh A, 2007, ALLERGY, V62, P830, DOI 10.1111/j.1398-9995.2007.01435.x; Sicherer SH, 2003, J ALLERGY CLIN IMMUN, V112, P1203, DOI 10.1016/S0091-6749(03)02026-8; Simons FER, 2007, J ALLERGY CLIN IMMUN, V120, pS2, DOI [10.1016/j.jaci.2007.05.001, 10.1016/j.jaci.2007.05.016]; Skolnick HS, 2001, J ALLERGY CLIN IMMUN, V107, P367, DOI 10.1067/mai.2001.112129; Sun JF, 2007, J IMMUNOL, V179, P6696, DOI 10.4049/jimmunol.179.10.6696; TERASHITA ZI, 1992, J PHARMACOL EXP THER, V260, P748; Vadas P, 2008, NEW ENGL J MED, V358, P28, DOI 10.1056/NEJMoa070030; Yamaguchi M, 1997, J EXP MED, V185, P663, DOI 10.1084/jem.185.4.663; Yu JW, 2006, J ALLERGY CLIN IMMUN, V118, P466, DOI 10.1016/j.jaci.2006.04.024	25	77	81	1	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2009	124	2					307	314		10.1016/j.jaci.2009.03.012	http://dx.doi.org/10.1016/j.jaci.2009.03.012			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	482CD	19409603				2022-12-18	WOS:000268860400018
J	Ochs, HD; Oukka, M; Torgerson, TR				Ochs, Hans D.; Oukka, Mohamed; Torgerson, Troy R.			T(H)17 cells and regulatory T cells in primary immunodeficiency diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Regulation of T effector cell lineage differentiation; T(H)17 cells; regulatory T cells; immune dysregulation; polyendocrinopathy; enteropathy; X-linked syndrome; forkhead box protein 3; autosomal dominant hyper-IgE syndrome; signal transducer and activator of transcription 3; IL-17; TGF-beta; IL-10	GROWTH-FACTOR-BETA; WISKOTT-ALDRICH-SYNDROME; HYPER-IGE SYNDROME; TGF-BETA; TH17 CELLS; SIGNAL TRANSDUCER; SYNDROME PROTEIN; STAT3 MUTATIONS; DIFFERENTIATION; CYTOKINE	After activation by unique cytokines, CD4+ naive T cells differentiate into lineages of helper/effector (T-H) and regulatory T (Treg) cells that are characterized by distinct developmental pathways and unique biologic functions. The trusted binary system of T(H)1 and T(H)2 has been expanded to include the IL-17-producing T(H)17 cell lineage, which plays a role in immune responses to infectious agents and maintenance of autoimmune diseases. Acting as counterbalance, Treg cells maintain peripheral tolerance and protect the host from autoaggressive lymphocytes. T(H)1 cells produce IFN-gamma and are involved in cell-mediated immunity, T(H)2 cells produce IL-4 and contribute to Immoral immunity, T(H)17 cells generate IL-17 and play an important role in immune responses to fungi and extracellular pathogens, and forkhead box protein 3-positive (FOXP3(+)) Treg cells secrete TGF-beta and IL-10 and downregulate effector T cells. Autosomal dominant hyper-IgE syndrome, a rare primary immunodeficiency disorder, is caused by hypomorphic heterozygous mutations of signal transducer and activator of transcription 3 (STAT3), preventing T(H)17 lineage differentiation and increasing susceptibility to Staphylococcus and Candida species infections. Mutations in the FOXP3 gene interfere with Treg cell development and cause immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome. Other single-gene defects resulting in reduced Treg cell function include CD25, signal transducer and activator of transcription 51), autoimmune regulator, and Wiskott-Aldrich syndrome protein. These observations emphasize the importance of functionally distinct T-cell lineages in maintaining a balanced innate and cognate immune system. (J Allergy Clin Immunol 2009;123:977-83.)	[Ochs, Hans D.] Univ Washington, Seattle Childrens Hosp, Seattle Childrens Res Inst, Dept Pediat, Seattle, WA 98101 USA; [Ochs, Hans D.; Torgerson, Troy R.] Univ Washington, Dept Pediat, Sch Med, Seattle, WA 98101 USA; [Oukka, Mohamed] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Mol Immunol,Ctr Neurol Dis, Boston, MA 02115 USA	Seattle Children's Hospital; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Ochs, HD (corresponding author), Univ Washington, Seattle Childrens Hosp, Seattle Childrens Res Inst, Dept Pediat, 1900 9th Ave,C9S-7, Seattle, WA 98101 USA.	hans.ochs@seattlechildrens.org			NIAID NIH HHS [R01 AI073542-03, R01 AI073542-01, R01 AI073542, R01 AI073542-02] Funding Source: Medline; NICHD NIH HHS [R37 HD017427-43, R37 HD017427] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD017427] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI073542] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Acosta-Rodriguez EV, 2007, NAT IMMUNOL, V8, P942, DOI 10.1038/ni1496; Acosta-Rodriguez EV, 2007, NAT IMMUNOL, V8, P639, DOI 10.1038/ni1467; Aggarwal S, 2003, J BIOL CHEM, V278, P1910, DOI 10.1074/jbc.M207577200; Anderson MS, 2002, SCIENCE, V298, P1395, DOI 10.1126/science.1075958; Andersson J, 2008, J EXP MED, V205, P1975, DOI 10.1084/jem.20080308; Bernasconi A, 2006, PEDIATRICS, V118, pE1584, DOI 10.1542/peds.2005-2882; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Brunkow ME, 2001, NAT GENET, V27, P68, DOI 10.1038/83784; Buckley RH, 2001, CLIN REV ALLERG IMMU, V20, P139, DOI 10.1385/CRIAI:20:1:139; Burchill MA, 2007, J IMMUNOL, V178, P280, DOI 10.4049/jimmunol.178.1.280; Caudy AA, 2007, J ALLERGY CLIN IMMUN, V119, P482, DOI 10.1016/j.jaci.2006.10.007; Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; Chen Z, 2007, ARTHRITIS RHEUM-US, V56, P2936, DOI 10.1002/art.22866; Clark LB, 1999, J IMMUNOL, V162, P2546; Cohen AC, 2006, J IMMUNOL, V177, P2770, DOI 10.4049/jimmunol.177.5.2770; Cua DJ, 2003, NATURE, V421, P744, DOI 10.1038/nature01355; D'Cruz LM, 2005, NAT IMMUNOL, V6, P1152, DOI 10.1038/ni1264; de Beaucoudrey L, 2008, J EXP MED, V205, P1543, DOI 10.1084/jem.20080321; Dudda JC, 2008, J EXP MED, V205, P1559, DOI 10.1084/jem.20072594; Dupuis-Girod S, 2003, PEDIATRICS, V111, pE622, DOI 10.1542/peds.111.5.e622; Fontenot JD, 2017, J IMMUNOL, V198, P986, DOI 10.1038/ni904; Fontenot JD, 2005, NAT IMMUNOL, V6, P1142, DOI 10.1038/ni1263; Fossiez F, 1996, J EXP MED, V183, P2593, DOI 10.1084/jem.183.6.2593; Gaffen SL, 2008, CYTOKINE, V43, P402, DOI 10.1016/j.cyto.2008.07.017; Grimbacher B, 1999, NEW ENGL J MED, V340, P692, DOI 10.1056/NEJM199903043400904; Harrington LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254; Harris TJ, 2007, J IMMUNOL, V179, P4313, DOI 10.4049/jimmunol.179.7.4313; HILL HR, 1974, LANCET, V2, P617; Hirota K, 2007, J EXP MED, V204, P2803, DOI 10.1084/jem.20071397; Holland SM, 2007, NEW ENGL J MED, V357, P1608, DOI 10.1056/NEJMoa073687; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Huang WT, 2004, J INFECT DIS, V190, P624, DOI 10.1086/422329; Humblet-Baron S, 2007, J CLIN INVEST, V117, P407, DOI 10.1172/JCI29539; Hwa V, 2005, J CLIN ENDOCR METAB, V90, P4260, DOI 10.1210/jc.2005-0515; Ivanov II, 2007, SEMIN IMMUNOL, V19, P409, DOI 10.1016/j.smim.2007.10.011; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Kekalainen E, 2007, J IMMUNOL, V178, P1208, DOI 10.4049/jimmunol.178.2.1208; Khattri R, 2003, NAT IMMUNOL, V4, P337, DOI 10.1038/ni909; Khattri R, 2001, J IMMUNOL, V167, P6312, DOI 10.4049/jimmunol.167.11.6312; Korn T, 2007, NATURE, V448, P484, DOI 10.1038/nature05970; Langrish CL, 2005, J EXP MED, V201, P233, DOI 10.1084/jem.20041257; Laurence A, 2007, NAT IMMUNOL, V8, P903, DOI 10.1038/ni0907-903; Lee YK, 2009, IMMUNITY, V30, P92, DOI 10.1016/j.immuni.2008.11.005; Liston A, 2003, NAT IMMUNOL, V4, P350, DOI 10.1038/ni906; Ma CS, 2008, J EXP MED, V205, P1551, DOI 10.1084/jem.20080218; Maillard MH, 2007, J EXP MED, V204, P381, DOI 10.1084/jem.20061338; Manel N, 2008, NAT IMMUNOL, V9, P641, DOI 10.1038/ni.1610; Mangan PR, 2006, NATURE, V441, P231, DOI 10.1038/nature04754; Marangoni F, 2007, J EXP MED, V204, P369, DOI 10.1084/jem.20061334; Matsuzaki G, 2007, MICROBIOL IMMUNOL, V51, P1139, DOI 10.1111/j.1348-0421.2007.tb04008.x; McGeachy MJ, 2007, SEMIN IMMUNOL, V19, P372, DOI 10.1016/j.smim.2007.10.012; Milner JD, 2008, NATURE, V452, P773, DOI 10.1038/nature06764; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Nakae S, 2002, IMMUNITY, V17, P375, DOI 10.1016/S1074-7613(02)00391-6; Nurieva R, 2007, NATURE, V448, P480, DOI 10.1038/nature05969; Ochs HD, 2006, J ALLERGY CLIN IMMUN, V117, P725, DOI 10.1016/j.jaci.2006.02.005; Onoda T, 2007, INT IMMUNOL, V19, P1191, DOI 10.1093/intimm/dxm090; Ouyang WJ, 2008, IMMUNITY, V28, P454, DOI 10.1016/j.immuni.2008.03.004; Park H, 2005, NAT IMMUNOL, V6, P1133, DOI 10.1038/ni1261; Peluso I, 2007, J IMMUNOL, V178, P732, DOI 10.4049/jimmunol.178.2.732; Renner ED, 2008, J ALLERGY CLIN IMMUN, V122, P181, DOI 10.1016/j.jaci.2008.04.037; Roifman CM, 2000, PEDIATR RES, V48, P6, DOI 10.1203/00006450-200007000-00004; Sakaguchi S, 2006, CURR TOP MICROBIOL, V305, P51, DOI 10.1007/3-540-29714-6_3; Sanchez-Sanchez N, 2006, J IMMUNOL, V176, P5153, DOI 10.4049/jimmunol.176.9.5153; Schneider MA, 2007, J EXP MED, V204, P735, DOI 10.1084/jem.20061405; SHEERIN KA, 1991, J ALLERGY CLIN IMMUN, V87, P803, DOI 10.1016/0091-6749(91)90126-9; SULLIVAN KE, 1994, J PEDIATR-US, V125, P876, DOI 10.1016/S0022-3476(05)82002-5; Torgerson TR, 2007, CURR OPIN ALLERGY CL, V7, P515, DOI 10.1097/ACI.0b013e3282f1a27a; Veldhoen M, 2006, IMMUNITY, V24, P179, DOI 10.1016/j.immuni.2006.01.001; Volpe E, 2008, NAT IMMUNOL, V9, P650, DOI 10.1038/ni.1613; Wei L, 2007, J BIOL CHEM, V282, P34605, DOI 10.1074/jbc.M705100200; WILLERFORD DM, 1995, IMMUNITY, V3, P521, DOI 10.1016/1074-7613(95)90180-9; Wilson NJ, 2007, NAT IMMUNOL, V8, P950, DOI 10.1038/ni1497; Wolk K, 2006, EUR J IMMUNOL, V36, P1309, DOI 10.1002/eji.200535503; Xiao S, 2008, J IMMUNOL, V181, P2277, DOI 10.4049/jimmunol.181.4.2277; Yang L, 2008, NATURE, V454, P350, DOI 10.1038/nature07021; Yang XXO, 2007, J BIOL CHEM, V282, P9358, DOI 10.1074/jbc.C600321200; Yao ZB, 1995, IMMUNITY, V3, P811, DOI 10.1016/1074-7613(95)90070-5; Yao Z, 2007, BLOOD, V109, P4368, DOI 10.1182/blood-2006-11-055756; Yen D, 2006, J CLIN INVEST, V116, P1310, DOI 10.1172/JCI21404	81	77	92	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2009	123	5					977	983		10.1016/j.jaci.2009.03.030	http://dx.doi.org/10.1016/j.jaci.2009.03.030			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	449CW	19410687	Green Accepted			2022-12-18	WOS:000266309400001
J	Goleva, E; Hauk, PJ; Boguniewicz, J; Martin, RJ; Leung, DYM				Goleva, Elena; Hauk, Pia J.; Boguniewicz, Juri; Martin, Richard J.; Leung, Donald Y. M.			Airway remodeling and lack of bronchodilator response in steroid-resistant asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						steroid-resistant asthma; airway remodeling; bronchodilator response; bronchoalveolar lavage cells	GLUCOCORTICOID-RECEPTOR-BETA; INHALED CORTICOSTEROIDS; TISSUE INHIBITOR; MATRIX-METALLOPROTEINASE-9; MECHANISMS; EXPRESSION; METALLOPROTEINASE-1; ASSOCIATION; CYTOKINE; UPDATE	Background: Steroid-resistant (SR) asthma is characterized by airway inflammation that fails to resolve despite treatment with corticosteroids, raising concerns that resistance to steroid therapy in asthma could lead to airway remodeling. Objective: We sought to determine whether SR asthma is accompanied by decreased airflow reversibility and could lead to airway remodeling. Methods: Spirometric results were evaluated for 40 asthmatic patients defined as having SR or steroid-sensitive (SS) asthma on the basis of a I-week course of oral prednisone. Twenty-three asthmatic patients underwent bronchoscopy with collection of bronchoalveolar lavage (BAL) fluid to analyze markers of airway remodeling in BAL fluid and cells. Results: Prednisone significantly improved FEV1 percent predicted in SS asthma (62.0% +/- 10.9% [mean +/- SD] to 79.4% +/- 11.3%, P <.001) but not in SR asthma (66.9% +/- 10.0% to 65.9% +/- 12.1%). The bronchodilator response was significantly greater in the SS than in the SR group (Delta FEV1 percent predicted, 33.5% +/- 22.5% vs 15.2% +/- 7.9%; P =.001), regardless of inhaled corticosteroid use. No difference in amounts of matrix metalloproteinase (MMP) 9, PMN elastase, or vascular endothelial growth factor was found in BAL fluid from both groups. Tissue inhibitor of metalloproteinases (TIMP) 1 levels were, however, significantly less in BAL fluid of patients with SR asthma compared with those in patients with SS asthma (921.9 +/- 313.4 vs 2267.0 +/- 456.8 pg/mL, P <.05), resulting in significantly higher MMP-9/TIMP-1 ratios in the BAL fluid of patients with SR asthma (0.24 +/- 0.04 vs 0.11 +/- 0.03, P <.01). Finally, dexamethasone treatment induced TIMP-1 mRNA in BAL fluid cells from patients with SS asthma (P <.01) but not in cells from patients with SR asthma. Conclusion: Bronchodilator reversibility is impaired in SR asthma and is associated with a shift in MMP-9/TIMP-1 ratio caused by inability of steroids to enhance TIMP-1 production, potentially promoting proteolytic activity in airways of patients with SR asthma and contributing to chronic airway remodeling. Clinical implications: SR asthma might lead to irreversible airways disease.	Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO USA; Natl Jewish Med & Res Ctr, Dept Med, Denver, CO USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pediat, Denver, CO 80262 USA	National Jewish Health; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Leung, DYM (corresponding author), Natl Jewish Med & Res Ctr, 1400 Jackson St,Room K926i, Denver, CO 80206 USA.	leungd@njc.org		Boguniewicz, Juri/0000-0002-9248-780X	NHLBI NIH HHS [R37 HL037260-13, HL36577, P01 HL036577, HL37260, P01 HL036577-120010, R37 HL037260] Funding Source: Medline; NIAID NIH HHS [R01 AI070140-01A1, R56 AI070140, R01 AI070140, AI070140, U01 AI147462] Funding Source: Medline; NIAMS NIH HHS [R01 AR041256-14A1, AR41256, R01 AR041256] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036577, R37HL037260, R01HL037260] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI070140, R56AI070140] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041256] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		[Anonymous], 1987, AM REV RESPIR DIS, V136, P225; [Anonymous], 1987, Am Rev Respir Dis, V136, P1066; BAMES PJ, 1996, EUR RESPIR J, V9, P636; Bergeron C, 2006, CHEST, V129, P1068, DOI 10.1378/chest.129.4.1068; Bergeron C, 2005, J ALLERGY CLIN IMMUN, V116, P983, DOI 10.1016/j.jaci.2005.07.029; Busse WW, 2002, J ALLERGY CLIN IMMUN, V110, P703, DOI 10.1067/mai.2002.129368; Chan MTS, 1998, J ALLERGY CLIN IMMUN, V101, P594, DOI 10.1016/S0091-6749(98)70165-4; Cundall M, 2003, J ALLERGY CLIN IMMUN, V112, P1064, DOI 10.1016/j.jaci.2003.08.013; DCMOLY P, 1999, CLIN EXP ALLERGY, V29, P1390; Drazen JM, 2000, BRIT MED BULL, V56, P1054, DOI 10.1258/0007142001903535; Goleva E, 2006, AM J RESP CRIT CARE, V173, P607, DOI 10.1164/rccm.200507-1046OC; Hamid QA, 1999, AM J RESP CRIT CARE, V159, P1600, DOI 10.1164/ajrccm.159.5.9804131; Holgate ST, 2006, J ALLERGY CLIN IMMUN, V117, P496, DOI 10.1016/j.jaci.2006.01.039; Holgate ST, 2006, LANCET, V368, P780, DOI 10.1016/S0140-6736(06)69288-X; Hoshino M, 1999, J ALLERGY CLIN IMMUN, V104, P356, DOI 10.1016/S0091-6749(99)70379-9; Hoshino M, 2004, CLIN REV ALLERG IMMU, V27, P59, DOI 10.1385/CRIAI:27:1:059; Hoshino M, 2001, CLIN EXP ALLERGY, V31, P722, DOI 10.1046/j.1365-2222.2001.01071.x; Ito K, 2006, J ALLERGY CLIN IMMUN, V117, P522, DOI 10.1016/j.jaci.2006.01.032; Johnatty RN, 1997, J IMMUNOL, V158, P2327; Kelly EAB, 2000, AM J RESP CRIT CARE, V162, P1157; Ko FWS, 2005, CHEST, V127, P1919, DOI 10.1378/chest.127.6.1919; Leung DYM, 1997, J EXP MED, V186, P1567, DOI 10.1084/jem.186.9.1567; Leung DYM, 2003, J ALLERGY CLIN IMMUN, V111, P3, DOI 10.1067/mai.2003.97; Matsumoto H, 2005, THORAX, V60, P277, DOI 10.1136/thx.2004.028936; Mattos W, 2002, CHEST, V122, P1543, DOI 10.1378/chest.122.5.1543; Nomura I, 2003, J IMMUNOL, V171, P3262, DOI 10.4049/jimmunol.171.6.3262; Pascual RM, 2005, J ALLERGY CLIN IMMUN, V116, P477, DOI 10.1016/j.jaci.2005.07.011; Rhen T, 2005, NEW ENGL J MED, V353, P1711, DOI 10.1056/NEJMra050541; Russell REK, 2002, AM J RESP CELL MOL, V26, P602, DOI 10.1165/ajrcmb.26.5.4685; Sacco O, 2006, RESP MED, V100, P307, DOI 10.1016/j.rmed.2005.05.011; SHER ER, 1994, J CLIN INVEST, V93, P33, DOI 10.1172/JCI116963; Slade DJ, 2006, CLIN CHEST MED, V27, P71, DOI 10.1016/j.ccm.2005.11.001; Sont JK, 1999, AM J RESP CRIT CARE, V159, P1043, DOI 10.1164/ajrccm.159.4.9806052; SZELLER SJ, 2002, J ALLERGY CLIN IMMUN, V109, P410; Vignola AM, 2005, ALLERGY, V60, P1511, DOI 10.1111/j.1398-9995.2005.00827.x; Vollmer WM, 2002, AM J RESP CRIT CARE, V165, P195, DOI 10.1164/ajrccm.165.2.2102127; Wenzel SE, 2006, LANCET, V368, P804, DOI 10.1016/S0140-6736(06)69290-8	37	77	87	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2007	120	5					1065	1072		10.1016/j.jaci.2007.07.042	http://dx.doi.org/10.1016/j.jaci.2007.07.042			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	231TZ	17900681	Green Accepted			2022-12-18	WOS:000250973400013
J	Godot, V; Arock, M; Garcia, G; Capel, F; Flys, C; Dy, M; Emilie, D; Humbert, M				Godot, Veronique; Arock, Michel; Garcia, Gilles; Capel, Francis; Flys, Carine; Dy, Michel; Emilie, Dominique; Humbert, Marc			H-4 histamine receptor mediates optimal migration of mast cell precursors to CXCL 12	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						mast cell precursors; CXCL12 histamine; H-4 receptor; cell migration	AIRWAY SMOOTH-MUSCLE; IN-VITRO; LYMPHOCYTE CHEMOATTRACTANT; PROGENITOR CELLS; DENDRITIC CELLS; STEEL FACTOR; CHEMOKINES; ASTHMA; EXPRESSION; RESPONSES	Background: CXCL12, a constitutive chemokine (ligand of CXCR4 and CXCR7), is expressed in the skin and airway epithelium and plays a significant role in allergic airway diseases. The pleiotropic effects of CXCL12 are enhanced by cofactors specific to the target cell. Objective: We hypothesized that histamine, a major mediator of allergic reactions, could interact with CXCL12 to promote human mast cell (MC) migration. Methods: The chemotactic effects of CXCL12 alone or in combination with histamine were evaluated on human precursor and mature MCs by using in vitro migration assays. Results: CXCL12 exerts a chemotactic activity on both precursor and fully mature MCs. Histamine and supernatants from IgE-activated MCs enhanced CXCL12 chemotactic activity on the precursor MC population. The synergy between histamine and CXCL12 was not observed with mature MCs, CD4(+) T cells, and monocytes. Inhibition of histamine receptors pharmacologically or with specific small interfering RNA (siRNA) indicated that synergy between histamine and CXCL12 required the H-4 receptor. Conclusion: Histamine released by allergen-activated mature MCs might promote MC-rich allergic inflammation by enhancing recruitment of their precursors in tissues constitutively expressing CXCL12, including skin and airways. Clinical implications: This work highlights a novel role of the H-4 receptor in the perpetuation of allergic responses and provides evidence for the Utility of H-4 receptor antagonists in the treatment of allergic diseases.	INSERMU764, F-92140 Clamart, France; Univ Paris 11, Inst Natl Sante Rech Med, Fac Med Paris Sud, Inst Fed Rech 143, Clamart, France; CNRS, Unite Mixte Rech 8113, Cachan, France; Assitance Publ Hop Paris, Hop Antoine Beclere, Serv Explorat Fonctionnelles Resp, Clamart, France; CNRS, Unite Mixte Rech 8147, Paris, France; Assitance Publ Hop Paris, Hop Antoine Beclere, Serv Microbiol Immunol Biol, Clamart, France; Assitance Publ Hop Paris, Hop Antoine Beclere, Serv Pneumol, Clamart, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Antoine-Beclere - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Antoine-Beclere - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Antoine-Beclere - APHP	Godot, V (corresponding author), INSERMU764, 32 Rue Carnets, F-92140 Clamart, France.	veronique.godot@gmail.com	Godot, Veronique/A-7863-2015; Humbert, Marc/ABD-5112-2021	Godot, Veronique/0000-0003-3557-308X; Humbert, Marc/0000-0003-0703-2892				ANDERSSON M, 1990, J ALLERGY CLIN IMMUN, V86, P815, DOI 10.1016/S0091-6749(05)80188-5; Balabanian K, 2005, J BIOL CHEM, V280, P35760, DOI 10.1074/jbc.M508234200; Balabanian K, 2002, BLOOD, V99, P427, DOI 10.1182/blood.V99.2.427; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; Buckland KF, 2003, BRIT J PHARMACOL, V140, P1117, DOI 10.1038/sj.bjp.0705530; Coulomb-L'Hermine A, 2000, AIDS RES HUM RETROV, V16, P1097, DOI 10.1089/08892220050075372; El-Shazly A, 2006, J IMMUNOL, V176, P1860, DOI 10.4049/jimmunol.176.3.1860; Galli SJ, 2005, NAT IMMUNOL, V6, P135, DOI 10.1038/ni1158; Gonzalo JA, 2000, J IMMUNOL, V165, P499, DOI 10.4049/jimmunol.165.1.499; Gutzmer R, 2005, J IMMUNOL, V174, P5224, DOI 10.4049/jimmunol.174.9.5224; Hodohara K, 2000, BLOOD, V95, P769, DOI 10.1182/blood.V95.3.769.003a49_769_775; Infantino S, 2006, J IMMUNOL, V176, P2197, DOI 10.4049/jimmunol.176.4.2197; Kim CH, 1998, BLOOD, V91, P100, DOI 10.1182/blood.V91.1.100.100_100_110; Lukacs NW, 2002, AM J PATHOL, V160, P1353, DOI 10.1016/S0002-9440(10)62562-X; Metcalfe DD, 1997, PHYSIOL REV, V77, P1033, DOI 10.1152/physrev.1997.77.4.1033; Ochi H, 1999, J EXP MED, V190, P267, DOI 10.1084/jem.190.2.267; OKAYAMA Y, 1994, ALLERGY, V49, P246, DOI 10.1111/j.1398-9995.1994.tb02657.x; Pablos JL, 1999, AM J PATHOL, V155, P1577, DOI 10.1016/S0002-9440(10)65474-0; Pease JE, 2006, J ALLERGY CLIN IMMUN, V118, P305, DOI 10.1016/j.jaci.2006.06.010; Repka-Ramirez M Susana, 2002, Clin Allergy Immunol, V17, P1; Rimaniol AC, 2003, J ALLERGY CLIN IMMUN, V112, P1139, DOI 10.1016/j.jaci.2003.09.041; Saito H, 1996, J IMMUNOL, V157, P343; Tan BL, 2003, BLOOD, V101, P4725, DOI 10.1182/blood-2002-08-2521; Weller CL, 2005, J EXP MED, V201, P1961, DOI 10.1084/jem.20042407; Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X	26	77	87	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2007	120	4					827	834		10.1016/j.jaci.2007.05.046	http://dx.doi.org/10.1016/j.jaci.2007.05.046			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	220LH	17681365				2022-12-18	WOS:000250157700016
J	Fujiwara, M; Hirose, K; Kagami, S; Takatori, H; Wakashin, H; Tamachi, T; Watanabe, N; Saito, Y; Iwamoto, I; Nakajima, H				Fujiwara, Michio; Hirose, Koichi; Kagami, Shin-ichiro; Takatori, Hiroaki; Wakashin, Hidefumi; Tamachi, Tomohiro; Watanabe, Norihiko; Saito, Yasushi; Iwamoto, Itsuo; Nakajima, Hiroshi			T-bet inhibits both T(H)2 cell-mediated eosinophil recruitment and T(H)17 cell-mediated neutrophil recruitment into the airways	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic inflammation; T-bet; eosinophils; T(H)2 cells; T(H)17 cells	ANTIGEN-INDUCED EOSINOPHIL; MICE LACKING; IFN-GAMMA; SEVERE ASTHMA; LINEAGE; DISTINCT; INFILTRATION; INFLAMMATION; LYMPHOCYTES; MECHANISMS	Background: Previous studies have shown that mice lacking T-bet, a critical transcription factor for T(H)1 cell differentiation, spontaneously develop airway inflammation with intense eosinophil infiltrates. However, the mechanism underlying T-bet-mediated inhibition of allergic airway inflammation is still unknown. Objective: To determine the regulatory role of T-bet in antigen-induced allergic airway inflammation. Methods: We examined the role of T-bet in antigen-induced allergic airway inflammation using T-bet(-/-) mice on a BALB/c background that did not develop spontaneous airway inflammation. We also examined the role of T-bet expression of CD4(+) T cells in airway inflammation by adoptive transfer experiments. Results: We found that antigen-induced eosinophil recruitment, goblet cell hyperplasia, and T(H)2 cytokine production in the airways were enhanced in T-bet-/- mice. However, in the absence of signal transducer and activator of transcription 6 (STAT6), T-bet deficiency could not induce the antigen-induced eosinophilic airway inflammation. Adoptive transfer of T-bet(-/-) or T-bet(+/+) CD4(+) T cells to T-bet(-/-)Rag-2(-/-) mice revealed that the expression of T-bet in CD4+ T cells was vital for the inhibition of antigen-induced eosinophilic airway inflammation. Interestingly, antigen-induced neutrophil recruitment in the airways was also enhanced in T-bet-/- mice. Moreover, T-bet(-/-) CD4(+) T cells preferentially differentiated into IL-17-producing cells that mediated neutrophilic airway inflammation. Conclusion: T-bet inhibits both TH2 cell-mediated eosinophilic inflammation and TH17 cell-mediated neutrophilic inflammation in the airways. Clinical implications: The dysfunction of T-bet may be involved in the pathogenesis of severe asthma, in which accumulation of neutrophils as well as eosinophils in the airways is a hallmark of disease.	Chiba Univ, Grad Sch Med, Dept Mol Genet, Chiba 2608670, Japan; Chiba Univ, Grad Sch Med, Dept Allergy & Clin Immunol, Chiba 2608670, Japan; Asahi Gen Hosp, Res Ctr Allergy & Clin Immunol, Chiba, Japan	Chiba University; Chiba University	Nakajima, H (corresponding author), Chiba Univ, Grad Sch Med, Dept Mol Genet, 1-8-1 Inohana, Chiba 2608670, Japan.	nakajimh@faculty.chiba-u.jp	Tamachi, Tomohiro/I-1468-2017; Nakajima, Hiroshi/AFU-9313-2022	Tamachi, Tomohiro/0000-0001-8295-1472; Nakajima, Hiroshi/0000-0001-8595-9381				Afkarian M, 2002, NAT IMMUNOL, V3, P549, DOI 10.1038/ni794; Chakir J, 2003, J ALLERGY CLIN IMMUN, V111, P1293, DOI 10.1067/mai.2003.1557; Cohn L, 2004, ANNU REV IMMUNOL, V22, P789, DOI 10.1146/annurev.immunol.22.012703.104716; Coyle AJ, 1996, J IMMUNOL, V156, P2680; Dong C, 2006, NAT REV IMMUNOL, V6, P329, DOI 10.1038/nri1807; Finotto S, 2005, INT IMMUNOL, V17, P993, DOI 10.1093/intimm/dxh281; Finotto S, 2002, SCIENCE, V295, P336, DOI 10.1126/science.1065544; Harrington LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254; Holgate ST, 2006, LANCET, V368, P780, DOI 10.1016/S0140-6736(06)69288-X; IWAMOTO I, 1993, J EXP MED, V177, P573, DOI 10.1084/jem.177.2.573; Kagami S, 2000, BLOOD, V95, P1370, DOI 10.1182/blood.V95.4.1370.004k29_1370_1377; Larche M, 2003, J ALLERGY CLIN IMMUN, V111, P450, DOI 10.1067/mai.2003.169; Larson KA, 1996, P NATL ACAD SCI USA, V93, P12370, DOI 10.1073/pnas.93.22.12370; Liu NS, 2003, NAT IMMUNOL, V4, P687, DOI 10.1038/ni941; Lugo-Villarino G, 2003, P NATL ACAD SCI USA, V100, P7749, DOI 10.1073/pnas.1332767100; Mathur AN, 2006, BLOOD, V108, P1595, DOI 10.1182/blood-2006-04-015016; McDevitt AL, 2001, GENE, V267, P23, DOI 10.1016/S0378-1119(01)00392-4; Molet S, 2001, J ALLERGY CLIN IMMUN, V108, P430, DOI 10.1067/mai.2001.117929; Moseley TA, 2003, CYTOKINE GROWTH F R, V14, P155, DOI 10.1016/S1359-6101(03)00002-9; Murphy KM, 2002, NAT REV IMMUNOL, V2, P933, DOI 10.1038/nri954; NAKAJIMA H, 1992, AM REV RESPIR DIS, V146, P374, DOI 10.1164/ajrccm/146.2.374; Nakajima H, 2000, INT ARCH ALLERGY IMM, V122, P20, DOI 10.1159/000053626; Park H, 2005, NAT IMMUNOL, V6, P1133, DOI 10.1038/ni1261; Raby BA, 2006, AM J RESP CRIT CARE, V173, P64, DOI 10.1164/rccm.200503-505OC; REINER SL, 1995, ANNU REV IMMUNOL, V13, P151, DOI 10.1146/annurev.iy.13.040195.001055; Seto Y, 2003, J IMMUNOL, V170, P1077, DOI 10.4049/jimmunol.170.2.1077; Sullivan BM, 2003, P NATL ACAD SCI USA, V100, P15818, DOI 10.1073/pnas.2636938100; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; Szabo SJ, 2002, SCIENCE, V295, P338, DOI 10.1126/science.1065543; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Wills-Karp M, 2001, J ALLERGY CLIN IMMUN, V107, P9, DOI 10.1067/mai.2001.112265	32	77	88	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2007	119	3					662	670		10.1016/j.jaci.2006.12.643	http://dx.doi.org/10.1016/j.jaci.2006.12.643			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	146HL	17336616				2022-12-18	WOS:000244925000020
J	Das-Munshi, J; Rubin, GJ; Wessely, S				Das-Munshi, Jayati; Rubin, G. James; Wessely, Simon			Multiple chemical sensitivities: A systematic review of provocation studies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						multiple chemical sensitivities; idiopathic environmental intolerance; MCS; IEI; cacosmia; provocation studies; functional somatic syndromes	EXPERIMENTAL CHALLENGE; ODOR PERCEPTION; CHRONIC-FATIGUE; DOUBLE-BLIND; SYMPTOMS; EXPOSURE; PERFORMANCE; ANNOYANCE; RESPONSES; INHALATION	A systematic review of provocation studies of persons reporting multiple chemical sensitivities (MCS) was conducted from databases searched from inception to May 2006. Thirty-seven studies were identified, testing 784 persons reporting MCS, 547 control subjects, and 180 individuals of whom a subset were chemically sensitive. Blinding was inadequate in most studies. In 21 studies odors of chemicals were probably apparent; 19 of these reported positive responses to provocations among chemically sensitive individuals, and 1 study demonstrated that negative expectations were significantly associated with increased symptom reporting after provocations. Seven studies used chemicals at or below odor thresholds, and 6 failed to show consistent responses among sensitive individuals after active provocation. Six studies used forced-choice discrimination and demonstrated that chemically sensitive individuals were not better at detecting odor thresholds than nonsensitive participants. Three studies tested individuals by using nose clips/face masks and confirmed response, possibly mediated through eye exposure. Three studies used olfactory masking agents to conceal stimuli, and none of these found associations between provocations and response. We conclude that persons with MCS do react to chemical challenges; however, these responses occur when they can discern differences between active and sham substances, suggesting that the mechanism of action is not specific to the chemical itself and might be related to expectations and prior beliefs.	Inst Psychiat, Epidemiol Sect, London SE5 8AF, England; Weston Educ Ctr, Inst Psychiat, Sect Gen Hosp Psychiat, Weston Educ Ctr, London WC2R 2LS, England	University of London; King's College London; University of London; King's College London	Das-Munshi, J (corresponding author), Inst Psychiat, Epidemiol Sect, POB 60,De Crespigny Pk, London SE5 8AF, England.	spsljdm@iop.kcl.ac.uk	Wessely, Simon C/A-8713-2008; Das-Munshi, Jayati/F-1910-2010	Das-Munshi, Jayati/0000-0002-3913-6859; Wessely, Simon Charles/0000-0002-6743-9929				ANDERSON JA, 1986, J ALLERGY CLIN IMMUN, V78, P269; Bell IR, 1998, INT J PSYCHOPHYSIOL, V28, P23, DOI 10.1016/S0167-8760(97)00069-X; Binkley KE, 1997, J ALLERGY CLIN IMMUN, V99, P570, DOI 10.1016/S0091-6749(97)70086-1; BORNSCHEIN S, 2005, J TOXICOL-CLIN TOXIC, V43, P436; Caccappolo E, 2000, J OCCUP ENVIRON MED, V42, P629, DOI 10.1097/00043764-200006000-00012; CAMP JE, 1984, SWEDISH COUNCIL BUIL, V3, P393; CULLEN MR, 1987, OCCUPATIONAL MED STA, V2; Dalton P, 2000, OCCUP MED-STATE ART, V15, P539; Dalton P, 1999, HEALTH PSYCHOL, V18, P579, DOI 10.1037/0278-6133.18.6.579; Dalton PH, 2000, AM IND HYG ASSOC J, V61, P340, DOI 10.1080/15298660008984542; Devriese S, 2004, INT ARCH OCC ENV HEA, V77, P200, DOI 10.1007/s00420-003-0488-8; DOTY RL, 1988, ARCH OTOLARYNGOL, V114, P1422; Fernandez M, 1999, TOXICOL IND HEALTH, V15, P577, DOI 10.1191/074823399678846970; Fiedler N, 2000, ENVIRON HEALTH PERSP, V108, P753, DOI 10.2307/3434729; Fiedler N, 2004, PSYCHOSOM MED, V66, P588, DOI 10.1097/01.psy.0000127872.53932.75; FRIGAS E, 1984, MAYO CLIN PROC, V59, P295, DOI 10.1016/S0025-6196(12)61423-2; Georgellis A, 2003, INT J HYG ENVIR HEAL, V206, P531, DOI 10.1078/1438-4639-00253; Graveling RA, 1999, OCCUP ENVIRON MED, V56, P73, DOI 10.1136/oem.56.2.73; Hummel T, 1996, REGUL TOXICOL PHARM, V24, pS79, DOI 10.1006/rtph.1996.0082; IREGREN A, 1986, SCAND J WORK ENV HEA, V12, P469, DOI 10.5271/sjweh.2110; Joffres MR, 2005, ENVIRON HEALTH PERSP, V113, P1178, DOI 10.1289/ehp.7198; Kakuta K, 2002, NEUROOPHTHALMOLOGY, V19, P176; Kimata H, 2004, INT J HYG ENVIR HEAL, V207, P159, DOI 10.1078/1438-4639-00262; KJAERGAARD SK, 1991, ATMOS ENVIRON A-GEN, V25, P1417; Kurtz D., 1993, Chemical Senses, V18, P584; Leznoff A, 1997, J ALLERGY CLIN IMMUN, V99, P438, DOI 10.1016/S0091-6749(97)70067-8; Leznoff A, 2000, OCCUP MED, V15, P529; LURSON CA, 1998, HLTH CARE INTERNET, V2, P57; Millqvist E, 1996, ALLERGY, V51, P434, DOI 10.1111/j.1398-9995.1996.tb00156.x; Millqvist E, 1999, ALLERGY, V54, P495, DOI 10.1034/j.1398-9995.1999.00031.x; MOLHAVE L, 1986, Environment International, V12, P167, DOI 10.1016/0160-4120(86)90027-9; Ojima M, 2002, TOHOKU J EXP MED, V198, P163, DOI 10.1620/tjem.198.163; Orbaek P, 1998, SCAND J WORK ENV HEA, V24, P432, DOI 10.5271/sjweh.366; Osterberg K, 2004, SCAND J WORK ENV HEA, V30, P486; Osterberg K, 2003, SCAND J WORK ENV HEA, V29, P40; PAN Y, 1989, CLIN ECOL, V6, P79; Papo D, 2006, J PSYCHOSOM RES, V60, P199, DOI 10.1016/j.jpsychores.2005.06.075; Poonai N, 2000, J ALLERGY CLIN IMMUN, V105, P358, DOI 10.1016/S0091-6749(00)90088-5; PUDDICOMBE D, 2006, OTTAWA SUN      0527; Randolph T.G., 1962, HUMAN ECOLOGY SUSCEP; REA W J, 1991, Boletin de la Asociacion Medica de Puerto Rico, V83, P383; REA WJ, 1976, ANN ALLERGY, V37, P101; REA WJ, 1978, ANN ALLERGY, V40, P243; REA WJ, 1977, ANN ALLERGY, V38, P245; REA WJ, 1989, CLIN ECOL, V6, P389; REA WJ, 1982, IMMUNOL ALLERGY PRAC, V4, P21; RUDELL B, 1997, APPL OCCUP ENV HYG, V12, P465; Shorter E, 1997, SCAND J WORK ENV HEA, V23, P35; Smith S, 2003, INT J BEHAV MED, V10, P162, DOI 10.1207/S15327558IJBM1002_05; STAUDENMAYER H, 1993, REGUL TOXICOL PHARM, V18, P44, DOI 10.1006/rtph.1993.1043; Van Den Bergh O, 2001, ANN NY ACAD SCI, V933, P278; Van den Bergh O, 2002, SCAND J PSYCHOL, V43, P147, DOI 10.1111/1467-9450.00280; van Thriel C, 2002, INT J HYG ENVIR HEAL, V204, P367; VIEREGGE S, 2000, CHEM SENSES, V25, P801; Winters W, 2003, PSYCHOSOM MED, V65, P332, DOI 10.1097/01.PSY.0000041468.75064.BE	55	77	79	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2006	118	6					1257	1264		10.1016/j.jaci.2006.07.046	http://dx.doi.org/10.1016/j.jaci.2006.07.046			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	117NP	17137865				2022-12-18	WOS:000242880300008
J	Matsunaga, K; Yanagisawa, S; Ichikawa, T; Ueshima, K; Akamatsu, K; Hirano, T; Nakanishi, M; Yamagata, T; Minakata, Y; Ichinose, M				Matsunaga, Kazuto; Yanagisawa, Satoru; Ichikawa, Tomohiro; Ueshima, Kazuhito; Akamatsu, Keiichirou; Hirano, Tsunahiko; Nakanishi, Masanori; Yamagata, Toshiyuki; Minakata, Yoshiaki; Ichinose, Masakazu			Airway cytokine expression measured by means of protein array in exhaled breath condensate: Correlation with physiologic properties in asthmatic patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						airway hyperresponsiveness; airway lability; airflow limitation; bronchial asthma; exhaled breath condensate; protein array; RANTES; TGF-beta; TNF-alpha	BRONCHOALVEOLAR LAVAGE; INFLAMMATION; METHACHOLINE; SPIROMETRY; ALPHA; MODEL; GAMMA	Background: Simultaneous monitoring of airway inflammation and physiology might be useful for asthma management. Objective: We examined the upregulated molecules in asthmatic airways. Furthermore, we investigated the relationship between these molecules and the airway physiologic properties of asthma. Methods: Ten nonsmoking healthy subjects and 16 steroid-naive asthmatic patients were enrolled. Exhaled breath condensate (EBC) sampling, spirometry, and methacholine inhalation challenge were performed on one occasion in this cross-sectional study. Peak expiratory flow was also measured for 4 weeks. Airway cytokine-chemokine-growth factor production was analyzed with a protein array. Results: The expressions of IL-4, IL-8, IL-17, TNF-alpha, RANTES, IFN-gamma-inducible protein 10, TGF-beta, and macrophage inflammatory protein la and 10 were significantly upregulated in asthmatic airways compared with those of nonsmoking healthy subjects. Among the upregulated molecules; RANTES expression was significantly correlated with the parameters that represent airway caliber, FEV1 and respiratory resistance values. In addition, the levels of both TNF-a and TGF-beta were significantly correlated with the methacholine threshold and peak expiratory flow variability for the week. Conclusion: Inflammatory molecule analysis with EBC appeared to be useful for monitoring the asthmatic airway condition. Clinical implications: Measurements of cytokine levels in EBC might be a promising approach to assess the efficacy of pharmacologic interventions and to investigate the pathophysiology of asthma.	Wakayama Med Univ, Sch Med, Dept Internal Med 3, Wakayama 6410012, Japan	Wakayama Medical University	Ichinose, M (corresponding author), Wakayama Med Univ, Sch Med, Dept Internal Med 3, 811-1 Kimiidera, Wakayama 6410012, Japan.	masakazu@wakayama-med.ac.jp	Minakata, Yoshiaki/AAD-7638-2020; Yanagisawa, Satoru/D-8292-2018	Yanagisawa, Satoru/0000-0003-3895-5518; Minakata, Yoshiaki/0000-0001-6993-0917; Hirano, Tsunahiko/0000-0002-5475-0806				[Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; [Anonymous], 1987, AM REV RESPIR DIS, V136, P225; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; Brightling CE, 2005, AM J RESP CRIT CARE, V171, P1103, DOI 10.1164/rccm.200409-1220OC; Chetta A, 1996, AM J RESP CRIT CARE, V153, P910, DOI 10.1164/ajrccm.153.3.8630572; Chu HW, 1998, AM J RESP CRIT CARE, V158, P1936, DOI 10.1164/ajrccm.158.6.9712073; Chung KF, 1999, THORAX, V54, P825, DOI 10.1136/thx.54.9.825; Enright PL, 1997, CHEST, V112, P895, DOI 10.1378/chest.112.4.895; Gauvreau GM, 1999, AM J RESP CRIT CARE, V160, P640, DOI 10.1164/ajrccm.160.2.9809130; GIMENO F, 1972, AM REV RESPIR DIS, V105, P68; Horvath I, 2005, EUR RESPIR J, V26, P523, DOI 10.1183/09031936.05.00029705; Howarth PH, 2005, THORAX, V60, P1012, DOI 10.1136/thx.2005.045260; Huang RP, 2001, J IMMUNOL METHODS, V255, P1, DOI 10.1016/S0022-1759(01)00394-5; Huang RP, 2001, ANAL BIOCHEM, V294, P55, DOI 10.1006/abio.2001.5156; Ichinose M, 2000, EUR RESPIR J, V15, P248, DOI 10.1034/j.1399-3003.2000.15b05.x; Medoff BD, 2002, J IMMUNOL, V168, P5278, DOI 10.4049/jimmunol.168.10.5278; Montuschi P, 2002, J ALLERGY CLIN IMMUN, V109, P615, DOI 10.1067/mai.2002.122461; Montuschi P, 2000, AM J RESP CRIT CARE, V162, P1175, DOI 10.1164/ajrccm.162.3.2001063; Mutlu GM, 2001, AM J RESP CRIT CARE, V164, P731, DOI 10.1164/ajrccm.164.5.2101032; *NAT HEART LUNG BL, 1990, STAT TECHN STAND PEA; PIN I, 1992, THORAX, V47, P25, DOI 10.1136/thx.47.1.25; Redington AE, 1997, AM J RESP CRIT CARE, V156, P642, DOI 10.1164/ajrccm.156.2.9605065; Shahid SK, 2002, AM J RESP CRIT CARE, V165, P1290, DOI 10.1164/rccm.2108082; SMITH DL, 1993, AM REV RESPIR DIS, V148, P523, DOI 10.1164/ajrccm/148.2.523; TAKISHIMA T, 1981, CHEST, V80, P600, DOI 10.1378/chest.80.5.600; Thomas PS, 2002, THORAX, V57, P774, DOI 10.1136/thorax.57.9.774; Turtinen LW, 2004, ANTIMICROB AGENTS CH, V48, P396, DOI 10.1128/AAC.48.2.396-403.2004; VIGNOLA AM, 1997, AM J RESP CRIT CARE, V160, P1001; *WHO, 2002, GLOB IN ASTHM GLOB S; WIGGS BR, 1992, AM REV RESPIR DIS, V145, P1251, DOI 10.1164/ajrccm/145.6.1251; YING L, 2003, CLIN CHEM LAB MED, V41, P139	32	77	85	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2006	118	1					84	90		10.1016/j.jaci.2006.04.020	http://dx.doi.org/10.1016/j.jaci.2006.04.020			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	065UH	16815142				2022-12-18	WOS:000239184800010
J	Grunwald, T; Bockisch, B; Spillner, E; Ring, J; Bredehorst, R; Ollert, MW				Grunwald, T; Bockisch, B; Spillner, E; Ring, J; Bredehorst, R; Ollert, MW			Molecular cloning and expression in insect cells of honeybee venom allergen acid phosphatase (Api m 3)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						honeybee venom; Api m 3; acid phosphatase; Apis mellifera; recombinant allergen; expression; insect cells	IGE-BINDING EPITOPES; BEE-VENOM; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; ANGSTROM RESOLUTION; PHOSPHOLIPASE-A2; HYALURONIDASE; PURIFICATION; PROTEIN; GLYCOSYLATION	Background: Acid phosphatase (Api m 3) is a major allergen in honeybee (Apis mellifera) venom, and its availability as a recombinant protein may facilitate the development of improved diagnostic tests and immunotherapies. Objective: One objective is the determination of the complete primary structure of Api m 3 and to obtain recombinant Api m 3 on the basis of expression in insect cells. Another objective is the quantitative analysis of patient serum IgE antibody reactive to recombinant Api m 3. Methods: The cloning of Api no 3 front venom gland cDNA and its expression as a full-length protein in eukaryotic insect cells is described. The immunoreactivity of serum IgE antibodies of honeybee venom-sensitized patients to recombinant Api m 3 was determined in an enzyme immunoassay. Results: PCR amplification generated a 1122-bp DNA fragment whose identity as the coding sequence of Api m 3 was verified by several means. Recombinant Api m 3, expressed in Trichoplusia ni cells, showed an expected molecular weight and enzymatic activity at pH 4.5. Analysis of tryptic fragments of purified recombinant Api m 3 by mass spectrometry confirmed its identity. In immunoassays, recombinant Api ni 3 is specifically recognized by IgE antibodies of pooled serum in Western blots and by 37% of the individual sera of honeybee venom-sensitized patients in ELISA analysis. Conclusion: The availability of recombinant Api m 3 provides a tool for both the development of improved diagnostic tests and the design of safer and more effective immunotherapeutic approaches for honeybee venom allergy. Clinical implications: The recombinant venom allergen Api m 3 is a key element in the search for an optimized component resolved approach to honeybee venom allergy with regard to both the development of superior diagnostic tests and the improvement of allergen immunotherapy.	Tech Univ Munich, Dept Dermatol & Allergy, D-80802 Munich, Germany; Prot Ligand Struct PLS Design GmbH, Hamburg, Germany; Univ Hamburg, Abt Biochem & Mol Biol, Inst Biochem & Lebensmittelchem, Hamburg, Germany; Tech Univ Munich, Clin Res Div Mol & Clin Allergotoxicol, D-80802 Munich, Germany	Technical University of Munich; University of Hamburg; Technical University of Munich	Ollert, MW (corresponding author), Tech Univ Munich, Dept Dermatol & Allergy, Biedersteinerstr 29, D-80802 Munich, Germany.	ollert@lrz.tum.de	Ring, Johannes/GLN-4341-2022; Spillner, E./G-3799-2010	Ring, Johannes/0000-0001-8236-3152; spillner, edzard/0000-0003-0999-5254; Ollert, Markus W./0000-0002-8055-0103				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ARBESMAN CE, 1976, CLIN ALLERGY, V6, P587, DOI 10.1111/j.1365-2222.1976.tb01945.x; BARBONI E, 1987, TOXICON, V25, P1097, DOI 10.1016/0041-0101(87)90266-2; *BAYL COLL MED HUM, 2005, GEN ASS VERS 3 0 AM; Beezhold DH, 1999, J ALLERGY CLIN IMMUN, V103, P1166, DOI 10.1016/S0091-6749(99)70194-6; Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; Burge CB, 1998, CURR OPIN STRUC BIOL, V8, P346, DOI 10.1016/S0959-440X(98)80069-9; DUDLER T, 1992, BIOCHIM BIOPHYS ACTA, V1165, P201, DOI 10.1016/0005-2760(92)90188-2; FORSTER E, 1995, J ALLERGY CLIN IMMUN, V95, P1229, DOI 10.1016/S0091-6749(95)70080-3; GMACHL M, 1993, P NATL ACAD SCI USA, V90, P3569, DOI 10.1073/pnas.90.8.3569; GRUNWALD T, 2004, CLONING HONEYBEE ALL; Hoffman D.R., 2005, J ALLERGY CLIN IMMUN, V115, pS107; Hoffman DR, 1996, ADV EXP MED BIOL, V391, P169; HOFFMAN DR, 1977, J ALLERGY CLIN IMMUN, V59, P364, DOI 10.1016/0091-6749(77)90019-7; HOFFMAN DR, 1977, J ALLERGY CLIN IMMUN, V59, P147, DOI 10.1016/0091-6749(77)90217-2; HOFFMANN DR, APIS MELLIFERA VENOM; Jenkins N, 1996, NAT BIOTECHNOL, V14, P975, DOI 10.1038/nbt0896-975; KEMENY DM, 1983, J ALLERGY CLIN IMMUN, V71, P505, DOI 10.1016/0091-6749(83)90469-4; KEMENY DM, 1981, BIOCHEM INT, V2, P145; King TP, 2000, INT ARCH ALLERGY IMM, V123, P99, DOI 10.1159/000024440; KING TP, 1979, ARCH BIOCHEM BIOPHYS, V172, P661; Kostrewa D, 1999, J MOL BIOL, V288, P965, DOI 10.1006/jmbi.1999.2736; Kostrewa D, 1997, NAT STRUCT BIOL, V4, P185, DOI 10.1038/nsb0397-185; KUCHLER K, 1989, EUR J BIOCHEM, V184, P249, DOI 10.1111/j.1432-1033.1989.tb15014.x; LIS H, 1993, EUR J BIOCHEM, V218, P1, DOI 10.1111/j.1432-1033.1993.tb18347.x; Markovic-Housley Z, 2000, STRUCTURE, V8, P1025, DOI 10.1016/S0969-2126(00)00511-6; MARZ L, 1983, TOXICON, V21, P893, DOI 10.1016/0041-0101(83)90080-6; Muller UR, 2003, CURR OPIN ALLERGY CL, V3, P299, DOI [10.1097/00130832-200308000-00011, 10.1097/01.all.0000083961.99396.de]; MULLER U, 1992, J ALLERGY CLIN IMMUN, V89, P529, DOI 10.1016/0091-6749(92)90319-W; Muller UR, 2002, ALLERGY, V57, P570, DOI 10.1034/j.1398-9995.2002.02157.x; Ollert M, 2005, CLIN CHEM, V51, P1241, DOI 10.1373/clinchem.2004.046565; OLLERT MW, 1995, J CLIN MICROBIOL, V33, P2543, DOI 10.1128/JCM.33.10.2543-2549.1995; OSTANIN K, 1993, J BIOL CHEM, V268, P20778; OSTANIN K, 1992, J BIOL CHEM, V267, P22830; Rueff F, 1996, ALLERGY, V51, P216, DOI 10.1111/j.1398-9995.1996.tb04596.x; SCHNEIDER G, 1993, EMBO J, V12, P2609, DOI 10.1002/j.1460-2075.1993.tb05921.x; Schramm G, 2001, CLIN EXP ALLERGY, V31, P331, DOI 10.1046/j.1365-2222.2001.01049.x; SCOTT DL, 1990, SCIENCE, V250, P1563, DOI 10.1126/science.2274788; SHKENDEROV S, 1979, Toxicon, V17, P169; Soldatova LN, 2000, J ALLERGY CLIN IMMUN, V105, pS378, DOI 10.1016/S0091-6749(00)91531-8; Soldatova LN, 1998, J ALLERGY CLIN IMMUN, V101, P691, DOI 10.1016/S0091-6749(98)70179-4; SOLDATOVA LN, 1999, ARBEITEN P EHRLICH I, V93, P189; TRETTER V, 1993, INT ARCH ALLERGY IMM, V102, P259, DOI 10.1159/000236534; VANETTEN RL, 1982, ANN NY ACAD SCI, V390, P27; VINCENT JB, 1992, TRENDS BIOCHEM SCI, V17, P105, DOI 10.1016/0968-0004(92)90246-6; VLASAK R, 1983, EUR J BIOCHEM, V135, P123, DOI 10.1111/j.1432-1033.1983.tb07626.x; Wang CQ, 1996, BIOCHEMISTRY-US, V35, P7299, DOI 10.1021/bi9517704	47	77	81	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2006	117	4					848	854		10.1016/j.jaci.2005.12.1331	http://dx.doi.org/10.1016/j.jaci.2005.12.1331			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	033QB	16630944				2022-12-18	WOS:000236862800020
J	Notarangelo, LD; Lanzi, G; Peron, S; Durandy, A				Notarangelo, LD; Lanzi, G; Peron, S; Durandy, A			Defects of class-switch recombination	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						immunodeficiency with hyper-IgM; class-switch recombination; somatic hypermutation	HYPER-IGM SYNDROME; AUTOSOMAL RECESSIVE FORM; CYTIDINE DEAMINASE AID; SOMATIC HYPERMUTATION; B-CELLS; CD40 DEFICIENCY; ACTIVATION; DNA; MUTATIONS; URACIL	Shaping of the secondary antibody repertoire is generated by means of class-switch recombination (CSR), which replaces IgM with other isotypes, and somatic hypermutation (SHM), which allows production of high-affinity antibodies. However, the molecular mechanisms underlying these important processes have long remained obscure. Immunodeficiency with hyper-IgM comprises a group of genetically heterogeneous defects of CSR variably associated with defects of SHM. The study of these patients has allowed us to recognize that both T-cell-B-cell interaction (resulting in CD40-mediated signaling) and intrinsic B-cell mechanisms are involved in CSR and SHM. Elucidation of the molecular defects underlying these disorders has been essential to better understand the molecular basis of Ig diversification and has offered the opportunity to define the clinical spectrum of these diseases and to prompt more accurate diagnostic and therapeutic approaches.	Univ Brescia, Spedali Civili, Dept Pediat, I-25123 Brescia, Italy; Univ Brescia, Angelo Nocivelli Inst Mol Med, I-25123 Brescia, Italy; Univ Paris 05, Hop Necker Enfants Malad, INSERM, U429, Paris, France; Assistance Publ Hop Paris, Paris, France	Hospital Spedali Civili Brescia; University of Brescia; University of Brescia; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Notarangelo, LD (corresponding author), Univ Brescia, Spedali Civili, Dept Pediat, I-25123 Brescia, Italy.	notarang@med.unibs.it	Notarangelo, Luigi D/F-9718-2016; PERON, SOPHIE/O-8364-2016; Durandy, Anne/H-7475-2017	Notarangelo, Luigi D/0000-0002-8335-0262; PERON, SOPHIE/0000-0002-0056-3271; Durandy, Anne/0000-0001-7706-8466				Akbari M, 2004, NUCLEIC ACIDS RES, V32, P5486, DOI 10.1093/nar/gkh872; Basu U, 2005, NATURE, V438, P508, DOI 10.1038/nature04255; Begum NA, 2004, SCIENCE, V305, P1160, DOI 10.1126/science.1098444; Brodeur SR, 2003, IMMUNITY, V18, P837, DOI 10.1016/S1074-7613(03)00149-3; Catalan N, 2003, J IMMUNOL, V171, P2504, DOI 10.4049/jimmunol.171.5.2504; Chaudhuri J, 2004, NATURE, V430, P992, DOI 10.1038/nature02821; Chaudhuri J, 2004, NAT REV IMMUNOL, V4, P541, DOI 10.1038/nri1395; Doffinger R, 2001, NAT GENET, V27, P277, DOI 10.1038/85837; Durandy A, 2005, IMMUNOL REV, V203, P67, DOI 10.1111/j.0105-2896.2005.00222.x; DURANDY A, 1993, EUR J IMMUNOL, V23, P2294, DOI 10.1002/eji.1830230936; Durandy A, 2004, ADV IMMUNOL, V82, P295, DOI 10.1016/S0065-2776(04)82007-8; DURANDY A, 2006, IN PRESS PRIMAYR IMM; Etzioni A, 2004, PEDIATR RES, V56, P519, DOI 10.1203/01.PDR.0000139318.65842.4A; Ferrari S, 2001, P NATL ACAD SCI USA, V98, P12614, DOI 10.1073/pnas.221456898; Fontana S, 2003, BLOOD, V102, P4099, DOI 10.1182/blood-2003-04-1244; GEHA RS, 2006, IN PRESS PRIMARY IMM; Gennery AR, 2004, BLOOD, V103, P1152, DOI 10.1182/blood-2003-06-2014; Gulino AV, 2003, CURR OPIN RHEUMATOL, V15, P422, DOI 10.1097/00002281-200307000-00009; Hanissian SH, 1997, IMMUNITY, V6, P379, DOI 10.1016/S1074-7613(00)80281-2; Imai K, 2005, CLIN IMMUNOL, V115, P277, DOI 10.1016/j.clim.2005.02.003; Imai K, 2003, NAT IMMUNOL, V4, P1023, DOI 10.1038/ni974; Imai K, 2003, J CLIN INVEST, V112, P136, DOI 10.1172/JCI200318161; Ito S, 2004, P NATL ACAD SCI USA, V101, P1975, DOI 10.1073/pnas.0307335101; Jabara HH, 2002, IMMUNITY, V17, P265, DOI 10.1016/S1074-7613(02)00394-1; Jain A, 2004, J CLIN INVEST, V114, P1593, DOI 10.1172/JCI200421345; Jain A, 1999, J CLIN INVEST, V103, P1151, DOI 10.1172/JCI5891; Kavli B, 2005, J EXP MED, V201, P2011, DOI 10.1084/jem.20050042; Kutukculer N, 2003, J PEDIATR-US, V142, P194, DOI 10.1067/mpd.2003.41; Lee WI, 2005, BLOOD, V105, P1881, DOI 10.1182/blood-2003-12-4420; Litinskiy MB, 2002, NAT IMMUNOL, V3, P822, DOI 10.1038/ni829; Maizels N, 2005, ANNU REV GENET, V39, P23, DOI 10.1146/annurev.genet.39.073003.110544; Muramatsu M, 1999, J BIOL CHEM, V274, P18470, DOI 10.1074/jbc.274.26.18470; Okazaki IM, 2002, NATURE, V416, P340, DOI 10.1038/nature727; Petersen S, 2001, NATURE, V414, P660, DOI 10.1038/414660a; Pohl T, 2002, P NATL ACAD SCI USA, V99, P4514, DOI 10.1073/pnas.072071599; Quezada SA, 2004, ANNU REV IMMUNOL, V22, P307, DOI 10.1146/annurev.immunol.22.012703.104533; Rada C, 2002, CURR BIOL, V12, P1748, DOI 10.1016/S0960-9822(02)01215-0; Revy P, 2000, CELL, V102, P565, DOI 10.1016/S0092-8674(00)00079-9; Schrader CE, 2005, J EXP MED, V202, P561, DOI 10.1084/jem.20050872; Shinkura R, 2004, NAT IMMUNOL, V5, P707, DOI 10.1038/ni1086; Ta VT, 2003, NAT IMMUNOL, V4, P843, DOI 10.1038/ni964; Winkelstein JA, 2003, MEDICINE, V82, P373, DOI 10.1097/01.md.0000100046.06009.b0; Xu ZM, 2005, ANN NY ACAD SCI, V1050, P146, DOI 10.1196/annals.1313.119; Zarnegar B, 2004, P NATL ACAD SCI USA, V101, P8108, DOI 10.1073/pnas.0402629101	44	77	78	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2006	117	4					855	864		10.1016/j.jaci.2006.01.043	http://dx.doi.org/10.1016/j.jaci.2006.01.043			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	033QB	16630945				2022-12-18	WOS:000236862800021
J	Ravensberg, AJ; Ricciardolo, FLM; van Schadewijk, A; Rabe, KF; Sterk, PJ; Hiemstra, PS; Mauad, T				Ravensberg, AJ; Ricciardolo, FLM; van Schadewijk, A; Rabe, KF; Sterk, PJ; Hiemstra, PS; Mauad, T			Eotaxin-2 and eotaxin-3 expression is associated with persistent eosinophilic bronchial inflammation in patients with asthma after allergen challenge	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; allergen; eotaxin-1 (CCL11); eotaxin-2 (CCL24); eotaxin-3 (CCL26); eosinophil; chemokines; bronchial biopsy; airways inflammation	HUMAN CC-CHEMOKINE; MESSENGER-RNA; AIRWAY HYPERRESPONSIVENESS; ATOPIC SUBJECTS; LESSER EXTENT; T-LYMPHOCYTES; MURINE MODEL; MAST-CELLS; BIOPSIES; RECEPTOR	Background: Eotaxin-1, eotaxin-2, and eotaxin-3 are chemokines involved in the activation and recruitment of eosinophils through activation of their main receptor, CC chemokine receptor 3. The differential roles of these chemokines still remain to be established. It has been suggested that eotaxin-1 is an important mediator in the early phase of allergen-induced recruitment of eosinophils into the airways. Eotaxin-2 and eotaxin-3 might play a role in the subsequent persistence of allergen-induced bronchial eosinophilia. Objective: The aim of this study was to determine the expression of eotaxins and eosinophil counts in the bronchial mucosa of subjects with mild asthma after resolution of the late-phase asthmatic response (LAR). Methods: The expression of eotaxins and eosinophil counts were determined in bronchial biopsy specimens obtained from 10 subjects with mild asthma 48 hours after diluent and allergen challenge by using immunohistochemistry. Positively stained cells were counted in a 125-mu m-deep zone of the lamina propria. Results: Eotaxin-2 and eotaxin-3 expression in bronchial mucosa was significantly increased 48 hours after allergen challenge (P = .001 and P = .013, respectively). At this time point, when marked tissue eosinophilia was still present, these increases were positively correlated with the magnitude of the LAR (r = 0.72, P = .019 and r = 0.64, P = .046, respectively). Furthermore, eotaxin-2 expression was associated with the number of eosinophils after allergen challenge (r = 0.72, P = .018). Conclusion: Our findings suggest that eotaxin-2 and eotaxin-3 might account for the persistence of bronchial eosinophilia after resolution of the LAR.	Leiden Univ, Ctr Med, Lung Funct Lab, Dept Pulm, NL-2300 RC Leiden, Netherlands; Gaslini Inst, Div Pulm, Genoa, Italy; Univ Sao Paulo, Sch Med, Dept Pathol, Sao Paulo, Brazil	Leiden University; Leiden University - Excl LUMC; University of Genoa; IRCCS Istituto Giannina Gaslini; Universidade de Sao Paulo	Ravensberg, AJ (corresponding author), Leiden Univ, Ctr Med, Lung Funct Lab, Dept Pulm, C2-P-62,POB 9600, NL-2300 RC Leiden, Netherlands.	A.J.J.Ravensberg@lumc.nl	Hiemstra, Pieter S/K-8587-2018; Sterk, P.J./AAK-8175-2020; Ricciardolo, F. L. M./K-5330-2018; Ravensberg, A. Janneke/ABC-8700-2021; Mauad, Thais/G-1254-2012; Rabe, Klaus F./AAW-6296-2021	Hiemstra, Pieter S/0000-0002-0238-5982; Ricciardolo, F. L. M./0000-0003-1826-5018; Ravensberg, A. Janneke/0000-0001-8360-6742; Mauad, Thais/0000-0002-3354-1466; Rabe, Klaus F./0000-0002-7020-1401				Banwell ME, 2002, CYTOKINE, V17, P317, DOI 10.1006/cyto.2002.1021; BENTLEY AM, 1993, AM J RESP CELL MOL, V8, P35, DOI 10.1165/ajrcmb/8.1.35; Berkman N, 2001, AM J RESP CELL MOL, V24, P682, DOI 10.1165/ajrcmb.24.6.4301; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BRADLEY BL, 1991, J ALLERGY CLIN IMMUN, V88, P661, DOI 10.1016/0091-6749(91)90160-P; Brown JR, 1998, CLIN EXP IMMUNOL, V114, P137; Campbell EM, 1998, J IMMUNOL, V161, P7047; COLLINS PD, 1995, J EXP MED, V182, P1169, DOI 10.1084/jem.182.4.1169; Dulkys Y, 2001, J INVEST DERMATOL, V116, P498, DOI 10.1046/j.1523-1747.2001.01299.x; Forssmann U, 1997, J EXP MED, V185, P2171, DOI 10.1084/jem.185.12.2171; Fujisawa T, 2000, J ALLERGY CLIN IMMUN, V106, P507; GarciaZepeda EA, 1996, NAT MED, V2, P449, DOI 10.1038/nm0496-449; Ghaffar O, 1999, AM J RESP CRIT CARE, V159, P1933, DOI 10.1164/ajrccm.159.6.9805039; GRIFFITHSJOHNSON DA, 1993, BIOCHEM BIOPH RES CO, V197, P1167, DOI 10.1006/bbrc.1993.2599; Humbles AA, 2002, P NATL ACAD SCI USA, V99, P1479, DOI 10.1073/pnas.261462598; Jeffery P, 2003, AM J RESP CRIT CARE, V168, pS1, DOI 10.1164/rccm.200202-150WS; JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881; Justice JP, 2003, AM J PHYSIOL-LUNG C, V284, pL169, DOI 10.1152/ajplung.00260.2002; Kagami S, 2003, CLIN EXP IMMUNOL, V134, P309, DOI 10.1046/j.1365-2249.2003.02273.x; Kitaura M, 1999, J BIOL CHEM, V274, P27975, DOI 10.1074/jbc.274.39.27975; Komiya A, 2003, CELL IMMUNOL, V225, P91, DOI 10.1016/j.cellimm.2003.10.001; Lezcano-Meza D, 2003, ALLERGY, V58, P1011, DOI 10.1034/j.1398-9995.2003.00174.x; Lilly CM, 2001, AM J RESP CRIT CARE, V163, P1669, DOI 10.1164/ajrccm.163.7.9812044; Lilly CM, 1997, J CLIN INVEST, V99, P1767, DOI 10.1172/JCI119341; Ma W, 2002, J CLIN INVEST, V109, P621, DOI 10.1172/JCI200214097; Meyer-Hoffert U, 2003, INT ARCH ALLERGY IMM, V131, P264, DOI 10.1159/000072138; Nakamura H, 2001, AM J PHYSIOL-LUNG C, V281, pL1288, DOI 10.1152/ajplung.2001.281.5.L1288; *NAT HEART LUNG BL, 1997, NIH PUBL; Palframan RT, 1998, BLOOD, V91, P2240, DOI 10.1182/blood.V91.7.2240.2240_2240_2248; Ponath PD, 1996, J CLIN INVEST, V97, P604, DOI 10.1172/JCI118456; QUANJER PH, 1993, EUR RESPIR J, V6, P5, DOI 10.1183/09041950.005s1693; Ricciardolo FLM, 2001, J ALLERGY CLIN IMMUN, V108, P198, DOI 10.1067/mai.2001.116572; Rothenberg ME, 1997, J EXP MED, V185, P785, DOI 10.1084/jem.185.4.785; Shinkai A, 1999, J IMMUNOL, V163, P1602; Sont JK, 2003, AM J RESP CRIT CARE, V167, P1496, DOI 10.1164/rccm.2205003; Sont JK, 1997, EUR RESPIR J, V10, P2602, DOI 10.1183/09031936.97.10112602; STERK PJ, 1993, EUR RESPIR J, V6, P53, DOI 10.1183/09041950.053s1693; Teixeira MM, 1997, J CLIN INVEST, V100, P1657, DOI 10.1172/JCI119690; Tenscher K, 1996, BLOOD, V88, P3195, DOI 10.1182/blood.V88.8.3195.bloodjournal8883195; Van den Toorn LM, 2001, AM J RESP CRIT CARE, V164, P2107, DOI 10.1164/ajrccm.164.11.2006165; Watanabe K, 2002, J IMMUNOL, V168, P1911, DOI 10.4049/jimmunol.168.4.1911; White JR, 1997, J LEUKOCYTE BIOL, V62, P667, DOI 10.1002/jlb.62.5.667; Yang Y, 1998, BLOOD, V92, P3912, DOI 10.1182/blood.V92.10.3912.422k23_3912_3923; Ying S, 1999, J IMMUNOL, V163, P3976; Ying S, 1997, EUR J IMMUNOL, V27, P3507, DOI 10.1002/eji.1830271252; Zuyderduyn S, 2004, J ALLERGY CLIN IMMUN, V114, P791, DOI 10.1016/j.jaci.2004.06.037; [No title captured]	47	77	80	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2005	115	4					779	785		10.1016/j.jaci.2004.11.045	http://dx.doi.org/10.1016/j.jaci.2004.11.045			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	916GM	15805998	Bronze			2022-12-18	WOS:000228373400017
J	Kussebi, F; Karamloo, F; Rhyner, C; Schmid-Grendelmeier, P; Salagianni, M; Mannhart, C; Akdis, M; Soldatova, L; Markovic-Housley, Z; von Beust, BR; Kundig, T; Kemeny, DM; Blaser, K; Crameri, R; Akdis, CA				Kussebi, F; Karamloo, F; Rhyner, C; Schmid-Grendelmeier, P; Salagianni, M; Mannhart, C; Akdis, M; Soldatova, L; Markovic-Housley, Z; von Beust, BR; Kundig, T; Kemeny, DM; Blaser, K; Crameri, R; Akdis, CA			A major allergen gene-fusion protein for potential usage in allergen-specific immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						specific immunnotherapy; allergy; bee venom; T cells; IgE	BIRCH POLLEN ALLERGEN; T-CELL; BEE VENOM; PHOSPHOLIPASE A(2); IGE; ANTIBODIES; INDUCTION; FRAGMENTS; BINDING; ANERGY	Background: Specific immunotherapy is a common treatment of allergic diseases and could potentially be applied to other immunologic disorders. Despite its use in clinical practice, more defined and safer allergy vaccine preparations are required. Differences between epitopes of IgE that recognize the 3-dimensional structure of allergens and T cells that recognize linear amino acid sequences provide a suitable tool for novel vaccine development for specific immunotherapy. Objective: The aim of the study was to delete B-cell epitopes and prevent IgE crosslinking, but to preserve T-cell epitopes by fusion of 2 major allergens of bee venom because of a change in the conformation. Methods: By genetic engineering, we produced a fusion protein composed of the 2 major bee venom allergens: phospholipase A(2) (Api m 1) and hyaluronidase (Api m 2). Results: The Api m [1/2] fusion protein induced T-cell proliferation and both T(H)1-type and T(H)2-type cytokine responses. In contrast, IgE reactivity was abolished, and profoundly reduced basophil degranulation and type 1 skin test reactivity was observed. Pretreatment of mice with Api m [1/2] fusion protein significantly suppressed the development of specific IgE as well as other antibody isotypes after immunization with the native allergen. Conclusion: The novel fusion protein of 2 major allergens bypasses IgE binding and mast cell/basophil IgE FcepsilonRI crosslinking and protects from IgE development.	Swiss Inst Allergy & Asthma Res, CH-7270 Davos, Switzerland; Dept Dermatol, Allergy Unit, Zurich, Switzerland; Rayne Inst, Sch Med, Dept Immunol, London, England; US FDA, Ctr Biol Evaluat & Res, Div Allergen Prod & Parasitol, Lab Immunobiochem, Bethesda, MD 20014 USA; Univ Basel, Biozentrum, Div Struct Biol, Basel, Switzerland	Swiss Institute of Allergy & Asthma Research; University of London; King's College London; US Food & Drug Administration (FDA); University of Basel	Kussebi, F (corresponding author), Charite, Childrens Hosp, Dept Pneumol & Immunol, Augustenburger Pl 1, D-13353 Berlin, Germany.	fatimah.kussebi@charite.de	Akdis, Cezmi/AAV-4844-2020	Akdis, Cezmi/0000-0001-8020-019X; Salagianni, Maria/0000-0001-9821-1559				Achatz G, 1997, SCIENCE, V276, P409, DOI 10.1126/science.276.5311.409; Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Akdis CA, 1998, EUR J IMMUNOL, V28, P914, DOI 10.1002/(SICI)1521-4141(199803)28:03<914::AID-IMMU914>3.0.CO;2-C; Akdis CA, 1999, FASEB J, V13, P603, DOI 10.1096/fasebj.13.6.603; Akdis CA, 1996, J CLIN INVEST, V98, P1676, DOI 10.1172/JCI118963; Akdis CA, 2001, TRENDS IMMUNOL, V22, P175, DOI 10.1016/S1471-4906(01)01862-2; Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; Brehler R, 2000, J ALLERGY CLIN IMMUN, V105, P1231, DOI 10.1067/mai.2000.105708; CAHEN YDM, 1997, SCHWEIZ MED WOCHENSC, V7, P5; CARBALLIDO JM, 1993, J IMMUNOL, V150, P3582; Clark ED, 2001, CURR OPIN BIOTECH, V12, P202, DOI 10.1016/S0958-1669(00)00200-7; Coyle AJ, 1996, J EXP MED, V183, P1303, DOI 10.1084/jem.183.4.1303; Durham SR, 1998, J ALLERGY CLIN IMMUN, V102, P157, DOI 10.1016/S0091-6749(98)70079-X; Faith A, 1997, J IMMUNOL, V159, P53; LIVINGSTONE AM, 1987, ANNU REV IMMUNOL, V5, P477, DOI 10.1146/annurev.immunol.5.1.477; Marcotte GV, 1998, J ALLERGY CLIN IMMUN, V101, P506, DOI 10.1016/S0091-6749(98)70358-6; MARSH DG, 1981, J ALLERGY CLIN IMMUN, V68, P449, DOI 10.1016/0091-6749(81)90199-8; MOSER M, 1992, J IMMUNOL, V149, P454; Muller U, 1998, J ALLERGY CLIN IMMUN, V101, P747, DOI 10.1016/S0091-6749(98)70402-6; Muller UR, 2001, INT ARCH ALLERGY IMM, V124, P447, DOI 10.1159/000053779; Neudecker P, 2003, BIOCHEM J, V376, P97, DOI 10.1042/BJ20031057; OBRIEN RM, 1995, IMMUNOLOGY, V86, P176; SCHNEIDER T, 1994, INT ARCH ALLERGY IMM, V104, P262, DOI 10.1159/000236675; Thomas MJ, 2002, J IMMUNOL, V168, P216, DOI 10.4049/jimmunol.168.1.216; Valenta R, 2002, NAT REV IMMUNOL, V2, P446, DOI 10.1038/nri824; van Neerven RJJ, 1999, J IMMUNOL, V163, P2944; Vrtala S, 2000, J IMMUNOL, V165, P6653, DOI 10.4049/jimmunol.165.11.6653; Vrtala S, 1997, J CLIN INVEST, V99, P1673, DOI 10.1172/JCI119330; Xu XB, 1998, BIOCHEMISTRY-US, V37, P7561, DOI 10.1021/bi980086x	30	77	86	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2005	115	2					323	329		10.1016/j.jaci.2004.11.041	http://dx.doi.org/10.1016/j.jaci.2004.11.041			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	897YU	15696088				2022-12-18	WOS:000227043600017
J	Henness, S; Johnson, CK; Ge, Q; Armour, CL; Hughes, JM; Ammit, AJ				Henness, S; Johnson, CK; Ge, Q; Armour, CL; Hughes, JM; Ammit, AJ			IL-17A augments TNF-alpha-induced IL-6 expression in airway smooth muscle by enhancing mRNA stability	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						inflammation; cytokines; adhesion molecules; transcription factors; stromal cells	COLONY-STIMULATING FACTOR; INDUCED SECRETION; PERIPHERAL-BLOOD; EPITHELIAL-CELLS; T-CELLS; INTERLEUKIN-6; FIBROBLASTS; MODULATION; MYOFIBROBLASTS; INFLAMMATION	Background: IL-17A is implicated in the regulation of inflammation and is found in increased amounts in the asthmatic airway. Human airway smooth muscle (ASM) cells synthesize cell adhesion molecules and cytokines in response to inflammatory mediators. Objective: In this study, we examined whether IL-17A modulated the synthetic function of ASM cells. Methods: Primary ASM cultures were treated with IL-17A alone and in combination with the proinflammatory cytokines TNF-alpha and IL-1beta. Intercellular adhesion molecule 1 expression, GM-CSF, and IL-6 secretion were measured by ELISA. Examination of transcriptional regulation was performed via transient transfection of promoter constructs, whereas mRNA stability was assessed by actinomycin D chase and quantitative real-time PCR. Results: Airway smooth muscle did not secrete IL-17A after stimulation of ASM with TNF-alpha and IL-1beta. Furthermore, IL-17A (0.1-10 ng/mL) had no effect on TNF-alpha-induced and IL-1beta-induced intercellular adhesion molecule 1 expression or GM-CSF secretion. However, IL-17A (10 ng/mL) significantly augmented TNF-alpha-induced IL-6 secretion 12-fold (TNF-alpha, 2.3 +/- 0.4 ng/mL; IL-17A and TNF-alpha, 27.5 +/- 4.8 ng/mL; P < .05) while having no effect on IL-1beta-induced IL-6. Although IL-17A had no effect on nuclear factor KB-mediated transcriptional regulation of IL-6 gene expression induced by TNF-alpha, IL-17A significantly augmented TNF-alpha-induced IL-6 mRNA stability. Conclusion: Collectively, these results demonstrate that IL-17A amplifies the synthetic function of ASM cells, acting via a posttranscriptional pathway, rather than transcriptional mechanisms, to augment TNF-alpha-induced secretion of IL-6 from ASM cells.	Univ Sydney, Fac Pharm, Sydney, NSW 2006, Australia; Univ Sydney, Dept Pharmacol, Resp Res Grp, Sydney, NSW 2006, Australia	University of Sydney; University of Sydney	Ammit, AJ (corresponding author), Univ Sydney, Fac Pharm, Sydney, NSW 2006, Australia.	ajammit@pharm.usyd.edu.au	Ge, Qi/D-3988-2013	Ammit, Alaina/0000-0003-0555-2544; Armour, Carol/0000-0002-2930-2227				Aggarwal S, 2002, J LEUKOCYTE BIOL, V71, P1; Ammit AJ, 2002, AM J RESP CELL MOL, V26, P465, DOI 10.1165/ajrcmb.26.4.4681; Ammit AJ, 2000, AM J RESP CELL MOL, V23, P794, DOI 10.1165/ajrcmb.23.6.4184; Andoh A, 2002, BBA-MOL CELL RES, V1591, P69, DOI 10.1016/S0167-4889(02)00250-1; BROIDE DH, 1992, J ALLERGY CLIN IMMUN, V89, P958, DOI 10.1016/0091-6749(92)90218-Q; Chen G, 2003, AM J PHYSIOL-LUNG C, V284, pL548, DOI 10.1152/ajplung.00091.2002; DE S, 1995, J APPL PHYSIOL, V78, P1555, DOI 10.1152/jappl.1995.78.4.1555; DUNCAN MR, 1991, J INVEST DERMATOL, V97, P686, DOI 10.1111/1523-1747.ep12483971; Eickelberg O, 1999, J BIOL CHEM, V274, P12933, DOI 10.1074/jbc.274.18.12933; Hellings PW, 2003, AM J RESP CELL MOL, V28, P42, DOI 10.1165/rcmb.4832; JOHNSON PRA, 1995, AM J PHYSIOL-LUNG C, V269, pL514, DOI 10.1152/ajplung.1995.269.4.L514; Jones CE, 2002, AM J RESP CELL MOL, V26, P748, DOI 10.1165/ajrcmb.26.6.4757; Kawaguchi M, 2001, J ALLERGY CLIN IMMUN, V108, P804, DOI 10.1067/mai.2001.119027; Laan M, 2002, EUR RESPIR J, V19, P534, DOI 10.1183/09031936.02.00280902; Lazaar Aili L., 2001, Current Opinion in Pharmacology, V1, P259, DOI 10.1016/S1471-4892(01)00046-7; Lazaar AL, 1997, AM J RESP CELL MOL, V16, P38, DOI 10.1165/ajrcmb.16.1.8998077; LAZAAR AL, 1994, J EXP MED, V180, P807, DOI 10.1084/jem.180.3.807; LOTZ M, 1991, J BIOL CHEM, V266, P2017; McKay S, 2000, AM J RESP CELL MOL, V23, P103, DOI 10.1165/ajrcmb.23.1.3765; Molet S, 2001, J ALLERGY CLIN IMMUN, V108, P430, DOI 10.1067/mai.2001.117929; Moseley TA, 2003, CYTOKINE GROWTH F R, V14, P155, DOI 10.1016/S1359-6101(03)00002-9; Rincon M, 1997, J EXP MED, V185, P461, DOI 10.1084/jem.185.3.461; ROUVIER E, 1993, J IMMUNOL, V150, P5445; SanchezGuerrero IM, 1997, EUR RESPIR J, V10, P2091, DOI 10.1183/09031936.97.10092091; Saunders MA, 1997, BRIT J PHARMACOL, V120, P545, DOI 10.1038/sj.bjp.0700998; Shalom-Barak T, 1998, J BIOL CHEM, V273, P27467, DOI 10.1074/jbc.273.42.27467; Shimada M, 2002, J IMMUNOL, V168, P861, DOI 10.4049/jimmunol.168.2.861; Sukkar MB, 2000, MEDIAT INFLAMM, V9, P161, DOI 10.1080/09629350020008673; Wang JM, 2000, J IMMUNOL, V165, P4051, DOI 10.4049/jimmunol.165.7.4051; YOO ZB, 1995, J IMMUNOL, V155, P5483	30	77	83	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2004	114	4					958	964		10.1016/j.jaci.2004.06.023	http://dx.doi.org/10.1016/j.jaci.2004.06.023			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	861SO	15480342				2022-12-18	WOS:000224439100036
J	Cho, YS; Lee, JC; Lee, TH; Lee, EY; Lee, KU; Park, JY; Moon, HB				Cho, YS; Lee, JC; Lee, TH; Lee, EY; Lee, KU; Park, JY; Moon, HB			alpha-Lipoic acid inhibits airway inflammation and hyperresponsiveness in a mouse model of asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic inflammation; airway hyperresponsiveness; antioxidant; alpha-lipoic acid	NF-KAPPA-B; GLUTATHIONE-PEROXIDASE ACTIVITY; SUPEROXIDE-DISMUTASE; OXIDATIVE STRESS; ASCORBIC-ACID; GENE-TRANSCRIPTION; INTRINSIC ASTHMA; MILD ASTHMA; VITAMIN-E; T-CELLS	Background: Oxidative stress may play an important role in the pathogenesis of bronchial asthma. Objective: We evaluated the therapeutic effect of alpha-lipoic acid, a nonenzymatic antioxidant, in a mouse model of asthma. Methods: BALB/c mice were immunized intraperitoneally with ovalbumin (OVA) on days 1 and 14 and challenged with inhaled OVA on days 28, 29, and 30. Mice were fed OVA-free standard mouse chow with 0%, 0.125%, 0.25%, 0.5%, and 1% (wt/wt) alpha-lipoic acid during the immunization and challenge periods. On day 31, mice were challenged with inhaled methacholine, and enhanced pause was measured as an index of airway hyperresponsiveness. Severity of airway inflammation was determined by means of differential cell count of bronchoalveolar lavage (BAL) fluid and by means of histopathologic lung analysis. Levels of OVA-specific IgE in serum, IL-4 and IL-5 in BAL fluid, and intracellular reactive oxygen species in alveolar macrophages and lymphocytes obtained from regional perihilar lymph nodes were measured. Nuclear factor kappaB DNA-binding activity in lung tissues was analyzed by means of electrophoretic gel mobility shift assay. Results: Compared with untreated asthmatic mice, mice treated with alpha-lipoic acid had significantly reduced airway hyperresponsiveness, a lower proportion of eosinophils among BAL cells, and significantly improved pathologic lesion scores of the lungs. alpha-Lipoic acid also significantly reduced serum OVA-specific IgE concentrations, IL-4 and IL-5 concentrations in BAL fluid, and intracellular reactive oxygen species and nuclear factor kappaB DNA-binding activity. Conclusion: These results suggest that oxidative stress plays an important role in asthmatic airway inflammation and that alpha-lipoic acid may be useful as adjuvant therapy for bronchial asthma.	Univ Ulsan, Coll Med, Asan Med Ctr, Dept Med,Div Allergy & Clin Immunol, Seoul, South Korea; Univ Ulsan, Coll Med, Asan Med Ctr, Div Endocrinol & Metab, Seoul, South Korea	University of Ulsan; Asan Medical Center; University of Ulsan; Asan Medical Center	Moon, HB (corresponding author), Univ Ulsan, Coll Med, Asan Med Ctr, Dept Med,Div Allergy & Clin Immunol, 388-1 Pungnap Dong, Seoul, South Korea.	hbmoon@amc.seoul.kr	Lee, Eun Young/J-5594-2012	Lee, Eun Young/0000-0001-6975-8627; Lee, Jaechun/0000-0003-1220-8282				Ametov AS, 2003, DIABETES CARE, V26, P770, DOI 10.2337/diacare.26.3.770; Assa'ad AH, 1998, ANN ALLERG ASTHMA IM, V80, P215, DOI 10.1016/S1081-1206(10)62960-2; BARNES PJ, 1990, FREE RADICAL BIO MED, V9, P235, DOI 10.1016/0891-5849(90)90034-G; Barnes PJ, 1997, INT J BIOCHEM CELL B, V29, P867, DOI 10.1016/S1357-2725(96)00159-8; Barrett EG, 2002, AM J RESP CRIT CARE, V165, P1410, DOI 10.1164/rccm.2106029; Blesa S, 2003, EUR RESPIR J, V21, P394, DOI 10.1183/09031936.03.00039602; Blesa S, 2002, PHARMACOL RES, V45, P135, DOI 10.1006/phrs.2001.0917; Butland BK, 1999, EUR RESPIR J, V13, P744, DOI 10.1034/j.1399-3003.1999.13d08.x; CAO XH, 1995, FREE RADICAL RES, V23, P365, DOI 10.3109/10715769509065257; CHANEZ P, 1990, EUR RESPIR J, V3, P1002; Chang LY, 2002, FREE RADICAL BIO MED, V33, P379, DOI 10.1016/S0891-5849(02)00919-X; Comhair SAA, 2000, LANCET, V355, P624, DOI 10.1016/S0140-6736(99)04736-4; Fogarty A, 2000, LANCET, V356, P1573, DOI 10.1016/S0140-6736(00)03132-9; Grievink L, 1998, THORAX, V53, P166, DOI 10.1136/thx.53.3.166; Hart LA, 1998, AM J RESP CRIT CARE, V158, P1585, DOI 10.1164/ajrccm.158.5.9706116; HASSELMARK L, 1993, ALLERGY, V48, P30; HASSELMARK L, 1990, ALLERGY, V45, P523, DOI 10.1111/j.1398-9995.1990.tb00528.x; Henderson WR, 2002, J IMMUNOL, V169, P5294, DOI 10.4049/jimmunol.169.9.5294; Kelly FK, 1999, LANCET, V354, P482, DOI 10.1016/S0140-6736(99)01812-7; KHARITONOV SA, 1994, LANCET, V343, P133, DOI 10.1016/S0140-6736(94)90931-8; Kongerud J, 2003, INHAL TOXICOL, V15, P101, DOI [10.1080/08958370390168184, 10.1080/08958370304477]; Li-Weber M, 2002, EUR J IMMUNOL, V32, P2401, DOI 10.1002/1521-4141(200209)32:9&lt;2401::AID-IMMU2401&gt;3.0.CO;2-S; MALO JL, 1986, J ALLERGY CLIN IMMUN, V78, P1153, DOI 10.1016/0091-6749(86)90265-4; MOHSENIN V, 1983, AM REV RESPIR DIS, V127, P143; Mori A, 1999, J ALLERGY CLIN IMMUN, V103, pS429, DOI 10.1016/S0091-6749(99)70158-2; Nadeem A, 2003, J ALLERGY CLIN IMMUN, V111, P72, DOI 10.1067/mai.2003.17; Omenaas E, 2003, RESP MED, V97, P134, DOI 10.1053/rmed.2003.1439; Packer L, 1998, DRUG METAB REV, V30, P245, DOI 10.3109/03602539808996311; PEARSON DJ, 1991, CLIN EXP ALLERGY, V21, P203, DOI 10.1111/j.1365-2222.1991.tb00831.x; Picado C, 2001, ALLERGY, V56, P43, DOI 10.1034/j.1398-9995.2001.00793.x; Rahman I, 1996, AM J RESP CRIT CARE, V154, P1055, DOI 10.1164/ajrccm.154.4.8887607; Rahman I, 2003, J BIOCHEM MOL BIOL, V36, P95; Romieu I, 2002, AM J RESP CRIT CARE, V166, P703, DOI 10.1164/rccm.2112074; Smith LJ, 1997, FREE RADICAL BIO MED, V22, P1301, DOI 10.1016/S0891-5849(96)00550-3; Stutz AM, 1999, J IMMUNOL, V163, P4383; Suzuki M, 1998, J ASTHMA, V35, P267, DOI 10.3109/02770909809068217; Trenga CA, 2001, ARCH ENVIRON HEALTH, V56, P242, DOI 10.1080/00039890109604448; VACHIER I, 1992, AM REV RESPIR DIS, V146, P1161, DOI 10.1164/ajrccm/146.5_Pt_1.1161; van Dam PS, 2002, DIABETES-METAB RES, V18, P176, DOI 10.1002/dmrr.287; Whitekus MJ, 2002, J IMMUNOL, V168, P2560, DOI 10.4049/jimmunol.168.5.2560; Wood LG, 2000, LIPIDS, V35, P967, DOI 10.1007/s11745-000-0607-x	41	77	84	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2004	114	2					429	435		10.1016/j.jaci.2004.04.004	http://dx.doi.org/10.1016/j.jaci.2004.04.004			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	847OU	15316528				2022-12-18	WOS:000223405600035
J	Miike, S; Kita, H				Miike, S; Kita, H			Human eosinophils are activated by cysteine proteases and release inflammatory mediators	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eosinophils; allergy; inflammation	PROTEIN-KINASE-C; DUST MITE ALLERGEN; DERMATOPHAGOIDES-FARINAE; EPITHELIAL-CELLS; MAST-CELL; RECEPTOR-2; PURIFICATION; CYTOKINES; CLEAVAGE; DER-P-1	Background: Recent studies suggest that serine proteases are involved in various biological responses through activation of protease-activated receptors (PARs). However, the functions of other proteases, such as cysteine proteases, are poorly understood and need elucidation. Objective: We examined the effects of an authentic cysteine protease, papain, and a protease derived from the mite allergen, Der f 1, on functions of human eosinophils. Methods: Purified eosinophils were incubated with papain or Der f 1. Eosinophil activation was monitored by superoxide anion generation and by degranulation. Intracellular signaling pathways were investigated through use of pharmacologic approaches. Results: We found that papain potently induces human eosinophils to degranulate and to produce superoxide anion. A cysteine protease inhibitor, E-64, abolished the stimulatory effects of papain, which suggests that the protease activity of papain is necessary to trigger eosinophil responses. The eosinophil's response to papain was enhanced by IL-5 and mediated by activation of the phosphatidylinositol 3-kinase/Akt pathway. Interestingly, whereas a serine protease, trypsin, activated eosinophils through PAR2, the effects of papain were not inhibited by an antibody to PAR2, which suggests another novel mechanism for the eosinophils' response to cysteine proteases. It is likely that these observations are clinically important, because eosinophils were activated by a natural cysteine protease allergen, Der f 1, and released granule proteins. Conclusion: Human eosinophils are probably equipped with machineries that recognize and respond to cysteine proteases, such as those found at allergic inflammation sites; the result is active release of proinflammatory mediators.	Mayo Clin & Mayo Fdn, Dept Med, Div Allerg Dis, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Immunol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Kita, H (corresponding author), Mayo Clin & Mayo Fdn, Dept Med, Div Allerg Dis, 200 1St St SW, Rochester, MN 55905 USA.				NIAID NIH HHS [AI34486, AI 49235] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI034486, R29AI034486, R01AI049235, R01AI034486] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABUGHAZALEH RI, 1989, J IMMUNOL, V142, P2393; ANDO T, 1991, INT ARCH ALLER A IMM, V96, P199, DOI 10.1159/000235495; ANDO T, 1993, CLIN EXP ALLERGY, V23, P777, DOI 10.1111/j.1365-2222.1993.tb00366.x; Asokananthan N, 2002, J IMMUNOL, V169, P4572, DOI 10.4049/jimmunol.169.8.4572; Barrett AJ, 2001, BIOL CHEM, V382, P727, DOI 10.1515/BC.2001.088; Bates ME, 2000, J BIOL CHEM, V275, P10968, DOI 10.1074/jbc.275.15.10968; Belham CL, 1996, BIOCHEM J, V320, P939, DOI 10.1042/bj3200939; Bohm SK, 1996, J BIOL CHEM, V271, P22003; Brass LF, 1997, THROMB HAEMOSTASIS, V78, P234; BROIDE DH, 1991, J ALLERGY CLIN IMMUN, V88, P637, DOI 10.1016/0091-6749(91)90158-K; Broide DH, 2001, J ALLERGY CLIN IMMUN, V108, pS65, DOI 10.1067/mai.2001.116436; BUTTERFIELD JH, 1995, SAMTERS IMMUNOLOGIC, V1, P501; Coffer PJ, 1998, BLOOD, V91, P2547, DOI 10.1182/blood.V91.7.2547.2547_2547_2557; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; Dent G, 1998, AM J RESP CELL MOL, V18, P136, DOI 10.1165/ajrcmb.18.1.2817; Dery O, 1998, AM J PHYSIOL-CELL PH, V274, pC1429, DOI 10.1152/ajpcell.1998.274.6.C1429; Furmonaviciene R, 2000, CLIN EXP ALLERGY, V30, P1307, DOI 10.1046/j.1365-2222.2000.00897.x; Giembycz MA, 1999, PHARMACOL REV, V51, P213; HANSEL TT, 1991, J IMMUNOL METHODS, V145, P105, DOI 10.1016/0022-1759(91)90315-7; HERBERT CA, 1995, AM J RESP CELL MOL, V12, P369, DOI 10.1165/ajrcmb.12.4.7695916; HEWITT CRA, 1995, J EXP MED, V182, P1537, DOI 10.1084/jem.182.5.1537; Horie S, 1996, J ALLERGY CLIN IMMUN, V98, P371, DOI 10.1016/S0091-6749(96)70161-6; Kanke T, 2001, J BIOL CHEM, V276, P31657, DOI 10.1074/jbc.M100377200; KERNEN P, 1991, J CLIN INVEST, V87, P2012, DOI 10.1172/JCI115230; King C, 1996, J ALLERGY CLIN IMMUN, V98, P739, DOI 10.1016/S0091-6749(96)70121-5; KITA H, 1998, ALLERGY PRINCIPLES P, V1, P242; KROEGEL C, 1988, IMMUNOLOGY, V64, P559; LARCHER G, 1992, FEBS LETT, V308, P65, DOI 10.1016/0014-5793(92)81052-N; LEE TC, 1984, J BIOL CHEM, V259, P5526; Lourbakos A, 1998, FEBS LETT, V435, P45, DOI 10.1016/S0014-5793(98)01036-9; Miike S, 2000, J LEUKOCYTE BIOL, V67, P117, DOI 10.1002/jlb.67.1.117; Miike S, 2001, J IMMUNOL, V167, P6615, DOI 10.4049/jimmunol.167.11.6615; QIU ZH, 1994, J BIOL CHEM, V269, P19480; REED SL, 1989, J IMMUNOL, V143, P189; Sabri A, 2000, CIRC RES, V86, P1054, DOI 10.1161/01.RES.86.10.1054; Sajid M, 2002, MOL BIOCHEM PARASIT, V120, P1, DOI 10.1016/S0166-6851(01)00438-8; SANTULLI RJ, 1995, P NATL ACAD SCI USA, V92, P9151, DOI 10.1073/pnas.92.20.9151; Schulz O, 1998, J EXP MED, V187, P271, DOI 10.1084/jem.187.2.271; SCHWARTZ LB, 1981, J BIOL CHEM, V256, P1939; SCHWARTZ LB, 1994, ALLERGY PROC, V15, P119, DOI 10.2500/108854194778702946; SEDGWICK JB, 1988, J ALLERGY CLIN IMMUN, V81, P876, DOI 10.1016/0091-6749(88)90945-1; Steinhoff M, 2000, NAT MED, V6, P151, DOI 10.1038/72247; Sun G, 2001, J IMMUNOL, V167, P1014, DOI 10.4049/jimmunol.167.2.1014; TCHOUPE JR, 1991, BIOCHIM BIOPHYS ACTA, V1076, P149, DOI 10.1016/0167-4838(91)90232-O; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Wan H, 1999, J CLIN INVEST, V104, P123, DOI 10.1172/JCI5844; Widmer F, 2000, CLIN EXP ALLERGY, V30, P571, DOI 10.1046/j.1365-2222.2000.00784.x	48	77	83	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2003	111	4					704	713		10.1067/mai.2003.1332	http://dx.doi.org/10.1067/mai.2003.1332			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	667WW	12704347				2022-12-18	WOS:000182258500006
J	Wensing, M; Knulst, AC; Piersma, S; O'Kane, F; Knol, EF; Koppelman, SJ				Wensing, M; Knulst, AC; Piersma, S; O'Kane, F; Knol, EF; Koppelman, SJ			Patients with anaphylaxis to pea can have peanut allergy caused by cross-reactive IgE to vicilin (Ara h 1)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						pea; peanut; vicilin; Ara h 1; cross-reactivity	LEGUME BOTANICAL FAMILY; PISUM-SATIVUM-L; FOOD HYPERSENSITIVITY; ATOPIC-DERMATITIS; ALLERGENICITY; CHILDREN; IDENTIFICATION; PROTEINS; CHALLENGES; BINDING	Background: Serologic cross-reactivity among legumes has been described; however, it is rarely clinically significant. In this study 3 patients with a history of anaphylaxis to pea are described who subsequently had symptoms after ingestion of peanut. Objective: We investigated whether the peanut-related symptoms were due to cross-reactivity between pea and peanut proteins. Methods: Peanut-related symptoms were documented according to case history or double-blind, placebo-controlled food challenge results. Skin prick tests were performed, and specific IgE levels were determined for pea and peanut with the CAP system FEIA. IgE-binding proteins in pea and peanut were identified by using immunoblot analysis. Cross-reactivity was studied by means of immunoblot and ELISA inhibition studies with whole extracts and purified allergens. Results: Peanut-related symptoms consisted of oral symptoms in all patients, with additional urticaria and dyspnea or angioedema in 2 patients. All patients had a positive skin prick test response and an increased IgE level to pea and peanut. Immunoblotting revealed strong IgE binding to mainly vicilin in pea extract and exclusively to Ara h 1 in crude peanut extract. Immunoblot and ELISA inhibition studies with crude extracts, as well as purified proteins, showed that IgE binding to peanut could be inhibited by pea but not or only partially the other way around. Conclusion: Clinically relevant cross-reactivity between pea and peanut does occur. Vicilin homologues in pea and peanut (Ara h 1) are the molecular basis for this cross-reactivity.	Univ Utrecht, Med Ctr, Dept Dermatol Allergol G02124, NL-3584 CX Utrecht, Netherlands; TNO, Nutr & Food Res Inst, Protein Technol Dept, NL-3700 AJ Zeist, Netherlands; TNO, WU, Ctr Prot Technol, NL-6700 AA Wageningen, Netherlands	Utrecht University; Netherlands Organization Applied Science Research; Netherlands Organization Applied Science Research	Wensing, M (corresponding author), Univ Utrecht, Med Ctr, Dept Dermatol Allergol G02124, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.			Knol, Edward/0000-0001-7368-9820				BARNETT D, 1987, J ALLERGY CLIN IMMUN, V79, P433, DOI 10.1016/0091-6749(87)90359-9; Beardslee TA, 2000, INT ARCH ALLERGY IMM, V123, P299, DOI 10.1159/000053642; BERNHISELBROADBENT J, 1989, J ALLERGY CLIN IMMUN, V83, P435, DOI 10.1016/0091-6749(89)90130-9; BERNHISELBROADBENT J, 1989, J ALLERGY CLIN IMMUN, V84, P701, DOI 10.1016/0091-6749(89)90298-4; BOCK SA, 1989, J ALLERGY CLIN IMMUN, V83, P900, DOI 10.1016/0091-6749(89)90103-6; BORA PS, 1994, J FOOD SCI, V59, P594, DOI 10.1111/j.1365-2621.1994.tb05570.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUIJNZEELKOOMEN C, 1995, ALLERGY, V50, P623, DOI 10.1111/j.1398-9995.1995.tb02579.x; BURKS AW, 1988, J ALLERGY CLIN IMMUN, V81, P1135, DOI 10.1016/0091-6749(88)90881-0; BURKS AW, 1991, J ALLERGY CLIN IMMUN, V88, P172, DOI 10.1016/0091-6749(91)90325-I; BURKS AW, 1995, J CLIN INVEST, V96, P1715, DOI 10.1172/JCI118216; Clarke MCA, 1998, CLIN EXP ALLERGY, V28, P1251, DOI 10.1046/j.1365-2222.1998.00386.x; De Jong EC, 1998, CLIN EXP ALLERGY, V28, P743, DOI 10.1046/j.1365-2222.1998.00301.x; DREBORG S, 1993, ALLERGY, V48, P49, DOI 10.1111/j.1398-9995.1993.tb04756.x; Eigenmann PA, 1996, J ALLERGY CLIN IMMUN, V98, P969, DOI 10.1016/S0091-6749(96)80014-5; Foucard T, 1999, ALLERGY, V54, P261, DOI 10.1034/j.1398-9995.1999.00924.x; GATEHOUSE JA, 1982, BIOCHEM J, V207, P629, DOI 10.1042/bj2070629; GATEHOUSE JA, 1981, EUR J BIOCHEM, V118, P627, DOI 10.1111/j.1432-1033.1981.tb05565.x; HEFLE SL, 1994, J ALLERGY CLIN IMMUN, V94, P167, DOI 10.1016/0091-6749(94)90036-1; Hourihane JO, 1997, J ALLERGY CLIN IMMUN, V100, P596, DOI 10.1016/S0091-6749(97)70161-1; Kleber-Janke T, 1999, INT ARCH ALLERGY IMM, V119, P265, DOI 10.1159/000024203; Koppelman SJ, 1999, J BIOL CHEM, V274, P4770, DOI 10.1074/jbc.274.8.4770; LOZA C, 1995, CLIN EXP ALLERGY, V25, P493, DOI 10.1111/j.1365-2222.1995.tb01086.x; MALLEY A, 1976, CLIN EXP IMMUNOL, V25, P159; MALLEY A, 1975, J ALLERGY CLIN IMMUN, V56, P282, DOI 10.1016/0091-6749(75)90102-5; Moneret-Vautrin DA, 1999, J ALLERGY CLIN IMMUN, V104, P883, DOI 10.1016/S0091-6749(99)70303-9; Niestijl Jansen Jeannette J., 1994, Journal of Allergy and Clinical Immunology, V93, P446, DOI 10.1016/0091-6749(94)90353-0; Pascual CY, 1999, J ALLERGY CLIN IMMUN, V103, P154, DOI 10.1016/S0091-6749(99)70539-7; Rabjohn P, 1999, J CLIN INVEST, V103, P535, DOI 10.1172/JCI5349; SAMPSON HA, 1990, J ALLERGY CLIN IMMUN, V86, P1, DOI 10.1016/S0091-6749(05)80115-0; San Ireneo MM, 2000, INT ARCH ALLERGY IMM, V121, P137, DOI 10.1159/000024309	31	77	82	0	8	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2003	111	2					420	424		10.1067/mai.2003.61	http://dx.doi.org/10.1067/mai.2003.61			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	644WF	12589366				2022-12-18	WOS:000180942700030
J	Sedgwick, JB; Menon, I; Gern, JE; Busse, WW				Sedgwick, JB; Menon, I; Gern, JE; Busse, WW			Effects of inflammatory cytokines on the permeability of human lung microvascular endothelial cell monolayers and differential eosinophil transmigration	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Permeability; transendothelial electrical resistance; rhinovirus; eosinophils; transmigration; asthma; cytokines; adhesion	AIRWAYS INFLAMMATION; INDUCED SPUTUM; RHINOVIRUS; ASTHMA; SUSCEPTIBILITY; INFECTIONS; ADHESION; INDEXES; GROWTH; VIRUS	Background: Rhinovirus (RV) infections can result in asthma exacerbations in both adults and children. Respiratory epithelium, the primary site of RV replication, responds to the viral infection by generating a variety of cytokines and chemokines capable of promoting airway inflammation and hence might increase asthma severity. Some of these mediators might also affect the permeability of underlying vascular endothelium. Objective: We hypothesized that RV infections can promote airway inflammation and thus asthma by enhancing local vascular permeability. Methods: Confluent human lung microvascular endothelial cell (HMVEC-L) monolayers were used as an in vitro model of vascular endothelium to determine whether cytokines associated with RV-induced infections are capable of modulating endothelial cell permeability as measured by means of transendothelial electrical resistance. Recombinant cytokines and chemokines were added to confluent HMVEC-L monolayers cultured on Transwell filters, and permeability was measured as decreased electrical resistance over time. Eosinophil transendothelial migration was assessed under the same experimental conditions. Results: TNF-alpha, IL-1beta, and IFN-gamma significantly increased HMVEC-L permeability. In contrast, GM-CSF, G-CSF, IL-8, IL-6, and RANTES had no effect. Although incubation of HMVEC-L monolayers with either TNF-alpha. or IL-1beta promoted eosinophil migration, IFN-gamma had no effect, indicating that enhanced permeability alone was not sufficient for eosinophil infiltration. Conclusion: Select cytokines, generated in response to RV infection, can increase vascular permeability and might provide a mechanism by which RV infection can lead to edema, cellular infiltration, and inflammation and thus compromised airflow.	Univ Wisconsin, Dept Med, Div Allergy & Immunol, Madison, WI USA; Univ Wisconsin, Dept Pediat, Madison, WI USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Sedgwick, JB (corresponding author), CSC-3244 H6-355 Allergy,600 Highland Ave, Madison, WI 53792 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060993] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-60993] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adamson RH, 1998, AM J PHYSIOL-HEART C, V274, pH1885, DOI 10.1152/ajpheart.1998.274.6.H1885; Ali MH, 1999, AM J PHYSIOL-LUNG C, V277, pL1057, DOI 10.1152/ajplung.1999.277.5.L1057; BEEKHUIZEN H, 1994, J VASC RES, V31, P230, DOI 10.1159/000159048; BEILKE MA, 1989, REV INFECT DIS, V11, P273; BEYNON HLC, 1993, CLIN EXP IMMUNOL, V91, P314; CALHOUN WJ, 1994, J CLIN INVEST, V94, P2200, DOI 10.1172/JCI117581; CARLEY WW, 1992, AM J RESP CELL MOL, V7, P620, DOI 10.1165/ajrcmb/7.6.620; Craig LE, 1998, MICROVASC RES, V55, P65, DOI 10.1006/mvre.1997.2045; FAHY JV, 1995, J ALLERGY CLIN IMMUN, V95, P843, DOI 10.1016/S0091-6749(95)70128-1; Folkerts G, 1998, AM J RESP CRIT CARE, V157, P1708, DOI 10.1164/ajrccm.157.6.9707163; FRAENKEL DJ, 1995, AM J RESP CRIT CARE, V151, P879; GAFFNEY AB, 1993, IMMUNOPHARMACOLOGY, V25, P1; Gern JE, 1999, CLIN MICROBIOL REV, V12, P9, DOI 10.1128/CMR.12.1.9; Griego SD, 2000, J IMMUNOL, V165, P5211, DOI 10.4049/jimmunol.165.9.5211; HANSEL TT, 1991, J IMMUNOL METHODS, V145, P105, DOI 10.1016/0022-1759(91)90315-7; IGARASHI Y, 1993, J ALLERGY CLIN IMMUN, V92, P722, DOI 10.1016/0091-6749(93)90016-9; Louis R, 2000, AM J RESP CRIT CARE, V161, P9, DOI 10.1164/ajrccm.161.1.9802048; Marcus BC, 1996, SURGERY, V120, P411, DOI 10.1016/S0039-6060(96)80317-5; Moore TM, 1998, AM J PHYSIOL-LUNG C, V275, pL203, DOI 10.1152/ajplung.1998.275.2.L203; Murphy HS, 1998, MICROVASC RES, V56, P203, DOI 10.1006/mvre.1998.2110; Pizzichini E, 1996, AM J RESP CRIT CARE, V154, P308, DOI 10.1164/ajrccm.154.2.8756799; Pizzichini MMM, 1998, AM J RESP CRIT CARE, V158, P1178, DOI 10.1164/ajrccm.158.4.9712082; RUBIN LL, 1991, J CELL BIOL, V115, P1725, DOI 10.1083/jcb.115.6.1725; SUBAUSTE MC, 1995, J CLIN INVEST, V96, P549, DOI 10.1172/JCI118067; Worthylake RA, 2001, CURR OPIN CELL BIOL, V13, P569, DOI 10.1016/S0955-0674(00)00253-2; Yamamoto H, 1998, J IMMUNOL, V161, P971	26	77	80	0	6	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2002	110	5					752	756		10.1067/mai.2002.128581	http://dx.doi.org/10.1067/mai.2002.128581			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	612NN	12417884				2022-12-18	WOS:000179082500010
J	Oosting, AJ; de Bruin-Weller, MS; Terreehorst, I; Tempels-Pavlica, Z; Aalberse, RC; de Monchy, JGR; van Wijk, RG; Bruijnzeel-Koomen, CAFM				Oosting, AJ; de Bruin-Weller, MS; Terreehorst, I; Tempels-Pavlica, Z; Aalberse, RC; de Monchy, JGR; van Wijk, RG; Bruijnzeel-Koomen, CAFM			Effect of mattress encasings on atopic dermatitis outcome measures in a double-blind, placebo-controlled study: The Dutch Mite Avoidance Study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; mattress encasing; randomized, double-blind, placebo-controlled study; house dust mite; allergen avoidance; Leicester sign score	HOUSE-DUST MITE; CONTROLLED TRIAL; PATCH TEST; ALLERGEN AVOIDANCE; ASTHMATIC-PATIENTS; REACTIVITY; ECZEMA; CYCLOSPORINE; MULTICENTER; SENSITIZATION	Background: House dust mite (HDM) allergen might induce and maintain atopic dermatitis (AD). Reduction of allergen load by applying encasings might improve the clinical symptoms of AD. Objective: We sought to investigate, in a randomized, double-blind, placebo-controlled study, whether reducing HDM allergen levels by using mattress, duvet, and pillow encasings for 12 months will result in improvement in AD symptoms. Methods: Patients with AD (8-50 years old and allergic to HDM), having a Leicester sign score (a dermatitis score) of at least 1% extent and a severity score of 6 points or greater, were randomly allocated to an active (n = 45) or a placebo allergen-avoidance group (n = 41). Avoidance measures consisted of applying HDM-impermeable encasings for mattresses, pillows, and duvets for the active treatment group and cotton encasings for the placebo group. Effect on allergen concentrations (Der p 1 and Der p 1 plus Der f 1), Leicester sign score extent and severity, visual analogue scale scores for itching and sleeplessness, intradermal test results, atopy patch test results, total serum IgE levels, anti-Der p 1-specific IgE levels, and total blood eosinophil counts were studied. Results: The active encasings reduced the Der p 1 allergen concentration in the mattress after 12 months with a factor 2.1 (P =.007) and the Der p 1 plus Der f 1 allergen concentration with a factor of 2.5 (P = .005); no significant change in allergen concentrations in mattresses was seen in the placebo group. Although the decrease in allergen load was significant, no differences in treatment-induced changes were seen between the placebo and active groups. Conclusions: Use of HDM-impermeable encasings resulted in a significant decrease in Der p 1 and Der p 1 plus Der f 1 allergen concentrations. However, this reduction in allergen load did not result in significant changes in clinical parameters between the groups. Reduction of allergens in other environments (work, school, and outdoors) might be equally important in improving symptoms of AD.	Univ Med Ctr Utrecht, Dept Dermatol & Allergol, Utrecht, Netherlands; Univ Rotterdam Hosp, Dept Allergol, Rotterdam, Netherlands; Univ Groningen Hosp, Dept Allergol, Groningen, Netherlands; Netherlands Red Cross, Blood Transfus Serv, Cent Lab, Amsterdam, Netherlands	Utrecht University; Utrecht University Medical Center; Erasmus University Rotterdam; Erasmus MC; University of Groningen	Bruijnzeel-Koomen, CAFM (corresponding author), Univ Med Ctr Utrecht, Dept Dermatol & Allergol, Heidelberglaan 100, Utrecht, Netherlands.			Terreehorst, Ingrid/0000-0002-3264-2740				AUGUST PJ, 1987, PRACTITIONER, V231, P495; Brinkman L, 1997, CLIN EXP ALLERGY, V27, P1043, DOI 10.1111/j.1365-2222.1997.tb01256.x; Brinkman L, 1997, EUR RESPIR J, V10, P1033, DOI 10.1183/09031936.97.10051033; BRUIJNZEEL-KOOMEN C A F M, 1989, Allergie et Immunologie (Paris), V21, P219; BRUIJNZEELKOOME.C, 1988, BRIT J DERMATOL, V118, P229; BRUIJNZEELKOOMEN CAFM, 1989, ACTA DERM-VENEREOL, P58; Carswell F, 1999, CLIN EXP ALLERGY, V29, P193, DOI 10.1046/j.1365-2222.1999.00499.x; CHARPIN D, 1991, AM REV RESPIR DIS, V143, P983, DOI 10.1164/ajrccm/143.5_Pt_1.983; Cloosterman SGM, 1999, CLIN EXP ALLERGY, V29, P1336, DOI 10.1046/j.1365-2222.1999.00627.x; Custovic A, 1998, ALLERGY, V53, P115, DOI 10.1111/j.1398-9995.1998.tb05011.x; Custovic A, 1998, THORAX, V53, P63, DOI 10.1136/thx.53.1.63; Darsow U, 1996, BRIT J DERMATOL, V135, P182, DOI 10.1111/j.1365-2133.1996.tb01144.x; Darsow U, 1999, J AM ACAD DERMATOL, V40, P187, DOI 10.1016/S0190-9622(99)70186-6; Finlay AY, 1996, BRIT J DERMATOL, V135, P509, DOI 10.1046/j.1365-2133.1996.d01-1031.x; Friedmann PS, 1998, ALLERGY, V53, P97, DOI 10.1111/j.1398-9995.1998.tb05007.x; Gotzsche PC, 1998, BRIT MED J, V317, P1105, DOI 10.1136/bmj.317.7166.1105; Grewe M, 1998, IMMUNOL TODAY, V19, P359, DOI 10.1016/S0167-5699(98)01285-7; Gutgesell C, 2001, BRIT J DERMATOL, V145, P70, DOI 10.1046/j.1365-2133.2001.04283.x; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; Holm L, 2001, ALLERGY, V56, P152, DOI 10.1034/j.1398-9995.2001.056002152.x; Hyndman SJ, 2000, CLIN EXP ALLERGY, V30, P1172, DOI 10.1046/j.1365-2222.2000.00858.x; Jirapongsananuruk O, 2000, ANN ALLERG ASTHMA IM, V84, P305, DOI 10.1016/S1081-1206(10)62778-0; LangeveldWildschut EG, 1996, J ALLERGY CLIN IMMUN, V98, P1019, DOI 10.1016/S0091-6749(96)80186-2; LANGEVELDWILDSCHUT EG, 1995, J ALLERGY CLIN IMMUN, V96, P66, DOI 10.1016/S0091-6749(95)70034-X; MARKS GB, 1994, CLIN EXP ALLERGY, V24, P1078, DOI 10.1111/j.1365-2222.1994.tb02746.x; Marks GB, 1995, CLIN EXP ALLERGY, V25, P1190, DOI 10.1111/j.1365-2222.1995.tb03043.x; MITCHELL EB, 1982, LANCET, V1, P127; NIEMEIJER NR, 1993, ALLERGY, V48, P498, DOI 10.1111/j.1398-9995.1993.tb01105.x; OWEN S, 1990, LANCET, V335, P396, DOI 10.1016/0140-6736(90)90219-U; Peat JK, 1996, AM J RESP CRIT CARE, V153, P141, DOI 10.1164/ajrccm.153.1.8542107; ROBERTS DLL, 1984, BRIT J DERMATOL, V110, P735, DOI 10.1111/j.1365-2133.1984.tb04714.x; SALEK MS, 1993, BRIT J DERMATOL, V129, P422, DOI 10.1111/j.1365-2133.1993.tb03170.x; SOWDEN JM, 1991, LANCET, V338, P137, DOI 10.1016/0140-6736(91)90134-B; SPORIK R, 1995, AM J RESP CRIT CARE, V151, P1388, DOI 10.1164/ajrccm.151.5.7735590; Tan BB, 1996, LANCET, V347, P15, DOI 10.1016/S0140-6736(96)91556-1; Thepen T, 1996, J ALLERGY CLIN IMMUN, V97, P828, DOI 10.1016/S0091-6749(96)80161-8; Tovey E, 1999, J ALLERGY CLIN IMMUN, V103, P179, DOI 10.1016/S0091-6749(99)70488-4; Tupker RA, 1996, J ALLERGY CLIN IMMUN, V97, P1064, DOI 10.1016/S0091-6749(96)70259-2; VANJOOST T, 1994, BRIT J DERMATOL, V130, P634; VANREE R, 1994, ALLERGY, V49, P254; Vichyanond P, 1999, ALLERGY, V54, P736, DOI 10.1034/j.1398-9995.1999.00060.x; Weeks J, 1995, CLIN EXP ALLERGY, V25, P1179, DOI 10.1111/j.1365-2222.1995.tb03041.x	42	77	78	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2002	110	3					500	506		10.1067/mai.2002.126791	http://dx.doi.org/10.1067/mai.2002.126791			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	592KM	12209102				2022-12-18	WOS:000177936900025
J	Traidl-Hoffmann, C; Kasche, A; Jakob, T; Huger, M; Plotz, S; Feussner, L; Ring, J; Behrendt, H				Traidl-Hoffmann, C; Kasche, A; Jakob, T; Huger, M; Plotz, S; Feussner, L; Ring, J; Behrendt, H			Lipid mediators from pollen act as chemoattractants and activators of polymorphonuclear granulocytes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						chemotaxis; polymorphonuclear granulocyte; pollen allergy; oxylipins	LEUKOTRIENE B-4 RECEPTOR; HUMAN NEUTROPHILS EXPRESS; HIGH-AFFINITY RECEPTOR; FC-EPSILON-RI; RELEASE; ANTAGONIST; POTENT; INFLAMMATION; RESPONSES; LY293111	Background: Under natural exposure conditions, pollen grains function as allergen carriers that release allergens from internal binding sites on contact with the aqueous phase of mucosa membranes. In addition, we recently demonstrated that pollen are a rich source of eicosanoid-like mediators, which are rapidly released on contact with the aqueous phase. Objective: The current study was designed to characterize the biochemical nature of pollen-derived lipid mediators in more detail and to delineate their biologic activity on polymorphonuclear granulocytes (PMNs). Methods: Aqueous and lipid extracts from Phleum pratense L and Betula alba L pollen were analyzed by means of HPLC. PMNs were exposed to aqueous extracts or lipid fractions from pollen or to HPLC-purified lipid mediators identified in pollen extracts. Effects on PMNs were tested with transwell migration, calcium mobilization, and surface expression of CD11b. Results: Aqueous pollen extracts (APEs) contained predominantly monohydroxylated products derived of linoleic acid and linolenic acid. In chemotaxis assays PMNs displayed significant migration to APEs. Lipid extracts from pollen and the HPLC fraction containing 13-hydroxy-octadecadienoic acid/hydroxy-linoleic acid and 13-hydroxy-octadecatrienoic acid/hydroxy-linolenic acid induced migratory responses, although to a lesser degree than the APEs. In addition, APE, as well as lipid, extracts induced PMN activation, as documented by means of calcium mobilization and upregulation of CD11b. Conclusion: Pollen grains release mediators that recruit and activate PMNs in vitro. Similar mechanisms may be effective in vivo, suggesting that pollen-derived lipid mediators may act as adjuvants in the elicitation phase of allergic reactions.	Tech Univ Munich, Div Environm Dermatol & Allergy TUM GSF, D-80802 Munich, Germany; Tech Univ Munich, Dept Dermatol & Allergy, D-80802 Munich, Germany; Inst Plant Genet & Crop Plant Res, Dept Mol Cell Biol, Gatersleben, Germany	Technical University of Munich; Technical University of Munich; Leibniz Institut fur Pflanzengenetik und Kulturpflanzenforschung	Traidl-Hoffmann, C (corresponding author), Tech Univ Munich, Div Environm Dermatol & Allergy TUM GSF, Biedersteinerstr 29, D-80802 Munich, Germany.		Jakob, Thilo/J-1621-2012; Ring, Johannes/GLN-4341-2022; Feussner, Ivo/H-9320-2013	Ring, Johannes/0000-0001-8236-3152; Feussner, Ivo/0000-0002-9888-7003; Traidl-Hoffmann, Claudia/0000-0001-5085-5179				Behrendt H, 2001, INT ARCH ALLERGY IMM, V124, P121, DOI 10.1159/000053688; Behrendt H, 2001, CURR OPIN IMMUNOL, V13, P709, DOI 10.1016/S0952-7915(01)00283-7; Berger S, 2001, BBA-MOL CELL BIOL L, V1533, P266, DOI 10.1016/S1388-1981(01)00161-5; Blackley C.H, 1959, EXPT RES CAUSES NATU; Byrum RS, 1997, J EXP MED, V185, P1065, DOI 10.1084/jem.185.6.1065; CARLOS TM, 1994, BLOOD, V84, P2068; Casale TB, 1996, AM J RESP CELL MOL, V15, P35, DOI 10.1165/ajrcmb.15.1.8679220; Davey PC, 2000, BRIT J HAEMATOL, V111, P934; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; GOULET JL, 1994, P NATL ACAD SCI USA, V91, P12852, DOI 10.1073/pnas.91.26.12852; Gounni AS, 2001, FASEB J, V15, P940, DOI 10.1096/fj.00-0378com; HENRICKS PAJ, 1991, EUR J PHARMACOL, V197, P233, DOI 10.1016/0014-2999(91)90530-4; HENSON PM, 1995, ASTHMA RHINITIS, P367; Iversen L, 1997, SKIN PHARMACOL, V10, P169, DOI 10.1159/000211501; Jackson WT, 1999, J PHARMACOL EXP THER, V288, P286; Kaplan AP, 2001, INT ARCH ALLERGY IMM, V124, P423, DOI 10.1159/000053777; LIM MC, 1995, AM J RESP CRIT CARE, V151, P136, DOI 10.1164/ajrccm.151.1.7812543; Liu XH, 1996, CANCER LETT, V109, P223, DOI 10.1016/S0304-3835(96)04462-X; Mueller MJ, 1998, CHEM BIOL, V5, pR323, DOI 10.1016/S1074-5521(98)90660-3; O'Byrne PM, 2000, AM J RESP CRIT CARE, V161, pS186, DOI 10.1164/ajrccm.161.supplement_2.a1q4-8; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SCHOLL PR, 1993, P NATL ACAD SCI USA, V90, P8847, DOI 10.1073/pnas.90.19.8847; SCHRODER JM, 1990, J IMMUNOL, V144, P2223; Sebastiani S, 2001, J IMMUNOL, V166, P996, DOI 10.4049/jimmunol.166.2.996; SHARON P, 1984, GASTROENTEROLOGY, V86, P453; Showell HJ, 1998, J PHARMACOL EXP THER, V285, P946; SMITH HR, 1992, J ALLERGY CLIN IMMUN, V89, P1076, DOI 10.1016/0091-6749(92)90291-9; SOBERMAN RJ, 1985, J BIOL CHEM, V260, P4508; Sofia MJ, 1997, ADV EXP MED BIOL, V400, P381; Soussi-Gounni A, 1998, J ALLERGY CLIN IMMUN, V101, pS173; TERAN LM, 1995, INT ARCH ALLERGY IMM, V107, P374, DOI 10.1159/000237040; Toborek M, 1997, J LIPID RES, V38, P2155; Turner CR, 1996, J CLIN INVEST, V97, P381, DOI 10.1172/JCI118426; Varga EM, 1999, EUR RESPIR J, V14, P610, DOI 10.1034/j.1399-3003.1999.14c21.x; Wagner JG, 2000, PHARMACOL REV, V52, P349; Weichert H, 1999, FEBS LETT, V464, P133, DOI 10.1016/S0014-5793(99)01697-X; YAMAOKA A, 1995, J IMMUNOL, V154, P3479; Yamaoka KA, 1996, INT IMMUNOL, V8, P479, DOI 10.1093/intimm/8.4.479; Yokomizo T, 2000, J EXP MED, V192, P421, DOI 10.1084/jem.192.3.421; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506; Yokomizo T, 2001, J BIOL CHEM, V276, P12454, DOI 10.1074/jbc.M011361200	41	77	79	1	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2002	109	5					831	838		10.1067/mai.2002.124655	http://dx.doi.org/10.1067/mai.2002.124655			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	553QW	11994708	Bronze, Green Submitted			2022-12-18	WOS:000175687800014
J	Charous, BL; Blanco, C; Tarlo, S; Hamilton, RG; Baur, X; Beezhold, D; Sussman, G; Yunginger, JW				Charous, BL; Blanco, C; Tarlo, S; Hamilton, RG; Baur, X; Beezhold, D; Sussman, G; Yunginger, JW			Natural rubber latex allergy after 12 years: Recommendations and perspectives	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						latex; natural rubber latex; occupation asthma; allergic sensitization; latex gloves; Standard Precautions	OCCUPATIONAL ASTHMA; SPINA-BIFIDA; RISK-FACTORS; IGE; SENSITIZATION; PREVALENCE; CHILDREN; GLOVES; APPRENTICES; FREQUENCY	Natural rubber latex (NRL) allergy is a "new" illness whose prevalence reached epidemic proportions in highly exposed populations during the last decade. In children with spina bifida and in patients exposed to NRL during radiologic procedures, institution of prophylactic safety measures has had demonstrable effects in preventing allergic reactions. The risk of NRL allergy appears to be largely linked to occupational exposure, and NRL-associated occupational asthma is due almost solely to powdered latex glove use. Prevalence of NRL-allergic sensitization in the general population is quite low; several studies of young adults demonstrate rates of positive skin test results that are less than 1%. After occupational exposure, rates of sensitization and NRL-induced asthma rise dramatically in individuals using powdered NRL gloves but not in individuals using powder-free gloves. Airborne NRL is dependent on the use of powdered NRL gloves; conversion to non-NRL or nonpowdered NRL substitutes results in predictable rapid disappearance of detectable levels of aeroallergen. For these reasons, adoption of the following institutional policies designed to prevent new cases of NRL allergy and maximize safety is recommended: (1) NRL gloves should be used only as mandated by accepted Standard Precautions; (2) only nonpowdered, nonsterile NRL gloves should be used; and (3) nonpowdered, sterile NRL gloves are preferred for use. Low-protein powdered, sterile gloves may be used, but only in conjunction with an ongoing assessment for development of allergic reactions.	Milwaukee Med Clin, Milwaukee, WI 53209 USA; Univ Toronto, Toronto, ON, Canada; Johns Hopkins Univ, Baltimore, MD 21218 USA; Univ Hamburg, Hamburg, Germany; Guthrie Res Inst, Sayre, PA USA; Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA	University of Toronto; Johns Hopkins University; University of Hamburg; Mayo Clinic	Charous, BL (corresponding author), Milwaukee Med Clin, 3003 W Good Hope Rd, Milwaukee, WI 53209 USA.		Blanco, Carlos/B-3895-2012	Blanco, Carlos/0000-0002-2893-6594; Beezhold, Donald/0000-0001-5543-5747; Tarlo, Susan/0000-0002-4746-5310				ARELLANO R, 1992, ANESTHESIOLOGY, V77, P905, DOI 10.1097/00000542-199211000-00011; Baur X, 1998, J ALLERGY CLIN IMMUN, V101, P24, DOI 10.1016/S0091-6749(98)70188-5; BLANCO C, 1994, ANN ALLERGY, V73, P309; Blanco C, 1998, CLIN EXP ALLERGY, V28, P971; Brehler R, 1997, ALLERGY, V52, P404, DOI 10.1111/j.1398-9995.1997.tb01019.x; CAPRILESHULETT A, 1995, ANN ALLERG ASTHMA IM, V75, P62; Charous BL, 2000, ANN ALLERG ASTHMA IM, V85, P285, DOI 10.1016/S1081-1206(10)62531-8; Ebo DG, 1997, J ALLERGY CLIN IMMUN, V100, P618, DOI 10.1016/S0091-6749(97)70165-9; Garabrant DH, 2001, AM J EPIDEMIOL, V153, P515, DOI 10.1093/aje/153.6.515; Gautrin D, 2000, AM J RESP CRIT CARE, V162, P1222, DOI 10.1164/ajrccm.162.4.2001023; Gautrin D, 2001, AM J RESP CRIT CARE, V163, P1501; Gautrin D, 1997, AM J RESP CRIT CARE, V155, P1841, DOI 10.1164/ajrccm.155.6.9196084; HADJILIADIS D, 1995, J ALLERGY CLIN IMMUN, V96, P431, DOI 10.1016/S0091-6749(95)70067-6; Hamilton RG, 1999, J ALLERGY CLIN IMMUN, V103, P925, DOI 10.1016/S0091-6749(99)70440-9; KELLY KJ, 1994, J ALLERGY CLIN IMMUN, V94, P53, DOI 10.1016/0091-6749(94)90071-X; LAGIER F, 1992, J ALLERGY CLIN IMMUN, V90, P319, DOI 10.1016/S0091-6749(05)80009-0; Laoprasert N, 1998, J ALLERGY CLIN IMMUN, V102, P998, DOI 10.1016/S0091-6749(98)70338-0; Levy DA, 2000, CLIN EXP ALLERGY, V30, P270, DOI 10.1046/j.1365-2222.2000.00751.x; Levy DA, 1999, JAMA-J AM MED ASSOC, V281, P988, DOI 10.1001/jama.281.11.988; Leynadier F, 2000, J ALLERGY CLIN IMMUN, V106, P585, DOI 10.1067/mai.2000.109173; Liss GM, 1997, OCCUP ENVIRON MED, V54, P335, DOI 10.1136/oem.54.5.335; Mace SR, 1998, ANN ALLERG ASTHMA IM, V80, P252, DOI 10.1016/S1081-1206(10)62966-3; Mazon A, 1997, J ALLERGY CLIN IMMUN, V99, P600, DOI 10.1016/S0091-6749(97)70019-8; MONERETVAUTRIN DA, 1993, J ALLERGY CLIN IMMUN, V92, P668, DOI 10.1016/0091-6749(93)90009-5; OWNBY DR, 1991, AM J ROENTGENOL, V156, P903, DOI 10.2214/ajr.156.5.2017949; Ownby DR, 2000, ANN ALLERG ASTHMA IM, V84, P193, DOI 10.1016/S1081-1206(10)62755-X; Petsonk EL, 2000, OCCUP MED, V15, P421; Pisati G, 1998, J ALLERGY CLIN IMMUN, V101, P327, DOI 10.1016/S0091-6749(98)70243-X; Poley GE, 2000, J ALLERGY CLIN IMMUN, V105, P1054, DOI 10.1067/mai.2000.106925; SOSOVEC D, 1998, SURG SERV MANAGE, V4, P11; Tarlo SM, 1997, J ALLERGY CLIN IMMUN, V99, P396, DOI 10.1016/S0091-6749(97)70058-7; TARLO SM, 1990, J ALLERGY CLIN IMMUN, V85, P626, DOI 10.1016/0091-6749(90)90103-B; Tarlo SM, 2001, J ALLERGY CLIN IMMUN, V108, P628, DOI 10.1067/mai.2001.118792; TURJANMAA K, 1987, CONTACT DERMATITIS, V17, P270, DOI 10.1111/j.1600-0536.1987.tb01476.x; TURJANMAA K, 1995, NATURAL RUBBER LATEX; *USFDA, 1999, FED REGISTER, P64; VANDENPLAS O, 1995, AM J RESP CRIT CARE, V151, P54, DOI 10.1164/ajrccm.151.1.7812572; VANDENPLAS O, 1995, EUR RESPIR J, V8, P1957, DOI 10.1183/09031936.95.08111957; Vandenplas O, 1999, ASTHMA WORKPLACE, P425; YASSIN MS, 1992, ANN ALLERGY, V69, P207; Yeang HY, 2000, ANN ALLERG ASTHMA IM, V84, P628, DOI 10.1016/S1081-1206(10)62415-5; Ylitalo L, 1997, J ALLERGY CLIN IMMUN, V100, P606, DOI 10.1016/S0091-6749(97)70163-5; YUNGINGER JW, 1994, J ALLERGY CLIN IMMUN, V93, P836, DOI 10.1016/0091-6749(94)90374-3; 1997, ANN ALLERGY ASTHMA I, V79, P487	44	77	79	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2002	109	1					31	34		10.1067/mai.2002.120953	http://dx.doi.org/10.1067/mai.2002.120953			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	519RM	11799362				2022-12-18	WOS:000173739300005
J	Elberink, JNGO; de Monchy, JGR; Golden, DBK; Brouwer, JLP; Guyatt, GH; Dubois, AEJ				Elberink, JNGO; de Monchy, JGR; Golden, DBK; Brouwer, JLP; Guyatt, GH; Dubois, AEJ			Development and validation of a health-related quality-of-life questionnaire in patients with yellow jacket allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						quality of life; yellow jacket allergy; insect allergy; Hymenoptera allergy; venom immunotherapy	CLINICAL-TRIALS; STINGS	Background: The effects of an anaphylactic reaction after a yellow jacket sting on health-related quality of life (HRQL) have not been studied and are thus unknown. Objective: Development of a disease-specific instrument to measure HRQL in patients with yellow jacket allergy and validation of this instrument both cross-sectionally and longitudinally. Methods: Quality-of-life items were generated from patient interviews. Items with the highest impact were considered and correlated cross-sectionally with an independent measure (consisting of 2 questions in which patients were asked what they expected would happen if they were stung again, "Expectation of Outcome" questionnaire). Cross-sectional and longitudinal validation was achieved by administering this instrument to 69 Dutch patients. The questionnaire was also administered to 50 patients with yellow,jacket allergy in Baltimore, Maryland, to establish cross-sectional validity of the English version. Results: The survey showed that patients experienced impairment in quality of life especially because of emotional distress. The resultant questionnaire has 14 items. The cross-sectional validation yielded a correlation coefficient of 0.69 for the Dutch version and 0.56 for the English version. The longitudinal validation yielded a correlation coefficient of 0.71. The responsiveness of this instrument was demonstrated by the questionnaire's ability to detect changes over time. It may be completed in approximately 10 minutes by patients without assistance. Conclusion: Patients with yellow jacket allergy experience impairment in quality of life especially because of emotional distress. It has, been possible to develop and validate a questionnaire (the Vespid Allergy Quality of Life Questionnaire) by which the HRQL of these patients can be measured. The instrument may be administered rapidly and is easy to use.	Univ Groningen Hosp, Dept Allergol, NL-9700 RB Groningen, Netherlands; Johns Hopkins Univ, Sch Med, Dept Clin Immunol, Baltimore, MD USA; McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada	University of Groningen; Johns Hopkins University; McMaster University	Elberink, JNGO (corresponding author), Univ Groningen Hosp, Dept Allergol, Hanzepl 1,POB 30-001, NL-9700 RB Groningen, Netherlands.							CHARPIN D, 1994, CLIN EXP ALLERGY, V24, P1010, DOI 10.1111/j.1365-2222.1994.tb02736.x; Cronbach LJ, 1951, PSYCHOMETRIKA, V16, P297; ELBERINK JNGO, UNPUB VERNOM IMMUNOT; JUNIPER EF, 1994, J ALLERGY CLIN IMMUN, V93, P413, DOI 10.1016/0091-6749(94)90349-2; JUNIPER EF, 1992, THORAX, V47, P76, DOI 10.1136/thx.47.2.76; MOSBECH H, 1983, ALLERGY, V38, P195, DOI 10.1111/j.1398-9995.1983.tb01606.x; Mueller H L, 1966, J Asthma Res, V3, P331; MULLER UR, 1990, MONOGRAPH INSECT STI, P33; MURPHY EE, 1994, ALLERGY PROC, V15, P57, DOI 10.2500/108854194778703026; Streiner DL., 2003, HLTH MEASUREMENT SCA; Ware J, 1992, MEASURING FUNCTIONIN; WIJKSTRA PJ, 1994, THORAX, V49, P465, DOI 10.1136/thx.49.5.465	12	77	78	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2002	109	1					162	170		10.1067/mai.2002.120552	http://dx.doi.org/10.1067/mai.2002.120552			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	519RM	11799384	Bronze			2022-12-18	WOS:000173739300027
J	Lotvall, J; Palmqvist, M; Arvidsson, P; Maloney, A; Ventresca, GP; Ward, J				Lotvall, J; Palmqvist, M; Arvidsson, P; Maloney, A; Ventresca, GP; Ward, J			The therapeutic ratio of R-albuterol is comparable with that of RS-albuterol in asthmatic patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; bronchodilators; treatment; safety; beta(2)-agonists	RACEMIC-SALBUTAMOL; S-ALBUTEROL; DISPOSITION; ENANTIOMERS; AGONISTS; DRUGS	Background: It has been suggested that R-albuterol produces bronchodilation that is comparable with that of racemic albuterol (RS-albuterol) on a 4:1 dose-for-dose basis but systemic side effects on a 2:1 basis, implying better therapeutic ratio for R-albuterol. Objective: We sought to carefully compare the bronchodilating and systemic effects of R- and RS-albuterol by using a crossover study design. Methods: Twenty asthmatic patients (15.1%-28.7% FEV1 reversibility) were given R-albuterol (6.25-1600 mug), S-albuterol (6.25-1600 mug), RS-albuterol (12.5-3200 mug), or placebo in a crossover, double-blind, placebo-controlled fashion. Cumulative doses were given with a Mefar dosimeter, and FEV1, heart rate, and plasma K+ levels were measured 20 minutes after each dose. Results: Both R- and RS-albuterol produced dose-related improvement in FEV1 and, at higher doses, increased heart rate and decreased plasma K+ levels. Neither placebo nor S-albuterol had any significant effect. Individual estimates of the potency ratio for R-albuterol/RS-albuterol were calculated and summarized across all subjects. The geometric mean potency ratio for effects on FEV1 was 1.9 (95% CI, 1.3-2.8), on HR of 1.9 (95% CI, 1.3-2.9), and on K+ level of 1.7 (95% CI, 1.3-2.1). Conclusion: All pharmacologic effects of RS-albuterol reside with the R-enantiomer, and S-albuterol is clinically inactive. The R-albuterol/RS-albuterol potency ratios for local (FEV1) and systemic effects (heart rate and K+) are similar, suggesting a comparable therapeutic ratio for R-albuterol and RS-albuterol in asthmatic subjects.	Gothenburg Univ, Dept Resp Med & Allergol, S-41345 Gothenburg, Sweden; GlaxoWellcome R&D, Med Data Sci, Greenford, Middx, England; GlaxoWellcome R&D, Resp Clin Pharmacol, Greenford, Middx, England	University of Gothenburg; GlaxoSmithKline; GlaxoSmithKline	Lotvall, J (corresponding author), Gothenburg Univ, Dept Resp Med & Allergol, S-41345 Gothenburg, Sweden.			Lotvall, Jan/0000-0001-9195-9249; Maloney, Alan/0000-0001-8873-1374				Bakale RP, 1996, CLIN REV ALLERG IMMU, V14, P7, DOI 10.1007/BF02772200; Boulton DW, 1996, BRIT J CLIN PHARMACO, V41, P35, DOI 10.1111/j.1365-2125.1996.tb00156.x; Clark DJ, 1997, CLIN PHARMACOKINET, V32, P58, DOI 10.2165/00003088-199732010-00003; Gawchik SM, 1999, J ALLERGY CLIN IMMUN, V103, P615, DOI 10.1016/S0091-6749(99)70233-2; Handley D, 1999, J ALLERGY CLIN IMMUN, V104, pS69, DOI 10.1016/S0091-6749(99)70276-9; Joyce KB, 1998, RAPID COMMUN MASS SP, V12, P1899, DOI 10.1002/(SICI)1097-0231(19981215)12:23<1899::AID-RCM417>3.0.CO;2-I; Lipworth BJ, 1997, THORAX, V52, P849, DOI 10.1136/thx.52.10.849; Lotvall J, 1999, BIODRUGS, V12, P279, DOI 10.2165/00063030-199912040-00005; Nelson HS, 1998, J ALLERGY CLIN IMMUN, V102, P943, DOI 10.1016/S0091-6749(98)70332-X; Penn RB, 1996, CLIN REV ALLERG IMMU, V14, P37, DOI 10.1007/BF02772201; PERRINFAYOLLE M, 1995, LANCET, V346, P1101, DOI 10.1016/S0140-6736(95)91775-6; Waldeck B, 1999, J ALLERGY CLIN IMMUN, V103, P742, DOI 10.1016/S0091-6749(99)70414-8; Ward JK, 2000, BRIT J CLIN PHARMACO, V49, P15, DOI 10.1046/j.1365-2125.2000.00102.x	13	77	77	1	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2001	108	5					726	731						6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	498RG	11692096				2022-12-18	WOS:000172523800011
J	Grote, M; Vrtala, S; Niederberger, V; Wiermann, R; Valenta, R; Reichelt, R				Grote, M; Vrtala, S; Niederberger, V; Wiermann, R; Valenta, R; Reichelt, R			Release of allergen-bearing cytoplasm from hydrated pollen: A mechanism common to a variety of grass (Poaceae) species revealed by electron microscopy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						grass pollen allergy; asthma; allergen release; immunogold labeling; electron microscopy	ASTHMA; PARTICLES; PROTEIN	Background: The release of submicronic particles from grass pollen after rainfall was suggested to be responsible for outbreaks of grass pollen asthma. Recently, we provided evidence for the release of respirable allergen-bearing particles from hydrated ryegrass (Lolium perenne) pollen as a possible explanation for this phenomenon. Objective. We investigated whether water-induced release of respirable allergen-bearing particles could be a mechanism common to several members of the sweet grass family Poaceae (Gramineae). Methods: Pollens from 6 different Poaceae species were hydrated in water and examined by means of scanning electron microscopy for release of cytoplasmic materials. Rabbit antisera raised against purified recombinant group 1 and 5 allergens were used for immunogold labeling of expelled materials by means of field emission scanning electron microscopy. In addition, group 1 and 5 allergens were immunogold-localized on ultrathin sections. Results: Fresh Poaceae pollens expelled cytoplasmic materials containing group 1 and 5 allergens on hydration in water. Expulsion of submicronic particles strongly decreased after 1 month of storage. Conclusions: Our results suggest expulsion of cytoplasm after hydration as a mechanism common to pollens of important allergenic grasses. The water-induced release of respirable allergen-bearing particles from grass pollens might explain asthma attacks observed after rainfall during the grass pollen season.	Univ Munster, Inst Med Phys & Biophys, D-48149 Munster, Germany; Univ Vienna, Dept Pathophysiol, Vienna, Austria; Univ Vienna, Dept Otorhinolaryngol, Vienna, Austria; Univ Munster, Inst Bot, D-4400 Munster, Germany	University of Munster; University of Vienna; University of Vienna; University of Munster	Grote, M (corresponding author), Univ Munster, Inst Med Phys & Biophys, Robert Koch Str 31, D-48149 Munster, Germany.			Vrtala, Susanne/0000-0003-4250-8243; Valenta, Rudolf/0000-0001-5944-3365				AGARWAL MK, 1984, J ALLERGY CLIN IMMUN, V74, P687, DOI 10.1016/0091-6749(84)90231-8; BELLOMO R, 1992, MED J AUSTRALIA, V156, P834, DOI 10.5694/j.1326-5377.1992.tb136994.x; Blackley C.H, 1959, EXPT RES CAUSES NATU; ESCH RE, 1999, ALLERGENS ALLERGEN I, P103; FREIDHOFF LR, 1986, J ALLERGY CLIN IMMUN, V78, P190; Grote M, 2000, J ALLERGY CLIN IMMUN, V105, P1140, DOI 10.1067/mai.2000.107044; HESLOP-HARRISON J, 1979, Annals of Botany (London), V44, P1; JOHNSON P, 1965, NATURE, V206, P935, DOI 10.1038/206935b0; Judd W.S., 1999, PLANT SYSTEMATICS PH; Knox RB, 1997, CLIN EXP ALLERGY, V27, P246; Lovborg U, 1998, INT ARCH ALLERGY IMM, V117, P220, DOI 10.1159/000024014; Niederberger V, 1998, J ALLERGY CLIN IMMUN, V101, P258, DOI 10.1016/S0091-6749(98)70391-4; Schappi GF, 1999, CLIN EXP ALLERGY, V29, P633, DOI 10.1046/j.1365-2222.1999.00567.x; Schappi GF, 1997, SEX PLANT REPROD, V10, P315, DOI 10.1007/s004970050105; SCHUMACHER MJ, 1988, J ALLERGY CLIN IMMUN, V82, P608, DOI 10.1016/0091-6749(88)90972-4; SINGH MB, 1991, P NATL ACAD SCI USA, V88, P1384, DOI 10.1073/pnas.88.4.1384; SPIEKSMA FTM, 1990, CLIN EXP ALLERGY, V20, P273, DOI 10.1111/j.1365-2222.1990.tb02683.x; SUPHIOGLU C, 1992, LANCET, V339, P569, DOI 10.1016/0140-6736(92)90864-Y; Suphioglu C, 1998, INT ARCH ALLERGY IMM, V116, P253, DOI 10.1159/000023953; Suphioglu C, 2000, CLIN EXP ALLERGY, V30, P1335, DOI 10.1046/j.1365-2222.2000.00955.x; Tovey E, 1999, J ALLERGY CLIN IMMUN, V103, P179, DOI 10.1016/S0091-6749(99)70488-4; Valenta R, 1996, IMMUNOL CELL BIOL, V74, P187, DOI 10.1038/icb.1996.26; VRTALA S, 1993, INT ARCH ALLERGY IMM, V102, P160, DOI 10.1159/000236567; Vrtala S, 1999, J IMMUNOL, V163, P5489	24	77	80	1	20	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2001	108	1					109	115						7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	458AN	11447390				2022-12-18	WOS:000170171200015
J	Rodriguez, J; Crespo, JF; Lopez-Rubio, A; de la Cruz-Bertolo, J; Ferrando-Vivas, P; Vives, R; Daroca, P				Rodriguez, J; Crespo, JF; Lopez-Rubio, A; de la Cruz-Bertolo, J; Ferrando-Vivas, P; Vives, R; Daroca, P			Clinical cross-reactivity among foods of the Rosaceae family	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food hypersensitivity; fruit; Rosaceae; double-blind placebo-controlled food challenge; skin prick lest; CAP system FEIA; clinical cross-reactivity; apple; peach; apricot	LIPID TRANSFER PROTEIN; ORAL ALLERGY SYNDROME; MAJOR ALLERGEN; POLLEN ALLERGY; DOUBLE-BLIND; PEACH; APPLE; HYPERSENSITIVITY; CHILDREN; CHERRY	been increasingly reported as causes of allergic reaction. Patients frequently have positive skin tests or radioallergosorbent test results for multiple members of this botanical family. Objective: Our purpose was to investigate the clinical crossreactivity assessed by double-blind, placebo-controlled food challenge (DBPCFC) of Rosaceae foods (apricot, almond, plum, strawberry, apple, peach, and pear). Methods: Thirty-four consecutive adult patients complaining of adverse reactions to Rosaceae were included in the study. Skin prick tests and CAP System (FEIA) were performed with Rosaceae foods in all patients. Clinical reactivity to Rosaceae was systematically evaluated by open food challenges (OFCs), unless there was a convincing history of a recent severe anaphylaxis, Positive reactions an OFCs were subsequently evaluated by DBPCFCs, Results: Twenty-six and 24 patients had positive skin prick tests and CAP FEIA with Rosaceae, respectively; from these 88% and 100% had positive tests with greater than or equal to 2. No evidence of clinical reactivity was found in 66% percent of positive skin prick tests and 63% of positive specific IgE determinations to fruits. A total of 226 food challenges (including OFC and DBPCFC) were performed in the 28 patients with positive skin prick tests or CAP System FEIA. Of 182 initial OFCs carried out, 26 (14%) reactions were confirmed by DBPCFCs, Overall, 40 reactions were considered positive in 22 patients with positive skin tests or CAP FEIA, Thirty-eight reactions had been previously reported, the remaining two were detected by systematic challenges. Most reactions were caused by peach (22 patients), apple (6), and apricot (5), Ten patients (46%) were clinically allergic to peach and other Rosaceae, Conclusion: Positive skin test and CAP System FEIA should not be taken as the only guide for multi-species dietary restrictions. Nevertheless, the potential clinical allergy to other Rosaceae should not be neglected. If the reported reaction is confirmed, current tolerance to other Rosaceae should be precisely established unless there has been ingestion without symptoms after the reaction.	Univ Madrid, Hosp Doce Octubre, Serv Alergia, E-28041 Madrid, Spain; Univ Madrid, Hosp Doce Octubre, Unidad Invest, E-28041 Madrid, Spain	Hospital Universitario 12 de Octubre; Hospital Universitario 12 de Octubre	Rodriguez, J (corresponding author), Univ Madrid, Hosp Doce Octubre, Serv Alergia, Ctra Andalucia,Km 5-400, E-28041 Madrid, Spain.							BERNHISELBROADBENT J, 1989, J ALLERGY CLIN IMMUN, V83, P435, DOI 10.1016/0091-6749(89)90130-9; BOCK SA, 1989, J ALLERGY CLIN IMMUN, V83, P900, DOI 10.1016/0091-6749(89)90103-6; BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; Cuesta-Herranz J, 1999, J ALLERGY CLIN IMMUN, V104, P688, DOI 10.1016/S0091-6749(99)70343-X; Cuesta-Herranz J, 1998, ALLERGY, V53, P78, DOI 10.1111/j.1398-9995.1998.tb03777.x; DREBORG S, 1993, ALLERGY, V48, P49, DOI 10.1111/j.1398-9995.1993.tb04756.x; DREBORG S, 1983, ALLERGY, V38, P167, DOI 10.1111/j.1398-9995.1983.tb01602.x; Greenacre M, 1992, Stat Methods Med Res, V1, P97, DOI 10.1177/096228029200100106; Inschlag C, 1998, INT ARCH ALLERGY IMM, V116, P22, DOI 10.1159/000023920; JONES SM, 1995, J ALLERGY CLIN IMMUN, V96, P341, DOI 10.1016/S0091-6749(95)70053-6; KIVITY S, 1994, CLIN EXP ALLERGY, V24, P19, DOI 10.1111/j.1365-2222.1994.tb00911.x; Noe D, 1998, ALLERGY, V53, P75, DOI 10.1111/j.1398-9995.1998.tb04967.x; ORTOLANI C, 1989, J ALLERGY CLIN IMMUN, V83, P683, DOI 10.1016/0091-6749(89)90083-3; PASTORELLO EA, 1994, J ALLERGY CLIN IMMUN, V94, P699, DOI 10.1016/0091-6749(94)90177-5; Pastorello EA, 1999, J ALLERGY CLIN IMMUN, V104, P1099, DOI 10.1016/S0091-6749(99)70095-3; Pastorello EA, 1999, J ALLERGY CLIN IMMUN, V103, P520, DOI 10.1016/S0091-6749(99)70480-X; *PESC AL, 1990, AL ESP 1990; Sanchez-Monge R, 1999, J ALLERGY CLIN IMMUN, V103, P514, DOI 10.1016/S0091-6749(99)70479-3; Scheurer S, 1999, MOL IMMUNOL, V36, P155, DOI 10.1016/S0161-5890(99)00033-4; VANEKKREBITZ M, 1995, BIOCHEM BIOPH RES CO, V214, P538, DOI 10.1006/bbrc.1995.2320; VANREE R, 1995, J ALLERGY CLIN IMMUN, V95, P726, DOI 10.1016/S0091-6749(95)70178-8	21	77	78	0	17	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2000	106	1	1				183	189		10.1067/mai.2000.106927	http://dx.doi.org/10.1067/mai.2000.106927			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	337ZH	10887323				2022-12-18	WOS:000088393300025
J	Laffer, S; Spitzauer, S; Susani, M; Pairleitner, H; Schweiger, C; Gronlund, H; Menz, G; Pauli, G; Ishii, T; Nolte, H; Ebner, C; Sehon, AH; Kraft, D; Eichler, HG; Valenta, R				Laffer, S; Spitzauer, S; Susani, M; Pairleitner, H; Schweiger, C; Gronlund, H; Menz, G; Pauli, G; Ishii, T; Nolte, H; Ebner, C; Sehon, AH; Kraft, D; Eichler, HG; Valenta, R			Comparison of recombinant timothy grass pollen allergens with natural extract for diagnosis of grass pollen allergy in different populations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						population study; recombinant timothy grass pollen allergens; Phl p 1; Phl p 2; Phl p 5; profilin; in vitro diagnosis; grass pollen allergy	PHLEUM-PRATENSE POLLEN; ESCHERICHIA-COLI; MAJOR ALLERGEN; CDNA CLONING; IGE-BINDING; P-II; PROFILIN; EXPRESSION	Background: Complementary DNAs coding for the major timothy grass pollen (Phleum pratense) allergens Phl p 1, Phl p 2, and Phl p 5 and birch profilin were isolated, expressed as recombinant nonfusion proteins in Escherichia coli, and purified. Objective: In this study the in vitro IgE-binding capacity of recombinant Phl p 1, Phl p 2, Phl p 5, and birch profilin and their IgE recognition frequencies were investigated by using sera from different populations. Methods: One hundred eighty-three sera from patients allergic to grass pollen were obtained from different populations in Europe, Japan, and Canada. The sera were selected according to clinical criteria, skin testing, and RAST (CAP system; Pharmacia, Uppsala, Sweden) and then tested for IgE reactivity with natural and purified recombinant timothy grass pollen allergens by ELISA and Western blot. Results: Most (94.5%) of the patients allergic to grass pollen could be diagnosed with a combination of recombinant Phl p 1, Phl p 2, Phl p 5, and profilin by means of ELISA. Sera that did not react with the recombinant allergens contained low levels of timothy grass pollen-specific IgE. Although considerable variability in IgE recognition frequency of the recombinant allergens was observed in certain populations, a good correlation was found between natural timothy CAP results and the combination of recombinant allergens in all 183 tested sera (r = 0.87). Conclusions: Despite considerable variability in the IgE recognition frequency, purified recombinant timothy grass pollen allergens (Phl p 1, Phl p 2, Phl p 5) and profilin permitted successful in vitro diagnosis of grass pollen allergy in 94.5% of allergic individuals from different populations. The addition of other recombinant allergens (e.g., recombinant Phl p 4) would only slightly improve the in vitro test sensitivity.	UNIV VIENNA,INST GEN & EXPT PATHOL,AKH,A-1090 VIENNA,AUSTRIA; UNIV VIENNA,INST CLIN CHEM & LAB DIAGNOST,AKH,VIENNA,AUSTRIA; AUSTRIAN ACAD SCI,INST MOL BIOL,ABS,A-5020 SALZBURG,AUSTRIA; PHARMACIA DIAGNOST AB,UPPSALA,SWEDEN; HOCHGEBIRGSKLIN DAVOS WOLFGANG,DAVOS,SWITZERLAND; HOP CIVIL,STRASBOURG,FRANCE; NATL SAGANIHARA HOSP,KANAGAWA,JAPAN; RIGSHOSP,DK-2100 COPENHAGEN,DENMARK; INST IMMUNOL,WINNIPEG,MB,CANADA; UNIV VIENNA,AKH,DEPT CLIN PHARMACOL,A-1010 VIENNA,AUSTRIA	University of Vienna; University of Vienna; Austrian Academy of Sciences; Pfizer; Pharmacia Corporation; CHU Strasbourg; Rigshospitalet; University of Copenhagen; University of Vienna				Gronlund, Hans/0000-0003-4882-7624; Valenta, Rudolf/0000-0001-5944-3365				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; DOLECEK C, 1993, FEBS LETT, V335, P299, DOI 10.1016/0014-5793(93)80406-K; Fischer S, 1996, J ALLERGY CLIN IMMUN, V98, P189, DOI 10.1016/S0091-6749(96)70242-7; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; FREIDHOFF LR, 1986, J ALLERGY CLIN IMMUN, V78, P1190, DOI 10.1016/0091-6749(86)90271-X; LAFFER S, 1994, J ALLERGY CLIN IMMUN, V94, P689, DOI 10.1016/0091-6749(94)90176-7; LAFFER S, 1994, J ALLERGY CLIN IMMUN, V94, P88, DOI 10.1016/0091-6749(94)90075-2; Laffer S, 1996, MOL IMMUNOL, V33, P417, DOI 10.1016/0161-5890(95)00152-2; Menz G, 1996, CLIN EXP ALLERGY, V26, P50, DOI 10.1111/j.1365-2222.1996.tb00056.x; Pauli G, 1996, J ALLERGY CLIN IMMUN, V97, P1100, DOI 10.1016/S0091-6749(96)70264-6; Schenk S, 1995, J ALLERGY CLIN IMMUN, V96, P986, DOI 10.1016/S0091-6749(95)70237-7; SUSANI M, 1995, BIOCHEM BIOPH RES CO, V215, P250, DOI 10.1006/bbrc.1995.2460; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; VALENTA R, 1992, INT ARCH ALLERGY IMM, V97, P287, DOI 10.1159/000236135; VALENTA R, 1994, BIOCHEM BIOPH RES CO, V199, P106, DOI 10.1006/bbrc.1994.1201; VRTALA S, 1993, J IMMUNOL, V151, P4773; VRTALA S, 1993, INT ARCH ALLERGY IMM, V102, P160, DOI 10.1159/000236567; Vrtala S, 1996, J ALLERGY CLIN IMMUN, V97, P781, DOI 10.1016/S0091-6749(96)80156-4; VRTALA S, IN PRESS J ALLERGY C; VRTALA S, UNPUB CROSSREACTIVIT	23	77	78	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1996	98	3					652	658		10.1016/S0091-6749(96)70099-4	http://dx.doi.org/10.1016/S0091-6749(96)70099-4			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VJ428	8828543				2022-12-18	WOS:A1996VJ42800022
J	KONZ, KR; CHIA, JK; KURUP, VP; RESNICK, A; KELLY, KJ; FINK, JN				KONZ, KR; CHIA, JK; KURUP, VP; RESNICK, A; KELLY, KJ; FINK, JN			COMPARISON OF LATEX HYPERSENSITIVITY AMONG PATIENTS WITH NEUROLOGIC DEFECTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						LATEX HYPERSENSITIVITY; NEUROIMMUNOLOGY; LATEX-SPECIFIC IGE; ANAPHYLAXIS; SPINA BIFIDA	IGE	Background: Latex hypersensitivity has been described in discrete populations including health cave workers and children with spina bifida (SB). Objective: This study was designed to determine whether the SB population is a unique neuroimmunologic group manifesting this sensitivity. Methods: Four groups of subjects were studied. These included: 36 patients with SE with or without clinical evidence of Eater hypersensitivity, 50 patients with spinal cord injury (SCI), and 10 patients with cerebrovascular accidents (CVAs), all of whom weve questioned regarding contact with and possible clinical allergic reactions to latex. Ten healthy control subjects weve also studied. We used a Eater sap extract previously shown to react with latex-specific IgE in a biotin-avidin ELISA, to determine latex-specific IgE antibody titers and to compare the groups. Results: Responses to questionnaires indicated that neither the patients with SCI nor the patients with CVA had histories suggestive of latex hypersensitivity. In contrast, 72% of the SE population had histories of clinical latex allergy. Comparisons of latex contact among the SB, SCI, CVA, and control groups revealed that the SB and SCI groups had similar latex exposure, whereas the other groups had less exposure. Both the SB and SCI groups had an average of two surgical procedures per year, which was greater than the average for the other groups. Comparisons of IgE latex antibody titers among the groups indicated that only the SB group had significant levels. The mean optical density values for each group were: 0.299 +/- 0.177 for patients with SE and positive skin prick test results, 0.072 +/- 0.066 for patients with SB and negative skin prick test results, 0.098 +/- 0.005 in patients with SCI, 0.073 +/- 0.038 in patients with CVA, and 0.053 +/- 0.034 in control subjects. The percentages of positive latex IgE antibody detection weve 72% for SB, 4% for SCI, 0% for CVA, and 0% for control groups Conclusions: The results suggest that the SB population is unique in demonstrating IgE responses to latex contact, which may be due to increased latex exposure or altered neuroimmunologic interactions.	MED COLL WISCONSIN,DEPT PEDIAT,DIV ALLERGY & IMMUNOL,MILWAUKEE,WI 53226; MED COLL WISCONSIN,DEPT MED,MILWAUKEE,WI 53226; MED COLL WISCONSIN,DIV NEUROSURG,MILWAUKEE,WI 53226; CHILDRENS HOSP WISCONSIN,MILWAUKEE,WI 53201; JOHN L DOYNE HOSP,MILWAUKEE,WI; VET AFFAIRS MED CTR,MILWAUKEE,WI	Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin; Children's Hospital of Wisconsin; US Department of Veterans Affairs; Veterans Health Administration (VHA)				Kelly, Kevin/0000-0002-2954-6117				Ader R., 1991, PSYCHONEUROIMMUNOLOG, V2nd Edn, P611; BIENENSTOCK J, 1991, AM REV RESPIR DIS, V143, pS55, DOI 10.1164/ajrccm/143.3_Pt_2.S55; BUBAK ME, 1992, MAYO CLIN PROC, V67, P1075, DOI 10.1016/S0025-6196(12)61122-7; Centers for Disease Control (CDC), 1991, MMWR Morb Mortal Wkly Rep, V40, P443; EGHRARISABET JS, 1993, J RESPIR DIS, V14, P473; FELTEN DL, 1991, PSYCHONEUROIMMUNOLOG, P3; FISHER AA, 1992, J ALLERGY CLIN IMMUN, V90, P729, DOI 10.1016/0091-6749(92)90095-J; KELLY KJ, 1994, J ALLERGY CLIN IMMUN, V94, P53, DOI 10.1016/0091-6749(94)90071-X; KURUP VP, 1993, J ALLERGY CLIN IMMUN, V91, P1128, DOI 10.1016/0091-6749(93)90314-6; KURUP VP, 1992, ALLERGY PROC, V13, P329, DOI 10.2500/108854192778816915; KWITTKEN PL, 1992, J ALLERGY CLIN IMMUN, V89, P225; METZGER WJ, 1990, LATE PHASE ALLERGIC, P347; MRAZEK DA, 1991, PSYCHONEUROIMMUNOLOG, P1013; PINCKARD RN, 1972, J ALLERGY CLIN IMMUN, V49, P301; REICHLIN S, 1993, NEW ENGL J MED, V329, P1246; REIJULA KE, 1994, J ALLERGY CLIN IMMUN, V94, P891, DOI 10.1016/0091-6749(94)90157-0; SLATER JE, 1989, NEW ENGL J MED, V320, P1126, DOI 10.1056/NEJM198904273201707; TARLO SM, 1992, J ALLERGY CLIN IMMUN, V90, P729	18	77	79	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1995	95	5	1				950	954		10.1016/S0091-6749(95)70094-3	http://dx.doi.org/10.1016/S0091-6749(95)70094-3			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QY917	7751515				2022-12-18	WOS:A1995QY91700005
J	SCHUMACHER, MJ; TVETEN, MS; EGEN, NB				SCHUMACHER, MJ; TVETEN, MS; EGEN, NB			RATE AND QUANTITY OF DELIVERY OF VENOM FROM HONEYBEE STINGS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						VENOM DELIVERY; KINETICS; HONEYBEE; APIS MELLIFERA; STING; ANAPHYLAXIS	DIAGNOSTIC METHODS; APIS-MELLIFERA; BEE; INSECT; SENSITIVITY; ANAPHYLAXIS; LETHALITY; SEVERITY	To determine the rate and completeness of delivery of venom from honeybee stings, European bees were collected at the entrance of a hive and studied with the use of two laboratory models. In one model bees were induced to sting the shaved skin of anesthetized rabbits. The stings were removed from the skin at various time intervals after autotomization, and residual venom was assayed with a hemolytic method. In the other model the bees were induced to sting preweighed filter paper disks, which were weighed again after removal of the sting at various intervals. Results of both experiments were in agreement, showing that at least 90% of the venom sac contents were delivered within 20 seconds and that venom delivery was complete within 1 minute. The data suggest that a bee sting must be removed within a few seconds after autotomization to prevent anaphylaxis in an allergic person. The extensive variation found in the amount of venom delivered at each time point may explain inconsistencies in relationships among reactions to field stings, sting challenge testing venom skin tests and RAST.	STEELE MEM CHILDRENS RES CTR,TUCSON,AZ		SCHUMACHER, MJ (corresponding author), UNIV ARIZONA,HLTH SCI CTR,DEPT PEDIAT,TUCSON,AZ 85724, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041068] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM41068] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLAAUW PJ, 1985, J ALLERGY CLIN IMMUN, V75, P556, DOI 10.1016/0091-6749(85)90029-6; KAMPELMACHER MJ, 1987, CLIN ALLERGY, V17, P317, DOI 10.1111/j.1365-2222.1987.tb02021.x; LICHTENSTEIN LM, 1974, NEW ENGL J MED, V290, P1223, DOI 10.1056/NEJM197405302902204; MULLER U, 1989, ALLERGY, V44, P412, DOI 10.1111/j.1398-9995.1989.tb04172.x; PARKER JL, 1982, J ALLERGY CLIN IMMUN, V69, P200, DOI 10.1016/0091-6749(82)90100-2; SCHUMACHER MJ, 1989, NATURE, V337, P413, DOI 10.1038/337413a0; SCHUMACHER MJ, 1990, AM J TROP MED HYG, V43, P79, DOI 10.4269/ajtmh.1990.43.79; SCHUMACHER MJ, 1992, J ALLERGY CLIN IMMUN, V90, P59, DOI 10.1016/S0091-6749(06)80011-4; SHING H, 1982, APIDOLOGIE, V13, P203, DOI 10.1051/apido:19820301; SNODGRASS R E, 1956, ANATOMY HONEY BEE, P154; VANDERLINDEN PWG, 1992, J ALLERGY CLIN IMMUN, V90, P110, DOI 10.1016/S0091-6749(06)80017-5; VANDERZWAN JK, 1993, J ALLERGY CLIN IMMUN, V91, P282	12	77	79	0	7	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1994	93	5					831	835		10.1016/0091-6749(94)90373-5	http://dx.doi.org/10.1016/0091-6749(94)90373-5			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NL919	8182223				2022-12-18	WOS:A1994NL91900004
J	ERBEN, AM; RODRIGUEZ, JL; MCCULLOUGH, J; OWNBY, DR				ERBEN, AM; RODRIGUEZ, JL; MCCULLOUGH, J; OWNBY, DR			ANAPHYLAXIS AFTER INGESTION OF BEIGNETS CONTAMINATED WITH DERMATOPHAGOIDES-FARINAE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ANAPHYLAXIS; BEIGNETS; DERMATOPHAGOIDES-FARINAE; ELISA INHIBITION; RAST INHIBITION		A 48-year-old man was evaluated for anaphylaxis associated with ingestion of beignets from a commercial mix. Microscopic examination of the patients' beignet mix revealed live Dermatophagoides farinae. Another unopened box from the same source was not infested. Skin test results to aeroallergens and foods, including all beignet mix ingredients, were positive only to D. farinae and D. pteronyssinus extracts. Skin prick test results to an infested mix extract (1:5 wt/vol) were also positive, but no reaction was observed with noninfested mix extract. ELISA inhibition studies demonstrated significant binding of the patients's serum binding to D. farinae strips by infected mix extract. Parallel inhibition curves were produced by the infested mix extract and a commercial D. farinae extract. Noninfested mix extract showed no inhibition. RAST analysis with beignet mix discs showed significant binding of the patient's serum IgE to infested mix discs but not to noninfested mix discs. RAST inhibition studies revealed more than 86% inhibition of binding of the patient's IgE to infested mix discs by infested mix extract and D. farinae extract. No inhibition was observed with noninfested mix or 5% fetal calf serum-phosphate-buffered saline. We conclude that the allergen to which the patient reacted was most likely D. farinae and that ingestion of D. farinae may cause anaphylaxis in sensitive persons.	HENRY FORD HOSP,DIV ALLERGY & CLIN IMMUNOL,2799 W GRAND BLVD,CFP 413,DETROIT,MI 48202	Henry Ford Health System; Henry Ford Hospital								GERN JE, 1991, NEW ENGL J MED, V324, P976, DOI 10.1056/NEJM199104043241407; METCALFE DD, 1984, J ALLERGY CLIN IMMUN, V73, P749, DOI 10.1016/0091-6749(84)90442-1; ROWE MS, 1986, J ALLERGY CLIN IMMUN, V77, P714, DOI 10.1016/0091-6749(86)90416-1; SAMPSON HA, 1986, J ALLERGY CLIN IMMUN, V73, P212	4	77	78	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1993	92	6					846	849		10.1016/0091-6749(93)90062-K	http://dx.doi.org/10.1016/0091-6749(93)90062-K			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ML893	8258619				2022-12-18	WOS:A1993ML89300010
J	HEJJAOUI, A; FERRANDO, R; DHIVERT, H; MICHEL, FB; BOUSQUET, J				HEJJAOUI, A; FERRANDO, R; DHIVERT, H; MICHEL, FB; BOUSQUET, J			SYSTEMIC REACTIONS OCCURRING DURING IMMUNOTHERAPY WITH STANDARDIZED POLLEN EXTRACTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IMMUNOTHERAPY; POLLENS; RUSH; SYSTEMIC REACTIONS; PREMEDICATION	DERMATOPHAGOIDES-PTERONYSSINUS EXTRACT; PLACEBO-CONTROLLED IMMUNOTHERAPY; INHALANT ALLERGEN IMMUNOTHERAPY; PARTIALLY PURIFIED EXTRACT; POLYMERIZED WHOLE RAGWEED; DOUBLE-BLIND; GRASS-POLLEN; HAY-FEVER; RUSH IMMUNOTHERAPY; CLADOSPORIUM-HERBARUM	Specific immunotherapy with standardized extracts administered by a rush protocol can induce systemic reactions (SRs). A prospective study was conducted in 454 pollen-allergic patients (aged 5 to 62 years) (1) to compare the incidence of SRs during a 3-day rush or step protocol, (2) to determine if patients presenting pollen asthma or those allergic to multiple pollen species would have an increased incidence of SRs, and (3) to attempt to decrease SRs. According to their sensitivity, patients received standardized extracts of orchard grass, and/or Parietaria, and/or olive, and/or plane-tree pollen with the same allergenically bioequivalent maintenance dose. Patients 10 years of age and older received 2000 BU; patients younger than 10 years, 1000 BU. The occurrence of SRs was carefully monitored. The incidence of SRs per patient ranged from 2.6% to 31.1%. With the rush protocol, there was a significant decrease in SRs after premedication (p < 0.015). Severe SRs decreased further when the increase in doses was stopped because large local reactions occurred. Step protocol was only slightly better tolerated than rush protocol. Bronchial adverse reactions occurred more often in patients presenting asthma during previous pollen seasons. No reaction started 45 minutes or later after the last injection.	CHU MONTPELLIER, MALADIES RESPIRATOIRES CLIN, AVE MAJOR FLANDRE, F-34059 MONTPELLIER, FRANCE	Universite de Montpellier; CHU de Montpellier			Bousquet, Jean/O-4221-2019					AAS K, 1978, ALLERGY, V33, P130, DOI 10.1111/j.1398-9995.1978.tb01522.x; ANDERSON JA, 1986, J ALLERGY CLIN IMMUN, V77, P271, DOI 10.1016/S0091-6749(86)80103-8; [Anonymous], 1986, BMJ-BRIT MED J, V293, P948; BACAL E, 1978, J ALLERGY CLIN IMMUN, V62, P289, DOI 10.1016/0091-6749(78)90160-4; BAUMGARTEN C, 1982, ALLERGOLOGIE, V5, P89; BOUSQUET J, 1985, J ALLERGY CLIN IMMUN, V76, P734, DOI 10.1016/0091-6749(85)90680-3; BOUSQUET J, 1985, CLIN ALLERGY, V15, P29, DOI 10.1111/j.1365-2222.1985.tb02251.x; BOUSQUET J, 1989, J ALLERGY CLIN IMMUN, V83, P797, DOI 10.1016/0091-6749(89)90017-1; BOUSQUET J, 1988, J ALLERGY CLIN IMMUN, V82, P971, DOI 10.1016/0091-6749(88)90133-9; BOUSQUET J, 1990, J ALLERGY CLIN IMMUN, V85, P490, DOI 10.1016/0091-6749(90)90160-6; BOUSQUET J, 1987, J ALLERGY CLIN IMMUN, V80, P591, DOI 10.1016/0091-6749(87)90013-3; BOUSQUET J, 1984, CLIN ALLERGY, V14, P249, DOI 10.1111/j.1365-2222.1984.tb02204.x; BOUSQUET J, 1985, CLIN ALLERGY, V15, P179, DOI 10.1111/j.1365-2222.1985.tb02272.x; BRUNO G, 1986, ANN ALLERGY, V56, P384; COCKCROFT DW, 1977, J ALLERGY CLIN IMMUN, V60, P56, DOI 10.1016/0091-6749(77)90083-5; CRAPS LP, 1985, BRONCHIAL ASTHMA MEC, P734; CRETICOS PS, 1984, J ALLERGY CLIN IMMUN, V73, P94, DOI 10.1016/0091-6749(84)90490-1; DREBORG S, 1986, ALLERGY, V41, P131, DOI 10.1111/j.1398-9995.1986.tb00289.x; DREBORG S, 1987, THESIS LINKOPING U S; EWAN PW, 1988, CLIN ALLERGY, V18, P501, DOI 10.1111/j.1365-2222.1988.tb02900.x; GOODMAN DH, 1975, ANN ALLERGY, V35, P17; GRAMMER LC, 1986, J ALLERGY CLIN IMMUN, V78, P1180, DOI 10.1016/0091-6749(86)90269-1; GRAMMER LC, 1982, J ALLERGY CLIN IMMUN, V69, P494, DOI 10.1016/0091-6749(82)90173-7; GRAMMER LC, 1989, J ALLERGY CLIN IMMUN, V83, P750, DOI 10.1016/0091-6749(89)90010-9; GRAMMER LC, 1986, J ALLERGY CLIN IMMUN, V77, P53, DOI 10.1016/0091-6749(86)90322-2; GREENBERG MA, 1986, J ALLERGY CLIN IMMUN, V77, P865, DOI 10.1016/0091-6749(86)90385-4; GREENBERG MA, 1988, J ALLERGY CLIN IMMUN, V82, P287, DOI 10.1016/0091-6749(88)91013-5; HEJJAOUI A, 1990, J ALLERGY CLIN IMMUN, V85, P473, DOI 10.1016/0091-6749(90)90157-Y; HENDRIX S, 1980, J ALLERGY CLIN IMMUN, V65, P57, DOI 10.1016/0091-6749(80)90177-3; HIRSCH SR, 1982, J ALLERGY CLIN IMMUN, V70, P183, DOI 10.1016/0091-6749(82)90040-9; HORST M, 1990, J ALLERGY CLIN IMMUN, V85, P460, DOI 10.1016/0091-6749(90)90156-X; JARISCH R, 1988, REDUCTION SIDE EFFEC, V82, P162; LESSOF M, 1983, EXPERIENCE SPECTRAL, P1; LOCKEY RF, 1987, J ALLERGY CLIN IMMUN, V79, P660, DOI 10.1016/S0091-6749(87)80164-1; MALLING HJ, 1986, ALLERGY, V41, P507, DOI 10.1111/j.1398-9995.1986.tb00336.x; METZGER WJ, 1978, J ALLERGY CLIN IMMUN, V61, P268, DOI 10.1016/0091-6749(78)90202-6; MILLER A, 1979, CLIN ALLERGY, V6, P557; NELSON BL, 1986, ANN ALLERGY, V56, P331; NORMAN PS, 1968, J ALLERGY, V42, P93, DOI 10.1016/0021-8707(68)90139-1; NORMAN PS, 1987, J ALLERGY CLIN IMMUN, V79, P572, DOI 10.1016/S0091-6749(87)80150-1; NORMAN PS, 1982, J ALLERGY CLIN IMMUN, V70, P248, DOI 10.1016/0091-6749(82)90061-6; OHMAN JL, 1984, J ALLERGY CLIN IMMUN, V74, P230, DOI 10.1016/0091-6749(84)90251-3; OSTERBALLE O, 1980, ALLERGY, V35, P473, DOI 10.1111/j.1398-9995.1980.tb01795.x; ROSENBERG G, 1982, Journal of Allergy and Clinical Immunology, V69, P115; SCHLEIMER RP, 1988, ALLERGY PRINCIPLES P, P739; SUDIN B, 1986, J ALLERGY CLIN IMMUN, V77, P478; SYMINGTON IS, 1977, CLIN ALLERGY, V7, P189, DOI 10.1111/j.1365-2222.1977.tb01441.x; THOMPSON RA, 1989, LANCET, V1, P259; TURKELTAUB PC, 1990, ALLERGY, V45, P528, DOI 10.1111/j.1398-9995.1990.tb00529.x; VANARSDEL PP, 1957, J ALLERGY, V28, P251, DOI 10.1016/0021-8707(57)90130-2; VANMETRE TE, 1980, J ALLERGY CLIN IMMUN, V66, P500, DOI 10.1016/0091-6749(80)90012-3; VERSTRAETEN JM, 1978, CLIN ALLERGY, V8, P435, DOI 10.1111/j.1365-2222.1978.tb01494.x; VERVLOET D, 1980, CLIN ALLERGY, V10, P59, DOI 10.1111/j.1365-2222.1980.tb02080.x	53	77	80	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1992	89	5					925	933		10.1016/0091-6749(92)90214-M	http://dx.doi.org/10.1016/0091-6749(92)90214-M			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HU542	1583250				2022-12-18	WOS:A1992HU54200002
J	SZEFLER, SJ				SZEFLER, SJ			GLUCOCORTICOID THERAPY FOR ASTHMA - CLINICAL-PHARMACOLOGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review							LONG-TERM TREATMENT; INHALED CORTICOSTEROID BUDESONIDE; NONSTEROID-DEPENDENT ASTHMATICS; BETA-ADRENERGIC RECEPTORS; BECLOMETHASONE DIPROPIONATE; BRONCHIAL RESPONSIVENESS; METHYLPREDNISOLONE ELIMINATION; AIRWAY HYPERRESPONSIVENESS; PREDNISOLONE DISPOSITION; SODIUM CROMOGLYCATE		NATL JEWISH CTR IMMUNOL & RESP MED, DEPT MED, DENVER, CO 80206 USA; UNIV COLORADO, HLTH SCI CTR, DEPT PEDIAT, DENVER, CO 80262 USA; UNIV COLORADO, HLTH SCI CTR, DEPT PHARMACOL, DENVER, CO 80262 USA; IRA J & JACQUELINE NEIMARK LAB CLIN PHARMACOL PEDI, DENVER, CO USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	SZEFLER, SJ (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED, DEPT PEDIAT, 1400 JACKSON ST, ROOM 926, GOODMAN BLDG, DENVER, CO 80206 USA.							ANDERSSON P, 1984, J PHARM PHARMACOL, V36, P763, DOI 10.1111/j.2042-7158.1984.tb04868.x; BALL BD, 1990, ANN ALLERGY, V65, P37; BARNES PJ, 1989, NEW ENGL J MED, V321, P1517; BARTOSZEK M, 1987, CLIN PHARMACOL THER, V42, P424, DOI 10.1038/clpt.1987.173; BEL EH, 1990, AM REV RESPIR DIS, V141, P21, DOI 10.1164/ajrccm/141.1.21; BOEKENOOGEN SJ, 1983, J CLIN ENDOCR METAB, V56, P702, DOI 10.1210/jcem-56-4-702; BOOIJNOORD H, 1971, J ALLERGY CLIN IMMUN, V48, P344, DOI 10.1016/0091-6749(71)90080-7; BOUDINOT FD, 1986, J PHARMACOKINET BIOP, V14, P469, DOI 10.1007/BF01059656; BRATTSAND R, 1982, EUR J RESPIR DIS, V63, P62; BRAUDE AC, 1982, ANN INTERN MED, V97, P59, DOI 10.7326/0003-4819-97-1-59; BRAUDE AC, 1983, LANCET, V2, P995; BRENNER M, 1989, PEDIATR ANN, V18, P810, DOI 10.3928/0090-4481-19891201-11; BROOKS SM, 1972, NEW ENGL J MED, V286, P1125, DOI 10.1056/NEJM197205252862103; BROOKS SM, 1977, J CLIN PHARMACOL, V17, P308, DOI 10.1002/j.1552-4604.1977.tb04610.x; BROWN PH, 1991, LANCET, V337, P576, DOI 10.1016/0140-6736(91)91639-C; BUFFINGTON GA, 1976, JAMA-J AM MED ASSOC, V236, P1958, DOI 10.1001/jama.236.17.1958; CAPEWELL S, 1990, BRIT MED J, V300, P1548, DOI 10.1136/bmj.300.6739.1548; CARMICHAEL J, 1981, BRIT MED J, V282, P1419, DOI 10.1136/bmj.282.6274.1419; CARRYER HM, 1950, J ALLERGY, V21, P282, DOI 10.1016/0021-8707(50)90059-1; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; CHAPLIN MD, 1980, CLIN PHARMACOL THER, V27, P402, DOI 10.1038/clpt.1980.54; CHAPLIN MD, 1980, J ALLERGY CLIN IMMUN, V65, P445, DOI 10.1016/0091-6749(80)90238-9; CHOI Y, 1971, J PHARMACOL EXP THER, V176, P27; CHROUSOS GP, 1982, J CLIN INVEST, V69, P1261, DOI 10.1172/JCI110565; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; COCKCROFT DW, 1987, J ALLERGY CLIN IMMUN, V79, P734, DOI 10.1016/0091-6749(87)90204-1; CONNEY A. H., 1965, LIFE SCI, V4, P1091, DOI 10.1016/0024-3205(65)90229-8; DAHLBERG E, 1984, MOL PHARMACOL, V25, P70; DAVIES AO, 1983, J CLIN INVEST, V71, P565, DOI 10.1172/JCI110801; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; DUNSKY EH, 1979, J ALLERGY CLIN IMMUN, V63, P426, DOI 10.1016/0091-6749(79)90217-3; DUTOIT JI, 1987, AM REV RESPIR DIS, V136, P1174, DOI 10.1164/ajrccm/136.5.1174; EDWARDS OM, 1974, LANCET, V2, P549; ELLULMICALLEF R, 1975, LANCET, V2, P1269; FRASER CM, 1980, BIOCHEM BIOPH RES CO, V94, P390, DOI 10.1016/S0006-291X(80)80233-6; GERGEN PJ, 1990, JAMA-J AM MED ASSOC, V264, P1688, DOI 10.1001/jama.264.13.1688; GLYNN AM, 1986, CLIN PHARMACOL THER, V39, P654, DOI 10.1038/clpt.1986.114; GODFREY S, 1978, J ALLERGY CLIN IMMUN, V62, P335, DOI 10.1016/0091-6749(78)90133-1; GREEN AW, 1984, AM J MED, V77, P1115, DOI 10.1016/0002-9343(84)90199-2; GREOS LS, AM REV RESPIR DIS; HAQUE N, 1972, J CLIN ENDOCR METAB, V34, P44, DOI 10.1210/jcem-34-1-44; HARGREAVE FE, 1990, J ALLERGY CLIN IMMUN, V85, P1098, DOI 10.1016/0091-6749(90)90056-A; HARRIS DM, 1975, POSTGRAD MED J, V51, P20; HARRIS JB, 1987, J PEDIATR-US, V110, P627, DOI 10.1016/S0022-3476(87)80567-X; HASKELL RJ, 1983, ARCH INTERN MED, V143, P1324, DOI 10.1001/archinte.143.7.1324; HENDRICKSE W, 1979, BRIT MED J, V1, P306, DOI 10.1136/bmj.1.6159.306; HILL MR, 1990, CLIN PHARMACOL THER, V48, P390, DOI 10.1038/clpt.1990.167; HILL MR, 1986, J IMMUNOL, V137, P858; JENKINS CR, 1988, THORAX, V43, P378, DOI 10.1136/thx.43.5.378; JENNE JW, 1987, LUNG BIOL HLTH DISEA, V31; JOHANSSON SA, 1982, EUR J CLIN PHARMACOL, V22, P523, DOI 10.1007/BF00609625; JUNIPER EF, 1990, AM REV RESPIR DIS, V142, P832, DOI 10.1164/ajrccm/142.4.832; KAY AB, 1981, CLIN EXP IMMUNOL, V44, P576; KERREBIJN KF, 1987, J ALLERGY CLIN IMMUN, V79, P653, DOI 10.1016/S0091-6749(87)80163-X; KIM CS, 1987, AM REV RESPIR DIS, V135, P157; KRAAN J, 1985, J ALLERGY CLIN IMMUN, V76, P628, DOI 10.1016/0091-6749(85)90786-9; KYRIAZOPOULOU V, 1984, J CLIN ENDOCR METAB, V59, P1204, DOI 10.1210/jcem-59-6-1204; LAFORCE CF, 1983, J ALLERGY CLIN IMMUN, V72, P34, DOI 10.1016/0091-6749(83)90049-0; LINDER MJ, 1989, J STEROID BIOCHEM, V32, P243, DOI 10.1016/0022-4731(89)90259-8; LUDWIG E A, 1987, Drug Intelligence and Clinical Pharmacy, V21, p5A; LUNDGREN R, 1988, EUR RESPIR J, V1, P883; MARTIN LE, 1974, CLIN PHARMACOL THER, V15, P267; MARTIN LE, 1975, POSTGRAD MED J, V51, P11; MARTIN RJ, 1991, AM REV RESPIR DIS, V143, P351, DOI 10.1164/ajrccm/143.2.351; MARTIN RJ, 1990, AM REV RESPIR DIS, V141, P33, DOI 10.1164/ajrccm/141.1.33; MOLLMANN H, 1985, EUR J CLIN PHARMACOL, V29, P85, DOI 10.1007/BF00547374; MORRISON PJ, 1980, BRIT J CLIN PHARMACO, V10, P87, DOI 10.1111/j.1365-2125.1980.tb00506.x; MUNCK A, 1990, AM REV RESPIR DIS, V141, pS2; NICHOLS AI, 1989, J PHARMACOKINET BIOP, V17, P209, DOI 10.1007/BF01059029; OOSTERHUIS B, 1986, J PHARMACOL EXP THER, V239, P919; OOSTERHUIS B, 1987, J PHARMACOL EXP THER, V243, P716; PEDEN NR, 1984, BRIT J CLIN PHARMACO, V18, P101, DOI 10.1111/j.1365-2125.1984.tb05030.x; PETERSON RE, 1955, J CLIN INVEST, V34, P1779, DOI 10.1172/JCI103233; PORTNER M, 1988, PHARMACEUT RES, V5, P623, DOI 10.1023/A:1015966618864; POZNANSKY MC, 1984, CLIN SCI, V67, P639, DOI 10.1042/cs0670639; REINBERG A, 1988, J ASTHMA, V25, P219, DOI 10.3109/02770908809071368; REINBERG A, 1983, J ALLERGY CLIN IMMUN, V71, P425, DOI 10.1016/0091-6749(83)90073-8; REINBERG A, 1974, CHRONOBIOLOGIA, V1, P333; REISS WG, 1990, J ALLERGY CLIN IMMUN, V85, P1058, DOI 10.1016/0091-6749(90)90051-5; ROSE JQ, 1980, J ALLERGY CLIN IMMUN, V66, P366, DOI 10.1016/0091-6749(80)90115-3; RYRFELDT A, 1982, EUR J RESPIR DIS, V63, P86; Schleimer RP, 1989, ANTIINFLAMMATORY STE; SCHWARTZ HJ, 1968, ANN INTERN MED, V69, P493, DOI 10.7326/0003-4819-69-3-493; SERTL K, 1990, AM REV RESPIR DIS, V141, pS1; SIRGO MA, 1985, CLIN PHARMACOL THER, V37, P534, DOI 10.1038/clpt.1985.84; STEPHAN WC, 1980, J ALLERGY CLIN IMMUN, V65, P105, DOI 10.1016/0091-6749(80)90193-1; STJERNHOLM MR, 1975, J CLIN ENDOCR METAB, V41, P887, DOI 10.1210/jcem-41-5-887; SVENDSEN UG, 1987, J ALLERGY CLIN IMMUN, V80, P68; SZEFLER SJ, 1989, J IMMUNOL, V142, P3985; SZEFLER SJ, 1991, CLIN PHARMACOL THER, V49, P59, DOI 10.1038/clpt.1991.11; SZEFLER SJ, 1980, J ALLERGY CLIN IMMUN, V66, P447, DOI 10.1016/0091-6749(80)90004-4; SZEFLER SJ, 1986, EUR J CLIN PHARMACOL, V30, P323, DOI 10.1007/BF00541537; SZEFLER SJ, 1982, CLIN PHARMACOL THER, V32, P166, DOI 10.1038/clpt.1982.143; SZEFLER SJ, 1982, J ALLERGY CLIN IMMUN, V69, P455, DOI 10.1016/0091-6749(82)90121-X; TAL A, 1990, PEDIATRICS, V86, P350; TOOGOOD JH, 1989, J ALLERGY CLIN IMMUN, V84, P688, DOI 10.1016/0091-6749(89)90297-2; TOOGOOD JH, 1982, J ALLERGY CLIN IMMUN, V70, P288, DOI 10.1016/0091-6749(82)90065-3; TOOGOOD JH, 1984, AM REV RESPIR DIS, V129, P723, DOI 10.1164/arrd.1984.129.5.723; TOOGOOD JH, 1989, ANTIINFLAMMATORY STE, P423; TURNERWARWICK M, 1986, ASTHMA CLIN PHARM TH, P347; URIBE M, 1981, GASTROENTEROLOGY, V80, P661; VARSANO I, 1990, J ALLERGY CLIN IMMUN, V85, P914, DOI 10.1016/0091-6749(90)90077-H; VICHYANOND P, 1989, J ALLERGY CLIN IMMUN, V84, P867, DOI 10.1016/0091-6749(89)90381-3; WEISS KB, 1990, JAMA-J AM MED ASSOC, V264, P1683, DOI 10.1001/jama.264.13.1683; WILKINSON JRW, 1989, J CLIN INVEST, V84, P1930, DOI 10.1172/JCI114381; WOOKCOCK AJ, 1989, J ALLERGY CLIN IMMUN, V84, P975; YOSS EB, 1990, AM J RESP CELL MOL, V2, P69, DOI 10.1165/ajrcmb/2.1.69; ZURCHER RM, 1989, CLIN PHARMACOL THER, V45, P366, DOI 10.1038/clpt.1989.42; 1990, MMWR, V39, P493	109	77	81	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1991	88	2					147	165		10.1016/0091-6749(91)90323-G	http://dx.doi.org/10.1016/0091-6749(91)90323-G			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GB225	1880315				2022-12-18	WOS:A1991GB22500002
J	ANDERSON, MW; DESHAZO, RD				ANDERSON, MW; DESHAZO, RD			STUDIES OF THE MECHANISM OF ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITOR-ASSOCIATED ANGIOEDEMA - THE EFFECT OF AN ACE INHIBITOR ON CUTANEOUS RESPONSES TO BRADYKININ, CODEINE, AND HISTAMINE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									TULANE UNIV,SCH MED,DEPT MED,ALLERGY IMMUNOL SECT,NEW ORLEANS,LA 70112; TULANE UNIV,SCH MED,DEPT PEDIAT,ALLERGY IMMUNOL SECT,NEW ORLEANS,LA 70112; UNIV SO ALABAMA,SCH MED,MOBILE,AL 36688	Tulane University; Tulane University; University of South Alabama								CASCIERI MA, 1984, MOL PHARMACOL, V25, P287; COULTER DM, 1987, BRIT MED J, V294, P1521, DOI 10.1136/bmj.294.6586.1521; FERNER RE, 1987, BRIT MED J, V294, P1119, DOI 10.1136/bmj.294.6580.1119; FOREMAN JC, 1987, ALLERGY, V42, P1, DOI 10.1111/j.1398-9995.1987.tb02180.x; FULLER RW, 1987, BRIT J CLIN PHARMACO, V23, P88, DOI 10.1111/j.1365-2125.1987.tb03014.x; NEWBALL HH, 1973, J APPL PHYSIOL, V35, P552, DOI 10.1152/jappl.1973.35.4.552; REGOLI D, 1980, PHARMACOL REV, V32, P1; SEMPLE PF, 1986, NEW ENGL J MED, V314, P61; SESOKO S, 1985, ARCH INTERN MED, V145, P1524; TOWN GI, 1987, NEW ZEAL MED J, V100, P161; WASSERMAN SI, 1983, J ALLERGY CLIN IMMUN, V72, P101, DOI 10.1016/0091-6749(83)90512-2; WEBB D, 1986, LANCET, V2, P1116; WILKIN JK, 1980, ARCH DERMATOL, V116, P902; WOOD SM, 1987, BRIT MED J, V294, P91, DOI 10.1136/bmj.294.6564.91	14	77	78	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1990	85	5					856	858		10.1016/0091-6749(90)90068-F	http://dx.doi.org/10.1016/0091-6749(90)90068-F			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DD959	2185292				2022-12-18	WOS:A1990DD95900006
J	BLACK, JL; MARTHAN, R; ARMOUR, CL; JOHNSON, PRA				BLACK, JL; MARTHAN, R; ARMOUR, CL; JOHNSON, PRA			SENSITIZATION ALTERS CONTRACTILE RESPONSES AND CALCIUM INFLUX IN HUMAN AIRWAY SMOOTH-MUSCLE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											BLACK, JL (corresponding author), UNIV SYDNEY, DEPT PHARMACOL, SYDNEY, NSW 2006, AUSTRALIA.		Black, Judith L/C-6559-2008	Armour, Carol/0000-0002-2930-2227; Marthan, Roger/0000-0001-5412-5712				ANDERSON SD, 1983, THORAX, V38, P284, DOI 10.1136/thx.38.4.284; ANDERSON SD, 1983, ALLERGY, V38, P289, DOI 10.1111/j.1398-9995.1983.tb04122.x; ANDERSSON KE, 1983, EUR J RESPIR DIS, V64, P49; ANTONISSEN LA, 1980, J PHARMACOL EXP THER, V213, P150; ANTONISSEN LA, 1979, J APPL PHYSIOL, V46, P681, DOI 10.1152/jappl.1979.46.4.681; ARMOUR CL, 1984, AM REV RESPIR DIS, V129, P907; ARMOUR CL, 1984, RESP PHYSIOL, V58, P223, DOI 10.1016/0034-5687(84)90150-6; ARMOUR CL, 1988, J PHARMACOL EXP THER, V245, P687; ARMOUR CL, 1981, EUR J PHARMACOL, V72, P93, DOI 10.1016/0014-2999(81)90302-2; BLACK J, 1986, EUR J PHARMACOL, V125, P159, DOI 10.1016/0014-2999(86)90023-3; CERRINA J, 1986, AM REV RESPIR DIS, V134, P57; COBURN RF, 1987, J APPL PHYSIOL, V62, P2320, DOI 10.1152/jappl.1987.62.6.2320; COCKCROFT DW, 1987, AM REV RESPIR DIS, V135, P264; DEJONGSTE JC, 1987, EUR J RESPIR DIS, V71, P23; DHILLON DS, 1981, BRIT J PHARMACOL, V74, pP180; ITO M, 1985, RESP PHYSIOL, V59, P143, DOI 10.1016/0034-5687(85)90003-9; MANSOUR S, 1987, CAN J PHYSIOL PHARM, V65, P1942, DOI 10.1139/y87-303; MARTHAN R, 1987, AM REV RESPIR DIS, V135, P185; MIDDLETON E, 1984, J ALLERGY CLIN IMMUN, V73, P643, DOI 10.1016/0091-6749(84)90298-7; MITCHELL RW, 1986, J PHARMACOL EXP THER, V236, P803; MORCILLO EJ, 1984, AM REV RESPIR DIS, V129, P948; RAEBURN D, 1988, GEN PHARMACOL, V19, P399, DOI 10.1016/0306-3623(88)90036-5; ROBERTS JA, 1985, THORAX, V40, P261, DOI 10.1136/thx.40.4.261; ROBERTS JA, 1984, THORAX, V39, P837, DOI 10.1136/thx.39.11.837; SALOME CM, 1980, CLIN ALLERGY, V10, P541, DOI 10.1111/j.1365-2222.1980.tb02135.x; SANGUINETTI MC, 1986, J GEN PHYSIOL, V88, P369, DOI 10.1085/jgp.88.3.369; SCHELLENBERG RR, 1984, INT ARCH ALLER A IMM, V75, P237, DOI 10.1159/000233622; SOUHRADA M, 1987, RESP PHYSIOL, V67, P323, DOI 10.1016/0034-5687(87)90062-4; SOUHRADA M, 1984, SCIENCE, V225, P723, DOI 10.1126/science.6087455; SOUHRADA M, 1981, RESP PHYSIOL, V46, P17, DOI 10.1016/0034-5687(81)90065-7; STEPHENS NL, 1986, J APPL PHYSIOL, V61, P1492, DOI 10.1152/jappl.1986.61.4.1492; VINCENC KS, 1983, AM REV RESPIR DIS, V128, P875; Whicker S D, 1988, Pulm Pharmacol, V1, P25, DOI 10.1016/0952-0600(88)90007-5	33	77	80	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1989	84	4	1				440	447		10.1016/0091-6749(89)90356-4	http://dx.doi.org/10.1016/0091-6749(89)90356-4			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AW760	2477428				2022-12-18	WOS:A1989AW76000004
J	SUBIZA, J; SUBIZA, JL; HINOJOSA, M; GARCIA, R; JEREZ, M; VALDIVIESO, R; SUBIZA, E				SUBIZA, J; SUBIZA, JL; HINOJOSA, M; GARCIA, R; JEREZ, M; VALDIVIESO, R; SUBIZA, E			ANAPHYLACTIC REACTION AFTER THE INGESTION OF CHAMOMILE TEA - A STUDY OF CROSS-REACTIVITY WITH OTHER COMPOSITE POLLENS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HOSP CLIN SAN CARLOS,SERV INMUNOL,MADRID,SPAIN; HOSP RAMON & CAJAL,SERV ALERGIA,MADRID,SPAIN	Hospital Clinico San Carlos; Hospital Universitario Ramon y Cajal	SUBIZA, J (corresponding author), HOSP CLIN SAN CARLOS,CTR ALERGIA & IMMUNOL CLIN,C GEN PARDINAS 116,E-28006 MADRID,SPAIN.							BENNER MH, 1973, J ALLERGY CLIN IMMUN, V52, P307, DOI 10.1016/0091-6749(73)90050-X; BOUSQUET J, 1985, J ALLERGY CLIN IMMUN, V75, P70, DOI 10.1016/0091-6749(85)90015-6; BOUSQUET J, 1984, ALLERGY, V39, P73, DOI 10.1111/j.1398-9995.1984.tb01936.x; CASTERLINE CL, 1980, JAMA-J AM MED ASSOC, V244, P332; COHEN SH, 1979, J ALLERGY CLIN IMMUN, V64, P270, DOI 10.1016/0091-6749(79)90143-X; FERNANDEZ C, 1986, REV ESP ALERGOL INMU, V1, P34; GLEICH GJ, 1974, J ALLERGY CLIN IMMUN, V53, P158, DOI 10.1016/0091-6749(74)90004-9; Hausen B M, 1978, Derm Beruf Umwelt, V26, P175; KETEL WG, 1982, CONTACT DERMATITIS, V8, P50; KLASCHKA F, 1988, ALLERGOLOGIE, V11, P100; LEIFERMAN KM, 1976, J ALLERGY CLIN IMMUN, V58, P140, DOI 10.1016/0091-6749(76)90149-4; LEWIS WH, 1983, AIRBORNE ALLERGENIC, P139; MANSFIELD LE, 1981, ANN ALLERGY, V47, P154; SOLOMON WR, 1983, ALLERGY PRINCIPLES P, V2, P1143; SUBIZA E, 1980, ALLERGOL IMMUNOPAT S, V6, P261; ZAPATA C, 1987, REV ESP ALERGOL IMMU, V2, P189; 1985, PLANTAS MED DIOSCORI, P808	17	77	78	0	10	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1989	84	3					353	358		10.1016/0091-6749(89)90420-X	http://dx.doi.org/10.1016/0091-6749(89)90420-X			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AR199	2674263	Bronze			2022-12-18	WOS:A1989AR19900013
J	ADINOFF, AD; ROSLONIEC, DM; MCCALL, LL; NELSON, HS				ADINOFF, AD; ROSLONIEC, DM; MCCALL, LL; NELSON, HS			A COMPARISON OF 6 EPICUTANEOUS DEVICES IN THE PERFORMANCE OF IMMEDIATE HYPERSENSITIVITY SKIN TESTING	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV COLORADO,HLTH SCI CTR,NATL JEWISH CTR IMMUNOL & RESP MED,DEPT MED,DENVER,CO 80206; UNIV COLORADO,HLTH SCI CTR,NATL JEWISH CTR IMMUNOL & RESP MED,SKIN TEST LAB,DENVER,CO 80206	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	ADINOFF, AD (corresponding author), UNIV COLORADO,HLTH SCI CTR,NATL JEWISH CTR IMMUNOL & RESP MED,DEPT PEDIAT,1400 JACKSON ST,DENVER,CO 80206, USA.							AAS K, 1980, ALLERGY, V35, P250, DOI 10.1111/j.1398-9995.1980.tb01763.x; AAS K, 1978, ALLERGY, V33, P130, DOI 10.1111/j.1398-9995.1978.tb01522.x; BASOMBA A, 1985, ALLERGY, V40, P395, DOI 10.1111/j.1398-9995.1985.tb02677.x; Blackey CH, 1873, EXPT RES CAUSES NATU; BROWN HM, 1981, CLIN ALLERGY, V11, P95, DOI 10.1111/j.1365-2222.1981.tb01571.x; DREBORG S, 1987, CLIN ALLERGY, V17, P537, DOI 10.1111/j.1365-2222.1987.tb02050.x; DREBORG S, 1987, ALLERGY, V42, P117, DOI 10.1111/j.1398-9995.1987.tb02369.x; GALANT SP, 1973, J ALLERGY CLIN IMMUN, V51, P11, DOI 10.1016/0091-6749(73)90003-1; GALANT SP, 1973, J ALLERGY CLIN IMMUN, V51, P245, DOI 10.1016/0091-6749(73)90144-9; GUERIN B, 1984, CLIN ALLERGY, V14, P319, DOI 10.1111/j.1365-2222.1984.tb02212.x; HUBER B, 1983, CLIN ALLERGY, V13, P467, DOI 10.1111/j.1365-2222.1983.tb02623.x; KNIKER WT, 1979, ANN ALLERGY, V43, P73; MALLING HJ, 1985, ALLERGY, V40, P354, DOI 10.1111/j.1398-9995.1985.tb00247.x; MALLING HJ, 1982, ALLERGY, V37, P563, DOI 10.1111/j.1398-9995.1982.tb02341.x; MALLING HJ, 1985, ALLERGY, V40, P400, DOI 10.1111/j.1398-9995.1985.tb02678.x; MALLING HJ, 1984, ALLERGY, V39, P596, DOI 10.1111/j.1398-9995.1984.tb01979.x; MENARDO JL, 1982, ANN ALLERGY, V48, P235; MOEGAARD F, 1988, ALLERGY, V43, P109; NELSON HS, 1983, ANN ALLERGY, V51, P411; OSTERBALLE O, 1979, ALLERGY, V34, P209, DOI 10.1111/j.1398-9995.1979.tb01700.x; OWNBY DR, 1982, J ALLERGY CLIN IMMUN, V69, P533, DOI 10.1016/0091-6749(82)90179-8; PERRIN LF, 1984, CLIN ALLERGY, V14, P581, DOI 10.1111/j.1365-2222.1984.tb02246.x; SANTILLI J, 1980, J ALLERGY CLIN IMMUN, V65, P406, DOI 10.1016/0091-6749(80)90232-8; SULLIVAN TJ, 1982, J ALLERGY CLIN IMMUN, V69, P260, DOI 10.1016/S0091-6749(82)80002-X; Taylor G, 1973, Clin Allergy, V3, P103, DOI 10.1111/j.1365-2222.1973.tb01314.x; TIPTON WR, 1980, ANN ALLERGY, V44, P204; TURKELTAUB PC, 1982, J ALLERGY CLIN IMMUN, V70, P343, DOI 10.1016/0091-6749(82)90023-9; VOORHORST R, 1973, ANN ALLERGY, V31, P137; VOORHORST R, 1980, ALLERGY, V35, P247, DOI 10.1111/j.1398-9995.1980.tb01762.x	29	77	78	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1989	84	2					168	174		10.1016/0091-6749(89)90321-7	http://dx.doi.org/10.1016/0091-6749(89)90321-7			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AL836	2760359				2022-12-18	WOS:A1989AL83600006
J	PAGE, CP				PAGE, CP			THE ROLE OF PLATELET-ACTIVATING FACTOR IN ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											PAGE, CP (corresponding author), UNIV LONDON,KINGS COLL,DEPT PHARMACOL CHELSEA CAMPUS,MANRESA RD,LONDON SW3 6LX,ENGLAND.							ARCHER CB, 1985, BRIT J PHARMACOL, V85, P109, DOI 10.1111/j.1476-5381.1985.tb08836.x; ARCHER CB, 1985, BRIT J DERMATOL, V112, P285, DOI 10.1111/j.1365-2133.1985.tb04855.x; ARNOUX B, 1983, INSERM S, V23, P335; BARBARO JF, 1966, P SOC EXP BIOL MED, V122, P1245; BARNES P J, 1986, British Journal of Pharmacology, V89, p764P; BARNES PJ, 1987, BRIT J PHARMACOL, V90, P709, DOI 10.1111/j.1476-5381.1987.tb11224.x; BEER HJ, 1984, THESIS U ZURICH ZURI; BENVENISTE J, 1982, THROMB RES, V25, P375, DOI 10.1016/0049-3848(82)90128-1; BENVENISTE J, 1979, CR ACAD SCI D NAT, V289, P1037; BENVENISTE J, 1972, J EXP MED, V136, P1356, DOI 10.1084/jem.136.6.1356; BLANK ML, 1979, BIOCHEM BIOPH RES CO, V90, P523; BRAQUET P, 1986, TRENDS PHARMACOL SCI, V7, P397, DOI 10.1016/0165-6147(86)90401-3; BRAQUET P, 1985, LANCET, V1, P1501; BRAQUET P, 1985, BLOOD VESSELS, V16, P559; CAMUSSI G, 1983, AM J PATHOL, V112, P78; CASALSSTENZEL J, 1987, IMMUNOPHARMACOLOGY, V13, P117, DOI 10.1016/0162-3109(87)90048-8; CASALSSTENZEL J, 1987, BRIT J PHARMACOL, V90, P139, DOI 10.1111/j.1476-5381.1987.tb16833.x; CHRISTMAN BW, 1986, AM REV RESPIR DIS, V133, P174; CHUNG KF, 1986, J PHARMACOL EXP THER, V236, P580; CHUNG KF, 1987, LANCET, V1, P248; CHUNG KF, 1985, J APPL PHYSIOL, V58, P1347, DOI 10.1152/jappl.1985.58.4.1347; COCKCROFT DW, 1987, J ALLERGY CLIN IMMUN, V79, P734, DOI 10.1016/0091-6749(87)90204-1; COYLE A, 1987, CLIN RES, V35, pA254; COYLE A, 1987, American Review of Respiratory Disease, V135, pA161; CUSS FM, 1986, LANCET, V2, P189; DARIUS H, 1986, SCIENCE, V232, P58, DOI 10.1126/science.3082008; DEEMING K, 1985, PROSTAGLANDINS, V30, P715; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DEMOPOULOS CA, 1979, J BIOL CHEM, V254, P9355; DUNNILL MS, 1960, J CLIN PATHOL, V13, P27, DOI 10.1136/jcp.13.1.27; FARR RS, 1980, CLIN IMMUNOL IMMUNOP, V15, P318, DOI 10.1016/0090-1229(80)90044-6; FITZGERALD MF, 1987, BRIT J PHARMACOL, V90, P112; FRIGAS E, 1986, J ALLERGY CLIN IMMUN, V77, P527, DOI 10.1016/0091-6749(86)90341-6; GATEAU O, 1984, AM REV RESPIR DIS S, V129, P3; GRANDORDY B M, 1987, American Review of Respiratory Disease, V135, pA161; HALONEN M, 1981, AM REV RESPIR DIS, V124, P416; HAMASAKI Y, 1984, AM REV RESPIR DIS, V129, P742, DOI 10.1164/arrd.1984.129.5.742; HENOCQ E, 1986, LANCET, V1, P1378; HENSON PM, 1977, J IMMUNOL, V119, P2179; HUMPHREY JH, 1954, J PHYSIOL-LONDON, V124, P305, DOI 10.1113/jphysiol.1954.sp005109; HWANG SB, 1985, J BIOL CHEM, V260, P5639; KORNECKI E, 1985, SCIENCE, V226, P1954; KRAAN J, 1985, J ALLERGY CLIN IMMUN, V76, P628, DOI 10.1016/0091-6749(85)90786-9; LATRIGUEMATTEI C, 1984, AGENTS ACTIONS, V15, P643; LEE TC, 1984, J BIOL CHEM, V259, P5526; LICHTENSTEIN LM, 1984, ASTHMA PHYSL IMMUNOP, P1; LYNCH JM, 1986, J IMMUNOL, V137, P2653; MAZZONI L, 1985, BR J PHARM, V86, P517; MAZZONI L, 1985, J PHYSL, V365; METZGER WJ, 1985, CHEST S, V87, P155; MONDOT S, 1985, 3 P INT C INFL NEW Y, P171; MORLEY J, 1984, LANCET, V2, P1142; MURPHY KR, 1986, AM REV RESPIR DIS, V134, P62; NISHIHIRA J, 1984, J BIOCHEM-TOKYO, V95, P1247, DOI 10.1093/oxfordjournals.jbchem.a134728; PAUWELS R, 1985, J ALLERGY CLIN IMMUN, V76, P583, DOI 10.1016/0091-6749(85)90779-1; PIROTZKY E, 1984, MICROCIRC ENDOTH LYM, V1, P107; REED CE, 1986, J ALLERGY CLIN IMMUN, V77, P537, DOI 10.1016/0091-6749(86)90342-8; ROBERTS NM, IN PRESS CLIN EXP PH; SCHELLENBERG RR, 1983, J ALLERGY CLIN IMMUN, V71, P145, DOI 10.1016/0091-6749(83)90351-2; SCHMITZSCHUMANN M, 1987, AGENTS ACTIONS, V21, P217; SHEN TY, 1985, P NATL ACAD SCI USA, V82, P672, DOI 10.1073/pnas.82.3.672; SNYDER F, 1985, MED RES REV, V5, P107, DOI 10.1002/med.2610050105; STEIGER J, IN PRESS CLIN EXP PH; TERASHITA Z, 1983, LIFE SCI, V32, P1975, DOI 10.1016/0024-3205(83)90049-8; THOMPSON PJ, 1984, AM REV RESPIR DIS, V129, P3; TUFFIN DP, 1985, PROSTAGLANDINS, V30, P702, DOI 10.1016/0090-6980(85)90046-2; VARGAFTIG BB, 1980, EUR J PHARMACOL, V65, P185, DOI 10.1016/0014-2999(80)90391-X; WARDLAW AJ, 1986, J CLIN INVEST, V78, P1701, DOI 10.1172/JCI112765	68	77	77	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1988	81	1					144	152		10.1016/0091-6749(88)90233-3	http://dx.doi.org/10.1016/0091-6749(88)90233-3			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	M0274	3276759				2022-12-18	WOS:A1988M027400022
J	KEMP, JP; MELTZER, EO; ORGEL, HA; WELCH, MJ; BUCHOLTZ, GA; MIDDLETON, E; SPECTOR, SL; NEWTON, JJ; PERHACH, JL				KEMP, JP; MELTZER, EO; ORGEL, HA; WELCH, MJ; BUCHOLTZ, GA; MIDDLETON, E; SPECTOR, SL; NEWTON, JJ; PERHACH, JL			A DOSE-RESPONSE STUDY OF THE BRONCHODILATOR ACTION OF AZELASTINE IN ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ALLERGY & ASTHMA MED GRP,RES CTR,SAN DIEGO,CA									ATKINS P, 1985, J ALLERGY CLIN IMMUN, V75, P167, DOI 10.1016/0091-6749(85)90385-9; CHAND N, 1985, J ALLERGY CLIN IMMUN, V75, P194, DOI 10.1016/0091-6749(85)90495-6; CHAND N, 1983, J ALLERGY CLIN IMMUN, V71, P149, DOI 10.1016/0091-6749(83)90365-2; CHAND N, 1985, ANN ALLERGY, V55, P393; CHAND N, 1983, EUR J PHARMACOL, V96, P227, DOI 10.1016/0014-2999(83)90311-4; CHAND N, 1985, PHARMACOLOGIST, V27, P162; CONNELL JT, 1985, ANN ALLERGY, V55, P392; COULD CAL, 1985, ANN ALLERGY, V55, P232; DIAMANTIS W, 1984, FED PROC, V43, P389; DIAMANTIS W, 1984, Journal of Allergy and Clinical Immunology, V73, P184; Diamantis W., 1981, PHARMACOLOGIST, V23, P149; KAMBUROFF P, 1981, B EUR PHYSIOPATHOL R, V17, pP8; MOTOJIMA S, 1985, ASIAN PAC J ALLERGY, V3, P174; PERHACH J, 1984, Journal of Allergy and Clinical Immunology, V73, P144; SPECTOR S, 1986, J ALLERGY CLIN IMMUN, V77, P249; STORMS W, 1985, J ALLERGY CLIN IMMUN, V75, P167, DOI 10.1016/0091-6749(85)90386-0; WEILER JM, 1986, J ALLERGY CLIN IMMUN, V77, P180	17	77	80	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1987	79	6					893	899		10.1016/0091-6749(87)90238-7	http://dx.doi.org/10.1016/0091-6749(87)90238-7			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	H9044	3294977				2022-12-18	WOS:A1987H904400010
J	BARNES, N; PIPER, PJ; COSTELLO, J				BARNES, N; PIPER, PJ; COSTELLO, J			THE EFFECT OF AN ORAL LEUKOTRIENE ANTAGONIST L-649,923 ON HISTAMINE AND LEUKOTRIENE-D4-INDUCED BRONCHOCONSTRICTION IN NORMAL MAN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ROYAL COLL SURG ENGLAND,DEPT PHARMACOL,LONDON WC2A 3PN,ENGLAND	Royal College of Surgeons of England	BARNES, N (corresponding author), KINGS COLL,SCH MED & DENT,DEPT THORAC MED,DENMARK HILL,LONDON SE5,ENGLAND.							BARNES NC, 1984, THORAX, V39, P500, DOI 10.1136/thx.39.7.500; BARNES NC, 1985, BR J CLIN PHARM, V20, P554; BISGAARD H, 1985, BRIT MED J, V290, P1468, DOI 10.1136/bmj.290.6480.1468; BOUHUYS A, 1969, J CLIN INVEST, V48, P1159, DOI 10.1172/JCI106073; CROPP GJA, 1980, ATS NEWS         SPR, P11; DAHLEN SE, 1980, NATURE, V288, P484, DOI 10.1038/288484a0; DUBOIS AB, 1956, J CLIN INVEST, V35, P327, DOI 10.1172/JCI103282; GRIFFIN M, 1983, NEW ENGL J MED, V308, P436, DOI 10.1056/NEJM198302243080807; HOLROYDE MC, 1981, LANCET, V2, P17; INGRAM RH, 1977, NEW ENGL J MED, V297, P596; JONES TR, 1986, CAN J PHYSIOL PHARM, V64, P1068, DOI 10.1139/y86-183; LEE TH, 1981, LANCET, V2, P304; LEWIS RA, 1980, P NATL ACAD SCI-BIOL, V77, P3710, DOI 10.1073/pnas.77.6.3710; MEAD J, 1967, J APPL PHYSIOL, V22, P95, DOI 10.1152/jappl.1967.22.1.95; MORRIS HR, 1980, NATURE, V285, P104, DOI 10.1038/285104a0; MURPHY RC, 1979, P NATL ACAD SCI USA, V76, P4275, DOI 10.1073/pnas.76.9.4275; PIPER PJ, 1981, PROSTAGLANDINS, V21, P793, DOI 10.1016/0090-6980(81)90236-7; PRIDE N B, 1971, British Journal of Diseases of the Chest, V65, P135, DOI 10.1016/S0007-0971(71)80034-7; PRIDE NB, 1979, BRIT J CLIN PHARMACO, V8, P193, DOI 10.1111/j.1365-2125.1979.tb01002.x; SAMHOUN MN, 1983, LEUKOTRIENES OTHER L, P161; SAMUELSSON B, 1979, PROSTAGLANDINS, V17, P785, DOI 10.1016/0090-6980(79)90052-2; SHAW RJ, 1985, NATURE, V316, P150, DOI 10.1038/316150a0; SIROIS P, 1981, PROSTAG LEUKOTR ESS, V7, P327, DOI 10.1016/0161-4630(81)90137-3; SMITH LJ, 1985, AM REV RESPIR DIS, V131, P368; WEISS JW, 1982, SCIENCE, V216, P196, DOI 10.1126/science.7063880; WEISS JW, 1983, JAMA-J AM MED ASSOC, V249, P2814, DOI 10.1001/jama.249.20.2814; WEISSMANN MD, 1983, NEW ENGL J MED, V308, P454; ZAKRZEWSKI JT, 1985, BR J CLIN PHARM, V19, P549; ZAKRZEWSKI JT, 1984, BR J CLIN PHARM, V19, P574	29	77	77	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1987	79	5					816	821		10.1016/0091-6749(87)90215-6	http://dx.doi.org/10.1016/0091-6749(87)90215-6			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	H4349	3553279				2022-12-18	WOS:A1987H434900018
J	JOAD, JP; AHRENS, RC; LINDGREN, SD; WEINBERGER, MM				JOAD, JP; AHRENS, RC; LINDGREN, SD; WEINBERGER, MM			RELATIVE EFFICACY OF MAINTENANCE THERAPY WITH THEOPHYLLINE, INHALED ALBUTEROL, AND THE COMBINATION FOR CHRONIC ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV IOWA,COLL MED,DEPT PEDIAT,JCP,IOWA CITY,IA 52242	University of Iowa					NCRR NIH HHS [RR-59] Funding Source: Medline; NIAID NIH HHS [AI 16151] Funding Source: Medline; NIGMS NIH HHS [GM 7442-07] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHRENS RC, 1985, J ALLERGY CLIN IMMUN, V75, P161, DOI 10.1016/0091-6749(85)90360-4; AHRENS RC, 1984, AM REV RESPIR DIS, V129, P903; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; DUSDIEKER L, 1982, J PEDIATR-US, V101, P281; EKWO E, 1978, J ALLERGY CLIN IMMUN, V61, P240, DOI 10.1016/0091-6749(78)90198-7; Freedman B J, 1972, Br J Dis Chest, V66, P222, DOI 10.1016/0007-0971(72)90033-2; HAMBLETON G, 1977, LANCET, V1, P381; HARRIS JB, 1986, J ALLERGY CLIN IMMUN, V77, P147; HENDELES L, 1984, CLIN PHARMACOKINET, V9, P95, DOI 10.2165/00003088-198409020-00001; HENDELES L, 1983, PHARMACOTHERAPY, V3, P2; HORN CR, 1984, LANCET, V1, P1143; HUHTI E, 1978, CHEST, V73, P348, DOI 10.1378/chest.73.3.348; JOAD JP, 1986, J ALLERGY CLIN IMMUN, V78, P1147, DOI 10.1016/0091-6749(86)90264-2; LARSSON S, 1977, AM REV RESPIR DIS, V116, P861; LEE HS, 1982, J PEDIATR-US, V101, P632, DOI 10.1016/S0022-3476(82)80728-2; MENEELY GR, 1962, AM REV RESPIR DIS, V85, P762; MILAVETZ G, 1986, J PEDIATR-US, V109, P351, DOI 10.1016/S0022-3476(86)80403-6; NASSIF EG, 1981, NEW ENGL J MED, V304, P71, DOI 10.1056/NEJM198101083040202; NELSON HS, 1977, AM REV RESPIR DIS, V116, P871; NEWMAN SP, 1981, EUR J RESPIR DIS, V62, P3; ORGEL HA, 1985, J ALLERGY CLIN IMMUN, V75, P55, DOI 10.1016/0091-6749(85)90012-0; REPSHER LH, 1984, CHEST, V85, P34, DOI 10.1378/chest.85.1.34; RIEGELMAN S, 1981, ASSESSMENT THEOPHYLL; SALOME CM, 1983, THORAX, V38, P854, DOI 10.1136/thx.38.11.854; SMITH JA, 1980, CHEST, V78, P816, DOI 10.1378/chest.78.6.816; TAYLOR DR, 1985, AM REV RESPIR DIS, V131, P747; VANDEWALKER ML, 1986, CHEST, V90, P198, DOI 10.1378/chest.90.2.198; WEINBERG.MM, 1974, J PEDIATR-US, V84, P421; WEINBERGER M, 1975, CLIN PHARMACOL THER, V17, P585; WEINBERGER M, 1983, NEW ENGL J MED, V308, P760, DOI 10.1056/NEJM198303313081306; WEINBERGER M, 1986, AM REV RESPIR DIS, V133, pA41; WILCOXON F, 1965, SOME RAPID APPROXIMA; WOOLCOCK AJ, 1984, AM REV RESPIR DIS, V130, P71; WRIGHT BM, 1978, BRIT MED J, V2, P1627, DOI 10.1136/bmj.2.6152.1627	34	77	77	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1987	79	1					78	85		10.1016/S0091-6749(87)80020-9	http://dx.doi.org/10.1016/S0091-6749(87)80020-9			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	F8810	3805550				2022-12-18	WOS:A1987F881000016
J	KATZ, AJ; TWAROG, FJ; ZEIGER, RS; FALCHUK, ZM				KATZ, AJ; TWAROG, FJ; ZEIGER, RS; FALCHUK, ZM			MILK-SENSITIVE AND EOSINOPHILIC GASTROENTEROPATHY - SIMILAR CLINICAL-FEATURES WITH CONTRASTING MECHANISMS AND CLINICAL COURSE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CTR BLOOD RES INC,BOSTON,MA; HARVARD UNIV,SCH MED,DEPT PEDIAT & MED,BOSTON,MA 02115; CHILDRENS HOSP MED CTR,DEPT PEDIAT,DIV GASTROENTEROL & ALLERGY,BOSTON,MA 02115; NEW ENGLAND DEACONESS HOSP,DEPT MED,DIV GASTROENTEROL,BOSTON,MA 02215	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital				Zeiger, Robert/0000-0001-5788-5063	NIADDK NIH HHS [AM32054] Funding Source: Medline	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AAS K, 1973, Clinical Allergy, V3, P255, DOI 10.1111/j.1365-2222.1973.tb01331.x; AMMANN AJ, 1971, MEDICINE, V50, P223, DOI 10.1097/00005792-197105000-00004; BAZIN H, 1976, IMMUNOLOGY, V30, P679; BOAT TF, 1975, J PEDIATR-US, V87, P23, DOI 10.1016/S0022-3476(75)80062-X; BOCK SA, 1978, J ALLERGY CLIN IMMUN, V62, P327, DOI 10.1016/0091-6749(78)90132-X; BRANDBORG LL, 1959, GASTROENTEROLOGY, V31, P1; BUTS JP, 1978, J PEDIATR, V90, P729; CALDWELL JH, 1975, NEW ENGL J MED, V292, P1388, DOI 10.1056/NEJM197506262922608; CALDWELL JH, 1978, GASTROENTEROLOGY, V74, P825; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; DAHLQUIST A, 1968, ANAL BIOCH, V22, P88; GOLDMAN AS, 1963, PEDIATRICS, V32, P425; GRYBOSKI JD, 1967, PEDIATRICS, V40, P354; IYNGKARAN N, 1978, ARCH DIS CHILD, V53, P150, DOI 10.1136/adc.53.2.150; JARRETT EEE, 1974, IMMUNOLOGY, V27, P365; KATZ AJ, 1977, GASTROENTEROLOGY, V73, P709; KJELLMAN NIM, 1976, CLIN ALLERGY, V6, P51, DOI 10.1111/j.1365-2222.1976.tb01411.x; KLEIN NC, 1970, MEDICINE, V49, P299, DOI 10.1097/00005792-197007000-00003; LEINBACH GE, 1970, GASTROENTEROLOGY, V59, P874; MAY CD, 1970, J ALLERGY, V46, P12, DOI 10.1016/0021-8707(70)90056-0; MAY CD, 1976, J ALLERGY CLIN IMMUN, V58, P500, DOI 10.1016/0091-6749(76)90194-9; TAYLOR B, 1973, LANCET, V2, P111; URELES AL, 1961, AM J MED, V30, P899, DOI 10.1016/0002-9343(61)90178-4; VAZ EM, 1971, IMMUNOLOGY, V21, P11; WALDMANN TA, 1967, NEW ENGL J MED, V276, P761, DOI 10.1056/NEJM196704062761401; WALDMANN TA, 1961, LANCET, V2, P121; WALKER WA, 1978, ARCH DIS CHILD, V53, P527, DOI 10.1136/adc.53.7.527; WALKER WA, 1977, SCIENCE, V197, P370, DOI 10.1126/science.877559; WALKER WA, 1972, SCIENCE, V177, P608, DOI 10.1126/science.177.4049.608; WILSON JF, 1974, J PEDIATR-US, V84, P335, DOI 10.1016/S0022-3476(74)80713-4	30	77	77	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	1					72	78		10.1016/0091-6749(84)90090-3	http://dx.doi.org/10.1016/0091-6749(84)90090-3			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SZ648	6547462				2022-12-18	WOS:A1984SZ64800011
J	BAUR, X; DEWAIR, M; FRUHMANN, G; ASCHAUER, H; PFLETSCHINGER, J; BRAUNITZER, G				BAUR, X; DEWAIR, M; FRUHMANN, G; ASCHAUER, H; PFLETSCHINGER, J; BRAUNITZER, G			HYPERSENSITIVITY TO CHIRONOMIDS (NON-BITING MIDGES) - LOCALIZATION OF THE ANTIGENIC DETERMINANTS WITHIN CERTAIN POLYPEPTIDE SEQUENCES OF HEMOGLOBINS (ERYTHROCRUORINS) OF CHIRONOMUS-THUMMI-THUMMI (DIPTERA)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MAX PLANCK INST BIOCHEM,D-8033 MARTINSRIED,FED REP GER	Max Planck Society	BAUR, X (corresponding author), UNIV MUNICH,KLINIKUM GROSSHADERN,MED 1 CLIN,PULM SECT,D-8000 MUNICH 70,FED REP GER.		Aschauer, Harald/G-8850-2016	Aschauer, Harald/0000-0002-4449-372X				AAS K, 1972, ACTA ALLERGOL, V27, P439; ASCHAUER H, 1981, H-S Z PHYSIOL CHEM, V362, P261, DOI 10.1515/bchm2.1981.362.1.261; ASCHAUER H, 1981, HOPPESEYLERS Z PHYSL, V362, P216; ATASSI MZ, 1975, IMMUNOCHEMISTRY, V12, P423, DOI 10.1016/0019-2791(75)90010-5; BOWEN R, 1951, SO MED J, V44, P886; BRAUN V, 1968, HOPPESEYLERS Z PHYSL, V339, P197; BRAUNITZER G, 1978, H-S Z PHYSIOL CHEM, V359, P137; BRAUNITZER G, 1969, DIPTERA NATURWISSENS, V56, P215; BUSE G, 1979, H-S Z PHYSIOL CHEM, V360, P89, DOI 10.1515/bchm2.1979.360.1.89; EDMAN P, 1967, EUR J BIOCHEM, V1, P80, DOI 10.1111/j.1432-1033.1967.tb00047.x; ELRAB MOG, 1980, J ALLERGY CLIN IMMUN, V66, P190; ELRAB MOG, 1980, CLIN EXPT IMMUNOLOGY, V41, P389; FREEMAN P, 1973, INSECTS OTHER ARTHRO, P189; FREEMAN PAUL, 1950, PROC ROY ENT SOC LONDON SER B, V19, P58; GROSS E, 1961, J AM CHEM SOC, V83, P1510, DOI 10.1021/ja01467a052; KAY AB, 1978, CLIN EXP IMMUNOL, V34, P106; KAZIM AL, 1980, BIOCHEM J, V191, P261, DOI 10.1042/bj1910261; KLEINSCHMIDT T, 1978, Justus Liebigs Annalen der Chemie, P1060; KLEINSCHMIDT T, 1978, HETEROCYCLES, V10, P251; LEWIS D, 1958, T R ENT SOC LOND, V110, P82; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNDKVIST U, 1975, ADV DIAGNOSIS ALLERG, P85; OMENN GS, 1970, J BIOL CHEM, V245, P1895; PEPYS J, 1973, Clinical Allergy, V3, P143, DOI 10.1111/j.1365-2222.1973.tb01318.x; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; PFLETSCHINGER J, 1980, H-S Z PHYSIOL CHEM, V361, P925, DOI 10.1515/bchm2.1980.361.1.925; PFLETSCHINGER J, 1980, Z NATURFORSCH C, V35, P840; SLADICSIMIC D, 1979, H-S Z PHYSIOL CHEM, V360, P115, DOI 10.1515/bchm2.1979.360.1.115; STEER W, 1979, Z NATURFORSCH C, V34, P882; STEIGEMANN W, 1979, J MOL BIOL, V127, P309, DOI 10.1016/0022-2836(79)90332-2; TEALE FWJ, 1959, BIOCHIM BIOPHYS ACTA, V35, P543, DOI 10.1016/0006-3002(59)90407-X; TWINING SS, 1979, J IMMUNOL METHODS, V30, P139, DOI 10.1016/0022-1759(79)90088-7; Zimmerman C L, 1977, Methods Enzymol, V47, P45, DOI 10.1016/0076-6879(77)47007-1	33	77	77	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	69	1					66	76		10.1016/0091-6749(82)90090-2	http://dx.doi.org/10.1016/0091-6749(82)90090-2			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MZ377	6172457				2022-12-18	WOS:A1982MZ37700012
J	RUFFIN, RE; ALPERS, JH; CROCKETT, AJ; HAMILTON, R				RUFFIN, RE; ALPERS, JH; CROCKETT, AJ; HAMILTON, R			REPEATED HISTAMINE INHALATION TESTS IN ASTHMATIC-PATIENTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											RUFFIN, RE (corresponding author), FLINDERS UNIV S AUSTRALIA,MED CTR,DEPT MED,BEDFORD PK,SA 5042,AUSTRALIA.		Crockett, Alan Joseph/K-3859-2019; Crockett, Alan J/F-4553-2013					CADE JF, 1971, AUST NZ J MED, V1, P22, DOI 10.1111/j.1445-5994.1971.tb02256.x; CASTERLINE CL, 1977, J ALLERGY CLIN IMMUN, V59, P420, DOI 10.1016/0091-6749(77)90004-5; CASTERLINE CL, 1976, J ALLERGY CLIN IMMUN, V58, P607, DOI 10.1016/0091-6749(76)90207-4; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; COCKCROFT DW, 1977, THORAX, V32, P429, DOI 10.1136/thx.32.4.429; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P1; CURRY JJ, 1946, J CLIN INVEST, V25, P785, DOI 10.1172/JCI101764; EMPEY DW, 1976, AM REV RESPIR DIS, V113, P131; ITKIN IH, 1967, J ALLERGY, V40, P245, DOI 10.1016/0021-8707(67)90087-1; JUNIPER EF, 1978, THORAX, V33, P705, DOI 10.1136/thx.33.6.705; KAMBUROFF P L, 1972, British Journal of Diseases of the Chest, V66, P21, DOI 10.1016/0007-0971(72)90002-2; Laitinen L A, 1974, Scand J Respir Dis Suppl, V86, P1; LAM S, 1979, J ALLERGY CLIN IMMUN, V63, P28, DOI 10.1016/0091-6749(79)90158-1; MAKINO S, 1966, J ALLERGY, V38, P127, DOI 10.1016/0021-8707(66)90036-0; PAIN MCF, 1972, MED J AUSTRALIA, V1, P522, DOI 10.5694/j.1326-5377.1972.tb46926.x; SCHOEFFEL RE, 1980, THORAX, V35, P164, DOI 10.1136/thx.35.3.164; Snedecor G.W., 1980, STAT METHODS, V7; SOKAL RR, 1969, BIOMETRY, P235; SPECTOR SL, 1975, J ALLERGY CLIN IMMUN, V56, P308, DOI 10.1016/0091-6749(75)90105-0	20	77	77	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	67	4					285	289		10.1016/0091-6749(81)90023-3	http://dx.doi.org/10.1016/0091-6749(81)90023-3			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LL697	7204784				2022-12-18	WOS:A1981LL69700006
J	SZENTIVANYI, A				SZENTIVANYI, A			RADIOLIGAND BINDING APPROACH IN THE STUDY OF LYMPHOCYTIC ADRENOCEPTORS AND THE CONSTITUTIONAL BASIS OF ATOPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material											SZENTIVANYI, A (corresponding author), UNIV S FLORIDA,COLL MED,DEPT PHARMACOL & THERAPEUT,TAMPA,FL 33612, USA.							AHLQUIST RP, 1977, FED PROC, V36, P2572; ALSTON WC, 1974, BRIT MED J, V1, P90, DOI 10.1136/bmj.1.5898.90; [Anonymous], NEUROTRANSMITTER REC; APOLD J, 1977, J ALLERGY CLIN IMMUN, V59, P343, DOI 10.1016/0091-6749(77)90015-X; ATLAS D, 1974, P NATL ACAD SCI USA, V71, P4246, DOI 10.1073/pnas.71.10.4246; AURBACH GD, 1974, SCIENCE, V186, P1223, DOI 10.1126/science.186.4170.1223; BERNSTEIN RA, 1973, J ALLERGY CLIN IMMUN, V51, P89, DOI 10.1016/S0091-6749(73)80025-9; BERNSTEIN RA, 1972, J ALLERGY CLIN IMMUN, V49, P86, DOI 10.1016/0091-6749(72)90060-7; BHATIA SP, 1975, BRIT J CLIN PHARMACO, V2, P463, DOI 10.1111/j.1365-2125.1975.tb00557.x; BISHOPRIC NH, 1980, J ALLERGY CLIN IMMUN, V65, P29, DOI 10.1016/0091-6749(80)90173-6; BROOKS SM, 1979, J ALLERGY CLIN IMMUN, V63, P401, DOI 10.1016/0091-6749(79)90213-6; BROWN EM, 1978, RECEPTORS HORMONE AC, V3, P102; BRUIJNZEEL PLB, 1979, ANN ALLERGY, V43, P105; BUSH RK, 1978, J ALLERGY CLIN IMMUN, V61, P80, DOI 10.1016/0091-6749(78)90229-4; BUSSE WW, 1976, J ALLERGY CLIN IMMUN, V58, P586, DOI 10.1016/0091-6749(76)90205-0; BUSSE WW, 1979, AM REV RESPIR DIS, V119, P561; BUSSE WW, 1977, AM REV RESPIR DIS, V115, P783; BUSSE WW, 1979, AM REV RESPIR DIS, V120, P377; COFFEY RG, 1972, J ALLERGY CLIN IMMUN, V49, P87; CONOLLY ME, 1976, J CLIN INVEST, V58, P1307, DOI 10.1172/JCI108586; COOKSON DU, 1963, AM REV RESPIR DIS, V88, P636; CSEUZ R, 1973, ENDOCRINOLOGY, V93, P752, DOI 10.1210/endo-93-3-752; FALLIERS CJ, 1971, J ALLERGY, V47, P207, DOI 10.1016/S0091-6749(71)80466-9; FIREMAN P, 1970, J ALLERGY, V45, P117; FISHEL CW, 1963, J ALLERGY, V34, P439, DOI 10.1016/0021-8707(63)90009-1; GIANNETTI A, 1979, P INT S ATOPIC DERMA; GREENACRE JK, 1978, BRIT J CLIN PHARMACO, V5, P199, DOI 10.1111/j.1365-2125.1978.tb01624.x; HADDOCK AM, 1975, BRIT MED J, V2, P357, DOI 10.1136/bmj.2.5967.357; INOUE S, 1967, J ALLERGY, V40, P337, DOI 10.1016/0021-8707(67)90023-8; JENNE JW, 1977, J ALLERGY CLIN IMMUN, V60, P346, DOI 10.1016/0091-6749(77)90065-3; KALISKER A, 1977, J ALLERGY CLIN IMMUN, V60, P259, DOI 10.1016/0091-6749(77)90141-5; KARIMAN K, 1977, CLIN RES, V25, pA503; KEIGHLEY JF, 1966, ANN INTERN MED, V65, P985, DOI 10.7326/0003-4819-65-5-985; KIRKPATRICK CH, 1967, AM REV RESPIR DIS, V96, P692; KRZANOWSKI JJ, 1979, CLIN EXP PHARMACOL P, V6, P111, DOI 10.1111/j.1440-1681.1979.tb00013.x; KRZANOWSKI JJ, 1978, N-S ARCH PHARMACOL, V303, P55, DOI 10.1007/BF00496185; KUNOS G, 1978, ANNU REV PHARMACOL, V18, P291, DOI 10.1146/annurev.pa.18.040178.001451; KUNOS G, 1968, NATURE, V217, P1077, DOI 10.1038/2171077a0; LANG P, 1978, J ALLERGY CLIN IMMUN, V61, P248, DOI 10.1016/0091-6749(78)90199-9; LARSSON S, 1977, J ALLERGY CLIN IMMUN, V59, P93, DOI 10.1016/0091-6749(77)90209-3; LEFKOWITZ RJ, 1974, BIOCHEM BIOPH RES CO, V60, P703, DOI 10.1016/0006-291X(74)90297-6; LEVITZKI A, 1974, P NATIONAL ACADEMY S, V71, P2772; LOCKEY SD, 1967, J ALLERGY, V40, P349, DOI 10.1016/0021-8707(67)90024-X; LOGSDON PJ, 1972, J ALLERGY CLIN IMMUN, V50, P45, DOI 10.1016/0091-6749(72)90078-4; LOGSDON PJ, 1973, J ALLERGY CLIN IMMUN, V52, P148, DOI 10.1016/0091-6749(73)90031-6; MAKINO S, 1970, J ALLERGY, V46, P178, DOI 10.1016/0021-8707(70)90096-1; MAKINO S, 1977, J ALLERGY CLIN IMMUN, V59, P348, DOI 10.1016/0091-6749(77)90016-1; MASELLI R, 1970, J ALLERGY, V45, P117; MIDDLETON E, 1968, J ALLERGY, V42, P288, DOI 10.1016/0021-8707(68)90022-1; MINOR TE, 1974, JAMA-J AM MED ASSOC, V227, P292, DOI 10.1001/jama.227.3.292; MINOR TE, 1976, AM REV RESPIR DIS, V113, P149; MORRIS HG, 1977, CLIN PHARMACOL THER, V22, P352; NELSON HS, 1975, J ALLERGY CLIN IMMUN, V55, P299, DOI 10.1016/0091-6749(75)90002-0; NICKERSON M, 1977, FED PROC, V36, P2580; PARKER C W, 1972, Clinical Research, V20, P418; PARKER CW, 1973, J CLIN INVEST, V52, P48, DOI 10.1172/JCI107173; PARKER CW, 1973, J CLIN INVEST, V52, P1342, DOI 10.1172/JCI107306; PARKER CW, 1973, J CLIN INVEST, V52, P1336, DOI 10.1172/JCI107305; POLSON JB, 1978, ADV CYCLIC NUCLEOTID, V9, P757; REED CE, 1976, J INVEST DERMATOL, V67, P333, DOI 10.1111/1523-1747.ep12514494; RINARD GA, 1979, P NATL ACAD SCI USA, V76, P1472, DOI 10.1073/pnas.76.3.1472; SCHULZ V, 1972, INT J CLIN PHARM S, V4, P167; SCHWARTZ HJ, 1973, J ALLERGY CLIN IMMUN, V51, P88, DOI 10.1016/S0091-6749(73)80024-7; SHEPPARD JR, 1977, P NATL ACAD SCI USA, V74, P1091, DOI 10.1073/pnas.74.3.1091; SIMI WW, 1977, J ALLERGY CLIN IMMUN, V59, P178, DOI 10.1016/0091-6749(77)90222-6; SOKOL WN, 1975, J ALLERGY CLIN IMMUN, V55, P310, DOI 10.1016/0091-6749(75)90003-2; STERNBERG TH, 1952, AMA ARCH DERM SYPH, V65, P392, DOI 10.1001/archderm.1952.01530230016002; Stoll A, 1943, HELV CHIM ACTA, V26, P2070, DOI 10.1002/hlca.19430260633; SVEDMYR NLV, 1976, CHEST, V69, P479, DOI 10.1378/chest.69.4.479; SZENTIVANYI A, 1963, J INFECT DIS, V113, P86, DOI 10.1093/infdis/113.2.86; SZENTIVANYI A, 1968, J ALLERGY, V42, P203, DOI 10.1016/S0021-8707(68)90117-2; SZENTIVANYI A, 1976, BRONCHIAL ASTHMA MEC, P137; SZENTIVANYI A, 1980, ALLERGIC DISEASES IN; SZENTIVANYI A, 1978, ALLERGY PRINCIPLES P, P265; SZENTIVANYI A, 1979, TRIANGLE, V18; SZENTIVANYI A, PATHOMECHANISMUS PAT; SZENTIVANYI A, ACTA DERM VENEREOL S; SZENTIVANYI A, 1979, 10 P INT C ALL OXF; SZENTIVANYI A, PHARMACOLOGY RETICUL, V5; SZENTIVANYI A, ANN NY ACAD SCI; SZENTIVANYI M, 1973, NATURE-NEW BIOL, V243, P276, DOI 10.1038/newbio243276a0; SZENTIVANYI M, 1970, American Journal of Physiology, V218, P869; SZENTIVANYI M, 1978, 7TH P INT C PHARM OX, P271; TOWNLEY RG, 1967, J ALLERGY, V39, P177, DOI 10.1016/0021-8707(67)90036-6; VERTESI C, 1978, 7TH P INT C PHARM OX, P271; WILLIAMS LT, 1976, J CLIN INVEST, V57, P149, DOI 10.1172/JCI108254; Williams LT, 1978, RECEPTOR BINDING STU	87	77	77	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	65	1					5	11		10.1016/0091-6749(80)90170-0	http://dx.doi.org/10.1016/0091-6749(80)90170-0			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JB459	6101282				2022-12-18	WOS:A1980JB45900002
J	SHIM, C; STOVER, DE; WILLIAMS, MH				SHIM, C; STOVER, DE; WILLIAMS, MH			RESPONSE TO CORTICOSTEROIDS IN CHRONIC-BRONCHITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									YESHIVA UNIV, ALBERT EINSTEIN COLL MED, DEPT MED, DIV PULM, BRONX, NY 10461 USA; BRONX MUNICIPAL HOSP CTR, DEPT MED, CHEST SERV, BRONX, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine								BEEREL F, 1963, NEW ENGL J MED, V268, P226, DOI 10.1056/NEJM196301312680502; BROCKBANK W, 1957, LANCET, V2, P666; BROWN HM, 1958, LANCET, V2, P1245; CLIFTON M, 1962, LANCET, V1, P1311; CULLEN JH, 1960, AM REV RESPIR DIS, V82, P508; EVANS JA, 1974, THORAX, V29, P401, DOI 10.1136/thx.29.4.401; FRANKLIN W, 1958, NEW ENGL J MED, V258, P774, DOI 10.1056/NEJM195804172581602; FREEDMAN BJ, 1963, BMJ-BRIT MED J, P1509, DOI 10.1136/bmj.2.5371.1509; FULEIHAN FJ, 1967, AM REV RESPIR DIS, V96, P678; HENNEMAN PH, 1949, J LAB CLIN MED, V34, P1017; HORN BR, 1975, NEW ENGL J MED, V292, P1152, DOI 10.1056/NEJM197505292922204; KLEIN RC, 1969, ANN INTERN MED, V71, P711, DOI 10.7326/0003-4819-71-4-711; LORRIMAN GERARD, 1959, THORAX, V14, P146, DOI 10.1136/thx.14.2.146; LOWELL FC, 1975, NEW ENGL J MED, V292, P1182, DOI 10.1056/NEJM197505292922210; MENEELY GR, 1962, AM REV RESPIR DIS, V85, P762; MOYES EN, 1957, LANCET, V2, P1187; PETTY TL, 1970, CHEST, V57, P204, DOI 10.1378/chest.57.2.204; PHEAR D, 1960, LANCET, V1, P139; 1956, LANCET, V2, P803	19	77	79	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	62	6					363	367		10.1016/0091-6749(78)90137-9	http://dx.doi.org/10.1016/0091-6749(78)90137-9			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GA292	361794	Bronze			2022-12-18	WOS:A1978GA29200008
J	SIRAGANIAN, RP				SIRAGANIAN, RP			AUTOMATED HISTAMINE ANALYSIS FOR INVITRO ALLERGY TESTING .2. CORRELATION OF SKIN-TEST RESULTS WITH INVITRO WHOLE-BLOOD HISTAMINE-RELEASE IN 82 PATIENTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NIDR,MICROBIOL & IMMUNOL LAB,CLIN IMMUNOL SECT,BETHESDA,MD 20014	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)								BRUCE CA, 1974, J ALLERGY CLIN IMMUN, V53, P230, DOI 10.1016/0091-6749(74)90085-2; GRUMET FC, 1971, NEW ENGL J MED, V285, P193, DOI 10.1056/NEJM197107222850403; LEVY DA, 1971, J CLIN INVEST, V50, P360, DOI 10.1172/JCI106503; LICHTENS.LM, 1968, AM J MED, V44, P514, DOI 10.1016/0002-9343(68)90052-1; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; LICHTENSTEIN LM, 1966, J CLIN INVEST, V45, P1126, DOI 10.1172/JCI105419; MILLER RG, 1966, SIMULTANEOUS STATIST; NORMAN PS, 1973, J ALLERGY CLIN IMMUN, V52, P210, DOI 10.1016/0091-6749(73)90059-6; SIRAGANIAN RP, 1975, J IMMUNOL METHODS, V7, P283, DOI 10.1016/0022-1759(75)90025-3; SIRAGANIAN RP, 1976, J ALLERGY CLIN IMMUN, V57, P525, DOI 10.1016/0091-6749(76)90003-8; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P393; SVEJGAAR.A, 1974, TISSUE ANTIGENS, V4, P95	12	77	77	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	59	3					214	222		10.1016/0091-6749(77)90152-X	http://dx.doi.org/10.1016/0091-6749(77)90152-X			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CZ249	65372				2022-12-18	WOS:A1977CZ24900005
J	Meng, JH; Moriyama, M; Feld, M; Buddenkotte, J; Buhl, T; Szollosi, A; Zhang, JM; Miller, P; Ghetti, A; Fischer, M; Reeh, PW; Shan, CX; Wang, JF; Steinhoff, M				Meng, Jianghui; Moriyama, Masaki; Feld, Micha; Buddenkotte, Joerg; Buhl, Timo; Szollosi, Attila; Zhang, Jingming; Miller, Paul; Ghetti, Andre; Fischer, Michael; Reeh, Peter W.; Shan, Chunxu; Wang, Jiafu; Steinhoff, Martin			New mechanism underlying IL-31-induced atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; pruritogens; brain-derived natriuretic peptide; pruritus; skin; dorsal root ganglion; keratinocytes; dendritic cells; soluble N-ethylmaleimide-sensitive factor activating protein receptors	SENSORY NEURONS; T-CELLS; ANTI-INTERLEUKIN-31 RECEPTOR; INFLAMMATORY PAIN; DENDRITIC CELLS; MURINE MODELS; IL-31; SKIN; ITCH; EXPRESSION	Background: T(H)2 cell-released IL-31 is a critical mediator in patients with atopic dermatitis (AD), a prevalent and debilitating chronic skin disorder. Brain-derived natriuretic peptide (BNP) has been described as a central itch mediator. The importance of BNP in peripheral (skin-derived) itch and its functional link to IL-31 within the neuroimmune axis of the skin is unknown. Objective: We sought to investigate the function of BNP in the peripheral sensory system and skin in IL-31-induced itch and neuroepidermal communication in patients with AD. Methods: Ca2+ imaging, immunohistochemistry, quantitative real-time PCR, RNA sequencing, knockdown, cytokine/phosphokinase arrays, enzyme immune assay, and pharmacologic inhibition were performed to examine the cellular basis of the IL-31-stimulated, BNP-related itch signaling in dorsal root ganglionic neurons (DRGs) and skin cells, transgenic AD-like mouse models, and human skin of patients with AD and healthy subjects. Results: In human DRGs we confirmed expression and co-occurrence of oncostatin M receptor beta subunit and IL-31 receptor A in a small subset of the neuronal population. Furthermore, IL-31 activated approximately 50% of endothelin-1-responsive neurons, and half of the latter also responded to histamine. In murine DRGs IL-31 upregulated Nppb and induced soluble N-ethylmaleimide-sensitive factor activating protein receptor-dependent BNP release. In Grhl3PAR2/(+) mice house dust mite-induced severe AD-like dermatitis was associated with Nppb upregulation. Lesional IL-31 transgenic mice also exhibited increased Nppb transcripts in DRGs and the skin; accordingly, skin BNP receptor levels were increased. Importantly, expression of BNP and its receptor were increased in the skin of patients with AD. In human skin cells BNP stimulated a proinflammatory and itch-promoting phenotype. Conclusion: For the first time, our findings show that BNP is implicated in AD and that IL-31 regulates BNP in both DRGs and the skin. IL-31 enhances BNP release and synthesis and orchestrates cytokine and chemokine release from skin cells, thereby coordinating the signaling pathways involved in itch. Inhibiting peripheral BNP function might be a novel therapeutic strategy for AD and pruritic conditions.	[Meng, Jianghui; Shan, Chunxu; Wang, Jiafu] Dublin City Univ, Int Ctr Neurotherapeut, Glasnevin Ave, Dublin 9, Ireland; [Meng, Jianghui; Szollosi, Attila; Shan, Chunxu; Steinhoff, Martin] Dept Dermatol, Dublin, Ireland; [Meng, Jianghui; Szollosi, Attila; Shan, Chunxu; Steinhoff, Martin] UCD Charles Inst Translat Dermatol, Dublin, Ireland; [Moriyama, Masaki; Steinhoff, Martin] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA; [Feld, Micha] Univ Hosp Dusseldorf, Dept Dermatol, Dusseldorf, Germany; [Buddenkotte, Joerg; Steinhoff, Martin] Qatar Univ, Dept Dermatol & Venereol, Hamad Med Corp, Doha, Qatar; [Buddenkotte, Joerg; Steinhoff, Martin] Weill Cornell Univ Qatar, Sch Med, Doha, Qatar; [Buddenkotte, Joerg; Steinhoff, Martin] Qatar Univ, Doha, Qatar; [Buhl, Timo] Univ Med Ctr Gottingen, Dept Dermatol, Gottingen, Germany; [Zhang, Jingming; Miller, Paul; Ghetti, Andre] AnaBios, San Diego, CA USA; [Fischer, Michael] Med Univ Vienna, Ctr Physiol & Pharmacol, Vienna, Austria; [Reeh, Peter W.] Univ Erlangen Nurnberg, Inst Physiol & Pathophysiol, Erlangen, Germany	Dublin City University; University of California System; University of California San Francisco; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf Hospital; Hamad Medical Corporation; Qatar University; Qatar Foundation (QF); Weill Cornell Medical College Qatar; Qatar University; University of Gottingen; Medical University of Vienna; University of Erlangen Nuremberg	Meng, JH (corresponding author), Dublin City Univ, Int Ctr Neurotherapeut, Glasnevin Ave, Dublin 9, Ireland.; Steinhoff, M (corresponding author), Qatar Univ, Rumailah Hosp, Hamad Med Corp, Dept Dermatol, POB 3050, Doha, Qatar.	jianghui.meng@dcu.ie; MSteinhoff@hamad.qa	Wang, Jiafu/AAX-9388-2020; Reeh, Peter W./J-8981-2012; Buhl, Timo/AFP-7298-2022; Fischer, Michael J.M./P-8715-2014	Wang, Jiafu/0000-0002-3654-4400; Reeh, Peter W./0000-0002-4367-094X; Fischer, Michael J.M./0000-0002-3811-7066; Meng, Jianghui/0000-0002-3107-4200	Science Foundation Ireland [15/SIRG/3508T, 13/CDA/2093]; Hamad Medical Corporation, Qatar	Science Foundation Ireland(Science Foundation IrelandEuropean Commission); Hamad Medical Corporation, Qatar	Science Foundation Ireland is thanked for funding this research through a Starting Investigator Award (to J.M.; grant no. 15/SIRG/3508T), a Principle Investigator Award (to M.S.) and a Career Development Award (13/CDA/2093 to J.W.). M.S. received Excellence seed funding from Hamad Medical Corporation, Qatar.	Albanesi Cristina, 2005, Current Drug Targets - Inflammation and Allergy, V4, P329, DOI 10.2174/1568010054022033; An JG, 2016, CELL PHYSIOL BIOCHEM, V39, P531, DOI 10.1159/000445645; Andoh T, 1998, J PHARMACOL EXP THER, V286, P1140; Azimi E, 2017, J ALLERGY CLIN IMMUN, V140, P447, DOI 10.1016/j.jaci.2016.12.980; Bando T, 2006, NEUROSCIENCE, V142, P1263, DOI 10.1016/j.neuroscience.2006.07.009; Bautista DM, 2014, NAT NEUROSCI, V17, P175, DOI 10.1038/nn.3619; Bieber T, 2008, NEW ENGL J MED, V358, P1483, DOI 10.1056/NEJMra074081; Bilsborough J, 2010, J IMMUNOL, V185, P6023, DOI 10.4049/jimmunol.0902769; Buddenkotte J, 2010, ALLERGY, V65, P805, DOI 10.1111/j.1398-9995.2010.01995.x; Campbell JJ, 1998, SCIENCE, V279, P381, DOI 10.1126/science.279.5349.381; Cevikbas F, 2014, J ALLERGY CLIN IMMUN, V133, P448, DOI 10.1016/j.jaci.2013.10.048; Cheung PFY, 2010, INT IMMUNOL, V22, P453, DOI 10.1093/intimm/dxq027; Davidson S, 2014, PAIN, V155, P1861, DOI 10.1016/j.pain.2014.06.017; Dhingra N, 2014, J INVEST DERMATOL, V134, P2071, DOI 10.1038/jid.2014.141; Dieu MC, 1998, J EXP MED, V188, P373, DOI 10.1084/jem.188.2.373; Dillon SR, 2004, NAT IMMUNOL, V5, P752, DOI 10.1038/ni1084; Ewald DA, 2017, J ALLERGY CLIN IMMUN, V139, P562, DOI 10.1016/j.jaci.2016.08.029; Fantini F, 1992, Exp Dermatol, V1, P127; Feld M, 2016, J ALLERGY CLIN IMMUN, V138, P500, DOI 10.1016/j.jaci.2016.02.020; Flier J, 2001, J PATHOL, V194, P398, DOI 10.1002/1096-9896(200108)194:4<397::AID-PATH899>3.0.CO;2-S; Frateschi S, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1162; GIANNETTI A, 1992, ACTA DERM-VENEREOL, P90; Giustizieri ML, 2001, J ALLERGY CLIN IMMUN, V107, P871, DOI 10.1067/mai.2001.114707; Grimstad O, 2009, EXP DERMATOL, V18, P35, DOI 10.1111/j.1600-0625.2008.00766.x; Harper JI, 2010, BRIT J DERMATOL, V162, P397, DOI 10.1111/j.1365-2133.2009.09467.x; Hawro T, 2014, ALLERGY, V69, P113, DOI 10.1111/all.12316; Kanda N, 2007, EUR J IMMUNOL, V37, P338, DOI 10.1002/eji.200636420; Kasutani K, 2014, BRIT J PHARMACOL, V171, P5049, DOI 10.1111/bph.12823; Kirkham BW, 2014, IMMUNOLOGY, V141, P133, DOI 10.1111/imm.12142; Koga C, 2008, J INVEST DERMATOL, V128, P2625, DOI 10.1038/jid.2008.111; Kolls JK, 2004, IMMUNITY, V21, P467, DOI 10.1016/j.immuni.2004.08.018; Krzysiek R, 2000, BLOOD, V96, P2338, DOI 10.1182/blood.V96.7.2338.h8002338_2338_2345; Li CL, 2016, CELL RES, V26, P83, DOI 10.1038/cr.2015.149; Li ZJ, 2016, ANN DERMATOL, V28, P579, DOI 10.5021/ad.2016.28.5.579; Liu XY, 2014, MOL PAIN, V10, DOI 10.1186/1744-8069-10-4; Malin SA, 2007, NAT PROTOC, V2, P152, DOI 10.1038/nprot.2006.461; Marchenkova A, 2015, MOL PAIN, V11, DOI 10.1186/s12990-015-0074-6; Matsukawa N, 1999, P NATL ACAD SCI USA, V96, P7403, DOI 10.1073/pnas.96.13.7403; Meng JH, 2007, J CELL SCI, V120, P2864, DOI 10.1242/jcs.012211; Meng JH, 2015, BBA-REV CANCER, V1856, P1, DOI 10.1016/j.bbcan.2015.04.002; Meng JH, 2009, J NEUROSCI, V29, P4981, DOI 10.1523/JNEUROSCI.5490-08.2009; Michels GM, 2016, VET DERMATOL, V27, P505, DOI 10.1111/vde.12364; Mishra SK, 2013, SCIENCE, V340, P968, DOI 10.1126/science.1233765; Morita R, 2003, J IMMUNOL, V170, P5869, DOI 10.4049/jimmunol.170.12.5869; Neumann S, 1996, NATURE, V384, P360, DOI 10.1038/384360a0; Oetjen LK, 2017, CELL, V171, P217, DOI 10.1016/j.cell.2017.08.006; Oh MH, 2013, J IMMUNOL, V191, P5371, DOI 10.4049/jimmunol.1300300; Pitake S, 2017, MOL PAIN, V13, DOI 10.1177/1744806917736993; Raap U, 2012, PEDIAT ALLERG IMM-UK, V23, P285, DOI 10.1111/j.1399-3038.2011.01241.x; Roosterman D, 2006, PHYSIOL REV, V86, P1309, DOI 10.1152/physrev.00026.2005; Ruzicka T, 2017, NEW ENGL J MED, V376, P2093, DOI 10.1056/NEJMc1704013; Ruzicka T, 2017, NEW ENGL J MED, V376, P826, DOI 10.1056/NEJMoa1606490; Sonkoly E, 2006, J ALLERGY CLIN IMMUN, V117, P411, DOI 10.1016/j.jaci.2005.10.033; Stander S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010968; Steinhoff M, 2006, J INVEST DERMATOL, V126, P1705, DOI 10.1038/sj.jid.5700231; Steinhoff M, 2012, J ALLERGY CLIN IMMUN, V130, P1015, DOI 10.1016/j.jaci.2012.08.006; Toda M, 2003, J ALLERGY CLIN IMMUN, V111, P875, DOI 10.1067/mai.2003.1414; Weidinger S, 2016, LANCET, V387, P1109, DOI 10.1016/S0140-6736(15)00149-X; Yu JH, 2017, LIFE SCI, V180, P17, DOI 10.1016/j.lfs.2017.04.019; Zhang FX, 2010, J NEUROSCI, V30, P10927, DOI 10.1523/JNEUROSCI.0657-10.2010	60	76	85	0	23	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2018	141	5					1677	+		10.1016/j.jaci.2017.12.1002	http://dx.doi.org/10.1016/j.jaci.2017.12.1002			21	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GF7KX	29427643	Bronze			2022-12-18	WOS:000432148200015
J	Bagci, IS; Ruzicka, T				Bagci, Isin Sinem; Ruzicka, Thomas			IL-31: A new key player in dermatology and beyond	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-31; receptors; interleukins; cytokines; pruritus; atopic eczema	ONCOSTATIN-M RECEPTOR; CHRONIC SPONTANEOUS URTICARIA; CLIENT-OWNED DOGS; ATOPIC-DERMATITIS; SERUM IL-31; SIGNAL-TRANSDUCTION; INTERLEUKIN 31; T-CELLS; LOKIVETMAB ZTS-00103289; MONOCLONAL-ANTIBODY	IL-31 is a novel cytokine expressed in many human tissues and involved mainly in T(H)2-weighted inflammation. IL-31 signals through a receptor complex consisting of IL-31 receptor a and oncostatin M receptor b. The available data show that IL-31 is strongly linked with chronic pruritic skin disorders, such as atopic eczema, and represents a novel target for directed drug therapy. Regulation of immune responses and cellular differentiation and proliferation are recently elucidated effects of IL-31, suggesting a more complex and diverse area of effect for this novel cytokine. This review summarizes the current knowledge on IL-31 and its receptors and the involvement of IL-31 in diseases both in human subjects and mouse models.	[Bagci, Isin Sinem; Ruzicka, Thomas] Ludwig Maximilians Univ Munchen, Dept Dermatol & Allergol, Frauenlobstr 9-11, D-80337 Munich, Germany	University of Munich	Bagci, IS (corresponding author), Ludwig Maximilians Univ Munchen, Dept Dermatol & Allergol, Frauenlobstr 9-11, D-80337 Munich, Germany.	Bagci.Isin_Sinem@med.uni-muenchen.de	BAGCI, ISIN/AAU-8312-2021	Bagci, Isin Sinem/0000-0002-9254-8588	Chugai Company	Chugai Company	T. Ruzicka has received consulting fees, travel support, and fees for participation in review activities from Chugai Company and has consultant arrangements with Galderma, Dermtreat, and Sebapharma. I. S. Bagci declares no relevant conflicts of interest.	Akdis M, 2016, J ALLERGY CLIN IMMUN, V138, P984, DOI 10.1016/j.jaci.2016.06.033; Altrichter S, 2016, J EUR ACAD DERMATOL, V30, P454, DOI 10.1111/jdv.12831; Arai I, 2013, EXP DERMATOL, V22, P669, DOI 10.1111/exd.12222; Arita K, 2008, AM J HUM GENET, V82, P73, DOI 10.1016/j.ajhg.2007.09.002; Bando T, 2006, NEUROSCIENCE, V142, P1263, DOI 10.1016/j.neuroscience.2006.07.009; Biedermann T, 2015, FRONT IMMUNOL, V6, P1, DOI 10.3389/fimmu.2015.00353; Bilsborough J, 2006, J ALLERGY CLIN IMMUN, V117, P418, DOI 10.1016/j.jaci.2005.10.046; Bilsborough J, 2010, J IMMUNOL, V185, P6023, DOI 10.4049/jimmunol.0902769; Bonciani D, 2017, J DERMATOL SCI, V87, P210, DOI 10.1016/j.jdermsci.2017.04.008; Cevikbas F, 2014, J ALLERGY CLIN IMMUN, V133, P448, DOI 10.1016/j.jaci.2013.10.048; Chai RN, 2017, IMMUNOTHERAPY-UK, V9, P331, DOI 10.2217/imt-2016-0131; Chattopadhyay S, 2007, J BIOL CHEM, V282, P3014, DOI 10.1074/jbc.M609655200; Chen DR, 2008, J PATHOL, V215, P290, DOI 10.1002/path.2361; Cheung PFY, 2010, INT IMMUNOL, V22, P453, DOI 10.1093/intimm/dxq027; Cornelissen C, 2011, BRIT J DERMATOL, V165, P966, DOI 10.1111/j.1365-2133.2011.10487.x; Cornelissen C, 2012, EUR J CELL BIOL, V91, P552, DOI 10.1016/j.ejcb.2011.07.006; Dambacher J, 2007, GUT, V56, P1257, DOI 10.1136/gut.2006.118679; Davidi S, 2017, ONCOTARGET, V8, P16430, DOI 10.18632/oncotarget.14857; Dillon SR, 2004, NAT IMMUNOL, V5, P752, DOI 10.1038/ni1084; Diveu C, 2003, J BIOL CHEM, V278, P49850, DOI 10.1074/jbc.M307286200; Diveu C, 2004, EUR CYTOKINE NETW, V15, P291; Dreuw A, 2004, J BIOL CHEM, V279, P36112, DOI 10.1074/jbc.M401122200; Ezzat MHM, 2011, J EUR ACAD DERMATOL, V25, P334, DOI 10.1111/j.1468-3083.2010.03794.x; Feld M, 2016, J ALLERGY CLIN IMMUN, V138, P500, DOI 10.1016/j.jaci.2016.02.020; Ferretti E, 2015, LEUKEMIA, V29, P958, DOI 10.1038/leu.2014.291; Ghilardi N, 2002, J BIOL CHEM, V277, P16831, DOI 10.1074/jbc.M201140200; Ginaldi L, 2015, BMC IMMUNOL, V16, DOI 10.1186/s12865-015-0125-9; Gonzales AJ, 2013, VET DERMATOL, V24, P48, DOI 10.1111/j.1365-3164.2012.01098.x; Grimstad O, 2009, EXP DERMATOL, V18, P35, DOI 10.1111/j.1600-0625.2008.00766.x; GROVES RW, 1995, P NATL ACAD SCI USA, V92, P11874, DOI 10.1073/pnas.92.25.11874; Hanel KH, 2016, J IMMUNOL, V196, P3233, DOI 10.4049/jimmunol.1402943; Hartmann K, 2013, J ALLERGY CLIN IMMUN, V132, P232, DOI 10.1016/j.jaci.2012.11.008; Hawro T, 2014, ALLERGY, V69, P113, DOI 10.1111/all.12316; Hermanns HM, 2015, CYTOKINE GROWTH F R, V26, P545, DOI 10.1016/j.cytogfr.2015.07.006; Hermanns HM, 2000, J BIOL CHEM, V275, P40742, DOI 10.1074/jbc.M005408200; Hong CH, 2012, ACTA DERM-VENEREOL, V92, P430, DOI 10.2340/00015555-1203; Ip WK, 2007, IMMUNOLOGY, V122, P532, DOI 10.1111/j.1365-2567.2007.02668.x; Kabashima K, 2017, 75 ANN M AM AC DERM; Kasraie S, 2011, ALLERGY, V66, P845, DOI 10.1111/j.1398-9995.2011.02545.x; Kausar T, 2011, CELL ONCOL, V34, P177, DOI 10.1007/s13402-011-0011-2; Kim EJ, 2005, J CLIN INVEST, V115, P798, DOI 10.1172/JCI200524826; Kunsleben N, 2015, J INVEST DERMATOL, V135, P1908, DOI 10.1038/jid.2015.106; Lan CCE, 2011, EXP DERMATOL, V20, P975, DOI 10.1111/j.1600-0625.2011.01374.x; Lange M, 2017, ACTA DERM-VENEREOL, V97, P47, DOI 10.2340/00015555-2474; Lei Z, 2008, ALLERGY, V63, P327, DOI 10.1111/j.1398-9995.2007.01566.x; Leung DYM, 2003, LANCET, V361, P151, DOI 10.1016/S0140-6736(03)12193-9; Lewis KE, 2017, J EUR ACAD DERMATOL, V31, P142, DOI 10.1111/jdv.13794; Lin MW, 2010, EUR J HUM GENET, V18, P26, DOI 10.1038/ejhg.2009.135; Liu WL, 2015, PEDIATR RES, V77, P20, DOI 10.1038/pr.2014.151; Maier E, 2015, J BIOL CHEM, V290, P24747, DOI 10.1074/jbc.M115.661306; Maier E, 2014, J IMMUNOL, V193, P645, DOI 10.4049/jimmunol.1301836; McCandless EE, 2014, VET IMMUNOL IMMUNOP, V157, P42, DOI 10.1016/j.vetimm.2013.10.017; Michels GM, 2016, VET DERMATOL, V27, P505, DOI 10.1111/vde.12364; Miyakawa Y, 2001, J BIOL CHEM, V276, P2494, DOI 10.1074/jbc.M002633200; Nattkemper LA, 2016, ACTA DERM-VENEREOL, V96, P894, DOI 10.2340/00015555-2417; Naumnik W., 2012, Experimental Oncology, V34, P348; Neis MM, 2006, J ALLERGY CLIN IMMUN, V118, P930, DOI 10.1016/j.jaci.2006.07.015; Nemoto O, 2016, BRIT J DERMATOL, V174, P296, DOI 10.1111/bjd.14207; Niyonsaba F, 2010, J IMMUNOL, V184, P3526, DOI 10.4049/jimmunol.0900712; Nobbe S, 2012, ACTA DERM-VENEREOL, V92, P24, DOI 10.2340/00015555-1191; Nygaard U, 2016, J EUR ACAD DERMATOL, V30, P1930, DOI 10.1111/jdv.13679; O'Shaughnessy RFL, 2010, HUM MOL GENET, V19, P2594, DOI 10.1093/hmg/ddq145; Ohmatsu H, 2012, ACTA DERM-VENEREOL, V92, P282, DOI 10.2340/00015555-1345; Perrigoue JG, 2009, J IMMUNOL, V182, P6088, DOI 10.4049/jimmunol.0802459; Raap U, 2017, CLIN EXP ALLERGY, V47, P499, DOI 10.1111/cea.12875; Raap U, 2008, J ALLERGY CLIN IMMUN, V122, P421, DOI 10.1016/j.jaci.2008.05.047; Raap U, 2012, PEDIAT ALLERG IMM-UK, V23, P285, DOI 10.1111/j.1399-3038.2011.01241.x; Raap U, 2010, EXP DERMATOL, V19, P464, DOI 10.1111/j.1600-0625.2010.01067.x; Ruzicka T, 2017, NEW ENGL J MED, V376, P826, DOI 10.1056/NEJMoa1606490; Saito S, 2017, ALLERGY ASTHMA CL IM, V13, DOI 10.1186/s13223-017-0194-9; Schulz F, 2007, J ALLERGY CLIN IMMUN, V120, P1097, DOI 10.1016/j.jaci.2007.07.065; Singer EM, 2013, J INVEST DERMATOL, V133, P2783, DOI 10.1038/jid.2013.227; Sokol CL, 2008, NAT IMMUNOL, V9, P310, DOI 10.1038/ni1558; Sonkoly E, 2006, J ALLERGY CLIN IMMUN, V117, P411, DOI 10.1016/j.jaci.2005.10.033; Steinhoff M, 2003, J NEUROSCI, V23, P6176; Stott B, 2013, J ALLERGY CLIN IMMUN, V132, P446, DOI 10.1016/j.jaci.2013.03.050; Szegedi K, 2012, EXP DERMATOL, V21, P431, DOI 10.1111/j.1600-0625.2012.01487.x; Takaoka A, 2005, EUR J PHARMACOL, V516, P180, DOI 10.1016/j.ejphar.2005.04.040; Tamura S, 2003, EUR J NEUROSCI, V17, P2287, DOI 10.1046/j.1460-9568.2003.02681.x; Tanaka T, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a016295; Tey HL, 2016, BRIT J DERMATOL, V174, P1345, DOI 10.1111/bjd.14391; Yagi Y, 2007, INT J MOL MED, V19, P941; Yamaoka K, 2009, INT ARCH ALLERGY IMM, V149, P73, DOI 10.1159/000211376; Yu JI, 2012, KOREAN J PATHOL, V46, P162, DOI 10.4132/KoreanJPathol.2012.46.2.162; Zeng X, 2016, DIS MARKERS, V2016, DOI 10.1155/2016/9262919; Zhang Q, 2008, CYTOKINE GROWTH F R, V19, P347, DOI 10.1016/j.cytogfr.2008.08.003	86	76	79	8	21	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2018	141	3					858	866		10.1016/j.jaci.2017.10.045	http://dx.doi.org/10.1016/j.jaci.2017.10.045			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FY6PR	29366565	Bronze			2022-12-18	WOS:000426974800003
J	Muniz, VS; Silva, JC; Braga, YAV; Melo, RCN; Ueki, S; Takeda, M; Hebisawa, A; Asano, K; Figueiredo, RT; Neves, JS				Muniz, Valdirene S.; Silva, Juliana C.; Braga, Yasmim A. V.; Melo, Rossana C. N.; Ueki, Shigeharu; Takeda, Masahide; Hebisawa, Akira; Asano, Koichiro; Figueiredo, Rodrigo T.; Neves, Josiane S.			Eosinophils release extracellular DNA traps in response to Aspergillus fumigatus	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Eosinophil; extracellular DNA traps; allergic bronchopulmonary aspergillosis; inflammation	ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; NADPH OXIDASE; CANDIDA-ALBICANS; ANTIMICROBIAL ACTIVITY; STAPHYLOCOCCUS-AUREUS; MITOCHONDRIAL-DNA; GRANULES; MYELOPEROXIDASE; CONTRIBUTES; MECHANISMS	Background: Eosinophils mediate the immune response in different infectious conditions. The release of extracellular DNA traps (ETs) by leukocytes has been described as an innate immune response mechanism that is relevant in many disorders including fungal diseases. Different stimuli induce the release of human eosinophil ETs (EETs). Aspergillus fumigatus is an opportunistic fungus that may cause eosinophilic allergic bronchopulmonary aspergillosis (ABPA). It has been reported that eosinophils are important to the clearance of A fumigatus in infected mice lungs. However, the immunological mechanisms that underlie the molecular interactions between A fumigatus and eosinophils are poorly understood. Objective: Here, we investigated the presence of EETs in the bronchial mucus plugs of patients with ABPA. We also determined whether A fumigatus induced the release of human eosinophil EETs in vitro. Methods: Mucus samples of patients with ABPA were analyzed by light and confocal fluorescence microscopy. The release of EETs by human blood eosinophils was evaluated using different pharmacological tools and neutralizing antibodies by fluorescence microscopy and a fluorimetric method. Results: We identified abundant nuclear histone-bearing EETs in the bronchial secretions obtained from patients with ABPA. In vitro, we demonstrated that A fumigatus induces the release of EETs through a mechanism independent of reactive oxygen species but associated with eosinophil death, histone citrullination, CD11b, and the Syk tyrosine kinase pathway. EETs lack the killing or fungistatic activities against A fumigatus. Conclusions: Our findings may contribute to the understanding of how eosinophils recognize and act as immune cells in response to A fumigatus, which may lead to novel insights regarding the treatment of patients with ABPA.	[Muniz, Valdirene S.; Neves, Josiane S.] Univ Fed Rio de Janeiro, Inst Biomed Sci, 373 Carlos Chagas Filho Ave, Rio De Janeiro, RJ, Brazil; [Silva, Juliana C.; Braga, Yasmim A. V.] Univ Fed Rio de Janeiro, Inst Microbiol Paulo de Goes, Inst Biomed Sci, Rio De Janeiro, Brazil; [Melo, Rossana C. N.] Univ Fed Rio de Janeiro, Inst Biol Sci, Dept Biol, Lab Cellular Biol, Juiz De Fora, Brazil; [Ueki, Shigeharu; Takeda, Masahide] Akita Univ, Dept Gen Internal Med & Clin Lab Med, Grad Sch Med, Akita, Japan; [Hebisawa, Akira] Tokyo Natl Hosp, Clin Res Ctr, Natl Hosp Org, Tokyo, Japan; [Hebisawa, Akira] Tokyo Natl Hosp, Pathol Div, Natl Hosp Org, Tokyo, Japan; [Asano, Koichiro] Tokai Univ, Div Pulm Med, Dept Med, Sch Med, Hiratsuka, Kanagawa, Japan; [Figueiredo, Rodrigo T.] Univ Fed Rio de Janeiro, Unit Xerem, Inst Biomed Sci, Rio De Janeiro, Brazil	Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro; Akita University; Tokai University; Universidade Federal do Rio de Janeiro	Neves, JS (corresponding author), Univ Fed Rio de Janeiro, Inst Biomed Sci, 373 Carlos Chagas Filho Ave, Rio De Janeiro, RJ, Brazil.	jneves@icb.ufrj.br	Muniz, Valdirene/AAW-3833-2021; Ueki, Shigeharu/I-3566-2019; Melo, Rossana C. N./B-8248-2013; Neves, Josiane S/C-3102-2009; Neves, Josiane Sabbadini/X-9801-2019; Figueiredo, Rodrigo/F-5176-2016	Ueki, Shigeharu/0000-0002-3537-7735; Melo, Rossana C. N./0000-0003-1736-0806; Neves, Josiane Sabbadini/0000-0002-6645-1715; da Costa Silva, Juliana/0000-0003-2516-0679; Figueiredo, Rodrigo/0000-0002-7551-8782; Muniz, Valdirene S/0000-0003-0102-2861	Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ); Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq); Research Grant on Allergic Disease and Immunology from the Japan Agency for Medical Research and Development; Charitable Trust Laboratory Medicine Research Foundation of Japan; JSPS [15KK0329, 16K08926]	Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ)(Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio De Janeiro (FAPERJ)); Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG)(Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG)); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Research Grant on Allergic Disease and Immunology from the Japan Agency for Medical Research and Development(Japan Agency for Medical Research and Development (AMED)); Charitable Trust Laboratory Medicine Research Foundation of Japan; JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	This study was funded by the Brazilian agencies Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ), Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG), Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES), and Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq). It was also funded by the Research Grant on Allergic Disease and Immunology from the Japan Agency for Medical Research and Development, Charitable Trust Laboratory Medicine Research Foundation of Japan, and JSPS (grant numbers 15KK0329 and 16K08926).	Arai Y, 2014, BIOCHEM BIOPH RES CO, V443, P556, DOI 10.1016/j.bbrc.2013.12.007; Berends ETM, 2010, J INNATE IMMUN, V2, P576, DOI 10.1159/000319909; BOSKEN CH, 1988, AM J SURG PATHOL, V12, P216, DOI 10.1097/00000478-198803000-00007; Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385; Bruns S, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000873; Byrd AS, 2013, J IMMUNOL, V190, P4136, DOI 10.4049/jimmunol.1202671; Chow OA, 2010, CELL HOST MICROBE, V8, P445, DOI 10.1016/j.chom.2010.10.005; de Buhr N, 2014, MICROBIOL-SGM, V160, P385, DOI 10.1099/mic.0.072199-0; Denning DW, 2006, EUR RESPIR J, V27, P615, DOI 10.1183/09031936.06.00074705; Douda DN, 2015, P NATL ACAD SCI USA, V112, P2817, DOI 10.1073/pnas.1414055112; Gabriel C, 2010, J IMMUNOL, V185, P4319, DOI 10.4049/jimmunol.1000893; Gazendam RP, 2016, J IMMUNOL, V196, P1272, DOI 10.4049/jimmunol.1501811; Greenberger PA, 2002, J ALLERGY CLIN IMMUN, V110, P685, DOI 10.1067/mai.2002.130179; Hosseinzadeh A, 2016, J LEUKOCYTE BIOL, V100, P1105, DOI 10.1189/jlb.3AB0815-379RR; Jakus Z, 2007, TRENDS CELL BIOL, V17, P493, DOI 10.1016/j.tcb.2007.09.001; Kenno S, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00879; Kerrigan AM, 2010, IMMUNOL REV, V234, P335, DOI 10.1111/j.0105-2896.2009.00882.x; Kita H, 2011, IMMUNOL REV, V242, P161, DOI 10.1111/j.1600-065X.2011.01026.x; Lappann M, 2013, MOL MICROBIOL, V89, P433, DOI 10.1111/mmi.12288; Latge JP, 1999, CLIN MICROBIOL REV, V12, P310, DOI 10.1128/CMR.12.2.310; Lilly LM, 2014, INFECT IMMUN, V82, P1315, DOI 10.1128/IAI.01172-13; Lin AM, 2011, J IMMUNOL, V187, P490, DOI 10.4049/jimmunol.1100123; McCormick A, 2010, MICROBES INFECT, V12, P928, DOI 10.1016/j.micinf.2010.06.009; Mejia SP, 2015, MICROBIOL-SGM, V161, P1008, DOI 10.1099/mic.0.000059; MESHULAM T, 1995, J INFECT DIS, V172, P1153, DOI 10.1093/infdis/172.4.1153; Moorthy AN, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00056; Morshed M, 2012, ALLERGY, V67, P1127, DOI 10.1111/j.1398-9995.2012.02868.x; Muniz VS, 2013, INT ARCH ALLERGY IMM, V162, P276, DOI 10.1159/000354934; Muniz VS, 2012, J LEUKOCYTE BIOL, V92, P281, DOI 10.1189/jlb.0212067; Neves JS, 2009, J IMMUNOL METHODS, V344, P64, DOI 10.1016/j.jim.2009.03.006; Papayannopoulos V, 2010, J CELL BIOL, V191, P677, DOI 10.1083/jcb.201006052; Parker H, 2012, J LEUKOCYTE BIOL, V92, P841, DOI 10.1189/jlb.1211601; Pilsczek FH, 2010, J IMMUNOL, V185, P7413, DOI 10.4049/jimmunol.1000675; Ponikau JU, 2006, CLIN REV ALLERG IMMU, V30, P187, DOI 10.1385/CRIAI:30:3:187; Remijsen Q, 2011, CELL RES, V21, P290, DOI 10.1038/cr.2010.150; Rohm M, 2014, INFECT IMMUN, V82, P1766, DOI 10.1128/IAI.00096-14; Rohrbach AS, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00360; Shah A, 2002, J ASTHMA, V39, P273, DOI 10.1081/JAS-120002284; Short KR, 2014, INFECT IMMUN, V82, P364, DOI 10.1128/IAI.01104-13; Spencer LA, 2010, IMMUNOL CELL BIOL, V88, P250, DOI 10.1038/icb.2009.115; Springer DJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010978; Steele C, 2005, PLOS PATHOG, V1, P323, DOI 10.1371/journal.ppat.0010042; Ueki S, 2016, CURR ALLERGY ASTHM R, V16, DOI 10.1007/s11882-016-0634-5; Ueki S, 2016, J ALLERGY CLIN IMMUN, V137, P258, DOI 10.1016/j.jaci.2015.04.041; Ueki S, 2013, BLOOD, V121, P2074, DOI 10.1182/blood-2012-05-432088; Urban CF, 2006, CELL MICROBIOL, V8, P668, DOI 10.1111/j.1462-5822.2005.00659.x; van Bruggen R, 2009, MOL IMMUNOL, V47, P575, DOI 10.1016/j.molimm.2009.09.018; Willment JA, 2005, EUR J IMMUNOL, V35, P1539, DOI 10.1002/eji.200425725; Yipp BG, 2012, NAT MED, V18, P1386, DOI 10.1038/nm.2847; Yoon J, 2008, J IMMUNOL, V181, P2907, DOI 10.4049/jimmunol.181.4.2907; Yousefi S, 2009, CELL DEATH DIFFER, V16, P1438, DOI 10.1038/cdd.2009.96; Yousefi S, 2008, NAT MED, V14, P949, DOI 10.1038/nm.1855	52	76	77	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2018	141	2					571	+		10.1016/j.jaci.2017.07.048	http://dx.doi.org/10.1016/j.jaci.2017.07.048			22	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FV2PQ	28943470				2022-12-18	WOS:000424410800014
J	Hussain, M; Borcard, L; Walsh, KP; Rodriguez, MP; Mueller, C; Kim, BS; Kubo, M; Artis, D; Noti, M				Hussain, Maryam; Borcard, Loic; Walsh, Kevin P.; Rodriguez, Maria Pena; Mueller, Christoph; Kim, Brian S.; Kubo, Masato; Artis, David; Noti, Mario			Basophil-derived IL-4 promotes epicutaneous antigen sensitization concomitant with the development of food allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IgE-mediated food allergy; atopic dermatitis; epicutaneous sensitization; T(H)2 polarization; thymic stromal lymphopoietin; basophils; mast cells; IgE; IL-4	ATOPIC-DERMATITIS; TYPE-2 IMMUNITY; MAST-CELLS; INFLAMED SKIN; MURINE MODEL; IN-VIVO; INFLAMMATION; EOSINOPHILS; RESPONSES; IGE	Background: Exaggerated thymic stromal lymphopoietin (TSLP) production and infiltration of basophils are associated with the pathogenesis of atopic dermatitis (AD), a recognized risk factor for the development of food allergies. Although TSLP and basophils have been implicated in promotion of food-induced allergic disorders in response to epicutaneous sensitization, the mechanisms by which TSLP-elicited basophils guide the progression of allergic inflammation in the skin to distant mucosal sites, such as the gastrointestinal tract, are poorly understood. Objective: We sought to test the role of basophil-intrinsic IL-4 production in TH2 sensitization to food antigens in the skin and effector food-induced allergic responses in the gut. Methods: Mice were epicutaneously sensitized with ovalbumin on an AD-like skin lesion, followed by intragastric antigen challenge to induce IgE-mediated food allergy. The requirement for basophil-derived IL-4 production for TH2 polarization and the pathogenesis of IgE-mediated food allergy was assessed in vitro by using coculture experiments with naive T cells and in vivo by using Il4 3'UTR mice that selectively lack IL-4 production in basophils. Results: Epicutaneous food antigen sensitization is associated with infiltration of IL-4-competent innate immune cells to the skin, with basophils and eosinophils representing the predominant populations. In contrast to basophils, absence of eosinophils did not alter disease outcome. Coculture of IL-4-competent basophils together with dendritic cells and naive T cells was sufficient to promote TH2 polarization in an IL-4-dependent manner in vitro, whereas absence of basophil-intrinsic IL-4 production in vivo was associated with reduced food-induced allergic responses. Conclusion: TSLP-elicited basophils promote epicutaneous sensitization to food antigens and subsequent IgE-mediated food allergy through IL-4. Strategies to target the TSLP-basophil-IL-4 axis in patients with AD might lead to innovative therapies that can prevent the progression of allergies to distant mucosal sites.	[Hussain, Maryam; Borcard, Loic; Rodriguez, Maria Pena; Mueller, Christoph; Noti, Mario] Univ Bern, Inst Pathol, Div Expt Pathol, CH-3008 Bern, Switzerland; [Hussain, Maryam] Univ Bern, Grad Sch Cellular & Biomed Sci, Bern, Switzerland; [Walsh, Kevin P.] Univ Penn, Dept Microbiol, Perelman Sch Med, Philadelphia, PA 19104 USA; [Kim, Brian S.] Washington Univ, Sch Med, Dept Med, Div Dermatol, St Louis, MO 63110 USA; [Kubo, Masato] Tokyo Univ Sci, Div Mol Pathol, Res Inst Biomed Sci, RIKEN,Ctr Integrat Med Sci IMS,Yokohama Inst,Lab, Noda, Chiba, Japan; [Artis, David] Cornell Univ, Dept Microbiol & Immunol, Weill Cornell Med Coll, Jill Roberts Inst Res Inflammatory Bowel Dis,Joan, Ithaca, NY 14853 USA	University of Bern; University of Bern; University of Pennsylvania; Pennsylvania Medicine; Washington University (WUSTL); RIKEN; Tokyo University of Science; Cornell University	Noti, M (corresponding author), Univ Bern, Inst Pathol, Div Expt Pathol, CH-3008 Bern, Switzerland.	mario.noti@pathology.unibe.ch	Kim, Brian/GZK-6649-2022; Noti, Mario/I-6581-2019; Mueller, Christoph/F-2233-2014	Kim, Brian/0000-0002-8100-7161; Noti, Mario/0000-0001-9386-1245; Mueller, Christoph/0000-0002-3921-8678; Artis, David/0000-0002-1753-4100	Swiss National Science Foundation [PZ00P3_154777]; Olga Mayenfisch Stiftung; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K08AR065577, R01AR070116] Funding Source: NIH RePORTER; Grants-in-Aid for Scientific Research [15H01267] Funding Source: KAKEN	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Olga Mayenfisch Stiftung; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	Research in the Noti laboratory is supported by the Swiss National Science Foundation (PZ00P3_154777 to M.N.) and the Olga Mayenfisch Stiftung (to M.N.).	Bartnikas LM, 2013, J ALLERGY CLIN IMMUN, V131, P451, DOI 10.1016/j.jaci.2012.11.032; Beck LA, 2014, NEW ENGL J MED, V371, P130, DOI 10.1056/NEJMoa1314768; Berin MC, 2015, CLIN EXP ALLERGY, V45, P1483, DOI 10.1111/cea.12598; Berin MC, 2009, MUCOSAL IMMUNOL, V2, P24, DOI 10.1038/mi.2008.72; Brandt EB, 2009, J ALLERGY CLIN IMMUN, V123, P53, DOI 10.1016/j.jaci.2008.10.001; Brough HA, 2015, J ALLERGY CLIN IMMUN, V135, P164, DOI 10.1016/j.jaci.2014.10.007; Burks AW, 2012, J ALLERGY CLIN IMMUN, V129, P906, DOI 10.1016/j.jaci.2012.02.001; Burton OT, 2013, MUCOSAL IMMUNOL, V6, P740, DOI 10.1038/mi.2012.112; Caubet JC, 2014, PEDIAT ALLERG IMM-UK, V25, P243, DOI 10.1111/pai.12207; Cheng LE, 2015, J EXP MED, V212, P513, DOI 10.1084/jem.20141671; Chinthrajah RS, 2016, J ALLERGY CLIN IMMUN, V137, P984, DOI 10.1016/j.jaci.2016.02.004; Chu DK, 2014, J EXP MED, V211, P1657, DOI 10.1084/jem.20131800; Gessner A, 2005, J IMMUNOL, V174, P1063, DOI 10.4049/jimmunol.174.2.1063; Ghazi A, 2012, EXPERT OPIN BIOL TH, V12, P113, DOI 10.1517/14712598.2012.642359; Giacomin PR, 2012, J IMMUNOL, V189, P4371, DOI 10.4049/jimmunol.1200691; Hadley C, 2006, EMBO REP, V7, P1080, DOI 10.1038/sj.embor.7400846; Han H, 2012, MUCOSAL IMMUNOL, V5, P342, DOI 10.1038/mi.2012.14; Han HW, 2014, J CLIN INVEST, V124, P5442, DOI 10.1172/JCI77798; Hussain M, 2016, DRUG DISCOV TODAY DI, V17-18, P55; Karasuyama H, 2011, ANNU REV IMMUNOL, V29, P45, DOI 10.1146/annurev-immunol-031210-101257; Kim BS, 2014, J IMMUNOL, V193, P3717, DOI 10.4049/jimmunol.1401307; Kim BS, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005374; Lacy P, 2011, BLOOD, V118, P9, DOI 10.1182/blood-2010-08-265892; Laviolette M, 2013, J ALLERGY CLIN IMMUN, V132, P1086, DOI 10.1016/j.jaci.2013.05.020; Leyva-Castillo JM, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3847; Leyva-Castillo JM, 2013, J INVEST DERMATOL, V133, P154, DOI 10.1038/jid.2012.239; Min B, 2004, J EXP MED, V200, P507, DOI 10.1084/jem.20040590; Moghaddam AE, 2014, J ALLERGY CLIN IMMUN, V134, P1453, DOI 10.1016/j.jaci.2014.07.032; Mohrs M, 2001, IMMUNITY, V15, P303, DOI 10.1016/S1074-7613(01)00186-8; Motomura Y, 2014, IMMUNITY, V40, P758, DOI 10.1016/j.immuni.2014.04.013; Muto T, 2014, INT IMMUNOL, V26, P539, DOI 10.1093/intimm/dxu058; Nakashima C, 2014, J ALLERGY CLIN IMMUN, V134, P100, DOI 10.1016/j.jaci.2014.02.026; Noti M, 2014, J ALLERGY CLIN IMMUN, V133, P1390, DOI 10.1016/j.jaci.2014.01.021; Noti M, 2013, NAT MED, V19, P1005, DOI 10.1038/nm.3281; Oetjen LK, 2016, SEMIN IMMUNOPATHOL, V38, P549, DOI 10.1007/s00281-016-0567-z; Oh K, 2007, BLOOD, V109, P2921, DOI 10.1182/blood-2006-07-037739; Otsuka A, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2740; Paul WE, 2010, NAT REV IMMUNOL, V10, P225, DOI 10.1038/nri2735; Pelly VS, 2016, MUCOSAL IMMUNOL, V9, P1407, DOI 10.1038/mi.2016.4; Pulendran B, 2012, SCIENCE, V337, P431, DOI 10.1126/science.1221064; Rivas MN, 2016, J ALLERGY CLIN IMMUN, V138, P801, DOI 10.1016/j.jaci.2016.02.030; Roediger B, 2013, NAT IMMUNOL, V14, P564, DOI 10.1038/ni.2584; Schroeder JT, 2001, J ALLERGY CLIN IMMUN, V107, P265, DOI 10.1067/mai.2001.112846; Sicherer SH, 2014, J ALLERGY CLIN IMMUN, V133, P291, DOI 10.1016/j.jaci.2013.11.020; Siracusa MC, 2011, NATURE, V477, P229, DOI 10.1038/nature10329; Stone KD, 2010, J ALLERGY CLIN IMMUN, V125, pS73, DOI 10.1016/j.jaci.2009.11.017; Sullivan BM, 2009, IMMUNITY, V30, P12, DOI 10.1016/j.immuni.2008.12.006; Thaci D, 2016, LANCET, V387, P40, DOI 10.1016/S0140-6736(15)00388-8; Tsakok T, 2016, J ALLERGY CLIN IMMUN, V137, P1071, DOI 10.1016/j.jaci.2015.10.049; van Gisbergen KPJM, 2005, J EXP MED, V201, P1281, DOI 10.1084/jem.20041276; Voehringer D, 2004, IMMUNITY, V20, P267, DOI 10.1016/S1074-7613(04)00026-3; Wakahara K, 2013, ALLERGY, V68, P180, DOI 10.1111/all.12072; Wenzel S, 2016, LANCET, V388, P31, DOI 10.1016/S0140-6736(16)30307-5	53	76	78	3	30	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2018	141	1					223	+		10.1016/j.jaci.2017.02.035	http://dx.doi.org/10.1016/j.jaci.2017.02.035			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FR8GH	28390860	Bronze			2022-12-18	WOS:000419312200028
J	Gevaert, E; Zhang, N; Krysko, O; Lan, F; Holtappels, G; De Ruyck, N; Nauwynck, H; Yousefi, S; Simon, HU; Bachert, C				Gevaert, Elien; Zhang, Nan; Krysko, Olga; Lan, Feng; Holtappels, Gabriele; De Ruyck, Natalie; Nauwynck, Hans; Yousefi, Shida; Simon, Hans-Uwe; Bachert, Claus			Extracellular eosinophilic traps in association with Staphylococcus aureus at the site of epithelial barrier defects in patients with severe airway inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chronic rhinosinusitis; polyps; Staphylococcus aureus; eosinophils; epithelial barrier; extracellular eosinophilic traps	CHRONIC RHINOSINUSITIS; DNA TRAPS; NASAL POLYPOSIS; DIFFERENTIATION; ENTEROTOXINS; EXPRESSION; CYTOKINES; DISEASES; PROTEIN	Background: Chronic rhinosinusitis with nasal polyps is characterized by T(H)2-biased eosinophilic inflammation. Eosinophils have been shown to generate so-called extracellular eosinophilic traps (EETs) under similar pathologic conditions. Objective: Our aim was to investigate a possible link between EET formation and the presence of Staphylococcus aureus, an organism frequently colonizing the upper airways, at the human mucosal site of the disease. Methods: Tissue slides were investigated for the presence of EETs and S aureus by using immunofluorescent staining and the PNA-Fish assay, respectively. An ex vivo human mucosal disease tissue model was used for artificial infection with S aureus. Cell markers were analyzed by using immunohistochemistry, the Luminex Multiplex assay, ELISA, PCR, and immunoblotting and linked to the presence of EETs. Results: About 8.8% +/- 4.8% of the infiltrating eosinophils exhibited EETs in patients' nasal polyp tissues. Formation of EETs was associated with increased IL-5 (P < .05) and periostin (P < .05) tissue levels and colonization with S aureus (P < .05). By using an ex vivo human mucosal disease tissue model, EET formation was induced (4.2 +/- 0.9-fold) on exposure to S aureus but not Staphylococcus epidermidis. Eosinophils were shown to migrate (P < .01) toward S aureus and entrap the bacteria both inside and outside the mucosal tissue. Blocking NAPDH oxidase activity led to a complete inhibition (P < .05) of EET formation by S aureus. Conclusion: Eosinophils are likely to be specifically recruited to S aureus and possibly other microorganisms and form EETs at sites of airway epithelial damage to protect the host from infections in patients with chronic rhinosinusitis with nasal polyps.	[Gevaert, Elien; Zhang, Nan; Krysko, Olga; Lan, Feng; Holtappels, Gabriele; De Ruyck, Natalie; Bachert, Claus] Univ Ghent, Fac Med, Upper Airways Res Lab, Ghent, Belgium; [Nauwynck, Hans] Univ Ghent, Fac Vet Med, Lab Virol, Ghent, Belgium; [Yousefi, Shida; Simon, Hans-Uwe] Univ Bern, Inst Pharmacol, Bern, Switzerland; [Bachert, Claus] Karolinska Inst, CLINTEC, Div ENT Dis, Stockholm, Sweden	Ghent University; Ghent University; University of Bern; Karolinska Institutet	Bachert, C (corresponding author), Univ Ghent, Upper Airways Res Lab, Pintelaan 185, B-9000 Ghent, Belgium.; Bachert, C (corresponding author), Univ Ghent, ENT Dept, Pintelaan 185, B-9000 Ghent, Belgium.	E-Claus.Bachert@ugent.be	Bachert, Claus/J-8825-2012; Krysko, Olga/C-2481-2009; Yousefi, Shida/AAU-7986-2020; Simon, Hans-Uwe/AAU-7410-2020; Simon, Hans-Uwe/AAU-5079-2020; Yousefi, Shida/L-9689-2016; Zhang, Nan/AAQ-3944-2020	Krysko, Olga/0000-0001-5019-0752; Yousefi, Shida/0000-0002-9855-4305; Simon, Hans-Uwe/0000-0002-9404-7736; Yousefi, Shida/0000-0002-9855-4305; Nauwynck, Hans/0000-0001-5470-0713	Fonds Wetenschappelijk Onderzoek Vlaanderen project [1515516N]; Interuniversity Attraction Poles Program; Belgian State; Belgian Science Policy-project [P7/30]; Ghent University [BOF 14-GOA-019]	Fonds Wetenschappelijk Onderzoek Vlaanderen project; Interuniversity Attraction Poles Program(Belgian Federal Science Policy Office); Belgian State; Belgian Science Policy-project; Ghent University(Ghent University)	Supported by project grants from Fonds Wetenschappelijk Onderzoek Vlaanderen project 1515516N, the Interuniversity Attraction Poles Program, Belgian State, Belgian Science Policy-project P7/30, and BOF 14-GOA-019 from Ghent University.	Bachert C, 2000, AM J RHINOL, V14, P279, DOI 10.2500/105065800781329573; Bachert C, 2010, J ALLERGY CLIN IMMUN, V126, pe1, DOI DOI 10.1016/J.JACI.2010.07.007; Bachert C, 2012, PEDIAT ALLERG IMM-UK, V23, P2, DOI 10.1111/j.1399-3038.2012.01318.x; Bachert C, 2010, J ALLERGY CLIN IMMUN, V126, P962, DOI 10.1016/j.jaci.2010.07.007; Blanchard C, 2008, MUCOSAL IMMUNOL, V1, P289, DOI 10.1038/mi.2008.15; Cunha AA, 2014, ALLERGY, V69, P1696, DOI 10.1111/all.12507; Dworski R, 2011, J ALLERGY CLIN IMMUN, V127, P1260, DOI 10.1016/j.jaci.2010.12.1103; Fokkens W, 2007, RHINOLOGY, P1; FRIGAS E, 1991, EUR RESPIR J, V4, pS123; Huvenne W, 2010, ALLERGY, V65, P1013, DOI 10.1111/j.1398-9995.2009.02313.x; Krysko O, 2011, ALLERGY, V66, P396, DOI 10.1111/j.1398-9995.2010.02498.x; Liu YJ, 2007, ANNU REV IMMUNOL, V25, P193, DOI 10.1146/annurev.immunol.25.022106.141718; Morshed M, 2012, ALLERGY, V67, P1127, DOI 10.1111/j.1398-9995.2012.02868.x; Papayannopoulos V, 2010, J CELL BIOL, V191, P677, DOI 10.1083/jcb.201006052; POPKENHARRIS P, 1994, J ALLERGY CLIN IMMUN, V94, P1282, DOI 10.1016/0091-6749(94)90343-3; Ramanathan M, 2007, AM J RHINOL, V21, P110, DOI 10.2500/ajr.2007.21.2997; Ramanathan M, 2008, AM J RHINOL, V22, P115, DOI 10.2500/ajr.2008.22.3136; Simon D, 2015, ALLERGY, V70, P443, DOI 10.1111/all.12570; Simon D, 2011, J ALLERGY CLIN IMMUN, V127, P194, DOI 10.1016/j.jaci.2010.11.002; Simon HU, 1997, J IMMUNOL, V158, P3902; Soragni A, 2015, MOL CELL, V57, P1011, DOI 10.1016/j.molcel.2015.01.026; Soyka MB, 2012, J ALLERGY CLIN IMMUN, V130, P1087, DOI 10.1016/j.jaci.2012.05.052; Ueki S, 2016, J ALLERGY CLIN IMMUN, V137, P258, DOI 10.1016/j.jaci.2015.04.041; Urban CF, 2006, CELL MICROBIOL, V8, P1687, DOI 10.1111/j.1462-5822.2006.00792.x; Van Zele T, 2006, ALLERGY, V61, P1280, DOI 10.1111/j.1398-9995.2006.01225.x; Van Zele T, 2004, J ALLERGY CLIN IMMUN, V114, P981, DOI 10.1016/j.jaci.2004.07.013; Vlaminck S, 2014, AM J RHINOL ALLERGY, V28, P260, DOI 10.2500/ajra.2014.28.4024; Wang M, 2015, J ALLERGY CLIN IMMUN, V136, P1700, DOI 10.1016/j.jaci.2015.09.005; Yousefi S, 2008, NAT MED, V14, P949, DOI 10.1038/nm.1855; Yousefi S, 2012, CURR OPIN IMMUNOL, V24, P736, DOI 10.1016/j.coi.2012.08.010; Zhang N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093754	31	76	78	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2017	139	6					1849	+		10.1016/j.jaci.2017.01.019	http://dx.doi.org/10.1016/j.jaci.2017.01.019			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EW7VG	28216437	Green Published			2022-12-18	WOS:000402724600016
J	Austin, PJ; Tsitsiou, E; Boardman, C; Jones, SW; Lindsay, MA; Adcock, IM; Chung, KF; Perry, MM				Austin, Philip J.; Tsitsiou, Eleni; Boardman, Charlotte; Jones, Simon W.; Lindsay, Mark A.; Adcock, Ian M.; Chung, Kian Fan; Perry, Mark M.			Transcriptional profiling identifies the long noncoding RNA plasmacytoma variant translocation (PVT1) as a novel regulator of the asthmatic phenotype in human airway smooth muscle	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; airway smooth muscle; proliferation; IL-6; transcriptome; long noncoding RNA; PVT1	CELL LUNG-CANCER; BREAST-CANCER; INFLAMMATION; EXPRESSION; PROTEIN; AMPLIFICATION; TARGET; GENES; PROLIFERATION; ASSOCIATION	Background: The mechanism underlying nonsevere and severe asthma remains unclear, although it is commonly associated with increased airway smooth muscle ( ASM) mass. Long noncoding RNAs ( lncRNAs) are known to be important in regulating healthy primary airway smooth muscle cells ( ASMCs), whereas changed expression has been observed in CD8 T cells from patients with severe asthma. Methods: Primary ASMCs were isolated from healthy subjects ( n = 5 9) and patients classified as having nonsevere ( n = 59) or severe ( n = 59) asthma. ASMCs were exposed to dexamethasone and FCS. mRNA and lncRNA expression was measured by using a microarray and quantitative real- time PCR. Bioinformatic analysis was used to examine relevant biological pathways. Finally, the lncRNA plasmacytoma variant translocation 1 ( PVT1) was inhibited by transfection of primary ASMCs with small interfering RNAs, and the effect on ASMC phenotype was examined. Results: The mRNA expression profile was significantly different between patient groups after exposure to dexamethasone and FCS, and these were associated with biological pathways that might be relevant to the pathogenesis of asthma, including cellular proliferation and pathways associated with glucocorticoid activity. We also observed a significant change inlncRNA expression, yet the expression of only one lncRNA( PVT1) is decreased in patients with corticosteroid- sensitive nonsevere asthma and increased in patients with corticosteroid- insensitive severe asthma. Subsequent targeting studies demonstrated the importance of this lncRNA in controlling both proliferation and IL- 6 release in ASMCs from patients with severe asthma. Conclusions: lncRNAs are associated with the aberrant phenotype observed in ASMCs from asthmatic patients. Targeting PVT1 might be effective in reducing airway remodeling in asthmatic patients.	[Austin, Philip J.; Boardman, Charlotte; Lindsay, Mark A.; Adcock, Ian M.; Chung, Kian Fan] Imperial Coll London, Airways Dis Natl Heart & Lung Inst, London, England; [Austin, Philip J.; Boardman, Charlotte; Lindsay, Mark A.; Adcock, Ian M.; Chung, Kian Fan] Royal Brompton NIHR Biomed Res Unit, London, England; [Tsitsiou, Eleni; Lindsay, Mark A.] Univ Manchester, Univ South Manchester Hosp, Resp Res Grp, Manchester M13 9PL, Lancs, England; [Jones, Simon W.] Univ Birmingham, Inst Inflammat & Ageing, Birmingham B15 2TT, W Midlands, England; [Lindsay, Mark A.] Univ Bath, Dept Pharm & Pharmacol, Bath BA2 7AY, Avon, England; [Perry, Mark M.] UCL Inst Child Hlth, Dubowitz Neuromuscular Ctr, Mol Neurosci Sect, Dev Neurosci Programme, 30 Guildford St, London WC1N 1EH, England	Imperial College London; University of Manchester; Wythenshawe Hospital NHS Foundation Trust; University of Birmingham; University of Bath; University of London; University College London	Perry, MM (corresponding author), UCL Inst Child Hlth, Dubowitz Neuromuscular Ctr, Mol Neurosci Sect, Dev Neurosci Programme, 30 Guildford St, London WC1N 1EH, England.	mark.perry@ucl.ac.uk	Adcock, Ian/L-3217-2019; Jones, Simon W/AAN-4513-2021; Chung, Kian Fan/B-1872-2012; Jones, Simon W/ABB-8625-2020	Jones, Simon W/0000-0001-6785-2310; Chung, Kian Fan/0000-0001-7101-1426; Lindsay, Mark/0000-0003-4807-5506; Adcock, Ian/0000-0003-2101-8843; Perry, Mark/0000-0002-8145-8042; Austin, Philip/0000-0002-8855-220X	Imperial College London; Asthma UK [08/041]; Wellcome Trust [085935]; NIHR Respiratory Disease Biomedical Research Unit at the Royal Brompton; Harefield NHS Foundation Trust and Imperial College London; Medical Research Council [G1001367, MR/K00414X/1, G1000758] Funding Source: researchfish; National Institute for Health Research [NF-SI-0515-10016] Funding Source: researchfish; Asthma UK [10/066] Funding Source: researchfish; MRC [MR/K00414X/1, G1001367] Funding Source: UKRI	Imperial College London(General Electric); Asthma UK; Wellcome Trust(Wellcome Trust); NIHR Respiratory Disease Biomedical Research Unit at the Royal Brompton; Harefield NHS Foundation Trust and Imperial College London; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR)); Asthma UK; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Supported by a fellowship from Imperial College London (to M.M.P.), grants from Asthma UK (08/041) and the Wellcome Trust (085935; to K.F.C.).This project was supported by the NIHR Respiratory Disease Biomedical Research Unit at the Royal Brompton and Harefield NHS Foundation Trust and Imperial College London.The views expressed in this publication are those of the authors(s) and not necessarily those of the National Health Service, National Institute for Health Research (NIHR), or Department of Health. K.F.C.is a Senior Investigator of the NIHR. M.M.P.was an Imperial College Research Fellow. M.M.P., I.M.A., and K.F.C.are members of the Interuniversity Attraction Poles Program- Belgian State- Belgian Science Policy- project P7/ 30.	Alvarez ML, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077468; Alvarez ML, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018671; Alwohhaib M, 2014, SAUDI J KIDNEY DIS T, V25, P577, DOI 10.4103/1319-2442.132190; Bisio A, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-552; Boardman C, 2014, PULM PHARMACOL THER, V29, P129, DOI 10.1016/j.pupt.2014.08.008; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720, DOI 10.1164/ajrccm.161.5.9903102; Buckanovich RJ, 1996, J NEUROSCI, V16, P1114; Carramusa L, 2007, J CELL PHYSIOL, V213, P511, DOI 10.1002/jcp.21133; Chung KF, 2000, EUR RESPIR J, V15, P961, DOI 10.1034/j.1399-3003.2000.15e26.x; Clifford RL, 2013, PULM PHARMACOL THER, V26, P75, DOI 10.1016/j.pupt.2012.07.002; Dooley AL, 2011, GENE DEV, V25, P1470, DOI 10.1101/gad.2046711; Guan YH, 2007, CLIN CANCER RES, V13, P5745, DOI 10.1158/1078-0432.CCR-06-2882; Iwakawa R, 2013, GENE CHROMOSOME CANC, V52, P802, DOI 10.1002/gcc.22076; Jude Joseph A, 2008, Proc Am Thorac Soc, V5, P15, DOI 10.1513/pats.200704-047VS; Kim HP, 2014, ONCOGENE, V33, P5434, DOI 10.1038/onc.2013.490; Kim YJ, 2013, BMC MED GENET, V14, DOI 10.1186/1471-2350-14-39; Kohno T, 2010, GENE CHROMOSOME CANC, V49, P342, DOI 10.1002/gcc.20746; Koziol-White CJ, 2011, IMMUNOL REV, V242, P178, DOI 10.1111/j.1600-065X.2011.01022.x; Kumawat K, 2014, EXPERT OPIN THER TAR, V18, P1023, DOI 10.1517/14728222.2014.934813; Larner-Svensson HM, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-68; Liu L, 2011, INVEST OPHTH VIS SCI, V52, P7282, DOI 10.1167/iovs.11-7463; Moiseeva EP, 1997, EUR J BIOCHEM, V248, P634, DOI 10.1111/j.1432-1033.1997.00634.x; O'Leary L, 2016, FEBS LETT, V590, P1324, DOI 10.1002/1873-3468.12168; Ober C, 2008, NEW ENGL J MED, V358, P1682, DOI 10.1056/NEJMoa0708801; Okubo C, 2006, J THORAC ONCOL, V1, P780, DOI 10.1097/01243894-200610000-00005; Perretti M, 2000, MICROCIRCULATION, V7, P147, DOI 10.1038/sj.mn.7300108; Perry MM, 2015, J BIOL CHEM, V290, P9111, DOI 10.1074/jbc.M114.612671; Perry MM, 2014, RESP RES, V15, DOI 10.1186/1465-9921-15-58; Perry MM, 2014, AM J RESP CELL MOL, V50, P7, DOI 10.1165/rcmb.2013-0067OC; Perry MM, 2011, AM J RESP CELL MOL, V45, P746, DOI 10.1165/rcmb.2010-0304OC; Shyur SD, 2008, EUR J HUM GENET, V16, P1283, DOI 10.1038/ejhg.2008.79; Takahashi Y, 2014, BRIT J CANCER, V110, P164, DOI 10.1038/bjc.2013.698; Thompson MA, 2014, AM J RESP CELL MOL, V51, P68, DOI 10.1165/rcmb.2013-0144OC; Yamabayashi C, 2012, AM J RESP CELL MOL, V47, P170, DOI 10.1165/rcmb.2011-0350OC; You L, 2011, BIOCHEM BIOPH RES CO, V407, P1, DOI 10.1016/j.bbrc.2011.02.027; Zhang ZQ, 2014, J GENET GENOMICS, V41, P187, DOI 10.1016/j.jgg.2014.03.006	36	76	85	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2017	139	3					780	789		10.1016/j.jaci.2016.06.014	http://dx.doi.org/10.1016/j.jaci.2016.06.014			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EP3QC	27484035	Green Published, Green Accepted, hybrid			2022-12-18	WOS:000397295800009
J	Bunyavanich, S; Rifas-Shiman, SL; Platts-Mills, TAE; Workman, L; Sordillo, JE; Gillman, MW; Gold, DR; Litonjua, AA				Bunyavanich, Supinda; Rifas-Shiman, Sheryl L.; Platts-Mills, Thomas A. E.; Workman, Lisa; Sordillo, Joanne E.; Gillman, Matthew W.; Gold, Diane R.; Litonjua, Augusto A.			Peanut allergy prevalence among school-age children in a US cohort not selected for any disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							FOOD ALLERGY; NATIONAL-HEALTH; UNITED-STATES; ASTHMA		[Bunyavanich, Supinda] Icahn Sch Med Mt Sinai, Dept Pediat, Dept Genet & Genom Sci, Div Pediat Allergy & Immunol, New York, NY 10029 USA; [Bunyavanich, Supinda] Icahn Sch Med Mt Sinai, Mindich Child Hlth & Dev Inst, New York, NY 10029 USA; [Rifas-Shiman, Sheryl L.; Gillman, Matthew W.] Harvard Pilgrim Hlth Care Inst, Dept Populat Med, Boston, MA USA; [Rifas-Shiman, Sheryl L.; Sordillo, Joanne E.; Gillman, Matthew W.; Gold, Diane R.; Litonjua, Augusto A.] Harvard Univ, Sch Med, Boston, MA USA; [Platts-Mills, Thomas A. E.; Workman, Lisa] Univ Virginia Hlth Syst, Asthma & Allerg Dis Ctr, Charlottesville, VA USA; [Sordillo, Joanne E.; Gold, Diane R.; Litonjua, Augusto A.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA 02115 USA; [Gold, Diane R.; Litonjua, Augusto A.] Brigham & Womens Hosp, Dept Med, Div Pulm & Crit Care Med, Boston, MA 02115 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Harvard Pilgrim Health Care; Harvard University; Harvard Medical School; University of Virginia; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital	Bunyavanich, S (corresponding author), Icahn Sch Med Mt Sinai, Dept Pediat, Dept Genet & Genom Sci, Div Pediat Allergy & Immunol, New York, NY 10029 USA.	supinda@post.harvard.edu		Platts-Mills, Thomas/0000-0002-1263-329X	NHLBI NIH HHS [HL68041, HL61907, R37 HL066289, T32 HL007427, HL64925, R01 HL064925, K24 HL068041] Funding Source: Medline; NIAID NIH HHS [R01 AI102960, AI093538, R01 AI035786, R01 AI020565, K08 AI093538, AI35786, AI102960] Funding Source: Medline; NICHD NIH HHS [HD34568, R37 HD034568, R01 HD034568] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R37HD034568, R01HD034568] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL066289, R01HL064925, T32HL007427, R01HL061907, K24HL068041] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI035786, R01AI102960, R01AI020565, R01AI035786, K08AI093538] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bunyavanich S, 2014, J ALLERGY CLIN IMMUN, V133, P1373, DOI 10.1016/j.jaci.2013.11.040; Gupta RS, 2011, PEDIATRICS, V128, pE9, DOI 10.1542/peds.2011-0204; Keet CA, 2014, ANN ALLERG ASTHMA IM, V112, P222, DOI 10.1016/j.anai.2013.12.007; Liu AH, 2010, J ALLERGY CLIN IMMUN, V126, P798, DOI 10.1016/j.jaci.2010.07.026; McGowan EC, 2013, J ALLERGY CLIN IMMUN, V132, P1216, DOI 10.1016/j.jaci.2013.07.018; Salo PM, 2014, J ALLERGY CLIN IMMUN, V134, P350, DOI 10.1016/j.jaci.2013.12.1071; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; Sicherer SH, 2014, J ALLERGY CLIN IMMUN, V133, P291, DOI 10.1016/j.jaci.2013.11.020; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, P1322, DOI 10.1016/j.jaci.2010.03.029	9	76	76	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2014	134	3					753	755		10.1016/j.jaci.2014.05.050	http://dx.doi.org/10.1016/j.jaci.2014.05.050			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AO5GR	25086866	Green Accepted			2022-12-18	WOS:000341372400039
J	Kracker, S; Curtis, J; Ibrahim, MAA; Sediva, A; Salisbury, J; Campr, V; Debre, M; Edgar, JDM; Imai, K; Picard, C; Casanova, JL; Fischer, A; Nejentsev, S; Durandy, A				Kracker, Sven; Curtis, James; Ibrahim, Mohammad A. A.; Sediva, Anna; Salisbury, Jon; Campr, Vit; Debre, Marianne; Edgar, J. David M.; Imai, Kohsuke; Picard, Capucine; Casanova, Jean-Laurent; Fischer, Alain; Nejentsev, Sergey; Durandy, Anne			Occurrence of B-cell lymphomas in patients with activated phosphoinositide 3-kinase delta syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							MAST-CELLS; PURIFICATION; DEFICIENCY		[Kracker, Sven; Fischer, Alain; Durandy, Anne] Necker Childrens Hosp, Natl Inst Hlth & Med Res, Paris, France; [Kracker, Sven; Picard, Capucine; Casanova, Jean-Laurent; Fischer, Alain; Durandy, Anne] Descartes Sorbonne Paris Cite Univ Paris, Imagine Inst, Paris, France; [Curtis, James; Nejentsev, Sergey] Univ Cambridge, Dept Med, Cambridge CB2 2QQ, England; [Ibrahim, Mohammad A. A.] Kings Coll London, Kings Hlth Partners, Kings Coll Hosp NHS Fdn Trust, Div Allergy Asthma & Lung Biol,Dept Immunol Med,S, London WC2R 2LS, England; [Sediva, Anna] Univ Hosp Motol, Inst Immunol, Prague, Czech Republic; [Salisbury, Jon] Kings Coll London, Kings Hlth Partners, Kings Coll Hosp NHS Fdn Trust, Dept Histopathol,Sch Med, London WC2R 2LS, England; [Campr, Vit] Charles Univ Prague, Fac Med 2, Dept Pathol, Prague, Czech Republic; [Campr, Vit] Motol Univ Hosp, Prague, Czech Republic; [Debre, Marianne; Picard, Capucine; Fischer, Alain; Durandy, Anne] Necker Childrens Hosp, AP HP, Dept Immunol & Hematol, Paris, France; [Edgar, J. David M.] Queens Univ Belfast, Royal Hosp, Reg Immunol Serv, Belfast, Antrim, North Ireland; [Imai, Kohsuke] Natl Def Med Coll, Dept Pediat, Saitama, Japan; [Picard, Capucine; Durandy, Anne] Necker Childrens Hosp, AP HP, Ctr Primary Immunodeficiencies CEDI, Paris, France; [Picard, Capucine; Casanova, Jean-Laurent] Necker Med Sch, Necker Branch, Lab Human Genet Infect Dis, Paris, France; [Casanova, Jean-Laurent] Rockefeller Univ, St Giles Lab Human Genet Infect Dis, Rockefeller Branch, New York, NY 10021 USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; University of Cambridge; King's College Hospital NHS Foundation Trust; University of London; King's College London; Motol University Hospital; King's College Hospital NHS Foundation Trust; University of London; King's College London; Charles University Prague; Motol University Hospital; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Queens University Belfast; National Defense Medical College - Japan; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Rockefeller University	Kracker, S (corresponding author), Necker Childrens Hosp, Natl Inst Hlth & Med Res, Paris, France.	sn262@cam.ac.uk; anne.durandy@inserm.fr	Casanova, Jean-Laurent/I-3418-2017; Sediva, Anna/AAE-2774-2019; Kracker, Sven/H-3681-2017; Sediva, Anna/J-5904-2017; Imai, Kohsuke/Q-2602-2015; Ibrahim, Mohammad A. A./G-1387-2011; Durandy, Anne/H-7475-2017; Picard, Capucine/H-3914-2017	Sediva, Anna/0000-0001-7730-2304; Kracker, Sven/0000-0003-4543-8236; Imai, Kohsuke/0000-0003-2132-8403; Ibrahim, Mohammad A. A./0000-0002-0116-597X; Durandy, Anne/0000-0001-7706-8466; Picard, Capucine/0000-0001-8788-5056; Edgar, John David Moore/0000-0003-2969-4475; Casanova, Jean-Laurent/0000-0002-7782-4169; Salisbury, Jonathan/0000-0002-5889-4276	Wellcome Trust [095198/Z/10/Z, 095198] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Angulo I, 2013, SCIENCE, V342, P866, DOI 10.1126/science.1243292; Bachelet I, 2005, J IMMUNOL, V175, P7989, DOI 10.4049/jimmunol.175.12.7989; BENYON RC, 1987, J IMMUNOL, V138, P861; Cunningham-Rundles C, 2010, BLOOD, V116, P7, DOI 10.1182/blood-2010-01-254417; Gibbs BF, 2008, CLIN EXP ALLERGY, V38, P480, DOI 10.1111/j.1365-2222.2007.02919.x; Kang S, 2006, P NATL ACAD SCI USA, V103, P1289, DOI 10.1073/pnas.0510772103; Lucas CL, 2014, NAT IMMUNOL, V15, P88, DOI 10.1038/ni.2771; Mizrahi S, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000818; Neven B, 2013, BLOOD, V122, P3713, DOI 10.1182/blood-2013-06-508267; Piliponsky AM, 2003, BLOOD, V101, P1898, DOI 10.1182/blood-2002-05-1488; Rickert RC, 2013, NAT REV IMMUNOL, V13, P578, DOI 10.1038/nri3487; Sander S, 2012, CANCER CELL, V22, P167, DOI 10.1016/j.ccr.2012.06.012; Webb HK, 2010, BLOOD ASH ANN MEET A, V116, p1774A; Zhang J, 2013, P NATL ACAD SCI USA, V110, P1398, DOI 10.1073/pnas.1205299110	14	76	83	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2014	134	1					233	236		10.1016/j.jaci.2014.02.020	http://dx.doi.org/10.1016/j.jaci.2014.02.020			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AL2BH	24698326	Green Accepted			2022-12-18	WOS:000338930300034
J	Hamilos, DL				Hamilos, Daniel L.			Host-microbial interactions in patients with chronic rhinosinusitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chronic rhinosinusitis; host; microbial; biofilm; innate; immunity; antimicrobial	TOLL-LIKE RECEPTORS; EXPERIMENTAL RHINOVIRUS INFECTION; SURFACTANT PROTEIN-A; NASAL POLYP TISSUES; SERUM-AMYLOID-A; BACTERIAL BIOFILMS; STAPHYLOCOCCUS-AUREUS; NITRIC-OXIDE; CHRONIC SINUSITIS; EPITHELIAL-CELLS	There has been considerable investigation of host-microbial interactions in patients with chronic rhinosinusitis (CRS) in hopes of elucidating mechanisms of disease and better treatment. Most attention has been paid to bacterial infection and potential underlying defects in innate immunity. Bacterial biofilm is present in most patients with CRS undergoing surgical intervention, and its presence is associated with more severe disease and worse surgical outcomes. A role for viral or fungal infection in patients with CRS is less clear. There is no evidence for a primary defect in mucociliary clearance in most patients with CRS. Decreased levels of certain antimicrobial proteins, most notably lactoferrin, have been found in sinus secretions, whereas levels of other antimicrobial proteins have been found to be normal. No primary defects in Toll-like receptors have been found in patients with CRS, although a 50% reduced expression of Toll-like receptor 9 was reported in patients with recalcitrant nasal polyps. A polymorphism in a bitter taste receptor was recently associated with refractory CRS and persistent Pseudomonas aeruginosa infection. A downregulation of innate immunity by maladaptive TH2 tissue inflammation has also been described in patients with recalcitrant nasal polyps, suggesting a link to persistent infection. To date, an effective means of restoring host-microbial balance and mitigating disease in patients with CRS remains elusive.	Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital	Hamilos, DL (corresponding author), Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, 55 Fruit St,Bulfinch 422, Boston, MA 02114 USA.	dhamilos@partners.org			Merck	Merck(Merck & Company)	D. L. Hamilos has consultant arrangements with and has received grants from Merck and received royalties from UpToDate.	Agnese DM, 2002, J INFECT DIS, V186, P1522, DOI 10.1086/344893; Akhtar M, 2003, FASEB J, V17, P1319, DOI 10.1096/fj.02-0950fje; Aujla SJ, 2008, NAT MED, V14, P275, DOI 10.1038/nm1710; Bals R, 2004, EUR RESPIR J, V23, P327, DOI 10.1183/09031936.03.00098803; BAROODY FM, 1995, ARCH OTOLARYNGOL, V121, P1396; Bartlett J, 2011, BIOCHEM SOC T, V39, P1012, DOI 10.1042/BST0391012; Basu R, 2012, IMMUNITY, V37, P1061, DOI 10.1016/j.immuni.2012.08.024; Becker MN, 2000, J BIOL CHEM, V275, P29731, DOI 10.1074/jbc.M000184200; Bernstein JM, 2003, AM J RHINOL, V17, P321, DOI 10.1177/194589240301700601; Blatt EN, 1999, AM J RESP CELL MOL, V21, P168, DOI 10.1165/ajrcmb.21.2.3691; Book DT, 2003, AM J RHINOL, V17, P87, DOI 10.1177/194589240301700204; Braun H, 2003, LARYNGO RHINO OTOL, V82, P330; BROOK I, 1981, JAMA-J AM MED ASSOC, V246, P967, DOI 10.1001/jama.246.9.967; Brook I, 2000, ARCH OTOLARYNGOL, V126, P174, DOI 10.1001/archotol.126.2.174; Brook I, 2001, ANN OTO RHINOL LARYN, V110, P148, DOI 10.1177/000348940111000210; Brook I, 1999, ANN OTO RHINOL LARYN, V108, P293, DOI 10.1177/000348949910800313; Brown GD, 2003, J EXP MED, V197, P1119, DOI 10.1084/jem.20021890; Casado B, 2005, PROTEOMICS, V5, P2949, DOI 10.1002/pmic.200401172; Chandra RK, 2011, AM J OTOLARYNG, V32, P388, DOI 10.1016/j.amjoto.2010.07.013; Chen B, 2007, AM J RHINOL, V21, P346, DOI 10.2500/ajr.2007.21.3029; Chiang WC, 2012, FEMS IMMUNOL MED MIC, V65, P245, DOI 10.1111/j.1574-695X.2012.00929.x; Cho HJ, 2012, J ALLERGY CLIN IMMUN, V129, P529, DOI 10.1016/j.jaci.2011.11.024; Claeys S, 2003, ALLERGY, V58, P748, DOI 10.1034/j.1398-9995.2003.00180.x; Cole AM, 1999, INFECT IMMUN, V67, P3267, DOI 10.1128/IAI.67.7.3267-3275.1999; Conley DB, 2006, AM J RHINOL, V20, P451, DOI 10.2500/ajr.2006.20.2880; Contoli M, 2006, NAT MED, V12, P1023, DOI 10.1038/nm1462; Corriveau MN, 2009, AM J RHINOL ALLERGY, V23, P461, DOI 10.2500/ajra.2009.23.3367; Cryer J, 2004, ORL-J OTO-RHIN-LARYN, V66, P155, DOI 10.1159/000079994; Cui YH, 2009, RHINOLOGY, V47, P187; Dahl M, 2004, J EXP MED, V199, P1391, DOI 10.1084/jem.20040111; Dal T, 1997, EUR ARCH OTO-RHINO-L, V254, P205, DOI 10.1007/BF00879275; DEGROOTE MA, 1995, CLIN INFECT DIS, V21, pS162, DOI 10.1093/clinids/21.Supplement_2.S162; DEIONGH R, 1992, THORAX, V47, P184, DOI 10.1136/thx.47.3.184; DEMOLY P, 1994, J ALLERGY CLIN IMMUN, V94, P95, DOI 10.1016/0091-6749(94)90076-0; Dennehy KM, 2007, J LEUKOCYTE BIOL, V82, P253, DOI 10.1189/jlb.1206753; Dentener MA, 2000, AM J RESP CELL MOL, V23, P146, DOI 10.1165/ajrcmb.23.2.3855; Desrosiers M, 2004, CURR ALLERGY ASTHM R, V4, P200, DOI 10.1007/s11882-004-0027-z; Dong Z, 2005, AM J RHINOL, V19, P236, DOI 10.1177/194589240501900303; Donlan RM, 2002, CLIN MICROBIOL REV, V15, P167, DOI 10.1128/CMR.15.2.167-193.2002; Ebbens FA, 2006, J ALLERGY CLIN IMMUN, V118, P1149, DOI 10.1016/j.jaci.2006.07.058; Ebbens FA, 2009, LARYNGOSCOPE, V119, P401, DOI 10.1002/lary.20064; Elsbach P, 1998, J LEUKOCYTE BIOL, V64, P14, DOI 10.1002/jlb.64.1.14; Elwany S, 1998, EUR ARCH OTO-RHINO-L, V255, P511, DOI 10.1007/s004050050109; Endam LM, 2009, OTOLARYNG HEAD NECK, V140, P741, DOI 10.1016/j.otohns.2008.12.058; Engelhardt KR, 2012, J ALLERGY CLIN IMMUN, V129, P294, DOI [10.1016/j.jaci.2011.12.966, 10.1016/j.jaci.2011.12.972]; Farhat K, 2008, J LEUKOCYTE BIOL, V83, P692, DOI 10.1189/jlb.0807586; Feazel LM, 2012, LARYNGOSCOPE, V122, P467, DOI 10.1002/lary.22398; Fenech C, 2009, FRONT CELL NEUROSCI, V3, DOI 10.3389/neuro.03.011.2009; Ferguson BJ, 2005, AM J RHINOL, V19, P452, DOI 10.1177/194589240501900506; Finegold SM, 2002, CLIN INFECT DIS, V35, P428, DOI 10.1086/341899; Foreman A, 2012, CURR ALLERGY ASTHM R, V12, P127, DOI 10.1007/s11882-012-0246-7; Foreman A, 2010, LARYNGOSCOPE, V120, P1701, DOI 10.1002/lary.21024; Foreman A, 2010, LARYNGOSCOPE, V120, P427, DOI 10.1002/lary.20705; Foreman A, 2009, AM J RHINOL ALLERGY, V23, P556, DOI 10.2500/ajra.2009.23.3413; FRYKSMARK U, 1985, Rhinology (Utrecht), V23, P247; FUKAMI M, 1993, EUR ARCH OTO-RHINO-L, V250, P133; Gakhar L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009098; Galli J, 2008, ANN OTO RHINOL LARYN, V117, P902, DOI 10.1177/000348940811701207; Ganeshan K, 2009, J ALLERGY CLIN IMMUN, V123, P231, DOI 10.1016/j.jaci.2008.10.011; Gantner BN, 2003, J EXP MED, V197, P1107, DOI 10.1084/jem.20021787; Girardin SE, 2003, J BIOL CHEM, V278, P8869, DOI 10.1074/jbc.C200651200; Gosepath J, 2004, AM J RHINOL, V18, P9, DOI 10.1177/194589240401800104; Guttman JA, 2009, BBA-BIOMEMBRANES, V1788, P832, DOI 10.1016/j.bbamem.2008.10.028; Ha KR, 2007, AM J RHINOL, V21, P339, DOI 10.2500/ajr.2007.21.3032; HAMILOS DL, 1995, J ALLERGY CLIN IMMUN, V96, P537, DOI 10.1016/S0091-6749(95)70298-9; HANDELSMAN DJ, 1984, NEW ENGL J MED, V310, P3, DOI 10.1056/NEJM198401053100102; HARLIN SL, 1988, J ALLERGY CLIN IMMUN, V81, P867, DOI 10.1016/0091-6749(88)90944-X; Harvey RJ, 2007, RHINOLOGY, V45, P3; Healy DY, 2008, OTOLARYNG HEAD NECK, V138, P641, DOI 10.1016/j.otohns.2008.02.002; Hekiert AM, 2009, OTOLARYNG HEAD NECK, V141, P448, DOI 10.1016/j.otohns.2009.06.090; Henares BM, 2012, ACS CHEM BIOL, V7, P1331, DOI 10.1021/cb300215t; Hiemstra PS, 2007, EXP LUNG RES, V33, P537, DOI 10.1080/01902140701756687; Hirata M, 1995, Prog Clin Biol Res, V392, P317; Hochstim CJ, 2010, OTOLARYNG HEAD NECK, V143, P697, DOI 10.1016/j.otohns.2010.07.017; Hochstitn CJ, 2010, ARCH OTOLARYNGOL, V136, P453, DOI 10.1001/archoto.2010.62; Hoyle B D, 1991, Prog Drug Res, V37, P91; Inoue Y, 2005, J IMMUNOL, V175, P5439, DOI 10.4049/jimmunol.175.8.5439; ISHIDA M, 1984, Rhinology (Utrecht), V22, P115; Jackson DJ, 2010, IMMUNOL ALLERGY CLIN, V30, P513, DOI 10.1016/j.iac.2010.08.004; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Jang YJ, 2006, AM J RHINOL, V20, P634, DOI 10.2500/ajr.2006.20.2899; Jardeleza C, 2011, INT FORUM ALLERGY RH, V1, P438, DOI 10.1002/alr.20083; Jurcisek JA, 2011, JOVE-J VIS EXP, DOI 10.3791/2481; Kaluskar S K, 1997, Ear Nose Throat J, V76, P884; Kato A, 2008, J ALLERGY CLIN IMMUN, V121, P1385, DOI 10.1016/j.jaci.2008.03.002; Koch A, 2001, JAMA-J AM MED ASSOC, V285, P1316, DOI 10.1001/jama.285.10.1316; Lai YY, 2011, J ALLERGY CLIN IMMUN, V128, P1207, DOI 10.1016/j.jaci.2011.09.001; Lane AP, 2006, AM J RHINOL, V20, P138, DOI 10.1177/194589240602000203; Lane AP, 2006, AM J RHINOL, V20, P117, DOI 10.1177/194589240602000122; Langrish CL, 2004, IMMUNOL REV, V202, P96, DOI 10.1111/j.0105-2896.2004.00214.x; Laurence A, 2008, NAT MED, V14, P247, DOI 10.1038/nm0308-247; Lee HM, 2006, LARYNGOSCOPE, V116, P328, DOI 10.1097/01.mlg.0000194223.22763.5f; Lee RE, 2005, OTOLARYNG HEAD NECK, V133, P407, DOI 10.1016/j.otohns.2005.04.022; Lee RJ, 2012, J CLIN INVEST, V122, P4145, DOI 10.1172/JCI64240; Liang SC, 2006, J EXP MED, V203, P2271, DOI 10.1084/jem.20061308; Liu Z, 2004, J ALLERGY CLIN IMMUN, V114, P783, DOI 10.1016/j.jaci.2004.04.052; Lu XA, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-28; LUNDBERG JON, 1995, NAT MED, V1, P370, DOI 10.1038/nm0495-370; Lundberg JO, 2008, ANAT REC, V291, P1479, DOI 10.1002/ar.20782; Malekzadeh S, 2003, CURR ALLERGY ASTHM R, V3, P221, DOI 10.1007/s11882-003-0043-4; Malekzadeh S, 2002, OTOLARYNG HEAD NECK, V127, P190, DOI 10.1067/mhn.2002.126800; Mallia P, 2011, AM J RESP CRIT CARE, V183, P734, DOI 10.1164/rccm.201006-0833OC; Marchiando AM, 2010, ANNU REV PATHOL-MECH, V5, P119, DOI 10.1146/annurev.pathol.4.110807.092135; Medzhitov R, 2007, NATURE, V449, P819, DOI 10.1038/nature06246; Meltzer Eli O, 2004, J Allergy Clin Immunol, V114, P155, DOI 10.1016/j.jaci.2004.09.029; Mfuna-Endam L, 2011, CURR ALLERGY ASTHM R, V11, P236, DOI 10.1007/s11882-011-0189-4; Mizoguchi A, 2012, INFLAMM BOWEL DIS, V18, P1777, DOI 10.1002/ibd.22929; Mosser AG, 2005, AM J RESP CRIT CARE, V171, P645, DOI 10.1164/rccm.200407-970OC; O'Regan GM, 2009, J ALLERGY CLIN IMMUN, V124, pR2, DOI 10.1016/j.jaci.2009.07.013; Okano M, 2011, CLIN EXP ALLERGY, V41, P171, DOI 10.1111/j.1365-2222.2010.03584.x; Oncel S, 2010, J OTOLARYNGOL-HEAD N, V39, P52, DOI 10.2310/7070.2009.090008; Ooi EH, 2007, LARYNGOSCOPE, V117, P51, DOI 10.1097/01.mlg.0000243196.75418.6f; Ooi EH, 2008, AM J RHINOL, V22, P13, DOI 10.2500/ajr.2008.22.3127; Ooi EH, 2007, AM J RHINOL, V21, P395, DOI 10.2500/ajr.2007.21.3048; Ooi EH, 2007, AM J RHINOL, V21, P367, DOI 10.2500/ajr.2007.21.3025; Oppmann B, 2000, IMMUNITY, V13, P715, DOI 10.1016/S1074-7613(00)00070-4; Orlandi RR, 2009, OTOLARYNG HEAD NECK, V141, P750, DOI 10.1016/j.otohns.2009.09.016; Orlandi RR, 2009, OTOLARYNGOL HEAD NEC, V141, pe1; Ostrowski LE, 2010, AM J RESP CELL MOL, V43, P55, DOI 10.1165/rcmb.2009-0118OC; Palaniyar N, 2010, INNATE IMMUN-LONDON, V16, P131, DOI 10.1177/1753425910370498; Panizzi JR, 2012, NAT GENET, V44, P714, DOI 10.1038/ng.2277; Park SK, 2009, OTOLARYNG HEAD NECK, V141, P462, DOI 10.1016/j.otohns.2009.06.013; Passali D, 1999, EUR ARCH OTO-RHINO-L, V256, P335, DOI 10.1007/s004050050158; Perloff JR, 2004, AM J RHINOL, V18, P377, DOI 10.1177/194589240401800607; Plate L, 2012, MOL CELL, V46, P449, DOI 10.1016/j.molcel.2012.03.023; Ponikau JU, 2005, J ALLERGY CLIN IMMUN, V115, P125, DOI 10.1016/j.jaci.2004.09.037; Ponikau JU, 2003, J ALLERGY CLIN IMMUN, V112, P877, DOI 10.1016/j.jaci.2003.08.009; Ponikau JU, 1999, MAYO CLIN PROC, V74, P877, DOI 10.4065/74.9.877; Prince AA, 2008, AM J RHINOL, V22, P239, DOI 10.2500/ajr.2008.22.3180; Psaltis AJ, 2008, LARYNGOSCOPE, V118, P895, DOI 10.1097/MLG.0b013e31816381d4; Psaltis AJ, 2008, AM J RHINOL, V22, P1, DOI 10.2500/ajr.2008.22.3119; Psaltis AJ, 2007, LARYNGOSCOPE, V117, P2030, DOI 10.1097/MLG.0b013e31812e01ab; Psaltis AJ, 2007, LARYNGOSCOPE, V117, P1302, DOI 10.1097/MLG.0b013e31806009b0; Ramanathan M, 2007, AM J RHINOL, V21, P110, DOI 10.2500/ajr.2007.21.2997; Ramanathan M, 2008, AM J RHINOL, V22, P115, DOI 10.2500/ajr.2008.22.3136; Ramanathan M, 2007, LARYNGOSCOPE, V117, P1839, DOI 10.1097/MLG.0b013e31811edd4f; Rank MA, 2010, J ALLERGY CLIN IMMUN, V126, P168, DOI 10.1016/j.jaci.2010.03.041; Richer SL, 2008, AM J RHINOL, V22, P228, DOI 10.2500/ajr.2008.22.3162; Roeder A, 2004, TRENDS MICROBIOL, V12, P44, DOI 10.1016/j.tim.2003.11.003; Ronaghi M, 2002, J CHROMATOGR B, V782, P67, DOI 10.1016/S1570-0232(02)00693-1; Sachse F, 2008, INT ARCH ALLERGY IMM, V145, P24, DOI 10.1159/000107463; Sanclement JA, 2005, LARYNGOSCOPE, V115, P578, DOI 10.1097/01.mlg.0000161346.30752.18; Sanders SP, 2004, J ALLERGY CLIN IMMUN, V113, P697, DOI 10.1016/j.jaci.2004.01.755; Sanderson AR, 2006, LARYNGOSCOPE, V116, P1121, DOI 10.1097/01.mlg.0000221954.05467.54; Schittek B, 2011, CURR PROBL DERMATOL, V41, P54, DOI 10.1159/000323296; Schleimer RP, 2007, J ALLERGY CLIN IMMUN, V120, P1279, DOI 10.1016/j.jaci.2007.08.046; Schlosser RJ, 2010, AM J RHINOL ALLERGY, V24, P21, DOI 10.2500/ajra.2010.24.3399; Seshadri S, 2012, ALLERGY, V67, P920, DOI 10.1111/j.1398-9995.2012.02848.x; Shah C, 2006, BLOOD, V108, P1751, DOI 10.1182/blood-2005-11-011932; Shin HW, 2012, AM J RESP CRIT CARE, V185, P944, DOI 10.1164/rccm.201109-1706OC; Shin SH, 2004, J ALLERGY CLIN IMMUN, V114, P1369, DOI 10.1016/j.jaci.2004.08.012; SHONE G R, 1990, Rhinology (Utrecht), V28, P265; Singhal D, 2010, AM J RHINOL ALLERGY, V24, P169, DOI 10.2500/ajra.2010.24.3462; Solyar A, 2012, OTOLARYNG HEAD NECK, V146, P1012, DOI 10.1177/0194599812437333; Sonnenberg GF, 2011, NAT IMMUNOL, V12, P383, DOI 10.1038/ni.2025; Sorensen OE, 2001, BLOOD, V97, P3951, DOI 10.1182/blood.V97.12.3951; Soyka MB, 2012, J ALLERGY CLIN IMMUN, V130, P1087, DOI 10.1016/j.jaci.2012.05.052; Stepanovic S, 2000, J MICROBIOL METH, V40, P175, DOI 10.1016/S0167-7012(00)00122-6; Stephenson MF, 2010, J OTOLARYNGOL-HEAD N, V39, P182, DOI 10.2310/7070.2009.090060; Strober W, 2008, MUCOSAL IMMUNOL, V1, pS5, DOI 10.1038/mi.2008.42; Sun WK, 2012, EUR J CLIN MICROBIOL, V31, P2755, DOI 10.1007/s10096-012-1624-8; Tan NCW, 2012, AM J RHINOL ALLERGY, V26, P444, DOI 10.2500/ajra.2012.26.3822; Tan NCW, 2012, LARYNGOSCOPE, V122, P1655, DOI 10.1002/lary.23317; Taube C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021799; THOMPSON RC, 1986, P NATL ACAD SCI USA, V83, P6692, DOI 10.1073/pnas.83.18.6692; Tichenor WS, 2012, EMERG INFECT DIS, V18, P1612, DOI 10.3201/eid1810.120164; Tieu DD, 2010, J ALLERGY CLIN IMMUN, V125, P667, DOI 10.1016/j.jaci.2009.11.045; Tripathi A, 2005, AM J RHINOL, V19, P327, DOI 10.1177/194589240501900401; Van Zele T, 2004, J ALLERGY CLIN IMMUN, V114, P981, DOI 10.1016/j.jaci.2004.07.013; VanderMeer J, 2004, ARCH OTOLARYNGOL, V130, P1374, DOI 10.1001/archotol.130.12.1374; Walsh D, 2013, CYTOKINE GROWTH F R, V24, P91, DOI 10.1016/j.cytogfr.2012.09.003; Wang JH, 2008, ARCH OTOLARYNGOL, V134, P424, DOI 10.1001/archotol.134.4.424; Wang Xin, 2010, Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, V24, P652; Weldon S, 2007, EXP LUNG RES, V33, P485, DOI 10.1080/01902140701756547; Weldon S, 2009, J IMMUNOL, V183, P8148, DOI 10.4049/jimmunol.0901716; Weschta M, 2004, J ALLERGY CLIN IMMUN, V113, P1122, DOI 10.1016/j.jaci.2004.03.038; Wiehler S, 2007, AM J PHYSIOL-LUNG C, V293, pL505, DOI 10.1152/ajplung.00066.2007; Woo HJ, 2008, ARCH OTOLARYNGOL, V134, P1182, DOI 10.1001/archotol.134.11.1182; Wood AJ, 2011, INT FORUM ALLERGY RH, V1, P95, DOI 10.1002/alr.20030; Woods CM, 2012, RHINOLOGY, V50, P147, DOI [10.4193/Rhin11.229, 10.4193/Rhino11.229]; Woodworth BA, 2006, AM J RHINOL, V20, P461, DOI 10.2500/ajr.2006.20.2892; Wu MM, 2012, ENT-EAR NOSE THROAT, V91, P282, DOI 10.1177/014556131209100706; Wu XF, 2011, AM J RESP CELL MOL, V45, P525, DOI 10.1165/rcmb.2010-0133OC; Yamasaki K, 2006, FASEB J, V20, P2068, DOI 10.1096/fj.06-6075com; Yamin M, 2008, J ALLERGY CLIN IMMUN, V122, P1145, DOI 10.1016/j.jaci.2008.09.033; Zaheer RS, 2009, J IMMUNOL, V182, P4854, DOI 10.4049/jimmunol.0802401; Zariwala MA, 2007, ANNU REV PHYSIOL, V69, P423, DOI 10.1146/annurev.physiol.69.040705.141301; Zelante T, 2011, EUR J IMMUNOL, V41, P270, DOI 10.1002/eji.201041246; Zernotti ME, 2010, J INVEST ALLERG CLIN, V20, P380; Zhang L, 1998, Zhonghua Er Bi Yan Hou Ke Za Zhi, V33, P219; Zhang Q, 2013, ACTA OTO-LARYNGOL, V133, P165, DOI 10.3109/00016489.2012.717713; Zhang XH, 2009, CLIN EXP ALLERGY, V39, P647, DOI 10.1111/j.1365-2222.2008.03198.x; Zhang Z, 2011, OTOLARYNG HEAD NECK, V144, P457, DOI 10.1177/0194599810394302; Zheng Y, 2008, NAT MED, V14, P282, DOI 10.1038/nm1720; Zuckerman JD, 2008, AM J RHINOL, V22, P589, DOI 10.2500/ajr.2008.22.3235	195	76	81	0	19	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2014	133	3					640	+		10.1016/j.jaci.2013.06.049	http://dx.doi.org/10.1016/j.jaci.2013.06.049			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EK	24290275	Bronze, Green Published			2022-12-18	WOS:000332397600004
J	van Neerven, RJJ; Knol, EF; Heck, JML; Savelkoul, HFJ				van Neerven, R. J. Joost; Knol, Edward F.; Heck, Jeroen M. L.; Savelkoul, Huub F. J.			Which factors in raw cow's milk contribute to protection against allergies?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; milk; breast-feeding; farm; processing	GUT MICROBIOTA; BREAST-MILK; ATOPIC MANIFESTATIONS; IMMUNE-RESPONSES; ORAL TOLERANCE; BOVINE-MILK; ASTHMA; OLIGOSACCHARIDES; CONSUMPTION; DISEASE	Several epidemiologic studies have shown that growing up in a farming environment is associated with a decreased risk of allergies. A factor that correlates strongly with this effect is the early ingestion of unheated cow's milk. Although, to date, no controlled studies on raw milk consumption have been performed to formally demonstrate this effect, several factors in bovine milk have been described that might explain how raw cow's milk consumption can decrease the risk of allergies. In addition, increasing knowledge on the immunologically active factors in breast milk have also contributed to our understanding of the effects of bovine milk in infants because many of the factors in bovine milk are expected to have functional effects in human subjects as well. Here we review these factors and their mechanisms of action and compare their presence in bovine milk and breast milk. A better understanding of these factors, as well as how to retain them, might ultimately lead to the development of mildly processed milk and infant nutrition products that could become a part of preventive strategies to reduce the incidence of allergic disease. (J Allergy Clin Immunol 2012; 130:853-8.)	[van Neerven, R. J. Joost; Savelkoul, Huub F. J.] Wageningen Univ, Cell Biol & Immunol Grp, Wageningen, Netherlands; [van Neerven, R. J. Joost; Heck, Jeroen M. L.] Friesland Campina, Amersfoort, Netherlands; [Knol, Edward F.] Univ Med Ctr Utrecht, Dept Dermatol Allergol, Utrecht, Netherlands	Wageningen University & Research; Utrecht University; Utrecht University Medical Center	van Neerven, RJJ (corresponding author), Harderwijkerstr 6, Deventer, Netherlands.	joost.vanneerven@wur.nl	van Neerven, Joost/GWZ-3214-2022; Savelkoul, Huub FJ/F-6026-2012	Heck, Jeroen/0000-0001-6772-2495; Knol, Edward/0000-0001-7368-9820; van Neerven, R.J.Joost/0000-0002-3991-5297				Arslanoglu S, 2008, J NUTR, V138, P1091, DOI 10.1093/jn/138.6.1091; Bode L., 2012, GLYCOBIOLOGY; Boehm G, 2007, J NUTR, V137, p847S, DOI 10.1093/jn/137.3.847S; Braun-Fahrlander C, 2011, CLIN EXP ALLERGY, V41, P29, DOI 10.1111/j.1365-2222.2010.03665.x; Cantor H, 2009, NAT REV IMMUNOL, V9, P137, DOI 10.1038/nri2460; Clemente JC, 2012, CELL, V148, P1258, DOI 10.1016/j.cell.2012.01.035; COLLINS AM, 1991, INT ARCH ALLER A IMM, V96, P362, DOI 10.1159/000235523; den Hartog G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018188; Dogaru CM, 2012, AM J RESP CRIT CARE, V185, P874, DOI 10.1164/rccm.201108-1490OC; Ege MJ, 2007, J ALLERGY CLIN IMMUN, V119, P1140, DOI 10.1016/j.jaci.2007.01.037; Fituch CC, 2004, ACTA PAEDIATR, V93, P1496, DOI 10.1080/08035250410022314; Heck JML, 2009, J DAIRY SCI, V92, P4745, DOI 10.3168/jds.2009-2146; Hettinga K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019433; Jensen RG, 1995, HDB MILK COMPOSITION; JUNGI TW, 1989, IMMUNOLOGY, V66, P143; Kalliomaki M, 2003, LANCET, V361, P1869, DOI 10.1016/S0140-6736(03)13490-3; Kay AB, 2001, NEW ENGL J MED, V344, P30, DOI 10.1056/NEJM200101043440106; Knol EF, 2006, MOL NUTR FOOD RES, V50, P620, DOI 10.1002/mnfr.200500272; Kull I, 2010, J ALLERGY CLIN IMMUN, V125, P1013, DOI 10.1016/j.jaci.2010.01.051; Kuntz S, 2008, BRIT J NUTR, V99, P462, DOI 10.1017/S0007114507824068; Loss G, 2011, J ALLERGY CLIN IMMUN, V128, P766, DOI 10.1016/j.jaci.2011.07.048; Ly NP, 2011, J ALLERGY CLIN IMMUN, V127, P1087, DOI 10.1016/j.jaci.2011.02.015; Manzoni P, 2009, JAMA-J AM MED ASSOC, V302, P1421, DOI 10.1001/jama.2009.1403; McLoughlin RM, 2011, J ALLERGY CLIN IMMUN, V127, P1097, DOI 10.1016/j.jaci.2011.02.012; Mosconi E, 2010, MUCOSAL IMMUNOL, V3, P461, DOI 10.1038/mi.2010.23; Murray CS, 2005, CLIN EXP ALLERGY, V35, P741, DOI 10.1111/j.1365-2222.2005.02259.x; Ober RJ, 2001, INT IMMUNOL, V13, P1551, DOI 10.1093/intimm/13.12.1551; Oddy WH, 2010, PEDIAT ALLERG IMM-UK, V21, P47, DOI 10.1111/j.1399-3038.2009.00913.x; Penders J, 2007, GUT, V56, P661, DOI 10.1136/gut.2006.100164; Qiao SW, 2008, P NATL ACAD SCI USA, V105, P9337, DOI 10.1073/pnas.0801717105; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Robinson DS, 2004, J CLIN INVEST, V114, P1389, DOI 10.1172/JCI200423595; Robinson DS, 2002, CURR BIOL, V12, pR322, DOI 10.1016/S0960-9822(02)00830-8; Rockova S, 2011, ANAEROBE, V17, P223, DOI 10.1016/j.anaerobe.2011.07.009; Strachan David P., 2000, Thorax, V55, pS2, DOI 10.1136/thorax.55.suppl_1.S2; Strober W, 2008, MUCOSAL IMMUNOL, V1, P92, DOI 10.1038/mi.2007.22; Tao N, 2008, J DAIRY SCI, V91, P3768, DOI 10.3168/jds.2008-1305; Thijs C, 2011, ALLERGY, V66, P58, DOI 10.1111/j.1398-9995.2010.02445.x; van Hoffen E, 2009, ALLERGY, V64, P484, DOI 10.1111/j.1398-9995.2008.01765.x; van Nimwegen FA, 2011, J ALLERGY CLIN IMMUN, V128, P948, DOI 10.1016/j.jaci.2011.07.027; van Odijk J, 2003, ALLERGY, V58, P833, DOI 10.1034/j.1398-9995.2003.00264.x; Verhasselt V, 2008, NAT MED, V14, P170, DOI 10.1038/nm1718; Waser M, 2007, CLIN EXP ALLERGY, V37, P661, DOI 10.1111/j.1365-2222.2006.02640.x; Wu SA, 2011, J PROTEOME RES, V10, P856, DOI 10.1021/pr101006u; Wu SA, 2010, J PROTEOME RES, V9, P4138, DOI 10.1021/pr100362f; Yazdanbakhsh M, 2002, SCIENCE, V296, P490, DOI 10.1126/science.296.5567.490; Yoshida M, 2006, J CLIN INVEST, V116, P2142, DOI 10.1172/JCI27821	47	76	76	0	44	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2012	130	4					853	858		10.1016/j.jaci.2012.06.050	http://dx.doi.org/10.1016/j.jaci.2012.06.050			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017MT	22939757				2022-12-18	WOS:000309594800003
J	Saffari, H; Peterson, KA; Fang, JC; Teman, C; Gleich, GJ; Pease, LF				Saffari, Hedieh; Peterson, Kathryn A.; Fang, John C.; Teman, Carolin; Gleich, Gerald J.; Pease, Leonard F., III			Patchy eosinophil distributions in an esophagectomy specimen from a patient with eosinophilic esophagitis: Implications for endoscopic biopsy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							HISTOPATHOLOGIC VARIABILITY; CONSENSUS RECOMMENDATIONS; CHILDREN; ADULTS		[Saffari, Hedieh; Pease, Leonard F., III] Univ Utah, Dept Chem Engn, Dept Internal Med, Div Gastroenterol, Salt Lake City, UT 84112 USA; [Teman, Carolin] Univ Utah, Dept Pathol, Salt Lake City, UT 84112 USA; [Gleich, Gerald J.] Univ Utah, Dept Dermatol, Salt Lake City, UT 84112 USA; [Pease, Leonard F., III] Univ Utah, Dept Pharmaceut & Pharmaceut Chem, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Saffari, H (corresponding author), Univ Utah, Dept Chem Engn, Dept Internal Med, Div Gastroenterol, Salt Lake City, UT 84112 USA.	Hedieh.Saffari@utah.edu			NATIONAL INSTITUTE ON AGING [R43AG039929] Funding Source: NIH RePORTER; NIA NIH HHS [1R43AG039929-D1, R43 AG039929-01, R43 AG039929] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Dellon ES, 2007, AM J GASTROENTEROL, V102, P2300, DOI 10.1111/j.1572-0241.2007.01396.x; Furuta GT, 2007, GASTROENTEROLOGY, V133, P1342, DOI 10.1053/j.gastro.2007.08.017; Gonsalves N, 2006, GASTROINTEST ENDOSC, V64, P313, DOI 10.1016/j.gie.2006.04.037; Gupta SK, 2006, J PEDIATR GASTR NUTR, V42, P22, DOI 10.1097/01.mpg.0000188740.38757.d2; Liacouras C, 2011, J ALLERGY CLIN IMMUN, V128, P3, DOI 10.1016/j.jaci.2011.02.040; Pease LF, 2011, J NANOPART RES, V13, P2157, DOI 10.1007/s11051-010-9974-6; Shah AA, 2009, AM J GASTROENTEROL, V104, P716, DOI 10.1038/ajg.2008.117; Straumann A, 2001, J ALLERGY CLIN IMMUN, V108, P954, DOI 10.1067/mai.2001.119917; Straumann A, 2003, GASTROENTEROLOGY, V125, P1660, DOI 10.1053/j.gastro.2003.09.024	9	76	79	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2012	130	3					798	800		10.1016/j.jaci.2012.03.009	http://dx.doi.org/10.1016/j.jaci.2012.03.009			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	001LZ	22502795	Green Accepted			2022-12-18	WOS:000308463500030
J	Westman, M; Stjarne, P; Asarnoj, A; Kull, I; van Hage, M; Wickman, M; Toskala, E				Westman, Marit; Stjarne, Par; Asarnoj, Anna; Kull, Inger; van Hage, Marianne; Wickman, Magnus; Toskala, Elina			Natural course and comorbidities of allergic and nonallergic rhinitis in children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic rhinitis; allergy; BAMSE; children; food allergy; IgE; rhinitis; sensitization	IGE-ANTIBODIES; FOOD HYPERSENSITIVITY; ASTHMA; IMPACT; RISK; PREVALENCE; GA(2)LEN; ONSET	Background: Not much data are available from large, unselected, birth cohort studies on the natural course and comorbidities of rhinitis in children. Objective: To study phenotypes of rhinitis in relation to the natural course and comorbidities of allergic diseases in preschool-age and early school-age children. Methods: We analyzed data from a birth cohort of 2024 children, for whom information on IgEs against 8 common inhaled allergens was available, collected at age 4 and 8 years. The children were assigned to groups of allergic rhinitis (rhinitis with sensitization to allergens), nonallergic rhinitis (rhinitis without sensitization), allergic sensitization but no rhinitis, or neither rhinitis nor sensitization. Results: The proportion of children with allergic rhinitis increased from 5% to 14% from age 4 to 8 years, whereas the proportion of children with nonallergic rhinitis decreased slightly over the same period of development, from 8% to 6%. Of the children with allergic rhinitis when they were 4 years old, 12% underwent remission by the time they were 8 years old; of the children with nonallergic rhinitis, 73% underwent remission during this period of development. Among 4-year-olds without rhinitis who were sensitized to allergen, 56% had allergic rhinitis when they were 8 years old. Among 4- and 8-year-olds, allergic rhinitis and nonallergic rhinitis were associated with asthma, eczema, and food hypersensitivity. Twenty-five percent of 8-year-olds with allergic rhinitis also had oral allergy syndrome. Conclusions: Fewer preschool-age children with allergic rhinitis undergo remission than do those with nonallergic rhinitis. Sensitization to inhaled allergens at an early age (4 years) precedes the development of allergic rhinitis, whereas symptoms of rhinitis do not. Oral allergy syndrome is common among 8-year-olds with allergic rhinitis. (J Allergy Clin Immunol 2012;129:403-8.)	[Westman, Marit; Asarnoj, Anna; Kull, Inger; Wickman, Magnus; Toskala, Elina] Karolinska Inst, Inst Environm Med, SE-17177 Stockholm, Sweden; [Westman, Marit; Stjarne, Par] Karolinska Inst, CLINTEC, SE-17177 Stockholm, Sweden; [Westman, Marit; Stjarne, Par] Karolinska Univ Hosp, Dept ENT Dis, Stockholm, Sweden; [Asarnoj, Anna] Astrid Lindgren Childrens Hosp, Stockholm, Sweden; [Kull, Inger] Soder Sjukhuset, Dept Educ & Clin Sci, Karolinska Inst, Stockholm, Sweden; [van Hage, Marianne] Karolinska Univ Hosp, Dept Med, Karolinska Inst, Stockholm, Sweden; [van Hage, Marianne] Karolinska Univ Hosp, Clin Immunol & Allergy Unit, Karolinska Inst, Stockholm, Sweden; [Wickman, Magnus] Soder Sjukhuset, Sachs Childrens Hosp, Stockholm, Sweden; [Toskala, Elina] Finnish Inst Occupat Hlth, Helsinki, Finland; [Toskala, Elina] Childrens Hosp Philadelphia, Res Inst, Philadelphia, PA 19104 USA	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Sodersjukhuset Hospital; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Sodersjukhuset Hospital; Finnish Institute of Occupational Health; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Westman, M (corresponding author), Karolinska Inst, Inst Environm Med, POB 210, SE-17177 Stockholm, Sweden.	marit.westman@ki.se	Asarnoj, Anna/ABC-4112-2020; van Hage, Marianne/A-9678-2017	van Hage, Marianne/0000-0003-3091-1596; Asarnoj, Anna/0000-0002-0797-2369; Kull, Inger/0000-0001-6096-3771	Stockholm County Council; "FrimurareBarnhuset" Stockholm Foundation	Stockholm County Council(Stockholm County Council); "FrimurareBarnhuset" Stockholm Foundation	This study was funded by the Stockholm County Council and the "FrimurareBarnhuset" Stockholm Foundation.	Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; Bachert C, 2006, ALLERGY, V61, P693, DOI 10.1111/j.1398-9995.2006.01054.x; Bertelsen RJ, 2010, PEDIAT ALLERG IMM-UK, V21, P612, DOI 10.1111/j.1399-3038.2010.01066.x; Bodtger U, 2006, ALLERGY, V61, P712, DOI 10.1111/j.1398-9995.2006.01140.x; Bohle B, 2007, ALLERGY, V62, P3, DOI 10.1111/j.1398-9995.2006.01258.x; Bousquet J, 2008, ALLERGY, V63, P842, DOI 10.1111/j.1398-9995.2008.01715.x; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Canonica GW, 2007, ALLERGY, V62, P17, DOI 10.1111/j.1398-9995.2007.01549.x; Chawes BLK, 2010, J ALLERGY CLIN IMMUN, V126, P567, DOI 10.1016/j.jaci.2010.06.026; ERIKSSON NE, 1982, ALLERGY, V37, P437, DOI 10.1111/j.1398-9995.1982.tb02323.x; Guerra S, 2002, J ALLERGY CLIN IMMUN, V109, P419, DOI 10.1067/mai.2002.121701; HUGGINS KG, 1975, LANCET, V2, P148; Katelaris CH, 2010, CURR OPIN ALLERGY CL, V10, P246, DOI 10.1097/ACI.0b013e32833973fb; Keil T, 2010, PEDIAT ALLERG IMM-UK, V21, P962, DOI 10.1111/j.1399-3038.2010.01046.x; Kulig M, 2000, J ALLERGY CLIN IMMUN, V106, P832, DOI 10.1067/mai.2000.110098; Marinho S, 2007, ALLERGY, V62, P385, DOI 10.1111/j.1398-9995.2006.01294.x; Meltzer EO, 2009, J ALLERGY CLIN IMMUN, V124, pS43, DOI 10.1016/j.jaci.2009.05.013; Molgaard E, 2007, ALLERGY, V62, P1033, DOI 10.1111/j.1398-9995.2007.01355.x; Ostblom E, 2008, ALLERGY, V63, P418, DOI 10.1111/j.1398-9995.2007.01575.x; Penard-Morand C, 2005, ALLERGY, V60, P1165, DOI 10.1111/j.1398-9995.2005.00860.x; Powe DG, 2010, CLIN EXP ALLERGY, V40, P987, DOI 10.1111/j.1365-2222.2010.03536.x; Rondon C, 2010, CURR OPIN ALLERGY CL, V10, P1, DOI 10.1097/ACI.0b013e328334f5fb; Rondon C, 2009, J ALLERGY CLIN IMMUN, V123, P1098, DOI 10.1016/j.jaci.2009.02.018; Settipane Russell A, 2007, Clin Allergy Immunol, V19, P23; Shaaban R, 2008, LANCET, V372, P1049, DOI 10.1016/S0140-6736(08)61446-4; Vieths S, 2002, ANN NY ACAD SCI, V964, P47; Wickman M, 2002, PEDIATR ALLERGY IMMU, V13, P11, DOI 10.1034/j.1399-3038.13.s.15.10.x; Wickman M, 2005, ALLERGY, V60, P650, DOI 10.1111/j.1398-9995.2004.00764.x	29	76	78	1	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2012	129	2					403	408		10.1016/j.jaci.2011.09.036	http://dx.doi.org/10.1016/j.jaci.2011.09.036			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	887TC	22056609				2022-12-18	WOS:000299951700016
J	Cakmak, S; Dales, RE; Coates, F				Cakmak, Sabit; Dales, Robert E.; Coates, Frances			Does air pollution increase the effect of aeroallergens on hospitalization for asthma?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; hospitalization; allergens; air pollution; epidemiology	DIESEL EXHAUST PARTICLES; INHALED ALLERGEN; NITROGEN-DIOXIDE; OZONE EXPOSURE; POLLEN; RESPONSES; AIRWAYS; VISITS; RISK	Background: Clinical experiments demonstrate that the asthmatic response to an aeroallergen can be enhanced by prior exposure to an air pollutant. Objective: We sought to compare the effects of ambient aeroallergens on hospitalization for asthma between high and low air pollution days in 11 large Canadian cities. Methods: Daily time-series analysis was used, and results were adjusted for day of the week, temperature, barometric pressure, and relative humidity. Results: The relative risk of admission for an interquartile increase in tree pollen levels was 1.124 (95% CI, 1.101-1.147) on days of lower values of fine particulate matter with a median aerodynamic diameter less than or equal to 2.5 mu m (PM2.5) compared with 1.179 (95% CI, 1.149-1.21) on days of higher PM2.5 values. Significant (P <= .05) differences in the relative risks of admission between lower versus higher values of particulate matter with a median aerodynamic diameter less than or equal to 10 mu m in diameter were 1.149 (95% CI, 1.118-1.181) versus 1.210 (95% CI, 1.161-1.261) for ascomycetes, 1.112 (95% CI, 1.085-1.14) versus 1.302 (95% CI, 1.242-1.364) for basidiomycetes, 1.159 (95% CI, 1.125-1.195) versus 1.149 (95% CI, 1.129-1.169) for deuteromycetes, and 1.061 (95% CI, 1.016-1.107) versus 1.117 (95% CI, 1.092-1.143) for weeds. Conclusion: We identified an association between aeroallergens and hospitalizations for asthma, which was enhanced on days of higher air pollution. Minimizing exposure to air pollution might reduce allergic exacerbations of asthma. (J Allergy Clin Immunol 2012;129:228-31.)	[Dales, Robert E.] Univ Ottawa, Ottawa Hosp, Dept Med, Ottawa, ON K1H 8L6, Canada; [Dales, Robert E.] Univ Ottawa, Ottawa Hosp, Dept Epidemiol, Ottawa, ON K1H 8L6, Canada; [Cakmak, Sabit] Hlth Canada, Environm Hlth Sci & Res Bur, Biostat & Epidemiol Div, Ottawa, ON K1A 0L2, Canada; [Coates, Frances] Aerobiol Res Labs, Ottawa, ON, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute; Health Canada	Dales, RE (corresponding author), Univ Ottawa, Ottawa Hosp, Dept Med, Gen Campus,501 Smyth Rd,Box 211, Ottawa, ON K1H 8L6, Canada.	rdales@ohri.ca		Cakmak, Sabit/0000-0001-9921-2107				Bayram H, 1998, AM J RESP CELL MOL, V18, P441, DOI 10.1165/ajrcmb.18.3.2882; Chehregani A, 2008, ECOTOX ENVIRON SAFE, V69, P568, DOI 10.1016/j.ecoenv.2007.05.007; D'Amato G, 2010, J INVEST ALLERG CLIN, V20, P95; Dales RE, 2000, AM J RESP CRIT CARE, V162, P2087, DOI 10.1164/ajrccm.162.6.2001020; Dales RE, 2004, J ALLERGY CLIN IMMUN, V113, P303, DOI 10.1016/j.jaci.2003.11.016; Gavett SH, 2003, ENVIRON HEALTH PERSP, V111, P1471, DOI 10.1289/ehp.6300; Hastie T. J., 1990, MONOGR STAT APPL PRO, V43, P335; Jenkins HS, 1999, AM J RESP CRIT CARE, V160, P33, DOI 10.1164/ajrccm.160.1.9808119; Jorres R, 1996, AM J RESP CRIT CARE, V153, P56, DOI 10.1164/ajrccm.153.1.8542163; Kehrl HR, 1999, J ALLERGY CLIN IMMUN, V104, P1198, DOI 10.1016/S0091-6749(99)70013-8; Knox RB, 1997, CLIN EXP ALLERGY, V27, P246; LINDSTROM MJ, 1990, BIOMETRICS, V46, P673, DOI 10.2307/2532087; MOLFINO NA, 1991, LANCET, V338, P199, DOI 10.1016/0140-6736(91)90346-Q; OHOLLAREN MT, 1991, NEW ENGL J MED, V324, P359, DOI 10.1056/NEJM199102073240602; PEDEN DB, 1995, AM J RESP CRIT CARE, V151, P1336, DOI 10.1164/ajrccm.151.5.7735583; Priestly M. B., 1981, SPECTRAL ANAL TIME S; SALVAGGIO J, 1971, J ALLERGY CLIN IMMUN, V48, P96, DOI 10.1016/0091-6749(71)90091-1; Sheppard L, 1999, EPIDEMIOLOGY, V10, P23, DOI 10.1097/00001648-199901000-00006; Strand V, 1997, AM J RESP CRIT CARE, V155, P881, DOI 10.1164/ajrccm.155.3.9117021; TARGONSKI PV, 1995, J ALLERGY CLIN IMMUN, V95, P955, DOI 10.1016/S0091-6749(95)70095-1; Villeneuve PJ, 2007, ENVIRON HEALTH-GLOB, V6, DOI 10.1186/1476-069X-6-40; Whitekus MJ, 2002, J IMMUNOL, V168, P2560, DOI 10.4049/jimmunol.168.5.2560; Zanobetti A, 2009, ENVIRON HEALTH PERSP, V117, P898, DOI 10.1289/ehp.0800108	23	76	79	0	19	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2012	129	1					228	231		10.1016/j.jaci.2011.09.025	http://dx.doi.org/10.1016/j.jaci.2011.09.025			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	869XT	22035655				2022-12-18	WOS:000298634000029
J	Takahashi, K; Hirose, K; Kawashima, S; Niwa, Y; Wakashin, H; Iwata, A; Tokoyoda, K; Renauld, JC; Iwamoto, I; Nakayama, T; Nakajima, H				Takahashi, Kentaro; Hirose, Koichi; Kawashima, Saki; Niwa, Yusuke; Wakashin, Hidefumi; Iwata, Arifumi; Tokoyoda, Koji; Renauld, Jean-Christophe; Iwamoto, Itsuo; Nakayama, Toshinori; Nakajima, Hiroshi			IL-22 attenuates IL-25 production by lung epithelial cells and inhibits antigen-induced eosinophilic airway inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic inflammation; asthma; IL-22; eosinophils; IL-25	NATURAL-KILLER-CELLS; ALLERGIC-ASTHMA; T-CELL; LYMPHOID-TISSUE; INTERLEUKIN 22; TH17 CELLS; MICE; IMMUNITY; INNATE; IL-17	Background: IL-22 functions as both a proinflammatory cytokine and an anti-inflammatory cytokine in various inflammations, depending on the cellular and cytokine milieu. However, the roles of IL-22 in the regulation of allergic airway inflammation are still largely unknown. Objective: We sought to determine whether IL-22 is involved in the regulation of allergic airway inflammation. Methods: We examined IL-22 production and its cellular source at the site of antigen-induced airway inflammation in mice. We also examined the effect of IL-22 neutralization, as well as IL-22 administration, on antigen-induced airway inflammation. We finally examined the effect of IL-22 on IL-25 production from a lung epithelial cell line (MLE-15 cells). Results: Antigen inhalation induced IL-22 production in the airways of sensitized mice. CD4(+) T cells, but not other lymphocytes or innate cells, infiltrating in the airways produced IL-22, and one third of IL-22-producing CD4(+) T cells also produced IL-17A. The neutralization of IL-22 by anti-IL-22 antibody enhanced antigen-induced IL-13 production, eosinophil recruitment, and goblet cell hyperplasia in the airways. On the other hand, intranasal administration of recombinant IL-22 attenuated antigen-induced eosinophil recruitment into the airways. Moreover, anti-IL-22 antibody enhanced antigen-induced IL-25 production in the airways, and anti-IL-25 antibody reversed the enhancing effect of anti-IL-22 antibody on antigen-induced eosinophil recruitment into the airways. Finally, IL22 inhibited IL-13-mediated enhancement of IL-25 expression in IL-1 beta- or LPS-stimulated MLE-15 cells. Conclusion: IL-22 attenuates antigen-induced airway inflammation, possibly by inhibiting IL-25 production by lung epithelial cells. (J Allergy Clin Immunol 2011;128:1067-76.)	[Takahashi, Kentaro; Hirose, Koichi; Kawashima, Saki; Niwa, Yusuke; Wakashin, Hidefumi; Iwata, Arifumi; Nakajima, Hiroshi] Chiba Univ, Grad Sch Med, Dept Mol Genet, Chiba 2608670, Japan; [Tokoyoda, Koji; Nakayama, Toshinori] Chiba Univ, Grad Sch Med, Dept Immunol, Chiba 2608670, Japan; [Renauld, Jean-Christophe] Catholic Univ Louvain, Ludwig Inst Canc Res, Brussels Branch, de Duve Inst, B-1200 Brussels, Belgium; [Iwamoto, Itsuo] Asahi Gen Hosp, Res Ctr Allergy & Clin Immunol, Chiba, Japan	Chiba University; Chiba University; Ludwig Institute for Cancer Research; Universite Catholique Louvain	Nakajima, H (corresponding author), Chiba Univ, Grad Sch Med, Dept Mol Genet, 1-8-1 Inohana, Chiba 2608670, Japan.	hirose-kh@faculty.chiba-u.jp; nakajimh@faculty.chiba-u.jp	Nakajima, Hiroshi/AFU-9313-2022; Renauld, Jean-Christophe/B-7268-2012; Nakayama, Toshinori/E-1067-2017	Nakajima, Hiroshi/0000-0001-8595-9381; Tokoyoda, Koji/0000-0001-6101-4826; Renauld, Jean-Christophe/0000-0003-1736-2131; Nakayama, Toshinori/0000-0002-1434-2007	Ministry of Education, Culture, Sports, Science and Technology; Japanese Government; (Global Center for Education and Research in Immune System Regulation and Treatment), MEXT, Japan; Grants-in-Aid for Scientific Research [22689014, 21390255] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japanese Government; (Global Center for Education and Research in Immune System Regulation and Treatment), MEXT, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	Supported in part by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology, the Japanese Government, and by the Global COE Program (Global Center for Education and Research in Immune System Regulation and Treatment), MEXT, Japan.	Aujla SJ, 2008, NAT MED, V14, P275, DOI 10.1038/nm1710; Ballantyne SJ, 2007, J ALLERGY CLIN IMMUN, V120, P1324, DOI 10.1016/j.jaci.2007.07.051; Besnard AG, 2011, AM J RESP CRIT CARE, V183, P1153, DOI 10.1164/rccm.201008-1383OC; Busse WW, 2001, NEW ENGL J MED, V344, P350, DOI 10.1056/NEJM200102013440507; Cella M, 2009, NATURE, V457, P722, DOI 10.1038/nature07537; Chakir J, 2003, J ALLERGY CLIN IMMUN, V111, P1293, DOI 10.1067/mai.2003.1557; Colonna M, 2009, IMMUNITY, V31, P15, DOI 10.1016/j.immuni.2009.06.008; Duhen T, 2009, NAT IMMUNOL, V10, P857, DOI 10.1038/ni.1767; Eyerich S, 2009, J CLIN INVEST, V119, P3573, DOI 10.1172/JCI40202; Fehervari Z, 2004, INT IMMUNOL, V16, P1769, DOI 10.1093/intimm/dxh178; Fort MM, 2001, IMMUNITY, V15, P985, DOI 10.1016/S1074-7613(01)00243-6; Gavett SH, 1999, J CLIN INVEST, V104, P721, DOI 10.1172/JCI6890; Hebenstreit D, 2005, MOL IMMUNOL, V42, P295, DOI 10.1016/j.molimm.2004.09.004; Hughes T, 2010, IMMUNITY, V32, P803, DOI 10.1016/j.immuni.2010.06.007; Lajoie S, 2010, NAT IMMUNOL, V11, P928, DOI 10.1038/ni.1926; Liang SC, 2006, J EXP MED, V203, P2271, DOI 10.1084/jem.20061308; Maezawa Y, 2006, J IMMUNOL, V176, P1013, DOI 10.4049/jimmunol.176.2.1013; McKinley L, 2008, J IMMUNOL, V181, P4089, DOI 10.4049/jimmunol.181.6.4089; Medoff BD, 2008, ANNU REV IMMUNOL, V26, P205, DOI 10.1146/annurev.immunol.26.021607.090312; Molet S, 2001, J ALLERGY CLIN IMMUN, V108, P430, DOI 10.1067/mai.2001.117929; NAKAJIMA H, 1992, AM REV RESPIR DIS, V146, P374, DOI 10.1164/ajrccm/146.2.374; Nograles KE, 2009, J ALLERGY CLIN IMMUN, V123, P1244, DOI 10.1016/j.jaci.2009.03.041; Pickert G, 2009, J EXP MED, V206, P1465, DOI 10.1084/jem.20082683; Saenz SA, 2008, IMMUNOL REV, V226, P172, DOI 10.1111/j.1600-065X.2008.00713.x; Satoh-Takayama N, 2008, IMMUNITY, V29, P958, DOI 10.1016/j.immuni.2008.11.001; Schnyder B, 2010, CYTOKINE, V50, P220, DOI 10.1016/j.cyto.2010.02.003; Sonnenberg GF, 2010, ADV IMMUNOL, V107, P1, DOI [10.1016/S0065-2776(10)07008-2, 10.1016/B978-0-12-381300-8.00001-0]; Sonnenberg GF, 2010, J EXP MED, V207, P1293, DOI 10.1084/jem.20092054; Sugimoto K, 2008, J CLIN INVEST, V118, P534, DOI [10.1172/JC133194, 10.1172/JCI33194]; Suto A, 2008, J EXP MED, V205, P1369, DOI 10.1084/jem.20072057; Swamy M, 2010, NAT IMMUNOL, V11, P656, DOI 10.1038/ni.1905; Takatori H, 2009, J EXP MED, V206, P35, DOI 10.1084/jem.20072713; Tamachi T, 2006, J ALLERGY CLIN IMMUN, V118, P606, DOI 10.1016/j.jaci.2006.04.051; Tokoyoda K, 2009, IMMUNITY, V30, P721, DOI 10.1016/j.immuni.2009.03.015; Trifari S, 2009, NAT IMMUNOL, V10, P864, DOI 10.1038/ni.1770; Umetsu DT, 2002, NAT IMMUNOL, V3, P715, DOI 10.1038/ni0802-715; Veldhoen M, 2008, NATURE, V453, P106, DOI 10.1038/nature06881; Wahl C, 2009, J IMMUNOL, V182, P4521, DOI 10.4049/jimmunol.0802810; Wakashin H, 2008, AM J RESP CRIT CARE, V178, P1023, DOI 10.1164/rccm.200801-086OC; Wenzel SE, 2006, LANCET, V368, P804, DOI 10.1016/S0140-6736(06)69290-8; Whittington HA, 2004, AM J RESP CELL MOL, V31, P220, DOI 10.1165/rcmb.2003-0285OC; WIKENHEISER KA, 1993, P NATL ACAD SCI USA, V90, P11029, DOI 10.1073/pnas.90.23.11029; Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255; Wolk K, 2004, IMMUNITY, V21, P241, DOI 10.1016/j.immuni.2004.07.007; Wolk K, 2006, CYTOKINE GROWTH F R, V17, P367, DOI 10.1016/j.cytogfr.2006.09.001; Zenewicz LA, 2007, IMMUNITY, V27, P647, DOI 10.1016/j.immuni.2007.07.023; Zenewicz LA, 2008, IMMUNITY, V29, P947, DOI 10.1016/j.immuni.2008.11.003; Zhao Y, 2010, INT ARCH ALLERGY IMM, V151, P297, DOI 10.1159/000250438; Zheng Y, 2007, NATURE, V445, P648, DOI 10.1038/nature05505; Zimmermann N, 2003, J ALLERGY CLIN IMMUN, V111, P227, DOI 10.1067/mai.2003.139	50	76	79	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2011	128	5					1067	U526		10.1016/j.jaci.2011.06.018	http://dx.doi.org/10.1016/j.jaci.2011.06.018			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	842FJ	21794904				2022-12-18	WOS:000296578200021
J	Kaplan, AP				Kaplan, Allen P.			Enzymatic pathways in the pathogenesis of hereditary angioedema: The role of C1 inhibitor therapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Angioedema; bradykinin; kallikrein; kininogen; factor XII; endothelial cells	ACQUIRED C1-INHIBITOR DEFICIENCY; FACTOR-XII; HAGEMAN-FACTOR; ANGIONEUROTIC-EDEMA; MISSENSE MUTATIONS; LARYNGEAL EDEMA; ACUTE ATTACKS; BRADYKININ; PLASMA; ACTIVATION	A functional abnormality of C1 inhibitor (C1INH) is present in types I and II hereditary angioedema (HAE), and normal C1INH may be rendered ineffective in the newly described type III HAE. C1INH inhibits factor XIIa, factor XII fragment (XIIf), kallikrein, and plasmin. Thus, in its absence, there is marked activation of the bradykinin-forming cascade resulting in severe angioedema. Factor XII may autoactivate on binding to endothelial cell surface gC1qR (receptor for the globular heads of C1q) thus initiating the cascade. Alternatively, stimuli that activate endothelial cells may liberate (or express at the cell surface) heat shock protein 90 or the enzyme prolylcarboxypeptidase, either of which can interact with the prekallikrein-high-molecular-weight kininogen complex to convert prekallikrein to kallikrein stoichiometrically. The kallikrein produced can cleave high-molecular-weight kininogen to produce bradykinin and also recruit factor XII by enzymatically activating it. Patients with type I or II HAE have mutant C1INH so that control of C1 activation is lost. Autoactivation of C1r in the absence of C1INH leads to C1s activation followed by C4 cleavage and depletion. An attack of swelling is accompanied by conversion of factor XIIa to factor XIIf and further enzymatic activation of C1r so that C4 levels drop further and C2 is depleted. New therapies for HAE focus on the bradykinin-forming cascade and include a kallikrein inhibitor and a bradykinin B-2 receptor antagonist in addition to administration of purified C1INH. (J Allergy Clin Immunol 2010; 126:918-25.)	[Kaplan, Allen P.] Med Univ S Carolina, Charleston, SC USA	Medical University of South Carolina	Kaplan, AP (corresponding author), 17 Logan St, Charleston, SC 29401 USA.	kaplana@musc.edu			ViroPharma Inc.	ViroPharma Inc.	Editorial support was provided by Innovative Strategic Communications LLC and was funded by ViroPharma Inc.	AGOSTONI A, 1992, MEDICINE, V71, P206, DOI 10.1097/00005792-199207000-00003; Agostoni A, 2004, J ALLERGY CLIN IMMUN, V114, pS51, DOI 10.1016/j.jaci.2004.06.047; ALSENZ J, 1987, NEW ENGL J MED, V316, P1360, DOI 10.1056/NEJM198705283162202; Bemstein JA, 2008, ANN ALLERG ASTHMA IM, V100, pS41, DOI 10.1016/S1081-1206(10)60585-6; Bork K, 2003, J AM DENT ASSOC, V134, P1088, DOI 10.14219/jada.archive.2003.0323; Bork K, 2000, MAYO CLIN PROC, V75, P349, DOI 10.4065/75.4.349; Bork K, 2007, J ALLERGY CLIN IMMUN, V119, P1497, DOI 10.1016/j.jaci.2007.02.012; Bork K, 2009, J ALLERGY CLIN IMMUN, V124, P129, DOI 10.1016/j.jaci.2009.03.038; Bossi F, 2009, J ALLERGY CLIN IMMUN, V124, P1303, DOI 10.1016/j.jaci.2009.08.007; Bouillet L, 2009, ANN ALLERG ASTHMA IM, V103, P448, DOI 10.1016/S1081-1206(10)60369-9; Bowen T, 2008, ANN ALLERG ASTHMA IM, V100, pS30, DOI 10.1016/S1081-1206(10)60584-4; Caldwell JR, 1972, CLIN IMMUNOL IMMUNOP, V1, P39; Cicardi M, 2010, NEW ENGL J MED, V363, P532, DOI 10.1056/NEJMoa0906393; Cicardi M, 2010, CURR MOL MED, V10, P354, DOI 10.2174/156652410791317066; Cicardi M, 2010, NEW ENGL J MED, V363, P523, DOI 10.1056/NEJMoa0905079; Cichon S, 2006, AM J HUM GENET, V79, P1098, DOI 10.1086/509899; Craig T, 2009, ANN ALLERG ASTHMA IM, V102, P366, DOI 10.1016/S1081-1206(10)60506-6; Cugno M, 2003, INT IMMUNOPHARMACOL, V3, P311, DOI 10.1016/S1567-5769(02)00162-5; CUGNO M, 1993, J LAB CLIN MED, V121, P38; Cugno M, 2009, TRENDS MOL MED, V15, P69, DOI 10.1016/j.molmed.2008.12.001; Dewald G, 2006, BIOCHEM BIOPH RES CO, V343, P1286, DOI 10.1016/j.bbrc.2006.03.092; Donaldson V H, 1977, Trans Assoc Am Physicians, V90, P174; DONALDSON VH, 1963, AM J MED, V35, P37, DOI 10.1016/0002-9343(63)90162-1; Duan QL, 2009, J ALLERGY CLIN IMMUN, V123, P906, DOI 10.1016/j.jaci.2008.12.010; Dunn CJ, 1999, DRUGS, V57, P1005, DOI 10.2165/00003495-199957060-00017; FIELDS T, 1983, J ALLERGY CLIN IMMUN, V72, P54, DOI 10.1016/0091-6749(83)90052-0; Frank MM, 2008, ANN ALLERG ASTHMA IM, V100, pS23, DOI 10.1016/S1081-1206(10)60583-2; GEHA RS, 1985, NEW ENGL J MED, V312, P534, DOI 10.1056/NEJM198502283120902; GHEBREHIWET B, 1983, J CLIN INVEST, V71, P1450, DOI 10.1172/JCI110898; Gompels MM, 2005, CLIN EXP IMMUNOL, V139, P379, DOI 10.1111/j.1365-2249.2005.02726.x; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; ICHINOSE A, 1986, J BIOL CHEM, V261, P3486; Joseph K, 2002, P NATL ACAD SCI USA, V99, P896, DOI 10.1073/pnas.022626899; Joseph K, 2001, THROMB HAEMOSTASIS, V85, P119; Joseph K, 2008, ANN ALLERG ASTHMA IM, V101, P279, DOI 10.1016/S1081-1206(10)60493-0; Joseph K, 2009, J ALLERGY CLIN IMMUN, V124, P143, DOI 10.1016/j.jaci.2009.02.006; Kaplan AP, 2005, J AM ACAD DERMATOL, V53, P373, DOI 10.1016/j.jaad.2004.09.032; Kaplan AP, 2002, J ALLERGY CLIN IMMUN, V109, P195, DOI 10.1067/mai.2002.121316; KAPLAN AP, 1971, J EXP MED, V133, P696, DOI 10.1084/jem.133.4.696; Krassilnikova SI, 2008, RECENT PATENTS INFLA, V2, P166, DOI 10.2174/187221308786241866; MALBRAN A, 1988, J ALLERGY CLIN IMMUN, V81, P1199, DOI 10.1016/0091-6749(88)90891-3; Milton J L, 1876, Edinb Med J, V22, P513; MOORE GP, 1988, ANN EMERG MED, V17, P1082, DOI 10.1016/S0196-0644(88)80450-5; Nzeako UC, 2001, ARCH INTERN MED, V161, P2417, DOI 10.1001/archinte.161.20.2417; Osler W, 1888, AM J MED SCI, V95, P362; Pappalardo E, 2008, MOL IMMUNOL, V45, P3536, DOI 10.1016/j.molimm.2008.05.007; Prada AE, 1998, IMMUNOBIOLOGY, V199, P377, DOI 10.1016/S0171-2985(98)80042-9; ROSEN FS, 1965, SCIENCE, V148, P957, DOI 10.1126/science.148.3672.957; Schneider L, 2007, J ALLERGY CLIN IMMUN, V120, P416, DOI 10.1016/j.jaci.2007.04.028; SHOEMAKER LR, 1994, CLIN EXP IMMUNOL, V95, P22; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; SIM TC, 1990, AM J MED, V88, P656, DOI 10.1016/0002-9343(90)90535-L; SMITH MA, 1985, IMMUNOLOGY, V56, P561; WIGGINS CA, 1988, J ALLERGY CLIN IMMUN, V82, P849, DOI 10.1016/0091-6749(88)90089-9; Zuraw BL, 2008, ANN ALLERG ASTHMA IM, V100, pS13, DOI 10.1016/S1081-1206(10)60581-9; Zuraw BL, 2010, NEW ENGL J MED, V363, P513, DOI 10.1056/NEJMoa0805538	56	76	89	1	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2010	126	5					918	925		10.1016/j.jaci.2010.08.012	http://dx.doi.org/10.1016/j.jaci.2010.08.012			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	674HB	20889195				2022-12-18	WOS:000283727100004
J	Zaba, LC; Fuentes-Duculan, J; Eungdamrong, NJ; Johnson-Huang, LM; Nograles, KE; White, TR; Pierson, KC; Lentini, T; Suarez-Farinas, M; Lowes, MA; Krueger, JG				Zaba, Lisa C.; Fuentes-Duculan, Judilyn; Eungdamrong, Narat John; Johnson-Huang, Leanne M.; Nograles, Kristine E.; White, Traci R.; Pierson, Katherine C.; Lentini, Tim; Suarez-Farinas, Mayte; Lowes, Michelle A.; Krueger, James G.			Identification of TNF-related apoptosis-inducing ligand and other molecules that distinguish inflammatory from resident dendritic cells in patients with psoriasis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						TRAIL; psoriasis; dendritic cell; inflammation; CCL20; Toll-like receptor 1; Toll-like receptor 2; S100A12; CD32	EXPRESSION; TRAIL; RECEPTOR; POPULATIONS; INHIBITION; ACTIVATION; INDUCTION; RELEVANCE; ALPHA; TH1	Background: Previous work has identified CD11c(+)CD1c(-) dendritic cells (DCs) as the major "inflammatory" dermal DC population in patients with psoriasis vulgaris and CD1c(+) DCs as the "resident" cutaneous DC population. Objective: We sought to further define molecular differences between these 2 myeloid dermal DC populations. Methods: Inflammatory and resident DCs were single-cell sorted from lesional skin biopsy specimens of patients with psoriasis, and the transcriptome of CD11c(+)CD1c(-) versus CD1c(+) DCs was determined. Results were confirmed with RT-PCR, flow cytometry, immunohistochemistry, and double-labeled immunofluorescence. Human keratinocytes were cultured for functional studies. Results: TNF-related apoptosis-inducing ligand (TRAIL), Toll-like receptors 1 and 2, S1000A12/ENRAGE, CD32, and many other inflammatory products were differentially expressed in inflammatory DCs compared with resident DCs. Flow cytometry and immunofluorescence confirmed higher protein expression on CD1c(-) versus CD1c(+) DCs. TRAIL receptors, death receptor 4, and decoy receptor 2 were expressed in keratinocytes and dermal cells. In vitro culture of keratinocytes with TRAIL induced CCL20 chemokine. Conclusions: CD11c(+)CD1c(-) inflammatory DCs in psoriatic lesional skin express a wide range of inflammatory molecules compared with skin-resident CD1c(+) DCs. Some molecules made by inflammatory DCs, including TRAIL, could have direct effects on keratinocytes or other skin cell types to promote disease pathogenesis. (J Allergy Clin Immunol 2010;125:1261-8.)	[Zaba, Lisa C.; Fuentes-Duculan, Judilyn; Eungdamrong, Narat John; Johnson-Huang, Leanne M.; Nograles, Kristine E.; White, Traci R.; Pierson, Katherine C.; Lentini, Tim; Suarez-Farinas, Mayte; Lowes, Michelle A.; Krueger, James G.] Rockefeller Univ, Lab Investigat Dermatol, New York, NY 10065 USA; [Suarez-Farinas, Mayte] Rockefeller Univ, Ctr Clin & Translat Sci, New York, NY 10065 USA	Rockefeller University; Rockefeller University	Krueger, JG (corresponding author), Rockefeller Univ, Lab Investigat Dermatol, 1230 York Ave,Box 178, New York, NY 10065 USA.	jgk@rockefeller.edu	Suarez-Farinas, Mayte/I-3558-2012; Nograles, Kristine/V-3648-2019; Zaba, Lisa/Q-9681-2019; Lowes, Michelle A/G-9585-2016	Suarez-Farinas, Mayte/0000-0001-8712-3553; Lowes, Michelle A/0000-0003-4256-478X; Zaba, Lisa/0000-0001-9036-5465	National Institutes of Health (NIH), National Center for Research Resources (NCRR) [UL1 RR024143]; NIH [UL1 RR024143, GM07739]; Dana Foundation; Rockefeller University; Doris Duke Charitable Foundation; Amgen;  [1 K23 AR052404-01A1]; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024143] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K23AR052404] Funding Source: NIH RePORTER	National Institutes of Health (NIH), National Center for Research Resources (NCRR)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Dana Foundation; Rockefeller University; Doris Duke Charitable Foundation(Doris Duke Charitable Foundation (DDCF)); Amgen(Amgen); ; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	Supported by National Institutes of Health (NIH) grant UL1 RR024143 from the National Center for Research Resources (NCRR). L. C. Z. is supported by NIH MSTP grant GM07739. K. C. P. is supported by the Dana Foundation (Human Immunology Consortium Grant). K. E. N. is supported by the Clinical Scholars Program at the Rockefeller University. M. S.-F. is partially supported by NIH grant UL1 RR024143. M. A. L. is supported by 1 K23 AR052404-01A1 and the Doris Duke Charitable Foundation.; Disclosure of potential conflict of interest: J. G. Krueger has received research support from Amgen. The rest of the authors have declared that they have no conflict of interest.	Boruchov AM, 2005, J CLIN INVEST, V115, P2914, DOI 10.1172/JCI24772; Chamian F, 2005, P NATL ACAD SCI USA, V102, P2075, DOI 10.1073/pnas.0409569102; Collison A, 2009, CLIN EXP PHARMACOL P, V36, P1049, DOI 10.1111/j.1440-1681.2009.05258.x; Gottlieb AB, 2005, J IMMUNOL, V175, P2721, DOI 10.4049/jimmunol.175.4.2721; Griffith TS, 1998, J IMMUNOL, V161, P2833; Guttman-Yassky E, 2008, J IMMUNOL, V181, P7420, DOI 10.4049/jimmunol.181.10.7420; Haider AS, 2008, J INVEST DERMATOL, V128, P606, DOI 10.1038/sj.jid.5701067; Hofmann MA, 1999, CELL, V97, P889, DOI 10.1016/S0092-8674(00)80801-6; Kavurma MM, 2008, J BIOL CHEM, V283, P7754, DOI 10.1074/jbc.M706927200; Kemp TJ, 2003, J IMMUNOL, V171, P212, DOI 10.4049/jimmunol.171.1.212; Kroll TM, 2005, J INVEST DERMATOL, V124, P798, DOI 10.1111/j.0022-202X.2005.23653.x; Kryczek I, 2008, J IMMUNOL, V181, P4733, DOI 10.4049/jimmunol.181.7.4733; Li JH, 2003, J IMMUNOL, V171, P1526, DOI 10.4049/jimmunol.171.3.1526; Li S, 2009, P NATL ACAD SCI USA, V106, P4349, DOI 10.1073/pnas.0810844106; Lowes MA, 2005, P NATL ACAD SCI USA, V102, P19057, DOI 10.1073/pnas.0509736102; Lowes MA, 2008, J INVEST DERMATOL, V128, P1207, DOI 10.1038/sj.jid.5701213; Lowes MA, 2007, NATURE, V445, P866, DOI 10.1038/nature05663; Machata S, 2008, J IMMUNOL, V181, P2028, DOI 10.4049/jimmunol.181.3.2028; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Ringner M, 2008, NAT BIOTECHNOL, V26, P303, DOI 10.1038/nbt0308-303; Sigmundsdottir H, 2004, EXP DERMATOL, V13, P426, DOI 10.1111/j.0906-6705.2004.00177.x; Stary G, 2007, J EXP MED, V204, P1441, DOI 10.1084/jem.20070021; Takeda K, 2002, J EXP MED, V195, P161, DOI 10.1084/jem.20011171; Vassina E, 2005, J INVEST DERMATOL, V125, P746, DOI 10.1111/j.0022-202X.2005.23878.x; Wang F, 2006, J INVEST DERMATOL, V126, P1590, DOI 10.1038/sj.jid.5700310; Weckmann M, 2007, NAT MED, V13, P1308, DOI 10.1038/nm1660; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Zaba LC, 2007, J EXP MED, V204, P3183, DOI 10.1084/jem.20071094; Zaba LC, 2007, J CLIN INVEST, V117, P2517, DOI 10.1172/JCI32282; Zaba LC, 2009, J ALLERGY CLIN IMMUN, V124, P1022, DOI 10.1016/j.jaci.2009.08.046; Zaba LC, 2009, J INVEST DERMATOL, V129, P79, DOI 10.1038/jid.2008.194; Zhang XR, 2003, CELL DEATH DIFFER, V10, P203, DOI 10.1038/sj.cdd.4401138	33	76	82	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2010	125	6					1261	1268		10.1016/j.jaci.2010.03.018	http://dx.doi.org/10.1016/j.jaci.2010.03.018			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	611PH	20471070	Green Accepted			2022-12-18	WOS:000278831000013
J	Gros, E; Bussmann, C; Bieber, T; Forster, I; Novak, N				Gros, Eva; Bussmann, Caroline; Bieber, Thomas; Foerster, Irmgard; Novak, Natalija			Expression of chemokines and chemokine receptors in lesional and nonlesional upper skin of patients with atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Dendritic cells; chemokines; chemokine receptors; atopic dermatitis; atopy patch test	DENDRITIC CELLS; LANGERHANS CELLS; T-CELLS; TACROLIMUS; INFLAMMATION; DISEASE	Background: Trafficking of dendritic cell (DC) subtypes to and from the skin plays a pivotal role in atopic dermatitis (AD). Objectives: We sought to determine the CCR pattern of epidermal DC subtypes and CCL expression in relation to the state of AD. Methods: Shave biopsy specimens were taken from patients with AD before and after 24 and 72 hours of atopy patch testing and from the skin of patients with chronic AD, skin of patients with psoriasis, and healthy skin. CCR expression of epidermal DCs was studied by using flow cytometry, and chemo me mRNA levels in the skin were quantified by means of real-time PCR. Results: The total number of CD1a(+) epidermal DCs increased and the proportion of Langerin-positive CD1a(+) DCs decreased whereas the percentage of Langerin-negative CD1a(+) DCs increased after allergen application. Expression of CCR5 and CCR6 of Langerin-negative CD1a(+) DCs was characteristic for acute AD. Expression of CCL1 CCL3, CCL4, and CCL11 mRNA was greater in patients with acute AD versus that seen in patients with chronic AD. Only a strong increase of CCLs, in particular CCL1, CCL17, and CCL18, went along with eczema development, and increased CCL1, CCL13, CCL17 and CCL18 expression was specific for patients with chronic AD compared with those with psoriasis. Conclusion: Modified recruitment and differentiation of DCs from their dermal and blood precursors occurs in the acute phase of AD. A boost in the amplitude of CCLs after allergen application goes along with eczema development. (J Allergy Clin Immunol 2009;124:753-60.)	[Gros, Eva; Bussmann, Caroline; Bieber, Thomas; Novak, Natalija] Univ Bonn, Med Ctr, Dept Dermatol & Allergy, D-53105 Bonn, Germany; [Foerster, Irmgard] Univ Dusseldorf, Inst Umweltmed Forsch, D-4000 Dusseldorf, Germany	University of Bonn; Heinrich Heine University Dusseldorf	Novak, N (corresponding author), Univ Bonn, Med Ctr, Dept Dermatol & Allergy, Sigmund Freud Str 25, D-53105 Bonn, Germany.	Natalija.Novak@ukb.uni-bonn.de	Förster, Irmgard/P-8545-2016	Förster, Irmgard/0000-0002-7644-5642	Deutsche Forschungsgemeinschaft (DFG) [N0454/1-4, SFB704 TPA1, SFB704 TPA4, SFB704 TPA15, NO454/5-2]; University of Bonn	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); University of Bonn	Supported by grants from the Deutsche Forschungsgemeinschaft (DFG N0454/1-4; SFB704 TPA1, TPA4 and TPA15) and a BONFOR grant of the University of Bonn. N. N. is supported by a Heisenberg-Professorship of the DFG NO454/5-2.	Bieber T, 2008, NEW ENGL J MED, V358, P1483, DOI 10.1056/NEJMra074081; Gombert M, 2005, J IMMUNOL, V174, P5082, DOI 10.4049/jimmunol.174.8.5082; Grewe M, 1998, IMMUNOL TODAY, V19, P359, DOI 10.1016/S0167-5699(98)01285-7; Gunther C, 2005, J IMMUNOL, V174, P1723, DOI 10.4049/jimmunol.174.3.1723; Hanifin JM, 1999, ARCH DERMATOL, V135, P1551, DOI 10.1001/archderm.135.12.1551; Homey B, 1999, CURR OPIN IMMUNOL, V11, P626, DOI 10.1016/S0952-7915(99)00028-X; Homey B, 2006, J ALLERGY CLIN IMMUN, V118, P178, DOI 10.1016/j.jaci.2006.03.047; Kerschenlohr K, 2003, J ALLERGY CLIN IMMUN, V111, P869, DOI 10.1067/mai.2003.1347; Kwiek B, 2008, J ALLERGY CLIN IMMUN, V122, P126, DOI 10.1016/j.jaci.2008.05.005; Merad M, 2008, NAT REV IMMUNOL, V8, P935, DOI 10.1038/nri2455; Novak N, 2004, J ALLERGY CLIN IMMUN, V114, P364, DOI 10.1016/j.jaci.2004.05.038; Novak N, 2004, J ALLERGY CLIN IMMUN, V113, P949, DOI 10.1016/j.jaci.2004.02.005; Ong PY, 2002, J INVEST DERMATOL, V119, P1463, DOI 10.1046/j.1523-1747.2002.19624.x; Park CW, 2005, BRIT J DERMATOL, V152, P1173, DOI 10.1111/j.1365-2133.2005.06474.x; Pastore S, 2004, EUR J DERMATOL, V14, P203; Pease JE, 2006, J ALLERGY CLIN IMMUN, V118, P305, DOI 10.1016/j.jaci.2006.06.010; Pivarcsi A, 2004, J IMMUNOL, V173, P5810, DOI 10.4049/jimmunol.173.9.5810; Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217; Schuller E, 2004, J ALLERGY CLIN IMMUN, V114, P137, DOI 10.1016/j.jaci.2004.03.021; Simon D, 2005, ALLERGY, V60, P944, DOI 10.1111/j.1398-9995.2005.00798.x; Simon D, 2004, J ALLERGY CLIN IMMUN, V114, P887, DOI 10.1016/j.jaci.2004.05.066; Wollenberg A, 1999, CYTOMETRY, V37, P147, DOI 10.1002/(SICI)1097-0320(19991001)37:2<147::AID-CYTO8>3.0.CO;2-Y; Wollenberg A, 1996, J INVEST DERMATOL, V106, P446, DOI 10.1111/1523-1747.ep12343596	23	76	78	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2009	124	4					753	760		10.1016/j.jaci.2009.07.004	http://dx.doi.org/10.1016/j.jaci.2009.07.004			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	506UV	19767072				2022-12-18	WOS:000270802800021
J	Matsui, EC; Matsui, W				Matsui, Elizabeth C.; Matsui, William			Higher serum folate levels are associated with a lower risk of atopy and wheeze	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; allergy; atopy; folate; National Health and Nutrition Examination Survey; Centers for Disease Control	INDOOR NITROGEN-DIOXIDE; INNER-CITY CHILDREN; LUPUS T-CELLS; FOLIC-ACID; DNA METHYLATION; ENVIRONMENTAL INTERVENTION; PARASITE INFECTION; ALLERGEN EXPOSURE; ASTHMA; CHILDHOOD	Background: Folic acid is known to be associated with inflammatory diseases, but the relationship between folic acid and allergic diseases is unclear. Objectives: The purpose of the study was to examine the relationship between serum folate levels and markers of atopy, wheeze, and asthma. Methods: Data were obtained from the 2005-2006 National Health and Nutrition Examination Survey in which serum folate and total IgE levels were measured in 8083 subjects 2 years of age and older. A high total IgE level was defined as greater than 100 kU/L. Allergen-specific IgE levels were measured for a panel of 5 common aeroallergens. Atopy was defined as at least 1 positive allergen-specific IgE level. Doctor-diagnosed asthma and wheeze in the previous 12 months were assessed by means of questionnaire. Results: Serum folate levels were inversely associated with total IgE levels (P < .001). The odds of a high total IgE level, atopy, and wheeze decreased across quintiles of serum folate levels, indicating a dose-response relationship between serum folate levels and these outcomes. Each of these associations remained statistically significant after adjusting for age, sex, race/ethnicity, and poverty index ratio. Adjusted odds ratios associated with the fifth quintile of folate relative to the first quintile were as follows: high IgE level, 0.70 (95% CI, 0.53-0.92); atopy, 0.69 (95% CI, 0.57-0.85); and wheeze, 0.60 (95% CI, 0.44-0.82). Higher folate levels were also associated with a lower risk of doctor-diagnosed asthma, but this finding was not statistically significant (odds ratio for fifth quintile vs first quintile, 0.84 [95% CI, 0.70-1.02]). Conclusions: Serum folate levels are inversely associated with high total IgE levels, atopy, and wheeze. (J Allergy Clin Immunol 2009;123:1253-9.)	[Matsui, Elizabeth C.] Johns Hopkins Sch Med, Div Pediat Allergy & Immunol, Baltimore, MD 21218 USA; [Matsui, William] Johns Hopkins Sch Med, Dept Oncol, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Matsui, EC (corresponding author), Johns Hopkins Univ Hosp, CMSC 1102,600 N Wolfe St, Baltimore, MD 21287 USA.	ematsui1@jhmi.edu	Matsui, William H/C-3383-2009	Matsui, William/0000-0002-3088-0964; Matsui, Elizabeth/0000-0001-8134-5593	National Institute of Allergy and Infectious Diseases [R01A1070630]; National Institutes of Environmental Health Sciences [5P50ES015903]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI070630] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P50ES015903] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institutes of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by grants front the National Institute of Allergy and Infectious Diseases (R01A1070630) and the National Institutes of Environmental Health Sciences (DISCOVER Award 5P50ES015903).	Arbes SJ, 2005, J ALLERGY CLIN IMMUN, V116, P377, DOI 10.1016/j.jaci.2005.05.017; Bonaa KH, 2006, NEW ENGL J MED, V354, P1578, DOI 10.1056/NEJMoa055227; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Bruniquel D, 2003, NAT IMMUNOL, V4, P235, DOI 10.1038/ni887; Burns JS, 2007, CHEST, V132, P238, DOI 10.1378/chest.07-0038; Camargo CA, 2007, AM J CLIN NUTR, V85, P788, DOI 10.1093/ajcn/85.3.788; Castro-Rodriguez JA, 2008, J PEDIATR-US, V152, P823, DOI 10.1016/j.jpeds.2008.01.003; Centers for Disease Control and Prevention, NAT HLTH NUTR EX SUR; Connor SL, 2004, J AM DIET ASSOC, V104, P1793, DOI 10.1016/j.jada.2004.09.023; Dagoye D, 2003, AM J RESP CRIT CARE, V167, P1369, DOI 10.1164/rccm.200210-1204OC; Eggleston PA, 2005, ANN ALLERG ASTHMA IM, V95, P518, DOI 10.1016/S1081-1206(10)61012-5; Forman JP, 2005, JAMA-J AM MED ASSOC, V293, P320, DOI 10.1001/jama.293.3.320; Friso S, 2002, P NATL ACAD SCI USA, V99, P5606, DOI 10.1073/pnas.062066299; Granell R, 2008, CLIN EXP ALLERGY, V38, P320, DOI 10.1111/j.1365-2222.2007.02902.x; Haberg SE, 2009, ARCH DIS CHILD, V94, P180, DOI 10.1136/adc.2008.142448; Hansel NN, 2008, ENVIRON HEALTH PERSP, V116, P1428, DOI 10.1289/ehp.11349; Hollingsworth JW, 2008, J CLIN INVEST, V118, P3462, DOI 10.1172/JCI34378; Husemoen LLN, 2006, INT J EPIDEMIOL, V35, P954, DOI 10.1093/ije/dyl094; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Johnston NW, 2006, J ALLERGY CLIN IMMUN, V117, P557, DOI 10.1016/j.jaci.2005.11.034; Kattan M, 2007, J ALLERGY CLIN IMMUN, V120, P618, DOI 10.1016/j.jaci.2007.05.014; Klerk M, 2002, JAMA-J AM MED ASSOC, V288, P2023, DOI 10.1001/jama.288.16.2023; Kurzawski M, 2007, PHARMACOGENOMICS, V8, P1551, DOI 10.2217/14622416.8.11.1551; Kusel MMH, 2007, J ALLERGY CLIN IMMUN, V119, P1105, DOI 10.1016/j.jaci.2006.12.669; Lee KS, 2007, EXP MOL MED, V39, P756, DOI 10.1038/emm.2007.82; Leonardi-Bee J, 2006, AM J RESP CRIT CARE, V174, P514, DOI 10.1164/rccm.200603-331OC; Lewis SA, 2002, AM J RESP CRIT CARE, V165, P961, DOI 10.1164/ajrccm.165.7.2103044; Li J, 2008, CHEST, V133, P100, DOI 10.1378/chest.07-1467; Linehan MF, 2007, J ALLERGY CLIN IMMUN, V119, P1079, DOI 10.1016/j.jaci.2006.12.672; Linneberg A, 2007, CLIN EXP ALLERGY, V37, P1137, DOI 10.1111/j.1365-2222.2007.02760.x; Lu QJ, 2005, J IMMUNOL, V174, P6212, DOI 10.4049/jimmunol.174.10.6212; Matsui EC, 2006, ANN ALLERG ASTHMA IM, V97, P514, DOI 10.1016/S1081-1206(10)60943-X; McDonald KL, 2008, J ALLERGY CLIN IMMUN, V121, P626, DOI 10.1016/j.jaci.2007.11.034; McDowell MA, 2008, BLOOD FOLATE LEVELS; Moens AL, 2007, AM J CARDIOL, V99, P476, DOI 10.1016/j.amjcard.2006.08.057; Moore K, 2008, ENVIRON HEALTH PERSP, V116, P1063, DOI 10.1289/ehp.10497; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; Mortimer K, 2008, EPIDEMIOLOGY, V19, P550, DOI 10.1097/EDE.0b013e31816a9dcb; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Oelke K, 2004, ARTHRITIS RHEUM-US, V50, P1850, DOI 10.1002/art.20255; Perzanowski MS, 2006, J ALLERGY CLIN IMMUN, V117, P1082, DOI 10.1016/j.jaci.2005.12.1348; Perzanowski MS, 2002, AM J RESP CRIT CARE, V166, P696, DOI 10.1164/rccm.2201035; Robertson KD, 2005, NAT REV GENET, V6, P597, DOI 10.1038/nrg1655; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Morris MS, 2007, AM J CLIN NUTR, V85, P193, DOI 10.1093/ajcn/85.1.193; Schroecksnadel K, 2003, CLIN CHIM ACTA, V338, P157, DOI 10.1016/j.cccn.2003.09.003; Scrivener S, 2001, LANCET, V358, P1493, DOI 10.1016/S0140-6736(01)06579-5; Selhub J, 2008, FOOD NUTR BULL, V29, pS67, DOI 10.1177/15648265080292S110; Solini A, 2006, INT J OBESITY, V30, P1197, DOI 10.1038/sj.ijo.0803265; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Spycher BD, 2008, J ALLERGY CLIN IMMUN, V122, P656, DOI 10.1016/j.jaci.2008.06.037; Squillace SP, 1997, AM J RESP CRIT CARE, V156, P1760, DOI 10.1164/ajrccm.156.6.9704026; Thorne PS, 2005, AM J RESP CRIT CARE, V172, P1371, DOI 10.1164/rccm.200505-758OC; Wang R, 2008, BIOCHEM BIOPH RES CO, V373, P151, DOI 10.1016/j.bbrc.2008.06.004; Willers SM, 2008, AM J RESP CRIT CARE, V178, P124, DOI 10.1164/rccm.200710-1544OC; Yeung L, 2008, JAMA-J AM MED ASSOC, V300, P2486, DOI 10.1001/jama.2008.742	56	76	80	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2009	123	6					1253	1259		10.1016/j.jaci.2009.03.007	http://dx.doi.org/10.1016/j.jaci.2009.03.007			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	455WO	19409604	Green Accepted			2022-12-18	WOS:000266799100014
J	Jensen, JM; Pfeiffer, S; Witt, M; Brautigam, M; Neumann, C; Weichenthal, M; Schwarz, T; Folster-Holst, R; Proksch, E				Jensen, Jens-Michael; Pfeiffer, Stephan; Witt, Magdalena; Braeutigam, Matthias; Neumann, Claudia; Weichenthal, Michael; Schwarz, Thomas; Foelster-Holst, Regina; Proksch, Ehrhardt			Different effects of pimecrolimus and betamethasone on the skin barrier in patients with atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; skin barrier; pimecrolimus; corticosteroid; skin penetration	TRANSEPIDERMAL WATER-LOSS; STRATUM-CORNEUM; PERMEABILITY BARRIER; EPIDERMAL DIFFERENTIATION; LANGERHANS CELLS; UNINVOLVED SKIN; IN-VIVO; FILAGGRIN; ECZEMA; PENETRATION	Background: Genetic defects leading to skin barrier dysfunction were recognized as risk factors for atopic dermatitis (AD). It is essential that drugs applied to patients with AD restore the impaired epidermal barrier to prevent sensitization by environmental allergens. Objectives: We investigated the effect of 2 common treatments, a calcineurin inhibitor and a corticosteroid, on the skin barrier. Methods: In a randomized study 15 patients with AD were treated on one upper limb with pimecrolimus and on the other with betamethasone twice daily for 3 weeks. Results: Stratum corneum hydration and transepidermal water loss, a marker of the inside-outside barrier, improved in both groups. Dye penetration, a marker of the outside-inside barrier, was also reduced in both drugs. Electron microscopic evaluation of barrier structure displayed prevalently ordered stratum corneum lipid layers and regular lamellar body extrusion in pimecrolimus-treated skin but inconsistent extracellular lipid bilayers and only partially filled lamellar bodies after betamethasone treatment. Both drugs normalized epidermal differentiation and reduced epidermal hyperproliferation. Betamethasone was superior in reducing clinical symptoms and epidermal proliferation; however, it led to epidermal thinning. Conclusion: The present study demonstrates that both betamethasone and pimecrolimus improve clinical and biophysical parameters and epidermal differentiation. Because pimecrolimus improved the epidermal barrier and did not cause atrophy, it might be more suitable for long-term treatment of AD. (J Allergy Clin Immunol 2009;123:1124-33.)	[Jensen, Jens-Michael; Witt, Magdalena; Neumann, Claudia; Weichenthal, Michael; Schwarz, Thomas; Foelster-Holst, Regina; Proksch, Ehrhardt] Univ Kiel, Dept Dermatol, D-24105 Kiel, Germany; [Pfeiffer, Stephan] Microscopy Serv, Flintbek, Germany; [Braeutigam, Matthias] Novartis Pharma GmbH, Clin Res, Nurnberg, Germany	University of Kiel; Novartis	Proksch, E (corresponding author), Univ Kiel, Dept Dermatol, Schittenhelmstr 7, D-24105 Kiel, Germany.	eproksch@dermatology.uni-kiel.de	Schwarz, Thomas/A-9148-2010; Fölster-Holst, Regina/A-9560-2010	Braeutigam, Matthias/0000-0002-1961-6396	Deutsche Forschungsgemeinschaft [SFB415/B2, SFB617/A7, A21]; Novartis Pharma, Nurnberg (Germany)	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Novartis Pharma, Nurnberg (Germany)	Supported by grants of the Deutsche Forschungsgemeinschaft (SFB415/B2 and SFB617/A7, A21) and Novartis Pharma, Nurnberg (Germany), given to E. Proksch and J.-M. Jensen. T. Schwarz and E. Proksch have acted as consultants to Novartis. M. Brautigam is employed by Novartis.; Disclosure of potential conflict of interest: J.-M. Jensen has received a travel grant from Novartis. T. Schwarz has received grants from Novartis and Therakos and has served as an advisor for Novartis. The rest of the authors have declared that they have no conflict of interest.	AALTOKORTE K, 1995, J AM ACAD DERMATOL, V33, P969, DOI 10.1016/0190-9622(95)90288-0; AGNER T, 1992, ACTA DERM-VENEREOL, P1; Allam JP, 2006, CLIN EXP DERMATOL, V31, P89, DOI 10.1111/j.1365-2230.2005.01980.x; BOS JD, 1994, LANCET, V343, P1338, DOI 10.1016/S0140-6736(94)92473-2; Cookson W, 2004, NAT REV IMMUNOL, V4, P978, DOI 10.1038/nri1500; Elias P M, 1999, Am J Contact Dermat, V10, P119, DOI 10.1016/S1046-199X(99)90054-4; Elias PM, 2008, J ALLERGY CLIN IMMUN, V121, P1337, DOI 10.1016/j.jaci.2008.01.022; ELIAS PM, 1991, ADV LIPID RES, V24, P1; ELIAS PM, 1975, J CELL BIOL, V65, P180, DOI 10.1083/jcb.65.1.180; Elias PM, 2001, ARCH DERMATOL, V137, P1079; Endo K, 2007, SKIN RES TECHNOL, V13, P425, DOI 10.1111/j.1600-0846.2007.00247.x; FARTASCH M, 1992, BRIT J DERMATOL, V127, P221, DOI 10.1111/j.1365-2133.1992.tb00118.x; Folster-Holst R, 2006, ALLERGY, V61, P629, DOI 10.1111/j.1398-9995.2006.01076.x; GUILLET G, 1992, ARCH DERMATOL, V128, P187, DOI 10.1001/archderm.128.2.187; HASHIMOTOKUMASAKA K, 1993, ACTA DERM-VENEREOL, V73, P335; Hazelbag HM, 2003, AM J SURG PATHOL, V27, P1530, DOI 10.1097/00000478-200312000-00005; Hengge UR, 2006, J AM ACAD DERMATOL, V54, P1, DOI 10.1016/j.jaad.2005.01.010; Hoetzenecker W, 2004, J INVEST DERMATOL, V122, P673, DOI 10.1111/j.0022-202X.2004.22324.x; Howell MD, 2007, J ALLERGY CLIN IMMUN, V120, P150, DOI 10.1016/j.jaci.2007.04.031; Jakasa I, 2006, BRIT J DERMATOL, V155, P104, DOI 10.1111/j.1365-2133.2006.07319.x; Jakasa I, 2007, J INVEST DERMATOL, V127, P129, DOI 10.1038/sj.jid.5700582; Jensen JM, 2004, J INVEST DERMATOL, V122, P1423, DOI 10.1111/j.0022-202X.2004.22621.x; Kato JS, 2003, J INVEST DERMATOL, V120, P456, DOI 10.1046/j.1523-1747.2003.12053.x; Kim BE, 2008, CLIN IMMUNOL, V126, P332, DOI 10.1016/j.clim.2007.11.006; Kolbe L, 2001, SKIN RES TECHNOL, V7, P73, DOI 10.1034/j.1600-0846.2001.70203.x; Leung DYM, 2003, LANCET, V361, P151, DOI 10.1016/S0140-6736(03)12193-9; LUFT JH, 1961, J BIOPHYS BIOCHEM CY, V9, P409, DOI 10.1083/jcb.9.2.409; Luger T, 2001, EUR J DERMATOL, V11, P343; Meingassner JG, 2005, EXP DERMATOL, V14, P752, DOI 10.1111/j.1600-0625.2005.00354.x; Meingassner JG, 2003, BRIT J DERMATOL, V149, P853, DOI 10.1046/j.1365-2133.2003.05559.x; Morar N, 2006, J ALLERGY CLIN IMMUN, V118, P24, DOI 10.1016/j.jaci.2006.03.037; Novak N, 2005, CLIN EXP DERMATOL, V30, P160, DOI 10.1111/j.1365-2230.2005.01709.x; Ogawa Hideoki, 1993, Journal of Dermatological Science, V5, P197, DOI 10.1016/0923-1811(93)90767-J; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; PINNAGODA J, 1990, CONTACT DERMATITIS, V22, P164, DOI 10.1111/j.1600-0536.1990.tb01553.x; Proksch E, 2003, CLIN DERMATOL, V21, P134, DOI 10.1016/S0738-081X(02)00370-X; Proksch E, 2006, J DERMATOL SCI, V43, P159, DOI 10.1016/j.jdermsci.2006.06.003; Queille-Roussel C, 2001, BRIT J DERMATOL, V144, P507, DOI 10.1046/j.1365-2133.2001.04076.x; REYNOLDS ES, 1963, J CELL BIOL, V17, P208, DOI 10.1083/jcb.17.1.208; Ruether A, 2006, BRIT J DERMATOL, V155, P1093, DOI 10.1111/j.1365-2133.2006.07500.x; SCOTT IR, 1986, DEV BIOL, V115, P84, DOI 10.1016/0012-1606(86)90230-7; Seguchi T, 1996, ARCH DERMATOL RES, V288, P442, DOI 10.1007/s004030050080; Sheu HM, 1997, BRIT J DERMATOL, V136, P884, DOI 10.1111/j.1365-2133.1997.tb03929.x; Stuetz A, 2001, SEMIN CUTAN MED SURG, V20, P233, DOI 10.1053/sder.2001.29066; Stuetz A, 2006, INT ARCH ALLERGY IMM, V141, P199, DOI 10.1159/000095289; Sugarman JL, 2003, ARCH DERMATOL, V139, P1417, DOI 10.1001/archderm.139.11.1417; Tate M, 2007, SKIN RES TECHNOL, V13, P293, DOI 10.1111/j.1600-0846.2007.00227.x; Tunggal JA, 2005, EMBO J, V24, P1146, DOI 10.1038/sj.emboj.7600605; Weidinger S, 2006, J ALLERGY CLIN IMMUN, V118, P214, DOI 10.1016/j.jaci.2006.05.004; Weidinger S, 2007, J INVEST DERMATOL, V127, P724, DOI 10.1038/sj.jid.5700630; Yoshiiki Takashi, 1993, Journal of Dermatological Science, V5, P92, DOI 10.1016/0923-1811(93)90076-2; ZESCH A, 1975, ARCH DERMATOL FORSCH, V252, P245, DOI 10.1007/BF00560364	52	76	81	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2009	123	5					1124	1133		10.1016/j.jaci.2009.03.032	http://dx.doi.org/10.1016/j.jaci.2009.03.032			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	449CW	19410693				2022-12-18	WOS:000266309400022
J	Donohue, KM; Al-Alem, U; Perzanowski, MS; Chew, GL; Johnson, A; Divjan, A; Kelvin, EA; Hoepner, LA; Perera, FP; Miller, RL				Donohue, Kathleen M.; Al-alem, Umaima; Perzanowski, Matthew S.; Chew, Ginger L.; Johnson, Alina; Divjan, Adnan; Kelvin, Elizabeth A.; Hoepner, Lori A.; Perera, Frederica P.; Miller, Rachel L.			Anti-cockroach and anti-mouse IgE are associated with early wheeze and atopy in an inner-city birth cohort	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Cockroach; mouse; allergy; wheeze; inner city; rhinitis; IgE; atopic dermatitis; eczema; asthma; sensitization	NEW-YORK-CITY; AGE 4 YEARS; ALLERGEN EXPOSURE; PRESCHOOL-CHILDREN; RISK-FACTOR; SERUM IGE; DUST-MITE; INHALANT ALLERGENS; PRENATAL EXPOSURE; CHILDHOOD ASTHMA	Background: The relationships between cockroach and mouse allergen exposure, anti-cockroach and anti-mouse IgE, and wheeze, rhinitis, and atopic dermatitis in children as young as age 3 years are of public health importance but have not been thoroughly evaluated. Objective: We hypothesized that inner-city children might have anti-cockroach and anti-mouse IgE by age 3 years, and their presence would be associated with respiratory and atopic symptoms. Methods: Children were followed prospectively from birth through age 3 years (n = 404). Residential levels of cockroach and mouse allergens, sera levels of anti-cockroach and anti-mouse IgE, and parental report of wheeze, rhinitis, and atopic dermatitis were measured. Results: The odds of early wheeze were significantly higher among children who had IgE to cockroach (odds ratio [OR], 3.3; 95% Cl, 1.8-6.2), mouse (OR, 4.6; 95% Cl, 2.3-9.0), or both (OR, 9.7; 95% Cl, 3.4-27.3). The odds or rhinitis or atopic dermatitis were also higher among children with IgE to cockroach, mouse, or both. Higher IgE class to cockroach and mouse was associated with wheeze and atopic dermatitis (tests for trend, P<.002). Conclusions: Children age 2 to 3 years who have anti-cockroach and anti-mouse IgE are at increased risk of wheeze and atopy. Moreover, a dose-response relationship was found between higher IgE class and increased prevalence of wheeze, rhinitis, or atopic dermatitis. These findings indicate the importance of reducing exposure to cockroach and mouse allergens for susceptible children. (J Allergy Clin Immunol 2008;122: 914-20.)	[Donohue, Kathleen M.; Johnson, Alina; Miller, Rachel L.] Columbia Univ Coll Phys & Surg, Dept Med, Div Pulm Allergy & Crit Care Med, New York, NY 10032 USA; [Perzanowski, Matthew S.; Chew, Ginger L.; Johnson, Alina; Divjan, Adnan; Hoepner, Lori A.; Perera, Frederica P.; Miller, Rachel L.] Columbia Univ, CCCEH, New York, NY USA; [Perzanowski, Matthew S.; Chew, Ginger L.; Divjan, Adnan; Hoepner, Lori A.; Perera, Frederica P.; Miller, Rachel L.] Columbia Univ, Mailman Sch Publ Hlth, Dept Environm Hlth Sci, New York, NY USA; [Kelvin, Elizabeth A.] New York State Psychiat Inst & Hosp, Data Coordinating Ctr, New York, NY 10032 USA; [Al-alem, Umaima] Univ Illinois, Sch Publ Hlth, Div Epidemiol & Biostat, Chicago, IL USA	Columbia University; Columbia University; Columbia University; New York State Psychiatry Institute; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Miller, RL (corresponding author), Columbia Univ Coll Phys & Surg, Dept Med, Div Pulm Allergy & Crit Care Med, 622 W 168th St,PH 8 E 101, New York, NY 10032 USA.	rlm14@columbia.edu	Al-alem, Umaima/AAW-2584-2021; Al-alem, Umaima/AHD-0666-2022	Al-alem, Umaima/0000-0003-2984-076X; Kelvin, Elizabeth/0000-0002-0566-8697; Divjan, Adnan/0000-0002-8895-5965; Hoepner, Lori/0000-0002-4404-8140	National Institute of Environmental Health Sciences [5 P01 ES009600, 5 R01 ES008977, P30 ES009089]; US Environmental Protection Agency [R827027, RD-832141]; Irving General Clinical Research Center [RR00645]; Educational Foundation of America; Horace W. Goldsmith Foundation; Gladys & Roland Harriman Foundation; John Merck Fund; New York Community Trust; Trustees of the Blanchette Hooker Rockefeller Fund; National Institutes of Health (NIH); National Institute of Environmental Health Sciences; Environmental Protection Agency; Sandler Program for Asthma Research; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000645] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES009089, R01ES008977, P01ES009600] Funding Source: NIH RePORTER	National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); US Environmental Protection Agency(United States Environmental Protection Agency); Irving General Clinical Research Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Educational Foundation of America; Horace W. Goldsmith Foundation; Gladys & Roland Harriman Foundation; John Merck Fund; New York Community Trust; Trustees of the Blanchette Hooker Rockefeller Fund; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Environmental Protection Agency(United States Environmental Protection Agency); Sandler Program for Asthma Research; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by the National Institute of Environmental Health Sciences (grant nos. 5 P01 ES009600, 5 R01 ES008977, and P30 ES009089), the US Environmental Protection Agency (grant nos. R827027 and RD-832141), the Irving General Clinical Research Center (grant no. RR00645), the Educational Foundation of America, the Horace W. Goldsmith Foundation, the Gladys & Roland Harriman Foundation. The John Merck Fund, The New York Community Trust, and the Trustees of the Blanchette Hooker Rockefeller Fund.; Disclosure of potential conflict of interest: M. S. Perzanowski hits received grant from the National Institutes of Health (NIH). G. L Chew has received grants from the National Institute of Environmental Health Sciences. R. L. Miller hits received grants or other research funding from the NIH, the Environmental Protection Agency, and the Sandler Program for Asthma Research. The rest of the authors have declared that they have no conflict of interest.	Arshad SH, 2001, PEDIATRICS, V108, part. no., DOI 10.1542/peds.108.2.e33; CALL RS, 1992, J PEDIATR-US, V121, P862, DOI 10.1016/S0022-3476(05)80329-4; Chew GL, 2008, J ALLERGY CLIN IMMUN, V121, P240, DOI 10.1016/j.jaci.2007.08.024; Chew GL, 2003, ENVIRON HEALTH PERSP, V111, P1348, DOI 10.1289/ehp.6124; Choudhry S, 2005, AM J RESP CRIT CARE, V172, P173, DOI 10.1164/rccm.200409-1232OC; Erwin EA, 2007, J ALLERGY CLIN IMMUN, V119, P359, DOI 10.1016/j.jaci.2006.12.648; Goldstein IF, 2005, INT ARCH ALLERGY IMM, V137, P249, DOI 10.1159/000086338; Hagendorens MM, 2004, PEDIAT ALLERG IMM-UK, V15, P308, DOI 10.1111/j.1399-3038.2004.00169.x; Illi S, 2001, J ALLERGY CLIN IMMUN, V108, P709, DOI 10.1067/mai.2001.118786; Illi S, 2006, LANCET, V368, P763, DOI 10.1016/S0140-6736(06)69286-6; Johnke H, 2006, PEDIAT ALLERG IMM-UK, V17, P591, DOI 10.1111/j.1399-3038.2006.00453.x; Johnson CC, 1998, AM J EPIDEMIOL, V147, P1145; KAM KL, 1994, ANN ALLERGY, V73, P329; Kattan M, 1997, PEDIATR PULM, V24, P253, DOI 10.1002/(SICI)1099-0496(199710)24:4<253::AID-PPUL4>3.0.CO;2-L; Kulig M, 1999, J ALLERGY CLIN IMMUN, V103, P1173, DOI 10.1016/S0091-6749(99)70195-8; Kulig M, 1998, CLIN EXP ALLERGY, V28, P1397, DOI 10.1046/j.1365-2222.1998.00439.x; LEIMGRUBER A, 1991, CLIN EXP ALLERGY, V21, P127, DOI 10.1111/j.1365-2222.1991.tb00814.x; Litonjua AA, 2001, J ALLERGY CLIN IMMUN, V107, P41, DOI 10.1067/mai.2001.111143; Lopes Maria Isabella L., 2006, J. Pediatr. (Rio J.), V82, P204, DOI 10.1590/S0021-75572006000300009; Marinho S, 2007, ALLERGY, V62, P1379, DOI 10.1111/j.1398-9995.2007.01502.x; Marks GB, 1998, ALLERGY, V53, P108, DOI 10.1111/j.1398-9995.1998.tb05010.x; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Matsui EC, 2007, J ALLERGY CLIN IMMUN, V119, P910, DOI 10.1016/j.jaci.2006.12.663; Matsui EC, 2006, ANN ALLERG ASTHMA IM, V97, P514, DOI 10.1016/S1081-1206(10)60943-X; Miller RL, 2001, AM J RESP CRIT CARE, V164, P995, DOI 10.1164/ajrccm.164.6.2011107; Nelson HS, 1999, J ALLERGY CLIN IMMUN, V104, P775, DOI 10.1016/S0091-6749(99)70287-3; Perzanowski MS, 2008, CLIN EXP ALLERGY, V38, P968, DOI 10.1111/j.1365-2222.2008.02967.x; Perzanowski MS, 2008, J ALLERGY CLIN IMMUN, V121, P1047, DOI 10.1016/j.jaci.2008.02.005; Perzanowski MS, 2006, J ALLERGY CLIN IMMUN, V117, P1082, DOI 10.1016/j.jaci.2005.12.1348; Phipatanakul W, 2000, J ALLERGY CLIN IMMUN, V106, P1075, DOI 10.1067/mai.2000.110795; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Platts-Mills TAE, 2007, J ALLERGY CLIN IMMUN, V120, P1058, DOI 10.1016/j.jaci.2007.06.032; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Sarpong SB, 1996, J ALLERGY CLIN IMMUN, V97, P1393, DOI 10.1016/S0091-6749(96)70209-9; Schafer T, 1999, J ALLERGY CLIN IMMUN, V104, P1280, DOI 10.1016/S0091-6749(99)70025-4; Sherrill DL, 1999, J ALLERGY CLIN IMMUN, V104, P28, DOI 10.1016/S0091-6749(99)70110-7; SIGURS N, 1994, J ALLERGY CLIN IMMUN, V94, P757, DOI 10.1016/0091-6749(94)90184-8; Simpson A, 2005, J ALLERGY CLIN IMMUN, V116, P744, DOI 10.1016/j.jaci.2005.06.032; Smit LAM, 2007, CLIN EXP ALLERGY, V37, P1602, DOI 10.1111/j.1365-2222.2007.02831.x; Szymanski W, 1995, Pneumonol Alergol Pol, V63 Suppl 2, P52; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7; Warner AM, 1996, PEDIAT ALLERG IMM-UK, V7, P61, DOI 10.1111/j.1399-3038.1996.tb00108.x; Wickman M, 2003, PEDIATR ALLERGY IMMU, V14, P441, DOI 10.1046/j.0905-6157.2003.00079.x; Wood RA, 2007, ANN ALLERG ASTHMA IM, V99, P34, DOI 10.1016/S1081-1206(10)60618-7; Wu CH, 1998, J ALLERGY CLIN IMMUN, V101, P832, DOI 10.1016/S0091-6749(98)70312-4	45	76	77	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2008	122	5					914	920		10.1016/j.jaci.2008.08.034	http://dx.doi.org/10.1016/j.jaci.2008.08.034			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	372ZF	19000580	Green Accepted, Bronze			2022-12-18	WOS:000260940100009
J	Rayens, MK; Burkhart, PV; Zhang, M; Lee, S; Moser, DK; Mannino, D; Hahn, EJ				Rayens, Mary Kay; Burkhart, Patricia V.; Zhang, Mei; Lee, Seongjik; Moser, Debra K.; Mannino, David; Hahn, Ellen J.			Reduction in asthma-related emergency department visits after implementation of a smoke-free law	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; asthma triggers; asthma exacerbation; secondhand tobacco smoke; environmental tobacco smoke; smoke-free legislation; asthma health outcomes	ENVIRONMENTAL TOBACCO-SMOKE; ACUTE MYOCARDIAL-INFARCTION; AIR-POLLUTION; HOSPITAL ADMISSIONS; EXPOSURE; HEALTH	Background: Secondhand tobacco smoke increases the risk for the development and increasing severity of asthma among adults and children. Reducing exposure to secondhand smoke decreases symptomatic exacerbations among patients with asthma. Emergency department (ED) visits for asthma were assessed before and after the implementation of smoke-free legislation in Lexington-Fayette County, Ky. Objective: To evaluate the effects of a smoke-free law on the rate of ED visits for asthma. Methods: The study included ED visits for asthma from 4 hospitals in Lexington-Fayette County, Ky. Age-adjusted rates of asthma ED visits were determined. Poisson regression analysis of ED visits from January 1, 2001, to December 31, 2006 compared the ED visit rates between prelaw and postlaw, adjusting for seasonality, secular trends over time, and differences among demographic subgroups. The actual rates were graphed with the Poisson curve showing the rates predicted by the model. A second prediction curve was generated to show the projected rates in the postlaw period if the law had not been implemented. Results: Adjusting for seasonality, secular trends, and demographic characteristics, ED visits for asthma declined 22% from prelaw to postlaw (P <.0001; 95% CI, 14% to 29%). The rate of decline was 24% in adults age 20 years and older (P <.0001), whereas the decrease among children 19 years or younger was 18% (P =.01). Conclusion: Although this study did not establish causation, the smoke-free law was associated with fewer asthma ED visits among both children and adults, with a more significant decline among adults.	[Rayens, Mary Kay; Burkhart, Patricia V.; Zhang, Mei; Lee, Seongjik; Moser, Debra K.; Hahn, Ellen J.] Univ Kentucky, Coll Nursing, Lexington, KY 40506 USA; [Rayens, Mary Kay; Hahn, Ellen J.] Univ Kentucky, Coll Publ Hlth, Lexington, KY 40506 USA; [Mannino, David] Univ Kentucky, Coll Med, Lexington, KY 40506 USA	University of Kentucky; University of Kentucky; University of Kentucky	Hahn, EJ (corresponding author), 760 Rose St, Lexington, KY 40536 USA.	ejhahn00@email.uky.edu		Mannino, David/0000-0003-3646-7828; Hahn, Ellen/0000-0002-8480-1010	Flight Attendant Medical Research Institute; National Institutes of Health-National Institute of Nursing Research; National Institutes of Health-Nation Heart, Lung, and Blood Institute; GlaxoSmithKline; Pfizer; Novartis	Flight Attendant Medical Research Institute; National Institutes of Health-National Institute of Nursing Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); National Institutes of Health-Nation Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); GlaxoSmithKline(GlaxoSmithKline); Pfizer(Pfizer); Novartis(Novartis)	Supported by the Flight Attendant Medical Research Institute.; Flight Attendant Medical Research Institute. D. K. Moser receives grant support from the National Institutes of Health-National Institute of Nursing Research and the National Institutes of Health-Nation Heart, Lung, and Blood Institute. D. Mannino is on the advisory board for GlaxoSmithKline and Pfizer and the Data Safety Monitoring Board for Boehringer-Ingelheim receives grant support from GlaxoSmithKline. Pfizer. and Novartis and has provided legal consultation or expert witness testimony in cases related to secondhand smoke and diacetyl exposure. M. K. Rayens receives grant support from the Flight Attendant Medical Research Institute. The rest of the authors have declared that they have no conflict of interest.	*AM NONSM RIGHTS F, 2008, OV LIST MAN SMOK FRE; American Lung Association. American Lung Association, 2007, TRENDS ASTHM MORB MO; Anonymous, 2007, Morbidity and Mortality Weekly Report, V56, P501; Barone-Adesi F, 2006, EUR HEART J, V27, P2468, DOI 10.1093/eurheartj/ehl201; Bartecchi C, 2006, CIRCULATION, V114, P1490, DOI 10.1161/CIRCULATIONAHA.106.615245; Bauer U., 2007, Morbidity and Mortality Weekly Report, V56, P705; *CDCP, 2004, BEH RISK FACT SURV S; *CDCP, 2003, ASTHM PREV HLTH CAR; *CDCP, 2006, NAT CTR HLTH STAT SU; CHILMONCZYK BA, 1993, NEW ENGL J MED, V328, P1665, DOI 10.1056/NEJM199306103282303; Eisner MD, 2005, THORAX, V60, P814, DOI 10.1136/thx.2004.037283; Eisner MD, 1998, AM J RESP CRIT CARE, V158, P170, DOI 10.1164/ajrccm.158.1.9801028; Eisner MD, 2002, CLIN CHEST MED, V23, P749, DOI 10.1016/S0272-5231(02)00033-3; Erbas B, 2005, INT J ENVIRON HEAL R, V15, P11, DOI 10.1080/09603120400018717; Hahn EJ, 2006, J OCCUP ENVIRON MED, V48, P906, DOI 10.1097/01.jom.0000215709.09305.01; Jaffe DH, 2003, ENVIRON RES, V91, P21, DOI 10.1016/S0013-9351(02)00004-X; Juster HR, 2007, AM J PUBLIC HEALTH, V97, P2035, DOI 10.2105/AJPH.2006.099994; Kahende J., 2007, Morbidity and Mortality Weekly Report, V56, P993; KUHN L, 1994, AM J EPIDEMIOL, V140, P943, DOI 10.1093/oxfordjournals.aje.a117183; Lee K, 2008, J ENVIRON HEALTH, V70, P24; Mannino DM, 2002, CHEST, V122, P409, DOI 10.1378/chest.122.2.409; Maurice E., 2006, Morbidity and Mortality Weekly Report, V55, P1148; McGhee SM, 2000, J EPIDEMIOL COMMUN H, V54, P673, DOI 10.1136/jech.54.9.673; Moorman Jeanne E., 2007, Morbidity and Mortality Weekly Report, V56, P1; National Heart Lung and Blood Institute. National Asthma Education and Prevention Program, 2007, 3 NAT HEART LUNG BLO; RAYENS MK, 2007, ASTHMA PREVALENCE LE; Sargent RP, 2004, BMJ-BRIT MED J, V328, P977, DOI 10.1136/bmj.38055.715683.55; Seo DC, 2007, J DRUG EDUC, V37, P217, DOI 10.2190/DE.37.3.a; U.S. Department of Health and Human Services, 2006, HLTH CONS INV EXP TO; *US CENS BUR, 2007, COUNT TOT POP POP CH; *US EPA, 1996, EPA600P93004CF; Vigotti MA, 2007, J TOXICOL ENV HEAL A, V70, P266, DOI 10.1080/15287390600884800; Weiss ST, 1999, ENVIRON HEALTH PERSP, V107, P891, DOI 10.2307/3434571; Wilson AM, 2004, ENVIRON INT, V30, P1109, DOI 10.1016/j.envint.2004.01.004	34	76	79	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2008	122	3					537	541		10.1016/j.jaci.2008.06.029	http://dx.doi.org/10.1016/j.jaci.2008.06.029			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	348TW	18692884				2022-12-18	WOS:000259234000014
J	Konstantinou, GN; Giavi, S; Kalohatsou, A; Hassilopoulou, E; Douladiris, N; Saxoni-Papageorgiou, P; Papadopoulos, NG				Konstantinou, George N.; Giavi, Stavroula; Kalohatsou, Aleksandra; Hassilopoulou, Emilia; Douladiris, Nikolaos; Saxoni-Papageorgiou, Photini; Papadopoulos, Nikolaos G.			Consumption of heat-treated egg by children allergic or sensitized to egg can affect the natural course of egg allergy: Hypothesisgenerating observations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							IGE CONCENTRATIONS; FOOD ALLERGY; CHALLENGES		[Konstantinou, George N.; Giavi, Stavroula; Kalohatsou, Aleksandra; Hassilopoulou, Emilia; Douladiris, Nikolaos; Saxoni-Papageorgiou, Photini; Papadopoulos, Nikolaos G.] Univ Athens, Dept Allergy, Pediat Hosp P & A Kiriakou, Athens 11528, Greece	National & Kapodistrian University of Athens	Konstantinou, GN (corresponding author), Univ Athens, Dept Allergy, Pediat Hosp P & A Kiriakou, Athens 11528, Greece.	georgenk@allergy.gr	N.G., Papadopoulos/L-8670-2013; Vassilopoulou, Emilia/AAE-7270-2021; Papadopoulos, Nikolaos/ABE-1774-2021	N.G., Papadopoulos/0000-0002-4448-3468; Vassilopoulou, Emilia/0000-0002-2665-5908; Papadopoulos, Nikolaos/0000-0002-4448-3468; Papadopoulos, Nikolaos/0000-0002-2508-3872; Konstantinou, George/0000-0003-1371-6764				Buchanan AD, 2007, J ALLERGY CLIN IMMUN, V119, P199, DOI 10.1016/j.jaci.2006.09.016; Cornelisse-Vermaat JR, 2008, EUR J PUBLIC HEALTH, V18, P115, DOI 10.1093/eurpub/ckm032; de Boissieu D, 2006, Eur Ann Allergy Clin Immunol, V38, P113; Eigenmann PA, 2000, J ALLERGY CLIN IMMUN, V105, P587, DOI 10.1067/mai.2000.104255; Hirose J, 2004, BIOSCI BIOTECH BIOCH, V68, P2490, DOI 10.1271/bbb.68.2490; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444, DOI 10.1016/S0091-6749(97)70133-7; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; Savage JH, 2007, J ALLERGY CLIN IMMUN, V120, P1413, DOI 10.1016/j.jaci.2007.09.040; Staden U, 2007, ALLERGY, V62, P1261, DOI 10.1111/j.1398-9995.2007.01501.x	9	76	79	1	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2008	122	2					414	415		10.1016/j.jaci.2008.05.032	http://dx.doi.org/10.1016/j.jaci.2008.05.032			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	337HO	18585768				2022-12-18	WOS:000258426300032
J	Canino, G; Vila, D; Normand, SLT; Acosta-Perez, E; Ramirez, R; Garcia, P; Rand, C				Canino, Glorisa; Vila, Doryliz; Normand, Sharon-Lise T.; Acosta-Perez, Edna; Ramirez, Rafael; Garcia, Pedro; Rand, Cynthia			Reducing asthma health disparities in poor Puerto Rican children: The effectiveness of a culturally tailored family intervention	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						family asthma management intervention; controlled clinical trial; Puerto Rican; children	INNER-CITY CHILDREN; CHILDHOOD ASTHMA; ENVIRONMENTAL INTERVENTION; PEDIATRIC ASTHMA; MANAGEMENT; IMPROVE; LATINO; QUESTIONNAIRE; PREVALENCE; VALIDATION	Background: Island and mainland Puerto Rican children have the highest rates of asthma and asthma morbidity of any ethnic group in the United States. Objective: We evaluated the effectiveness of a culturally adapted family asthma management intervention called CALMA (an acronym of the Spanish for "Take Control, Empower Yourself and Achieve Management of Asthma") in reducing asthma morbidity in poor Puerto Rican children with asthma. Methods: Low-income children with persistent asthma were selected from a national health plan insurance claims database by using a computerized algorithm. After baseline, families were randomly assigned to either the intervention or a control group. Results: No significant differences between control and intervention group were found for the primary outcome of symptom-free days. However, children in the CALMA intervention group had 6.5% more symptom-free nights, were 3 times more likely to have their asthma under control, and were less likely to visit the emergency department and be hospitalized as compared to the control group. Caregivers receiving CALMA were significantly less likely to feel helpless, frustrated, or upset because of their child's asthma and more likely to feel confident to manage their child's asthma. Conclusion: A home-based asthma intervention program tailored to the cultural needs of low income Puerto Rican families is a promising intervention for reducing asthma morbidity.	[Canino, Glorisa; Vila, Doryliz; Acosta-Perez, Edna; Ramirez, Rafael; Garcia, Pedro] Univ Puerto Rico, Behav Sci Res Inst, San Juan, PR 00936 USA; [Normand, Sharon-Lise T.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA; [Rand, Cynthia] Johns Hopkins Univ, Sch Med, Baltimore, MD USA	University of Puerto Rico; University of Puerto Rico Medical Sciences Campus; Harvard University; Harvard Medical School; Johns Hopkins University	Canino, G (corresponding author), Univ Puerto Rico, Behav Sci Res Inst, Med Sci Campus,POB 365067, San Juan, PR 00936 USA.	gcanino@rcm.upr.edu	Pérez, Edna Acosta/AAW-6672-2021	Normand, Sharon-Lise/0000-0001-7027-4769; acosta, edna/0000-0001-7101-3157; ramirez, rafael/0000-0002-9504-7260	NATIONAL CENTER ON MINORITY HEALTH AND HEALTH DISPARITIES [P20MD000537] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH073469] Funding Source: NIH RePORTER; NIMHD NIH HHS [P20 MD000537, P20 MD000537-01] Funding Source: Medline; NIMH NIH HHS [P50 MH073469-01, P50 MH073469] Funding Source: Medline; PHS HHS [1P50 MHO 73469-01] Funding Source: Medline	NATIONAL CENTER ON MINORITY HEALTH AND HEALTH DISPARITIES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Apter AJ, 1998, AM J RESP CRIT CARE, V157, P1810, DOI 10.1164/ajrccm.157.6.9712007; BERNARDBONNIN AC, 1995, J ALLERGY CLIN IMMUN, V95, P34, DOI 10.1016/S0091-6749(95)70150-8; Bonner S, 2002, J ASTHMA, V39, P167, DOI 10.1081/JAS-120002198; Brown JV, 2002, J PEDIATR PSYCHOL, V27, P677, DOI 10.1093/jpepsy/27.8.677; Bursch B, 1999, J ASTHMA, V36, P115, DOI 10.3109/02770909909065155; Cohen RT, 2007, CHEST, V131, P1331, DOI 10.1378/chest.06-1917; Evans R, 1999, J PEDIATR-US, V135, P332, DOI 10.1016/S0022-3476(99)70130-7; Guevara JP, 2003, BMJ-BRIT MED J, V326, P1308, DOI 10.1136/bmj.326.7402.1308; Homa DM, 2000, AM J RESP CRIT CARE, V161, P504, DOI 10.1164/ajrccm.161.2.9906025; Hunninghake GM, 2006, AM J RESP CRIT CARE, V173, P143, DOI 10.1164/rccm.200508-1232SO; Jones JA, 2001, PATIENT EDUC COUNS, V42, P67, DOI 10.1016/S0738-3991(00)00102-6; Juniper EF, 1999, CHEST, V115, P1265, DOI 10.1378/chest.115.5.1265; Kelly CS, 2000, PEDIATRICS, V105, P1029, DOI 10.1542/peds.105.5.1029; Kelly HW, 2005, ANN PHARMACOTHER, V39, P931, DOI 10.1345/aph.1E611; KOREN PE, 1992, REHABIL PSYCHOL, V37, P305, DOI 10.1037/0090-5550.37.4.305; Lara M, 2006, PEDIATRICS, V117, P43, DOI 10.1542/peds.2004-1714; Ledogar RJ, 2000, AM J PUBLIC HEALTH, V90, P929, DOI 10.2105/AJPH.90.6.929; Loyo-Berrios NI, 2006, J ASTHMA, V43, P619, DOI 10.1080/02770900600878693; Matias-Carrelo LE, 2003, CULT MED PSYCHIAT, V27, P291, DOI 10.1023/A:1025399115023; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008; Riekert KA, 2003, PEDIATRICS, V111, DOI 10.1542/peds.111.3.e214; Roberts RO, 1996, J CLIN EPIDEMIOL, V49, P989, DOI 10.1016/0895-4356(96)00143-6; Shields AE, 2004, PEDIATRICS, V113, P496, DOI 10.1542/peds.113.3.496; Strunk Robert C., 2002, Journal of Allergy and Clinical Immunology, V109, P229, DOI 10.1067/mai.2002.120950; Tinkelman D, 2004, AM J MANAG CARE, V10, P948; Wakefield DB, 2006, PEDIATR PULM, V41, P962, DOI 10.1002/ppul.20476; Wallerstein NB, 2006, HEALTH PROMOT PRACT, V7, P312, DOI 10.1177/1524839906289376; *WHO, 2003, ADH LONG TERM THER P; Williams SG, 2006, J NATL MED ASSOC, V98, P249	30	76	75	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2008	121	3					665	670		10.1016/j.jaci.2007.10.022	http://dx.doi.org/10.1016/j.jaci.2007.10.022			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	273GR	18061648	Green Accepted			2022-12-18	WOS:000253918900019
J	Flinterman, AE; Akkerdaas, JH; Jager, CFDH; Rigby, NM; Fernandez-Rivas, M; Hoekstra, MO; Bruijnzeel-Koomen, CA; Knuist, AC; van Ree, R; Pasmans, SG				Flinterman, Annebeth E.; Akkerdaas, Jaap H.; Jager, Constance F. den Hartog; Rigby, Neil M.; Fernandez-Rivas, Montserrat; Hoekstra, Maarten O.; Bruijnzeel-Koomen, Carla A.; Knuist, Andr C.; van Ree, Ronald; Pasmans, Suzanne G.			Lipid transfer protein-linked hazelnut allergy in children from a non-Mediterranean birch-endemic area	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						hazelnut allergy; birch pollen; Cor a 1; pediatric allergy; Cor a 8; lipid transfer protein	IN-VITRO DIAGNOSIS; NUT ALLERGY; POLLEN; FOOD; IGE; SENSITIZATION; ANTIBODIES; QUANTIFICATION; IDENTIFICATION; EXPRESSION	Background: Hazelnut allergy in birch pollen-exposed areas is usually due to cross-reactivity (Cor a 1 and 2) and is usually mild in nature (oral allergy). In areas without birches, severe reactions are more prevalent and linked to sensitization to the lipid transfer protein (LTP) Cor a 8. Objective: We sought to investigate whether sensitization to LTP plays a role in more severe (objective) hazelnut-induced symptoms in children from a birch-endemic area. Methods: Sensitization to Cor a 8, Cor a 2, Cor a 1, and Bet v 1 was determined by means of RASTs and immunoblotting in hazelnut-sensitized children with (n = 8) and without (n = 18) objective reactions during double-blind, placebo-controlled food challenges. Additionally, samples from 191 hazelnut-sensitized nonchallenged children were analyzed. Results: Children with objective reactions during double-blind, placebo-controlled food challenge had higher IgE titers to hazelnut (P < .001) and recognized more allergens on immunoblotting (P = .001) than those without such reactions. All children with objective symptoms were sensitized to Cor a 8 (0.51-23.3 IU/rnL) compared with only 1 child without objective reactions (0.90 IU/mL). In a multivariate analysis only IgE against Cor a 8 remained as an independent risk factor (undefined odds ratio; P < .0001). In the group of nonchallenged children (n = 191), the prevalence of LTP sensitization was greater than 30%. Unexpectedly, sensitization to Cor a I was observed in children not sensitized to Bet v 1. Conclusion: Sensitization to hazelnut LTP is a risk factor for objective symptoms in children from a birch-endemic area.	[Flinterman, Annebeth E.; Jager, Constance F. den Hartog; Bruijnzeel-Koomen, Carla A.; Knuist, Andr C.; Pasmans, Suzanne G.] Univ Med Ctr, Dept Dermatol Allergol, NL-3508 GA Utrecht, Netherlands; [Hoekstra, Maarten O.] Univ Med Ctr, Dept Paediat, NL-3508 GA Utrecht, Netherlands; [Akkerdaas, Jaap H.; van Ree, Ronald] Univ Amsterdam, Acad Med Ctr, Dept Expt Immunol, NL-1105 AZ Amsterdam, Netherlands; [Rigby, Neil M.] Inst Food Res, Norwich, Norfolk, England; [Fernandez-Rivas, Montserrat] Hosp Clin San Carlos, Serv Alergia, Madrid, Spain	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; University of Amsterdam; Academic Medical Center Amsterdam; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Quadram Institute; University of East Anglia; Hospital Clinico San Carlos	Flinterman, AE (corresponding author), Univ Med Ctr, Dept Dermatol Allergol, G02-124,POB 85500, NL-3508 GA Utrecht, Netherlands.	a.e.flinterman@umcutrecht.nl	Pasmans, Suzanne/AAI-6016-2021	Pasmans, Suzanne/0000-0003-1018-4475				AALBERSE RC, 1980, ALLERGY, V35, P236, DOI 10.1111/j.1398-9995.1980.tb01759.x; AKKERDAAS JH, 1995, ALLERGY, V50, P215, DOI 10.1111/j.1398-9995.1995.tb01136.x; ASERO R, 2006, ALLERG IMMUNOL PARIS, V38, P118; Beyer K, 2002, J ALLERGY CLIN IMMUN, V110, P517, DOI 10.1067/mai.2002.127434; Clark AT, 2003, CLIN EXP ALLERGY, V33, P1041, DOI 10.1046/j.1365-2745.2003.01624.x; Cudowska B, 2004, Rocz Akad Med Bialymst, V49, P111; Fernandez-Rivas M, 2003, J ALLERGY CLIN IMMUN, V112, P789, DOI 10.1016/S0091-6749(03)02016-5; Fernandez-Rivas M, 2006, J ALLERGY CLIN IMMUN, V118, P481, DOI 10.1016/j.jaci.2006.05.012; Flinterman AE, 2006, J ALLERGY CLIN IMMUN, V118, P1186, DOI 10.1016/j.jaci.2006.08.017; HIRSCHWEHR R, 1992, J ALLERGY CLIN IMMUN, V90, P927, DOI 10.1016/0091-6749(92)90465-E; Julge K, 2001, CLIN EXP ALLERGY, V31, P1854, DOI 10.1046/j.1365-2222.2001.01235.x; Kulig M, 1999, J ALLERGY CLIN IMMUN, V103, P1173, DOI 10.1016/S0091-6749(99)70195-8; Lauer I, 2004, BIOCHEM J, V383, P327, DOI 10.1042/BJ20041062; Luttkopf D, 2002, MOL IMMUNOL, V38, P515, DOI 10.1016/S0161-5890(01)00087-6; Reuter A, 2006, CLIN EXP ALLERGY, V36, P815, DOI 10.1111/j.1365-2222.2006.2492.x; Salcedo G, 2004, CLIN EXP ALLERGY, V34, P1336, DOI 10.1111/j.1365-2222.2004.02018.x; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Sancho AI, 2005, ALLERGY, V60, P1262, DOI 10.1111/j.1398-9995.2005.00876.x; Schad SG, 2005, INT ARCH ALLERGY IMM, V136, P159, DOI 10.1159/000083324; Schocker F, 2004, J ALLERGY CLIN IMMUN, V113, P141, DOI 10.1016/j.jaci.2003.09.013; Schuurman J, 1997, CLIN EXP ALLERGY, V27, P1095, DOI 10.1111/j.1365-2222.1997.tb01262.x; Sicherer SH, 2001, J ALLERGY CLIN IMMUN, V108, P128, DOI 10.1067/mai.2001.115755; VANREE R, 1992, INT ARCH ALLERGY IMM, V98, P97, DOI 10.1159/000236171; Vassilopoulou E, 2007, INT ARCH ALLERGY IMM, V143, P92, DOI 10.1159/000098657; Wensing M, 2002, CLIN EXP ALLERGY, V32, P1757, DOI 10.1046/j.1365-2222.2002.01555.x; Zuidmeer L, 2005, INT ARCH ALLERGY IMM, V137, P273, DOI 10.1159/000086420	26	76	78	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2008	121	2					423	428		10.1016/j.jaci.2007.10.009	http://dx.doi.org/10.1016/j.jaci.2007.10.009			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	265CX	18036652				2022-12-18	WOS:000253337800022
J	Schulz, F; Marenholz, I; Folster-Holst, R; Chen, C; Sternjak, A; Baumgrass, R; Esparza-Gordillo, J; Grueber, C; Nickel, R; Schreiber, S; Stoll, M; Kurek, M; Rueschendorf, F; Hubner, N; Wahn, U; Lee, YA				Schulz, Florian; Marenholz, Ingo; Folster-Holst, Regina; Chen, Christiane; Sternjak, Alexander; Baumgrass, Ria; Esparza-Gordillo, Jorge; Grueber, Christoph; Nickel, Renate; Schreiber, Stefan; Stoll, Monika; Kurek, Michael; Rueschendorf, Franz; Hubner, Norbert; Wahn, Ulrich; Lee, Young-Ae			A common haplotype of the IL-31 gene influencing gene expression is associated with nonatopic eczema	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eczema; nonatopic eczema; IL-31; pruritus; genetic association; promoter; polymorphism; haplotype; gene expression	ATOPIC-DERMATITIS; T-CELLS; CONTROLLED TRIAL; TRANSCRIPTION; GATA-3; FAMILY	Background: IL-31 is a novel cytokine that, when overexpressed in transgenic mice, induces severe itching dermatitis resembling human eczema. Objective: We aimed to evaluate the importance of polymorphisms in the human IL-31 gene (IL31) in the genetic susceptibility to eczema. Methods: We sequenced the entire IL-31 gene, including the promoter region, and determined the haplotype structure. Single nucleotide polymorphisms tagging the main haplotypes were genotyped in 3 independent European populations comprising 690 affected families. An association analysis of IL31 gene variants with atopic and nonatopic eczema was performed. Results: We found significant association of a common IL31 haplotype with the nonatopic type of eczema in all 3 study populations (combined P = 4.5 X 10(-5)). Analysis of PBMCs in healthy individuals revealed a strong induction IL31 mRNA expression on stimulation with anti-CD3 and anti-CD28 that was 3.8-fold higher in individuals homozygous for the risk haplotype (AA) in contrast to non-A haplotype carriers, suggesting that altered regulation of IL-31 gene expression is the disease-causing factor. Conclusion: Our results lend strong support to an important role of IL-31 in the pathogenesis of nonatopic eczema. Clinical implications: This study presents the first genetic risk factor for the nonatopic type of eczema and indicates a primary role of IL-31-induced pruritus in the initiation of this disease, thus proposing a new target for the prevention and therapy of eczema.	Charite Univ Med Berlin, Campus Virchow Klinikum, D-13353 Berlin, Germany; Max Delbruck Ctr Mol Med, Berlin, Germany; Univ Clin Schleswig Holstein, Dept Dermatol, Kiel, Germany; German Rheumatism Res Ctr, Berlin, Germany; Inst Clin Mol Biol, Kiel, Germany; Leibniz Inst Arteriosclerosis Res, Munster, Germany; Pomeranian Acad Med, Dept Clin Allergol, Szczecin, Poland	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of Kiel; Schleswig Holstein University Hospital; Deutsches Rheuma-Forschungszentrum (DRFZ); Pomeranian Medical University	Lee, YA (corresponding author), Charite Univ Med Berlin, Campus Virchow Klinikum, Augustenburger Pl 1, D-13353 Berlin, Germany.	yolee@mdc-berlin.de	Fölster-Holst, Regina/A-9560-2010	Baumgrass, Ria/0000-0002-3289-1608				Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Bilsborough J, 2006, J ALLERGY CLIN IMMUN, V117, P418, DOI 10.1016/j.jaci.2005.10.046; Dillon SR, 2004, NAT IMMUNOL, V5, P752, DOI 10.1038/ni1084; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; KUSTER W, 1990, ARCH DERMATOL RES, V282, P98, DOI 10.1007/BF00493466; LARSEN FS, 1986, J AM ACAD DERMATOL, V15, P487; Leung DYM, 2004, J CLIN INVEST, V113, P651, DOI 10.1172/JCI200421060; Murphy KM, 2002, NAT REV IMMUNOL, V2, P933, DOI 10.1038/nri954; Schwenger GTF, 2001, J BIOL CHEM, V276, P48502, DOI 10.1074/jbc.M107836200; Schwenger GTF, 2005, BIOCHEMISTRY-MOSCOW+, V70, P1065, DOI 10.1007/s10541-005-0225-x; Sonkoly E, 2006, J ALLERGY CLIN IMMUN, V117, P411, DOI 10.1016/j.jaci.2005.10.033; Spielman RS, 1996, AM J HUM GENET, V59, P983; Tan BB, 1996, LANCET, V347, P15, DOI 10.1016/S0140-6736(96)91556-1; Warner JO, 2001, J ALLERGY CLIN IMMUN, V108, P929, DOI 10.1067/mai.2001.120015; Williams HC, 2005, NEW ENGL J MED, V352, P2314, DOI 10.1056/NEJMcp042803; Wuthrich B, 2003, J INVEST ALLERG CLIN, V13, P1; Yosipovitch G, 2003, LANCET, V361, P690, DOI 10.1016/S0140-6736(03)12570-6	18	76	84	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2007	120	5					1097	1102		10.1016/j.jaci.2007.07.065	http://dx.doi.org/10.1016/j.jaci.2007.07.065			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	231TZ	17900679				2022-12-18	WOS:000250973400017
J	Bergeron, C; Boulet, LP; Page, N; Laviolette, M; Zimmermann, N; Rothenberg, ME; Hamid, Q				Bergeron, Celine; Boulet, Louis-Philippe; Page, Nathalie; Laviolette, Michel; Zimmermann, Nives; Rothenberg, Marc E.; Hamid, Qutayba			Influence of cigarette smoke on the arginine pathway in asthmatic airways: Increased expression of arginase I	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						arginase I; iNOS; ornithine decarboxylase; ornithine decarboxylase; asthma; cigarette smoke	NITRIC-OXIDE SYNTHASE; OBSTRUCTIVE PULMONARY-DISEASE; RESPIRATORY SYMPTOMS; BRONCHIAL BIOPSIES; MESSENGER-RNA; LUNG-FUNCTION; INFLAMMATION; INDUCTION; ADULTS; CELLS	Background: Up to 30% of asthmatic subjects are smokers, and smoking might be an important contributor to asthma pathology. Inducible nitric oxide synthase (iNOS), ornithine decarboxylase (ODC), and arginase I are involved in the arginine pathway. We have shown that arginase I and iNOS are upregulated in asthma. Smoking asthmatic subjects are reported to have low exhaled nitric oxide levels. The effect of cigarette smoking on the expression of arginase I in asthma is unknown. Objectives: The aims of this study were to investigate the expression of arginase 1, ODC, and iNOS in asthmatic airways of smokers and nonsmokers and in vitro after nicotine stimulation. Methods: Endobronchial biopsies were performed on 24 steroid-naive subjects with mild asthma: 12 smokers and 12 nonsmokers. Arginase I, ODC, and iNOS levels were assessed by means of immunohistochemistry and in situ hybridization (arginase I). In vitro stimulation of airway cells with nicotine was performed, followed by real-time PCR. Results: Arginase I, ODC, and iNOS were expressed in the epithelium and smooth muscle bundles of both subgroups of asthmatic subjects. There was an increase of arginase I and ODC immunoreactivities in smoking compared with nonsmoking asthmatic subjects. There was no significant difference in immunoreactivity for iNOS between groups. Nicotine induced a 2-fold increase in arginase I and ODC expression in airway epithelial cells and fibroblasts. Conclusion: This study demonstrates that the expression of arginase I and ODC is increased in airways of smoking compared with nonsmoking asthmatic subjects and in vitro by nicotine. Clinical implications: Increased expression of arginase I might lead to low exhaled nitric oxide and chronic obstructive pulmonary disease-like airway remodeling in smoking asthmatic subjects.	McGill Univ, Meakins Christie Labs, Montreal, PQ H2X 2P2, Canada; Hop Laval, Ctr Rech, Inst Univ Cardiol & Pneumol, Laval, PQ, Canada; Cincinnati Childrens Hosp, Med Ctr, Div Allergy & Immunol, Cincinnati, OH USA	McGill University; Laval University; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Hamid, Q (corresponding author), McGill Univ, Meakins Christie Labs, 3626 St Urbain St, Montreal, PQ H2X 2P2, Canada.	qutayba.hamid@mcgill.ca	Bergeron, Celine/CAH-4596-2022		PHS HHS [R01 A153479] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Althuis MD, 1999, J ASTHMA, V36, P257, DOI 10.3109/02770909909075409; Amin K, 2003, THORAX, V58, P135, DOI 10.1136/thorax.58.2.135; Arif AA, 2003, EUR RESPIR J, V21, P827, DOI 10.1183/09031936.03.00054103a; Bartal M, 2001, Monaldi Arch Chest Dis, V56, P545; Bergeron C, 2003, CLIN EXP ALLERGY, V33, P1389, DOI 10.1046/j.1365-2222.2003.01785.x; Boulet LP, 2006, CHEST, V129, P661, DOI 10.1378/chest.129.3.661; Bruch-Gerharz D, 2003, AM J PATHOL, V162, P203, DOI 10.1016/S0002-9440(10)63811-4; Chalmers GW, 2001, CHEST, V120, P1917, DOI 10.1378/chest.120.6.1917; Fabbri LM, 2003, AM J RESP CRIT CARE, V167, P418, DOI 10.1164/rccm.200203-183OC; Gounni AS, 2004, J IMMUNOL, V173, P2771, DOI 10.4049/jimmunol.173.4.2771; HAMID Q, 1987, P NATL ACAD SCI USA, V84, P6760, DOI 10.1073/pnas.84.19.6760; HAMID Q, 1993, LANCET, V342, P1510, DOI 10.1016/S0140-6736(05)80083-2; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; HERBST EJ, 1981, MED BIOL, V59, P410; Hoyt JC, 2003, EXP LUNG RES, V29, P17, DOI 10.1080/01902140303759; Hu FB, 1997, J ASTHMA, V34, P67, DOI 10.3109/02770909709071205; HURD SZ, 1991, J ALLERGY CLIN IMMUN, V88, P808; Ichinose M, 2000, AM J RESP CRIT CARE, V162, P701, DOI 10.1164/ajrccm.162.2.9908132; James AL, 2005, AM J RESP CRIT CARE, V171, P109, DOI 10.1164/rccm.200402-230OC; LEUENBERGER P, 1994, AM J RESP CRIT CARE, V150, P1222, DOI 10.1164/ajrccm.150.5.7952544; Meurs H, 2003, TRENDS PHARMACOL SCI, V24, P450, DOI 10.1016/S0165-6147(03)00227-X; Morris CR, 2004, AM J RESP CRIT CARE, V170, P148, DOI 10.1164/rccm.200309-1304OC; PEGG AE, 1988, CANCER RES, V48, P759; Saleh D, 1998, FASEB J, V12, P929, DOI 10.1096/fasebj.12.11.929; Siroux V, 2000, EUR RESPIR J, V15, P470, DOI 10.1034/j.1399-3003.2000.15.08.x; STA, 1987, AM REV RESP DIS, V136, P225; Verleden GM, 1999, CHEST, V116, P59, DOI 10.1378/chest.116.1.59; Withers NJ, 1998, AM J RESP CRIT CARE, V158, P352, DOI 10.1164/ajrccm.158.2.9705079; Zimmermann N, 2003, J CLIN INVEST, V111, P1863, DOI 10.1172/JCI200317912	29	76	77	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2007	119	2					391	397		10.1016/j.jaci.2006.10.030	http://dx.doi.org/10.1016/j.jaci.2006.10.030			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	137YB	17291856				2022-12-18	WOS:000244327900017
J	Garcia-Robaina, JC; Sanchez, I; de la Torre, F; Fernandez-Caldas, E; Casanovas, M				Garcia-Robaina, Jose-Carlos; Sanchez, Inmaculada; de la Torre, Fernando; Fernandez-Caldas, Enrique; Casanovas, Miguel			Successful management of mite-allergic asthma with modified extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae in a double-blind, placebo-controlled study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						modified allergen vaccines; immunotherapy; depigmentation; allergoids; asthma; mites; Dermatophagoides spp; Canary Islands	QUALITY-OF-LIFE; BRONCHIAL REACTIVITY; SKIN-TEST; SIGNIFICANT IMPROVEMENT; IMMUNOTHERAPY; CHALLENGE; INFLAMMATION; CHILDREN; BRONCHOPROVOCATION; EXPOSURE	Background: Mite sensitivity is highly prevalent in tropical and subtropical regions, such as the Canary Islands. Objectives: To evaluate the clinical efficacy and safety of a depigmented polymerized allergen vaccine containing a 50% mixture of Dermatophagoides pteronyssinus and Dermatophagoides farinae. Methods: Sixty-four patients participated in the study. It was prospective, double-blind, and placebo-controlled, with random allocation of patients to receive active treatment or placebo. The active group received a mixture of modified allergen extracts containing 50% D pterouyssinus and 50% D farinae; the control group received placebo. All individuals were diagnosed with mild/moderate asthma and rhinoconjunctivitis caused by sensitization to D pteronyssinus and D farinae. Bronchial provocation test (BPT) was considered the main outcome to document clinical efficacy. Results: Fifty-four patients completed the study. The active group experienced a significant improvement in BPT (P < .001), whereas the placebo group did not (P =.648). At the end of the study, 20 patients in the active versus 9 in the placebo group (P =.013; odds ratio, 5.71 [1.76, 18.511) needed more than twice the amount of allergen to obtain a positive BPT. The median improvement in the active group over placebo was 53.76% in total symptom and 58.09% in medication scores. Conclusion: Immunotherapy with a mixture of modified allergen extracts of D pteronyssinus and D farinae is safe and efficacious to treat mite-allergic asthma. Clinical implications: This immunotherapy modifies the natural course of the illness because it improves all clinical outcomes measured and prevents the worsening of specific bronchial hyperreactivity.	Labs LETI SL, Madrid 28760, Spain; Hosp Nuestra Senora Candelaria, Serv Alergia, Santa Cruz de La Palma, Tenerife, Spain		Casanovas, M (corresponding author), Labs LETI SL, C-Sol 5, Madrid 28760, Spain.	mcasanovas@leti.com						Abramson M, 1999, ALLERGY, V54, P1022, DOI 10.1034/j.1398-9995.1999.00102.x; Altman DG, 1991, PRACTICAL STAT MED R, P396; Alvarez-Cuesta E, 2005, CLIN EXP ALLERGY, V35, P572, DOI 10.1111/j.1365-2222.2005.02245.x; Ameal A, 2005, ALLERGY, V60, P1178, DOI 10.1111/j.1398-9995.2005.00862.x; [Anonymous], 1993, NIH PUBLICATION, V93-3352; Bousquet J, 1998, ALLERGY, V53, P4; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Branco Ferreira M, 2005, Allergol Immunopathol (Madr), V33, P80, DOI 10.1157/13072918; CASANOVAS M, 1994, CLIN EXP ALLERGY, V24, P134, DOI 10.1111/j.1365-2222.1994.tb00209.x; *CDER, 2000, GUID IND ALL RHIN CL; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; Colas C, 2006, J ALLERGY CLIN IMMUN, V117, P810, DOI 10.1016/j.jaci.2005.11.039; CROPP GJA, 1975, PEDIATRICS, V56, P860; Dokic D, 2005, ALLERGO J, V14, P337; DRAPER SV, 2004, HAWTHORNE EFFECT OTH; DREBORG S, 1986, ALLERGY, V41, P131, DOI 10.1111/j.1398-9995.1986.tb00289.x; Echechipia S, 1995, J INVEST ALLERG CLIN, V5, P325; European Academy of Allergology and Clinical Immunology (EAACI), 1993, ALLERGY, V48, P7; FERNANDEZCALDAS E, 1990, ALLERGY PROC, V11, P263, DOI 10.2500/108854190778879710; Ferrer A, 2003, J INVEST ALLERG CLIN, V13, P244; FISH JE, 1981, AM REV RESPIR DIS, V123, P609; FISH JE, 1979, J ALLERGY CLIN IMMUN, V64, P592, DOI 10.1016/0091-6749(79)90019-8; Frolund L, 1996, ALLERGY, V51, P11; Garcia-Selles J, 2003, Allergol Immunopathol (Madr), V31, P63, DOI 10.1157/13045071; Guerra F, 2003, J INVEST ALLERG CLIN, V13, P108; Ibero M, 2006, J INVEST ALLERG CLIN, V16, P194; Kemp SF, 1997, CLIN EXP ALLERGY, V27, P893, DOI 10.1111/j.1365-2222.1997.tb01229.x; KOPFERSCHMITTKUBLER MC, 1987, J ALLERGY CLIN IMMUN, V80, P730, DOI 10.1016/0091-6749(87)90295-8; Kumar RK, 2004, CLIN EXP ALLERGY, V34, P1796, DOI 10.1111/j.1365-2222.2004.02097.x; MACHIELS JJ, 1993, AM REV RESPIR DIS, V147, P1407, DOI 10.1164/ajrccm/147.6_Pt_1.1407; Malet A, 1994, Allergol Immunopathol (Madr), V22, P226; MARKS GB, 1992, J CLIN EPIDEMIOL, V45, P461, DOI 10.1016/0895-4356(92)90095-5; Mcmillan SJ, 2004, CLIN EXP ALLERGY, V34, P497, DOI 10.1111/j.1365-2222.2004.01895.x; Nelson RP, 1996, J ALLERGY CLIN IMMUN, V98, P258, DOI 10.1016/S0091-6749(96)70148-3; Nordic Council on Medicines, 1989, NLN PUBLICATION, V23, P1; PLATTSMILLS TAE, 1989, J ALLERGY CLIN IMMUN, V83, P416, DOI 10.1016/0091-6749(89)90128-0; ROBAINA JCG, 1996, ALLERGOL IMMUNOPATH, V24, P135; ROISMAN GL, 1995, J CLIN INVEST, V96, P12, DOI 10.1172/JCI118011; ROSENTHAL RR, 1975, J ALLERGY CLIN IMMUN, V56, P338, DOI 10.1016/0091-6749(75)90127-X; RUFFIN RE, 1978, J ALLERGY CLIN IMMUN, V61, P42, DOI 10.1016/0091-6749(78)90472-4; Sackett DL., 1997, EVIDENCE BASED MED P; SHUSTER JJ, 1990, HDB SAMPLE SIZE GUID; Snibson KJ, 2005, CLIN EXP ALLERGY, V35, P146, DOI 10.1111/j.1365-2222.2005.02137.x; SPECTOR S, 1976, AM REV RESPIR DIS, V113, P43; SPITZER WO, 1987, J CHRON DIS, V40, P465, DOI 10.1016/0021-9681(87)90002-6; Tabar AI, 2005, J ALLERGY CLIN IMMUN, V116, P109, DOI 10.1016/j.jaci.2005.05.005; Terreehorst I, 2003, NEW ENGL J MED, V349, P237, DOI 10.1056/NEJMoa023171; Terreehorst I, 2005, ALLERGY, V60, P888, DOI 10.1111/j.1398-9995.2004.00677.x; Tran MUT, 2004, CLIN EXP ALLERGY, V34, P1627, DOI 10.1111/j.1365-2222.2004.02057.x; Woodcock A, 2003, NEW ENGL J MED, V349, P225, DOI 10.1056/NEJMoa023175	51	76	81	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2006	118	5					1026	1032		10.1016/j.jaci.2006.07.043	http://dx.doi.org/10.1016/j.jaci.2006.07.043			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	137GY	17088125				2022-12-18	WOS:000244282300005
J	KleinJan, A; Willart, M; van Rijt, LS; Braunstahl, GJ; Leman, K; Jung, S; Hoogsteden, HC; Lambrecht, BN				KleinJan, Alex; Willart, Monique; van Rijt, Leonie S.; Braunstahl, Gert-Jan; Leman, Karolina; Jung, Steffen; Hoogsteden, Henk C.; Lambrecht, Bart N.			An essential role for dendritic cells in human and experimental allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic rhinitis; antigen-presenting cell; dendritic cell; eosinophils; human; mouse; nasal mucosa; specific IgE	MESSENGER-RNA EXPRESSION; ANTIGEN-PRESENTING CELLS; IN-VIVO DEPLETION; FC-EPSILON-RI; NASAL-MUCOSA; AIRWAY INFLAMMATION; T-CELLS; LANGERHANS CELLS; IL-5; RECRUITMENT	Background: In allergic rhinitis (AR) CD4(+) T(H)2 lymphocytes control inflammation by secreting T(H)2 cytokines, but little is known about how these cells are activated to cause disease. Objective: We sought to study the contribution of antigen-presenting dendritic cells (DCs) in activating TH2 cells and controlling allergic inflammation. Methods: Nasal mucosal biopsy specimens were taken from patients with house dust mite allergy and perennial AR and healthy control subjects. DC numbers were evaluated by using immunohistochemistry. The functional role of DCs was studied in a novel mouse model for AR using BALB/c mice and CD11c-diphtheria toxin (DT) receptor transgenic mice. Results: In symptomatic patients with perennial AR, the number of CD1a(+) and CD11c(+) MHCII+ PCs was higher in the epithelium and lamina propria of the nasal mucosa compared with that seen in healthy control subjects. In patients with AR, DCs had a more mature (CD86(+)) phenotype and were found in close approximation with T lymphocytes. Similarly, in a mouse model of ovalbumin (OVA)-induced AR, CD11c(+) DCs accumulated in areas of nasal eosinophilic inflammation and clustered with CD4(+) T lymphocytes. CD11c(+) DCs were conditionally depleted during allergen challenge by means of systemic administration of DT to CD11c-diphtheria toxin receptor transgenic mice to address the functional role of DCs in maintaining inflammation. In the absence of CD11c(+) DCs, nasal OVA challenge in OVA-sensitized mice did not induce nasal eosinophilia and did not boost OVA-specific IgE levels or T(H)2 cytokine production in the cervical lymph nodes. Conversely, when OVA-pulsed PCs were administered intranasally to sensitized mice, they strongly enhanced OVA-induced nasal eosinophilia and T(H)2 cytokine production. Conclusions: These data in human subjects and mice suggest an essential role for nasal PCs in activation of effector T(H)2 function leading to AR. Clinical implications: Nasal PCs play an essential role in AR and therefore constitute a novel target for therapeutic intervention. Clinical implications: Nasal DCs play an essential role in AR and therefore constitute a novel target for therapeutic intervention.	Erasmus MC, Dept Pulm Med, NL-3015 GE Rotterdam, Netherlands; Weizman Inst, Rehovot, Israel	Erasmus University Rotterdam; Erasmus MC; Weizmann Institute of Science	Lambrecht, BN (corresponding author), Erasmus MC, Dept Pulm Med, Room Ee2257b,Dr MOlewaterpl 50, NL-3015 GE Rotterdam, Netherlands.	b.lambrecht@erasmusmc.nl	Lambrecht, Bart N/K-2484-2014; Jung, Steffen/K-1409-2012; Braunstahl, Gert-Jan/AAA-3047-2020	Lambrecht, Bart N/0000-0003-4376-6834; Jung, Steffen/0000-0003-4290-5716; Braunstahl, Gert-Jan/0000-0001-7671-3742				BIEBER T, 1994, IMMUNOL TODAY, V15, P52, DOI 10.1016/0167-5699(94)90132-5; Boulay ME, 2003, CURR OPIN ALLERGY CL, V3, P51, DOI 10.1097/01.all.0000053268.39029.19; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Dubois B, 1997, J EXP MED, V185, P941, DOI 10.1084/jem.185.5.941; DURHAM SR, 1992, J IMMUNOL, V148, P2390; Eisenbarth SC, 2003, CURR OPIN IMMUNOL, V15, P620, DOI 10.1016/j.coi.2003.09.003; Faith A, 2005, J ALLERGY CLIN IMMUN, V116, P1136, DOI 10.1016/j.jaci.2005.08.002; FOKKENS WJ, 1991, IMMUNOBIOLOGY, V182, P135, DOI 10.1016/S0171-2985(11)80197-X; Fokkens WJ, 1998, CLIN EXP ALLERGY, V28, P187; Fokkens WJ, 1997, ALLERGY, V52, P29, DOI 10.1111/j.1398-9995.1997.tb04819.x; Godthelp T, 1996, CLIN EXP ALLERGY, V26, P677, DOI 10.1046/j.1365-2222.1996.1072451.x; Hammad H, 2002, J IMMUNOL, V169, P1524, DOI 10.4049/jimmunol.169.3.1524; Hammad H, 2001, BLOOD, V98, P1135, DOI 10.1182/blood.V98.4.1135; Hellings PW, 2001, CLIN EXP ALLERGY, V31, P782, DOI 10.1046/j.1365-2222.2001.01081.x; Holm A, 2001, J ALLERGY CLIN IMMUN, V107, P627, DOI 10.1067/mai.2001.113520; Humbert M, 1997, AM J RESP CRIT CARE, V156, P704, DOI 10.1164/ajrccm.156.3.9610033; Humbert M, 1999, IMMUNOL TODAY, V20, P528, DOI 10.1016/S0167-5699(99)01535-2; Itano AA, 2003, NAT IMMUNOL, V4, P733, DOI 10.1038/ni957; Jahnsen FL, 2000, J IMMUNOL, V165, P4062, DOI 10.4049/jimmunol.165.7.4062; Jahnsen FL, 2001, THORAX, V56, P823, DOI 10.1136/thorax.56.11.823; Jung S, 2002, IMMUNITY, V17, P211, DOI 10.1016/S1074-7613(02)00365-5; KleinJan A, 1997, J ALLERGY CLIN IMMUN, V99, P515, DOI 10.1016/S0091-6749(97)70079-4; KleinJan A, 1999, J ALLERGY CLIN IMMUN, V103, P441, DOI 10.1016/S0091-6749(99)70469-0; Kuipers H, 2004, CURR OPIN IMMUNOL, V16, P702, DOI 10.1016/j.coi.2004.09.010; Lambrecht BN, 2001, CURR OPIN ALLERGY CL, V1, P51, DOI 10.1097/00130832-200102000-00010; Lambrecht BN, 2003, NAT REV IMMUNOL, V3, P994, DOI 10.1038/nri1249; Lambrecht BN, 1998, J IMMUNOL, V160, P4090; Larche M, 1998, J IMMUNOL, V161, P6375; Masuyama K, 1998, J ALLERGY CLIN IMMUN, V102, P610, DOI 10.1016/S0091-6749(98)70277-5; Maurer D, 1996, J IMMUNOL, V157, P607; McCusker CT, 2004, CURR OPIN ALLERGY CL, V4, P11, DOI 10.1097/01.all.0000113683.18759.cc; Novak N, 2004, CURR ALLERGY ASTHM R, V4, P263, DOI 10.1007/s11882-004-0069-2; Okano M, 2001, AM J RESP CRIT CARE, V164, P1501, DOI 10.1164/ajrccm.164.8.2011072; Rescigno M, 2001, NAT IMMUNOL, V2, P361, DOI 10.1038/86373; Saito H, 2001, IMMUNOLOGY, V104, P226, DOI 10.1046/j.1365-2567.2001.01253.x; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Takano K, 2005, J HISTOCHEM CYTOCHEM, V53, P611, DOI 10.1369/jhc.4A6539.2005; Till SJ, 2001, ALLERGY, V56, P126, DOI 10.1034/j.1398-9995.2001.056002126.x; Upham JW, 2002, CLIN EXP ALLERGY, V32, P818, DOI 10.1046/j.1365-2222.2002.01375.x; van Rijt LS, 2005, J EXP MED, V201, P981, DOI 10.1084/jem.20042311; van Rijt LS, 2002, BLOOD, V100, P3663, DOI 10.1182/blood-2002-03-0673; Vinke JG, 1999, EUR RESPIR J, V13, P797, DOI 10.1034/j.1399-3003.1999.13d17.x; Vuckovic S, 2005, J LEUKOCYTE BIOL, V77, P344, DOI 10.1189/jlb.1004559; Zammit DJ, 2005, IMMUNITY, V22, P561, DOI 10.1016/j.immuni.2005.03.005; Zhou BH, 2005, NAT IMMUNOL, V6, P1047, DOI 10.1038/ni1247	45	76	84	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2006	118	5					1117	1125		10.1016/j.jaci.2006.05.030	http://dx.doi.org/10.1016/j.jaci.2006.05.030			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	137GY	17088138				2022-12-18	WOS:000244282300018
J	Pease, JE; Williams, TJ				Pease, James Edward; Williams, Timothy John			Chemokines and their receptors in allergic disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						chemokine; chemokine receptor; allergy; asthma; leukocyte migration; chemotaxis; antagonist	HUMAN CC-CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN-1-ALPHA; MONOCYTE CHEMOATTRACTANT PROTEIN-1; CELL-DERIVED FACTOR-1-ALPHA; CD4(+)CD25(+) T-CELLS; GUINEA-PIG MODEL; IN-VIVO; DENDRITIC CELLS; MAST-CELLS; AIRWAY HYPERRESPONSIVENESS	Mechanisms of chemoattraction underlie the spatial organization of the cells of the immune system under basal conditions and the localization of these cells to sites of inflammation. The chemokines, a family of around 50 small proteins, play a major role in these processes. Leukocytes are equipped with cell-surface sensors for chemokines. There are 19 such receptors that are differentially expressed on leukocytes: the repertoire of receptor expression depending on the type of leukocyte and its stage in maturation. From observations in animal models, clinical studies, in vitro cell biology, and molecular analysis, a working hypothesis has been established to explain the cellular interactions underlying allergic responses and the chemokines-chemokine receptors involved. Chemokines signal through G protein-coupled receptors that are used typically for sensory functions (eg, detection of olfactory signals in the nose). This type of receptor can be blocked selectively by small-molecule antagonists. This provides the opportunity for the development of therapeutic compounds designed to suppress the recruitment of particular leukocyte types in allergic reactions.	Univ London Imperial Coll Sci & Technol, Fac Med, Natl Heart & Lung Inst, Leukocyte Biol Sect, London SW7 2AZ, England	Imperial College London	Pease, JE (corresponding author), Univ London Imperial Coll Sci & Technol, Fac Med, Natl Heart & Lung Inst, Leukocyte Biol Sect, S Kensington Campus,Sir Alexander Fleming Bldg,Ex, London SW7 2AZ, England.	j.pease@imperial.ac.uk	Pease, James/X-4521-2018	Pease, James/0000-0003-3749-0341	Medical Research Council [G0400503B] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)		Abonia JP, 2005, BLOOD, V105, P4308, DOI 10.1182/blood-2004-09-3578; ALAM R, 1992, J EXP MED, V176, P781, DOI 10.1084/jem.176.3.781; Alam R, 1996, AM J RESP CRIT CARE, V153, P1398, DOI 10.1164/ajrccm.153.4.8616572; Ali H, 1999, J BIOL CHEM, V274, P6027, DOI 10.1074/jbc.274.10.6027; Auger GA, 2002, EUR J IMMUNOL, V32, P1052, DOI 10.1002/1521-4141(200204)32:4<1052::AID-IMMU1052>3.0.CO;2-L; Ballesteros JA, 2001, J BIOL CHEM, V276, P29171, DOI 10.1074/jbc.M103747200; Bannert N, 2001, J EXP MED, V194, P1661, DOI 10.1084/jem.194.11.1661; Barlic J, 2000, NAT IMMUNOL, V1, P227, DOI 10.1038/79767; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; Bellinghausen I, 2003, J ALLERGY CLIN IMMUN, V111, P862, DOI 10.1067/mai.2003.1412; Berkman N, 1996, AM J RESP CRIT CARE, V154, P1804, DOI 10.1164/ajrccm.154.6.8970374; Berkman N, 2001, AM J RESP CELL MOL, V24, P682, DOI 10.1165/ajrcmb.24.6.4301; Bilenki L, 2004, EUR J IMMUNOL, V34, P345, DOI 10.1002/eji.200324303; Bishop B, 2003, J IMMUNOL, V170, P4810, DOI 10.4049/jimmunol.170.9.4810; Blanpain C, 2003, J BIOL CHEM, V278, P5179, DOI 10.1074/jbc.M205684200; Blease K, 2000, J IMMUNOL, V165, P2603, DOI 10.4049/jimmunol.165.5.2603; Blease K, 2000, J IMMUNOL, V165, P1564, DOI 10.4049/jimmunol.165.3.1564; Bleul CC, 1997, P NATL ACAD SCI USA, V94, P1925, DOI 10.1073/pnas.94.5.1925; Bochner BS, 2003, J ALLERGY CLIN IMMUN, V112, P930, DOI 10.1016/j.jaci.2003.08.012; Bohm SK, 1997, BIOCHEM J, V322, P1; Bonecchi R, 1998, J EXP MED, V187, P129, DOI 10.1084/jem.187.1.129; Boyce JA, 2002, BLOOD, V99, P2890, DOI 10.1182/blood.V99.8.2890; Brightling CE, 2005, AM J RESP CRIT CARE, V171, P1103, DOI 10.1164/rccm.200409-1220OC; Bromley SK, 2005, NAT IMMUNOL, V6, P895, DOI 10.1038/ni1240; BURROWS SD, 1994, BIOCHEMISTRY-US, V33, P12741, DOI 10.1021/bi00209a002; Campbell EM, 1999, J IMMUNOL, V163, P2160; Campbell EM, 1998, J IMMUNOL, V161, P7047; Campbell JJ, 2001, J IMMUNOL, V166, P2842, DOI 10.4049/jimmunol.166.4.2842; Charo IF, 2006, NEW ENGL J MED, V354, P610, DOI 10.1056/NEJMra052723; Chensue SW, 2001, J EXP MED, V193, P573, DOI 10.1084/jem.193.5.573; Chung CD, 2003, J IMMUNOL, V170, P581, DOI 10.4049/jimmunol.170.1.581; Chvatchko Y, 2000, J EXP MED, V191, P1755, DOI 10.1084/jem.191.10.1755; COLLINS PD, 1995, J EXP MED, V182, P1169, DOI 10.1084/jem.182.4.1169; Conroy DM, 2003, J LEUKOCYTE BIOL, V74, P558, DOI 10.1189/jlb.0103030; Conti P, 1997, BLOOD, V89, P4120, DOI 10.1182/blood.V89.11.4120; Cronshaw DG, 2004, J IMMUNOL, V172, P7761, DOI 10.4049/jimmunol.172.12.7761; DAHINDEN CA, 1994, J EXP MED, V179, P751, DOI 10.1084/jem.179.2.751; de Mendonca FL, 2005, J BIOL CHEM, V280, P4808, DOI 10.1074/jbc.M412267200; Debes GF, 2005, NAT IMMUNOL, V6, P889, DOI 10.1038/ni1238; DELLABONA P, 1994, J EXP MED, V180, P1171, DOI 10.1084/jem.180.3.1171; Devouassoux G, 1999, J IMMUNOL, V163, P2877; Dhanak D, 2001, BIOORG MED CHEM LETT, V11, P1445, DOI 10.1016/S0960-894X(01)00249-9; Dieu MC, 1998, J EXP MED, V188, P373, DOI 10.1084/jem.188.2.373; Duchesnes UE, 2006, MOL IMMUNOL, V43, P1221, DOI 10.1016/j.molimm.2005.07.015; Eum SY, 1995, P NATL ACAD SCI USA, V92, P12290, DOI 10.1073/pnas.92.26.12290; Fahy O, 2001, AM J PATHOL, V158, P1053, DOI 10.1016/S0002-9440(10)64052-7; Fainaru O, 2005, P NATL ACAD SCI USA, V102, P10598, DOI 10.1073/pnas.0504787102; Farzan M, 1999, CELL, V96, P667, DOI 10.1016/S0092-8674(00)80577-2; Flood-Page P, 2003, J CLIN INVEST, V112, P1029, DOI 10.1172/JCI200317974; Fong AM, 2002, P NATL ACAD SCI USA, V99, P7478, DOI 10.1073/pnas.112198299; Forssmann U, 1997, J EXP MED, V185, P2171, DOI 10.1084/jem.185.12.2171; Forster R, 1999, CELL, V99, P23, DOI 10.1016/S0092-8674(00)80059-8; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; Fredriksson R, 2003, MOL PHARMACOL, V63, P1256, DOI 10.1124/mol.63.6.1256; Freeman CM, 2005, J IMMUNOL, V174, P1962, DOI 10.4049/jimmunol.174.4.1962; Fryer AD, 2006, J CLIN INVEST, V116, P228, DOI 10.1172/JCI25423; Fulkerson PC, 2004, P NATL ACAD SCI USA, V101, P1987, DOI 10.1073/pnas.0308544100; GarciaZepeda EA, 1996, J IMMUNOL, V157, P5613; Garton KJ, 2001, J BIOL CHEM, V276, P37993; Gong JH, 1996, J BIOL CHEM, V271, P10521, DOI 10.1074/jbc.271.18.10521; Gonzalo JA, 2000, J IMMUNOL, V165, P499, DOI 10.4049/jimmunol.165.1.499; Gonzalo JA, 1998, J EXP MED, V188, P157, DOI 10.1084/jem.188.1.157; Goodarzi K, 2003, NAT IMMUNOL, V4, P965, DOI 10.1038/ni972; Govaerts C, 2003, J BIOL CHEM, V278, P1892, DOI 10.1074/jbc.M205685200; Goya I, 2003, J IMMUNOL, V170, P2138, DOI 10.4049/jimmunol.170.4.2138; Greaves DR, 1997, J EXP MED, V186, P837, DOI 10.1084/jem.186.6.837; *GSK, 2004, GSK ANN REP; Gu L, 2000, NATURE, V404, P407, DOI 10.1038/35006097; Gunn MD, 1999, J EXP MED, V189, P451, DOI 10.1084/jem.189.3.451; Gurish MF, 2002, J IMMUNOL, V168, P5730, DOI 10.4049/jimmunol.168.11.5730; Haagerup A, 2002, ALLERGY, V57, P680, DOI 10.1034/j.1398-9995.2002.23523.x; Hammad H, 2002, J IMMUNOL, V169, P1524, DOI 10.4049/jimmunol.169.3.1524; Heath H, 1997, J CLIN INVEST, V99, P178, DOI 10.1172/JCI119145; Heinemann A, 2000, J IMMUNOL, V165, P7224, DOI 10.4049/jimmunol.165.12.7224; Holgate ST, 1997, AM J RESP CRIT CARE, V156, P1377, DOI 10.1164/ajrccm.156.5.9610064; Humbles AA, 1997, J EXP MED, V186, P601, DOI 10.1084/jem.186.4.601; Humbles AA, 2002, P NATL ACAD SCI USA, V99, P1479, DOI 10.1073/pnas.261462598; Humbles AA, 2004, SCIENCE, V305, P1776, DOI 10.1126/science.1100283; Iikura M, 2001, J LEUKOCYTE BIOL, V70, P113; Janetopoulos C, 2001, SCIENCE, V291, P2408, DOI 10.1126/science.1055835; JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881; Jourdan P, 1998, J IMMUNOL, V160, P4153; Juremalm M, 2002, BIOCHEM BIOPH RES CO, V297, P480, DOI 10.1016/S0006-291X(02)02244-1; Juremalm M, 2000, EUR J IMMUNOL, V30, P3614, DOI 10.1002/1521-4141(200012)30:12<3614::AID-IMMU3614>3.0.CO;2-B; Kaburagi Y, 2001, ARCH DERMATOL RES, V293, P350, DOI 10.1007/s004030100230; Kakinuma T, 2001, J ALLERGY CLIN IMMUN, V107, P535, DOI 10.1067/mai.2001.113237; Kang JH, 2005, CELL, V123, P833, DOI 10.1016/j.cell.2005.09.011; Kim CH, 2002, BLOOD, V100, P11, DOI 10.1182/blood-2001-12-0196; Kim Y, 2001, J IMMUNOL, V166, P5183, DOI 10.4049/jimmunol.166.8.5183; Kimura T, 2004, J IMMUNOL, V172, P5782, DOI 10.4049/jimmunol.172.9.5782; Kitaura M, 1999, J BIOL CHEM, V274, P27975, DOI 10.1074/jbc.274.39.27975; Klunker S, 2003, J IMMUNOL, V171, P1078, DOI 10.4049/jimmunol.171.2.1078; Koth LL, 2004, RESP RES, V5, DOI 10.1186/1465-9921-5-12; KUNA P, 1992, J EXP MED, V175, P489, DOI 10.1084/jem.175.2.489; Kuna P, 1998, AM J RESP CRIT CARE, V157, P873, DOI 10.1164/ajrccm.157.3.9610052; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Lee JJ, 2004, SCIENCE, V305, P1773, DOI 10.1126/science.1099472; LELLEM A, 2001, J EXP MED, V194, P847; Li HM, 1996, J IMMUNOL, V157, P1207; Ling EM, 2004, LANCET, V363, P608, DOI 10.1016/S0140-6736(04)15592-X; Lloyd CM, 2000, J EXP MED, V191, P265, DOI 10.1084/jem.191.2.265; Loetscher P, 2001, J BIOL CHEM, V276, P2986, DOI 10.1074/jbc.M005652200; LU ZH, 1995, J BIOL CHEM, V270, P26239; Lukacs NW, 2002, AM J PATHOL, V160, P1353, DOI 10.1016/S0002-9440(10)62562-X; Ma W, 2002, J CLIN INVEST, V109, P621, DOI 10.1172/JCI200214097; Martin C, 2003, IMMUNITY, V19, P583, DOI 10.1016/S1074-7613(03)00263-2; Matloubian M, 2000, NAT IMMUNOL, V1, P298, DOI 10.1038/79738; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Menzies-Gow A, 2002, J IMMUNOL, V169, P2712, DOI 10.4049/jimmunol.169.5.2712; Miyazaki D, 2005, J CLIN INVEST, V115, P434, DOI 10.1172/JCI200518452; Monteclaro FS, 1996, J BIOL CHEM, V271, P19084, DOI 10.1074/jbc.271.32.19084; Morgan AJ, 2005, J ALLERGY CLIN IMMUN, V116, P594, DOI 10.1016/j.jaci.2005.03.052; Morokata T, 2006, J PHARMACOL EXP THER, V317, P244, DOI 10.1124/jpet.105.097048; Motsinger A, 2002, J EXP MED, V195, P869, DOI 10.1084/jem.20011712; Murphy PM, 2000, PHARMACOL REV, V52, P145; Murphy PM, 2002, PHARMACOL REV, V54, P227, DOI 10.1124/pr.54.2.227; Nagase H, 2000, J IMMUNOL, V164, P5935, DOI 10.4049/jimmunol.164.11.5935; Nakamura T, 2005, IMMUNOL RES, V33, P213, DOI 10.1385/IR:33:3:213; Naya A, 2001, BIOORG MED CHEM LETT, V11, P1219, DOI 10.1016/S0960-894X(01)00176-7; Ochi H, 1999, J EXP MED, V190, P267, DOI 10.1084/jem.190.2.267; Ohl L, 2004, IMMUNITY, V21, P279, DOI 10.1016/j.immuni.2004.06.014; Oravecz T, 1997, J EXP MED, V186, P1865, DOI 10.1084/jem.186.11.1865; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Palframan RT, 1998, J EXP MED, V188, P1621, DOI 10.1084/jem.188.9.1621; Palframan RT, 1998, BLOOD, V91, P2240, DOI 10.1182/blood.V91.7.2240.2240_2240_2248; Panina-Bordignon P, 2001, J CLIN INVEST, V107, P1357, DOI 10.1172/JCI12655; Patel VP, 1997, J EXP MED, V185, P1163, DOI 10.1084/jem.185.7.1163; Pease JE, 1998, J BIOL CHEM, V273, P19972, DOI 10.1074/jbc.273.32.19972; Penna G, 2001, J IMMUNOL, V167, P1862, DOI 10.4049/jimmunol.167.4.1862; Phillips RM, 2003, J IMMUNOL, V170, P6190, DOI 10.4049/jimmunol.170.12.6190; Pilette C, 2004, EUR RESPIR J, V23, P876, DOI 10.1183/09031936.04.00102504; Ponath PD, 1996, J EXP MED, V183, P2437, DOI 10.1084/jem.183.6.2437; Powell N, 1996, EUR RESPIR J, V9, P2454, DOI 10.1183/09031936.96.09122454; Power CA, 1997, J EXP MED, V186, P825, DOI 10.1084/jem.186.6.825; POWER CA, 1995, J BIOL CHEM, V270, P19495, DOI 10.1074/jbc.270.33.19495; Proost P, 1999, J BIOL CHEM, V274, P3988, DOI 10.1074/jbc.274.7.3988; Proudfoot AEI, 1996, J BIOL CHEM, V271, P2599, DOI 10.1074/jbc.271.5.2599; Rajakulasingam K, 1997, AM J RESP CRIT CARE, V155, P696, DOI 10.1164/ajrccm.155.2.9032215; Romagnani P, 1999, AM J PATHOL, V155, P1195, DOI 10.1016/S0002-9440(10)65222-4; Rot A, 2004, ANNU REV IMMUNOL, V22, P891, DOI 10.1146/annurev.immunol.22.012703.104543; Rothenberg ME, 1997, J EXP MED, V185, P785, DOI 10.1084/jem.185.4.785; Sabroe I, 2000, J BIOL CHEM, V275, P25985, DOI 10.1074/jbc.M908864199; Sabroe I, 1997, J IMMUNOL, V158, P1361; Sabroe I, 1998, J IMMUNOL, V161, P6139; Sabroe I, 1999, J IMMUNOL, V162, P2946; Saeki T, 2001, BIOCHEM BIOPH RES CO, V281, P779, DOI 10.1006/bbrc.2001.4372; Sallusto F, 2000, ANNU REV IMMUNOL, V18, P593, DOI 10.1146/annurev.immunol.18.1.593; Sallusto F, 1998, J EXP MED, V187, P875, DOI 10.1084/jem.187.6.875; Sallusto F, 1997, SCIENCE, V277, P2005, DOI 10.1126/science.277.5334.2005; Sauty A, 1999, J IMMUNOL, V162, P3549; Schuh JM, 2002, FASEB J, V16, P1313, DOI 10.1096/fj.02-0193fje; Sebastiani S, 2001, J IMMUNOL, V166, P996, DOI 10.4049/jimmunol.166.2.996; SEHMI R, 1992, BLOOD, V79, P2952; Shahabuddin S, 2000, J IMMUNOL, V164, P3847, DOI 10.4049/jimmunol.164.7.3847; Shinkai A, 1999, J IMMUNOL, V163, P1602; Simmons G, 1997, SCIENCE, V276, P276, DOI 10.1126/science.276.5310.276; Sozzani S, 1998, J IMMUNOL, V161, P1083; Stassen M, 2004, J IMMUNOL, V173, P267, DOI 10.4049/jimmunol.173.1.267; Struyf S, 1999, J IMMUNOL, V162, P4903; Suzuki K, 2006, BIOCHEM BIOPH RES CO, V339, P1217, DOI 10.1016/j.bbrc.2005.11.141; Tan JQ, 2000, J ALLERGY CLIN IMMUN, V106, P313, DOI 10.1067/mai.2000.108108; Tang HL, 1999, SCIENCE, V284, P819, DOI 10.1126/science.284.5415.819; THELEN M, 1988, FASEB J, V2, P2702, DOI 10.1096/fasebj.2.11.2840318; Tillie-Leblond I, 2000, AM J RESP CRIT CARE, V162, P586, DOI 10.1164/ajrccm.162.2.9907014; Toda M, 2004, J BIOL CHEM, V279, P48443, DOI 10.1074/jbc.M408725200; TRNER L, 1995, BIOCH SOC T S, V23, pS283; Uguccioni M, 1997, J CLIN INVEST, V100, P1137, DOI 10.1172/JCI119624; Varnes JG, 2004, BIOORG MED CHEM LETT, V14, P1645, DOI 10.1016/j.bmcl.2004.01.059; Vestergaard C, 2000, J INVEST DERMATOL, V115, P640, DOI 10.1046/j.1523-1747.2000.00115.x; Walker JKL, 2003, J CLIN INVEST, V112, P566, DOI 10.1172/JCI200317265; Warmington KS, 1999, AM J PATHOL, V154, P1407, DOI 10.1016/S0002-9440(10)65394-1; Warrior U, 2003, J BIOMOL SCREEN, V8, P324, DOI 10.1177/1087057103008003010; Weller CL, 2005, J EXP MED, V201, P1961, DOI 10.1084/jem.20042407; Wells TNC, 2006, TRENDS PHARMACOL SCI, V27, P41, DOI 10.1016/j.tips.2005.11.001; White JR, 2000, J BIOL CHEM, V275, P36626, DOI 10.1074/jbc.M006613200; White JR, 1997, J LEUKOCYTE BIOL, V62, P667, DOI 10.1002/jlb.62.5.667; Xanthou G, 2003, EUR J IMMUNOL, V33, P2241, DOI 10.1002/eji.200323787; Yamada H, 2000, ALLERGY, V55, P392, DOI 10.1034/j.1398-9995.2000.00474.x; Yang S, 2005, J IMMUNOL, V175, P4914, DOI 10.4049/jimmunol.175.8.4914; Yang Y, 1998, BLOOD, V92, P3912, DOI 10.1182/blood.V92.10.3912.422k23_3912_3923; Ying S, 1997, EUR J IMMUNOL, V27, P3507, DOI 10.1002/eji.1830271252; Yoshida R, 1997, J BIOL CHEM, V272, P13803, DOI 10.1074/jbc.272.21.13803; Zeibecoglou K, 1999, ALLERGY, V54, P730, DOI 10.1034/j.1398-9995.1999.00058.x; Zhang LW, 2002, J BIOL CHEM, V277, P33799, DOI 10.1074/jbc.M205488200; Zimmermann N, 2000, J IMMUNOL, V165, P5839, DOI 10.4049/jimmunol.165.10.5839; Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X	186	76	78	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2006	118	2					305	318		10.1016/j.jaci.2006.06.010	http://dx.doi.org/10.1016/j.jaci.2006.06.010			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	075IH	16890751				2022-12-18	WOS:000239877700002
J	Vassilopoulou, E; Rigby, N; Moreno, FJ; Zuidmeer, L; Akkerdaas, J; Tassios, I; Papadopoulos, NG; Saxoni-Papageorgiou, P; van Ree, R; Mills, C				Vassilopoulou, Emilia; Rigby, Neil; Moreno, F. Javier; Zuidmeer, Laurian; Akkerdaas, Jaap; Tassios, Ioannis; Papadopoulos, Nikos G.; Saxoni-Papageorgiou, Photini; van Ree, Ronald; Mills, Clare			Effect of in vitro gastric and duodenal digestion on the allergenicity of grape lipid transfer protein	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						grape; lipid transfer protein; gastric digestion; duodenal digestion; phosphatidylcholine; basophil histamine release; skin prick testing; food allergy	PLANT FOOD ALLERGENS; MAJOR ALLERGEN; IGE; PEACH; IDENTIFICATION; REACTIVITY; STABILITY; APPLE; SENSITIZATION; EPITOPES	Background: Severe grape allergy has been linked to lipid transfer protein (LTP) sensitization. LTPs are known to be resistant to pepsin digestion, although the effect of gastroduodenal digestion on its allergenicity has not been reported. Objective: We sought to investigate the effect of gastric and gastroduodenal digestion on the allergenic activity of grape LTP. Methods: The proteolytic stability of grape UP was investigated by using an in vitro model of gastrointestinal digestion. The allergenicity of UP and its digesta was assessed in vitro by means of IgE immunoblotting, RASTs, and in vivo skin prick tests in the same patients with grape allergy. Results: Grape LTP was resistant to gastric digestion, and yielded a 6000-d relative molecular mass C-terminally trimmed fragment after duodenal digestion. This fragment retained the in vitro IgE reactivity of the intact protein. Inclusion of phosphatidylcholine during gastric digestion protected the UP to a limited extent against digestion. Digestion did not affect the in vivo (skin prick test) biologic activity of LTP. Conclusion: The allergenic activity of grape UP was highly resistant to in vitro digestion. This property might facilitate sensitization through the gastrointestinal tract and might also potentiate the ability of LTPs to elicit severe allergic reactions in sensitized individuals. fClinical implications: Purified natural allergens will facilitate the development of component-resolved diagnostic approaches, including allergen chips. This study contributes to our understanding of the role digestion plays in symptom elicitation in true food allergy.	Univ Athens, Allergy Res Labs, Pediat Clin 2, Athens 11527, Greece; Food Res Inst, Norwich, Norfolk, England; Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands	National & Kapodistrian University of Athens; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Quadram Institute; University of Amsterdam; Academic Medical Center Amsterdam	Vassilopoulou, E (corresponding author), Univ Athens, Allergy Res Labs, Pediat Clin 2, 41 Fidippidou Str, Athens 11527, Greece.	emi@allergy.gr	N.G., Papadopoulos/L-8670-2013; Zuidmeer, Laurian/B-5494-2008; Moreno, F. Javier/B-1817-2008; Papadopoulos, Nikolaos/ABE-1774-2021; Vassilopoulou, Emilia/AAE-7270-2021	N.G., Papadopoulos/0000-0002-4448-3468; Moreno, F. Javier/0000-0002-7637-9542; Papadopoulos, Nikolaos/0000-0002-4448-3468; Vassilopoulou, Emilia/0000-0002-2665-5908; Papadopoulos, Nikolaos/0000-0002-2508-3872; Zuidmeer-Jongejan, Laurian/0000-0003-3245-5555; Tasios, Ioannis/0000-0002-6328-3277	Biotechnology and Biological Sciences Research Council [BBS/E/F/00042240] Funding Source: Medline; BBSRC [BBS/E/F/00042240] Funding Source: UKRI	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Asero R, 1999, ANN ALLERG ASTHMA IM, V83, P377, DOI 10.1016/S1081-1206(10)62834-7; Asero R, 2000, INT ARCH ALLERGY IMM, V122, P20, DOI 10.1159/000024355; BJORKSTEN F, 1980, ALLERGY, V35, P671, DOI 10.1111/j.1398-9995.1980.tb02020.x; Breiteneder H, 2005, J ALLERGY CLIN IMMUN, V115, P14, DOI 10.1016/j.jaci.2004.10.022; Budde IK, 2000, ALLERGY, V55, P653; Duffort OA, 2002, J AGR FOOD CHEM, V50, P7738, DOI 10.1021/jf0258398; Garcia-Casado G, 2003, J ALLERGY CLIN IMMUN, V112, P599, DOI 10.1037/mai.2003.1638; Heinzerling L, 2005, ALLERGY, V60, P1287, DOI 10.1111/j.1398-9995.2005.00895.x; Jenkins JA, 2005, J ALLERGY CLIN IMMUN, V115, P163, DOI 10.1016/j.jaci.2004.10.026; Lombardero M, 2004, CLIN EXP ALLERGY, V34, P1415, DOI 10.1111/j.1365-2222.2004.02053.x; Mills ENC, 2004, CRIT REV FOOD SCI, V44, P379, DOI 10.1080/10408690490489224; Moreno FJ, 2004, BBA-PROTEINS PROTEOM, V1698, P175, DOI 10.1016/j.bbapap.2003.11.007; Moreno FJ, 2005, FEBS J, V272, P341, DOI 10.1111/j.1742-4658.2004.04472.x; Pastorello EA, 2002, J ALLERGY CLIN IMMUN, V109, P563, DOI 10.1067/mai.2002.121946; Pastorello EA, 1999, J ALLERGY CLIN IMMUN, V103, P520, DOI 10.1016/S0091-6749(99)70480-X; Pastorello EA, 2003, J ALLERGY CLIN IMMUN, V111, P350, DOI 10.1067/mai.2003.35; Rodriguez A, 2004, ALLERGY, V59, P364, DOI 10.1046/j.1398-9995.2003.00298.x; Sanchez-Monge R, 1999, J ALLERGY CLIN IMMUN, V103, P514, DOI 10.1016/S0091-6749(99)70479-3; Sancho AI, 2005, ALLERGY, V60, P1262, DOI 10.1111/j.1398-9995.2005.00876.x; Schad SG, 2005, INT ARCH ALLERGY IMM, V136, P159, DOI 10.1159/000083324; Scheurer S, 2004, J ALLERGY CLIN IMMUN, V114, P900, DOI 10.1016/j.jaci.2004.06.017; Schocker F, 2004, J ALLERGY CLIN IMMUN, V113, P141, DOI 10.1016/j.jaci.2003.09.013; Schuurman J, 1997, INT ARCH ALLERGY IMM, V113, P262, DOI 10.1159/000237566; SIRAGANIAN RP, 1975, J IMMUNOL METHODS, V7, P283, DOI 10.1016/0022-1759(75)90025-3; VANDERZEE JS, 1988, J ALLERGY CLIN IMMUN, V82, P270, DOI 10.1016/0091-6749(88)91011-1; VANREE R, 1995, J ALLERGY CLIN IMMUN, V95, P726, DOI 10.1016/S0091-6749(95)70178-8; VIGNEC AJ, 1954, J PEDIATR-US, V44, P294, DOI 10.1016/S0022-3476(54)80318-0	27	76	79	1	27	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2006	118	2					473	480		10.1016/j.jaci.2006.04.057	http://dx.doi.org/10.1016/j.jaci.2006.04.057			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	075IH	16890774				2022-12-18	WOS:000239877700025
J	Roifman, CM; Gu, YP; Cohen, A				Roifman, CM; Gu, YP; Cohen, A			Mutations in the RNA component of RNase mitochondrial RNA processing might cause Omenn syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						primary immunodeficiency; mutation	CARTILAGE-HAIR HYPOPLASIA; SHORT-LIMBED DWARFISM; RECOMBINATION ACTIVATING GENES; COMBINED IMMUNE-DEFICIENCY; CELL-CYCLE PROGRESSION; V(D)J RECOMBINATION; COMBINED IMMUNODEFICIENCY; RAG MUTATIONS; BONE-MARROW; MRP	Background: Omenn syndrome is a variant of severe combined immunodeficiency disease, which most prominently presents with erythroderma, eosinophilia, and susceptibility to various pathogens. Mutations in the nucleases of recombination activating genes 1 and 2 (RAG1/RAG2) or Artemis were found in some, but not all, patients with Omenn syndrome. We identified 2 patients who presented with clinical features consistent with Omenn syndrome but had no mutations in RAG or Artemis. Both patients also had cartilage-hair hypoplasia (CHH). Objectives: We sought to define the molecular basis and characterize the features of severe combined immunodeficiency and Omenn syndrome in these patients. Methods: We have studied Immoral and cellular immunity using standard assays. T-cell repertoire was investigated by quantitating V beta families. The RNase mitochondrial RNA processing (RMRP) RNA gene was sequenced by using standard techniques. Results: Sequence analysis of the RMRP RNA gene showed that each patient had an insertion-duplication on one allele and a point mutation on the other allele. These point mutations were novel, and they might be related to the unusual presentation of Omenn syndrome in addition to CHH in these patients. Indeed, analysis of the thymus showed residual mature T lymphocytes. This leaky thymus might be responsible for the skewed release of some T-cell clones into the circulation, which might trigger the phenotype of Omenn syndrome. Conclusion: We have demonstrated that mutations in the RMRP RNA gene might be associated with Omenn syndrome. Clinical implications: This discovery will aid clinicians in the early recognition and treatment of CHH-associated Omenn syndrome.	Hosp Sick Children, Div Immunol Allergy & Infect, Immun Injury & Repair Program, Toronto, ON M5G 1X8, Canada; Univ Toronto, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Roifman, CM (corresponding author), Hosp Sick Children, Div Immunol Allergy & Infect, Immun Injury & Repair Program, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	chaim.roifman@sickkids.ca						Aleman K, 2001, EUR J PEDIATR, V160, P718, DOI 10.1007/s004310100816; ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; BARTH RF, 1972, LANCET, V2, P503; Berthet F, 1996, EUR J PEDIATR, V155, P286; Bonafe L, 2002, CLIN GENET, V61, P146, DOI 10.1034/j.1399-0004.2002.610210.x; Cai T, 2002, GENETICS, V161, P1029; CHANG DD, 1987, SCIENCE, V235, P1178, DOI 10.1126/science.2434997; CLAYTON DA, 1994, P NATL ACAD SCI USA, V91, P4615, DOI 10.1073/pnas.91.11.4615; DESAINTBASILE G, 1991, J CLIN INVEST, V87, P1352, DOI 10.1172/JCI115139; DOHERTY PJ, 1991, MOL IMMUNOL, V28, P607, DOI 10.1016/0161-5890(91)90129-8; Ege M, 2005, BLOOD, V105, P4179, DOI 10.1182/blood-2004-12-4861; GATTI RA, 1969, J PEDIATR-US, V75, P675, DOI 10.1016/S0022-3476(69)80465-8; Gennery AR, 2005, CLIN IMMUNOL, V116, P246, DOI 10.1016/j.clim.2005.04.014; Gill T, 2004, MOL CELL BIOL, V24, P945, DOI 10.1128/MCB.24.3.945-953.2004; Kuijpers TW, 2003, J MED GENET, V40, P761, DOI 10.1136/jmg.40.10.761; Li X, 2004, NUCLEIC ACIDS RES, V32, P3703, DOI 10.1093/nar/gkh689; Ma YM, 2002, CELL, V108, P781, DOI 10.1016/S0092-8674(02)00671-2; Makitie O, 2000, J PEDIATR-US, V137, P487, DOI 10.1067/mpd.2000.108102; Makitie O, 1999, J PEDIATR-US, V134, P315, DOI 10.1016/S0022-3476(99)70456-7; Makitie O, 1998, EUR J PEDIATR, V157, P816, DOI 10.1007/s004310050943; MAKITIE O, 1993, EUR J PEDIATR, V152, P211, DOI 10.1007/BF01956147; Makitie O, 2001, ARCH DIS CHILD, V84, P65, DOI 10.1136/adc.84.1.65; MCKUSICK VA, 1965, B JOHNS HOPKINS HOSP, V116, P285; MELAMED I, 1994, CLIN EXP IMMUNOL, V95, P14; Moshous D, 2001, CELL, V105, P177, DOI 10.1016/S0092-8674(01)00309-9; Nakashima E, 2003, AM J MED GENET A, V123A, P253, DOI 10.1002/ajmg.a.20281; Noordzij JG, 2003, BLOOD, V101, P1446, DOI 10.1182/blood-2002-01-0187; OETTINGER MA, 1992, IMMUNOGENETICS, V35, P97, DOI 10.1007/BF00189518; OMENN GS, 1965, NEW ENGL J MED, V273, P427, DOI 10.1056/NEJM196508192730806; Ridanpaa M, 2003, AM J MED GENET C, V121C, P81, DOI 10.1002/ajmg.c.20006; Ridanpaa M, 2002, EUR J HUM GENET, V10, P439, DOI 10.1038/sj.ejhg.5200824; Ridanpaa M, 2001, CELL, V104, P195, DOI 10.1016/S0092-8674(01)00205-7; Roifman CM, 2005, IMMUNOL REV, V203, P143, DOI 10.1111/j.0105-2896.2005.00236.x; ROIFMAN CM, 1989, J EXP MED, V170, P2177, DOI 10.1084/jem.170.6.2177; Roman CAJ, 1996, P NATL ACAD SCI USA, V93, P2333, DOI 10.1073/pnas.93.6.2333; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SCHMITT ME, 1993, FASEB J, V7, P208, DOI 10.1096/fasebj.7.1.7678563; SCHOFER O, 1991, J PEDIATR-US, V118, P86, DOI 10.1016/S0022-3476(05)81853-0; Schwarz K, 1996, SCIENCE, V274, P97, DOI 10.1126/science.274.5284.97; Sharfe N, 1997, J CLIN INVEST, V100, P3036, DOI 10.1172/JCI119858; Signorini S, 1999, BLOOD, V94, P3468, DOI 10.1182/blood.V94.10.3468.422k34_3468_3478; SILVER DP, 1993, P NATL ACAD SCI USA, V90, P6100, DOI 10.1073/pnas.90.13.6100; Villa A, 1998, CELL, V93, P885, DOI 10.1016/S0092-8674(00)81448-8; Villa A, 2001, BLOOD, V97, P81, DOI 10.1182/blood.V97.1.81; WIRT DP, 1989, NEW ENGL J MED, V321, P370, DOI 10.1056/NEJM198908103210606; Zhang JY, 2005, PEDIATRICS, V116, pE445, DOI 10.1542/peds.2005-0369	46	76	79	1	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2006	117	4					897	903		10.1016/j.jaci.2006.01.003	http://dx.doi.org/10.1016/j.jaci.2006.01.003			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	033QB	16630949				2022-12-18	WOS:000236862800026
J	Litonjua, AA; Celedon, JC; Hausmann, J; Nikolov, M; Sredl, D; Ryan, L; Platts-Mills, TAE; Weiss, ST; Gold, DR				Litonjua, AA; Celedon, JC; Hausmann, J; Nikolov, M; Sredl, D; Ryan, L; Platts-Mills, TAE; Weiss, ST; Gold, DR			Variation in total and specific IgE: Effects of ethnicity and socioeconomic status	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						immunologic sensitization; ethnic group; socioeconomic factors; asthma	NUTRITION EXAMINATION SURVEY; SKIN-TEST REACTIVITY; 2ND NATIONAL-HEALTH; UNITED-STATES; ALLERGEN SENSITIZATION; ASTHMATIC-CHILDREN; COCKROACH ALLERGEN; RISK-FACTORS; SOCIAL-CLASS; DUST-MITE	Background: Asthma is common in minority and disadvantaged populations, whereas atopic disorders other than asthma appear to be less prevalent. It is unclear whether the same holds true for objective markers of sensitization. Objective: To determine the association of asthma, atopic disorders, and specific sensitization with race and socioeconomic factors. Methods: We analyzed total and specific IgE among 882 women (577 white, 169 black, and 136 Hispanic) who delivered a child at a large tertiary hospital in Boston, Mass, and who were screened for participation in a family and birth cohort study. Race/ethnicity and other characteristics were obtained from screening questionnaires. Addresses were geocoded, and 3 census-based geographic area socioeconomic variables were derived from block group information from the 1990 US Census. Results: Black and Hispanic women were more likely to come from areas with low socioeconomic indicators and were more likely to have asthma than white women. However, these women were less likely to have hay fever and eczema than their white counterparts. Compared with white women, black women had higher mean total IgE levels; had greater proportions of sensitization to indoor, outdoor, and fungal allergens; and were more than twice as likely to be sensitized to >= 3 aeroallergens. Conclusion: The racial/ethnic disparities in atopic disorders may represent either underdiagnosis or underreporting and suggest that allergy testing may be underused in some populations. Differences in total IgE levels and specific allergen sensitization are likely a result of the complex interplay between exposures associated with socioeconomic disadvantage.	Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Div Pulm & Crit Care Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; Univ Virginia, Charlottesville, VA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; University of Virginia	Litonjua, AA (corresponding author), Brigham & Womens Hosp, Dept Med, Channing Lab, 75 Francis St, Boston, MA 02115 USA.	augusto.litonjua@channing.harvard.edu	Ryan, Louise M/A-4562-2009	Ryan, Louise M/0000-0001-5957-2490; Hausmann, Jonathan/0000-0003-0786-8788; Litonjua, Augusto/0000-0003-0422-5875; Platts-Mills, Thomas/0000-0002-1263-329X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035786] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 35786] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARRIGHI HM, 1995, ANN ALLERG ASTHMA IM, V74, P321; Boulet LP, 1997, CLIN EXP ALLERGY, V27, P52, DOI 10.1111/j.1365-2222.1997.tb00672.x; *BUR CENS US DEP C, 1990, CENS 90 BAS; Celedon JC, 2004, CHEST, V125, P85, DOI 10.1378/chest.125.1.85; Chen JT, 2002, ENVIRON HEALTH PERSP, V110, P211, DOI 10.1289/ehp.02110s2211; Court CS, 2002, CLIN EXP ALLERGY, V32, P1033, DOI 10.1046/j.1365-2222.2002.01406.x; Eggleston PA, 1999, ENVIRON HEALTH PERSP, V107, P439, DOI 10.1289/ehp.99107s3439; EVANS R, 1987, CHEST S, V91, P65; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573, DOI 10.1164/ajrccm/147.3.573; GERGEN PJ, 1987, J ALLERGY CLIN IMMUN, V80, P669, DOI 10.1016/0091-6749(87)90286-7; GERGEN PJ, 1992, J ALLERGY CLIN IMMUN, V90, P579, DOI 10.1016/0091-6749(92)90130-T; GERGEN PJ, 1988, PEDIATRICS, V81, P1; Gold DR, 1999, AM J RESP CRIT CARE, V160, P227, DOI 10.1164/ajrccm.160.1.9807104; Heinrich J, 1998, AM J PUBLIC HEALTH, V88, P1319, DOI 10.2105/AJPH.88.9.1319; Kitch BT, 2000, ENVIRON HEALTH PERSP, V108, P301, DOI 10.2307/3454347; Leaderer BP, 2002, ENVIRON HEALTH PERSP, V110, P419, DOI 10.1289/ehp.02110419; Lester LA, 2001, J ALLERGY CLIN IMMUN, V108, P357, DOI 10.1067/mai.2001.117796; Lewis SA, 2002, AM J RESP CRIT CARE, V165, P961, DOI 10.1164/ajrccm.165.7.2103044; Lewis SA, 2001, J ALLERGY CLIN IMMUN, V107, P615, DOI 10.1067/mai.2001.113523; Litonjua AA, 1999, PEDIATR PULM, V28, P394, DOI 10.1002/(SICI)1099-0496(199912)28:6<394::AID-PPUL2>3.0.CO;2-6; Marsh DG, 1997, NAT GENET, V15, P389; *MASS STAT DAT CTR, 1992, 1990 CENS POP HOUS; Phipatanakul W, 2000, J ALLERGY CLIN IMMUN, V106, P1070, DOI 10.1067/mai.2000.110796; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Sarpong SB, 1996, J ALLERGY CLIN IMMUN, V97, P1393, DOI 10.1016/S0091-6749(96)70209-9; SCHWARTZ J, 1990, AM REV RESPIR DIS, V142, P555, DOI 10.1164/ajrccm/142.3.555; SHERMAN CB, 1993, AM REV RESPIR DIS, V148, P98, DOI 10.1164/ajrccm/148.1.98; Stevenson LA, 2001, J ALLERGY CLIN IMMUN, V108, P747, DOI 10.1067/mai.2001.119410; Strunk Robert C., 2002, Journal of Allergy and Clinical Immunology, V109, P229, DOI 10.1067/mai.2002.120950; *US STAT CENS BUR, 1997, AM HOUS SURV 1997 NA; Zoratti EM, 1998, AM J RESP CRIT CARE, V158, P371, DOI 10.1164/ajrccm.158.2.9608039	31	76	76	0	11	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2005	115	4					751	757		10.1016/j.jaci.2004.12.1138	http://dx.doi.org/10.1016/j.jaci.2004.12.1138			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	916GM	15805994	Bronze			2022-12-18	WOS:000228373400013
J	Szeplaki, G; Varga, L; Valentin, S; Kleiber, M; Karadi, I; Romics, L; Fust, G; Farkas, H				Szeplaki, G; Varga, L; Valentin, S; Kleiber, M; Karadi, I; Romics, L; Fust, G; Farkas, H			Adverse effects of danazol prophylaxis on the lipid profiles of patients with hereditary angioedema	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						hereditary angioedema; danazol; adverse effects; lipids; high-density lipoprotein; low-density lipoprotein; atherosclerosis	SERUM LIPOPROTEIN(A) LEVELS; LONG-TERM TREATMENT; ATTENUATED ANDROGENS; EDEMA; ENDOMETRIOSIS; PLASMA; WOMEN; ATHEROSCLEROSIS; EXPERIENCE; MANAGEMENT	Background: Hereditary angioedema (HAE) is a rare disorder caused by the deficiency of the C1-inhibitor gene (C1INH). Patients experience recurrent bouts of edema, which can occur in almost any region of the body. As regards the treatment of the disease, danazol (an attenuated androgen) is used, among other agents, for long-term prophylaxis. Objective: The aim of this study was to investigate the possible adverse effects of danazol on serum lipid profile, as well as to ascertain whether danazol treatment is associated with an increased risk of atherosclerosis. Methods: Serum concentrations of total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL), triglycerides, apolipoprotein A-I, apolipoprotein B-100, and lipoprotein(a) were compared between danazol-treated patients with HAE and 2 control groups tie, patients who did not receive long-term danazol prophylaxis and untreated healthy subjects). Results: Serum concentrations of HDL (P = .0002 and P < .0001) and apolipoprotein A-I (P = .0015 and P < .0001) were significantly lower, whereas LDL (P = .0129 and P = .0127) and apolipoprotein B-100 (P = .0456 and P = .0013) were higher in the danazol-treated patients compared with the 2 control groups, respectively. No significant difference was found in total cholesterol, triglyceride, or lipoprotein(a) levels. Patients who received danazol had an 11.6 (95% CI, 2.7-49.7) times higher risk for abnormally low HDL levels and a 4.4 (95% CI, 1.2-16.0) times lower risk for high LDL concentrations. Conclusions: Our findings indicate that the long-term use of danazol is associated with an increased risk for early atherosclerosis in patients with HAE. Consequently, monitoring of HDL and LDL levels at regular intervals is recommended during follow-up.	Semmelweis Univ, Kutvolgyi Clin Ctr, Allergol & Angioedema Outpatient Clin, H-1125 Budapest, Hungary; Semmelweis Univ, Fac Med, Dept Internal Med 3, H-1125 Budapest, Hungary; Semmelweis Univ, Kutvolgyi Clin Ctr, Cent Lab, H-1125 Budapest, Hungary; Semmelweis Univ, Res Grp Atherosclerosis & Metab, H-1125 Budapest, Hungary; Hungarian Acad Sci, H-1051 Budapest, Hungary	Semmelweis University; Semmelweis University; Semmelweis University; Semmelweis University; Hungarian Academy of Sciences	Farkas, H (corresponding author), Semmelweis Univ, Kutvolgyi Clin Ctr, Allergol & Angioedema Outpatient Clin, Kutvolgyi Ut 4, H-1125 Budapest, Hungary.	farkash@kut.sote.hu	Varga, Lilian/F-2491-2010	Farkas, Henriette/0000-0003-2929-1721; Szeplaki, Gabor/0000-0003-3795-1240; Karadi, Istvan/0000-0002-8253-2654; Varga, Lilian/0000-0002-5484-364X				Agostoni A, 2004, J ALLERGY CLIN IMMUN, V114, pS51, DOI 10.1016/j.jaci.2004.06.047; ANDRIOLE GL, 1986, J UROLOGY, V135, P44, DOI 10.1016/S0022-5347(17)45509-1; Bork K, 1999, LANCET, V353, P1066, DOI 10.1016/S0140-6736(99)00110-5; Bork K, 2002, J HEPATOL, V36, P707, DOI 10.1016/S0168-8278(02)00035-1; Bowen T, 2004, J ALLERGY CLIN IMMUN, V114, P629, DOI 10.1016/j.jaci.2004.06.043; Carugati A, 2001, MOL IMMUNOL, V38, P161, DOI 10.1016/S0161-5890(01)00040-2; Cicardi M, 1997, J ALLERGY CLIN IMMUN, V99, P194, DOI 10.1016/S0091-6749(97)70095-2; CICARDI M, 1991, J ALLERGY CLIN IMMUN, V87, P768, DOI 10.1016/0091-6749(91)90120-D; CICARDI M, 1983, J ALLERGY CLIN IMMUN, V72, P294, DOI 10.1016/0091-6749(83)90034-9; CROOK D, 1992, ATHEROSCLEROSIS, V92, P41, DOI 10.1016/0021-9150(92)90008-5; Crook D, 1997, METABOLISM, V46, P735, DOI 10.1016/S0026-0495(97)90115-3; DAHLEN GH, 1994, ATHEROSCLEROSIS, V108, P111, DOI 10.1016/0021-9150(94)90106-6; DIEPLINGER H, 1995, J LIPID RES, V36, P813; Farkas H, 2003, TRANSFUS APHER SCI, V29, P229, DOI 10.1016/j.transci.2003.08.003; Farkas H, 1999, J ORAL MAXIL SURG, V57, P404, DOI 10.1016/S0278-2391(99)90280-X; Farkas H, 2002, PEDIAT ALLERG IMM-UK, V13, P153, DOI 10.1034/j.1399-3038.2002.01014.x; FORD I, 1994, THROMB HAEMOSTASIS, V72, P218; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GELFAND JA, 1976, NEW ENGL J MED, V295, P1444, DOI 10.1056/NEJM197612232952602; HOOGERBRUGGE N, 1995, J INTERN MED, V237, P603; HOSEA SW, 1980, ANN INTERN MED, V93, P809, DOI 10.7326/0003-4819-93-6-809; Kalina A, 2001, CLIN CHIM ACTA, V309, P45, DOI 10.1016/S0009-8981(01)00500-9; Kalmar L, 2003, HUM MUTAT, V22, DOI 10.1002/humu.9202; LUCIANO AA, 1982, ATHEROSCLEROSIS, V43, P133, DOI 10.1016/0021-9150(82)90105-8; Mantel-Teeuwisse AK, 2001, DRUG SAFETY, V24, P443, DOI 10.2165/00002018-200124060-00003; Oksjoki R, 2003, CURR OPIN LIPIDOL, V14, P477, DOI 10.1097/00041433-200310000-00008; Osler W, 1888, AM J MED SCI, V95, P362; PACKARD CJ, 1994, ACTA OBSTET GYN SCAN, V73, P35; Quincke H, 1882, MONATSH PRAKT DERMAT, V1, P129; SCANU AM, 1991, ANN INTERN MED, V115, P209, DOI 10.7326/0003-4819-115-3-209; SHEPHERD J, 1995, INT J GYNECOL OBSTET, V50, pS23, DOI 10.1016/0020-7292(95)02511-A; ZURLO JJ, 1990, FERTIL STERIL, V54, P64	32	76	76	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2005	115	4					864	869		10.1016/j.jaci.2004.12.1130	http://dx.doi.org/10.1016/j.jaci.2004.12.1130			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	916GM	15806011				2022-12-18	WOS:000228373400030
J	Hilger, C; Bessot, JC; Hutt, N; Grigioni, F; de Blay, F; Pauli, G; Hentges, F				Hilger, C; Bessot, JC; Hutt, N; Grigioni, F; de Blay, F; Pauli, G; Hentges, F			IgE-mediated anaphylaxis caused by bites of the pigeon tick Argas reflexus: Cloning and expression of the major allergen Arg r 1	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						anaphylaxis; pigeon tick; Argas reflevus; major allergen; cDNA cloning; lipocalin; Arg r I	LIPOCALIN; PROTEINS; VENOM; SHOCK; BINDING; FAMILY	Background: Anaphylactic reactions caused by bites of the European pigeon tick Argas reflexus are repeatedly reported. This soft-backed tick is a parasite of wild pigeons colonizing urban buildings and houses. Occasionally the ticks can bite human beings, inducing anaphylactic reactions in sensitized patients. Objective: Our aim was to characterize the major allergen implicated in a series of anaphylactic reactions caused by Argas bites and to produce the allergen as recombinant protein for diagnostic purposes. Methods: Protein extracts were prepared from whole A reflexus bodies, and IgE immunoblots were performed with sera from 13 patients who had an anaphylactic reaction with pigeon tick bites. A cDNA expression library was constructed from whole ticks and screened with a polyclonal rabbit antiserum raised against the major allergen. Results: The cDNA coding for the dominant allergen Arg r 1 could be isolated. It encodes a protein belonging to the lipocalin family. Allergenicity of the recombinant Arg r 1 was confirmed by immunoblot, ELISA, and intradermal skin tests. Conclusion: The dominant allergen of A reflexus has been isolated and the corresponding cDNA cloned. The recombinant protein, a lipocalin, was expressed in Escherichia coli and was shown to be immunoreactive in vitro and in vivo. Recombinant Arg r 1 was used as a diagnostic tool in a series of anaphylactic reactions caused by pigeon tick bites.	Ctr Hosp Luxembourg, Ctr Rech Publ Sante, Lab Immunogenet & Allergol, Luxembourg, Luxembourg; Hop Univ Strasbourg, Serv Pneumol, Strasbourg, France	Luxembourg Hospital Center; Luxembourg Institute of Health; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Hilger, C (corresponding author), CRP Sante Lab Immunogenet & Allergol, 84,Val Fleuri, L-1526 Luxembourg, Luxembourg.	christiane.hilger@crp-sante.lu	Grigioni, Francesco/AAL-3603-2020	Hilger, Christiane/0000-0001-9455-5442				Acero S, 2003, ALLERGY, V58, P824, DOI 10.1034/j.1398-9995.2003.00211.x; Bessot JC, 1997, REV FR ALLERGOL, V37, P431, DOI 10.1016/S0335-7457(97)80070-6; Chapman MD, 2000, J ALLERGY CLIN IMMUN, V106, P409, DOI 10.1067/mai.2000.109832; Chappard Colette, 1996, Biomedical Research (Aligarh), V7, P11; CHASTEL C, 1994, ACTA VIROL, V38, P285; COUDERT J, 1972, B SOC PATHOL EXOT, V54, P884; Dal Monte Alberto, 1994, Recenti Progressi in Medicina, V85, P384; Dautel H, 1998, OECOLOGIA, V113, P46, DOI 10.1007/s004420050352; Dautel H, 1999, ZBL BAKT-INT J MED M, V289, P745; DAUTEL H, 1991, J APPL ENTOMOL, V11, P380; Fernandez-Soto P, 2001, ANN TROP MED PARASIT, V95, P97, DOI 10.1080/00034980020035960; Flower DR, 1996, BIOCHEM J, V318, P1; GAUCI M, 1989, CLIN EXP ALLERGY, V19, P279, DOI 10.1111/j.1365-2222.1989.tb02384.x; KELLER PM, 1993, J BIOL CHEM, V268, P5450; KEMENY DM, 1983, J ALLERGY CLIN IMMUN, V72, P376, DOI 10.1016/0091-6749(83)90503-1; Kleine-Tebbe J, 1998, J ALLERGY CLIN IMMUN, V101, pS159; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Mans BJ, 2003, MOL BIOL EVOL, V20, P1158, DOI 10.1093/molbev/msg126; MIADONNA A, 1982, ANN ALLERGY, V49, P293; Moneret-Vautrin DA, 1998, J ALLERGY CLIN IMMUN, V101, P144; Paesen GC, 1999, MOL CELL, V3, P661, DOI 10.1016/S1097-2765(00)80359-7; Reininger R, 2003, INT ARCH ALLERGY IMM, V130, P275, DOI 10.1159/000070214; Sangamnatdej S, 2002, INSECT MOL BIOL, V11, P79, DOI 10.1046/j.0962-1075.2001.00311.x; Sirianni MC, 2000, ALLERGY, V55, P303, DOI 10.1034/j.1398-9995.2000.00525.x; Sonenshine DE, 1991, BIOL TICKS, V1; SPIEWAK R, 2004, 23 EAACI C AMST 12 1, P157; VANWYE JE, 1991, NEW ENGL J MED, V324, P777; Veraldi S, 1996, INT J DERMATOL, V35, P34, DOI 10.1111/j.1365-4362.1996.tb01612.x; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WUTHRICH B, 1981, SCHWEIZ MED WSCHR, V111, P1756	30	76	84	0	5	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2005	115	3					617	622		10.1016/j.jaci.2004.11.052	http://dx.doi.org/10.1016/j.jaci.2004.11.052			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	907AN	15753913				2022-12-18	WOS:000227687000028
J	Siroux, V; Curt, F; Oryszczyn, MP; Maccario, J; Kauffmann, F				Siroux, V; Curt, F; Oryszczyn, MP; Maccario, J; Kauffmann, F			Role of gender and hormone-related events on IgE, atopy, and eosinophils in the Epidemiological Study on the Genetics and Environment of Asthma, Bronchial Hyperresponsiveness and Atopy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; gender; hormone; eosinophils; IgE	SKIN-TEST REACTIVITY; GENERAL-POPULATION; SERUM IGE; EGEA; ASSOCIATION; SEVERITY; RISK; INFLAMMATION; MECHANISMS; CHILDHOOD	Background: The pattern of asthma over the lifespan is different in male and female patients, but etiologic differences according to gender are only partially understood. In women, information regarding factors explaining perimenstrual asthma and the role of hormone-related aspects on asthma-related phenotypes is scanty. Objective: To assess the relationships of eosinophils, IgE, and atopy with (1) asthma according to gender and age of onset and (2) hormone-related events. Methods: Using data from the Epidemiological study on the Genetics and Environment of Asthma, Bronchial Hyperresponsiveness and Atopy, adults and children with asthma recruited in chest clinics (n = 313) and first-degree relatives of patients with asthma (n = 214) were compared with nonasthmatic controls (n = 334) and first-degree relatives without asthma (n = 595). Results: Among asthmatic women, eosinophilia was significantly associated with perimenstrual asthma independently from age, smoking, and asthma severity (eosinophils/mm(3) 330 vs 194; P = .01). In nonasthmatic women, IgE level was significantly decreased (by half) and atopy decreased with menopause, and IgE increased with oral contraceptive use, independently from age and smoking. Considering both genders, the increase of eosinophil counts with asthma was significantly greater in women with childhood-onset asthma than in women with adulthood-onset or in men in general. No interaction between gender and asthma was observed for eosinophils in children and for IgE level and atopy in children and adults. Conclusion: Results suggest a role of hormone-related events on asthma-related traits and support the hypothesis of the role of eosinophils in the persistence and severity of asthma.	INSERM, U472, IFR69, F-94807 Villejuif, France; Dept Med Aigue Specialisee, Grenoble, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Kauffmann, F (corresponding author), INSERM, U472, IFR69, 16 Ave PV Couturier, F-94807 Villejuif, France.	kauffmann@vjf.inserm.fr	siroux, valerie/N-1865-2013	siroux, valerie/0000-0001-7329-7237				Agarwal SK, 1999, ANN ALLERG ASTHMA IM, V83, P222, DOI 10.1016/S1081-1206(10)62644-0; BAILEY WC, 1992, AM J MED, V93, P263, DOI 10.1016/0002-9343(92)90231-Y; Baldacci S, 2001, EUR RESPIR J, V17, P773, DOI 10.1183/09031936.01.17407730; Becklake MR, 1999, THORAX, V54, P1119, DOI 10.1136/thx.54.12.1119; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BOUZIGON E, 2002, GEN EPIDEMIOL, V23, P269; BUIST S, 2003, EUROPEAN RESP MONOGR, V8; BURROWS B, 1980, AM REV RESPIR DIS, V122, P709, DOI 10.1164/arrd.1980.122.5.709; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; Busse WW, 2003, AM J RESP CRIT CARE, V167, P102, DOI 10.1164/rccm.2211004; Chen Y, 2003, J CLIN EPIDEMIOL, V56, P180, DOI 10.1016/S0895-4356(02)00593-0; Cioffi M, 2002, MATURITAS, V41, P187, DOI 10.1016/S0378-5122(01)00286-9; Gleich GJ, 2000, J ALLERGY CLIN IMMUN, V105, P651, DOI 10.1067/mai.2000.105712; Global Initiative for Asthma, 2002, NIH PUBL; GUERRA S, 2004, AM J RESP CRIT CARE; Hamano N, 1998, ACTA OTO-LARYNGOL, P27; HAPPLE R, 1982, INT ARCH ALLER A IMM, V68, P90, DOI 10.1159/000233072; Hellings PW, 2003, CLIN EXP ALLERGY, V33, P1457, DOI 10.1046/j.1365-2222.2003.01743.x; Jansen DF, 1999, AM J RESP CRIT CARE, V159, P924, DOI 10.1164/ajrccm.159.3.9804024; Karakoc F, 2002, CLIN EXP ALLERGY, V32, P51, DOI 10.1046/j.0022-0477.2001.01273.x; Kauffmann F, 1999, CLIN EXP ALLERGY, V29, P17; Kauffmann F, 1997, AM J RESP CRIT CARE, V156, pS123, DOI 10.1164/ajrccm.156.4.12tac9; Kauffmann F, 2002, REV MAL RESPIR, V19, P323; Kauffmann F, 2001, REV EPIDEMIOL SANTE, V49, P343; KAUFFMANN F, 2003, EUROPEAN RESP MONOGR, V5, P288; Krieger N, 2003, INT J EPIDEMIOL, V32, P652, DOI 10.1093/ije/dyg156; Lange P, 2001, THORAX, V56, P613, DOI 10.1136/thorax.56.8.613; Lewis SA, 2001, CHEST, V119, P105, DOI 10.1378/chest.119.1.105; Leynaert B, 1997, AM J RESP CRIT CARE, V156, P1413, DOI 10.1164/ajrccm.156.5.9701060; LIANG KY, 1993, ANNU REV PUBL HEALTH, V14, P43, DOI 10.1146/annurev.pu.14.050193.000355; Maccario J, 2003, J ALLERGY CLIN IMMUN, V111, P750, DOI 10.1067/mai.2003.1386; Mendonca EMC, 2003, AM J IND MED, V43, P611, DOI 10.1002/ajim.10210; MUND E, 2003, EUROPEAN RESP MONOGR, V8, P26; OConnor BJ, 1997, THORAX, V52, P591, DOI 10.1136/thx.52.7.591; Oryszczyn MP, 2000, AM J RESP CRIT CARE, V161, P1241, DOI 10.1164/ajrccm.161.4.9905027; Palmer LJ, 2001, GENET EPIDEMIOL, V20, P356, DOI 10.1002/gepi.6; PETERSON AP, 1981, J ALLERGY CLIN IMMUN, V68, P212, DOI 10.1016/0091-6749(81)90186-X; Pin I, 2002, AM J RESP CRIT CARE, V165, P185, DOI 10.1164/ajrccm.165.2.2012019; Prescott E, 1997, THORAX, V52, P287, DOI 10.1136/thx.52.3.287; Rabe KF, 2000, EUR RESPIR J, V16, P802, DOI 10.1183/09031936.00.16580200; REDLINE S, 1994, AM J RESP CRIT CARE, V150, P1219, DOI 10.1164/ajrccm.150.5.7952543; Romieu I, 2003, AM J EPIDEMIOL, V158, P165, DOI 10.1093/aje/kwg131; ROORDA RJ, 1993, EUR RESPIR J, V6, P509; Siroux V, 2003, CLIN EXP ALLERGY, V33, P746, DOI 10.1046/j.1365-2222.2003.01674.x; SPORIK R, 1995, AM J RESP CRIT CARE, V151, P1388, DOI 10.1164/ajrccm.151.5.7735590; TROISI RJ, 1995, AM J RESP CRIT CARE, V152, P1183, DOI 10.1164/ajrccm.152.4.7551368; Turnbull AV, 1999, PHYSIOL REV, V79, P1, DOI 10.1152/physrev.1999.79.1.1; Vellutini M, 1997, EUR J EPIDEMIOL, V13, P931, DOI 10.1023/A:1007472407010; Vrieze A, 2003, J ALLERGY CLIN IMMUN, V112, P271, DOI 10.1067/mai.2003.1676; Yoshimoto T, 2000, NAT IMMUNOL, V1, P132, DOI 10.1038/77811; Zang YCQ, 2002, J NEUROIMMUNOL, V124, P106, DOI 10.1016/S0165-5728(02)00016-4	51	76	76	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2004	114	3					491	498		10.1016/j.jaci.2004.05.027	http://dx.doi.org/10.1016/j.jaci.2004.05.027			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	853AX	15356546	Bronze			2022-12-18	WOS:000223799600003
J	Duffy, SM; Berger, P; Cruse, G; Yang, WD; Bolton, SJ; Bradding, P				Duffy, SM; Berger, P; Cruse, G; Yang, WD; Bolton, SJ; Bradding, P			The K+ channel iK(CA)1 potentiates Ca2+ influx and degranulation in human lung mast cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						mast cell; human; K+; ion channel; Ca2+; histamine	BRONCHOALVEOLAR LAVAGE; T-LYMPHOCYTES; CALCIUM; ACTIVATION; PROLIFERATION; MECHANISM; ASTHMA; IKCA1	Background: Human lung and blood-derived mast cells express a Ca2+-activated K+ channel (K-CA) that has electrophysiological properties resembling the intermediate conductance K-CA (iK(CA)1). This channel is predicted to enhance IgE-dependent mast cell responses. Objective: To confirm the identity of this channel as iKCA1 in human lung mast cells and to examine the effect of an iKCA1 2, opener, 1-ethyl-2-benzimidazolinone (1-EBIO), on Ca2+ influx and degranulation after IgE-dependent activation. Methods: iKCA1 expression was examined by using RT-PCR. Ion currents were measured by using the patch clamp technique in human peripheral blood-derived mast cells, freshly isolated human lung mast cells (HLMCs), and long-term cultured HLMCs (LTHLMCs). Currents were manipulated with the specific iKCA1 opener 1-EBIO and the iK(CA)1 blockers clotrimazole and TRAM-34. Ratiometric Ca2+ imaging was performed on single fura-2-loaded cells, and histamine release was measured by radioenzymatic assay. Results: Both fresh HLMCs and LTHLMCs expressed iK(CA)1 mRNA. The iK(CA)1 opener 1-EBIO induced iKCA1 currents in 89% of human peripheral blood-derived mast cells, 12% of fresh HLMCs, and 67% of LTHLMCs, which were blocked by the iKCA1 blockers clotrimazole and TRAM-34. After cell activation with a suboptimal concentration of anti-IgE, 1-EBIO enhanced the IgE-dependent rise in cytosolic-free Ca2+ and potentiated IgE-dependent histamine release. Conclusion: Opening of iK(CA)1 enhances IgE-dependent Ca2+ influx and histamine release in HLMCs. Inhibition of iK(CA)1 may provide a novel approach to the treatment of mast cell-mediated disease.	Univ Leicester, Sch Med, Inst Lung Hlth, Dept Infect Immun & Inflammat, Leicester, Leics, England; Univ Victor Segalen, Lab Physiol Cellulaire Resp, Bordeaux, France	University of Leicester; UDICE-French Research Universities; Universite de Bordeaux	Bradding, P (corresponding author), Glenfield Gen Hosp, Dept Resp Med, Groby Rd, Leicester LE3 9QP, Leics, England.	pbradding@hotmail.com	Berger, Patrick/D-8779-2012; Cruse, Glenn/B-4597-2012; Cruse, Glenn/AAZ-1093-2021	Berger, Patrick/0000-0003-4702-0343; Bradding, Peter/0000-0001-8403-0319; Bolton, Sarah/0000-0002-6098-6903; Cruse, Glenn/0000-0002-7511-0082				Bradding P, 1999, CRIT REV ONCOL HEMAT, V31, P119, DOI 10.1016/S1040-8428(99)00010-4; Bradding P, 2003, CURR OPIN ALLERGY CL, V3, P45, DOI 10.1097/01.all.0000053267.39029.fd; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; CASOLARO V, 1989, AM REV RESPIR DIS, V139, P1375, DOI 10.1164/ajrccm/139.6.1375; DJUKANOVIC R, 1992, EUR RESPIR J, V5, P538; Duffy SM, 2003, J ALLERGY CLIN IMMUN, V112, P965, DOI 10.1016/j.jaci.2003.07.004; Duffy SM, 2001, J IMMUNOL, V167, P4261, DOI 10.4049/jimmunol.167.8.4261; Fanger CM, 2001, J BIOL CHEM, V276, P12249, DOI 10.1074/jbc.M011342200; FLINT KC, 1985, BRIT MED J, V291, P923, DOI 10.1136/bmj.291.6500.923; Frenz AM, 1997, INFLAMM RES, V46, P35, DOI 10.1007/s000110050045; Ghanshani S, 2000, J BIOL CHEM, V275, P37137, DOI 10.1074/jbc.M003941200; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Ishii TM, 1997, P NATL ACAD SCI USA, V94, P11651, DOI 10.1073/pnas.94.21.11651; Jensen BS, 1998, AM J PHYSIOL-CELL PH, V275, pC848, DOI 10.1152/ajpcell.1998.275.3.C848; Jensen BS, 1999, P NATL ACAD SCI USA, V96, P10917, DOI 10.1073/pnas.96.19.10917; Khanna R, 1999, J BIOL CHEM, V274, P14838, DOI 10.1074/jbc.274.21.14838; MACGLASHAN D, 1991, J IMMUNOL, V147, P2259; Olsson N, 2000, J ALLERGY CLIN IMMUN, V105, P455, DOI 10.1067/mai.2000.104380; Pedersen KA, 1999, BBA-BIOMEMBRANES, V1420, P231, DOI 10.1016/S0005-2736(99)00110-8; Sanmugalingam D, 2000, J LEUKOCYTE BIOL, V68, P38; WALKER C, 1994, AM J RESP CRIT CARE, V150, P1038, DOI 10.1164/ajrccm.150.4.7921434; WENZEL SE, 1991, J ALLERGY CLIN IMMUN, V87, P540, DOI 10.1016/0091-6749(91)90013-E; Wulff H, 2000, P NATL ACAD SCI USA, V97, P8151, DOI 10.1073/pnas.97.14.8151	24	76	83	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2004	114	1					66	72		10.1016/j.jaci.2004.04.005	http://dx.doi.org/10.1016/j.jaci.2004.04.005			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	836DA	15241346	Bronze			2022-12-18	WOS:000222534300010
J	Jogie-Brahim, S; Min, HK; Fukuoka, Y; Xia, HZ; Schwartz, LB				Jogie-Brahim, S; Min, HK; Fukuoka, Y; Xia, HZ; Schwartz, LB			Expression of alpha-tryptase and beta-tryptase by human basophils	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						basophil; tryptase	MAST-CELL TRYPTASE; PERIPHERAL-BLOOD; COMPLEMENTARY-DNA; ANAPHYLAXIS; ACTIVATION; CHYMASE; MASTOCYTOSIS; QUANTITATION; TETRAMER; CLONING	Background: alpha and beta-Tryptase levels in serum are clinical tools for the evaluation of systemic anaphylaxis and systemic mastocytosis. Basophils and mast cells are known to produce these proteins. Objective: The current study examines the effect of the alpha,beta-tryptase genotype on basophil tryptase levels and the type of tryptase stored in these cells. Methods: Tryptase extracted from purified peripheral blood basophils from 20 subjects was examined by using ELISAs measuring mature and total tryptase and by using an enzymatic assay with tosyl-Gly-Pro-Lys-p-nitroanilide. Tryptase genotypes (4:0, 3:1, and 2:2 beta/alpha ratios) were assessed by using a hot-stop PCR technique with alpha,beta-tryptase-specific primers. Total alpha,beta-tryptase mRNA was measured by means of competitive RT-PCR, and ratios of alpha to beta-tryptase mRNA were measured by means of hot-stop RT-PCR. Results: Tryptase in all but one of the basophil preparations was mature and enzymatically active. Tryptase quantities in basophils were less than 1% of those in tissue mast cells. Tryptase genotypes (beta/alpha) among the 20 donors were 4:0 in 7, 3:1 in 7, and 2:2 in 6. Tryptase protein and mRNA levels per basophil were not affected by the tryptase genotype. Conclusion: Basophils from healthy subjects contain modest amounts of mature and enzymatically active tryptase unaffected by the tryptase genotype.	Virginia Commonwealth Univ, Dept Internal Med, Div Rheumatol Allergy & Immunol, Richmond, VA 23298 USA	Virginia Commonwealth University	Schwartz, LB (corresponding author), Virginia Commonwealth Univ, Dept Internal Med, Div Rheumatol Allergy & Immunol, POB 980263, Richmond, VA 23298 USA.				NIAID NIH HHS [AI 20487, AI 27157] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020487, R37AI020487, R13AI027157, R21AI020487] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BLOM T, 1993, SCAND J IMMUNOL, V37, P203, DOI 10.1111/j.1365-3083.1993.tb01757.x; CASTELLS MC, 1987, J IMMUNOL, V138, P2184; Caughey GH, 2000, J IMMUNOL, V164, P6566, DOI 10.4049/jimmunol.164.12.6566; Daniels RJ, 2001, HUM MOL GENET, V10, P339, DOI 10.1093/hmg/10.4.339; Foster B, 2002, J ALLERGY CLIN IMMUN, V109, P287, DOI 10.1067/mai.2002.121454; Guida M, 2000, PHARMACOGENETICS, V10, P389, DOI 10.1097/00008571-200007000-00002; KEPLEY C, 1994, J IMMUNOL METHODS, V175, P1, DOI 10.1016/0022-1759(94)90326-3; Li LX, 1998, J IMMUNOL, V161, P5079; MILLER JS, 1990, J CLIN INVEST, V86, P864, DOI 10.1172/JCI114786; MILLER JS, 1989, J CLIN INVEST, V84, P1188, DOI 10.1172/JCI114284; Pereira PJB, 1998, NATURE, V392, P306, DOI 10.1038/32703; Sakai K, 1996, J CLIN INVEST, V97, P988, DOI 10.1172/JCI118523; Schwartz LB, 1995, J CLIN INVEST, V96, P2702, DOI 10.1172/JCI118337; SCHWARTZ LB, 1987, NEW ENGL J MED, V316, P1622, DOI 10.1056/NEJM198706253162603; Schwartz LB, 2003, J IMMUNOL, V170, P5667, DOI 10.4049/jimmunol.170.11.5667; SCHWARTZ LB, 1989, J CLIN INVEST, V83, P1551, DOI 10.1172/JCI114051; SCHWARTZ LB, 1987, J IMMUNOL, V138, P2611; SCHWARTZ LB, 1986, J BIOL CHEM, V261, P7372; SMITH PL, 1980, J CLIN INVEST, V66, P1072, DOI 10.1172/JCI109936; Soto D, 2002, CLIN EXP ALLERGY, V32, P1000, DOI 10.1046/j.1365-2222.2002.01416.x; Sperr WR, 2001, BLOOD, V98, P2200, DOI 10.1182/blood.V98.7.2200; Ueijma H, 2000, NAT GENET, V25, P375, DOI 10.1038/78040; VANDERLINDEN PWG, 1992, J ALLERGY CLIN IMMUN, V90, P110, DOI 10.1016/S0091-6749(06)80017-5; VANDERSLICE P, 1990, P NATL ACAD SCI USA, V87, P3811, DOI 10.1073/pnas.87.10.3811; Xia HZ, 1997, J IMMUNOL, V159, P2911; XIA HZ, 1995, J IMMUNOL, V154, P5472	26	76	78	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2004	113	6					1086	1092		10.1016/j.jaci.2004.02.032	http://dx.doi.org/10.1016/j.jaci.2004.02.032			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	829ZI	15208589				2022-12-18	WOS:000222091000013
J	Matsui, EC; Wood, RA; Rand, C; Kanchanaraksa, S; Swartz, L; Eggleston, PA				Matsui, EC; Wood, RA; Rand, C; Kanchanaraksa, S; Swartz, L; Eggleston, PA			Mouse allergen exposure and mouse skin test sensitivity in suburban, middle-class children with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						mouse allergen; pediatric asthma; mouse allergy; indoor allergen exposure	LABORATORY-ANIMALS; LIPOCALIN PROTEINS; SENSITIZATION; DESIGN	Background: Exposure to mouse allergen is prevalent in inner-city homes and is associated with an increased risk of mouse skin test sensitivity in inner-city children with asthma. Objective: To determine the distribution of mouse allergen and its relationship to mouse skin test sensitivity in a primarily suburban, middle-class population of asthmatic children. Methods: Children with asthma, 6 to 17 years old, were recruited from 3 pediatric practices located in counties surrounding the city of Baltimore and from 1 practice located within the city limits. Participants underwent skin prick testing and completed a baseline questionnaire. Their homes were inspected, and settled dust samples were collected for allergen analysis. Results: Two hundred fifty-seven of 335 (76.7%) participants resided outside the city, and 53.7% had annual incomes >$50,000. Mouse allergen was detected in 74.9% of bedrooms, and 13.1% were sensitized to mouse. Lower maternal education (odds ratio [OR], 2.17; 95% CI, 1.28-3.67), city residence (OR, 5.39; 95% CI, 2.23-13.02), and higher bedroom cockroach allergen levels (OR, 9.61; 95% CI, 1.17-79.03) were independent predictors of high bedroom mouse allergen. The risk of mouse skin test sensitivity increased with increasing bedroom Mus m 1 exposure (OR, 1.43; 95% CI, 1.04-1.96, with each increase in quartile), and dog skin test sensitivity was a strong independent predictor of mouse skin test sensitivity (OR, 7.23; 95% CI, 3.03-17.22). Conclusion: Mouse allergen exposure is common among suburban, middle-class asthmatic children. Increasing bedroom levels of Mus m 1 and dog skin test sensitivity are risk factors for mouse skin test sensitivity.	Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA; Johns Hopkins Univ, Dept Med, Baltimore, MD USA; Johns Hopkins Univ, Dept Pediat, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins University	Matsui, EC (corresponding author), Johns Hopkins Univ Hosp, CMSC 1102,600 N Wolfe St, Baltimore, MD 21287 USA.	ematsui@jhmi.edu		Matsui, Elizabeth/0000-0001-8134-5593	NHLBI NIH HHS [R18 HL 058942] Funding Source: Medline; NIAID NIH HHS [T32 AI 07007] Funding Source: Medline; NIEHS NIH HHS [P01 ES 09606] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R18HL058942] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007007] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES009606] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AOYAMA K, 1992, BRIT J IND MED, V49, P41; CHAPMAN MD, 1988, J IMMUNOL, V140, P812; Cherniack R, 1999, CONTROL CLIN TRIALS, V20, P91; CUZICK J, 1985, STAT MED, V4, P87, DOI 10.1002/sim.4780040112; Gautrin D, 2001, EUR RESPIR J, V17, P904, DOI 10.1183/09031936.01.17509040; Gautrin D, 2001, AM J RESP CRIT CARE, V163, P899, DOI 10.1164/ajrccm.163.4.2008011; Hollander A, 1996, J ALLERGY CLIN IMMUN, V98, P545, DOI 10.1016/S0091-6749(96)70088-X; Hollander A, 1997, CLIN EXP ALLERGY, V27, P617; Konieczny A, 1997, IMMUNOLOGY, V92, P577, DOI 10.1046/j.1365-2567.1997.00386.x; Matsui EC, 2003, J ALLERGY CLIN IMMUN, V112, P87, DOI 10.1067/mai.2003.1588; Mitchell H, 1997, PEDIATR PULM, V24, P237; OHMAN JL, 1994, J ALLERGY CLIN IMMUN, V94, P810, DOI 10.1016/0091-6749(94)90147-3; Phipatanakul W, 2000, J ALLERGY CLIN IMMUN, V106, P1070, DOI 10.1067/mai.2000.110796; Phipatanakul W, 2000, J ALLERGY CLIN IMMUN, V106, P1075, DOI 10.1067/mai.2000.110795; SCHUMACHER MJ, 1981, J ALLERGY CLIN IMMUN, V68, P310, DOI 10.1016/0091-6749(81)90157-3; SPITZAUER S, 1994, J ALLERGY CLIN IMMUN, V93, P614, DOI 10.1016/S0091-6749(94)70073-7; Virtanen T, 1999, INT ARCH ALLERGY IMM, V120, P247, DOI 10.1159/000024277; WOOD RA, 1988, AM REV RESPIR DIS, V137, P358, DOI 10.1164/ajrccm/137.2.358	18	76	76	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2004	113	5					910	915		10.1016/j.jaci.2004.02.034	http://dx.doi.org/10.1016/j.jaci.2004.02.034			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	818UC	15131574				2022-12-18	WOS:000221269000014
J	Reich, K; Westphal, G; Konig, IR; Mossner, R; Kruger, U; Ziegler, A; Neumann, C; Schnuch, A				Reich, K; Westphal, G; Konig, IR; Mossner, R; Kruger, U; Ziegler, A; Neumann, C; Schnuch, A			Association of allergic contact dermatitis with a promoter polymorphism in the IL16 gene	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-16; proinoter; polymorphism; contact allergy; atopic dermatitis; white	DENDRITIC CELLS; IL-16 GENE; NICKEL; SUSCEPTIBILITY; EPIDEMIOLOGY; DISEASE	Background: There is evidence that IL-16, a cytokine that induces chemotactic responses in CD4(+) T cells, eosinophils, and dendritic cells, plays an important role during different types of cutaneous inflammatory responses, including allergic contact dermatitis (ACD) and atopic dermatitis (AD). Objectives: We sought to test for association between a promoter polymorphism in the IL16 gene (T to C transition at position -295) and ACD and AD, respectively. Methods: IL16 -295 genotypes were determined in samples from 2 separate case-control studies with white individuals. The first study included healthy individuals (n = 310) and patients with ACD (n = 86). These patients were polysensitized as defined by a contact sensitization to para-substituted aryl compounds and at least one other structurally unrelated allergen. The second study comprised healthy subjects (n = 214) and patients with AD (n = 94). Results: IL16 -295 genotypes were differently distributed among polysensitized and healthy control subjects (P = .0021). In particular, the IL16 -295*C/C genotype was overrepresented among polysensitized individuals (7.0% vs 1.0% in the control group; odds ratio, 7.68; 95% Cl, 1.59-48.12). In contrast, there was no evidence for an association between the IL16 -295 polymorphism and AD. Conclusion: The IL16 -295 promoter polymorphism might influence susceptibility to contact allergy.	Univ Gottingen, Dept Dermatol, D-37075 Gottingen, Germany; Univ Gottingen, Dept Occupat Med, D-37075 Gottingen, Germany; Univ Gottingen, Dept Dermatol, Informat Network, D-37075 Gottingen, Germany; Med Univ Lubeck, Inst Med Biometry & Stat, D-23538 Lubeck, Germany	University of Gottingen; University of Gottingen; University of Gottingen; University of Lubeck	Reich, K (corresponding author), Univ Gottingen, Dept Dermatol, Von Siebold Str 3, D-37075 Gottingen, Germany.		König, Inke R/A-4544-2009; Ziegler, Andreas/G-4246-2012	König, Inke R/0000-0003-0504-6465; Ziegler, Andreas/0000-0002-8386-5397				Antonopoulos H, 2001, J IMMUNOL, V166, P3672, DOI 10.4049/jimmunol.166.6.3672; Bidwell J, 1999, GENES IMMUN, V1, P3, DOI 10.1038/sj.gene.6363645; Center DM, 1996, IMMUNOL TODAY, V17, P476, DOI 10.1016/0167-5699(96)10052-I; Emtestam L, 1996, ACTA DERM-VENEREOL, V76, P344; EMTESTAM L, 1989, TISSUE ANTIGENS, V33, P531, DOI 10.1111/j.1399-0039.1989.tb01704.x; Fregert S., 1981, MANUAL CONTACT DERMA, V2nd ed.; Glas J, 2003, CLIN IMMUNOL, V106, P197, DOI 10.1016/S1521-6616(03)00021-4; Kaser A, 1999, J IMMUNOL, V163, P3232; Laberge S, 1998, J ALLERGY CLIN IMMUN, V102, P645, DOI 10.1016/S0091-6749(98)70282-9; Lappin MB, 1996, ARCH DERMATOL RES, V288, P109, DOI 10.1007/BF02505819; McFadden JP, 2000, CONTACT DERMATITIS, V42, P123, DOI 10.1034/j.1600-0536.2000.042003123.x; MEHTA CR, 1985, J AM STAT ASSOC, V80, P969, DOI 10.2307/2288562; MENNE T, 1986, SEMIN DERMATOL, V5, P301; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Morton NE, 1998, P NATL ACAD SCI USA, V95, P11389, DOI 10.1073/pnas.95.19.11389; MOSS C, 1985, CLIN EXP IMMUNOL, V61, P232; Nakayama EE, 2000, GENES IMMUN, V1, P293, DOI 10.1038/sj.gene.6363672; NIELSEN NH, 1992, ACTA DERM-VENEREOL, V72, P456; Reich K, 2003, BRIT J DERMATOL, V148, P1237, DOI 10.1046/j.1365-2133.2003.05307.x; Reich K, 2002, J INVEST DERMATOL, V118, P155, DOI 10.1046/j.0022-202x.2001.01642.x; Reich K, 2002, J ALLERGY CLIN IMMUN, V109, P681, DOI 10.1067/mai.2002.122234; Reich K, 2001, J IMMUNOL, V167, P6321, DOI 10.4049/jimmunol.167.11.6321; REICH K, 2001, GIORN ITAL DERMAT V, V136, P351; Schnuch A, 2002, CONTACT DERMATITIS, V47, P32, DOI 10.1034/j.1600-0536.2002.470107.x; Skov L, 1998, BRIT J DERMATOL, V138, P216; Svedman C, 2003, CONTACT DERMATITIS, V48, P217, DOI 10.1034/j.1600-0536.2003.00094.x; Uter W, 1998, EUR J DERMATOL, V8, P36; UTER W, 1995, CONTACT DERMATITIS, V32, P135, DOI 10.1111/j.1600-0536.1995.tb00802.x; Westphal GA, 2003, CONTACT DERMATITIS, V48, P93, DOI 10.1034/j.1600-0536.2003.480208.x; Westphal GA, 2000, BRIT J DERMATOL, V142, P1121, DOI 10.1046/j.1365-2133.2000.03536.x; Yoshimoto T, 2000, BLOOD, V95, P2869, DOI 10.1182/blood.V95.9.2869.009k18_2869_2874	31	76	75	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2003	112	6					1191	1194		10.1016/j.jaci.2003.09.012	http://dx.doi.org/10.1016/j.jaci.2003.09.012			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	752HC	14657881				2022-12-18	WOS:000187154200024
J	Diaz-Perales, A; Sanz, ML; Garcia-Casado, G; Sanchez-Monge, R; Garcia-Selles, FJ; Lombardero, M; Polo, F; Gamboa, PM; Barber, D; Salcedo, G				Diaz-Perales, A; Sanz, ML; Garcia-Casado, G; Sanchez-Monge, R; Garcia-Selles, FJ; Lombardero, M; Polo, F; Gamboa, PM; Barber, D; Salcedo, G			Recombinant Pru p 3 and natural Pru p 3, a major peach allergen, show equivalent immunologic reactivity: A new tool for the diagnosis of fruit allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						recombinant allergen; fruit allergy; lipid transfer protein; diagnosis; IgE binding; basophil activation; histamine release; sulphidoleukotriene production	LIPID-TRANSFER PROTEIN; CROSS-REACTIVITY; ARTEMISIA POLLEN; FOOD ALLERGENS; IN-VITRO; BINDING; EXPRESSION; APRICOT; FAMILY; CHERRY	Background: The peach lipid transfer protein Pro p 3 has been identified as a major allergen from this fruit. Homologous cross-reactive allergens have been found in several plant foods and pollens. Recombinant Pru p 3 has been recently produced in the yeast Pichia pastoris. Objective: We sought to evaluate the potential role of recombinant Pru p 3 as a novel tool for the diagnosis of fruit allergy. Methods: Circular dichroism analysis was used to compare the protein folding of natural Pro p 3 and recombinant Pro p 3. IgE binding by both molecular forms was quantified by means of ELISA and ELISA inhibition assays, and their biologic activity was estimated by using basophil activation, histamine release, and sulphidoleukotriene production tests. Individual sera or blood samples from patients with peach allergy (up to 17) were used in the assays. Results: A nearly identical circular dichroism spectra was shown by using natural Pru p 3 and recombinant Pro p 3, indicating that both protein forms are similarly folded. No difference was detected in the IgE-binding capacity of the 2 molecular versions. Basophil activation and induction of sulphidoleukotriene production were positive in 9 of 10 patients, and histamine release was induced in at least half of the patients, with similar effects of the natural and recombinant forms in the 3 assays. Conclusion: Recombinant Pro p 3 shows a strong immunologic activity equivalent to that of its natural counterpart, and therefore it can be a useful tool for diagnosis (and future immunotherapy) of fruit allergy.	ETS Ingn Agronomos, Dept Biotechnol, Unidad Bioquim, Madrid 28040, Spain; Univ Navarra Clin, Dept Alergol & Inmunol Clin, Pamplona, Spain; Hosp Virgen Arrixaca, Secc Alergia, Murcia, Spain; ALK Abello, Dept I&D, Madrid, Spain; Hosp Basurto, Serv Alergia, Bilbao, Spain	University of Navarra; Hospital Clinico Universitario Virgen de la Arrixaca; ALK-Abello AS; Basurto Hospital	Salcedo, G (corresponding author), ETS Ingn Agronomos, Dept Biotechnol, Unidad Bioquim, Ciudad Univ, Madrid 28040, Spain.		Barber, Domingo/Y-9516-2019; Díaz-Perales, Araceli/D-8433-2016	Barber, Domingo/0000-0002-5488-5700; Díaz-Perales, Araceli/0000-0002-1093-3627				Asero R, 2000, INT ARCH ALLERGY IMM, V122, P20, DOI 10.1159/000024355; BOHM G, 1992, PROTEIN ENG, V5, P191, DOI 10.1093/protein/5.3.191; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chapman MD, 2000, J ALLERGY CLIN IMMUN, V106, P409, DOI 10.1067/mai.2000.109832; Diaz-Perales A, 2002, CLIN EXP ALLERGY, V32, P87, DOI 10.1046/j.0022-0477.2001.01257.x; Diaz-Perales A, 2000, CLIN EXP ALLERGY, V30, P1403, DOI 10.1046/j.1365-2222.2000.00909.x; Duro G, 1997, INT ARCH ALLERGY IMM, V112, P348, DOI 10.1159/000237479; Garcia-Selles FJ, 2002, INT ARCH ALLERGY IMM, V128, P115, DOI 10.1159/000059401; Han GW, 2001, J MOL BIOL, V308, P263, DOI 10.1006/jmbi.2001.4559; Hiller R, 2002, FASEB J, V16, P414, DOI 10.1096/fj.01-0711fje; Kader JC, 1996, ANNU REV PLANT PHYS, V47, P627, DOI 10.1146/annurev.arplant.47.1.627; Lindorff-Larsen K, 2001, FEBS LETT, V488, P145, DOI 10.1016/S0014-5793(00)02424-8; Lorenz AR, 2001, J CHROMATOGR B, V756, P255, DOI 10.1016/S0378-4347(01)00086-X; PASTORELLO EA, 1994, J ALLERGY CLIN IMMUN, V94, P699, DOI 10.1016/0091-6749(94)90177-5; Pastorello EA, 1998, ALLERGY, V53, P48, DOI 10.1111/j.1398-9995.1998.tb04960.x; Pastorello EA, 2000, J ALLERGY CLIN IMMUN, V105, P371, DOI 10.1016/S0091-6749(00)90090-3; Pastorello EA, 2000, J ALLERGY CLIN IMMUN, V106, P744, DOI 10.1067/mai.2000.108712; Rodriguez J, 2000, J ALLERGY CLIN IMMUN, V106, P183, DOI 10.1067/mai.2000.106927; ROSANO A, 1995, J INVEST ALLERG CLIN, V5, P289; Sanchez-Monge R, 1999, J ALLERGY CLIN IMMUN, V103, P514, DOI 10.1016/S0091-6749(99)70479-3; Sanz ML, 2001, CLIN EXP ALLERGY, V31, P1007, DOI 10.1046/j.1365-2222.2001.01122.x; Scheurer S, 2001, J ALLERGY CLIN IMMUN, V107, P724, DOI 10.1067/mai.2001.113864; Sicherer SH, 2001, J ALLERGY CLIN IMMUN, V108, P881, DOI 10.1067/mai.2001.118515; SIRAGANIAN RP, 1983, TRENDS PHARMACOL SCI, V4, P432, DOI 10.1016/0165-6147(83)90478-9	24	76	79	1	16	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2003	111	3					628	633		10.1067/mai.2003.75	http://dx.doi.org/10.1067/mai.2003.75			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	656YW	12642848				2022-12-18	WOS:000181639500029
J	Brugnolo, F; Sampognaro, S; Liotta, F; Cosmi, L; Annunziato, F; Manuelli, C; Campi, P; Maggi, E; Romagnani, S; Parronchi, P				Brugnolo, F; Sampognaro, S; Liotta, F; Cosmi, L; Annunziato, F; Manuelli, C; Campi, P; Maggi, E; Romagnani, S; Parronchi, P			The novel synthetic immune response modifier R-848 (Resiquimod) shifts human allergen-specific CD4(+) T(H)2 lymphocytes into IFN-gamma-producing cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						T(H)1/T(H)2; allergy; cytokines; immunomodulators	IMMUNOSTIMULATORY DNA; T-CELLS; IMIQUIMOD; TH1; IMMUNOMODULATORS; IMMUNOGENICITY; INTERLEUKIN-12; EXPRESSION; S-28463; HERPES	Background: In experimental models, imidazoquinolines exhibit several immunomodulatory activities via Toll-like receptor signaling on cells of the innate immunity. Objective: The aim of our study was to investigate whether R-848 (Resiquimod), a small-molecular-weight synthetic compound belonging to the imidazoquinoline family and known for its ability to substantially delay the onset of recurrent genital herpes lesions in both animals and human beings, could influence, at least in vitro, the cytokine production profile of human hapten- or allergen-specific T cells. Methods: Ampicillin- and Der p1-specific T-cell lines were derived from peripheral blood of allergic donors in the absence or presence of R-848 and assessed by flow cytometry at the single-cell level for their ability to produce IL-4 and/or IFN-gamma. Results: R-848 induced both hapten- and allergen-specific circulating T cells, including T(H)2 effectors, to produce IFN-gamma and even to lose the ability to produce IL-4, thus shifting their phenotype of cytokine production to a type 0 (T(H)0) or even T(H)1 profile. This effect was associated with an increase in the production of IL-12, IFN-alpha, IL-18, TNF-alpha, IL-10, and IL-15 by CD14(+) cells, as well as an increase in the proportions of IFN-gamma-producing CD3-CD16(+) (natural killer) cells. Conclusions: These results suggest that R-848, and probably other imidazoquinolines, might be used as adjuvants in view of novel allergen-specific immunotherapeutic regimens for the treatment of allergic disorders.	Univ Florence, Dept Internal Med, Immunoallergol & Resp Dis Unit, Florence, Italy; Univ Florence, Dept Dermatol Dis, Florence, Italy	University of Florence; University of Florence	Romagnani, S (corresponding author), Policlin Careggi, Sez Immunoallergol, Dipartimento Med Interna, Viale Morgagni 85, I-50134 Florence, Italy.		Maggi, Enrico/AAA-8045-2019; Parronchi, Paola/AAE-5422-2022; Annunziato, Francesco/C-1155-2013	Maggi, Enrico/0000-0002-1824-3583; Parronchi, Paola/0000-0002-9184-5089; Annunziato, Francesco/0000-0001-8798-7589				Agrawal S, 1998, CURR OPIN CHEM BIOL, V2, P519, DOI 10.1016/S1367-5931(98)80129-4; Annunziato F, 2001, J ALLERGY CLIN IMMUN, V108, P815; Bernstein DI, 2001, J INFECT DIS, V183, P844, DOI 10.1086/319262; Brugnolo F, 1999, J IMMUNOL, V163, P1053; Buates S, 1999, J INFECT DIS, V179, P1485, DOI 10.1086/314782; Buates S, 2001, ANTIMICROB AGENTS CH, V45, P1137, DOI 10.1128/AAC.45.4.1137-1142.2001; Burns RP, 2000, CLIN IMMUNOL, V94, P13, DOI 10.1006/clim.1999.4804; Dockrell DH, 2001, J ANTIMICROB CHEMOTH, V48, P751, DOI 10.1093/jac/48.6.751; Hemmi H, 2002, NAT IMMUNOL, V3, P196, DOI 10.1038/ni758; Hengge UR, 2000, ANN INTERN MED, V132, P95, DOI 10.7326/0003-4819-132-1-200001040-00024; Jurk M, 2002, NAT IMMUNOL, V3, P499, DOI 10.1038/ni0602-499; Klinman DM, 1997, J IMMUNOL, V158, P3635; Leadbetter EA, 2002, NATURE, V416, P603, DOI 10.1038/416603a; Lipper GM, 2000, JAMA-J AM MED ASSOC, V283, P175, DOI 10.1001/jama.283.2.175; MANETTI R, 1995, EUR J IMMUNOL, V25, P2656, DOI 10.1002/eji.1830250938; MANETTI R, 1994, J EXP MED, V179, P1273, DOI 10.1084/jem.179.4.1273; Marks R, 2001, J AM ACAD DERMATOL, V44, P807, DOI 10.1067/mjd.2001.113689; Moisan J, 2001, ANTIMICROB AGENTS CH, V45, P3059, DOI 10.1128/AAC.45.11.3059-3064.2001; Parronchi P, 1999, J IMMUNOL, V163, P5946; Parronchi P, 1999, CURR TOP MICROBIOL, V238, P27; PARRONCHI P, 1992, J IMMUNOL, V149, P2977; Romagnani S, 2000, J ALLERGY CLIN IMMUN, V105, P399, DOI 10.1067/mai.2000.104575; Sato S, 2002, INT IMMUNOL, V14, P783, DOI 10.1093/intimm/dxf046; Sato Y, 1996, SCIENCE, V273, P352, DOI 10.1126/science.273.5273.352; Sauder DN, 2000, J AM ACAD DERMATOL, V43, pS6; Spruance SL, 2001, J INFECT DIS, V184, P196, DOI 10.1086/322007; Tighe H, 2000, J ALLERGY CLIN IMMUN, V106, P124, DOI 10.1067/mai.2000.107927; Underhill DM, 2002, CURR OPIN IMMUNOL, V14, P103, DOI 10.1016/S0952-7915(01)00304-1; Wagner TL, 1999, CELL IMMUNOL, V191, P10, DOI 10.1006/cimm.1998.1406	29	76	81	0	5	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2003	111	2					380	388		10.1067/mai.2003.102	http://dx.doi.org/10.1067/mai.2003.102			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	644WF	12589360				2022-12-18	WOS:000180942700024
J	Kihlstrom, A; Lilja, G; Pershagen, G; Hedlin, G				Kihlstrom, A; Lilja, G; Pershagen, G; Hedlin, G			Exposure to birch pollen in infancy and development of atopic disease in childhood	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						aeroallergens; atopy; infancy; sensitization; tolerance	ENVIRONMENTAL RISK-FACTORS; BCG VACCINATION; IMMUNE-SYSTEM; SENSITIZATION; CHILDREN; ALLERGY; PREVALENCE; ASTHMA; SUPPRESSION; RESPONSES	Background: The relationship between early allergen exposure, sensitization, and development of atopic disease remains controversial. In 1993. extremely high levels of birch pollen,Acre recorded in Stockholm, Sweden, creating the unique opportunity to study children with different exposures during infancy. Objective: We sought to assess the influence of early high-dose exposure to an inhalant allergen (birch pollen) on sensitization and development of atopic disease in children. Methods: A total of 583 children with atopic heredity born in Stockholm in February through April 1992, 1993, or 1994 were investigated at age 4.5 to 5 years. The children were examined and underwent skin prick testing with inhalant and food allergens. IgE antibodies (RAST) against birch pollen and recombinant birch pollen allergen (rBet v 1) were analyzed in serum. Results: The children born in 1993 (high-dose exposure at 0-3 months) were more often sensitized (ie, positive skin prick test response) to birch pollen than the children born in 1994 (low-dose exposure; 17.8% and 8.8%, respectively, odds ratio [OR], 2.4; 95% Cl, 1.2-4.6). A tendency in the same direction was seen for children born in 1992 (high-dose exposure at 12-15 months; OR, 1.7; 95% CI, 0.9-3.2). The results were supported by the RAST analyses. The prevalence of bronchial asthma, allergic rhinoconjunctivitis, and atopic dermatitis did not differ between the birth-year groups. However, the prevalence of pollen- and animal dander-induced allergic asthma was increased in the children born in 1993 (OR, 2.6; 95% CI, 1.25.6). An interaction between early high-dose exposure to birch pollen and cat in the household was suggested for sensitization to cat (P =.06). Conclusion: Exposure to high levels of birch pollen in infancy increases the risk of sensitization to the same allergen, as well as the risk of allergic asthma.	Karolinska Hosp, Dept Paediat, S-10401 Stockholm, Sweden; Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden; Sachs Childrens Hosp, Dept Paediat, Stockholm, Sweden; Karolinska Inst, Huddinge Hosp, Dept Paediat, S-10401 Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska Institutet	Kihlstrom, A (corresponding author), Huddinge Univ Hosp, Dept Paediat B57, S-14186 Huddinge, Sweden.			Pershagen, Goran/0000-0002-9701-1130				ABERG N, 1995, CLIN EXP ALLERGY, V25, P815, DOI 10.1111/j.1365-2222.1995.tb00023.x; Alm JS, 1997, LANCET, V350, P400, DOI 10.1016/S0140-6736(97)02207-1; Alm JS, 1999, LANCET, V353, P1485, DOI 10.1016/S0140-6736(98)09344-1; BERGGREN B, 1994, POLLENSASONGEN 1992; BJORKSTEN F, 1980, CLIN ALLERGY, V10, P585, DOI 10.1111/j.1365-2222.1980.tb02140.x; BJORKSTEN F, 1976, CLIN ALLERGY, V6, P165, DOI 10.1111/j.1365-2222.1976.tb01894.x; BRABACK L, 1994, CLIN EXP ALLERGY, V24, P826, DOI 10.1111/j.1365-2222.1994.tb01805.x; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28, DOI 10.1046/j.1365-2222.1999.00479.x; BUSINCO L, 1988, CLIN ALLERGY, V18, P269, DOI 10.1111/j.1365-2222.1988.tb02869.x; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; HATTEVIG G, 1984, CLIN ALLERGY, V14, P551, DOI 10.1111/j.1365-2222.1984.tb02243.x; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; HIRST JM, 1952, ANN APPL BIOL, V39, P257, DOI 10.1111/j.1744-7348.1952.tb00904.x; Holt PG, 2000, ALLERGY, V55, P688, DOI 10.1034/j.1398-9995.2000.00118.x; *ISAAC STEER COMM, 2001, LANCET, V351, P1225; JARRETT E, 1979, NATURE, V280, P145, DOI 10.1038/280145a0; JARRETT EEE, 1984, LANCET, V2, P797; JARRETT EEE, 1983, IMMUNOLOGY, V48, P49; Jenmalm MC, 1997, INT ARCH ALLERGY IMM, V114, P175, DOI 10.1159/000237664; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; Lindfors A, 1999, J ALLERGY CLIN IMMUN, V104, P755, DOI 10.1016/S0091-6749(99)70284-8; LINDFORS A, 1995, ARCH DIS CHILD, V73, P408, DOI 10.1136/adc.73.5.408; Macaubas C, 2000, PEDIATR ALLERGY IMMU, V11, P9, DOI 10.1034/j.1399-3038.2000.00502.x; Nilsson L, 1997, ARCH DIS CHILD, V76, P341, DOI 10.1136/adc.76.4.341; Pepys J., 1975, , Clinical aspects of immunology., P877; Pershagen G, 1997, ALLERGY, V52, P1045, DOI 10.1111/j.1398-9995.1997.tb00174.x; Prescott SL, 1998, J IMMUNOL, V160, P4730; Ronmark E, 1998, RESP MED, V92, P316, DOI 10.1016/S0954-6111(98)90115-9; SCHAFER T, 1993, ALLERGY, V48, P291, DOI 10.1111/j.1398-9995.1993.tb00731.x; Strannegard IL, 1998, ALLERGY, V53, P249, DOI 10.1111/j.1398-9995.1998.tb03884.x; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7; Warner JO, 2000, PEDIATR ALLERGY IMMU, V11, P6, DOI 10.1034/j.1399-3038.2000.00501.x; Weiland SK, 1999, EUR RESPIR J, V14, P862, DOI 10.1034/j.1399-3003.1999.14d23.x	34	76	79	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2002	110	1					78	84		10.1067/mai.2002.125829	http://dx.doi.org/10.1067/mai.2002.125829			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	574CF	12110825	Bronze			2022-12-18	WOS:000176870300017
J	Simons, FER; Gu, XC; Silver, NA; Simons, KJ				Simons, FER; Gu, XC; Silver, NA; Simons, KJ			EpiPen Jr versus EpiPen in young children weighing 15 to 30 kg at risk for anaphylaxis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						epinephrine; adrenaline; intramuscular injection; children; systemic anaphylaxis; severe acute allergic reaction; food allergy; Hymenoptera venom allergy; latex allergy	EPINEPHRINE; HISTORY; ALLERGY; INFANTS; PEANUT	Background; The EpiPen Jr (0.15 mg) and EpiPen (0.3 mg) auto-injectors, widely prescribed for the out-of-hospital treatment of anaphylaxis, have not been compared prospectively in young children. Objective; The purpose of this investigation was to study the rate and extent of epinephrine absorption after use of the EpiPen Jr and the EpiPen in children weighing 15 to 30 kg. Methods. In a randomized, double-blinded, parallel-group pilot study, children at risk for anaphylaxis self-injected epinephrine using either an EpiPen Jr or an EpiPen with the aid of a physician. Plasma epinephrine concentrations, blood glucose, blood pressure, heart rate, and adverse effects were monitored before and for 180 minutes after the injection. Results: Children (age [mean +/- SEM], 5.4 +/- 0.4 years; weight [mean +/- SEM], 18.0 +/- 0.6 kg) who injected epinephrine with an EpiPen Jr achieved a maximum plasma concentration (mean +/- SEM) of 2037 +/- 541 pg/mL at 16 +/- 3 minutes. Children (6.6 +/- 0.5 years; 25.4 +/- 1.5 kg) who injected epinephrine with an EpiPen achieved a maximum plasma concentration of 2289 +/- 405 pg/mL at 15 +/- 3 minutes. Mean systolic blood pressure 30 minutes after epinephrine injection was significantly higher with the EpiPen than with the EpiPen Jr. After injection with the EpiPen Jr, every child experienced transient pallor; some also experienced tremor and anxiety. After injection with the EpiPen, every child developed transient pallor, tremor, anxiety, and palpitations or other cardiovascular effects; some also developed headache and nausea. Conclusion: Epinephrine injection with the EpiPen rather than the EpiPen Jr raised the systolic blood pressure significantly but also caused more adverse effects. The beneficial pharmacologic effects and the adverse pharmacologic effects of epinephrine cannot be dissociated. For the out-of-hospital treatment of anaphylaxis, additional premeasured, fixed doses of epinephrine would facilitate more precise dosing in young children.	Univ Manitoba, Dept Pediat & Child Hlth, Fac Med, Winnipeg, MB R3T 2N2, Canada; Univ Manitoba, Fac Pharm, Winnipeg, MB R3T 2N2, Canada	University of Manitoba; University of Manitoba	Simons, KJ (corresponding author), Childrens Hosp, 820 Sherbrook St, Winnipeg, MB R3A 1R9, Canada.							AAAI Board Directors, 1998, J ALLERGY CLIN IMMUN, V102, P173; BUTTE MJ, 1999, PEDIATRICS, P104; Edwards KH, 1997, PEDIAT EMERGENCY MED, P619; Grouhi M, 1999, J ALLERGY CLIN IMMUN, V104, P190, DOI 10.1016/S0091-6749(99)70134-X; Hoffmann BB, 1996, GOODMAN GILMANS PHAR, P204; KURACHEK SC, 1985, JAMA-J AM MED ASSOC, V253, P1441, DOI 10.1001/jama.253.10.1441; LINZER JF, 1999, GELLIS KAGANS CURREN, P1058; NETER J, 1990, REGRESSION ANAL VARI, P517; NICKLAS RA, 1998, J ALLERGY CLIN IMMUN, V101, pS465; Pumphrey RSH, 2000, CLIN EXP ALLERGY, V30, P1144, DOI 10.1046/j.1365-2222.2000.00864.x; SAFF R, 1993, ANN ALLERGY, V70, P396; SALHANICK SD, 2001, PRIMARY PEDIAT CARE, P1947; Schiff RI, 1996, RUDOLPHS PEDIAT, P474; SCHWEICH PJ, 1999, OSKIS PEDIAT PRINCIP, P566; Sicherer SH, 2001, J ALLERGY CLIN IMMUN, V108, P128, DOI 10.1067/mai.2001.115755; Sicherer SH, 2001, ANN ALLERG ASTHMA IM, V86, P597, DOI 10.1016/S1081-1206(10)62284-3; Simons FER, 2001, J ALLERGY CLIN IMMUN, V108, P1040, DOI 10.1067/mai.2001.119916; Simons FER, 2000, PEDIATRICS, V106, P1040, DOI 10.1542/peds.106.5.1040; SIMONS FER, 1994, CAN MED ASSOC J, V150, P337; Simons FER, 2001, ANN ALLERG ASTHMA IM, V86, P622, DOI 10.1016/S1081-1206(10)62289-2; Simons FER, 1998, J ALLERGY CLIN IMMUN, V101, P33, DOI 10.1016/S0091-6749(98)70190-3; SLY RM, 2000, NELSONS TXB PEDIAT, P686; SPEER F, 1970, ANN ALLERGY, V28, P50; Vander Leek TK, 2000, J PEDIATR-US, V137, P749, DOI 10.1067/mpd.2000.109376; 2001, PHYSICIANS DESK REFE	25	76	87	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2002	109	1					171	175		10.1067/mai.2002.120758	http://dx.doi.org/10.1067/mai.2002.120758			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	519RM	11799385	Bronze			2022-12-18	WOS:000173739300028
J	Ricciardolo, FLM; Timmers, MC; Geppetti, P; van Schadewijk, A; Brahim, JJ; Sont, JK; de Gouw, HWFM; Hiemstra, PS; van Krieken, JHJM; Sterk, PJ				Ricciardolo, FLM; Timmers, MC; Geppetti, P; van Schadewijk, A; Brahim, JJ; Sont, JK; de Gouw, HWFM; Hiemstra, PS; van Krieken, JHJM; Sterk, PJ			Allergen-induced impairment of bronchoprotective nitric oxide synthesis in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; airway hyperresponsiveness; allergen; ecNOS; nNOS; iNOS; nitric oxide; bradykinin	INDUCED AIRWAY HYPERREACTIVITY; BRADYKININ-INDUCED BRONCHOCONSTRICTION; GUINEA-PIG TRACHEA; HYPERRESPONSIVENESS; DEFICIENCY; EPITHELIUM; EXPOSURE; RELEASE; RESPONSIVENESS; INFLAMMATION	Background: Eudogenous nitric oxide protects against airway hyperresponsiveness (AHR) to bradykinin in mild asthma, whereas AHR to bradykinin is enhanced by inhaled allergens. Objective: Hypothesizing that allergen exposure impairs bronchoprotective nitric oxide within the airways, we studied the effect of the inhaled nitric ox:ide synthase. (NOS) inhibitor N-G-monomethyl-L-arginine, (L-NMMA) on AHR to bradykinin before and after allergen challenge in 10 subjects with atopic asthma. Methods: The study consisted or 3 periods (1 diluent and 2 allergen challenges). AHR to bradylkinin (PD20BK) was examined before and 48 hours after allergen challenge, both after double-blinded pretreatment with L-NMMA or placebo. The accompanying expression of the various NOS isoforms (ecNOS, nNOS, and iNOS) was examined by means of immunohistochemistry in bronchial biopsies obtained after diluent and allergen challenge. Results: After placebo, AHR to BK worsened after allergen challenge in comparison with before allergen challenge (PD20BK, 70.8 nmol [range, 6.3-331] and 257 nmol [35.5-2041], respectively; P=.0004). After L-NMMA, preallergen and postallergen PD20BK values (50.1 nmol [1.8-200] vs 52.5 nmol [6.9-204]; P =.88) were similarly reduced (P <.01) and not different from the postplacebo/postallergen value (P>.05). After allergen challenge, the intensity of staining in bronchial epithelium decreased for ecNOS (P=.03) and increased for iNOS (P=.009). These changes in immunostaining were correlated with the accompanying worsening in AHR to BK (R-s = -0.66 and 0.71; P<.04). Conclusions: These data indicate that allergen exposure in asthma induces increased airway hyperresponsiveness to bradykinin through impaired release of bronchoprotective nitric oxide associated with downregulation of ecNOS. This suggests that new therapeutic strategies towards restoring the balance among the NOS isoforms during asthma exacerbations are warranted.	Leiden Univ, Med Ctr, Dept Pulmonol, Lung Funct Lab, NL-2300 RC Leiden, Netherlands; Bergamo Gen Hosp, Dept Resp Dis, Bergamo, Italy; Univ Ferrara, Dept Expt & Clin Med, I-44100 Ferrara, Italy; Radboud Univ Nijmegen Med Ctr, Dept Pathol, Nijmegen, Netherlands; Leiden Univ, Med Ctr, Dept Med Decis Making, Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Ferrara; Radboud University Nijmegen; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Sterk, PJ (corresponding author), Leiden Univ, Med Ctr, Dept Pulmonol, Lung Funct Lab, C2-P,Albinusdreef 2,POB 9600, NL-2300 RC Leiden, Netherlands.	p.j.sterk@lumc.nl	Geppetti, Pierangelo/AHA-7897-2022; Sterk, P.J./AAK-8175-2020; Sont, Jacob K/J-8071-2015; Ricciardolo, F. L. M./K-5330-2018; Hiemstra, Pieter S/K-8587-2018; van Krieken, Joannes H J M/D-4138-2009	Sont, Jacob K/0000-0002-5840-0651; Ricciardolo, F. L. M./0000-0003-1826-5018; Hiemstra, Pieter S/0000-0002-0238-5982; van Krieken, Joannes H J M/0000-0001-6544-1040				BARNES PJ, 1986, LANCET, V1, P242; BARNES PJ, 1997, ASTHMA, P577; BELVISI MG, 1992, EUR J PHARMACOL, V210, P221, DOI 10.1016/0014-2999(92)90676-U; Bentley AM, 1997, CLIN EXP ALLERGY, V27, P71, DOI 10.1111/j.1365-2222.1997.tb01830.x; BERMAN AR, 1995, J APPL PHYSIOL, V78, P1844, DOI 10.1152/jappl.1995.78.5.1844; CHRISTIANSEN SC, 1992, AM REV RESPIR DIS, V145, P900, DOI 10.1164/ajrccm/145.4_Pt_1.900; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; COCKCROFT DW, 1987, AM REV RESPIR DIS, V135, P264; Coers W, 1998, J HISTOCHEM CYTOCHEM, V46, P1385, DOI 10.1177/002215549804601207; De Sanctis GT, 1999, J EXP MED, V189, P1621, DOI 10.1084/jem.189.10.1621; deBoer J, 1996, BRIT J PHARMACOL, V119, P1109; DIROSA M, 1990, P NATL ACAD SCI USA, V87, P10043; Djukanovic R, 1996, THORAX, V51, P575, DOI 10.1136/thx.51.6.575; Figini M, 1996, AM J RESP CRIT CARE, V153, P918, DOI 10.1164/ajrccm.153.3.8630573; FOLKERTS G, 1995, J CLIN INVEST, V95, P26, DOI 10.1172/JCI117649; Folkerts G, 1998, TRENDS PHARMACOL SCI, V19, P334, DOI 10.1016/S0165-6147(98)01232-2; FROSSARD N, 1990, AGENTS ACTIONS, V31, P204, DOI 10.1007/BF01997609; Gaston B, 1998, LANCET, V351, P1317, DOI 10.1016/S0140-6736(97)07485-0; GLEICH GJ, 1988, J ALLERGY CLIN IMMUN, V81, P776, DOI 10.1016/0091-6749(88)90931-1; Holgate ST, 1997, LANCET, V350, P5; ICHINOSE M, 1992, LANCET, V340, P1248, DOI 10.1016/0140-6736(92)92948-F; LEIKAUF GD, 1985, AM J PHYSIOL, V248, pF48, DOI 10.1152/ajprenal.1985.248.1.F48; Lund DD, 2000, CIRCULATION, V101, P1027, DOI 10.1161/01.CIR.101.9.1027; Mehta S, 1997, AM J PHYSIOL-LUNG C, V273, pL656, DOI 10.1152/ajplung.1997.273.3.L656; Meurs H, 1999, BRIT J PHARMACOL, V126, P559, DOI 10.1038/sj.bjp.0702372; MORRIS SM, 1994, AM J PHYSIOL, V266, pE829, DOI 10.1152/ajpendo.1994.266.6.E829; *NAT HEART LUNG BL, 1997, NIH PUBL; OBYRNE PM, 1987, AM REV RESPIR DIS, V136, P740, DOI 10.1164/ajrccm/136.3.740; PlattsMills TAE, 1997, NEW ENGL J MED, V336, P1382, DOI 10.1056/NEJM199705083361909; QUANJER PH, 1993, EUR RESPIR J, V6, P5, DOI 10.1183/09041950.005s1693; REIF DW, 1995, ARCH BIOCHEM BIOPHYS, V320, P170, DOI 10.1006/abbi.1995.1356; Ricciardolo FLM, 1996, LANCET, V348, P374, DOI 10.1016/S0140-6736(96)04450-9; Ricciardolo FLM, 2000, AM J RESP CELL MOL, V22, P97, DOI 10.1165/ajrcmb.22.1.3706; RICCIARDOLO FLM, 1994, BRIT J PHARMACOL, V113, P1147, DOI 10.1111/j.1476-5381.1994.tb17117.x; Ricciardolo FLM, 1997, LANCET, V350, P1297, DOI 10.1016/S0140-6736(05)62474-9; Roisman CL, 1996, AM J RESP CRIT CARE, V153, P381, DOI 10.1164/ajrccm.153.1.8542147; Schuiling M, 1998, BRIT J PHARMACOL, V123, P1450, DOI 10.1038/sj.bjp.0701738; Schuiling M, 1998, AM J RESP CRIT CARE, V158, P1442, DOI 10.1164/ajrccm.158.5.9803027; Sont JK, 1997, AM J RESP CELL MOL, V16, P549, DOI 10.1165/ajrcmb.16.5.9160837; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; STERK PJ, 1993, EUR RESPIR J, V6, P53, DOI 10.1183/09041950.053s1693; Toward TJ, 2000, BRIT J PHARMACOL, V131, P271, DOI 10.1038/sj.bjp.0703589; Villain M, 2000, J BIOL CHEM, V275, P2676, DOI 10.1074/jbc.275.4.2676; Xiong YL, 1999, J IMMUNOL, V162, P445; Zapol W.M., 1997, NITRIC OXIDE LUNG	45	76	77	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2001	108	2					198	204		10.1067/mai.2001.116572	http://dx.doi.org/10.1067/mai.2001.116572			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	465HY	11496234	Bronze			2022-12-18	WOS:000170584600006
J	Soussi-Gounni, A; Kontolemos, M; Hamid, Q				Soussi-Gounni, A; Kontolemos, M; Hamid, Q			Role of IL-9 in the pathophysiology of allergic diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						IL-9; inflammatory cells; cytokines; asthma; bronchial hyperresponsiveness	CELL GROWTH FACTOR-P40; ALPHA-SUBUNIT EXPRESSION; ACTIVATED MAST-CELLS; HUMAN T-CELLS; AIRWAY INFLAMMATION; EPITHELIAL-CELLS; TRANSGENIC MICE; RECEPTOR GENE; GM-CSF; POLYMORPHONUCLEAR NEUTROPHILS	Considerable evidence from both human and animal studies indicates that CD4(+) cells are the predominant cell type involved in the regulation of airway inflammation through the expression of T(H)2-type cytokines, The effects of T(H)2-type cytokines, particularly IL-4 and IL-5, on inflammatory and structural cells in airways have been studied in great detail, They were shown to be important for inflammatory cell maturation, activation and proliferation, IgE production, chemokine expression, mucus secretion, and bronchial hyperresponsiveness, Recent work has shown the potential importance of another T(H)2-type cytokine, IL-9, The development of transgenic mice overexpressing IL-9 has suggested a kev role for this cytokine in the development of the asthmatic phenotype, including eosinophilic inflammation, bronchial hyperresponsiveness, elevated IgE levels, and increased mucus secretion. IL-9 has been shown to act on many cell types involved in asthma, including T cells, B cells, mast cells, eosinophils, neutrophils, and epithelial cells, and thus might be important in the pathophysiology of allergic asthma.	McGill Univ, Meakins Christie Labs, Montreal, PQ H2X 2P2, Canada	McGill University	Hamid, Q (corresponding author), McGill Univ, Meakins Christie Labs, 3626 St Urbain St, Montreal, PQ H2X 2P2, Canada.		Gounni, Abdelilah Soussi/AAH-3456-2020	Soussi Gounni, Abdelilah/0000-0002-7282-0388; Gounni, Abdelilah/0000-0003-1265-6560				AMAOUT MA, 1986, J CLIN INVEST, V78, P597; Bauer JH, 1998, J BIOL CHEM, V273, P9255, DOI 10.1074/jbc.273.15.9255; BOCHNER BS, 1994, ANNU REV IMMUNOL, V12, P295; BONFIELD TL, 1995, AM J RESP CELL MOL, V13, P257, DOI 10.1165/ajrcmb.13.3.7544594; BOSHETTO P, 1989, EUR RESPIR J, V6, pS456; Bradding P, 1996, CLIN EXP ALLERGY, V26, P13, DOI 10.1111/j.1365-2222.1996.tb00051.x; BURD PR, 1995, J EXP MED, V181, P1373, DOI 10.1084/jem.181.4.1373; Campbell E, 1999, AM J PATHOL, V154, P1259, DOI 10.1016/S0002-9440(10)65377-1; CASALE TB, 1987, J CLIN INVEST, V80, P1507, DOI 10.1172/JCI113234; CASSATELLA MA, 1995, IMMUNOL TODAY, V16, P21, DOI 10.1016/0167-5699(95)80066-2; CHANG MS, 1994, BLOOD, V83, P3199; Dale DC, 1998, AM J HEMATOL, V57, P7, DOI 10.1002/(SICI)1096-8652(199801)57:1<7::AID-AJH2>3.0.CO;2-0; De Smedt M, 2000, J IMMUNOL, V164, P1761, DOI 10.4049/jimmunol.164.4.1761; Demoulin JB, 1999, J BIOL CHEM, V274, P25855, DOI 10.1074/jbc.274.36.25855; Demoulin JB, 2000, CANCER RES, V60, P3971; Demoulin JB, 1996, MOL CELL BIOL, V16, P4710; Dong Q, 1999, EUR J IMMUNOL, V29, P2130, DOI 10.1002/(SICI)1521-4141(199907)29:07<2130::AID-IMMU2130>3.0.CO;2-S; Doull IJM, 1996, AM J RESP CRIT CARE, V153, P1280, DOI 10.1164/ajrccm.153.4.8616554; DUGAS B, 1993, EUR J IMMUNOL, V23, P1687, DOI 10.1002/eji.1830230743; EKLUND KK, 1993, J IMMUNOL, V151, P4266; FLINT KC, 1985, BRIT MED J, V291, P923, DOI 10.1136/bmj.291.6500.923; GESSNER A, 1993, IMMUNOBIOLOGY, V189, P419, DOI 10.1016/S0171-2985(11)80414-6; Girard D, 1997, BIOCHEM J, V325, P147, DOI 10.1042/bj3250147; GORDON JR, 1990, IMMUNOL TODAY, V11, P458, DOI 10.1016/0167-5699(90)90176-A; Grasso L, 1998, J BIOL CHEM, V273, P24016, DOI 10.1074/jbc.273.37.24016; HOUSSIAU FA, 1995, J IMMUNOL, V154, P2624; HOUSSIAU FA, 1992, J IMMUNOL, V148, P3147; Hultner L, 2000, J IMMUNOL, V164, P5556, DOI 10.4049/jimmunol.164.11.5556; HULTNER L, 1990, EUR J IMMUNOL, V20, P1413, DOI 10.1002/eji.1830200632; Jeannin P, 1998, BLOOD, V91, P1355, DOI 10.1182/blood.V91.4.1355; KAY AB, 1991, J ALLERGY CLIN IMMUN, V87, P893, DOI 10.1016/0091-6749(91)90408-G; KELLEHER K, 1991, BLOOD, V77, P1436; KERMOUNI A, 1995, GENOMICS, V29, P371, DOI 10.1006/geno.1995.9992; KIMURA Y, 1995, INT IMMUNOL, V7, P115, DOI 10.1093/intimm/7.1.115; Lamblin C, 1999, J ALLERGY CLIN IMMUN, V104, P85, DOI 10.1016/S0091-6749(99)70118-1; Levitt RC, 1999, J ALLERGY CLIN IMMUN, V103, pS485, DOI 10.1016/S0091-6749(99)70165-X; Longphre M, 1999, J CLIN INVEST, V104, P1375, DOI 10.1172/JCI6097; Louahed J, 1996, J IMMUNOL, V156, P3704; Louahed J, 2000, AM J RESP CELL MOL, V22, P649, DOI 10.1165/ajrcmb.22.6.3927; LOUAHED J, 1995, J IMMUNOL, V154, P5061; LUKACS NW, 1995, AM J RESP CELL MOL, V13, P1; McLane MP, 1998, AM J RESP CELL MOL, V19, P713, DOI 10.1165/ajrcmb.19.5.3457; MOCK BA, 1990, IMMUNOGENETICS, V31, P265, DOI 10.1007/BF00204898; MODI WS, 1991, CYTOGENET CELL GENET, V57, P114, DOI 10.1159/000133126; Monteyne P, 1997, J IMMUNOL, V159, P2616; Nicolaides NC, 1997, P NATL ACAD SCI USA, V94, P13175, DOI 10.1073/pnas.94.24.13175; OKADA S, 1995, J ALLERGY CLIN IMMUN, V95, P1236, DOI 10.1016/S0091-6749(95)70081-1; Perdow-Hickman S, 2000, J INTERF CYTOK RES, V20, P603, DOI 10.1089/10799900050044804; PETITFRERE C, 1993, IMMUNOLOGY, V79, P146; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; RENAULD JC, 1990, J IMMUNOL, V144, P4235; RENAULD JC, 1992, P NATL ACAD SCI USA, V89, P5690, DOI 10.1073/pnas.89.12.5690; RENAULD JC, 1995, BLOOD, V85, P1300, DOI 10.1182/blood.V85.5.1300.bloodjournal8551300; RENAULD JC, 1995, J LEUKOCYTE BIOL, V57, P353, DOI 10.1002/jlb.57.3.353; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; SCHMITT E, 1994, J IMMUNOL, V153, P3989; Sehmi R, 1997, J CLIN INVEST, V100, P2466, DOI 10.1172/JCI119789; Shimbara A, 2000, J ALLERGY CLIN IMMUN, V105, P108, DOI 10.1016/S0091-6749(00)90185-4; SIBILLE Y, 1990, AM REV RESPIR DIS, V141, P471, DOI 10.1164/ajrccm/141.2.471; SIMPSON RJ, 1989, EUR J BIOCHEM, V183, P715, DOI 10.1111/j.1432-1033.1989.tb21103.x; Soussi-Gounni A, 1999, J ALLERGY CLIN IMMUN, V103, pS241; SOUSSIGOUNNI A, 2001, J IMMUNOL, V166, P2768; SOUSSIGOUNNI A, 2000, BLOOD, V96, P2163; SOUSSIGOUNNI A, 2000, J ALLERGY CLIN IMMUN, V106, P460; Stassen M, 2000, J IMMUNOL, V164, P5549, DOI 10.4049/jimmunol.164.11.5549; Temann UA, 1998, J EXP MED, V188, P1307, DOI 10.1084/jem.188.7.1307; Ulbrecht M, 1997, J ALLERGY CLIN IMMUN, V99, P828, DOI 10.1016/S0091-6749(97)80018-8; UYTTENHOVE C, 1988, P NATL ACAD SCI USA, V85, P6934, DOI 10.1073/pnas.85.18.6934; VANLEEUWEN BH, 1989, BLOOD, V73, P1142; Vermeesch JR, 1997, HUM MOL GENET, V6, P1, DOI 10.1093/hmg/6.1.1; Vink A, 1999, J EXP MED, V189, P1413, DOI 10.1084/jem.189.9.1413; WELLER PF, 1991, NEW ENGL J MED, V324, P1110; WEN LP, 1995, BIOCHIM BIOPHYS ACTA, V1314, P183; YANG YC, 1989, BLOOD, V74, P1880	74	76	84	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2001	107	4					575	582		10.1067/mai.2001.114238	http://dx.doi.org/10.1067/mai.2001.114238			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	423RG	11295641				2022-12-18	WOS:000168190100002
J	Chu, HW; Kraft, M; Krause, JE; Rex, MD; Martin, RJ				Chu, HW; Kraft, M; Krause, JE; Rex, MD; Martin, RJ			Substance P and its receptor neurokinin 1 expression in asthmatic airways	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; neuropeptides; substance P; neurokinin 1; mucus; Mycoplasma pneumoniae	NEUROGENIC INFLAMMATION; SENSORY NEUROPEPTIDES; MYCOPLASMA-PNEUMONIAE; BRONCHIAL-ASTHMA; GENE-EXPRESSION; NERVES; CELLS; IMMUNOREACTIVITY; EPITHELIUM; POTENTIATION	Background: Neural mechanisms have been suggested to contribute to the pathogenesis of chronic asthma, The expression of neuropeptides such as substance P may be regulated by infectious pathogens, including Mycoplasma species. In contrast to substance P, the substance P receptor neurokinin 1 has not been examined at the protein level in asthmatic airways. Objective: This study evaluated substance P and neurokinin 1 protein expression and mucus content in endobronchial biopsy specimens from normal control subjects and asthmatic subjects. Detection of Mycoplasma pneumoniae was performed in both biopsy and bronchoalveolar lavage specimens, Methods: Biopsy specimens were collected from 10 normal control subjects and 18 asthmatic subjects before and after a 6-week treatment with a macrolide antibiotic (n = 11) or placebo (n = 7) and were stained for substance P, neurokinin 1, and mucus. M pneumoniae was evaluated by PCR, Results: At baseline, compared with normal control subjects, asthmatic subjects demonstrated increased expression of substance P and neurokinin 1 and mucus content in the airway epithelium. Epithelial mucus content correlated with epithelial substance P expression (r(s) = 0.45, P =.04) and FEV1 percent predicted (r(s) = -0.51, P = .019). After antibiotic treatment, both epithelial substance P and neurokinin 1 expression were significantly reduced in asthmatic subjects. M pneumoniae was found in 8 of 18 asthmatic subjects, Asthmatic subjects with M pneumoniae, compared with those without M pneumoniae, showed higher baseline epithelial neurokinin 1 expression, which was significantly reduced after antibiotic treatment (P = .02). Conclusion: Our data suggest that abnormalities in neural mechanisms may exist in the epithelium of asthmatic airways, and M pneumoniae is possibly involved in this process. Antibiotic intervention may be effective in the treatment of asthma partly through the downregulation of the neurogenic process.	Natl Jewish Med & Res Ctr, Dept Med, Denver, CO 80206 USA; Univ Colorado, Ctr Hlth Sci, Denver, CO 80202 USA; Neurogen Corp, Branford, CT USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Martin, RJ (corresponding author), Natl Jewish Med & Res Ctr, Dept Med, 1400 Jackson St,Room J116, Denver, CO 80206 USA.				NHLBI NIH HHS [HL36577] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036577] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADCOCK IM, 1993, J MOL ENDOCRINOL, V11, P1, DOI 10.1677/jme.0.0110001; ARDELT AA, 1996, J COMP NEUROL, V376, P1; BAI TR, 1995, AM J PHYSIOL-LUNG C, V269, pL309, DOI 10.1152/ajplung.1995.269.3.L309; Barnes PJ, 1996, AM J RESP CRIT CARE, V153, pS5, DOI 10.1164/ajrccm/153.6_Pt_2.S5; BARNES PJ, 1995, CHEST, V107, P119; Baseman JB, 1996, AM J RESP CRIT CARE, V154, pS137, DOI 10.1164/ajrccm/154.4_Pt_2.S137; BOWDEN JJ, 1994, AM J RESP CRIT CARE, V150, P1391, DOI 10.1164/ajrccm.150.5.7524980; Bowden JJ, 1996, AM J PHYSIOL-LUNG C, V270, pL393; BOWDEN JJ, 1994, P NATL ACAD SCI USA, V91, P8964, DOI 10.1073/pnas.91.19.8964; Chanez P, 1998, AM J RESP CRIT CARE, V158, P985, DOI 10.1164/ajrccm.158.3.9608104; CHU HW, 1995, CLIN EXP IMMUNOL, V100, P319; Cunningham AF, 1998, EUR RESPIR J, V11, P345, DOI 10.1183/09031936.98.11020345; DAVIS BM, 1984, NEUROSCIENCE, V13, P1311, DOI 10.1016/0306-4522(84)90300-2; DUNNILL MS, 1969, THORAX, V24, P176, DOI 10.1136/thx.24.2.176; Folkerts G, 1998, AM J RESP CRIT CARE, V157, P1708, DOI 10.1164/ajrccm.157.6.9707163; Germonpre PR, 1999, EUR RESPIR J, V14, P776, DOI 10.1034/j.1399-3003.1999.14d08.x; GERMONPRE PR, 1998, AM J RESP CRIT CARE, V157, pA489; HOWARTH PH, 1995, AM J RESP CELL MOL, V13, P288, DOI 10.1165/ajrcmb.13.3.7654385; JOOS GF, 1994, EUR RESPIR J, V7, P1161; Kraft M, 1998, AM J RESP CRIT CARE, V158, P998, DOI 10.1164/ajrccm.158.3.9711092; KRAFT M, 1997, AM J RESP CRIT CARE, V155, pA65; LILLY CM, 1995, AM J RESP CRIT CARE, V151, P548, DOI 10.1164/ajrccm.151.2.7531100; Lou YP, 1998, AM J RESP CRIT CARE, V157, P1927, DOI 10.1164/ajrccm.157.6.9709113; LOVELESS RW, 1992, INFECT IMMUN, V60, P4015, DOI 10.1128/IAI.60.10.4015-4023.1992; MARTIN RJ, 1991, AM REV RESPIR DIS, V143, P351, DOI 10.1164/ajrccm/143.2.351; MCDONALD DM, 1991, J CLIN INVEST, V87, P787, DOI 10.1172/JCI115082; Minshall EM, 1997, AM J RESP CELL MOL, V17, P326, DOI 10.1165/ajrcmb.17.3.2733; NIEBER K, 1992, J ALLERGY CLIN IMMUN, V90, P646, DOI 10.1016/0091-6749(92)90138-R; OCONNELL F, 1995, AM J RESP CRIT CARE, V152, P2068, DOI 10.1164/ajrccm.152.6.8520777; OLLERENSHAW SL, 1991, EUR RESPIR J, V4, P673; RENNICK RE, 1992, THORAX, V47, P1044, DOI 10.1136/thx.47.12.1044; Scaglione F., 1998, Journal of Antimicrobial Chemotherapy, V41, P47, DOI 10.1093/jac/41.suppl_2.47; Shimura S, 1996, EUR RESPIR J, V9, P1395, DOI 10.1183/09031936.96.09071395; Sont JK, 1997, AM J RESP CELL MOL, V16, P549, DOI 10.1165/ajrcmb.16.5.9160837; TAKIZAWA H, 1995, BIOCHEM BIOPH RES CO, V210, P781, DOI 10.1006/bbrc.1995.1727; TOMAKI M, 1995, AM J RESP CRIT CARE, V151, P613; WEINSTOCK JV, 1989, J IMMUNOL, V142, P3256	37	76	79	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2000	106	4					713	722		10.1067/mai.2000.109829	http://dx.doi.org/10.1067/mai.2000.109829			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	365ZP	11031342				2022-12-18	WOS:000089980600015
J	Fagiolo, U; Kricek, F; Ruf, C; Peserico, A; Amadori, A; Cancian, M				Fagiolo, U; Kricek, F; Ruf, C; Peserico, A; Amadori, A; Cancian, M			Effects of complement inactivation and IgG depletion on skin reactivity to autologous serum in chronic idiopathic urticaria	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						chronic idiopathic urticaria; IgE receptor; autoantibodies; histamine release; cutaneous response	FC-EPSILON-RI; ALPHA AUTOANTIBODIES; HISTAMINE-RELEASE; CELL ACTIVATION; ANTI-IGE; RECEPTOR	Background: Intradermal injection of autologous serum elicits a wheal-and-flare response in about 60% of patients with chronic idiopathic urticaria (CIU). This reactivity has been attributed to the presence of IgG autoantibodies directed against IgE or the alpha-chain of the high-affinity IgE receptor (Fc epsilon RI alpha) expressed on basophils and mast cells, leading to the hypothesis that at least some forms of CIU could be sustained by an autoimmune profess. Objectives: The aim of this study was to investigate the relationship between the presence of anti-IgE or anti-Fc epsilon RI antibodies and the ability to induce wheal-and-flare responses in CIU sera selected for the capacity to give a positive skin test response. Methods: Fifteen patients with CIU and a positive skin test response to autologous serum were injected intradermally with native serum and with serum heated at 56 degrees C for 30 minutes and then adsorbed on Sepharose-protein G to obtain IgG depletion. Serum levels of anti-IgE and anti-Fc epsilon RI alpha antibodies were measured by ELISA by using purified IgE and recombinant RI alpha-soluble double-fusion protein RI alpha-human serum albumin-RI alpha, respectively. The histamine-releasing activity of sera was tested by using ELISA with whole human blood from a healthy donor. Results: All patients had positive cutaneous responses to native serum injection, Anti-Fc epsilon RI alpha antibodies were present in 14 of 15 native sera, only two of which were able to induce in vitro basophil degranulation. On the contrary, detectable amounts of anti-IgE antibodies were not found in any serum. IgG depletion by protein G resulted in complete (10/14 samples) or considerable (4/14 samples) removal of anti-Fc epsilon RI alpha antibodies. The two sera endowed with functional activity lost their capacity to trigger histamine release from basophils after heating and protein G adsorption. Nonetheless, heat-decomplemented/IgG-depleted sera elicited wheal-and-flare reactions comparable with those observed with untreated sera. Conclusions: These results strongly suggest that skin reactivity to autologous serum could be due to as yet unidentified non-Ig reactants present in the sera of patients with CIU.	Univ Padua, Dept Med & Surg Sci, Padua, Austria; Univ Padua, Inst Clin Dermatol, Padua, Austria; Univ Padua, Dept Oncol & Surg Sci, Padua, Austria; Novartis Forschungsinst, Vienna, Austria	University of Padua; University of Padua; University of Padua; Novartis	Fagiolo, U (corresponding author), Univ Padua, Dipartimento Sci Med & Chirurg, Via Giustiniani 2, I-35128 Padua, Italy.							AMADORI A, 1989, J IMMUNOL, V143, P2146; CHAMPION RH, 1990, CLIN EXP ALLERGY, V20, P21; CHARLESWORTH EN, 1995, HUMAN BASOPHILS MAST, P84; FAGIOLO U, 1991, Giornale Italiano di Allergologia e Immunologia Clinica, V1, P147; Fagiolo U, 1999, J ALLERGY CLIN IMMUN, V103, P1143, DOI 10.1016/S0091-6749(99)70190-9; Ferrer M, 1998, J ALLERGY CLIN IMMUN, V101, P672, DOI 10.1016/S0091-6749(98)70176-9; Ferrer M, 1999, J ALLERGY CLIN IMMUN, V104, P169, DOI 10.1016/S0091-6749(99)70129-6; Fiebiger E, 1995, J CLIN INVEST, V96, P2606, DOI 10.1172/JCI118325; Fiebiger E, 1998, J CLIN INVEST, V101, P243, DOI 10.1172/JCI511; GRATTAN CEH, 1986, BRIT J DERMATOL, V114, P583, DOI 10.1111/j.1365-2133.1986.tb04065.x; GRATTAN CEH, 1991, CLIN EXP ALLERGY, V21, P695, DOI 10.1111/j.1365-2222.1991.tb03198.x; GREAVES MW, 1995, NEW ENGL J MED, V332, P1767, DOI 10.1056/NEJM199506293322608; GRUBER BL, 1988, J INVEST DERMATOL, V90, P213, DOI 10.1111/1523-1747.ep12462239; HIDE M, 1993, NEW ENGL J MED, V328, P1599, DOI 10.1056/NEJM199306033282204; Horn MP, 1999, EUR J IMMUNOL, V29, P1139, DOI 10.1002/(SICI)1521-4141(199904)29:04<1139::AID-IMMU1139>3.0.CO;2-J; Niimi N, 1996, J INVEST DERMATOL, V106, P1001, DOI 10.1111/1523-1747.ep12338544; Rudolf MP, 1996, J IMMUNOL, V157, P5646; Tong LJ, 1997, J ALLERGY CLIN IMMUN, V99, P461, DOI 10.1016/S0091-6749(97)70071-X	18	76	79	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2000	106	3					567	572		10.1067/mai.2000.108913	http://dx.doi.org/10.1067/mai.2000.108913			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	356YN	10984379				2022-12-18	WOS:000089471900022
J	Merget, R; Kulzer, R; Dierkes-Globisch, A; Breitstadt, R; Gebler, A; Kniffka, A; Artelt, S; Koenig, HP; Alt, F; Vormberg, R; Baur, X; Schultze-Werninghaus, G				Merget, R; Kulzer, R; Dierkes-Globisch, A; Breitstadt, R; Gebler, A; Kniffka, A; Artelt, S; Koenig, HP; Alt, F; Vormberg, R; Baur, X; Schultze-Werninghaus, G			Exposure-effect relationship of platinum salt allergy in a catalyst production plant: Conclusions from a 5-year prospective cohort study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						platinum; exposure; allergy; catalyst; sensitization; occupational; asthma; rhinitis; risk assessment	REFINERY WORKERS; SMOKING; TESTS	Background: There is a high incidence of occupational asthma and rhinitis caused by platinum (Pt) salts in precious-metal refineries. Objective: We sought to assess exposure to Pt salts and the incidence of Pt salt allergy in a catalyst production plant. Methods: A 5-year prospective cohort study was performed in 159 catalyst production workers (94.6% of recruited), 50 craftsmen (92.6% of recruited), and 66 control subjects (76.7% of recruited) at yearly intervals. Subjects were assigned to exposure categories of high levels of Pt (n = 115), persistently low levels of Pt (n = 51), intermittently low levels of Pt (n = 61), or no Pt (n = 48) after the initial survey according to job title and job location. Skin prick test conversion from a negative response to a 4 mm or larger wheal response with a 10(-2) mol/L hexachloroplatinic acid solution was chosen as the outcome variable. Results: Exposure assessment of airborne Pt and Pt in the serum of workers demonstrated clear differences between exposure categories. The threshold limit value of 2 mu g/m(3) for soluble Pt was exceeded in 3 (4%) of 78 measurements. Thirteen subjects assigned to high exposure showed skin test conversion, and new allergic symptoms were associated with exposure. Among the high-exposure category, the incidence rate of skin prick test conversion was 5.9 per 100 person-years for newly employed subjects (n = 79) acid 2.1 per 100 person-years for those who had already been employed at the time of the initial survey (n = 36). A predicting factor for skin test conversion in highly exposed subjects was smoking status (relative risk, 3.9; 95% confidence interval, 1.6-9.7) but not atopy or bronchial hyperresponsiveness. Conclusion: Sensitization to Pt salts may develop in workers of catalyst production plants. Both the exposure to Pt salts and the incidence of Pt salt allergy were lower compared with reported data from precious-metal refineries.	Univ Hosp Bergmannsheil, Dept Internal Med, Div Pneumonol Allergol & Sleep Med, D-44789 Bochum, Germany; Degussa AG, Dept Med, Frankfurt, Germany; Degussa AG, Dept Corp Res Funct, Frankfurt, Germany; Degussa AG, Dept Med, Hanau, Germany; Degussa AG, Dept Med, Rheinfelden, Germany; Ruhr Univ Bochum, Dept Med Comp Sci Biometr & Epidemiol, D-4630 Bochum, Germany; Fraunhofer Inst Toxicol & Aerosol Res, Hannover, Germany; Inst Spectrochem & Appl Spect, Dortmund, Germany; BGFA, Res Inst Occupat Med, Bochum, Germany	Ruhr University Bochum; Evonik Industries; Evonik Industries; Evonik Industries; Evonik Industries; Ruhr University Bochum; Fraunhofer Gesellschaft; Ruhr University Bochum	Merget, R (corresponding author), Univ Hosp Bergmannsheil, Dept Pneumonol Allergol & Sleep Med, Burkle de la Camp Pl 1, D-44789 Bochum, Germany.							Artelt S, 1999, ATMOS ENVIRON, V33, P3559, DOI 10.1016/S1352-2310(99)00109-0; BAKER DB, 1990, AM J IND MED, V18, P653, DOI 10.1002/ajim.4700180604; CALVERLEY AE, 1995, OCCUP ENVIRON MED, V52, P661, DOI 10.1136/oem.52.10.661; CLEARE MJ, 1976, CLIN ALLERGY, V6, P183, DOI 10.1111/j.1365-2222.1976.tb01897.x; GLADKOVA EN, 1974, GIG T PROF ZABOL, V3, P10; *HLTH SAF EX OCC M, 1985, MDHS, V46; Linnett PJ, 1999, OCCUP ENVIRON MED, V56, P191, DOI 10.1136/oem.56.3.191; MERGET R, 1991, BRIT J IND MED, V48, P830; Merget R, 1996, OCCUP ENVIRON MED, V53, P422, DOI 10.1136/oem.53.6.422; MESSERSCHMIDT J, 1992, FRESEN J ANAL CHEM, V343, P391, DOI 10.1007/BF00322878; Niezborala M, 1996, OCCUP ENVIRON MED, V53, P252, DOI 10.1136/oem.53.4.252; OCONNOR G, 1987, AM REV RESPIR DIS, V136, P1412, DOI 10.1164/ajrccm/136.6.1412; Philippeit G., 1999, Umweltmedizin in Forschung und Praxis, V4, P3; QUANJER PH, 1993, EUR RESPIR J, V6, P5, DOI 10.1183/09041950.005s1693; Rosner G, 2000, ANTHROPOGENIC PLATINUM-GROUP ELEMENT EMISSIONS, P267; Schlogl R, 1987, ANGEW CHEM, V99, P312; VENABLES KM, 1989, BMJ-BRIT MED J, V299, P939, DOI 10.1136/bmj.299.6705.939	17	76	77	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2000	105	2	1				364	370		10.1016/S0091-6749(00)90089-7	http://dx.doi.org/10.1016/S0091-6749(00)90089-7			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	285RQ	10669860				2022-12-18	WOS:000085402200024
J	Agarwal, SK; Marshall, GD				Agarwal, SK; Marshall, GD			beta-adrenergic modulation of human type-1/type-2 cytokine balance	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						type-1/type-2 cytokines; adrenergic agonist; asthma	CD4+ T-CELLS; INTERLEUKIN-10 PRODUCTION; INTERFERON-GAMMA; IGE PRODUCTION; ASTHMA; ACTIVATION; EXPRESSION; RECEPTORS; AGONISTS; IL-4	Background: Neuroendocrine mediators are increasingly recognized as immunomodulatory agents. Lymphocytes and monocytes express receptors for a variety of neuroendocrine mediators, including catecholamines, It has been reported that beta-adrenergic agonists decrease IFN-gamma production, with varying effects on IL-4 and 1L-5 production. Objective: Our purpose was to determine the effects of catecholamines (including beta-adrenergic agonists) on the type-1/type-2 cytokine balance in tetanus-stimulated human PBMCs. Method: Human PBMCs were stimulated with tetanus in the presence of epinephrine (EPI), norepinephrine, or terbutaline, IFN-gamma, IL-4, IL-5, and IL-10 levels in the supernatants were determined by ELISA. Results: PBMCs stimulated in the presence of EPI produced decreased levels of IFN-gamma and increased levels of IL-10, IL-4, and 1L-5. A small decrease in IFN-gamma production and an increase in IL-10, IL-4, and IL-5 production were also observed with norepinephrine. Terbutaline induced similar alterations in the type-1/type-2 cytokine balance compared with EPI, indicating that the beta(2)adrenergic receptor is involved in these cytokine alterations. Furthermore, these cytokine alterations were blocked by propranolol. Finally, IL-12p70 prevented the cytokine alterations, suggesting that the mechanism of beta-adrenergic-induced cytokine alterations involves a decrease in IL-12. Conclusion: beta-Adrenergic agonists induce a shift in the human type-1/type-2 cytokine balance toward a type-2 response. These data provide a potential mechanism to explain the paradoxical increase in asthma morbidity and mortality associated with the chronic use of scheduled dosing of short-acting beta-adrenergic agonists.	Univ Texas, Sch Med, Dept Internal Med, Div Allergy & Clin Immunol, Houston, TX 77030 USA	University of Texas System	Marshall, GD (corresponding author), Univ Texas, Sch Med, Dept Internal Med, Div Allergy & Clin Immunol, 6431 Fannin MSB 4-044, Houston, TX 77030 USA.		Marshall, Gailen D./R-7459-2019					Agarwal SK, 1998, HUM IMMUNOL, V59, P99, DOI 10.1016/S0198-8859(97)00261-9; Agarwal SK, 1998, J INTERF CYTOK RES, V18, P1059, DOI 10.1089/jir.1998.18.1059; AndradeMena CE, 1997, J NEUROIMMUNOL, V76, P10, DOI 10.1016/S0165-5728(97)00015-5; BLALOCK JE, 1985, J NEUROIMMUNOL, V10, P31, DOI 10.1016/0165-5728(85)90032-3; Blotta MH, 1997, J IMMUNOL, V158, P5589; Braquet P, 1991, Clin Exp Allergy, V21 Suppl 1, P268, DOI 10.1111/j.1365-2222.1991.tb01740.x; Coqueret O, 1996, EUR RESPIR J, V9, P220, DOI 10.1183/09031936.96.09020220; COQUERET O, 1994, ANN NY ACAD SCI, V725, P44, DOI 10.1111/j.1749-6632.1994.tb39788.x; DAILEY MO, 1988, J IMMUNOL, V140, P2931; DELPRETE GF, 1993, EUR J IMMUNOL, V23, P1445, DOI 10.1002/eji.1830230707; DENT LA, 1990, J EXP MED, V172, P1425, DOI 10.1084/jem.172.5.1425; Elenkov IJ, 1996, P ASSOC AM PHYSICIAN, V108, P374; FINKELMAN FD, 1994, J EXP MED, V179, P1563, DOI 10.1084/jem.179.5.1563; Jeannin P, 1996, J IMMUNOL, V156, P3159; LEUNG DYM, 1995, J EXP MED, V181, P33, DOI 10.1084/jem.181.1.33; Marshall GD, 1998, BRAIN BEHAV IMMUN, V12, P297, DOI 10.1006/brbi.1998.0537; MARSHALL JD, 1993, CELL IMMUNOL, V152, P18, DOI 10.1006/cimm.1993.1264; Mohede ICM, 1996, INT J IMMUNOPHARMACO, V18, P193, DOI 10.1016/0192-0561(96)00008-2; Mosmann TR, 1996, IMMUNOL TODAY, V17, P138, DOI 10.1016/0167-5699(96)80606-2; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; PaninaBordignon P, 1997, J CLIN INVEST, V100, P1513, DOI 10.1172/JCI119674; POCHET R, 1979, CLIN EXP IMMUNOL, V38, P578; Ramer-Quinn DS, 1997, J IMMUNOL, V159, P4857; ROBINSON D, 1993, J ALLERGY CLIN IMMUN, V92, P313, DOI 10.1016/0091-6749(93)90175-F; ROMAGNANI S, 1989, CLIN IMMUNOL IMMUNOP, V50, P13; Sanders VM, 1997, J IMMUNOL, V158, P4200; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; SINCLAIR BL, 1987, THORAX, V42, P670, DOI 10.1136/thx.42.9.670; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; Suberville S, 1996, EUR J IMMUNOL, V26, P2601, DOI 10.1002/eji.1830261110; SWAIN SL, 1988, J IMMUNOL, V141, P3445	31	76	77	0	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2000	105	1	1				91	98		10.1016/S0091-6749(00)90183-0	http://dx.doi.org/10.1016/S0091-6749(00)90183-0			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	278LW	10629458				2022-12-18	WOS:000084992100013
J	Park, HS; Kim, HY; Nahm, DH; Son, JW; Kim, YY				Park, HS; Kim, HY; Nahm, DH; Son, JW; Kim, YY			Specific IgG, but not specific IgE, antibodies to toluene diisocyanate-human serum albumin conjugate are associated with toluene diisocyanate bronchoprovocation test results	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Specific IgG; Specific IgE; toluene diisocyanate-human serum albumin conjugate; toluene diisocyanate bronchoprovocation test	OCCUPATIONAL ASTHMA; ISOCYANATES; WORKERS	Background: The role of specific IgG to toluene diisocyanate (TDI) in the pathogenesis of TDI-induced asthma still remains unclear. Objective: We sought to evaluate the clinical significance of serum-specific IgG to TDI-human serum albumin (HSA) conjugate in subjects with TDI-induced asthma compared with specific IgE antibody. Methods: One hundred three subjects were enrolled and divided into 4 groups according to specific bronchoprovocation test (BPT) results: 50 subjects with TDI-induced asthma with positive results on TDI BPT were defined as group 1, 13 symptomatic workers exposed to TDI with negative results on TDI BPT were defined as group 2, 20 unexposed patients with allergic asthma were defined as group 3, and 20 unexposed healthy control subjects were defined as group 4, Serum-specific Ige and IgE antibodies to TDI-HSA conjugate were detected by means of ELISA, Results: The prevalence of specific IgG antibody to TDI-HSA conjugate was significantly higher in group I than in group 2 (46% vs 7.7%, P = .01) or group 3 (0%, P < .01). NO significant difference was noted between group 2 and group 3 (P > .05). However, the prevalence of specific IgE antibody to TDI-HSA conjugate was not significantly different between group 1 and group 2 (14% vs 7.7%, P > .05) or group 2 and group 3 (7.7% vs 0%, P > .05), There was no significant difference in prevalence of specific IgE or specific IgG according to the type of asthmatic response during the TDI BPT (P > .05), Overall, statistically significant association was noted between the prevalence of specific IgE and Ige antibodies in 103 subjects (P < .05), but no difference was noted within group 1 subjects only (P > .05), Conclusion: These findings demonstrate that the presence of serum-specific Ige is closely related to TDI BPT results, and it may contribute to the development of TDI-induced asthma.	Ajou Univ, Sch Med, Dept Allergy & Clin Immunol, Suwon 441749, South Korea; Seoul Natl Univ Hosp, Div Clin Immunol & Allergy, Dept Med, Seoul 110744, South Korea	Ajou University; Seoul National University (SNU); Seoul National University Hospital	Park, HS (corresponding author), Ajou Univ, Sch Med, Dept Allergy & Clin Immunol, Paldalgu Wonchondong San 5, Suwon 441749, South Korea.		Park, Hae-Sim/S-7974-2019	Park, Hae-Sim/0000-0003-2614-0303				Akimoto T, 1992, Nihon Kyobu Shikkan Gakkai Zasshi, V30, P458; BENTLEY AM, 1992, J ALLERGY CLIN IMMUN, V89, P821, DOI 10.1016/0091-6749(92)90437-7; CARTIER A, 1989, J ALLERGY CLIN IMMUN, V84, P507, DOI 10.1016/0091-6749(89)90364-3; CHANYEUNG M, 1990, CHEST, V98, pS148, DOI 10.1378/chest.98.5.148S; FABBRI LM, 1987, AM REV RESPIR DIS, V136, P36, DOI 10.1164/ajrccm/136.1.36; FORSTER MW, 1998, ALLERGY, V9, P294; KAROL MH, 1978, AM IND HYG ASSOC J, V39, P454, DOI 10.1080/0002889778507789; KIM YY, 1994, KOREAN J INTERN MED, V47, P439; LEE M, 1998, J KOREAN MED SCI, V13, P409; LUSHNIAK B D, 1990, Journal of Allergy and Clinical Immunology, V85, P251; MODESTO RR, 1973, BIOCHIM BIOPHYS ACTA, V295, P283, DOI 10.1016/0005-2795(73)90095-0; Park Hae Sim, 1992, Journal of Korean Medical Science, V7, P122; Park Hae-Sim, 1996, Journal of Korean Medical Science, V11, P314; PARK HS, 1991, CLIN EXP ALLERGY, V21, P357, DOI 10.1111/j.1365-2222.1991.tb01668.x; PARK HS, 1999, IN PRESS CLIN EXP AL; Son Minsik, 1998, Journal of Korean Medical Science, V13, P147; Tee RD, 1998, J ALLERGY CLIN IMMUN, V101, P709, DOI 10.1016/S0091-6749(98)70181-2; TSE CST, 1979, TOXICOL APPL PHARM, V51, P39, DOI 10.1016/0041-008X(79)90006-1; Yokota K, 1998, CLIN EXP ALLERGY, V28, P694; Zock JP, 1996, CLIN EXP ALLERGY, V26, P542, DOI 10.1046/j.1365-2222.1996.d01-344.x	20	76	76	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1999	104	4	1				847	851		10.1016/S0091-6749(99)70297-6	http://dx.doi.org/10.1016/S0091-6749(99)70297-6			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	248NG	10518831				2022-12-18	WOS:000083281200018
J	Pastorello, EA; Farioli, L; Pravettoni, V; Ispano, M; Conti, A; Ansaloni, R; Rotondo, F; Incorvaia, C; Bengtsson, A; Rivolta, F; Trambaioli, C; Previdi, M; Ortolani, C				Pastorello, EA; Farioli, L; Pravettoni, V; Ispano, M; Conti, A; Ansaloni, R; Rotondo, F; Incorvaia, C; Bengtsson, A; Rivolta, F; Trambaioli, C; Previdi, M; Ortolani, C			Sensitization to the major allergen of Brazil nut is correlated with the clinical expression of allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food allergy; Brazil nut; immunoblotting; major allergen	BERTHOLLETIA-EXCELSA HBK; AMINO-ACID-SEQUENCE; STORAGE PROTEIN; IDENTIFICATION; SEED; PEANUT; FAMILY; SYSTEM	Background: Only a few studies have investigated the clinical role of food allergens, especially the relationship between sensitization to a given allergen and occurrence of adverse reactions when eating the relevant food item. Objective: This study evaluated the clinical role of the allergens of Brazil nut by comparing the patterns of IgE binding in sera from II patients with anaphylaxis after eating Brazil nuts with those from 10 subjects with no symptoms to this food item. Both groups had specific IgE to Brazil nut. Methods: Allergens in the in-house extract of Brazil nut were identified by SDS-PAGE/immunoblotting, the major allergen was purified by HPLC, and its N-terminal sequence was determined by a protein sequencer. Results: SDS-PAGE/immunoblotting detected a number of allergenic components with molecular weights ranging from 4 to 58 kd. All sera from symptomatic patients recognized a 9-kd allergen corresponding (as established by amino acid sequencing) to a 2S albumin already described as a major allergen of Brazil nut, whereas the other allergens each bound IgE from less than 50% of sera. No sera from asymptomatic subjects showed IgE binding to the 9-kd allergen, but they did recognize components from 25 to 58 kd, which are minor allergens. Conclusions: These findings indicate that the allergen underlying clinical reactions to Brazil nut is a 2S albumin of 9 kd and that in vitro reactivity to this allergen identifies subjects who react in vivo to ingestion of this food.	Osped Maggiore, IRCCS, Allergy Ctr, Div Gen Med 3, Milan, Italy; Unita Operat Osped Med Lavoro, Unita Socio Sanitaria Locale 41, Milan, Italy; Niguarda Ca Granda Hosp, Bizzozzero Div, Milan, Italy; Pharmacia & Upjohn Diagnost AB, Uppsala, Sweden; Natl Res Council, Turin, Italy	IRCCS Ca Granda Ospedale Maggiore Policlinico; IRCCS Ca Granda Ospedale Maggiore Policlinico; Pfizer; Pharmacia Corporation	Pastorello, EA (corresponding author), Padiglione Granelli, Div Gen Med 3, Via Francesco Sforza 35, I-20122 Milan, Italy.		PASTORELLO, ELIDE ANNA/E-3897-2017	PASTORELLO, ELIDE ANNA/0000-0002-3753-1783				AAS K, 1973, Clinical Allergy, V3, P255, DOI 10.1111/j.1365-2222.1973.tb01331.x; AMPE C, 1986, EUR J BIOCHEM, V159, P597, DOI 10.1111/j.1432-1033.1986.tb09926.x; ARSHAD SH, 1991, CLIN EXP ALLERGY, V21, P373, DOI 10.1111/j.1365-2222.1991.tb01671.x; Bartolome B, 1997, Allergol Immunopathol (Madr), V25, P135; BERNHISELBROADBENT J, 1994, J ALLERGY CLIN IMMUN, V93, P1047, DOI 10.1016/S0091-6749(94)70054-0; BURKS AW, 1991, J ALLERGY CLIN IMMUN, V88, P172, DOI 10.1016/0091-6749(91)90325-I; DAUL C B, 1991, Journal of Allergy and Clinical Immunology, V87, P192, DOI 10.1016/0091-6749(91)91497-H; ERICSON ML, 1986, J BIOL CHEM, V261, P4576; Ewan PW, 1996, BRIT MED J, V312, P1074; Hide D. W., 1983, British Medical Journal, V287, P900; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MENENDEZARIAS L, 1988, EUR J BIOCHEM, V177, P159, DOI 10.1111/j.1432-1033.1988.tb14357.x; MONSALVE RI, 1990, J EXP BOT, V41, P89, DOI 10.1093/jxb/41.1.89; NEVILLE DM, 1971, J BIOL CHEM, V246, P6328; Nordlee JA, 1996, NEW ENGL J MED, V334, P688, DOI 10.1056/NEJM199603143341103; PASTORELLO EA, 1994, J ALLERGY CLIN IMMUN, V94, P699, DOI 10.1016/0091-6749(94)90177-5; Pastorello EA, 1997, CLIN REV ALLERG IMMU, V15, P415, DOI 10.1007/BF02737737; SAMPSON HA, 1995, J ALLERGY CLIN IMMUN, V95, P329; SAMPSON HA, 1993, ALLERGY PRINCIPLES P, P1661; SHANTI KN, 1993, J IMMUNOL, V151, P5354; SHARIEF FS, 1982, J BIOL CHEM, V257, P4753; SHEWRY PR, 1995, PLANT CELL, V7, P945, DOI 10.1105/tpc.7.7.945; SUN SSM, 1987, J AGR FOOD CHEM, V35, P232, DOI 10.1021/jf00074a016; TERRAS FRG, 1993, FEBS LETT, V316, P233, DOI 10.1016/0014-5793(93)81299-F; TOWBIN H, 1984, J IMMUNOL METHODS, V72, P313, DOI 10.1016/0022-1759(84)90001-2	25	76	86	0	6	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1998	102	6	1				1021	1027		10.1016/S0091-6749(98)70341-0	http://dx.doi.org/10.1016/S0091-6749(98)70341-0			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	150XE	9847444	Bronze			2022-12-18	WOS:000077690700021
J	Kelly, HW				Kelly, HW			Establishing a therapeutic index for the inhaled corticosteroids: Part I. Pharmacokinetic/pharmacodynamic comparison of the inhaled corticosteroids	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						corticosteroids; pharmacokinetics; dose-response relationship; clearance; inhalers; clinical trials	METERED-DOSE INHALER; DRY POWDER INHALER; FLUTICASONE PROPIONATE; BECLOMETHASONE DIPROPIONATE; SEVERE ASTHMA; TRIAMCINOLONE ACETONIDE; MODERATE ASTHMA; RECEPTOR-BINDING; LUNG DEPOSITION; DOUBLE-BLIND	The inhaled corticosteroids contain physicochemical differences that alter both glucocorticoid receptor-binding characteristics and the pharmacokinetic variables of these drugs. Differences in receptor-binding affinity translate into differences in potency for different drugs. Differences in pharmacokinetics, however, determine the topical effect to systemic effect ratio, or the "pulmonary targeting" of the drug, Beneficial pharmacokinetic properties that may improve pulmonary targeting include low oral bioavailability, rapid systemic clearance, and slow absorption from the lung. Delivery devices ran produce clinically significant differences in topical activity by altering the dose deposited in the lung and, for orally absorbed drugs, the amount deposited in the oropharynx and swallowed. Clinical trials have confirmed that differences in potency or drug delivery of 2-fold or more can he detected in patients with asthma, However, because of the relatively flat nature of the dose-response curve for morning peak expiratory flow and forced expiratory volume in 1 second, the trials must be adequately powered and well controlled. The use of bronchial provocation measures are problematic because of the prolonged lag time for response. Study design flaws can lead to misinterpretation of results. Clinical studies have indicated the following relative potency differences: fluticasone propionate > budesonide = beclomethasone dipropionate > triamcinolone acetonide = flunisolide. Current evidence suggests that potency differences can be overcome by giving larger doses of the less potent drug. However, because of these potency differences, studies of systemic effects should not be done in isolation of adequate topical activity studies to define the pulmonary targeting of the drugs.	Univ New Mexico, Hlth Sci Ctr, Coll Pharm, Albuquerque, NM 87131 USA; Univ New Mexico, Hlth Sci Ctr, Dept Pediat, Albuquerque, NM 87131 USA	University of New Mexico; University of New Mexico's Health Sciences Center; University of New Mexico; University of New Mexico's Health Sciences Center	Kelly, HW (corresponding author), Univ New Mexico, Hlth Sci Ctr, Coll Pharm, 2502 Marble NE, Albuquerque, NM 87131 USA.							Adcock IM, 1996, AM J RESP CRIT CARE, V154, pS58, DOI 10.1164/ajrccm/154.2_Pt_2.S58; AGERTOFT L, 1993, ARCH DIS CHILD, V69, P130, DOI 10.1136/adc.69.1.130; Agertoft L, 1997, J ALLERGY CLIN IMMUN, V99, P773, DOI 10.1016/S0091-6749(97)80011-5; ANDERSSON N, 1994, AM J RESP CRIT CARE, V149, pA467; AYRES JG, 1995, EUR RESPIR J, V8, P579; Backman R, 1996, J ALLERGY CLIN IMMUN, V97, P267; BARNES NC, 1993, EUR RESPIR J, V6, P877; Barnes NC, 1998, RESP MED, V92, P95, DOI 10.1016/S0954-6111(98)90039-7; BARNES PJ, 1995, NEW ENGL J MED, V332, P868, DOI 10.1056/NEJM199503303321307; Barnes PJ, 1996, AM J RESP CRIT CARE, V154, pS21, DOI 10.1164/ajrccm/154.2_Pt_2.S21; Bisgaard H, 1997, J ASTHMA, V34, P443, DOI 10.3109/02770909709055389; BOE J, 1994, EUR RESPIR J, V7, P2179, DOI 10.1183/09031936.94.07122179; BOOTSMA GP, 1995, ATS, V24, pA41; BORGSTROM L, 1994, EUR RESPIR J, V7, P69, DOI 10.1183/09031936.94.07010069; BRATTSAND R, 1982, EUR J RESPIR DIS, V63, P62; Brattsand R, 1997, EUR RESPIR REV, V7, P356; BROWN PH, 1993, THORAX, V48, P967, DOI 10.1136/thx.48.10.967; BROWN PH, 1990, THORAX, V45, P736, DOI 10.1136/thx.45.10.736; CHAPLIN MD, 1980, CLIN PHARMACOL THER, V27, P402, DOI 10.1038/clpt.1980.54; CHAPLIN MD, 1980, J ALLERGY CLIN IMMUN, V65, P445, DOI 10.1016/0091-6749(80)90238-9; CHERVINSKY P, 1994, J ALLERGY CLIN IMMUN, V94, P676, DOI 10.1016/0091-6749(94)90174-0; Condemi JJ, 1997, J ALLERGY CLIN IMMUN, V100, P467, DOI 10.1016/S0091-6749(97)70137-4; CONNOLLY A, 1995, EUR J CLIN RES, V7, P15; Cook D, 1998, AM J RESP CRITICAL S, V157, pA416; Crimi E, 1998, AM J RESP CRIT CARE, V157, P4, DOI 10.1164/ajrccm.157.1.9703002; DAHL R, 1993, CHEST, V104, P1352, DOI 10.1378/chest.104.5.1352; DAHLBERG E, 1984, MOL PHARMACOL, V25, P70; DAVIES B, 1993, BRIT J CLIN PRACT, V47, P87; DAVIES RJ, 1997, THORAX S6, V52, pA58; Derendorf H, 1997, RESP MED, V91, P22, DOI 10.1016/S0954-6111(97)90102-5; DERENDORF H, 1993, J CLIN PHARMACOL, V33, P115, DOI 10.1002/j.1552-4604.1993.tb03930.x; Devadason SG, 1997, EUR RESPIR J, V10, P2023, DOI 10.1183/09031936.97.10092023; EDSBACKER S, 1985, EUR J CLIN PHARMACOL, V29, P477, DOI 10.1007/BF00613465; ENGEL T, 1989, ALLERGY, V44, P220, DOI 10.1111/j.1398-9995.1989.tb02266.x; ENGLISH AF, 1994, AM J RESP CRIT CAR S, V149, pA212; FABBRI L, 1993, THORAX, V48, P817, DOI 10.1136/thx.48.8.817; Falcoz C., 1996, European Respiratory Journal Supplement, V9, p162S; FREEZER NJ, 1995, EUR RESPIR J, V8, P1488; FRIEDMAN B, 1998, J ALLERGY CLIN IMMUN, V101, pA39; FULLER R, 1995, J AEROSOL MED, V8, pS11, DOI 10.1089/jam.1995.8.Suppl_2.S-11; *GLOB IN ASTHM GLO, 1995, NIH NAT HEART LUNG B; GonzalezRothi RJ, 1996, PHARMACEUT RES, V13, P1699, DOI 10.1023/A:1016448908909; Grossner C, 1996, INT J EXPERT SYST, V9, P255; GUSTAFSSON P, 1993, ARCH DIS CHILD, V69, P206, DOI 10.1136/adc.69.2.206; HAAHTELA T, 1994, NEW ENGL J MED, V331, P700, DOI 10.1056/NEJM199409153311103; Haley KJ, 1998, AM J RESP CRIT CARE, V157, P1; Harrison L., 1996, European Respiratory Journal Supplement, V9, p256S; Hill LS, 1998, RESP MED, V92, P105, DOI 10.1016/S0954-6111(98)90040-3; Hochhaus G, 1997, J CLIN PHARMACOL, V37, P881, DOI 10.1002/j.1552-4604.1997.tb04262.x; HOCHHAUS G, 1995, PHARMACEUT RES, V12, P134, DOI 10.1023/A:1016259225244; Hoekx JCM, 1996, EUR RESPIR J, V9, P2263, DOI 10.1183/09031936.96.09112263; HOGGER P, 1994, STEROIDS, V59, P597, DOI 10.1016/0039-128X(94)90054-X; Jenner WN, 1988, BIOANALYSIS DRUGS ME, P77; JOHANSSON SA, 1982, EUR J RESPIR DIS, V63, P74; Johnson M, 1996, J ALLERGY CLIN IMMUN, V97, P169, DOI 10.1016/S0091-6749(96)80217-X; JUNIPER EF, 1990, AM REV RESPIR DIS, V142, P832, DOI 10.1164/ajrccm/142.4.832; JUNIPER EF, 1991, J ALLERGY CLIN IMMUN, V87, P483, DOI 10.1016/0091-6749(91)90006-A; JUSKO WJ, 1990, J CLIN PHARMACOL, V30, P303, DOI 10.1002/j.1552-4604.1990.tb03598.x; KAM JC, 1993, J IMMUNOL, V151, P3460; Kamada AK, 1996, AM J RESP CRIT CARE, V153, P1739, DOI 10.1164/ajrccm.153.6.8665030; Kelly HW, 1998, ANN PHARMACOTHER, V32, P220, DOI 10.1345/aph.17014; KERSTJENS HAM, 1994, THORAX, V49, P1109, DOI 10.1136/thx.49.11.1109; KRAAN J, 1988, AM REV RESPIR DIS, V137, P44, DOI 10.1164/ajrccm/137.1.44; LANGDON CG, 1994, BR J CLIN RES, V5, P73; LANGDON CG, 1994, BR J CLIN RES, V5, P85; Leach C. L., 1996, European Respiratory Journal Supplement, V9, p255S; LEBLANC P, 1994, ALLERGY, V49, P380, DOI 10.1111/j.1398-9995.1994.tb02286.x; Lipworth BJ, 1996, PULM PHARMACOL THER, V9, P19, DOI 10.1006/pulp.1996.0002; LIPWORTH BJ, 1995, THORAX, V50, P105, DOI 10.1136/thx.50.2.105; LUNDBACK B, 1993, RESP MED, V87, P609, DOI 10.1016/S0954-6111(05)80264-1; Mackie AE, 1996, BRIT J CLIN PHARMACO, V41, P539, DOI 10.1046/j.1365-2125.1996.36110.x; MCKENZIE AW, 1962, ARCH DERMATOL, V86, P611, DOI 10.1001/archderm.1962.01590110047006; *MED EC CO, 1998, PHYS DESK REF, P1027; MOLLMANN H, 1985, EUR J CLIN PHARMACOL, V29, P85, DOI 10.1007/BF00547374; Mollmann H, 1997, J CLIN PHARMACOL, V37, P893; MURRAY JJ, 1998, AM J RESP CRIT CARE, V157, pA407; MURRAY JJ, 1998, J ALLERGY CLIN IMMUN, V101, pA964; NAMSIRIKUL P, 1989, EUR RESPIR J, V2, P317; *NAT ASTHM ED PREV, 1997, NIH NAT HEART LUNG B; *NAT ASTHM ED PROG, 1991, NIH NAT HEART LUNG B; NEWMAN SP, 1985, CHEST, V88, pS152, DOI 10.1378/chest.88.2.152S; OCALLAGHAN C, 1994, THORAX, V49, P961, DOI 10.1136/thx.49.10.961; OLSSON B, 1995, J AEROSOL MED S3, V8; Pauwels R, 1997, EUR RESPIR J, V10, P2127, DOI 10.1183/09031936.97.10092127; PAUWELS RA, 1995, AM J RESP CRIT CARE, V151, pA276; PEDERSEN S, 1990, ARCH DIS CHILD, V65, P308, DOI 10.1136/adc.65.3.308; PEDERSEN S, 1995, J ALLERGY CLIN IMMUN, V95, P29, DOI 10.1016/S0091-6749(95)70149-4; Pedersen S, 1997, ALLERGY, V52, P1, DOI 10.1111/j.1398-9995.1997.tb05047.x; PHILLIPPS GH, 1990, RESP MED, V84, P19, DOI 10.1016/S0954-6111(08)80003-0; RAPHAEL GD, 1998, J ALLERGY CLIN IMMUN, V101, pA24; Ringdal N, 1996, MEDIAT INFLAMM, V5, P382, DOI 10.1155/S0962935196000555; Robinson DS, 1996, J ASTHMA, V33, P5, DOI 10.3109/02770909609077758; Rohatagi S, 1995, J CLIN PHARMACOL, V35, P1187, DOI 10.1002/j.1552-4604.1995.tb04045.x; Rohdewald P., 1994, European Respiratory Journal, V7, p382S; RYRFELDT A, 1982, EUR J RESPIR DIS, V63, P86; RYRFELDT A, 1984, CLIN PHARMACOL THER, V35, P525, DOI 10.1038/clpt.1984.71; SALMERON S, 1989, AM REV RESPIR DIS, V140, P167, DOI 10.1164/ajrccm/140.1.167; SELROOS O, 1994, ALLERGY, V49, P833, DOI 10.1111/j.1398-9995.1994.tb00783.x; SELROOS O, 1991, THORAX, V46, P891, DOI 10.1136/thx.46.12.891; SPAHN JD, 1995, AM J RESP CRIT CARE, V151, P1709, DOI 10.1164/ajrccm.151.6.7767511; Spahn JD, 1996, J ALLERGY CLIN IMMUN, V98, P1073, DOI 10.1016/S0091-6749(96)80194-1; Srebro SH, 1998, J ALLERGY CLIN IMMUN, V101, pS6; SREBRO SH, 1998, AM J RESP CRIT CARE, V157, pA406; STEINMETZ KO, 1996, AM J RESP CRIT CARE, V153, pA338; SVENDSEN UG, 1992, ALLERGY, V47, P174, DOI 10.1111/j.1398-9995.1992.tb00960.x; THORSSON L, 1994, EUR RESPIR J, V7, P1839, DOI 10.1183/09031936.94.07101839; Thorsson L, 1997, BRIT J CLIN PHARMACO, V43, P155, DOI 10.1046/j.1365-2125.1997.d01-1425.x; THORSSON L, 1995, J AEROSOL MED S3, V8; TJWA MKT, 1995, ANN ALLERG ASTHMA IM, V75, P107; Toogood JH, 1997, J ALLERGY CLIN IMMUN, V99, P186, DOI 10.1016/S0091-6749(97)70094-0; Toogood JH, 1996, J ALLERGY CLIN IMMUN, V98, P555, DOI 10.1016/S0091-6749(96)70089-1; WAALKENS HJ, 1993, AM REV RESPIR DIS, V148, P1252, DOI 10.1164/ajrccm/148.5.1252; Williams J., 1995, European Respiratory Journal, V8, p469S	113	76	77	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1998	102	4	2				S36	S51		10.1016/S0091-6749(98)70004-1	http://dx.doi.org/10.1016/S0091-6749(98)70004-1			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	133CT	9798722				2022-12-18	WOS:000076669400006
J	Dold, S; Heinrich, J; Wichmann, HE; Wjst, M				Dold, S; Heinrich, J; Wichmann, HE; Wjst, M			Ascaris-specific IgE and allergic sensitization in a cohort of school children in the former East Germany	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; asthma; IgE; parasites; Ascaris; helminthic infection	HELMINTH INFECTION; TROPICAL SLUM; DISEASE; ASTHMA; LUMBRICOIDES; PREVALENCE; REACTIVITY; PARASITES	Background: Helminthic infections induce an IL-4-dependent polyclonal stimulation of IgE synthetization. It is still unclear, however, what role helminths play in allergic sensitization. Objective: We sought to determine the relationship between Ascaris-specific IgE and allergic sensitization in a nontropical country. Methods: In 2 consecutive cross-sectional surveys in 1992-1993 and 1995-1996, data from school entrants (age range, 5 to 7 years), third graders (age range, 8 to 10 years), and sixth graders (age range, 11 to 14 years) were collected. The 2 younger groups were reexamined in the second survey. Data for about 2300 children, including a cohort of 700 subjects, were analyzed. Ascaris IgE and total and specific IgE to inhalant allergens were measured, and skin prick tests were performed, Information about asthma and allergic rhinitis was collected by a questionnaire. Results: Children who were Ascaris-IgE seropositive (>0.35 IU/mL) in both surveys had 10-fold higher levels of total IgE (451 IU/mL vs 45 IU/mL, P <.001) and higher prevalence rates of allergen-specific IgE seropositivity (56.3% vs 26.6%, P <.001). They also had a higher prevalence of allergic rhinitis (12.6% vs 3.7%, P <.001) and asthma (5.7% vs 1.6%, P <.05). In subjects who were Ascaris-seronegative in the first survey but seropositive in the second survey, total and specific IgE increased markedly. Sensitization to Dermatophagoides pteronyssinus increased nearly 3-fold in this group. In contrast, in children who became Ascaris-seronegative, total and specific IgE decreased. Conclusions: Contact with low doses of helminthic antigen is associated with an increase of total and specific IgE production. Helminthic infections in East German children are not the cause for a low prevalence of allergies in the former East Germany.	GSF Forschungszentrum Umwelt & Gesundheit GMBH, Inst Epidemiol, Oberschleissheim, Germany; Univ Munich, Lehrstuhl Epidemiol, Oberschleissheim, Germany	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich	Wjst, M (corresponding author), GSF Forschungszentrum Umwelt & Gesundheit GMBH, Inst Epidemiol, Ingolstaedter Landstr 1, D-85758 Neuherberg, Germany.		Wichmann, Heinz Erich/AAA-5695-2022; Heinrich, Joachim/N-1720-2013	Heinrich, Joachim/0000-0002-9620-1629				ANDERELE WI, 1981, T R SOC TROP MED HYG, V75, P675; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Behrendt H, 1993, ALLERGO J, V2, P31; BERNHARD K, 1980, Angewandte Parasitologie, V21, P6; BUIJS J, 1994, AM J EPIDEMIOL, V140, P839, DOI 10.1093/oxfordjournals.aje.a117332; Burney P, 1997, J ALLERGY CLIN IMMUN, V99, P314, DOI 10.1016/S0091-6749(97)70048-4; CHRISTIE JF, 1993, CLIN EXP IMMUNOL, V92, P125, DOI 10.1111/j.1365-2249.1993.tb05958.x; ELSE KJ, 1994, J EXP MED, V179, P347, DOI 10.1084/jem.179.1.347; GROVE DI, 1982, ALLERGY, V37, P139, DOI 10.1111/j.1398-9995.1982.tb01889.x; GUYATT HL, 1991, T ROY SOC TROP MED H, V85, P778, DOI 10.1016/0035-9203(91)90453-6; HAGEL I, 1993, CLIN EXP IMMUNOL, V94, P80, DOI 10.1111/j.1365-2249.1993.tb05981.x; HAGEL I, 1995, T ROY SOC TROP MED H, V89, P562, DOI 10.1016/0035-9203(95)90109-4; HOLLAND CV, 1995, PARASITOLOGY, V110, P535, DOI 10.1017/S0031182000065252; JARRETT E E E, 1973, Clinical Allergy, V3, P203, DOI 10.1111/j.1365-2222.1973.tb01322.x; JARRETT EEE, 1972, INT ARCH ALLER A IMM, V42, P775, DOI 10.1159/000230657; JOUBERT JR, 1980, S AFR MED J, V57, P409; JOUBERT JR, 1979, S AFR MED J, V56, P599; KING CL, 1993, J IMMUNOL, V150, P1873; LARRICK JW, 1983, J ALLERGY CLIN IMMUN, V71, P184, DOI 10.1016/0091-6749(83)90097-0; LYNCH NR, 1993, J ALLERGY CLIN IMMUN, V92, P404, DOI 10.1016/0091-6749(93)90119-Z; LYNCH NR, 1984, J ALLERGY CLIN IMMUN, V73, P229, DOI 10.1016/S0091-6749(84)80012-3; MARETTA J, 1979, IMMUNOLOGY, V37, P609; MASTERS S, 1985, EPIDEMIOL REV, V7, P49, DOI 10.1093/oxfordjournals.epirev.a036285; MOQBEL R, 1990, CLIN EXP ALLERGY, V20, P611, DOI 10.1111/j.1365-2222.1990.tb02699.x; Muller W A, 1975, Z Gesamte Inn Med, V30, P239; MUTIUS VM, 1994, AM JR ESP CRIT CARE, V149, P358; Nowak D, 1996, EUR RESPIR J, V9, P2541, DOI 10.1183/09031936.96.09122541; Ockert G, 1965, Z Arztl Fortbild (Jena), V59, P850; REVOLTELLA R, 1980, INT ARCH ALLER A IMM, V62, P23, DOI 10.1159/000232480; SMITH HV, 1993, J CLIN IMMUNOASSAY, V16, P131; Trepka Mary Jo, 1996, Reviews on Environmental Health, V11, P119; TURNER KJ, 1980, AUST J EXP BIOL MED, V58, P249, DOI 10.1038/icb.1980.25; WJST M, 1994, ALLERGY, V49, P766, DOI 10.1111/j.1398-9995.1994.tb02100.x	33	76	79	0	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1998	102	3					414	420		10.1016/S0091-6749(98)70129-0	http://dx.doi.org/10.1016/S0091-6749(98)70129-0			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	124ZN	9768582	Bronze			2022-12-18	WOS:000076212800014
J	Peng, ZK; Li, HB; Simons, FER				Peng, ZK; Li, HB; Simons, FER			Immunoblot analysis of salivary allergens in 10 mosquito species with worldwide distribution and the human IgE responses as these allergens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						salivary allergen; antigen; mosquito allergy; immunoblot; Western blot; A-aegypti; A-albopictus; A-vexans; A-togoi; C-pipiens; C-quinquefasciatus; C-tarsalis; A-sinensis; A-triseriatus; C-inornata	AEDES-AEGYPTI; ANTIBODIES; EXTRACTS; ANTIGENS; PROTEINS; APYRASE; VEXANS	Background: Most people develop skin reactions to mosquito bites, however, little is known about mosquito salivary aller gens and the IgE responses to them. Objectives: We sought to identify these allergens and the specific IgE responses the elicit, Methods: Saliva or salivary gland extracts were prepared from 10 mosquito species, including seven species with worldwide distribution: Aedes (AE.) aegypti, Ae. vexans, Ae. albopictus, Ae. togoi, Ae. triseriatus, Culex (Cx.) quinquefasciatus, Cx. pipiens, Cx. tarsalis, Anopheles (An.) sinensis, and Culiseta (Cs.) inornata. Proteins from these preparations were separated by sodium dodecylsulfate-polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes, which were immunoblotted by sequential incubations with human serum, monoclonal anti-human IgE, and enzyme-conjugated goat anti-mouse IgG. Salivary allergens were analyzed by using a pooled serum from subjects allergic to mos quitos. Individual IgE responses to each allergen were evaluated in 12 subjects allergic to mosquitos living in Canada, the United States, and China, as well as in five subjects not allergic to mosquito bites. To study species-shared allergens, the membranes were immunoblotted with two rabbit antibodies specific to recombinant mosquito salivary proteins. Results: Three to sixteen salivary allergens with molecular masses ranging from 16 to 95 kd were found in each species. Both species-shared and species-specific allergens were identified by molecular masses, binding to the two rabbit antibodies, and individual IgE responses to species indigenous to and absent from the regions where the subjects lived. Salivary allergens, especially from Ae. aegypti, Ae. vexans, and Ae. albopictus, elicited higher IgE responses in subjects allergic to mosquitos than in nonallergic subjects. Conclusions: Species-shared and species-specific allergens that cause IgE responses in subjects allergic to mosquitos are immunologically identified, Species-shared allergens are the most important for potential use in diagnosis and immunotherapy.	Univ Manitoba, Fac Med, Allergy & Clin Immunol Sect, Winnipeg, MB, Canada; Univ Manitoba, Fac Med, Dept Immunol, Winnipeg, MB R3E 0W3, Canada; Univ Manitoba, Dept Pediat & Child Hlth, Winnipeg, MB R3T 2N2, Canada	University of Manitoba; University of Manitoba; University of Manitoba	Peng, ZK (corresponding author), MS746A-820 Sherbrook St, Winnipeg, MB R3A 1R9, Canada.							BOORMAN J, 1987, MED VET ENTOMOL, V1, P211, DOI 10.1111/j.1365-2915.1987.tb00346.x; BROWN Alan, 1938, Southern Medical Journal, V31, P590, DOI 10.1097/00007611-193806000-00002; BRUMMERKORVENKONTIO H, 1994, J ALLERGY CLIN IMMUN, V93, P551, DOI 10.1016/S0091-6749(94)70066-4; CHAMPAGNE DE, 1995, P NATL ACAD SCI USA, V92, P694, DOI 10.1073/pnas.92.3.694; CHRISTOPHERS SR, 1960, AEDES AEGYPTI L YELL, P739; FRAZIER CA, 1973, ARCH DERMATOL, V107, P400, DOI 10.1001/archderm.107.3.400; GLUCK JC, 1986, ANN ALLERGY, V56, P492; HUDSON A, 1960, SCIENCE, V131, P1730, DOI 10.1126/science.131.3415.1730; HUDSON ANNE, 1958, MOSQUITO NEWS, V18, P249; JAMES AA, 1991, MOL BIOCHEM PARASIT, V44, P245, DOI 10.1016/0166-6851(91)90010-4; KILLBY VA, 1967, AM J TROP MED HYG, V16, P374, DOI 10.4269/ajtmh.1967.16.374; Knight K.L., 1977, CATALOG MOSQUITOES W, Vxi; Larsen JN, 1996, J ALLERGY CLIN IMMUN, V97, P577; LELONG M, 1986, Allergie et Immunologie (Paris), V18, P25; LILIJA G, 1990, ALLERGY, V45, P436; MCCORMACK DR, 1995, ANN ALLERG ASTHMA IM, V74, P39; MELLANBY K, 1946, NATURE, V158, P554, DOI 10.1038/158554c0; OKA K, 1989, Journal of Dermatology (Tokyo), V16, P341; PENG Z, 1998, IN PRESS J ALLERGY C; Peng ZK, 1996, ANN ALLERG ASTHMA IM, V77, P238, DOI 10.1016/S1081-1206(10)63262-0; PENG ZK, 1995, ANN ALLERG ASTHMA IM, V74, P259; Peng ZK, 1997, J ALLERGY CLIN IMMUN, V100, P192, DOI 10.1016/S0091-6749(97)70224-0; Peng ZK, 1996, INT ARCH ALLERGY IMM, V110, P46, DOI 10.1159/000237309; PENNEYS NS, 1989, ARCH DERMATOL, V125, P219, DOI 10.1001/archderm.125.2.219; RACIOPPI JV, 1987, INSECT BIOCHEM, V17, P503, DOI 10.1016/0020-1790(87)90010-2; REUNALA T, 1994, J ALLERGY CLIN IMMUN, V94, P902, DOI 10.1016/0091-6749(94)90158-9; RIBEIRO JMC, 1984, COMP BIOCHEM PHYS B, V79, P81, DOI 10.1016/0305-0491(84)90081-6; SAVAGE HM, 1994, J AM MOSQUITO CONTR, V10, P440; SHEN HD, 1989, ANN ALLERGY, V63, P143; WOOD DM, 1979, AGR CAN PUBL, V1686, P272; WU CH, 1989, INT ARCH ALLER A IMM, V90, P271, DOI 10.1159/000235036; XU W, 1997, J ALLERGY CLIN IMMUN, V99, pS512; YANG J, 1997, J ALLERGY CLIN IMMUN, V99, P152	33	76	81	0	8	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1998	101	4	1				498	505		10.1016/S0091-6749(98)70357-4	http://dx.doi.org/10.1016/S0091-6749(98)70357-4			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZH469	9564803				2022-12-18	WOS:000073113500012
J	DAmato, G; Liccardi, G; Russo, M; Barber, D; DAmato, M; Carreira, J				DAmato, G; Liccardi, G; Russo, M; Barber, D; DAmato, M; Carreira, J			Clothing is a carrier of cat allergens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ALK,ABELLO GRP,DEPT BIOL INVEST,MADRID,SPAIN	ALK-Abello AS	DAmato, G (corresponding author), HOSP A CARDARELLI,DIV PNEUMOL & ALLERGOL,DEPT CHEST DIS,VIA RIONE SIRIGNANO 10,I-80121 NAPLES,ITALY.		D'Amato, Maria/H-3074-2012; Barber, Domingo/Y-9516-2019	D'Amato, Maria/0000-0002-5906-5701; Barber, Domingo/0000-0002-5488-5700				ENBERG RN, 1993, ANN ALLERGY, V70, P471; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573, DOI 10.1164/ajrccm/147.3.573; LUCZYNSKA CM, 1990, AM REV RESPIR DIS, V141, P361, DOI 10.1164/ajrccm/141.2.361; Tovey ER, 1995, J ALLERGY CLIN IMMUN, V96, P999, DOI 10.1016/S0091-6749(95)70239-3; WOOD RA, 1993, CLIN EXP ALLERGY, V23, P733, DOI 10.1111/j.1365-2222.1993.tb00360.x	5	76	76	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1997	99	4					577	578		10.1016/S0091-6749(97)70088-5	http://dx.doi.org/10.1016/S0091-6749(97)70088-5			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WU274	9111506	Bronze			2022-12-18	WOS:A1997WU27400024
J	Rona, RJ; DuranTauleria, E; Chinn, S				Rona, RJ; DuranTauleria, E; Chinn, S			Family size, atopic disorders in parents, asthma in children, and ethnicity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; wheezing; atopic conditions; family size; familial aggregation	PREVALENCE; REACTIVITY; SYMPTOMS; SIBLINGS; HEALTH; GROWTH; HEIGHT; RISK	Background: Several studies have reported an association between family size and atopic conditions, but few have found an association between asthma and family size. Objective: This study was designed to assess the effect of familial aggregation and sibling number on asthma in children. Methods: Children from 5 to 11 years of age in England and Scotland participated in a study in 1990 or 1991 in which responses to questions on asthma and wheezing in children and atopic conditions in parents were ascertained. Data on 11,924 complete family sets of child, mother, and father in three samples (the ''representative'' samples of England and Scotland and the English ''inner city'' sample) were analyzed. Results: The following factors were highly associated with child's asthma or wheezing: mother's or father's asthma or wheezing (with the same odds ratio [OR], 2.4; 95% confidence interval [CI], 2.0 to 2.9), other atopic condition in mothers and fathers (OR, 1.5; 95% CI, 1.3 to 1.8 and OR, 1.4; 93% CI, 1.2 to 1.7, respectively), and three or more siblings compared with no siblings (OR, 0.5; 95% CI, 0.4 to 0.6). Conclusion: The negative relation between family size and wheezing or asthma indicates a protective effect of number of children sharing an environment at a younp age, The level of association of asthma or wheezing in the parents and the child and the association between the child's asthma or wheezing and other atopic conditions in parents suggest that a general susceptibility and a lung-specific susceptibility are important in the etiology of asthma.			Rona, RJ (corresponding author), UNITED MED & DENT SCH, DIV PUBL HLTH SCI, LONDON SE1 7EH, ENGLAND.		Rona, Roberto J/C-2348-2011	Rona, Roberto/0000-0003-3739-5571				ABDULRAZZAQ YM, 1994, ALLERGY, V49, P737, DOI 10.1111/j.1398-9995.1994.tb02096.x; BENER A, 1992, EUR J EPIDEMIOL, V8, P733, DOI 10.1007/BF00145392; BURNEY PGJ, 1990, BRIT MED J, V300, P1306, DOI 10.1136/bmj.300.6735.1306; BURNEY PGJ, 1992, ASTHMA, P254; BURROWS B, 1995, AM J RESP CRIT CARE, V152, P1497, DOI 10.1164/ajrccm.152.5.7582283; CHINN S, 1994, PAEDIATR PERINAT EP, V8, P90, DOI 10.1111/j.1365-3016.1994.tb00438.x; COOKSON WOCM, 1992, LANCET, V340, P381, DOI 10.1016/0140-6736(92)91468-N; CRANE J, 1994, BRIT MED J, V309, P272, DOI 10.1136/bmj.309.6949.272; DAVIS JB, 1981, THORAX, V36, P185, DOI 10.1136/thx.36.3.185; DOLD S, 1992, ARCH DIS CHILD, V67, P1018, DOI 10.1136/adc.67.8.1018; GOLDING J, 1986, BIRTH 5 STUDY HLTH B, P171; HOPP RJ, 1988, ANN ALLERGY, V61, P184; Jenkins M A, 1993, Paediatr Perinat Epidemiol, V7, P67, DOI 10.1111/j.1365-3016.1993.tb00602.x; MARTINEZ FD, 1994, THORAX, V49, P1189, DOI 10.1136/thx.49.12.1189; MELIA RJW, 1988, BRIT MED J, V296, P1438, DOI 10.1136/bmj.296.6634.1438; MOFFATT F, 1994, LANCET, V343, P1597, DOI 10.1016/S0140-6736(94)93057-0; Osborn A.F., 1984, SOCIAL LIFE BRITAINS; PANHUYSEN CIM, 1995, ALLERGY, V50, P863, DOI 10.1111/j.1398-9995.1995.tb02491.x; PEAT JK, 1994, BMJ-BRIT MED J, V308, P1591, DOI 10.1136/bmj.308.6944.1591; PEPYS J, 1986, J ALLERGY CLIN IMMUN, V78, P959, DOI 10.1016/0091-6749(86)90285-X; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; RONA RJ, 1986, ANN HUM BIOL, V13, P453, DOI 10.1080/03014468600008631; SHAW R, 1994, NEW ZEAL MED J, V107, P387; SMITH JM, 1976, BRIT J DIS CHEST, V70, P73; STODDARD JJ, 1995, AM J EPIDEMIOL, V141, P96, DOI 10.1093/oxfordjournals.aje.a117418; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; VONMUTIUS E, 1994, BRIT MED J, V308, P692, DOI 10.1136/bmj.308.6930.692	27	76	77	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1997	99	4					454	460		10.1016/S0091-6749(97)70070-8	http://dx.doi.org/10.1016/S0091-6749(97)70070-8			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WU274	9111488				2022-12-18	WOS:A1997WU27400006
J	Gainer, JV; Nadeau, JH; Ryder, D; Brown, NJ				Gainer, JV; Nadeau, JH; Ryder, D; Brown, NJ			Increased sensitivity to bradykinin among African Americans	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						bradykinin; angioedema; race; ACE inhibitor; intradermal; wheal; hypertension; kininase II	ANGIOTENSIN-CONVERTING-ENZYME; SKIN BLOOD-FLOW; INTRADERMAL BRADYKININ; HEREDITARY ANGIOEDEMA; HYPERTENSIVE RATS; ACE-INHIBITOR; RESPONSES; HISTAMINE; ENALAPRIL; CAPTOPRIL	Background: Angioedema is a potentially life-threatening side effect of angiotensin-converting enzyme (ACE) inhibitors. Although the mechanism of angioedema is not certain, bradykinin has been implicated in its pathogenesis. Compared with Caucasians, African Americans are at an increased risk of ACE inhibitor-associated angioedema, independent of ACE inhibitor dose or concurrent medications. Because urinary kallikrein levels are decreased in African Americans with hypertension, we hypothesized that endogenous bradykinin levels may be decreased in African Americans and that they therefore may be more sensitive to ACE inhibitor-induced increases in bradykinin or to exogenous bradykinin. Objective: To test this hypothesis, we measured the wheal response to intradermal injection of bradykinin in salt-replete hypertensive and normotensive African Americans and Caucasians. Methods: Two doses of bradykinin, 1 mu g and 10 mu g, were administered on separate days in a randomized, double-blind fashion. Results: Higher bradykinin dose (analysis of variance: F = 38.33, p < 0.001), African American race (analysis of variance: F = 17.90, p < 0.001), and hypertension (analysis of variance: F = 4.37, p = 0.05) were all associated with an increased wheal response to bradykinin. Conclusion: These data provide additional support for racial differences in the kallikrein-kinin system and also implicate abnormalities of the tissue kallikrein-kinin system in essential hypertension.			Gainer, JV (corresponding author), VANDERBILT UNIV,MED CTR,DIV CLIN PHARMACOL,560 MRB-1,23RD AVE,S & PIERCE AVE,NASHVILLE,TN 37232, USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000095] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR 00095-533] Funding Source: Medline; NIGMS NIH HHS [GM-07569-19] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON MW, 1990, J ALLERGY CLIN IMMUN, V85, P856, DOI 10.1016/0091-6749(90)90068-F; BASRAN GS, 1982, LANCET, V1, P935; BROWN N, IN PRESS CLIN PHARM; CRIMI N, 1992, CLIN EXP ALLERGY, V22, P933, DOI 10.1111/j.1365-2222.1992.tb02067.x; CROSSMAN DC, 1988, BRIT J CLIN PHARMACO, V26, P113, DOI 10.1111/j.1365-2125.1988.tb03375.x; DAVIDSON DC, 1994, LANCET, V343, P1575, DOI 10.1016/S0140-6736(94)92978-5; ELLIOT R, 1934, ENDOCRINOLOGY, V18, P462; EMOND C, 1991, AM J PHYSIOL, V260, pF626, DOI 10.1152/ajprenal.1991.260.5.F626; FERNER RE, 1990, BRIT J CLIN PHARMACO, V29, P363, DOI 10.1111/j.1365-2125.1990.tb03649.x; FERNER RE, 1987, BRIT MED J, V294, P1119, DOI 10.1136/bmj.294.6580.1119; FERNER RE, 1989, BRIT J CLIN PHARMACO, V27, P337, DOI 10.1111/j.1365-2125.1989.tb05374.x; FIELDS T, 1983, J ALLERGY CLIN IMMUN, V72, P54, DOI 10.1016/0091-6749(83)90052-0; FULLER RW, 1987, BRIT J CLIN PHARMACO, V23, P88, DOI 10.1111/j.1365-2125.1987.tb03014.x; HALL JM, 1992, PHARMACOL THERAPEUT, V56, P131, DOI 10.1016/0163-7258(92)90016-S; LEVY SB, 1977, J CLIN INVEST, V60, P129, DOI 10.1172/JCI108749; MANNING DC, 1991, CLIN PHARMACOL THER, V50, P721, DOI 10.1038/clpt.1991.212; MARGOLIUS H S, 1987, Journal of Clinical Hypertension, V3, p51S; MCALPINE LG, 1989, BRIT J CLIN PHARMACO, V27, P870, DOI 10.1111/j.1365-2125.1989.tb03452.x; MEGERIAN CA, 1992, LARYNGOSCOPE, V102, P256; OVERLACK A, 1981, HYPERTENSION, V3, P18; POLOSA R, 1993, J ALLERGY CLIN IMMUN, V92, P683, DOI 10.1016/0091-6749(93)90011-4; RAJA SN, 1992, CLIN SCI, V83, P337, DOI 10.1042/cs0830337; ROSCHER AA, 1990, J CARDIOVASC PHARM, V15, pS39, DOI 10.1097/00005344-199015061-00008; SCHAPIRA M, 1983, NEW ENGL J MED, V308, P1050, DOI 10.1056/NEJM198305053081802; SCHULMAN G, 1993, J AM SOC NEPHROL, V3, P1563; WA TCLK, 1989, EUR J CLIN PHARMACOL, V37, P471, DOI 10.1007/BF00558126; WA TCLK, 1992, J PHARM PHARMACOL, V44, P869, DOI 10.1111/j.2042-7158.1992.tb03224.x; WA TCLK, 1993, EUR J CLIN PHARMACOL, V44, P41; WA TCLK, 1993, BRIT J CLIN PHARMACO, V35, P8, DOI 10.1111/j.1365-2125.1993.tb05663.x; WALLENGREN J, 1992, BRIT J DERMATOL, V126, P111, DOI 10.1111/j.1365-2133.1992.tb07806.x; WARREN JB, 1988, BRIT J CLIN PHARMACO, V26, P803, DOI 10.1111/j.1365-2125.1988.tb05324.x; WEIR MR, 1995, HYPERTENSION, V25, P124; WILLIAMS RR, 1988, J CARDIOVASC PHAR S3, V12, pS7; WOODLEYMILLER C, 1989, J HYPERTENS, V7, P865, DOI 10.1097/00004872-198911000-00003	34	76	78	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1996	98	2					283	287		10.1016/S0091-6749(96)70151-3	http://dx.doi.org/10.1016/S0091-6749(96)70151-3			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VC995	8757204				2022-12-18	WOS:A1996VC99500006
J	Shimoda, T; Kohno, S; Takao, A; Fujiwara, C; Matsuse, H; Sakai, H; Watanabe, T; Hara, K; Asai, S				Shimoda, T; Kohno, S; Takao, A; Fujiwara, C; Matsuse, H; Sakai, H; Watanabe, T; Hara, K; Asai, S			Investigation of the mechanism of alcohol induced bronchial asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						bronchial asthma; alcohol; Asians; Caucasians; histamine release; acetaldehyde	ALDEHYDE DEHYDROGENASE; ACETALDEHYDE; POLYMORPHISM; SENSITIVITY; METABOLISM	Background: Many Japanese patients with asthma experience episodes or exacerbation of asthma after alcohol consumption. This phenomenon is not seen in Caucasians and is specific to Asians. This has been thought to be attributable to a difference in alcohol metabolism, in particular the metabolism of acetaldehyde, between Asians and Caucasians. Methods: An oral ethanol challenge rest, a leukocyte histamine release test, and an ELISA for detection of IgE specific to acetaldehyde-human serum albumin conjugate were carried out in 42 adults with bronchial asthma and nine healthy adults. Results: Fifty-five percent of the patients with asthma responded to the ethanol challenge and showed a 20% or greater reduction in forced expiratory volume in 1 second. Blood acetaldehyde and plasma histamine levels were significantly higher in responders than in nonresponders. The leukocyte histamine release test revealed no ethanol-induced histamine release. Acetaldehyde, on the other hand was found to induce histamine release in a volume dependent manner. The histamine release was significantly higher in the asthma group (both responders and nonresponders) than in the healthy control group. ELISA did not detect any IgE specific to acetaldehyde-human serum albumin conjugate. Conclusion: Alcohol-induced bronchial asthma seems to develop as follows. Alcohol elevates blood acetaldehyde levels, which leads to degranulation of mast cells (or basophils). The resultant release of chemical mediators, such as histamine, induces asthma.	SASEBO MUNICIPAL GEN HOSP,SASEBO,JAPAN		Shimoda, T (corresponding author), NAGASAKI UNIV,SCH MED,DEPT INTERNAL MED 2,1-7-1 SAKAMOTO MACHI,NAGASAKI 852,JAPAN.							BRESLIN A B X, 1973, Clinical Allergy, V3, P71, DOI 10.1111/j.1365-2222.1973.tb01311.x; DAHL R, 1986, J ALLERGY CLIN IMMUN, V78, P1126, DOI 10.1016/0091-6749(86)90261-7; DONOHUE TM, 1983, ARCH BIOCHEM BIOPHYS, V220, P239, DOI 10.1016/0003-9861(83)90406-X; EADE NR, 1959, J PHARMACOL EXP THER, V127, P29; GEPPERT EF, 1978, AM REV RESPIR DIS, V118, P135; GOEDDE HW, 1985, ALCOHOL, V2, P383, DOI 10.1016/0741-8329(85)90099-0; GONG H, 1981, CHEST, V80, P167, DOI 10.1378/chest.80.2.167; HARADA S, 1982, Substance and Alcohol Actions-Misuse, V3, P107; HARADA S, 1979, H-S Z PHYSIOL CHEM, V360, P278; HARADA S, 1991, J ANTHROPOL SOC NIP, V99, P123; HARADA S, 1985, ALCOHOL, V2, P391, DOI 10.1016/0741-8329(85)90100-4; IJIRI I, 1974, JPN J STUD ALCOHOL, V9, P35; KUROSAWA M, 1990, J INT MED RES, V18, P435, DOI 10.1177/030006059001800513; MAKINO S, 1993, LIFE SCI MED, P6; MIZOI Y, 1979, PHARMACOL BIOCHEM BE, V10, P303, DOI 10.1016/0091-3057(79)90105-9; MIZOI Y, 1985, ALCOHOL, V2, P393, DOI 10.1016/0741-8329(85)90101-6; MORROWBROWN H, 1987, PRACTITIONER, V231, P584; PIKKARAINEN PH, 1981, J LAB CLIN MED, V97, P631; REED TE, 1976, CAN MED ASSOC J, V115, P851; WOLFF PH, 1972, SCIENCE, V175, P449, DOI 10.1126/science.175.4020.449; WOLFF PH, 1973, AM J HUM GENET, V25, P193; ZEINER AR, 1974, ALCOHOL CLIN EXP RES, V3, P11	22	76	80	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1996	97	1	1				74	84		10.1016/S0091-6749(96)70285-3	http://dx.doi.org/10.1016/S0091-6749(96)70285-3			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TR947	8568140				2022-12-18	WOS:A1996TR94700010
J	WANG, JH; TRIGG, CJ; DEVALIA, JL; JORDAN, S; DAVIES, RJ				WANG, JH; TRIGG, CJ; DEVALIA, JL; JORDAN, S; DAVIES, RJ			EFFECT OF INHALED BECLOMETHASONE DIPROPIONATE ON EXPRESSION OF PROINFLAMMATORY CYTOKINES AND ACTIVATED EOSINOPHILS IN THE BRONCHIAL EPITHELIUM OF PATIENTS WITH MILD ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						BRONCHIAL EPITHELIUM; GM-CSF; IL-8; EOSINOPHIL; BECLOMETHASONE DIPROPIONATE; MILD ASTHMA	COLONY-STIMULATING FACTOR; MAJOR BASIC-PROTEIN; FACTOR GM-CSF; INFLAMMATORY CYTOKINES; MUCOSAL INFLAMMATION; BLOOD EOSINOPHILS; T-CELLS; SURVIVAL; INVITRO; INTERLEUKIN-5	Increasing evidence suggests that cytokines play a role in airway inflammation by attracting and activating inflammatory cells. This may lead to epithelial cell damage and airway hyperresponsiveness. Bronchial provocative concentration of histamine causing a 20% fall in forced expiratory volume in 1 second was measured in patients with mild asthma, and bronchial biopsy specimens were stained for granulocyte-macrophage colony-stimulating factor (GM-CSF, interleukin (IL)-8, and activated eosinophils (EG2) in the bronchial epithelium. The effect of inhaled beclomethasone dipropionate was also assessed in a placebo-controlled double-blind manner. There was a correlation between GM-CSF expression and EG2-staining cells (r = 0.484 p < 0.05) in the epithelium. Provocative concentration of histamine causing a 20% fall in forced expiratory volume in 1 second was correlated with GM-CSF expression (r = -0.462, p < 0.05). Treatment with inhaled beclomethasone dipropionate 500 mu g twice a day led to a significant decrease in both the expression of GM-CSF (p < 0.01) and IL-8 (p < 0.02) and the number of EG2-staining cells (p < 0.01) in the epithelium. The changes in GM-CSF (r = 0.798, p < 0.01) and 11-8 (r = 0.653, p < 0.02) expression were correlated with the changes in EG2-staining cells after treatment. These results suggest that GM-CSF may influence eosinophil activation in the epithelium in vivo and participate in the etiology of bronchial hyperresponsiveness in mild asthma. Also, beclomethasone dipropionate may inhibit eosinophil activation partly by downregulating the expression of GM-CSF and IL-8 in the bronchial epithelium.	UNIV LONDON ST BARTHOLOMEWS HOSP & MED COLL,DEPT RESP MED & ALLERGY,LONDON EC1A 7BE,ENGLAND; UNIV LONDON ST BARTHOLOMEWS HOSP & MED COLL,DEPT IMMUNOCYTOCHEM,LONDON EC1A 7BE,ENGLAND	University of London; Queen Mary University London; University of London; Queen Mary University London								Alam R, 1990, Agents Actions Suppl, V31, P147; ARMITAGE P, 1987, STATISTICAL METHODS; AYARS GH, 1989, AM REV RESPIR DIS, V140, P125; BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; BENNETT JB, 1987, BRIT J DIS CHEST, V81, P252, DOI 10.1016/0007-0971(87)90158-6; BRADDING P, 1993, J IMMUNOL, V151, P3853; BROIDE DH, 1992, J CLIN INVEST, V90, P1414, DOI 10.1172/JCI116008; BURKE LA, 1991, J ALLERGY CLIN IMMUN, V88, P226, DOI 10.1016/0091-6749(91)90333-J; CORRIGAN CJ, 1992, IMMUNOL TODAY, V13, P501, DOI 10.1016/0167-5699(92)90026-4; COX G, 1991, AM J RESP CELL MOL, V4, P525, DOI 10.1165/ajrcmb/4.6.525; DAVIES RJ, 1992, ASTHMA BASIC MECHANI, P143; DENBURG JA, 1991, ACI NEWS, V3, P179; DEVALIA JL, 1993, AM J RESP CELL MOL, V9, P271, DOI 10.1165/ajrcmb/9.3.271; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; DJUKANOVIC R, 1992, AM REV RESPIR DIS, V145, P660; DUNNILL MS, 1960, J CLIN PATHOL, V13, P27, DOI 10.1136/jcp.13.1.27; DUNNILL MS, 1987, PULMONARY PATHOLOGY, P61; FILLEY WV, 1982, LANCET, V2, P11; FRIGAS E, 1981, MAYO CLIN PROC, V56, P345; FUKUDA T, 1990, Japanese Journal of Thoracic Diseases, V28, P1288; HALLSWORTH MP, 1992, IMMUNOLOGY, V75, P382; HOWARTH PH, 1991, EUR RESPIR REV, V1, P276; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745, DOI 10.1164/ajrccm/140.6.1745; JORNES PG, 1993, AM REV RESPIR DIS S, V148, P890; KAY AB, 1992, AM REV RESPIR DIS, V145, pS22, DOI 10.1164/ajrccm/145.2_Pt_2.S22; KITA H, 1991, J EXP MED, V174, P745, DOI 10.1084/jem.174.3.745; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599, DOI 10.1164/arrd.1985.131.4.599; LAMAS AM, 1991, J IMMUNOL, V147, P254; LOZEWICZ S, 1990, THORAX, V45, P12, DOI 10.1136/thx.45.1.12; LOZEWICZ S, 1992, J ALLERGY CLIN IMMUN, V89, P951, DOI 10.1016/0091-6749(92)90217-P; MAKINO S, 1990, INFLAMMATION MEDIATO, P115; MARINI M, 1992, J ALLERGY CLIN IMMUN, V89, P1001, DOI 10.1016/0091-6749(92)90223-O; MOTOJIMA S, 1989, AM REV RESPIR DIS, V139, P801, DOI 10.1164/ajrccm/139.3.801; OBASHI Y, 1992, AM REV RESPIR DIS, V145, P1469; POSTON RN, 1990, MICRO 90 ED, V15, P525; SOLOPERTO M, 1991, AM J PHYSIOL, V260, pL530, DOI 10.1152/ajplung.1991.260.6.L530; SONODA Y, 1989, LEUKEMIA, V3, P14; SOUSA AR, 1993, AM REV RESPIR DIS, V147, P1557, DOI 10.1164/ajrccm/147.6_Pt_1.1557; SPRY CJF, 1992, IMMUNOL TODAY, V13, P384, DOI 10.1016/0167-5699(92)90085-L; TAI PC, 1991, CLIN EXP IMMUNOL, V85, P312; TEPPER RI, 1990, CELL, V62, P457, DOI 10.1016/0092-8674(90)90011-3; WALLEN N, 1991, J IMMUNOL, V147, P3490; WELLER PF, 1992, CLIN IMMUNOL IMMUNOP, V62, pS55, DOI 10.1016/0090-1229(92)90041-L	43	76	78	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1994	94	6	1				1025	1034		10.1016/0091-6749(94)90121-X	http://dx.doi.org/10.1016/0091-6749(94)90121-X			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PY230	7798535				2022-12-18	WOS:A1994PY23000011
J	MICAN, JAM; ARORA, N; BURD, PR; METCALFE, DD				MICAN, JAM; ARORA, N; BURD, PR; METCALFE, DD			PASSIVE CUTANEOUS ANAPHYLAXIS IN MOUSE SKIN IS ASSOCIATED WITH LOCAL ACCUMULATION OF INTERLEUKIN-6 MESSENGER-RNA AND IMMUNOREACTIVE INTERLEUKIN-6 PROTEIN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						MAST CELL; IGE; MURINE; SKIN; IL-6; ALLERGY; IMMEDIATE HYPERSENSITIVITY	TUMOR-NECROSIS-FACTOR; MACROPHAGE INFLAMMATORY PROTEIN-1; FC-EPSILON-RI; MAST-CELLS; FACTOR-ALPHA; LATE PHASE; IGE; IL-6; EXPRESSION; CYTOKINES	We used a BALB/c model of passive cutaneous anapkylaxis (PCA), an IgE-mediated, mast cell-dependent reaction, to demonstrate the early production of the proinflammatory cytokine interleukin-6 (IL-6) mRNA and protein product. Northern blot analysis detects IL-6 mRNA 1, and 2 hours after antigen challenge (dinitrophenyl30-40 human serum albumin [DNP30-40-HSA]) and in situ hybridization reveals that it is primarily cells with round-to-oval nuclei within the dermis (1 to 3 per high-power field) expressing IL-6 mRNA. Immunohistochemistry revealed perinuclear and cytoplasmic staining for immunoreactive IL-6 in mononuclear dermal cells and also cells within the basal keratinocyte layer. Injection of recombinant murine IL-6 (rmIL-6) either systemically or locally during antidinitrophenyl IgE skin sensitization resulted in increased vasopermeability at the PCA site after DNP30-40-HSA. However, this increased permeabiliiy was not associated with a change in the character of the cellular infiltrate at the PCA site 8 hours later. Although the specific role of IL-6 in the generation of the allergic response remains unknown, its detection during PCA unequivocally demonstrates that IL-6 be considered one of the mediators identified in inflammation that follows allergic reactions.			MICAN, JAM (corresponding author), NIAID,CLIN INVEST LAB,MAST CELL PHYSIOL SECT,BLDG 10 2C410,BETHESDA,MD 20892, USA.							AKIRA S, 1990, FASEB J, V4, P2860, DOI 10.1096/fasebj.4.11.2199284; BLANTON RA, 1989, P NATL ACAD SCI USA, V86, P1273, DOI 10.1073/pnas.86.4.1273; BOCHNER BS, 1990, J ALLERGY CLIN IMMUN, V86, P830, DOI 10.1016/S0091-6749(05)80143-5; BURD PR, 1987, J IMMUNOL, V139, P3126; BURD PR, 1989, J EXP MED, V170, P245, DOI 10.1084/jem.170.1.245; COSTA JJ, 1990, FASEB J, V4, pA1943; DINARELLO CA, 1988, FASEB J, V2, P108, DOI 10.1096/fasebj.2.2.3277884; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GAULDIE J, 1990, J IMMUNOL, V144, P3804; GORDON JR, 1991, J EXP MED, V174, P103, DOI 10.1084/jem.174.1.103; GURISH MF, 1991, J IMMUNOL, V146, P1527; HELLE M, 1988, EUR J IMMUNOL, V18, P957, DOI 10.1002/eji.1830180619; HIRANO T, 1990, IMMUNOL TODAY, V11, P443, DOI 10.1016/0167-5699(90)90173-7; HIRANO T, 1986, NATURE, V324, P73, DOI 10.1038/324073a0; HOHMAN RJ, 1991, TRANSPL P, V23, P2907; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P557; HULTSCH T, 1990, J IMMUNOL, V144, P1; ISHIMI Y, 1990, J IMMUNOL, V145, P3297; KIMER I, 1989, INT ARCH ALLER A IMM, V89, P149; KUPPER TS, 1989, ANN NY ACAD SCI, V557, P454; LAGUNOFF D, 1983, ANNU REV PHARMACOL, V23, P331, DOI 10.1146/annurev.pa.23.040183.001555; LARRICK JW, 1989, J LEUKOCYTE BIOL, V45, P429, DOI 10.1002/jlb.45.5.429; LEE CE, 1992, J ALLERGY CLIN IMMUN, V89, P1010, DOI 10.1016/0091-6749(92)90224-P; LEMANSKE RF, 1988, ALLERGY PRINCIPLES P, P229; LOTZ M, 1988, J EXP MED, V167, P1253, DOI 10.1084/jem.167.3.1253; MARTIN CA, 1991, CELL IMMUNOL, V135, P245, DOI 10.1016/0008-8749(91)90269-H; MIZEL SB, 1989, FASEB J, V3, P2379, DOI 10.1096/fasebj.3.12.2676681; NUSSENBLATT RB, 1986, PROG ALLERGY, V38, P130; PIONA A, 1991, Journal of Allergy and Clinical Immunology, V87, P157, DOI 10.1016/0091-6749(91)91357-Y; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; RILEY JF, 1968, EXPERIENTIA, V24, P1237, DOI 10.1007/BF02146643; RILEY JF, 1966, LANCET, V2, P1457; SAUDER DN, 1984, J INVEST DERMATOL, V82, P605, DOI 10.1111/1523-1747.ep12261439; SCHINDLER R, 1990, BLOOD, V75, P40; SEHGAL PB, 1990, MOL BIOL MED, V7, P117; SMITH PL, 1980, J CLIN INVEST, V66, P1072, DOI 10.1172/JCI109936; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; WANG JM, 1990, IMMUNOLOGY, V71, P364; WERSHIL BK, 1991, J CLIN INVEST, V87, P446, DOI 10.1172/JCI115016; WILSON SD, 1990, J IMMUNOL, V145, P2745; WILSON SD, 1988, J IMMUNOL, V141, P1563; WOLPE SD, 1989, FASEB J, V3, P2565, DOI 10.1096/fasebj.3.14.2687068; ZACHARIAE COC, 1990, J EXP MED, V171, P2177, DOI 10.1084/jem.171.6.2177	44	76	77	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1992	90	5					815	824		10.1016/0091-6749(92)90107-D	http://dx.doi.org/10.1016/0091-6749(92)90107-D			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JZ319	1430707				2022-12-18	WOS:A1992JZ31900013
J	LLERENA, LP; FERNANDEZCALDAS, E; GRACIA, LRC; LOCKEY, RF				LLERENA, LP; FERNANDEZCALDAS, E; GRACIA, LRC; LOCKEY, RF			SENSITIZATION TO BLOMIA-TROPICALIS AND LEPIDOGLYPHUS-DESTRUCTOR IN DERMATOPHAGOIDES SPP-ALLERGIC INDIVIDUALS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						SPECIFIC IGE; STORAGE MITES; ALLERGIC DISEASES; CARTAGENA; COLOMBIA	HOUSE DUST MITES; STORAGE MITES; CROSS-REACTIVITY; FARMING POPULATION; PTERONYSSINUS; FARMERS; ASTHMA; EUROGLYPHUS; DISEASE; ECOLOGY	Serum was collected from 77 atopic subjects from Cartagena, Colombia, who had a positive skin test (greater-than-or-equal-to 3 mm) to either Dermatophagoides farinae (Df) (73) or D. pteronyssinus (Dp) (70). Twenty-nine healthy volunteers with negative allergy histories and negative skin tests were used as control subjects. RAST and RAST-inhibition assays were used to study the prevalence of specific IgE to Blomia tropicalis (Bt), Lepidoglyphus destructor (Ld), and Df. RAST results were considered positive when a serum bound greater-than-or-equal-to 1% of the total counts added; 69 atopic subjects (89.6%) were positive to Df, 66 (85.5%) to Bt, and 46 subjects (59.7%) were positive to Ld. RAST results, analyzed by regression analysis, revealed the following correlation coefficients: Df versus Bt, r = 0.59; Df versus Ld, r = 0.44; and Bt versus Ld, r = 0.52. RAST-inhibition assays with a serum pool of 11 individuals highly allergic to all three mites (mean specific IgE to all mites, greater-than-or-equal-to 18.2 percent total counts bound) demonstrated considerable cross-reactivity between Bt and Ld and moderate cross-reactivity between Df and Bt and Ld. Bt, Df, and Ld possess unique, as well as common, allergens. Sensitization to Bt and Ld is very common in mite-allergic individuals in Cartagena, Colombia.	UNIV CARTAGENA,IMMUNOL LAB,CARTAGENA,COLOMBIA; UNIV S FLORIDA,COLL MED,DIV ALLERGY & CLIN IMMUNOL,TAMPA,FL 33612; JAMES A HALEY VET AFFAIRS HOSP,TAMPA,FL	Universidad de Cartagena; State University System of Florida; University of South Florida; US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital								ARLIAN LG, 1989, IMMUNOL ALLERGY CLIN, V9, P339; BLAINEY AD, 1989, J ALLERGY CLIN IMMUN, V84, P296, DOI 10.1016/0091-6749(89)90411-9; BLAINEY AD, 1988, THORAX, V43, P697, DOI 10.1136/thx.43.9.697; BONER AL, 1989, ANN ALLERGY, V63, P82; CARABALLO L, 1990, Journal of Allergy and Clinical Immunology, V85, P248; CARABALLO LR, 1990, TISSUE ANTIGENS, V35, P182, DOI 10.1111/j.1399-0039.1990.tb01777.x; CROCE J, 1988, NER ALLERGYN P, V9, P342; CUTHBERT OD, 1990, CLIN REV ALLERG, V8, P69; FERNANDEZ-CALDAS E, 1991, Journal of Allergy and Clinical Immunology, V87, P322, DOI 10.1016/0091-6749(91)92013-Q; FERNANDEZCALDAS E, 1990, ALLERGY PROC, V11, P263, DOI 10.2500/108854190778879710; FERNANDEZCALDAS E, 1991, ALLERGEN IMMUNOTHERA, P69; FERNANDEZCALDAS E, 1991, CLIN ALLERGY, P69; FERNANDEZCALDAS E, 1988, NER ALLERGY P, V9, P283; GABRIEL M, 1982, CLIN ALLERGY, V12, P157, DOI 10.1111/j.1365-2222.1982.tb01635.x; GRIFFIN P, 1989, J ALLERGY CLIN IMMUN, V84, P108, DOI 10.1016/0091-6749(89)90184-X; HART BJ, 1990, CLIN EXP ALLERGY, V20, P203, DOI 10.1111/j.1365-2222.1990.tb02669.x; HUGHES AM, 1961, TECH B, V9; HURTADO I, 1987, ANN ALLERGY, V59, P128; IVERSEN M, 1990, CLIN EXP ALLERGY, V20, P211, DOI 10.1111/j.1365-2222.1990.tb02670.x; IVERSEN M, 1990, ALLERGY, V45, P81, DOI 10.1111/j.1398-9995.1990.tb00462.x; KORSGAARD J, 1985, ALLERGOL IMMUNOPATH, V13, P143; Krantz GW, 1978, MANUAL ACAROLOGY, P77; LESKINEN L, 1987, EUR J RESPIR DIS, V71, P101; LUCZYNSKA CM, 1990, CLIN EXP ALLERGY, V20, P403, DOI 10.1111/j.1365-2222.1990.tb02801.x; MIYAMOTO T, 1969, J ALLERGY, V44, P228, DOI 10.1016/0021-8707(69)90089-6; MULLA MS, 1980, ACAROS COLOMBIA BION; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V80, P755, DOI 10.1016/S0091-6749(87)80261-0; PLATTSMILLS TAE, 1989, J ALLERGY CLIN IMMUN, V83, P416, DOI 10.1016/0091-6749(89)90128-0; SANCHEZ M, 1990, Journal of Allergy and Clinical Immunology, V85, P185; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; SILTON RP, 1991, J ALLERGY CLIN IMMUN, V88, P595, DOI 10.1016/0091-6749(91)90153-F; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TANDON N, 1990, ANN ALLERGY, V64, P155; TERHO EO, 1985, ALLERGY, V40, P23, DOI 10.1111/j.1398-9995.1985.tb04150.x; VANHAGEHAMSTEN M, 1990, INT ARCH ALLER A IMM, V91, P186, DOI 10.1159/000235113; VANHAGEHAMSTEN M, 1988, ALLERGY, V43, P545, DOI 10.1111/j.1398-9995.1988.tb00926.x; VANHAGEHAMSTEN M, 1989, J ALLERGY CLIN IMMUN, V83, P581, DOI 10.1016/0091-6749(89)90069-9; VANHAGEHAMSTEN M, 1987, CLIN ALLERGY, V17, P417; VANHAGEHAMSTEN M, 1987, CLIN ALLERGY, V17, P23; VANHAGEHAMSTEN M, 1985, CLIN ALLERGY, V15, P555; VOORHURST M, 1969, HOUSE DUST ATOPY HOU; WRAITH DG, 1979, CLIN ALLERGY, V9, P545, DOI 10.1111/j.1365-2222.1979.tb00478.x; 1988, HIMAT PEAM016 I COL	43	76	82	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1991	88	6					943	950		10.1016/0091-6749(91)90252-J	http://dx.doi.org/10.1016/0091-6749(91)90252-J			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GW262	1744365				2022-12-18	WOS:A1991GW26200016
J	DEGROOT, H; GOEI, KGH; VANSWIETEN, P; AALBERSE, RC				DEGROOT, H; GOEI, KGH; VANSWIETEN, P; AALBERSE, RC			AFFINITY PURIFICATION OF A MAJOR AND A MINOR ALLERGEN FROM DOG EXTRACT - SEROLOGIC ACTIVITY OF AFFINITY-PURIFIED CAN-FI AND OF CAN-FI-DEPLETED EXTRACT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							FEL-D-I; MONOCLONAL-ANTIBODIES; CROSS-REACTIVITY; IGE ANTIBODIES; DANDER EXTRACT; HISTAMINE; ASSAY; DUST; IDENTIFICATION; SPECIFICITY	Most dog-allergic patients react to a major 25 kd component on sodium dodecyl sulfate blots, Can f I (Ag 13). We initially raised monoclonal antibodies (Cf-3 and Cf-2) reactive with IgE-binding components distinct from Can f I. After a slight modification, we immunized other strains of mice and produced monoclonal antibodies coded Cf-1a and Cf-1b reactive with Can f I. We affinity purified the allergens, Can f I and "dog allergen 2" with Cf-1a and Cf-2 ascites, respectively, and house dust-rich dog dander. Comparison of purified Can f I with dog saliva in RAST demonstrated that Can f I is a potent allergen for most dog-allergic patients (average response, 70%). After depletion of dog saliva of Can f I, a slightly lower contribution for Can f I was found, but the overall results supported the conclusion that Can f I is a major allergen in dog saliva. Comparison of purified dog allergen 2 with dog dander in RAST demonstrated that dog allergen 2 is less important for dog-allergic patients (average response, 23%). We radiolabeled the purified allergens and developed assays to measure Can f I and dog allergen 2 in allergen extracts and dust samples. Dog saliva was a strong allergen source, dog urine and feces contained very little of the allergens, and both allergens were found to a variable degree in the nine dog breeds tested.	NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,CENT LAB,POB 9406,1006 AK AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,EXPTL & CLIN IMMUNOL LAB,AMSTERDAM,NETHERLANDS	University of Amsterdam								AALBERSE RC, 1981, J ALLERGY CLIN IMMUN, V68, P356, DOI 10.1016/0091-6749(81)90133-0; AALBERSE RC, 1986, J IMMUNOL METHODS, V87, P51, DOI 10.1016/0022-1759(86)90343-1; ASTALDI GCB, 1980, J IMMUNOL, V125, P1411; BRANDT R, 1980, INT ARCH ALLER A IMM, V61, P361, DOI 10.1159/000232463; CALKHOVEN PG, 1987, ALLERGY, V42, P382, DOI 10.1111/j.1398-9995.1987.tb02225.x; CHAPMAN MD, 1988, J IMMUNOL, V140, P812; DEGROOT H, 1988, J ALLERGY CLIN IMMUN, V82, P778, DOI 10.1016/0091-6749(88)90079-6; DYBENDAL T, 1989, ALLERGY, V44, P401, DOI 10.1111/j.1398-9995.1989.tb04171.x; FORD AW, 1989, CLIN EXP ALLERGY, V19, P183, DOI 10.1111/j.1365-2222.1989.tb02362.x; HAAHTELA T, 1981, ALLERGY, V36, P251, DOI 10.1111/j.1398-9995.1981.tb01571.x; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; KJELLMAN B, 1983, ALLERGY, V38, P65, DOI 10.1111/j.1398-9995.1983.tb00858.x; KOHLER G, 1976, EUR J IMMUNOL, V6, P511, DOI 10.1002/eji.1830060713; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; LARSEN JN, 1988, J ALLERGY CLIN IMMUN, V82, P318, DOI 10.1016/0091-6749(88)90002-4; LEITERMANN K, 1984, J ALLERGY CLIN IMMUN, V74, P147, DOI 10.1016/0091-6749(84)90278-1; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; LOWENSTEIN H, 1981, ALLERGOLOGIE, V4, P265; LUCZYNSKA CM, 1990, AM REV RESPIR DIS, V141, P361, DOI 10.1164/ajrccm/141.2.361; MCLEAN AC, 1980, ANN ALLERGY, V45, P199; OHMAN JL, 1975, J ALLERGY CLIN IMMUN, V57, P560; PIERCE J, 1977, ANAL BIOCHEM, V81, P478, DOI 10.1016/0003-2697(77)90723-0; PLATTSMILLS TAE, 1989, J ALLERGY CLIN IMMUN, V83, P416, DOI 10.1016/0091-6749(89)90128-0; SCHOU C, 1990, Journal of Allergy and Clinical Immunology, V85, P170; SIRAGANIAN RP, 1975, J IMMUNOL METHODS, V7, P283, DOI 10.1016/0022-1759(75)90025-3; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P383, DOI 10.1016/0003-2697(74)90093-1; VANDERZEE JS, 1988, J ALLERGY CLIN IMMUN, V81, P884, DOI 10.1016/0091-6749(88)90946-3; VARGA JM, 1972, INT ARCH ALLER A IMM, V42, P438, DOI 10.1159/000230624; VIANDER M, 1983, INT ARCH ALLER A IMM, V71, P252, DOI 10.1159/000233399; WOOD RA, 1988, AM REV RESPIR DIS, V137, P358, DOI 10.1164/ajrccm/137.2.358	30	76	82	1	7	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1991	87	6					1056	1065		10.1016/0091-6749(91)92150-Y	http://dx.doi.org/10.1016/0091-6749(91)92150-Y			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FR066	2045611	Bronze			2022-12-18	WOS:A1991FR06600004
J	BORISH, L; TAMIR, R; ROSENWASSER, LJ				BORISH, L; TAMIR, R; ROSENWASSER, LJ			INTRAVENOUS DESENSITIZATION TO BETA-LACTAM ANTIBIOTICS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											BORISH, L (corresponding author), NEW ENGLAND MED CTR,DEPT MED,DIV ALLERGY,171 HARRISON AVE,BOSTON,MA 02111, USA.							ADKINSON NF, 1980, MANUAL CLIN IMMUNOLO, P822; BENVENISTE J, 1972, J EXP MED, V136, P1356, DOI 10.1084/jem.136.6.1356; CAMERON W, 1984, ANN ALLERGY, V53, P455; Cochrane C G, 1973, Adv Immunol, V16, P185, DOI 10.1016/S0065-2776(08)60298-9; DELAFUENTE JC, 1979, ANN ALLERGY, V43, P337; DIXON FJ, 1958, ARCH PATHOL, V65, P18; ELIOPOULOS GM, 1982, ANN INTERN MED, V97, P755, DOI 10.7326/0003-4819-97-5-755; GOREVIC PD, 1981, J ALLERGY CLIN IMMUN, V68, P267, DOI 10.1016/0091-6749(81)90150-0; GRAYBILL JR, 1974, SOUTH MED J, V67, P62, DOI 10.1097/00007611-197401000-00017; GREEN GR, 1971, J ALLERGY CLIN IMMUN, V48, P331, DOI 10.1016/0091-6749(71)90079-0; GREEN GR, 1967, ANN INTERN MED, V67, P235, DOI 10.7326/0003-4819-67-2-235; GRIECO MH, 1964, ANN INTERN MED, V60, P203; HENSEN PM, 1971, J EXP MED S, V134, pS554; HENSON PM, 1971, J EXP MED, V133, P554, DOI 10.1084/jem.133.3.554; KNIKER WT, 1968, J EXP MED, V127, P119, DOI 10.1084/jem.127.1.119; LAWLEY TJ, 1985, NEW ENGL J MED, V312, P1328; LEVINE BB, 1969, J ALLERGY, V43, P231, DOI 10.1016/0021-8707(69)90066-5; LEVINE BB, 1967, ANN NY ACAD SCI, V145, P298, DOI 10.1111/j.1749-6632.1967.tb50227.x; LEVINE BB, 1973, J INFECT DIS, V128, P364; NEU HC, 1982, ANN INTERN MED, V97, P408, DOI 10.7326/0003-4819-97-3-408; NEWMAN KA, 1981, AM J MED, V70, P423, DOI 10.1016/0002-9343(81)90783-X; PARKER CW, 1972, CRITICAL REV TOXICOL, V1, P261; PECK SM, 1948, JAMA-J AM MED ASSOC, V138, P631, DOI 10.1001/jama.1948.02900090005002; ROBERTS AE, 1953, AMA ARCH IND HYG OCC, V8, P340; SIEGEL BB, 1964, J ALLERGY, V35, P488, DOI 10.1016/0021-8707(64)90080-2; SOLLEY GO, 1982, J ALLERGY CLIN IMMUN, V69, P238, DOI 10.1016/0091-6749(82)90105-1; STARK B J, 1984, Journal of Allergy and Clinical Immunology, V73, P112; SULLIVAN TJ, 1981, J ALLERGY CLIN IMMUN, V68, P171, DOI 10.1016/0091-6749(81)90180-9; SULLIVAN TJ, 1982, J ALLERGY CLIN IMMUN, V69, P275, DOI 10.1016/S0091-6749(82)80004-3; VANDELLEN RG, 1971, J ALLERGY, V47, P230, DOI 10.1016/S0091-6749(71)80468-2; WENDEL GD, 1985, NEW ENGL J MED, V312, P1229, DOI 10.1056/NEJM198505093121905	31	76	78	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1987	80	3	1				314	319		10.1016/0091-6749(87)90037-6	http://dx.doi.org/10.1016/0091-6749(87)90037-6			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K1036	3040836	Bronze			2022-12-18	WOS:A1987K103600013
J	SEARS, MR; REA, HH				SEARS, MR; REA, HH			PATIENTS AT RISK FOR DYING OF ASTHMA - NEW-ZEALAND EXPERIENCE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									GREEN LANE HOSP,AUCKLAND 3,NEW ZEALAND		SEARS, MR (corresponding author), UNIV OTAGO,SCH MED,DEPT MED,POB 913,DUNEDIN,NEW ZEALAND.							BEAGLEHOLE R, IN PRESS NZ MED J; Breslow N. E., 1980, IARC SCI PUBLICATION, V32; JACKSON RT, 1982, BRIT MED J, V285, P771, DOI 10.1136/bmj.285.6344.771; REA HH, 1986, THORAX, V41, P833, DOI 10.1136/thx.41.11.833; REA HH, 1987, NEW ZEAL MED J, V100, P10; ROTHWELL RPG, 1987, NEW ZEAL MED J, V100, P199; SEARS MR, 1986, AM J EPIDEMIOL, V124, P1004, DOI 10.1093/oxfordjournals.aje.a114470; SEARS MR, 1986, BRIT MED J, V293, P1342, DOI 10.1136/bmj.293.6558.1342; SEARS MR, 1985, NEW ZEAL MED J, V98, P271; SEARS MR, 1985, NEW ZEAL MED J, V98, P765; SEARS MR, 1987, BRIT MED J, V294, P477, DOI 10.1136/bmj.294.6570.477; SEARS MR, 1986, ARCH DIS CHILD, V61, P6, DOI 10.1136/adc.61.1.6; SEARS MR, IN PRESS J ALLERGY C; STRUNK RC, 1985, JAMA-J AM MED ASSOC, V254, P1193; SUTHERLAND DC, 1984, NEW ZEAL MED J, V97, P845; WILSON JD, 1981, LANCET, V1, P1235; 1985, VITAL HLTH STATISTIC	17	76	76	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1987	80	3	2	S			477	481		10.1016/0091-6749(87)90079-0	http://dx.doi.org/10.1016/0091-6749(87)90079-0			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K1037	3624702	Bronze			2022-12-18	WOS:A1987K103700027
J	KATZ, HR; STEVENS, RL; AUSTEN, KF				KATZ, HR; STEVENS, RL; AUSTEN, KF			HETEROGENEITY OF MAMMALIAN MAST-CELLS DIFFERENTIATED INVIVO AND INVITRO	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT RHEUMATOL & IMMUNOL,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital					NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM035984] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022531, R37AI022531] Funding Source: NIH RePORTER; NIADDK NIH HHS [AM-35984, AM-35907] Funding Source: Medline; NIAID NIH HHS [AI-22531] Funding Source: Medline	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BEAVEN MA, 1983, J PHARMACOL EXP THER, V224, P620; BEFUS AD, 1982, J IMMUNOL, V128, P2475; CAULFIELD JP, 1980, J CELL BIOL, V85, P299, DOI 10.1083/jcb.85.2.299; CHURCH MK, 1982, J IMMUNOL, V129, P2116; CROWLE PK, 1982, FED PROC, V41, P581; CROWLE PK, 1983, EXP CELL BIOL, V51, P130; CZARNETZKI BM, 1983, INT ARCH ALLER A IMM, V71, P161, DOI 10.1159/000233381; DENBURG JA, 1980, IMMUNOLOGY, V41, P195; DUBUSKE L, 1984, J IMMUNOL, V133, P1535; ENERBACK L, 1966, ACTA PATHOL MIC SC, V66, P303, DOI 10.1111/apm.1966.66.3.303; ENERBACK L, 1966, ACTA PATHOL MIC SC, V66, P289, DOI 10.1111/apm.1966.66.3.289; GRANT JA, 1974, J IMMUNOL, V112, P897; HAIG DM, 1982, NATURE, V300, P188, DOI 10.1038/300188a0; ISHIZAKA T, 1972, J IMMUNOL, V108, P1000; KATZ HR, 1985, J IMMUNOL, V134, P2617; KATZ HR, 1983, P NATL ACAD SCI-BIOL, V80, P5916, DOI 10.1073/pnas.80.19.5916; KITAMURA Y, 1977, NATURE, V268, P442, DOI 10.1038/268442a0; LAGUNOFF D, 1976, ARCH BIOCHEM BIOPHYS, V173, P554, DOI 10.1016/0003-9861(76)90292-7; LEWIS RA, 1975, J IMMUNOL, V114, P87; LEWIS RA, 1982, J IMMUNOL, V129, P1627; MAYRHOFER G, 1981, INT ARCH ALLER A IMM, V64, P320, DOI 10.1159/000232710; MAYRHOFER G, 1979, CELL IMMUNOL, V47, P312, DOI 10.1016/0008-8749(79)90341-1; MENCIAHUERTA JM, 1983, J IMMUNOL, V130, P1885; MENCIAHUERTA JM, 1983, J IMMUNOL, V131, P2958; METCALFE DD, 1979, J CLIN INVEST, V64, P1537, DOI 10.1172/JCI109613; OGAWA M, 1983, P NATL ACAD SCI-BIOL, V80, P4494, DOI 10.1073/pnas.80.14.4494; PATERSON NAM, 1976, J IMMUNOL, V117, P1356; PEARCE FL, 1982, J IMMUNOL, V128, P2481; PRETLOW TG, 1970, AM J PATHOL, V61, P323; RAZIN E, 1981, P NATL ACAD SCI-BIOL, V78, P5793, DOI 10.1073/pnas.78.9.5793; RAZIN E, 1983, J EXP MED, V157, P189, DOI 10.1084/jem.157.1.189; RAZIN E, 1984, J IMMUNOL, V132, P1479; RAZIN E, 1982, J BIOL CHEM, V257, P7229; RAZIN E, 1982, P NATL ACAD SCI-BIOL, V79, P4665, DOI 10.1073/pnas.79.15.4665; RUITENBER EJ, 1976, NATURE, V264, P258, DOI 10.1038/264258a0; SAGE H, 1979, J BIOL CHEM, V254, P9893; SCHRADER JW, 1981, J IMMUNOL, V126, P452; SCHULMAN ES, 1982, J IMMUNOL, V129, P2662; SCHWARTZ LB, 1981, J IMMUNOL, V126, P2071; SCHWARTZ LB, 1981, J BIOL CHEM, V256, P1939; SELDIN DC, P NATL ACAD SCI US; SELDIN DC, J BIOL CHEM; SELDIN DC, 1985, P URTICARIAS; SREDNI B, 1983, J IMMUNOL, V131, P915; STEVENS RL, 1983, J BIOL CHEM, V258, P5977; TADAKORO K, 1983, J EXP MED, V158, P857; TAS J, 1977, J HISTOCHEM CYTOCHEM, V25, P1058, DOI 10.1177/25.9.71326; VARTIO T, 1981, J BIOL CHEM, V256, P471; WONG GHW, 1982, P NATL ACAD SCI-BIOL, V79, P6989, DOI 10.1073/pnas.79.22.6989; WOODBURY RG, 1978, P NATL ACAD SCI USA, V75, P2785, DOI 10.1073/pnas.75.6.2785; WOODBURY RG, 1978, BIOCHEMISTRY-US, V17, P4298, DOI 10.1021/bi00613a029; WOODBURY RG, 1981, METHOD ENZYMOL, V80, P588; WOODBURY RG, 1982, IMMUNOLOGY, V46, P487; YURT RW, 1977, J BIOL CHEM, V252, P518	54	76	76	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	2					250	259		10.1016/0091-6749(85)90638-4	http://dx.doi.org/10.1016/0091-6749(85)90638-4			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	APE89	2410474	Bronze			2022-12-18	WOS:A1985APE8900002
J	PIENKOWSKI, MM; NORMAN, PS; LICHTENSTEIN, LM				PIENKOWSKI, MM; NORMAN, PS; LICHTENSTEIN, LM			SUPPRESSION OF LATE-PHASE SKIN REACTIONS BY IMMUNOTHERAPY WITH RAGWEED EXTRACT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHNS HOPKINS UNIV,GOOD SAMARITAN HOSP,SCH MED,DIV CLIN IMMUNOL,5601 LOCH RAVEN BLVD,BALTIMORE,MD 21239	Johns Hopkins University					NIAID NIH HHS [AI-04866, AI-20136, AI-08270] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI008270, R37AI004866, R01AI004866, R37AI008270, P50AI020136] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADKINSON NF, 1980, MANUAL CLIN IMMUNOLO, P794; Askenase P W, 1977, Prog Allergy, V23, P199, DOI 10.1159/000314242; BEHRENS BL, 1984, AM REV RESPIR DIS, V130, P1134; CRETICOS PS, 1984, J ALLERGY CLIN IMMUN, V73, P94, DOI 10.1016/0091-6749(84)90490-1; DVORAK HF, 1974, LAB INVEST, V31, P111; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P261, DOI 10.1016/0091-6749(82)90062-8; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P160, DOI 10.1016/0091-6749(82)90037-9; GRONNEBERG R, 1981, ALLERGY, V36, P201, DOI 10.1111/j.1398-9995.1981.tb01835.x; HAMILTON RG, 1979, J IMMUNOL, V122, P1073; KALINER MM, 1984, J ALLERGY CLIN IMMUN, V73, P311, DOI 10.1016/0091-6749(84)90401-9; LICHTENS.LM, 1968, AM J MED, V44, P514, DOI 10.1016/0002-9343(68)90052-1; METZGER WJ, 1983, J ALLERGY CLIN IMMUN, V71, P119, DOI 10.1016/0091-6749(83)90245-2; NACLERIO R, 1984, Journal of Allergy and Clinical Immunology, V73, P148; NORMAN PS, 1982, PROG ALLERGY, V32, P318; PATTERSON R, 1978, ALLERGY PRINCIPLES P, P877; ROCKLIN RE, 1983, J ALLERGY CLIN IMMUN, V72, P323, DOI 10.1016/0091-6749(83)90492-X; SHERMAN WILLIAM B., 1940, JOUR ALLERGY, V11, P225, DOI 10.1016/S0021-8707(40)90568-8; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; STARR MS, 1970, INT ARCH ALLER A IMM, V38, P514, DOI 10.1159/000230304; TAYLOR WW, 1978, J ALLERGY CLIN IMMUN, V61, P283, DOI 10.1016/0091-6749(78)90048-9; VALENTINE MD, 1984, J ALLERGY CLIN IMMUN, V73, P299, DOI 10.1016/0091-6749(84)90397-X; WARNER JO, 1978, LANCET, V2, P912	22	76	77	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	5					729	734		10.1016/0091-6749(85)90679-7	http://dx.doi.org/10.1016/0091-6749(85)90679-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AUU34	4056258				2022-12-18	WOS:A1985AUU3400013
J	SIMONS, FER; SIMONS, KJ; FRITH, EM				SIMONS, FER; SIMONS, KJ; FRITH, EM			THE PHARMACOKINETICS AND ANTIHISTAMINIC OF THE H-1 RECEPTOR ANTAGONIST HYDROXYZINE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV MANITOBA,FAC MED,DEPT PEDIAT,ALLERGY & CLIN IMMUNOL SECT,WINNIPEG R3T 2N2,MANITOBA,CANADA; UNIV MANITOBA,FAC PHARM,WINNIPEG R3T 2N2,MANITOBA,CANADA	University of Manitoba; University of Manitoba								BAIN WA, 1951, ANALYST, V76, P573, DOI 10.1039/an9517600573; BARAF CS, 1976, CURR THER RES CLIN E, V19, P32; BAUMGARTNER TG, 1979, AM J HOSP PHARM, V36, P1660, DOI 10.1093/ajhp/36.12.1660; BIERMAN CW, 1975, JAMA-J AM MED ASSOC, V234, P295; BIERMAN CW, 1980, PEDIATRIC PHARM THER, P213; BRANDON ML, 1980, ANN ALLERGY, V45, P8; BURNS JJ, 1963, ANN NY ACAD SCI, V104, P881, DOI 10.1111/j.1749-6632.1963.tb57090.x; COOK J, 1980, BRIT J PHARMACOL, V69, P579, DOI 10.1111/j.1476-5381.1980.tb07907.x; COOK TJ, 1973, J ALLERGY CLIN IMMUN, V51, P71, DOI 10.1016/S0091-6749(73)80002-8; Douglas W. W., 1980, PHARMACOL BASIS THER, P609; DUNDAS E, 1961, J ALLERGY, V32, P1, DOI 10.1016/0021-8707(61)90032-6; FOUDA HG, 1979, J PHARM SCI, V68, P1456, DOI 10.1002/jps.2600681134; FOWLE ASE, 1971, EUR J CLIN PHARMACOL, V3, P215, DOI 10.1007/BF00565009; GALANT SP, 1973, J ALLERGY CLIN IMMUN, V51, P11, DOI 10.1016/0091-6749(73)90003-1; GIBALDI M, 1982, PHARMACOKINETICS, P1; GOTH A, 1978, ALLERGY PRINCIPLES P, P454; HEURICH A, 1972, RESPIRATION, V29, P135, DOI 10.1159/000192865; KLEIN GL, 1980, ANN ALLERGY, V44, P142; MAGERA BE, 1981, PEDIATRICS, V67, P280; MATTHEWS CN, 1973, BRIT J DERMATOL, V88, P279; PONG SF, 1974, J PHARM SCI, V63, P1527, DOI 10.1002/jps.2600631008; REINBERG A, 1965, J ALLERGY, V36, P273, DOI 10.1016/0021-8707(65)90086-9; RHOADES RB, 1975, J ALLERGY CLIN IMMUN, V55, P180, DOI 10.1016/0091-6749(75)90014-7; SCHAAF L, 1979, J ALLERGY CLIN IMMUN, V63, P129, DOI 10.1016/0091-6749(79)90203-3; SUMMERS R, 1981, J ALLERGY CLIN IMMUN, V67, P456, DOI 10.1016/0091-6749(81)90099-3; WAGNER JG, 1976, ARZNEIMITTEL-FORSCH, V26, P105; WONG L, 1981, J ALLERGY CLIN IMMUN, V67, P223, DOI 10.1016/0091-6749(81)90065-8; YAMAOKA K, 1978, J PHARMACOKINET BIOP, V6, P547, DOI 10.1007/BF01062109	28	76	78	1	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	1					69	75		10.1016/0091-6749(84)90486-X	http://dx.doi.org/10.1016/0091-6749(84)90486-X			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SB990	6141198	Bronze			2022-12-18	WOS:A1984SB99000010
J	KAUFFMAN, HF; BEAUMONT, F; MEURS, H; VANDERHEIDE, S; DEVRIES, K				KAUFFMAN, HF; BEAUMONT, F; MEURS, H; VANDERHEIDE, S; DEVRIES, K			COMPARISON OF ANTIBODY MEASUREMENTS AGAINST ASPERGILLUS-FUMIGATUS BY MEANS OF DOUBLE-DIFFUSION AND ENZYME-LINKED IMMUNOSORBENT-ASSAY (ELISA)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									STATE UNIV HOSP GRONINGEN,INTERNAL MED CLIN,DEPT PULM,9713 EZ GRONINGEN,NETHERLANDS	University of Groningen	KAUFFMAN, HF (corresponding author), STATE UNIV HOSP GRONINGEN,INTERNAL MED CLIN,DEPT ALLERGOL,9713 EZ GRONINGEN,NETHERLANDS.							BARDANA EJ, 1974, ANN NY ACAD SCI, V221, P64, DOI 10.1111/j.1749-6632.1974.tb28200.x; BUSH RK, 1982, CLIN ALLERGY, V20, P29; GREENBERGER PA, 1982, J LAB CLIN MED, V99, P289; HOEHNE JH, 1973, CHEST, V63, P177, DOI 10.1378/chest.63.2.177; HOMMEL M, 1976, NOUV PRESSE MED, V5, P2789; KAUFFMAN HF, 1980, INT ARCH ALLER A IMM, V62, P252, DOI 10.1159/000232521; KAUFFMANN HF, 1980, INT ARCH ALLER A IMM, V62, P265, DOI 10.1159/000232522; LONGBOTTOM JL, 1964, J PATHOL BACTERIOL, V88, P141, DOI 10.1002/path.1700880119; MALO JL, 1977, THORAX, V32, P254, DOI 10.1136/thx.32.3.254; MALO JL, 1981, CLIN ALLERGY, V11, P333, DOI 10.1111/j.1365-2222.1981.tb01603.x; MANTYJARVI RA, 1980, CLIN ALLERGY, V10, P187, DOI 10.1111/j.1365-2222.1980.tb02096.x; MARX JJ, 1982, J ALLERGY CLIN IMMUN, V70, P109, DOI 10.1016/0091-6749(82)90237-8; OUCHTERLONY O, 1953, ACTA PATHOL MIC SC, V32, P231; ROSENBERG M, 1977, ANN INTERN MED, V86, P405, DOI 10.7326/0003-4819-86-4-405; SCHWARTZ RH, 1981, J ALLERGY CLIN IMMUN, V68, P290, DOI 10.1016/0091-6749(81)90154-8; SEPULVEDA R, 1979, CLIN ALLERGY, V9, P359, DOI 10.1111/j.1365-2222.1979.tb02494.x; VOLLER A, 1976, B WORLD HEALTH ORGAN, V53, P55	17	76	76	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	72	3					255	261		10.1016/0091-6749(83)90029-5	http://dx.doi.org/10.1016/0091-6749(83)90029-5			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RH938	6411795				2022-12-18	WOS:A1983RH93800005
J	CHANYEUNG, M				CHANYEUNG, M			IMMUNOLOGICAL AND NON-IMMUNOLOGIC MECHANISMS IN ASTHMA DUE TO WESTERN RED CEDAR (THUJA-PLICATA)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											CHANYEUNG, M (corresponding author), UNIV BRITISH COLUMBIA,VANCOUVER GEN HOSP,DEPT MED,VANCOUVER V5Z 1G1,BC,CANADA.							BEAVEN MA, 1972, CLIN CHIM ACTA, V37, P91, DOI 10.1016/0009-8981(72)90419-6; BERRENS L, 1974, ANN NY ACAD SCI, V221, P153, DOI 10.1111/j.1749-6632.1974.tb28213.x; BERRENS L, 1972, INT ARCH ALLER A IMM, V43, P347, DOI 10.1159/000230850; BOUSHEY HA, 1980, AM REV RESPIR DIS, V121, P389; BRYANT D H, 1975, Clinical Allergy, V5, P145, DOI 10.1111/j.1365-2222.1975.tb01847.x; BRYANT DH, 1976, CLIN ALLERGY, V6, P533; CHANYEUNG M, 1982, AM J MED, V72, P411, DOI 10.1016/0002-9343(82)90497-1; CHANYEUNG M, 1978, J OCCUP ENVIRON MED, V20, P323; CHANYEUNG M, 1980, J ALLERGY CLIN IMMUN, V65, P333, DOI 10.1016/0091-6749(80)90209-2; CHANYEUNG M, 1973, AM REV RESPIR DIS, V108, P1094; COCKCROFT DW, 1979, AM REV RESPIR DIS, V120, P1053; Hugli T E, 1978, Adv Immunol, V26, P1, DOI 10.1016/S0065-2776(08)60228-X; LAM S, 1979, J ALLERGY CLIN IMMUN, V63, P28, DOI 10.1016/0091-6749(79)90158-1; LAM S, UNPUB RELATIONSHIP T; TSE KS, CLIN ALLERGY; WARREN CPW, 1978, THORAX, V33, P315, DOI 10.1136/thx.33.3.315; 1973, PHS NIOSH78215 PUBL	17	76	76	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	70	1					32	37		10.1016/0091-6749(82)90198-1	http://dx.doi.org/10.1016/0091-6749(82)90198-1			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NY715	6177724	Bronze			2022-12-18	WOS:A1982NY71500009
J	FERGUSON, AC; MURRAY, AB; TZE, WJ				FERGUSON, AC; MURRAY, AB; TZE, WJ			SHORT STATURE AND DELAYED SKELETAL MATURATION IN CHILDREN WITH ALLERGIC DISEASE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV BRITISH COLUMBIA, DEPT PEDIAT, DIV ALLERGY, VANCOUVER V6T 1W5, BC, CANADA; UNIV BRITISH COLUMBIA, DEPT PEDIAT, DIV ENDOCRINOL, VANCOUVER V6T 1W5, BC, CANADA	University of British Columbia; University of British Columbia				Ferguson, Alexander C./0000-0002-3143-5619				Cohen MB, 1940, AM J DIS CHILD, V60, P1058, DOI 10.1001/archpedi.1940.02000050042005; COHEN MB, 1948, J ALLERGY, V19, P165, DOI 10.1016/0021-8707(48)90049-5; DAWSON B, 1969, LANCET, V1, P827; FAIRSHTER RD, 1977, J ALLERGY CLIN IMMUN, V59, P243, DOI 10.1016/0091-6749(77)90157-9; FAIRSHTER RD, 1979, J ALLERGY CLIN IMMUN, V63, P39, DOI 10.1016/0091-6749(79)90160-X; FALLIERS CJ, 1961, J ALLERGY, V32, P420, DOI 10.1016/0021-8707(61)90020-X; FALLIERS CJ, 1963, AM J DIS CHILD, V105, P127, DOI 10.1001/archpedi.1963.02080040129002; FISH JE, 1980, J ALLERGY CLIN IMMUN, V65, P154, DOI 10.1016/0091-6749(80)90201-8; GOULD JB, 1980, PEDIATRICS, V65, P713; GROSSMAN J, 1975, J ALLERGY CLIN IMMUN, V55, P49, DOI 10.1016/S0091-6749(75)80007-8; HAUSPIE R, 1977, J ALLERGY CLIN IMMUN, V59, P200, DOI 10.1016/0091-6749(77)90150-6; LEBOVITZ HE, 1973, ENDOCRINOLOGY, P150; MCNICOL KN, 1973, BRIT MED J, V4, P7, DOI 10.1136/bmj.4.5883.7; MORRIS HG, 1975, PEDIATR RES, V9, P579, DOI 10.1203/00006450-197507000-00005; MURRAY AB, 1976, LANCET, V2, P197; SANDERS SS, 1969, BRIT MED J, V3, P25, DOI 10.1136/bmj.3.5661.25; SHELHAMER JH, 1980, J ALLERGY CLIN IMMUN, V66, P52, DOI 10.1016/0091-6749(80)90138-4; SMITH DW, 1977, GROWTH ITS DISORDERS, P1; SNYDER RD, 1967, CLIN PEDIATR, V6, P389, DOI 10.1177/000992286700600705; SPOCK A, 1965, ANN ALLERGY, V23, P608; STENNETT RG, 1969, C J PUBLIC HEALTH, V60, P465; STERLING K, 1979, NEW ENGL J MED, V300, P173, DOI 10.1056/NEJM197901253000405; STUART HC, 1946, AM J PUBLIC HEALTH, V36, P1365; SULLIVAN CE, 1981, LANCET, V1, P862; SZEZLIK A, 1977, ACTA ALLERGOL, V32, P382, DOI 10.1111/j.1398-9995.1977.tb01362.x; TANNER JM, 1970, ARCH DIS CHILD, V45, P755, DOI 10.1136/adc.45.244.755; TONKIN SL, 1979, PEDIATRICS, V63, P261; TOWNLEY RG, 1975, J ALLERGY CLIN IMMUN, V56, P427, DOI 10.1016/0091-6749(75)90061-5; TZE WJ, 1976, J PEDIATR-US, V88, P565, DOI 10.1016/S0022-3476(76)80007-8; VANMETRE TE, 1959, J ALLERGY, V30, P103, DOI 10.1016/0021-8707(59)90079-6; ZWILLICH CW, 1981, AM REV RESPIR DIS, V124, P158; 1979, LANCET, V1, P25	32	76	79	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	69	5					461	466		10.1016/0091-6749(82)90122-1	http://dx.doi.org/10.1016/0091-6749(82)90122-1			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NP934	7076986				2022-12-18	WOS:A1982NP93400009
J	GRIFFIN, MP; MCFADDEN, ER; INGRAM, RH				GRIFFIN, MP; MCFADDEN, ER; INGRAM, RH			AIRWAY COOLING IN ASTHMATIC AND NON-ASTHMATIC SUBJECTS DURING NASAL AND ORAL BREATHING	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									BRIGHAM & WOMENS HOSP,SHIPLEY INST MED,BOSTON,MA 02115; PETER BENT BRIGHAM HOSP,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School					NHLBI NIH HHS [HL-17873, HL-07010] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRESLIN FJ, 1980, J APPL PHYSIOL, V48, P619, DOI 10.1152/jappl.1980.48.4.619; BRISCOE WA, 1958, J CLIN INVEST, V37, P1279, DOI 10.1172/JCI103715; CHEN W Y, 1981, Physiologist, V24, P28; COLE P, 1954, J Laryngol Otol, V68, P295, DOI 10.1017/S0022215100049690; COLE P, 1953, J Laryngol Otol, V67, P669, DOI 10.1017/S0022215100049161; DEAL EC, 1979, J APPL PHYSIOL, V46, P484, DOI 10.1152/jappl.1979.46.3.484; DEAL EC, 1978, J APPL PHYSIOL, V45, P238, DOI 10.1152/jappl.1978.45.2.238; DEAL EC, 1979, J APPL PHYSIOL, V46, P467, DOI 10.1152/jappl.1979.46.3.467; DEAL EC, 1979, J APPL PHYSIOL, V46, P476, DOI 10.1152/jappl.1979.46.3.476; DUBOIS AB, 1956, J CLIN INVEST, V35, P327, DOI 10.1172/JCI103282; DUBOIS AB, 1956, J CLIN INVEST, V35, P322, DOI 10.1172/JCI103281; FANTA CH, 1980, AM REV RESPIR DIS, V122, P381; GRIFFIN MP, THORAX; INGLESTEDT S, 1956, ACTA OTOLARYNGOL S S, V131, P1; NIIMIAA V, 1980, RESPIR PHYSL, V42, P61; Saibene F, 1965, Boll Soc Ital Biol Sper, V41, P1550; SAIBENE F, 1978, PFLUG ARCH EUR J PHY, V378, P65, DOI 10.1007/BF00581959; SAKETKHOO K, 1979, J APPL PHYSIOL, V46, P369, DOI 10.1152/jappl.1979.46.2.369; SHTURMANELLSTEIN R, 1978, AM REV RESPIR DIS, V118, P65; TAKAGI Y, 1969, ANN OTO RHINOL LARYN, V78, P40, DOI 10.1177/000348946907800104; 1962, AM REV RESPIR DIS, V85, P762	21	76	78	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	69	4					354	359		10.1016/0091-6749(82)90145-2	http://dx.doi.org/10.1016/0091-6749(82)90145-2			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NL280	7069070				2022-12-18	WOS:A1982NL28000004
J	SMITH, JA; MANSFIELD, LE; DESHAZO, RD; NELSON, HS				SMITH, JA; MANSFIELD, LE; DESHAZO, RD; NELSON, HS			EVALUATION OF THE PHARMACOLOGIC INHIBITION OF THE IMMEDIATE AND LATE CUTANEOUS REACTION TO ALLERGEN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									FITZSIMONS ARMY MED CTR,ALLERGY IMMUNOL SERV,AURORA,CO 80045									AUSTEN KF, 1975, AM REV RESPIR DIS, V112, P423; CARLSSON SA, 1969, ACTA PHYSIOL SCAND, V77, P449, DOI 10.1111/j.1748-1716.1969.tb04589.x; DESHAZO RD, 1979, J IMMUNOL, V122, P692; DOLOVICH J, 1972, J ALLERGY CLIN IMMUN, V49, P43, DOI 10.1016/0091-6749(72)90122-4; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; DRAZEN JM, 1978, AM REV RESPIR DIS, V117, P479; HUTCHCROFT BJ, 1979, J ALLERGY CLIN IMMUN, V63, P376, DOI 10.1016/0091-6749(79)90209-4; ISHIZAKA T, 1972, J IMMUNOL, V108, P513; LICHTENSTEIN LM, 1975, J PHARMACOL EXP THER, V192, P441; NEWBALL HH, 1975, NATURE, V254, P635, DOI 10.1038/254635a0; PHANUPHAK P, 1978, CLIN ALLERGY, V8, P429, DOI 10.1111/j.1365-2222.1978.tb01493.x; ROBERTSON DG, 1974, J ALLERGY CLIN IMMUN, V54, P244, DOI 10.1016/0091-6749(74)90067-0; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; SOLOMON LM, 1968, J INVEST DERMATOL, V51, P280, DOI 10.1038/jid.1968.128; UMEMOTO L, 1976, J ALLERGY CLIN IMMUN, V58, P60, DOI 10.1016/0091-6749(76)90107-X; UMEMOTO L, 1977, ANN ALLERGY, V38, P101; VANE JR, 1971, NATURE, V268, P231; VAUGHAN WT, 1924, SOUTH MED J, V17, P749; Walker I C, 1917, J Med Res, V35, P487; WASSERMAN SI, 1974, J IMMUNOL, V112, P351	20	76	76	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	65	2					118	121		10.1016/0091-6749(80)90195-5	http://dx.doi.org/10.1016/0091-6749(80)90195-5			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JF199					2022-12-18	WOS:A1980JF19900006
J	KAY, AB				KAY, AB			ROLE OF THE EOSINOPHIL	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											KAY, AB (corresponding author), UNIV EDINBURGH, SCH MED, DEPT PATHOL, EDINBURGH EH8 9AG, MIDLOTHIAN, SCOTLAND.							ANDERSON RGW, 1977, NATURE, V270, P695, DOI 10.1038/270695a0; ANWAR ARE, 1977, J IMMUNOL, V119, P976; ANWAR ARE, 1977, NATURE, V269, P522, DOI 10.1038/269522a0; ANWAR ARE, 1978, J IMMUNOL, V121, P1245; ANWAR ARE, 1979, J IMMUNOL, V122, P628; ANWAR ARE, UNPUBLISHED; ARCHER GT, 1965, BIOCHIM BIOPHYS ACTA, V99, P96, DOI 10.1016/S0926-6593(65)80010-8; BASS DA, 1975, J CLIN INVEST, V55, P1229, DOI 10.1172/JCI108041; BRYANT DH, 1977, CLIN ALLERGY, V7, P211, DOI 10.1111/j.1365-2222.1977.tb01445.x; BRYANT DH, 1977, CLIN ALLERGY, V7, P219, DOI 10.1111/j.1365-2222.1977.tb01446.x; BUFFONI F, 1966, PHARMACOL REV, V18, P1163; BUTTERWORTH AE, 1975, NATURE, V256, P727, DOI 10.1038/256727a0; BUTTERWORTH AE, 1979, J IMMUNOL, V122, P221; BUTTERWORTH AE, 1977, J IMMUNOL, V118, P2230; CAPRON A, 1975, NATURE, V253, P474, DOI 10.1038/253474a0; CAPRON M, 1978, J IMMUNOL, V121, P2518; CLARK RAF, 1975, J EXP MED, V142, P1462, DOI 10.1084/jem.142.6.1462; DARWIN C, 1872, ORIGIN SPECIES, P162; DEAN DA, 1974, AM J TROP MED HYG, V23, P420, DOI 10.4269/ajtmh.1974.23.420; DECHATELET LR, 1977, BLOOD, V50, P525; GLEICH GJ, 1976, J CLIN INVEST, V57, P633, DOI 10.1172/JCI108319; GOETZL EJ, 1975, P NATL ACAD SCI USA, V72, P4123, DOI 10.1073/pnas.72.10.4123; GOETZL EJ, 1976, MOL BIOL ASPECTS ACU, P417; GROVE DI, 1975, MED J AUSTRALIA, V1, P336, DOI 10.5694/j.1326-5377.1975.tb111423.x; GROVE DI, 1977, J EXP MED, V145, P755, DOI 10.1084/jem.145.3.755; GUPTA S, 1976, BLOOD, V48, P755; JONES DG, 1976, IMMUNOLOGY, V31, P333; KATER LA, 1976, J CLIN INVEST, V57, P1173, DOI 10.1172/JCI108385; KAY AB, 1971, J IMMUNOL, V107, P899; KAY AB, 1976, BRIT J HAEMATOL, V33, P313, DOI 10.1111/j.1365-2141.1976.tb03546.x; KAY AB, 1970, CLIN EXP IMMUNOL, V6, P75; KAY AB, 1971, J EXP MED, V133, P602, DOI 10.1084/jem.133.3.602; KAY AB, 1976, IMMUNOLOGY, V30, P83; KAY AB, CLIN EXP IMMUNOL; MAHMOUD AAF, 1975, J EXP MED, V142, P805, DOI 10.1084/jem.142.4.805; MAHMOUD AAF, 1973, J EXP MED, V137, P1526, DOI 10.1084/jem.137.6.1526; MARCHALONIS JJ, 1977, IMMUNITY EVOLUTION; MCKEAN JR, UNPUBLISHED; MCLAREN DJ, 1978, PARASITOLOGY, V77, P313, DOI 10.1017/S0031182000050277; MCLAREN DJ, 1977, CLIN EXP IMMUNOL, V30, P105; OLSSON I, 1974, BLOOD, V44, P235, DOI 10.1182/blood.V44.2.235.235; RAMALHOPINTO FJ, 1978, J EXP MED, V147, P147, DOI 10.1084/jem.147.1.147; RILEY JF, 1959, MAST CELLS, P5; SHER A, 1977, J IMMUNOL, V119, P722; SMITHERS SR, 1969, PROC R SOC SER B-BIO, V171, P483, DOI 10.1098/rspb.1969.0007; TAI PC, 1976, CLIN EXP IMMUNOL, V24, P415; TAUBER AI, 1976, BLOOD, V48, P968; TAYLOR MG, 1976, J HELMINTHOL, V50, P1, DOI 10.1017/S0022149X00028753; TURNBULL LW, 1977, IMMUNOLOGY, V32, P57; TURNBULL LW, 1976, IMMUNOLOGY, V31, P797; VADAS MA, 1979, J IMMUNOL, V122, P1228; WASSERMAN SI, 1975, J IMMUNOL, V114, P645; ZEIGER RS, 1974, PEDIATR RES, V8, P421, DOI 10.1203/00006450-197404000-00488	53	76	76	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	64	2					90	104		10.1016/0091-6749(79)90042-3	http://dx.doi.org/10.1016/0091-6749(79)90042-3			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HG426	458057				2022-12-18	WOS:A1979HG42600002
J	INCAUDO, G; SCHATZ, M; PATTERSON, R; ROSENBERG, M; YAMAMOTO, F; HAMBURGER, RN				INCAUDO, G; SCHATZ, M; PATTERSON, R; ROSENBERG, M; YAMAMOTO, F; HAMBURGER, RN			ADMINISTRATION OF LOCAL-ANESTHETICS TO PATIENTS WITH A HISTORY OF PRIOR ADVERSE REACTION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									USN,REG MED CTR,CTR CLIN INVEST,SAN DIEGO,CA 92134; USN,DEPT MED,MED CTR,REG,SAN DIEGO,CA 92134; NORTHWESTERN UNIV,MCGRAW MED CTR,DEPT MED,ALLERGY IMMUNOL SECT,CHICAGO,IL 60611; UNIV CALIF SAN DIEGO,SCH MED,DEPT PEDIAT,DIV PEDIAT IMMUNOL & ALLERGY,SAN DIEGO,CA 92103	United States Department of Defense; United States Navy; United States Department of Defense; United States Navy; Northwestern University; University of California System; University of California San Diego	INCAUDO, G (corresponding author), USN,NAVAL REGIONAL MED CTR,DEPT PEDIAT,SAN DIEGO,CA 92134, USA.							Adriani J, 1972, Int Anesthesiol Clin, V10, P127, DOI 10.1097/00004311-197201010-00011; ADRIANI J, 1970, ANESTH ANALG, V49, P182; ALDRETE JA, 1969, J AMER MED ASSOC, V207, P356, DOI 10.1001/jama.207.2.356; ALDRETE TA, 1970, ANAESTH ANALG, V49, P173; BOOTH BH, 1972, ALLERGIC DISEASES DI, P63; CUTTING W, 1967, HDB PHARMACOLOGY, P498; DESWARTE RD, 1972, ALLERGIC DISEASES DI, P393; EYRE, 1971, LANCET, V1, P264; GAUL LE, 1955, ANESTHESIOLOGY, V16, P606, DOI 10.1097/00000542-195507000-00016; LEDON MA, 1971, JADA, V82, P366; LEHNER T, 1971, LANCET, V1, P1245; LEVINE BB, 1969, J ALLERGY, V43, P231, DOI 10.1016/0021-8707(69)90066-5; LEVINE BB, 1966, ANNU REV MED, V17, P23, DOI 10.1146/annurev.me.17.020166.000323; NELSON HS, 1977, ADV ASTHMA ALLERGIES, V4, P32; NOBLE DS, 1961, LANCET, V2, P1436; PARKER CW, 1975, NEW ENGL J MED, V292, P957, DOI 10.1056/NEJM197505012921806; ROTHMAN S, 1945, J INVEST DERMATOL, V6, P191, DOI 10.1038/jid.1945.15; SADOVE MS, 1952, JAMA-J AM MED ASSOC, V148, P17, DOI 10.1001/jama.1952.02930010019004; SIEGAL S, 1958, J ALLERGY, V29, P329, DOI 10.1016/0021-8707(58)90038-8; WALDMAN HB, 1967, J AM DENT ASSOC, V74, P747, DOI 10.14219/jada.archive.1967.0111; WELLINS SL, 1969, ORAL SURG ORAL MED O, V28, P761, DOI 10.1016/0030-4220(69)90425-3	21	76	77	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	61	5					339	345		10.1016/0091-6749(78)90057-X	http://dx.doi.org/10.1016/0091-6749(78)90057-X			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EY714	641268				2022-12-18	WOS:A1978EY71400011
J	OHMAN, JL; KENDALL, S; LOWELL, FC				OHMAN, JL; KENDALL, S; LOWELL, FC			IGE ANTIBODY TO CAT ALLERGENS IN AN ALLERGIC POPULATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MASSACHUSETTS GEN HOSP,MED SERV,ALLERGY UNIT,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School								AAS K, 1971, J ALLERGY CLIN IMMUN, V48, P134, DOI 10.1016/0091-6749(71)90008-X; AHLSTEDT S, 1974, CLIN ALLERGY, V4, P131, DOI 10.1111/j.1365-2222.1974.tb01370.x; APOLD J, 1974, Clinical Allergy, V4, P401, DOI 10.1111/j.1365-2222.1974.tb01401.x; BERG T, 1976, INT ARCH ALLER A IMM, V51, P471, DOI 10.1159/000231621; BERG T, 1971, INT ARCH ALLER A IMM, V40, P770, DOI 10.1159/000230461; BRANDT R, 1973, INT ARCH ALLER A IMM, V45, P447, DOI 10.1159/000231062; BRYANT D H, 1975, Clinical Allergy, V5, P145, DOI 10.1111/j.1365-2222.1975.tb01847.x; EVANS R, 1972, J ALLERGY CLIN IMMUN, V49, P285, DOI 10.1016/0091-6749(72)90096-6; FAGERBERG E, 1970, INT ARCH ALLER A IMM, V39, P301, DOI 10.1159/000230356; GLEICH GJ, 1975, J ALLERGY CLIN IMMUN, V55, P346, DOI 10.1016/0091-6749(75)90006-8; HENDERSON LL, 1975, J ALLERGY CLIN IMMUN, V55, P10, DOI 10.1016/S0091-6749(75)80003-0; HOFFMAN DR, 1974, J ALLERGY CLIN IMMUN, V54, P165, DOI 10.1016/0091-6749(74)90053-0; IPSEN J, 1970, BANCROFTS INTRO BIOS, P79; JOHANSSON SG, 1971, INT ARCH ALLER A IMM, V41, P443, DOI 10.1159/000230538; OHMAN JL, 1976, CLIN ALLERGY, V6, P419, DOI 10.1111/j.1365-2222.1976.tb01926.x; OHMAN JL, 1976, J ALLERGY CLIN IMMUN, V57, P560, DOI 10.1016/0091-6749(76)90007-5; OHMAN JL, 1973, J ALLERGY CLIN IMMUN, V52, P231, DOI 10.1016/0091-6749(73)90061-4; OHMAN JL, 1974, J IMMUNOL, V113, P1668; VARGA JM, 1972, INT ARCH ALLER A IMM, V42, P438, DOI 10.1159/000230624	19	76	78	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	60	5					317	323		10.1016/0091-6749(77)90112-9	http://dx.doi.org/10.1016/0091-6749(77)90112-9			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EA243	72087	Bronze			2022-12-18	WOS:A1977EA24300008
J	LEIFERMAN, KM; GLEICH, GJ				LEIFERMAN, KM; GLEICH, GJ			CROSS-REACTIVITY OF IGE ANTIBODIES WITH POLLEN ALLERGENS .1. ANALYSES OF VARIOUS SPECIES OF GRASS POLLENS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MAYO CLIN & MAYO FDN,DEPT MED,ROCHESTER,MN 55901; MAYO CLIN & MAYO FDN,DEPT IMMUNOL,ROCHESTER,MN 55901; MAYO CLIN & MAYO FDN,DEPT MICROBIOL,ROCHESTER,MN 55901; MAYO CLIN & MAYO FDN,SCH MED,ALLERGIC DIS RES LAB,ROCHESTER,MN 55901	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic								AUGUSTIN R, 1959, IMMUNOLOGY, V2, P148; BAER H, 1974, J ALLERGY CLIN IMMUN, V54, P157, DOI 10.1016/0091-6749(74)90052-9; DIXON WJ, 1969, INTRO STATISTICAL AN, P222; FAGERBERG E, 1970, INT ARCH ALLER A IMM, V39, P301, DOI 10.1159/000230356; FEINBERG JG, 1960, INT ARCH ALLER A IMM, V16, P1; GLEICH GJ, 1976, J ALLERGY CLIN IMMUN, V58, P31, DOI 10.1016/0091-6749(76)90104-4; GLEICH GJ, 1974, J ALLERGY CLIN IMMUN, V53, P158, DOI 10.1016/0091-6749(74)90004-9; Hitchcock AS., 1950, MANUAL GRASSES US; MALLEY A, 1962, J ALLERGY, V33, P84, DOI 10.1016/0021-8707(62)90067-9; MARSH DG, 1970, J ALLERGY, V46, P107, DOI 10.1016/0021-8707(70)90078-X; POHL R, 1968, GRASSES; WIDE L, 1967, LANCET, V2, P1105; WODEHOUSE RP, 1955, INT ARCH ALLER A IMM, V6, P65, DOI 10.1159/000228150; YUNGINGER JW, 1972, J ALLERGY CLIN IMMUN, V50, P109, DOI 10.1016/0091-6749(72)90006-1; YUNGINGER JW, 1973, J CLIN INVEST, V52, P1268, DOI 10.1172/JCI107294	15	76	77	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	58	1					129	139		10.1016/0091-6749(76)90148-2	http://dx.doi.org/10.1016/0091-6749(76)90148-2			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	BX744	956553				2022-12-18	WOS:A1976BX74400002
J	WARREN, P; CHERNIACK, RM; TSE, KS				WARREN, P; CHERNIACK, RM; TSE, KS			HYPERSENSITIVITY REACTIONS TO GRAIN DUST	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV MANITOBA, FAC MED, MRC, DEPT MED, GRP ALLERGY RES, WINNIPEG R3E OW3, MANITOBA, CANADA; HLTH SCI CTR, CLIN INVEST UNIT, WINNIPEG R3E OW3, MANITOBA, CANADA; UNIV MANITOBA, FAC MED, DEPT IMMUNOL, MRC, GRP ALLERGY RES, WINNIPEG R3E OW3, MANITOBA, CANADA	University of Manitoba; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Manitoba								BATES DV, 1950, CLIN SCI, V9, P17; BOOIJ-NOORD H, 1972, Clinical Allergy, V2, P43, DOI 10.1111/j.1365-2222.1972.tb01267.x; CADE JF, 1971, CLIN SCI, V40, P381, DOI 10.1042/cs0400381; CHANYEUNG M, 1971, CAN MED ASSOC J, V105, P56; CHERNIACK RM, 1972, AM REV RESPIR DIS, V106, P38, DOI 10.1164/arrd.1972.106.1.38; CHERNIACK RM, UNPUBLISHED DATA; DUNNER L, 1946, BRIT J RADIOL, V19, P506, DOI 10.1259/0007-1285-19-228-506; HUNTER D, 1969, DISEASES OCCUPATIONS; KERIGAN AT, 1973, J ALLERGY CLIN IMMUN, V51, P95, DOI 10.1016/S0091-6749(73)80039-9; KLEINFELD M, 1969, ARCH ENVIRON HEALTH, V16, P380; LUNN JA, 1967, BRIT J IND MED, V24, P158; McCarthy DS, 1971, CLIN ALLERGY, V1, P261, DOI DOI 10.1111/J.1365-2222.1971.TB; OLIVE JT, 1972, AM REV RESPIR DIS, V106, P366, DOI 10.1164/arrd.1972.106.3.366; PEPYS J, 1964, AM REV RESPIR DIS, V89, P842; PEPYS J, 1969, MONOGRAPHS ALLERGY 4; PERNIS B, 1961, BRIT J IND MED, V18, P120; RAMAZZINI B, 1940, DISEASES WORKERS LAT; SIMENS H, UNPUBLISHED; SINHA RN, 1969, ECOLOGY, V50, P536, DOI 10.2307/1936244; SKOULAS A, 1964, J Occup Med, V6, P359; TSE KS, 1973, ARCH ENVIRON HEALTH, V27, P74, DOI 10.1080/00039896.1973.10666321; WILLIAMS NORMAN, 1964, J OCCUP MED, V6, P319, DOI 10.1097/00043764-196408000-00001	22	76	76	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1974	53	3					139	149		10.1016/0091-6749(74)90002-5	http://dx.doi.org/10.1016/0091-6749(74)90002-5			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	S3550	4813889				2022-12-18	WOS:A1974S355000002
J	Panganiban, RA; Sun, MY; Dahlin, A; Park, HR; Kan, MY; Himes, BE; Mitchel, JA; Iribarren, C; Jorgenson, E; Randell, SH; Israel, E; Tantisira, K; Shore, S; Park, JA; Weiss, ST; Wu, AC; Lu, Q				Panganiban, Ronald A.; Sun, Maoyun; Dahlin, Amber; Park, Hae-Ryung; Kan, Mengyuan; Himes, Blanca E.; Mitchel, Jennifer A.; Iribarren, Carlos; Jorgenson, Eric; Randell, Scott H.; Israel, Elliot; Tantisira, Kelan; Shore, Stephanie; Park, Jin-Ah; Weiss, Scott T.; Wu, Ann Chen; Lu, Quan			A functional splice variant associated with decreased asthma risk abolishes the ability of gasdermin B to induce epithelial cell pyroptosis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; gasdermin B; GSDMB; 17q21 locus; genetics; airway epithelium; pyroptosis	GENOME-WIDE ASSOCIATION; GENOTYPE IMPUTATION; ORMDL3 EXPRESSION; GENETIC-VARIATION; AMERICAN; COVERAGE; DISEASE; DESIGN; HEALTH; FAMILY	Background: Genetic variants in the chromosomal region 17q21 are consistently associated with asthma. However, mechanistic studies have not yet linked any of the associated variants to a function that could influence asthma, and as a result, the identity of the asthma gene(s) remains elusive. Objectives: We sought to identify and characterize functional variants in the 17q21 locus. Methods: We used the Exome Aggregation Consortium browser to identify coding (amino acid-changing) variants in the 17q21 locus. We obtained asthma association measures for these variants in both the Genetic Epidemiology Research in Adult Health and Aging (GERA) cohort (16,274 cases and 38,269 matched controls) and the EVE Consortium study (5,303 asthma cases and 12,560 individuals). Gene expression and protein localization were determined by quantitative RT-PCR and fluorescence immunostaining, respectively. Molecular and cellular studies were performed to determine the functional effects of coding variants. Results: Two coding variants (rs2305480 and rs11078928) of the gasdermin B (GSDMB) gene in the 17q21 locus were associated with lower asthma risk in both GERA (odds ratio, 0.92; P = 1.01 x 10(-6)) and EVE (odds ratio, 0.85; joint P-EVE = 1.31 x 10(-13)). In GERA, rs11078928 had a minor allele frequency (MAF) of 0.45 in unaffected (nonasthmatic) controls and 0.43 in asthma cases. For European Americans in EVE, the MAF of rs2305480 was 0.45 for controls and 0.39 for cases; for all EVE subjects, the MAF was 0.32 for controls and 0.27 for cases. GSDMB is highly expressed in differentiated airway epithelial cells, including the ciliated cells. We found that, when the GSDMB protein is cleaved by inflammatory caspase-1 to release its N-terminal fragment, potent pyroptotic cell death is induced. The splice variant rs11078928 deletes the entire exon 6, which encodes 13 amino acids in the critical N-terminus, and abolishes the pyroptotic activity of the GSDMB protein. Conclusions: Our study identified a functional asthma variant in the GSDMB gene of the 17q21 locus and implicates GSDMB-mediated epithelial cell pyroptosis in pathogenesis.	[Panganiban, Ronald A.; Sun, Maoyun; Mitchel, Jennifer A.; Shore, Stephanie; Park, Jin-Ah; Lu, Quan] Harvard TH Chan Sch Publ Hlth, Program Mol & Integrat Physiol Sci, Dept Environm Hlth, Boston, MA 02115 USA; [Panganiban, Ronald A.; Sun, Maoyun; Mitchel, Jennifer A.; Shore, Stephanie; Park, Jin-Ah; Lu, Quan] Harvard TH Chan Sch Publ Hlth, Program Mol & Integrat Physiol Sci, Dept Genet & Complex Dis, Boston, MA USA; [Dahlin, Amber; Park, Hae-Ryung; Tantisira, Kelan; Weiss, Scott T.; Wu, Ann Chen] Brigham & Womens Hosp, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA; [Dahlin, Amber; Park, Hae-Ryung; Israel, Elliot; Tantisira, Kelan; Weiss, Scott T.; Wu, Ann Chen] Harvard Med Sch, Boston, MA USA; [Kan, Mengyuan; Himes, Blanca E.] Univ Penn, Dept Biostat Epidemiol & Informat, Philadelphia, PA 19104 USA; [Iribarren, Carlos; Jorgenson, Eric] Kaiser Permanente Northern Calif, Div Res, Oakland, CA USA; [Randell, Scott H.] Univ N Carolina, Marsico Lung Inst, Cyst Fibrosis Ctr, Chapel Hill, NC USA; [Israel, Elliot] Brigham & Womens Hosp, Asthma Res Ctr, 75 Francis St, Boston, MA 02115 USA; [Wu, Ann Chen] Harvard Med Sch, Precis Med Translat Res Ctr, Dept Populat Med, Boston, MA USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Pennsylvania; Kaiser Permanente; University of North Carolina; University of North Carolina Chapel Hill; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Lu, Q (corresponding author), Harvard TH Chan Sch Publ Hlth, Program Mol & Integrat Physiol Sci, 665 Huntington Ave, Boston, MA 02115 USA.	qlu@hsph.harvard.edu	Panganiban, Ronald Allan/AAH-3859-2020; Park, Hae-Ryung/AEY-9186-2022; Wu, Ann/AAY-4293-2020; Park, Hae-Ryung/AAG-8872-2022	Panganiban, Ronald Allan/0000-0003-0894-1318; Wu, Ann/0000-0003-0599-9063; Park, Hae-Ryung/0000-0002-7531-8844; Mitchel, Jennifer/0000-0002-4480-3193	National Institutes of Health (NIH) [R01HL114769, P30ES000002, DK065988, R00 HL105663, R01 HL133433, P01HL120839]; American Asthma Foundation Scholar award; American Heart Association [13SDG14320004];  [K01 HL130629-01]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD085993] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [RC2HL101651, P01HL120839, R01HL114769, R00HL105663, K01HL130629, T32HL007118, R01HL133433] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK065988] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES013307, P30ES000002] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Asthma Foundation Scholar award; American Heart Association(American Heart Association); ; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work was supported by National Institutes of Health (NIH) grants (grant nos. R01HL114769 and P30ES000002) and an American Asthma Foundation Scholar award to Q.L. A.D. was supported by grant K01 HL130629-01. B.E.H. was partially supported by the NIH (grant no. R00 HL105663 and R01 HL133433). J.-P. was supported by the American Heart Association (grant no. 13SDG14320004) and by the NIH (grant no. P01HL120839). S.H.R. was supported in part by the NIH (grant no. DK065988).	Akinbami Lara J, 2012, NCHS Data Brief, P1; Barnett SBL, 2011, J ALLERGY CLIN IMMUN, V127, P145, DOI 10.1016/j.jaci.2010.10.020; Braman SS, 2006, CHEST, V130, p4S, DOI 10.1378/chest.130.1_suppl.4S; Cao XF, 2015, RESP RES, V16, DOI 10.1186/s12931-015-0191-9; Chao KL, 2017, P NATL ACAD SCI USA, V114, pE1128, DOI 10.1073/pnas.1616783114; Cookson WOC, 2000, HUM MOL GENET, V9, P2359, DOI 10.1093/hmg/9.16.2359; Dahlin A, 2016, AM THOR SOC ANN M; Das S, 2016, P NATL ACAD SCI USA, V113, P13132, DOI 10.1073/pnas.1610433113; Delaneau O, 2012, NAT METHODS, V9, P179, DOI [10.1038/NMETH.1785, 10.1038/nmeth.1785]; Ding JJ, 2016, NATURE, V535, P111, DOI 10.1038/nature18590; Fahy JV, 2015, NAT REV IMMUNOL, V15, P57, DOI 10.1038/nri3786; Fang QR, 2011, BMC MED GENET, V12, DOI 10.1186/1471-2350-12-133; Ferreira MAR, 2011, EUR J HUM GENET, V19, P458, DOI 10.1038/ejhg.2010.191; Forno E, 2009, CURR OPIN ALLERGY CL, V9, P154, DOI 10.1097/ACI.0b013e3283292207; Grotenboer NS, 2013, J ALLERGY CLIN IMMUN, V131, P856, DOI 10.1016/j.jaci.2012.11.028; Hao K, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1003029; Hoffmann TJ, 2011, GENOMICS, V98, P422, DOI 10.1016/j.ygeno.2011.08.007; Hoffmann TJ, 2011, GENOMICS, V98, P79, DOI 10.1016/j.ygeno.2011.04.005; Howie B, 2012, NAT GENET, V44, P955, DOI 10.1038/ng.2354; Howie B, 2011, G3-GENES GENOM GENET, V1, P457, DOI 10.1534/g3.111.001198; Howie BN, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000529; Hrvatin S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089459; Igartua C, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6965; Kayagaki N, 2015, NATURE, V526, P666, DOI 10.1038/nature15541; Kvale MN, 2015, GENETICS, V200, P1051, DOI 10.1534/genetics.115.178905; Lek M, 2016, NATURE, V536, P285, DOI 10.1038/nature19057; Liu X, 2016, NATURE, V535, P153, DOI 10.1038/nature18629; Lluis A, 2011, J ALLERGY CLIN IMMUN, V127, P1587, DOI 10.1016/j.jaci.2011.03.015; Marchini J, 2010, NAT REV GENET, V11, P499, DOI 10.1038/nrg2796; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Morrison FS, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-627; Ober C, 2006, GENES IMMUN, V7, P95, DOI 10.1038/sj.gene.6364284; Ober C, 2011, IMMUNOL REV, V242, P10, DOI 10.1111/j.1600-065X.2011.01029.x; Park KS, 2006, AM J RESP CELL MOL, V34, P151, DOI 10.1165/rcmb.2005-0332OC; R Development Core Team, 2016, R LANG ENV STAT COMP; Rose MC, 2006, PHYSIOL REV, V86, P245, DOI 10.1152/physrev.00010.2005; Saeki N, 2009, GENE CHROMOSOME CANC, V48, P261, DOI 10.1002/gcc.20636; Shi JJ, 2015, NATURE, V526, P660, DOI 10.1038/nature15514; Tamura M, 2007, GENOMICS, V89, P618, DOI 10.1016/j.ygeno.2007.01.003; Tavendale R, 2008, J ALLERGY CLIN IMMUN, V121, P860, DOI 10.1016/j.jaci.2008.01.015; Thomas B, 2010, J ALLERGY CLIN IMMUN, V126, P722, DOI 10.1016/j.jaci.2010.05.046; Tilley AE, 2015, ANNU REV PHYSIOL, V77, P379, DOI 10.1146/annurev-physiol-021014-071931; Torgerson DG, 2011, NAT GENET, V43, P887, DOI 10.1038/ng.888; Verlaan DJ, 2009, AM J HUM GENET, V85, P377, DOI 10.1016/j.ajhg.2009.08.007; Wan YI, 2012, THORAX, V67, P762, DOI 10.1136/thoraxjnl-2011-201262; Wanner A, 1996, AM J RESP CRIT CARE, V154, P1868, DOI 10.1164/ajrccm.154.6.8970383; Wenzel SE, 2012, NAT MED, V18, P716, DOI 10.1038/nm.2678; You YJ, 2004, AM J PHYSIOL-LUNG C, V286, pL650, DOI 10.1152/ajplung.00170.2003	49	75	81	1	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2018	142	5					1469	+		10.1016/j.jaci.2017.11.040	http://dx.doi.org/10.1016/j.jaci.2017.11.040			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GZ5BL	29330013	hybrid, Green Accepted, Green Submitted			2022-12-18	WOS:000449429800010
J	Li, X; Michaeloudes, C; Zhang, YL; Wiegman, CH; Adcock, IM; Lian, QZ; Mak, JCW; Bhavsar, PK; Chung, KF				Li, Xiang; Michaeloudes, Charalambos; Zhang, Yuelin; Wiegman, Coen H.; Adcock, Ian M.; Lian, Qizhou; Mak, Judith C. W.; Bhavsar, Pankaj K.; Chung, Kian Fan			Mesenchymal stem cells alleviate oxidative stress-induced mitochondrial dysfunction in the airways	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Mesenchymal stem cell; chronic obstructive pulmonary disease; oxidative stress; airway smooth muscle; mitochondria; cigarette smoke; ozone; airway hyperresponsiveness; apoptosis; inflammation	OBSTRUCTIVE PULMONARY-DISEASE; INDUCED LUNG INFLAMMATION; SMOOTH-MUSCLE-CELLS; EPITHELIAL-CELLS; REGENERATIVE MEDICINE; TUNNELING NANOTUBES; COPD; PATHOGENESIS; ATTENUATION; SENSITIVITY	Background: Oxidative stress-induced mitochondrial dysfunction can contribute to inflammation and remodeling in patients with chronic obstructive pulmonary disease (COPD). Mesenchymal stem cells protect against lung damage in animal models of COPD. It is unknown whether these effects occur through attenuating mitochondrial dysfunction in airway cells. Objective: We sought to examine the effect of induced pluripotent stem cell-derived mesenchymal stem cells (iPSC-MSCs) on oxidative stress-induce mitochondrial dysfunction in human airway smooth muscle cells (ASMCs) in vitro and in mouse lungs in vivo. Methods: ASMCs were cocultured with iPSC-MSCs in the presence of cigarette smoke medium (CSM), and mitochondrial reactive oxygen species (ROS) levels, mitochondrial membrane potential (DCm), and apoptosis were measured. Conditioned medium from iPSC-MSCs and transwell cocultures were used to detect any paracrine effects. The effect of systemic injection of iPSC-MSCs on airway inflammation and hyperresponsiveness in ozone-exposed mice was also investigated. Results: Coculture of iPSC-MSCs with ASMCs attenuated CSM-induced mitochondrial ROS, apoptosis, and Delta Psi m loss in ASMCs. iPSC-MSC-conditioned medium or transwell cocultures with iPSC-MSCs reduced CSM-induced mitochondrial ROS but not Delta Psi m or apoptosis in ASMCs. Mitochondrial transfer from iPSC-MSCs to ASMCs was observed after direct coculture and was enhanced by CSM. iPSC-MSCs attenuated ozone-induced mitochondrial dysfunction, airway hyperresponsiveness, and inflammation in mouse lungs. Conclusion: iPSC-MSCs offered protection against oxidative stress-induced mitochondrial dysfunction in human ASMCs and in mouse lungs while reducing airway inflammation and hyperresponsiveness. These effects are, at least in part, dependent on cell-cell contact, which allows for mitochondrial transfer, and paracrine regulation. Therefore iPSC-MSCs show promise as a therapy for oxidative stress-dependent lung diseases, such as COPD.	[Li, Xiang; Michaeloudes, Charalambos; Wiegman, Coen H.; Adcock, Ian M.; Bhavsar, Pankaj K.; Chung, Kian Fan] Imperial Coll London, Natl Heart & Lung Inst, London, England; [Li, Xiang; Zhang, Yuelin; Lian, Qizhou; Mak, Judith C. W.] Univ Hong Kong, Dept Med, Hong Kong, Hong Kong, Peoples R China; [Zhang, Yuelin; Lian, Qizhou] Univ Hong Kong, Sch Biomed Sci, Hong Kong, Hong Kong, Peoples R China; [Mak, Judith C. W.] Univ Hong Kong, Dept Pharmacol & Pharm, Hong Kong, Hong Kong, Peoples R China; [Lian, Qizhou; Mak, Judith C. W.] Univ Hong Kong, Shenzhen Inst Res & Innovat, Hong Kong, Hong Kong, Peoples R China	Imperial College London; University of Hong Kong; University of Hong Kong; University of Hong Kong; University of Hong Kong	Lian, QZ; Mak, JCW (corresponding author), Univ Hong Kong, Dept Med, Hong Kong, Hong Kong, Peoples R China.; Lian, QZ (corresponding author), Univ Hong Kong, Sch Biomed Sci, Hong Kong, Hong Kong, Peoples R China.; Mak, JCW (corresponding author), Univ Hong Kong, Dept Pharmacol & Pharm, Hong Kong, Hong Kong, Peoples R China.; Lian, QZ; Mak, JCW (corresponding author), Univ Hong Kong, Shenzhen Inst Res & Innovat, Hong Kong, Hong Kong, Peoples R China.; Bhavsar, PK (corresponding author), Natl Heart & Lung Inst, Dovehouse St, London SW3 6LY, England.	qzlian@hku.hk; judymak@hku.hk; p.bhavsar@imperial.ac.uk	Adcock, Ian/L-3217-2019; Zhang, Yuelin/C-4569-2009; Lian, Qizhou/Y-1613-2019; Chung, Kian Fan/B-1872-2012	Chung, Kian Fan/0000-0001-7101-1426; Wiegman, Coen/0000-0001-9161-0581; Michaeloudes, Charalambos/0000-0002-4107-4028; Mak, Judith/0000-0002-8234-1313; Adcock, Ian/0000-0003-2101-8843; Zhang, Yuelin/0000-0002-0065-1116; Lian, Qizhou/0000-0001-8189-7160	Imperial College Trust; National Natural Science Fund of China (NSFC) [81370140, 31571407]; National Natural Science Fund of China (STFGD) [2015B020225001]; National Natural Science Fund of China (RGC/GRF) [HKU17113816]; Respiratory Disease Biomedical Research Unit at the Royal Brompton NHS Foundation Trust; Imperial College London; Medical Research Council [G1000758, G1000758B] Funding Source: researchfish; Asthma UK [MRC-AsthmaUKCentre, MRC-Asthma UK Centre] Funding Source: researchfish	Imperial College Trust; National Natural Science Fund of China (NSFC)(National Natural Science Foundation of China (NSFC)); National Natural Science Fund of China (STFGD)(National Natural Science Foundation of China (NSFC)); National Natural Science Fund of China (RGC/GRF); Respiratory Disease Biomedical Research Unit at the Royal Brompton NHS Foundation Trust; Imperial College London(General Electric); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Asthma UK	Supported by project grants from the Imperial College Trust, the National Natural Science Fund of China (NSFC no. 81370140 to J.C.W.M.; STFGD no. 2015B020225001; RGC/GRF no. HKU17113816; and NSFC No. 31571407 to Q.L.), and the Respiratory Disease Biomedical Research Unit at the Royal Brompton NHS Foundation Trust and Imperial College London. K.F.C. is a Senior Investigator of the National Institute of Health Research, United Kingdom.	Agarwal AR, 2012, AM J PHYSIOL-LUNG C, V303, pL889, DOI 10.1152/ajplung.00219.2012; Ahmad T, 2015, FASEB J, V29, P2912, DOI 10.1096/fj.14-268276; Ahmad T, 2014, EMBO J, V33, P994, DOI 10.1002/embj.201386030; Aravamudan B, 2014, AM J PHYSIOL-LUNG C, V306, pL840, DOI 10.1152/ajplung.00155.2013; Barnes PJ, 2000, NEW ENGL J MED, V343, P269, DOI 10.1056/NEJM200007273430407; Cho HY, 2001, AM J PHYSIOL-LUNG C, V280, pL537, DOI 10.1152/ajplung.2001.280.3.L537; Chung KF, 2008, EUR RESPIR J, V31, P1334, DOI 10.1183/09031936.00018908; Chung KF, 2005, P AM THORAC SOC, V2, P371; Chung Kian Fan, 2005, Proc Am Thorac Soc, V2, P347, DOI 10.1513/pats.200504-028SR; Cloonan SM, 2016, NAT MED, V22, P163, DOI 10.1038/nm.4021; Demedts IK, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-53; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hoffmann RF, 2013, RESP RES, V14, DOI 10.1186/1465-9921-14-97; Hogg JC, 2004, NEW ENGL J MED, V350, P2645, DOI 10.1056/NEJMoa032158; Howarth Peter H, 2004, J Allergy Clin Immunol, V114, pS32, DOI 10.1016/j.jaci.2004.04.041; Islam MN, 2012, NAT MED, V18, P759, DOI 10.1038/nm.2736; Jarai G, 2004, EUR J PHARMACOL, V497, P255, DOI 10.1016/j.ejphar.2004.06.055; Johnson K, 2016, INT J CHRONIC OBSTR, V11, P799, DOI 10.2147/COPD.S102375; Lau WKW, 2012, TOXICOL SCI, V125, P569, DOI 10.1093/toxsci/kfr305; Li X, 2017, J CELL MOL MED, V21, P265, DOI 10.1111/jcmm.12962; Li X, 2014, AM J RESP CELL MOL, V51, P455, DOI 10.1165/rcmb.2013-0529OC; Lian QZ, 2010, CIRCULATION, V121, P1113, DOI 10.1161/CIRCULATIONAHA.109.898312; Louhelainen Noora, 2009, BMC Pulm Med, V9, P25, DOI 10.1186/1471-2466-9-25; Marchi Saverio, 2012, J Signal Transduct, V2012, P329635, DOI 10.1155/2012/329635; Mathers CD, 2006, PLOS MED, V3, DOI 10.1371/journal.pmed.0030442; Michaeloudes C, 2011, AM J PHYSIOL-LUNG C, V300, pL295, DOI 10.1152/ajplung.00134.2010; Mitani A, 2016, AM J RESP CRIT CARE, V193, P143, DOI 10.1164/rccm.201503-0593OC; Mizumura K, 2014, J CLIN INVEST, V124, P3987, DOI 10.1172/JCI74985; Oltmanns U, 2008, PULM PHARMACOL THER, V21, P292, DOI 10.1016/j.pupt.2007.07.001; Pasquier J, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-94; Rustom A, 2004, SCIENCE, V303, P1007, DOI 10.1126/science.1093133; Spees JL, 2006, P NATL ACAD SCI USA, V103, P1283, DOI 10.1073/pnas.0510511103; Teo AKK, 2010, BIOCHEM J, V428, P11, DOI 10.1042/BJ20100102; Triantaphyllopoulos K, 2011, AM J PHYSIOL-LUNG C, V300, pL691, DOI 10.1152/ajplung.00252.2010; Vallabhaneni KC, 2012, STEM CELLS DEV, V21, P3104, DOI 10.1089/scd.2011.0691; Walters MJ, 2005, MOL PHARMACOL, V68, P1343, DOI 10.1124/mol.105.012591; Weiss DJ, 2014, STEM CELLS, V32, P16, DOI 10.1002/stem.1506; Weiss Daniel J, 2011, Proc Am Thorac Soc, V8, P223, DOI 10.1513/pats.201012-071DW; Wiegman CH, 2015, J ALLERGY CLIN IMMUN, V136, P769, DOI 10.1016/j.jaci.2015.01.046; Wiegman CH, 2014, CLIN SCI, V126, P425, DOI 10.1042/CS20130039; Williams AS, 2007, J PHARMACOL EXP THER, V322, P351, DOI 10.1124/jpet.107.121624; Zhang YL, 2016, STEM CELL REP, V7, P749, DOI 10.1016/j.stemcr.2016.08.009; Zhang YL, 2012, CELL TRANSPLANT, V21, P2225, DOI 10.3727/096368912X653020	43	75	80	2	20	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2018	141	5					1634	+		10.1016/j.jaci.2017.08.017	http://dx.doi.org/10.1016/j.jaci.2017.08.017			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GF7KX	28911970	Green Accepted			2022-12-18	WOS:000432148200011
J	Steelant, B; Seys, SF; Van Gerven, L; Van Woensel, M; Farre, R; Wawrzyniak, P; Krohn, IK; Bullens, DM; Talavera, K; Raap, U; Boon, L; Akdis, CA; Boeckxstaens, G; Ceuppens, JL; Hellings, PW				Steelant, Brecht; Seys, Sven F.; Van Gerven, Laura; Van Woensel, Matthias; Farre, Ricard; Wawrzyniak, Paulina; Krohn, Inge Kortekaas; Bullens, Dominique M.; Talavera, Karel; Raap, Ulrike; Boon, Louis; Akdis, Cezmi A.; Boeckxstaens, Guy; Ceuppens, Jan L.; Hellings, Peter W.			Histamine and T helper cytokine-driven epithelial barrier dysfunction in allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic rhinitis; idiopathic rhinitis; tight junctions; histamine; T(H)2 cells; primary nasal epithelial cells	NECROSIS-FACTOR-ALPHA; TIGHT JUNCTION BARRIER; TNF-ALPHA; IDIOPATHIC RHINITIS; UP-REGULATION; INFLAMMATORY CELLS; E-CADHERIN; EXPRESSION; MODULATION; ASTHMA	Background: Allergic rhinitis (AR) is characterized by mucosal inflammation, driven by activated immune cells. Mast cells and T(H)2 cells might decrease epithelial barrier integrity in AR, maintaining a leaky epithelial barrier. Objective: We sought to investigate the role of histamine and T(H)2 cells in driving epithelial barrier dysfunction in AR. Methods: Air-liquid interface cultures of primary nasal epithelial cells were used to measure transepithelial electrical resistance, paracellular flux of fluorescein isothiocyanate-dextran 4 kDa, and mRNA expression of tight junctions. Nasal secretions were collected from healthy control subjects, AR patients, and idiopathic rhinitis patients and were tested in vitro. In addition, the effect of activated T(H)1 and T(H)2 cells, mast cells, and neurons was tested in vitro. The effect of IL-4, IL-13, IFN-gamma, and TNF-alpha on mucosal permeability was tested in vivo. Results: Histamine as well as nasal secretions of AR but not idiopathic rhinitis patients rapidly decreased epithelial barrier integrity in vitro. Pretreatment with histamine receptor-1 antagonist, azelastine prevented the early effect of nasal secretions of AR patients on epithelial integrity. Supernatant of activated T(H)1 and T(H)2 cells impaired epithelial integrity, while treatment with anti-TNF-alpha or anti-IL-4R alpha monoclonal antibodies restored the T(H)1- and T(H)2-induced epithelial barrier dysfunction, respectively. IL-4, IFN-gamma, and TNF-alpha enhanced mucosal permeability in mice. Antagonizing IL-4 prevented mucosal barrier disruption and tight junction downregulation in a mouse model of house dust mite allergic airway inflammation. Conclusions: Our data indicate a key role for allergic inflammatory mediators in modulating nasal epithelial barrier integrity in the pathophysiology in AR.	[Steelant, Brecht; Seys, Sven F.; Van Gerven, Laura; Krohn, Inge Kortekaas; Ceuppens, Jan L.; Hellings, Peter W.] KU, Dept Microbiol & Immunol, Lab Clin Immunol, Leuven, Belgium; [Van Gerven, Laura; Hellings, Peter W.] Univ Hosp Leuven, Clin Dept Otorhinolaryngol Head & Neck Surg, Leuven, Belgium; [Van Woensel, Matthias] Katholieke Univ Leuven, Lab Expt Neurosurg & Neuroanat, Leuven, Belgium; [Van Woensel, Matthias] Univ Libre Bruxelles, Lab Galen Pharm & Biopharm, Brussels, Belgium; [Farre, Ricard; Boeckxstaens, Guy] Katholieke Univ Leuven, Translat Res Ctr Gastro Intestinal Disorders, Leuven, Belgium; [Wawrzyniak, Paulina; Akdis, Cezmi A.] Univ Zurich, Swiss Inst Allergy & Asthma Res, Davos, Switzerland; [Bullens, Dominique M.] Katholieke Univ Leuven, Dept Microbiol & Immunol, Lab Pediat Immunol, Leuven, Belgium; [Bullens, Dominique M.] Univ Hosp Leuven, Clin Dept Pediat, Leuven, Belgium; [Talavera, Karel] Katholieke Univ Leuven, Dept Cellular & Mol Med, Lab Ion Channel Res, Leuven, Belgium; [Raap, Ulrike] Carl von Ossietzky Univ Oldenburg, Dept Dermatol, Oldenburg, Germany; [Boon, Louis] Epirus Biopharmaceut Netherlands, Utrecht, Netherlands; [Hellings, Peter W.] Univ Amsterdam, Acad Med Ctr, Dept Otorhinolaryngol, Amsterdam, Netherlands; [Hellings, Peter W.] Univ Hosp Ghent, Dept Otorhinolaryngol, Ghent, Belgium	KU Leuven; KU Leuven; University Hospital Leuven; KU Leuven; Universite Libre de Bruxelles; KU Leuven; Swiss Institute of Allergy & Asthma Research; University of Zurich; KU Leuven; KU Leuven; University Hospital Leuven; KU Leuven; Carl von Ossietzky Universitat Oldenburg; University of Amsterdam; Academic Medical Center Amsterdam; Ghent University; Ghent University Hospital	Hellings, PW (corresponding author), Katholieke Univ Leuven, Univ Hosp Leuven, Clin Div Otorhinolaryngol Head & Neck Surg, Kapueijnenvoer 33, B-3000 Leuven, Belgium.	Peter.hellings@kuleuven.be	Hellings, Peter W/I-4068-2018; Akdis, Cezmi/AAV-4844-2020; Boeckxstaens, Guy/AAP-2502-2020; Wawrzyniak, Paulina/HCG-8924-2022; Wawrzyniak, Paulina/AAD-7265-2020; Farre, Ricard/O-4549-2016; Boon, Laurence/HCI-3629-2022; Wawrzyniak, Paulina/AAG-3548-2019; Bullens, Dominique M A/T-6211-2017; Farre, Ricard/M-9275-2013; Van Gerven, Laura/ABG-5800-2021; Steelant, Brecht/H-8335-2018	Hellings, Peter W/0000-0001-6898-688X; Akdis, Cezmi/0000-0001-8020-019X; Wawrzyniak, Paulina/0000-0001-9641-2103; Farre, Ricard/0000-0001-7158-171X; Bullens, Dominique M A/0000-0002-4595-9579; Farre, Ricard/0000-0001-7158-171X; Van Gerven, Laura/0000-0002-5325-7956; Steelant, Brecht/0000-0002-0358-9362; Ceuppens, Jan/0000-0003-4502-2679; Kortekaas Krohn, Inge/0000-0003-3649-1131; Boon, Louis/0000-0002-0937-9171; Seys, Sven/0000-0002-4399-9892	Belgian Federal Government [IUAP P7/30]; Innovatie door Wetenschap en Technologie (IWT) [130260]; research council of the KU Leuven [GOA 2009/07, 14/011]; Fund of Scientific Research (FWO), Flanders, Belgium; FWO; research council of KU Leuven [PDMK/14/189]	Belgian Federal Government; Innovatie door Wetenschap en Technologie (IWT)(Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT)); research council of the KU Leuven(KU Leuven); Fund of Scientific Research (FWO), Flanders, Belgium(FWO); FWO(FWO); research council of KU Leuven(KU Leuven)	The authors' laboratories are supported by grants from the Belgian Federal Government (IUAP P7/30), Innovatie door Wetenschap en Technologie (IWT) (TBM project 130260), and the research council of the KU Leuven (GOA 2009/07 and 14/011). This work was partly supported by a research grant of the Fund of Scientific Research (FWO), Flanders, Belgium. P.W.H. and D.M.B. are recipients of a senior researcher fellowship from FWO. S.F.S. is supported by the research council of KU Leuven (PDMK/14/189).	Al-Sadi R, 2013, AM J PATHOL, V183, P1871, DOI 10.1016/j.ajpath.2013.09.001; Babu SK, 2011, CLIN IMMUNOL, V140, P18, DOI 10.1016/j.clim.2011.03.005; Bachert C, 2016, JAMA-J AM MED ASSOC, V315, P469, DOI 10.1001/jama.2015.19330; Baraniuk JN, 2009, ANN NY ACAD SCI, V1170, P604, DOI 10.1111/j.1749-6632.2009.04481.x; Berry MA, 2006, NEW ENGL J MED, V354, P697, DOI 10.1056/NEJMoa050580; Borish LC, 2001, J ALLERGY CLIN IMMUN, V107, P963, DOI 10.1067/mai.2001.115624; Bousquet J, 2008, ALLERGY, V63, P842, DOI 10.1111/j.1398-9995.2008.01715.x; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Brightling C, 2008, J ALLERGY CLIN IMMUN, V121, P5, DOI 10.1016/j.jaci.2007.10.028; Capaldo CT, 2009, BBA-BIOMEMBRANES, V1788, P864, DOI 10.1016/j.bbamem.2008.08.027; Chung KF, 2016, LANCET, V388, P3, DOI 10.1016/S0140-6736(16)30311-7; De Benedetto Anna, 2011, J Allergy Clin Immunol, V127, P773, DOI 10.1016/j.jaci.2010.10.018; De Benedetto A, 2011, J ALLERGY CLIN IMMUN, V127, P773, DOI 10.1016/j.jaci.2010.10.018; Descoeur J, 2011, EMBO MOL MED, V3, P266, DOI 10.1002/emmm.201100134; Dinh QT, 2005, CLIN EXP ALLERGY, V35, P1443, DOI 10.1111/j.1365-2222.2005.02359.x; Fahy JV, 2015, NAT REV IMMUNOL, V15, P57, DOI 10.1038/nri3786; Flynn AN, 2009, P NATL ACAD SCI USA, V106, P3591, DOI 10.1073/pnas.0813393106; Georas SN, 2014, J ALLERGY CLIN IMMUN, V134, P509, DOI 10.1016/j.jaci.2014.05.049; Greiner AN, 2011, LANCET, V378, P2112, DOI 10.1016/S0140-6736(11)60130-X; Guo Y, 2007, PHARM RES-DORDR, V24, P1824, DOI 10.1007/s11095-007-9309-1; Hamano N, 1998, INT ARCH ALLERGY IMM, V115, P220, DOI 10.1159/000023904; Hamilos DL, 2015, J ALLERGY CLIN IMMUN, V136, P1454, DOI 10.1016/j.jaci.2015.10.011; Hardyman MA, 2013, J ALLERGY CLIN IMMUN, V132, P665, DOI 10.1016/j.jaci.2013.03.005; Knipping S, 2009, EUR ARCH OTO-RHINO-L, V266, P1249, DOI 10.1007/s00405-008-0898-z; Ko JA, 2009, FEBS LETT, V583, P2148, DOI 10.1016/j.febslet.2009.05.010; Krohn IK, 2013, SCAND J IMMUNOL, V78, P352, DOI 10.1111/sji.12085; Lambrecht BN, 2015, NAT IMMUNOL, V16, P45, DOI 10.1038/ni.3049; Lee HJ, 2016, AM J RHINOL ALLERGY, V30, P173, DOI 10.2500/ajra.2016.30.4295; Ma TY, 2005, AM J PHYSIOL-GASTR L, V288, pG422, DOI 10.1152/ajpgi.00412.2004; Muraro A, 2017, ALLERGY, V72, P173, DOI 10.1111/all.13058; Nielsen OH, 2013, NEW ENGL J MED, V369, P754, DOI 10.1056/NEJMct1209614; Olsen NJ, 2004, NEW ENGL J MED, V350, P2167, DOI 10.1056/NEJMra032906; Pache I, 2009, SWISS MED WKLY, V139, P278, DOI smw-12549; Pawankar R, 2011, ASIA PAC ALLERGY, V1, P157, DOI 10.5415/apallergy.2011.1.3.157; Pfeiffer F, 2011, ACTA NEUROPATHOL, V122, P601, DOI 10.1007/s00401-011-0883-2; Powell N, 2010, NAT REV GASTRO HEPAT, V7, P146, DOI 10.1038/nrgastro.2010.5; Raap U, 2008, CLIN EXP ALLERGY, V38, P1493, DOI 10.1111/j.1365-2222.2008.03035.x; Saatian B, 2013, TISSUE BARRIERS, V1, DOI 10.4161/tisb.24333; Sarin S, 2006, J ALLERGY CLIN IMMUN, V118, P999, DOI 10.1016/j.jaci.2006.09.013; Schmitz H, 1999, J CELL SCI, V112, P137; Soyka MB, 2012, J ALLERGY CLIN IMMUN, V130, P1087, DOI 10.1016/j.jaci.2012.05.052; Steelant B, 2016, RHINOLOGY, V54, P195, DOI 10.4193/Rhino15.376; Steelant B, 2016, J ALLERGY CLIN IMMUN, V137, P1043, DOI 10.1016/j.jaci.2015.10.050; Suenaert P, 2002, AM J GASTROENTEROL, V97, P2000; Suenaert P, 2010, INFLAMM BOWEL DIS, V16, P1322, DOI 10.1002/ibd.21211; Togias Alkis, 2003, Journal of Allergy and Clinical Immunology, V112, pS60, DOI 10.1016/S0091-6749(03)01878-5; Van Gerven L, 2017, J ALLERGY CLIN IMMUN, V140, P437, DOI 10.1016/j.jaci.2017.03.014; Van Gerven L, 2014, J ALLERGY CLIN IMMUN, V133, P1332, DOI 10.1016/j.jaci.2013.08.026; Van Itallie C, 2001, J CLIN INVEST, V107, P1319, DOI 10.1172/JCI12464; van Rijswijk JB, 2005, ALLERGY, V60, P1471, DOI 10.1111/j.1398-9995.2005.00975.x; van Rijswijk JB, 2003, RHINOLOGY, V41, P25; Walsh SV, 2000, ADV DRUG DELIVER REV, V41, P303, DOI 10.1016/S0169-409X(00)00048-X; Wang Z, 2016, ONCOTARGET, V7, P31299, DOI 10.18632/oncotarget.8896; Wawrzyniak P, 2017, J ALLERGY CLIN IMMUN, V139, P93, DOI 10.1016/j.jaci.2016.03.050; Wise SK, 2014, INT FORUM ALLERGY RH, V4, P361, DOI 10.1002/alr.21298; Xiao C, 2011, J ALLERGY CLIN IMMUN, V128, P549, DOI 10.1016/j.jaci.2011.05.038; Zabner J, 2003, J APPL PHYSIOL, V95, P394, DOI 10.1152/japplphysiol.01134.2002; Zeissig S, 2007, GUT, V56, P61, DOI 10.1136/gut.2006.094375	58	75	85	5	28	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2018	141	3					951	+		10.1016/j.jaci.2017.08.039	http://dx.doi.org/10.1016/j.jaci.2017.08.039			21	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FY6PR	29074456	Green Published, Green Accepted, hybrid			2022-12-18	WOS:000426974800015
J	Hourihane, JO; Allen, KJ; Shreffler, WG; Dunngalvin, G; Nordlee, JA; Zurzolo, GA; Dunngalvin, A; Gurrin, LC; Baumert, JL; Taylor, SL				Hourihane, Jonathan O'B.; Allen, Katrina J.; Shreffler, Wayne G.; Dunngalvin, Gillian; Nordlee, Julie A.; Zurzolo, Giovanni A.; Dunngalvin, Audrey; Gurrin, Lyle C.; Baumert, Joseph L.; Taylor, Steve L.			Peanut Allergen Threshold Study (PATS): Novel single-dose oral food challenge study to validate eliciting doses in children with peanut allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Eliciting dose; food allergy related quality of life questionnaire; single dose; peanut thresholds; oral food challenges; Voluntary Incidental Trace Allergen Labelling; Peanut Allergen Threshold Study	DOUBLE-BLIND; PLACEBO; VALIDITY	Background: Eliciting doses (EDs) of allergenic foods can be defined by the distribution of threshold doses for subjects within a specific population. The ED05 is the dose that elicits a reaction in 5% of allergic subjects. The predicted ED05 for peanut is 1.5 mg of peanut protein (6 mg of whole peanut). Objective: We sought to validate the predicted peanut ED05 (1.5 mg) with a novel single-dose challenge. Methods: Consecutive eligible children with peanut allergy in 3 centers were prospectively invited to participate, irrespective of previous reaction severity. Predetermined criteria for objective reactions were used to identify ED05 single-dose reactors. Results: Five hundred eighteen children (mean age, 6.8 years) were eligible. No significant demographic or clinical differences were identified between 381 (74%) participants and 137 (26%) nonparticipants or between subjects recruited at each center. Three hundred seventy-eight children (206 male) completed the study. Almost half the group reported ignoring precautionary allergen labeling. Two hundred forty-five (65%) children experienced no reaction to the single dose of peanut. Sixty-seven (18%) children reported a subjective reaction without objective findings. Fifty-eight (15%) children experienced signs of a mild and transient nature that did not meet the predetermined criteria. Only 8 (2.1%; 95% CI, 0.6%-3.4%) subjects met the predetermined criteria for an objective and likely related event. No child experienced more than a mild reaction, 4 of the 8 received oral antihistamines only, and none received epinephrine. Food allergy-related quality of life improved from baseline to 1 month after challenge regardless of outcome (eta(2) = 0.2, P < .0001). Peanut skin prick test responses and peanut-and Ara h 2-specific IgE levelswere not associated with objective reactivity to peanut ED05. Conclusion: A single administration of 1.5 mg of peanut protein elicited objective reactions in fewer than the predicted 5% of patients with peanut allergy. The novel single-dose oral food challenge appears clinically safe and patient acceptable, regardless of the outcome. It identifies the most highly dose-sensitive population with food allergy not otherwise identifiable by using routinely available peanut skin prick test responses or specific IgE levels, but this single-dose approach has not yet been validated for risk assessment of individual patients.	[Hourihane, Jonathan O'B.; Dunngalvin, Gillian; Dunngalvin, Audrey] Univ Coll, Paediat & Child Hlth, Cork, Ireland; [Dunngalvin, Gillian; Dunngalvin, Audrey] Univ Coll, Sch Appl Psychol, Cork, Ireland; [Allen, Katrina J.; Zurzolo, Giovanni A.] Univ Melbourne, Dept Paediat, Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Allen, Katrina J.] Royal Childrens Hosp, Dept Allergy & Immunol, Melbourne, Vic, Australia; [Shreffler, Wayne G.] Food Allergy Ctr, Boston, MA USA; [Shreffler, Wayne G.] Ctr Immunol & Inflammatory Dis, Boston, MA USA; [Shreffler, Wayne G.] Massachusetts Gen Hosp, Boston, MA USA; [Shreffler, Wayne G.] Harvard Med Sch, Boston, MA USA; [Nordlee, Julie A.; Baumert, Joseph L.; Taylor, Steve L.] Univ Nebraska, Food Allergy Res & Resource Program, Lincoln, NE USA; [Zurzolo, Giovanni A.] Victoria Univ, Coll Hlth & Biomed, Ctr Chron Dis, Melbourne, Vic, Australia; [Gurrin, Lyle C.] Univ Melbourne, Melbourne Sch Populat & Global Hlth, Melbourne, Vic, Australia	University College Cork; University College Cork; Murdoch Children's Research Institute; University of Melbourne; Royal Children's Hospital Melbourne; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of Nebraska System; University of Nebraska Lincoln; Victoria University; University of Melbourne	Hourihane, JO (corresponding author), Univ Coll Cork, Paediat & Child Hlth, Cork, Ireland.	J.Hourihane@ucc.ie	Taylor, Steve L./V-1341-2019; DunnGalvin, Audrey/G-1741-2012; Allen, Katrina/I-4361-2018	Allen, Katrina/0000-0002-1921-4493; Zurzolo, Giovanni/0000-0002-0623-9333; Gurrin, Lyle/0000-0001-7052-1969	Food Allergy Research & Resource Program (FARRP);  [1UL1TR001102-01]	Food Allergy Research & Resource Program (FARRP); 	This project is funded by the Food Allergy Research & Resource Program (FARRP) and supported by grant no. 1UL1TR001102-01.	Ahrens B, 2014, CLIN EXP ALLERGY, V44, P572, DOI 10.1111/cea.12284; Allen KJ, 2014, J ALLERGY CLIN IMMUN, V133, P156, DOI 10.1016/j.jaci.2013.06.042; [Anonymous], 2010, J ALLERGY CLIN IMMUN, V126, pS5, DOI 10.1016/j.jaci.2010.10.007; Ballmer-Weber BK, 2015, J ALLERGY CLIN IMMUN, V135, P964, DOI 10.1016/j.jaci.2014.10.047; DunnGalvin A, 2015, ALLERGY, V70, P1039, DOI 10.1111/all.12614; DunnGalvin A, 2010, CLIN EXP ALLERGY, V40, P476, DOI 10.1111/j.1365-2222.2010.03454.x; Fidell L.S., 2001, USING MULTIVARIATE S, V4th; Field A.P., 2013, DISCOVERING STAT USI, V4th; Hourihane JO, 2005, CLIN EXP ALLERGY, V35, P1227, DOI 10.1111/j.1365-2222.2005.02312.x; Osborne NJ, 2010, CLIN EXP ALLERGY, V40, P1516, DOI 10.1111/j.1365-2222.2010.03562.x; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Sampson HA, 2012, J ALLERGY CLIN IMMUN, V130, P1260, DOI 10.1016/j.jaci.2012.10.017; Sullivan Gail M, 2012, J Grad Med Educ, V4, P279, DOI 10.4300/JGME-D-12-00156.1; Taylor SL, 2014, FOOD CHEM TOXICOL, V63, P9, DOI 10.1016/j.fct.2013.10.032; Taylor SL, 2009, FOOD CHEM TOXICOL, V47, P1198, DOI 10.1016/j.fct.2009.02.011; Turner PJ, 2016, ALLERGY, V71, P1241, DOI 10.1111/all.12924; Zurzolo GA, 2013, ALLERGY ASTHMA CL IM, V9, DOI 10.1186/1710-1492-9-35; Zurzolo GA, 2013, MED J AUSTRALIA, V198, P621, DOI 10.5694/mja12.11669	18	75	76	0	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2017	139	5					1583	1590		10.1016/j.jaci.2017.01.030	http://dx.doi.org/10.1016/j.jaci.2017.01.030			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ET7HI	28238744	Green Published			2022-12-18	WOS:000400465300019
J	Pongracic, JA; Krouse, RZ; Babineau, DC; Zoratti, EM; Cohen, RT; Wood, RA; Hershey, GKK; Kercsmar, CM; Gruchalla, RS; Kattan, M; Teach, SJ; Johnson, CC; Bacharier, LB; Gern, JE; Sigelman, SM; Gergen, PJ; Togias, A; Visness, CM; Busse, WW; Liu, AH				Pongracic, Jacqueline A.; Krouse, Rebecca Z.; Babineau, Denise C.; Zoratti, Edward M.; Cohen, Robyn T.; Wood, Robert A.; Hershey, Gurjit K. Khurana; Kercsmar, Carolyn M.; Gruchalla, Rebecca S.; Kattan, Meyer; Teach, Stephen J.; Johnson, Christine C.; Bacharier, Leonard B.; Gern, James E.; Sigelman, Steven M.; Gergen, Peter J.; Togias, Alkis; Visness, Cynthia M.; Busse, William W.; Liu, Andrew H.			Distinguishing characteristics of difficult-to-control asthma in inner-city children and adolescents	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Child; asthma; inner-city asthma; asthma phenotype; asthma morbidity; asthma severity; asthma exacerbations; pulmonary function; rhinitis; allergen sensitization; IgE	ALLERGIC RHINITIS; YOUNG-ADULTS; IMPACT; CHILDHOOD; RESPONSIVENESS; OBSTRUCTION; VALIDATION; MANAGEMENT; MORBIDITY; SEVERITY	Background: Treatment levels required to control asthma vary greatly across a population with asthma. The factors that contribute to variability in treatment requirements of inner-city children have not been fully elucidated. Objective: We sought to identify the clinical characteristics that distinguish difficult-to-control asthma from easy-to-control asthma. Methods: Asthmatic children aged 6 to 17 years underwent baseline assessment and bimonthly guideline-based management visits over 1 year. Difficult-to-control and easy-to-control asthma were defined as daily therapy with 500 mg of fluticasone or greater with or without a long-acting beta-agonist versus 100 mu g or less assigned on at least 4 visits. Forty-four baseline variables were used to compare the 2 groups by using univariate analyses and to identify the most relevant features of difficult-to-control asthma by using a variable selection algorithm. Nonlinear seasonal variation in longitudinal measures (symptoms, pulmonary physiology, and exacerbations) was examined by using generalized additive mixed-effects models. Results: Among 619 recruited participants, 40.9% had difficult-to-control asthma, 37.5% had easy-to-control asthma, and 21.6% fell into neither group. At baseline, FEV1 bronchodilator responsiveness was the most important characteristic distinguishing difficult-to-control asthma from easy-to-control asthma. Markers of rhinitis severity and atopy were among the other major discriminating features. Over time, difficult-tocontrol asthma was characterized by high exacerbation rates, particularly in spring and fall; greater daytime and nighttime symptoms, especially in fall and winter; and compromised pulmonary physiology despite ongoing high-dose controller therapy. Conclusions: Despite good adherence, difficult-to-control asthma showed little improvement in symptoms, exacerbations, or pulmonary physiology over the year. In addition to pulmonary physiology measures, rhinitis severity and atopy were associated with high-dose asthma controller therapy requirement.	[Pongracic, Jacqueline A.] Ann & Robert H Lurie Childrens Hosp Chicago, Chicago, IL 60611 USA; [Krouse, Rebecca Z.; Babineau, Denise C.; Visness, Cynthia M.] Rho Fed Syst Div, Chapel Hill, NC USA; [Zoratti, Edward M.; Johnson, Christine C.] Henry Ford Hlth Syst, Detroit, MI USA; [Cohen, Robyn T.] Boston Univ, Sch Med, Boston, MA 02118 USA; [Wood, Robert A.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA; [Hershey, Gurjit K. Khurana; Kercsmar, Carolyn M.] Cincinnati Childrens Hosp, Cincinnati, OH USA; [Gruchalla, Rebecca S.] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA; [Kattan, Meyer] Columbia Univ, Coll Phys & Surg, New York, NY USA; [Teach, Stephen J.] Childrens Natl Hlth Syst, Washington, DC USA; [Teach, Stephen J.] George Washington Univ, Sch Med & Hlth Sci, Washington, DC 20052 USA; [Bacharier, Leonard B.] St Louis Childrens Hosp, St Louis, MO 63178 USA; [Gern, James E.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA; [Sigelman, Steven M.; Gergen, Peter J.; Togias, Alkis] NIAID, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Liu, Andrew H.] Natl Jewish Hlth, Denver, CO USA; [Liu, Andrew H.] Childrens Hosp Colorado, Aurora, CO USA; [Liu, Andrew H.] Univ Colorado, Sch Med, Aurora, CO USA	Ann & Robert H. Lurie Children's Hospital of Chicago; Henry Ford Health System; Henry Ford Hospital; Boston University; Johns Hopkins University; Cincinnati Children's Hospital Medical Center; University of Texas System; University of Texas Southwestern Medical Center Dallas; Columbia University; Children's National Health System; George Washington University; St. Louis Children's Hospital; Washington University (WUSTL); University of Wisconsin System; University of Wisconsin Madison; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Jewish Health; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus	Pongracic, JA (corresponding author), 225 E Chicago Av 60, Chicago, IL 60614 USA.	jpongracic@luriechildrens.org	Cohen, Robyn/AAC-9326-2019	Cohen, Robyn/0000-0002-6902-3118; Bacharier, Leonard/0000-0003-0432-2704	National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services [HHSN272200900052C, HHSN272201000052I, 1UM1AI114271-01]; National Center for Research Resources (NCRR); National Center for Advancing Translational Sciences (NCATS), NIH [NCRR/NIH UL1TR000451, UL1RR025780, UL1TR000075 Q1, NCATS/NIH UL1TR000154, UL1TR001082, UL1TR000077-04, UL1TR000040, UL1TR000150, UL1TR001105]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001105, UL1TR000451] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [UM1AI114271, UM2AI117870] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services; National Center for Research Resources (NCRR)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Center for Advancing Translational Sciences (NCATS), NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This project has been funded in whole or in part with federal funds from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services (under contract nos. HHSN272200900052C and HHSN272201000052I, and 1UM1AI114271-01). Additional support was provided by the National Center for Research Resources (NCRR), and the National Center for Advancing Translational Sciences (NCATS), NIH (under grant nos. NCRR/NIH UL1TR000451, UL1RR025780, UL1TR000075 Q1 and NCATS/NIH UL1TR000154, UL1TR001082, UL1TR000077-04, UL1TR000040, UL1TR000150, and UL1TR001105). GlaxoSmithKline (GSK) provided Ventolin, Flovent, Advair, and Flonase under a clinical trial agreement with NIH NIAID; GSK did not have a role in the development or approval of the protocol, conduct of the trial, data analysis, manuscript preparation, or the decision to submit the manuscript for publication.	[Anonymous], 2015, GLOB STRAT ASTHM MAN; Boulet LP, 2007, RESP MED, V101, P2240, DOI 10.1016/j.rmed.2007.06.031; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Brozek JL, 2010, J ALLERGY CLIN IMMUN, V126, P466, DOI 10.1016/j.jaci.2010.06.047; COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404; de Groot EP, 2012, THORAX, V67, P582, DOI 10.1136/thoraxjnl-2011-201168; Eigen H, 2001, AM J RESP CRIT CARE, V163, P619, DOI 10.1164/ajrccm.163.3.2002054; Galant SP, 2011, J PEDIATR-US, V158, P953, DOI 10.1016/j.jpeds.2010.11.029; Hansen JE, 2008, RESP MED, V102, P1777, DOI 10.1016/j.rmed.2008.06.019; Kainu A, 2008, CHEST, V134, P387, DOI 10.1378/chest.07-2207; Kattan M, 2010, J ALLERGY CLIN IMMUN, V125, P584, DOI 10.1016/j.jaci.2010.01.053; Koga T, 2006, J ASTHMA, V43, P71, DOI 10.1080/02770900500448662; Koster ES, 2011, J ASTHMA, V48, P694, DOI 10.3109/02770903.2011.601780; Kuczmarski R.J., 2000, CDC GROWTH CHARTS US; Kursa MB, 2010, J STAT SOFTW, V36, P1, DOI 10.18637/jss.v036.i11; Lang A, 2010, PEDIAT ALLERG IMM-UK, V21, P945, DOI 10.1111/j.1399-3038.2010.01072.x; Liu AH, 2007, J ALLERGY CLIN IMMUN, V119, P817, DOI 10.1016/j.jaci.2006.12.662; Liu AH, 2010, J ALLERGY CLIN IMMUN, V126, P267, DOI 10.1016/j.jaci.2010.05.031; Lohia S, 2013, ALLERGY, V68, P569, DOI 10.1111/all.12124; Matsui EC, 2006, ANN ALLERG ASTHMA IM, V97, P514, DOI 10.1016/S1081-1206(10)60943-X; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; Oka A, 2014, J ALLER CL IMM-PRACT, V2, P172, DOI 10.1016/j.jaip.2013.09.018; Peters-Golden M, 2006, EUR RESPIR J, V27, P495, DOI 10.1183/09031936.06.00077205; Pongracic JA, 2010, J ALLERGY CLIN IMMUN, V125, P593, DOI 10.1016/j.jaci.2009.10.036; Ponte EV, 2008, ALLERGY, V63, P564, DOI 10.1111/j.1398-9995.2007.01624.x; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Salo PM, 2014, J ALLERGY CLIN IMMUN, V134, P350, DOI 10.1016/j.jaci.2013.12.1071; Schatz M, 2006, J ALLERGY CLIN IMMUN, V117, P549, DOI 10.1016/j.jaci.2006.01.011; Schatz M, 2007, AM J MANAG CARE, V13, P661; Sorkness RL, 2008, J APPL PHYSIOL, V104, P394, DOI 10.1152/japplphysiol.00329.2007; Strunk RC, 2002, J ALLERGY CLIN IMMUN, V110, P395, DOI 10.1067/mai.2002.127433; Strunk RC, 2015, J ALLER CL IMM-PRACT, V3, P765, DOI 10.1016/j.jaip.2015.05.009; Szefler S, 2008, LANCET, V372, P1065, DOI 10.1016/S0140-6736(08)61448-8; Tepper RS, 2012, J ALLERGY CLIN IMMUN, V129, pS65, DOI 10.1016/j.jaci.2011.12.986; Togias A, 2003, J ALLERGY CLIN IMMUN, V111, P1171, DOI 10.1067/mai.2003.1592; Wildfire JJ, 2012, J ALLERGY CLIN IMMUN, V129, P694, DOI 10.1016/j.jaci.2011.12.962	38	75	77	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2016	138	4					1030	1041		10.1016/j.jaci.2016.06.059	http://dx.doi.org/10.1016/j.jaci.2016.06.059			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DZ0AP	27720017	Green Accepted, Bronze			2022-12-18	WOS:000385499400008
J	Gueguen, C; Bouley, J; Moussu, H; Luce, S; Duchateau, M; Chamot-Rooke, J; Pallardy, M; Lombardi, V; Nony, E; Baron-Bodo, V; Mascarell, L; Moingeon, P				Gueguen, Claire; Bouley, Julien; Moussu, Helene; Luce, Sonia; Duchateau, Magalie; Chamot-Rooke, Julia; Pallardy, Marc; Lombardi, Vincent; Nony, Emmanuel; Baron-Bodo, Veronique; Mascarell, Laurent; Moingeon, Philippe			Changes in markers associated with dendritic cells driving the differentiation of either T(H)2 cells or regulatory T cells correlate with clinical benefit during allergen immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergen; biomarker; dendritic cell; monocyte; sublingual immunotherapy	GRASS-POLLEN IMMUNOTHERAPY; YELLOW-FEVER VACCINE; SUBLINGUAL IMMUNOTHERAPY; ANTIBODY-RESPONSES; IMMUNOGLOBULIN-E; B-CELLS; EXPRESSION; TH2; INDUCTION; MECHANISMS	Background: Regulatory dendritic cell (DC) markers, such as C1Q, are upregulated in PBMCs of patients with grass pollen allergy exhibiting clinical benefit during allergen immunotherapy (AIT). Objectives: We sought to define markers differentially expressed in human monocyte-derived DCs differentiated toward a proallergic (DCs driving the differentiation of T(H)2 cells [DC2s]) phenotype and investigate whether changes in such markers in the blood correlate with AIT efficacy. Methods: Transcriptomes and proteomes of monocyte-derived DCs polarized toward DCs driving the differentiation of T(H)1 cells (DC1s), DC2s, or DCs driving the differentiation of regulatory T cells (DCreg cells) profiles were compared by using genome-wide cDNA microarrays and label-free quantitative proteomics, respectively. Markers differentially regulated in DC2s and DCreg cells were assessed by means of quantitative PCR in PBMCs from 80 patients with grass pollen allergy before and after 2 or 4 months of sublingual AIT in parallel with rhinoconjunctivitis symptom scores. Results: We identified 20 and 26 new genes/proteins overexpressed in DC2s and DCreg cells, respectively. At an individual patient level, DC2-associated markers, such as CD141, GATA3, OX40 ligand, and receptor-interacting serine/threonine-protein kinase 4 (RIPK4), were downregulated after a 4-month sublingual AIT course concomitantly with an upregulation of DCreg cell-associated markers, including complement C1q subcomponent subunit A (C1QA), Fc gamma RIIIA, ferritin light chain (FTL), and solute carrier organic anion transporter family member 2B1 (SLCO2B1), in the blood of clinical responders as opposed to nonresponders. Changes in such markers were better correlated with clinical benefit than alterations of allergen-specific CD4(+) T-cell or IgG responses. Conclusions: A combination of 5 markers predominantly expressed by blood DCs (ie, C1Q and CD141) or shared with lymphoid cells (ie, FcgRIIIA, GATA3, and RIPK4) reflecting changes in the balance of regulatory/proallergic responses in peripheral blood can be used as early as after 2 months to monitor the early onset of AIT efficacy.	[Gueguen, Claire; Bouley, Julien; Moussu, Helene; Luce, Sonia; Lombardi, Vincent; Nony, Emmanuel; Baron-Bodo, Veronique; Mascarell, Laurent; Moingeon, Philippe] Stallergenes, Res & Pharmaceut Dev, 6 Rue Alexis de Tocqueville, F-92183 Antony, France; [Duchateau, Magalie; Chamot-Rooke, Julia] Inst Pasteur, Unite Spectrometrie Masse Struct & Proteom, Paris, France; [Pallardy, Marc] Univ Paris Sud, Fac Pharm, INSERM, UMR 996, Chatenay Malabry, France	Stallergenes Greer; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Moingeon, P (corresponding author), Stallergenes, Res & Pharmaceut Dev, 6 Rue Alexis de Tocqueville, F-92183 Antony, France.	pmoingeon@stallergenes.com	Duchateau, Magalie/AAH-4360-2021; Chamot-Rooke, Julia/F-3644-2014	Duchateau, Magalie/0000-0001-5475-3065; Chamot-Rooke, Julia/0000-0002-9427-543X; Nony, Emmanuel/0000-0003-1820-8881	CIFRE fellowship from ANRT (Association Nationale de la Recherche et de la Technologie [1470/2011]; Stallergenes	CIFRE fellowship from ANRT (Association Nationale de la Recherche et de la Technologie(French National Research Agency (ANR)); Stallergenes	Supported by Stallergenes. C.G. was supported by a CIFRE fellowship from ANRT (Association Nationale de la Recherche et de la Technologie; grant no. 1470/2011). C.G., J.B., H.M., E.N., V.B.-B., L.M., and P.M. are employees at Stallergenes SA.	Adams S, 2007, J INVEST DERMATOL, V127, P538, DOI 10.1038/sj.jid.5700588; Akdis M, 2014, J ALLERGY CLIN IMMUN, V133, P621, DOI 10.1016/j.jaci.2013.12.1088; Alonso MN, 2011, BLOOD, V118, P3311, DOI 10.1182/blood-2011-03-341065; Bahceciler NN, 2005, INT ARCH ALLERGY IMM, V136, P287, DOI 10.1159/000083956; Banchereau R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6283; Baron-Bodo V, 2013, CLIN EXP ALLERGY, V43, P1362, DOI 10.1111/cea.12187; Bottcher I, 2008, IMMUNOLOGY, V123, P139, DOI 10.1111/j.1365-2567.2007.02754.x; Bohle B, 2007, J ALLERGY CLIN IMMUN, V120, P707, DOI 10.1016/j.jaci.2007.06.013; Bonvalet M, 2012, CLIN EXP ALLERGY, V42, P1745, DOI 10.1111/cea.12015; Bratke K, 2009, J ALLERGY CLIN IMMUN, V123, P1192, DOI 10.1016/j.jaci.2008.12.1132; Bruhns P, 2012, BLOOD, V119, P5640, DOI 10.1182/blood-2012-01-380121; Canonica GW, 2009, ALLERGY, V64, P1, DOI 10.1111/j.1398-9995.2009.02309.x; Castellano G, 2007, EUR J IMMUNOL, V37, P2803, DOI 10.1002/eji.200636845; Cox L, 2011, J ALLERGY CLIN IMMUN, V127, DOI 10.1016/j.jaci.2010.09.034; Ebner C, 1997, CLIN EXP ALLERGY, V27, P1007, DOI 10.1111/j.1365-2222.1997.tb01252.x; Ebner S, 1998, IMMUNOBIOLOGY, V198, P568, DOI 10.1016/S0171-2985(98)80079-X; Fowell DJ, 1999, IMMUNITY, V11, P399, DOI 10.1016/S1074-7613(00)80115-6; Francis JN, 2008, J ALLERGY CLIN IMMUN, V121, P1120, DOI 10.1016/j.jaci.2008.01.072; Gardner LM, 2004, CLIN EXP ALLERGY, V34, P1209, DOI 10.1111/j.1365-2222.2004.02009.x; Gaucher D, 2008, J EXP MED, V205, P3119, DOI 10.1084/jem.20082292; Hammad H, 2010, J EXP MED, V207, P2097, DOI 10.1084/jem.20101563; Horak F, 2009, J ALLERGY CLIN IMMUN, V124, P471, DOI 10.1016/j.jaci.2009.06.006; Huang Y, 2012, GENE, V498, P91, DOI 10.1016/j.gene.2012.02.006; Hur GY, 2008, J ALLERGY CLIN IMMUN, V122, P774, DOI 10.1016/j.jaci.2008.07.034; Ippoliti F, 2003, PEDIATR ALLERGY IMMU, V14, P216, DOI 10.1034/j.1399-3038.2003.00025.x; Jain N, 2009, J IMMUNOL, V183, P4192, DOI 10.4049/jimmunol.0902041; Jakobsen CG, 2005, CLIN EXP ALLERGY, V35, P193, DOI 10.1111/j.1365-2222.2005.02160.x; Jenkins SJ, 2007, J IMMUNOL, V179, P3515, DOI 10.4049/jimmunol.179.6.3515; Jonsson F, 2012, BLOOD, V119, P2533, DOI 10.1182/blood-2011-07-367334; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; Kasturi SP, 2011, NATURE, V470, P543, DOI 10.1038/nature09737; Keilholz U, 2002, J IMMUNOTHER, V25, P97, DOI 10.1097/00002371-200203000-00001; Kim SH, 2010, CLIN EXP IMMUNOL, V160, P489, DOI 10.1111/j.1365-2249.2010.04118.x; Kramar A, 2001, COMPUT METH PROG BIO, V66, P199, DOI 10.1016/S0169-2607(00)00129-2; Leon B, 2007, IMMUNITY, V26, P519, DOI 10.1016/j.immuni.2007.01.017; Maddur MS, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5092; Marelli-Berg FM, 2013, J CELL SCI, V126, P2343, DOI 10.1242/jcs.124099; McLachlan JB, 2008, NAT MED, V14, P536, DOI 10.1038/nm1757; Mo JH, 2013, ASIA PAC ALLERGY, V3, P186, DOI 10.5415/apallergy.2013.3.3.186; Moingeon P, 2013, J ALLER CL IMM-PRACT, V1, P228, DOI 10.1016/j.jaip.2013.03.013; Mueller C, 2003, J IMMUNOL, V170, P5056, DOI 10.4049/jimmunol.170.10.5056; Nagao M, 2008, INT ARCH ALLERGY IMM, V146, P47, DOI 10.1159/000126061; Nayak A, 2010, IMMUNOL LETT, V131, P139, DOI 10.1016/j.imlet.2010.03.012; Oliveira LJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013213; Park IH, 2011, AM J RHINOL ALLERGY, V25, pE107, DOI 10.2500/ajra.2011.25.3581; Pilette C, 2013, ALLERGY, V68, P312, DOI 10.1111/all.12090; Plantinga M, 2013, IMMUNITY, V38, P322, DOI 10.1016/j.immuni.2012.10.016; Pulendran B, 2010, NAT IMMUNOL, V11, P647, DOI 10.1038/ni.1894; Querec TD, 2009, NAT IMMUNOL, V10, P116, DOI 10.1038/ni.1688; Rountree RB, 2010, J INVEST DERMATOL, V130, P102, DOI 10.1038/jid.2009.223; Scadding GW, 2010, CLIN EXP ALLERGY, V40, P598, DOI 10.1111/j.1365-2222.2010.03462.x; Segura E, 2013, IMMUNITY, V38, P336, DOI 10.1016/j.immuni.2012.10.018; Shamji MH, 2012, ALLERGY, V67, P217, DOI 10.1111/j.1398-9995.2011.02745.x; Shamji MH, 2011, CLIN EXP ALLERGY, V41, P1235, DOI 10.1111/j.1365-2222.2011.03804.x; van de Veen W, 2013, J ALLERGY CLIN IMMUN, V131, P1204, DOI 10.1016/j.jaci.2013.01.014; Van Overtvelt L, 2011, ALLERGY, V66, P1530, DOI 10.1111/j.1398-9995.2011.02696.x; Vlad G, 2005, J IMMUNOL, V174, P5907, DOI 10.4049/jimmunol.174.10.5907; Wachholz PA, 2002, IMMUNOLOGY, V105, P56, DOI 10.1046/j.1365-2567.2002.01338.x; Wilson DR, 2001, CLIN EXP ALLERGY, V31, P1705, DOI 10.1046/j.1365-2222.2001.01231.x; Yerkovich ST, 2009, J ALLERGY CLIN IMMUN, V123, P209, DOI 10.1016/j.jaci.2008.09.009; Yu CI, 2014, J IMMUNOL, V193, P4335, DOI 10.4049/jimmunol.1401159; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8; Zimmer A, 2012, J ALLERGY CLIN IMMUN, V129, P1020, DOI 10.1016/j.jaci.2012.02.014; Zimmer A, 2011, J IMMUNOL, V186, P3966, DOI 10.4049/jimmunol.1003184	64	75	81	0	21	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2016	137	2					545	558		10.1016/j.jaci.2015.09.015	http://dx.doi.org/10.1016/j.jaci.2015.09.015			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DC5BN	26522402				2022-12-18	WOS:000369235500024
J	Schmitt, J; Schwarz, K; Stadler, E; Wustenberg, EG				Schmitt, Jochen; Schwarz, Kristin; Stadler, Erich; Wuestenberg, Eike Gunther			Allergy immunotherapy for allergic rhinitis effectively prevents asthma: Results from a large retrospective cohort study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic rhinitis; allergy immunotherapy; asthma; cohort study; epidemiology; prevention; effectiveness	PHASE-III; FOLLOW-UP; CHILDREN; IMPACT; BURDEN; UPDATE; SAMPLE; PAT	Background: Allergic rhinitis (AR) is a main risk factor for the development of asthma. Two randomized open-label trials indicated that allergy immunotherapy (AIT) prevents the onset of asthma in patients with AR. However, these trials have methodological limitations, and it is unclear to what extent this experimental efficacy translates into clinical effectiveness. Objectives: We sought to investigate the effectiveness of AIT to prevent asthma in patients with AR. Methods: Using routine health care data from German National Health Insurance beneficiaries, we identified a consecutive cohort of 118,754 patients with AR but without asthma who had not received AIT in 2005. These patients were stratified into one group starting AIT in 2006 and one group receiving no AIT in 2006. Both groups were observed regarding the risk of incident asthma in 2007 to 2012. Risk ratios (RRs) were calculated with generalized linear models by using a Poisson link function with robust error variance and adjustment for age, sex, health care use because of AR, and use of antihistamines. Results: In a total of 2431 (2.0%) patients, AIT was started in 2006. Asthma was newly diagnosed from 2007-2012 in 1646 (1.4%) patients. The risk of incident asthma was significantly lower in patients exposed to AIT (RR, 0.60; 95% CI, 0.42-0.84) compared with patients receiving no AIT in 2006. Sensitivity analyses suggested significant preventive effects of subcutaneous immunotherapy (RR, 0.54; 95% CI, 0.38-0.84) and AIT including native (nonallergoid) allergens (RR, 0.22; 95% CI, 0.02-0.68). AIT for 3 or more years tended to have stronger preventive effects than AIT for less than 3 years. Conclusion: AIT effectively prevents asthma in patients with AR in a real-world setting. Confounding by indication cannot be excluded but would lead to an underestimation of the true preventive effects of AIT.	[Schmitt, Jochen; Schwarz, Kristin; Stadler, Erich] Tech Univ Dresden, Med Fac Carl Gustav Carus, Ctr Evidence Based Healthcare, D-01307 Dresden, Germany; [Wuestenberg, Eike Gunther] Tech Univ Dresden, Med Fac Carl Gustav Carus, Dept Otorhinolaryngol, D-01307 Dresden, Germany	Technische Universitat Dresden; Carl Gustav Carus University Hospital; Technische Universitat Dresden; Carl Gustav Carus University Hospital	Schmitt, J (corresponding author), Tech Univ Dresden, Med Fac Carl Gustav Carus, Ctr Evidence Based Healthcare, Fetscherstr 74, D-01307 Dresden, Germany.	jochen.schmitt@uniklinikum-dresden.de			Novartis; ALK-Abello; MSD; Pfizer; Abbott	Novartis(Novartis); ALK-Abello; MSD; Pfizer(Pfizer); Abbott(Abbott Laboratories)	J. Schmitt has received research support from Novartis, ALK-Abello, MSD, Pfizer, and Abbott. E. G. Wustenberg is employed by and has stock/stock options in ALK-Abello. The rest of the authors declare that they have no relevant conflicts of interest.	Biermann J, 2013, ALLERGO J, V22, P366; Bjorksten B, 2008, PEDIAT ALLERG IMM-UK, V19, P110, DOI 10.1111/j.1399-3038.2007.00601.x; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Bousquet J, 2012, J ALLERGY CLIN IMMUN, V130, P1049, DOI 10.1016/j.jaci.2012.07.053; Croisant S, 2014, ADV EXP MED BIOL, V795, P17, DOI 10.1007/978-1-4614-8603-9_2; Del Giudice MM, 2011, INT J IMMUNOPATH PH, V24, P25, DOI 10.1177/03946320110240S406; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Durham SR, 2012, J ALLERGY CLIN IMMUN, V129, P717, DOI 10.1016/j.jaci.2011.12.973; European Medicines Agency, 2015, COMM MED PROD HUM US; Global Initiative for Asthma, 2015, GLOB STRAT ASTHM MAN; Greiner AN, 2011, LANCET, V378, P2112, DOI 10.1016/S0140-6736(11)60130-X; Henmar H, 2008, CLIN EXP IMMUNOL, V153, P316, DOI 10.1111/j.1365-2249.2008.03710.x; Heydenreich B, 2012, IMMUNOLOGY, V136, P208, DOI 10.1111/j.1365-2567.2012.03571.x; Ihle P, 2008, GESUNDHEITSWESEN, V70, P54, DOI 10.1055/s-2007-1022529; Ismaila AS, 2013, BMC PULM MED, V13, DOI 10.1186/1471-2466-13-70; Jacobsen L, 2007, ALLERGY, V62, P943, DOI 10.1111/j.1398-9995.2007.01451.x; Maziak W, 2003, ALLERGY, V58, P572, DOI 10.1034/j.1398-9995.2003.00161.x; Meltzer EO, 2011, ANN ALLERG ASTHMA IM, V106, pS12, DOI 10.1016/j.anai.2010.10.014; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; Niggemann B, 2006, ALLERGY, V61, P855, DOI 10.1111/j.1398-9995.2006.01068.x; Novembre E, 2004, J ALLERGY CLIN IMMUN, V114, P851, DOI 10.1016/j.jaci.2004.07.012; Passalacqua G, 2007, J ALLERGY CLIN IMMUN, V119, P881, DOI 10.1016/j.jaci.2007.01.045; Rosner B., 2000, FUNDAMENTALS BIOSTAT; Schmitt J, 2009, BRIT J DERMATOL, V161, P878, DOI 10.1111/j.1365-2133.2009.09309.x; Schmitt J, 2008, ITAL J PUBLIC HLTH, V5, P187; Schmitt J, 2009, JAMA-J AM MED ASSOC, V301, P724, DOI 10.1001/jama.2009.136; Trikojat K, 2015, PSYCHOL MED, V45, P1289, DOI 10.1017/S0033291714002384; Valovirta E, 2011, CLIN THER, V33, P1537, DOI 10.1016/j.clinthera.2011.09.013; Wheatley LM, 2015, NEW ENGL J MED, V372, P456, DOI 10.1056/NEJMcp1412282; Yonekura S, 2012, INT ARCH ALLERGY IMM, V157, P73, DOI 10.1159/000324475	30	75	77	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2015	136	6					1511	1516		10.1016/j.jaci.2015.07.038	http://dx.doi.org/10.1016/j.jaci.2015.07.038			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CX9RZ	26371838				2022-12-18	WOS:000366044300011
J	Fornasa, G; Tsilingiri, K; Caprioli, F; Botti, F; Mapelli, M; Meller, S; Kislat, A; Homey, B; Di Sabatino, A; Sonzogni, A; Viale, G; Diaferia, G; Gori, A; Longhi, R; Penna, G; Rescigno, M				Fornasa, Giulia; Tsilingiri, Katerina; Caprioli, Flavio; Botti, Fiorenzo; Mapelli, Marina; Meller, Stephan; Kislat, Andreas; Homey, Bernhard; Di Sabatino, Antonio; Sonzogni, Angelica; Viale, Giuseppe; Diaferia, Giuseppe; Gori, Alessandro; Longhi, Renato; Penna, Giuseppe; Rescigno, Maria			Dichotomy of short and long thymic stromal lymphopoietin isoforms in inflammatory disorders of the bowel and skin	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Thymic stromal lymphopoietin; gut homeostasis; skin homeostasis; anti-inflammatory drugs; ulcerative colitis; celiac disease; atopic dermatitis	NF-KAPPA-B; ATOPIC-DERMATITIS; EPITHELIAL-CELLS; DENDRITIC CELLS; TSLP; EXPRESSION; INDUCE; ASTHMA; POLYMORPHISMS; RECEPTOR	Background: Thymic stromal lymphopoietin (TSLP) is a cytokine with pleiotropic functions in the immune system. It has been associated with allergic reactions in the skin and lungs but also homeostatic tolerogenic responses in the thymus and gut. Objective: In human subjects TSLP is present in 2 isoforms, short and long. Here we wanted to investigate the differential expression of the TSLP isoforms and discern their biological implications under homeostatic or inflammatory conditions. Methods: We evaluated the expression of TSLPs in tissues from healthy subjects, patients with ulcerative colitis, patients with celiac disease, and patients with atopic dermatitis and on epithelial cells and keratinocytes under steady-state conditions or after stimulation. We then tested the immune activity of TSLP isoforms both in vitro and in vivo. Results: We showed that TSLP isoforms are responsible for 2 opposite immune functions. The short isoform is expressed under steady-state conditions and exerts anti-inflammatory activities by affecting the capacity of PBMCs and dendritic cells to produce inflammatory cytokines. Moreover, the short isoform TSLP ameliorates experimental colitis in mice and prevents endotoxin shock. The long isoform of TSLP is proinflammatory and is only expressed during inflammation. The isoforms are differentially regulated by pathogenic bacteria, such as Salmonella species and adhesive-invasive Escherichia coli. Conclusions: We have solved the dilemma of TSLP being both homeostatic and inflammatory. The TSLP isoform ratio is altered during several inflammatory disorders, with strong implications in disease treatment and prevention. Indeed, targeting of the long isoform of TSLP at the C-terminal portion, which is common to both isoforms, might lead to unwanted side effects caused by neutralization of the homeostatic short isoform.	[Fornasa, Giulia; Tsilingiri, Katerina; Mapelli, Marina; Diaferia, Giuseppe; Penna, Giuseppe; Rescigno, Maria] European Inst Oncol, Dept Expt Oncol, I-20139 Milan, Italy; [Caprioli, Flavio; Botti, Fiorenzo] Univ Milan, Osped Maggiore Policlin Milano, Fdn IRCCS Ca Granda, Unita Operat Gastroenterol & Endoscop, Milan, Italy; [Caprioli, Flavio; Botti, Fiorenzo] Univ Milan, Dipartimento Fisiopatol Med Chirurg & Trapianti, Milan, Italy; [Meller, Stephan; Kislat, Andreas; Homey, Bernhard] Univ Dusseldorf, Fac Med, Dept Dermatol, Dusseldorf, Germany; [Di Sabatino, Antonio] Univ Pavia, St Matteo Hosp, Dept Med 1, I-27100 Pavia, Italy; [Sonzogni, Angelica; Viale, Giuseppe] European Inst Oncol, Dept Pathol & Lab Med, I-20139 Milan, Italy; [Gori, Alessandro; Longhi, Renato] CNR, Ist Chim Riconoscimento Mol, I-20133 Milan, Italy; [Rescigno, Maria] Univ Milan, Dipartimento Sci Salute, Milan, Italy	IRCCS European Institute of Oncology (IEO); IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; University of Milan; Heinrich Heine University Dusseldorf; University of Pavia; IRCCS European Institute of Oncology (IEO); Consiglio Nazionale delle Ricerche (CNR); Istituto di Chimica del Riconoscimento Molecolare (ICRM-CNR); University of Milan	Rescigno, M (corresponding author), European Inst Oncol, Dept Expt Oncol, I-20139 Milan, Italy.	maria.rescigno@ieo.eu	Fornasa, Giulia/AAB-8912-2019; Meller, Stephan/GYA-5568-2022; Viale, Giuseppe/AAE-8921-2019; Rescigno, Maria/J-9704-2012; Caprioli, Flavio/AAB-5176-2019; Penna, Giuseppe/AAB-8784-2019; Sonzogni, Angelica/C-1193-2017; Di Sabatino, Antonio/K-8015-2016; Mapelli, Marina/AAC-7346-2022; Diaferia, Giuseppe/AAN-5910-2020; Gori, Alessandro/A-1357-2019	Fornasa, Giulia/0000-0002-2250-7983; Rescigno, Maria/0000-0002-6464-509X; Caprioli, Flavio/0000-0002-8077-8175; Penna, Giuseppe/0000-0003-3534-7090; Sonzogni, Angelica/0000-0002-4769-4316; Di Sabatino, Antonio/0000-0002-0302-8645; Mapelli, Marina/0000-0001-8502-0649; Diaferia, Giuseppe/0000-0003-4022-8483; Gori, Alessandro/0000-0003-1640-7238	European Council of Research (ERC) [202896, 324615, 615735]; FUV (Fondazione Umberto Veronesi); AIRC (Associazione Italiana per la Ricerca sul Cancro)	European Council of Research (ERC); FUV (Fondazione Umberto Veronesi)(Fondazione Umberto Veronesi); AIRC (Associazione Italiana per la Ricerca sul Cancro)(Fondazione AIRC per la ricerca sul cancro)	Supported by grants from the European Council of Research (ERC): starting grant Dendroworld (202896), Proof of concept 7TReImHo (324615), and consolidator grant HomeoGUT (615735). G.F. is the recipient of fellowships from FUV (Fondazione Umberto Veronesi) and from AIRC (Associazione Italiana per la Ricerca sul Cancro). K.T. is the recipient of a fellowship from AIRC (Associazione Italiana per la Ricerca sul Cancro).	Atreya I, 2008, J INTERN MED, V263, P591, DOI 10.1111/j.1365-2796.2008.01953.x; Bjerkan L, 2015, MUCOSAL IMMUNOL, V8, P49, DOI 10.1038/mi.2014.41; Cheng HM, 2014, J ALLERGY CLIN IMMUN, V133, P1048, DOI 10.1016/j.jaci.2013.10.055; Cultrone A, 2013, EUR J IMMUNOL, V43, P1053, DOI 10.1002/eji.201142340; Dajee M, 2006, J INVEST DERMATOL, V126, P1792, DOI 10.1038/sj.jid.5700307; Darfeuille-Michaud A, 2004, GASTROENTEROLOGY, V127, P412, DOI 10.1053/j.gastro.2004.04.061; De la Fuente M, 2014, INT J MED MICROBIOL, V304, P384, DOI 10.1016/j.ijmm.2014.01.002; El Taieb MA, 2013, DERMATITIS, V24, P296, DOI 10.1097/DER.0000000000000010; Ferreira DS, 2012, CLIN EXP ALLERGY, V42, P1459, DOI 10.1111/j.1365-2222.2012.04047.x; Gao PS, 2010, J ALLERGY CLIN IMMUN, V125, P1403, DOI 10.1016/j.jaci.2010.03.016; Han H, 2012, MUCOSAL IMMUNOL, V5, P342, DOI 10.1038/mi.2012.14; Hanabuchi S, 2010, J IMMUNOL, V184, P2999, DOI 10.4049/jimmunol.0804106; Harada M, 2011, AM J RESP CELL MOL, V44, P787, DOI 10.1165/rcmb.2009-0418OC; Hunninghake GM, 2010, ALLERGY, V65, P1566, DOI 10.1111/j.1398-9995.2010.02415.x; Iliev ID, 2009, GUT, V58, P1481, DOI 10.1136/gut.2008.175166; Isaksen DE, 1999, J IMMUNOL, V163, P5971; Ito T, 2005, J EXP MED, V202, P1213, DOI 10.1084/jem.20051135; Kim BS, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005374; Lack G, 2012, J ALLERGY CLIN IMMUN, V129, P1187, DOI 10.1016/j.jaci.2012.02.036; Liu W, 2012, EXP LUNG RES, V38, P375, DOI 10.3109/01902148.2012.714840; Margolis DJ, 2014, JAMA DERMATOL, V150, P254, DOI 10.1001/jamadermatol.2013.7954; Noti M, 2013, NAT MED, V19, P1005, DOI 10.1038/nm.3281; Pandey A, 2000, NAT IMMUNOL, V1, P59, DOI 10.1038/76923; Park LS, 2000, J EXP MED, V192, P659, DOI 10.1084/jem.192.5.659; Rimoldi M, 2005, NAT IMMUNOL, V6, P507, DOI 10.1038/ni1192; Silverberg JI, 2014, AM J CLIN DERMATOL, V15, P149, DOI 10.1007/s40257-014-0062-z; Siracusa MC, 2011, NATURE, V477, P229, DOI 10.1038/nature10329; Sonesson A, 2011, EXP DERMATOL, V20, P1004, DOI 10.1111/j.1600-0625.2011.01391.x; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Spergel JM, 2010, ANN ALLERG ASTHMA IM, V105, P99, DOI 10.1016/j.anai.2009.10.002; Tanaka A, 2007, J INVEST DERMATOL, V127, P855, DOI 10.1038/sj.jid.5700603; Verstraete K, 2014, NAT STRUCT MOL BIOL, V21, P375, DOI 10.1038/nsmb.2794; Wang SS, 2014, PEDIAT ALLERG IMM-UK, V25, P30, DOI 10.1111/pai.12167; Wang TT, 2005, MOL ENDOCRINOL, V19, P2685, DOI 10.1210/me.2005-0106; Watanabe N, 2004, NAT IMMUNOL, V5, P426, DOI 10.1038/ni1048; Watanabe N, 2005, NATURE, V436, P1181, DOI 10.1038/nature03886; Wilson SR, 2013, CELL, V155, P285, DOI 10.1016/j.cell.2013.08.057; Xie Y, 2012, J DERMATOL SCI, V66, P233, DOI 10.1016/j.jdermsci.2012.03.007; Ying S, 2005, J IMMUNOL, V174, P8183, DOI 10.4049/jimmunol.174.12.8183; Ziegler SF, 2012, J ALLERGY CLIN IMMUN, V130, P845, DOI 10.1016/j.jaci.2012.07.010; Ziegler SF, 2010, NAT IMMUNOL, V11, P289, DOI 10.1038/ni.1852	41	75	81	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2015	136	2					413	422		10.1016/j.jaci.2015.04.011	http://dx.doi.org/10.1016/j.jaci.2015.04.011			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CO2RS	26014813	hybrid, Green Published			2022-12-18	WOS:000359004900023
J	Harb, H; Renz, H				Harb, Hani; Renz, Harald			Update on epigenetics in allergic disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Epigenetics; allergy; asthma; DNA methylation; histone modifications	POLYCYCLIC AROMATIC-HYDROCARBONS; HISTONE H3 PHOSPHORYLATION; NEURAL-TUBE DEFECTS; DNA METHYLATION; GENE-EXPRESSION; IFN-GAMMA; MOUSE MODEL; T-HELPER; DIFFERENTIAL EXPRESSION; ADIPOSE-TISSUE	Chronic inflammatory diseases, including allergies and asthma, are the result of complex gene-environment interactions. One of the most challenging questions in this regard relates to the biochemical mechanism of how exogenous environmental trigger factors modulate and modify gene expression, subsequently leading to the development of chronic inflammatory conditions. Epigenetics comprises the umbrella of biochemical reactions and mechanisms, such as DNA methylation and chromatin modifications on histones and other structures. Recently, several lifestyle and environmental factors have been investigated in terms of such biochemical interactions with the gene expression-regulating machinery: allergens; microbes and microbial compounds; dietary factors, including vitamin B12, folic acid, and fish oil; obesity; and stress. This article aims to update recent developments in this context with an emphasis on allergy and asthma research.	[Harb, Hani; Renz, Harald] Univ Marburg, Inst Lab Med & Pathobiochem, D-35043 Marburg, Germany	Philipps University Marburg	Renz, H (corresponding author), Univ Marburg, Inst Lab Med, Baldingerstr, D-35043 Marburg, Germany.	renzh@med.uni-marburg.de	Harb, Hani/J-6517-2019; Harb, Hani/HGB-7333-2022	Harb, Hani/0000-0001-8218-2538; Harb, Hani/0000-0001-8218-2538				Adcock IM, 2007, CURR OPIN IMMUNOL, V19, P694, DOI 10.1016/j.coi.2007.07.016; Adcock Ian M, 2005, COPD, V2, P445; Adenuga D, 2009, AM J RESP CELL MOL, V40, P464, DOI 10.1165/rcmb.2008-0255OC; Akbarian S, 2009, BIOL PSYCHIAT, V65, P198, DOI 10.1016/j.biopsych.2008.08.015; Amarasekera M, 2014, FASEB J; Bachman KE, 2001, J BIOL CHEM, V276, P32282, DOI 10.1074/jbc.M104661200; Bannister AJ, 2011, CELL RES, V21, P381, DOI 10.1038/cr.2011.22; Barua S, 2014, J BIOMED SCI, V21, DOI 10.1186/s12929-014-0077-z; Benard A, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-531; Blumer N, 2005, CLIN EXP ALLERGY, V35, P397, DOI 10.1111/j.1365-2222.2005.02184.x; Brand S, 2012, J ALLERGY CLIN IMMUN, V129, P1602, DOI 10.1016/j.jaci.2011.12.963; Brand S, 2011, J ALLERGY CLIN IMMUN, V128, P618, DOI 10.1016/j.jaci.2011.04.035; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Breton CV, 2011, EPIGENETICS-US, V6, P895, DOI 10.4161/epi.6.7.15768; Calder PC, 2014, BIOCH BIOPHYS ACTA; Chaturvedi P, 2014, PHYSIOL GENOMICS, V46, P245, DOI 10.1152/physiolgenomics.00168.2013; Chen W, 2013, AM J RESP CRIT CARE, V187, P584, DOI 10.1164/rccm.201210-1789OC; Cheng RYS, 2014, ENVIRON MOL MUTAGEN, V55, P244, DOI 10.1002/em.21851; Ciprandi G, 2014, ALLERGY ASTHMA PROC, V35, pE62, DOI 10.2500/aap.2014.35.3773; COX R, 1986, Toxicologic Pathology, V14, P477; Cummins TD, 2014, AM J PHYSIOL-ENDOC M, V307, pE262, DOI 10.1152/ajpendo.00271.2013; Denny KJ, 2013, BIRTH DEFECTS RES A, V97, P602, DOI 10.1002/bdra.23177; Dietze J, 2012, ALLERGY, V67, P1519, DOI 10.1111/all.12031; Dolinoy DC, 2008, NUTR REV, V66, pS7, DOI 10.1111/j.1753-4887.2008.00056.x; Domann FE, 2004, AM J PATHOL, V164, P1883, DOI 10.1016/S0002-9440(10)63748-0; Ege MJ, 2011, J ALLERGY CLIN IMMUN, V127, P138, DOI 10.1016/j.jaci.2010.09.041; Engel LS, 2002, AM J EPIDEMIOL, V156, P95, DOI 10.1093/aje/kwf018; Fields PE, 2002, J IMMUNOL, V169, P647, DOI 10.4049/jimmunol.169.2.647; Fischer R, 2014, J LIPID RES, V55, P1150, DOI 10.1194/jlr.M047357; Foster SL, 2007, NATURE, V447, P972, DOI 10.1038/nature05836; Fujimaki W, 2008, CLIN DEV IMMUNOL, DOI 10.1155/2008/305859; Fujita N, 2003, J BIOL CHEM, V278, P24132, DOI 10.1074/jbc.M302283200; Gaudet F, 1998, J BIOL CHEM, V273, P32725, DOI 10.1074/jbc.273.49.32725; Han SY, 2006, BIOCHEM J, V400, P439, DOI 10.1042/BJ20061085; He X, 2005, NATURE, V433, P826, DOI 10.1038/nature03338; Healy S, 2012, BIOCHEM CELL BIOL, V90, P39, DOI [10.1139/o11-092, 10.1139/O11-092]; HOLLIDAY R, 1990, PHILOS T ROY SOC B, V326, P329, DOI 10.1098/rstb.1990.0015; Hollingsworth JW, 2008, J CLIN INVEST, V118, P3462, DOI 10.1172/JCI34378; Hsieh CL, 1999, MOL CELL BIOL, V19, P8211; Imbard A, 2013, INT J ENV RES PUB HE, V10, P4352, DOI 10.3390/ijerph10094352; Ito K., 2001, FASEB Journal, V15, P1110; Jing HR, 2014, J SURG RES, V187, P252, DOI 10.1016/j.jss.2013.10.009; Kehrmann J, 2014, IMMUNOLOGY, V142, P384, DOI 10.1111/imm.12261; Kim SV, 2013, SCIENCE, V340, P1456, DOI 10.1126/science.1237013; Kim YJ, 2014, CLIN EXP OTORHINOLAR, V7, P7, DOI 10.3342/ceo.2014.7.1.7; Klingbeil EC, 2014, IMMUNOL RES, V58, P369, DOI 10.1007/s12026-014-8508-1; Kohli A, 2012, CLIN EPIGENETICS, V4, DOI 10.1186/1868-7083-4-17; Kull I, 2006, ALLERGY, V61, P1009, DOI 10.1111/j.1398-9995.2006.01115.x; Liu F, 2010, ONCOGENE, V29, P3650, DOI 10.1038/onc.2010.129; Liu J, 2013, J TOXICOL-US, V2013, DOI 10.1155/2013/967029; Liu J, 2008, TOXICOL SCI, V102, P76, DOI 10.1093/toxsci/kfm290; Lluis A, 2014, J ALLERGY CLIN IMMUN, V133, P551, DOI 10.1016/j.jaci.2013.06.034; Mackay DJG, 2008, NAT GENET, V40, P949, DOI 10.1038/ng.187; Makar KW, 2004, J IMMUNOL, V173, P4402, DOI 10.4049/jimmunol.173.7.4402; Maksimoska J, 2014, BIOCHEMISTRY-US, V53, P3415, DOI 10.1021/bi500380f; Michel S, 2013, ALLERGY, V68, P355, DOI 10.1111/all.12097; Molina-Martinez LM, 2014, BRAIN BEHAV IMMUN; Mosmann TR, 2005, J IMMUNOL, V175, P5; Nilsson E, 2014, DIABETES, V63, P2962, DOI 10.2337/db13-1459; Notenboom ML, 2011, CLIN EXP ALLERGY, V41, P407, DOI 10.1111/j.1365-2222.2010.03672.x; Onodera A, 2010, J EXP MED, V207, P2493, DOI 10.1084/jem.20100760; Osoata GO, 2009, BIOCHEM BIOPH RES CO, V384, P366, DOI 10.1016/j.bbrc.2009.04.128; Pascual M, 2011, EPIGENETICS-US, V6, P1131, DOI 10.4161/epi.6.9.16061; Perera F, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004488; Prescott SL, 2009, CURR OPIN ALLERGY CL, V9, P417, DOI 10.1097/ACI.0b013e328330634f; Rastogi D, 2013, SCI REP-UK, V3, DOI 10.1038/srep02164; Renz H, 2011, NAT IMMUNOL, V12, P273, DOI 10.1038/ni0411-273; RICHMAN R, 1988, J CELL BIOL, V106, P1017, DOI 10.1083/jcb.106.4.1017; Rouse R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109477; Rui JX, 2012, J IMMUNOL, V189, P1380, DOI 10.4049/jimmunol.1201077; Saraiva M, 2005, J IMMUNOL, V175, P1041, DOI 10.4049/jimmunol.175.2.1041; Sawicka A, 2012, BIOCHIMIE, V94, P2193, DOI 10.1016/j.biochi.2012.04.018; Schaub B, 2008, ALLERGY, V63, P1438, DOI 10.1111/j.1398-9995.2008.01685.x; Schaub Bianca, 2009, J Allergy Clin Immunol, V123, P774, DOI 10.1016/j.jaci.2009.01.056; Schieck M, 2014, ALLERGY, V69, P1171, DOI 10.1111/all.12450; Seuter S, 2013, NUCLEIC ACIDS RES, V41, P110, DOI 10.1093/nar/gks959; Shang Y, 2013, AM J RESP CELL MOL, V49, P279, DOI 10.1165/rcmb.2012-0403OC; Sharma S, 2014, J ALLERGY CLIN IMMUN, V133, P1246, DOI 10.1016/j.jaci.2013.10.039; Shorter KR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104942; Singh SP, 2010, EUR J IMMUNOL, V40, P3183, DOI 10.1002/eji.201040443; Slaats GGG, 2012, ALLERGY, V67, P895, DOI 10.1111/j.1398-9995.2012.02831.x; Snowden AW, 2002, CURR BIOL, V12, P2159, DOI 10.1016/S0960-9822(02)01391-X; Su SY, 2014, TWIN RES HUM GENET, V17, P183, DOI 10.1017/thg.2014.22; Suter M, 2010, METABOLISM, V59, P1481, DOI 10.1016/j.metabol.2010.01.013; Thomas LR, 2008, J IMMUNOL, V181, P485, DOI 10.4049/jimmunol.181.1.485; Thomson NC, 2007, CURR ALLERGY ASTHM R, V7, P303, DOI 10.1007/s11882-007-0045-8; Verma M, 2014, MOL BIOL REP, V41, P4413, DOI 10.1007/s11033-014-3312-5; von Mutius E, 1998, CLIN EXP ALLERGY, V28, P1454; Wan ES, 2012, HUM MOL GENET, V21, P3073, DOI 10.1093/hmg/dds135; Weaver ICG, 2002, ENDOCR RES, V28, P699, DOI 10.1081/ERC-120016989; White GP, 2002, J IMMUNOL, V168, P2820, DOI 10.4049/jimmunol.168.6.2820; Wilhelm-Benartzi CS, 2012, ENVIRON HEALTH PERSP, V120, P296, DOI 10.1289/ehp.1103927; Willers SM, 2008, AM J RESP CRIT CARE, V178, P124, DOI 10.1164/rccm.200710-1544OC; Word B, 2013, INT J TOXICOL, V32, P23, DOI 10.1177/1091581812465902; Wright RJ, 1998, THORAX, V53, P1066, DOI 10.1136/thx.53.12.1066; Xue BZ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045990; Yang L, 2014, GENET MOL RES, V13, P6746, DOI 10.4238/2014.August.28.18; Yao HW, 2012, AM J PHYSIOL-LUNG C, V303, pL557, DOI 10.1152/ajplung.00175.2012; Yu Q, 2012, P NATL ACAD SCI USA, V109, P541, DOI 10.1073/pnas.1103803109; Zardo G, 2005, CELL RES, V15, P679, DOI 10.1038/sj.cr.7290337; Zentner GE, 2013, NAT STRUCT MOL BIOL, V20, P259, DOI 10.1038/nsmb.2470; Zheng WP, 2004, J IMMUNOL, V172, P114, DOI 10.4049/jimmunol.172.1.114	102	75	78	1	56	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2015	135	1					15	24		10.1016/j.jaci.2014.11.009	http://dx.doi.org/10.1016/j.jaci.2014.11.009			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AY0PG	25567039				2022-12-18	WOS:000347298200002
J	Nakagome, K; Bochkov, YA; Ashraf, S; Brockman-Schneider, RA; Evans, MD; Pasic, TR; Gern, JE				Nakagome, Kazuyuki; Bochkov, Yury A.; Ashraf, Shamaila; Brockman-Schneider, Rebecca A.; Evans, Michael D.; Pasic, Thomas R.; Gern, James E.			Effects of rhinovirus species on viral replication and cytokine production	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; cellular cytotoxicity; chemokine; cytokine; rhinovirus	AIRWAY EPITHELIAL-CELLS; INDUCED ASTHMA EXACERBATIONS; RESPIRATORY-INFECTIONS; INTERFERON-LAMBDA; IN-VITRO; CHILDREN; VIRUSES; SEVERITY; PROPAGATION; ASSOCIATION	Background: Epidemiologic studies provide evidence of differential virulence of rhinovirus species (RV). We recently reported that RV-A and RV-C induced more severe illnesses than RV-B, which suggests that the biology of RV-B might be different from RV-A or RV-C. Objective: To test the hypothesis that RV-B has lower replication and induces lesser cytokine responses than RV-A or RV-C. Methods: We cloned full-length cDNA of RV-A16, A36, B52, B72, C2, C15, and C41 from clinical samples and grew clinical isolates of RV-A7 and RV-B6 in cultured cells. Sinus epithelial cells were differentiated at the air-liquid interface. We tested for differences in viral replication in epithelial cells after infection with purified viruses (10(8) RNA copies) and measured virus load by quantitative RT-PCR. We measured lactate dehydrogenase (LDH) concentration as a marker of cellular cytotoxicity, and cytokine and/or chemokine secretion by multiplex ELISA. Results: At 24 hours after infection, the virus load of RV-B (RV-B52, RV-B72, or RV-B6) in adherent cells was lower than that of RV-A or RV-C. The growth kinetics of infection indicated that RV-B types replicate more slowly. Furthermore, RV-B released less LDH than RV-A or RV-C, and induced lower levels of cytokines and chemokines such as CXCL10, even after correction for viral replication. RV-B replicates to lower levels also in primary bronchial epithelial cells. Conclusions: Our results indicate that RV-B types have lower and slower replication, and lower cellular cytotoxicity and cytokine and/or chemokine production compared with RV-A or RV-C. These characteristics may contribute to reduced severity of illnesses that has been observed with RV-B infections.	[Nakagome, Kazuyuki; Bochkov, Yury A.; Ashraf, Shamaila; Brockman-Schneider, Rebecca A.; Gern, James E.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pediat, Madison, WI 53792 USA; [Evans, Michael D.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Biostat & Med Informat, Madison, WI 53792 USA; [Pasic, Thomas R.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Surg, Madison, WI 53792 USA; [Gern, James E.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53792 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Gern, JE (corresponding author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Pediat & Med, 600 Highland Ave, Madison, WI 53792 USA.	Gern@medicine.wisc.edu		Evans, Michael/0000-0001-7449-3993; Bochkov, Yury/0000-0003-2618-4496	National Institute of Health [U19 AI104317, P01 HL070831]; Banyu Fellowship Program - Banyu Life Science Foundation International; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL070831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI070503, U19AI104317] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Banyu Fellowship Program - Banyu Life Science Foundation International; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institute of Health grants U19 AI104317 and P01 HL070831, and by the Banyu Fellowship Program sponsored by Banyu Life Science Foundation (K. Nakagome).	Arden KE, 2010, J MED VIROL, V82, P1458, DOI 10.1002/jmv.21819; Arruda E, 1996, J CLIN MICROBIOL, V34, P1277, DOI 10.1128/JCM.34.5.1277-1279.1996; Ashraf S, 2013, VIROLOGY, V436, P143, DOI 10.1016/j.virol.2012.11.002; Bizzintino J, 2011, EUR RESPIR J, V37, P1037, DOI 10.1183/09031936.00092410; Bochkov YA, 2010, MUCOSAL IMMUNOL, V3, P69, DOI 10.1038/mi.2009.109; Bochkov YA, 2012, MICROBES INFECT, V14, P485, DOI 10.1016/j.micinf.2011.12.011; Bochkov YA, 2011, NAT MED, V17, P627, DOI 10.1038/nm.2358; Calvo C, 2010, PEDIATR INFECT DIS J, V29, P717, DOI 10.1097/INF.0b013e3181d7a708; Contoli M, 2006, NAT MED, V12, P1023, DOI 10.1038/nm1462; Cordey S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010588; DeMore JP, 2009, J ALLERGY CLIN IMMUN, V124, P245, DOI 10.1016/j.jaci.2009.05.030; Donnelly RP, 2010, J INTERF CYTOK RES, V30, P555, DOI 10.1089/jir.2010.0078; Drake JW, 1999, ANN NY ACAD SCI, V870, P100, DOI 10.1111/j.1749-6632.1999.tb08870.x; Fotakis G, 2006, TOXICOL LETT, V160, P171, DOI 10.1016/j.toxlet.2005.07.001; Friedlander SL, 2005, J ALLERGY CLIN IMMUN, V116, P267, DOI 10.1016/j.jaci.2005.06.003; Fry AM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017780; Gaajetaan GR, 2013, J INFECTION, V66, P163, DOI 10.1016/j.jinf.2012.11.008; Gern JE, 2012, AM J RESP CRIT CARE, V185, P468, DOI 10.1164/rccm.201112-2195ED; Gern JE, 2010, J VIROL, V84, P7418, DOI 10.1128/JVI.02290-09; Gerna G, 2009, J MED VIROL, V81, P1498, DOI 10.1002/jmv.21548; Gray TE, 1996, AM J RESP CELL MOL, V14, P104, DOI 10.1165/ajrcmb.14.1.8534481; Hao WD, 2012, J VIROL, V86, P13524, DOI 10.1128/JVI.02094-12; Harvala H, 2009, J CLIN VIROL, V45, P1, DOI 10.1016/j.jcv.2009.03.009; Iwane MK, 2011, J INFECT DIS, V204, P1702, DOI 10.1093/infdis/jir634; Jakiela B, 2008, AM J RESP CELL MOL, V38, P517, DOI 10.1165/rcmb.2007-0050OC; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Johnston SL, 1996, AM J RESP CRIT CARE, V154, P654, DOI 10.1164/ajrccm.154.3.8810601; Khetsuriani N, 2008, EMERG INFECT DIS, V14, P1793, DOI 10.3201/eid1411.080386; Kistler AL, 2007, VIROL J, V4, DOI 10.1186/1743-422X-4-40; Konno S, 2002, AM J RESP CELL MOL, V26, P594, DOI 10.1165/ajrcmb.26.5.4438; Larre I, 2010, P NATL ACAD SCI USA, V107, P11387, DOI 10.1073/pnas.1000500107; Lee WM, 2007, J CLIN MICROBIOL, V45, P2626, DOI 10.1128/JCM.02501-06; Lee WM, 2012, AM J RESP CRIT CARE, V186, P886, DOI 10.1164/rccm.201202-0330OC; LEE WM, 1995, VIRUS GENES, V9, P177, DOI 10.1007/BF01702661; LEE WM, 1993, J VIROL, V67, P2110, DOI 10.1128/JVI.67.4.2110-2122.1993; Linsuwanon P, 2009, J INFECTION, V59, P115, DOI 10.1016/j.jinf.2009.05.009; Mak RKY, 2011, PEDIATR INFECT DIS J, V30, P749, DOI 10.1097/INF.0b013e31821b8c71; Miller EK, 2012, AM J RESP CRIT CARE, V185, P508, DOI 10.1164/rccm.201108-1462OC; Miller EK, 2009, J CLIN VIROL, V46, P85, DOI 10.1016/j.jcv.2009.06.007; Miller EK, 2009, J ALLERGY CLIN IMMUN, V123, P98, DOI 10.1016/j.jaci.2008.10.007; Mosser AG, 2005, AM J RESP CRIT CARE, V171, P645, DOI 10.1164/rccm.200407-970OC; Mosser AG, 2002, J INFECT DIS, V185, P734, DOI 10.1086/339339; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; Osur SL, 2002, ANN ALLERG ASTHMA IM, V89, P553, DOI 10.1016/S1081-1206(10)62101-1; Palmenberg AC, 2010, J ALLERGY CLIN IMMUN, V125, P1190, DOI 10.1016/j.jaci.2010.04.010; Palmenberg AC, 2009, SCIENCE, V324, P55, DOI 10.1126/science.1165557; Papadopoulos NG, 2007, ALLERGY, V62, P457, DOI 10.1111/j.1398-9995.2007.01341.x; Schroth MK, 1999, AM J RESP CELL MOL, V20, P1220, DOI 10.1165/ajrcmb.20.6.3261; Spurrell JCL, 2005, AM J PHYSIOL-LUNG C, V289, pL85, DOI 10.1152/ajplung.00397.2004; Takeyama A, 2012, J MED VIROL, V84, P1135, DOI 10.1002/jmv.23306; Wang WS, 1998, J VIROL, V72, P1210, DOI 10.1128/JVI.72.2.1210-1218.1998; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Wark PAB, 2007, J ALLERGY CLIN IMMUN, V120, P586, DOI 10.1016/j.jaci.2007.04.046; Wark PAB, 2009, RESPIROLOGY, V14, P180, DOI 10.1111/j.1440-1843.2009.01480.x; Watters K, 2011, J VIROL, V85, P10874, DOI 10.1128/JVI.00718-11	55	75	78	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2014	134	2					332	+		10.1016/j.jaci.2014.01.029	http://dx.doi.org/10.1016/j.jaci.2014.01.029			20	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AO5GB	24636084	Green Accepted			2022-12-18	WOS:000341370800012
J	Sturm, GJ; Kranzelbinder, B; Schuster, C; Sturm, EM; Bokanovic, D; Vollmann, J; Crailsheim, K; Hemmer, W; Aberer, W				Sturm, Gunter J.; Kranzelbinder, Bettina; Schuster, Christian; Sturm, Eva M.; Bokanovic, Danijela; Vollmann, Jutta; Crailsheim, Karl; Hemmer, Wolfgang; Aberer, Werner			Sensitization to Hymenoptera venoms is common, but systemic sting reactions are rare	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asymptomatic sensitization; basophil activation test; component-resolved diagnosis; IgE determination; intradermal test; large local reaction; sting challenge; systemic sting reaction; total IgE	BASOPHIL ACTIVATION TEST; API M 1; IGE ANTIBODIES; WASP VENOM; DOUBLE POSITIVITY; V 5; ALLERGY; DIAGNOSIS; BEE; IMMUNOTHERAPY	Background: Sensitization to Hymenoptera venom without systemic sting reactions (SSRs) is commonly observed in the general population. Clinical relevance for a future sting has not yet been investigated. Objective: We aimed to evaluate the effect of these debatable sensitizations with deliberate sting challenges and to monitor serologic changes for up to 2 years. Methods: One hundred thirty-one challenges with bees and wasps were performed in 94 subjects with a hitherto irrelevant sensitization. The clinical outcome was recorded, and results of specific IgE (sIgE) determinations, skin tests, and basophil activation tests were correlated to the sting reaction. sIgE levels were monitored in reactors and nonreactors after 3 hours, 1 week, 4 weeks, and 1 year. Results: Only 5 (5.3%) patients had SSRs, but 41 (43.6%) had large local reactions (LLRs) after the sting. Compared with the general population, there was a 9.5-fold higher risk for LLRs but not for SSRs. Three hours after the sting, sIgE levels slightly decreased, but none of the 94 subjects' results turned negative. After 1 week, sIgE levels already increased, increasing up to 3.5-fold (range, 0.2- to 34.0-fold) baseline levels after 4 weeks. To assess the clinical relevance of this increase, we randomly selected 18 patients for a re-sting. Again, 50% had an LLR, but none had an SSR. Conclusion: Although sensitization to Hymenoptera venoms was common, the risk of SSRs in sensitized subjects was low in our study. The sIgE level increase after the sting was not an indicator for conversion into symptomatic sensitization. Currently available tests were not able to distinguish between asymptomatic sensitization, LLRs, and SSRs.	[Sturm, Gunter J.; Kranzelbinder, Bettina; Schuster, Christian; Bokanovic, Danijela; Aberer, Werner] Med Univ Graz, Dept Dermatol, Div Environm Dermatol & Venerol, A-8036 Graz, Austria; [Sturm, Eva M.] Med Univ Graz, Inst Expt & Clin Pharmacol, A-8036 Graz, Austria; [Vollmann, Jutta; Crailsheim, Karl] Graz Univ, Inst Zool, A-8010 Graz, Austria; [Hemmer, Wolfgang] Floridsdorf Allergy Ctr, Vienna, Austria	Medical University of Graz; Medical University of Graz; University of Graz	Sturm, GJ (corresponding author), Med Univ Graz, Dept Dermatol, Auenbruggerpl 8, A-8036 Graz, Austria.	gunter.sturm@medunigraz.at		Sturm, Eva/0000-0003-4898-884X	Austrian Society for Dermatology and Venereology	Austrian Society for Dermatology and Venereology	Supported by a grant from the Austrian Society for Dermatology and Venereology.	Bilo BM, 2005, ALLERGY, V60, P1339, DOI 10.1111/j.1398-9995.2005.00963.x; Bilo MB, 2009, CLIN EXP ALLERGY, V39, P1467, DOI 10.1111/j.1365-2222.2009.03324.x; Blaauw PJ, 1996, J ALLERGY CLIN IMMUN, V98, P39, DOI 10.1016/S0091-6749(96)70224-5; Bokanovic D, 2011, ALLERGY, V66, P1395, DOI 10.1111/j.1398-9995.2011.02659.x; Golden DBK, 1996, J ALLERGY CLIN IMMUN, V97, P579, DOI 10.1016/S0091-6749(96)70302-0; HEINIG JH, 1988, CLIN ALLERGY, V18, P71, DOI 10.1111/j.1365-2222.1988.tb02845.x; Hemmer W, 2001, J ALLERGY CLIN IMMUN, V108, P1045, DOI 10.1067/mai.2001.120013; Hofmann SC, 2011, J ALLERGY CLIN IMMUN, V127, P265, DOI 10.1016/j.jaci.2010.06.042; KEMENY DM, 1989, INT ARCH ALLER A IMM, V88, P247, DOI 10.1159/000234799; Korosec P, 2011, J ALLERGY CLIN IMMUN, V128, P671, DOI 10.1016/j.jaci.2011.03.012; MOSBECH H, 1986, CLIN ALLERGY, V16, P433, DOI 10.1111/j.1365-2222.1986.tb01978.x; Muller UR, 2009, ALLERGY, V64, P543, DOI 10.1111/j.1398-9995.2008.01794.x; PARKER JL, 1982, J ALLERGY CLIN IMMUN, V69, P200, DOI 10.1016/0091-6749(82)90100-2; PRZYBILLA B, 1988, HAUTARZT, V39, P662; Przybilla B, 2011, ALLERGO J, V20, P318, DOI 10.1007/BF03362543; Rieger-Ziegler V, 1999, INT ARCH ALLERGY IMM, V120, P166, DOI 10.1159/000024235; Schafer T, 1996, ALLERGY, V51, P372; Sturm GJ, 2007, ALLERGY, V62, P884, DOI 10.1111/j.1398-9995.2007.01413.x; Sturm GJ, 2009, ALLERGY, V64, P1319, DOI 10.1111/j.1398-9995.2009.02004.x; Sturm GJ, 2004, ALLERGY, V59, P1110, DOI 10.1111/j.1398-9995.2004.00400.x; Sturm GJ, 2012, J ALLERGY CLIN IMMUN, V130, P817, DOI 10.1016/j.jaci.2012.05.047; Sturm GJ, 2011, J ALLERGY CLIN IMMUN, V128, P247, DOI 10.1016/j.jaci.2011.02.021; Sturm GJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020842; Sturm GJ, 2009, INT ARCH ALLERGY IMM, V148, P261, DOI 10.1159/000161586; VANDERLINDEN PWG, 1994, J ALLERGY CLIN IMMUN, V94, P151, DOI 10.1053/ai.1994.v94.a54889; WRIGHT DN, 1990, ALLERGY PROC, V11, P23, DOI 10.2500/108854190778999474	26	75	76	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2014	133	6					1635	+		10.1016/j.jaci.2013.10.046	http://dx.doi.org/10.1016/j.jaci.2013.10.046			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AI2FI	24365141				2022-12-18	WOS:000336672500016
J	Drake, KA; Torgerson, DG; Gignoux, CR; Galanter, JM; Roth, LA; Huntsman, S; Eng, C; Oh, SS; Yee, SW; Lin, L; Bustamante, CD; Moreno-Estrada, A; Sandoval, K; Davis, A; Borrell, LN; Farber, HJ; Kumar, R; Avila, PC; Brigino-Buenaventura, E; Chapela, R; Ford, JG; LeNoir, MA; Lurmann, F; Meade, K; Serebrisky, D; Thyne, S; Rodriguez-Cintron, W; Sen, S; Rodriguez-Santana, JR; Hernandez, RD; Giacomini, KM; Burchard, EG				Drake, Katherine A.; Torgerson, Dara G.; Gignoux, Christopher R.; Galanter, Joshua M.; Roth, Lindsey A.; Huntsman, Scott; Eng, Celeste; Oh, Sam S.; Yee, Sook Wah; Lin, Lawrence; Bustamante, Carlos D.; Moreno-Estrada, Andres; Sandoval, Karla; Davis, Adam; Borrell, Luisa N.; Farber, Harold J.; Kumar, Rajesh; Avila, Pedro C.; Brigino-Buenaventura, Emerita; Chapela, Rocio; Ford, Jean G.; LeNoir, Michael A.; Lurmann, Fred; Meade, Kelley; Serebrisky, Denise; Thyne, Shannon; Rodriguez-Cintron, William; Sen, Saunak; Rodriguez-Santana, Jose R.; Hernandez, Ryan D.; Giacomini, Kathleen M.; Burchard, Esteban G.			A genome-wide association study of bronchodilator response in Latinos implicates rare variants	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Bronchodilator response; genome-wide association study; admixture mapping; Latinos; asthma; rare variants	LOCAL ANCESTRY; PUERTO-RICANS; ASTHMA; PHARMACOGENETICS; POLYMORPHISMS; ALBUTEROL; GENE; RESPONSIVENESS; MEXICANS; CHILDREN	Background: The primary rescue medication to treat acute asthma exacerbation is the short-acting beta(2)-adrenergic receptor agonist; however, there is variation in how well a patient responds to treatment. Although these differences might be due to environmental factors, there is mounting evidence for a genetic contribution to variability in bronchodilator response (BDR). Objective: To identify genetic variation associated with bronchodilator drug response in Latino children with asthma. Methods: We performed a genome-wide association study (GWAS) for BDR in 1782 Latino children with asthma using standard linear regression, adjusting for genetic ancestry and ethnicity, and performed replication studies in an additional 531 Latinos. We also performed admixture mapping across the genome by testing for an association between local European, African, and Native American ancestry and BDR, adjusting for genomic ancestry and ethnicity. Results: We identified 7 genetic variants associated with BDR at a genome-wide significant threshold (P<5x10(-8)), all of which had frequencies of less than 5%. Furthermore, we observed an excess of small P values driven by rare variants (frequency, <5%) and by variants in the proximity of solute carrier (SLC) genes. Admixture mapping identified 5 significant peaks; fine mapping within these peaks identified 2 rare variants in SLC22A15 as being associated with increased BDR in Mexicans. Quantitative PCR and immunohistochemistry identified SLC22A15 as being expressed in the lung and bronchial epithelial cells. Conclusion: Our results suggest that rare variation contributes to individual differences in response to albuterol in Latinos, notably in SLC genes that include membrane transport proteins involved in the transport of endogenous metabolites and xenobiotics. Resequencing in larger, multiethnic population samples and additional functional studies are required to further understand the role of rare variation in BDR.	[Drake, Katherine A.; Torgerson, Dara G.; Gignoux, Christopher R.; Galanter, Joshua M.; Roth, Lindsey A.; Huntsman, Scott; Eng, Celeste; Oh, Sam S.; Burchard, Esteban G.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94158 USA; [Yee, Sook Wah; Lin, Lawrence; Hernandez, Ryan D.; Giacomini, Kathleen M.; Burchard, Esteban G.] Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94158 USA; [Thyne, Shannon] Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94158 USA; [Sen, Saunak] Univ Calif San Francisco, Dept Biostat, San Francisco, CA 94158 USA; [Bustamante, Carlos D.; Moreno-Estrada, Andres; Sandoval, Karla] Stanford Univ, Dept Genet, Stanford, CA 94305 USA; [Davis, Adam; Meade, Kelley] Childrens Hosp & Res Ctr Oakland, Oakland, CA USA; [Borrell, Luisa N.] CUNY Herbert H Lehman Coll, Dept Hlth Sci, Grad Program Publ Hlth, Bronx, NY 10468 USA; [Farber, Harold J.] Baylor Coll Med, Dept Pediat, Sect Pulmonol, Houston, TX 77030 USA; [Farber, Harold J.] Texas Childrens Hosp, Houston, TX 77030 USA; [Kumar, Rajesh] Northwestern Univ, Childrens Mem Hosp, Chicago, IL 60614 USA; [Kumar, Rajesh] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA; [Avila, Pedro C.] Northwestern Univ, Feinberg Sch Med, Div Allergy Immunol, Chicago, IL 60611 USA; [Brigino-Buenaventura, Emerita] Kaiser Permanente Vallejo Med Ctr, Dept Allergy & Immunol, Vallejo, CA USA; [Chapela, Rocio] INER, Mexico City, DF, Mexico; [Ford, Jean G.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA; [LeNoir, Michael A.] Bay Area Pediat, Oakland, CA USA; [Lurmann, Fred] Sonoma Technol, Petaluma, CA USA; [Serebrisky, Denise] Jacobi Med Ctr, Pediat Pulm Div, Bronx, NY USA; [Rodriguez-Cintron, William] Vet Caribbean Hlth Care Syst, San Juan, PR USA; [Rodriguez-Santana, Jose R.] Ctr Neumol Pediat, San Juan, PR USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Stanford University; Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland; City University of New York (CUNY) System; Lehman College (CUNY); Baylor College of Medicine; Baylor College of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Kaiser Permanente; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Jacobi Medical Center	Torgerson, DG (corresponding author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94158 USA.	dara.torgerson@ucsf.edu	Moreno-Estrada, Andres/R-3950-2017; Moreno-Estrada, Andres/AAP-4657-2021; Giacomini, Kathleen/AEF-2452-2022; Borrell, Luisa N./G-8753-2018	Moreno-Estrada, Andres/0000-0001-8329-8292; Moreno-Estrada, Andres/0000-0001-8329-8292; Borrell, Luisa N./0000-0002-0560-4853; Sandoval, Karla/0000-0002-6175-2463; Galanter, Joshua/0000-0002-2561-6384; Yee, Sook Wah/0000-0001-8121-8746; Lin, Lawrence/0000-0003-4248-9740; Bustamante, Carlos D./0000-0002-4187-7920; Kumar, Rajesh/0000-0002-1962-7108	National Institute of Health [HL088133, HL078885, M01-RR00188, T32GM07175]; National Institute on Minority Health and Health Disparities [P60MD006902]; National Institutes of Environmental Health Sciences [ES015794]; Flight Attendant Medical Research Institute (FAMRI); Sandler Foundation; Ernest Bazley Grant; NATIONAL CANCER INSTITUTE [R25CA113710] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000188] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007185, K23HL111636, R01HL078885, R01HL088133] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES015794] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007175, T32GM007546] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD)); National Institutes of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Flight Attendant Medical Research Institute (FAMRI); Sandler Foundation; Ernest Bazley Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Supported by grants from the National Institute of Health (HL088133 and HL078885 to E.G.B. and M01-RR00188 to Texas Children's Hospital General Clinical Research Center), the National Institute on Minority Health and Health Disparities (P60MD006902), the National Institutes of Environmental Health Sciences (ES015794 to E.G.B.), the National Institutes of Health Training Grant (T32GM07175), the Flight Attendant Medical Research Institute (FAMRI), the Sandler Foundation, and an Ernest Bazley Grant (to P.C.A.).	Alexander DH, 2009, GENOME RES, V19, P1655, DOI 10.1101/gr.094052.109; Altshuler D, 2010, NATURE, V467, P1061, DOI 10.1038/nature09534; Baran Y, 2012, BIOINFORMATICS, V28, P1359, DOI 10.1093/bioinformatics/bts144; Blake K, 2008, CHEST, V134, P981, DOI 10.1378/chest.07-2991; Browning SR, 2006, AM J HUM GENET, V78, P903, DOI 10.1086/503876; Burchard EG, 2004, AM J RESP CRIT CARE, V169, P386, DOI 10.1164/rccm.200309-1293OC; Casella, 2002, STAT INFERENCE, P660; Choudhry S, 2005, AM J RESP CRIT CARE, V171, P563, DOI 10.1164/rccm.200409-1286OC; Contopoulos-Ioannidis DG, 2006, PHARMACOGENET GENOM, V16, P705, DOI 10.1097/01.fpc.0000236332.11304.8f; Cropp CD, 2008, MOL PHARMACOL, V73, P1151, DOI 10.1124/mol.107.043117; Delaneau O, 2012, NAT METHODS, V9, P179, DOI [10.1038/NMETH.1785, 10.1038/nmeth.1785]; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; Drazen JM, 2000, BRIT MED BULL, V56, P1054, DOI 10.1258/0007142001903535; Duan QL, 2013, PHARMACOGENOMICS J, V13, P130, DOI 10.1038/tpj.2011.56; Eraly SA, 2002, BIOCHEM BIOPH RES CO, V297, P1159, DOI 10.1016/S0006-291X(02)02343-4; Giacomini KM, 2006, GOODMAN GILMANS PHAR, P41; Gravel S, 2011, P NATL ACAD SCI USA, V108, P11983, DOI 10.1073/pnas.1019276108; Himes BE, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002824; Hoffmann TJ, 2011, GENOMICS, V98, P422, DOI 10.1016/j.ygeno.2011.08.007; Howie BN, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000529; Litonjua AA, 2008, AM J RESP CRIT CARE, V178, P688, DOI 10.1164/rccm.200709-1363OC; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Martinez FD, 1997, J CLIN INVEST, V100, P3184, DOI 10.1172/JCI119874; Myers RM, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001046; Naqvi M, 2007, J ASTHMA, V44, P639, DOI 10.1080/02770900701554441; NELSON HS, 1995, NEW ENGL J MED, V333, P499, DOI 10.1056/NEJM199508243330807; Palmer LJ, 2002, AM J RESP CRIT CARE, V165, P861, DOI 10.1164/ajrccm.165.7.2109096; Poon AH, 2008, PHARMACOGENET GENOM, V18, P373, DOI 10.1097/FPC.0b013e3282fa760a; Sankararaman S, 2008, AM J HUM GENET, V82, P290, DOI 10.1016/j.ajhg.2007.09.022; Schlessinger A, 2010, PROTEIN SCI, V19, P412, DOI 10.1002/pro.320; Silverman EK, 2003, J ALLERGY CLIN IMMUN, V112, P870, DOI 10.1016/S0091-6749(03)02023-2; Tantisira KG, 2005, HUM MOL GENET, V14, P1671, DOI 10.1093/hmg/ddi175; Team RDC R: A language and environment for statistical computing, R LANG ENV STAT COMP; Torgerson DG, 2012, J ALLERGY CLIN IMMUN, V130, P76, DOI 10.1016/j.jaci.2012.02.040; Yamashita N, 2005, CELL IMMUNOL, V235, P85, DOI 10.1016/j.cellimm.2005.07.006; Yan XL, 2010, J CLIN ENDOCR METAB, V95, P1412, DOI 10.1210/jc.2009-2277	36	75	75	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2014	133	2					370	+		10.1016/j.jaci.2013.06.043	http://dx.doi.org/10.1016/j.jaci.2013.06.043			24	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EF	23992748	Green Accepted			2022-12-18	WOS:000332397100009
J	Kazani, S; Planaguma, A; Ono, E; Bonini, M; Zahid, M; Marigowda, G; Wechsler, ME; Levy, BD; Israel, E				Kazani, Shamsah; Planaguma, Anna; Ono, Emiko; Bonini, Matteo; Zahid, Muhammad; Marigowda, Gautham; Wechsler, Michael E.; Levy, Bruce D.; Israel, Elliot			Exhaled breath condensate eicosanoid levels associate with asthma and its severity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; biomarkers; breath tests; eicosanoids; leukotriene B-4; lipoxin A(4)	ASPIRIN-TRIGGERED 15-EPI-LXA(4); LIPOXIN A(4); AIRWAY INFLAMMATION; ANTI-INFLAMMATION; LIPID MEDIATORS; LEUKOTRIENE B-4; RESPONSES; CHILDREN; DISEASE; SPUTUM	Background: The relationship between anti-inflammatory lipoxins and proinflammatory leukotrienes might be important in the pathobiology and severity of asthma. Objective: We sought to investigate whether exhaled breath condensate (EBC) lipoxin and leukotriene measurements can noninvasively characterize the asthmatic diathesis and its severity. Methods: We measured lipoxin A(4) (LXA(4)) and leukotriene B-4 (LTB4) levels in EBC collected from patients with asthma of different severities and from healthy control subjects. Results: EBC LXA(4) and LTB4 levels are increased in asthmatic patients compared with those seen in healthy control subjects (LXA(4): 31.40 vs 2.41 pg/mL EBC, respectively [P < .001]; LTB4: 45.62 vs 3.82 pg/mL EBC, respectively [P < .001]). Although levels of both eicosanoids are increased in asthmatic patients, the LXA(4)/LTB4 ratio decreases with increasing asthma severity. It is 41% lower in patients with severe versus moderate asthma (0.52 vs 0.88, P = .034). EBC LXA(4) levels correlate with the degree of airflow obstruction measured by using FEV1 (r = 0.28, P = .018). An LXA(4) cutoff value of 7 pg/mL EBC provides 90% sensitivity and 92% specificity for the diagnosis of asthma (area under the curve, 0.96; P < .001). An LTB4 cutoff value of 11 pg/mL EBC provides 100% sensitivity and 100% specificity for the diagnosis of asthma (area under the curve, 1; P < .001). Conclusions: Proresolving and proinflammatory eicosanoids are generated in the airways of all asthmatic patients. The proportion of proresolving compounds decreases with asthma severity. These findings support the role for EBC eicosanoid measurements in the noninvasive diagnosis of asthma and suggest that proresolving eicosanoid pathways are dysregulated in patients with severe asthma.	[Kazani, Shamsah; Planaguma, Anna; Ono, Emiko; Bonini, Matteo; Zahid, Muhammad; Marigowda, Gautham; Wechsler, Michael E.; Levy, Bruce D.; Israel, Elliot] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Internal Med,Pulm & Crit Care Div, Cambridge, MA 02138 USA	Harvard University; Brigham & Women's Hospital	Kazani, S (corresponding author), Brigham & Womens Hosp, PBB Clin 3, 75 Francis St, Boston, MA 02115 USA.	skazani@partners.org	Bonini, Matteo/AAB-1093-2019; Wechsler, Michael/AAC-5506-2019	BONINI, Matteo/0000-0002-3042-0765	NIH/NLHBI [HL069349, HL107166, HL109172]; NIH/NIAID [AI068084]; NIH/NCRR [RR022292, RR025757, RR025758]; National Institutes of Health (National Heart Lung and Blood Institute's Severe Asthma Research Program and Asthma Clinical Research Network); American Lung Institute; KL2 Medical Research Investigator Training (MeRIT) award from Harvard Catalyst \ The Harvard Clinical and Translational Science Center (National Center for Research Resources; KL2 Medical Research Investigator Training (MeRIT) award from National Center for Advancing Translational Sciences, National Institutes of Health Award [8KL2TR000168-05]; Merck; National Institutes of Health; Aerovance; Amgen; i3 Research (Biota); Genentech; MedImmune; Novartis; Spanish Society of Allergy & Immunology (SEAIC Congress-Madrid); Western Society of Allergy, Asthma & Immunology (WSAAI-Maui); World Allergy Congress (WAC-Cancun); World Allergy Congress (WAC-India); NATIONAL CENTER FOR RESEARCH RESOURCES [KL2RR025757, UL1RR025758, K30RR022292] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U10HL109172, U10HL051831, R01HL069349, P50HL107166] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI068084, R01AI068084] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM095467] Funding Source: NIH RePORTER	NIH/NLHBI; NIH/NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH/NCRR(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Institutes of Health (National Heart Lung and Blood Institute's Severe Asthma Research Program and Asthma Clinical Research Network); American Lung Institute; KL2 Medical Research Investigator Training (MeRIT) award from Harvard Catalyst \ The Harvard Clinical and Translational Science Center (National Center for Research Resources; KL2 Medical Research Investigator Training (MeRIT) award from National Center for Advancing Translational Sciences, National Institutes of Health Award; Merck(Merck & Company); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Aerovance; Amgen(Amgen); i3 Research (Biota); Genentech(Roche HoldingGenentech); MedImmune(AstraZenecaMedimmune); Novartis(Novartis); Spanish Society of Allergy & Immunology (SEAIC Congress-Madrid); Western Society of Allergy, Asthma & Immunology (WSAAI-Maui); World Allergy Congress (WAC-Cancun); World Allergy Congress (WAC-India); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Supported by NIH/NLHBI grants HL069349, HL107166, and HL109172; NIH/NIAID grant AI068084; and NIH/NCRR grants RR022292, RR025757, and RR025758.; S. Kazani has received research and travel support from the National Institutes of Health (National Heart Lung and Blood Institute's Severe Asthma Research Program and Asthma Clinical Research Network) and the American Lung Institute. The work was conducted with the support of a KL2 Medical Research Investigator Training (MeRIT) award from Harvard Catalyst vertical bar The Harvard Clinical and Translational Science Center (National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health Award 8KL2TR000168-05). The content is solely the responsibility of the authors and does not necessarily represent the official views of Harvard Catalyst, Harvard University and its affiliated academic health care centers, or the National Institutes of Health. M. E. Wechsler has consultant arrangements with GlaxoSmithKline, Novartis, Cephalon/TEVA, Sepracor/SUNOVION, Schering-Plough, NKT Therapeutics, Asthmatx/BSCI, Genzyme, MapPharma, Genentech, Boehringer Ingelheim, Merck, and Cytos and has received payment for lectures from Merck. B. D. Levy has received research support from the National Institutes of Health; has consultant arrangements with Novartis, Eisai, and Fresenius; and is coinventor on patents issued on lipoxins in airway diseases that were outlicensed by Brigham and Women's Hospital for clinical development. E. Israel has consultant arrangements with Abbott, Amgen, Cowen & Co, Infinity Pharmaceuticals, MedImmune (now AstraZeneca), Merck, newMentor, NKT Therapeutics, Ono Pharmaceuticals, Regeneron Pharmaceuticals, Schering Plough, TEVA Specialty Pharmaceuticals, Gilead Sciences, Johnson & Johnson, and Agenzia Italiana del Farmico; has provided expert testimony for Campbell, Campbell, Edwards & Conroy, Diedrich & Donohue, Ficksman & Conley, Ryan Ryan Deluca LLP, and Sullway & Hollis; has received grants from Aerovance, Amgen, i3 Research (Biota), Genentech, MedImmune, and Novartis; has received payment for lectures from Merck, the Spanish Society of Allergy & Immunology (SEAIC Congress-Madrid), Western Society of Allergy, Asthma & Immunology (WSAAI-Maui), and the World Allergy Congress (WAC-Cancun and WAC-India); and has received royalties from UpToDate. The rest of the authors declare that they have no relevant conflicts of interest.	[Anonymous], 2000, AM J RESP CRIT CARE, V162, P2341; BADR KF, 1989, P NATL ACAD SCI USA, V86, P3438, DOI 10.1073/pnas.86.9.3438; Bandeira-Melo C, 2002, ADV EXP MED BIOL, V507, P211; Bhavsar PK, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-71; Bonnans C, 2002, AM J RESP CRIT CARE, V165, P1531, DOI 10.1164/rccm.200201-053OC; Borish L, 2002, ANN ALLERG ASTHMA IM, V88, P16, DOI 10.1016/S1081-1206(10)62024-8; Bozinovski S, 2012, P NATL ACAD SCI USA, V109, P935, DOI 10.1073/pnas.1109382109; Celik GE, 2007, CLIN EXP ALLERGY, V37, P1494, DOI 10.1111/j.1365-2222.2007.02806.x; Chiron R, 2008, J CYST FIBROS, V7, P463, DOI 10.1016/j.jcf.2008.04.002; CHRISTIE PE, 1992, AM REV RESPIR DIS, V145, P1281, DOI 10.1164/ajrccm/145.6.1281; CLAESSON HE, 1992, INT J IMMUNOPHARMACO, V14, P441, DOI 10.1016/0192-0561(92)90174-J; Csoma Z, 2002, AM J RESP CRIT CARE, V166, P1345, DOI 10.1164/rccm.200203-233OC; Drazen JM, 1999, NEW ENGL J MED, V340, P197, DOI 10.1056/NEJM199901213400306; Fritscher LG, 2012, J BREATH RES, V6, DOI 10.1088/1752-7155/6/2/026001; Gras D, 2012, J ALLERGY CLIN IMMUN, V129, P1259, DOI 10.1016/j.jaci.2012.01.073; Gronert K, 2001, AM J PATHOL, V158, P3, DOI 10.1016/S0002-9440(10)63937-5; Hasan RA, 2012, PEDIATR CRIT CARE ME, V13, P141, DOI 10.1097/PCC.0b013e3182231644; Horvath I, 2005, EUR RESPIR J, V26, P523, DOI 10.1183/09031936.05.00029705; Kazani S, 2010, J BREATH RES, V4, DOI 10.1088/1752-7155/4/4/047001; Kostikas K, 2005, CHEST, V127, P1553, DOI 10.1378/chest.127.5.1553; Kowal-Bielecka O, 2005, ARTHRITIS RHEUM-US, V52, P3783, DOI 10.1002/art.21432; LEE TH, 1989, CLIN SCI, V77, P195, DOI 10.1042/cs0770195; Levy BD, 2002, NAT MED, V8, P1018, DOI 10.1038/nm748; Levy BD, 2005, AM J RESP CRIT CARE, V172, P824, DOI 10.1164/rccm.200410-1413OC; Levy BD, 2007, J IMMUNOL, V178, P496, DOI 10.4049/jimmunol.178.1.496; McGrath KW, 2012, AM J RESP CRIT CARE, V185, P612, DOI 10.1164/rccm.201109-1640OC; Mondino C, 2004, J ALLERGY CLIN IMMUN, V114, P761, DOI 10.1016/j.jaci.2004.06.054; Moore WC, 2007, J ALLERGY CLIN IMMUN, V119, P405, DOI 10.1016/j.jaci.2006.11.639; National Institutes of Health, 2010, NIH PUBL, V08-4051; Ogawa Y, 2006, J ALLERGY CLIN IMMUN, V118, P789, DOI 10.1016/j.jaci.2006.08.009; Planaguma A, 2008, AM J RESP CRIT CARE, V178, P574, DOI 10.1164/rccm.200801-061OC; Sanak M, 2000, EUR RESPIR J, V16, P44, DOI 10.1034/j.1399-3003.2000.16a08.x; Serhan CN, 2003, CHEM IMMUNOL, V83, P115; Serhan CN, 2002, PROSTAG OTH LIPID M, V68-9, P433, DOI 10.1016/S0090-6980(02)00047-3; Silkoff PE, 2001, CHEST, V119, P1322, DOI 10.1378/chest.119.5.1322; Szefler SJ, 2012, J ALLERGY CLIN IMMUN, V129, pS9, DOI 10.1016/j.jaci.2011.12.979; Vachier I, 2005, J ALLERGY CLIN IMMUN, V115, P55, DOI 10.1016/j.jaci.2004.09.038; Wu SH, 2010, PEDIATR PULM, V45, P333, DOI 10.1002/ppul.21186; Yang J, 2012, FREE RADICAL BIO MED, V53, P160, DOI 10.1016/j.freeradbiomed.2012.05.001	39	75	76	0	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2013	132	3					547	553		10.1016/j.jaci.2013.01.058	http://dx.doi.org/10.1016/j.jaci.2013.01.058			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	207OS	23608729	Green Accepted			2022-12-18	WOS:000323612000004
J	Frei, R; Ferstl, R; Konieczna, P; Ziegler, M; Simon, T; Rugeles, TM; Mailand, S; Watanabe, T; Lauener, R; Akdis, CA; O'Mahony, L				Frei, Remo; Ferstl, Ruth; Konieczna, Patrycja; Ziegler, Mario; Simon, Tunde; Rugeles, Tulia Mateus; Mailand, Susanne; Watanabe, Takeshi; Lauener, Roger; Akdis, Cezmi A.; O'Mahony, Liam			Histamine receptor 2 modifies dendritic cell responses to microbial ligands	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Dendritic cell; microbiota; pattern recognition receptors; histamine; histamine receptors; nuclear factor kB; cyclic AMP; Lactobacillus rhamnosus	TOLL-LIKE RECEPTORS; T REGULATORY CELLS; CYTOKINE PRODUCTION; ADAPTIVE IMMUNITY; INNATE; MICE; H-2-RECEPTOR; INFLAMMATION; INHIBITION; INFECTION	Background: The induction of tolerance and protective immunity to microbes is significantly influenced by host-and microbiota-derived metabolites, such as histamine. Objective: We sought to identify the molecular mechanisms for histamine-mediated modulation of pattern recognition receptor signaling. Methods: Human monocyte-derived dendritic cells (MDDCs), myeloid dendritic cells, and plasmacytoid dendritic cells were examined. Cytokine secretion, gene expression, and transcription factor activation were measured after stimulation with microbial ligands and histamine. Histamine receptor 2 (H2R)-deficient mice, histamine receptors, and their signaling pathways were investigated. Results: Histamine suppressed MDDC chemokine and proinflammatory cytokine secretion, nuclear factor kappa B and activator protein 1 activation, mitogen-activated protein kinase phosphorylation, and T(H)1 polarization of naive lymphocytes, whereas IL-10 secretion was enhanced in response to LPS and Pam3Cys. Histamine also suppressed LPS-induced myeloid dendritic cell TNF-alpha secretion and suppressed CpG-induced plasmacytoid dendritic cell IFN-alpha gene expression. H2R signaling through cyclic AMP and exchange protein directly activated by cyclic AMP was required for the histamine effect on LPS-induced MDDC responses. Lactobacillus rhamnosus, which secretes histamine, significantly suppressed Peyer patch IL-2, IL-4, IL-5, IL-12, TNF-alpha, and GM-CSF secretion in wild-type but not H2R-deficient animals. Conclusion: Both host-and microbiota-derived histamine significantly alter the innate immune response to microbes through H2R.	[Frei, Remo; Ferstl, Ruth; Konieczna, Patrycja; Ziegler, Mario; Rugeles, Tulia Mateus; Mailand, Susanne; Akdis, Cezmi A.; O'Mahony, Liam] Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Davos, Switzerland; [Frei, Remo; Lauener, Roger; Akdis, Cezmi A.] Christine Kuhne Ctr Allergy Res & Educ, Davos, Switzerland; [Simon, Tunde] Univ Debrecen, Dept Immunol, Med & Hlth Sci Ctr, Debrecen, Hungary; [Watanabe, Takeshi] Kyoto Univ, Kyoto 6068501, Japan; [Lauener, Roger] Hochgebirgsklin Davos Wolfgang, Davos, Switzerland	Swiss Institute of Allergy & Asthma Research; University of Zurich; University of Debrecen; Kyoto University	O'Mahony, L (corresponding author), SIAF, Obere Str 22, CH-7270 Davos, Switzerland.	liam.omahony@siaf.uzh.ch	Frei, Remo/AAI-9180-2020; O'Mahony, Liam/AAG-5838-2019; Ferstl, Ruth/ABB-9679-2021; Lauener, Roger P/O-8612-2016; Akdis, Cezmi/AAV-4844-2020	O'Mahony, Liam/0000-0003-4705-3583; Lauener, Roger P/0000-0002-8412-606X; Akdis, Cezmi/0000-0001-8020-019X	Swiss National Foundation [310030-127356, 32003027618/1]; Christine Kuhne-Center for Allergy Research and Education (CK-CARE); European Union [BM0806]; MEXT; Kuhne Foundation and the European Union; Grants-in-Aid for Scientific Research [24111009] Funding Source: KAKEN	Swiss National Foundation(Swiss National Science Foundation (SNSF)); Christine Kuhne-Center for Allergy Research and Education (CK-CARE); European Union(European Commission); MEXT(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Kuhne Foundation and the European Union; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	Supported by Swiss National Foundation grants (project nos. 310030-127356 and 32003027618/1), the Christine Kuhne-Center for Allergy Research and Education (CK-CARE), European Union research grants, COSTAction BM0806, and European Union Marie Curie grants.; Disclosure of potential conflict of interest: T. Watanabe has received grants and travel support from MEXT. R. Lauener has received grants from the Kuhne Foundation and the European Union and serves on advisory boards of Merck Sharp & Dohme, Novartis, Nestle, and Menarini. C. A. Akdis has consultant arrangements with Actellion, Aventis, Stallergenes, Allergopharma, and Circacia; is employed by the Swiss Institute of Allergy and Asthma Research; and has received grants from Novartis, PREDICTA: European Commission's Seventh Framework, the Swiss National Science Foundation, MeDALL: European Commission's Seventh Framework Programme, and the Christine Kuhne- Center for Allergy Research and Education. L. O'Mahony has received grants from the Swiss National Science Foundation and the European Union and has consultant arrangements with Alimentary Health Ltd. The rest of the authors declare that they have no relevant conflicts of interest.	Aronoff DM, 2005, J IMMUNOL, V174, P595, DOI 10.4049/jimmunol.174.2.595; Beghdadi W, 2008, J EXP MED, V205, P395, DOI 10.1084/jem.20071548; Chen KQ, 2011, INT IMMUNOPHARMACOL, V11, P1391, DOI 10.1016/j.intimp.2011.05.003; Coton E, 2005, J MICROBIOL METH, V63, P296, DOI 10.1016/j.mimet.2005.04.001; Coton M, 2010, FOOD MICROBIOL, V27, P1078, DOI 10.1016/j.fm.2010.07.012; Ferstl R, 2012, FRONT BIOSCI-LANDMRK, V17, P40, DOI 10.2741/3914; Frei R, 2012, ALLERGY, V67, P451, DOI 10.1111/j.1398-9995.2011.02783.x; Handley SA, 2006, P NATL ACAD SCI USA, V103, P9268, DOI 10.1073/pnas.0510414103; Hormannsperger G, 2012, J ALLERGY CLIN IMMUN, V129, P1452, DOI 10.1016/j.jaci.2011.12.993; Iwasaki A, 2010, SCIENCE, V327, P291, DOI 10.1126/science.1183021; Jutel M, 2009, CLIN EXP ALLERGY, V39, P1786, DOI 10.1111/j.1365-2222.2009.03374.x; Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863; Kobayashi T, 2000, J CLIN INVEST, V105, P1741, DOI 10.1172/JCI9441; Konieczna P, 2012, GUT, V61, P354, DOI 10.1136/gutjnl-2011-300936; Lever A, 2007, BMJ-BRIT MED J, V335, P879, DOI 10.1136/bmj.39346.495880.AE; Liew FY, 2005, NAT REV IMMUNOL, V5, P446, DOI 10.1038/nri1630; Maslowski KM, 2009, NATURE, V461, P1282, DOI 10.1038/nature08530; Mazzoni A, 2001, J CLIN INVEST, V108, P1865, DOI 10.1172/JCI200113930; Meijer K, 2010, CURR OPIN CLIN NUTR, V13, P715, DOI 10.1097/MCO.0b013e32833eebe5; Meiler F, 2008, J EXP MED, V205, P2887, DOI 10.1084/jem.20080193; Metz M, 2011, INT ARCH ALLERGY IMM, V155, P355, DOI 10.1159/000321614; Novak N, 2012, J ALLERGY CLIN IMMUN, V130, P1153, DOI 10.1016/j.jaci.2012.04.039; O'Mahony L, 2011, J ALLERGY CLIN IMMUN, V128, P1153, DOI 10.1016/j.jaci.2011.06.051; O'Mahony L, 2010, AUTOIMMUNITY, V43, P493, DOI 10.3109/08916931003674725; Reece P, 2011, J ALLERGY CLIN IMMUN, V127, P447, DOI 10.1016/j.jaci.2010.11.006; Roduit C, 2011, J ALLERGY CLIN IMMUN, V127, P179, DOI 10.1016/j.jaci.2010.10.010; Shirshev SV, 2011, BIOCHEMISTRY-MOSCOW+, V76, P981, DOI 10.1134/S000629791109001X; Teuscher C, 2004, AM J PATHOL, V164, P883, DOI 10.1016/S0002-9440(10)63176-8; Thomas CM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031951; Vanbervliet B, 2011, J ALLERGY CLIN IMMUN, V127, P943, DOI 10.1016/j.jaci.2010.12.002; Wood LG, 2011, CLIN EXP ALLERGY, V41, P640, DOI 10.1111/j.1365-2222.2010.03669.x	31	75	79	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2013	132	1					194	U330		10.1016/j.jaci.2013.01.013	http://dx.doi.org/10.1016/j.jaci.2013.01.013			23	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	173BF	23465664				2022-12-18	WOS:000321052300024
J	Stoevesandt, J; Hain, J; Kerstan, A; Trautmann, A				Stoevesandt, Johanna; Hain, Johannes; Kerstan, Andreas; Trautmann, Axel			Over- and underestimated parameters in severe Hymenoptera venom-induced anaphylaxis: Cardiovascular medication and absence of urticaria/angioedema	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ACE inhibitor; allergy; anaphylaxis; beta-blocker; cardiovascular medication; Hymenoptera venom; mastocytosis; risk factor; tryptase; urticaria	BASAL SERUM TRYPTASE; INSECT STING ALLERGY; FATAL ANAPHYLAXIS; EUROPEAN ACADEMY; IMMUNOTHERAPY; MASTOCYTOSIS; HISTORY; DEATHS; HYPERSENSITIVITY; MANAGEMENT	Background: Severe anaphylaxis in Hymenoptera venom allergy has been associated with a number of risk factors including elevation of baseline serum tryptase (BST), older age, concomitant diseases, and concurrent medication. Objective: The aim of this study was to evaluate indicators and risk factors for severe anaphylaxis due to Hymenoptera field stings with an emphasis on details related to the sting reaction and concurrent medication. Methods: In this single-center observational cohort study, we included 657 consecutive patients fulfilling the criteria for venom immunotherapy. Severity of sting-induced anaphylaxis was analyzed in relation to patient-specific risk factors (age and sex, preexisting cardiopulmonary conditions, cardiovascular medication) and details related to the sting reaction (culprit insect, localization of the sting, time interval to onset of symptoms, and presence or absence of cutaneous involvement). BST was determined in a subgroup of patients with moderate to severe anaphylaxis. Results: Four significant indicators and risk factors of severe anaphylaxis were identified (P < .001): (1) elevation of BST, (2) absence of urticaria or angioedema during anaphylaxis, (3) time interval of less than 5 minutes from sting to onset of symptoms, and (4) senior age. The absence of urticaria/angioedema is significantly related to BST elevation (P = .02). No relationship could be established between the severity of anaphylaxis and comorbidities or concurrent cardiovascular medication. Conclusions: Absence of urticaria/angioedema is an indicator of severe anaphylaxis and possibly mastocytosis, requiring determination of BST. Study data do not provide evidence for an aggravation of sting-induced anaphylaxis by concurrent beta-blockade or angiotensin-converting enzyme inhibition. (J Allergy Clin Immunol 2012;130:698-704.)	[Stoevesandt, Johanna; Kerstan, Andreas; Trautmann, Axel] Univ Wurzburg, Dept Dermatol Venereol & Allergol, D-97080 Wurzburg, Germany; [Hain, Johannes] Univ Wurzburg, Dept Stat, Inst Math, D-97080 Wurzburg, Germany	University of Wurzburg; University of Wurzburg	Stoevesandt, J (corresponding author), Univ Wurzburg, Dept Dermatol Venereol & Allergol, Josef Schneider Str 2, D-97080 Wurzburg, Germany.	Stoevesandt_J@klinik.uni-wuerzburg.de		Kerstan, Andreas/0000-0001-6483-0191				Bains SN, 2010, ANN ALLERG ASTHMA IM, V104, P1, DOI 10.1016/j.anai.2009.11.006; BARNARD JH, 1973, J ALLERGY CLIN IMMUN, V52, P259, DOI 10.1016/0091-6749(73)90044-4; Bilo BM, 2008, CURR OPIN ALLERGY CL, V8, P330, DOI 10.1097/ACI.0b013e32830638c5; Bilo BM, 2005, ALLERGY, V60, P1339, DOI 10.1111/j.1398-9995.2005.00963.x; Blum S, 2011, ALLERGY, V66, P222, DOI 10.1111/j.1398-9995.2010.02470.x; Bonadonna P, 2010, CURR OPIN ALLERGY CL, V10, P347, DOI 10.1097/ACI.0b013e32833b280c; Bonifazi F, 2005, ALLERGY, V60, P1459, DOI 10.1111/j.1398-9995.2005.00960.x; Brockow K, 2008, ALLERGY, V63, P226, DOI 10.1111/j.1398-9995.2007.01569.x; Clark S, 2005, J ALLERGY CLIN IMMUN, V116, P643, DOI 10.1016/j.jaci.2005.06.026; Cox L, 2011, J ALLERGY CLIN IMMUN, V127, DOI 10.1016/j.jaci.2010.09.034; Elberink JNGO, 1997, J ALLERGY CLIN IMMUN, V99, P153, DOI 10.1016/S0091-6749(97)70314-2; Foody JM, 2002, JAMA-J AM MED ASSOC, V287, P883, DOI 10.1001/jama.287.7.883; Freemantle N, 1999, BMJ-BRIT MED J, V318, P1730, DOI 10.1136/bmj.318.7200.1730; Fricker M, 1997, J ALLERGY CLIN IMMUN, V100, P11, DOI 10.1016/S0091-6749(97)70188-X; Golden DBK, 2011, J ALLERGY CLIN IMMUN, V127, P852, DOI 10.1016/j.jaci.2011.01.025; Golden DB, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Golden DBK, 2005, J ALLERGY CLIN IMMUN, V115, P439, DOI 10.1016/j.jaci.2005.01.005; Greenberger PA, 2007, ANN ALLERG ASTHMA IM, V98, P252, DOI 10.1016/S1081-1206(10)60714-4; Guenova E, 2010, ALLERGY, V65, P919, DOI 10.1111/j.1398-9995.2009.02302.x; Haeberli G, 2003, CLIN EXP ALLERGY, V33, P1216, DOI 10.1046/j.1365-2222.2003.01755.x; Helbling A, 2004, CLIN EXP ALLERGY, V34, P285, DOI 10.1111/j.1365-2222.2004.01882.x; Kucharewicz I, 2007, J INVEST ALLERG CLIN, V17, P65; LOCKEY RF, 1988, J ALLERGY CLIN IMMUN, V82, P370, DOI 10.1016/0091-6749(88)90008-5; Mueller UR, 2007, CURR OPIN ALLERGY CL, V7, P337, DOI 10.1097/ACI.0b013e328259c328; Muller UR, 2005, J ALLERGY CLIN IMMUN, V115, P606, DOI [10.1016/j.jaci.2004.11.012, 10.1016/j.jsci.2004.11.012]; Muraro A, 2007, ALLERGY, V62, P857, DOI 10.1111/j.1398-9995.2007.01421.x; Potier A, 2009, CLIN EXP ALLERGY, V39, P717, DOI 10.1111/j.1365-2222.2009.03210.x; Pumphrey R, 2004, CURR OPIN ALLERGY CL, V4, P285, DOI 10.1097/01.all.0000136762.89313.0b; Pumphrey RSH, 2000, CLIN EXP ALLERGY, V30, P1144, DOI 10.1046/j.1365-2222.2000.00864.x; REISMAN RE, 1992, J ALLERGY CLIN IMMUN, V90, P335, DOI 10.1016/S0091-6749(05)80012-0; RING J, 1977, LANCET, V1, P466; Rueff F, 2001, J ALLERGY CLIN IMMUN, V108, P1027, DOI 10.1067/mai.2001.119154; Rueff F, 2010, J ALLERGY CLIN IMMUN, V126, P105, DOI 10.1016/j.jaci.2010.04.025; Rueff F, 2009, J ALLERGY CLIN IMMUN, V124, P1047, DOI 10.1016/j.jaci.2009.08.027; SASVARY T, 1994, SCHWEIZ MED WSCHR, V124, P1887; Simon MR, 2008, ALLERGY, V63, P1077, DOI 10.1111/j.1398-9995.2008.01737.x; Simons FER, 2010, J ALLERGY CLIN IMMUN, V125, pS161, DOI 10.1016/j.jaci.2009.12.981; Stojiljkovic L, 2007, CURR PHARM DESIGN, V13, P1335, DOI 10.2174/138161207780618768; Sturm GJ, 2007, ALLERGY, V62, P884, DOI 10.1111/j.1398-9995.2007.01413.x; Triggiani M, 2008, CLIN EXP IMMUNOL, V153, P7, DOI 10.1111/j.1365-2249.2008.03714.x; Valent P, 2007, EUR J CLIN INVEST, V37, P435, DOI 10.1111/j.1365-2362.2007.01807.x; VANDERLINDEN PWG, 1994, J ALLERGY CLIN IMMUN, V94, P151, DOI 10.1053/ai.1994.v94.a54889; White KM, 2008, ANN ALLERG ASTHMA IM, V101, P426, DOI 10.1016/S1081-1206(10)60321-3	43	75	75	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2012	130	3					698	+		10.1016/j.jaci.2012.03.024	http://dx.doi.org/10.1016/j.jaci.2012.03.024			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	001LZ	22554708				2022-12-18	WOS:000308463500019
J	Schmitt, J; Apfelbacher, C; Chen, CM; Romanos, M; Sausenthaler, S; Koletzko, S; Bauer, CP; Hoffmann, U; Kramer, U; Berdel, D; von Berg, A; Wichmann, HE; Heinrich, J				Schmitt, Jochen; Apfelbacher, Christian; Chen, Chih-Mei; Romanos, Marcel; Sausenthaler, Stefanie; Koletzko, Sibylle; Bauer, Carl-Peter; Hoffmann, Ute; Kraemer, Ursula; Berdel, Dietrich; von Berg, Andrea; Wichmann, H. -Erich; Heinrich, Joachim		German Infant Nutr Intervention Pl	Infant-onset eczema in relation to mental health problems at age 10 years: Results from a prospective birth cohort study (German Infant Nutrition Intervention plus)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Eczema; cohort study; depression; emotional problems; hyperactivity; infant; risk; Strengths and Difficulties Questionnaire	ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; DIFFICULTIES QUESTIONNAIRE SDQ; ATOPIC ECZEMA; CHILDREN; ASTHMA; SAMPLE; LIFE; DERMATITIS; STRENGTHS; STRESS	Background: Cross-sectional studies suggest an association between eczema and mental health problems, but the temporal relationship is unclear. Objective: To assess the association between infant-onset eczema and mental health problems in a prospective study. Methods: Between 1995 and 1998, a birth cohort study was recruited and followed until age 10 years. Physician-diagnosed eczema, comorbidities, and a broad set of environmental exposures were assessed at age 1, 2, 3, 4, 6, and 10 years. First, we investigated the association between infant-onset eczema (age 1-2 years) and mental health problems at age 10 years according to the Strengths and Difficulties Questionnaire. Second, we analyzed the likelihood of mental health problems at age 10 years in relation to the course of eczema. Results: A total of 2916 infants were eligible for analysis. Compared with participants never diagnosed as having eczema, children with infant-onset eczema had a significantly increased risk for possible/probable mental health problems (Strengths and Difficulties Questionnaire total score) at age 10 years (odds ratio, 1.49; 95% CI, 1.13-1.96) and for emotional symptoms (odds ratio, 1.62; 95% CI, 1.25-2.09). Eczema limited to infancy predicted a significantly higher risk for conduct problems at age 10 years. The strength of the association between eczema and emotional problems at age 10 years increased with increasing eczema persistence. Conclusion: Infants with eczema are at increased risk for mental health problems at age 10 years. Even if cleared afterward, eczema at age 1 to 2 years may cause persistent emotional and behavioral difficulties. (J Allergy Clin Immunol 2010;125:404-10.)	[Schmitt, Jochen] Tech Univ Dresden, Dept Dermatol, Univ Hosp Carl Gustav Carus, D-01307 Dresden, Germany; [Apfelbacher, Christian] Univ Heidelberg Hosp, Dept Clin Social Med, Heidelberg, Germany; [Chen, Chih-Mei; Sausenthaler, Stefanie; Wichmann, H. -Erich; Heinrich, Joachim] German Res Ctr Environm Hlth, Inst Epidemiol, Helmholtz Zentrum Munchen, Neuherberg, Germany; [Romanos, Marcel] Univ Clin Wurzburg, Dept Child & Adolescent Psychiat Psychosomat & Ps, Wurzburg, Germany; [Chen, Chih-Mei; Koletzko, Sibylle] Univ Munich, Dr von Hauner Childrens Hosp, Munich, Germany; [Wichmann, H. -Erich] Univ Munich, Inst Med Data Management Biometr & Epidemiol, Munich, Germany; [Bauer, Carl-Peter; Hoffmann, Ute] Tech Univ Munich, Dept Pediat, Munich, Germany; [Kraemer, Ursula] Univ Dusseldorf, Inst Umweltmed Forsch, Dusseldorf, Germany; [Berdel, Dietrich; von Berg, Andrea] Marine Hosp Wesel, Dept Pediat, Wesel, Germany	Technische Universitat Dresden; Carl Gustav Carus University Hospital; Ruprecht Karls University Heidelberg; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Wurzburg; University of Munich; University of Munich; Technical University of Munich; Heinrich Heine University Dusseldorf	Schmitt, J (corresponding author), Tech Univ Dresden, Dept Dermatol, Univ Hosp Carl Gustav Carus, Fetscherstr 74, D-01307 Dresden, Germany.	jochen.schmitt@uniklinikum-dresden.de	Wichmann, Heinz Erich/AAA-5695-2022; Apfelbacher, Christian/X-1051-2019; Romanos, Marcel/D-7695-2017; Heinrich, Joachim/N-1720-2013	Apfelbacher, Christian/0000-0003-3805-8219; Romanos, Marcel/0000-0001-7628-8299; Heinrich, Joachim/0000-0002-9620-1629	Federal Ministry for Education. Science, Research and Technology [01 EE 9401-4]; Federal Ministry of Environment (Institut fur Umweltmedizinische Forschung) [FKZ 20462296]; Ludivig-Maximilians-Universitat's innovative research priority; Nestle Nutrition; Mead Johnson	Federal Ministry for Education. Science, Research and Technology; Federal Ministry of Environment (Institut fur Umweltmedizinische Forschung); Ludivig-Maximilians-Universitat's innovative research priority; Nestle Nutrition(Nestle SA); Mead Johnson	The German Infant Nuttition Intervention study was funded for 3 years by grants of the Federal Ministry for Education. Science, Research and Technology (grant no. 01 EE 9401-4). The 6-year follow-up of the German Infant Nutrition Intervention plus study was partly funded by the Federal Ministry of Environment (Institut fur Umweltmedizinische Forschung, FKZ 20462296). This study was supported in part by Ludivig-Maximilians-Universitat's innovative research priority project MC-Health (subproject 1).; Disclosure of potential conflict of interest: S. Koletzko has received speakers' honoraria from Nestle Nutrition and Danone and has received research support from Nestle Nutrition and Mead Johnson. A. von Berg has received a speakers' honorarium from Nestle and has provided legal consultation services or expert witness testimony relevant to Airsonett. The rest of the authors have declared that they have no conflict of interest.	Becker A, 2004, EUR CHILD ADOLES PSY, V13, P11, DOI 10.1007/s00787-004-2003-5; Ben-Gashir MA, 2004, J AM ACAD DERMATOL, V50, P349, DOI 10.1016/j.jaad.2003.09.004; Blackman JA, 2007, J DEV BEHAV PEDIATR, V28, P92, DOI 10.1097/01.DBP.0000267557.80834.e5; Bockelbrink A, 2006, ALLERGY, V61, P1397, DOI 10.1111/j.1398-9995.2006.01186.x; Buske-Kirschbaum A, 2004, PSYCHONEUROENDOCRINO, V29, P705, DOI 10.1016/S0306-4530(03)00100-8; Chrousos GP, 2009, NAT REV ENDOCRINOL, V5, P374, DOI 10.1038/nrendo.2009.106; DIERISHIRCHE J, 2009, HATUTARZT; Filipiak B, 2007, J PEDIATR-US, V151, P352, DOI 10.1016/j.jpeds.2007.05.018; Finlay AY, 2001, J AM ACAD DERMATOL, V45, pS64, DOI 10.1067/mjd.2001.117010; Fivenson David, 2002, J Manag Care Pharm, V8, P333; Foreman David M, 2008, Child Adolesc Psychiatry Ment Health, V2, P32, DOI 10.1186/1753-2000-2-32; Froehlich TE, 2007, ARCH PEDIAT ADOL MED, V161, P857, DOI 10.1001/archpedi.161.9.857; Kilpelainen M, 2002, CLIN EXP ALLERGY, V32, P256, DOI 10.1046/j.1365-2222.2002.01282.x; Muris P, 2003, EUR CHILD ADOLES PSY, V12, P1, DOI 10.1007/s00787-003-0298-2; Paavonen EJ, 2009, PEDIATRICS, V123, pE857, DOI 10.1542/peds.2008-2164; ROMANOS M, 2009, J EPIDEMIOL COM 0819; RYSTEDT I, 1985, ACTA DERM-VENEREOL, P117; Schmitt J, 2009, BRIT J DERMATOL, V161, P878, DOI 10.1111/j.1365-2133.2009.09309.x; Schmitt J, 2009, JAMA-J AM MED ASSOC, V301, P724, DOI 10.1001/jama.2009.136; Schmitt J, 2007, J ALLERGY CLIN IMMUN, V120, P1389, DOI 10.1016/j.jaci.2007.08.011; Smaldone A, 2007, PEDIATRICS, V119, pS29, DOI 10.1542/peds.2006-2089F; SPERGEL A, 2003, J ALLERGY CLIN IM S6, V112, pS118; Stevenson J, 2003, PSYCHOSOM MED, V65, P971, DOI 10.1097/01.PSY.0000097343.76844.90; SZKLO M, 2005, EPIDEMIOLOGY BASICS; von Berg A, 2003, J ALLERGY CLIN IMMUN, V111, P533, DOI 10.1067/mai.2003.101; von Berg A, 2008, J ALLERGY CLIN IMMUN, V121, P1442, DOI 10.1016/j.jaci.2008.04.021; von Berg A, 2007, J ALLERGY CLIN IMMUN, V119, P718, DOI 10.1016/j.jaci.2006.11.017; Williams HC, 2005, NEW ENGL J MED, V352, P2314, DOI 10.1056/NEJMcp042803; Williams HC, 2000, CLIN EXP DERMATOL, V25, P522, DOI 10.1046/j.1365-2230.2000.00698.x; Woerner W, 2002, Z KINDER JUG-PSYCH, V30, P105, DOI 10.1024//1422-4917.30.2.105	30	75	77	1	20	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2010	125	2					404	410		10.1016/j.jaci.2009.10.055	http://dx.doi.org/10.1016/j.jaci.2009.10.055			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	558RU	20159252				2022-12-18	WOS:000274764000019
J	Wu, H; Romieu, I; Shi, M; Hancock, DB; Li, HL; Sienra-Monge, JJ; Chiu, GY; Xu, H; del Rio-Navarro, BE; London, SJ				Wu, Hao; Romieu, Isabelle; Shi, Min; Hancock, Dana B.; Li, Huiling; Sienra-Monge, Juan-Jose; Chiu, Grace Y.; Xu, Hong; Estela del Rio-Navarro, Blanca; London, Stephanie J.			Evaluation of candidate genes in a genome-wide association study of childhood asthma in Mexicans	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; asthma; genetic predisposition to disease; genome-wide association study; single nucleotide polymorphism	SUSCEPTIBILITY GENES; POLYMORPHISMS; CYTOKINE; RISK; EXPRESSION; COVERAGE; CLUSTER; T1/ST2; IL18R1; ORMDL3	Background: More than 200 asthma candidate genes have been examined in human association studies or identified with knockout mouse approaches. However, many have not been systematically replicated in human populations, especially those containing a large number of tagging single nucleotide polymorphisms (SNPs). Objective: We comprehensively evaluated the association of previously implicated asthma candidate genes with childhood asthma in a Mexico City population. Methods: From the literature, we identified candidate genes with at least 1 positive report of association with asthma phenotypes in human subjects or implicated in asthma pathogenesis using knockout mouse experiments. We performed a genome-wide association study in 492 asthmatic children aged 5 to 17 years and both parents using the Illumina HumanHap 5500 BeadChip. Separate candidate gene analyses were performed for 2933 autosomal SNPs in the 237 selected genes by using the log-linear method with a log-additive risk model. Results: Sixty-one of the 237 genes had at least 1 SNP with a P value of less than .05 for association with asthma. The 9 most significant results were observed for rs2241715 in the gene encoding TGF-beta 1 (TCFB1; P = 3.3 x 10(-5)), rs13431828 and rs1041973 in the gene encoding IL-1 receptor-like 1 (IL1RL1; P = 2 x 10(-4) and 3.5 x 10(-4)), 5 SNPs in the gene encoding dipeptidyl-peptidase 10 (DPP10; P = 1.6 x 10(-4) to 4.5 x 10(-4)), and rs17599222 in the gene encoding cytoplasmic FMR1 interacting protein 2 (CYFIP2; P = 4.1 x 10(-4)). False discovery rates were less than 0.1 for all 9 SNPs. Multimarker analysis identified TGFB1, IL1RL1, the gene encoding IL-18 receptor 1 (IL18R1), and DPP10 as the genes most significantly associated with asthma. Conclusions: This comprehensive analysis of literature-based candidate genes suggests that SNPs in several candidate genes, including TGFBI, IL1RL1, IL18R1, and DPP10, might contribute to childhood asthma susceptibility in a Mexican population. (J Allergy Clin Immunol 2010;125:321-7.)	[Wu, Hao; Shi, Min; Hancock, Dana B.; Li, Huiling; Xu, Hong; London, Stephanie J.] NIEHS, Div Intramural Res, NIH, Dept Hlth & Human Serv, Res Triangle Pk, NC 27709 USA; [Romieu, Isabelle] Natl Inst Publ Hlth, Cuernavaca, Morelos, Mexico; [Sienra-Monge, Juan-Jose; Estela del Rio-Navarro, Blanca] Hosp Infantil Mexico Dr Federico Gomez, Mexico City, DF, Mexico; [Chiu, Grace Y.] WESTAT Corp, Res Triangle Pk, NC USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Instituto Nacional de Salud Publica; Hospital Infantil de Mexico Federico Gomez; Westat	London, SJ (corresponding author), NIEHS, Div Intramural Res, NIH, Dept Hlth & Human Serv, POB 12233,MD A3-05, Res Triangle Pk, NC 27709 USA.	london2@niehs.nih.gov	Shi, Min/GXM-3977-2022; Hancock, Dana/D-8577-2012; London, Stephanie/C-3734-2019	Hancock, Dana/0000-0003-2240-3604; Xu, Hong/0000-0003-1995-4675; London, Stephanie/0000-0003-4911-5290	National Institutes of Health, National Institute of Environmental Health Sciences [Z01 ES49019]; National Council of Science anti Technology, Mexico [26206-M]; National Center for Environmental Health at the Centers for Disease Control; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES025045, ZICES102546, Z01ES049019, ZIAES049019] Funding Source: NIH RePORTER	National Institutes of Health, National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); National Council of Science anti Technology, Mexico; National Center for Environmental Health at the Centers for Disease Control; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by the Intramural Research Program of the National Institutes of Health, National Institute of Environmental Health Sciences (Z01 ES49019). Subject enrollment was supported in part by the National Council of Science anti Technology (grant 26206-M), Mexico. I. R. was supported in part by the National Center for Environmental Health at the Centers for Disease Control.	Allen M, 2003, NAT GENET, V35, P258, DOI 10.1038/ng1256; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; Barrett JC, 2006, NAT GENET, V38, P659, DOI 10.1038/ng1801; Blakey JD, 2009, THORAX, V64, P381, DOI 10.1136/thx.2008.102053; Chanock SJ, 2007, NATURE, V447, P655, DOI 10.1038/447655a; Cherry WB, 2008, J ALLERGY CLIN IMMUN, V121, P1484, DOI 10.1016/j.jaci.2008.04.005; Dale M, 1999, GENOMICS, V57, P177, DOI 10.1006/geno.1999.5767; DUNNE A, 2003, SCI STKE, pRE3, DOI DOI 10.1126/STKE.2003.171.RE3; Gudbjartsson DF, 2009, NAT GENET, V41, P342, DOI 10.1038/ng.323; Hancock DB, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000623; Jenkins MA, 1996, INT J EPIDEMIOL, V25, P609, DOI 10.1093/ije/25.3.609; Kere J, 2004, CURR OPIN IMMUNOL, V16, P689, DOI 10.1016/j.coi.2004.09.011; Li C, 2008, HUM HERED, V65, P129, DOI 10.1159/000109730; Li HL, 2007, HUM GENET, V121, P529, DOI 10.1007/s00439-007-0337-z; Li MY, 2008, EUR J HUM GENET, V16, P635, DOI 10.1038/sj.ejhg.5202007; Mangan NE, 2007, EUR J IMMUNOL, V37, P1302, DOI 10.1002/eji.200636520; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Nakanishi K, 2001, CYTOKINE GROWTH F R, V12, P53, DOI 10.1016/S1359-6101(00)00015-0; *NAT HEART LUNG BL, 1998, POCK GUID ASTHM MAN; Ober C, 2006, GENES IMMUN, V7, P95, DOI 10.1038/sj.gene.6364284; Oshikawa K, 2001, AM J RESP CRIT CARE, V164, P277, DOI 10.1164/ajrccm.164.2.2008120; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Reijmerink NE, 2008, J ALLERGY CLIN IMMUN, V122, P651, DOI 10.1016/j.jaci.2008.06.030; Rogers AJ, 2009, AM J RESP CRIT CARE, V179, P1084, DOI 10.1164/rccm.200812-1860OC; Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015; Shi M, 2007, AM J HUM GENET, V81, P53, DOI 10.1086/518670; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Thomas G, 2008, NAT GENET, V40, P310, DOI 10.1038/ng.91; van den Oord EJCG, 2003, TRENDS GENET, V19, P537, DOI 10.1016/j.tig.2003.08.003; van den Oord EJCG, 2000, AM J HUM GENET, V66, P335, DOI 10.1086/302708; Vercelli D, 2008, NAT REV IMMUNOL, V8, P169, DOI 10.1038/nri2257; Wedzicha JA, 2003, THORAX, V58, P1, DOI 10.1136/thorax.58.1.1; Weinberg CR, 1998, AM J HUM GENET, V62, P969, DOI 10.1086/301802; Wilcox AJ, 1998, AM J EPIDEMIOL, V148, P893; Wu H, 2009, ALLERGY, V64, P629, DOI 10.1111/j.1398-9995.2008.01912.x; Zhang J, 2008, RESP RES, V9, DOI 10.1186/1465-9921-9-4; Zhu GH, 2008, EUR J HUM GENET, V16, P1083, DOI 10.1038/ejhg.2008.67	37	75	79	2	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2010	125	2					321	327		10.1016/j.jaci.2009.09.007	http://dx.doi.org/10.1016/j.jaci.2009.09.007			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	558RU	19910030	Green Accepted, Bronze			2022-12-18	WOS:000274764000006
J	Leach, C; Colice, GL; Luskin, A				Leach, Chet; Colice, Gene L.; Luskin, Allan			Particle size of inhaled corticosteroids: Does it matter?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Inhaled corticosteroids; particle size; delivery devices; clinical outcomes; pharmacoeconomics	HYDROFLUOROALKANE-134A BECLOMETHASONE DIPROPIONATE; 800 MU-G; FLUTICASONE PROPIONATE; EXTRAFINE AEROSOL; SMALL AIRWAYS; ASTHMA CONTROL; APPROXIMATELY HALF; COST-EFFECTIVENESS; HFA-BDP; DEPOSITION	A question with respect to asthma therapy revolves around the issue of whether better efficacy occurs with an ultrafine-particle inhaled corticosteroid because of better lung deposition into the distal airways. This article reviews particle size and delivery devices of different steroids, clinical outcomes of small-versus large-particle steroids, and the issue of pharmacoeconomics. (J Allergy Clin Immunol 2009;124:S88-93.)	[Leach, Chet] Lovelace Resp Res Inst, Albuquerque, NM USA; [Colice, Gene L.] George Washington Univ, Sch Med, Dept Med, Washington, DC USA; [Luskin, Allan] Med Care Ctr, Sun Prairie, WI USA	Lovelace Respiratory Research Institute; George Washington University	Leach, C (corresponding author), Care of Martin RJ, Natl Jewish Hlth, 1400 Jackson St, Denver, CO 80206 USA.				Teva Respiratory, LLC	Teva Respiratory, LLC	Supported by an unrestricted grant from Teva Respiratory, LLC.	Adcock IM, 1996, AM J RESP CRIT CARE, V154, P771, DOI 10.1164/ajrccm.154.3.8810618; Allen Edith B., 2003, Restoration Ecology, V11, P1, DOI 10.1046/j.1526-100X.2003.01111.x; Aubier M, 2001, RESP MED, V95, P212, DOI 10.1053/rmed.2000.1025; Bacsi A, 2006, J ALLERGY CLIN IMMUN, V118, P844, DOI 10.1016/j.jaci.2006.07.006; Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC; Briggs AH, 2006, ALLERGY, V61, P531, DOI 10.1111/j.1398-9995.2006.01038.x; Busse WW, 1999, J ALLERGY CLIN IMMUN, V104, P1215, DOI 10.1016/S0091-6749(99)70016-3; Carroll N, 1997, EUR RESPIR J, V10, P292, DOI 10.1183/09031936.97.10020292; Chetta A, 1997, CHEST, V111, P852, DOI 10.1378/chest.111.4.852; Corren J, 2001, ANN ALLERG ASTHMA IM, V87, P405, DOI 10.1016/S1081-1206(10)62922-5; Davies R, 1999, HOSP MED, V60, P263, DOI 10.12968/hosp.1999.60.4.1093; Davies RJ, 1998, RESP MED, V92, P23, DOI 10.1016/S0954-6111(98)90214-1; Devadason SG, 2003, EUR RESPIR J, V21, P1007, DOI 10.1183/09031936.03.00087803; Fairfax AJ, 2000, RESP MED, V94, pS31, DOI 10.1016/S0954-6111(00)90122-7; Friedman HS, 2007, J ALLERGY CLIN IMMUN, V119, pS250, DOI 10.1016/j.jaci.2006.12.346; Friedman HS, 2007, CURR MED RES OPIN, V23, P427, DOI 10.1185/030079906X167417; Gabrio BJ, 1999, INT J PHARMACEUT, V186, P3, DOI 10.1016/S0378-5173(99)00133-7; Goldin JG, 1999, J ALLERGY CLIN IMMUN, V104, pS258, DOI 10.1016/S0091-6749(99)70043-6; Gross G, 1999, CHEST, V115, P343, DOI 10.1378/chest.115.2.343; Haley KJ, 1998, AM J RESP CRIT CARE, V158, P565, DOI 10.1164/ajrccm.158.2.9705036; Hamid Q, 1997, J ALLERGY CLIN IMMUN, V100, P44, DOI 10.1016/S0091-6749(97)70193-3; Harrison LI, 1999, J PHARM PHARMACOL, V51, P263, DOI 10.1211/0022357991772439; Holgate ST, 2000, J ALLERGY CLIN IMMUN, V105, P193, DOI 10.1016/S0091-6749(00)90066-6; Jeffery PK, 2001, AM J RESP CRIT CARE, V164, pS28, DOI 10.1164/ajrccm.164.supplement_2.2106061; Juniper EF, 2002, CHEST, V121, P1824, DOI 10.1378/chest.121.6.1824; KEMP L, 2009, J ALLERGY CLIN IMMUN; LAITINEN LA, 1992, J ALLERGY CLIN IMMUN, V90, P32, DOI 10.1016/S0091-6749(06)80008-4; Lawrence M, 1997, AM J RESP CRIT CARE, V156, P744, DOI 10.1164/ajrccm.156.3.9608058; Leach C, 1999, J ALLERGY CLIN IMMUN, V104, pS250, DOI 10.1016/S0091-6749(99)70041-2; Leach CL, 2006, J AEROSOL MED, V19, P117, DOI 10.1089/jam.2006.19.117; Leach CL, 1998, J AEROSOL MED, V11, pS29; Leach CL, 1998, EUR RESPIR J, V12, P1346, DOI 10.1183/09031936.98.12061346; Leach CL, 1998, RESP MED, V92, P3, DOI 10.1016/S0954-6111(98)90211-6; Leach CL, 1998, INT J CLIN PRACT, P23; Malone DC, 2003, RESP MED, V97, P1269, DOI 10.1016/j.rmed.2003.07.006; *NAT I HLTH CLIN E, ASTHM IN AD CORT; National Institutes of Health, 2007, NIH PUBL, V02-3659; Olivieri D, 1997, AM J RESP CRIT CARE, V155, P1864, DOI 10.1164/ajrccm.155.6.9196087; Richards J, 2001, J AEROSOL MED, V14, P197, DOI 10.1089/08942680152484126; Roller CM, 2007, EUR RESPIR J, V29, P299, DOI 10.1183/09031936.00051106; Shih YCT, 2007, PHARMACOECONOMICS, V25, P577, DOI 10.2165/00019053-200725070-00004; Taylor PE, 2002, J ALLERGY CLIN IMMUN, V109, P51, DOI 10.1067/mai.2002.120759; Thompson PJ, 1998, RESP MED, V92, P33, DOI 10.1016/S0954-6111(98)90215-3; Thongngarm T, 2005, J ASTHMA, V42, P257, DOI 10.1081/JAS-200057888; TRIGG CJ, 1994, AM J RESP CRIT CARE, V150, P17, DOI 10.1164/ajrccm.150.1.8025745; Van Schayck CP, 2004, INT J CLIN PRACT, V58, P786, DOI 10.1111/j.1368-5031.2004.00274.x; Vanden Burgt JA, 2000, J ALLERGY CLIN IMMUN, V106, P1210, DOI 10.1067/mai.2000.111582; Verbanck S, 2006, J ALLERGY CLIN IMMUN, V118, P340, DOI 10.1016/j.jaci.2006.04.056; Yamaguchi M, 2009, PULM PHARMACOL THER, V22, P326, DOI 10.1016/j.pupt.2009.01.005; Zeiger RS, 2008, J ALLERGY CLIN IMMUN, V121, P885, DOI 10.1016/j.jaci.2007.12.1178; ZIEGER RS, 2008, J ALLERGY CLIN IMMUN, V121, pE5	51	75	76	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2009	124	6		S			S88	S93		10.1016/j.jaci.2009.09.050	http://dx.doi.org/10.1016/j.jaci.2009.09.050			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	536VJ	19962042				2022-12-18	WOS:000273071700005
J	Greenhawt, MJ; Singer, AM; Baptist, AP				Greenhawt, Matthew J.; Singer, Andrew M.; Baptist, Alan P.			Food allergy and food allergy attitudes among college students	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; college students; anaphylaxis; self-injectable epinephrine; food allergy attitudes	TREE NUT ALLERGY; NATURAL-HISTORY; ANAPHYLACTIC REACTIONS; RISK-TAKING; EPIDEMIOLOGY; ADOLESCENTS; FATALITIES; PREVALENCE; PEANUT	Background: Little information is known about food allergy among college students. Objective: We sought to assess food allergy trends and behavioral attitudes on a large university campus. Methods: An online survey was distributed by e-mail to local university undergraduate students. Symptom severity was determined based on previously published criteria for anaphylaxis. Results: A total of 513 individuals responded, with 57% reporting an allergic reaction to food. Of this group, 36.2% reported symptoms consistent with anaphylaxis, and these reactions frequently occurred while enrolled. Allergy to milk (P = .032), tree nut (P < .0001), shellfish (P < .0001), and peanut (P < .0001) was significantly associated with having symptoms of anaphylaxis. Some form of emergency medication was reportedly maintained in 47.7%, including self-injectable epinephrine (SIE; 21 %), although only 6.6 % reported always carrying this device. Medication maintenance was significantly lower among students who had not had a reaction while enrolled (P < .0001). Only 39.7% reported always avoiding foods to which they were allergic. Within the group that reported intentionally consuming known allergens, there were significantly lower numbers of individuals who reported carrying SIE (P < .0001) and significantly higher numbers of individuals with a history of a reaction that had not resulted in symptoms of anaphylaxis (P = .026). Conclusion: Potentially life-threatening anaphylactic reactions to foods are occurring on college campuses. Only 39.7% of students with food allergy avoided a self-identified food allergen, and more than three fourths did not maintain SIE. Such behaviors might place these students at increased risk for adverse events. (J Allergy Clin Immunol :2009; 124:323-7.)	[Greenhawt, Matthew J.; Singer, Andrew M.; Baptist, Alan P.] Univ Michigan Hlth Syst, Div Clin Immunol & Allergy, Ann Arbor, MI 48106 USA; [Singer, Andrew M.] Allergy & Asthma Affiliates PC, Knoxville, TN USA	University of Michigan System; University of Michigan	Greenhawt, MJ (corresponding author), Univ Michigan Hlth Syst, Div Clin Immunol & Allergy, 24 Frank Lloyd Wright Dr,Box 442,Lobby H-2100, Ann Arbor, MI 48106 USA.	mgreenha@med.umich.edu		Greenhawt, Matthew/0000-0002-2365-9372	American College of Allergy, Asthma & Immunology	American College of Allergy, Asthma & Immunology	Disclosure of potential conflict of interest: M. Greenhawt received research assistance from the Food Allergy & Anaphylaxis Network. A. Baptist received a Young Faculty Support Award from the American College of Allergy, Asthma & Immunology.	Bock SA, 2007, J ALLERGY CLIN IMMUN, V119, P1016, DOI 10.1016/j.jaci.2006.12.622; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; BRAUN AM, 2008, NCHS DATA BRIEF, V10, P1; Decker WW, 2008, J ALLERGY CLIN IMMUN, V122, P1161, DOI 10.1016/j.jaci.2008.09.043; Fleischer DM, 2005, J ALLERGY CLIN IMMUN, V116, P1087, DOI 10.1016/j.jaci.2005.09.002; *FOOD ALL AN NETW, COLL U GUID MAN STUD; JESSICA HS, 2007, J ALLERGY CLIN IMMUN, V120, P1413; Keet CA, 2007, IMMUNOL ALLERGY CLIN, V27, P193, DOI 10.1016/j.iac.2007.03.005; Pereira B, 2005, J ALLERGY CLIN IMMUN, V116, P884, DOI 10.1016/j.jaci.2005.05.047; Pumphrey RSH, 2007, J ALLERGY CLIN IMMUN, V119, P1018, DOI 10.1016/j.jaci.2007.01.021; Rolison MR, 2002, ADOLESCENCE, V37, P585; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Sampson MA, 2006, J ALLERGY CLIN IMMUN, V117, P1440, DOI 10.1016/j.jaci.2006.03.009; Sicherer SH, 2007, J ALLERGY CLIN IMMUN, V120, P491, DOI 10.1016/j.jaci.2007.07.015; Sicherer SH, 2003, J ALLERGY CLIN IMMUN, V112, P1203, DOI 10.1016/S0091-6749(03)02026-8; Sicherer SH, 2006, J ALLERGY CLIN IMMUN, V117, pS470, DOI 10.1016/j.jaci.2005.05.048; Skripak JM, 2007, J ALLERGY CLIN IMMUN, V120, P1172, DOI 10.1016/j.jaci.2007.08.023; SNYDER TD, 2008, 2008022 US DEP ED I; Wood RA, 2003, PEDIATRICS, V111, P1631; Yocum MW, 1999, J ALLERGY CLIN IMMUN, V104, P452, DOI 10.1016/S0091-6749(99)70392-1; 1997, MMWR CDC SURVEILL SU, V46, P1	21	75	75	21	55	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2009	124	2					323	327		10.1016/j.jaci.2009.05.028	http://dx.doi.org/10.1016/j.jaci.2009.05.028			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	482CD	19560802				2022-12-18	WOS:000268860400020
J	Taveras, EM; Rifas-Shiman, SL; Camargo, CA; Gold, DR; Litonjua, AA; Oken, E; Weiss, ST; Gillman, MW				Taveras, Elsie M.; Rifas-Shiman, Sheryl L.; Camargo, Carlos A., Jr.; Gold, Diane R.; Litonjua, Augusto A.; Oken, Emily; Weiss, Scott T.; Gillman, Matthew W.			Higher adiposity in infancy associated with recurrent wheeze in a prospective cohort of children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; wheeze; adiposity; children; prospective study	BODY-MASS INDEX; BIRTH-WEIGHT; EARLY-CHILDHOOD; NUTRITION EXAMINATION; RESPIRATORY SYMPTOMS; ASTHMA PREVALENCE; DIAGNOSED ASTHMA; NATIONAL-HEALTH; UNITED-STATES; FETAL-GROWTH	Background: Few prospective data link early childhood adiposity with asthma-related symptoms. Objective: We sought to examine the associations of weight-for-length (WFL) at age 6 months with incidence of wheezing by age 3 years. Methods: We studied 932 children in a prospective cohort of children. The main outcome was recurrent wheezing, which was defined as parents' report of wheezing between 2 and 3 years of age plus wheezing in either year I or 2 of life. Secondary outcomes included any wheezing from 6 months to 3 years and current asthma. We used multiple logistic regression to examine associations of 6-month WFL z scores with these outcomes. Results: At 6 months, the infants' mean WFL z score was 0.68 (SD, 0.94; range -2.96 to 3.24). By age 3 years, 14% of children had recurrent wheezing. After adjustment for a variety of potential confounders, we found that each 1-unit increment in 6-month WFL z score was associated with greater odds of recurrent wheezing (odds ratio [OR], 1.46; 95% CI, 1.11-1.91) and any wheezing (OR, 1.23; 95 % CI, 1.03-1.48). We observed a weaker association between 6-month WFL z score and current asthma (OR, 1.22; 95% CI, 0.94-1.59). Conclusion: Infants with higher WFL z scores at 6 months of age had a greater risk of recurrent wheezing by age 3 years. It is unclear whether the relationship of infant adiposity and earlylife wheeze extends to allergic asthma or wheeze that can persist into later childhood. Our findings suggest that early interventions to prevent excess infant adiposity might help reduce children's risk of asthma-related symptoms.	[Taveras, Elsie M.; Rifas-Shiman, Sheryl L.; Oken, Emily; Gillman, Matthew W.] Harvard Pilgrim Hlth Care, Dept Ambulatory Care & Prevent, Obes Prevent Program, Boston, MA 02215 USA; [Taveras, Elsie M.; Rifas-Shiman, Sheryl L.; Oken, Emily; Gillman, Matthew W.] Harvard Univ, Sch Med, Boston, MA 02215 USA; [Camargo, Carlos A., Jr.; Gold, Diane R.; Litonjua, Augusto A.] Brigham & Womens Hosp, Channing Lab, Dept Med, Boston, MA 02115 USA; [Gillman, Matthew W.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Cambridge, MA 02138 USA	Harvard Pilgrim Health Care; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health	Taveras, EM (corresponding author), Harvard Pilgrim Hlth Care, Dept Ambulatory Care & Prevent, Obes Prevent Program, 133 Brookline Ave,6th Floor, Boston, MA 02215 USA.	Elsie_Taveras@hphc.org	Camargo, Carlos A./C-2145-2008	Camargo, Carlos A./0000-0002-5071-7654; Litonjua, Augusto/0000-0003-0422-5875	NHLBI NIH HHS [HL 64925, HL 68041, R01 HL064925, K24 HL068041] Funding Source: Medline; NICHD NIH HHS [HD 34568, R01 HD034568, R37 HD034568] Funding Source: Medline; NIDDK NIH HHS [P30 DK040561, P30 DK040561-13] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD034568, R37HD034568] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064925, K24HL068041] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK040561] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENN RT, 1971, BRIT J PREV SOC MED, V25, P42; Beuther DA, 2006, AM J RESP CRIT CARE, V174, P112, DOI 10.1164/rccm.200602-231PP; BJORKSTEN B, 1987, CLIN REV ALLERG, V5, P339; Bolte G, 2004, CLIN EXP ALLERGY, V34, P381, DOI 10.1111/j.1365-2222.2004.01890.x; Camargo CA, 2007, AM J CLIN NUTR, V85, P788, DOI 10.1093/ajcn/85.3.788; Cassol VE, 2006, J ASTHMA, V43, P57, DOI 10.1080/02770900500448597; Castro-Rodriguez JA, 2000, AM J RESP CRIT CARE, V162, P1403, DOI 10.1164/ajrccm.162.4.9912111; Castro-Rodriguez LA, 2001, AM J RESP CRIT CARE, V163, P1344, DOI 10.1164/ajrccm.163.6.2006140; *CDCP NAT CTR HLTH, CDC GROWTH CHARTS; Dik N, 2004, CHEST, V126, P1147, DOI 10.1378/chest.126.4.1147; Fantuzzi G, 2005, J ALLERGY CLIN IMMUN, V115, P911, DOI 10.1016/j.jaci.2005.02.023; Fawzi WW, 2004, ANN EPIDEMIOL, V14, P754, DOI 10.1016/j.annepidem.2004.03.001; Figueroa-Munoz JI, 2001, THORAX, V56, P133, DOI 10.1136/thorax.56.2.133; Gennuso J, 1998, ARCH PEDIAT ADOL MED, V152, P1197; Gilliland FD, 2003, AM J EPIDEMIOL, V158, P406, DOI 10.1093/aje/kwg175; Gillman MW, 2004, J PEDIATR-US, V144, P240, DOI 10.1016/j.jpeds.2003.10.064; GOLD DR, 1993, AM REV RESPIR DIS, V148, P10, DOI 10.1164/ajrccm/148.1.10; Gold DR, 1999, AM J RESP CRIT CARE, V160, P227, DOI 10.1164/ajrccm.160.1.9807104; Gold DR, 2003, PEDIATR PULM, V36, P514, DOI 10.1002/ppul.10376; Gunnbjomsdottir MI, 2004, EUR RESPIR J, V24, P116, DOI 10.1183/09031936.04.00042603; Hallstrand TS, 2005, J ALLERGY CLIN IMMUN, V116, P1235, DOI 10.1016/j.jaci.2005.09.016; Hedley AA, 2004, JAMA-J AM MED ASSOC, V291, P2847, DOI 10.1001/jama.291.23.2847; Hersoug LG, 2007, ALLERGY, V62, P1205, DOI 10.1111/j.1398-9995.2007.01506.x; Huang SL, 1999, CLIN EXP ALLERGY, V29, P323, DOI 10.1046/j.1365-2222.1999.00455.x; Katz KA, 2003, CLIN EXP ALLERGY, V33, P737, DOI 10.1046/j.1365-2222.2003.01670.x; Kilpelainen M, 2006, RESP MED, V100, P1518, DOI 10.1016/j.rmed.2006.01.011; Linneberg A, 2001, CLIN EXP ALLERGY, V31, P1409, DOI 10.1046/j.1365-2222.2001.01178.x; Lohman TG, 1988, RELIABILITY ACCURACY; Luder E, 1998, J PEDIATR-US, V132, P699, DOI 10.1016/S0022-3476(98)70363-4; Ly NP, 2006, PEDIATRICS, V117, pE1132, DOI 10.1542/peds.2005-2271; Mannino DM, 2006, INT J OBESITY, V30, P6, DOI 10.1038/sj.ijo.0803145; Mei ZG, 2002, AM J CLIN NUTR, V75, P978, DOI 10.1093/ajcn/75.6.978; Merrill CT, 2005, HOSP US 2002 HCUP FA; Moonie SA, 2006, J SCHOOL HEALTH, V76, P18, DOI 10.1111/j.1746-1561.2006.00062.x; Oddy WH, 2004, AM J PUBLIC HEALTH, V94, P1531, DOI 10.2105/AJPH.94.9.1531; Ogden CL, 1997, PEDIATRICS, V99, part. no., DOI 10.1542/peds.99.4.e1; Ogden CL, 2006, JAMA-J AM MED ASSOC, V295, P1549, DOI 10.1001/jama.295.13.1549; Oken Emily, 2003, BMC Pediatr, V3, P6, DOI 10.1186/1471-2431-3-6; Platts-Mills TAE, 2003, J ALLERGY CLIN IMMUN, V111, P123, DOI 10.1067/mai.2003.10; Rodriguez MA, 2002, ARCH PEDIAT ADOL MED, V156, P269, DOI 10.1001/archpedi.156.3.269; Rona RJ, 2005, THORAX, V60, P549, DOI 10.1136/thx.2004.032359; SCHWARTZ J, 1990, AM REV RESPIR DIS, V142, P555, DOI 10.1164/ajrccm/142.3.555; SEIDMAN DS, 1991, ARCH DIS CHILD, V66, P584, DOI 10.1136/adc.66.5.584; SHERMAN CB, 1990, AM J EPIDEMIOL, V132, P83, DOI 10.1093/oxfordjournals.aje.a115646; Shorr IJ., 1986, WEIGH MEASURE CHILDR; Sin DD, 2004, ARCH PEDIAT ADOL MED, V158, P60, DOI 10.1001/archpedi.158.1.60; SOMERVILLE SM, 1984, ARCH DIS CHILD, V59, P940, DOI 10.1136/adc.59.10.940; Strauss RS, 2001, JAMA-J AM MED ASSOC, V286, P2845, DOI 10.1001/jama.286.22.2845; Tantisira KG, 2001, THORAX, V56, P64; Taveras EM, 2006, PEDIATR PULM, V41, P643, DOI 10.1002/ppul.20427; von Mutius E, 2001, THORAX, V56, P835, DOI 10.1136/thorax.56.11.835; Wahn U, 2000, ALLERGY, V55, P591, DOI 10.1034/j.1398-9995.2000.00111.x; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Wellen KE, 2003, J CLIN INVEST, V112, P1785, DOI 10.1172/JCI20514; Xu BZ, 2000, J ALLERGY CLIN IMMUN, V105, P393, DOI 10.1016/S0091-6749(00)90095-2; Xu BZ, 2002, EUR J PUBLIC HEALTH, V12, P166, DOI 10.1093/eurpub/12.3.166; Yuan W, 2002, INT J EPIDEMIOL, V31, P1240, DOI 10.1093/ije/31.6.1240; YUNGINGER JW, 1992, AM REV RESPIR DIS, V146, P888, DOI 10.1164/ajrccm/146.4.888; ZERAH F, 1993, CHEST, V103, P1470, DOI 10.1378/chest.103.5.1470	59	75	77	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2008	121	5					1161	1166		10.1016/j.jaci.2008.03.021	http://dx.doi.org/10.1016/j.jaci.2008.03.021			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	302IJ	18466784	Green Accepted			2022-12-18	WOS:000255961700013
J	Real, FG; Svanes, C; Omenaas, ER; Anto, JM; Plana, E; Jarvis, D; Janson, C; Neukirch, F; Zemp, E; Dratva, J; Wjst, M; Svanes, K; Leynaert, B; Sunyer, J				Real, Francisco Gomez; Svanes, Cecilie; Omenaas, Ernst Reidar; Anto, Josep Maria; Plana, Estel; Jarvis, Deborah; Janson, Christer; Neukirch, Francoise; Zemp, Elisabeth; Dratva, Julia; Wjst, Matthias; Svanes, Knut; Leynaert, Benedicte; Sunyer, Jordi			Lung function, respiratory symptoms, and the menopausal transition	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						menopause; lung function; asthma; allergy; body mass index; sex hormones; estrogens; follicle-stimulating hormone; hormone replacement therapy; European Community Respiratory Health Survey	HORMONE REPLACEMENT THERAPY; SEX-STEROID-HORMONES; BODY-MASS INDEX; INSULIN-RESISTANCE; POSTMENOPAUSAL WOMEN; MONONUCLEAR-CELLS; CIGARETTE-SMOKING; HEALTH-SURVEY; ESTROGEN; ASTHMA	Background: There is limited information on potential changes in respiratory health when women enter the menopausal transition. Objective: We sought to investigate whether the menopausal transition is related to lung function and asthma and whether body mass index (BMI) modifies associations. Methods: Four thousand two hundred fifty-nine women from 21 centers (ECRHS II, 2002) responded to a questionnaire concerning women's health. Women aged 45 to 56 years not using exogenous sex hormones (n = 1274) were included in the present analysis. Lung function measurements (n = 1120) and serum markers of hormonal status (follicle-stimulating hormone, luteinizing hormone, and estradiol; n = 710) were available. Logistic and linear regression analyses were adjusted for BMI, age, years of education, smoking status, center, and height. Results: Women not menstruating for the last 6 months (n = 432, 34 %) had significantly lower FEV1 values (- 120 mL [95 % CI, -177 to -63]), lower forced vital capacity values (-115 mL [95% CI, -181 to -50]), and more respiratory symptoms (odds ratio [OR], 1.82 [95% CI, 1.27-2.61]) than those menstruating regularly. Results were similar when restricting analyses to those who never smoked. Associations were significantly stronger in women with BMIs of less than 23 kg/m(2) (respiratory symptoms: OR, 4.07 [95% CI, 1.88-8.80]; FEV1 adjusted difference: -166 [95% CI -263 to -70]) than in women with BMIs of 23 to 28 kg/m(2) (respiratory symptoms: OR, 1.10 [95% CI, 0.61-1.97], P-interaction = .04; FEV1 adjusted difference, -54 [95% CI, -151 to 43], P-interaction = .06). Conclusions: Menopause is associated with lower lung function and more respiratory symptoms, especially among lean women.	[Real, Francisco Gomez] Haukeland Hosp, Dept Gynaecol & Obstet, N-5021 Bergen, Norway; [Real, Francisco Gomez; Svanes, Cecilie; Anto, Josep Maria; Plana, Estel; Sunyer, Jordi] Inst Municipal Invest Med IMIM IMAS, Ctr Recerca Epidemiol Ambiental CREAL, Barcelona, Spain; [Svanes, Cecilie; Omenaas, Ernst Reidar] Haukeland Hosp, Dept Thorac Med, N-5021 Bergen, Norway; [Omenaas, Ernst Reidar] Haukeland Hosp, Clin Res Ctr, N-5021 Bergen, Norway; [Anto, Josep Maria; Plana, Estel; Sunyer, Jordi] Univ Pompeu Fabra UPF, Dept Ciencies Expt Vida, Barcelona, Spain; [Jarvis, Deborah] Imperial Coll, Dept Med Sci, London, England; [Janson, Christer] Uppsala Univ, Dept Med Sci Resp Med & Allergol, Uppsala, Sweden; [Neukirch, Francoise; Leynaert, Benedicte] Fac Xavier Bichat, INSERM U700, Epidemiol MAladies Resp, Paris, France; [Zemp, Elisabeth; Dratva, Julia] Univ Basel, Inst Social & Prevent Med, Basel, Switzerland; [Wjst, Matthias] GSF, Natl Res Ctr Environm & Hlth, Neuherberg, Germany; [Svanes, Knut] Haukeland Hosp, Inst Surg, N-5021 Bergen, Norway	University of Bergen; Haukeland University Hospital; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Pompeu Fabra University; University of Bergen; Haukeland University Hospital; University of Bergen; Haukeland University Hospital; Pompeu Fabra University; Imperial College London; Uppsala University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Basel; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Bergen; Haukeland University Hospital	Real, FG (corresponding author), Haukeland Hosp, Dept Gynaecol & Obstet, N-5021 Bergen, Norway.	francisco.real@realned.uib.no	Anto, J M/H-2676-2014; Leynaert, Benedicte/N-5251-2018; Svanes, Cecilie/N-7556-2017; Jarvis, Deborah/E-6494-2011; Sunyer, Jordi/G-6909-2014	Anto, J M/0000-0002-4736-8529; Svanes, Cecilie/0000-0001-8512-5192; Sunyer, Jordi/0000-0002-2602-4110; Leynaert, Benedicte/0000-0001-5045-2492; Gomez Real, Francisco/0000-0001-5407-3270; Jarvis, Deborah/0000-0002-1753-3896; Plana, Estel/0000-0001-8675-7503				Balzano G, 2001, ALLERGY, V56, P13, DOI 10.1034/j.1398-9995.2001.00128.x; BARON JA, 1990, AM J OBSTET GYNECOL, V162, P502, DOI 10.1016/0002-9378(90)90420-C; Becklake MR, 1999, THORAX, V54, P1119, DOI 10.1136/thx.54.12.1119; BRAMBILLA DJ, 1994, AM J EPIDEMIOL, V140, P1091, DOI 10.1093/oxfordjournals.aje.a117209; BRUNING PF, 1988, ANN NY ACAD SCI, V538, P257; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954, DOI 10.1183/09031936.94.07050954; Carr MC, 2003, J CLIN ENDOCR METAB, V88, P2404, DOI 10.1210/jc.2003-030242; Chinn S, 2005, LANCET, V365, P1629, DOI 10.1016/S0140-6736(05)66511-7; Cooper GS, 1999, EPIDEMIOLOGY, V10, P771, DOI 10.1097/00001648-199911000-00021; Dandona P, 2004, TRENDS IMMUNOL, V25, P4, DOI 10.1016/j.it.2003.10.013; Davis WA, 2004, DIABETES CARE, V27, P752, DOI 10.2337/diacare.27.3.752; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Engstrom G, 2003, J INTERN MED, V253, P574, DOI 10.1046/j.1365-2796.2003.01138.x; Fernandez EC, 2003, EUR HEART J, V24, P279, DOI 10.1016/S0195-668X(03)94681-1; Ghanim H, 2004, CIRCULATION, V110, P1564, DOI 10.1161/01.CIR.0000142055.53122.FA; Grodstein F, 2003, NEW ENGL J MED, V348, P645, DOI 10.1056/NEJMsb022365; Hastie T, 1995, Stat Methods Med Res, V4, P187, DOI 10.1177/096228029500400302; Hu PF, 2006, ATHEROSCLEROSIS, V185, P347, DOI 10.1016/j.atherosclerosis.2005.06.011; Jarvis D, 2002, EUR RESPIR J, V20, P1071, DOI 10.1183/09031936.02.00046802; Kalish GM, 2003, J CLIN ENDOCR METAB, V88, P1646, DOI 10.1210/jc.2002-021375; Key TJA, 1996, BRIT J CANCER, V74, P1313, DOI 10.1038/bjc.1996.536; Kuh D, 2005, BJOG-INT J OBSTET GY, V112, P476, DOI 10.1111/j.1471-0528.2005.00416.x; LANGE P, 1989, EUR RESPIR J, V2, P14; Lawlor DA, 2004, DIABETOLOGIA, V47, P195, DOI 10.1007/s00125-003-1310-6; Lazarus R, 1998, EUR RESPIR J, V12, P641, DOI 10.1183/09031936.98.12030641; LINDHEIM SR, 1993, FERTIL STERIL, V60, P664; Livingstone C, 2002, CLIN SCI, V102, P151, DOI 10.1042/cs1020151; Lukanova A, 2004, EUR J ENDOCRINOL, V150, P161, DOI 10.1530/eje.0.1500161; Pauwels Romain A., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1256; Pekkanen J, 2005, EUR RESPIR J, V26, P28, DOI 10.1183/09031936.05.00120104; Randolph JF, 2006, J CLIN ENDOCR METAB, V91, P3034, DOI 10.1210/jc.2006-0243; RANNEVIK G, 1995, MATURITAS, V21, P103, DOI 10.1016/0378-5122(94)00869-9; Real FG, 2006, THORAX, V61, P34, DOI 10.1136/thx.2005.040881; Real FG, 2007, J ALLERGY CLIN IMMUN, V120, P557, DOI 10.1016/j.jaci.2007.04.041; Salam MT, 2006, J ALLERGY CLIN IMMUN, V117, P1001, DOI 10.1016/j.jaci.2006.02.004; Simpson ER, 2005, ENDOCR REV, V26, P322, DOI 10.1210/er.2004-0020; Simpson ER, 2001, ANN NY ACAD SCI, V949, P58; Simpson ER, 2003, J STEROID BIOCHEM, V86, P225, DOI 10.1016/S0960-0760(03)00360-1; Speroff L., 1999, CLIN GYNECOLOGIC END, P643; Speroff L., 1999, CLIN GYNECOLOGIC END, V6th, P421; Speroff L, 1999, CLIN GYNECOLOGIC END, P487; Stopinska-Gluszak U, 2006, J REPROD IMMUNOL, V69, P65, DOI 10.1016/j.jri.2005.07.006; Svanes C, 2005, THORAX, V60, P445, DOI 10.1136/thx.2004.032615; TROISI RJ, 1995, AM J RESP CRIT CARE, V152, P1183, DOI 10.1164/ajrccm.152.4.7551368	44	75	75	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2008	121	1					72	80		10.1016/j.jaci.2007.08.057	http://dx.doi.org/10.1016/j.jaci.2007.08.057			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	251KM	18028993				2022-12-18	WOS:000252372000011
J	Ryan, JG; De Koning, HD; Beck, LA; Boot, MG; Kastner, DL; Simon, A				Ryan, John G.; De Koning, Heleen D.; Beck, Lisa A.; Boot, Matthew G.; Kastner, Daniel L.; Simon, Anna			IL-1 blockade in Schnitzler syndrome: Ex vivo findings correlate with clinical remission	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Ryan, John G.; De Koning, Heleen D.; Boot, Matthew G.; Kastner, Daniel L.; Simon, Anna] Univ Rochester, Natl Inst Arthritis & Musculoskeletal & Skin Dis, Genet & Genom Branch, Rochester, NY 14627 USA; [Beck, Lisa A.] Univ Rochester, Dept Dermatol, Rochester, NY 14627 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); University of Rochester; University of Rochester	Ryan, JG (corresponding author), Univ Rochester, Natl Inst Arthritis & Musculoskeletal & Skin Dis, Genet & Genom Branch, Rochester, NY 14627 USA.	ryanj2@mail.nih.gov	RYAN, JOHN/C-1012-2008; Booty, Matthew G/G-9536-2012; de Koning, Heleen/A-5374-2011; Simon, Anna/D-3757-2009	Simon, Anna/0000-0002-6141-7921; Booty, Matthew/0000-0002-0835-3439	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [Z01AR041123, Z01AR041180] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		de Koning HD, 2006, ANN RHEUM DIS, V65, P542, DOI 10.1136/ard.2005.045245; deCastro FR, 1996, DERMATOLOGY, V193, P94, DOI 10.1159/000246220; DEKONING HD, 2007, SEM ARTHR RHEUM; LIN RY, 2005, INTERNET J ASTHMA AL, V4; Lipsker D, 2001, MEDICINE, V80, P37, DOI 10.1097/00005792-200101000-00004; Martinez-Taboada VM, 2005, ARTHRITIS RHEUM, V52, P2226, DOI 10.1002/art.21101; Thonhofer R, 2007, RHEUMATOLOGY, V46, P1041, DOI 10.1093/rheumatology/kem048	7	75	79	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2008	121	1					260	262		10.1016/j.jaci.2007.09.021	http://dx.doi.org/10.1016/j.jaci.2007.09.021			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	251KM	17936890	Bronze			2022-12-18	WOS:000252372000044
J	Kim, HJ; Barajas, B; Chan, RCF; Nel, AE				Kim, Hyon-Jeen; Barajas, Berenice; Chan, Ray Chun-Fai; Nel, Andre E.			Glutathione depletion inhibits dendritic cell maturation and delayed-type hypersensitivity: Implications for systemic disease and immunosenescence	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						dendritic cells; T(H)1; glutathione; delayed-type hypersensitivity; skin dermatitis; aging; antigen-presenting cells; redox	EXHAUST PARTICLE CHEMICALS; NF-KAPPA-B; INDUCTION; APOPTOSIS; RESPONSES	Background: Dendritic cells (DCs) play a key role as antigen-presenting cells in the immune system. There is growing evidence that the redox equilibrium of these cells influences their ability to induce T-cell activation and to regulate the polarity of the immune response. This could affect the outcome of the immune response during systemic diseases and aging. Objective: Our aim was to elucidate the mechanism by which the redox equilibrium of antigen-presenting DCs affects the delayed-type hypersensitivity (DTH) response during experimental modification of glutathione levels, as well as during aging. Methods: We looked at the effect of glutathione depletion by diethyl maleate in DCs as well as during systemic administration on the DTH response to the contact-sensitizing antigens, oxazolone, and 2,4-dinitro-1-fluorobenzene. We also determined whether glutathione repletion with N-acetyl cysteine could influence the decline of the DTH response in aged mice. Results: Glutathione depletion in bone marrow-derived DCs interfered in their ability to mount a DTH response on adoptive transfer into recipient mice. Glutathione depletion interfered in IL-12 production and costimulatory receptor expression in DCs, leading to decreased IFN-gamma production in the skin of recipient mice. Systemic diethyl maleate treatment exerted similar effects on the DTH response and IFN-gamma production, whereas N-acetyl cysteine administration reversed the decline of the DTH response in aged animals. Conclusion: Glutathione depletion downregulates T-H(1) immunity through a perturbation of DC maturation and IL-12 production. Clinical implications: These data show that the induction of oxidative stress in the immune system, under disease conditions and aging, interferes in T-H(1) immunity.	Univ Calif Los Angeles, Dept Med, Div Clin Immunol & Allergy, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Nel, AE (corresponding author), Univ Calif Los Angeles, Dept Med, Div Clin Immunol & Allergy, Los Angeles, CA 90095 USA.	anel@mednet.ucla.edu	Nel, Andre E/J-2808-2012		NIAID NIH HHS [U19 AI070453] Funding Source: Medline; NIA NIH HHS [R01 AG14992] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI070453] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG014992] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Becker C, 2001, J IMMUNOL, V167, P2608, DOI 10.4049/jimmunol.167.5.2608; Castle SC, 1999, MECH AGEING DEV, V107, P137, DOI 10.1016/S0047-6374(98)00141-9; Cavalli V, 2001, MOL CELL, V7, P421, DOI 10.1016/S1097-2765(01)00189-7; Cella M, 1997, CURR OPIN IMMUNOL, V9, P10, DOI 10.1016/S0952-7915(97)80153-7; Chan RCF, 2006, J ALLERGY CLIN IMMUN, V118, P455, DOI 10.1016/j.jaci.2006.06.006; DENEKE SM, 1989, AM J PHYSIOL, V257, pL163, DOI 10.1152/ajplung.1989.257.4.L163; Deveci F, 2004, ANN ALLERG ASTHMA IM, V93, P91, DOI 10.1016/S1081-1206(10)61452-4; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; Dobmeyer TS, 1997, FREE RADICAL BIO MED, V22, P775, DOI 10.1016/S0891-5849(96)00403-0; Finkelman FD, 2004, J IMMUNOL, V172, P3808, DOI 10.4049/jimmunol.172.6.3808; Fontenot JD, 2005, IMMUNITY, V22, P329, DOI 10.1016/j.immuni.2005.01.016; Fuchs J, 2001, FREE RADICAL BIO MED, V30, P337, DOI 10.1016/S0891-5849(00)00482-2; GASPARI AA, 2003, CURRENT PROTOCOLS IM; Hildeman DA, 2003, J CLIN INVEST, V111, P575, DOI 10.1172/JCI200318007; Kantengwa S, 2003, AM J RESP CRIT CARE, V167, P431, DOI 10.1164/rccm.200205-425OC; Kim HJ, 2005, J IMMUNOL, V175, P2948, DOI 10.4049/jimmunol.175.5.2948; Krasteva M, 1998, J IMMUNOL, V160, P1181; Kuppner MC, 2003, BLOOD, V102, P3668, DOI 10.1182/blood-2003-05-1408; Li JF, 1999, J IMMUNOL, V163, P6386; Matteucci E, 2004, CLIN EXP IMMUNOL, V136, P549, DOI 10.1111/j.1365-2249.2004.02470.x; Meydani SN, 2005, IMMUNOL REV, V205, P269, DOI 10.1111/j.0105-2896.2005.00274.x; Murphy KM, 2002, NAT REV IMMUNOL, V2, P933, DOI 10.1038/nri954; Peterson JD, 1998, P NATL ACAD SCI USA, V95, P3071, DOI 10.1073/pnas.95.6.3071; Plackett TP, 2004, J LEUKOCYTE BIOL, V76, P291, DOI 10.1189/jlb.1103592; RICHIE JP, 1992, EXP GERONTOL, V27, P615, DOI 10.1016/0531-5565(92)90015-R; Rutault K, 1999, FREE RADICAL BIO MED, V26, P232, DOI 10.1016/S0891-5849(98)00194-4; Schodde H, 1996, ALCOHOL CLIN EXP RES, V20, P890, DOI 10.1111/j.1530-0277.1996.tb05268.x; VANDESTOLPE A, 1994, J BIOL CHEM, V269, P6185; Verhasselt V, 1999, J IMMUNOL, V162, P2569; Xiao GG, 2003, J BIOL CHEM, V278, P50781, DOI 10.1074/jbc.M306423200	30	75	81	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2007	119	5					1225	1233		10.1016/j.jaci.2007.01.016	http://dx.doi.org/10.1016/j.jaci.2007.01.016			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	167CB	17335885	Bronze			2022-12-18	WOS:000246427200026
J	Southam, DS; Ellis, R; Wattie, J; Inman, MD				Southam, David S.; Ellis, Russ; Wattie, Jennifer; Inman, Mark D.			Components of airway hyperresponsiveness and their associations with inflammation and remodeling in mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; pathophysiology; bronchial hyperreactivity; fibrosis; smooth muscle; time course	SMOOTH-MUSCLE; SUBEPITHELIAL FIBROSIS; EXTRACELLULAR-MATRIX; ALLERGEN CHALLENGE; CHRONIC ASTHMA; TGF-BETA; RESPONSIVENESS; DYSFUNCTION; EXPRESSION; EOSINOPHILS	Background: Pathologic changes, including inflammation and remodeling, occur in the asthmatic airway. However, their relative contribution to the components of airway hyperresponsiveness (AHR) remains unclear. Objective: Attempting to delineate AHR into discrete immune-mediated and structural remodeling components, we performed a detailed time course of the development, progression, and persistence of maximal respiratory system resistance, airway reactivity, and airway sensitivity. Methods: Mice exposed to increasing durations of persistent allergen were assessed for airway function, morphometry, and inflammation. Results: Allergen exposure resulted in increases for all indices of AHR that persisted for at least 4 weeks after chronic allergen exposure (P <.01 for all values). Early increases in AHR were associated with increases in immune-mediated events, including airway eosinophils (P <.01), whereas sustained AHR was associated with structural remodeling events. Increased maximal respiratory system resistance, evident by 6 weeks postallergen and persisting for at least 4 weeks after 8 weeks of chronic exposure, was associated with an increase in collagen deposition (P <.01). Increased airway reactivity and sensitivity, each evident by I week after allergen and persisting for at least 4 weeks after 8 weeks of chronic exposure, were associated with an increase in airway smooth muscle area (P <.01). Conclusion: Our novel observation of distinct temporal relationships in the development, progression, and persistence of the individual indices of AHR supports our hypothesis that multiple underlying factors contribute to airway dysfunction. Clinical implications: These findings illustrate the importance of clearly addressing specific components of airway dysfunction to provide greater insight into specific pathophysiologic mechanisms in airway disease.	McMaster Univ, Firestone Inst Resp Hlth, St Josephs Healthcare, Dept Med, Hamilton, ON L8N 4A6, Canada	McMaster University	Inman, MD (corresponding author), McMaster Univ, Firestone Inst Resp Hlth, St Josephs Healthcare, Dept Med, 50 Charlton Ave E, Hamilton, ON L8N 4A6, Canada.	inmanma@mcmaster.ca						Adler A, 2004, J APPL PHYSIOL, V97, P286, DOI 10.1152/japplphysiol.00821.2003; Boulet L P, 1998, Can Respir J, V5, P16; Boulet LP, 2000, AM J RESP CRIT CARE, V162, P1308, DOI 10.1164/ajrccm.162.4.9910051; Boulet LP, 1997, CHEST, V112, P45, DOI 10.1378/chest.112.1.45; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; Boxall C, 2006, EUR RESPIR J, V27, P208, DOI 10.1183/09031936.06.00130004; BRAND PLP, 1992, EUR RESPIR J, V5, P21; Busse W, 1999, AM J RESP CRIT CARE, V160, P1035, DOI 10.1164/ajrccm.160.3.9902064; Chakir J, 2003, J ALLERGY CLIN IMMUN, V111, P1293, DOI 10.1067/mai.2003.1557; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; Cox G, 2006, AM J RESP CRIT CARE, V173, P965, DOI 10.1164/rccm.200507-1162OC; Elias JA, 1999, J CLIN INVEST, V104, P1001, DOI 10.1172/JCI8124; Ellis R, 2003, LAB INVEST, V83, P1285, DOI 10.1097/01.LAB.0000087586.25982.B5; FLANDERS KC, 1989, J CELL BIOL, V108, P653, DOI 10.1083/jcb.108.2.653; Halayko AJ, 2003, RESP PHYSIOL NEUROBI, V137, P209, DOI 10.1016/S1569-9048(03)00148-4; Hirst SJ, 2000, AM J RESP CELL MOL, V23, P335, DOI 10.1165/ajrcmb.23.3.3990; Humbles AA, 2004, SCIENCE, V305, P1776, DOI 10.1126/science.1100283; Inman MD, 1999, AM J RESP CELL MOL, V21, P473, DOI 10.1165/ajrcmb.21.4.3622; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745, DOI 10.1164/ajrccm/140.6.1745; Johnson JR, 2004, AM J RESP CRIT CARE, V169, P378, DOI 10.1164/rccm.200308-1094OC; Kumar RK, 2004, CLIN EXP ALLERGY, V34, P567, DOI 10.1111/j.1365-2222.2004.1917.x; LAMBERT RK, 1993, J APPL PHYSIOL, V74, P2771, DOI 10.1152/jappl.1993.74.6.2771; Laprise C, 1999, EUR RESPIR J, V14, P63, DOI 10.1034/j.1399-3003.1999.14a12.x; Latourelle J, 2002, J APPL PHYSIOL, V92, P771, DOI 10.1152/japplphysiol.01090.2000; Lee JJ, 2004, SCIENCE, V305, P1773, DOI 10.1126/science.1099472; Leigh R, 2004, J APPL PHYSIOL, V97, P2258, DOI 10.1152/japplphysiol.00597.2004; Leigh R, 2004, AM J RESP CRIT CARE, V170, P851, DOI 10.1164/rccm.200311-1488OC; Leigh R, 2004, AM J RESP CRIT CARE, V169, P860, DOI 10.1164/rccm.200305-706OC; Leigh R, 2002, AM J RESP CELL MOL, V27, P526, DOI 10.1165/rcmb.2002-0048OC; McMillan SJ, 2005, J IMMUNOL, V174, P5774, DOI 10.4049/jimmunol.174.9.5774; Mcmillan SJ, 2004, CLIN EXP ALLERGY, V34, P497, DOI 10.1111/j.1365-2222.2004.01895.x; McParland BE, 2003, J APPL PHYSIOL, V95, P426, DOI 10.1152/japplphysiol.00159.2003; Moir LM, 2003, AM J PHYSIOL-LUNG C, V284, pL148, DOI 10.1152/ajplung.00105.2002; O'Byrne PM, 2003, CHEST, V123, p411S, DOI 10.1378/chest.123.3_suppl.411S; Parameswaran K, 2006, CELL BIOCHEM BIOPHYS, V44, P139, DOI 10.1385/CBB:44:1:139; Pepe C, 2005, J ALLERGY CLIN IMMUN, V116, P544, DOI 10.1016/j.jaci.2005.06.011; SKLOOT G, 1995, J CLIN INVEST, V96, P2393, DOI 10.1172/JCI118296; Sont JK, 1999, AM J RESP CRIT CARE, V159, P1043, DOI 10.1164/ajrccm.159.4.9806052; Southam DS, 2002, AM J PHYSIOL-LUNG C, V282, pL833, DOI 10.1152/ajplung.00173.2001; Stampfli MR, 1998, J CLIN INVEST, V102, P1704, DOI 10.1172/JCI4160; STERK PJ, 1989, EUR RESPIR J, V2, P267; Tomioka S, 2002, J APPL PHYSIOL, V93, P263, DOI 10.1152/japplphysiol.01129.2001; Vignola AM, 2000, J ALLERGY CLIN IMMUN, V105, P1041, DOI 10.1067/mai.2000.107195; Volgyesi GA, 2000, J APPL PHYSIOL, V89, P413, DOI 10.1152/jappl.2000.89.2.413	44	75	75	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2007	119	4					848	854		10.1016/j.jaci.2006.12.623	http://dx.doi.org/10.1016/j.jaci.2006.12.623			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	157OK	17321577				2022-12-18	WOS:000245729500012
J	Bachelet, I; Munitz, A; Levi-Schaffer, F				Bachelet, Ido; Munitz, Ariel; Levi-Schaffer, Francesca			Abrogation of allergic reactions by a bispecific antibody fragment linking IgE to CD300a	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; CD300a; mast cells; bispecific antibody	FC-EPSILON-RI; MAST-CELLS; INHIBITORY RECEPTORS; T-CELLS; PROTEIN; ASTHMA; RECOMBINATION; PATHOGENESIS; BASOPHILS; IRP60	Background: Initiated and regulated by mast cells, allergic responses are balanced through an intricate network of positive and negative signals. We have recently shown that the inhibitory receptor CD300a is expressed on human mast cells and modulates a large array of their functions. Objective: We sought to evaluate CD300a as a negative regulator of allergic inflammation in vivo by means of a bispecific antibody linking CD300a with IgE. Methods: Bispecific antibody fragments were generated by chemical conjugation of Fab' fragments of anti-human IgE and CD300a (IE1(H)) and anti-mouse IgE and CD300a (IE1(M)). IgE-sensitized human mast cells were activated simultaneously with anti-IgE and IE1(H). Phosphorylation of signaling proteins and calcium influx were evaluated by using fluorescence-activate cell sorting. Degranulation was assessed on the basis of tryptase and IL-4 release. IE1(M) was administered simultaneously with allergen challenge in 2 murine models of allergic disease. Passive cutaneous anaphylaxis was assessed by means of dye exudation. Experimental airway inflammation was assessed on the basis of tryptase and cytokine content, eosinophilic infiltration, and lung histology (hematoxylin and eosin and periodic acid-Schiff stain). Results: IE1(H) potently inhibited IgE-mediated mast cell degranulation in a dose-dependent manner by inhibiting the signaling events induced by Fe epsilon RI. IE1(M) completely abolished dye exudation in passive cutaneous anaphylaxis. IE1(M) abrogated allergic airway inflammation. Conclusion: Our results demonstrate that specific targeting of CD300a on mast cells is a potent strategy for inhibiting allergic reactions. Clinical implications: This work demonstrates a potent approach for the therapy of allergic diseases.	Hebrew Univ Jerusalem, Fac Med, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Levi-Schaffer, F (corresponding author), Hebrew Univ Jerusalem, Fac Med, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel.	fls@cc.huji.ac.il		Levi-Schaffer, Francesca/0000-0003-0620-2810				Bachelet I, 2005, J IMMUNOL, V175, P7989, DOI 10.4049/jimmunol.175.12.7989; BRENNAN M, 1985, SCIENCE, V229, P81, DOI 10.1126/science.3925553; Cantoni C, 1999, EUR J IMMUNOL, V29, P3148, DOI 10.1002/(SICI)1521-4141(199910)29:10<3148::AID-IMMU3148>3.0.CO;2-L; Carter P, 2001, NAT REV CANCER, V1, P118, DOI 10.1038/35101072; Daheshia M, 2001, J EXP MED, V194, P227, DOI 10.1084/jem.194.2.227; Galli SJ, 2005, ANNU REV IMMUNOL, V23, P749, DOI 10.1146/annurev.immunol.21.120601.141025; Galli SJ, 1997, J EXP MED, V186, P343, DOI 10.1084/jem.186.3.343; Gould HJ, 2003, ANNU REV IMMUNOL, V21, P579, DOI 10.1146/annurev.immunol.21.120601.141103; Graziano Robert F., 2004, V283, P71; Katz HR, 2002, CURR OPIN IMMUNOL, V14, P698, DOI 10.1016/S0952-7915(02)00400-4; Kay AB, 2001, NEW ENGL J MED, V344, P30, DOI 10.1056/NEJM200101043440106; Kinet JP, 1999, ANNU REV IMMUNOL, V17, P931, DOI 10.1146/annurev.immunol.17.1.931; Kumagai H, 2003, BIOCHEM BIOPH RES CO, V307, P719, DOI 10.1016/S0006-291X(03)01245-2; Long EO, 1999, ANNU REV IMMUNOL, V17, P875, DOI 10.1146/annurev.immunol.17.1.875; Mukai K, 2005, IMMUNITY, V23, P191, DOI 10.1016/j.immuni.2005.06.011; Tam SW, 2004, ALLERGY, V59, P772, DOI 10.1111/j.1398-9995.2004.00332.x; van Rijt LS, 2004, J IMMUNOL METHODS, V288, P111, DOI 10.1016/j.jim.2004.03.004; Veillette A, 2002, ANNU REV IMMUNOL, V20, P669, DOI 10.1146/annurev.immunol.20.081501.130710; Yamada T, 2003, J BIOL CHEM, V278, P32818, DOI 10.1074/jbc.M304590200; Yoshida S, 2003, BLOOD, V101, P2300, DOI 10.1182/blood-2002-03-0831; Zhu DC, 2005, NAT MED, V11, P446, DOI 10.1038/nm1219; Zhu DC, 2002, NAT MED, V8, P518, DOI 10.1038/nm0502-518; Zimmermann N, 2003, J CLIN INVEST, V111, P1863, DOI 10.1172/JCI200317912	23	75	80	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2006	117	6					1314	1320		10.1016/j.jaci.2006.04.031	http://dx.doi.org/10.1016/j.jaci.2006.04.031			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	053UX	16750992				2022-12-18	WOS:000238332300017
J	Tantisira, KG; Fuhlbrigge, AL; Tonascia, J; Van Natta, M; Zeiger, RS; Strunk, RC; Szefler, SJ; Weiss, ST				Tantisira, Kelan G.; Fuhlbrigge, Anne L.; Tonascia, James; Van Natta, Mark; Zeiger, Robert S.; Strunk, Robert C.; Szefler, Stanley J.; Weiss, Scott T.		Childhood Asthma Management Progra	Bronchodilation and bronchoconstriction: Predictors of future lung function in childhood asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						FEV1; PC20; methacholine; bronchodilator; corticosteroid; asthma; natural history	AIRWAY HYPERRESPONSIVENESS; BRONCHIAL RESPONSIVENESS; PULMONARY-FUNCTION; NATURAL-HISTORY; RISK-FACTORS; FOLLOW-UP; CHILDREN; GROWTH; HYPERREACTIVITY; CORTICOSTEROIDS	Background: Persistently low levels of lung function are associated with subsequent symptoms in patients with asthma as children. Objectives: We hypothesized that objective measures of baseline pulmonary function would be independently associated with future lung function in the Childhood Asthma Management Program and that these associations might vary with treatment. Methods: We evaluated the association of FEV1, airway responsiveness, and bronchodilator response at randomization as predictors of longitudinal growth in FEV1 at the 48-month follow-up visit in the 1041 Childhood Asthma Management Program participants. Results: Baseline levels of airway responsiveness and bronchodilator response were significantly associated with baseline level of lung function. In multivariate models, higher bronchodilator response (P = 0.22; P <.0001), log PC20 (P = 1.82; P <.0001), and FEV1 (0 = 0.58; P <.0001) at randomization were each associated with higher levels of prebronchodilator FEV1, as a percent of predicted, after 4 years. Similar associations were noted for prebronchodilator forced vital capacity and FEV1/forced vital capacity ratio. Baseline bronchodilator response was a particularly powerful predictor of lung function improvements while on inhaled corticosteroids, whereas airway responsiveness was a better predictor in subjects not randomized to any controller medications. Conclusion: We conclude that baseline bronchodilator response, airway responsiveness, and level of FEV1 are independent predictors of subsequent level of FEV1 in childhood asthma and may have treatment-specific prognostic significance for persistence of symptoms into early adulthood. Clinical implications: In asthma, bronchodilator and bronchoconstrictor responses are independent predictors of future lung function and should not be used interchangeably; bronchodilator response may indicate good response to inhaled corticosteroids.	Harvard Univ, Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Pulm, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Tantisira, KG (corresponding author), Harvard Univ, Brigham & Womens Hosp, Channing Lab, 181 Longwood Ave, Boston, MA 02115 USA.	kelan.tantisira@channing.harvard.edu		Zeiger, Robert/0000-0001-5788-5063	NCRR NIH HHS [RR00036, M01 RR00051, M01RR00051, M01RR0099718-24, M01RR07219-14] Funding Source: Medline; NHLBI NIH HHS [U01 HL065899, P01 HL67664, U01 HL65899] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000997, M01RR000051] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL067664, U01HL065899] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson GP, 2000, AM J RESP CRIT CARE, V161, pS188, DOI 10.1164/ajrccm.161.supplement_2.a1q4-9; BLAIR H, 1977, ARCH DIS CHILD, V52, P613, DOI 10.1136/adc.52.8.613; Cherniack R, 1999, CONTROL CLIN TRIALS, V20, P91; COULTAS DB, 1988, AM REV RESPIR DIS, V138, P1386, DOI 10.1164/ajrccm/138.6.1386; Covar RA, 2004, AM J RESP CRIT CARE, V170, P234, DOI 10.1164/rccm.200308-1174OC; Dixon AE, 2005, CURR OPIN PULM MED, V11, P51, DOI 10.1097/01.mcp.0000148663.53798.72; Djukanovic R, 2002, J ALLERGY CLIN IMMUN, V109, pS539, DOI 10.1067/mai.2002.124568; Douma WR, 1997, EUR RESPIR J, V10, P2772, DOI 10.1183/09031936.97.10122772; Faul JL, 2002, CHEST, V121, P1414, DOI 10.1378/chest.121.5.1414; Fuhlbrigge AL, 2001, J ALLERGY CLIN IMMUN, V107, P61, DOI 10.1067/mai.2001.111590; GERRITSEN J, 1989, AM REV RESPIR DIS, V140, P1325, DOI 10.1164/ajrccm/140.5.1325; GODDEN DJ, 1994, AM J RESP CRIT CARE, V149, P106, DOI 10.1164/ajrccm.149.1.8111567; Grol MH, 1999, AM J RESP CRIT CARE, V160, P1830, DOI 10.1164/ajrccm.160.6.9812100; in't Veen JCCM, 1999, AM J RESP CRIT CARE, V160, P93; KERSTJENS HAM, 1993, EUR RESPIR J, V6, P868; Kitch BT, 2004, CHEST, V126, P1875, DOI 10.1378/chest.126.6.1875; KJELLMAN B, 1994, ACTA PAEDIATR, V83, P854; Kleinbaum D.G., 1998, APPL REGRESSION ANAL, P212; KNUDSON RJ, 1983, AM REV RESPIR DIS, V127, P725; MARTIN AJ, 1980, BRIT MED J, V280, P1397, DOI 10.1136/bmj.280.6229.1397; *NAT ASTH ED PREV, 1997, NAT I HLTH PUBL PUBL; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Oswald H, 1997, PEDIATR PULM, V23, P14, DOI 10.1002/(SICI)1099-0496(199701)23:1<14::AID-PPUL2>3.0.CO;2-P; POSTMA DS, 1988, EUR RESPIR J, V1, P483; POSTMA DS, 1986, AM REV RESPIR DIS, V134, P276; POSTMA DS, 1989, AM REV RESPIR DIS, V140, pS100, DOI 10.1164/ajrccm/140.3_Pt_2.S100; RAMSDELL JW, 1982, AM REV RESPIR DIS, V126, P829; Rasmussen F, 2002, PEDIATR PULM, V34, P164, DOI 10.1002/ppul.10155; ROORDA RJ, 1994, J ALLERGY CLIN IMMUN, V93, P575, DOI 10.1016/S0091-6749(94)70069-9; Roth M, 2002, LANCET, V360, P1293, DOI 10.1016/S0140-6736(02)11319-5; Schuh S, 2000, NEW ENGL J MED, V343, P689, DOI 10.1056/NEJM200009073431003; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Strunk RC, 2003, J ALLERGY CLIN IMMUN, V112, P883, DOI 10.1016/j.jaci.2003.08.014; Szefler S, 2000, NEW ENGL J MED, V343, P1054; Szefler SJ, 2002, J ALLERGY CLIN IMMUN, V109, P410, DOI 10.1067/mai.2002.122635; Ulrik CS, 1999, EUR RESPIR J, V13, P904, DOI 10.1034/j.1399-3003.1999.13d35.x; Ulrik CS, 1996, J ALLERGY CLIN IMMUN, V97, P761, DOI 10.1016/S0091-6749(96)80153-9; ULRIK CS, 1995, RESP MED, V89, P547, DOI 10.1016/0954-6111(95)90156-6; VANSCHAYCK CP, 1991, AM REV RESPIR DIS, V144, P1297, DOI 10.1164/ajrccm/144.6.1297; Weiss ST, 2000, AM J RESP CRIT CARE, V162, P50, DOI 10.1164/ajrccm.162.1.9811005; Xuan W, 2000, AM J RESP CRIT CARE, V161, P1820, DOI 10.1164/ajrccm.161.6.9809118; Zeiger RS, 2006, J ALLERGY CLIN IMMUN, V117, P45, DOI 10.1016/j.jaci.2005.10.012	42	75	78	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2006	117	6					1264	1271		10.1016/j.jaci.2006.01.050	http://dx.doi.org/10.1016/j.jaci.2006.01.050			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	053UX	16750985				2022-12-18	WOS:000238332300010
J	Li, HL; Romieu, I; Sienra-Monge, JJ; Ramirez-Aguilar, M; del Rio-Navarro, BE; Kistner, EO; Gjessing, HK; Lara-Sanchez, ID; Chiu, GY; London, SJ				Li, HL; Romieu, I; Sienra-Monge, JJ; Ramirez-Aguilar, M; del Rio-Navarro, BE; Kistner, EO; Gjessing, HK; Lara-Sanchez, ID; Chiu, GY; London, SJ			Genetic polymorphisms in arginase I and II and childhood asthma and atopy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ARG1; ARG2; genetic predisposition to disease; SNP; polymorphism; single nucleotide; respiratory hypersensitivity; skin tests; asthma; tobacco smoke pollution	NITRIC-OXIDE; AIRWAY HYPERREACTIVITY; POSITIONAL CLONING; ARGININE; IDENTIFICATION; DEFICIENCY; GENOTYPE; LOCUS	Background: A recent microarray study implicated arginase I (ARGI) and arginase II (ARG2) in mouse allergic asthma models and human asthma. Objectives: To examine the association between genetic variation in ARGI and ARG2 and childhood asthma and atopy risk. Methods: We enrolled 433 case-parent triads, consisting of patients with asthma 4 to 17 years old and their biologic parents, from the allergy clinic of a public hospital in Mexico City between 1998 and 2003. Atopy to 24 aeroallergens was determined by skin prick tests. We genotyped 4 single nucleotide polymorphisms (SNPs) of ARG1 and 4 SNPs of ARG2 with minor allele frequencies higher than 10% by using the TaqMan assay (Roche Molecular Systems, Pleasanton, Calif). Results: ARGI SNPs and haplotypes were not associated with asthma, but all 4 ARGI SNPs were associated with the number of positive skin tests (P = .007-.018). Carrying 2 copies of minor alleles for either of 2 highly associated ARG2 SNPs was associated with a statistically significant increased relative risk (RR) of asthma (1.5, 95% CI = 1.1-2.1 for arg2s1; RR = 1.6, 95% CI = 1.1-2.3 for arg2s2). The association was slightly stronger among children with a smoking parent (arg2s1 RR 2.1, 95% CI = 1.2 - 3.9 with a smoking parent; RR = 1.2, 95% CI = 0.8-1.9 without; interaction P = .025). Haplotype analyses reduced the sample size but supported the single SNP results. One ARG2 SNP was related to the number of positive skin tests (P = .027).	Natl Inst Environm Hlth Sci, Lab Resp Biol, Res Triangle Pk, NC 27709 USA; Natl Inst Environm Hlth Sci, Epidemiol Branch, Res Triangle Pk, NC 27709 USA; Natl Inst Environm Hlth Sci, Biostat Branch, Div Intramural Res, NIH,Dept Hlth & Human Sci, Res Triangle Pk, NC 27709 USA; Natl Inst Publ Hlth, Cuernavaca, Morelos, Mexico; Hosp Infantil Mexico Dr Federico Gomez, Mexico City, DF, Mexico; Norwegian Inst Publ Hlth, Oslo, Norway; Westat Corp, Res Triangle Pk, NC USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Instituto Nacional de Salud Publica; Hospital Infantil de Mexico Federico Gomez; Norwegian Institute of Public Health (NIPH); Westat	London, SJ (corresponding author), Natl Inst Environm Hlth Sci, Lab Resp Biol, POB 12233,MD A3-05, Res Triangle Pk, NC 27709 USA.	london2@niehs.nih.gov	Gjessing, Hakon K/A-5871-2012; London, Stephanie/C-3734-2019	London, Stephanie/0000-0003-4911-5290	Intramural NIH HHS [Z01 ES049019] Funding Source: Medline; NIEHS NIH HHS [Z01 ES049019-10] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES049019] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Allen M, 2003, NAT GENET, V35, P258, DOI 10.1038/ng1256; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; AUS K, 1973, INT ARCH ALLER A IMM, V45, P57; Cederbaum SD, 2004, MOL GENET METAB, V81, pS38, DOI 10.1016/j.ymgme.2003.10.012; Davis BJ, 2004, J IMMUNOL, V173, P6914, DOI 10.4049/jimmunol.173.11.6914; de Boer J, 1999, BRIT J PHARMACOL, V128, P1114, DOI 10.1038/sj.bjp.0702882; deBoer J, 1996, BRIT J PHARMACOL, V119, P1109; DEVLIN B, 1995, GENOMICS, V29, P311, DOI 10.1006/geno.1995.9003; Endo M, 2003, AM J PHYSIOL-LUNG C, V285, pL313, DOI 10.1152/ajplung.00434.2002; Floreani A A, 1999, Curr Opin Pulm Med, V5, P38, DOI 10.1097/00063198-199901000-00007; GJESSING HK, 2005, IN PRESS ANN HUM GEN; Gotoh T, 1997, BIOCHEM BIOPH RES CO, V233, P487, DOI 10.1006/bbrc.1997.6473; Hakonarson H, 2002, AM J HUM GENET, V71, P483, DOI 10.1086/342205; Horvath S, 2004, GENET EPIDEMIOL, V26, P61, DOI 10.1002/gepi.10295; Hutchison SJ, 2001, CHEST, V120, P2004, DOI 10.1378/chest.120.6.2004; Johnson PRA, 2004, J ALLERGY CLIN IMMUN, V113, P690, DOI 10.1016/j.jaci.2003.12.312; Kistner EO, 2004, GENET EPIDEMIOL, V27, P33, DOI 10.1002/gepi.20001; Kormann MSD, 2005, AM J RESP CRIT CARE, V171, P1358, DOI 10.1164/rccm.200410-1312OC; KUROSAWA M, 1992, ALLERGY, V47, P638, DOI 10.1111/j.1398-9995.1992.tb02388.x; Laitinen T, 2004, SCIENCE, V304, P300, DOI 10.1126/science.1090010; LEVONTIN RC, 1988, GENETICS, V120, P849; Malerba Giovanni, 2005, Journal of Applied Genetics, V46, P93; Mehta S, 1997, AM J PHYSIOL-LUNG C, V273, pL656, DOI 10.1152/ajplung.1997.273.3.L656; Meurs H, 2003, TRENDS PHARMACOL SCI, V24, P450, DOI 10.1016/S0165-6147(03)00227-X; Miura M, 1997, AM J RESP CRIT CARE, V156, P217, DOI 10.1164/ajrccm.156.1.9606040; Morris CR, 2004, AM J RESP CRIT CARE, V170, P148, DOI 10.1164/rccm.200309-1304OC; *NHLBI, 1998, NIH PUBL; O'Connell JR, 1998, AM J HUM GENET, V63, P259, DOI 10.1086/301904; Perez-Padilla R, 2003, PEDIATR PULM, V35, P177, DOI 10.1002/ppul.10232; Rutschman R, 2001, J IMMUNOL, V166, P2173, DOI 10.4049/jimmunol.166.4.2173; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; Smith KR, 2005, P NATL ACAD SCI USA, V102, P2186, DOI 10.1073/pnas.0409591102; Umbach DH, 2000, AM J HUM GENET, V66, P251, DOI 10.1086/302707; Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878; Vercelli D, 2003, J CLIN INVEST, V111, P1815, DOI 10.1172/JCI200318908; Wedzicha JA, 2003, THORAX, V58, P1, DOI 10.1136/thorax.58.1.1; Weinberg CR, 1998, AM J HUM GENET, V62, P969, DOI 10.1086/301802; Wilcox AJ, 1998, AM J EPIDEMIOL, V148, P893; Wilson JW, 1997, CLIN EXP ALLERGY, V27, P363; Xia Y, 1996, P NATL ACAD SCI USA, V93, P6770, DOI 10.1073/pnas.93.13.6770; Zhang YM, 2003, NAT GENET, V34, P181, DOI 10.1038/ng1166; Zimmermann N, 2003, J CLIN INVEST, V111, P1863, DOI 10.1172/JCI200317912; Zimmermann N, 2004, J IMMUNOL, V172, P1815, DOI 10.4049/jimmunol.172.3.1815	43	75	77	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2006	117	1					119	126		10.1016/j.jaci.2005.09.026	http://dx.doi.org/10.1016/j.jaci.2005.09.026			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IK	16387594	Green Accepted			2022-12-18	WOS:000235687100019
J	Linneberg, A; Simonsen, JB; Petersen, J; Stensballe, LG; Benn, CS				Linneberg, A; Simonsen, JB; Petersen, J; Stensballe, LG; Benn, CS			Differential effects of risk factors on infant wheeze and atopic dermatitis emphasize a different etiology	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; birth cohort; epidemiology; infant; wheezing	YOUNG-CHILDREN; ASTHMA; SMOKING; BIRTH; LIFE	Background: Atopic dermatitis (AD) often develops in infancy as the first manifestation of the atopic phenotype. Wheezing is also common in infancy, but it is less clear whether infant wheezing should be considered as an atopic phenotype. If infant wheeze and AD share a common aetiology, this would indicate that infant wheezing is an atopic phenotype. Objective: To investigate whether potential risk factors for infant wheeze and AD have similar effects on these 2 phenotypes, indicating a common etiology. Methods: A total of 34.793 mother-child pairs enrolled in the Danish National Birth Cohort were followed prospectively. Information on wheezing episodes, AD, and prenatal, perinatal, and postnatal risk factors was collected by interview at 12 and 30 weeks of gestation, at 6 and 18 months of age, and by linkage to the Danish Medical Birth Register. Data were analyzed by binary and polytomous logistic regression models. Results: The following variables had significantly differential effects on infant wheezing and AD: parental hay fever, parental asthma, parental AD, sex, maternal age, maternal occupation, smoking during pregnancy, season of birth, birth weight, gestational age, head circumference, breast-feeding, number of older siblings, day care attendance, and pets in the home. Conclusion: The majority of risk factors had differential effects on infant wheeze and AD indicative of a different etiology. Infant wheezing does not seem to be etiologically linked to the epidemic of atopic disease, and infant wheezing should not be used as an indicator of the atopic phenotype.	Glostrup Univ Hosp, Res Ctr Prevent & Hlth, DK-2600 Glostrup, Denmark; Statens Serum Inst, Danish Epidemiol Sci Ctr, Copenhagen, Denmark	University of Copenhagen; Aarhus University; Statens Serum Institut	Linneberg, A (corresponding author), Glostrup Univ Hosp, Res Ctr Prevent & Hlth, 57 Nrd Ringvej,Bldg 84-85, DK-2600 Glostrup, Denmark.	alli@glostruhosp.kbhamt.dk	Stensballe, Lone Graff/AAS-4137-2020	Stensballe, Lone Graff/0000-0003-1569-153X; Simonsen, Jacob/0000-0002-8700-4826; Petersen, Janne/0000-0001-7323-2548; Linneberg, Allan/0000-0002-0994-0184				Benn CS, 2003, ACTA DERM-VENEREOL, V83, P347; BISGAARD H, 1987, ACTA PAEDIATR SCAND, V76, P719, DOI 10.1111/j.1651-2227.1987.tb10555.x; Fogg MI, 2003, J ALLERGY CLIN IMMUN, V112, P796, DOI 10.1016/S0091-6749(03)01715-9; HALKEN S, 1991, ALLERGY, V46, P507, DOI 10.1111/j.1398-9995.1991.tb00613.x; Illi S, 2004, J ALLERGY CLIN IMMUN, V113, P925, DOI 10.1016/j.jaci.2004.01.778; Ludvigsson JF, 2005, PEDIAT ALLERG IMM-UK, V16, P201, DOI 10.1111/j.1399-3038.2005.00257.x; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Olsen J, 2001, SCAND J PUBLIC HEALT, V29, P300, DOI 10.1177/14034948010290040201; PEARCE N, 1998, ASTHMA EPIDEMIOLOGY; ROBERTS RS, 1978, J CHRON DIS, V31, P119, DOI 10.1016/0021-9681(78)90097-8; Rusconi F, 1999, AM J RESP CRIT CARE, V160, P1617, DOI 10.1164/ajrccm.160.5.9811002; Sicherer SH, 2005, J ALLERGY CLIN IMMUN, V116, P153, DOI 10.1016/j.jaci.2005.03.017; Strachan DP, 1998, THORAX, V53, P117, DOI 10.1136/thx.53.2.117; Szefler SJ, 2005, J ALLERGY CLIN IMMUN, V115, P470, DOI 10.1016/j.jaci.2004.12.1123; TAGER IB, 1995, AM J RESP CRIT CARE, V152, P977, DOI 10.1164/ajrccm.152.3.7663813; Tattersfield AE, 2002, LANCET, V360, P1313, DOI 10.1016/S0140-6736(02)11312-2; Wood RA, 2002, JAMA-J AM MED ASSOC, V288, P745, DOI 10.1001/jama.288.6.745	17	75	77	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2006	117	1					184	189		10.1016/j.jaci.2005.09.042	http://dx.doi.org/10.1016/j.jaci.2005.09.042			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IK	16387604				2022-12-18	WOS:000235687100029
J	Pykalainen, M; Kinos, R; Valkonen, S; Rydman, P; Kilpelalainen, M; Laitinen, LA; Karjalainen, J; Nieminen, M; Hurme, M; Kere, J; Laitinen, T; Lahesmaa, R				Pykalainen, M; Kinos, R; Valkonen, S; Rydman, P; Kilpelalainen, M; Laitinen, LA; Karjalainen, J; Nieminen, M; Hurme, M; Kere, J; Laitinen, T; Lahesmaa, R			Association analysis of common variants of STAT6, GATA3, and STAT4 to asthma and high serum IgE phenotypes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						association analysis; common variant; STAT6; GATA3; STAT4; asthma; serum IgE; haplotype	SINGLE-NUCLEOTIDE POLYMORPHISMS; TRANSCRIPTION FACTOR GATA-3; LINKAGE DISEQUILIBRIUM; SIGNAL TRANSDUCER; GENE-EXPRESSION; BINDING-SITE; TH2 CELLS; PROMOTER; MARKERS; IDENTIFICATION	Background: Immune responses characterized by T(H)2 type cells and IgE are important for the development of asthma and atopy. The transcription factors STATE, GATA3, and STAT4 mediate the cytokine-induced development of naive CD4(+) T cells into either T(H)1 or T(H)2 type. Objective: We studied genetic variation of the STATE, GATA3, and STAT4 genes and examined whether single nucleotide polymorphisms(SNPs) in these loci were associated with asthma or serum high IgE levels in the Finnish asthmatic families. Methods: With denaturing high-performance liquid chromatography we screened all exons and exon-intron boundaries of the genes in 14 to 22 patients. All identified SNPs were genotyped in 120 nuclear families, and the haplotypes were analyzed by Haplotype Pattern Mining based statistical analysis. When potential association was observed, the analysis was replicated among 245 asthmatic patients and 405 population-based control subjects. Results: A total of 23 SNPs were identified, of which 8 were not previously listed in the SNP database. Interestingly, a haplotype analysis of GATA3 showed 3 related haplotypes that associated with different asthma and atopy related phenotypes among both the family and case-control data sets. For STATE and STAT4, no significant association to asthma or serum total IgE levels was observed. Conclusions: We identified a panel of novel SNPs in genes coding for proteins important in the T(H)1/T(H)2 cell differentiation. SNPs of the GATA3 gene showed an initial association to asthma-related phenotypes. Elucidation of the importance of the identified panel of SNPs in other T(H)1/T(H)2 mediated diseases will be of great interest.	Univ Turku, Turku Ctr Biotechnol, FIN-20520 Turku, Finland; Abo Akad Univ, FIN-20520 Turku, Finland; Turku Grad Sch Biomed Sci, FIN-20520 Turku, Finland; GeneOS Ltd, Helsinki, Finland; Dept Pulm Dis & Clin Allergol, Turku, Finland; Tampere Univ, Dept Resp Med, FIN-33101 Tampere, Finland; Tampere Univ Hosp, Dept Microbiol & Immunol, FIN-33101 Tampere, Finland; Univ Helsinki, Biomedicum Helsinki, Dept Med Genet, FIN-00014 Helsinki, Finland; Karolinska Inst, Dept Biosci, Novum, Stockholm, Sweden	University of Turku; Abo Akademi University; University of Turku; Tampere University; Tampere University; Tampere University Hospital; University of Helsinki; Karolinska Institutet	Pykalainen, M (corresponding author), Univ Turku, Turku Ctr Biotechnol, POB 124, FIN-20520 Turku, Finland.	maritta.pykalainen@btk.fi	Kere, Juha/A-9179-2008; Kere, Juha/AAX-9117-2021	Kere, Juha/0000-0003-1974-0271; Kere, Juha/0000-0003-1974-0271; Hurme, Mikko/0000-0002-8614-1044				Akimoto T, 1998, J EXP MED, V187, P1537, DOI 10.1084/jem.187.9.1537; Asnagli H, 2002, J IMMUNOL, V168, P4268, DOI 10.4049/jimmunol.168.9.4268; Barnes KC, 1996, GENOMICS, V37, P41, DOI 10.1006/geno.1996.0518; Barnes KC, 1999, J ALLERGY CLIN IMMUN, V104, P485, DOI 10.1016/S0091-6749(99)70398-2; Duetsch G, 2002, HUM MOL GENET, V11, P613, DOI 10.1093/hmg/11.6.613; Fishman D, 1998, J CLIN INVEST, V102, P1369, DOI 10.1172/JCI2629; Gao PS, 2000, J MED GENET, V37, P380; Gibson AW, 2001, J IMMUNOL, V166, P3915, DOI 10.4049/jimmunol.166.6.3915; Heinzmann A, 2000, CLIN EXP ALLERGY, V30, P1554; HO IC, 1991, EMBO J, V10, P1187, DOI 10.1002/j.1460-2075.1991.tb08059.x; Hoffjan S, 2002, CURR OPIN IMMUNOL, V14, P709, DOI 10.1016/S0952-7915(02)00393-X; JOULIN V, 1991, EMBO J, V10, P1809, DOI 10.1002/j.1460-2075.1991.tb07706.x; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; Kaplan MH, 1996, NATURE, V382, P174, DOI 10.1038/382174a0; Karjalainen J, 2002, J ALLERGY CLIN IMMUN, V110, P429, DOI 10.1067/mai.2002.126784; Kuklin A, 1997, GENET TEST, V1, P201, DOI 10.1089/gte.1997.1.201; Kuperman D, 1998, J EXP MED, V187, P939, DOI 10.1084/jem.187.6.939; Laitinen T, 1997, HUM MOL GENET, V6, P2069, DOI 10.1093/hmg/6.12.2069; Laitinen T, 2000, AM J RESP CRIT CARE, V161, P700, DOI 10.1164/ajrccm.161.3.9810056; Mann V, 2001, J CLIN INVEST, V107, P899, DOI 10.1172/JCI10347; Marsh DG, 1997, NAT GENET, V15, P389; Murphy KM, 2000, ANNU REV IMMUNOL, V18, P451, DOI 10.1146/annurev.immunol.18.1.451; Nagase M, 2002, ELEC SOC S, V2002, P47; Nickel R, 1997, GENOMICS, V46, P159, DOI 10.1006/geno.1997.5013; Nickel RG, 2000, J IMMUNOL, V164, P1612, DOI 10.4049/jimmunol.164.3.1612; O'Connell JR, 1998, AM J HUM GENET, V63, P259, DOI 10.1086/301904; OOSTERWEGEL M, 1992, DEV IMMUNOL, V3, P1, DOI 10.1155/1992/27903; Ouyang W, 1998, IMMUNITY, V9, P745, DOI 10.1016/S1074-7613(00)80671-8; Ouyang WJ, 2000, IMMUNITY, V12, P27, DOI 10.1016/S1074-7613(00)80156-9; Patel BKR, 1998, GENOMICS, V52, P192, DOI 10.1006/geno.1998.5436; ROSENWASSER LJ, 1995, CLIN EXP ALLERGY, V25, P74, DOI 10.1111/j.1365-2222.1995.tb00428.x; Shao CC, 2004, J HUM GENET, V49, P115, DOI 10.1007/s10038-003-0118-z; Shen LX, 1999, P NATL ACAD SCI USA, V96, P7871, DOI 10.1073/pnas.96.14.7871; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; Takeda K, 1996, J IMMUNOL, V157, P3220; Tamura K, 2001, CLIN EXP ALLERGY, V31, P1509, DOI 10.1046/j.1365-2222.2001.01191.x; Ting CN, 1996, NATURE, V384, P474, DOI 10.1038/384474a0; Toivonen HTT, 2000, AM J HUM GENET, V67, P133, DOI 10.1086/302954; Tokuhiro S, 2003, NAT GENET, V35, P341, DOI 10.1038/ng1267; Turner D, 2002, HUM IMMUNOL, V63, P508, DOI 10.1016/S0198-8859(02)00392-0; von Ahsen N, 2004, BLOOD, V103, P586, DOI 10.1182/blood-2003-02-0419; Wilkinson J, 1998, GENOMICS, V53, P251, DOI 10.1006/geno.1998.5485; Wjst M, 1999, GENOMICS, V58, P1, DOI 10.1006/geno.1999.5806; Yamamoto K, 1997, CYTOGENET CELL GENET, V77, P207, DOI 10.1159/000134578; Ylikoski E, 2004, CLIN EXP ALLERGY, V34, P1049, DOI 10.1111/j.1365-2222.2004.01995.x; Zhang DH, 1999, IMMUNITY, V11, P473, DOI 10.1016/S1074-7613(00)80122-3; Zhang DH, 1997, J BIOL CHEM, V272, P21597, DOI 10.1074/jbc.272.34.21597; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8	48	75	81	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2005	115	1					80	87		10.1016/j.jaci.2004.10.006	http://dx.doi.org/10.1016/j.jaci.2004.10.006			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	886XS	15637551				2022-12-18	WOS:000226267000011
J	Hanania, NA; Sockrider, M; Castro, M; Holbrook, JT; Tonascia, J; Wise, R; Atmar, RL				Hanania, NA; Sockrider, M; Castro, M; Holbrook, JT; Tonascia, J; Wise, R; Atmar, RL		Amer Lung Assoc Asthma Clin Res Ce	Immune response to influenza vaccination in children and adults with asthma: Effect of corticosteroid therapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Annual Scientific Meeting of the American-Thoracic-Society	MAY 17-22, 2002	ATLANTA, GA	American Thoracic Soc		asthma; influenza; vaccination; inhaled corticosteroids; immune response; antibodies	ANTIBODY-RESPONSE; VIRUS VACCINE; UNITED-STATES; HOSPITALIZATION; IMMUNOGENICITY; PREDNISONE; TRIVALENT; INFECTION; EFFICACY; IMPACT	Background: Annual influenza vaccination is currently recommended as a preventative measure for all patients with asthma. However, the effect of maintenance corticosteroid therapy on the immune response to influenza vaccine has received limited evaluation. Objective: In this study, we evaluated the effect of corticosteroid therapy on the immune response to influenza vaccine in children and adults with asthma. Methods: This was a substudy of a larger multicenter, randomized, double-masked, placebo-controlled, crossover study investigating the safety of trivalent influenza vaccine in patients with asthma. At baseline, 294 subjects were randomized to receive either placebo first (n = 139) or inactivated trivalent split-virus influenza vaccine first (n = 155). Study subjects were categorized into 2 groups: subjects in group 1 (n = 148) were receiving medium-dose or high-dose inhaled corticosteroids (ICSs) or oral corticosteroids, whereas subjects in group 2 (n = 146) were not receiving corticosteroids or were receiving low-close ICSs. Serum hemagglutination inhibition antibody titers for the vaccine antigens were measured before and 4 weeks after the administration of placebo or vaccine. Results: Serologic responses to each influenza vaccine antigen were significantly higher in vaccine than in placebo recipients and were similar among influenza vaccine recipients in groups 1 and 2 for the following endpoints: rise in antibody titer, percent of participants who developed a serological response, and percent of subjects who developed a serum hemagglutination inhibition antibody titer greater than or equal to1:32. Post hoc subgroup analyses demonstrated an attenuated response to influenza B antigen in subjects receiving high-dose ICS compared with subjects who were steroid-naive (P < .05). Conclusion: The immune response to the A antigens of the inactivated influenza vaccine in subjects with asthma is not adversely affected by ICS therapy. High-dose ICS therapy may diminish the response to the B antigen of the vaccine, an observation that needs further investigation.	Baylor Coll Med, Houston, TX 77030 USA; Washington Univ, St Louis, MO USA; Johns Hopkins Univ, Baltimore, MD USA	Baylor College of Medicine; Washington University (WUSTL); Johns Hopkins University	Hanania, NA (corresponding author), Baylor Coll Med, 1504 Taub Loop, Houston, TX 77030 USA.	Hanania@bcm.tmc.edu	Atmar, Robert/AFQ-5392-2022; Hanania, Nicola A/C-5875-2016	Atmar, Robert/0000-0001-9989-6772; Hanania, Nicola A/0000-0003-3087-9530; Wise, Robert/0000-0002-8353-2349				Ashwell JD, 2000, ANNU REV IMMUNOL, V18, P309, DOI 10.1146/annurev.immunol.18.1.309; BARKER WH, 1986, AM J PUBLIC HEALTH, V76, P761, DOI 10.2105/AJPH.76.7.761; BAXTER JD, 1975, TRANSPLANT P, V7, P55; BELL TD, 1978, CHEST, V73, P140, DOI 10.1378/chest.73.2.140; BUTLER WT, 1975, TRANSPLANT P, V7, P49; Castro M, 2001, NEW ENGL J MED, V345, P1529, DOI 10.1056/NEJMoa011961; Couch RB, 2000, NEW ENGL J MED, V343, P1778, DOI 10.1056/NEJM200012143432407; DUPONT WD, 1990, CONTROL CLIN TRIALS, V11, P116, DOI 10.1016/0197-2456(90)90005-M; Fairchok MP, 1998, ARCH PEDIAT ADOL MED, V152, P1191; FRANK AL, 1980, J CLIN MICROBIOL, V12, P426, DOI 10.1128/JCM.12.3.426-432.1980; Glezen WP, 2000, JAMA-J AM MED ASSOC, V283, P499, DOI 10.1001/jama.283.4.499; GROSS PA, 1985, REV INFECT DIS, V7, P613; Halperin SA, 2002, VACCINE, V20, P1240, DOI 10.1016/S0264-410X(01)00428-5; HANANIA NA, 1995, AM J MED, V98, P196, DOI 10.1016/S0002-9343(99)80404-5; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179, DOI 10.1164/ajrccm.159.1.9712108; HERRON A, 1979, JAMA-J AM MED ASSOC, V242, P53, DOI 10.1001/jama.242.1.53; Iorio AM, 1997, VACCINE, V15, P97, DOI 10.1016/S0264-410X(96)00057-6; Izurieta HS, 2000, NEW ENGL J MED, V342, P232, DOI 10.1056/NEJM200001273420402; Keitel WA, 2002, PERSP MED V, V7, P145; Kelly HW, 2003, J ALLERGY CLIN IMMUN, V112, P469, DOI 10.1067/mai.2003.1718; KONDO S, 1991, CHEST, V100, P1235, DOI 10.1378/chest.100.5.1235; Kubiet MA, 1996, CHEST, V110, P367, DOI 10.1378/chest.110.2.367; Lambkin R, 2000, VACCINE, V18, P2307, DOI 10.1016/S0264-410X(99)00437-5; *NAT ASTHM ED PREV, 1997, NIH PUBL; Nathan RA, 2001, ANN ALLERG ASTHMA IM, V87, P447, DOI 10.1016/S1081-1206(10)62255-7; Neuzil KM, 2000, NEW ENGL J MED, V342, P225, DOI 10.1056/NEJM200001273420401; Neuzil KM, 2000, J PEDIATR-US, V137, P856, DOI 10.1067/mpd.2000.110445; Neuzil KM, 2001, J PEDIATR-US, V138, P301, DOI 10.1067/mpd.2001.113101; OCHIAI H, 1986, MICROBIOL IMMUNOL, V30, P1151, DOI 10.1111/j.1348-0421.1986.tb03044.x; Palache AM, 1997, DRUGS, V54, P841, DOI 10.2165/00003495-199754060-00004; Park CL, 1996, PEDIATRICS, V98, P196; PICKERING LK, 2000, 2000 RED BOOK, P354; POTTER CW, 1979, BRIT MED BULL, V35, P69, DOI 10.1093/oxfordjournals.bmb.a071545; Rani S, 2022, SPAT INF RES, V30, P417, DOI 10.1007/s41324-022-00442-9; Revicki DA, 1998, CHEST, V114, P998, DOI 10.1378/chest.114.4.998; SUGAYA N, 1994, JAMA-J AM MED ASSOC, V272, P1122, DOI 10.1001/jama.272.14.1122; SULLIVAN KM, 1993, AM J PUBLIC HEALTH, V83, P1712, DOI 10.2105/AJPH.83.12.1712; 2000, RECEIVING INFLUENZA, P22	38	75	77	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2004	113	4					717	724		10.1016/j.jaci.2003.12.584	http://dx.doi.org/10.1016/j.jaci.2003.12.584			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	814DY	15100679				2022-12-18	WOS:000220956600021
J	Pastorello, EA; Pravettoni, V; Farioli, L; Rivolta, F; Conti, A; Ispano, M; Fortunato, D; Bengtsson, A; Bianchi, M				Pastorello, EA; Pravettoni, V; Farioli, L; Rivolta, F; Conti, A; Ispano, M; Fortunato, D; Bengtsson, A; Bianchi, M			Hypersensitivity to mugwort (Artemisia vulgaris) in patients with peach allergy is due to a common lipid transfer protein allergen and is often without clinical expression	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						oral allergy syndrome; mugwort pollen; crossreactivity; lipid transfer protein	CROSS-REACTIVITY; POLLEN ALLERGENS; IGE; BINDING; PATTERN; CELERY; SYSTEM	Background: The observation of mugwrort-specific IgE antibodies in patients with peach allergy suggests that mugwort sensitization might play a role in sensitization to peach. Objective: We sought to study the clinical manifestations of mugwort hypersensitivity in patients with peach allergy, identify the common allergens, and evaluate their IgE cross-reactivity. Methods: Patients with oral allergy syndrome for peach and specific IgE antibodies to mugwort were investigated for respiratory symptoms during the mugwort season. Peach and mugwort allergens were identified by means of SDS-PAGE and IgE immunoblotting. Immunoblotting inhibition experiments were done to study cross-reactivity between peach and mugwort and other pollens. Results: Seventeen patients were studied, 10 with no seasonal respiratory symptoms and 7 with clear late summer respiratory symptoms. In IgE immunoblotting the 10 asymptomatic patients reacted only to a 9-kd allergen of both mugwort and peach, whereas the 7 patients with pollinosis reacted to other allergens. Ten patients with mugwort allergy, no history of allergy to peach, and negative results for peach-specific IgE antibodies were also studied. The mugwort 9-kd protein was identified as a lipid transfer protein (LTP) homologous to peach LTP. Immunoblotting inhibition showed that IgE binding to the peach 9-kd band was totally inhibited by 4 mug of peach LTP but only by 400 mug of mugwort LTP, whereas 4 mug of both mugwort and peach LTP totally inhibited the mugwort immunoblotting. The results were similar with other pollens. Conclusions: Patients sensitized only to the 9-kd LTP of mugwort do not present hay fever symptoms, and this sensitization is a consequence of the peach sensitization.	Osped Maggiore, Div Gen Med 3, Allergy Ctr, IRCCS, Milan, Italy; Pharmacia & Upjohn Diagnost AB, Uppsala, Sweden; Osped Niguarda Ca Granda, Bizzozzero Div, Milan, Italy; CNR, Turin, Italy; ICP, CEMOC, UOOML, Milan, Italy	IRCCS Ca Granda Ospedale Maggiore Policlinico; Pfizer; Pharmacia Corporation; IRCCS Ca Granda Ospedale Maggiore Policlinico; Ospedale Niguarda Ca' Granda; Consiglio Nazionale delle Ricerche (CNR)	Pastorello, EA (corresponding author), 3 Div Gen Med 3, Padiglione Graneli, Via Francesco Sforza 35, I-20122 Milan, Italy.		PASTORELLO, ELIDE ANNA/E-3897-2017	PASTORELLO, ELIDE ANNA/0000-0002-3753-1783				Bauer L, 1996, CLIN EXP ALLERGY, V26, P1161, DOI 10.1111/j.1365-2222.1996.tb00503.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Colombo P, 1998, ALLERGY, V53, P917, DOI 10.1111/j.1398-9995.1998.tb03791.x; Cuesta-Herranz J, 1998, ALLERGY, V53, P78, DOI 10.1111/j.1398-9995.1998.tb03777.x; Diaz-Perales A, 2000, CLIN EXP ALLERGY, V30, P1403, DOI 10.1046/j.1365-2222.2000.00909.x; DREBORD S, 1982, ALLERGY, V38, P167; DREBORG S, 1989, ALLERGY S10, V44, P27; KIVITY S, 1994, CLIN EXP ALLERGY, V24, P19, DOI 10.1111/j.1365-2222.1994.tb00911.x; Leitner A, 1998, ALLERGY, V53, P36, DOI 10.1111/j.1398-9995.1998.tb03771.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NEVILLE DM, 1971, J BIOL CHEM, V246, P6328; ORTOLANI C, 1988, ANN ALLERGY, V61, P47; PASTORELLO EA, 1994, J ALLERGY CLIN IMMUN, V94, P699, DOI 10.1016/0091-6749(94)90177-5; PASTORELLO EA, 1992, ALLERGY, V47, P463, DOI 10.1111/j.1398-9995.1992.tb00665.x; Pastorello EA, 1999, J ALLERGY CLIN IMMUN, V104, P1099, DOI 10.1016/S0091-6749(99)70095-3; Pastorello EA, 1999, J ALLERGY CLIN IMMUN, V103, P520, DOI 10.1016/S0091-6749(99)70480-X; Rodriguez R, 2001, INT ARCH ALLERGY IMM, V125, P185, DOI 10.1159/000053815; Sanchez-Monge R, 1999, J ALLERGY CLIN IMMUN, V103, P514, DOI 10.1016/S0091-6749(99)70479-3	18	75	77	0	6	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2002	110	2					310	317	UNSP 1/87/125830	10.1067/mai.2002.125830	http://dx.doi.org/10.1067/mai.2002.125830			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	585DY	12170274				2022-12-18	WOS:000177509800018
J	Beltrani, VS				Beltrani, VS			The clinical spectrum of atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Conference on Atopic Dermatitis - An Update for the Next Millennium	OCT, 1998	NEW YORK, NY			atopy; allergy; immunologic aberrations; T-H1/T-H2; IgE antibodies; mast cells; eosinophils; pruritus; allokinesis; eczema; isomorphic response; xerosis	DOUBLE-BLIND; OCULAR COMPLICATIONS; LANGERHANS CELLS; HUMAN PHENOTYPES; LESIONAL SKIN; YOUNG-ADULTS; DUST MITE; ECZEMA; IGE; CONTACT	Updating our clinical concept of atopic dermatitis (AD) evolves from the better understanding of all the immunologic aberrations expressed by the polygenic combinations and permutations associated with the atopic diathesis, Recognizing the immunopathologic features of AD readily underscores that AD without "atopy" is an oxymoron, Appreciating "pruritus" as the impetus to scratch, which isomorphically gives rise to the "eczema," shifts the goal of management from suppressing inflammation to avoiding the triggers of pruritus, Recognizing the full spectrum of dermatologic findings in AD endorses the preferred label as a dermatitis, rather than the inferred restrictive label, atopic eczema. As our knowledge of immunology evolves, our criteria for the diagnosis and management of the atopic diathesis are sure to change.	Columbia Univ, Coll Phys & Surg, Dept Dermatol, New York, NY 10032 USA; UMDNJ, New Jersey Med Sch, Dept Med, Div Allergy Immunol & Rheumatol, Newark, NJ USA	Columbia University; Rutgers State University New Brunswick; Rutgers State University Medical Center	Beltrani, VS (corresponding author), 29 Fox St, Poughkeepsie, NY 12601 USA.							ACKERMAN AB, 1978, HISTOLOGIC DIAGNOSIS, P75; AIZAWA H, 1989, PEDIATR DERMATOL, V6, P6, DOI 10.1111/j.1525-1470.1989.tb00257.x; Beltrani VS, 1997, IMMUNOL ALLERGY CLIN, V17, P431, DOI 10.1016/S0889-8561(05)70319-2; BELTRANI VS, 1996, ATOPIC DERMATITIS PA, P1; Boguniewicz Mark, 1996, P209; Bohm I, 1997, HAUTARZT, V48, P223, DOI 10.1007/s001050050573; BOS JD, 1992, ARCH DERMATOL, V128, P1509, DOI 10.1001/archderm.128.11.1509; BRAUNSTEIN WB, 1993, CUTIS, V51, P191; BREIT R, 1997, Z HAUTKR S, V2, P72; BROBERG A, 1992, ACTA DERM-VENEREOL, V72, P187; BURTON JL, 1986, TXB DERMATOLOGY, P367; Carucci JA, 1998, ARCH DERMATOL, V134, P785, DOI 10.1001/archderm.134.7.785; CLARK RAF, 1989, J AM ACAD DERMATOL, V21, P863, DOI 10.1016/S0190-9622(89)70269-3; CLARK RAF, 1989, CLIN IMMUNOL IMMUNOP, V53, pS132, DOI 10.1016/0090-1229(89)90078-0; CROSSEN JR, 1996, DERMATOLOGIC THERAPY, V1, P94; EBLING FJG, 1986, TXB DERMATOLOGY, P1435; Ely H, 1997, CUTIS, V59, P67; Ely H, 1997, CUTIS, V59, P13; Fleischer AB, 1999, J ALLERGY CLIN IMMUN, V104, pS126, DOI 10.1016/S0091-6749(99)70055-2; GALLI SJ, 1993, NEW ENGL J MED, V328, P257; GARRITY JA, 1984, CAN J OPHTHALMOL, V19, P21; Georgala Sophia, 1994, Journal of Dermatological Science, V8, P125, DOI 10.1016/0923-1811(94)90006-X; GIANNETTI A, 1989, BRIT J DERMATOL, V121, P681, DOI 10.1111/j.1365-2133.1989.tb08209.x; Grabbe J, 1996, J INVEST DERMATOL, V107, P419, DOI 10.1111/1523-1747.ep12363402; HAGERMARK O, 1996, DERMATOL THER, V1, P75; HALBERT AR, 1995, J AM ACAD DERMATOL, V33, P1008, DOI 10.1016/0190-9622(95)90295-3; Hamelmann E, 1997, P NATL ACAD SCI USA, V94, P1350, DOI 10.1073/pnas.94.4.1350; HANIFIN JM, 1991, PEDIATR CLIN N AM, V38, P763; HANIFIN JM, 1992, MAST CELL HLTH DIS, P639; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; HAUSER C, 1996, ATOPIC DERMATITIS PA, P67; HEPER G, 1997, J DERMATOL, V24, P621; HOFFMAN DR, 1975, J ALLERGY CLIN IMMUN, V55, P256, DOI 10.1016/0091-6749(75)90145-1; HOGAN D, 1994, SEMIN DERMATOL, V31, P467; HOGAN DJ, 1990, SEMIN DERMATOL, V9, P233; HURLBUT WB, 1954, AMA ARCH OPHTHALMOL, V52, P852; Huston DP, 1997, JAMA-J AM MED ASSOC, V278, P1804, DOI 10.1001/jama.278.22.1804; ISHIZAKA K, 1966, J IMMUNOL, V97, P840; JOHNSON EE, 1974, J ALLERGY CLIN IMMUN, V54, P94, DOI 10.1016/0091-6749(74)90037-2; JOHNSON HH, 1960, J INVEST DERMATOL, V34, P237, DOI 10.1038/jid.1960.38; JOHNSSON SGO, 1970, BRIT J DERMATOL, V82, P10; JONES HE, 1975, BRIT J DERMATOL, V92, P17; JONES SM, 1996, ATOPIC DERMATITIS PA, P41; JUHLIN L, 1969, ARCH DERMATOL, V100, P12, DOI 10.1001/archderm.100.1.12; JUHLIN L, 1967, ACTA DERM-VENEREOL, V47, P383; KAGI MK, 1992, DERMATOLOGY, V185, P88, DOI 10.1159/000247419; Kane GC, 1996, J ALLERGY CLIN IMMUN, V97, P646, DOI 10.1016/S0091-6749(96)70310-X; KANG K, 1987, INT J DERMATOL, V26, P27, DOI 10.1111/j.1365-4362.1987.tb04572.x; KEMMETT D, 1993, BRIT J DERMATOL, V125, P59; KISSLING S, 1994, HAUTARZT, V45, P368, DOI 10.1007/s001050050085; Koblenzer CS, 1999, J ALLERGY CLIN IMMUN, V104, pS109, DOI 10.1016/S0091-6749(99)70052-7; Kraft S, 1998, J IMMUNOL, V161, P1000; KRUTMANN J, 1996, DERMATOLOGICAL THERA, V1, P24; KUBOTA Y, 1992, Journal of Dermatology (Tokyo), V19, P177, DOI 10.1111/j.1346-8138.1992.tb03202.x; LEBEL B, 1980, ACTA DERM-VENEREOL, P57; LEIFERMAN KM, 1985, NEW ENGL J MED, V313, P282, DOI 10.1056/NEJM198508013130502; Leung DYM, 1999, J ALLERGY CLIN IMMUN, V104, pS99, DOI 10.1016/S0091-6749(99)70051-5; LEUNG DYM, 1999, 55 AAAAI ANN M ORL F; Lippert U, 1998, INT ARCH ALLERGY IMM, V116, P36, DOI 10.1159/000023922; MELHOP PD, 1997, P NATL ACAD SCI USA, V94, P1350; MONROE EW, 1989, J AM ACAD DERMATOL, V21, P135, DOI 10.1016/S0190-9622(89)80353-6; Moore C, 1998, ANN ALLERG ASTHMA IM, V81, P452, DOI 10.1016/S1081-1206(10)63145-6; MORGAN DB, 1948, ARCH DERMATOL SYPH, V57, P1050, DOI 10.1001/archderm.1948.01520190129018; MORREN MA, 1994, J AM ACAD DERMATOL, V31, P467, DOI 10.1016/S0190-9622(94)70213-6; MOSMANN T, 1996, CLIN IMMUNOLOGY PRIN, P217; MUSGROVE K, 1976, BRIT J DERMATOL, V95, P365, DOI 10.1111/j.1365-2133.1976.tb00837.x; NASSIF A, 1994, ARCH DERMATOL, V130, P1402, DOI 10.1001/archderm.130.11.1402; Okada Shigeru, 1996, Journal of Dermatology (Tokyo), V23, P247; PLATTSMILLS TAE, 1983, CLIN EXP DERMATOL, V8, P233, DOI 10.1111/j.1365-2230.1983.tb01776.x; PRZYBILLA B, 1990, SEMIN DERMATOL, V9, P220; RAJKA G, 1975, ATOPIC DERMATITIS MA, V3, P4; RICH LF, 1985, INT OPHTHALMOL CLIN, V25, P61, DOI 10.1097/00004397-198502510-00005; RING J, 1993, HDB ATOPIC ECZEMA, P3; RING J, 1996, DERMATOL THER, V1, P51; ROMAGNANI S, 1989, CLIN IMMUNOL IMMUNOP, V50, pS13, DOI 10.1016/0090-1229(89)90110-4; ROMAGNANI S, 1998, ACI INT, V10, P158; Rothenberg ME, 1998, NEW ENGL J MED, V338, P1592, DOI 10.1056/NEJM199805283382206; RUSTIN MH, 1996, DERMATOL THERAPY, V1, P83; RUZICKA T, 1983, ARCH DERMATOL RES, V275, P41, DOI 10.1007/BF00516553; SAMPSON HA, 1984, J ALLERGY CLIN IMMUN, V74, P26, DOI 10.1016/0091-6749(84)90083-6; SAVOLAINEN J, 1993, CLIN EXP ALLERGY, V23, P332, DOI 10.1111/j.1365-2222.1993.tb00331.x; SHMUNES E, 1983, J AM ACAD DERMATOL, V9, P861, DOI 10.1016/S0190-9622(83)70199-4; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V104, pS114, DOI 10.1016/S0091-6749(99)70053-9; SOWDEN JM, 1991, LANCET, V338, P137, DOI 10.1016/0140-6736(91)90134-B; STEIGER T, 1991, HDB ATOPIC ECZEMA, P415; SULZBERGER MB, 1954, CLIN SIGNIFICANCE DI, P113; SVENSSON A, 1985, ACTA DERM-VENEREOL, P33; SVENSSON A, 1986, CONTACT DERMATITIS, V15, P178, DOI 10.1111/j.1600-0536.1986.tb01321.x; SVENSSON A, 1989, DIAGNOSIS ATOPIC SKI, P68; SVENSSON A, 1985, ACTA DERM-VENEREOL, V114, P52; SVENSSON A, 1989, DIAGNOSIS ATOPIC SKI, P41; Tan BB, 1996, LANCET, V347, P15, DOI 10.1016/S0140-6736(96)91556-1; TANAKA Y, 1995, ARCH DERMATOL RES, V287, P712, DOI 10.1007/BF01105794; THEGPEN T, 1996, J ALLERGY CLIN IMMUN, V97, P828; Tupker RA, 1996, J ALLERGY CLIN IMMUN, V97, P1064, DOI 10.1016/S0091-6749(96)70259-2; UEHARA M, 1989, ARCH DERMATOL, V125, P366, DOI 10.1001/archderm.125.3.366; UEHARN M, 1977, ARCH DERMATOL, V113, P622; Wahlgren C F, 1991, Acta Derm Venereol Suppl (Stockh), V165, P1; WAHLGREN CF, 1991, ACTA DERM-VENEREOL, V71, P488; WAHLGREN CF, 1995, ARCH DERMATOL RES, V287, P572, DOI 10.1007/BF00374079; WERNER Y, 1982, ACTA DERM-VENEREOL, V62, P334; WERNER Y, 1985, ACTA DERM-VENEREOL, V65, P102; Whitfield A, 1938, BRIT J DERMATOL SYPH, V50, P71, DOI 10.1111/j.1365-2133.1938.tb10475.x; WILLIAMS REA, 1990, BRIT J DERMATOL, V123, P493; WIRTH H, 1981, ARCH DERMATOL RES, V270, P167, DOI 10.1007/BF00408228; Wollenberg A, 1996, J INVEST DERMATOL, V106, P446, DOI 10.1111/1523-1747.ep12343596; WUTHRICH B, 1996, ALLERGY CLIN IMMUNOL, V8, P77; YU B, 1988, ARCH DERMATOL, V124, P1530, DOI 10.1001/archderm.124.10.1530; Zhang J, 1997, J ALLERGY CLIN IMMUN, V99, pS52	109	75	81	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1999	104	3	2	S			S87	S98		10.1016/S0091-6749(99)70050-3	http://dx.doi.org/10.1016/S0091-6749(99)70050-3			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	242FP	10482859	Bronze			2022-12-18	WOS:000082928500002
J	Sousa, AR; Lane, SJ; Soh, C; Lee, TH				Sousa, AR; Lane, SJ; Soh, C; Lee, TH			In vivo resistance to corticosteroids in bronchial asthma is associated with enhanced phosphorylation of JUN N-terminal kinase and failure of prednisolone to inhibit JUN N-terminal kinase phosphorylation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						corticosteroids; asthma; JUN N-terminal kinase; activating protein-1; proto-oncogene	GLUCOCORTICOID RECEPTOR; TRANSCRIPTIONAL REGULATION; HORMONE; AP-1; CELL; RAT; INTERLEUKIN-2; STIMULATION; ACTIVATION; EXPRESSION	Background: Corticosteroid-resistant (CR) asthma is associated with increased in vitro activity of the proinflammatory transcription factor activating peptide (AP)-1 in PBMCs resulting from increased c-POS synthesis. Increased AP-1 may sequester the glucocorticoid receptor to produce a CR state. Using the tuberculin-induced inflammatory responses in the skin, we have previously demonstrated that a therapeutically effective dose of prednisolone suppressed T-cell, macrophage, and eosinophil infiltration into purified protein derivative-induced lesional skin of corticosteroid-sensitive (CS), but not CR, individuals. Objective: Skin biopsy specimens from a tuberculin-induced model of dermal inflammation have been evaluated for the effect of corticosteroids in regulating components of AP-1 in vivo. Methods: Immunohistochemical analysis of the tuberculin-mediated cutaneous response has been performed on 9 subjects with CS asthma and 6 subjects with CR asthma for the regulatory components of AP-1 before and after 9 days of either 40 mg prednisolone or placebo, Results: Significantly greater expression of c-FOS, phosphorylated c-JUN, and phosphorylated JUN N-terminal kinase (JNK) protein has been identified in CR than in CS subjects. Corticosteroids suppressed phosphorylation of c-JUN and MK in the CS Group (P = .004 for both) but enhanced phosphorylation of c-JUN and JNK in the CR group (P = .031 for both), Conclusion: Resistance to corticosteroids in asthmatic subjects may be caused, at least in part, by failure to suppress JNK phosphorylation, leading to failure to suppress c-JUN N-phosphorylation, Increased JNK may be one of the mechanisms central to the mechanism of CR asthma.	Guys Hosp, Dept Resp Med & Allergy, London SE1 9RT, England; Univ London Kings Coll, Dept Resp Med & Allergy, London WC2R 2LS, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Lee, TH (corresponding author), Guys Hosp, Dept Resp Med & Allergy, 5th Floor,Thomas Guy House, London SE1 9RT, England.		Lee, Tak/AAA-9526-2020	Lee, Tak/0000-0002-7554-4059				ADCOCK IM, 1995, J EXP MED, V182, P1951, DOI 10.1084/jem.182.6.1951; ADCOCK IM, 1995, J IMMUNOL, V154, P3500; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; BARNES PJ, 1995, NEW ENGL J MED, V332, P868, DOI 10.1056/NEJM199503303321307; Beato M, 1996, STEROIDS, V61, P240, DOI 10.1016/0039-128X(96)00030-X; Caelles C, 1997, GENE DEV, V11, P3351, DOI 10.1101/gad.11.24.3351; Chen CY, 1998, SCIENCE, V280, P1945, DOI 10.1126/science.280.5371.1945; CHIKANZA IC, 1993, EUR J CLIN INVEST, V23, P845, DOI 10.1111/j.1365-2362.1993.tb00740.x; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; FENG ZW, 1995, J CELL BIOL, V131, P1095, DOI 10.1083/jcb.131.4.1095; Ferrer I, 1996, MOL BRAIN RES, V38, P91, DOI 10.1016/0169-328X(95)00334-O; GOODE N, 1992, J BIOL CHEM, V267, P16878; GRONEMEYER H, 1992, FASEB J, V6, P2524, DOI 10.1096/fasebj.6.8.1592204; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; Kanatani Y, 1996, CELL GROWTH DIFFER, V7, P187; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Karin M, 1996, PHILOS T ROY SOC B, V351, P127, DOI 10.1098/rstb.1996.0008; Lane SJ, 1998, J CLIN INVEST, V102, P2156, DOI 10.1172/JCI2680; Lane SJ, 1996, AM J RESP CRIT CARE, V154, pS49, DOI 10.1164/ajrccm/154.2_Pt_2.S49; Lane SJ, 1997, BRIT J HOSP MED, V57, P394; LANE SJ, 1998, AM J RESP CRIT CARE, V157, pA874; LANE SJ, 1997, ALLERGY CLIN IMMUNOL, V9, P165; LANGHOFF E, 1986, LANCET, V1, P1296; Leung DYM, 1997, J EXP MED, V186, P1567, DOI 10.1084/jem.186.9.1567; LUO LA, 1995, ENDOCRINOLOGY, V136, P2705, DOI 10.1210/en.136.6.2705; Meyer T, 1997, DNA CELL BIOL, V16, P919, DOI 10.1089/dna.1997.16.919; SAATCIOGLU F, 1994, SEMIN CANCER BIOL, V5, P347; SHER ER, 1994, J CLIN INVEST, V93, P33, DOI 10.1172/JCI116963; Sousa AR, 1996, J ALLERGY CLIN IMMUN, V97, P698, DOI 10.1016/S0091-6749(96)70317-2; Swantek JL, 1997, MOL CELL BIOL, V17, P6274, DOI 10.1128/MCB.17.11.6274; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; TURK JL, 1996, INT ARCH ALLER A IMM, V30, P248; WANG WW, 1994, GENE, V143, P261, DOI 10.1016/0378-1119(94)90107-4; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946	35	75	81	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1999	104	3	1				565	574		10.1016/S0091-6749(99)70325-8	http://dx.doi.org/10.1016/S0091-6749(99)70325-8			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	241EP	10482829				2022-12-18	WOS:000082870000017
J	Mikkola, JH; Alenius, H; Kalkkinen, N; Turjanmaa, K; Palosuo, T; Reunala, T				Mikkola, JH; Alenius, H; Kalkkinen, N; Turjanmaa, K; Palosuo, T; Reunala, T			Hevein-like protein domains as a possible cause for allergen cross-reactivity between latex and banana	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						latex allergy; IgE cross-reactivity; banana (Musa acuminata); hevein; Hev b 6.02; chitinases	NATURAL-RUBBER LATEX; IGE-BINDING; ASPERGILLUS-FUMIGATUS; POLLEN ALLERGEN; SPINA-BIFIDA; IDENTIFICATION; HYPERSENSITIVITY; PROFILIN; EPITOPE; FAMILY	Background: Patients allergic to natural rubber latex (NRL) frequently exhibit immediate hypersensitivity reactions to banana, but the molecular basis of these putative cross-reactions is unknown. Objective: We wanted to examine whether proteins resembling hevein, a major NRL allergen, exist in banana and whether coexisting allergy to NRL and banana can be explained by IgE cross-reactivity to these proteins. Methods: Allergens in banana cross-reacting with hevein were identified by IgE immunoblot inhibition. The cross-reacting proteins were purified by reversed-phase chromatography and characterized by amino acid sequencing. Allergen cross-reactivity was further assessed by IgE ELISA, IgE ELISA inhibition, and skin prick testing. Results: In immunoblotting, 9 of 15 sera from patients allergic to NRL with IgE to hevein showed IgE binding to 32- and 33-kd banana proteins. These 2 protein bands were also targets to IgG from a hevein-immunized rabbit. IgE binding to both 32- and 33-kd protein hands was totally inhibited by hevein (10 ng/mL) in all 5 sera from patients allergic to NRL sera studied. N-terminal sequencing of the purified 32- and 33-kd proteins revealed 80% identity to the N-terminus of hevein. An internal peptide (19 amino acids) of the 33-kd protein gave over 90% identity to endochitinases of several plants. In ELISA all IS sera from patients allergic to NRL had IgE to the purified 32-kd banana protein. In ELISA inhibition hevein (10 ng/mL) inhibited approximately 50% of IgE binding to the solid-phase 32-kd banana protein in a pool of sera from patients allergic to NRL. Conclusion: These results suggest that the commonly occurring hypersensitivity to banana in patients allergic to NRL could be explained by cross-reacting IgE antibodies binding to epitopes in hevein and in a hevein-like domain of a previously undescribed endochitinase in banana.	Finnish Inst Occupat Hlth, Lab Immunotoxicol, FIN-00250 Helsinki, Finland; Natl Publ Hlth Inst, Helsinki, Finland; Univ Helsinki, Inst Biotechnol, FIN-00014 Helsinki, Finland; Tampere Univ Hosp, Dept Dermatol, Tampere, Finland; Univ Helsinki Hosp, Dept Dermatol, Helsinki, Finland; Univ Hosp Skin & Allerg Dis, Helsinki, Finland	Finnish Institute of Occupational Health; Finland National Institute for Health & Welfare; University of Helsinki; Tampere University; Tampere University Hospital; University of Helsinki; Helsinki University Central Hospital	Alenius, H (corresponding author), Finnish Inst Occupat Hlth, Lab Immunotoxicol, Haartmaninkatu 1, FIN-00250 Helsinki, Finland.		Kalkkinen, Nisse EJ/B-3923-2010	Alenius, Harri/0000-0003-0106-8923				Alenius H, 1996, CLIN EXP ALLERGY, V26, P341, DOI 10.1046/j.1365-2222.1996.d01-312.x; Alenius H, 1996, J IMMUNOL, V156, P1618; Alenius H., 1996, Journal of Allergy and Clinical Immunology, V97, P321, DOI 10.1016/S0091-6749(96)80772-X; AXELSSON IGK, 1988, ACTA PAEDIATR SCAND, V77, P314, DOI 10.1111/j.1651-2227.1988.tb10652.x; Banerjee B, 1997, J IMMUNOL, V159, P5724; Batanero E, 1996, EUR J BIOCHEM, V241, P772, DOI 10.1111/j.1432-1033.1996.00772.x; Beezhold DH, 1996, CLIN EXP ALLERGY, V26, P416, DOI 10.1046/j.1365-2222.1996.d01-334.x; Beezhold DH, 1997, CLIN EXP IMMUNOL, V108, P114, DOI 10.1046/j.1365-2249.1997.d01-983.x; BREITENEDER H, 1993, EUR J BIOCHEM, V212, P355, DOI 10.1111/j.1432-1033.1993.tb17669.x; Chen ZP, 1997, J ALLERGY CLIN IMMUN, V99, P402, DOI 10.1016/S0091-6749(97)70059-9; Crameri R, 1996, J EXP MED, V184, P265, DOI 10.1084/jem.184.1.265; Delbourg MF, 1996, ANN ALLERG ASTHMA IM, V76, P321, DOI 10.1016/S1081-1206(10)60032-4; Diaz-Perales A, 1998, J ALLERGY CLIN IMMUN, V102, P127, DOI 10.1016/S0091-6749(98)70063-6; EBNER C, 1995, J ALLERGY CLIN IMMUN, V95, P962, DOI 10.1016/S0091-6749(95)70096-X; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; KELLY KJ, 1994, J ALLERGY CLIN IMMUN, V94, P53, DOI 10.1016/0091-6749(94)90071-X; Laffer S, 1996, J IMMUNOL, V157, P4953; LAVAUD F, 1995, J ALLERGY CLIN IMMUN, V95, P557, DOI 10.1016/S0091-6749(95)70318-7; LEVY DA, 1992, ALLERGY, V47, P579, DOI 10.1111/j.1398-9995.1992.tb02378.x; Liebers V, 1996, CLIN EXP ALLERGY, V26, P494, DOI 10.1111/j.1365-2222.1996.tb00570.x; MAKINENKILJUNEN S, 1994, J ALLERGY CLIN IMMUN, V93, P990, DOI 10.1016/S0091-6749(94)70046-X; Mayer C, 1997, INT ARCH ALLERGY IMM, V113, P213, DOI 10.1159/000237550; MOURAD W, 1988, J IMMUNOL, V141, P3486; MRAIHI L, 1991, J ALLERGY CLIN IMMUN, V87, P129, DOI 10.1016/0091-6749(91)90224-C; OLSEN E, 1991, J IMMUNOL, V147, P205; Palosuo T, 1998, ALLERGY, V53, P59, DOI 10.1111/j.1398-9995.1998.tb03774.x; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; RODRIGUEZ M, 1993, ANN ALLERGY, V70, P31; ROSS BD, 1992, J ALLERGY CLIN IMMUN, V90, P409, DOI 10.1016/S0091-6749(05)80023-5; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; SLATER J, 1989, NEW ENGL J MED, V320, P626; TOSI LL, 1993, J PEDIATR ORTHOPED, V13, P709, DOI 10.1097/01241398-199311000-00003; TURJANMAA K, 1994, DERMATOL CLIN, V12, P561, DOI 10.1016/S0733-8635(18)30160-8; Turjanmaa K, 1996, ALLERGY, V51, P593, DOI 10.1111/j.1398-9995.1996.tb04678.x; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; VALENTA R, 1993, J BIOL CHEM, V268, P22777; WRANGSJO K, 1988, CONTACT DERMATITIS, V19, P264, DOI 10.1111/j.1600-0536.1988.tb02925.x; WRIGHT HT, 1991, J MOL EVOL, V33, P283, DOI 10.1007/BF02100680	39	75	79	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1998	102	6	1				1005	1012		10.1016/S0091-6749(98)70339-2	http://dx.doi.org/10.1016/S0091-6749(98)70339-2			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	150XE	9847442				2022-12-18	WOS:000077690700019
J	Goldberg, A; ConfinoCohen, R				Goldberg, A; ConfinoCohen, R			Timing of venom skin tests and IgE determinations after insect sting anaphylaxis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							LARGE LOCAL REACTIONS; HUMAN BASOPHILS; HISTAMINE-RELEASE; CELL ACTIVATION; ANTIGEN-BINDING; DESENSITIZATION; ALLERGY				Goldberg, A (corresponding author), MEIR HOSP,ALLERGY & CLIN IMMUNOL UNIT,SAPIR MED CTR,IL-44281 KEFAR SAVA,ISRAEL.							BARR SE, 1971, ANN ALLERGY, V29, P49; DEMBO M, 1980, CELL, V22, P59, DOI 10.1016/0092-8674(80)90154-3; DROBIS JD, 1976, J IMMUNOL, V117, P1049; GOLDEN DBK, 1987, CLIN REV ALLERG, V5, P119; GREEN AW, 1980, J ALLERGY CLIN IMMUN, V66, P186, DOI 10.1016/0091-6749(80)90037-8; MACGLASHAN D, 1983, J IMMUNOL, V130, P2337; MACGLASHAN D, 1983, J IMMUNOL, V130, P2330; MAURIELLO PM, 1984, J ALLERGY CLIN IMMUN, V74, P494, DOI 10.1016/0091-6749(84)90384-1; ORDMAN D, 1965, INT ARCH ALLER A IMM, V28, P366, DOI 10.1159/000229682; SCHWARTZ HJ, 1965, JAMA-J AM MED ASSOC, V194, P113; SIRAGANIAN RP, 1979, J IMMUNOL, V122, P1719	11	75	75	1	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1997	100	2					182	184		10.1016/S0091-6749(97)70222-7	http://dx.doi.org/10.1016/S0091-6749(97)70222-7			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XR351	9275138	Bronze			2022-12-18	WOS:A1997XR35100007
J	Dodge, R; Martinez, FD; Cline, MG; Lebowitz, MD; Burrows, B				Dodge, R; Martinez, FD; Cline, MG; Lebowitz, MD; Burrows, B			Early childhood respiratory symptoms and the subsequent diagnosis of asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						infant; early childhood; wheezing; cough; asthma	LIFE; CHILDREN; DISEASE	Background: Respiratory symptoms are frequent in very young children, and the relation of these symptoms to later asthma in some of these children is unknown. Objective: The aim of the study was to describe the natural history of respiratory symptoms in a community-based sample of young children who were prospectively observed for as long as 11 years. Methods: Subjects were participants in the Tucson Epidemiologic Study of Airways Obstructive Disease. They were under 5 years of age at enrollment and were studied by means of a parent-administered mail survey instrument every 1 to 2 years for 3 to 11 years. Results: Among subjects younger than 1 year of age, no single respiratory symptom, such as cough or wheeze only with colds, significantly increased the risk of a subsequent diagnosis of asthma. Among 1- and 2-year-olds, however, those with wheeze only with colds and those with attacks of shortness of breath with wheeze were more likely to be diagnosed with asthma later when compared with children without those symptoms (odds ratio = 2.1; p < 0.05 for wheeze only with colds). At ages 3 to 4 years, symptoms were even more strongly associated with subsequent asthma (odds ratio = 7.2; p < 0.0001 for attacks of shortness of breath with wheeze). Conclusion: Although respiratory symptoms reported by parents very early in life are not significantly associated with future asthma, those symptoms that begin at or persist through ages 3 to 4 years are.			Dodge, R (corresponding author), UNIV ARIZONA,COLL MED,RESP SCI CTR,TUCSON,AZ 85724, USA.				NHLBI NIH HHS [HL-14135] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLAND JM, 1974, B PHYSIO-PATHOL RESP, V10, P699; BOESEN I, 1953, Acta Paediatr, V42, P87, DOI 10.1111/j.1651-2227.1953.tb05571.x; Breslow N.E., 1980, STAT METHODS CANC RE, P192; BURROWS B, 1991, J ALLERGY CLIN IMMUN, V88, P870, DOI 10.1016/0091-6749(91)90243-H; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; BURROWS B, 1980, AM REV RESPIR DIS, V122, P813; DODGE R, 1993, J ALLERGY CLIN IMMUN, V92, P744, DOI 10.1016/0091-6749(93)90018-B; DODGE R, 1994, J ALLERGY CLIN IMMUN, V94, P831, DOI 10.1016/0091-6749(94)90150-3; GODFREY S, 1984, RECENT ADV PAEDIAT, V7, P137; LEBOWITZ MD, 1975, AM J EPIDEMIOL, V102, P137, DOI 10.1093/oxfordjournals.aje.a112141; LUNN JE, 1967, BRIT J PREV SOC MED, V21, P7; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MARTINEZ FD, 1991, AM REV RESPIR DIS, V143, P312, DOI 10.1164/ajrccm/143.2.312; MCNICOL KN, 1973, BRIT MED J, V4, P7, DOI 10.1136/bmj.4.5883.7; MORGAN WJ, 1984, PEDIATR CLIN N AM, V31, P851; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P327; SCHENKER MB, 1983, AM REV RESPIR DIS, V128, P1038; SPORIK R, 1991, ARCH DIS CHILD, V66, P1051; WRIGHT AL, 1989, AM J EPIDEMIOL, V129, P1232, DOI 10.1093/oxfordjournals.aje.a115243	19	75	76	1	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1996	98	1					48	54		10.1016/S0091-6749(96)70225-7	http://dx.doi.org/10.1016/S0091-6749(96)70225-7			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VA692	8765817				2022-12-18	WOS:A1996VA69200006
J	BRUMMERKORVENKONTIO, H; LAPPALAINEN, P; REUNALA, T; PALOSUO, T				BRUMMERKORVENKONTIO, H; LAPPALAINEN, P; REUNALA, T; PALOSUO, T			DETECTION OF MOSQUITO SALIVA-SPECIFIC IGE AND IGG4 ANTIBODIES BY IMMUNOBLOTTING	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IGE; IGG4; IGG SUBCLASS; ALLERGY; MOSQUITO SALIVA; IMMUNOBLOTTING	AEDES-AEGYPTI; ANOPHELES-STEPHENSI; ALLERGIC PATIENTS; GLANDS; EXTRACTS; INSECTS	IgE and IgG subclass antibodies against Aedes communis mosquito saliva were studied by immunoblotting in 12 adults with immediate and/or delayed skin reactions to mosquito bites. Four antigenic proteins, with molecular weights of 22, 30, 36, and 64 kd, were found in the mosquito saliva. Almost all subjects (11 of 12) had anti-mosquito saliva-specific IgE antibodies directed against the 36 kd protein. The IgG antibody response appeared to be restricted mostly to IgG4 (11 of 12) and IgG1 (8 of 11) subclasses against the same 36 kd antigen. Ten of the 12 subjects had both IgE and IgG4 antibodies to the 36 kd protein. No anti-mosquito antibodies were found in pooled sera of five infants never exposed to mosquito bites. These results show that most persons with immediate skin reactivity to A. communis mosquito bites have both IgE and IgG4 antibodies that recognize the 36 kd antigen present in the mosquito saliva, suggesting that anti-saliva antibodies may play a role in the pathogenesis of mosquito bite reactions.	UNIV HELSINKI, SF-00100 HELSINKI 10, FINLAND	University of Helsinki	BRUMMERKORVENKONTIO, H (corresponding author), NATL PUBL HLTH INST, DEPT HIV, MANNERHEIMINTIE 166, SF-00300 HELSINKI, FINLAND.			Lappalainen, Pekka/0000-0001-6227-0354				AGARWAL MK, 1991, ANN ALLERGY, V67, P598; BALDO BA, 1988, INT ARCH ALLER A IMM, V85, P278, DOI 10.1159/000234518; BOORMAN J, 1987, MED VET ENTOMOL, V1, P211, DOI 10.1111/j.1365-2915.1987.tb00346.x; BRUMMERKORVENKONTIO H, 1990, INT ARCH ALLER A IMM, V93, P14, DOI 10.1159/000235273; DAS MK, 1991, J AM MOSQUITO CONTR, V7, P319; DESVAUX FX, 1989, INT ARCH ALLER A IMM, V89, P281, DOI 10.1159/000234961; DJURUP R, 1985, ALLERGY, V40, P469, DOI 10.1111/j.1398-9995.1985.tb00253.x; FRAZIER CA, 1984, INSECT ALLERGY; JAMES AA, 1991, MOL BIOCHEM PARASIT, V44, P245, DOI 10.1016/0166-6851(91)90010-4; JEEP S, 1992, CLIN EXP ALLERGY, V22, P297, DOI 10.1111/j.1365-2222.1992.tb03086.x; KINO T, 1987, J ALLERGY CLIN IMMUN, V79, P857, DOI 10.1016/0091-6749(87)90233-8; KONISHI E, 1990, J MED ENTOMOL, V27, P519, DOI 10.1093/jmedent/27.4.519; MARINOTTI O, 1990, INSECT BIOCHEM, V20, P619, DOI 10.1016/0020-1790(90)90074-5; NUSSLEIN HG, 1990, J CLIN LAB ANAL, V4, P414, DOI 10.1002/jcla.1860040605; PENNEYS NS, 1989, ARCH DERMATOL, V125, P219, DOI 10.1001/archderm.125.2.219; POEHLING HM, 1980, INSECT BIOCHEM, V10, P189, DOI 10.1016/0020-1790(80)90073-6; REUNALA T, 1991, CLIN EXP ALLERGY, V21, P617, DOI 10.1111/j.1365-2222.1991.tb00855.x; RIBEIRO JMC, 1984, COMP BIOCHEM PHYS B, V79, P81, DOI 10.1016/0305-0491(84)90081-6; RIBEIRO JMC, 1992, J EXP BIOL, V165, P61; ROSSIGNOL PA, 1986, COMP BIOCHEM PHYS B, V83, P819, DOI 10.1016/0305-0491(86)90153-7; SHEN HD, 1989, ANN ALLERGY, V63, P143; WIERENGA EA, 1991, J IMMUNOL, V147, P2942; WU CH, 1989, INT ARCH ALLER A IMM, V90, P271, DOI 10.1159/000235036	23	75	78	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1994	93	3					551	555		10.1016/S0091-6749(94)70066-4	http://dx.doi.org/10.1016/S0091-6749(94)70066-4			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ND140	8151057				2022-12-18	WOS:A1994ND14000001
J	MURRAY, AB				MURRAY, AB			THE DECREASE IN SEVERITY OF ASTHMA IN CHILDREN OF PARENTS WHO SMOKE SINCE THE PARENTS HAVE BEEN EXPOSING THEM TO LESS CIGARETTE-SMOKE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						SMOKE POLLUTION; ASTHMA SEVERITY; CHILDREN; COUNSELING	HOUSE DUST MITE; BRONCHIAL RESPONSIVENESS; PASSIVE SMOKING; REACTIVITY; HISTAMINE; SYMPTOMS; ALLERGY; MOTHER; SAMPLE	Background. In 1985 we became aware that the smoking of parents aggravates their children's asthma. Since then we have advised all referring doctors to urge parents not to expose their asthmatic children to smoke. Methods: We investigated 807 nonsmoking asthmatic children, from 1 through 17 years of age, who were consecutively referred between 1983 and 1990. We compared the children who were seen before July 1986 with those seen after that date. Results: Those seen in the later period had intimate exposure to a far smaller number of cigarettes smoked per day, both by mothers (7 vs 3, p = 0.005) and by fathers (5 vs 2, p = 0.001). A concurrent improvement was observed in adjusted measures of asthma severity in their children (asthma score 7.5 vs 6.5, p = 0.047;forced expiratory volume in 1 second as a percent of predicted [FEV1%] 79.2 vs 93.7, p = 0.000; and forced expiratory flow rate during middle half of forced vital capacity [FEF25%-75%] 67.3 vs 82.0, p = 0.009), and for every cigarette less smoked in the room with the child the FEV1 increased by 3%. When parents of those seen in the later period were asked whether they had been told that smoke would aggravate their child's asthma, 80% affirmed that they had. The difference in asthma severity between the two time periods was much less in children of nonsmokers than in children of smokers. Conclusion: It appears that if parents are aware that smoke will aggravate their child's asthma, the child will be exposed to fewer cigarettes, and the asthma will be less severe.	UNIV BRITISH COLUMBIA,DEPT PEDIAT,VANCOUVER V6T 1W5,BC,CANADA; UNIV BRITISH COLUMBIA,DEPT HLTH CARE & EPIDEMIOL,VANCOUVER V6T 1W5,BC,CANADA	University of British Columbia; University of British Columbia								BARBEE RA, 1991, CHEST, V99, P20, DOI 10.1378/chest.99.1.20; BATES DV, 1990, ENVIRON RES, V51, P51, DOI 10.1016/S0013-9351(05)80182-3; CHANYEUNG M, 1987, AM REV RESPIR DIS, V135, P950, DOI 10.1164/arrd.1987.135.4.950; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; JARVIS MJ, 1986, THORAX, V41, P886, DOI 10.1136/thx.41.11.886; MARTINEZ FD, 1988, AM REV RESPIR DIS, V138, P518, DOI 10.1164/ajrccm/138.3.518; MURRAY AB, 1983, CAN MED ASSOC J, V129, P828; MURRAY AB, 1988, CHEST, V94, P701, DOI 10.1378/chest.94.4.701; MURRAY AB, 1986, J ALLERGY CLIN IMMUN, V77, P575, DOI 10.1016/0091-6749(86)90348-9; MURRAY AB, 1992, CHEST, V101, P16, DOI 10.1378/chest.101.1.16; MURRAY AB, 1983, J ALLERGY CLIN IMMUN, V71, P21, DOI 10.1016/0091-6749(83)90542-0; MURRAY AB, 1990, J ALLERGY CLIN IMMUN, V86, P732, DOI 10.1016/S0091-6749(05)80177-0; MURRAY AB, 1981, J ALLERGY CLIN IMMUN, V68, P119, DOI 10.1016/0091-6749(81)90169-X; MURRAY AB, 1989, PEDIATRICS, V84, P451; MURRAY AB, 1986, EFFECTS INVOLUNTARY, P12; OCONNOR GT, 1987, AM REV RESPIR DIS, V135, P800, DOI 10.1164/arrd.1987.135.4.800; POLGAR G, 1971, STANDARD VALUES PULM, P179; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; 1986, CAN MED ASSOC J, V135, P321; 1990, CAN MED ASSOC J, V143, P905	21	75	79	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1993	91	1	1				102	110		10.1016/0091-6749(93)90302-V	http://dx.doi.org/10.1016/0091-6749(93)90302-V			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KK044	8423267				2022-12-18	WOS:A1993KK04400009
J	GEHA, RS				GEHA, RS			REGULATION OF IGE SYNTHESIS IN HUMANS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							HUMAN B-CELLS; C-EPSILON TRANSCRIPTS; INTERFERON-GAMMA; V(D)J RECOMBINATION; HUMAN-LYMPHOCYTES; INTERLEUKIN-4; INDUCTION; SWITCH; RAG-1				GEHA, RS (corresponding author), HARVARD UNIV,CHILDRENS HOSP,SCH MED,DEPT PEDIAT,DIV IMMUNOL,300 LONGWOOD AVE,BOSTON,MA 02115, USA.							BERTON MT, 1990, J EXP MED, V172, P375, DOI 10.1084/jem.172.1.375; COFFMAN RL, 1986, J IMMUNOL, V136, P949; ESSER C, 1990, ANNU REV IMMUNOL, V8, P717, DOI 10.1146/annurev.iy.08.040190.003441; GAUCHAT JF, 1990, J EXP MED, V172, P463, DOI 10.1084/jem.172.2.463; JABARA HH, 1991, J IMMUNOL, V147, P1557; JABARA HH, 1990, J EXP MED, V172, P1861, DOI 10.1084/jem.172.6.1861; JABARA HH, 1990, J IMMUNOL, V145, P3468; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; PARRONCHI P, 1990, J IMMUNOL, V144, P2102; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; ROMAGNANI S, 1990, IMMUNOL TODAY, V11, P316, DOI 10.1016/S0167-5699(10)80004-0; ROTHMAN P, 1988, J EXP MED, V168, P2385, DOI 10.1084/jem.168.6.2385; SARFATI M, 1989, J EXP MED, V170, P1775, DOI 10.1084/jem.170.5.1775; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SHAPIRA SK, 1991, DELETIONAL SWITCH RE, V88, P7528; THYPHRONITIS G, 1989, P NATL ACAD SCI USA, V86, P5580, DOI 10.1073/pnas.86.14.5580; VERCELLI D, 1989, J EXP MED, V169, P1295, DOI 10.1084/jem.169.4.1295; VERCELLI D, 1989, J CLIN IMMUNOL, V9, P75, DOI 10.1007/BF00916934; VERCELLI D, 1990, J IMMUNOL, V144, P57086; WIERENGA EA, 1990, EUR J IMMUNOL, V20, P1519, DOI 10.1002/eji.1830200717; YANCOPOULOS GD, 1986, EMBO J, V5, P3259, DOI 10.1002/j.1460-2075.1986.tb04637.x	21	75	79	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1992	90	2					143	150		10.1016/0091-6749(92)90064-9	http://dx.doi.org/10.1016/0091-6749(92)90064-9			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JJ423	1500620				2022-12-18	WOS:A1992JJ42300001
J	PARKER, PJ; PARRINELLO, JT; CONDEMI, JJ; ROSENFELD, SI				PARKER, PJ; PARRINELLO, JT; CONDEMI, JJ; ROSENFELD, SI			PENICILLIN RESENSITIZATION AMONG HOSPITALIZED-PATIENTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						PENICILLIN ALLERGY; RESENSITIZATION; INTRAVENOUS BETA-LACTAM ANTIBIOTICS; SKIN TESTING	ALLERGY; EXPERIENCE; DIAGNOSIS	The purpose of this study was to determine the frequency of resensitization to penicillin after oral or intravenous treatment with beta-lactam antibiotics in hospitalized patients with histories of penicillin allergy. Seventeen adults (aged 24 to 76 years) and one child (aged 10 years) were treated intravenously and/or orally with beta-lactam antibiotics after negative skin tests were obtained with benzylpenicilloyl polylysine, potassium penicillin G, and alkaline hydrolysis products of penicillin G as minor determinant mixture. Repeat skin testing was performed 1 to 12 months after the therapy. Three patients (16%) became skin test positive after the treatment. Two patients reacted to potassium penicillin G alone, and the other patient reacted to benzylpenicilloyl polylysine and minor determinant mixture. These three patients were among the 15 patients who were treated with intravenous antibiotics. This study reveals a high percentage of skin test conversion after intravenously administered penicillin therapy and confirms the present practice of advising patients with a history of penicillin allergy who have successfully completed penicillin treatment to have a repeat skin test before future exposure to beta-lactam antibiotics.	UNIV ROCHESTER,SCH MED & DENT,DEPT MED,ALLERGY IMMUNOL & RHEUMATOL UNIT,BOX 695,ROCHESTER,NY 14642	University of Rochester								ADKINSON NF, 1971, NEW ENGL J MED, V285, P22, DOI 10.1056/NEJM197107012850104; BUDD MA, 1964, JAMA-J AM MED ASSOC, V190, P203; GREEN GR, 1977, J ALLERGY CLIN IMMUN, V60, P334; MENDELSON LM, 1984, J ALLERGY CLIN IMMUN, V73, P76, DOI 10.1016/0091-6749(84)90487-1; PATTERSON R, 1985, ALLERGIC DISEASES DI; SOLLEY GO, 1982, J ALLERGY CLIN IMMUN, V69, P238, DOI 10.1016/0091-6749(82)90105-1; SULLIVAN TJ, 1981, J ALLERGY CLIN IMMUN, V68, P171, DOI 10.1016/0091-6749(81)90180-9; SULLIVAN TJ, 1983, GERIATRICS, V38, P63; VANDELLEN RG, 1971, J ALLERGY, V47, P230, DOI 10.1016/S0091-6749(71)80468-2; WARRINGTON RJ, 1978, CAN MED ASSOC J, V118, P787	10	75	77	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1991	88	2					213	217		10.1016/0091-6749(91)90331-H	http://dx.doi.org/10.1016/0091-6749(91)90331-H			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GB225	1880322				2022-12-18	WOS:A1991GB22500010
J	SWEINBERG, SK; WODELL, RA; GRODOFSKY, MP; GREENE, JM; CONLEY, ME				SWEINBERG, SK; WODELL, RA; GRODOFSKY, MP; GREENE, JM; CONLEY, ME			RETROSPECTIVE ANALYSIS OF THE INCIDENCE OF PULMONARY-DISEASE IN HYPOGAMMAGLOBULINEMIA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						X-LINKED AGAMMAGLOBULINEMIA; COMMON VARIABLE IMMUNODEFICIENCY; GAMMA-GLOBULIN; PNEUMONIA; ANTIBIOTICS; IMMUNODEFICIENCY; PULMONARY FUNCTION TESTS; ATELECTASIS; OBSTRUCTIVE LUNG DISEASE	COMMON VARIABLE HYPOGAMMAGLOBULINEMIA; IMMUNE GLOBULIN THERAPY; INTRAVENOUS IMMUNOGLOBULIN; IMMUNODEFICIENCY; DEFICIENCY; EFFICACY	To determine the best predictors of chronic pulmonary disease in patients with hypogammaglobulinemia, we evaluated the clinical records, chest x-ray films, and pulmonary function tests of 10 patients with X-linked agammaglobulinemia (XLA) followed for a mean of 12.5 years, and 12 patients with common variable immunodeficiency (CVID) followed for a mean of 10.5 years. These patients, most of whom were treated with intramuscular gamma globulin and long-term oral antibiotics, had very few pneumonias after diagnosis. The patients with XLA had 0.10 pneumonias per treatment year, and the patients with CVID had 0.18 pneumonias per treatment year. Seven of the 10 patients with XLA had normal chest x-ray films 8 to 15 years after diagnosis, and none had bronchiectasis. Pulmonary disease was more common and more severe in the group with CVID, but five patients in this group also had normal chest x-ray films after long follow-up. In the entire group of 22 patients, nine of the 10 patients with abnormal chest x-ray films on most recent evaluation already had pulmonary disease at the initial visit (p = 0.00002). These studies indicate that the best predictors of good pulmonary function in patients with hypogammaglobulinemia are early diagnosis and good compliance with gamma globulin replacement therapy and oral antibiotics.	UNIV PENN,CHILDRENS HOSP,SCH MED,DEPT PEDIAT,PHILADELPHIA,PA 19104	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia					NIAID NIH HHS [AI 25129] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025129, R37AI025129, R56AI025129] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMMANN AJ, 1982, CLIN IMMUNOL IMMUNOP, V22, P60, DOI 10.1016/0090-1229(82)90022-8; BERNATOWSKA E, 1987, CLIN IMMUNOL IMMUNOP, V43, P153, DOI 10.1016/0090-1229(87)90123-1; CLAUSEN JL, 1982, PULMONARY FUNCTION T, P49; CONLEY ME, 1988, J PEDIATR-US, V112, P688, DOI 10.1016/S0022-3476(88)80683-8; CONLEY ME, 1986, J PEDIATR-US, V108, P915, DOI 10.1016/S0022-3476(86)80927-1; CONLEY ME, 1986, BLOOD, V67, P1251; CUNNINGHAMRUNDLES C, 1984, ANN INTERN MED, V101, P435, DOI 10.7326/0003-4819-101-4-435; DUBOIS AB, 1956, J CLIN INVEST, V35, P322, DOI 10.1172/JCI103281; DUKES RJ, 1978, THORAX, V33, P603, DOI 10.1136/thx.33.5.603; HAUSSER C, 1983, AM J DIS CHILD, V137, P833, DOI 10.1001/archpedi.1983.02140350011004; HERMANS PE, 1976, AM J MED, V61, P221, DOI 10.1016/0002-9343(76)90173-X; KNUDSON RJ, 1983, AM REV RESPIR DIS, V127, P725; KOHLER P, CHEST S, V86, P24; LEDERMAN HM, 1985, MEDICINE, V64, P590; PIROFSKY B, 1984, AM J MED, V76, P53, DOI 10.1016/0002-9343(84)90320-6; ROIFMAN CM, 1985, AM J MED, V79, P171, DOI 10.1016/0002-9343(85)90006-3; SORENSEN RU, 1984, AM J MED, V76, P83, DOI 10.1016/0002-9343(84)90325-5; WATTS WJ, 1986, AM REV RESPIR DIS, V134, P699; WHITE WB, 1987, AM J MED, V83, P431, DOI 10.1016/0002-9343(87)90752-2	19	75	78	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1991	88	1					96	104		10.1016/0091-6749(91)90306-9	http://dx.doi.org/10.1016/0091-6749(91)90306-9			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FY204	2071789				2022-12-18	WOS:A1991FY20400012
J	PERRIN, B; CARTIER, A; GHEZZO, H; GRAMMER, L; HARRIS, K; CHAN, H; CHANYEUNG, M; MALO, JL				PERRIN, B; CARTIER, A; GHEZZO, H; GRAMMER, L; HARRIS, K; CHAN, H; CHANYEUNG, M; MALO, JL			REASSESSMENT OF THE TEMPORAL PATTERNS OF BRONCHIAL OBSTRUCTION AFTER EXPOSURE TO OCCUPATIONAL SENSITIZING AGENTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							LATE ASTHMATIC REACTIONS; WESTERN RED CEDAR; TOLUENE-DIISOCYANATE; DIPHENYLMETHANE DIISOCYANATE; PROVOCATION TESTS; ANTIBODIES; HISTAMINE; METHACHOLINE; ISOCYANATES; SENSITIVITY	Typical asthmatic reactions after exposure to common or occupational allergens have been classified as isolated immediate, early late, late, and dual (Pepys and Hutchcroft, 1975(6)). Atypical reactions can also occur, but their temporal behavior and frequency are unknown. We analyzed 69 bronchospastic reactions after exposure to three types of occupational sensitizers in the laboratory: isocyanates, western red cedar, and IgE sensitizing agents. Graphs of the reactions were presented to three observers in a blind, randomized way. Reactions were defined as follows: (1) typical patterns, that is, isolated immediate, early late, late, and dual, as put forward by Pepys and Hutchcroft, 6 and (2) atypical patterns including progressive (onset, during, or minutes after exposure, progressing to a maximum reaction 5 to 6 hours later) and square waved (similar to a dual reaction but with only partial recovery [< 10%] between the immediate and late falls in FEV1). Some curves were also analyzed by polynomial regression. The three observers agreed in 59/69 cases (86%), and a consensus was reached after discussion for the remaining subjects. Fifteen of 63 (22%) reactions were atypical. IgE-mediated reactions and reactions to red cedar were, respectively, mainly of the immediate and late types. The distribution of reactions to isocyanates, however, was significantly different (chi-square, 6.1; p = 0.01), the "progressive" pattern occurring in 7/23 instances (30%). There was a satisfactory concordance between visual assessment and polynomial fit analysis in distinguishing dual from square-waved reactions. We conclude that isocyanates frequently cause atypical progressive bronchospastic reactions that are rarely observed after exposure to IgE agents and western red cedar.	HOP SACRE COEUR, DEPT CHEST MED, 5400 W GOUIN, MONTREAL H4J 1C5, QUEBEC, CANADA; NORTHWESTERN UNIV, SCH MED, DEPT MED, OCCUPAT MED SECT, CHICAGO, IL 60611 USA; NORTHWESTERN UNIV, SCH MED, DEPT MED, ALLERGY IMMUNOL SECT, CHICAGO, IL 60611 USA; VANCOUVER GEN HOSP, DEPT MED, VANCOUVER V5Z 1M9, BC, CANADA	Universite de Montreal; Northwestern University; Northwestern University; University of British Columbia				Grammer, Leslie/0000-0001-6860-2014	NIAID NIH HHS [AI 11403] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011403] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], 1987, Am Rev Respir Dis, V136, P1285; BLOCK G, 1983, CLIN ALLERGY, V13, P359, DOI 10.1111/j.1365-2222.1983.tb02610.x; CARTIER A, 1989, J ALLERGY CLIN IMMUN, V84, P507, DOI 10.1016/0091-6749(89)90364-3; CARTIER A, 1986, J ALLERGY CLIN IMMUN, V77, P639, DOI 10.1016/0091-6749(86)90359-3; CARTIER A, 1989, J ALLERGY CLIN IMMUN, V84, P823, DOI 10.1016/0091-6749(89)90346-1; CHANG KC, 1984, CLIN ALLERGY, V14, P329, DOI 10.1111/j.1365-2222.1984.tb02213.x; CHANYEUNG M, 1973, AM REV RESPIR DIS, V108, P1094; CHEN SE, 1982, J ALLERGY CLIN IMMUN, V70, P383, DOI 10.1016/0091-6749(82)90029-X; CLOUTIER Y, 1989, EUR RESPIR J, V2, P769; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; DEHAUT P, 1983, THORAX, V38, P516, DOI 10.1136/thx.38.7.516; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; FABBRI LM, 1987, AM REV RESPIR DIS, V136, P36, DOI 10.1164/ajrccm/136.1.36; GERVAIS P, 1986, 12 P INT C ALL CLIN, P480; KNUDSON RJ, 1983, AM REV RESPIR DIS, V127, P725; LAGIER F, 1990, REV MAL RESPIR, V7, P337; LAGIER F, 1990, J ALLERGY CLIN IMMUN, V85, P785, DOI 10.1016/0091-6749(90)90199-E; LAM S, 1987, J ALLERGY CLIN IMMUN, V80, P44, DOI 10.1016/S0091-6749(87)80189-6; MALO JL, 1983, AM REV RESPIR DIS, V128, P8, DOI 10.1164/arrd.1983.128.1.8; MAPP CE, 1986, EUR J RESPIR DIS, V69, P276; MOIRA CY, 1986, AM REV RESPIR DIS, V133, P686; OBRIEN IM, 1979, CLIN ALLERGY, V9, P1, DOI 10.1111/j.1365-2222.1979.tb01516.x; PATTERSON R, 1983, J ALLERGY CLIN IMMUN, V71, P604, DOI 10.1016/0091-6749(83)90443-8; PATTERSON R, 1987, INT ARCH ALLER A IMM, V84, P93, DOI 10.1159/000234404; PAULI G, 1986, B EUR PHYSIOPATH RES, V22, P399; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; RYAN G, 1981, AM REV RESPIR DIS, V123, P195; SEGUIN P, 1987, J OCCUP ENVIRON MED, V29, P340; TSE KS, 1982, CLIN ALLERGY, V12, P249, DOI 10.1111/j.1365-2222.1982.tb02525.x; WELINDER H, 1988, CLIN ALLERGY, V18, P85, DOI 10.1111/j.1365-2222.1988.tb02847.x; ZAMMITTABONA M, 1983, AM REV RESPIR DIS, V128, P226	31	75	75	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1991	87	3					630	639		10.1016/0091-6749(91)90381-W	http://dx.doi.org/10.1016/0091-6749(91)90381-W			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FB801	2005315				2022-12-18	WOS:A1991FB80100005
J	FUKUDA, T; GLEICH, GJ				FUKUDA, T; GLEICH, GJ			HETEROGENEITY OF HUMAN EOSINOPHILS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material									DOKKYO UNIV,SCH MED,DEPT CLIN IMMUNOL,MIBU,TOCHIGI 32102,JAPAN; MAYO CLIN & MAYO FDN,DEPT IMMUNOL,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DIV ALLERG DIS & INTERNAL MED,ROCHESTER,MN 55905	Dokkyo Medical University; Mayo Clinic; Mayo Clinic	FUKUDA, T (corresponding author), DOKKYO UNIV,SCH MED,DEPT MED,MIBU,TOCHIGI 32102,JAPAN.							BARNES PJ, 1988, J ALLERGY CLIN IMMUN, V81, P919, DOI 10.1016/0091-6749(88)90952-9; BASS DA, 1980, J CLIN INVEST, V66, P1265, DOI 10.1172/JCI109978; CAMPBELL HD, 1987, P NATL ACAD SCI USA, V84, P6629, DOI 10.1073/pnas.84.19.6629; CAPRON M, 1985, J IMMUNOL, V134, P3013; CAPRON M, 1986, J EXP MED, V164, P72, DOI 10.1084/jem.164.1.72; CAPRON M, 1984, J IMMUNOL, V132, P462; CAPRON M, 1985, INT ARCH ALLER A IMM, V77, P246, DOI 10.1159/000233801; CONNELL JT, 1968, J ALLERGY, V41, P1, DOI 10.1016/0021-8707(68)90002-6; DESIMONE C, 1983, INT ARCH ALLER A IMM, V71, P193, DOI 10.1159/000233389; DESIMONE C, 1982, CLIN EXP IMMUNOL, V48, P249; FRICK WE, 1988, J ALLERGY CLIN IMMUN, V82, P119, DOI 10.1016/0091-6749(88)90061-9; FRICK WE, 1988, J ALLERGY CLIN IMMUN, V81, P208, DOI 10.1016/0091-6749(88)90396-X; FUKUDA T, 1985, AM REV RESPIR DIS, V132, P981; FUKUDA T, IN PRESS EOSINOPHILS; GARTNER I, 1980, IMMUNOLOGY, V40, P133; GUINOT P, 1987, PROSTAGLANDINS, V34, P723, DOI 10.1016/0090-6980(87)90295-4; KAJITA T, 1985, INT ARCH ALLER A IMM, V78, P406, DOI 10.1159/000233922; KAUFFMAN HF, 1987, J ALLERGY CLIN IMMUN, V79, P611, DOI 10.1016/S0091-6749(87)80157-4; KAY AB, 1985, CLIN EXP IMMUNOL, V62, P1; KHALIFE J, 1986, J IMMUNOL, V137, P1659; KLOPROGGE E, 1989, J ALLERGY CLIN IMMUN, V83, P393, DOI 10.1016/0091-6749(89)90124-3; LEE TC, 1984, J BIOL CHEM, V259, P5526; LELLOUCHTUBIANA A, 1988, AM REV RESPIR DIS, V137, P948, DOI 10.1164/ajrccm/137.4.948; METZGER WJ, 1986, CHEST, V89, P477, DOI 10.1378/chest.89.4.477; OLOFSSON T, 1980, SCAND J HAEMATOL, V24, P254; OWEN WF, 1987, J EXP MED, V166, P129, DOI 10.1084/jem.166.1.129; PETERS MS, 1988, BLOOD, V71, P780; PINCUS SH, 1981, BLOOD, V58, P1175; PRIN L, 1986, CLIN EXP IMMUNOL, V63, P249; PRIN L, 1983, INT ARCH ALLER A IMM, V72, P336, DOI 10.1159/000234893; PRIN L, 1984, CLIN EXP IMMUNOL, V57, P735; ROTHENBERG ME, 1988, J ALLERGY CLIN IMMUN, V81, P209, DOI 10.1016/0091-6749(88)90401-0; SHAW RJ, 1985, NATURE, V316, P150, DOI 10.1038/316150a0; SHULT PA, 1988, J ALLERGY CLIN IMMUN, V81, P429, DOI 10.1016/0091-6749(88)90912-8; SPRY CJF, 1976, CLIN EXP IMMUNOL, V24, P423; TAI PC, 1985, CLIN EXP IMMUNOL, V60, P427; VADAS MA, 1979, J IMMUNOL, V122, P1228; WELLER PF, 1984, J ALLERGY CLIN IMMUN, V73, P1, DOI 10.1016/0091-6749(84)90474-3; WINQVIST I, 1982, IMMUNOLOGY, V47, P531	39	75	76	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1989	83	2	1				369	373		10.1016/0091-6749(89)90120-6	http://dx.doi.org/10.1016/0091-6749(89)90120-6			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	T4489	2645342				2022-12-18	WOS:A1989T448900001
J	KONIG, P				KONIG, P			INHALED CORTICOSTEROIDS - THEIR PRESENT AND FUTURE-ROLE IN THE MANAGEMENT OF ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review											KONIG, P (corresponding author), N SHORE UNIV HOSP, DEPT PEDIAT PULM MED, 300 COMMUNITY DR, MANHASSET, NY 11030 USA.		König, Peter/ABB-2380-2020	König, Peter/0000-0003-3654-5267				ADELROTH E, 1985, ALLERGY, V40, P58, DOI 10.1111/j.1398-9995.1985.tb04155.x; AGNEW RAL, 1977, CLIN ALLERGY, V7, P183, DOI 10.1111/j.1365-2222.1977.tb01440.x; ANDERSSON E, 1975, POSTGRAD MED J, V51, P32; BALFOURLYNN L, 1986, ARCH DIS CHILD, V61, P1049, DOI 10.1136/adc.61.11.1049; BARAN D, 1987, BRIT J DIS CHEST, V81, P170, DOI 10.1016/0007-0971(87)90135-5; BERNSTEIN IL, 1982, CHEST, V81, P20, DOI 10.1378/chest.81.1.20; BHAGAT RG, 1984, PEDIATRICS, V73, P626; BJORKANDER J, 1982, EUR J RESPIR DIS, V63, P108; BLAISS MS, 1982, ANN ALLERGY, V48, P210; BLODGETT FM, 1956, NEW ENGL J MED, V254, P636, DOI 10.1056/NEJM195604052541402; BOYD G, 1985, CLIN ALLERGY, V15, P383, DOI 10.1111/j.1365-2222.1985.tb03007.x; BROWN HM, 1972, BRIT MED J, V1, P585, DOI 10.1136/bmj.1.5800.585; CARMICHAEL J, 1978, BRIT MED J, V2, P657, DOI 10.1136/bmj.2.6138.657; CLARK TJH, 1985, J ALLERGY CLIN IMMUN, V76, P330, DOI 10.1016/0091-6749(85)90649-9; CLARKE PS, 1982, J ASTHMA, V19, P91, DOI 10.3109/02770908209104741; COCKCROFT DW, 1987, J ALLERGY CLIN IMMUN, V79, P734, DOI 10.1016/0091-6749(87)90204-1; COSTELLO JF, 1974, THORAX, V29, P571, DOI 10.1136/thx.29.5.571; DAHL R, 1982, EUR J RESPIR DIS, V63, P268; DICKSON W, 1973, ARCH DIS CHILD, V48, P671, DOI 10.1136/adc.48.9.671; DRY J, 1985, J INT MED RES, V13, P289, DOI 10.1177/030006058501300508; DUTOIT JI, 1987, AM REV RESPIR DIS, V136, P1174, DOI 10.1164/ajrccm/136.5.1174; EBDEN P, 1986, THORAX, V41, P869, DOI 10.1136/thx.41.11.869; EDMUNDS AT, 1979, BRIT J DIS CHEST, V73, P149, DOI 10.1016/S0007-0971(79)80124-2; EIGEN H, 1987, J ALLERGY CLIN IMMUN, V80, P612, DOI 10.1016/0091-6749(87)90016-9; FIELD HV, 1982, ARCH DIS CHILD, V57, P864, DOI 10.1136/adc.57.11.864; FRANCIS RS, 1984, CLIN ALLERGY, V14, P537, DOI 10.1111/j.1365-2222.1984.tb02241.x; FRANK A, 1985, RESPIRATION, V48, P122, DOI 10.1159/000194811; FURUKAWA CT, 1988, J ALLERGY CLIN IMMUN, V81, P83, DOI 10.1016/0091-6749(88)90224-2; GADDIE J, 1973, LANCET, V2, P280; GALE AE, 1981, ANN ALLERGY, V46, P268; GLUCK OS, 1981, ARTHRITIS RHEUM-US, V24, P892, DOI 10.1002/art.1780240705; GODFREY S, 1974, ARCH DIS CHILD, V49, P591, DOI 10.1136/adc.49.8.591; GODFREY S, 1978, J ALLERGY CLIN IMMUN, V62, P335, DOI 10.1016/0091-6749(78)90133-1; GOLDSTEIN DE, 1983, PEDIATRICS, V72, P60; GRAFFLONNEVIG V, 1979, ALLERGY, V34, P57, DOI 10.1111/j.1398-9995.1979.tb02001.x; GRIECO MH, 1978, ARCH INTERN MED, V138, P1337, DOI 10.1001/archinte.138.9.1337; HARRISON BDW, 1982, CLIN ENDOCRINOL, V17, P109, DOI 10.1111/j.1365-2265.1982.tb01570.x; HODGKIN JE, 1986, CHEST, V90, pS62, DOI 10.1378/chest.90.5.62S; JOHANSSON SA, 1982, EUR J CLIN PHARMACOL, V22, P523, DOI 10.1007/BF00609625; JOHANSSON SA, 1982, EUR J RESPIR DIS, V63, P74; KAY AB, 1987, J ALLERGY CLIN IMMUN, V80, P1, DOI 10.1016/S0091-6749(87)80183-5; KERREBIJN KF, 1976, J PEDIATR-US, V89, P821, DOI 10.1016/S0022-3476(76)80816-5; KERSHNAR H, 1978, PEDIATRICS, V62, P189; KEWLEY GD, 1980, AUST PAEDIATR J, V16, P117; KLEIN R, 1977, PEDIATRICS, V60, P7; KONIG P, 1985, CHEST, V88, P276, DOI 10.1378/chest.88.2.276; KONIG P, 1984, J ALLERGY CLIN IMMUN, V73, P686, DOI 10.1016/0091-6749(84)90306-3; KONIG P, 1987, PEDIATR PULM, V3, P264, DOI 10.1002/ppul.1950030413; KONIG P, 1979, ANN ALLERGY, V43, P293; KRAAN J, 1988, AM REV RESPIR DIS, V137, P44, DOI 10.1164/ajrccm/137.1.44; KRAEMER R, 1985, PROG RESPIR RES, V19, P406; KUZEMKO JA, 1974, POSTGRAD MED J, V50, P53; LAW CM, 1986, LANCET, V1, P942; LEWIS LD, 1983, LANCET, V2, P634; LITTLEWOOD JM, 1988, LANCET, V1, P115; LOFDAHL CG, 1984, EUR J RESPIR DIS, V65, P69; LOWHAGEN O, 1985, J ALLERGY CLIN IMMUN, V75, P460, DOI 10.1016/S0091-6749(85)80018-X; MAAYAN C, 1986, PEDIATR PULM, V2, P9, DOI 10.1002/ppul.1950020106; MCGIVERN DV, 1984, THORAX, V39, P933, DOI 10.1136/thx.39.12.933; MELLIS CM, 1977, THORAX, V32, P29, DOI 10.1136/thx.32.1.29; MELTZER EO, 1982, PEDIATRICS, V69, P340; MELTZER EO, 1985, AM REV RESPIR DIS, V131, P732; MESSERLI C, 1975, PNEUMONOLOGIE, V153, P29, DOI 10.1007/BF02096333; MITCHELL I, 1976, BRIT MED J, V2, P457, DOI 10.1136/bmj.2.6033.457-a; MUNCH EP, 1985, EUR J RESPIR DIS, V67, P254; MUNCH EP, 1982, EUR J RESPIR DIS, V63, P143; NASSIF E, 1987, J ALLERGY CLIN IMMUN, V80, P518, DOI 10.1016/0091-6749(87)90002-9; NASSIF EG, 1981, NEW ENGL J MED, V304, P71, DOI 10.1056/NEJM198101083040202; NEWHOUSE MT, 1986, NEW ENGL J MED, V315, P870, DOI 10.1056/NEJM198610023151406; PEDERSEN W, 1987, ALLERGY, V42, P272, DOI 10.1111/j.1398-9995.1987.tb02209.x; RACHELEFSKY GS, 1986, PEDIATRICS, V78, P1133; RAFFERTY P, 1985, BRIT J DIS CHEST, V79, P244; REID DM, 1986, BMJ-BRIT MED J, V293, P1463, DOI 10.1136/bmj.293.6560.1463; REID IR, 1986, J CLIN ENDOCR METAB, V62, P379, DOI 10.1210/jcem-62-2-379; REIMER LG, 1975, J ALLERGY CLIN IMMUN, V55, P224, DOI 10.1016/0091-6749(75)90141-4; REISER J, 1986, PEDIATR PULM, V2, P237, DOI 10.1002/ppul.1950020412; ROOKLIN AR, 1979, J ALLERGY CLIN IMMUN, V63, P383, DOI 10.1016/0091-6749(79)90210-0; RUEGSEGGER P, 1983, EUR J CLIN PHARMACOL, V25, P615, DOI 10.1007/BF00542348; RYAN G, 1985, J ALLERGY CLIN IMMUN, V75, P25, DOI 10.1016/0091-6749(85)90007-7; SHAPIRO GG, 1981, CHEST, V80, P671, DOI 10.1378/chest.80.6.671; SHAPIRO GG, 1985, PHARMACOTHERAPY, V5, P156; SHAPIRO GG, 1976, J ALLERGY CLIN IMMUN, V57, P430, DOI 10.1016/0091-6749(76)90058-0; SHERMAN B, 1982, J ALLERGY CLIN IMMUN, V69, P208, DOI 10.1016/0091-6749(82)90101-4; SHIM CS, 1987, ANN INTERN MED, V106, P700, DOI 10.7326/0003-4819-106-5-700; SIEGEL SC, 1985, J ALLERGY CLIN IMMUN, V76, P312, DOI 10.1016/0091-6749(85)90647-5; SMITH JM, 1978, CLIN ALLERGY, V8, P95; SMITH MJ, 1983, THORAX, V38, P676, DOI 10.1136/thx.38.9.676; SMITH MJ, 1983, LANCET, V1, P265, DOI 10.1016/S0140-6736(83)91686-0; SOTOMAYOR H, 1984, AM REV RESPIR DIS, V130, P56; SPECTOR SL, 1982, CLIN ALLERGY, V12, P269, DOI 10.1111/j.1365-2222.1982.tb02527.x; SPITZER SA, 1976, CHEST, V70, P38, DOI 10.1378/chest.70.1.38; SPRINGER C, 1987, ARCH DIS CHILD, V62, P815, DOI 10.1136/adc.62.8.815; STIKSA G, 1982, EUR J RESPIR DIS, V63, P266; STIKSA G, 1985, ANN ALLERGY, V55, P49; STORR J, 1986, ARCH DIS CHILD, V61, P270, DOI 10.1136/adc.61.3.270; SVENDSEN UG, 1987, J ALLERGY CLIN IMMUN, V80, P68; TOOGOOD JH, 1980, J ALLERGY CLIN IMMUN, V65, P145, DOI 10.1016/0091-6749(80)90200-6; TOOGOOD JH, 1982, J ALLERGY CLIN IMMUN, V70, P288, DOI 10.1016/0091-6749(82)90065-3; TOOGOOD JH, 1984, AM REV RESPIR DIS, V129, P723, DOI 10.1164/arrd.1984.129.5.723; TOOGOOD JH, 1984, EUR J RESPIR DIS, V65, P35; TOOGOOD JH, 1981, J ALLERGY CLIN IMMUN, V67, P317, DOI 10.1016/0091-6749(81)90028-2; TOOGOOD JH, 1984, EUR J RESPIR DIS, V65, P321; TSE CST, 1984, PHARMACOTHERAPY, V4, P334; TUKIAINEN P, 1987, EUR J RESPIR DIS, V70, P239; VAZ R, 1982, J PEDIATR-US, V100, P660, DOI 10.1016/S0022-3476(82)80781-6; VERMEIRE PA, 1986, CHEST, V90, pS58, DOI 10.1378/chest.90.5_Supplement.58S; VLASSES PH, 1981, CLIN PHARMACOL THER, V29, P643, DOI 10.1038/clpt.1981.89; VOGT FC, 1979, ANN ALLERGY, V43, P205; WILLEY RF, 1982, BRIT J DIS CHEST, V76, P61, DOI 10.1016/0007-0971(82)90009-2; WILLIAMS AJ, 1983, THORAX, V38, P813, DOI 10.1136/thx.38.11.813; WILSON JD, 1981, LANCET, V1, P1235; WOOD BR, 1987, PEDIATR ASTHMA ALLER, V1, P111; WYATT R, 1978, NEW ENGL J MED, V299, P1387, DOI 10.1056/NEJM197812212992504; 1974, LANCET, V2, P303	114	75	75	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1988	82	2					297	306		10.1016/0091-6749(88)91015-9	http://dx.doi.org/10.1016/0091-6749(88)91015-9			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	P8741	3042840				2022-12-18	WOS:A1988P874100025
J	KAPLAN, AP; NATBONY, SF; TAWIL, AP; FRUCHTER, L; FOSTER, M				KAPLAN, AP; NATBONY, SF; TAWIL, AP; FRUCHTER, L; FOSTER, M			EXERCISE-INDUCED ANAPHYLAXIS AS A MANIFESTATION OF CHOLINERGIC URTICARIA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									LONG ISL JEWISH HILLSIDE MED CTR,DEPT PEDIAT,DIV PEDIAT ALLERGY & IMMUNOL,NEW HYDE PK,NY 11040	Northwell Health	KAPLAN, AP (corresponding author), SUNY STONY BROOK,HLTH SCI CTR,DEPT MED,DIV ALLERGY RHEUMATOL & CLIN IMMUNOL,STONY BROOK,NY 11794, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI016337] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 16337-02] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BEAVEN MA, 1972, CLIN CHIM ACTA, V37, P91, DOI 10.1016/0009-8981(72)90419-6; DUBOIS AB, 1956, J CLIN INVEST, V35, P327, DOI 10.1172/JCI103282; DUBOIS AB, 1956, J CLIN INVEST, V35, P322, DOI 10.1172/JCI103281; GOREVIC PD, 1980, INT J DERMATOL, V19, P417, DOI 10.1111/j.1365-4362.1980.tb05893.x; Grant RT, 1936, CLIN SCI, V2, P253; KAPLAN AP, 1975, J ALLERGY CLIN IMMUN, V55, P394, DOI 10.1016/0091-6749(75)90078-0; MCNEILL RS, 1966, Q J MED, V35, P55; SHEFFER AL, 1980, J ALLERGY CLIN IMMUN, V66, P106, DOI 10.1016/0091-6749(80)90056-1; SIGLER RW, 1979, J ALLERGY CLIN IMMUN, V63, P35, DOI 10.1016/0091-6749(79)90159-3; SOTER NA, 1980, NEW ENGL J MED, V302, P604, DOI 10.1056/NEJM198003133021104; WARIN RP, 1974, MAJOR PROBLEMS DERMA, V1, P136	11	75	75	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	68	4					319	324		10.1016/0091-6749(81)90158-5	http://dx.doi.org/10.1016/0091-6749(81)90158-5			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ML525	6169753				2022-12-18	WOS:A1981ML52500012
J	WEBER, RW; PETTY, WE; NELSON, HS				WEBER, RW; PETTY, WE; NELSON, HS			AEROSOLIZED TERBUTALINE IN ASTHMATICS - COMPARISON OF DOSAGE STRENGTH, SCHEDULE, AND METHOD OF ADMINISTRATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									USA,FITZSIMONS ARMY MED CTR,ALLERGY IMMUNOL SERV,DENVER,CO 80240									AMORY DW, 1975, CHEST, V67, P279, DOI 10.1378/chest.67.3.279; CAMPBELL RC, 1974, STATISTICS BIOL, P177; Chaieb J A, 1974, Curr Med Res Opin, V2, P275, DOI 10.1185/03007997409115234; CHOOKANG YF, 1973, PRACTITIONER, V211, P801; CHOOKANG YFJ, 1975, BRIT MED J, V2, P119, DOI 10.1136/bmj.2.5963.119; DOLOVICH MB, 1977, AM REV RESPIR DIS, V115, P397; GLASS P, 1975, CURR THER RES CLIN E, V18, P425; GOLD MI, 1975, CHEST, V67, P469, DOI 10.1378/chest.67.4.469; MARANETRA N, 1973, MED J AUSTRALIA, V1, P988, DOI 10.5694/j.1326-5377.1973.tb110855.x; MOORE RB, 1972, J ALLERGY CLIN IMMUN, V49, P137, DOI 10.1016/0091-6749(72)90107-8; PETTY TL, 1974, CHEST, V66, P1, DOI 10.1378/chest.66.1.1-a; SHENFIELD GM, 1973, AM REV RESPIR DIS, V108, P501; SHENFIELD GM, 1973, THORAX, V28, P124, DOI 10.1136/thx.28.2.124; SMELZER TH, 1973, JAMA-J AM MED ASSOC, V223, P884; SMITH PR, 1977, CHEST, V71, P129, DOI 10.1378/chest.71.2.129; THIRINGER G, 1976, SCAND J RESPIR DIS, V57, P17; THIRINGER G, 1974, SCAND J RESPIR DIS S, V80, P56; TINKELMAN DG, 1977, J ALLERGY CLIN IMMUN, V59, P109, DOI 10.1016/0091-6749(77)90211-1	18	75	75	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	63	2					116	121		10.1016/0091-6749(79)90201-X	http://dx.doi.org/10.1016/0091-6749(79)90201-X			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GJ748	365919	Bronze			2022-12-18	WOS:A1979GJ74800009
J	GROVE, DI; BURSTON, TO; WELLBY, ML; MUNROFORD, R; FORBES, IJ				GROVE, DI; BURSTON, TO; WELLBY, ML; MUNROFORD, R; FORBES, IJ			HUMORAL AND CELLULAR IMMUNITY IN ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									QUEEN ELIZABETH HOSP, DEPT CLIN CHEM, ADELAIDE, AUSTRALIA; UNIV ADELAIDE, DEPT MED, ADELAIDE, AUSTRALIA; ROY ADELAIDE HOSP, ADELAIDE, AUSTRALIA	University of Adelaide; Royal Adelaide Hospital								BERG T, 1969, INT ARCH ALLER A IMM, V36, P219, DOI 10.1159/000230745; BUCKLEY RH, 1968, PEDIATRICS, V41, P600; COLLINSW.C, 1967, ANN ALLERGY, V25, P177; DAVIES AJS, 1970, IMMUNOLOGY, V19, P945; DIXON WJ, 1969, INTRO STATISTICAL AN, P243; FIELD EJ, 1971, LANCET, V2, P95; FORBES IJ, 1971, AUST NZ J MED, V1, P160, DOI 10.1111/j.1445-5994.1971.tb02284.x; GREENERT S, 1971, LANCET, V2, P1121; GROVE DI, IN PRESS; HENDERSON LL, 1971, J ALLERGY CLIN IMMUN, V48, P361, DOI 10.1016/0091-6749(71)90082-0; HESS MW, 1968, EXPTL THYMECTOMY; HOBBS JR, 1969, IMMUNOLOGY DEVELOPME, P114; HUNTLEY CC, 1963, AM J DIS CHILD, V106, P545, DOI 10.1001/archpedi.1963.02080050547003; JOHANSSO.SG, 1967, LANCET, V2, P951; KAUFMAN HS, 1970, LANCET, V2, P1061; KUHNS SJ, 1952, J EXPTL MEDICINE, V4, P363; KUMAR L, 1971, J ALLERGY CLIN IMMUN, V48, P305, DOI 10.1016/0091-6749(71)90032-7; LESKOWITZ S, 1972, Clinical Allergy, V2, P237, DOI 10.1111/j.1365-2222.1972.tb01288.x; LING NR, 1968, LYMPHOCYTE STIMULATI; MOMMA K, 1965, ACTA PAEDIATR JAPON, V7, P1; PARADINE CJ, 1960, STATISTICAL METHODS, P112; ROWE DS, 1969, B WORLD HEALTH ORGAN, V40, P613; ROWE DS, 1970, INT ARCH ALLER A IMM, V39, P1; SALVAGGIO J, 1971, INT ARCH ALLERGY, V40, P520; SALVAGGIO JE, 1964, J ALLERGY, V35, P62, DOI 10.1016/0021-8707(64)90050-4; SCADDING JG, 1963, BRIT MED J, P1425, DOI 10.1136/bmj.2.5370.1425; SCHWARTZ HJ, 1971, INT ARCH ALLER A IMM, V40, P520, DOI 10.1159/000230435; TAYLOR B, 1973, LANCET, V2, P111; WILLIAMS DA, 1964, NATURE ASTHMA S KING	29	75	75	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1975	55	3					152	163		10.1016/0091-6749(75)90011-1	http://dx.doi.org/10.1016/0091-6749(75)90011-1			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	V8448	1089697				2022-12-18	WOS:A1975V844800002
J	FACKTOR, MA; BERNSTEI.RA; FIREMAN, P				FACKTOR, MA; BERNSTEI.RA; FIREMAN, P			HYPERSENSITIVITY TO TETANUS TOXOID	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV PITTSBURGH,SCH MED,PITTSBURGH,PA 15213; CHILDRENS HOSP,PITTSBURGH,PA 15213	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh								BRINDLE MJ, 1962, BMJ-BRIT MED J, P1116; Cooke RA, 1940, J AMER MED ASSOC, V114, P1854; EDSALL G, 1967, J AMER MED ASSOC, V202, P17, DOI 10.1001/jama.1967.03130140075009; EISEN AH, 1963, NEW ENGL J MED, V269, P1408, DOI 10.1056/NEJM196312262692605; EPSTEIN S, 1963, J ALLERGY, V34, P225, DOI 10.1016/0021-8707(63)90024-8; FACKTOR MA, 1972, J ALLERGY CLIN IMMUN, V49, P108; GRIFFITH AH, 1967, PRINCIPLES TETANUS, P299; KITTLER FJ, 1966, SOUTHERN MED J, V59, P149, DOI 10.1097/00007611-196602000-00005; KUHNS WILLIAM J., 1962, JOUR IMMUNOL, V89, P652; KUHNS WJ, 1952, J EXP MED, V95, P363, DOI 10.1084/jem.95.4.363; LAWRENCE HS, 1956, J EXP MED, V104, P321, DOI 10.1084/jem.104.3.321; LEVINE L, 1961, AM J HYG, V73, P20, DOI 10.1093/oxfordjournals.aje.a120163; LEVINE L, 1960, J PEDIATR-US, V57, P836, DOI 10.1016/S0022-3476(60)80134-5; LING NR, 1964, LANCET, V1, P353; LONG D. A., 1959, JOUR HYG, V57, P216; MCCOMB JA, 1961, NEW ENGL J MED, V265, P1152, DOI 10.1056/NEJM196112072652307; OPPENHEIM JJ, 1970, J IMMUNOL, V104, P835; PEEBLES TC, 1969, NEW ENGL J MED, V280, P575, DOI 10.1056/NEJM196903132801102; PEPYS J, 1968, CLINICAL ASPECTS IMM; REISMAN R E, 1969, Journal of Allergy, V43, P245, DOI 10.1016/0021-8707(69)90067-7; SMITH RE, 1962, ANN ALLERGY, V20, P809; STEIGMAN AJ, 1968, J PEDIATR-US, V72, P753, DOI 10.1016/S0022-3476(68)80033-2; UHR JW, 1957, J EXP MED, V105, P11, DOI 10.1084/jem.105.1.11; WHITE WG, 1967, PRINCIPLES TETANUS, P401; WILSON RJ, 1967, PRINCIPLES TETANUS, P281	25	75	82	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1973	52	1					1	12		10.1016/0091-6749(73)90115-2	http://dx.doi.org/10.1016/0091-6749(73)90115-2			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	Q1826	4268453				2022-12-18	WOS:A1973Q182600001
J	Bahri, R; Custovic, A; Korosec, P; Tsoumani, M; Barron, M; Wu, JK; Sayers, R; Weimann, A; Ruiz-Garcia, M; Patel, N; Robb, A; Shamji, MH; Fontanella, S; Silar, M; Mills, ENC; Simpson, A; Turner, PJ; Bulfone-Paus, S				Bahri, Rajia; Custovic, Adnan; Korosec, Peter; Tsoumani, Marina; Barron, Martin; Wu, Jiakai; Sayers, Rebekah; Weimann, Alf; Ruiz-Garcia, Monica; Patel, Nandinee; Robb, Abigail; Shamji, Mohamed H.; Fontanella, Sara; Silar, Mira; Mills, E. N. Clare; Simpson, Angela; Turner, Paul J.; Bulfone-Paus, Silvia			Mast cell activation test in the diagnosis of allergic disease and anaphylaxis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Anaphylaxis; basophil activation test; diagnosis; food allergy; mast cells; mast cell activation test; peanut allergy	BASOPHIL ACTIVATION; FOOD ALLERGY; IGE-SENSITIZATION; PEANUT; CHILDREN; PREVALENCE; DEGRANULATION; METAANALYSIS; TOLERANCE; CULTURE	Background: Food allergy is an increasing public health issue and the most common cause of life-threatening anaphylactic reactions. Conventional allergy tests assess for the presence of allergen-specific IgE, significantly overestimating the rate of true clinical allergy and resulting in overdiagnosis and adverse effect on health-related quality of life. Objective: To undertake initial validation and assessment of a novel diagnostic tool, we used the mast cell activation test (MAT). Methods: Primary human blood-derived mast cells (MCs) were generated from peripheral blood precursors, sensitized with patients' sera, and then incubated with allergen. MC degranulation was assessed by means of flow cytometry and mediator release. We compared the diagnostic performance of MATs with that of existing diagnostic tools to assess in a cohort of peanut-sensitized subjects undergoing double-blind, placebo-controlled challenge. Results: Human blood-derived MCs sensitized with sera from patients with peanut, grass pollen, and Hymenoptera (wasp venom) allergy demonstrated allergen-specific and dose-dependent degranulation, as determined based on both expression of surface activation markers (CD63 and CD107a) and functional assays (prostaglandin D-2 and beta-hexosaminidase release). In this cohort of peanut-sensitized subjects, the MAT was found to have superior discrimination performance compared with other testing modalities, including component-resolved diagnostics and basophil activation tests. Using functional principle component analysis, we identified 5 clusters or patterns of reactivity in the resulting dose-response curves, which at preliminary analysis corresponded to the reaction phenotypes seen at challenge. Conclusion: The MAT is a robust tool that can confer superior diagnostic performance compared with existing allergy diagnostics and might be useful to explore differences in effector cell function between basophils and MCs during allergic reactions.	[Bahri, Rajia; Barron, Martin; Wu, Jiakai; Bulfone-Paus, Silvia] Univ Manchester, Sch Biol Sci, Div Musculoskeletal & Dermatol Sci, Manchester, Lancs, England; [Bahri, Rajia; Barron, Martin; Wu, Jiakai; Bulfone-Paus, Silvia] Univ Manchester, Sch Biol Sci, MCCIR, Manchester, Lancs, England; [Custovic, Adnan; Ruiz-Garcia, Monica; Patel, Nandinee; Fontanella, Sara; Turner, Paul J.] Imperial Coll London, Dept Med, Paediat Sect, London, England; [Shamji, Mohamed H.] Imperial Coll London, Natl Heart & Lung Inst, Sect Allergy & Clin Immunol, London, England; [Korosec, Peter; Silar, Mira] Univ Hosp Resp & Allerg Dis, Lab Clin Immunol & Mol Genet, Golnik, Slovenia; [Tsoumani, Marina; Sayers, Rebekah; Robb, Abigail; Mills, E. N. Clare; Simpson, Angela] Univ Manchester, Sch Biol Sci, Div Infect Immun & Resp Med, Manchester, Lancs, England; [Tsoumani, Marina; Sayers, Rebekah; Robb, Abigail; Mills, E. N. Clare; Simpson, Angela] Cent Manchester Univ Hosp NHS Fdn Trust, NIHR Manchester Biomed Res Ctr, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England; [Weimann, Alf] EUROIMMUN AG, Lubeck, Germany	University of Manchester; University of Manchester; Imperial College London; Imperial College London; University Clinic Golnik; University of Manchester; University of Manchester; EUROIMMUN	Bulfone-Paus, S (corresponding author), Univ Manchester, Sch Biol Sci, Core Technol Facil, MCCIR,FBMH, Room 2-18a,46 Grafton St, Manchester M13 9PT, Lancs, England.; Turner, PJ (corresponding author), Imperial Coll London, Paediat Sect, Norfolk Pl, London W2 1PG, England.	p.tumer@imperial.ac.uk; silvia.bulfone-paus@manchester.ac.uk	Patel, Nandinee/Y-2927-2019; Custovic, Adnan/A-2435-2012; Bahri, Rajia/ABE-1725-2021; Fontanella, Sara/ABA-7890-2021; Shamji, Mohamed/AAD-1788-2019; Shamji, Mohamed/AAU-8811-2020	Patel, Nandinee/0000-0002-4997-9411; Custovic, Adnan/0000-0001-5218-7071; Shamji, Mohamed/0000-0003-3425-3463; Simpson, Angela/0000-0003-2733-6666; wu, jiakai/0000-0002-1494-5633; Turner, Paul/0000-0001-9862-5161	Medical Research Council (MRC) Confidence-in-Concepts award [MC-PC-15038]; MRC Clinician Scientist [MR/K010468/1]; National Institute for Health Research (NIHR) Clinical Research Facility; Manchester Allergy and Respiratory Thoracic Surgery (Man-ARTS) Biobank at University Hospital of South Manchester National Health Service (NHS) Foundation Trust; NIHR Manchester Biomedical Research Centre; NIHR Biomedical Research Centre based at Imperial College Healthcare NHS Trust and Imperial College London; European Union's Seventh Framework Program for research, technological development, and demonstration [312147]; Slovenian Research Agency [J3-6787]; UK Biotechnology and Biological Sciences Research Council through a cooperative award in science and engineering with Campden BRI; Imperial/NIHR Biomedical Research Centre; MRC [MC_PC_16053, MR/K010468/1, MC_PC_15038] Funding Source: UKRI	Medical Research Council (MRC) Confidence-in-Concepts award(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC Clinician Scientist(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Institute for Health Research (NIHR) Clinical Research Facility(National Institute for Health Research (NIHR)); Manchester Allergy and Respiratory Thoracic Surgery (Man-ARTS) Biobank at University Hospital of South Manchester National Health Service (NHS) Foundation Trust; NIHR Manchester Biomedical Research Centre(National Institute for Health Research (NIHR)); NIHR Biomedical Research Centre based at Imperial College Healthcare NHS Trust and Imperial College London; European Union's Seventh Framework Program for research, technological development, and demonstration; Slovenian Research Agency(Slovenian Research Agency - Slovenia); UK Biotechnology and Biological Sciences Research Council through a cooperative award in science and engineering with Campden BRI(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Imperial/NIHR Biomedical Research Centre; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Supported by the following grants: Medical Research Council (MRC) Confidence-in-Concepts award to the University of Manchester (sub-award to S.B.-P. and P.J.T., reference MC-PC-15038); an MRC Clinician Scientist award funded (reference MR/K010468/1; to P.J.T.); and National Institute for Health Research (NIHR) Clinical Research Facility and Manchester Allergy and Respiratory Thoracic Surgery (Man-ARTS) Biobank at University Hospital of South Manchester National Health Service (NHS) Foundation Trust, which is supported by the NIHR Manchester Biomedical Research Centre. The clinical challenges were funded through the NIHR Biomedical Research Centre based at Imperial College Healthcare NHS Trust and Imperial College London; the European Union's Seventh Framework Program for research, technological development, and demonstration under grant agreement no. 312147 (Integrated Approaches to Food Allergen and Allergy Risk Management [iFAAM]); and the Slovenian Research Agency (reference J3-6787). R.S. was supported by the UK Biotechnology and Biological Sciences Research Council through a cooperative award in science and engineering with Campden BRI. P.J.T. and A.C. are supported by the Imperial/NIHR Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily those of the NHS, NIHR, or the Department of Health.	Blanc F, 2009, CLIN EXP ALLERGY, V39, P1277, DOI 10.1111/j.1365-2222.2009.03294.x; Charrad M, 2014, J STAT SOFTW, V61, P1; Custovic A, 2011, J ALLERGY CLIN IMMUN, V127, P631, DOI 10.1016/j.jaci.2011.01.026; Dwyer DF, 2016, NAT IMMUNOL, V17, P878, DOI 10.1038/ni.3445; Eisenberg DTA, 2016, INT J EPIDEMIOL, V45, P1295, DOI 10.1093/ije/dyw191; Falissard B, 2011, COMPUTER METHODS PRO, V104, P112; Gentinetta T, 2011, J ALLERGY CLIN IMMUN, V128, P1227, DOI 10.1016/j.jaci.2011.07.021; Hoffmann HJ, 2015, ALLERGY, V70, P1393, DOI 10.1111/all.12698; Huang H, 2016, SEMIN IMMUNOPATHOL, V38, P539, DOI 10.1007/s00281-016-0562-4; Johansson SGO, 2005, ALLERGY, V60, P1192, DOI 10.1111/j.1398-9995.2005.00870.x; Joulia R, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7174; Kirshenbaum AS, 2014, INT ARCH ALLERGY IMM, V164, P265, DOI 10.1159/000365729; Korosec P, 2015, CLIN EXP ALLERGY, V45, P1579, DOI 10.1111/cea.12582; Korosec P, 2017, J ALLERGY CLIN IMMUN, V140, P750, DOI 10.1016/j.jaci.2016.12.989; Ladics GS, 2008, REGUL TOXICOL PHARM, V51, P288, DOI 10.1016/j.yrtph.2008.04.012; MacGlashan DW, 2013, J ALLERGY CLIN IMMUN, V132, P777, DOI 10.1016/j.jaci.2013.06.038; Masthoff LJN, 2013, J ALLERGY CLIN IMMUN, V132, P393, DOI 10.1016/j.jaci.2013.02.024; Metcalfe DD, 2016, WORLD ALLERGY ORGAN, V9, DOI 10.1186/s40413-016-0094-3; Mukai K, 2017, J ALLERGY CLIN IMMUN, V139, P889, DOI 10.1016/j.jaci.2016.04.060; Nicolaou N, 2011, CURR OPIN ALLERGY CL, V11, P222, DOI 10.1097/ACI.0b013e32834656c2; Nicolaou N, 2010, J ALLERGY CLIN IMMUN, V125, P191, DOI 10.1016/j.jaci.2009.10.008; Nwaru BI, 2014, ALLERGY, V69, P992, DOI 10.1111/all.12423; Osborne NJ, 2011, J ALLERGY CLIN IMMUN, V127, P668, DOI 10.1016/j.jaci.2011.01.039; Passante Egle, 2014, Methods Mol Biol, V1192, P101, DOI 10.1007/978-1-4939-1173-8_8; Patelis A, 2016, CLIN EXP ALLERGY, V46, P1022, DOI 10.1111/cea.12761; Reber LL, 2017, J ALLERGY CLIN IMMUN, V140, P335, DOI 10.1016/j.jaci.2017.06.003; Roberts G, 2016, ALLERGY, V71, P1540, DOI 10.1111/all.12939; Saito H, 2006, NAT PROTOC, V1, P2178, DOI 10.1038/nprot.2006.344; Sampson HA, 2012, J ALLERGY CLIN IMMUN, V130, P1260, DOI 10.1016/j.jaci.2012.10.017; Santos AF, 2017, CLIN EXP ALLERGY, V47, P1115, DOI 10.1111/cea.12964; Santos AF, 2016, CLIN TRANSL ALLERGY, V6, DOI 10.1186/s13601-016-0098-7; Santos AF, 2015, J ALLERGY CLIN IMMUN, V135, P1249, DOI 10.1016/j.jaci.2015.01.012; Santos AF, 2014, J ALLERGY CLIN IMMUN, V134, P645, DOI 10.1016/j.jaci.2014.04.039; Schmetzer O, 2014, J IMMUNOL METHODS, V413, P62, DOI 10.1016/j.jim.2014.07.003; Sicherer SH, 2017, PEDIATRICS; Silverman BW, 2005, FUNCTIONAL DATA ANAL; Soares-Weiser K, 2014, ALLERGY, V69, P76, DOI 10.1111/all.12333; Thomas K, 2008, FOOD CHEM TOXICOL, V46, P3219, DOI 10.1016/j.fct.2008.06.078; Turner PJ, 2015, J ALLERGY CLIN IMMUN, V135, P956, DOI 10.1016/j.jaci.2014.10.021; Turner PJ, 2014, CURR OPIN CLIN NUTR, V17, P285, DOI 10.1097/MCO.0000000000000052	40	74	80	1	32	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2018	142	2					485	+		10.1016/j.jaci.2018.01.043	http://dx.doi.org/10.1016/j.jaci.2018.01.043			28	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GP2LN	29518421	hybrid, Green Published			2022-12-18	WOS:000440664400017
J	Szefler, SJ; Murphy, K; Harper, T; Boner, A; Laki, I; Engel, M; El Azzi, G; Moroni-Zentgraf, P; Finnigan, H; Hamelmann, E				Szefler, Stanley J.; Murphy, Kevin; Harper, Thomas, III; Boner, Attilio; Laki, Istvan; Engel, Michael; El Azzi, Georges; Moroni-Zentgraf, Petra; Finnigan, Helen; Hamelmann, Eckard			A phase III randomized controlled trial of tiotropium add-on therapy in children with severe symptomatic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Anticholinergic drug; asthma; asthma control; children; efficacy; FEV1; lung function; Respimat; safety; tiotropium	QUALITY-OF-LIFE; LUNG-FUNCTION; INHALED CORTICOSTEROIDS; ADOLESCENTS; SALMETEROL; IMPACT; EXACERBATIONS; QUESTIONNAIRE; TRAJECTORIES; ADHERENCE	Background: Studies in adults and adolescents have demonstrated that tiotropium is efficacious as an add-on therapy to inhaled corticosteroids (ICSs) with or without other maintenance therapies in patients with moderate or severe symptomatic asthma. Objective: We sought to assess the efficacy and safety of once-daily tiotropium Respimat add-on therapy to high-dose ICS with 1 or more controller medications, or medium-dose ICS with 2 or more controller medications, in the first phase III trial of tiotropium in children with severe symptomatic asthma. Methods: In this 12-week, double-blind, placebo-controlled, parallel-group trial, 401 participants aged 6 to 11 years were randomized to receive once-daily tiotropium 5 mu g (2 puffs of 2.5 mu g) or 2.5 mu g (2 puffs of 1.25 mu g), or placebo (2 puffs), administered through the Respimat device as add-on to background therapy. Results: Compared with placebo, tiotropium 5 mg, but not 2.5 mg, add-on therapy improved the primary end point, peak FEV1 within 3 hours after dosing (5 mu g, 139 mL [95% CI, 75-203; P < .001]; 2.5 mu g, 35 mL [95% CI, -28 to 99; P 5.27]), and the key secondary end point, trough FEV1 (5 mu g, 87 mL [95% CI, 19-154; P = .01]; 2.5 mu g, 18 mL [95% CI, -48 to 85; P = .59]). The safety and tolerability of tiotropium were comparable with those of placebo. Conclusions: Once-daily tiotropium Respimat 5 mu g improved lung function and was well tolerated as add-on therapy to ICS with other maintenance therapies in children with severe symptomatic asthma.	[Szefler, Stanley J.] Childrens Hosp Colorado, Dept Pediat, 13123 E 16th Ave, Aurora, CO 80045 USA; [Szefler, Stanley J.] Univ Colorado, Sch Med, Breathing Inst, 13123 E 16th Ave, Aurora, CO 80045 USA; [Murphy, Kevin] Boys Town Natl Res Hosp, Boys Town, NE USA; [Harper, Thomas, III] Charleston Allergy & Asthma, Charleston, SC USA; [Boner, Attilio] Policlin G Rossi, Dipartimento Sperimentale Pediat, UO Pediat, Verona, Italy; [Laki, Istvan] Dept Paediat Pulmonol, Torokbalint, Hungary; [Engel, Michael; El Azzi, Georges] Boehringer Ingelheim Pharma GmbH & Co KG, Therapeut Area Resp Dis, Ingelheim, Germany; [Moroni-Zentgraf, Petra] Boehringer Ingelheim GmbH & Co KG, Sydney, NSW, Australia; [Finnigan, Helen] Boehringer Ingelheim GmbH & Co KG, Biostat & Data Sci, Bracknell, Berks, England; [Hamelmann, Eckard] Evangel Krankenhaus Bielefeld, Bielefeld, Germany; [Hamelmann, Eckard] Ruhr Univ, Allergy Ctr, Bochum, Germany	Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Boys Town National Research Hospital; University of Verona; Azienda Ospedaliera Universitaria Integrata Verona; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Evangelical Hospital Bethel (EvKB) - House Gilead I; Ruhr University Bochum	Szefler, SJ (corresponding author), Childrens Hosp Colorado, Dept Pediat, 13123 E 16th Ave, Aurora, CO 80045 USA.; Szefler, SJ (corresponding author), Univ Colorado, Sch Med, Breathing Inst, 13123 E 16th Ave, Aurora, CO 80045 USA.	Stanley.Szefler@childrenscolorado.org	Hamelmann, Eckard/AAJ-9124-2021	Szefler, Stanley/0000-0002-6911-3199	Boehringer Ingelheim Pharmaceuticals	Boehringer Ingelheim Pharmaceuticals(Boehringer Ingelheim)	Supported by Boehringer Ingelheim Pharmaceuticals. Efficacy and Safety of 2 Doses of Tiotropium Respimat Compared to Placebo in Children With Severe Persistent Asthma; ClinicalTrials.gov no. NCT01634152.	Anderson WC, 2015, J ALLERGY CLIN IMMUN, V136, P848, DOI 10.1016/j.jaci.2015.07.007; Asthma UK, ASTHMA FACTS FAQS; Bacharier LB, 2004, AM J RESP CRIT CARE, V170, P426, DOI 10.1164/rccm.200308-1178OC; Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC; Bateman ED, 2015, J ALLERGY CLIN IMMUN, V136, P914, DOI 10.1016/j.jaci.2015.03.023; Bateman ED, 2011, J ALLERGY CLIN IMMUN, V128, P315, DOI 10.1016/j.jaci.2011.06.004; Beeh KM, 2014, RESP RES, V15, DOI 10.1186/1465-9921-15-61; Belgrave DCM, 2014, AM J RESP CRIT CARE, V189, P1101, DOI 10.1164/rccm.201309-1700OC; Blackman JA, 2007, J DEV BEHAV PEDIATR, V28, P92, DOI 10.1097/01.DBP.0000267557.80834.e5; Burgess S, 2011, PULM MED, V2011, DOI 10.1155/2011/973849; Cabana MD, 2006, PEDIATRICS, V117, P2149, DOI 10.1542/peds.2005-1055; Cates CJ, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010005.pub2; Cates CJ, 2014, COCHRANE DB SYST REV, V2; Chowdhury BA, 2011, NEW ENGL J MED, V364, P2473, DOI 10.1056/NEJMp1104375; Custovic A, 2013, ALLERGY, V68, P1520, DOI 10.1111/all.12275; Dalby R, 2004, INT J PHARM, V283, P1, DOI 10.1016/j.ijpharm.2004.06.018; de Benedictis D, 2007, PEDIATR PULM, V42, P683, DOI 10.1002/ppul.20650; Demoly P, 2009, EUR RESPIR REV, V18, P105, DOI 10.1183/09059180.00001209; Desai M, 2011, CURR ALLERGY ASTHM R, V11, P454, DOI 10.1007/s11882-011-0227-2; Diette GB, 2000, ARCH PEDIAT ADOL MED, V154, P923, DOI 10.1001/archpedi.154.9.923; Fuhlbrigge AL, 2001, J ALLERGY CLIN IMMUN, V107, P61, DOI 10.1067/mai.2001.111590; Global Initiative For Asthma, 2016, GLOB STRAT ASTHM MAN; Gustafsson D, 2000, PEDIATR ALLERGY IMMU, V11, P241, DOI 10.1034/j.1399-3038.2000.00089.x; Gustafsson PM, 2006, INT J CLIN PRACT, V60, P321, DOI 10.1111/j.1368-5031.2006.00798.x; Hackshaw A, 2008, EUR RESPIR J, V32, P1141, DOI 10.1183/09031936.00136408; Hamelmann E, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.01100-2016; Hamelmann E, 2016, J ALLERGY CLIN IMMUN, V138, P441, DOI 10.1016/j.jaci.2016.01.011; Hedlin G, 2010, EUR RESPIR J, V36, P196, DOI 10.1183/09031936.00104809; Juniper EF, 2005, RESP MED, V99, P553, DOI 10.1016/j.rmed.2004.10.008; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; Kamps AWA, 2002, ACTA PAEDIATR, V91, P159, DOI 10.1080/080352502317285144; Kerstjens HAM, 2015, LANCET RESP MED, V3, P367, DOI 10.1016/S2213-2600(15)00031-4; Kerstjens HAM, 2012, NEW ENGL J MED, V367, P1198, DOI 10.1056/NEJMoa1208606; Kew KM, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011438.pub2; Lange P, 2015, NEW ENGL J MED, V373, P111, DOI 10.1056/NEJMoa1411532; Masoli M, 2004, ALLERGY, V59, P469, DOI 10.1111/j.1398-9995.2004.00526.x; McGeachie MJ, 2016, NEW ENGL J MED, V374, P1842, DOI 10.1056/NEJMoa1513737; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Montella S, 2013, PEDIATR PULM, V48, P1160, DOI 10.1002/ppul.22761; Navaratnam P, 2010, PATIENT PREFER ADHER, V4, P197; Ohta K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124109; Orrell-Valente JK, 2008, PEDIATRICS, V122, pE1186, DOI 10.1542/peds.2008-0292; Paggiaro P, 2016, J ALLER CL IMM-PRACT, V4, P104, DOI 10.1016/j.jaip.2015.08.017; Partridge MR, 2011, PRIM CARE RESP J, V20, P315, DOI 10.4104/pcrj.2011.00056; Price D, 2010, BMC PULM MED, V10, DOI 10.1186/1471-2466-10-1; Price David, 2002, Prim Care Respir J, V11, P30, DOI 10.1038/pcrj.2002.13; Quezada W, 2016, ANN ALLERG ASTHMA IM, V116, P112, DOI 10.1016/j.anai.2015.11.011; Rao DR, 2012, J ASTHMA, V49, P586, DOI 10.3109/02770903.2012.690481; Rau Joseph L, 2005, Respir Care, V50, P1346; Schmier JK, 2007, ANN ALLERG ASTHMA IM, V98, P245, DOI 10.1016/S1081-1206(10)60713-2; Simon MR, 2010, J ALLERGY CLIN IMMUN, V126, P527, DOI 10.1016/j.jaci.2010.05.016; Simons FER, 1997, PEDIATRICS, V99, P655, DOI 10.1542/peds.99.5.655; Stempel DA, 2016, NEW ENGL J MED, V375, P840, DOI 10.1056/NEJMoa1606356; Stempel DA, 2016, NEW ENGL J MED, V374, P1822, DOI 10.1056/NEJMoa1511049; Stores G, 1998, ARCH DIS CHILD, V78, P413, DOI 10.1136/adc.78.5.413; Teach SJ, 2015, J ALLERGY CLIN IMMUN, V135, P1465, DOI 10.1016/j.jaci.2014.12.1942; Thomas M, 2010, BMC PULM MED, V10, DOI 10.1186/1471-2466-10-29; Timmer W, 2015, RESP MED, V109, P329, DOI 10.1016/j.rmed.2014.12.005; Verver S, 1996, FAM PRACT, V13, P35, DOI 10.1093/fampra/13.1.35; Vogelberg C, 2014, RESP MED, V108, P1268, DOI 10.1016/j.rmed.2014.06.011; Weinstein AG, 2011, ANN ALLERG ASTHMA IM, V106, P283, DOI 10.1016/j.anai.2011.01.016	61	74	79	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2017	140	5					1277	1287		10.1016/j.jaci.2017.01.014	http://dx.doi.org/10.1016/j.jaci.2017.01.014			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FL5RV	28189771	hybrid			2022-12-18	WOS:000414304300008
J	Ewald, DA; Noda, S; Oliva, M; Litman, T; Nakajima, S; Li, X; Xu, H; Workman, CT; Scheipers, P; Svitacheva, N; Labuda, T; Krueger, JG; Suarez-Farinas, M; Kabashima, K; Guttman-Yassky, E				Ewald, David A.; Noda, Shinji; Oliva, Margeaux; Litman, Thomas; Nakajima, Saeko; Li, Xuan; Xu, Hui; Workman, Christopher T.; Scheipers, Peter; Svitacheva, Naila; Labuda, Tord; Krueger, James G.; Suarez-Farinas, Mayte; Kabashima, Kenji; Guttman-Yassky, Emma			Major differences between human atopic dermatitis and murine models, as determined by using global transcriptomic profiling	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; TH1; TH2; TH17; psoriasis; contact dermatitis; mouse model; NC/Nga; filaggrin; oxazolone; ovalbumin; IL-2	TOPICAL APPLICATION; SIGNAL TRANSDUCER; IMMUNE-RESPONSES; MAST-CELLS; SKIN; PSORIASIS; BARRIER; GENE; FEATURES; EXPRESSION	Background: Atopic dermatitis (AD) is caused by a complex interplay between immune and barrier abnormalities. Murine models of AD are essential for preclinical assessments of new treatments. Although many models have been used to simulate AD, their transcriptomic profiles are not fully understood, and a comparison of these models with the human AD transcriptomic fingerprint is lacking. Objective: We sought to evaluate the transcriptomic profiles of 6 common murine models and determine how they relate to human AD skin. Methods: Transcriptomic profiling was performed by using microarrays and quantitative RT-PCR on biopsy specimens from NC/Nga, flaky tail, Flg-mutated, ovalbumin-challenged, oxazolone-challenged, and IL-23-injected mice. Gene expression data of patients with AD, psoriasis, and contact dermatitis were obtained from previous patient cohorts. Criteria of a fold change of 2 or greater and a false discovery rate of 0.05 or less were used for gene arrays. Results: IL-23-injected, NC/Nga, and oxazolone-challenged mice show the largest homology with our human meta-analysisderived AD transcriptome (37%, 18%, 17%, respectively). Similar to human AD, robust T(H)1, T(H)2, and also T(H)17 activation are seen in IL-23-injected and NC/Nga mice, with similar but weaker inflammation in ovalbumin-challenged mice. Oxazolone-challenged mice show a TH1-centered reaction, and flaky tail mice demonstrate a strong TH17 polarization. Flg-mutated mice display filaggrin downregulation without significant inflammation. Conclusion: No single murine model fully captures all aspects of the AD profile; instead, each model reflects different immune or barrier disease aspects. Overall, among the 6 murine models, IL-23-injected mice best simulate human AD; still, the translational focus of the investigation should determine which model is most applicable.	[Ewald, David A.; Noda, Shinji; Li, Xuan; Krueger, James G.; Suarez-Farinas, Mayte; Guttman-Yassky, Emma] Rockefeller Univ, Invest Dermatol Lab, 1230 York Ave, New York, NY 10021 USA; [Ewald, David A.; Litman, Thomas; Scheipers, Peter] LEO Pharma AS, Exploratory Biol, Ballerup, Denmark; [Ewald, David A.; Workman, Christopher T.] Tech Univ Denmark, Ctr Biol Sequence Anal, Dept Syst Biol, Regulatory Genom,Integrat Syst Biol, Lyngby, Denmark; [Oliva, Margeaux; Xu, Hui; Guttman-Yassky, Emma] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY 10029 USA; [Oliva, Margeaux; Guttman-Yassky, Emma] Icahn Sch Med Mt Sinai, Lab Inflammatory Skin Dis, New York, NY 10029 USA; [Suarez-Farinas, Mayte] Icahn Sch Med Mt Sinai, Dept Dermatol, Dept Populat Hlth Sci & Policy, New York, NY 10029 USA; [Suarez-Farinas, Mayte] Icahn Sch Med Mt Sinai, Icahn Inst Genom & Multiscale Biol, New York, NY 10029 USA; [Litman, Thomas] Univ Copenhagen, Fac Hlth & Med Sci, Dept Immunol & Microbiol, Copenhagen, Denmark; [Nakajima, Saeko; Kabashima, Kenji] Kyoto Univ, Grad Sch Med, Dept Dermatol, Kyoto, Japan; [Svitacheva, Naila] LEO Pharma AS, Vivo Biol, Ballerup, Denmark; [Labuda, Tord] LEO Pharma AS, Translat Med, Ballerup, Denmark; [Kabashima, Kenji] ASTAR, Singapore Immunol Network SIgN, Singapore, Singapore; [Kabashima, Kenji] ASTAR, Inst Med Biol, Singapore, Singapore	Rockefeller University; LEO Pharma; Technical University of Denmark; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; University of Copenhagen; Kyoto University; LEO Pharma; LEO Pharma; Agency for Science Technology & Research (A*STAR); A*STAR - Singapore Immunology Network (SIgN); Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Medical Biology (IMB)	Guttman-Yassky, E (corresponding author), Icahn Sch Med Mt Sinai, Med Ctr, Dept Dermatol, 5 E 98th St, New York, NY 10029 USA.	Emma.Guttman@mountsinai.org	Workman, Christopher T/K-1066-2015; Nakajima, Saeko/AAB-1577-2021; Kabashima, Kenji/G-2521-2014	Workman, Christopher T/0000-0002-2210-3743; Litman, Thomas/0000-0002-6068-901X; Kabashima, Kenji/0000-0002-0773-0554; Ewald, David Adrian/0000-0001-6620-2738; Nakajima, Saeko/0000-0003-0831-1447	LEO Pharma; National Center for Research Resources (NCRR), National Institutes of Health (NIH) [5UL1RR024143-02]; Danish Ministry of Science and Higher Education; NIH Roadmap for Medical Research; Grants-in-Aid for Scientific Research [15H05790] Funding Source: KAKEN	LEO Pharma(LEO Pharma); National Center for Research Resources (NCRR), National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Danish Ministry of Science and Higher Education; NIH Roadmap for Medical Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	Supported by a research grant (to E.G.-Y.) from LEO Pharma A/S. S.N., M.S.-F., and J.G.K. were supported by grant no. 5UL1RR024143-02 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and the NIH Roadmap for Medical Research. D.A.E. is partly funded by the Danish Ministry of Science and Higher Education.	Amano W, 2015, J ALLERGY CLIN IMMUN, V136, P667, DOI 10.1016/j.jaci.2015.03.051; Ando T, 2013, J INVEST DERMATOL, V133, P2695, DOI 10.1038/jid.2013.250; Anthoni M, 2007, J INVEST DERMATOL, V127, P1923, DOI 10.1038/sj.jid.5700809; Bae IH, 2010, J DERMATOL SCI, V59, P57, DOI 10.1016/j.jdermsci.2010.04.008; Beck LA, 2014, NEW ENGL J MED, V371, P130, DOI 10.1056/NEJMoa1314768; Bonefeld CM, 2016, BRIT J DERMATOL, V175, P706, DOI 10.1111/bjd.14570; Bromley SK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058196; Carretero M, 2016, J INVEST DERMATOL, V136, P136, DOI 10.1038/JID.2015.362; Chan JR, 2006, J EXP MED, V203, P2577, DOI 10.1084/jem.20060244; da Rosa JC, 2015, J ALLERGY CLIN IMMUN, V135, P712, DOI 10.1016/j.jaci.2014.11.017; Danso MO, 2014, J INVEST DERMATOL, V134, P1941, DOI 10.1038/jid.2014.83; De Benedetto A, 2011, J ALLERGY CLIN IMMUN, V127, P773, DOI 10.1016/j.jaci.2010.10.018; Dhingra N, 2014, J ALLERGY CLIN IMMUN, V134, P362, DOI 10.1016/j.jaci.2014.03.009; Durinck S, 2005, BIOINFORMATICS, V21, P3439, DOI 10.1093/bioinformatics/bti525; Esaki H, 2015, J ALLERGY CLIN IMMUN, V135, P153, DOI 10.1016/j.jaci.2014.10.037; Ewald DA, 2015, BMC MED GENOMICS, V8, DOI 10.1186/s12920-015-0133-x; Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405; Gittler JK, 2012, J ALLERGY CLIN IMMUN, V130, P1344, DOI 10.1016/j.jaci.2012.07.012; Groneberg DA, 2005, ALLERGY, V60, P90, DOI 10.1111/j.1398-9995.2004.00628.x; Guttman-Yassky E, 2011, J ALLERGY CLIN IMMUN, V127, P1110, DOI 10.1016/j.jaci.2011.01.053; Hamilton JD, 2014, J ALLERGY CLIN IMMUN, V134, P1293, DOI 10.1016/j.jaci.2014.10.013; Hay RJ, 2014, J INVEST DERMATOL, V134, P1527, DOI 10.1038/jid.2013.446; Hedrick MN, 2009, J CLIN INVEST, V119, P2317, DOI 10.1172/JCI37378; Hodak E, 1996, J INVEST DERMATOL, V106, P564, DOI 10.1111/1523-1747.ep12344044; Howell MD, 2007, J ALLERGY CLIN IMMUN, V120, P150, DOI 10.1016/j.jaci.2007.04.031; Johnson-Huang LM, 2010, J INVEST DERMATOL, V130, P2654, DOI 10.1038/jid.2010.166; Kabashima K, 2013, J DERMATOL SCI, V70, P3, DOI 10.1016/j.jdermsci.2013.02.001; Kawasaki H, 2012, J ALLERGY CLIN IMMUN, V129, P1538, DOI 10.1016/j.jaci.2012.01.068; Khattri S, 2014, J ALLERGY CLIN IMMUN, V133, P1626, DOI 10.1016/j.jaci.2014.03.003; Koga C, 2008, J INVEST DERMATOL, V128, P2625, DOI 10.1038/jid.2008.111; Kuo IH, 2013, J INVEST DERMATOL, V133, P988, DOI 10.1038/jid.2012.437; Li M, 2006, P NATL ACAD SCI USA, V103, P11736, DOI 10.1073/pnas.0604575103; Lottaz C, 2006, BIOINFORMATICS, V22, P2315, DOI 10.1093/bioinformatics/btl385; Man MQ, 2008, J INVEST DERMATOL, V128, P79, DOI 10.1038/sj.jid.5701011; Matsuda H, 1997, INT IMMUNOL, V9, P461, DOI 10.1093/intimm/9.3.461; Moniaga CS, 2010, AM J PATHOL, V176, P2385, DOI 10.2353/ajpath.2010.090957; Nakajima S, 2014, J INVEST DERMATOL, V134, P2122, DOI 10.1038/jid.2014.51; Noda S, 2015, J ALLERGY CLIN IMMUN, V136, P1254, DOI 10.1016/j.jaci.2015.08.015; Noda S, 2015, J ALLERGY CLIN IMMUN, V135, P324, DOI 10.1016/j.jaci.2014.11.015; Osawa Rinko, 2011, Allergology International, V60, P1, DOI 10.2332/allergolint.10-RAI-0270; Otsuka A, 2014, J ALLERGY CLIN IMMUN, V133; Oyoshi MK, 2009, J ALLERGY CLIN IMMUN, V124, P485, DOI 10.1016/j.jaci.2009.05.042; Quaranta M, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008946; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Rivals I, 2007, BIOINFORMATICS, V23, P401, DOI 10.1093/bioinformatics/btl633; Sasaki T, 2013, J ALLERGY CLIN IMMUN, V132, P1111, DOI 10.1016/j.jaci.2013.08.027; Saunders SP, 2013, J ALLERGY CLIN IMMUN, V132, P1121, DOI 10.1016/j.jaci.2013.08.046; Shemer A, 2013, J ALLERGY CLIN IMMUN, V131, P577, DOI 10.1016/j.jaci.2012.11.010; Shimodaira H, 2002, SYST BIOL, V51, P492, DOI 10.1080/10635150290069913; Shroff Anjali, 2015, JAAD Case Rep, V1, P25, DOI 10.1016/j.jdcr.2014.10.007; Simon D, 2004, ALLERGY, V59, P561, DOI 10.1111/j.1398-9995.2004.00476.x; Spergel JM, 1998, J CLIN INVEST, V101, P1614, DOI 10.1172/JCI1647; Spergel JM, 1999, J CLIN INVEST, V103, P1103, DOI 10.1172/JCI5669; Strid J, 2016, J INVEST DERMATOL, V136, P561, DOI 10.1016/j.jid.2015.12.025; Suarez-Farinas M, 2015, J ALLERGY CLIN IMMUN, V135, P1218, DOI 10.1016/j.jaci.2015.03.003; Suarez-Farinas M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084634; Suarez-Farinas M, 2013, J ALLERGY CLIN IMMUN, V132, P361, DOI 10.1016/j.jaci.2013.04.046; Suarez-Farinas M, 2011, J ALLERGY CLIN IMMUN, V127, P954, DOI 10.1016/j.jaci.2010.12.1124; Suarez-Farinas M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010247; Swindell WR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033204; Swindell WR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018266; Thaci D, 2016, LANCET, V387, P40, DOI 10.1016/S0140-6736(15)00388-8; Thyssen JP, 2014, J ALLERGY CLIN IMMUN, V134, P792, DOI 10.1016/j.jaci.2014.06.014; Tian SY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044274; Tintle S, 2011, J ALLERGY CLIN IMMUN, V128, P583, DOI 10.1016/j.jaci.2011.05.042; Turner MJ, 2013, PEDIATR DERMATOL, V30, P574, DOI 10.1111/pde.12187; Wang G, 2007, CLIN EXP ALLERGY, V37, P151, DOI 10.1111/j.1365-2222.2006.02621.x; Westerberg R, 2004, J BIOL CHEM, V279, P5621, DOI 10.1074/jbc.M310529200; Yang Xinan, 2006, Journal of Bioinformatics and Computational Biology, V4, P693, DOI 10.1142/S0219720006002120; Zhang J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/450386	70	74	76	0	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2017	139	2					562	571		10.1016/j.jaci.2016.08.029	http://dx.doi.org/10.1016/j.jaci.2016.08.029			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EO9IM	27702671	Bronze, Green Submitted			2022-12-18	WOS:000397002400022
J	Barcik, W; Pugin, B; Westermann, P; Perez, NR; Ferstl, R; Wawrzyniak, M; Smolinska, S; Jutel, M; Hessel, EM; Michalovich, D; Akdis, CA; Frei, R; O'Mahony, L				Barcik, Weronika; Pugin, Benoit; Westermann, Patrick; Perez, Noelia Rodriguez; Ferstl, Ruth; Wawrzyniak, Marcin; Smolinska, Sylwia; Jutel, Marek; Hessel, Edith M.; Michalovich, David; Akdis, Cezmi A.; Frei, Remo; O'Mahony, Liam			Histamine-secreting microbes are increased in the gut of adult asthma patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Barcik, Weronika; Pugin, Benoit; Westermann, Patrick; Perez, Noelia Rodriguez; Ferstl, Ruth; Wawrzyniak, Marcin; Akdis, Cezmi A.; Frei, Remo; O'Mahony, Liam] Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Davos, Switzerland; [Smolinska, Sylwia; Jutel, Marek] Wroclaw Med Univ, Dept Clin Immunol, Wroclaw, Poland; [Smolinska, Sylwia; Jutel, Marek] Wroclaw Med Univ, ALL MED Med Res Inst, Wroclaw, Poland; [Hessel, Edith M.; Michalovich, David] GlaxoSmithKline, Stevenage, Herts, England; [Akdis, Cezmi A.; Frei, Remo] CK CARE, Davos, Switzerland	Swiss Institute of Allergy & Asthma Research; University of Zurich; Wroclaw Medical University; Wroclaw Medical University; GlaxoSmithKline	O'Mahony, L (corresponding author), Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Davos, Switzerland.	liam.omahony@siaf.uzh.ch	Barcik, Weronika/L-5094-2019; Wawrzyniak, Marcin/E-5878-2017; Hessel, Edith M/AAB-6002-2021; Wawrzyniak, Marcin/AAT-9094-2021; Pugin, Benoit/X-2984-2018; Ferstl, Ruth/ABB-9679-2021; O'Mahony, Liam/AAG-5838-2019; Frei, Remo/AAI-9180-2020; Akdis, Cezmi/AAV-4844-2020; Smolinska, Sylwia/ABH-7971-2020	Hessel, Edith M/0000-0002-2339-4482; Wawrzyniak, Marcin/0000-0002-6911-8010; Pugin, Benoit/0000-0001-7132-9477; O'Mahony, Liam/0000-0003-4705-3583; Akdis, Cezmi/0000-0001-8020-019X; Smolinska, Sylwia/0000-0001-6736-2696; Michalovich, David/0000-0003-4452-5776; Barcik, Weronika/0000-0001-8580-9690; JUTEL, MAREK/0000-0003-1555-9379				Arrieta MC, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab2271; Feng C, 2016, CLIN REV ALLERG IMMU, V50, P64, DOI 10.1007/s12016-015-8467-x; Ferstl R, 2014, J ALLERGY CLIN IMMUN, V134, P744, DOI 10.1016/j.jaci.2014.04.034; Frei R, 2012, ALLERGY, V67, P451, DOI 10.1111/j.1398-9995.2011.02783.x; Gao CX, 2015, MBIO, V6, DOI 10.1128/mBio.01358-15; Huang YJ, 2015, J ALLERGY CLIN IMMUN, V135, P25, DOI 10.1016/j.jaci.2014.11.011; Marsland BJ, 2015, ANN AM THORAC SOC, V12, pS150, DOI 10.1513/AnnalsATS.201503-133AW; O'Mahony L, 2011, J ALLERGY CLIN IMMUN, V128, P1153, DOI 10.1016/j.jaci.2011.06.051; Smolinska S, 2014, ALLERGY, V69, P273, DOI 10.1111/all.12330	9	74	76	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2016	138	5					1491	1494		10.1016/j.jaci.2016.05.049	http://dx.doi.org/10.1016/j.jaci.2016.05.049			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EE4AA	27576125	Bronze			2022-12-18	WOS:000389542700043
J	Bonvini, SJ; Birrell, MA; Grace, MS; Maher, SA; Adcock, JJ; Wortley, MA; Dubuis, E; Ching, YM; Ford, AP; Shala, F; Miralpeix, M; Tarrason, G; Smith, JA; Belvisi, MG				Bonvini, Sara J.; Birrell, Mark A.; Grace, Megan S.; Maher, Sarah A.; Adcock, John J.; Wortley, Michael A.; Dubuis, Eric; Ching, Yee-Man; Ford, Anthony P.; Shala, Fisnik; Miralpeix, Montserrat; Tarrason, Gema; Smith, Jaclyn A.; Belvisi, Maria G.			Transient receptor potential cation channel, subfamily V, member 4 and airway sensory afferent activation: Role of adenosine triphosphate	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Transient receptor potential; sensory nerves; vagus; cough; ion channels; hypotonicity; ATP	OBSTRUCTIVE PULMONARY-DISEASE; MICE LACKING TRPV4; ATP RELEASE; GUINEA-PIG; CITRIC-ACID; ION-CHANNEL; COUGH; CHALLENGE; SENSATION; CAPSAICIN	Background: Sensory nerves innervating the airways play an important role in regulating various cardiopulmonary functions, maintaining homeostasis under healthy conditions and contributing to pathophysiology in disease states. Hypoosmotic solutions elicit sensory reflexes, including cough, and are a potent stimulus for airway narrowing in asthmatic patients, but the mechanisms involved are not known. Transient receptor potential cation channel, subfamily V, member 4 (TRPV4) is widely expressed in the respiratory tract, but its role as a peripheral nociceptor has not been explored. Objective: We hypothesized that TRPV4 is expressed on airway afferents and is a key osmosensor initiating reflex events in the lung. Methods: We used guinea pig primary cells, tissue bioassay, in vivo electrophysiology, and a guinea pig conscious cough model to investigate a role for TRPV4 in mediating sensory nerve activation in vagal afferents and the possible downstream signaling mechanisms. Human vagus nerve was used to confirm key observations in animal tissues. Results: Here we show TRPV4-induced activation of guinea pig airway-specific primary nodose ganglion cells. TRPV4 ligands and hypo-osmotic solutions caused depolarization of murine, guinea pig, and human vagus and firing of Ad-fibers (not C-fibers), which was inhibited by TRPV4 and P2X3 receptor antagonists. Both antagonists blocked TRPV4-induced cough. Conclusion: This study identifies the TRPV4-ATP-P2X3 interaction as a key osmosensing pathway involved in airway sensory nerve reflexes. The absence of TRPV4-ATP-mediated effects on C-fibers indicates a distinct neurobiology for this ion channel and implicates TRPV4 as a novel therapeutic target for neuronal hyperresponsiveness in the airways and symptoms, such as cough.	[Bonvini, Sara J.; Birrell, Mark A.; Maher, Sarah A.; Adcock, John J.; Wortley, Michael A.; Dubuis, Eric; Shala, Fisnik; Belvisi, Maria G.] Imperial Coll London, Resp Pharmacol Grp, Airway Dis Sect, Natl Heart & Lung Inst, Exhibit Rd, London SW7 2AZ, England; [Ching, Yee-Man] Imperial Coll London, Airway Dis Infect Sect, Natl Heart & Lung Inst, London, England; [Grace, Megan S.] RMIT Univ, Sch Med Sci, Bundoora, Vic, Australia; [Grace, Megan S.] RMIT Univ, Hlth Innovat Res Inst, Bundoora, Vic, Australia; [Smith, Jaclyn A.] Univ Manchester, Univ Hosp South Manchester, Resp & Allergy Ctr, Manchester, Lancs, England; [Ford, Anthony P.] Afferent Pharmaceut, San Mateo, CA USA; [Miralpeix, Montserrat; Tarrason, Gema] Almirall SA, R&D Ctr, Resp Therapeut Area Discovery, Barcelona, Spain	Imperial College London; Imperial College London; Royal Melbourne Institute of Technology (RMIT); Royal Melbourne Institute of Technology (RMIT); University of Manchester; Wythenshawe Hospital NHS Foundation Trust; Almirall	Belvisi, MG (corresponding author), Imperial Coll London, Resp Pharmacol Grp, Airway Dis Sect, Natl Heart & Lung Inst, Exhibit Rd, London SW7 2AZ, England.	m.belvisi@imperial.ac.uk	Grace, Megan/AAA-7285-2019	Smith, Jaclyn/0000-0001-8837-4928; Bonvini, Sara/0000-0002-5292-8316	Medical Research Council (MRC, UK) [G0800195, MR/K020293/1]; MRC studentship; MRC/Asthma UK Centre studentship; National Heart and Lung Institute; North West Lung Centre Charity; NIHR Respiratory Disease Biomedical Research Unit at the Royal Brompton and Harefield NHS Foundation Trust and Imperial College London; Imperial Confidence in Concept Fund; Medical Research Council [G0701918, G0800195, MR/K020293/1] Funding Source: researchfish; MRC [MR/K020293/1, G0800195, G0701918] Funding Source: UKRI	Medical Research Council (MRC, UK)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC studentship(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC/Asthma UK Centre studentship; National Heart and Lung Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); North West Lung Centre Charity; NIHR Respiratory Disease Biomedical Research Unit at the Royal Brompton and Harefield NHS Foundation Trust and Imperial College London; Imperial Confidence in Concept Fund; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Supported by S.A.M., M.S.G., E.D. were funded by project grants from the Medical Research Council (MRC, UK; M.S.G.: G0800195; S.A.M. and E.D.: MR/K020293/1). M.A.W., Y.-M.C., and S.J.B. were supported on an MRC studentship, an MRC/Asthma UK Centre studentship, and the National Heart and Lung Institute, respectively. M.A.W. was also funded by the North West Lung Centre Charity. The human vagus experiments in this study were undertaken with the support of the NIHR Respiratory Disease Biomedical Research Unit at the Royal Brompton and Harefield NHS Foundation Trust and Imperial College London and the Imperial Confidence in Concept Fund.	Abdulqawi R, 2015, LANCET, V385, P1198, DOI 10.1016/S0140-6736(14)61255-1; Adcock JJ, 2003, BRIT J PHARMACOL, V138, P407, DOI 10.1038/sj.bjp.0705056; Aizawa N, 2012, NEUROUROL URODYNAM, V31, P148, DOI 10.1002/nau.21212; Alessandri-Haber N, 2003, NEURON, V39, P497, DOI 10.1016/S0896-6273(03)00462-8; ALLEGRA L, 1980, EUR J RESPIR DIS, V61, P41; ANDERSON SD, 1983, THORAX, V38, P284, DOI 10.1136/thx.38.4.284; Andre E, 2009, BRIT J PHARMACOL, V158, P1621, DOI 10.1111/j.1476-5381.2009.00438.x; Baxter M, 2014, THORAX, V69, P1080, DOI 10.1136/thoraxjnl-2014-205467; Birrell MA, 2009, AM J RESP CRIT CARE, V180, P1042, DOI 10.1164/rccm.200905-0665OC; Dubuis E, 2013, CUR PROTOC PHARM, V62; Dubuis E, 2013, CURR PROTOC PHARM, V62; Everaerts W, 2010, P NATL ACAD SCI USA, V107, P19084, DOI 10.1073/pnas.1005333107; FULLER RW, 1984, THORAX, V39, P766, DOI 10.1136/thx.39.10.766; Gever JR, 2010, BRIT J PHARMACOL, V160, P1387, DOI 10.1111/j.1476-5381.2010.00796.x; Grace MS, 2014, BRIT J PHARMACOL, V171, P2593, DOI 10.1111/bph.12538; Grace M, 2012, THORAX, V67, P891, DOI 10.1136/thoraxjnl-2011-201443; Guler AD, 2002, J NEUROSCI, V22, P6408; Hamanaka K, 2010, AM J PHYSIOL-LUNG C, V299, pL353, DOI 10.1152/ajplung.00315.2009; Idzko M, EXTRACELLULAR ATP TR, V13, P913; Jia YL, 2004, AM J PHYSIOL-LUNG C, V287, pL272, DOI 10.1152/ajplung.00393.2003; JORIS L, 1993, AM REV RESPIR DIS, V148, P1633, DOI 10.1164/ajrccm/148.6_Pt_1.1633; Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412; Kwong K, 2008, AM J PHYSIOL-LUNG C, V295, pL858, DOI 10.1152/ajplung.90360.2008; LALLOO UG, 1995, J APPL PHYSIOL, V79, P1082, DOI 10.1152/jappl.1995.79.4.1082; LAUDE EA, 1993, PULM PHARMACOL, V6, P171, DOI 10.1006/pulp.1993.1023; Liedtke W, 2000, CELL, V103, P525, DOI 10.1016/S0092-8674(00)00143-4; Liedtke W, 2006, J ENDOCRINOL, V191, P515, DOI 10.1677/joe.1.07000; Lieu TM, 2012, AM J PHYSIOL-LUNG C, V302, pL941, DOI 10.1152/ajplung.00366.2011; Lieu T, 2011, AM J PHYSIOL-LUNG C, V300, pL790, DOI 10.1152/ajplung.00449.2010; Lommatzsch M, 2010, AM J RESP CRIT CARE, V181, P928, DOI 10.1164/rccm.200910-1506OC; Maher SA, 2009, AM J RESP CRIT CARE, V180, P923, DOI 10.1164/rccm.200903-0388OC; McAlexander MA, 2014, J PHARMACOL EXP THER, V349, P118, DOI 10.1124/jpet.113.210203; Mizuno A, 2003, AM J PHYSIOL-CELL PH, V285, pC96, DOI 10.1152/ajpcell.00559.2002; Mochizuki T, 2009, J BIOL CHEM, V284, P21257, DOI 10.1074/jbc.M109.020206; Morice AH, 2004, EUR RESPIR J, V24, P481, DOI 10.1183/09031936.04.00027804; Munoz A, 2012, BJU INT, V110, pE409, DOI 10.1111/j.1464-410X.2012.11189.x; Nilius B, 2004, AM J PHYSIOL-CELL PH, V286, pC195, DOI 10.1152/ajpcell.00365.2003; Raemdonck K, 2012, THORAX, V67, P19, DOI 10.1136/thoraxjnl-2011-200365; Sato D, 2014, CELL MOL NEUROBIOL, V34, P851, DOI 10.1007/s10571-014-0062-9; Schappert SM, 2006, VITAL HLTH STAT, V159, P1; Schroeder K, 2002, BRIT MED J, V324, P329, DOI 10.1136/bmj.324.7333.329; Seminario-Vidal L, 2011, J BIOL CHEM, V286, P26277, DOI 10.1074/jbc.M111.260562; Shi M, 2013, ACTA NEUROPATHOL, V126, P725, DOI 10.1007/s00401-013-1166-x; Suzuki M, 2003, J BIOL CHEM, V278, P22664, DOI 10.1074/jbc.M302561200; Thorneloe KS, 2008, J PHARMACOL EXP THER, V326, P432, DOI 10.1124/jpet.108.139295; Thorneloe KS, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004276; Virginio C, 1998, MOL PHARMACOL, V53, P969; Watanabe H, 2002, J BIOL CHEM, V277, P13569, DOI 10.1074/jbc.M200062200; Wu LJ, 2010, PHARMACOL REV, V62, P381, DOI 10.1124/pr.110.002725; Zhu GH, 2009, HUM MOL GENET, V18, P2053, DOI 10.1093/hmg/ddp111	50	74	83	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2016	138	1					249	+		10.1016/j.jaci.2015.10.044	http://dx.doi.org/10.1016/j.jaci.2015.10.044			25	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DR1IL	26792207	Green Published, hybrid, Green Submitted			2022-12-18	WOS:000379659100027
J	Zolkipli, Z; Roberts, G; Cornelius, V; Clayton, B; Pearson, S; Michaelis, L; Djukanovic, R; Kurukulaaratchy, R; Arshad, SH				Zolkipli, Zaraquiza; Roberts, Graham; Cornelius, Victoria; Clayton, Bernie; Pearson, Sarah; Michaelis, Louise; Djukanovic, Ratko; Kurukulaaratchy, Ramesh; Arshad, S. Hasan			Randomized controlled trial of primary prevention of atopy using house dust mite allergen oral immunotherapy in early childhood	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopy; house dust mite; oral immunotherapy; primary prevention; randomized controlled trial; allergen; infant; early childhood	GRASS-POLLEN IMMUNOTHERAPY; REGULATORY T-CELLS; PEANUT ALLERGY; FOLLOW-UP; ASTHMA; INFANCY; RISK; AVOIDANCE; AGE; CHILDREN	Background: Children born to atopic parents are at increased risk of sensitization to environmental allergens. Objective: We sought to demonstrate proof of concept for oral immunotherapy to high-dose house dust mite (HDM) allergen in infancy in the prevention of allergen sensitization and allergic diseases. Methods: This was a prospective, randomized, double-blind, placebo-controlled, proof-of-concept study involving 111 infants less than 1 year of age at high risk of atopy (>= 2 first-degree relatives with allergic disease) but with negative skin prick test responses to common allergens at randomization. HDM extract (active) and appropriate placebo solution were administered orally twice daily for 12 months, and children were assessed every 3 months. Coprimary outcomes were cumulative sensitization to HDM and sensitization to any common allergen during treatment, whereas development of eczema, wheeze, and food allergy were secondary outcomes. All adverse events were recorded. Results: There was a significant (P = .03) reduction in sensitization to any common allergen (16.0%; 95% CI, 1.7% to 30.4%) in the active (5 [9.4%]) compared with placebo (13 [25.5%]) treatment groups. There was no treatment effect on the coprimary outcome of HDM sensitization and the secondary outcomes of eczema, wheeze, and food allergy. The intervention was well tolerated, with no differences between active and placebo treatments in numbers or nature of adverse events. Conclusion: Prophylactic HDM oral immunotherapy is well tolerated in children at high heredity risk. The results met the trial's prespecified criteria for proof of concept in reducing sensitization to any allergen; however, no significant preventive effect was observed on HDM sensitization or allergy-related symptoms.	[Zolkipli, Zaraquiza; Roberts, Graham; Cornelius, Victoria; Pearson, Sarah; Michaelis, Louise; Djukanovic, Ratko; Arshad, S. Hasan] Univ Hosp Southampton NHS Fdn Trust, NIHR Southampton Resp Biomed Res Unit, Southampton, Hants, England; [Djukanovic, Ratko; Kurukulaaratchy, Ramesh; Arshad, S. Hasan] Univ Hosp Southampton NHS Fdn Trust, Dept Resp Med, Southampton, Hants, England; [Roberts, Graham; Djukanovic, Ratko; Kurukulaaratchy, Ramesh; Arshad, S. Hasan] Univ Southampton, Fac Med, Clin & Expt Sci Acad Unit, Southampton SO9 5NH, Hants, England; [Roberts, Graham; Clayton, Bernie; Kurukulaaratchy, Ramesh; Arshad, S. Hasan] St Marys Hosp, David Hide Asthma & Allergy Res Ctr, Isle Of Wight, England; [Cornelius, Victoria] Kings Coll London, Dept Primary Care & Publ Hlth Sci, London WC2R 2LS, England	University of Southampton; University Hospital Southampton NHS Foundation Trust; University of Southampton; University Hospital Southampton NHS Foundation Trust; University of Southampton; University of London; King's College London	Arshad, SH (corresponding author), Southampton Gen Hosp, Mailpoint 810,Level F,South Block,Tremona Rd, Southampton SO16 6YD, Hants, England.	sha@soton.ac.uk		Kurukulaaratchy, Ramesh/0000-0002-1588-2400; Roberts, Graham/0000-0003-2252-1248; Djukanovic, Ratko/0000-0001-6039-5612; Cornelius, Victoria/0000-0002-0080-1065	National Institute for Health Research (NIHR), United Kingdom; NIHR RBRU; National Institute for Health Research [NF-SI-0514-10085] Funding Source: researchfish	National Institute for Health Research (NIHR), United Kingdom(National Institute for Health Research (NIHR)); NIHR RBRU; National Institute for Health Research(National Institute for Health Research (NIHR))	Supported by the National Institute for Health Research (NIHR), United Kingdom. This report is independent research by the NIHR RBRU Funding Scheme. The views expressed in this publication are those of the authors and not necessarily those of the National Health Service, the NIHR, or the Department of Health.	Akinbami Lara J, 2012, NCHS Data Brief, P1; [Anonymous], 2014, FAQS; ARSHAD SH, 1992, LANCET, V339, P1493, DOI 10.1016/0140-6736(92)91260-F; Arshad SH, 2005, CHEST, V127, P502, DOI 10.1378/chest.127.2.502; Arshad SH, 2003, THORAX, V58, P489, DOI 10.1136/thorax.58.6.489; Arshad SH, 2007, J ALLERGY CLIN IMMUN, V119, P307, DOI 10.1016/j.jaci.2006.12.621; Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; Bufe A, 2011, CLIN EXP ALLERGY, V41, P1256, DOI 10.1111/j.1365-2222.2011.03740.x; Calderon MA, 2015, J ALLERGY CLIN IMMUN, V136, P38, DOI 10.1016/j.jaci.2014.10.012; Dean T, 2007, J ALLERGY CLIN IMMUN, V120, P1166, DOI 10.1016/j.jaci.2007.06.042; Du Toit G, 2008, J ALLERGY CLIN IMMUN, V122, P984, DOI 10.1016/j.jaci.2008.08.039; Du Toit G, 2015, NEW ENGL J MED, V372, P803, DOI 10.1056/NEJMoa1414850; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Francis JN, 2003, J ALLERGY CLIN IMMUN, V111, P1255, DOI 10.1067/mai.2003.1570; GREENLAND S, 1991, BIOMETRICS, V47, P319, DOI 10.2307/2532517; Gregory LG, 2011, TRENDS IMMUNOL, V32, P402, DOI 10.1016/j.it.2011.06.006; Grindebacke H, 2009, J IMMUNOL, V183, P4360, DOI 10.4049/jimmunol.0901091; Haddeland U, 2005, PEDIAT ALLERG IMM-UK, V16, P104, DOI 10.1111/j.1399-3038.2005.00250.x; HIDE DW, 1994, J ALLERGY CLIN IMMUN, V93, P842, DOI 10.1016/0091-6749(94)90375-1; Holt PG, 2013, J ALLERGY CLIN IMMUN, V132, P991, DOI 10.1016/j.jaci.2013.04.049; Holt PG, 2010, J ALLERGY CLIN IMMUN, V125, P653, DOI 10.1016/j.jaci.2009.12.018; Holt PG, 2010, J ALLERGY CLIN IMMUN, V125, pe1; Jacobsen L, 2007, ALLERGY, V62, P943, DOI 10.1111/j.1398-9995.2007.01451.x; Josefowicz SZ, 2012, ANNU REV IMMUNOL, V30, P531, DOI 10.1146/annurev.immunol.25.022106.141623; Krauss-Etschmann S, 2013, THORAX, V68, P380, DOI 10.1136/thoraxjnl-2012-201902; Lazic N, 2013, ALLERGY, V68, P764, DOI 10.1111/all.12134; Mosbech H, 2011, ALLERGY, V66, P55, DOI 10.1111/j.1398-9995.2011.02641.x; Muraro A, 2014, ALLERGY, V69, P590, DOI 10.1111/all.12398; Niederberger V, 2001, J INVEST DERMATOL, V117, P848, DOI 10.1046/j.0022-202x.2001.01470.x; Pajno GB, 2001, CLIN EXP ALLERGY, V31, P1392, DOI 10.1046/j.1365-2222.2001.01161.x; Penagos M, 2006, ANN ALLERG ASTHMA IM, V97, P141, DOI 10.1016/S1081-1206(10)60004-X; Piantadosi A., 2005, SAMPLE SIZE POWER CL; Rask C, 2010, J ALLERGY CLIN IM S1, V125, pAB1; Sato MN, 1998, IMMUNOLOGY, V95, P193, DOI 10.1046/j.1365-2567.1998.00594.x; Schoos AMM, 2015, ALLERGY, V70, P41, DOI 10.1111/all.12523; Scott M, 2012, THORAX, V67, P1046, DOI 10.1136/thoraxjnl-2012-202150; Tariq SM, 2000, PEDIATR ALLERGY IMMU, V11, P162, DOI 10.1034/j.1399-3038.2000.00077.x; Wu AC, 2015, ANN AM THORAC SOC, V12, P161, DOI 10.1513/AnnalsATS.201410-459OC	38	74	88	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2015	136	6					1541	U174		10.1016/j.jaci.2015.04.045	http://dx.doi.org/10.1016/j.jaci.2015.04.045			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CX9RZ	26073754	Bronze, Green Submitted			2022-12-18	WOS:000366044300015
J	Gill, P; Jindal, NL; Jagdis, A; Vadas, P				Gill, Parwinder; Jindal, Nina Lakhani; Jagdis, Amanda; Vadas, Peter			Platelets in the immune response: Revisiting platelet-activating factor in anaphylaxis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; anaphylaxis; mast cells; platelet-activating factor; acetylhydrolase; signaling; receptor antagonists; platelets; sepsis; mediators	FACTOR ACETYLHYDROLASE ACTIVITY; FACTOR RECEPTOR ANTAGONIST; PHOSPHOLIPASE A(2) INHIBITOR; CORONARY-ARTERY-DISEASE; HUMAN NASAL AIRWAY; PHASE-II TRIAL; DOUBLE-BLIND; FACTOR PAF; CLINICAL-TRIAL; SEVERE SEPSIS	Anaphylaxis is an acute, severe, life-threatening multisystem allergic reaction resulting from the sudden systemic release of biochemical mediators and chemotactic substances. Release of both preformed granule-associated mediators and newly generated lipid-derived mediators contributes to the amplification and prolongation of anaphylaxis. Platelet-activating factor (PAF) is a potent phospholipid-derived mediator the central role of which has been well established in experimental models of both immune-mediated and non-immune mediated anaphylaxis. It is produced and secreted by several types of cells, including mast cells, monocytes, tissue macrophages, platelets, eosinophils, endothelial cells, and neutrophils. PAF is implicated in platelet aggregation and activation through release of vasoactive amines in the inflammatory response, resulting in increased vascular permeability, circulatory collapse, decreased cardiac output, and various other biological effects. PAF is rapidly hydrolyzed and degraded to an inactive metabolite, lysoPAF, by the enzyme PAF acetylhydrolase, the activity of which has shown to correlate inversely with PAF levels and predispose to severe anaphylaxis. In addition to its role in anaphylaxis, PAF has also been implicated as a mediator in both allergic and nonallergic inflammatory diseases, including allergic rhinitis, sepsis, atherosclerotic disease, and malignancy, in which PAF signaling has an established role. The therapeutic role of PAF antagonism has been investigated for several diseases, with variable results thus far. Further investigation of its role in pathology and therapeutic modulation is highly anticipated because of the pressing need for more selective and targeted therapy for the management of severe anaphylaxis.	[Gill, Parwinder; Jindal, Nina Lakhani; Vadas, Peter] Univ Toronto, St Michaels Hosp, Div Clin Immunol & Allergy, Toronto, ON M5B 1W8, Canada; [Jagdis, Amanda] Univ British Columbia, Div Allergy & Immunol, Vancouver, BC V5Z 1M9, Canada	University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of British Columbia	Vadas, P (corresponding author), Univ Toronto, St Michaels Hosp, Div Clin Immunol & Allergy, 30 Bond St, Toronto, ON M5B 1W8, Canada.	vadasp@smh.ca						Adkinson NF, 2014, MIDDLETONS ALLERGY P; Albert DH, 1998, J PHARMACOL EXP THER, V284, P83; Arias K, 2009, J ALLERGY CLIN IMMUN, V124, P307, DOI 10.1016/j.jaci.2009.03.012; AUSTIN CE, 1993, BRIT J PHARMACOL, V110, P113, DOI 10.1111/j.1476-5381.1993.tb13779.x; BARBARO JF, 1966, P SOC EXP BIOL MED, V122, P1245; Bastien Y, 1999, J IMMUNOL, V162, P5498; Belanger C, 2008, IMMUNOLOGY, V124, P295, DOI 10.1111/j.1365-2567.2007.02767.x; BENVENISTE J, 1977, NATURE, V269, P170, DOI 10.1038/269170a0; BENVENISTE J, 1972, J EXP MED, V136, P1356, DOI 10.1084/jem.136.6.1356; BENVENISTE J, 1974, NATURE, V249, P581, DOI 10.1038/249581a0; BRAQUET P, 1987, IMMUNOL TODAY, V8, P345, DOI 10.1016/0167-5699(87)90010-7; Brock T, PLATELET ACTIVATING; Cao Y, 1998, J BIOL CHEM, V273, P4012, DOI 10.1074/jbc.273.7.4012; CHAO W, 1993, BIOCHEM J, V292, P617, DOI 10.1042/bj2920617; CHUNG KF, 1986, J PHARMACOL EXP THER, V236, P580; Cines DB, 1998, BLOOD, V91, P3527; Compalati E, 2013, CURR MED RES OPIN, V29, P1539, DOI 10.1185/03007995.2013.822855; CUNDELL DR, 1995, NATURE, V377, P435, DOI 10.1038/377435a0; CUSS FM, 1986, LANCET, V2, P189; Davidson MH, 2008, AM J CARDIOL, V101, p51F, DOI 10.1016/j.amjcard.2008.04.019; Detopoulou P, 2015, EUR J NUTR, V54, P25, DOI 10.1007/s00394-014-0682-3; DHAINAUT JFA, 1994, CRIT CARE MED, V22, P1720, DOI 10.1097/00003246-199422110-00005; Dhainaut JFA, 1998, CRIT CARE MED, V26, P1963, DOI 10.1097/00003246-199812000-00021; DIEZ FL, 1989, J CLIN INVEST, V83, P1733, DOI 10.1172/JCI114074; Dyer KD, 2010, J IMMUNOL, V184, P6327, DOI 10.4049/jimmunol.0904043; Fan P, 2012, PEDIATR RES, V72, P426, DOI 10.1038/pr.2012.87; FELEZ MA, 1994, AM J RESP CRIT CARE, V150, P369, DOI 10.1164/ajrccm.150.2.8049817; Froon AMF, 1996, SHOCK, V5, P313, DOI 10.1097/00024382-199605000-00001; Gardner AA, 2010, BIOCHEM J, V428, P269, DOI 10.1042/BJ20100039; Gomez FP, 1998, AM J RESP CRIT CARE, V157, P1559, DOI 10.1164/ajrccm.157.5.9711088; GRAHAM RM, 1994, J LIPID MEDIAT CELL, V9, P167; Hackler PC, 2014, CANCER GROWTH METAST, V7, P27, DOI 10.4137/CGM.S14501; Hakkinen T, 1999, ARTERIOSCL THROM VAS, V19, P2909, DOI 10.1161/01.ATV.19.12.2909; IMAIZUMI TA, 1995, J INTERN MED, V238, P5, DOI 10.1111/j.1365-2796.1995.tb00894.x; Ishii S, 1998, J EXP MED, V187, P1779, DOI 10.1084/jem.187.11.1779; Jonsson F, 2011, J CLIN INVEST, V121, P1484, DOI 10.1172/JCI45232; Kajiwara N, 2010, J ALLERGY CLIN IMMUN, V125, P1137, DOI 10.1016/j.jaci.2010.01.056; Karasawa K, 2003, PROG LIPID RES, V42, P93, DOI 10.1016/S0163-7827(02)00049-8; Karasuyama H, 2010, CHEM IMMUNOL ALLERGY, V95, P85, DOI 10.1159/000315939; Kasperska-Zajac A, 2008, INFLAMMATION, V31, P112, DOI 10.1007/s10753-007-9056-9; Kasperska-Zajac A, 2008, RECENT PATENTS INFLA, V2, P72, DOI 10.2174/187221308783399306; Kemp SF, 2002, J ALLERGY CLIN IMMUN, V110, P341, DOI 10.1067/mai.2002.126811; Khakpour H, 2009, CARDIOL REV, V17, P222, DOI 10.1097/CRD.0b013e3181b2434e; Kispert SE, 2014, AM J PHYSIOL-CELL PH, V307, pC951, DOI 10.1152/ajpcell.00218.2014; Kolodgie FD, 2006, ARTERIOSCL THROM VAS, V26, P2523, DOI 10.1161/01.ATV.0000244681.72738.bc; Larkin EK, 2015, AM J RESP CRIT CARE, V191, P45, DOI 10.1164/rccm.201405-0948OC; LEGGIERI E, 1991, ALLERGY, V46, P466, DOI 10.1111/j.1398-9995.1991.tb04363.x; Li S, 2009, J CLIN PHARM THER, V34, P447, DOI 10.1111/j.1365-2710.2008.01014.x; Lieberman P, 2010, J ALLERGY CLIN IMMUN, V126, pe142; Lieberman P, 2010, J ALLERGY CLIN IMMUN, V126, P477, DOI 10.1016/j.jaci.2010.06.022; Marathe GK, 2014, J LIPID RES, V55, P1847, DOI 10.1194/jlr.R045492; Marshall JC, 2003, NAT REV DRUG DISCOV, V2, P391, DOI 10.1038/nrd1084; Mathiak G, 1997, SHOCK, V7, P391, DOI 10.1097/00024382-199706000-00001; McIntyre TM, 2012, BBA-BIOMEMBRANES, V1818, P2456, DOI 10.1016/j.bbamem.2012.03.004; Merlos M, 1997, J PHARMACOL EXP THER, V280, P114; MIADONNA A, 1989, AM REV RESPIR DIS, V140, P142, DOI 10.1164/ajrccm/140.1.142; Montrucchio G, 2000, PHYSIOL REV, V80, P1669, DOI 10.1152/physrev.2000.80.4.1669; Munoz-Cano R, 2013, AM J RHINOL ALLERGY, V27, pE48, DOI 10.2500/ajra.2013.27.3856; Nankar SA, 2013, BIOCHIMIE, V95, P1196, DOI 10.1016/j.biochi.2013.01.011; Narita Shin-Ichiro, 1993, Auris Nasus Larynx, V20, P175; Neto HCCF, 2005, MEM I OSWALDO CRUZ, V100, P83, DOI 10.1590/S0074-02762005000900014; Ninio E., PLATELET ACTIVATING; O'Donoghue ML, 2014, JAMA-J AM MED ASSOC, V312, P1006, DOI 10.1001/jama.2014.11061; Opal S, 2004, CRIT CARE MED, V32, P332, DOI 10.1097/01.CCM.0000108867.87890.6D; Pawlowic MC, 2012, MOL BIOCHEM PARASIT, V186, P11, DOI 10.1016/j.molbiopara.2012.08.005; Perelman B, 2014, ALLERGY ASTHMA CL IM, V10, DOI 10.1186/1710-1492-10-20; PINCKARD RN, 1979, J IMMUNOL, V123, P1847; Poeze M, 2000, SHOCK, V14, P421, DOI 10.1097/00024382-200014040-00001; Pravettoni V, 2014, J ALLERGY CLIN IMMUN, V133, P1218, DOI 10.1016/j.jaci.2013.10.033; Prescott SM, 2000, ANNU REV BIOCHEM, V69, P419, DOI 10.1146/annurev.biochem.69.1.419; Ring J, 2014, CHEM IMMUNOL ALLERGY, V100, P54, DOI 10.1159/000358503; Sahu RP, 2014, CANCER RES, V74, P7069, DOI 10.1158/0008-5472.CAN-14-2043; Sahu RP, 2012, CARCINOGENESIS, V33, P1360, DOI 10.1093/carcin/bgs152; Samsamshariat S, 2011, J RES MED SCI, V16, P674; SANZ MJ, 1994, BRIT J PHARMACOL, V113, P513, DOI 10.1111/j.1476-5381.1994.tb17019.x; Schuster DP, 2003, CRIT CARE MED, V31, P1612, DOI 10.1097/01.CCM.0000063267.79824.DB; Serruys PW, 2008, CIRCULATION, V118, P1172, DOI 10.1161/CIRCULATIONAHA.108.771899; Shibamoto T, 2008, PHARMACOLOGY, V82, P114, DOI 10.1159/000141516; SHINOZAKI K, 1994, LIFE SCI, V54, P429, DOI 10.1016/0024-3205(94)00701-2; Shirasaki H, 2005, ANN ALLERG ASTHMA IM, V95, P190, DOI 10.1016/S1081-1206(10)61210-0; Sicherer SH, 2014, J ALLERGY CLIN IMMUN, V133, P324, DOI 10.1016/j.jaci.2013.11.013; Simons FER, 2012, CURR OPIN ALLERGY CL, V12, P389, DOI 10.1097/ACI.0b013e328355b7e4; Singh P, 2013, FITOTERAPIA, V84, P180, DOI 10.1016/j.fitote.2012.11.002; SIRAGANIAN RP, 1983, TRENDS PHARMACOL SCI, V4, P432, DOI 10.1016/0165-6147(83)90478-9; SIRAGANIAN RP, 1971, J IMMUNOL, V106, P1244; SORENSEN J, 1994, INTENS CARE MED, V20, P555, DOI 10.1007/BF01705721; SPENCER DA, 1991, THORAX, V46, P441, DOI 10.1136/thx.46.6.441; Stafforini DM, 2009, CARDIOVASC DRUG THER, V23, P73, DOI 10.1007/s10557-008-6133-8; Stafforini DM, 2003, CRIT REV CL LAB SCI, V40, P643, DOI 10.1080/714037693; Stafforini DM, 1997, J BIOL CHEM, V272, P17895, DOI 10.1074/jbc.272.29.17895; Suputtamongkol Y, 2000, ANTIMICROB AGENTS CH, V44, P693, DOI 10.1128/AAC.44.3.693-696.2000; Tawakol A, 2014, J AM COLL CARDIOL, V63, P86, DOI 10.1016/j.jacc.2013.07.050; TEDESCHI A, 1994, EUR RESPIR J, V7, P1445, DOI 10.1183/09031936.94.07081445; Thivierge M, 1996, J IMMUNOL, V157, P4681; THOMAS Y, 1986, CR ACAD SCI III-VIE, V303, P699; Tjoelker LW, 2000, BBA-MOL CELL BIOL L, V1488, P102, DOI 10.1016/S1388-1981(00)00114-1; Triggiani M, 1997, AM J RESP CRIT CARE, V156, P94, DOI 10.1164/ajrccm.156.1.9608084; TRIGGIANI M, 1991, J IMMUNOL, V147, P660; Tsoupras A. B., 2009, Infectious Disorders - Drug Targets, V9, P390; Turner PJ, 2000, BRIT J PHARMACOL, V129, P525, DOI 10.1038/sj.bjp.0703095; Vadas P., 2003, Journal of Allergy and Clinical Immunology, V111, pS206, DOI 10.1016/S0091-6749(03)80712-1; Vadas P, 2008, NEW ENGL J MED, V358, P28, DOI 10.1056/NEJMoa070030; Vadas P, 2012, J ALLERGY CLIN IMMUN, V129, P1329, DOI 10.1016/j.jaci.2012.02.027; VENABLE ME, 1993, J LIPID RES, V34, P691; Vincent JL, 2000, CRIT CARE MED, V28, P638, DOI 10.1097/00003246-200003000-00006; WARDLAW AJ, 1990, AM REV RESPIR DIS, V141, P386, DOI 10.1164/ajrccm/141.2.386; White HD, 2014, NEW ENGL J MED, V370, P1702, DOI 10.1056/NEJMoa1315878; Winkler K, 2005, CIRCULATION, V111, P980, DOI 10.1161/01.CIR.0000156457.35971.C8; Yoshida H, 1996, AM J HEMATOL, V53, P158, DOI 10.1002/(SICI)1096-8652(199611)53:3<158::AID-AJH2>3.3.CO;2-8; Yost CC, 2010, BIOCHIMIE, V92, P692, DOI 10.1016/j.biochi.2010.02.011; Yost CC, 2009, BLOOD, V113, P6419, DOI 10.1182/blood-2008-07-171629; Zheng GH, 2014, MOL BIOL REP, V41, P7141, DOI 10.1007/s11033-014-3597-4; Zimmerman GA, 2002, CRIT CARE MED, V30, pS294, DOI 10.1097/00003246-200205001-00020	113	74	75	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2015	135	6					1424	1432		10.1016/j.jaci.2015.04.019	http://dx.doi.org/10.1016/j.jaci.2015.04.019			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CK0ZC	26051949	Bronze			2022-12-18	WOS:000355933400003
J	Hussain, S; Berki, DM; Choon, SE; Burden, AD; Allen, MH; Arostegui, JI; Chaves, A; Duckworth, M; Irvine, AD; Mockenhaupt, M; Navarini, AA; Seyger, MMB; Soler-Palacin, P; Prins, C; Valeyrie-Allanore, L; Vicente, MA; Trembath, RC; Smith, CH; Barker, JN; Capon, F				Hussain, Safia; Berki, Dorottya M.; Choon, Siew-Eng; Burden, A. David; Allen, Michael H.; Arostegui, Juan I.; Chaves, Antonio; Duckworth, Michael; Irvine, Alan D.; Mockenhaupt, Maja; Navarini, Alexander A.; Seyger, Marieke M. B.; Soler-Palacin, Pere; Prins, Christa; Valeyrie-Allanore, Laurence; Vicente, M. Asuncion; Trembath, Richard C.; Smith, Catherine H.; Barker, Jonathan N.; Capon, Francesca			IL36RN mutations define a severe autoinflammatory phenotype of generalized pustular psoriasis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							INTERLEUKIN-36-RECEPTOR ANTAGONIST DEFICIENCY; RECEPTOR ANTAGONIST		[Hussain, Safia; Berki, Dorottya M.; Allen, Michael H.; Duckworth, Michael; Navarini, Alexander A.; Smith, Catherine H.; Barker, Jonathan N.; Capon, Francesca] Kings Coll London, Div Genet & Mol Med, London WC2R 2LS, England; [Choon, Siew-Eng] Hosp Sultanah Aminah, Dept Dermatol, Johor Baharu, Malaysia; [Burden, A. David] Univ Glasgow, Dept Dermatol, Glasgow G12 8QQ, Lanark, Scotland; [Arostegui, Juan I.] Hosp Clin Barcelona, Dept Immunol CDB, Barcelona, Spain; [Chaves, Antonio] Hosp Infanta Cristina, Dept Dermatol, Badajoz, Spain; [Irvine, Alan D.] Our Ladys Childrens Hosp, Paediat Dermatol, Dublin, Ireland; [Irvine, Alan D.] Trinity Coll Dublin, Med Clin, Dublin, Ireland; [Mockenhaupt, Maja] Univ Hautklin, Dokumentationszentrum Schwerer Hautreaktionen dZh, Dept Dermatol, Freiburg, Germany; [Navarini, Alexander A.] Univ Zurich Hosp, Dept Dermatol, CH-8091 Zurich, Switzerland; [Seyger, Marieke M. B.] Radboud Univ Nijmegen, Med Ctr, Dept Dermatol, NL-6525 ED Nijmegen, Netherlands; [Soler-Palacin, Pere] Hosp Univ Vall dHebron, Pediat Infect Dis & Immunodeficiencies Unit, Barcelona, Spain; [Prins, Christa] Univ Hosp Geneva, Dermatol Serv, Geneva, Switzerland; [Valeyrie-Allanore, Laurence] Henri Mondor Hosp, Dept Dermatol, Paris, France; [Vicente, M. Asuncion] Hosp St Joan de Deu, Dept Dermatol, Esplugues, Spain; [Trembath, Richard C.] Queen Mary Univ London, Barts & London Sch Med & Dent, London, England	University of London; King's College London; University of Glasgow; University of Barcelona; Hospital Clinic de Barcelona; National Children's Research Centre (NCRC); Our Ladys Children Hospital Crumlin; Trinity College Dublin; University of Freiburg; University of Zurich; University Zurich Hospital; Radboud University Nijmegen; Hospital Universitari Vall d'Hebron; University of Geneva; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; University of London; Queen Mary University London	Hussain, S (corresponding author), Kings Coll London, Div Genet & Mol Med, London WC2R 2LS, England.	jonathan.barker@kcl.ac.uk; francesca.capon@kcl.ac.uk	Seyger, M.M.B./L-4648-2015; Soler-Palacin, Pere/N-2373-2014; Irvine, Alan D/A-3982-2008; Smith, Catherine H./G-5268-2012; Capon, Francesca/F-4763-2011; CHOON, SIEW ENG/AAU-8192-2021; Navarini, Alexander/C-5504-2014	Soler-Palacin, Pere/0000-0002-0346-5570; Irvine, Alan D/0000-0002-9048-2044; Smith, Catherine H./0000-0001-9918-1144; Capon, Francesca/0000-0003-2432-5793; CHOON, SIEW ENG/0000-0002-7796-5746; Arostegui, Juan Ignacio/0000-0003-4757-504X; Navarini, Alexander/0000-0001-7059-632X; Trembath, Richard/0000-0003-0550-3400; Barker, Jonathan/0000-0002-9030-183X; Duckworth, Michael/0000-0003-0295-9621	Department of Health [13/50/17] Funding Source: Medline; National Institute for Health Research [NF-SI-0507-10379] Funding Source: researchfish	Department of Health; National Institute for Health Research(National Institute for Health Research (NIHR))		Aksentijevich I, 2011, NAT REV RHEUMATOL, V7, P468, DOI 10.1038/nrrheum.2011.94; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; Dietrich D, 2014, NAT REV RHEUMATOL; Griffith CE, 2010, ROOKS TXB DERMATOLOG, P20; Marrakchi S, 2011, NEW ENGL J MED, V365, P620, DOI 10.1056/NEJMoa1013068; Onoufriadis A, 2011, AM J HUM GENET, V89, P432, DOI 10.1016/j.ajhg.2011.07.022; Rossi-Semerano L, 2013, PEDIATRICS, V132, pE1043, DOI 10.1542/peds.2012-3935; Setta-Kaffetzi N, 2013, J INVEST DERMATOL, V133, P1366, DOI 10.1038/jid.2012.490; Sugiura K, 2013, J INVEST DERMATOL, V133, P2514, DOI 10.1038/jid.2013.230; Tauber M, 2014, BRIT J DERMATOL, V170, P1198, DOI 10.1111/bjd.12805; Wolf J, 2014, EXPERT OPIN THER PAT, V24, P477, DOI 10.1517/13543776.2014.881473	11	74	78	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2015	135	4					1067	1070		10.1016/j.jaci.2014.09.043	http://dx.doi.org/10.1016/j.jaci.2014.09.043			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CF0MQ	25458002				2022-12-18	WOS:000352238600032
J	Mahdavinia, M; Suh, LA; Carter, RG; Stevens, WW; Norton, JE; Kato, A; Tan, BK; Kern, RC; Conley, DB; Chandra, R; Lavin, J; Peters, AT; Grammer, LC; Schleimer, RP				Mahdavinia, Mahboobeh; Suh, Lydia A.; Carter, Roderick G.; Stevens, Whitney W.; Norton, James E.; Kato, Atsushi; Tan, Bruce K.; Kern, Robert C.; Conley, David B.; Chandra, Rakesh; Lavin, Jennifer; Peters, Anju T.; Grammer, Leslie C., III; Schleimer, Robert P.			Increased noneosinophilic nasal polyps in chronic rhinosinusitis in US second-generation Asians suggest genetic regulation of eosinophilia	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							INFLAMMATION; FEATURES; PROTEIN		[Mahdavinia, Mahboobeh; Suh, Lydia A.; Carter, Roderick G.; Stevens, Whitney W.; Norton, James E.; Kato, Atsushi; Peters, Anju T.; Grammer, Leslie C., III; Schleimer, Robert P.] Northwestern Univ, Feinberg Sch Med, Div Allergy Immunol, Dept Med, Chicago, IL 60611 USA; [Tan, Bruce K.; Kern, Robert C.; Conley, David B.; Chandra, Rakesh; Lavin, Jennifer] Northwestern Univ, Feinberg Sch Med, Dept Otolaryngol, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	Mahdavinia, M (corresponding author), Northwestern Univ, Feinberg Sch Med, Div Allergy Immunol, Dept Med, Chicago, IL 60611 USA.	rpschleimer@northwestern.edu		Kato, Atsushi/0000-0001-9144-3138; Mahdavinia, mahboobeh/0000-0003-4004-203X; Grammer, Leslie/0000-0001-6860-2014	NHLBI NIH HHS [R01 HL078860, R37 HL068546, R21 HL113913] Funding Source: Medline; NIAID NIH HHS [U19 AI106683, R01 AI104733, R01 AI106683, P01 AI106683] Funding Source: Medline; NIDCD NIH HHS [K23 DC012067] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL068546, R01HL078860, R21HL113913] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI106683, P01AI106683, R01AI104733] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [K23DC012067] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Bachert C, 2010, J ALLERGY CLIN IMMUN, V126, P962, DOI 10.1016/j.jaci.2010.07.007; Cao PP, 2009, J ALLERGY CLIN IMMUN, V124, P478, DOI 10.1016/j.jaci.2009.05.017; Hu Y, 2012, LARYNGOSCOPE, V122, P498, DOI 10.1002/lary.22507; Jankowski R, 2002, RHINOLOGY, V40, P173; Katotomichelakis M, 2013, AM J RHINOL ALLERGY, V27, P354, DOI 10.2500/ajra.2013.27.3922; Kim SJ, 2013, OTOLARYNG HEAD NECK, V149, P431, DOI 10.1177/0194599813495363; Mahdavinia M, 2014, J ALLERGY CLIN IMMUN, V133, P1759, DOI 10.1016/j.jaci.2013.12.1092; Nakayama T, 2011, RHINOLOGY, V49, P392, DOI 10.4193/Rhino10.261; Peric A, 2012, J LARYNGOL OTOL, V126, P495, DOI 10.1017/S0022215112000485; Sakuma Y, 2011, AURIS NASUS LARYNX, V38, P583, DOI 10.1016/j.anl.2011.01.007; Shi LL, 2013, ALLERGY, V68, P101, DOI 10.1111/all.12064; Tikaram A, 2013, Med J Malaysia, V68, P445; Zhang N, 2008, J ALLERGY CLIN IMMUN, V122, P961, DOI 10.1016/j.jaci.2008.07.008	13	74	80	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2015	135	2					576	+		10.1016/j.jaci.2014.08.031	http://dx.doi.org/10.1016/j.jaci.2014.08.031			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CB1FL	25312761	Green Accepted			2022-12-18	WOS:000349372300039
J	Sordillo, JE; Scirica, CV; Rifas-Shiman, SL; Gillman, MW; Bunyavanich, S; Camargo, CA; Weiss, ST; Gold, DR; Litonjua, AA				Sordillo, Joanne E.; Scirica, Christina V.; Rifas-Shiman, Sheryl L.; Gillman, Matthew W.; Bunyavanich, Supinda; Camargo, Carlos A., Jr.; Weiss, Scott T.; Gold, Diane R.; Litonjua, Augusto A.			Prenatal and infant exposure to acetaminophen and ibuprofen and the risk for wheeze and asthma in children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; antipyretic; analgesic; respiratory infection	RESPIRATORY-TRACT INFECTIONS; PARACETAMOL USE; CHILDHOOD; SYMPTOMS; ASSOCIATION; MEDICATION; ASPIRIN; DISEASE; ECZEMA; ADULTS	Background: Several studies have reported an association between use of over-the-counter antipyretics during pregnancy or infancy and increased asthma risk. An important potential limitation of these observational studies is confounding by indication. Objectives: We investigated the association of antipyretic intake during pregnancy and during the first year of life (infancy) with asthma-related outcomes before and after controlling for early-life respiratory tract infections. Methods: We included 1490 mother-child pairs in Project Viva, a longitudinal prebirth cohort study. We categorized prenatal acetaminophen exposure as the maximum intake (never, 1-9 times, or >= 10 times) in early pregnancy or midpregnancy and ibuprofen intake as presence or absence in early pregnancy. We expressed intake of antipyretics in infancy as never, 1 to 5 times, 6 to 10 times, or more than 10 times. We examined the associations of acetaminophen and ibuprofen (per unit increase in exposure category) during pregnancy and infancy with wheeze, asthma, and allergen sensitization in early childhood (3-5 years of age, n = 1419) and midchildhood (7-10 years of age, n = 1220). Results: Unadjusted models showed an increased asthma risk in early childhood for higher infant acetaminophen (odds ratio [OR], 1.21; 95% CI 1.04-1.41) and ibuprofen (OR, 1.35; 95% CI, 1.19-1.52) intake. Controlling for respiratory tract infections attenuated estimates for acetaminophen (OR, 1.03; 95% CI, 0.88-1.22) and ibuprofen (OR, 1.19; 95% CI, 1.05-1.36). Prenatal acetaminophen was associated with increased asthma OR, 1.26; 95% CI, 1.02-1.58) in early childhood but not midchildhood. Conclusions: Adjustment for respiratory tract infections in early life substantially diminished associations between infant antipyretic use and early childhood asthma. Respiratory tract infections should be accounted for in studies of antipyretics and asthma to mitigate bias caused by confounding by indication.	[Sordillo, Joanne E.; Scirica, Christina V.; Camargo, Carlos A., Jr.; Weiss, Scott T.; Gold, Diane R.; Litonjua, Augusto A.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA 02115 USA; [Sordillo, Joanne E.; Scirica, Christina V.; Camargo, Carlos A., Jr.; Weiss, Scott T.; Gold, Diane R.; Litonjua, Augusto A.] Harvard Univ, Sch Med, Boston, MA USA; [Rifas-Shiman, Sheryl L.; Gillman, Matthew W.] Harvard Univ, Sch Med, Dept Populat Med, Obes Prevent Program, Boston, MA USA; [Rifas-Shiman, Sheryl L.; Gillman, Matthew W.] Harvard Pilgrim Hlth Care Inst, Boston, MA USA; [Bunyavanich, Supinda] Mt Sinai Hosp, Child Hlth & Dev Inst, New York, NY 10029 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard Pilgrim Health Care; Icahn School of Medicine at Mount Sinai	Litonjua, AA (corresponding author), Brigham & Womens Hosp, Channing Div Network Med, Boston, MA 02115 USA.	augusto.litonjua@channing.harvard.edu	Camargo, Carlos A./C-2145-2008	Camargo, Carlos A./0000-0002-5071-7654	National Institutes of Health [R01 HL 075504, R01 HL/HD 064925, R01 AI102960, 5 T32 HL07427-23]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD034568, R37HD034568] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007427, R01HL075504, R01HL064925, R37HL066289] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI093538, R01AI102960] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grants R01 HL 075504, R01 HL/HD 064925, R01 AI102960, and 5 T32 HL07427-23.	Amberbir A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093869; Amberbir A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022551; ARROWSMITH JB, 1987, PEDIATRICS, V79, P858; Bakkeheim E, 2011, ACTA PAEDIATR, V100, P90, DOI 10.1111/j.1651-2227.2010.01942.x; Barr RG, 2004, AM J RESP CRIT CARE, V169, P836, DOI 10.1164/rccm.200304-596OC; Beasley RW, 2011, AM J RESP CRIT CARE, V183, P171, DOI 10.1164/rccm.201005-0757OC; Cohet C, 2004, J EPIDEMIOL COMMUN H, V58, P852, DOI 10.1136/jech.2003.019182; Davey G, 2005, J ALLERGY CLIN IMMUN, V116, P863, DOI 10.1016/j.jaci.2005.05.045; Dworski R, 2000, THORAX, V55, pS51, DOI 10.1136/thorax.55.suppl_2.S51; Etminan M, 2009, CHEST, V136, P1316, DOI 10.1378/chest.09-0865; Gillman MW, 2004, J PEDIATR-US, V144, P240, DOI 10.1016/j.jpeds.2003.10.064; Goksor E, 2011, ACTA PAEDIATR, V100, P1567, DOI 10.1111/j.1651-2227.2011.02403.x; Kang EM, 2009, OBSTET GYNECOL, V114, P1295, DOI 10.1097/AOG.0b013e3181c225c0; Kreiner-Moller E, 2012, J ALLERGY CLIN IMMUN, V130, P1434, DOI 10.1016/j.jaci.2012.09.017; Kurukulaaratchy RJ, 2012, RESP MED, V106, P329, DOI 10.1016/j.rmed.2011.12.006; Lesko SM, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e20; Levy S, 2001, DRUG SAFETY, V24, P829, DOI 10.2165/00002018-200124110-00004; Lowe AJ, 2010, BMJ-BRIT MED J, V341, pe4616; Mannino David M, 2002, MMWR Surveill Summ, V51, P1; McKeever TM, 2005, AM J RESP CRIT CARE, V171, P966, DOI 10.1164/rccm.200409-1269OC; Newson RB, 2000, EUR RESPIR J, V16, P817, DOI 10.1183/09031936.00.16581700; Nuttall SL, 2003, J CLIN PHARM THER, V28, P289, DOI 10.1046/j.1365-2710.2003.00493.x; Persky V, 2008, ANN ALLERG ASTHMA IM, V101, P271, DOI 10.1016/S1081-1206(10)60492-9; Perzanowski MS, 2010, THORAX, V65, P118, DOI 10.1136/thx.2009.121459; Rebordosa C, 2008, INT J EPIDEMIOL, V37, P583, DOI 10.1093/ije/dyn070; Rothman KJ, 2002, EPIDEMIOLOGY INTRO; Rusconi F, 2011, INT J EPIDEMIOL, V40, P662, DOI 10.1093/ije/dyq263; Schnabel E, 2010, J ALLERGY CLIN IMMUN, V126, P1071, DOI 10.1016/j.jaci.2010.08.023; Shaheen S, 2008, EUR RESPIR J, V32, P1231, DOI 10.1183/09031936.00039208; Shaheen SO, 2010, J ALLERGY CLIN IMMUN, V126, P1141, DOI 10.1016/j.jaci.2010.08.047; Shaheen SO, 2005, CLIN EXP ALLERGY, V35, P18, DOI 10.1111/j.1365-2222.2005.02151.x; Shaheen SO, 2000, THORAX, V55, P266, DOI 10.1136/thorax.55.4.266; Shaheen SO, 2002, THORAX, V57, P958, DOI 10.1136/thorax.57.11.958; Signorello Lisa B, 2002, Am J Ther, V9, P199, DOI 10.1097/00045391-200205000-00005	34	74	76	0	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2015	135	2					441	448		10.1016/j.jaci.2014.07.065	http://dx.doi.org/10.1016/j.jaci.2014.07.065			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CB1FL	25441647	Green Accepted			2022-12-18	WOS:000349372300015
J	Loss, G; Depner, M; Ulfman, LH; van Neerven, RJJ; Hose, AJ; Genuneit, J; Karvonen, AM; Hyvarinen, A; Kaulek, V; Roduit, C; Weber, J; Lauener, R; Pfefferle, PI; Pekkanen, J; Vaarala, O; Dalphin, JC; Riedler, J; Braun-Fahrlander, C; von Mutius, E; Ege, MJ				Loss, Georg; Depner, Martin; Ulfman, Laurien H.; van Neerven, R. J. Joost; Hose, Alexander J.; Genuneit, Jon; Karvonen, Anne M.; Hyvarinen, Anne; Kaulek, Vincent; Roduit, Caroline; Weber, Juliane; Lauener, Roger; Pfefferle, Petra Ina; Pekkanen, Juha; Vaarala, Outi; Dalphin, Jean-Charles; Riedler, Josef; Braun-Fahrlaender, Charlotte; von Mutius, Erika; Ege, Markus J.		PASTURE Study Grp	Consumption of unprocessed cow's milk protects infants from common respiratory infections	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Respiratory infections; rhinitis; otitis; fever; inflammation; C-reactive protein; infancy; milk; prevention; epidemiology	1ST YEAR; ATOPIC SENSITIZATION; CHILDHOOD ASTHMA; VIRAL-INFECTIONS; BIRTH-COHORT; LIFE; CHILDREN; INFLAMMATION; PREVENTION; PROTEINS	Background: Breast-feeding is protective against respiratory infections in early life. Given the co-evolutionary adaptations of humans and cattle, bovine milk might exert similar anti-infective effects in human infants. Objective: To study effects of consumption of raw and processed cow's milk on common infections in infants. Methods: The PASTURE birth cohort followed 983 infants from rural areas in Austria, Finland, France, Germany, and Switzerland, for the first year of life, covering 37,306 person-weeks. Consumption of different types of cow's milk and occurrence of rhinitis, respiratory tract infections, otitis, and fever were assessed by weekly health diaries. C-reactive protein levels were assessed using blood samples taken at 12 months. Results: When contrasted with ultra-heat treated milk, raw milk consumption was inversely associated with occurrence of rhinitis (adjusted odds ratio from longitudinal models [95% CI]: 0.71 [0.54-0.94]), respiratory tract infections (0.77 [0.59-0.99]), otitis (0.14 [0.05-0.42]), and fever (0.69 [0.47-1.01]). Boiled farm milk showed similar but weaker associations. Industrially processed pasteurized milk was inversely associated with fever. Raw farm milk consumption was inversely associated with C-reactive protein levels at 12 months (geometric means ratio [95% CI]: 0.66 [0.45-0.98]). Conclusions: Early life consumption of raw cow's milk reduced the risk of manifest respiratory infections and fever by about 30%. If the health hazards of raw milk could be overcome, the public health impact of minimally processed but pathogen-free milk might be enormous, given the high prevalence of respiratory infections in the first year of life and the associated direct and indirect costs.	[Loss, Georg; Depner, Martin; Hose, Alexander J.; Weber, Juliane; von Mutius, Erika; Ege, Markus J.] Univ Munich, Dr von Hauner Childrens Hosp, D-80337 Munich, Germany; [Loss, Georg; Braun-Fahrlaender, Charlotte] Swiss Trop & Publ Hlth Inst, Basel, Switzerland; [Loss, Georg; Braun-Fahrlaender, Charlotte] Univ Basel, CH-4003 Basel, Switzerland; [Ulfman, Laurien H.; van Neerven, R. J. Joost] Friesland Campina, Amersfoort, Netherlands; [van Neerven, R. J. Joost] Wageningen Univ, NL-6700 AP Wageningen, Netherlands; [Genuneit, Jon] Univ Ulm, Inst Epidemiol & Med Biometry, D-89069 Ulm, Germany; [Karvonen, Anne M.; Hyvarinen, Anne; Pekkanen, Juha] Natl Inst Hlth & Welf, Dept Environm Hlth, Kuopio, Finland; [Kaulek, Vincent; Dalphin, Jean-Charles] Univ Hosp Besancon, UMR CNRS Chronoenvironm 6249, Dept Resp Dis, Besancon, France; [Roduit, Caroline] Univ Zurich, Childrens Hosp, Zurich, Switzerland; [Roduit, Caroline; Lauener, Roger] Christine Kuhne Ctr Allergy Res & Educ, Davos, Switzerland; [Lauener, Roger] Childrens Hosp Eastern Switzerland, St Gallen, Switzerland; [Pfefferle, Petra Ina] Univ Marburg, Inst Lab Med & Pathobiochem, D-35032 Marburg, Germany; [Pfefferle, Petra Ina] German Ctr Lung Res, Hannover, Germany; [Pekkanen, Juha] Univ Eastern Finland, Kuopio, Finland; [Vaarala, Outi] Natl Inst Hlth & Welf, Dept Vaccinat & Immune Protect, Helsinki, Finland; [Riedler, Josef] Childrens Hosp, Schwarzach, Austria; [von Mutius, Erika; Ege, Markus J.] German Ctr Lung Res, Comprehens Pneumol Ctr Munich CPC M, Munich, Germany	University of Munich; University of Basel; Swiss Tropical & Public Health Institute; University of Basel; Wageningen University & Research; Ulm University; Finland National Institute for Health & Welfare; Universite de Franche-Comte; CHU Besancon; University Children's Hospital Zurich; University of Zurich; Philipps University Marburg; University of Eastern Finland; Finland National Institute for Health & Welfare	Loss, G (corresponding author), Univ Munich, Dr von Hauner Childrens Hosp, Lindwurmstr 4, D-80337 Munich, Germany.	georg.loss@med.uni-muenchen.de	Loss, Georg/AAE-7296-2019; van Neerven, Joost/GWZ-3214-2022; Roduit, Caroline/S-4928-2017; riedler, josef/AAQ-4666-2020; Lauener, Roger/O-8612-2016; Roponen, Marjut/C-2086-2017; Genuneit, Jon/I-9323-2012	Loss, Georg/0000-0003-1090-812X; Lauener, Roger/0000-0002-8412-606X; van Neerven, R.J.Joost/0000-0002-3991-5297; Ege, Markus/0000-0001-6643-3923; von Mutius, Erika/0000-0002-8893-4515; Roponen, Marjut/0000-0002-4442-9090; Prof. Dr. med. Schaub, Bianca/0000-0003-1652-8873; Genuneit, Jon/0000-0001-5764-1528; Roduit, Caroline/0000-0002-5988-0570; Hyvarinen, Anne/0000-0002-2823-0866	European Commission [QLK4-CT-2001-00250, FOOD-CT-2006-31708, KBBE-2007-2-2-06]; European Research Council [250268]; FrieslandCampina; German Center for Lung Research, Federal Initiative for Health Research; Universities of Giessen and Marburg Lung Centre (UGMLC), a LOEWE center founded by the state of Hessen	European Commission(European CommissionEuropean Commission Joint Research Centre); European Research Council(European Research Council (ERC)European Commission); FrieslandCampina; German Center for Lung Research, Federal Initiative for Health Research; Universities of Giessen and Marburg Lung Centre (UGMLC), a LOEWE center founded by the state of Hessen	This work has been supported by the European Commission (research grants QLK4-CT-2001-00250, FOOD-CT-2006-31708, and KBBE-2007-2-2-06), the European Research Council (grant no. 250268), and an unrestricted grant by FrieslandCampina. It was also supported in part by the German Center for Lung Research, Federal Initiative for Health Research; and the Universities of Giessen and Marburg Lung Centre (UGMLC), a LOEWE center founded by the state of Hessen.	Allerberger Franz, 2003, International Journal of Infectious Diseases, V7, P42, DOI 10.1016/S1201-9712(03)90041-5; Burger J, 2007, P NATL ACAD SCI USA, V104, P3736, DOI 10.1073/pnas.0607187104; Davis PJ, 1998, ALLERGY, V53, P102, DOI 10.1111/j.1398-9995.1998.tb04975.x; Depner M, 2013, J ALLERGY CLIN IMMUN, V131, P781, DOI 10.1016/j.jaci.2012.11.048; Dowd JB, 2010, AM J PREV MED, V39, P314, DOI 10.1016/j.amepre.2010.05.014; Ehlken B, 2005, EUR J PEDIATR, V164, P607, DOI 10.1007/s00431-005-1705-0; Gabay C, 1999, NEW ENGL J MED, V340, P448, DOI 10.1056/NEJM199902113400607; Hettinga K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019433; Holland JW, 2011, J AGR FOOD CHEM, V59, P1837, DOI 10.1021/jf104395v; Holt PG, 2012, NAT MED, V18, P726, DOI 10.1038/nm.2768; Illi S, 2012, J ALLERGY CLIN IMMUN, V129, P1470, DOI 10.1016/j.jaci.2012.03.013; Kusel MMH, 2007, J ALLERGY CLIN IMMUN, V119, P1105, DOI 10.1016/j.jaci.2006.12.669; Kusel MMH, 2006, PEDIATR INFECT DIS J, V25, P680, DOI 10.1097/01.inf.0000226912.88900.a3; Labbok MH, 2004, NAT REV IMMUNOL, V4, P565, DOI 10.1038/nri1393; Latzin P, 2007, PEDIATR PULM, V42, P41, DOI 10.1002/ppul.20542; Lorenzen PC, 2011, INT J DAIRY TECHNOL, V64, P166, DOI 10.1111/j.1471-0307.2010.00656.x; Loss G, 2011, J ALLERGY CLIN IMMUN, V128, P766, DOI 10.1016/j.jaci.2011.07.048; Manzoni P, 2009, JAMA-J AM MED ASSOC, V302, P1421, DOI 10.1001/jama.2009.1403; Michalski MC, 2006, TRENDS FOOD SCI TECH, V17, P423, DOI 10.1016/j.tifs.2006.02.004; Morales FJ, 2000, INT J FOOD SCI TECH, V35, P193, DOI 10.1046/j.1365-2621.2000.00334.x; Mustonen K, 2013, PEDIAT ALLERG IMM-UK, V24, P395, DOI 10.1111/pai.12072; Mustonen K, 2012, PEDIAT ALLERG IMM-UK, V23, P522, DOI 10.1111/j.1399-3038.2012.01306.x; Oliver SP, 2009, FOODBORNE PATHOG DIS, V6, P793, DOI 10.1089/fpd.2009.0302; Pan Y, 2006, INT DAIRY J, V16, P1252, DOI 10.1016/j.idairyj.2006.06.010; Pappas G, 2005, NEW ENGL J MED, V352, P2325, DOI 10.1056/NEJMra050570; Quigley MA, 2009, ARCH DIS CHILD, V94, P148, DOI 10.1136/adc.2008.146126; Roduit C, 2012, J ALLERGY CLIN IMMUN, V130, P130, DOI 10.1016/j.jaci.2012.02.043; Tsukagoshi H, 2013, FRONT MICROBIOL, V4, DOI 10.3389/fmicb.2013.00278; van der Zalm MM, 2009, PEDIATR INFECT DIS J, V28, P472, DOI 10.1097/INF.0b013e318195e26e; van Neerven RJJ, 2012, J ALLERGY CLIN IMMUN, V130, P853, DOI 10.1016/j.jaci.2012.06.050; von Mutius E, 2006, ALLERGY, V61, P407, DOI 10.1111/j.1398-9995.2006.01009.x; World Health Organization, 2002, WORLD HLTH REP, P192; Yu Y, 2012, J BIOL CHEM, V287, P44784, DOI 10.1074/jbc.M112.425819	33	74	75	0	51	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2015	135	1					56	U487		10.1016/j.jaci.2014.08.044	http://dx.doi.org/10.1016/j.jaci.2014.08.044			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AY0PG	25441645				2022-12-18	WOS:000347298200007
J	Nwaru, BI; Takkinen, HM; Kaila, M; Erkkola, M; Ahonen, S; Pekkanen, J; Simell, O; Veijola, R; Ilonen, J; Hyoty, H; Knip, M; Virtanen, SM				Nwaru, Bright I.; Takkinen, Hanna-Mari; Kaila, Minna; Erkkola, Maijaliisa; Ahonen, Suvi; Pekkanen, Juha; Simell, Olli; Veijola, Riitta; Ilonen, Jorma; Hyoty, Heikki; Knip, Mikael; Virtanen, Suvi M.			Food diversity in infancy and the risk of childhood asthma and allergies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; allergic rhinitis; atopic eczema; wheeze; food diversity; children	ATOPIC-DERMATITIS; GUT MICROBIOTA; INTESTINAL MICROBIOTA; COMPLEMENTARY FOODS; FEEDING PRACTICES; IMMUNE-SYSTEM; SOLID FOODS; SENSITIZATION; AGE; CHILDREN	Background: Recently, the bacterial diversity of the intestinal flora and the diversity of various environmental factors during infancy have been linked to the development of allergies in childhood. Food is an important environmental exposure, but the role of food diversity in the development of asthma and allergies in childhood is poorly defined. Objective: We studied the associations between food diversity during the first year of life and the development of asthma and allergies by age 5 years. Methods: In a Finnish birth cohort we analyzed data on 3142 consecutively born children. We studied food diversity at 3, 4, 6, and 12 months of age. Asthma, wheeze, atopic eczema, and allergic rhinitis were measured by using the International Study of Asthma and Allergies in Childhood questionnaire at age 5 years. Results: By 3 and 4 months of age, food diversity was not associated with any of the allergic end points. By 6 months of age, less food diversity was associated with increased risk of allergic rhinitis but not with the other end points. By 12 months of age, less food diversity was associated with increased risk of any asthma, atopic asthma, wheeze, and allergic rhinitis. Conclusion: Less food diversity during the first year of life might increase the risk of asthma and allergies in childhood. The mechanisms for this association are unclear, but increased dietary antigen exposure might contribute to this link.	[Nwaru, Bright I.; Takkinen, Hanna-Mari; Ahonen, Suvi; Virtanen, Suvi M.] Univ Tampere, Sch Hlth Sci, Tampere 33014, Finland; [Nwaru, Bright I.] Univ Edinburgh, Allergy & Resp Res Grp, Ctr Populat Hlth Sci, Edinburgh EH8 9YL, Midlothian, Scotland; [Takkinen, Hanna-Mari; Virtanen, Suvi M.] Natl Inst Hlth & Welf, Dept Lifestyle & Participat, Nutr Unit, Helsinki, Finland; [Kaila, Minna; Knip, Mikael; Virtanen, Suvi M.] Tampere Univ Hosp, Dept Pediat, Tampere, Finland; [Kaila, Minna] Univ Helsinki, Hjelt Inst, FIN-00014 Helsinki, Finland; [Erkkola, Maijaliisa] Univ Helsinki, Div Nutr, Dept Food & Environm Sci, FIN-00014 Helsinki, Finland; [Ahonen, Suvi; Virtanen, Suvi M.] Pirkanmaa Hosp Dist, Ctr Sci, Tampere, Finland; [Pekkanen, Juha] Natl Inst Hlth & Welf, Environm Epidemiol Unit, Kuopio, Finland; [Pekkanen, Juha] Univ Eastern Finland, Unit Publ Hlth & Clin Nutr, Kuopio, Finland; [Simell, Olli] Univ Turku, Dept Pediat, SF-20500 Turku, Finland; [Veijola, Riitta] Oulu Univ Hosp, Dept Pediat, Med Res Ctr, Oulu, Finland; [Veijola, Riitta] Univ Oulu, SF-90100 Oulu, Finland; [Ilonen, Jorma] Univ Turku, Immunogenet Lab, SF-20500 Turku, Finland; [Ilonen, Jorma] Univ Eastern Finland, Dept Clin Microbiol, Kuopio, Finland; [Hyoty, Heikki] Univ Tampere, Sch Med, FIN-33101 Tampere, Finland; [Hyoty, Heikki] Fimlab Labs, Tampere, Finland; [Knip, Mikael] Folkhalsan Res Ctr, Helsinki, Finland; [Knip, Mikael] Univ Helsinki, Childrens Hosp, FIN-00014 Helsinki, Finland; [Knip, Mikael] Univ Helsinki, Cent Hosp, FIN-00014 Helsinki, Finland; [Knip, Mikael] Univ Helsinki, Diabet & Obes Res Program, FIN-00014 Helsinki, Finland	Tampere University; University of Edinburgh; Finland National Institute for Health & Welfare; Tampere University; Tampere University Hospital; University of Helsinki; University of Helsinki; Pirkanmaa Hospital District; Finland National Institute for Health & Welfare; University of Eastern Finland; University of Turku; University of Oulu; University of Oulu; University of Turku; University of Eastern Finland; Tampere University; Folkhalsan Research Center; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; University of Helsinki	Nwaru, BI (corresponding author), Univ Tampere, Sch Hlth Sci, Medisiinarinkatu 3, Tampere 33014, Finland.	bright.nwaru@uta.fi	Virtanen, Suvi/AAP-1922-2021; Knip, Mikael/AAL-3773-2020; Erkkola, Maijaliisa/J-5539-2018	Ilonen, Jorma/0000-0002-9973-2062; Pekkanen, Juha/0000-0002-1083-8777; Knip, Mikael/0000-0003-0474-0033; Erkkola, Maijaliisa/0000-0002-6966-1523; Virtanen, Suvi/0000-0001-8928-0878; Nwaru, Bright/0000-0002-2876-6089; Hyoty, Heikki/0000-0003-0370-4145; Kaila, Minna/0000-0002-9645-4925	Academy of Finland [44105, 48724, 80846, 201988, 126813, 129492]; Academy of Finland (Centre of Excellence in Molecular Systems Immunology and Physiology Research) [250114]; Prevaller Consortium; Foundation for Pediatric Research; Tampere Tuberculosis Foundation; Juho Vainio Foundation; Yrjo Jahnsson Foundation; Medical Research Funds, Turku; Oulu University Hospital; Tampere University Hospital; Juvenile Diabetes Research Foundation; Novo Nordisk Foundation; EU Biomed 2 Program [BMH4-CT98-3314]; National Institutes of Health; Alma och K. A. Snellman Foundation; Finland Foundation for Pediatric Research; Novo Nordisk Farma; Eli Lilly Finland	Academy of Finland(Academy of Finland); Academy of Finland (Centre of Excellence in Molecular Systems Immunology and Physiology Research)(Academy of Finland); Prevaller Consortium; Foundation for Pediatric Research; Tampere Tuberculosis Foundation; Juho Vainio Foundation; Yrjo Jahnsson Foundation; Medical Research Funds, Turku; Oulu University Hospital; Tampere University Hospital; Juvenile Diabetes Research Foundation(Juvenile Diabetes Research Foundation); Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); EU Biomed 2 Program; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Alma och K. A. Snellman Foundation; Finland Foundation for Pediatric Research; Novo Nordisk Farma(Novo Nordisk); Eli Lilly Finland(Eli Lilly)	Supported by the Academy of Finland (grants 44105, 48724, 80846, 201988, 126813, 129492 and Centre of Excellence in Molecular Systems Immunology and Physiology Research 2012-17, grant 250114); the Prevaller Consortium; the Foundation for Pediatric Research; the Tampere Tuberculosis Foundation; the Juho Vainio Foundation; the Yrjo Jahnsson Foundation; Medical Research Funds, Turku; Oulu and Tampere University Hospitals; the Juvenile Diabetes Research Foundation; the Novo Nordisk Foundation; and EU Biomed 2 Program (BMH4-CT98-3314).; R. Veijola has received research support from the Juvenile Diabetes Research Foundation, Oulu University Hospital Research Funds, the National Institutes of Health, Alma och K. A. Snellman Foundation, and the Finland Foundation for Pediatric Research; has received travel support from the Juvenile Diabetes Research Foundation, Novo Nordisk, Medtronic, Pfizer, Lilly, and Merck Serono; and has board memberships with Novo Nordisk Diabetes, Finland, Medtronic Nordic, and Lilly Diabetes, Finland. M. Knip has received payment for lectures from Novo Nordisk Farma and Eli Lilly Finland. The rest of the authors declare that they have no relevant conflicts of interest.	Abrahamsson TR, 2012, J ALLERGY CLIN IMMUN, V129, P434, DOI 10.1016/j.jaci.2011.10.025; Adlerberth I, 2007, J ALLERGY CLIN IMMUN, V120, P343, DOI 10.1016/j.jaci.2007.05.018; Agostoni C, 2008, J PEDIATR GASTR NUTR, V46, P99, DOI 10.1097/01.mpg.0000304464.60788.bd; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Azad MB, 2013, J ALLERGY CLIN IMMUN, V131, P247, DOI 10.1016/j.jaci.2012.10.044; Bailey M, 2005, P NUTR SOC, V64, P451, DOI 10.1079/PNS2005452; Bailey M, 2001, P NUTR SOC, V60, P427, DOI 10.1079/PNS2001118; Bisgaard H, 2011, J ALLERGY CLIN IMMUN, V128, P646, DOI 10.1016/j.jaci.2011.04.060; Bjorksten B, 2005, CURR OPIN ALLERGY CL, V5, P249, DOI 10.1097/01.all.0000168790.82206.17; Calder PC, 2006, BRIT J NUTR, V96, P774, DOI [10.1079/BJN20061917, 10.1079/BJN20061881]; Chahine BG, 2010, CURR OPIN ALLERGY CL, V10, P394, DOI 10.1097/ACI.0b013e32833982ab; Chuang CH, 2011, PEDIAT ALLERG IMM-UK, V22, P43, DOI 10.1111/j.1399-3038.2010.01007.x; De Luca G, 2010, J MATERN-FETAL NEO M, V23, P80, DOI 10.3109/14767058.2010.509931; Dreskin SC, 2010, CLIN IMMUNOL, V137, P366, DOI 10.1016/j.clim.2010.08.009; Filipiak B, 2007, J PEDIATR-US, V151, P352, DOI 10.1016/j.jpeds.2007.05.018; Fiocchi A, 2006, ANN ALLERG ASTHMA IM, V97, P10, DOI 10.1016/S1081-1206(10)61364-6; Frei R, 2012, ALLERGY, V67, P451, DOI 10.1111/j.1398-9995.2011.02783.x; Greer FR, 2008, PEDIATRICS, V121, P183, DOI 10.1542/peds.2007-3022; Haahtela T, 2008, ALLERGY, V63, P634, DOI 10.1111/j.1398-9995.2008.01712.x; Hanski I, 2012, P NATL ACAD SCI USA, V109, P8334, DOI 10.1073/pnas.1205624109; Hesselmar B, 2010, ACTA PAEDIATR, V99, P1861, DOI 10.1111/j.1651-2227.2010.01939.x; Holt PG, 2000, ALLERGY, V55, P688, DOI 10.1034/j.1398-9995.2000.00118.x; Joseph CLM, 2011, J ALLERGY CLIN IMMUN, V127, P1203, DOI 10.1016/j.jaci.2011.02.018; Knutsen AP, 2010, ALLERGY, V65, P1367, DOI 10.1111/j.1398-9995.2010.02382.x; Kozyrskyj AL, 2011, CURR OPIN ALLERGY CL, V11, P400, DOI 10.1097/ACI.0b013e328349b166; Kupila A, 2001, DIABETOLOGIA, V44, P290, DOI 10.1007/s001250051616; Mihrshahi S, 2007, CLIN EXP ALLERGY, V37, P671, DOI 10.1111/j.1365-2222.2007.02696.x; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Nauta AJ, 2013, AM J CLIN NUTR, V98, p586S, DOI 10.3945/ajcn.112.039644; Nurmatov U, 2012, ALLERGY, V67, P1041, DOI 10.1111/j.1398-9995.2012.02858.x; Nwaru BI, 2013, ALLERGY, V68, P507, DOI 10.1111/all.12118; Nwaru BI, 2013, J ALLERGY CLIN IMMUN, V131, P78, DOI 10.1016/j.jaci.2012.10.028; Nwaru BI, 2010, PEDIATRICS, V125, P50, DOI 10.1542/peds.2009-0813; Nwaru BI, 2011, CLIN RESPIR J, V5, P211, DOI 10.1111/j.1752-699X.2010.00222.x; Pekkanen J, 2012, EUR J EPIDEMIOL, V27, P281, DOI 10.1007/s10654-012-9649-y; Penders J, 2007, ALLERGY, V62, P1223, DOI 10.1111/j.1398-9995.2007.01462.x; Poole JA, 2006, PEDIATRICS, V117, P2175, DOI 10.1542/peds.2005-1803; Prescott SL, 2005, MED J AUSTRALIA, V182, P464, DOI 10.5694/j.1326-5377.2005.tb06787.x; Prescott SL, 2003, CURR OPIN ALLERGY CL, V3, P125, DOI 10.1097/01.all.0000064776.57552.32; Prescott SL, 2010, CURR OPIN ALLERGY CL, V10, P258, DOI 10.1097/ACI.0b013e328339ab25; Remes ST, 1998, ALLERGY, V53, P682, DOI 10.1111/j.1398-9995.1998.tb03954.x; Roduit C, 2012, J ALLERGY CLIN IMMUN, V130, P130, DOI 10.1016/j.jaci.2012.02.043; Snijders BEP, 2008, PEDIATRICS, V122, pE115, DOI 10.1542/peds.2007-1651; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Virtanen SM, 2006, DIABETOLOGIA, V49, P1512, DOI 10.1007/s00125-006-0236-1; Virtanen SM, 2010, BRIT J NUTR, V103, P266, DOI 10.1017/S0007114509991541; White SR, 2010, EUR RESPIR J, V35, P925, DOI 10.1183/09031936.00164809; Zutavern A, 2006, PEDIATRICS, V117, P401, DOI 10.1542/peds.2004-2521; Zutavern A, 2004, ARCH DIS CHILD, V89, P303, DOI 10.1136/adc.2002.025353; Zutavern A, 2008, PEDIATRICS, V121, pE44, DOI 10.1542/peds.2006-3553	50	74	77	1	29	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2014	133	4					1084	1091		10.1016/j.jaci.2013.12.1069	http://dx.doi.org/10.1016/j.jaci.2013.12.1069			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AD8QW	24472626				2022-12-18	WOS:000333531700019
J	Li, XN; Hawkins, GA; Ampleford, EJ; Moore, WC; Li, HS; Hastie, AT; Howard, TD; Boushey, HA; Busse, WW; Calhoun, WJ; Castro, M; Erzurum, SC; Israel, E; Lemanske, RF; Szefler, SJ; Wasserman, SI; Wenzel, SE; Peters, SP; Meyers, DA; Bleecker, ER				Li, Xingnan; Hawkins, Gregory A.; Ampleford, Elizabeth J.; Moore, Wendy C.; Li, Huashi; Hastie, Annette T.; Howard, Timothy D.; Boushey, Homer A.; Busse, William W.; Calhoun, William J.; Castro, Mario; Erzurum, Serpil C.; Israel, Elliot; Lemanske, Robert F., Jr.; Szefler, Stanley J.; Wasserman, Stephen I.; Wenzel, Sally E.; Peters, Stephen P.; Meyers, Deborah A.; Bleecker, Eugene R.			Genome-wide association study identifies T(H)1 pathway genes associated with lung function in asthmatic patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Lung function; FEV1; asthma; T(H)1; IL12A; IL12RB1; STAT4; IRF2	SYSTEMIC-LUPUS-ERYTHEMATOSUS; PRIMARY BILIARY-CIRRHOSIS; SUSCEPTIBILITY LOCI; RESEARCH-PROGRAM; VARIANTS; DISEASE; METAANALYSIS; POPULATION; ANGIOGENESIS; EXPRESSION	Background: Recent meta-analyses of genome-wide association studies in general populations of European descent have identified 28 loci for lung function. Objective: We sought to identify novel lung function loci specifically for asthma and to confirm lung function loci identified in general populations. Methods: Genome-wide association studies of lung function (percent predicted FEV1 [ppFEV(1)], percent predicted forced vital capacity, and FEV1/forced vital capacity ratio) were performed in 4 white populations of European descent (n = 1544), followed by meta-analyses. Results: Seven of 28 previously identified lung function loci (HHIP, FAM13A, THSD4, GSTCD, NOTCH4-AGER, RARB, and ZNF323) identified in general populations were confirmed at single nucleotide polymorphism (SNP) levels (P < .05). Four of 32 loci (IL12A, IL12RB1, STAT4, and IRF2) associated with ppFEV(1) (P < 10(-4)) belong to the T(H)1 or IL-12 cytokine family pathway. By using a linear additive model, these 4 T(H)1 pathway SNPs cumulatively explained 2.9% to 7.8% of the variance in ppFEV(1) values in 4 populations (P = 3 x 10(-11)). Genetic scores of these 4 SNPs were associated with ppFEV1 values (P = 2 x 10(-7)) and the American Thoracic Society severe asthma classification (P = .005) in the Severe Asthma Research Program population. T(H)2 pathway genes (IL13, TSLP, IL33, and IL1RL1) conferring asthma susceptibility were not associated with lung function. Conclusion: Genes involved in airway structure/remodeling are associated with lung function in both general populations and asthmatic subjects. T(H)1 pathway genes involved in anti-virus/ bacterial infection and inflammation modify lung function in asthmatic subjects. Genes associated with lung function that might affect asthma severity are distinct from those genes associated with asthma susceptibility.	[Li, Xingnan; Hawkins, Gregory A.; Ampleford, Elizabeth J.; Moore, Wendy C.; Li, Huashi; Hastie, Annette T.; Howard, Timothy D.; Peters, Stephen P.; Meyers, Deborah A.; Bleecker, Eugene R.] Wake Forest Sch Med, Ctr Genom & Personalized Med Res, Winston Salem, NC 27157 USA; [Boushey, Homer A.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [Busse, William W.] Univ Wisconsin, Dept Med, Madison, WI 53706 USA; [Calhoun, William J.] Univ Texas Med Branch Galveston, Dept Internal Med, Galveston, TX USA; [Castro, Mario] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; [Erzurum, Serpil C.] Lerner Res Inst, Cleveland, OH USA; [Israel, Elliot] Brigham & Womens Hosp, Div Pulm & Crit Care, Boston, MA 02115 USA; [Israel, Elliot] Harvard Univ, Sch Med, Boston, MA USA; [Lemanske, Robert F., Jr.] Univ Wisconsin, Sch Med & Publ Hlth, Ctr Clin Sci, Madison, WI 53706 USA; [Szefler, Stanley J.] Natl Jewish Hlth, Dept Pediat, Denver, CO USA; [Wasserman, Stephen I.] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; [Wenzel, Sally E.] Univ Pittsburgh, Dept Med, Pittsburgh, PA 15260 USA	Wake Forest University; University of California System; University of California San Francisco; University of Wisconsin System; University of Wisconsin Madison; University of Texas System; University of Texas Medical Branch Galveston; Washington University (WUSTL); Cleveland Clinic Foundation; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Wisconsin System; University of Wisconsin Madison; National Jewish Health; University of California System; University of California San Diego; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Li, XN (corresponding author), Wake Forest Sch Med, Ctr Genom & Personalized Med Res, Med Ctr Blvd, Winston Salem, NC 27157 USA.	xinli@wakehealth.edu		Calhoun, William/0000-0001-7075-712X; Wenzel, Sally/0000-0002-4242-0164; Szefler, Stanley/0000-0002-6911-3199	National Institutes of Health (NIH); National Heart, Lung, and Blood Institute (NHLBI); NHLBI; NIH/NHLBI; GlaxoSmithKline; Genentech; Allergy, Asthma, and Immunology Foundation of Northern California; Breathe California; NIH/National Institute of Allergy and Infectious Diseases; NIH; American Lung Association; Asthmatx/Boston Scientific; Amgen; Ception/Cephalon/Teva; MedImmune; Merck; Novartis; Sanofi-Aventis; Vectura; Aerovance; i3 Research (Biota); Spanish Society of Allergy Immunology; Western Society of Allergy, Asthma Immunology; World Allergy Congress; Michigan Public Health Institute; Allegheny General Hospital; American Academy of Pediatrics; West Allegheny Health Systems; California Chapter 4 of the American Academy of Pediatrics; Colorado Allergy Society; Pennsylvania Allergy and Asthma Association; Harvard Pilgrim Health; California Society of Allergy; New York City Allergy Society; World Allergy Organization; American College of Chest Physicians; APAPARi; American Academy of Allergy, Asthma Immunology; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000448] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR007122, M01RR003186, M01RR018390, UL1RR024992] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069116, R01HL069170, R01HL069174, R01HL069149, R01HL069130, R01HL069155, R01HL076285, R01HL087665, RC2HL101487, R01HL069349, R01HL069167, R01HL091762] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Heart, Lung, and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIH/NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); GlaxoSmithKline(GlaxoSmithKline); Genentech(Roche HoldingGenentech); Allergy, Asthma, and Immunology Foundation of Northern California; Breathe California; NIH/National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Lung Association; Asthmatx/Boston Scientific; Amgen(Amgen); Ception/Cephalon/Teva(Teva Pharmaceutical Industries); MedImmune(AstraZenecaMedimmune); Merck(Merck & Company); Novartis(Novartis); Sanofi-Aventis(Sanofi-Aventis); Vectura; Aerovance; i3 Research (Biota); Spanish Society of Allergy Immunology; Western Society of Allergy, Asthma Immunology; World Allergy Congress; Michigan Public Health Institute; Allegheny General Hospital(General Electric); American Academy of Pediatrics; West Allegheny Health Systems; California Chapter 4 of the American Academy of Pediatrics; Colorado Allergy Society; Pennsylvania Allergy and Asthma Association; Harvard Pilgrim Health; California Society of Allergy; New York City Allergy Society; World Allergy Organization; American College of Chest Physicians(General Electric); APAPARi; American Academy of Allergy, Asthma Immunology; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	X. Li, G. A. Hawkins, H. Li, and T. D. Howard have received grants from the National Institutes of Health (NIH). W. C. Moore has received grants from the National Heart, Lung, and Blood Institute (NHLBI) and was a subinvestigator in clinical trials performed at Wake Forest University for Aerovance, Amgen, AstraZeneca, Boehringer Ingelheim, Centocor, Ception, Forest, Genentech, GlaxoSmithKline, MedImmune, Novartis, Pfizer, Sanofi-Aventis, and Wyeth. A. T. Hastie has received a grant from the NHLBI. H. A. Boushey has received research support from the NIH/NHLBI; has consultant arrangements with Merck, GlaxoSmithKline, Genentech, Kalbios, Pharmaxis, and Johnson & Johnson; has received research support from GlaxoSmithKline and Genentech; has received payment for lectures from the Allergy, Asthma, and Immunology Foundation of Northern California and Breathe California; and has received royalties from the McGraw Hill Companies. W. W. Busse has a board membership with Merck; has consultant arrangements with Amgen, Novartis, GlaxoSmithKline, MedImmune, and Genentech; has received grants from the NIH/National Institute of Allergy and Infectious Diseases and the NIH/NHLBI; and has received royalties from Elsevier. W. J. Calhoun has consultant arrangements with Genentech and receives grants from the Federal Emergency Management Agency. M. Castro has received grants from the NIH, the American Lung Association, Asthmatx/Boston Scientific, Amgen, Ception/Cephalon/Teva, Genentech, MedImmune, Merck, Novartis, GlaxoSmithKline, Sanofi-Aventis, and Vectura; has received travel support from the NIH; has consultant arrangements with Asthmatx/Boston Scientific, Genentech, IPS, Pulmagen, and Sanofi-Aventis; has received payment for lectures from Pfizer, Merck, GlaxoSmithKline, Genentech, and Asthmatx/Boston Scientific; and receives royalties from Elsevier. E. Israel has consultant arrangements with Abbott, Amgen, Cowen & Co, Infinity Pharmaceuticals, MedImmune (now AstraZeneca), Merck, newMentor, NKT Therapeutics, Ono Pharmaceuticals, Regeneron Pharmaceuticals, Schering-Plough, TEVA Specialty Pharmaceuticals, Gilead Sciences, Johnson & Johnson, and Agenzia Italiana del Farmico; has provided expert testimony for Campbell, Campbell, Edwards & Conroy, Diedrich & Donohue, Ficksman & Conley, Ryan Ryan Deluca LLP, and Sullway & Hollis; has received grants from Aerovance, Amgen, i3 Research (Biota), Genentech, MedImmune, and Novartis; has received payment for lectures from Merck, the Spanish Society of Allergy & Immunology, theWestern Society of Allergy, Asthma & Immunology, and the World Allergy Congress; and has received royalties from UpToDate. R. F.; Lemanske has received grants, travel support, and fees for participation in review activities from the NIH; has consultant arrangements with Merck, Sepracor, SA Voney and Associates LTD, GlaxoSmithKline, American Institute of Research, Genentech, Double Helix Development, and Boehringer Ingelheim; is employed by the University of Wisconsin School of Medicine and Public Health; has received grants from the NHLBI and Pharmaxis; has received payment for lectures from the Michigan Public Health Institute, Allegheny General Hospital, the American Academy of Pediatrics, West Allegheny Health Systems, California Chapter 4 of the American Academy of Pediatrics, the Colorado Allergy Society, the Pennsylvania Allergy and Asthma Association, Harvard Pilgrim Health, the California Society of Allergy, the New York City Allergy Society, the World Allergy Organization, the American College of Chest Physicians, and the APAPARi; has received payment for manuscript preparation from the American Academy of Allergy, Asthma & Immunology; and has received royalties from Elsevier and UpToDate. S. J. Szefler has received grants, travel support, payment for participation in review activities, and payment for writing or reviewing the manuscript from the NHLBI; has consultant arrangements with Merck, Genentech, Boehringer Ingelheim, and GlaxoSmithKline; has received grants from GlaxoSmithKline; has received payment for lectures from Merck; has received payment for manuscript preparation from Genentech; and has a submitted patent for a b-adrenergic receptor polymorphism for the CARE Network. S. I. Wasserman has received grants from the NIH and the American Lung Association, is President of the American Board of Allergy and Immunology, and has provided expert testimony for Scharf, Banks, Marmor in Chicago, Illinois. S. P. Peters has received grants from the NIH and the NHLBI; has consultant arrangements with AstraZeneca, Aerocrine, Airsonett, AB, GlaxoSmithKline, Merck, Targacept, and TEVA; has received payment for lectures from Integrity CE and Merck; and has received royalties from UpToDate. The rest of the authors declare that they have no relevant conflicts of interest.	Allen HL, 2010, NATURE, V467, P832, DOI 10.1038/nature09410; [Anonymous], GLOB STRAT ASTHM MAN; ARTIGAS MS, 2011, NAT GENET, V43, P1082, DOI DOI 10.1038/NG.941; Bosco A, 2010, MUCOSAL IMMUNOL, V3, P399, DOI 10.1038/mi.2010.13; Bosse Y, 2007, ANNU REV MED, V58, P171, DOI 10.1146/annurev.med.58.071105.111738; California Department of Corrections and Rehabilitation, 2007, EXP PAN REP EXP PAN; Chen H, 2000, MATRIX BIOL, V19, P597, DOI 10.1016/S0945-053X(00)00107-4; De Jager PL, 2009, NAT GENET, V41, P776, DOI 10.1038/ng.401; Dolan CM, 2004, ANN ALLERG ASTHMA IM, V92, P32, DOI 10.1016/S1081-1206(10)61707-3; Dubois PCA, 2010, NAT GENET, V42, P295, DOI 10.1038/ng.543; Favre CJ, 2003, AM J PHYSIOL-HEART C, V285, pH1917, DOI 10.1152/ajpheart.00983.2002; Graham RR, 2008, NAT GENET, V40, P1059, DOI 10.1038/ng.200; Han JW, 2009, NAT GENET, V41, P1234, DOI 10.1038/ng.472; Hancock DB, 2010, NAT GENET, V42, P45, DOI 10.1038/ng.500; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179, DOI 10.1164/ajrccm.159.1.9712108; Hardin M, 2012, AM J RESP CELL MOL, V47, P203, DOI 10.1165/rcmb.2012-0011OC; Hirschfield GM, 2009, NEW ENGL J MED, V360, P2544, DOI 10.1056/NEJMoa0810440; Hom G, 2008, NEW ENGL J MED, V358, P900, DOI 10.1056/NEJMoa0707865; Hunt KA, 2008, NAT GENET, V40, P395, DOI 10.1038/ng.102; Imboden M, 2012, J ALLERGY CLIN IMMUN, V129, P1218, DOI 10.1016/j.jaci.2012.01.074; Johnson AD, 2008, BIOINFORMATICS, V24, P2938, DOI 10.1093/bioinformatics/btn564; Kochi Y, 2010, NAT GENET, V42, P515, DOI 10.1038/ng.583; Lee PH, 2012, BIOINFORMATICS, V28, P1797, DOI 10.1093/bioinformatics/bts191; Li XN, 2012, J ALLERGY CLIN IMMUN, V130, P861, DOI 10.1016/j.jaci.2012.04.041; Li XN, 2011, J ALLERGY CLIN IMMUN, V127, P1457, DOI 10.1016/j.jaci.2011.01.056; Li XN, 2010, J ALLERGY CLIN IMMUN, V125, P328, DOI 10.1016/j.jaci.2009.11.018; Liu XD, 2010, NAT GENET, V42, P658, DOI 10.1038/ng.627; Mallia P, 2006, CHEST, V130, P1203, DOI 10.1378/chest.130.4.1203; Massaro GD, 2000, PHYSIOL GENOMICS, V4, P51, DOI 10.1152/physiolgenomics.2000.4.1.51; Mells GF, 2011, NAT GENET, V43, P329, DOI 10.1038/ng.789; Message SD, 2008, P NATL ACAD SCI USA, V105, P13562, DOI 10.1073/pnas.0804181105; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Moon CM, 2010, LIFE SCI, V86, P661, DOI 10.1016/j.lfs.2010.02.016; Moore WC, 2007, J ALLERGY CLIN IMMUN, V119, P405, DOI 10.1016/j.jaci.2006.11.639; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; N'Diaye A, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002298; Peters SP, 2010, NEW ENGL J MED, V363, P1715, DOI 10.1056/NEJMoa1008770; Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Qi JH, 2003, NAT MED, V9, P407, DOI 10.1038/nm846; Radstake TRDJ, 2010, NAT GENET, V42, P426, DOI 10.1038/ng.565; Repapi E, 2010, NAT GENET, V42, P36, DOI 10.1038/ng.501; Sharma S, 2012, PEDIAT ALLERG IMM-UK, V23, P315, DOI 10.1111/j.1399-3038.2011.01243.x; Stahl EA, 2010, NAT GENET, V42, P508, DOI 10.1038/ng.582; Sumino K, 2012, J ALLERGY CLIN IMMUN, V129, P1267, DOI 10.1016/j.jaci.2012.02.033; Tantisira KG, 2005, HUM MOL GENET, V14, P1671, DOI 10.1093/hmg/ddi175; Tien ES, 2004, J BIOL CHEM, V279, P24053, DOI 10.1074/jbc.M401489200; Torgerson DG, 2011, NAT GENET, V43, P887, DOI 10.1038/ng.888; Vignali DAA, 2012, NAT IMMUNOL, V13, P722, DOI 10.1038/ni.2366; Warburton D, 2005, PEDIATR RES, V57, p26R, DOI 10.1203/01.PDR.0000159570.01327.ED; Wright FA, 2011, NAT GENET, V43, P539, DOI 10.1038/ng.838; Xu JF, 2001, AM J HUM GENET, V68, P1437, DOI 10.1086/320589	52	74	75	0	19	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2013	132	2					313	+		10.1016/j.jaci.2013.01.051	http://dx.doi.org/10.1016/j.jaci.2013.01.051			23	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	194KL	23541324	Green Accepted			2022-12-18	WOS:000322631700007
J	Hawkins, GA; Robinson, MB; Hastie, AT; Li, XN; Li, HS; Moore, WC; Howard, TD; Busse, WW; Erzurum, SC; Wenzel, SE; Peters, SP; Meyers, DA; Bleecker, ER				Hawkins, Gregory A.; Robinson, Mac B.; Hastie, Annette T.; Li, Xingnan; Li, Huashi; Moore, Wendy C.; Howard, Timothy D.; Busse, William W.; Erzurum, Serpil C.; Wenzel, Sally E.; Peters, Stephen P.; Meyers, Deborah A.; Bleecker, Eugene R.		SARP	The IL6R variation Asp(358)Ala is a potential modifier of lung function in subjects with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Soluble IL-6 receptor; IL-6; asthma; pulmonary lung function; severe asthma; IL-6 transsignaling; genetic variation; single nucleotide polymorphism rs2228145	SOLUBLE INTERLEUKIN-6 RECEPTOR; TOCILIZUMAB; GENETICS; HEART	Background: The IL6R single nucleotide polymorphism (SNP) rs4129267 has recently been identified as an asthma susceptibility locus in subjects of European ancestry but has not been characterized with respect to asthma severity. The SNP rs4129267 is in linkage disequilibrium (r(2) = 1) with the IL6R coding SNP rs2228145 (Asp(358)Ala). This IL6R coding change increases IL-6 receptor (IL-6R) shedding and promotes IL-6 transsignaling. Objectives: We sought to evaluate the IL6R SNP rs2228145 with respect to asthma severity phenotypes. Methods: The IL6R SNP rs2228145 was evaluated in subjects of European ancestry with asthma from the Severe Asthma Research Program (SARP). Lung function associations were replicated in the Collaborative Study on the Genetics of Asthma (CSGA) cohort. Serum soluble IL-6R levels were measured in subjects from SARP. Immunohistochemistry was used to qualitatively evaluate IL-6R protein expression in bronchoalveolar lavage cells and endobronchial biopsies. Results: The minor C allele of IL6R SNP rs2228145 was associated with a lower percent predicted FEV1 in the SARP cohort (P = .005), the CSGA cohort (P = .008), and in a combined cohort analysis (P = .003). Additional associations with percent predicted forced vital capacity (FVC), FEV1/FVC ratio, and PC20 were observed. The rs2228145 C allele (Ala(358)) was more frequent in severe asthma phenotypic clusters. Elevated serum soluble IL-6R levels were associated with lower percent predicted FEV1 (P 5.02) and lower percent predicted FVC (P = .008) (n = 146). IL-6R protein expression was observed in bronchoalveolar lavage macrophages, airway epithelium, vascular endothelium, and airway smooth muscle. Conclusions: The IL6R coding SNP rs2228145 (Asp(358)Ala) is a potential modifier of lung function in subjects with asthma and might identify subjects at risk for more severe asthma. IL-6 transsignaling might have a pathogenic role in the lung. (J Allergy Clin Immunol 2012; 130:510-5.)	[Hawkins, Gregory A.; Robinson, Mac B.; Hastie, Annette T.; Li, Xingnan; Li, Huashi; Moore, Wendy C.; Howard, Timothy D.; Peters, Stephen P.; Meyers, Deborah A.; Bleecker, Eugene R.] Wake Forest Sch Med, Ctr Genom & Personalized Med Res, Winston Salem, NC 27157 USA	Wake Forest University	Hawkins, GA (corresponding author), Wake Forest Sch Med, Ctr Genom & Personalized Med Res, Winston Salem, NC 27157 USA.	ghawkins@wakehealth.edu	Fain, Sean B./K-4260-2016	Fain, Sean B./0000-0001-5461-0646; Wenzel, Sally/0000-0002-4242-0164	Children's Healthcare of Atlanta Center for Developmental Lung Biology; National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID); NIH/National Heart, Lung, and Blood Institute (NHLBI); NIH/NHLBI;  [HL69116];  [HL69130];  [HL69155];  [HL69167];  [HL69170];  [HL69174];  [HL69349];  [HL091762];  [HL087665];  [HL101487];  [KL2RR025009];  [M01 RR02635];  [M01 RR03186];  [M01 RR007122-14];  [1UL1RR024153];  [1UL1RR024989];  [1UL1RR024992];  [1UL1RR025008];  [1UL1RR025011];  [U01 HL56899]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000448, UL1TR000439, UL1TR000427, KL2TR000455, UL1TR000454, UL1TR000005] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR007122, UL1RR024153, UL1RR024992, UL1RR024989, M01RR003186, UL1RR025008, UL1RR025011, KL2RR025009, M01RR002635] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [RC2HL101487, R01HL069155, R01HL069170, R01HL069174, R01HL091762, U01HL065899, R01HL069130, R01HL069116, R01HL087665, R01HL069349, R01HL069167] Funding Source: NIH RePORTER	Children's Healthcare of Atlanta Center for Developmental Lung Biology; National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH/National Heart, Lung, and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIH/NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by grants HL69116, HL69130, HL69155, HL69167, HL69170, HL69174, HL69349, HL091762, HL087665, HL101487, KL2RR025009, M01 RR02635, M01 RR03186, M01 RR007122- 14, 1UL1RR024153, 1UL1RR024989, 1UL1RR024992, 1UL1RR025008, 1UL1RR025011, and U01 HL56899, and the Children's Healthcare of Atlanta Center for Developmental Lung Biology.; W. W. Busse is on the Centocor, Merck advisory board; is a consultant for Amgen, AstraZeneca, Novartis, GlaxoSmithKline, MedImmune, and Genentech; and has received research support from the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) and the NIH/National Heart, Lung, and Blood Institute (NHLBI). S. P. Peters and D. A. Meyers have received research support from the NIH/NHLBI. The rest of the authors declare that they have no relevant conflicts of interest.	[Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; [Anonymous], 2000, Am J Respir Crit Care Med, V162, P2341; [Anonymous], 2010, MED LETT DRUGS THER, V52, P47; Brulhart L, 2010, JOINT BONE SPINE, V77, P625, DOI 10.1016/j.jbspin.2010.08.004; De Bandt M, 2009, ANN RHEUM DIS, V68, P153, DOI 10.1136/ard.2008.088179; Febbraio MA, 2010, CLIN PHARMACOL THER, V87, P396, DOI 10.1038/clpt.2010.1; Ferreira MAR, 2011, LANCET, V378, P1006, DOI 10.1016/S0140-6736(11)60874-X; Galicia JC, 2004, GENES IMMUN, V5, P513, DOI 10.1038/sj.gene.6364120; Hagihara K, 2010, J RHEUMATOL, V37, P1075, DOI 10.3899/jrheum.091185; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179, DOI 10.1164/ajrccm.159.1.9712108; Jones SA, 2001, FASEB J, V15, P43, DOI 10.1096/fj.99-1003rev; Kawabata H, 2007, HAEMATOLOGICA, V92, P857, DOI 10.3324/haematol.10794; Kluger N, 2009, MED HYPOTHESES, V72, P479, DOI 10.1016/j.mehy.2008.12.002; Lester LA, 2001, J ALLERGY CLIN IMMUN, V108, P357, DOI 10.1067/mai.2001.117796; Li XN, 2011, J ALLERGY CLIN IMMUN, V127, P1457, DOI 10.1016/j.jaci.2011.01.056; Matthews V, 2003, J BIOL CHEM, V278, P38829, DOI 10.1074/jbc.M210584200; Meyers DA, 2001, GENET EPIDEMIOL, V21, pS4, DOI 10.1002/gepi.2001.21.s1.s4; Mima T, 2009, CURR OPIN RHEUMATOL, V21, P224, DOI 10.1097/BOR.0b013e3283295fec; Moore WC, 2007, J ALLERGY CLIN IMMUN, V119, P405, DOI 10.1016/j.jaci.2006.11.639; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; Rose-John S, 2009, CURR PHARM DESIGN, V15, P2095, DOI 10.2174/138161209788489140; Wilk JB, 2007, BMC MED GENET, V8, DOI 10.1186/1471-2350-8-S1-S8; Yokoyama A, 1997, AM J RESP CRIT CARE, V156, P1688, DOI 10.1164/ajrccm.156.5.9610070	24	74	78	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2012	130	2					510	+		10.1016/j.jaci.2012.03.018	http://dx.doi.org/10.1016/j.jaci.2012.03.018			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	981WC	22554704	Green Accepted			2022-12-18	WOS:000307002200035
J	Akinbami, LJ; Sullivan, SD; Campbell, JD; Grundmeier, RW; Hartert, TV; Lee, TA; Smith, RA				Akinbami, Lara J.; Sullivan, Sean D.; Campbell, Jonathan D.; Grundmeier, Robert W.; Hartert, Tina V.; Lee, Todd A.; Smith, Robert A.			Asthma outcomes: Healthcare utilization and costs	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma hospital admissions; asthma emergency department visits; asthma outpatient visits; asthma medication use; asthma intervention resource use; asthma study perspective	INNER-CITY CHILDREN; QUALITY-OF-CARE; TO-TREAT ASTHMA; ACTIVITY IMPAIRMENT; WORK PRODUCTIVITY; CHILDHOOD ASTHMA; TIME; INTERVENTION; MOTION; IMPACT	Background: Measures of healthcare utilization and indirect impact of asthma morbidity are used to assess clinical interventions and estimate cost. Objective: National Institutes of Health institutes and other federal agencies convened an expert group to propose standardized measurement, collection, analysis, and reporting of healthcare utilization and cost outcomes in future asthma studies. Methods: We used comprehensive literature reviews and expert opinion to compile a list of asthma healthcare utilization outcomes that we classified as core (required in future studies), supplemental (used according to study aims and standardized), and emerging (requiring validation and standardization). We also have identified methodology to assign cost to these outcomes. This work was discussed at an National Institutes of Health-organized workshop in March 2010 and finalized in September 2011. Results: We identified 3 ways to promote comparability across clinical trials for measures of healthcare utilization, resource use, and cost: (1) specify the study perspective (patient, clinician, payer, and society); (2) standardize the measurement period (ideally 12 months); and (3) use standard units to measure healthcare utilization and other asthma-related events. Conclusions: Large clinical trials and observational studies should collect and report detailed information on healthcare utilization, intervention resources, and indirect impact of asthma, so that costs can be calculated and cost-effectiveness analyses can be conducted across several studies. Additional research is needed to develop standard, validated survey instruments for collection of provider-reported and participant-reported data regarding asthma-related health care. (J Allergy Clin Immunol 2012; 129: S49-64.)	[Smith, Robert A.] NHLBI, DLD, NIH, Bethesda, MD 20892 USA; [Akinbami, Lara J.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA; [Sullivan, Sean D.] Univ Washington, Seattle, WA 98195 USA; [Campbell, Jonathan D.] Univ Colorado, Aurora, CO USA; [Grundmeier, Robert W.] Childrens Hosp Philadelphia, Philadelphia, PA USA; [Hartert, Tina V.] Vanderbilt Univ, Med Ctr, Nashville, TN USA; [Lee, Todd A.] Univ Illinois, Chicago, IL USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS); University of Washington; University of Washington Seattle; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Vanderbilt University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Smith, RA (corresponding author), NHLBI, DLD, NIH, 6701 Rockledge Dr, Bethesda, MD 20892 USA.	smithra3@nhlbi.nih.gov	Smith, Robert/AAB-6682-2020; Campbell, Jonathan/C-1279-2015	Akinbami, Lara/0000-0001-6876-6262; Lee, Todd/0000-0003-3619-5367	National Institute of Allergy and Infectious Diseases; National Heart, Lung, and Blood Institute; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Environmental Health Sciences; Agency for Healthcare Research and Quality; Merck Childhood Asthma Network; Robert Wood Johnson Foundation; US Environmental Protection Agency; Merck; AHRQ; NIH; MCHB	National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Eunice Kennedy Shriver National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); Merck Childhood Asthma Network; Robert Wood Johnson Foundation(Robert Wood Johnson Foundation (RWJF)); US Environmental Protection Agency(United States Environmental Protection Agency); Merck(Merck & Company); AHRQ(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); MCHB	The Asthma Outcomes work shop was funded by contributions from the National Institute of Allergy and Infectious Diseases; the National Heart, Lung, and Blood Institute; the Eunice Kennedy Shriver National Institute of Child Health and Human Development; the National Institute of Environmental Health Sciences; the Agency for Healthcare Research and Quality; and the Merck Childhood Asthma Network, as well as by a grant from the Robert Wood Johnson Foundation. Contributions from the National Heart, Lung, and Blood Institute; the National Institute of Allergy and Infectious Diseases; the Eunice Kennedy Shriver National Institute of Child Health and Human Development; the National Institute of Environmental Health Sciences; and the US Environmental Protection Agency funded the publication of this article and all other articles in this supplement.; Disclosure of potential conflict of interest: S. D. Sullivan has received research support from Merck. J. D. Campbell is a consultant for VeriTech Corp and has received research support from the Agency for Healthcare Research and Quality. R. W. Grundmeier has received research support from AHRQ, the NIH, and MCHB. T. V. Hartert has received research support from the NIH and AHRQ; is an Associate Editor for the ATS; and is a consultant for Merck. The rest of the authors declare that they have no relevant conflicts of interest.	Agrawal S, 2006, CURR MED RES OPIN, V22, P1903, DOI 10.1185/030079906X132532; Akinbami LJ, 2009, PEDIATRICS, V123, pS131, DOI 10.1542/peds.2008-2233C; Alliance of Community Health Plans, 2010, ALL ASTHM TOOL KIT; ALTMAN DG, 1994, BRIT MED J, V309, P996, DOI 10.1136/bmj.309.6960.996; Alvarez G G, 2005, Can Respir J, V12, P265; Ampt Amanda, 2007, J Health Serv Res Policy, V12, P18; Asper F, 2009, USING MEDICARE HOSP; Babigumira JB, 2009, BMC HEALTH SERV RES, V9, DOI 10.1186/1472-6963-9-192; BINDMAN AB, 1995, JAMA-J AM MED ASSOC, V274, P305, DOI 10.1001/jama.274.4.305; Bland JM, 1996, BRIT MED J, V312, P1079; Bratt JH, 1999, HEALTH POLICY PLANN, V14, P374, DOI 10.1093/heapol/14.4.374; Briggs A, 2006, HDB HLTH EC EVALUATI; Brixner Diana I, 2006, J Natl Compr Canc Netw, V4, P197; Cannell C F, 1977, Vital Health Stat 2, pi; Centers for Disease Control and Prevention, 2008, 2008 BEH RISK FACT S; Centers for Disease Control and Prevention National Center for Health Statistics, 2008, 2008 NAT HLTH INT QU; Centers for Disease Control and Prevention National Center for Health Statistics, 2003, SLAITS NAT ASTHM SUR; Centers for Medicare & Medicaid Services, 2009, PHYS FEE SCHED SEARC; Chen H, 2008, VALUE HEALTH, V11, P231, DOI 10.1111/j.1524-4733.2007.00229.x; Crawford B, 2003, ISPOR 1 AS PAC C SEP; Diette GB, 2000, ARCH PEDIAT ADOL MED, V154, P923, DOI 10.1001/archpedi.154.9.923; Drummond MF, 2005, METHODS EC EVALUATIO; Ferrie JE, 2005, OCCUP ENVIRON MED, V62, P74, DOI 10.1136/oem.2004.013896; FINKLER SA, 1993, HEALTH SERV RES, V28, P577; Florea NR, 2003, AM J HEALTH-SYST PH, V60, P2321, DOI 10.1093/ajhp/60.22.2321; Flores G, 2009, J ASTHMA, V46, P392, DOI 10.1080/02770900802712971; FMCP Format Executive Committee, 2010, J Manag Care Pharm, V16, P1; Garrison LP, 2003, VALUE HEALTH, V6, P6, DOI 10.1046/j.1524-4733.2003.00003.x; Gold MR, 1996, COST EFFECTIVENESS H; GUARISCO S, 1994, J GEN INTERN MED, V9, P272, DOI 10.1007/BF02599655; Halterman JS, 2001, AMBUL PEDIATR, V1, P201, DOI 10.1367/1539-4409(2001)001<0201:SRAUCW>2.0.CO;2; Harpole LH, 2003, GEN HOSP PSYCHIAT, V25, P238, DOI 10.1016/S0163-8343(03)00023-9; Hartert TV, 2003, AM J OBSTET GYNECOL, V189, P1705, DOI 10.1016/S0002-9378(03)00857-3; Huberty TJ, 2000, J SCHOOL PSYCHOL, V38, P259, DOI 10.1016/S0022-4405(00)00031-5; Johansen SE, 2004, THESIS U S FLORIDA T; Kattan M, 2005, J ALLERGY CLIN IMMUN, V116, P1058, DOI 10.1016/j.jaci.2005.07.032; Kattan M, 2006, PEDIATRICS, V117, pE1095, DOI 10.1542/peds.2005-2160; Knoppert D C, 1984, Can J Hosp Pharm, V37, P102; Knoppert DC, 1984, CAN J HOSP PHARM, V37, P7; LaPlante MP, 2002, HEALTH SERV RES, V37, P397, DOI 10.1111/1475-6773.029; Loeppke R, 2003, J OCCUP ENVIRON MED, V45, P349, DOI 10.1097/01.jom.0000063619.37065.e2; Lumley T, 2002, ANNU REV PUBL HEALTH, V23, P151, DOI 10.1146/annurev.publhealth.23.100901.140546; Mattke S, 2009, PEDIATRICS, V123, pS199, DOI 10.1542/peds.2008-2233K; Mattke S, 2007, AM J MANAG CARE, V13, P211; Mauskopf JA, 1998, PHARMACOECONOMICS, V13, P277, DOI 10.2165/00019053-199813030-00002; Murray M D, 1995, Pharm Pract Manag Q, V15, P44; Murray MD, 1998, J AM MED INFORM ASSN, V5, P546, DOI 10.1136/jamia.1998.0050546; National Asthma Education and Prevention Program NH Lung and Blood Institute National Institutes of Health US Department of Health and Human Services., 2007, 3 US DEP HLTH HUM SE; ODDONE E, 1993, ACAD MED, V68, P859, DOI 10.1097/00001888-199311000-00016; Pleis John R, 2009, Vital Health Stat 10, P1; Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST; Reilly MC, 1996, CLIN DRUG INVEST, V11, P278, DOI 10.2165/00044011-199611050-00004; REILLY MC, 1993, PHARMACOECONOMICS, V4, P353, DOI 10.2165/00019053-199304050-00006; Reynolds K, 2009, LIT REV DEV STANDARD; RIED LD, 1991, AM J HOSP PHARM, V48, P1211, DOI 10.1093/ajhp/48.6.1211; Rudis MI, 2004, ANN EMERG MED, V43, P386, DOI 10.1016/j.annemergmed.2003.10.011; Salm M, 2008, ADV HEALTH ECON HEAL, V20, P271, DOI 10.1016/S0731-2199(08)20011-7; Schiller B, 2008, HEMODIAL INT, V12, P441, DOI 10.1111/j.1542-4758.2008.00308.x; Sculpher MJ, 2003, RESP MED, V97, P508, DOI 10.1053/rmed.2002.1474; Smith MW, 2003, MED CARE RES REV, V60, p74S, DOI 10.1177/1077558703257001; Sullivan S, 1996, AM J RESP CRIT CARE, V154, pS84, DOI 10.1164/ajrccm/154.3_Pt_2.S84; Sullivan SD, 2007, ALLERGY, V62, P126, DOI 10.1111/j.1398-9995.2006.01254.x; Sullivan SD, 2005, ARCH PEDIAT ADOL MED, V159, P428, DOI 10.1001/archpedi.159.5.428; Sullivan SD, 2002, J ALLERGY CLIN IMMUN, V110, P576, DOI 10.1067/mai.2002.128009; van Poppel MNM, 2002, OCCUP MED-OXFORD, V52, P485, DOI 10.1093/occmed/52.8.485; Webber MP, 2005, PEDIATR PULM, V40, P487, DOI 10.1002/ppul.20307; Williams SA, 2009, J OCCUP ENVIRON MED, V51, P780, DOI 10.1097/JOM.0b013e3181abb019	67	74	74	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2012	129	3		S			S49	S64		10.1016/j.jaci.2011.12.984	http://dx.doi.org/10.1016/j.jaci.2011.12.984			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	901OL	22386509	Green Accepted			2022-12-18	WOS:000300976600005
J	Osborne, NJ; Ukoumunne, OC; Wake, M; Allen, KJ				Osborne, Nicholas J.; Ukoumunne, Obioha C.; Wake, Melissa; Allen, Katrina J.			Prevalence of eczema and food allergy is associated with latitude in Australia	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							BULLOUS ERUPTION; REGIONAL-VARIATION; PRESCRIPTIONS; IGE		[Osborne, Nicholas J.] Univ Exeter, European Ctr Environm & Human Hlth, Truro, England; [Ukoumunne, Obioha C.] Univ Exeter, PenCLAHRC, Peninsula Coll Med & Dent, Exeter, Devon, England; [Osborne, Nicholas J.; Wake, Melissa; Allen, Katrina J.] Univ Melbourne, Dept Paediat, Melbourne, Vic 3010, Australia; [Allen, Katrina J.] Royal Childrens Hosp, Dept Allergy & Immunol, Melbourne, Vic, Australia	University of Exeter; University of Exeter; University of Plymouth; University of Melbourne; Royal Children's Hospital Melbourne	Osborne, NJ (corresponding author), Univ Exeter, European Ctr Environm & Human Hlth, Truro, England.	nicholas.osborne@pcmd.ac.uk	Wake, Melissa/J-1396-2012; Allen, Katrina/I-4361-2018; Osborne, Nicholas/D-2086-2011	Wake, Melissa/0000-0001-7501-9257; Allen, Katrina/0000-0002-1921-4493; Osborne, Nicholas/0000-0002-6700-2284				Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; Bencheton AL, 2011, J EUR ACAD DERMATOL, V25, P599, DOI 10.1111/j.1468-3083.2010.03804.x; BOCK SA, 1987, PEDIATRICS, V79, P683; Camargo CA, 2007, J ALLERGY CLIN IMMUN, V120, P131, DOI 10.1016/j.jaci.2007.03.049; Fletcher CL, 2002, CLIN EXP DERMATOL, V27, P74, DOI 10.1046/j.0307-6938.2001.00967.x; Goddard J, 2008, SOUTH MED J, V101, P854, DOI 10.1097/SMJ.0b013e31817be9db; KINNEAR J, 1948, LANCET, V252, P55, DOI 10.1016/S0140-6736(48)90447-4; Leverkus M, 2006, J INVEST DERMATOL, V126, P91, DOI 10.1038/sj.jid.5700012; Liebold K, 2003, J EUR ACAD DERMATOL, V17, P461, DOI 10.1046/j.1468-3083.2003.00778.x; Masetti M, 2007, PARASITOL INT, V56, P81, DOI 10.1016/j.parint.2006.12.002; Mullins RJ, 2010, PEDIAT ALLERG IMM-UK, V21, pE413, DOI 10.1111/j.1399-3038.2009.00962.x; Mullins RJ, 2009, ANN ALLERG ASTHMA IM, V103, P488, DOI 10.1016/S1081-1206(10)60265-7; Mumcuoglu KY, 2008, ISR MED ASSOC J, V10, P388; Osborne NJ, 2011, J ALLERGY CLIN IMMUN, V127, P668, DOI 10.1016/j.jaci.2011.01.039; Osborne NJ, 2011, J ALLERGY CLIN IMMUN, V127, pe2; PARSONS D J, 1955, Ohio State Med J, V51, P669; Rudders SA, 2010, ANN ALLERG ASTHMA IM, V104, P413, DOI 10.1016/j.anai.2010.01.022; SANSOM JE, 1992, ARCH DERMATOL, V128, P272, DOI 10.1001/archderm.128.2.272; Scarupa MD, 2006, J ALLERGY CLIN IMMUN, V117, P1508, DOI 10.1016/j.jaci.2006.03.034; Soloff C, 2005, SAMPLE DESIGN; Stucki A, 2008, NEW ENGL J MED, V359, P1047, DOI 10.1056/NEJMicm060268; Ter Poorten MC, 2005, PEDIATR DERMATOL, V22, P183, DOI 10.1111/j.1525-1470.2005.22301.x; Tharakaram S, 1999, CLIN EXP DERMATOL, V24, P241, DOI 10.1046/j.1365-2230.1999.00467.x; Vassallo MF, 2010, J ALLERGY CLIN IMMUN, V126, P217, DOI 10.1016/j.jaci.2010.06.011	24	74	79	0	20	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2012	129	3					865	867		10.1016/j.jaci.2012.01.037	http://dx.doi.org/10.1016/j.jaci.2012.01.037			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	904IW	22305679				2022-12-18	WOS:000301189300042
J	Thompson, GR; Patterson, TF				Thompson, George R., III; Patterson, Thomas F.			Fungal disease of the nose and paranasal sinuses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Fungal colonization; fungus balls; allergic fungal rhinosinusitis; chronic rhinosinusitis; granulomatous fungal sinusitis; acute fulminant fungal rhinosinusitis	CHRONIC HYPERTROPHIC RHINOSINUSITIS; AMPHOTERICIN-B; DOUBLE-BLIND; SINUSITIS; DIAGNOSIS; IMMUNOTHERAPY; BALLS	Fungal infections of the nose and paranasal sinuses represent a spectrum of diseases ranging from colonization to invasive rhinosinusitis. Clinical manifestations are largely dependent on the immune status of the host, and given the ubiquitous nature of these organisms, exposure is unavoidable. Noninvasive disease includes asymptomatic fungal colonization, fungus balls, and allergic fungal rhinosinusitis. Invasive disease includes indolent chronic rhinosinusitis, granulomatous fungal sinusitis, and acute fulminant fungal rhinosinusitis. A differentiation of these somewhat overlapping syndromes and the disparate treatment regimens required for effective management are the focus of this review. (J Allergy Clin Immunol 2012;129:321-6.)	[Thompson, George R., III] Univ Calif Davis, Dept Internal Med, Div Infect Dis, Coccidioidomycosis Serol Lab,Dept Med Microbiol &, Davis, CA 95616 USA; [Thompson, George R., III] Univ Calif Davis Med Ctr, Dept Internal Med, Div Infect Dis, Sacramento, CA 95817 USA; [Patterson, Thomas F.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA; [Patterson, Thomas F.] S Texas Vet Hlth Care Syst, San Antonio, TX USA	University of California System; University of California Davis; University of California System; University of California Davis; University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital	Thompson, GR (corresponding author), Univ Calif Davis, Dept Internal Med, Div Infect Dis, Coccidioidomycosis Serol Lab,Dept Med Microbiol &, 1 Shields Ave,Tupper Hall,Rm 3146, Davis, CA 95616 USA.	grthompson@ucdavis.edu			Pfizer; Astellas Pharma US; Merck	Pfizer(Pfizer); Astellas Pharma US(Astellas Pharmaceuticals); Merck(Merck & Company)	G. R. Thompson has received research support from Pfizer. T. F. Patterson has consultant arrangements with Pfizer, Viamet Pharmaceuticals, Toyama, Merck, and Astellas Pharma US and has received research support from Astellas Pharma US, Merck, and Pfizer.	BENT JP, 1994, OTOLARYNG HEAD NECK, V111, P580, DOI 10.1016/S0194-5998(94)70525-9; Broglie MA, 2009, RHINOLOGY, V47, P379, DOI 10.4193/Rhin09.026; Carter KD, 1999, AM J OPHTHALMOL, V127, P189, DOI 10.1016/S0002-9394(98)00371-7; Chakrabarti A, 2009, LARYNGOSCOPE, V119, P1809, DOI 10.1002/lary.20520; Challa S, 2010, EUR ARCH OTO-RHINO-L, V267, P1239, DOI 10.1007/s00405-010-1202-6; DelGaudio JM, 2003, ARCH OTOLARYNGOL, V129, P236, DOI 10.1001/archotol.129.2.236; DelGaudio JM, 2009, LARYNGOSCOPE, V119, P180, DOI 10.1002/lary.20014; Deshazo RD, 2009, MED MYCOL, V47, pS309, DOI 10.1080/13693780802213399; Downs SH, 2001, AM J RESP CRIT CARE, V164, P455, DOI 10.1164/ajrccm.164.3.2008042; DRAKOS PE, 1993, BONE MARROW TRANSPL, V12, P203; Dufour X, 2006, MED MYCOL, V44, P61, DOI 10.1080/13693780500235728; Ebbens FA, 2006, J ALLERGY CLIN IMMUN, V118, P1149, DOI 10.1016/j.jaci.2006.07.058; Ebbens FA, 2009, LARYNGOSCOPE, V119, P401, DOI 10.1002/lary.20064; Ferguson BJ, 2007, LARYNGOSCOPE, V117, P2036, DOI 10.1097/MLG.0b013e318123f2d7; Ferguson BJ, 2000, OTOLARYNG CLIN N AM, V33, P441, DOI 10.1016/S0030-6665(00)80018-3; Ferguson BJ, 2000, OTOLARYNG CLIN N AM, V33, P389, DOI 10.1016/S0030-6665(00)80013-4; Glass D, 2011, OCHSNER J, V11, P272; Groppo ER, 2011, ARCH OTOLARYNGOL, V137, P1005, DOI 10.1001/archoto.2011.170; Harvey RJ, 2007, RHINOLOGY, V45, P3; HORST M, 1990, J ALLERGY CLIN IMMUN, V85, P460, DOI 10.1016/0091-6749(90)90156-X; Ikram Mubasher, 2009, Ear Nose Throat J, V88, pE8; Kennedy DW, 2005, LARYNGOSCOPE, V115, P1793, DOI 10.1097/01.mlg.0000175683.81260.26; Kuhn FA, 2000, AM J RHINOL, V14, P149, DOI 10.2500/105065800782102780; Kuhn FA, 2000, OTOLARYNG CLIN N AM, V33, P419, DOI 10.1016/S0030-6665(00)80016-X; Mabry RL, 1998, OTOLARYNG HEAD NECK, V119, P648, DOI 10.1016/S0194-5998(98)70027-0; Marple B, 2002, OTOLARYNG HEAD NECK, V127, P361, DOI 10.1067/mhn.2002.129806; Pleis John R, 2009, Vital Health Stat 10, P1; Ponikau JU, 1999, MAYO CLIN PROC, V74, P877, DOI 10.4065/74.9.877; Revankar SG, 2010, CLIN MICROBIOL REV, V23, P884, DOI 10.1128/CMR.00019-10; Schubert MS, 2009, MED MYCOL, V47, pS324, DOI 10.1080/13693780802314809; Schubert MS, 2004, J ALLERGY CLIN IMMUN, V114, P1376, DOI 10.1016/j.jaci.2004.08.029; Schubert MS, 1998, J ALLERGY CLIN IMMUN, V102, P395, DOI 10.1016/S0091-6749(98)70126-5; Schubert MS, 2001, ANN ALLERG ASTHMA IM, V87, P181, DOI 10.1016/S1081-1206(10)62222-3; Shin SH, 2004, J ALLERGY CLIN IMMUN, V114, P1369, DOI 10.1016/j.jaci.2004.08.012; Smith J, 2006, ANTIMICROB AGENTS CH, V50, P1570, DOI 10.1128/AAC.50.4.1570-1572.2006; Thompson GR, 2009, CLIN CHEST MED, V30, P203, DOI 10.1016/j.ccm.2009.02.001; Venarske DL, 2002, CHEST, V121, P1670, DOI 10.1378/chest.121.5.1670; Walsh TJ, 2008, CLIN INFECT DIS, V46, P327, DOI 10.1086/525258; ZINREICH SJ, 1988, RADIOLOGY, V169, P439, DOI 10.1148/radiology.169.2.3174990	39	74	75	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2012	129	2					321	326		10.1016/j.jaci.2011.11.039	http://dx.doi.org/10.1016/j.jaci.2011.11.039			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	887TC	22206776				2022-12-18	WOS:000299951700004
J	Balaji, H; Heratizadeh, A; Wichmann, K; Niebuhr, M; Crameri, R; Scheynius, A; Werfel, T				Balaji, Hari; Heratizadeh, Annice; Wichmann, Katja; Niebuhr, Margarete; Crameri, Reto; Scheynius, Annika; Werfel, Thomas			Malassezia sympodialis thioredoxin-specific T cells are highly cross-reactive to human thioredoxin in atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						T-cell autoreactivity; autoantigen; skin-homing T cells; T(H)17; T(H)22; atopic dermatitis; thioredoxin; Malassezia sympodialis	CRYSTAL-STRUCTURE; ALLERGEN; SKIN; SENSITIZATION; MEMBER; BLOOD	Background: IgE-mediated cross-reactivity between fungal antigens and human proteins has been described in patients with atopic dermatitis (AD), but it remains to be elucidated whether there is also cross-reactivity at the T-cell level. Objective: We sought to explore cross-reactivity at the T-cell level between the fungal thioredoxin (Mala s 13) of the skin-colonizing yeast Malassezia sympodialis and its homologous human thioredoxin (hTrx). Methods: T-cell lines (TCLs) were generated in the presence of rMala s 13 from the peripheral blood and from skin biopsy specimens of positive patch test reactions of patients with AD sensitized to Mala s 13 and hTrx. Patients with AD not sensitized to Malassezia species, healthy subjects, and patients with psoriasis served as control subjects. Mala s 13-specific T-cell clones (TCCs) were generated from TCLs. TCCs were characterized by antigen specificity, phenotype, and cytokine secretion pattern. Human keratinocytes were stimulated with IFN-gamma, TNF-alpha, and IL-4, and the release of hTrx was determined by means of ELISA. Results: Mala s 13-specific TCLs and TCCs from the blood and skin of patients with AD sensitized to Mala s 13 and hTrx were fully cross-reactive with hTrx. Mala s 13- and hTrx-specific TCCs could not be generated from control subjects. The majority of cross-reactive TCCs were CD4(+) and coexpressed cutaneous lymphocyte antigen. In addition to T(H)1 and T(H)2 TCCs, we could also identify TCCs secreting IL-17 and IL-22. After stimulation with IFN-gamma and TNF-alpha, keratinocytes released substantial amounts of thioredoxin. Conclusion: In patients with AD sensitized to Malassezia species, cross-reactivity at the T-cell level to Mala s 13 and the homologous hTrx is detectable. hTrx autoreactive skin-homing T cells might be relevant for cutaneous inflammation in patients with AD. (J Allergy Clin Immunol 2011; 128:	[Balaji, Hari; Heratizadeh, Annice; Wichmann, Katja; Niebuhr, Margarete; Werfel, Thomas] Hannover Med Sch, Div Immunodermatol & Allergy Res, Dept Dermatol & Allergy, D-30449 Hannover, Germany; [Crameri, Reto] Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Davos, Switzerland; [Scheynius, Annika] Karolinska Inst, Dept Med Solna, Clin Allergy Res Unit, Stockholm, Sweden	Hannover Medical School; Swiss Institute of Allergy & Asthma Research; University of Zurich; Karolinska Institutet	Balaji, H (corresponding author), Hannover Med Sch, Div Immunodermatol & Allergy Res, Dept Dermatol & Allergy, Ricklinger Str 5, D-30449 Hannover, Germany.	heratizadeh.annice@mh-hannover.de	Werfel, Thomas/B-6921-2012		Deutsche Forschungsgemeinschaft [KliFO 250, GRK 1441/1]; Swedish Research Council Medicine; Swiss Federal Science Foundation [316030_128813/1]; European Community [HEALTH-F2-2010-260338]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Swedish Research Council Medicine(Swedish Research Council); Swiss Federal Science Foundation; European Community(European Commission)	Supported by grants from Deutsche Forschungsgemeinschaft (KliFO 250 and GRK 1441/1) and the Swedish Research Council Medicine. Work at SIAF was supported by the Swiss Federal Science Foundation grant 316030_128813/1 and by the European Community's Seventh Framework Program (FP7 2007-2013) under grant agreement HEALTH-F2-2010-260338 "ALLFUN."	Akdis CA, 2006, J ALLERGY CLIN IMMUN, V118, P152, DOI 10.1016/j.jaci.2006.03.045; Akdis M, 2000, EUR J IMMUNOL, V30, P3533, DOI 10.1002/1521-4141(2000012)30:12<3533::AID-IMMU3533>3.0.CO;2-5; Bieber T, 2008, NEW ENGL J MED, V358, P1483, DOI 10.1056/NEJMra074081; Boguniewicz M, 2010, J ALLERGY CLIN IMMUN, V125, P4, DOI 10.1016/j.jaci.2009.11.027; Bohle B, 2003, EUR J IMMUNOL, V33, P3303, DOI 10.1002/eji.200324321; Casagrande BF, 2006, J INVEST DERMATOL, V126, P2414, DOI 10.1038/sj.jid.5700431; Duhen T, 2009, NAT IMMUNOL, V10, P857, DOI 10.1038/ni.1767; Eyerich K, 2009, J ALLERGY CLIN IMMUN, V123, P59, DOI 10.1016/j.jaci.2008.10.031; Eyerich S, 2009, J CLIN INVEST, V119, P3573, DOI 10.1172/JCI40202; Gaitanis G, 2010, MALASSEZIA AND THE SKIN: SCIENCE AND CLINICAL PRACTICE, P201, DOI 10.1007/978-3-642-03616-3; Glaser AG, 2008, ALLERGY, V63, P1617, DOI 10.1111/j.1398-9995.2008.01777.x; Glaser AG, 2006, BIOCHEM J, V396, P41, DOI 10.1042/BJ20051708; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44; Heratizadeh A, 2011, BRIT J DERMATOL, V164, P316, DOI 10.1111/j.1365-2133.2010.10090.x; Johansson C, 2002, J INVEST DERMATOL, V118, P1044, DOI 10.1046/j.1523-1747.2002.01758.x; Limacher A, 2007, J IMMUNOL, V178, P389, DOI 10.4049/jimmunol.178.1.389; Niebuhr M, 2010, J ALLERGY CLIN IMMUN, V126, P1176, DOI 10.1016/j.jaci.2010.07.041; Niebuhr M, 2010, CURR OPIN ALLERGY CL, V10, P463, DOI 10.1097/ACI.0b013e32833e3163; Powis G, 2001, ANNU REV PHARMACOL, V41, P261, DOI 10.1146/annurev.pharmtox.41.1.261; Scheynius A, 2002, INT ARCH ALLERGY IMM, V127, P161, DOI 10.1159/000053860; Schmid-Grendelmeier P, 2006, CHEM IMMUNOL ALLERGY, V91, P98; Schmid-Grendelmeier P, 2005, J ALLERGY CLIN IMMUN, V115, P1068, DOI 10.1016/j.jaci.2005.01.065; Selander C, 2006, ALLERGY, V61, P1002, DOI 10.1111/j.1398-9995.2006.01108.x; Selander C, 2009, J IMMUNOL, V182, P4208, DOI 10.4049/jimmunol.0800885; Sugita T, 2006, MICROBIOL IMMUNOL, V50, P549, DOI 10.1111/j.1348-0421.2006.tb03825.x; Turjanmaa K, 2006, ALLERGY, V61, P1377, DOI 10.1111/j.1398-9995.2006.01136.x; Valenta R, 2009, TRENDS IMMUNOL, V30, P109, DOI 10.1016/j.it.2008.12.004; Vilhelmsson M, 2008, MOL IMMUNOL, V46, P294, DOI 10.1016/j.molimm.2008.07.036; Weichel M, 2006, J ALLERGY CLIN IMMUN, V117, P676, DOI 10.1016/j.jaci.2005.11.040; Werfel T, 1998, ALLERGY, V53, P731; Werfel T, 1997, J IMMUNOL, V158, P2500; Wittmann M, 2005, J INVEST DERMATOL, V124, P1225, DOI 10.1111/j.0022-202X.2005.23715.x; Zeller S, 2008, INT ARCH ALLERGY IMM, V145, P87, DOI 10.1159/000108133; Zeller S, 2009, J ALLERGY CLIN IMMUN, V124, P278, DOI 10.1016/j.jaci.2009.05.015	34	74	75	1	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2011	128	1					92	U153		10.1016/j.jaci.2011.02.043	http://dx.doi.org/10.1016/j.jaci.2011.02.043			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	785RE	21489611				2022-12-18	WOS:000292245600011
J	Chawes, BLK; Bonnelykke, K; Kreiner-Moller, E; Bisgaard, H				Chawes, Bo Lund Krogsgaard; Bonnelykke, Klaus; Kreiner-Moller, Eskil; Bisgaard, Hans			Children with allergic and nonallergic rhinitis have a similar risk of asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic rhinitis; nonallergic rhinitis; asthma; children; united airways	EXHALED NITRIC-OXIDE; BRONCHIAL HYPERRESPONSIVENESS; SCHOOL-CHILDREN; AIRWAY; POPULATION; CHILDHOOD; NASAL; CLASSIFICATION; FILAGGRIN; ONSET	Background: Both allergic and nonallergic rhinitis have been associated with increased prevalence of asthma. Objective: To characterize asthma and intermediary asthma endpoints in young children with allergic and nonallergic rhinitis. Methods: Thirty-eight 7-year-old children with allergic rhinitis, 67 with nonallergic rhinitis, and 185 without rhinitis from the Copenhagen Prospective Study on Asthma in Childhood birth cohort were compared for prevalence of asthma, eczema, food sensitization, filaggrin null-mutations, total IgE, blood eosinophil count, fractional exhaled nitric oxide (FeNO), lung function, and bronchial responsiveness. Results: Children with allergic rhinitis compared with asymptomatic controls had increased prevalence of asthma (21% vs 5%; P = .002), food sensitization (47% vs 13%; P < .001), and eczema (66% vs 43%; P = .01) and increased total IgE (155 kU/L vs 41 kU/L; P <.001), blood eosinophil count (0.46 x 10(9)/L vs 0.30 x 10(9)/L; P = .01), FeNO (15.9 ppb vs 6.6 ppb; P <.001), and bronchial hyperresponsiveness (23% vs 9%; P = .008). Filaggrin null-mutations were associated with allergic rhinitis (odds ratio, 3.3; 95% CI, 1.3-8.3) but did not modify these associations. Children with nonallergic rhinitis also had increased asthma prevalence (20% vs 5%; P = .001) but showed no association with filaggrin null-mutations, eczema, food sensitization, total IgE, blood eosinophil count, FeNO, or bronchial responsiveness. Conclusion: Asthma is similarly associated with allergic and nonallergic rhinitis, suggesting a link between upper and lower airways beyond allergy associated inflammation. Only children with allergic rhinitis had increased bronchial responsiveness and elevated FeNO, suggesting different endotypes of asthma symptoms in young children with allergic and nonallergic rhinitis. (J Allergy Clin Immunol 2010;126:567-73.)	[Bisgaard, Hans] Univ Copenhagen, DK-2820 Gentofte, Denmark; Copenhagen Univ Hosp, Danish Pediat Asthma Ctr, DK-2820 Gentofte, Denmark	University of Copenhagen; University of Copenhagen	Bisgaard, H (corresponding author), Univ Copenhagen, Ledreborg Alle 34, DK-2820 Gentofte, Denmark.	bisgaard@copsac.com	Kronow, Joern/B-1054-2011; Bisgaard, Hans/N-4761-2016	Bisgaard, Hans/0000-0003-4131-7592; Bonnelykke, Klaus/0000-0003-2003-1018; Chawes, Bo/0000-0001-6846-6243; Kreiner, Eskil/0000-0003-1204-2438	Lundbeck Foundation; Pharmacy Foundation; Danish Medical Research Council; Danish Pediatric Asthma Center; Danish Lung Association; Hans Skoubys og hustru Emma Skoubys Fond; Oda Pedersens Legat; Augustinus Foundation	Lundbeck Foundation(Lundbeckfonden); Pharmacy Foundation; Danish Medical Research Council(Danish Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Danish Pediatric Asthma Center; Danish Lung Association; Hans Skoubys og hustru Emma Skoubys Fond; Oda Pedersens Legat; Augustinus Foundation	Supported by the Lundbeck Foundation, the Pharmacy Foundation of 1991, the Danish Medical Research Council, the Danish Pediatric Asthma Center, the Danish Lung Association, Hans Skoubys og hustru Emma Skoubys Fond, and Oda Pedersens Legat.; Disclosure of potential conflict of interest: K. Bonnelykke is a consultant and paid lecturer for Merck and GlaxoSmithKline. H. Bisgaard is a paid lecturer for AstraZeneca and Merck; is a consultant for Merck and Chiesi; receives research support from the Lunbeck Foundation, the Pharmacy Foundation of 1991, the Augustinus Foundation, the Danish Medical Research Council, and the Danish Pediatric Asthma Center; and has provided legal consultation/expert witness testimony for the EMEA regarding guidelines on pediatric studies for documenting asthma drugs. The rest of the authors have declared that they have no conflict of interest.	American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST; Bachert C, 2006, ALLERGY, V61, P693, DOI 10.1111/j.1398-9995.2006.01054.x; Ballardini N, 2006, ALLERGY, V61, P337, DOI 10.1111/j.1398-9995.2005.00936.x; Bisgaard H, 2005, CHEST, V128, P355, DOI 10.1378/chest.128.1.355; Bisgaard H, 2004, ANN ALLERG ASTHMA IM, V93, P381, DOI 10.1016/S1081-1206(10)61398-1; Bisgaard H, 2006, NEW ENGL J MED, V354, P1998, DOI 10.1056/NEJMoa054692; Bisgaard H, 1995, EUR RESPIR J, V8, P2067, DOI 10.1183/09031936.95.08122067; Bisgaard H, 2008, PLOS MED, V5, DOI 10.1371/journal.pmed.0050131; Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; Bisgaard H, 2009, AM J RESP CRIT CARE, V179, P179, DOI 10.1164/rccm.200809-1436OC; Bonay M, 2006, ALLERGY, V61, P111, DOI 10.1111/j.1398-9995.2006.00967.x; BONNELYKKE K, 2010, PEDIAT ALLERGY  0621; Bousquet J, 2008, ALLERGY, V63, P842, DOI 10.1111/j.1398-9995.2008.01715.x; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; BraunFahrlander C, 1997, PEDIATR ALLERGY IMMU, V8, P75, DOI 10.1111/j.1399-3038.1997.tb00147.x; Braunstahl GJ, 2000, AM J RESP CRIT CARE, V161, P2051, DOI 10.1164/ajrccm.161.6.9906121; Brutsche MH, 2006, THORAX, V61, P671, DOI 10.1136/thx.2005.052241; Buchvald F, 2005, J ALLERGY CLIN IMMUN, V115, P1130, DOI 10.1016/j.jaci.2005.03.020; Buchvald F, 2001, AM J RESP CRIT CARE, V163, P699, DOI 10.1164/ajrccm.163.3.2004233; Bugiani M, 2005, ALLERGY, V60, P165, DOI 10.1111/j.1398-9995.2005.00659.x; Chawes BLK, 2009, ALLERGY, V64, P1547, DOI 10.1111/j.1398-9995.2009.02085.x; Chawes BLK, 2010, CHEST, V137, P1332, DOI 10.1378/chest.09-2601; Choi SH, 2007, ALLERGY, V62, P1051, DOI 10.1111/j.1398-9995.2007.01403.x; Ciprandi G, 2008, ALLERGY, V63, P255, DOI 10.1111/j.1398-9995.2007.01544.x; Ciprandi G, 2004, RESP MED, V98, P826, DOI 10.1016/j.rmed.2004.02.021; Cuttitta G, 2003, PEDIAT ALLERG IMM-UK, V14, P458, DOI 10.1046/j.0905-6157.2003.00067.x; Downie SR, 2004, ALLERGY, V59, P320, DOI 10.1111/j.1398-9995.2003.00419.x; Ferdousi HA, 2005, PEDIAT ALLERG IMM-UK, V16, P478, DOI 10.1111/j.1399-3038.2005.00296.x; FOKKENS W, 2007, RHINOL S, V20, P1; Gaga M, 2000, CLIN EXP ALLERGY, V30, P663; Halkjaer LB, 2006, ARCH DERMATOL, V142, P561, DOI 10.1001/archderm.142.5.561; Hens G, 2008, ALLERGY, V63, P261, DOI 10.1111/j.1398-9995.2007.01545.x; Howarth Peter H, 2005, J Allergy Clin Immunol, V115, pS414, DOI 10.1016/j.jaci.2004.12.1134; Hurst JR, 2004, RESP MED, V98, P767, DOI 10.1016/j.rmed.2004.01.010; Marinho S, 2007, ALLERGY, V62, P385, DOI 10.1111/j.1398-9995.2006.01294.x; Molgaard E, 2007, ALLERGY, V62, P1033, DOI 10.1111/j.1398-9995.2007.01355.x; Nielsen KG, 2000, AM J RESP CRIT CARE, V161, P1805, DOI 10.1164/ajrccm.161.6.9905098; Nielsen Kim Gjerum, 2005, Paediatr Respir Rev, V6, P255, DOI 10.1016/j.prrv.2005.09.013; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Powe DG, 2006, CLIN EXP ALLERGY, V36, P1367, DOI 10.1111/j.1365-2222.2006.02593.x; Ragab A, 2004, AM J RHINOL, V18, P15, DOI 10.1177/194589240401800105; Rolla G, 2007, CHEST, V131, P1345, DOI 10.1378/chest.06-2618; Shaaban R, 2008, LANCET, V372, P1049, DOI 10.1016/S0140-6736(08)61446-4; Shaaban R, 2007, AM J RESP CRIT CARE, V176, P659, DOI 10.1164/rccm.200703-427OC; Stern DA, 2008, LANCET, V372, P1058, DOI 10.1016/S0140-6736(08)61447-6; Takhar P, 2005, J IMMUNOL, V174, P5024, DOI 10.4049/jimmunol.174.8.5024; Weidinger S, 2008, J ALLERGY CLIN IMMUN, V121, P1203, DOI 10.1016/j.jaci.2008.02.014; Wickman M, 2003, PEDIATR ALLERGY IMMU, V14, P441, DOI 10.1046/j.0905-6157.2003.00079.x	48	74	75	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2010	126	3					567	U269		10.1016/j.jaci.2010.06.026	http://dx.doi.org/10.1016/j.jaci.2010.06.026			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	646CF	20816191				2022-12-18	WOS:000281512500024
